<SEC-DOCUMENT>0001193125-23-196280.txt : 20230727
<SEC-HEADER>0001193125-23-196280.hdr.sgml : 20230727
<ACCEPTANCE-DATETIME>20230727172811
ACCESSION NUMBER:		0001193125-23-196280
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		137
FILED AS OF DATE:		20230727
DATE AS OF CHANGE:		20230727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frequency Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001703647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472324450
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273490
		FILM NUMBER:		231119507

	BUSINESS ADDRESS:	
		STREET 1:		75 HAYDEN AVENUE
		STREET 2:		SUITE 300
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-315-4600

	MAIL ADDRESS:	
		STREET 1:		75 HAYDEN AVENUE
		STREET 2:		SUITE 300
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>d451428ds4.htm
<DESCRIPTION>S-4
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:freq="http://www.frequencytherapeutics.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-4</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2023To03_31_2023">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2023To03_31_2023">0001703647</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden84370518" contextRef="P01_01_2023To03_31_2023">MA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden84370519" contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">MA</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="freq-20230331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2014To03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2014-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_20_2019To09_20_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-20</xbrli:startDate> <xbrli:endDate>2019-09-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_13_2023To02_13_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-13</xbrli:startDate> <xbrli:endDate>2023-02-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_10_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_17_2022To08_17_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-17</xbrli:startDate> <xbrli:endDate>2022-08-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:LongTermMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:LongTermMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_StockCompensationPlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:StockCompensationPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >freq:LexingtonMassachusettsFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_StockCompensationPlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:StockCompensationPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >freq:LexingtonMassachusettsFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MAsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:MA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MAsrtStatementGeographicalAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:MA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandAndFourteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MAsrtStatementGeographicalAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:MA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >freq:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >freq:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MAsrtStatementGeographicalAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:MA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-11</xbrli:startDate> <xbrli:endDate>2020-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:PrimeRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-11</xbrli:startDate> <xbrli:endDate>2020-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2020To12_11_2020_AREMARegionNo20LLCMembersrtCounterpartyNameAxis_LeasesTerminationAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AREMARegionNo20LLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LeasesTerminationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-11</xbrli:startDate> <xbrli:endDate>2020-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:PrimeRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-11</xbrli:startDate> <xbrli:endDate>2020-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >freq:PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-11</xbrli:startDate> <xbrli:endDate>2020-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >freq:PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-11</xbrli:startDate> <xbrli:endDate>2020-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >freq:PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-11</xbrli:startDate> <xbrli:endDate>2020-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_10_2021To12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:ShareDistributionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-10</xbrli:startDate> <xbrli:endDate>2021-12-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:ShareDistributionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_13_2014_TwoThousandAndFourteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2014-11-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_17_2019_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-20</xbrli:startDate> <xbrli:endDate>2019-09-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To06_30_2021_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2017_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2019_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >freq:PatentLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-12-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-12-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-12-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >freq:PatentLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-01</xbrli:startDate> <xbrli:endDate>2018-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-01</xbrli:startDate> <xbrli:endDate>2018-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_NonExclusivePatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >freq:NonExclusivePatentLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To07_31_2019_AsiaMembersrtStatementGeographicalAxis_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase3ClinicalTrailMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:AsiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >freq:Phase3ClinicalTrailMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_EuropeMembersrtStatementGeographicalAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase3ClinicalTrailMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >freq:Phase3ClinicalTrailMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To07_31_2019_AsiaMembersrtStatementGeographicalAxis_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase2bClinicalTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >freq:Phase2bClinicalTrialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:AsiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_EuropeMembersrtStatementGeographicalAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase2bClinicalTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >freq:Phase2bClinicalTrialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >freq:LexingtonLeaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:HaydenLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_08_2022_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_08_2022To06_30_2023_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-08</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To07_31_2024_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2024-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_13_2023To02_13_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-13</xbrli:startDate> <xbrli:endDate>2023-02-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_StockCompensationPlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:StockCompensationPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >freq:LexingtonMassachusettsFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OutstandingStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >freq:OutstandingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >freq:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AcceleratedDepreciationChargesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >freq:AcceleratedDepreciationChargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >freq:AcceleratedfxthreetwotwochargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >freq:AcceleratedfxthreetwotwochargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AcceleratedfxthreefourfivechargesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >freq:AcceleratedfxthreefourfivechargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >freq:AtTheMarketProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis" >dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OutstandingStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >freq:OutstandingStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >freq:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >freq:AtTheMarketProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_19_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-19</xbrli:startDate> <xbrli:endDate>2019-09-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To01_31_2023_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_06_2023To04_06_2023_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-06</xbrli:startDate> <xbrli:endDate>2023-04-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2023To03_29_2023_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-29</xbrli:startDate> <xbrli:endDate>2023-03-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2023To02_21_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-21</xbrli:startDate> <xbrli:endDate>2023-02-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_08_2022To07_07_2023_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-08</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_08_2023To07_07_2024_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-08</xbrli:startDate> <xbrli:endDate>2024-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_07_2020To01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >freq:HaydenLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >freq:LexingtonLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-07</xbrli:startDate> <xbrli:endDate>2020-01-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2014To12_31_2014_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2014-12-31</xbrli:startDate> <xbrli:endDate>2014-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_31_2020To11_30_2022_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >freq:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-31</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >freq:AcceleratedfxthreetwotwochargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AcceleratedfxthreefourfivechargesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >freq:AcceleratedfxthreefourfivechargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >freq:AcceleratedfxthreetwotwochargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft" > <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Term" > <xbrli:measure>freq:Term</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;;font-weight: bold;"><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">As filed with the Securities and Exchange Commission on July&#160;27, 2023 </div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">SECURITIES </div>AND EXCHANGE <div style="display:inline;">COMMISSION</div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Washington</div>, D.C. 20549 </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2023To03_31_2023">S-4</ix:nonNumeric></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2023To03_31_2023">Frequency Therapeutics, Inc.</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2023To03_31_2023">2834</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2023To03_31_2023">47-2324450</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Primary Standard Industrial</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Classification Code Number)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification Number)</div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To03_31_2023">75 Hayden Avenue</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2023To03_31_2023">Suite 300</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To03_31_2023">Lexington</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden84370518">MA</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To03_31_2023">02421</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To03_31_2023">781</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To03_31_2023">315-4600</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">David L. Lucchino</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">President and Chief Executive Officer </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">75 Hayden Avenue</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Suite 300</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Lexington</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden84370519">MA</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">02421</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">781</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">315-4600</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Bradley C. Faris</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">John H. Chory</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Jennifer A. Yoon</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Latham&#160;&amp; Watkins LLP</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">200 Clarendon Street</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Boston, MA 02116</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(617) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">948-6000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Ram Aiyar</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">President and Chief Executive Officer</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Korro Bio, Inc.</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">One Kendall Square, Building <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">600-700</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Suite <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-401</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cambridge, MA 02139</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(617) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">468-1999</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Kingsley L. Taft</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Marianne C. Sarrazin</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwin Procter LLP</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">100 Northern Avenue</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Boston, MA 02210</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(617) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">570-1000</div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public: </div></div>As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box:&#160;&#160;&#9744; </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">If this Form is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-effective</div> amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, or a smaller reporting company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 15%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 62%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">Exchange Act Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13e-4(i)</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Cross-Border</div> Issuer Tender Offer)&#160;&#160;&#9744; </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;">Exchange Act Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14d-1(d)</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Cross-Border</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Third-Party</div> Tender Offer)&#160;&#160;&#9744; </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><br/></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this proxy statement/prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED JULY&#160;27, 2023 </span></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:1pt;text-align:center">


<img src="g451428g00f02.jpg" alt="LOGO" />
</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g03g00.jpg" alt="LOGO" />
</p> <p style="font-size:4pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PROPOSED MERGER </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">YOUR VOTE IS VERY IMPORTANT </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders of Frequency Therapeutics, Inc. and Korro Bio, Inc., </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc., a Delaware corporation, or Frequency, and Korro Bio, Inc., a Delaware corporation, or Korro Bio, entered into an Agreement and Plan of Merger, or the Merger Agreement, on July 14, 2023, pursuant to which a direct, wholly owned subsidiary of Frequency, Frequency Merger Sub, Inc., or Merger Sub, will merge with and into Korro Bio, with Korro Bio surviving as a direct, wholly owned subsidiary of Frequency, and the surviving corporation of the merger, which transaction is referred to herein as the Merger. Frequency following the Merger is also referred to herein as the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time the certificate of merger is filed with and accepted by the Secretary of State of the State of Delaware, or the Effective Time, as described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger&#8212;Effective Time of the Merger</span>&#8221; beginning on page 185 of the accompanying proxy statement/prospectus, each share of Korro Bio common stock will be converted into the right to receive a number of shares of Frequency common stock equal to the total number of shares of Frequency common stock to be issued in the Merger multiplied by the applicable Korro Bio stockholder&#8217;s percentage interest in Korro Bio as set forth in the allocation certificate to be provided by Korro Bio, or the Allocation Certificate, and as described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;</span><span style="font-style:italic">Allocation Certificate</span>&#8221; beginning on page 191 of the accompanying proxy statement/prospectus. The Korro Bio common stock that will be converted in the Merger includes Korro Bio common stock issued pursuant to the subscription agreement by and among Korro Bio and certain parties to purchase shares of Korro Bio&#8217;s common stock for an aggregate purchase price of approximately $117.3&#160;million, which transaction is referred to as the Pre-Closing Financing. If any Korro Bio common stock outstanding immediately prior to the Effective Time is unvested or is subject to a repurchase option or a risk of forfeiture under any applicable agreement with Korro Bio, then the shares of Frequency common stock issued in exchange for such shares of Korro Bio common stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency common stock will be marked with appropriate legends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, each option to purchase shares of Korro Bio common stock outstanding as of immediately prior to the Effective Time shall automatically be converted, at the Effective Time, into an option to acquire the number of shares of Frequency common stock equal to the number of shares of Korro Bio common stock subject to such option as of immediately prior to the Effective Time multiplied by the exchange ratio formula in the Merger Agreement and rounding that result down to the nearest whole number of shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Frequency common stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such shares, subject to a proposed reverse stock split of Frequency&#8217;s issued and outstanding common stock at a ratio ranging from any whole number between 1-for-&#160;&#160;&#160;&#160; and 1-for-&#160;&#160;&#160;&#160; as determined by the Frequency board of directors in its discretion, or Reverse Stock Split, as described in the section titled &#8220;<span style="font-style:italic">Matters Being Submitted to a Vote of Frequency Stockholders&#8212;Proposal No. 2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split</span>&#8221; beginning on page 234 will be unaffected by the Merger. Each outstanding option to purchase shares of Frequency common stock, which is referred to as a Frequency Option, will remain outstanding and such options, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan or </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2014 Stock Incentive Plan, as applicable, to reflect the Reverse Stock Split and the issuance of the contingent value rights, or CVRs, will be unaffected by the Merger, provided that each Frequency Option that is outstanding and unvested will vest in full immediately prior to the Effective Time. Each restricted stock unit covering shares of Frequency common stock that is outstanding will remain outstanding and such restricted stock units, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan to reflect the Reverse Stock Split and issuance of the CVRs, will be unaffected by the Merger, provided that each restricted stock unit award that vests solely based on the holder&#8217;s continued employment or service will vest in full immediately prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the Merger, Frequency securityholders as of immediately prior to the Merger are expected to own approximately 8% of the outstanding shares of the combined company on a fully-diluted basis and former Korro Bio securityholders (including purchasers in the Pre-Closing Financing) are expected to own approximately 92% of the outstanding shares of the combined company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Frequency&#8217;s net cash as of closing being equal to $25 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Frequency common stock are currently listed on The Nasdaq Global Select Market, or Nasdaq, under the symbol &#8220;FREQ.&#8221; Frequency intends to file an initial listing application for the combined company with the Nasdaq Stock Market LLC. After completion of the Merger, Frequency will be renamed &#8220;Korro Bio, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;KRRO.&#8221; On &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of Frequency common stock was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency stockholders are cordially invited to attend the annual meeting of Frequency stockholders, or the Frequency Annual Meeting. Frequency is holding the Frequency Annual Meeting, on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2023, at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Eastern Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger or other matters. The Frequency Annual Meeting will be held entirely online. Frequency stockholders will be able to attend and participate in the Frequency Annual Meeting online by visiting www.proxydocs.com/FREQ where they will be able to listen to the meeting live, submit questions and vote. At the Frequency Annual Meeting, Frequency will ask its stockholders: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the issuance of shares of common stock of Frequency to stockholders of Korro Bio, Inc. pursuant to the terms of the Agreement and Plan of Merger dated as of July 14, 2023, by and among Frequency, Korro Bio, and Merger Sub, a copy of which is attached as <span style="font-style:italic">Annex A</span> to the accompanying proxy statement/prospectus, pursuant to which Merger Sub will merge with and into Korro Bio, with Korro Bio surviving as a wholly owned subsidiary of Frequency, and the surviving corporation of the merger and the change of control resulting from the merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve an amendment to the Restated Certificate of Incorporation of Frequency, a copy of which is attached as <span style="font-style:italic">Annex H</span> to the accompanying proxy statement/prospectus, to effect a reverse stock split of Frequency&#8217;s issued and outstanding common stock at a ratio ranging from any whole number between 1-for-&#160;&#160;&#160;&#160; and 1-for-&#160;&#160;&#160;&#160;, as determined by the Frequency board of directors in its discretion, subject to the Frequency board of directors&#8217; authority to abandon such amendment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To elect David L. Lucchino as a Class I director to hold office until the annual meeting of stockholders to be held in 2026 and until his respective successor has been duly elected and qualified; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To ratify, in a non-binding vote, the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the 2023 Stock Option and Incentive Plan, a copy of which is attached as <span style="font-style:italic">Annex&#160;I</span> to the accompanying proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">6.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the 2023 Employee Stock Purchase Plan, a copy of which is attached as <span style="font-style:italic">Annex&#160;J</span> to the accompanying proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">7.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To consider and vote upon an adjournment of the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">8.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To transact such other business as may properly come before the stockholders at the Frequency Annual Meeting or any adjournment or postponement thereof. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the accompanying proxy statement/prospectus, certain Frequency stockholders who in the aggregate owned approximately 3.5% of the outstanding shares of Frequency as of July&#160;14, 2023, and certain Korro Bio stockholders who in the aggregate owned approximately 98% of the outstanding shares of Korro Bio common stock as of July&#160;14, 2023, are parties to stockholder support agreements with Frequency and Korro Bio, respectively, whereby such stockholders have agreed to vote in favor of the approval of the transactions contemplated therein, including, with respect to such Korro Bio stockholders, adoption of the Merger Agreement and approval of the Merger and, with respect to such Frequency stockholders, the issuance of Frequency common stock in the Merger pursuant to the Merger Agreement, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form S-4 of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Korro Bio stockholders holding a sufficient number of shares of Korro Bio common stock to adopt the Merger Agreement and approve the Merger and related transactions will execute written consents providing for such adoption and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After careful consideration, each of the Frequency and Korro Bio boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the Merger. The Frequency board of directors has approved the proposals described in the accompanying proxy statement/prospectus and unanimously recommends that its stockholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the director nominee and &#8220;<span style="font-weight:bold">FOR</span>&#8221; the other proposals described in the accompanying proxy statement/prospectus. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:11pt; font-family:Times New Roman;font-weight:bold">More information about Frequency, Korro Bio, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. Frequency urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;<a href="#rom451428_22">RISK FACTORS</a>&#8221; BEGINNING ON PAGE 32 OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency and Korro Bio are excited about the opportunities the Merger brings to Frequency&#8217;s and Korro Bio&#8217;s stockholders and thank you for your consideration and continued support. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:2%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">David L. Lucchino <span style="font-style:italic"></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">President and Chief Executive Officer </span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Frequency Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Ram Aiyar</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">President and Chief Executive Officer </span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Korro Bio, Inc.</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying proxy statement/prospectus is dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023 and is first being mailed to Frequency stockholders on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FREQUENCY THERAPEUTICS, INC. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">75 HAYDEN AVENUE, SUITE 300 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">LEXINGTON, MA 02421 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(781) <span style="white-space:nowrap">315-4600</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders of Frequency Therapeutics, Inc., or Frequency: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOTICE IS HEREBY GIVEN</span> that the annual meeting of stockholders of Frequency, or the Frequency Annual Meeting, will be held on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,<span style="font-weight:bold"></span>&#160;2023, at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Eastern Time, unless postponed or adjourned to a later date. The Frequency Annual Meeting will be held entirely online. You will be able to attend and participate in the Frequency Annual Meeting online by visiting www.proxydocs.com/FREQ where you will be able to listen to the Frequency Annual Meeting live, submit questions and vote. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Frequency Annual Meeting will be held for the following purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the issuance of shares of common stock of Frequency to stockholders of Korro Bio, Inc., or Korro Bio, pursuant to the terms of the Agreement and Plan of Merger dated as of July&#160;14, 2023, by and among Frequency, Korro Bio, and Frequency Merger Sub, Inc., a direct, wholly owned subsidiary of Frequency, or Merger Sub, a copy of which is attached as <span style="font-style:italic">Annex A</span> to the accompanying proxy statement/prospectus, pursuant to which Merger Sub will merge with and into Korro Bio, with Korro Bio surviving as a wholly owned subsidiary of Frequency, and the surviving corporation of the merger, or the Merger, and the change of control resulting from the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve an amendment to the Restated Certificate of Incorporation of Frequency, a copy of which is attached as <span style="font-style:italic">Annex H</span> to the accompanying proxy statement/prospectus, to effect a reverse stock split of Frequency&#8217;s issued and outstanding common stock at a ratio ranging from any whole number between <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</span></span> as determined by the Frequency board of directors in its discretion subject to the Frequency board of directors&#8217; authority to abandon such amendment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To elect David L. Lucchino as a Class&#160;I director to hold office until the annual meeting of stockholders to be held in 2026 and until his respective successor has been duly elected and qualified; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To ratify, in a <span style="white-space:nowrap">non-binding</span> vote, the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the 2023 Stock Option and Incentive Plan a copy of which is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex I</span>. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">6.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the 2023 Employee Stock Purchase Plan a copy of which is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex J</span>. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">7.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To consider and vote upon an adjournment of the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos.&#160;1 and 2; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">8.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To transact such other business as may properly come before the stockholders at the Frequency Annual Meeting or any adjournment or postponement thereof. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%;vertical-align:top" align="left"><span style="font-weight:bold">Record&#160;Date:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency&#8217;s board of directors has fixed &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023 as the record date for the determination of stockholders entitled to notice of, and to vote at, the Frequency Annual Meeting and any adjournment or postponement thereof. Only holders of record of shares of Frequency common stock at the close of business on the record date are entitled to notice of, and to vote at, the Frequency Annual Meeting. At the close of business on the record date, Frequency had &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock outstanding and entitled to vote.<span style="font-weight:bold"> </span> </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Your vote is important. The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon, assuming a quorum is present, is required for approval of Proposal Nos.&#160;1, 4, 5, 6 and 7. The affirmative vote of the holders of a majority of the outstanding shares of Frequency common stock entitled to vote thereon is required for approval of Proposal No.&#160;2. The plurality of the votes cast by the holders of shares present in attendance or represented by proxy at the Frequency Annual Meeting and entitled to vote on the matter, assuming a quorum is present, is required for approval of Proposal No.&#160;3. Approval of Proposal No.&#160;1 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1 and 2. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Even if you plan to attend the Frequency Annual Meeting, Frequency requests that you sign, date and promptly return the enclosed proxy card or vote by mail or online to ensure that your shares will be represented at the Frequency Annual Meeting. You may change or revoke your proxy at any time before it is voted at the Frequency Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY&#8217;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO FREQUENCY AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. FREQUENCY&#8217;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT FREQUENCY STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of Frequency&#8217;s Board of Directors, </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David L. Lucchino </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">President and Chief Executive Officer </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexington, MA </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ABOUT THIS PROXY STATEMENT/PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document, which forms part of a registration statement on Form <span style="white-space:nowrap">S-4</span> filed with the U.S. Securities and Exchange Commission, or the SEC, by Frequency Therapeutics, Inc., or Frequency, constitutes a prospectus of Frequency under the Securities Act of 1933, as amended, or the Securities Act, with respect to the shares of common stock of Frequency to be issued (or reserved for issuance) to the securityholders of Korro Bio, Inc., or Korro Bio, pursuant to the Agreement and Plan of Merger dated as of July&#160;14, 2023, by and among Frequency, Korro Bio and Frequency Merger Sub, Inc., a direct, wholly owned subsidiary of Frequency, or Merger Sub, as it may be amended from time to time, or the Merger Agreement, pursuant to which Merger Sub will merge with and into Korro Bio, with Korro Bio surviving as a wholly owned subsidiary of Frequency, and the surviving corporation of the merger, or the Merger. This document also constitutes a proxy statement of Frequency under Section&#160;14(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. It also constitutes a notice of meeting with respect to the annual meeting of Frequency stockholders, or the Frequency Annual Meeting, at which Frequency stockholders will be asked to consider and vote, among other matters, on the issuance of the shares of Frequency common stock pursuant to the Merger Agreement and the change of control resulting from the Merger. Frequency following the Merger is referred to in this proxy statement/prospectus as the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency has supplied all information contained in this proxy statement/prospectus relating to Frequency. Korro Bio has supplied all information contained in this proxy statement/prospectus relating to Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this proxy statement/prospectus. Frequency and Korro Bio have not authorized anyone to provide you with information that is different from that contained in this proxy statement/prospectus. This proxy statement/prospectus is dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, and you should not assume that the information contained in this proxy statement/prospectus is accurate as of any date other than such date. Neither the mailing of this proxy statement/prospectus to Frequency stockholders nor the issuance by Frequency of shares of Frequency common stock pursuant to the Merger Agreement will create any implication to the contrary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except where otherwise noted, the information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split of Frequency&#8217;s issued and outstanding common stock at a ratio ranging from any whole number between <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;</span></span> as determined by the Frequency board of directors in its discretion, or the proposed Reverse Stock Split, described in the section titled &#8220;<span style="font-style:italic">Matters Being Submitted to a Vote of Frequency Stockholders &#8212; Proposal No. 2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split</span>&#8221; beginning on page 234 of this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency and Korro Bio have proprietary rights to trademarks, trade names and service marks appearing in this proxy statement/prospectus that are important to their respective businesses. Solely for convenience, the trademarks, trade names and service marks may appear in this proxy statement/prospectus without the <sup style="font-size:75%; vertical-align:top">&#174;</sup> and TM symbols, but any such references are not intended to indicate, in any way, that Frequency or Korro Bio forgo or will not assert, to the fullest extent under applicable law, their rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in this proxy statement/prospectus are the property of their respective owners. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:96%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_1">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_2">QUESTIONS AND ANSWERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_3">Questions and Answers About the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_4">Questions and Answers About the Frequency Annual Meeting and Voting</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_5">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_6">The Companies</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_7">The Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_8">Reasons for the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_9">Opinion of Frequency&#8217;s Financial Advisor</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_10">Interests of Certain Directors and Executive Officers of Frequency and Korro Bio</a></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_11">Management Following the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">26</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_12">Overview of the Merger Agreement and Agreements Related to the Merger Agreement</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_13">Material U.S. Federal Income Tax Consequences of the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_14">Nasdaq Stock Market Listing</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_15">Anticipated Accounting Treatment</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_16">Appraisal Rights and Dissenters&#8217; Rights</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_17">Comparison of Stockholder Rights</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_18">Risk Factors</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_20">MARKET PRICE AND DIVIDEND INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">31</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_21">Dividends</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_22">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">32</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_23">Risks Related to the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_24">Risks Related to the Proposed Reverse Stock Split</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_25">Risks Related to the Combined Company</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_26">Risks Related to Frequency&#8217;s Business</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_26a">Risks Related to Korro Bio&#8217;s Business </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_36">THE MERGER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">153</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_37">Background of the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_38">Frequency Reasons for the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_39">Korro Bio Reasons for the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_40a">Opinion of Frequency&#8217;s Financial Advisor</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_41">Financial Forecasts</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_42">Interests of Frequency Directors and Executive Officers in the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_45">Interests of Korro Bio Directors and Executive Officers in the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_300">Indemnification and Insurance for Directors and Officers </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_46">Effective Time of the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_47">Regulatory Approvals</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_48">Anticipated Accounting Treatment</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_49">Nasdaq Stock Market Listing</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_50">Appraisal Rights and Dissenters&#8217; Rights</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_51">THE MERGER AGREEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">190</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_52">Structure</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_53">Completion and Effectiveness of the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_54">Merger Consideration</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_54a">Allocation Certificate </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_301">Korro Merger Shares </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_302">Pre-Closing Financing Merger Shares </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_55">Calculation of Frequency&#8217;s Final Net Cash</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_303">Treatment of Korro Bio Warrants </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_56">Treatment of Korro Bio Options</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:96%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_57">Treatment of Frequency Common Stock, Frequency Options, Frequency Restricted Stock Units and Frequency Performance Stock Units</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_304">Frequency Employee Stock Purchase Plan </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_58">Procedures for Exchanging Korro Bio Stock Certificates</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_59">Directors and Officers of Frequency Following the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_60">Amendment of the Restated Certificate of Incorporation of Frequency</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_305">Potential Asset Sale </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_61">Representations and Warranties</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_62">Covenants; Conduct of Business Pending the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_63">Contingent Value Rights</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_64"><span style="white-space:nowrap">Non-Solicitation</span></a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_65">Board Recommendation Change</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_66">Meeting of Frequency&#8217;s Stockholders and Written Consent of Korro Bio&#8217;s Stockholders</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_67">Regulatory Approvals</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_68">Indemnification and Insurance for Directors and Officers</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_306">2023 Plan and 2023 ESPP </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_307">Frequency 401(k) Plan </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_69">Additional Agreements</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_70">Conditions to the Completion of the Merger</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_71">Termination and Termination Fees</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_72">Amendment and Waiver</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_73">Fees and Expenses</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_74">AGREEMENTS RELATED TO THE MERGER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">212</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_75">Support Agreements</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_76"><span style="white-space:nowrap">Lock-Up</span> Agreements</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_77">Contingent Value Rights Agreement</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_79">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">223</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_80">THE ANNUAL MEETING OF FREQUENCY STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">227</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_81">Date, Time and Place</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">227</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_82">Purposes of the Frequency Annual Meeting</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">227</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_83">Recommendation of the Frequency Board of Directors</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">227</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_84">Record Date and Voting Power</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_85">Voting and Revocation of Proxies</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_86">Required Vote</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_87">Solicitation of Proxies</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_88">Other Matters</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_89">MATTERS BEING SUBMITTED TO A VOTE OF FREQUENCY STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">233</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_90">PROPOSAL NO. 1: APPROVAL OF THE ISSUANCE OF COMMON STOCK IN THE MERGER AND THE CHANGE OF CONTROL RESULTING FROM THE MERGER</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_91">PROPOSAL NO. 2: APPROVAL OF THE AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF FREQUENCY EFFECTING THE REVERSE STOCK SPLIT</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_93">PROPOSAL NO. 3: TO ELECT DAVID L. LUCCHINO AS A CLASS I DIRECTOR</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_94">PROPOSAL NO. 4: TO RATIFY, IN A <span style="white-space:nowrap">NON-BINDING</span> VOTE, THE APPOINTMENT OF RSM US LLP AS FREQUENCY&#8217;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR DECEMBER&#160;31, 2023</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_95">PROPOSAL NO. 5: APPROVAL OF 2023 STOCK OPTION AND INCENTIVE PLAN</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_96">PROPOSAL NO. 6: APPROVAL OF 2023 EMPLOYEE STOCK PURCHASE PLAN</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_98">PROPOSAL NO. 7: APPROVAL OF ADJOURNMENT OF THE FREQUENCY ANNUAL MEETING</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_99">FREQUENCY&#8217;S BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">264</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_100">Overview</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_104">Frequency&#8217;s multiple sclerosis (MS) program</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_107">Intellectual property</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:96%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_109">Competition</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_110">Government regulation</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_111">Foreign regulation</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_112">Coverage and reimbursement</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_113">Healthcare reform</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_114">Data privacy and security laws</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_115">Cybersecurity</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_116">Environmental, Social, and Governance Initiatives</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_117">Frequency&#8217;s Corporate Information</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_118">KORRO BIO&#8217;S BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">282</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_501"><span style="font-style:italic">Overview</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_508"><span style="font-style:italic">Korro Bio&#8217;s Team</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_308">Korro Bio&#8217;s Strategy </a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_509"><span style="font-style:italic">Expanding the Frontiers of Genetic Medicines: RNA Editing</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_510"><span style="font-style:italic">ADAR-mediated RNA editing</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_511"><span style="font-style:italic">Key advantages of Oligonucleotide-based ADAR-mediated RNA editing as a therapeutic modality</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_512"><span style="font-style:italic">Korro Bio&#8217;s OPERA &#8211; Oligonucleotide Promoted Editing of RNA &#8211; Platform</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_513"><span style="font-style:italic">Korro Bio&#8217;s Pipeline Demonstrates the Versatility of the OPERA Platform</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_514"><span style="font-style:italic">Korro Bio&#8217;s AATD Program: RNA Editing to Repair Pathogenic Missense Variant</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_515"><span style="font-style:italic">Korro Bio&#8217;s Parkinson&#8217;s Disease Program: Repairing Pathogenic Variants</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_516"><span style="font-style:italic">Korro Bio&#8217;s Severe Alcoholic-Associated Hepatitis Program: Disrupting Protein-Protein Interactions</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_517"><span style="font-style:italic">Korro Bio&#8217;s Amyotrophic Lateral Sclerosis Program: Disrupting Protein Aggregation</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_518"><span style="font-style:italic">Korro Bio&#8217;s Pain Program: Selective Modulation of Ion Channels</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_519"><span style="font-style:italic">Korro Bio&#8217;s Cardiometabolic Disease Program: Activating Kinases</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_520"><span style="font-style:italic">Pioneering RNA Editing to Deliver the Future of Medicine</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_521"><span style="font-style:italic">Manufacturing</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_522"><span style="font-style:italic">Competition</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_524"><span style="font-style:italic">Intellectual Property</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">312</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_525"><span style="font-style:italic">Governmental Regulation</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_526"><span style="font-style:italic">Employees and Human Capital Resources</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_527"><span style="font-style:italic">Facilities</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_528"><span style="font-style:italic">Legal Proceedings</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_119">FREQUENCY MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">331</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_120">Overview</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_122">License and collaboration agreements</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_123">Components of Frequency&#8217;s results of operations</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_124">Results of operations</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_125">Liquidity and capital resources</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_126">Critical accounting policies and use of estimates</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_127">Recent accounting pronouncements</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_128">Emerging growth company status</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_121">Frequency&#8217;s quantitative and qualitative disclosures about market risk</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_129">KORRO BIO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">345</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_130">Overview</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_131">Recent Developments</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_132">Financial Operations Overview</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_133">Results of Operations</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_134">Liquidity and Capital Resources</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">352</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_135">Critical Accounting Policies and Estimates</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iv </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:96%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_136"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><a href="#rom451428_137">Recent Accounting Pronouncements</a></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_50a">MANAGEMENT FOLLOWING THE MERGER </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">357</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_19">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">362</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_139">FREQUENCY DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">374</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_141">FREQUENCY EXECUTIVE AND DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">382</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_142">KORRO BIO EXECUTIVE AND DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">391</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_143">CERTAIN RELATED PERSON TRANSACTIONS OF FREQUENCY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">397</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_144">CERTAIN RELATED PERSON TRANSACTIONS OF THE COMBINED COMPANY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">400</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_145">FREQUENCY&#8217;S DESCRIPTION OF CAPITAL STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">404</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_146">COMPARISON OF RIGHTS OF HOLDERS OF FREQUENCY CAPITAL STOCK AND KORRO BIO CAPITAL STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">408</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_147">PRINCIPAL STOCKHOLDERS OF FREQUENCY </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">418</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_148">PRINCIPAL STOCKHOLDERS OF KORRO BIO</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">420</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_149">PRINCIPAL STOCKHOLDERS OF COMBINED COMPANY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">423</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_150">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">426</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_151">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">426</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_152">OTHER MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">427</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#rom451428_153">INDEX TO FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"><span style="white-space:nowrap">F-1</span></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_154"><span style="font-weight:bold">Annex A</span>&#8212;Agreement and Plan of Merger <span style="font-weight:bold"></span></a><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_155"><span style="font-weight:bold">Annex B</span>&#8212;Opinion of Cowen and Company, LLC </a> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_156"><span style="font-weight:bold">Annex C</span>&#8212;Form of Frequency Stockholder Support Agreement <span style="font-weight:bold"></span></a><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_157"><span style="font-weight:bold">Annex D</span>&#8212;Form of Korro Bio Stockholder Support Agreement <span style="font-weight:bold"></span></a><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_158"><span style="font-weight:bold">Annex E</span>&#8212;Form of Contingent Value Rights Agreement <span style="font-weight:bold"></span></a><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_159"><span style="font-weight:bold">Annex F</span>&#8212;Form of Frequency <span style="white-space:nowrap">Lock-Up</span> Agreement <span style="font-weight:bold"></span></a><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_160"><span style="font-weight:bold">Annex G</span>&#8212;Form of Korro Bio <span style="white-space:nowrap">Lock-Up</span> Agreement <span style="font-weight:bold"></span></a><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_161"><span style="font-weight:bold">Annex H</span>&#8212;Certificate of Amendment Effecting the Reverse Stock Split </a> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_162"><span style="font-weight:bold">Annex I</span>&#8212;2023 Stock Option and Incentive Plan </a> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_163"><span style="font-weight:bold">Annex J</span>&#8212;2023 Employee Stock Purchase Plan </a> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><a href="#rom451428_164"><span style="font-weight:bold">Annex K</span>&#8212;Appraisal Rights (Section 262 of the Delaware General Corporation Law) </a> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">v </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_1">CAUTIONARY STATEMENT CONCERNING <span style="white-space:nowrap">FORWARD-LOOKING</span> STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus contains <span style="white-space:nowrap">forward-looking</span> statements relating to Frequency, Korro Bio, the Merger, the combined company, and the other proposed transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These <span style="white-space:nowrap">forward-looking</span> statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. These <span style="white-space:nowrap">forward-looking</span> statements should not be relied upon as predictions of future events as Frequency and Korro Bio cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. You can identify <span style="white-space:nowrap">forward-looking</span> statements by the use of <span style="white-space:nowrap">forward-looking</span> terminology including &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro forma,&#8221; &#8220;estimates&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of these words and phrases or comparable terminology. All statements other than statements of historical fact are statements that could be deemed <span style="white-space:nowrap">forward-looking</span> statements. <span style="white-space:nowrap">Forward-looking</span> statements include, but are not limited to, any statements regarding the strategies, prospects, plans, expectations or objectives of management of Frequency or Korro Bio for future operations of the combined company, the progress, scope or timing of the development of the combined company&#8217;s product candidates, the benefits that may be derived from any future products or the commercial or market opportunity with respect to any future products of the combined company, the ability of the combined company to protect its intellectual property rights, the anticipated operations, financial position, ability to raise capital to fund operations, revenues, costs or expenses of Frequency, Korro Bio or the combined company, statements regarding future economic conditions or performance, statements of belief and any statement of assumptions underlying any of the foregoing. <span style="white-space:nowrap">Forward-looking</span> statements may also include any statements regarding the approval and closing of the Merger, including the timing of the consummation of the Merger, Frequency&#8217;s ability to solicit a sufficient number of proxies to approve the Merger, satisfaction of conditions to the completion of the Merger, the expected benefits of the Merger, the ability of Frequency and Korro Bio to complete the Merger and any statement of assumptions underlying any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the factors that may cause Frequency, Korro Bio or the combined company&#8217;s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such <span style="white-space:nowrap">forward-looking</span> statements, or for a discussion of risks associated with the ability of Frequency and Korro Bio to complete the Merger and the effect of the Merger on the business of Frequency, Korro Bio and the combined company, see the section&#160;titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 32 of this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of Frequency, Korro Bio or the combined company could differ materially from the <span style="white-space:nowrap">forward-looking</span> statements. All <span style="white-space:nowrap">forward-looking</span> statements in this proxy statement/prospectus are current only as of the date of this proxy statement/prospectus. Frequency and Korro Bio do not undertake any obligation to (and expressly disclaim any such obligation to) publicly update any <span style="white-space:nowrap">forward-looking</span> statement to reflect events or circumstances after the date of this proxy statement/prospectus or to reflect the occurrence of unanticipated events. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_2">QUESTIONS AND ANSWERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following section provides answers to frequently asked questions about the Merger, general information about the Frequency Annual Meeting and voting. For some questions, this section provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_3">Questions and Answers About the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What is the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> Frequency and Korro Bio have entered into the Merger Agreement, dated as of July&#160;14, 2023, a copy of which is attached as <span style="font-style:italic">Annex A</span> to this proxy statement/prospectus. The Merger Agreement contains the terms and conditions of the proposed business combination of Frequency and Korro Bio. Pursuant to the Merger Agreement, Merger Sub, a direct, wholly owned subsidiary of Frequency, will merge with and into Korro Bio, with Korro Bio surviving as a wholly owned subsidiary of Frequency and the surviving corporation. In connection with the Merger, Frequency will change its corporate name to &#8220;Korro Bio, Inc.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Effective Time, each share of Korro Bio common stock will be converted into the right to receive a number of shares of Frequency common stock equal to the total number of shares of Frequency common stock to be issued in the Merger multiplied by the applicable Korro Bio stockholder&#8217;s percentage interest in Korro Bio as set forth in the Allocation Certificate, and as described in more detail in the section&#160;titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;</span><span style="font-style:italic">Allocation Certificate</span>&#8221; beginning on page 191 of the accompanying proxy statement/prospectus. If any Korro Bio common stock outstanding immediately prior to the Effective Time is unvested or is subject to a repurchase option or a risk of forfeiture under any applicable agreement with Korro Bio, then the shares of Frequency common stock issued in exchange for such shares of Korro Bio common stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency common stock will be marked with appropriate legends. Each option to purchase shares of Korro Bio common stock outstanding as of immediately prior to the Effective Time shall automatically be converted, at the Effective Time, into an option to acquire, on the same terms and conditions (including the same vesting and exercisability terms and conditions), the number of shares of Frequency common stock equal to the number of shares of Korro Bio common stock subject to such option as of immediately prior to the Effective Time multiplied by the exchange ratio formula in the Merger Agreement and rounding that result down to the nearest whole number of shares, as described in more detail in the sections titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic"></span><span style="font-style:italic"></span><span style="font-style:italic">Treatment of Korro Bio Warrants</span>&#8221; and &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Treatment of Korro Bio Options</span>&#8221; beginning on page&#160;194 of this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding Frequency Option will remain outstanding and such options, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan or 2014 Stock Incentive Plan, as applicable, to reflect the Reverse Stock Split and the issuance of the CVRs, will be unaffected by the Merger, provided that each such Frequency Option that is unvested will vest in full immediately prior to the Effective Time. Each restricted stock unit award covering shares of Frequency common stock that is outstanding will remain outstanding and such restricted stock unit awards, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan to reflect the Reverse Stock Split and issuance of the CVRs, will be unaffected by the Merger, provided that each restricted stock unit award that vests solely based on the holder&#8217;s continued employment or service will vest in full immediately prior to the Effective Time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Why are the two companies proposing to combine? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> Frequency and Korro Bio believe that combining the two companies will result in a company with a robust pipeline, strong leadership team and substantial capital resources, positioning it to become a leading company researching, developing and commercializing therapies for diseases. For a more complete description of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasons for the Merger, please see the sections titled &#8220;<span style="font-style:italic">The Merger&#8212;Frequency Reasons for the Merger</span>&#8221; and &#8220;<span style="font-style:italic">The Merger&#8212;Korro Bio Reasons for the Merger</span>&#8221; beginning on pages 165 and 169, respectively, of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What will Korro Bio stockholders and optionholders receive in the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>Korro Bio stockholders will receive shares of Frequency common stock, and Korro Bio optionholders will receive options to purchase Frequency common stock. The Korro Bio securityholders as of immediately before the Merger (including purchasers in the Pre-Closing Financing) are expected to own approximately 92% of the aggregate number of shares of the combined company&#8217;s common stock on a fully-diluted basis, and Frequency securityholders immediately before the Merger are expected to own approximately 8% of the aggregate number of shares of the combined company common stock on a fully-diluted basis, in each case subject to certain assumptions, including, but not limited to, Frequency&#8217;s net cash as of closing being equal to $25&#160;million. If any Korro Bio common stock outstanding immediately prior to the Effective Time is unvested or is subject to a repurchase option or a risk of forfeiture under any applicable agreement with Korro Bio, then the shares of Frequency common stock issued in exchange for such shares of Korro Bio common stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency common stock will be marked with appropriate legends. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger, each option to purchase shares of Korro Bio common stock outstanding as of immediately prior to the Effective Time shall automatically be converted, at the Effective Time, into an option to acquire, on the same terms and conditions (including the same vesting and exercisability terms and conditions), the number of shares of Frequency common stock equal to the number of shares of Korro Bio common stock subject to such option as of immediately prior to the Effective Time multiplied by the exchange ratio formula in the Merger Agreement and rounding that result down to the nearest whole number of shares, and will be eligible to be registered on Form <span style="white-space:nowrap">S-8.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a more complete description of what Korro Bio stockholders and optionholders will receive in the Merger, please see the sections titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Merger Consideration</span>,&#8221; &#8220;<span style="font-style:italic">The Merger Agreement&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">Treatment of Korro Bio Warrants</span>&#8221; and &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Treatment of Korro Bio Options</span>&#8221; beginning on pages 190, and 194, respectively, of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Will the common stock of the combined company trade on an exchange? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>Shares of Frequency common stock are currently listed on The Nasdaq Global Select Market, or Nasdaq, under the symbol &#8220;FREQ.&#8221; Frequency intends to file an initial listing application for the combined company with the Nasdaq Stock Market LLC. After completion of the Merger, Frequency will be renamed &#8220;Korro Bio, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;KRRO.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Who will be the directors of the combined company following the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>Immediately following the Merger, the combined company&#8217;s board of directors will be composed of seven members, consisting of (i)&#160;four current Korro Bio board members, namely Ram Aiyar, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, (ii)&#160;two members to be determined by mutual agreement of the Frequency board designee and the Korro Bio board designees, namely &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, each of whom shall meet Nasdaq&#8217;s independence requirements, and (iii)&#160;one current Frequency board member, namely David L. Lucchino. The staggered structure of the Frequency board of directors will remain in place for the combined company following the completion of the Merger. The Frequency board of directors has determined that each of the directors other than Ram Aiyar and David&#160;L. Lucchino meet the Nasdaq independence requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is anticipated the director classes of the combined company board of directors will be as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;I directors (term ending 2026): &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;II directors (term ending 2024): &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;III directors (term ending 2025): &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Who will be the executive officers of the combined company immediately following the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> Immediately following the Merger, the executive management team of the combined company is expected to consist of members of the Korro Bio executive management team prior to the Merger, including: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:22%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:77%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Title</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Ram Aiyar</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Steve Colletti</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Chief Scientific Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Vineet Agarwal</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Todd Chappell</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Senior Vice President, Strategy and Portfolio Planning</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Shelby Walker</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">General Counsel</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;When do you expect the Merger to be consummated? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>The Merger is anticipated to close in the fourth quarter of 2023, but the exact timing cannot be predicted. For more information, please see the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Conditions to the Completion of the Merger</span>&#8221; beginning on page 207 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;As a Frequency stockholder, how does Frequency&#8217;s board of directors recommend that I vote? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> After careful consideration, Frequency&#8217;s board of directors unanimously recommends that Frequency stockholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the director nominee and &#8220;<span style="font-weight:bold">FOR</span>&#8221; all of the proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What risks should I consider in deciding whether to vote in favor of the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>You should carefully review the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 32 of this proxy statement/prospectus, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks and uncertainties to which each of Frequency and Korro Bio, as independent companies, are subject. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What are the CVRs being issued to Frequency stockholders? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> Prior to the Effective Time, unless (i)&#160;the disposition of any of Frequency&#8217;s assets related to its multiple sclerosis program, or the MS Asset Disposition, has been consummated prior to or on the closing date of the Merger and (ii)&#160;all proceeds from the MS Asset Disposition are taken into account in the final Frequency Net Cash and there are no contingent payments, licenses, fees or royalties, equity securities or other non-cash assets or rights that may be payable by any acquiror of any of Frequency&#8217;s assets related to its multiple sclerosis program, or MS Assets, or otherwise as a result of the MS Asset Disposition after the closing of the Merger, Frequency and Computershare Trust Company, N.A. and Computershare Inc., collectively as the Rights Agent, as rights agent, will enter into a Contingent Value Rights Agreement, or the CVR Agreement, pursuant to which Frequency stockholders of record as of the close of business on the last business day prior to the day on which the Effective Time occurs will receive one CVR for each outstanding share of Frequency common stock held by such stockholder on such date. A copy of the form of CVR Agreement is included as <span style="font-style:italic">Annex&#160;E</span> to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CVRs represent the contractual right to receive payments from Frequency upon the actual receipt by Frequency or its subsidiaries of cash consideration that is paid to or received by Frequency or its subsidiaries as a result of any MS Asset Disposition or revenue received from the license of its MS Assets, or as a result of Frequency&#8217;s equity ownership in any subsidiary that is established to hold such assets or the subsequent disposition of any such equity securities, or, collectively, the CVR Milestones, net of certain income taxes required to be paid in cash, transaction costs and certain other expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no CVR Milestones occur, holders </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any CVR Milestones will be achieved or that any holders of CVRs will receive payments with respect thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Frequency or the combined company or any of its subsidiaries. No interest will accrue on any amounts payable in respect of the CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a more detailed description of the CVRs and the CVR Agreement, see &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Contingent Value Rights Agreement</span>&#8221; beginning on page&#160;214 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What are the material U.S. federal income tax consequences of the issuance of the CVRs and of the receipt of payments on the CVRs (if any) to holders of Frequency common stock? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> The U.S. federal income tax treatment of the CVRs and payments (if any) thereon is uncertain. Except to the extent otherwise required pursuant to a change in applicable law after the date of the CVR Agreement, neither Frequency nor the Rights Agent will report the issuance of the CVRs as a current distribution and will report each payment (if any) on the CVRs as a distribution by Frequency for U.S. federal income tax purposes. This position may be challenged by the Internal Revenue Service, or the IRS, in which case holders of Frequency common stock could be required to recognize taxable income in respect of the issuance of the CVRs without a corresponding receipt of cash. See the section titled &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Contingent Value Rights Agreement&#8212;Material U.S. Federal Income Tax Consequences of the CVRs to Holders of Frequency Common Stock</span>&#8221; beginning on page&#160;218 for a discussion of the material U.S. federal income tax consequences of the issuance of the CVRs and the receipt of payments (if any) thereon to holders of Frequency common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What are the material U.S. federal income tax consequences of the Merger to holders of Korro Bio common stock? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> Frequency and Korro Bio intend the Merger to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended, or the Code. Assuming the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, subject to the limitations and qualifications described in the section titled &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 223, holders of Korro Bio common stock that exchange their Korro Bio stock for Frequency common stock in the Merger generally should not recognize gain or loss for U.S. federal income tax purposes on such exchange. However, if the Merger does not qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of&#160;the Code, the Merger would be a taxable transaction to U.S. Holders (as defined in the section titled &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221;), but <span style="white-space:nowrap">Non-U.S.</span> Holders (as defined in the section titled &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221;) generally would not be subject to U.S. federal income tax on any gain realized in connection with the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the Merger is not conditioned upon the receipt of an opinion of counsel or a ruling from the IRS regarding the U.S. federal income tax treatment of the Merger, and no opinion of counsel or ruling from the IRS will be requested regarding such treatment. Accordingly, there can be no assurance that the IRS will not challenge the qualification of the Merger as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code or that a court will not sustain such a challenge by the IRS. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax consequences to you of the Merger will depend on your particular facts and circumstances. Please consult your tax advisor as to the tax consequences of the Merger in your particular circumstances, including the applicability and effect of U.S. federal, state, local and foreign income and other tax laws. For a more detailed discussion of the material U.S. federal income tax consequences of the Merger, see &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page&#160;223. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_4">Questions and Answers About the Frequency Annual Meeting and Voting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Who is entitled to vote at the Frequency Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>Holders of record of shares of Frequency common stock as of the close of business on &#160;&#160;&#160;&#160;, 2023, or the Record Date, are entitled to notice of and to vote at the Frequency Annual Meeting and any continuation, postponement or adjournment thereof. At the close of business on the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of Frequency common stock issued and outstanding and entitled to vote. Each share of Frequency common stock is entitled to one vote on any matter presented to stockholders at the Frequency Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;How do I attend the Frequency Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> The Frequency Annual Meeting will be held on &#160;&#160;&#160;&#160; , 2023 at &#160;&#160;&#160;&#160;&#160;a.m. &#160;&#160;&#160;&#160;&#160;Eastern Time via a live webcast. Prior registration at www.proxydocs.com/FREQ to attend the Frequency Annual Meeting is required by &#160;&#160;&#160;&#160;&#160;a.m. Eastern Time on &#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;2023, or the Registration Deadline. You will need the control number that appears on your proxy card, or the Control Number, to register to attend the meeting. If your shares are held in &#8220;street name&#8221;, you should use your Control Number provided on your notice or voting instruction form, or otherwise vote through the bank, broker or other nominee. The meeting webcast will begin promptly at a.m. Eastern Time. We encourage you to access the meeting prior to the start time. We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting website by calling the technical support number provided by email one hour prior to the Frequency Annual Meeting. After completion of your registration by the Registration Deadline, further instructions, including a unique link to access the Frequency Annual Meeting, will be emailed to you. For any questions on how to register for the Frequency Annual Meeting, please contact our General Counsel, James P. Abely, at (781) <span style="white-space:nowrap">315-4623</span> or jabely@frequencytx.com. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What proposals will be voted on at the Frequency Annual Meeting in connection with the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> Pursuant to the terms of the Merger Agreement, Proposal No.&#160;1 to approve the issuance of shares of common stock of Frequency to stockholders of Korro Bio, pursuant to the terms of the Merger Agreement and the change of control resulting from the Merger must be approved by the requisite stockholder vote at the Frequency Annual Meeting in order for the Merger to close. Proposal No.&#160;1 is referred to in this proxy statement/prospectus as the Merger Proposal. Approval of the Merger Proposal is a condition to completion of the Merger. Therefore, the Merger cannot be consummated without the approval of the Merger Proposal and Proposal No. 2. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived for the Merger to close. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Conditions to the Completion of the Merger</span>&#8221; beginning on page 207 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What proposals are to be voted on at the Frequency Annual Meeting, other than in connection with the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> At the Frequency Annual Meeting, the holders of Frequency common stock will also be asked to consider the following proposals: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Proposal No.&#160;3 to elect David L. Lucchino as a Class&#160;I director to hold office until the annual meeting of stockholders to be held in 2026 and until his respective successor has been duly elected and qualified; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Proposal No.&#160;4 to ratify, in a <span style="white-space:nowrap">non-binding</span> vote, the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Proposal No.&#160;5 to approve the 2023 Stock Option and Incentive Plan; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Proposal No.&#160;6 to approve the 2023 Employee Stock Purchase Plan; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Proposal No.<span style="font-weight:bold"></span>&#160;7 to consider and vote upon an adjournment of the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Merger Proposal and Proposal No. 2. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of Proposal Nos. 3, 4, 5, 6 and 7. are not a condition to the Merger closing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What are the material U.S. federal income tax consequences of the proposed Reverse Stock Split to U.S. Holders of Frequency common stock? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> A U.S. Holder (as defined in the section titled &#8220;<span style="font-style:italic">Matters Being Submitted to a Vote of Frequency Stockholders&#8212;Proposal No. 2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split&#8212;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split to U.S. Holders of Frequency Common Stock</span>&#8221; beginning on page 242) of Frequency common stock generally should not recognize gain or loss upon the proposed Reverse Stock Split, except to the extent such holder receives cash in lieu of a fractional share of Frequency common stock, and subject to the discussion in the section titled &#8220;<span style="font-style:italic">Matters Being Submitted to a Vote of Frequency Stockholders&#8212;</span><span style="font-style:italic">Proposal </span><span style="font-style:italic">No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split&#8212;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split to U.S. Holders of Frequency Common Stock</span>&#8221; beginning on page&#160;242, which provides a more complete description of the material U.S. federal income tax consequences of the Reverse Stock Split to U.S. Holders of Frequency common stock, including possible alternative treatments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;As a Frequency stockholder, how does Frequency&#8217;s board of directors recommend that I vote? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> After careful consideration, Frequency&#8217;s board of directors unanimously recommends that Frequency stockholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the director nominee and &#8220;<span style="font-weight:bold">FOR</span>&#8221; all of the proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;How do I vote my shares? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>We recommend that stockholders vote by proxy even if they plan to attend the Frequency Annual Meeting and vote electronically. If you are a stockholder of record, there are three ways to vote by proxy: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by Telephone&#8212;You can vote by telephone by calling <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">1-866-390-5362</span></span></span> and following the instructions on the proxy card; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by Internet&#8212;You can vote over the Internet at www.proxypush.com/FREQ by following the instructions on the proxy card; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by Mail&#8212;You can vote by mail by signing, dating and mailing the proxy card, which you may have received by mail. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone and Internet voting facilities for stockholders of record will be available 24 hours a day and will close at 11:59 p.m. Eastern Time on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#8220;street name&#8221; by a bank, broker or other nominee, you will receive instructions on how to vote from the bank, broker or other nominee. You must follow the instructions of such bank, broker or other nominee in order for your shares to be voted. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;How can I vote my shares at the Frequency Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> If you have registered to attend the Frequency Annual Meeting, you may vote at the Frequency Annual Meeting through www.proxydocs.com/FREQ. To be admitted to the Frequency Annual Meeting and vote your shares, you must register by the Registration Deadline and provide the Control Number. Even if you plan to attend the Frequency Annual Meeting, we encourage you to vote in advance by Internet, telephone or mail so that your vote will be counted even if you later decide not to attend the Frequency Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What is the difference between being a &#8220;record holder&#8221; and holding shares in &#8220;street name&#8221;? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> A record holder (also called a &#8220;registered holder&#8221;) holds shares in his or her name. Shares held in &#8220;street name&#8221; means that shares are held in the name of a bank, broker or other nominee on the holder&#8217;s behalf. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What do I do if my shares are held in &#8220;street name&#8221;? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> If your shares are held in a brokerage account or by a bank or other holder of record, you are considered the &#8220;beneficial owner&#8221; of shares held in &#8220;street name.&#8221; This proxy statement/prospectus has been forwarded to you by your broker, bank or other nominee who is considered, with respect to those shares, the stockholder of record. As the beneficial owner, you have the right to direct your broker, bank or nominee on how to vote your shares by following their instructions for voting. Please refer to the information from your bank, broker or other nominee on how to submit your voting instructions. In addition, if you are a &#8220;street name&#8221; stockholder, you are invited to attend and vote your shares at the Frequency Annual Meeting live via webcast so long as you register to attend the Frequency Annual Meeting at www.proxydocs.com/FREQ by the Registration Deadline and have requested a legal proxy from your broker, bank, or nominee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What are broker <span style="white-space:nowrap">non-votes?</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>A &#8220;broker <span style="white-space:nowrap">non-vote&#8221;</span> occurs when shares held by a broker in &#8220;street name&#8221; for a beneficial owner are not voted with respect to a proposal because (1)&#160;the broker has not received voting instructions from the stockholder who beneficially owns the shares and (2)&#160;the broker lacks the authority to vote the shares at their discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under current NYSE interpretations that govern broker <span style="white-space:nowrap">non-votes,</span> the Merger Proposal, Proposal No.&#160;3 for the election of directors, Proposal No. 5 to approve the 2023 Stock Option and Incentive Plan, Proposal No. 6 to approve the 2023 Employee Stock Purchase Plan and Proposal No.&#160;7 to adjourn the meeting to seek additional proxies are considered a <span style="white-space:nowrap">non-discretionary</span> matter, and a broker does not have the authority to vote uninstructed shares at its discretion on such proposals. Proposal No. 2 to amend Frequency&#8217;s Restated Certificate of Incorporation to effect a reverse stock split of Frequency common stock and Proposal No.&#160;4 for the ratification of the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm are considered discretionary matters, and a broker is permitted to exercise its discretion to vote uninstructed shares on the proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;How many shares must be present to hold the Frequency Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A</span>: A quorum must be present at the Frequency Annual Meeting for any business to be conducted. The holders of a majority in voting power of Frequency capital stock issued and outstanding and entitled to vote, present by remote communication or represented by proxy, constitutes a quorum. If you sign and return your paper proxy card or authorize a proxy to vote electronically or telephonically, your shares will be counted to determine whether there is a quorum even if you abstain or fail to vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker <span style="white-space:nowrap">non-votes</span> will also be considered present for the purpose of determining whether there is a quorum for the Frequency Annual Meeting. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What if a quorum is not present at the Frequency Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>If a quorum is not present or represented at the scheduled time of the Frequency Annual Meeting, (i)&#160;the chairperson of the Frequency Annual Meeting or (ii)&#160;a majority in voting power of the stockholders entitled to vote at the Frequency Annual Meeting, present by remote communication or represented by proxy, may adjourn the Frequency Annual Meeting until a quorum is present or represented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;How many votes are required to approve each proposal? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>The table below summarizes the proposals that will be voted on, the vote required to approve each item and how votes are counted:<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:20%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Proposal</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Votes&#160;Required</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Voting Options</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Impact of<br />&#8220;Withhold&#8221;<br />or<br />&#8220;Abstain&#8221;<br />Votes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Broker<br />Discretionary<br />Voting</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Allowed</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;1: Approval of the Issuance of Common Stock in the Merger and the Change of Control Resulting from the Merger</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">No<sup style="font-size:75%; vertical-align:top">(3)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The affirmative vote of the holders of a majority of the outstanding shares of Frequency common stock entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Have the same effect as votes &#8220;AGAINST&#8221; Proposal No. 2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Yes<sup style="font-size:75%; vertical-align:top">(4)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;3: Election of David L. Lucchino as a Class&#160;I Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The plurality of the votes cast by the holders of shares present in attendance or represented by proxy at the Frequency Annual Meeting and entitled to vote on the matter.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;FOR ALL&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;WITHHOLD&#160;ALL&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8220;FOR&#160;ALL&#160;EXCEPT&#8221;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(2)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">No<sup style="font-size:75%; vertical-align:top">(3)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;4: Ratification of Appointment of Independent Registered Public Accounting Firm</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Yes<sup style="font-size:75%; vertical-align:top">(4)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;5: Approval of the 2023 Stock Option and Incentive Plan</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">No<sup style="font-size:75%; vertical-align:top">(3)</sup></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:20%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;6: Approval of the 2023 Employee Stock Purchase Plan</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">No<sup style="font-size:75%; vertical-align:top">(3)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;7: Approval of Adjournment of the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals&#160;Nos. 1 and 2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Yes<sup style="font-size:75%; vertical-align:top">(4)</sup></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A vote marked as an &#8220;Abstention&#8221; is not considered a vote cast and will, therefore, not affect the outcome of this proposal. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Votes that are &#8220;withheld&#8221; will have the same effect as an abstention and will not count as a vote &#8220;FOR&#8221; or &#8220;AGAINST&#8221; a director, because directors are elected by plurality voting. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As this proposal is not considered a discretionary matter, brokers lack authority to exercise their discretion to vote uninstructed shares on this proposal. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As this proposal is considered a discretionary matter, brokers are permitted to exercise their discretion to vote uninstructed shares on this proposal. We do not expect any broker non-votes in connection with this proposal. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors and certain executive officers of Frequency have entered into stockholder support agreements pursuant to which they have agreed to vote all shares of Frequency common stock owned by them as of the Record Date in favor of Proposal Nos.&#160;1 and 2 and against any competing &#8220;acquisition proposal&#8221; (as defined in the support agreements). As of the Record Date, the directors and certain executive officers of Frequency owned or controlled &#160;&#160;&#160;&#160;% of the outstanding shares of Frequency common stock entitled to vote at the Frequency Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What happens if I do not vote or submit a proxy but do not provide voting instructions? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>Failure to vote will have the same effect as a vote &#8220;AGAINST&#8221; Proposal No.&#160;2 and no effect on Proposal Nos.&#160;1, 3, 4, 5, 6 and 7. If you submit a proxy but do not provide any voting instructions, the persons named as proxies will vote in accordance with the recommendations of the Frequency board of directors. The Frequency board of director&#8217;s recommendations are set forth above, as well as with the description of each proposal in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Can I revoke or change my vote after I submit my proxy? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A: </span>Yes. Whether you have voted by Internet, telephone or mail, if you are a stockholder of record, you may change your vote and revoke your proxy by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sending a written statement to that effect to the attention of our Secretary at our corporate offices at 75 Hayden Avenue, Lexington, MA 02421, provided such statement is received no later than &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">voting again by Internet or telephone at a later time before the closing of those voting facilities at 11:59&#160;p.m. Eastern Time on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submitting a properly signed proxy card with a later date that is received no later than &#160;&#160;&#160;&#160;, 2023; or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attending the Frequency Annual Meeting, revoking your proxy and voting electronically, provided you have registered for the meeting by the Registration Deadline. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold shares in &#8220;street name&#8221;, you may submit new voting instructions by contacting your bank, broker or other nominee. If you are a &#8220;street name&#8221; stockholder, you are invited to attend and vote your shares at the Frequency Annual Meeting live via webcast so long as you register to attend the Frequency Annual Meeting at www.proxydocs.com/FREQ by the Registration Deadline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your most recent proxy card or telephone or Internet proxy is the one that is counted. Your attendance at the Frequency Annual Meeting by itself will not revoke your proxy unless you give written notice of revocation to Frequency before your proxy is voted or you vote electronically at the Frequency Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Who counts the votes? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> A representative of Mediant Communications Inc. has been engaged as Frequency&#8217;s independent agent to tabulate stockholder votes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Who is paying for this proxy solicitation? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> Frequency will pay the cost of printing and filing of this proxy statement/prospectus and the proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Frequency common stock for the forwarding of solicitation materials to the beneficial owners of Frequency common stock. Frequency will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses they incur in connection with the forwarding of solicitation materials. Frequency has retained Morrow Sodali LLC, or Morrow Sodali, to assist it in soliciting proxies. Frequency will pay the fees of Morrow Sodali, which Frequency expects to be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, plus reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: &#160;&#160;&#160;&#160;How can I find out the results of the voting at the Frequency Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> Preliminary voting results will be announced at the Frequency Annual Meeting. Final voting results will be published in a Current Report on Form <span style="white-space:nowrap">8-K,</span> or Form <span style="white-space:nowrap">8-K,</span> that Frequency will file with the SEC within four business days after the Frequency Annual Meeting. If final voting results are not available in time to file a Form <span style="white-space:nowrap">8-K</span> within four business days after the Frequency Annual Meeting, Frequency intends to file a Form <span style="white-space:nowrap">8-K</span> to publish preliminary results and, within four business days after the final results are known, file an additional Form <span style="white-space:nowrap">8-K</span> to publish the final results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;What does it mean if I receive more than one set of proxy materials? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> It means that your shares are held in more than one account at the transfer agent and/or with banks, brokers or other nominees in &#8220;street name&#8221; as described below. Please vote all of your shares. To ensure that all of your shares are voted, for each set of proxy materials, please submit your proxy by phone, via the Internet, or, if you received printed copies of the proxy materials, by signing, dating and returning the enclosed proxy card in the enclosed envelope. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q:&#160;&#160;&#160;&#160;Who can help answer my questions? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A:</span> If you are a Frequency stockholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Frequency Annual Meeting, including the procedures for voting your shares, you should contact: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Frequency Therapeutics, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 Hayden Avenue, Suite 300 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Lexington, Massachusetts 02421 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Telephone: Tel: (781) <span style="white-space:nowrap">315-4600</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Attn: James Abely </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in street name, please contact the your bank, broker or other nominee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ensure timely delivery of documents prior to the Frequency Annual Meeting, any requests must be made no later than &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_5">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the Frequency Annual Meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_6">The Companies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">75 Hayden Avenue, Suite 300 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexington, MA 02421 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (781) <span style="white-space:nowrap">315-4600</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s business has focused on developing therapeutics that activate a person&#8217;s innate regenerative potential through its proprietary approach, called progenitor cell activation, or PCA. Frequency first applied its PCA approach for the restoration of the cochlea, with a focus on treating sensorineural hearing loss, or SNHL. Beginning in 2019, Frequency ran five clinical studies of FX-322 aimed at understanding safety as well as severities and etiologies that FX-322 might treat and the appropriate dose regime. In 2021, Frequency commenced its sixth study, a Phase 2b clinical trial of FX-322, or the FX-322-208 study, and introduced a second hearing program, FX-345, which Frequency believed might expand the opportunity to treat different types of SNHL. In February 2023, Frequency announced that the FX-322-208 study failed to achieve its primary endpoint of an improvement in speech perception. Frequency decided to discontinue the FX-322 development program and, given the similarities between the mechanisms of FX-322 and FX-345, decided to discontinue the FX-345 development program as well. Following this decision, Frequency focused its efforts on developing a product candidate designed to activate oligodendrocyte precursor cells with the goal of inducing remyelination and functional recovery for individuals living with multiple sclerosis, or the MS Program, and to explore strategic alternatives for the MS Program, including the sale of the MS Program. On July 14, 2023, Frequency entered into the Merger Agreement with Korro Bio and Merger Sub. Upon completion of the Merger, the business of Korro Bio will continue as the business of the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency Merger Sub, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">75 Hayden Avenue, Suite 300 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexington, MA 02421 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (781) 315-4600 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: James Abely </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub is a direct, wholly owned subsidiary of Frequency and was formed solely for the purpose of carrying out the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korro Bio, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Kendall Square, Building 600-700, Suite 6-401 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korro Bio is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korro Bio is generating a portfolio of differentiated programs that harness the body&#8217;s natural RNA editing </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro Bio expects to bring its life changing medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Advances in Genetic Medicines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The advent of large-scale genome sequencing has progressively revealed causal genetic variation underlying several human diseases, both rare and highly prevalent. Genetic mutations, including single nucleotide variants, or SNVs, implicated in disease have been found to be diverse in nature and can affect the function of genes and its associated downstream biochemical pathways. These discoveries have driven tremendous advances in technologies designed to introduce specific yet permanent changes at the DNA level to treat diseases. While these DNA editing approaches offer great promise for the treatment of certain rare diseases, they present significant risks from potential permanent adverse &#8220;off-target&#8221; edits. Additionally, the complex nature of DNA editing drug products presents multiple challenges including lack of efficient delivery to target cells and scalable manufacturing, impeding their application to treat complex and highly prevalent diseases. These potential limitations have spurred exploration of alternative approaches to genetic medicine development, such as RNA editing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mammals and other lower species like cephalopods have an endogenous process of modifying single bases on RNA, referred to as RNA editing. RNA editing is a natural physiological process that occurs in cells, including a mechanism mediated by an enzyme called Adenosine Deaminase Acting on RNA, or ADAR. Korro Bio&#8217;s RNA editing approach involves co-opting this endogenous editing system via a proprietary engineered oligonucleotide to introduce precise edits to RNA. Korro Bio iteratively optimizes the editing efficiency of its product candidates using a combination of ADAR biology, chemistry and machine learning expertise. Using this approach, Korro Bio can edit the transcriptome with high efficiency and specificity. The application of such an approach can provide the ability to alter a SNV and affect biology in meaningful ways. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Solution: Korro Bio&#8217;s OPERA Platform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korro Bio has assembled the preeminent suite of technologies and capabilities to build its RNA editing platform, Oligonucleotide Promoted Editing of RNA, or OPERA. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g00a12.jpg" alt="LOGO" />
 </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPERA relies on the following key components that enable Korro Bio to generate its differentiated RNA editing product candidates: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Deep understanding of ADAR biology</span>, supported by extensive preclinical research using <span style="font-style:italic">in vitro</span> assays and proprietary mouse models as well as the fundamental work of our scientific advisors and founders to elucidate key insights and know-how of ADAR biology. This enables an understanding of ADAR activity in different species and disease states, allowing Korro Bio to develop novel product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Expertise in oligonucleotide chemistry</span>, enabled by the ability to identify and incorporate chemical modifications to generate a fully modified synthetic oligonucleotide drug candidate. This increases the ability to bring drug-like properties, thereby increasing the editing and translational efficiency of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Machine learning optimization of oligonucleotides</span>, driven by data science and computational capabilities for rapid design and iteration resulting in optimal RNA editing product candidates for each disease being pursued. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Fit-for-purpose delivery</span>, made possible by tissue-specific delivery technologies that can enhance biodistribution, specificity, durability and editing efficiency of product candidates for each given disease </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The versatility of RNA editing combined with Korro Bio&#8217;s OPERA platform broadens the therapeutic target space significantly. While Korro Bio&#8217;s approach can be used to repair pathogenic SNVs, it can also engineer <span style="font-style:italic">de novo</span> SNVs and change amino acids on proteins to endow them with desired properties while preserving their broader functional capabilities. Korro Bio has demonstrated that single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate ion channels and activate kinases. These modification approaches can unlock validated target classes that have historically been difficult to drug, enabling Korro Bio to pursue a broad range of diseases traditionally out-of-scope for other genetic medicine approaches and current traditional drug modalities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s Pipeline </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Korro Bio&#8217;s programs demonstrate the versatility of the oligonucleotide-based ADAR-mediated RNA editing approach to bring additional precision and tunability to address a broad range of rare and highly prevalent diseases. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Repairing pathogenic variants</span>: An SNV that is a G to A mutation on DNA, leading to an aberrant amino acid on a protein can be repaired using RNA editing. Such an approach is relevant when the patient population has a spectrum of disease manifestations from mild-to-severe. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Disrupting protein-protein interactions</span>: A single SNV observed in human genetic association studies has the potential to inform how to transiently activate a protein pathway. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Preventing protein aggregation</span>: In instances where protein aggregation can lead to cellular dysfunction or be harmful to the cell, engineering an SNV using learnings from biochemistry and human genetics to prevent the aggregation while maintaining the protein&#8217;s normal function. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Other target classes</span>: There are multiple other target classes that can be addressed such as selectively modulating ion channels and activating kinases that have been traditionally hard to leverage for developing medicines. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pipeline chart below demonstrates the breadth of indications and applications enabled by Korro Bio&#8217;s </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OPERA platform, with an initial focus on six potential programs that are all wholly-owned. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g00a13.jpg" alt="LOGO" />
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Subject to submission of regulatory filing and authorization to proceed </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s most advanced program is a product candidate for Alpha-1 Antitrypsin Deficiency, or AATD, where, using its proprietary RNA editing approach, it is repairing a pathogenic variant on RNA. Korro Bio&#8217;s product candidate has the potential to be disease-modifying and establish a new standard of care. AATD is an inherited genetic disorder that can cause severe progressive lung and liver disease due to a lack of normal alpha-1 antitrypsin protein, or A1AT, caused by SNV mutations in the SERPINA1 gene. There are an estimated 3.4 million individuals with deficiency allele combinations worldwide. Despite being minimally effective and not fully addressing the needs of many AATD patients, augmentation therapy currently represents ~$1.4 billion in annual sales worldwide. Korro Bio&#8217;s product candidate has the potential to elevate the standard of care and expand the number of patients on treatment and potential to be a leader with a large market opportunity worldwide. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s AATD product candidate is a proprietary oligonucleotide that utilizes an established lipid nanoparticle, or LNP, based delivery system administered intravenously to transiently restore production of normal A1AT in liver hepatocytes. By correcting the pathogenic G to A SNV in the SERPINA1 gene, Korro Bio aims to bring individuals with the Z mutation to a phenotype where over 50% of RNA has been corrected to produce normal A1AT protein, preserving lung and liver function and preventing further damage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has generated compelling preclinical data demonstrating proof of concept across multiple RNA editing oligonucleotides that have the potential to become the lead development candidate. These potential development candidates have each achieved targeted durability, high editing efficiency (greater than 50% editing of hepatocytes) and clinically meaningful expression of normal A1AT protein in an <span style="font-style:italic">in vivo</span> mouse model. Korro Bio has also shown that its product candidates have high translation of RNA editing efficiency from mice to non- human primates, or NHPs, demonstrating the potential applicability of its approach in humans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the totality of the preclinical data generated to date, Korro Bio intends to nominate its development candidate in the second half of 2023. The development candidate will then be tested in studies to enable a regulatory filing in the second half of 2024. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Korro Bio&#8217;s programs demonstrate the versatility of the ADAR-mediated RNA editing approach. Importantly, Korro Bio can not only address classes of diseases caused by deleterious effects of misfolded or misdirected proteins, but it can also potentially utilize genetics to identify highly prevalent diseases where therapeutic benefit can be generated through alteration of protein function or expression. Korro Bio will continue to selectively identify and pursue additional targets and indications based on a range of technical, clinical, and commercial factors, to build a robust and differentiated pipeline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s Team &amp; Investors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is led by an experienced team with deep expertise in genetic medicines, development of oligonucleotide-based therapeutics, building novel therapeutic platforms, and bringing multiple therapeutics to market. In addition, Korro Bio&#8217;s executive leadership team has a successful track record of company building and leading biotech companies including Ram Aiyar, Ph.D., President and Chief Executive Officer, an experienced executive and company builder with 20 years of diverse industry experience including research, business and strategy; Steve Colletti, Ph.D., Chief Scientific Officer who brings nearly 30 years of drug discovery and development experience covering a broad range of therapeutic areas and modalities; and Vineet Agarwal, Chief Financial Officer, who brings more than 14 years of financial and industry experience as a biotech investment banker with J.P. Morgan Chase &amp; Co. Korro Bio also has an accomplished scientific advisory board comprised of leading experts in the fields of ADAR biology, chemistry, translation medicine, and nucleic acid therapeutics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Korro Bio has raised $223.6 million in capital before this transaction. If this transaction is completed, Korro Bio will raise an additional $117.3 million from premier venture capital funds, healthcare- dedicated funds, major mutual funds and other leading investors that share its vision of creating transformative genetic medicines for diseases with high prevalence. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s Strategy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s mission is to discover, develop and commercialize a new class of RNA editing therapies capable of improving the lives of patients with rare and highly prevalent diseases. Korro Bio does this by applying its RNA editing platform, OPERA, which combines its unique expertise in ADAR biology, RNA chemistry, machine learning-driven oligonucleotide optimization and fit-for-purpose tissue-delivery. Korro Bio&#8217;s novel RNA editing product candidates harness one of the body&#8217;s natural RNA editing processes to make precise single base RNA edits. Korro Bio&#8217;s goal is to develop a portfolio of RNA editing product candidates with best- </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in-class properties across a range of diseases by executing on the following key pillars of their strategy: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Develop a novel class of RNA editing therapies using a combination of learnings from genetics and approved medicines to mitigate clinical risk </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Develop and rapidly advance into the clinic a differentiated disease-modifying therapy for patients with AATD </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Deploy Korro Bio&#8217;s versatile OPERA platform to develop a portfolio of programs that modify proteins transiently to expand into highly prevalent diseases </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reinforce Korro Bio&#8217;s leadership position in RNA editing by continuing to optimize and enhance its OPERA platform </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Maximize the potential of its OPERA platform through collaborations and strategic partnerships </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Invest in human capital and encourage innovation to maintain its leadership position and advance the frontiers of genetic medicines </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_7"><span style="font-weight:bold">The Merger </span>(see page 153)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 14, 2023, Frequency entered into the Merger Agreement with Korro Bio and Merger Sub, pursuant to which Merger Sub will merge with and into Korro Bio, with Korro Bio surviving as a direct, wholly owned subsidiary of Frequency. In connection with the Merger, Frequency will change its corporate name to &#8220;Korro Bio, Inc.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the Merger, Frequency securityholders as of immediately prior to the Merger are expected to own approximately 8% of the outstanding shares of the combined company on a fully-diluted basis and former Korro Bio securityholders, including the pre-closing financing, or Pre-Closing Financing, investors are expected to own approximately 92% of the outstanding shares of the combined company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Frequency&#8217;s net cash as of closing being equal to $25 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time, each share of Korro Bio common stock will be converted into the right to receive a number of shares of Frequency common stock equal to the total number of shares of Frequency common stock to be issued in the Merger multiplied by the applicable Korro Bio stockholder&#8217;s percentage interest in Korro Bio as set forth in the Allocation Certificate required under the Merger Agreement. If any Korro Bio common stock outstanding immediately prior to the Effective Time is unvested or is subject to a repurchase option or a risk of forfeiture under any applicable agreement with Korro Bio, then the shares of Frequency common stock issued in exchange for such shares of Korro Bio common stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency common stock will be marked with appropriate legends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, each option to purchase shares of Korro Bio common stock outstanding as of immediately prior to the Effective Time shall automatically be converted, at the Effective Time, into an option to acquire the number of shares of Frequency common stock equal to the number of shares of Korro Bio common stock subject to such option as of immediately prior to the Effective Time multiplied by the exchange ratio formula in the Merger Agreement and rounding that result down to the nearest whole number of shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Frequency common stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such shares, subject to the Reverse Stock Split, will be unaffected by the Merger. Each outstanding Frequency Option will remain outstanding and such options, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan or 2014 Stock Incentive Plan, as applicable, to reflect the Reverse Stock Split and the issuance of the CVRs, will be unaffected by the Merger, provided that each Frequency Option that is outstanding and unvested will vest in full immediately prior to the Effective Time. Each restricted stock unit covering shares of Frequency common stock that is outstanding will remain outstanding and such restricted stock units, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan to reflect the Reverse Stock Split and issuance of the CVRs, will be unaffected by the Merger, provided that each restricted stock unit award that vests solely based on the holder&#8217;s continued employment or service will vest in full immediately prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger will be completed as promptly as practicable, but in no event later than two (2) business days after all of the conditions precedent set forth in the Merger Agreement have been satisfied or waived (other than those conditions that, by their nature, are to be satisfied at the closing of the Merger) or at such other time, date and place as Frequency and Korro Bio may mutually agree in writing, including the approval by the Frequency stockholders of the issuance of Frequency common stock in the Merger. The Merger is anticipated to close promptly after the Frequency Annual Meeting scheduled to be held on , 2023. However, Frequency and Korro Bio cannot predict the exact timing of the completion of the Merger because it is subject to the satisfaction or waiver of various conditions. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more complete description of the Merger, please see the sections titled &#8220;<span style="font-style:italic">The Merger</span>&#8221; and &#8220;<span style="font-style:italic">The Merger Agreemen</span>t&#8221; in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_8"><span style="font-weight:bold">Reasons for the Merger </span>(see pages 165 and 169)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Frequency Reasons for the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the course of evaluating the Merger, the Frequency board of directors held numerous meetings and consulted with Frequency&#8217;s senior management, legal counsel and financial advisor, and, in reaching its decision to approve the Merger, the Frequency board of directors considered a wide variety of factors, including, among others, the following material factors (which factors are not necessarily presented in any order of relative importance): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the review of the business, financial position, and prospects of Frequency on a standalone basis, noting that Frequency&#8217;s assets and liabilities are comprised primarily of cash (net of liabilities) and the assets and rights relating to Frequency&#8217;s MS Program, and determination that Frequency could not reasonably be expected to fund its MS Program on a standalone basis without substantial additional investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the current financial market conditions and historical market prices, volatility and trading information with respect to Frequency Common Stock and that Frequency is not expected to have any continuing business operations on a standalone basis, assuming divestiture of the MS Program, other than those incidental to Frequency&#8217;s status as a publicly traded company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the review of the business, strategy, financial position and prospects of Korro Bio and the opportunity for Korro Bio&#8217;s RNA editing technology to generate substantial long-term value for the combined company and its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Merger represents the best transaction alternative reasonably available to Frequency and its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if applicable, the related CVR provides the opportunity for Frequency&#8217;s stockholders to receive the value realized from any divestiture of the MS Program in connection with the proposed transaction; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Merger would provide the existing Frequency stockholders an opportunity to participate in the potential growth and value creation of the combined company by virtue of their continued ownership of Frequency Common Stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korro Bio Reasons for the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the course of reaching its decision to approve the Merger, the Korro Bio board of directors held numerous meetings, consulted with Korro Bio&#8217;s senior management, its financial advisors and legal counsel, and considered a wide variety of factors, including, among others, the following material factors (which factors are not necessarily presented in any order of relative importance): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Korro Bio&#8217;s pipeline, compared to the investors Korro Bio could otherwise gain access to if it continued to operate as a privately-held company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential benefits from increased public market awareness of Korro and its pipeline; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical and current information concerning Korro Bio&#8217;s business, including its financial performance and condition, operations, management and pre-clinical data; </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expected financial position, operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned pre-clinical and clinical trials), including the impact of the CVR agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms and conditions of the Merger Agreement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_9"><span style="font-weight:bold">Opinion of Frequency&#8217;s Financial Advisor </span>(see page 171)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has engaged Cowen and Company, LLC, or TD Cowen, as Frequency&#8217;s financial advisor in connection with the Merger. In connection with this engagement, TD Cowen delivered a written opinion, dated July&#160;13, 2023, to the Frequency board of directors as to the fairness, from a financial point of view and as of the date of such opinion, to Frequency of the Korro Bio Equity Value provided for pursuant to the Merger Agreement. For purposes of TD Cowen&#8217;s financial analyses and opinion, the term &#8220;Korro Bio Equity Value&#8221; refers to the equity value of $325,639,194.78 ascribed to Korro Bio pursuant to the Merger Agreement. The full text of TD Cowen&#8217;s written opinion, dated July&#160;13, 2023, is attached as <span style="font-style:italic">Annex B</span> to this proxy statement/prospectus and is incorporated herein by reference. <span style="font-weight:bold">The summary of TD Cowen&#8217;s written opinion set forth</span> <span style="font-weight:bold">herein</span> <span style="font-weight:bold">is qualified in its entirety by reference to the full text of such opinion. TD Cowen&#8217;s analyses and opinion were prepared for and addressed to the Frequency board of directors and were directed only to the fairness, from a financial point of view, to Frequency of the Korro Bio Equity Value. TD Cowen&#8217;s opinion did not in any manner address Frequency&#8217;s underlying business decision to effect the Merger or related transactions or the relative merits of the Merger or related transactions as compared to other business strategies or transactions that might be available to Frequency. The Korro Bio Equity Value was determined through negotiations between Frequency and Korro Bio and TD Cowen&#8217;s opinion does not constitute a recommendation to any securityholder or any other person as to how to vote or act with respect to the Merger, any related transactions or otherwise.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_10"><span style="font-weight:bold">Interests of Certain Directors and Executive Officers of Frequency and Korro Bio </span>(see pages&#160;178 and 183)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interests of Frequency Directors and Executive Officers in the Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Frequency board of directors with respect to issuing shares of Frequency common stock in the Merger and the other matters to be acted upon by the Frequency stockholders at the Frequency Annual Meeting, Frequency stockholders should be aware that the directors and executive officers of Frequency have interests in the Merger that may be different from, or in addition to, the interests of Frequency stockholders generally. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is party to a second amended and restated executive employment agreement with David L. Lucchino. Under the employment agreement, in the event Mr.&#160;Lucchino is terminated by Frequency without &#8220;cause&#8221;, or if he resigns for &#8220;good reason&#8221;, on or within 12&#160;months following a &#8220;change in control&#8221; (as such terms are defined his employment agreement), he will be entitled to (i)&#160;base salary continuation for a period of 18&#160;months, (ii)&#160;100% of his target annual bonus, and (iii)&#160;all equity awards held by Mr.&#160;Lucchino will accelerate and vest (including performance vesting awards, which will vest at target level of achievement). To the extent Mr.&#160;Lucchino is covered under Frequency&#8217;s health plan at the time of such termination or resignation, Frequency is required to pay the employer&#8217;s portion of Consolidated Omnibus Budget Reconciliation Act of 1985, or COBRA, premium payments for Mr.&#160;Lucchino and his covered dependents through the severance period. The severance payments and benefits provided under the employment agreement are subject to Mr.&#160;Lucchino&#8217;s execution and non-revocation of a release of claims in favor of Frequency and continued compliance with certain restrictive covenants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is party to an amended and restated employment agreement with Dr.&#160;Christopher R. Loose. In the event Dr.&#160;Loose is terminated by Frequency without &#8220;cause&#8221;, or if he resigns for &#8220;good reason&#8221;, within 12&#160;months following a &#8220;change in control&#8221; (as such terms are defined his employment agreement), he will be </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitled to (i)&#160;base salary continuation for a period of 12&#160;months, (ii)&#160;an amount equal to 100% of his target annual bonus, and (iii)&#160;his unvested equity incentive awards will vest immediately prior to such termination or resignation. To the extent Dr.&#160;Loose is covered under Frequency&#8217;s health plan at the time of such termination or resignation, Frequency is required to pay the employer&#8217;s portion of COBRA premium payments for Dr.&#160;Loose and his covered dependents through the severance period. The severance payments and benefits provided under the employment agreement are subject to Dr.&#160;Loose&#8217;s execution and non-revocation of a release of claims in favor of Frequency and continued compliance with certain restrictive covenants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Lucchino is currently a director of Frequency and will continue as a director of the combined company after the Effective Time. Following the Effective Time, it is expected that the combined company will provide compensation to non-employee directors pursuant to a new non-employee director compensation policy that is expected to be adopted post-closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023, Frequency&#8217;s non-employee directors and executive officers beneficially owned, in the aggregate, approximately 2.21% of the shares of Frequency common stock, excluding any shares of Frequency common stock issuable upon exercise or settlement of stock options, restricted stock units or performance stock units held by such individuals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors was aware of and considered these potential conflicts of interest, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Frequency stockholders approve the proposals to be presented to the stockholders for consideration at the Frequency Annual Meeting as contemplated in this proxy statement/prospectus. For more information, please see the section titled &#8220;<span style="font-style:italic">The Merger&#8212;Interests of Frequency Directors and Executive Officers in the Merger</span>&#8221; beginning on page 178 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interests of Korro Bio Directors and Executive Officers in the Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Korro Bio board of directors with respect to approving the Merger, Korro Bio stockholders should be aware that certain members of Korro Bio&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Korro Bio stockholders generally. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr. Aiyar, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are currently directors of Korro Bio and are expected to become directors of the combined company, and all of Korro Bio&#8217;s executive officers are expected to become the executive officers of the combined company, upon the closing of the merger, in connection with which the executive officers may enter into new employment agreements to reflect their status as executive officers of a publicly-traded company. Following completion of the Merger, it is expected that the combined company will provide compensation to non-employee directors pursuant to a new non-employee director compensation policy that is expected to be adopted post-closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&#160;24, 2023, Korro Bio&#8217;s then-current non-employee directors and executive officers beneficially owned, in the aggregate, approximately 3.85% of the shares of Korro Bio capital stock, excluding any Korro Bio shares issuable upon exercise of Korro Bio stock options held by such individuals. Such shares of Korro Bio capital stock will be converted into shares of Frequency common stock at the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Korro Bio stockholders approve the Merger as contemplated by this proxy statement/prospectus. For more information, please see the section titled &#8220;<span style="font-style:italic">The Merger&#8212;Interests of </span><span style="font-style:italic">Korro Bio </span><span style="font-style:italic">Directors and Executive Officers in the Merger</span>&#8221; beginning on page 183 of this proxy statement/prospectus. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_12">Overview of the Merger Agreement and Agreements Related to the Merger Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Merger Consideration </span></span><span style="font-style:italic">(see page 190)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Effective Time (after giving effect to the conversion of Korro Bio preferred stock as described below), upon the terms and subject to the conditions set forth in the Merger Agreement, each share of Korro Bio common stock outstanding immediately prior to the Effective Time (excluding Korro Bio common stock issued in the pre-closing financing) will be converted solely into the right to receive a number of shares of Frequency common stock equal to the amount of Korro Merger Shares described in the section&#160;titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Korro Merger Shares</span>&#8221; beginning on page 192 in this proxy statement/prospectus multiplied by the applicable stockholder&#8217;s percentage interest in Korro Bio. If any Korro Bio common stock outstanding immediately prior to the Effective Time is unvested or is subject to a repurchase option or a risk of forfeiture under any applicable agreement with Korro Bio, then the shares of Frequency common stock issued in exchange for such shares of Korro Bio common stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency common stock will be marked with appropriate legends. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Effective Time, by virtue of the Merger, upon the terms and subject to the conditions set forth in the Merger Agreement, the Korro Bio common stock issued in the Pre-Closing Financing will be converted solely into the right to receive a number of shares of Frequency common stock equal to the amount of Pre-Closing Financing Merger Shares described in the section&#160;titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic">&#8212;Pre-Closing Financing Merger Shares</span>&#8221; beginning on page 192 in this proxy statement/prospectus multiplied by the percentage of the proceeds of the Pre-Closing Financing represented by the applicable stockholder&#8217;s investment in the Pre-Closing Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Effective Time, by virtue of the Merger, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of common stock, $0.01 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Korro Bio preferred stock will be converted into Korro Bio common stock as of immediately prior to the Effective Time in accordance with, and pursuant to the terms and conditions of, the organizational documents of Korro Bio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Treatment of Korro Bio Options </span></span><span style="font-style:italic">(see page 194)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each option to purchase shares of Korro Bio common stock outstanding as of immediately prior to the Effective Time, or Korro Bio Options, shall automatically be converted, at the Effective Time, into an option to acquire, on the same terms and conditions (including the same vesting and exercisability terms and conditions), the number of shares of Frequency common stock equal to the number of shares of Korro Bio common stock subject to such option as of immediately prior to the Effective Time multiplied by the exchange ratio formula in the Merger Agreement and rounding that result down to the nearest whole number of shares<span style="font-style:italic">.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Treatment of Korro Bio Warrants (see page 194) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant issued by Korro Bio outstanding immediately prior to the Effective Time will automatically be converted, at the Effective Time, into a warrant to acquire, on the same terms and conditions (including, without limitation, the exercisability terms and conditions) as were applicable under the warrant issued by Korro Bio to SVB as described in Note 8 of Korro Bio&#8217;s audited consolidated financial statements included elsewhere in this proxy statement/prospectus, the number of shares of Frequency common stock equal to the number of shares of Korro Bio common stock subject to such warrant as of immediately prior to the Effective Time determined by the Warrant Exchange Ratio in the Merger Agreement and rounding that result down to the nearest whole number of shares. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Treatment of Frequency Common Stock, Frequency Options, Frequency Restricted Stock Units and Frequency Performance Stock Units </span></span><span style="font-style:italic">(see pages&#160;195)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding Frequency Option will remain outstanding and such options, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan or 2014 Stock Incentive Plan, as applicable, to reflect the Reverse Stock Split and the issuance of the CVRs, will be unaffected by the Merger, provided that each such Frequency Option that is unvested will vest in full immediately prior to the Effective Time. Each restricted stock unit award covering shares of Frequency common stock that is outstanding will remain outstanding and such restricted stock unit awards, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan to reflect the Reverse Stock Split and issuance of the CVRs, will be unaffected by the Merger, provided that each restricted stock unit award that vests solely based on the holder&#8217;s continued employment or service will vest in full immediately prior to the Effective Time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Conditions to the Completion of the Merger </span></span><span style="font-style:italic">(see page 207)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To complete the Merger, Frequency stockholders must approve Proposal No. 1 and Korro Bio must adopt the Merger Agreement and approve the Merger and the additional transactions contemplated thereby. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Solicitation</span> </span></span><span style="font-style:italic">(see page 201)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, each of Frequency and Korro Bio have agreed that neither it nor any of its subsidiaries, directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives, will directly or indirectly: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry (as each term is defined in the section of this proxy statement/prospectus entitled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Non-Solicitation&#8221;</span>)<span style="font-style:italic"> </span>or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">furnish any non-public information regarding such party to any person (other than Korro Bio or Frequency) in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approve, endorse or recommend any Acquisition Proposal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction (as defined in the section of this proxy statement/prospectus entitled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Non-Solicitation&#8221;</span>)<span style="font-style:italic"> </span>or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publicly propose to do any of the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement affords Frequency certain fiduciary exceptions to the non-solicitation provision to allow the Frequency Board to consider a Superior Offer (as defined in the section of this proxy statement/prospectus entitled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Non-Solicitation&#8221;</span>)<span style="font-style:italic"> </span>under certain circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Board Recommendation Change </span></span><span style="font-style:italic">(see page&#160;203)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency and Korro Bio agreed (and, with respect to Frequency, subject to specified exceptions described in the Merger Agreement and in the section of this proxy statement/prospectus entitled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Board Recommendation Change</span>&#8221;beginning on page 203) that their boards of directors may not take any of the following actions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of their boards of directors in a manner adverse to the other party; </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">resolve, or have any committee of their boards of directors resolve, to withdraw or modify their recommendation in a manner adverse to the other party; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Termination of the Merger Agreement </span></span><span style="font-style:italic">(see page&#160;209)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Either Frequency or Korro Bio may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Termination Fee </span></span><span style="font-style:italic">(see page&#160;209)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Merger Agreement is terminated under certain circumstances, either Frequency could be required to pay Korro Bio a termination fee of $1.5 million, or Korro Bio could be required to pay Frequency a termination fee of $4&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Support Agreements </span></span><span style="font-style:italic">(see page&#160;212)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain Korro Bio stockholders are party to a support agreement with Frequency pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a Korro Bio stockholder, to vote all of his, her or its shares of Korro Bio capital stock in favor of (i) the adoption of the Merger Agreement and approval of the Merger, (ii) the approval of the related transactions contemplated by the Merger Agreement, (iii)&#160;the conversion of each share of Korro Bio preferred stock into shares of Korro Bio common stock immediately prior to and contingent upon the closing and (iv) the approval of certain additional proposals in connection with the Merger that the Korro Bio board of directors may recommend. These Korro Bio stockholders also agreed to vote against (i) any competing Acquisition Proposal (as defined in the section of this proxy statement/prospectus entitled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Non-Solicitation</span>&#8221; beginning on page&#160;201) and (ii) any action, proposal, agreement, transaction or proposed transaction that would reasonably be expected to materially impede, interfere with, delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement, subject to certain specified exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July 14, 2023, the Korro Bio stockholders that are party to a support agreement with Frequency owned an aggregate of 4,691,654 shares of Korro Bio common stock and 97,637,593 shares of Korro Bio preferred stock, representing approximately 98.0% of the outstanding shares of Korro Bio capital stock on an as converted to common stock basis. These stockholders include executive officers and directors of Korro Bio, as well as certain other stockholders owning a significant portion of the outstanding shares of Korro Bio capital stock. Following the effectiveness of the registration statement on Form S-4 of which this proxy statement/prospectus is a part and pursuant to the Merger Agreement, Korro Bio stockholders holding a sufficient number of shares of Korro Bio capital stock to adopt the Merger Agreement and approve the Merger and related transactions will execute written consents providing for such adoption and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain Frequency stockholders have entered into support agreements with Korro Bio pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a Frequency stockholder, to vote all of his, her or its shares of Frequency common stock in favor of (i) the approval of the Merger Agreement, (ii) the transactions contemplated thereby, including the issuance of Frequency common stock to Korro Bio stockholders, (iii) an amendment to the amended and restated certificate of incorporation of Frequency to effect the Reverse Stock Split, (iv) any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes for the approval of the Merger Agreement and the transactions contemplated therein and (v) the approval of certain additional proposals in connection with the Merger that the Frequency board of directors </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may recommend. These Frequency stockholders also agreed to vote against (i) any competing Acquisition Proposal with respect to Frequency (as defined in the section of this proxy statement/prospectus entitled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Non-Solicitation</span>&#8221; beginning on page&#160;201) and (ii) any action, proposal, agreement, transaction or proposed transaction that would reasonably be expected to materially impede, interfere with, delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement, subject to certain specified exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July 14, 2023, the Frequency stockholders that are party to a support agreement owned approximately 3.5% of the outstanding shares of Frequency common stock. These stockholders include certain executive officers and directors of Frequency. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Lock-Up</span> Agreements </span></span><span style="font-style:italic">(see page&#160;213)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of Korro Bio&#8217;s executive officers, directors and stockholders have entered into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, any shares of Frequency&#8217;s common stock, including, as applicable, shares received in the Merger and shares issuable upon exercise of options, warrants or convertible securities, until 180 days after the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Korro Bio stockholders who have executed lock-up agreements as of July 14, 2023, owned in the aggregate, approximately 98% of the shares of Korro Bio&#8217;s outstanding capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of Frequency&#8217;s executive officers, directors and stockholders have entered into lock-up agreements, pursuant to which such stockholders have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, any Frequency securities or shares of Frequency common stock, including, as applicable, shares issuable upon exercise of certain options, warrants or convertible securities, until 180 days after the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency stockholders who have executed lock-up agreements as of July 14, 2023 owned, in the aggregate, approximately 3.5% of the outstanding shares of Frequency common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Contingent Value Rights Agreement </span></span><span style="font-style:italic">(see page&#160;214)</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At or prior to the Effective Time, Frequency and Computershare Trust Company, N.A. and Computershare Inc., collectively as Rights Agent, will enter into the CVR Agreement. As provided in the Merger Agreement, unless (i) the MS Asset Disposition has been consummated prior to or on the closing date of the Merger and (ii) all proceeds from the MS Asset Disposition are taken into account in the final Frequency Net Cash and there are no contingent payments, licenses, fees or royalties, equity securities or other non-cash assets or rights that may be payable by any acquiror of any MS Assets or otherwise as a result of the MS Asset Disposition after the closing of the Merger, Frequency shall declare a distribution to its common stockholders of record the right to receive one CVR for each outstanding share of Frequency common stock held by such stockholder as of the record date, each representing the non-transferable contractual right to receive certain contingent payments from Frequency upon the occurrence of certain events within agreed time periods. The record date for such distribution will be the close of business on the last business day prior to the day on which the Effective Time occurs and the payment date for which shall be three business days after the Effective Time; provided that the payment of such distribution may be conditioned upon the occurrence of the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the CVR Agreement, each CVR holder is entitled to certain contingent cash payments, which are payable by Frequency to the Rights Agent for subsequent distribution to the CVR holders (such payments, the </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CVR Payments), of the CVR Proceeds, which will equal the net amount (calculated in accordance with GAAP consistently applied) of the following proceeds actually received by Frequency or its subsidiaries, collectively, the Gross Proceeds, after the end of each fiscal quarter of Frequency following the first anniversary of the closing: cash consideration that is paid to or received by Frequency or any of its subsidiaries during the period beginning immediately following the Effective Time and ending on the tenth anniversary of the closing date in respect of any MS Asset Disposition, or resulting from the ownership of equity securities in any subsidiary established by Frequency during the period beginning on the execution date of the Merger Agreement and ending on the one-year anniversary of the closing date, or the Disposition Period, or the subsequent disposition of any such equity securities (regardless of whether such disposition occurs during the Disposition Period). Such proceeds are subject to certain permitted deductions, including for certain income taxes required to be paid in cash, certain reasonable and documented out-of-pocket costs and expenses incurred by Frequency or its subsidiaries, losses incurred or reasonably expected to be incurred by Frequency or its subsidiaries due to a third party proceeding in connection with a disposition and certain wind-down costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any Gross Proceeds result from the MS Assets or from the ownership of equity securities in any subsidiary established by Frequency during the Disposition Period or the subsequent disposition of any such equity securities, then CVR holders will receive 100% of such CVR Proceeds, as a CVR Payment, regardless of when such disposition is consummated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CVRs may not be transferred, pledged, hypothecated, encumbered, assigned or otherwise disposed of (whether by sale, merger, consolidation, liquidation, dissolution, dividend, distribution or otherwise), in whole or in part, subject to certain limited exceptions specified in the CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CVRs will not be evidenced by a certificate or any other instrument. The CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of the CVRs. The CVRs will not represent any equity or ownership interest in Frequency, any constituent company to the Merger, or any of its subsidiaries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_11"><span style="font-weight:bold">Management Following the Merger </span>(<span style="font-style:italic">see page</span>&#160;357)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the closing of the Merger, the combined company&#8217;s executive officers are expected to be members of the Korro Bio executive management team prior to the Merger, including: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:66%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Title</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Aiyar, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President and Chief Executive Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vineet Agarwal</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve Colletti</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Scientific Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Chappell</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Senior Vice President, Strategy and Portfolio Planning</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shelby Walker</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">General Counsel</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_13"><span style="font-weight:bold">Material U.S.&#160;Federal Income Tax Consequences of the Merger </span>(<span style="font-style:italic">see page</span>&#160;223)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency and Korro Bio intend the Merger to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code. Assuming the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, subject to the limitations and qualifications described in the section titled &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Merger</span>,&#8221; holders of Korro Bio common stock that exchange their Korro Bio common stock for Frequency common stock in the Merger generally should not recognize gain or loss for U.S. federal income tax purposes on such exchange. However, if the Merger does not qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, the Merger would be a taxable transaction to U.S. Holders (as defined in the section titled &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221;), </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
but <span style="white-space:nowrap">Non-U.S.</span> Holders (as defined in the section titled &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221;) generally would not be subject to U.S. federal income tax on any gain realized in connection with the Merger. The closing of the Merger is not conditioned upon the receipt of an opinion of counsel or a ruling from the IRS regarding the U.S. federal income tax treatment of the Merger, and no opinion of counsel or ruling from the IRS will be requested regarding such treatment. Accordingly, there can be no assurance that the IRS will not challenge the qualification of the Merger as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code or that a court will not sustain such a challenge by the IRS. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax consequences to you of the Merger will depend on your particular facts and circumstances. Please consult your tax advisor as to the tax consequences of the Merger in your particular circumstances, including the applicability and effect of U.S. federal, state, local and foreign income and other tax laws. For a more detailed discussion of the material U.S. federal income tax consequences of the Merger, see &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page&#160;223. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_14"><span style="font-weight:bold">Nasdaq Stock Market Listing </span>(<span style="font-style:italic">see page</span>&#160;186)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency intends to file an initial listing application for the combined company common stock with the Nasdaq Stock Market LLC. If such application is accepted, Frequency anticipates that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;KRRO.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_15"><span style="font-weight:bold">Anticipated Accounting Treatment </span>(<span style="font-style:italic">see page</span>&#160;186)<span style="font-weight:bold"> </span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger is expected to be treated by Frequency as a reverse merger and will be accounted for as a reverse recapitalization in accordance with United States Generally Accepted Accounting Principles, or U.S. GAAP. For accounting purposes, Korro Bio is considered to be acquiring the assets and liabilities of Frequency in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Korro Bio&#8217;s stockholders will own a substantial majority of the voting rights of the combined company; (ii)&#160;Korro Bio will designate a majority (4 of 7) of the initial members of the board of directors of the combined company; (iii)&#160;Korro Bio&#8217;s executive management team will become the management of the combined company; and (iv)&#160;the combined company will be named Korro Bio, Inc. and be headquartered in Cambridge, MA. See &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Statements</span><span style="font-style:italic">&#8221;</span> included elsewhere in this proxy statement/prospectus for additional information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_16"><span style="font-weight:bold">Appraisal Rights and Dissenters&#8217; Rights </span>(<span style="font-style:italic">see page</span>&#160;186)<span style="font-weight:bold"> </span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders of Frequency common stock are not entitled to appraisal rights in connection with the Merger under Delaware law. Stockholders of Korro Bio common stock are entitled to appraisal rights in connection with the Merger under Delaware law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_17"><span style="font-weight:bold">Comparison of Stockholder Rights </span>(<span style="font-style:italic">see page</span>&#160;408)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both Frequency and Korro Bio are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the DGCL. If the Merger is completed, Korro Bio stockholders will become Frequency stockholders, and their rights will be governed by the DGCL, the Amended and Restated Bylaws of Frequency and the Restated Certificate of Incorporation of Frequency, as may be amended by Proposal No.&#160;2 if approved by the Frequency stockholders at the Frequency Annual Meeting. The rights of Frequency stockholders contained in the Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws of Frequency differ from the rights of Korro Bio stockholders under the Amended and Restated Certificate of Incorporation and Bylaws of Korro Bio, as more fully described under the section titled &#8220;<span style="font-style:italic">Comparison of Rights of Holders of Frequency Capital Stock and Korro Bio Capital Stock</span>&#8221; beginning on page&#160;408 of this proxy statement/prospectus. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_18"><span style="font-weight:bold">Risk Factors </span>(<span style="font-style:italic">see page</span>&#160;32)<span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both Frequency and Korro Bio are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Merger </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The exchange ratio will not be adjusted based on the market price of Frequency common stock so the merger consideration at the closing may have a greater or lesser value than at the time the Merger Agreement was signed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Failure to complete the Merger may result in Frequency or Korro Bio paying a termination fee to the other party, which could harm the Frequency common stock price and the future business and operations of each company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Some Frequency and Korro Bio executive officers and directors have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency stockholders and Korro Bio stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the conditions to the Merger are not satisfied or waived, the Merger may not occur. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the Merger is not completed, Frequency&#8217;s stock price may decline significantly. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Frequency </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Failure to complete, or delays in completing, the proposed merger with Korro Bio could expose Frequency to other operational and financial risks. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency stockholders may not receive any payment on the CVRs, and the CVRs may expire valueless. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency has a limited operating history, no history of commercializing products, has incurred significant losses since inception and anticipates continuing to incur net losses for the foreseeable future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the Merger is not consummated and should Frequency resume development of product candidates, it will require additional capital to fund its operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If Frequency fails to obtain necessary financing, it will not be able to complete the development and commercialization of such product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of its </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">common stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Korro Bio </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio has incurred significant losses since inception. Korro Bio expects to incur losses for the foreseeable future and may never achieve or maintain profitability. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There is substantial doubt about Korro Bio&#8217;s ability to continue as a going concern. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio has never generated revenue from product sales and may never become profitable. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio will need substantial additional funding. If Korro Bio is unable to raise capital when needed, it will be forced to delay, reduce, eliminate or prioritize among its research and development programs or future commercialization efforts. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The gene editing field and RNA editing in particular is relatively new and is evolving rapidly. Korro Bio is very early in its development efforts and may not be successful in identifying and developing product candidates. It will be many years before Korro Bio or its collaborators commercialize a product candidate or generate any revenues, if ever. Additionally, other gene editing technologies may be discovered that provide significant advantages over RNA editing, which could materially harm its business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">RNA editing is a novel technology that is not yet clinically validated for human therapeutic use. The approaches Korro Bio takes to discover and develop novel therapeutics are unproven and may never lead to marketable products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio is very early in its development efforts, and its preclinical studies and clinical trials may not be successful. If Korro Bio is unable to commercialize its product candidates or experiences significant delays in doing so, its business will be materially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any product candidates Korro Bio develops may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If Korro Bio is not able to obtain or protect intellectual property rights related to any of its product candidates, development and commercialization of its product candidates may be adversely affected. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to the Combined Company </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Merger may be completed even though material adverse effects may result from the announcement of the Merger, industry-wide changes and other causes. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expectations regarding the combined company&#8217;s cash runway and ability to reach data inflection points are based on numerous assumptions that may prove to be untrue. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The combined company may be required to raise capital sooner than anticipated and its exposure to certain contingent liabilities and contractual obligations may be greater than anticipated. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of the combined company&#8217;s common stock following the Merger may decline as a result of the Merger. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of the combined company&#8217;s common stock is expected to be volatile, the market price of the common stock may drop following the merger and an active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all; If the assets subject to the CVR Agreement are not disposed of in a timely manner, the combined company may have to incur time and resources to wind down or dispose of such assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Provisions in the combined company&#8217;s charter documents and under Delaware law could make an acquisition of the combined company more difficult and may discourage any takeover attempts which stockholders may consider favorable, and may lead to entrenchment of management; </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">After completion of the merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Dianthus pre-closing financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These risks and other risks are discussed in greater detail under the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page&#160;32 of this proxy statement/prospectus. Frequency and Korro Bio both encourage you to read and consider all of these risks carefully. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_20">MARKET PRICE AND DIVIDEND INFORMATION </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing price of Frequency common stock on July&#160;13, 2023, the last trading day prior to the public announcement of the Merger, was $0.40 per share, as reported on Nasdaq. The closing price of the Frequency common stock on July 26, 2023, the last practicable date before the date of this proxy statement/prospectus, as reported on Nasdaq, was $0.54 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the market price of Frequency common stock is subject to fluctuation, the market value of the shares of Frequency common stock that Korro Bio stockholders will be entitled to receive in the Merger may increase or decrease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is a private company, and its shares of common stock and preferred stock are not publicly traded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming approval of Proposal Nos. 1 and 2 and successful application for initial listing with Nasdaq, following the consummation of the Merger, the Frequency common stock will trade on Nasdaq under Frequency&#8217;s new name, &#8220;Korro Bio, Inc.,&#8221; and new trading symbol &#8220;KRRO.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, the Record Date for the Annual meeting, there were approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; registered holders of record of the Frequency common stock. As of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, Korro Bio had &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; holders of record of Korro Bio common stock and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; holders of record of Korro Bio preferred stock. For detailed information regarding the beneficial ownership of certain Frequency and Korro Bio stockholders, see the sections of this proxy statement/prospectus titled &#8220;<span style="font-style:italic">Principal Stockholders of Frequency</span>&#8221; and &#8220;<span style="font-style:italic">Principal Stockholders of Korro Bio</span>&#8221; beginning on pages 418 and 420, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_21">Dividends </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has never declared or paid cash dividends on its capital stock. Korro Bio has never paid or declared any cash dividends on its capital stock. Korro Bio intends to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any cash dividends on its capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined company&#8217;s board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the combined company&#8217;s board of directors deems relevant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_22">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of Frequency common stock. You should also read and consider the other information in this proxy statement/prospectus. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_23">Risks Related to the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The exchange ratio will not be adjusted based on the market price of Frequency common stock so the merger consideration at the closing may have a greater or lesser value than at the time the Merger Agreement was signed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time, outstanding shares of Korro Bio common stock will be converted into shares of Frequency common stock. The former Korro Bio securityholders, including purchasers in the Pre-Closing Financing, immediately before the Merger are expected to own approximately 92% of the aggregate number of shares of Frequency common stock following the Merger on a fully-diluted basis, and Frequency securityholders immediately before the Merger are expected to own approximately 8% of the aggregate number of shares of Frequency common stock following the Merger on a fully-diluted basis, subject to certain assumptions, including, but not limited to, (a) a valuation of Frequency equal to its net cash as of the business day immediately prior to the closing date of the Merger, plus $15.0 million, (b) a valuation for Korro Bio equal to $325.6 million and (c) Korro Bio issuing approximately $117.3 million of Korro Bio common stock in the Pre-Closing Financing described elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in the market price of Frequency common stock before the completion of the Merger will not affect the number of shares Korro Bio stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the Merger, the market price of Frequency common stock increases from the market price on the date of the Merger Agreement, then Korro Bio stockholders could receive merger consideration with substantially more value for their shares of Korro Bio common stock than the parties had negotiated when they established the exchange ratio. Similarly, if before the completion of the Merger the market price of Frequency common stock declines from the market price on the date of the Merger Agreement, then Korro Bio stockholders could receive merger consideration with substantially lower value. The Merger Agreement does not include a price-based termination right. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to complete the Merger may result in Frequency paying a termination fee to Korro Bio, which could harm the Frequency common stock price and future business and operations of Frequency. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger is not completed, Frequency is subject to the following risks: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the Merger Agreement is terminated under specified circumstances, Frequency will be required to pay Korro Bio a termination fee of $1.5 million; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the price of Frequency common stock may decline and could fluctuate significantly; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to the Merger, such as financial advisor, legal and accounting fees, which Frequency estimates will total approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, which must be paid even if the Merger is not completed. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger Agreement is terminated and the board of directors of Frequency determines to seek another business combination, there can be no assurance that Frequency will be able to find a partner with whom a business combination would yield greater benefits than the benefits to be provided under the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the conditions to the Merger are not satisfied or waived, the Merger may not occur. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the Merger is approved by the stockholders of Korro Bio and the Merger Proposal is approved by the Frequency stockholders, specified conditions must be satisfied or waived to complete the Merger. These </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions are set forth in the Merger Agreement and described in the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Conditions to the Completion of the Merger</span>&#8221; beginning on page 207 of this proxy statement/prospectus. Among other things, the Merger Agreement requires the existing shares of Frequency common stock to be continually listed with the Nasdaq Stock Market LLC through the Effective Time. The listing of Frequency common stock with the Nasdaq Stock Market LLC will depend on many factors, including those discussed in the risk factor entitled <span style="font-style:italic">&#8220;</span><span style="font-style:italic">Frequency&#8217;s failure to meet the continued listing requirements of the Nasdaq Stock Market LLC could result in a delisting of its common stock.&#8221;</span> Frequency and Korro Bio cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or the closing may be delayed, and Frequency and Korro Bio each may lose some or all of the intended benefits of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, neither Frequency nor Korro Bio is obligated to complete the Merger if there is a material adverse effect affecting the other party between July&#160;14, 2023, the date of the Merger Agreement, and the closing of the Merger. However, certain types of changes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include but are not limited to changes in general economic or political conditions, industry wide changes, changes resulting from the announcement of the Merger, natural disasters, pandemics, other public health events and changes in GAAP. Therefore, if any of these events were to occur impacting Frequency or Korro Bio, the other party would still be obliged to consummate the closing of the Merger. If any such adverse changes occur and Frequency and Korro Bio consummate the closing of the Merger, the stock price of the combined company may suffer. This in turn may reduce the value of the Merger to the stockholders of Frequency, Korro Bio or both. For a more complete discussion of what constitutes a material adverse effect on Frequency or Korro Bio, see the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Representations and Warranties</span>&#8221; beginning on page 197 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Frequency and Korro Bio complete the Merger, the combined company will need to raise additional capital by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional financing may not be available to the combined company when it is needed or may not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the combined company, including Frequency&#8217;s <span style="white-space:nowrap">pre-Merger</span> stockholders and Korro Bio&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the combined company&#8217;s common stock. Any debt financing the combined company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the combined company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Some Frequency and Korro Bio directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors and executive officers of Frequency and Korro Bio may have interests in the Merger that are different from, or in addition to, the interests of other Frequency stockholders generally. These interests with respect to Frequency&#8217;s directors and executive officers may include, among others, acceleration of Frequency Options, Frequency restricted stock units, retention bonus payments, severance payments and benefits if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage. David L. Lucchino, a current member of the Frequency board of directors will continue as a director of the combined company after the Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Following the Effective Time, it is expected that the combined company will provide compensation to non-employee directors pursuant to a new non-employee director compensation policy that is expected to be adopted post-closing. These interests with respect to Korro Bio&#8217;s directors and executive officers may include, among others, certain of Korro Bio&#8217;s directors and executive officers have options, subject to vesting, to purchase shares of Korro Bio common stock which, after the Effective Time, will be converted into and become options to purchase shares of the common stock of the combined company; Korro Bio&#8217;s executive officers are expected to continue as executive officers of the combined company after the Effective Time; and all of Korro Bio&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement. Further, certain current members of Korro Bio&#8217;s board of directors will continue as directors of the combined company after the Effective Time, and, following the Effective Time, it is expected that the combined company will provide compensation to non-employee directors pursuant to a new non-employee director compensation policy that is expected to be adopted post-closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of both Frequency and Korro Bio were aware of and considered these interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger, approve the issuance of Frequency common stock in the Merger, and recommend the approval of the Merger Agreement to Korro Bio stockholders and the issuance of the Frequency common stock to Korro Bio stockholders in the Merger to the Frequency stockholders. These interests, among other factors, may have influenced the directors and executive officers of Frequency and Korro Bio to support or approve the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information regarding the interests of Frequency and Korro Bio directors and executive officers in the Merger, please see the sections titled &#8220;<span style="font-style:italic">The Merger&#8212;Interests of Frequency Directors and Executive Officers in the Merger</span>&#8221; beginning on page 178 and &#8220;<span style="font-style:italic">The Merger&#8212;Interests of Korro Bio Directors and Executive Officers in the Merger</span>&#8221; beginning on page 183 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, Frequency stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the Merger is not completed, Frequency&#8217;s stock price may decline significantly. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of Frequency common stock is subject to significant fluctuations. During the <span style="white-space:nowrap">12-month</span> period ended June&#160;30, 2023, the closing sales price of Frequency common stock on Nasdaq ranged from a high of $5.4750 on January&#160;24, 2023 to a low of $0.3318 on June&#160;21, 2023. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of Frequency common stock will likely be volatile based on whether stockholders and other investors believe that Frequency can complete the Merger or otherwise raise additional capital to support Frequency&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of Frequency common stock is exacerbated by low trading volume. Additional factors that may cause the market price of Frequency common stock to fluctuate include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse publicity relating to the combined company&#8217;s business and product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the loss of key employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future sales of common stock; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general and industry-specific economic conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the failure to meet industry analyst expectations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> fluctuations in financial results. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See also &#8220;<span style="font-style:italic">Risks related to Frequency common stock&#8212;The market price of Frequency common stock has been volatile and fluctuated and may in future fluctuate substantially, which could result in substantial losses for Frequency&#8217;s stockholders</span>&#8221;. Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Frequency common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency and Korro Bio securityholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of the Merger, the current stockholders of Frequency and Korro Bio will own a smaller percentage of the combined company than their ownership of their respective companies prior to the Merger. Immediately after the Merger, Frequency securityholders as of immediately prior to the Merger are expected to own approximately 8% of the outstanding shares of the combined company on a fully-diluted basis and former Korro Bio securityholders, including purchasers in the Pre-Closing Financing, are expected to own approximately 92% of the outstanding shares of the combined company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, (a) a valuation of Frequency equal to its net cash as of the business day immediately prior to the closing date of the Merger, plus $15.0 million, (b) a valuation for Korro Bio equal to $325.6 million and (c) Korro Bio issuing approximately $117.3 million of Korro Bio common stock in the Pre-Closing Financing described elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">During the pendency of the Merger, Frequency and Korro Bio may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Covenants in the Merger Agreement impede the ability of Frequency and Korro Bio to make acquisitions during the pendency of the Merger, subject to specified exceptions. As a result, if the Merger is not completed, the parties may be at a disadvantage to their competitors during that period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from soliciting, proposing, seeking or knowingly encouraging, facilitating or supporting any inquiries, indications of interest, proposals or offers that constitute or may reasonably be expected to lead to certain transactions involving a third party, including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to such party&#8217;s stockholders, but the parties may be unable to pursue them. For more information, see the sections titled &#8220;<span style="font-style:italic">The Merger <span style="white-space:nowrap">Agreement&#8212;Non-Solicitation</span></span>&#8221; beginning on page 201. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Merger Agreement prohibit each of Frequency and Korro Bio from soliciting competing proposals or cooperating with persons making unsolicited takeover proposals, except in limited circumstances as described in further detail in the section titled &#8220;<span style="font-style:italic">The Merger <span style="white-space:nowrap">Agreement&#8212;Non-Solicitation</span></span>&#8221; beginning on page 201. In addition, if Frequency terminates the Merger Agreement under specified circumstances, Frequency would be required to pay Korro Bio a termination fee of $1.5 million. This termination fee may discourage third parties from submitting competing proposals to Frequency or its stockholders, and may cause the Frequency board of directors to be less inclined to recommend a competing proposal. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because the lack of a public market for Korro Bio&#8217;s stock makes it difficult to evaluate the fair market value of Korro Bio&#8217;s stock, Frequency may pay more than the fair market value of Korro Bio&#8217;s stock and/or the stockholders of Korro Bio may receive consideration in the Merger that is less than the fair market value of Korro Bio&#8217;s stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Korro Bio common stock is privately held and is not traded in any public market. The lack of a public market makes it difficult to determine the fair market value of Korro Bio&#8217;s stock. Because the percentage of Frequency equity to be issued to Korro Bio stockholders was determined based on negotiations between the parties, it is possible that the value of the Frequency common stock to be received by Korro Bio stockholders will be less than the fair market value of Korro Bio&#8217;s stock, or Frequency may pay more than the aggregate fair market value for Korro Bio&#8217;s stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency stockholders may not receive any payment on the CVRs, and the CVRs may expire valueless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of Frequency stockholders to receive any future payment on or derive any value from the CVRs will be contingent solely upon the occurrence of the CVR Milestones within the time periods specified in the CVR Agreement and the consideration received being greater than the amounts permitted to be withheld or deducted by Frequency under the CVR Agreement. There is no guarantee that Frequency will be able to successfully collaborate or sell any of these assets or establish a viable entity to manage the development of these assets. In the event that no CVR Milestones occur within the time periods specified in the CVR Agreement, no payments will be made under the CVR Agreement, and the CVRs will expire valueless. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the CVRs will be unsecured obligations of the combined company and all payments under the CVRs, all other obligations under the CVR Agreement and the CVRs and any rights or claims relating thereto may be subordinated in right of payment to the prior payment in full of all current or future senior obligations of the combined company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The tax treatment of the CVRs is unclear. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments under, the CVRs, and there can be no assurance that the IRS would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, as discussed in the section titled &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Contingent Value Rights Agreement&#8212;Material U.S. Federal Income Tax Consequences of the CVRs to Holders of Frequency Common Stock</span>&#8221; beginning on page&#160;218 of this proxy statement/prospectus, Frequency does not intend to report the issuance of the CVRs as a current distribution of property with respect to its stock, but it is possible that the IRS could assert that Frequency stockholders are treated as having received a distribution of property equal to the fair market value of the CVRs on the date the CVRs are distributed, which could be taxable to Frequency stockholders without the corresponding receipt of cash. In addition, it is possible that the IRS or a court could determine that the issuance of the CVRs (and/or any payments thereon) and the Reverse Stock Split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes with the CVRs constituting taxable &#8220;boot&#8221; received in such recapitalization exchange. In such case, the tax consequences of the CVRs and the Reverse Stock Split would differ from those described in this proxy statement/prospectus, including with respect to the timing and character of income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_24">Risks Related to the Proposed Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Reverse Stock Split may not increase the combined company&#8217;s stock price over the long-term. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purpose of the Reverse Stock Split is to increase the <span style="white-space:nowrap">per-share</span> market price of Frequency common stock above the minimum bid price requirement under the Nasdaq rules so that Frequency can maintain </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its listing on Nasdaq. It cannot be assured, however, that the Reverse Stock Split will accomplish this objective for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of common stock will proportionally increase the market price of Frequency common stock, it cannot be assured that the Reverse Stock Split will increase the market price of its common stock by enough to maintain the listing of Frequency common stock on Nasdaq, or result in any permanent or sustained increase in the market price of Frequency common stock, which is dependent upon many factors, including Frequency&#8217;s business and financial performance, general market conditions, and prospects for future success. Thus, while the stock price of Frequency might meet the continued listing requirements for Nasdaq initially, it cannot be assured that it will continue to do so. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Reverse Stock Split may decrease the liquidity of the combined company&#8217;s common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Frequency board of directors believes that the anticipated increase in the market price of the combined company&#8217;s common stock resulting from the proposed Reverse Stock Split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the Reverse Stock Split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock. In addition, the Reverse Stock Split may not result in an increase in the combined company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the combined company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Reverse Stock Split may lead to a decrease in the combined company&#8217;s overall market capitalization. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should the market price of the combined company&#8217;s common stock decline after the Reverse Stock Split, the percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the Reverse Stock Split. A Reverse Stock Split is often viewed negatively by the market and, consequently, can lead to a decrease in the combined company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the Reverse Stock Split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the <span style="white-space:nowrap">per-share</span> stock price of companies that have effected reverse stock splits subsequently declined back to <span style="white-space:nowrap">pre-reverse</span> split levels, and accordingly, it cannot be assured that the total market value of the combined company&#8217;s common stock will remain the same after the Reverse Stock Split is effected, or that the Reverse Stock Split will not have an adverse effect on the combined company&#8217;s stock price due to the reduced number of shares outstanding after the Reverse Stock Split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_25">Risks Related to the Combined Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the events described in &#8220;<span style="font-style:italic">Risks Related to Frequency&#8217;s Business</span>&#8221; or &#8220;<span style="font-style:italic">Risks Related to Korro Bio&#8217;s Business</span>&#8221; occur, those events could cause potential benefits of the Merger not to be realized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the Merger, the combined company will be susceptible to many of the risks described in the sections herein entitled &#8220;<span style="font-style:italic">Risks Related to Frequency&#8217;s Business</span>&#8221; and &#8220;<span style="font-style:italic">Risks Related to Korro Bio&#8217;s Business</span>&#8221; beginning on pages 46 and 96. To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the combined company could be adversely affected in a material way. This could cause the market price of the combined company&#8217;s common stock to decline. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of the combined company&#8217;s common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company&#8217;s common stock to fluctuate include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of clinical trials and preclinical studies of the combined company&#8217;s product candidates, or those of the combined company&#8217;s competitors or the combined company&#8217;s existing or future collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed financial and development projections the combined company may provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed the financial and development projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actions taken by regulatory agencies with respect to the combined company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company&#8217;s ability to obtain patent protection for its technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or departures of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant lawsuits, including patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of securities by the combined company or its securityholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the combined company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of the combined company&#8217;s common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the introduction of technological innovations or new therapies that compete with the products and services of the combined company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> fluctuations in the combined company&#8217;s financial results. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the combined company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The combined company may incur losses for the foreseeable future and might never achieve profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company may never become profitable, even if the combined company is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The combined company will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several years. Even if the combined company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Following the Merger, the combined company may be unable to integrate successfully the businesses of Frequency and Korro Bio and realize the anticipated benefits of the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger involves the combination of two companies that currently operate as independent companies. Following the Merger, the combined company will be required to devote significant management attention and resources to integrating its business practices and operations. The combined company may fail to realize some or all of the anticipated benefits of the Merger if the integration process takes longer than expected or is more costly than expected. Potential difficulties the combined company may encounter in the integration process include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to successfully combine the businesses of Frequency and Korro Bio in a manner that permits the combined company to achieve the anticipated benefits from the merger, which would result in the anticipated benefits of the Merger not being realized partly or wholly in the time frame currently anticipated or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">creation of uniform standards, controls, procedures, policies and information systems; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Merger. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Frequency and Korro Bio have operated and, until the completion of the Merger, will continue to operate, independently. It is possible that the integration process also could result in the diversion of each company&#8217;s management&#8217;s attention, the disruption or interruption of, or the loss of momentum in, each company&#8217;s ongoing businesses or inconsistencies in standards, controls, procedures and policies, any of which could adversely affect the combined company&#8217;s ability to maintain its business relationships or the ability to achieve the anticipated benefits of the Merger, or could otherwise adversely affect the business and financial results of the combined company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The combined company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the combined company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or <span style="white-space:nowrap">in-licensing</span> or acquisition of new assets and could impact negatively its ability to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implement successfully its business plan. If the combined company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The combined company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company will require substantial additional funds to conduct the costly and time-consuming clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate. The combined company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute its stockholders&#8217; ownership interests or inhibit the combined company&#8217;s ability to achieve its business objectives. If the combined company raises additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely the rights of its common stockholders. In addition, any debt financing may subject the combined company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the combined company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the combined company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the combined company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the combined company or its stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company will incur significant legal, accounting and other expenses as a public company that Korro Bio did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act. The combined company&#8217;s management team will consist of the executive officers of Korro Bio prior to the Merger, some of whom have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the combined company complies with all of these requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Upon completion of the Merger, failure by the combined company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Merger, Frequency, under the new name &#8220;Korro Bio, Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, Frequency agreed to use its commercially reasonable efforts to cause the shares of Frequency common stock being issued in the Merger to be approved for listing on Nasdaq at or prior to the Effective Time. Based on information currently available to Frequency, Frequency anticipates that its stock will be unable to meet the $4.00 (or, to the extent applicable, $3.00) minimum bid price initial listing requirement at the closing of the Merger unless it effects a reverse stock split. The board of directors of Frequency intends to effect a reverse stock split of the shares of Frequency common stock at a ratio of between 1:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to 1:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the combined company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the combined company that its shares of common stock will not be listed on Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a potential delisting from Nasdaq, if the common stock of the combined company is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the combined company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the combined company. Also, it may be difficult for the combined company to raise additional capital if the combined company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the combined company and could have a material adverse effect on the combined company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Once the combined company is no longer an emerging growth company, a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the combined company will be subject to additional laws and regulations affecting public companies that will increase the combined company&#8217;s costs and the demands on management and could harm the combined company&#8217;s operating results and cash flows. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that the combined company file with the SEC, annual, quarterly and current reports with respect to the combined company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as an emerging growth company, the combined company may take advantage of exemptions from various requirements such as an exemption from the requirement to have the combined company&#8217;s independent auditors attest to the combined company&#8217;s internal control over financial reporting under Section&#160;404 of the Sarbanes-Oxley Act of 2002 as well as an exemption from the &#8220;say on pay&#8221; voting requirements pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. The combined company will no longer qualify as an emerging growth company after December&#160;31, 2023. After the combined company no longer qualifies as an emerging growth company, Frequency and Korro Bio expect the combined company to still qualify as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule <span style="white-space:nowrap">12b-2</span> under the Exchange Act, in at least the near term, which will allow the combined company to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the combined company&#8217;s periodic reports and proxy statements. Once the combined company is no longer an emerging growth company or a smaller reporting company or otherwise no longer qualifies for these exemptions, the combined company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the combined company is not able to comply with the requirements in a timely manner or at all, the combined company&#8217;s financial condition or the market price of the combined company&#8217;s common stock may be harmed. For example, if the combined company or its independent auditor identifies deficiencies in the combined company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the combined company could face additional costs to remedy those </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deficiencies, the market price of the combined company&#8217;s stock could decline or the combined company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided the combined company continues to be listed on Nasdaq, the combined company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and internal control over financial reporting. The combined company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form <span style="white-space:nowrap">10-K</span> filing for that year, as required by Section&#160;404 of the Sarbanes-Oxley Act. As a private company, Korro Bio has never been required to test its internal controls within a specified period. This will require that the combined company incur substantial professional fees and internal costs to expand its accounting and finance functions and that it expends significant management efforts. The combined company may experience difficulty in meeting these reporting requirements in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company may discover weaknesses in its system of internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. The combined company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the combined company is not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The unaudited pro forma condensed combined financial information for Frequency and Korro Bio included in this proxy statement/prospectus are preliminary, and the combined company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma financial information for Frequency and Korro Bio included in this proxy statement/prospectus are presented for illustrative purposes only and is not necessarily indicative of the combined company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the period presented. The combined company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/prospectus. The exchange ratio formula reflected in this proxy statement/prospectus is preliminary. The final exchange ratio will be determined in accordance with the formula in the Merger Agreement and could differ materially from the preliminary exchange ratio used to prepare the pro forma adjustments. For more information see the section titled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; beginning on page&#160;362. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger is completed, Frequency&#8217;s bylaws and Frequency&#8217;s charter, as amended by the amendments thereto attached to this proxy statement/prospectus as <span style="font-style:italic">Annex H</span> and, assuming Proposal No.&#160;2 are approved by Frequency stockholders at the Frequency Annual Meeting, will become the combined company&#8217;s bylaws and certificate of incorporation. Provisions that will be included in the combined company&#8217;s certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the combined company that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#8217;s common stock, thereby depressing the market price of its common stock. In addition, because the combined company&#8217;s board of directors will be responsible for appointing the members of the combined company&#8217;s management team, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the combined company&#8217;s board of directors. Among other things, these provisions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish a classified board of directors such that all members of the board are not elected at one time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">allow the authorized number of its directors to be changed only by resolution of its board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limit the manner in which stockholders can remove directors from the board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by its stockholders by written consent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limit who may call a special meeting of stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize its board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by its board of directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require the approval of the holders of at least 66.67% of the votes that all its stockholders would be entitled to cast to amend or repeal certain provisions of its charter or bylaws. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because the combined company will be incorporated in Delaware, it is governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined company voting stock from merging or combining with the combined company. Although Frequency and Korro Bio believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with the combined company&#8217;s board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The bylaws of the combined company will provide that, unless the combined company consents in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between the combined company and its stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the combined company or its directors, officers, employees or agents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The bylaws of the combined company will provide that, unless it consents in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (i)&#160;any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
derivative action or proceeding brought on its behalf, (ii)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any of its current or former directors, officers, or other employees to the combined company or its stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL, its charter or its bylaws, or (iv)&#160;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act and the Exchange Act. The bylaws of the combined company will further provide that, unless it consents in writing to an alternative forum, federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the &#8220;Federal Forum Provision.&#8221; In addition, the bylaws of the combined company will provide that any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived its compliance with the U.S. federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders of the combined company in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in the bylaws of the combined company may limit its stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with the combined company or its directors, officers or employees, which may discourage such lawsuits against the combined company and its directors, officers and employees even though an action, if successful, might benefit its stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency and Korro Bio do not anticipate that the combined company will pay any cash dividends in the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current expectation is that the combined company will retain its future earnings, if any, to fund the growth of the combined company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the combined company will be your sole source of gain, if any, for the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Merger, there had been no public market for shares of Korro Bio capital stock. An active trading market for the combined company&#8217;s shares of common stock may never develop or be sustained. If an active market for the combined company&#8217;s common stock does not develop or is not sustained, it may be difficult for its stockholders to sell their shares at an attractive price or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If existing securityholders of Frequency and Korro Bio sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, after giving effect to the estimated exchange ratio, which has been adjusted to reflect the proposed Reverse Stock Split, the Pre-Closing Financing and shares expected to be issued upon completion of the Merger, the combined company is expected to have outstanding a total of approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock immediately following the completion of the Merger. Of the shares of common stock, approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares will be available for sale in the public market beginning 180 days after the closing of the Merger as a result of the expiration of <span style="white-space:nowrap">lock-up</span> agreements between Frequency and Korro Bio on the one hand and certain securityholders of Frequency </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Korro Bio on the other hand. All other outstanding shares of common stock, other than shares held by affiliates of the combined company and shares of Frequency common stock issued in exchange for shares of Korro Bio common stock issued in the Pre-Closing Financing will be freely tradable, without restriction, in the public market. In addition, shares of common stock that are subject to outstanding options or warrants of Korro Bio will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of the combined company&#8217;s common stock could decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Merger, and giving effect to the issuance of the Pre-Closing Financing, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the combined company&#8217;s outstanding shares of common stock, subject to certain assumptions, including, but not limited to, Frequency&#8217;s net cash as of closing being not less than $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; million or greater than $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; million. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for the combined company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the combined company&#8217;s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts or the content and opinions included in their reports. The price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Pre-Closing Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company will have broad discretion over the use of the cash and cash equivalents of the combined company and the proceeds from the Pre-Closing Financing. You may not agree with the combined company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The combined company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the combined company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the combined company&#8217;s cash resources. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in tax laws or in their implementation or interpretation may adversely affect the combined company&#8217;s business and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect the combined company&#8217;s business and financial condition. In recent years, many such changes have been made and changes are likely to continue to occur in the future. The combined company cannot predict whether, when, in what form or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided or whether they could increase its tax liability or require changes in the manner in which it operates in order to minimize increases in its tax liability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The combined company&#8217;s ability to use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company&#8217;s ability to utilize net operating loss carryforwards, or NOLs, and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed below, in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the combined company earns taxable income, such limitations could result in increased future income tax liability to the combined company, and the combined company&#8217;s future cash flows could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more complete discussion of the risks related to the net operating loss carryforwards and certain other tax attributes of Frequency and Korro Bio, please see the discussions under &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Frequency&#8217;s Business&#8212;Risks Related to Frequency&#8217;s financial position and need for additional capital&#8212;Frequency&#8217;s ability to use its net operating loss carryforwards to offset future taxable income, or tax credit carryforwards to offset future income tax liabilities, may be subject to certain limitations</span>&#8221; and &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Korro Bio&#8217;s Financial Position and Need for Capital&#8212;Korro Bio&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited,</span>&#8221; respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unfavorable global economic conditions could adversely affect the combined company&#8217;s business, financial condition, results of operations or cash flows. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the combined company&#8217;s business, including, weakened demand for the combined company&#8217;s product candidates and the combined company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the combined company&#8217;s suppliers, possibly resulting in supply disruption, or cause the combined company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the combined company&#8217;s business and the combined company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_26">Risks Related to Frequency&#8217;s Business </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks related to Frequency&#8217;s financial position and need for additional capital </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency has incurred significant losses since inception and anticipates that Frequency will continue to incur losses for the foreseeable future. Frequency is not currently profitable, and Frequency may never achieve or sustain profitability. If Frequency is unable to achieve or sustain profitability, the market value of Frequency common stock will likely decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is a preclinical-stage biotechnology company with a limited operating history. As a result, Frequency is not profitable and has incurred significant losses since the formation. Frequency had net losses of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$19.5&#160;million and $81.6&#160;million for the three months ended March&#160;31, 2023, and the year ended December&#160;31, 2022, respectively. As of March&#160;31, 2023, Frequency had an accumulated deficit of $281.2&#160;million. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. Frequency has not commercialized any products and has never generated revenue from the commercialization of any product. To date, Frequency has devoted most of its financial resources to licensing technologies and research and development, including its preclinical platform development activities and clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency expects to incur significant additional operating losses to advance any product candidate, including a potential therapeutic candidate for MS, through clinical development, clinical trials, regulatory approval and commercialization. The costs of advancing product candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any product candidate to marketing approval in even a single jurisdiction are substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, Frequency is unable to accurately predict the timing or amount of increased expenses or when, or if, Frequency will be able to begin generating revenue from the commercialization of any product candidates or achieve or maintain profitability. Frequency&#8217;s expenses will also increase substantially if Frequency: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">develops and commences clinical trials for any product candidate, including for its MS Program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expands its development programs based on its PCA approach; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">further develops its PCA approach; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seeks regulatory approvals for any other product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">secures a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any product candidate for which Frequency obtains regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishes a sales, marketing and distribution infrastructure to commercialize any product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintains, expands, and protects its intellectual property portfolio; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acquires or <span style="white-space:nowrap">in-licenses</span> other product candidates or technologies. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, Frequency&#8217;s ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#8220;<span style="font-style:italic">Risks related to development, clinical testing, manufacturing, and regulatory approval</span>&#8221; and &#8220;<span style="font-style:italic">Risks related to commercialization</span>.&#8221; As a result, Frequency expects to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on Frequency&#8217;s stockholders&#8217; equity and working capital. The amount of its future net losses will depend, in part, on the rate of future growth of its expenses and its ability to generate revenues. If Frequency is unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, Frequency will not achieve profitability. Even if Frequency successfully commercializes any product candidates, Frequency may continue to incur substantial research and development and other expenses to identify and develop other product candidates. Even if Frequency does achieve profitability, Frequency may not be able to sustain profitability or meet outside expectations for its profitability. If Frequency is unable to achieve or sustain profitability or to meet outside expectations for its profitability, the value of Frequency common stock will be materially adversely affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency will require additional capital to fund its operations, and if Frequency fails to obtain necessary financing, Frequency may not be able to complete the development and commercialization of any product candidates or explore additional product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency will require additional capital to enable Frequency to develop any product candidate, which it may acquire through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Adequate additional financing may not be available to Frequency on acceptable terms, or at all. Frequency&#8217;s failure to raise capital as and when needed would have a negative effect on Frequency&#8217;s financial condition and its ability to pursue its business strategy. In addition, attempting to secure additional financing may divert the time and attention of Frequency&#8217;s management from <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities and harm its development efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changing circumstances, including any unanticipated expenses, could cause Frequency to consume capital significantly faster than Frequency currently anticipates, and Frequency may need to spend more than currently expected because of circumstances beyond its control. Because the length of time and scope of activities associated with successful development of any product candidate Frequency may develop is highly uncertain, Frequency is unable to estimate the actual funds it will require for development and any marketing and commercialization activities. Its future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the initiation, progress, timing, costs and results of clinical trials through all phases of development, including any unforeseen costs Frequency may incur as a result of public health emergencies or other causes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome, timing and cost of meeting regulatory requirements established by the FDA, and other comparable foreign regulatory authorities, including any clinical trials required by the FDA or other comparable foreign regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of the FDA and other comparable foreign regulatory authorities to accept its clinical trial designs, as well as data from clinical trials and preclinical studies, as the basis for review and approval of any product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of filing, prosecuting, defending, and enforcing its patent claims and other intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against Frequency; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing technological and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of completion of commercial-scale manufacturing activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of operating as a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which Frequency <span style="white-space:nowrap">in-licenses</span> or acquires other product candidates or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of establishing sales, marketing and distribution capabilities for its product candidates, if approved; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the initiation, progress, and timing of commercialization of any product candidate, if approved. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on its business performance, the economic climate and market conditions, Frequency may be unable to raise additional funds through any sources. Market volatility resulting from the <span style="white-space:nowrap">COVID-19</span> global pandemic, international geopolitical conflict, global supply chain issues, and increased inflation could also adversely impact its ability to access capital as and when needed. If Frequency is unable to raise additional capital in sufficient amounts or on terms acceptable to Frequency, Frequency may have to significantly delay, scale back or discontinue the development or commercialization of any product candidates, or potentially discontinue operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Frequency maintains the majority of its cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and its deposits at certain of these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where Frequency maintains its cash and cash equivalents, there can be no assurance that Frequency would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect its business and financial position. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency has a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for its future viability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency was established and began operations in 2014. Its operations to date have been limited to financing and staffing Frequency, licensing technologies, developing its PCA approach, developing and conducting preclinical and clinical studies for the treatment of SNHL, and developing a pipeline of preclinical and research programs, including its remyelination program in MS. Frequency has not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial-scale product, or arrange for a third party to do so on Frequency&#8217;s behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about its future success or viability may not be as accurate as they could be if Frequency had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a business with a limited operating history, Frequency may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Its <span style="white-space:nowrap">FX-322</span> Phase 2b results <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-208),</span></span> for example, showed no statistically significant difference at day 90 between those administered <span style="white-space:nowrap">FX-322</span> versus those receiving placebo in the proportion of individuals that demonstrated an improvement in speech perception. Frequency will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. Frequency may not be successful in such a transition and, as a result, its business may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency expects its financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond its control. Accordingly, the results of any quarterly or annual period are not necessarily indicative of future operating performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s ability to use its net operating loss carryforwards to offset future taxable income, or tax credit carryforwards to offset future income tax liabilities, may be subject to certain limitations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, Frequency had NOLs of $174.1&#160;million for federal income tax purposes and $141.3&#160;million for state income tax purposes, which may be available to offset its future taxable income, if any. Frequency&#8217;s NOLs expire in various amounts through 2042, provided that federal NOLs generated in taxable years beginning after December&#160;31, 2017, will not be subject to expiration. However, although federal NOLs generated in taxable years beginning after December&#160;31, 2017, may be carried forward indefinitely, such NOLs may only be used to offset 80% of Frequency&#8217;s taxable income in taxable years beginning after December&#160;31, 2020, which may require Frequency to pay federal income taxes in future years despite generating federal NOLs in prior years. As of December&#160;31, 2022, Frequency also had federal and state research and development and other tax credit carryforwards of approximately $8.2&#160;million and $3.6&#160;million, respectively, available to reduce future income tax liabilities. Frequency&#8217;s tax credit carryforwards expire at various dates through 2042. These NOLs and tax credit carryforwards could expire unused, to the extent subject to expiration, and be unavailable to offset future taxable income or income tax liabilities, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in general, under Sections 382 and 383 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to use its <span style="white-space:nowrap">pre-change</span> NOLs and tax credit carryforwards to offset future taxable income. For these purposes, an ownership change generally occurs where one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases their ownership </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. Frequency believes it has experienced ownership changes in 2017 and 2019. As a result of the ownership changes in 2017 and 2019, $0.01&#160;million and $0.04&#160;million of NOL carryforwards are limited under Section&#160;382 of the Code. Frequency may experience ownership changes in the future as a result of future transactions in its stock, some of which may be outside its control. In particular, the Merger and the Pre-Closing Financing, if consummated, are likely to constitute an ownership change within the meaning of Section&#160;382 of the Code, which could eliminate or otherwise substantially limit Frequency&#8217;s ability to use its NOLs and tax credit carryforwards. For these reasons, Frequency may not be able to use a material portion of its NOLs or tax credit carryforwards, even if Frequency attains profitability. Frequency has recorded a full valuation allowance related to its NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future tax benefit of such assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in tax laws or in their implementation or interpretation may adversely affect Frequency&#8217;s business and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect Frequency&#8217;s business and financial condition. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Frequency cannot predict whether, when, in what form or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided or whether they could increase its tax liability or require changes in the manner in which it operates in order to minimize increases in its tax liability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_28"><span style="font-style:italic">Risks related to development, clinical testing, manufacturing, and regulatory approval </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency is heavily dependent on the MS Program, and if it is unable to enter into a strategic transaction for its MS Program, or is unable to develop an MS product candidate or such MS product candidate does not receive regulatory approval or is not successfully commercialized, its business could be materially adversely harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, Frequency has invested a significant portion of its efforts and financial resources in the development of <span style="white-space:nowrap">FX-322</span> for the treatment of SNHL. Frequency recently discontinued its <span style="white-space:nowrap">FX-322</span> and <span style="white-space:nowrap">FX-345</span> development programs following the results of its <span style="white-space:nowrap">FX-322</span> Phase 2b study which showed no statistically significant difference at day 90 between those administered <span style="white-space:nowrap">FX-322</span> versus those receiving placebo in the proportion of individuals that demonstrated an improvement in speech perception. Frequency&#8217;s future success is substantially dependent on its ability to successfully enter into a strategic transaction for its MS Program or complete development for, obtain regulatory approval for, and successfully commercialize an MS product candidate, which may never occur. Frequency currently has no products that are approved for commercial sale and may never be able to develop a marketable product. An MS development program will require a substantial portion of Frequency&#8217;s efforts and expenditures and will require clinical development, management of clinical and manufacturing activities, regulatory approval, establishing commercial scale manufacturing, and significant sales, marketing, and distribution efforts before Frequency can generate any revenues from any commercial sales. Frequency cannot be certain that it will be able to successfully complete any of these activities or that, even if it receives regulatory approval, a remyelinating therapeutic will be as effective as anticipated at treating MS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, labeling, approval, sale, packaging, marketing, and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. Frequency is not permitted to market an MS product candidate until Frequency receive regulatory approval from the FDA or comparable regulatory authorities in other countries, and Frequency may never receive such regulatory approval. Furthermore, Frequency cannot be certain that it will be able to enter into any strategic transaction for the MS Program or that it will be able to enter into a strategic transaction on favorable terms. As a result, its financial position could be materially adversely affected, and Frequency may not be able to generate sufficient revenue to continue its business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency utilizes its PCA approach to develop product candidates that are designed to activate progenitor cells, which is a new approach to therapeutic intervention and, as a result, successful development, approval, and commercialization of any product candidates, including an MS product candidate, is uncertain. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency utilizes its PCA approach to develop product candidates, including in its MS development program. Frequency&#8217;s PCA approach is designed to identify pathways to activate progenitor cells already present in the body to treat conditions or diseases through cellular regeneration. Frequency has not, nor to its knowledge has any other company, received regulatory approval utilizing this mechanism of cellular regeneration. Given the novelty of its approach, Frequency could encounter a longer than expected regulatory review process, increased development costs, or unexpected delays in, or even prevention of, the regulatory approval and commercialization of its product candidates, and Frequency cannot be certain that its approach will lead to the development of any approvable or marketable products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical trials are expensive, time consuming, and difficult to design and implement, and involve an uncertain outcome. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that Frequency advances into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and completed clinical trials are not necessarily predictive of future results, and any product candidates Frequency develops may not be further developed or may have additional unfavorable results in later studies or trials. Clinical trial failure may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection, placebo effect, subject enrollment criteria, selection of subjects based on subject misrepresentations, and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing, which may result in setbacks in development or a determination to no longer pursue a particular product candidate or indication. For example, later-stage clinical trials in its hearing program failed to meet their primary end points despite promising results from earlier clinical trials and, as a result, Frequency ended its hearing program. Further, based upon negative or inconclusive results or a need for additional information, Frequency may decide, or regulatory authorities may require Frequency, to conduct additional clinical trials or preclinical studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency may experience delays in initiating and completing any clinical trials that Frequency intends to conduct, and Frequency does not know whether its clinical trials will begin on time, need to be redesigned, enroll subjects on time, or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of its clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining regulatory approval to commence a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining Institutional Review Board, or IRB, approval at each site within the United States, or Independent Ethics Committee, or IEC, approval at sites outside the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business interruptions resulting from public health emergencies, such as the <span style="white-space:nowrap">COVID-19</span> pandemic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recruiting suitable subjects to participate in a trial in a timely manner and in sufficient numbers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">having subjects complete a trial or return for post-treatment <span style="white-space:nowrap">follow-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites or investigators to adhere to regulatory requirements or follow trial protocols; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical sites deviating from the trial protocol or dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">addressing subject safety concerns that arise during a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adding a sufficient number of clinical trial sites; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing sufficient quantities of a product candidate for use in clinical trials. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency could also encounter delays if a clinical trial is suspended or terminated by Frequency, the IRBs or IECs of the institutions in which such trials are being conducted, the FDA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board, or DSMB, for such trial. Such authorities may impose a suspension or termination or recommend an alteration due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or its clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, Frequency relies on CROs and clinical trial sites to ensure the proper and timely conduct of its clinical trials and, while Frequency has agreements governing its committed activities, Frequency has limited influence over its actual performance, as described in the section titled &#8220;<span style="font-style:italic">Risks related to Frequency&#8217;s dependence on third parties</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency experiences delays in the commencement or completion of any clinical trials, or if Frequency terminates a clinical trial prior to completion, the commercial prospects of any product candidate Frequency develops could be harmed, and its ability to generate revenues may be delayed. In addition, any delays in its clinical trials could increase its costs, slow the development and approval process and jeopardize its ability to commence product sales and generate revenues. Any of these occurrences may materially harm its business, financial condition, and results of operations. In addition, many of the factors that may cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of its product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time- consuming, and inherently unpredictable, and if Frequency is ultimately unable to obtain regulatory approval for any product candidates, its business will be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate&#8217;s clinical development and may vary among jurisdictions. The approval process may also be delayed by changes in government regulation, future legislation or administrative action. Frequency has not obtained regulatory approval for any product candidate and it is possible that Frequency will never obtain regulatory approval for any product candidate. Frequency is not permitted to market any of its product candidates in the United States until Frequency receives approval of an NDA from the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, Frequency must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. In addition, data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may not interpret its data as favorably as Frequency does, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Furthermore, as more competing drug candidates within a class of drugs proceed through clinical development to regulatory review and approval, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the amount and type of clinical data that may be required by regulatory authorities may increase or change. Even if Frequency believes the preclinical or clinical data for its product candidates are promising, such data may not be sufficient to support approval by the FDA and other comparable regulatory authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or any foreign regulatory authority can delay, limit, or deny approval of a product candidate that Frequency develops or requires Frequency to conduct additional preclinical or clinical testing or abandon a program for many reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of its clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">serious and unexpected drug-related side effects experienced by participants in its clinical trials or by individuals using drugs similar to its product candidates, or other products containing an active ingredient in its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or ambiguous results from its clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may disagree with its interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the data collected from clinical trials of its product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and Frequency may be required to conduct additional clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s disagreement regarding the formulation, the labeling, and/or the specifications of its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which Frequency contracts for clinical and commercial supplies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering its clinical data insufficient for approval; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant regulatory GxP <span style="white-space:nowrap">non-compliance</span> or data integrity findings from FDA Bioresearch Monitoring inspections or <span style="white-space:nowrap">pre-approval</span> inspections inclusive of clinical investigator sites, contracted partners and their company&#8217;s quality management system and execution thereof. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in Frequency&#8217;s failing to obtain regulatory approval to market its product candidates, which would significantly harm its business, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA or the applicable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than Frequency originally requested, and the FDA or applicable foreign regulatory authority may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing circumstances could materially harm the commercial prospects for its product candidates and its business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Enrollment and retention of individuals in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Frequency&#8217;s control. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their protocols depends, among other things, on Frequency&#8217;s ability to enroll a sufficient number of subjects who remain in the study until its conclusion. Frequency may encounter delays in enrolling, or be unable to enroll, a sufficient number of subjects to complete any of its clinical trials, and even once enrolled, Frequency may be unable to retain a sufficient number of subjects to complete any of its trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject enrollment and retention in clinical trials depends on many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the subject eligibility criteria defined in the protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size of the subject population required for analysis of the trial&#8217;s primary endpoints; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the nature of the trial protocol, trial design, side effects or other results that may arise in development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the existing body of safety and efficacy data with respect to the product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the proximity of subjects to clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">its ability to recruit clinical trial investigators with the appropriate competencies, motivation and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications Frequency is investigating; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competing clinical trials being conducted by other companies or institutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">its ability to obtain and maintain subject consents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that subjects enrolled in clinical trials will drop out of the trials before completion; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any ongoing impact of the <span style="white-space:nowrap">COVID-19</span> pandemic, see &#8220;<span style="font-style:italic">The COVID-19 pandemic has caused and could continue to cause disruptions to Frequency&#8217;s business, including its preclinical studies, clinical trials and operations and could adversely impact its financial condition and results of operation</span><span style="font-weight:bold"><span style="font-style:italic">s</span></span><span style="font-style:italic">.&#8221;</span>; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Frequency&#8217;s clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as its product candidates, and this competition will reduce the number and types of subjects available to Frequency, because some people who might have opted to enroll in its trials may instead opt to enroll in a trial being conducted by one of its competitors. Furthermore, any negative results Frequency may report in clinical trials of any product candidate may make it difficult or impossible to recruit and retain people in other clinical trials of that same product candidate. Delays or failures in planned subject enrollment or retention may result in increased costs or program delays, which could have a harmful effect on its ability to develop a product candidate or could render further development impossible. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Results of preclinical studies, clinical trials, or analyses may not be indicative of results that may be obtained in later trials or preclinical studies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of preclinical studies, clinical trials, or analyses of the results from such trials may not be predictive of the results of later preclinical studies or clinical trials. Product candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising results. Frequency&#8217;s <span style="white-space:nowrap">FX-322</span> Phase 2b results <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-208),</span></span> for example, showed no statistically significant difference at day 90 between those administered <span style="white-space:nowrap">FX-322</span> versus those receiving placebo in the proportion of individuals that demonstrated an improvement in speech perception. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and post hoc analysis of data from its Phase 1/2 clinical trial of <span style="white-space:nowrap">FX-322</span> for the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment of SNHL <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-201),</span></span> may be shown to be incorrect in subsequent clinical trials that have <span style="white-space:nowrap">pre-specified</span> end points or may not be considered adequate by regulatory authorities. Further, Frequency has in the past and may in the future abandon product candidates that Frequency initially advanced for development based on positive preclinical results due to unfavorable results from additional preclinical studies. For example, Frequency recently discontinued its <span style="white-space:nowrap">FX-322</span> and <span style="white-space:nowrap">FX-345</span> development programs after the results of the <span style="white-space:nowrap"><span style="white-space:nowrap">FX-322-208</span></span> clinical trial. Even if Frequency completes later clinical trials as planned, Frequency cannot be certain that its results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, its clinical development plans may be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interim and preliminary <span style="white-space:nowrap">&#8220;top-line&#8221;</span> data from its clinical trials that Frequency announces or publishes from time to time may change as more subject data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Frequency may publicly disclose interim, <span style="white-space:nowrap">top-line</span> or preliminary data from its clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Frequency also makes assumptions, estimations, calculations and conclusions as part of its analyses of data, and Frequency may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the <span style="white-space:nowrap">top-line</span> or preliminary results that Frequency reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. <span style="white-space:nowrap">Top-line</span> or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the <span style="white-space:nowrap">top-line</span> or preliminary data Frequency previously published. As a result, <span style="white-space:nowrap">top-line</span> and preliminary data should be viewed with caution until the final data are available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Frequency may also disclose interim data from its preclinical studies and clinical trials. Interim data from clinical trials that Frequency may complete are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more subject data become available. Adverse differences between interim data and final data could significantly harm its business prospects. Further, disclosure of interim data by Frequency or by its competitors could result in volatility in the price of Frequency common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with Frequency&#8217;s assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and its company in general. In addition, the information Frequency chooses to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Frequency determines is material or otherwise appropriate information to include in its disclosure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the interim, <span style="white-space:nowrap">top-line</span> or preliminary data that Frequency reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, its ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, operating results, prospects or financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any of Frequency&#8217;s product candidates or component of a product candidate that Frequency develops or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Serious adverse events or undesirable side effects caused by its product candidates or component of a product candidate Frequency develops could cause Frequency or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of any clinical trial Frequency conducts could reveal a high and unacceptable severity and prevalence of side effects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If unacceptable side effects arise in the development of any product candidate, Frequency, the FDA, or the IRBs or IECs at the institutions in which its studies are conducted, or the DSMB, if constituted for their clinical trials, could recommend a suspension or termination of their clinical trials, or the FDA or comparable foreign regulatory authorities could order Frequency to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect subject recruitment or the ability of enrolled subjects to complete a trial or result in potential product liability claims. These side effects also may not be appropriately recognized or managed by the treating medical staff. Frequency may have to train medical personnel regarding the proper administration protocol for their product candidates and to understand the side effect profiles for their clinical trials and upon any commercialization of any of their product candidates. Inadequate training in recognizing or managing the potential side effects of their product candidates could result in subject injury or death. Any of these occurrences may harm its business, financial condition, and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any product candidates Frequency develops receives marketing approval, and Frequency or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may suspend, withdraw, or limit approvals of such product, or seek an injunction against its manufacture or distribution; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require Frequency to recall a product or Frequency may decide to initiate a voluntary recall of a product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional restrictions may be imposed on the marketing of the product or the manufacturing processes for the product or any component thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to subjects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency may be required to conduct post-market studies or agree to post marketing commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency could be sued and held liable for harm caused to subjects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the product may become less competitive; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s reputation may suffer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent Frequency from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm its business, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Disruptions at the FDA and other government agencies caused by funding shortages, changes in the federal administration or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact Frequency&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect Frequency&#8217;s business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs or the FDA experiences other delays, it could significantly impact the ability of the FDA to timely review and process their regulatory submissions, which could have a material adverse effect on their business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <span style="white-space:nowrap">COVID-19</span> pandemic, the FDA postponed most inspections of foreign and domestic manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of their employees and those of the firms it regulates as it adapts to the evolving <span style="white-space:nowrap">COVID-19</span> pandemic, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <span style="white-space:nowrap">COVID-19</span> pandemic or issue guidance materially affecting the conduct of clinical trials. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process its regulatory submissions, which could have a material adverse effect on its business. Further, in Frequency&#8217;s operations as a public company, future government shutdowns or delays could impact its ability to access the public markets and obtain necessary capital in order to properly capitalize and continue its operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency may not be successful in its efforts to identify additional product candidates. Due to Frequency&#8217;s limited resources and access to capital, Frequency must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency may fail to identify viable new product candidates for clinical development for several reasons. If Frequency fails to identify additional potential product candidates, its business could be materially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research programs to develop additional product candidates based on its PCA approach require substantial technical, financial, and human resources whether or not they are ultimately successful. Frequency&#8217;s research programs may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for several reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the research methodology used may not be successful in identifying potential indications or product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential product candidates may, after further study, be shown to have harmful or unexpected adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may take greater human and financial resources than Frequency possesses to identify additional therapeutic opportunities for its product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting its ability to develop, diversify, and expand its product portfolio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Frequency has limited financial and human resources, Frequency focuses on research programs and product candidates for a limited set of indications. As a result, Frequency may forego or delay pursuit of opportunities with other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Frequency&#8217;s resource allocation decisions may cause Frequency to fail to capitalize on viable commercial products or profitable market opportunities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance that Frequency will ever be able to identify additional therapeutic opportunities for its product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect its future growth and prospects. Frequency may focus its efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency has never obtained marketing approval for a product candidate and Frequency may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that Frequency submits for its product candidates or may conclude after review of its data that Frequency&#8217;s applications are insufficient to obtain marketing approval of its product candidates. Frequency believes its approach of activating progenitor cells to treat conditions or diseases through cellular regeneration is novel and, as a result, the process for, and the outcome of, FDA approval is especially uncertain. If the FDA does not accept or approve its NDAs for its product candidates, it may require that Frequency conducts additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider its applications. Depending on the extent of these or any other <span style="white-space:nowrap">FDA-required</span> studies, approval of any NDA that Frequency submits may be delayed or may require Frequency to expend more resources than Frequency has available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve its NDAs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent Frequency from commercializing its product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, Frequency may be forced to abandon its development efforts for its product candidates, which could significantly harm Frequency&#8217;s business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if Frequency obtains FDA approval for a product candidate in the United States, Frequency may never obtain approval for or commercialize the product candidate in any other jurisdiction, which would limit its ability to realize its full market potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product in a particular jurisdiction, Frequency or its collaborators must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact Frequency&#8217;s or its collaborators&#8217; ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for Frequency and require additional preclinical studies or clinical trials which could be costly and time- consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of its products in those countries. Frequency does not have any product candidates approved for sale in any jurisdiction, including in international markets, and Frequency does not have experience in obtaining regulatory approval in international markets. If Frequency fails to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, its target market will be reduced and Frequency will be unable to realize the full market potential of any product Frequency develops. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if Frequency obtains regulatory approval for any product candidate, Frequency will still face extensive and ongoing regulatory requirements and obligations, which may result in significant additional expense, and any product candidates, if approved, may face future development and regulatory difficulties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate for which Frequency obtains marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, and requirements for any clinical trials that Frequency conducts post-approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If a product candidate receives marketing approval, the accompanying label may limit the approved indicated use of the product, which could limit sales of the product. The FDA may also require costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding <span style="white-space:nowrap">off-label</span> use, and if Frequency markets its products for uses beyond their approved indications, Frequency may be subject to enforcement action for <span style="white-space:nowrap">off-label</span> marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs, may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown adverse events or other problems with its products, manufacturers, or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on manufacturing such products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the labeling or marketing of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on product distribution or use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requirements to conduct post-marketing studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">warning letters or untitled letters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to approve pending applications or supplements to approved applications that Frequency submit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recalls or market withdrawals of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, restitution, or disgorgement of profits or revenues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or withdrawal of marketing approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to permit the import or export of its products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions, consent decrees, or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. If Frequency is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Frequency is not able to maintain regulatory compliance, Frequency may lose any marketing approval that it may have obtained, which would adversely affect its business, prospects, and ability to achieve or sustain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The policies of the FDA and of other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. If Frequency is slow or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Frequency is not able to maintain regulatory compliance, Frequency may be subject to enforcement action, and it may not achieve or sustain profitability, which would adversely affect its business, prospects, financial condition, and results of operations. Furthermore, noncompliance by Frequency or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in significant financial penalties, which would adversely affect its business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential product liability lawsuits against Frequency could cause Frequency to incur substantial liabilities and limit commercialization of any products that it may develop. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of any product candidate Frequency may develop in clinical trials and the sale of any products for which Frequency obtains marketing approval exposes Frequency to the risk of product liability claims. Product liability claims might be brought against Frequency by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with its products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If Frequency cannot successfully defend against product liability claims, it could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impairment of its business reputation and significant negative media attention; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of participants from its clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant costs to defend the litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">distraction of management&#8217;s attention from its primary business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to patients or other claimants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to commercialize a product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product recalls, withdrawals or labeling, marketing or promotional restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased market demand for any product; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The product liability insurance Frequency currently carries, and any additional product liability insurance coverage Frequency acquires in the future, may not be sufficient to reimburse Frequency for any expenses or losses Frequency may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, Frequency may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect Frequency against losses due to liability. If Frequency obtains marketing approval for any product candidate, Frequency intends to acquire insurance coverage to include the sale of commercial products; however, Frequency may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against Frequency could cause its share price to decline and, if judgments exceed its insurance coverage, could adversely affect its results of operation and business, including preventing or limiting the commercialization of any product candidates Frequency develops. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The <span style="white-space:nowrap">COVID-19</span> pandemic has caused and could continue to cause disruptions to Frequency&#8217;s business, including its preclinical studies, clinical trials and operations and could adversely impact its financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global outbreak of <span style="white-space:nowrap">COVID-19</span> continues to rapidly evolve and continues to have indeterminable adverse effects on general commercial activity and the world economy. Due to the uncertain nature of the effects of the outbreak, particularly in the United States, enrollment, participation and retention in Frequency&#8217;s planned trials may be reduced, and for a number of the clinical sites, halted for an unknown period of time. Any reduction in enrollment, participation and retention and any halts may delay clinical trials and development plans for any product candidates, which could have an adverse impact on Frequency&#8217;s business and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If <span style="white-space:nowrap">COVID-19</span> or its variants again spread in the United States and worldwide, and measures to mitigate the ongoing effects of the pandemic, such as stay home orders and/or advisories persist or are reintroduced, Frequency may continue to experience disruptions and other effects on its business that could severely impact its business, operations, preclinical studies and clinical trials, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays, difficulties or postponement in enrolling and retaining subjects in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays, difficulties or postponement in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversion of healthcare resources away from the conduct of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption of, or delays in receiving, supplies of its product candidates from its contract manufacturing organizations, or CMOs, due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruptions in planned trials due to restricted or limited operations at its laboratory facility; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continual changes to operating requirements and related expenses, limitations in employee resources that would otherwise be focused on the conduct of its preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people and resulting losses of productivity and employee work culture; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risk that participants enrolled in its clinical trials will acquire <span style="white-space:nowrap">COVID-19</span> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA, or other government agencies, to accept data from clinical trials in these affected geographies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption or delayed to its sourced discovery and clinical activities, and; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to obtain additional financing or access the financial markets. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which <span style="white-space:nowrap">COVID-19</span> may continue to impact Frequency&#8217;s business, preclinical studies, clinical trials and operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence. In addition, if Frequency or any of the third parties with whom Frequency engages were to experience shutdowns or additional business disruptions, Frequency&#8217;s ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively impacted, which could have a material adverse effect on its business and its financial results. The <span style="white-space:nowrap">COVID-19</span> pandemic has resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide, resulting in an economic downturn that could continue to significantly impact its business, financial condition and results of operations. To the extent the <span style="white-space:nowrap">COVID-19</span> pandemic adversely affects Frequency&#8217;s business, financial condition and results of operations, it may also have the effect of heightening many of the other risks described in this &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; section. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_29"><span style="font-style:italic">Risks related to commercialization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency faces significant competition from biotechnology and pharmaceutical companies, and its operating results will suffer if Frequency fails to compete effectively. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Frequency&#8217;s success is highly dependent on its ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If a product candidate Frequency develops is approved, Frequency will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies, and early-stage companies, particularly if the early-stage company has a collaborative arrangement with a large and established company. Frequency is aware of several companies developing programs with research and development efforts to treat MS through the regeneration of myelin. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition could render any product candidate Frequency develops obsolete, less competitive, or uneconomical. Frequency&#8217;s competitors may, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have significantly greater name recognition and financial, manufacturing, marketing, product development, technical, and human resources than Frequency does, with mergers and acquisitions in the biotechnology and pharmaceutical industries resulting in even more resources being concentrated in its competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">more effectively recruit and retain qualified scientific and management personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">more effectively establish clinical trial sites and subject registration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain quicker regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary for, its programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implement more effective approaches to sales, marketing, pricing, coverage, and reimbursement; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">form more advantageous strategic alliances or collaborations. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency is not able to effectively compete for any of the foregoing reasons, its business will be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The successful commercialization of any product candidate Frequency develops will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for its product candidates, if approved, could limit Frequency&#8217;s or its collaborators&#8217; ability to market those products and decrease Frequency&#8217;s or its collaborators&#8217; ability to generate revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford prescription medications. Frequency&#8217;s ability to achieve acceptable levels of coverage and reimbursement for products or procedures using its products by governmental authorities, private health insurers and other organizations will influence its ability to successfully commercialize any product candidates Frequency develops. Assuming Frequency obtains coverage for any product candidates or procedures using its products by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <span style="white-space:nowrap">co-payments</span> that patients find unacceptably high. Frequency cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product Frequency commercializes, and any reimbursement that may become available may be decreased or eliminated in the future. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and the current presidential administration and Congress have introduced several proposals related to drug pricing. Many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. A third-party payor may consider such a drug as substitutable and only offer to reimburse patients for the less expensive product. Even if Frequency shows improved efficacy, pricing of existing drugs may limit the amount Frequency will be able to charge for any product Frequency commercializes. Payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable Frequency to realize a satisfactory return on its investment in its product candidates. If reimbursement is not available or is available only at limited levels, Frequency may not be able to successfully commercialize its product candidates and may not be able to obtain a satisfactory financial return on its product candidates. Additionally, Frequency&#8217;s ability to obtain a satisfactory financial return depends on what, if any, proposals related to drug pricing may be implemented and, if implemented, when they might take effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require <span style="white-space:nowrap">pre-approval</span> of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, and one third-party payor&#8217;s decision to cover a product does not ensure that other payors will also provide similar coverage. Additionally, the process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the reimbursement rate that the payor will pay for the product once coverage is approved. As a result, the determination of coverage and reimbursement is often a time-consuming and costly process that will require Frequency to provide scientific and clinical support for the use of Frequency&#8217;s product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and Frequency believes that changes in these rules and regulations are likely. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any product Frequency commercializes. Frequency expects to experience pricing pressures in connection with the sale of any product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations, and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency may also be subject to extensive governmental price controls and other market regulations outside of the United States, and Frequency believes the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that Frequency is able to charge for products Frequency commercializes. Accordingly, in markets outside the United States, the reimbursement for products Frequency or commercialize may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if a product candidate Frequency develops receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product candidate Frequency develops receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. In addition, physicians, patients, and third-party payors may prefer other novel products to Frequency&#8217;s. If a product candidate does not achieve an adequate level of acceptance, Frequency may not generate significant product revenues or become profitable. The degree of market acceptance of its product candidates, if approved, will depend on several factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the efficacy and potential advantages compared to alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effectiveness of sales and marketing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of treatment in relation to alternative treatments, including any similar generic treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s ability to offer its products for sale at competitive prices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the convenience and ease of administration compared to alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the strength of marketing and distribution support; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of third-party coverage and adequate reimbursement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any side effects; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any restrictions on the use of its product together with other medications. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Frequency expects sales of its product candidates, if approved, to generate substantially all its revenues for the foreseeable future, the failure of its product candidates to find market acceptance would harm its business and could require Frequency to seek additional financing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Frequency is unable to establish sales and marketing capabilities either on its own or in collaboration with third parties, Frequency may not be successful in commercializing any product candidate Frequency develops, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market and successfully commercialize any product candidate Frequency develops, if approved, Frequency must build its sales and marketing capabilities or enter into collaborations with third parties for these services. Frequency currently has no sales, marketing or distribution capabilities and as a company have no experience in marketing products. To the extent that Frequency depends on collaborators for sales and marketing activities, any revenues Frequency receives will depend upon the success of those collaborators&#8217; sales and marketing teams and the collaborators&#8217; prioritization of its product and compliance with applicable regulatory requirements, and there can be no assurance that the collaborators&#8217; efforts will be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency is unable to enter into a collaboration for the commercialization of product candidates Frequency develops, if approved, Frequency may be forced to delay the commercialization of its product candidates or reduce the scope of its sales or marketing activities, which would have an adverse effect on its business, operating results and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A variety of risks associated with operating internationally could materially adversely affect Frequency&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s business strategy includes potentially expanding internationally if any of its product candidates receive regulatory approval. Doing business internationally involves several risks, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">multiple, conflicting, and changing laws and regulations, such as data privacy and security laws and regulations, tax laws, export and import restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by Frequency to obtain and maintain regulatory approvals for the use of its products in various countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional potentially relevant third-party patent rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complexities and difficulties in obtaining protection and enforcing its intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in staffing and managing foreign operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient <span style="white-space:nowrap">self-pay</span> systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limits in its ability to penetrate international markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for its products, and exposure to foreign currency exchange rate fluctuations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain expenses, including, among others, expenses for travel, translation, and insurance; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and corruption. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could significantly harm any future international expansion and operations and, consequently, Frequency&#8217;s results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_30"><span style="font-style:italic">Risks related to Frequency&#8217;s dependence on third parties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency may not succeed in establishing and maintaining collaborations, which may significantly limit its ability to successfully develop and commercialize any product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency may seek collaborations for the development and commercialization of any product candidates. The process of establishing and maintaining collaborative relationships is difficult, time-consuming, and involves significant uncertainty, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may shift its priorities and resources away from its product candidates due to a change in business strategies, or a merger, acquisition, sale, or downsizing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may seek to renegotiate or terminate its relationships with Frequency due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may cease development in therapeutic areas which are the subject of its collaboration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may not devote sufficient capital or resources towards its product candidates, or may fail to comply with applicable regulatory requirements; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a significant delay in initiation of certain development activities by a collaborator will also delay payment of milestones tied to such activities, thereby impacting its ability to fund its own activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator could develop a product that competes, either directly or indirectly, with its product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the marketing, distribution, or sale of a product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to meet demand requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may terminate a strategic alliance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a dispute may arise between Frequency and a collaborator concerning the research, development, or commercialization of a product candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management&#8217;s attention and resources; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may use its products or technology in such a way as to invite litigation from a third party. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, Frequency&#8217;s research, clinical development, manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for Frequency to assume responsibility for expenses or activities that would otherwise have been the responsibility of its collaborator. If Frequency is unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, Frequency may have to delay or discontinue further development of one or more of its product candidates, undertake development and commercialization activities at its own expense, or find alternative sources of capital, which would have a material adverse impact on Frequency&#8217;s clinical development plans and business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties Frequency may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties Frequency may engage in connection with development and commercialization of its product candidates, could engage in misconduct, including intentional, reckless, or negligent conduct or unauthorized activities that violate applicable laws, rules, and regulations including: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse, and other healthcare laws and regulations; or laws that require the reporting of true, complete, and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these or other laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to Frequency&#8217;s reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions Frequency takes to detect and prevent this activity may not be effective in controlling </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unknown or unmanaged risks or losses or in protecting Frequency from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, Frequency is subject to the risk that a person or government agency could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against Frequency or them and Frequency is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of its operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency currently intends to rely on third-party CMOs for the production of clinical supply and the production of commercial supply of any product candidates, as well as to supply raw materials necessary to produce its product candidates. Frequency&#8217;s dependence on CMOs may impair the development of its product candidates and may impair their commercialization, which would adversely impact its business and financial position. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency does not own facilities for manufacturing any product candidate. Instead, Frequency relies on and expects to continue to rely on CMOs for the supply of cGMP grade clinical trial materials of any product candidates Frequency develops and, in future, for commercial quantities. Reliance on CMOs may expose Frequency to more risk than if Frequency was to manufacture its product candidates itself. If any CMO Frequency engages is unable to provide sufficient supply of any product candidate Frequency develops, Frequency may be unable to arrange for an alternative supply or to do so on commercially reasonable terms or in a timely manner, which could delay any clinical trials, the commercial launch of its product candidates, if approved, or, regarding any commercial supply, result in a shortage in supply that could negatively impact its revenues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used to manufacture any product candidates Frequency develops must be inspected by the FDA and comparable foreign regulatory authorities. While Frequency provides oversight of manufacturing activities, Frequency does not and will not control the execution of manufacturing activities by, and are or will be dependent on, its CMOs for compliance with cGMP requirements for the manufacture of any product candidates. As a result, Frequency is subject to the risk that any product candidates may have manufacturing defects that Frequency has limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to its specifications and the regulatory requirements, Frequency will not be able to secure or maintain regulatory approval for the use of its product candidates in clinical trials, or for commercial distribution of any product candidates, if approved. Frequency has limited control over the ability of its CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and Frequency was not involved in developing its CMOs&#8217; policies and procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of Frequency&#8217;s product candidates or if it withdraws any such approval or finds deficiencies in the future, Frequency may need to find alternative manufacturing facilities, which would delay its development program and significantly impact its ability to develop, obtain regulatory approval for, or commercialize its product candidates, if approved. In addition, any failure to achieve and maintain compliance with laws, regulations, and standards related to manufacturing could subject Frequency to risks, including the risk that Frequency may have to suspend the manufacture of its product candidates, that obtained approvals could be revoked, and that the FDA or another governmental regulatory authority may take enforcement actions, including untitled letters, warning letters, seizures, injunctions, or product recalls. Furthermore, CMOs may breach existing agreements they have with Frequency because of factors beyond its control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for Frequency. If Frequency was unable to find an adequate CMO or another acceptable solution in time, its clinical trials could be delayed, or its commercial activities could be harmed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency contracts for the supply of the active pharmaceutical ingredient, or API, and other raw material necessary to produce any product candidates Frequency develops. Supplies of API or other raw material could be interrupted from time to time and Frequency cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. The extent to which the <span style="white-space:nowrap">COVID-19</span> pandemic impacts Frequency&#8217;s ability to procure sufficient supplies for the development of its products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to mitigate the spread of <span style="white-space:nowrap">COVID-19</span> or treat its effects and may cause delays. In addition, a disruption in the supply of API or other raw material could delay the commercial launch of its product candidates, if approved, or result in a shortage in supply, which would impair its ability to generate revenues. Growth in the costs and expenses of API or other raw material may also impair its ability to cost-effectively manufacture its product candidates. In addition, there may be a limited number of suppliers for API or other raw material that Frequency may use to manufacture its product candidates, and Frequency cannot be certain that Frequency will be able to engage such suppliers in a timely manner or at all. If Frequency is unable to do so, clinical development of its product candidates, commercialization for any approved product, or its business could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finding new CMOs or third-party suppliers involves additional cost and requires its management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although Frequency has not, and does not intend to, begin a clinical trial unless Frequency believes it has on hand, or will be able to obtain, a sufficient supply of its product candidates to complete the clinical trial, any significant delay in the supply of its product candidates or the raw materials needed to produce its product candidates, could considerably delay conducting its clinical trials and potential regulatory approval of its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of their manufacture of Frequency&#8217;s product candidates, its CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to Frequency, Frequency may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact its ability to develop, obtain regulatory approval for, or commercialize its product candidates, if approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency intends to rely on third parties to conduct, supervise, and monitor its clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has relied, and will continue to rely, on CROs, <span style="white-space:nowrap">CRO-contracted</span> vendors, and clinical trial sites to ensure the proper and timely conduct of its clinical trials and any future clinical trials of other product candidates. Frequency&#8217;s reliance on CROs and clinical trial sites for clinical development activities limits its control over these activities and Frequency was not involved in developing their policies and procedures, but Frequency remains responsible for ensuring that each of its trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency and its CROs will be required to comply with the Good Laboratory Practice requirements for its preclinical studies and GCP requirements for its clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If Frequency or its CROs fail to comply with GCP requirements, the clinical data generated in its clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Frequency to perform additional clinical trials before approving its marketing applications. Frequency cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of its clinical trials comply with GCP requirements. In addition, its clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if its CROs fail to comply with these requirements, Frequency may be required to repeat clinical trials, which would delay the regulatory approval process. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s CROs are not its employees, and Frequency does not control whether they devote sufficient time and resources to its clinical trials. Frequency&#8217;s CROs may also have relationships with other commercial entities, including its competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm its competitive position. Frequency faces the risk of potential unauthorized disclosure or misappropriation of its intellectual property by CROs, which may reduce its trade secret protection and allow Frequency&#8217;s potential competitors to access and exploit its proprietary technology. If its CROs do not successfully carry out their contractual duties or obligations, or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to its clinical protocols or regulatory requirements or for any other reason, its clinical trials may be extended, delayed or terminated, and Frequency may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that Frequency develops. As a result, its financial results and the commercial prospects for any product candidate that Frequency develops would be harmed, its costs could increase, and its ability to generate revenue could be delayed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If its relationship with any CROs terminates, Frequency may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact its ability to meet its desired clinical development timelines. While the <span style="white-space:nowrap">COVID-19</span> pandemic and government measures taken in response have had a significant impact on its CROs and their ability to conduct clinical trials, there is potential they will face disruption in the future, which may affect its ability to initiate and complete its clinical trials. Though Frequency intends to carefully manage its relationships with its CROs, there can be no assurance that Frequency will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on its business, financial condition, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_31"><span style="font-style:italic">Risks related to healthcare laws and other legal compliance matters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Enacted and future healthcare legislation may increase the difficulty and cost for Frequency to obtain marketing approval of and commercialize its product candidates, if approved, and may affect the prices Frequency may set. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and other jurisdictions, there have been, and Frequency expects there will continue to be, a number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect its future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of health care. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the biotechnology and pharmaceutical industries include the following: an annual, <span style="white-space:nowrap">non-deductible</span> fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents; </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. It is unclear how healthcare reform measures, if any, will impact its business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In March 2021, the American Rescue Plan Act of 2021 was signed into law, which, among other things, eliminated the statutory cap on drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability, effective January&#160;1, 2024. Under current law enacted as part of the ACA, drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability is capped at 100% of the average manufacturer price for a covered outpatient drug. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices Frequency may obtain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been administration efforts, Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. Most recently, on August&#160;16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. Frequency expects that additional U.S. federal healthcare reform measures will be implemented in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for its product candidates or additional pricing pressures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm its business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for its product candidates or put pressure on its product pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Frequency cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If Frequency or any third parties Frequency may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Frequency or such third parties are not able to maintain regulatory compliance, its product candidates may lose any regulatory approval that may have been obtained and Frequency may not achieve or sustain profitability. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose Frequency to penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s business operations and current and future arrangements with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose Frequency to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which Frequency conducts its operations, including how Frequency researches, markets, sells, and distributes its product candidates, if approved. Such laws include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. federal false claims, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, pharmaceutical manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain <span style="white-space:nowrap">non-physician</span> practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives) and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to its business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">similar healthcare laws and regulations in the European Union, or EU, and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">laws and regulations prohibiting bribery and corruption such as the FCPA, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of Frequency&#8217;s business activities, including its consulting agreements and other relationships with healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that its current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that its business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency&#8217;s operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to Frequency, Frequency may be subject to actions including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if Frequency becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, and curtailment or restructuring of its operations, any of which could adversely affect its ability to operate its business and its results of operations. If any of the physicians or other providers or entities with whom Frequency expects to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect its ability to operate its business. Further, defending against any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if Frequency is successful in defending against any such actions that may be brought against Frequency, its business may be impaired. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect Frequency&#8217;s business, results of operations, and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global data protection landscape is rapidly evolving, and Frequency is or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that Frequency may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and Frequency cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on its business. This evolution may create uncertainty in its business, affect its ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in its contracts, result in liability or impose additional costs on Frequency. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by Frequency to comply with federal, state or foreign laws or regulation, its internal policies and procedures or its contracts governing its processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to its reputation, any of which could have a material adverse effect on its operations, financial performance and business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Frequency&#8217;s operations and business grow, Frequency may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Frequency may obtain health information from third parties (including research institutions from which Frequency obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. While Frequency does not believe that Frequency is currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under <span style="white-space:nowrap"><span style="white-space:nowrap">aiding-and-abetting</span></span> or conspiracy principles. Consequently, depending on the facts and circumstances, Frequency could be subject to significant penalties if Frequency violates HIPAA. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for Frequency and its future customers and strategic partners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Frequency may also be or become subject to other state laws governing the privacy, processing and protection of personal information. For example, the California Consumer Privacy Act, or CCPA, went into effect on January&#160;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase Frequency&#8217;s compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the California Privacy Rights Act, or CPRA, passed in California and it significantly amends the CCPA. It will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions went into effect on January&#160;1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Connecticut, Utah, Colorado, and Iowa and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that Frequency is subject to or affected by HIPAA, the CCPA, the CPRA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect its financial condition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For example, in Europe, the EU General Data Protection Regulation, or GDPR, went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States; in July 2020, the Court of Justice of the EU, or CJEU, limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses, or SCCs. In March 2022, the US and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new <span style="white-space:nowrap">EU-US</span> Data Privacy Framework has not been implemented beyond an executive order signed by President Biden on October&#160;7, 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. European court and regulatory decisions subsequent to the CJEU decision of July&#160;16, 2020 have taken a restrictive approach to international data transfers. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, Frequency could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if Frequency is otherwise unable to transfer personal data between and among countries and regions in which Frequency operates, it could affect the manner in which Frequency provides its services, the geographical location or segregation of its relevant systems and operations, and could adversely affect its financial results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, from January&#160;1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20&#160;million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. As Frequency continues to expand into other foreign countries and jurisdictions, Frequency may be subject to additional laws and regulations that may affect how Frequency conducts business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Frequency works to comply with applicable laws, regulations and standards, its contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which Frequency must comply. Any failure or perceived failure by Frequency or its employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to Frequency, damage its reputation, and adversely affect its business and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency is subject to environmental, health and safety laws and regulations, and Frequency may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s operations, including its development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If Frequency fails to comply with such laws and regulations, Frequency could be subject to fines or other sanctions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As with other companies engaged in activities similar to Frequency, it faces a risk of environmental liability inherent in its current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. Frequency may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of its third-party manufacturers or its development efforts may be interrupted or delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_32"><span style="font-style:italic">Risks related to Frequency&#8217;s intellectual property </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Frequency is unable to obtain, maintain, enforce and protect patent protection for its technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize technology and products similar or identical to Frequency, and its ability to successfully develop and commercialize its technology and product candidates may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s success depends in large part on its ability to obtain and maintain protection of the intellectual property Frequency may own solely and jointly with others, or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates Frequency develops. Frequency seeks to protect its proprietary position by filing patent applications in the United States and abroad related to its technologies and product candidates that are important to its business and by <span style="white-space:nowrap">in-licensing</span> intellectual property related to such technologies and product candidates. If Frequency is unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, its business, financial condition, results of operations and prospects could be materially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming, and complex, and Frequency may not be able to file, prosecute, maintain, defend, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that Frequency will fail to identify patentable aspects of its research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, Frequency does not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain, enforce, and defend the patents, covering technology that Frequency licenses from third parties. Therefore, these <span style="white-space:nowrap">in-licensed</span> patents, and applications may not be prepared, filed, prosecuted, maintained, defended, and enforced in a manner consistent with the best interests of its business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect its rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. With respect to both owned and <span style="white-space:nowrap">in-licensed</span> patent rights, Frequency cannot predict whether the patent applications Frequency and its licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, Frequency may not be aware of all third-party intellectual property rights potentially relating to its product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither Frequency nor its licensors can know with certainty whether either Frequency or its licensors were the first to make the inventions claimed in the patents and patent applications Frequency owns or <span style="white-space:nowrap">in-licenses</span> now or in the future, or that either Frequency or its licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of Frequency&#8217;s owned and <span style="white-space:nowrap">in-licensed</span> patent rights are uncertain. Moreover, its owned and <span style="white-space:nowrap">in-licensed</span> pending and future patent applications may not result in patents being issued that protect its technology and product candidates, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of its patents and its ability to obtain, protect, maintain, defend, and enforce its patent rights, narrow the scope of its patent protection and, more generally, could affect the value or narrow the scope of its patent rights. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, Frequency or its licensors may be subject to a third-party <span style="white-space:nowrap">pre-issuance</span> submission of prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review, or interference proceedings challenging its patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, its patent rights, allow third parties to commercialize its technology or product candidates and compete directly with Frequency, without payment to Frequency, or result in its inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by its patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with Frequency to license, develop or commercialize current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if Frequency&#8217;s owned and <span style="white-space:nowrap">in-licensed</span> patent applications issue as patents, they may not issue in a form that will provide Frequency with any meaningful protection, prevent competitors from competing with Frequency, or otherwise provide Frequency with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and its owned and <span style="white-space:nowrap">in-licensed</span> patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit its ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of its technology and product candidates. Such proceedings also may result in substantial cost and require significant time from its management and employees, even if the eventual outcome is favorable to Frequency. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, its competitors may be able to circumvent its owned or <span style="white-space:nowrap">in-licensed</span> patents by developing similar or alternative technologies or products in a <span style="white-space:nowrap">non-infringing</span> manner. As a result, its owned and <span style="white-space:nowrap">in-licensed</span> patent portfolio may not provide Frequency with sufficient rights to exclude others from commercializing technology and products similar or identical to any of its technology and product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect Frequency&#8217;s competitive position on its product candidates for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States <span style="white-space:nowrap">non-provisional</span> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering its product candidates are obtained, once the patent life has expired, Frequency may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, its owned and licensed patent portfolio may not provide Frequency with sufficient rights to exclude others from commercializing products similar or identical to Frequency. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Frequency is unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with its obligations under such agreements, its business could be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It may be necessary for Frequency to use the patented or proprietary technology of third parties to commercialize its products, in which case Frequency would be required to obtain a license from these third parties. If Frequency is unable to license such technology, or if Frequency is forced to license such technology on unfavorable terms, its business could be materially harmed. If Frequency is unable to obtain a necessary license, Frequency may be unable to develop or commercialize the affected product candidates, which could materially harm its business and the third parties owning such intellectual property rights could seek either an injunction prohibiting its sales or an obligation on its part to pay royalties and/or other forms of compensation. Even if Frequency is able to obtain a license, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving its competitors access to the same technologies licensed to Frequency. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency is unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights Frequency has, Frequency may be required to expend significant time and resources to redesign its technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Frequency is unable to do so, Frequency may be unable to develop or commercialize the affected technology and product candidates, which could significantly harm its business, financial condition, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if Frequency fails to comply with its obligations under license agreements, its counterparties may have the right to terminate these agreements, in which event Frequency might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of Frequency&#8217;s rights under these agreements, or restrictions on its ability to freely assign or sublicense its rights under such agreements when it is in the interest of its business to do so, may result in its having to negotiate new or reinstated agreements with less favorable terms, cause Frequency to lose its rights under these agreements, including its rights to important intellectual property or technology, or impede, or delay or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Frequency does not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of its marketing exclusivity for any product candidates Frequency may develop, its business may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the patent term of a patent that covers an <span style="white-space:nowrap">FDA-approved</span> drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions may be available in Europe and certain other <span style="white-space:nowrap">non-United</span> States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when Frequency&#8217;s product candidates receive FDA approval, Frequency expects to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with its assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Frequency may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than Frequency requests. If Frequency is unable to obtain any patent term extension or the term of any such extension is less than Frequency requests, its competitors may obtain approval of competing products following the expiration of its patent rights, and its business, financial condition, results of operations, and prospects could be materially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that Frequency will not obtain patent term extension under the Hatch-Waxman Act for a United States patent covering any of its product candidates that Frequency may identify even where that patent is eligible for patent term extension, or if Frequency obtains such an extension, it may be for a shorter period than Frequency had sought. Further, for its licensed patents, Frequency may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of its licensed patents is eligible for patent term extension under the Hatch-Waxman Act, Frequency may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Frequency may be unable to obtain patents covering its product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if Frequency submits a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of its product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to Frequency of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Although Frequency is not currently involved in any litigation related to its intellectual property, Frequency may become involved in lawsuits to protect or enforce its patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors and other third parties may infringe, misappropriate or otherwise violate Frequency&#8217;s issued patents or other intellectual property. As a result, Frequency may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming. Any claims Frequency asserts against perceived infringers could provoke such parties to assert counterclaims against Frequency alleging that it infringes, misappropriates, or otherwise violates their intellectual property. In addition, in a patent infringement proceeding, such parties could counterclaim that the patents Frequency have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or <span style="white-space:nowrap">non-enablement.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <span style="white-space:nowrap">re-examination,</span> post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An adverse result in any such proceeding could put one or more of Frequency&#8217;s patents at risk of being invalidated or interpreted narrowly and could put any of its patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that its patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of its confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on its business, financial condition, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference or derivation proceedings provoked by third parties or brought by Frequency or declared by the USPTO may be necessary to determine the priority of inventions with respect to its patents or patent applications. An unfavorable outcome could require Frequency to cease using the related technology or to attempt to license rights to it from the prevailing party. Its business could be harmed if the prevailing party does not offer Frequency a license on commercially reasonable terms or at all, or if a <span style="white-space:nowrap">non-exclusive</span> license is offered and its competitors gain access to the same technology. Its defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs, and distract its management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on its ability to raise the funds necessary to continue its clinical trials, continue its research programs, license necessary technology from third parties, or enter into development partnerships that would help Frequency bring its product candidates to market. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Frequency&#8217;s confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of its common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third parties may initiate legal proceedings alleging that Frequency is infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s commercial success depends upon its ability to develop, manufacture, market and sell its product candidates and use its proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. Frequency may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to its technology and product candidates, including interference proceedings, post grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which Frequency is pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that its technologies or product candidates that Frequency may identify may be subject to claims of infringement of the patent rights of third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and its adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than Frequency can. The risks of being involved in such litigation and proceedings may increase if and as Frequency&#8217;s product candidates near commercialization and as Frequency gains the greater visibility associated with being a public company. Third parties may assert infringement claims against Frequency based on existing patents or patents that may be granted in the future, regardless of merit. Frequency may not be aware of all such intellectual property rights potentially relating to its technology and product candidates and their uses, or Frequency may incorrectly conclude that third party intellectual property is invalid or that its activities and product candidates do not infringe such intellectual property. Thus, Frequency does not know with certainty that its technology and product candidates, or its development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that Frequency is employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of the product candidates that Frequency may identify or related to its technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that Frequency may develop may be found to infringe. In addition, third parties may obtain patents in the future and claim that use of its technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that Frequency is not aware of or that Frequency has incorrectly concluded are invalid or not infringed by its activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that Frequency may develop, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block its ability to commercialize such product candidate unless Frequency obtained a license under the applicable patents, or until such patents expire. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against Frequency may obtain injunctive or other equitable relief, which could effectively block its ability to further develop and commercialize the product candidates that Frequency may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from its business. In the event of a successful claim of infringement against us, Frequency may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign its infringing products, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency may choose to take a license or, if Frequency is found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, Frequency could also be required to obtain a license from such third party to continue developing, manufacturing and marketing its technology and product candidates. However, Frequency may not be able to obtain any required license on commercially reasonable terms or at all. Even if Frequency was able to obtain a license, it could be <span style="white-space:nowrap">non-exclusive,</span> thereby giving its competitors and other third parties access to the same technologies licensed to Frequency and could require Frequency to make substantial licensing and royalty payments. Frequency could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, Frequency could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if Frequency is found to have willfully infringed a patent or other intellectual property right and could be forced to indemnify its customers or collaborators. A finding of infringement could prevent Frequency from commercializing its product candidates or force Frequency to cease some of its business operations, which could materially harm the business. In addition, Frequency may be forced to redesign its product candidates, seek new regulatory approvals, and indemnify third parties pursuant to contractual agreements. Claims that Frequency has misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on its business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property litigation or other legal proceedings relating to intellectual property could cause Frequency to spend substantial resources and distract Frequency&#8217;s personnel from their normal responsibilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in Frequency&#8217;s favor, litigation or other legal proceedings relating to intellectual property claims may cause Frequency to incur significant expenses and could distract its technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Frequency common stock. Such litigation or proceedings could substantially increase its operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. Frequency may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of its competitors may be able to sustain the costs of such litigation or proceedings more effectively than Frequency can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise its ability to compete in the marketplace. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and Frequency&#8217;s patent protection could be reduced or eliminated for noncompliance with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of its owned and <span style="white-space:nowrap">in-licensed</span> patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, Frequency relies on its licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to its patents, Frequency relies on an annuity service, outside firms, and outside </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
counsel to remind Frequency of the due dates and to make payment after Frequency instructs them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. Under certain circumstances, Frequency may be unable to comply with requirements. For example, due to the sanctions imposed by the United States on Russia as a result of the conflict in Ukraine, it is not possible to pay fees on Russian patents and the future of such patents is uncertain. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If Frequency or its licensors fail to maintain the patents and patent applications covering its product candidates, it would have a material adverse effect on its business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing Frequency&#8217;s ability to protect its products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of Frequency&#8217;s owned and <span style="white-space:nowrap">in-licensed</span> patent applications and the maintenance, enforcement, or defense of its owned and <span style="white-space:nowrap">in-licensed</span> issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution, and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Frequency&#8217;s patent applications and the enforcement or defense of its issued patents, all of which could have a material adverse effect on its business, financial condition, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on its patent rights and its ability to protect, defend and enforce its patent rights in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency may not be able to protect its intellectual property and proprietary rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, Frequency may not be able to prevent third parties from practicing its inventions in all countries outside the United States, or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors may use its technologies in jurisdictions where Frequency has not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtained patent protection to develop its own products and, further, may export otherwise infringing products to territories where Frequency has patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with its products, and its patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for Frequency to stop the infringement of its patents or marketing of competing products in violation of its intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent or at all, inventions that constitute new methods of treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, <span style="white-space:nowrap">geo-political</span> actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of its patent applications or those of any current or future licensors and the maintenance, enforcement or defense of its issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to Russia&#8217;s conflict in Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of its patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on its business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, Frequency would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, Frequency&#8217;s competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce Frequency&#8217;s intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert its efforts and attention from other aspects of its business, could put Frequency&#8217;s patents at risk of being invalidated or interpreted narrowly, could put its patent applications at risk of not issuing, and could provoke third parties to assert claims against Frequency. Frequency may not prevail in any lawsuits that Frequency initiates, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, its efforts to enforce its intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that Frequency develops or licenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If Frequency or any of its licensors are forced to grant a license to third parties with respect to any patents relevant to its business, Frequency&#8217;s competitive position may be impaired, and its business, financial condition, results of operations, and prospects may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, Europe is implementing a Unified Patent Court that may present uncertainties for its ability to protect and enforce Frequency&#8217;s patent rights in Europe and the ability of third parties to do the same. In 2012, regulations were passed with the goal of providing a <span style="white-space:nowrap">pan-European</span> Unitary Patent and a new European Unified Patent Court, or UPC, for litigation involving European patents. Implementation is currently scheduled for June&#160;1, 2023. Under the UPC, all European patents granted in countries that have ratified the UPC Agreement, including those patents issued prior to the UPC, will automatically fall under the jurisdiction of the UPC. The UPC will provide Frequency&#8217;s competitors with a new forum to centrally revoke European patents, and allow for the possibility of a competitor to obtain injunctions in multiple European countries in a single UPC action. It will </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be several years before Frequency will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Note that Frequency will have the option to opt its patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude Frequency from realizing the benefits of the new unified court. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Frequency fails to comply with any obligations in its intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to its business relationships with its licensors, Frequency could lose intellectual property rights that are important to its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency may enter into licensing and funding arrangements with third parties that may impose, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations on Frequency. If Frequency fails to comply with such obligations under future license and funding agreements, its counterparties may have the right to terminate these agreements or require Frequency to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of its rights under these agreements may result in Frequency&#8217;s having to negotiate new or reinstated agreements with less favorable terms, or cause Frequency to lose its rights under these agreements, including its rights to important intellectual property or technology, which would have a material adverse effect on its business, financial condition, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which its technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sublicensing of patent and other rights under its collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">its diligence obligations under the license agreement and what activities satisfy those diligence obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inventorship and ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by its licensors and Frequency and its partners; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the priority of invention of patented technology. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which Frequency currently licenses intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what Frequency believes to be the scope of its rights to the relevant intellectual property or technology, or increase what Frequency believes to be its financial or other obligations under the relevant agreement, either of which could have a material adverse effect on its business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that Frequency has licensed prevent or impair its ability to maintain its current licensing arrangements on commercially acceptable terms, Frequency may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on its business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that its licensors are not the sole and exclusive owners of the patents and patent applications Frequency <span style="white-space:nowrap">in-licenses.</span> If other third parties have ownership rights to patents and/or patent applications Frequency <span style="white-space:nowrap">in-licenses,</span> they may be able to license such patents to its competitors, and its competitors could market competing products and technology. This could have a material adverse effect on its competitive position, business, financial conditions, results of operations, and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of Frequency&#8217;s best efforts, its licensors might conclude that Frequency has materially breached its license agreements and might therefore terminate the license agreements, thereby removing its ability to develop and commercialize product candidates and technology covered by these license agreements. If these <span style="white-space:nowrap">in-licenses</span> are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to Frequency&#8217;s. This could have a material adverse effect on Frequency&#8217;s competitive position, business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency or its licensors may be subject to claims that former employees, collaborators or other third parties have an interest in its owned or <span style="white-space:nowrap">in-licensed</span> patents, trade secrets, or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> For example, Frequency or its licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing its product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or Frequency&#8217;s or its licensors&#8217; ownership of its owned or <span style="white-space:nowrap">in-licensed</span> patents, trade secrets, or other intellectual property. If Frequency or its licensors fail in defending any such claims, in addition to paying monetary damages, Frequency may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to its product candidates. Even if Frequency is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on its business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Frequency is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of its technology and product candidates, Frequency also relies on trade secrets and confidentiality agreements to protect its unpatented <span style="white-space:nowrap">know-how,</span> technology, and other proprietary information, to maintain its competitive position. Frequency seeks to protect its trade secrets and other proprietary technology, in part, by entering into <span style="white-space:nowrap">non-disclosure</span> and confidentiality agreements with parties who have access to them, such as its employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. Frequency also enters into confidentiality and invention or patent assignment agreements with its employees and consultants. Frequency cannot guarantee that Frequency has entered into such agreements with each party that may have or has had access to its trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose its proprietary information, including its trade secrets, and Frequency may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of its trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, Frequency would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with Frequency. If any of its trade secrets were to be disclosed to or independently developed by a competitor or other third party, Frequency&#8217;s competitive position would be materially and adversely harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Frequency&#8217;s trademarks and trade names are not adequately protected, then Frequency may not be able to build name recognition in its markets of interest and Frequency&#8217;s business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s registered and unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. Frequency may not be able to protect its rights to these trademarks and trade names, which Frequency needs to build name recognition among </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential collaborators or customers in its markets of interest. At times, competitors may adopt trade names or trademarks similar to Frequency, thereby impeding its ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trade names or trademarks that incorporate variations of its unregistered trade names or trademarks. Over the long term, if Frequency is unable to successfully register its trade names and trademarks and establish name recognition based on its trade names and trademarks, then Frequency may not be able to compete effectively, and its business may be adversely affected. Frequency&#8217;s efforts to enforce or protect its proprietary rights related to trade names and trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely impact its financial condition or results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights do not necessarily address all potential threats. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by Frequency&#8217;s intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect Frequency&#8217;s business or permit Frequency to maintain its competitive advantage. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency, or its license partners or current or future collaborators, might not have been the first to file patent applications covering certain of Frequency&#8217;s or their inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may independently develop similar or alternative technologies or duplicate any of its technologies without infringing its owned or <span style="white-space:nowrap">in-licensed</span> intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that its owned and <span style="white-space:nowrap">in-licensed</span> pending patent applications or those Frequency may own or <span style="white-space:nowrap">in-license</span> in the future will not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents that Frequency holds rights to may be held invalid or unenforceable, including as a result of legal challenges by its competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">its competitors might conduct research and development activities in countries where Frequency does not have patent rights and then use the information learned from such activities to develop competitive products for sale in its major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency cannot ensure that any of its pending patent applications, if issued, or those of its licensors, will include claims having a scope sufficient to protect its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency cannot ensure that any patents issued to Frequency or its licensors will provide a basis for an exclusive market for its commercially viable product candidates or will provide Frequency with any competitive advantages; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency cannot ensure that its commercial activities or product candidates will not infringe upon the patents of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency cannot ensure that Frequency will be able to successfully commercialize its product candidates on a substantial scale, if approved, before the relevant patents that Frequency owns, or license expires; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency may not develop additional proprietary technologies that are patentable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents of others may harm its business; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency may choose not to file a patent in order to maintain certain trade secrets or <span style="white-space:nowrap">know-how,</span> and a third party may subsequently file a patent covering such intellectual property. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on its business, financial condition, results of operations, and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_33"><span style="font-style:italic">Risks related to Frequency&#8217;s employees, managing its growth and its operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s business depends on its ability to retain its key personnel and to attract, retain and motivate qualified personnel. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is highly dependent on the expertise of the principal members of its management and scientific teams. Although Frequency has employment agreements, offer letters or consulting agreements with its executive officers, these agreements do not prevent them from terminating their services at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency loses one or more of its executive officers or key employees, its ability to implement Frequency&#8217;s business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period because of the limited number of individuals in its industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and Frequency may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. Frequency also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions. Frequency may also decide not to replace an executive officer, which may have an adverse effect on its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Frequency relies on consultants and advisors, including scientific and clinical advisors, to assist Frequency in formulating its research and development and commercialization strategy. Frequency&#8217;s consultants and advisors may be engaged by other companies or organizations and may have commitments that limit their availability. If Frequency is unable to continue to attract and retain highly qualified personnel, its ability to develop and commercialize its product candidates will be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s recent reduction in force undertaken to better align its workforce with the needs of Frequency&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2023, Frequency implemented a reduction in force affecting approximately 55% of the workforce to better align its workforce with the needs of Frequency&#8217;s business and focus more of its capital resources on its MS Program. In May 2023, Frequency implemented another reduction in force affecting approximately 55% of the workforce to better align its workforce with its business needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reduction in force may result in unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees, decreased morale among its remaining employees, and the risk that Frequency may not achieve the anticipated benefits of the reduction in force. In addition, while positions have been eliminated certain functions necessary to its operations remain, and Frequency may be unsuccessful in distributing the duties and obligations of departed employees among its remaining employees. The reduction in workforce could also make it difficult for Frequency to pursue, or prevent Frequency from pursuing, new opportunities and initiatives due to insufficient personnel, or require Frequency to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. If Frequency is unable to realize the anticipated benefits from the reduction in force, or if Frequency experiences significant adverse consequences from the reduction in force, its business, financial condition, and results of operations may be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency may engage in transactions that could disrupt its business, cause dilution to its stockholders or reduce its financial resources. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the Merger Agreement, Frequency may enter into transactions to acquire or <span style="white-space:nowrap">in-license</span> rights to product candidates, products or technologies, or to acquire other businesses. If Frequency does identify suitable candidates, Frequency may not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions or <span style="white-space:nowrap">in-licenses</span> may not strengthen its competitive position, and these transactions may be viewed </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
negatively by analysts, investors, customers, or other third parties with whom Frequency has relationships. Frequency may decide to incur debt in connection with an acquisition, or <span style="white-space:nowrap">in-license</span> or issue its common stock or other equity securities as consideration for the acquisition, which would reduce the percentage ownership of its existing stockholders. Frequency could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification Frequency may obtain from the sellers of the acquired business. In addition, Frequency may not be able to successfully integrate the acquired personnel, technologies, and operations into its existing business in an effective, timely, and nondisruptive manner. Such transactions may also divert management attention from <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> responsibilities, increase its expenses, and reduce its cash available for operations and other uses. Frequency cannot predict the number, timing or size of future acquisitions or <span style="white-space:nowrap">in-licenses</span> or the effect that any such transactions might have on its operating results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s business and operations would suffer in the event of security breaches or information technology system failures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of its business, Frequency and third parties with which Frequency has relationships will continue to collect and store sensitive data, including clinical trial data, proprietary business information, personal data and personally identifiable information of its clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to its operations. Despite the implementation of security measures, its computer systems, as well as those of its CROs and other contractors and consultants, are vulnerable to attack, damage and interruption from computer viruses and malware (e.g. ransomware), malicious code, unauthorized access, malfeasance, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication, electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft of misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside its organization, or persons with access to systems inside its organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. For instance, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with <span style="white-space:nowrap">COVID-19</span> global pandemic, and the recent hostilities between Russia and Ukraine may result in increased attacks that could either directly or indirectly impact Frequency. Frequency may also face increased cybersecurity risks due to its reliance on internet technology and the number of its employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, Frequency may be unable to anticipate these techniques or implement adequate preventative measures. Frequency may also experience security breaches that may remain undetected for an extended period. Even if identified, Frequency may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency and certain of its service providers are from time to time subject to cyberattacks and security incidents. While Frequency does not believe that its network has experienced any significant system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in its operations, it could result in delays and/or material disruptions of its research and development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing, or planned trials could result in delays in its regulatory approval efforts and significantly increase its costs to recover or reproduce the data. Likewise, Frequency currently relies and intends to rely in the future on third parties for the manufacture of its product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on its business. If a security breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to privacy and security laws. Any such access, disclosure, notifications, <span style="white-space:nowrap">follow-up</span> actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under data protection laws, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event could disrupt its operations, cause Frequency to incur remediation costs, damage its reputation, and cause a loss of confidence in Frequency and its or such third parties&#8217; ability to conduct clinical trials, which could adversely affect its reputation and delay the clinical development of Frequency&#8217;s product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s employees work remotely and in a shared office with its sublessor, and Frequency may be subject to heightened operational, confidentiality and cybersecurity risks. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of Frequency&#8217;s employees work remotely from home at times. In addition, when in the office, its employees share an open, undivided office space with its sublessor. This subjects Frequency to heightened operational risks. For example, technologies in its employees&#8217; homes may not be as robust and could cause the networks, information systems, applications, and other tools available to employees to be more limited or less reliable, and Frequency may be subject to increased cybersecurity risk which could expose Frequency to risks of data or financial loss. In Frequency&#8217;s office, there are risks that individuals accessing its shared office space who are not associated with Frequency may have access to confidential data, including from its clinical trials. There is no guarantee that the security and privacy safeguards Frequency will put in place both for remote work and for its shared office space will be completely effective or that Frequency will not encounter risks associated with unauthorized access to its data and information. If any of these risks were to occur, its business and operations could be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_34"><span style="font-style:italic">Risks related to Frequency common stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of Frequency common stock has been volatile and fluctuated and may in future fluctuate substantially, which could result in substantial losses for Frequency&#8217;s stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of Frequency common stock has been highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond its control. In addition to the factors discussed in this section titled &#8220;<span style="font-style:italic">Risks related to Frequency&#8217;s business</span>&#8221;, these factors include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the announcement of the Merger and other public communications related to the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any delay in the enrollment or ultimate completion of any clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the results of any clinical trials or clinical trials of competitors for the same or similar indication. For example, the price of Frequency common stock decreased significantly following the announcement of its <span style="white-space:nowrap">FX-322</span> Phase 2a <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-202)</span></span> interim results and its <span style="white-space:nowrap">FX-322</span> Phase 2b <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-208)</span></span> results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">its ability to develop product candidates based on its PCA approach; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any delay in submitting a regulatory filing and any adverse development or perceived adverse development with respect to the regulatory review of such filing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to successfully develop any product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to obtain additional funding; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory or legal developments in the United States and other countries applicable to its PCA approach or any product candidate: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory decisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the structure of healthcare payment systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse developments concerning its CMOs or CROs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to obtain adequate product supply for its other product candidates, or the inability to do so at acceptable prices; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">introduction of new products, services or technologies by its competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">its ability to effectively manage its growth; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed financial projections Frequency provides to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed the estimates and projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of companies similar to Frequency; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions in the biotechnology and pharmaceutical sectors, and the issuance of new or changed securities analysts&#8217; reports or recommendations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by Frequency or its competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the termination of a collaboration agreement, licensing agreement or other strategic arrangement, or the inability to establish additional collaboration arrangements that Frequency needs on favorable terms, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant lawsuits and their outcomes, including patent or stockholder litigation, and disputes or other developments relating to its proprietary rights, including patents, litigation matters, and its ability to obtain patent protection for its product candidates and PCA approach; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or departures of key scientific or management personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of Frequency common stock by Frequency or its stockholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of its common stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general economic, industry and market conditions, including the effects of recession or slow economic growth in the U.S. and abroad, interest rates, inflation rates, labor shortages, supply chain difficulties, fuel prices, international currency fluctuations, corruption, political instability, acts of war, international geopolitical conflict, acts of terrorism, and the <span style="white-space:nowrap">COVID-19</span> pandemic or other public health crises. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the trading prices for common stock of biopharmaceutical companies continue to be highly volatile as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic and general market conditions, among other reasons. The <span style="white-space:nowrap">COVID-19</span> pandemic and fluctuations in the global economy continue to evolve and remain unpredictable. The extent to which a public health emergency, such as the <span style="white-space:nowrap">COVID-19</span> pandemic, may impact its business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s failure to meet the continued listing requirements of the Nasdaq Stock Market LLC, or Nasdaq, could result in a delisting of its common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency common stock is currently listed on the Nasdaq Stock Market LLC. Nasdaq requires listed companies to meet certain listing criteria including total number of stockholders, corporate governance requirements, minimum closing bid price, total value of public float, and in some cases total stockholders&#8217; equity and market capitalization requirements. If Frequency fails to satisfy the continued listing standards, including with respect to the maintenance of a minimum share price, or if Nasdaq, in its discretion, determines that a condition exists that makes further dealings of its company on the exchange unwarranted, Nasdaq may issue a <span style="white-space:nowrap">non-compliance</span> letter or initiate delisting proceedings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, on March&#160;28, 2023, Frequency received a notification letter from the Listing Qualifications Department of Nasdaq notifying Frequency that, for the last 30 consecutive business days, the bid price for its common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1), or the Bid Price Requirement. In </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with Nasdaq Listing Rule 5810(c)(3)(A), Frequency has been provided an initial compliance period of 180 calendar days from receipt of the notification letter, or until September&#160;25, 2023, to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price for Frequency common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to September&#160;25, 2023, unless Nasdaq exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If Frequency does not regain compliance with the Bid Price Requirement by September&#160;25, 2023, Frequency may be eligible for an additional 180 calendar day compliance period. There can be no assurance Frequency will be able to regain compliance or that Nasdaq will extend the compliance period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If for any reason Frequency common stock does not maintain eligibility for listing on Nasdaq, Frequency may list its common stock elsewhere, such as one of the OTC markets, which are generally considered less liquid and more volatile than a national securities exchange, and could mean that certain institutional investors could no longer hold or purchase its stock, and as a result, a purchaser of its common stock may find it more difficult to dispose of, or to obtain accurate quotations as to the price of their shares. This could materially and adversely affect the liquidity of its common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because Frequency does not anticipate paying any cash dividends on its common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for its stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has never declared or paid any cash dividends on its common stock. Frequency currently anticipates that Frequency will retain future earnings for the development, operation and expansion of its business and does not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of its common stock will be the sole source of gain on an investment in its common stock for the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency will continue to incur increased costs as a result of operating as a public company, and its management will continue to devote substantial time to compliance initiatives and corporate governance practices. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after Frequency no longer qualifies as an emerging growth company, Frequency will continue to incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Frequency&#8217;s management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase its legal and financial compliance costs and will make some activities more time consuming and costly. For example, these rules and regulations may make it more expensive for Frequency to obtain director and officer liability insurance, which in turn could make it more difficult for Frequency to attract and retain qualified senior management personnel or members for its board of directors. In addition, these rules and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;404 of SOX, or Section&#160;404, Frequency is required to furnish a report by its senior management on its internal control over financial reporting, and its independent registered public accounting firm is required to provide an attestation report on its internal control over financial reporting. However, while Frequency remains an emerging growth company, its independent registered public accounting firm will not be required to provide the attestation report. To ensure compliance with Section&#160;404, Frequency continues to engage in a process to document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, Frequency will need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite its efforts, there is a risk that Frequency will not be able to conclude, within the prescribed timeframe or at all, that its internal control over financial reporting is effective as required by Section&#160;404. If Frequency identifies one or more material weaknesses, it could result in an adverse reaction on the price of its common stock in the market due to a loss of confidence in the reliability of its financial statements. Furthermore, if Frequency is unable to conclude that its internal control over financial reporting is effective, its investors may lose confidence in the accuracy and completeness of its financial reports and the market price of its common stock could decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency is an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make its common stock less attractive to investors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and a &#8220;smaller reporting company&#8221; as defined under the rules promulgated under the Securities Act. As an emerging growth company and a smaller reporting company Frequency may follow reduced disclosure requirements and does not have to make all the disclosures that public companies that are not emerging growth companies or smaller reporting companies do. Frequency will remain an emerging growth company until the earlier of (a)&#160;the last day of the fiscal year in which Frequency has total annual gross revenues of $1.07&#160;billion or more; (b)&#160;the last day of the fiscal year following the fifth anniversary of the date of the completion of its initial public offering; (c)&#160;the date on which Frequency has issued more than $1&#160;billion in nonconvertible debt during the previous three years; or (d)&#160;the date on which Frequency is deemed to be a large accelerated filer under the rules of the SEC, which means the market value of its voting and <span style="white-space:nowrap">non-voting</span> common stock that is held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the last business day of its second fiscal quarter. For so long as Frequency remains an emerging growth company, Frequency is permitted and intends to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">not being required to comply with the auditor attestation requirements of Section&#160;404; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with the requirement of the PCAOB regarding the communication of critical audit matters in the auditor&#8217;s report on the financial statements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">progressively adding to the number of years of audited financial statements required to be included in Frequency&#8217;s periodic reports; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation, stockholder approval of any golden parachute payments not previously approved and having to disclose the ratio of the compensation of its chief executive officer to the median compensation of its employees. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Frequency has elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, its financial statements may not be comparable to companies that comply with public company effective dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is also a smaller reporting company, and Frequency will remain a smaller reporting company until the fiscal year following the determination that its voting and <span style="white-space:nowrap">non-voting</span> common stock held by <span style="white-space:nowrap">non-affiliates</span> is more than $250&#160;million measured on the last business day of Frequency&#8217;s second fiscal quarter, or its annual revenues are more than $100&#160;million during the most recently completed fiscal year and its voting and <span style="white-space:nowrap">non-voting</span> common stock held by <span style="white-space:nowrap">non-affiliates</span> is more than $700&#160;million measured on the last business day of Frequency&#8217;s second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section&#160;404, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency may choose to take advantage of some, but not all, of the available exemptions for emerging growth companies and smaller reporting companies. Frequency cannot predict whether investors will find its common stock less attractive if Frequency relies on these exemptions. If some investors find its common stock less attractive as a result, there may be a less active trading market for its common stock and its shares price may be more volatile. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provisions in Frequency&#8217;s Restated Certificate of Incorporation and Frequency&#8217;s Amended and Restated Bylaws or Delaware law may discourage, delay or prevent a merger, acquisition or other change in control of its company that its stockholders may consider favorable, including transactions in which its stockholders might otherwise receive a premium for their shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Restated Certificate of Incorporation and Frequency&#8217;s Amended and Restated Bylaws include certain anti-takeover provisions, including those establishing: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of its board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the exclusive right of its board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on its board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of its board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of its board of directors to alter its Amended and Restated Bylaws without obtaining stockholder approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal its Amended and Restated Bylaws or repeal the provisions of its Restated Certificate of Incorporation regarding the election and removal of directors: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president, or the board of directors, which may delay the ability of its stockholders to force consideration of a proposal or to take action, including the removal of directors: and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advance notice procedures that stockholders must comply with in order to nominate candidates to its board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of Frequency. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions could also limit the price that investors might be willing to pay in the future for shares of Frequency common stock, thereby depressing the market price of its common stock. In addition, because its board of directors is responsible for appointing the members of its management team, these provisions may frustrate or prevent any attempts by its stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of its board of directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because Frequency is incorporated in Delaware, Frequency is governed by the provisions of Section&#160;203 of the DGCL, which prohibits a person who owns in excess of 15% of Frequency&#8217;s outstanding voting stock from merging or combining with Frequency for a period of three years after the date of the transaction in which the person acquired in excess of 15% of its outstanding voting stock, unless the Merger or combination is approved in a prescribed manner. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws designates specific courts as the exclusive forum for certain litigation that may be initiated by its stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with Frequency. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Restated Certificate of Incorporation specifies that, unless Frequency consents in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on its behalf, (2)&#160;any action asserting a claim for breach of a fiduciary duty owed by any of its directors, officers, or other employees to Frequency or its stockholders, (3)&#160;any action asserting a claim arising pursuant to any provision of the DGCL, Frequency&#8217;s Restated Certificate of Incorporation, or Frequency&#8217;s Amended and Restated Bylaws, (4)&#160;any action to interpret, apply, enforce, or determine the validity of its Restated Certificate of Incorporation or its Amended and Restated Bylaws, or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. Under its Restated Certificate of Incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. In addition, its Amended and Restated Bylaws specifies that unless Frequency consents in writing to the selection of an alternative forum, the federal district courts of the United States shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with Frequency or its directors, officers, or other employees, which may discourage such lawsuits against Frequency and its directors, officers and other employees. For example, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to Frequency than to Frequency&#8217;s stockholders. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against Frequency, a court could find the choice of forum provisions contained in its Restated Certificate of Incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provisions contained in its Restated Certificate of Incorporation or Amended and Restated Bylaws to be inapplicable or unenforceable in an action, Frequency may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect its business, financial condition, or results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_35"><span style="font-style:italic">General Risk Factors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to Frequency&#8217;s stockholders, restrict its operations or require Frequency to relinquish rights to its technologies or product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as Frequency can generate substantial revenues, Frequency may finance its cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Frequency does not currently have any committed external source of funds. In addition, Frequency may seek additional capital due to favorable market conditions or strategic considerations, even if Frequency believes that Frequency has sufficient funds for its current or future operating plans. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that Frequency raises additional capital through the sale of equity or convertible debt securities, its existing stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of its common stock holders. In addition, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Frequency raises additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, Frequency may be required to relinquish valuable rights to its technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to Frequency. Furthermore, any capital raising efforts may divert its management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may adversely affect Frequency&#8217;s ability to advance research programs, product development activities or product candidates. If Frequency is unable to raise additional funds when needed, Frequency may be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency may be subject to claims by third parties asserting that its employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or Frequency has wrongfully used or disclosed alleged trade secrets of their current or former employers, or claims asserting Frequency has misappropriated their intellectual property, or claiming ownership of what Frequency regards as its own intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of Frequency&#8217;s employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including its competitors or potential competitors. In addition, Frequency shares an undivided, open office space with its sublessor, and its employees or other individuals who are in Frequency&#8217;s offices may have access to information regarding its sublessor&#8217;s business, including potentially proprietary information. Although Frequency tries to ensure that its employees, consultants, and contractors do not use the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for Frequency, Frequency may be subject to claims that these individuals or Frequency has used or disclosed intellectual property, including trade secrets or other proprietary information. Litigation may be necessary to defend against these claims. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is Frequency&#8217;s policy to require its employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to Frequency, it may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that Frequency regards as its own. Frequency&#8217;s intellectual property assignment agreements with them may not be self-executing or may be breached, and Frequency may be forced to bring claims against third parties, or defend claims they may bring against Frequency, to determine the ownership of what Frequency regards as its intellectual property. Such claims could have a material adverse effect on its business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency fails in prosecuting or defending any such claims, in addition to paying monetary damages, Frequency may lose valuable intellectual property rights or personnel, which could have a material adverse effect on its competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and Frequency could be required to obtain a license from such third party to commercialize its technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be <span style="white-space:nowrap">non-exclusive.</span> Even if Frequency is successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to its management and employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency is currently subject to stockholder litigation and could be subject to similar or other litigation in the future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action and other stockholder litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for Frequency because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency can make no assurances as to the time or resources that will need to be devoted to these lawsuits or their final outcomes, or the impact, if any, of these lawsuits or any proceedings on its business, financial condition, results of operations and cash flows. While Frequency is vigorously defending against all claims asserted, these lawsuits could result in substantial costs to Frequency and a diversion of its management&#8217;s attention and resources, which could harm its business. In addition, the uncertainty of the pending lawsuits or potential filing of additional lawsuits could lead to more volatility and a reduction in its stock price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts issue an adverse or misleading opinion regarding Frequency common stock, its stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for its common stock is influenced by the research and reports that industry or securities analysts publish about Frequency or its business. If any of the analysts who cover Frequency issue an adverse or misleading opinion regarding Frequency, its business model, its intellectual property or its stock performance, or if its clinical studies and operating results fail to meet the expectations of analysts, its stock price would likely decline. If one or more of these analysts cease coverage of Frequency or fail to publish reports on Frequency regularly, it could lose visibility in the financial markets, which in turn could cause its stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The trading price of Frequency common stock has been highly volatile. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of Frequency common stock has been highly volatile, particularly over the last year. For example, on March&#160;31, 2022, the closing price of Frequency common stock was $2.12 per share and on March&#160;31, 2023 it was $0.50 per share. Frequency&#8217;s stock price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and economic factors that are beyond its control. In addition, while the stock market in general has experienced high volatility, biotechnology companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to operating performance. Broad market and industry factors may negatively affect the market price of its common stock, regardless of its actual operating performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sales of a substantial number of shares of Frequency common stock, or the perception that substantial sales might occur, could cause the price of its common stock to fall. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of Frequency common stock, or the perception that these sales might occur, could depress the market price of its common stock and could impair its ability to raise capital through the sale of additional equity securities. The shares of common stock that were sold in the initial public offering of Frequency common stock are freely transferable without restrictions or further registration under the Securities Act, except for any shares acquired by its affiliates, as defined in Rule 144 under the Securities Act. The remaining shares of its common stock that are outstanding are either unrestricted or restricted as a result of securities laws. In addition, there are shares of common stock that are either subject to outstanding Frequency Options, Frequency Restricted Stock Units, Frequency Performance Stock Units or reserved for future issuance under Frequency&#8217;s existing equity incentive plans and may become eligible for future sale subject to vesting, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of its common stock could decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The increasing focus on environmental sustainability and social initiatives could increase its costs, harm Frequency&#8217;s reputation and adversely impact its financial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been increasing public focus by investors, customers environmental activists, the media and governmental and nongovernmental organizations on a variety of environmental, social and other sustainability matters. Frequency may experience pressure to make commitments relating to sustainability matters that affect Frequency, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. If Frequency is not effective in addressing environmental, social and other sustainability matters </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affecting its business, or setting and meeting relevant sustainability goals, its reputation and financial results may suffer. Frequency may experience increased costs in order to execute upon its sustainability goals and measure achievement of those goals, which could have an adverse impact on its business and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this emphasis on environmental, social and other sustainability matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements. If Frequency fails to comply with new laws, regulations or reporting requirements, its reputation and business could be adversely impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financial volatility or geopolitical instability outside of the United States may adversely impact the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency could be adversely affected by general conditions in the global economy and in the global financial markets. Global credit and financial markets have recently experienced volatility and disruptions, including severely diminished liquidity and credit availability, rising interest rates, declines in consumer confidence, declines in economic growth, increase in unemployment rates and uncertainty about economic stability. Frequency&#8217;s business and stock price may be adversely affected by any such economic downturn, volatile business environment or large-scale unpredictable or unstable market conditions and international geopolitical conflict which could have a lasting impact on regional and global economies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_26a">Risks Related to Korro Bio&#8217;s Business </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_27b"><span style="font-style:italic">Risks Related to Korro Bio&#8217;s Financial Position and Need for Capital </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio has incurred significant losses since inception. Korro Bio expects to incur losses for the foreseeable future and may never achieve or maintain profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Korro Bio has incurred significant operating losses. Korro Bio&#8217;s net loss was $22.0&#160;million, $58.0&#160;million, $13.6&#160;million, and $19.6&#160;million for the years ended December&#160;31, 2021 and 2022, and the three months ended March&#160;31, 2022 and 2023, respectively. As of March&#160;31, 2023, Korro Bio had an accumulated deficit of $121.4&#160;million. Korro Bio has financed its operations primarily through private placements of its preferred stock. Substantially all of Korro Bio&#8217;s losses have resulted from expenses incurred in connection with its research and development and from general and administrative costs associated with its operations. Korro Bio expects to continue to incur significant expenses, increasing operating losses, and negative operating cash flows for the foreseeable future. The net losses Korro Bio incurs may fluctuate significantly from quarter to quarter. Korro Bio anticipates that its expenses will increase substantially if and as it: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continues current research programs and preclinical development of any product candidates it may identify; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seeks to identify additional research programs and product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiates preclinical studies and clinical trials for any product candidates it may identify; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">further develops OPERA, its RNA editing platform; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintains, expands, enforces, defends and protects its intellectual property portfolio and provides reimbursement of third-party expenses related to its intellectual property portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seeks marketing approvals for any product candidates that successfully complete clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">develops, maintains and enhances a sustainable, scalable, reproducible and transferable manufacturing process for the product candidates it may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ultimately establishes a sales, marketing and distribution infrastructure to commercialize any therapies for which it may obtain marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">hires additional research and development personnel; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">hires clinical and commercial personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adds operational, financial and management information systems and personnel, including personnel to support its product development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acquires or <span style="white-space:nowrap">in-licenses</span> product candidates, intellectual property and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishes and maintains collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">should it decide to do so, builds and maintains commercial-scale current Good Manufacturing Practices, or cGMP, manufacturing facility; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experiences any delays or interruptions due to global pandemics, such as the recent <span style="white-space:nowrap">COVID-19</span> pandemic, or other events unrelated to its business such as the Russian invasion of Ukraine that could result in delays in preclinical testing and clinical trials or interruptions in the supply chain; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">operates as a public company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has not initiated clinical development of any potential product candidate and expects that it will be many years, if ever, before it has a RNA editing therapy ready for commercialization. To become and remain profitable, Korro Bio must develop and, either directly or through collaborators, eventually commercialize a therapy or therapies with market potential. This will require Korro Bio to be successful in a range of challenging activities, including identifying product candidates, completing preclinical studies and clinical trials of product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those therapies for which it may obtain marketing approval and satisfying any post-marketing requirements. Korro Bio may never succeed in these activities and, even if it does, may never generate revenues that are significant or large enough to achieve profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has transitioned from discovery, research and development to early preclinical development for its most advanced product candidate. Because of the numerous risks and uncertainties associated with developing oligonucleotide product candidates, Korro Bio is unable to predict the extent of any future losses or when it will become profitable, if at all. If Korro Bio does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. Korro Bio&#8217;s failure to become and remain profitable would decrease the value of its company and could impair its ability to raise capital, maintain its research and development efforts, expand business or continue its operations. A decline in the value of Korro Bio could also cause you to lose all or part of your investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There is substantial doubt about Korro Bio&#8217;s ability to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A history of operating losses and negative cash flows from operations combined with Korro Bio&#8217;s anticipated use of cash to fund operations raises substantial doubt about its ability to continue as a going concern beyond the <span style="white-space:nowrap">12-month</span> period from the issuance date of its audited financial statements for year ended December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s future viability as an ongoing business is dependent on its ability to generate cash from its operating activities or to raise additional capital to finance its operations, such as through the Pre-Closing Financing and completion of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that Korro Bio will succeed in obtaining sufficient funding on terms acceptable to it to fund continuing operations, if at all. The perception that Korro Bio might be unable to continue as a going concern may also make it more difficult to obtain financing for the continuation of its operations on terms that are favorable to it, or at all, and could result in the loss of confidence by investors and employees. Korro Bio&#8217;s financial statements do not include any adjustments that might result from the outcome of this uncertainty. If Korro Bio is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on its financial statements, and it is likely that its investors will lose all or a part of their investment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio has never generated revenue from product sales and may never become profitable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s ability to generate revenue from product sales and achieve profitability depends on its ability, alone or with collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, product candidates it may identify for development. Korro Bio does not anticipate generating revenues from product sales for many years, if ever. Korro Bio&#8217;s ability to generate future revenues from product sales depends heavily on its, or its collaborators&#8217;, ability to successfully: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identify product candidates and successfully complete research and development of such product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek and obtain regulatory and marketing approvals for any product candidates for which Korro Bio completes clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launch and commercialize any product candidates for which Korro Bio may obtain regulatory and marketing approval by establishing a sales force, marketing and distribution infrastructure, or alternatively, collaborating with a commercialization partner; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which Korro Bio may obtain regulatory and marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for any product candidates for which Korro Bio obtain regulatory and marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for the product candidates Korro Bio may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">address competing technological and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negotiate favorable terms in any collaboration, licensing or other arrangements into which Korro Bio may enter and performing its obligations in such collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">receive market acceptance by physicians, patients, healthcare payors, and others in the medical community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain, protect, enforce, defend and expand Korro Bio&#8217;s portfolio of intellectual property and other proprietary rights, including patents, trade secrets and <span style="white-space:nowrap">know-how;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">defend against third party intellectual property claims of infringement, misappropriation or other violation; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract top talent and retain qualified personnel. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s expenses could increase beyond expectations if it is required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other regulatory authorities to perform clinical and other studies in addition to those that it currently anticipates. Even if one or more of the product candidates Korro Bio may develop are approved for commercial sale, Korro Bio anticipates incurring significant costs associated with commercializing any approved product candidate. Additionally, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives. Even if Korro Bio is able to generate revenues from the sale of any approved product candidates, it may not become profitable and may need to obtain additional funding to continue operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio will need substantial additional funding. If Korro Bio is unable to raise capital when needed, it will be forced to delay, reduce, eliminate or prioritize among its research and development programs or future commercialization efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio expects its expenses to continue to increase in connection with its ongoing activities, particularly as it identifies, continues the research and development of, initiates preclinical studies and clinical trials of, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seeks marketing approval for, product candidates. Because Korro Bio has limited financial and managerial resources, it has prioritized its research programs and lead optimization efforts in specific indications among many potential options. Specifically, Korro Bio&#8217;s initial development programs target liver and central nervous systems indications, amongst others. As a result of this prioritization, Korro Bio may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater clinical or commercial potential and it may need to reprioritize its focus in the future. Korro Bio&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Korro Bio&#8217;s spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if Korro Bio obtains marketing approval for any product candidates it may develop, it expects to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a collaborator. Furthermore, upon the closing of this offering, Korro Bio expects to incur additional costs associated with operating as a public company. Accordingly, Korro Bio will need to obtain substantial additional funding in connection with its continuing operations. If Korro Bio is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and product development programs or future commercialization efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, Korro Bio&#8217;s cash and cash equivalents and short-term investments were $79.5&#160;million, excluding restricted cash, or $84.7&#160;million, including restricted cash. Korro Bio expects to have a cash balance of approximately $170.0&#160;million at the closing of the Merger and the Pre-Closing Financing, and believes its existing cash and cash equivalents and short-term investments, assuming the Merger and Pre-Closing Financing are successfully completed, will be sufficient to fund its operating expenses and capital expenditure requirements through several value-creating milestones and into 2026. However, Korro Bio&#8217;s operating plan may change as a result of factors currently unknown, and expectations regarding its cash runway and ability to reach data inflection points are based on numerous assumptions that may prove to be untrue. For example, Korro Bio&#8217;s assumptions relating to the amounts of Frequency&#8217;s cash available to it at the closing of the Merger, including amounts that may be required to negotiate early lease terminations and costs associated with Frequency&#8217;s ongoing litigation, may prove to be incorrect. As a result, Korro Bio may be required to raise capital sooner than anticipated and its exposure to certain contingent liabilities and contractual obligations may be greater than anticipated. Korro Bio&#8217;s future capital requirements will depend on many other factors, including those discussed in the risk factor entitled <span style="font-style:italic">&#8220;Korro Bio has incurred significant losses since inception. Korro Bio expects to incur losses for the foreseeable future and may never achieve or maintain profitability.&#8221;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert Korro Bio&#8217;s management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may adversely affect its ability to develop and commercialize any product candidates it may develop. Korro Bio cannot be certain that additional funding will be available on acceptable terms or at all. Korro Bio has no committed source of additional capital and, if it is unable to raise additional capital in sufficient amounts or on terms acceptable to it, Korro Bio may have to significantly delay, scale back or discontinue the development or commercialization of any product candidates or other research and development initiatives. Korro Bio could be required to seek collaborators for potential product candidates earlier than it would otherwise plan or on terms that are less favorable than might otherwise be available. Korro Bio could also be required to relinquish or license its rights to product candidates on unfavorable terms in certain markets where it otherwise would seek to pursue development or commercialization itself. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to Korro Bio&#8217;s stockholders, restrict its operations or require it to relinquish rights to its technologies or product candidates it may develop. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as Korro Bio can generate substantial product revenues, it expects to finance its capital needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. Korro Bio does not have any committed external source of funds. To the extent that </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Korro Bio raises additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting Korro Bio&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends and possibly other restrictions. In addition, if Korro Bio raises funds through additional license and collaboration agreements, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable rights to its intellectual property, technologies, future revenue streams, research programs or product candidates it may develop, or it may have to grant licenses on terms that may not be favorable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s short operating history may make it difficult for you to evaluate the success of its business to date and to assess its future viability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is an early-stage company. Korro Bio was founded in September 2018 and commenced operations in October 2019. Korro Bio&#8217;s operations to date have been limited to organizing and staffing, business planning, raising capital, acquiring and developing its platform and technology and identifying and beginning to advance preclinical testing of potential product candidates. All of Korro Bio&#8217;s programs are still in the research or preclinical stage of development and their risk of failure is high. Korro Bio has not yet demonstrated an ability to initiate or successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale therapy, arrange for a third party to do so on its behalf or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes about 10 to 15&#160;years to develop a new therapy from the time it is discovered to when it is available for treating patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s limited operating history, particularly in light of the rapidly evolving gene editing field, may make it difficult to evaluate its technology and industry and predict its future performance. Korro Bio&#8217;s short history as an operating company makes any assessment of its future success or viability subject to significant uncertainty. Korro Bio will encounter risks and difficulties frequently experienced by very early-stage companies in rapidly evolving fields. If Korro Bio does not address these risks successfully, its business will suffer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a new business, Korro Bio may encounter other unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. Korro Bio will need to transition from a company with a research focus to a company capable of supporting commercial activities. Korro Bio may not be successful in such a transition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since Korro Bio&#8217;s inception, it has incurred losses and it may never achieve profitability. As of December&#160;31, 2022, Korro Bio had federal and state NOLs of $72.1 million and $70.3 million, respectively. Under current law, Korro Bio&#8217;s federal NOLs generated in taxable years ending after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Korro Bio&#8217;s taxable income annually for tax years beginning after December&#160;31, 2020. Federal NOLs generated in taxable years ending on or prior to December&#160;31, 2017, however, have a <span style="white-space:nowrap">20-year</span> carryforward period, but are not subject to the 80% limitation. Korro Bio&#8217;s state NOLs expire at various dates from 2038 through 2042. As of December&#160;31, 2022, Korro Bio had federal research and development tax credit carryforwards of $3.5 million that expire at various dates from 2040 through 2042. In addition, as of December 31, 2022, Korro Bio had state research and development tax credit carryforwards of $2.6 million that expire at various dates from 2034 through 2037. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as one or more shareholders or groups of shareholders who own at least 5&#160;percent of the corporation&#8217;s equity increasing their equity ownership in the aggregate by more than 50 percentage points (by value) over a rolling three-year period, the corporation&#8217;s ability to use its <span style="white-space:nowrap">pre-change</span> NOLs and other <span style="white-space:nowrap">pre-change</span> tax attributes </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(such as research and development tax credits) to offset its post-change income or taxes may be limited. Similar rules may apply under state tax laws. Korro Bio&#8217;s prior equity offerings and other changes in its stock ownership may have resulted in such ownership changes in the past. Korro Bio has not conducted a formal study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. In addition, Korro Bio may experience ownership changes in the future as a result of future securities offering or subsequent shifts in its stock ownership, some of which are outside of its control. In particular, the Merger and the Pre-Closing Financing, if consummated, may constitute an ownership change within the meaning of Section 382 of the Code, which could eliminate or otherwise substantially limit Korro Bio&#8217;s ability to use its NOLs and tax credit carryforwards. As a result, if Korro Bio earns net taxable income in the future, its ability to use its <span style="white-space:nowrap">pre-change</span> NOLs or other <span style="white-space:nowrap">pre-change</span> tax attributes to offset U.S. federal taxable income or income taxes may be subject to limitations, which could potentially result in increased future tax liability to Korro Bio. Additional limitations on Korro Bio&#8217;s ability to utilize its NOLs to offset future taxable income may arise as a result of its corporate structure whereby NOLs generated by its subsidiary may not be available to offset taxable income earned by its subsidiary. There is a risk that due to changes under the tax law, regulatory changes or other unforeseen reasons, Korro Bio&#8217;s existing NOLs or business tax credits could expire or otherwise be unavailable to offset future income tax liabilities. At the state level, there may also be periods during which the use of NOLs or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed by Korro Bio. For these reasons, Korro Bio may not be able to realize a tax benefit from the use of its NOLs or tax credits, even if it attains profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in tax laws or in their implementation or interpretation may adversely affect Korro Bio&#8217;s business and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect Korro Bio&#8217;s business and financial condition. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Korro Bio cannot predict whether, when, in what form or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided or whether they could increase its tax liability or require changes in the manner in which it operates in order to minimize increases in its tax liability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_28a"><span style="font-weight:bold"><span style="font-style:italic">Risks Related to Discovery, Development and Commercialization</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The gene editing field and RNA editing in particular is relatively new and is evolving rapidly. Korro Bio is very early in its development efforts and may not be successful in identifying and developing product candidates. It will be many years before Korro Bio or its collaborators commercialize a product candidate or generate any revenues, if ever. Additionally, other gene editing technologies may be discovered that provide significant advantages over RNA editing, which could materially harm its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of Korro Bio&#8217;s business depends primarily upon its ability to identify, develop and commercialize product candidates. Korro Bio is very early in its development efforts and has focused its research and development efforts to date on developing OPERA, its RNA editing platform, and identifying its initial targeted disease indications. Although Korro Bio believes it can demonstrate many of the key advantages of RNA editing, because it is very early in its development efforts, Korro Bio is not yet certain of the results it may achieve, which may be important for registration and commercialization of its products. Such uncertainties include, but are not limited to, the delivery of product candidates to target tissues, the adequate level of editing efficiency needed to have a disease impact, Korro Bio&#8217;s ability to achieve pharmacological activity in humans and associated safety of its edits. Korro Bio has also not yet shown that preclinical editing activity can result in clinically important effects, nor that the data generated by its preclinical studies can translate into positive results in clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of Korro Bio&#8217;s product development programs are still in the research or preclinical stage of development. Korro Bio&#8217;s research methodology may be unsuccessful in identifying product candidates, its product candidates may be shown to have harmful side effects in preclinical <span style="font-style:italic">in vitro</span> experiments or animal model studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmacological properties ascribed to the product candidates Korro Bio is testing in preclinical studies may not be positively demonstrated in clinical trials in patients, and they may interact with human biological systems in unforeseen, ineffective or harmful ways. If Korro Bio&#8217;s product candidates prove to be ineffective, unsafe or commercially unviable, OPERA and Korro Bio&#8217;s pipeline would have little, if any, value, which would substantially harm Korro Bio&#8217;s business, financial condition, results of operations and prospects. In addition, Korro Bio&#8217;s approach, which focuses on using oligonucleotides for drug development, as opposed to multiple or other, more advanced proven technologies, and new products and technologies that may enter the market, may expose it to additional financial risks and make it more difficult to raise additional capital if Korro Bio is not successful in developing one or more product candidates that receive regulatory approval. Korro Bio&#8217;s ability to generate product revenue, which it does not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of any product candidates it may discover, which may never occur. Korro Bio currently generates no revenue from sales of any product, and it may never be able to develop or commercialize a marketable product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, although Korro Bio believes OPERA, its RNA editing platform, will position it to rapidly expand its portfolio of product candidates beyond the initial product candidates it may develop, it has not yet successfully developed any product candidate and its ability to expand its portfolio may never materialize. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing clinical trials in the United States is also subject to acceptance by the FDA of any future investigational new drug, or IND, applications and finalization of trial designs based on discussions with the FDA and other regulatory authorities. Even after Korro Bio receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that Korro Bio has satisfied their requirements to commence any clinical trial or change their position on the acceptability of Korro Bio&#8217;s trial designs or any clinical endpoints selected, which may require Korro Bio to complete additional studies or trials or impose stricter approval conditions than Korro Bio expects. There are equivalent processes and risks applicable to clinical trial applications, or CTAs, in other countries, including in Europe, the UK and Australia. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Korro Bio completes the necessary clinical trials, it cannot predict when, or if, it will obtain regulatory approval to commercialize its product candidates in the United States or any other jurisdiction, if at all, and any such approval may be for a narrower indication than Korro Bio seeks. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Korro Bio may conduct one or more of its clinical trials with one or more trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA, and there can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that Korro Bio conducts outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt its development of the applicable product candidates. Similarly, marketing approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commercialization of any product candidates Korro Bio may develop will also require obtaining manufacturing supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. If Korro Bio does not successfully commercialize any product candidates it may develop, it could experience a material harm to its business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">RNA editing is a novel technology that is not yet clinically validated for human therapeutic use. The approaches Korro Bio takes to discover and develop novel therapeutics are unproven and may never lead to marketable products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is focused on developing therapies based on RNA editing. Although there have been significant advances in the field of gene editing in recent years, RNA editing technologies are new and largely unproven. The technologies that Korro Bio has developed have not yet been clinically tested, nor is it aware of any clinical trials for safety or efficacy having been completed by third parties using RNA editing or similar technologies. The scientific evidence to support the feasibility of developing product candidates based on these technologies is both preliminary and limited. Successful development of product candidates by Korro Bio will require solving a number of issues, including optimizing the efficiency and specificity of such product candidates, and ensuring the therapeutic selectivity of such product candidates. There can be no assurance Korro Bio will be successful in solving any or all of these issues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has concentrated its research efforts to date on preclinical work to bring therapeutics to the clinic for its initial indications, and its future success is highly dependent on the successful development of OPERA, its RNA editing platform, as well as cellular delivery methods and therapeutic applications of that technology. While some of the existing, <span style="white-space:nowrap">non-RNA</span> editing, gene editing technologies developed by third parties have progressed to clinical trials, they continue to suffer from various limitations, and such limitations may affect Korro Bio&#8217;s future success. While a number of clinical trials for oligonucleotide products conducted by other companies have not been successful, some have received regulatory approval. The pharmacological properties ascribed to the product candidates Korro Bio is testing or will test in the future may not be positively demonstrated in clinical trials in patients, and they may interact with human biological systems in unforeseen, ineffective or harmful ways. If Korro Bio&#8217;s product candidates prove to be ineffective, unsafe or commercially unviable, Korro Bio&#8217;s OPERA platform and its pipeline would have little, if any, value, which would substantially harm Korro Bio&#8217;s business, financial condition, results of operations and prospects. Korro Bio may decide to alter or abandon its initial programs as new data becomes available and it gains experience in developing base editing therapeutics. Korro Bio cannot be sure that its technologies will yield satisfactory products that are safe and effective, scalable or profitable in its initial indications or any other indication it pursues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development activities in the field of RNA editing are currently subject to a number of risks related to the ownership and use of certain intellectual property rights that are subject to patent reexamination and inter partes proceedings in the United States and opposition proceedings in Europe. For additional information regarding the risks that may apply to Korro Bio&#8217;s and its licensors&#8217; intellectual property rights, see the section entitled <span style="font-style:italic">&#8220;&#8212;Risks Related to Intellectual Property</span>&#8221; appearing elsewhere in this prospectus for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio is very early in its development efforts, and its preclinical studies and clinical trials may not be successful. If Korro Bio is unable to commercialize its product candidates or experiences significant delays in doing so, its business will be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is very early in its development of product candidates and has focused its efforts to date on platform development, discovery, research, and preclinical development. Currently, all of Korro Bio&#8217;s programs are still in the research or preclinical stage of development. Korro Bio&#8217;s ability to generate product revenues, which it does not expect will occur for many years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of its product candidates, which may never occur. Korro Bio has not yet generated revenue from product sales or otherwise, and it may never be able to develop or commercialize a marketable product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires Korro Bio to complete additional preclinical studies or Korro Bio is required to satisfy other FDA requests prior to commencing clinical trials, the start of its first clinical trials may be delayed or it may be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unsuccessful obtaining clearance to proceed into clinical development. Even after Korro Bio receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that it have satisfied their requirements to commence any clinical trial or change their position on the acceptability of Korro Bio&#8217;s trial designs or the clinical endpoints selected, which may require it to complete additional preclinical studies or clinical trials, delay the enrollment of its clinical trials, abandon its clinical development plans or meet stricter approval conditions than Korro Bio currently expects. There are equivalent processes and risks applicable to CTAs in other countries, including countries in the European Union, or EU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commercialization of any product candidates Korro Bio may develop will require preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the EMA; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of Korro Bio&#8217;s product candidates will depend on many factors, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effective INDs or comparable foreign applications that allow commencement of its planned clinical trials or future clinical trials for any product candidates Korro Bio may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful enrollment and completion of clinical trials, including under the FDA&#8217;s current GCPs, current Good Laboratory Practices, or GLPs, and any additional regulatory requirements from foreign regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">positive results from its future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">receipt of marketing approvals from applicable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishment of arrangements through its own facilities or with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any product candidates Korro Bio may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commercial launch of any product candidates Korro Bio may develop, if approved, whether alone or in collaboration with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance of the benefits and use of the product candidates Korro Bio may develop, including method of administration, if and when approved, by patients, the medical community and third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effective competition with other therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates Korro Bio may develop following approval; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishment and maintenance of healthcare coverage and adequate reimbursement by payors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio does not succeed in one or more of these factors in a timely manner or at all, it could experience significant delays or an inability to successfully commercialize any product candidates it may develop, which would materially harm its business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any product candidates Korro Bio develops may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval for the commercial distribution of any of its product candidates, Korro Bio must conduct, at its own expense, extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of its product candidates. Preclinical and clinical testing are expensive, difficult to design and implement, can take many years to complete, are uncertain as to outcome, and the historical failure rate for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drugs in preclinical and clinical development is high. For example, Korro Bio depends on the availability of <span style="white-space:nowrap">non-human</span> primates to conduct certain preclinical studies. Over the past several years there has been an increasing global shortage of <span style="white-space:nowrap">non-human</span> primates available for drug development that has matured into an acute global supply chain issue. The supply of these <span style="white-space:nowrap">non-human</span> primates is currently constrained due to factors such as their limited worldwide availability, domestic regulatory restrictions and trade relations. If Korro Bio is unable to obtain access to a sufficient supply of these <span style="white-space:nowrap">non-human</span> primates in a timely manner or at all, its timelines and its ability to complete preclinical testing and submit IND or CTA applications may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of one or more of Korro Bio&#8217;s product candidates can fail at any stage of testing. Korro Bio may experience numerous unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent regulatory approval or Korro Bio&#8217;s ability to commercialize its product candidates, including:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">its preclinical studies or clinical trials may produce negative or inconclusive results, including results that may not meet the level of significance or clinical benefit required by the FDA or other regulators, and Korro Bio may decide, or regulators may require Korro Bio, to conduct additional preclinical studies or clinical trials, or Korro Bio may abandon projects that it had expected to be promising; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in filing INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or institutional review boards, or IRBs, in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conditions imposed on it by the FDA or comparable foreign authorities regarding the scope or design of Korro Bio&#8217;s clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">divergent views between FDA and other homologue regulatory authorities as to the objectives and/or design of the clinical trials required in support of marketing registration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">problems in obtaining or maintaining IRB approval of trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in enrolling patients or volunteers into clinical trials, and variability in the number and types of patients eligible for clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an inability to open study sites, or enroll, treat, and monitor patients due to local restrictions, including as a result of <span style="white-space:nowrap">COVID-19</span> or any other pandemic or other events, such as the Russian invasion of Ukraine; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in developing and receiving regulatory approval for companion diagnostic tests, to the extent such tests are needed, to identify patients for its clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">high <span style="white-space:nowrap">drop-out</span> rates for patients in clinical trials and substantial missing data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or inconclusive results from its clinical trials or the clinical trials of others for product candidates similar to Korro Bio&#8217;s; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results from future clinical trials may not confirm positive results, if any, from earlier preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to consistently manufacture, inadequate supply, or unacceptable quality of product candidate materials or other materials necessary for the conduct of Korro Bio&#8217;s clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater than anticipated clinical trial costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">serious and unexpected side effects that may or may not be related to the product candidate being tested that are experienced by participants in Korro Bio&#8217;s clinical trials or by individuals using drugs similar to Korro Bio&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">poor or disappointing effectiveness of its product candidates during clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unfavorable outcome of FDA or other regulatory agency inspection and review of a manufacturing or clinical trial site or other records relating to the clinical investigation; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of its third-party contractors, investigators, or collaboration partners to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around manufacturing, preclinical, or clinical testing generally or with respect to Korro Bio&#8217;s product candidates class, in particular; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">varying interpretations of data by the FDA and similar foreign regulatory agencies. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio does not successfully conduct clinical development, it will not be able to market and sell products derived from its product candidates and to generate product revenues. Even if Korro Bio does successfully complete clinical trials, those results are not necessarily predictive of results of additional trials that may be needed before it can submit an application for regulatory approval to the FDA or foreign regulatory agencies. If the development of any of Korro Bio&#8217;s product candidates fails or is delayed to a point where such product candidate is no longer commercially viable, its business may be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may not be able to conduct clinical trials successfully due to various process-related factors that could negatively impact its business plans. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful initiation and completion of any of Korro Bio&#8217;s clinical trials, within timeframes consistent with its business plans, is dependent on various factors, which include, but are not limited to, its ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">retain and recruit employees, contractors or consultants with the required level of knowledge and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">retain and recruit, in a timely manner, a sufficient number of patients necessary to conduct a clinical trial, which is a function of many factors, including the impact of the <span style="white-space:nowrap">COVID-19</span> global pandemic, the proximity of participants to clinical sites, the size of the relevant population, the eligibility criteria for the trial, possible adverse effects from treatments, the existence of competing clinical trials, the involvement of patient advocacy groups, the availability of new or alternative treatments, lack of efficacy, personnel issues and ease of participation in Korro Bio&#8217;s clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manage the impact of the <span style="white-space:nowrap">COVID-19</span> pandemic or other global health pandemics on Korro Bio&#8217;s early-stage discovery efforts and clinical trials; open study sites, and enroll, treat, and monitor patients due to local restrictions implemented in response to remaining <span style="white-space:nowrap">COVID-19</span> effects or other global health pandemics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">develop companion diagnostic tests for use with certain of Korro Bio&#8217;s product candidates or identify partners with such expertise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacture and maintain a sufficient amount of clinical material, internally or through third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ensure adherence to trial designs and protocols agreed upon and approved by regulatory authorities and applicable regulatory and legal guidelines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">apply the appropriate pharmacovigilance measures in case of adverse effects emerging during a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">execute clinical trial designs and protocols approved by regulatory authorities without deficiencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">timely and effectively contract with (under reasonable terms), manage and work with investigators, institutions, hospitals and the CROs involved in the clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negotiate contracts and other related documents with clinical trial parties and IRBs, CRO agreements and site agreements, which can be subject to extensive negotiations that could cause significant delays in the clinical trial process, with terms possibly varying significantly among different trial sites and CROs and possibly subjecting Korro Bio to various risks; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conduct clinical trials in a cost-effective manner, including management of foreign currency risk in clinical trials conducted in foreign jurisdictions and cost increases due to unforeseen or unexpected complications such as enrollment delays, or needing to outsource certain functions during the clinical trial. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio is not able to manage the clinical trial process successfully, Korro Bio&#8217;s business plans could be delayed or be rendered unfeasible for it to execute within its planned or required time frames, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio cannot successfully manufacture its product candidates for its research and development and preclinical activities, or manufacture sufficient amounts of its product candidates to meet its clinical requirements and timelines, its business may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to develop Korro Bio&#8217;s product candidates, apply for regulatory approvals and commercialize its product candidates, Korro Bio will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. In addition to the oligonucleotides that Korro Bio manufactures internally, it may utilize CMOs to manufacture the oligonucleotides required for its preclinical studies and clinical trials. There are a limited number of manufacturers that supply oligonucleotides. There are risks inherent in pharmaceutical manufacturing that could affect Korro Bio&#8217;s ability or the ability of its CMOs to meet delivery time requirements or provide adequate amounts of material to meet its clinical trial demands on its projected timelines. Included in these risks are potential synthesis and purification failures and/or contamination during the manufacturing process, as well as other issues with Korro Bio&#8217;s facility or the CMOs&#8217; facilities and ability to comply with the applicable manufacturing requirements and quality standards, which could result in unusable product and cause delays in Korro Bio&#8217;s manufacturing timelines and ultimately delay Korro Bio&#8217;s clinical trials, as well as result in additional expense. To manufacture Korro Bio&#8217;s oligonucleotides, it relies on third parties to supply the required raw materials. Korro Bio will likely need to secure alternative suppliers for these raw materials, and such alternative suppliers are limited and may not be readily available, or it may be unable to enter into agreements with them on reasonable terms and in a timely manner. For example, Korro Bio sources certain materials used in the manufacture of its products from China and other countries outside of the United States; the coronavirus outbreak or other similar global disruptions has made access to its existing supply chain difficult and further supply chain disruptions could impact its business. Additionally, Korro Bio&#8217;s cost of goods development is at an early stage. The actual cost to manufacture and process its product candidates could be greater than expected and could materially and adversely affect the commercial viability of Korro Bio&#8217;s product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The process of manufacturing oligonucleotides is complex and Korro Bio may encounter difficulties in production, particularly with respect to process development or <span style="white-space:nowrap">scaling-up</span> of its manufacturing capabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of manufacturing oligonucleotides is complex, highly-regulated and subject to multiple risks. The complex processes associated with the manufacture of Korro Bio&#8217;s product candidates expose Korro Bio to various manufacturing challenges and risks, which may include delays in manufacturing adequate supply of its product candidates, limits on its ability to increase manufacturing capacity, and the potential for product failure and product variation in quality that may interfere with preclinical studies and clinical trials, along with additional costs. Korro Bio also may make changes to its manufacturing process at various points during development, and even after commercialization, for various reasons, such as optimizing costs, achieving scale, decreasing processing time, increasing manufacturing success rate, or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause Korro Bio&#8217;s product candidates to perform differently and affect the results of current or future clinical trials, or the performance of the product, once commercialized. In some circumstances, changes in the manufacturing process may require Korro Bio to perform ex vivo comparability studies, and/or conduct animal studies, and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in Korro Bio&#8217;s process during the course of clinical development may require it to show the comparability of the product used in earlier clinical trials or at earlier portions of a trial to the product used in later clinical trials or later portions of the trial. Korro Bio may also make further changes to its manufacturing process before or after commercialization, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such changes may require it to show the comparability of the resulting product to the product produced via earlier manufacturing processes and supplied in clinical studies. Korro Bio may be required to collect additional preclinical and/or clinical data from any modified process prior to obtaining marketing approval for the product candidate produced with such modified process. If preclinical and/or clinical data are not ultimately comparable to those seen in the earlier trials, Korro Bio may be required to make further changes to its process and/or undertake additional clinical testing, either of which could significantly delay the clinical development or commercialization of the associated product candidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Korro Bio continues to build on its experience in manufacturing oligonucleotides, it has limited experience as a company manufacturing product candidates for commercial supply. Korro Bio may never be successful in manufacturing product candidates in sufficient quantities or with sufficient quality for commercial use. Korro Bio&#8217;s manufacturing capabilities could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, operator error, natural disasters, unavailability of qualified personnel, difficulties with logistics and shipping, problems regarding yields or stability of product, contamination or other quality control issues, power failures, and numerous other factors that could prevent it from realizing the intended benefits of its manufacturing strategy and have a material adverse effect on Korro Bio&#8217;s business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, compliance with cGMP requirements and other quality issues may arise during any internal efforts to <span style="white-space:nowrap">scale-up</span> manufacturing, and with Korro Bio&#8217;s current or any future CMOs. If contaminants are discovered in Korro Bio&#8217;s supply of its product candidates or in the manufacturing facilities of its CMOs, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Korro Bio cannot assure you that any stability failures or other issues relating to the manufacture of its product candidates will not occur in the future. Additionally, Korro Bio&#8217;s CMOs may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If Korro Bios CMOs were to encounter any of these difficulties, its ability to provide its product candidate to patients in clinical trials, or to provide product for treatment of patients once approved, would be jeopardized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Korro Bio has limited financial resources, it intends to focus on developing product candidates for specific indications that it identifies as most likely to succeed, in terms of both regulatory approval and commercialization. As a result, Korro Bio may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential. Its resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Korro Bio&#8217;s spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If Korro Bio does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for Korro Bio to retain sole development and commercialization rights to such product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio has not tested any of its proposed delivery methods or gene editing approaches in clinical trials and any favorable results it may have may not be predictive of results that may be observed in later preclinical studies or clinical trials. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scientific evidence to support the feasibility of developing product candidates based on Korro Bio&#8217;s RNA editing technology is both preliminary and limited. Korro Bio has not tested any of its potential delivery modalities or gene editing approaches in clinical trials and any favorable results it may have may not be predictive of results that may be observed in later preclinical studies or clinical trials. For example, Korro Bio </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may use LNPs or other delivery modalities to deliver its product candidates. While LNPs have been used to deliver RNA molecules, such as siRNA, they have not been clinically proven to deliver oligonucleotides for RNA editing, such as the ones Korro Bio intends to use for its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Korro Bio&#8217;s RNA editing technology itself may lead to other issues, such as inability to deliver the desired efficacy or safety-related consequences as it is tested in clinical trials. Korro Bio has not generated any clinical trial results to date. The design of a clinical trial can determine whether its results will support approval of a product candidate and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Furthermore, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Many product candidates that initially showed promise in early stage testing for treating a variety of diseases have later been found to lack efficacy or to cause side effects that prevented further clinical development of the product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s future product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has not evaluated any product candidates in human clinical trials. Moreover, there have been only a limited number of clinical trials involving the use of gene editing technologies and none involving RNA editing technology similar to Korro Bio&#8217;s technology. It is impossible to predict when, or if, any product candidates Korro Bio may develop will prove safe in humans. In the genetic medicine field, there have been several significant adverse events from gene therapy treatments in the past, including reported cases of leukemia and death. There can be no assurance that RNA editing technologies will not cause undesirable side effects, such as lymphoma, leukemia, or other cancers, or other aberrantly functioning cells. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such adverse events occur, Korro Bio&#8217;s future clinical trials could be suspended or terminated. If Korro Bio is unable to demonstrate that any adverse events were caused by the administration process or related procedures, the FDA, the European Commission, the EMA or other regulatory authorities could order Korro Bio to cease further development of, or deny approval of, any future product candidates for any or all targeted indications. Even if Korro Bio can demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete any future trial. Moreover, if Korro Bio elects, or is required, to not initiate, delay, suspend or terminate any future clinical trial of any of Korro Bio&#8217;s product candidates, the commercial prospects of such product candidates may be harmed and Korro Bio&#8217;s ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm Korro Bio&#8217;s ability to develop other product candidates, and may adversely affect Korro Bio&#8217;s business, financial condition, results of operations and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any of Korro Bio&#8217;s future product candidates receives marketing approval, the FDA could require Korro Bio to adopt a REMS to ensure that the benefits of the product outweigh its risks, which may include, for example, a Medication Guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners, or other elements to assure safe use of the product. Furthermore, if Korro Bio or others later identify undesirable side effects caused by any of Korro Bio&#8217;s future product candidates, several potentially significant negative consequences could result, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may suspend or withdraw approvals of such product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio may be required to change the way a product candidate is administered or conduct additional clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio could be sued and held liable for harm caused to patients; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio&#8217;s reputation may suffer. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these occurrences may harm Korro Bio&#8217;s business, financial condition, results of operations and prospects significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio is unable to successfully identify patients who are likely to benefit from therapy with any product candidates it develops, or experience significant delays in doing so, it may not realize the full commercial potential of any medicines it may develop. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s success may depend, in part, on its ability to identify patients who are likely to benefit from therapy with any medicines it may develop, which may require those potential patients to have their DNA analyzed for the presence or absence of a particular sequence. If Korro Bio, or any third parties that it engages to assist it, are unable to successfully identify such patients, or experience delays in doing so, then: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio&#8217;s ability to develop any product candidates may be adversely affected if Korro Bio is unable to appropriately select patients for enrollment in Korro Bio&#8217;s clinical trials; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio may not realize the full commercial potential of any product candidates it develops that receive marketing approval if, among other reasons, Korro Bio is unable to appropriately select patients who are likely to benefit from therapy with its medicines. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these factors, Korro Bio may be unable to successfully develop and realize the commercial potential of any product candidates Korro Bio may identify and develop, and its business, financial condition, results of operations, and prospects would be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio is unable to successfully develop or obtain regulatory approval for companion diagnostic tests for its product candidates, or experience significant delays in doing so, its clinical trials may be delayed and its business could be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development programs for some of Korro Bio&#8217;s product candidates contemplate the development of companion diagnostic tests, which are assays or tests to identify an appropriate patient population. If safe and effective use of any of Korro Bio&#8217;s product candidates it may develop depends on a companion diagnostic, it may not receive marketing approval, or marketing approval may be delayed, if Korro Bio is unable to or are delayed in developing, identifying, or obtaining regulatory approval or clearance for the companion diagnostic product for use with Korro Bio&#8217;s product candidate. Identifying a manufacturer of the companion diagnostic and entering into an agreement with the manufacturer could also delay the development of Korro Bio&#8217;s product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio is unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any future product candidates, it may be unable to generate any revenues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio currently does not have an organization for the sales, marketing and distribution of any future product candidates and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. To market any products that may be approved, Korro Bio must build its sales, marketing, managerial and other <span style="white-space:nowrap">non-technical</span> capabilities or make arrangements with third parties to perform these services. With respect to certain of Korro Bio&#8217;s current programs as well as future programs, Korro Bio may rely completely on an alliance partner for sales and marketing. In addition, although Korro Bio intends to establish a sales organization if it is able to obtain approval to market any product candidates, it may enter into strategic alliances with third parties to develop and commercialize any future product candidates, including in markets outside of the United States or for other large markets that are beyond its resources. This will reduce the revenue generated from the sales of these products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future strategic alliance partners may not dedicate sufficient resources to the commercialization of Korro Bio&#8217;s product candidates or may otherwise fail in their commercialization due to factors beyond its control. If Korro Bio is unable to establish effective alliances to enable the sale of its product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by its </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
own marketing and sales force, or if its potential future strategic alliance partners do not successfully commercialize the product candidates, Korro Bio&#8217;s ability to generate revenues from product sales will be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio is unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, it may not be able to generate sufficient product revenue and may not become profitable. Korro Bio will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, Korro Bio may be unable to compete successfully against these more established companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if Korro Bio receives regulatory approval to market its product candidates, the market may not be receptive to its product candidates upon their commercial introduction, which will prevent it from becoming profitable.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s product candidates are based upon new discoveries, technologies and therapeutic approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payors and consumers, may not adopt a product intended to improve therapeutic results that is based on the technology employed by oligonucleotides. As a result, it may be more difficult for Korro Bio to convince the medical community and third-party payors to accept and use its product, or to provide favorable reimbursement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other factors that Korro Bio believes will materially affect market acceptance of its product candidates include:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of its receipt of any regulatory approvals, the terms of any approvals and the countries in which approvals are obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to consistently manufacture Korro Bio&#8217;s products within acceptable quality standards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the safety and efficacy of its product candidates, as demonstrated in clinical trials and as compared with alternative treatments, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the incidence, seriousness and severity of any side effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative convenience and ease of administration of its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of patients to accept potentially new routes of administration and their risk tolerance as it relates to potentially serious side effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of its physician education programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of government and third-party payor coverage and adequate reimbursement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the pricing of its products, particularly as compared to alternative treatments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of alternative effective treatments for the diseases that product candidates it develops are intended to treat and the relative risks, benefits and costs of those treatments. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Korro Bio estimates regarding the potential market size may be materially different from what it currently expect by the time it commences commercialization, which could result in significant changes in its business plan and may significantly harm its results of operations and financial condition.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The pharmaceutical industry is intensely competitive. If Korro Bio is unable to compete effectively with existing drugs, new treatment methods and new technologies, it may be unable to commercialize successfully any drugs that it develops.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical industry is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organizations are pursuing the development of novel drugs for the same diseases that Korro Bio is targeting or expect to target. Many of Korro Bio&#8217;s competitors have:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">much greater financial, technical and human resources than Korro Bio has at every stage of the discovery, development, manufacture and commercialization of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">more extensive experience in designing and conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing, marketing and selling pharmaceutical products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product candidates that are based on previously tested or accepted technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">products that have been approved or are in late stages of development; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborative arrangements in Korro Bio&#8217;s target markets with leading companies and research institutions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which it may develop therapies. Korro Bio also expects to face competition from new drugs that enter the market. Korro Bio believes a significant number of drugs are currently under development, and may become commercially available in the future, for the treatment of conditions that its current or future product candidates are or may be designed to treat. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products Korro Bio develops.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s competitors may develop or commercialize products with significant advantages over any products Korro Bio is able to develop and commercialize based on many different factors, including:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the safety and effectiveness of its products relative to alternative therapies, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ease with which its products can be administered and the extent to which patients accept relatively new routes of administration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and scope of regulatory approvals for these products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability and cost of manufacturing, marketing and sales capabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">price; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">more extensive coverage and higher levels of reimbursement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent position. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s competitors may therefore be more successful in commercializing their products than Korro Bio is, which could adversely affect Korro Bio&#8217;s competitive position and business. Competitive products may make any products Korro Bio develops obsolete or noncompetitive before it can recover the expenses of developing and commercializing its product candidates. Such competitors could also recruit Korro Bio&#8217;s employees, which could negatively impact its level of expertise and its ability to execute on its business plan.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for Korro Bio&#8217;s product candidates, if approved, could limit its ability to market those products and decrease its ability to generate product revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio expects that coverage and reimbursement by third-party payors will be essential for most patients to be able to afford any gene therapies for which it is able to successfully complete clinical development. Accordingly, sales of any future products will depend substantially, both domestically and internationally, on the extent to which the costs of any such products will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Even if coverage is provided, the approved </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement amount may not be high enough to allow Korro Bio to establish or maintain pricing sufficient to realize a sufficient return on is investment. If Korro Bio is unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those product candidates and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in both the United States and globally. Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and Korro Bio believes the increasing emphasis on cost-containment initiatives in the United States, the EU, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as its product candidates. Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for its product candidates. Korro Bio expects to experience pricing pressures in connection with the sale of any of its product candidates due to the trend toward managed healthcare, the increasing influence of certain third-party payors, such as health maintenance organizations, and additional legislative changes. For an overview and discussion of the regulatory framework for pricing and reimbursement, see &#8220;<span style="font-style:italic">Korro Bio&#8217;s Business&#8212;Government Regulation&#8212;Patients Rely on Insurance Coverage by Third-Party Payors (third-party payors include Medicare and Medicaid (government payors) and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.) to Pay for Products.&#8221;</span><span style="font-style:italic"></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the market opportunities for any product candidates Korro Bio may develop are smaller than it believes they are, Korro Bio&#8217;s potential revenues may be adversely affected, and its business may suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with product candidates it may develop, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. Additionally, Korro Bio&#8217;s estimates regarding the potential market size may be materially different from what it currently expects by the time it commences commercialization. The number of patients in the United States, Europe, and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with Korro Bio&#8217;s product candidates, or may become increasingly difficult to identify or gain access to, all of which would adversely affect its business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">While Korro Bio intends to seek designations for its product candidates with the FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process or an accelerated regulatory pathway, there can be no assurance that Korro Bio will successfully obtain such designations. In addition, even if one or more of Korro Bio&#8217;s product candidates are granted such designations, Korro Bio may not be able to realize the intended benefits of such designations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations include fast track, or breakthrough therapy, among others, and may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority review. However, there can be no assurance that Korro Bio will successfully obtain such designations for any product candidates. See &#8220;<span style="font-style:italic">Korro Bio&#8217;s Business&#8212;Government Regulation&#8212;Expedited Development and Review Programs for Drugs</span>&#8221; for more information regarding these designations. While such designations could expedite the development or approval process, they generally do not change the standards for approval. Even if Korro Bio obtains such designations for one or more of its product candidates, there can be no assurance that it will realize their intended benefits. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, Korro Bio may also seek approval of product candidates under the FDA&#8217;s accelerated approval pathway or request priority review. There can be no assurance that FDA would allow any of the product candidates Korro Bio may develop to proceed on an accelerated approval pathway or grant priority review, and even if FDA did allow such pathway, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. Moreover, even if Korro Bio received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals Korro Bio has obtained. Receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the EU, Korro Bio may seek to participate in The PRIority Medicines, or PRIME scheme for its product candidates. The PRIME scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation, where the marketing authorization application will be made through the centralized procedure in the EU. There is no guarantee, however, that Korro Bio&#8217;s product candidates would be deemed eligible for the PRIME scheme and even if Korro Bio does participate in the PRIME scheme, where during the course of development a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. For more information regarding PRIME and the EU regulatory framework, see &#8220;<span style="font-style:italic">Korro Bio&#8217;s Business&#8212;Government Regulation&#8212;Regulation Outside of the United States</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unfavorable global economic conditions could adversely affect Korro Bio&#8217;s business, financial condition or results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, or additional global financial crises, could result in a variety of risks to Korro Bio&#8217;s business, including weakened demand for any future product candidates, if approved, or its ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain Korro Bio&#8217;s suppliers, possibly resulting in supply disruption. Any of the foregoing could harm Korro Bio&#8217;s business and Korro Bio cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s business may be impacted by macroeconomic conditions, including fears concerning the financial services industry, inflation, rising interest rates and volatile market conditions, and other uncertainties beyond its control.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual events involving limited liquidity, defaults, <span style="white-space:nowrap">non-performance</span> or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or&#160;concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank Signature Bank and Silvergate Capital Corp. were each swept into receivership by the Federal Deposit Insurance Corporation and then a syndicate of U.S. banks infused $30&#160;billion in First Republic Bank; and later that same week, the Swiss Central Bank provided $54&#160;billion in covered loan and short-term liquidity facilities to Credit Suisse Group AG, all in an attempt to reassure depositors and calm fears of a banking contagion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s ability to effectively run its business could be adversely affected by general conditions in the global economy and in the financial services industry. Various macroeconomic factors could adversely affect Korro Bio&#8217;s business, including fears concerning the banking sector, changes in inflation, interest rates and overall economic conditions and uncertainties. A severe or prolonged economic downturn could result in a variety of risks, including Korro Bio&#8217;s ability to raise additional funding on a timely basis or on acceptable terms. A weak or declining economy could also impact third parties upon whom Korro Bio depends to run its business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Increasing concerns over bank failures and bailouts and their potential broader effects and potential systemic risk on the banking sector generally and on the biotechnology industry and its participants may adversely affect Korro Bio&#8217;s access to capital and its business and operations more generally. Although Korro Bio assess it banking relationships as it believes necessary or appropriate, its access to funding sources in amounts adequate to finance or capitalize its current and projected future business operations could be significantly impaired by factors that affect Korro Bio, the financial institutions with which Korro Bio has arrangements directly, or the financial services industry or economy in general. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Regulatory, Legal, and Clinical Trials </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because Korro Bio is developing oligonucleotides, which are considered a relatively new class of drugs, there is increased risk that the outcome of its clinical trials will not be sufficient to obtain regulatory approval.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and comparable <span style="white-space:nowrap">ex-U.S.</span> regulatory agencies have relatively limited experience with oligonucleotides, which may increase the complexity, uncertainty and length of the regulatory review process for any future product candidates. Even though the FDA issued two draft guidance documents in December 2021 relating to IND submissions for individualized antisense oligonucleotide drugs for severely debilitating or life-threatening genetic diseases, one with clinical focus, the other with chemistry manufacturing and controls focus, and in June 2022 a draft guidance on clinical pharmacology considerations for the development of oligonucleotide therapeutics, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to overall development considerations for oligonucleotide drugs. The general lack of policies, practices or guidelines specific to oligonucleotides may hinder or slow review by the FDA or other foreign homologues of any regulatory filings that Korro Bio may submit. Moreover, the FDA or other foreign homologues may respond to these submissions by defining requirements Korro Bio may not have anticipated. Addressing such requirements could lead to significant delays in the development of Korro Bio&#8217;s product candidates. In addition, because there may be approved treatments for some of the diseases for which Korro Bio may seek approval, in order to receive regulatory approval, Korro Bio may need to demonstrate through clinical trials that the product candidates it develops to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Furthermore, in recent years, there has been increased public and political pressure on the FDA with respect to the approval process for new drugs. As a result of the foregoing factors, Korro Bio may never receive regulatory approval to market and commercialize any product candidate. Even if Korro Bio obtains regulatory approval, the approval may be for disease indications or patient populations that are not as broad as Korro Bio intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. Korro Bio may be&#160;required to perform additional or unanticipated clinical trials to obtain regulatory approval or be subject to additional post-marketing studies or other requirements to maintain such approval. As a result, Korro Bio may never succeed in developing a marketable product, it may not become profitable and the value of its common stock could decline.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Enacted and future legislation may increase the difficulty and cost for Korro Bio to obtain marketing approval of and commercialize its product candidates and may affect the prices Korro Bio may set. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Korro Bio&#8217;s product candidates. Korro Bio cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If Korro Bio is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Korro Bio is not able to maintain regulatory compliance, Korro Bio may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability. For more information, see the section below titled &#8220;<span style="font-style:italic">Korro Bio&#8217;s Business&#8212;Governmental Regulation</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on it. In addition, other legislative changes have been proposed and adopted since </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the ACA was enacted. Korro Bio may choose to seek an expanded access program for its product candidates, or to utilize comparable rules in other countries that allow the use of a drug, on a named patient basis or under a compassionate use program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio expects that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that it receives for any approved product. Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those Korro Bio is developing. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent Korro Bio from being able to generate revenue, attain profitability, or commercialize its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. Korro Bio cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of its product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject Korro Bio to more stringent product labeling and post-marketing testing and other requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because Korro Bio is developing product candidates in the field of genetic medicines in which there is little clinical experience, there is increased risk that the FDA, the EMA or other regulatory authorities may not consider the endpoints of its clinical trials to provide clinically meaningful results and that these results may be difficult to analyze. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to proceed into clinical development of any product candidates Korro Bio identifies, it will need to submit INDs or comparable foreign applications to regulatory authorities and obtain regulatory clearance to commence clinical development. Because the product candidates Korro Bio identifies are based on novel gene-editing technology, Korro Bio may be unsuccessful in obtaining clearance from regulatory authorities to proceed into clinical development. In order to commence clinical development, Korro Bio will need to identify success criteria and endpoints such that the FDA, the EMA or other regulatory authorities will be able to determine the clinical efficacy and safety profile of any product candidates Korro Bio may develop. As Korro Bio is initially seeking to identify and develop product candidates to treat diseases in which there is little clinical experience using new technologies, and while it may have opportunities to discuss its clinical development plans with regulatory authorities prior to commencing clinical development, there is heightened risk that the FDA, the EMA or other regulatory authorities may not consider the clinical trial endpoints that Korro Bio proposes to provide clinically meaningful results (reflecting a tangible benefit to patients). In addition, the resulting clinical data and results may be difficult to analyze. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA does find Korro Bio&#8217;s success criteria to be sufficiently validated and clinically meaningful, it may not achieve the <span style="white-space:nowrap">pre-specified</span> endpoints to a degree of statistical significance. Furthermore, even if Korro Bio does achieve the <span style="white-space:nowrap">pre-specified</span> criteria, it may produce results that are unpredictable or inconsistent with the results of the <span style="white-space:nowrap">non-primary</span> endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of regulatory approval. Other regulatory authorities in the EU and other countries may make similar comments with respect to these endpoints and data. Any product candidates Korro Bio may develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. No gene editing therapeutic product has been approved in the United States or in Europe. Within the broader genome product field, only a limited number of gene therapy products, such as uniQure&#160;N.V.&#8217;s Glybera and Abecma from Bristol Myers Squibb and bluebird bio, have received </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing authorization or marketing approval from the European Commission or the FDA. Some of these products have taken years to register and have had to deal with significant issues in their post-marketing experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If preclinical studies or clinical trials of any product candidates Korro Bio may identify and develop fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, Korro Bio may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of any product candidates Korro Bio may identify and develop, Korro Bio must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio and its collaborators, if any, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent its ability to receive marketing approval or commercialize any product candidates it may identify and develop, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching a consensus with regulators on trial design; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators, IRBs, or independent ethics committees may not authorize Korro Bio or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching or failing to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trials of any product candidates Korro Bio may develop may produce negative or inconclusive results, and Korro Bio may decide, or regulators may require Korro Bio, to conduct additional clinical trials or abandon product development or research programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulty in designing well-controlled clinical trials due to ethical considerations that may render it inappropriate to conduct a trial with a control arm that can be effectively compared to a treatment arm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulty in designing clinical trials and selecting endpoints for diseases that have not been well-studied and for which the natural history and course of the disease is poorly understood; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of patients required for clinical trials of any product candidates Korro Bio may develop may be larger than it anticipates; enrollment of suitable participants in these clinical trials, which may be particularly challenging for some of the rare genetically defined diseases Korro Bio is targeting in its most advanced programs, may be delayed or slower than it anticipate; or patients may drop out of these clinical trials at a higher rate than it anticipates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio&#8217;s third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to it in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators, IRBs, or independent ethics committees may require that Korro Bio or its investigators suspend or terminate clinical research or clinical trials of any product candidates Korro Bio may develop for various reasons, including noncompliance with regulatory requirements, a finding of undesirable side effects or other unexpected characteristics, or that the participants are being exposed to unacceptable health risks or after an inspection of Korro Bio&#8217;s clinical trial operations or trial sites; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of clinical trials of any product candidates it may develop may be greater than Korro Bio anticipates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supply or quality of any product candidates Korro Bio may develop or other materials necessary to conduct clinical trials of any product candidates it may develop may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing, and delivery of any product candidates it may develop to the clinical sites by it or by third parties with whom Korro Bio has contracted to perform certain of those functions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in having patients complete participation in a trial or return for post-treatment <span style="white-space:nowrap">follow-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">occurrence of serious adverse events associated with any product candidates Korro Bio may develop that are viewed to outweigh their potential benefits; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio or its collaborators are required to conduct additional clinical trials or other testing of any product candidates it may develop beyond those that it currently contemplates, if Korro Bio or its collaborators are unable to successfully complete clinical trials or other testing of any product candidates it may develop, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, Korro Bio or its collaborators may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be delayed in obtaining marketing approval for any such product candidates Korro Bio may develop or not obtain marketing approval at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval for indications or patient populations that are not as broad as intended or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to changes in the way the product is administered; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a REMS or through modification to an existing REMS; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be sued; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience damage to Korro Bio&#8217;s reputation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product development costs will also increase if Korro Bio or its collaborators experience delays in clinical trials or other testing or in obtaining marketing approvals. Korro Bio does not know whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which Korro Bio may have the exclusive right to commercialize any product candidates it may develop, could allow Korro Bio&#8217;s competitors to bring products to market before it does, and could impair its ability to successfully commercialize any product candidates it may develop, any of which may harm its business, financial condition, results of operations, and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio experiences delays or difficulties in the enrollment of patients in clinical trials, its receipt of necessary regulatory approvals could be delayed or prevented.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the <span style="white-space:nowrap">COVID-19</span> global pandemic or emerging or future variants of <span style="white-space:nowrap">COVID-19,</span> the size of the patient population, the age and condition of the patients, the stage and severity of disease, the nature and requirements of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. Delays or difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments, can result in increased costs, longer development times or termination of a clinical trial.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if Korro Bio completes the necessary preclinical studies and clinical trials, it cannot predict when, or if, it will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than Korro Bio seeks. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to commercialization, any of Korro Bio&#8217;s product candidates must be approved by the FDA pursuant to a new drug application, or NDA, in the United States and pursuant to similar marketing applications by the EMA and similar regulatory authorities outside the United States. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent it from commercializing the product candidate. Korro Bio has not received approval to market any of its product candidates from regulatory authorities in any jurisdiction. Korro Bio has no experience in submitting and supporting the applications necessary to gain marketing approvals, and, in the event regulatory authorities indicate that Korro Bio may submit such applications, Korro Bio may be unable to do so as quickly and efficiently as desired. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Korro Bio&#8217;s product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Korro Bio obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept or file any application or may decide that Korro Bio&#8217;s data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of any of Korro Bio&#8217;s product candidates may be delayed or refused for many reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Korro Bio&#8217;s clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio may be unable to demonstrate, to the satisfaction of the FDA or comparable foreign regulatory authorities, that its product candidates are safe and effective for any of their proposed indications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio may be unable to demonstrate that its product candidates&#8217; clinical and other benefits outweigh their safety risks; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may disagree with Korro Bio&#8217;s interpretation of data from preclinical programs or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the data collected from clinical trials of Korro Bio&#8217;s product candidates may not be sufficient to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the facilities of third-party manufacturers with which Korro Bio contracts or procures certain service or raw materials, may not be adequate to support approval of its product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Korro Bio&#8217;s clinical data insufficient for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Korro Bio&#8217;s product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or Korro Bio may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends <span style="white-space:nowrap">non-approval</span> or restrictions on approval. In addition, Korro Bio may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or REMS. These regulatory authorities may require precautions or contra-indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of Korro Bio&#8217;s product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for Korro Bio&#8217;s product candidates and adversely affect its business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may be unable to obtain regulatory approval in the United States or foreign jurisdictions and, as a result, be unable to commercialize its product candidates and its ability to generate revenue will be materially impaired.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, quality, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical studies and clinical trials, and an extensive regulatory approval process are required to be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain, and subject to a continuously evolving regulatory environment and unanticipated delays. It is possible that none of the product candidates Korro Bio may develop will obtain the regulatory approvals necessary for it or its collaborators to begin selling them.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating companies such as Korro Bio&#8217;s are not always applied predictably or uniformly and can change. Any analysis Korro Bio performs of data from chemistry, manufacturing and controls, preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Korro Bio&#8217;s may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay or failure in obtaining required approvals could adversely affect Korro Bio&#8217;s ability to generate revenues from the particular product candidate for which it is seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which Korro Bio may market the product or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as a condition of approval, which may impose further requirements or restrictions on the distribution or safe use of an approved drug, such as limiting prescribing rights to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients as specially defined by the indication statement or who meet certain <span style="white-space:nowrap">safe-use</span> criteria, and requiring treated patients to enroll in a registry, among other requirements. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and payment. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above, as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not ensure approval by comparable regulatory authorities outside of the United States and vice versa.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any product candidate for which Korro Bio obtains marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and Korro Bio may be subject to penalties if it fails to comply with regulatory requirements or if it experiences unanticipated problems with its product candidates, when and if any of them are approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s product candidates and the activities associated with their development and potential commercialization, including their testing, manufacturing, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other U.S. and international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, including cGMPs, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities and requirements regarding the distribution of samples to providers and recordkeeping. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If Korro Bio promotes its product candidates in a manner inconsistent with <span style="white-space:nowrap">FDA-approved</span> labeling or otherwise not in compliance with FDA regulations, it may be subject to enforcement action. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws and similar laws in international jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown adverse events or other problems with Korro Bio&#8217;s product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on such product candidates, manufacturers or manufacturing processes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the labeling or marketing of a product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on product distribution or use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requirements to conduct post-marketing studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">warning or untitled letters; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of any approved product from the market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to approve pending applications or supplements to approved applications that Korro Bio may submit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recall of product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, restitution or disgorgement of profits or revenues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or withdrawal of marketing approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to permit the import or export of Korro Bio&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-compliance</span> with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if Korro Bio obtains regulatory approvals, its marketed drugs will be subject to ongoing regulatory oversight. If Korro Bio fails to comply with continuing U.S. and foreign requirements, its approvals, if obtained, could be limited or withdrawn, Korro Bio could be subject to other penalties, and its business would be seriously harmed.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following any initial regulatory approval of any drugs Korro Bio may develop, Korro Bio will also be subject to continuing regulatory oversight, including the review of adverse drug experiences and safety data that are reported after its drug products are made commercially available. This would include results from any post-marketing studies or surveillance to monitor the safety and efficacy of the drug product required as a condition of approval or agreed to by Korro Bio. Any regulatory approvals that Korro Bio receives for its product candidates may also be subject to limitations on the approved uses for which the product may be marketed. Other ongoing regulatory requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing, as well as continued maintenance of Korro Bio&#8217;s marketing application, compliance with cGMP requirements and quality oversight, compliance with post-marketing commitments, and compliance with GCP for any clinical trials that Korro Bio conducts post-approval. Failure to comply with these requirements could result in warning or untitled letters, criminal or civil penalties, recalls, or product withdrawals. In addition, Korro Bio intends to seek approval to market its product candidates in jurisdictions outside of the United States, and therefore will be subject to, and must comply with, regulatory requirements in those jurisdictions.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials for a variety of reasons. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio, its CMOs, and the manufacturing facilities it uses to make its product candidates will also be subject to ongoing assessment of product quality, compliance with cGMP, and periodic inspection by the FDA and potentially other regulatory agencies. Korro Bio or its CMOs may not be able to comply with applicable cGMP regulations or similar regulatory requirements outside of the United States. Korro Bio&#8217;s failure, or the failure of its CMOs, to comply with applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations, warning letters or sanctions being imposed on Korro Bio, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Korro Bio&#8217;s products. Korro Bio may not have the ability or capacity to manufacture material at a broader commercial scale in the future. Korro Bio and its </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CMOs currently manufacture a limited supply of clinical trial materials. Reliance on CMOs entails risks to which Korro Bio would not be subject if it manufactured all of the material themselves, including reliance on the CMO for regulatory compliance. Korro Bio&#8217;s product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio or its collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which Korro Bio may seek to market its products, Korro Bio or they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit the import or export of products, operating restrictions, injunction, consent decree, civil penalties and criminal prosecution.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any drugs Korro Bio develops may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming its business.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Korro Bio&#8217;s product candidates represent new approaches to the treatment of genetic-based diseases, it cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, its product candidates or assure that coverage and reimbursement will be available for any product that it may develop. The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Korro Bio is monitoring these regulations as several of its programs move into later stages of development; however, many of its programs are currently in the earlier stages of development and Korro Bio will not be able to assess the impact of price regulations for a number of years. As a result, Korro Bio might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that could delay its commercial launch of the product and negatively impact any potential revenues it may be able to generate from the sale of the product in that country and potentially in other countries due to reference pricing.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement/payment for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if Korro Bio succeeds in bringing one or more products to the market, these products may&#160;not be considered medically necessary and/or cost-effective, and the amount reimbursed for any products may be insufficient to allow it to sell its products on a competitive basis. At this time, Korro Bio is unable to determine their cost effectiveness or the likely level or method of reimbursement for its product candidates. Increasingly, third-party payors, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts paid for pharmaceutical products. If the price Korro Bio is able to charge for any products it develops, or the payments provided for such products, is inadequate in light of Korro Bio&#8217;s development and other costs, its return on investment could be adversely affected.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio currently expects that any drugs it develops may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain drugs that are not usually self-administered (such as most injectable drugs) may be eligible for coverage under the Medicare Part B program if:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">they are incident to a physician&#8217;s services; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">they have been approved by the FDA and meet other requirements of the statute. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining coverage for newly-approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable foreign regulatory authorities. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to pay all or part of the costs associated with their prescription drugs. Patients are unlikely to use Korro Bio&#8217;s products unless coverage is provided and payment is adequate to cover all or a significant portion of the cost of Korro Bio&#8217;s products. Therefore, coverage and adequate payment is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Moreover, eligibility for coverage does not imply that any drug will be paid for in all cases or at a rate that covers Korro Bio&#8217;s costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover Korro Bio&#8217;s costs and may not be made permanent. Reimbursement may be based on payments allowed for lower-cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. However, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require Korro Bio to provide scientific and clinical support for the use of its products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Korro Bio&#8217;s inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for new drugs that it develops and for which Korro Bio obtains regulatory approval could adversely affect Korro Bio&#8217;s operating results, its ability to raise capital needed to commercialize products, and its overall financial condition.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio believes that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare system in the United States and other major healthcare markets have been proposed and/or adopted in recent years, and such efforts have expanded substantially in recent years. For more information on these changes, see the section below titled &#8220;<span style="font-style:italic">Korro Bio&#8217;s Business&#8212;Governmental Regulation&#8212;Affordable Care Act and Legislative Reform Measures</span>.&#8221; It is unclear how any additional healthcare reform measures may increase the pressure on drug pricing or limit the availability of coverage and adequate reimbursement for Korro Bio&#8217;s future candidates. Korro Bio expects ongoing initiatives in the United States to increase pressure on drug pricing and reimbursement. Such reforms could have an adverse effect on anticipated revenues from product candidates that Korro Bio may successfully develop and for which Korro Bio may obtain regulatory approval and may affect its overall financial condition and ability to develop product candidates.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may not be able to obtain orphan drug exclusivity for one or more of its product candidates, and even if it does, that exclusivity may not prevent the FDA or the EMA from approving other competing products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan product candidates by the EMA in the EU. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for another product candidate for the same orphan therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the EU. The exclusivity period in the EU can be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reduced to six years if a product no longer meets the criteria for orphan designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#8217;s standards for granting orphan drug exclusivity in the gene therapy context are unclear and evolving. In order for the FDA to grant orphan drug exclusivity to one of Korro Bio&#8217;s product candidates, the agency must find that the product candidate is indicated for the treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. The FDA may conclude that the condition or disease for which Korro Bio seeks orphan drug exclusivity does not meet this standard. Even if Korro Bio obtains orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product candidate for the same condition if the FDA concludes that the later product candidate is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care compared with the product that has orphan exclusivity. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, the Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s <span style="white-space:nowrap">pre-existing</span> regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. Korro Bio does not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect its business. Depending on what changes the FDA may make to its orphan drug regulations and policies, Korro Bio&#8217;s business could be adversely impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio does not comply with laws regulating the protection of the environment and health and human safety, its business could be adversely affected.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s research, development and manufacturing processes involve the use of hazardous materials. Korro Bio maintains quantities of various flammable and toxic chemicals in its facilities that are required for its research, development and manufacturing activities. Korro Bio is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Korro Bio&#8217;s procedures for storing, handling and disposing of these materials are reviewed against the relevant guidelines and laws of the jurisdictions in which its facilities are located on a regular basis. Although Korro Bio believes that its safety procedures for handling and disposing of these materials sufficiently mitigate the risk of accidental contamination or injury from these materials, the risk cannot be completely eliminated. If an accident occurs, Korro Bio could be held liable for resulting damages, which could be substantial. Korro Bio is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. Although Korro Bio maintains workers&#8217; compensation insurance to cover it for costs and expenses it may incur due to injuries to its employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. Korro Bio does not maintain insurance for environmental liability or toxic tort claims that may be asserted against it in connection with its storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting Korro Bio&#8217;s operations may become applicable in the future. Korro Bio may incur substantial costs to comply with, and substantial fines or penalties if it violates any of, these laws or regulations.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio or its collaborators, manufacturers, service providers or other third parties fail to comply with applicable healthcare laws and regulations, Korro Bio could be subject to enforcement actions, which could affect its ability to develop, market and sell its products and may harm its reputation.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is currently, or may in the future, be subject to federal, state, local, and comparable foreign healthcare laws and regulations relating to areas such as fraud and abuse and patients&#8217; rights. These laws may constrain the business or financial arrangements and relationships through which Korro Bio conducts its operations, including how Korro Bio researches, markets, sells and distributes its products for which it obtains marketing approval. For more information on these laws, see the section below titled &#8220;<span style="font-style:italic">Korro Bio&#8217;s Business&#8212;Governmental Regulation</span><span style="font-style:italic">&#8212;Other Healthcare Laws</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio&#8217;s operations are found to be in violation of any such requirements, Korro Bio may be subject to penalties, including civil or criminal penalties, criminal prosecution, monetary damages, the curtailment or restructuring of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in federal healthcare programs including Medicare and Medicaid, the imposition of a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services,&#160;disgorgement, individual imprisonment, contractual damages, reputational harm, and diminished profits and future earnings, any of which could adversely affect its financial results and adversely affect its ability to operate its business. Korro Bio intends to develop and implement a comprehensive corporate compliance program prior to the commercialization of its product candidates. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against Korro Bio for an alleged or suspected violation could cause it to incur significant legal expenses, could divert Korro Bio management&#8217;s attention from the operation of its business, and could harm its reputation, even if its defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to Korro Bio in terms of money, time and resources.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio or its collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, Korro Bio could be subject to enforcement actions, which could affect its ability to develop, market and sell its products successfully and could harm its reputation and lead to reduced acceptance of its products by the market. These enforcement actions include, among others:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory inspection findings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">warning and/or untitled letters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on, or prohibitions against, marketing Korro Bio products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on, or prohibitions against, importation or exportation of Korro Bio products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension of review or refusal to approve pending applications or supplements to approved applications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exclusion from participation in government-funded healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exclusion from eligibility for the award of government contracts for Korro Bio products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or withdrawal of product approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">consent decrees; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">civil and criminal penalties, up to and including criminal prosecution resulting in fines, exclusion from healthcare reimbursement programs and imprisonment. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Moreover, federal, state or foreign laws or regulations are subject to change, and while Korro Bio, its collaborators, manufacturers and/or service providers currently may be compliant, that could change due to changes in interpretation, prevailing industry standards or other reasons.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio employees, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is exposed to the risk of fraud and other misconduct by its employees, consultants and collaborators. Such misconduct could include intentional failures to comply with FDA and other foreign agency regulations, provide accurate information to the FDA, comply with manufacturing standards required by the FDA or Korro Bio, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to Korro Bio. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could&#160;also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to Korro Bio&#8217;s reputation. It is not always possible to identify and deter such misconduct, and the precautions Korro Bio takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting it from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against Korro Bio, and Korro Bio is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including the imposition of significant fines or other sanctions.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Product liability lawsuits against Korro Bio could cause it to incur substantial liabilities and could limit commercialization of any medicines that it may develop. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio faces an inherent risk of product liability exposure related to the testing in human clinical trials of any product candidates it may develop and will face an even greater risk if it commercially sell any medicines that it may develop. If Korro Bio cannot successfully defend itself against claims that its product candidates or medicines caused injuries, Korro Bio could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for any product candidates or medicines that Korro Bio may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to Korro Bio&#8217;s reputation and significant negative media attention; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant time and costs to defend the related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to trial participants or patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize any medicines that Korro Bio may develop. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio anticipates that it will need to increase its insurance coverage when it begins clinical trials and if Korro Bio successfully commercialize any medicine. Insurance coverage is increasingly expensive. Korro Bio may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s internal computer and information systems, or those used by its CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of its development programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of appropriate security measures, Korro Bio&#8217;s internal computer and information systems and those of its current and any future CROs, CMOs and other contractors or consultants may become vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While Korro Bio has not experienced any such material system failure, or accident, and is unaware of any security breach to date, if such an event were to occur and cause interruptions in it operations, it could result in a material disruption of its development programs and its business operations, whether due to a loss of its trade secrets or other proprietary information or other similar disruptions. For example, the loss of data from completed or future preclinical studies or clinical trials could result in significant delays in Korro Bio&#8217;s regulatory approval efforts and significantly increase its costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, Korro Bio&#8217;s data or applications, or inappropriate disclosure of confidential or proprietary information, Korro Bio could incur liability, its competitive position could be harmed and the further development and commercialization of its product candidates could be significantly delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may be unable to adequately protect its information systems from cyberattacks, which could result in the disclosure of confidential information, damage its reputation, and subject it to significant financial and legal exposure. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, <span style="white-space:nowrap"><span style="white-space:nowrap">denial-of-service,</span></span> social engineering fraud or other means to threaten data confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for Korro Bio, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. To date, Korro Bio has not experienced a material compromise of its data or information systems. However, although Korro Bio devotes resources to protect its information systems, Korro Bio realizes that cyberattacks are a threat, and there can be no assurance that its efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to it, or would have a material adverse effect on its results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s failure to obtain regulatory approval in international jurisdictions would prevent it from marketing its product candidates outside the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To market and sell Korro Bio&#8217;s future product candidates in other jurisdictions, Korro Bio must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, Korro Bio must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Failure to obtain foreign regulatory approvals or <span style="white-space:nowrap">non-compliance</span> with foreign regulatory requirements could result in significant delays, difficulties and costs for Korro Bio and could delay or prevent the introduction of its product candidates in certain countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio fails to comply with the regulatory requirements in international markets and receives applicable marketing approvals, its target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Korro Bio may not obtain foreign regulatory approvals on a timely basis, if at all. Korro Bio&#8217;s failure to obtain approval of any of its product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and its business prospects could decline. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact Korro Bio&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect Korro Bio&#8217;s business. For example, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio is subject to a variety of privacy and data security laws, and its failure to comply with them could harm its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio maintains a large quantity of sensitive information, including confidential business and patient health information in connection with its preclinical studies, and is subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations and constantly evolving. The collection, use, disclosure, transfer or other processing of personal data originating from the European Economic Area, or EEA, and United Kingdom, or UK, is governed by the General Data Protection Regulation, or EU GDPR, and the UK General Data Protection Regulation, or UK GDPR, which, together with the EU GDPR, is referred to as the GDPR. For additional information on these regimes, see &#8220;<span style="font-style:italic">Korro Bio&#8217;s Business&#8212;Government Regulation&#8212;Privacy and Cybersecurity</span><span style="font-style:italic"></span><span style="font-style:italic"></span>&#8221;. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and Korro Bio may be required to put in place additional mechanisms to ensure compliance, and despite those efforts, if Korro Bio fails to comply with any such laws or regulations, it may face significant fines and penalties that could adversely affect its reputation, business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_30a"><span style="font-style:italic">Risks Related to Korro Bio&#8217;s Third Party Relationships </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may be subject to claims that Korro Bio or its employees or consultants have wrongfully used or disclosed alleged trade secrets of employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if Korro Bio does not successfully do so, it may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of Korro Bio&#8217;s employees were previously employed at universities or biotechnology or pharmaceutical companies, including its competitors or potential competitors. Although no claims against Korro Bio are currently pending, it may be subject to claims that these employees or Korro Bio has inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If Korro Bio fails in defending such claims, in addition to paying monetary damages, Korro Bio may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper Korro Bio&#8217;s ability to commercialize, or prevent it from commercializing, its product candidates, which could severely harm its business. Even if Korro Bio is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio expects to rely on third parties to conduct its clinical trials and some aspects of its research, as well as some aspects of its delivery methods, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio currently, and expects to continue to, rely on third parties, such as CROs, clinical data management organizations, medical institutions, preclinical laboratories and clinical investigators, to conduct some aspects of its research. For example, Korro Bio may rely on a third party to supply LNPs, or to conduct some of its preclinical animal experiments. Any of these third parties may terminate their engagements with Korro Bio at any time under certain criteria. If Korro Bio needs to enter into alternative arrangements, it may delay its product development activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s reliance on these third parties for research and development activities will reduce its control over these activities but will not relieve Korro Bio of its responsibilities. For example, Korro Bio will remain responsible for ensuring that each of its clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA, the EMA and other regulatory authorities require Korro Bio and the study sites and investigators Korro Bio works with to comply with standards, commonly referred to as GLPs and GCPs for conducting, recording and reporting the results of preclinical studies and clinical trials to assure, amongst other things, that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may not be successful in finding strategic collaborators for continuing development of certain of its future product candidates or successfully commercializing or competing in the market for certain indications. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, Korro Bio may decide to collaborate with <span style="white-space:nowrap">non-profit</span> organizations, universities, pharmaceutical and biotechnology companies for the development and potential commercialization of existing and new product candidates. Korro Bio faces significant competition in seeking appropriate collaborators. Whether Korro Bio reaches a definitive agreement for a collaboration will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to Korro Bio&#8217;s ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with Korro Bio for its product candidate. The terms of any additional collaborations or other arrangements that Korro Bio may establish may not be favorable to Korro Bio. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If Korro Bio is unable to do so, it may have to curtail the development of the product candidate for which Korro Bio is seeking to collaborate, reduce or delay its development program or one or more of Korro Bio&#8217;s other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase its expenditures and undertake development or commercialization activities at its own expense. If Korro Bio elects to increase its expenditures to fund development or commercialization activities on its own, Korro Bio may need to obtain additional capital, which may not be available to it on acceptable terms or at all. If Korro Bio does not have sufficient funds, it may not be able to further develop its product candidates or bring them to market and generate product revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any potential collaboration arrangements will depend heavily on the efforts and activities of Korro Bio&#8217;s collaborators. Collaborators generally have significant discretion in determining the efforts and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of such collaboration arrangements. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect Korro Bio financially and could harm its business reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future acquisitions or strategic alliances could disrupt Korro Bio&#8217;s business and harm its financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio may acquire additional businesses or drugs, form strategic alliances or create joint ventures with third parties that it believes will complement or augment its existing business. If Korro Bio acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if Korro Bio is unable to successfully integrate them with its existing operations and company culture. Korro Bio may encounter numerous difficulties in developing, manufacturing and marketing any new drugs resulting from a strategic alliance or acquisition that delay or prevent it from realizing their expected benefits or enhancing its business. Korro Bio cannot assure you that, following any such acquisition, it will achieve the expected synergies to justify the transaction. The risks Korro Bio faces in connection with acquisitions, include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversion of management time and focus from operating its business to addressing acquisition integration challenges; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">coordination of research and development efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">retention of key employees from the acquired company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in relationships with strategic partners as a result of product acquisitions or strategic positioning resulting from the acquisition; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cultural challenges associated with integrating employees from the acquired company into Korro Bio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the need to implement or improve controls, procedures, and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities, and other known liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unanticipated write-offs or charges; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s failure to address these risks or other problems encountered in connection with its past or future acquisitions or strategic alliances could cause it to fail to realize the anticipated benefits of these transactions, cause it to incur unanticipated liabilities and harm the business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm Korro Bio&#8217;s financial condition or results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio relies, and anticipates that it will rely, on third parties to design, conduct, supervise and monitor its preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm its business.<sup style="font-size:75%; vertical-align:top">&#160;</sup> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio relies, and anticipates that it will rely, on third party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials of its product candidates. Because Korro Bio relies on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, Korro Bio has less control over the timing, quality and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other aspects&#160;of preclinical studies and clinical trials than it would if it conducted them on its own, including Korro Bio&#8217;s inability to control whether sufficient resources are applied to its programs. If any of Korro Bio&#8217;s CROs are acquired or consolidated, these concerns are likely to be exacerbated and its preclinical studies or clinical trials may be further impacted due to potential integration, streamlining, staffing and logistical changes. These investigators, CROs and consultants are not Korro Bio employees and Korro Bio has limited control over the amount of time and resources that they dedicate to its programs. These third parties may have contractual relationships with other entities, some of which may be Korro Bio&#8217;s competitors, which may draw time and resources from Korro Bio programs. Further, these third parties may not be diligent, careful or timely in conducting Korro Bio&#8217;s preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, Korro Bio&#8217;s preclinical and clinical development programs could be delayed and otherwise adversely affected. In all events, Korro Bio is responsible for ensuring that each of its preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA and other health authorities require certain preclinical studies to be conducted in accordance with GLP, and clinical trials to be conducted in accordance with GCP, including conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. If Korro Bio or its CROs fail to comply with these requirements, the data generated in Korro Bio&#8217;s clinical trials may be deemed unreliable or uninterpretable and the FDA and other health authorities may require Korro Bio to perform additional clinical trials. Korro Bio&#8217;s reliance on third parties that it does not control does not relieve it of these responsibilities and requirements. In the United States, Korro Bio is also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Any such event could adversely affect Korro Bio&#8217;s business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio relies on third parties in the supply and manufacture of its product candidates for its research, preclinical and clinical activities, and may do the same for commercial supplies of its product candidates.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has not yet manufactured its product candidates on a commercial scale, and may not be able to do so for any of its product candidates. Korro Bio currently relies on third parties in the supply and manufacture of materials for its research, preclinical and clinical activities and may continue to do so for the foreseeable future, including if it received regulatory approval for any product candidate. Korro Bio may do the same for the commercial supply of its drug product. Korro Bio uses third parties to perform additional steps in the manufacturing process, such as the filling, finishing and labeling of vials and storage of its product candidates and Korro Bio expects to do so for the foreseeable future. There can be no assurance that Korro Bio&#8217;s supply of research, preclinical and clinical development drug candidates and other materials will not be limited, interrupted or restricted or will be of satisfactory quality or continue to be available at acceptable prices. Replacement of any of the third parties Korro Bio may engage could require significant effort and expertise because there may be a limited number of qualified replacements. In addition, raw materials, reagents, and components used in the manufacturing process, particularly those for which Korro Bio has no other source or supplier, may not be available, may not be suitable or acceptable for use due to material or component defects, or may introduce variability into the supply of its product candidates. Furthermore, with the increase of companies developing nucleic acid therapeutics, there may be increased competition for the supply of the raw materials that are necessary to make Korro Bio&#8217;s oligonucleotides, which could severely impact the manufacturing of its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and they must be acceptable to the FDA or approved by foreign regulatory </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorities Suppliers and manufacturers, including Korro Bio, must meet applicable manufacturing requirements, including compliance with cGMP regulations, and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards. In the event that any of Korro Bio&#8217;s suppliers or manufacturers fail to comply with such requirements or to perform their obligations to Korro Bio in relation to quality, timing or otherwise, some of which may be out of their or Korro Bio&#8217;s control, or if Korro Bio&#8217;s supply of components or other materials becomes limited or interrupted for other reasons, Korro Bio may be forced to increase the manufacturing of the materials itself, for which its currently has limited capabilities and resources, or enter into an agreement with another third party, which it may not be able to do on reasonable terms, if at all. Any interruption of the development or operation of the manufacturing of Korro Bio&#8217;s product candidates, such as order delays for equipment or materials, equipment malfunction, quality control and quality assurance issues, regulatory delays and possible negative effects of such delays on supply chains and expected timelines for product availability, production yield issues, shortages of qualified personnel, discontinuation of a facility or business or failure or damage to a facility resulting from natural disasters, could result in the cancellation of shipments, loss of product in the manufacturing process or a shortfall in available product candidates or materials. In some cases, the technical skills or technology required to manufacture Korro Bio&#8217;s product candidates may be unique or proprietary to the original manufacturer and Korro Bio may have difficulty, or there may be contractual restrictions prohibiting Korro Bio from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase Korro Bio&#8217;s reliance on such manufacturer or require it to obtain a license from such manufacturer in order to have another third party manufacture Korro Bio&#8217;s product candidates. If Korro Bio is required to change manufacturers for any reason, Korro Bio will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect Korro Bio&#8217;s ability to develop product candidates in a timely manner or within budget.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio may also be required to enter into long-term manufacturing agreements that contain exclusivity provisions and/or substantial termination penalties which could have a material adverse effect on its business prior to or after commercialization of any of its product candidates. If Korro Bio is unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, Korro Bio may not be able to develop and commercialize its product candidates successfully. Failure to execute on Korro Bio&#8217;s manufacturing requirements, either by Korro Bio or by one of its third-party vendors, could adversely affect Korro Bio&#8217;s business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and other healthcare laws and regulations, which could expose it to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and prescription of any product candidates that Korro Bio may develop for which it obtains marketing approval. Korro Bio&#8217;s future arrangements with third-party payors and customers may expose it to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which Korro Bio markets, sells, and distributes its medicines for which it obtains marketing approval. Restrictions under applicable federal and state healthcare laws and regulations listed in the section above titled &#8220;<span style="font-style:italic">Risks Related to Regulatory, Legal, and Clinical Trials</span>&#8221;, including certain laws and regulations applicable only if Korro Bio has marketed products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some state laws also require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that Korro Bio&#8217;s business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that Korro Bio&#8217;s business practices may not comply with healthcare laws and regulations. If Korro Bio&#8217;s operations are found to be in violation of any of the laws described above or any other government regulations that apply to Korro Bio, it may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of Korro Bio&#8217;s operations, any of which could adversely affect its business, financial condition, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="rom451428_31a"><span style="font-weight:bold"><span style="font-style:italic">Risks Related to Korro Bio&#8217;s Personnel, Operations and Growth</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio is unable to attract and retain qualified key management and scientists, staff, consultants and advisors, its ability to implement its business plan may be adversely affected.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is highly dependent upon its senior management and its scientific, clinical and medical staff and advisors. The loss of the service of any of the members of Korro Bio&#8217;s senior management or other key employees could delay its research and development programs and materially harm its business, financial condition, results of operations and prospects. In addition, Korro Bio expect that it will continue to have an increased need to recruit and hire qualified personnel as it advances its programs and expands operations. Failure to successfully recruit and retain personnel could impact Korro Bio&#8217;s anticipated development plans and timelines. For example, as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic, Korro Bio has faced challenges in retaining and attracting employees to support its research and development efforts, and its failure to do so could have an adverse effect on its ability to execute on its business plan. Korro Bio is dependent on the continued service of its technical personnel because of the highly technical and novel nature of its product candidates, platform and technologies and the specialized nature of the regulatory approval process. Replacing such personnel may be difficult and may take an extended period of time because of the limited number of individuals in Korro Bio&#8217;s industry with the breadth of skills and experience required to successfully execute its business strategy, and Korro Bio cannot assure you that it will be able to identify or employ qualified personnel for any such position on acceptable terms, if at all. Many of the biotechnology and pharmaceutical companies with whom Korro Bio competes for qualified personnel have greater financial and other resources, different risk profiles and longer histories in the industry than Korro Bio does. Because Korro Bio&#8217;s management team and key employees are not obligated to provide Korro Bio with continued service, they could terminate their employment with Korro Bio at any time without penalty. Korro Bio does not maintain key person life insurance policies on any of its management team members or key employees. Korro Bio&#8217;s future success will depend in large part on its continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in preclinical and clinical testing, manufacturing, governmental regulation and commercialization. In order to do so, Korro Bio may need to pay higher compensation or fees to its employees or consultants than it currently expect, and such higher compensation payments may have a negative effect on its </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operating results. Korro Bio faces increased competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. If Korro Bio is unable to attract and retain qualified personnel, the rate and success at which Korro Bio may be able to discover and develop its product candidates and implement its business plan will be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio expects to expand its research, development, delivery, manufacturing, commercialization, regulatory and future sales and marketing capabilities over time, and as a result, Korro Bio may encounter difficulties in managing its growth, which could disrupt its operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&#160;18, 2023, Korro Bio had 85 full-time employees, including 30 who hold Ph.D. degrees, and 1 part-time employee; 63 employees are engaged in research and development and 23 employees in management or general and administrative activities. In connection with the growth and advancement of Korro Bio&#8217;s pipeline and becoming a public company, Korro Bio expects to increase the number of its employees and the scope of its operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To manage its anticipated future growth, Korro Bio must continue to implement and improve its managerial, operational and financial systems, expand its facilities, and continue to recruit and train additional qualified personnel. Due to Korro Bio&#8217;s limited financial resources and the limited experience of its management team in managing a company with such anticipated growth, Korro Bio may not be able to effectively manage the expected expansion of its operations or recruit and train additional qualified personnel. Moreover, Korro Bio&#8217;s current physical laboratory space may be insufficient for its near-term research and development hiring plans, and the expected physical expansion of Korro Bio&#8217;s operations may lead to significant costs and may divert its management and business development resources. Any inability to manage growth could delay the execution of Korro Bio&#8217;s business plans or disrupt its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a growing biotechnology company, Korro Bio is actively pursuing new platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to Korro Bio&#8217;s limited resources, it may not be able to effectively manage this simultaneous execution and the expansion of its operations or recruit and train additional qualified personnel. This may result in weaknesses in Korro Bio&#8217;s infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of Korro Bio&#8217;s operations may lead to significant costs and may divert financial resources from other projects, such as the development of Korro Bio&#8217;s potential product candidates. If Korro Bio&#8217;s management is unable to effectively manage the expected development and expansion, Korro Bio&#8217;s expenses may increase more than expected, its ability to generate or increase its revenue could be reduced and it may not be able to implement it business strategy. Korro Bio&#8217;s future financial performance and its ability to compete effectively and commercialize any product candidates it may develop will depend in part on its ability to effectively manage the future development and expansion of Korro Bio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_32a"><span style="font-style:italic">Risks Related to Intellectual Property </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio is not able to obtain or protect intellectual property rights related to any of its product candidates, development and commercialization of its product candidates may be adversely affected.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Korro Bio&#8217;s industry, the majority of an innovative product&#8217;s commercial value is usually realized during the period in which it has market exclusivity. Market exclusivity is comprised of both patent and other intellectual property protection, as well as regulatory exclusivity. In the United States and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there usually are very substantial and rapid declines in the product&#8217;s sales.<span style="font-weight:bold"><span style="font-style:italic"></span></span>&#160;Accordingly, Korro Bio&#8217;s success depends in part on its ability to obtain and maintain patents and other forms of intellectual property rights, including trademarks, trade secrets and, where necessary <span style="white-space:nowrap">in-licenses</span> of intellectual property rights of others, in the United States and in other countries for its product candidates and platform technologies, as well as for methods used to manufacture its </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates, and methods for treating patients for approved indications using its product candidates, as well as its ability to preserve Korro Bio&#8217;s trade secrets, to prevent third parties from infringing upon Korro Bio&#8217;s proprietary rights and to operate without infringing upon the proprietary rights of others. Certain research and development activities involved in pharmaceutical development are exempt from patent infringement in the United States and other jurisdictions, for example, in the United States by the provisions of 35 U.S.C. &#167;&#160;271(e)(1), or the Safe Harbor. However, in the United States and certain other jurisdictions, the Safe Harbor exemption can terminate when the sponsor submits an application for marketing approval (e.g., a New Drug Application, or NDA, in the United States). Therefore, the risk that a third party might allege patent infringement may increase as Korro Bio&#8217;s product candidates approach commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio cannot offer any assurances about which of its patent applications will issue, the breadth of any resulting patent or whether any of the issued patents will be found invalid and unenforceable or will be threatened by third parties. Korro Bio cannot offer any assurances that the breadth of its granted patents will be sufficient to stop a competitor from developing and commercializing a product. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to Korro Bio in the future after patent issuance could deprive Korro Bio of rights necessary for the successful commercialization of any of its product candidates. Further, if Korro Bio encounter delays in regulatory approvals, the period of time during which it could market a product candidate under patent protection could be reduced. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio may not be able to apply for patents or obtain patent protection on certain aspects of its product candidates or its RNA editing platform OPERA in a timely fashion or at all. The patent prosecution process is expensive and time-consuming. Korro Bio may not be able to prepare, file and prosecute all necessary or desirable patent applications at a commercially reasonable cost or in a timely manner or in all jurisdictions. It is also possible that Korro Bio may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Korro Bio may not be able to obtain or maintain patent applications and patents due to the subject matter claimed in such patent applications and patents being in the public domain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s existing issued and granted patents and any future patents it obtains may not be sufficiently broad to prevent others from using its technology or from developing competing products and technology. There is no guarantee that any of Korro Bio&#8217;s pending patent applications will result in issued or granted patents, that any of Korro Bio&#8217;s issued or granted patents will not later be found to be invalid or unenforceable, or that any issued or granted patents will include claims that are sufficiently broad to cover Korro Bio&#8217;s product candidates, platform technologies, or any methods relating to them, or to provide meaningful protection from competitors. Consequently, it is unknown whether its platform technology or product candidates will be protectable or remain protected by valid and enforceable patents. Any failure to obtain, maintain or defend its patents and other intellectual property could have a material adverse effect on Korro Bio&#8217;s business, financial conditions, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio cannot be certain that it is the first to invent the inventions covered by pending patent applications and, if they are not, it may be subject to entitlement disputes. Korro Bio may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which Korro Bio is not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which Korro Bio are aware, but which it does not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Since patent applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, Korro Bio cannot be certain that it was in the past or will be in the future the first to file any patent application related to its product candidates. For example, some patent applications in the United States may be maintained in secrecy until the patents are issued. Further, publications in the scientific literature often lag behind actual discoveries. Consequently, Korro Bio cannot be certain that others have not filed patent applications for technology covered by its owned and issued patents or pending applications, or that Korro Bio or, if applicable, a licensor were the first to invent or first to file an application for the technology. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies can be highly uncertain and involves complex legal and factual questions. As a result, the issuance, scope, validity, enforceability and commercial value of any patent rights are highly uncertain. Korro Bio will be able to protect its proprietary rights from unauthorized use by third parties only to the extent that its current and future proprietary technology and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate Korro Bio&#8217;s proprietary rights, it may materially and adversely impact Korro Bio&#8217;s position in the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of Korro Bio&#8217;s patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, maintenance or enforcement of Korro Bio&#8217;s patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair Korro Bio&#8217;s ability to prevent competition from third parties, which may have an adverse impact on its business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal issues related to the patentability of biopharmaceuticals, and methods of their manufacture and use, are complex and uncertain in some countries. In some countries, applicants are not able to protect methods of treating human beings or medical treatment processes. Intellectual property protection varies throughout the world and is subject to change over time. Certain jurisdictions have enacted various rules and laws precluding issuance of patents encompassing any methods a doctor may practice on a human being or any other animal to treat a disease or condition. Further, many countries have enacted laws and regulatory regimes that do not allow patent protection for methods of use of known compounds. Thus, in some countries and jurisdictions, it may not be possible to patent some of Korro Bio&#8217;s product candidates at all. In some countries and jurisdictions, only composition claims may be obtained, and only when those compositions are or contain compounds that are new and/or novel. Also, patents issued with composition claims (<span style="font-style:italic">i.e., </span>covering product candidates) cannot always be enforced to protect methods of using those compositions to treat or diagnose diseases or medical conditions. Legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Lack of intellectual property protection in such cases may have a materially adverse effect on Korro Bio&#8217;s business and financial condition.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates, their manufacture or their use might expire before or shortly after those candidates receive regulatory&#160;approval and are commercialized. As a result, Korro Bio&#8217;s patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Korro Bio&#8217;s. Korro Bio expects to seek extensions of patent terms where these are available upon regulatory approval in those countries where Korro Bio is prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of the patent. However, the applicable authorities, including the FDA in the United States, and any equivalent regulatory authority in other countries, may not agree with Korro Bio&#8217;s assessment of whether such extensions are available, and may refuse to grant extensions to Korro Bio&#8217;s patents, or may grant more limited extensions than it request. If this occurs, Korro Bio&#8217;s competitors may take advantage of Korro Bio&#8217;s investment in development and clinical trials by referencing its clinical and preclinical data and launch their product earlier than might otherwise be possible.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent prosecution process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, or loss of right to enforce patent claims, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not uniform, can vary substantially from country to country, and are not always applied </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
predictably, requiring country-specific patent expertise in each jurisdiction in which patent protection is sought. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, Korro Bio does not know the degree of future protection that it will have on its product candidates and RNA editing technology. While Korro Bio will endeavor to try to protect its product candidates and RNA editing technology with intellectual property rights such as patents, as appropriate, the process of filing and prosecuting patent applications, and obtaining, maintaining and defending patents is time-consuming, expensive, uncertain, and sometimes unpredictable.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s pending patent applications may not issue as patents, and even issued patents may not provide sufficient protection of its RNA editing platform OPERA and its product candidates and issued patents may not provide. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to claims directed toward the technology underlying Korro Bio&#8217;s OPERA platform, Korro Bio&#8217;s patents and patent applications contain claims directed to compositions of matter on the active pharmaceutical ingredients, or APIs, in Korro Bio&#8217;s product candidates, as well as <span style="white-space:nowrap"><span style="white-space:nowrap">methods-of-use</span></span> directed to the use of an API for a specified treatment. <span style="white-space:nowrap"><span style="white-space:nowrap">Composition-of-matter</span></span> patents on the active pharmaceutical ingredient in prescription drug products provide protection without regard to any particular method of use of the API used. <span style="white-space:nowrap"><span style="white-space:nowrap">Method-of-use</span></span> patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the patented method. Moreover, with respect to <span style="white-space:nowrap"><span style="white-space:nowrap">method-of-use</span></span> patents, even if competitors or other third parties do not actively promote their product for Korro Bio&#8217;s targeted indications or uses for which Korro Bio may obtain patents, providers may recommend that patients use these products <span style="white-space:nowrap">off-label,</span> or patients may do so themselves. Although <span style="white-space:nowrap">off-label</span> use may infringe or contribute to the infringement of <span style="white-space:nowrap"><span style="white-space:nowrap">method-of-use</span></span> patents, the practice is common and this type of infringement is difficult to prevent or prosecute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that Korro Bio owns or may in-license in the future may fail to result in issued patents with claims that cover its product candidates or uses thereof in the United States or in other foreign countries. For example, while Korro Bio&#8217;s patent applications are pending, it may be subject to a third party preissuance submission of prior art to the USPTO or become involved derivation proceedings, or equivalent proceedings in foreign jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if patents do successfully issue, third parties may challenge their inventorship, validity, enforceability or scope, including through opposition, revocation, reexamination, post-grant and <span style="font-style:italic">inter partes</span> review proceedings. An adverse determination in any such submission, proceeding or litigation may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit Korro Bio&#8217;s ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of Korro Bio&#8217;s technology and product candidates. Furthermore, even if they are unchallenged, Korro Bio&#8217;s patents and patent applications may not adequately protect its intellectual property or prevent others from designing around Korro Bio&#8217;s claims. Moreover, some of Korro Bio&#8217;s patents and patent applications may be <span style="white-space:nowrap">co-owned</span> with third parties. If Korro Bio is unable to obtain an exclusive license to any such third-party <span style="white-space:nowrap">co-owners&#8217;</span> interest in such patents or patent applications, such <span style="white-space:nowrap">co-owners</span> may be able to license their rights to other third parties, including Korro Bio&#8217;s competitors, and Korro Bio&#8217;s competitors could market competing products and technology. In addition, Korro Bio may need the cooperation of any such <span style="white-space:nowrap">co-owners</span> of its patents in order to enforce such patents against third parties, and such cooperation may not be provided to Korro Bio. If the breadth or strength of protection provided by the patent applications Korro Bio holds with respect to its product candidates is threatened, it could dissuade companies from collaborating with it to develop, and threaten Korro Bio&#8217;s ability to commercialize, its product candidates. Further, if Korro Bio encounters delays in development, testing, and regulatory review of new product candidates, the period of time during which Korro Bio could market its product candidates under patent protection would be reduced. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect its ability to develop and market its products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other parties have developed technologies that may be related or competitive to Korro Bio&#8217;s, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in Korro Bio&#8217;s own patent applications or issued patents, with respect to either the same methods or formulations or the same subject matter, in either case, that it may rely upon to dominate its patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, Korro Bio cannot know with certainty whether it was the first to make the inventions claimed in its owned or licensed patents or pending patent applications, or that it was the <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of Korro Bio&#8217;s patent rights cannot be predicted with any certainty. Korro Bio&#8217;s competitors may have filed, and may in the future file, patent applications covering its products or technology similar to its own. Any such patent application may have priority over Korro Bio&#8217;s patent applications or patents, which could require Korro Bio to obtain rights to issued patents covering such technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio cannot guarantee that any of its patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can it be certain that it has identified each and every third-party patent and pending application in the United&#160;States and abroad that is relevant to or necessary for the commercialization of its programs in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Korro Bio&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Korro Bio may incorrectly determine that its products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Korro Bio&#8217;s determination of the expiration date of any patent in the United States or abroad that it considers relevant may be incorrect. Korro Bio&#8217;s failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products. Moreover, it is also possible that prior art may exist that it is aware of but does not believe is relevant to its current or future patents, but that could nevertheless be determined to render its patents invalid. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may be involved in lawsuits to protect or enforce its patents, which could be expensive, time consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe the patents for which Korro Bio have applied. To counter infringement or unauthorized use, Korro Bio may be required to file infringement claims, which can be expensive and time-consuming. If Korro Bio initiate legal proceedings against a third party to enforce a patent covering one of its product candidates, the defendant could counterclaim that the patent covering Korro Bio&#8217;s product or product candidate is invalid and/or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability are common, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, lack of written disclosure, obviousness, or <span style="white-space:nowrap">non-enablement.</span> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal allegations of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, Korro Bio cannot be certain that there is no invalidating prior art, of which Korro Bio and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, Korro Bio would lose at least part, and perhaps all, of the patent protection on one or more of Korro Bio&#8217;s products or certain aspects of its platform technology. Further, a court or administrative body could construe certain patent claims narrowly or refuse to prevent the other party from using the technology at issue on the ground that Korro Bio&#8217;s patents do not cover the technology. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an infringement proceeding, a court may decide that the patent claims Korro Bio are asserting are invalid and/or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that its patent claims do not cover the technology in question. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <span style="white-space:nowrap">re-examination,</span> post grant review, inter partes review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in revocation of or amendment to Korro Bio&#8217;s patents in such a way that they no longer cover its product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, Korro Bio cannot be certain that there is no invalidating prior art, of which Korro Bio, its patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, Korro Bio would lose at least part, and perhaps all, of the patent protection on its product candidates. An adverse result in any litigation or defense proceedings could put one or more of Korro Bio&#8217;s patents at risk of being invalidated or interpreted narrowly, could put its patent applications at risk of not issuing and could have a material adverse impact on its business. Such a loss of patent protection could negatively impact Korro Bio&#8217;s business. Patents and other intellectual property rights also will not protect Korro Bio&#8217;s technology if competitors design around its protected technology without legally infringing Korro Bio&#8217;s patents or other intellectual property rights.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An unfavorable outcome could require Korro Bio to cease using the related technology or force Korro Bio to take a license under the patent rights of the prevailing party, if available. Furthermore, Korro Bio&#8217;s business could be harmed if the prevailing party does not offer a license on commercially reasonable terms. Korro Bio&#8217;s defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract its management and other employees. Korro Bio may not be able to prevent misappropriation of its intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Korro Bio establishes infringement of any of its patents by a competitive product, a court may decide not to grant an injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should instead pay Korro Bio a &#8220;reasonable royalty&#8221; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related product would have a material adverse impact on Korro Bio business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio <span style="white-space:nowrap">in-licenses</span> patent rights in the future, Korro Bio may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for Korro Bio. If Korro Bio is not able to directly assert its licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on Korro Bio behalf, Korro Bio may have difficulty competing in certain markets where such potential infringers conduct their business, and its commercialization efforts may suffer as a result. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Korro Bio or its future licensors, as the case may be, may not be able to detect infringement against its owned or <span style="white-space:nowrap">in-licensed</span> patents, which may be especially difficult for manufacturing processes or formulation patents. Even if Korro Bio or its future licensors detect infringement by a third party of owned or future <span style="white-space:nowrap">in-licensed</span> patents, Korro Bio or its licensors, as the case may be, may choose not to pursue litigation against or settlement with the third party. If Korro Bio or its licensors later sue such third party for patent infringement, the third party may have certain legal defenses available to it that otherwise would not be available but for the delay between when the infringement was first detected and when the suit was brought. These legal defenses may make it impossible for Korro Bio or its licensors to enforce owned or future <span style="white-space:nowrap">in-licensed</span> patents, as the case may be, against that third party. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Korro Bio&#8217;s confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of Korro Bio&#8217;s common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party claims of intellectual property infringement may prevent, delay or otherwise interfere with Korro Bio&#8217;s product discovery and development efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s commercial success depends in part on its ability to develop, manufacture, market and sell its product candidates and use its proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, <span style="font-style:italic">inter partes</span> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Korro Bio may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that Korro Bio&#8217;s product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which Korro Bio is developing its product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that Korro Bio&#8217;s product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including Korro Bio, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in Korro Bio&#8217;s field, third parties may allege they have patent rights encompassing Korro Bio&#8217;s product candidates, technologies or methods. Korro Bio is aware of competitors in the oligonucleotide space whose patent application filings and/or issued patents may include claims directed to technologies and/or products related to some of Korro Bio&#8217;s programs and product candidates. For example, Korro Bio is aware of patents and patent applications owned by third parties that have generic claims that may relate to its technologies and products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a third party claims that Korro Bio infringes, misappropriates or otherwise violates its intellectual property rights, Korro Bio may face a number of issues, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">infringement and other intellectual property claims that, regardless of merit, may be expensive and time-consuming to litigate and may divert Korro Bio&#8217;s management&#8217;s attention from Korro Bio&#8217;s core business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial damages for infringement, which Korro Bio may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, Korro Bio could be ordered to pay treble damages plus the patent owner&#8217;s attorneys&#8217; fees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a court prohibiting Korro Bio from developing, manufacturing, marketing or selling its product candidates, or from using Korro Bio&#8217;s proprietary technologies, unless the third party licenses its product rights to it, which it is not required to do, on commercially reasonable terms or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if a license is available from a third party, Korro Bio may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the requirement that Korro Bio redesign its product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Korro Bio&#8217;s common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of Korro Bio&#8217;s competitors may be able to sustain the costs of complex patent litigation more effectively than Korro Bio can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Korro Bio&#8217;s ability to raise the funds necessary to continue Korro Bio&#8217;s operations or could otherwise have a material adverse effect on its business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that Korro Bio is employing their proprietary technology without authorization, including by enforcing its patents against it by filing a patent infringement lawsuit against it. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which Korro Bio is currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of its product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that Korro Bio&#8217;s product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of Korro Bio&#8217;s technologies infringes upon these patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of Korro Bio&#8217;s product candidates, or materials used in or formed during the manufacturing process, or any final product itself, the holders of those patents may be able to block Korro Bio&#8217;s ability to commercialize its product candidate unless Korro Bio obtains a license under the applicable patents, or until those patents were to expire or those patents are finally determined to be invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of Korro Bio&#8217;s formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of that patent may be able to block Korro Bio&#8217;s ability to develop and commercialize the product candidate unless it obtain a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, a license may not be available on commercially reasonable terms, or at all, particularly if such patent is owned or controlled by one of Korro Bio&#8217;s primary competitors. If Korro Bio is unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, Korro Bio&#8217;s ability to commercialize its product candidates may be impaired or delayed, which could significantly harm its business. Even if Korro Bio obtains a license, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving Korro Bio&#8217;s competitors access to the same technologies licensed to it. In addition, if the breadth or strength of protection provided by Korro Bio&#8217;s patents and patent applications is threatened, it could dissuade companies from collaborating with Korro Bio to license, develop or commercialize current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against Korro Bio may seek and obtain injunctive or other equitable relief, which could effectively block Korro Bio&#8217;s ability to further develop and commercialize its product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee time and resources from Korro Bio&#8217;s business. In the event of a successful claim of infringement against Korro Bio, it may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign Korro Bio&#8217;s infringing products, which may be impossible or require substantial time and monetary expenditure. Korro Bio cannot predict whether any license of this nature would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, Korro Bio may need to obtain licenses from third parties to advance Korro Bio&#8217;s research or allow commercialization of Korro Bio&#8217;s product candidates and it may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, Korro Bio would be unable to further develop and commercialize Korro Bio&#8217;s product candidates, which could significantly harm Korro Bio&#8217;s business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Likewise, Korro Bio&#8217;s patents and patent applications, if issued as patents, directed to Korro Bio&#8217;s proprietary technologies and Korro Bio&#8217;s product candidates are expected to expire from 2040 through 2044, without taking into account any possible patent term adjustments or extensions. Korro Bio&#8217;s earliest <span style="white-space:nowrap">in-licensed</span> patents may expire before, or soon after, Korro Bio&#8217;s first product achieves marketing approval in the United States or foreign jurisdictions. Additionally, Korro Bio cannot be assured that the USPTO or relevant foreign patent offices will grant any of the pending patent applications it owns or <span style="white-space:nowrap">in-license</span> currently or in the future. Upon the expiration of Korro Bio&#8217;s current patents, it may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on Korro Bio&#8217;s business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio or its future licensors, collaborators or strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. Korro Bio may be generally obligated under its future potential license or collaboration agreements to indemnify and hold harmless its licensors or collaborators for damages arising from intellectual property infringement by Korro Bio. If Korro Bio or its future licensors, collaborators or strategic partners are found to infringe a third-party patent or other intellectual property rights, Korro Bio could be required to pay damages, potentially including treble damages, if Korro Bio is found to have willfully infringed. In addition, Korro Bio or its future licensors, collaborators or strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be <span style="white-space:nowrap">non-exclusive,</span> which could give Korro Bio&#8217;s competitors access to the same technology or intellectual property rights licensed to it. If Korro Bio fails to obtain a required license, Korro Bio or its future collaborators may be unable to effectively market product candidates based on its technology, which could limit Korro Bio&#8217;s ability to generate revenue or achieve profitability and possibly prevent Korro Bio from generating revenue sufficient to sustain its operations. In addition, Korro Bio may find it necessary to pursue claims or initiate lawsuits to protect or enforce its patent or other intellectual property rights. The cost to Korro Bio in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in its favor, could be substantial, and litigation would divert Korro Bio&#8217;s management&#8217;s attention. Some of Korro Bio&#8217;s competitors may be able to sustain the costs of complex patent litigation more effectively than Korro Bio can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay Korro Bio&#8217;s research and development efforts and limit its ability to continue its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Korro Bio may be required to protect its patents through procedures created to attack the validity of a&#160;patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, Korro Bio&#8217;s patent rights, which could adversely affect Korro Bio&#8217;s competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may not be successful in acquiring or <span style="white-space:nowrap">in-licensing</span> necessary rights to key technologies or any product candidates it may develop. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The future growth of Korro Bio&#8217;s business may depend in part on Korro Bio&#8217;s ability to <span style="white-space:nowrap">in-license</span> or otherwise acquire the rights to additional product candidates and technologies. There has been extensive patenting activity in the field of gene editing. Pharmaceutical companies, biotechnology companies and academic institutions are competing with Korro Bio or are expected to compete with it in the in the field of gene editing technology and filing patent applications potentially relevant to Korro Bio&#8217;s business. In order to market Korro Bio&#8217;s product candidates, it may find it necessary or prudent to obtain licenses from third-party intellectual property holders. However, Korro Bio may be unable to secure such licenses or otherwise acquire <span style="white-space:nowrap">or&#160;in-license&#160;any</span> compositions, methods of use, processes, or other intellectual property rights from third parties that it identifies as necessary to develop or commercialize its product candidates or other key technologies. Korro </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bio may also require licenses from third parties for certain additional technologies, including technologies relating to RNA editing, such as guide RNA modification, or target sequences as well as delivery technologies for product candidates it may develop. Korro Bio may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent it from commercializing Korro Bio&#8217;s product candidates or allow Korro Bio&#8217;s competitors or other third parties the chance to access technology that is important to Korro Bio&#8217;s business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Korro Bio may collaborate with academic institutions to accelerate its research or development under written agreements with these institutions. In certain cases, these institutions may provide it with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if Korro Bio holds such an option, it may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to it. If Korro Bio is unable to do so, such institution may offer the intellectual property rights to others, potentially blocking its ability to pursue its program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that it may consider attractive or necessary. These established companies may have a competitive advantage over Korro Bio due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Korro Bio to be a competitor may be unwilling to assign or license rights to Korro Bio. Korro Bio also may be unable to license or acquire third-party intellectual property rights on terms that would allow it to make an appropriate return on its investment or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that Korro Bio may be unable to obtain required licenses at a reasonable cost or on reasonable terms, if at all. Even if Korro Bio is able to obtain a license, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving Korro Bio&#8217;s competitors access to the same technologies licensed to it. In that event, Korro Bio may be required to expend significant time and resources to redesign its technology, programs, or the methods for manufacturing them or to develop or license&#160;replacement technology, all of which may not be feasible on a technical or commercial basis. If Korro Bio is unable to do so, it may be unable to develop or commercialize the affected programs, which could harm its business, financial condition, results of operations, and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise between Korro Bio and its future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which Korro Bio&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; its right to sublicense patents and other&#160;rights to third parties; its right to transfer or assign the license; the inventorship and ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by its future licensors and it and its partners; and the priority of invention of patented technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio is unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights it has, Korro Bio may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on Korro Bio&#8217;s business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio may become subject to claims challenging the inventorship or ownership of its patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio may be subject to claims that former employees, collaborators or other third parties have an interest in its patents or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
matter of the patent, conflicting obligations of third parties involved in developing Korro Bio&#8217;s programs or as a result of questions regarding <span style="white-space:nowrap">co-ownership</span> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, Korro Bio may enter into agreements to clarify the scope of its rights in such intellectual property. If Korro Bio fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Korro Bio&#8217;s business. Even if Korro Bio is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that its licensors are not the sole and exclusive owners of the patents it <span style="white-space:nowrap">in-licensed.</span> If other third parties have ownership rights or other rights to Korro Bio&#8217;s <span style="white-space:nowrap">in-licensed</span> patents, they may be able to license such patents to its competitors, and its competitors could market competing products and technology. This could have a material adverse effect on Korro Bio&#8217;s competitive position, business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third parties may assert that Korro Bio&#8217;s employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, Korro Bio employs individuals that are currently or were previously employed at universities, research institutions or other biotechnology or pharmaceutical companies, including its competitors or potential competitors. Although Korro Bio tries to ensure that its employees, consultants, and advisors do not use the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for it, Korro Bio may be subject to claims that it or these individuals have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Also, Korro Bio has in the past and may in the future be subject to claims that these individuals are violating <span style="white-space:nowrap">non-compete</span> agreements with their former employers. Korro Bio may then have to pursue litigation to defend against these claims. If Korro Bio fails in defending any such claims, in addition to paying monetary damages, Korro Bio may lose valuable intellectual property rights or personnel. Even if Korro Bio is successful in defending against such claims, litigation could result in substantial costs and be a distraction to its technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of its common stock. This type of litigation or proceeding could substantially increase Korro Bio&#8217;s operating losses and reduce its resources available for development activities, and Korro Bio may not have sufficient financial or other resources to adequately conduct this type of litigation or proceedings. For example, some of Korro Bio&#8217;s competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than Korro Bio can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect Korro Bio&#8217;s ability to compete in the marketplace. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining Korro Bio&#8217;s patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and Korro Bio&#8217;s patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications are due to be paid to the USPTO and foreign patent agencies outside of the United States over the lifetime of Korro Bio&#8217;s owned or licensed patents and applications. The USPTO and foreign patent agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. Korro Bio is also dependent on its licensors to take the necessary action to comply with these requirements with respect to its licensed intellectual property. While an inadvertent lapse can be cured </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by payment of a late fee or by other means in accordance with the applicable rules, there are situations, however, in which <span style="white-space:nowrap">non-compliance</span> can result a partial or complete loss of patent rights in the relevant jurisdiction. Were a noncompliance event to occur, Korro Bio&#8217;s competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on Korro Bio&#8217;s business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio has limited foreign intellectual property rights and may not be able to protect its intellectual property and proprietary rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has limited intellectual property rights outside the United States. Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and Korro Bio&#8217;s intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of foreign countries do not protect intellectual property rights to the same extent as federal and state laws of the United States. In addition, Korro Bio&#8217;s intellectual property license agreements may not always include worldwide rights. Consequently, Korro Bio may not be able to prevent third parties from practicing Korro Bio&#8217;s inventions in all countries outside the United States, or from selling or importing products made using Korro Bio&#8217;s inventions in and into the United States or other jurisdictions. Competitors may use Korro Bio&#8217;s technologies in jurisdictions where it has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where Korro Bio has patent protection but where enforcement is not as strong as that in the United States. These products may compete with Korro Bio&#8217;s product candidates and its patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for Korro Bio to stop the infringement of its patents or marketing of competing products against third parties in violation of its intellectual property and proprietary rights generally. Proceedings to enforce Korro Bio&#8217;s patents and intellectual property rights in foreign jurisdictions could result in substantial costs and divert its efforts and attention from other aspects of Korro Bio&#8217;s business, could put Korro Bio&#8217;s patents at risk of being invalidated or interpreted narrowly and its patent applications at risk of not issuing, and could provoke third parties to assert claims against Korro Bio. Korro Bio may not prevail in any lawsuits that it initiates, and the damages or other remedies awarded, if any, may not be commercially meaningful. Moreover, the initiation of proceedings by third parties to challenge the scope or validity of Korro Bio&#8217;s patent rights in foreign jurisdictions could result in substantial cost and divert Korro Bio&#8217;s efforts and attention from other aspects of its business. Accordingly, Korro Bio&#8217;s efforts to enforce its intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that Korro Bio develops or licenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If Korro Bio or any of its licensors is forced to grant a license to third parties with respect to any patents relevant to Korro Bio&#8217;s business, its competitive position may be impaired, and its business, financial condition, results of operations, and prospects may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, filing, prosecuting and defending patents on programs worldwide would be prohibitively expensive and Korro Bio&#8217;s intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States. As such, Korro Bio may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if Korro Bio applies for them. Korro Bio&#8217;s competitors may operate in countries where Korro Bio does not have patent protection and can freely use its technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where Korro Bio does have patent protection or pending patent applications. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in patent law in the United States and in <span style="white-space:nowrap">non-U.S.</span> jurisdictions could diminish the value of patents in general, thereby impairing Korro Bio&#8217;s ability to protect its RNA editing platform technology and product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotech and pharmaceutical companies, Korro Bio&#8217;s success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of Korro Bio&#8217;s issued patents and pending patent applications. For example, in March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, the United States transitioned from a &#8220;first to invent&#8221; to a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> patent system. Under a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system, assuming that other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on an invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after March 2013, but before Korro Bio could therefore be awarded a patent covering an invention of Korro Bio&#8217;s even if it had made the invention before it was made by such third party. This will require Korro Bio to be cognizant going forward of the time from invention to filing of a patent application. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, Korro Bio cannot be certain that Korro Bio or its licensors were the first to either file any patent application related to its technology or product candidates or invent any of the inventions claimed in Korro Bio&#8217;s or its licensor&#8217;s patents or patent applications. The America Invents Act also includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, allowing third party submission of prior art and establishing a post-grant review system including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate Korro Bio&#8217;s patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, recent U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to Korro Bio&#8217;s ability to obtain patents in the future, these rulings have created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken Korro Bio&#8217;s ability to obtain new patents or to enforce its existing patents and patents that Korro Bio might obtain in the future. Korro Bio cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of Korro Bio&#8217;s patents. Any adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on Korro Bio&#8217;s business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on Korro Bio&#8217;s business. In addition, a decree was </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adopted by the Russian government in March&#160;2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, Korro Bio would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, Korro Bio&#8217;s competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, recently the European Unified Patent Court, or UPC, was created as a common patent court to hear patent infringement and revocation proceedings effective for member states of the EU. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. Although Korro Bio does not currently own any European patents or applications, if Korro Bio obtains such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on its business and its ability to commercialize or license its technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect Korro Bio&#8217;s ability to enforce or defend the validity of any European patents it may obtain. Korro Bio may decide to opt out from the UPC any future European patent applications that Korro Bio may file and any patents Korro Bio may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for <span style="white-space:nowrap">non-compliance</span> and brought under the jurisdiction of the UPC. Korro Bio cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if Korro Bio decides to opt out of the UPC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for Korro Bio&#8217;s technology and product candidates, Korro Bio also relies on <span style="white-space:nowrap">know-how</span> and trade secret protection, as well as confidentiality agreements, <span style="white-space:nowrap">non-disclosure</span> agreements and invention assignment agreements with its employees, consultants and third-parties, to protect its confidential and proprietary information, especially where it does not believe patent protection is appropriate or obtainable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is Korro Bio&#8217;s policy to require its employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties to execute confidentiality agreements upon the commencement of employment or consulting relationships with Korro Bio. These agreements provide that all confidential information concerning Korro Bio&#8217;s business or financial affairs developed by or made known to the individual or entity during the course of the party&#8217;s relationship with Korro Bio is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related to Korro Bio&#8217;s current or planned business or research and development or made during normal working hours, on Korro Bio&#8217;s premises or using its equipment or proprietary information, are Korro Bio&#8217;s exclusive property. In the case of consultants and other third parties, the agreements provide that all inventions conceived in connection with the services provided are Korro Bio&#8217;s exclusive property. However, Korro Bio cannot guarantee that it has entered into such agreements with each party that may have or have had access to its trade secrets or proprietary technology and processes. Additionally, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and Korro Bio may be forced to bring claims against third parties, or defend claims that they may bring against Korro Bio, to determine the ownership of what Korro Bio regards as its intellectual property. Any of these parties may breach the agreements and disclose Korro Bio&#8217;s proprietary information, including its trade secrets, and Korro Bio may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to contractual measures, Korro Bio tries to protect the confidential nature of its proprietary information through other appropriate precautions, such as physical and technological security measures. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
However, trade secrets and <span style="white-space:nowrap">know-how</span> can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for Korro Bio&#8217;s proprietary information. Korro Bio&#8217;s security measures may not prevent an employee or consultant from misappropriating its trade secrets and providing them to a competitor, and any recourse Korro Bio might take against this type of misconduct may not provide an adequate remedy to protect its interests fully. In addition, trade secrets may be independently developed by others in a manner that could prevent Korro Bio from receiving legal recourse. If any of Korro Bio&#8217;s confidential or proprietary information, such as its trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, Korro Bio&#8217;s competitive position could be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, some courts inside and outside the United States are sometimes less willing or unwilling to protect trade secrets. If Korro Bio chooses to go to court to stop a third party from using any of its trade secrets, Korro Bio may incur substantial costs. Even if Korro Bio is successful, these types of lawsuits may consume its time and other resources. Any of the foregoing could have a material adverse effect on Korro Bio&#8217;s business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect Korro Bio&#8217;s competitive position on its product candidates for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. The terms of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest <span style="white-space:nowrap">non-provisional</span> filing date in the applicable country. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions including PTE and PTA, may be available, but the life of a patent, and the protection it affords, is limited. For more information regarding PTA and PTE, please see &#8220;<span style="font-style:italic">Korro Bio&#8217;s Business&#8212;Intellectual Property</span>&#8221;. Even if patents covering Korro Bio&#8217;s product candidates are obtained, once the patent life has expired, Korro Bio may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting Korro Bio&#8217;s product candidates might expire before or shortly after Korro Bio or its partners commercialize those candidates. As a result, Korro Bio&#8217;s owned and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Korro Bio&#8217;s. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio does not obtain PTE and data exclusivity for any product candidates it may develop, its business may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates Korro Bio may develop, one or more of its U.S. patents may be eligible for limited PTE under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments PTE term of up to five years as compensation for patent term lost during the FDA regulatory review process. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, even if Korro Bio were to seek a PTE, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than Korro Bio requests. If Korro Bio is unable to obtain PTE or term of any such extension is less than it requests, Korro Bio&#8217;s competitors may obtain approval of competing products following its patent expiration, and Korro Bio&#8217;s business, financial condition, results of operations, and prospects could be materially harmed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights do not necessarily address all potential threats. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by Korro Bio&#8217;s intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect Korro Bio&#8217;s business or permit it to maintain its competitive advantage. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product candidates it may develop will eventually become commercially available in generic or biosimilar product forms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make gene therapy products that are similar to any product candidates Koro may develop or utilize similar base editing technology but that are not covered by the claims of the patents that Korro Bio may own in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio, or its future license partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that Korro Bio licenses or may own in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio, or its future license partners or collaborators, might not have been the first to file patent applications covering certain of Korro Bio&#8217;s or their inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio, or its future license partners or collaborators, may fail to meet Korro Bio&#8217;s obligations to the U.S. government regarding any <span style="white-space:nowrap">in-licensed</span> patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may independently develop similar or alternative technologies or duplicate any of Korro Bio&#8217;s technologies without infringing its owned or licensed intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that Korro Bio&#8217;s pending patent applications or those that it may own in the future will not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that there are prior public disclosures that could invalidate Korro Bio&#8217;s patents, or parts of Korro Bio&#8217;s owned or <span style="white-space:nowrap">in-licensed</span> patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering Korro Bio&#8217;s product candidates or technology similar to Korro Bio&#8217;s; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that Korro Bio&#8217;s patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents that Korro Bio holds rights to may be held invalid, unenforceable, or narrowed in scope, including as a result of legal challenges by its competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the claims of Korro Bio&#8217;s issued patents or patent applications, if and when issued, may not cover its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the laws of foreign countries may not protect Korro Bio&#8217;s proprietary rights or the proprietary rights of its future license partners or collaborators to the same extent as the laws of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inventors of Korro Bio&#8217;s patents or patent applications may become involved with competitors, develop products or processes that design around its patents, or become hostile to Korro Bio or the patents or patent applications on which they are named as inventors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio&#8217;s competitors might conduct research and development activities in countries where it does not have patent rights and then use the information learned from such activities to develop competitive products for sale in Korro Bio&#8217;s major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio has engaged in scientific collaborations in the past and will continue to do so in the future and its collaborators may develop adjacent or competing products that are outside the scope of Korro Bio&#8217;s patents; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio may not develop additional proprietary technologies that are patentable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product candidates Korro Bio develops may be covered by third parties&#8217; patents or other exclusive rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a third party may challenge, invalidate, circumvent or weaken Korro Bio&#8217;s patents, and as a result, a court could hold that Korro Bio&#8217;s patents are not valid, enforceable and infringed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio&#8217;s competitors may conduct research and development activities in countries where Korro Bio does not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in Korro Bio&#8217;s major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents of others may harm Korro Bio&#8217;s business; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio may choose not to file a patent in order to maintain certain trade secrets or <span style="white-space:nowrap">know-how,</span> and a third party may subsequently file a patent covering such intellectual property. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on Korro Bio&#8217;s business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s use of open source software could impose limitations on Korro Bio&#8217;s ability to commercialize its product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s use of open source software could impose limitations on Korro Bio&#8217;s ability to commercialize its product candidates. Korro Bio&#8217;s technology utilizes open source software that contains modules licensed for use from third-party authors under open source licenses. In particular, some of the software that powers OPERA may be provided under license arrangements that allow use of the software for research or other <span style="white-space:nowrap">non-commercial</span> purposes. As a result, in the future, as Korro Bio seeks to use its platform in connection with commercially available products, Korro Bio may be required to license that software under different license terms, which may not be possible on commercially reasonable terms, if at all. If Korro Bio is unable to license software components on terms that permit its use for commercial purposes, Korro Bio may be required to replace those software components, which could result in delays, additional cost and additional regulatory approvals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the software code. Some open source licenses contain requirements that Korro Bio make available source code for modifications or derivative works it creates based upon the type of open source software Korro Bio uses. If Korro Bio combines its proprietary software with open source software in a certain manner, it could, under certain of the open source licenses, be required to release the source code of its proprietary software to the public. This could allow Korro Bio&#8217;s competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product sales for it. Although Korro Bio monitors its use of open source software, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on Korro Bio&#8217;s ability to commercialize its product candidates. Korro Bio could be required to seek licenses from third parties in order to continue offering its product candidates, to <span style="white-space:nowrap">re-engineer</span> its product candidates or to discontinue the sale of its product candidates in the event <span style="white-space:nowrap">re-engineering</span> cannot be accomplished on a timely basis, any of which could materially and adversely affect its business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korro Bio&#8217;s trademarks and trade names are not adequately protected, then it may not be able to build name recognition in its markets of interest and Korro Bio&#8217;s business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. Korro Bio may not be able to protect its rights to these trademarks and trade names, which it needs to build name recognition among potential </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partners or customers in its markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to Korro Bio&#8217;s, thereby impeding its ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of Korro Bio&#8217;s registered or unregistered trademarks or trade names. Over the long term, if Korro Bio is unable to establish name recognition based on its trademarks and trade names, then Korro Bio may not be able to compete effectively and its business may be adversely affected. Korro Bio&#8217;s efforts to enforce or protect its proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect its business, financial condition, results of operations and growth prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s business could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disease outbreaks, epidemics and pandemics in regions where Korro Bio may have clinical trial sites or other business operations could adversely affect its business, including by causing significant disruptions in its operations and/or in the operations of CROs upon whom it may rely. Disease outbreaks, epidemics and pandemics have negative impacts on its ability to initiate new clinical trial sites, to enroll new patients and to maintain existing patients who are participating in its clinical trials, which may include increased clinical trial costs, longer timelines and delay in Korro Bio&#8217;s ability to obtain regulatory approvals of product candidates, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General supply chain issues may be exacerbated during disease outbreaks, epidemics and pandemics and may also impact the ability of Korro Bio&#8217;s clinical trial sites to obtain basic medical supplies used in its trials in a timely fashion, if at all. If any of Korro Bio&#8217;s raw materials or components suppliers become subject to acts or orders of U.S. or foreign government entities to allocate or prioritize raw materials or components to the manufacture or distribution of vaccines or medical supplies needed to test or treat patients in a disease outbreak, epidemic or pandemic, this could delay Korro Bio&#8217;s clinical trials, perhaps substantially, which could materially and adversely affect its business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General Risk Factors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond its control, which could harm its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s facilities are located in Massachusetts. Korro Bio has not undertaken a systematic analysis of the potential consequences to its business and financial results from a major flood, power loss, terrorist activity, pandemics or other disasters and do not have a recovery plan for such events. In addition, Korro Bio does not carry sufficient insurance to compensate it for actual losses from interruption of its business that may occur, and any losses or damages incurred by it could harm its business. The occurrence of any of these business disruptions could seriously harm Korro Bio&#8217;s operations and financial condition and increase its costs and expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Litigation costs and the outcome of litigation could have a material adverse effect on Korro Bio&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time Korro Bio may be subject to litigation claims through the ordinary course of its business operations regarding, but not limited to, employment matters, security of employee personal information, contractual relations with third parties and intellectual property rights. Litigation to defend itself against claims by third parties, or to enforce any rights that Korro Bio may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of its resources, causing a material adverse effect on its business, financial condition, results of operations or cash flows. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_36">THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This section&#160;and the section&#160;titled &#8220;The Merger Agreement&#8221; beginning on page 190 of this proxy statement/prospectus describe the material aspects of the Merger and the Merger Agreement. While Frequency and Korro Bio believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_37">Background of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to enhance stockholder value, Frequency&#8217;s Board of Directors, or the Frequency Board, and senior management regularly review and discuss Frequency&#8217;s near and long-term operating and strategic priorities. Among other things, these reviews and discussions focus on the opportunities and risks associated with Frequency&#8217;s development programs and financial condition and its strategic relationships and potential long-term strategic options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Frequency had focused its business on using its Progenitor Cell Activation, or PCA, platform to identify and develop product candidates. Frequency&#8217;s former lead product candidate, <span style="white-space:nowrap">FX-322,</span> was designed to treat sensorineural hearing loss. After promising early clinical trial results, Frequency advanced <span style="white-space:nowrap">FX-322</span> into Phase 2 development. On March&#160;23, 2021, Frequency announced that its Phase 2a clinical trial <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-202),</span></span> or the Phase 2a Trial, did not meet its primary endpoint and did not show improvements in hearing versus placebo. Based on the information Frequency gained from the Phase 2a Trial, Frequency revised its clinical development approach for its Phase 2b clinical trial <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-208),</span></span> or the Phase 2b Trial. For the Phase 2b Trial, Frequency changed to a single dose from multiple doses used in the Phase 2a Trial, implemented structures during testing to reduce the potential for bias among test subjects, and met with the Federal Food and Drug Administration to agree on using speech perception as the primary efficacy endpoint. Nonetheless, on February&#160;13, 2023, Frequency announced that the Phase 2b Trial failed to achieve its primary efficacy endpoint. The Phase 2b Trial was the sixth and most advanced clinical trial Frequency conducted on <span style="white-space:nowrap">FX-322</span> for the treatment of hearing loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Phase 2b Trial results, the Frequency Board and senior management met several times to review Frequency&#8217;s development of <span style="white-space:nowrap">FX-322</span> and Frequency&#8217;s strategic opportunities. The Frequency Board considered, among other things, the negative data from the Phase 2a Trial and Phase 2b Trial, the significant decline in Frequency&#8217;s stock price following announcement of these data, and the dependence of Frequency&#8217;s business on <span style="white-space:nowrap">FX-322,</span> its only product candidate in clinical development. Accordingly, the Frequency Board and senior management determined to discontinue development of <span style="white-space:nowrap">FX-322</span> and focus development efforts on Frequency&#8217;s discovery-stage program to use its PCA platform to identify and develop a product candidate for the treatment of multiple sclerosis, or the MS Program, and on obtaining sufficient financing in order to advance the MS Program to the clinical development stage, while also exploring other strategic opportunities including equity financing, a potential sale of the MS Program and a potential strategic transaction involving all of Frequency. To align its resources with its new development focus on the MS Program, on February&#160;13, 2023, Frequency announced a reduction of approximately 55% of its workforce. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From February&#160;13, 2023 into May 2023, Frequency&#8217;s senior management and scientific and finance teams held meetings with eight companies, excluding Korro Bio, regarding potential collaborations on the MS Program and other strategic opportunities. Of these companies, four companies conducted due diligence on the MS Program and Frequency&#8217;s business. Party A, initially conducted further due diligence as a potential acquiror of Frequency, and three other parties, Party C, Party D and Party P, conducted due diligence with regard to a potential acquisition of the MS Program. The discussions with respect to the potential acquisition of the MS Program continue as of the date of this proxy statement/prospectus with Party C and Party D. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also from February&#160;13, 2023 through April 2023, Frequency&#8217;s senior management and scientific and finance teams contacted 22 potential investors and held meetings with 14 of these potential investors to discuss a private placement, or the PIPE Financing. Of these 14 potential investors, five decided not to proceed after the initial meeting with senior management. Nine potential investors conducted preliminary due diligence and of these potential investors, Party B indicated an interest in acting as lead investor for the PIPE Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, Christopher Loose, Ph.D., Frequency&#8217;s Chief Scientific Officer, held an introductory call with Party A to discuss a potential collaboration involving the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2023, Dr.&#160;Loose met with Party A to continue discussions regarding a potential collaboration on the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;21, 2023, the Frequency Board held a meeting, attended by members of Frequency&#8217;s management, representatives from Latham&#160;&amp; Watkins LLP, or Latham, legal advisor to Frequency and, at Frequency management&#8217;s invitation, Cowen and Company, LLC, or TD Cowen. To assist the Frequency Board in assessing opportunities for its MS Program, the meeting also was joined by Frequency Clinical Advisory Board member Dr.&#160;Richard Rudick to discuss the clinical history and path in the remyelination space and consultant, Greg Lief, to discuss the commercial opportunity of the remyelination space. At this meeting, TD Cowen was requested to review with the Frequency Board certain potential strategic alternatives that TD Cowen had discussed with Frequency&#8217;s management, including a sale of all or a portion of Frequency. Based on such discussion, the Frequency Board instructed Frequency&#8217;s management to proceed with engaging a financial advisor in connection with a potential sale process and, given TD Cowen&#8217;s extensive industry experience and reputation, Frequency subsequently engaged TD Cowen for such purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2023, Dr.&#160;Loose met with Party A to discuss the process for exchanging information as part of a potential collaboration on the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;23, 2023, Dr.&#160;Loose attended an introductory call with Vineet Agarwal, Korro Bio&#8217;s Chief Financial Officer, to discuss a potential strategic transaction involving Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;3, 2023, David Lucchino, Frequency&#8217;s Chief Executive Officer, Dr.&#160;Loose, Sanjay Magavi, Frequency&#8217;s Vice President of Discovery Biology, Quentin McCubbin, Ph.D., at the time Frequency&#8217;s Chief Manufacturing Officer, and Dana Hilt, at the time Frequency&#8217;s acting Chief Medical Officer, presented to senior management of Party A on Frequency&#8217;s PCA platform and MS Program. Party A&#8217;s senior management also presented on Party A&#8217;s development programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;9, 2023, the Frequency Board held a meeting, which representatives from Latham and TD Cowen attended. TD Cowen led a discussion with the Frequency Board concerning potential targets for strategic partnerships and investment for Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;13, 2023, at the direction of the Frequency Board, Frequency commenced a process, with the assistance of TD Cowen, to solicit third-party indications of interest in a potential transaction involving all or a part of Frequency. Over the course of March, April and May 2023, consistent with the Frequency Board&#8217;s directives, Frequency&#8217;s management and TD Cowen contacted or were contacted by 34 potential counterparties. Of these parties, 18 parties expressed interest in continuing to evaluate a potential acquisition of all or a portion of Frequency and received Frequency&#8217;s process letter requesting <span style="white-space:nowrap">non-binding</span> indications of interest by March&#160;29, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on March&#160;13, 2023, Drs. Loose, Magavi, McCubbin and Hilt discussed the MS Program&#8217;s clinical development plan with Party C. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;14, 2023, Frequency received a <span style="white-space:nowrap">non-binding</span> indication of interest from Korro Bio, which proposed a reverse triangular merger with Frequency pursuant to which Korro Bio&#8217;s current stockholders would </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
own 84% of the outstanding common stock of the combined company before any proposed concurrent financing. Korro Bio&#8217;s proposal valued Frequency at $60&#160;million (consisting of $45&#160;million projected target net cash at closing and a $15&#160;million enterprise value) and valued Korro Bio at $322&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;15, 2023, Drs. Loose, Magavi and McCubbin, Richard Mitrano, Frequency&#8217;s Vice President of Finance, and members of Frequency&#8217;s finance department met with members of Party A&#8217;s finance department and reviewed Frequency&#8217;s program costs and financial position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2023, Drs. Loose, Magavi and McCubbin met with Party B and reviewed Frequency&#8217;s PCA platform. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between March 20, 2023 and May 10, 2023, Frequency executed mutual confidentiality agreements with each of Party D, Party K, Party M, Party N, Party R and Party V. Each of the foregoing mutual confidentiality agreements contained a (i) customary &#8220;standstill&#8221; provision to facilitate the Frequency Board&#8217;s oversight of the confidential discussions, subject to a &#8220;sunset&#8221; provision allowing the counterparty to submit competing acquisition proposals after the date on which Frequency enters into a change in control transaction, such as the Merger, with any other counterparty and (ii) &#8220;don&#8217;t ask, don&#8217;t waive&#8221; provision preventing each party from making any requests to amend or waive the standstill, but the provision permitted each party to make such request to amend or waive the standstill if the request would not be reasonably be likely to cause public disclosure of such request. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 20, 2023, Frequency and Korro Bio executed a mutual confidentiality agreement, which contained a customary &#8220;standstill&#8221; provision to facilitate the Frequency Board&#8217;s oversight of the confidential discussions, subject to a &#8220;sunset&#8221; provision allowing Korro Bio to submit competing acquisition proposals after the date on which Frequency enters into a change in control transaction, such as the Merger, with any other counterparty. The mutual confidentiality agreement between Frequency and Korro Bio did not contain a &#8220;don&#8217;t ask, don&#8217;t waive&#8221; provision preventing Korro Bio from making any requests to amend or waive the standstill. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;20, 2023, Drs. Loose, Magavi, McCubbin and Hilt met with Party B and reviewed Frequency&#8217;s clinical development plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2023, Dr.&#160;Magavi reviewed the MS Program with Party C. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;22, 2023, Messrs. Lucchino and Mitrano and Drs. Loose and Magavi met with Mr.&#160;Agarwal, Ram Aiyar, Ph.D., Korro Bio&#8217;s Chief Executive Officer, Steve Colletti, Ph.D., Korro Bio&#8217;s Chief Scientific Officer, and other members of Korro Bio&#8217;s finance team. Frequency&#8217;s management reviewed Frequency&#8217;s development program, and Korro Bio&#8217;s management reviewed Korro Bio&#8217;s development program. Later that day, the Frequency Board held a meeting, which representatives from Latham and TD Cowen attended. The Frequency Board received an update on recent discussions with Korro Bio and other potential counterparties, and discussed the qualitative aspects of strategic alternatives, including the PIPE Financing, the sale of the MS Program and a potential reverse merger. After discussion, the Frequency Board directed management to continue pursuing strategic alternatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;23, 2023, Dr.&#160;Magavi met with Party E to discuss the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;24, 2023, Party A indicated that it had decided not to proceed with the collaboration opportunity, citing the MS Program&#8217;s modality, clinical development timeline and capital requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;29, 2023, Frequency received <span style="white-space:nowrap">non-binding</span> indications of interest from three private biotech companies, Party K, Party L and Party M, each proposing a reverse merger involving Frequency, a <span style="white-space:nowrap">non-binding</span> indication of interest from Party C that proposed an acquisition of the MS Program&#8217;s assets and a <span style="white-space:nowrap">non-binding</span> indication of interest from a public biotech company, Party N, that proposed a merger of equals transaction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2023, a meeting of the Frequency Board was held, which meeting was attended by Frequency&#8217;s management and representatives of TD Cowen and Latham. Frequency&#8217;s management and TD Cowen provided an update to the Frequency Board on the strategic alternatives review process, including the outreach to potential counterparties, the need to align on an approach with respect to the MS Program, such as whether to sell the MS Program&#8217;s assets, arrange a private investment in such program or continue to conduct the MS Program without involvement of a third party, and the possibility of evaluating a potential reverse merger or other similar transaction. After discussion, the Frequency Board directed Frequency&#8217;s management, with the assistance of Frequency&#8217;s advisors, to proceed with negotiations and due diligence with Korro Bio, Party K and Party L. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;4, 2023, Messrs. Lucchino and Mitrano, members of Frequency&#8217;s finance team and Drs. Magavi and McCubbin met with Drs. Aiyar and Colletti, Mr.&#160;Agarwal and members of Korro Bio&#8217;s finance and business development team to conduct due diligence on Korro Bio&#8217;s development programs and business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;4, 2023, at the direction of the Frequency Board, TD Cowen spoke with Party C to express the Frequency Board&#8217;s concern over the significant discount implied by Party C&#8217;s valuation of the MS Program&#8217;s assets relative to Frequency&#8217;s view as to the valuation of such assets. Party C stated that it might be able to improve its valuation and requested more information on Frequency&#8217;s intellectual property and preclinical data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;4, 2023, at the direction of the Frequency Board, TD Cowen contacted three additional biotechnology companies to gauge their respective interest in a potential reverse merger with Frequency. Each of these parties declined to evaluate a potential reverse merger citing Frequency&#8217;s limited cash position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;4, 2023, at the direction of the Frequency Board, TD Cowen spoke with Party D, which inquired whether a license for <span style="white-space:nowrap">FREQ-162</span> in exchange for an equity stake in Party D would be of interest to Frequency. Consistent with discussions held with the Frequency Board, TD Cowen stated that an exclusive license for primarily upfront cash consideration would be preferable to Frequency given that an equity investment would be challenging from a structural perspective and that an acquisition of Frequency for cash consideration would also be considered. Party D stated that it could begin due diligence and prepare a term sheet in parallel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;4, 2023, at the direction of the Frequency Board, TD Cowen spoke with Mr.&#160;Agarwal to communicate the Frequency Board&#8217;s view that the Korro Bio valuation should be lower. Mr.&#160;Agarwal stated that Korro Bio could have some flexibility on Korro Bio&#8217;s valuation and the PIPE Financing size, but would need exclusivity in order to consider adjusting such valuation and PIPE Financing size. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;4, 2023, at the direction of the Frequency Board, TD Cowen spoke with representatives of<span style="font-weight:bold"> </span>Party R<span style="font-weight:bold"> </span>and Party S to gauge their respective interest in an acquisition of Frequency or other strategic transaction. The representative of Party R stated that Party R may be interested in an asset-focused transaction but not in an acquisition of Frequency. The representatives of Party S stated that Party S may be interested in a strategic transaction but would need certain due diligence information, which Frequency management deemed too competitively sensitive to share without a written proposal and confidentiality agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;4, 2023, Mr.&#160;Lucchino and Dr.&#160;Loose also met with Party B to discuss the potential PIPE Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;5, 2023, Party D delivered a <span style="white-space:nowrap">non-binding</span> term sheet for the licensing of the MS Program&#8217;s assets for $2&#160;million in cash upfront and a 10% equity stake in a newly formed company, to which Party D would guarantee $25&#160;million in funding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;5, 2023, at the direction of the Frequency Board, TD Cowen contacted Party K and the financial advisor to Party L to convey that the Frequency Board had determined to advance Party K and Party L to the next stage of the process, which would include management presentations and additional due diligence. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;5, 2023, Party B expressed continued interest in leading the PIPE Financing, but indicated that it would need until the end of the month to prepare a term sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;6, 2023, Frequency provided intellectual property due diligence to Party C and a counterproposal regarding the acquisition by Party C of the MS Program&#8217;s assets for $5&#160;million in cash upfront, $5&#160;million upon IND submission and $20&#160;million upon entry to Phase 2. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;6, 2023, at the direction of the Frequency Board, Frequency delivered a counterproposal to Korro Bio, which contemplated a reverse triangular merger with Frequency pursuant to which Korro Bio&#8217;s current stockholders would own 85% of the outstanding common stock of the combined company before any proposed concurrent financing. Frequency&#8217;s proposal valued Frequency at $50&#160;million (consisting of $30&#160;million of projected target net cash at closing and a $20&#160;million enterprise value) and valued Korro Bio at $277&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;10, 2023, Korro delivered a counterproposal to Frequency, which contemplated a reverse triangular merger with Frequency pursuant to which Korro Bio&#8217;s current stockholders would own 88% of the outstanding common stock of the combined company before any proposed concurrent financing. Korro Bio&#8217;s proposal valued Frequency at $45&#160;million (consisting of $30&#160;million projected target net cash at closing and a $15&#160;million enterprise value) and valued Korro Bio at $325&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;11, 2023, at the direction of the Frequency Board, representatives of TD Cowen informed Party&#160;M and Party N that the Frequency Board had determined that their respective proposals did not present the best business case for long-term value for Frequency&#8217;s stockholders and that they would not be advanced to the next stage of the process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;11, 2023, Frequency&#8217;s management held meetings with the respective managements of Party K and Party L, during which meetings Party K and Party L reviewed with Frequency&#8217;s management their respective clinical development roadmaps. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, Drs. Loose, Magavi, McCubbin and Hilt met with Party P and discussed the biology, clinical development roadmap and runway of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;12, 2023, Mr.&#160;Lucchino and Drs. Loose, Magavi, McCubbin and Hilt met with Party B and further discussed the biology, clinical development roadmap and runway of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;12, 2023, Party C delivered a revised proposal regarding the acquisition of the MS Program&#8217;s assets for $5&#160;million in cash upfront, $5&#160;million upon the first patient dosing in a Phase 1b trial and $15&#160;million upon the first patient dosing in a Phase 2 trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;12, 2023, a member of Frequency&#8217;s legal team contacted a member of Korro Bio&#8217;s legal team to review certain transaction-related matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;13, 2023, Dr.&#160;Loose and a member of Frequency&#8217;s legal team met with Dr.&#160;Aiyar and a member of Korro Bio&#8217;s finance team to review Frequency&#8217;s intellectual property portfolio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;13, 2023, Drs. Loose and Magavi and Party D held a call to discuss the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;13, 2023, at the direction of the Frequency Board, TD Cowen spoke with Party T to discuss Party T&#8217;s interest in a transaction with Frequency. The representative of Party T stated that Party T<span style="font-weight:bold"> </span>was interested in a transaction regarding the MS Program but that it would not be able to provide a proposal at this time given internal resource constraints, and that it would be interested in being considered if the process remained active at a later date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;14, 2023, the Frequency Board held a meeting with representatives from Latham and TD Cowen present. At the meeting, Latham reviewed the Frequency Board&#8217;s fiduciary duties with respect to potential transaction alternatives, including a potential reverse merger transaction. TD Cowen then reviewed potential strategic alternatives that could be available for Frequency, including the PIPE Financing, the sale of the MS Program and a reverse merger. The members of the Frequency Board discussed the due diligence process and timing for a reverse merger, and determined to approve Korro Bio&#8217;s request for exclusivity. It was noted that Korro Bio had requested an exclusivity agreement that would preclude Frequency from evaluating the standalone PIPE Financing for Frequency, and the Frequency Board instructed management to negotiate for the ability of Frequency to continue to pursue standalone PIPE Financing alternatives. The Frequency Board also requested that senior management conduct additional due diligence on Korro Bio&#8217;s business and that TD Cowen provide additional financial information regarding the strategic options discussed with the Frequency Board to allow the Frequency Board to further assess such strategic options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;14, 2023, following the meeting of the Frequency Board and in accordance with the Frequency Board&#8217;s recommendation, Mr.&#160;Lucchino contacted Dr.&#160;Aiyar confirming that Frequency would provide Korro Bio with exclusivity, assuming Frequency could continue to pursue standalone PIPE Financing options during the pendency of the Korro Bio negotiations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;14, 2023, at the direction of the Frequency Board, TD Cowen contacted Party B, which conveyed that its valuation for the PIPE Financing would be determined by Frequency&#8217;s market value and that it would provide a term sheet shortly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&#160;15 and April&#160;17, 2023, Frequency and Korro Bio negotiated the terms of an exclusivity agreement. Korro Bio noted that it would not agree that Frequency could continue to solicit standalone PIPE Financing alternatives under the exclusivity agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2023, Party B informed Frequency&#8217;s management that it would need more time to prepare a term sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;17, 2023, a representative of Party R contacted TD Cowen and stated that Party R would not be submitting a proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;17, 2023, Dr.&#160;Loose and other members of Frequency&#8217;s scientific team as well as Frequency consultants Dr.&#160;Dan Anderson and Greg Sephton met with Drs. Aiyar and Colletti, Mr.&#160;Agarwal and another member of the Korro Bio finance team to address technology questions from Dr.&#160;Dan Anderson, an MIT professor and expert in RNA therapeutics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, at the direction of the Frequency Board, TD Cowen contacted Party J and requested that Party J deliver a <span style="white-space:nowrap">non-binding</span> indication of interest in pursuing a transaction involving Frequency by April&#160;20, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;19, 2023, J.P. Morgan Securities LLC, or J.P. Morgan, financial advisor to Korro Bio, contacted TD Cowen emphasizing the importance to Korro Bio of exclusivity, stating that Korro Bio would halt further discussions if an exclusivity agreement was not executed by the end of the week. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;19, 2023, Dr.&#160;Loose, other members of Frequency&#8217;s research and development team and a member of Frequency&#8217;s legal team met with Dr.&#160;Aiyar and representatives from Fenwick&#160;&amp; West LLP, intellectual property counsel to Korro Bio, to review Korro&#8217;s intellectual property portfolio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;19, 2023, Mr.&#160;Lucchino and Dr.&#160;Loose met with Party B to discuss the potential PIPE Financing. Party B then submitted a term sheet stating its role as lead investor with a $5&#160;million to $10&#160;million investment contingent on preclinical data from the latest MS Program asset study. Later on April&#160;19, 2023, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&#160;Loose contacted representatives of Party B to discuss potentially dividing the PIPE Financing into two tranches, with the first tranche to be financed upfront and the second tranche to be financed at a later date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;20, 2023, Dr.&#160;Loose spoke with Party B to discuss expanding its commitment to the potential PIPE Financing. Party B provided Frequency with a revised term sheet for the PIPE Financing, or the April&#160;20 Term Sheet, stating Party B&#8217;s role as lead investor with a $15&#160;million investment in a $40&#160;million tranched financing, consisting of $13&#160;million upfront and $27&#160;million upon IND acceptance and first dosing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;20, 2023, Party J informed TD Cowen that Party J had decided not to submit a proposal given its decision to remain a private company and lack of strategic fit of its operations with the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on April&#160;20, 2023, a meeting of the Frequency Board was held with representatives from Latham, TD Cowen and other invitees in attendance. At the meeting, an academic and scientific expert in the field of RNA editing reviewed his due diligence findings with respect to Korro Bio&#8217;s business. The Frequency Board discussed the potential for success for Korro Bio&#8217;s platform technology and safety considerations related to Korro Bio&#8217;s approach. A representative from Haug Partners LLP also reviewed his findings with respect to Korro Bio&#8217;s intellectual property. The Frequency Board then discussed Korro Bio&#8217;s next anticipated value inflection point and timing for an investigational new drug application to the FDA. TD Cowen reviewed the term sheet for the potential PIPE Financing, including certain business terms and Frequency&#8217;s ability to attract additional investors. TD Cowen also provided an update regarding the proposed reverse merger with Korro Bio, including certain financial information provided by Korro Bio and the proposed pro forma equity ownership of the combined company, noting that Korro Bio had indicated that it would terminate discussions with Frequency if Frequency had not entered into an exclusivity agreement with Korro Bio by the end of the week. It was noted that the exclusivity agreement proposed by Korro Bio would prevent Frequency from continuing to explore standalone PIPE Financing alternatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;21, 2023, a meeting of the Frequency Board was held with representatives from Latham and TD Cowen present. At the meeting, TD Cowen provided an overview of potential risks, opportunities and financial considerations regarding the PIPE Financing, the sale of the MS Program and a reverse merger. Representatives from Latham answered questions from the members of the Frequency Board regarding legal considerations and fiduciary duties related to the various strategic alternatives. The Frequency Board then met in an executive session. In the closed session, the Frequency Board discussed Korro Bio&#8217;s valuation, and the Frequency Board expressed the view that Frequency should seek a lower valuation for Korro Bio. The Frequency Board also discussed the inability to enter into an exclusivity agreement with Korro Bio while also continuing discussions on the PIPE Financing, and the desire to conduct additional due diligence on Frequency&#8217;s strategic options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;22, 2023, at the direction of the Frequency Board, Frequency delivered a counterproposal to Korro Bio, which contemplated a reverse triangular merger with Frequency pursuant to which Korro Bio&#8217;s current stockholders would own 83% of the outstanding common stock of the combined company. Frequency&#8217;s proposal noted that Frequency was open to adjusting the stated valuation of either or both companies to achieve this equity split. It was noted that Frequency was not in a position to enter exclusivity at that time, given pending discussions regarding standalone PIPE Financing options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;23, 2023, Korro Bio delivered what it referred to as its &#8220;best and final&#8221; proposal to Frequency, which contemplated a reverse triangular merger with Frequency pursuant to which Korro Bio&#8217;s current stockholders would own 86.5% of the outstanding common stock of the combined company before any proposed concurrent offering. Korro Bio&#8217;s proposal valued Frequency at $50.7&#160;million (consisting of $30&#160;million of projected target net cash at closing and a $20.7&#160;million enterprise value) and valued Korro Bio at $325&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;24, 2023, Party U stated that it was declining to submit a proposal for the MS Program&#8217;s assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;25, 2023, a meeting of the Frequency Board was held with Frequency&#8217;s senior management and representatives from Latham and TD Cowen present. At the meeting, the members of the Frequency Board asked </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
questions regarding the financial aspects of a merger with Korro Bio and alternative opportunities. TD Cowen then reviewed the April&#160;20 Term Sheet from Party B with the Frequency Board. The members of the Frequency Board asked questions regarding certain milestone requirements for funding, Frequency&#8217;s ability to secure additional investors and complete the PIPE Financing and general market conditions for private placements in public biotechnology companies. The Frequency Board then met in an executive session to discuss the PIPE Financing and the potential reverse merger with Korro Bio. Latham responded to questions from the Frequency Board regarding fiduciary duties and other legal considerations. The Frequency Board determined to pursue the PIPE Financing at that time, and instructed TD Cowen to communicate to J.P. Morgan that Frequency was not prepared to proceed at that time on the basis of the Korro Bio proposal, which TD Cowen subsequently communicated to J.P. Morgan as instructed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;26, 2023, Drs. Loose and Magavi met with Party Q and reviewed the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;28, 2023, Party D informed TD Cowen that Party D had determined not to submit an improved term sheet, but would be willing to proceed on the terms contemplated by its prior term sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From April&#160;20, 2023 to May&#160;1, 2023, at the direction of the Frequency Board, Frequency&#8217;s management, with the assistance of Latham and TD Cowen, negotiated the <span style="white-space:nowrap">non-binding</span> term sheet for the PIPE Financing with Party B and, on May&#160;1, 2023, Party B and Frequency signed such term sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;1, 2023, Drs. Loose, Magavi, and McCubbin met with Party P and addressed questions on the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;5, 2023, at the direction of the Frequency Board, TD Cowen spoke with representatives of the financial advisor to Party L to convey that Frequency was interested in conducting further due diligence on Party L in connection with the Frequency Board&#8217;s evaluation of Party L&#8217;s proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;8, 2023, Mr.&#160;Marcus resigned from the Frequency Board. Mr.&#160;Marcus&#8217; resignation was not the result of any disagreement with Frequency on any matter relating to the potential transaction, its operations, policies or practices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on May&#160;8, 2023, Dr.&#160;Magavi met with Party E to notify Party E that Frequency was interested in selling its MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;10, 2023, Frequency and Party L executed an amended mutual confidentiality agreement, which amended the former mutual confidentiality agreement between Frequency and Party L, neither of which contained a &#8220;standstill&#8221; provision, and commenced mutual due diligence, but Party L did not subsequently submit a revised indication of interest regarding a reverse merger involving Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;16, 2023, Mr.&#160;Lucchino met with Mr.&#160;Agarwal to discuss continued interest in a potential reverse merger with Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;17, 2023, Frequency received preclinical data related to the MS Program, which renewed Frequency&#8217;s interest in pursuing discussions with Korro Bio. That day, Mr.&#160;Lucchino contacted Mr.&#160;Agarwal to indicate that Frequency expected to revisit the potential reverse merger transaction with Korro Bio at an upcoming Frequency Board meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2023, Dr.&#160;Loose and Mr.&#160;Lucchino held a call with Party B to discuss the preclinical data for the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on May&#160;18, 2023, on behalf of Korro Bio, J.P. Morgan delivered a <span style="white-space:nowrap">non-binding</span> indication of interest, or the May&#160;18, 2023 Proposal, together with a draft exclusivity agreement, to Frequency confirming Korro Bio&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest in pursuing a reverse triangular merger with Frequency pursuant to which Korro Bio&#8217;s current stockholders would own 86.5% of the outstanding common stock of the combined company before any proposed concurrent offering. Korro Bio&#8217;s indication of interest valued Frequency at $50.7&#160;million (consisting of $30&#160;million of projected target net cash at closing and a $20.7&#160;million enterprise value) and valued Korro Bio at a $325&#160;million <span style="white-space:nowrap">pre-money</span> equity valuation. This <span style="white-space:nowrap">non-binding</span> indication of interest was on substantially the same terms as Korro Bio&#8217;s &#8220;best and final&#8221; offer proposal from April&#160;23, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the evening of May&#160;18, 2023, a meeting of the Frequency Board was held with Frequency&#8217;s senior management and representatives from Latham and TD Cowen present. At the meeting, Dr.&#160;Loose reviewed preclinical data for the MS Program and the PIPE Financing with Party B. Mr.&#160;Lucchino then reviewed two potential lead investors other than Party B for the PIPE Financing. TD Cowen noted that approximately 22 potential investors for the PIPE Financing had been contacted and believed that Party B and the two other parties mentioned by Mr.&#160;Lucchino would be the most likely to lead the PIPE Financing. After discussion, the Frequency Board determined that Frequency would not be able to fund the MS Program on a standalone basis without substantial additional investment. TD Cowen then provided an update on the potential reverse merger with Korro Bio. The Frequency Board discussed Frequency&#8217;s ability to sell the MS Program while pursuing a reverse merger with Korro Bio, as well as the potential for a contingent value right if the MS Program was not sold before closing of the merger. The Frequency Board discussed potential strategies for approaching Party B and Korro Bio and determined that in the near term Frequency should either attempt to secure more favorable terms for the PIPE Financing from Party B or seek to reengage with Korro Bio on the basis of its most recent proposal and, in that context, agree to exclusivity with Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2023, Drs. Loose and Magavi met with Party Q. Party Q expressed progress in its due diligence and continued interest in a potential investment. Drs. Loose and Magavi then reviewed the preclinical data for the MS Program and informed Party Q that Frequency did not expect to be able to pursue the MS Program on a standalone basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;19, 2023, Drs. Loose and Magavi met with Party B and reviewed the preclinical data for the MS Program and informed Party B that Frequency would not be able to pursue the MS Program on a standalone basis. As a result, Frequency and Party B determined to terminate the PIPE Financing discussions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on May&#160;19, Dr.&#160;Loose had a conversation with Party Q during which Party Q withdrew its interest from participating in a PIPE Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on May&#160;19, 2023, at the direction of the Frequency Board, representatives of TD Cowen informed representatives of J.P. Morgan that Frequency was willing to enter into exclusivity and proceed on the basis of Korro Bio&#8217;s proposed terms as set forth in the May&#160;18, 2023 Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on May&#160;19, 2023, Drs. Loose and Magavi met with Party F to discuss the preclinical data for the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;20, 2023, Frequency conducted a due diligence call with Party L. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on May&#160;20, 2023, on behalf of Korro Bio, J.P. Morgan submitted further revised terms to the May&#160;18, 2023 Proposal related to Frequency&#8217;s net cash amount at closing, the amount of the Korro Bio <span style="white-space:nowrap">pre-closing</span> financing and timing for announcement of a transaction, together with a revised draft exclusivity agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;22, 2023, Frequency and Korro Bio executed a <span style="white-space:nowrap">30-day</span> exclusivity agreement, subject to certain extensions, pursuant to which neither party could solicit or initiate any inquiry, proposal or offer from any third party relating to a competing transaction. The exclusivity agreement specifically permitted Frequency to continue its divestiture process for the MS Program. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;23, 2023, at the direction of the Frequency Board, TD Cowen notified Party L that Frequency had entered into an exclusivity agreement with another party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;24, 2023 and during the following week, at the direction of the Frequency Board, TD Cowen spoke with Party C to discuss due diligence topics and next steps regarding a potential sale of the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;25, 2023, Mr.&#160;Lucchino, James Abely, Frequency&#8217;s General Counsel, representatives from RSM LLP, or RSM, Frequency&#8217;s accountants, representatives from Latham and representatives from TD Cowen met with Dr.&#160;Aiyar, Mr.&#160;Agarwal, Shelby Walker, Korro Bio&#8217;s General Counsel, representatives from J.P. Morgan, representatives from Ernst&#160;&amp; Young LLP, or E&amp;Y, Korro Bio&#8217;s accountants, representatives from Davis, Polk&#160;&amp; Wardwell LLP, or Davis Polk, outside counsel to J.P. Morgan in its placement agent role, and representatives of Goodwin Procter LLP, legal advisor to Korro Bio, or Goodwin, met to review business, financial, legal and regulatory due diligence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;25, 2023, Drs. Loose, Magavi and Cubbin met with Party C to discuss the preclinical data for the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;28, 2023, Messrs. Mitrano and Abely met with Mr.&#160;Agarwal and members of Korro Bio&#8217;s finance team to review Frequency&#8217;s finances and financial model, including its anticipated expenses and cash availability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;29, 2023, representatives of Latham delivered to representatives of Goodwin an initial draft of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;31, 2023, Messrs. Lucchino and Abely, representatives from RSM and representatives from Latham met with Dr.&#160;Aiyar, Mr.&#160;Agarwal, Ms.&#160;Walker, representatives from J.P. Morgan, representatives from E&amp;Y, representatives from Davis Polk and representatives from Goodwin to conduct legal due diligence on Frequency and discuss the timeline for a potential strategic transaction. Representatives from TD Cowen also attended this meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on May&#160;31, 2023, to align its expenditures with its decision to no longer pursue the MS Program on a standalone basis and to conserve resources, Frequency announced a reduction of approximately 55% of its workforce. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;1, 2023, Dr.&#160;Magavi met with Party E and discussed the biology, preclinical data, and clinical roadmap of the MS Program, as well as the runway of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;7, 2023 and June&#160;13, 2023, Drs. Magavi and Hilt met with Party C and discussed further detail on potential clinical trial designs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;8, 2023, an organizational meeting was held among Frequency, Korro Bio and their respective legal and financial advisors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2023, at the direction of the Frequency Board, representatives of Latham delivered the initial draft of the CVR Agreement to representatives of Goodwin. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;12, 2023, at the direction of the Frequency Board, TD Cowen contacted Party C and Party D regarding the status of ongoing negotiations regarding the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on June&#160;12, 2023, Frequency received an inquiry from Party O regarding a potential reverse merger. Frequency did not respond to Party O at that time and directed TD Cowen to inform Party O that it had entered into an exclusivity agreement with another party. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;14, 2023, Dr.&#160;Magavi met with Party E and discussed further detail on timelines and runways relating to the MS Program.<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;15, 2023, at the direction of the Frequency Board, TD Cowen informed Party O that Frequency had entered into an exclusivity agreement with another party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;16, 2023, representatives of Goodwin delivered revised drafts of the Merger Agreement and CVR Agreement to representatives of Latham, which, among other things, with respect to the Merger Agreement, reflected Korro Bio&#8217;s position on the permitted deductions for the determination of Frequency Net Cash at the closing date of the Merger, revisions to the representations and warranties of the two companies and also included additional covenants to be made by the parties and with respect to the CVR Agreement, changes to the permitted deductions and the composition of a <span style="white-space:nowrap">sub-committee</span> of the Frequency Board post-closing to administer the CVR Agreement, or the CVR Committee.<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;20, 2023, Dr.&#160;Magavi and Mr.&#160;Abely met with Party D to discuss the preclinical data for the MS Program. During this meeting, Party D stated its continued interest in purchasing the MS Program for $2&#160;million upfront plus an equity investment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on June&#160;20, 2023, Dr.&#160;Magavi met with Party G to discuss the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;21, 2023, at the direction of the Frequency Board, TD Cowen had a <span style="white-space:nowrap">follow-up</span> call with Party G to gauge Party G&#8217;s interest in the MS Program, which indicated it would revert with a request for a later meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2023, Messrs. Lucchino and Agarwal met to discuss a potential timeline for the potential reverse merger transaction, and Korro Bio provided a revised proposal to Frequency proposing a sliding equity premium scale for Frequency ranging from 50% to 40% depending on the level of Frequency&#8217;s net cash at closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2023, Dr.&#160;Magavi met with Party E and discussed further details related to a potential transaction involving the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;29, 2023, Dr.&#160;Magavi met with Party H to discuss the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on June&#160;29, 2023, Dr.&#160;Magavi and Mr.&#160;Abely met with Party F to discuss timelines and paths forward relating to the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on June&#160;29, 2023, at the direction of the Frequency Board, TD Cowen held a discussion with Party G confirming Party G&#8217;s interest in the MS Program and requesting that Party G provide a term sheet that could be reviewed by the Frequency Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on June&#160;29, 2023, representatives of Latham delivered revised drafts of the Merger Agreement and CVR Agreement to representatives of Goodwin, which, among other things, with respect to the Merger Agreement, clarified the Merger conversion mechanics and permitted deductions to the calculation of Frequency&#8217;s net cash and also updated the covenants and closing deliverables to be made and provided at closing of the Merger and, with respect to the CVR Agreement, changes to the permitted deductions and the CVR Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;5, 2023, Messrs. Lucchino and Agarwal held a meeting during which Mr.&#160;Agarwal mentioned that the equity premium implied in the transaction could be $15&#160;million assuming a certain minimum level of Frequency&#8217;s net cash at closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on July&#160;5, 2023, representatives of Goodwin delivered revised drafts of the Merger Agreement and CVR Agreement to representatives of Latham, which, among other things, with respect to the Merger </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, reflected Korro Bio&#8217;s position on certain Merger conversion and valuation mechanics contemplated by the Merger Agreement, and, with respect to the CVR Agreement, additional changes to the permitted deductions and the CVR Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;6, 2023, at the direction of the Frequency Board, TD Cowen held discussions with J.P. Morgan, during which TD Cowen informed J.P. Morgan that an equity premium below $20.7&#160;million would not be acceptable to Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on July&#160;6, 2023, representatives of Goodwin delivered drafts of the forms of Support Agreement and <span style="white-space:nowrap">Lock-Up</span> Agreement to representatives of Latham, which, among other things, set forth terms regarding scope of the matters to be approved by certain of Frequency&#8217;s and Korro Bio&#8217;s respective stockholders, and the exclusions regarding the restricted shares of Frequency Common Stock at closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on July&#160;6, 2023, at the direction of the Frequency Board, TD Cowen held a discussion with Party C, which indicated that it anticipated sending a new term sheet regarding a potential acquisition of the MS Program in the next few days. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on July&#160;6, 2023, Dr.&#160;Magavi met with Party I to discuss the MS Program. Later that same day, Dr.&#160;Magavi met with Party E to continue discussions regarding the MS Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, representatives of Latham delivered revised drafts of the Merger Agreement, CVR Agreement and form of Support Agreement to representatives of Goodwin, which, among other things, with respect to the Merger Agreement, further revised Merger certain conversion and valuation mechanics contemplated by the Merger Agreement, and, with respect to the CVR Agreement, additional changes to the permitted deductions, and, with respect to the Support Agreement, changes to the proposals that the parties would be voting on, and amendments regarding <span style="white-space:nowrap">non-solicitation</span> and irrevocable proxy matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;8, 2023, at the direction of the Frequency Board, TD Cowen held a discussion with J.P. Morgan, during which TD Cowen reiterated the Frequency Board&#8217;s position that an equity premium below $20.7&#160;million would not be acceptable to Frequency, while J.P. Morgan reiterated Korro Bio&#8217;s position that such equity premium would need to reflect a sliding equity risk premium dependent on Frequency&#8217;s net cash at closing, including $15&#160;million at a certain minimum level of Frequency&#8217;s net cash at closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;10, 2023, Korro Bio proposed a sliding equity premium scale for Frequency which would apply a $12.5&#160;million to $20.0&#160;million premium, depending on the level of Frequency&#8217;s net cash at closing, which sliding equity premium scale was subsequently agreed to by Frequency and Korro Bio on July&#160;11, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on July&#160;10, 2023, representatives of Goodwin delivered revised drafts of the Merger Agreement and CVR Agreement to representatives of Latham, which, among other things, proposed an outside termination date of November&#160;14, 2023, subject to extension. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;12, 2023, Frequency and Korro agreed on, among other things, the terms of the CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on July&#160;12, 2023, Messrs. Lucchino and Agarwal had a call to discuss the remaining business terms of the Merger Agreement, including, among other things, the termination fees payable by the parties, the outside termination date and certain conversion and valuation mechanics (including with respect to the treatment of Frequency options) contemplated by the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on July&#160;12, 2023, a meeting of the Frequency Board was held, with Frequency&#8217;s management team and representatives from TD Cowen and Latham present. At the meeting, TD Cowen reviewed with the Frequency Board TD Cowen&#8217;s preliminary financial analysis of the Korro Equity Value. Members of the Frequency Board asked questions regarding the formula to be used to determine the number of shares to be issued to Korro Bio at </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the closing of the Merger based on Frequency&#8217;s cash position at that time. Latham then reviewed the material terms of the Merger Agreement. The members of the Frequency Board asked questions and discussed the key open terms in the Merger Agreement such as the termination fees payable by the parties and the outside termination date of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on July&#160;12, 2023 and July&#160;13, 2023, Latham and Goodwin exchanged drafts of the Merger Agreement and met to negotiate and resolve the then-remaining open terms of the Merger Agreement, including the outside termination date and termination fees payable by the parties if the Merger Agreement was terminated under certain circumstances. The parties agreed to (i)&#160;a termination fee payable by Frequency to Korro Bio under certain circumstances of $1.5&#160;million and a termination fee payable by Korro Bio to Frequency under certain circumstances of $4.0&#160;million, and (ii)&#160;an outside termination date of November&#160;14, 2023, with a <span style="white-space:nowrap">60-day</span> extension in the event the proxy statement/prospectus for the transaction was not declared effective as of 25 business days prior to such date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the afternoon of July&#160;13, 2023, Latham circulated final versions of the Merger Agreement and CVR Agreement, and substantially final versions of the Frequency Support Agreement and Frequency <span style="white-space:nowrap">Lock-Up</span> Agreements to Frequency&#8217;s senior management who then circulated such documents to the Frequency Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the evening of July&#160;13, 2023, a meeting of the Frequency Board was held, with Frequency&#8217;s senior management team and representatives from Latham and TD Cowen present. Latham reviewed the final terms of the Merger Agreement, focusing on the changes to the Merger Agreement since the Frequency Board meeting on July&#160;12, 2023. Latham informed the Frequency Board that Korro Bio had agreed to (i)&#160;a $1.5&#160;million termination fee in the event that Frequency terminates the Merger Agreement under certain circumstances and a $4.0&#160;million termination fee in the event Korro Bio terminates the Merger Agreement under certain circumstances, and (ii)&#160;an outside termination date of November&#160;14, 2023 coupled with a <span style="white-space:nowrap">60-day</span> extension in the event the proxy statement/prospectus for the transaction was not declared effective as of 25 business days prior to such date. At the request of the Frequency Board, TD Cowen then reviewed with the Frequency Board TD Cowen&#8217;s financial analysis of the Korro Bio Equity Value and delivered an oral opinion, confirmed by delivery of a written opinion dated July&#160;13, 2023, to the Frequency Board to the effect that, based on and subject to the various assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken by TD Cowen as set forth in such opinion, as of July&#160;13, 2023, the Korro Bio Equity Value provided for pursuant to the Merger Agreement was fair, from a financial point of view, to Frequency. After discussion, taking into account (i)&#160;Frequency&#8217;s financial condition and prospects, including Frequency&#8217;s limited cash runway, (ii)&#160;Frequency&#8217;s inability to raise additional capital in the PIPE Financing, (iii)&#160;outreach efforts conducted on behalf of Frequency, (iv)&#160;Frequency&#8217;s decision to no longer pursue its MS Program on a standalone basis, (v)&#160;the potential value of Korro Bio&#8217;s product candidate development, (vi)&#160;the potential for Frequency&#8217;s stockholders to benefit from the future growth of the combined company, (vii)&#160;the proposed terms of the Merger Agreement and (viii)&#160;the other factors described under the heading &#8220;&#8212;<span style="font-style:italic">Frequency&#8217;s Reasons for the Merger</span>,&#8221; the Frequency Board unanimously determined that the Merger Agreement and the other Transactions were advisable and in the best interests of Frequency and its stockholders, approved and declared advisable the Merger and the Transactions, and recommended that Frequency&#8217;s stockholders vote to approve the issuance of shares of Frequency Common Stock in the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout the night of July&#160;13, 2023, Frequency and Korro Bio continued to finalize the support and <span style="white-space:nowrap">lock-up</span> agreements for the transaction. In the early morning of July&#160;14, 2023, after finalizing the support and <span style="white-space:nowrap">lock-up</span> agreements, Frequency and Korro Bio executed the Merger Agreement, certain Frequency stockholders executed the Frequency Support Agreement and <span style="white-space:nowrap">Lock-Up</span> Agreements, and certain Korro Bio stockholders executed the Korro Bio Support Agreement and <span style="white-space:nowrap">Lock-Up</span> Agreements. Before the opening of trading on Nasdaq on July&#160;14, 2023, Frequency and Korro Bio issued a joint press release announcing their entry into the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_38">Frequency Reasons for the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, Frequency&#8217;s board of directors held numerous meetings, consulted with Frequency&#8217;s senior </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management, legal counsel and financial advisor, and reviewed a significant amount of information. Frequency&#8217;s board of directors considered the following factors in reaching its conclusion to approve the Merger Agreement and the transactions contemplated thereby and to recommend that the Frequency stockholders approve the Merger and the issuance of shares of Frequency Common Stock in the Merger, all of which the Frequency board of directors viewed as supporting its decision: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors review of the business, financial position and prospects of Frequency on a standalone basis, noting that Frequency&#8217;s assets and liabilities are comprised primarily of cash (net of liabilities) and the assets and rights relating to Frequency&#8217;s MS Program, and determination that Frequency could not reasonably be expected to fund its MS Program on a standalone basis without substantial additional investment. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors review of the range of strategic alternatives available to Frequency, including a potential sale of all or a part of Frequency, a potential reverse merger of Frequency with a privately held biotechnology company and a potential third party investment in Frequency to allow it to fund its MS Program on a standalone basis, and which involved outreach to 34 potential counterparties for a sale of all or a part of, or a reverse merger with, Frequency and 22 potential investors in Frequency, and its determination that the proposed Merger represents the best transaction alternative reasonably available to Frequency and its stockholders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors believes, in the absence of substantial additional investment in Frequency on a standalone basis, that a divestiture of the MS Program represents the best alternative to realize value for the MS Program. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors reviewed the current financial market conditions and historical market prices, volatility and trading information with respect to Frequency Common Stock and also considered that Frequency is not expected to have any continuing business operations on a standalone basis, assuming divestiture of the MS Program, other than those incidental to Frequency&#8217;s status as a publicly traded company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors considered, based on the Frequency Equity Value (as defined in the Merger Agreement), that the Merger provides value for Frequency&#8217;s public company listing in addition to its net cash. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors considered the fact that the Merger Agreement and, if applicable, the related CVR provides the opportunity for Frequency&#8217;s stockholders to receive the value realized from any divestiture of the MS Program in connection with the proposed transaction. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors review of the business, strategy, financial position and prospects of Korro Bio and, in that context, the opportunity for Korro Bio&#8217;s RNA editing technology to generate substantial long-term value for the combined company and its stockholders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors believes that Korro Bio&#8217;s focus on RNA editing technology is positioned to leverage genetics transiently, expanding the target space to intervene in biology in a unique manner. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors considered the financial resources available to the combined company as a result of the Pre-Closing Financing as well as the fact that the Pre-Closing Financing will be completed at the same implied equity value of Korro Bio as provided for pursuant to the Merger Agreement, as well as the possibility that the combined company would be able to take advantage of the potential benefits resulting from the Frequency public company structure to raise additional funds in the future, if necessary. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors view, following a review with Frequency&#8217;s management and scientific consultants of Korro Bio&#8217;s current development plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Korro&#160;Bio&#8217;s pipeline through upcoming value inflection points. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors concluded that the Merger would provide the existing Frequency stockholders an opportunity to participate in the potential growth and value creation of the combined company following the Merger by virtue of their continued ownership of Frequency Common Stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors also considered that the combined organization is expected to be led by a highly experienced and accomplished senior management team and a board of directors with representation from each of the current boards of directors of Frequency and Korro Bio as well as two new independent directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s board of directors considered the financial presentation and opinion of TD Cowen, dated July 13, 2023, to Frequency&#8217;s board of directors as to the fairness, from a financial point of view and as of the date of such opinion, to Frequency of the Korro Bio Equity Value provided for pursuant to the Merger Agreement, which opinion was based on and subject to the various assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken by TD Cowen set forth in such opinion as more fully described under the heading &#8220;<span style="font-style:italic">The Merger&#8212;Opinion of Frequency&#8217;s Financial Advisor.</span>&#8221; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s board of directors also reviewed the terms of the Merger Agreement and associated transactions, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the net cash calculation used to determine the aggregate valuation of Frequency and the various factors considered therein; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the financing in Korro Bio contemplated by the subscription agreement, the limited number and nature of conditions to the obligation of the proposed investors in Korro Bio to consummate the financing contemplated by the subscription agreement and that entry into the subscription agreement (including Korro Bio&#8217;s receipt of at least $100&#160;million pursuant to thereto) is a closing condition under the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the limited number and nature of the conditions to Korro Bio&#8217;s obligation to consummate the Merger and the limited risk of <span style="white-space:nowrap">non-satisfaction</span> of such conditions as well as the likelihood that the Merger will be consummated on a timely basis, as more fully described below under the caption &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Conditions to the Completion of the Merger</span>,&#8221; beginning on page&#160;207 in this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights of Frequency under the Merger Agreement to consider certain unsolicited Acquisition Proposals under certain circumstances should Frequency receive a Superior Proposal, as more fully described below under the caption &#8220;<span style="font-style:italic">The Merger <span style="white-space:nowrap">Agreement&#8212;Non-Solicitation</span></span>,&#8221; beginning on page&#160;201 in this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the right of each party to terminate the Merger Agreement and the reasonableness of the potential termination fees of $1.5&#160;million, in the case of the fee payable by Frequency, and $4&#160;million, in the case of the fee payable by Korro Bio, which could become payable by either Frequency or Korro Bio, as applicable, to the other party if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Termination and Termination Fees</span>,&#8221; beginning on page&#160;209 in this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the support agreements, pursuant to which certain stockholders of Frequency and Korro Bio agreed, solely in their capacity as stockholders, to vote all of their shares of Frequency or Korro Bio capital stock, as applicable, in favor of adoption of the Merger Agreement and the transactions contemplated thereby, as more fully described below under the caption &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Support Agreements</span>,&#8221; beginning on page&#160;212 in this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">lock-up</span> agreements, pursuant to which certain stockholders of Frequency and Korro Bio agreed, subject to certain exceptions and solely in their capacity as stockholders, to refrain from transferring or disposing of Frequency common stock for a period of 180 days after the completion of the Merger, as </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
more fully described below under the caption &#8220;<span style="font-style:italic">Agreements Related to the <span style="white-space:nowrap">Merger&#8212;Lock-Up</span> Agreements</span>,&#8221; beginning on page 213 in this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential ability of Frequency&#8217;s stockholders to realize value for the sale of the assets and rights relating to Frequency&#8217;s MS Program under the CVR Agreement, as more fully described below under the caption &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Potential Asset Sale</span>,&#8221; beginning on page 196 in this proxy statement/prospectus and &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Contingent Value Rights Agreement</span>,&#8221; beginning on page 214 in this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the agreement of Korro Bio to provide written consent of its stockholders necessary to adopt the Merger Agreement thereby approving the Merger and related transactions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the belief that the terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, are reasonable under the circumstances. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of its deliberations, the Frequency board of directors also considered a variety of risks and other countervailing factors related to entering into the Merger, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that Frequency&#8217;s stockholders may not approve the Merger proposals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the $1.5&#160;million termination fee payable to Korro Bio upon the occurrence of certain events and the potential effect of such termination fee in deterring other potential acquirers from proposing an alternative transaction that may be more advantageous to Frequency stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prohibition on Frequency to solicit alternative acquisition proposals during the pendency of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the substantial expenses to be incurred in connection with the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">under the &#8220;Frequency Net Cash&#8221; calculation contemplated by the Merger Agreement, and as more fully described below under the caption &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Calculation of Frequency&#8217;s Net Cash</span>&#8221; beginning on page 193, certain considerations including, among others, Frequency&#8217;s (i) transaction expenses incurred in connection with the Merger, (ii) unpaid indebtedness and other liabilities, (iii) accrued contractual obligations, (iv) wind-down costs and expenses, (v) lender termination fees in connection with the repayment of indebtedness, (vi) accounts payable and accrued expenses, (vii) payables or obligations associated with Frequency&#8217;s lease agreement with HCP/King 75 Hayden LLC, (viii) payroll taxes and (ix) expenses associated with certain pending litigation matters, which reduce Frequency Net Cash and therefore reduce the ownership of Frequency stockholders of the combined company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possible volatility of the trading price of the Frequency common stock resulting from the Merger announcement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the Merger might not be consummated in a timely manner or at all and the potential adverse effect of the public announcement of the Merger or on the delay or failure to complete the Merger on the reputation of Frequency; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk to the business of Frequency and its operations and financial results in the event that the Merger is not consummated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the strategic direction of the combined company following the completion of the Merger, which will be determined by a board of directors of which the members of the current Frequency board of directors will comprise a minority; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that Frequency&#8217;s stockholders may not receive any value for the sale of the assets and rights relating to Frequency&#8217;s MS Program under the CVR Agreement, including if the MS Program is not divested prior to the first anniversary of the closing of the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">various other risks associated with the combined organization and the Merger, including those described in the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 32 in this proxy statement/prospectus. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing information and factors considered by Frequency&#8217;s board of directors are not intended to be exhaustive but are believed to include certain material factors considered by Frequency&#8217;s board of directors. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, Frequency&#8217;s board of directors did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of Frequency&#8217;s board of directors may have given different weight to different factors. Frequency&#8217;s board of directors conducted an overall review of the factors described above and considered the factors overall to be favorable to, and to support, its determination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_39">Korro Bio Reasons for the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of reaching its decision to approve the Merger, the Korro Bio board of directors held numerous meetings, consulted with Korro Bio&#8217;s senior management, its financial advisors and legal counsel, and considered a wide variety of factors, including, among others, the following material factors (which factors are not necessarily presented in any order of relative importance): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Merger will provide Korro Bio&#8217;s current stockholders with greater liquidity by owning publicly-traded stock, and expanding the range of investors potentially available as a public company, compared to the investors Korro Bio could otherwise gain access to if it continued to operate as a privately-held company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical and current information concerning Korro Bio&#8217;s business, including its financial performance and condition, operations, management and pre-clinical data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the competitive nature of the industry in which Korro Bio operates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korro Bio board of directors&#8217; fiduciary duties to Korro Bio&#8217;s stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the board&#8217;s belief that no alternatives to the Merger were reasonably likely to create greater value for Korro Bio&#8217;s stockholders, after reviewing the various financing and other strategic options to enhance stockholder value that were considered by the Korro Bio board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the projected financial position, operations, management structure, geographic locations, operating plans, cash burn rate and financial projections of the combined company, including the expected cash resources of the combined organization (including the ability to support the combined company&#8217;s current and planned clinical trials and operations); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of appraisal rights under the DGCL to holders of Korro Bio&#8217;s capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Korro Bio capital stock as determined by the Delaware Court of Chancery; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms and conditions of the Merger Agreement, including the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the determination that the expected relative percentage ownership of Frequency&#8217;s stockholders and Korro Bio&#8217;s stockholders in the combined organization was appropriate, based on the Korro Bio board of directors&#8217; judgment and assessment of the approximate valuations of Frequency and Korro Bio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expectation that the Merger will be treated as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code for U.S. federal income tax purposes, with the result that in the Merger the Korro Bio stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the limited number and nature of the conditions of the obligation of Frequency to consummate the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights of Korro Bio under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Korro Bio receive a superior proposal; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the conclusion of the Korro Bio board of directors that the potential termination fee of $4 million, payable by Korro Bio to Frequency, and the circumstances when such fee may be payable, were reasonable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the conclusion of the Korro Bio board of directors that the potential termination fee of $1.5 million, payable by Frequency to Korro Bio, and the circumstances when such fee may be payable, were reasonable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the shares of Frequency&#8217;s common stock issued to Korro Bio&#8217;s stockholders will be registered on a Form S-4 registration statement and will become freely tradable for Korro Bio&#8217;s stockholders who are not affiliates of Korro Bio and who are not parties to lock-up agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the support agreements, pursuant to which certain directors, officers and stockholders of Korro Bio and Frequency, respectively, have agreed, solely in their capacity as stockholders of Korro Bio and Frequency, respectively, to vote all of their shares of Korro Bio capital stock or Frequency common stock in favor of the adoption or approval, respectively, of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Korro Bio Therapeutics, Inc. upon the closing of the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the likelihood that the Merger will be consummated on a timely basis. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that the Merger might not be completed for a variety of reasons, such as the failure of Frequency to obtain the required stockholder vote, and the potential adverse effect of the public announcement of the Merger on the reputation of Korro Bio and the ability of Korro Bio to obtain financing in the future in the event the Merger is not completed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that future sales of common stock by existing Frequency stockholders may cause the price of Frequency common stock to fall, thus reducing the potential value of Frequency common stock received by Korro Bio stockholders following the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the exchange ratio used to establish the number of shares of Frequency&#8217;s common stock to be issued to Korro Bio&#8217;s stockholders in the Merger is fixed, except for adjustments due to the parties&#8217; respective cash balances and outstanding capital stock at closing, and thus the relative percentage ownership of Frequency&#8217;s stockholders and Korro Bio&#8217;s stockholders in the combined organization immediately following the completion of the Merger is similarly fixed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the termination fee of $4 million, payable by Korro Bio to Frequency upon the occurrence of certain events, and the potential effect of such termination fee in deterring other potential acquirers from proposing an alternative transaction that may be more advantageous to Korro Bio&#8217;s stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential reduction of Frequency&#8217;s net cash prior to the closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that Frequency could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the Merger might not be consummated in a timely manner or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs involved in connection with completing the Merger, the time and effort of Korro Bio senior management required to complete the Merger, the related disruptions or potential disruptions to Korro </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Bio&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Korro Bio, and related administrative challenges associated with combining the companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that Frequency will not be able to successfully sell Frequency&#8217;s MS Assets under the CVR Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the additional expenses and obligations to which Korro Bio&#8217;s business will be subject following the Merger that Korro Bio has not previously been subject to, and the operational changes to Korro Bio&#8217;s business, in each case that may result from being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post-closing; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">various other risks associated with the combined organization and the Merger, including the risks described in the section entitled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 32 in this proxy statement/prospectus. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing information is not intended to be exhaustive, but summarizes the material factors considered by the Korro Bio board of directors in its consideration of the Merger Agreement and the transactions contemplated. The Korro Bio board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. After considering these and other factors, the Korro Bio board of directors unanimously approved the Merger Agreement, the Merger and the other transactions contemplated by the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_40a">Opinion of Frequency&#8217;s Financial Advisor </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has engaged TD Cowen as its financial advisor in connection with the Merger. In connection with this engagement, the Frequency board of directors requested that TD Cowen evaluate the fairness, from a financial point of view, to Frequency of the Korro Bio Equity Value provided for pursuant to the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At a meeting of the Frequency board of directors held on July&#160;13, 2023, TD Cowen reviewed with the Frequency board of directors TD Cowen&#8217;s financial analysis of the Korro Bio Equity Value and delivered an oral opinion, confirmed by delivery of a written opinion dated July&#160;13, 2023, to the Frequency board of directors to the effect that<span style="font-style:italic">,</span> based on and subject to the various assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken by TD Cowen as set forth in such opinion, as of July&#160;13, 2023, the Korro Bio Equity Value provided for pursuant to the Merger Agreement was fair, from a financial point of view, to Frequency. For purposes of TD Cowen&#8217;s financial analyses and opinion, the term &#8220;Korro Bio Equity Value&#8221; refers to the equity value of $325,639,194.78 ascribed to Korro Bio pursuant to the Merger Agreement. <span style="font-weight:bold">The full text of TD Cowen&#8217;s written opinion, dated July&#160;13, 2023, is attached as </span><span style="font-weight:bold"><span style="font-style:italic">Annex&#160;B </span></span><span style="font-weight:bold">to this proxy statement/prospectus and is incorporated herein by reference. The summary of TD Cowen&#8217;s written opinion set forth herein is qualified in its entirety by reference to the full text of such</span> <span style="font-weight:bold">opinion. TD Cowen&#8217;s analyses and opinion were prepared for and addressed to the Frequency board of directors and were directed only to the fairness, from a financial point of view, to Frequency of the Korro Bio Equity Value. TD Cowen&#8217;s opinion did not in any manner address Frequency&#8217;s underlying business decision to effect the Merger or related transactions or the relative merits of the Merger or related transactions as compared to other business strategies or transactions that might be available to Frequency. The Korro Bio Equity Value was determined through negotiations between Frequency and Korro Bio and TD Cowen&#8217;s opinion does not constitute a recommendation to any securityholder or any other person as to how to vote or act with respect to the Merger, any related transactions or otherwise.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its opinion, TD Cowen reviewed and considered such financial and other matters as it deemed relevant, including, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an execution version, provided to TD Cowen on July&#160;13, 2023, of the Merger Agreement; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain publicly available financial and other information for Frequency and certain other relevant financial and operating data furnished to TD Cowen by the management of Frequency; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain financial and other information for Korro Bio and certain other relevant financial and operating data furnished to TD Cowen by the managements of Frequency and Korro Bio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain internal financial analyses, probability-adjusted financial forecasts, reports and other information concerning Korro Bio prepared by the management of Korro Bio as adjusted by the management of Frequency (as adjusted, referred to in this section as the &#8220;Korro Bio forecasts&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussions TD Cowen had with certain members of the managements of Frequency and Korro Bio,<span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top"> </sup></span>as the case may be, concerning the historical and current business operations, financial conditions and prospects of Frequency and Korro Bio and such other matters that TD Cowen deemed relevant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain operating results of, and financial and stock market information for, Korro Bio as compared to similar information for certain publicly traded companies that TD Cowen deemed relevant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such other information, financial studies, analyses and investigations and such other factors that TD Cowen deemed relevant for the purposes of its opinion. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conducting its review and arriving at its opinion, TD Cowen, at the direction of the Frequency board of directors, assumed and relied, without independent investigation, upon the accuracy and completeness of all financial and other information provided to TD Cowen by Frequency and Korro Bio or which was publicly available or was otherwise reviewed by TD Cowen. TD Cowen did not undertake any responsibility for the accuracy, completeness or reasonableness of, or independent verification of, such information. TD Cowen relied upon the respective representations of Frequency and Korro Bio that all information provided to TD Cowen by Frequency and Korro Bio was accurate and complete in all material respects and TD Cowen expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting its opinion of which TD Cowen becomes aware after the date of TD Cowen&#8217;s opinion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen was advised, given that Frequency&#8217;s assets and liabilities are comprised solely of cash (net of liabilities) and the MS Assets (which currently are contemplated to be sold) and that Frequency was not expected to have any continuing business operations on a standalone basis other than those incidental to Frequency&#8217;s status as a publicly traded company, that the management of Frequency had not prepared financial forecasts relating to Frequency. Accordingly, TD Cowen did not perform a financial analysis of Frequency or the CVRs. TD Cowen also assumed, at the direction of the Frequency board of directors, that the Korro Bio forecasts (as adjusted by the management of Frequency) were reasonably prepared by the managements of Frequency and Korro Bio, as the case may be, on bases reflecting the best currently available estimates and good faith judgments of such managements as to the future performance of Korro Bio and the other matters covered thereby, and that such Korro Bio forecasts utilized in TD Cowen&#8217;s analyses provided a reasonable basis for TD Cowen&#8217;s opinion. TD Cowen relied on the assessments of the managements of Frequency and Korro<sup style="font-size:75%; vertical-align:top"> </sup>Bio as to, among other things, (i)&#160;the product pipeline, future products, technology and intellectual property of Korro Bio, including the viability of and risks associated with such product pipeline, future products, technology and intellectual property, and (ii)&#160;the terms of the Pre-Closing Financing, including with respect to the timing, amount, valuation and other terms involved and potential impact thereof. TD Cowen assumed that there would be no developments with respect to any such matters that would have an adverse effect on Korro Bio, Frequency, the Merger or related transactions (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to TD Cowen&#8217;s analyses or opinion. TD Cowen expressed no opinion as to the Korro Bio forecasts or the assumptions on which they were based. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, TD Cowen assumed that there had been no material changes in the assets, liabilities, financial condition, results of operations, businesses or prospects of Korro Bio or Frequency since the dates of the last financial statements made available to TD Cowen. TD Cowen did not make or obtain any independent evaluations, valuations or appraisals of the assets or liabilities (contingent, accrued, derivative, <span style="white-space:nowrap">off-balance</span> sheet </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or otherwise) of Korro Bio, Frequency or any other entity, nor was TD Cowen furnished with such materials. TD Cowen did not conduct nor did TD Cowen assume any obligation to conduct any physical inspection of the properties or facilities of Korro Bio, Frequency or any other entity. TD Cowen also did not evaluate the solvency or fair value of Korro Bio, Frequency or any other entity under any state, federal or foreign laws relating to bankruptcy, insolvency or similar matters. In addition, TD Cowen did not undertake an independent evaluation of any actual or potential litigation, settlements, governmental or regulatory proceedings or investigations, possible unasserted claims or other contingent liabilities to which Korro Bio, Frequency or any other entity may be a party or subject. TD Cowen assumed that the Merger would qualify for the intended tax treatment contemplated by the Merger Agreement. TD Cowen&#8217;s opinion did not address any legal, tax, accounting or regulatory matters related to the Merger Agreement, the Merger or any related transactions, as to which TD Cowen assumed that Frequency and the Frequency board of directors received such advice from legal, tax, accounting and regulatory advisors as each determined appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen&#8217;s opinion addressed only the fairness of the Korro Bio Equity Value, from a financial point of view, to Frequency. TD Cowen expressed no view as to any related transactions, the CVRs or any other aspect or implication of the Merger, including, without limitation, any support or <span style="white-space:nowrap">lock-up</span> agreements, subscription agreements or any other agreement, arrangement or understanding entered into in connection with the Merger, any related transactions or otherwise. TD Cowen&#8217;s opinion was necessarily based upon economic and market conditions and other circumstances as they existed and could be evaluated by TD Cowen on the date of such opinion. It should be understood that although subsequent developments may affect TD Cowen&#8217;s opinion, TD Cowen does not have any obligation to update, revise or reaffirm its opinion and TD Cowen expressly disclaims any responsibility to do so. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen did not consider any potential legislative or regulatory changes currently being considered or recently enacted by the United States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the SEC, the Financial Accounting Standards Board, or any similar foreign regulatory body or board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of rendering its opinion, TD Cowen assumed in all respects material to its analyses that the representations and warranties of each party contained in the Merger Agreement were true and correct, that each party would perform all of the covenants and agreements required to be performed by it under the Merger Agreement and that all conditions to the consummation of the Merger and related transactions would be satisfied without waiver thereof. TD Cowen also assumed that the executed form of the Merger Agreement would be substantially similar to the execution version reviewed by TD Cowen. TD Cowen further assumed that all governmental, regulatory and other consents and approvals contemplated by the Merger Agreement would be obtained and that in the course of obtaining any of those consents no restrictions would be imposed or waivers made that would have an adverse effect on Korro Bio, Frequency, the Merger or related transactions (including the contemplated benefits thereof). In addition, TD Cowen assumed that the Merger and related transactions would be consummated in a manner that complies with the applicable provisions of the Securities Act, the Exchange Act and all other applicable state or federal statutes, rules and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It was understood that TD Cowen&#8217;s opinion was intended for the benefit and use of the Frequency board of directors (in its capacity as such) in its evaluation of the Korro Bio Equity Value. TD Cowen&#8217;s opinion did not and does not constitute a recommendation to the Frequency board of directors, any securityholder or any other person as to how to vote or act with respect to the Merger, any related transactions or otherwise. TD Cowen expressed no opinion as to the actual value, price or trading range of any securities of Frequency (including Frequency common stock and the CVRs) or Korro Bio (including Korro Bio common stock, Korro Bio preferred stock, Korro Bio options and Korro Bio warrants) upon or following announcement or consummation of the Merger and related transactions. TD Cowen was not requested to opine as to, and its opinion did not in any manner address, Frequency&#8217;s underlying business decision to effect the Merger or related transactions or the relative merits of the Merger or related transactions as compared to other business strategies or transactions that might be available to Frequency, including a liquidation of Frequency. In addition, TD Cowen was not requested </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to opine as to, and its opinion did not in any manner address, (i)&#160;the fairness of the amount or nature of the compensation to the officers, directors or employees, or class of such persons, of any parties to the Merger or any related transactions relative to the Korro Bio Equity Value or otherwise or (ii)&#160;the fairness of the Merger, any related transactions or the Korro Bio Equity Value to the holders of any class of securities, creditors or other constituencies of Frequency or Korro Bio. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financial Analyses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary of the financial analyses described below under this heading &#8220;&#8212;<span style="font-style:italic">Financial Analyses</span>&#8221; is a summary of the material financial analyses performed by TD Cowen to arrive at its opinion. Some of the summaries of TD Cowen&#8217;s financial analyses include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data set forth in the tables without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses. TD Cowen performed certain procedures, including each of the financial analyses described below, and reviewed with the Frequency board of directors certain assumptions on which such analyses were based and other factors, including the historical and projected financial results of Korro Bio. Approximate implied equity value reference ranges derived from the financial analyses described below were rounded to the nearest $5&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selected Publicly Traded Companies Analysis.</span> TD Cowen reviewed selected financial and stock market information of Korro Bio and certain biotechnology companies, the securities of which are publicly traded, with technology platforms addressing genetically determined diseases and that TD Cowen<span style="font-weight:bold"> </span>considered generally relevant for purposes of analysis (collectively, the &#8220;selected companies&#8221;). These companies were: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Avidity Biosciences, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Dyne Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Entrada Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PepGen Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Prime Medicine, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ProQR Therapeutics N.V. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Stoke Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Verve Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Voyager Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Wave Life Sciences Ltd. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial data reviewed included estimated enterprise values, calculated as implied equity values based on closing stock prices on July&#160;12, 2023 plus total debt and less cash and cash equivalents. Financial data of the selected companies were based on publicly available Wall Street research analysts&#8217; estimates, public filings and other publicly available information. Financial data of Korro Bio was based on financial information prepared by the management of Korro Bio. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall low to high estimated enterprise values observed for the selected companies was approximately $(3) million to $1,326&#160;million (with a 25th percentile of $145&#160;million, a 75th percentile of $416&#160;million and a median of $209 million). TD Cowen then selected a range of enterprise values derived from the selected companies of $145&#160;million to $415&#160;million. This analysis indicated the following approximate implied equity value reference range for Korro Bio, as compared to the Korro Bio Equity Value: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Approximate Implied Equity Value Reference Range</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00px solid #000000;vertical-align:bottom">Korro&#160;Bio&#160;Equity&#160;Value</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">$225&#160;million &#8211; $495&#160;million</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">325,639,194.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the selected companies were used for comparison purposes, none of those companies is directly comparable to Korro Bio. Accordingly, an analysis of the results of such a comparison is not purely mathematical, but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies and other factors that could affect the public trading values of the selected companies. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Discounted Cash Flow Analysis.</span> TD Cowen performed a discounted cash flow analysis of Korro Bio by calculating the estimated present value of the standalone unlevered, <span style="white-space:nowrap">after-tax</span> free cash flows that Korro Bio was forecasted to generate during the fiscal years ending December&#160;31, 2023 through December&#160;31, 2045 based on the Korro Bio forecasts (inclusive of the impact of Korro Bio&#8217;s potential net operating loss carryforwards per the management of Korro Bio). For purposes of this analysis, stock-based compensation was treated as a cash expense. TD Cowen calculated implied terminal values for Korro Bio by applying to Korro Bio&#8217;s estimated unlevered, <span style="white-space:nowrap">after-tax</span> free cash flows for the fiscal year ending December&#160;31, 2045 a perpetuity growth rate of (33)% and a selected range of probability of success rates of 10% to 20%. The present values of the cash flows and terminal values were then calculated using a selected range of discount rates of 14% to 16%. This analysis indicated the following approximate implied equity value reference range for Korro Bio, as compared to the Korro Bio Equity Value: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Approximate Implied Equity Value Reference Range</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00px solid #000000;vertical-align:bottom">Korro&#160;Bio&#160;Equity&#160;Value</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">$185&#160;million &#8211; $670&#160;million</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">325,639,194.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Miscellaneous </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary set forth above does not purport to be a complete description of all the analyses performed by TD Cowen. The preparation of a fairness opinion involves various determinations as to the most appropriate and relevant methods of financial analysis and the application of these methods to the particular circumstances and, therefore, such an opinion is not readily susceptible to partial analysis or summary description. TD Cowen did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Accordingly, notwithstanding the separate factors summarized above, TD Cowen believes that its analyses must be considered as a whole and that selecting portions of its analyses and the factors considered by it, without considering all analyses and factors, could create an incomplete view of the process underlying its opinion. In performing its analyses, TD Cowen made numerous assumptions with respect to industry performance, business and economic conditions and other matters, many of which are beyond the control of Frequency and Korro Bio. The analyses performed by TD Cowen are not necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by such analyses. In addition, analyses relating to the value of businesses do not purport to be appraisals or to reflect the prices at which businesses or securities may actually be sold. Accordingly, such analyses and estimates are inherently subject to uncertainty and are based upon numerous factors or events beyond the control of the parties or their respective advisors. None of Frequency, Korro Bio, TD Cowen or any other person assumes responsibility if future results are materially different from those projected. The analyses performed by TD Cowen and its opinion were only one among many factors taken into consideration by the Frequency board of directors in evaluating the Korro Bio Equity Value and should not be considered as determinative of the views of the Frequency board of directors or Frequency management with respect to the Merger, the Korro Bio Equity Value or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen was selected by Frequency to act as financial advisor to Frequency in connection with the Merger because TD Cowen is a nationally recognized investment banking firm and because, as part of its investment banking business, TD Cowen is continually engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen is acting as financial advisor to Frequency in connection with the Merger and will receive from Frequency for such services an aggregate fee of $2.0&#160;million, of which a portion was payable in connection with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TD Cowen&#8217;s opinion and $1.5&#160;million is payable contingent upon consummation of the Merger. In addition, Frequency has agreed to reimburse TD Cowen&#8217;s expenses, including fees and expenses of counsel, and indemnify TD Cowen for certain liabilities, including liabilities under federal securities laws, that may arise out of TD Cowen&#8217;s engagement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although TD Cowen has not had a material relationship with Frequency unrelated to the Merger or Korro Bio during the two years preceding the date of TD Cowen&#8217;s opinion, TD Cowen in the future may provide services to Frequency, Korro Bio and/or their respective affiliates and may receive compensation for the rendering of such services. In addition, in the ordinary course of its business, TD Cowen and its affiliates may actively trade the securities of Frequency and/or its affiliates for their own account and for the accounts of their customers, and, accordingly, may at any time hold a long or short position in such securities. The issuance of TD Cowen&#8217;s opinion was approved by TD Cowen&#8217;s fairness opinion review committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_41">Certain Unaudited Financial Projections for Korro Bio </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a matter of course, Korro Bio does not publicly disclose long-term projections of future financial performance given among other things, the inherent difficulty of predicting financial performance for future periods and the possibility that the underlying assumptions and estimates may not be realized. However, in connection with the exploration of strategic opportunities described in the this proxy statement/prospectus, Korro Bio management prepared certain <span style="white-space:nowrap">non-public,</span> unaudited projections of financial performance for Korro Bio, which were provided to Frequency and adjusted by Frequency as further detailed in this section, or the Korro Bio Projections, based on its view of the prospects of Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio Projections did not give effect to any changes or expenses as a result of the Merger or any other effects of the Merger or any impact should the Merger fail to be consummated. The Korro Bio Projections were prepared solely for internal use and are subjective in many respects. As a result, there can be no assurance that the forecasted results will be realized or that actual results will not be significantly higher or lower than estimated. The estimates and assumptions underlying the Korro Bio Projections involve judgments with respect to, among other things, future economic, competitive, regulatory and financial market conditions that may not materialize and are inherently subject to significant uncertainties and contingencies, all of which are difficult to predict and many of which are beyond Korro Bio&#8217;s control. There can be no assurance that the Korro Bio Projections will be realized and actual results may vary materially from those shown. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospective financial information included in this proxy statement/prospectus was not prepared with a view toward public dissemination or compliance with published guidelines of the SEC or established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information or generally accepted accounting principles, or GAAP, but, in the view of Korro Bio management, was prepared on a reasonable basis, reflected, at the time the prospective financial information was prepared, the best currently available estimates and judgments of Korro Bio management, and presented, to the best of Korro Bio management&#8217;s knowledge and belief at that time, the expected course of action and the expected future financial performance of Korro Bio. However, this information is not fact and should not be relied upon as necessarily predictive of actual future results and readers of this proxy statement/prospectus are cautioned not to place undue reliance, if any, on the prospective financial information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio Projections are included in this proxy statement/prospectus solely to give Frequency&#8217;s and Korro Bio&#8217;s stockholders access to certain long-term financial analyses and forecasts that were made available to Frequency and its financial advisor, and is not included in this proxy statement/prospectus to influence a Frequency stockholder&#8217;s decision whether to vote for the Merger Proposal or for any other purpose. The inclusion of the Korro Bio Projections in this proxy statement/prospectus does not constitute an admission or representation that the information is material. The inclusion of the Korro Bio Projections should not be regarded as an indication that Korro Bio and/or its affiliates, officers, directors, advisors or other representatives consider the Korro Bio Projections to be necessarily predictive of actual future events and this information should not be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relied upon as such. None of Korro Bio, Frequency and/or their respective affiliates, officers, directors, advisors or other representatives gives any stockholder of Frequency or Korro Bio any assurance that actual results will not differ materially from the Korro Bio Projections. The Korro Bio Projections do not take into account any circumstances, transactions or events occurring after the date on which they were prepared. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KORRO BIO HAS NOT UPDATED AND, EXCEPT AS REQUIRED BY APPLICABLE LAW, DOES NOT INTEND TO UPDATE OR OTHERWISE REVISE THE KORRO BIO PROJECTIONS TO REFLECT CIRCUMSTANCES EXISTING AFTER THE DATE WHEN MADE OR TO REFLECT THE OCCURRENCE OF FUTURE EVENTS, EVEN IN THE EVENT THAT ANY OR ALL OF THE ASSUMPTIONS UNDERLYING SUCH PROSPECTIVE FINANCIAL INFORMATION ARE NO LONGER APPROPRIATE. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the measures included in the Korro Bio Projections may be considered <span style="white-space:nowrap">non-GAAP</span> financial measures. <span style="white-space:nowrap">Non-GAAP</span> financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and <span style="white-space:nowrap">non-</span> GAAP financial measures as used by Korro Bio may not be comparable to similarly titled amounts used by other companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial measures provided to a financial advisor are excluded from the definition of <span style="white-space:nowrap">non-GAAP</span> financial measures and therefore, are not subject to SEC rules regarding disclosures of <span style="white-space:nowrap">non-GAAP</span> financial measures, which would otherwise require a reconciliation of a <span style="white-space:nowrap">non-GAAP</span> financial measure to a GAAP financial measure. Reconciliations of <span style="white-space:nowrap">non-GAAP</span> financial measures were not relied upon by the Frequency Board in connection with its consideration of the Merger or by TD Cowen for purposes of its financial analyses. Accordingly, Korro Bio has not provided a reconciliation of the <span style="white-space:nowrap">non-GAAP</span> financial measures included in the Korro Bio Projections. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the foregoing and other reasons, readers of this proxy statement/prospectus are cautioned that the inclusion of a summary of the Korro Bio Projections in this proxy statement/prospectus should not be regarded as a representation or guarantee that the targets will be achieved nor that they should place undue reliance, if any, on the Korro Bio Projections. The Korro Bio Projections constitute forward-looking statements and are subject to risks and uncertainties that could cause actual results to differ materially from the projected results. See also &#8220;<span style="font-style:italic">Cautionary Statement Concerning Forward-Looking Statements</span>&#8221; beginning on page 1 of this proxy statement/prospectus. The Korro Bio Projections are also subject to many risks and uncertainties and you are urged to review the section entitled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 32 of this proxy statement/prospectus for a description of risk factors relating to the Merger and Korro Bio&#8217;s business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio Projections are based on numerous variables and assumptions that were deemed reasonable as of the date on which such projections were finalized, including, among other things, the following material assumptions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">net sales consisting only of sales of Korro Bio&#8217;s product candidate for AATD in the United States and the United Kingdom, Germany, France, Spain and Italy, or collectively, the EU5; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a PiZZ genotype AATD population of approximately 100,000 in the United States and approximately 125,000 in the EU5 of which approximately 35% are estimated to be symptomatic patients and assuming a continued increase in treatable patients with growing awareness of AATD and diagnosis rate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a PiMZ genotype AATD population of approximately 6.2 million in the United States and approximately 6.9 million in the EU5 of which approximately 10% are estimated to be symptomatic patients and assuming treatable patients continue to increase over time; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2030 launch for a product to treat the PiZZ genotype of AATD and 2032 for a product to treat the PiMZ genotype of AATD in the United States and 2032 for both products in the EU5. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio Projections were adjusted by Frequency management (i) to apply to estimated unlevered free cash flow for the fiscal year ending December 31, 2045 a perpetuity growth rate of negative 33%, (ii) to apply a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
selected range of probability of success rate of 10% to 20%, (iii) to made certain adjustments to stock-based compensation expense for the fiscal years ending December 31, 2023, 2024 and 2025 and (iv) to apply a growth rate to stock-based compensation expense of 3% until a loss-of-exclusivity date of 2043 for the United States and 2044 for the EU5 and a proportional decrease based on revenue after such dates, or (i) through (iv) collectively, the Frequency Adjustments. The Korro Bio Projections as adjusted by Frequency management were provided to TD Cowen for its use and reliance in connection with its financial analyses and opinion described above in &#8220;<span style="font-style:italic">Opinion of Frequency&#8217;s Financial Advisor</span>&#8221; beginning on page 171. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of the Korro Bio Projections prepared by Korro Bio management, as adjusted by the Frequency Adjustments made by Frequency management. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">($ in millions)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2025E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2026E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2027E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2028E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2029E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2030E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2031E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2032E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2033E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2034E</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Total Adjusted Revenue<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">-</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">-</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">-</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">-</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">-</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">-</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">-</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">32</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">91</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">221</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">367</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">536</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Earnings Before Interest and Taxes<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">77</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">80</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">69</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">27</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">125</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">233</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">358</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPAT<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">77</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">80</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">69</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">118</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">167</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">254</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Unlevered Free Cash Flow<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">73</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">82</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">58</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">64</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">32</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">($</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">105</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">153</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">237</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:94%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">($ in millions)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2035E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2036E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2037E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2038E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2039E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2040E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2041E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2042E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2043E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2044E</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2045E</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Total Adjusted Revenue<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">662</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">734</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">799</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">813</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">827</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">841</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">855</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">870</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">713</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">486</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">331</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Earnings Before Interest and Taxes<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">442</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">491</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">536</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">546</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">555</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">565</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">575</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">585</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">473</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">312</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">201</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPAT<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">314</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">349</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">381</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">387</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">394</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">401</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">408</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">415</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">336</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">222</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">143</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Unlevered Free Cash Flow<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">301</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">342</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">374</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">386</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">393</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">400</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">407</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">414</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">351</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">244</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Equal to total risk-adjusted global net sales. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Earnings before interest and taxes is defined as total adjusted revenue less cost of goods sold, research and development expense, sales and marketing expense, general and administrative expense and stock-based compensation. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">NOPAT is Net Operating Profits After Taxes and is defined as EBIT less taxes. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Unlevered free cash flow is defined as earnings before interest and taxes, less tax expense (if profitable), plus depreciation and amortization, less capital expenditures, and less change in net working capital. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_42">Interests of Frequency Directors and Executive Officers in the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Frequency board of directors with respect to issuing shares of Frequency common stock in the Merger and the other matters to be acted upon by the Frequency stockholders at the Frequency Annual Meeting, Frequency stockholders should be aware that the directors and executive officers of Frequency have interests in the Merger that may be different from, or in addition to, the interests of Frequency stockholders generally. These interests may present such directors and executive officers with actual or potential conflicts of interest, and these interests, to the extent material, are described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors was aware of and considered these potential conflicts of interest, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Frequency stockholders approve the proposals to be presented to the stockholders for consideration at the Frequency Annual Meeting as contemplated in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_43"><span style="font-style:italic">Ownership Interests </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023, Frequency&#8217;s <span style="white-space:nowrap">non-employee</span> directors and executive officers beneficially owned, in the aggregate, approximately 2.21% of the shares of Frequency common stock, excluding any shares of Frequency common stock issuable upon exercise or settlement of stock options, restricted stock units or performance stock units held by such individuals. The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual meeting by the holders entitled to vote thereon, assuming a quorum is present, is required for approval of Proposal Nos. 1, 4, 5, 6 and 7. The affirmative vote of the holders of a majority of the outstanding shares of Frequency common stock entitled to vote at the Frequency Annual </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting is required for approval of Proposal No.&#160;2. The plurality of the votes cast by the holders of shares present in attendance or represented by proxy at the Frequency Annual Meeting and entitled to vote on the matter, assuming a quorum is present, is required for approval of Proposal No.&#160;3. David L. Lucchino, Christopher R. Loose and each of Frequency&#8217;s <span style="white-space:nowrap">non-employee</span> directors have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Support Agreements</span>&#8221; beginning on page 212 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_44"><span style="font-style:italic">Treatment of Frequency Equity Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Frequency Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding option to purchase shares of Frequency common stock, which is referred to as a Frequency Option, that is outstanding and unvested will vest in full immediately prior to the Effective Time, including those Frequency Options held by Frequency&#8217;s executive officers and <span style="white-space:nowrap">non-employee</span> directors. The number of shares of Frequency common stock underlying such options and the exercise price of such options will be adjusted in accordance with Frequency&#8217;s 2019 Incentive Award Plan or 2014 Stock Incentive Plan, as applicable, to reflect the proposed Reverse Stock Split, as described under &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split&#8211;Principal Effects of the Reverse Stock Split&#8211;Equity Compensation Plans and Outstanding Equity-Based Awards</span>&#8221; on page 239 of this proxy statement/prospectus, and the issuance of the CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency estimates that the aggregate amount that would be payable, net of exercise price, to Frequency&#8217;s executive officers and non-employee directors as a group if they exercised their Frequency Options, whether vested or unvested, and immediately sold the Frequency common stock acquired upon exercise is $0. None of Frequency&#8217;s executive officers or non-employee directors hold Frequency Options for which the exercise price is less than $0.62, which is the average closing trading price of Frequency common stock over the first five business days following the first public announcement of the transactions contemplated by the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth information regarding the Frequency Options held as of July 14, 2023 by each person who is or has been during the period beginning on January&#160;1, 2022 through the date of this proxy statement/prospectus, an executive officer or <span style="white-space:nowrap">non-employee</span> director of Frequency. The number of shares of Frequency common stock underlying such options and the exercise price of such options will be adjusted in accordance with Frequency&#8217;s 2019 Incentive Award Plan or 2014 Stock Incentive Plan, as applicable, to reflect the proposed Reverse Stock Split, as described under &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split&#8211;Principal Effects of the Reverse Stock Split&#8211;Equity Compensation Plans and Outstanding Equity-Based Awards</span>&#8221; on page 239 of this proxy statement/prospectus, and the issuance of the CVRs. Depending on when the Effective Time occurs, certain options shown in the table may vest in accordance with their terms prior to the Effective Time. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:56%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />Vested<br />Options</span><br /><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value<br />of&#160;Vested<br />Options</span><br /><span style="font-weight:bold">($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />Unvested<br />Options</span><br /><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value&#160;of<br />Unvested<br />Options</span><br /><span style="font-weight:bold">($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,644,039</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">149,967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher R. Loose</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">974,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quentin McCubbin(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,374</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carl P. LeBel(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter P. Pfreundschuh(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy S. Arnold(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">157,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:56%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />Vested<br />Options</span><br /><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value<br />of&#160;Vested<br />Options</span><br /><span style="font-weight:bold">($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br />Unvested<br />Options</span><br /><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value&#160;of<br />Unvested<br />Options</span><br /><span style="font-weight:bold">($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">387,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy J. Barberich</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Huang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia L. Feldmann</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joel S. Marcus(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc A. Cohen(7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The estimated value of Frequency Options is the excess, if any, of (i) $0.62, which is the average closing trading price of Frequency common stock over the first five business days following the first public announcement of the transactions contemplated by the Merger Agreement on July 14, 2023, over (ii)&#160;the exercise price of the Frequency Option, multiplied by the number of shares underlying the vested or unvested portion, as applicable, of the Frequency Option as of July 14, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;McCubbin, Frequency&#8217;s former Chief Manufacturing Officer, terminated employment with Frequency on June&#160;9, 2023, but continues to provide services to Frequency under a consulting agreement, dated June&#160;10, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;LeBel, Frequency&#8217;s former Chief Development Officer, terminated employment with Frequency on March&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Pfreundschuh, Frequency&#8217;s former Chief Financial Officer, terminated employment with Frequency on March&#160;31, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Arnold, Frequency&#8217;s former Chief People Officer, terminated employment with Frequency on March&#160;31, 2023, but continues to provide services to Frequency under a consulting agreement, dated April&#160;1, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Marcus resigned as a member of Frequency&#8217;s board of directors on May&#160;5, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Cohen&#8217;s term on Frequency&#8217;s board of directors ended in June 2022. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Frequency Restricted Stock Units and Frequency Performance Stock Units </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each restricted stock unit award covering shares of Frequency common stock that vests solely based on the holder&#8217;s continued employment or service, which is referred to as a Frequency Restricted Stock Unit, that is outstanding and unvested will vest in full immediately prior to the Effective Time, including those Frequency Restricted Stock Units held by Frequency&#8217;s executive officers. Each restricted stock unit award covering shares of Frequency common stock that does not vest solely based on the holder&#8217;s continued employment or service, including each such award that is subject to performance-vesting conditions, which is referred to as a Frequency Performance Stock Unit, that is outstanding and unvested immediately prior to the Effective Time will remain outstanding and subject to the same terms and conditions (including the same vesting terms and conditions) as were applicable under Frequency&#8217;s 2019 Incentive Award Plan after the Effective Time. The Frequency Restricted Stock Units and the Frequency Performance Stock Units will be adjusted in accordance with Frequency&#8217;s 2019 Incentive Award Plan to reflect the issuance of the CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of each executive officer&#8217;s employment or letter agreement, in the event such executive officer&#8217;s employment is terminated by Frequency without cause or by the executive officer for good reason within 12 months after the Merger, the outstanding Frequency Performance Stock Units that are outstanding and unvested will vest in full (or, in the case of Mr.&#160;Lucchino, at target level of achievement) immediately prior to the executive officer&#8217;s termination or resignation. The number of shares of Frequency common stock underlying the Frequency Restricted Stock Units and Frequency Performance Stock Units will be adjusted to reflect the proposed Reverse Stock Split, as described under &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split&#8212;Principal Effects of the Reverse Stock Split&#8212;Equity Compensation Plans and Outstanding Equity-Based Awards</span>&#8221; beginning on page&#160;239 of this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency estimates that the aggregate value of the shares of Frequency common stock that would be payable to Frequency&#8217;s executive officers as a group upon vesting and settlement of the Frequency Restricted Stock Units and Frequency Performance Stock Units is $361,731 and $454,498, respectively. The amounts above are determined using a per share Frequency stock price of $0.62, which is the average closing trading price of Frequency common stock over the first five business days following the first public announcement of the transactions contemplated by the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth information regarding the Frequency Restricted Stock Units and Frequency Performance Stock Units held as of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023 by each person who is or has been during the period beginning on January&#160;1, 2022 and the date of this proxy statement/prospectus, an executive officer of Frequency. Frequency&#8217;s <span style="white-space:nowrap">non-employee</span> directors did not hold any Frequency Restricted Stock Units or Frequency Performance Stock Units as of such date. The Frequency Restricted Stock Units and Frequency Performance Stock Units will be adjusted in accordance with Frequency&#8217;s 2019 Incentive Award Plan to reflect the proposed Reverse Stock Split, as described under &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2: Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split&#8212;Principal Effects of the Reverse Stock Split&#8212;Equity Compensation Plans and Outstanding Equity-Based Awards&#8221;</span> beginning on page&#160;239 of this proxy statement/prospectus, and the issuance of the CVRs. Depending on when the Effective Time occurs, certain Frequency Restricted Stock Units and Frequency Preferred Stock Units shown in the table may vest in accordance with their terms prior to the Effective Time. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:52%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Unvested<br />Restricted<br />Stock<br />Units</span><br /><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value of<br />Unvested<br />Restricted<br />Stock<br />Units</span><br /><span style="font-weight:bold">($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Unvested<br />Performance<br />Stock Units</span><br /><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value of</span><br /><span style="font-weight:bold">Unvested<br />Performance<br />Stock Units</span><br /><span style="font-weight:bold">($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><span style="font-weight:bold">Executive Officers</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">280,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">174,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">186,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Christopher R. Loose</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">105,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">65,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">124,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Quentin McCubbin(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">105,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">65,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">120,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">74,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Carl P. LeBel(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Peter P. Pfreundschuh(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Wendy S. Arnold(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">91,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">56,657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">68,486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The estimated value of each unvested Frequency Restricted Stock Unit and Frequency Performance Stock Unit is $0.62, which is the average closing trading price of Frequency common stock over the first five business days following the first public announcement of the transactions contemplated by the Merger Agreement on July&#160;14, 2023. The Frequency Performance Stock Units vest in one installment upon a determination by Frequency&#8217;s board of directors of the completion of a bona fide, third-party security financing transaction in which Frequency receives gross proceeds of at least $25&#160;million that occurs on or before December&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;McCubbin, Frequency&#8217;s former Chief Manufacturing Officer, terminated employment with Frequency on June&#160;9, 2023, but continues to provide services to Frequency under a consulting agreement, dated June&#160;10, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;LeBel, Frequency&#8217;s former Chief Development Officer, terminated employment with Frequency on March&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Pfreundschuh, Frequency&#8217;s former Chief Financial Officer, terminated employment with Frequency on March&#160;31, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Arnold, Frequency&#8217;s former Chief People Officer, terminated employment with Frequency on March&#160;31, 2023, but continues to provide services to Frequency under a consulting agreement, dated April&#160;1, 2023. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Frequency Employee Stock Purchase Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency sponsors its 2019 Employee Stock Purchase Plan, which is referred to as the Frequency ESPP, in which executive officers and other employees are eligible to participate. The Merger Agreement provides that, as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
soon as practicable after the date of the Merger Agreement, Frequency&#8217;s board of directors will adopt resolutions to provide that (a)&#160;no offering periods or purchase periods will begin after or in addition to the offering period underway as of the date of the Merger Agreement under the Frequency ESPP, (b)&#160;no payroll deductions or other contributions will be made or effected after the current offering period with respect to the Frequency ESPP, and (c)&#160;each Frequency ESPP participant&#8217;s accumulated contributions under the Frequency ESPP will be returned to the participant in accordance with the terms of the Frequency ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Employment Arrangements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">David L. Lucchino</span>. Frequency is party to a second amended and restated executive employment agreement with Mr.&#160;Lucchino. Under the employment agreement, in the event Mr.&#160;Lucchino is terminated by Frequency without &#8220;cause&#8221;, or if he resigns for &#8220;good reason&#8221;, on or within 12 months following a &#8220;change in control&#8221; (as such terms are defined his employment agreement), he will be entitled to (i)&#160;base salary continuation for a period of 18 months, (ii) 100% of his target annual bonus, and (iii)&#160;all equity awards held by Mr.&#160;Lucchino will accelerate and vest (including performance vesting awards, which will vest at target level of achievement). To the extent Mr.&#160;Lucchino is covered under Frequency&#8217;s health plan at the time of such termination or resignation, Frequency is required to pay the employer&#8217;s portion of Consolidated Omnibus Budget Reconciliation Act of 1985, or COBRA, premium payments for Mr.&#160;Lucchino and his covered dependents through the severance period. The severance payments and benefits provided under the employment agreement are subject to Mr.&#160;Lucchino&#8217;s execution and <span style="white-space:nowrap">non-revocation</span> of a release of claims in favor of Frequency and continued compliance with certain restrictive covenants described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Christopher R. Loose, Ph.D.</span> Frequency is party to an amended and restated employment agreement with Dr.&#160;Loose. In the event Dr.&#160;Loose is terminated by Frequency without &#8220;cause&#8221;, or if he resigns for &#8220;good reason&#8221;, within 12 months following a &#8220;change in control&#8221; (as such terms are defined his employment agreement), he will be entitled to (i)&#160;base salary continuation for a period of 12 months, (ii)&#160;an amount equal to 100% of his target annual bonus, and (iii)&#160;his unvested equity incentive awards will vest immediately prior to such termination or resignation. To the extent Dr.&#160;Loose is covered under Frequency&#8217;s health plan at the time of such termination or resignation, Frequency is required to pay the employer&#8217;s portion of COBRA premium payments for Dr.&#160;Loose and his covered dependents through the severance period. The severance payments and benefits provided under the employment agreement are subject to Dr.&#160;Loose&#8217;s execution and <span style="white-space:nowrap">non-revocation</span> of a release of claims in favor of Frequency and continued compliance with certain restrictive covenants described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the executive officers have entered into restrictive covenant agreements with Frequency that generally contain <span style="white-space:nowrap">12-month</span> post-employment <span style="white-space:nowrap">non-competition</span> and <span style="white-space:nowrap">non-solicitation</span> covenants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drs. LeBel and McCubbin, Mr.&#160;Pfreundschuh, and Ms.&#160;Arnold each previously terminated employment with Frequency and none of them are entitled to receive compensatory payments in connection with the Merger; however, Dr.&#160;McCubbin and Ms.&#160;Arnold&#8217;s Frequency equity awards, including Frequency Options and Frequency Restricted Stock Units, shall continue to vest in accordance with their terms until the termination of their consulting agreements, dated June 10, 2023 and May&#160;1, 2023, respectively, collectively referred to herein as the Consulting Agreements. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Consulting Agreements, Dr. McCubbin and Ms. Arnold provide counsel and support as requested on manufacturing and operational and employee matters, respectively, for a fee of $300 per hour, not to exceed 15 hours per month for Dr. McCubbin or 12 hours per month for Ms. Arnold, in each case, without the prior written consent of Mr. Lucchino. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Position Following the Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Lucchino is currently a director of Frequency and will continue as a director of the combined company after the Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_45">Interests of Korro Bio Directors and Executive Officers in the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Korro Bio board of directors with respect to approving the Merger, stockholders should be aware that certain members of Korro Bio&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Korro Bio stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of Korro Bio was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Korro Bio stockholders approve the Merger as contemplated by this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ownership Interests </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July 24, 2023, Korro Bio&#8217;s <span style="white-space:nowrap">then-current&#160;non-employee&#160;directors</span> and executive officers beneficially owned, in the aggregate, approximately 3.85% of the shares of Korro Bio capital stock, which for purposes of this subsection&#160;excludes any Korro Bio shares issuable upon exercise of Korro Bio stock options held by such individuals. Such shares of Korro Bio capital stock will be converted into shares of Frequency common stock at the Effective Time. Each of Korro Bio&#8217;s officers, directors and affiliated stockholders have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section&#160;titled &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Support Agreements</span>&#8221; beginning on page&#160;212 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s directors and executive officers currently hold options, subject to vesting, to purchase shares of Korro Bio common stock. At the Effective Time, each option to purchase Korro Bio common stock that is outstanding and unexercised immediately prior to the Effective Time under the Korro Bio, Inc. 2019 Stock Incentive Plan, which has been amended and restated from time to time and was most recently amended in March 2023, or the Korro Bio 2019 Plan, whether or not vested, will be converted into an option to purchase Frequency common stock. Frequency will assume the Korro Bio 2019 Plan. All rights with respect to Korro Bio common stock under Korro Bio options assumed by Frequency will be converted into rights with respect to Frequency common stock. Accordingly, from and after the Effective Time, each Korro Bio stock option assumed by Frequency may be exercised for such number of shares of Frequency common stock as is determined by multiplying the number of shares of Korro Bio common stock subject to the option by the exchange ratio formula in the Merger Agreement and rounding that result down to the nearest whole number of shares of Frequency common stock. The per share exercise price of the converted option will be determined by dividing the existing exercise price of the option by the exchange ratio formula in the Merger Agreement and rounding that result up to the nearest whole cent. Any restrictions on the exercise of any Korro Bio option assumed by Frequency will continue following the conversion and the term, exercisability, vesting schedules and other provisions of assumed Korro Bio options will generally remain unchanged. The table below sets forth certain information with respect to such options, without giving effect to the conversion and assumption of the Korro Bio options at the Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table details the outstanding options held by Korro Bio&#8217;s directors and executive officers as of July 24, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:71%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-style:italic"></span><span style="font-weight:bold"><span style="font-style:italic">Executive Officers</span></span><span style="font-style:italic"></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of<br />Common<br />Stock<br />Underlying<br />Options (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Volume<br />Weighted<br />Average<br />Option<br />Exercise<br />Price ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Aiyar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,088,195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">0.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vineet Agarwal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">994,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Chappell</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">477,443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">0.79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve Colletti</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,044,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.09</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shelby Walker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">477,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.09</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Directors</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nessan Bermingham</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,846,992</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">0.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omar Khwaja</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ali Behbahani</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hannah Chang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Francois Formela</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Colin Walsh</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Management Following the Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described elsewhere in this proxy statement/prospectus, including in the section&#160;captioned &#8220;<span style="font-style:italic">Management Following the Merger</span>,&#8221; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of Korro Bio&#8217;s directors and all of Korro Bio&#8217;s executive officers are expected to become the directors and executive officers, respectively, of the combined company upon the closing of the Merger, in connection with which they may enter into new employment agreements to reflect their status as executive officers of a publicly-traded company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Indemnification and Insurance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the indemnification and insurance provisions related to the Frequency directors and officers under the Merger Agreement, please see the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page&#160;205 <span style="text-decoration:underline"></span>below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee Interlocks and Insider Participation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing, the combined company&#8217;s board of directors is expected to select members of the compensation committee. Each member of the compensation committee is expected to be a <span style="white-space:nowrap">&#8220;non-employee&#8221;</span> director within the meaning of <span style="white-space:nowrap">Rule&#160;16b-3&#160;of</span> the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. None of the proposed combined company&#8217;s executive officers serves as a member of the board of directors or compensation committee of any entity that has one or more executive officers who is proposed to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Director Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&#160;31, 2022, Korro Bio did not have a formal <span style="white-space:nowrap">non-employee</span> director compensation program; however, Korro Bio has provided certain <span style="white-space:nowrap">non-employee</span> directors with cash retainers for their services as members of the board of directors. Following completion of the Merger, it is expected that the combined company will provide compensation to <span style="white-space:nowrap">non-employee</span> directors pursuant to a new <span style="white-space:nowrap">non-employee</span> director compensation policy that is expected to be adopted post-closing, and which will be designed to enable the combined company to attract and retain, on a long-term basis, highly qualified <span style="white-space:nowrap">non-employee</span> directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2023 Stock Option and Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;, Frequency&#8217;s board of directors, subject to stockholder approval and the closing, adopted the 2023 Stock Option and Incentive Plan, or the 2023 Plan. If Frequency&#8217;s stockholders approve the 2023 Plan, it will become effective upon the closing of the Merger. For a summary of the 2023 Plan, see Proposal No. 5 in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2023 Employee Stock Purchase Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , Frequency&#8217;s board of directors, subject to stockholder approval and the closing, adopted the 2023 Employee Stock Purchase Plan, or the 2023 ESPP. If Frequency&#8217;s stockholders approve the Frequency 2023 ESPP, it will become effective upon the closing of the Merger. For a summary of the 2023 ESPP, see Proposal No. 6 in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_300">Indemnification and Insurance for Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, from the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, Frequency and the surviving corporation in the merger agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the Effective Time, a director or officer of Frequency or Korro Bio, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of Frequency or of Korro Bio, whether asserted or claimed prior to, at or after the Effective Time. From and after the Effective Time, Frequency and the surviving corporation in the Merger will also fulfill Frequency&#8217;s and Korro Bio&#8217;s indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the Effective Time, a director or officer of Frequency or Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that the provisions of the amended and restated certificate of incorporation and amended and restated bylaws of Frequency with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Frequency that are presently set forth in the amended and restated certificate of incorporation and amended and restated bylaws of Frequency will not be amended modified or repealed for a period of six years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Frequency, unless such modification is required by applicable law. The amended and restated certificate of incorporation and amended and restated bylaws of the surviving corporation will contain, and Frequency will cause the amended and restated certificate of incorporation and amended and restated bylaws of the surviving corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the amended and restated certificate of incorporation and amended and restated bylaws of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the Effective Time, Frequency will maintain director and officers&#8217; liability insurance policies, with an effective date as of the closing date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Frequency. In addition, Frequency will secure and purchase a six year &#8220;tail policy&#8221; on Frequency&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_46">Effective Time of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;(2) business days unless any conditions remain unsatisfied or unwaived) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including the adoption of the Merger Agreement by the Korro Bio stockholders and the approval by the Frequency stockholders of the issuance of Frequency common stock and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The Merger will become effective upon the filing of a certificate of merger with the Secretary of State of the State of Delaware or at such later time as is agreed by Frequency and Korro Bio and specified in the certificate of merger. Neither Frequency nor Korro Bio can predict the exact timing of the consummation of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_47">Regulatory Approvals </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, Frequency must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of Frequency common stock to Korro Bio&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC. Frequency does not intend to seek any regulatory approval from antitrust authorities to consummate the transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_48">Anticipated Accounting Treatment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is expected to be treated by Frequency as a reverse merger and will be accounted for as a reverse recapitalization in accordance with U.S.&#160;GAAP. For accounting purposes, Korro Bio is considered to be acquiring the assets and liabilities of Frequency in this transaction based on the terms of the Merger Agreement and other factors, including: (i) Korro Bio&#8217;s stockholders will own a substantial majority of the voting rights of the combined company; (ii) Korro Bio will designate a majority (4 of 7) of the initial members of the board of directors of the combined company; (iii)&#160;Korro Bio&#8217;s executive management team will become the management of the combined company; and (iv)&#160;the combined company will be named Korro Bio, Inc. and be headquartered in Cambridge, MA. See the &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_49">Nasdaq Stock Market Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Frequency common stock are currently listed on Nasdaq under the symbol &#8220;FREQ.&#8221; Frequency has agreed to use commercially reasonable efforts to cause the shares of Frequency common stock being issued in the Merger to be approved for listing (subject to notice of issuance) on Nasdaq at or prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Merger Agreement, each of Frequency&#8217;s and Korro Bio&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the Merger, of various conditions, including that the shares of Frequency common stock to be issued in the Merger have been approved for listing (subject to official notice of issuance) on Nasdaq as of the closing of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Nasdaq Listing Application is accepted, Frequency anticipates that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;KRRO.&#8221; As of July&#160;26<span style="text-decoration:underline"></span>, 2023, the closing stock price of Frequency common stock was $0.54<span style="text-decoration:underline"></span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_50">Appraisal Rights and Dissenters&#8217; Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, Frequency stockholders are not entitled to appraisal rights in connection with the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below is not a complete summary regarding Korro Bio stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as<span style="font-style:italic"> Annex K.</span> Stockholders intending to exercise appraisal rights should carefully review<span style="font-style:italic"> Annex&#160;K</span>. Failure to follow precisely any of the statutory procedures set forth in<span style="font-style:italic"> Annex K</span> may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Korro Bio stockholders exercise their appraisal rights under Delaware law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&#160;262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within ten days after the effective date of such merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger is completed, within ten days after the effective date of the Merger, Korro Bio will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of Korro Bio common stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to Korro Bio within 20 days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform Korro Bio of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Korro Bio common stock held by such stockholder. Failure to deliver a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to Korro Bio, Inc., c/o Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210, Attention: Kingsley Taft, and should be executed by, or on behalf of, the record holder of shares of Korro Bio common stock. ALL DEMANDS MUST BE RECEIVED BY KORRO BIO WITHIN 20 DAYS AFTER THE DATE KORRO BIO MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the merger consideration for your shares of Korro Bio common stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Korro Bio common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be effective, a demand for appraisal by a holder of shares of Korro Bio common stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Korro Bio. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">187 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold your shares of Korro Bio common stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time within 60 days after the Effective Time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Korro Bio. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the merger consideration for your shares of Korro Bio common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 120 days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within ten days after the stockholder&#8217;s written request is received by the surviving corporation or within ten days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120 days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and Korro Bio, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20 days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">188 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining fair value, and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In <span style="font-style:italic">Weinberger v. UOP, Inc.</span>, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In <span style="font-style:italic">Cede</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&amp; Co. v. Technicolor, Inc.</span>, the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In <span style="font-style:italic">Weinberger</span>, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should be aware that the fair value of your shares as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement. An opinion of an investment banking firm as to the fairness, from a financial point of view, of the consideration payable in a merger is not an opinion as to, and does not in any manner address, fair value under Section 262. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the Effective Time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the Effective Time; however, if no petition for appraisal is filed within 120 days after the Effective Time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60 days after the Effective Time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her Korro Bio common stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60 days after the Effective Time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">189 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_51">THE MERGER AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached to this proxy statement/prospectus as Annex&#160;A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about Frequency, Korro Bio or Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Merger Agreement contains representations and warranties that Frequency and Merger Sub, on the one hand, and Korro Bio, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Merger Agreement. While Frequency and Korro Bio do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Frequency or Korro Bio, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Frequency, Merger Sub and Korro Bio and are modified by the disclosure schedules. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_52">Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, and subject to the applicable provisions of Delaware law, at the completion of the Merger, Merger Sub, a wholly owned subsidiary of Frequency formed by Frequency in connection with the Merger, will merge with and into Korro Bio, with Korro Bio surviving as a wholly owned subsidiary of Frequency. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_53">Completion and Effectiveness of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the Merger will take place remotely no later than the second business day after all of the conditions precedent set forth in Article VI of the Merger Agreement have been satisfied or waived (other than those conditions that, by their nature, are to be satisfied at the closing of the Merger) or at such other time, date and place as Frequency and Korro Bio may mutually agree in writing. Frequency and Korro Bio are working to complete the Merger as quickly as practicable and expect that the Merger will be completed during the fourth quarter of 2023, subject to the approval of Frequency&#8217;s stockholders. However, Frequency and Korro Bio cannot predict the completion of the Merger or the exact timing of the completion of the Merger because it is subject to various conditions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_54">Merger Consideration </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time (after giving effect to the conversion of Korro Bio preferred stock as described below), upon the terms and subject to the conditions set forth in the Merger Agreement, each share of Korro Bio common stock outstanding immediately prior to the Effective Time (excluding Korro Bio common stock issued in the Pre-Closing Financing) will be converted solely into the right to receive a number of shares of Frequency common stock equal to the amount of Korro Merger Shares described in the section&#160;titled &#8220;<span style="font-style:italic">The Merger Agreement&#8211;</span><span style="font-style:italic">Korro</span><span style="font-style:italic"> Merger Shares</span>&#8221; beginning on page&#160;192 in this proxy statement/prospectus multiplied by the applicable stockholder&#8217;s percentage interest in Korro Bio as set forth on the Allocation Certificate required under the Merger Agreement. If any Korro Bio common stock outstanding immediately prior to the Effective Time is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">190 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unvested or is subject to a repurchase option or a risk of forfeiture under any applicable agreement with Korro Bio, then the shares of Frequency common stock issued in exchange for such shares of Korro Bio common stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency common stock will be marked with appropriate legends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time, by virtue of the Merger, upon the terms and subject to the conditions set forth in the Merger Agreement, the Korro Bio common stock issued in the <span style="white-space:nowrap">Pre-Closing</span> Financing will be converted solely into the right to receive a number of shares of Frequency common stock equal to the amount of the Pre-Closing Financing Merger Shares described in the section&#160;titled &#8220;<span style="font-style:italic">The Merger Agreement</span>&#8211;<span style="font-style:italic">Pre-Closing Financing Merger Shares</span>&#8221; beginning on page&#160;192 in this proxy statement/prospectus multiplied by the percentage of the proceeds of the <span style="white-space:nowrap">Pre-Closing</span> Financing represented by the applicable stockholder&#8217;s investment in the <span style="white-space:nowrap">Pre-Closing</span> Financing, as set forth on the Allocation Certificate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares of Frequency common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Frequency common stock resulting from the conversion of Korro Bio capital stock into the right to receive a number of Frequency common stock to a holder of Korro Bio common stock would otherwise be entitled to receive shall be aggregated together first prior to eliminating any remaining fractional share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time, by virtue of the Merger, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of common stock, $0.01 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the combined company. If applicable, each stock certificate of Merger Sub evidencing ownership of any such shares shall, as of the Effective Time, evidence ownership of such shares of common stock of the combined company until presented for transfer or exchange. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Korro Bio preferred stock will be converted into Korro Bio common stock as of immediately prior to the Effective Time in accordance with, and pursuant to the terms and conditions of, the organizational documents of Korro Bio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_54a">Allocation Certificate </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Merger Agreement, prior to the closing date, Korro Bio will prepare and deliver to Frequency a certificate, or the Allocation Certificate, setting forth (as of immediately prior to the Effective Time): (a) the name and address of each holder of Korro Bio Capital Stock, Korro Bio Options or Korro Bio Warrants, and the number and type of Korro Bio Capital Stock held as of the closing date for each such holder or, with respect to each Korro Bio Option or Korro Bio Warrant, the grant date of such Korro Bio Option or Korro Bio Warrant and the number of shares subject to such Korro Bio Option or Korro Bio Warrant, (b) the number of shares of Frequency Common Stock to be issued to such holder pursuant to the Merger Agreement in respect of the Korro Bio Capital Stock held by such holder as of immediately prior to the Effective Time or, with respect to each Korro Bio Option or Korro Bio Warrant, the number of shares of Frequency Common Stock to be subject to the applicable Assumed Option or Assumed Warrant as of immediately prior to the Effective Time following the conversion of such Korro Bio Option or Korro Bio Warrant into an Assumed Option or Assumed Warrant in accordance with the Merger Agreement, and (c) each investor in the Pre-Closing Financing, the total investment to be made by such investor in the Pre-Closing Financing, the percentage of the proceeds of the Pre-Closing Financing represented by such stockholder&#8217;s investment in the Pre-Closing Financing, and the number of shares of Frequency Common Stock to be issued to such holder pursuant to the Merger Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">191 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_301">Korro Merger Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The formula to calculate Korro Merger Shares, subject to the terms and conditions of the Merger Agreement, is the product determined by multiplying (i)&#160;the Post-Closing Frequency Shares by (ii)&#160;the Korro Allocation Percentage, in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Aggregate Valuation&#8221; means the sum of (A)&#160;the Korro Equity Value, plus (B)&#160;the Frequency Valuation, plus (C)&#160;the proceeds of the Pre-Closing Financing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Frequency Allocation Percentage&#8221; means the quotient (rounded to four decimal places) determined by dividing (A)&#160;the Frequency Valuation by (B)&#160;the Aggregate Valuation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Frequency Equity Value&#8221; means (A)&#160;if Frequency Net Cash (as described in the section titled &#8220;<span style="font-style:italic">The Merger Agreement &#8211; Calculation of Frequency</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s Net Cash</span>&#8221;) is $22,000,000 or less at closing, then $12,500,000, (B) if Frequency Net Cash is more than $22,000,000 but less than or equal to $25,000,000 at closing, then $15,000,000 or (C)&#160;if Frequency Net Cash is more than $25,000,000 at closing, then an amount equal to (i)&#160;Frequency Net Cash minus (ii) $10,000,000. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Frequency Outstanding Shares&#8221; means, subject to the terms and conditions of the Merger Agreement (including, without limitation, the effects of the Reverse Stock Split), the total number of shares of Frequency common stock outstanding immediately prior to the Effective Time expressed on a fully-diluted basis, and assuming, without limitation or duplication, (A)&#160;the issuance of shares of Frequency common stock in respect of all Frequency Options that do not have an exercise price equal to or greater than $1.00 per share (as adjusted for any stock splits or reverse stock splits after the date of the Merger Agreement) that will be outstanding as of immediately prior to the Effective, (B)&#160;the settlement in shares of Frequency common stock of Frequency restricted stock units that vest solely based on the holder&#8217;s employment or service and that are outstanding as of immediately prior to the Effective Time on a net settlement basis as provided in the Merger Agreement and (C)&#160;the exclusion of shares of Frequency common stock held by Frequency as treasury stock or owned by Korro Bio or any of its subsidiaries or any subsidiary of Frequency immediately prior to the Effective Time. Notwithstanding any of the foregoing, Frequency Options that have an exercise price equal to or greater than $1.00 per share (as adjusted for any stock splits or reverse stock splits after the date of the Merger Agreement) shall not be included in the total number of shares of Frequency common stock outstanding for purposes of determining the Frequency Outstanding Shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Frequency Valuation&#8221; means (A)&#160;the Frequency Equity Value plus (B)&#160;Frequency Net Cash. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Korro Allocation Percentage&#8221; means the quotient (rounded to four decimal places) determined by dividing (A)&#160;the Korro Equity Value by (B)&#160;the Aggregate Valuation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Korro Equity Value&#8221; means $325,639,194.78. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Post-Closing Frequency Shares&#8221; mean the quotient determined by dividing (A)&#160;the Frequency Outstanding Shares by (B)&#160;the Frequency Allocation Percentage. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the proceeds from the Pre-Closing Financing will not be included in the calculation or determination of the Korro Equity Value, the Frequency Valuation or any component thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_302">Pre-Closing Financing Merger Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The formula to calculate the Pre-Closing Financing Merger Shares, subject to the terms and conditions of the Merger Agreement, is the product determined by multiplying (i)&#160;the Post-Closing Frequency Shares by (ii)&#160;the Pre-Closing Financing Allocation Percentage, in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Post-Closing Frequency Shares&#8221; is defined above. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Pre-Closing Financing Allocation Percentage&#8221; means the quotient (rounded to four decimal places) determined by dividing (A)&#160;the proceeds of the <span style="white-space:nowrap">Pre-Closing</span> Financing by (B)&#160;the Aggregate Valuation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Aggregate Valuation&#8221; is defined above. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">192 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_55">Calculation of Frequency&#8217;s Net Cash </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement, Frequency&#8217;s &#8220;Net Cash&#8221; means the sum (without duplication) of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s cash and cash equivalents and marketable securities (including any proceeds received, or to be received, by Frequency or any of its subsidiaries in connection with the MS Asset Disposition described under the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8211;Potential Asset Sale</span>&#8221;); </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">minus</span></span>: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fees and expenses of Frequency incurred in connection with the transactions contemplated by the Merger Agreement, including for the avoidance of doubt, transaction expenses of Frequency to the extent unpaid as of the closing of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unpaid indebtedness for borrowed money of Frequency and its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any and all liabilities of Frequency (A)&#160;to any current or former employee, officer, director, consultant, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Frequency or any of its subsidiaries for change in control or transaction bonuses, retention bonuses, severance or similar compensatory payments or benefits that are due and payable as a result of the completion of the transactions contemplated by the Merger Agreement, together with any other event (including the employer portion of any payroll taxes payable with respect thereto), (B) with respect to the unfunded or underfunded portion of any defined benefit pension plan, accrued employer contributions to a defined contribution pension plan, postretirement health and welfare benefit plan, and supplemental </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">executive retirement plan, and (C)&#160;accrued but unpaid bonuses, severance and vacation or paid time off (including the employer portion of any payroll taxes payable with respect thereto); </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">plus</span></span>: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all prepaid expenses set forth in the Frequency disclosure schedule; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses paid, or liabilities incurred, prior to closing, that are approved in writing by Korro Bio to be covered by Frequency&#8217;s D&amp;O insurance in excess of the deductible and within overall policy limits; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">deposits set forth in the Frequency disclosure schedule; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">minus</span></span>: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sum of Frequency&#8217;s consolidated short-term and long-term contractual obligations accrued at the date of the closing of the Merger (but excluding deferred revenue and any accruals otherwise accounted for in Frequency Net Cash); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all costs and expenses relating to the winding down of Frequency&#8217;s or any of its subsidiaries prior research and development activities, including any such accounts payable or accrued expenses associated with the termination of any contractual arrangement of Frequency contemplated by the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any <span style="white-space:nowrap">pre-payment,</span> termination <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;end-of-term&#8221;</span></span> or similar fee or charge payable to any lender in connection with the repayment of indebtedness by Frequency at or prior to the Effective Time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any accounts payable and accrued expenses (other than accrued expenses which are transaction expenses and excluding any accruals otherwise accounted for in Frequency Net Cash); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all payables or obligations, whether absolute, contingent or otherwise, related to Frequency under that certain Lease Agreement, dated January&#160;7, 2020, by and between Frequency and HCP/King 75 Hayden LLC, as may be amended or supplemented from time to time (net of any rights of Frequency to receive payments relating to the property subject to such lease); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the employer portion of any payroll taxes payable as a result of the vesting and settlement of each outstanding and unvested Frequency restricted stock unit pursuant to the terms of the Merger Agreement; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">193 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all costs, fees and expenses relating to the legal matter(s) set forth in the Frequency disclosure schedule and any settlement(s) related thereto. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For avoidance of doubt, the cash and cash equivalents received in the <span style="white-space:nowrap">Pre-Closing</span> Financing will be excluded from the calculation of Frequency Net Cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not less than ten business days prior to the anticipated date of the closing of the Merger as mutually agreed in good faith by Frequency and Korro Bio, Frequency will deliver to Korro Bio a net cash schedule setting forth, in reasonable detail, Frequency&#8217;s good faith estimated calculation of its Net Cash as of the close of business on the closing date of the Merger, prepared and certified by Frequency&#8217;s Chief Financial Officer (or if there is no Chief Financial Officer, the principal financial and accounting officer of Frequency) together with the relevant work papers and back&#160;-up materials used or useful in preparing the net cash schedule as reasonably requested by Korro Bio. Within five business days after delivery of such Net Cash schedule (the last day of such period referred to as the response date), Korro Bio will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to Frequency (referred to herein as a dispute notice). Any dispute notice will identify in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Frequency&#8217;s Net Cash calculation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korro Bio disputes the Net Cash schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of net cash. If the parties are unable to negotiate an agreed-upon determination of net cash or any component thereof within two calendar days after the delivery of Korro Bio&#8217;s dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing jointly selected by Frequency and Korro Bio or another independent auditor of recognized national standing mutually agreed upon by Frequency and Korro Bio. The determination of the amount of net cash made by such accounting firm shall be final and binding on Frequency and Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Net Cash balance is subject to numerous factors, some of which are outside of Frequency&#8217;s control. The actual amount of Net Cash will depend significantly on the timing of the closing of the Merger. In addition, the closing of the Merger could be delayed if Frequency and Korro Bio are not able to agree upon the amount of Frequency&#8217;s Net Cash as of the cash determination time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_303">Treatment of Korro Bio Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant issued by Korro Bio outstanding immediately prior to the Effective Time will automatically be&#160;converted, at the Effective Time, into a warrant, or an Assumed Warrant, to acquire, on the same terms and conditions (including, without limitation, the exercisability terms and conditions) as were applicable under the warrant issued by Korro Bio to SVB as described in Note&#160;8 of Korro Bio&#8217;s audited consolidated financial statements included elsewhere in this proxy statement/prospectus to such Korro Bio warrant immediately prior to the Effective Time, the number of shares of Frequency common stock under the Assumed Warrant determined by multiplying the number of shares of Korro Bio common stock subject to such Korro Bio warrant immediately prior to the Effective Time by the applicable holder&#8217;s percentage interest in Korro Bio with respect to such Korro Bio warrant as set forth on the Allocation Certificate (such percentage interest, the &#8220;Warrant Exchange Ratio&#8221;), rounding down to the nearest whole number of shares, at a per share exercise price determined by dividing the per share exercise price of such Korro Bio warrant immediately prior to the Effective Time by the Warrant Exchange Ratio, rounding up to the nearest whole cent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_56">Treatment of Korro Bio Options </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each option to purchase shares of Korro Bio common stock outstanding as of immediately prior to the Effective Time shall automatically be converted, at the Effective Time, into an option to acquire, on the same terms and conditions (including the same vesting and exercisability terms and conditions), the number of shares of Frequency common stock equal to the number of shares of Korro Bio common stock subject to such option as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">194 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of immediately prior to the Effective Time multiplied by the exchange ratio formula in the Merger Agreement and rounding that result down to the nearest whole number of shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_57">Treatment of Frequency Common Stock, Frequency Options, Frequency Restricted Stock Units and Frequency Performance Stock Units </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding Frequency Option will remain outstanding and such options, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan or 2014 Stock Incentive Plan, as applicable, to reflect the Reverse Stock Split and the issuance of the CVRs, will be unaffected by the Merger, provided that each such Frequency Option that is unvested will vest in full immediately prior to the Effective Time. Each restricted stock unit award covering shares of Frequency common stock that is outstanding will remain outstanding and such restricted stock unit awards, subject to proportionate adjustment in accordance with the terms of Frequency&#8217;s 2019 Incentive Award Plan to reflect the Reverse Stock Split and issuance of the CVRs, will be unaffected by the Merger, provided that each restricted stock unit award that vests solely based on the holder&#8217;s continued employment or service will vest in full immediately prior to the Effective Time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_304">Frequency Employee Stock Purchase Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the date of the Merger Agreement, Frequency&#8217;s board of directors will adopt resolutions to provide that (a) no offering periods or purchase periods will begin after or in addition to the offering period underway as of the date of the Merger Agreement under the Frequency ESPP, (b) no payroll deductions or other contributions will be made or effected after the current offering period with respect to the Frequency ESPP, (c) each Frequency ESPP participant&#8217;s accumulated contributions under the Frequency ESPP will be returned to the participant in accordance with the terms of the Frequency ESPP, and (d) the Frequency ESPP will be terminated immediately prior to the Effective Time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_58">Procedures for Exchanging Korro Bio Stock Certificates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or prior to the closing date, Frequency and Korro Bio will jointly select an exchange agent and, at the Effective Time, Frequency will deposit with the exchange agent evidence of book-entry shares representing the shares of Frequency capital stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Korro Bio common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the Effective Time, the exchange agent will mail to each record holder of Korro Bio common stock that were converted into the right to receive Korro Merger Shares (i)&#160;a letter of transmittal and (ii)&#160;instructions effecting the surrender of Korro Bio common stock in exchange for book-entry shares of Frequency capital stock. Upon delivery to the exchange agent of a duly executed letter of transmittal and such other documents as may reasonably be required by the exchange agent or Frequency, the holder of such Korro Bio common stock shall be entitled to receive in exchange therefor book-entry shares representing that Korro Merger Shares that such holder has the right to receive pursuant to the Merger Agreement. No dividends or other distributions declared or made with respect to Frequency capital stock with a record date after the Effective Time shall be paid to the holder of any Korro Bio common stock with respect to the shares of Frequency capital stock that such holder has the right to receive in the Merger until such holder delivers a duly executed letter of transmittal (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar laws, to receive all such dividends and distributions, without interest). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any shares of Frequency capital stock deposited with the exchange agent that remain undistributed to holders of Korro Bio common stock as of the date that is 180 days after the closing date shall be delivered to Frequency upon demand, and any holders of Korro Bio common stock who have not theretofore delivered a duly executed letter of transmittal in accordance with the terms and conditions of the Merger Agreement shall thereafter look only to Frequency for satisfaction of their claims for Frequency capital stock and any dividends or distributions with respect to shares of Frequency capital stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">195 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">HOLDERS OF KORRO BIO COMMON STOCK SHOULD NOT SEND IN THEIR KORRO BIO STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF KORRO BIO STOCK CERTIFICATES. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_59">Directors and Officers of Frequency Following the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, each of the directors and officers of Frequency who will not continue as directors or officers of Frequency following the Effective Time will resign effective as of the Effective Time. Effective as of the Effective Time, the Frequency board of directors will consist of a total of seven directors, four of whom will be designated by Korro Bio, two of whom will be independent directors, and one of whom will be designated by Frequency. Korro Bio has designated Ram Aiyar, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to serve as members of the Frequency board of directors and Frequency has designated David Lucchino to serve as a member of the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon the closing of the Merger, Ram Aiyar, PhD will serve as President and Chief Executive Officer, Steve Colletti, PhD will serve as Chief Scientific Officer, Vineet Agarwal will serve as Chief Financial Officer, Todd Chappell will serve as Senior Vice President, Strategy and Portfolio Planning and Shelby Walker will serve as Senior Vice President, and General Counsel. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_60">Amendment of the Restated Certificate of Incorporation of Frequency </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency agreed to amend its Restated Certificate of Incorporation to (i)&#160;change the name of Frequency to &#8220;Korro Bio, Inc.&#8221;, (ii) effect the proposed Reverse Stock Split if deemed necessary by Frequency and Korro Bio and authorize sufficient Frequency common stock for the issuance of Frequency common stock to the stockholders of Korro Bio pursuant to the terms of the Merger Agreement and (iii)&#160;make such other changes as are mutually agreeable to Frequency and Korro Bio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_305">Potential Asset Sale </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is entitled, but under no obligation, to sell, transfer, license, assign or otherwise divest any or all of the assets and rights relating to Frequency&#8217;s MS remyelination program, or the MS Assets, in a transaction or series of transactions, or the MS Asset Disposition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party acknowledges that Frequency may not be successful in completing, or may determine not to proceed with, the MS Asset Disposition. Notwithstanding the foregoing, Frequency may not enter into any agreement with respect to the MS Asset Disposition that would result in a material continuing obligation or liability without the prior written consent of Korro Bio (not to be unreasonably withheld, conditioned or delayed), provided, however, that Frequency will provide Korro Bio with a copy of any agreement with respect to an MS Asset Disposition that would be reasonably likely to result in a material continuing obligation or liability of either Frequency or Korro Bio on or after the Effective Time at least five business days prior to entry into such agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the MS Asset Disposition has not occurred on or prior to the closing of the Merger, for a period of one year following the closing of the Merger, Frequency will use commercially reasonable efforts to sell, transfer, assign, <span style="white-space:nowrap">out-license</span> or otherwise divest the MS Assets with a term of not more than 10 years. The net proceeds from such sale, transfer, license, assignment or other divestiture or commercialization of the MS Assets following the Effective Time shall be payable to the holders of CVRs pursuant to the CVR Agreement as described below in the sections titled &#8220;<span style="font-style:italic">The Merger Agreement&#8211;</span><span style="font-style:italic">Contingent Value Rights</span>&#8221; beginning on page&#160;201 of this proxy statement/prospectus and &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8211;Contingent Value Rights Agreement</span>&#8221; beginning on page&#160;214 in this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">196 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_61">Representations and Warranties </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains customary representations and warranties of Frequency and Korro Bio for a transaction of this type relating to, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">due organization; subsidiaries, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">organizational documents, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authority; binding nature of the Merger Agreement, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">vote required, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">non-contravention;</span> consents, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">capitalization, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial statements, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">absence of changes, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">absence of undisclosed liabilities, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">title to assets, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real property; leasehold, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">intellectual property, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">agreements, contracts and commitments, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance; permits; restrictions, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal proceedings; orders, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">tax matters, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">employee and labor matters; benefit plans, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">environmental matters, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">insurance, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no financial advisors, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">transactions with affiliates, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privacy and data security, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">opinion of Frequency&#8217;s financial advisor. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio makes additional representations and warranties, relating to the Pre-Closing Financing described in the section titled &#8220;<span style="font-style:italic">Korro</span><span style="font-style:italic"> Bio Management</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency makes additional representations and warranties relating to, among other things, SEC filings and the valid issuance of Frequency common stock in connection with the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger, but their accuracy forms the basis of one of the conditions to the obligations of Frequency and Korro Bio to complete the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_62">Covenants; Conduct of Business Pending the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has agreed that until the earlier of the Effective Time and the termination of the Merger Agreement, except as required by applicable law, as otherwise provided by the Merger Agreement and the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">197 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions contemplated thereby or with Frequency&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Korro Bio will, and will cause its subsidiaries to, use their commercially reasonable efforts to conduct its operations in the ordinary course of its business and to preserve intact the present business organizations and goodwill of the business and the present relationships of the business with material customers and suppliers. Without limiting the generality of the foregoing, until the earlier of the Effective Time and the termination of the Merger Agreement, except as required by applicable law, as otherwise provided by the Merger Agreement and the transactions contemplated thereby or with Frequency&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Korro Bio will not, and will cause its subsidiaries not to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sell, lease, license or otherwise dispose of any material assets of Korro Bio, or in either case, any interests therein, except (i)&#160;pursuant to existing contracts, (ii)&#160;for sales or licensing of products to customers or (iii)&#160;otherwise in the ordinary course of its business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">take any action with respect to any equity interests of Korro Bio or any of its subsidiaries, including any issuance, sale, transfer, redemption, repurchase, recapitalization, adjustment, split, combination, reclassification, dividend, distribution or any other action in respect thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">create, incur, assume, guarantee or repay (other than any mandatory repayments) any indebtedness, other than the incurrence of indebtedness in the ordinary course of its business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issue, deliver, sell, grant, pledge, transfer, subject to any encumbrance or dispose of any Korro Bio capital stock or the securities of any subsidiary of Korro Bio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">create or otherwise incur any encumbrance on any material asset of Korro Bio or any of its subsidiaries, other than permitted encumbrances; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any loans, advances or capital contributions to, or investments in, any person other than Korro Bio, other than in the ordinary course of its business in all material respects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adversely amend or otherwise adversely modify in any material respect or terminate (excluding any expiration in accordance with its terms) any material contract, other than any amendment or modification entered into in the ordinary course of its business and containing terms not materially less favorable to Korro Bio than the terms of such contract in effect as of the date of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any contract that would be required to be disclosed as a material contract if such contract were in effect as of the date of the Merger Agreement, other than any such contract entered into in the ordinary course of its business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">except in the ordinary course of its business, as required by any Korro Bio employee plan or as required by applicable law, (i)&#160;increase any salary, wage or other compensation or benefit to, or enter into or amend any employment, retention, <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control,</span></span> termination or severance agreement with, any current or former employee, consultant, officer, director, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Korro Bio or any of its subsidiaries, provided that such increases do not, individually or in the aggregate, result in any material increase in costs, obligations or liabilities for Korro Bio and its subsidiaries, (ii)&#160;grant or pay any bonuses to any current or former employee, consultant, officer, director, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Korro Bio or any of its subsidiaries, (iii)&#160;establish, enter into or adopt any new Korro Bio employee plan or amend or modify, in a manner that would, individually or in the aggregate, materially increase costs, obligations or liabilities for Korro Bio and its subsidiaries or the combined company, any existing Korro Bio employee plan or accelerate the vesting of any compensation (including stock options, restricted stock, restricted stock units, phantom units, warrants, other shares of capital stock or rights of any kind to acquire any shares of capital stock or equity-based awards) for the benefit of any current or former employee, consultant, officer, director, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Korro Bio or any of its subsidiaries, (iv)&#160;take any action to accelerate any payment or benefit, or the funding of any payment or benefit, payable or to be provided to any current or former employee, consultant, officer, director, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">198 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of Korro Bio or any of its subsidiaries, (v)&#160;grant any new long-term incentive or equity-based awards, or amend or modify the terms of any such outstanding awards under any Korro Bio employee plan or (vi)&#160;hire, terminate (other than for cause), promote or change the employment status or title of any current or former employee, consultant, officer, director, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Korro Bio or any of its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adopt, enter into, amend or terminate any collective bargaining agreement or contract with any labor union, works council or labor organization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">settle any material legal proceeding involving Korro Bio or any of its subsidiaries or relating to the transactions contemplated by the Merger Agreement, other than in the ordinary course of its business in all material respects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make or change any material tax election, change any annual tax accounting period, enter into any closing agreement with a governmental authority with respect to material taxes or settle any tax claim with respect to material taxes, in each case, except if such action would not reasonably be expected to have a material and adverse effect on Korro Bio following the completion of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to prevent the Merger from qualifying as a &#8220;plan of reorganization&#8221; for purposes of Sections 354, 361 and 368 of the Code and within the meaning of Section&#160;368 of the Code and Treasury Regulations <span style="white-space:nowrap">Section&#160;1.368-2(g);</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any material change in any method of financial accounting or financial accounting practice of Korro Bio or any of its subsidiaries, except for any such change required by reason of a change in GAAP or other applicable financial accounting standards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other than in connection with actions contemplated by the Merger Agreement, adopt, approve, consent to or propose any change in the organizational documents of Korro Bio or any of its subsidiaries; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">agree or commit to do any of the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has agreed that until the earlier of the Effective Time and the termination of the Merger Agreement, except as required by applicable law, as otherwise provided by the Merger Agreement and the transactions contemplated thereby or with Korro Bio&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Frequency will, and will cause its subsidiaries to, use their commercially reasonable efforts to conduct its operations in the ordinary course of its business and to preserve intact the present business organizations and goodwill of the business and the present relationships of the business with material customers and suppliers. Without limiting the generality of the foregoing, until the earlier of the Effective Time and the termination of the Merger Agreement, except as required by applicable law, as otherwise provided by the Merger Agreement and the transactions contemplated thereby or with Korro Bio&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Frequency will not, and will cause its subsidiaries not to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sell, lease, license or otherwise dispose of any material assets of Frequency, or in either case, any interests therein, except (i)&#160;pursuant to existing contracts, (ii)&#160;for sales or licensing of products to customers or (iii)&#160;otherwise in the ordinary course of its business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">take any action with respect to any equity interests of Frequency or any of its subsidiaries, including any issuance, sale, transfer, redemption, repurchase, recapitalization, adjustment, split, combination, reclassification, dividend, distribution or any other action in respect thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">create, incur, assume, guarantee or repay (other than any mandatory repayments) any indebtedness; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issue, deliver, sell, grant, pledge, transfer, subject to any encumbrance or dispose of any Frequency capital stock or the securities of any subsidiary of Frequency; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">create or otherwise incur any encumbrance on any material asset of Frequency or any of its subsidiaries, other than permitted encumbrances; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">199 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any loans, advances or capital contributions to, or investments in, any person other than Frequency; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adversely amend or otherwise adversely modify in any material respect or terminate (excluding any expiration in accordance with its terms) any material contract, other than any amendment or modification entered into in the ordinary course of its business and containing terms, not materially less favorable to Frequency than the terms of such contract in effect as of the date of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any contract that would be required to be disclosed as a material contract if such contract were in effect as of the date the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">except as required by any Frequency employee plan, as required by applicable law or with respect to the adoption and approval of the 2023 Plan and the 2023 ESPP (i) increase any salary, wage or other compensation or benefit to, or enter into or amend any employment, retention, <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control,</span></span> termination or severance agreement with, any current or former employee, officer, director, consultant, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Frequency or any of its subsidiaries, other than annual increases in base compensation in the ordinary course of business with respect to employees whose annual base compensation is less than $135,000 and provided that such increases do not, individually or in the aggregate, result in any material increase in costs, obligations or liabilities for Frequency and its subsidiaries, (ii)&#160;grant or pay any bonuses to any current or former employee, officer, director, consultant, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Frequency or any of its subsidiaries, (iii)&#160;establish, enter into or adopt any new Frequency employee plan or amend or modify, in a manner that would, individually or in the aggregate, materially increase costs, obligations or liabilities for Frequency and its subsidiaries or the combined company, any existing Frequency employee plan or accelerate the vesting of any compensation (including stock options, restricted stock, restricted stock units, phantom units, warrants, other shares of capital stock or rights of any kind to acquire any shares of capital stock or equity-based awards) for the benefit of any current or former employee, officer, director, consultant, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Frequency or any of its subsidiaries, (iv)&#160;take any action to accelerate any payment or benefit, or the funding of any payment or benefit, payable or to be provided to any current or former employee, officer, director, consultant, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Frequency or any of its subsidiaries, (v)&#160;grant any new long-term incentive or equity-based awards, or amend or modify the terms of any such outstanding awards under any Frequency employee plan or (vi)&#160;hire, terminate (other than for cause), promote or change the employment status or title of any current or former employee, officer, director, consultant, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Frequency or any of its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adopt, enter into, amend or terminate any collective bargaining agreement or contract with any labor union, works council or labor organization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">settle any material legal proceeding involving Frequency or relating to the transactions contemplated by the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make or change any material tax election, change any annual tax accounting period, enter into any closing agreement with a governmental authority with respect to material taxes or settle any tax claim with respect to material taxes, in each case, except if such action would not reasonably be expected to have a material and adverse effect on Frequency following the completion of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to prevent the Merger from qualifying as a &#8220;plan of reorganization&#8221; for purposes of Sections 354, 361 and 368 of the Code and within the meaning of Section&#160;368 of the Code and Treasury Regulations <span style="white-space:nowrap">Section&#160;1.368-2(g);</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any material change in any method of financial accounting or financial accounting practice of Frequency, except for any such change required by reason of a change in GAAP or other applicable financial accounting standards; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">200 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other than in connection with actions contemplated by the Merger Agreement, adopt, approve, consent to or propose any change in the organizational documents of Frequency; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">agree or commit to do any of the foregoing. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_63">Contingent Value Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Effective Time, unless (i)&#160;the MS Asset Disposition has been consummated prior to or on the closing date of the Merger and (ii)&#160;all proceeds from the MS Asset Disposition are taken into account in the final Frequency Net Cash and there are no contingent payments, licenses, fees or royalties, equity securities or other <span style="white-space:nowrap">non-cash</span> assets or rights that may be payable by any acquiror of any MS Assets or otherwise as a result of the MS Asset Disposition after the closing of the Merger, Frequency will declare a distribution to its common stockholders of record of the right to receive one CVR for each outstanding share of Frequency common stock held by such stockholder as of the record date, each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the CVR Agreement, discussed in greater detail under the section&#160;titled &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8211;Contingent Value Rights Agreement</span>&#8221; beginning on page&#160;214 in this proxy statement/prospectus. The record date for such distribution will be the close of business on the last business day prior to the day on which the Effective Time occurs and the payment date for which shall be three business days after the Effective Time; <span style="font-style:italic">provided </span>that the payment of such distribution may be conditioned upon the occurrence of the Effective Time. In connection with such distribution, Frequency will cause the CVR Agreement to be duly authorized, executed and delivered by Frequency and Computershare Trust Company, N.A. (or such other nationally recognized rights agent agreed to between Frequency and Korro Bio). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_64">Non-Solicitation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Frequency and Korro Bio have agreed that, except as described below, Frequency and Korro Bio and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">furnish any <span style="white-space:nowrap">non-public</span> information regarding such party to any person (other than Korro Bio or Frequency) in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approve, endorse or recommend any Acquisition Proposal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publicly propose to do any of the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Korro Bio, on the one hand, or Frequency, on the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal, other than, as applicable, with respect to the potential asset sale described in the section titled, &#8220;<span style="font-style:italic">The Merger Agreement &#8211; Potential Asset Sale</span>&#8221;<span style="font-style:italic"> </span>or the Pre-Closing Financing described in the section titled, &#8220;<span style="font-style:italic">Korro</span><span style="font-style:italic"> Bio Management</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s Discussion and Analysis of Financial Condition and Results of Operations&#8211;Recent Developments-Proposed Merger &amp; <span style="white-space:nowrap">Pre-Closing</span> Financing</span>&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">201 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#8220;Acquisition Proposal&#8221; means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Korro Bio or any of its affiliates, on the one hand, or by or on behalf of Frequency or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any Acquisition Transaction with such party, other than, as applicable, with respect to the potential asset sale described in the section titled, &#8220;<span style="font-style:italic">The Merger Agreement &#8211; Potential Asset Sale</span>&#8221;<span style="font-style:italic"> </span>or the Pre-Closing Financing described in the section titled, &#8220;<span style="font-style:italic">Korro</span><span style="font-style:italic"> Bio Management</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s Discussion and Analysis of Financial Condition and Results of Operations&#8211;Recent Developments-Proposed Merger &amp; <span style="white-space:nowrap">Pre-Closing</span> Financing</span>&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than, as applicable, with respect to the potential asset sale described in the section titled, &#8220;<span style="font-style:italic">The Merger Agreement &#8211; Potential Asset Sale</span>&#8221;<span style="font-style:italic"> </span>or the Pre-Closing Financing described in the section titled, &#8220;<span style="font-style:italic">Korro</span><span style="font-style:italic"> Bio Management</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s Discussion and Analysis of Financial Condition and Results of Operations&#8211;Recent Developments-Proposed Merger &amp; <span style="white-space:nowrap">Pre-Closing</span> Financing</span>&#8221;) involving: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (A)&#160;in which a party is a constituent entity, (B)&#160;in which a person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a party or any of its subsidiaries or (C)&#160;in which a party or any of its subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a party and its subsidiaries, taken as a whole. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, before obtaining the applicable approvals of the Frequency stockholders required to consummate the Merger, Frequency may furnish non-public information regarding Frequency or its subsidiaries to, and may enter into discussions or negotiations with, any person in response to a bona fide written Acquisition Proposal by Frequency, which Frequency&#8217;s board of directors determines in good faith, after consultation Frequency&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in, a Superior Offer (and is not withdrawn), if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">neither Frequency nor any representative shall have breached the <span style="white-space:nowrap">non-solicitation</span> provisions of the Merger Agreement in any material respect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Frequency board of directors concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to result in a breach of the fiduciary duties of the Frequency board of directors under applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least two business days prior to initially furnishing any such <span style="white-space:nowrap">non-public</span> information to, or entering into discussions with, such person, Frequency gives Korro Bio written notice of the identity of such person to Korro Bio, and of Frequency&#8217;s intention to furnish <span style="white-space:nowrap">non-public</span> information to, or enter into discussions with, such person; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency receives from such person an executed confidentiality agreement in accordance with the terms and conditions of the Merger Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least two business days prior to furnishing any such <span style="white-space:nowrap">non-public</span> information to such person, Frequency furnishes such <span style="white-space:nowrap">non-public</span> information to Korro Bio (to the extent such information has not been previously furnished by Frequency to Korro Bio). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;Superior Offer&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 70%) that: (i)&#160;was not obtained or made </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">202 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as a direct or indirect result of a breach of (or in violation of) the Merger Agreement and (ii)&#160;is on terms and conditions that the Korro Bio board of directors or the Frequency board of directors, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof, the financing terms thereof and any termination or <span style="white-space:nowrap">break-up</span> fees and conditions to consummation), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Korro Bio&#8217;s stockholders or Frequency&#8217;s stockholders, as applicable, than the terms of the Merger Agreement and the transactions contemplated thereby and is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that if any party or any representative of such party receives an Acquisition Proposal or Acquisition Inquiry, then such party shall promptly (and in no event later than one business day after such party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other party orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the person making or submitting such Acquisition Proposal or Acquisition Inquiry, and provide a copy of the Acquisition Proposal or Acquisition Inquiry, of if the Acquisition Proposal or Acquisition Inquiry is not written, the terms thereof). The Merger Agreement provides that such party shall keep the other party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto. Additionally, each party shall provide the other party with at least four business days&#8217; written notice of a meeting of its board of directors (or any committee thereof) at which its board of directors (or any committee thereof) is reasonably expected to consider an Acquisition Proposal or Acquisition Inquiry it has received. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_65">Board Recommendation Change </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, subject to certain exceptions described below, Frequency agreed that its board of directors may not take any of the following actions, each of which are referred to in this proxy statement/prospectus as a &#8220;Frequency Board Adverse Recommendation Change&#8221;: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of the Frequency board of directors in a manner adverse to Korro Bio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">resolve, or have any committee of the Frequency board of directors resolve, to withdraw or modify the recommendation of the Frequency board of directors in a manner adverse to Korro Bio; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, notwithstanding the foregoing, at any time prior to the approval of the proposals to be considered at the Frequency stockholder meeting by the necessary vote of Frequency stockholders, if Frequency has received a bona fide written Superior Offer, the Frequency board of directors may make a Frequency Board Adverse Recommendation Change if, but only if, following the receipt of and on account of such Superior Offer: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Frequency board of directors determines in good faith, after consultation with its outside legal counsel, that the failure to make a Frequency Board Adverse Recommendation Change would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency has, and has caused its financial advisors and outside legal counsel to, during a five business day period commencing on the date that the Frequency board of directors notifies Korro Bio in writing of its intent to make a Frequency Board Adverse Recommendation Change, negotiated with Korro Bio in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if after Korro Bio shall have delivered to Frequency a written offer to alter the terms or conditions of the Merger Agreement during the five business day period commencing on the date that the Frequency </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">203 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
board of directors notifies Korro Bio in writing of its intent to make a Frequency Board Adverse Recommendation Change, the Frequency board of directors shall have determined in good faith, after consultation with its outside legal counsel, that the failure to withhold, amend, withdraw or modify the recommendation of the Frequency board of directors would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement); provided that (x)&#160;Korro Bio receives written notice from Frequency confirming that the Frequency board of directors has determined to change its recommendation during such five business day period, which notice shall include a description in reasonable detail of the reasons for such Frequency Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (y)&#160;during any such five business day period, Korro Bio shall be entitled to deliver to Frequency one or more counterproposals to such Acquisition Proposal and Frequency will, and cause its representatives to, negotiate with Korro Bio in good faith (to the extent Korro Bio desires to negotiate) to make such adjustments in the terms and conditions of the Merger Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z)&#160;in the event of any material amendment to any Superior Offer (including any revision in price or percentage of the combined company that Frequency&#8217;s stockholders would receive as a result of such potential Superior Offer), Frequency shall be required to provide Korro Bio with notice of such material amendment and such five business day period shall be extended, if applicable, to ensure that at least two business days remain in the requisite notice period following such notification during which the parties shall comply again with the requirements of the Merger Agreement and the Frequency board of directors shall not make a Frequency Board Adverse Recommendation Change prior to the end of such notice period as so extended. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, subject to certain exceptions described below, Korro Bio agreed that its board of directors may not take any of the following actions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdraw or modify (or publicly propose to withdraw or modify) the recommendation of the Korro Bio board of directors in a manner adverse to Frequency; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">resolve, or have any committee of the Korro Bio board of directors resolve, to withdraw or modify the recommendation of the Korro Bio board of directors in a manner adverse to Frequency; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_66">Meeting of Frequency&#8217;s Stockholders and Written Consent of Korro Bio&#8217;s Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is obligated under the Merger Agreement to take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of Frequency common stock to consider and vote to approve the Merger Agreement and the transactions contemplated thereby, including the issuance of the shares of Frequency common stock to the stockholders of Korro Bio pursuant to the terms of the Merger Agreement and the amendments to the Restated Certificate of Incorporation of Frequency described in the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8211;Amendment of the Restated Certificate of Incorporation of Frequency</span>&#8221;. The Frequency stockholder meeting shall be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, and in any event no later than 45 days after the effective date of the Registration Statement. Frequency shall take reasonable measures to ensure that all proxies solicited in connection with the Frequency stockholder meeting are solicited in compliance with all applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in the Merger Agreement, if on the date of the Frequency stockholder meeting, or a date preceding the date on which the Frequency stockholder meeting is scheduled, Frequency reasonably believes that (i)&#160;it will not receive proxies sufficient to obtain the requisite Frequency stockholder vote, whether or not a quorum would be present or (ii)&#160;it will not have sufficient shares of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">204 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Frequency common stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Frequency stockholder meeting, Frequency may postpone or adjourn, or make one or more successive postponements or adjournments of, the Frequency stockholder meeting as long as the date of the Frequency stockholder meeting is not postponed or adjourned more than an aggregate of 30 calendar days in connection with any postponements or adjournments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two business days thereafter, Korro Bio shall prepare, with the cooperation of Frequency, and cause to be mailed to the stockholders of Korro Bio an information statement, which shall include a copy of the Proxy Statement, and the Korro Bio stockholder written consent, in order to solicit the approval of Korro Bio&#8217;s stockholders, including but not limited to Korro Bio&#8217;s stockholders sufficient for the requisite Korro Bio stockholder vote in lieu of a meeting pursuant to Section&#160;228 of Delaware law, for purposes of (i)&#160;adopting and approving the Merger Agreement and the transaction contemplated thereby, (ii)&#160;acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of Delaware law, a copy of which will be attached thereto, and that such stockholder has received and read a copy of Section&#160;262 of Delaware law and (iii)&#160;acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives an rights to receive payment of the fair value of its capital stock under Delaware law. Korro Bio shall use its reasonable best efforts to cause Korro Bio&#8217;s stockholders sufficient for the requisite Korro Bio stockholder vote to execute and deliver to Korro Bio the Korro Bio stockholder written consent promptly following delivery thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_67">Regulatory Approvals </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties will use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority. Frequency and Korro Bio will respond as promptly as is practicable to respond in compliance with: (i)&#160;any inquiries or requests received from the Federal Trade Commission or the Department of Justice for additional information or documentation and (ii)&#160;any inquiries or requests received from any state attorney general, foreign antitrust or competition authority or other governmental authority in connection with antitrust or competition matters. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_68">Indemnification and Insurance for Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, from the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, Frequency and the combined company agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the Effective Time, a director or officer of Frequency or Korro Bio, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of Frequency or of Korro Bio, whether asserted or claimed prior to, at or after the Effective Time. From and after the Effective Time, Frequency and the combined company will also fulfill Frequency&#8217;s and Korro Bio&#8217;s indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the Effective Time, a director or officer of Frequency or Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that the provisions of the certificate of incorporation and bylaws of Frequency with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Frequency that are presently set forth in the certificate of incorporation and bylaws of Frequency will not be amended modified or repealed for a period of six years from the Effective Time in a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">205 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Frequency, unless such modification is required by applicable law. The certificate of incorporation and bylaws of the combined company will contain, and Frequency will cause the certificate of incorporation and bylaws of the combined company to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the Effective Time, Frequency will maintain director&#8217; and officers&#8217; liability insurance policies, with an effective date as of the closing date of the Merger, on commercially available terms and conditions and with coverage limits customary for U.S.&#160;public companies similarly situated to Frequency. In addition, Frequency will secure and purchase a six year &#8220;tail policy&#8221; on Frequency&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee Interlocks and Insider Participation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Merger, the combined company&#8217;s board of directors is expected to select members of the compensation committee. Each member of the compensation committee is expected to be <span style="white-space:nowrap">a&#160;&#8220;non-employee&#8221;&#160;director</span> within the meaning of <span style="white-space:nowrap">Rule&#160;16b-3&#160;of</span> the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. None of the proposed combined company&#8217;s executive officers serves as a member of the board of directors or compensation committee of any entity that has one or more executive officers who is proposed to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_306">2023 Plan and 2023 ESPP </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Effective Time, the Frequency board of directors will adopt the 2023 Plan and 2023 ESPP, each in form and substance as agreed to by Frequency and Korro Bio, reserving for issuance a number of shares of Frequency common stock to be mutually agreed upon by Korro Bio and Frequency (described in the sections titled &#8220;<span style="font-style:italic">Interests of Korro Bio Directors and Executive Officers in the Merger&#8211;2023 Stock Incentive Plan&#8221; and &#8220;Interests of Korro Bio Directors and Executive Officers in the Merger&#8211;2023 Employee Stock Purchase Plan</span>&#8221;). Approval of the 2023 Plan and the 2023 ESPP by Frequency&#8217;s stockholders is not a condition to closing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_307">Frequency 401(k) Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless Korro Bio requests otherwise, Frequency will, effective as of at least one day prior to the closing date but subject to the closing, terminate any Frequency employee plan that is intended to meet the requirements of Section 401(k) of the Code and no further contributions will be made to such plan and all participant account balances will become 100% vested. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_69">Additional Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Frequency and Korro Bio has agreed to use reasonable efforts to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or contract, or otherwise) in connection with the transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated by the Merger Agreement; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">206 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, Frequency and Korro Bio have further agreed, among other things, that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency will use commercially reasonable efforts to (a)&#160;maintain a listing on Nasdaq until the Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b)&#160;to the extent required by Nasdaq, prepare and submit to Nasdaq a notification form for the listing the shares of Frequency common stock to be issued in connection with the transactions contemplated by the Merger Agreement and to cause the shares to be approved for listing; (c)&#160;prepare and timely submit to Nasdaq a notification form of the Reverse Stock Split and to submit a copy of the amendment to Frequency&#8217;s certificate of incorporation to effect the Reverse Stock Split and other amendments contemplated by the Merger Agreement certified by the Secretary of State of the State of Delaware, to Nasdaq on or before the closing of the Merger; and (d)&#160;to the extent required by Nasdaq Marketplace Rule 5110, assist Korro Bio in preparing and filing an initial listing application for the Frequency common stock on Nasdaq. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each party will keep the other party reasonably informed regarding any stockholder litigation against Frequency or any of its directors relating to Merger Agreement or the transactions contemplated by the Merger Agreement. Prior to the closing of the Merger, Frequency will have the right to control the defense and settlement of any such stockholder litigation, but will reasonably consult with Korro Bio and consider any advice from Korro Bio and its representatives. Frequency will promptly advise Korro Bio of the initiation of, and will keep Korro Bio reasonably apprised of any material developments in connection with, any such stockholder litigation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each party intends that the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. Each party will for all tax purposes report consistently with the foregoing, and no party will take any position on any tax return that is inconsistent with the foregoing, unless otherwise required by a governmental authority as a result of a &#8220;determination&#8221; within the meaning of Section 1313(a) of the Code. In addition, each party will use commercially reasonable efforts to promptly notify each other if such party becomes aware of any non-public fact or circumstance that would reasonably be likely to prevent or impede the Merger from qualifying for the foregoing tax treatment. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_70">Conditions to the Completion of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party&#8217;s obligation to effect the Merger and otherwise consummate the transactions contemplated under the Merger Agreement are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the completion of the Merger, of each of the following conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the transactions contemplated by the Merger Agreement shall have been issued by any court of competent jurisdiction or other governmental authority of competent jurisdiction and remain in effect and there shall not be any law which has the effect of making the consummation of the transactions contemplated by the Merger Agreement illegal. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each party shall have obtained its requisite stockholder vote. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The approval of the listing of the additional shares of Frequency common stock on Nasdaq shall have been obtained and the shares of Frequency common stock to be issued in the Merger pursuant to the Merger Agreement shall have been approved for listing (subject to official notice of issuance) on Nasdaq. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The <span style="white-space:nowrap">lock-up</span> agreements will continue to be in full force and effect as of immediately following the Effective Time. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">207 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio shall have effected the conversion of Korro Bio preferred stock to Korro Bio common stock immediately prior to the Effective Time in accordance with, and pursuant to the terms and conditions of, the organizational documents of Korro Bio. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The representations and warranties of each of Frequency and Korro Bio with respect to due organization, subsidiaries, organizational documents, authority, the binding nature of the Merger Agreement, required vote and no financial advisors shall have been true and correct in all material respects as of the date of the Merger Agreement and shall be true and correct on and as of the date of the completion of the Merger with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The representations and warranties of each of Frequency and Korro Bio with respect to capitalization shall have been true and correct in all respects as of the date of the Merger Agreement and shall be true and correct on and as of the date of the completion of the Merger with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are de minimis, individually or in the aggregate, or (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The remaining representations and warranties of each of Frequency and Korro Bio shall have been true and correct as of the date of the Merger Agreement and shall be true and correct on and as of the date of the completion of the Merger with the same force and effect as if made on such date except (i)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a material adverse effect (without giving effect to any references therein to any Frequency material adverse effect or Korro Bio material adverse effect, as applicable, or other materiality qualifications) or (ii)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (i), as of such particular date). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each party shall have performed and complied in all material respects with all covenants and agreements required to be performed or complied with by it under the Merger Agreement at or prior to the date of the completion of the Merger. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A material adverse effect with respect to either party shall not have occurred since the date of the Merger Agreement and be continuing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each party shall have delivered to the other party customary closing certificates signed by an executive officer of such party. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the obligation of Korro Bio to complete the Merger is further subject to the continual listing of the existing shares of Frequency common stock on Nasdaq as of and from the date of the Merger Agreement through the completion of the Merger. The obligation of Frequency and Merger Sub to complete the Merger is further subject to the subscription agreement relating to the Pre-Closing Financing being in full force and effect and cash proceeds of not less than $100&#160;million shall have been received by Korro Bio, or will be received by Korro Bio substantially simultaneously with the completion of the Merger, in connection with the consummation of the transactions contemplated by the subscription agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">208 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_71">Termination and Termination Fees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination of the Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement may be terminated at any time before the Effective Time, whether before or after the required stockholder approvals to complete the Merger have been obtained, as set forth below: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by mutual written consent of Frequency and Korro Bio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either Frequency or Korro Bio, if the Merger has not been consummated by November&#160;14, 2023 (subject to possible extension as provided in the Merger Agreement); <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur on or before November&#160;14, 2023 and such action or failure to act constitutes a breach of the Merger Agreement; and <span style="font-style:italic">provided</span>, <span style="font-style:italic">further</span>, that such date will be extended by 60 days upon request of either party in the event that the SEC has not declared effective the registration statement on Form S-4, of which this proxy statement/prospectus is a part, by the date which is 25 business prior to November&#160;14, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either Frequency or Korro Bio, if a court of competent jurisdiction or governmental authority has issued a final and non-appealable order or taken any other action that permanently restrains, enjoins or otherwise prohibits the Merger or any of the other transactions contemplated by the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Frequency, if the affirmative vote of the holders of at least 66% of the then outstanding shares of Korro Bio preferred stock, voting as a single class on <span style="white-space:nowrap">an-as</span> converted basis, necessary to adopt the Merger Agreement and approve the Merger and related matters has not been obtained within five business days of the registration statement on Form S-4, of which this proxy statement/prospectus is a part, becoming effective; <span style="font-style:italic">provided</span> that this right to terminate the Merger Agreement will not be available to Frequency once Korro Bio obtains such stockholder approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either Frequency or Korro Bio, if the Frequency stockholder meeting has been held and completed and Frequency stockholders have taken a final vote on the Merger proposal set forth herein to be considered at the Frequency stockholder meeting, including the issuance of Frequency common stock to Korro Bio stockholders in connection with the Merger, and such Merger proposal has not been approved by the Frequency stockholders; <span style="font-style:italic">provided</span>, that Frequency may not terminate the Merger Agreement pursuant to this provision if the failure to obtain the approval of Frequency stockholders was caused by the action or failure to act of Frequency and such action or failure to act constitutes a breach by Frequency of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Korro Bio, at any time prior to the approval by Frequency stockholders of the Merger proposal set forth herein to be considered at the Frequency stockholder meeting, if any of the following circumstances shall occur: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency fails to include in this proxy statement/prospectus the Frequency board of directors&#8217; recommendation that Frequency stockholders vote to approve the Merger proposal set forth herein to be considered at the Frequency stockholder meeting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Frequency board of directors, or any committee thereof, makes a recommendation change adverse to Korro Bio or approves, endorses or recommends any Acquisition Proposal; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(g)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Frequency, at any time prior to the adoption of the Merger Agreement and approval of the transactions contemplated therein by the Korro Bio stockholders, if any of the following circumstances shall occur: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korro Bio board of directors makes a recommendation change adverse to Frequency or approves, endorses or recommends any Acquisition Proposal; or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">209 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(h)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Korro Bio, if Frequency or Merger Sub has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Frequency or Merger Sub has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span style="font-style:italic">provided </span>that Korro Bio is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement; <span style="font-style:italic">provided</span>, <span style="font-style:italic">further</span>, if such breach or inaccuracy is curable by Frequency or Merger Sub, then the Merger Agreement will not terminate pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30-day period after delivery of written notice of such breach or inaccuracy from Korro Bio to Frequency or Merger Sub and Korro Bio&#8217;s intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Frequency or Merger Sub is cured prior to such termination becoming effective); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Frequency, if Korro Bio has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Korro Bio has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span style="font-style:italic">provided </span>that Frequency is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement; <span style="font-style:italic">provided</span>, <span style="font-style:italic">further</span>, if such breach or inaccuracy is curable, then the Merger Agreement will not terminate pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30-day period after delivery of written notice of such breach or inaccuracy from Frequency to Korro Bio and Frequency&#8217;s intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Korro Bio is cured prior to such termination becoming effective). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The party desiring to terminate the Merger Agreement will give the other party written notice of such termination, specifying the provisions hereof pursuant to which such termination is made and the basis for termination described in reasonable detail. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination Fees Payable by Frequency </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency must pay Korro Bio a termination fee of $1.5&#160;million if (i)&#160;the Merger Agreement is terminated by (A)&#160;Frequency or Korro Bio pursuant to clause&#160;(e) above, (B)&#160;at any time after the date of the Merger Agreement and prior to the Frequency stockholder meeting an Acquisition Proposal with respect to Frequency will have been publicly announced, disclosed or otherwise communicated to the Frequency board of directors (and will not have been withdrawn), and (C)&#160;within 12 months after the date of such termination, Frequency enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction, or (ii)&#160;the Merger Agreement is terminated by Korro Bio pursuant to clause&#160;(f) above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination Fees Payable by Korro Bio </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio must pay Frequency a termination fee of $4&#160;million if the Merger Agreement is terminated by Frequency pursuant to clause (d)&#160;or (g) above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_72">Amendment and Waiver </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement may not be amended except by an instrument in writing signed on behalf of each of Korro Bio, Merger Sub and Frequency. Such amendment requires the approval of the respective boards of directors of Korro Bio, Merger Sub and Frequency at any time, except that after the Merger Agreement has been </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">210 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adopted and approved by the Korro Bio stockholders or Frequency stockholders, no amendment which by law requires further approval by the Koro Bio stockholders or Frequency stockholders, as the case may be, may be made without such further approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision of the Merger Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party. The waiver must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be valid in the specific instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any power, right, privilege or remedy under the Merger Agreement will operate as a waiver of that said power, right, privilege or remedy. Furthermore, no single or partial exercise of any such power, right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency and Korro Bio have determined that, in light of the Reverse Stock Split, Frequency will not need to authorize additional shares of Frequency common stock. Accordingly, the parties have agreed that the authorization of additional shares of Frequency common stock will not be required under the terms and conditions of the Merger Agreement and will not be a condition to closing under the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_73">Fees and Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides all fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby shall be paid by the party incurring such expenses, whether or not the Merger is consummated, except as described above in the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#8211;Termination and Termination Fees</span>&#8221; beginning on page 209 of this proxy statement/prospectus, and except that Korro Bio will pay the costs and expenses incurred in relation to the filings by the parties under any antitrust law applicable to the Merger Agreement and the transactions contemplated by the Merger Agreement, and Korro Bio and Frequency will share equally in all fees and expenses incurred in relation to the printing and filing with the SEC of the registration statement on Form S-4 (including any financial statements and exhibits) and any related amendments or supplements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">211 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_74">AGREEMENTS RELATED TO THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_75">Support Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to induce Frequency to enter into the Merger Agreement, certain Korro Bio stockholders are parties to a support agreement with Frequency pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a Korro Bio stockholder, to vote all of his, her or its shares of Korro Bio capital stock in favor of (i)&#160;the adoption of the Merger Agreement and approval of the Merger, (ii)&#160;the approval of the related transactions contemplated by the Merger Agreement, (iii)&#160;the conversion of each share of Korro Bio preferred stock into shares of Korro Bio common stock immediately prior to and contingent upon the closing and (iv)&#160;the approval of certain additional proposals in connection with the Merger that the Korro Bio board of directors may recommend, including, if applicable, to approve any proposal to adjourn or postpone the meeting to a&#160;later date, if there are not sufficient votes for the adoption of the Merger Agreement on the date on which a meeting of such stockholders is held. These Korro Bio stockholders also agreed to vote against (i)&#160;any competing Acquisition Proposal with respect to Korro Bio and (ii)&#160;a any agreement, transaction or other matter that is intended to, or would reasonably be expected to, impede, interfere with, delay, postpone, discourage or materially and adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement, subject to certain specified exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These Korro Bio stockholders have also granted Korro Bio an irrevocable proxy to vote their respective shares of Korro Bio common stock or Korro Bio preferred stock in accordance with the support agreements. The Korro Bio stockholders may vote their shares of Korro Bio common stock or Korro Bio preferred stock on all other matters not referred to in such proxy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&#160;14, 2023, the Korro Bio stockholders that are party to a support agreement with Frequency owned an aggregate of 4,691,654 shares of Korro Bio common stock and 97,637,593 shares of Korro Bio preferred stock, representing approximately 98.0% of the outstanding shares of Korro Bio capital stock on an as converted to common stock basis. These stockholders include executive officers and directors of Korro Bio, as well as certain other stockholders owning a significant portion of the outstanding shares of Korro Bio capital stock. Following the effectiveness of the registration statement on <span style="white-space:nowrap">Form&#160;S-4&#160;of</span> which this proxy statement/prospectus is a part and pursuant to the Merger Agreement, Korro Bio stockholders holding a sufficient number of shares of Korro Bio capital stock to adopt the Merger Agreement and approve the Merger and related transactions will execute written consents providing for such adoption and approval. Therefore, holders of a sufficient number of shares of Korro Bio capital stock required to adopt the Merger Agreement and approve the Merger and related transactions that are contractually obligated to adopt the Merger Agreement are expected to adopt the Merger Agreement via written consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these support agreements, subject to certain exceptions, such stockholders have also agreed not to sell or transfer their shares of Korro Bio capital stock and securities convertible into shares of Korro Bio capital stock held by them, or any voting rights with respect thereto, until the earlier of the termination of the Merger Agreement and the completion of the Merger, subject to certain exceptions. To the extent that any such sale or transfer is permitted pursuant to the exceptions included in the support agreement, each person to which any shares of Korro Bio capital stock or securities convertible into shares of Korro Bio capital stock are so sold or transferred must agree in writing to be bound by the terms and provisions of the support agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in order to induce Korro Bio to enter into the Merger Agreement, certain Frequency stockholders have entered into support agreements with Korro Bio pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a Frequency stockholder, to vote all of his, her or its shares of Frequency common stock in favor of (i)&#160;the approval of the Merger Agreement, (ii)&#160;the transactions contemplated thereby, including the issuance of Frequency common stock to Korro Bio stockholders, (iii)&#160;an amendment to the amended and restated certificate of incorporation of Frequency to effect the proposed Reverse Stock Split, (iv)&#160;any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">212 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the approval of the Merger Agreement and the transactions contemplated therein and (v)&#160;the approval of certain additional proposals in connection with the Merger that the Frequency board of directors may recommend. These Frequency stockholders also agreed to vote against (i)&#160;any competing Acquisition Proposal with respect to Frequency and (ii)&#160;any action, proposal, agreement, transaction or proposed transaction that would reasonably be expected to materially impede, interfere with, delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement, subject to certain specified exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These Frequency Stockholders have also granted Korro Bio an irrevocable proxy to vote their respective shares of Frequency common stock in accordance with the support agreements. Frequency stockholders may vote their shares of Frequency common stock on all other matters not referred to in such proxy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&#160;14, 2023, the Frequency stockholders that are party to a support agreement owned approximately 3.5% of the outstanding shares of Frequency common stock. These stockholders include certain executive officers and directors of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these support agreements, subject to certain exceptions, such stockholders have also agreed not to sell or transfer their shares of Frequency common stock and securities convertible into shares of Frequency common stock held by them until the earlier of the termination of the Merger Agreement and the completion of the Merger, subject to certain exceptions. To the extent that any such sale or transfer is permitted pursuant to the exceptions included in the support agreements, each person to which any shares of Frequency common stock or securities convertible into shares of Frequency common stock are so sold or transferred must agree in writing to be bound by the terms and provisions of the support agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the support agreements does not purport to be complete and is qualified in its entirety by the full text of the forms of support agreements, which are attached hereto as<span style="font-style:italic">&#160;Annex C</span>&#160;and<span style="font-style:italic">&#160;Annex D</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_76"><span style="white-space:nowrap">Lock-Up</span> Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of Korro Bio&#8217;s executive officers, directors and stockholders have entered <span style="white-space:nowrap">into&#160;lock-up&#160;agreements,</span> pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, any shares of Frequency&#8217;s common stock, including, as applicable, shares received in the Merger and shares issuable upon exercise of options, warrants or convertible securities, until 180 days after the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio stockholders who have <span style="white-space:nowrap">executed&#160;lock-up&#160;agreements</span> as of July&#160;14, 2023, owned in the aggregate, approximately 98% of the shares of Korro Bio&#8217;s outstanding capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of Frequency&#8217;s executive officers, directors and stockholders have entered <span style="white-space:nowrap">into&#160;lock-up&#160;agreements,</span> pursuant to which such stockholders have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, any Frequency securities or shares of Frequency common stock, including, as applicable, shares issuable upon exercise of certain options, warrants or convertible securities, until 180 days after the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency stockholders who have <span style="white-space:nowrap">executed&#160;lock-up&#160;agreements</span> as of July&#160;14, 2023 owned, in the aggregate, approximately 3.5% of the shares of outstanding Frequency common stock as of June 30, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of <span style="white-space:nowrap">the&#160;lock-up&#160;agreements</span> does not purport to be complete and is qualified in its entirety by the full text of the form <span style="white-space:nowrap">of&#160;lock-up&#160;agreement,</span> which is attached hereto as<span style="font-style:italic">&#160;Annex F </span>and<span style="font-style:italic"> Annex G</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">213 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_77">Contingent Value Rights Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">CVR Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in the Merger Agreement and discussed under the section titled &#8220;<span style="font-style:italic">The Merger Agreement &#8212;Contingent Value Rights</span>&#8221; beginning on page 214 in this proxy statement/prospectus, unless (i) the MS Asset Disposition has been consummated prior to or on the closing date of the Merger and (ii) all proceeds from the MS Asset Disposition are taken into account in the final Frequency Net Cash and there are no contingent payments, licenses, fees or royalties, equity securities or other non-cash assets or rights that may be payable by any acquiror of any MS Assets or otherwise as a result of the MS Asset Disposition after the closing of the Merger, Frequency will declare a distribution to its common stockholders of record (determined as of the close of business on the last business day prior to the day on which the Effective Time occurs) the right to receive one CVR for each outstanding share of Frequency common stock held by such stockholder as of such date, each representing the non-transferable contractual right to receive certain contingent payments from Frequency upon the occurrence of certain events. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVRs will be governed by the terms of the CVR Agreement, which will be entered into at or prior to the Effective Time by Frequency and Computershare Trust Company, N.A. and Computershare Inc., collectively as Rights Agent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Characteristics of the CVRs; Restrictions on Transfer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVRs may not be transferred, pledged, hypothecated, encumbered, assigned or otherwise disposed of (whether by sale, merger, consolidation, liquidation, dissolution, dividend, distribution or otherwise), in whole or in part, other than pursuant to any of the following permitted transfers: (i)&#160;upon death, by will or intestacy; (ii)&#160;by instrument to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (iii)&#160;pursuant to a court order of a court of competent jurisdiction (such as in connection with divorce, bankruptcy or liquidation); (iv) by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (v)&#160;in the case of CVRs payable to a nominee, from a nominee to a beneficial owner (and, if applicable, through an intermediary) or from such nominee to another nominee for the same beneficial owner, in each case as permitted by The Depository Trust Company; (vi)&#160;to Frequency or its subsidiaries; or (vii)&#160;upon abandonment of a CVR by the holder thereof in accordance with the CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVRs will not be evidenced by a certificate or any other instrument. The CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of the CVRs. The CVRs will not represent any equity or ownership interest in Frequency, any constituent company to the Merger, or any of its subsidiaries. The Rights Agent will maintain <span style="white-space:nowrap"><span style="white-space:nowrap">an&#160;up-to-date&#160;register,</span></span> or the CVR Register, for the purposes of (i)&#160;identifying the holders of CVRs, (ii)&#160;determining holders&#8217; entitlement to CVRs, and (iii)&#160;registering the CVRs and permitted transfers thereof. Frequency&#8217;s obligation to make the CVR payment, if any becomes due, is neither secured nor guaranteed by Frequency or any of its subsidiaries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">214 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">CVR Payments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the CVR Agreement, each CVR holder is entitled to certain contingent cash payments, which are payable by Frequency to the Rights Agent for subsequent distribution to the CVR holders (such payments, the CVR Payments), of the CVR Proceeds, which will equal the net amount (calculated in accordance with GAAP consistently applied) of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The following proceeds actually received by Frequency or its subsidiaries, collectively, the Gross Proceeds, after the end of each fiscal quarter of Frequency following the first anniversary of the closing: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cash consideration that is paid to or received by Frequency or any of its subsidiaries during the period beginning immediately following the Effective Time and ending on the tenth anniversary of the closing date: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in respect of any MS Asset Disposition, or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">resulting from the ownership of equity securities in any subsidiary established by Frequency during the period beginning on the execution date of the Merger Agreement and ending on <span style="white-space:nowrap">the&#160;one-year&#160;anniversary</span> of the closing date, or the Disposition Period, or the subsequent disposition of any such equity securities (regardless of whether such disposition occurs during the Disposition Period). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">less</span> all applicable reasonably documented permitted deductions, collectively, the Permitted Deductions, as of the date of payment, which include: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain income taxes required to be paid in cash as a result of the receipt of the Gross Proceeds, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any reasonable and <span style="white-space:nowrap"><span style="white-space:nowrap">documented&#160;out-of-pocket&#160;costs</span></span> and expenses incurred by Frequency or its subsidiaries in respect of its performance of the CVR Agreement, or in respect of its performance of any agreement, in connection with the MS Assets, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any reasonable and <span style="white-space:nowrap"><span style="white-space:nowrap">documented&#160;out-of-pocket&#160;costs</span></span> and expenses incurred by Frequency or its subsidiaries in respect of the negotiation, entry into or the closing of any the MS Asset Disposition, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any losses incurred or reasonably expected to be incurred by Frequency or its subsidiaries arising out of any third-party claims relating to or in connection with any MS Asset Disposition, including indemnification obligations of Frequency or any of its subsidiaries set forth in a definitive written agreement with respect to any MS Asset Disposition, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any liabilities borne by Frequency or its subsidiaries pursuant to contracts related to the MS Assets, including costs arising from the termination thereof. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an MS Asset Disposition is consummated: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">on or prior to the closing date, then the proceeds from such disposition will be included in the calculation of Frequency Net Cash pursuant to the Merger Agreement; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">following the closing date and for a period of ten years thereafter, then CVR holders will receive 100% of the CVR Proceeds, as a CVR Payment. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Gross Proceeds result from the MS Assets or from the ownership of equity securities in any subsidiary established by Frequency during the Disposition Period or the subsequent disposition of any such equity securities, then CVR holders will receive 100% of the CVR Proceeds, as a CVR Payment, regardless of when such disposition is consummated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVR Agreement provides that Frequency and the Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, from any payment payable to CVR holders pursuant to the CVR </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">215 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, such amounts as they are required to deduct and withhold with respect to the making of such payment under any provision of applicable law relating to taxes. To the extent that amounts are so deducted and withheld and timely paid over to the appropriate governmental authority, such deducted and withheld amounts will be treated for all purposes of the CVR Agreement as having been paid to the CVR holder in respect of which such deduction and withholding was made. Prior to making any such tax deductions or withholdings or causing any such tax deductions or withholdings to be made with respect to any CVR holder, the Rights Agent will, to the extent reasonably practicable, provide notice to the CVR holder of such potential tax deduction or withholding and a reasonable opportunity for the CVR holder to provide any necessary tax forms in order to avoid or reduce such withholding amounts. However, the time period for the payment of amounts payable to such CVR holder in accordance with the CVR Agreement will be extended by a period equal to any delay caused by the CVR holder in providing such forms, and in no event will such period be extended for more than ten business days (unless otherwise requested by the CVR holder for the purpose of delivering such forms and agreed to by the Rights Agent). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Payment Procedures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As promptly as practicable after CVR Proceeds are actually received, but no later than 45 days following the end of each fiscal quarter of Frequency following the first anniversary of the closing, Frequency will (i)&#160;deliver to the Rights Agent an officer&#8217;s certificate certifying for such fiscal quarter the aggregate amount of (a)&#160;the CVR Proceeds received by Frequency or its subsidiaries during such fiscal quarter (or in the case of the first delivery of such certificate, all CVR Proceeds received through the end of such fiscal quarter), (b) the Permitted Deductions reflected in such CVR Proceeds and (c)&#160;the CVR payment payable to the CVR holders, if any, and (d) deliver to the Rights Agent, or as the Rights Agent directs, the CVR payments (if any) by wire transfer of immediately transferable funds to an account designated by the Rights Agent. Upon receipt of the wire transfer referred to in the foregoing sentence, the Rights Agent shall promptly (and in any event, within ten business days) pay, by check mailed, first-class postage prepaid, to the address of each CVR holder set forth in the CVR Register at such time or by other method of delivery as specified by the applicable holder in writing to the Rights Agent, an amount equal to the product determined by multiplying (i) the quotient determined by dividing (A) the applicable CVR Payment by (B) the total number of CVRs registered in the CVR Register at such time, by (ii) the number of CVRs registered to such holder in the CVR Register at such time. For the avoidance of doubt Frequency shall have no further liability in respect of the relevant CVR Payment upon delivery of such CVR Payment to the Rights Agent and the satisfaction of each of Frequency&#8217;s obligations set forth hereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">CVR Special Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVR Agreement provides that the Frequency board of directors shall have delegated to a special committee of Frequency board of directors, or the CVR Special Committee, comprised of the two independent Frequency board designees, one designee of Frequency and one designee of Korro Bio the sole responsibility, authority and discretion during the Disposition Period, with respect to (i)&#160;managing the MS Assets (ii)&#160;conducting any sale process (including the engagement of advisors) with respect to an MS Asset Disposition during the Disposition Period and (iii)&#160;otherwise divesting or disposing of the MS Assets during the Disposition Period pursuant to a license with a term of not more than ten years. The CVR Special Committee shall also be empowered with the authority to authorize and direct any officer of Frequency to negotiate, execute and deliver a definitive written agreement with respect to an MS Asset Disposition in the name and on behalf of Frequency, provided that no such agreement shall be entered into without the approval of the Frequency board of directors (such approval not to be unreasonably withheld, conditioned or delayed). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the Disposition Period, if and to the extent the CVR Special Committee authorizes the execution and delivery of a definitive written agreement with respect to an MS Asset Disposition, Frequency will, and will cause its subsidiaries to, use commercially reasonable efforts to effectuate the disposition of MS Assets pursuant to such agreement in accordance with its terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">216 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Disposition Period, Frequency will be permitted to take any action in respect of the MS Assets in order to satisfy any liabilities of or arising from the MS Assets, including any wind-down or termination costs of the MS Assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment and Termination of the CVR Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency may, at any time and from time to time, unilaterally enter into one or more amendments to the CVR Agreement for any of the following purposes, without the consent of any of the holders of CVRs or the Rights Agent: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to evidence the appointment of another person as a successor Rights Agent and the assumption by any successor Rights Agent of the covenants and obligations of the Rights Agent pursuant to the CVR Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to evidence the succession of another person to Frequency and the assumption of any such successor of the covenants of Frequency pursuant to the CVR Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to add to the covenants of Frequency further covenants, restrictions, conditions or provisions for the protection and benefit of the holders of CVRs, provided that in each case, such provisions shall not adversely affect the interests of the holders of CVRs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to cure any ambiguity, to correct or supplement any provision in the CVR Agreement that may be defective or inconsistent with any other provision in the CVR Agreement, or to make any other provisions with respect to matters or questions arising under the CVR Agreement, provided that in each case, such provisions shall not adversely affect the interests of the holders of CVRs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">as may be necessary or appropriate to ensure that CVRs are not subject to registration under the&#160;Securities Act&#160;or the&#160;Exchange Act&#160;and the rules and regulations made thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">as may be necessary or appropriate to ensure that Frequency is not required to produce a prospectus or an admission document in order to comply with applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to cancel CVRs (i)&#160;in the event that any holder of CVRs has abandoned its rights to such CVRs or (ii)&#160;following a transfer of such CVRs to Frequency or its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">as may be necessary or appropriate to ensure that Frequency complies with applicable law; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to effect any other amendment to the CVR Agreement that would provide any additional rights or benefits to the holders of CVRs or that does not adversely affect the legal rights under the CVR Agreement of any such holder of CVRs. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the consent of the holders of not less than a majority of the outstanding CVRs, Frequency and the Rights Agent may enter into any amendment to the CVR Agreement, even if such amendment is adverse to the interests of the holders of the CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency will (or will cause the Rights Agent to) provide notice in general terms of the substance of any amendment to the CVR Agreement to the holders of the CVRs promptly after execution by Frequency and the Rights Agent, if applicable, of such amendment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVR Agreement will automatically terminate and of no force or effect, and the parties will have no liability thereunder, upon the tenth anniversary of the closing date.<span style="font-weight:bold">&#160;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Provisions of the CVR Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVR Agreement also provides, among other things, for: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the duties, responsibilities, rights and immunities of the Rights Agent, and procedures for the resignation or removal of the Rights Agent and appointment of a successor; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">217 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a prohibition on Frequency granting any lien, security, interest, pledge or similar interest in any MS Assets or any CVR Proceeds, unless approved by the CVR Special Committee; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the application of laws of the State of Delaware, exclusive jurisdiction over the parties by the Chancery Court of the State of Delaware, County of New Castle, or, if under applicable law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the District of Delaware (and appellate courts thereof), and waiver of trial by jury.<span style="font-style:italic">&#160;</span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the CVR Agreement does not purport to be complete and is qualified in its entirety by the full text of the form of CVR Agreement, which is attached hereto as<span style="font-style:italic">&#160;Annex E</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_78"><span style="font-style:italic">Material U.S.&#160;Federal Income Tax Consequences of the CVRs to Holders of Frequency Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax consequences of the issuance of the CVRs and payments (if any) thereon to holders of Frequency common stock, but does not purport to be a&#160;complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or <span style="white-space:nowrap">non-U.S.</span> tax laws are not discussed. Furthermore, the following discussion does not address any tax consequences of transactions effectuated before, after or at the same time as the distribution of the CVRs (except, to the limited extent discussed below, the Reverse Stock Split), whether or not they are in connection with the distribution of the CVRs. The CVRs generally may not be transferred or assigned except for certain permitted transfers; accordingly, this discussion assumes the CVRs are not transferable or assignable and does not address any consequences of transferring, assigning or otherwise disposing of the CVRs or any interest therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case, as in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a holder of Frequency common stock. Frequency has not sought and will not seek an opinion of counsel or any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the issuance of the CVRs and payments (if any) thereon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to holders of Frequency common stock who hold their Frequency common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to the particular circumstances of a holder of Frequency common stock, including the impact of the Medicare contribution tax on net investment income and the alternative minimum tax. In addition, it does not address consequences relevant to holders of Frequency common stock that are subject to particular rules, including, without limitation: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. expatriates or former citizens or long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding Frequency common stock as part of a hedge, straddle, or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks, insurance companies, and other financial institutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts or regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">brokers, dealers, or traders in securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">S corporations, partnerships, or other entities or arrangements treated as pass-through entities for U.S. federal income tax purposes (and investors therein); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">218 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations, qualified retirement plans, individual retirement accounts or other tax deferred accounts, or governmental organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons deemed to sell Frequency common stock under the constructive sale provisions of the Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who hold or receive Frequency common stock pursuant to the exercise of any employee stock options or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations, passive foreign investment companies, and corporations that accumulate earnings to avoid U.S. federal income tax. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to special tax accounting rules as a result of any item of gross income with respect to the Frequency common stock or the CVRs being taken into account in an applicable financial statement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, or an entity treated as a partnership for U.S. federal income tax purposes, holds Frequency common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships holding Frequency common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THIS DISCUSSION IS NOT TAX ADVICE. HOLDERS OF FREQUENCY COMMON STOCK SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE ISSUANCE OF THE CVRS, AND PAYMENTS (IF ANY) THEREON, ARISING UNDER OTHER U.S. FEDERAL TAX LAWS (INCLUDING ESTATE AND GIFT TAX LAWS), UNDER THE LAWS OF ANY STATE, LOCAL, OR <span style="white-space:nowrap">NON-U.S.</span> TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material U.S. Federal Income Tax Consequences for U.S. Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Frequency common stock that, for U.S. federal income tax purposes, is or is treated as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust that (1)&#160;is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code), or (2)&#160;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tax Treatment of the CVRs and the Proposed Reverse Stock Split </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the matter is not free from doubt, Frequency intends to treat the issuance of the CVRs (together with any payments on the CVRs) and the proposed Reverse Stock Split as separate transactions for U.S. federal income tax purposes, and the following discussion (except as discussed below under &#8220;&#8212;<span style="font-style:italic">Alternative Treatment of the CVRs and the Reverse Stock Split as a Single Recapitalization</span>&#8221;) assumes this treatment will be respected. The IRS could challenge this position, however. Frequency urges you to consult your tax advisor with respect to whether the issuance of the CVRs (and any payments on the CVRs), on the one hand, and the proposed Reverse Stock Split, on the other, constitute separate transactions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">219 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tax Treatment of the CVRs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no authority directly on point addressing whether contingent value rights with characteristics similar to the CVRs should be treated for federal income tax purposes as a distribution of property with respect to Frequency stock, an &#8220;open transaction,&#8221; or in some other manner, and such questions are inherently factual in nature. Accordingly, holders are urged to consult with their tax advisors regarding this issue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, based on the specific characteristics of the CVRs, and unless otherwise required by a change in law after the date of the CVR Agreement, Frequency intends to take the position that the fair market value of the CVRs cannot be reasonably ascertained on the date of the issuance of the CVRs, or the CVR Distribution Date, and, accordingly, the issuance of the CVRs constitutes an &#8220;open transaction.&#8221; Accordingly, absent a change in law requiring otherwise, the combined company will not report the issuance of the CVRs as a current distribution of property with respect to its stock and will instead report each future cash payment (if any) on the CVRs as a distribution by the combined company for U.S. federal income tax purposes, with each such payment being reported as a dividend to the extent of the combined company&#8217;s current and accumulated earnings and profits in the year in which such payment is made. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency&#8217;s intended reporting position is correct, a U.S. Holder would generally not recognize income in respect of the CVRs on the CVR Distribution Date and would take no tax basis in the CVRs. Any future cash payments would constitute a dividend to the extent of Frequency&#8217;s current and accumulated earnings and profits (as determined for U.S. federal income tax purposes) in the taxable year of such payment, then as a <span style="white-space:nowrap">non-taxable</span> return of capital to the extent of such holder&#8217;s basis in its Frequency common stock, and finally as capital gain from the sale or exchange of Frequency common stock. Dividends received by individual U.S. Holders are eligible for reduced rates of taxation applicable to long-term capital gains, provided certain holding period requirements are met. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the IRS could instead assert that the issuance of the CVRs should be treated as a &#8220;closed transaction.&#8221; Under &#8220;closed transaction&#8221; treatment, a U.S. Holder would be treated as receiving a distribution equal to the fair market value (determined on the CVR Distribution Date) of the CVRs issued to such U.S. Holder on the CVR Distribution Date. The amount of this distribution generally would be treated first as a taxable dividend to the extent of the U.S. Holder&#8217;s pro rata share of Frequency&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a <span style="white-space:nowrap">non-taxable</span> return of capital to the extent of the U.S. Holder&#8217;s basis in its Frequency common stock, and finally as capital gain from the sale or exchange of Frequency common stock. A U.S. Holder&#8217;s tax basis in the CVRs received would equal the fair market value of the CVRs on the CVR Distribution Date and the holding period of the CVRs received would begin on the day following the CVR Distribution Date. Although not free from doubt, a future cash payment under a CVR would likely be treated as a <span style="white-space:nowrap">non-taxable</span> return of a U.S. Holder&#8217;s adjusted tax basis in the CVR to the extent thereof, although the timing of the recovery of a U.S. Holder&#8217;s tax basis is unclear. A payment in excess of such amount may be treated as a&#160;payment with respect to a sale of a capital asset, ordinary income or dividends. Additionally, it is possible that a portion of future cash payments would constitute imputed interest and taxed as such. A U.S. Holder might recognize loss, which might be a capital loss and could be a long-term capital loss, upon the expiration of the CVR to the extent cash payments ultimately received pursuant to such CVR were less than the U.S. Holder&#8217;s adjusted tax basis in the CVRs, but whether and when such a loss would be recognized is unclear. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible, although Frequency believes unlikely, that the issuance of the CVRs could be treated as one or more &#8220;debt instruments&#8221; or as a&#160;distribution of equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders are urged to consult their tax advisors with respect to the proper characterization of the CVRs and the tax consequences thereof (including any future cash payments made under the CVRs). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">220 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Alternative Treatment of the CVRs and the Proposed Reverse Stock Split as a Single Recapitalization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding Frequency&#8217;s position that the CVRs and the proposed Reverse Stock Split are appropriately treated as separate transactions, it is possible that the IRS or a court could determine that the issuance of the CVRs (and/or any payments thereon) and the proposed Reverse Stock Split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes with the CVRs constituting taxable &#8220;boot&#8221; received in such recapitalization exchange. In such case, the tax consequences of the CVRs and the proposed Reverse Stock Split would differ from those described above, including the timing and character of income, which would depend in part on many of the same considerations described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">DUE TO THE SUBSTANTIAL UNCERTAINTY REGARDING THE TAX TREATMENT OF THE CVRS (AND ANY FUTURE CASH PAYMENTS UNDER THE CVRS) AND THE POSSIBLE INTEGRATION OF THE CVRS AND THE PROPOSED REVERSE STOCK SPLIT, U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS CONCERNING THE RECOGNITION OF GAIN, INCOME AND/OR LOSS IN CONNECTION WITH THE CVRS AND THE PROPOSED REVERSE STOCK SPLIT AND THE APPLICABILITY OF INFORMATION REPORTING AND BACKUP WITHHOLDING. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material U.S. Federal Income Tax Consequences for <span style="white-space:nowrap">Non-U.S.</span> Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below applies to beneficial owners of Frequency common stock that are not U.S. Holders or entities treated as partnerships or other pass-through entities for U.S. federal income tax purposes (such beneficial owners, <span style="white-space:nowrap">Non-U.S.</span> Holders). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed above under &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences for U.S. Holders&#8212;Tax Treatment of the CVRs and the Proposed Reverse Stock Split</span>&#8221; and &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences for U.S. Holders&#8212;Tax Treatment of the CVRs</span>,&#8221; Frequency intends to take the position that any future cash payments on the CVRs are distributions with respect to Frequency common stock and that such distributions constitute dividends to the extent payable out of Frequency&#8217;s current and accumulated earnings and profits (as determined under U.S. federal income tax principles) in the taxable year of such future cash payment. Assuming such position is correct, amounts not treated as dividends for U.S. federal income tax purposes would constitute a return of capital and first be applied against and reduce a <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis in its common stock, but not below zero, and any excess would be treated as capital gain with respect to such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s Frequency common stock. However, this intended position is subject to substantial uncertainty, and, accordingly, <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors with respect to the proper characterization of the CVRs and the tax consequences thereof (including any future cash payments made under the CVRs). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of Frequency&#8217;s intended reporting position, it is expected that <span style="white-space:nowrap">Non-U.S.</span> Holders would generally be subject to U.S. federal withholding tax at a rate of 30% on any future cash payments on the CVRs. Such withholding may be reduced or eliminated if the <span style="white-space:nowrap">Non-U.S.</span> Holder properly certifies qualification for a lower withholding rate under an applicable income tax treaty or an exemption from withholding as a result of dividends on the Frequency common stock being effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <span style="white-space:nowrap">Non-U.S.</span> Holder maintains a permanent establishment in the United States to which such dividends are attributable). A <span style="white-space:nowrap">Non-U.S.</span> Holder that is a corporation also could be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on income attributable to the CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">DUE TO THE LEGAL AND FACTUAL UNCERTAINTY REGARDING THE TAX TREATMENT OF THE CVRS (AND ANY FUTURE CASH PAYMENTS UNDER THE CVRS), <span style="white-space:nowrap">NON-U.S.</span> HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS CONCERNING THE RECOGNITION OF GAIN, INCOME AND/OR LOSS OR WITHHOLDING THAT MAY APPLY IN CONNECTION WITH THE CVRS. <span style="white-space:nowrap">NON-U.S.</span> HOLDERS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">221 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">
APPLICABILITY OF INFORMATION REPORTING AND BACKUP WITHHOLDING AND/OR WITHHOLDING UNDER THE FOREIGN ACCOUNT TAX COMPLIANCE ACT WITH RESPECT TO THE CVRS AND ANY FUTURE CASH PAYMENTS UNDER THE CVRS, PARTICULARLY IN LIGHT OF THE UNCERTAINTY UNDER U.S. FEDERAL INCOME TAX LAW RELATING TO THE TAX TREATMENT OF THE CVRS. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">222 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_79">MATERIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax consequences for certain holders of Korro Bio common stock that exchange, pursuant to the Merger, their Korro Bio common stock for Frequency common stock. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or <span style="white-space:nowrap">non-U.S.</span> tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case, as in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change may be applied retroactively in a manner that could adversely affect a holder of Korro Bio common stock. Frequency has not sought and will not seek an opinion of counsel or any rulings from the IRS regarding the matters discussed below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to holders of Korro Bio common stock who hold their Korro Bio common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). In addition, this discussion does not address (a)&#160;all U.S. federal income tax consequences relevant to the particular circumstances of a stockholder of Korro Bio common stock, including the impact of the Medicare contribution tax on net investment income and the alternative minimum tax, (b)&#160;the tax consequences of transactions effectuated before, after or at the same time as the Merger, whether or not they are in connection with the Merger, including, without limitation, transactions in which shares of Korro Bio common stock are acquired or disposed of other than in exchange for shares of Frequency common stock in the Merger; (c)&#160;the tax consequences to holders of Korro Bio convertible notes, or options or warrants issued by Korro Bio which are assumed in connection with the Merger; (c)&#160;the tax consequences of the ownership of shares of Frequency common stock following the Merger; or (d)&#160;consequences relevant to holders of Korro Bio common stock that are subject to particular rules, including, without limitation: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">brokers, dealers, or traders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons whose functional currency is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations, qualified retirement plans, individual retirement accounts or other tax deferred accounts, or governmental organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks or other financial institutions, underwriters, insurance companies, real estate investment trusts or regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. expatriates or former citizens or long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that own (directly, indirectly, or by attribution) 5% or more (by vote or value) of the stock of Korro Bio prior to the Merger or of Frequency after the Merger (except as specifically addressed herein); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">S corporations, partnerships or other pass-through entities or arrangements for U.S. federal income tax purposes or beneficial owners of partnerships or other pass-through entities or arrangements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding Korro Bio common stock as part of a straddle, hedging or conversion transaction, constructive sale, or other arrangement involving more than one position; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to special tax accounting rules as a result of any item of income relating to Korro Bio common stock being recognized on an applicable financial statement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. Holders (as defined below) that hold Korro Bio common stock in connection with a trade or business conducted outside the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that hold or received Korro Bio common stock pursuant to the exercise of any employee stock option or otherwise as compensation for services; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. Holders of Korro Bio common stock that hold such stock as Section&#160;306 stock (within the meaning of Section&#160;306(c) of the Code); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">223 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;qualified foreign pension funds&#8221; as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations, passive foreign investment companies, and corporations that accumulate earnings to avoid U.S. federal income tax. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, or an entity treated as a partnership for U.S. federal income tax purposes, holds Korro Bio common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships holding Korro Bio common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THIS DISCUSSION IS NOT TAX ADVICE. HOLDERS OF KORRO BIO STOCK SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE MERGER ARISING UNDER OTHER U.S. FEDERAL TAX LAWS (INCLUDING ESTATE AND GIFT TAX LAWS), UNDER THE LAWS OF ANY STATE, LOCAL, OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that the Merger shall qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code and the Treasury Regulations promulgated thereunder. The parties to the Merger Agreement have agreed to report the Merger as qualifying as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code for U.S. federal income tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the Merger is not conditioned upon the receipt of an opinion of counsel or a ruling from the IRS regarding the U.S. federal income tax treatment of the Merger, and no opinion of counsel or ruling from the IRS will be requested regarding such treatment. Accordingly, there can be no assurance that the IRS will not challenge the qualification of the Merger as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code or that a court will not sustain such a challenge by the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material U.S. Federal Income Tax Consequences for U.S. Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Korro Bio common stock that, for U.S. federal income tax purposes, is or is treated as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust that (1)&#160;is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code), or (2)&#160;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, a U.S. Holder that exchanges shares of Korro Bio common stock in the Merger for Frequency common stock generally should not recognize any gain or loss on such exchange. In such case, the aggregate adjusted tax basis of the Frequency common stock received in the Merger by a U.S. Holder should be equal to the adjusted tax basis of the Korro Bio common stock surrendered in the Merger in exchange therefor and the holding period of the Frequency common stock should include the holding period during which the Korro Bio common stock surrendered in the Merger in exchange therefor. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">224 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger does not qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, a U.S. Holder that exchanges Korro Bio common stock in the Merger for Frequency common stock generally would be required to recognize gain or loss equal to the difference, if any, between (i)&#160;the fair market value as of the Effective Time of the Frequency common stock received by such U.S. Holder and (ii)&#160;such U.S. Holder&#8217;s adjusted tax basis in the Korro Bio common stock exchanged therefor. Such gain or loss would be capital gain or loss and generally would be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for such shares of Korro Bio common stock exceeds one year. Net short-term capital gain generally is taxed at regular ordinary income tax rates. Long-term capital gain recognized by non-corporate U.S. Holders may be taxed at reduced rates. The deductibility of capital losses is subject to limitations. A U.S. Holder would have an aggregate tax basis in any Frequency common stock received in the Merger that is equal to the fair market value of such Frequency common stock as of the Effective Time, and the holding period of such Frequency common stock would begin on the day following the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency common stock received in the Merger by a U.S. Holder that acquired different blocks of Korro Bio common stock at different times or at different prices will be allocated pro rata to each block of Korro Bio common stock of such U.S. Holder, and the basis and holding period of such shares of Frequency common stock will be determined using a block for block approach and will depend on the basis and holding period of each block of Korro Bio common stock exchanged for such Frequency common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material U.S. Federal Income Tax Consequences for Non-U.S. Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below applies to beneficial owners of Frequency common stock that are not U.S. Holders or entities treated as partnerships or other pass-through entities for U.S. federal income tax purposes (such beneficial owners, Non-U.S. Holders). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the U.S. federal income tax consequences relating to the Merger for a Non-U.S. Holder that exchanges its shares of Korro Bio common stock for Frequency common stock in the Merger will be the same as those described above for a U.S. Holder, except that, even if the Merger did not qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, a Non-U.S. Holder generally will not be subject to U.S. federal income tax on any gain realized in connection with the Merger unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment of the Non-U.S. Holder in the United States); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Non-U.S. Holder is an individual who is present in the United States for 183&#160;days or more in the taxable year in which the Merger occurs and certain other conditions are met; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">shares of Korro Bio common stock constituted a &#8220;United States real property interest&#8221;, or a USRPI, by reason of Korro Bio&#8217;s status as a &#8220;United States real property holding corporation&#8221;, or a USRPHC, for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of the Merger or the period that such Non-U.S. Holder held shares of Korro Bio common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such Non-U.S. Holder were a U.S. Holder. A Non-U.S. Holder that is a corporation also may be subject to an additional branch profits tax at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on its effectively connected earnings and profits for the taxable year, subject to certain adjustments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Non-U.S. Holder described in the second bullet point above will be subject to U.S. federal income tax with respect to such gain at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty), which may be offset by such Non-U.S. Holder&#8217;s U.S. source capital losses, if any, provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">225 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the third bullet point above, Korro Bio does not believe it is, or has been during the five-year period ending on the date of the Merger, a USRPHC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-U.S. Holders should consult their tax advisors regarding the potential application of income tax treaties that may provide for different rules with respect to any gain recognized by a Non-U.S. Holder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Reporting Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code, each U.S. Holder that is a &#8220;significant transferor&#8221; must include a statement on or with such transferor&#8217;s U.S. federal income tax return for the taxable year of the Merger. For this purpose, a significant transferor is generally a person that transferred property to a corporation and received stock of the transferee corporation if, immediately after the exchange, such person (i) owns at least five percent (5%) (by vote or value) of the total outstanding stock of the transferee corporation if the stock owned by such person is publicly traded, or (ii) owned at least one percent&#160;(1%) (by vote or value) of the total outstanding stock of the transferee corporation if the stock owned by such person is not publicly traded. It is expected that the Frequency common stock will be publicly traded for this purpose. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE PRECEDING DISCUSSION IS INTENDED ONLY AS A SUMMARY OF CERTAIN U.S. FEDERAL INCOME TAX CONSEQUENCES RELATING TO THE MERGER. IT IS NOT A COMPLETE ANALYSIS OR DISCUSSION OF ALL POTENTIAL TAX EFFECTS THAT MAY BE IMPORTANT TO A PARTICULAR HOLDER OF SHARES OF KORRO BIO COMMON STOCK. ALL HOLDERS OF SHARES OF KORRO BIO COMMON STOCK ARE STRONGLY ENCOURAGED TO CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE U.S. FEDERAL INCOME TAX CONSEQUENCES RELATING TO THE MERGER FOR THEM IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES, INCLUDING THE APPLICABILITY AND EFFECT OF TAX REPORTING REQUIREMENTS, AND THE APPLICABILITY AND EFFECT OF ANY OTHER U.S. FEDERAL TAX LAWS, AND U.S. STATE OR LOCAL, NON-U.S. OR OTHER TAX LAWS. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">226 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_80">THE ANNUAL MEETING OF FREQUENCY STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_81">Date, Time and Place </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency Annual Meeting will be held on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, commencing at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a.m. Eastern Time, unless postponed or adjourned to a later date. The Frequency Annual Meeting will be held entirely online. Frequency is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by Frequency&#8217;s board of directors for use at the Frequency Annual Meeting and any adjournments or postponements of the Frequency Annual Meeting. This proxy statement/prospectus is first being sent to Frequency stockholders on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_82">Purposes of the Frequency Annual Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Frequency Annual Meeting is: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the issuance of shares of common stock of Frequency to stockholders of Korro Bio pursuant to the terms of the Merger Agreement, a copy of which is attached as <span style="font-style:italic">Annex A</span> to this proxy statement/prospectus, pursuant to which Merger Sub will merge with and into Korro Bio, with Korro Bio surviving as a wholly owned subsidiary of Frequency, and the surviving corporation of the Merger, and the change of control resulting from the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve an amendment to the Restated Certificate of Incorporation of Frequency, a copy of which is attached as <span style="font-style:italic">Annex H </span>to this proxy statement/prospectus, to effect a reverse stock split of Frequency&#8217;s issued and outstanding common stock at a ratio ranging from any whole number between 1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and 1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, as determined by the Frequency board of directors in its discretion, subject to the Frequency board of directors&#8217; authority to abandon such amendments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To elect David L. Lucchino as a Class I director to hold office until the annual meeting of stockholders to be held in 2026 and until his respective successor has been duly elected and qualified; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To ratify, in a non-binding vote, the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the 2023 Stock Option and Incentive Plan, a copy of which is attached as <span style="font-style:italic">Annex I</span> to the accompanying proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">6.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the 2023 Employee Stock Purchase Plan, a copy of which is attached as <span style="font-style:italic">Annex J</span> to the accompanying proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">7.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To consider and vote upon an adjournment of the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">8.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To transact such other business as may properly come before the stockholders at the Frequency Annual Meeting or any adjournment or postponement thereof. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposal No.&#160;1 is referred to herein as the Merger Proposal. The Merger Proposal is a condition to completion of the Merger. The issuance of Frequency common stock in connection with the Merger cannot take place unless the Merger Proposal is approved by the Frequency stockholders. Therefore, the Merger cannot be consummated without the approval of the Merger Proposal and Proposal No. 2. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_83">Recommendation of the Frequency Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors recommends that you vote: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">FOR</span> the approval of the issuance of shares of Frequency common stock pursuant to terms of the Merger Agreement and the change of control resulting from the Merger (Proposal No.&#160;1). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">227 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">FOR</span> the approval of an amendment to the Restated Certificate of Incorporation of Frequency to effect a the Reverse Stock Split, subject to the Frequency board of directors&#8217; authority to abandon such amendments, as described in this proxy statement/prospectus (Proposal No.&#160;2). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">FOR</span> the election of David L. Lucchino as a Class I director to hold office until the 2026 Annual Meeting and until his successor has been duly elected and qualified to the Frequency board of directors, as described in this proxy statement/prospectus (Proposal No.&#160;3). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">FOR</span> the ratification of the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2023 (Proposal No.&#160;4). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">FOR</span> the approval and adoption of the 2023 Stock Option and Incentive Plan (Proposal No.&#160;5). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">FOR</span> the approval and adoption of the 2023 Employee Stock Purchase Plan (Proposal No.&#160;6). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">FOR</span> the adjournment of the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Frequency Annual Meeting to approve Proposal Nos. 1 and 2 (Proposal No.&#160;7). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_84">Record Date and Voting Power </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only stockholders of record of Frequency common stock at the close of business on the record date &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, are entitled to notice of, and to vote at, the Frequency Annual Meeting. As of the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; stockholders of record and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of Frequency common stock issued and outstanding. Each share of Frequency common stock entitles the stockholder thereof to one vote on each matter submitted for stockholder approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_85">Voting and Revocation of Proxies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy accompanying this proxy statement/prospectus is solicited on behalf of Frequency&#8217;s board of directors for use at the Frequency Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, as of the Record Date, your shares were registered directly in your name with the transfer agent for Frequency common stock, Computershare Trust Company, N.A., then you are a stockholder of record. Whether or not you plan to attend the Frequency Annual Meeting online, Frequency urges you to fill out and return the proxy card or vote over the telephone or on the Internet as instructed below to ensure your vote is counted. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The procedures for voting are as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may vote at the Frequency Annual Meeting. Alternatively, you may vote by proxy by using the accompanying proxy card, over the Internet or by telephone. Whether or not you plan to attend the Frequency Annual Meeting, Frequency encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the Frequency Annual Meeting, you may still attend and participate in the Frequency Annual Meeting online by accessing www.proxydocs.com/FREQ. In such case, your previously submitted proxy will be disregarded. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote at the Frequency Annual Meeting, attend the Frequency Annual Meeting online and follow the instructions posted at www.proxydocs.com/FREQ. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote using the proxy card, simply complete, sign and date the accompanying proxy card and return it promptly in the envelope provided. If you return your signed proxy card before the Frequency Annual Meeting, Frequency will vote your shares in accordance with the proxy card. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote by proxy over the Internet at www.proxypush.com/FREQ, follow the instructions on the proxy card. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote by telephone by calling 1-866-390-5362, follow the instructions on the proxy card. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">228 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank or other nominee, you should have received a voting instruction card and voting instructions with these proxy materials from your broker, bank or other nominee. Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote live at the Frequency Annual Meeting, you must obtain a valid proxy from your broker, bank or other nominee. Follow the instructions from your broker, bank or other nominee included with these proxy materials, or contact your broker, bank or other nominee to request a proxy form. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current Nasdaq interpretations that govern broker non-votes, the Merger Proposal, Proposal No.&#160;2 for the amendment of the Restated Certificate of Incorporation, Proposal No.&#160;3 for the election of directors, Proposal No.&#160;5 for the 2023 Stock Option and Incentive Plan, Proposal No.&#160;6 for the 2023 Employee Stock Purchase Plan and Proposal No.&#160;7 to adjourn the meeting to seek additional proxies are considered a non-discretionary matter, and a broker does not have the authority to vote uninstructed shares at its discretion on such proposals. Proposal No.&#160;4 for the ratification of the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm is considered a discretionary matter, and a broker is permitted to exercise its discretion to vote uninstructed shares on the proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All properly executed proxies that are not revoked will be voted at the Frequency Annual Meeting and at any adjournments or postponements of the Frequency Annual Meeting in accordance with the instructions contained in the proxy. <span style="font-weight:bold">If a holder of Frequency common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all of the proposals in accordance with the recommendation of Frequency&#8217;s board of directors.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record of Frequency and you have not executed a support agreement, you may change your vote at any time before your proxy is voted at the Frequency Annual Meeting in any one of the following ways: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You may submit another properly completed proxy with a later date by mail or via the Internet. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You can provide your proxy instructions via telephone at a later date. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You may send a written notice that you are revoking your proxy to Frequency&#8217;s Corporate Secretary at 75 Hayden Avenue, Suite 300, Lexington, MA 02421. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You may attend the Frequency Annual Meeting online and vote by following the instructions at www.proxydocs.com/FREQ. Simply attending the Frequency Annual Meeting will not, by itself, revoke your proxy. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker, bank or other agent, you should follow the instructions provided by them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#8220;street name&#8221; by a bank, broker or other nominee, you will receive instructions on how to vote from the bank, broker or other nominee. You must follow the instructions of such bank, broker or other nominee in order for your shares to be voted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_86">Required Vote </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence, remote communication or represented by proxy, at the Frequency Annual Meeting of the stockholders of a majority in voting power of Frequency capital stock issued and outstanding and entitled to vote at the Frequency Annual Meeting is necessary to constitute a quorum at the meeting. Abstentions and broker <span style="white-space:nowrap">non-votes</span> will be counted towards a quorum. The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon, assuming a quorum is present, is required for approval of Proposal Nos. 1, 4, 5, 6 and 7. The affirmative vote of the holders of a majority of the outstanding shares of Frequency common stock entitled to vote thereon is required for approval of Proposal No.&#160;2. The plurality of the votes cast by the holders of shares present in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">229 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attendance or represented by proxy at the Frequency Annual Meeting and entitled to vote on the matter, assuming a quorum is present, is required for approval of Proposal No.&#160;3. Approval of Proposal No.&#160;1, referred to as the Merger Proposal, is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos.&#160;1 and 2. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the proposals that will be voted on, the vote required to approve each item and how votes are counted: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:25%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:22%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:22%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:17%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:10%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Proposal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Votes&#160;Required</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Voting Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Impact of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8220;Withhold&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">or</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8220;Abstain&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Votes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Discretionary</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Voting</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Allowed</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;1:<br />Approval of the Issuance of Common Stock in the Merger and the Change of Control Resulting from the Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of the stockholders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the stockholders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">No<sup style="font-size:75%; vertical-align:top">(3)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;2:<br />Approval of the Amendment to the Restated Certificate of Incorporation of Frequency Effecting the Reverse Stock Split</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of the stockholders of a majority of the outstanding shares of Frequency common stock entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Have&#160;the same effect as votes &#8220;AGAINST&#8221; Proposal No. 2</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Yes<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;3: Election of David L. Lucchino as a Class I Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The plurality of the votes cast by the stockholders of shares present in attendance or represented by proxy at the Frequency Annual Meeting and entitled to vote on the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;FOR ALL&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;WITHHOLD&#160;ALL&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;FOR&#160;ALL&#160;EXCEPT&#8221;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(2)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">No<sup style="font-size:75%; vertical-align:top">(3)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;4: Ratification of Appointment of Independent Registered Public Accounting Firm</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of the stockholders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the stockholders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Yes<sup style="font-size:75%; vertical-align:top">(4)</sup></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">230 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:25%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:22%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:22%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:17%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:10%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Proposal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Votes&#160;Required</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Voting Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Impact of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8220;Withhold&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">or</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8220;Abstain&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Votes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Discretionary</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Voting</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Allowed</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;5: Approval of the 2023 Stock Option and Incentive Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">No<sup style="font-size:75%; vertical-align:top">(3)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;6: Approval of the 2023 Employee Stock Purchase Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">No<sup style="font-size:75%; vertical-align:top">(3)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal No.&#160;7: Approval of Adjournment of the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals Nos. 1 and 2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of the stockholders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the stockholders entitled to vote thereon.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;FOR&#8221;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;AGAINST&#8221;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8220;ABSTAIN&#8221;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Yes<sup style="font-size:75%; vertical-align:top">(4)</sup></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A vote marked as an &#8220;Abstention&#8221; is not considered a vote cast and will, therefore, not affect the outcome of this proposal. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Votes that are &#8220;withheld&#8221; will have the same effect as an abstention and will not count as a vote &#8220;FOR&#8221; or &#8220;AGAINST&#8221; a director, because directors are elected by plurality voting. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As this proposal is not considered a discretionary matter, brokers lack authority to exercise their discretion to vote uninstructed shares on this proposal. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As this proposal is considered a discretionary matter, brokers are permitted to exercise their discretion to vote uninstructed shares on this proposal. We do not expect any broker non-votes in connection with this proposal. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors and certain executive officers of Frequency have entered into stockholder support agreements pursuant to which they have agreed to vote all shares of Frequency common stock owned by them as of the Record Date in favor of Proposal Nos. 1 and 2 and against any competing &#8220;acquisition proposal&#8221; (as defined in the support agreements). As of the Record Date, the directors and certain executive officers of Frequency owned or controlled &#160;&#160;&#160;&#160;% of the outstanding shares of Frequency common stock entitled to vote at the Frequency Annual Meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">231 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_87">Solicitation of Proxies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to solicitation by mail, the directors, officers, employees and agents of Frequency may solicit proxies from Frequency stockholders by personal interview, telephone, email, fax or otherwise. Frequency will pay the cost of printing and filing of this proxy statement/prospectus and the proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Frequency common stock for the forwarding of solicitation materials to the beneficial owners of Frequency common stock. Frequency will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials. Frequency has retained Morrow Sodali to assist it in soliciting proxies. Frequency will pay the fees of Morrow Sodali, which Frequency expects to be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, plus reimbursement of out-of-pocket expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_88">Other Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, Frequency&#8217;s board of directors does not know of any business to be presented at the Frequency Annual Meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Frequency Annual Meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">232 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_89">MATTERS BEING SUBMITTED TO A VOTE OF FREQUENCY STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_90">PROPOSAL NO. 1: APPROVAL OF THE ISSUANCE OF COMMON STOCK IN THE MERGER AND THE CHANGE OF CONTROL RESULTING FROM THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Frequency Annual Meeting, Frequency stockholders will be asked to approve the issuance of Frequency common stock in the Merger. Immediately following the Merger, it is expected that the former Korro Bio securityholders, including purchasers in the Pre-Closing Financing, will own approximately 92% of the <span style="white-space:nowrap">fully-diluted</span> common stock of Frequency, with the Frequency securityholders as of immediately prior to the Merger holding approximately 8% of the <span style="white-space:nowrap">fully-diluted</span> common stock of Frequency, subject to certain assumptions, including, but not limited to, Frequency&#8217;s net cash as of closing being equal to $25 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of, reasons for and other aspects of the Merger Agreement, the Merger and the issuance of Frequency common stock in the Merger and securities of the combined company are described in detail in the other sections&#160;in this proxy statement/prospectus. A copy of the Merger Agreement is attached as <span style="font-style:italic">Annex A</span> to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued will have, upon issuance, voting power equal to or in excess of 20% of the voting power of the shares of common stock outstanding before such issuance. The potential issuance of the shares of Frequency common stock in the Merger exceeds the 20% under Nasdaq Listing Rule&#160;5635(a)(1) and is expected to represent approximately &#160;&#160;&#160;&#160;% of the voting power of Frequency common stock following the Merger. Accordingly, in order to ensure compliance with Nasdaq Listing Rule 5635(a)(1), Frequency must obtain the approval of Frequency stockholders for the issuance of the shares of common stock to be issued in the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of securities that will result in a &#8220;change of control&#8221; of the company. Although Nasdaq has not adopted any rule as to what constitutes a &#8220;change of control&#8221; for purposes of Rule 5635(b), Nasdaq has previously indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20% of the common stock (or securities convertible into or exercisable for common stock) or voting power of an issuer could constitute a change of control. Accordingly, in order to ensure compliance with Nasdaq Listing Rule 5635(b), Frequency must obtain the approval of Frequency stockholders of the change of control resulting from the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Required Vote </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority in voting power of the votes cast affirmatively or negatively in attendance or represented by proxy at the Frequency Annual Meeting and entitled to vote on the matter is required to approve the issuance of Frequency common stock in the Merger and the change of control of Frequency resulting from the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY&#8217;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 1 TO APPROVE THE ISSUANCE OF FREQUENCY COMMON STOCK IN THE MERGER AND THE CHANGE OF CONTROL OF FREQUENCY RESULTING FROM THE MERGER. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the issuance of Frequency common stock in the Merger and the change of control of Frequency resulting from the Merger. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">233 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_91">PROPOSAL NO. 2: APPROVAL OF THE AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF FREQUENCY EFFECTING THE REVERSE STOCK SPLIT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors has approved and, subject to stockholder approval, adopted a resolution (1)&#160;declaring advisable, and recommending to the Frequency stockholders for their approval, an amendment to the Restated Certificate of Incorporation, to give the Frequency&#8217;s board of directors discretionary authority to effect a Reverse Stock Split of Frequency&#8217;s issued and outstanding common stock at a ratio ranging from any whole number between <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</span></span> as determined by the Frequency board of directors in its discretion, subject to the Frequency board of directors&#8217; authority to determine when to file the amendment and to abandon the other amendments notwithstanding prior stockholder approval of such amendments, (2)&#160;directing that such proposed amendments to Frequency&#8217;s Restated Certificate of Incorporation be submitted to the Frequency stockholders for their approval and adoption, and (3)&#160;recommending that the Frequency stockholders approve and adopt the proposed amendment. The text of the form of Certificate of Amendment would be filed with the Delaware Secretary of State to effect the Reverse Stock Split, are set forth in <span style="font-style:italic">Annex H</span> to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency fails to obtain stockholder approval of this proposal at the Annual Meeting, Frequency may propose to adjourn the Frequency Annual Meeting, for a period of not more than 60&#160;days, for the purpose of soliciting additional proxies to approve this proposal. Frequency currently does not intend to propose adjournment at the Frequency Annual Meeting if there are sufficient votes to approve this proposal and Proposal Nos.&#160;1 and 2. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reverse Stock Split Amendment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By approving this proposal, stockholders will approve alternative amendments to the Frequency Restated Certificate of Incorporation pursuant to which a number of outstanding shares of Frequency common stock between &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, inclusive, would be combined into one share of Frequency common stock. The number of shares of common stock underlying outstanding equity awards and available for future awards under Frequency&#8217;s equity incentive plans, would also be proportionately reduced in the same manner as a result of the Reverse Stock Split. Upon receiving stockholder approval, the Frequency board of directors will have the authority, but not the obligation, in its sole discretion, to elect, without further action on the part of the stockholders, whether to effect the Reverse Stock Split and, if so, to determine the Reverse Stock Split ratio from among the approved range described above and to effect the Reverse Stock Split by filing a Certificate of Amendment with the Secretary of State of the State of Delaware to be effective prior to the Effective Time, and all other amendments will be abandoned. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors&#8217; decision as to whether and when to effect the Reverse Stock Split will be&#160;based on a number of factors, including, without limitation, general market and economic conditions, the historical and then-prevailing trading price and trading volume of Frequency common stock, the anticipated impact of the Reverse Stock Split on the trading price and trading volume of Frequency common stock, the anticipated impact on Frequency&#8217;s market capitalization, and the continued listing requirements of Nasdaq. Although the Frequency stockholders may approve the Reverse Stock Split, Frequency will not effect the Reverse Stock Split if the Frequency board of directors does not deem it to be in the best interests of Frequency and its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the Reverse Stock Split will decrease the number of outstanding shares of Frequency common stock by a ratio in the range of <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span> to <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span> but would not effect a decrease to the number of shares of common stock that Frequency will be authorized to issue, the proposed Reverse Stock Split Amendments would result in a relative increase in the number of authorized and unissued shares of Frequency common stock. For more information on the relative increase in the number of authorized shares of Frequency common stock, see &#8220;&#8212;<span style="font-style:italic">Principal Effects of the Reverse Stock Split-Issued and Outstanding Shares of Common stock</span>&#8221; below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">234 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purpose of the Reverse Stock Split </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors submits Proposal No.&#160;2 to its stockholders for approval and adoption with the primary intent of increasing the per share price of Frequency common stock for the following principal reasons: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to ensure compliance with the $1.00 per share of common stock minimum bid price requirement for continued listing on Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to encourage increased investor interest in Frequency common stock and promote greater liquidity for its stockholders; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to help attract, retain, and motivate employees; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to ensure the continued listing of Frequency common stock to facilitate the closing of the Merger. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nasdaq Requirements for Continued Listing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency common stock is quoted on Nasdaq under the symbol &#8220;FREQ.&#8221; For Frequency common stock to continue trading on Nasdaq, Frequency must comply with various listing standards, including that Frequency maintain a minimum closing bid price of $1.00 per share of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;29, 2023, Frequency received a letter from the Listing Qualifications Department of Nasdaq notifying it that, for 30 consecutive business days, the closing bid price for the Frequency common stock closed below the minimum $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule&#160;5450(a)(1), or the Minimum Bid Price Requirement. Under Nasdaq Listing Rule 5810(c)(3)(A), Frequency was granted an initial 180 calendar day grace period, or until September&#160;25, 2023, to regain compliance with the Minimum Bid Price Requirement, which required Frequency common stock to have a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 <span style="white-space:nowrap">calendar-day</span> grace period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency does not regain compliance with the Minimum Bid Price Requirement by September&#160;25, 2023, Frequency may be eligible for an additional 180 calendar day compliance period. To qualify, Frequency must submit an application to transfer the listing of the Frequency common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market, which requires Frequency to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the Minimum Bid Price Requirement. Frequency would also need to pay an application fee to Nasdaq and to provide written notice of Frequency&#8217;s intention to cure the deficiency during the additional compliance period. As part of its review process, Nasdaq will make a determination of whether it believes Frequency will be able to cure this deficiency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency fails to regain compliance within the applicable compliance period, Nasdaq will provide written notification that Frequency&#8217;s securities will be delisted. At that time, Frequency may appeal Nasdaq&#8217;s determination to a Hearings Panel. If Frequency appeals, the Hearings Panel will request a plan to regain compliance. Hearings Panels have generally viewed a reverse stock split as the only definitive plan to resolve a bid price deficiency. There can be no assurance that such an appeal would be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency common stock is delisted from Nasdaq, the Frequency board of directors believe that the trading market for Frequency common stock could become significantly less liquid, which could reduce the trading price of Frequency common stock and increase the transaction costs of trading in shares of Frequency common stock. Such delisting from Nasdaq and continued or further decline in Frequency&#8217;s stock price could also impair Frequency&#8217;s ability to raise additional necessary capital through equity or debt financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Reverse Stock Split is effected, it would cause a decrease in the total number of shares of Frequency common stock outstanding and increase the market price of Frequency common stock. The Frequency board of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">235 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors intend to effect the Reverse Stock Split only if it believes that a decrease in the number of shares outstanding is in the best interests of Frequency and its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">IF THIS PROPOSAL IS NOT APPROVED, FREQUENCY MAY BE UNABLE TO MAINTAIN THE LISTING OF FREQUENCY&#8217;S COMMON STOCK ON NASDAQ, WHICH COULD ADVERSELY AFFECT THE LIQUIDITY AND MARKETABILITY OF FREQUENCY&#8217;S COMMON STOCK AND ADVERSELY IMPACT FREQUENCY&#8217;S ABILITY TO COMPLY WITH CERTAIN CONTRACTUAL OBLIGATIONS REQUIRED BY FREQUENCY&#8217;S SECURED LOAN AGREEMENTS AND THE MERGER. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investor Interest and Liquidity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in approving the proposed Reverse Stock Split Amendments, the Frequency board of directors considered that the Reverse Stock Split and the resulting increase in the per share price of Frequency common stock could encourage increased investor interest in Frequency common stock and promote greater liquidity for its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Frequency common stock were to be delisted from Nasdaq, Frequency common stock would likely trade in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market. If Frequency common stock were to trade on the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, selling Frequency common stock could be more difficult because smaller quantities of shares would likely be bought and sold, and transactions could be delayed. In addition, many brokerage houses and institutional investors have internal policies and practices that prohibit them from investing in <span style="white-space:nowrap">low-priced</span> stocks or tend to discourage individual brokers from recommending <span style="white-space:nowrap">low-priced</span> stocks to their customers, further limiting the liquidity of Frequency common stock. These factors could result in lower prices and larger spreads in the bid and ask prices for Frequency common stock. Additionally, investors may be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower priced stocks. A greater price per share of Frequency common stock could allow a broader range of institutions to invest in Frequency common stock. For all of these reasons, Frequency believes the Reverse Stock Split could potentially increase marketability, trading volume, and liquidity of Frequency common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employee Retention </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors believe that Frequency&#8217;s employees and directors who are compensated in the form of Frequency&#8217;s equity-based securities may be less incentivized and invested in Frequency if Frequency is no longer listed on Nasdaq. Accordingly, the Frequency board of directors believe that maintaining Nasdaq listing qualifications for Frequency common stock, can help attract, retain, and motivate employees and members of the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the factors mentioned above, the Frequency board of directors unanimously approved the proposed Reverse Stock Split Amendments to effect the Reverse Stock Split as Frequency&#8217;s best means of increasing and maintaining the price of Frequency common stock to above $1.00 per share in compliance with Nasdaq requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Frequency board of directors Discretion to Implement the Reverse Stock Split </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors believe that stockholder approval of a range of ratios (as opposed to a single Reverse Stock Split ratio) is in the best interests of Frequency and stockholders because it is not possible to predict market conditions at the time the Reverse Stock Split would be effected. Frequency believes that a range of Reverse Stock Split ratios provides Frequency with the most flexibility to achieve the desired results of the Reverse Stock Split. The Reverse Stock Split ratio to be selected by the Frequency board of directors will be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">236 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a whole number in a range of <span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></span> The Frequency board of directors can only authorize the filing of one Reverse Stock Split Amendment and all other Reverse Stock Split Amendments will be abandoned. The Frequency board of directors also has the authority to abandon all Reverse Stock Split Amendments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the Reverse Stock Split ratio and whether and when to effect the Reverse Stock Split following the receipt of stockholder approval, the Frequency board of directors will consider a number of factors, including, without limitation: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s ability to maintain the listing of its common stock on Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical trading price and trading volume of Frequency common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of shares of Frequency common stock outstanding immediately before and after the Reverse Stock Split; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the then-prevailing trading price and trading volume of Frequency common stock and the anticipated impact of the Reverse Stock Split on the trading price and trading volume of its common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the anticipated impact of a particular ratio on Frequency&#8217;s market capitalization; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prevailing general market and economic conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency believes that granting the Frequency board of directors the authority to set the ratio for the Reverse Stock Split is essential because it allows Frequency to take these factors into consideration and to react to changing market conditions. If the Frequency board of directors choose to implement the Reverse Stock Split, Frequency will make a public announcement regarding the determination of the Reverse Stock Split ratio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Associated with the Reverse Stock Split </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks associated with the Reverse Stock Split, including that the Reverse Stock Split may not result in a sustained increase in the per share price of Frequency common stock. For risks associated with the Reverse Stock Split see &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to the Proposed Reverse Stock Split</span>&#8221; in this proxy statement/prospectus beginning on page&#160;36. Stockholders should note that the effect of the Reverse Stock Split, if any, upon the trading price of Frequency common stock cannot be accurately predicted. In particular, Frequency cannot assure you that the price for a share of Frequency common stock after the Reverse Stock Split will increase in proportion to the reduction in the number of shares of Frequency common stock outstanding before the Reverse Stock Split or, even if it does, that such price will be maintained for any period of time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if an increased per share price can be maintained, the Reverse Stock Split may not achieve the desired results that have been outlined above under &#8220;<span style="font-style:italic">Purpose of the Reverse Stock Split</span>.&#8221; Moreover, because some investors may view the Reverse Stock Split negatively, Frequency cannot assure you that the Reverse Stock Split will not adversely impact the market price of the common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Frequency&#8217;s aim is that the Reverse Stock Split will be sufficient to maintain Frequency&#8217;s listing on Nasdaq, it is possible that, even if the Reverse Stock Split results in a bid price for Frequency common stock that exceeds $1.00&#160;per share of common stock, Frequency may not be able to continue to satisfy Nasdaq&#8217;s additional requirements and standards for continued listing of Frequency common stock on Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency believes that the Reverse Stock Split may result in greater liquidity for its stockholders. However, it is also possible that such liquidity could be adversely affected by the reduced number of shares outstanding after the Reverse Stock Split, particularly if the price of Frequency common stock does not increase as a result of the Reverse Stock Split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the Reverse Stock Split is implemented, it may increase the number of stockholders who own &#8220;odd lots&#8221; of less than 100&#160;shares of common stock. A purchase or sale of less than 100 shares (an &#8220;odd lot&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">237 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction) may result in incrementally higher trading costs through certain brokers, particularly &#8220;full service&#8221; brokers. Therefore, those stockholders who own fewer than 100 shares of Frequency common stock following the Reverse Stock Split may be required to pay higher transaction costs if they sell their shares of Frequency common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Principal Effects of the Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Issued and Outstanding Shares of Common stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Reverse Stock Split is approved and effected, each holder of Frequency common stock outstanding immediately prior to the effectiveness of the Reverse Stock Split will own a reduced number of shares of Frequency common stock upon effectiveness of the Reverse Stock Split. The Reverse Stock Split would be effected simultaneously at the same exchange ratio for all outstanding shares of common stock, as required by Frequency&#8217;s Restated Certificate of Incorporation. Except for adjustments that may result from the treatment of fractional shares (as described below), the Reverse Stock Split would affect all stockholders uniformly and would not change any stockholder&#8217;s relative percentage ownership interest in Frequency, voting rights, or other rights that accompany shares of Frequency common stock. Shares of Frequency common stock issued pursuant to the Reverse Stock Split will remain fully paid and <span style="white-space:nowrap">non-assessable,</span> and the par value per share of common stock will remain $0.001. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Relative Increase in Number of Authorized Shares of Common stock for Issuance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Reverse Stock Split will not affect the number of authorized shares or the par value of Frequency&#8217;s capital stock, which will remain at 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, the preferred stock and the together with the Frequency common stock, the Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the number of authorized shares of Capital Stock will not change as a result of the Reverse Stock Split, the number of shares of Frequency common stock issued and outstanding will be reduced in proportion to the ratio selected by the Frequency board of directors. Thus, the Reverse Stock Split will effectively increase the number of authorized and unissued shares of Frequency common stock available for future issuance by the amount of the reduction effected by the Reverse Stock Split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the proposed Reverse Stock Split Amendments are approved, all or any of the authorized and unissued shares of Frequency common stock may be issued in the future for such corporate purposes and such consideration as the Frequency board of directors deem advisable from time to time, without further action by the&#160;stockholders of Frequency and without first offering such shares to its stockholders. When and if additional shares of Frequency common stock are issued, these new shares would have the same voting and other rights and privileges as the currently issued and outstanding shares of common stock, including the right to cast one vote per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except pursuant to Frequency&#8217;s equity incentive plans, the Sales Agreement with Oppenheimer&#160;&amp; Co. Inc. (as described below), Frequency presently has no plan, commitment, arrangement, understanding, or agreement regarding the issuance of common stock other than the Merger Agreement and the Merger. However, Frequency regularly considers its capital requirements and may conduct securities offerings, including equity and/or equity linked offerings, in the future. Any shares issuable pursuant to a above described plans and the ATM Program (as defined below) will be subject to the Reverse Stock Split ratio determined by the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the stockholders have no preemptive rights to purchase or subscribe for any of the unissued shares of common stock, the future issuance of additional shares of common stock will reduce Frequency&#8217;s current stockholders&#8217; percentage ownership interest in the total outstanding shares of common stock. In the absence of a proportionate increase in Frequency&#8217;s future earnings and book value, an increase in the number of Frequency&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">238 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding shares of common stock would dilute Frequency&#8217;s projected future earnings per share, if any, and book value per share of all Frequency&#8217;s outstanding shares of common stock. If these factors were reflected in the price per share of Frequency common stock, the potential realizable value of a stockholder&#8217;s investment could be adversely affected. An issuance of additional shares could therefore have an adverse effect on the potential realizable value of a stockholder&#8217;s investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equity Compensation Plans and Outstanding Equity-Based Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency maintains the Frequency Therapeutics, Inc. 2014 Stock Incentive Plan, or the Frequency 2014 Plan, the Frequency Therapeutics, Inc. 2019 Incentive Award Plan, or the Frequency 2019 Plan, and the Frequency ESPP, and collectively and together with any <span style="white-space:nowrap">sub-plans</span> thereunder, the Frequency Plans, which are designed primarily to provide stock-based incentives to individual service providers of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors generally has the discretion to determine the appropriate adjustments to the Frequency Plans and outstanding awards and purchase rights under the Frequency Plans in the event of a Reverse Stock Split. Accordingly, if the Reverse Stock Split is approved and effected, consistent with the terms of the Plans and outstanding award agreements, the total number of shares of common stock issuable upon exercise, vesting or settlement of such awards or purchase rights and the total number of shares of common stock remaining available for future awards or purchase under the Frequency Plans, as well as any share-based limits in the Frequency Plans, would be proportionately reduced based on the Reverse Stock Split ratio selected by the Frequency board of directors, and any fractional shares that may result therefrom shall be rounded down to the nearest whole share. Furthermore, the exercise or purchase price of any outstanding Frequency Options or purchase rights would be proportionately increased based on the Reverse Stock Split ratio selected by the Frequency board of directors, and any fractional cents that may result therefrom shall be rounded up to the nearest whole cent. In addition, the numbers of shares subject to awards to be automatically granted in the future under the Frequency 2019 Plan pursuant to the <span style="white-space:nowrap">non-employee</span> director compensation program will be proportionately reduced based on the Reverse Stock Split ratio selected by the Frequency board of directors. The Frequency board of directors has authorized Frequency to effect any changes necessary, desirable or appropriate to give effect to the Reverse Stock Split under the Frequency Plans, including any applicable technical, conforming changes thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Additional Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December&#160;2021, Frequency entered into an Equity Distribution Agreement with Oppenheimer&#160;&amp; Co. Inc., or Oppenheimer, to sell shares of Frequency common stock, having an aggregate offering price of up to $125.0&#160;million, from time to time, through an &#8220;at the market&#8221; equity offering program, or the ATM Program, under which Oppenheimer will act as sales agent and/or principal. During the year ended December&#160;31, 2022, Frequency sold 12,767&#160;shares of common stock under the ATM Program for net proceeds of approximately $50&#160;thousand and paid $2&#160;thousand to Oppenheimer in sales agent fees. However, there can be no assurance as to whether or, if so, how many or when, any shares will be issued and sold thereunder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">239 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Illustration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of illustration, the following table contains approximate information relating to Frequency common stock if the Reverse Stock Split is effected at a ratio of: <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</span></span> or <span style="white-space:nowrap">1-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</span> based on share information as of the close of business on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, but does not give effect to any other changes, including any issuance of securities after &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Pre-Reverse</span><br />Split</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;</span></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;</span></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;</span></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">1-for-&#160;&#160;&#160;&#160;</span></span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued and Outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserved for future issuance pursuant to equity incentive and employee benefit plans<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares issuable upon exercise of outstanding Frequency Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares issuable upon vesting of outstanding Frequency Restricted Stock Units</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares issuable upon vesting of outstanding Performance Stock Units</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized but unissued and unreserved<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Excludes shares issuable under outstanding equity-based awards (other than outstanding purchase rights under the Frequency ESPP). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Shares authorized but unissued and unreserved represent common stock available for future issuance beyond shares issuable under outstanding equity-based awards and shares reserved for future issuance pursuant to equity incentive and employee benefit plans, and includes shares of common stock, if any, that may be issued under the ATM Program. See also note (1)&#160;above. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Procedure for Effecting the Reverse Stock Split and Exchange of Stock Certificates, if Applicable </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the proposed Reverse Stock Split Amendments are approved by Frequency&#8217;s stockholders and Frequency&#8217;s board of directors determines to effect the Reverse Stock Split, the Reverse Stock Split will become effective upon the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware. At the Effective Time, shares of Frequency common stock issued and outstanding immediately prior thereto will be combined, automatically and without any action on the part of the stockholders, into new shares of common stock, in accordance with the Reverse Stock Split ratio contained in the Certificate of Amendment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Registered &#8220;Book-Entry&#8221; Stockholders of Frequency Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the Effective Time, stockholders will be notified by the transfer agent that the Reverse Stock Split has been effected. As all of the outstanding shares of Frequency common stock are held in book-entry form, you will not need to take any action to receive post-Reverse Stock Split shares of Frequency common stock upon the filing of the Certificate of Amendment. As soon as practicable after the Effective Time, the transfer agent will send to your registered address a transmittal letter along with a statement of ownership indicating the number of post-Reverse Stock Split shares of common stock you hold. If applicable, a check representing a cash payment in lieu of fractional shares will also be mailed to your registered address as soon as practicable after the Effective Time (see &#8220;&#8212;<span style="font-style:italic">Fractional Shares</span>&#8221; below). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Beneficial Stockholders of Frequency Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the implementation of the Reverse Stock Split, Frequency intends to treat shares of common stock held by stockholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian, or other nominee), in the same </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">240 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manner as registered &#8220;book-entry&#8221; stockholders of common stock. Banks, brokers, custodians or other nominees will be instructed to effect the Reverse Stock Split for their beneficial stockholders holding Frequency common stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the Reverse Stock Split and making payment for fractional shares. If a stockholder holds shares of Frequency common stock with a bank, broker, custodian, or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian, or other nominee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholders of Certificated Shares of Frequency Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates, if applicable. If you are a stockholder holding <span style="white-space:nowrap">pre-Reverse</span> Stock Split shares in certificate form, you will receive a transmittal letter from the transfer agent as soon as practicable after the Effective Time. The transmittal letter will be accompanied by instructions specifying how you can exchange your certificate or certificates representing the <span style="white-space:nowrap">pre-Reverse</span> Stock Split shares of Frequency common stock for a statement of ownership. When you submit your certificate or certificates representing the <span style="white-space:nowrap">pre-Reverse</span> Stock Split shares of Frequency common stock, your post-Reverse Stock Split shares of Frequency common stock will be held electronically in book-entry form in the Direct Registration System. This means that, instead of receiving a new stock certificate representing the aggregate number of post-Reverse Stock Split shares you own, you will receive a statement indicating the number of post-Reverse Stock Split shares you own in book-entry form. Frequency will no longer issue physical stock certificates unless you make a specific request for a certificate representing your post-Reverse Stock Split ownership interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Fractional Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No scrip or fractional shares would be issued if, as a result of the Reverse Stock Split, a stockholder would otherwise become entitled to a fractional share because the number of shares of common stock they hold before the Reverse Stock Split is not evenly divisible by the split ratio ultimately determined by the Frequency board of directors. Instead, each stockholder will be entitled to receive a cash payment in lieu of such fractional share. The cash payment to be paid will be equal to the fraction of a share to which such stockholder would otherwise be entitled multiplied by the closing price per share of common stock on the date of the Effective Time as reported by Nasdaq (as adjusted to give effect to the Reverse Stock Split). No transaction costs would be assessed to stockholders for the cash payment. Stockholders would not be entitled to receive interest for their fractional shares for the period of time between the Effective Time and the date payment is issued or received. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the Reverse Stock Split, then-current stockholders would have no further interest in Frequency with respect to their fractional shares. A person entitled to a fractional share would not have any voting, dividend or other rights in respect of their fractional share except to receive the cash payment as described above. Such cash payments would reduce the number of post-Reverse Stock Split stockholders to the extent that there are stockholders holding fewer than that number of <span style="white-space:nowrap">pre-Reverse</span> Stock Split shares within the Reverse Stock Split ratio that is determined by the Frequency board of directors as described above. Reducing the number of post-Reverse Stock Split stockholders, however, is not the purpose of this proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where Frequency is domiciled and where the funds for fractional shares would be deposited, sums due to stockholders in payment for fractional shares that are not timely claimed after the Effective Time may be required to be paid to the designated agent for each such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds may have to seek to obtain them directly from the state to which they were paid. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Appraisal Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, Frequency&#8217;s stockholders will not be entitled to appraisal rights with respect to the Reverse Stock Split, and Frequency does not intend to independently provide stockholders with any such right. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">241 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Going Private Transaction </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the decrease in the number of outstanding shares following the Reverse Stock Split, the Frequency board of directors does not intend for this transaction to be the first step in a series of plans or proposals of a &#8220;going private transaction&#8221; within the meaning of Rule <span style="white-space:nowrap">13e-3</span> of the Exchange Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Certain Persons in the Proposal </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of Frequency&#8217;s officers and directors have an interest in this proposal as a result of their ownership of shares of Frequency common stock, as set forth below in the section entitled &#8220;<span style="font-style:italic">Principal Stockholders of Frequency</span>&#8221;. However, Frequency does not believe that its officers or directors have interests in this proposal that are different from or greater than those of any of the other stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-takeover Effects of Proposed Amendment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Release <span style="white-space:nowrap">No.&#160;34-15230</span> of the staff of the SEC requires disclosure and discussion of the effects of any action, including the proposed Reverse Stock Split Amendments discussed herein, that may be used as an anti-takeover mechanism. An additional effect of the Reverse Stock Split would be to increase the relative amount of authorized but unissued shares of common stock, which may, under certain circumstances, be construed as having an anti-takeover effect. Although not designed or intended for such purposes, the effect of the increased available shares might be to make more difficult or to discourage an attempt to take over or otherwise acquire control of Frequency (for example, by permitting issuances that would dilute the stock ownership of a person or entity seeking to effect a change in the composition of the board of directors or contemplating a tender offer or other change in control transaction). In addition, Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws include provisions that may have an anti-takeover effect. These provisions, among things, permit the Frequency board of directors to issue preferred stock with rights senior to those of the common stock without any further vote or action by the stockholders and do not provide for cumulative voting rights, which could make it more difficult for stockholders to effect certain corporate actions and may delay or discourage a change in control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors is not presently aware of any attempt, or contemplated attempt, to acquire control of Frequency, and the Reverse Stock Split Proposal is not part of any plan by the Frequency board of directors to recommend or implement a series of anti-takeover measures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Accounting Treatment of the Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Reverse Stock Split is effected, the par value per share of Frequency common stock will remain unchanged at $0.001. Accordingly, at the Effective Time, the stated capital on Frequency&#8217;s consolidated balance sheets attributable to Frequency common stock will be reduced in proportion to the size of the Reverse Stock Split ratio, and the additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital</span></span> account will be increased by the amount by which the stated capital is reduced. The stockholders&#8217; equity, in the aggregate, will remain unchanged. Per share net income or loss will be increased because there will be fewer shares of common stock outstanding. Frequency does not anticipate that any other accounting consequences, including changes to the amount of stock-based compensation expense to be recognized in any period, will arise as a result of the Reverse Stock Split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material U.S. Federal Income Tax Consequences of the Reverse Stock Split to U.S. Holders of Frequency Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax consequences of the Reverse Stock Split to U.S. Holders of Frequency common stock, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or <span style="white-space:nowrap">non-U.S.</span> tax laws are not discussed. Furthermore, the following discussion does not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">242 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address any tax consequences of transactions effectuated before, after or at the same time as the Reverse Stock Split (except, to the limited extent discussed in the section entitled &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Contingent Value Rights Agreement&#8212;Material U.S. Federal Income Tax Consequences of the CVRs to Holders of Frequency Common Stock</span>,&#8221; the distribution of the CVRs), whether or not they are in connection with the Reverse Stock Split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case, as in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. Frequency has not sought and will not seek an opinion of counsel or any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the Reverse Stock Split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to U.S. Holders who hold their Frequency common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to the particular circumstances of a U.S. Holder, including the impact of the Medicare contribution tax on net investment income and the alternative minimum tax. In addition, it does not address consequences relevant to U.S. Holders that are subject to particular rules, including, without limitation: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. expatriates or former citizens or long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons whose functional currency is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding Frequency common stock as part of a hedge, straddle, or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks, insurance companies, and other financial institutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts or regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">brokers, dealers, or traders in securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">S corporations, partnerships, or other entities or arrangements treated as pass-through entities for U.S.&#160;federal income tax purposes (and investors therein); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations, qualified retirement plans, individual retirement accounts or other tax deferred accounts, or governmental organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons deemed to sell Frequency common stock under the constructive sale provisions of the Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who hold or receive Frequency common stock pursuant to the exercise of any employee stock options or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who are not U.S. Holders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">corporations that accumulate earnings to avoid U.S. federal income tax; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to special tax accounting rules as a result of any item of gross income with respect to the Frequency common stock being taken into account in an applicable financial statement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, or an entity treated as a partnership for U.S. federal income tax purposes, holds Frequency common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships holding Frequency common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">243 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THIS DISCUSSION IS NOT TAX ADVICE. HOLDERS OF FREQUENCY COMMON STOCK SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER OTHER U.S. FEDERAL TAX LAWS (INCLUDING ESTATE AND GIFT TAX LAWS), UNDER THE LAWS OF ANY STATE, LOCAL, OR <span style="white-space:nowrap">NON-U.S.</span> TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material U.S. Federal Income Tax Consequences for U.S. Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Frequency common stock that, for U.S. federal income tax purposes, is or is treated as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust that (1)&#160;is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code), or (2)&#160;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Reverse Stock Split should constitute a &#8220;recapitalization&#8221; for U.S. federal income tax purposes. As a result, a U.S. Holder generally should not recognize gain or loss upon the Reverse Stock Split, except as described below with respect to cash received in lieu of fractional shares. A U.S. Holder&#8217;s aggregate tax basis in the shares of the Frequency common stock received pursuant to the Reverse Stock Split should equal such holder&#8217;s aggregate tax basis in the shares of the Frequency common stock surrendered (excluding any portion of such basis that is allocated to any fractional share of Frequency common stock), and such holder&#8217;s holding period in the shares of the Frequency common stock received should include the holding period of the shares of the Frequency common stock surrendered. Treasury Regulations promulgated under the Code provide detailed rules for allocating the tax basis and holding period of the shares of Frequency common stock surrendered to the shares of Frequency common stock received pursuant to the Reverse Stock Split. U.S. Holders holding shares of Frequency common stock that were acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder who receives cash in lieu of a fractional share of Frequency common stock should be treated as first receiving such fractional share and then receiving cash in redemption of such fractional share. A U.S. Holder who receives cash in lieu of a fractional share in the Reverse Stock Split should recognize capital gain or loss in an amount equal to the difference between the amount of the cash received and the portion of such stockholder&#8217;s adjusted tax basis in the shares of Frequency common stock surrendered that is allocated to the fractional share. Such capital gain or loss should be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Frequency common stock surrendered exceeded one year at the Effective Time of the Reverse Stock Split. The deductibility of capital losses is subject to limitations. U.S. Holders should consult their tax advisors regarding the tax effects to them of receiving cash in lieu of fractional shares based on their particular circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders (other than corporations and certain other exempt recipients) may be subject to information reporting with respect to any cash received in exchange for a fractional share interest in a new share in the Reverse Stock Split. U.S. Holders who are subject to information reporting and who do not provide a correct taxpayer identification number and other required information (such as by submitting a properly completed IRS Form <span style="white-space:nowrap">W-9)</span> may also be subject to backup withholding at the applicable rate. Backup withholding is not an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">244 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional tax. Any amounts withheld under the backup withholding rules may be refunded or credited against the U.S. Holder&#8217;s U.S. federal income tax liability, if any, provided that the required information is properly furnished in a timely manner to the IRS. U.S. Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Required Vote </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the outstanding shares of Frequency common stock entitled to vote on the matter is required to approve amendments to the Restated Certificate of Incorporation of Frequency, subject to the Frequency board of directors&#8217; authority to abandon such amendments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO.&#160;2 TO APPROVE THE AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION EFFECTING THE REVERSE STOCK SPLIT. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the amendment to the Restated Certificate of Incorporation of Frequency to effect the Reverse Stock Split. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">245 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_93">PROPOSAL NO. 3: TO ELECT DAVID L. LUCCHINO AS A CLASS I DIRECTOR </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Size and Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Restated Certificate of Incorporation as currently in effect provides that the number of directors shall be established from time to time by the Frequency board of directors. The Frequency board of directors has fixed the number of directors at seven, and currently has five directors serving on the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Restated Certificate of Incorporation provides that the Frequency board of directors be divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III. Each class must consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Frequency board of directors. Each class of directors must stand for re-election no later than the third annual meeting of stockholders subsequent to their initial appointment or election to the Frequency board of directors, provided that the term of each director will continue until the election and qualification of his or her successor and is subject to his or her earlier death, resignation or removal. Generally, vacancies or newly created directorships on the Frequency board of directors will be filled only by vote of a majority of the directors then in office and will not be filled by the stockholders, unless the Frequency board of directors determines by resolution that any such vacancy or newly created directorship will be filled by the stockholders. A director appointed by the Frequency board of directors to fill a vacancy will hold office until the next election of the class for which such director was chosen, subject to the election and qualification of his or her successor and his or her earlier death, resignation or removal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Current Directors and Terms </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency current directors and their respective classes and terms are set forth below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Class&#160;I Director&#160;-</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current&#160;Term&#160;Ending&#160;at</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">2023&#160;Annual&#160;Meeting</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Class&#160;II&#160;Director&#160;-</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current&#160;Term&#160;Ending&#160;at</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">2024&#160;Annual&#160;Meeting</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Class&#160;III&#160;Director&#160;-</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current&#160;Term&#160;Ending&#160;at</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">2025&#160;Annual&#160;Meeting</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">David L. Lucchino</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Cynthia L. Feldmann</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Michael Huang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Timothy J. Barberich</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Robert S. Langer</p></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nominee for Director </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Lucchino has been nominated by the Frequency board of directors to stand for election. As the director assigned to Class&#160;I, Mr.&#160;Lucchino&#8217;s current term of service will expire at the Frequency Annual Meeting. If elected by the stockholders at the Frequency Annual Meeting, Mr.&#160;Lucchino will serve for a term expiring at the annual meeting of stockholders to be held in 2026, or the 2026 Annual Meeting, subject to the election and qualification of his successor or until his earlier death, resignation or removal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominee for election has agreed to serve if elected, and management has no reason to believe that the nominee will be unable to serve. If, however, prior to the Frequency Annual Meeting, the Frequency board of directors should learn that the nominee will be unable to serve for any reason, the proxies that otherwise would have been voted for the nominee will be voted for a substitute nominee as selected by the Frequency board of directors. Proxies cannot be voted for a greater number of persons than the number of nominees named in this proposal. The Frequency board of directors has no reason to believe that the nominee will be unable to serve. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information About Board Nominee and Continuing Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following pages contain certain biographical information for the nominee for director and each director whose term as a director will continue after the Frequency Annual Meeting, including all positions he or she holds, his or her principal occupation and business experience for the past five years, and the names of other publicly-held companies of which the director or nominee currently serves as a director or has served as a director during the past five years. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">246 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency believes that all of the directors and the nominee: display personal and professional integrity; satisfactory levels of education and/or business experience; broad-based business acumen; an appropriate level of understanding of the business and its industry and other industries relevant to the business; the ability and willingness to devote adequate time to the work of the Frequency board of directors and its committees; skills and personalities that complement those of the other directors and that help build a board of directors that is effective, collegial and responsive to the needs of Frequency; strategic thinking and a willingness to share ideas; a diversity of experiences, expertise and background; and the ability to represent the interests of all of the stockholders. The information presented below regarding the nominee and each continuing director also sets forth specific experience, qualifications, attributes and skills that led the Frequency board of directors to the conclusion that such individual should serve as a director in light of the business and structure. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nominee for Election to Three Year Term Expiring at the 2026 Annual Meeting of Stockholders </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:43%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Class&#160;I Director Nominee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Director Since</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current Position at</span><br /><span style="font-weight:bold">Frequency</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">54</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">November&#160;2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">President,&#160;Chief&#160;Executive<br />Officer and Director</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">David L. Lucchino</span></span> has served as the President and Chief Executive Officer and a member of the Frequency board of directors since November 2014 and was a co-founder of Frequency with Dr.&#160;Robert&#160;S. Langer and Dr.&#160;Christopher&#160;R. Loose. From December 2014 until June 2016, Mr.&#160;Lucchino served as the President of Entrega Bio, a biotechnology company focused on oral drug delivery technology. Prior to that, Mr.&#160;Lucchino co-founded Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr.&#160;Lucchino oversaw the development of Semprus&#8217; lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr.&#160;Lucchino worked at the investment firm Polaris Partners. He started his biotech career by Co-Founding LaunchCyte, an investment firm where he was also a Managing Director. Mr.&#160;Lucchino is the past chairman of the board of directors of MassBio, a nonprofit organization that represents over 1,500 life science firms and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Massachusetts&#8217; Governor Charlie Baker as a member of the Commonwealth&#8217;s STEM Advisory Council. Mr.&#160;Lucchino also served as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility for fifteen&#160;years, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of NOLS (The National Outdoor Leadership School). Mr.&#160;Lucchino holds an MBA from the Massachusetts Institute of Technology&#8217;s Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University. Frequency believes Mr.&#160;Lucchino&#8217;s position as the Chief Executive Officer and extensive management experience in the biotechnology and pharmaceutical industry qualifies him to serve on the Frequency board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Class II Directors Whose Terms Expire at the 2024 Annual Meeting </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:53%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Class&#160;II&#160;Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Director&#160;Since</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current&#160;Position&#160;at</span><br /><span style="font-weight:bold">Frequency</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia L. Feldmann</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">September&#160;2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Huang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">October 2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Director</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Cynthia L. Feldmann</span></span> has served on the Frequency board of directors since September 2020 and is the Chair of Frequency&#8217;s Audit Committee. In March 2022, Ms.&#160;Feldmann joined the board of Alexandria Real Estate Equities, Inc., or Alexandria, an urban office real estate investing trust focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations. She serves on Alexandria&#8217;s Science&#160;&amp; Technology Board Committee. Ms.&#160;Feldmann has served as a member of the board of directors of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">247 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
UFP Technologies, Inc., or UFPT, since June 2017. She chairs the UFPT Audit Committee and serves on the Nominating&#160;&amp; Governance Committee. Since 2005, Ms.&#160;Feldmann has served on the board of directors of STERIS PLC, or STERIS, a provider of infection prevention, decontamination, and health science technologies, products and services. She is the Chair of STERIS&#8217; Nominating&#160;&amp; Governance Committee and previously chaired and is a current member of the Audit Committee. Ms.&#160;Feldmann also served from 2003 to 2018 on the board of directors of Hanger Inc., or Hanger, a provider of orthotic and prosthetic services and products, and the largest orthotic and prosthetic managed care network in the U.S. Ms.&#160;Feldmann served on the Audit Committee, including as Chair of the Audit Committee, the Compensation Committee and the Quality and Technology Committee of Hanger. Ms.&#160;Feldmann currently serves on the board of trustees and as a member of the Finance Committee of Falmouth Academy, an academically rigorous, co-ed college preparatory day school for grades 7 to 12. Ms.&#160;Feldmann previously served as a director and chair of the Audit Committee and as a member of the Nominating&#160;&amp; Governance, Compensation, and Quality and Technology Committees of HeartWare International, Inc., a medical device company, from 2012 until its acquisition by Medtronic PLC in August 2016. Previously, Ms.&#160;Feldmann had a 27-year career in public accounting; she was Partner at KPMG LLP, holding various leadership roles in the firm&#8217;s Medical Technology and Health Care&#160;&amp; Life Sciences industry groups and was National Partner-in-Charge of the Life Sciences practice for Coopers&#160;&amp; Lybrand (now PricewaterhouseCoopers LLP) among other leadership positions she held during her career there. Ms.&#160;Feldmann was a founding board member of Mass Medic, a Massachusetts trade association for medical technology companies, where she also served as treasurer and as a member of the board&#8217;s Executive Committee during her tenure from 1997 to 2001. Ms.&#160;Feldmann is a retired CPA and holds a Masters Professional Director Certification from the American College of Corporate Directors. As a result of these and other professional experiences, Ms.&#160;Feldmann possesses particular knowledge and experience in accounting, finance, and capital markets, and public company experience particularly in the medical device industry, that qualifies her to serve on the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Michael Huang </span></span>has served as a member of the Frequency board of directors since October 2018. Since 2021, Mr.&#160;Huang has served as a member of the board of directors of Windgap Medical, Inc. Mr.&#160;Huang has served as a member of the board of directors of Viracta Therapeutics since 2019. Mr.&#160;Huang serves as Managing Partner at Taiwania Capital Management Corporation, a venture capital firm. From 2014 to 2017, Mr.&#160;Huang served as Chief Executive Officer of NeuroVive Pharmaceutical Asia, Inc., a biopharmaceutical company. Mr.&#160;Huang holds an MBA from Rice University, a M.A. in Chemistry from the University of Texas, Arlington, and a B.S. from the University of Texas, Austin. Frequency believes Mr.&#160;Huang&#8217;s extensive investment experience in the life sciences industry qualifies him to serve on the Frequency board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Class III Directors Whose Terms Expire at the 2025 Annual Meeting </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:41%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Class&#160;III&#160;Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Director&#160;Since</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current&#160;Position&#160;at</span><br /><span style="font-weight:bold">Frequency</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy J. Barberich</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">September&#160;2016</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Vice&#160;Chairman&#160;and&#160;Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer, Sc.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">September 2016</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Director</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Timothy J. Barberich</span></span> has served as a member of the Frequency board of directors since September 2016 and as Vice Chairman of the Frequency board of directors since March 2022. Mr.&#160;Barberich has served on the board of directors of TScan Therapeutics, Inc. since 2019, and Gila Therapeutics, Inc. since 2022. Mr.&#160;Barberich previously served on the boards of directors for Verastem, Inc. from 2014 to 2022, for GI Dynamics, Inc. from 2011 to 2021, for Tokai Pharmaceuticals, Inc. from 2009 to 2017, for HeartWare International, Inc. from 2008 to 2016, for Inotek Pharmaceuticals Corporation from 2016 to 2017, and for Neurovance, Inc. from 2010 to 2016. Mr.&#160;Barberich is co-founder, and served as the CEO and Chairman of Sepracor Inc. from 1984 to 2009. He holds a B.S. in Chemistry from Kings College. Frequency believes Mr.&#160;Barberich&#8217;s extensive experience in the life sciences industry qualifies him to serve on the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Robert S. Langer, Sc.D.,</span></span> has served as a member of the Frequency board of directors since September 2016. Dr.&#160;Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology since </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">248 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2005. Dr.&#160;Langer currently serves on the boards of directors Moderna, Inc., Seer, Abpro bio and Puretech Health plc, and previously served on the boards of directors of Momenta Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., Fibrocell Science, Inc. and Millipore Corp. Dr.&#160;Langer holds a Sc.D. in Chemical Engineering from MIT and a B.S. in Chemical Engineering from Cornell University. Frequency believes Dr.&#160;Langer&#8217;s pioneering academic work, extensive medical and scientific knowledge, and experience serving on public company boards of directors qualify him to serve on the Frequency board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Required Vote </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plurality of the votes cast by the holders of shares present in attendance or represented by proxy at the Frequency Annual Meeting and entitled to vote on the matter, assuming a quorum is present, is required to elect David L. Lucchino as a Class I director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 3 TO ELECT DAVID L. LUCCHINO AS A CLASS I DIRECTOR UNTIL THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD IN 2026 AND UNTIL HIS RESPECTIVE SUCCESSOR HAS BEEN DULY ELECTED AND QUALIFIED OR UNTIL HIS EARLIER DEATH, RESIGNATION OR REMOVAL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy statement/prospectus to vote shares &#8220;<span style="font-weight:bold">FOR</span>&#8221; the election of David L. Lucchino as a Class I director until the annual meeting of stockholders to be held in 2026 and until his respective successor has been duly elected and qualified or until his earlier death, resignation or removal. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">249 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_94">PROPOSAL NO. 4: TO RATIFY, IN A NON-BINDING VOTE, THE APPOINTMENT OF RSM US LLP AS FREQUENCY&#8217;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR DECEMBER 31, 2023 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appointment of Independent Registered Public Accounting Firm </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee appoints the independent registered public accounting firm. In this regard, the audit committee evaluates the qualifications, performance and independence of the independent registered public accounting firm and determines whether to re-engage the current firm. As part of its evaluation, the audit committee considers, among other factors, the quality and efficiency of the services provided by the firm, including the performance, technical expertise, industry knowledge and experience of the lead audit partner and the audit team assigned to Frequency&#8217;s account; the overall strength and reputation of the firm; the firm&#8217;s global capabilities relative to Frequency&#8217;s business; and the firm&#8217;s knowledge of Frequency&#8217;s operations. RSM US LLP has served as Frequency&#8217;s independent registered public accounting firm since 2017. Neither the accounting firm nor any of its members has any direct or indirect financial interest in or any connection with Frequency in any capacity other than as the auditors and providing audit and permissible non-audit related services. Upon consideration of these and other factors, the audit committee has appointed RSM US LLP to serve as Frequency&#8217;s independent registered public accounting firm for the year ending December&#160;31, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although ratification is not required, the Frequency board of directors is submitting the selection of RSM US LLP to the stockholders for ratification because Frequency values the stockholders&#8217; views on the independent registered public accounting firm and it is a good corporate governance practice. If the stockholders do not ratify the selection, it will be considered as notice to the Frequency board of directors and the audit committee to consider the selection of a different firm. Even if the selection is ratified, the audit committee, in its discretion, may select a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of Frequency and the stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Representatives of RSM US LLP are expected to attend the Frequency Annual Meeting and to have an opportunity to make a statement and be available to respond to appropriate questions from stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independent Registered Public Accounting Firm Fees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary and description of fees incurred by RSM US LLP for the fiscal years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fiscal</span><br /><span style="font-weight:bold">Year 2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fiscal</span><br /><span style="font-weight:bold">Year 2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">275,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">249,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">349,703</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">373,605</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Audit fees consist of fees for Frequency&#8217;s quarterly reviews and audit of Frequency&#8217;s annual financial statements. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Audit-related fees in 2021 consist of fees related to the preparation of a proxy statement/prospectus for Frequency&#8217;s at-the-market stock sale program. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Tax fees are related to tax advisory services. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pre-Approval Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The formal written charter for the audit committee requires that the audit committee pre-approve all audit services to be provided to Frequency, whether provided by the principal auditor or other firms, and all other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">250 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services (review, attest and non-audit) to be provided to Frequency by the independent registered public accounting firm, other than de minimis non-audit services approved in accordance with applicable rules of the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee has adopted a pre-approval policy that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent registered public accounting firm may be pre-approved. This pre-approval policy generally provides that the audit committee will not engage an independent registered public accounting firm to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i)&#160;explicitly approved by the audit committee or (ii)&#160;entered into pursuant to the pre-approval policies and procedures described in the pre-approval policy. Unless a type of service to be provided by the independent registered public accounting firm has received this latter general pre-approval under the pre-approval policy, it requires specific pre-approval by the audit committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee periodically reviews and generally pre-approves services (and annually approves related fee levels or budgeted amounts) that may be provided by the independent registered public accounting firm without first obtaining specific pre-approval from the audit committee. The audit committee may revise the list of general pre-approved services from time to time, based on subsequent determinations. Any member of the audit committee to whom the committee delegates authority to make pre-approval decisions must report any such pre-approval decisions to the audit committee at its next scheduled meeting. If circumstances arise where it becomes necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval categories or above the pre-approved amounts, the audit committee requires pre-approval for such additional services or such additional amounts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Frequency Board of Directors Recommendation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors unanimously recommends a vote<span style="font-weight:bold"> FOR</span> the ratification of the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee Report </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee operates pursuant to a charter which is reviewed annually by the audit committee. Additionally, a brief description of the primary responsibilities of the audit committee is included in this proxy statement/prospectus under the discussion of &#8220;<span style="font-style:italic">Frequency Directors, Officers and Corporate Governance&#8212; Audit Committee</span>.&#8221; Under the audit committee charter, management is responsible for the preparation, presentation and integrity of Frequency&#8217;s financial statements, the application of accounting and financial reporting principles and Frequency&#8217;s internal controls and procedures designed to assure compliance with accounting standards and applicable laws and regulations. The independent registered public accounting firm is responsible for auditing the financial statements and expressing an opinion as to their conformity with accounting principles generally accepted in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the performance of its oversight function, the audit committee reviewed and discussed with management and RSM US LLP, as Frequency&#8217;s independent registered public accounting firm, Frequency&#8217;s audited financial statements for the fiscal year ended December&#160;31, 2022. The audit committee also discussed with Frequency&#8217;s independent registered public accounting firm the matters required to be discussed by applicable standards of the Public Company Accounting Oversight Board, or the PCAOB, and the SEC. In addition, the audit committee received and reviewed the written disclosures and the letters from Frequency&#8217;s independent registered public accounting firm required by applicable requirements of the PCAOB, regarding such independent registered public accounting firm&#8217;s communications with the audit committee concerning independence, and discussed with Frequency&#8217;s independent registered public accounting firm their independence from Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the review and discussions described in the preceding paragraph, the audit committee recommended to the Frequency board of directors that Frequency&#8217;s audited financial statements be included in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 filed with the SEC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">251 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Submitted by the audit committee of the Frequency board of directors: </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cynthia L. Feldmann (Chair) </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Timothy J. Barberich </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Huang </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Required Vote </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote on the matter is required to ratify, in a non-binding vote, the appointment of RSM US LLP as Frequency&#8217;s independent registered public accounting firm for the year ending December&#160;31, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 4 TO RATIFY, IN A NON-BINDING VOTE, THE APPOINTMENT OF RSM US LLP AS FREQUENCY&#8217;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR DECEMBER 31, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy statement/prospectus to vote shares &#8220;<span style="font-weight:bold">FOR</span>&#8221; the ratification of RSM US LLP as Frequency&#8217;s independent registered public accounting firm for the year ending December&#160;31, 2023. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">252 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_95">PROPOSAL NO.&#160;5: APPROVAL OF 2023 STOCK OPTION AND INCENTIVE PLAN </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in this proxy statement/prospectus, Frequency is asking its stockholders to consider and vote upon a proposal to approve and adopt the Korro Bio, Inc. 2023 Stock Option and Incentive Plan, or the 2023 Plan, a copy of which is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex&#160;I</span>, or the Equity Incentive Plan Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan is intended to replace the Korro Bio 2019 Plan as well as the Frequency 2014 Plan and the Frequency 2019 Plan, or, together with the Frequency 2014 Plan, the Frequency Incentive Plans. If the 2023 Plan becomes effective, then no additional awards will be granted under the Korro Bio 2019 Plan as in effect immediately prior to the closing date of the Merger or the Frequency Incentive Plans, although all outstanding stock awards granted under the Korro Bio 2019 Plan as in effect immediately prior to the closing of the Merger will be assumed and converted into stock awards of the combined company and will remain subject to the terms and conditions of the agreements evidencing such awards and the terms of the Korro Bio 2019 Plan. Each Frequency restricted stock unit award that is outstanding immediately prior to the Effective Time will remain outstanding and such restricted stock unit awards, subject to proportionate adjustment in accordance with the terms of the Frequency 2019 Plan to reflect the Reverse Stock Split and the issuance of the CVRs, will be unaffected by the Merger, provided that each restricted stock unit that vests solely based on the holder&#8217;s continued employment or service will vest in full immediately prior to the Effective Time. In addition, all outstanding and unvested Frequency Options shall vest in full in accordance with the terms of the Merger Agreement and remain outstanding following the Effective Time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reasons to Approve the 2023 Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the 2023 Plan is to enhance the ability of the combined company to attract, retain and incentivize employees, independent contractors and directors and promote the success of its business. Equity compensation can play an important role in the success of the combined company by encouraging and enabling employees, independent contractors and directors, upon whose judgment, initiative and efforts the combined company largely depends for the successful conduct of its business, to acquire a proprietary interest in the combined company. Accordingly, the ability to grant stock awards at competitive levels will be a vital element of the combined company&#8217;s compensation program and is, therefore, in the best interest of the combined company and its stockholders. If Frequency&#8217;s stockholders do not approve the 2023 Plan, the Frequency 2019 Plan will remain in effect in accordance with its terms. In such event, the combined company&#8217;s board of directors may consider whether to adopt alternative arrangements based on its assessment of the combined company&#8217;s needs. Without stockholder approval of the 2023 Plan, the combined company could be limited in its ability to offer a competitive equity compensation program to attract, retain and motivate the talented and qualified employees necessary for the continued growth and success of the combined company, especially in an industry that increasingly relies on equity compensation as a key component of overall employee compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the 2023 Plan by Frequency&#8217;s stockholders is required, among other things, in order to comply with stock exchange rules requiring stockholder approval of equity compensation plans and allow the grant of incentive stock options under the 2023 Plan. If the 2023 Plan is approved by Frequency&#8217;s stockholders, the 2023 Plan will become effective as of the Effective Time and the combined company will register the necessary shares of its common stock on a Registration Statement on Form S-8. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares will be reserved for issuance under the 2023 Plan. As of July 14, 2023, the closing price on Nasdaq per share of Frequency common stock was $0.7099. Based upon a price per share of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, the maximum aggregate market value that could potentially be issued under the 2023 Plan at the Effective Time is $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. The Frequency board of directors approved the 2023 Plan on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, subject to the closing and approval by Frequency&#8217;s stockholders. If the closing does not occur or the 2023 Plan </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">253 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is not approved by Frequency&#8217;s stockholders, the 2023 Plan will not become effective and no stock awards will be granted thereunder, and the Frequency 2019 Plan will remain in full force and effect and available for the grant of stock awards thereunder (subject to the terms of the plan). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material features of the 2023 Plan. This summary is qualified in its entirety by the full text of the 2023 Plan, a copy of which is included as <span style="font-style:italic">Annex I</span> to this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of the Material Provisions of the Korro Bio, Inc. 2023 Stock Option and Incentive Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan in intended to allow the combined company to make equity and equity-based incentive awards to officers, employees, directors and consultants. The combined company anticipates that providing such persons with a direct stake in the combined company will assure a closer alignment of the interests of such individuals with those of the combined company and its stockholders, thereby stimulating their efforts on the combined company&#8217;s behalf and strengthening their desire to remain with the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum aggregate number of shares that may be issued under the 2023 Plan is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares, or the Initial Limit. The 2023 Plan provides that the number of shares reserved and available for issuance under the 2023 Plan will automatically increase each January&#160;1, beginning on January&#160;1, 2024, by 5% of the outstanding number of shares on the immediately preceding December&#160;31, or such lesser amount as determined by the plan administrator, or the Annual Increase. This limit is subject to adjustment in the event of a reorganization, recapitalization, reclassification, stock split, stock dividend, reverse stock split or other similar change in the combined company&#8217;s capitalization. The maximum aggregate number of shares that may be issued upon exercise of incentive stock options under the 2023 Plan shall not exceed the Initial Limit cumulatively increased on January&#160;1, 2024 and on each January&#160;1 thereafter by the lesser of the Annual Increase or &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares. Shares underlying any awards under the 2023 Plan and the shares underlying awards under the Korro Bio 2019 Plan or Frequency Plans that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the combined company prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise) shall be added back to the shares available for issuance under the 2023 Plan and, to the extent permitted under Section&#160;422 of the Code and the regulations promulgated thereunder, the shares that may be issued as incentive stock options. Awards that may be settled solely in cash will not be counted against the shares available for issuance under the 2023 Plan and will not reduce the shares authorized for grant to a grantee in any calendar year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan contains a limitation whereby the value of all awards under the 2023 Plan and all other cash compensation paid to any non-employee director for services as a non-employee director may not exceed $750,000 in any calendar year; provided, however, that such amount will be $1,000,000 for the first calendar year a non-employee director is initially appointed to the combined company&#8217;s board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan will be administered by the combined company&#8217;s board of directors, the compensation committee of the combined company&#8217;s board of directors or such other similar committee pursuant to the terms of the 2023 Plan. The plan administrator, which initially will be the compensation committee of the combined company&#8217;s board of directors, will have full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2023 Plan. The plan administrator may delegate to a committee consisting of one or more officers the authority to grant stock options and other awards to employees who are not subject to the reporting and other provisions of Section&#160;16 of the Exchange Act and not members of the delegated committee, subject to certain limitations and guidelines. Persons eligible to participate in the 2023 Plan will be officers, employees, non-employee directors and consultants of the combined company as selected from time to time by the plan administrator in its discretion. </p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">254 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following completion of the Merger, the combined company is expected to have a total of approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; employees and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; non-employee directors who will be eligible to be granted stock awards from the 2023 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan permits the granting of both options to purchase shares intended to qualify as incentive stock options under Section&#160;422 of the Code and options that do not so qualify. Options granted under the 2023 Plan will be non-qualified options if they fail to qualify as incentive stock options or exceed the annual limit on incentive stock options. Incentive stock options may only be granted to employees of the combined company and its subsidiaries. Non-qualified options may be granted to any persons eligible to receive awards under the 2023 Plan. The option exercise price of each option will be determined by the plan administrator but generally may not be less than 100% of the fair market value of the combined company&#8217;s share on the date of grant or, in the case of an incentive stock option granted to a 10% stockholder, 110% of such share&#8217;s fair market value. The term of each option will be fixed by the plan administrator and may not exceed ten years from the date of grant or, in the case of an incentive stock option granted to a ten percent stockholder, five years from the date of grant. The plan administrator will determine at what time or times each option will vest and may be exercised, including the ability to accelerate the vesting of such options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon exercise of options, the option exercise price must be paid in full either in cash, by certified or bank check or other instrument acceptable to the plan administrator or by delivery (or attestation to the ownership) of shares that are beneficially owned by the optionee free of restrictions or were purchased in the open market. Subject to applicable law, the exercise price may also be delivered by a broker pursuant to irrevocable instructions to the broker from the optionee. In addition, the plan administrator may permit non-qualified options to be exercised using a &#8220;net exercise&#8221; arrangement that reduces the number of shares issued to the optionee by the largest whole number of shares with fair market value that does not exceed the aggregate exercise price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares or cash, equal to the value of the appreciation in the combined company&#8217;s stock price over the exercise price. The exercise price generally may not be less than 100% of the fair market value of the combined company&#8217;s share on the date of grant. The term of each stock appreciation right will be fixed by the plan administrator and may not exceed ten years from the date of grant. The plan administrator will determine at what time or times each stock appreciation right will vest and may be exercised, including the ability to accelerate the vesting of such stock appreciation right. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator may award restricted shares and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with the combined company through a specified vesting period. The plan administrator may also grant shares that are free from any restrictions under the 2023 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. The plan administrator may grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator may grant cash-based awards under the 2023 Plan to participants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan requires the plan administrator to make appropriate adjustments to the number of shares of common stock that are subject to the 2023 Plan, to certain limits in the 2023 Plan, and to any outstanding awards to reflect stock dividends, stock splits, extraordinary cash dividends and similar events. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan provides that upon the effectiveness of a &#8220;sale event,&#8221; as defined in the 2023 Plan, an acquirer or successor entity may assume, continue or substitute for the outstanding awards under the 2023 Plan. To the extent that awards granted under the 2023 Plan are not assumed or continued or substituted by the successor entity, all awards granted under the 2023 Plan shall terminate and in such case, except as may be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">255 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise provided in the relevant award agreement, all stock options and stock appreciation rights with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the sale event and held by grantees who have had a continuous service relationship with the combined company for at least one year prior to the effective time of the sale event shall become fully vested and exercisable as of the effective time of the sale event, all other awards with time-based vesting conditions or restrictions shall, if held by grantees who have had a continuous service relationship with the combined company for at least one year prior to the effective time of the sale event, become fully vested and nonforfeitable as of the effective time of the sale event, and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a sale event in the plan administrator&#8217;s discretion or to the extent specified in the relevant award agreement. In the event of such termination, individuals holding options and stock appreciation rights will, for each such award, either (a)&#160;receive a payment in cash or in kind for each share subject to such award that is exercisable in an amount equal to the per share cash consideration payable to stockholders in the sale event less the applicable per share exercise price (provided that, in the case of an option or stock appreciation right with an exercise price equal to or greater than the per share cash consideration payable to stockholders in the sale event, such option or stock appreciation right shall be cancelled for no consideration) or (b)&#160;be permitted to exercise such options and stock appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event. The plan administrator shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other awards in an amount equal to the per share cash consideration payable to stockholders in the sale event multiplied by the number of vested shares under such awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participants in the 2023 Plan are responsible for the payment of any federal, state or local taxes that the combined company is required by law to withhold upon the exercise of options or stock appreciation rights or vesting of other awards. The plan administrator may cause any tax withholding obligation of the combined company to be satisfied, in whole or in part, by the combined company withholding from shares to be issued pursuant to an award a number of shares with an aggregate fair market value that would satisfy the withholding amount due. The plan administrator may also require any tax withholding obligation of the combined company to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares issued pursuant to any award are immediately sold and proceeds from such sale are remitted to the combined company in an amount that would satisfy the withholding amount due. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan generally does not allow for the transfer or assignment of awards, other than by will or by the laws of descent and distribution or pursuant to a domestic relations order; however, the plan administrator may permit the transfer of non-qualified stock options by gift to an immediate family member, to trusts for the benefit of family members, or to partnerships in which such family members are the only partners. All awards will be subject to any combined company clawback policy as set forth in such clawback policy or the applicable award agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator may amend or discontinue the 2023 Plan and the plan administrator may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may materially and adversely affect rights under an award without the holder&#8217;s consent. The plan administrator may not reduce the exercise price of outstanding options or stock appreciation rights, effect the repricing of such awards through cancellation and re-grants or cancel such awards in exchange for cash or other awards without prior stockholder approval. Certain amendments to the 2023 Plan require the approval of the combined company&#8217;s stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No awards may be granted under the 2023 Plan after the date that is ten years from the Effective Time. No awards under the 2023 Plan have been made prior to the date hereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Form S-8 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Merger, the combined company will file with the SEC a registration statement on Form S-8 covering the shares issuable under the 2023 Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">256 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain U.S. Federal Income Tax Consequences </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the principal U.S. federal income tax consequences of certain transactions under the 2023 Plan. It does not describe all federal tax consequences under the 2023 Plan, nor does it describe state or local tax consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Incentive Stock Options</span></span>. No taxable income is generally recognized by the optionee upon the grant or exercise of an incentive stock option. If shares issued to an optionee pursuant to the exercise of an incentive stock option are sold or transferred after two years from the date of grant and after one year from the date of exercise, then generally (i)&#160;upon sale of such shares, any amount realized in excess of the option exercise price (the amount paid for the shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained will be a long-term capital loss, and (ii)&#160;the combined company will not be entitled to any deduction for federal income tax purposes; provided that such incentive stock option otherwise meets all of the technical requirements of an incentive stock option. The exercise of an incentive stock option will give rise to an item of tax preference that may result in alternative minimum tax liability for the optionee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If shares acquired upon the exercise of an incentive stock option are disposed of prior to the expiration of the two-year and one-year holding periods described above (a &#8220;disqualifying disposition&#8221;), generally (i)&#160;the optionee will recognize ordinary income in the year of disposition in an amount equal to the excess (if any) of the fair market value of the shares at exercise (or, if less, the amount realized on a sale of such shares) over the option price thereof, and (ii)&#160;the combined company will be entitled to deduct such amount. Special rules will apply where all or a portion of the exercise price of the incentive stock option is paid by tendering shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an incentive stock option is exercised at a time when it no longer qualifies for the tax treatment described above, the option is treated as a non-qualified option. Generally, an incentive stock option will not be eligible for the tax treatment described above if it is exercised more than three months following termination of employment (or one year in the case of termination of employment by reason of disability). In the case of termination of employment by reason of death, the three-month rule does not apply. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No income is generally recognized by the optionee at the time a non-qualified option is granted. Generally (i)&#160;at exercise, ordinary income is recognized by the optionee in an amount equal to the difference between the option exercise price and the fair market value of the shares on the date of exercise, and the combined company will receive a tax deduction for the same amount, and (ii)&#160;at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital gain or loss depending on how long the shares have been held. Special rules will apply where all or a portion of the exercise price of the non-qualified option is paid by tendering shares. Upon exercise, the optionee will also be subject to social security taxes on the excess of the fair market value over the exercise price of the option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">All Other Awards. </span>For all other awards under the 2023 Plan, the combined company generally will be entitled to a tax deduction in connection with other awards under the 2023 Plan in an amount equal to the ordinary income recognized by the participant at the time the participant recognizes such income. Participants typically are subject to income tax and recognize such tax at the time that an award is exercised, vests or becomes non-forfeitable, unless the award provides for deferred settlement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 162(m) of the Code limits the deduction certain employers may take for otherwise deductible compensation payable to certain executive officers of the employer to the extent the compensation paid to such an officer for the year exceeds $1 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vesting of any portion of an award that is accelerated due to the occurrence of a change in control (such as a sale event) may cause all or a portion of the payments with respect to such accelerated awards to be treated as &#8220;excess parachute payments&#8221; as defined in Section 280G of the Code. Any such excess parachute payments may be non-deductible to the combined company, in whole or in part, and may subject the recipient to a non-deductible 20% federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">257 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Application of Section 409A of the Code </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 409A of the Code imposes an additional 20% tax and interest on an individual receiving nonqualified deferred compensation under a plan that fails to satisfy certain requirements. For purposes of Section 409A, &#8220;nonqualified deferred compensation&#8221; includes equity-based incentive programs, including some stock options, stock appreciation rights and restricted stock units. Generally speaking, Section 409A does not apply to incentive stock options, and non-discounted non-qualified stock options and stock appreciation rights if no deferral is provided beyond exercise, or restricted stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The awards made pursuant to the 2023 Plan are expected to be designed in a manner intended to comply with the requirements of Section 409A of the Code such that no adverse tax consequences under Section 409A apply to the extent the awards granted under the 2023 Plan are not exempt from coverage. However, if the 2023 Plan fails to comply with Section 409A in operation, a participant could be subject to the additional taxes and interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">State, local and foreign tax consequences may in some cases differ from the U.S. federal income tax consequences described above. The aforementioned summary of the U.S. federal income tax consequences in respect of the 2023 Plan is for general information only. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interested parties should consult their own advisors as to specific tax consequences of their awards. The 2023 Plan is not subject to the Employee Retirement Income Security Act of 1974, as amended, and is not intended to be qualified under Section 401(a) of the Code. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Plan Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No awards have been previously granted under the 2023 Plan and no awards have been granted that are contingent on stockholder approval of the 2023 Plan. The awards that are to be granted to any participant or group of participants are indeterminable at the date of this proxy statement/prospectus because participation and the types of awards that may be granted under the 2023 Plan are subject to the discretion of the plan administrator. Consequently, no new plan benefits table is included in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Certain Persons in this Proposal </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of financial and personal interests of one or more of Frequency&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he or she may believe is in the best interests of Frequency and its stockholders and what he or she may believe is best for himself or herself in determining to recommend that stockholders vote for the proposals. In addition, Frequency&#8217;s officers have interests in the Merger that may conflict with the interests of Frequency&#8217;s stockholders. See the section entitled &#8220;The Merger&#8212;Interests of Frequency Directors and Executive Officers in the Merger&#8221; for a further discussion of these considerations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Required Vote </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote on the matter is required to approve the Equity Incentive Plan Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO.&#160;5 TO APPROVE THE EQUITY INCENTIVE PLAN PROPOSAL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy statement/prospectus to vote shares &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the Equity Incentive Plan Proposal. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">258 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_96">PROPOSAL NO. 6: APPROVAL OF 2023 EMPLOYEE STOCK PURCHASE PLAN </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in this proxy statement/prospectus, Frequency is asking its stockholders to consider and vote upon a proposal to approve the Korro Bio, Inc. 2023 Employee Stock Purchase Plan, or the 2023 ESPP, a copy of which is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex J</span>, or the ESPP Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the 2023 ESPP becomes effective, then no additional awards will be granted under the Frequency ESPP. If the 2023 ESPP does not become effective, the Frequency ESPP will remain in full force and effect and available for the grant of awards thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reasons to Approve the 2023 ESPP </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the 2023 ESPP is to provide employees of the combined company with an opportunity to acquire shares, which will enable the combined company to attract, retain and motivate valued employees. Approval of the 2023 ESPP by Frequency&#8217;s stockholders is required, among other things, in order to comply with stock exchange rules requiring stockholder approval of equity compensation plans. A component of the 2023 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. If the 2023 ESPP is approved by Frequency&#8217;s stockholders, the 2023 ESPP will become effective as of the Effective Time and the combined company will register the necessary shares of its common stock on a Registration Statement on Form S-8. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares will be reserved for issuance under the 2023 ESPP. As of July 14, 2023, the closing price on Nasdaq per share of Frequency common stock was $0.7099. Based upon a price per share of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, the maximum aggregate market value that could potentially be issued under the 2023 ESPP at the Effective Time is $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.The Frequency board of directors approved the 2023 ESPP on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023, subject to approval by Frequency&#8217;s stockholders and the closing. If the 2023 ESPP is approved by Frequency&#8217;s stockholders, the 2023 ESPP will become effective at the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material features of the 2023 ESPP. This summary is qualified in its entirety by the full text of the 2023 ESPP, a copy of which is included as <span style="font-style:italic">Annex J</span> to this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of the Material Provisions of the 2023 ESPP </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An aggregate of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares, or the Initial Reserve, will be reserved and available for issuance under the 2023 ESPP. The 2023 ESPP provides that the number of shares reserved and available for issuance under the plan will automatically increase each January&#160;1, beginning on January&#160;1, 2024, by the lesser of a number of shares equal to the Initial Reserve, 1% of the outstanding number of shares on the immediately preceding December&#160;31, or such lesser amount as determined by the plan administrator. If the combined company&#8217;s capital structure changes because of a stock dividend, stock split or similar event, the number of shares that can be issued under the 2023 ESPP will be appropriately adjusted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 ESPP will be administered by the person or persons appointed by the combined company&#8217;s board of directors. Initially, the compensation committee of the combined company&#8217;s board of directors will administer the plan and will have full authority to make, administer and interpret such rules and regulations regarding the 2023 ESPP as it deems advisable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any employee of the combined company or one of its subsidiaries that has been designated to participate in the 2023 ESPP is eligible to participate in the 2023 ESPP so long as the employee is customarily employed for more than 20 hours a week. No person who owns or holds, or as a result of participation in the 2023 ESPP would own or hold, shares or options to purchase shares, that together equal to 5% or more of total combined voting power or value of all classes of stock of the combined company or any parent or subsidiary is entitled to participate in the 2023 ESPP. No employee may exercise an option granted under the 2023 ESPP that permits the employee to purchase shares having a value of more than $25,000 (determined using the fair market value of the stock at the time such option is granted) in any calendar year. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">259 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participation in the 2023 ESPP is limited to eligible employees who authorize payroll deductions equal to a whole percentage of base pay to the 2023 ESPP. Employees may authorize payroll deductions, with a minimum of 1% of base pay and a maximum of 15% of base pay. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following completion of the Merger, the combined company is expected to have a total of approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; employees who will be eligible participate the 2023 ESPP. Once an employee becomes a participant in the 2023 ESPP, that employee will automatically participate in successive offering periods, as described below, until such time as that employee withdraws from the 2023 ESPP, becomes ineligible to participate in the 2023 ESPP, or his or her employment ceases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company may make one or more offerings under the 2023 ESPP, consisting of one or more purchase periods, for employees to purchase shares under the 2023 ESPP, which is referred to as an &#8220;offering period.&#8221; The plan administrator may, in its discretion, determine when each offering shall occur, including the duration of any offering period; provided, that no offering period will exceed 27 months in duration. . Shares are purchased on the last day of each purchase period or if such purchase period is the last purchase period of the offering period, the last day of such offering period, with that day being referred to as an &#8220;exercise date.&#8221; Unless otherwise determined by the plan administrator, participants will only be permitted to participate in one offering at a time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first day of an offering period, employees participating in that offering period will be granted an option to purchase shares. On the exercise date of each purchase period, the employee is deemed to have exercised the option, at the exercise price, for the lowest of (i)&#160;a number of shares determined by dividing such employee&#8217;s accumulated payroll deductions or contributions on such exercise date by the exercise price; (ii)&#160;a number of shares determined by dividing $25,000 by the fair market value per share on the first day of the offering period; or (iii)&#160;such lesser number as established by the plan administrator in advance of the offering. The exercise price is equal to the lesser of (i)&#160;85% the fair market value per share on the first day of the offering period or (ii)&#160;85% of the fair market value per share on the exercise date. The maximum number of shares that may be issued to any employee under the 2023 ESPP in a calendar year is a number of shares determined by dividing $25,000, valued at the start of the offering period, or such other lesser number of shares as determined by the plan administrator from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, if an employee is no longer a participant on an exercise date, the employee&#8217;s option will be automatically terminated, and the amount of the employee&#8217;s accumulated payroll deductions will be refunded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may be permitted by the plan administrator in advance of an offering, a participant may not increase or decrease the amount of his or her payroll deductions during any offering period but may increase or decrease his or her payroll deduction with respect to the next offering period by filing a new enrollment form at least 15 business days before the first day of such offering period, or such other deadline established by the plan administrator. A participant may withdraw from an offering period at any time without affecting his or her eligibility to participate in future offering periods. If a participant withdraws from an offering period, that participant may not again participate in the same offering period, but may enroll in subsequent offering periods. An employee&#8217;s withdrawal will be effective as of the next business day following the date that the plan administrator receives the employee&#8217;s written notice of withdrawal under the 2023 ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of and subject to the consummation of a &#8220;sale event,&#8221; the plan administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following actions under the 2023 ESPP or with respect to any right under the 2023 ESPP or to facilitate such transactions or events: (a)&#160;to provide for either (i)&#160;termination of any outstanding option in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such option had such option been currently exercisable or (ii)&#160;the replacement of such outstanding option with other options or property selected by the plan administrator in its sole discretion; (b)&#160;to provide that the outstanding options under </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">260 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the 2023 ESPP shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for similar options covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices; (c)&#160;to make adjustments in the number and type of shares (or other securities or property) subject to outstanding options under the 2023 ESPP and/or in the terms and conditions of outstanding options and options that may be granted in the future; (d)&#160;to provide that the offering with respect to which an option relates will be shortened by setting a new exercise date on which such offering will end; and (e)&#160;to provide that all outstanding options shall terminate without being exercised and all amounts in the accounts of participants shall be promptly refunded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 ESPP will automatically terminate on the 10-year anniversary of the Effective Time. The combined company&#8217;s board of directors may, in its discretion, at any time, terminate or amend the 2023 ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Form S-8 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Effective Time and subject to the approval of the 2023 ESPP by Frequency&#8217;s stockholders, the combined company will file with the SEC a registration statement on Form S-8 covering the shares issuable under the 2023 ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain U.S. Federal Income Tax Consequences </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is only a summary of the effect of the U.S. income tax laws and regulations upon an employee and the combined company with respect to an employee&#8217;s participation in the 2023 ESPP. This summary does not purport to be a complete description of all federal tax implications of participation in the 2023 ESPP, nor does it discuss the income tax laws of any municipality, state or foreign country in which a participant may reside or otherwise be subject to tax. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant in the 2023 ESPP generally recognizes no taxable income either as a result of participation in the 2023 ESPP or upon exercise of an option to purchase shares under the terms of the 2023 ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant disposes of shares purchased upon exercise of an option granted under the 2023 ESPP within two years from the first day of the applicable offering period or within one year from the exercise date, which is referred to as a &#8220;disqualifying disposition,&#8221; the participant will generally recognize ordinary income in the year of that disposition equal to the amount by which the fair market value of the shares on the date the shares were purchased exceeds the purchase price. The amount of ordinary income will be added to the participant&#8217;s basis in the shares, and any additional gain or resulting loss recognized on the disposition of the shares will be a capital gain or loss. A capital gain or loss will generally be long-term if the participant&#8217;s holding period is more than 12 months, or short-term if the participant&#8217;s holding period is 12 months or less. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the participant disposes of shares purchased upon exercise of an option granted under the 2023 ESPP at least two years after the first day of the applicable offering period and at least one year after the exercise date, the participant will recognize ordinary income in the year of disposition equal to the lesser of (1)&#160;the excess of the fair market value of the shares at the time the option was granted over the amount paid and (2)&#160;the excess of the amount actually received for the shares over the amount paid. The amount of any ordinary income will be added to the participant&#8217;s basis in the shares, and any additional gain recognized upon the disposition after that basis adjustment will be a long-term capital gain. If the fair market value of the shares on the date of disposition is less than the exercise price, there will be no ordinary income and any loss recognized will be a long-term capital loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company is generally entitled to a tax deduction in the year of a disqualifying disposition equal to the amount of ordinary income recognized by the participant as a result of that disposition. In all other cases, the combined company is not allowed a deduction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">261 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Plan Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because participation in the 2023 ESPP is voluntary, the benefits or amounts that will be received by or allocated to any individual or group of individuals under the 2023 ESPP in the future are not determinable and no awards have been granted that are contingent on stockholder approval of the 2023 ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Certain Persons in this Proposal </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of financial and personal interests of one or more of Frequency&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he or she may believe is in the best interests of Frequency and its stockholders and what he or she may believe is best for himself or herself in determining to recommend that stockholders vote for the proposals. In addition, Frequency&#8217;s officers have interests in the Merger that may conflict with the interests of Frequency&#8217;s stockholders. See the section entitled &#8220;<span style="font-style:italic">The Merger&#8212;Interests of Frequency Directors and Executive Officers in the Merger</span>&#8221; for a further discussion of these considerations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Required Vote </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote on the matter is required to approve the ESPP Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 6 TO APPROVE THE 2023 EMPLOYEE STOCK PURCHASE PLAN. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy statement/ prospectus to vote shares &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the ESPP Proposal. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">262 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_98">PROPOSAL NO. 7: APPROVAL OF ADJOURNMENT OF THE FREQUENCY ANNUAL MEETING </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency fails to receive a sufficient number of votes to approve Proposal Nos. 1 and 2, Frequency may propose to adjourn the Frequency Annual Meeting, for a period of not more than 60 days, for the purpose of soliciting additional proxies to approve Proposal Nos. 1 and 2. Frequency currently does not intend to propose adjournment at the Frequency Annual Meeting if there are sufficient votes to approve Proposal Nos. 1 and 2. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Required Vote </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Frequency Annual Meeting by the holders entitled to vote on the matter is required to approve the adjournment of the Frequency Annual Meeting for the purpose of soliciting additional proxies to approve Proposal No. 1. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 7 TO ADJOURN THE FREQUENCY ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSAL NOS.&#160;1 and 2. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy statement/prospectus to vote shares &#8220;<span style="font-weight:bold">FOR</span>&#8221; the ratification to adjourn the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">263 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_99">FREQUENCY&#8217;S BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_100">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s business has focused on developing therapeutics that activate a person&#8217;s innate regenerative potential through its proprietary PCA approach. Frequency first applied its PCA approach for the restoration of the cochlea, with a focus on treating SNHL. Beginning in 2019, Frequency ran five clinical studies of FX-322 aimed at understanding safety as well as severities and etiologies that FX-322 might treat and the appropriate dose regime. In 2021, Frequency commenced its sixth study, the FX-322-208 study, and introduced a second hearing program, FX-345, which Frequency believed might expand the opportunity to treat different types of SNHL. In February 2023, Frequency announced that the FX-322-208 study failed to achieve its primary endpoint of an improvement in speech perception. Frequency decided to discontinue the FX-322 development program and, given the similarities between the mechanisms of FX-322 and FX-345, decided to discontinue the FX-345 development program as well. Following this decision, Frequency focused its efforts on developing the MS Program and to explore strategic alternatives for the MS Program, including the sale of the MS Program. On July 14, 2023, Frequency entered into the Merger Agreement with Korro Bio and Merger Sub. Upon completion of the Merger, the business of Korro Bio will continue as the business of the combined company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_104">Frequency&#8217;s multiple sclerosis (MS) program</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The symptoms of MS include numbness or tingling, weakness, dizziness and vertigo, spasticity, vision problems, sexual problems, bladder or bowel problems, pain, cognitive changes, emotional changes, and depression. Initially, most individuals experience a relapsing-remitting experience course of disease, with periods of new or relapsing symptoms followed by recovery and periods of remission. Early in the disease course, the individuals are partially able to remyelinate the demyelinated nerves. As the disease progresses the ability of the body to remyelinate axons significantly decreases leading to progressive and irreversible neurological deficits. According to the National Multiple Sclerosis Society, nearly one million people in the United States are living with MS.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has approved a number of&#160;disease-modifying therapies for MS that reduce the immune system attack on myelin, which may reduce the number of relapses, delay progression of disability, and limit new disease activity. However, none of these products directly induce the remyelination of the nerve fibers. There are no FDA approved remyelinating therapies for MS and Frequency believes this remains the largest unmet medical need in individuals with MS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MS induces demyelination, stripping axons of the myelin sheaths that support nerve signal conduction and axonal survival. The MS Program focused on inducing remyelination by activating oligodendrocyte progenitor cells, or OPCs, in the central nervous system to generate new oligodendrocytes and regenerate myelin, potentially repairing the damage caused by MS. Frequency&#8217;s efforts focused on advancing proprietary Frequency compounds in preclinical safety studies. Frequency is currently exploring strategic alternatives for the MS Program, including the sale of the MS Program.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential for pharmacologic therapy to induce remyelination in MS has been supported by multiple clinical trials. Clinical trials testing clemastine, histamine receptor 3 inverse agonists, anti-LINGO antibodies, and bexarotene have shown modest improvements in electrophysiological or MRI measures of MS.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, to maximize the benefit to individuals with MS, Frequency believes it is likely that significantly more effective remyelinating agents will be necessary. To create such a therapeutic, Frequency established an independent internal research program to explore the biology underlying remyelination and develop novel chemical entities, or NCEs. Frequency has identified a novel target that modulates oligodendrocyte differentiation and remyelination. Frequency&#8217;s internal discovery efforts have yielded a number of potential NCEs that have shown encouraging remyelination inducing activity in preclinical studies. Frequency compared </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">264 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
some of its internally discovered preclinical stage compounds to three known compounds, thyroid hormone, anti-LINGO antibody, and clemastine, in <span style="font-style:italic">in vivo</span> models. In these models, Frequency&#8217;s internally discovered preclinical stage compounds induced significantly more oligodendrocyte differentiation (Exhibit 1) and remyelination (Exhibit 2) <span style="font-style:italic">in vivo</span> than the published comparator compounds. Frequency&#8217;s internally discovered preclinical stage compounds were shown to be effective even in aged animals and drove remyelination in both white and gray matter, which are critical in motor, sensory and cognitive aspects of MS. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 1: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g28a32.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 2: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g28b32.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_107">Intellectual property</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency strives to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of its business, including by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. Frequency also relies on trade secrets, confidential information and know-how, continuing technological innovation, and in-licensing opportunities to develop, strengthen, and maintain its proprietary position in the field.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">265 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s future success depends, in part, on its ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to Frequency&#8217;s business; defend and enforce Frequency&#8217;s intellectual property rights, in particular its patent rights; preserve the confidentiality of Frequency&#8217;s trade secrets; and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Frequency&#8217;s ability to stop third parties from making, using, selling, offering to sell, or importing products identical or similar to Frequency may depend on the extent to which Frequency has rights under valid and enforceable patents or trade secrets that cover these activities.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology and pharmaceutical companies like Frequency are generally uncertain and can involve complex legal, scientific, and factual issues. Frequency cannot predict whether the patent applications it is currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Frequency also cannot ensure that patents will issue with respect to any patent applications that Frequency or its licensors may file in the future, nor can Frequency ensure that any of Frequency owned or licensed patents or future patents will be commercially useful in protecting its product candidates and methods of manufacturing. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, Frequency cannot guarantee that any of Frequency&#8217;s products will be protected or remain protectable by enforceable patents. Moreover, any patents that Frequency holds may be challenged, circumvented, or invalidated by third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office, or USPTO, may be significantly narrowed before issuance, if issued at all. Frequency expects this may be the case with respect to some of its pending patent applications referred to below.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency owns intellectual property directed to the treatment of MS and Frequency advises on an exclusively in-licensed portfolio of intellectual property directed to the treatment of MS from The Scripps Research Institute. As of February&#160;1, 2023, no development candidate has been designated, but the intellectual property portfolio for its MS research program currently includes 3 patent families including 4 U.S. patents, 15 ex-U.S. patents, 1 pending U.S. utility patent application, 10 ex-U.S. patent applications, and 1 PCT patent application. While Frequency believes that the specific and generic claims, contained in its U.S. and ex-U.S. patents provide protection for the claimed pharmaceutical compositions and methods of use, third parties may nevertheless challenge such claims. If any such claims are invalidated or rendered unenforceable for any reason, Frequency will lose valuable intellectual property rights, and its ability to prevent others from competing with Frequency would be impaired. Any U.S. or ex-U.S. patents that may issue from pending applications that Frequency owns or exclusively in-licensed, if any, for its MS program are projected to have a statutory expiration date between 2032 and 2042, excluding any additional term for patent term adjustments or patent term extensions. The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which Frequency files, the patent term is 20 years from the earliest date of filing a non-provisional patent application.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but the remaining term of a patent cannot be extended beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued patents covering the use of products from Frequency&#8217;s intellectual property may be entitled to patent term extensions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, Frequency relies upon trade secrets, confidential information and know-how, and continuing technological innovation to develop and maintain its competitive position. However, trade </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">266 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
secrets and confidential information and know-how are difficult to protect. Frequency seeks to protect its proprietary information, in part, using confidentiality agreements with any collaborators, scientific advisors, employees, and consultants; and invention assignment agreements with its employees. Frequency also has agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and Frequency may not have an adequate remedy for any such breach. In addition, Frequency&#8217;s trade secrets and/or confidential information and know-how may become known or be independently developed by a third party, or misused by any collaborator to whom Frequency discloses such information. Despite any measures taken to protect Frequency&#8217;s intellectual property, unauthorized parties may attempt to copy aspects of its products or obtain or use information that Frequency regards as proprietary. Although Frequency takes steps to protect its proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to its proprietary information. As a result, Frequency may be unable to meaningfully protect Frequency&#8217;s trade secrets and proprietary information.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require Frequency to alter its strategies, obtain licenses, or cease certain activities. Frequency&#8217;s breach of any license agreements or failure to obtain a license to proprietary rights that Frequency may require may have an adverse impact on Frequency&#8217;s business. If third parties have prepared and filed patent applications prior to March&#160;16, 2013, in the United States that also claim technology to which Frequency has rights, Frequency may have to participate in interference proceedings in the USPTO to determine priority of inventions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_109">Competition</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a clinical-stage biotechnology company, Frequency faces competition from a wide array of companies in the pharmaceutical and biotechnology industries. These include both small companies and large companies with much greater financial and technical resources and far longer operating histories than Frequency. Frequency also competes with the intellectual property, technology, and product development efforts of academic, governmental, and private research institutions.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than Frequency does. These competitors also compete with Frequency in recruiting and retaining qualified scientific, sales, marketing, and management personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Frequency&#8217;s programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of any Frequency product candidates are likely to be their efficacy, safety, convenience, price, and the availability of reimbursement from government and other third-party payors. The commercial opportunity for any product Frequency candidate could be reduced or eliminated if its competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient, or are less expensive. Frequency&#8217;s competitors also may obtain FDA or other regulatory approval for their products more rapidly and may commercialize products more quickly.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are multiple therapeutic options for treating the symptoms of MS, as well as the underlying disease. However, all approved therapies are directed at blocking demyelination, and, to Frequency&#8217;s knowledge, there are no approved therapies that are designed to promote remyelination. Frequency is aware of numerous efforts to identify drugs or biologics that can stimulate&#160;oligodendrocyte regeneration and myelin repair in the central nervous system. These include companies such as Clene Inc., which has an ongoing Phase 2 trial of CNM-Au8, a gold nanocrystal suspension, and Pipeline Therapeutics, which completed a Phase 1 trial for PIPE-307, a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">267 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
selective M1 receptor antagonist to treat multiple sclerosis and other demyelinating disorders. In March 2022, Pipeline received IND clearance to initiate a Phase 1b/2a study of PIPE-307. Idorsia Pharma completed two Phase 1 studies in 2019 and 2020 for ACT-1004-1239, a small molecule CXCR7 inhibitor involved in OPC differentiation. NervGen Pharma is developing NVG-291, a therapeutic peptide which is a mimetic of the intracellular domain of protein tyrosine phosphatase (PTP<span style="FONT-FAMILY:SYMBOL">&#115;</span>). In October 2022, NervGen Pharma announced plans to initiate a Phase 2 trial of NVG-291 in 2023 in patients with RRMS.&#160;This is an active research area with a number of entities researching compounds, antibodies, and proteins which may enhance remyelination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_110">Government regulation</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those Frequency is developing. These agencies and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of Frequency&#8217;s product candidates.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. drug development process</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of preclinical laboratory tests and formulation studies, as well as animal safety studies, in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations, as appropriate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an independent IRB at each clinical site before each trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials in accordance with GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an NDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">endorsement by an FDA advisory committee, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA inspection of the clinical site(s), and related services involved in the conduct of the clinical studies to assess compliance with GCPs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice, or cGMP, requirements, and to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA prior to commercial marketing or sale of the drug in the United States; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">268 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with any post-approval requirements, including the potential requirement to implement a REMS or to conduct a post-approval study or studies. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical studies</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with&#160;manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the submission including to one or more proposed clinical trials and places the clinical trial on a partial or full clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or noncompliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical trials</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific time frames to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and, if possible, to gain an early indication of its effectiveness. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unreasonable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">269 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate, and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. There are also requirements governing the registration of, reporting of ongoing clinical trials and completed trial results to public registries.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Marketing approval</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more&#160;indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision. Specifically, the FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the submitted information supports that the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product&#8217;s continued safety, quality, and purity.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require submission of a REMS plan to ensure that for certain medications with serious safety concerns the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">270 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval letter, or, in some cases, a Complete Response Letter, or CRL. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application for approval. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver, or the indication sought is for an orphan condition. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current, or fails to submit a request for approval of a pediatric formulation. In some situations, the requirement for studies in pediatric populations can be waived if there is no relevant use. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA-expedited development and review programs</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has various programs, including orphan drug designation, rare pediatric disease designation, fast track designation, accelerated approval priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and the FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition, demonstrates the potential to address an unmet medical need, and is actively developing the drug for the disease. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">271 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application is six months, rather than the standard review of 10 months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and 10-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review, and, if relevant, accelerated approval.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, passed in July 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for priority review and accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. The designation includes all the benefits of a fast track designation. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, priority review, and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Frequency may explore some of these opportunities for its product candidates as appropriate.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-approval requirements</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and&#160;approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state and local agencies and are subject to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">272 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
periodic unannounced inspections by government agencies for compliance with cGMP and other requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warning or other safety information about the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters, or holds on post-approval clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Marketing exclusivity</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section&#160;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">273 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA alternatively provides three to five years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the modification for which the drug received approval based on the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity and extends patent life of a related patent if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other healthcare laws and compliance requirements</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the state, local, and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, and transparency laws and regulations, as well as similar foreign laws in the jurisdictions outside the U.S. State laws may require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, as well as require the registration of pharmaceutical sales representatives and the reporting of pricing information and marketing expenditures. Violations of such laws, or any other governmental regulations that apply, may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting and oversight obligations, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs, and individual imprisonment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_111">Foreign regulation</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, Frequency will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products. Whether or not Frequency obtains FDA approval for a product, Frequency must obtain approval by the comparable regulatory authorities of foreign countries before Frequency can commence clinical trials in those countries, if relevant, and market application approval by foreign countries or economic areas, such as the European Union, or EU, before Frequency may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Non-clinical Studies and Clinical Trials</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly to the United States, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">274 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCPs as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January&#160;31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member&#160;states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i)&#160;prior to January&#160;31, 2022 under the Clinical Trials Directive, or (ii)&#160;between January&#160;31, 2022 and January&#160;31, 2023 and for which the sponsor has opted for the application of the Clinical Trials Directive remain governed by said Directive until January&#160;31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicines used in clinical trials must be manufactured in accordance with Good Manufacturing Practice, or GMP. Other national and EU-wide regulatory requirements may also apply. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Marketing Authorization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market its product candidates in the EU and many other foreign jurisdictions, Frequency must obtain separate regulatory approvals. More concretely, in the EU, medicinal product candidates can only be commercialized after obtaining a marketing authorization, or MA. To obtain regulatory approval of a product candidate under EU regulatory systems, Frequency must submit a MA application, or MAA. The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid throughout the EU. The centralized procedure is mandatory for certain types of products, such as (i)&#160;medicinal products derived from biotechnology processes, (ii)&#160;designated orphan medicinal products, (iii)&#160;advanced therapy medicinal products, or ATMPs (such as gene therapy, somatic cell therapy and tissue engineered products) and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">275 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
disorders, diabetes, auto-immune, and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU; for products that constitute a significant therapeutic, scientific or technical innovation; or for products that are in the interest of public health in the EU. National MAs&#8221; are issued by the competent authorities of the EU member states and only cover their respective territory, and are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure, an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the above described procedures, in order to grant the MA, the EMA or the competent authorities of the EU member states make an assessment of the risk benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EU assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Data and Marketing Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As in the United States, it may be possible in foreign countries to obtain a period of market and/or data exclusivity that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic product. For example, in the EU new products authorized for marketing (<span style="font-style:italic">i.e.</span>, reference products) generally receive eight years of data exclusivity and an additional two years of marketing exclusivity upon MA. If granted, the data exclusivity period prevents generic and biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of the reference product in the EU. The overall ten-year market exclusivity period can be extended to a maximum of eleven years, if during the data exclusivity period (the first eight years of the ten year marketing exclusivity period) the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. In Japan, its products may be eligible for eight years of data exclusivity. There can be no assurance that a product candidate will qualify for such regulatory exclusivity, or that such exclusivity will prevent competitors from seeking approval solely on the basis of their own studies.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">276 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Brexit and the Regulatory Framework in the United Kingdom </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the end of the Brexit transition period on January&#160;1,2021, Great Britain (England, Scotland and Wales) has not been subject to EU laws. However under the terms of the Ireland/Northern Ireland Protocol, Northern Ireland continues to follow EU law. The EU laws that have been transposed into United Kingdom, or UK, law through secondary legislation remain applicable in Great Britain. However, under the Retained EU Law (Revocation and Reform) Bill 2022, which is currently before the UK parliament, any retained EU law not expressly preserved and &#8220;assimilated&#8221; into domestic law or extended by ministerial regulations (to no later than 23&#160;June 2026) will automatically expire and be revoked by December&#160;31, 2023. In addition, new legislation such as the EU CTR is not applicable. The UK government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#8216;appropriate authority&#8217; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, is the UK&#8217;s standalone medicines and medical devices regulator. The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in Great Britain (only), free of charge on January&#160;1, 2021, unless the MA holder chose to opt-out. After Brexit, companies established in the UK cannot use the centralized procedure and instead must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the UK. For a period of three years from 1&#160;January 2021, the MHRA may rely on a decision taken by the EU Commission on the approval of a new (centralized procedure) MA when determining an application for a Great Britain authorization; or use the MHRA&#8217;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in Great Britain. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_112">Coverage and reimbursement</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product to each payor separately, and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are more and more challenging the prices charged, examining the medical necessity, and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">277 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability of manufacturers to sell products profitably.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_113">Healthcare reform</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and certain foreign jurisdictions, there have been, and Frequency expects there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect the pharmaceutical industry. In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contained a number of provisions of particular import to the pharmaceutical industry, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and fraud and abuse changes. Additionally, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required the collection of rebates for drugs paid by Medicaid managed care organizations; imposed a nondeductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded the eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conducts comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative changes have been proposed and adopted since the ACA was enacted. On March&#160;11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, or AMP, beginning January&#160;1, 2024. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most recently, on August&#160;16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">278 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference-pricing systems and publication of discounts and list prices.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_114">Data privacy and security laws</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_115">Cybersecurity</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, Frequency may collect and store personal information and other sensitive information, including proprietary and confidential business information, trade secrets, intellectual property, information regarding trial participants in connection with clinical trials, sensitive third-party information and employee information. To protect this information, its existing cybersecurity policies require monitoring and detection programs, network security precautions, encryption of critical data, and security assessment of vendors. Frequency maintains various protections designed to safeguard against cyberattacks. Frequency has established and test its disaster recovery plan and Frequency protects against business interruption by backing up its major systems. In addition, Frequency scans its environment for any vulnerabilities, perform penetration testing and engage third parties to assess effectiveness of its data security practices. A third party security consultant conducts regular network security reviews, scans and audits.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s cybersecurity program is comprised of its employees and a third-party cybersecurity vendor, all of whom are highly skilled cybersecurity professionals. Frequency&#8217;s program incorporates industry-standard frameworks, policies and practices designed to protect the privacy and security of its sensitive information.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of Frequency&#8217;s cybersecurity program, its security measures cannot guarantee that a significant cyberattack will not occur. A successful attack on its information technology systems could have significant consequences to the business. While Frequency devotes resources to its security measures to protect its systems and information, these measures cannot provide absolute security. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_116">Environmental, Social, and Governance Initiatives</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate sustainability and environmental responsibility</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency understands the importance of reducing its environmental impact. Frequency is proud to be headquartered in a LEED certified building, a globally recognized symbol of sustainability achievement and leadership. Frequency continues to promote sustainability within its office by limiting single-use plastic and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">279 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implementing compost and recycling programs. Frequency&#8217;s current hybrid work model allows employees to work remotely for a portion of the week, decreasing the emissions associated with employees commuting to the office. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Diversity&#160;&amp; Inclusion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is committed to creating and maintaining a workplace free from discrimination or harassment on the basis of color, race, sex, national origin, ethnicity, religion, age, disability, sexual orientation, gender identification or expression, or any other status protected by applicable law. Frequency&#8217;s management team and employees are expected to exhibit and promote honest, ethical and respectful conduct in the workplace. All of its employees must adhere to a code of conduct that sets standards for appropriate behavior and are required to attend training upon hire and at its request to help prevent, identify, report and stop any type of discrimination and harassment. Ongoing acknowledgment of its anti-harassment policy is required on an annual basis. Frequency&#8217;s recruitment, hiring, development, training, compensation and advancement at Frequency is based on qualifications, performance, skills and experience without regard to gender, race and ethnicity. Frequency&#8217;s Diversity, Equity&#160;&amp; Inclusion (DEI) Committee is an employee-led group that works to raise awareness for DEI initiatives and identify ways Frequency can continue to promote inclusion within its corporate culture. Although Frequency is a smaller reporting company, its board of directors meets the requirements under NASDAQ&#8217;s Board Diversity Rule for accelerated and large-accelerated filers with two diverse directors.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employees and Human Capital Resources </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, in connection with the discontinuation of the hearing program, Frequency announced a restructuring of its business including a downsizing of personnel by approximately 55%. On May&#160;31, 2023, Frequency announced a reduction in force of approximately 55% of its workforce to better align its workforce with the needs of its business. As of July&#160;27, 2023, Frequency had 11 employees, including 10 full-time employees and 1 part-time employee. From time to time, Frequency also retains independent contractors to support its organization. None of the employees are represented by a labor union or covered by collective bargaining agreements, and Frequency believes its relationship with the employees is good. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency strives to provide pay, comprehensive benefits and services that help meet the varying needs of the employees. Its total rewards package includes competitive pay; comprehensive healthcare benefits package for employees, with family member healthcare benefits covered at 90%; a health savings account with company contribution; unlimited paid time off and paid holidays; family medical leave; and flexible work schedules. In addition, Frequency offers every full-time employee, both exempt and non-exempt, the benefit of equity ownership in Frequency through stock option grants, restricted stock units, and employee stock purchase plan. Frequency also sponsors a 401(k) plan with a 5% match. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency focuses on attracting, retaining, and cultivating talented individuals. Frequency emphasizes employee development and training by providing access to a wide range of online and instructor led development and continual learning programs. Employees are encouraged to attend scientific, clinical and technological meetings and conferences and have access to broad resources they need to be successful. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Safety </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety, health and wellness of its employees is a top priority. In response to public health emergencies, including COVID-19, Frequency has implemented safety protocols including a flexible hybrid work schedule for non-lab based employees, optional wearing of masks, regular cleaning procedures and readily available hand sanitizer. These protocols are designed to comply with health and safety standards as required by federal, state and local government agencies, taking into consideration guidelines of the Centers for Disease Control and Prevention and other public health authorities.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">280 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_117">Frequency&#8217;s Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is incorporated under the laws of the state of Delaware in November 2014. Frequency&#8217;s principal executive offices are located at 75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421 and the telephone number is (781)&#160;315-4600. Frequency&#8217;s corporate website address is <span style="font-style:italic">www.frequencytx.com</span>. The information contained in, or accessible through, its website is not incorporated by reference into this proxy statement/prospectus and you should not consider information on its website to be a part of this proxy statement/prospectus. Frequency has included its website address in this proxy statement/prospectus solely as an inactive textual reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Properties </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s principal office is located at 75 Hayden Avenue, Lexington, Massachusetts 02421, where it leases approximately 61,307 square feet of office and laboratory space. The lease term commenced on December&#160;11, 2020 and expires on May&#160;31, 2031. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 16, &#8220;Commitments and contingencies &#8211; Legal Contingencies&#8221; in the unaudited consolidated financial statements of Frequency for the three months ended March&#160;31, 2023 and 2022 found elsewhere in this proxy statement/prospectus, for more information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">281 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_118">KORRO BIO&#8217;S BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_501">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is generating a portfolio of differentiated programs that harness the body&#8217;s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro Bio expects to bring its life changing medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The advent of large-scale genome sequencing has progressively revealed causal genetic variation underlying several human diseases, both rare and highly prevalent. Genetic mutations, including single nucleotide variants, or SNVs, implicated in disease have been found to be diverse in nature and can affect the function of genes and its associated downstream biochemical pathways. Data correlating DNA to RNA to disease phenotype have demonstrated that SNVs lead to a loss-of-function or a gain-of-function of the gene. In addition, the majority of SNVs implicated in complex diseases are due to modulation of gene function. By editing SNVs on RNA, Korro Bio believes it will be able to address unmet patient need by transiently modifying gene function. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Korro Bio&#8217;s understanding of genetic drivers of disease has increased, significant advances have been made in technologies designed to introduce specific yet permanent changes at the DNA level to treat diseases. While these DNA editing approaches offer great promise for the treatment of certain rare diseases, they present significant risks from potential permanent adverse &#8220;off-target&#8221; edits. Additionally, the complex nature of DNA editing drug products presents multiple challenges including lack of efficient delivery to target cells and scalable manufacturing, impeding their application to treat complex highly prevalent diseases of larger patient populations. These potential limitations have spurred exploration of alternative approaches to genetic medicine development, such as RNA editing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mammals and other lower species like cephalopods have an endogenous process of modifying single bases on RNA, referred to as RNA editing. RNA editing is a natural physiological process that occurs in cells, including a mechanism mediated by an enzyme called Adenosine Deaminase Acting on RNA, or ADAR. Korro Bio&#8217;s RNA editing approach involves co-opting this endogenous editing system via a proprietary engineered oligonucleotide to introduce precise edits to RNA. Korro Bio iteratively optimizes the editing efficiency of its product candidates using a combination of ADAR biology, chemistry and machine learning expertise. Using this approach, Korro Bio can edit the transcriptome with high efficiency and specificity. The application of such an approach can provide the ability to alter a SNV and affect biology in meaningful ways. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has assembled the preeminent suite of technologies and capabilities to build its RNA editing platform, Oligonucleotide Promoted Editing of RNA, or OPERA. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">282 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g00a12.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPERA relies on the following key components that enable Korro Bio to generate its differentiated RNA editing product candidates: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Deep understanding of ADAR biology</span>, supported by extensive preclinical research using <span style="font-style:italic">in vitro</span> assays and proprietary mouse models as well as the fundamental work of our scientific advisors and founders to elucidate key insights and know-how of ADAR biology. This enables an understanding of ADAR activity in different species and disease states, allowing Korro Bio to develop novel product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Expertise in oligonucleotide chemistry</span>, enabled by the ability to identify and incorporate chemical modifications to generate a fully modified synthetic oligonucleotide drug candidate. This increases the ability to bring drug-like properties, thereby increasing the editing and translational efficiency of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Machine learning optimization of oligonucleotides</span>, driven by data science and computational capabilities for rapid design and iteration resulting in optimal RNA editing product candidates for each disease being pursued. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Fit-for-purpose delivery</span>, made possible by tissue-specific delivery technologies that can enhance biodistribution, specificity, durability and editing efficiency of product candidates for each given disease. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The versatility of RNA editing combined with Korro Bio&#8217;s OPERA platform broadens the therapeutic target space significantly. While Korro Bio&#8217;s approach can be used to repair pathogenic SNVs, it can also engineer <span style="font-style:italic">de novo</span> SNVs and change amino acids on proteins to endow them with desired properties while preserving their broader functional capabilities. Korro Bio has demonstrated that single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate ion channels and activate kinases. These modification approaches can unlock validated target classes that have historically been difficult to drug, enabling Korro Bio to pursue a broad range of diseases traditionally out-of-scope for other genetic medicine approaches and current traditional drug modalities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Korro Bio&#8217;s programs demonstrate the versatility of the oligonucleotide-based ADAR-mediated RNA editing approach to bring additional precision and tunability to address a broad range of rare and highly prevalent diseases. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Repairing pathogenic variants:</span> An SNV that is a G to A mutation on DNA, leading to an aberrant amino acid on a protein can be repaired using RNA editing. Such an approach is relevant when the patient population has a spectrum of disease manifestations from mild-to-severe. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Disrupting protein-protein interactions:</span> A single SNV observed in human genetic association studies has the potential to inform how to transiently activate a protein pathway. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">283 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Preventing protein aggregation:</span> In instances where protein aggregation can lead to cellular dysfunction or be harmful to the cell, engineering an SNV using learnings from biochemistry and human genetics to prevent the aggregation while maintaining the protein&#8217;s normal function. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Other target classes:</span> There are multiple other target classes that can be addressed such as selectively modulating ion channels and activating kinases that have been traditionally hard to leverage for developing medicines. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pipeline chart below demonstrates the breadth of indications and applications enabled by Korro Bio&#8217;s OPERA platform, with an initial focus on six potential programs that are all wholly-owned. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g00a13.jpg" alt="LOGO" />
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Subject to submission of regulatory filing and authorization to proceed </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s most advanced program is a product candidate for Alpha-1 Antitrypsin Deficiency, or AATD, where, using its proprietary RNA editing approach, it is repairing a pathogenic variant on RNA. Korro Bio&#8217;s product candidate has the potential to be disease-modifying and establish a new standard of care. AATD is an inherited genetic disorder that can cause severe progressive lung and liver disease due to a lack of normal alpha-1 antitrypsin protein, or A1AT, caused by SNV mutations in the SERPINA1 gene. There are an estimated 3.4&#160;million individuals with deficiency allele combinations worldwide. Despite being minimally effective and not fully addressing the needs of many AATD patients, augmentation therapy currently represents ~$1.4 billion in annual sales worldwide. Korro Bio&#8217;s product candidate has the potential to elevate the standard of care and expand the number of patients on treatment and potential to be a leader with a large market opportunity worldwide. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s AATD product candidate is a proprietary oligonucleotide that utilizes an established lipid nanoparticle, or LNP, based delivery system administered intravenously to transiently restore production of normal A1AT in liver hepatocytes. By correcting the pathogenic G to A SNV in the SERPINA1 gene, Korro Bio aims to bring individuals with the Z mutation to a phenotype where over 50% of RNA has been corrected to produce normal A1AT protein, preserving lung and liver function and preventing further damage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio believes its approach for treating AATD has multiple potential advantages: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Provides a disease modifying therapy for both lung and liver manifestations by transiently editing over 50% of RNA transcripts in hepatocytes to restore normal A1AT protein </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Provides a treatment option that can be tailored to address the broad spectrum of severity within the AATD population </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Potential to enable physiologic regulation of A1AT using endogenous ADAR, thereby increasing normal A1AT production during inflammation </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Fit-for-purpose delivery using a proven LNP to maximize editing efficiency, leading to greater potential clinical benefit </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">284 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has generated compelling preclinical data demonstrating proof of concept across multiple RNA editing oligonucleotides that have the potential to become the lead development candidate. These potential development candidates have each achieved targeted durability, high editing efficiency (greater than 50% editing of hepatocytes) and clinically meaningful expression of normal A1AT protein in an <span style="font-style:italic">in vivo </span>mouse model. Korro Bio has also shown that its product candidates have high translation of RNA editing efficiency from mice to non-human primates, or NHPs, demonstrating the potential applicability of its approach in humans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the totality of the preclinical data generated to date, Korro Bio intends to nominate its development candidate in the second half of 2023. The development candidate will then be tested in studies to enable a regulatory filing in the second half of 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_508">Korro Bio&#8217;s Team </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio was launched in 2018 and was co-founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal and Andrew Fraley. Its science was based on pioneering research from the laboratory of Joshua Rosenthal, Ph.D., at the Marine Biological Laboratory, or MBL in Woods Hole. Dr.&#160;Rosenthal&#8217;s work includes landmark discoveries in RNA editing based on adenosine deamination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is led by an experienced team with deep expertise in genetic medicines, development of oligonucleotide-based therapeutics, building novel therapeutic platforms, and bringing multiple therapeutics to market. In addition, our executive leadership team has a successful track record of company building and leading biotech companies including Ram Aiyar, Ph.D., President and Chief Executive Officer, an experienced executive and company builder with 20 years of diverse industry experience including research, business and strategy; Steve Colletti, Ph.D., Chief Scientific Officer who brings nearly 30 years of drug discovery and development experience covering a broad range of therapeutic areas and modalities; and Vineet Agarwal, Chief Financial Officer, who brings more than 14 years of financial and industry experience as a biotech investment banker with J.P. Morgan Chase&#160;&amp; Co. Korro Bio also has an accomplished scientific advisory board comprised of leading experts in the fields of ADAR biology, chemistry, translation medicine, and nucleic acid therapeutics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is a mission-driven organization and thrives through a strong culture of scientific innovation and behavior that embodies its core values and principles. Korro Bio is actively working to rewrite the future of medicine by remaining on the cutting edge of science and research. Korro Bio believes its success is enabled by working better together and embracing diversity, leading it to employ a dynamic team with varied expertise, enabled by kindness and integrity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has attracted a talented team of industry experts and experienced scientists as part of a high-performing, nimble organization. Its research and development organization are comprised of individuals with expertise in DNA editing technologies, liver biology, CNS biology, medicinal chemistry, biochemistry and drug delivery, translational medicine and conducting preclinical studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Korro Bio has raised $226 million in capital before the Pre-Closing Financing and Merger. If this transaction is completed, Korro Bio will raise an additional $117 million from premier venture capital funds, healthcare-dedicated funds, major mutual funds and other leading investors that share its vision of creating transformative genetic medicines for diseases with high prevalence. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_308">Korro Bio&#8217;s Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s mission is to discover, develop and commercialize a new class of RNA editing therapies capable of improving the lives of patients with rare and highly prevalent diseases. Korro Bio does this by applying its RNA editing platform, OPERA, which combines its unique expertise in ADAR biology and oligonucleotide chemistry with machine learning-driven optimization and fit-for-purpose delivery. Korro Bio&#8217;s novel RNA editing product candidates harness the body&#8217;s natural RNA editing processes to make a precise single </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">285 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
base edit. Korro Bio&#8217;s goal is to develop a portfolio of RNA editing product candidates with best-in-class properties across a range of diseases by executing on the following key pillars of their strategy: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Develop a novel class of RNA editing therapies using learnings from a combination of genetics and approved medicines.</span> Korro Bio is leveraging significant advances in the understanding of the correlation between DNA, RNA and disease phenotypes to develop novel therapeutic approaches across a range of validated biological targets. This novel class of RNA editing therapeutics combines the precision of genomic therapies with the properties associated with traditional approved drugs, such as titratability and ability to re-dose. In addition, Korro Bio&#8217;s oligonucleotide editing product candidates are structurally similar to other clinically and commercially validated drug modalities such as antisense oligonucleotides, or ASOs, and small-interfering siRNAs, conferring potential advantages in manufacturing, regulatory review and clinical adoption. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Develop and rapidly advance into the clinic a differentiated disease-modifying therapy for patients with AATD. </span>Korro Bio&#8217;s most advanced program is a product candidate for AATD that has the potential to establish a new standard of care by addressing both the liver and lung pathologies. Korro Bio&#8217;s RNA editing oligonucleotide product candidates have generated compelling preclinical data that demonstrates restoration of normal A1AT protein while preventing the aggregation of dysfunctional A1AT in the liver. Korro Bio&#8217;s preclinical <span style="font-style:italic">in vivo</span> data has demonstrated durability and high editing efficiency in both mice and NHPs, illustrating the potential applicability in humans. Korro Bio anticipates nominating a development candidate for this program in the second half of 2023 and regulatory filing in the second half of 2024. Depending on the evidence of efficacy and tolerability, Korro Bio intends to pursue expedited regulatory pathways. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Deploy Korro Bio&#8217;s versatile OPERA platform to develop a portfolio of programs that modify proteins transiently to expand into highly prevalent diseases.</span> OPERA has the ability to generate unique RNA editing therapies that can modify protein function or endow proteins with engineered changes that will potentially result in desirable properties to treat disease. Korro Bio has demonstrated that single RNA changes can disrupt a protein-protein interaction, prevent protein aggregation, selectively modulate an ion channel and selectively activate a kinase. These modification approaches can unlock validated target classes that have historically been deemed undruggable, enabling Korro Bio to pursue a broad range of diseases, including those with high prevalence. Korro Bio is evaluating potential applications of its OPERA platform for use in other highly prevalent indications including the CNS, liver, and cardiometabolic therapeutic areas. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Reinforce Korro Bio&#8217;s leadership position in RNA editing by continuing to optimize and enhance its OPERA platform.</span> Korro Bio believes it has built the leading RNA editing company through a combination of its OPERA platform, intellectual property strategy and human capital. Korro Bio&#8217;s computationally driven approach enables rapid design and optimization of potential oligonucleotide product candidates. In development of its AATD program, Korro Bio was able to go from &#8220;design-to-data&#8221; in 5-6 weeks. Korro Bio intends to continue to incorporate new data into these machine learning models to improve their ability to predict editing efficiency and to more expeditiously optimize and nominate new product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Maximize the potential of its OPERA platform through collaborations and strategic partnerships. </span>Korro Bio currently retains worldwide development and commercialization rights to its programs and platform. Korro Bio actively collaborates with clinical leaders, academic medical centers of excellence, and patient advocacy groups to continue to enhance its expertise in its focus therapeutic areas. Given the versatility and broad potential of its OPERA platform across therapeutic areas, especially in diseases with high prevalence, Korro Bio may enter into strategic partnerships with external parties that have complementary capabilities to broaden and accelerate access to its RNA editing therapies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Invest in human capital and encourage innovation to maintain its leadership position and advance the frontiers of genetic medicines. </span>Korro Bio is a mission-driven organization, and it thrives through a strong culture that embodies its core values. Korro Bio is actively working to rewrite the future of medicine and remain on the cutting edge of science and research by working better together and embracing diversity in employing a dynamic team with varied expertise, enabled by kindness and integrity. Korro Bio has attracted a talented team of industry experts and experienced scientists as part of a high-performing and nimble </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">286 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
organization. Its research and development organization is comprised of individuals with expertise in editing technologies, RNA biology, liver biology, CNS biology, medicinal chemistry, biochemistry and delivery, translational medicine, preclinical and clinical development. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_509">Expanding the Frontiers of Genetic Medicines: RNA Editing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The advent of large-scale genome sequencing has progressively revealed causal genetic variation underlying several human diseases, both rare and highly prevalent. Genetic mutations, including SNVs, implicated in disease have been found to be diverse in nature and can affect the function of genes and its associated downstream biochemical pathways. Natural genetic variations, revealed by population-level genomic studies, have also been shown to protect against or to increase the risk of disease. Beyond these developments, groundbreaking advances in gene therapy, cell therapy and RNA therapeutics have resulted in several approvals that have transformed the treatment of certain genetic diseases and cancers as well as the prevention of infectious diseases, such as COVID-19. In addition, various DNA editing approaches have been developed that introduce specific genetic changes to DNA to treat diseases. First generation CRISPR-Cas9 DNA editing has demonstrated the potential to knockout pathogenic mutations at the single gene level with several programs in clinical development and the first <span style="font-style:italic">ex vivo</span> DNA editing therapeutic for a rare hematological condition on file at the FDA. Next generation DNA editing approaches have recently entered the clinic and hold the promise to edit DNA at the single nucleotide level. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite these advances, significant risks exist with DNA editing approaches. A key concern is the introduction of unwanted DNA modifications (&#8220;off-target&#8221; edits) which could have permanent adverse effects such as chromosomal integration and non-specific insertions, deletions and substitutions. Additionally, due to the complexity of a multicomponent DNA editing product, delivery to target cells can be challenging and even more so if there is a need to edit multiple genetic loci. Furthermore, manufacturing is highly complex and expanding to commercial scale remains challenging, specifically for a highly prevalent indication. Given these challenges, DNA editing approaches will likely remain a focus for certain rare diseases, while its ability to treat diseases of high prevalence continues to be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_510">ADAR-mediated RNA editing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RNA editing involves altering a sequence of RNA which intrinsically has the potential to address some of the limitations of DNA editing. RNA editing mediated by adenosine deaminase acting on RNA, or &#8220;ADAR-mediated&#8221; RNA editing, has recently emerged as a differentiated approach that can generate product candidates having features that combine the precision of genomic therapies with the properties commonly associated with current approved drugs such as titratability and ability to re-dose. Importantly, these drug-like characteristics enable ADAR-mediated RNA editing candidates to be potentially safer and target diseases with high prevalence that would be difficult for DNA editing approaches to address. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADARs are a family of enzymes present inside a cell, that bind RNA. ADARs bind double-stranded RNA structures, and convert a single base of Adenosine (&#8220;A&#8221;) on RNA, into an Inosine (&#8220;I&#8221;) that is typically translated as a Guanosine (&#8220;G&#8221;), using an enzymatic process. ADAR mediated editing is found at high levels in cephalopods both on the coding and non-coding regions of the RNA. In humans, there are fewer recoding events, and most of the endogenous editing events occur in non-coding regions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Humans have two known active endogenous ADAR enzymes, ADAR1 and ADAR2. ADAR1 is constitutively expressed and is present in most tissues within the body, whereas ADAR2 is more highly expressed in tissues such as the brain. The ADARs are essential enzymes for normal physiologic function. ADAR-driven RNA editing has been found to be critical for the function of a number of proteins, such as the glutamate ionotropic receptor, which has been found to be almost always RNA-edited in humans. Given ADARs&#8217; natural function to catalyze A-to-I edits, this endogenous editing system can be leveraged to make programmed edits to RNA. This ability to introduce programmed highly targeted edits into RNA has the potential to expand the reach of genetic medicines with an ability to modify proteins to achieve a desired function. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">287 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oligonucleotide-based ADAR-mediated RNA Editing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are multiple therapeutic approaches to utilize ADAR-mediated RNA editing, including synthetic oligonucleotides, engineered ADARs, and Cas-based editing approaches. Korro Bio&#8217;s therapeutic approach delivers oligonucleotides to target tissues and cells to introduce precise edits to RNA through recruitment of endogenous ADAR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Normally, ADARs are recruited to target RNA editing sites through recognition of specific double-stranded RNA structures such as naturally occurring hairpins or loops in endogenous transcripts. Importantly, one can mimic these double-stranded RNA structures by introducing complementary synthetic oligonucleotides into cells. An oligonucleotide can be engineered to mimic the double-stranded RNA structure such that endogenous ADAR is recruited. Using this targeted approach, a site directed specific A-to-I edit can be introduced. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g00a16.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_511">Key Advantages of Oligonucleotide-Based ADAR-Mediated RNA Editing as a Therapeutic Modality </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio believes that oligonucleotide-based ADAR-mediated RNA editing is a groundbreaking technology that is ideally suited to expand the application of genetic medicines for indications that DNA editing is unable to address. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g17n01.jpg" alt="LOGO" />
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Specificity:</span> Oligonucleotide-based ADAR-mediated RNA editing enables highly precise edits at the target single nucleotide level on the RNA with low risk of off-target or bystander edits, addressing a key safety </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">288 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
concern associated with other DNA editing approaches that carry the risk of permanent insertions and deletions as well as chromosomal integration. Using synthetic oligonucleotides, appropriate chemical modifications can be introduced to increase the overall specificity and targeting efficiency for the site directed RNA editing. The OPERA oligonucleotides are designed to be highly site selective with minimal to no bystander effects or halo effects. To assess global off-target editing, Korro Bio uses a bulk RNA-seq approach to detect base frequency changes at potential off target sites between control and treated samples. Korro Bio sequences target amplicons via NGS and assesses potential A to G editing at all sites across the transcript. In preclinical <span style="font-style:italic">in vivo</span> studies, Korro Bio has shown that off-target RNA editing using its technology is negligible and transient. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt; text-indent:4%">


<img src="g451428g17g02.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 1. Overview of off-target editing observed in mice across multiple oligonucleotides </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Delivery:</span> Oligonucleotide-based ADAR-mediated RNA leverages well established, clinically precedented delivery approaches used in other approved products such as LNPs and ligand-based approaches. LNP-based delivery of oligonucleotides is a well established and clinically validated delivery approach that provides sustained targeted delivery and editing efficiency, resulting in infrequent dosing and an acceptable tolerability profile. Additionally, LNP delivery of RNA-editing oligonucleotides enhances optimal distribution to targeted cells. One example of a well-established and clinically validated ligand-based delivery approach is GalNAc delivery of oligonucleotides, which provides highly specific and effective delivery to hepatocytes with improved durability. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Tolerability</span>: ADAR-mediated RNA editing has a low risk of immunogenicity and can potentially lower off-target editing events resulting in an improved tolerability profile compared to DNA editing approaches. The lower risk of immunogenicity enables the ability to re-dose patients if required, a significant limitation of editing approaches that utilize viral vectors and bacterial Cas systems that carry a higher risk of immunogenicity. The transient and reversible nature of ADAR-based editing confers an ability to modify or cease dosing as needed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Manufacturing</span>: Reliance on endogenous ADAR enzymes and the simple drug constructs of oligonucleotide-based therapies has significant advantages over the complexities associated with the manufacturing and delivery of multi-component exogenous complexes used in DNA editing. Manufacturing processes for oligonucleotide-based therapies are well established, cost efficient and scalable to effectively address highly prevalent indications. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Regulatory:</span> Precedence of marketed oligonucleotide drugs with similar size and types of chemical modifications that therapeutic RNA editing product candidates exhibit. Guidance for the development of oligonucleotide therapeutics by global agencies, including the FDA, provides for an established pathway for the approval of this class of therapeutics. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">289 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_512">Korro Bio&#8217;s OPERA &#8211; Oligonucleotide Promoted Editing of RNA &#8211; Platform </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio believes it is the leading RNA editing company and has assembled a suite of technologies and capabilities called OPERA, Oligonucleotide Promoted Editing of RNA, to generate differentiated RNA editing product candidates. A key challenge in developing a therapeutic approach for site-directed RNA editing is to design and optimize oligonucleotides that can drive high-efficiency. This efficiency is facilitated both by the ability to repurpose and optimize oligonucleotide constructs based on existing methods as well as utilizing computational methods to innovate on chemistry and design of the constructs. Korro Bio&#8217;s RNA editing product candidates are oligonucleotides capable of forming Watson-Crick base pairing with the target RNA and efficiently inducing the deamination reaction by endogenously recruiting ADAR enzymes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has assembled the preeminent suite of technologies and capabilities to build its RNA editing platform, Oligonucleotide Promoted Editing of RNA, or OPERA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPERA relies on the following key components that enable Korro Bio to generate its differentiated RNA editing product candidates: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Deep understanding of ADAR biology:</span> Korro Bio&#8217;s insights and know-how of ADAR biology allow it to design oligonucleotides that efficiently recruit ADARs and promote deamination while maintaining selectivity and stability. RNA editing is dependent on endogenous ADAR expression levels and requires a deep understanding of the physiological role of ADAR, its cell and tissue distribution, the factors that lead to efficient recruitment of ADAR to targeted sites and any consequences that may arise from co-opting ADAR from its normal function. Korro Bio has developed a cell-free <span style="font-style:italic">in vitro </span>RNA editing assay with purified human ADAR1 and ADAR2 that predicts the RNA editing activity with Korro Bio&#8217;s oligonucleotides. With its cell free assay capability, Korro Bio is able to limit the number of components implicated in screening (target gene, RNA editing product candidates and ADAR), allowing it to measure the kinetics of RNA editing more accurately. Using only three components including the target RNA, oligonucleotide, and ADAR, Korro Bio has shown that target editing efficiency is correlated with the chemical modification pattern of an oligonucleotide. Furthermore, Korro Bio has found that this activity predicts the rank order of oligonucleotides in both <span style="font-style:italic">in vitro</span> cell-based systems and <span style="font-style:italic">in vivo</span> in rodents. This assay capability supports Korro Bio&#8217;s understanding of the key steps required to edit RNA at a level of detail that is not possible in cells. These platform biology assay capabilities have enabled detailed mechanistic studies into the tissue distribution and subcellular localization of ADAR proteins and Korro Bio&#8217;s RNA editing product candidates. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">290 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio has found no evidence that its RNA editing oligonucleotides interfere with endogenous RNA editing occurring naturally in a cell. ADAR naturally edits thousands of targets for a variety of reasons. Korro Bio has looked at natural editing sites and chose AJUBA, COG and COPA as they have shown to be edited by ADAR to different degrees. In this experiment outlined in Figure 2, ZZ HLC cell lines were transfected with RNA editing product candidates targeting two different genes. The assays were evaluated for % editing for Target A and Target B sites as well as natural editing sites in COG, COPA and AJUBA. As shown below, natural editing sites remained unaffected compared to the control group, demonstrating that Korro Bio&#8217;s RNA editing product candidates are not likely to have any effect on the degree of editing of native RNA molecules. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g01a65.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 2. Korro Bio&#8217;s RNA editing product candidates show no evidence of interference with endogenous ADAR editing as demonstrated at the above sites </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Expertise in oligonucleotide chemistry:</span> Korro Bio has a differentiated ability to create oligonucleotide designs capable of efficiently recruiting endogenous ADAR with chemical modifications that direct high specificity editing. Korro Bio&#8217;s oligonucleotides increase the potency and durability of ADAR activation, thereby increasing the editing efficiency and translational efficacy of its product candidates. Korro Bio has identified critical structural, sequence, and chemistry requirements for its product candidates that drive efficient recruitment of ADARs and subsequent A-to-I editing. Examples of differentiation include oligonucleotide length for efficient ADAR recruitment, use of precedented and proprietary chemistries within the oligonucleotide, as well as backbone chemistries that provide improved metabolic stability. Additionally, Korro Bio combines this with 2&#8217; modification chemistries that, together, create oligonucleotides with improved editing efficiency and durability. As RNA editing is an emerging technology, there is a lack of guiding principles to design site-selective RNA editing oligonucleotide product candidates. To address this knowledge gap, Korro Bio developed a robust in-house process using its high-throughput cell-based assay and machine learning capabilities to design and synthesize up to approximately 1,200 oligonucleotides per month and generate up to 6,000 assay data points for any given target. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">291 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Machine learning optimization of oligonucleotides:</span> Korro Bio has built data science capabilities and a dedicated team to extract lessons from existing and newly generated experimental data to expeditiously design and optimize RNA editing product candidates. Korro Bio&#8217;s proprietary machine learning models have been trained to accurately predict oligonucleotide structure and observed levels of editing. Korro Bio has been able to demonstrate that these models are able to make accurate editing predictions even for previously unseen chemical modifications demonstrating their generalizability across targets. Korro Bio has demonstrated the utility of its machine learning models through an increase in overall editing efficiency of new product candidates over the last several quarters. In some cases, Korro Bio has been able to go from design-to-data in as little as 5&#160;weeks. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g01a66.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 3. Korro Bio has shown its ability to rapidly iterate product candidates to maximize editing efficiency</span> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Structural modeling is another tool that complements Korro Bio&#8217;s ability to increase the efficiency of its RNA editing candidates. Detailed structural modeling includes shape, size and orientation requirements that can lead to successful deamination at the editing site. These aspects have an important impact on Korro Bio&#8217;s ability to optimize RNA editing product candidates. As an example, a modification predicted by structural analyses led to a conformational change that was shown to improve editing efficiency in the coding region of the Target&#160;A <span style="font-style:italic">in vivo</span>. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g37a02.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 4. Korro Bio has a demonstrated ability to improve editing in target coding regions </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Fit-for-purpose delivery:</span> Korro Bio&#8217;s product candidates utilize short synthetic oligonucleotides, which can be efficiently delivered using precedented technologies such as LNP or GalNAc. These delivery </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">292 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
technologies are well established and clinically validated and have been developed for precedented modalities such as siRNAs and ASOs. Each of these delivery vehicles has optimal characteristics suited for a given therapeutic application. Korro Bio has shown that LNP can be used in ADAR mediated editing processes to achieve high editing efficiency. Additionally, LNP mediated delivery of RNA editing product candidates provides sustained delivery and an acceptable tolerability profile that can be manufactured at a scale sufficient to serve the target population. In addition to LNP based delivery approach, ligand-based approaches (ex., GalNAc for liver hepatocytes) can also be used for effective delivery and to improve durability with OPERA&#8217;s RNA editing product candidates. In contrast to treatments targeting liver hepatocytes where there is a need for a delivery system, Korro Bio&#8217;s RNA editing product candidates can be delivered intrathecally to the central nervous system without a need for any delivery system. Thus, Korro Bio&#8217;s choice of delivery system is a fit-for-purpose model that is dependent on the oligonucleotide design as well the suitability for the indication and tissue localization of the target. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_513">Korro Bio&#8217;s Pipeline Demonstrates the Versatility of the OPERA Platform </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is advancing a broad pipeline of six potential programs that are wholly owned and demonstrate the versatility of its OPERA platform. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g00a13.jpg" alt="LOGO" />
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Subject to submission of regulatory filing and authorization to proceed </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s proprietary oligonucleotides co-opt endogenous ADAR to perform a single A-to-I base edit on RNA to modify protein function. Delivery of these proprietary oligonucleotides into a cell forms an oligonucleotide-RNA duplex which recruits endogenous ADAR, ultimately editing a target adenosine &#8220;A&#8221; to inosine &#8220;I&#8221; on RNA. The location of the edit can lead to a multitude of effects including changes in expression and regulation of mRNA. In the event an edit is made in the coding region of the gene, the mRNA is then translated to a protein with the &#8220;I&#8221; inosine read as a &#8220;G&#8221; guanosine, resulting in a modified protein. The resultant therapeutic protein can be applied to go beyond repairing pathogenic SNVs by changing amino acids on proteins implicated in disease biology. Single amino acid changes to non-mutated RNA can create <span style="font-style:italic">de novo</span> modified protein variants with desired altered properties while preserving their broader functional capabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Repairing pathogenic variants:</span> Korro Bio&#8217;s OPERA platform enables the development of RNA editing therapies that can repair SNVs on mRNA to express normal proteins through the introduction of precise genetic changes without creating permanent changes to the genome. These normal proteins can be uniquely expressed at desired levels and duration to address both rare and highly prevalent diseases caused by a pathogenic SNV. This </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">293 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approach is especially relevant when the same underlying genetic SNV manifests in a broad disease phenotype from mild to severe forms of the disease. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g00z04.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 5. RNA editing of a single nucleotide can restore normal protein expression </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s lead program for AATD addresses a single genetic SNV in the SERPINA1 gene that causes the development of A1AT deficiency, which has a high unmet medical need and for which there are no disease modifying treatment options. The disease manifests with a heterogenous population having both liver and lung pathologies. By specifically editing a single nucleotide, the normal synthesis of A1AT is restored, resulting in secretion of normal A1AT to levels which are predicted to protect the lung from further decline in function. The correction of a subset of A1AT produced also prevents aggregation of A1AT protein in the liver, thereby potentially alleviating damage to the liver. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, Korro Bio is developing a product candidate that addresses a LRRK2 mutation for PD patients. Mutations in LRRK2 that are associated with aberrantly enhanced kinase activity are the most common cause of genetic PD. The G2019S mutation in the LRRK2 protein is the most common pathogenic mutation, accounting for 1&#8211;6% of sporadic and 3&#8211;19% of familial PD cases. Repairing the G2019S mutated nucleotide can restore the normal LRRK2 protein and return its activity to a physiological state, which Korro Bio believes may be disease modifying in these patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Other protein modifications </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 85% of the human proteome has historically been considered undruggable through traditional therapeutic modalities as many proteins lack defined small molecule binding sites or are inaccessible by biologics. The versatility of RNA editing, combined with Korro Bio&#8217;s OPERA platform, addresses a meaningful portion of the undruggable human proteome and broadens the target space. Korro Bio&#8217;s target identification and selection for programs is based on strong genetic evidence implicating each target in its disease pathology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s initial focus is to make edits to the coding region of a transcriptome. Making changes post-transcriptionally, after the mRNA has been created and prior to the protein being translated, provides an exquisite, selective approach for modifying proteins. Korro Bio has demonstrated that single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate an ion channel and selectively activate a kinase. These modification approaches have the potential to unlock validated target classes that have historically been difficult to drug, enabling Korro Bio to pursue a broad range of diseases, including those with high prevalence and large market opportunities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">294 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g08y97.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Disrupting Protein-Protein Interaction: </span>Modulating protein-protein interactions provides a novel modality to target intracellular proteins specifically for increasing the activity of the protein. Single amino acid changes to non-mutated RNA can disrupt binding of inhibitors to target proteins, including transcription factors, promoting enhanced biological activity of the target protein. There are two ways this could provide increasing activation, either through a hyperactive protein, or through the presence of a longer half-life or both. Such an approach highlights the broad capabilities of what an RNA editing platform can accomplish in driving biological change. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g28p69.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:7%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 6. Korro Bio&#8217;s oligonucleotides have the ability to disrupt protein-protein interactions using precise edits</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of Korro Bio&#8217;s programs for disrupting protein-protein interactions is in development for the treatment of severe alcohol-associated hepatitis (sAH). Korro Bio is selectively modulating a validated transcription factor protein implicated in the disease pathology for sAH. This oligonucleotide product candidate leads to the synthesis of a protein variant that disrupts interaction with its inhibitor and, as a result, increases expression of clinically beneficial downstream target genes. Other approaches have attempted to disrupt the interaction with non-selective small molecules, resulting in unacceptable side effects, or by knocking down the regulatory protein, which is also responsible for regulating other important proteins. In a retrospective analysis of a study looking at sAH patient liver samples, increased expression of these target genes has been shown to have better prognosis. In addition to sAH, this transcription factor is a validated target for other liver, cardiometabolic and inflammatory diseases, which may provide a &#8220;pipeline-in-a-product&#8221; opportunity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preventing Protein Aggregation: </span>Intracellular protein aggregation is a cause of multiple diseases across the body. Specifically in neurodegenerative diseases, accumulation of specific proteins within neurons are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">295 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pathogenic including Alzheimer&#8217;s disease, PD, and ALS. Creating a protein variant that can prevent the aggregation, while preserving its intrinsic function, is a therapeutic approach that has the potential to provide a differentiated therapeutic option over knocking down or silencing the protein through alternate mechanisms. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g01b69.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 7. Korro Bio&#8217;s product candidates can reduce pathogenic aggregation of undesirable proteins </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of Korro Bio&#8217;s programs for disrupting protein aggregation is in early-stage discovery for the treatment of ALS. Korro Bio is selectively modulating TDP-43, an RNA/DNA-binding protein, which carries out a variety of important functions in healthy neurons including initiation of transcription, pre-mRNA splicing, and miRNA processing. In pathological conditions, such as ALS, TDP-43 is depleted from the nucleus and accumulates as protein aggregates in the cytoplasm in hyperphosphorylated, ubiquitinated, and cleaved forms. These aggregates are observed in more than 90% of ALS patients. A single RNA edit to TDP-43 is predicted to lead to the synthesis of a protein variant that does not aggregate and preserves its normal function. Given TDP-43 is essential for neuronal health, knocking down the protein could be detrimental. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Target Classes: </span>In addition to disrupting protein-protein interactions and protein aggregation, Korro Bio is also advancing product candidates to selectively modulate ion channels and activate kinases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio believes that the elegance and versatility of its RNA editing approach will enable a robust pipeline of potentially disease modifying product candidates to treat diseases previously unattainable by genetic medicine approaches. While the above examples demonstrate the breadth of applications enabled by OPERA, Korro Bio believes its RNA editing approach will bring the first genetic medicine to address the complex genetic underpinnings of highly prevalent diseases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_514">Korro Bio&#8217;s AATD Program: RNA Editing to Repair Pathogenic Missense Variant </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s most advanced program is a product candidate for Alpha-1 Antitrypsin Deficiency (&#8220;AATD&#8221;) that has the potential to be disease-modifying and establish a new standard of care. AATD is an inherited genetic disorder that can cause severe progressive lung and liver disease due to a lack of normal alpha-1 antitrypsin protein (&#8220;A1AT&#8221;), with varying intensity based on patient genotype and environmental factors. Patients often develop chronic obstructive pulmonary disorder (&#8220;COPD&#8221;) in the lungs and cirrhosis of the liver, which can result in liver failure or death. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are an estimated 3.4&#160;million individuals with deficiency allele combinations worldwide. There is a single approved modality, a once-a-week infusion of pooled human plasma derived A1AT, that does not adequately address the lung or liver manifestations of AATD. Within the U.S. alone, the opportunity to improve the existing standard of care and expand the treated population represents a large market opportunity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s product candidate is a proprietary RNA editing oligonucleotide that is delivered to liver cells using an established LNP platform to restore production of normal A1AT. The product candidate is expected to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">296 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be delivered via intravenous infusion, where it co-opts endogenous ADAR to repair the pathogenic SNV and restore production of normal A1AT, creating a clinically differentiated benefit for both liver and lung function in affected individuals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the inherent benefits of ADAR-based RNA editing described earlier, Korro Bio believes its approach has additional potential advantages: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Provides a disease modifying therapy for both lung and liver manifestations by transiently editing over 50% of RNA transcripts in hepatocytes to restore normal A1AT protein </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Provides a treatment option that can be tailored to address the broad spectrum of severity within the AATD population </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Potential to enable physiologic regulation of A1AT using endogenous ADAR, thereby increasing normal A1AT production during inflammation </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Fit-for-purpose delivery using a proven LNP to maximize editing efficiency, leading to greater potential clinical benefit </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has generated compelling preclinical data demonstrating proof of concept across multiple RNA editing oligonucleotides that have the potential to become the lead development candidate. These potential development candidates have each achieved targeted durability, high editing efficiency (greater than 50% editing of hepatocytes) and clinically meaningful expression of normal A1AT protein in an <span style="font-style:italic">in vivo </span>mouse model. Korro Bio has also shown that its product candidates have high translation of RNA editing efficiency from mice to non-human primates (&#8220;NHPs&#8221;), demonstrating the potential applicability of its approach in humans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the totality of the preclinical data generated to date, Korro Bio intends to nominate its development candidate in the second half of 2023. The development candidate will then be tested in studies to enable a regulatory filing in the second half of 2024. Depending on the evidence of efficacy and tolerability for its candidate in its first clinical study, Korro Bio plans to pursue expedited regulatory pathways, including potentially requesting Fast Track Designation and Breakthrough Therapy Designation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">AATD Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">A1AT function </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A1AT is a protease inhibitor belonging to the Serpin family. It is produced in the liver and circulates in its native state in human blood at approximately 1.5 g/L, one of the highest concentrations observed for protease inhibitors. The main role of A1AT is to protect tissue from proteases released by neutrophils, such as neutrophil elastase. Neutrophil elastase is an enzyme that fights infections in the lungs but can also attack normal lung tissue. If not sufficiently inhibited by A1AT, neutrophil elastase destroys elastin in the lung, leading to degradation of lung function. Factors that increase lung inflammation, such as smoking or infections, increase the elastase burden in the lung, leading to severe and potentially life-threatening lung damage in AATD patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Genotypes of AATD </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AATD is an inherited, autosomal recessive genetic disorder that is most frequently caused by a single nucleotide variant (&#8220;SNV&#8221;) mutation in the SERPINA1 gene. The most common of these SNVs is the &#8220;Z&#8221; mutation, corresponding to a mutation of glutamate 342 to lysine, or E342K. A healthy individual typically exhibits an &#8220;MM&#8221; genotype (&#8220;PiMM&#8221;), while an individual with a single Z allele would exhibit a heterozygous (&#8220;PiMZ&#8221;) genotype and an individual with two Z alleles would exhibit a homozygous (&#8220;PiZZ&#8221;) genotype. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">297 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g48h62.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 8. PiMM genotype (normal liver and lung) </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Impact of Z mutations on liver and lung function </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence of a single Z allele can lead to insufficient production of normal A1AT protein, as well as the production of dysfunctional A1AT protein, causing manifestations of disease in both the lungs and liver. The severity of disease manifestation can vary according to each patient&#8217;s genotype, as well as environmental factors, such as exposure to inflammatory respiratory agents or other complications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PiZZ individuals experience greater manifestations of disease as a result of their very low levels of normal A1AT (10%&#8212;15% of normal levels), which are insufficient to prevent lung damage post an influx of neutrophils. They are also at high risk of developing emphysema or COPD, which can present in individuals as early as in their thirties and forties. PiZZ individuals with additional environmental risk factors such as smoking or infection frequently develop COPD as early adults and develop very severe symptoms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to lung disease, PiZZ individuals can also manifest with liver disease as a result of dysfunctional A1AT aggregating in the liver. In adults, this can cause liver inflammation and cirrhosis, ultimately leading to liver failure or cancer. In addition, as many as 10% of newborns with the PiZZ genotype develop cholestatic hepatitis. A quarter of impacted neonates suffer acute liver failure and require an emergency transplant. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g48h63.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 9. PiZZ genotype that results in fibrotic liver and decreased lung function </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">298 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data from the UK Biobank (&#8220;UKBB&#8221;), as well as published literature, have allowed researchers to determine the threshold levels of circulating A1AT that are directly linked to the PiMZ and PiZZ genotypes. In Figure 10 below, the range of A1AT levels associated with normal individuals (&#8220;PiMM&#8221;) is compared with the range of A1AT levels observed in mutated PiMZ and PiZZ patients. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g62m07.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 10. Median Levels of A1AT and link to outcomes in liver and lung </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Figure 11 below, the Odds Ratios associated with developing COPD and cirrhosis of the liver are compared across the two genotypes, with key findings summarized below: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">COPD:</span> PiMZ individuals have minimal increased risk of developing COPD relative to healthy PiMM individuals, while PiZZ individuals are at very high risk with an OR of 8.8 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Cirrhosis of the liver:</span> PiMZ individuals have mildly elevated risk of developing cirrhosis of the liver with an OR of 1.5, while PiZZ individuals have significantly elevated risk with an OR of 7.8 </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g38a01.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 11. Risk of developing COPD and cirrhosis for different genotypes associated with AATD. Adapted from &#8220;The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes.&#8221; by Nakanishi T, Forgetta V, Handa T, et al. Eur Respir J 2020; 56:2001441 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on these findings, Korro Bio believes that achieving normal A1AT protein levels between the ranges of the PiMZ and PiMM genotypes has the potential to alleviate the increased risk of COPD and cirrhosis of the liver, and to meaningfully improve clinical outcomes for PiZZ patients. Korro Bio further believes that by achieving &gt;50% editing efficiency across cells, it can reach these target levels and modify disease progression. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">299 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Prevalence of AATD and limitations of currently approved therapy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AATD is one of the three most common, potentially lethal, rare diseases affecting those of European descent. Worldwide, there are an estimated 3.4&#160;million individuals with deficiency allele combinations. Studies suggest that clinical unawareness of AATD results in a significant number of patients that go undiagnosed or misdiagnosed. There are currently an estimated 100,000 patients in the U.S. with a PiZZ genotype, and 125,000 patients across the United Kingdom, Germany, France, Spain and Italy. Studies of PiMZ prevalence suggest as many as 1 in 49 individuals in the U.S. and 1 in 58 individuals across Europe. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The only FDA-approved treatment for patients with lung manifestations of AATD (co-indicated with COPD) is augmentation therapy, which utilizes A1AT protein purified from pooled human plasma. The purified A1AT is administered weekly by intravenous infusion with the goal of maintaining a serum level of A1AT above the 11&#160;&#181;M threshold. Even when the serum level can be maintained at or above this threshold, augmentation therapy has not clearly demonstrated its ability to adequately address lung damage nor liver inflammation caused by A1AT aggregation. Augmentation therapy is approved in only a few countries due to its limited efficacy. Lung and/or liver transplantation are the only other available treatment options, outside of standard management of the disease manifestations of AATD. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite being minimally effective and not fully addressing the needs of many AATD patients, augmentation therapy currently represents ~$1.4 billion in annual sales worldwide. Korro Bio&#8217;s product candidate has the potential to elevate the standard of care and expand the number of patients on treatment and potential to be a leader with a large market opportunity worldwide. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitations of Alternative Treatments in Development for AATD </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of therapies in development to treat AATD. Certain DNA editing approaches attempt to add a normal copy of SERPINA1 gene or permanently correct the mutation within the SERPINA1 gene. DNA editing as a treatment would likely be evaluated on a risk-benefit trade-off relative to the severity of the manifestation of AATD, limiting the applicability of DNA editing approaches to the broader AATD patient population. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional approaches outside of DNA editing are also in development. There are approaches which attempt to use siRNA to knock-out the production of dysfunctional A1AT protein, which only alleviates the liver manifestation of AATD, while potentially worsening the lung manifestation. Replacing plasma derived protein for augmentation therapy with a fusion protein is another approach in development. This fusion protein aims to introduce A1AT on an antibody scaffold to improve upon the existing dosing paradigm and activity levels achieved in augmentation therapy. Fusion proteins do not resolve the liver manifestation and are unable to physiologically regulate A1AT levels. Lastly, small molecule correctors attempt to promote proper folding of the Z-AAT protein. To date, small molecule correctors have been unable to achieve normal A1AT levels and clinical development is focused only on the liver manifestation of AATD. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio believes many of these approaches have inherent limitations including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Inability to adequately address the spectrum of clinical pathologies associated with AATD </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Inability to achieve adequate expression of normal A1AT to bring patients back to PiMM genotype </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Considerable safety and tolerability concerns </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Potential issues around manufacturability and scalability for the AATD population </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio&#8217;s Approach to Overcome the Limitations: Transiently Correcting the SERPINA1 Variant on RNA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is developing a product candidate to treat patients with AATD that is designed to leverage endogenous ADAR to make a single base edit in SERPINA1 mRNA, correcting the amino acid codon created by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">300 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the pathogenic E342K SNV which stems from a single G-to-A mutation. Korro Bio&#8217;s product candidates edit the Adenosine (A)&#160;to an Inosine (I), correcting the faulty amino acid and leading to the production of normal A1AT protein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s goal is to bring individuals with the Z mutation to a phenotype where over 50% of RNA has been corrected to produce normal A1AT protein. This would result in levels of A1AT consistent with individuals in the upper half of the PiMZ genotype and the fully healthy PiMM genotype. Through human transgenic mouse models, Korro Bio has shown its ability to drive the required change in RNA sequence with high efficiency, leading to secretion of A1AT at target levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio believes its approach has multiple potential advantages, in addition to those conferred by the RNA editing modality: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Provides a tailored disease modifying treatment option to address the heterogeneity of the AATD population: </span>Korro Bio leverages a transient base editing approach leading to restoration of normal A1AT. The transient nature of Korro Bio&#8217;s approach allows it to address a broader AATD patient population, inclusive of PiMZ and PiZZ genotypes. As transient editing is not permanent in nature, Korro Bio has the ability to adjust dosing and even cease dosing as needed, providing a meaningful benefit in potential safety profile. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Provides a disease modifying therapy for both lung and liver manifestations: </span>By transiently editing over 50% of RNA transcripts in hepatocytes, Korro Bio believes it can restore levels of normal A1AT protein consistent with a PiMZ to PiMM phenotype. These levels of normal A1AT have the potential to prevent further lung damage and reduce the risk of dysfunctional A1AT aggregating in the liver. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Potential to enable physiologic regulation of A1AT using endogenous ADAR: </span>Augmentation therapy and other treatments targeting static thresholds for A1AT expression do not address the underlying mechanism of A1AT regulation, which is endogenously regulated by inflammation and can sometimes lead to as much as 90uM of A1AT in humans. During an inflammatory response, there is a simultaneous increase in ADAR levels. Korro Bio&#8217;s ADAR-based therapy has the potential to restore natural physiologic regulation by increasing the prevalence of editing during periods of greater A1AT production. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Uniform distribution of drug to liver cells to maximize editing: </span>Unlike other modalities that focus on DNA editing, Korro Bio&#8217;s product candidates have demonstrated a uniform distribution within the liver, including in NHPs. Korro Bio believes this will allow its therapy to restore production of normal A1AT protein in every cell, reducing reliance on the chance of a survival benefit for edited cells as in DNA editing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Efficient delivery using a proven LNP:</span> A1AT is the fifth most abundant protein in circulation, with a large number of transcripts that require editing to achieve expression of normal protein. LNPs provide a significant benefit to delivery of RNA-editing oligonucleotides by increasing the likelihood of sufficient distribution into liver cells. In March 2023, Korro Bio entered into an agreement with Genevant, a well established leader in the LNP space, to provide access to clinically validated LNP technology to optimize delivery of Korro Bio&#8217;s product candidate. Internal comparisons of this LNP delivery technology have demonstrated improved dose-dependent efficacy with reduced clinical chemistry adverse effects in preclinical studies. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">301 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure&#160;12 below outlines some of the differences between Korro&#8217;s RNA editing approach and the other potential candidates in development. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g02a39.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure&#160;12. Korro Bio&#8217;s approach potentially provides superior patient benefit over other modalities in AATD </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Summary of Korro Bio&#8217;s preclinical studies and data generated to date </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has generated highly compelling preclinical data that forms the basis for its proof of mechanism. Korro Bio has affirmed that multiple disease modifying product candidates have demonstrated proof-of-concept in in vivo studies and have the potential to be a development candidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These potential development candidates have independently achieved clinically meaningful expression of normal A1AT protein consistent with a PiMZ genotype within preclinical <span style="font-style:italic">in vivo </span>animal models while using clinically relevant doses administered on a weekly basis. Given that human protein half-life is much longer than other species, Korro Bio believes its therapies will support a longer dose interval in the clinic. Korro Bio has initiated preclinical dose-limiting toxicity safety studies and intends to nominate a development candidate in the second half of 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline"><span style="font-style:italic">In Vitro</span> activity in human cells:</span> Korro Bio&#8217;s initial design iterations for RNA-editing oligonucleotides were conducted in <span style="font-style:italic">in vitro</span> human systems, specifically containing human ADAR and human SERPINA1 genes with a Z allele. By leveraging the capabilities of its OPERA platform, Korro Bio has generated multiple product candidates that achieved increased editing activity in human <span style="font-style:italic">in vitro</span> systems. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">302 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Figure&#160;13 below, Korro Bio was able to demonstrate greater than 50% editing efficiency at the E342K mutation within stem cell derived hepatocyte like cells (&#8220;HLCs&#8221;) when using the highest dose of drug substance. HLCs harbor both alleles, an important quality that has the potential to be predictive of function <span style="font-style:italic">in vivo</span>. Korro Bio also demonstrated editing in MZ primary human hepatocytes (&#8220;PHH&#8221;) which harbor a single Z allele. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g451428g94e51.jpg" alt="LOGO" />
 </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure&#160;13. &gt;50% editing achieved in the right system &#8211; human gene with human ADAR </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Preclinical <span style="font-style:italic">in vivo</span> activity in mice:</span> Korro Bio&#8217;s preclinical pharmacology studies have been conducted using the PiZ mouse model and licensed by Korro Bio from Dr.&#160;Jeff Teckmann&#8217;s laboratory at St. Louis University. Dr.&#160;Teckmann is the preeminent expert on the study of AATD. The PiZ transgenic mouse model replicates many of the phenotypes of human AATD disease, including the presence and utilization of ADAR-based editing. Mice have only 1 allele, either a healthy M allele or mutated Z allele (&#8220;PiZ&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of Korro Bio&#8217;s preclinical studies, it has evaluated multiple oligonucleotides in varying doses in PiZ mice. Following intravenous administration of a single 3mg/kg dose using a standard MC3 LNP encapsulating its product candidate, Korro Bio subsequently evaluated the editing efficiency achieved and levels of A1AT protein after 1, 4 and 7 days. Multiple of Korro Bio&#8217;s optimized lead oligonucleotides demonstrated editing efficiency of greater than 50% editing of the SERPINA1 mRNA at the E342K site, which it believes is a key threshold to achieve clinically meaningful levels of normal A1AT secretion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">303 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 14 below outlines the editing efficiency of one of Korro Bio&#8217;s lead product candidates, Oligo A, which was measured as demonstrating editing efficiency as high as 63% on day 4 following the administration of a single 3mg/kg dose. Normal M-A1AT protein was observed at an 18 &#181;M concentration on day 4, demonstrating the potential relationship between editing efficiency and secretion of normal A1AT. Korro Bio believes this is the highest preclinical<span style="font-style:italic"> in vivo</span> editing efficiency and normal A1AT protein observed across any modality based on data published to date. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g67a27.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 14. Demonstrated 50% editing in PiZ mice model with a single 3mg/kg dose delivered using an MC3 LNP </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Durability:</span></span> Upon observing the high editing efficiency of Oligo A, Korro Bio proceeded to conduct an additional preclinical <span style="font-style:italic">in vivo</span> study where four groups of mice were given a lower dose and observed in a multi-dose study that lasted up to four weeks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the four groups received an initial dose of 2mg/kg of Oligo A, which was administered intravenously using an MC3 LNP as in the single dose study above. Thereafter, each group received weekly doses of Oligo A for a period of either 1, 2, 3 or 4 weeks. The mice were assessed seven days after the initial dose and seven days after each subsequent dose to observe editing efficiency, normal A1AT protein levels and total A1AT protein levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As detailed in Figure 15 below, key takeaways included the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Groups 3 and 4, which received 3 and 4 doses of Oligo A, achieved 54% and 47% editing efficiency as measured 7 days after their most recent dose </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Groups 3 and 4 also demonstrated a meaningful increase in both total and normal A1AT, with up to 20 &#181;M of normal A1AT in Group 4 </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">304 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Liver polymers associated with the dysfunctional A1AT protein in Group 4 were reduced at day 28 as shown by the histopathology images below, pointing to a potential to provide liver benefit through clearing of aggregates </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g01b77.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 15. Potential to provide liver benefit by clearing aggregation and preventing further lung damage due to level of M-A1AT in secretion </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The half-life of A1AT in mice and NHPs has been observed to be around 1-2 days and 2-4 days, respectively. Human A1AT has a longer half-life of 4-6 days, and when coupled with the optimization of Korro Bio&#8217;s oligonucleotide drug product and the accumulation of drug product observed in the multi-dose preclinical studies, Korro Bio believes that it will be able to achieve greater durability and a longer dosing interval in the clinic than the current once weekly interval in its preclinical studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Translation in NHPs:</span> In addition to Korro Bio&#8217;s preclinical <span style="font-style:italic">in vivo</span> studies conducted using the PiZ mouse model, it has also generated a translational model to validate the potential for delivery and ability to edit the SERPINA1 gene in NHPs with an earlier generation oligonucleotide. Since the human SERPINA1 gene in NHPs does not harbor the E342K mutation, Korro Bio is demonstrating its oligonucleotide&#8217;s ability to edit within the coding region of the SERPINA1 gene and the ability to translate that preclinical <span style="font-style:italic">in vivo</span> editing from the PiZ mouse model to NHPs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NHPs received a 2mg/kg intravenous dose of Korro Bio&#8217;s earlier generation oligonucleotide formulated in an MC3 LNP, followed by two additional intravenous doses once per week. The liver editing was measured four days after the initial dose, and four days after the final dose. Editing of the SERPINA1 coding region in both NHPs and PiZ mice showed species translation at both time periods, with increasing editing efficiency upon receiving additional doses in NHPs. Additionally, mutated protein generated by this engineered RNA edit on the human SERPINA1 gene in NHPs was observed to be closely correlated with editing the mRNA at the same time points. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">305 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g11t01.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 16. Editing of SERPINA1 coding region in NHPs and PiZ model showed correlation </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Optimization of Korro Bio&#8217;s product candidate </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s preclinical studies to identify product candidates have previously been conducted using an LNP delivery vehicle comprising lipids used in the approved product ONPATTRO<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Over the past decade, the field of LNP delivery has made advancements as measured by safety profile and tolerability. Korro Bio&#8217;s product candidates, when combined with current generation LNP delivery technology from Genevant, have demonstrated optimized editing efficiency, safety and tolerability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a preclinical study to compare the editing efficiency of a previous generation LNP (the comparator LNP) and current generation Genevant LNPs (GVT-1 and GVT-2), Korro Bio evaluated PiZ mice after receiving a single 2mg/kg dose of Oligo A via each of the three delivery vehicles. As detailed below in Figure 17, GVT-1 and GVT-2 achieved comparable or higher editing of 37% and 65%, respectively, as compared to 29% editing for the comparator LNP. For reference, the same Oligo A achieved comparable editing of 63-65% at a dose of 3mg/kg with the comparator LNP compared to a lower dose of 2mg/kg with GVT-2. The percentage of normal A1AT protein in plasma at baseline is 0% due to all of the circulating protein being mutated A1AT. Post a single LNP dose, the percentage of normal-A1AT increased to 66% for GVT-1 and 85% for GVT-2, compared to 56% for the comparator LNP, showing potential for disease-modifying effects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">306 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g01m30.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 17. Comparison of editing efficiency and circulating normal protein in PiZ mice between MC3 LNP and current generation Genevant LNPs (GVT-1 and GVT-2) </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio also evaluated the potential editing efficiency of GVT-1 and GVT-2 for the SERPINA1 coding region in NHPs. As detailed in Figure&#160;18, the observed editing rate of GVT-2 was meaningfully higher at 34%, relative to 13% in the historical MC3 study. ALT levels, a measure of safety and tolerability, were meaningfully lower in GVT-1 and on par between GVT-2 and the LNP comparator. These results show that Korro Bio&#8217;s product candidates, when combined with current generation Genevant LNPs, can demonstrate a desirable safety profile while increasing the editing efficiency. These results further illustrate the translation of GVT-1 and GVT-2 across mouse and NHP preclinical species. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g451428g21a60.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 18. Comparison of editing translation in NHPs between MC3 LNP and current generation Genevant LNPs (GVT-1 and GVT-2) </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Next Steps </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the totality of the preclinical data generated to date, Korro Bio intends to nominate a development candidate in the second half of 2023. The development candidate will then be tested in studies to enable a regulatory filing in the second half of 2024 to enable the initiation of human clinical studies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">307 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_515">Korro Bio&#8217;s Parkinson&#8217;s Disease Program: Repairing Pathogenic Variants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is developing proprietary oligonucleotides that address the leucine-rich repeat kinase-2 (LRRK2) mutation for Parkinson&#8217;s disease (&#8220;PD&#8221;) patients. This is the second program that leverages OPERA&#8217;s ability to repair pathogenic variants, similar to the AATD program. PD is a complex, multifactorial progressive disease that is caused, in part, by the loss of dopaminergic neurons in the structure of the brain called the substantia nigra, which controls body movement. Approximately 10% of PD cases are attributed to inherited genetic mutations, while the remaining cases are considered idiopathic or sporadic. Mutations in genes such as LRRK2 are the most common cause of genetic PDs and increasing evidence also provides support for a role of LRRK2 in idiopathic PD. PD is the second most common neurodegenerative disease with approximately one million people in the U.S. diagnosed. Despite the large commercial market opportunity, there remains significant unmet needs as there is no cure and available therapies only relieve the symptoms of PD. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LRRK2 activity has been linked to several cellular processes including mitochondrial function, endocytosis, vesicle trafficking, and autophagy. Additionally, LRRK2 is considered a modulator of neuroinflammation because its kinase activity regulates microglial reactivity and the levels of pro-inflammatory cytokines. There are various mutations in LRRK2 that can result in PD, the most common of which is the pathogenic G2019S mutation that accounts for 1&#8211;6% of sporadic and 3&#8211;19% of familial PD cases. CNS-targeted viral vector-based gene delivery has been challenging due to the unpredictable nature of these vectors, inability to titrate dosing, and safety concerns, including immunogenicity that limits the ability to re-dose patients, if required. Korro Bio is leveraging its RNA editing technology to make a single base edit to the mutated G2019S nucleotide to repair the mutant LRRK2 protein to return its activity to the normal physiological state, which Korro Bio believes may result in disease modification. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_516">Korro Bio&#8217;s Severe Alcohol-Associated Hepatitis Program: Disrupting Protein-Protein Interactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of Korro Bio&#8217;s investigational development programs is focused on the treatment of severe alcohol-associated hepatitis (sAH) and demonstrates the versatility of Korro Bio&#8217;s platform to modulate proteins. This program leverages Korro Bio&#8217;s RNA editing technology to modulate the activity of a naturally occurring protein by disrupting protein-protein interactions. Korro Bio is selectively modulating a protein transcription factor implicated in the disease pathophysiology for sAH. This RNA editing drug product leads to the synthesis of a protein variant that disrupts interaction with its inhibitor and as a result, is unencumbered to express clinically beneficial downstream target genes. sAH patients with higher levels of expression of these downstream target genes have been shown to have better prognosis in a prior study examining liver biopsies at the time of diagnosis. This suggests that Korro Bio&#8217;s approach to unencumbering the transcription factor could result in clinically meaningful benefit. Additionally, since only low levels of editing efficiency are required for this target to affect meaningful downstream activity, Korro Bio&#8217;s efficient RNA editing approach may confer potentially significant therapeutic benefit as compared to other approaches. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Severe Alcohol-Associated Hepatitis Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The burden of alcohol use and alcohol use disorders contributes significantly to the health care costs for alcohol-related diseases. These patients incur direct costs to the health care system for medical care, and indirect costs to society due to a loss of workforce productivity, absenteeism, injury, early retirement and mortality. Alcohol overconsumption can lead to the development of liver damage that can manifest as fatty liver disease, alcohol-associated hepatitis and cirrhosis. The amount of alcohol intake that puts an individual at risk for alcohol-associated hepatitis is not known, but most patients have a history of heavy alcohol use for two or more decades. It is estimated that two million people die of liver disease each year, and up to half of these cases are due in part to alcohol overconsumption. There are around 300,000 hospitalizations per year for severe alcohol-associated hepatitis in the United States. sAH is an acute condition with a mortality rate of 25%&#8212;45% within 90 days of hospitalization. There are no FDA-approved treatments for sAH. Prednisolone is used off-label in this setting and is the only treatment available. However, many patients fail to respond to prednisolone or are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">308 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contraindicated, and studies have failed to show survival benefit at 90 days. Physicians may also prescribe pentoxifylline, an anti-inflammatory, or N-acetyl cysteine, an antioxidant, but the benefit of these drugs for sAH is not well established. Additionally, some sAH patients may be candidates for a liver transplant. It has been documented that survival for sAH patients is mainly driven by liver injury and not significantly impacted by alcohol-relapse. Current strategies to address harmful alcohol use and the development of pharmacotherapies remain largely ineffective, leading to substantial unmet need for advancement of policy efforts and development of novel therapies with effective mechanisms of action. Specifically for novel therapies, healthcare providers and payers are looking for therapies that demonstrate improved clinical and economic outcomes such as lower hospital length of stay and readmission rates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Korro Bio&#8217;s Differentiated Approach for the Treatment of sAH </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conventional small molecule drug development approaches in sAH have been ineffective and limited by reduced therapeutic index, suboptimal onset of action and safety concerns. In contrast, Korro Bio&#8217;s RNA editing approach is well-suited for the treatment of sAH. sAH is an acute condition that lends itself well to transient expression which can be delivered by RNA editing, compared to permanent editing approaches such as DNA editing which have the potential to lead to greater complications. In addition, only moderate to low editing efficiency may be required in sAH to translate to significant clinical benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is developing a product candidate that increases expression of a transcription factor implicated in sAH. By selectively modifying a single amino acid, Korro Bio is able to disrupt protein-to-protein interaction between the target protein and its inhibitor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has generated preclinical data for its sAH product candidates, demonstrating activation of target transcription factor activity both preclinical <span style="font-style:italic">in vitro</span> and <span style="font-style:italic">in vivo</span> studies. <span style="font-style:italic">In vitro, </span>Korro Bio&#8217;s oligonucleotides dose-dependently edited the target gene mRNA in human liver cells with up to 60% editing efficiency. <span style="font-style:italic">In vivo</span>, Korro Bio&#8217;s product candidates edited the target mRNA and induced expression of downstream target genes by up to 40x with observed statistical significance in mouse liver tissue. The product candidate has also demonstrated efficacy in an <span style="font-style:italic">in vitro</span> model of sAH, demonstrating protection against alcohol-induced inflammation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Severe alcohol-associated hepatitis is a large market opportunity with significant unmet medical need with no currently approved FDA therapies and limited competitive pipeline products in development. An RNA editing drug product has the potential to be differentiated by selectively addressing a validated target that has been historically difficult to drug with other modalities. In addition to its role in sAH, this transcription factor has been clinically validated to be implicated in the pathophysiology of other liver diseases, as well as a broad range of additional diseases such as cardiometabolic or immune-inflammatory conditions, enabling the opportunity to expand Korro Bio&#8217;s pipeline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_517">Korro Bio&#8217;s Amyotrophic Lateral Sclerosis Program: Disrupting Protein Aggregation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is developing proprietary oligonucleotides targeting the mRNA for TAR DNA binding protein 43 (TDP-43); a protein associated with the etiology of amyotrophic lateral sclerosis (&#8220;ALS&#8221;). ALS is an adult-onset, progressive, and fatal neurodegenerative neuromuscular system disorder that causes muscle weakness, paralysis, and ultimately death. A majority of patients diagnosed with ALS die from respiratory failure within three to five years after symptom appearance, with a small percentage of patients surviving beyond 10 years. Despite being classified as a rare disease by the FDA and the EMA, ALS is considered one of the more common neuromuscular diseases worldwide. Prevalence estimates vary, but it is widely accepted that there are approximately 25,000 ALS patients in the U.S. There is currently no cure for ALS, and currently approved therapies either only provide symptomatic relief or slow the overall progression of the disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is seeking to selectively modulate TDP-43, an RNA/DNA-binding protein, which carries out a variety of important functions in healthy neurons, including initiation of transcription, pre-mRNA splicing and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">309 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
miRNA processing. Hyper-phosphorylated and ubiquitinated TDP-43 deposits form inclusion bodies in the brain and spinal cord of patients with ALS and frontotemporal degeneration (&#8220;FTD&#8221;). The majority of ALS cases are sporadic and more than 90% of patients have TDP-43 aggregations in their motor neurons, while approximately 45% of patients with FTD have aggregations in neuronal cells. Mutations in TARDBP, the gene encoding TDP-43, are responsible for up to 10% of cases of familial ALS. Given the importance of TDP-43&#8217;s role in maintaining healthy neurons, the creation of a protein variant with the desired non-aggregating characteristic could have therapeutic benefit for the majority of ALS and FTD patients. Leveraging the unique ability of RNA editing to affect a single base edit to TDP-43 can lead to the synthesis of a protein variant that does not aggregate, and hence, restore its normal function. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has created a series of variants of TDP-43 containing single amino acid changes designed to alter its post-translational modification by phosphorylation, ubiquitination, acetylation or cleavage with the intent of reducing its ability to aggregate while maintaining its function in RNA metabolism. Korro Bio believes that modulating TDP-43 through the introduction of specific amino acid changes into the normal TDP-43 mRNA sequence is preferable to other approaches that inhibit overall TDP-43 production or that try to address protein aggregates after they form. Korro Bio has engineered mutations amenable to an RNA edit using Korro Bio&#8217;s OPERA platform that limit the formation of TDP-43 inclusion bodies <span style="font-style:italic">in vitro</span>. Additionally, Korro Bio has demonstrated meaningful editing of TDP-43 target sites with RNA editing oligonucleotides. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio intends to initially pursue ALS with this approach and has the opportunity to expand its pipeline to other neurodegenerative diseases, such as FTD. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_518">Korro Bio&#8217;s Pain Program: Selective Modulation of Ion Channels </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is developing proprietary oligonucleotides that selectively modulate ion channels associated with pain. Pain is a condition that millions of patients experience and is often a component of rare and highly prevalent diseases. Pain can be generally classified as either acute or chronic, that can be further segmented into subcategories including nociceptive or neuropathic pain. There are several classes of therapeutics utilized to target the numerous pathways that cause pain, including opioids, nerve growth factors and ion channel blockers. Many of these treatment methods involve unspecific targeting of pathways that lead to off-target effects. Despite a large commercial market opportunity, there remains significant unmet needs for safe and effective pain management, including non-opioid markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The introduction of genetic changes into the mRNA for Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7 demonstrates the potential of RNA editing to create highly differentiated, exquisitely selective, and potentially highly effective therapies for ion channels and beyond. Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7 is a voltage-gated sodium channel and plays a critical role in the generation and conduction of action potentials and is thus important for electrical signaling in the nervous system. Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7 is predominantly expressed in the pain sensing dorsal root ganglion neuron. Genetic inactivation of SCN9A, the gene encoding Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7, in mice results in the inability to sense pain from inflammatory stimuli. In humans, mutations that lead to inactivation of Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7 function result in a genetic condition known as Channelopathy-associated insensitivity to pain (&#8220;CIP&#8221;). Individuals with CIP have severely diminished ability to sense pain. By contrast, mutations that activate Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7 result in intense pain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several classes of drugs, including local anesthetics, such as lidocaine, are ion channel blockers, although they do not show a high degree of specificity and thus inhibit many types of sodium channels rather than selectively blocking Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7. No highly selective small molecule product candidates have been FDA-approved as therapeutics. One of the challenges in developing a small molecule inhibitor of Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7 is the high degree of homology with other voltage gated sodium channels, inhibition of which has been linked to safety concerns. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through its RNA editing technology, Korro Bio has generated a series of site-specific changes in Na<sub style="font-size:75%; vertical-align:bottom">V</sub>1.7 that modulate its ion transport activity such that it mimics that of a small molecule sodium channel blocker. Korro Bio believes that using RNA editing to introduce these changes in patients has the potential to deliver </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">310 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potent analgesic activity without the dose-limiting toxicities that have been observed other sodium channel blockers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s approach to treating pain has the potential to deliver a differentiated therapeutic with significant clinical benefit for a very large market with unmet need. In addition to treating pain, ion channels have been implicated in other diseases, including epilepsy and cardiovascular disease, which provides for further expansion opportunity of Korro Bio&#8217;s pipeline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_519">Korro Bio&#8217;s Cardiometabolic Disease Program: Activating Kinases </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is developing proprietary oligonucleotides that activate a kinase involved in cardiometabolic disease. Cardiometabolic disease encompasses a broad range of complex, multifactorial diseases including cardiovascular disease, diabetes, chronic renal failure and obesity, among others. A number of validated cardiometabolic disease targets such as kinases have been identified but have historically been difficult to drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has generated a site-specific change in a validated kinase that is a central regulator of energy homeostasis. In an <span style="font-style:italic">in vitro </span>mutagenesis study, a site-specific change led to activation of the kinase and an increase in the phosphorylation of its downstream target. Korro Bio believes that using RNA editing to introduce these changes with an oligonucleotide in patients has the potential to deliver efficacy that has been unattainable when using other modalities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_520">Pioneering RNA Editing to Deliver the Future of Medicine </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Korro Bio&#8217;s programs demonstrate the versatility of the ADAR-mediated RNA editing approach. Importantly, Korro Bio is able to not only address classes of diseases caused by deleterious effects of misfolded or misdirected proteins, but it can also potentially utilize genetics to identify highly prevalent diseases where therapeutic benefit can be generated through alteration of protein function or expression. Korro Bio will continue to selectively identify and pursue additional targets and indications based on a range of technical, clinical, and commercial factors to build a robust and differentiated pipeline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_521">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio currently has no commercial manufacturing capabilities. For its initial wave of clinical programs, it intends to use qualified third-party CMOs with relevant manufacturing experience in genetic medicines. Korro Bio plans to partner with suppliers and CMOs to produce or process critical raw materials, bulk compounds, formulated compounds, viral vectors or engineered cells for IND-supporting activities and early-stage clinical trials. At the appropriate time in the product development process, Korro Bio will determine whether to establish in-house GMP manufacturing capabilities for some core technologies or continue to rely on third parties to manufacture commercial quantities for any products that it may successfully develop. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_522">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries, including the gene therapy and gene editing fields, are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property. While Korro Bio believes that its differentiated technology, scientific expertise, and intellectual property position provide it with competitive advantages, it faces potential competition from a variety of companies in these fields. There are several companies using synthetic oligonucleotide or base editing technology, including Beam Therapeutics, Verve Therapeutics, Prime Medicine, ProQR, and Wave Life Sciences. Several additional companies utilize other editing technologies, including Edigene and Shape Therapeutics. In addition, Korro Bio faces competition from companies utilizing gene therapy, oligonucleotides, and DNA editing technologies such as base and prime editing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">311 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidates that Korro Bio successfully develops and commercializes will compete with existing therapies and new therapies that may become available in the future that are approved to treat the same diseases for which Korro Bio may obtain approval for its product candidates. This may include other types of therapies, such as small molecule, antibody, and/or protein therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many of Korro Bio&#8217;s current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and approved products than it does today. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in even more resources being concentrated among a smaller number of its competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Korro Bio also competes with these companies in recruiting, hiring and retaining qualified scientific and management talent, establishing clinical trial sites and patient registration for clinical trials, obtaining manufacturing slots at contract manufacturing organizations, and in acquiring technologies complementary to, or necessary for, its programs. Korro Bio&#8217;s commercial opportunity could be reduced or eliminated if its competitors develop and commercialize products that are safer, more effective, particularly if they represent cures, have fewer or less severe side effects, are more convenient, or are less expensive than any products that it may develop. Korro Bio&#8217;s competitors also may obtain FDA or other regulatory approval for their products more rapidly than Korro Bio may obtain approval for its, which could result in its competitors establishing a strong market position before it is able to enter the market. The key competitive factors affecting the success of all of its programs are likely to be their efficacy, safety, convenience, and availability of reimbursement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_524">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio strives to protect the proprietary technology that Korro Bio believes is important to its business, including seeking and maintaining patent protection in the United States and internationally for its current and future product candidates. Korro Bio also relies on trademarks, copyrights, trade secrets, confidentiality procedures, employee disclosure, invention assignment agreements, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain its proprietary position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio seeks to obtain domestic and international patent protection, and endeavors to promptly file patent applications for new commercially valuable inventions. Korro Bio also relies on trade secrets to protect aspects of its business that are not amenable to, or that Korro Bio does not consider appropriate for, patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio plans to continue to expand its intellectual property estate by filing patent applications directed to platform technologies and improvements thereof, pharmaceutical compositions, methods of treatment, methods of manufacture or identified from its ongoing development of Korro Bio&#8217;s product candidates. Korro Bio&#8217;s success will depend on its ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to Korro Bio&#8217;s business, defend and enforce any patents that Korro Bio&#8217;s may obtain, preserve the confidentiality of Korro Bio&#8217;s trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of companies like Korro Bio are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent may be challenged in courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. Korro Bio cannot guarantee that its pending patent applications, or any patent applications that Korro Bio may in the future file or license from third parties, will result in the issuance of patents. Korro Bio cannot predict whether the patent </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">312 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications Korro Bio is currently pursuing will issue as patents in any particular jurisdiction or at all, whether the claims of any patent applications, should they issue, will cover Korro Bio&#8217;s product candidates, or whether the claims of any issued patents will provide sufficient protection from competitors or otherwise provide any competitive advantage. Korro Bio cannot predict the scope of claims that may be allowed or enforced in its patents. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, Korro Bio may not obtain or maintain adequate patent protection for any of its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18&#160;months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries and patent application filings, Korro Bio cannot be certain of the priority of inventions covered by pending patent applications. Accordingly, Korro Bio may not have been the first to invent the subject matter disclosed in some of Korro Bio&#8217;s patent applications or the first to file patent applications covering such subject matter, and Korro Bio may have to participate in interference proceedings or derivation proceedings declared by the USPTO to determine priority of invention. For more information regarding the risks related to Korro Bio&#8217;s intellectual property, see &#8221;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Korro Bio&#8217;s Business&#8212;Risks Related to Intellectual Property</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent Portfolio </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s patent portfolio includes patents and patent applications in the United States and selected jurisdictions outside of the United States. As of July 13, 2023, Korro Bio&#8217;s patent portfolio in total consisted of 2&#160;issued U.S. patents and 1 issued patent in foreign jurisdictions (e.g., Canada), 19 PCT applications, 16 pending non-provisional applications, and 7 pending U.S. provisional applications, which include claims directed to compositions and methods of use. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent Term </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which Korro Bio files, including the United States, the base term is 20&#160;years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a U.S. patent can be lengthened by patent term adjustment, which compensates the owner of the patent for administrative delays at the USPTO. In some cases, the term of a U.S. patent is shortened by terminal disclaimer that reduces its term to that of an earlier-expiring patent. The term of a U.S. patent may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act, to account for at least some of the time the drug is under development and regulatory review after the patent is granted. With regard to a drug for which FDA approval is the first permitted marketing of the active ingredient, the Hatch-Waxman Act allows for extension of the term of one U.S. patent that includes at least one claim covering the composition of matter of such an FDA-approved drug, an FDA-approved method of treatment using the drug and/or a method of manufacturing the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or fourteen years from the date of the FDA approval of the drug, and a patent cannot be extended more than once or for more than a single product. During the period of extension, if granted, the scope of exclusivity is limited to the approved product for approved uses. Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, if and when Korro Bio&#8217;s product candidates receive FDA approval, Korro Bio expects to apply, if appropriate, for patent term extension on patents directed to those product candidates, their methods of use and/or methods of manufacture. However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with Korro Bio&#8217;s assessment of whether such extensions should be granted, and if granted, the length of such extensions. For more information regarding the risks related to Korro Bio&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">313 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property, see &#8221;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Korro Bio&#8217;s Business&#8212;Risks Related to Intellectual Property</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trade Secrets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, Korro Bio relies on trade secrets and know-how to develop and maintain its competitive position. Korro Bio typically relies on trade secrets to protect aspects of its business that are not amenable to, or that Korro Bio does not consider appropriate for, patent protection. Korro Bio protects trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with its employees, consultants, scientific advisors, contractors and collaborators. These agreements provide that all confidential information developed or made known during the course of an individual or entities&#8217; relationship with Korro Bio must be kept confidential during and after the relationship. These agreements also provide that all inventions resulting from work performed for Korro Bio or relating to Korro Bio&#8217;s business and conceived or completed during the period of employment or assignment, as applicable, shall be Korro Bio&#8217;s exclusive property. In addition, Korro Bio takes other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of its proprietary information by third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Korro Bio takes steps to protect its proprietary information and trade secrets, including through contractual means with its employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to Korro Bio&#8217;s trade secrets or disclose Korro Bio&#8217;s technology. Thus, Korro Bio may not be able to meaningfully protect its trade secrets. For more information regarding the risks related to Korro Bio&#8217;s intellectual property, see &#8221;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Korro Bio&#8217;s Business&#8212;Risks Related to Intellectual Property</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_525">Governmental Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, clinical trial, testing, manufacture, quality control, import, export, safety, efficacy, labeling, packaging, storage, distribution, recordkeeping, approval, distribution, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. Korro Bio, along with its vendors, CROs, clinical investigators and CMOs will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which Korro Bio wishes to conduct studies or seek approval of its product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Overview of U.S. Drugs Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drug products under the FD&amp;C Act and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. If Korro Bio fails to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other regulatory requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, Korro Bio may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#8217;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">314 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s product candidates must be approved for therapeutic indications by the FDA before they may be marketed in the United States. For drug product candidates regulated under the FD&amp;C Act, FDA must approve a NDA. The process generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements and applicable requirements for the humane use of laboratory animals or other applicable regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an Investigational New Drug application, or IND, which must become effective before clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payment of user fees for FDA review of the NDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an IRB or independent ethics committee at each clinical trial site before each trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation and submission to the FDA of an NDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug product&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of potential FDA audit of the preclinical study clinical trial sites that generated the data in support of the NDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA, including, where applicable, consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical Studies and Clinical Trials for Drugs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of product chemistry, formulation and stability, as well as<span style="font-style:italic"> in vitro</span> and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulation and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to the FDA as part of an IND. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials. The IND also includes the results of animal and <span style="font-style:italic">in vitro</span> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full or partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">315 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the terms originally specified in the IND. A clinical hold can also be imposed once a trial has already begun, thereby halting the trial until the deficiencies articulated by FDA are corrected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, who generally are physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of Health. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a clinical trial may move forward at designated check points based on access that only the group maintains to available data from the trial and may recommend halting the clinical trial if it determines that the participants or patients are being exposed to an unacceptable health risk or other grounds, such as no demonstration of efficacy. Other reasons for suspension or termination may be made by Korro Bio based on evolving business objectives and/or competitive climate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was well-designed and well-conducted in accordance with GCP requirements, including that the clinical trial was performed by a qualified investigator(s); the data are applicable to the U.S. population and U.S. medical practice; and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 1</span> &#8211; Phase 1 clinical trials involve initial introduction of the investigational product in a limited population of healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 2</span> &#8211; Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#8217;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 3</span> &#8211; Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">316 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling. Generally, two adequate and well-controlled Phase 3 trials are required by the FDA for approval of an NDA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of NDA approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or<span style="font-style:italic"> in vitro</span> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information. During the development of a new drug product, sponsors have the opportunity to meet with the FDA at certain points, including prior to submission of an IND, at the end of Phase 2 and before submission of an NDA. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Review and Approval Process for Drugs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. An NDA is a request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#8217;s safety and efficacy for the requested indications. The marketing application is required to include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug, to the satisfaction of the FDA. FDA must approve an NDA before a drug may be marketed in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs to ensure they are sufficiently complete to permit substantive review before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things, whether the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">317 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product is safe and effective for the indications sought and whether the facility in which it is manufactured, processed, packaged or held meets standards, including cGMP requirements, designed to assure and preserve the product&#8217;s continued identity, strength, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six months from the filing date of a new molecular entity NDA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, under PDUFA, as amended, each NDA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require submission of a REMS if it believes that a REMS is necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, special monitoring or other risk-minimization tools. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may require additional clinical or preclinical testing or recommend other actions, such as requests for additional information or clarification, that the applicant might take in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, depending on the specific risk(s) to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">318 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan Drug Designation and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population of 200,000 or more individuals in the United States when there is no reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and user-fee waivers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#8217;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of Korro Bio&#8217;s products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before Korro Bio does, unless Korro Bio is able to demonstrate that Korro Bio&#8217;s product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may further reevaluate its regulations and policies under the Orphan Drug Act. It is unclear as to how, if at all, the FDA may change the orphan drug regulations and policies in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs for Drugs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients more quickly than standard FDA review timelines typically permit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A new drug is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">319 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application is filed. Rolling review means that the FDA may review portions of the marketing application before the sponsor submits the complete application. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, alone or in combination with one or more other drugs, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient product development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review, once an NDA is submitted, if the product that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#8217;s goal date to take action on the marketing application is six months compared to ten months for a standard review. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Accelerated Approval is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, adequate and well-controlled additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit, and under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA may require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Further, under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a product or an indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, for products being considered for Accelerated Approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has passed, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination or publication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Post-Approval Requirements for Drugs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">320 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although physicians may prescribe approved products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, including not only by company employees but also by agents of the company or those speaking on the company&#8217;s behalf, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Promotional materials for approved drugs must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. In addition, manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs and those supplying products, ingredients and components of them, are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements on sponsors and their CMOs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon Korro Bio and any third-party manufacturers that a sponsor may use. Additionally, manufacturers and other parties involved in the drug supply chain for prescription drugs must also comply with product tracking and tracing requirements and for notifying FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend time money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with statutory and regulatory requirements may subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual program user fee for any marketed product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on post-approval clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">321 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mandated modification of promotional materials and labeling and issuance of corrective information. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Patent Term Restoration and Marketing Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA approval of Korro Bio&#8217;s future product candidates, some of Korro Bio&#8217;s United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, Korro Bio may apply for restoration of patent term for its currently owned or licensed patents to add patent life beyond a patent&#8217;s current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing exclusivity provisions under the FDCA also can delay the submission or the approval of certain drug product applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2)&#160;NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Privacy and Cybersecurity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s operations entail the collection, use, disclosure, transfer, and processing of sensitive and personal information. These operations are subject to multiple jurisdictions&#8217; privacy and data security laws and regulations, including those within the U.S., the EEA, and the UK. Korro Bio&#8217;s operations extend to commercial partnerships and third-party processors, each of which may be governed by their distinct privacy regulations and data security laws. These laws are constantly evolving and subject to varying interpretations, requiring Korro Bio to periodically update its policies and measures to maintain compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR in the EU and the UK, which have been incorporated into their respective laws, impose stringent requirements on the processing of health and other sensitive data. These requirements encompass: (i)&#160;providing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">322 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information to individuals regarding data processing activities; (ii)&#160;obtaining consent from individuals to whom the data processing relates; (iii)&#160;responding to data subject requests; (iv)&#160;imposing requirements to notify the competent national data protection authorities and data subjects of personal data breaches; (v)&#160;implementing safeguards in connection with the security and confidentiality of the personal data; (vi)&#160;accountability requirements; and (vii)&#160;taking certain measures when engaging third-party processors. The GDPR is also the regulation that informs Korro Bio&#8217;s obligations with respect to any clinical trials conducted in the EEA or UK. The GDPR&#8217;s definition of personal data includes coded data, and it requires changes to informed consent practices and detailed notices for clinical trial subjects and investigators. Failure to comply with the GDPR can result in significant practical, legal, and financial repercussions, including the destruction of improperly gathered or used personal data, substantial fines of up to &#8364;20&#160;million (&#163;17.5 million) or 4% of the company&#8217;s global annual turnover, mandatory audits, orders to cease or modify data use, and a private right of action enabling data subjects to seek damages. In addition, the GDPR provides that EU member states or the UK may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric, or health data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the UK has recently introduced a new Data Protection&#160;&amp; Digital Information (No. 2) Bill. This development could reshape the UK&#8217;s data protection landscape, distancing it from the EU&#8217;s data protection regime. This lack of clarity on future UK laws and regulations and their interaction with those of the EU could add legal risk, uncertainty, complexity, and cost; and any resulting divergence in laws could increase Korro Bio&#8217;s risk profile and necessitate further compliance measures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To enable the transfer of personal data outside of the EU or the UK, adequate safeguards must be implemented in compliance with the GDPR. On June&#160;4, 2021, the European Commission issued new forms of standard contractual clauses, or SCCs, for data transfers from controllers or processors in the EU (or otherwise subject to the GDPR) to controllers or processors established outside the EU (and not subject to the GDPR). As of December&#160;27, 2022 the new SCCs replace the SCCs that were adopted previously under the EU Data Protection Directive. The UK is not subject to the European Commission&#8217;s new SCCs, and instead it has published the UK International Data Transfer Agreement, or IDTA, and the International Data Transfer Addendum to the new SCCs, or the Addendum, which enable transfers from the UK. For new transfers, the IDTA (or SCCs and Addendum) must be in place, and such measures must be in place for all existing transfers from the UK from March&#160;21, 2024. Companies relying on SCCs or the IDTA to govern transfers of personal data to third countries will also need to assess whether the data importer can ensure sufficient guarantees for safeguarding the personal data under GDPR, including an analysis of the laws in the recipient&#8217;s country. When conducting restricted data transfers under the EU and UK GDPR, Korro Bio will need to implement these new safeguards, and doing so will require significant effort and cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to implement valid mechanisms for personal data transfers from Europe may result in increased exposure to regulatory actions, substantial fines and injunctions against processing personal data from Europe. Inability to export personal data may also: (i)&#160;restrict Korro Bio&#8217;s activities outside Europe; (ii)&#160;limit the ability to collaborate with partners as well as other service providers, contractors and other companies outside of Europe; and/or (iii)&#160;require Korro Bio to increase its processing capabilities within Europe at significant expense or otherwise cause it to change the geographical location or segregation of its relevant systems and operations &#8211; any or all of which could adversely affect its operations or financial results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S., privacy and security of personal information are regulated by various federal and state laws, such as health information privacy laws, security breach notification laws, and consumer protection laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these multifaceted privacy and data security laws can be time-consuming, and failure to comply with any of these regulations could lead to significant fines and penalties (potentially including criminal prosecution), adversely affecting Korro Bio&#8217;s reputation, business, financial condition, and operational results. Changes in statutes, regulations, or interpretations of existing regulations could impose additional requirements on Korro Bio&#8217;s operations, such as modifications to data processing arrangements, changes to privacy policies, recall or discontinuation of certain data processing methods, or additional recordkeeping requirements. These changes could adversely affect the operation of Korro Bio&#8217;s business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">323 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a further risk that Korro Bio may not be able to adequately protect its information systems from cyberattacks. Such breaches could result in the disclosure of confidential, protected, or personal information, damage its reputation, and expose it to significant financial and legal exposure, including potential civil fines and penalties, litigation, and regulatory investigations or enforcement actions under laws such as HIPAA, the GDPR, and the CCPA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the risks outlined above, the legal or regulatory actions may also divert Korro Bio&#8217;s management from their primary operations. Prohibitions, restrictions, or allegations of violations of these laws could materially and adversely affect Korro Bio&#8217;s business. Hence, ensuring consistent compliance with privacy and data security laws and regulations remains a critical operational imperative for Korro Bio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Regulatory Matters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing, labeling, packaging, distribution, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to which Korro Bio may be subject. Additionally, the activities associated with the commercialization of product candidates are subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the CMS, other divisions of the U.S. Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical drugs is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of such pharmaceutical products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with any of these laws or regulatory requirements may subject firms to legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a firm to enter into supply contracts, including government contracts. Any claim or action against Korro Bio for violation of these laws, even if Korro Bio successfully defends against it, could cause Korro Bio to incur significant legal expenses and divert its management&#8217;s attention from the operation of its business. Prohibitions or restrictions on marketing, sales or withdrawal of future products marketed by Korro Bio could materially affect Korro Bio&#8217;s business in an adverse way. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in statutes, regulations, or the interpretation of existing regulations could impact Korro Bio&#8217;s business in the future by requiring, for example: (i)&#160;changes to Korro Bio&#8217;s manufacturing arrangements; (ii)&#160;additions or modifications to product labeling or packaging; (iii)&#160;the recall or discontinuation of Korro Bio&#8217;s products; or (iv)&#160;additional recordkeeping requirements. If any such changes were to be imposed, they could adversely affect the operation of Korro Bio&#8217;s business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation Outside of the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, Korro Bio is subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and distribution of Korro Bio&#8217;s products. Most countries outside of the United States require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In the EU, for example, an application must be submitted to the national competent authority and an independent ethics committee in each country in which Korro Bio intends to conduct clinical trials, much like the FDA and IRB, respectively. Under the new CTR (EU) No 536/2014, which </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">324 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
replaced the Clinical Trials Directive 2001/20/EC on January&#160;31, 2022, a single application is now made through the Clinical Trials Information System, or CTIS, for clinical trial authorization in up to 30 EU/EEA countries at the same time and with a single set of documentation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assessment of applications for clinical trials is divided into two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted, or Member States concerned of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the Member State concerned, however overall related timelines are defined by the CTR. The new CTR also provides for simplified reporting procedures for clinical trial sponsors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, whether or not Korro obtains FDA approval for a product, Korro Bio must obtain approval of a product by the comparable regulatory authorities of countries outside the United States before it can commence marketing of the product in those countries. The approval process and requirements vary from country to country, so the number and type of nonclinical, clinical, and manufacturing studies needed may differ, and the time may be longer or shorter than that required for FDA approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of Korro Bio&#8217;s medicinal products under the EU&#8217;s regulatory system, Korro Bio is required to submit a marketing authorization application, or MAA, to be assessed in the centralized procedure. The centralized procedure allows applicants to obtain a marketing authorization, or MA, that is valid throughout the EU, and the additional Member States of the European Economic Area (Iceland, Liechtenstein and Norway) (EEA). It is compulsory for medicinal products manufactured using biotechnological processes, orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic <span style="white-space:nowrap">cell-EU</span> and which is intended for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, auto-immune and other immune dysfunctions, viral diseases or diabetes. The centralized procedure is optional for any other products containing new active substances not authorized in the EU or for products which constitute a significant therapeutic, scientific, or technical innovation or for which a centralized authorization is in the interests of patients at EU level. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an application directly to the European Medicines Agency, or EMA, to be assessed by the Committee for Medicinal Products for Human Use, or CHMP. The CHMP is responsible for conducting the assessment of whether a medicine meets the required quality, safety, and efficacy requirements, and whether the product has a positive risk/benefit profile. Once the CHMP has completed its assessment, the CHMP will give a favorable or unfavorable opinion as to whether to grant the authorization. The time limit for the evaluation procedure is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). The EMA then has fifteen days to forward its opinion to the European Commission, which will make a binding decision on the grant of an MA within 67 days of the receipt of the CHMP opinion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition that affects no more than five in 10,000 persons in the EU when the application is made. In addition, orphan designation can be granted if the product is intended for a life threatening, seriously debilitating, or serious and chronic condition in the EU and when, without incentives, it is unlikely that sales of the product in the EU would be sufficient to justify the necessary investment in its development. Orphan designation is only available if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the applicable orphan condition, or if such a method exists, the proposed orphan medicinal product will be of significant benefit to patients affected by such condition, as defined in Regulation (EC) 847/2000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan designation provides opportunities for fee reductions, protocol assistance, and access to the centralized procedure. In addition, if a product which has an orphan designation subsequently receives a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">325 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
centralized MA for the indication for which it has such designation, the product is entitled to orphan market exclusivity, which means the EMA may not approve any other application to market a similar medicinal product for the same indication for a period of ten years. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The exclusivity period may be reduced to six years if, at the end of the fifth year, it is shown that the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, an MA may be granted to a similar medicinal product for the same indication at any time if: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the MA holder of the authorized product consents to a second orphan medicinal product application; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the MA holder of the authorized product cannot supply enough orphan medicinal product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A pediatric investigation plan, or PIP, in the EU is aimed at ensuring that the necessary data are obtained to support the authorization of a medicine for children, through studies in children. All applications for MAs for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when an MA holder wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized and covered by intellectual property rights. Several rewards and incentives for the development of pediatric medicines for children are available in the EU. Medicines authorized across the EU with the results of studies from a PIP included in the product information are eligible for an extension of their supplementary protection certificate, or SPC, by six months (provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires). This is the case even when the studies&#8217; results are negative. For orphan medicinal products, the incentive is an additional two years of market exclusivity. Scientific advice and protocol assistance at the EMA are free of charge for questions relating to the development of pediatric medicines. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the EMA launched an initiative, the Priority Medicines scheme, or the PRIME scheme, to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme is intended to encourage development of products in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and <span style="white-space:nowrap">medium-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling <span style="white-space:nowrap">non-clinical</span> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact and rapporteur from the CHMP or from the Committee for Advanced Therapies, or CAT, are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the EEA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United Kingdom left the EU on January&#160;31, 2020, and the United Kingdom and the generally applicable in the EEA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United Kingdom left the have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January&#160;1, 2021 and has been formally applicable since May&#160;1, 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">326 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of United Kingdom and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended). Except in respect of the new EU Clinical Trials Regulation, the regulatory regime in Great Britain therefore largely aligns with current EU medicines regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of United Kingdom and EU pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of EU pharmaceutical legislation under the TCA, under a new framework which will be put in place by the Medicines and Healthcare products Regulatory Agency, or MHRA, the United Kingdom&#8217;s medicines regulator, from January&#160;1, 2024, the MHRA will take into account decisions on the approval of MAs from the EMA (and certain other regulators) when considering an application for a Great Britain MA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;27, 2023, the United Kingdom government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the United Kingdom. In particular, the MHRA will be responsible for approving all medicinal products destined for the United Kingdom market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single United Kingdom-wide MA will be granted by the MHRA for all medicinal products to be sold in the United Kingdom, enabling products to be sold in a single pack and under a single authorization throughout the United Kingdom. On June&#160;9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from 1&#160;January 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is now no <span style="white-space:nowrap">pre-MA</span> orphan designation in Great Britain. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MAA. The criteria are essentially the same, but have been tailored for the Great Britain market, i.e., the prevalence of the condition in Great Britain (rather than the EU) must not be more than five in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in Great Britain or the EU, wherever is earliest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patients Rely on Insurance Coverage by Third-Party Payors (third-party payors include Medicare and Medicaid (government payors) and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.) to Pay for Products </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Korro Bio&#8217;s ability to successfully commercialize its product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">327 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which products they will pay for and establish reimbursement levels. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. As a result, the coverage determination process is often a time-consuming and costly process that will require Korro Bio to provide scientific and clinical support for the use of Korro Bio&#8217;s products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow Korro Bio to establish or maintain pricing sufficient to realize a sufficient return on Korro Bio&#8217;s investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Uniform Policy Exists for Coverage and Reimbursement in the U.S. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, during to the COVID-19 pandemic, millions of individuals lost employer-based insurance coverage. It is unclear what effect, if any, the American Rescue Plan will have on the number of covered individuals, which may adversely affect Korro Bio&#8217;s ability to commercialize its products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Healthcare Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which Korro Bio researches, as well as sells, markets and distributes any products for which Korro Bio obtains marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If Korro Bio&#8217;s operations are found to be in violation of any of such laws or any other governmental regulations that apply, Korro Bio may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Affordable Care Act and Legislative Reform Measures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those Korro Bio is developing. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact Korro Bio&#8217;s ability to sell its products profitably. In particular, in 2010, the ACA was enacted, which, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">328 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been numerous judicial, administrative, and executive, challenges to certain aspects of the ACA. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&#160;1, 2024. Further, the Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions by Congress that include aggregate reductions of Medicare payments to providers of 2%&#160;per fiscal year, which remain in effect through 2031. Medicare payments to providers will be further reduced starting in 2025 absent further legislation. The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, on May&#160;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Inflation Reduction Act of 2022, or IRA, includes several provisions that may impact Korro Bio&#8217;s business to varying degrees, including provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs under Medicare Part D; allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs without generic competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition.&#160;If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. Further, judicial challenges to the IRA may have an impact on the implementation of the IRA&#8217;s provisions; and the overall effects of the IRA on Korro Bio&#8217;s business and the healthcare industry in general is not yet known. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices Korro Bio may obtain for any product candidates for which Korro Bio may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other U.S. Environmental, Health and Safety Laws and Regulations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, Korro Bio&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if Korro Bio contracts with third parties for the disposal of these materials and waste products, Korro Bio cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of Korro Bio&#8217;s hazardous </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">329 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
materials, Korro Bio could be held liable for any resulting damages, and any liability could exceed Korro Bio&#8217;s resources. Korro Bio also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio maintains workers&#8217; compensation insurance to cover costs and expenses Korro Bio may incur due to injuries to its employees as well as insurance for environmental liability, but this insurance may not provide adequate coverage against potential liabilities. However, Korro Bio does not maintain insurance for toxic tort claims that may be asserted against Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Korro Bio may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair Korro Bio&#8217;s research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_526">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July 18, 2023, Korro Bio had 85 full-time employees, including 30 who hold Ph.D. degrees, and 1 part-time employee; 63 employees are engaged in research and development and 23 employees are engaged in management or general and administrative activities. None of Korro Bio&#8217;s employees are subject to a collective bargaining agreement or represented by a trade or labor union. Korro Bio considers its relationship with its employees to be good. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating its existing and additional employees. The principal purposes of Korro Bio&#8217;s equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_527">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s principal office is located at One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139, where Korro Bio leases approximately 22,500 square feet of office space. The lease term began in August 2020 and will end in December 2023. Korro Bio also leases 18,148 square feet of laboratory and office space at 42 &amp; 45 Cummings Park in Woburn, Massachusetts. Korro Bio has plans to relocate its headquarters and occupy 50,453 square feet of laboratory and office space at 60 First Street in Cambridge, Massachusetts upon completion of the buildout of the space in 2024. Korro Bio believes that these facilities will be adequate for its near-term needs. If required, Korro Bio believes that suitable additional or substitute space will be available in the future on commercially reasonable terms to accommodate any such expansion of its operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_528">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Korro Bio may be involved in various other claims and legal proceedings relating to claims arising out of Korro Bio&#8217;s operations. Korro Bio is not currently a party to any material legal proceedings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">330 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_119">FREQUENCY MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion and analysis of Frequency&#8217;s financial condition and results of operations together with the section titled &#8220;Unaudited Pro Forma Combined Financial Data&#8221; and Frequency&#8217;s consolidated financial statements and related notes included elsewhere in this proxy statement/prospectus. This discussion and other parts of this proxy statement/prospectus contain forward-looking statements that involve risks and uncertainties, such as its plans, objectives, expectations, intentions, and beliefs. Frequency&#8217;s actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled &#8220;Risk Factors&#8212;Risks Related to Frequency&#8217;s Business&#8221; included elsewhere in this proxy statement/prospectus. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_120">Overview</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s business has focused on developing therapeutics that activate a person&#8217;s innate regenerative potential through its proprietary PCA approach. Frequency first applied its PCA approach for the restoration of the cochlea, with a focus on treating SNHL. Beginning in 2019, Frequency ran five clinical studies of FX-322 aimed at understanding safety as well as severities and etiologies that FX-322 might treat and the appropriate dose regime. In 2021, Frequency commenced its sixth study, the FX-322-208 study, and introduced a second hearing program, FX 345, which Frequency believed might expand the opportunity to treat different types of SNHL. In February 2023, Frequency announced that the FX-322-208 study failed to achieve its primary endpoint of an improvement in speech perception. Frequency decided to discontinue the FX-322 development program and, given the similarities between the mechanisms of FX-322 and FX 345, decided to discontinue the FX-345 development program as well. Following this decision, Frequency decided to focus its efforts on developing the MS Program and to explore strategic alternatives for the MS Program, including the sale of the MS Program. On July 14, 2023, Frequency entered into the Merger Agreement with Korro Bio and Merger Sub. Upon completion of the Merger, the business of Korro Bio will continue as the business of the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;8, 2022, Frequency announced a reduction in force of approximately 30% of its workforce to better align the workforce with the near-term needs of the business and focus more of Frequency&#8217;s capital resources on research and development programs for hearing and remyelination in MS. On February&#160;13, 2023, in connection with the discontinuation of the hearing program, Frequency announced a restructuring of its business including a downsizing of personnel by approximately 55%. On May 31, 2023, Frequency announced a reduction in force of approximately 55% of its workforce to better align its workforce with the needs of its business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since formation in 2014, Frequency has devoted substantially all its resources to developing its PCA approach, conducting research and development activities, including product candidate development, recruiting skilled personnel, establishing its intellectual property portfolio, and providing general and administrative support for these operations. Frequency has financed its operations primarily through private and public securities financings, a term loan, and amounts received under a collaboration agreement.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Frequency has incurred significant operating losses and has not generated any revenue from the sale of products. Frequency&#8217;s ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of its product candidates. Frequency&#8217;s net losses were $19.5 million and $81.6 million for the three months ended March&#160;31, 2023 and year ended December&#160;31, 2022, respectively. As of March&#160;31, 2023, Frequency had an accumulated deficit of $281.2 million.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s operating expenses discussed in this section reflect its development programs around FX-322, FX-345, MS and any future programs as well as its operations as a public company. Frequency will not generate revenue from product sales unless&#160;and until it successfully completes clinical development, obtains regulatory </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">331 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval for, and successfully commercializes its product candidates. If Frequency obtains regulatory approval for any of its product candidates, Frequency expects to incur significant expenses related to developing its commercialization capability to support product sales, marketing and distribution.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these anticipated expenditures, Frequency will need additional financing to support its continuing operations. Until such time as Frequency can generate significant revenue from product sales, if ever, Frequency expects to finance its cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. Adequate additional financing may not be available to Frequency on acceptable terms, or at all. Frequency&#8217;s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. Frequency cannot be sure that it will ever generate sufficient revenue to achieve profitability.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with the development of therapeutics, Frequency is unable to predict the timing or amount of increased expenses or when or if it will be able to achieve or maintain profitability. Even if Frequency can generate revenue from product sales, Frequency may not become profitable. If Frequency fails to become profitable or are unable to sustain profitability on a continuing basis, then Frequency may be required to raise additional capital on terms that are unfavorable to it or Frequency may be unable to continue its operations at planned levels and be forced to reduce or terminate its operations.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_122">License and collaboration agreements</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Astellas Pharma Inc.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, Frequency entered into a license and collaboration agreement, or the Astellas Agreement with Astellas Pharma, Inc., or Astellas, under which Frequency granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek, and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, including Frequency&#8217;s product candidate FX-322, outside of the United States. On April&#160;14, 2023, the Astellas Agreement was terminated. Frequency is not subject to any payments or costs as a result of this termination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Massachusetts Institute of Technology</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, Frequency entered into an Exclusive Patent License Agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which Frequency received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products and to develop and perform processes that incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. Frequency was required to pay certain annual license maintenance fees ranging from $30&#160;thousand to $0.1&#160;million to MIT under the MIT License. On July 6, 2023, the MIT License was terminated. Frequency is not subject to any payments or costs as a result of this termination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, Frequency entered into an <span style="white-space:nowrap">Non-Exclusive</span> Patent License Agreement, or the MEE License, with the Massachusetts Eye and Ear, or MEE, under which Frequency received a <span style="white-space:nowrap">non-exclusive,</span> <span style="white-space:nowrap"><span style="white-space:nowrap">non-sub-licensable,</span></span> worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, and to develop and perform processes that incorporate the licensed technology for the treatment or prevention of hearing loss. Frequency was obligated to pay certain annual license maintenance fees between $5&#160;thousand and $7.5&#160;thousand per each MEE patent family case number included in the licensed MEE patent rights under the MEE License. On April&#160;4, 2023, the MEE License was terminated. Frequency is not subject to any payments or costs as a result of this termination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">332 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Scripps Research Institute (California Institute for Biomedical Research)</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, Frequency entered into a license agreement, or the CALIBR License, with the California Institute for Biomedical Research, or CALIBR, a division of Scripps, under which Frequency received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products that incorporate licensed technology for the treatment of MS. On April&#160;28, 2023, the CALIBR License was terminated. Frequency is not subject to any payments or costs as a result of this termination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_123">Components of Frequency&#8217;s results of operations</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and development expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses presented in this section consist primarily of costs related to activities largely focused on hearing restoration and MS. These expenses include the following:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses incurred under agreements with third parties, CROs, and other third parties that conduct preclinical research and development activities and clinical trials on Frequency&#8217;s behalf; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs to manufacture o Frequency&#8217;s clinical trial material for use in Frequency&#8217;s preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of outside consultants, including their fees and related travel expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">option and license payments made to third parties, for intellectual property used in research and development activities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically, identifiable to research activities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency tracks external research and development costs, including the cost of services, outsourced research and development, clinical trials, contract manufacturing, laboratory equipment and maintenance, and certain other development costs, by product candidate when the costs are specifically identifiable to a product candidate. Internal and external costs associated with infrastructure resources, other research and development costs, facility-related costs, and depreciation and amortization that are not identifiable to a specific product candidate are included in the platform development, early-stage research, and unallocated expenses category. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency cannot determine with certainty the duration and costs of future clinical trials of any product candidate it may develop or if, when, or to what extent it will generate revenue from the commercialization and sale of any product candidate for which Frequency obtains marketing approval. The duration, costs, and timing of clinical trials and development of any product candidate Frequency may develop will depend on a variety of factors, including:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, rate of progress, expense and results of clinical trials of product candidates and other research and development activities that Frequency may conduct; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the actual probability of success for Frequency&#8217;s product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability, and commercial viability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant and changing government regulation and regulatory guidance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and receipt of any marketing approvals; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">333 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the progress of the development efforts of parties with whom Frequency may enter into collaboration agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s ability to secure manufacturing supply through relationships with third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the commercialization of product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of public health emergencies on planned trials. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and administrative expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in Frequency&#8217;s executive, finance, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; investor and public relations costs; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities, and other operating costs that are not specifically attributable to research and development activities.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest income</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest earned on cash equivalents and marketable securities.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists of interest paid on Frequency&#8217;s term loan.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other income, net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net consists of amortization expense and accretion income on investments as well as sublease income.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income taxes</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s total provision is based on the United States federal statutory income tax rate of 21%, increased by state taxes and reduced by a full valuation allowance on Frequency&#8217;s deferred tax assets. The income tax expense for the three months ended March&#160;31, 2023 and 2022 represents state taxes on interest income earned by Frequency&#8217;s subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, Frequency has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2022 because Frequency has determined that it is more likely than not that it will not recognize the benefits of its federal and state deferred tax assets primarily due to Frequency&#8217;s cumulative loss position and, as a result, a valuation allowance has been established.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception in 2014, Frequency has generated cumulative federal and state net operating loss and research and development credit carryforwards for which Frequency has not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within their respective carryforward periods.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">334 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_124">Results of operations</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of three months ended March&#160;31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Frequency&#8217;s results of operations for the three months ended March&#160;31, 2023 and 2022:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:63%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months Ended</span><br /><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase</span><br /><span style="font-weight:bold">(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="10" align="center"><span style="font-weight:bold">(in&#160;thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,426</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(321</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,747</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,511</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,747</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">523</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(284</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(178</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(106</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">786</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,519</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,374</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,386</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and development expenses</span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months Ended</span><br /><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase</span><br /><span style="font-weight:bold">(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="10" align="center"><span style="font-weight:bold">(in&#160;thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by therapeutic area and product candidate:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">FX-322</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,621</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">FX-345</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">647</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiple Sclerosis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,795</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platform development, early-stage research</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">and unallocated expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(682</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory supplies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outsourced research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(285</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility-related costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(337</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">294</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(146</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platform development, early-stage research and unallocated expenses total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,221</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,426</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $1.1&#160;million of costs related to <span style="white-space:nowrap">FX-322</span> incurred for the three months ended March&#160;31, 2023 consisted of clinical costs associated with the Phase 2b clinical trial <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-208)</span></span> which concluded in the first quarter 2023. The $2.7&#160;million of costs related to <span style="white-space:nowrap">FX-322</span> incurred in the three months ended March&#160;31, 2022 consisted primarily of $2.5&#160;million of clinical costs associated with the Phase 2b clinical trial <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-208)</span></span> and $0.2&#160;million of drug development and manufacturing costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $0.6&#160;million of costs related to <span style="white-space:nowrap">FX-345</span> incurred for the three months ended March&#160;31, 2023 consisted of clinical trial costs associated with the planned Phase 1b trial <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-345-101),</span></span> which was discontinued in the first quarter of 2023. The $1.0&#160;million of costs related to <span style="white-space:nowrap">FX-345</span> incurred for the three months ended March&#160;31, 2022 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">335 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consisted of $0.9&#160;million of drug development and manufacturing costs and $0.1&#160;million related to preclinical safety costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $1.8&#160;million of costs related to the MS development program incurred for the three months ended March&#160;31, 2023 consisted primarily of $0.9&#160;million of chemistry and compound characterization costs, $0.2&#160;million of drug development and manufacturing costs, and $0.6&#160;million of preclinical safety costs. Similarly, the $1.0&#160;million of costs related to the MS development program incurred for the three months ended March&#160;31, 2022 consisted primarily of $0.6&#160;million of chemistry and compound characterization costs, $0.2&#160;million of preclinical safety costs, and $0.1&#160;million of drug development and manufacturing costs.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $7.8&#160;million of platform development, early-stage research and unallocated expenses incurred for the three months ended March&#160;31, 2023, consisted primarily of $5.4&#160;million in employee-related costs, including $0.8&#160;million of stock-based compensation expense, and $1.4&#160;million in facility-related costs. The decrease in platform development, early-stage research and unallocated expenses of $1.2&#160;million during the three months ended March&#160;31, 2023, compared to the three months ended March&#160;31, 2022, is primarily attributable to a decrease of $0.7&#160;million in employee-related costs, including salary, bonus, and stock-based compensation costs, as a result of the reduction in force implemented in April 2022, as well as a $0.3&#160;million decrease in facility-related costs due to a combination of reduced headcount and the initiation of cost sharing with SalioGen Therapeutics, Inc. in connection with Frequency&#8217;s sublease. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and administrative expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $9.2&#160;million of general and administrative expenses for the three months ended March&#160;31, 2023 consisted primarily of $6.1&#160;million in employee-related costs, including $2.6&#160;million of stock-based compensation, $1.4&#160;million in facility-related costs, $1.4&#160;million in professional services costs, and $0.3&#160;million in depreciation expense. General and administrative expenses decreased by $0.3&#160;million from the three months ended March&#160;31, 2022 due primarily to a $0.2&#160;million decrease in professional services costs as Frequency reduced reliance on third-party consulting and public relations vendors.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest income</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income was $0.5&#160;million for the three months ended March&#160;31, 2023 compared to interest income of $0.1&#160;million for the three months ended March&#160;31, 2022. This increase is due to the increase in interest rates from the previous year.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense was $0.3&#160;million for the three months ended March&#160;31, 2023 compared to interest expense of $0.2&#160;million for the three months ended March&#160;31, 2022. This increase is due to the increase in interest rates from the previous year.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other income, net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net was $0.8&#160;million for the three months ended March&#160;31, 2023 as compared to other expense, net of $33&#160;thousand for the three months ended March&#160;31, 2022. This increase is due to the sublease income generated in the three months ended March&#160;31, 2023.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income tax provision </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax provision was $24&#160;thousand for the three months ended March&#160;31, 2023 as compared to income tax provision of $12&#160;thousand for the three months ended March&#160;31, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">336 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of years ended December&#160;31, 2022 and 2021</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Frequency&#8217;s results of operations for the years ended December&#160;31, 2022 and 2021:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,418</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,923</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,099</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,002</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(84,031</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(961</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(764</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain (loss) on investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange (loss) gain</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(266</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(81,582</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(84,671</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax benefit (provision)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(81,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(84,686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No revenue was recognized for the year ended December&#160;31, 2022 compared to $14.1&#160;million for the year ended December&#160;31, 2021. In July 2019, Frequency entered into the Astellas Agreement and received an upfront license fee payment of $80.0&#160;million. In accordance with ASC 606, Frequency recognized the $80.0&#160;million as revenue over the period that research and development services were provided and the Phase 2a clinical study for <span style="white-space:nowrap">FX-322</span> was carried out using the input method. These research and development services concluded in June 2021.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and development expenses</span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:63%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase</span><br /><span style="font-weight:bold">(Decrease)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">(in&#160;thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by therapeutic area and product candidate:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">FX-322</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">521</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">FX-345</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,254</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiple Sclerosis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,845</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platform development, early-stage research and</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">unallocated expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,542</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory supplies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">716</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(444</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outsourced research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,902</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility-related</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(495</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(563</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platform development, early-stage research and unallocated expenses total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,564</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,927</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,418</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,923</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">337 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $10.9&#160;million of costs related to <span style="white-space:nowrap">FX-322</span> incurred for the year ended December&#160;31, 2022 consisted primarily of $10.0&#160;million of clinical costs associated with ongoing trials, including the recently completed Phase 2b clinical trial <span style="white-space:nowrap"><span style="white-space:nowrap">(FX-322-208),</span></span> and $0.6&#160;million of drug development and manufacturing costs. The $10.3&#160;million of costs related to <span style="white-space:nowrap">FX-322</span> incurred for the year ended December&#160;31, 2021 consisted primarily of $8.4&#160;million of clinical costs associated with ongoing trials and $1.9&#160;million of drug development and manufacturing costs. The overall increase from the year ended December&#160;31, 2021 is due primarily to the <span style="white-space:nowrap"><span style="white-space:nowrap">FX-322-208</span></span> clinical trial activity in the year ended December&#160;31, 2022.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $4.2&#160;million of costs related to <span style="white-space:nowrap">FX-345</span> incurred for the year ended December&#160;31, 2022 consisted primarily of $2.6&#160;million of drug development and manufacturing costs, $1.2&#160;million in clinical costs associated with the <span style="white-space:nowrap"><span style="white-space:nowrap">FX-345-101</span></span> trial, which Frequency initiated in 2022, and $0.4&#160;million in preclinical safety costs. The $5.5&#160;million of costs related to <span style="white-space:nowrap">FX-345</span> incurred for the year ended December&#160;31, 2021 consisted of $3.1&#160;million in preclinical safety costs and $2.3&#160;million in drug development and manufacturing costs. The overall decrease from the year ended December&#160;31, 2021 is due primarily to the conclusion of preclinical safety work partially offset by costs related to the initiation of the <span style="white-space:nowrap"><span style="white-space:nowrap">FX-345-101</span></span> trial in the year ended December&#160;31, 2022.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $4.8&#160;million of costs related to MS incurred for the year ended December&#160;31, 2022 consisted primarily of $2.6&#160;million of chemistry and compound characterization costs, $0.7&#160;million in drug development and manufacturing costs, $0.6&#160;million in preclinical safety costs, and $0.4&#160;million in <span style="font-style:italic">in vitro</span> and <span style="font-style:italic">in vivo </span>testing costs. The $6.6&#160;million of costs related to MS incurred for the year ended December&#160;31, 2021 consisted of $3.0&#160;million in preclinical safety costs, $1.6&#160;million in chemistry and compound characterization costs, $0.9&#160;million in <span style="font-style:italic">in vitro</span> and <span style="font-style:italic">in vivo</span> testing costs, and $0.8&#160;million in drug development and manufacturing costs. The overall decrease from the year ended December&#160;31, 2021 is due primarily to a reduction in development and testing costs as Frequency progressed from exploratory activities to identification of specific proprietary compounds that act as Frequency&#8217;s novel target for remyelination in MS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $29.6&#160;million of platform development, early-stage research and unallocated expenses incurred for the year ended December&#160;31, 2022 consisted primarily of $20.0&#160;million in employee related costs, including $7.7&#160;million in stock-based compensation expense, $6.4&#160;million of facility-related costs, and $1.6&#160;million of depreciation expense. The decrease from the year ended December&#160;31, 2021 is primarily attributable to a $5.5&#160;million decrease in employee-related expenses due predominantly to Frequency&#8217;s April 2022 reduction in force, a $1.9&#160;million decrease in outsourced research and development expenses as Frequency decreased sponsored research, and a $0.6&#160;million decrease in other research and development expenses as Frequency reduced its reliance on third-party consulting.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and administrative expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $33.6&#160;million of general and administrative expenses for the year ended December&#160;31, 2022 consisted primarily of $20.6&#160;million of employee-related costs, including $12.1&#160;million in stock-based compensation expense, $5.6&#160;million of professional services costs, $2.7&#160;million in directors&#8217; and officers&#8217; insurance costs, $1.6&#160;million in rent expense, including utilities and common area maintenance, or CAM, charges, and $1.1&#160;million in depreciation expense. General and administrative expenses decreased $3.6&#160;million from December&#160;31, 2021 due to a $2.1&#160;million decrease in professional services costs as Frequency reduced its reliance on third-party consulting and public relations vendors, a $0.6&#160;million decrease in directors&#8217; and officers&#8217; insurance costs, and a $0.5&#160;million decrease in employee-related costs due primarily to the April 2022 reduction in force.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest income</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income was $1.3&#160;million for the year ended December&#160;31, 2022 compared to $0.4&#160;million for the year ended December&#160;31, 2021, due to increases in interest rates from the previous year.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">338 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense was $1.0&#160;million for the year ended December&#160;31, 2022 compared to $0.8&#160;million for the year ended December&#160;31, 2021, due to increases in the interest rate on our term loan.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Realized gain (loss) on investments</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realized gain on investments was $3,000 for the year ended December&#160;31, 2022 compared to a loss of $23,000 for the year ended December&#160;31, 2021 due to changes in the composition of investments year over year.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Foreign exchange (loss) gain </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign exchange loss was $5,000 for the year ended December&#160;31, 2022 compared to a gain of $16,000 for the year ended December&#160;31, 2021. The decrease was due to differences in foreign exchange remeasurement of the financial statements of Frequency&#8217;s foreign subsidiaries.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other income (expense), net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net was $1.1&#160;million for the year ended December&#160;31, 2022 compared to expense of $0.3&#160;million for the year ended December&#160;31, 2021. The change from the prior year is due to the inclusion of sublease income beginning in the third quarter of 2022.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax benefit was $2,000 for the year ended December&#160;31, 2022 compared to expense of $15,000 for the year ended December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_125">Liquidity and capital resources</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Frequency has incurred significant operating losses. Frequency expects to continue to incur significant expenses and operating losses for the foreseeable future. Frequency expects that its research and development and general and administrative costs will continue to fluctuate, to the extent that it conducts preclinical studies and clinical trials for product candidates, contracts with CMOs to support preclinical studies and clinical trials, expands its intellectual property portfolio, and provides general and administrative support for its operations. As a result, Frequency will need additional capital to fund its operations, which Frequency may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency does not currently have any approved products and has never generated any revenue from product sales. Frequency has financed its operations primarily through proceeds from private and public securities financings, a term loan, and amounts received under a collaboration agreement. To date, Frequency has raised approximately $378.3&#160;million, including from grants and option exercises. Frequency&#8217;s cash, cash equivalents and marketable securities totaled $66.7&#160;million as of March&#160;31, 2023. As of March&#160;31, 2023, Frequency had $11.7&#160;million of current debt. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2020, Frequency entered into a Loan and Security Agreement with a commercial bank for a term loan with a principal balance of $15.0&#160;million. Frequency made monthly interest only payments through November&#160;30, 2022. On April&#160;3, 2023, Frequency prepaid the remaining $11.7&#160;million due under the term loan. Frequency was not subject to any prepayment premium as the prepayment occurred after the second anniversary of the closing date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, Frequency entered into an Equity Distribution Agreement with Oppenheimer&#160;&amp; Co. Inc., or Oppenheimer, to sell shares of Frequency common stock, having an aggregate offering price of up to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">339 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$125.0&#160;million, from time to time, through an &#8220;at the market&#8221; equity offering program under which Oppenheimer will act as sales agent and/or principal, or the ATM Program. During the year ended December&#160;31, 2022, Frequency sold 12,767 shares of Frequency common stock under the ATM Program for net proceeds of approximately $50,000 and paid $2,000 to Oppenheimer in sales agent fees. No shares of common stock have been sold under the ATM Program in 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;8, 2022, Frequency announced a reduction in force of approximately 30% of its workforce to better align the workforce with the needs of the business and focus more of Frequency&#8217;s capital resources on its research and development programs. The total costs related to this reduction in force are approximately $1.0&#160;million in research and development expense and $0.2&#160;million in general and administrative expense, primarily related to severance costs and related expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, in connection with the discontinuation of the <span style="white-space:nowrap">FX-322</span> and <span style="white-space:nowrap">FX-345</span> hearing programs, Frequency announced a restructuring that included downsizing personnel by approximately 55%. These changes are expected to&#160;preserve capital, ensuring that Frequency is appropriately resourced to complete a first clinical trial of its MS development program. The total costs related to this restructuring are approximately $4.3&#160;million, of which $3.8 million is related to severance costs and related expenses, $0.4&#160;million is related to accelerated depreciation, and $0.1&#160;million is related to accelerated hearing program costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash flows</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Frequency&#8217;s sources and uses of cash for the three months ended March&#160;31, 2022 and 2023:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months Ended</span><br /><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(in&#160;thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,132</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,499</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,662</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,468</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,101</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29,805</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash flows for the three months ended March&#160;31, 2023</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the three months ended March&#160;31, 2023 was $14.1&#160;million, consisting of a net loss of $19.5&#160;million. In addition, Frequency had <span style="white-space:nowrap">non-cash</span> charges of $4.9&#160;million for depreciation, stock-based compensation expense, <span style="white-space:nowrap">non-cash</span> lease expense, and <span style="white-space:nowrap">non-cash</span> gain on investments. Net cash used in operating activities was also impacted by a net $3.6&#160;million decrease in operating assets and liabilities, including a $2.1&#160;million decrease in prepaid expenses and other current assets, a $0.5&#160;million decrease in lease liabilities, a $0.4&#160;million decrease in accrued expenses, and a $0.7&#160;million decrease in accounts payable.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in net cash used in operating activities for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022 was primarily due to a $3.9&#160;million decrease in net loss. This decrease was partially offset by a $1.8&#160;million decrease in stock based compensation expense and various changes in operating assets and liabilities quarter over quarter.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investing activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities for the three months ended March&#160;31, 2023 was $5.5&#160;million, which was primarily attributable to $7.6&#160;million in redemptions of marketable securities, partially offset by $2.0&#160;million purchases of marketable securities.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">340 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in net cash provided by investing activities for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022 was primarily due to a $18.8&#160;million decrease in the purchase of marketable securities partially offset by a $0.6&#160;million decrease in redemptions of marketable securities.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financing activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities for the three months ended March&#160;31, 2023 was $2.5&#160;million, primarily attributable to term loan repayments. This represents an increase in net cash used in financing activities when compared to the three months ended March&#160;31, 2022 as no such repayments were made in the three months ended March&#160;31, 2022.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash flows for the three months ended March&#160;31, 2022</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the three months ended March&#160;31, 2022 was $17.3&#160;million, consisting of a net loss of $23.4&#160;million. In addition, Frequency had <span style="white-space:nowrap">non-cash</span> charges of $6.9&#160;million for depreciation, stock-based compensation expense, <span style="white-space:nowrap">non-cash</span> lease expense, and <span style="white-space:nowrap">non-cash</span> interest expense. Net cash used in operating activities was also impacted by a net $3.6&#160;million decrease in operating assets and liabilities, including a decrease in accrued expenses of $1.4&#160;million, a $0.4&#160;million decrease in accounts payable, and a $1.4&#160;million decrease in prepaid expenses and other current assets.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investing activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the three months ended March&#160;31, 2022 was $12.7&#160;million, which was attributable to $20.8&#160;million of purchases of marketable securities, partially offset by $8.1&#160;million in redemptions of marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financing activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the three months ended March&#160;31, 2022 was primarily attributable to $0.2&#160;million in proceeds from the issuance of common stock and the sale of shares of common stock under the Employee Stock Purchase Plan.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Frequency&#8217;s sources and uses of cash for the years ended December&#160;31, 2021 and 2022:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:71%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended</span><br /><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(in&#160;thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(58,237</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(76,059</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(66,126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(577</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(27,681</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(140,827</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash flows for the year ended December&#160;31, 2022</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&#160;31, 2022 was $58.2&#160;million, consisting of a net loss of $81.6&#160;million. The net loss was partially offset by <span style="white-space:nowrap">non-cash</span> items related to normal business operations including stock-based compensation expense of $19.8&#160;million, depreciation expense of $2.8&#160;million, <span style="white-space:nowrap">non-cash</span> lease expense of $2.4&#160;million and <span style="white-space:nowrap">non-cash</span> interest expense of $0.4&#160;million. Net cash used in operating activities was also impacted by a net $2.0&#160;million decrease in operating assets and liabilities, primarily the result of the continued reduction of lease liabilities over the term of the Frequency leased office space.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">341 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in net cash used in operating activities for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021 is primarily due to changes in operating assets and liabilities year over year. Specifically, deferred revenue decreased $14.1&#160;million in the year ended December&#160;31, 2021 due to the recognition of revenue related to the Astellas Agreement. No such decrease occurred in the year ended December&#160;31, 2022. The decrease from December&#160;31, 2021 is also partially due to a $3.1&#160;million decrease in net loss.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investing activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities for the year ended December&#160;31, 2022 was $31.1&#160;million, which was attributable to $85.3&#160;million in redemptions of marketable securities and $17&#160;thousand in sales of property and equipment partially offset by $54.2&#160;million of purchases of marketable securities.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in net cash provided by investing activities for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021 is primarily due to a $56.1&#160;million increase in the redemption of marketable securities and a $38.2&#160;million decrease in the purchase of marketable securities. The increase is also due to a $2.9&#160;million decrease in purchases of property and equipment from the year ended December&#160;31, 2021 as Frequency furnished its new office and laboratory space in 2021 and did not incur such expenditures in 2022.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financing activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities for the year ended December&#160;31, 2022 was $0.6&#160;million, primarily attributable to $0.8&#160;million in term loan repayments partially offset by $0.2&#160;million in proceeds from the Employee Stock Purchase Plan and $60&#160;thousand in proceeds from the issuance of common stock under the ATM and exercises of common stock.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in net cash used in financing activities for the year ended December&#160;31, 2022 compared to December&#160;31, 2021 is primarily attributable to the $1.2&#160;million decrease in proceeds from the issuance of common stock. Additionally, Frequency began making principle repayments on its term loan in the year ended December&#160;31, 2022.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash flows for the year ended December&#160;31, 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&#160;31, 2021 was $76.1&#160;million, consisting of a net loss of $84.7&#160;million. The net loss was partially offset by <span style="white-space:nowrap">non-cash</span> items related to normal business operations including stock-based compensation expense of $21.8&#160;million, depreciation expense of $2.8&#160;million, <span style="white-space:nowrap">non-cash</span> lease expense of $1.1&#160;million and <span style="white-space:nowrap">non-cash</span> interest expense of $0.4&#160;million. Net cash used in operating activities was also impacted by a net $17.3&#160;million decrease in operating assets and liabilities, primarily due to the $14.1&#160;million reduction in deferred revenue as all remaining&#160;revenue related to the Astellas Agreement was recognized in the year ended December&#160;31, 2021 as well as a $2.3&#160;million decrease in accounts payable due to the timing of invoice receipt and payment.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investing activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&#160;31, 2021 was $66.1&#160;million, which was attributable to $92.4&#160;million of purchases of marketable securities and $2.9&#160;million of purchases of property and equipment, partially offset by $29.2&#160;million in redemptions of marketable securities.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financing activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the year ended December&#160;31, 2021 was $1.4&#160;million, primarily attributable to $1.3&#160;million in proceeds from the exercise of Frequency Options and $60&#160;thousand in proceeds from the Employee Stock Purchase Plan.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">342 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Funding requirements</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency expects its future operating expenses to reflect any research and development activities, preclinical activities, studies for INDs, and initiation of clinical trials. In addition, Frequency expects to maintain general and administrative costs to manage the requirements of operating as a public company.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency believes that its cash, cash equivalents, and marketable securities as of March&#160;31, 2023 will enable it to fund Frequency&#8217;s operating expenses and capital expenditure requirements into 2025. Frequency has based this estimate on assumptions that may prove to be incorrect, and Frequency could utilize its available capital resources sooner than expected.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with the research, development, and commercialization of therapeutics, it is difficult to estimate with certainty the amount of Frequency&#8217;s working capital requirements. Frequency&#8217;s future funding requirements will depend on many factors, including:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the progress, costs, and results of any research and preclinical development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome, timing and cost of meeting regulatory requirements established by the FDA and comparable foreign regulatory authorities, if applicable, for product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business and operations interruptions resulting from public health emergencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of internal process development, manufacturing activities, and clinical trial management associated with product candidates Frequency advances through preclinical and clinical development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Frequency&#8217;s ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results, and costs of any product candidates that Frequency may derive from its PCA approach or any other product candidates Frequency may develop alone or with collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which Frequency <span style="white-space:nowrap">in-licenses</span> or acquires rights to other products, product candidates, or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or departures of key scientific or management personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and protecting Frequency&#8217;s intellectual property rights, and defending against any intellectual property-related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution for any product candidates for which Frequency or its collaborators obtain marketing approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time as Frequency can generate significant revenue from product sales, if ever, Frequency expects to finance its cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. To the extent that Frequency raises additional capital through the sale of equity or convertible debt securities, Frequency&#8217;s existing stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of Frequency common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Frequency&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Frequency raises additional funds through other sources, such as collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, Frequency may have to relinquish valuable rights to its technologies, future revenue streams, product development, and research programs or product candidates, or grant licenses on terms that may not be favorable to Frequency. If Frequency is unable to raise </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">343 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional funds when needed, Frequency may be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market products or product candidates that Frequency would otherwise prefer to develop and market itself.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_126">Critical accounting policies and use of estimates</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s management&#8217;s discussion and analysis of financial condition and results of operations is based on its audited consolidated financial statements and unaudited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of Frequency&#8217;s consolidated financial statements and related disclosures requires Frequency to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in Frequency&#8217;s consolidated financial statements. Frequency base its estimates on historical experience, known trends and events, and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Frequency evaluates its estimates and assumptions on an ongoing basis. Frequency&#8217;s actual results may differ from these estimates under different assumptions or conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s significant accounting policies are described in more detail in the notes to Frequency&#8217;s audited consolidated financial statements for the years ended December&#160;31, 2021 and 2022 and unaudited consolidated financial statements for the three months ended March&#160;31, 2022 and 2023 included elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_127">Recent accounting pronouncements</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recent accounting pronouncements that may potentially impact Frequency&#8217;s financial position, results of operations, or cash flows is disclosed in <span style="font-style:italic">Note 2</span> to Frequency&#8217;s unaudited consolidated financial statements for the three months ended March&#160;31, 2022 and 2023 included in this proxy statement/prospectus.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_128">Emerging growth company status</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act of 2012 permits an &#8220;emerging growth company,&#8221; such as Frequency, to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. Frequency has elected to take advantage of this extended transition period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_121">Frequency&#8217;s quantitative and qualitative disclosures about market risk </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is exposed to market risks in the ordinary course of its business. These risks primarily include interest rate sensitivities. Frequency&#8217;s interest-earning assets consist of cash, cash equivalents and marketable securities, which are denominated in U.S. dollars. Frequency had cash, cash equivalents and marketable securities of $83.1 million, or 69% of its total assets, at December&#160;31, 2022. Interest income earned on these assets was $1.3 million for the year ended December&#160;31, 2022. Frequency also had interest expense of $1.0 million on its term loan for the year ended December&#160;31, 2022. Frequency&#8217;s interest income and interest expense are sensitive to changes in the general level of interest rates, primarily U.S. interest rates. Such instruments carry a degree of interest rate risk; however, if a change by 10% in interest rates were to have immediately occurred on December&#160;31, 2022, such change would not have had a material impact on Frequency&#8217;s financial position or results of operations. Frequency had $10.0 million of current debt and $4.2 million non-current debt outstanding as of December&#160;31, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">344 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_129">KORRO BIO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion and analysis of Korro Bio&#8217;s financial condition and results of operations together with Korro Bio&#8217;s audited consolidated financial statements and related notes and unaudited condensed consolidated financial statements and related notes appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to Korro Bio&#8217;s plans and strategy for its business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this proxy statement/ prospectus, Korro Bio&#8217;s actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_130">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is a is a biopharmaceutical company creating transformative genetic medicines targeted to treat both rare and highly prevalent diseases. Korro Bio&#8217;s initial focus is to bring additional precision and tunability to genetic medicines by developing therapies based on editing RNA instead of DNA, which is expected to lead to an improved safety profile and increased clinical activity and specificity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is generating a portfolio of differentiated programs that harness the body&#8217;s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro Bio expects to bring its life changing medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The versatility of RNA editing combined with Korro Bio&#8217;s OPERA platform broadens the therapeutic target space significantly. While Korro Bio&#8217;s approach can be used to repair pathogenic SNVs, it can also engineer de novo SNVs and change amino acids on proteins to endow them with desired properties while preserving their broader functional capabilities. Korro Bio has demonstrated that single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate ion channels and activate kinases. These modification approaches can unlock validated target classes that have historically been difficult to drug, enabling Korro Bio to pursue a broad range of diseases traditionally out-of-scope for other genetic medicine approaches and current traditional drug modalities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s most advanced program is a product candidate for Alpha-1 Antitrypsin Deficiency, or AATD, where, using its proprietary RNA editing approach, it is repairing a pathogenic variant on RNA. Korro Bio&#8217;s product candidate has the potential to be disease-modifying and establish a new standard of care. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Korro Bio has focused primarily on organizing and staffing its company, business planning, raising capital, securing related intellectual property, and conducting research and development activities for its potential programs and product candidates. Since inception, Korro Bio has funded its operations primarily through the private placement of its equity securities. To date, Korro Bio has raised approximately $223.6&#160;million of aggregate gross proceeds from the sale of its convertible preferred stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has incurred significant operating losses since inception. Korro Bio&#8217;s net losses were $58.0&#160;million and $22.0&#160;million for the years ended December&#160;31, 2022 and 2021, respectively, and $19.6&#160;million and $13.6&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively. Korro Bio had an accumulated deficit of $121.4&#160;million as of March&#160;31, 2023. Korro Bio expects to continue to incur significant and increasing expenses and operating losses and negative operating cash flows for the foreseeable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">345 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future as it continues its research and development efforts, advances product candidates through clinical stages, and seeks regulatory approvals for its pipeline candidates. If the Merger is successful, Korro Bio also expects to incur additional costs associated with maintaining compliance with Nasdaq listing rules and the requirements of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company. Korro Bio&#8217;s net losses may fluctuate significantly from <span style="white-space:nowrap"><span style="white-space:nowrap">quarter-to-quarter</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">year-to-year,</span></span> depending on the timing of its preclinical studies, initiation and conduct of any clinical trials, and its expenditures on other research and development activities, including the expansion of its pipeline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio does not have any product candidates approved for sale and has not generated any revenue from product sales. Korro Bio will not generate revenue from product sales unless and until it successfully obtains regulatory approval for its product candidates, if ever, and as appropriate, moves pipeline candidates into the clinic and completes clinical development. Korro Bio has yet to commence clinical trials on any of its program candidates. If Korro Bio obtains regulatory approval for its product candidates and does not enter into third-party commercialization partnerships, it expects to incur significant expenses related to developing commercialization capabilities to support product sales, marketing, manufacturing and distribution activities. As a result, Korro Bio will need substantial additional funding to support its continuing operations and pursue its development and growth strategy. Until Korro Bio can generate significant revenue from product sales, if ever, Korro Bio expects to finance its operations through a combination of public or private offerings of securities, debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. Korro Bio may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Korro Bio&#8217;s failure to raise capital or enter into such agreements as, and when needed, could have a negative effect on its business, results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_131">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposed Merger&#160;&amp; Pre-Closing Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;14, 2023, Korro Bio entered into the Merger Agreement with Frequency and Merger Sub. Pursuant to the Merger Agreement, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Korro Bio, with Korro Bio continuing as a wholly owned subsidiary of Frequency and the surviving corporation of the Merger. The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. The Merger Agreement was approved by the members of the board of directors of both Korro Bio and Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the execution of the Merger Agreement, certain new and current investors agreed to purchase shares of common stock of Korro Bio at $2.78 per share for the aggregate amount of $117.3&#160;million. Completion of this Pre-Closing Financing is expected in the fourth quarter of 2023, is subject to approval by Frequency&#8217;s and Korro Bio&#8217;s stockholders of the Merger, and the satisfaction or waiver of certain other customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, (a)&#160;each outstanding share of Korro Bio common stock (including common stock issued upon the conversion of Korro Bio&#8217;s preferred stock and excluding the common stock issued in the Pre-Closing Financing) will be converted into the right to receive a number of shares of Frequency common stock equal to the Korro merger shares multiplied by the applicable stockholder&#8217;s percentage interest in Korro per the Merger Agreement (&#8220;Korro Merger Shares&#8221;); and (b)&#160;each then outstanding Korro Bio&#8217;s stock option will be converted into an option to acquire, on the same terms and conditions as prior to the closing of the Merger, the number of shares of Frequency common stock equal to the Korro option exchange ratio per the Merger Agreement (&#8220;Korro Option Exchange Ratio&#8221;). If any Korro Bio common stock outstanding immediately prior to the Effective Time is unvested or is subject to a repurchase option or a risk of forfeiture under any applicable agreement with Korro Bio, then the shares of Frequency common stock issued in exchange for such shares of Korro Bio common stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">346 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency common stock will be marked with appropriate legends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately after the Merger, Korro Bio&#8217;s former securityholders, including purchasers in the Pre-Closing Financing, as of immediately prior to the Merger are currently estimated to own approximately 92% of the outstanding shares of the combined company on a fully-diluted basis and securityholders of Frequency as of immediately prior to the Merger are currently estimated to own approximately 8% of the outstanding shares of the combined company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, (a)&#160;a valuation for Frequency equal to $25.0 million net cash as of the business day immediately prior to the closing date of the Merger, plus $15.0&#160;million and (b)&#160;a valuation for Korro Bio equal to $325.6&#160;million, plus the gross proceeds of the Pre-Closing Financing of $117.3 million, in each case as further described in the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_132">Financial Operations Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for Korro Bio&#8217;s research activities, including its discovery of novel genetic medicines and the development of its product candidates, salaries and benefits, and third-party license fees. Korro Bio expenses research and development costs as incurred, which include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation and other related costs for those employees involved in research and development efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">external research and development expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) as well as with consultants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">laboratory supplies and research materials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payments made under third-party licensing agreements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">direct and allocated expenses for facilities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to Korro Bio by its vendors and analyzing the progress of its preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s external research and development expenses consist primarily of fees paid to CROs and outside consultants in connection with its preclinical development activities. Its external research and development expenses also include fees incurred under license agreements. As a <span style="white-space:nowrap">pre-clinical</span> company, Korro Bio does not yet track these external research and development costs on a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> basis. Korro Bio plans to track program costs upon nomination of a development candidate or filing of an Investigational New Drug (&#8220;IND&#8221;) application. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio characterizes research and development costs incurred prior to the identification of a product candidate as discovery costs. Korro Bio uses internal resources primarily to conduct its research and discovery activities as well as for managing its preclinical development activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful development of Korro Bio&#8217;s product candidates is highly uncertain. Korro Bio plans to substantially increase its research and development expenses for the foreseeable future as it continues the development of its product candidates, conducts discovery and research activities for its preclinical programs, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">347 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and expands its pipeline. Korro Bio cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of its product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. Korro Bio anticipates that it will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and its ongoing assessments as to each product candidate&#8217;s commercial potential. Korro Bio&#8217;s clinical development costs are expected to increase significantly as it commences clinical trials. Korro Bio anticipates that its expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, rate of progress, and expenses of Korro Bio&#8217;s ongoing research activities as well as any preclinical studies, clinical trials and other research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing an appropriate safety profile with IND enabling studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful enrollment in and completion of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether Korro Bio&#8217;s product candidates show safety and efficacy in its clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">receipt of marketing approvals from applicable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making arrangements with third-party manufacturers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continued acceptable safety profile of products following any regulatory approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in the outcome of any of these variables with respect to the development of Korro Bio&#8217;s product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. Korro Bio may never succeed in achieving regulatory approval for any of its product candidates. Korro Bio may obtain unexpected results from its clinical trials. Korro Bio may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates. For example, if the U.S. Food and Drug Administration (&#8220;FDA&#8221;), European Medicines Agency (&#8220;EMA&#8221;) or another regulatory authority were to delay the planned start of clinical trials or require Korro Bio to conduct clinical trials or other testing beyond those that it currently expects or if Korro Bio experiences significant delays in enrollment in any planned clinical trial, it could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of employee related costs, including salaries, bonuses, benefits, stock-based compensation and other related costs for Korro Bio&#8217;s executive and administrative functions. General and administrative expenses also include professional services, including legal, accounting, auditing, tax services and other consulting fees. General and administrative expenses also include facility costs not otherwise included in research and development expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio anticipates that its general and administrative expenses will increase in the future as Korro Bio increases its headcount to support its continued research activities and development of its product candidates. Korro Bio also anticipates that it will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">348 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Income, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net primarily consists of interest income on Korro Bio&#8217;s short-term investments. For the year ended December&#160;31, 2021, Korro Bio also recorded a gain pertaining to a change in the fair value of the preferred stock tranche liability that was originally recognized in 2020 and subsequently extinguished in July 2021 in connection with the purchase of&#160;additional shares of Series A convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;) by existing investors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_133">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Three Months Ended March&#160;31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korro Bio&#8217;s results of operations for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:65%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months Ended<br />March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(in thousands)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 14,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 9,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 5,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,086</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,635</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,451</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,577</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,028</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korro Bio&#8217;s research and development expenses for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:69%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months Ended<br />March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(in thousands)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 3,646</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,499</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research and license fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab supplies&#160;&amp; consumables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $5.1&#160;million from $9.6&#160;million for the three months ended March&#160;31, 2022 to $14.7&#160;million for the three months ended March&#160;31, 2023. The increase in research and development expenses was primarily driven by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$2.5&#160;million of increased sponsored research and license fees primarily attributable to a $2.5&#160;million upfront cash payment made to a third-party in March 2023 upon execution of a collaboration and license agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.7&#160;million of increased personnel-related expenses driven by an increase in headcount to support the expansion of Korro Bio&#8217;s research and development function; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">349 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.7&#160;million of increased consulting costs to support overall growth in research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.5&#160;million of increased facilities-related costs primarily due to depreciation of lab equipment and the expansion of our <span style="white-space:nowrap">mixed-use</span> office spaces; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.5&#160;million of increased external research and development expense due to increased CRO support. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korro Bio&#8217;s general and administrative expenses for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months<br />Ended March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(in thousands)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">942</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">376</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $1.3&#160;million from $4.1&#160;million for the three months ended March&#160;31, 2022 to $5.4&#160;million for the three months ended March&#160;31, 2023. The increase in general and administrative expenses was primarily driven by $1.0&#160;million of increased professional service fees, including transactional legal fees, intellectual property costs, and strategy consulting costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Income, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net increased by $0.4&#160;million from $0.1&#160;million for the three months ended March&#160;31, 2022 to $0.5&#160;million for the three months ended March&#160;31, 2023. The increase in other income, net was primarily attributable to increased rates of return on Korro Bio&#8217;s short-term investments as a result of rising interest rates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Years Ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korro Bio&#8217;s results of operations for the years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(in thousands)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 42,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 23,805</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 18,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,108</td>
<td style="white-space:nowrap;vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(58,998</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,504</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">944</td>
<td style="white-space:nowrap;vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,537</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,561</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(58,022</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36,065</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(58,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,959</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36,073</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">350 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korro Bio&#8217;s research and development expenses for the years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:67%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(in thousands)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 8,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 5,818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab supplies&#160;&amp; consumables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research and license fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">376</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,805</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $18.4&#160;million from $23.8&#160;million for the year ended December&#160;31, 2021 to $42.2&#160;million for the year ended December&#160;31, 2022. The increase in research and development expenses was primarily attributable to the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$5.8&#160;million of increased external research and development expenses primarily attributable to increased oligonucleotide synthesis costs, screening and sequencing expenses and <span style="font-style:italic">in vivo</span> studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$3.8&#160;million of increased personnel-related expenses driven by an increase in headcount to support the expansion of Korro Bio&#8217;s research and development function; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$4.4&#160;million of increased lab supplies and consumables, primarily attributable to consumables purchased for screening and sequencing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$2.2&#160;million of increased facility-related expense due to the depreciation of lab equipment and leasehold improvements and the expansion of Korro Bio&#8217;s <span style="white-space:nowrap">mixed-use</span> office space; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.3&#160;million of increased consulting costs to support the overall growth in research and development activities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.8&#160;million of increased other research and development expenses, including lab maintenance, shipping fees and software licensing fees. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korro Bio&#8217;s general and administrative expenses for the years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(in thousands)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 8,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 6,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">607</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">351 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $5.1&#160;million from to $11.7&#160;million for the year ended December&#160;31, 2021 to $16.8&#160;million for the year ended December&#160;31, 2022. The increase in general and administrative expenses was primarily attributable to the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$2.7&#160;million of increased personnel-related expenses driven by an increase in headcount; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.3&#160;million of increased professional service fees primarily attributable to recruiting efforts and increased intellectual property legal fees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.6&#160;million of increased other general and administrative expense primarily attributable to increased software licensing fees and corporate expenses; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.5&#160;million of increased facilities expenses primarily attributable to the expansion of Korro Bio&#8217;s <span style="white-space:nowrap">mixed-use</span> office space. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Income, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total other income, net decreased by $12.5&#160;million from $13.5&#160;million for the year ended December&#160;31, 2021 to $1.0&#160;million for the year ended December&#160;31, 2022. This decrease was primarily attributable to the recognition of a $13.5&#160;million gain pertaining to a change in the fair value of the preferred stock tranche liability that was originally recognized in 2020 and subsequently extinguished in July 2021 in connection with the purchase of Series A Preferred Stock by existing investors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_134">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sources of Liquidity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since Korro Bio&#8217;s inception, it has generated recurring net losses. Korro Bio has not yet commercialized any product and it does not expect to generate revenue from sales of any products for several years, if at all. Since inception, Korro Bio has funded its operations primarily through proceeds from the issuance of convertible preferred stock. To date, Korro Bio has raised approximately $223.6&#160;million of aggregate gross proceeds from the sale of its convertible preferred stock. As of March&#160;31, 2023, Korro Bio had cash, cash equivalents and short-term investments of $79.5&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Going Concern </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has incurred significant operating losses since inception and, as of March&#160;31, 2023, had an accumulated deficit of $121.4&#160;million. In addition, Korro Bio expects to continue to incur significant expenses, operating losses, and negative operating cash flows for the foreseeable future. These factors raise substantial doubt about Korro Bio&#8217;s ability to continue as a going concern. Korro Bio believes that its current cash resources will not be sufficient to allow Korro Bio to fund current planned operations beyond the next twelve months from the date of this proxy statement/prospectus without additional capital. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio is seeking to complete a the Merger and the Pre-Closing Financing, as described in the notes to Korro Bio&#8217;s unaudited condensed consolidated financial statements included elsewhere in this proxy statement/prospectus. Upon the completion of the Merger and the Pre-Closing Financing, Korro Bio expects to have enough cash resources to funds its operating expenses and capital expenditure requirements at least into 2026. Korro Bio has based this estimate on assumptions that may prove to be wrong, and Korro Bio could expend its capital resources sooner than it expects. Korro Bio may also pursue additional cash resources through public or private equity, collaborations or debt financings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Funding Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio expects to continue to incur significant expenses, operating losses, and negative operating cash flows for the foreseeable future as Korro Bio continues its novel genetic medicine discovery efforts, advances its </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">352 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pipeline candidates into the clinic and through clinical trials, seeks regulatory approval of its product candidates and pursues commercialization of any approved product candidates. In addition, upon the completion of the proposed Merger, Korro Bio expects to incur additional costs associated with operating as a public company. Because of the numerous risks and uncertainties associated with research, development and commercialization of its product candidates, Korro Bio is unable to estimate the exact amount of its working capital requirements. Korro Bio&#8217;s future capital requirements will depend on many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of continuing to build Korro Bio&#8217;s Oligonucleotide Promoted Editing of RNA (&#8220;OPERA&#8221;) platform and discover additional novel genetic medicines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results, and costs of discovery, preclinical development, laboratory testing, manufacturing and clinical trials for the product candidates Korro Bio may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which Korro Bio partners its programs, acquires or <span style="white-space:nowrap">in-licenses</span> other product candidates and technologies or enters into additional collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of milestone and royalty payments that Korro Bio is required to make or eligible to receive under any future collaboration and license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korro Bio&#8217;s headcount growth and associated costs as it expands its research and development efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of expanding, maintaining and enforcing its intellectual property portfolio, including filing, prosecuting, defending and enforcing its patent claims and other intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against Korro Bio or any of its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidates for which Korro Bio receives marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of completion of commercial-scale manufacturing activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing technological and market developments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of operating as a public company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as Korro Bio can generate substantial product revenues to support its cost structure, Korro Bio expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations and other similar arrangements. To the extent that Korro Bio raises additional capital through the sale of equity or convertible securities, the ownership interest of its stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of its common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting Korro Bio&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Korro Bio raises funds through collaborations, or other similar arrangements with third parties, Korro Bio may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to it and/or may reduce the value of its common shares. If Korro Bio is unable to raise additional funds through equity or debt financings when needed, Korro Bio may be required to delay, limit, reduce or terminate its product research and development or grant rights to develop and market its product candidates even if it would otherwise prefer to develop and market such product candidates itself. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">353 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Three Months Ended March&#160;31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korro Bio&#8217;s cash flows for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months Ended<br />March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(in thousands)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,689</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,322</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 41,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(26,141</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Used in Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the three months ended March&#160;31, 2023 was $19.7&#160;million, compared to net cash used in operating activities of $12.8&#160;million for the three months ended March&#160;31, 2022. Cash used in operating activities increased by $6.9&#160;million primarily due to the overall increase in Korro Bio&#8217;s operating expenses during that same period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Provided by (Used in) Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities for the three months ended March&#160;31, 2023 was $15.5&#160;million, compared to net cash used in investing activities of $13.3&#160;million for the three months ended March&#160;31, 2022. This change of $28.8&#160;million was primarily due to increased proceeds from the maturities of investments and decreased purchases of investments during the three months ended March&#160;31, 2023 as compared to the three months ended March&#160;31, 2022 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Provided by (Used in) Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the three months ended March&#160;31, 2023 was $45.4&#160;million, compared to net cash used in financing activities of less than $0.1&#160;million for the three months ended March&#160;31, 2022. This change of $45.4&#160;million was primarily due to $45.5&#160;million of net cash proceeds received from the sale of Series <span style="white-space:nowrap">B-2</span> convertible preferred stock during the three months ended March&#160;31, 2023. No comparable proceeds were received from financing activities during the three months ended March&#160;31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Years Ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korro Bio&#8217;s cash flows for the years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(in thousands)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(53,645</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(32,094</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39,501</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(42,567</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 44,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">354 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Used in Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&#160;31, 2022 was $53.6&#160;million, compared to net cash used in operating activities of $32.1&#160;million for the year ended December&#160;31, 2021. Cash used in operating activities increased by $21.6&#160;million primarily due to the overall increase in Korro Bio&#8217;s operating expenses during that same period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Provided by (Used in) Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities for the year ended December&#160;31, 2022 was $11.1&#160;million, compared to net cash used in investing activities of $39.5&#160;million for the year ended December&#160;31, 2021. This change of $50.6&#160;million was primarily due to proceeds from the maturities of investments during the year ended December&#160;31, 2022 to which there were no comparable maturities during the year ended December&#160;31, 2021.<span style="font-weight:bold"> </span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Provided by Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the year ended December&#160;31, 2022 was less than $0.1&#160;million, compared to $115.9&#160;million for the year ended December&#160;31, 2021. Cash provided by financing activities decreased by $115.9&#160;million due to net cash proceeds received from the sale of Series A convertible preferred stock and Series <span style="white-space:nowrap">B-1</span> convertible preferred stock during the year ended December&#160;31, 2021. No comparable proceeds were received from financing activities during the year ended December&#160;31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_135">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United&#160;States. The preparation of these consolidated financial statements requires Korro Bio to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in its financial statements. Korro Bio bases its estimates on historical experience, known trends and events and various other factors that Korro Bio believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Korro Bio evaluates its estimates and assumptions on an ongoing basis. Korro Bio&#8217;s actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, Korro Bio evaluates its judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Korro Bio&#8217;s significant accounting policies are described in more detail in Note 2 to its audited consolidated financial statements and in Note 2 to its unaudited condensed consolidated financial statements both appearing elsewhere in this proxy statement/prospectus, Korro Bio believes that the following accounting policies are those most critical to the judgments and estimates used in the preparation of its consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Accrued Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing the consolidated financial statements, Korro Bio is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when Korro Bio has not yet been invoiced or otherwise notified of actual costs. The majority of Korro Bio&#8217;s service providers require advance payments; however, some providers invoice Korro Bio in arrears for services performed, on a <span style="white-space:nowrap">pre-determined</span> schedule or when contractual milestones are met. Korro Bio makes estimates of its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to it at that time. Korro Bio periodically confirms the accuracy of the estimates with the service providers and make adjustments if necessary. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">355 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio recognizes expenses related to preclinical studies and other studies on its estimates of the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and other studies on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to Korro Bio&#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, Korro Bio estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, Korro Bio adjusts the accrual or prepaid expense accordingly. Although Korro Bio does not expect its estimates to be materially different from amounts actually incurred, Korro Bio&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, Korro Bio has not made any material adjustments to its prior estimates of accrued research and development expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio recognizes stock-based compensation expense in an amount equal to the estimated grant date fair value of each stock-based payment, including stock options and restricted common stock, on a straight-line basis over the estimated period of service and vesting. This estimation of the fair value of each stock-based payment on the date of grant involves numerous assumptions by management. Although Korro Bio calculates the fair value under the Black-Scholes option-pricing model, which is a standard option pricing model, this model still requires the use of numerous estimates, including, the expected term of the award, the volatility of the underlying equity security, a risk-free interest rate, fair value of common stock, and expected dividends. The use of different values by management in connection with these estimates in the Black-Scholes option-pricing model could produce substantially different results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on Korro Bio&#8217;s stock-based payments, refer to Note 2 and Note 11 to its audited consolidated financial statements appearing elsewhere in this proxy statement/prospectus.<span style="font-weight:bold"> </span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_136"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio did not have during the periods presented, and does not currently have any <span style="white-space:nowrap">off-balance</span> sheet arrangements, as defined in the rules and regulations of the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom451428_137">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued and recently adopted accounting pronouncements applicable to Korro Bio&#8217;s financial position and results of operations is included in Note 2 to its audited consolidated financial statements and in Note 2 to its unaudited condensed consolidated financial statements both appearing elsewhere in this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">356 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_50a">MANAGEMENT FOLLOWING THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers and Directors of the Combined Company Following the Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company&#8217;s board of directors will initially be fixed at seven members, consisting of (i) four current Korro Bio board members, namely Ram Aiyar,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, (ii) two members to be determined by mutual agreement of the Frequency board designee and the Korro Bio board designees, namely&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, each of whom shall meet Nasdaq&#8217;s independence requirements, and (iii) one current Frequency board member, namely David L. Lucchino. The staggered structure of the current Frequency board of directors will remain in place for the combined company following the completion of the Merger. The Frequency board of directors has determined that each of the directors other than Ram Aiyar, David L. Lucchino and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; meet the Nasdaq independence requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table lists the names and ages, as of July&#160;14, 2023, and positions of the individuals who are expected to serve as executive officers and directors of the combined company upon completion of the Merger: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:39%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:54%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Age</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers:</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Aiyar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">45</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President, Chief Executive Officer and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vineet Agarwal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">41</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve Colletti</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">58</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Scientific Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Chappell</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Senior Vice President, Strategy and Portfolio Planning</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shelby Walker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">General Counsel</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Directors:</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">54</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Ram Aiyar, Ph.D., M.B.A.</span></span>&#160;Dr. Aiyar has served as Chief Executive Officer and as a director of Korro Bio since November 2020, and has served as its President since January 2022. Prior to joining Korro Bio, Dr. Aiyar co-founded Corvidia Therapeutics, Inc. and most recently served its as Chief Financial Officer from January 2020 to November 2020 and Executive Vice President, Corporate and Business Development from February 2016 to November 2020. Prior to that, Dr. Aiyar held leadership roles in corporate development, product development, management, research, finance and strategy at BeneVir BioPharma, Inc., BioHealth Innovation, Inc., FlowMetric, Inc., Sofinnova Partners, J.P. Morgan Chase and Johnson &amp; Johnson Pharmaceuticals (NYSE:JNJ). Dr. Aiyar is a co-founder and director of Protean Bio, Inc., a director of Triveni Bio, Inc. and a past director of Avidea Technologies, Inc.&#160;Dr. Aiyar holds an M.B.A. in finance and business strategy from INSEAD (France/Singapore), an M.S. in computer engineering and a Ph.D. in electrical and computer engineering from Drexel University, and a B.E. in electronics engineering from Mumbai University. Korro Bio believes Dr. Aiyar is qualified to serve on the board of directors of the combined company because of his significant operational and senior management experience in the biopharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Vineet Agarwal, M.B.A.</span></span> Mr. Agarwal has served as Chief Financial Officer of Korro Bio since May 2021. Prior to joining Korro Bio, Mr. Agarwal served as Executive Director, Biotech Investment Banking at J.P. Morgan Chase &amp; Co. from January 2019 until May 2021 and as Vice President, Biotech Investment Banking from January 2016 until January 2019. Mr. Agarwal previously served in numerous leadership roles at J.P. Morgan Chase &amp; Co. across different countries. Mr. Agarwal holds an M.B.A. from the Institute of Management Technology, India, and a Bachelor&#8217;s degree in finance from Shri Ram College of Commerce, India. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">357 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Steve Colletti, Ph.D.</span></span> Dr. Colletti has served as Chief Scientific Officer of Korro Bio since February 2023. Dr. Colletti most recently served as Senior Vice President of Drug Discovery Research and Development at Zymergen, Inc. from May 2021 to January 2023. Prior to this role, he served as Chief Scientific Officer of Lodo Therapeutics from March 2020 to May 2021 and as Senior Vice President, Head of Research and Development from September 2018 to March 2020. He previously held multiple leadership roles at Merck (NYSE:MRK), including in small molecule, natural products, oligonucleotide, peptide and fusion protein bioconjugate drug discovery, targeting programs in cardiovascular and respiratory disease, diabetes and obesity, immunological disorders, infectious diseases, neuroscience and oncology. Also at Merck, Dr. Colletti built and led the RNA Therapeutics Medicinal Chemistry department and was a core member of multiple development teams responsible for discovering more than a dozen preclinical candidates and advancing them to clinical development. Dr. Colletti is an inventor and author of over 130 patents and publications. Dr. Colletti holds a Ph.D. in chemistry from Boston University and a B.S. in chemistry from Loyola University, and was a National Institutes of Health postdoctoral fellow in chemistry at the Scripps Research Institute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Todd Chappell, M.B.A.</span></span> Mr. Chappell has served as Senior Vice President, Strategy and Portfolio Planning of Korro Bio since March 2021. Mr. Chappell most recently served as Chief Executive Officer of Rasio Therapeutics, Inc. from June 2019 until March 2021. Prior to this role, he served as Chief Executive Officer of Perceptive Navigation, LLC from June 2015 until May 2019. Mr. Chappell previously managed a portfolio of start-up pharmaceutical and medical device companies as an entrepreneur-in-residence at BioHealth Innovation, Inc. Prior to that, Mr. Chappell was a Vice President of Operations at Shape Pharmaceuticals, Inc., a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations for the development of a novel HDAC inhibitor for cutaneous t-cell lymphoma. Prior to this role, Mr. Chappell was an Executive Director of New Products at CombinatoRx, Inc., where he led the advancement of three programs from assay stage into human clinical studies. Mr. Chappell holds an M.B.A. from Boston University and a B.S. in biology from the University of California, Los Angeles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Shelby J. Walker, M.S., J.D.</span></span> Ms. Walker has served as Senior Vice President and General Counsel of Korro Bio since May 2023. Ms. Walker most recently served as Senior Vice President and Head of Intellectual Property at CRISPR Therapeutics (Nasdaq:CRSP) from March 2018 to April 2023. She previously served as General Counsel at Ginkgo Bioworks, a synthetic biology company, from May 2016 to March 2018. Prior to this role, she served as Vice President, Associate General Counsel and Chief Intellectual Property Counsel at Dyax Corporation, and previously held intellectual property leadership roles at Novo Nordisk (NYSE:NVO) and ZymoGenetics. Ms. Walker holds a J.D. and L.L.M. in intellectual property law from the University of New Hampshire School of Law, master&#8217;s degrees in biotechnology and regulatory science from Johns Hopkins University, and a B.S. in biotechnology from Worcester Polytechnic Institute. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">David L. Lucchino</span></span> has served as the President and Chief Executive Officer and a member of the Frequency board of directors since November 2014 and was a co-founder of Frequency with Dr. Robert S. Langer and Dr.&#160;Christopher R. Loose. From December 2014 until June 2016, Mr. Lucchino served as the President of Entrega Bio, a biotechnology company focused on oral drug delivery technology. Prior to that, Mr. Lucchino cofounded Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr. Lucchino oversaw the development of Semprus&#8217; lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr. Lucchino worked at the investment firm Polaris Partners. He started his biotech career by Co-Founding LaunchCyte, an investment firm where he was also a Managing Director. Mr. Lucchino is the past chairman of the board of directors of MassBio, a nonprofit organization that represents over 1,500 life science firms and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Massachusetts&#8217; Governor Charlie Baker as a member of the Commonwealth&#8217;s STEM Advisory Council. Mr.&#160;Lucchino also served as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility for fifteen </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">358 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of NOLS (The National Outdoor Leadership School). Mr. Lucchino holds an MBA from the Massachusetts Institute of Technology&#8217;s Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University. Mr. Lucchino is qualified to serve on the board of directors of the combined company because of his extensive management experience in the biotechnology and pharmaceutical industry. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Election of Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s executive officers are appointed by, and serve at the discretion of, Korro Bio&#8217;s board of directors. There are no family relationships among any of Korro Bio&#8217;s directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board of Directors of the Combined Company Following the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s board of directors currently consists of seven directors divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three-year term. The classified structure of the combined company board of directors will remain in place for the combined company following the completion of the Merger. It is anticipated that the incoming directors will be appointed to applicable vacant director seats of the combined company board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the proposed combined company directors and officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Committees of the Combined Company&#8217;s Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the completion of the Merger, the standing committees of the board of directors of the combined company will continue to be the following: audit committee, compensation committee and a nominating and corporate governance committee, and each will continue to operate pursuant to a charter, which is expected to be amended and restated by the combined company&#8217;s board of directors in connection with the completion of the Merger. The combined company&#8217;s board of directors may establish other committees from time to time to assist it and its board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company&#8217;s audit committee will oversee its corporate accounting and financial reporting process. Among other matters, the audit committee&#8217;s responsibilities will include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appointing, approving the compensation of, and assessing the independence of, the combined company&#8217;s independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">pre-approving</span> auditing and permissible <span style="white-space:nowrap">non-audit</span> services, and the terms of such services, to be provided by the combined company&#8217;s independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the overall audit plan with the combined company&#8217;s independent registered public accounting firm and members of management responsible for preparing the combined company&#8217;s financial statements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and the combined company&#8217;s independent registered public accounting firm the combined company&#8217;s annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by the combined company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">coordinating the oversight and reviewing the adequacy of the combined company&#8217;s internal control over financial reporting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">359 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending, based upon the audit committee&#8217;s review and discussions with management and the combined company&#8217;s independent registered public accounting firm, whether the combined company&#8217;s audited financial statements shall be included in the combined company&#8217;s Annual Report on <span style="white-space:nowrap">Form&#160;10-K;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">monitoring the integrity of the combined company&#8217;s financial statements and the combined company&#8217;s compliance with legal and regulatory requirements as they relate to the combined company&#8217;s financial statements and accounting matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparing the audit committee report required by SEC rules to be included in the combined company&#8217;s annual proxy statement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing all related person transactions for potential conflict of interest situations and approving all such transactions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing quarterly earnings releases. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Merger, the members of the audit committee are expected to be &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to be the chair of the audit committee and is a financial expert under the rules of the SEC. To qualify as independent to serve on the combined company&#8217;s audit committee, listing standards of Nasdaq and the applicable SEC rules require that a director not accept any consulting, advisory or other compensatory fee from the combined company, other than for service as a director, or be an affiliated person of the combined company. Frequency and Korro Bio believe that, following the completion of the Merger, the composition of the audit committee will comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company&#8217;s compensation committee will oversee policies relating to compensation and benefits of its officers and employees. Among other matters, the compensation committee&#8217;s responsibilities include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the compensation of the combined company&#8217;s Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating the performance of the combined company&#8217;s Chief Executive Officer in light of such corporate goals and objectives and, based on such evaluation, recommending to the board of directors the cash compensation of the combined company&#8217;s Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining the cash compensation of the combined company&#8217;s other executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing and administering the combined company&#8217;s compensation and similar plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">retaining and approving the compensation of any compensation advisors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the grant of equity-based awards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to the board of directors the compensation of the combined company&#8217;s directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparing the compensation committee report required by SEC rules, if and when required, to be included in the combined company&#8217;s annual proxy statement. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">360 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Merger, the members of the compensation committee are expected to be &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to be the chair of the compensation committee. Each member of the combined company&#8217;s compensation committee is expected to be a <span style="white-space:nowrap">&#8220;non-employee&#8221;</span> director within the meaning of Rule <span style="white-space:nowrap">16b-3</span> of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. Frequency and Korro Bio believe that, following the completion of the Merger, the composition of the compensation committee will comply with the applicable requirements of the rules and regulations of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance responsibilities will include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and recommending to the board of directors criteria for board and committee membership; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to advise the combined company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying individuals qualified to become members of the board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to the board of directors the persons to be nominated for election as directors and to each of the board&#8217;s committees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to the board of directors appropriate corporate governance guidelines; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing the evaluation of the board of directors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Merger, the members of the nominating and corporate governance committee are expected to be &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is expected be the chair of the nominating and corporate governance committee. Frequency and Korro Bio believe that, after the completion of the Merger, the composition of the nominating and corporate governance committee will meet the requirements for independence under, and the functioning of such nominating and corporate governance committee will comply with, any applicable requirements of the rules and regulations of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee Interlocks and Insider Participation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each member of the compensation committee will be a <span style="white-space:nowrap">&#8220;non-employee&#8221;</span> director within the meaning of <span style="white-space:nowrap">Rule&#160;16b-3</span> of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. None of the proposed combined company&#8217;s executive officers serves as a member of the board of directors or compensation committee of any entity that has one or more executive officers who is proposed to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Merger, Korro Bio did not have a formal policy to provide any cash or equity compensation to its <span style="white-space:nowrap">non-employee</span> directors for their service on its board of directors or committees of its board of directors, nor did any <span style="white-space:nowrap">non-employee</span> director receive any compensation for serving on Korro Bio&#8217;s board of directors, except for Dr.&#160;Bermingham who received an annual payment of $250,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with closing of the Merger, it is expected that the combined company will provide compensation to <span style="white-space:nowrap">non-employee</span> directors pursuant to a new non-employee director compensation policy that is expected to be adopted post-closing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">361 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_19">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;14, 2023, Frequency Therapeutics, Inc., a Delaware corporation, or Frequency, entered into an Agreement and Plan of Merger, or the Merger Agreement, with Korro Bio, Inc., a Delaware corporation, or Korro Bio, and Frequency Merger Sub, Inc.,&#160;a Delaware corporation and wholly owned subsidiary of Frequency, or Merger Sub. Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Korro Bio, with Korro Bio surviving the Merger as a wholly owned subsidiary of Frequency, or the Merger. The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time the certificate of merger is filed with and accepted by the Secretary of State of the State of Delaware, or the Effective Time, (i)&#160;each share of Korro Bio common stock will be converted into the right to receive a number of shares of Frequency common stock equal to the total number of shares of Frequency common stock to be issued in the Merger multiplied by the applicable Korro Bio stockholder&#8217;s percentage interest in Korro Bio as set forth in the allocation certificate to be provided by Korro Bio, or the Allocation Certificate, and (ii)&#160;each option to purchase shares of Korro Bio common stock outstanding as of immediately prior to the Effective Time shall automatically be converted, at the Effective Time, into an option to acquire the number of shares of Frequency common stock equal to the number of shares of Korro Bio common stock subject to such option as of immediately prior to the Effective Time multiplied by the exchange ratio formula in the Merger Agreement and rounding that result down to the nearest whole number of shares, and (iii)&#160;each warrant to purchase shares of Korro Bio common stock that is outstanding and unexercised as of immediately prior to the Effective Time and after giving effect to the automatic conversion of the Korro Bio preferred stock, will be converted into and become a warrant to purchase Frequency common stock, and Frequency will assume each Korro Bio warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the Merger, all then issued and outstanding shares of Korro Bio&#8217;s preferred stock will be automatically converted into shares of Korro Bio common stock, and no shares of Korro Bio preferred stock will be outstanding at the Effective Time. In addition, immediately prior to the Merger, Korro Bio is expected to issue approximately $117.3&#160;million of its common stock in the Pre-Closing Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securityholders of Frequency immediately prior to the Effective Time are expected to own approximately 8% of the aggregate number of outstanding shares of Frequency common stock immediately after the Effective Time, and the securityholders of Korro Bio immediately prior to the Effective Time are expected to own approximately 92% of the aggregate number of outstanding shares of Frequency common stock immediately after the Effective Time on a fully-diluted basis, subject to certain assumptions, including, but not limited to (a) a valuation for Frequency equal to its net cash as of the business day immediately prior to the closing date of the Merger, plus $15.0 million, (b) a valuation for Korro Bio equal to $325.6 million and (c) Korro Bio issuing approximately $117.3 million of Korro Bio common stock in the Pre-Closing Financing described elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for as a reverse recapitalization under United States Generally Accepted Accounting Principles, or U.S. GAAP. Korro Bio is considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger: (i)&#160;Korro Bio stockholders will own a substantial majority of the voting rights of the combined organization; (ii)&#160;Korro Bio will designate a majority (four of seven) of the initial members of the board of directors of the combined organization; and (iii)&#160;Korro Bio&#8217;s senior management will hold all key positions in senior management of the combined organization. The transaction is expected to be accounted for as a reverse recapitalization of Frequency by Korro Bio because on the effective date of the Merger, the <span style="white-space:nowrap">pre-combination</span> assets of Frequency are expected to be primarily cash and other <span style="white-space:nowrap">non-operating</span> assets. Korro Bio expects that any in process research and development assets potentially still remaining as of the combination will be de-minimis when compared to the cash and investments obtained through the transaction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">362 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of Korro Bio being treated as the accounting acquirer, Korro Bio&#8217;s assets and liabilities will be recorded at their <span style="white-space:nowrap">pre-combination</span> carrying amounts. Frequency&#8217;s assets and liabilities will be measured and recognized at their fair values, which are expected to approximate their carrying values as of the effective date of the Merger, and combined with the assets, liabilities, and results of operations of Korro Bio after the consummation of the Merger. As a result, upon consummation of the Merger, the historical financial statements of Korro Bio will become the historical consolidated financial statements of the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet data assumes that the Merger took place on March&#160;31, 2023, and combines the historical balance sheets of Frequency and Korro Bio as of such date. The unaudited pro forma condensed combined statements of operations and comprehensive loss for the three-month period ended March&#160;31, 2023 and for the year ended December&#160;31, 2022 assumes that the Merger took place as of January&#160;1, 2022 and combines the historical results of Frequency and Korro Bio for the period then ended. The unaudited pro forma condensed combined financial information was prepared pursuant to the rules and regulations of Article 11 of SEC Regulation <span style="white-space:nowrap">S-X.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information is provided for illustrative purposes only, does not necessarily reflect what the actual consolidated results of operations would have been had the acquisition occurred on the dates assumed and may not be useful in predicting the future consolidated results of operations or financial position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the closing of the Merger, will occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the combined company&#8217;s future results of operations and financial position. Differences between the preliminary estimates and final amounts will likely occur as a result of the amount of cash used for Frequency&#8217;s operations, changes in the fair value of Frequency common stock, or other changes in Frequency&#8217;s assets and liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited pro forma condensed combined financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this pro forma financial information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information, including the notes thereto, should be read in conjunction with the separate historical financial statements of Frequency and Korro Bio, and their respective management&#8217;s discussion and analysis of financial condition and results of operations included elsewhere in, or incorporated by reference to, this proxy statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting rules require evaluation of certain assumptions, estimates, or determination of financial statement classifications. The accounting policies of Frequency may materially vary from those of Korro Bio. During preparation of the unaudited pro forma condensed combined financial information, management has performed a preliminary analysis and is not aware of any material differences, and accordingly, this unaudited pro forma condensed combined financial information assumes no material differences in accounting policies. Following the acquisition, management will conduct a final review of Frequency&#8217;s accounting policies in order to determine if differences in accounting policies require adjustment or reclassification of Frequency&#8217;s results of operations or reclassification of assets or liabilities to conform to Korro Bio&#8217;s accounting policies and classifications. As a result of this review, management may identify differences that, when conformed, could have a material impact on these unaudited pro forma condensed combined financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">363 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Unaudited Pro Forma Condensed Combined Balance Sheets </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">As of March&#160;31, 2023 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:54%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Therapeutics,<br />Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Korro Bio,<br />Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br />Accounting<br />Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro</span><br /><span style="font-weight:bold">Forma<br />Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">77,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">A</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">235,636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,643</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">81,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">268,239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,829</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,942</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash, less current portion</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,541</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <span style="white-space:nowrap">non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">B</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">318,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">A,B,C,D</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current portion</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan, current portion</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48,252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">209,321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(209,321</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">E</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; equity (deficit):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">E,F,G</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">334,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">H</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">367,107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">G</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(281,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(121,438</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">275,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">I</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(126,820</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(118,231</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">305,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">240,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, and stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">318,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The accompanying notes are an integral part of this unaudited pro forma condensed combined financial information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">364 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Unaudited Pro Forma Condensed Combined Statement of Operations and Comprehensive Loss </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the Three Month Period Ended March&#160;31, 2023 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share data) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Therapeutics,<br />Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Korro Bio,<br />Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br />Accounting<br />Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro<br />Forma<br />Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,049</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,511</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,086</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(40,597</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">523</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(284</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(284</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">992</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,519</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39,124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax benefit (provision)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39,148</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on <span style="white-space:nowrap"><span style="white-space:nowrap">available-for-sale</span></span> investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">134</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,409</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,600</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39,009</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.09</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,324,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103,179,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">302,050,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold">K</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,553,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The accompanying notes are an integral part of this unaudited pro forma condensed combined financial information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">365 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Unaudited Pro Forma Condensed Combined Statement of Operations and Comprehensive Loss </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the Year Ended December&#160;31, 2022 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share data) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Therapeutics,<br />Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Korro Bio,</span><br /><span style="font-weight:bold">Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br />Accounting<br />Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro</span><br /><span style="font-weight:bold">Forma<br />Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,418</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">D,J</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92,942</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">D,J</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">147,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,002</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(58,998</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(147,382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(961</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,079</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,420</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(81,582</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(58,022</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(144,986</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax benefit (provision)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(81,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(58,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(144,994</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain (loss) on <span style="white-space:nowrap"><span style="white-space:nowrap">available-for-sale</span></span> investments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(136</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(134</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(81,716</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(58,030</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(145,128</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2.33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.56</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,075,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102,850,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">301,467,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">K</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">439,393,576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The accompanying notes are an integral part of this unaudited pro forma condensed combined financial information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">366 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">1.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Description of the Transaction </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Korro Bio, Frequency, and Merger Sub, Inc. have entered into the Merger Agreement, pursuant to which Merger Sub, a wholly owned subsidiary of Frequency, will merge with and into Korro Bio, with Korro Bio surviving as the surviving company. As a result of the Merger, Korro Bio will be a wholly owned subsidiary of Frequency. Upon the Effective Time, all shares of Korro Bio&#8217;s common stock (including Korro common stock issued upon the conversion of Korro Bio preferred stock prior to the Effective Time and in the <span style="white-space:nowrap">Pre-Closing</span> Financing, which is expected to close immediately prior to the Effective Time) outstanding and issuable upon exercise of outstanding warrants and option to purchase common stock immediately prior to the Effective Time will be converted into the right to receive approximately 439,676,069 shares of Frequency&#8217;s common stock, based on the estimated exchange ratio of 2.7731, which has not been adjusted to reflect the proposed Reverse Stock Split as it is not final. This exchange ratio is an estimate only and the final exchange ratio will be determined pursuant to the calculation of Korro Bio Merger Shares described in more detail in the Merger Agreement. If any Korro Bio common stock outstanding immediately prior to the Effective Time is unvested or is subject to a repurchase option or a risk of forfeiture under any applicable agreement with Korro Bio, then the shares of Frequency common stock issued in exchange for such shares of Korro Bio common stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency common stock will be marked with appropriate legends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Frequency will assume outstanding and unexercised options to purchase shares of Korro Bio capital stock, and in connection with the Merger they will be converted into options to purchase shares of Frequency Common Stock based on the exchange ratio formula in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Korro Bio estimates that the aggregate value of the consideration to be paid in the Merger will be approximately $26.4&#160;million. The fair value of consideration transferred is based on the number of common shares Frequency stockholders will own upon consummation of the Merger, multiplied by the closing price of Frequency common stock on July&#160;14, 2023, the most recent practicable date prior to the filing of this registration statement. The number and value of the shares of Frequency common stock to be issued pursuant to the Merger will not be determined until the completion of the Merger and therefore, the final aggregate value of the consideration paid in the Merger, may be more or less than $26.4&#160;million. The fair value of consideration transferred is not indicative of the combined entities enterprise value upon consummation of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At the Effective Time, each person who as of immediately prior to the Effective Time was a stockholder of record of Frequency or had the right to receive Frequency&#8217;s common stock will be entitled to receive a contractual contingent value right, or CVR, issued by Frequency subject to and in accordance with the terms and conditions of a Contingent Value Rights Agreement between Frequency, the holder&#8217;s representative and the Rights Agent, or the CVR Agreement, representing the contractual right to receive cash consideration from the post-closing combined company upon the receipt of certain proceeds from a disposition of Frequency&#8217;s <span style="white-space:nowrap">pre-merger</span> assets, calculated in accordance with the CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Consummation of the Merger is subject to certain customary closing conditions, including, among other things, approval by the Frequency stockholders and Korro Bio stockholders, the continued listing of the common stock on the Nasdaq, and the conversion of all Korro Bio preferred stock to common stock prior to the Effective Time. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">2.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Basis of Pro Forma Presentation </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with SEC Regulation <span style="white-space:nowrap">S-X</span> Article 11, or Article 11. The unaudited pro forma condensed combined statements of operations and comprehensive loss for the three-month period ended March&#160;31, 2023 and for the year ended December&#160;31, 2022, give effect to the Merger as if it had been consummated on January&#160;1, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">367 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2023 gives effect to the Merger and combines the historical balance sheets of Frequency and Korro Bio as of such date. Based on Korro Bio&#8217;s preliminary review of Korro Bio&#8217;s and Frequency&#8217;s summary of significant accounting policies and preliminary discussions between management teams of Korro Bio and Frequency, the nature and amount of any adjustments to the historical financial statements of Frequency to conform its accounting policies to those of Korro Bio are not expected to be material. Upon completion of the Merger, further review of Frequency&#8217;s accounting policies may result in additional revisions to Frequency&#8217;s accounting policies and classifications to conform to those of Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For accounting purposes, Korro Bio is considered to be the acquiring company and the Merger is expected to be accounted for as a reverse recapitalization of Frequency by Korro Bio because on the Merger date, the <span style="white-space:nowrap">pre-combination</span> assets of Frequency are expected to be primarily cash and other <span style="white-space:nowrap">non-operating</span> assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not give effect to the proposed Reverse Stock Split because the Reverse Stock Split is not final. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet does not reflect contingent consideration with respect to the CVR because the value of the corresponding <span style="white-space:nowrap">in-process</span> research and development assets cannot be reasonably estimated as of the date of this filing and the value is not expected to be material to Korro Bio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of these pro forma financial statements, the estimated purchase price consideration consists of the following (in thousands, except share and per share amounts): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated number of shares of the combined company to be owned by Frequency&#8217;s stockholders (i)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,926,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by the assumed price per share of Frequency&#8217;s common stock (ii)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated purchase price</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of Frequency equity awards based on <span style="white-space:nowrap">pre-combination</span> service (iii)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total estimated purchase price (iv)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the number of shares of common stock of the combined company that Frequency equity holders would own as of the closing pursuant to the Merger Agreement. This amount is calculated, for purposes of this unaudited pro forma condensed combined financial information, based on shares of Frequency&#8217;s common stock outstanding as of July&#160;14, 2023. The estimated number of shares does not reflect the impact of the reverse stock split that is expected to be effected prior to consummation of the Merger because the reverse stock split is not final. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the price per share of Frequency common stock, which is the closing trading price of Frequency&#8217;s common stock on July&#160;26, 2023, the most recent practicable date prior to the filing of this registration statement. The actual purchase price will fluctuate until the Effective Date of the transaction. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">368 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the estimated acquisition-date fair value of the assumed Frequency&#8217;s equity awards attributable to <span style="white-space:nowrap">pre-combination</span> service (which amount is determined based on the closing trading price of Frequency common stock on July&#160;14, 2023, the number of Frequency equity awards expected to be outstanding as of the Effective Time, and the estimated period of service provided by the holders of the awards prior to the Effective Time). The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the estimated acquisition-date fair value of the assumed Frequency&#8217;s equity awards: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:89%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The final purchase price arising from the number of shares of Frequency common stock and the fair market value of Frequency common stock outstanding, as well as the fair value of the Frequency equity awards, immediately prior to the closing of the Merger could result in a total purchase price different from that assumed in this unaudited pro forma condensed combined financial information, and that difference may be material. Therefore, the estimated purchase price expected to be transferred reflected in this unaudited pro forma condensed combined financial information does not purport to represent what the actual purchase price will be when the Merger is completed. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The actual purchase consideration for the net assets of Frequency will vary based on the net cash calculation prior to closing, the Exchange Ratio, and Frequency share price at closing as described above and that difference could be material. As such, the estimated purchase consideration reflected in these unaudited pro forma condensed combined financial information does not purport to represent what the actual purchase consideration will be when the Merger is completed. The actual purchase price will fluctuate until the closing date of the Merger, and the final valuation of the purchase consideration could differ significantly from the current estimate. Due to reverse recapitalization accounting, the changes in purchase price are not expected to have an impact on financial statements as any difference between purchase price and the net assets are recorded through equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Under reverse recapitalization accounting, the assets and liabilities of Frequency will be recorded, as of the completion of the Merger, at their fair value. Any difference between the consideration transferred and the fair value of the net assets of Frequency following determination of the actual purchase consideration for Frequency will be reflected as an adjustment to additional <span style="white-space:nowrap">paid-in</span> capital. Consequently, under reverse recapitalization accounting, the subsequent financial statements of Korro Bio will reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former stockholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. The accompanying unaudited proforma condensed combined financial information is derived from the historical financial statements of Frequency and Korro Bio and include adjustments to give pro forma effect to reflect the accounting for the transaction in accordance with U.S. GAAP. The historical financial statements of Korro Bio shall become the historical financial statements of the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Korro Bio and Frequency may incur significant costs associated with integrating the operations of Korro Bio and Frequency after the Merger is completed. The unaudited pro forma condensed combined financial information does not reflect the costs of any integration activities or benefits that may result from realization of future cost savings from operating efficiencies expected to result from the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information may differ from the final purchase accounting for a number of reasons, including the fact that the estimates of the fair values of Frequency net cash is preliminary and subject to change up to the closing date. The differences that may occur between the preliminary estimates and the final purchase accounting could have a material impact on the accompanying unaudited pro forma condensed combined financial information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">369 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">3.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Shares of Frequency Common Stock Issued to Korro Bio Stockholders upon closing of the Merger </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Prior to the Merger, all outstanding shares of Korro Bio&#8217;s preferred stock are expected to be converted into Korro Bio common stock, which will be exchanged for shares of Frequency common stock based on the exchange ratio determined in accordance with the Korro Bio Merger Shares formula described in the Merger Agreement. The estimated exchange ratio for purposes of the unaudited pro forma condensed combined financial information was derived on a fully-diluted basis as of July&#160;14, 2023 using a stipulated value of Korro Bio of approximately $325.6&#160;million, $117.3 million from the Pre-Closing Financing, and of Frequency of approximately $40.0&#160;million. The estimated number of shares of common stock that Frequency expects to issue (or reserve for issuance) to Korro Bio&#8217;s securityholders (ignoring rounding of fractional shares) is determined as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korro Bio common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,662,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korro Bio preferred stock convertible into Korro Bio common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,714,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korro Bio&#8217;s common stock issuable upon exercise of outstanding warrants and options to purchase common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,997,444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated shares of Korro common stock to be issued upon consummation of the <span style="white-space:nowrap">Pre-Closing</span> Financing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,176,255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Korro Bio common equivalent shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">158,550,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Exchange Ratio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.7731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated shares of Frequency common stock expected to be issued (or reserved for issuance) to Korro Bio stockholders upon closing of the Merger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">439,676,069</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated exchange ratio and estimated shares of Frequency common stock issued to Korro Bio&#8217;s securityholders have not been adjusted to give effect to the Reverse Stock Split because the Reverse Stock Split is not final. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">4.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Adjustments to Unaudited Pro Forma Condensed Combined Financial Statements </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Adjustments included in the column under the heading &#8220;Pro Forma Accounting Adjustments&#8221; are primarily based on information contained within the Merger Agreement. Further analysis will be performed after the completion of the Merger to confirm these estimates or make adjustments in the final purchase price allocation, as necessary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Given Korro Bio&#8217;s history of net losses and valuation allowance, management assumed a statutory tax rate of 0%. Therefore, the pro forma adjustments to the condensed combined statements of operations and comprehensive loss resulted in no additional income tax adjustment to the pro forma financials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma adjustments included in the unaudited pro forma condensed combined financial information are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">A.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect the cash proceeds of $117.3&#160;million from the sale and issuance of 42,176,255 shares of Korro Bio common stock at a purchase price of $2.78 per share pursuant to the Subscription Agreement entered in connection with the Pre-Closing Financing. Korro Bio expects to incur $6.2&#160;million of estimated direct and incremental transaction costs in connection with the Pre-Closing Financing, which are reflected as an increase to accrued liabilities. As the Merger will be accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets, primarily cash and investments, of Frequency, these direct and incremental costs are treated as a reduction of the proceeds received resulting in an adjustment to additional paid in capital of $111.1&#160;million. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">370 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">B.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect preliminary estimated transaction costs of $5.8&#160;million that are expected to be incurred by Korro Bio in connection with the Merger, such as legal fees, accounting expenses and consulting fees. Of this amount $0.2&#160;million of transaction costs were paid during the period ended March&#160;31, 2023, and are reflected in other current assets as of March&#160;31, 2023. The estimated transaction costs are reflected as a decrease to other current assets by $0.2&#160;million and an increase to accrued liabilities of $5.6&#160;million. As the Merger will be accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets, primarily cash and investments, of Frequency, these direct and incremental costs are treated as a reduction of the net proceeds received within additional <span style="white-space:nowrap">paid-in</span> capital. Note there are additional transaction costs related to the Pre-Closing Financing further discussed in tickmark A. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">C.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect preliminary estimated transaction costs of $4.2&#160;million that are expected to be incurred by Frequency in connection with the Merger, such as adviser fees, audit and legal fees, and printing fees, as an increase in accrued liabilities and accumulated deficit in the unaudited proforma condensed combined balance sheet. These expenses are not reflected in the proforma condensed combined income statement as they will not be recorded by Korro Bio as the accounting acquirer. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">D.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Compensation expense of $4.7&#160;million related to severance resulting from employment agreements entered into by Frequency in contemplation of the Merger is reflected as a <span style="white-space:nowrap">non-recurring</span> increase to accumulated deficit and accrued liabilities in the unaudited pro forma condensed combined balance sheet. In the unaudited pro forma condensed combined statement of operations and comprehensive loss for the year ended December&#160;31, 2022, $1.1&#160;million and $3.6&#160;million is reflected as research and development and general and administrative expense, respectively. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">E.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect the conversion of 97,714,516 shares of Korro Bio&#8217;s convertible preferred stock into shares of Korro Bio&#8217;s common stock immediately prior to the Merger on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-to-one</span></span> basis. The conversion of Korro Bio&#8217;s convertible preferred stock into common stock results in an increase of $0.1&#160;million common stock par value and an increase of $209.2&#160;million to additional <span style="white-space:nowrap">paid-in</span> capital. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">F.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect the exchange of 103,376,685 shares of Korro Bio&#8217;s common stock and 42,176,255 shares of Korro Bio common stock issued in the Pre-Closing Financing into 403,632,858 shares of Frequency&#8217;s common stock based on the assumed Exchange Ratio for purposes of these pro forma condensed combined financial information. The exchange of Korro Bio common stock for Frequency common stock results in an increase of $0.3&#160;million common stock par value and a decrease of $0.3&#160;million to additional <span style="white-space:nowrap">paid-in</span> capital. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">G.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect the elimination of Frequency&#8217;s historical equity, including 35,324,053 weighted-average outstanding shares of common stock at their par value of $0.001, $285.4&#160;million of accumulated deficit including Frequency&#8217;s estimated transaction costs of $4.2&#160;million, $334.5&#160;million additional <span style="white-space:nowrap">paid-in</span> capital, $0.1&#160;million of accumulated other comprehensive income for the period ended March&#160;31, 2023, and record the effect of the reverse recapitalization of Frequency for a total of $49.1&#160;million, which is the expected net assets of Frequency as of the time of the Merger. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-combination</span> Frequency additional <span style="white-space:nowrap">paid-in</span> capital:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Frequency additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(334,485</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <span style="white-space:nowrap">pre-combination</span> Frequency additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(334,485</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-combination</span> Frequency accumulated deficit:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frequency transaction costs (Note C)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Frequency accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">281,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <span style="white-space:nowrap">pre-combination</span> Frequency accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">285,379</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frequency common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frequency accumulated other comprehensive loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total adjustment to historical equity (net assets of Frequency)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(49,078</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">371 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">H.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The pro forma adjustments recorded to additional <span style="white-space:nowrap">paid-in</span> capital as noted above, include: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of <span style="white-space:nowrap">pre-combination</span> Frequency additional <span style="white-space:nowrap">paid-in</span> capital (Note G)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(334,485</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record purchase of Frequency historical net assets (Note G)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected transaction costs of Korro Bio (Note B)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,814</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Korro Bio common stock (Note F)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208,886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceleration of post-combination stock compensation expense (Note J)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">691</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Closing</span> Financing (Note A)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">111,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total adjustment to additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">I.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The pro forma adjustments recorded to accumulated deficit as noted above, include: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of historical Frequency accumulated deficit (Note G)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">285,379</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance costs of Frequency employees (Note D)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,691</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceleration of post-combination stock compensation expense (Note J)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(691</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frequency transaction costs (Note C)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,171</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total adjustment to accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">275,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">J.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect the non-recurring estimated stock-based of $0.7&#160;million, which is reflected as an increase in additional <span style="white-space:nowrap">paid-in</span> capital and accumulated deficit in the pro forma condensed combined balance sheet related to the acceleration of vesting upon the change of control and termination of employment for certain awards. In the unaudited pro forma condensed combined statement of operations and comprehensive loss for the year ended December&#160;31, 2022, $0.2&#160;million and $0.5&#160;million is reflected as research and development and general and administrative expense, respectively. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">372 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">K.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The pro forma combined basic and diluted earnings per share have been adjusted to reflect the pro forma net income for the year ended December&#160;31, 2022, and the three months ended March&#160;31, 2023. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company for the respective periods. As the combined organization is in a net loss position for both periods presented, any adjustment for potentially dilutive shares would be anti-dilutive, and as such basic and diluted loss per share are the same for both periods presented. The estimated number of shares does not reflect the impact of the Reverse Stock Split that is expected to be effected prior to consummation of the Merger because the Reverse Stock Split is not final. For the year ended December&#160;31, 2022, and the three-months ended March&#160;31, 2023, the pro forma weighted average shares outstanding has been calculated as follows: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">March&#160;31,<br />2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br />2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korro Bio weighted-average shares of common stock outstanding-basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,464,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,135,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of Korro Bio&#8217;s convertible preferred stock assuming conversion as of January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,714,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,714,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of the <span style="white-space:nowrap">Pre-Closing</span> Financing shares assuming consummation as of January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,176,255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,176,255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prior to exchange ratio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145,355,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145,026,325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application of estimated exchange ratio to historical Korro Bio weighted-average shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.7731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.7731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted Korro Bio weighted-average shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">403,084,788</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">402,172,502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Frequency weighted-average shares of common stock outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,324,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,075,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of Frequency common shares related to stock awards assuming accelerated vesting as of January 1, 2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,145,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,145,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total pro forma combined weighted average shares of common stock outstanding-basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,553,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">439,393,576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">373 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_139">FREQUENCY DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below identifies and sets forth certain biographical and other information regarding Frequency&#8217;s executive officers. There are no family relationships among any of the executive officers or directors. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:46%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Position(s)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">In</span><br /><span style="font-weight:bold">Current</span><br /><span style="font-weight:bold">Position</span><br /><span style="font-weight:bold">Since</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief&#160;Executive&#160;Officer,&#160;President&#160;and&#160;Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher R. Loose, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Scientific Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">David L. Lucchino</span></span> has served as Frequency&#8217;s President and Chief Executive Officer and a member of the Frequency board of directors since November 2014 and was a <span style="white-space:nowrap">co-founder</span> of Frequency with Dr.&#160;Robert&#160;S. Langer and Dr.&#160;Christopher&#160;R. Loose. From December 2014 until June 2016, Mr.&#160;Lucchino served as the President of Entrega Bio, a biotechnology company focused on oral drug delivery technology. Prior to that, Mr.&#160;Lucchino <span style="white-space:nowrap">co-founded</span> Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr.&#160;Lucchino oversaw the development of Semprus&#8217; lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr.&#160;Lucchino worked at the investment firm Polaris Partners. He started his biotech career by <span style="white-space:nowrap">Co-Founding</span> LaunchCyte, an investment firm where he was also a Managing Director. Mr.&#160;Lucchino is the past chairman of the board of directors of MassBio, a nonprofit organization that represents over 1,500 life science firms and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Massachusetts&#8217; Governor Charlie Baker as a member of the Commonwealth&#8217;s STEM Advisory Council. Mr.&#160;Lucchino also served as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility for fifteen years, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of NOLS (The National Outdoor Leadership School). Mr.&#160;Lucchino holds an MBA from the Massachusetts Institute of Technology&#8217;s Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Christopher R. Loose, Ph.D.</span></span> <span style="white-space:nowrap">co-founded</span> Frequency and has served as the Chief Scientific Officer since January 2016. Prior to Frequency, Dr.&#160;Loose <span style="white-space:nowrap">co-founded</span> Semprus with Mr.&#160;Lucchino and Dr.&#160;Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012. At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr.&#160;Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr.&#160;Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. From 2014 to 2021, Dr.&#160;Loose served as an Associate Professor Adjunct of Urology at the Yale School of Medicine and Executive Director of Yale University&#8217;s Center for Biomedical Innovation and Technology, and he continues to serve as a Lecturer in Yale School of Management. Dr.&#160;Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Governance Guidelines </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors has adopted Corporate Governance Guidelines. A copy of these Corporate Governance Guidelines can be found in the &#8220;<span style="font-style:italic">Corporate Governance&#8212;Governance Documents</span>&#8221; section of the &#8220;<span style="font-style:italic">Investors</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&amp; Media</span>&#8221; page of Frequency&#8217;s website located at<span style="font-style:italic"> www.frequencytx.com</span>, or by writing to the Corporate Secretary at 75 Hayden Avenue, Suite 300, Lexington, MA 02421. Among the topics addressed in the Corporate Governance Guidelines are: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Board size, independence and qualifications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Stock ownership</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Executive sessions of independent directors</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Board access to senior management</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Board leadership structure</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Board access to independent advisors</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">374 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Selection of new directors</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Board self-evaluations</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Director orientation and continuing education</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Board meetings</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Limits on board service</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Meeting attendance by directors and <span style="white-space:nowrap">non-directors</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Change of principal occupation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Meeting materials</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Term limits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&#160;Board&#160;committees,&#160;responsibilities&#160;and&#160;independence</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Director responsibilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Succession planning</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">- Director compensation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Risk management</p></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Corporate Governance Guidelines provide the Frequency board of directors with flexibility to combine or separate the positions of Chair of the Frequency board of directors and Chief Executive Officer in accordance with its determination that utilizing one or the other structure would be in the best interests of Frequency and the stockholders. If the Chair of the Frequency board of directors is a member of management or does not otherwise qualify as independent, the Corporate Governance Guidelines allow for the appointment by the independent directors of a lead independent director. The lead independent director&#8217;s responsibilities include, but are not limited to: presiding over all meetings of the Frequency board of directors at which the Chair of the Frequency board of directors is not present, including any executive sessions of the independent directors; approving Frequency board of directors meeting schedules and agendas; and acting as the liaison between the independent directors and the Chief Executive Officer and Chair of the Frequency board of directors. The Corporate Governance Guidelines provide that, at such times as the Chair of the Frequency board of directors qualifies as independent, the Chair of the Frequency board of directors will serve as lead independent director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency currently does not have a Chair of the Frequency board of directors. Mr.&#160;Barberich serves as Vice Chair of the Frequency board of directors, a position specified in the Amended and Restated Bylaws, and presides at all meetings of the Frequency board of directors and fulfills all duties that would be required of the Chair of the Frequency board of directors. Mr.&#160;Lucchino serves as the Chief Executive Officer and President. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors believes the current leadership structure of Chief Executive Officer and Vice Chair of the Frequency board of directors being held by two separate individuals is in the best interests of Frequency and its stockholders and strikes the appropriate balance between the Chief Executive Officer&#8217;s responsibility for the strategic direction, <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> leadership and performance of Frequency and the Vice Chair of the Frequency board of directors&#8217; responsibility to guide overall strategic direction of Frequency and provide oversight of the corporate governance and guidance to the Chief Executive Officer and to set the agenda for and preside over Frequency board of directors meetings. Frequency recognizes that different leadership structures may be appropriate for companies in different situations and believe that no one structure is suitable for all companies. Accordingly, the Frequency board of directors will continue to periodically review the leadership structure and make such changes in the future as it deems appropriate and in the best interests of Frequency and its stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Corporate Governance Guidelines and the Nasdaq Stock Market listing rules, the Nasdaq rules, a director is not independent unless the Frequency board of directors affirmatively determines that he or she does not have a direct or indirect material relationship with Frequency or any of Frequency&#8217;s subsidiaries. In addition, the director must meet the bright-line tests for independence set forth by the Nasdaq rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors has undertaken a review of its composition, the composition of its committees and the independence of its directors and considered whether any director has a material relationship with Frequency that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, the Frequency board of directors has </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">375 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined that none of Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang, Robert S. Langer, Sc.D., representing five of the five current directors, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors qualifies as &#8220;independent&#8221; as that term is defined under the Nasdaq rules. The Frequency board of directors also determined that Joel S. Marcus was independent during the time he served on the Frequency board of directors in 2022 and 2023. In making this determination, the Frequency board of directors considered the relationships that each <span style="white-space:nowrap">non-employee</span> director has with Frequency and all other facts and circumstances the Frequency board of directors deemed relevant in determining their independence, including the director&#8217;s beneficial ownership of Frequency common stock and the relationships of Frequency&#8217;s <span style="white-space:nowrap">non-employee</span> directors with certain of the significant stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Committees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors has established three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and the responsibilities described below. In addition, from time to time, special committees may be established under the direction of the Frequency board of directors when necessary to address specific issues. Each of the audit committee, the compensation committee and the nominating and corporate governance committee operates pursuant to a written charter. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:58%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Audit</span><br /><span style="font-weight:bold">Committee</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nominating</span><br /><span style="font-weight:bold">and</span><br /><span style="font-weight:bold">Corporate</span><br /><span style="font-weight:bold">Governance</span><br /><span style="font-weight:bold">Committee</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Compensation</span><br /><span style="font-weight:bold">Committee</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy J. Barberich</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Chair</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia L. Feldmann</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Chair</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Huang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Chair</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">X</td>
<td style="white-space:nowrap;vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer, Sc.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is responsible for, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appointing, approving the compensation of, and assessing the independence of the registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing the work of the registered public accounting firm, including through the receipt and consideration of reports from such firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and the registered public accounting firm the annual and quarterly financial statements and related disclosures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">coordinating the Frequency board of directors&#8217; oversight of the internal control over financial reporting, disclosure controls and procedures and Code of Business Conduct and Ethics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussing Frequency&#8217;s risk management policies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving or ratifying any related person transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">pre-approving</span> all audit and <span style="white-space:nowrap">non-audit</span> services provided to Frequency by the independent auditor (other than those provided pursuant to appropriate <span style="white-space:nowrap">pre-approval</span> policies established by the committee or exempt from such requirement under SEC rules); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing procedures for the receipt, retention and treatment of complaints received by Frequency regarding accounting, internal accounting controls or auditing matters, and for the confidential and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">376 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
anonymous submission by Frequency&#8217;s employees of concerns regarding questionable accounting or auditing matters and, more generally, suspected violations of the Code of Business Conduct and Ethics; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparing the audit committee report required by SEC rules. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee currently consists of Cynthia L. Feldmann, Timothy J. Barberich and Michael Huang, with Ms.&#160;Feldmann serving as chair. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All members of the audit committee meet the requirements for financial literacy under the applicable Nasdaq rules and regulations. The Frequency board of directors has affirmatively determined that each member of the audit committee qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s heightened standards and <span style="white-space:nowrap">Rule&#160;10A-3</span> of the Exchange Act, applicable to audit committee members, and that each member of the audit committee qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item&#160;407(d)(5) of <span style="white-space:nowrap">Regulation&#160;S-K.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee is responsible for, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving, or recommending for approval by the Frequency board of directors, the compensation of the Chief Executive Officer and the other executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing and administering Frequency&#8217;s cash and the Plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and making recommendations to the Frequency board of directors with respect to director compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing annually with management the &#8220;Compensation Discussion and Analysis,&#8221; to the extent required; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparing the annual compensation committee report required by SEC rules, to the extent required. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee may delegate its authority under its charter to one or more subcommittees as it deems appropriate from time to time as further described in its charter. The compensation committee may also delegate to one or more of the executive officers the authority to grant equity awards to certain employees, as further described in its charter and subject to the terms of the Plans and any such delegation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee currently consists of Timothy J. Barberich, Robert S. Langer, Sc.D., and Michael Huang, with Mr.&#160;Barberich serving as chair. The Frequency board of directors has determined that each of Mr.&#160;Barberich, Dr.&#160;Langer, and Mr.&#160;Huang qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s heightened standards applicable to compensation committee members and that Messrs. Barberich and Huang are each a <span style="white-space:nowrap">&#8220;non-employee</span> director&#8221; as defined in <span style="white-space:nowrap">Section&#160;16b-3</span> of the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee has established a <span style="white-space:nowrap">sub-committee</span> comprised of <span style="white-space:nowrap">&#8220;non-employee</span> directors,&#8221; who review and approve equity compensation for the executive officers. This <span style="white-space:nowrap">sub-committee</span> currently consists of Timothy J. Barberich and Michael Huang. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chief Executive Officer makes recommendations to the compensation committee regarding the compensation of Frequency&#8217;s executive officers. The compensation committee has the authority to retain or obtain the advice of compensation consultants, legal counsel and other advisors to assist in carrying out its responsibilities. Before selecting any such consultant, counsel or advisor, the compensation committee reviews and considers the independence of such consultant, counsel or advisor in accordance with applicable Nasdaq rules. Frequency must provide appropriate funding for payment of reasonable compensation to any advisor retained by the compensation committee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">377 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Consultant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with its authority to retain consultants and advisors described above, the compensation committee has engaged Pay Governance, LLC, or Pay Governance, to provide executive and director compensation consulting services to the compensation committee. In 2022, Pay Governance provided services to the compensation committee, which included providing information and data on current trends and developments in executive and director compensation, analyzing benchmarking data and evaluating Frequency&#8217;s peer group composition. Pay Governance reported directly to the compensation committee. However, certain of Frequency&#8217;s executive officers and other members of senior management consulted with Pay Governance with respect to assessments of executive and director compensation and related matters to be provided to the compensation committee. The compensation committee reviewed compensation assessments provided by Pay Governance comparing Frequency&#8217;s compensation to that of a group of peer companies within the industry and met with Pay Governance to discuss compensation of Frequency&#8217;s executive officers and to receive their input and advice. In addition to its consulting services related to the compensation and benefits of Frequency&#8217;s directors and officers in 2022, Pay Governance also provided benchmarking data related to the compensation and benefits of Frequency&#8217;s employees in 2022. The fees for this additional data in 2022 were less than $120,000. The compensation committee evaluated whether any of the work performed by Pay Governance during 2022 raised any conflict of interest and determined that it did not. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nominating and Corporate Governance Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee is responsible for, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying individuals qualified to become members of the Frequency board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to the Frequency board of directors the persons to be nominated for election as directors and to each committee of the Frequency board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and recommending to the Frequency board of directors corporate governance guidelines, and reviewing and recommending to the Frequency board of directors proposed changes to the corporate governance guidelines from time to time; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing a periodic evaluation of the Frequency board of directors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee currently consists of Michael Huang and Robert S. Langer, Sc.D., with Mr. Huang serving as chair. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Frequency Board of Directors and Committee Meetings and Attendance </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2022, the Frequency board of directors met twelve times, the audit committee met five times, the compensation committee met four times, and the nominating and corporate governance committee met three times. Four of the five incumbent directors attended at least 75% of the total of the meetings of the Frequency board of directors and the committees on which he or she served as a member during the year ended December&#160;31, 2022, except for Mr. Huang and Dr. Langer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Sessions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive sessions, which are meetings of the <span style="white-space:nowrap">non-management</span> members of the Frequency board of directors, are regularly scheduled throughout the year. In addition, at least twice a year, the independent directors meet in a private session that excludes management and any <span style="white-space:nowrap">non-independent</span> directors. At each of these meetings, the <span style="white-space:nowrap">non-management</span> and independent directors in attendance, as applicable, determine which member will preside at such session. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Attendance at Annual Meeting of Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency does not have a formal policy regarding the attendance of members of the Frequency board of directors at the annual meetings of stockholders, but Frequency expects all directors to make every effort to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">378 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attend any meeting of stockholders. Ms.&#160;Feldmann and Messrs. Barberich, Huang, Lucchino, and Marcus attended the Annual Meeting of Stockholders in 2022. Mr.&#160;Cohen did not attend the Annual Meeting of Stockholders in 2022 due to an illness. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Nominations Process </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee is responsible for recommending candidates to serve on the Frequency board of directors and its committees. In considering whether to recommend any particular candidate to serve on the Frequency board of directors or its committees or for inclusion in the Frequency board of directors&#8217; slate of recommended director nominees for election at an annual meeting of stockholders, the nominating and corporate governance committee considers the criteria set forth in the Corporate Governance Guidelines. Specifically, the nominating and corporate governance committee may take into account many factors, including: personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly held company; strong finance experience; relevant social policy concerns; experience relevant to Frequency&#8217;s industry; experience as a board member or executive officer of another publicly held company; relevant academic expertise or other proficiency in an area of Frequency&#8217;s operations; diversity of expertise and experience in substantive matters pertaining to Frequency&#8217;s business relative to other board members; diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience; practical and mature business judgment, including, but not limited to, the ability to make independent analytical inquiries; and any other relevant qualifications, attributes or skills. In determining whether to recommend a director for <span style="white-space:nowrap">re-election,</span> the nominating and corporate governance committee may also consider the director&#8217;s past attendance at meetings and participation in and contributions to the activities of the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency does not have a formal policy with regard to the consideration of diversity in identifying director nominees. The Frequency board of directors evaluates each individual in the context of the Frequency board of directors as a whole, with the objective of assembling a group that can best perpetuate the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In identifying prospective director candidates, the nominating and corporate governance committee may seek referrals from other members of the Frequency board of directors, management, stockholders and other sources, including third party recommendations. The nominating and corporate governance committee also may, but need not, retain a search firm in order to assist it in identifying candidates to serve as directors of Frequency. The nominating and corporate governance committee uses the same criteria for evaluating candidates regardless of the source of the referral or recommendation. When considering director candidates, the nominating and corporate governance committee seeks individuals with backgrounds and qualities that, when combined with those of the incumbent directors, provide a blend of skills and experience to further enhance the Frequency board of directors&#8217; effectiveness. In connection with its annual recommendation of a slate of nominees, the nominating and corporate governance committee also may assess the contributions of those directors recommended for <span style="white-space:nowrap">re-election</span> in the context of the Frequency board of directors evaluation process and other perceived needs of the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The director nominee to be elected at the Frequency Annual Meeting was recommended by the nominating and corporate governance committee, and evaluated in accordance with the standard review process for director candidates in connection with their initial appointment and their nomination for election at the Frequency Annual Meeting. When considering whether the directors and nominee have the experience, qualifications, attributes and skills, taken as a whole, to enable the Frequency board of directors to satisfy its oversight responsibilities effectively in light of the business and structure, the Frequency board of directors focused primarily on the experience described in each of the member&#8217;s biographical information set forth above. Frequency believes that the directors provide an appropriate mix of experience and skills relevant to the size and nature of the business. This process resulted in the Frequency board of directors&#8217; nomination of the incumbent director named in this proxy statement/prospectus and proposed for election by you at the Frequency Annual Meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">379 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee will consider director candidates recommended by stockholders, and such candidates will be considered and evaluated under the same criteria described above. Any recommendation submitted to Frequency should be in writing and should include any supporting material the stockholder considers appropriate in support of that recommendation, but must include information that would be required under the rules of the SEC to be included in a proxy statement/prospectus soliciting proxies for the election of such candidate and a written consent of the candidate to serve as one of Frequency&#8217;s directors if elected and must otherwise comply with the requirements under the Amended and Restated Bylaws for stockholders to recommend director nominees. Stockholders wishing to propose a candidate for consideration may do so by submitting the above information to the attention of the Corporate Secretary at Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, MA 02421. All recommendations for nominations received by the Corporate Secretary that satisfy the Amended and Restated Bylaws&#8217; requirements relating to such director nominations will be presented to the nominating and corporate governance committee for its consideration. Stockholders also must satisfy the notification, timeliness, consent and information requirements set forth in the Amended and Restated Bylaws. These timing requirements are also described under the caption &#8220;<span style="font-style:italic">Stockholder Proposals and Director Nominations</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Diversity Matrix </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below provides certain self-identified characteristics of the current directors, in accordance with Nasdaq Rule 5606. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:53%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" colspan="16" align="center"><span style="font-weight:bold">Board Diversity Matrix (As of July&#160;27, 2023)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total number of directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#160;</td>
<td colspan="13" style="vertical-align:bottom;white-space:nowrap">5</td>
<td style="vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Female</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Male</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">Non-Binary</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">Did&#160;Not&#160;Disclose&#160;Gender</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="16"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part I: Gender Identity</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="16"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part II: Demographic Background</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African American or Black</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaskan Native or Native American</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic or Latinx</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td colspan="13" style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Did Not Disclose Demographic Background</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td colspan="13" style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Role in Risk Oversight </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors has overall responsibility for risk oversight, including, as part of regular Frequency board of directors and committee meetings, general oversight of executives&#8217; management of risks relevant to Frequency. A fundamental part of risk oversight is not only understanding the material risks a company faces and the steps management is taking to manage those risks, but also understanding what level of risk is appropriate for Frequency. The involvement of the Frequency board of directors in reviewing the business strategy is an integral aspect of the Frequency board of directors&#8217; assessment of management&#8217;s tolerance for risk and its determination of what constitutes an appropriate level of risk for Frequency. While the Frequency board of directors has overall responsibility for risk oversight, it is supported in this function by its audit committee, compensation committee and nominating and corporate governance committee. Each of the committees regularly reports to the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee assists the Frequency board of directors in fulfilling its risk oversight responsibilities by periodically reviewing the accounting, reporting and financial practices, including the integrity of its financial </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">380 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements, the surveillance of administrative and financial controls, Frequency&#8217;s compliance with legal and regulatory requirements and its enterprise risk management program. Through its regular meetings with management, including the finance, legal, tax, compliance, and information technology functions, the audit committee reviews and discusses significant areas of the business and summarizes for the Frequency board of directors areas of risk and the appropriate mitigating factors. The compensation committee assists the Frequency board of directors by overseeing and evaluating risks related to Frequency&#8217;s compensation structure and compensation programs. The nominating and corporate governance committee assists the Frequency board of directors by overseeing and evaluating programs and risks associated with the independence of the Frequency board of directors and potential conflicts of interest. In addition, the Frequency board of directors receives periodic detailed operating performance reviews from management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committee Charters and Corporate Governance Guidelines </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporate Governance Guidelines, charters of the audit committee, compensation committee and nominating and corporate governance committee, and other corporate governance information are available in the &#8220;<span style="font-style:italic">Corporate Governance&#8212;Governance Documents</span>&#8221; section of the &#8220;<span style="font-style:italic">Investors</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&amp; Media</span>&#8221; page of Frequency&#8217;s website located at<span style="font-style:italic"> www.frequencytx.com</span>, or by writing to Frequency&#8217;s Corporate Secretary at the offices at 75 Hayden Avenue, Suite 300, Lexington, MA 02421. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has adopted a Code of Business Conduct and Ethics, or the Code of Conduct, that applies to all of the directors, officers and employees, including the principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. A copy of the Code of Conduct is available under the &#8220;<span style="font-style:italic">Corporate Governance&#8212;Governance Documents</span>&#8221; section of the &#8220;<span style="font-style:italic">Investors</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&amp; Media</span>&#8221; page of Frequency&#8217;s website located at<span style="font-style:italic"> www.frequencytx.com</span>, or by writing to Frequency&#8217;s Corporate Secretary at the offices at 75 Hayden Avenue, Suite 300, Lexington, MA 02421. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency intends to disclose on its website any amendment to, or waiver from, a provision of the Code of Conduct that applies to directors and executive officers and that is required to be disclosed pursuant to the rules of the SEC and the Nasdaq rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Hedging Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Frequency board of directors has adopted an Insider Trading Compliance Policy, which applies to all of the directors, officers and employees. The policy prohibits the directors, officers and employees from engaging in hedging or monetization transactions, such as <span style="white-space:nowrap">zero-cost</span> collars and forward sale contracts; short sales; and transactions in publicly traded options, such as puts, calls and other derivatives involving Frequency&#8217;s equity securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stockholder Communications with the Frequency Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any stockholder or any other interested party who desires to communicate with the Frequency board of directors, non-management directors or any specified individual director, may do so by directing such correspondence to the attention of Frequency&#8217;s Corporate Secretary at Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, MA 02421. The Corporate Secretary will forward the communication to the appropriate director or directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">381 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_141">FREQUENCY EXECUTIVE AND DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for Frequency&#8217;s executive officers who are named in the 2022 Summary Compensation Table below. In 2022, Frequency&#8217;s &#8220;named executive officers&#8221; and their positions were: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">David L. Lucchino, President and Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Carl P. LeBel, Former Chief Development Officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Christopher R. Loose, Chief Scientific Officer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;LeBel ceased to be an employee in March 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2022 Summary Compensation Table </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name and principal position</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br />awards<br />($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option</span><br /><span style="font-weight:bold">awards</span><br /><span style="font-weight:bold">($)(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-equity</span></span><br /><span style="font-weight:bold">incentive</span><br /><span style="font-weight:bold">plan</span><br /><span style="font-weight:bold">compensation</span><br /><span style="font-weight:bold">($)(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All other</span><br /><span style="font-weight:bold">compensation</span><br /><span style="font-weight:bold">($)(4)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">630,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,209,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">927,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">378,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,159,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">600,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,883,032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">324,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,821,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carl P. LeBel</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">480,344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">604,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">254,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192,138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,546,704</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former&#160;Chief Development Officer</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">461,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">286,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,831,138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">157,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,750,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher R. Loose Chief&#160;Scientific Officer</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">480,344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">604,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">226,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192,138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,518,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts represent the full grant date value of Frequency Restricted Stock Units issued during the given year, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. With respect to the Frequency Performance Stock Units, the grant date fair value is reported based on the probable outcome of the performance conditions as of the grant date, which is $0. The maximum potential value as of the grant date of the Frequency Performance Stock Units is $420,000 for Mr.&#160;Lucchino and $280,000 for Drs. LeBel and Loose. These amounts do not reflect the extent to which the named executive officer realized or will realize an actual financial benefit from the awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts represent the incremental fair value expensed in connection with the repricing of Frequency Options held by the named individual that was approved in August 2022, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts represent incentive compensation awarded in recognition of individual and company performance under Frequency&#8217;s annual incentive compensation program. Refer to &#8220;<span style="font-style:italic">2022 Bonuses</span>&#8221; below for additional information regarding 2022 awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts represent employer contributions to Frequency&#8217;s 401(k) plan for each of Frequency&#8217;s named executive officers. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative to 2022 Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s executive compensation program is designed to align compensation with business objectives and the creation of stockholder value, while also enabling Frequency to attract, motivate and retain individuals who contribute to its long-term success. For 2022, the compensation of Frequency&#8217;s named executive officers primarily consisted of a base salary, an annual cash incentive bonus opportunity, equity compensation in the form of Frequency Restricted Stock Units, and health and welfare benefits. Pursuant to their employment agreements, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">382 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
during 2022, Frequency&#8217;s named executive officers were also eligible to receive certain payments and benefits upon a termination of employment under certain circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2022 Salaries </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the named executive officers receives a base salary to provide a fixed component of compensation intended to reflect the executive&#8217;s skill set, experience, role and responsibilities. Annual base salaries are reviewed periodically by the compensation committee and the Frequency board of directors. Effective January&#160;1, 2022, the compensation committee approved an increase in the base salary for Mr.&#160;Lucchino from $600,000 to $630,000, for Dr.&#160;LeBel from $461,869 to $480,344, and for Dr.&#160;Loose from $461,869 to $480,344. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2022 Bonuses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency offers its named executive officers the opportunity to earn annual performance bonuses to compensate them for attaining short-term company and individual goals established by the Frequency board of directors. Each named executive officer has an established target annual performance bonus amount, expressed as a percentage of the named executive officer&#8217;s annual base salary. The target bonus amounts for Mr.&#160;Lucchino, Dr.&#160;LeBel, and Dr.&#160;Loose in 2022 were 60%, 40%, and 40%, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2023, the compensation committee evaluated the current named executive officers&#8217; performance against the relevant bonus goals and approved the amounts earned by Frequency&#8217;s named executive officers under Frequency&#8217;s annual bonus program for 2022 and included above in the 2022 Summary Compensation Table. Mr.&#160;Lucchino, Dr.&#160;LeBel, and Dr.&#160;Loose met their target bonus, earning amounts based on the performance of Frequency in 2022, as determined by the compensation committee. Specifically, the compensation committee considered, among other things, Frequency&#8217;s completion of enrollment in a Phase 2b study of <span style="white-space:nowrap">FX-322,</span> initiation of a Phase 1b study of <span style="white-space:nowrap">FX-345,</span> and progress in the preclinical program for remyelination in multiple sclerosis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Equity Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Frequency&#8217;s does not have a formal policy with respect to the grant of equity incentive awards to its executive officers, including Frequency&#8217;s named executive officers, or any formal equity ownership guidelines applicable to them, Frequency believes that equity grants provide its executive officers with a strong link to Frequency&#8217;s long-term performance, create an ownership culture and help to align the interests of its executive officers and its stockholders. In addition, Frequency believes that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes its executive officers to remain in Frequency&#8217;s employment during the vesting period. Accordingly, the Frequency board of directors periodically reviews the equity incentive compensation of its executives, including its named executive officers, and from time to time may grant equity incentive awards to them. To date, Frequency&#8217;s equity awards have been made in the form of Frequency Options, Frequency Restricted Stock Units, and Frequency Performance Stock Units. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&#160;31, 2022, Frequency granted Frequency Restricted Stock Units and Frequency Performance Stock Units to each of its named executive officers, as shown in more detail in the &#8220;<span style="font-style:italic">Outstanding Equity Awards at 2022 Fiscal <span style="white-space:nowrap">Year-End</span></span>&#8221; table below. The time-based restricted stock units were granted in February 2022 and consist of 300,000 restricted stock units granted to Mr.&#160;Lucchino, and 150,000 restricted stock units granted to each of Dr.&#160;LeBel and Dr.&#160;Loose. The Frequency Restricted Stock Units vest in one installment on July&#160;4, 2023, subject to the applicable executive&#8217;s continued employment with Frequency. The Frequency Performance Stock Units were granted in April 2022 and consist of 300,000 restricted stock units granted to Mr.&#160;Lucchino, and 200,000 restricted stock units granted to each of Drs. LeBel and Loose. The Frequency Performance Stock Units generally vest upon a determination by the Frequency board of directors of the completion of a bona fide, third-party security financing transaction in which Frequency receives gross proceeds of at least $25&#160;million that occurs on or before December&#160;31, 2023, subject to the applicable executive&#8217;s continued employment through such vesting date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">383 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on August&#160;17, 2022, the Frequency board of directors approved the repricing of all Frequency Options granted under the 2019 Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Frequency common stock on August&#160;17, 2022 by reducing the exercise price of each such Frequency Option to $2.14, the closing price per share of the Frequency common stock on August&#160;17, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Elements of Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Retirement Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency maintains a 401(k) retirement savings plan, or the 401(k) Plan, for its employees including its named executive officers, who satisfy certain eligibility requirements. Frequency&#8217;s named executive officers are eligible to participate in the 401(k) Plan on the same terms as other full-time employees. Under this plan, during 2022 Frequency matched 100% of the first 5% of participants&#8217; contributions. Frequency believes that providing a vehicle for <span style="white-space:nowrap">tax-deferred</span> retirement savings though its 401(k) Plan adds to the overall desirability of its executive compensation package and further incentivizes its employees, including its named executive officers, in accordance with its compensation policies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Health and Welfare Plans </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During their employment, Frequency&#8217;s named executive officers are eligible to participate in Frequency&#8217;s employee benefit plans and programs, including medical, dental and vision benefits, to the same extent as its other full-time employees, subject to the terms and eligibility requirements of those plans. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">384 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at 2022 Fiscal <span style="white-space:nowrap">Year-End</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:29%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="4" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br />Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br /><span style="font-weight:bold">securities</span><br /><span style="font-weight:bold">underlying</span><br /><span style="font-weight:bold">unexercised</span><br /><span style="font-weight:bold">Frequency<br />Options (#)</span><br /><span style="font-weight:bold">exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br /><span style="font-weight:bold">securities</span><br /><span style="font-weight:bold">underlying</span><br /><span style="font-weight:bold">unexercised</span><br /><span style="font-weight:bold">Frequency<br />Options (#)</span><br /><span style="font-weight:bold">unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Option</span><br /><span style="font-weight:bold">exercise</span><br /><span style="font-weight:bold">price ($)<br />(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Option<br />Expiration<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />of Shares<br />or Units<br />of Stock<br />that have<br />not<br />Vested(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market<br />Value of<br />Shares or<br />Units of<br />Stock that<br />have not<br />Vested ($)<br />(2)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/11/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,155,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,155,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/15/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/14/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/12/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">(6)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">176,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/11/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/2/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(7)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">565,576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">148,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/1/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/17/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(8)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">435,113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/16/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/17/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/16/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carl P. LeBel (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/11/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">770,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">577,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/15/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">(6)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/14/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/12/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">(7)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/11/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/2/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(8)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/1/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/17/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(9)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/16/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/17/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/16/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/12/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/11/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher R. Loose</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/11/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">770,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">577,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/15/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">(6)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,541</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/14/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/12/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">(7)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/11/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/2/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(8)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/1/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/17/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(9)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">353,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/16/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/17/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">128,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/16/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5/22/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">207,570</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5/21/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/29/2017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/28/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All Frequency Options issued under the 2019 Plan with an exercise price greater than $2.14 were repriced on August&#160;17, 2022 as approved by the Frequency board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Market value based on the closing price of the Frequency common stock as of December&#160;30, 2022 of $3.85 per share, the last trading day in 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;LeBel, Frequency&#8217;s former Chief Development Officer, terminated employment with Frequency on March&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Frequency Performance Stock Units vest in one installment upon a determination by the Frequency board of directors of the completion of a bona fide, third-party security financing transaction in which Frequency receives gross proceeds of at least $25&#160;million that occurs on or before December&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Frequency Restricted Stock Units vest in one installment on July&#160;4, 2023, subject to continued employment through the applicable vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Frequency Option vests in 48 equal monthly installments beginning on February&#160;1 of the year of grant, subject to continued employment through each applicable vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Frequency Option vests in 48 equal monthly installments beginning on February&#160;1 of the year of grant, subject to continued employment through each applicable vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Frequency Option vests in 48 equal monthly installments beginning November&#160;2 of the year of grant, subject to continued employment through each applicable vesting date. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">385 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Frequency Option vests in 48 equal monthly installments beginning on February&#160;1 of the year of grant, subject to continued employment through each applicable vesting date. The Frequency Option vests in full in the event of a change in control. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Compensation Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Mr.&#160;Lucchino </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency entered into a second amended and restated executive employment agreement with Mr.&#160;Lucchino on September&#160;20, 2019, pursuant to which Frequency employs Mr.&#160;Lucchino as its President and Chief Executive Officer. The employment agreement also provides for Mr.&#160;Lucchino to serve as a member of the Frequency board of directors for as long as he is employed as its Chief Executive Officer. The employment agreement has an indefinite term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment agreement provides for an annual base salary of $525,000, which was increased to $630,000 effective January&#160;1, 2022, and for a target annual performance bonus equal to 55%, which was increased to 60% effective January&#160;1, 2021, of Mr.&#160;Lucchino&#8217;s annual base salary to be based on the attainment of predetermined performance objectives agreed upon between Mr.&#160;Lucchino and the Frequency board of directors. In the event of certain corporate transactions, including a <span style="white-space:nowrap">spin-off</span> of assets or a restructuring, Mr.&#160;Lucchino is entitled to the same relative ownership percentage in the resulting entity or entities as he had in Frequency immediately before the corporate transaction. If a &#8220;change in control&#8221; (as such term is defined in his employment agreement) occurs, all of Mr.&#160;Lucchino&#8217;s time-based equity awards will accelerate and vest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Frequency terminates Mr.&#160;Lucchino&#8217;s employment without &#8220;cause&#8221;, he resigns for &#8220;good reason&#8221; or his employment terminates as a result of &#8220;disability&#8221; (as such terms are defined in the employment agreement) or death, subject to his execution and <span style="white-space:nowrap">non-revocation</span> of a release in favor of Frequency, he is entitled to receive the following termination payments: (i)&#160;twelve months&#8217; base salary, (ii) 100% of his target annual bonus and (iii)&#160;a <span style="white-space:nowrap">pro-rated</span> portion of his annual target bonus based on the portion of the year he was employed. The payments under clauses (i)-(iii) are payable in a single lump sum on the first payroll date following the 60th day after his termination of employment. Mr.&#160;Lucchino may also receive up to twelve months&#8217; continued coverage, at Frequency&#8217;s expense, under COBRA, if he elects such continued coverage. In addition to the termination payments, all time-based equity awards granted to Mr.&#160;Lucchino will accelerate and vest as to the number of shares that would have vested had he remained employed for an additional six months following his date of termination. If such a qualifying termination occurs following a &#8220;change in control&#8221;, subject to his execution and <span style="white-space:nowrap">non-revocation</span> of a release, Mr.&#160;Lucchino will be entitled to receive the same termination payments except (i)&#160;the severance payment will be equal to eighteen months&#8217; base salary and (ii)&#160;all equity awards held by Mr.&#160;Lucchino will accelerate and vest (including performance vesting awards, which will vest at target level of achievement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Lucchino is also party to restrictive covenant agreements, pursuant to which he has agreed to refrain from competing with Frequency or soliciting its customers or employees during his employment and for one year following termination of his employment and from disclosing Frequency&#8217;s proprietary information during or at any time following his employment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dr. LeBel </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency entered into an employment agreement with Dr.&#160;LeBel on September&#160;19, 2019, pursuant to which Frequency employed Dr.&#160;LeBel as its Chief Development Officer. The employment agreement for Dr.&#160;LeBel provided for an annual salary of $425,000, which was increased to $480,344 effective January&#160;1, 2022, with a target annual performance bonus equal to 40% of his base salary based on the attainment of predetermined individual and company performance objectives determined by the Frequency board of directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">386 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dr.&#160;LeBel&#8217;s employment agreement, if Frequency terminated Dr.&#160;LeBel&#8217;s employment without &#8220;cause&#8221; or he resigned for &#8220;good reason&#8221; (as such terms were defined in the employment agreement), subject to his execution and <span style="white-space:nowrap">non-revocation</span> of a release in favor of Frequency, he was entitled to receive the following termination payments: (i)&#160;twelve months&#8217; continued base salary in equal installments following his termination, (ii) 100% of his target annual bonus paid in a lump sum within 14 days following his execution of the release and (iii)&#160;if he makes an election, up to twelve months continued coverage under COBRA, with Frequency paying the same portion of the COBRA premiums as it pays for active employees. If such a qualifying termination occurred within 12 months following a &#8220;change in control&#8221; (as defined in his employment agreement), Dr.&#160;LeBel&#8217;s equity awards would accelerate and vest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;LeBel is party to restrictive covenant agreements, pursuant to which he agreed to refrain from competing with Frequency or soliciting its customers or employees during his employment and for one year following termination of his employment and from disclosing Frequency&#8217;s proprietary information during or at any time following his employment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;23, 2023, Frequency entered into a separation agreement with Dr.&#160;LeBel pursuant to which, in exchange for a general release of claims in favor of Frequency and its affiliates, he is entitled to receive the severance payments and benefits provided under his employment agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dr.&#160;Loose </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency entered into an amended and restated employment agreement with Dr.&#160;Loose on September&#160;20, 2019, pursuant to which Frequency employs Dr.&#160;Loose as its Chief Scientific Officer. The employment agreement has an indefinite term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment agreement for Dr.&#160;Loose provides for an annual base salary of $425,000, which was increased to $480,344 effective January&#160;1, 2022, and a target annual performance bonus equal to 40% of his base salary, and is based on the attainment of predetermined individual and company performance objectives agreed upon between Dr.&#160;Loose and Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event Frequency terminates Dr.&#160;Loose&#8217;s employment without &#8220;cause&#8221; or he resigns for &#8220;good reason&#8221; (as such terms are defined in the employment agreement), subject to his execution and <span style="white-space:nowrap">non-revocation</span> of a release in favor of Frequency, he is entitled to receive the following termination payments: (i)&#160;twelve months&#8217; continued base salary in equal installments following his termination, (ii) 100% of his target annual bonus paid in a lump sum within fourteen days following his execution of the release and (iii)&#160;if he makes an election, up to twelve months continued coverage under COBRA, with Frequency paying the same portion of the COBRA premiums as it pays for active employees. If such a qualifying termination occurs within twelve months following a &#8220;change in control&#8221; (as defined in his employment agreement), Dr.&#160;Loose&#8217;s equity awards will accelerate and vest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Loose is party to restrictive covenant agreements, pursuant to which he has agreed to refrain from competing with Frequency or soliciting its customers or employees during his employment and for one year following termination of his employment and from disclosing Frequency&#8217;s proprietary information during or at any time following his employment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective on the initial public offering of Frequency common stock in October 2019, Frequency adopted and its stockholders approved a compensation program for Frequency&#8217;s <span style="white-space:nowrap">non-employee</span> directors under which each <span style="white-space:nowrap">non-employee</span> director receives the following amounts for their services on the Frequency board of directors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an option to purchase 29,693 shares of Frequency common stock upon the director&#8217;s initial election or appointment to the Frequency board of directors, </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">387 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the director has served on the Frequency board of directors for at least six months as of the date of an annual meeting of stockholders, an option to purchase 14,846 shares of Frequency common stock on the date of the annual meeting, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an annual director fee of $35,000, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the director serves on a committee of the Frequency board of directors or in the other capacities stated below, an additional annual fee as follows: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">chairman of the board, vice chairman of the board, or lead independent director, $30,000 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">chairman of the audit committee, $15,000, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">audit committee member other than the chairman, $7,500, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">chairman of the compensation committee, $10,000, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compensation committee member other than the chairman, $5,000, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">chairman of the nominating and corporate governance committee, $8,000, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">nominating and corporate governance committee member other than the chairman, $4,000. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency Options granted to Frequency&#8217;s <span style="white-space:nowrap">non-employee</span> directors under the program have an exercise price equal to the fair market value of Frequency common stock on the date of grant and expire not later than ten years after the date of grant. The Frequency Options granted upon a director&#8217;s initial election or appointment vest in 36 substantially equal monthly installments following the date of grant. The Frequency Options granted annually to directors vest in a single installment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvested Frequency Options vest in full upon the occurrence of a change in control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Director fees under the program are payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar quarter, provided that the amount of each payment is prorated for any portion of a quarter that a director is not serving as <span style="white-space:nowrap">non-employee</span> member of the Frequency board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Lucchino, Frequency&#8217;s President and Chief Executive Officer, serves on the Frequency board of directors but does not receive additional compensation for his service as a director. Refer to the discussion of named executive officer compensation elsewhere in this section for information regarding Mr.&#160;Lucchino&#8217;s 2022 compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2022 Director Compensation Table </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:59%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees</span><br /><span style="font-weight:bold">earned</span><br /><span style="font-weight:bold">or paid</span><br /><span style="font-weight:bold">in cash</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Option</span><br /><span style="font-weight:bold">($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All other</span><br /><span style="font-weight:bold">compensation&#160;($)(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc A. Cohen (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy J. Barberich</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Huang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia L. Feldmann</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts represent the full grant date fair value of Frequency Options issued during 2022, computed in accordance with ASC Topic 718, and the incremental fair value expensed in connection with the repricing of Frequency Options held by the Frequency directors that was approved in August 2022, computed in </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">388 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. The assumptions used to calculate the grant date fair value of all Frequency Options made to the Frequency directors are set forth in the financial statements included in this proxy statement/prospectus. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts represent consulting fees paid pursuant to a verbal consulting agreement with Frequency. The agreement entitles Dr.&#160;Langer to $5,000 in consulting fees per month until it is terminated either by Frequency upon six months&#8217; notice or by Dr.&#160;Langer upon 30 days&#8217; notice. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Cohen&#8217;s term on our Board of Directors ended in June 2022. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the aggregate numbers of Frequency Options held as of December&#160;31, 2022 by each <span style="white-space:nowrap">non-employee</span> director who served on the Frequency board of directors in 2022. None of Frequency&#8217;s <span style="white-space:nowrap">non-employee</span> directors held unvested restricted shares as of December&#160;31, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Options</span><br /><span style="font-weight:bold">outstanding&#160;at</span><br /><span style="font-weight:bold">fiscal&#160;year&#160;end</span><br /><span style="font-weight:bold">(exercisable)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Options</span><br /><span style="font-weight:bold">outstanding&#160;at</span><br /><span style="font-weight:bold">fiscal&#160;year&#160;end</span><br /><span style="font-weight:bold">(unexercisable)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc A. Cohen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124,745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">372,234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy J. Barberich</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102.141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Huang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joel S. Marcus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia L. Feldmann</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2022 Equity Compensation Plan Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information on Frequency equity compensation plans as of December&#160;31, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Plan Category</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br /><span style="font-weight:bold">Securities to</span><br /><span style="font-weight:bold">be Issued</span><br /><span style="font-weight:bold">Upon</span><br /><span style="font-weight:bold">Exercise of</span><br /><span style="font-weight:bold">Outstanding</span><br /><span style="font-weight:bold">Frequency<br />Options,</span><br /><span style="font-weight:bold">Warrants</span><br /><span style="font-weight:bold">and Rights</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Weighted-</span><br /><span style="font-weight:bold">Average</span><br /><span style="font-weight:bold">Exercise</span><br /><span style="font-weight:bold">Price of</span><br /><span style="font-weight:bold">Outstanding</span><br /><span style="font-weight:bold">Frequency<br />Options,</span><br /><span style="font-weight:bold">Warrants,</span><br /><span style="font-weight:bold">and Rights</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br /><span style="font-weight:bold">Securities</span><br /><span style="font-weight:bold">Available<br />for</span><br /><span style="font-weight:bold">Future</span><br /><span style="font-weight:bold">Issuance</span><br /><span style="font-weight:bold">Under the</span><br /><span style="font-weight:bold">Plans</span><br /><span style="font-weight:bold">(excludes</span><br /><span style="font-weight:bold">securities</span><br /><span style="font-weight:bold">Reflected<br />in</span><br /><span style="font-weight:bold">first<br />column)</span><br /><span style="font-weight:bold">(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,843,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,213,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,843,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,213,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pursuant to the terms of the 2019 Plan, the number of shares of common stock available for issuance under the 2019 Plan automatically increases on each January&#160;1 until and including January&#160;1, 2029, by an amount equal to the lesser of: (a) 4% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b)&#160;such smaller number of shares as is determined by the Frequency board of directors. Pursuant to the terms of the Frequency ESPP, the number of shares of common stock available for issuance under the Frequency ESPP automatically increases on each January&#160;1 until and including January&#160;1, 2029, by an amount equal to the lesser of: (a) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b)&#160;such smaller number of shares as is determined by the Frequency board of directors. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">389 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of the 2014 Plan, the 2019 Plan, and the Frequency ESPP. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 2,477,586 outstanding Frequency Options to purchase shares of common stock under the 2014 Plan, 3,264,467 outstanding Frequency Options to purchase common stock under the 2019 Plan and 3,101,650 Frequency Restricted Stock Units under the 2019 Plan, which includes 1,150,000 shares representing the maximum number of shares that may be issued subject to Frequency Performance stock Units under the 2019 Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December&#160;31, 2022, the weighted-average exercise price of outstanding Frequency Options under the 2014 Plan was $2.51 and the weighted-average exercise price per share of outstanding Frequency Options under the 2019 Plan was $2.22. Frequency Restricted Stock Units do not have an exercise price and were not included in calculating weighted average exercise prices. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December&#160;31, 2022, a total of 2,213,743 shares of common stock were available for issuance, consisting of (a) 1,225,527 shares of common stock available for future issuance under the Frequency ESPP, none of which shares were subject to outstanding purchase rights under the Frequency ESPP, and (b) 988,216 shares of common stock available for future issuance under the 2019 Plan. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">390 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_142">KORRO BIO EXECUTIVE AND DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2022 Director Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation for each person who served as a non-employee director of the Korro Bio board of directors during 2022. Dr. Aiyar, Korro Bio&#8217;s Chief Executive Officer and President, did not receive any additional compensation from Korro Bio for his services on the Korro Bio board of directors. The compensation received by Dr. Aiyar as a named executive officer, or NEO, of Korro Bio is set forth below in &#8220;<span style="font-style:italic">Executive Compensation Prior to the Merger&#8212;2022 Summary Compensation Table.</span>&#8221; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees&#160;Paid<br />or&#160;Earned<br />in Cash<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nessan Bermingham(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ali Behbahani(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hannah Chang(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Francois Formela(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omar Khwaja(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Colin Walsh(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr. Bermingham&#8217;s cash fees are paid for his services as Chairman of the Korro Bio board of directors. As of December 31, 2022, Dr. Bermingham held options to purchase 1,349,645 shares of Korro Bio&#8217;s common stock and 202,150 shares of Korro Bio&#8217;s restricted stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December 31, 2022, none of Dr. Behbahani, Dr. Chang, Dr. Formela or Dr. Walsh held any outstanding equity awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr. Khwaja&#8217;s cash fees are paid for his services on the Korro Bio board of directors. As of December 31, 2022, Dr. Khwaja held options to purchase 75,000 shares of Korro Bio&#8217;s common stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Executive</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Compensation</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Prior</span><span style="font-weight:bold"> </span><span style="font-weight:bold">to</span><span style="font-weight:bold"> </span><span style="font-weight:bold">the</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Merger</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, any reference in this section of this proxy statement/prospectus to &#8220;Korro Bio&#8221; refers to Korro Bio and its consolidated subsidiaries prior to the consummation of the Merger and to Korro Bio and its consolidated subsidiaries following the Merger. As an emerging growth company, Korro Bio has opted to comply with the executive compensation disclosure rules applicable to &#8220;smaller reporting companies&#8221; as such term is defined in the rules promulgated under the Securities Act, which require compensation disclosure for its principal executive officer and its two other most highly compensated executive officers who will continue with the combined company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program offered to the executive officers of Korro Bio who would have been &#8220;named executive officers&#8221; for 2022 and who will serve as the executive officers of the combined company following the consummation of the Merger. Such executive officers consist of the following persons, referred to herein as Korro Bio&#8217;s NEOs: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Ram Aiyar, Korro Bio&#8217;s Chief Executive Officer and President; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Vineet Agarwal, Korro Bio&#8217;s Chief Financial Officer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Korro Bio&#8217;s NEOs will serve the combined company in the same capacities after the consummation of the Merger. This discussion may contain forward-looking statements that are based on Korro Bio&#8217;s current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that Korro Bio adopts following the consummation of the Merger could vary significantly from Korro Bio&#8217;s historical practices and currently planned programs summarized in this discussion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">391 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2022 Summary Compensation Table</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the total compensation awarded to, earned by and paid to Korro Bio&#8217;s NEOs for services during 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:49%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nonequity<br />Incentive Plan<br />Compensation<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation<br />($)(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Aiyar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">472,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">546,835</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,196,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vineet Agarwal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">404,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">629,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported represent the aggregate grant date fair value of the stock option awards granted to Korro Bio&#8217;s NEOs during 2022, calculated in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock option awards reported in this column are set forth in note 11&#160;of Korro Bio&#8217;s financial statements included elsewhere in this proxy statement/prospectus. The amounts reported in this column reflect the accounting cost for these stock option awards and do not correspond to the actual economic value that may be received by Korro Bio&#8217;s NEOs upon the exercise of the stock option awards or any sale of the underlying shares of Korro Bio common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents Korro Bio&#8217;s matching contributions to the NEO&#8217;s 401(k) account. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Narrative</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Disclosure</span><span style="font-weight:bold"> </span><span style="font-weight:bold">to the</span><span style="font-weight:bold"> </span><span style="font-weight:bold">2022 Summary</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Compensation</span><span style="font-weight:bold"> </span><span style="font-weight:bold">Table</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2022 Base Salaries </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the NEOs&#8217; base salary is a fixed component of annual compensation for performing specific duties and functions. Base salaries are adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. For the fiscal year ended December 31, 2022, the base salaries for Dr. Aiyar and Mr. Agarwal were $472,500 and $404,250, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2022 Annual Bonuses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2022, Dr. Aiyar and Mr. Agarwal were each eligible to earn an annual bonus based on Korro Bio&#8217;s performance. For the year ended December 31, 2022, the target annual bonuses for Dr. Aiyar and Mr. Agarwal were equal to 40% and 35%, respectively, of their applicable annual base salary. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Equity Incentive Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019 Korro Bio&#8217;s board of directors adopted the Korro Bio 2019 Plan. Although Korro Bio does not have a formal policy with respect to the grant of equity incentive awards to Korro Bio&#8217;s executive officers, Korro Bio believes that equity awards provide Korro Bio&#8217;s executive officers with a strong link to Korro Bio&#8217;s long-term performance, create an ownership culture and help to align the interests of Korro Bio&#8217;s executives and Korro Bio&#8217;s stockholders. In addition, Korro Bio believes that equity awards with a time-based vesting feature promote executive retention because this feature incentivizes Korro Bio&#8217;s executive officers to remain in Korro Bio&#8217;s employment during the applicable vesting period. Accordingly, Korro Bio&#8217;s board of directors periodically reviews the equity incentive compensation of Korro Bio&#8217;s NEOs and from time to time may grant equity incentive awards to them. In 2022, Korro Bio granted options to Korro Bio&#8217;s NEOs with the aggregate grant date fair values set forth in the 2022 Summary Compensation Table above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Perquisites </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio generally does not provide perquisites to Korro Bio&#8217;s employees, other than certain de minimis perquisites available to all of Korro Bio&#8217;s employees, including Korro Bio&#8217;s NEOs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">392 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">401(k) Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio maintains the Korro Bio 401K Retirement Plan, a tax-qualified retirement plan that provides eligible employees, including the NEOs, with an opportunity to save for retirement on a tax-advantaged basis. Plan participants are able to defer eligible compensation subject to applicable annual limits under the Code. Participants&#8217; pre-tax or Roth contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. Participants are immediately and fully vested in their contributions. Korro Bio matches each participant&#8217;s contribution up to a maximum of 3% of their eligible compensation with participants vesting immediately and fully in such matching contributions. Korro Bio&#8217;s 401(k) plan is intended to be qualified under Section 401(a) of the Code with its 401(k) plan&#8217;s related trust intended to be tax exempt under Section 501(a) of the Code. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Offer Letters and Employment Agreements with Korro Bio&#8217;s NEOs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has entered into offer letters with its NEOs, which were in effect in 2022 and are described below. However, Korro Bio may enter new agreements with its NEOs following the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Ram Aiyar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 13, 2020, Korro Bio entered into an offer letter with Ram Aiyar, or the Aiyar Offer Letter, who currently serves as Korro Bio&#8217;s Chief Executive Officer. The Aiyar Offer Letter sets forth his initial annual base salary of $450,000, initial target bonus opportunity equal to 40% of Dr. Aiyar&#8217;s base salary, initial equity grant, and his eligibility to participate in Korro Bio&#8217;s employee benefit plans generally. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Aiyar Offer Letter provides that in the event that Dr. Aiyar&#8217;s employment is terminated by Korro Bio without &#8220;cause&#8221; or by him for &#8220;good reason&#8221; (as such terms are defined in the Aiyar Offer Letter), in either case within three months before or 12 months following a change in control, or the Aiyar Change in Control Period, subject to Dr. Aiyar&#8217;s signing and complying with a separation agreement and release, Dr. Aiyar will be entitled to the following severance benefits: (i) a lump sum cash payment equal to sum of (x) 12 months of his then-current base salary (or the base salary in effect immediately prior to the change in control, if higher), plus (y) 100% of Dr. Aiyar&#8217;s target annual bonus for the year of termination, without regard to whether the metrics have been established or achieved for such year; (ii) if Dr. Aiyar elects COBRA health continuation, a monthly payment to the group health plan provider or the COBRA provider for up to 12 months, and (iii) 100% of all equity awards held by Dr. Aiyar will immediately accelerate in vesting and become fully exercisable or non-forfeitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that Dr. Aiyar&#8217;s employment is terminated by Korro Bio without &#8220;cause&#8221; or by him for &#8220;good reason&#8221;, in either case outside the Aiyar Change in Control Period, subject to Dr. Aiyar&#8217;s signing and complying with a separation agreement and release, Dr. Aiyar will be entitled to the severance benefits as described in the preceding paragraph, payable in substantially equal installments over a 12-month period, provided that Dr. Aiyar will not be entitled to any acceleration of vesting of his equity awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Vineet Agarwal</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 12, 2021, Korro Bio entered into an employment agreement with Vineet Agarwal, or the Agarwal Employment Agreement, who currently serves as Korro Bio&#8217;s Chief Financial Officer. The Agarwal Employment Agreement sets forth his initial annual base salary of $385,000, initial target bonus opportunity equal to 35% of Mr. Agarwal&#8217;s base salary, initial equity grant, and his eligibility to participate in Korro Bio&#8217;s employee benefit plans generally. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agarwal Employment Agreement provides that in the event that Mr. Agarwal&#8217;s employment is terminated by Korro Bio without &#8220;cause&#8221; or by him for &#8220;good reason&#8221; (as such terms are defined in the Agarwal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">393 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Employment Agreement), in either case within 12 months following a change in control, or the Agarwal Change in Control Period, subject to Mr. Agarwal&#8217;s signing and complying with a separation agreement and release, Mr.&#160;Agarwal will be entitled to the following severance benefits: (i) a lump sum cash payment equal to sum of (x) nine months of his then-current base salary (or the base salary in effect immediately prior to the change in control, if higher), plus (y) 100% of Mr. Agarwal&#8217;s target annual bonus for the year of termination, without regard to whether the metrics have been established or achieved for such year; (ii) if Mr. Agarwal elects COBRA health continuation, a monthly payment to the group health plan provider or the COBRA provider for up to nine months, and (iii) 100% of all equity awards subject to time-based vesting held by Mr. Agarwal will immediately accelerate in vesting and become fully exercisable or non-forfeitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that Mr. Agarwal&#8217;s employment is terminated by Korro Bio without &#8220;cause&#8221; or by him for &#8220;good reason&#8221;, in each case outside the Agarwal Change in Control Period, subject to Mr. Agarwal&#8217;s signing and complying with a separation agreement and release, Mr. Agarwal will be entitled to the severance benefits as described in the preceding paragraph, payable in substantially equal installments over a nine-month period, provided that Mr. Agarwal will not be entitled to any acceleration of vesting of his equity awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at 2022 Fiscal Year-End </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards held by each of the NEOs as of December 31, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards (1)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vesting<br />Commencement<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options (#)<br />Exercisable </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options (#)</span><br /><span style="font-weight:bold">Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Exercise<br />Price<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Expiration<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Aiyar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/2/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">(2)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,428,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,313,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/1/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/27/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(2)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">740,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/26/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vineet Agarwal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5/11/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">(2)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">325,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">496,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5/29/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/27/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(2)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/26/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each equity award is subject to the terms of the Korro Bio 2019 Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">1/4 of the shares subject to the stock option vest on the first anniversary of the vesting commencement date, and 1/48 of the shares subject to the stock option vest each month thereafter, in each case, subject to the NEO&#8217;s continuous service relationship with Korro Bio through each applicable vesting date. The stock option is also subject to certain acceleration of vesting provisions as provided in the applicable NEO&#8217;s offer letter or employment agreement, as applicable. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Employee</span><span style="font-weight:bold"> </span><span style="font-weight:bold">benefit</span><span style="font-weight:bold"> </span><span style="font-weight:bold">and</span><span style="font-weight:bold"> </span><span style="font-weight:bold">equity</span><span style="font-weight:bold"> </span><span style="font-weight:bold">compensation</span><span style="font-weight:bold"> </span><span style="font-weight:bold">plans</span><span style="font-weight:bold"> </span><span style="font-weight:bold">and</span><span style="font-weight:bold"> </span><span style="font-weight:bold">arrangements</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio 2019 Stock Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio 2019 Plan allows for the grant of incentive stock options to Korro Bio&#8217;s employees and any of Korro Bio&#8217;s parent or subsidiary corporations&#8217; employees, and for the grant of nonqualified stock options, stock awards and restricted stock units awards to Korro Bio employees, officers, directors and consultants of Korro Bio and its parent or subsidiary corporations. The Korro Bio 2019 Plan will be assumed by Frequency in connection with the closing of the Merger, and the Korro Bio 2019 Plan will continue to govern awards granted thereunder that will be assumed by Frequency. However, if the 2023 Plan is approved by Frequency&#8217;s stockholders (Proposal No.&#160;5), the combined company does not plan to grant any additional awards under the Korro Bio 2019 Plan following consummation of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Korro Bio 2019 Plan, Korro Bio reserved for issuance an aggregate of 15,048,960 shares of Korro Bio common stock. The number of shares of Korro Bio common stock reserved for issuance is subject to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">394 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjustment in the event of a stock dividend, stock split or combination of shares, recapitalization or other similar change affecting the outstanding Korro Bio common stock and no more than 15,048,960 shares may be issued pursuant to incentive stock options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio 2019 Plan is administered by the Korro Bio board of directors or a committee appointed by it, referred to herein as the plan administrator. The plan administrator has full power to, among other things, select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to accelerate the time at which a Korro Bio stock award may be exercised or vest, to amend the Korro Bio 2019 Plan and to determine the specific terms and conditions of each award, subject to the provisions of the Korro Bio 2019 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator may, with consent of affected option holders, effect repricing through cancellation of outstanding stock options and by granting such holders new awards in replacement of the cancelled options in accordance with the terms of the Korro Bio 2019 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options may be granted under the Korro Bio 2019 Plan. The exercise price per share of all stock options must equal at least 100% of the fair market value per share of Korro Bio common stock on the date of grant. The term of a stock option may not exceed ten years. An incentive stock option granted to a participant who owns more than 10% of the total combined voting power of all classes of Korro Bio capital stock on the date of grant, or any parent or subsidiary corporations, may not have a term in excess of five years and must have an exercise price of at least 110% of the fair market value per share of Korro Bio common stock on the date of grant. The plan administrator will determine the methods of payment of the exercise price of an option, which may include cash, shares or certain other property or other consideration acceptable to the plan administrator. After a participant&#8217;s termination of service, the participant generally may exercise their stock options, to the extent vested as of such date of termination, during a period of three months after termination of service. If a termination of service is due to death or disability, the option generally will remain exercisable, to the extent vested as of such date of termination, until the one-year anniversary of such termination of service. However, in no event may an option be exercised later than the expiration of its term. If a termination of service is for misconduct (as defined in an applicable award agreement), the stock option automatically expires upon the date of the termination of service. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock awards may be granted under the Korro Bio 2019 Plan. A stock award may be vested upon grant or may vest in one or more installments. The plan administrator determines the terms and conditions of stock awards, including the number of Korro Bio common stock shares granted, the vesting criteria (which may include specified performance criteria and/or continued service to Korro Bio) and the form of consideration payable for the shares (including cash, services, or any other valid consideration under Delaware law). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock units may be granted under the Korro Bio 2019 Plan. A restricted stock unit is an award that covers a number of shares of Korro Bio common stock that will be settled upon vesting by the issuance of the underlying shares. The plan administrator determines the terms and conditions of restricted stock units, including the number of units granted, the vesting criteria (which may include specified performance criteria and/or continued service to Korro Bio) and the form and timing of payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio 2019 Plan generally does not allow for the transfer or assignment of awards, other than at the discretion of the plan administrator, by gift to an immediate family member or to trusts for the benefit of family members. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of certain changes in Korro Bio&#8217;s capitalization, the exercise prices of and the number of shares subject to outstanding awards, and the purchase price of and the numbers of shares subject to outstanding awards will be proportionately adjusted, subject to any required action by Korro Bio&#8217;s board of directors or stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korro Bio 2019 Plan provides that upon the effectiveness of a &#8220;change in control,&#8221; as defined in the Korro Bio 2019 Plan, the plan administrator may provide (i) that an acquirer or successor entity may assume, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">395 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue or substitute for the outstanding awards under the Korro Bio 2019 Plan, (ii) all awards may be continued in full force and effect pursuant to the terms of the transaction, or (iii) that awards be replaced with a cash retention program of the acquiror that preserves the spread existing on the unvested shares subject to an award at the time of the transaction. To the extent that awards granted under the Korro Bio 2019 Plan are not assumed or continued or substituted by acquirer or the successor entity, all stock options and all other awards granted under the Korro Bio 2019 Plan shall automatically vest in full. In connection with the accelerated vesting of awards under the Korro Bio 2019 Plan upon a change in control, Korro Bio may make or provide for a cash payment equal to (A) in the case of options, the difference between (1) the fair market value of a share of Korro Bio common stock (as determined by the plan administrator) times the number of shares subject to the options being cancelled and (2) the aggregate exercise price of the options and (B) in the case of restricted stock and restricted stock unit awards, the fair market value of a share of Korro Bio common stock multiplied by the number of shares of stock subject to such stock awards (payable at the time of the change in control or upon any escrow, holdback or earn-out provided for in the definitive agreement effecting the change in control, as determined by the plan administrator). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, options to purchase up to 9,280,477 shares of Korro Bio common stock were outstanding under the Korro Bio 2019 Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">396 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_143">CERTAIN RELATED PERSON TRANSACTIONS OF FREQUENCY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Policies and Procedures Regarding Transactions with Related Persons </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s board of directors recognizes that transactions with related persons present a heightened risk of conflicts of interests and/or improper valuation (or the perception thereof). Frequency&#8217;s board of directors has adopted a written policy on transactions with related persons that is in conformity with the requirements for issuers having publicly held common stock listed on the Nasdaq. Frequency&#8217;s related person transaction policy requires that the audit committee approve or ratify related person transactions required to be disclosed pursuant to Item 404(a) of Regulation <span style="white-space:nowrap">S-K</span> (which are transactions in which Frequency was or is to be a participant and the amount involved exceeds the lesser of (i) $120,000 or (2)&#160;one percent of the average of Frequency&#8217;s total assets at fiscal <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years, and in which any &#8220;related person&#8221; as defined under Item 404(a) of Regulation <span style="white-space:nowrap">S-K</span> had or will have a direct or indirect material interest). It is Frequency&#8217;s policy that directors interested in a related person transaction will recuse themselves from any vote on a related person transaction in which they have an interest. Each of the transactions described below entered into following the adoption of Frequency&#8217;s related person transaction policy was approved in accordance with such policy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Related Person Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Leases </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, Frequency entered into a lease for laboratory, office and storage facilities in Woburn, Massachusetts with <span style="white-space:nowrap">ARE-MA</span> Region No.&#160;20, LLC, an entity affiliated with Alexandria. Joel S. Marcus, a former director of Frequency&#8217;s board of directors, is executive chairman of Alexandria. Under the lease, which was amended in November 2019, January 2020 and December 2020, and terminated in May 2021, Frequency paid monthly base rent and operating expenses. The total rent paid under this lease was $230&#160;thousand and $0 for the years ended December&#160;31, 2021 and 2022, respectively. There was also an early termination payment of $100&#160;thousand in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Massachusetts Institute of Technology License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, Frequency entered into the MIT License, with MIT. The patents <span style="white-space:nowrap">in-licensed</span> by Frequency from MIT pursuant to the MIT License claim inventions created by, among others, Robert S. Langer, one of the Frequency&#8217;s directors. Pursuant to MIT policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to Frequency under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, Frequency entered into the Astellas Agreement, under which Frequency granted Astellas an exclusive, royalty-bearing, <span style="white-space:nowrap">sub-licensable,</span> nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a <span style="white-space:nowrap">GSK-3</span> inhibitor and an HDAC inhibitor, including the product candidate <span style="white-space:nowrap">FX-322,</span> outside of the United States. Pursuant to the Astellas Agreement, Frequency received an $80&#160;million upfront payment in July 2019, or the Astellas Royalty Payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the MIT License Agreement, Frequency is obligated to pay royalties and a portion of sublicensing income to MIT. Frequency was required to pay MIT a royalty of $16&#160;million on the $80&#160;million Astellas Royalty Payment. Dr.&#160;Langer is entitled to receive a portion of the amounts Frequency pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that Frequency may receive pursuant to the Astellas Agreement. Accordingly, Dr.&#160;Langer received $11&#160;thousand and $6&#160;thousand from MIT under the MIT Policy during the year ended December&#160;31, 2021 and 2022, respectively. The MIT License Agreement has since been terminated. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">397 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Registration Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency entered into a second amended and restated investors&#8217; rights agreement, or the Investors&#8217; Rights Agreement, in July 2019 with each holder of Frequency preferred stock, which included certain holders of more than 5% of Frequency common stock at the time and certain of Frequency&#8217;s directors and executive officers. The Investors&#8217; Rights Agreement grants the parties thereto certain registration rights in respect of the &#8220;registrable securities&#8221; held by them, which securities include (1)&#160;the shares of Frequency common stock issuable or issued upon the conversion of shares of Frequency convertible preferred stock, (2)&#160;any shares of Frequency common stock, or any common stock issued or issuable upon conversion and/or exercise of any of Frequency&#8217;s securities acquired by the parties after the date of the Investors&#8217; Rights Agreement, and (3)&#160;any shares of Frequency common stock issued as a dividend or other distribution with respect to, or in exchange for, or in replacement of, the shares described in the foregoing clauses (1)&#160;and (2). The registration of shares of Frequency common stock pursuant to the exercise of these registration rights would enable the holders thereof to sell such shares under the&#160;Securities Act&#160;when the applicable registration statement is declared effective. Under the Investors&#8217; Rights Agreement, Frequency will pay all expenses relating to such registrations, including the reasonable fees of one special counsel for the participating stockholders, and the stockholders will pay all underwriting discounts and commissions relating to the sale of their shares. The Investors&#8217; Rights Agreement also includes customary indemnification and procedural terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Form</span><span style="text-decoration:underline"></span><span style="text-decoration:underline"><span style="white-space:nowrap">&#160;S-1</span></span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;registration rights</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time the holders of at least 40% of the registrable securities request in writing that Frequency effects a registration with respect to at least 25% of such registrable securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of selling expenses, would exceed $10.0 million), Frequency is obligated to register their shares. Frequency is obligated to effect at most two registrations in response to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Piggyback registration rights</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time Frequency proposes to register any shares of Frequency common stock under the&#160;Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their registrable securities in the registration. If Frequency&#8217;s proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Form</span><span style="text-decoration:underline"></span><span style="text-decoration:underline"><span style="white-space:nowrap">&#160;S-3</span></span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;registration rights</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, at any time after Frequency becomes entitled under the&#160;Securities Act&#160;to register Frequency&#8217;s shares on a registration statement on <span style="white-space:nowrap">Form&#160;S-3,&#160;the</span> holders of the registrable securities request in writing that Frequency effects a registration with respect to registrable securities at an aggregate price to the public in the offering of at least $1,000,000, net of expenses borne by the holders, Frequency is obligated to effect such registration. Frequency is not obligated to effect more than one <span style="white-space:nowrap">S-3</span> registration in any 12 month period. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Expenses and indemnification</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts and commissions, Frequency will be required to pay all expenses incurred by Frequency related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration, filing and qualification fees, printing and accounting fees, fees and disbursements of Frequency&#8217;s counsel, and reasonable fees and disbursements of a counsel for the selling securityholders. Additionally, Frequency has agreed to indemnify selling stockholders for damages, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">398 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any legal or other expenses reasonably incurred, arising from or based upon any untrue statement or alleged untrue statement of a material fact contained in any registration statement, an omission or alleged omission to state a material fact required to be stated in any registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the indemnifying party of securities laws, subject to certain exceptions. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Termination of registration rights</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights expire on the earlier of (1)&#160;the date that is five years after the closing of Frequency&#8217;s IPO and (2)&#160;with respect to each stockholder, at such time as such stockholder can sell all of its shares pursuant to Rule&#160;144&#160;of the&#160;Securities Act&#160;or another similar exemption under the&#160;Securities Act&#160;during any three month period without registration. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Indemnification agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency enters into indemnification agreements with each of its directors and executive officers. These agreements, among other things, require Frequency to indemnify each director and executive officer (and in certain cases their related venture capital funds) to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of Frequency, arising out of the person&#8217;s services as a director or executive officer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">399 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_144">CERTAIN RELATED PERSON TRANSACTIONS OF THE COMBINED COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Korro Bio&#8217;s and Frequency&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<span style="font-style:italic">Directors and Officers of Frequency Following the Merger</span>,&#8221; &#8220;<span style="font-style:italic">Korro Bio Executive and Director Compensation</span>&#8221; and &#8220;<span style="font-style:italic">Frequency Executive and Director Compensation</span>,&#8221; the following is a description of each transaction involving Frequency since January&#160;1, 2021, each transaction involving Korro Bio since January&#160;1, 2021 and each currently proposed transaction in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">either Korro Bio or Frequency has been or is to be a participant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Korro Bio&#8217;s or Frequency&#8217;s total assets at <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years, as applicable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the case of Frequency, any of Frequency&#8217;s directors, executive officers or holders of more than 5% of Frequency&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest; and in the case of Korro Bio any of Korro Bio&#8217;s directors or executive officers who will become directors or executive officers of the combined company, or holders of more than 5% of Korro Bio&#8217;s capital stock who will become holders of more than 5% of the combined company&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korro Bio Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of transactions or series of transactions since January&#160;1, 2021, to which Korro Bio was or will be a party, in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount involved in the transaction exceeds, or will exceed, the lesser of $120,000 or one percent of the average of Korro Bio&#8217;s total assets for the last two completed fiscal years; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in which any of Korro Bio&#8217;s directors or executive officers who will become directors or executive officers of the combined company, or holders of more than 5% of Korro Bio&#8217;s capital stock who will become holders of more than 5% of the combined company&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation arrangements for Korro Bio named executive officers and directors are described elsewhere in this proxy statement/prospectus under &#8220;<span style="font-style:italic">Korro Bio Executive </span><span style="font-style:italic">and</span> <span style="font-style:italic">Director Compensation</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Private Placements of Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Series A Convertible Preferred Stock Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2021, Korro Bio sold an aggregate of 20,424,108 shares of Series A Preferred Stock at a purchase price of $2.24 per share for aggregate gross proceeds of $45.8&#160;million. The following table summarizes purchases of Korro Bio&#8217;s Series A Preferred Stock by related persons: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:73%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Participant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of</span><br /><span style="font-weight:bold">Series A</span><br /><span style="font-weight:bold">Preferred</span><br /><span style="font-weight:bold">Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total Cash</span><br /><span style="font-weight:bold">Purchase</span><br /><span style="font-weight:bold">Price</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund XI, L.P. (1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,678,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 17, L.P. (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,464,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000,001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platanus Investment LLC (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,464,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000,001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qiming U.S. Healthcare Fund II, L.P. (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,790,179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,250,001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel&#160;Multi-Strategy&#160;Equities&#160;Master&#160;Fund&#160;Ltd.&#160;(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,232,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,000,000.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Cormorant Asset Management LP&#160;(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,232,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,000,000.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">400 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Atlas Venture Fund XI, L.P., or Atlas, beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Jean-Fran&#231;ois Formela is a Partner at Atlas and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">New Enterprise Associates 17, L.P. (&#8220;NEA&#8221;) beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Ali Behbahani is a Partner at NEA and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Platanus Investment LLC (&#8220;Platanus&#8221;) beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Hannah Chang is a Partner at Platanus and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Qiming U.S. Healthcare Fund II, L.P. (&#8220;Qiming&#8221;) beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Colin Walsh is a Partner at Qiming and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Citadel Multi-Strategy Equities Master Fund Ltd. owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Cormorant Asset Management LP own more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Series B Convertible Preferred Stock Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, December 2021 and March 2023, Korro Bio sold an aggregate of 43,085,531 shares of its Series B preferred stock at a purchase price of $2.61 and $2.78 per share for aggregate gross proceeds of $116.0&#160;million. The following table summarizes purchases of Korro Bio&#8217;s Series B preferred stock by related persons: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:71%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Participant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of</span><br /><span style="font-weight:bold">Series B</span><br /><span style="font-weight:bold">Preferred</span><br /><span style="font-weight:bold">Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span><br /><span style="font-weight:bold">Purchase</span><br /><span style="font-weight:bold">Price</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund XI, L.P. (1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,064,273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,250,001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 17, L.P. (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,971,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platanus Investment LLC (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,764,279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,750,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qiming U.S. Healthcare Fund II, L.P. (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,114,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Fund Series Trust, on behalf of Eventide Healthcare&#160;&amp; Life Sciences Fund (5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,428,540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P. (6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,571,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point72 Biotech Private Investments, LLC (7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,571,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Ram Aiyar Irrevocable Trust (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Fidelity Investments (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,285,675</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd.&#160;(10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">835,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,249,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Cormorant Asset Management LP&#160;(11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">835,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,249,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Atlas beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Jean-Fran&#231;ois Formela is a Partner at Atlas and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">NEA beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Ali Behbahani is a Partner at NEA and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Platanus beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Hannah Chang is a Partner at Platanus and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Qiming beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Colin Walsh is a Partner at Qiming and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mutual Fund Series Trust, on behalf of Eventide Healthcare&#160;&amp; Life Sciences Fund (&#8220;Eventide&#8221;) owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Invus Public Equities, L.P. owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Point72 Biotech Private Investments, LLC (&#8220;Point72&#8221;) owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ram Aiyar is the grantor of The Ram Aiyar Irrevocable Trust and an officer and member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Fidelity Investments own more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">401 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Citadel Multi-Strategy Equities Master Fund Ltd. owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Cormorant Asset Management LP own more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korro Bio <span style="white-space:nowrap">Pre-Closing</span> Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger Agreement, Korro Bio entered into a Subscription Agreement in July 2023 with certain investors to consummate the Pre-Closing Financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an aggregate of 42,176,255 shares of Korro Bio common stock, at a price of $2.78&#160;per share, for aggregate gross proceeds of $117.3 million. The closing of the Pre-Closing Financing is conditioned upon the satisfaction or waiver of the conditions to the Merger as well as certain other conditions. Seven of the investors or their affiliates are beneficial holders of more than 5% of Korro Bio&#8217;s capital stock, and the table below sets forth the number of shares of Korro Bio common stock expected to be purchased by such holders at the closing of the Pre-Closing Financing: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:71%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Participant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of<br />Korro Bio<br />Common<br />Stock </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span><br /><span style="font-weight:bold">Purchase</span><br /><span style="font-weight:bold">Price</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund XI, L.P. (1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,597,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 17, L.P. (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,597,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Fidelity Investments (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,395,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd.(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,395,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platanus Investment LLC (5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">179,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qiming U.S. Healthcare Fund II, L.P. (6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">719,424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Fund Series Trust, on behalf of Eventide Healthcare &amp; Life Sciences Fund (7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,597,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,877,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point72 Biotech Private Investments, LLC (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,395,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Cormorant Asset Management LP&#160;(10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,395,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Atlas beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Jean-Fran&#231;ois Formela is a Partner at Atlas and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">NEA beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Ali Behbahani is a Partner at NEA and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Fidelity Investments own more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Citadel owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Platanus beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Hannah Chang is a Partner at Platanus and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Qiming beneficially owns more than five percent of Korro Bio&#8217;s outstanding capital stock. Colin Walsh is a Partner at Qiming and a member of Korro Bio&#8217;s board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Eventide owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Invus Public Equities, L.P. owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Point72 Biotech Private Investments, LLC (&#8220;Point72&#8221;) owns more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Cormorant Asset Management LP own more than five percent of Korro Bio&#8217;s outstanding capital stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Agreements with Korro Bio Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Korro Bio&#8217;s Series B convertible preferred stock financing, Korro Bio entered into investors&#8217; rights, voting and right of first refusal and <span style="white-space:nowrap">co-sale</span> agreements containing registration rights, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">402 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information rights, voting rights and rights of first refusal, among other things, with certain holders of Korro Bio preferred stock and certain holders of Korro Bio common stock. These stockholder agreements will terminate upon the closing of the Merger, except for the registration rights granted under Korro Bio&#8217;s investors&#8217; rights agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indemnification Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has entered into agreements to indemnify its directors and executive officers. These agreements will, among other things, require Korro Bio to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in Korro Bio&#8217;s right, on account of any services undertaken by such person on Korro Bio&#8217;s behalf or that person&#8217;s status as a member of Korro Bio&#8217;s board of directors to the maximum extent allowed under Delaware law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Policies for Approval of Related Party Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s board of directors reviews and approves transactions with its directors, officers and holders of 5% or more of its voting securities and their affiliates, each a related party. Prior to this offering, the material facts as to the related party&#8217;s relationship or interest in the transaction are disclosed to Korro Bio&#8217;s board of directors prior to their consideration of such transaction, and the transaction is not considered approved by the board of directors unless a majority of the directors who are not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#8217;s relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in good faith. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">403 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_145">FREQUENCY&#8217;S DESCRIPTION OF CAPITAL STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Description of capital stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes some of the terms of the Restated Certificate of Incorporation and Amended and Restated Bylaws of Frequency and of the DGCL. This description is summarized from, and qualified in its entirety by reference to, Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws, each of which has been publicly filed with the SEC, as well as the relevant provisions of the DGCL. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Capital stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders of Frequency common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by Frequency stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of Frequency stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matters. Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws also provide that Frequency&#8217;s directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of its Restated Certificate of Incorporation. See below under &#8220;<span style="font-style:italic">Anti-takeover effects of Delaware law and Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws-Amendment of charter provisions</span>.&#8221; Stockholders of common stock are entitled to receive proportionately any dividends as may be declared by its board of directors, subject to any preferential dividend rights of any series of preferred stock that Frequency may designate and issue in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of Frequency&#8217;s liquidation or dissolution, the holders of Frequency common stock are entitled to receive proportionately Frequency&#8217;s net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of Frequency common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of Frequency common stock are subject to, and may be adversely affected by, the rights of the stockholders of shares of any series of Frequency preferred stock that Frequency may designate and issue in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of Frequency&#8217;s Restated Certificate of Incorporation, Frequency&#8217;s board of directors is authorized to direct Frequency to issue shares of preferred stock in one or more series without stockholder approval. Frequency&#8217;s board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of Frequency preferred stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">404 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of authorizing Frequency&#8217;s board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of its outstanding voting stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-takeover effects of Delaware law and Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, Frequency&#8217;s Restated Certificate of Incorporation and Frequency&#8217;s Amended and Restated Bylaws could make the following transactions more difficult: an acquisition of Frequency by means of a tender offer; an acquisition of Frequency by means of a proxy contest or otherwise; or the removal of Frequency&#8217;s incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in Frequency&#8217;s best interests, including transactions which provide for payment of a premium over the market price for Frequency&#8217;s shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of Frequency to first negotiate with its board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Undesignated preferred stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of Frequency&#8217;s board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by Frequency&#8217;s board of directors could impede the success of any attempt to change control of Frequency. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of Frequency. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Amended and Restated Bylaws provide that a special meeting of stockholders may be called only by Frequency&#8217;s chairman of the board of directors, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of Frequency&#8217;s board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Requirements for advance notification of stockholder nominations and proposals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Amended and Restated Bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Elimination of stockholder action by written consent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Restated Certificate of Incorporation eliminates the right of stockholders to act by written consent without a meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Staggered board </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by its stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of Frequency, because it generally makes it more difficult for stockholders to replace a majority of the directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">405 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Removal of directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Restated Certificate of Incorporation provides that no member of its board of directors may be removed from office by Frequency&#8217;s stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of Frequency common stock entitled to vote in the election of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholders not entitled to cumulative voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Restated Certificate of Incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of Frequency common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of Frequency preferred stock may be entitled to elect. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delaware anti-takeover statute </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency is subject to Section&#160;203 of the DGCL, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Choice of forum </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Restated Certificate of Incorporation provides that, unless Frequency consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for: (1)&#160;any derivative action or proceeding brought on Frequency&#8217;s behalf; (2)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of Frequency&#8217;s directors, officers, employees or agents to Frequency or its stockholders; (3)&#160;any action asserting a claim against Frequency arising pursuant to any provision of the DGCL or Frequency&#8217;s Restated Certificate of Incorporation or Amended and Restated Bylaws; (4)&#160;any action to interpret, apply, enforce or determine the validity of Frequency&#8217;s Restated Certificate of Incorporation or Amended and Restated Bylaws; or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. Under Frequency&#8217;s Restated Certificate of Incorporation, this exclusive forum provision&#160;does&#160;not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. Frequency&#8217;s Restated Certificate of Incorporation&#160;also provides&#160;that any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock will be deemed to have notice of and to have consented to this choice of forum provision. Frequency&#8217;s Restated Certificate of Incorporation further provides&#160;that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. It is possible that a court of law could rule that the choice of forum provision contained in Frequency&#8217;s Restated Certificate of Incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">406 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of charter provisions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions, except for the provision making it possible for Frequency&#8217;s board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon. The provisions of Delaware law, Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of its common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of Frequency&#8217;s board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">407 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_146">COMPARISON OF RIGHTS OF HOLDERS OF FREQUENCY CAPITAL STOCK AND KORRO BIO CAPITAL STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger is completed, Korro Bio stockholders will receive shares of Frequency common stock, pursuant to the terms of the Merger Agreement. Immediately prior to the closing of the Merger, Frequency&#8217;s Restated Certificate of Incorporation will be amended to effect the Reverse Stock Split, as set forth in the form of Certificate of Amendment attached as <span style="font-style:italic">Annex H</span> to this proxy statement/prospectus. In addition, after the completion of the Merger, Frequency&#8217;s Restated Certificate of Incorporation will be amended to change its corporate name to &#8220;Korro Bio, Inc.&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency and Korro Bio are both incorporated under the laws of the State of Delaware. The rights of Frequency stockholders and Korro Bio stockholders are generally governed by the DGCL. Upon completion of the Merger, Korro Bio stockholders will become Frequency stockholders, and their rights will be governed by the DGCL, the Amended and Restated Bylaws of Frequency and the Restated Certificate of Incorporation of Frequency, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material differences between the current rights of Korro Bio stockholders under the Korro Bio Amended and Restated Certificate of Incorporation and Bylaws and their rights as Frequency stockholders, after the Merger, under the Frequency Restated Certificate of Incorporation and the Amended and Restated Bylaws, both as will be in effect immediately following the completion of the Merger, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of Frequency or Korro Bio before the Merger and being an Frequency stockholder following the completion of the Merger. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Organizational Documents</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The rights of Frequency stockholders are governed by Frequency&#8217;s Restated Certificate of Incorporation, Frequency&#8217;s Amended and Restated Bylaws and the DGCL.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">The rights of Korro Bio stockholders are governed by Korro Bio&#8217;s amended and restated certificate of incorporation, as amended, Korro Bio&#8217;s bylaws and the DGCL.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Authorized Capital Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Frequency is authorized to issue is 210,000,000, of which 200,000,000 shares are common stock, par value $0.001 per share, and 10,000,000 shares are preferred stock, par value $0.001 per share. The number of authorized shares of Frequency preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of Frequency entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of Frequency entitled to vote,</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korro Bio is authorized to issue two classes of capital stock, which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Korro Bio is authorized to issue is 214,852,546, of which 117,138,030 shares are common stock, par value $0.001 per share, and 97,714,516 shares are preferred stock, par value $0.001 per share. The number of authorized shares of Korro Bio preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the Requisite Holders (as defined in Korro Bio&#8217;s amended and restated certificate of incorporation), and, under certain circumstances, (i)&#160;the number of authorized shares of Korro Bio&#8217;s Series B Preferred Stock may be increased or decreased only by the affirmative vote of the holders of at least a majority</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">408 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">irrespective of the provisions of Section&#160;242(b)(2) of the DGCL.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">of the outstanding shares of Series B Preferred Stock, and (ii)&#160;the number of authorized shares of Korro Bio&#8217;s Series A Preferred Stock may be increased or decreased only by the affirmative vote of the holders of at least a majority of the outstanding shares of Series A Preferred Stock. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the Requisite Holders (as defined in Korro Bio&#8217;s amended and restated certificate of incorporation) and the holders of a majority of capital stock, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Common Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency&#8217;s authorized common stock consists of 200,000,000 shares of common stock. Each holder of a share of Frequency common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders, provided, however, that, except as otherwise required by law, holders of Frequency common stock will not be entitled to vote on any amendment to the Frequency&#8217;s Restated Certificate of Incorporation, as amended that relates solely to the terms of one or more outstanding series of Frequency preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to the Frequency&#8217;s Restated Certificate of Incorporation or the DGCL.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korro Bio&#8217;s authorized common stock consists of 117,138,030 shares of common stock.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each holder of a share of Korro Bio common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Preferred Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency&#8217;s authorized preferred stock consists of 10,000,000 shares of preferred stock. No shares of Frequency preferred stock are currently outstanding.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korro Bio&#8217;s authorized preferred stock consists of 97,714,516 shares of preferred stock, of which (a) 4,000,000 shares have been designated &#8220;Series Seed 1 Preferred Stock&#8221;, all of which are currently issued and outstanding, (b) 2,000,000 shares have been designated &#8220;Series Seed 2 Preferred Stock&#8221;, all of which are currently issued and outstanding, (c) 7,780,769 shares have been designated &#8220;Series Seed 3 Preferred Stock&#8221;, all of which are currently issued and outstanding, (d) 40,848,216 shares have been designated &#8220;Series A Preferred Stock&#8221;, all of which are currently issued and outstanding, (e) 22,222,223 shares have been designated &#8220;Series <span style="white-space:nowrap">B-1</span> Preferred Stock&#8221;, all of which are currently issued and outstanding and (f) 20,863,308 shares have been designated &#8220;Series <span style="white-space:nowrap">B-2</span> Preferred Stock&#8221;, all of which are currently issued and are outstanding.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">409 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Number and Qualification of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The Frequency board of directors consists of one or more members, and the number of directors is fixed from time to time by resolution of the Frequency board of directors. The Frequency board of directors currently consists of seven members. No decrease in the authorized number of directors constituting the Frequency board of directors will shorten the term of any incumbent director. Directors of Frequency need not be stockholders of Frequency.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Korro Bio board of directors consists of one or more members, and the number of directors is fixed from time to time by resolution of the Korro Bio board of directors and by the written consent or vote of the requisite stockholders of Korro Bio. The Korro Bio board of directors currently consists of nine members. No decrease in the authorized number of directors constituting the Korro Bio board of directors will shorten the term of any incumbent director. Directors of Korro Bio need not be stockholders of Korro Bio.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Structure of Board of Directors; Term of Directors; Election of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Other than any directors elected by the separate vote of the holders of any series of Frequency preferred stock, the Frequency board of directors is divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. Directors are assigned to each class in accordance with a resolution or resolutions adopted by the Frequency board of directors. Subject to the rights of holders of any series of Frequency preferred stock to elect directors, each director will serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected; provided that each director initially assigned to Class&#160;I will serve for a term expiring at Frequency&#8217;s first annual meeting of stockholders held after the effectiveness of the Frequency&#8217;s Restated Certificate of Incorporation; each director initially assigned to Class&#160;II will serve for a term expiring at Frequency&#8217;s second annual meeting of stockholders held after the effectiveness of the Frequency&#8217;s Restated Certificate of Incorporation; and each director initially assigned to Class&#160;III shall serve for a term expiring at Frequency&#8217;s third annual meeting of stockholders held after the effectiveness of the Frequency&#8217;s Restated Certificate of Incorporation. The term of each director will continue until the election and qualification of his or her successor and be subject to his or her earlier death, resignation or removal.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The holders of record of the shares of Series Seed Preferred Stock, exclusively and as a separate class, are entitled to elect two directors of the Korro Bio board of directors, the holders of record of the shares of Series A Preferred Stock, exclusively and as a separate class, are entitled to elect two directors of the Korro Bio board of directors, and the holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, are entitled to elect two directors of the Korro Bio board of directors. The holders of record of the shares of Common Stock, exclusively and as a separate class, are entitled to elect one director of the Korro Bio board of directors, and the holders of record of the shares of Preferred Stock and Common Stock, voting together as a single class, are entitled to elect the balance of the total number of directors of Korro Bio. If the holders of shares of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as the holders of the applicable shares of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, or Common Stock, as the case may be, elect a person to fill such directorship. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and together as a single class, shall be entitled to elect the balance of the total number of directors of Korro Bio. The members of the board of directors serve on the Korro Bio board of directors until their successors are duly elected and qualified or until their earlier death, resignation, disqualification, or removal.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">410 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Removal of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Subject to the special rights of the holders of one or more series of Frequency preferred stock to elect directors, or except as otherwise provided by the DGCL, the Frequency board of directors or any individual director may be removed from office but only for cause and only by the affirmative vote of the holders of at least <span style="white-space:nowrap">two-thirds</span> in voting power of the outstanding shares of capital stock of Frequency entitled to vote at an election of directors.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to the special rights of the holders of one or more series of Korro Bio preferred stock to elect directors, or except as otherwise provided by the DGCL or the Korro Bio amended and restated certificate of incorporation, the Korro Bio board of directors or any individual director may be removed from office at any time, with or without cause, by the holders of a majority of shares entitled to vote at an election of directors, provided that (i)&#160;such removal is directed or approved by the affirmative vote of the person or groups with the right to designate the applicable directors, or (ii)&#160;the person or groups originally entitled to designate or approve such director is no longer so entitled to designate or approve such director.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Vacancies on the Board of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Subject to the rights of holders of any series of Frequency preferred stock, any vacancy or newly created directorship in the Frequency board of directors will be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director and will not be filled by the stockholders, unless the Frequency board of directors determines by resolution that any such vacancy or newly created directorship will be filled by the stockholders. A director elected to fill a vacancy will hold office until the next election of the class for which such director has been chosen, subject to the election and qualification of a successor and to such director&#8217;s earlier death, resignation or removal.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any director may resign at any time upon notice in writing or electronic transmission to Korro Bio&#8217;s Secretary. Such resignation is effective at the time of delivery to the Secretary unless the resignation specifies a later effective date or an effective date determined upon the happening of an event or events.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to any limitations imposed by applicable law and subject to the rights of the holders of any series of Korro Bio preferred stock, any vacancies resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, will, unless the Korro Bio board of directors determines by resolution that any such vacancies or newly created directorships will be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum, or by a sole remaining director, and not by the stockholders. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor is elected and qualified.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Stockholder Action by Written Consent</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">No action that is required or permitted to be taken by the stockholders of Frequency at any annual or special meeting of stockholders may be effected by written consent of stockholders in lieu of a meeting.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Action may be taken by the stockholders at an annual or special meeting of stockholders called in accordance with Korro Bio&#8217;s amended and restated bylaws, or by the written consent or electronic</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">411 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">transmission of the Korro Bio stockholders entitled to vote thereon.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Quorum</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Unless otherwise provided by law, the Frequency&#8217;s Restated Certificate of Incorporation or Frequency&#8217;s Amended and Restated Bylaws, the holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, will constitute a quorum for the transaction of business at all meetings of the stockholders. If a quorum is not present or represented at any meeting of the stockholders, then either (a)&#160;the chairperson of the meeting or (b)&#160;a majority in voting power of the stockholders entitled to vote thereon, present in person, or by remote communication, if applicable, or represented by proxy, will have power to adjourn the meeting from time to time until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Unless otherwise provided by law, Korro Bio&#8217;s amended and restated certificate of incorporation, or Korro Bio&#8217;s amended and restated bylaws, at each meeting of stockholders the holders of a majority of the shares of stock entitled to vote at the meeting, present in person, by remote communication, if applicable, or represented by proxy, will constitute a quorum for the transaction of business. If a quorum fails to attend any meeting, the chairperson of the meeting or the holders of a majority of the shares entitled to vote who are present, in person, by remote communication, if applicable, or by proxy, at the meeting may adjourn or recess the meeting.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Special Meetings of Stockholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Special meetings of stockholders for any purpose or purposes may be called at any time only by the Frequency board of directors, the chairperson of the Frequency board of directors, the chief executive officer or the president (in the absence of a chief executive officer) of Frequency. The Frequency board of directors will determine the time and place, if any, of such special meeting. Special meetings may not be called by any other person or persons.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Special meetings of stockholders for any purpose or purposes may be called at any time by the President or Secretary of Korro Bio, pursuant to a resolution adopted by a quorum of directors then serving on the Korro Bio board of directors, or by the holders of shares entitled to cast not less than 10% of the votes at the meeting. The Korro Bio board of directors will determine the time and place, if any, of such special meeting. Special meetings may not be called by any other person or persons.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Notice of Stockholder Meetings</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Notice of all meetings of stockholders is to be given in writing or by electronic transmission in the manner provided by law and Frequency&#8217;s Amended and Restated Bylaws, stating the place, if any, date and hour, of the meeting, and, in the case of a special meeting, the purpose or purposes of the meeting, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting), and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. Unless otherwise required by applicable law, such notice is to be given not less than ten (10)&#160;nor more than sixty</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Notice of all meetings of stockholders is to be given in writing or by electronic transmission in the manner provided by law and Korro Bio&#8217;s amended and restated bylaws, stating the place, date and hour, of the meeting and, in the case of a special meeting, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. Unless otherwise required by applicable law or Korro Bio&#8217;s amended and restated certificate of incorporation, such notice is to be given not less than ten nor more than 60 days before the date of the</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">412 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">(60)&#160;days before the date of the meeting to each stockholder of record entitled to vote at such meeting.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">meeting to each stockholder of record entitled to vote at such meeting.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Advance Notice Requirements for Stockholder Proposals</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Nominations of persons for election to the Frequency board of directors and the proposal of business other than nominations to be considered by the stockholders may be made at an annual meeting of stockholders only (i)&#160;by or at the direction of the Frequency board of directors or any committee thereof, or (ii)&#160;by any stockholder of Frequency who is a stockholder of record at the time the written notice provided is delivered to the Corporate Secretary of Frequency, who is entitled to vote at the meeting and who complies with the notice procedures set forth in Frequency&#8217;s Amended and Restated Bylaws. For the avoidance of doubt, the foregoing clause (ii)&#160;is the exclusive means for a stockholder to make director nominations and submit other business (other than matters properly included in the corporation&#8217;s notice of meeting of stockholders and proxy statement under Rule <span style="white-space:nowrap">14a-8</span> under the Exchange Act) before an annual meeting of stockholders.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Nominations of persons for election to the Korro Bio board of directors to be considered by the stockholders may be made at an annual meeting of stockholders only (i)&#160;pursuant to Korro Bio&#8217;s notice of such meeting, (ii)&#160;by or at the direction of the Korro Bio board of directors or (iii)&#160;by any stockholder of Korro Bio who is a stockholder of record at the time the notice provided is delivered to the Secretary of Korro Bio, who is entitled to vote at the meeting and who complies with the notice procedures set forth in Korro Bio&#8217;s amended and restated bylaws.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Amendment of Restated Certificate of Incorporation</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> in voting power of the outstanding shares of capital stock of Frequency entitled to vote thereon will be required to amend certain provisions of Frequency&#8217;s Restated Certificate of Incorporation, including removal of directors, actions by written consent, and forum selection.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provisions of Frequency&#8217;s Restated Certificate of Incorporation, Frequency&#8217;s Amended and Restated Bylaws, or any provision of law which might otherwise permit a lesser vote or no vote, stockholders may vote to amend Frequency&#8217;s Restated Certificate of Incorporation pursuant to Section&#160;242 of the DGCL.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of holders of at least a majority of the outstanding shares of Series B Preferred Stock, voting together as a single class, will be required to amend certain provisions of Korro Bio&#8217;s amended and restated certificate of incorporation, in a manner that adversely affects the Series B Preferred Stock. The affirmative vote of holders of at least a majority of the outstanding shares of Series A Preferred Stock, voting together as a single class, will be required to amend certain provisions of Korro Bio&#8217;s amended and restated certificate of incorporation, in a manner that adversely affects the Series A Preferred Stock. The affirmative vote of the Requisite Holders (as defined in Korro Bio&#8217;s amended and restated certificate of incorporation), voting separately as a class, will be required to amend Korro Bio&#8217;s amended and restated certificate of incorporation, including provisions relating to increasing the authorized capital stock and authorizing the creation of additional series of capital stock.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provisions of Korro Bio&#8217;s amended and restated certificate of incorporation, Korro Bio&#8217;s amended and restated bylaws, or any provision of law which might otherwise permit a lesser vote or no vote, stockholders may vote to amend Korro Bio&#8217;s amended and restated certificate</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">413 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">of incorporation pursuant to Section&#160;242 of the DGCL.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Amendment of Bylaws</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> in voting power of the outstanding shares of capital stock of Frequency is required to amend or repeal Frequency&#8217;s Amended and Restated Bylaws. The Frequency board of directors also has the power to adopt, amend or repeal Frequency&#8217;s Amended and Restated Bylaws by the approval of a majority of the authorized number of directors.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of the Requisite Holders (as defined in Korro Bio&#8217;s amended and restated certificate of incorporation), voting separately as a class, is required to amend or repeal Korro Bio&#8217;s amended and restated bylaws. The affirmative vote of holders of at least a majority of the outstanding shares of Series B Preferred Stock, voting together as a single class, will be required to amend certain provisions of Korro Bio&#8217;s amended and restated bylaws, in a manner that adversely affects the Series B Preferred Stock. The affirmative vote of holders of at least a majority of the outstanding shares of Series A Preferred Stock, voting together as a single class, will be required to amend certain provisions of Korro Bio&#8217;s amended and restated bylaws, in a manner that adversely affects the Series A Preferred Stock. Subject to the foregoing votes, the Korro Bio board of directors also has the power to adopt, amend or repeal Korro Bio&#8217;s amended and restated bylaws by the approval of a majority of the authorized number of directors.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Limitation on Director Liability</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The liability of the Frequency directors for monetary damages is and will be eliminated to the fullest extent under applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to Frequency will be eliminated or limited to the fullest extent permitted by applicable law as so amended.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The liability of the Korro Bio directors for monetary damages is and will be eliminated to the fullest extent under applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to Korro Bio will be eliminated or limited to the fullest extent permitted by applicable law as so amended.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Indemnification</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">To the fullest extent permitted by applicable law, Frequency is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of Frequency (and any other persons to which applicable law permits Frequency to provide indemnification) through provisions of Frequency&#8217;s Amended and Restated Bylaws, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to Frequency will be eliminated or limited to the</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">To the fullest extent permitted by applicable law, Korro Bio is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of Korro Bio (and any other persons to which applicable law permits Korro Bio to provide indemnification) through provisions of Korro Bio&#8217;s amended and restated bylaws, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to Korro Bio</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">414 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">fullest extent permitted by applicable law as so amended.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">will be eliminated or limited to the fullest extent permitted by applicable law as so amended.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Conversion Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency does not have any outstanding shares of preferred stock.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korro Bio&#8217;s amended and restated certificate of incorporation provides that holders of Korro Bio preferred stock have the right to convert such shares into shares of common stock at any time at a conversion rate in accordance with the terms of Korro Bio&#8217;s amended and restated certificate of incorporation. In addition, upon the closing of the sale of shares of common stock in a firm-commitment underwritten public offering in which the per share price is at least $5.56 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock) and which results in at least $75&#160;million of proceeds or upon the affirmative election of the Requisite Holders (as defined in Korro Bio&#8217;s amended and restated certificate of incorporation), all outstanding shares of preferred stock will be converted into shares of common stock.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Right of First Refusal</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency does not have a right of first refusal in place.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pursuant to a Third Amended and Restated Right of First Refusal and <span style="white-space:nowrap">Co-Sale</span> Agreement dated November&#160;8, 2021, or the Right of First Refusal Agreement, certain stockholders party to the Right of First Refusal Agreement, or a Key Holder, wishing to transfer any shares of Korro Bio Common Stock must first provide Korro Bio with the right to purchase such shares. In such an event, if Korro Bio does not elect to exercise its right of first refusal in full, any holder of preferred stock that is party to the Right of First Refusal Agreement, or a Korro Bio Investor, has a secondary right of first refusal to purchase all or any portion of the shares of Korro Bio Common Stock which are proposed for sale or transfer by the Key Holders.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Right of <span style="white-space:nowrap">Co-Sale</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency does not have a right of <span style="white-space:nowrap">co-sale</span> in place.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pursuant to the Right of First Refusal Agreement, each Korro Bio Investor has a right of <span style="white-space:nowrap">co-sale</span> with respect to any Korro Bio Common Stock proposed to be transferred or sold by any Key Holder which is not earlier purchased by Korro Bio by exercise of its right of first refusal (as further described above) or by any Korro Bio Investor by exercise of their secondary right of first refusal (as further described above).</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">415 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Preemptive Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency stockholders do not have <span style="white-space:nowrap">pre-emptive</span> rights. Thus, if additional shares of Frequency common stock are issued, the current holders of Frequency common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pursuant to the Third Amended and Restated Investors&#8217; Rights Agreement, dated November&#160;8, 2021, or the IRA, if Korro Bio proposes to offer or sell new equity securities, Korro Bio shall first offer such securities to certain holders of preferred stock of Korro Bio, or the Korro Bio Major Investors. Each of the Korro Bio Major Investors will then have the right to purchase securities in such new offering equal to the proportion of the ownership interest of such Korro Bio Major Investor prior to such offering.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Distributions to Stockholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dividends upon Frequency capital stock, subject to the provisions of Frequency&#8217;s Restated Certificate of Incorporation and applicable law, if any, may be declared by the Frequency board of directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of Frequency&#8217;s Restated Certificate of Incorporation and applicable law.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Dividends upon Korro Bio capital stock, subject to the provisions of Korro Bio&#8217;s amended and restated certificate of incorporation and applicable law, if any, may be declared by the Korro Bio board of directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of Korro Bio&#8217;s amended and restated certificate of incorporation and applicable law. The Korro Bio board of directors may fix a record date for the determination of holders of Korro Bio common stock entitled to receive payment of a dividend or distribution declared thereon, which record date is not to precede the date upon which the resolution fixing the record date is adopted, and which record date may not be more than 60 days prior to the date fixed for the payment thereof.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Exclusive Forum</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Unless Frequency consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of Frequency; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Frequency to Frequency or Frequency stockholders; (iii)&#160;any action asserting a claim against Frequency arising pursuant to any provision of the DGCL, Frequency&#8217;s Restated Certificate of Incorporation or Frequency&#8217;s Amended and Restated Bylaws; or (iv)&#160;any action asserting a claim against Frequency governed by the internal affairs doctrine. The federal district courts of the United States will be the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of Frequency will be</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Unless Korro Bio consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of Korro Bio; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Korro Bio to Korro Bio or Korro Bio&#8217;s stockholders; (iii)&#160;any action asserting a claim against Korro Bio arising pursuant to any provision of the DGCL, Korro Bio&#8217;s amended and restated certificate of incorporation or Korro Bio&#8217;s amended and restated bylaws; or (iv)&#160;any action asserting a claim against Korro Bio governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of Korro Bio will be deemed to have notice of and to have consented to the forum selection provision of</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">416 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Frequency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Korro Bio</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">deemed to have notice of and to have consented to the forum selection provision of Frequency&#8217;s Restated Certificate of Incorporation.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korro Bio&#8217;s amended and restated certificate of incorporation.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Registration Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">See &#8220;<span style="font-style:italic">Certain Related Person Transactions of Frequency</span>&#8221; beginning on page 397 of this proxy statement/prospectus.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Under the IRA, certain holders of Korro Bio preferred stock that are party to the IRA have certain registration rights, including the right to demand that Korro Bio file a registration statement, so called &#8220;demand&#8221; registration rights, or request that their shares be covered by a registration statement that Korro Bio is otherwise filing, <span style="white-space:nowrap">so-called</span> &#8220;piggyback&#8221; registration rights.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"><span style="font-style:italic">Stock Transfer Restrictions Applicable to Stockholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Shares of Frequency are transferable in the manner prescribed by the DGCL.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shares of Korro Bio are transferable in the manner prescribed by the DGCL.</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">417 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_147">PRINCIPAL STOCKHOLDERS OF FREQUENCY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information relating to the beneficial ownership of Frequency common stock as of June&#160;30, 2023, by (i)&#160;each person, or group of affiliated persons, known by Frequency to beneficially own more than 5% of Frequency&#8217;s outstanding shares of common stock; (ii)&#160;each of its directors; (iii)&#160;each of its named executive officers; and (iv)&#160;all directors and executive officers as a group. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, a person is deemed to be a &#8220;beneficial&#8221; owner of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. Except as indicated in the footnotes below, Frequency believes, based on the information furnished and information filed with the SEC, that the individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by them, subject to any applicable community property laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of shares beneficially owned is computed on the basis of 35,963,706 shares of Frequency common stock outstanding as of as of June&#160;30, 2023. Shares of Frequency common stock that a person has the right to acquire within 60 days of as of June&#160;30, 2023 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless otherwise indicated, the address for each of the stockholders in the table below is c/o Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, MA 02421. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beneficial&#160;Ownership<br />Prior&#160;to&#160;this&#160;Offering</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="8"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Holders of More than 5%, Directors and Named Executive Officers:</p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,391,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher R. Loose(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,180,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy J. Barberich(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia L. Feldmann(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Huang(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer, Sc.D.(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">627,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (six persons)(7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,499,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Represents beneficial ownership of less than 1%. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 438,830 shares of Frequency common stock, (ii) 1,668,140 shares of Frequency common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023, and (iii) 300,000 shares of Frequency restricted stock units vesting within 60 days of June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 57,758 shares of Frequency common stock, (ii) 980,479 shares of Frequency common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023, and (iii) 150,000 shares of Frequency restricted stock units vesting within 60 days of June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 80,650 shares of Frequency common stock held by the Barberich Family Trust and (ii)&#160;116,987 shares of Frequency common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 58,559 shares of Frequency common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 44,538 shares of Frequency common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 214,326 shares of Frequency common stock held directly by Robert Langer; (ii) 8,565 shares of Frequency common stock held directly by The Michael D. Langer 2014 Trust dated 12/15/2014; (iii)&#160;8,565 shares of Frequency common stock held directly by The Samuel A. Langer 2014 Trust dated </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">418 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
12/15/2014; (iv) 8,565 shares of Frequency common stock held directly by The Susan K. Langer 2014 Trust dated 12/15/2014; and (v) 387,080 shares of Frequency common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 794,142 shares of Frequency common stock, (ii) 3,255,783 shares of Frequency common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023; and (iii)&#160;450,000 shares of Frequency common stock underlying Frequency restricted stock units which are or will become exercisable within 60 days of June&#160;30, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">419 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_148">PRINCIPAL STOCKHOLDERS OF KORRO BIO </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes set forth certain information with respect to the beneficial ownership of Korro Bio common stock at June&#160;30, 2023 for: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of Korro Bio&#8217;s directors as of June&#160;30, 2023 who will become a director of the combined company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of Korro Bio&#8217;s named executive officers who will become an executive officer of the combined company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of Korro Bio&#8217;s current directors and executive officers who will be directors and executive officers of the combined company as a group; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person, or group of affiliated persons, who beneficially owned more than 5% of Korro Bio&#8217;s outstanding shares of common stock and who will become the beneficial owner of more than 5% of the combined company upon completion of the Merger and the Pre-Closing Financing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korro Bio has determined beneficial ownership in accordance with the rules of the Securities and Exchange Commission, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, Korro Bio believes, based on information furnished to it, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares of common stock that they beneficially owned, subject to applicable community property laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership prior to the completion of the Merger is based on 103,376,685 shares of Korro Bio common stock outstanding as of June&#160;30, 2023, after giving effect to the conversion of all outstanding shares of Korro Bio&#8217;s Preferred Stock into an aggregate of 97,714,516 shares of Korro Bio common stock and without giving effect to any purchases in the Pre-Closing Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, Korro Bio deemed to be outstanding all shares of common stock subject to options held by that person or entity that are currently exercisable or that will become exercisable within 60 days of June&#160;30, 2023. Korro Bio did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Korro Bio, Inc., One Kendall Square, Building <span style="white-space:nowrap">600-700,</span> Suite <span style="white-space:nowrap">6-401,</span> Cambridge, MA 02139. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beneficial Ownership<br />Prior to the Merger</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">5% or Greater Stockholders:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund XI, L.P.(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,959,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 17, L.P.(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,053,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.46</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platanus Investment LLC(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,692,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Fidelity Investments(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,285,675</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.98</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Fund Series Trust, on behalf of Eventide Healthcare &amp; Life Sciences Fund(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,428,540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qiming U.S. Healthcare Fund II, L.P.(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,694,639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.48</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.(7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,571,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.39</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point72 Biotech Private Investments, LLC(8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,571,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.39</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd.(9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,299,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Cormorant Asset</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management LP(10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,299,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">420 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beneficial Ownership<br />Prior to the Merger</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Named Executive Officers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Aiyar(11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,270,757</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.20</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ali Behbahani</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nessan Bermingham(12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,180,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hannah Chang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&#231;ois Formela</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omar Khwaja(13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Colin Walsh</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vineet Agarwal(14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">510,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11 persons)(15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,221,562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.96</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 3,000,000 shares of Korro Bio common stock held by Atlas, (ii) 4,000,000 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series Seed 1 preferred stock held by Atlas, (iii) 2,000,000 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series Seed 2 preferred stock held by Atlas, (iv) 1,538,462 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series Seed 3 preferred stock held by Atlas, (v) 5,357,142 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series A preferred stock held by Atlas and (vi) 3,064,273 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Atlas. The general partner of Atlas is Atlas Venture Associates XI, L.P., or Atlas XI LP, and the general partner of Atlas XI LP is Atlas Venture Associates XI, LLC, or Atlas XI LLC. The members of Atlas XI LLC collectively make decisions on behalf of Atlas XI LLC. Jean-Francois Formela is a member of Atlas XI LLC and a member of Korro Bio&#8217;s board of directors. Each of Atlas XI LP, Atlas XI LLC and Mr.&#160;Formela may be deemed to beneficially own the shares held by Atlas. Each of Atlas XI LP, Atlas XI LLC and Mr.&#160;Formela expressly disclaim beneficial ownership of the securities owned by Atlas, except to the extent of its pecuniary interest therein, if any. The address for Atlas, Atlas XI LP and Atlas XI LLC is 300 Technology Sq., 8th Floor, Cambridge, MA 02139. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 6,126,923 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series Seed 3 preferred stock held by New Enterprise Associates 17, L.P., or New Enterprise 17, (ii) 8,928,572 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series A preferred stock held by New Enterprise 17 and (iii) 2,971,416 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by New Enterprise 17. The general partner of New Enterprise 17 is NEA Partners 17, L.P., or NEA 17 LP, and the general partner of NEA 17 LP is NEA 17 GP, LLC, or NEA 17 LLC. Ali Behbahani, M.D. is a member of NEA 17 LLC and a member of Korro Bio&#8217;s board of directors. Each of NEA 17 LP, NEA 17 LLC and Dr.&#160;Behbahani may be deemed to beneficially own the shares held by New Enterprise 17. Each of NEA 17 LP, NEA 17 LLC and Dr.&#160;Behbahani expressly disclaim beneficial ownership of the securities owned by New Enterprise 17, except to the extent of its pecuniary interest therein, if any. The address for New Enterprise 17, NEA 17 LP and NEA 17 LLC is 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 8,928,572 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series A preferred stock held by Platanus Investment LLC, or Platanus and (ii) 1,764,279 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Platanus. Hannah Chang, M.D., Ph.D. is a member of Platanus and a member of Korro Bio&#8217;s board of directors. The address for Platanus is 3 E 3rd Ave, Suite 200, San Mateo, CA 94401. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 1,857,134 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Fidelity Select Portfolios: Biotechnology Portfolio, (ii) 468,077 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held held by Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, (iii) 2,785,157 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held held by Fidelity Mt. Vernon </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">421 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Street Trust: Fidelity Growth Company Fund, (iv) 3,439,923 shares of the combined company&#8217;s common stock held by Fidelity Growth Company Commingled Pool and (v) 735,384 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held held by Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund. The principal address for the Fidelity Investments entities is 245 Summer Street, Boston, MA 02205. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 7,428,540 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Mutual Fund Series Trust, on behalf of Eventide Healthcare&#160;&amp; Life Sciences Fund, or Eventide. Eventide is governed by a board of trustees, which collectively make decisions on behalf of Eventide. The address for Eventide is U.S. Bank Trust Services, Physical Processing, <span style="white-space:nowrap"><span style="white-space:nowrap">MK-WI-S302,</span></span> 1555 N RiverCenter Drive, Suite 302, Milwaukee, WI 53212. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 5,580,358 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series A preferred stock held by Qiming U.S. Healthcare Fund II, L.P., or Qiming and (ii) 1,114,281 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Qiming. The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC, or Qiming LLC. Colin Walsh, Ph.D. is a member of Qiming LLC and a member of Korro Bio&#8217;s board of directors. The address for Qiming and Qiming LLC is 11100 NE 8<sup style="font-size:75%; vertical-align:top">th</sup> Street, Suite 200, Bellevue, WA 98004. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 5,571,405 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Invus Public Equities L.P., or Invus. The address for Invus is 750 Lexington Avenue, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 5,571,405 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Point72 Biotech Private Investments, LLC, or Point72. The address for Point72 is c/o Point72, L.P., 72 Cummings Point Road, Stamford, CT 06902. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 4,464,286 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series A preferred stock held by Citadel Multi-Strategy Equities Master Fund Ltd., or Citadel Multi-Strategy Ltd., and (ii) 835,710 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Citadel Multi-Strategy Ltd. The portfolio manager of Citadel Multi-Strategy Ltd. is Citadel Advisors LLC. The address for Citadel Multi-Strategy Ltd. and Citadel Advisors LLC is 601 Lexington Avenue, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 930,358 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series A preferred stock held by Cormorant Global Healthcare Master Fund, LP, (ii) 3,533,928 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series A preferred stock held by Cormorant Private Healthcare Fund II, LP and (iii) 835,710 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by Cormorant Private Healthcare Fund II, LP. The principal address for the Cormorant Asset Management LP entities is 200 Clarendon Street 52nd Floor, Boston, Massachusetts 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;92,857 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock held by The Ram Aiyar Irrevocable Trust, or the Trust, and (ii)&#160;2,177,900 shares of Korro Bio common stock underlying options which are exercisable or will become exercisable within 60 days of June 30, 2023. The address of the Trust is c/o Steven M. Burke, P.O. Box 326, Manchester, NH 03105. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;706,702 shares of Korro Bio common stock and (ii)&#160;1,473,981 shares of Korro Bio common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 54,687 shares of Korro Bio common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 510,178 shares of Korro Bio common stock underlying options which are exercisable or will become exercisable within 60 days of June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;706,702 shares of Korro Bio common stock, (ii)&#160;92,857 shares of Korro Bio common stock issuable upon conversion of Korro Bio Series B preferred stock and (ii)&#160;4,422,003 shares of Korro Bio common stock underlying options which are exercisable or will become exercisable within 60&#160;days of June&#160;30, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">422 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_149">PRINCIPAL STOCKHOLDERS OF COMBINED COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed Reverse Stock Split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding beneficial ownership of the combined company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on June&#160;30, 2023 for: each stockholder expected by Frequency and Korro Bio to become the beneficial owner of more than 5% of the combined company&#8217;s outstanding common stock, each person expected to be a named executive officer of the combined company, each person expected to be a director of the combined company, and all of the combined company&#8217;s expected directors and executive officers as a group. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power with respect to the securities as well as any shares of common stock that the individual or entity has the right to acquire within 60 days of June&#160;30, 2023 the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, Frequency and Korro Bio believe, based on the information provided to them, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table lists applicable percentage ownership based on 439,074,950&#160;shares of common stock expected to be outstanding upon consummation of the Merger, after giving effect to the Pre-Closing Financing and prior to giving effect to the proposed Reverse Stock Split. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60 days, including upon the exercise of stock options and the vesting of restricted stock units. These stock options and restricted stock units shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">423 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the Merger, Frequency securityholders as of immediately prior to the Merger are expected to own approximately 8% of the outstanding shares of the combined company, former Korro Bio securityholders, including shares purchased in the Pre-Closing Financing, are expected to own approximately 92% of the outstanding shares of the combined company and shares issued in the Pre-Closing Financing are expected to represent approximately 9.61% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including, but not limited to, Frequency&#8217;s net cash as of closing being equal to $25.0&#160;million. The table below assumes that, based on Frequency&#8217;s and Korro Bio&#8217;s capitalization as of July 14,&#160;2023, the date the Merger Agreement was executed, the exchange ratio is estimated to be equal to approximately 2.7731&#160;shares of Frequency common stock, prior to giving effect to the proposed Reverse Stock Split. The estimated exchange ratio was derived on a fully-diluted basis as of July&#160;14, 2023 using a stipulated value of Korro Bio of approximately $442.9&#160;million (including the Pre-Closing Financing) and of Frequency of approximately $40.0&#160;million. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beneficial Ownership</span><br /><span style="font-weight:bold">After the Merger</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">5% or Greater Stockholders:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund XI, L.P.(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,552,140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 17, L.P.(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,039,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.67</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Fidelity Investments(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,712,435</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.27</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Fund Series Trust, on behalf of Eventide Healthcare &amp; Life Sciences Fund(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,574,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.96</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point72 Biotech Private Investments, LLC(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,412,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.93</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platanus Investment LLC(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,150,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.87</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd.(7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,659,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.76</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Cormorant Asset Management LP(8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,659,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.76</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.(9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,429,955</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Named Executive Officers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vineet Agarwal(10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,414,758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Aiyar(11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,296,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ali Behbahani</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nessan Bermingham(12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,047,186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.37</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hannah Chang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&#231;ois Formela</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David L. Lucchino(13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,391,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omar Khwaja(14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Colin Walsh</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Chappell(15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">569,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (12&#160;persons)(16)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,871,312</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 62,552,140&#160;shares of the combined company&#8217;s common stock held by Atlas XI. The general partner of Atlas&#160;XI is Atlas XI LP and the general partner of Atlas XI LP is Atlas XI LLC. The members of Atlas XI LLC collectively make decisions on behalf of Atlas XI LLC. Jean-Francois Formela is a member of Atlas XI LLC and a member of Korro Bio&#8217;s board of directors. Each of Atlas XI LP, Atlas XI LLC and Mr.&#160;Formela may be deemed to beneficially own the shares held by Atlas XI. Each of Atlas XI LP, Atlas XI LLC and Mr.&#160;Formela expressly disclaim beneficial ownership of the securities owned by Atlas XI, except to the extent of its pecuniary interest therein, if any. The address for Atlas XI, Atlas XI LP and Atlas XI LLC is 300 Technology Sq., 8th Floor, Cambridge, MA 02139. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 60,039,619&#160;shares of the combined company&#8217;s common stock held by New Enterprise 17. The general partner of New Enterprise 17 is NEA 17 LP, and the general partner of NEA 17 LP is NEA 17 LLC. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">424 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Ali Behbahani, M.D. is a member of NEA 17 LLC and a member of Korro Bio&#8217;s board of directors. Each of NEA 17 LP, NEA 17 LLC and Dr.&#160;Behbahani may be deemed to beneficially own the shares held by New Enterprise 17. Each of NEA 17 LP, NEA 17 LLC and Dr.&#160;Behbahani expressly disclaim beneficial ownership of the securities owned by New Enterprise 17, except to the extent of its pecuniary interest therein, if any. The address for New Enterprise 17, NEA 17 LP and NEA 17 LLC is 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;10,137,498&#160;shares of the combined company&#8217;s common stock held by Fidelity Select Portfolios: Biotechnology Portfolio, (ii)&#160;2,254,711&#160;shares of the combined company&#8217;s common stock held by Fidelity Mt.&#160;Vernon Street Trust: Fidelity Series Growth Company Fund, (iii)&#160;11,029,794&#160;shares of the combined company&#8217;s common stock held by Fidelity Mt.&#160;Vernon Street Trust: Fidelity Growth Company Fund, (iv)&#160;14,041,595&#160;shares of the combined company&#8217;s common stock held by Fidelity Growth Company Commingled Pool and (v)&#160;3,248,834&#160;shares of the combined company&#8217;s common stock held by Fidelity Mt.&#160;Vernon Street Trust: Fidelity Growth Company&#160;K6 Fund. The principal address for the Fidelity Investments entities is 245 Summer Street, Boston, MA 02205. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 30,574,933&#160;shares of the combined company&#8217;s common stock held by Mutual Fund Series Trust, on behalf of Eventide. Eventide is governed by a board of trustees, which collectively make decisions on behalf of Eventide. The address for Eventide is U.S. Bank Trust Services, Physical Processing, <span style="white-space:nowrap"><span style="white-space:nowrap">MK-WI-S302,</span></span> 1555 N RiverCenter Drive, Suite 302, Milwaukee, WI 53212. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 30,412,504&#160;shares of the combined company&#8217;s common stock held by Point72. The address for Point72 is c/o Point72, L.P., 72 Cummings Point Road, Stamford, CT 06902. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 30,150,778&#160;shares of the combined company&#8217;s common stock held by Platanus. Hannah Chang, M.D., Ph.D. is a member of Platanus and a member of Korro Bio&#8217;s board of directors. The address for Platanus is 3&#160;E&#160;3rd Ave, Suite&#160;200, San Mateo, CA 94401. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 29,659,866&#160;shares of the combined company&#8217;s common stock held by Citadel Multi-Strategy Equities Master Fund Ltd., or Citadel Multi-Strategy Ltd. The portfolio manager of Citadel Multi-Strategy Ltd. is Citadel Advisors LLC. The address for Citadel Multi-Strategy Ltd. and Citadel Advisors LLC is 601&#160;Lexington Avenue, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;2,579,947&#160;shares of the combined company&#8217;s common stock held by Cormorant Global Healthcare Master Fund, LP and (ii)&#160;27,079,919&#160;shares of the combined company&#8217;s common stock held by Cormorant Private Healthcare Fund II, LP. The principal address for the Cormorant Asset Management LP entities is 200&#160;Clarendon Street 52nd&#160;Floor, Boston, Massachusetts 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 23,429,955&#160;shares of Korro Bio common stock issuable upon conversion of Korro Bio Series&#160;B preferred stock held by Invus Public Equities L.P., or Invus. The address for Invus is 750&#160;Lexington Avenue, New York, NY&#160;10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 1,414,758&#160;shares of the combined company&#8217;s common stock underlying options which are exercisable or will become exercisable within 60 days of June 30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 257,498&#160;shares of the combined company&#8217;s common stock held by The Ram Aiyar Irrevocable Trust, or the Trust, and (ii) 6,039,468&#160;shares of the combined company&#8217;s common stock underlying options which are exercisable or will become exercisable within 60 days of June 30, 2023. The address of the Trust is c/o Steven M. Burke, P.O. Box 326, Manchester, NH 03105. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 1,959,734&#160;shares of the combined company&#8217;s common stock and (ii) 4,087,452&#160;shares of the combined company&#8217;s common stock underlying options which are exercisable or will become exercisable within 60 days of June 30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 2,391,561 shares of the combined company&#8217;s common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 151,650&#160;shares of the combined company&#8217;s common stock underlying options which are exercisable or will become exercisable within 60 days of June 30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 569,191&#160;shares of the combined company&#8217;s common stock underlying options which are exercisable or will become exercisable within 60 days of June 30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 4,608,793&#160;shares of the combined company&#8217;s common stock and (ii) 12,262,519&#160;shares of the combined company&#8217;s common stock underlying options which are exercisable or will become exercisable within 60 days of June 30, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">425 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_150">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Latham&#160;&amp; Watkins LLP will pass upon the validity of Frequency common stock offered by this proxy statement/prospectus. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_151">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Frequency Therapeutics Inc. as of December&#160;31, 2022 and 2021 and for the years then ended have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report thereon included in this Registration Statement and proxy/prospectus in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Korro Bio, Inc. at December&#160;31, 2022 and 2021, and for the years then ended, included in this proxy statement/prospectus have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">426 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_152">OTHER MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stockholder Proposals and Director Nominations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency stockholders who intend to have a proposal considered for inclusion in Frequency&#8217;s proxy materials for presentation at Frequency annual meeting of stockholders to be held in 2024, or the 2024 Annual Meeting, pursuant to Rule <span style="white-space:nowrap">14a-8</span> under the Exchange Act must submit the proposal to Frequency&#8217;s Secretary at Frequency&#8217;s offices at 75 Hayden Avenue, Lexington, MA 02421 in writing not later than &#160;&#160;&#160;&#160;, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency stockholders intending to present a proposal at Frequency&#8217;s 2024 Annual Meeting, but not to include the proposal in its proxy statement, or to nominate a person for election as a director, must comply with the requirements set forth in the Amended and Restated Bylaws of Frequency. The Amended and Restated Bylaws of Frequency require, among other things, that Frequency&#8217;s Secretary receive written notice from a stockholder of record of their intent to present such a proposal or nomination not earlier than the 120th day and not later than the 90th day prior to the anniversary of the preceding year&#8217;s annual meeting of stockholders. Therefore, Frequency must receive notice of such a proposal or nomination for the 2024 Annual Meeting no earlier than &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 and no later than &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024. The notice must contain the information required by the Amended and Restated Bylaws of Frequency. In the event that the date of the 2024 Annual Meeting is more than 30 days before or more than 60 days after &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, then Frequency&#8217;s Secretary must receive such written notice not earlier than the close of business on the 120th day prior to the 2024 Annual Meeting and not later than the close of business of the 90th day prior to the 2024 Annual Meeting or, if later, the close of business of the 10th day following the day on which public disclosure of the date of such meeting is first made by Frequency. SEC rules permit management to vote proxies in its discretion in certain cases if the stockholder does not comply with this deadline and, in certain other cases notwithstanding the Frequency stockholder&#8217;s compliance with this deadline. In addition to satisfying the foregoing requirements under the Amended and Restated Bylaws of Frequency, to comply with the universal proxy rules (once they become effective), Frequency stockholders who intend to solicit proxies in support of director nominees other than Frequency&#8217;s nominees must provide notice that sets forth the information required by Rule <span style="white-space:nowrap">14a-19</span> under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency reserves the right to reject, rule out of order or take other appropriate action with respect to any proposal that does not comply with these or other applicable requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency intends to file a proxy statement and WHITE proxy card with the SEC in connection with the solicitation of proxies for Frequency&#8217;s 2024 Annual Meeting of Frequency stockholders. Frequency stockholders may obtain the proxy statement (and any amendments and supplements thereto) and other documents as and when filed by Frequency with the SEC without charge from the SEC&#8217;s website at: www.sec.gov. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Householding of Proxy Statement/Prospectus </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and notices with respect to two or more stockholders sharing the same address by delivering a single proxy statement or a single notice addressed to those stockholders. This process, which is commonly referred to as &#8220;householding&#8221;, provides cost savings for companies and helps the environment by conserving natural resources. Some brokers also household proxy materials, delivering a single proxy statement or notice to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Frequency agrees to deliver promptly, upon written or oral request, a separate copy of the notice or proxy materials, as requested, to any Frequency stockholder at the shared address to which a single copy of those documents was delivered. If you would like to receive a separate copy of these documents, or if you receive multiple copies and would like to receive a single copy of these documents, please follow the instructions found on the notice, by telephone at (866) <span style="white-space:nowrap">648-8133</span> or by emailing paper@investorelections.com and providing the Control Number found on your proxy card. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">427 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" /><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" id="hidden84371167" contextRef="P01_01_2022To12_31_2022">2014-11-30</ix:nonNumeric><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" id="hidden84371168" contextRef="P01_01_2023To03_31_2023">2014-11-30</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentPaymentTerms" id="hidden84371525" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">The Company made monthly interest only payments through November 30, 2022. The principal balance and interest were to be repaid in equal monthly installments after the interest only period and continue through May 1, 2024 (Loan Maturity Date).</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="freq-20230331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="rom451428_153" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Financial Statements of Frequency Therapeutics, Inc. for the Years Ended December&#160;31, 2022 and 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 96%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_1">Report of an Independent Registered Public Accounting Firm</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_2">Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_3">Consolidated Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_4">Consolidated Statements of Comprehensive Loss</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_5">Consolidated Statements of Stockholders&#8217; Equity</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_6">Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_7">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-8</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Consolidated Financial Statements of Frequency Therapeutics, Inc. for the Three Months Ended March&#160;31, 2023 and 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_8">Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-34</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_9">Consolidated Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-35</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_10">Consolidated Statements of Comprehensive Loss</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-36</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_11">Consolidated Statements of Stockholders&#8217; Equity</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-37</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_12">Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-38</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_13">Notes to Unaudited Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-39</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Financial Statements of Korro Bio, Inc. for the Years Ended December&#160;31, 2022 and 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_14">Report of Independent Registered Public Accounting Firm</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-53</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_15">Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-54</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_16">Consolidated Statements of Operations and Comprehensive Loss</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-55</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_17">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-56</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_18">Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-58</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_19">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-59</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Consolidated Financial Statements of Korro Bio, Inc. for the Three Months Ended March&#160;31, 2023 and 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_20">Condensed Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-83</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_21">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-84</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_22">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-85</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_23">Condensed Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-86</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin451428_24">Notes to Condensed Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-87</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin451428_1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Stockholders and the Board of Directors of Frequency Therapeutics, Inc. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Frequency Therapeutics, Inc. and its subsidiaries (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2017. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ RSM US LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Boston, Massachusetts </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;10, 2023 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_2" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Balance Sheets </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,954</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">79,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,072</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,041</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,493</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">134,748</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,719</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,350</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:OtherLongTermAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:OtherLongTermAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">320</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">185,358</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and Stockholders&#8217; Equity</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,748</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,747</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">833</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,026</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,429</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermLoansFromBank" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermLoansFromBank" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,043</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,534</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized, <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued or outstanding at December&#160;31, 2022 and December&#160;31, 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">35,262,083</ix:nonFraction></ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">34,611,213</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2022 and December&#160;31, 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">331,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">310,936</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">261,665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">180,085</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">69,195</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">185,358</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_3" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Operations </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,068</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,418</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,923</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,002</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">98,099</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,002</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,031</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">961</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Realized gain (loss) on investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange (loss) gain</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense), net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,056</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,671</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax benefit (provision)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:Earningpersharebasicanddiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">2.33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:Earningpersharebasicanddiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">2.47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">35,075,924</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">34,351,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_4" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Comprehensive Loss </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,716</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_5" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statement of Stockholders&#8217; Equity </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common<br/> shares issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common<br/> par&#160;value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/> capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> other<br/> comprehensive<br/> loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> stockholders&#8217;<br/> equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">33,964,000</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">287,829</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">95,399</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">192,491</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases under Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,064</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock upon exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">642,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,297</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of restricted stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">34,611,213</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">310,936</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">62</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">180,085</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,824</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases under Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">76,606</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock upon exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock under equity offering</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:StockIssuedDuringPeriodSharesUnderEquityOffering" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">12,767</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock pursuant to restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">551,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">35,262,083</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">331,023</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">261,665</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">69,195</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_6" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Cash Flows </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from operating activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:NonCashLeaseExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:NonCashLeaseExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,066</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on disposal of assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">681</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">677</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,292</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,068</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:IncreaseDecreaseInLeaseLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:IncreaseDecreaseInLeaseLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">398</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">58,237</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">76,059</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from investing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:ProceedsFromPaymentForPropertyAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:ProceedsFromPaymentForPropertyAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92,445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemption of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,338</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by (used in) investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">66,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from financing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">833</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash (used in) provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">577</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,358</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net decrease in cash, cash equivalents, and restricted cash</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,681</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">140,827</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,334</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,334</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosures:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">703</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_7" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Amounts in thousands, except share and per share amounts) </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Lexington, Massachusetts, was incorporated in <span style="-sec-ix-hidden:hidden84371167">November 2014</span> as a Delaware corporation. Frequency Japan was closed down in February 2021. The Company is a preclinical-stage regenerative medicine company focused on developing therapeutics to activate a person&#8217;s innate regenerative potential to restore function. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and capital resources </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has funded its operations primarily with proceeds from private and public securities financings, a term loan, and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">261,665</ix:nonFraction>. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371085"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of significant accounting policies </div></div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards</div></div> Codification (ASC). </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan through the date of its dissolution. All intercompany transactions and balances have been eliminated. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. </div></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-8 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_84371085" continuedAt="TextSelectionAppend_84371085_1"><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. Net loss and other comprehensive loss are reported net of any related tax effect to arrive at comprehensive loss. Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the years ended December&#160;31, 2022 and 2021 consist of unrealized loss on marketable securities. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Segment information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, view the Company&#8217;s operations and manage its business as a single operating segment, which is in the business of developing therapeutics to activate a person&#8217;s innate regenerative potential to restore function. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2022 and 2021 the Company recorded $<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction> of foreign currency exchange loss and $<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction> of foreign currency exchange gain, respectively. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2022 and 2021 consists entirely of cash and money market funds. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has $<ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2022_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2021_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></ix:nonFraction> of restricted cash as of December&#160;31, 2022 and December&#160;31, 2021, which represents a security deposit on the Company&#8217;s Lexington, Massachusetts facility. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketable securities represent holdings of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable securities mature within one year from the balance sheet date while long-term marketable securities mature after one year. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are reflected as a component of other expense. Interest on securities sold is determined based on the specific identification method and reflected as interest income. Any realized gains or losses on the sale of investment are reflected as realized gain (loss) on investments. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371128"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of credit risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and </div></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-9 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371085_1" continuedAt="TextSelectionAppend_84371085_2"><ix:continuation id="TextSelection_84371128"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">restricted cash at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of short term and long term investments. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </div></ix:continuation><ix:nonNumeric name="freq:SignificantSuppliersPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Significant suppliers </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div> (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Quoted prices in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371131"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div></div><ix:nonNumeric name="freq:PropertyAndEquipmentTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of lab equipment, furniture and office equipment and software recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen">3 years</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen">3 years</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2022_FurnitureAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen">3 years</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></ix:continuation><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-10 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371085_2" continuedAt="TextSelectionAppend_84371085_3"><ix:continuation id="TextSelection_84371131"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations. </div></ix:continuation><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of long-lived assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognize any impairment losses for the years ended December&#160;31, 2022 and 2021. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs and accruals </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, preclinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for leases under ASC 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>. The Company determines if an arrangement is, or contains, a lease at inception and, if so, records a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) asset and a lease liability on the consolidated balance sheet for any lease with a term longer than 12 months. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does <ix:nonFraction name="freq:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t include an option to purchase the underlying asset that the Company is reasonably certain to exercise. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, the Company has elected to account for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, such as common area maintenance charges, as a single lease component. </div></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-11 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371085_3" continuedAt="TextSelectionAppend_84371085_4"><ix:nonNumeric name="us-gaap:CollaborativeArrangementAccountingPolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371135"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC&#160;808, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative Arrangements</div></div> (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (ASC 606). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> clinical activities are recognized as research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> agreements that are within the scope of ASC 606. The terms of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></ix:continuation><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-12 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371085_4" continuedAt="TextSelectionAppend_84371085_5"><ix:continuation id="TextSelection_84371135"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (Astellas), as further described in Note 13, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration agreement</div></div>&#8221;, of notes to consolidated financial statements. </div></ix:continuation><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371136"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this standard. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC&#160;606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a)&#160;a good or service (or bundle of goods and services) that is distinct, or (b)&#160;a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> research and development activities, and/or manufacturing services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated </div></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:continuation><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-13 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371085_5" continuedAt="TextSelectionAppend_84371085_6"><ix:continuation id="TextSelection_84371136"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. </div> </ix:continuation><ix:nonNumeric name="freq:PatentCostsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371138"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-09</div> which identifies areas for simplification of several areas of share-based payment transactions. The Company treats <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> The Company believes the fair value of the stock options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> is more reliably determinable than the fair value of the services provided. </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-14 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371085_6" continuedAt="TextSelectionAppend_84371085_7"><ix:continuation id="TextSelection_84371138"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses the fair value of its share-based compensation awards to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> on a straight-line basis over the requisite service period, which is generally the vesting period. </div> </ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2022 and 2021, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 11, <div style="null;text-indent: 0px;;display:inline;">&#8220;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes</div></div>&#8221;). </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371140"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss per share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2022 and 2021 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-15 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371085_7"><ix:continuation id="TextSelection_84371140"><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">35,075,924</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">34,351,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:Earningpersharebasicanddiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">2.33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:Earningpersharebasicanddiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">2.47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Recently issued and adopted accounting pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses</div></div> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted this standard on <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:date-monthname-day-year-en">January 1, 2023</ix:nonNumeric> and it did not have a material <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true">impact</ix:nonNumeric> on the consolidated financial statements. </div></ix:nonNumeric> </ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371088"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair value measurements </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371145"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December&#160;31, 2022 and 2021 are summarized as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gain&#160;(Loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,649</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">137</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,928</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-16 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_84371088"><ix:continuation id="TextSelection_84371145">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,116</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,072</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,719</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">110,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2022 and 2021, we held 14 and 18 debt securities, respectively, that were in an unrealized loss position. The unrealized losses at December&#160;31, 2022 and 2021 were attributable to changes in interest rates and do not represent credit losses. The Company does not intend to sell the investments before recovery of their amortized cost bases, which may be at maturity. All investments mature within twelve months from December&#160;31, 2022. <ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371146">The following tables summarize the Company&#8217;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position.</ix:nonNumeric> </div><ix:continuation id="TextSelection_84371146"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than&#160;12&#160;Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,719</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,719</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,710</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,710</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Prepaid expenses and other current assets </div></div><ix:nonNumeric name="freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Rent and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:PrepaidRentAndDepositsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:PrepaidRentAndDepositsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">470</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:PrepaidResearchAndDevelopmentExpenseCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,084</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:PrepaidResearchAndDevelopmentExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:PrepaidAccountsReceivableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:PrepaidAccountsReceivableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Insurance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">185</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,041</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-17 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and equipment </div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment include the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,706</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,177</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,235</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,706</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,766</ix:nonFraction> and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,775</ix:nonFraction> of depreciation expense for the years ended December&#160;31, 2022 and 2021, respectively. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued expenses </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payroll and employee related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">767</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Third-party research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">773</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">840</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">525</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Debt </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2020, the Company entered into a Loan and Security Agreement (Loan Agreement) with a commercial bank for a term loan with a principal balance of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,000</ix:nonFraction>. <span style="-sec-ix-hidden:hidden84371525">The Company made <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis">monthly</ix:nonNumeric> interest only payments through <ix:nonNumeric name="freq:DebtInstrumentInterestOnlyPaymentMaturityDate" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis" format="ixt:date-monthname-day-year-en">November 30, 2022</ix:nonNumeric>. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continue through <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis" format="ixt:date-monthname-day-year-en">May 1, 2024</ix:nonNumeric> (Loan Maturity Date).</span> Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.50</ix:nonFraction>% plus the Prime Rate (as reported in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Wall Street Journal</div></div>, subject to an interest rate floor of <ix:nonFraction name="freq:DebtInstrumentFloorInterestRatePercentage" contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen">zero</ix:nonFraction>) or (ii) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2022To12_31_2022_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.75</ix:nonFraction>%. The interest rate at December&#160;31, 2022 was <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.0</ix:nonFraction>%. Interest expense related to the Loan Agreement was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">961</ix:nonFraction> for the year ended December&#160;31, 2022 and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">764</ix:nonFraction> for the year ended December&#160;31, 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) <ix:nonFraction name="freq:DebtInstrumentPrepaymentPremiumPercentage" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.0</ix:nonFraction>% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) <ix:nonFraction name="freq:DebtInstrumentPrepaymentPremiumPercentage" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) <ix:nonFraction name="freq:DebtInstrumentPrepaymentPremiumPercentage" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction>% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the term loan is refinanced by the bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will pay a final payment of $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150</ix:nonFraction>, which will occur on the earliest of: (i)&#160;the Loan Maturity Date; (ii)&#160;the date that the Company prepays all of the outstanding principal in full; (iii)&#160;the date the loan payments are accelerated due to an event of default; or (iv)&#160;the termination of the Loan Agreement. The Company is accruing the final payment over the term of the loan. The term loan is secured by substantially all of the Company&#8217;s assets, excluding intellectual property. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-18 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Stockholders&#8217; equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has authorized <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> shares of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> par value preferred stock of which <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares were issued or outstanding as of December&#160;31, 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Common stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has authorized <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction> shares of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> par value common stock of which <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">35,262,083</ix:nonFraction></ix:nonFraction> were issued and outstanding as of December&#160;31, 2022. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors. </div><ix:nonNumeric name="freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has reserved the following shares of common stock for future issuance as of December&#160;31, 2022 and 2021: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,742,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,830,037</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares available for future grant under stock option plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_StockCompensationPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">988,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021_StockCompensationPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,552,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,730,269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,382,667</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Equity Offerings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;10, 2021, the Company entered into an Equity Distribution Agreement (Sales Agreement) with Oppenheimer&#160;&amp; Co. Inc. (Sales Agent) to sell shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> per share, with aggregate gross sales proceeds of up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P12_10_2021To12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>, from time to time, through an &#8220;at the market&#8221; equity offering program. Subject to the terms and conditions of the Sales Agreement, the Sales Agent may sell the shares by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made through The Nasdaq Global Select Market, on any other existing trading market for the Common Stock, to or through a market maker, or, if expressly authorized by the Company, in privately negotiated transactions. The Company or Sales Agent may terminate the Sales Agreement upon notice to the other party and subject to other conditions. The Company will pay the Sales Agent a commission equal to <ix:nonFraction name="freq:SalesAgentCommission" contextRef="PAsOn12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction>% of the gross proceeds of any Common Stock sold through the Sales Agent under the Sales Agreement and has provided the Sales Agent with customary indemnification rights. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issuance costs incurred related to the Sales Agreement are classified as long-term assets on the balance sheet at December&#160;31, 2022. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371100"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Stock-based compensation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&#8217;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn11_13_2014_TwoThousandAndFourteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,550,415</ix:nonFraction> shares of common stock for issuance under the 2014 Plan. As of December&#160;31, 2022, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2022_TwoThousandAndFourteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of common stock available for future grants under the 2014 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2019, the Company&#8217;s board of directors and on September&#160;19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (2019 Plan). Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries. A total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn09_17_2019_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,100,000</ix:nonFraction> shares of common stock were approved to be </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-19 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371100" continuedAt="TextSelectionAppend_84371100_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371100_1" continuedAt="TextSelectionAppend_84371100_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371100_2" continuedAt="TextSelectionAppend_84371100_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371100_3" continuedAt="TextSelectionAppend_84371100_4"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">initially reserved for issuance under the 2019 plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="P01_01_2022To12_31_2022_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis">In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" contextRef="P01_01_2022To12_31_2022_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten-year</ix:nonNumeric></div> term of the 2019 Plan, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by the amount equal to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="P01_01_2022To12_31_2022_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</ix:nonNumeric> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stock option grants are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&#8217;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:durwordsen">four years</ix:nonNumeric> and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock options </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise&#160;price<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">&#160;(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term&#160;(in&#160;years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> intrinsic<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,816,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.45</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">171,415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,357,426</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">32.76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.07</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">642,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">701,873</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">16.48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,830,037</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">7.76</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">221,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.32</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,299,113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.04</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,742,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.69</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,579,486</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.39</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,071</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options unvested as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,162,567</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">7.84</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,043</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:8.3px">(1)</div> On August&#160;17, 2022, the Company&#8217;s Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $<ix:nonFraction name="us-gaap:StockOptionExercisePriceDecrease" contextRef="P08_17_2022To08_17_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.14</ix:nonFraction>, the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022.<div style="background-color:#ffffff;;display:inline;"> </div><div style="null;text-indent: 0px;;display:inline;"></div><div style="display:inline;"><div style="background-color:#ffffff;;display:inline;">See &#8220;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="background-color:#ffffff;;display:inline;">Repricing of stock options</div></div></div><div style="background-color:#ffffff;;display:inline;">&#8221; section for more information. </div></div></div> </ix:nonNumeric><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-20 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_84371100_4" continuedAt="TextSelectionAppend_84371100_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_84371100_5" continuedAt="TextSelectionAppend_84371100_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371100_6" continuedAt="TextSelectionAppend_84371100_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371100_7"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock option valuation </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">80.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">79.8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of options granted to employees during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.58</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">22.39</ix:nonFraction> respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total grant date fair value of options vested during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,219</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,304</ix:nonFraction>, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Repricing of stock options </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;17, 2022, the Board of Directors approved the repricing of each Underwater Option to $<ix:nonFraction name="us-gaap:StockOptionExercisePriceDecrease" contextRef="P08_17_2022To08_17_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.14</ix:nonFraction>, the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022. Except for the modification of the exercise price, all other terms and conditions of the Underwater Options remain in effect. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option repricing resulted in incremental stock-based compensation of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,505</ix:nonFraction>, of which $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,630</ix:nonFraction> was recorded as expense in the year ended December&#160;31, 2022 and $<ix:nonFraction name="freq:ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">875</ix:nonFraction> will be recognized as expense over the remaining vesting period. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted stock units </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes restricted stock unit activity within the Company&#8217;s 2019 Incentive Award Plan for the year ended December&#160;31, 2022. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average&#160;fair<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">626,300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Awarded</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,576,650</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.01</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">551,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">549,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.06</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,101,650</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,831</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,750</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021 respectively, is included in research and development and general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, total unrecognized stock-based compensation expense relating to unvested stock options and restricted stock units was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,537</ix:nonFraction> and $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,112</ix:nonFraction>, respectively. This amount is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">1.55</ix:nonNumeric> years and <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">2.49</ix:nonNumeric> years, respectively. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-21 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="freq:EmployeeStockPurchasePlanDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Employee stock purchase plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (ESPP) which became effective on the date of the Company&#8217;s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction name="freq:PercentageOfEligibleEmployeeCompensation" contextRef="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first <ix:nonNumeric name="freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" contextRef="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> of the term of the ESPP, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by an amount equal to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s first offering period of 2021 concluded on June&#160;30, 2021 with the purchase of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2021To06_30_2021_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,064</ix:nonFraction> shares in July 2021 related to this offering period. The Company&#8217;s second offering period of 2021 concluded on December&#160;31, 2021 with the purchase of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">31,832</ix:nonFraction> shares in January 2022. The Company&#8217;s first offering period of 2022 concluded on June&#160;30, 2022 with the purchase of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2022To06_30_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">44,774</ix:nonFraction> shares in July 2022 related to this offering period. As of December&#160;31, 2022, a total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,225,527</ix:nonFraction> shares remain for future offering periods. The Company&#8217;s second offering period of 2022 concluded on December&#160;31, 2022 with the purchase of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P07_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">24,754</ix:nonFraction> shares in January 2023 related to this offering. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371105"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Income taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which the Company has <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P12_31_2014To12_31_2014_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had federal net operating loss carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MAsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">174,107</ix:nonFraction> and Massachusetts state operating loss carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_MAsrtStatementGeographicalAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">141,318</ix:nonFraction> which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $<ix:nonFraction name="freq:NetOperatingLossCarryforwardsExpirationWithLimitation" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,399</ix:nonFraction> available to reduce future taxable income through <ix:nonNumeric name="freq:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">2037</ix:nonNumeric> and approximately $<ix:nonFraction name="freq:NetOperatingLossCarryforwardsExpirationWithoutLimitation" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,708</ix:nonFraction> which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through <ix:nonNumeric name="freq:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2042</ix:nonNumeric>. As of December&#160;31, 2022, the Company also had federal and Massachusetts research and development tax credit carryforwards of $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,177</ix:nonFraction> and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2022_MAsrtStatementGeographicalAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,556</ix:nonFraction>, respectively, which are available to offset federal and state tax liabilities through <ix:nonNumeric name="freq:TaxCreditCarryforwardExpirationYear" contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">2042</ix:nonNumeric> and <ix:nonNumeric name="freq:TaxCreditCarryforwardExpirationYear" contextRef="P01_01_2022To12_31_2022_MAsrtStatementGeographicalAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2037</ix:nonNumeric>, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a <ix:nonNumeric name="freq:PeriodOfCumulativeChangeInOwnership" contextRef="P01_01_2022To12_31_2022_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> period in excess of <ix:nonFraction name="freq:CumulativeChangeInOwnershipPercentage" contextRef="P01_01_2022To12_31_2022_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>%, as provided under Sections 382 and 383 of the Code, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382 of the Code, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a rolling three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn02_28_2017_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,400</ix:nonFraction> of the U.S. net operating loss carryforwards which were incurred prior to March 2017 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-ownership</div> change) is limited under Section&#160;382 of the Code. After the limitations under Section&#160;382 of the Code, the Company may utilize approximately $<ix:nonFraction name="freq:OperatingLossCarryforwardsUsageAfterOwnershipChange" contextRef="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,800</ix:nonFraction> of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-ownership</div> change net operating loss carryforwards based upon an annual usage of approximately $<ix:nonFraction name="freq:OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" contextRef="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,600</ix:nonFraction> for each of the next five years after the ownership change and approximately $<ix:nonFraction name="freq:OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" contextRef="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">180</ix:nonFraction> for each of the 15 years thereafter. The remaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-March</div> 2017 ownership change net operating losses of approximately $<ix:nonFraction name="freq:RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" contextRef="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,600</ix:nonFraction> were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> rate. These </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-22</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371105" continuedAt="TextSelectionAppend_84371105_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371105_1" continuedAt="TextSelectionAppend_84371105_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371105_2" continuedAt="TextSelectionAppend_84371105_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371105_3" continuedAt="TextSelectionAppend_84371105_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">carryforwards may be subject to further annual limitations under Section&#160;382 of the Code in the event of future changes in ownership. Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO. Accordingly, utilization of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn10_31_2019_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,123</ix:nonFraction> of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section&#160;382 of the Code. The Company has determined it will be able to utilize the entire $46,123 of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-ownership</div> change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section&#160;382 of the Code in the event of future changes in ownership. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2022 and 2021 because the Company&#8217;s management has determined that it is more likely than not that the Company will <ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,288</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,931</ix:nonFraction> as of December&#160;31, 2022 and 2021 has been established. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> interest or penalties were recorded for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. </div><ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss for the years ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,586</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:PreTaxNetLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:PreTaxNetLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,671</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_84371105_4" continuedAt="TextSelectionAppend_84371105_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371105_5" continuedAt="TextSelectionAppend_84371105_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371105_6" continuedAt="TextSelectionAppend_84371105_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371105_7"><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s provision at December&#160;31, 2022 and 2021 consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total (benefit) provision</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S federal statutory income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income taxes, net of federal benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.4</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.7</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.6</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State rate changes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.7</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation deductions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">2.8</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.6</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other items</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in deferred tax asset valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">32.3</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">28.2</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effective income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s deferred tax assets at December&#160;31, 2022 and 2021 consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,512</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,590</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,163</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,026</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,042</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangibles</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">478</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">392</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,507</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,554</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">357</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">176</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">282</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">265</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="freq:DeferredTaxAssetsLeasingArrangements" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,735</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="freq:DeferredTaxAssetsLeasingArrangements" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,269</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,076</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,379</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,288</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,931</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,788</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,448</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="freq:DeferredTaxAssetsRightOfUseAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,788</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="freq:DeferredTaxAssetsRightOfUseAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,448</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset (liability)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-24 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="freq:LicenseAgreementTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371841"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Research and license agreements </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Massachusetts Institute of Technology </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <ix:nonNumeric name="freq:LicenseAgreementEnteredDate" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt:date-monthname-year-en">December 2016</ix:nonNumeric>, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322.</div> <ix:nonNumeric name="freq:DescriptionOfFutureDevelopmentObligations" contextRef="P01_01_2022To12_31_2022_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">The Company&#8217;s future development obligations are: (i)&#160;to commence a Phase 3 clinical trial for such Product within five years of the IND filing for such product, (ii)&#160;to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii)&#160;to make a first commercial sale of such Product within 11 years of the IND filing for such Product.</ix:nonNumeric> The Company also has certain development obligations for a second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fails to cure such breach within ninety (90)&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent applications, and its rights to enforce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents are subject to certain limitations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering into the MIT License Agreement, the Company paid a $<ix:nonFraction name="freq:LicenseFeePayment" contextRef="PAsOn12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction> license fee payment and issued to MIT shares of our common stock equal to <ix:nonFraction name="freq:PercentageOfSharesOfCommonStockIssued" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $<ix:nonFraction name="freq:MilestonePayments" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,900</ix:nonFraction> on each Licensed Product or Licensed Process. In addition, the Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-twenties</div> royalty on sublicense revenues. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. <ix:nonNumeric name="freq:DescriptionOfConditionsToTerminateLicenseAgreement" contextRef="P01_01_2022To12_31_2022_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">The Company has the right to terminate for any reason upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="freq:RightToTerminateAgreementUponPriorWrittenNotice" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" format="ixt-sec:durmonth">3</ix:nonNumeric>-month</div> prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (<ix:nonNumeric name="freq:RightToTerminateAgreementIfBreachRemainsUncured" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" format="ixt-sec:durday">90</ix:nonNumeric>)&#160;days (or thirty (<ix:nonNumeric name="freq:RightToTerminateAgreementIncaseOfNonpayment" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric>)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringed</div> (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, the Company entered into an amendment with MIT, removing a patent and certain patent applications from the MIT License Agreement which were unrelated to the Company&#8217;s hearing and MS programs and which were not being utilized by the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-25</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371841" continuedAt="TextSelectionAppend_84371841_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371841_1" continuedAt="TextSelectionAppend_84371841_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371841_2" continuedAt="TextSelectionAppend_84371841_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371841_3" continuedAt="TextSelectionAppend_84371841_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr.&#160;Langer, one of the Company&#8217;s directors. Pursuant to MIT&#8217;s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr.&#160;Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr.&#160;Langer has received $<ix:nonFraction name="us-gaap:PaymentForManagementFee" contextRef="P01_01_2022To12_31_2022_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction> and $<ix:nonFraction name="us-gaap:PaymentForManagementFee" contextRef="P01_01_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction> from MIT under the MIT Policy during the years ended December&#160;31, 2022 and 2021, respectively. Refer to Note 18, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related party transactions</div></div>&#8221;, for all related party disclosures. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">The Scripps Research Institute (California Institute for Biomedical Research) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <ix:nonNumeric name="freq:LicenseAgreementEnteredDate" contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt:date-monthname-year-en">September 2018</ix:nonNumeric>, the Company entered into a license agreement (CALIBR License Agreement) with the California Institute for Biomedical Research (CALIBR) under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> licenses to other nonprofit or academic institutions, for any internal research and educational purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR Licensed Product. The Company is also subject to certain milestone timeline obligations, which may be extended in certain circumstances as set forth in the CALIBR License Agreement. In October 2021, the Company entered into an amendment with CALIBR which updated the milestone obligations to: (i)&#160;initiate a Phase 2 clinical trial (or equivalent) for a CALIBR Licensed Product by December&#160;31, 2023 and (ii)&#160;initiate a Phase 3 clinical trial (or equivalent) for a CALIBR Licensed Product by December&#160;31, 2025. The Company does not have the right to control prosecution of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent applications, and the Company&#8217;s rights to enforce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents are subject to certain limitations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering into the CALIBR License Agreement, the Company made a $<ix:nonFraction name="freq:LicenseFeePayment" contextRef="PAsOn09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction> license fee payment and is required to make milestone payments up to $<ix:nonFraction name="freq:MilestonePayments" contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,000</ix:nonFraction> for each Category of CALIBR Licensed Products (Category 1 is any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 is any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursor cells from <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> studies and/or are active in animal models relevant to MS). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-teen</div> percentage to <ix:nonFraction name="freq:PercentageOfRoyaltyOnSublicenseRevenue" contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>%. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and CALIBR Licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Product-by-CALIBR</div></div> Licensed Product basis upon the later of (1)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> prior written notice. <ix:nonNumeric name="freq:DescriptionOfConditionsToTerminateLicenseAgreement" contextRef="P01_01_2022To12_31_2022_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (<ix:nonNumeric name="freq:RightToTerminateLicensedPatentsUponPriorWrittenNotice" contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" format="ixt-sec:durday">90</ix:nonNumeric>)&#160;days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (<ix:nonNumeric name="freq:RightToTerminateAgreementIfBreachRemainsUncured" contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric>)&#160;days. CALIBR has the right to terminate or reduce the license to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.</ix:nonNumeric> </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-26 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_84371841_4" continuedAt="TextSelectionAppend_84371841_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371841_5" continuedAt="TextSelectionAppend_84371841_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371841_6" continuedAt="TextSelectionAppend_84371841_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371841_7"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <ix:nonNumeric name="freq:LicenseAgreementEnteredDate" contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_NonExclusivePatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt:date-monthname-year-en">February 2019</ix:nonNumeric>, the Company entered into an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Exclusive</div> Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss (MEE licensed products). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is obligated to use diligent efforts to develop and commercialize the MEE licensed products. The Company met one of its milestone timeline obligations by dosing a first subject in a Phase 2 trial by December&#160;31, 2020. The Company is still subject to a milestone timeline obligation to dose a first subject in a Phase 3 trial by December&#160;31, 2024. The Company does not control the filing, prosecution, enforcement, and defense of any licensed patent rights. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering the MEE License, the Company made a $<ix:nonFraction name="freq:LicenseFeePayment" contextRef="PAsOn02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction> license fee payment. The Company is obligated to pay certain annual license maintenance fees between $<ix:nonFraction name="freq:AnnualLicenseFeePerShare" contextRef="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">5</ix:nonFraction> and $<ix:nonFraction name="freq:AnnualLicenseFeePerShare" contextRef="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="1" scale="0" format="ixt:num-dot-decimal">7.5</ix:nonFraction> per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. The Company is also obligated to pay a minimum annual royalty payment of $<ix:nonFraction name="freq:RoyaltyExpensePerShare" contextRef="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">15</ix:nonFraction> per each MEE patent family case number included in the licensed MEE patent rights after first commercial sale of an MEE licensed product. The Company is also obligated to make milestone payments up to $<ix:nonFraction name="freq:MilestonePayments" contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">350</ix:nonFraction> on each product or process that incorporates the licensed patent rights. In addition, the Company has agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. <ix:nonNumeric name="freq:DescriptionOfConditionsToTerminateLicenseAgreement" contextRef="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">The Company has the right to terminate the MEE License Agreement at will by giving thirty (<ix:nonNumeric name="freq:RightToTerminateAgreementUponPriorWrittenNotice" contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric>)&#160;business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (<ix:nonNumeric name="freq:RightToTerminateAgreementIncaseOfNonpayment" contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric>)&#160;business days</ix:nonNumeric> after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (<ix:nonNumeric name="freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" format="ixt-sec:durday">45</ix:nonNumeric>)&#160;business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (<ix:nonNumeric name="freq:RightToTerminateAgreementIfBreachRemainsUncured" contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" format="ixt-sec:durday">60</ix:nonNumeric>)&#160;business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. </div></ix:continuation><ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371107"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Collaboration agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensable,</div> nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GSK-3</div> inhibitor and an HDAC inhibitor (Astellas Licensed Products), including the product candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322,</div> outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These parties have agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">age-related</div> hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-27 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371107" continuedAt="TextSelectionAppend_84371107_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371107_1" continuedAt="TextSelectionAppend_84371107_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371107_2" continuedAt="TextSelectionAppend_84371107_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371107_3" continuedAt="TextSelectionAppend_84371107_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collaboration is governed by a joint steering committee (JSC) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&#8217;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $<ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,000</ix:nonFraction> in July 2019 and has agreed to pay potential development milestone payments up to $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">230,000</ix:nonFraction> and commercialization milestones of up to $<ix:nonFraction name="freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">315,000</ix:nonFraction>. Specifically, the Company would receive development milestone payments of $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_EuropeMembersrtStatementGeographicalAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase2bClinicalTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P07_01_2019To07_31_2019_AsiaMembersrtStatementGeographicalAxis_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase2bClinicalTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,000</ix:nonFraction> upon the first dosing of a subject in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_EuropeMembersrtStatementGeographicalAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase3ClinicalTrailMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P07_01_2019To07_31_2019_AsiaMembersrtStatementGeographicalAxis_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase3ClinicalTrailMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,000</ix:nonFraction> upon the first dosing of a subject in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $<ix:nonFraction name="freq:RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">315,000</ix:nonFraction> in potential commercial milestone payments and also tiered royalties at rates ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-</div> to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teen</div> percentages. The parties shall share equally, on a 50/50 basis, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis until the latest of (i)&#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii)&#160;a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon <ix:nonNumeric name="freq:AgreementTerminationNoticePeriod" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">60</ix:nonNumeric> days&#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#8217;s material breach if such breach remains uncured for <ix:nonNumeric name="freq:RightToTerminateAgreementIfBreachRemainsUncured" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">90</ix:nonNumeric>&#160;days (or <ix:nonNumeric name="freq:RightToTerminateAgreementIncaseOfNonpayment" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">45</ix:nonNumeric> days in the case of nonpayment) or if the other party becomes bankrupt. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-28</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_84371107_4" continuedAt="TextSelectionAppend_84371107_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371107_5" continuedAt="TextSelectionAppend_84371107_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371107_6" continuedAt="TextSelectionAppend_84371107_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371107_7"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue associated with this single performance obligation was recognized as the research and development work was performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurred over this time period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligation. The Company determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and continued until the completion of the Phase 2a clinical trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202).</div></div> The transaction price of $<ix:nonFraction name="freq:RevenueRecognitionTransactionPrice" contextRef="P01_01_2021To06_30_2021_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,000</ix:nonFraction> was allocated to the single combined performance obligation and recorded as deferred revenue in July 2019 when it was received. This upfront payment was recognized as revenue over the period from July 2019 until June&#160;30, 2021, the completion date of the Phase 2a clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202),</div></div> using the input method. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&#8217;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statements of operations during the development period. In the year ended December&#160;31, 2022 and 2021, the Company invoiced Astellas $<ix:nonFraction name="freq:JointCost" contextRef="P01_01_2022To12_31_2022_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">392</ix:nonFraction> and $<ix:nonFraction name="freq:JointCost" contextRef="P01_01_2021To12_31_2021_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">885</ix:nonFraction> for joint costs. </div></ix:continuation><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371109"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (Lease Termination Agreement) with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARE-MA</div> Region No.&#160;20, LLC (Landlord) for the Company&#8217;s office and laboratory space in Woburn, Massachusetts. The Lease Termination Agreement provides that the Lease Agreement, dated as of August&#160;14, 2016, by and between the Company and Landlord (as the same may have been amended, the Lease) will terminate on <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="P12_11_2020To12_11_2020_AREMARegionNo20LLCMembersrtCounterpartyNameAxis_LeasesTerminationAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en">March 31, 2021</ix:nonNumeric>, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May&#160;31, 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;7, 2020 the Company entered into an indenture of lease (Lexington Lease) with HCP/KING 75 Hayden LLC, for the lease of approximately <ix:nonFraction name="us-gaap:NetRentableArea" contextRef="PAsOn01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_sqft" decimals="INF" scale="0" format="ixt:num-dot-decimal">61,307</ix:nonFraction> square feet of rentable area in Lexington, Massachusetts or (Lexington Premises). The Lexington Lease commenced on <ix:nonNumeric name="freq:OperatingLeaseCommencementDate" contextRef="P01_07_2020To01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis" format="ixt:date-monthname-day-year-en">December 11, 2020</ix:nonNumeric>. In the second quarter of 2021, the Company began using the Lexington Premises as its principal executive offices and laboratory for research and development. The term of the Lexington Lease is expected to end on <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="P01_07_2020To01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis" format="ixt:date-monthname-day-year-en">May 31, 2031</ix:nonNumeric>. The Company also has the option to extend the Initial Term for <ix:nonFraction name="freq:OperatingLeaseNumberOfAdditionalExtensionTerms" contextRef="PAsOn01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_Term" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> additional terms of <ix:nonNumeric name="freq:OperatingLeasesAdditionalExtensionTerm" contextRef="P01_07_2020To01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric> each. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-29</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371109" continuedAt="TextSelectionAppend_84371109_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371109_1" continuedAt="TextSelectionAppend_84371109_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371109_2" continuedAt="TextSelectionAppend_84371109_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371109_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s rent expense for the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,802</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,960</ix:nonFraction>, respectively. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other information</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining operating lease term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear">8.4</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December&#160;31, 2022. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,273</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,534</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,670</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,219</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: amount of lease payments representing interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of future lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,782</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Noncurrent lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future aggregate minimum payments under the noncancelable operating lease as of December&#160;31, 2022 are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,273</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,534</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,670</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027 and beyond</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,219</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="freq:Sublease" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371827"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Sublease </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;8, 2022, the Company entered into a Sublease Agreement with SalioGen Therapeutics, Inc. (SalioGen) to sublease approximately <ix:nonFraction name="us-gaap:NetRentableArea" contextRef="PAsOn07_08_2022_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_sqft" decimals="0" scale="0" format="ixt:num-dot-decimal">30,040</ix:nonFraction> rentable square feet of the Company&#8217;s office space in Lexington, MA for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> term. The base sublease rent per month for the first and second year of the sublease is $<ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" contextRef="P07_08_2022To06_30_2023_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" contextRef="P07_01_2023To07_31_2024_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">203</ix:nonFraction>, respectively. In addition to base rent, SalioGen will pay 49% of operating costs and taxes payable under the Company&#8217;s lease for the Lexington, MA office space. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since commencement, the Company has accounted for the Lexington, MA office space as an operating lease. In accordance with ASC 842, the Company concluded the sublease is also an operating lease. The Company recognized sublease income of $<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,186</ix:nonFraction> for the year ended December&#160;31, 2022. The below table shows the expected future sublease income as of December&#160;31, 2022. </div><ix:nonNumeric name="freq:SummaryOfExpectedFutureSubleaseIncome" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371166"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sublease&#160;Income</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,371</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,383</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total future sublease income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,754</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:continuation id="TextSelection_84371827"><ix:continuation id="TextSelection_84371166">&#160;</ix:continuation></ix:continuation></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-30 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_84371110">16. Commitments and contingencies </ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371110" continuedAt="TextSelectionAppend_84371110_1"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contract commitments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable.</div> Payments due upon cancellation consist only of payments for services provided or expenses incurred, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Guarantees </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Guarantees</div></div>. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office space in Lexington, Massachusetts under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">ten-year</div></div> noncancelable lease. The $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2022_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,699</ix:nonFraction> security deposit for this lease is classified as restricted cash as of December&#160;31, 2022. The Company exited the Woburn, Massachusetts facility in the second quarter of 2021. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, the Company had <ix:nonFraction name="us-gaap:LossContingencyLossInPeriod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:LossContingencyLossInPeriod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Legal Contingencies </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#8217;s accrued liabilities would be recorded in the period in which such determination is made. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-31</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_84371110_1" continuedAt="TextSelectionAppend_84371110_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371110_2" continuedAt="TextSelectionAppend_84371110_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371110_3" continuedAt="TextSelectionAppend_84371110_4"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371110_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;3, 2021 and June&#160;22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company and the Company&#8217;s Chief Executive Officer, President, and Director, David Lucchino. On March&#160;21, 2022, the two lawsuits were consolidated into a single lawsuit, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones et al. v. Frequency Therapeutics, Inc. et al</div></div>. and on May&#160;16, 2022, the Company&#8217;s Chief Development Officer, Dr.&#160;Carl LeBel, was added as a defendant. The plaintiffs allege violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#8217;s Phase 2a clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202)</div></div> for its product candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> in the Company&#8217;s public disclosures between October&#160;29, 2020 and March&#160;22, 2021. The lawsuit seeks, among other things, damages in connection with the Company&#8217;s allegedly artificially inflated stock price between October&#160;29, 2020 and March&#160;22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#8217; fees and costs. The Company intends to vigorously defend against all claims asserted in the lawsuit. The Company filed a motion to dismiss the Amended Complaint on July&#160;15, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;21, 2022, the Delaware Chancery Court dismissed a lawsuit brought by two purported stockholders against the Company and others. For previously reported information on this lawsuit, refer to Part I, Item 3, &#8220;Legal Proceedings&#8221; of the Company&#8217;s 2021 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> On August&#160;16, 2022, these same two purported stockholders of the Company filed a similar lawsuit in Delaware Superior Court against (i)&#160;the Company, (ii)&#160;Computershare Inc., and (iii)&#160;Computershare Trust Company, N.A., entitled <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Gregory J. Parseghian Revocable Trust</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">et al.</div></div> v. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Frequency Therapeutics, Inc., et al.</div></div> The lawsuit alleges causes of action against the Company for breach of the statutory duty of care, negligence, conversion, and unjust enrichment, based on allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The Company intends to vigorously defend against all claims asserted in the lawsuit. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;30, 2022, a purported stockholder of the Company filed a shareholder derivative complaint in the U.S. District Court for the District of Delaware purportedly on the Company&#8217;s behalf against members of the Company&#8217;s board of directors and the Company as a nominal defendant, entitled <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dewey v. Cohen et. al.</div></div> The complaint alleges (i)&#160;violations of Section&#160;10(b) and Rule 10b5 of the Exchange Act, (ii)&#160;breach of fiduciary duty, (iii)&#160;aiding and abetting breach of fiduciary duty, (iv)&#160;unjust enrichment, and (v)&#160;waste of corporate assets. The claims are based on the same underlying allegations as the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones</div></div> case (described above). The complaint seeks, among other things, monetary damages, interest, attorneys&#8217; fees and costs. On September&#160;27, 2022, this lawsuit was stayed pending resolution of the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones</div></div> case. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company&#8217;s board members are each party to an indemnification agreement with the Company that may require the Company to reimburse the board members for c<div style="display:inline;">er</div>tain expenses and other costs related to this lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, <ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> accruals have been recorded as of December&#160;31, 2022. </div></ix:continuation><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">17. Employee benefit plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees of the Company are eligible to participate in the Company&#8217;s 401(k) retirement plan (401(k) Plan). Partic<div style="display:inline;">ipan</div>ts may contribute up to <ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">90</ix:nonFraction>% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the first <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of employee contributions and vests <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% at time of match. For the years ended December&#160;31, 2022 and 2021, the Company made matching contributions of $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">550</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">723</ix:nonFraction>, respectively. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-32 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">18. Related party transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As disclosed in Note 12, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and license agreements</div></div>&#8221;, the Company entered into the MIT License Agreement in December 2016. The patents <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr.&#160;Langer, one of the Company&#8217;s directors. Accordingly, Dr.&#160;Langer has received $<ix:nonFraction name="us-gaap:PaymentForManagementFee" contextRef="P01_01_2022To12_31_2022_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction> and $<ix:nonFraction name="us-gaap:PaymentForManagementFee" contextRef="P01_01_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction> from MIT under the MIT Policy during the years ended December&#160;31, 2022 and 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s lease for its Woburn, Massachusetts facility, terminated in May 2021 as disclosed in Note&#160;14, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>&#8221;, was with an entity affiliated with one of the Company&#8217;s directors and shareholders. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">19. Subsequent events </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March&#160;10, 2023, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows: </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company announced a restructuring in which its hearing program was discontinued. As a result, the Company reduced its workforce by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P02_13_2023To02_13_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>% to better align with the needs of its business. The total personnel costs related to the restructuring are estimated to be approximately $<ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="P02_13_2023To02_13_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,000</ix:nonFraction> in future cash outlays primarily related to severance costs and related expenses. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-33 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Frequency Therapeutics, Inc. </div></div></div></div></div> <div id="fin451428_8" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Balance Sheets </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts) </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(unaudited) </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,853</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,954</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,643</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">69,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,493</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,350</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:OtherLongTermAssets" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:OtherLongTermAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and Stockholders&#8217; Equity</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,715</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,567</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,667</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,037</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,026</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, net of current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,215</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, net of current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermLoansFromBank" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermLoansFromBank" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,043</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized, <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued or outstanding at March&#160;31, 2023 and December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">35,751,956</ix:nonFraction></ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">35,262,083</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">334,485</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">331,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">281,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">261,665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">69,195</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equity</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-34 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_9" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Operations </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts) </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(unaudited) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,355</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,511</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,511</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">523</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense), net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">753</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,519</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,374</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:Earningpersharebasicanddiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:Earningpersharebasicanddiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">35,324,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">34,810,676</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-35 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div> <div id="fin451428_10" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Comprehensive Loss </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands) </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(unaudited) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive gain (loss):</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain (loss) on marketable securities and money market funds</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other comprehensive gain (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,620</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes. </div></div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-36 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_11" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements Stockholders&#8217; Equity </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts) </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(unaudited) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common<br/> shares issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common<br/> par&#160;value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/> capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> other<br/> comprehensive<br/> income</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> stockholders&#8217;<br/> equity<br/> (deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">34,611,213</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">310,936</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">62</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">180,085</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,824</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of common stock under Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">31,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock, net</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">22,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock pursuant to restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">310,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, March&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">34,976,409</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">316,402</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">296</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">203,471</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">112,670</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">35,262,083</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">331,023</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">261,665</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">69,195</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of common stock under Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,754</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock, net</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,969</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock pursuant to restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">462,150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive gain</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, March&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">35,751,956</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">334,485</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">281,208</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,249</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-37 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_12" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Cash Flows </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands) </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(unaudited) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from operating activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">726</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:NonCashLeaseExpenses" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:NonCashLeaseExpenses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">593</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> interest (income) expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,051</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,385</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">697</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">429</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:IncreaseDecreaseInLeaseLiabilities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">479</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:IncreaseDecreaseInLeaseLiabilities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">412</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">413</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,352</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from investing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:ProceedsFromPaymentForPropertyAndEquipment" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:ProceedsFromPaymentForPropertyAndEquipment" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemption of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by (used in) investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,499</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,662</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from financing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash (used in) provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,468</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net decrease in cash, cash equivalents and restricted cash</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,805</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,334</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,552</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,529</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-38 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Frequency Therapeutics, Inc. </div></div><div id="fin451428_13" style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Unaudited Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Amounts in thousands, except share and per share amounts) </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371084"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization and basis of presentation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Organization </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, and Frequency Therapeutics Securities Corporation (the Company) headquartered in Lexington, Massachusetts, was incorporated in <span style="-sec-ix-hidden:hidden84371168">November 2014</span> as a Delaware corporation. The Company is a preclinical-stage regenerative medicine company focused on developing therapeutics to activate a person&#8217;s innate regenerative potential to restore function. On February&#160;13, 2023, the Company announced a restructuring of the business which included the discontinuation of its hearing program and a downsizing of personnel by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P02_13_2023To02_13_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>%. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and capital resources </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has funded its operations primarily with proceeds from private and public securities financings, a term loan, and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of March&#160;31, 2023, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">281,208</ix:nonFraction>. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources and the cost savings generated from the restructuring announced in February 2023 will be sufficient to fund planned operations for at least twelve months from the date the financial statements were available to be issued. </div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements are consistent with those discussed in Note 2, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of significant accounting policies</div></div>,&#8221; in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K).</div> </div></ix:nonNumeric> <ix:nonNumeric name="freq:UnauditedInterimFinancialInformationPolicyTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371963"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited interim financial information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated balance sheet as of March&#160;31, 2023 and the consolidated statements of operations, the consolidated statements of comprehensive loss, the consolidated statements of stockholders&#8217; equity and the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-39 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_84371084"><ix:continuation id="TextSelection_84371963"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March&#160;31, 2023, the results of its operations for the three months ended March&#160;31, 2023 and 2022, and cash flows for the three months ended March&#160;31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three months ended March&#160;31, 2023 and 2022 are also unaudited. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023, any other interim periods, or any future year or period. The consolidated balance sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December&#160;31, 2022 included in the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Recently adopted and issued accounting standards </div></div><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the JOBS Act). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, the Company will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses</div></div> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted the standard on January&#160;1, 2023 and it did not have a material impact on the consolidated financial statements. </div></ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371087"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair value measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy at March&#160;31, 2023 and December&#160;31, 2022 are summarized as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,844</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-40 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_84371087">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,649</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Silicon Valley Bank (SVB) was closed on March&#160;10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. The FDIC then reopened SVB as Silicon Valley Bridge Bank, N.A. (SVBB). At March&#160;31, 2023, SVBB continues to hold the Company&#8217;s term loan, deposit and sweep accounts, and security deposit for the Company&#8217;s office space under the existing terms and covenants which were in place at SVB prior to the receivership. The Company is actively working to move these accounts to another financial institution. </div></ix:continuation><ix:nonNumeric name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371807"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Investments </div></div><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the Company&#8217;s investments, all of which are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and recorded at fair value: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s short-term marketable securities were held in investment advisory accounts with SVB Asset Management (SAM). On March&#160;27, 2023, following the closure of SVB, SAM&#8217;s former parent company, and the creation of SVBB, the FDIC entered into a purchase and assumption agreement for certain assets of SVBB with First-Citizens Bank&#160;&amp; Trust Company (FCB). As a result of this transaction, SAM became a wholly owned subsidiary of FCB. Although the accounts are held under the terms in place prior to the transaction, the Company is actively working to move these accounts to another financial institution. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the appropriate classification of investments at the time of purchase and reviews any investment when its fair value is less than its amortized cost and when evidence indicates that the investment&#8217;s carrying amount is not recoverable within a reasonable period of time. The Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-41 </div></ix:exclude></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_84371807" continuedAt="TextSelectionAppend_84371807_1"><div></div></ix:continuation></div><div><div style="line-height:normal;background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_84371807_1" continuedAt="TextSelectionAppend_84371807_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371807_2" continuedAt="TextSelectionAppend_84371807_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371807_3" continuedAt="TextSelectionAppend_84371807_4"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371807_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the investment is compared to its amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to a credit loss is recognized in other comprehensive (loss) income. The unrealized losses at March&#160;31, 2023 and December&#160;31, 2022 were attributable to changes in interest rates and do not represent credit losses. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At March&#160;31, 2023 and December&#160;31, 2022 the Company held <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn03_31_2023" unitRef="Unit_Term" decimals="0" scale="0" format="ixt:num-dot-decimal">9</ix:nonFraction> and <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2022" unitRef="Unit_Term" decimals="0" scale="0" format="ixt:num-dot-decimal">14</ix:nonFraction> debt securities, respectively, that were in an unrealized loss position. The Company does not intend to sell the investments before recovery of their amortized cost bases, which may be at maturity. All investments mature within twelve months from March&#160;31, 2023. <ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371877">The following tables summarize the Company&#8217;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position. </ix:nonNumeric></div><ix:continuation id="TextSelection_84371877"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities in unrealized loss position</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,407</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,350</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,407</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,350</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities in unrealized loss position</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and equipment </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment include the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,747</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,706</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,276</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,235</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,444</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">726</ix:nonFraction> of depreciation expense for the three months ended March&#160;31, 2023 and 2022, respectively. The Company accelerated depreciation of $<ix:nonFraction name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">360</ix:nonFraction> on certain lab equipment for the three months ended March&#160;31, 2023 as discussed in Note 17, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Restructuring&#8221;.</div></div> </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-42 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued expenses </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payroll and employee related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">550</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Third-party research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">457</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">773</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">729</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">525</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,567</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Debt </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2020, the Company entered into a Loan and Security Agreement (Loan Agreement) with Silicon Valley Bank for a term loan with a principal balance of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,000</ix:nonFraction>. <ix:nonNumeric name="us-gaap:DebtInstrumentPaymentTerms" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">The Company made <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="P10_31_2020To11_30_2022_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">monthly</ix:nonNumeric> interest only payments through <ix:nonNumeric name="freq:DebtInstrumentInterestOnlyPaymentMaturityDate" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en">November 30, 2022</ix:nonNumeric>. The principal balance and interest were to be repaid in equal monthly installments after the interest only period and continue through <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en">May 1, 2024</ix:nonNumeric> (Loan Maturity Date).</ix:nonNumeric> Advances under the Loan Agreement would bear an interest rate equal to the greater of either (i) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.50</ix:nonFraction>% plus the Prime Rate (as reported in The Wall Street Journal, subject to an interest rate floor of <ix:nonFraction name="freq:DebtInstrumentFloorInterestRatePercentage" contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen">zero</ix:nonFraction>) or (ii) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2023To03_31_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.75</ix:nonFraction>%. The interest rate at March&#160;31, 2023 was <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.25</ix:nonFraction>%. Interest expense related to the Loan Agreement was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">284</ix:nonFraction> for the three months ended March&#160;31, 2023 and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">178</ix:nonFraction> for the three months ended March&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2023, the Company prepaid the remaining $<ix:nonFraction name="freq:DebtDue" contextRef="PAsOn04_03_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,667</ix:nonFraction> due under the Loan Agreement. The final payment of $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="PAsOn04_03_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150</ix:nonFraction>, which the Company had been accruing over the term of the loan, was also paid. The Company was not subject to any prepayment premium as the prepayment occurred after the second anniversary of the closing date. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371819"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Net loss per share </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371821">Diluted net loss per share is the same as basic net loss per share for the three months ended March&#160;31, 2023 and 2022 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </ix:nonNumeric></div><ix:continuation id="TextSelection_84371821"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net Loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">35,324,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">34,810,676</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:Earningpersharebasicanddiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="freq:Earningpersharebasicanddiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-43</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371819" continuedAt="TextSelectionAppend_84371819_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371819_1" continuedAt="TextSelectionAppend_84371819_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371819_2" continuedAt="TextSelectionAppend_84371819_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371819_3"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To03_31_2023_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,642,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,165,350</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To03_31_2023_OutstandingStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,600,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022_OutstandingStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,610,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">9,242,253</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,776,013</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Stockholders&#8217; equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has authorized <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> shares of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> par value preferred stock of which <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares were issued or outstanding as of March&#160;31, 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has authorized <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> par value common stock of which there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">35,751,956</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">35,262,083</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors. </div><ix:nonNumeric name="freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has reserved the following shares of common stock for future issuance as of March&#160;31, 2023 and December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,600,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,742,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares available for future grant under incentive plans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2023_StockCompensationPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,690,405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_StockCompensationPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">988,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,290,493</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,730,269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Equity Offerings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;10, 2021, the Company entered into an Equity Distribution Agreement (the Sales Agreement) with Oppenheimer&#160;&amp; Co. Inc. (the Sales Agent) to sell shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_10_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> per share, with aggregate gross sales proceeds of up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P12_10_2021To12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>, from time to time, through an &#8220;at the market&#8221; equity offering program. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issuance costs incurred related to the Sales Agreement are classified as long-term assets on the balance sheet at March&#160;31, 2023. During the three months ended March&#160;31, 2022, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To03_31_2022_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">12,767</ix:nonFraction> shares of common stock under the ATM program for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To03_31_2022_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction>. <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To03_31_2023_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> shares were sold during the three months ended March&#160;31, 2023. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-44 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371099"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stock-based compensation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock options </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes stock option activity within the Company&#8217;s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares<br/> in Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise&#160;price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term&#160;(in&#160;years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> intrinsic<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,742,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.69</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">27,350</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.66</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.61</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,969</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.07</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">166,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,600,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">5.63</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,789,470</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">5.29</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options unvested as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">810,618</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">7.65</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock option valuation </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">92.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.58</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.55</ix:nonFraction>, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total grant date fair value of options vested during the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,874</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,097</ix:nonFraction>, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Repricing of stock options </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;17, 2022, the Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $<ix:nonFraction name="us-gaap:StockOptionExercisePriceDecrease" contextRef="P08_17_2022To08_17_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.14</ix:nonFraction>, the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022. Except for the modification of the exercise price, all other terms and conditions of the Underwater Options remain in effect. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option repricing resulted in incremental stock-based compensation of $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" contextRef="P08_17_2022To08_17_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,505</ix:nonFraction>, of which $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">170</ix:nonFraction> was recorded as expense in the three months ended March&#160;31, 2023. At March&#160;31, 2023, $<ix:nonFraction name="freq:ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">705</ix:nonFraction> incremental expense remains which will be recognized as expense over the requisite service period in which the options vest. </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-45 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371099" continuedAt="TextSelectionAppend_84371099_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371099_1" continuedAt="TextSelectionAppend_84371099_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371099_2" continuedAt="TextSelectionAppend_84371099_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371099_3"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes restricted stock unit activity within the Company&#8217;s 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average&#160;fair<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,101,650</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Awarded</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,666,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">306,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">819,050</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,642,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation </div></div></div><ix:nonNumeric name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,592</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,965</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, total unrecognized stock-based compensation expense relating to unvested stock options and restricted stock units was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,610</ix:nonFraction>. This amount is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:duryear">1.72</ix:nonNumeric> years. </div></ix:continuation><ix:nonNumeric name="freq:EmployeeStockPurchasePlanDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Employee stock purchase plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the ESPP) which became effective on the date of the Company&#8217;s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction name="freq:PercentageOfEligibleEmployeeCompensation" contextRef="P09_20_2019To09_20_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first <ix:nonNumeric name="freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" contextRef="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> of the term of the ESPP, beginning with January&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="P09_19_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>, 2020 and ending with January&#160;1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2022To01_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">31,832</ix:nonFraction> shares were purchased under the ESPP in January 2022 related to the second offering period of 2021, which concluded on December&#160;31, 2021. <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2023To01_31_2023_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">24,754</ix:nonFraction> shares were purchased in January 2023 related to the second offering period of 2022, which concluded on December&#160;31, 2022. As of March&#160;31, 2023, a total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2023_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,553,394</ix:nonFraction> shares remain available for future issuance under the ESPP. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371104"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Income taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s total provision is based on the United States statutory rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction></ix:nonFraction>%, increased by state taxes and reduced by a full valuation allowance on the Company&#8217;s deferred tax assets. The income tax expense for the three months ended March&#160;31, 2023 and 2022 represents state taxes on interest income earned by the Company&#8217;s subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-46</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371104" continuedAt="TextSelectionAppend_84371104_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371104_1" continuedAt="TextSelectionAppend_84371104_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371104_2" continuedAt="TextSelectionAppend_84371104_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371104_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will <ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at March&#160;31, 2023 and December&#160;31, 2022 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2014To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> net tax benefit has been recorded due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </div></ix:continuation><ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Collaboration agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensable,</div> nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GSK-3</div> inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322,</div> outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $<ix:nonFraction name="us-gaap:ProceedsFromCollaborators" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,000</ix:nonFraction> in July 2019 and has agreed to pay potential development milestone payments up to $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">230,000</ix:nonFraction> and commercialization milestones of up to $<ix:nonFraction name="freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">315,000</ix:nonFraction>. The parties agreed to share equally, on a 50/50 basis, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;11, 2023, Astellas sent the Company a notice stating that Astellas would be terminating the Astellas Agreement in its entirety on April&#160;14, 2023. The Company agreed to the terms of the notice and on April&#160;14, 2023, the Astellas Agreement was terminated in its entirety. The Company was not subject to any payments or costs as a result of this termination. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement was a collaborative agreement that is within the scope of ASC 808, Collaborative Arrangements. Under the provisions of ASC 808, the Company determined that it would apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company recognized the $<ix:nonFraction name="freq:UpfrontFeeRecognizedAsRevenue" contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,000</ix:nonFraction> upfront fee, which was initially recorded as deferred revenue, as revenue over the period from July 2019 until June&#160;30, 2021, when the Phase 2a clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202),</div></div> the Company&#8217;s performance obligation, was completed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company invoices Astellas for all joint costs. In the three months ended March&#160;31, 2023 and 2022, the Company invoiced Astellas $<ix:nonFraction name="freq:JointCost" contextRef="P01_01_2023To03_31_2023_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction> and $<ix:nonFraction name="freq:JointCost" contextRef="P01_01_2022To03_31_2022_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">193</ix:nonFraction>, respectively, for joint costs. </div></ix:nonNumeric><ix:nonNumeric name="freq:LicenseAgreementTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371842"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. License agreements </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Massachusetts Institute of Technology </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <ix:nonNumeric name="freq:LicenseAgreementEnteredDate" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt:date-monthname-year-en">December 2016</ix:nonNumeric>, the Company entered into an exclusive patent license agreement (MIT License Agreement) with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-47</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371842" continuedAt="TextSelectionAppend_84371842_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation></div><ix:continuation id="TextSelectionAppend_84371842_1" continuedAt="TextSelectionAppend_84371842_2"><div></div></ix:continuation></div><div><div style="line-height:normal;background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_84371842_2" continuedAt="TextSelectionAppend_84371842_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371842_3" continuedAt="TextSelectionAppend_84371842_4"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371842_4" continuedAt="TextSelectionAppend_84371842_5"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering into the MIT License Agreement, the Company paid a $<ix:nonFraction name="freq:LicenseFeePayment" contextRef="PAsOn12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction> license fee payment and issued to MIT shares of our common stock equal to <ix:nonFraction name="freq:PercentageOfSharesOfCommonStockIssued" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $<ix:nonFraction name="freq:MilestonePayments" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,900</ix:nonFraction> on each Licensed Product or Licensed Process. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. <ix:nonNumeric name="freq:DescriptionOfConditionsToTerminateLicenseAgreement" contextRef="P01_01_2023To03_31_2023_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">The Company has the right to terminate for any reason upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="freq:RightToTerminateAgreementUponPriorWrittenNotice" contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" format="ixt-sec:durmonth">3</ix:nonNumeric>-month</div> prior written notice.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, the Company entered into a second amendment with MIT, removing a patent and certain patent applications from the MIT License Agreement which were unrelated to the Company&#8217;s hearing and multiple sclerosis (MS) programs and which were not being utilized by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;6, 2023, the Company sent MIT a notice stating that the Company would be terminating the MIT License Agreement in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" contextRef="P04_06_2023To04_06_2023_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis" format="ixt-sec:durmonth">3</ix:nonNumeric>-months&#8217;</div> time. The Company is not subject to any payments or costs as a result of this termination. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">The Scripps Research Institute (California Institute for Biomedical Research) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <ix:nonNumeric name="freq:LicenseAgreementEnteredDate" contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt:date-monthname-year-en">September 2018</ix:nonNumeric>, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of MS. The Company also has the right to grant sublicenses of its rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> licenses to other nonprofit or academic institutions, for any internal research and educational purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering into the CALIBR License Agreement, the Company made a $<ix:nonFraction name="freq:LicenseFeePayment" contextRef="PAsOn09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction> license fee payment. The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. The Company may terminate the CALIBR License Agreement at will upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> prior written notice. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;29, 2023, <ix:nonNumeric name="freq:DescriptionOfConditionsToTerminateLicenseAgreement" contextRef="P03_29_2023To03_29_2023_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">the Company sent CALIBR a notice stating that the Company would be terminating the CALIBR License Agreement in <ix:nonNumeric name="freq:RightToTerminateAgreementIfBreachRemainsUncured" contextRef="P03_29_2023To03_29_2023_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; time.</ix:nonNumeric> The termination became final on or around April&#160;28, 2023. The Company is not subject to any payments or costs as a result of this termination. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <ix:nonNumeric name="freq:LicenseAgreementEnteredDate" contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_NonExclusivePatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt:date-monthname-year-en">February 2019</ix:nonNumeric>, the Company entered into an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Exclusive</div> Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss (MEE licensed products). </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-48</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_84371842_5" continuedAt="TextSelectionAppend_84371842_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371842_6" continuedAt="TextSelectionAppend_84371842_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371842_7" continuedAt="TextSelectionAppend_84371842_8"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371842_8"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering the MEE License, the Company made a $<ix:nonFraction name="freq:LicenseFeePayment" contextRef="PAsOn02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction> license fee payment. The Company was obligated to pay certain annual license maintenance fees between $<ix:nonFraction name="freq:AnnualLicenseFeePerShare" contextRef="P01_01_2023To03_31_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">5</ix:nonFraction> and $<ix:nonFraction name="freq:AnnualLicenseFeePerShare" contextRef="P01_01_2023To03_31_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="1" scale="0" format="ixt:num-dot-decimal">7.5</ix:nonFraction> per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;21, 2023, <ix:nonNumeric name="freq:DescriptionOfConditionsToTerminateLicenseAgreement" contextRef="P02_21_2023To02_21_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">the Company sent MEE a notice stating that the Company would be terminating the MEE License Agreement in <ix:nonNumeric name="freq:RightToTerminateAgreementIfBreachRemainsUncured" contextRef="P02_21_2023To02_21_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric> business days&#8217; time.</ix:nonNumeric> The termination became final on or around April&#160;4, 2023. The Company is not subject to any payments or costs as a result of this termination. </div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_84371111"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Commitments and contingencies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contract commitments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also enters into contracts in the normal course of business with contract researc<div style="display:inline;">h org</div>anizations, contract manufacturing organizations, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by the Company upon prior written notice although, purchase orders for clinical materials are generally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable.</div> Payments due upon cancellation consist only of payments for services provided or expenses incurred, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> obligations of the Company&#8217;s service providers, up to the date of cancellation or upon the completion of a manufacturing run. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Guarantees </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Guarantees</div></div>. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office space in Lexington, Massachusetts under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn03_31_2023_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis" format="ixt-sec:durwordsen">ten-year</ix:nonNumeric></div> noncancelable operating lease. The $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2023_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,699</ix:nonFraction> security deposit for this lease is classified as restricted cash as of March&#160;31, 2023. The Company has standard indemnification arrangements under this lease that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, the Company had <ix:nonFraction name="us-gaap:LossContingencyLossInPeriod" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Legal Contingencies </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-49 </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_84371111" continuedAt="TextSelectionAppend_84371111_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371111_1" continuedAt="TextSelectionAppend_84371111_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_84371111_2" continuedAt="TextSelectionAppend_84371111_3"><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_84371111_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#8217;s accrued liabilities would be recorded in the period in which such determination is made. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;3, 2021 and June&#160;22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company and the Company&#8217;s Chief Executive Officer, President, and Director, David Lucchino. On March&#160;21, 2022, the two lawsuits were consolidated into a single lawsuit, Quinones et al. v. Frequency Therapeutics, Inc. et al. and on May&#160;16, 2022, the Company&#8217;s Chief Development Officer, Dr.&#160;Carl LeBel, was added as a defendant. The plaintiffs alleged violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#8217;s Phase 2a clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202)</div></div> for its product candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> in the Company&#8217;s public disclosures between October&#160;29, 2020 and March&#160;22, 2021. The lawsuit sought, among other things, damages in connection with the Company&#8217;s allegedly artificially inflated stock price between October&#160;29, 2020 and March&#160;22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#8217; fees and costs. The Company filed a motion to dismiss the Amended Complaint on July&#160;15, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. On March&#160;29, 2023, the Company&#8217;s motion to dismiss was granted and the lawsuit was dismissed in its entirety. On April&#160;27, 2023, Plaintiff filed a notice of appeal to the United States Court of Appeals for the First Circuit from the order dismissing the lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, <div style="display:inline;">no</div> accruals have been recorded as of March&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;21, 2022, the Delaware Chancery Court dismissed a lawsuit brought by two purported stockholders against the Company and others. For previously reported information on this lawsuit, refer to Part I, Item 3, &#8220;Legal Proceedings&#8221; of the Company&#8217;s 2021 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> On August&#160;16, 2022, these same two purported stockholders of the Company filed a similar lawsuit in Delaware Superior Court against (i)&#160;the Company, (ii)&#160;Computershare Inc., and (iii)&#160;Computershare Trust Company, N.A., entitled The Gregory J. Parseghian Revocable Trust, et al. v. Frequency Therapeutics, Inc., et al. The lawsuit alleges causes of action against the Company for breach of the statutory duty of care, negligence, conversion, and unjust enrichment, based on allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The Company intends to vigorously defend against all claims asserted in the lawsuit. The Company filed a motion to dismiss the complaint on November&#160;14, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of March&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;30, 2022, a purported stockholder of the Company filed a shareholder derivative complaint in the U.S. District Court for the District of Delaware purportedly on the Company&#8217;s behalf against members of the Company&#8217;s board of directors and the Company as a nominal defendant, entitled <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dewey v. Cohen et. al.</div></div> The complaint alleges (i)&#160;violations of Section&#160;10(b) and Rule 10b5 of the Exchange Act, (ii)&#160;breach of fiduciary duty, (iii)&#160;aiding and abetting breach of fiduciary duty, (iv)&#160;unjust enrichment, and (v)&#160;waste of corporate assets. The claims are based on the same underlying allegations as the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones</div></div> case (described above). The complaint seeks, among other things, monetary damages, interest, attorneys&#8217; fees and costs. On September&#160;27, 2022, this lawsuit was stayed pending final resolution of the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones</div></div> case. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company&#8217;s board members are each party to an indemnification agreement with the Company that may require the Company to reimburse the board members for certain expenses and other costs related to this lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, <div style="display:inline;">no</div> accruals have been recorded as of March&#160;31, 2023. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-50 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">16. Sublease </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;8, 2022, the Company entered into a Sublease Agreement with SalioGen Therapeutics, Inc. (SalioGen) to sublease approximately <ix:nonFraction name="us-gaap:NetRentableArea" contextRef="PAsOn07_08_2022_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_sqft" decimals="0" scale="0" format="ixt:num-dot-decimal">30,040</ix:nonFraction> rentable square feet of the Company&#8217;s office space in Lexington, MA for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> term. The base sublease rent per month for the first and second year of the sublease is $<ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" contextRef="P07_08_2022To07_07_2023_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" contextRef="P07_08_2023To07_07_2024_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">203</ix:nonFraction>, respectively. In addition to base rent, SalioGen will pay 49% of operating costs and taxes payable under the Company&#8217;s lease for the Lexington, MA office space. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since commencement, the Company has accounted for the Lexington, MA office space as an operating lease. In accordance with ASC 842, the Company concluded the sublease is also an operating lease. The Company recognized sublease income of $<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">593</ix:nonFraction> for the three months ended March&#160;31, 2023. The below table shows the expected future sublease income as of March&#160;31, 2023. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sublease&#160;Income</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,779</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,383</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total future sublease income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><ix:nonNumeric name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">17. Restructuring </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company announced the topline results for the Phase 2b study of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-208)</div></div> which failed to achieve its primary efficacy endpoint of an improvement in speech perception. As a result, the Company also announced that it would be discontinuing the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-345</div> hearing development programs and focusing resources on its remyelination in MS development program. This restructuring resulted in a <ix:nonFraction name="freq:ReductionInWorkforceDueToRestructuring" contextRef="P02_13_2023To02_13_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>% reduction in the Company&#8217;s workforce. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expects to incur a total of approximately $<ix:nonFraction name="freq:RestructuringRelatedExpenses" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,329</ix:nonFraction> in restructuring-related expenses, of which $<ix:nonFraction name="freq:RestructuringRelatedExpenses" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,970</ix:nonFraction> was expensed in the three months ended March&#160;31, 2023. The total estimated restructuring charges consist of accelerated depreciation expense of $<ix:nonFraction name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">360</ix:nonFraction></ix:nonFraction>, accelerated hearing program expense of $<ix:nonFraction name="freq:AcceleratedHearingProgramCharges" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="freq:AcceleratedHearingProgramCharges" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></ix:nonFraction>, and severance and other benefit-related costs of $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,840</ix:nonFraction></ix:nonFraction>, of which $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,481</ix:nonFraction></ix:nonFraction> was expensed in the three months ended March&#160;31, 2023 and the remaining $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">359</ix:nonFraction></ix:nonFraction> will be expensed in the second quarter of 2023. </div><ix:nonNumeric name="freq:ScheduleOfRestructingRelatedChargesTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended March&#160;31, 2023, the following restructuring-related charges were included in the Consolidated Statement of Operations: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance&#160;and&#160;other<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">benefit-related</div><br/> costs</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated<br/> depreciation<br/> charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated<br/> hearing&#160;program<br/> charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,932</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_AcceleratedDepreciationChargesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,421</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_AcceleratedDepreciationChargesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,970</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At March&#160;31, 2023, the liability for the restructuring is classified as current and included in accrued expenses in the Consolidated Balance Sheets. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="freq:ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated&#160;hearing<br/> program charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance&#160;and&#160;other<br/> benefit-related costs</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingLiabilities" contextRef="PAsOn12_31_2022_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingLiabilities" contextRef="PAsOn12_31_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingLiabilities" contextRef="PAsOn12_31_2022_AcceleratedfxthreefourfivechargesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net charges</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingNetCharge" contextRef="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingNetCharge" contextRef="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingNetCharge" contextRef="P01_01_2023To03_31_2023_AcceleratedfxthreefourfivechargesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability balance as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingLiabilities" contextRef="PAsOn03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingLiabilities" contextRef="PAsOn03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="freq:RestructingLiabilities" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-51 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">18. Subsequent events </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through May&#160;12, 2023, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows: </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2023, the Company prepaid the remaining $<ix:nonFraction name="freq:DebtDue" contextRef="PAsOn04_03_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,667</ix:nonFraction> due under the term loan. Upon prepayment of the term loan, the final payment of $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="PAsOn04_03_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150</ix:nonFraction>, which the Company had been accruing over the term of the loan, was also paid. The Company was not subject to any prepayment premium as the prepayment occurred after the second anniversary of the closing date. Refer to Note 7, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Debt&#8221;.</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;4, 2023, the Company&#8217;s termination of the MEE License Agreement became final. No termination costs were incurred as a result of terminating this license agreement. Refer to Note 14, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;License agreements&#8221;.</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;6, 2023, the Company provided written notice of termination of the MIT License Agreement. Pursuant to the terms of the agreement, the Company has the right to terminate for any reason upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-month</div> prior written notice. No termination costs will be incurred as a result of terminating this license agreement. Refer to Note 14, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;License agreements&#8221;.</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;14, 2023, the Astellas Agreement was terminated in its entirety. No termination costs will be incurred as a result of terminating this collaboration agreement. Refer to Note 13, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Collaboration agreement&#8221;.</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;28, 2023, the Company&#8217;s termination of the CALIBR License Agreement became final. No termination costs were incurred as a result of terminating this license agreement. Refer to Note 14, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;License agreements&#8221;.</div></div> </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-52 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin451428_14" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Report of Independent Registered Public Accounting Firm </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of Korro Bio, Inc. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Opinion on the Financial Statements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Korro Bio, Inc. (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">The Company&#8217;s Ability to Continue as a Going Concern </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company is not currently generating revenue, expects to continue incurring significant operating losses and negative operating cash flows for the foreseeable future, requires additional financing and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis for Opinion </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <div style="display:inline;">audits </div>included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&#160;&amp; Young LLP </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s auditor since 2020. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&#160;27, 2023 </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-53 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_15" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Balance Sheets </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(amounts in thousands, except par value amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83,492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,835</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119,775</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Advance payments for property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">659</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities, convertible preferred stock and stockholders&#8217; deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,605</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred rent, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,701</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,949</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred rent, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,920</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies (Note 13)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series Seed convertible preferred stock, $0.001 par value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">13,781 shares authorized, issued and outstanding at December&#160;31, 2022 and 2021 (aggregate liquidation preference of $16,115 at December&#160;31, 2022 and 2021)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A convertible preferred stock, $0.001 par value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">40,848 shares authorized, issued and outstanding at December&#160;31, 2022 and 2021 (aggregate liquidation preference of $91,500 at December&#160;31, 2022 and 2021)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> convertible preferred stock, $0.001 par value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">22,222 shares authorized, issued and outstanding at December&#160;31, 2022 and 2021 (aggregate liquidation preference of $58,000 at December&#160;31, 2022 and 2021)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> convertible preferred stock, $0.001 par value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">20,863 shares authorized and 4,496 shares issued and outstanding at December&#160;31, 2022 and 2021 (aggregate liquidation preference of $12,500 at December&#160;31, 2022 and 2021)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $0.001 par value; 115,838 shares authorized at December&#160;31, 2022 and 2021; 5,462 and 5,276 shares issued at December&#160;31, 2022 and 2021, respectively; 5,404 and 4,788 shares outstanding at December&#160;31, 2022 and 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101,833</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43,801</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(99,031</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(42,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-54 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_16" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Operations and Comprehensive Loss </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(amounts in thousands, except per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,805</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,998</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35,494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of preferred stock tranche liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,537</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,022</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,959</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11.30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4.94</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average common shares outstanding, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,959</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain (loss) on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,030</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,966</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-55 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_17" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(amounts in thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:37%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;Seed</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Series&#160;B-1</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Series&#160;B-2</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In&#160;Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Stockholders&#8217;<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,842</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,156</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A convertible preferred stock, net of issuance costs of $42</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclassification of preferred stock tranche asset upon issuance of Series A convertible preferred stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,451</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> convertible preferred stock, net of issuance costs of $297</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> convertible preferred stock, net of issuance costs of $0</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,500</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercises of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of restricted common stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of warrant to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,959</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,959</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,500</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,788</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43,801</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(42,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-56 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:35%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;Seed</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Series&#160;B-1</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Series&#160;B-2</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In&#160;Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Stockholders&#8217;<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercises of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of restricted common stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for services rendered</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,781</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,924</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">40,848</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">77,736</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,222</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">57,703</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,496</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,500</div></div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,404</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,802</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(101,833</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(99,031</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-57 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_18" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Cash Flows </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(amounts in thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,959</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of preferred stock tranche liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net amortization of premiums and discounts on investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(145</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on disposal of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(398</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,198</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred rent</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(123</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53,645</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(32,094</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Investing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35,067</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from maturities of investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,136</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,752</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Advance payments for property and equipment not yet received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(695</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from sale of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by (used in) investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39,501</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Series A convertible preferred stock, net of issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> convertible preferred stock, net of issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> convertible preferred stock, net of issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from exercises of stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other financing activities, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net (decrease) increase in cash, cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(42,567</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash, beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84,044</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash, end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84,044</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment capitalized under tenant improvement allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment in accounts payable and accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financing costs in accounts payable and accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities arising from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental cash flow information:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-58 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_19" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. The Company and Liquidity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nature of Business </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korro Bio, Inc. (the &#8220;Company&#8221;) is an RNA editing company focused on the discovery and development of novel genetic medicines. The Company was incorporated in September 2018 as RNABIO, Inc. and subsequently renamed in November 2018. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical testing and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Topic&#160;205-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Presentation of Financial Statements&#8212;Going Concern</div></div>, an entity is required to assess whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has been financed from its inception through December&#160;31, 2022 primarily through $15.9&#160;million of net cash proceeds received from the sale of Series Seed convertible preferred stock (the &#8220;Series Seed Preferred Stock&#8221;), $91.2&#160;million of net cash proceeds received from the sale of Series A convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;), $57.7&#160;million of net cash proceeds received from the sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> convertible preferred stock (the &#8220;Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock&#8221;) and $12.5&#160;million of net cash proceeds received from the sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> convertible preferred stock (the &#8220;Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock&#8221;). As outlined further within Note 16, &#8220;Subsequent Events&#8221;, the Company also received $45.5&#160;million of net cash proceeds in March 2023 from the sale of additional shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not currently generating revenue, expects to continue incurring significant operating losses and negative operating cash flows for the foreseeable future and has no currently available sources of financing. As such, the Company will require additional financing. However, if the Company is unable to obtain additional financing, the Company would be forced to delay, reduce or eliminate its research and development programs and/or relinquish valuable rights to its technology and product candidates. There is no assurance that the Company will be successful in obtaining sufficient financing on acceptable terms to continue funding its operations. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the above considerations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year from July&#160;27, <div style="display:inline;">2023</div>, the date these consolidated financial statements were issued. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-59 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Consolidation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). These consolidated financial statements have been prepared on the going concern basis of accounting, which assumes continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of Korro Bio, Inc. and its wholly-owned subsidiary, Korro Mass Securities, Inc., which was established in December 2020.&#160;All intercompany transactions and balances have been eliminated in consolidation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment. The Company operates only in the United States. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include, but are not limited to, accrued expenses and stock-based compensation expense. During the year ended December&#160;31, 2021, the Company&#8217;s estimates also included the valuation of the preferred stock tranche asset and liability related to the Series A Preferred Stock. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. Actual results could differ from those estimates. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div>, (&#8220;ASC 820&#8221;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly. </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-60 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations. Cash equivalents are reflected at fair value based on quoted market prices, as further described in Note 3, &#8220;Fair Value Measurements&#8221;. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investments consist of securities with original maturities greater than three months when purchased. Short-term investments consist of investments that are available for use in current operations. Long-term investments consist of investments with maturities of greater than one year that are not available for use in current operations. The Company did not maintain any long-term investments as of December&#160;31, 2022 or 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies all of its investments as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. Accordingly, these investments are recorded at fair value. Realized gains and losses and amortization and accretion of discounts and premiums are included in &#8220;Other income, net&#8221;. Unrealized gains and losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are included in &#8220;Accumulated other comprehensive loss&#8221; as a component of stockholders&#8217; deficit until realized. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviews its investment portfolio to identify and evaluate investments that have indicators of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are recorded at cost and consists of laboratory equipment, furniture and office equipment, computer equipment, leasehold improvements, and construction in progress. The Company capitalizes property and equipment that is acquired for research and development activities and that has alternative future use. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Property and equipment not yet placed into service is capitalized as&#160;construction in progress and is depreciated once placed into service. Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Depreciation, including depreciation for assets recorded under capital leases, is calculated over the estimated useful lives of the assets using the straight-line method. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by comparing the carrying value of the asset to the future undiscounted cash flows from the use and eventual disposition of the asset. If an asset is considered to be impaired, the impairment loss to be recognized is measured as the amount by which the carrying value of the asset exceeds its fair value. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenditures relating to research and development are expensed as incurred. Research and development expenses include external expenses incurred under arrangements with third parties, academic and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-61 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">institutions and consultants; salaries and personnel-related costs, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> stock-based compensation expense; license fees to acquire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> technology and other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued research and development expenses as of each balance sheet date. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have been performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">contract-to-contract</div></div> and may result in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses legal costs related to patent applications as they are incurred. Such costs are classified as general and administrative expenses within the consolidated statements of operations and comprehensive loss. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based payments in accordance with ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation </div></div>(&#8220;ASC 718&#8221;).<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>This guidance requires all stock-based payments, including grants of stock options and restricted common stock, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. For stock options granted to employees, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> and members of the Company&#8217;s Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each stock option using the Black-Scholes option-pricing model. For restricted common stock granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> the Company estimates the grant date fair value of each award using the intrinsic value, which is based on the value of the underlying common stock less any purchase price. For stock-based payments subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based payment on a straight-line basis over the requisite service period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates the grant date fair value of its common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Valuation of Privately-Held</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Company</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Securities</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issued</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">as</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation</div></div>. Historically, the Company has utilized a market approach to determine its total equity value and the option pricing method (&#8220;OPM&#8221;) to allocate this equity value among various classes of securities. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under the OPM, the common stock has value only if the funds available for distribution to stockholders exceeds the value of the convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-62 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">conditions, guideline public company information, the prices at which the Company sold convertible preferred stock to third parties in arms&#8217; length transactions, the rights and preferences of securities senior to the Company&#8217;s common stock at the time and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options and restricted stock at each valuation date, as applicable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the grant date fair value of the Company&#8217;s common stock, the Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i)&#160;the calculation of expected term of the stock-based payment, (ii)&#160;the risk-free interest rate, (iii)&#160;the expected stock price volatility and (iv)&#160;the expected dividend yield. The Company uses the simplified method as proscribed by SEC Staff Accounting Bulletin No.&#160;107 to calculate the expected term for stock options granted to employees as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The Company determines the risk-free interest rate based on a treasury instrument whose term is consistent with the expected term of the stock options. Because there is no public market for the Company&#8217;s common stock, there is a lack of Company-specific historical and implied volatility data. Accordingly, the Company bases its estimates of expected volatility on the historical volatility of a group of publicly-traded companies with similar characteristics to itself, including stage of product development and therapeutic focus within the life sciences industry. Historical volatility is calculated over a period of time commensurate with the expected term of the stock-based payment. The Company uses an assumed dividend yield of zero as the Company has never paid dividends on its common stock, nor does it expect to pay dividends on its common stock in the foreseeable future. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for forfeitures of all stock-based payments when such forfeitures occur. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income taxes are recorded in accordance with ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest and penalty charges, if any, related to income taxes would be classified as a component of the &#8220;Provision for income taxes&#8221; in the consolidated statements of operations and comprehensive loss. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss per Share </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, including any dilutive effect from convertible preferred stock, outstanding stock options, outstanding warrants or unvested restricted common stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method when computing net loss per share for periods when issued shares that meet the definition of participating securities are outstanding. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method calls for the calculation </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-63 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method requires income available to common stockholders to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Net losses are not allocated to the Company&#8217;s preferred stockholders as they do not have an obligation to share in the Company&#8217;s net losses. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. Cash balances are deposited with federally-insured financial institutions in the United States and may, at times, exceed federally-insured limits. The Company maintains its cash, cash equivalents and investments with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s cash equivalents are comprised of money market funds that are invested in U.S. Treasury and government agency obligations. The Company&#8217;s investments are comprised of commercial paper and government securities. Credit risk in these securities is reduced as a result of the Company&#8217;s investment policy to limit the amount invested in any single issuer and to only invest in securities of a high credit quality. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has no significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842)</div></div>, which requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. The new standard includes a short-term lease exception for leases with a term of 12 months or less, as part of which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance. In July 2018, the FASB also issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842): Targeted Improvements</div></div>, which permits entities to continue applying legacy guidance in ASC Topic 840, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div> (&#8220;ASC 840&#8221;), including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. Under this transition method, the cumulative effect of initially applying ASC 842 is recognized as an adjustment to the opening balance of retained earnings or accumulated deficit at the beginning of the annual reporting period that includes the date of initial application. Finally, in June 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-05,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities</div></div>, whereby the effective date of this standard was deferred to annual reporting periods beginning after December&#160;15, 2021 and interim periods within annual reporting periods beginning after December&#160;15, 2022, and early adoption was still permitted. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, the Company adopted ASC 842, as amended, on January&#160;1, 2022 using the modified retrospective approach, which provides a method for recording existing leases at adoption and does not require restating comparative financial information. For the comparative period presented in these consolidated financial statements, lease-related disclosures continue to be presented in accordance with ASC 840. The Company also elected to utilize certain&#160;practical&#160;expedients under ASC 842, which among other things, permit the Company to i) maintain the lease classification for any existing leases, ii) maintain the Company&#8217;s determination as to whether any expired or existing contracts are or contain leases and iii) not separate nonlease components. Additionally, the Company elected an accounting policy whereby it does not apply the recognition requirements of ASC 842 to short-term leases with a term of 12 months or less. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the adoption of ASC 842, the Company removed its legacy deferred rent balances that were previously recorded under ASC 840 and established an operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset of $2.9&#160;million, an operating lease </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-64 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">liability, current of $1.6&#160;million and an operating lease liability, net of current portion of $3.3&#160;million, all relating to the Company&#8217;s existing operating lease for its current corporate headquarters. There was no impact to the opening balance of accumulated deficit as a result of the adoption of ASC 842. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a summary of the amount by which each financial statement line item was affected by the adoption of ASC 842 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:42%"></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Prior&#160;to&#160;the&#160;Adoption</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of&#160;ASC&#160;842</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect&#160;of&#160;Adoption</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsequent&#160;to&#160;the</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adoption&#160;of&#160;ASC&#160;842</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred rent, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(939</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred rent, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(969</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adoption of ASC 842 did not have a material impact on the consolidated statement of operations and comprehensive loss or the consolidated statement of cash flows for the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div>, which eliminates certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities when investment ownership changes. In addition, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> simplifies the accounting for the interim period effects of changes in tax laws or rates and transactions that result in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in the tax basis of goodwill. This guidance is effective for annual reporting periods beginning after December&#160;15, 2021 and interim periods within annual reporting periods beginning after December&#160;15, 2022, and early adoption is permitted. The Company adopted this new standard effective January&#160;1, 2022, and there was no impact to the consolidated financial statements as a result of the adoption of this guidance. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements&#8212;Yet to be Adopted </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div>. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This guidance was originally effective for annual reporting periods beginning after December&#160;15, 2020 and interim periods within fiscal years beginning after December&#160;31, 2021, and early adoption was permitted. In November 2019, the FASB subsequently issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</div></div>, whereby the effective date of this standard was deferred to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those annual reporting periods, and early adoption is still permitted. Accordingly, the Company will adopt this new standard effective January&#160;1, 2023, and it does not expect that the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> will have a material impact on the consolidated financial statements. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Investments also include commercial paper and government securities that are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-65 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and other significant inputs derived from or corroborated by observable market data. The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets measured at fair value on a recurring basis as of December&#160;31, 2022 were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:43%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices&#160;in</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;Markets&#160;for</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Identical&#160;Assets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds, included in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,935</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,935</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets measured at fair value on a recurring basis as of December&#160;31, 2021 were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices&#160;in</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;Markets&#160;for</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Identical&#160;Assets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds, included in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<br/>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;<br/>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><br/>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no liabilities measured at fair value on a recurring basis as of December&#160;31, 2022 or 2021. However, as outlined further within Note 10, &#8220;Preferred Stock&#8221;, the Company sold 20,424,108 shares of Series A Preferred Stock in June and July 2020 pursuant to a Series A Preferred Stock Purchase Agreement (the &#8220;Series A Agreement&#8221;). Included in the terms of the Series A Agreement was a right (the &#8220;Series A Tranche Right&#8221;) that was initially accounted for as a liability under ASC Topic 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div> (&#8220;ASC 480&#8221;) and measured at fair value at each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2021, the holders of the Series A Preferred Stock elected to waive the milestone conditions outlined further within Note 10, &#8220;Preferred Stock&#8221;, and exercise the Series A Tranche Right. Accordingly, the holders purchased 20,424,108 additional shares of Series A Preferred Stock at a price of $2.24 per share. As a result, the preferred stock tranche liability was measured at fair value contemporaneously with the exercise of the Series A Tranche Right. The Company utilized the market-adjusted equity method and the option-pricing method to determine the fair value of the Series A Preferred Stock being purchased under the Series A Tranche Right. Based upon this valuation, the Company determined that a preferred stock tranche asset existed in the amount of $2.5&#160;million due to the fair value of the Series A Preferred Stock being $2.12 per share, an amount less than the contractual purchase price. As a result of the change in the fair value of the preferred stock tranche asset, the Company recognized a $13.5&#160;million gain in the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2021. The preferred stock tranche asset was then extinguished in conjunction with the issuance of the related Series A Preferred Stock. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-66 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of the preferred stock tranche liability (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tranche&#160;Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,054</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value upon exercise of Series A Tranche Right</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclassification to Series A Preferred Stock upon extinguishment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,451</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimates outlined above were based, in part, on subjective assumptions. Changes to these assumptions could have had a significant impact on the reported fair values of the preferred stock tranche liability and/or the preferred stock tranche asset. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no changes in valuation techniques, nor were there any transfers among the fair value hierarchy levels during the years ended December&#160;31, 2022 or 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Investments </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents and short-term investments as of December&#160;31, 2022 were comprised as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:53%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized&#160;Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds, included in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,935</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,935</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents and short-term investments as of December&#160;31, 2021 were comprised as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:53%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized&#160;Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds, included in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, the aggregate fair value of securities that were in an unrealized loss position for less than twelve months was $4.0&#160;million and $12.1&#160;million, respectively. As of December&#160;31, 2022 and 2021 the Company held no securities that were in an unrealized loss position for more than twelve months. As of December&#160;31, 2022, the Company did not intend to sell, and would not be more likely than not required to sell, the securities in an unrealized loss position before recovery of their amortized cost bases. Furthermore, the Company determined that there was no material change in the credit risk of these securities. As a result, the Company determined it did not hold any securities with any other-than-temporary impairment as of December&#160;31, 2022. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-67 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Restricted Cash </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company maintained current restricted cash of $0.6&#160;million and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> restricted cash of $4.5&#160;million. As of December&#160;31, 2021, the Company maintained <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> restricted cash of $0.6&#160;million. Such current amounts are included within &#8220;Prepaid expenses and other current assets&#8221; and such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> amounts are included within &#8220;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets&#8221; in the consolidated balance sheets. All restricted cash amounts are comprised solely of letters of credit required pursuant to the Company&#8217;s facility leases. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash as of December&#160;31, 2022 and 2021 that sums to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83,492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">552</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84,044</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Property and Equipment, Net </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, as of December&#160;31, 2022 and 2021 was comprised as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimated&#160;Useful&#160;Life</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(in&#160;Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Shorter of useful life or remaining lease term</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,941</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,883</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,049</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,744</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had construction in progress of $2.0&#160;million, predominately related to laboratory equipment received but not yet installed and capitalizable costs related to the Company&#8217;s future corporate headquarters. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&#160;31, 2022 and 2021 was $2.5&#160;million and $1.6&#160;million, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Accrued Expenses and Other Current Liabilities </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities as of December&#160;31, 2022 and 2021 were comprised as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Annual bonus</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,883</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other employee compensation and benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">External research and development services</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-68 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. SVB Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2021, the Company and Silicon Valley Bank (&#8220;SVB&#8221;) entered into a Loan and Security Agreement (the &#8220;SVB Agreement&#8221;). Under the original terms of the SVB Agreement, the Company had the ability to borrow up to $15.0&#160;million at any time prior to December&#160;31, 2021. The SVB Agreement was subsequently amended in December 2021 to extend this borrowing availability period through December&#160;31, 2022. The Company did not borrow any amounts under the SVB Agreement prior to the expiry of the borrowing availability period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the execution of the SVB Agreement, the Company issued SVB a warrant to purchase 162,000 shares of common stock at an exercise price of $0.58 per share. This warrant was exercisable immediately upon issuance and expires on January&#160;21, 2031. The Company determined that this warrant represents a debt issuance cost associated with the overall credit facility. As such, the warrant was recorded as a deferred financing cost and as a component of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital on the consolidated balance sheets. This deferred financing cost, as well as others incurred in conjunction with the execution of the SVB Agreement were amortized from the date of issuance through December&#160;31, 2022, the expiry of the SVB Agreement&#8217;s borrowing availability period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the fair value of the warrant upon issuance, the Company utilized the Black-Scholes option-pricing model with the following assumptions: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumption</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon these assumptions, the fair value of the warrant issued to SVB was determined to be less than $0.1&#160;million. As of December&#160;31, 2022, the warrant had not been exercised by SVB. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Common Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company was authorized to issue 115,838,000 shares of common stock. Holders of common stock are entitled to one vote per share. In addition, holders of common stock are entitled to receive dividends, if and when declared by the Company&#8217;s Board of Directors. As of December&#160;31, 2022, no dividends had been declared. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, the Company had reserved for future issuance the following number of shares of common stock (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of outstanding Series Seed Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of outstanding Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of outstanding Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of outstanding Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Future issuances of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of restricted common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercises of outstanding stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of outstanding warrant</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Future issuances under 2019 Stock Incentive Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total reserved for future issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">111,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-69 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Preferred Stock </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Series Seed Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into a Series Seed Stock Purchase Agreement (the &#8220;Series Seed 1 and 2 Agreement&#8221;). Under this Series Seed 1 and 2 Agreement, the Company sold an aggregate of 4,000,000 shares of Series Seed Preferred Stock at a price of $1.00 per share. In addition, the Company was previously party to a Simple Agreement for Future Equity (the &#8220;SAFE&#8221;) with Atlas Venture Fund XI, L.P. (&#8220;Atlas&#8221;) whereby the Company received $2.0&#160;million in exchange for granting Atlas the right to participate in a future equity financing. In conjunction with the execution of the Series Seed 1 and 2 Agreement, the SAFE converted into 2,000,000 additional shares of Series Seed Preferred Stock. Subsequently, the Company entered into a Series Seed 3 Preferred Stock Purchase Agreement (the &#8220;Series Seed 3 Agreement&#8221;) in August 2019 under which it sold 7,780,769 additional shares of Series Seed Preferred Stock at a price of $1.30 per share. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Series Seed 1 and 2 Agreement and the Series Seed 3 Agreement, the Company received aggregate net cash proceeds of $13.9&#160;million, after deducting offering expenses paid by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Series Seed Preferred Stock and concluded that it should be classified outside of permanent equity in the consolidated balance sheets, as the Series Seed Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event that is outside of the Company&#8217;s control. Accordingly, the Company has classified the Series Seed Preferred Stock within temporary equity in the consolidated balance sheets. As of December&#160;31, 2022, the Series Seed Preferred Stock is not being accreted to redemption as a deemed liquidation event is not considered to be probable. Further information on the rights, preferences and privileges of the Series Seed Preferred Stock is outlined below. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Series A Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2020, the Company entered into the Series A Agreement. Under the Series A Agreement, the Company sold 18,191,965 shares at an initial closing in June 2020 and 2,232,143 shares at an additional closing in July 2020, both at a price of $2.24 per share. The Company received aggregate net cash proceeds of $45.5&#160;million from these sales, after deducting offering expenses paid by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As outlined within Note 3, &#8220;Fair Value Measurements&#8221;, the Series A Agreement also included the Series A Tranche Right whereby investors would be obligated to purchase, and the Company obligated to sell, an additional 20,424,108 shares of Series A Preferred Stock at $2.24 per share upon the achievement of certain research and development milestones prior to December&#160;31, 2021 (the &#8220;Series A Milestone Closing&#8221;). Investors could also elect to waive the conditions of the Series A Milestone Closing and purchase their allotment of additional shares at any time prior to the Series A Milestone Closing. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Series A Preferred Stock and concluded that it should be classified outside of permanent equity in the consolidated balance sheets, as the Series A Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event that is outside of the Company&#8217;s control. Accordingly, the Company has classified the Series A Preferred Stock within temporary equity in the consolidated balance sheets. As of December&#160;31, 2022, the Series A Preferred Stock is not being accreted to redemption as a deemed liquidation event is not considered to be probable. Further information on the rights, preferences and privileges of the Series A Preferred Stock is outlined below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also assessed the Series A Tranche Right and concluded that it met the definition of a freestanding financial instrument as it was both legally detachable and separately exercisable from the Series A Preferred Stock. In accordance with ASC 480, the Series A Tranche Right was initially classified as a liability in the consolidated balance sheet because the underlying Series A Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event that is outside of the Company&#8217;s control. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-70 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company first allocated the Series A Preferred Stock proceeds to the Series A Tranche Right based upon its fair value at the date of issuance, and the remaining proceeds were allocated to the Series A Preferred Stock. The fair value of the Series A Tranche Right on the date of issuance was determined to be $11.1&#160;million using a probability-weighted present value model that considered the probability of triggering the Series A Tranche Right through the achievement of the certain research and development milestones outlined in the Series A Agreement. The Company converted the future values to their present values using a discount rate it considered to be appropriate for probability-adjusted cash flows. As the Series A Tranche Right was classified as a liability, it was subsequently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> at fair value at each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2021, the holders of the Series A Preferred Stock elected to waive the conditions of the Series A Milestone Closing and exercise the Series A Tranche Right. Accordingly, the holders purchased 20,424,108 additional shares of Series A Preferred Stock at a price of $2.24 per share. The Company received aggregate net cash proceeds of $45.7&#160;million from this sale, after deducting offering expenses paid by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As detailed further within Note 3, &#8220;Fair Value Measurements&#8221;, the preferred stock tranche liability was measured at fair value contemporaneously with the exercise of the Series A Tranche Right. Based upon this valuation, the Company determined that a preferred stock tranche asset existed due to the fair value of the Series A Preferred Stock being $2.12, an amount less than the contractual purchase price. As a result of the change in the fair value of the preferred stock tranche asset, the Company recognized a $13.5&#160;million gain in the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2021. The preferred stock tranche asset was then extinguished in conjunction with the issuance of the related Series A Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Series B Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2021, the Company entered into the Series B Preferred Stock Purchase Agreement (the &#8220;Series B Agreement&#8221;). Under the Series B Agreement, the Company initially sold 17,289,273 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock at a price of $2.61 per share. The Series B Agreement also contemplates the issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock, as outlined further below. The Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock and the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock are collectively referred to as the &#8220;Series B Preferred Stock&#8221; unless specifically noted. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series B Agreement also includes a right (the &#8220;Series B Tranche Right&#8221;) whereby investors would be obligated to purchase, and the Company obligated to sell, 16,232,013 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock at $2.78 per share upon the achievement of a certain research and development milestone (the &#8220;Series B Milestone Closing&#8221;). Investors can also elect to waive the conditions of the Series B Milestone Closing and purchase their allotment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock at any time prior to the Series B Milestone Closing. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2021, the Company subsequently amended the Series B Agreement (the &#8220;Series B Agreement Amendment&#8221;) to include two additional investors. Under the Series B Agreement Amendment, the Company sold an additional 4,932,950 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock at a price of $2.61 per share. Additionally, one investor elected to waive the conditions of the Series B Milestone Closing and purchase 4,496,403 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock at a price of $2.78 per share. The other investor included in the Series B Agreement Amendment maintains the Series B Tranche Right to purchase 134,892 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In total, the Company received aggregate net cash proceeds of $57.7&#160;million from the sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock and $12.5&#160;million from the sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock, after deducting offering expenses paid by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Series B Preferred Stock and concluded that it should be classified outside of permanent equity in the consolidated balance sheets, as the Series B Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event that is outside of the Company&#8217;s control. Accordingly, the Company has classified the Series B Preferred Stock within temporary equity in the consolidated balance sheets. As of December&#160;31, 2022, the Series B Preferred Stock is not being accreted to redemption as a deemed liquidation event is not considered to be probable. Further information on the rights, preferences and privileges of the Series B Preferred Stock is outlined below. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-71 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also assessed the Series B Tranche Right and concluded that, while separately exercisable, it is not legally detachable from the Series B Preferred Stock. Accordingly, the Company concluded that the Series B Tranche Right does not meet the definition of a freestanding financial instrument and is instead an embedded feature of the Series B Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Rights, Preferences and Privileges of Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights, preferences and privileges of the Series Seed Preferred Stock, the Series A Preferred Stock, the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock and the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock are as follows. In the discussion below, the Series Seed Preferred Stock and the Series A Preferred Stock, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock and the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock are collectively referred to as the &#8220;Preferred Stock&#8221; unless specifically noted. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of common stock as is determined by dividing the original issuance price by the conversion price in effect at the time of conversion. The original conversion price of the Series Seed 1 Preferred Stock and Series Seed 2 Preferred Stock is $1.00, the original conversion price of the Series Seed 3 Preferred Stock is $1.30, the original conversion price of the Series A Preferred Stock is $2.24, the original conversion price of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock is $2.61 and the original conversion price of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock is $2.78. Shares of preferred stock are subject to adjustments to reflect the issuance of common stock, options, warrants, or other rights to subscribe for or to purchase common stock for a consideration per share, less than the conversion price then in effect and subsequent stock dividends, stock splits, combinations, or recapitalizations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Stock is subject to mandatory conversion upon the closing of a sale of common stock to the public at a price of at least $5.56 per share (subject to appropriate adjustment in the event of a stock dividend, stock split, combination or other similar recapitalization) in a firm-commitment underwritten public offering resulting in at least $75.0&#160;million of gross proceeds to the Company. The Preferred Stock is also subject to mandatory conversion upon the vote or written consent of the holders of at least 66% of the then-outstanding shares of Preferred Stock, voting as a single class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Stock, in preference to common stockholders, are entitled to receive, when, as and if declared by the Company&#8217;s Board of Directors, dividends at a rate of 8% annually. Dividends on Preferred Stock are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cumulative</div> and are payable only when and if declared by the Company&#8217;s Board of Directors. The holders of Preferred Stock are entitled to participate in dividends on common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis when and if declared by the Company&#8217;s Board of Directors. Since the Company&#8217;s inception, no dividends have been declared. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of the Company, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of common stock, an amount equal to the original issue price per share plus any dividends declared but unpaid thereon. For clarity, the original issue price of the Series Seed 1 Preferred Stock and Series Seed 2 Preferred Stock was $1.00 per share, the original issue price of the Series Seed 3 Preferred Stock was $1.30 per share, the original issue price of the Series A Preferred Stock was $2.24 per share, the original issue price of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock was $2.61 per share and the original issue price of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock was $2.78 per share. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-72 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If upon any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of the Company, the assets of the Company available for distribution are insufficient to pay the holders of Preferred Stock the full amount to which they are entitled, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event, which includes a merger or a sale of substantially all of the assets of the Company. As of December&#160;31, 2022, a deemed liquidation event is not considered to be probable. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The holders of Preferred Stock are entitled to vote based on the number of common shares that their preferred shares convert into on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis at the time of such vote. Except in specific circumstances, holders of Preferred Stock shall vote as a single class with the common stockholders. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The holders of record of the shares of the Series Seed Preferred Stock, voting exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis, are entitled to elect two members to the Company&#8217;s Board of Directors. The holders of record of the shares of the Series A Preferred Stock, voting exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis, are entitled to elect two members to the Company&#8217;s Board of Directors. The holders of record of the shares of the Series B Preferred Stock, voting exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis, are entitled to elect two members to the Company&#8217;s Board of Directors. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Stock-based Compensation </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2019 Stock Incentive Plan </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In January 2019, the Company&#8217;s Board of Directors adopted the 2019 Stock Incentive Plan (the &#8220;2019 Plan&#8221;). The 2019 Plan provides for the grant of stock options, stock awards and restricted stock units to employees, members of the Company&#8217;s Board of Directors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> consultants and advisors. The 2019 Plan initially provided for the issuance of up to 2,219,565 shares of common stock. The 2019 Plan was subsequently amended in May 2019, June 2020, October 2020, April 2021 and November 2021 to modify the number of shares of common stock issuable under the 2019 Plan. Subsequent to the November 2021 amendment to the 2019 Plan, the Company can now issue up to 13,748,930 shares of common stock under the 2019 Plan. As of December&#160;31, 2022, there were 3,217,888 shares available for future issuance under the 2019 Plan. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based Compensation Expense </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense recognized in the consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2022 and 2021 was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">897</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">807</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-73 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Common Stock Activity </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to the adoption of the 2019 Plan, the Company issued shares of restricted common stock to its founders as well as to certain employees. The restrictions on the common stock generally lapse over two to four years. In the event that a recipient ceases to provide service to the Company, the Company has the right to repurchase any unvested shares of restricted common stock at their original purchase price. As a result of this repurchase right, the Company recorded the issuance of such restricted common stock as a liability in the consolidated balance sheets. Amounts are reclassified to common stock at par and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital as the restricted common stock vests and restrictions lapse. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes restricted common stock activity during the year ended December&#160;31, 2022 (in thousands, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 15%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 15%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average&#160;Grant</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date&#160;Fair&#160;Value&#160;per&#160;Share</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">488</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(430</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested as of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate fair value of restricted common stock that vested during the years ended December&#160;31, 2022 and 2021, based upon the fair value of the underlying restricted common stock on the day of vesting, was $0.5&#160;million and $0.3&#160;million, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Option Activity </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of stock options granted during the years ended December&#160;31, 2022 and 2021 was calculated on the date of grant using the following weighted-average assumptions: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the years ended December&#160;31, 2022 and 2021 was $0.73 and $0.41 per share, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes changes in stock option activity during the year ended December&#160;31, 2022 (in thousands, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual&#160;Term</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,156</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(176</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancelled</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,203</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-74 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2022 and 2021 was $0.1&#160;million and $0.2&#160;million, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, there was unrecognized stock-based compensation expense related to unvested stock options of $2.5&#160;million, which the Company expects to recognize over a weighted-average period of approximately 2.7 years. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Income Taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The provision for income taxes for the years ended December&#160;31, 2022 and 2021 was comprised as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2022&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2021&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total provision for income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax computed at federal statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent items</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(32.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-75 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 were comprised as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,871</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capitalized research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,279</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">855</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other temporary differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,217</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,094</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(552</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(571</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(580</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(580</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, the Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $72.1&#160;million and $70.3&#160;million, respectively. Federal NOLs may be carried forward indefinitely. State NOLs expire at various dates from 2038 through 2042. As of December&#160;31, 2022, the Company had federal research and development tax credit carryforwards of $3.5&#160;million that expire at various dates from 2040 through 2042. In addition, as of December&#160;31, 2022, the Company had state research and development tax credit carryforwards of $2.6&#160;million that expire at various dates from 2034 through 2037. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which primarily pertain to NOL carryforwards, tax credit carryforwards and capitalized research and development. The Company has determined that it is more likely than not that it will not realize the benefits of its deferred tax assets, and as a result, a valuation allowance of $36.1&#160;million has been established at December&#160;31, 2022. The increase in the valuation allowance of $19.0&#160;million during the year ended December&#160;31, 2022 was primarily due to the additional operating loss generated by the Company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code (&#8220;IRC&#8221;). This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company&#8217;s value immediately prior to the ownership change. As a result of ownership changes in the Company from its inception through December&#160;31, 2022, the Company&#8217;s NOL and tax credit carryforwards allocable to the periods preceding each such ownership change could be subject to limitations under IRC Section&#160;382, however the Company has not yet completed an IRC Section&#160;382 study. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had no unrecognized tax benefits as of either December&#160;31, 2022 or 2021. The Company has not conducted a study of its research and development credit carryforwards generated during any year. This study, once completed, may result in an adjustment to the Company&#8217;s research and development credit carryforwards. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-76 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credit carryforwards, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated statements of operations and comprehensive loss if an adjustment were required. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the United States federal tax jurisdiction and the Massachusetts state tax jurisdiction. Because the Company is in a loss carryforward position, it is generally subject to examination by federal and state tax authorities for all tax years in which a loss carryforward is available. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company has not incurred any material interest or penalty charges. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Commitments and Contingencies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">790 Memorial Drive Lease </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, the Company entered into an operating lease agreement (&#8220;the 790 Memorial Drive Lease&#8221;) to occupy 3,407 square feet of laboratory and office space at 790 Memorial Drive in Cambridge, Massachusetts. The 790 Memorial Drive Lease term commenced on June&#160;15, 2020 and subsequently expired on June&#160;30, 2021. Pursuant to ASC 840, the Company recorded total rent expense of $0.1&#160;million for the year ended December&#160;31, 2021 related to the 790 Memorial Drive Lease. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">OKS Building 600/700 Lease </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the Company entered into an operating lease agreement (the &#8220;OKS Building 600/700 Lease&#8221;) to occupy 12,165 square feet of laboratory and office space at One Kendall Square in Cambridge, Massachusetts (the &#8220;OKS Facility&#8221;). The OKS Building 600/700 Lease term commenced on January&#160;21, 2021 and was originally set to expire on January&#160;31, 2024. The Company provided the landlord with a security deposit in the form of a $0.3&#160;million letter of credit, which was originally recorded as restricted cash and included within &#8220;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets&#8221; as of December&#160;31, 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The OKS Building 600/700 Lease also provided the Company with a tenant improvement allowance of $2.4&#160;million, the entirety of which was utilized as of December&#160;31, 2021. Leasehold improvements related to the OKS Building 600/700 Lease were originally being amortized over the lease term, commencing with the date that the leasehold improvements were placed into service. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">OKS Sublease </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the Company entered into an operating sublease agreement (the &#8220;OKS Sublease&#8221;) with an unrelated biotechnology company to occupy an additional 5,094 square feet of laboratory and office space in the OKS Facility. The OKS Sublease term commenced on October&#160;25, 2021 and was originally set to expire on March&#160;31, 2023, unless the sublessor notified the Company in writing by July&#160;1, 2022 that it wished to extend the sublease term through December&#160;31, 2024. The Company provided the sublessor with a security deposit in the form of a $0.2&#160;million letter of credit, which was originally recorded as restricted cash and included within &#8220;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets&#8221; as of December&#160;31, 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">OKS Sublease Extension and OKS Combined Facility Lease </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, the sublessor of the OKS Sublease provided the lease extension notification to the Company. As a result of this election, commencing on June&#160;1, 2022, the Company was required to take control over an additional 5,302 square feet for a total occupancy of 10,396 square feet. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-77 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2022, however, the Company entered into an amended lease agreement (the &#8220;OKS Combined Facility Lease&#8221;) with the landlord of the OKS Facility, the primary effects of which were the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Effective September&#160;1, 2022, the space originally leased from the unrelated biotechnology company would now be leased directly from the OKS Facility landlord. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The monthly lease payment amounts owed by the Company were not modified from the original One Kendall Square Sublease, however the Company is now obligated to make an additional payment of $0.3&#160;million at the conclusion of the OKS Combined Facility Lease term. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The lease term for the entirety of the Company&#8217;s leased space at the One Kendall Square Facility was amended to expire on December&#160;31, 2023. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company provided the landlord of the OKS Facility with an additional security deposit in the form of a $0.3&#160;million letter of credit. The $0.3&#160;million letter of credit previously issued to the sublessor of the OKS Sublease was subsequently cancelled. </div></td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting under ASC 840 </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company obtained access to the OKS Building 600/700 Lease space in August 2020, it concluded that this represented the lease commencement date for accounting purposes. Prior to the adoption of ASC 842, and pursuant to the legacy guidance within ASC 840, the Company recorded rent expense on a straight-line basis from this date through the end of the lease term and also recorded deferred rent on the consolidated balance sheets. The Company recorded the tenant improvement allowance as a deferred lease incentive and was amortizing the deferred lease incentive as a reduction of rent expense ratably over the lease term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the OKS Sublease, the Company similarly recorded rent expense on a straight-line basis through the full potential lease term that would expire on December&#160;31, 2024. The full potential lease term was utilized as the lease extension provision was at the sole discretion of the sublessor. In addition, this straight-line rent expense calculation assumed that, as of April&#160;1, 2023, the Company would occupy the entire 10,396 square feet premises contemplated by the OKS Sublease. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the future minimum lease payments due under the OKS Building 600/700 Lease and the OKS Sublease were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:62%"></td>
<td style="vertical-align:bottom;width:32%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Future&#160;Minimum&#160;Lease&#160;Payments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,067</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total future minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to ASC 840, the Company recorded total rent expense of $0.6&#160;million for the year ended December&#160;31, 2021 related to the OKS Building 600/700 Lease and the OKS Sublease. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting under ASC 842 </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the adoption of ASC 842 on January&#160;1, 2022, the Company initially recorded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and corresponding lease liabilities for the OKS Building 600/700 Lease and the OKS Sublease. As there was no rate implicit in either lease, the Company estimated its incremental borrowing rate based upon a synthetic credit rating and yield curve analysis. Based upon this analysis, the Company calculated a discount rate of 5.09% for both the OKS Building 600/700 Lease and the OKS Sublease as of January&#160;1, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company then assessed the OKS Combined Facility Lease as a lease modification, concluding that the modification did not result in a separate contract pursuant to ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">842-10-25-8.</div></div></div> Based upon this assessment, and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-78 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">842-10-25-15,</div></div></div> the Company has accounted for the modification as a termination of the existing leases and the creation of a new operating lease. As there was no rate implicit in the OKS Combined Facility Lease, the Company again estimated its incremental borrowing rate based upon a synthetic credit rating and yield curve analysis. Based upon this analysis, the Company calculated a discount rate of 7.87% as of August&#160;31, 2022, the effective date of the modification. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the OKS Combined Facility Lease term ends on December&#160;31, 2023, the Company is now amortizing the leasehold improvements originally related to the OKS Building 600/700 Lease through December&#160;31, 2023. Additionally, the combined $0.6&#160;million letters of credit issued to the OKS Facility landlord are classified as restricted cash and included within &#8220;Prepaid expenses and other current assets&#8221; as of December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the future minimum lease payments due under the OKS Combined Facility Lease were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: effect of discounting</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(92</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to ASC 842, the Company recorded operating lease expense of $1.4&#160;million and variable lease expense of $0.7&#160;million for the year ended December&#160;31, 2022 related to the OKS Building 600/700 Lease, OKS Sublease and OKS Combined Facility Lease. As of December&#160;31, 2022, the remaining lease term of the OKS Combined Facility Lease was 1.0 year. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cummings Park Sublease </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2022, the Company entered into an operating sublease agreement (the &#8220;Cummings Park Sublease&#8221;) to occupy 18,148 square feet of laboratory and office space at Cummings Park in Woburn, Massachusetts. The Cummings Park Sublease term commenced on February&#160;23, 2022 and will expire on July&#160;31, 2024. Contemporaneously with the execution of the Cummings Park Sublease, the Company provided the landlord with a cash security deposit in the amount of $0.1&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Cummings Park Sublease, the Company was not obligated to make rental payments until 91 days after the Cummings Park Sublease commencement date (the &#8220;Cummings Park Rent Commencement Date&#8221;). Rental payments will escalate on each successive anniversary of the Cummings Park Rent Commencement Date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the future minimum lease payments due under the Cummings Park Sublease were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total remaining minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: effect of discounting</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">601</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to ASC 842, the Company recorded operating lease expense of $0.3&#160;million and variable lease expense of less than $0.1&#160;million for the year ended December&#160;31, 2022 related to the Cummings Park Sublease. As of December&#160;31, 2022, the remaining lease term of the Cummings Park Sublease was 1.6 years. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-79 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">60 First Street Lease </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2022, the Company entered into an operating lease agreement (the &#8220;60 First Street Lease&#8221;) to occupy 50,453 square feet of laboratory and office space in Cambridge, Massachusetts (the &#8220;60 First Street Facility&#8221;). The 60 First Street Lease term will commence on the later of i) the substantial completion of the landlord&#8217;s base building improvements or ii) October&#160;31, 2022 (such date the &#8220;60 First Street Lease Commencement Date&#8221;). Rental payments will commence 12 months following the 60 First Street Lease Commencement Date (such date the &#8220;60 First Street Rent Commencement Date&#8221;), and the 60 First Street Lease will expire on the last day of the 120<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">th</div> full calendar month following the 60 First Street Rent Commencement Date. Rental payments will escalate on each successive anniversary of the 60 First Street Rent Commencement Date, and the total rental payments over the term of the 60 First Street Lease are expected to be $76.7&#160;million. In addition, the 60 First Street Lease also provides the Company with a tenant improvement allowance of $13.1&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provided the landlord with a security deposit in the form of a $4.5&#160;million letter of credit, which has been recorded as restricted cash and included within &#8220;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets&#8221; as of December&#160;31, 2022. This letter of credit will be reduced to $3.4&#160;million upon substantial completion of the Company&#8217;s tenant improvements and then to $2.3&#160;million upon the third anniversary of the 60 First Street Lease Commencement Date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the landlord had not yet delivered the 60 First Street Facility to the Company. Accordingly, the Company concluded that the lease commencement date had not occurred and no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, lease liability or operating lease expense related to the 60 First Street Lease was recorded as of or for the year ended December&#160;31, 2022. Additionally, the Company did not utilize any portion of the $13.1&#160;million tenant improvement allowance as of December&#160;31, 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not a party to any litigation, nor had it established any reserves for litigation liabilities as of December&#160;31, 2022 or 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. 401(k) Savings Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a defined-contribution savings plan under Section&#160;401(k) of the IRC (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation, subject to statutory limitations. Beginning on April&#160;1, 2022, the Company matches 100% of an employee&#8217;s 401(k) contributions up to a maximum of 3% of the participant&#8217;s salary, subject to employer match limitations under the IRC. As such, the Company made $0.2&#160;million of matching contributions to the 401(k) Plan during the year ended December&#160;31, 2022. The Company did not make any matching contributions during the year ended December&#160;31, 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Related Party Transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of Atlas&#8217; ownership of the Company&#8217;s Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock, Atlas represents an affiliate of the Company. During the years ended December&#160;31, 2022 and 2021, the Company incurred expenses of less than $0.1&#160;million and $0.1&#160;million, respectively, related to consulting services provided by an affiliate of Atlas. As of December&#160;31, 2021, the Company had amounts due to this affiliate of $0.1&#160;million. No such amounts were due to this affiliate as of December&#160;31, 2022. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-80 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16. Net Loss per Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following common stock equivalents have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series Seed Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">488</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding warrant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,847</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17. Subsequent Events </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company <div style="display:inline;">has </div>evaluated subsequent events for recognition and disclosure purposes through July&#160;27, 2023, the date these consolidated financial statements were issued. Except for the matters described below, the Company has concluded that no other events or transactions have occurred that require disclosure in the consolidated financial statements. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;">In March 2023, <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company entered into a collaboration and license agreement (the &#8220;Genevant Agreement&#8221;) with Genevant Sciences GmbH (&#8220;Genevant&#8221;) to combine the Company&#8217;s RNA editing technology with Genevant&#8217;s lipid nanoparticle technology to develop and potentially commercialize an RNA therapeutic for alpha-1 antitrypsin deficiency. Key financial terms under the Genevant Agreement are as follows:</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px; border-spacing: 0px;;text-indent: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 24.4688px; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 8.15625px; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made a $2.5&#160;million payment to Genevant in March 2023 upon execution of the Genevant Agreement.</div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px; border-spacing: 0px;;text-indent: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 24.4688px; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 8.15625px; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company will reimburse Genevant for certain<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and full-time equivalent costs incurred as a result of research and development activities performed under the Genevant Agreement.</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px; border-spacing: 0px;;text-indent: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 24.4688px; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 8.15625px; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant is entitled to receive payments from the Company upon the achievement of specified clinical, regulatory and commercial milestones, including potential precommercial milestone payments up to an aggregate total of $40.5&#160;million per product and potential commercial milestone payments up to an aggregate total of $57.0&#160;million.</div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px; border-spacing: 0px;;text-indent: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 24.4688px; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 8.15625px; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Genevant is eligible to receive <div style="display:inline;">royalties </div>at tiered percentage rates beginning in the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digits,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>based on future annual net sales of licensed products within the scope of the Genevant Agreement.</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has paid Genevant $2.8 million through July&#160;27, 2023, the date these consolidated financial statements were issued, and has recorded the $2.5 million nonrefundable, payment within research and development expense in the condensed consolidated statement of operations for the three months ended March 31, 2023. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;">In March 2023, the holders of the Series B Preferred Stock elected to waive the conditions of the Series B Milestone Closing and exercise the Series B Tranche Right. Accordingly, the holders purchased 16,366,905 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock at a price of $2.78 per share. The Company received aggregate net cash proceeds of $45.5&#160;million from this sale. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-81 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger Agreement&#160;&amp; Pre-Closing Financing </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;14, 2023, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Frequency Therapeutics, Inc., a Delaware corporation (&#8220;Frequency&#8221;) and Frequency Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Frequency (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Korro Bio, Inc., with Korro Bio, Inc. surviving the Merger as a wholly owned subsidiary of Frequency (the &#8220;merger&#8221;). In contemplation of the proposed merger, the Company also entered into a subscription agreement with certain parties to purchase shares of the Company&#8217;s common stock for an aggregate purchase price of approximately $117.3&#160;million (the &#8220;pre-closing financing&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the terms and conditions of the Merger Agreement, immediately prior to the effective time of the merger (&#8220;Effective Time&#8221;), each then outstanding share of the Company&#8217;s common stock (including common stock issued upon the conversion of the Company&#8217;s preferred stock but excluding the common stock issued in the pre-closing financing) will be converted into the right to receive a number of shares of Frequency&#8217;s common stock calculated in accordance with the Merger Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s pre-closing financing is contingent on and will occur prior to the closing of the merger, subject to customary closing conditions. Shares of the Company&#8217;s common stock issued pursuant to the pre-closing financing will be converted into the right to receive a number of shares of Frequency common stock calculated in accordance with Merger Agreement at the Effective Time of the merger. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger and the pre-closing financing are expected to close in the fourth quarter of 2023. The merger is subject to approval by the stockholders of the Company and Frequency as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the transaction. If Frequency is unable to satisfy certain closing conditions or if other mutual closing conditions are not satisfied, the Company will not be obligated to complete the merger. The Merger Agreement contains certain termination rights of the Company and Frequency. The merger is expected to be treated as a reverse recapitalization in accordance with U.S. GAAP. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-82 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_20" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Condensed Consolidated Balance Sheets </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(amounts in thousands, except par value amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,835</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Advance payments for property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,845</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100,130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities, convertible preferred stock and stockholders&#8217; deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,605</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,701</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series Seed convertible preferred stock, $0.001 par value 13,781 shares authorized, issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022 (aggregate liquidation preference of $16,115 at March&#160;31, 2023 and December&#160;31, 2022)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A convertible preferred stock, $0.001 par value 40,848 shares authorized, issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022 (aggregate liquidation preference of $91,500 at March&#160;31, 2023 and December&#160;31, 2022)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> convertible preferred stock, $0.001 par value 22,222 shares authorized, issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022 (aggregate liquidation preference of $58,000 at March&#160;31, 2023 and December&#160;31, 2022)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> convertible preferred stock, $0.001 par value 20,863 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 20,863 and 4,496 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively (aggregate liquidation preference of $58,000 and $12,500 at March&#160;31, 2023 and December&#160;31, 2022, respectively)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; deficit<br/>Common stock, $0.001 par value; 117,138 and 115,838 shares authorized at March&#160;31, 2023 and December&#160;31, 2022, respectively; 5,555 and 5,462 shares issued at March&#160;31, 2023 and December&#160;31, 2022, respectively; 5,526 and 5,404 shares outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(121,438</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101,833</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118,231</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(99,031</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100,130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-83</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_21" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Condensed Consolidated Statements of Operations and Comprehensive Loss </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(amounts in thousands, except per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,086</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,635</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,577</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3.59</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average common shares outstanding, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,878</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,577</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain (loss) on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,600</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,632</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-84</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_22" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(amounts in thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:31%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series Seed<br/>Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series A<br/>Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div><br/>Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div><br/>Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-left: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div><br/>Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Stockholders&#8217;<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-left: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101,833</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(99,031</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> convertible preferred stock, net of issuance costs of $42</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for services rendered</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercises of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of restricted common stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at March&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,781</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,924</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">40,848</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">77,736</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,222</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">57,703</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,863</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">57,958</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,526</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,201</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(121,438</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(118,231</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="8" style="height:3.75pt"></td>
<td colspan="8" style="height:3.75pt"></td>
<td colspan="8" style="height:3.75pt"></td>
<td colspan="8" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="8" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series Seed<br/>Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series A<br/>Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div><br/>Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div><br/>Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-left: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div><br/>Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Stockholders&#8217;<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-left: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,788</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43,801</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(42,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercises of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of restricted common stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,577</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,577</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at March&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,781</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,924</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">40,848</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">77,736</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,222</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">57,703</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,496</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,500</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,977</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,901</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(62</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(57,378</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(55,534</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-85</div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Korro Bio, Inc. </div></div><div id="fin451428_23" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Condensed Consolidated Statements of Cash Flows </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(amounts in thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,577</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">512</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net amortization of premiums and discounts on investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(341</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(542</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(454</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(695</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(420</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets and liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(102</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,689</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Investing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,098</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from maturities of investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,513</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(926</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Advance payments for property and equipment not yet received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by (used in) investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,322</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> convertible preferred stock, net of issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from exercises of stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other financing activities, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by (used in) financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26,141</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash, beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84,044</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash, end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment in accounts payable and accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financing costs in accounts payable and accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities arising from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental cash flow information:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">744</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-86</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Korro Bio, Inc. </div></div></div><div id="fin451428_24" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Condensed Consolidated Financial Statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. The Company and Liquidity </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nature of Business </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Korro Bio, Inc. (the &#8220;Company&#8221;) is an RNA editing company focused on the discovery and development of novel genetic medicines. The Company was incorporated in September 2018 as RNABIO, Inc. and subsequently renamed in November 2018. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical testing and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Presentation of Financial Statements&#8212;Going Concern</div></div>, an entity is required to assess whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has been financed from its inception through March&#160;31, 2023 primarily through $15.9&#160;million of net cash proceeds received from the sale of Series Seed convertible preferred stock (the &#8220;Series Seed Preferred Stock&#8221;), $91.2&#160;million of net cash proceeds received from the sale of Series A convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;), $57.7&#160;million of net cash proceeds received from the sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> convertible preferred stock (the &#8220;Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock&#8221;) and $58.0&#160;million of net cash proceeds received from the sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> convertible preferred stock (the &#8220;Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not currently generating revenue, expects to continue incurring significant operating losses and negative operating cash flows for the foreseeable future and has no currently available sources of financing. As such, the Company will require additional financing. However, if the Company is unable to obtain additional financing, the Company would be forced to delay, reduce or eliminate its research and development programs and/or relinquish valuable <div style="display:inline;">rights </div>to its technology and product candidates. There is no assurance that the Company will be successful in obtaining sufficient financing on acceptable terms to continue funding its operations. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the above considerations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year from July&#160;27, 2023, the date these condensed consolidated financial statements were issued. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Consolidation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements as of March&#160;31, 2023 and December&#160;31, 2022, and for the three months ended March&#160;31, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and generally accepted accounting </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-87</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">principles in the United States of America (&#8220;GAAP&#8221;) as found in the ASC of the FASB for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all normal recurring adjustments which are necessary for a fair presentation of the Company&#8217;s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained elsewhere in this proxy statement/prospectus. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information presented in the condensed consolidated financial statements and related notes as of March&#160;31, 2023, and for the three months ended March&#160;31, 2023 and 2022, is unaudited. The condensed consolidated balance sheet as of December&#160;31, 2022 included herein was derived from the audited financial statements as of that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2023, or any future period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The condensed consolidated financial statements include the accounts of Korro Bio, Inc. and its wholly-owned subsidiary, Korro Mass Securities, Inc., which was established in December 2020.&#160;All intercompany transactions and balances have been eliminated in consolidation. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The significant accounting policies and estimates used in the preparation of the condensed consolidated financial statements are described in the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included elsewhere in this proxy statement/prospectus. There have been no material changes in the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2023. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company&#8217;s management evaluates its estimates which include, but are not limited to, accrued expenses and stock-based compensation expense. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. Actual results could differ from those estimates. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div>. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This guidance was originally effective for annual reporting periods beginning after December&#160;15, 2020 and interim periods within fiscal years beginning after December&#160;31, 2021, and early adoption was permitted. In November 2019, the FASB subsequently issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</div></div>, whereby the effective date of this standard was deferred to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those annual reporting periods. The Company adopted this new standard effective January&#160;1, 2023, and there was no impact to the condensed consolidated financial statements as a result of the adoption of this guidance. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-88</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Investments also include commercial paper and government securities which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The carrying amounts reflected in the condensed consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets measured at fair value on a recurring basis as of March&#160;31, 2023 were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:43%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>for Identical<br/>Assets (Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other<br/>Observable<br/>Inputs (Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds, included in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets measured at fair value on a recurring basis as of December&#160;31, 2022 were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>for Identical<br/>Assets (Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other<br/>Observable<br/>Inputs (Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds, included in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,935</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,935</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no liabilities measured at fair value on a recurring basis as of March&#160;31, 2023 or December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no changes in valuation techniques, nor were there any transfers among the fair value hierarchy levels during the three months ended March&#160;31, 2023 or during the year ended December&#160;31, 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Investments </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents and short-term investments as of March&#160;31, 2023 were comprised as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds, included in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-89</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents and short-term investments as of December&#160;31, 2022 were comprised as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds, included in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,935</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,935</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, the Company held no securities that were in an unrealized loss position. As of December&#160;31, 2022, the aggregate fair value of securities that were in an unrealized loss position for less than twelve months was $4.0&#160;million. The Company did not record any charges for credit-related impairments during the three months ended March&#160;31, 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Restricted Cash </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of both March&#160;31, 2023 and December&#160;31, 2022, the Company maintained current restricted cash of $0.6&#160;million and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> restricted cash of $4.5&#160;million. Such current amounts are included within &#8220;Prepaid expenses and other current assets&#8221; and such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> amounts are included within &#8220;Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets&#8221; in the condensed consolidated balance sheets. All restricted cash amounts are comprised solely of letters of credit required pursuant to the Company&#8217;s facility leases. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash as of March&#160;31, 2023 and 2022 that sums to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued Expenses and Other Current Liabilities </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were comprised as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Annual bonus</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">787</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other employee compensation and benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">External research and development services</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-90</div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Common Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, the Company is authorized to issue 117,138,030 shares of common stock. Holders of common stock are entitled to one vote per share. In addition, holders of common stock are entitled to receive dividends, if and when declared by the Company&#8217;s Board of Directors. As of March&#160;31, 2023, no dividends had been declared. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had reserved for future issuance the following number of shares of common stock (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of outstanding Series Seed Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of outstanding Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of outstanding Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of outstanding Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,863</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Future issuances of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of restricted common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercises of outstanding stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of outstanding warrant</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Future issuances under 2019 Stock Incentive Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total reserved for future issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">111,610</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Preferred Stock </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Series Seed Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into a Series Seed Stock Purchase Agreement (the &#8220;Series Seed 1 and 2 Agreement&#8221;). Under this Series Seed 1 and 2 Agreement, the Company sold an aggregate of 4,000,000 shares of Series Seed Preferred Stock at a price of $1.00 per share. In addition, the Company was previously party to a Simple Agreement for Future Equity (the &#8220;SAFE&#8221;) with Atlas Venture Fund XI, L.P. (&#8220;Atlas&#8221;) whereby the Company received $2.0&#160;million in exchange for granting Atlas the right to participate in a future equity financing. In conjunction with the execution of the Series Seed 1 and 2 Agreement, the SAFE converted into 2,000,000 additional shares of Series Seed Preferred Stock. Subsequently, the Company entered into a Series Seed 3 Preferred Stock Purchase Agreement (the &#8220;Series Seed 3 Agreement&#8221;) in August 2019 under which it sold 7,780,769 additional shares of Series Seed Preferred Stock at a price of $1.30 per share. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Series Seed 1 and 2 Agreement and the Series Seed 3 Agreement, the Company received aggregate net cash proceeds of $13.9&#160;million, after deducting offering expenses paid by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Series Seed Preferred Stock and concluded that it should be classified outside of permanent equity in the condensed consolidated balance sheets, as the Series Seed Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event that is outside of the Company&#8217;s control. Accordingly, the Company has classified the Series Seed Preferred Stock within temporary equity in the condensed consolidated balance sheets. As of March&#160;31, 2023, the Series Seed Preferred Stock is not being accreted to redemption as a deemed liquidation event is not considered to be probable. Further information on the rights, preferences and privileges of the Series Seed Preferred Stock is outlined below. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-91</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2020, the Company entered into the Series A Preferred Stock Purchase Agreement (the &#8220;Series A Agreement&#8221;). Under the Series A Agreement, the Company sold 18,191,965 shares at an initial closing in June 2020 and 2,232,143 shares at an additional closing in July 2020, both at a price of $2.24 per share. The Company received aggregate net cash proceeds of $45.5&#160;million from these sales, after deducting offering expenses paid by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A Agreement also included a right (the &#8220;Series A Tranche Right&#8221;) whereby investors would be obligated to purchase, and the Company obligated to sell, an additional 20,424,108 shares of Series A Preferred Stock at $2.24 per share upon the achievement of certain research and development milestones prior to December&#160;31, 2021 (the &#8220;Series A Milestone Closing&#8221;). Investors could also elect to waive the conditions of the Series A Milestone Closing and purchase their allotment of additional shares at any time prior to the Series A Milestone Closing. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Series A Preferred Stock and concluded that it should be classified outside of permanent equity in the condensed consolidated balance sheets, as the Series A Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event that is outside of the Company&#8217;s control. Accordingly, the Company has classified the Series A Preferred Stock within temporary equity in the condensed consolidated balance sheets. As of March&#160;31, 2023, the Series A Preferred Stock is not being accreted to redemption as a deemed liquidation event is not considered to be probable. Further information on the rights, preferences and privileges of the Series A Preferred Stock is outlined below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also assessed the Series A Tranche Right and concluded that it met the definition of a freestanding financial instrument as it was both legally detachable and separately exercisable from the Series A Preferred Stock. In accordance with ASC Topic 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div>, the Series A Tranche Right was initially classified as a liability in the consolidated balance sheet since the underlying Series A Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event that is outside of the Company&#8217;s control. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company first allocated the Series A Preferred Stock proceeds to the Series A Tranche Right based upon its fair value at the date of issuance, and the remaining proceeds were allocated to the Series A Preferred Stock. The fair value of the Series A Tranche Right on the date of issuance was determined to be $11.1&#160;million. As the Series A Tranche Right was classified as a liability, it was subsequently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> at fair value at each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2021, the holders of the Series A Preferred Stock elected to waive the conditions of the Series A Milestone Closing and exercise the Series A Tranche Right. Accordingly, the holders purchased 20,424,108 additional shares of Series A Preferred Stock at a price of $2.24 per share. The Company received aggregate net cash proceeds of $45.7&#160;million from this sale, after deducting offering expenses paid by the Company. The Company recognized a $13.5&#160;million gain from the settlement of the Series A Tranche Right and subsequently extinguished the preferred stock tranche asset in conjunction with the issuance of the related Series A Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Series B Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2021, the Company entered into the Series B Preferred Stock Purchase Agreement (the &#8220;Series B Agreement&#8221;). Under the Series B Agreement, the Company initially sold 17,289,273 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock at a price of $2.61 per share. The Series B Agreement also contemplated the issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock, as outlined further below. The Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock and the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock are collectively referred to as the &#8220;Series B Preferred Stock&#8221; unless specifically noted.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Series B Agreement also included a right (the &#8220;Series B Tranche Right&#8221;) whereby investors would be obligated to purchase, and the Company obligated to sell, 16,232,013 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock at </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-92</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$2.78 per share upon the achievement of a certain research and development milestone (the &#8220;Series B Milestone Closing&#8221;). Investors could also elect to waive the conditions of the Series B Milestone Closing and purchase their allotment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock at any time prior to the Series B Milestone Closing. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2021, the Company subsequently amended the Series B Agreement (the &#8220;Series B Agreement Amendment&#8221;) to include two additional investors. Under the Series B Agreement Amendment, the Company sold an additional 4,932,950 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock at a price of $2.61 per share. Additionally, one investor elected to waive the conditions of the Series B Milestone Closing and purchase 4,496,403 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock at a price of $2.78 per share. The other investor included in the Series B Agreement Amendment maintained the Series B Tranche Right to purchase 134,892 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In total during November and December 2021, the Company received aggregate net cash proceeds of $57.7&#160;million from the sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock and $12.5&#160;million from the sale of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock, after deducting offering expenses paid by the Company. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also assessed the Series B Tranche Right and concluded that, while separately exercisable, it was not legally detachable from the Series B Preferred Stock. Accordingly, the Company concluded that the Series B Tranche Right did not meet the definition of a freestanding financial instrument and was instead an embedded feature of the Series B Preferred Stock. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In March 2023, the holders of the Series B Preferred Stock elected to waive the conditions of the Series B Milestone Closing and exercise the Series B Tranche Right. Accordingly, the holders purchased 16,366,905 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock at a price of $2.78 per share. The Company received aggregate net cash proceeds of $45.5&#160;million from this sale, after deducting offering expenses paid by the Company. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assessed the terms and features of the Series B Preferred Stock and concluded that it should be classified outside of permanent equity in the condensed consolidated balance sheets, as the Series B Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event that is outside of the Company&#8217;s control. Accordingly, the Company has classified the Series B Preferred Stock within temporary equity in the condensed consolidated balance sheets. As of March&#160;31, 2023, the Series B Preferred Stock is not being accreted to redemption as a deemed liquidation event is not considered to be probable. Further information on the rights, preferences and privileges of the Series B Preferred Stock is outlined below. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rights, Preferences and Privileges of Preferred Stock </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The rights, preferences and privileges of the Series Seed Preferred Stock, the Series A Preferred Stock, the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock and the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock are as follows. In the discussion below, the Series Seed Preferred Stock and the Series A Preferred Stock, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock and the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock are collectively referred to as the &#8220;Preferred Stock&#8221; unless specifically noted. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of common stock as is determined by dividing the original issuance price by the conversion price in effect at the time of conversion. The original conversion price of the Series Seed 1 Preferred Stock and Series Seed 2 Preferred Stock is $1.00, the original conversion price of the Series Seed 3 Preferred Stock is $1.30, the original conversion price of the Series A Preferred Stock is $2.24, the original conversion price of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock is $2.61 and the original conversion price of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock is $2.78. Shares of preferred stock are subject to adjustments to reflect the issuance of common stock, options, warrants, or other rights to subscribe for or to purchase common stock for a consideration per share, less than the conversion price then in effect and subsequent stock dividends, stock splits, combinations, or recapitalizations. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-93</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Preferred Stock is subject to mandatory conversion upon the closing of a sale of common stock to the public at a price of at least $5.56 per share (subject to appropriate adjustment in the event of a stock dividend, stock split, combination or other similar recapitalization) in a firm-commitment underwritten public offering resulting in at least $75.0&#160;million of gross proceeds to the Company. The Preferred Stock is also subject to mandatory conversion upon the vote or written consent of the holders of at least 66% of the then-outstanding shares of Preferred Stock, voting as a single class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The holders of Preferred Stock, in preference to common stockholders, are entitled to receive, when, as and if declared by the Company&#8217;s Board of Directors, dividends at a rate of 8% annually. Dividends on Preferred Stock are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cumulative</div> and are payable only when and if declared by the Company&#8217;s Board of Directors. The holders of Preferred Stock are entitled to participate in dividends on common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis when and if declared by the Company&#8217;s Board of Directors. Since the Company&#8217;s inception, no dividends have been declared. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the event of any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of the Company, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of common stock, an amount equal to the original issue price per share plus any dividends declared but unpaid thereon. For clarity, the original issue price of the Series Seed 1 Preferred Stock and Series Seed 2 Preferred Stock was $1.00 per share, the original issue price of the Series Seed 3 Preferred Stock was $1.30 per share, the original issue price of the Series A Preferred Stock was $2.24 per share, the original issue price of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock was $2.61 per share and the original issue price of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock was $2.78 per share. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If upon any voluntary or involuntary liquidation, dissolution, winding up or deemed liquidation event of the Company, the assets of the Company available for distribution are insufficient to pay the holders of Preferred Stock the full amount to which they are entitled, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Preferred Stock is contingently redeemable upon the occurrence of a deemed liquidation event, which includes a merger or a sale of substantially all of the assets of the Company. As of March&#160;31, 2023, a deemed liquidation event is not considered to be probable. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The holders of Preferred Stock are entitled to vote based on the number of common shares that their preferred shares convert into on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis at the time of such vote. Except in specific circumstances, holders of Preferred Stock shall vote as a single class with the common stockholders. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The holders of record of the shares of the Series Seed Preferred Stock, voting exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis, are entitled to elect two members to the Company&#8217;s Board of Directors. The holders of record of the shares of the Series A Preferred Stock, voting exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis, are entitled to elect two members to the Company&#8217;s Board of Directors. The holders of record of the shares of the Series B Preferred Stock, voting exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis, are entitled to elect two members to the Company&#8217;s Board of Directors. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-94</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Stock-based Compensation </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2019 Stock Incentive Plan </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In January 2019, the Company&#8217;s Board of Directors adopted the 2019 Stock Incentive Plan (the &#8220;2019 Plan&#8221;). The 2019 Plan provides for the grant of stock options, stock awards and restricted stock units to employees, members of the Company&#8217;s Board of Directors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> consultants and advisors. The 2019 Plan initially provided for the issuance of up to 2,219,565 shares of common stock. The 2019 Plan was subsequently amended in May 2019, June 2020, October 2020, April 2021, November 2021 and March 2023 to modify the number of shares of common stock issuable under the 2019 Plan. Subsequent to the March 2023 amendment to the 2019 Plan, the Company can now issue up to 15,048,960 shares of common stock under the 2019 Plan. As of March&#160;31, 2023, there were 2,583,926 shares available for future issuance under the 2019 Plan. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based Compensation Expense </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2023 and 2022 was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Common Stock Activity </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to the adoption of the 2019 Plan, the Company issued shares of restricted common stock to its founders as well as to certain employees. The restrictions on the common stock generally lapse over two to four years. In the event that a recipient ceases to provide service to the Company, the Company has the right to repurchase any unvested shares of restricted common stock at their original purchase price. As a result of this repurchase right, the Company recorded the issuance of such restricted common stock as a liability in the condensed consolidated balance sheets. Amounts are reclassified to common stock at par and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital as the restricted common stock vests and restrictions lapse. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes restricted common stock activity during the three months ended March&#160;31, 2023 (in thousands, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average&#160;Grant</div><br/>Date&#160;Fair&#160;Value&#160;per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested as of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested as of March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate fair value of restricted common stock that vested during the three months ended March&#160;31, 2023 and 2022, based upon the fair value of the underlying restricted common stock on the day of vesting, was less than $0.1&#160;million and $0.1&#160;million, respectively. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-95</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Option Activity </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of stock options granted during the three months ended March&#160;31, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the three months ended March&#160;31, 2023 and 2022 was $0.67 and $0.74 per share, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes changes in stock option activity during the three months ended March&#160;31, 2023 (in thousands, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 41%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/>Exercise Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/>Remaining<br/>Contractual Term<br/>(in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(87</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancelled</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(170</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,929</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value of stock options exercised during the three months ended March&#160;31, 2023 and 2022 was less than $0.1&#160;million and $0.1&#160;million, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2023, there was unrecognized stock-based compensation expense related to unvested stock options of $3.5&#160;million, which the Company expects to recognize over a weighted-average period of approximately 2.8 years. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Genevant Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2023, </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company entered into a collaboration and license agreement (the &#8220;Genevant Agreement&#8221;) with Genevant Sciences GmbH (&#8220;Genevant&#8221;). Key financial terms under the Genevant Agreement are as follows:</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 40.7969px;">&#160;</td>
<td style="width: 24.4688px; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 8.15625px; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made a $2.5&#160;million payment to Genevant in March 2023 upon execution of the Genevant Agreement.</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 40.7969px;">&#160;</td>
<td style="width: 24.4688px; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 8.15625px; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company will reimburse Genevant for certain<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and full-time equivalent costs incurred as a result of research and development activities performed under the Genevant Agreement.</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 40.7969px;">&#160;</td>
<td style="width: 24.4688px; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 8.15625px; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant is entitled to receive payments from the Company upon the achievement of specified clinical, regulatory and commercial milestones, including potential precommercial milestone payments up to an aggregate total of $40.5&#160;million per product and potential commercial milestone payments up to an aggregate total of $57.0&#160;million.</div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 40.7969px;">&#160;</td>
<td style="width: 24.4688px; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 8.15625px; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Genevant is eligible to receive royalties at tiered percentage rates beginning in the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digits,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>based on future annual net sales of licensed products within the scope of the Genevant Agreement.</div></td></tr></table><div style="font-size: 8pt; letter-spacing: 0px;;display:inline;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-96</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Apart from the $2.5&#160;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">million payment, no other payments were made to Genevant through March&#160;31, 2023. The Company recorded the nonrefundable payment within research and development expense in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Net Loss per Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of the diluted net loss per share calculation, convertible preferred stock, outstanding stock options, outstanding warrants and unvested restricted common stock are considered to be potentially dilutive securities, however the following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series Seed Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,863</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding warrant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,847</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Subsequent Events </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has completed an evaluation of all subsequent events after the unaudited condensed consolidated balance sheet date of March&#160;31, 2023 through July&#160;27, 2023, the date these condensed consolidated financial statements were issued, to ensure that these condensed consolidated financial statements include appropriate disclosure of events both recognized in the condensed consolidated financial statements as of March&#160;31, 2023, and events which occurred subsequently but were not recognized in the condensed <div style="display:inline;">consolidated </div>financial statements. <div style="white-space:nowrap;display:inline;">Non-recognizable</div> subsequent events through July&#160;27, 2023 are summarized below. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger Agreement&#160;&amp; Pre-Closing Financing </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;14, 2023, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Frequency Therapeutics, Inc., a Delaware corporation (&#8220;Frequency&#8221;) and Frequency Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Frequency (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Korro Bio, Inc., with Korro Bio, Inc. surviving the Merger as a wholly owned subsidiary of Frequency (the &#8220;merger&#8221;). In contemplation of the proposed merger, the Company also entered into a subscription agreement with certain parties to purchase shares of the Company&#8217;s common stock for an aggregate purchase price of approximately $117.3&#160;million (the &#8220;pre-closing financing&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">Subject to the terms and conditions of the Merger Agreement, immediately prior to the effective time of the merger (&#8220;Effective Time&#8221;), each then outstanding share of the Company&#8217;s common stock (including common stock issued upon the conversion of the Company&#8217;s preferred stock but excluding the common stock issued in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-closing</div> financing) will be converted into the right to receive a number of shares of Frequency&#8217;s common stock calculated in accordance with the Merger Agreement. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Company&#8217;s pre-closing financing is contingent on and will occur prior to the closing of the merger, subject to customary closing conditions. Shares of the Company&#8217;s common stock issued pursuant to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-closing</div> financing will be converted into the right to receive a number of shares of Frequency common stock calculated in accordance with Merger Agreement at the Effective Time of the merger. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-97</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger and the pre-closing financing are expected to close in the fourth quarter of 2023. The merger is subject to approval by the stockholders of the Company and Frequency as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the transaction. If Frequency is unable to satisfy certain closing conditions or if other mutual closing conditions are not satisfied, the Company will not be obligated to complete the merger. The Merger Agreement contains certain termination rights of the Company and Frequency. The merger is expected to be treated as a reverse recapitalization in accordance with U.S. GAAP. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-98</div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_154">Annex A </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Execution Version </span></p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AGREEMENT AND PLAN OF MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">by and among: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FREQUENCY THERAPEUTICS, INC.; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FREQUENCY MERGER SUB, INC.; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">KORRO BIO, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Dated as of JULY&#160;14, 2023 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:88%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_1">ARTICLE I DEFINITIONS AND INTERPRETATIVE PROVISIONS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_2">Definitions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_3">Other Definitional and Interpretative Provisions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-20</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_4">ARTICLE II THE MERGER </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-21</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_5">The Merger</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-21</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_6">Closing</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-21</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_7">Organizational Documents; Directors and Officers</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-21</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_8">Conversion of Shares</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-22</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_9">Contingent Value Right</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-23</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_10">Closing of Korro&#8217;s Transfer Books</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-24</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_11">Surrender of Korro Common Stock</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-24</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_12">Calculation of Net Cash</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-25</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_13">Further Action</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-26</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_14">Withholding</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-26</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_15">ARTICLE III REPRESENTATIONS AND WARRANTIES OF KORRO </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-26</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_16">Due Organization; Subsidiaries</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-26</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_17">Organizational Documents</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-27</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_18">Authority; Binding Nature of Agreement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-27</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_19">Vote Required</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-27</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_20"><span style="white-space:nowrap">Non-Contravention;</span> Consents</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-27</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_21">Capitalization</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-28</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_22">Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-29</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_23">Absence of Changes</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-30</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_24">Absence of Undisclosed Liabilities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-30</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_25">Title to Assets</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-30</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_26">Real Property; Leasehold</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-30</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_27">Intellectual Property</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-31</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_28">Agreements, Contracts and Commitments</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-34</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_29">Compliance; Permits; Restrictions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-36</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.15</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_30">Legal Proceedings; Orders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-37</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.16</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_31">Tax Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-37</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.17</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_32">Employee and Labor Matters; Benefit Plans</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-39</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.18</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_33">Environmental Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-41</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.19</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_34">Insurance</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-41</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.20</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_35">No Financial Advisors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-41</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.21</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_36">Transactions with Affiliates</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-41</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.22</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_37">Privacy and Data Security</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-41</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.23</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_38">Concurrent Financing</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-42</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.24</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_39">No Other Representations or Warranties</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-42</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_40">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF FREQUENCY AND MERGER SUB</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-43</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_41">Due Organization; Subsidiaries</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-43</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_42">Organizational Documents</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-43</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_43">Authority; Binding Nature of Agreement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-43</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_44">Vote Required</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-44</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_45"><span style="white-space:nowrap">Non-Contravention;</span> Consents</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-44</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_46">Capitalization</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_47">SEC Filings; Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_48">Absence of Changes</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.9</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_49">Absence of Undisclosed Liabilities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_50">Title to Assets</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_51">Real Property; Leasehold</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_52">Intellectual Property</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.13</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_53">Agreements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.14</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_54">Compliance; Permits; Restrictions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.15</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_55">Legal Proceedings; Orders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.16</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_56">Tax Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.17</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_57">Employee and Labor Matters; Benefit Plans</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.18</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_58">Environmental Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.19</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_59">Insurance</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.20</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_60">Transactions with Affiliates</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.21</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_61">No Financial Advisors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.22</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_62">Valid Issuance; No Bad Actor</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.23</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_63">Privacy and Data Security</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.24</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_64">Opinion of Financial Advisor</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.25</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_65">No Other Representations or Warranties</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_66">ARTICLE V COVENANTS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_67">Conduct of Korro&#8217;s Business</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_68">Conduct of Frequency&#8217;s Business</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_69">Access and Investigation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_70">No Solicitation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_71">Notification of Certain Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_72">MS Asset Disposition</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_73">Registration Statement; Proxy Statement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_74">Korro Stockholder Written Consent</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_75">Frequency Stockholder Meeting</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_76">Efforts; Regulatory Approvals</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_77">Disclosures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_78">Frequency Options</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.13</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_79">Frequency Restricted Stock Units</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.14</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_80">Frequency ESPP</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.15</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_81">Indemnification of Officers and Directors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.16</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_82">Tax Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.17</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_83">Listing</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.18</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_84">Legends</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.19</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_85">Officers and Directors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.20</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_86">Termination of Certain Agreements and Rights</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.21</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_87">Section&#160;16 Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.22</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_88">Allocation Certificate</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.23</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_89">Nasdaq Reverse Split</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.24</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_90">Obligations of Merger Sub</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.25</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_91">Takeover Statutes</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.26</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_92">Stockholder Litigation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.27</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_93">Concurrent Financing</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.28</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_94">Frequency Equity Plan</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.29</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_95">Frequency 401(k)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_96">ARTICLE VI CONDITIONS TO CONSUMMATION OF THE MERGER </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-77</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_97">Conditions Precedent to Obligations of Each Party</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-77</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_98">Conditions Precedent to Obligations of Korro</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-77</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_99">Conditions Precedent to Obligations of</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-78</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_100">Frustration of Closing Conditions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-79</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_101">ARTICLE VII CLOSING DELIVERIES </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-79</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_102">Closing Deliveries of Korro</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-79</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_103">Closing Deliveries of Frequency</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-79</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_104">ARTICLE VIII TERMINATION </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-79</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_105">Termination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-79</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_106">Effect of Termination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-81</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_107">Expenses; Termination Fees</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-81</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_108">ARTICLE IX GENERAL PROVISIONS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-82</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_109"><span style="white-space:nowrap">Non-Survival</span> of Representations and Warranties</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-82</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_110">Amendment</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-82</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_111">Waiver</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-82</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_112">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-83</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_113">Applicable Law; Jurisdiction</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-83</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_114">Assignability</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-83</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.7</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_115">Notices</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-83</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.8</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_116">Cooperation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-84</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.9</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_117">Severability</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-84</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_118">Other Remedies; Specific Performance</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-84</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman"><a href="#anxa451428_119">No Third-Party Beneficiaries</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-85</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-iv </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">EXHIBITS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:9%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:88%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit A</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Frequency Stockholder Support Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit B</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Korro Stockholder Support Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit C</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Frequency <span style="white-space:nowrap">Lock-Up</span> Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Korro <span style="white-space:nowrap">Lock-Up</span> Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit E</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Korro Stockholder Written Consent</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">CVR Agreement</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-v </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AGREEMENT AND PLAN OF MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">T<small>HIS</small> A<small>GREEMENT</small> <small>AND</small> P<small>LAN</small> <small>OF</small> M<small>ERGER</small> (this &#8220;<span style="font-weight:bold">Agreement</span>&#8221;)<span style="font-weight:bold"> </span>is made and entered into as of July&#160;14, 2023, by and among F<small>REQUENCY</small> T<small>HERAPEUTICS</small>, I<small>NC</small>., a Delaware corporation <span style="font-weight:bold">(</span>&#8220;<span style="font-weight:bold">Frequency</span>&#8221;), F<small>REQUENCY</small> M<small>ERGER</small> S<small>UB</small> I<small>NC</small>., a Delaware corporation and wholly owned subsidiary of Frequency <span style="font-weight:bold">(</span>&#8220;<span style="font-weight:bold">Merger Sub</span>&#8221;),<span style="font-weight:bold"> </span>and K<small>ORRO</small> B<small>IO</small>, I<small>NC</small>.,<span style="font-weight:bold"> </span>a Delaware corporation (&#8220;<span style="font-weight:bold">Korro</span>&#8221;).<span style="font-weight:bold"> </span>Certain capitalized terms used in this Agreement are defined in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1</span>. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">RECITALS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Frequency and Korro intend to effect a merger of Merger Sub with and into Korro (the &#8220;<span style="font-weight:bold">Merger</span>&#8221;) in accordance with this Agreement and Delaware Law. Upon consummation of the Merger, Merger Sub will cease to exist and Korro will become a wholly owned subsidiary of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The board of directors of Frequency (the &#8220;<span style="font-weight:bold">Frequency Board</span>&#8221;) has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Frequency and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Frequency Capital Stock to the stockholders of Korro pursuant to the terms of this Agreement, (iii)&#160;determined that the Charter Amendment Proposals are advisable and in the best interests of Frequency and its stockholders, (iv)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Frequency vote to (a)&#160;approve this Agreement and thereby approve the Contemplated Transactions and (b)&#160;authorize the issuance of the Frequency Capital Stock in accordance with Nasdaq Listing Rule 5635 (the &#8220;<span style="font-weight:bold">Nasdaq Issuance Proposal</span>&#8221;) and (v)&#160;agreed to determine to recommend, upon the terms and subject to the conditions set forth in this Agreement, as promptly as practicable after the forms thereof are mutually agreed to by Frequency and Korro, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Frequency vote to (a)&#160;authorize sufficient Frequency Common Stock for the issuance of Frequency Capital Stock to the stockholders of Korro pursuant to the terms of this Agreement (the &#8220;<span style="font-weight:bold">Authorized Share Increase Proposal</span>&#8221;), and (b)&#160;approve an amendment to Frequency&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split (the &#8220;<span style="font-weight:bold">Reverse Stock Split Proposal</span>&#8221; and, together with the Authorized Share Increase Proposal, the &#8220;<span style="font-weight:bold">Charter Amendment Proposals</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. The board of directors of Merger Sub (the &#8220;<span style="font-weight:bold">Merger Sub Board</span>&#8221;) has (i)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Korro&#8217;s willingness to enter into this Agreement, the stockholders, officers and directors of Frequency set forth on <span style="text-decoration:underline">Section A</span> of the Frequency Disclosure Schedule (solely in their capacity as stockholders of Frequency) are executing support agreements in favor of Korro in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit A</span> (the &#8220;<span style="font-weight:bold">Frequency Stockholder Support </span><span style="font-weight:bold">Agreement</span>&#8221;),<span style="font-weight:bold"> </span>pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Frequency Capital Stock in favor of this Agreement, the Nasdaq Issuance Proposal and the Charter Amendment Proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Frequency&#8217;s willingness to enter into this Agreement, the officers, directors and stockholders (together with their Affiliates) of Korro set forth on <span style="text-decoration:underline">Section A</span> of the Korro Disclosure Schedule (solely in their capacity as stockholders of Korro) are executing support agreements in favor of Frequency in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit B</span> (the &#8220;<span style="font-weight:bold">Korro Stockholder Support Agreement</span>&#8221;),<span style="font-weight:bold"> </span>pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Korro Capital Stock in favor of this Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Korro&#8217;s willingness to enter into this Agreement, the officers and directors of Frequency set forth on <span style="text-decoration:underline">Section B</span> of the Frequency Disclosure Schedule are executing <span style="white-space:nowrap">lock-up</span> agreements in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit C</span> (collectively, the <span style="font-weight:bold">&#8220;Frequency <span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Frequency&#8217;s willingness to enter into this Agreement, the officers, directors and stockholders of Korro set forth on <span style="text-decoration:underline">Section B</span> of the Korro Disclosure Schedule are executing <span style="white-space:nowrap">lock-up</span> agreements in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit D</span> (collectively, the &#8220;<span style="font-weight:bold">Korro <span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">H. It is expected that promptly after the Registration Statement is declared effective under the Securities Act, the stockholders of Korro sufficient to adopt and approve this Agreement and the Merger as required under Delaware Law and Korro&#8217;s Organizational Documents will execute and deliver an action by written consent in order to obtain the Required Korro Stockholder Vote in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit E</span> (each, a &#8220;<span style="font-weight:bold">Korro Stockholder Written Consent</span>&#8221;<span style="font-weight:bold"> </span>and collectively, the &#8220;<span style="font-weight:bold">Korro Stockholder Written Consents</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I. Concurrently with the execution and delivery of this Agreement, certain investors have executed a Subscription Agreement by and among Korro and the Persons named therein (representing an aggregate commitment no less than the Concurrent Investment Amount), pursuant to which such Persons will have agreed to purchase the number of shares of Korro Common Stock set forth therein immediately prior to the Effective Time in connection with the Concurrent Financing (the &#8220;<span style="font-weight:bold">Subscription Agreement</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J. Each of the parties hereto intends that, for United States federal income tax purposes, the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended (the &#8220;<span style="font-weight:bold">Code</span>&#8221;) and the Treasury Regulations, with respect to which each of Frequency, Merger Sub, and Korro are a &#8220;party to a reorganization&#8221; under Section&#160;368(b) of the Code, and this Agreement is intended to constitute a &#8220;plan of reorganization&#8221; for purposes of Sections 354, 361 and 368 of the Code and within the meaning of Section&#160;368 of the Code and Treasury Regulations <span style="white-space:nowrap">Section&#160;1.368-2(g)</span> (the &#8220;<span style="font-weight:bold">Intended Tax Treatment</span>&#8221;). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties, intending to be legally bound, agree as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_1">ARTICLE I </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DEFINITIONS AND INTERPRETATIVE PROVISIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_2">1.1 <span style="text-decoration:underline">Definitions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) For purposes of the Agreement (including this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1</span>): </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">2023 Equity Incentive Plan</span>&#8221; shall mean an equity incentive plan of Frequency in form and substance as agreed to by Frequency and Korro (such agreement not to be unreasonably withheld, conditioned or delayed by either Party), reserving for issuance a number of shares of Frequency Common Stock to be mutually agreed upon by Korro and Frequency (such agreement not to be unreasonably withheld, conditioned or delayed by either Party). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">2023 ESPP</span>&#8221; shall mean an &#8220;employee stock purchase plan&#8221; of Frequency in form and substance as agreed to by Frequency and Korro (such agreement not to be unreasonably withheld, conditioned or delayed by either Party), reserving for issuance a number of shares of Frequency Common Stock to be mutually agreed upon by Korro and Frequency (such agreement not to be unreasonably withheld, conditioned or delayed by either Party). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">2023 Plans</span>&#8221; shall mean both the 2023 ESPP and the 2023 Equity Incentive Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acceptable Confidentiality Agreement</span>&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, <span style="white-space:nowrap">non-solicitation</span> or no hire provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acquisition Inquiry</span>&#8221; means, with respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Korro, on the one hand, or Frequency, on the other hand, to the other Party) that would reasonably be expected to lead to an Acquisition Proposal, other than, as applicable, with respect to the MS Asset Disposition and the Concurrent Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acquisition Proposal</span>&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Korro or any of its Affiliates, on the one hand, or by or on behalf of Frequency or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party, other than, as applicable, with respect to the MS Asset Disposition and the Concurrent Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acquisition Transaction</span>&#8221; means any transaction or series of related transactions (other than, as applicable, the MS Asset Disposition and the Concurrent Financing) involving: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (A)&#160;in which a Party is a constituent entity, (B)&#160;in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries or (C)&#160;in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Affiliate</span>&#8221; means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with such other Person. For purposes of this definition, &#8220;<span style="text-decoration:underline">control</span>&#8221; when used with respect to any Person means the power to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities or partnership or other ownership interests, by contract or otherwise, and the terms &#8220;<span style="text-decoration:underline">controlling</span>&#8221; and &#8220;<span style="text-decoration:underline">controlled</span>&#8221; have correlative meanings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Business Day</span>&#8221; means any day other than a day on which banks in the State of New York are authorized or obligated to be closed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Cash</span> <span style="font-weight:bold">and</span> <span style="font-weight:bold">Cash Equivalents</span>&#8221; means all (i)&#160;cash and cash equivalents and (ii)&#160;marketable securities, in each case determined in accordance with GAAP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">COBRA</span>&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section&#160;4980B of the Code and Part 6 of Title I of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Combined Corporation</span>&#8221; means, collectively, Frequency and each of its Subsidiaries immediately following the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Concurrent Financing</span>&#8221; means an acquisition of shares of Korro Common Stock to be consummated immediately prior to the Effective Time pursuant to the Subscription Agreement with aggregate gross cash proceeds of at least the Concurrent Investment Amount. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Concurrent Financing Allocation Percentage</span>&#8221; means the quotient (rounded to four decimal places) determined by <span style="font-style:italic"><span style="text-decoration:underline">dividing</span></span> (A)&#160;the Concurrent Financing Proceeds <span style="font-style:italic"><span style="text-decoration:underline">by</span></span> (B)&#160;the Aggregate Valuation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Concurrent Financing Merger Shares</span>&#8221; means, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(f)</span>, the product determined by <span style="font-style:italic"><span style="text-decoration:underline">multiplying</span></span> (i)&#160;the Post-Closing Frequency Shares <span style="font-style:italic">by </span>(ii)&#160;the Concurrent Financing Allocation Percentage. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Concurrent Financing Proceeds</span>&#8221; means the proceeds resulting from the Concurrent Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Concurrent Investment Amount</span>&#8221; means $100,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Confidentiality Agreement</span>&#8221;<span style="font-weight:bold"> </span>means the Confidentiality Agreement, dated as of March&#160;20, 2023, by and between Korro and Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Consent</span>&#8221;<span style="font-weight:bold"> </span>means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contemplated Transactions</span>&#8221;<span style="font-weight:bold"> </span>means the Merger<span style="font-weight:bold"> </span>and the other transactions contemplated by the Agreement, including the CVR Agreement (if applicable), the Concurrent Financing and the Charter Amendment Proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contract</span>&#8221;<span style="font-weight:bold"> </span>means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Delaware Law</span>&#8221;<span style="font-weight:bold"> </span>means the General Corporation Law of the State of Delaware. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Delaware Law Amendment Approval</span>&#8221;<span style="font-weight:bold"> </span>means the final Governmental Authorization (including signing by the Delaware Governor into law) of the amendments to the voting requirements under &#167; 242 of Title 8 of Delaware Law contemplated by An Act to Amend Title 8 of the Delaware Code Relating to the General Corporation Law, S. 114, Gen. Assem. (2023). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Effect</span>&#8221;<span style="font-weight:bold"> </span>means any effect, change, event, circumstance, or development. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Employee Plan</span>&#8221;<span style="font-weight:bold"> </span>means (i)&#160;each &#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3) of ERISA whether or not subject to ERISA; (ii)&#160;any other plan, program, policy, agreement or arrangement providing for stock options, stock purchases, restricted stock, restricted stock units, phantom equity, other equity or equity-based incentives, bonuses, commissions, severance, retention, deferred compensation, change in control, transaction, vacation, retirement, pension, profit-sharing, post-retirement health and welfare, fringe, life insurance, perquisites, health, medical, dental, vision, welfare, employee assistance or similar benefits; and (iii)&#160;all other plans, programs, policies, agreements or arrangements (whether written or unwritten) providing compensation or benefits to any employee, officer, director, individual independent contractor and other <span style="white-space:nowrap">non-employee</span> service provider. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Encumbrance</span>&#8221;<span style="font-weight:bold"> </span>means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Enforceability Exceptions</span>&#8221;<span style="font-weight:bold"> </span>means the (i)&#160;Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (ii)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Entity</span>&#8221;<span style="font-weight:bold"> </span>means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Environmental Law</span>&#8221;<span style="font-weight:bold"> </span>means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">ERISA</span>&#8221; means the Employee Retirement Income Security Act of 1974, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">ERISA Affiliate</span>&#8221;<span style="font-weight:bold"> </span>means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity, part of the same &#8220;controlled group&#8221; as such Entity or under common control with such Entity under Sections 414(b),(c),(m) or (o)&#160;of the Code, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Exchange Act</span>&#8221;<span style="font-weight:bold"> </span>means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Associate</span>&#8221;<span style="font-weight:bold"> </span>means any current or former employee, officer, director, consultant, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Frequency or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Balance Sheet</span>&#8221; means the audited balance sheet of Frequency for the years ended December&#160;31, 2021 and December&#160;31, 2022<span style="font-weight:bold">.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Capital Stock</span>&#8221;<span style="font-weight:bold"> </span>means the Frequency Common Stock and the Frequency Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Capitalization Representations</span>&#8221;<span style="font-weight:bold"> </span>means the representations and warranties of Frequency and Merger Sub set forth in <span style="text-decoration:underline">Sections 4.6(a)</span> and <span style="text-decoration:underline">4.6(d)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Contract</span>&#8221; means any Contract: (i)&#160;to which Frequency is a party, (ii)&#160;by which Frequency or any Frequency IP Rights or any other asset of Frequency is or may become bound or under which Frequency has, or may become subject to, any obligation or (iii)&#160;under which Frequency has or may acquire any right or interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Covered Person</span>&#8221; means, with respect to Frequency as an &#8220;issuer&#8221; for purposes of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Employee Plan</span>&#8221; means any Employee Plan (other than the 2023 Plans) that Frequency or any of its Subsidiaries (i)&#160;sponsors, maintains, administers, or contributes to, or (ii)&#160;provides benefits under or through, or (iii)&#160;has any obligation to contribute to or provide benefits under or through, or (iv)&#160;may reasonably be expected to have any Liability with respect to, or (v) utilizes to provide benefits to or otherwise cover any Frequency Associate (or their spouses, dependents, or beneficiaries). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency ESPP</span>&#8221; means the Frequency 2019 Employee Stock Purchase Plan, as amended from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Fundamental Representations</span>&#8221; means the representations and warranties of Frequency and Merger Sub set forth in <span style="text-decoration:underline">Sections 4.1(a)</span>, <span style="text-decoration:underline">4.1(b)</span>, <span style="text-decoration:underline">4.2</span>, <span style="text-decoration:underline">4.3</span>, <span style="text-decoration:underline">4.4</span> and <span style="text-decoration:underline">4.21</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency IP Rights</span>&#8221; means all Intellectual Property owned, licensed or controlled by Frequency that is necessary for, or used or held for use in, the operation of the business of Frequency as presently conducted. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency IP Rights Agreement</span>&#8221; means any Contract governing, related or pertaining to any Frequency IP Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Lease Agreement</span>&#8221; means that certain Lease Agreement, dated January&#160;7, 2020, by and between Frequency and HCP/King 75 Hayden LLC, as may be amended or supplemented from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Material Adverse Effect</span>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Frequency Material Adverse Effect, has had or would reasonably be expected to have a material adverse effect on the business, assets, liabilities, financial condition or results of operations of Frequency or its Subsidiaries, taken as a whole; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that Effects arising or resulting from the following, alone or in combination, shall not be taken into account in determining whether there has been a Frequency Material Adverse Effect: (i)&#160;the announcement of the Agreement, the pendency or the consummation of the Contemplated Transactions, including any adverse change in customer, supplier, governmental, landlord, employee or similar relationships resulting therefrom or with respect thereto, (ii)&#160;the taking of any action, or the failure to take any action, by Frequency that is expressly required under the terms of the Agreement, (iii)&#160;any natural disaster or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (iv)&#160;any change in GAAP or applicable Law or the interpretation thereof, (v)&#160;general economic, financial and capital markets, political conditions or conditions generally affecting the industries in which Frequency and its Subsidiaries operate, or (vi)&#160;any failure of Frequency to meet any projections, business plans or forecasts (provided that, this clause (vi)&#160;shall not prevent a determination that any change or effect underlying such failure to meet projections, business plans or forecasts has resulted in a Frequency Material Adverse Effect (to the extent such change or effect is not otherwise excluded from this definition of Frequency Material Adverse Effect)); except in each case with respect to clauses (iii), (iv) and (v), to the extent disproportionately affecting Frequency and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Frequency and its Subsidiaries operate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Net Cash</span>&#8221;<span style="font-weight:bold"> </span>means without duplication, (i)&#160;Frequency&#8217;s Cash and Cash Equivalents (including any MS Asset Proceeds received, or to be received, by Frequency or any of its Subsidiaries prior to or on the Closing Date pursuant to the MS Asset Disposition), <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (ii)&#160;fees and expenses of Frequency incurred in connection with the Contemplated Transactions, including for the avoidance of doubt, Transaction Expenses of Frequency to the extent unpaid as of the Closing, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (iii)&#160;unpaid indebtedness for borrowed money of Frequency and its Subsidiaries, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (iv)&#160;any and all Liabilities of Frequency (A)&#160;to any Frequency Associate for change in control or transaction bonuses, retention bonuses, severance or similar compensatory payments or benefits that are due and payable as a result of the completion of the Contemplated Transactions, together with any other event (including the employer portion of any payroll Taxes payable with respect thereto), (B) with respect to the unfunded or underfunded portion of any defined benefit pension plan, accrued employer contributions to a defined contribution pension plan, post-retirement health and welfare benefit plan, and supplemental executive retirement plan, and (C)&#160;accrued but unpaid bonuses, severance and vacation or paid time off (including the employer portion of any payroll Taxes payable with respect thereto), <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (v)&#160;all prepaid expenses set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1(a)</span> of the Frequency Disclosure Schedule, <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (vi)&#160;expenses paid, or Liabilities incurred, prior to Closing, that are approved in writing by Korro to be covered by Frequency&#8217;s D&amp;O insurance in excess of the deductible and within overall policy limits, <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (vii)&#160;deposits set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1(a)</span> of the Frequency Disclosure Schedule, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (viii)&#160;the sum of Frequency&#8217;s consolidated short-term and long-term contractual obligations accrued at the Closing Date (but excluding deferred revenue and any accruals otherwise accounted for in Frequency Net Cash), <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (ix)&#160;all costs and expenses relating to the winding down of Frequency&#8217;s or any of its Subsidiaries prior research and development activities, including any such accounts payable or accrued expenses associated with the termination of any contractual arrangement of Frequency contemplated hereby, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (x)&#160;any <span style="white-space:nowrap">pre-payment,</span> termination <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;end-of-term&#8221;</span></span> or similar fee or charge payable to any lender in connection with the repayment of indebtedness by Frequency at or prior to the Effective Time, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (xi)&#160;any accounts payable and accrued expenses (other than accrued expenses which are Transaction Expenses and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excluding any accruals otherwise accounted for in Frequency Net Cash), <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (xii)&#160;all payables or obligations, whether absolute, contingent or otherwise, related to the Frequency Lease Agreement (net of any rights of Frequency to receive payments relating to the property subject to the Frequency Lease Agreement), <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (xiii) <span style="font-style:italic"></span>the employer portion of any payroll Taxes payable as a result of the vesting and settlement of each outstanding and unvested Frequency Restricted Stock Unit pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.13</span>) and <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (xiv)&#160;all costs, fees and expenses relating to the legal matter(s) set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1(a)</span> of the Frequency Disclosure Schedule and any settlement(s) related thereto. For avoidance of doubt, the Cash and Cash Equivalents received in the Concurrent Financing will be excluded from the calculation of Frequency Net Cash. Each component of Frequency Net Cash, to the extent applicable, shall be determined (a)&#160;in a manner consistent with <span style="text-decoration:underline">Annex A</span>, (b)&#160;to the extent not inconsistent with clause (a)&#160;above, the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Frequency SEC Documents and the Frequency Balance Sheet, and (c)&#160;to the extent not addressed in clauses (a)&#160;or (b) above, GAAP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Options</span>&#8221;<span style="font-weight:bold"> </span>means options to purchase shares of Frequency Common Stock granted by Frequency pursuant to the Frequency 2014 Stock Incentive Plan, as amended from time to time or the Frequency 2019 Incentive Award Plan, as amended from time to time, but excluding the Frequency ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Registered IP</span>&#8221;<span style="font-weight:bold"> </span>means all Frequency IP Rights that are owned or exclusively licensed by Frequency that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all Patents, registered copyrights and registered trademarks and all applications for any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Restricted Stock Units</span>&#8221;<span style="font-weight:bold"> </span>means a restricted stock unit award covering shares of Frequency Common Stock that is subject to vesting conditions based on continued employment or service or subject to performance-based vesting conditions (or a combination of both) granted under the Frequency 2019 Incentive Award Plan, as amended from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Triggering Event</span>&#8221; shall be deemed to have occurred if: (i)&#160;Frequency shall have failed to include in the Proxy Statement the Frequency Board Recommendation, (ii)&#160;the Frequency Board or any committee thereof shall have made a Frequency Board Adverse Recommendation Change or approved, endorsed or recommended any Acquisition Proposal (other than with Korro) or (iii)&#160;Frequency shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4</span>). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Frequency Underwater Options</span>&#8221; means Frequency Options with an exercise price equal to or greater than $1.00 per share (as adjusted for any stock splits or reverse stock splits after the date hereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">GAAP</span>&#8221; means United States generally accepted accounting principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Governmental Authority</span>&#8221;<span style="font-weight:bold"> </span>means any: (i)&#160;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (ii)&#160;federal, state, local, municipal, foreign, supra-national or other government, (iii)&#160;governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority) or (iv)&#160;self-regulatory organization (including Nasdaq). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Governmental Authorization</span>&#8221;<span style="font-weight:bold"> </span>means any: (i)&#160;permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law or (ii)&#160;right under any Contract with any Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Hazardous Materials</span>&#8221;<span style="font-weight:bold"> </span>means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or <span style="white-space:nowrap">by-products.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Intellectual Property</span>&#8221;<span style="font-weight:bold"> </span>means any and all intellectual property and similar proprietary rights throughout the world, including any and all state, United States, international and/or foreign or other territorial or regional rights in, arising out of or associated with any of the following: (i)&#160;United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisional, continuations, <span style="white-space:nowrap"><span style="white-space:nowrap">continuations-in-part,</span></span> reissues, renewals, extensions, supplementary protection certificates, reexaminations, term extensions, confirmations, certificates of invention and the equivalents of any of the foregoing, and statutory invention registrations (collectively, &#8220;<span style="font-weight:bold">Patents</span>&#8221;),<span style="font-weight:bold"> </span>(ii) trademarks, service marks, trade names, domain names, corporate names, brand names, URLs or other names and locators associated with the internet, trade dress, logos and other source identifiers, including registrations and applications for registration thereof and goodwill associated therewith and symbolized thereby, (iii)&#160;works of authorship (whether or not copyrightable) and all copyrights, copyrightable works, derivative works, including registrations and applications for registration thereof, and all renewals, extensions, restorations or reversions of the foregoing, including all rights of authorship, use, publication, publicity, reproduction, distribution, income, performance and transformation, (iv)&#160;software, including all source code, object code, firmware, development tools files, records and data, all media on which any of the foregoing is recorded, and all related documentation, (v)&#160;all inventions, invention disclosures, improvements, formulae, customer lists, trade secrets, <span style="white-space:nowrap">know-how</span> (including recipes, specifications, formulae, manufacturing and other processes, operating procedures, methods, techniques and all research and development information), technology, technical data, databases, data collections, confidential information and other proprietary rights and intellectual property, whether patentable or not, and all documentation relating to any of the foregoing and (vi)&#160;all rights to sue or recover and retain damages and costs and attorneys&#8217; fees for the past, present or future infringement, dilution, misappropriation, or other violation of any of the foregoing anywhere in the world. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">IRS</span>&#8221;<span style="font-weight:bold"> </span>means the United States Internal Revenue Service. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Key Employee</span>&#8221;<span style="font-weight:bold"> </span>means, with respect to any Person, (i)&#160;an executive officer of such Person; and (ii)&#160;any employee of such Person, that reports directly to the board of directors of such Person, or to an executive officer of such Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Knowledge</span>&#8221;<span style="font-weight:bold"> </span>means, with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment responsibilities. Any Person that is an Entity shall have Knowledge if any executive officer or director of such Person as of the date such knowledge is imputed has or should reasonably be expected to have Knowledge of such fact or other matter. With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual Property rights clearance searches. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro 2019 Plan</span>&#8221; means the Korro 2019 Stock Incentive Plan, as amended from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Associate</span>&#8221;<span style="font-weight:bold"> </span>means any current or former employee, consultant, officer, director, independent contractor or other <span style="white-space:nowrap">non-employee</span> service provider of Korro or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Balance Sheet</span>&#8221; means the audited balance sheets of Korro for the years ended December&#160;31, 2021 and December&#160;31, 2022<span style="font-weight:bold">.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Board</span>&#8221; means the board of directors of Korro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Capital Stock</span>&#8221;<span style="font-weight:bold"> </span>means Korro Common Stock and Korro Preferred Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Capitalization Representations</span>&#8221; means the representations and warranties of Korro set forth in <span style="text-decoration:underline">Sections 3.6(a)</span> and <span style="text-decoration:underline">3.6(d)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Common Stock</span>&#8221; means the common stock, $0.001 par value per share, of Korro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Contract</span>&#8221;<span style="font-weight:bold"> </span>means any Contract: (i)&#160;to which Korro or any of its Subsidiaries is a Party, (ii)&#160;by which Korro or any of its Subsidiaries is or may become bound or under which Korro or any of its Subsidiaries has, or may become subject to, any obligation or (iii)&#160;under which Korro or any of its Subsidiaries has or may acquire any right or interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Employee Plan</span>&#8221; means any Employee Plan that Korro or any of its Subsidiaries (i)&#160;sponsors, maintains, administers, or contributes to, or (ii)&#160;provides benefits under or through, or (iii)&#160;has any obligation to contribute to or provide benefits under or through, or (iv)&#160;may reasonably be expected to have any Liability with respect to, or (v)&#160;utilizes to provide benefits to or otherwise cover any Korro Associate (or their spouses, dependents, or beneficiaries). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Fundamental Representations</span>&#8221;<span style="font-weight:bold"> </span>means the representations and warranties of Korro set forth in <span style="text-decoration:underline">Sections&#160;3.1(a)</span>, <span style="text-decoration:underline">3.1(b)</span>, <span style="text-decoration:underline">3.2</span>, <span style="text-decoration:underline">3.3</span>, <span style="text-decoration:underline">3.4</span> and <span style="text-decoration:underline">3.20</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro IP Rights</span>&#8221;<span style="font-weight:bold"> </span>means all Intellectual Property owned, licensed, or controlled by Korro or its Subsidiaries that is necessary for, or used or held for use in, the operation of the business of Korro and its Subsidiaries as presently conducted or proposed to be conducted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro IP Rights Agreement</span>&#8221;<span style="font-weight:bold"> </span>means any Contract governing, related to or pertaining to any Korro IP Rights other than any confidential information provided under confidentiality agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Material Adverse Effect</span>&#8221;<span style="font-weight:bold"> </span>means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Korro Material Adverse Effect, has had or would reasonably be expected to have a material adverse effect on the business, assets, liabilities, financial condition or results of operations of Korro or its Subsidiaries, taken as a whole; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that Effects arising or resulting from the following, alone or in combination, shall not be taken into account in determining whether there has been a Korro Material Adverse Effect: (i)&#160;the announcement of the Agreement, the pendency or the consummation of the Contemplated Transactions, including any adverse change in customer, supplier, governmental, landlord, employee or similar relationships resulting therefrom or with respect thereto, (ii)&#160;the taking of any action, or the failure to take any action, by Korro that is expressly required under the terms of the Agreement, (iii)&#160;any natural disaster or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (iv)&#160;any change in GAAP or applicable Law or the interpretation thereof, (v)&#160;general economic, financial and capital markets, political conditions or conditions generally affecting the industries in which Korro and its Subsidiaries operate, (v)&#160;any failure of Korro to meet any projections, business plans or forecasts (provided that, this clause (vi)&#160;shall not prevent a determination that any change or effect underlying such failure to meet projections, business plans or forecasts has resulted in a Korro Material Adverse Effect (to the extent such change or effect is not otherwise excluded from this definition of Korro Material Adverse Effect)); except in each case with respect to clauses (iii), (iv) and (v), to the extent disproportionately affecting Korro and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Korro and its Subsidiaries operate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Merger Shares</span>&#8221;<span style="font-weight:bold"> </span>means, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(f)</span>, the product determined by <span style="font-style:italic"><span style="text-decoration:underline">multiplying</span></span> (i)&#160;the <span style="white-space:nowrap">Post-Closing</span> Frequency Shares <span style="font-style:italic">by </span>(ii)&#160;the Korro Allocation Percentage, in which: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#8220;<span style="font-weight:bold">Aggregate Valuation</span>&#8221;<span style="font-weight:bold"> </span>means the sum of (A)&#160;the Korro Equity Value, <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (B)&#160;the Frequency Valuation, <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (C)&#160;the Concurrent Financing Proceeds. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) &#8220;<span style="font-weight:bold">Frequency Allocation Percentage</span>&#8221; means the quotient (rounded to four decimal places) determined by <span style="font-style:italic"><span style="text-decoration:underline">dividing</span></span> (A)&#160;the Frequency Valuation <span style="font-style:italic"><span style="text-decoration:underline">by</span></span> (B)&#160;the Aggregate Valuation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) &#8220;<span style="font-weight:bold">Frequency Equity Value</span>&#8221; means (A)&#160;if Frequency Net Cash is $22,000,000 or less at Closing, then $12,500,000, (B) if Frequency Net Cash is more than $22,000,000 but less than or equal to $25,000,000 at Closing, then $15,000,000 or (C)&#160;if Frequency Net Cash is more than $25,000,000 at Closing, then an amount equal to (i)&#160;Frequency Net Cash <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (ii) $10,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) &#8220;<span style="font-weight:bold">Frequency Outstanding Shares</span>&#8221; means, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(f)</span> (including, without limitation, the effects of the Nasdaq Reverse Split), the total number of shares of Frequency Common Stock outstanding immediately prior to the Effective Time expressed on a fully-diluted basis, and assuming, without limitation or duplication, (A)&#160;the issuance of shares of Frequency Common Stock in respect of all Frequency Options that are not Frequency Underwater Options that will be outstanding as of immediately prior to the Effective Time, (B)&#160;the settlement in shares of Frequency Common Stock of Frequency Restricted Stock Units that vest solely based on the holder&#8217;s employment or service and that are outstanding as of immediately prior to the Effective Time on a net settlement basis as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.13</span> and (C)&#160;the exclusion of shares of Frequency Common Stock held by Frequency as treasury stock or owned by Korro or any of its Subsidiaries or any Subsidiary of Frequency immediately prior to the Effective Time. Notwithstanding any of the foregoing, Frequency Underwater Options shall not be included in the total number of shares of Frequency Common Stock outstanding for purposes of determining the Frequency Outstanding Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &#8220;<span style="font-weight:bold">Frequency Valuation</span>&#8221; means (A)&#160;the Frequency Equity Value <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (B)&#160;Frequency Net Cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) &#8220;<span style="font-weight:bold">Korro Allocation Percentage</span>&#8221;<span style="font-weight:bold"> </span>means the quotient (rounded to four decimal places) determined by <span style="font-style:italic"><span style="text-decoration:underline">dividing</span></span> (A)&#160;the Korro Equity Value <span style="font-style:italic"><span style="text-decoration:underline">by</span></span> (B)&#160;the Aggregate Valuation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) &#8220;<span style="font-weight:bold">Korro Equity Value</span>&#8221;<span style="font-weight:bold"> </span>means $325,639,194.78. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) &#8220;<span style="font-weight:bold">Post-Closing Frequency Shares</span>&#8221;<span style="font-weight:bold"> </span>mean the quotient determined by <span style="font-style:italic"><span style="text-decoration:underline">dividing</span></span> (A)&#160;the Frequency Outstanding Shares <span style="font-style:italic">by</span> (B)&#160;the Frequency Allocation Percentage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Concurrent Financing Proceeds shall not be included in the calculation or determination of the Korro Equity Value, the Frequency Valuation or any component thereof. Set forth on <span style="text-decoration:underline">Annex&#160;B</span> attached hereto is an illustrative example of the calculation of Korro Merger Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Option Ex</span><span style="font-weight:bold">change Ratio</span>&#8221;<span style="font-weight:bold"> </span>means the quotient obtained by dividing (i)&#160;the number of Korro Merger Shares by (ii)&#160;the number of Korro Outstanding Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Options</span>&#8221; means options to purchase Korro Common Stock granted by Korro pursuant to the Korro 2019 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Outstanding Shares</span>&#8221; means the total number of shares of Korro Common Stock outstanding immediately prior to the Effective Time (after giving effect to the Korro Preferred Stock Conversion, but without giving effect to the Concurrent Financing) expressed on a fully-diluted and <span style="white-space:nowrap">as-converted</span> to Korro Common Stock basis and assuming, without limitation or duplication, the issuance of all shares of Korro Common Stock that would be issued assuming the acceleration and exercise and conversion of all Korro Options and Korro Warrants outstanding as of immediately prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Preferred Stock</span>&#8221; means the preferred stock, $0.001 par value per share, of Korro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Registered IP</span>&#8221; means all Korro IP Rights that are owned or exclusively licensed by Korro or any of its Subsidiaries that are registered, filed, issued or otherwise granted under the authority of, with or by any Governmental Authority, including all Patents, registered copyrights and registered trademarks and all applications and registrations for any of the foregoing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Restricted Stock Awards</span>&#8221; means restricted stock awards under the Korro 2019 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Triggering Event</span>&#8221; shall be deemed to have occurred if: (i)&#160;the Korro Board or any committee thereof shall have made any change in the Korro Board Recommendation or approved, endorsed or recommended any Acquisition Proposal or (ii)&#160;Korro shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korro Warrants</span>&#8221; means the warrants issued under the Warrant Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Law</span>&#8221;<span style="font-weight:bold"> </span>means any federal, state, national, supra-national, foreign, local or municipal or other law. statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Legal Proceeding</span>&#8221;<span style="font-weight:bold"> </span>means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Authority or any arbitrator or arbitration panel, which, for avoidance of doubt, includes the legal matter(s) set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1(a)</span> of the Frequency Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">MS Asset Proceeds</span>&#8221; means the net proceeds, if any, resulting from the MS Asset Disposition actually received by Frequency or its Subsidiaries prior to or on the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Multiemployer Plan</span>&#8221;<span style="font-weight:bold"> </span>means a &#8220;multiemployer plan,&#8221; as defined in Section&#160;3(37) or 4001 (a)(3) of ERISA </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Multiple Employer Plan</span>&#8221;<span style="font-weight:bold"> </span>means a &#8220;multiple employer plan&#8221; as described in Section&#160;413(c) of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Multiple Employer Welfare Arrangement</span>&#8221;<span style="font-weight:bold"> </span>means a &#8220;multiple employer welfare arrangement&#8221; within the meaning of Section&#160;3(40) of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Nasdaq</span>&#8221;<span style="font-weight:bold"> </span>means The Nasdaq Stock Market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Nasdaq Reverse Split</span>&#8221;<span style="font-weight:bold"> </span>means a reverse stock split of all outstanding shares of Frequency Common Stock at a reverse stock split ratio as mutually agreed to by Frequency and Korro that is effected by Frequency for the purpose of maintaining compliance with Nasdaq listing standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Notice Period</span>&#8221; means a period of at least five Business Days commencing on the date the Frequency Board notifies Korro in writing of its intent to make a Frequency Board Adverse Recommendation Change. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Order</span>&#8221;<span style="font-weight:bold"> </span>means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement, or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court or Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Ordinary Course of Business</span>&#8221;<span style="font-weight:bold"> </span>means, in the case of each of Korro and Frequency, such actions taken in the ordinary course of its normal operations and consistent with its past practices. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Organizational Documents</span>&#8221;<span style="font-weight:bold"> </span>means, with respect to any Person (other than an individual), (i)&#160;the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (ii)&#160;all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Party</span>&#8221;<span style="font-weight:bold"> or </span>&#8220;<span style="font-weight:bold">Parties</span>&#8221;<span style="font-weight:bold"> </span>means Korro, Frequency and Merger Sub. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Permitted Encumbrance</span>&#8221;<span style="font-weight:bold"> </span>means (i)&#160;any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith and for which adequate reserves have been made on the Korro Balance Sheet or the Frequency Balance Sheet, as applicable, in accordance with GAAP, (ii)&#160;liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of Korro or Frequency, as applicable, (iii)&#160;statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements, (iv)&#160;deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law, (v)&#160;statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies and (vi)&#160;liens arising under applicable securities Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Person</span>&#8221;<span style="font-weight:bold"> </span>means any individual, Entity or Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Personal Information</span>&#8221;<span style="font-weight:bold"> </span>means (i)&#160;data and information concerning an identifiable natural person, or (ii)&#160;any information that is regulated or protected by one or more Privacy Laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Privacy Laws</span>&#8221;<span style="font-weight:bold"> </span>mean Laws relating to privacy, security and/or collection, use or other processing of Personal Information. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Representatives</span>&#8221;<span style="font-weight:bold"> </span>means, with respect to any Person, such Person&#8217;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Sarbanes-Oxley Act</span>&#8221;<span style="font-weight:bold"> </span>means the Sarbanes-Oxley Act of 2002. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SEC</span>&#8221; means the United States Securities and Exchange Commission. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Securities Act</span>&#8221;<span style="font-weight:bold"> </span>means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Subsequent Transaction</span>&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Subsidiary</span>&#8221;<span style="font-weight:bold"> </span>means, with respect to a Person, an Entity of which more than 50% of the voting power of the equity securities or equity interests is owned, directly or indirectly, by such Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Superior Offer</span>&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 70% for these purposes) that: (i)&#160;was not obtained or made as a direct or indirect result of a breach of (or in violation of) the Agreement and (ii)&#160;is on terms and conditions that the Korro Board or the Frequency Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof, the financing terms thereof and any termination or <span style="white-space:nowrap">break-up</span> fees and conditions to consummation), as well as any written offer by the other Party to the Agreement to amend the terms of the Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Korro&#8217;s stockholders or Frequency&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions and is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax</span>&#8221;<span style="font-weight:bold"> </span>means any federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, unemployment tax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, customs duty, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alternative or <span style="white-space:nowrap">add-on</span> minimum or other tax or similar charge (whether imposed directly or through withholding and whether or not disputed), and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the nonpayment thereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax Return</span>&#8221;<span style="font-weight:bold"> </span>means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Transaction Expenses</span>&#8221;<span style="font-weight:bold"> </span>means, with respect to Frequency, the aggregate amount (without duplication) of all costs, fees and expenses incurred by Frequency or any of its Subsidiaries (including Merger Sub), or for which Frequency or any of its Subsidiaries are or may become liable in connection with the Contemplated Transactions and the negotiation, preparation and execution of this Agreement or any other agreement, document, instrument, filing, certificate, schedule, exhibit, letter or other document prepared or executed in connection with the Contemplated Transactions, including (A)&#160;any fees and expenses of legal counsel and accountants, the maximum amount of fees and expenses payable to financial advisors, investment bankers, brokers, consultants, tax advisors, transfer agents, proxy solicitor and other advisors of Frequency; (B)&#160;the premiums, commissions and other fees paid or payable in connection with obtaining Frequency&#8217;s D&amp;O tail policy as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15(d)</span>; and (C)&#160;the CVR Fees (if any).<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Treasury Regulations</span>&#8221;<span style="font-weight:bold"> </span>means the United States Treasury regulations promulgated under the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">WARN Act</span>&#8221; means the Worker Adjustment and Retraining Notification Act of 1988, as amended, and any similar or related law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Warrant Agreement</span>&#8221; means that certain Warrant to Purchase Common Stock, by and between Korro and Silicon Valley Bank, issued on January&#160;22, 2021 for 162,000 shares of Korro Common Stock at an exercise price of $0.58 per share (subject to adjustments). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each of the following terms is defined in the Section set forth opposite such term: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Term</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Section</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">401(k) Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.29</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Accounting Firm</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(e)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Preamble</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Allocation Certificate</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.22</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Anticipated Closing Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Assumed Option</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.4(f)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Assumed Warrant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.4(i)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Authorized Share Increase Proposal</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cash Determination Time</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Certificate of Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.1</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Charter Amendment Proposals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Closing</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.2</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Closing Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.2</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Code</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Costs</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.15(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Current Offering Period</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.14</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">CVR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">CVR Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(a)</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Term</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Section</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">CVR Fees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">D&amp;O Indemnified Parties</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.15(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">D&amp;O tail policy</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.15(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Delivery Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dispute Notice</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Disqualifying Event</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.22</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Drug Regulatory Agency</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Effective Time</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.1</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exchange Agent</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">FDA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">FDCA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Final Frequency Net Cash</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Form <span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Preamble</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Board</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Board Adverse Recommendation Change</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.9(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Board Recommendation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.9(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Certifications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Closing Certificate</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.2(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.6(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Designee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.19(a)(i)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Disclosure Schedule</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Article IV</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency IT Systems</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.23(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency <span style="white-space:nowrap">Lock-Up</span> Agreements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Material Contract</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.13(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Net Cash Calculation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Net Cash Schedule</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency <span style="white-space:nowrap">Non-Voting</span> Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Permits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.14(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.6(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Product Candidates</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.14(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Regulatory Permits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.14(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Real Estate Leases</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.11</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Stockholder Matters</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.9(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Stockholder Meeting</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.9(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Frequency Stockholder Support Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Information Statement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Intended Tax Treatment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Preamble</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Board Recommendation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.8(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Certification</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Closing Certificate</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.3(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Designee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.19(a)(i)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Disclosure Schedule</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Article III</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Financial Statements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro IT Systems</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.22(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro <span style="white-space:nowrap">Lock-Up</span> Agreements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Material Contract</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.13(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Permits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Preferred Stock Conversion</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.4(h)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Product Candidates</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(d)</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Term</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Section</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Real Estate Leases</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.11</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Regulatory Permits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Stockholder Support Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Korro Stockholder Written Consents</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Liability</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.9</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Merger Sub</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Preamble</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Merger Sub Board</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">MS Assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.6</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">MS Asset Disposition</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.6</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Nasdaq Issuance Proposal</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Ordinary Course Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.16(f)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Outside Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">8.1(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">PHSA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">Pre-Closing</span> Distribution</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">Pre-Closing</span> Period</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.1</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Privacy Policies</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.22(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proxy Statement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Purchasers</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.23</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Registration Statement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Required Frequency Stockholder Vote</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.4</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Required Korro Stockholder Vote</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.4</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Response Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Reverse Stock Split Proposal</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Rights Agent</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Subscription Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Surviving Corporation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.1</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Transaction Litigation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.26</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Transfer Tax</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.16(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Warrant Exchange Ratio</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.4(i)</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_3">1.2 <span style="text-decoration:underline">Other Definitional and Interpretative Provisions</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections, Exhibits and Schedules are to Sections, Exhibits and Schedules of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, <span style="white-space:nowrap">re-enacted</span> thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree that the Korro Disclosure Schedule or the Frequency Disclosure Schedule shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in <span style="text-decoration:underline">Article III</span> or <span style="text-decoration:underline">Article IV</span> respectively. The disclosures in any section or subsection of the Korro Disclosure Schedule or the Frequency Disclosure Schedule shall qualify other sections and subsections in <span style="text-decoration:underline">Article III</span> or <span style="text-decoration:underline">Article IV</span> respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. The words &#8220;delivered&#8221; or &#8220;made available&#8221; mean, with respect to any documentation, that prior to 7:00 p.m. (New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been posted to and made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions. The inclusion of any information in the Korro Disclosure Schedule or Frequency Disclosure Schedule (or any update thereto) shall not be deemed to be an admission or acknowledgement, in and of itself, that such information is required by the terms hereof to be disclosed, is material, has resulted in or would result in a Korro Material Adverse Effect or Frequency Material Adverse Effect, as the case may be, or is outside the Ordinary Course of Business. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_4">ARTICLE II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_5">2.1 <span style="text-decoration:underline">The Merger</span>. Upon the terms and subject to the conditions set forth in this Agreement and subject to the applicable provisions of Delaware Law, at the Closing, Frequency and Korro shall cause Merger Sub to be merged with and into Korro, whereupon the separate existence of Merger Sub shall cease and Korro shall continue as the Surviving Corporation of the Merger and as a wholly owned subsidiary of Frequency (the &#8220;<span style="font-weight:bold">Surviving Corporation</span>&#8221;). At the Closing, Frequency and Korro shall cause the Merger to be consummated and effective under Delaware Law by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying the applicable requirements of Delaware Law (the &#8220;<span style="font-weight:bold">Certificate of Merger</span>&#8221;).<span style="font-weight:bold"> </span>The Merger shall become effective at the time of the filing of such Certificate of Merger and the acceptance by the Secretary of State of the State of Delaware, or at such later time as may be specified in such Certificate of Merger with the consent of Frequency and Korro (the time as of which the Merger becomes effective being referred to as the &#8220;<span style="font-weight:bold">Effective Time</span>&#8221;).<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_6">2.2 <span style="text-decoration:underline">Closing</span>. Subject to the satisfaction or waiver of the conditions set forth in this Agreement, the consummation of the Merger (the &#8220;<span style="font-weight:bold">Closing</span>&#8221;)<span style="font-weight:bold"> </span>shall take place remotely, (a)&#160;no later than the second Business Day after all the conditions precedent set forth in <span style="text-decoration:underline">Article VI</span> shall have been satisfied or waived (other than those conditions that, by their nature, are to be satisfied at the Closing (provided such conditions would be so satisfied)) or (b)&#160;at such other time, date and place as the Parties may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#8220;<span style="font-weight:bold">Closing Date</span>&#8221;.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_7">2.3 <span style="text-decoration:underline">Organizational Documents; Directors and Officers</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Certificate of Incorporation</span>. The certificate of incorporation of the Surviving Corporation shall be amended and restated at or prior to the Effective Time as set forth in an exhibit to the Certificate of Merger, and as so amended and restated shall be the certificate of incorporation of the Surviving Corporation until thereafter amended as provided by Delaware Law. Frequency shall further take all actions necessary so that the certificate of incorporation of Frequency shall remain in effect following the Effective Time, until thereafter amended as provided by Delaware Law and, provided, however, that at or prior to the Effective Time, Frequency shall file </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
one or more amendments to its certificate of incorporation to (i)&#160;change the name of Frequency to &#8220;Korro Bio, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split and the Authorized Share Increase Proposal and (iii)&#160;make such other changes as are mutually agreeable to Frequency and Korro. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Bylaws</span>. The bylaws of the Surviving Corporation shall be amended and restated as of the Effective Time to be the same as the bylaws of Merger Sub as in effect immediately prior to the Effective Time (with the name of Korro as the Surviving Corporation&#8217;s name) until thereafter amended in accordance with Delaware Law and as provided in the Surviving Corporation&#8217;s Organizational Documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Directors and Officers</span>. The directors and officers, each to hold office in accordance with the provisions of Delaware Law and the Surviving Corporation&#8217;s Organizational Documents immediately after the Effective Time, shall be as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.18</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_8">2.4 <span style="text-decoration:underline">Conversion of Shares</span><span style="text-decoration:underline">; Korro Options; Korro Preferred Stock and Korro Warrants</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time (after giving effect to the Korro Preferred Stock Conversion), by virtue of the Merger and without any further action on the part of Frequency, Merger Sub, Korro or any stockholder of Korro, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(d)</span>, the Korro Common Stock outstanding immediately prior to the Effective Time (excluding Korro Common Stock issued in the Concurrent Financing) shall be converted solely into the right to receive a number of shares of Frequency Common Stock equal to the amount of Korro Merger Shares multiplied by the applicable stockholder&#8217;s percentage interest in Korro as set forth on the Allocation Certificate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At the Effective Time, by virtue of the Merger and without any further action on the part of Frequency, Merger Sub, Korro or any stockholder of Korro, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(d)</span>, the Korro Common Stock issued in the Concurrent Financing shall be converted solely into the right to receive a number of shares of Frequency Common Stock equal to the amount of Concurrent Financing Merger Shares multiplied by the percentage of the Concurrent Financing Proceeds represented by the applicable stockholder&#8217;s investment in the Concurrent Financing, as set forth on the Allocation Certificate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If any Korro Common Stock outstanding immediately prior to the Effective Time is unvested or is subject to a repurchase option or a risk of forfeiture under any applicable restricted stock, profits interests, restricted stock unit award agreement or other similar agreement with Korro, then the shares of Frequency Common Stock issued in exchange for such Korro Common Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Frequency Common Stock shall accordingly be marked with appropriate legends. Korro shall take all actions that may be necessary to ensure that, from and after the Effective Time, Frequency is entitled to exercise any such repurchase option or other right set forth in any such restricted stock unit award agreement or other agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) No fractional shares of Frequency Common Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Frequency Common Stock a holder of Korro Common Stock would otherwise be entitled to receive shall be aggregated together first prior to eliminating any remaining fractional share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) At the Effective Time, by virtue of the Merger and without any further action on the part of Frequency, Merger Sub, Korro or any stockholder of Korro, each share of common stock, $0.01 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the Surviving Corporation. If applicable, each stock certificate of Merger Sub evidencing ownership of any such shares shall, as of the Effective Time, evidence ownership of such shares of common stock of the Surviving Corporation until presented for transfer or exchange. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) If, between the date of this Agreement and the Effective Time, the outstanding Korro Common Stock or Frequency Common Stock shall have been changed into, or exchanged for, a different number of shares or a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not previously been taken into account in calculating Korro Merger Shares), combination or exchange of shares or other like change, Korro Merger Shares shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Korro Common Stock and Frequency Common Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that nothing herein will be construed to permit Korro or Frequency to take any action with respect to Korro Common Stock or Frequency Common Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Each Korro Option outstanding immediately prior to the Effective Time shall automatically be converted, at the Effective Time, into an option (an &#8220;<span style="font-weight:bold">Assumed Option</span>&#8221;) to acquire, on the same terms and conditions (including, without limitation, the same vesting and exercisability terms and conditions) as were applicable under the Korro 2019 Plan and option agreement to such Korro Option immediately prior to the Effective Time, the number of shares of Frequency Common Stock under the Assumed Option determined by multiplying the number of shares of Korro Common Stock subject to such Korro Option immediately prior to the Effective Time (on a fully-diluted basis but before giving effect to the Concurrent Financing) by the Korro Option Exchange Ratio as set forth on the Allocation Certificate, rounding down to the nearest whole number of shares, at a per share exercise price determined by dividing the per share exercise price of such Korro Option immediately prior to the Effective Time by the Korro Option Exchange Ratio, rounding up to the nearest whole cent, and Frequency shall assume the Korro 2019 Plan; provided, that the conversion of the Korro Options will be made in a manner consistent with Treasury Regulations <span style="white-space:nowrap">Section&#160;1.424-1,</span> such that the conversion will not constitute a &#8220;modification&#8221; of such Korro Option for purposes of Section&#160;409A or Section&#160;424 of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) All Korro Preferred Stock shall be converted into Korro Common Stock as of immediately prior to the Effective Time in accordance with, and pursuant to the terms and conditions of, the Organizational Documents of Korro (the &#8220;<span style="font-weight:bold">Korro Preferred Stock Conversion</span>&#8221;).<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each Korro Warrant outstanding immediately prior to the Effective Time shall automatically be converted, at the Effective Time, into a warrant (an &#8220;<span style="font-weight:bold">Assumed Warrant</span>&#8221;) to acquire, on the same terms and conditions (including, without limitation, the exercisability terms and conditions) as were applicable under the Warrant Agreement to such Korro Warrant immediately prior to the Effective Time, the number of shares of Frequency Common Stock under the Assumed Warrant determined by multiplying the number of shares of Korro Common Stock subject to such Korro Warrant immediately prior to the Effective Time by the applicable holder&#8217;s percentage interest in Korro with respect to such Korro Warrant as set forth on the Allocation Certificate (such percentage interest, the &#8220;<span style="font-weight:bold">Warrant Exchange Ratio</span>&#8221;), rounding down to the nearest whole number of shares, at a per share exercise price determined by dividing the per share exercise price of such Korro Warrant immediately prior to the Effective Time by the Warrant Exchange Ratio, rounding up to the nearest whole cent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_9">2.5 <span style="text-decoration:underline">Contingent Value Right</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Effective Time, unless (i)&#160;the MS Asset Disposition has been consummated prior to or on the Closing Date and (ii)&#160;all MS Asset Proceeds are taken into account in the Final Frequency Net Cash and there are no contingent payments, licenses, fees or royalties, equity securities or other <span style="white-space:nowrap">non-cash</span> assets or rights that may be payable by any acquiror of any MS Assets or otherwise as a result of the MS Asset Disposition after the Closing Date, Frequency shall declare a distribution (the &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Pre-Closing</span> Distribution</span>&#8221;) to holders of Frequency Common Stock of record (as described below), the right to receive one contingent value right (each, a &#8220;<span style="font-weight:bold">CVR</span>&#8221;) for each outstanding share of Frequency Common Stock held by such stockholder as of such date, each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement in the form attached hereto as <span style="text-decoration:underline">Exhibit F</span>, to be entered into between Frequency and Computershare Trust Company, N.A. (or such other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nationally recognized rights agent agreed to between Frequency and Korro) (the &#8220;<span style="font-weight:bold">Rights Agent</span>&#8221;), with such revisions thereto requested by the Rights Agent that are not, individually or in the aggregate, materially detrimental to the holders of CVRs and reasonably acceptable to Korro and Frequency, (the &#8220;<span style="font-weight:bold">CVR Agreement</span>&#8221;). The record date for the <span style="white-space:nowrap">Pre-Closing</span> Distribution shall be the close of business on the last Business Day prior to the day on which the Effective Time occurs and the payment date for the <span style="white-space:nowrap">Pre-Closing</span> Distribution shall be three Business Days after the Effective Time; provided that the payment of such dividend may be conditioned upon the occurrence of the Effective Time. In connection with the <span style="white-space:nowrap">Pre-Closing</span> Distribution, Frequency shall cause the CVR Agreement to be duly authorized, executed and delivered by Frequency and the Exchange Agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Frequency agrees to pay all reasonable costs and fees associated with any action permitted by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.5</span> (the &#8220;<span style="font-weight:bold">CVR Fees</span>&#8221;), which shall be deducted from Frequency Net Cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_10">2.6 <span style="text-decoration:underline">Closing of Korro</span><span style="text-decoration:underline">&#8217;</span><span style="text-decoration:underline">s Transfer Books</span>. At the Effective Time: (a)&#160;all Korro Common Stock outstanding immediately prior to the Effective Time shall be treated in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(a)</span>, and all holders of certificates representing Korro Common Stock that were outstanding immediately prior to the Effective Time shall cease to have any rights as stockholders of Korro (other than the right to receive the Korro Merger Shares) and (b)&#160;the stock transfer books of Korro shall be closed with respect to all Korro Common Stock outstanding immediately prior to the Effective Time. No further transfer of any such Korro Common Stock shall be made on such stock transfer books after the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_11">2.7 <span style="text-decoration:underline">Surrender of Korro Common Stock</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Closing Date, Frequency and Korro shall jointly select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#8220;<span style="font-weight:bold">Exchange Agent</span>&#8221;). At the Effective Time, Frequency shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Frequency Capital Stock issuable pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(a)</span> in exchange for Korro Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of Korro Common Stock that were converted into the right to receive Korro Merger Shares: (i)&#160;a letter of transmittal in customary form and containing such provisions as Frequency may reasonably specify and (ii)&#160;instructions for effecting the surrender of Korro Common Stock in exchange for book-entry shares of Frequency Capital Stock. Upon surrender of a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Frequency, the holder of such Korro Common Stock shall be entitled to receive in exchange therefor book-entry shares representing Korro Merger Shares (in a number of whole shares of Frequency Capital Stock) that such holder has the right to receive pursuant to the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No dividends or other distributions declared or made with respect to Frequency Capital Stock with a record date after the Effective Time shall be paid to the holder of any Korro Common Stock with respect to the shares of Frequency Capital Stock that such holder has the right to receive in the Merger until such holder delivers a duly executed letter of transmittal (at which time (or, if later, on the applicable payment date) such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Any shares of Frequency Capital Stock deposited with the Exchange Agent that remain undistributed to holders of Korro Common Stock as of the date that is 180 days after the Closing Date shall be delivered to Frequency upon demand, and any holders of Korro Common Stock who have not theretofore delivered a duly executed letter of transmittal in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span> shall thereafter look only to Frequency for satisfaction of their claims for Frequency Capital Stock and any dividends or distributions with respect to shares of Frequency Capital Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No Party shall be liable to any holder of any Korro Common Stock or to any other Person with respect to any shares of Frequency Capital Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_12">2.8 <span style="text-decoration:underline">Calculation of Net Cash</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Not less than ten Business Days prior to the anticipated date for Closing as mutually agreed in good faith by Frequency and Korro (the &#8220;<span style="font-weight:bold">Anticipated Closing Date</span>&#8221;),<span style="font-weight:bold"> </span>Frequency will deliver to Korro a schedule (the &#8220;<span style="font-weight:bold">Frequency Net Cash Schedule</span>&#8221;, and the date of delivery of the Frequency Net Cash Schedule, the &#8220;<span style="font-weight:bold">Delivery Date</span>&#8221;)<span style="font-weight:bold"> </span>setting forth, in reasonable detail, Frequency&#8217;s good faith, estimated calculation of Frequency Net Cash (the &#8220;<span style="font-weight:bold">Frequency Net Cash Calculation</span>&#8221;)<span style="font-weight:bold"> </span>as of the close of business on the Closing Date (the &#8220;<span style="font-weight:bold">Cash Determination Time</span>&#8221;)<span style="font-weight:bold"> </span>prepared and certified by Frequency&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Frequency). Frequency shall make available to Korro (electronically to the greatest extent possible), as reasonably requested by Korro, the work papers and <span style="white-space:nowrap">back-up</span> materials used or useful in preparing the Frequency Net Cash Schedule and, if reasonably requested by Korro, Frequency&#8217;s accountants and counsel at reasonable times and upon reasonable notice. The Frequency Net Cash Calculation shall include Frequency&#8217;s determination, as of the Cash Determination Time, of the defined terms in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1(a)</span> necessary to calculate Korro Merger Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Within five Business Days after the Delivery Date (the last day of such period, the &#8220;<span style="font-weight:bold">Response Date</span>&#8221;), Korro shall have the right to dispute any part of the Frequency Net Cash Calculation by delivering a written notice to that effect to Frequency (a &#8220;<span style="font-weight:bold">Dispute Notice</span>&#8221;). Any Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Frequency Net Cash Calculation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, on or prior to the Response Date, Korro notifies Frequency in writing that it has no objections to the Frequency Net Cash Calculation or, if prior to 5:00 p.m. (New York City time) on the Response Date, Korro has failed to deliver a Dispute Notice as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8(b)</span>, then the Frequency Net Cash Calculation as set forth in the Frequency Net Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Frequency Net Cash at the Cash Determination Time (the &#8220;<span style="font-weight:bold">Final Frequency Net Cash</span>&#8221;) for purposes of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If Korro delivers a Dispute Notice on or prior to 5:00 p.m. (New York City time) on the Response Date, then Representatives of Frequency and Korro shall promptly, and in no event later than one calendar day after the Response Date, meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Frequency Net Cash, which agreed upon Frequency Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Final Frequency Net Cash for purposes of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If Representatives of Frequency and Korro are unable to negotiate an agreed-upon determination of Final Frequency Net Cash pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8(d)</span> within two calendar days after delivery of the Dispute Notice (or such other period as Frequency and Korro may mutually agree upon), then any remaining disagreements as to the calculation of Frequency Net Cash shall be referred to an independent auditor of recognized national standing jointly selected by Frequency and Korro or another independent auditor of recognized national standing mutually agreed upon by Frequency and Korro (the &#8220;<span style="font-weight:bold">Accounting Firm</span>&#8221;). Frequency shall promptly deliver to the Accounting Firm all work papers and <span style="white-space:nowrap">back-up</span> materials used in preparing the Frequency Net Cash Schedule, and Frequency and Korro shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within five calendar days of accepting its selection. Frequency and Korro shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that no such presentation or discussion shall occur without the presence of a Representative of each of Frequency and Korro. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Frequency Net Cash made by the Accounting Firm shall be made in writing delivered to each of Frequency and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Korro, shall be final and binding on Frequency and Korro and shall be deemed to have been finally determined for purposes of this Agreement and to represent the Final Frequency Net Cash for purposes of this Agreement. The Parties shall delay the Closing until the resolution of the matters described in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8(e)</span>. The fees and expenses of the Accounting Firm shall be allocated between Frequency and Korro in the same proportion that the disputed amount of the Frequency Net Cash that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Frequency Net Cash amount and such portion of the costs and expenses of the Accounting Firm borne by Korro and any other fees, costs or expenses incurred by Korro following the Anticipated Closing Date in connection with the procedures set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8(e)</span> shall be deducted from the final determination of the amount of Frequency Net Cash, to the extent of available amounts. If this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8(e)</span> applies as to the determination of the Final Frequency Net Cash described in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8(a)</span>, upon resolution of the matter in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8(e)</span>, the Parties shall not be required to determine Frequency Net Cash again even though the Closing Date may occur later than the Anticipated Closing Date, except that either Frequency and Korro may require a redetermination of the Final Frequency Net Cash if the Closing Date is more than ten calendar days after the Anticipated Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_13">2.9 <span style="text-decoration:underline">Further Action</span>. If, at any time after the Effective Time, any further action is determined by the Surviving Corporation to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of Korro, then the officers and manager of the Surviving Corporation shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of Korro, in the name of Merger Sub, in the name of the Surviving Corporation and otherwise) to take such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_14">2.10 <span style="text-decoration:underline">Withholding</span>. Each of the Exchange Agent, Frequency and the Surviving Corporation shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement (including the <span style="white-space:nowrap">Pre-Closing</span> Distribution) such amounts as are required to be deducted or withheld from such consideration under the Code or under any other applicable Law. To the extent such amounts are so deducted or withheld, and remitted to the appropriate taxing authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. Frequency shall use commercially reasonable efforts to give reasonable advance notice of any required deduction or withholding to Korro (other than where such deduction or withholding is with respect to an amount treated as compensation under the Code or is due to a failure of the payee to provide any applicable Tax forms required under the letter of transmittal described under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span> or the failure of Korro to provide the certificate described in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.16(b)</span>) and shall reasonably cooperate with Korro to eliminate or reduce any such required deduction or withholding. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_15">ARTICLE III </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">REPRESENTATIONS AND WARRANTIES OF KORRO </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the written disclosure schedule delivered by Korro to Frequency (the &#8220;<span style="font-weight:bold">Korro Disclosure Schedule</span>&#8221;),<span style="font-weight:bold"> </span>Korro represents and warrants to Frequency and Merger Sub as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_16">3.1 <span style="text-decoration:underline">Due Organization; Subsidiaries</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Korro is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i)&#160;to conduct its business in the manner in which its business is currently being conducted, (ii)&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii)&#160;to perform its obligations under all Contracts by which it is bound. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of Korro and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Korro Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.1(c)</span> of the Korro Disclosure Schedule, Korro has no Subsidiaries and Korro does not directly or indirectly own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or indirectly, any other Entity. Korro is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Korro has not agreed and is not obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Korro has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_17">3.2 <span style="text-decoration:underline">Organizational Documents</span>. Korro has delivered to Frequency accurate and complete copies of Korro&#8217;s Organizational Documents. Korro is not in breach or violation of its Organizational Documents in any material respect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_18">3.3 <span style="text-decoration:underline">Authority; Binding Nature of Agreement</span>. Korro has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Korro Board (at meetings duly called and held) has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Korro and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend the Korro Board Recommendation to the stockholders of Korro. This Agreement has been duly executed and delivered by Korro and assuming the due authorization, execution and delivery by Frequency and Merger Sub, constitutes the legal, valid and binding obligation of Korro, enforceable against Korro in accordance with its terms, subject to the Enforceability Exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_19">3.4 <span style="text-decoration:underline">Vote Required</span>. The affirmative vote of the holders of at least 66% of the then outstanding shares of Korro Preferred Stock, voting as a single class on an <span style="white-space:nowrap">as-converted</span> basis (the &#8220;<span style="font-weight:bold">Required Korro</span> <span style="font-weight:bold">Stockholder Vote</span>&#8221;),<span style="font-weight:bold"> </span>is the only vote of the holders of any class or series of Korro Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions. No interest in Korro is subject to any appraisal or dissenters rights in connection with the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_20">3.5 <span style="text-decoration:underline"><span style="white-space:nowrap">Non-Contravention;</span> Consents</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to obtaining the Required Korro Stockholder Vote and the filing of the Certificate of Merger required by Delaware Law, neither (x)&#160;the execution, delivery or performance of this Agreement by Korro, nor (y)&#160;the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Korro or its Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) contravene, conflict with or result in a material violation of,<span style="font-weight:bold"> </span>or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Korro or its Subsidiaries, or any of the assets owned or used by Korro or its Subsidiaries, is subject; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Korro or its Subsidiaries or that otherwise relates to the business of Korro, or any of the assets owned, leased or used by Korro; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Korro Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any remedy under any Korro Material Contract, (B)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any such Korro Material Contract, (C)&#160;accelerate the maturity or performance of any Korro Material Contract or (D)&#160;cancel, terminate or modify any term of any Korro Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Korro or its Subsidiaries (except for Permitted Encumbrances). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except for (i)&#160;any Consent set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.5</span> of the Korro Disclosure Schedule under any Korro Contract, (ii)&#160;the Required Korro Stockholder Vote, (iii)&#160;the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to Delaware Law and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, neither Korro nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&#160;the execution, delivery or performance of this Agreement or (y)&#160;the consummation of the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Korro Board has taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of Delaware Law are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_21">3.6 <span style="text-decoration:underline">Capitalization</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The authorized Korro Capital Stock as of the date of this Agreement consists of (i) 117,138,030 shares of Korro Common Stock, of which (a) 5,662,169 shares have been issued and are outstanding as of the date of this Agreement and (b)&#160;Korro Warrants exercisable for 162,000 shares of Korro Common Stock have been issued and are outstanding as of the date of this Agreement, and (ii) 97,714,516 shares of Korro Preferred Stock, of which (a) 4,000,000 shares have been designated Series Seed 1 Preferred Stock, all of which are issued and outstanding as of the date of this Agreement, (b) 2,000,000 shares have been designated Series Seed 2 Preferred Stock, all of which are issued and outstanding as of the date of this Agreement, (c) 7,780,769 shares have been designated Series Seed 3 Preferred Stock, all of which are issued and outstanding as of the date of this Agreement, (d) 40,848,216 shares have been designated Series A Preferred Stock, all of which are issued and outstanding as of the date of this Agreement, (e) 22,222,223 shares have been designated Series <span style="white-space:nowrap">B-1</span> Preferred Stock, all of which are issued and outstanding as of the date of this Agreement and (f) 20,863,308 shares have been designated Series <span style="white-space:nowrap">B-2</span> Preferred Stock, all of which are issued and are outstanding as of the date of this Agreement. Korro does not hold any shares of its capital stock in its treasury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding shares of Korro Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than under applicable securities Laws. None of the outstanding shares of Korro Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right. None of the outstanding shares of Korro Common Stock is subject to any right of first refusal in favor of Korro. Except as contemplated herein, there is no Korro Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Korro Common Stock. Korro is not under any obligation, nor is Korro bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Korro Common Stock or other securities. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.6(b)</span> of the Korro Disclosure Schedule accurately and completely describes all repurchase rights held by Korro with respect to shares of Korro Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except for the Korro 2019 Plan and the Korro Options and Korro Restricted Stock Awards granted thereunder, Korro does not have any stock option plan or any other plan, program, agreement or arrangement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
providing for any equity-based compensation for any Person and there were no other equity or equity-based awards outstanding as of the date of this Agreement. As of the date of this Agreement, Korro has reserved 15,048,960 shares of Korro Common Stock for issuance under the Korro 2019 Plan, of which 685,175 shares have been issued and are currently outstanding pursuant to Korro Restricted Stock Awards, 766,069 shares have been issued and are currently outstanding pursuant to the exercise of Korro Options, Korro Options to purchase 12,837,152 shares of Korro Common Stock have been granted and are currently outstanding, and 760,564 shares of Korro Common Stock remain available for future issuance pursuant to the Korro 2019 Plan. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.6(c)</span> of the Korro Disclosure Schedule sets forth a true and complete list, as of the date of this Agreement, of each outstanding Korro Option and Korro Restricted Stock Award: (i)&#160;the name (or employee identification number) of the holder, (ii)&#160;the number of shares of Korro Common Stock subject to such Korro Option or Korro Restricted Stock Award, (iii)&#160;the exercise price of each Korro Option, (iv)&#160;the date on which such Korro Option or Korro Restricted Stock Award was granted, (v)&#160;the applicable vesting schedule, including any acceleration provisions, and the number of vested and unvested shares, (vi)&#160;the expiration date, as applicable, and (vii)&#160;whether the Korro Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a <span style="white-space:nowrap">non-qualified</span> stock option. Korro has made available to Frequency accurate and complete copies of the following: (A)&#160;the standard form of agreement evidencing Korro Options and Korro Restricted Stock Awards; and (B)&#160;each agreement evidencing a Korro Option or Korro Restricted Stock Award that does not conform in all material respects to the standard form agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.6(c)</span> of the Korro Disclosure Schedule, there is no: (i)&#160;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Korro, (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Korro, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Korro is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv)&#160;condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Korro. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All outstanding shares of Korro Common Stock, and other securities of Korro have been issued and granted in compliance with (i)&#160;all applicable securities laws and other applicable Law and (ii)&#160;all requirements set forth in applicable Contracts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_22">3.7 <span style="text-decoration:underline">Financial Statements</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.7(a)</span> of the Korro Disclosure Schedule includes true and complete copies of (i)&#160;the Korro Balance Sheet and the related audited statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit and cash flows for the years ended December&#160;31, 2021 and December&#160;31, 2022 (the &#8220;<span style="font-weight:bold">Korro Audited Financial Statements</span>&#8221;), and (ii)&#160;Korro&#8217;s unaudited balance sheet and the related unaudited statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit and cash flows for the three months ended March&#160;31, 2023 (the &#8220;<span style="font-weight:bold">Korro Interim Financial Statements</span>&#8221; and collectively, with the Korro Audited Financial Statements, the &#8220;<span style="font-weight:bold">Korro</span> <span style="font-weight:bold">Financial Statements</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Korro Financial Statements (i)&#160;were prepared in accordance with GAAP (except the Korro Interim Financial Statements may not have notes thereto and other presentation items that may be required by GAAP and are subject to normal and recurring <span style="white-space:nowrap">year-end</span> adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (ii)&#160;fairly present, in all material respects, the financial position of Korro as of the respective dates thereof and the results of operations and cash flows of Korro for the periods covered thereby. Other than as expressly disclosed in the Korro Financial Statements, there has been no material change in Korro&#8217;s accounting methods or principles that would be required to be disclosed in Korro&#8217;s financial statements in accordance with GAAP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial officer, or general counsel of Korro, the Korro Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Korro maintains a system of internal control over financial reporting that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&#160;that Korro maintains records that in reasonable detail accurately and fairly reflect Korro&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)&#160;that receipts and expenditures are made only in accordance with authorizations of management and the Korro Board and (iv)&#160;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Korro&#8217;s assets that could have a material effect on Korro&#8217;s financial statements. Korro has evaluated the effectiveness of Korro&#8217;s internal control over financial reporting. Korro has disclosed to Korro&#8217;s auditors (and made available to Frequency a summary of the significant aspects of such disclosure)&#160;(A) all significant deficiencies, if any, in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Korro&#8217;s ability to record, process, summarize and report financial information and (B)&#160;any fraud that involves management or other employees who have a significant role in Korro or its Subsidiaries&#8217; internal control over financial reporting. Except as disclosed in the Korro Financial Statements, Korro&#8217;s internal control over financial reporting is effective and Korro has not identified any material weaknesses in the design or operation of Korro&#8217;s internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Korro Financial Statements are in a form that is compliant with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) for inclusion in the Proxy Statement and the Registration Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_23">3.8 <span style="text-decoration:underline">Absence of Changes</span>. Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.8</span> of the Korro Disclosure Schedule, since January&#160;1, 2022, Korro and its Subsidiaries have conducted their business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a)&#160;Korro Material Adverse Effect or (b)&#160;action, event or occurrence that would have required consent of Frequency pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_24">3.9 <span style="text-decoration:underline">Absence of Undisclosed Liabilities</span>. Neither Korro nor any of its Subsidiaries has any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (each a &#8220;<span style="font-weight:bold">Liability</span>&#8221;), in each case, of a type required to be reflected or reserved for on a balance sheet prepared in accordance with GAAP, except for: (a)&#160;Liabilities disclosed, reflected or reserved against in the Korro Balance Sheet, (b)&#160;normal and recurring current Liabilities that have been incurred by Korro or its Subsidiaries since the date of the Korro Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement, or violation of Law), (c) Liabilities for performance of obligations of Korro or any of its Subsidiaries under Korro Contracts, (d)&#160;Liabilities incurred in connection with the Contemplated Transactions and (e)&#160;Liabilities described in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.9</span> of the Korro Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_25">3.10 <span style="text-decoration:underline">Title to Assets</span>. Each of Korro and its Subsidiaries has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&#160;all tangible assets reflected on the Korro Balance Sheet and (b)&#160;all other tangible assets reflected in the books and records of Korro as being owned by Korro. All of such assets are owned or, in the case of leased assets, leased by Korro or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_26">3.11 <span style="text-decoration:underline">Real Property; Leasehold</span>. Neither Korro nor any of its Subsidiaries owns or has ever owned any real property. Korro has made available to Frequency (a)&#160;an accurate and complete list of all real properties with respect to which Korro directly or indirectly holds a valid leasehold interest as well as any other real estate that is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the possession of or leased by Korro or any of its Subsidiaries and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;<span style="font-weight:bold">Korro</span> <span style="font-weight:bold">Real Estate Leases</span>&#8221;), each of which is in full force and effect, with no existing material default thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_27">3.12 <span style="text-decoration:underline">Intellectual Property</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">3.12(a)</span> of the Korro Disclosure Schedule is an accurate, true and complete listing of all Korro Registered IP including for each item (i)&#160;the record owner (and name of any other Person with an ownership interest in such item of Korro Registered IP, if any), jurisdiction (or, with respect to domain names, the applicable registrar), status, date and registration or application number of each item, as applicable, (ii)&#160;the name of the record owner and any other Person that has an ownership interest in such item of Korro Registered IP, and the nature of such ownership interest, and (iii)&#160;any actions that are required to be taken within 180 days of the Closing Date, including the payment of any registration, maintenance or renewal fees or the filing of or response to any documents, applications or certificates, for the purposes of prosecuting, obtaining, perfecting, maintaining or renewing any Korro Registered IP. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(a)</span> of the Korro Disclosure Schedule also sets forth, as of the date of this Agreement, a list of all internet domain names with respect to which Korro or any of its Subsidiaries are the registrant and, with respect to each domain name, the record owner of such domain name and if different, the legal and beneficial owner(s) of such domain name and the applicable domain name registrar. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">3.12(b)</span> of the Korro Disclosure Schedule accurately identifies (i)&#160;all Korro Contracts pursuant to which any Korro IP Rights are licensed to Korro (other than (A)&#160;any <span style="white-space:nowrap">non-customized</span> software that (1)&#160;is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing, or distribution of, any of Korro&#8217;s or its Subsidiaries&#8217; products or services, (B)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials, (C)&#160;any confidential information provided under confidentiality agreements and (D)&#160;agreements between Korro or its Subsidiaries and their respective employees in Korro&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to Korro or its Subsidiaries are exclusive or nonexclusive. Each Korro Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(b)</span> of the Korro Disclosure Schedule is in full force and effect and constitutes a legal, valid, and binding obligation of Korro or its Subsidiaries and each other party thereto, and is enforceable against Korro or its Subsidiaries and each other party thereto in accordance with its terms. Neither Korro, its Subsidiaries, nor, to the Knowledge of Korro, any other party to any Korro Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(b)</span> of the Korro Disclosure Schedule has been or is, or has been or is alleged to be, in material default under, or has provided or received any notice of, breach under, or intention to terminate (including by <span style="white-space:nowrap">non-renewal),</span> any Korro Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(b)</span> of the Korro Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except for instances that would not reasonably be expected to have, individually or in the aggregate, a Korro Material Adverse Effect, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(c)</span> of the Korro Disclosure Schedule accurately identifies each Korro Contract pursuant to which any Person has been granted any license under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Korro IP Rights (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Korro IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Korro&#8217;s or its Subsidiaries&#8217; benefit). Each Korro Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(c)</span> of the Korro Disclosure Schedule is in full force and effect and constitutes a legal, valid, and binding obligation of Korro or its Subsidiaries and each other party thereto, and is enforceable against Korro or its Subsidiaries and each other party thereto in accordance with its terms. Neither Korro or its Subsidiaries nor, to the Knowledge of Korro, any other party to any Korro Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(c)</span> of the Korro Disclosure Schedule has been or is, or has been or is alleged to be, in material default under, or has provided or received any notice of, breach under, or intention to terminate (including by <span style="white-space:nowrap">non-renewal),</span> any Korro Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(c)</span> of the Korro Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as identified on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(d)</span> of the Korro Disclosure Schedule, neither Korro nor any of its Subsidiaries is bound by, and no Korro IP Rights are subject to, any Contract containing any covenant or other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provision that in any way limits or restricts the ability of Korro or any of its Subsidiaries to use, exploit, assert, or enforce any Korro IP Rights anywhere in the world. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Korro or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Korro IP Rights (other than (i)&#160;Korro IP Rights licensed to Korro, or <span style="white-space:nowrap">co-owned</span> rights each as identified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(b)</span> of the Korro Disclosure Schedule, (ii)&#160;any <span style="white-space:nowrap">non-customized</span> software that (A)&#160;is licensed to Korro or its Subsidiaries solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B)&#160;is not incorporated into, or material to the development, manufacturing, or distribution of, any of Korro&#8217;s or its Subsidiaries&#8217; products or services and (iii)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To the Knowledge of Korro, all documents and instruments necessary to register or apply for or renew registration of Korro Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority. To the Knowledge of Korro, Korro has filed all statements of use and paid all renewal and maintenance fees, annuities and other fees with respect to the Korro Registered IP that are due or payable as of the date of this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Except for instances that would not reasonably be expected to have, individually or in the aggregate, a Korro Material Adverse Effect, each Person who is or was an employee, contractor or consultant of Korro or any of its Subsidiaries and who is or was involved in the creation, discovery, reduction to practice or development of any Intellectual Property for Korro or any of its Subsidiaries has signed a valid, enforceable written agreement containing a present assignment of all right, title and interest in and to such Intellectual Property to Korro or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Korro and its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To the Knowledge of Korro, no current or former member, officer, director, or employee of Korro or any of its Subsidiaries has any claim, right (whether or not currently exercisable), or interest to or in any Korro IP Rights purported to be owned by Korro. To the Knowledge of Korro, no employee of Korro or any of its Subsidiaries is (A)&#160;bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Korro or such Subsidiary or (B)&#160;in breach of any Contract with any former employer or other Person concerning Korro IP Rights purported to be owned by Korro or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Korro IP Rights purported to be owned by Korro or such Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) No funding, facilities, or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Korro IP Rights in which Korro or any of its Subsidiaries has an ownership interest, and no educational institution has any right to, or right to royalties for, or to impose any requirement on the manufacture or commercialization of any product incorporating, any Korro IP Rights. No Governmental Authority has any right to (including any <span style="white-space:nowrap">&#8220;step-in&#8221;</span> or <span style="white-space:nowrap">&#8220;march-in&#8221;</span> rights with respect to), ownership of, commercialization of, or right to royalties or other payments for any Korro IP Rights. Without limiting the generality of the foregoing, no invention claimed or covered by any Patent within the Korro IP Rights (A)&#160;was conceived or reduced to practice in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, (B)&#160;is a &#8220;subject invention&#8221; as that term is described in 35 U.S.C. Section&#160;201(e), or (C)&#160;is otherwise subject to the provisions of the Bayh-Dole Act or any similar Law of any other jurisdiction, including with respect to any Patents that are part of the Korro IP Rights. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Korro and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect, maintain and enforce its rights in all proprietary information that Korro or such Subsidiary holds, or purports to hold, as confidential or a trade secret. To the Knowledge of Korro, neither Korro nor any of its Subsidiaries has made any of its trade secrets or other material confidential or proprietary information that it intended to maintain as confidential information available to any other Person </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
except pursuant to written agreements requiring such Person to maintain the confidentiality of such trade secrets or confidential information. To the Knowledge of Korro, there have been no material security breaches, outages, violations or unauthorized access to any of the proprietary information that Korro or any of its Subsidiaries holds, or purports to hold, as confidential or a trade secret. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Neither Korro nor any of its Subsidiaries has assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Korro IP Rights to any other Person. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) To the Knowledge of Korro, neither Korro nor any of its Subsidiaries has taken or failed to take any action that could be reasonably expected to result in the abandonment, invalidity, cancellation, forfeiture, relinquishing, invalidation or unenforceability of any Korro IP Rights (including with respect to any trademark, a failure to exercise adequate quality controls or an assignment in gross without the accompanying goodwill). Each item of Korro IP Rights has been duly maintained and is not expired, abandoned or cancelled. To the Knowledge of Korro, each of the Patents included in the Korro IP Rights identifies each and every inventor of the claims thereof as determined in accordance with the applicable laws of the jurisdiction in which such Patent is issued or pending. To the Knowledge of Korro, neither Korro nor any of its Subsidiaries has engaged in patent or copyright misuse or any fraud or inequitable conduct in connection with any Korro IP Right. To the Knowledge of Korro, each of Korro and its Subsidiaries and their respective patent counsel have complied with its duty of candor and disclosure and have made no material misrepresentations in the filings submitted to the applicable Governmental Authorities with respect to all Patents included in the Korro IP Rights for which Korro or any of its Subsidiaries is responsible for prosecuting. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) To the Knowledge of Korro, the Korro IP Rights constitute all Intellectual Property necessary for Korro to conduct its business as currently conducted or proposed to be conducted; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that the foregoing representation is not a representation with respect to noninfringement of Intellectual Property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Korro has delivered, or made available to Frequency, a complete and accurate copy of all Korro IP Rights Agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) To the Knowledge of Korro, the manufacture, marketing, sale, offering for sale, importation, use or intended use or other disposal of any product as currently sold or under development by Korro does not violate any license or agreement between Korro or its Subsidiaries and any other third party in any material respect, and, to the Knowledge of Korro, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Korro Material Adverse Effect. To the Knowledge of Korro, no third party is infringing upon any Patents owned by Korro within the Korro IP Rights, or otherwise violating any Korro IP Rights Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) As of the date of this Agreement, neither Korro nor any of its Subsidiaries is a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Korro IP Rights. None of the Korro IP Rights have been adjudged invalid or unenforceable in whole or part, and all Korro IP Rights are in full force and effect. No Korro IP Rights have been subject to any interference, derivation, reexamination (including ex parte reexamination, inter partes reexamination, inter partes review, or post grant review), reissue, cancellation, opposition, claim, allegation or other action, including any proceeding in which the scope, validity, inventorship, ownership or enforceability of any Korro IP Rights is being, has been, or could reasonably be expected to be, contested or challenged. Neither Korro nor any of its Subsidiaries has received any written notice asserting that any Korro IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods, or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Korro or any of its Subsidiaries has otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To the Knowledge of Korro, no trademark (whether registered or unregistered) or trade name owned, used, or applied for by Korro conflicts or interferes with any trademark (whether registered or unregistered) or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trade name owned, used, or applied for by any other Person except as would not have a Korro Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Korro or its Subsidiaries has or purports to have an ownership interest has been impaired as determined by Korro in accordance with GAAP. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(i)</span> of the Korro Disclosure Schedule sets forth all material unregistered trademarks included in the Korro IP Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Except (i)&#160;as would reasonably not be expected to have a Korro Material Adverse Effect, (ii)&#160;as may be set forth in <span style="text-decoration:underline">Sections 3.12(a)</span> or <span style="text-decoration:underline">3.12(b)</span> of the Korro Disclosure Schedule or (iii)&#160;as contained in license, distribution or service agreements entered into in the Ordinary Course of Business by Korro: (A)&#160;neither Korro nor any of its Subsidiaries is bound by any Contract to indemnify, defend, hold harmless, or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to Korro or any of its Subsidiaries, taken as a whole and (B)&#160;neither Korro nor any of its Subsidiaries has ever assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Neither Korro nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will (i)&#160;cause the grant, assignment, or transfer to any other third party of any license or other right to or in any Korro IP Rights, (ii)&#160;result in breach of, default under, termination of, or acceleration or modification of such Contract with respect to any Korro IP Rights, (iii)&#160;alter, encumber, impair or extinguish, or result in any Encumbrance with respect to, the right of Korro or the Surviving Corporation and its Subsidiaries to use, sell or license or enforce any Korro IP Rights or portion thereof, or (iv)&#160;result in Korro or any of its Subsidiaries being bound by or subject to any exclusivity obligations, <span style="white-space:nowrap">non-compete</span> or other restrictions on the operation or scope of their respective businesses, or to any obligation to grant any rights in or to any Korro IP Rights, except, in each of (i), (ii), (iii) and (iv), for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Korro Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_28">3.13 <span style="text-decoration:underline">Agreements, Contracts and Commitments</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">3.13(a)</span> of the Korro Disclosure Schedule lists the following Korro Contracts in effect as of the date of this Agreement (each, a &#8220;<span style="font-weight:bold">Korro</span> <span style="font-weight:bold">Material Contract</span>&#8221; and collectively, the &#8220;<span style="font-weight:bold">Korro</span> <span style="font-weight:bold">Material Contracts</span>&#8221;): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) each Korro Contract that is a collective bargaining agreement or other agreement or arrangement with any labor union, works council or labor organization; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) each Korro Contract for the employment or engagement of any individual on an employee, consulting or other basis that provides for annual base compensation in excess of $350,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) each Korro Contract with any Korro Associate that provides for retention, change in control, transaction or other similar payments or benefits, whether or not payable as a result of the Contemplated Transactions; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) each Korro Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) each Korro Contract containing (A)&#160;any covenant limiting the freedom of Korro or any of its Subsidiaries or the Surviving Corporation to engage in any line of business or compete with any Person, or limiting the development, manufacture, or distribution of Korro&#8217;s products or services, (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision or (D)&#160;any <span style="white-space:nowrap">non-solicitation</span> provision; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) each Korro Contract (A)&#160;pursuant to which any Person granted Korro an exclusive license under any Intellectual Property, or (B)&#160;pursuant to which Korro granted any Person an exclusive license under any Korro IP Rights; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) each Korro Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) each Korro Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) each Korro Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Korro or any loans or debt obligations with officers or directors of Korro; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) each Korro Contract requiring payment by or to Korro after the date of this Agreement in excess of $500,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any preclinical or clinical development activities of Korro, (C)&#160;any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Korro or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Korro or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Korro or such Subsidiary or (D)&#160;any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Korro or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Korro or any of its Subsidiaries, in each case, except for Korro Contracts entered into in the Ordinary Course of Business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) each Korro Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Korro in connection with the Contemplated Transactions; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) each Korro Contract to which Korro or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, Korro or such Subsidiary in excess of $100,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) a Korro Real Estate Lease; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) a Contract disclosed in or required to be disclosed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(a)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(b)</span> of the Korro Disclosure Schedule; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) any other Korro Contract that is not terminable at will (with no penalty or payment) by Korro or any of its Subsidiaries, and (A)&#160;which involves payment or receipt by Korro or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $250,000 in the aggregate, or obligations after the date of this Agreement in excess of $250,000 in the aggregate or (B)&#160;that is material to the business or operations of Korro and its Subsidiaries taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Korro has delivered or made available to Frequency accurate and complete copies of all Korro Material Contracts, including all amendments thereto. There are no Korro Material Contracts that are not in written form. Korro has not, nor to the Knowledge of Korro, as of the date of this Agreement, has any other party to a Korro Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Korro Material Contract in such manner as would permit any other party to cancel or terminate any such Korro Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Korro Material Adverse Effect. As to Korro and its Subsidiaries, as of the date of this Agreement, each Korro Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Korro Material Contract to change, any material amount paid or payable to Korro under any Korro Material Contract or any other material term or provision of any Korro Material Contract. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_29">3.14 <span style="text-decoration:underline">Compliance; Permits; Restrictions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Korro and each of its Subsidiaries is, and since January&#160;1, 2020 has been, in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order, or other action by any Governmental Authority is pending or, to the Knowledge of Korro, threatened against Korro or any of its Subsidiaries. There is no agreement or Order binding upon Korro or any of its Subsidiaries which (i)&#160;has or could reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Korro or any of its Subsidiaries, any acquisition of material property by Korro or any of its Subsidiaries or the conduct of business by Korro or any of its Subsidiaries as currently conducted, (ii)&#160;is reasonably likely to have an adverse effect on Korro&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii)&#160;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of Korro and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Korro as currently conducted (collectively, the &#8220;<span style="font-weight:bold">Korro</span> <span style="font-weight:bold">Permits</span>&#8221;).<span style="font-weight:bold"> </span><span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.14(b)</span> of the Korro Disclosure Schedule identifies each Korro Permit. Each of Korro and its Subsidiaries is in material compliance with the terms of Korro Permits. No Legal Proceeding is pending or, to the Knowledge of Korro, threatened, which seeks to revoke, substantially limit, suspend, or materially modify any Korro Permit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There are no Legal Proceedings pending or, to the Knowledge of Korro, threatened with respect to an alleged material violation by Korro or any of its Subsidiaries of the Federal Food, Drug, and Cosmetic Act <span style="font-weight:bold">(</span>&#8220;<span style="font-weight:bold">FDCA</span>&#8221;)<span style="font-weight:bold">, </span>the Public Health Service Act <span style="font-weight:bold">(</span>&#8220;<span style="font-weight:bold">PHSA</span>&#8221;),<span style="font-weight:bold"> </span>Food and Drug Administration <span style="font-weight:bold">(</span>&#8220;<span style="font-weight:bold">FDA</span>&#8221;)<span style="font-weight:bold"> </span>regulations adopted thereunder, the Controlled Substances Act or any other Law promulgated by the FDA or other Governmental Authority responsible for regulation of the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug products <span style="font-weight:bold">(</span>&#8220;<span style="font-weight:bold">Drug Regulatory Agency</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each of Korro and its Subsidiaries holds all required material Governmental Authorizations issuable by any Drug Regulatory Agency necessary for the conduct of the business of Korro as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its products or product candidates (the &#8220;<span style="font-weight:bold">Korro</span> <span style="font-weight:bold">Product Candidates</span>&#8221;)<span style="font-weight:bold"> </span>(collectively, the &#8220;<span style="font-weight:bold">Korro</span> <span style="font-weight:bold">Regulatory Permits</span>&#8221;)<span style="font-weight:bold"> </span>and no such Korro Regulatory Permit has been (i)&#160;revoked, withdrawn, suspended, cancelled or terminated or (ii)&#160;modified in any material, adverse manner. Korro has timely maintained and is in compliance in all material respects with the Korro Regulatory Permits and neither Korro nor any of its Subsidiaries has, since January&#160;1, 2020, received any written notice or other written communication from any Drug Regulatory Agency regarding (A)&#160;any material violation of or failure to comply materially with any term or requirement of any Korro Regulatory Permit or (B)&#160;any revocation, withdrawal, suspension, cancellation, termination or material modification of any Korro Regulatory Permit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All clinical trials, preclinical studies and other studies and tests conducted by or on behalf of, or sponsored by, Korro and its Subsidiaries or in which Korro Product Candidates have participated, were and, if still pending, are being conducted in compliance in all material respects with the applicable regulations of the Drug Regulatory Agencies and other applicable Law, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58 and 312. Neither Korro nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug Regulatory Agency requiring, or, to the Knowledge of Korro, any action to place a clinical hold order on, or otherwise terminate, delay, or suspend any clinical studies conducted by or on behalf of, or sponsored by, Korro or any of its Subsidiaries or in which Korro Product Candidates have participated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither Korro nor any of its Subsidiaries, and, to the Knowledge of Korro, any contract manufacturer with respect to any Korro Product Candidate, is the subject of any pending or, to the Knowledge of Korro, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto, or any other applicable Law. To the Knowledge of Korro, neither Korro nor any of its Subsidiaries nor any contract manufacturer with respect to any Korro Product Candidate has committed any acts, made any statement, or failed to make any statement, in each case in respect of Korro&#8217;s business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto, or any other applicable Law. None of Korro, any of its Subsidiaries, and to the Knowledge of Korro, any contract manufacturer with respect to any Korro Product Candidate, or any of their respective officers, employees or agents has been convicted of any crime or engaged in any conduct that could result in a debarment or exclusion under (i) 21 U.S.C. Section&#160;335a, (ii)&#160;42 U.S.C. &#167; <span style="white-space:nowrap">1320a-7,</span> or (iii)&#160;any other applicable Law. To the Knowledge of Korro, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Korro, any of its Subsidiaries, and to the Knowledge of Korro, any contract manufacturer with respect to any Korro Product Candidate, or any of its respective officers, employees or agents. Neither Korro nor any of its Subsidiaries is a party to or has any reporting obligations under any corporate integrity agreements, monitoring agreements, deferred or <span style="white-space:nowrap">non-prosecution</span> agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) All manufacturing operations conducted by, or to the Knowledge of Korro, for the benefit of, Korro or its Subsidiaries in connection with any Korro Product Candidate, since January&#160;1, 2020, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211, <span style="white-space:nowrap">600-680,</span> and 1271, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) No laboratory or manufacturing site owned by Korro or its Subsidiaries, and to the Knowledge of Korro, no manufacturing site of a contract manufacturer or laboratory, with respect to any Korro Product Candidate, (i)&#160;is subject to a Drug Regulatory Agency shutdown or import or export prohibition or (ii)&#160;has since January&#160;1, 2020 received any unresolved Form FDA 483, notice of violation, warning letter, untitled letter, or similar correspondence or notice from the FDA or other Governmental Authority alleging or asserting material noncompliance with any applicable Law, and, to the Knowledge of Korro, neither the FDA nor any other Governmental Authority is considering such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_30">3.15 <span style="text-decoration:underline">Legal Proceedings; Orders</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) There is no pending Legal Proceeding and, to the Knowledge of Korro, no Person has threatened in writing to commence any Legal Proceeding: (i)&#160;that involves Korro or any of its Subsidiaries or any Korro Associate (in his or her capacity as such) or any of the material assets owned or used by Korro or any of its Subsidiaries or (ii)&#160;that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) There is no Order to which Korro or any of its Subsidiaries, or any of the material assets owned or used by Korro or any of its Subsidiaries, is subject. To the Knowledge of Korro, no officer or other Key Employee of Korro or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of Korro or any of its Subsidiaries or to any material assets owned or used by Korro or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_31">3.16 <span style="text-decoration:underline">Tax Matters</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of Korro and each of its Subsidiaries has timely filed all income Tax Returns and all other material Tax Returns that were required to be filed by or with respect to it under applicable Law. All such Tax Returns were correct and complete in all material respects and have been prepared in material compliance with all </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Law. Subject to exceptions as would not be material, no claim has ever been made by a Governmental Authority in a jurisdiction where Korro or any of its Subsidiaries does not file a particular type of Tax Return that Korro or any of its Subsidiaries is subject to taxation by that jurisdiction that would be the subject of such a Tax Return. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All material amounts of Taxes due and owing by Korro and each of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid. The unpaid Taxes of Korro and each of its Subsidiaries for periods (or portions thereof) ending on or prior to the date of the Korro Balance Sheet do not materially exceed the accruals for current Taxes set forth on the Korro Balance Sheet. Since the date of the Korro Balance Sheet, neither Korro nor any of its Subsidiaries has incurred any material Liability for Taxes outside the Ordinary Course of Business or otherwise inconsistent with past custom and practice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each of Korro and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) There are no Encumbrances for material Taxes (other Encumbrances described in clause (i)&#160;of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of Korro or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No deficiencies for a material amount of Taxes with respect to Korro or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any Liability in respect of Taxes of Korro or any of its Subsidiaries. Neither Korro nor any of its Subsidiaries has waived any statute of limitations in respect of material Taxes or agreed to any extension of time with respect to a material Tax assessment or deficiency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither Korro nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than customary indemnification provisions in commercial Contracts entered into in the Ordinary Course of Business with vendors, customers, lenders, or landlords (an &#8220;<span style="font-weight:bold">Ordinary Course Agreement</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Neither Korro nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Korro). Neither Korro nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Korro) under Treasury Regulations <span style="white-space:nowrap">Section&#160;1.1502-6</span> (or any similar provision of state, local, or foreign law), as a transferee or successor, by Contract (other than an Ordinary Course Agreement) or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Neither Korro nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Neither Korro nor any of its Subsidiaries has entered into any transaction identified as a &#8220;reportable transaction&#8221; for purposes of Treasury Regulations Sections <span style="white-space:nowrap">1.6011-4(b)(2)</span> or <span style="white-space:nowrap">301.6111-2(b)(2).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Neither Korro nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i)&#160;change in, or use of improper, method of accounting for a taxable period ending on or prior to the Closing Date; (ii)&#160;&#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or foreign income Tax law) executed on or prior to the Closing Date; (iii)&#160;installment sale or open transaction disposition made on or prior to the Closing Date; (iv)&#160;prepaid amount, advance payments or deferred revenue received or accrued on or prior to the Closing Date other than in respect of such amounts reflected in the Korro Balance Sheet or received in the Ordinary Course of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business since the date of the Korro Balance Sheet; or (v)&#160;intercompany transaction or excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">3.16(k)</span> of the Korro Disclosure Schedule sets forth the entity classification of Korro and each of its Subsidiaries for U.S. federal income tax purposes. Neither Korro nor any of its Subsidiaries has made an election or taken any other action to change its federal and state income tax classification from such classification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Neither Korro nor any of its Subsidiaries has taken or knowingly failed to take any action, nor to the Knowledge of Korro, are there any facts or circumstances, in each case, that would reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax Treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_32">3.17 <span style="text-decoration:underline">Employee and Labor Matters; Benefit Plans</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither Korro nor any of its Subsidiaries is a party to, bound by the terms of, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union, works council or labor organization representing any Korro Associate, and there are no labor unions, works council or labor organizations representing or, to the Knowledge of Korro, purporting to represent or seeking to represent any Korro Associates, including through the filing of a petition for representation election. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">3.17(b)</span> of the Korro Disclosure Schedule lists all material Korro Employee Plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As applicable with respect to each material Korro Employee Plan, Korro has made available to Frequency, true and complete copies of (i)&#160;the plan document, including all amendments thereto, and in the case of an unwritten Employee Plan, a written description of all material terms thereof, (ii)&#160;all related trust instruments or other funding-related documents and insurance contracts, (iii)&#160;the summary plan description and each summary of material modifications thereto, (iv)&#160;the financial statements for the most recent year for which such financial statements are available (in audited form, if available or required by ERISA) and, where applicable, annual reports with any Governmental Authority (<span style="font-style:italic">e.g.</span>,<span style="font-style:italic"> </span>Form 5500 and all schedules thereto), (v) the most recent IRS determination or opinion letter, (vi)&#160;written results of any required compliance testing for the three most recent plan years, and (vii)&#160;all material, <span style="white-space:nowrap">non-routine</span> notices, filings or correspondence during the past three years with any Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each Korro Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination letter or may rely on a favorable opinion letter with respect to such qualified status from the IRS to the effect that such plan is qualified under Section&#160;401(a) of the Code and the related trust is exempt from federal income Taxes under Section&#160;501(a) of the Code. To the Knowledge of Korro, nothing has occurred that would reasonably be expected to cause the loss of the qualified status of any such Korro Employee Plan or the Tax exempt status of any related trust. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each Korro Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms and all applicable Laws, including, without limitation, the Code and ERISA. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Korro, threatened with respect to any Korro Employee Plan. All material payments and/or contributions required to have been made with respect to all Korro Employee Plans have been made in accordance with the terms of the applicable Korro Employee Plan and applicable Law in all material respects and neither the Korro nor any Korro ERISA Affiliate has any material liability for any such unpaid contributions with respect to any Korro Employee Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither Korro, any of its Subsidiaries nor any of their ERISA Affiliates maintains, contributes to or is required to contribute to, or has any Liability with respect to (i)&#160;any &#8220;employee benefit plan&#8221; (within the meaning </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Section&#160;3(2) of ERISA) that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii)&#160;a Multiemployer Plan, (iii)&#160;any Multiple Employer Plan, or (iv)&#160;any Multiple Employer Welfare Arrangement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) No Korro Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (i)&#160;pursuant to COBRA or an analogous state law requirement (the full cost of which is borne by such Person or such Person&#8217;s dependents or beneficiaries) or (ii)&#160;continuation coverage through the end of the month in which such termination or retirement occurs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) No Korro Employee Plan is subject to any law of a foreign jurisdiction outside of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each Korro Employee Plan that constitutes in any part a nonqualified deferred compensation plan within the meaning of Section&#160;409A of the Code has been operated and maintained in all material respects in operational and documentary compliance with Section&#160;409A of the Code and applicable guidance thereunder. No payment to be made under any Korro Employee Plan is, or to the Knowledge of Korro, will be, subject to the penalties of Section&#160;409A(a)(1) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Korro and its Subsidiaries are, and since January&#160;1, 2020 have been, in material compliance in all material respects with all applicable Laws respecting labor, employment and employment practices, including terms and conditions of employment, worker classification, tax withholding, prohibited discrimination, harassment, equal employment, fair employment practices, meal and rest periods, immigration status, employee safety and health, wages (including overtime wages), compensation, and hours of work. There are no Legal Proceedings pending or, to the Knowledge of Korro, threatened or reasonably anticipated against Korro or any of its Subsidiaries relating to any Korro Associate. Korro is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state, or local agency or Governmental Authority with respect to employment practices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Korro has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Korro or any of its Subsidiaries has been under any requirement or obligation to issue any such notification), or incurred any Liability or obligation under the WARN Act that remains unsatisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) There has never been, nor to the Knowledge of Korro has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, affecting Korro or its Subsidiaries. No event has occurred within the past six months, and no condition or circumstance exists, that would reasonably be expected to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) There is no contract, agreement, plan or arrangement to which Korro or any of its Subsidiaries is a party or by which it is bound to make any payment or compensate any Korro Associate for Taxes incurred pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Neither the execution and delivery of this Agreement, the shareholder approval of this Agreement, nor the consummation of the Contemplated Transactions (either alone or in conjunction with any other event, including without limitation, a termination of employment) will result in any (i)&#160;payment (including severance, forgiveness of indebtedness or otherwise) or benefit becoming due to Korro Associate, (ii)&#160;increase in any benefits or the compensation payable under any Korro Employee Plan, (iii)&#160;acceleration of the time of payment, funding or vesting of any such compensation or benefits or any loan forgiveness, (iv)&#160;restriction on the right of Korro or any of its Subsidiaries or, after the consummation of Contemplated Transactions, the Surviving Corporation, to merge, amend, terminate or transfer any Korro Employee Plan, or (v)&#160;&#8220;excess parachute payment&#8221; (within the meaning of Section&#160;280G of the Code). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_33">3.18 <span style="text-decoration:underline">Environmental Matters</span>. Since January&#160;1, 2020, Korro and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Korro of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Korro Material Adverse Effect. Neither Korro nor any of its Subsidiaries has received since January&#160;1, 2020, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Korro or any of its Subsidiaries is not in compliance with any Environmental law, and, to the Knowledge of Korro, there are no circumstances that may prevent or interfere with Korro&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Korro Material Adverse Effect. To the Knowledge of Korro: (a)&#160;no current or prior owner of any property leased or controlled by Korro or any of its Subsidiaries has received since January&#160;1, 2020, any written notice or other communication relating to property owned or leased at any time by Korro or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Korro or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (b)&#160;neither Korro nor any of its Subsidiaries has any material liability under any Environmental Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_34">3.19 <span style="text-decoration:underline">Insurance</span>. Korro has made available to Frequency accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Korro and its Subsidiaries. Each of such insurance policies is in full force and effect and Korro and its Subsidiaries are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January&#160;1, 2020, neither Korro nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (a)&#160;cancellation or invalidation of any insurance policy or (b)&#160;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Korro and its Subsidiaries has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Korro or such Subsidiary for which Korro or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Korro of its intent to do so. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_35">3.20 <span style="text-decoration:underline">No Financial Advisors</span>. Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.20</span> of the Korro Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Korro. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_36">3.21 <span style="text-decoration:underline">Transactions with Affiliates</span>. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.21</span> of the Korro Disclosure Schedule describes any material transactions or relationships, since January&#160;1, 2020, between, on one hand, Korro and, on the other hand, any (a)&#160;executive officer or director of Korro or any of such executive officer&#8217;s or director&#8217;s immediate family members, (b)&#160;owner of more than five percent of the voting power of the outstanding shares of Korro Common Stock or (c)&#160;to the Knowledge of Korro, any &#8220;related person&#8221; (within the meaning of Item 404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Act) of any such officer, director or owner (other than Korro) in the case of each of (a), (b) or (c)&#160;that is of the type that would be required to be disclosed under Item 404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_37">3.22 <span style="text-decoration:underline">Privacy and Data Security</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Korro and its Subsidiaries have complied with all applicable Privacy Laws and the applicable terms of any Korro Contracts relating to privacy, security, collection or use of Personal Information of any individuals (including clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists) that interact with Korro or any of its Subsidiaries in connection with the operation of Korro&#8217;s and its Subsidiaries&#8217; business, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Korro Material Adverse Effect. To the Knowledge of Korro, Korro has implemented and maintains reasonable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written policies and procedures, satisfying the requirements of applicable Privacy Laws, concerning the privacy, security, collection and use of Personal Information (the &#8220;<span style="font-weight:bold">Privacy Policies</span>&#8221;) and has complied with the same, except for such noncompliance as has not to the Knowledge of Korro had, and would not reasonably be expected to have, individually or in the aggregate, a Korro Material Adverse Effect. To the Knowledge of Korro, as of the date hereof, no claims have been asserted or threatened against Korro by any Person alleging a violation of Privacy Laws, Privacy Policies and/or the applicable terms of any Korro Contracts relating to privacy, security, collection or use of Personal Information of any individuals. To the Knowledge of Korro, there have been no data security incidents, personal data breaches or other adverse events or incidents related to Personal Information or Korro data in the custody or control of Korro or any service provider acting on behalf of Korro, in each case where such incident, breach or event would result in a notification obligation to any Person under applicable law or pursuant to the terms of any Korro Contract. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The information technology assets and equipment of Korro and its Subsidiaries (collectively, &#8220;<span style="font-weight:bold">Korro IT Systems</span>&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of Korro and its Subsidiaries as currently conducted, and to the Knowledge of Korro, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. Korro and its Subsidiaries have implemented and maintain commercially reasonable physical, technical and administrative safeguards to protect Personal Information processed by or on behalf of Korro and its Subsidiaries, any other material confidential information and the integrity and security of Korro IT Systems used in connection with their businesses, and during the past three years, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or Liability or the duty to notify any other Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_38">3.23 <span style="text-decoration:underline">Concurrent Financing</span>.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Korro has delivered to Frequency true, correct and complete copies of all definitive agreements related to the Concurrent Financing, including the Subscription Agreement, pursuant to which the Purchasers (as defined in the Subscription Agreement) party thereto (collectively, the &#8220;<span style="font-weight:bold">Purchasers</span>&#8221;) have agreed, subject to the terms and conditions set forth therein, to purchase the number of shares of Korro Common Stock set forth therein in connection with the transactions contemplated by this Agreement. The Subscription Agreement has not been amended or modified prior to the date of this Agreement and as of the date hereof, no such amendment or modification is contemplated (other than amendments or modifications that are permitted by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.27</span>), and as of the date hereof, the respective obligations and commitments contained in the Subscription Agreement have not been withdrawn or rescinded in any respect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As of the date hereof, the Subscription Agreement is in full force and effect and is the legal, valid, binding and enforceable obligation of Korro, and, to the Knowledge of Korro, each of the Purchasers. There are no conditions precedent or other contingencies related to the funding of the full amount of the Concurrent Financing, other than as expressly set forth in the Subscription Agreement. As of the date hereof, no event has occurred which, with or without notice, lapse of time or both, would reasonably be expected to constitute a default or breach on the part of Korro or, to the Knowledge of Korro, any Purchaser under the Subscription Agreement. As of the date hereof, Korro has no reason to believe that any of the conditions to the Concurrent Financing as contemplated by the Subscription Agreement will not be satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_39">3.24 <span style="text-decoration:underline">No Other Representations or Warranties</span>. Korro hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Frequency nor any other person on behalf of Frequency makes any express or implied representation or warranty with respect to Frequency or with respect to any other information provided to Korro, any of its stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Frequency set forth in <span style="text-decoration:underline">Article IV</span> (in each case as qualified and limited by the Frequency Disclosure Schedule)) none of Korro, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_40">ARTICLE IV </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">REPRESENTATIONS AND WARRANTIES OF FREQUENCY AND MERGER SUB </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except (i)&#160;as set forth in the written disclosure schedule delivered by Frequency to Korro (the &#8220;<span style="font-weight:bold">Frequency Disclosure Schedule</span>&#8221;)<span style="font-weight:bold"> </span>or (ii)&#160;a<span style="font-weight:bold">s </span>disclosed in the Frequency SEC<span style="font-weight:bold"> </span>Documents filed with the SEC on or before the day that is one (1)&#160;Business Day prior to the date hereof and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (A)&#160;without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B)&#160;excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood that any matter disclosed in the Frequency SEC Documents shall not be deemed disclosed for purposes of <span style="text-decoration:underline">Sections</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.1(a)</span>, <span style="text-decoration:underline">4.1(b)</span> or <span style="text-decoration:underline">4.3</span>, Frequency and Merger Sub represent and warrant to Korro as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_41">4.1 <span style="text-decoration:underline">Due Organization; Subsidiaries</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of Frequency and its Subsidiaries (including Merger Sub) is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i)&#160;to conduct its business in the manner in which its business is currently being conducted, (ii)&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii)&#160;to perform its obligations under all Contracts by which it is bound. Since the date of its formation, Merger Sub has not engaged in any activities other than in connection with or as contemplated by this Agreement. All of Frequency&#8217;s Subsidiaries are wholly owned by Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of Frequency and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Frequency Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.1(c)</span> of the Frequency Disclosure Schedule, Frequency has no Subsidiaries other than Merger Sub and Frequency does not directly or indirectly own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or indirectly, any other Entity other than Merger Sub. Frequency is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Frequency has not agreed and is not obligated to make, nor is Frequency bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Frequency has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_42">4.2 <span style="text-decoration:underline">Organizational Documents</span>. Frequency has delivered to Korro accurate and complete copies of the Organizational Documents of Frequency and Merger Sub. Neither Frequency nor Merger Sub is in breach or violation of its Organizational Documents in any material respect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_43">4.3 <span style="text-decoration:underline">Authority; Binding Nature of Agreement</span>. Each of Frequency and Merger Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Frequency Board (at meetings duly called and held) has: (a)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Frequency and its stockholders, (b)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Frequency Capital Stock to the stockholders of Korro pursuant to the terms of this Agreement, (c)&#160;determined to recommend the Frequency Board Recommendation to the stockholders of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Frequency, and (d) determined to approve and recommend the forms of the Charter Amendment Proposals to the stockholders of Frequency as promptly as practicable after the forms thereof are mutually agreed to by Frequency and Korro. The Merger Sub Board (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder, (y)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions. This Agreement has been duly executed and delivered by Frequency and Merger Sub and, assuming the due authorization, execution and delivery by Korro, constitutes the legal, valid and binding obligation of Frequency and Merger Sub, enforceable against each of Frequency and Merger Sub in accordance with its terms, subject to the Enforceability Exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_44">4.4 <span style="text-decoration:underline">Vote Required</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The affirmative vote of a majority of the votes cast at the Frequency Stockholder Meeting (at which quorum is present) is the only vote of the holders of any class or series of Frequency Capital Stock necessary to approve this Agreement and the Contemplated Transactions, including the issuance of the shares of Frequency Common Stock to the stockholders of Korro in the Merger pursuant to the terms of this Agreement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) If the Frequency Stockholder Meeting occurs after the Delaware Law Amendment Approval is obtained, the only vote of the holders of any class or series of Frequency Capital Stock necessary to approve an amendment to Frequency&#8217;s certificate of incorporation to effect the Charter Amendment Proposals is a vote at the Frequency Stockholder Meeting (at which quorum is present) in which the number of votes cast in favor of the Charter Amendment Proposals exceeds the number of votes cast against the Charter Amendment Proposals; or (ii)&#160;if the Delaware Law Amendment Approval is not obtained, the affirmative vote in favor of the Charter Amendment Proposals of a majority of the outstanding shares of Frequency Common Stock entitled to vote thereon is the only vote of the holders of any class or series of Frequency Capital Stock necessary to approve an amendment to Frequency&#8217;s certificate of incorporation to affect the Charter Amendment Proposals (together with clause (a), the &#8220;<span style="font-weight:bold">Required Frequency Stockholder Vote</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_45">4.5 <span style="text-decoration:underline"><span style="white-space:nowrap">Non-Contravention;</span> Consents</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to obtaining the Required Frequency Stockholder Vote and the filing of the Certificate of Merger required by Delaware Law, neither (x)&#160;the execution, delivery or performance of this Agreement by Frequency or Merger Sub, nor (y)&#160;the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Frequency or its Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Frequency or its Subsidiaries, or any of the assets owned or used by Frequency or its Subsidiaries, is subject; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Frequency or its Subsidiaries or that otherwise relates to the business of Frequency, or any of the assets owned, leased or used by Frequency; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Frequency Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Frequency Material Contract, (B)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any such Frequency Material Contract, (C)&#160;accelerate the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
maturity or performance of any Frequency Material Contract or (D)&#160;cancel, terminate or modify any term of any Frequency Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Frequency or its Subsidiaries (except for Permitted Encumbrances). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except for (i)&#160;any Consent set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.5</span> of the Frequency Disclosure Schedule under any Frequency Contract, (ii)&#160;the Required Frequency Stockholder Vote, (iii)&#160;the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to Delaware Law and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, neither Frequency nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&#160;the execution, delivery or performance of this Agreement or (y)&#160;the consummation of the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Frequency Board and the Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of Delaware Law are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_46">4.6 <span style="text-decoration:underline">Capitalization</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Frequency consists of (i) 200,000,000 shares of common stock, par value $0.001 per share (&#8220;<span style="font-weight:bold">Frequency Common Stock</span>&#8221;), of which 36,926,285 shares have been issued and are outstanding as of July&#160;12, 2023 and (ii)&#160;10,000,000 shares of preferred stock, par value $0.001 per share (&#8220;<span style="font-weight:bold">Frequency Preferred Stock</span>&#8221;), of which no shares have been issued and are outstanding as of July&#160;12, 2023. Frequency does not hold any shares of its capital stock in its treasury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding shares of Frequency Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than under applicable securities Laws. None of the outstanding shares of Frequency Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Frequency Common Stock is subject to any right of first refusal in favor of Frequency. Except as contemplated herein, there is no Frequency Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Frequency Common Stock. Frequency is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Frequency Common Stock or other securities. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6(b)</span> of the Frequency Disclosure Schedule accurately and completely lists all repurchase rights held by Frequency with respect to shares of Frequency Common Stock (including shares issued pursuant to the exercise of options) and specifies which of those repurchase rights are currently exercisable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">4.6(c)</span> of the Frequency Disclosure Schedule sets forth a true and complete list, as of July&#160;12, 2023, of each outstanding Frequency Option and Frequency Restricted Stock Unit award, including: (i)&#160;the name (or employee identification number) of the holder, (ii)&#160;the number of shares of Frequency Common Stock subject to such Frequency Option and/or Frequency Restricted Stock Units, (iii)&#160;the exercise price of each Frequency Option, (iv)&#160;the date of grant, (v)&#160;the applicable vesting schedule, including any acceleration provisions and the number of vested and unvested shares (and, if applicable, assuming achievement of the applicable performance metrics), (vi) the expiration date, as applicable, and (vii)&#160;whether the Frequency Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a <span style="white-space:nowrap">non-qualified</span> stock option. Frequency has made available to Korro accurate and complete copies of the following (except for such documents that are filed as an exhibit to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a Frequency SEC Document): (A) the standard form of agreement evidencing Frequency Options and Frequency Restricted Stock Unit awards; and (B)&#160;each agreement evidencing a Frequency Option or Frequency Restricted Stock Unit award that does not conform in all material respects to the standard form agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6(c)</span> of the Frequency Disclosure Schedule, there is no: (i)&#160;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Frequency, (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Frequency, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Frequency is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv)&#160;condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All outstanding shares of Frequency Common Stock and other securities of Frequency have been issued and granted in material compliance with (i)&#160;all applicable securities laws and other applicable Law and (ii)&#160;all requirements set forth in applicable Contracts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_47">4.7 <span style="text-decoration:underline">SEC Filings; Financial Statements</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Frequency has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act since January&#160;1, 2020 (the &#8220;<span style="font-weight:bold">Frequency SEC </span><span style="font-weight:bold">Documents</span>&#8221;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Frequency SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the Frequency SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i)&#160;Rule <span style="white-space:nowrap">13a-14</span> under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section 906 of the Sarbanes-Oxley Act) relating to the Frequency SEC Documents (collectively, the &#8220;<span style="font-weight:bold">Frequency Certifications</span>&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.7</span>, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The financial statements (including any related notes) contained or incorporated by reference in the Frequency SEC Documents: (i)&#160;complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations of the SEC applicable thereto, (ii)&#160;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form <span style="white-space:nowrap">10-Q</span> of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring <span style="white-space:nowrap">year-end</span> adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii)&#160;fairly present, in all material respects, the financial position of Frequency as of the respective dates thereof and the results of operations and cash flows of Frequency for the periods covered thereby. Other than as expressly disclosed in the Frequency SEC Documents filed prior to the date hereof, there has been no material change in Frequency&#8217;s accounting methods or principles that would be required to be disclosed in Frequency&#8217;s financial statements in accordance with GAAP. The books of account and other financial records of Frequency and each of its Subsidiaries are true and complete in all material respects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Frequency&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i)&#160;a registered public accounting firm (as defined in Section&#160;2(a)(12) of the <span style="white-space:nowrap">Sarbanes-Oxley</span> Act), (ii) to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Knowledge of Frequency, &#8220;independent&#8221; with respect to Frequency within the meaning of Regulation <span style="white-space:nowrap">S-X</span> under the Exchange Act and (iii)&#160;to the Knowledge of Frequency, in compliance with subsections (g)&#160;through (l) of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.7(d)</span> of the Frequency Disclosure Schedule, Frequency has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of Frequency Common Stock on Nasdaq. Frequency has not disclosed any unresolved comments in the Frequency SEC Documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, or general counsel of Frequency, the Frequency Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.7(f)</span> of the Frequency Disclosure Schedule, Frequency is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules and regulations of Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Frequency maintains a system of internal control over financial reporting (as defined in Rules <span style="white-space:nowrap">13a-15(f)</span> and <span style="white-space:nowrap">15d-l5(f)</span> of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&#160;that Frequency maintains records that in reasonable detail accurately and fairly reflect Frequency&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)&#160;that receipts and expenditures are made only in accordance with authorizations of management and the Frequency Board and (iv)&#160;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Frequency&#8217;s assets that could have a material effect on Frequency&#8217;s financial statements. Frequency has evaluated the effectiveness of Frequency&#8217;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Frequency SEC Document that is a report on Form <span style="white-space:nowrap">10-K</span> or Form <span style="white-space:nowrap">10-Q</span> (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Frequency has disclosed to Frequency&#8217;s auditors and the Audit Committee of the Frequency Board (and made available to Frequency a summary of the significant aspects of such disclosure)&#160;(A) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Frequency&#8217;s ability to record, process, summarize and report financial information and (B)&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in Frequency or its Subsidiaries&#8217; internal control over financial reporting. Except as disclosed in the Frequency SEC Documents filed prior to the date hereof, Frequency&#8217;s internal control over financial reporting is effective and Frequency has not identified any material weaknesses in the design or operation of Frequency&#8217;s internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Frequency&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules <span style="white-space:nowrap">13a-15(e)</span> and <span style="white-space:nowrap">15d-15(e)</span> of the Exchange Act) are designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Frequency in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Frequency&#8217;s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Frequency Certifications and such disclosure controls and procedures are effective. Frequency has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by Rule <span style="white-space:nowrap">13a-l5</span> of the Exchange Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Frequency has not been and is not currently a &#8220;shell company&#8221; as defined under <span style="white-space:nowrap">Section&#160;12b-2</span> of the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_48">4.8 <span style="text-decoration:underline">Absence of Changes</span>. Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.8</span> of the Frequency Disclosure Schedule, since January&#160;1, 2023, Frequency and its Subsidiaries have conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a)&#160;Frequency Material Adverse Effect or (b)&#160;action, event or occurrence that would have required consent of Frequency pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_49">4.9 <span style="text-decoration:underline">Absence of Undisclosed Liabilities</span>. Neither Frequency nor any of its Subsidiaries has any Liability of a type required to be reflected or reserved for on a balance sheet prepared in accordance with GAAP, except for: (a)&#160;Liabilities disclosed, reflected or reserved against in the Frequency Balance Sheet, (b)&#160;normal and recurring current Liabilities that have been incurred by Frequency or its Subsidiaries since the date of the Frequency Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement, or violation of Law), (c) Liabilities for performance of obligations of Frequency or any of its Subsidiaries under Frequency Contracts, (d)&#160;Liabilities incurred in connection with the Contemplated Transactions and the Subscription Agreement and (e)&#160;Liabilities listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.9</span> of the Frequency Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_50">4.10 <span style="text-decoration:underline">Title to Assets</span>. Each of Frequency and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&#160;all tangible assets reflected on the Frequency Balance Sheet and (b)&#160;all other tangible assets reflected in the books and records of Frequency as being owned by Frequency. All of such assets are owned or, in the case of leased assets, leased by Frequency or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_51">4.11 <span style="text-decoration:underline">Real Property; Leasehold</span>. Neither Frequency nor any of its Subsidiaries owns or has ever owned any real property. Frequency has made available to Korro (a)&#160;an accurate and complete list of all real properties with respect to which Frequency directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Frequency or any of its Subsidiaries and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;<span style="font-weight:bold">Frequency Real Estate Leases</span>&#8221;), each of which is in full force and effect, with no existing material default thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_52">4.12 <span style="text-decoration:underline">Intellectual Property</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">4.12(a)</span> of the Frequency Disclosure Schedule is an accurate, true and complete listing of all Frequency Registered IP including for each item (i)&#160;the record owner (and name of any other Person with an ownership interest in such item of Frequency Registered IP, if any), jurisdiction (or, with respect to domain names, the applicable registrar), status, date and registration or application number of each item, as applicable, (ii)&#160;the name of the record owner and any other Person that has an ownership interest in such item of Frequency Registered IP, and the nature of such ownership interest, and (iii)&#160;to the Knowledge of Frequency, any actions that are required to be taken within 180 days of the Closing Date, including the payment of any registration, maintenance or renewal fees or the filing of or response to any documents, applications or certificates, for the purposes of prosecuting, obtaining, perfecting, maintaining or renewing any Frequency Registered IP. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(a)</span> of the Frequency Disclosure Schedule also sets forth, as of the date of this Agreement, a list of all internet domain names with respect to which Frequency or any of its Subsidiaries are the registrant and, with respect to each domain name, the record owner of such domain name and if different, the legal and beneficial owner(s) of such domain name and the applicable domain name registrar. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">4.12(b)</span> of the Frequency Disclosure Schedule accurately identifies (i)&#160;all Frequency Contracts pursuant to which any Frequency IP Rights are licensed to Frequency (other than (A)&#160;any <span style="white-space:nowrap">non-customized</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
software that (1)&#160;is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing, or distribution of, any of Frequency&#8217;s or any of its Subsidiaries&#8217; products or services, (B)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials, (C)&#160;any confidential information provided under confidentiality agreements and (D)&#160;agreements between Frequency or its Subsidiaries and their respective employees in Frequency&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to Frequency are exclusive or nonexclusive. Each Frequency Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(b) </span>of the Frequency Disclosure Schedule is in full force and effect and constitutes a legal, valid, and binding obligation of Frequency, its Subsidiaries and each other party thereto, and is enforceable against Frequency, its Subsidiaries and each other party thereto in accordance with its terms. Neither Frequency, its Subsidiaries, nor, to the Knowledge of Frequency, any other party to any Frequency Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(b)</span> of the Frequency Disclosure Schedule has been or is, or has been or is alleged to be, in material default under, or has provided or received any notice of, breach under, or intention to terminate (including by <span style="white-space:nowrap">non-renewal),</span> any Frequency Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(b)</span> of the Frequency Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except for instances that would not reasonably be expected to have, individually or in the aggregate, a Frequency Material Adverse Effect, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(c)</span> of the Frequency Disclosure Schedule accurately identifies each Frequency Contract pursuant to which any Person has been granted any license under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Frequency IP Rights (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Frequency IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Frequency&#8217;s or its Subsidiaries&#8217; benefit). Each Frequency Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(c)</span> of the Frequency Disclosure Schedule is in full force and effect and constitutes a legal, valid, and binding obligation of Frequency, its Subsidiaries and each other party thereto, and is enforceable against Frequency, its Subsidiaries and each other party thereto in accordance with its terms. Neither Frequency, its Subsidiaries nor, to the Knowledge of Frequency, any other party to any Frequency Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(c)</span> of the Frequency Disclosure Schedule has been or is, or has been or is alleged to be, in material default under, or has provided or received any notice of, breach under, or intention to terminate (including by <span style="white-space:nowrap">non-renewal),</span> any Frequency Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(c)</span> of the Frequency Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as identified on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(d)</span> of the Frequency Disclosure Schedule, neither Frequency nor any of its Subsidiaries is bound by, and no Frequency IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of Frequency or any of its Subsidiaries to use, exploit, assert, or enforce any Frequency IP Rights anywhere in the world. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Frequency or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Frequency IP Rights (other than (i)&#160;Frequency IP Rights licensed to Frequency, or <span style="white-space:nowrap">co-owned</span> rights each as identified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(c)</span> of the Frequency Disclosure Schedule, (ii)&#160;Frequency IP Rights that Frequency intends to abandon as identified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(a)</span> of the Frequency Disclosure Schedule, (iii)&#160;any <span style="white-space:nowrap">non-customized</span> software that (A)&#160;is licensed to Frequency or its Subsidiaries solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B)&#160;is not incorporated into, or material to the development, manufacturing, or distribution of, any of Frequency or its Subsidiaries&#8217; products or services and (iv)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To the Knowledge of Frequency, all documents and instruments necessary to register or apply for or renew registration of Frequency Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority. To the Knowledge of Frequency, Frequency has filed all statements of use and paid all renewal and maintenance fees, annuities and other fees with respect to the Frequency Registered IP that are due or payable as of the date of this Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Except for instances that would not reasonably be expected to have, individually or in the aggregate, a Frequency Material Adverse Effect, each Person who is or was an employee, contractor or consultant of Frequency or any of its Subsidiaries and who is or was involved in the creation, discovery, reduction to practice or development of any Intellectual Property for Frequency or any of its Subsidiaries has signed a valid, enforceable written agreement containing a present assignment of all right, title and interest in and to such Intellectual Property to Frequency or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Frequency and its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To the Knowledge of Frequency, no current or former member, officer, director, or employee of Frequency or any of its Subsidiaries has any claim, right (whether or not currently exercisable), or interest to or in any Frequency IP Rights purported to be owned by Frequency. To the Knowledge of Frequency, no employee of Frequency or any of its Subsidiaries is (A)&#160;bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Frequency or such Subsidiary or (B)&#160;in breach of any Contract with any former employer or other Person concerning Frequency IP Rights purported to be owned by Frequency or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Frequency IP Rights purported to be owned by Frequency or such Subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) No funding, facilities, or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Frequency IP Rights in which Frequency or any of its Subsidiaries has an ownership interest, and no educational institution has any right to, or right to royalties for, or to impose any requirement on the manufacture or commercialization of any product incorporating, any Frequency IP Rights. No Governmental Authority has any right to (including any <span style="white-space:nowrap">&#8220;step-in&#8221;</span> or <span style="white-space:nowrap">&#8220;march-in&#8221;</span> rights with respect to), ownership of, commercialization of, or right to royalties or other payments for any Frequency IP Rights. Without limiting the generality of the foregoing, no invention claimed or covered by any Patent within the Frequency IP Rights (A)&#160;was conceived or reduced to practice in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, (B)&#160;is a &#8220;subject invention&#8221; as that term is described in 35 U.S.C. Section&#160;201(e), or (C)&#160;is otherwise subject to the provisions of the Bayh-Dole Act or any similar Law of any other jurisdiction, including with respect to any Patents that are part of the Frequency IP Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Frequency and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect, maintain and enforce its rights in all proprietary information that Frequency or such Subsidiary holds, or purports to hold, as confidential or a trade secret. To the Knowledge of Frequency, neither Frequency nor any of its Subsidiaries has made any of its trade secrets or other material confidential or proprietary information that it intended to maintain as confidential information available to any other Person except pursuant to written agreements requiring such Person to maintain the confidentiality of such trade secrets or confidential information. To the Knowledge of Frequency, there have been no material security breaches, outages, violations or unauthorized access to any of the proprietary information that Frequency or any of its Subsidiaries holds, or purports to hold, as confidential or a trade secret. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Neither Frequency nor any of its Subsidiaries has assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Frequency IP Rights to any other Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) To the Knowledge of Frequency, neither Frequency nor any of its Subsidiaries has taken or failed to take any action that could be reasonably expected to result in the abandonment, invalidity, cancellation, forfeiture, relinquishing, invalidation or unenforceability of any Frequency IP Rights (including with respect to any trademark, a failure to exercise adequate quality controls or an assignment in gross without the accompanying goodwill). Each item of Frequency IP Right has been duly maintained and is not expired, abandoned or cancelled. To the Knowledge of Frequency, each of the Patents included in the Frequency IP Rights identifies each and every inventor of the claims thereof as determined in accordance with the applicable laws of the jurisdiction in which such Patent is issued or pending. To the Knowledge of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Frequency, neither Frequency nor any of its Subsidiaries has engaged in patent or copyright misuse or any fraud or inequitable conduct in connection with any Frequency IP Right. To the Knowledge of Frequency, each of Frequency and its Subsidiaries and their respective patent counsel have complied with its duty of candor and disclosure and have made no material misrepresentations in the filings submitted to the applicable Governmental Authorities with respect to all Patents included in the Frequency IP Rights for which Frequency or any of its Subsidiaries is responsible for prosecuting. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) To the Knowledge of Frequency, the Frequency IP Rights constitute all Intellectual Property necessary for Frequency to conduct its business as currently conducted or proposed to be conducted; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that the foregoing representation is not a representation with respect to <span style="white-space:nowrap">non-infringement</span> of Intellectual Property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Frequency has delivered, or made available to Korro, a complete and accurate copy of all material Frequency IP Rights Agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) To the Knowledge of Frequency, the manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Frequency does not violate any license or agreement between Frequency or its Subsidiaries and any third party in any material respect, and, to the Knowledge of Frequency, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Frequency Material Adverse Effect. To the Knowledge of Frequency, no third party is infringing upon any Patents owned by Frequency within the Frequency IP Rights, or otherwise violating any Frequency IP Rights Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) As of the date of this Agreement, neither Frequency nor any of its Subsidiaries is a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Frequency IP Rights. To the Knowledge of Frequency, none of the Frequency IP Rights have been adjudged invalid or unenforceable in whole or part, and all Frequency IP Rights are in full force and effect. None of the Frequency IP Rights have been subject to any interference, derivation, reexamination (including ex parte reexamination, inter partes reexamination, inter partes review, or post grant review), reissue, cancellation, opposition, claim, allegation or other action, including any proceeding in which the scope, validity, inventorship, ownership or enforceability of any Frequency IP Rights is being, has been, or could reasonably be expected to be, contested or challenged. Neither Frequency nor any of its Subsidiaries received any written notice asserting that any Frequency IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods, or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Frequency or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To the Knowledge of Frequency, no trademark (whether registered or unregistered) or trade name owned, used, or applied for by Frequency conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used, or applied for by any other Person except as would not have a Frequency Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Frequency or its Subsidiaries has or purports to have an ownership interest has been impaired as determined by Frequency in accordance with GAAP. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(i)</span> of the Frequency Disclosure Schedule sets forth all material unregistered trademarks included in the Frequency IP Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Except (i)&#160;as would reasonably be expected to have a Frequency Material Adverse Effect, (ii)&#160;as may be set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(b)</span> or <span style="text-decoration:underline">4.12(c)</span><span style="font-weight:bold"> </span>of the Frequency Disclosure Schedule or as contained in license, distribution or service agreements entered into in the Ordinary Course of Business by Frequency (A)&#160;neither Frequency nor any of its Subsidiaries is bound by any Contract to indemnify, defend, hold harmless, or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is material to Frequency or any of its Subsidiaries, taken as a whole and (B)&#160;neither Frequency nor any of its Subsidiaries has ever assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Neither Frequency nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will (i)&#160;cause the grant, assignment or transfer to any other third party of any license or other right to or in any Frequency IP Rights, (ii)&#160;result in breach of, default under termination of, or acceleration or modification of such Contract with respect to any Frequency IP Rights, (iii)&#160;alter, encumber, impair or extinguish, or result in any Encumbrance with respect to, the right of Frequency or the Surviving Corporation and its Subsidiaries to use, sell or license or enforce any Frequency IP Rights or portion thereof or (iv)&#160;result in Frequency or any of its Subsidiaries being bound by or subject to any exclusivity obligations, <span style="white-space:nowrap">non-compete</span> or other restrictions on the operation or scope of their respective businesses, or to any obligation to grant any rights in or to any Frequency IP Rights, except, in each of (i), (ii), (iii) and (iv), for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Frequency Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_53">4.13 <span style="text-decoration:underline">Agreements</span><span style="text-decoration:underline">, Contracts and Commitments</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">4.13</span> of the Frequency Disclosure Schedule lists the following Frequency Contracts in effect as of the date of this Agreement other than the Subscription Agreement (each, a &#8220;<span style="font-weight:bold">Frequency Material Contract</span>&#8221;<span style="font-weight:bold"> </span>and collectively, the &#8220;<span style="font-weight:bold">Frequency Material Contracts</span>&#8221;): </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) each Frequency Contract that is a collective bargaining agreement or other agreement or arrangement with any labor union, works council or labor organization; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) each Frequency Contract for the employment or engagement of any individual on an employee, consulting or other basis that provides for annual base compensation in excess of $350,000; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) each Frequency Contract with any Frequency Associate that provides for retention, change in control, transaction or other similar payments or benefits, whether or not payable as a result of the Contemplated Transactions; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) each Frequency Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) each Frequency Contract containing (A)&#160;any covenant limiting the freedom of Frequency or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development, manufacture, or distribution of Frequency&#8217;s products or services, (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision or (D)&#160;any <span style="white-space:nowrap">non-solicitation</span> provision; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) each Frequency Contract (A)&#160;pursuant to which any Person granted Frequency an exclusive license under any Intellectual Property, or (B)&#160;pursuant to which Frequency granted any Person an exclusive license under any Frequency IP Rights; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) each Frequency Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) each Frequency Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) each Frequency Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Frequency or any loans or debt obligations with officers or directors of Frequency; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) each Frequency Contract requiring payment by or to Frequency after the date of this Agreement in excess of $500,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any preclinical or clinical development activities of Frequency, (C)&#160;any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Frequency or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Frequency or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Frequency or such Subsidiary or (D)&#160;any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Frequency or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Frequency or any of its Subsidiaries, in each case, except for Frequency Contracts entered into in the Ordinary Course of Business; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) each Frequency Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Frequency in connection with the Contemplated Transactions; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) each Frequency Contract to which Frequency or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, Frequency or such Subsidiary in excess of $100,000; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) a Frequency Real Estate Lease; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) a Contract disclosed in or required to be disclosed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(b)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.12(c)</span> of the Frequency Disclosure Schedule; or </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) any other Frequency Contract that is not terminable at will (with no penalty or payment) by Frequency or any of its Subsidiaries, and (A)&#160;which involves payment or receipt by Frequency or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $250,000 in the aggregate, or obligations after the date of this Agreement in excess of $250,000 in the aggregate or (B)&#160;that is material to the business or operations of Frequency and its Subsidiaries taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Frequency has delivered or made available to Korro accurate and complete copies of all Frequency Material Contracts, including all amendments thereto. There are no Frequency Material Contracts that are not in written form. Frequency has not, nor, to Frequency&#8217;s Knowledge as of the date of this Agreement, has any other party to a Frequency Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Frequency Material Contract in such manner as would permit any other party to cancel or terminate any such Frequency Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Frequency Material Adverse Effect. As to Frequency and its Subsidiaries, as of the date of this Agreement, each Frequency Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Frequency Material Contract to change, any material amount paid or payable to Frequency under any Frequency Material Contract or any other material term or provision of any Frequency Material Contract. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_54">4.14 <span style="text-decoration:underline">Compliance; Permits; Restrictions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Frequency and each of its Subsidiaries is, and since January&#160;1, 2020, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order, or other action by any Governmental Authority is pending or, to the Knowledge of Frequency, threatened against Frequency or any of its Subsidiaries. There is no agreement or Order binding upon Frequency or any of its Subsidiaries which (i)&#160;has or could reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Frequency or any of its Subsidiaries, any acquisition of material property by Frequency or any of its Subsidiaries or the conduct of business by Frequency or any of its Subsidiaries as currently conducted, (ii)&#160;is reasonably likely to have an adverse effect on Frequency&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii)&#160;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of Frequency and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Frequency and Merger Sub as currently conducted (collectively, the &#8220;<span style="font-weight:bold">Frequency Permits</span>&#8221;).<span style="font-weight:bold"> </span><span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.14(b)</span> of the Frequency Disclosure Schedule identifies each Frequency Permit. Each of Frequency and its Subsidiaries is in material compliance with the terms of the Frequency Permits. No Legal Proceeding is pending or, to the Knowledge of Frequency, threatened, which seeks to revoke, substantially limit, suspend, or materially modify any Frequency Permit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There are no Legal Proceedings pending or, to the Knowledge of Frequency, threatened with respect to an alleged material violation by Frequency or any of its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other Law promulgated by a Drug Regulatory Agency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each of Frequency and its Subsidiaries holds all required material Governmental Authorizations issuable by any Drug Regulatory Agency necessary for the conduct of the business of Frequency and Merger Sub as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its product candidates (the &#8220;<span style="font-weight:bold">Frequency Product Candidates</span>&#8221;)<span style="font-weight:bold"> </span>(collectively, the &#8220;<span style="font-weight:bold">Frequency Regulatory Permits</span>&#8221;)<span style="font-weight:bold"> </span>and no such Frequency Regulatory Permit has been (i)&#160;revoked, withdrawn, suspended, cancelled or terminated or (ii)&#160;modified in any material, adverse manner. Frequency has timely maintained and is in compliance in all material respects with the Frequency Regulatory Permits and neither Frequency nor any of its Subsidiaries has, since January&#160;1, 2020, received any written notice or other written communication from any Drug Regulatory Agency regarding (A)&#160;any material violation of or failure to comply materially with any term or requirement of any Frequency Regulatory Permit or (B)&#160;any revocation, withdrawal, suspension, cancellation, termination or material modification of any Frequency Regulatory Permit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All clinical trials, preclinical studies and other studies and tests conducted by or on behalf of, or sponsored by, Frequency or its Subsidiaries, in which the Frequency Product Candidates have participated, were and, if still pending, are being conducted in compliance in all material respects with the applicable regulations of the Drug Regulatory Agencies and other applicable Law, including, without limitation, 21&#160;C.F.R. Parts 50, 54, 56, 58 and 312. Other than as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.14(e)</span> of the Frequency Disclosure Schedule, neither Frequency nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug Regulatory Agency requiring, or, to the Knowledge of Frequency, any action to place a clinical hold order on, or otherwise terminate, delay, or suspend any clinical studies conducted by or on behalf of, or sponsored by, Frequency or any of its Subsidiaries or in which the Frequency Product Candidates have participated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither Frequency nor any of its Subsidiaries has, and, to the Knowledge of Frequency, any contract manufacturer with respect to any Frequency Product Candidate, is the subject of any pending or, to the Knowledge of Frequency, threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto, or any other applicable Law. To the Knowledge </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Frequency, neither Frequency nor any of its Subsidiaries nor any contract manufacturer with respect to any Frequency Product Candidate has committed any acts, made any statement, or failed to make any statement, in each case in respect of Frequency&#8217;s business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto, or any other applicable Law. None of Frequency, any of its Subsidiaries, and to the Knowledge of Frequency, any contract manufacturer with respect to any Frequency Product Candidate, or any of their respective officers, employees or agents has been convicted of any crime or engaged in any conduct that could result in a material debarment or exclusion under (i) 21 U.S.C. Section&#160;335a (ii) 42 U.S.C. &#167; <span style="white-space:nowrap">1320a-7,</span> or (iii)&#160;any other applicable Law. To the Knowledge of Frequency, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Frequency, any of its Subsidiaries, and to the Knowledge of the Frequency, any contract manufacturer with respect to any Frequency Product Candidate, or any of its officers, employees or agents. Neither Frequency nor any of its Subsidiaries is a party to or has any reporting obligations under any corporate integrity agreements, monitoring agreements, deferred or <span style="white-space:nowrap">non-prosecution</span> agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) All manufacturing operations conducted by, or to the Knowledge of Frequency, for the benefit of, Frequency or its Subsidiaries in connection with any Frequency Product Candidate, since January&#160;1, 2020, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) No laboratory or manufacturing site owned by Frequency or its Subsidiaries, and to the Knowledge of Frequency, no manufacturing site of a contract manufacturer or laboratory, with respect to any Frequency Product Candidate, (i)&#160;is subject to a Drug Regulatory Agency shutdown or import or export prohibition or (ii)&#160;has since January&#160;1, 2020, received any unresolved Form FDA 483, notice of violation, warning letter, untitled letter, or similar correspondence or notice from the FDA or other Governmental Authority alleging or asserting material noncompliance with any applicable Law, and, to the Knowledge of Frequency, neither the FDA nor any other Governmental Authority is considering such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_55">4.15 <span style="text-decoration:underline">Legal Proceedings; Orders</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.15</span> of the Frequency Disclosure Schedule, there is no pending Legal Proceeding and, to the Knowledge of Frequency, no Person has threatened in writing to commence any Legal Proceeding: (i)&#160;that involves Frequency or any of its Subsidiaries or any Frequency Associate (in his or her capacity as such) or any of the material assets owned or used by Frequency or any of its Subsidiaries or (ii)&#160;that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) There is no Order to which Frequency or any of its Subsidiaries, or any of the material assets owned or used by Frequency or any of its Subsidiaries is subject. To the Knowledge of Frequency, no officer or other Key Employee of Frequency or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of Frequency or any of its Subsidiaries or to any material assets owned or used by Frequency or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_56">4.16 <span style="text-decoration:underline">Tax Matters</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of Frequency and each of its Subsidiaries has timely filed all income Tax Returns and all other material Tax Returns that were required to be filed by or with respect to it under applicable Law. All such Tax Returns were correct and complete in all material respects and have been prepared in material compliance with&#160;all applicable Law. Subject to exceptions as would not be material, no claim has ever been made by a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governmental Authority in a jurisdiction where Frequency or any of its Subsidiaries does not file a particular type of Tax Return that Frequency or any of its Subsidiaries is subject to taxation by that jurisdiction that would be the subject of such a Tax Return. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All material amounts of Taxes due and owing by Frequency and each of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid. The unpaid Taxes of Frequency and each of its Subsidiaries for periods (or portions thereof) ending on or prior to the date of the Frequency Balance Sheet do not materially exceed the accruals for current Taxes set forth on the Frequency Balance Sheet. Since the date of the Frequency Balance Sheet, neither Frequency nor any of its Subsidiaries has incurred any material Liability for Taxes outside the Ordinary Course of Business or otherwise inconsistent with past custom and practice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each of Frequency and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) There are no Encumbrances for material Taxes (other Encumbrances described in clause (i)&#160;of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of Frequency or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No deficiencies for a material amount of Taxes with respect to Frequency or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, examinations, assessments or other actions for or relating to any Liability in respect of Taxes of Frequency or any of its Subsidiaries. Neither Frequency nor any of its Subsidiaries has waived any statute of limitations in respect of material Taxes or agreed to any extension of time with respect to a material Tax assessment or deficiency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither Frequency nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Neither Frequency nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Frequency). Neither Frequency nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Frequency and Merger Sub) under Treasury Regulations <span style="white-space:nowrap">Section&#160;1.1502-6</span> (or any similar provision of state, local, or foreign law), as a transferee or successor, by Contract (other than an Ordinary Course Agreement) or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Neither Frequency nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Neither Frequency nor any of its Subsidiaries has entered into any transaction identified as a &#8220;reportable transaction&#8221; for purposes of Treasury Regulations <span style="white-space:nowrap">Sections&#160;1.6011-4(b)(2)</span> or <span style="white-space:nowrap">301.6111-2(b)(2).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Neither Frequency nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i)&#160;change in, or use of improper, method of accounting for a taxable period ending on or prior to the Closing Date; (ii)&#160;&#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or foreign income Tax law) executed on or prior to the Closing Date; (iii)&#160;installment sale or open transaction disposition made on or prior to the Closing Date; (iv)&#160;prepaid amount, advance payments or deferred revenue received or accrued on or prior to the Closing Date other than in respect of such amounts reflected in the Frequency Balance Sheet or received in the Ordinary Course of Business since the date of the Frequency Balance Sheet; or (v)&#160;intercompany transaction or excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">4.16(k)</span> of the Frequency Disclosure Schedule sets forth the entity classification of Frequency and each of its Subsidiaries for U.S. federal income tax purposes. Neither Frequency nor any of its Subsidiaries has made an election or taken any other action to change its federal and state income tax classification from such classification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Neither Frequency nor any of its Subsidiaries has taken or knowingly failed to take any action, nor to the Knowledge of Frequency, are there any facts or circumstances, in each case, that would reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax Treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_57">4.17 <span style="text-decoration:underline">Employee and Labor Matters; Benefit Plans</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither Frequency nor any of its Subsidiaries is a party to, bound by the terms of, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union, works council or labor organization representing any Frequency Associate, and there are no labor unions, works council or labor organizations representing or, to the Knowledge of Frequency, purporting to represent or seeking to represent any Frequency Associates, including through the filing of a petition for representation election. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">4.17</span><span style="text-decoration:underline">(b)</span> of the Frequency Disclosure Schedule lists all material Frequency Employee Plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As applicable with respect to each material Frequency Employee Plan, Frequency has made available to Korro, true and complete copies of (i)&#160;the plan document, including all amendments thereto, and in the case of an unwritten Employee Plan, a written description of all material terms thereof, (ii)&#160;all related trust instruments or other funding-related documents and insurance contracts, (iii)&#160;the summary plan description and each summary of material modifications thereto, (iv)&#160;the financial statements for the most recent year for which such financial statements are available (in audited form, if available or required by ERISA) and, where applicable, annual reports with any Governmental Authority (<span style="font-style:italic">e.g.</span>,<span style="font-style:italic"> </span>Form 5500 and all schedules thereto), (v) the most recent IRS determination or opinion letter, (vi)&#160;written results of any required compliance testing for the three most recent plan years, and (vii)&#160;all material, <span style="white-space:nowrap">non-routine</span> notices, filings or correspondence during the past three years with any Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each Frequency Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination letter or may rely on a favorable opinion letter with respect to such qualified status from the IRS to the effect that such plan is qualified under Section&#160;401(a) of the Code and the related trust is exempt from federal income Taxes under Section&#160;501(a) of the Code. To the Knowledge of Frequency, nothing has occurred that would reasonably be expected to cause the loss of the qualified status of any such Frequency Employee Plan or the Tax exempt status of any related trust. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each Frequency Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms and all applicable Laws, including, without limitation, the Code and ERISA. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Frequency, threatened with respect to any Frequency Employee Plan. All payments and/or contributions required to have been made with respect to all Frequency Employee Plans have been made in accordance with the terms of the applicable Frequency Employee Plan and applicable Law in all material respects and neither the Frequency nor any Frequency ERISA Affiliate has any Liability for any such unpaid contributions with respect to any Frequency Employee Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither Frequency, any of its Subsidiaries nor any of their ERISA Affiliates maintains, contributes to or is required to contribute to, or has any Liability with respect to (i)&#160;any &#8220;employee benefit plan&#8221; (within the meaning of Section&#160;3(2) of ERISA) that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii)&#160;a Multiemployer Plan, (iii)&#160;any Multiple Employer Plan, or (iv)&#160;any Multiple Employer Welfare Arrangement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) No Frequency Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (i)&#160;pursuant to COBRA or an analogous state law requirement (the full cost of which is borne by such Person or such Person&#8217;s dependents or beneficiaries) or (ii)&#160;continuation coverage through the end of the month in which such termination or retirement occurs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) No Frequency Employee Plan is subject to any law of a foreign jurisdiction outside of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each Frequency Employee Plan that constitutes in any part a nonqualified deferred compensation plan within the meaning of Section&#160;409A of the Code has been operated and maintained in all material respects in operational and documentary compliance with Section&#160;409A of the Code and applicable guidance thereunder. No payment to be made under any Frequency Employee Plan is, or to the Knowledge of Frequency, will be, subject to the penalties of Section&#160;409A(a)(1) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Frequency and its Subsidiaries are, and since January&#160;1, 2020 have been, in material compliance in all material respects with all applicable Laws respecting labor, employment and employment practices, including terms and conditions of employment, worker classification, tax withholding, prohibited discrimination, harassment, equal employment, fair employment practices, meal and rest periods, immigration status, employee safety and health, wages (including overtime wages), compensation, and hours of work. There are no Legal Proceedings pending or, to the Knowledge of Frequency, threatened or reasonably anticipated against Frequency or any of its Subsidiaries relating to any Frequency Associate. Frequency is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state, or local agency or Governmental Authority with respect to employment practices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Frequency has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Frequency or any of its Subsidiaries been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) There has never been, nor to the Knowledge of Frequency has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, affecting Frequency or its Subsidiaries. No event has occurred within the past six months, and no condition or circumstance exists, that would reasonably be expected to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) There is no contract, agreement, plan or arrangement to which Frequency or any of its Subsidiaries is a party or by which it is bound to make any payment or compensate any Frequency Associate for Taxes incurred pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Neither the execution and delivery of this Agreement, the shareholder approval of this Agreement, nor the consummation of the Contemplated Transactions (either alone or in conjunction with any other event, including without limitation, a termination of employment) will result in any (i)&#160;payment (including severance, forgiveness of indebtedness or otherwise) or benefit becoming due to Frequency Associate, (ii)&#160;increase in any benefits or the compensation payable under any Frequency Employee Plan, (iii)&#160;acceleration of the time of payment, funding or vesting of any such compensation or benefits or any loan forgiveness, (iv)&#160;restriction on the right of Frequency or any of its Subsidiaries or, after the consummation of Contemplated Transactions, the Surviving Corporation, to merge, amend, terminate or transfer any Frequency Employee Plan, or (v)&#160;&#8220;excess parachute payment&#8221; (within the meaning of Section&#160;280G of the Code). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_58">4.18 <span style="text-decoration:underline">Environmental Matters</span>. Since January&#160;1, 2020, Frequency and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Frequency of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Frequency Material Adverse Effect. Neither Frequency nor any of its Subsidiaries has received since January&#160;1, 2020, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Frequency or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge of Frequency, there are no circumstances that may prevent or interfere with Frequency&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Frequency Material Adverse Effect. To the Knowledge of Frequency: (a)&#160;no current or prior owner of any property leased or controlled by Frequency or any of its Subsidiaries has received since January&#160;1, 2020, any written notice or other communication relating to property owned or leased at any time by Frequency or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Frequency or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (b)&#160;neither Frequency nor any of its Subsidiaries has any material liability under any Environmental Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_59">4.19 <span style="text-decoration:underline">Insurance</span>. Frequency has made available to Korro accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Frequency and its Subsidiaries (including Merger Sub). Each of such insurance policies is in full force and effect and Frequency and its Subsidiaries (including Merger Sub) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January&#160;1, 2020, neither Frequency nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (a)&#160;cancellation or invalidation of any insurance policy or (b)&#160;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Frequency and its Subsidiaries (including Merger Sub) has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Frequency or such Subsidiary for which Frequency or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Frequency or any of its Subsidiaries of its intent to do so. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_60">4.20 <span style="text-decoration:underline">Transactions with Affiliates</span>. Except as set forth in the Frequency SEC Documents filed prior to the date of this Agreement, since the date of Frequency&#8217;s last proxy statement filed in 2022 with the SEC, no event has occurred that would be required to be reported by Frequency pursuant to Item 404 of Regulation <span style="white-space:nowrap">S-K</span> promulgated by the SEC. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.20</span> of the Frequency Disclosure Schedule identifies each Person who is (or who may be deemed to be) an Affiliate of Frequency as of the date of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_61">4.21 <span style="text-decoration:underline">No Financial Advisors</span>. Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.21</span> of the Frequency Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_62">4.22 <span style="text-decoration:underline">Valid Issuance; No Bad Actor</span>. The Frequency Capital Stock to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. To the Knowledge of Frequency, as of the date of this Agreement and as of the Closing, no &#8220;bad actor&#8221; disqualifying event described in Rule 506(d)(l)(i)-(viii) of the Securities Act (a &#8220;<span style="font-weight:bold">Disqualifying Event</span>&#8221;)<span style="font-weight:bold"> </span>is applicable to Frequency or, to Frequency&#8217;s Knowledge, any Frequency Covered Person, except for a Disqualifying Event as to which Rule <span style="white-space:nowrap">506(d)(2)(ii-iv)</span> or (d)(3) of the Securities Act is applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_63">4.23 <span style="text-decoration:underline">Privacy and Data Security</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Frequency and its Subsidiaries have complied with all applicable Privacy Laws and the applicable terms of any Frequency Contracts relating to privacy, security, collection or use of Personal Information of any individuals (including clinical trial participants, patients, patient family members, caregivers or advocates, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
physicians and other health care professionals, clinical trial investigators, researchers, pharmacists) that interact with Frequency or any of its Subsidiaries in connection with the operation of Frequency&#8217;s and its Subsidiaries&#8217; business, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Frequency Material Adverse Effect. To the Knowledge of Frequency, Frequency has implemented and maintains reasonable Privacy Policies and has complied with its Privacy Policies, except for such noncompliance as has not to the Knowledge of the Frequency had, and would not reasonably be expected to have, individually or in the aggregate, a Frequency Material Adverse Effect. To the Knowledge of Frequency, as of the date hereof, no claims have been asserted or threatened against Frequency by any Person alleging a violation of Privacy Laws, Privacy Policies and/or the applicable terms of any Frequency Contracts relating to privacy, security, collection or use of Personal Information of any individuals. To the Knowledge of Frequency, there have been no data security incidents, personal data breaches or other adverse events or incidents related to Personal Information or Frequency data in the custody or control of Frequency or any service provider acting on behalf of Frequency, in each case where such incident, breach or event would result in a notification obligation to any Person under applicable law or pursuant to the terms of any Frequency Contract. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The information technology assets and equipment of Frequency and its Subsidiaries (collectively, &#8220;<span style="font-weight:bold">Frequency IT Systems</span>&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of Frequency and its Subsidiaries as currently conducted, and to the Knowledge of Frequency, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. Frequency and its Subsidiaries have implemented and maintain commercially reasonable physical, technical and administrative safeguards to protect Personal Information processed by or on behalf of Frequency and its Subsidiaries, any other material confidential information and the integrity and security of Frequency IT Systems used in connection with their businesses, and during the past three years, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_64">4.24 <span style="text-decoration:underline">Opinion of Financial Advisor</span>. The&#160;Frequency Board has received an opinion from Cowen and Company, LLC to the effect that, as of the date of such opinion and based upon and subject to the various assumptions made, procedures followed, matters considered and limitation and qualifications on the review undertaken set forth therein, the&#160;Korro Equity Value was fair, from a financial point of view, to Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_65">4.25 <span style="text-decoration:underline">No Other Representations or Warranties</span>. Frequency hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Frequency nor any of its Subsidiaries nor any other person on behalf of Frequency or its Subsidiaries makes any express or implied representation or warranty with respect to Frequency or its Subsidiaries or with respect to any other information provided to Korro, its stockholders or any of its Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Frequency set forth in <span style="text-decoration:underline">Article IV</span> (in each case as qualified and limited by the Frequency Disclosure Schedule)) none of Korro, its Representatives, stockholders or members, has relied on any such information (including the accuracy or completeness thereof). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_66">ARTICLE V </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">COVENANTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_67">5.1 <span style="text-decoration:underline">Conduct of Korro</span><span style="text-decoration:underline">&#8217;</span><span style="text-decoration:underline">s Business</span>. From the date hereof until the earlier of the Effective Time and the termination of this Agreement in accordance with <span style="text-decoration:underline">Article VIII</span> (the &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Pre-Closing</span> Period</span>&#8221;), except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span> of the Korro Disclosure Schedule, as required by applicable Law, as otherwise provided by this Agreement and the Contemplated Transactions or with Frequency&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Korro shall, and shall cause its Subsidiaries to, use their commercially reasonable efforts to conduct its operations in the Ordinary Course of Business and to preserve intact the present business organizations and goodwill of the business and the present relationships of the business with material </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
customers and suppliers. Without limiting the generality of the foregoing, during the <span style="white-space:nowrap">Pre-Closing</span> Period, except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span> of the Korro Disclosure Schedule, as required by applicable Law, as otherwise specifically provided by this Agreement and the Contemplated Transactions or with Frequency&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Korro shall not, and shall cause its Subsidiaries not to: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) sell, lease, license or otherwise dispose of any material assets of Korro, or in either case, any interests therein, except (i)&#160;pursuant to existing Contracts, (ii)&#160;for sales or licensing of products to customers or (iii)&#160;otherwise in the Ordinary Course of Business; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) take any action with respect to any equity interests of Korro or any of its Subsidiaries, including any issuance, sale, transfer, redemption, repurchase, recapitalization, adjustment, split, combination, reclassification, dividend, distribution or any other action in respect thereof;<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) create, incur, assume, guarantee or repay (other than any mandatory repayments) any indebtedness, other than the incurrence of indebtedness in the Ordinary Course of Business; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) issue, deliver, sell, grant, pledge, transfer, subject to any Encumbrance or dispose of any Korro Capital Stock or the securities of any Subsidiary of Korro; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) create or otherwise incur any Encumbrance on any material asset of Korro or any of its Subsidiaries, other than Permitted Encumbrances; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) make any loans, advances or capital contributions to, or investments in, any Person other than Korro, other than in the Ordinary Course of Business in all material respects; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) adversely amend or otherwise adversely modify in any material respect or terminate (excluding any expiration in accordance with its terms) any Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12</span> of the Korro Disclosure Schedule, other than any amendment or modification entered into in the Ordinary Course of Business and containing terms not materially less favorable to Korro than the terms of such Contract in effect as of the date of this Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) enter into any Contract that would be required to be disclosed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12</span> of the Korro Disclosure Schedule if such Contract were in effect as of the date of this Agreement, other than any such Contract entered into in the Ordinary Course of Business; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) except as required by any Korro Employee Plan or as required by applicable Law, (i)&#160;increase any salary, wage or other compensation or benefit to, or enter into or amend any employment, retention, <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control,</span></span> termination or severance agreement with, any Korro Associate provided that such increases do not, individually or in the aggregate, result in any material increase in costs, obligations or liabilities for Korro and its Subsidiaries, (ii)&#160;grant or pay any bonuses to any Korro Associate, (iii)&#160;establish, enter into or adopt any new Korro Employee Plan or any plan, program, policy, agreement or arrangement that would be a Korro Employee Plan if it was in effect on the date hereof or amend or modify, in a manner that would, individually or in the aggregate, materially increase costs, obligations or liabilities for Korro and its Subsidiaries or the Surviving Corporation, any existing Korro Employee Plan or accelerate the vesting of any compensation (including stock options, restricted stock, restricted stock units, phantom units, warrants, other shares of capital stock or rights of any kind to acquire any shares of capital stock or equity-based awards) for the benefit of any Korro Associate, (iv)&#160;take any action to accelerate any payment or benefit, or the funding of any payment or benefit, payable or to be provided to any Korro Associate, (v)&#160;grant any new long-term incentive or equity-based awards, or amend or modify the terms of any such outstanding awards under any Korro Employee Plan or (vi)&#160;hire, terminate (other than for cause), promote or change the employment status or title of any Korro Associate, except that in each case for (i)&#160;through (vi) in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(i)</span>, Korro shall be permitted to take any action as set forth herein in the Ordinary Course of Business; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) adopt, enter into, amend or terminate any collective bargaining agreement or Contract with any labor union, works council or labor organization; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) settle any material Legal Proceeding involving Korro or any of its Subsidiaries or relating to the transactions contemplated by this Agreement, other than in the Ordinary Course of Business in all material respects; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) make or change any material Tax election, change any annual Tax accounting period, enter into any closing agreement with a Governmental Authority with respect to material Taxes or settle any Tax claim with respect to material Taxes, in each case, except if such action would not reasonably be expected to have a material and adverse effect on Korro following the Closing; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) make any material change in any method of financial accounting or financial accounting practice of Korro or any of its Subsidiaries, except for any such change required by reason of a change in GAAP or other applicable financial accounting standards; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) other than in connection with actions contemplated by this Agreement, adopt, approve, consent to or propose any change in the Organizational Documents of Korro or any of its Subsidiaries; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) agree or commit to do any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the generality of the foregoing, nothing set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span> shall restrict Korro&#8217;s right to effectuate the Concurrent Financing. Nothing contained in this Agreement shall give Frequency, directly or indirectly, the right to control or direct the operations of Korro prior to the Effective Time. Prior to the Effective Time, Korro shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_68">5.2 <span style="text-decoration:underline">Conduct of Frequency</span><span style="text-decoration:underline">&#8217;</span><span style="text-decoration:underline">s Business</span>. During the <span style="white-space:nowrap">Pre-Closing</span> Period, except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span> of the Frequency Disclosure Schedule, as required by applicable Law, as otherwise provided by this Agreement and the Contemplated Transactions or with Korro&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Frequency shall, and shall cause its Subsidiaries to, use their commercially reasonable efforts to conduct its operations in the Ordinary Course of Business and to preserve intact the present business organizations and goodwill of the business and the present relationships of the business with material customers and suppliers. Without limiting the generality of the foregoing, during the <span style="white-space:nowrap">Pre-Closing</span> Period, except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span> of the Frequency Disclosure Schedule, as required by applicable Law, as otherwise specifically provided by this Agreement and the Contemplated Transactions or with Korro&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Frequency shall not, and shall cause its Subsidiaries not to: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) sell, lease, license or otherwise dispose of any material assets of Frequency, or in either case, any interests therein, except (i)&#160;pursuant to existing Contracts, (ii)&#160;for sales or licensing of products to customers or (iii)&#160;otherwise in the Ordinary Course of Business; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) take any action with respect to any equity interests of Frequency or any of its Subsidiaries, including any issuance, sale, transfer, redemption, repurchase, recapitalization, adjustment, split, combination, reclassification, dividend, distribution or any other action in respect thereof; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) create, incur, assume, guarantee or repay (other than any mandatory repayments) any indebtedness; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) issue, deliver, sell, grant, pledge, transfer, subject to any Encumbrance or dispose of any Frequency Capital Stock or the securities of any Subsidiary of Frequency; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) create or otherwise incur any Encumbrance on any material asset of Frequency, other than Permitted Encumbrances; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) make any loans, advances or capital contributions to, or investments in, any Person other than Frequency; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) adversely amend or otherwise adversely modify in any material respect or terminate (excluding any expiration in accordance with its terms) any Contract listed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.13</span> of the Frequency Disclosure Schedule, other than any amendment or modification entered into in the Ordinary Course of Business and containing terms, not materially less favorable to Frequency than the terms of such Contract in effect as of the date of this Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) enter into any Contract that would be required to be disclosed in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.13</span> of the Frequency Disclosure Schedule if such Contract were in effect as of the date of this Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) except as required by any Frequency Employee Plan, as required by applicable Law or with respect to the adoption and approval of the 2023 Plans, (i)&#160;increase any salary, wage or other compensation or benefit to, or enter into or amend any employment, retention, <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control,</span></span> termination or severance agreement with, any Frequency Associate, other than annual increases in base compensation in the Ordinary Course of Business with respect to employees whose annual base compensation is less than $135,000 and provided that such increases do not, individually or in the aggregate, result in any material increase in costs, obligations or liabilities for Frequency and its Subsidiaries, (ii)&#160;grant or pay any bonuses to any Frequency Associate, (iii)&#160;establish, enter into or adopt any new Frequency Employee Plan or any plan, program, policy, agreement or arrangement that would be a Frequency Employee Plan if it was in effect on the date hereof or amend or modify, in a manner that would, individually or in the aggregate, materially increase costs, obligations or liabilities for Frequency and its Subsidiaries or the Surviving Corporation, any existing Frequency Employee Plan or accelerate the vesting of any compensation (including stock options, restricted stock, restricted stock units, phantom units, warrants, other shares of capital stock or rights of any kind to acquire any shares of capital stock or equity-based awards) for the benefit of any Frequency Associate, (iv)&#160;take any action to accelerate any payment or benefit, or the funding of any payment or benefit, payable or to be provided to any Frequency Associate, (v)&#160;grant any new long-term incentive or equity-based awards, or amend or modify the terms of any such outstanding awards under any Frequency Employee Plan or (vi)&#160;hire, terminate (other than for cause), promote or change the employment status or title of any Frequency Associate; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) adopt, enter into, amend or terminate any collective bargaining agreement or Contract with any labor union, works council or labor organization; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) settle any material Legal Proceeding involving Frequency or relating to the transactions contemplated by this Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) make or change any material Tax election, change any annual Tax accounting period, enter into any closing agreement with a Governmental Authority with respect to material Taxes or settle any Tax claim with respect to material Taxes, in each case, except if such action would not reasonably be expected to have a material and adverse effect on Frequency following the Closing; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) make any material change in any method of financial accounting or financial accounting practice of Frequency, except for any such change required by reason of a change in GAAP or other applicable financial accounting standards; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) other than in connection with actions contemplated by this Agreement, adopt, approve, consent to or propose any change in the Organizational Documents of Frequency; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) agree or commit to do any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the generality of the foregoing, nothing set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span> shall restrict Frequency&#8217;s right to effectuate the MS Asset Disposition. Nothing contained in this Agreement shall give Korro, directly or indirectly, the right to control or direct the operations of Frequency prior to the Effective Time. Prior to the Effective Time, Frequency shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_69">5.3 <span style="text-decoration:underline">Access</span><span style="text-decoration:underline"> and Investigation</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the <span style="white-space:nowrap">Pre-Closing</span> Period, upon reasonable notice, Frequency, on the one hand, and Korro, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (i)&#160;provide the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries, (ii)&#160;provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request, (iii)&#160;permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem reasonably necessary or appropriate, and (iv)&#160;provide the other Party with copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the Contemplated Transactions. Any investigation conducted by either Frequency or Korro pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.3</span> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything herein to the contrary in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.3</span>, no access or examination contemplated by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.3</span> shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law; provided, that such Party or its Subsidiary (i)&#160;shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (ii)&#160;shall provide to the other Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii)&#160;shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_70">5.4 <span style="text-decoration:underline">No Solicitation</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of Frequency and Korro agrees that, during the <span style="white-space:nowrap">Pre-Closing</span> Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of its Representatives to, directly or indirectly: (i)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any <span style="white-space:nowrap">non-public</span> information regarding such Party to any Person (other than Korro or Frequency) in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii)&#160;engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&#160;approve, endorse or recommend any Acquisition Proposal (subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9</span>), (v) execute or enter into any letter of intent or any Contract </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplating or otherwise relating to any Acquisition Transaction or (vi)&#160;publicly propose to do any of the foregoing; provided, however, that, notwithstanding anything contained in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(a)</span> and subject to compliance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(a)</span>, prior to the approval of this Agreement by Frequency&#8217;s stockholders (i.e., the Required Frequency Stockholder Vote), Frequency may furnish <span style="white-space:nowrap">non-public</span> information regarding Frequency or its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by Frequency which the Frequency Board determines in good faith, after consultation with Frequency&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A)&#160;neither Frequency nor any Representative shall have breached this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(a)</span> in any material respect, (B)&#160;the Frequency Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to result in a breach of the fiduciary duties of the Frequency Board under applicable Law, (C)&#160;at least two Business Days prior to initially furnishing any such <span style="white-space:nowrap">non-public</span> information to, or entering into discussions with, such Person, Frequency gives Korro written notice of the identity of such Person to Korro, and of Frequency&#8217;s intention to furnish <span style="white-space:nowrap">non-public</span> information to, or enter into discussions with, such Person, (D)&#160;Frequency receives from such Person an executed Acceptable Confidentiality Agreement and (E)&#160;at least two Business Days prior to furnishing any such <span style="white-space:nowrap">non-public</span> information to such Person, Frequency furnishes such <span style="white-space:nowrap">non-public</span> information to Korro (to the extent such information has not been previously furnished by Frequency to Korro). Without limiting the generality of the foregoing, Frequency acknowledges and agrees that, in the event any Representative of Frequency takes any action that, if taken by Frequency, would constitute a breach of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(a)</span> by Frequency, the taking of such action by such Representative shall be deemed to constitute a breach of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(a)</span> by Frequency for purposes of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the <span style="white-space:nowrap">Pre-Closing</span> Period, then such Party shall promptly (and in no event later than one Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and provide a copy of the Acquisition Proposal or Acquisition Inquiry, of if the Acquisition Proposal or Acquisition Inquiry is not written, the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto. In addition to the foregoing, each Party shall provide the other Party with at least four Business Days&#8217; written notice of a meeting of its board of directors (or any committee thereof) at which its board of directors (or any committee thereof) is reasonably expected to consider an Acquisition Proposal or Acquisition Inquiry it has received. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any <span style="white-space:nowrap">non-public</span> information provided to such Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_71">5.5 <span style="text-decoration:underline">Notification of Certain Matters</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the <span style="white-space:nowrap">Pre-Closing</span> Period, each of Korro, on the one hand, and Frequency, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (i)&#160;any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions, (ii)&#160;any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party or, to the Knowledge of such Party, any director, officer or Key Employee of such Party, (iii)&#160;such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (iv)&#160;the failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in <span style="text-decoration:underline">Article VI</span> impossible or materially less likely. No such notice shall be deemed to supplement or amend the Korro </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Disclosure Schedule or the Frequency Disclosure Schedule for the purpose of (A)&#160;determining the accuracy of any of the representations and warranties made by Korro or Frequency in this Agreement or (B)&#160;determining whether any condition set forth in <span style="text-decoration:underline">Article VI</span> has been satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) During the <span style="white-space:nowrap">Pre-Closing</span> Period, Frequency shall use reasonable best efforts to consult with Korro during the negotiation process for, and prior to taking any material action with respect to, any amendment to, sublicence or the potential early termination of the Frequency Lease Agreement, and shall consider any input received from Korro in good faith prior to taking any such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any failure by either Party to provide notice pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.5</span> shall not be deemed to be a breach for purposes of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(b)</span> or <span style="text-decoration:underline">6.3(b)</span>, as applicable, unless such failure to provide such notice was knowing and intentional. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_72">5.6 <span style="text-decoration:underline">MS Asset Disposition</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Closing, Frequency shall be entitled, but under no obligation, to sell, transfer, license, assign or otherwise divest any or all of the assets and rights relating to Frequency&#8217;s MS remyelination program (the &#8220;<span style="font-weight:bold">MS Assets</span>&#8221;) in a transaction or series of transactions (the &#8220;<span style="font-weight:bold">MS Asset Disposition</span>&#8221;). Subject to the provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.6(a)</span> and the CVR Agreement, Frequency may, in contemplation of the MS Asset Disposition, (a)&#160;establish one or more Subsidiaries to hold the MS Assets, (b)&#160;transfer to any such Subsidiary any or all of the MS Assets and the liabilities and obligations related thereto and (c)&#160;take such other steps that are reasonably necessary to prepare for the MS Asset Disposition. For clarity, if Frequency transfers the MS Assets to one or more Subsidiaries, the terms of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.6</span> shall apply to such Subsidiaries in addition to Frequency. Each Party further acknowledges that Frequency may not be successful in completing, or may determine not to proceed, with the MS Asset Disposition. Notwithstanding the foregoing, Frequency may not enter into any agreement with respect to the MS Asset Disposition that would result in a material continuing obligation or liability without the prior written consent of Korro (not to be unreasonably withheld, conditioned or delayed), provided, however, that Frequency shall provide Korro with a copy of any agreement with respect to an MS Asset Disposition that would be reasonably likely to result in a material continuing obligation or liability of either Frequency or Korro on or after the Effective Time at least five Business Days prior to entry into such agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that the MS Asset Disposition has not occurred on or prior to the Closing Date, for a period of one year following the Closing Date, Frequency shall use commercially reasonable efforts to sell, transfer, assign, <span style="white-space:nowrap">out-license</span> or otherwise divest the MS Assets with a term of not more than 10 years. For the avoidance of doubt, the net proceeds from such sale, transfer, license, assignment or other divestiture or commercialization of the MS Assets following the Effective Time shall be payable to the holders of CVRs pursuant to the CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_73">5.7 <span style="text-decoration:underline">Registration Statement; Proxy Statement</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable after the date of this Agreement, (i)&#160;Frequency shall, in cooperation with Korro, prepare and file with the SEC a proxy statement relating to the Frequency Stockholder Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;<span style="font-weight:bold">Proxy Statement</span>&#8221;) and (ii)&#160;Frequency, in cooperation with Korro, shall prepare and file with the SEC a registration statement on Form <span style="white-space:nowrap">S-4</span> (the &#8220;<span style="font-weight:bold">Form <span style="white-space:nowrap">S-4</span></span>&#8221;), in which the Proxy Statement shall be included as a part (the Proxy Statement and the Form <span style="white-space:nowrap">S-4,</span> collectively, the &#8220;<span style="font-weight:bold">Registration Statement</span>&#8221;), in connection with the registration under the Securities Act of the shares of Frequency Common Stock to be issued by virtue of the Merger. Each of Frequency and Korro shall use their reasonable best efforts to respond promptly to any comments of the SEC or its staff and to cause the Registration Statement to become effective as promptly as practicable, and shall take all or any action required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Frequency Common Stock pursuant to the Merger. Each of the Parties shall furnish all </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information concerning itself and their Affiliates, as applicable, to the other Parties as the other Parties may reasonably request in connection with such actions and the preparation of the Registration Statement and Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Frequency covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein not misleading. Korro covenants and agrees that the information supplied by or on behalf of Korro and its Subsidiaries to Frequency for inclusion in the Registration Statement (including the Korro Financial Statements) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, Frequency makes no covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by Korro or its Subsidiaries or any of their Representatives for inclusion therein. Korro and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments on the SEC prior to the filing thereof with the SEC; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that the foregoing shall not apply to any amendment to the Registration Statement pertaining to a Frequency Board Adverse Recommendation Change. Each of the Parties shall use commercially reasonable efforts to cause the Registration Statement to comply with the applicable rules and regulations promulgated by the SEC, to respond promptly to any comments of the SEC or its staff and to have the Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each of the Parties shall cause the Proxy Statement to be mailed to Frequency&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If Frequency, Merger Sub or Korro become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to the Frequency stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Korro shall reasonably cooperate with Frequency and provide, and cause its Representatives to provide, Frequency and its Representatives, with all true, correct and complete information regarding Korro and its Subsidiaries that is required by Law to be included in the Registration Statement or reasonably requested by Frequency to be included in the Registration Statement. Without limiting the foregoing, Korro will use commercially reasonable efforts to cause to be delivered to Frequency a letter of Korro&#8217;s independent accounting firm, dated no more than two Business Days before the date on which the Registration Statement becomes effective (and reasonably satisfactory in form and substance to Frequency), that is customary in scope and substance for letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_74">5.8 <span style="text-decoration:underline">Korro Stockholder Written Consent</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two Business Days thereafter, Korro shall prepare, with the cooperation of Frequency, and cause to be mailed to its stockholders an information statement, which shall include a copy of the Proxy Statement (the &#8220;<span style="font-weight:bold">Information Statement</span>&#8221;), and the Korro Stockholder Written Consent, in order to solicit the approval of Korro&#8217;s stockholders, including but not limited to Korro&#8217;s stockholders sufficient for the Required Korro Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of Delaware Law, for purposes of (i)&#160;adopting and approving this Agreement and the Contemplated Transactions, (ii)&#160;acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of Delaware Law, a copy of which will be attached thereto, and that such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder has received and read a copy of Section&#160;262 of Delaware Law and (iii)&#160;acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives an rights to receive payment of the fair value of its capital stock under Delaware Law. Korro shall use its reasonable best efforts to cause Korro&#8217;s stockholders sufficient for the Required Korro Stockholder Vote to execute and deliver to Korro the Korro Stockholder Written Consent promptly following delivery thereof. Promptly following receipt of the duly executed Korro Stockholder Written Consent, Korro shall deliver a copy of the duly executed Korro Stockholder Written Consent to Frequency. Under no circumstances shall Korro assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Promptly following receipt of the Required Korro Stockholder Vote, Korro shall prepare and mail a notice to every stockholder of Korro that did not execute the Korro Stockholder Written Consent. Such notice shall (i)&#160;be a statement to the effect that the Korro Board determined that the Merger is advisable in accordance with Section&#160;251(b) of Delaware Law and in the best interests of the stockholders of Korro and approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (ii)&#160;provide the stockholders of Korro to whom it is sent with notice of the actions taken in the Korro Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e) of Delaware Law and Korro&#8217;s Organizational Documents and (iii)&#160;include a description of the appraisal rights of Korro&#8217;s stockholders available under Delaware Law, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of Korro in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.8(b)</span> shall be subject to Frequency&#8217;s advance review and reasonable approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Korro agrees that: (i)&#160;the Korro Board shall recommend that Korro&#8217;s stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.8(a)</span> (the recommendation of the Korro Board that Korro&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;<span style="font-weight:bold">Korro Board Recommendation</span>&#8221;) and (ii)&#160;the Korro Board Recommendation shall not be withdrawn or modified (and the Korro Board shall not publicly propose to withdraw or modify the Korro Board Recommendation) in a manner adverse to Frequency, and no resolution by the Korro Board or any committee thereof to withdraw or modify the Korro Board Recommendation in a manner adverse to Frequency or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Korro&#8217;s obligation to solicit the consent of its stockholders to sign the Korro Stockholder Written Consent in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.8(a)</span> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_75">5.9 <span style="text-decoration:underline">Frequency Stockholder Meeting</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Frequency shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Frequency Common Stock to consider and vote to approve this Agreement and the Contemplated Transactions, including the issuance of the shares of Frequency Common Stock to the stockholders of Korro pursuant to the terms of this Agreement and<span style="font-weight:bold"> </span>the Charter Amendment Proposals (collectively, the &#8220;<span style="font-weight:bold">Frequency</span> <span style="font-weight:bold">Stockholder Matters</span>&#8221; and such meeting, the &#8220;<span style="font-weight:bold">Frequency Stockholder Meeting</span>&#8221;). The Frequency Stockholder Meeting shall be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, and in any event no later than 45 days after the effective date of the Registration Statement. Frequency shall take reasonable measures to ensure that all proxies solicited in connection with the Frequency Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Frequency Stockholder Meeting, or a date preceding the date on which the Frequency Stockholder Meeting is scheduled, Frequency reasonably believes that (i)&#160;it will not receive proxies sufficient to obtain the Required Frequency Stockholder Vote, whether or not a quorum would be present or (ii)&#160;it will not have sufficient shares of Frequency Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Frequency Stockholder Meeting, Frequency may postpone or adjourn, or make one or more successive postponements or adjournments of, the Frequency Stockholder Meeting as long as the date of the Frequency Stockholder Meeting is not postponed or adjourned more than an aggregate of 30 calendar days in connection with any postponements or adjournments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Frequency agrees that, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9(c)</span>: (i) the Frequency Board shall recommend that the holders of Frequency Common Stock vote to approve the Frequency Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9(a)</span> above, (ii)&#160;the Proxy Statement shall include a statement to the effect that the Frequency Board recommends that Frequency&#8217;s stockholders vote to approve the Frequency Stockholder Matters (the recommendation of the Frequency Board being referred to as the &#8220;<span style="font-weight:bold">Frequency </span><span style="font-weight:bold">Board Recommendation</span>&#8221;) and (iii)&#160;the Frequency Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Frequency Board shall not publicly propose to withhold, amend, withdraw or modify the Frequency Board Recommendation) in a manner adverse to Korro, and no resolution by the Frequency Board or any committee thereof to withdraw or modify the Frequency Board Recommendation in a manner adverse to Korro or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, a &#8220;<span style="font-weight:bold">Frequency </span><span style="font-weight:bold">Board Adverse Recommendation Change</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary contained in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9(b)</span>, and subject to compliance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9</span>, at any time prior to the approval of Frequency Stockholder Matters by the Required Frequency Stockholder Vote, Frequency receives a bona fide written Superior Offer, the Frequency Board may make a Frequency Board Adverse Recommendation Change if, but only if, in the receipt of and on account of such Superior Offer, (i)&#160;the Frequency Board determines in good faith, after consultation with its outside legal counsel, that the failure to make a Frequency Board Adverse Recommendation Change would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii)&#160;Frequency has, and has caused its financial advisors and outside legal counsel to, during the Notice Period, negotiate with Korro in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii)&#160;if after Korro shall have delivered to Frequency a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Frequency Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Frequency Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); <span style="font-style:italic">provided </span>that (x)&#160;Korro receives written notice from Frequency confirming that the Frequency Board has determined to change its recommendation during the Notice Period, which notice shall include a description in reasonable detail of the reasons for such Frequency Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (y)&#160;during any Notice Period, Korro shall be entitled to deliver to Frequency one or more counterproposals to such Acquisition Proposal and Frequency will, and cause its Representatives to, negotiate with Korro in good faith (to the extent Korro desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z)&#160;in the event of any material amendment to any Superior Offer (including any revision in price or percentage of the Combined Corporation that Frequency&#8217;s stockholders would receive as a result of such potential Superior Offer), Frequency shall be required to provide Korro with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least two Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9(c)</span> and the Frequency Board shall not make a Frequency Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Frequency&#8217;s obligation to call, give notice of and hold the Frequency Stockholder Meeting in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9(a)</span> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or Acquisition Proposal, or by any withdrawal or modification of the Frequency Board Recommendation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Nothing contained in this Agreement shall prohibit Frequency or the Frequency Board from complying with Rules <span style="white-space:nowrap">14d-9</span> and <span style="white-space:nowrap">14e-2(a)</span> promulgated under the Exchange Act; provided, however, that any disclosure made by Frequency or the Frequency Board pursuant to Rules <span style="white-space:nowrap">14d-9</span> and <span style="white-space:nowrap">14e-2(a)</span> shall be limited to a statement that Frequency is unable to take a position with respect to the bidder&#8217;s tender offer unless the Frequency Board determines in good faith, after consultation with its outside legal counsel, that such statement would result in a breach of its fiduciary duties under applicable Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_76">5.10 <span style="text-decoration:underline">Efforts; Regulatory Approvals</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Parties shall use reasonable best efforts to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party: (i)&#160;shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii)&#160;shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii)&#160;shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. Frequency and Korro shall respond as promptly as is practicable to respond in compliance with: (i)&#160;any inquiries or requests received from the Federal Trade Commission or the Department of Justice for additional information or documentation and (ii)&#160;any inquiries or requests received from any state attorney general, foreign antitrust or competition authority or other Governmental Authority in connection with antitrust or competition matters. Each of the Parties will promptly notify the other Party of the details of any material communication it receives from any Governmental Authority relating to the matters that are subject to this Agreement and the Contemplated Transactions, and permit the other Party to review in advance, to the extent permitted by Law, any proposed material communication to any Governmental Authority. Each of the Parties will provide the other Party with advance notice of and, to the extent permitted by such Governmental Authority, give the other party the opportunity to attend and participate in any meeting with the Governmental Authority in respect of any filings, investigations, or other inquiries. Subject to applicable Laws, the Parties will coordinate and cooperate fully and promptly with one another in exchanging such information and providing such assistance as the other Party may reasonably request in connection with the foregoing. Subject to applicable Laws, each of the Parties will provide, or cause to be provided, to the other, copies of all material correspondence, filings, or communications between them or any of their Representatives, on the one hand, and any Governmental Authority or members of its staff, on the other hand, with respect to this Agreement and the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_77">5.11 <span style="text-decoration:underline">Disclosures</span>. Without limiting any Party&#8217;s obligations under the Confidentiality Agreement, no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any disclosure (to any customers or employees of such Party, to the public or otherwise) regarding the Contemplated Transactions unless: (a)&#160;the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b)&#160;such Party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding, the text of such press release or disclosure; provided, however, that each of Korro and Frequency may make any statement in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public statements made by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Korro and Frequency in compliance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.11</span>. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9(d)</span> or with an Acquisition Proposal, or Frequency Board Adverse Recommendation Change with respect to Frequency only pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9(e)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_78">5.12 <span style="text-decoration:underline">Frequency Options</span>. Prior to the Closing, the Frequency Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that the vesting and exercisability of each unexpired, unexercised and unvested Frequency Option shall be accelerated in full effective as of immediately prior to the Effective Time, contingent on the occurrence of the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_79">5.13 <span style="text-decoration:underline">Frequency Restricted Stock Units</span>. Prior to the Closing, the Frequency Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that (a)&#160;the vesting of each outstanding and unvested Frequency Restricted Stock Unit that vests solely based on the holder&#8217;s continued employment or service shall be accelerated in full effective as of immediately prior to the Effective Time, contingent on the occurrence of the Closing and (b)&#160;for each outstanding and unsettled Frequency Restricted Stock Unit that vests solely based on the holder&#8217;s continued employment or service, the holder thereof shall receive, immediately prior to the Effective Time a number of shares of Frequency Common Stock equal to the number of vested and unsettled shares of Frequency Common Stock underlying such Frequency Restricted Stock Units. Notwithstanding anything herein to the contrary, the tax withholding obligations for each holder receiving shares of Frequency Common Stock in accordance with the preceding sentence shall be satisfied by Frequency withholding from issuance that number of shares of Frequency Common Stock calculated by multiplying the maximum statutory withholding rate for such holder in connection with such issuance by the number of shares of Frequency Common Stock to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities. For the avoidance of doubt, Frequency Restricted Stock Units that do not vest solely based on the holder&#8217;s continued employment or service shall remain outstanding and subject to the terms set forth in the Frequency 2019 Incentive Award Plan, as amended from time to time, and the applicable Frequency Restricted Stock Unit award agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_80">5.14 <span style="text-decoration:underline">Frequency ESPP</span>. As soon as reasonably practicable following the date of this Agreement, the Frequency Board shall adopt appropriate resolutions to provide that (a)&#160;no offering periods or purchase periods shall be commenced following or in addition to the offering period underway as of the date hereof under the Frequency ESPP (the &#8220;<span style="font-weight:bold">Current Offering Period</span>&#8221;), (b) no payroll deductions or other contributions shall be made or effected after the Current Offering Period with respect to the Frequency ESPP, and (c)&#160;each Frequency ESPP participant&#8217;s accumulated contributions under the Frequency ESPP shall be returned to the participant in accordance with the terms of the Frequency ESPP. Unless Korro requests otherwise in writing no later than ten Business Days prior to the Closing Date, prior to the Closing Date, the Frequency Board shall adopt appropriate resolutions to provide that the Frequency ESPP is terminated immediately prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_81">5.15 <span style="text-decoration:underline">Indemnification of Officers and Directors</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, each of Frequency and the Surviving Corporation shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of Frequency or Korro, respectively (the &#8220;<span style="font-weight:bold">D&amp;O Indemnified Parties</span>&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;<span style="font-weight:bold">Costs</span>&#8221;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Frequency or of Korro, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted under Delaware Law. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Frequency and the Surviving Corporation, jointly and severally, upon receipt by Frequency or the Surviving Corporation from the D&amp;O Indemnified Party of a request therefor; provided that </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such person to whom expenses are advanced provides an undertaking to Frequency, to the extent then required by Delaware Law, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The provisions of Frequency&#8217;s Organizational Documents with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Frequency that are presently set forth in Frequency&#8217;s Organizational Documents shall not be amended, modified or repealed for a period of six years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Frequency, unless such modification is required by applicable Law. The Surviving Corporation&#8217;s Organizational Documents shall contain, and Frequency shall cause the certificate of incorporation of the Surviving Corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in Frequency&#8217;s Organizational Documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) From and after the Effective Time, (i)&#160;the Surviving Corporation shall fulfill and honor in all respects the obligations of Korro to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Korro&#8217;s Organizational Documents and pursuant to any indemnification agreements between Korro and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii)&#160;Frequency shall fulfill and honor in all respects the obligations of Frequency to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Frequency&#8217;s Organizational Documents and pursuant to any indemnification agreements between Frequency and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) From and after the Effective Time, Frequency shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Frequency. In addition, Frequency shall purchase, prior to the Effective Time, a <span style="white-space:nowrap">six-year</span> prepaid &#8220;D&amp;O tail policy&#8221; for the <span style="white-space:nowrap">non-cancellable</span> extension of the directors&#8217; and officers&#8217; liability coverage of Frequency&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Frequency&#8217;s existing policies as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Frequency by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in connection with this Agreement or the Contemplated Transactions or in connection with Frequency&#8217;s initial public offering of shares of Frequency Common Stock). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) From and after the Effective Time, Frequency shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the persons referred to in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span> in connection with their enforcement of the rights provided to such persons in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Frequency and Korro by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) In the event Frequency or the Surviving Corporation or any of their respective successors or assigns (i)&#160;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii)&#160;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Frequency or the Surviving Corporation, as the case may be, shall succeed to the obligations set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span>. Frequency shall cause the Surviving Corporation to perform all of the obligations of the Surviving Corporation under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_82">5.16 <span style="text-decoration:underline">Tax Matters</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All transfer, documentary, sales, use, stamp, registration, excise, recording, registration value added and other such similar Taxes and fees (including any penalties and interest) that become payable in connection with or by reason of the execution of this Agreement and the transactions contemplated hereby (collectively, &#8220;<span style="font-weight:bold">Transfer Taxes</span>&#8221;) shall be borne and paid by Frequency. Unless otherwise required by applicable law, Frequency shall timely file any Tax Return or other document with respect to such Taxes or fees (and Korro shall reasonably cooperate with respect thereto as necessary). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At the Closing, Korro shall deliver to Frequency a certificate pursuant to Treasury Regulations Sections <span style="white-space:nowrap">1.1445-2(c)</span> and <span style="white-space:nowrap">1.897-2(h),</span> together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations <span style="white-space:nowrap">Section&#160;1.897-2(h),</span> in each case, in form and substance reasonably acceptable to Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The parties intend that, for United States federal income tax purposes, the Merger shall qualify for the Intended Tax Treatment. The Merger shall be reported by the parties for all Tax purposes in accordance with the foregoing, and no party shall take any position on any Tax Return that is inconsistent with the Intended Tax Treatment, unless otherwise required by a Governmental Authority as a result of a &#8220;determination&#8221; within the meaning of Section&#160;1313(a) of the Code. The parties shall cooperate with each other and their respective counsel to document and support the Tax treatment of the Merger as qualifying for the Intended Tax Treatment, including by taking the actions described on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.16(c)</span> of the Korro Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Frequency shall use commercially reasonable efforts to promptly notify Korro, and Korro shall use commercially reasonable efforts to promptly notify Frequency, in each case if either party becomes aware of any <span style="white-space:nowrap">non-public</span> fact or circumstance that, to such party&#8217;s Knowledge, would reasonably be likely to prevent or impede the Merger from qualifying for the Intended Tax Treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_83">5.17 <span style="text-decoration:underline">Listing</span>. At or prior to the Effective Time, Frequency shall use commercially reasonable efforts to (a)&#160;maintain a listing on Nasdaq until the Effective Time and to obtain approval of the listing of the Combined Corporation on Nasdaq; (b)&#160;to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Frequency Common Stock to be issued in connection with the Contemplated Transactions and to cause such shares to be approved for listing; (c)&#160;prepare and timely submit to Nasdaq a notification form of the Nasdaq Reverse Split and to submit a copy of the amendment to Frequency&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split and other amendments contemplated by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4</span> certified by the Secretary of State of the State of Delaware, to Nasdaq on or before the Closing Date; and (d)&#160;to the extent required by Nasdaq Marketplace Rule 5110, assist Korro in preparing and filing an initial listing application for the Frequency Common Stock on Nasdaq (the &#8220;<span style="font-weight:bold">Nasdaq Listing Application</span>&#8221;). The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application and promptly furnish to such filing Party all information concerning itself and its stockholders that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.17</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_84">5.18 <span style="text-decoration:underline">Legends</span>. Frequency shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Frequency Capital Stock to be received in the Merger by equityholders of Korro who may be considered &#8220;affiliates&#8221; of Frequency for purposes of Rule 145 under the Securities Act reflecting the restrictions set forth in Rule 145 and to issue appropriate stop transfer instructions to the transfer agent for Frequency Capital Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_85">5.19 <span style="text-decoration:underline">Officers and Directors</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Directors and Officers of Frequency</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Frequency shall cause, effective as of the Effective Time, the Frequency Board to consist of seven (7)&#160;individuals, which shall consist of (A)&#160;four (4) members selected by the Korro Board as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.19(a)(i)</span> of the Frequency Disclosure Schedule (each, a &#8220;<span style="font-weight:bold">Korro Designee</span>&#8221;), (B) one (1)&#160;member selected by the Frequency Board as set forth on <span style="text-decoration:underline">Schedule </span><span style="text-decoration:underline">5.19(a)(i)</span> of the Frequency Disclosure Schedule (each, a &#8220;<span style="font-weight:bold">Frequency Designee</span>&#8221;) and (C)&#160;two (2) members who shall be independent. If any Korro Designee or Frequency Designee is unable or unwilling to serve as director of Frequency, the Party appointing such Person shall designate a successor. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Frequency shall cause the directors and officers of Frequency listed on <span style="text-decoration:underline">Schedule 5.19(a)(ii)</span> of the Frequency Disclosure Schedule to sign written resignations in forms reasonably satisfactory to Korro, dated on or before the Closing Date and effective as of the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Immediately following the Effective Time, Frequency shall take all necessary action to appoint the officers of Korro to become the equivalent officers of Frequency until the earlier of their resignation or removal or until their respective successors are duly elected or appointed and qualified, as the case may be. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Directors and Officers of the Surviving Corporation</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Parties shall take all actions necessary (A)&#160;so that from and after the Effective Time, the Surviving Corporation&#8217;s board of directors shall be constituted with those members as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.19(b)</span> of the Frequency Disclosure Schedule and (B)&#160;to secure the resignations of the existing members of the committees of the Surviving Corporation, if any. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Parties shall take all actions necessary so that the officers of Korro immediately prior to the Effective Time shall, from and after the Effective Time, be the officers of the Surviving Corporation, until the earlier of their resignation or removal or until their respective successors are duly elected or appointed and qualified, as the case may be. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) On the Closing Date, the Surviving Corporation shall enter into customary indemnification agreements reasonably satisfactory to Korro with each individual to be appointed to, or serving on, the board of directors of the Surviving Corporation upon the Closing, which indemnification agreements shall continue to be effective following the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_86">5.20 <span style="text-decoration:underline">Termination of Certain Agreements and Rights</span>. Korro shall cause any stockholder agreements, voting agreements, registration rights agreements, <span style="white-space:nowrap">co-sale</span> agreements and any other similar Contracts between Korro and any holders of Korro Capital Stock, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights to be terminated immediately prior to the Effective Time, without any liability being imposed on the part of Frequency or the Surviving Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_87">5.21 <span style="text-decoration:underline">Section 16</span><span style="text-decoration:underline"> Matters</span>. Prior to the Effective Time, Frequency shall take all such steps as may be required to cause any acquisitions of Frequency Common Stock and any options to purchase Frequency Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Frequency, to be exempt under Rule <span style="white-space:nowrap">16b-3</span> promulgated under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_88">5.22 <span style="text-decoration:underline">Allocation Certificate</span>. Korro will prepare and deliver to Frequency at least two Business Days prior to the Closing Date a certificate signed by an executive officer of Korro in a form reasonably acceptable to Frequency setting forth (as of immediately prior to the Effective Time)&#160;(a) each holder of Korro Capital Stock, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Korro Options or Korro Warrants, (b)&#160;such holder&#8217;s name and address, (c)&#160;the number and type of Korro Capital Stock held as of the Closing Date for each such holder or, with respect to each Korro Option or Korro Warrant, the grant date of such Korro Option or Korro Warrant and the number of shares subject to such Korro Option or Korro Warrant, (d)&#160;the number of shares of Frequency Common Stock to be issued to such holder pursuant to this Agreement in respect of the Korro Capital Stock held by such holder as of immediately prior to the Effective Time or, with respect to each Korro Option or Korro Warrant, the number of shares of Frequency Common Stock to be subject to the applicable Assumed Option or Assumed Warrant as of immediately prior to the Effective Time following the conversion of such Korro Option or Korro Warrant into an Assumed Option in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(f)</span> or into an Assumed Warrant in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(i)</span> (as applicable), and (e)&#160;each investor in the Concurrent Financing, the total investment to be made by such investor in the Concurrent Financing, the percentage of the Concurrent Financing Proceeds represented by such stockholder&#8217;s investment in the Concurrent Financing, and the number of shares of Frequency Common Stock to be issued to such holder pursuant to this Agreement (the &#8220;<span style="font-weight:bold">Allocation Certificate</span>&#8221;). For the avoidance of doubt, the Allocation Certificate shall be prepared in good faith, in accordance with the Organizational Documents of Korro and contracts applicable to Korro Capital Stock, Korro Options and Korro Warrants, and shall show each holder&#8217;s percentage ownership interest in Korro on a fully diluted basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_89">5.23 <span style="text-decoration:underline">Nasdaq Reverse Split</span>. Frequency shall submit to Frequency&#8217;s stockholders at the Frequency Stockholder Meeting the Reverse Stock Split Proposal, and the Parties shall take such other actions as shall be reasonably necessary to effectuate the Nasdaq Reverse Split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_90">5.24 <span style="text-decoration:underline">Obligations of Merger Sub</span>. Frequency will take all action necessary to cause Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_91">5.25 <span style="text-decoration:underline">Takeover Statutes</span>. If any takeover statute is or may become applicable to the Contemplated Transactions, each of Korro, the Korro Board, Frequency and the Frequency Board, as applicable, shall grant such approvals and take such actions as are necessary, to the extent permitted by Law, so that the Contemplated Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such statute or regulation on the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_92">5.26 <span style="text-decoration:underline">Stockholder Litigation</span>. Each Party shall keep the other Party reasonably informed regarding any stockholder litigation against Frequency or any of its directors relating to this Agreement or the Contemplated Transactions (&#8220;<span style="font-weight:bold">Transaction Litigation</span>&#8221;). Prior to the Closing, Frequency shall have the right to control the defense and settlement of any Transaction Litigation, but shall reasonably consult with Korro and consider any advice from Korro and its Representatives with respect to Transaction Litigation. Frequency shall promptly advise Korro of the initiation of, and shall keep Korro reasonably apprised of any material developments in connection with, any such Transaction Litigation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_93">5.27 <span style="text-decoration:underline">Concurrent Financing</span>.<span style="text-decoration:underline"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Agreement, Korro shall use commercially reasonable efforts to obtain the Concurrent Financing on the terms and conditions described in the Subscription Agreement and satisfy the conditions to the Concurrent Financing as described in the Subscription Agreement and shall not permit any termination, amendment or modification to be made to, or any waiver of any provision under, or any replacement of, the Subscription Agreement if such termination, amendment, modification, waiver or replacement (i)&#160;reduces the aggregate amount of the Concurrent Financing or (ii)&#160;imposes new or additional conditions or otherwise expands, amends or modifies any of the conditions to the receipt of the Concurrent Financing, or otherwise expands, amends or modifies any other provision of the Subscription Agreement, in a manner that would reasonably be expected to (x)&#160;delay or prevent the funding of the Concurrent Financing (or satisfaction of the conditions to the Concurrent Financing) at or substantially simultaneously with the Closing or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(y)&#160;adversely impact the ability of Korro to enforce its rights against other parties to the Subscription Agreement. Korro shall promptly deliver to Frequency copies of any such termination, amendment, modification, waiver or replacement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Korro shall use commercially reasonable efforts (i)&#160;to maintain in effect the Subscription Agreement, (ii)&#160;to enforce its rights under the Subscription Agreement and (iii)&#160;to comply with its obligations under the Subscription Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Korro shall give Frequency prompt notice (i)&#160;of any breach or default by any party to the Subscription Agreement or definitive agreements related to the Concurrent Financing of which Korro becomes aware, (ii)&#160;of the receipt of any written notice or other written communication from any Purchaser with respect to any (x)&#160;actual breach, default, termination or repudiation by any party to the Subscription Agreement or definitive agreements related to the Concurrent Financing of any provisions of the Subscription Agreement or definitive agreements related to the Concurrent Financing or (y)&#160;material dispute or disagreement relating to the Concurrent Financing with respect to the obligation to fund the Concurrent Financing at or substantially simultaneously with the Closing, and (iii)&#160;if at any time for any reason Korro believes in good faith that it will not be able to obtain all or any portion of the Concurrent Financing on the terms and conditions, in the manner or from the sources contemplated by the Subscription Agreement or definitive agreements related to the Concurrent Financing. Korro shall promptly provide information reasonably requested by Frequency relating to the circumstances referred to in clauses (i), (ii) or (iii)&#160;of the immediately preceding sentence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_94">5.28 <span style="text-decoration:underline">Frequency Equity Plan</span><span style="text-decoration:underline">s</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Effective Time, Frequency will use commercially reasonable efforts to cause the Frequency Board to adopt the 2023 Equity Incentive Plan, subject to the Closing and effective as of the Effective Time, and will include provisions in the Proxy Statement for the stockholders of Frequency to approve the 2023 Equity Incentive Plan. Subject to the approval of the 2023 Equity Incentive Plan by the stockholders of Frequency prior to the Effective Time, Frequency shall file with the SEC, promptly after the Effective Time and at Korro&#8217;s expense, a registration statement on Form <span style="white-space:nowrap">S-8</span> (or any successor form), if available for use by Frequency, relating to the shares of Frequency Common Stock issuable with respect to the 2023 Equity Incentive Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Prior to the Effective Time, Frequency will use commercially reasonable efforts to cause the Frequency Board to adopt the 2023 ESPP, subject to the Closing and effective as of the Effective Time, and will include provisions in the Proxy Statement for the stockholders of Frequency to approve the 2023 ESPP. Subject to the approval of the 2023 ESPP by the stockholders of Frequency prior to the Effective Time, Frequency shall file with the SEC, promptly after the Effective Time and at Korro&#8217;s expense, a registration statement on Form <span style="white-space:nowrap">S-8</span> (or any successor form), if available for use by Frequency, relating to the shares of Frequency Common Stock issuable with respect to the 2023 ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the avoidance of doubt, approval of the 2023 Plans by the stockholders of Frequency shall not be a condition to Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_95">5.29 <span style="text-decoration:underline">Frequency 401(k)</span><span style="text-decoration:underline"> Plan</span>. Unless Korro requests otherwise in writing no later than ten Business Days prior to the Closing Date, Frequency shall, effective as of at least one (1)&#160;day prior to the Closing Date but subject to the Closing, terminate any Frequency Employee Plan that is intended to meet the requirements of Section&#160;401(k) of the Code, and which is sponsored, or contributed to, by Frequency or any of its ERISA Affiliates (the &#8220;<span style="font-weight:bold">401(k) Plan</span>&#8221;) and no further contributions shall be made to the 401(k) Plan and all participant account balances in such plan shall become 100% vested. Frequency shall provide to Korro executed resolutions of the board of directors of Frequency authorizing such termination that are sufficient to assure compliance with all applicable requirements of the Code and regulations thereunder, including such that the <span style="white-space:nowrap">tax-qualified</span> status of the 401(k) Plan will be maintained at the time of termination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_96">ARTICLE VI </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDITIONS TO CONSUMMATION OF THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_97">6.1 <span style="text-decoration:underline">Conditions Precedent to Obligations of Each Party</span>. The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) No temporary restraining order, preliminary or permanent injunction or other Order preventing the consummation of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Frequency shall have obtained the Required Frequency Stockholder Vote, and Korro shall have obtained the Required Korro Stockholder Vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The approval of the listing of the additional shares of Frequency Common Stock on Nasdaq shall have been obtained and the shares of Frequency Common Stock to be issued in the Merger pursuant to this Agreement shall have been approved for listing (subject to official notice of issuance) on Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Subscription Agreement shall be in full force and effect and cash proceeds of not less than the Concurrent Investment Amount shall have been received by Korro, or will be received by Korro substantially simultaneously with the Closing, in connection with the consummation of the transactions contemplated by the Subscription Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Frequency <span style="white-space:nowrap">Lock-Up</span> Agreements and Korro <span style="white-space:nowrap">Lock-Up</span> Agreements will continue to be in full force and effect as of immediately following the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Korro shall have effected the Korro Preferred Stock Conversion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_98">6.2 <span style="text-decoration:underline">Conditions Precedent to Obligations of </span><span style="text-decoration:underline">Korro</span>. The obligations of Korro to effect the Merger and otherwise consummate the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by Korro, at or prior to the Closing, of each of the following conditions: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of the Frequency Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Frequency Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are de minimis, individually or in the aggregate or (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of Frequency and Merger Sub contained in this Agreement (other than the Frequency Fundamental Representations and the Frequency Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (i)&#160;in each case, or in the aggregate, where the failure to be true and correct </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would not reasonably be expected to have a Frequency Material Adverse Effect (without giving effect to any references therein to any Frequency Material Adverse Effect or other materiality qualifications) or (ii)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (i), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Frequency Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Frequency and Merger Sub shall have performed and complied in all material respects with all covenants and agreements required to be performed or complied with by them under this Agreement at or prior to the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) A Frequency Material Adverse Effect shall not have occurred since the date of this Agreement and be continuing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The existing shares of Frequency Common Stock shall have been continually listed on Nasdaq as of and from the date of this Agreement through the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Frequency shall have delivered to Korro a certificate (the &#8220;<span style="font-weight:bold">Frequency Closing Certificate</span>&#8221;), dated the Closing Date and signed by an executive officer of Frequency, certifying to the effect that the conditions set forth in <span style="text-decoration:underline">Sections </span><span style="text-decoration:underline">6.2(a)</span>, <span style="text-decoration:underline">6.2(b)</span> and <span style="text-decoration:underline">6.2(c)</span> have been satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_99">6.3 <span style="text-decoration:underline">Conditions Precedent to Obligations of</span><span style="text-decoration:underline"> </span><span style="text-decoration:underline">Frequency</span>. The obligations of Frequency and Merger Sub to effect the Merger and otherwise consummate the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by Frequency, at or prior to the Closing, of each of the following conditions: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of the Korro Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Korro Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are de minimis, individually or in the aggregate or (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of Korro contained in this Agreement (other than the Korro Fundamental Representations and the Korro Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (i)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Korro Material Adverse Effect (without giving effect to any references therein to any Korro Material Adverse Effect or other materiality qualifications) or (ii)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (i), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Korro Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Korro shall have performed and complied in all material respects with all covenants and agreements required to be performed or complied with by it under this Agreement at or prior to the Closing Date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) A Korro Material Adverse Effect shall not have occurred since the date of this Agreement and be continuing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Korro shall have delivered to Frequency a certificate (the &#8220;<span style="font-weight:bold">Korro</span> <span style="font-weight:bold">Closing Certificate</span>&#8221;), dated the Closing Date and signed by an executive officer of Korro, certifying to the effect that (i)&#160;the conditions set forth in <span style="text-decoration:underline">Sections </span><span style="text-decoration:underline">6.3(a)</span>, <span style="text-decoration:underline">6.3(b)</span> and <span style="text-decoration:underline">6.3(c)</span> have been satisfied and (ii)&#160;the information set forth in the Allocation Certificate delivered by Korro in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.20</span> is true and accurate in all respects as of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_100">6.4 <span style="text-decoration:underline">Frustration of Closing Conditions</span>. Neither Frequency nor Merger Sub may rely on the failure of any conditions set forth in <span style="text-decoration:underline">Sections </span><span style="text-decoration:underline">6.1</span> or <span style="text-decoration:underline">6.3</span> to be satisfied if the primary cause of such failure was the failure of Frequency or Merger Sub to perform any of its obligations under this Agreement. Korro may not rely on the failure of any conditions set forth in <span style="text-decoration:underline">Sections </span><span style="text-decoration:underline">6.1</span> or <span style="text-decoration:underline">6.2</span> to be satisfied if the primary cause of such failure was the failure of Korro to perform any of its obligations under this Agreement. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_101">ARTICLE VII </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CLOSING DELIVERIES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_102">7.1 <span style="text-decoration:underline">Closing Deliveries of Korro</span>. The obligations of Frequency and Merger Sub to effect the Merger and otherwise consummate the Contemplated Transactions are subject to Frequency receiving the following documents, each of which shall be in full force and effect, or the written waiver by Frequency of delivery: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Korro Stockholder Written Consents; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Allocation Certificate; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the Korro Closing Certificate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_103">7.2 <span style="text-decoration:underline">Closing Deliveries of </span><span style="text-decoration:underline">Frequency</span>. The obligations of Korro to effect the Merger and otherwise consummate the Contemplated Transactions are subject to Korro receiving the following documents, each of which shall be in full force and effect, or the written waiver by Korro of delivery: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Frequency Net Cash Schedule; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Frequency Closing Certificate; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.5</span>, the executed CVR Agreement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) written resignations in forms satisfactory to Korro, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Frequency who are not to continue as officers or directors of Frequency pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.18</span> hereof. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_104">ARTICLE VIII </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TERMINATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_105">8.1 <span style="text-decoration:underline">Termination</span>. This Agreement may be terminated, and the Merger and the Contemplated Transactions may be abandoned at any time prior to the Effective Time, whether before or (subject to the terms hereof) after approval of the Frequency Stockholder Matters by Frequency&#8217;s stockholders, unless otherwise specified below: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of Frequency and Korro; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) by either Frequency and Korro if the Merger shall not have been consummated by November&#160;14, 2023 (subject to possible extension as provided in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(b)</span>, the &#8220;<span style="font-weight:bold">Outside Date</span>&#8221;); provided, however, that the right to terminate this Agreement under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(b)</span> shall not be available to Frequency or Korro if such Party&#8217;s action or failure to act has been a principal cause of the failure of the Merger to occur on or before the Outside Date and such action or failure to act constitutes a breach of this Agreement, provided, further, however, that, in the event that the SEC has not declared effective under the Securities Act the Registration Statement by the date which is 25 Business Days prior to the Outside Date, then either Frequency or Korro shall be entitled to extend the Outside Date for an additional 60 days; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) by either Frequency and Korro if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable Order, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) by Frequency if the Required Korro Stockholder Vote shall not have been obtained and evidence thereof delivered to Frequency within five Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; provided, however, that once the Required Korro Stockholder Vote has been obtained, Frequency may not terminate this Agreement pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(d)</span>; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) by either Frequency and Korro if (i)&#160;the Frequency Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Frequency&#8217;s stockholders shall have taken a final vote on the Frequency Stockholder Matters and (ii)&#160;the Frequency Stockholder Matters shall not have been approved at the Frequency Stockholder Meeting (or at any adjournment or postponement thereof) by the Required Frequency Stockholder Vote; provided, however, that the right to terminate this Agreement under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(e)</span> shall not be available to Frequency where the failure to obtain the Required Frequency Stockholder Vote shall have been caused by the action or failure to act of Frequency and such action or failure to act constitutes a breach of this Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) by Korro (at any time prior to the approval of the Frequency Stockholder Matters by the Required Frequency Stockholder Vote) if a Frequency Triggering Event shall have occurred; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) by Frequency (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Korro Stockholder Vote) if a Korro Triggering Event shall have occurred; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) by Korro, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Frequency or Merger Sub or if any representation or warranty of Frequency or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(a)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(b)</span> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided that Korro is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further, that if such inaccuracy in Frequency&#8217;s or Merger Sub&#8217;s representations and warranties or breach by Frequency or Merger Sub is curable by Frequency or Merger Sub, then this Agreement shall not terminate pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(h)</span> as a result of such particular breach or inaccuracy until the expiration of a <span style="white-space:nowrap">30-day</span> period commencing upon delivery of written notice from Korro to Frequency or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(h)</span> (it being understood that this Agreement shall not terminate pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(h)</span> as a result of such particular breach or inaccuracy if such breach by Frequency or Merger Sub is cured prior to such termination becoming effective); or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) by Frequency, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Korro or if any representation or warranty of Korro shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(a)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(b)</span> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided that Frequency </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further, that if such inaccuracy in Korro&#8217;s representations and warranties or breach by Korro is curable by Korro then this Agreement shall not terminate pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(i)</span> as a result of such particular breach or inaccuracy until the expiration of a <span style="white-space:nowrap">30-day</span> period commencing upon delivery of written notice from Frequency to Korro of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(i)</span> (it being understood that this Agreement shall not terminate pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(i)</span> as a result of such particular breach or inaccuracy if such breach by Korro is cured prior to such termination becoming effective). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Party desiring to terminate this Agreement pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1</span> (other than pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(a)</span>) shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_106">8.2 <span style="text-decoration:underline">Effect of Termination</span>. In the event of the termination of this Agreement as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1</span>, this Agreement shall be of no further force or effect; provided, however, that (a)&#160;this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.2</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span>, and <span style="text-decoration:underline">Article IX</span> shall survive the termination of this Agreement and shall remain in full force and effect and (b)&#160;the termination of this Agreement and the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_107">8.3 <span style="text-decoration:underline">Expenses; Termination Fees</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated; provided, however, that (i)&#160;Korro shall pay the costs and expenses incurred in relation to the filings by the Parties under any antitrust Law applicable to this Agreement and the transactions contemplated hereby, and (ii)&#160;that Frequency and Korro shall share equally all fees and expenses incurred in relation to the printing and filing with the SEC of the Registration Statement (including any financial statements and exhibits) and any amendments or supplements thereto and paid to a financial printer or the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&#160;this Agreement is terminated by Frequency or Korro pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(e)</span>, (ii) at any time after the date of this Agreement and prior to the Frequency Stockholder Meeting an Acquisition Proposal with respect to Frequency shall have been publicly announced, disclosed or otherwise communicated to the Frequency Board (and shall not have been withdrawn) and (iii)&#160;within 12 months after the date of such termination, Frequency enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Frequency shall pay to Korro, within four Business Days after such entry into a definitive agreement and/or consummation of a Subsequent Transaction, a nonrefundable fee in an amount equal to $1,500,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If this Agreement is terminated by Korro pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(f)</span>, then Frequency shall pay to Korro, within four Business Days after termination, a nonrefundable fee in an amount equal to $1,500,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If this Agreement is terminated by Frequency pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(d)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(g)</span>, then Korro shall pay to Frequency, within four Business Days after termination, a nonrefundable fee in an amount equal to $4,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If either Party fails to pay when due any amount payable by it under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span>, then (i)&#160;such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Parties agree that, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.2</span>, the payment of the fees and expenses set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> that result in the payment of such fees, it being understood that in no event shall either Frequency or Korro be required to pay the individual fees or damages payable pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> on more than one occasion. Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.2</span>, following the termination of this Agreement under the circumstances described in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> and the payment of the fees set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> by a Party, (i)&#160;such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii)&#160;no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, affiliate, agent or other representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii)&#160;all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges that (x)&#160;the agreements contained in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> are an integral part of the Contemplated Transactions, (y)&#160;without these agreements, the Parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa451428_108">ARTICLE IX </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">GENERAL PROVISIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_109">9.1 <span style="text-decoration:underline"><span style="white-space:nowrap">Non-Survival</span> of Representations and Warranties</span>. The representations and warranties of Korro, Frequency and Merger Sub contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time and this <span style="text-decoration:underline">Article IX</span> shall survive the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_110">9.2 <span style="text-decoration:underline">Amendment</span>. This Agreement may be amended with the approval of the respective boards of directors of Korro, Merger Sub and Frequency at any time (whether before or after obtaining the Required Korro Stockholder Vote and the Required Frequency Stockholder Vote); <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that after any such approval of this Agreement by a Party&#8217;s stockholders or members, no amendment shall be made which by Law requires further approval of such stockholders or members without the further approval of such stockholders or members. This Agreement may not be amended except by an instrument in writing signed on behalf of each of Korro, Merger Sub and Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_111">9.3 <span style="text-decoration:underline">Waiver</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_112">9.4 <span style="text-decoration:underline">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span>. This Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_113">9.5 <span style="text-decoration:underline">Applicable Law; Jurisdiction</span>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: irrevocably and unconditionally (a)&#160;consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.5</span>, (c) waives any objection to laying venue in any such action or proceeding in such courts, (d)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e)&#160;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.7</span> of this Agreement and (f)&#160;irrevocably and unconditionally waives the right to trial by jury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_114">9.6 <span style="text-decoration:underline">Assignability</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_115">9.7 <span style="text-decoration:underline">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand or (c)&#160;on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. New York City time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to Frequency or Merger Sub: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">75 Hayden Ave </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lexington, MA 02421 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: David Lucchino, Jim Abely </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: dlucchino@frequencytx.com, jabely@frequencytx.com </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Latham&#160;&amp; Watkins LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">200 Clarendon Street </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Boston, MA 02116 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: John H. Chory, Bradley C. Faris </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: john.chory@lw.com; bradley.faris@lw.com </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to Korro: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Korro Bio </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Kendall Square, Suite 600 Cambridge MA </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Ram Aiyar, CEO, Shelby Walker, General Counsel </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: raiyar@korrobio.com, legal@korrobio.com </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">100 Northern Avenue </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Kingsley L. Taft, Andrew H. Goodman </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: ktaft@goodwinlaw.com, agoodman@goodwinlaw.com </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_116">9.8 <span style="text-decoration:underline">Cooperation</span>. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_117">9.9 <span style="text-decoration:underline">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_118">9.10 <span style="text-decoration:underline">Other Remedies; Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa451428_119">9.11 <span style="text-decoration:underline">No Third-Party Beneficiaries</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span>) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Remainder of page intentionally left blank</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">I<small>N</small> </span><span style="font-weight:bold">W</span><span style="font-weight:bold"><small>ITNESS</small> W<small>HEREOF</small></span><small></small>, the Parties have caused this Agreement to be executed as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">F<small>REQUENCY</small> T<small>HERAPEUTICS</small>, I<small>NC</small>. </span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Lucchino</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">David Lucchino</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President &amp; Chief Executive Officer</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">F<small>REQUENCY</small> M<small>ERGER</small> S<small>UB</small>, I<small>NC</small>.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Lucchino</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">David Lucchino</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">K<small>ORRO</small> B<small>IO</small>, I<small>NC</small>. </span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ram Aiyar</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Ram Aiyar</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</p></td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit A </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Form of Frequency Stockholder Support Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Intentionally Omitted] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit B </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Form of Korro Stockholder Support Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Intentionally Omitted] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit C </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Form of Frequency <span style="white-space:nowrap">Lock-Up</span> Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Intentionally Omitted] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit D </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Form of Korro <span style="white-space:nowrap">Lock-Up</span> Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Intentionally Omitted] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit E </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Form of Korro Stockholder Written Consent </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Intentionally Omitted] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit F </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">CVR Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Intentionally Omitted] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_155">Annex B </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Opinion of Cowen and Company, LLC </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&#160;13, 2023 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">75 Hayden Avenue, Suite 300 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexington, Massachusetts 02421 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In your capacity as the Board of Directors (the &#8220;Board of Directors&#8221;) of Frequency Therapeutics, Inc. (&#8220;Frequency&#8221;), you have requested our opinion (the &#8220;Opinion&#8221;), as investment bankers, as to the fairness, from a financial point of view, to Frequency of the Korro Equity Value (as defined below) provided for pursuant to the terms of an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) proposed to be entered into among Frequency, Frequency Merger Sub, Inc., a wholly owned subsidiary of Frequency (&#8220;Merger Sub&#8221;), and Korro Bio, Inc. (&#8220;Korro&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As more fully described in the Merger Agreement, and subject to the terms and conditions set forth therein, Merger Sub will be merged with and into Korro (the &#8220;Merger&#8221;), with Korro<sup style="font-size:75%; vertical-align:top"> </sup>surviving the Merger as a wholly owned subsidiary of Frequency, in connection with which Korro will be ascribed an aggregate equity value of $325,639,194.78 (the &#8220;Korro Equity Value&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We understand that, in connection with the Merger, (i)&#160;the outstanding shares of the common stock, par value $0.001 per share, of Korro (&#8220;Korro Common Stock&#8221;) will be converted into the right to receive shares of the common stock, par value $0.001 per share, of Frequency (&#8220;Frequency Common Stock&#8221;), (ii) Korro will effect the conversion of all outstanding shares of the preferred stock, par value $0.001 per share, of Korro (&#8220;Korro Preferred Stock&#8221;) into shares of Korro Common Stock immediately prior to the effective time of the Merger, (iii)&#160;Korro options and warrants will be converted into options and warrants to acquire shares of Frequency Common Stock (as applicable, &#8220;Korro Assumed Options&#8221; or &#8220;Korro Assumed Warrants&#8221;), (iv) Frequency may dispose of its assets and rights relating to its MS remyelination program (the &#8220;MS Assets&#8221;) and holders of Frequency Common Stock may receive contingent value rights relating to the net proceeds received from any such disposition (or commercialization of such program) to the extent consummated following consummation of the Merger (&#8220;Frequency CVRs&#8221;), (v) Korro will consummate a financing immediately prior to the effective time of the Merger through the sale of its capital stock for aggregate gross proceeds of at least $100&#160;million based on a <span style="white-space:nowrap">pre-money</span> equity valuation for Korro equal to the Korro Equity Value (the &#8220;Concurrent Financing&#8221;) and (vi)&#160;Frequency will effect a reverse stock split of all outstanding shares of Frequency Common Stock after giving effect to the Concurrent Financing and the Merger (the transactions described in the foregoing clauses (i)&#160;through (vi) and the other transactions contemplated by the Merger Agreement (other than the Merger), collectively, the &#8220;related transactions&#8221;). The terms and conditions of the Merger and the related transactions are more fully set forth in the Merger Agreement and related documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC (&#8220;we&#8221; or &#8220;TD Cowen&#8221;), as part of its investment banking business, is continually engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. In the ordinary course of our business, we and our affiliates may actively trade the securities of Frequency and/or its affiliates for our own account and for the accounts of our customers and, accordingly, may at any time hold a long or short position in such securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as financial advisor to Frequency in connection with the Merger and will receive a fee from Frequency for our services, a significant portion of which is contingent upon consummation of the Merger. We also will receive a fee in connection with this Opinion. In addition, Frequency has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. Although TD Cowen has </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not had a material relationship with Frequency unrelated to the Merger or Korro during the two years preceding the date of this Opinion, TD Cowen in the future may provide services to Frequency, Korro and/or their respective affiliates and may receive compensation for the rendering of such services. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our Opinion, we have reviewed and considered such financial and other matters as we have deemed relevant, including, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an execution version, provided to us on July&#160;13, 2023, of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain publicly available financial and other information for Frequency and certain other relevant financial and operating data furnished to TD Cowen by the management of Frequency; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain financial and other information for Korro and certain other relevant financial and operating data furnished to TD Cowen by the managements of Frequency and Korro; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain internal financial analyses, probability-adjusted financial forecasts, reports and other information concerning Korro prepared by the management of Korro as adjusted by the management of Frequency (as adjusted, the &#8220;Korro Forecasts&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussions we have had with certain members of the managements of Frequency and Korro,<span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top"> </sup></span>as the case may be, concerning the historical and current business operations, financial conditions and prospects of Frequency and Korro and such other matters that we deemed relevant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain operating results of, and financial and stock market information for, Korro<sup style="font-size:75%; vertical-align:top"> </sup>as compared to similar information for certain publicly traded companies that we deemed relevant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such other information, financial studies, analyses and investigations and such other factors that we deemed relevant for the purposes of this Opinion. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conducting our review and arriving at our Opinion, we have, at your direction, assumed and relied, without independent investigation, upon the accuracy and completeness of all financial and other information provided to us by Frequency and Korro or which is publicly available or was otherwise reviewed by us. We have not undertaken any responsibility for the accuracy, completeness or reasonableness of, or independent verification of, such information. We have relied upon the respective representations of Frequency and Korro<sup style="font-size:75%; vertical-align:top"> </sup>that all information provided to us by Frequency and Korro is accurate and complete in all material respects and we expressly disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our Opinion of which we become aware after the date hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been advised, given that Frequency&#8217;s assets and liabilities are comprised solely of cash (net of liabilities) and the MS Assets (which currently are contemplated to be sold) and that Frequency is not expected to have any continuing business operations on a standalone basis other than those incidental to Frequency&#8217;s status as a publicly traded company, that the management of Frequency has not prepared financial forecasts relating to Frequency. Accordingly, we have not performed a financial analysis of Frequency or Frequency CVRs. We also have assumed, at your direction, that the Korro<sup style="font-size:75%; vertical-align:top"> </sup>Forecasts (as adjusted by the management of Frequency) were reasonably prepared by the managements of Frequency and Korro, as the case may be, on bases reflecting the best currently available estimates and good faith judgments of such managements as to the future performance of Korro and the other matters covered thereby, and that such Korro Forecasts utilized in our analyses provide a reasonable basis for our Opinion. We have relied on the assessments of the managements of Frequency and Korro<sup style="font-size:75%; vertical-align:top"> </sup>as to, among other things, (i)&#160;the product pipeline, future products, technology and intellectual property of Korro, including the viability of and risks associated with such product pipeline, future products, technology and intellectual property, and (ii)&#160;the terms of the Concurrent Financing, including with respect to the timing, amount, valuation and other terms involved and potential impact thereof. We have assumed that there will be no developments with respect to any such matters that would have an adverse effect on Korro, Frequency, the Merger or the related transactions (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to our analyses or Opinion. We express no opinion as to the Korro Forecasts or the assumptions on which they are based. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have assumed that there have been no material changes in the assets, liabilities, financial condition, results of operations, businesses or prospects of Korro or Frequency since the dates of the last financial statements made available to us. We have not made or obtained any independent evaluations, valuations or appraisals of the assets or liabilities (contingent, accrued, derivative, <span style="white-space:nowrap">off-balance</span> sheet or otherwise) of Korro, Frequency or any other entity, nor have we been furnished with such materials. We have not conducted nor have we assumed any obligation to conduct any physical inspection of the properties or facilities of Korro, Frequency or any other entity. We also have not evaluated the solvency or fair value of Korro, Frequency or any other entity under any state, federal or foreign laws relating to bankruptcy, insolvency or similar matters. In addition, we have not undertaken an independent evaluation of any actual or potential litigation, settlements, governmental or regulatory proceedings or investigations, possible unasserted claims or other contingent liabilities to which Korro, Frequency or any other entity may be a party or subject. We have assumed that the Merger will qualify for the intended tax treatment contemplated by the Merger Agreement. Our Opinion does not address any legal, tax, accounting or regulatory matters related to the Merger Agreement, the Merger or any related transactions, as to which we have assumed that Frequency and the Board of Directors have received such advice from legal, tax, accounting and regulatory advisors as each has determined appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Opinion addresses only the fairness of the Korro Equity Value, from a financial point of view, to Frequency. We express no view as to any related transactions, Frequency CVRs or any other aspect or implication of the Merger, including, without limitation, any support or <span style="white-space:nowrap">lock-up</span> agreements, subscription agreements or any other agreement, arrangement or understanding entered into in connection with the Merger, any related transactions or otherwise. Our Opinion is necessarily based upon economic and market conditions and other circumstances as they exist and can be evaluated by us on the date hereof. It should be understood that although subsequent developments may affect our Opinion, we do not have any obligation to update, revise or reaffirm our Opinion and we expressly disclaim any responsibility to do so. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not considered any potential legislative or regulatory changes currently being considered or recently enacted by the United States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission, the Financial Accounting Standards Board, or any similar foreign regulatory body or board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of rendering our Opinion, we have assumed in all respects material to our analyses that the representations and warranties of each party contained in the Merger Agreement are true and correct, that each party will perform all of the covenants and agreements required to be performed by it under the Merger Agreement and that all conditions to the consummation of the Merger and the related transactions will be satisfied without waiver thereof. We also have assumed that the final executed form of the Merger Agreement will be substantially similar to the execution version reviewed by us. We further have assumed that all governmental, regulatory and other consents and approvals contemplated by the Merger Agreement will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed or waivers made that would have an adverse effect on Korro, Frequency, the Merger or the related transactions (including the contemplated benefits thereof). In addition, we have assumed that the Merger and the related transactions will be consummated in a manner that complies with the applicable provisions of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and all other applicable state or federal statutes, rules and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is understood that our Opinion is intended for the benefit and use of the Board of Directors (in its capacity as such) in its evaluation of the Korro Equity Value. Our Opinion should not be disclosed, referred to, or communicated (in whole or in part) to any third party for any purpose whatsoever except with our prior written approval. However, our Opinion may be reproduced in full in any proxy statement or registration statement relating to the Merger that Frequency is required to file under the Securities Exchange Act of 1934, as amended, and mail to securityholders of Frequency. Our Opinion does not constitute a recommendation to the Board of Directors on whether or not to approve the Merger or any related transactions or to any securityholder or any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other person as to how to vote or act with respect to the Merger, any related transactions or otherwise. We are not expressing any opinion as to the actual value, price or trading range of any securities of Frequency (including Frequency Common Stock and Frequency CVRs) or Korro (including Korro Common Stock, Korro Preferred Stock, Korro Assumed Options and Korro Assumed Warrants) upon or following announcement or consummation of the Merger and the related transactions. We have not been requested to opine as to, and our Opinion does not in any manner address, Frequency&#8217;s underlying business decision to effect the Merger or the related transactions or the relative merits of the Merger or the related transactions as compared to other business strategies or transactions that might be available to Frequency, including a liquidation of Frequency. In addition, we have not been requested to opine as to, and our Opinion does not in any manner address, (i)&#160;the fairness of the amount or nature of the compensation to the officers, directors or employees, or class of such persons, of any parties to the Merger or any related transactions relative to the Korro Equity Value or otherwise or (ii)&#160;the fairness of the Merger, any related transactions or the Korro Equity Value to the holders of any class of securities, creditors or other constituencies of Frequency or Korro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of this Opinion was reviewed and approved by TD Cowen&#8217;s Fairness Opinion Review Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein, it is our opinion that, as of the date hereof, the Korro Equity Value provided for pursuant to the Merger Agreement is fair, from a financial point of view, to Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COWEN AND COMPANY, LLC </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_156">Annex C </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Execution Version </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">KORRO BIO, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SUPPORT AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THIS SUPPORT AGREEMENT</span> (this &#8220;<span style="text-decoration:underline">Agreement</span>&#8221;), dated as of July&#160;14, 2023 is made by and among Frequency Therapeutics, Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Frequency</span>&#8221;), Korro Bio, Inc., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;), and the undersigned holders (each a &#8220;<span style="text-decoration:underline">Stockholder</span>&#8221;) of shares of capital stock (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, Frequency, Frequency Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Frequency (&#8220;<span style="text-decoration:underline">Merger Sub</span>&#8221;), and the Company, have entered into an Agreement and Plan of Merger, dated of even date herewith (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), providing for the merger of Merger Sub with and into the Company (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, each Stockholder beneficially owns and has sole or shared voting power with respect to the number of Shares, and holds Korro Options to acquire the number of Shares, indicated opposite such Stockholder&#8217;s name on <span style="text-decoration:underline">Schedule</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span><sup style="font-size:75%; vertical-align:top"> </sup>attached hereto; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, as an inducement and a condition to the willingness of the Company to enter into the Merger Agreement, each Stockholder has agreed to enter into and perform this Agreement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, all capitalized terms used in this Agreement without definition herein shall have the meanings ascribed to them in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOW, THEREFORE</span>, in consideration of, and as a condition to, the Company&#8217;s entering into the Merger Agreement, each Stockholder, Frequency and the Company agree as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Agreement to Vote Shares</span>. Each Stockholder agrees that, prior to the Expiration Date (as defined in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2</span> below), at any meeting of the stockholders of the Company or any adjournment or postponement thereof, or in connection with any written consent of the stockholders of the Company, with respect to the Merger, the Merger Agreement or any Acquisition Proposal, such Stockholder shall: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;appear at such meeting or otherwise cause the Shares and any New Shares (as defined in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> below) to be counted as present thereat for purposes of calculating a quorum; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;from and after the date hereof until the Expiration Date, vote (or cause to be voted), or deliver a written consent (or cause a written consent to be delivered) covering all of the Shares and any New Shares that Stockholder shall be entitled to so vote: (i)&#160;in favor of all of the matters set forth in the Korro Stockholder Written Consent; (ii)&#160;against any Acquisition Proposal, or any agreement, transaction or other matter that is intended to, or would reasonably be expected to, impede, interfere with, delay, postpone, discourage or materially and adversely affect the consummation of the Merger, the Concurrent Financing and all of the other Contemplated Transactions; and (iii)&#160;to approve any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes for the adoption of the Merger Agreement on the date on which such meeting is held. Stockholder shall not take or commit or agree to take any action inconsistent with the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Expiration Date</span>. As used in this Agreement, the term &#8220;<span style="text-decoration:underline">Expiration Date</span>&#8221; shall mean the earlier to occur of (a)&#160;the Effective Time, (b)&#160;such date and time as the Merger Agreement shall be terminated pursuant to <span style="text-decoration:underline">Article VIII</span> thereof or otherwise, (c)&#160;any amendment to the Merger Agreement is effected without the Stockholder&#8217;s written consent that decreases the amount, or changes the form, of consideration payable to all stockholders of the Company pursuant to the terms of the Merger Agreement or (d)&#160;the mutual written agreement of the parties to terminate this Agreement. </p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Additional Acquisitions</span>. Each Stockholder agrees that any shares of capital stock or other equity securities of the Company that such Stockholder acquires or with respect to which such Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution of this Agreement and prior to the Expiration Date, whether by the exercise of any Korro Options or otherwise, including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares (&#8220;<span style="text-decoration:underline">New Shares</span>&#8221;), shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted the Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Agreement to Retain Shares</span>. From and after the date hereof until the Expiration Date, each Stockholder shall not, directly or indirectly, (a)&#160;sell, assign, transfer, tender, or otherwise dispose of (including, without limitation, by the creation of any Liens (as defined in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5(c)</span> below)) any Shares or any New Shares, (b)&#160;deposit any Shares or New Shares into a voting trust or enter into a voting agreement or similar arrangement with respect to such Shares or New Shares or grant any proxy or power of attorney with respect thereto (other than this Agreement), (c)&#160;enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect sale, transfer, assignment or other disposition of (including, without limitation, by the creation of any Liens) any Shares or New Shares, or (d)&#160;take any action that would make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of preventing or disabling such Stockholder from performing such Stockholder&#8217;s obligations under this Agreement. Any action taken in violation of the foregoing sentence shall be null and void <span style="font-style:italic">ab initio</span>. Notwithstanding the foregoing, each Stockholder may make (1)&#160;transfers by will or by operation of Law or other transfers for estate-planning purposes, in which case this Agreement shall bind the transferee, (2)&#160;with respect to such Stockholder&#8217;s Korro Options (and any Shares underlying such Korro Options) which expire on or prior to the Expiration Date, transfers, sale, or other disposition of Shares to Korro (or effecting a &#8220;net exercise&#8221; of a Korro Option) as payment for the (i)&#160;exercise price of such Stockholder&#8217;s Korro Options and (ii)&#160;taxes applicable to the exercise of such Stockholder&#8217;s Korro Options, (3)&#160;if Stockholder is an entity, partnership or limited liability company, a transfer to one or more equityholders, partners or members of Stockholder or to an Affiliated person, corporation, trust or other Entity controlling or under common control with Stockholder, or if Stockholder is a trust, a transfer to a beneficiary, provided that in each such case the applicable transferee has signed a voting agreement in substantially the form hereof, (4)&#160;make transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement, and (5)&#160;transfers, sales or other dispositions as the Company may otherwise agree in writing in its sole discretion. If any voluntary or involuntary transfer of any Shares covered hereby shall occur (including a transfer or disposition permitted by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4(1)</span> through <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4(5)</span>, sale by a Stockholder&#8217;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#8217;s or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect, notwithstanding that such transferee is not a Stockholder and has not executed a counterpart hereof or joinder hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Representations and Warranties of Stockholder</span>. Each Stockholder hereby, severally but not jointly, represents and warrants to Frequency and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;If such Stockholder is an Entity: (i)&#160;such Stockholder is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, organized or constituted, (ii)&#160;such Stockholder has all necessary power and authority to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby, and (iii)&#160;the execution and delivery of this Agreement, performance of such Stockholder&#8217;s obligations hereunder and the consummation of the transactions contemplated hereby by such Stockholder have been duly authorized by all necessary action on the part of such Stockholder and no other proceedings on the part of such Stockholder are necessary to authorize this Agreement, or to consummate the transactions contemplated hereby. If such Stockholder is an individual, such Stockholder has the legal capacity to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby; </p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;this Agreement has been duly executed and delivered by or on behalf of such Stockholder and, to such Stockholder&#8217;s knowledge and assuming this Agreement constitutes a valid and binding agreement of the Company and Frequency, constitutes a valid and binding agreement with respect to such Stockholder, enforceable against such Stockholder in accordance with its terms, except as enforcement may be limited by general principles of equity whether applied in a court of Law or a court of equity and by bankruptcy, insolvency and similar Laws affecting creditors&#8217; rights and remedies generally; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;such Stockholder beneficially owns the number of Shares indicated opposite such Stockholder&#8217;s name on <span style="text-decoration:underline">Schedule</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span>, and will own any New Shares, free and clear of any liens, claims, charges or other encumbrances or restrictions of any kind whatsoever (&#8220;<span style="text-decoration:underline">Liens</span>&#8221;), and has sole or shared, and otherwise unrestricted, voting power with respect to such Shares or New Shares and none of the Shares or New Shares is subject to any voting trust or other agreement, arrangement or restriction with respect to the voting of the Shares or the New Shares, except as contemplated by this Agreement and the stockholder agreements and arrangements referenced in the Merger Agreement and except for customary arrangements with the Stockholder&#8217;s prime broker and/or custodian; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;to the knowledge of such Stockholder, the execution and delivery of this Agreement by such Stockholder does not, and the performance by such Stockholder of his, her or its obligations hereunder and the compliance by such Stockholder with any provisions hereof will not, violate or conflict with, result in a material breach of or constitute a default (or an event that with notice or lapse of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of any Liens on any Shares or New Shares pursuant to, any agreement, instrument, note, bond, mortgage, Contract, lease, license, permit or other obligation or any order, arbitration award, judgment or decree to which such Stockholder is a party or by which such Stockholder is bound, or any Law, statute, rule or regulation to which such Stockholder is subject or, in the event that such Stockholder is a corporation, partnership, trust or other Entity, any bylaw or other Organizational Document of such Stockholder; except for any of the foregoing as would not reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#160;&#160;&#160;&#160;the execution and delivery of this Agreement by such Stockholder does not, and the performance of this Agreement by such Stockholder does not and will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority or regulatory authority by such Stockholder except for applicable requirements, if any, of the Exchange Act, and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#160;&#160;&#160;&#160;no investment banker, broker, finder or other intermediary is entitled to a fee or commission from Frequency or the Company in respect of this Agreement based upon any Contract made by or on behalf of such Stockholder; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#160;&#160;&#160;&#160;as of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of such Stockholder, threatened against such Stockholder that would reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Irrevocable Proxy</span>. Subject to the penultimate sentence of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6</span>, by execution of this Agreement, each Stockholder does hereby appoint the Company and any of its designees with full power of substitution and resubstitution, as such Stockholder&#8217;s true and lawful attorney and irrevocable proxy, to the fullest extent of such Stockholder&#8217;s rights with respect to the Shares, to vote and exercise all voting and related rights, including the right to sign such Stockholder&#8217;s name (solely in its capacity as a stockholder) to any Stockholder consent, if such Stockholder fails to vote his, her or its Shares solely with respect to the matters set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span> hereof by 5:00 p.m. (Eastern Time) on the day immediately preceding the meeting date (or date </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon which written consents are requested to be submitted), provided the Stockholder has received information regarding the meeting or request for written consent at least five (5)&#160;Business Days before such shareholder meeting or any consent solicitation or other vote taken of the Company&#8217;s stockholders . Each Stockholder intends this proxy to be irrevocable and coupled with an interest hereunder until the Expiration Date, hereby revokes any proxy previously granted by such Stockholder with respect to the Shares and represents that none of such previously-granted proxies are irrevocable. The Stockholder hereby affirms that the proxy set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6</span> is given in connection with, and granted in consideration of, and as an inducement to the Company, Frequency and Merger Sub to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span>. The irrevocable proxy and power of attorney granted herein shall survive the death or incapacity of such Stockholder and the obligations of such Stockholder shall be binding on such Stockholder&#8217;s heirs, personal representatives, successors, transferees and assigns. Each Stockholder hereby agrees not to grant any subsequent powers of attorney or proxies with respect to any Shares with respect to the matters set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span> until after the Expiration Date. Notwithstanding anything contained herein to the contrary, this irrevocable proxy shall automatically terminate upon the Expiration Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">[Intentionally Omitted]</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Legal Actions</span>. Each Stockholder will not in its capacity as a stockholder of the Company bring, commence, institute, maintain, prosecute or voluntarily aid any Legal Proceeding which (i)&#160;challenges the validity or seeks to enjoin the operation of any provision of this Agreement or (ii)&#160;alleges that the execution and delivery of this Agreement by such Stockholder, either alone or together with the other voting agreements and proxies to be delivered in connection with the execution of the Merger Agreement, constitutes a breach of any fiduciary duty of the Company Board or any member thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Other Remedies; Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with, and not exclusive of, any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof without the need of posting bond in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at Law or in equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Directors and Officers</span>.&#160;This Agreement shall apply to each Stockholder solely in such Stockholder&#8217;s capacity as a stockholder of the Company and/or holder of Korro Options and/or Korro Warrants and not in such Stockholder&#8217;s capacity as a director, officer or employee of the Company or any of its Subsidiaries or in such Stockholder&#8217;s capacity as a trustee or fiduciary of any employee benefit plan or trust.&#160;Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall (or require Stockholder to attempt to) limit or restrict a director and/or officer of the Company in the exercise of his or her fiduciary duties consistent with the terms of the Merger Agreement as a director and/or officer of the Company or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to create any obligation on the part of any director and/or officer of the Company or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee and/or fiduciary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Ownership Interest</span>.&#160;Nothing contained in this Agreement shall be deemed to vest in the Company any direct or indirect ownership or incidence of ownership of or with respect to any Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to such Stockholder, and the Company does not have authority to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of the Company or exercise any power or authority to direct such Stockholder in the voting of any of the Shares, except as otherwise provided herein. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Termination</span>.&#160;This Agreement shall terminate and shall have no further force or effect as of the Expiration Date.&#160;Notwithstanding the foregoing, upon termination or expiration of this Agreement, no party shall have any further obligations or liabilities under this Agreement; provided, <span style="font-style:italic">however</span><span style="text-decoration:underline">, </span>nothing set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;12</span> or elsewhere in this Agreement shall relieve any party from liability for any fraud or for any willful and material breach of this Agreement prior to termination hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Further Assurances</span>. Each Stockholder shall, from time to time, execute and deliver, or cause to be executed and delivered, such additional or further consents, documents and other instruments as the Company or Frequency may reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement and the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Disclosure</span>. Each Stockholder hereby agrees that Frequency and the Company may publish and disclose in the Proxy Statement, any prospectus filed with any regulatory authority in connection with the Contemplated Transactions and any related documents filed with such regulatory authority and as otherwise required by Law, such Stockholder&#8217;s identity and ownership of Shares and the nature of such Stockholder&#8217;s commitments, arrangements and understandings under this Agreement and may further file this Agreement as an exhibit to the Proxy Statement or prospectus or in any other filing made by Frequency or the Company as required by Law or the terms of the Merger Agreement, including with the SEC or other regulatory authority, relating to the Contemplated Transactions, all subject to prior review and a reasonable opportunity to comment by Stockholder&#8217;s counsel. Prior to the Closing, each Stockholder shall not, and shall use its reasonable best efforts to cause its representatives not to, directly or indirectly, make any press release, public announcement or other public communication without the prior written consent of Frequency and the Company, <span style="font-style:italic">provided</span> that the foregoing shall not limit or affect any actions taken by such Stockholder (or any affiliated officer or director of such Stockholder) that would be permitted to be taken by such Stockholder, Frequency or the Company pursuant to the Merger Agreement; <span style="font-style:italic">provided</span>, <span style="font-style:italic">further</span>, that the foregoing shall not effect any actions of Stockholder the prohibition of which would be prohibited under applicable Law and shall not prohibit Stockholder or its affiliates from making any publicly-available filings required by applicable law, regulation or legal process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Notice</span>. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or sent by overnight courier (providing proof of delivery), by facsimile transmission (providing confirmation of transmission) or by electronic transmission (providing confirmation of transmission) to the Company or Frequency, as the case may be, in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.7</span> of the Merger Agreement and to each Stockholder at his, her or its address or email address (providing confirmation of transmission) set forth on <span style="text-decoration:underline">Schedule</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span> attached hereto (or at such other address for a party as shall be specified by like notice). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Assignability</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties hereto and their respective successors and assigns; <span style="font-style:italic">provided, however</span>, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated by such party without the prior written consent of the other parties hereto, and any attempted assignment or delegation of this </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Waivers</span>. No waivers of any breach of this Agreement extended by the Company or Frequency to such Stockholder shall be construed as a waiver of any rights or remedies of the Company or Frequency, as applicable, with respect to any other stockholder of the Company who has executed an agreement substantially in the form of this Agreement with respect to Shares held or subsequently held by such stockholder or with respect to any subsequent breach of Stockholder or any other such stockholder of the Company. No waiver of any provisions hereof by any party shall be deemed a waiver of any other provisions hereof by any such party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Applicable Law; Jurisdiction</span>. This Agreement shall be governed by, and construed in accordance with, the Laws of the state of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws. In any action or Legal Proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the state of Delaware or to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii)&#160;agrees that all claims in respect of such action or Legal Proceeding shall be heard and determined exclusively in accordance with clause (i)&#160;of this Section&#160;19, (iii)&#160;waives any objection to laying venue in any such action or Legal Proceeding in such courts, (iv)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (v)<span style="text-decoration:underline"></span>&#160;agrees that service of process upon such party in any such action or Legal Proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section&#160;15</span> of this Agreement. Each party irrevocably consents to service of process inside or outside the territorial jurisdiction of the courts referred to in this <span style="text-decoration:underline">Section&#160;19</span> in the manner provided for notices in <span style="text-decoration:underline">Section&#160;15</span>. Nothing in this Agreement will affect the right of any party to serve process in any other manner permitted by applicable Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Waiver of Jury Trial</span>. The parties hereto hereby waive any right to trial by jury with respect to any action or Legal Proceeding related to or arising out of this Agreement, any document executed in connection herewith and the matters contemplated hereby and thereby. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Agreement Until Executed</span>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement shall not constitute or be deemed to evidence a Contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&#160;the Company Board has approved, for purposes of any applicable anti-takeover Laws and regulations and any applicable provision of the certificate of incorporation of the Company, the Merger Agreement and the Contemplated Transactions, (b)&#160;the Merger Agreement is executed by all parties thereto, and (c)&#160;this Agreement is executed by all parties hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Entire Agreement; Counterparts; Exchanges by Facsimile</span>. This Agreement and the other agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission via &#8220;.pdf&#8221; shall be sufficient to bind the parties to the terms and conditions of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.&#160;&#160;&#160;&#160;Amendment. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be modified or waived, except by an instrument in writing signed on behalf of each party hereto; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that the rights or obligations of any Stockholder may be waived, amended or otherwise modified in a writing signed by Frequency, the Company and such Stockholder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Fees and Expenses</span>. Except as otherwise specifically provided herein, the Merger Agreement or any other agreement contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Voluntary Execution of Agreement</span>. This Agreement is executed voluntarily and without any duress or undue influence on the part or behalf of the parties. Each of the parties hereby acknowledges, represents and warrants that (i)&#160;it has read and fully understood this Agreement and the implications and consequences thereof; (ii)&#160;it has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of its own choice, or it has made a voluntary and informed decision to decline to seek such counsel; and (iii)&#160;it is fully aware of the legal and binding effect of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Definition of Merger Agreement</span>. For purposes of this Agreement, the term &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221; may include such agreement as amended or modified as long as such amendments or modifications (a)&#160;do not (i)&#160;change the form or amount of consideration payable under the Merger Agreement, (ii)&#160;extend the Outside Date past November&#160;14, 2023 (other than any extension provided for in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(b)</span> of the Merger Agreement with respect to the Proxy Statement), or (iii)&#160;otherwise change the terms and conditions of the Merger, the Concurrent Financing or the other Contemplated Transaction in a manner materially adverse to such Stockholder or (b)&#160;have been agreed to in writing by such Stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Construction</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; and &#8220;Schedules&#8221; are intended to refer to Sections of this Agreement and Schedules to this Agreement, respectively. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#160;&#160;&#160;&#160;The underlined headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Remainder of Page has Intentionally Been Left Blank</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:19%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:80%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">[STOCKHOLDER]</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Signature:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">Signature Page to Korro Support Agreement</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">FREQUENCY THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><span style="font-size:10pt">Name:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><span style="font-size:10pt">Title:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
</table></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">KORRO BIO, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><span style="font-size:10pt">Name:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><span style="font-size:10pt">Title:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">Signature Page to Korro Support Agreement</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCHEDULE 1 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:58%"></td>

<td style="vertical-align:bottom;width:21%"></td>
<td></td>

<td style="vertical-align:bottom;width:21%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name, Address and Email Address of Stockholder</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares&#160;of&#160;Frequency<br />Common Stock</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Options</span></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_157">Annex&#160;D </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Execution Version </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FREQUENCY THERAPEUTICS, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SUPPORT AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THIS SUPPORT AGREEMENT</span> (this &#8220;<span style="text-decoration:underline">Agreement</span>&#8221;), dated as of July&#160;14, 2023 is made by and among Frequency Therapeutics, Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Frequency</span>&#8221;), Korro Bio, Inc., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;), and the undersigned holders (each a &#8220;<span style="text-decoration:underline">Stockholder</span>&#8221;) of shares of capital stock (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, Frequency, Frequency Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Frequency (&#8220;<span style="text-decoration:underline">Merger Sub</span>&#8221;), and the Company, have entered into an Agreement and Plan of Merger, dated of even date herewith (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), providing for the merger of Merger Sub with and into the Company (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, each Stockholder beneficially owns and has sole or shared voting power with respect to the number of Shares, and holds Frequency Options to acquire the number of Shares, indicated opposite such Stockholder&#8217;s name on <span style="text-decoration:underline">Schedule</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span><sup style="font-size:75%; vertical-align:top"> </sup>attached hereto; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, as an inducement and a condition to the willingness of the Company to enter into the Merger Agreement, each Stockholder has agreed to enter into and perform this Agreement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, all capitalized terms used in this Agreement without definition herein shall have the meanings ascribed to them in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOW, THEREFORE</span>, in consideration of, and as a condition to, the Company&#8217;s entering into the Merger Agreement, each Stockholder, Frequency and the Company agree as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Agreement to Vote Shares</span>. Each Stockholder agrees that, prior to the Expiration Date (as defined in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2</span> below), at any meeting of the stockholders of Frequency or any adjournment or postponement thereof, or in connection with any written consent of the stockholders of Frequency, with respect to the Merger, the Merger Agreement or any Acquisition Proposal, such Stockholder shall: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;appear at such meeting or otherwise cause the Shares and any New Shares (as defined in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> below) to be counted as present thereat for purposes of calculating a quorum; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;from and after the date hereof until the Expiration Date, vote (or cause to be voted), or deliver a written consent (or cause a written consent to be delivered) covering all of the Shares and any New Shares that Stockholder shall be entitled to so vote: (i)&#160;in favor of (A)&#160;all of the Frequency Stockholder Matters and (B)&#160;any matter that could reasonably be expected to facilitate the Merger, the Concurrent Financing and the Contemplated Transactions; (ii)&#160;against any Acquisition Proposal, or any agreement, transaction or other matter that is intended to, or would reasonably be expected to, impede, interfere with, delay, postpone, discourage or materially and adversely affect the consummation of the Merger, the Concurrent Financing and all of the other Contemplated Transactions; and (iii)&#160;to approve any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes for the adoption of the Merger Agreement on the date on which such meeting is held. Stockholder shall not take or commit or agree to take any action inconsistent with the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Expiration Date</span>. As used in this Agreement, the term &#8220;<span style="text-decoration:underline">Expiration Date</span>&#8221; shall mean the earlier to occur&#160;of (a)&#160;the Effective Time, (b)&#160;such date and time as the Merger Agreement shall be terminated pursuant to&#160;<span style="text-decoration:underline">Article&#160;VIII</span> thereof or otherwise, (c)&#160;any amendment to the Merger Agreement is effected without the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholder&#8217;s written consent that increases the amount, or changes the form, of consideration payable to all stockholders of the Company pursuant to the terms of the Merger Agreement or (d)&#160;the mutual written agreement of the parties to terminate this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Additional Acquisitions</span>. Each Stockholder agrees that any shares of capital stock or other equity securities of Frequency that such Stockholder acquires or with respect to which such Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution of this Agreement and prior to the Expiration Date, whether by the exercise of any Frequency Options or otherwise, including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares (&#8220;<span style="text-decoration:underline">New Shares</span>&#8221;), shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted the Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Agreement to Retain Shares</span>. From and after the date hereof until the Expiration Date, each Stockholder shall not, directly or indirectly, (a)&#160;sell, assign, transfer, tender, or otherwise dispose of (including, without limitation, by the creation of any Liens (as defined in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5(c)</span> below)) any Shares or any New Shares, (b)&#160;deposit any Shares or New Shares into a voting trust or enter into a voting agreement or similar arrangement with respect to such Shares or New Shares or grant any proxy or power of attorney with respect thereto (other than this Agreement), (c)&#160;enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect sale, transfer, assignment or other disposition of (including, without limitation, by the creation of any Liens) any Shares or New Shares, or (d)&#160;take any action that would make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of preventing or disabling such Stockholder from performing such Stockholder&#8217;s obligations under this Agreement. Any action taken in violation of the foregoing sentence shall be null and void <span style="font-style:italic">ab initio</span>. Notwithstanding the foregoing, each Stockholder may make (1)&#160;transfers by will or by operation of Law or other transfers for estate-planning purposes, in which case this Agreement shall bind the transferee, (2)&#160;with respect to such Stockholder&#8217;s Frequency Options (and any Shares underlying such Frequency Options) which expire on or prior to the Expiration Date, transfers, sale, or other disposition of Shares to Frequency (or effecting a &#8220;net exercise&#8221; of a Frequency Option) as payment for the (i)&#160;exercise price of such Stockholder&#8217;s Frequency Options and (ii)&#160;taxes applicable to the exercise of such Stockholder&#8217;s Frequency Options, (3)&#160;if Stockholder is an entity, partnership or limited liability company, a transfer to one or more equityholders, partners or members of Stockholder or to an Affiliated person, corporation, trust or other Entity controlling or under common control with Stockholder, or if Stockholder is a trust, a transfer to a beneficiary, provided that in each such case the applicable transferee has signed a voting agreement in substantially the form hereof, (4)&#160;make transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement, and (5)&#160;transfers, sales or other dispositions as the Company may otherwise agree in writing in its sole discretion. If any voluntary or involuntary transfer of any Shares covered hereby shall occur (including a transfer or disposition permitted by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4(1)</span> through <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4(5)</span>, sale by a Stockholder&#8217;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#8217;s or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take&#160;and hold such Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect, notwithstanding that such transferee is not a Stockholder and has not executed a counterpart hereof or joinder hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Representations and Warranties of Stockholder</span>. Each Stockholder hereby, severally but not jointly, represents and warrants to Frequency and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If such Stockholder is an Entity: (i)&#160;such Stockholder is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, organized or constituted, (ii)&#160;such Stockholder has all necessary power and authority to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby, and (iii)&#160;the execution and delivery of this Agreement, performance of such Stockholder&#8217;s obligations hereunder and the consummation of the transactions contemplated hereby by such Stockholder have been duly authorized by all necessary action on the part of such Stockholder and no other proceedings on the part </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of such Stockholder are necessary to authorize this Agreement, or to consummate the transactions contemplated hereby. If&#160;such Stockholder is an individual, such Stockholder has the legal capacity to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Agreement has been duly executed and delivered by or on behalf of such Stockholder and, to such Stockholder&#8217;s knowledge and assuming this Agreement constitutes a valid and binding agreement of the Company and Frequency, constitutes a valid and binding agreement with respect to such Stockholder, enforceable against such Stockholder in accordance with its terms, except as enforcement may be limited by general principles of equity whether applied in a court of Law or a court of equity and by bankruptcy, insolvency and similar Laws affecting creditors&#8217; rights and remedies generally; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such Stockholder beneficially owns the number of Shares indicated opposite such Stockholder&#8217;s name on <span style="text-decoration:underline">Schedule</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span>, and will own any New Shares, free and clear of any liens, claims, charges or other encumbrances or restrictions of any kind whatsoever (&#8220;<span style="text-decoration:underline">Liens</span>&#8221;), and has sole or shared, and otherwise unrestricted, voting power with respect to such Shares or New Shares and none of the Shares or New Shares is subject to any voting trust or other agreement, arrangement or restriction with respect to the voting of the Shares or the New Shares, except as contemplated by this Agreement and the stockholder agreements and arrangements referenced in the Merger Agreement and except for customary arrangements with the Stockholder&#8217;s prime broker and/or custodian; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the knowledge of such Stockholder, the execution and delivery of this Agreement by such Stockholder does not, and the performance by such Stockholder of his, her or its obligations hereunder and the compliance by such Stockholder with any provisions hereof will not, violate or conflict with, result in a material breach of or constitute a default (or an event that with notice or lapse of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of any Liens on any Shares or New Shares pursuant to, any agreement, instrument, note, bond, mortgage, Contract, lease, license, permit or other obligation or any order, arbitration award, judgment or decree to which such Stockholder is a party or by which such Stockholder is bound, or any Law, statute, rule or regulation to which such Stockholder is subject or, in the event that such Stockholder is a corporation, partnership, trust or other Entity, any bylaw or other Organizational Document of such Stockholder; except for any of the foregoing as would not reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the execution and delivery of this Agreement by such Stockholder does not, and the performance of this Agreement by such Stockholder does not and will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority or regulatory authority by such Stockholder except for applicable requirements, if any, of the Exchange Act, and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no investment banker, broker, finder or other intermediary is entitled to a fee or commission from Frequency or the Company in respect of this Agreement based upon any Contract made by or on behalf of such Stockholder; and </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;as of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of such Stockholder, threatened against such Stockholder that would reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Irrevocable Proxy</span>. Subject to the penultimate sentence of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6</span>, by execution of this Agreement, each Stockholder does hereby appoint the Company and any of its designees with full power of substitution and resubstitution, as such Stockholder&#8217;s true and lawful attorney and irrevocable proxy, to the fullest extent of such Stockholder&#8217;s rights with respect to the Shares, to vote and exercise all voting and related rights, including the right to sign such Stockholder&#8217;s name (solely in its capacity as a stockholder) to any Stockholder consent, if such Stockholder fails to vote his, her or its Shares solely with respect to the matters set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span> hereof by 5:00 p.m. (Eastern Time) on the day immediately preceding the meeting date (or date upon which written consents are requested to be submitted), provided the Stockholder has received information regarding the meeting or request for written consent at least five (5)&#160;Business Days before such shareholder meeting or any consent solicitation or other vote taken of the Company&#8217;s stockholders. Each Stockholder intends this proxy to be irrevocable and coupled with an interest hereunder until the Expiration Date, hereby revokes any proxy previously granted by such Stockholder with respect to the Shares and represents that none of such previously-granted proxies are irrevocable. The Stockholder hereby affirms that the proxy set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6</span> is given in connection with, and granted in consideration of, and as an inducement to the Company, Frequency and Merger Sub to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span>. The irrevocable proxy and power of attorney granted herein shall survive the death or incapacity of such Stockholder and the obligations of such Stockholder shall be binding on such Stockholder&#8217;s heirs, personal representatives, successors, transferees and assigns. Each Stockholder hereby agrees not to grant any subsequent powers of attorney or proxies with respect to any Shares with respect to the matters set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span> until after the Expiration Date. Notwithstanding anything contained herein to the contrary, this irrevocable proxy shall automatically terminate upon the Expiration Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">[Intentionally Omitted]</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Legal Actions</span>. Each Stockholder will not in its capacity as a stockholder of Frequency bring, commence, institute, maintain, prosecute or voluntarily aid any Legal Proceeding which (i)&#160;challenges the validity or seeks to enjoin the operation of any provision of this Agreement or (ii)&#160;alleges that the execution and delivery of this Agreement by such Stockholder, either alone or together with the other voting agreements and proxies to be delivered in connection with the execution of the Merger Agreement constitutes a breach of any fiduciary duty of the Frequency Board or any member thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Other Remedies; Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with, and not exclusive of, any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof without the need of posting bond in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at Law or in equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Directors and Officers</span>.&#160;This Agreement shall apply to each Stockholder solely in such Stockholder&#8217;s capacity as a stockholder of Frequency and/or holder of Frequency Options and not in such Stockholder&#8217;s capacity as a director, officer or employee of Frequency or any of its Subsidiaries or in such Stockholder&#8217;s capacity as a trustee or fiduciary of any employee benefit plan or trust.&#160;Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall (or require Stockholder to attempt to) limit or restrict a director and/or officer of Frequency in the exercise of his or her fiduciary duties consistent with the terms of the Merger Agreement as a director and/or officer of Frequency or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to create any obligation on the part of any director and/or officer of Frequency or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee and/or fiduciary. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Ownership Interest</span>.&#160;Nothing contained in this Agreement shall be deemed to vest in the Company any direct or indirect ownership or incidence of ownership of or with respect to any Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to such Stockholder, and the Company does not have authority to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of Frequency or exercise any power or authority to direct such Stockholder in the voting of any of the Shares, except as otherwise provided herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Termination</span>.&#160;This Agreement shall terminate and shall have no further force or effect as of the Expiration Date.&#160;Notwithstanding the foregoing, upon termination or expiration of this Agreement, no party shall have any further obligations or liabilities under this Agreement; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, nothing set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;12</span> or elsewhere in this Agreement shall relieve any party from liability for any fraud or for any willful and material breach of this Agreement prior to termination hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Further Assurances</span>. Each Stockholder shall, from time to time, execute and deliver, or cause to be executed and delivered, such additional or further consents, documents and other instruments as the Company or Frequency may reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement and the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Disclosure</span>. Each Stockholder hereby agrees that Frequency and the Company may publish and disclose in the Proxy Statement, any prospectus filed with any regulatory authority in connection with the Contemplated Transactions and any related documents filed with such regulatory authority and as otherwise required by Law, such Stockholder&#8217;s identity and ownership of Shares and the nature of such Stockholder&#8217;s commitments, arrangements and understandings under this Agreement and may further file this Agreement as an exhibit to the Proxy Statement or prospectus or in any other filing made by Frequency or the Company as required by Law or the terms of the Merger Agreement, including with the SEC or other regulatory authority, relating to the Contemplated Transactions, all subject to prior review and a reasonable opportunity to comment by Stockholder&#8217;s counsel. Prior to the Closing, each Stockholder shall not, and shall use its reasonable best efforts to cause its representatives not to, directly or indirectly, make any press release, public announcement or other public communication without the prior written consent of Frequency and the Company, <span style="font-style:italic">provided</span> that the foregoing shall not limit or affect any actions taken by such Stockholder (or any affiliated officer or director of such Stockholder) that would be permitted to be taken by such Stockholder, Frequency or the Company pursuant to the Merger Agreement; <span style="font-style:italic">provided</span>, <span style="font-style:italic">further</span>, that the foregoing shall not effect any actions of Stockholder the prohibition of which would be prohibited under applicable Law and shall not prohibit Stockholder or its affiliates from making any publicly-available filings required by applicable law, regulation or legal process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Notice</span>. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or sent by overnight courier (providing proof of delivery), by facsimile transmission (providing confirmation of transmission) or by electronic transmission (providing confirmation of transmission) to the Company or Frequency, as the case may be, in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.7</span> of the Merger Agreement and to each Stockholder at his, her or its address or email address (providing confirmation of transmission) set forth on <span style="text-decoration:underline">Schedule</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span> attached hereto (or at such other address for a party as shall be specified by like notice). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Assignability</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties hereto and their respective successors and assigns; <span style="font-style:italic">provided, however</span>, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated by such party without the prior written consent of the other parties hereto, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Waivers</span>. No waivers of any breach of this Agreement extended by the Company or Frequency to such Stockholder shall be construed as a waiver of any rights or remedies of the Company or Frequency, as applicable, with respect to any other stockholder of Frequency who has executed an agreement substantially in the form of this Agreement with respect to Shares held or subsequently held by such stockholder or with respect to any subsequent breach of Stockholder or any other such stockholder of Frequency. No waiver of any provisions hereof by any party shall be deemed a waiver of any other provisions hereof by any such party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Applicable Law; Jurisdiction</span>. This Agreement shall be governed by, and construed in accordance with, the Laws of the state of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws. In any action or Legal Proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the state of Delaware or to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii)<span style="text-decoration:underline"></span>&#160;agrees that all claims in respect of such action or Legal Proceeding shall be heard and determined exclusively in accordance with clause (i)<span style="text-decoration:underline"></span>&#160;of this <span style="text-decoration:underline">Section&#160;19</span>, (iii)<span style="text-decoration:underline"></span>&#160;waives any objection to laying venue in any such action or Legal Proceeding in such courts, (iv)<span style="text-decoration:underline"></span>&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (v)<span style="text-decoration:underline"></span>&#160;agrees that service of process upon such party in any such action or Legal Proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section&#160;15</span> of this Agreement. Each party irrevocably consents to service of process inside or outside the territorial jurisdiction of the courts referred to in this <span style="text-decoration:underline">Section&#160;19</span> in the manner provided for notices in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;15</span>. Nothing in this Agreement will affect the right of any party to serve process in any other manner permitted by applicable Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Waiver of Jury Trial</span>. The parties hereto hereby waive any right to trial by jury with respect to any action or Legal Proceeding related to or arising out of this Agreement, any document executed in connection herewith and the matters contemplated hereby and thereby. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Agreement Until Executed</span>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement shall not constitute or be deemed to evidence a Contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&#160;the Frequency Board has approved, for purposes of any applicable anti-takeover Laws and regulations and any applicable provision of the certificate of incorporation of Frequency, the Merger Agreement and the Contemplated Transactions, (b)&#160;the Merger Agreement is executed by all parties thereto, and (c)&#160;this Agreement is executed by all parties hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Entire Agreement; Counterparts; Exchanges by Facsimile</span>. This Agreement and the other agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. This Agreement may be executed in several counterparts, each of which shall be deemed an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission via &#8220;.pdf&#8221; shall be sufficient to bind the parties to the terms and conditions of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Amendment</span>. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be modified or waived, except by an instrument in writing signed on behalf of each party hereto; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that the rights or obligations of any Stockholder may be waived, amended or otherwise modified in a writing signed by Frequency, the Company and such Stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Fees and Expenses</span>. Except as otherwise specifically provided herein, the Merger Agreement or any other agreement contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Voluntary Execution of Agreement</span>. This Agreement is executed voluntarily and without any duress or undue influence on the part or behalf of the parties. Each of the parties hereby acknowledges, represents and warrants that (i)&#160;it has read and fully understood this Agreement and the implications and consequences thereof; (ii)&#160;it has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of its own choice, or it has made a voluntary and informed decision to decline to seek such counsel; and (iii)&#160;it is fully aware of the legal and binding effect of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Definition of Merger Agreement</span>. For purposes of this Agreement, the term &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221; may include such agreement as amended or modified as long as such amendments or modifications (a)&#160;do not (i)&#160;change the form or amount of consideration payable under the Merger Agreement, (ii)&#160;extend the Outside Date past November&#160;14, 2023 (other than any extension provided for in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.1(b)</span> of the Merger Agreement with respect to the Proxy Statement), or (iii)&#160;otherwise change the terms and conditions of the Merger, the Concurrent Financing or the other Contemplated Transaction in a manner materially adverse to such Stockholder or (b)&#160;have been agreed to in writing by such Stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Construction</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; and &#8220;Schedules&#8221; are intended to refer to Sections of this Agreement and Schedules to this Agreement, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The underlined headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Remainder of Page has Intentionally Been Left Blank</span>] </p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:19%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:74%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5">EXECUTED as of the date first above written.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">[STOCKHOLDER]</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Signature:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Signature Page to Frequency Support Agreement </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first above written. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">FREQUENCY THERAPEUTICS, INC. </span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:18pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">KORRO BIO, INC. </span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Signature Page to Frequency Support Agreement </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">SCHEDULE 1 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:66%"></td>

<td style="vertical-align:bottom;width:17%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:17%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name, Address and Email Address of Stockholder</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares&#160;of&#160;Frequency<br />Common Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Frequency<br />Options</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_158">Annex E </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Final Form</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">CONTINGENT VALUE RIGHTS AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">BETWEEN </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">FREQUENCY THERAPEUTICS, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">COMPUTERSHARE TRUST COMPANY, N.A. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">and COMPUTERSHARE INC., collectively, as Rights Agent </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Dated as of [&#160;<span style="FONT-SIZE:70%">&#9899;</span>&#160;] </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:11%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:79%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxe451428_1">ARTICLE&#160;1 DEFINITIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;1.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_2">Definitions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxe451428_3">ARTICLE&#160;2 CONTINGENT VALUE RIGHTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_4">Holders of CVRs; Appointment of Rights Agent</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_5"><span style="white-space:nowrap">Non-transferable</span></a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_6">No Certificate; Registration; Registration of Transfer; Change of Address</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_7">Payment Procedures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.5</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_8">No Voting, Dividends or Interest; No Equity or Ownership Interest</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.6</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_9">Ability to Abandon CVR</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxe451428_10">ARTICLE&#160;3 THE RIGHTS AGENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_11">Certain Duties and Responsibilities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_12">Certain Rights of Rights Agent</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_13">Resignation and Removal; Appointment of Successor</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_14">Acceptance of Appointment by Successor</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxe451428_15">ARTICLE&#160;4 COVENANTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_16">List of Holders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_17">CVR Committee; Efforts</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_18">Prohibited Actions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxe451428_19">ARTICLE&#160;5 AMENDMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_20">Amendments Without Consent of Holders or Rights Agent</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_21">Amendments with Consent of Holders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_22">Effect of Amendments</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxe451428_23">ARTICLE&#160;6 CONSOLIDATION, MERGER, SALE OR CONVEYANCE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;6.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_24">Frequency May Not Consolidate, Etc.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;6.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_25">Successor Substituted</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxe451428_26">ARTICLE&#160;7 MISCELLANEOUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_27">Notices to Rights Agent and to Frequency</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_28">Notice to Holders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_29">Entire Agreement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_30">Merger or Consolidation or Change of Name of Rights Agent</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.5</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_31">Successors and Assigns</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.6</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_32">Benefits of Agreement; Action by Majority of Holders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.7</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_33">Governing Law</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.8</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_34">Jurisdiction</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.9</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_35"><span style="font-weight:bold">WAIVER OF JURY TRIAL</span></a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_36">Severability Clause</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_37">Counterparts; Effectiveness</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_38">Termination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.13</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_39">Force Majeure</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.14</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxe451428_40">Construction</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM OF </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONTINGENT VALUE RIGHTS AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THIS CONTINGENT VALUE RIGHTS AGREEMENT</span> (this &#8220;<span style="text-decoration:underline">Agreement</span>&#8221;), dated as of <span style="font-weight:bold">[</span><span style="font-weight:bold">&#160;</span><span style="font-weight:bold"></span><span style="FONT-SIZE:70%">&#9899;</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;]</span>, is entered into by and between Frequency Therapeutics, Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Frequency</span>&#8221;), and Computershare Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Computershare</span>&#8221;), and its affiliate, Computershare Trust Company, N.A., a national banking association, collectively, as initial Rights Agent (as defined herein). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PREAMBLE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Frequency, Frequency Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Frequency (&#8220;<span style="text-decoration:underline">Merger Sub</span>&#8221;), and Korro Bio, Inc., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;), have entered into an Agreement and Plan of Merger, dated as of July&#160;14, 2023 (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), pursuant to which Merger Sub will merge with and into the Company (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;), with the Company surviving the Merger as a wholly-owned subsidiary of Frequency (the &#8220;<span style="text-decoration:underline">Surviving Corporation</span>&#8221;); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the Merger Agreement, Frequency has agreed to provide to the Holders (as defined herein) contingent value rights as hereinafter described; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties have done all things necessary to make the contingent value rights, when issued pursuant to this Agreement, the valid obligations of Frequency and to make this Agreement a valid and binding agreement of Frequency, in accordance with its terms; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders, as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxe451428_1">ARTICLE&#160;1 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DEFINITIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_2">Section&#160;1.1 <span style="font-style:italic">Definitions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement. The following terms have the meanings ascribed to them as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Business Day</span>&#8221; means any day other than a day on which banks in the State of New York are authorized or obligated to be closed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Closing Date</span>&#8221; means the date on which the Closing actually takes place. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">CVR</span>&#8221; means a contingent contractual right of Holders to receive CVR Payments under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">CVR Payment</span>&#8221; means the CVR Proceeds for a given payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">CVR Period</span>&#8221; means the period beginning immediately following the Effective Time and ending on the tenth anniversary of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">CVR Proceeds</span>&#8221; means, upon the consummation of any MS Asset Disposition following the Closing Date and prior to expiration of the Disposition Period or, if applicable, the fiscal quarter during the CVR Period in which the proceeds of any MS Asset Disposition are received, the amount of Gross Proceeds actually received by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Frequency or any of its Subsidiaries upon such consummation or during the applicable fiscal quarter, less the applicable reasonably documented Permitted Deductions with respect to such Gross Proceeds, in each case as calculated in accordance with GAAP consistently applied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Disposition Period</span>&#8221; means the period beginning on the execution date of the Merger Agreement and ending on the one year anniversary of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Effective Time</span>&#8221; means the time at which the Merger shall become effective at the time of the filing of the Certificate of Merger and the acceptance by the Secretary of State of the State of Delaware, or at such later time as may be specified in such Certificate of Merger with the consent of Frequency and Korro. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Gross Proceeds</span>&#8221; means, without duplication, all cash consideration that is paid to, or is received by, Frequency or any of its Subsidiaries during the CVR Period in consideration for an MS Asset Disposition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Holder</span>&#8221; means, at the relevant time, a Person in whose name CVRs are registered in the CVR Register. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Majority of Holders</span>&#8221; means, at any time, the registered Holder or Holders of more than 50% of the total number of CVRs registered at such time, as set forth on the CVR Register. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">MS Assets</span>&#8221; means the assets, rights and interests held by or on behalf of Frequency or any of its Subsidiaries as of the execution date of the Merger Agreement relating to Frequency&#8217;s MS remyelination program, including but not limited to any such intellectual property rights and data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">MS Asset Disposition</span>&#8221; means the sale, transfer, license, assignment or other divestiture, disposition or commercialization of any MS Assets (including any such sale or disposition of equity securities in any Subsidiary that was established by Frequency during the Disposition Period solely to hold any right, title or interest in or to all or any MS Assets) in a transaction or series of transactions, in each case entered into during the Disposition Period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Officer&#8217;s Certificate</span>&#8221; means a certificate signed by the chief executive officer or the chief financial officer of Frequency, in their respective official capacities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Permitted Deductions</span>&#8221; means the following costs or expenses, without duplication: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">any income Taxes required to be paid in cash by Frequency or any of its Subsidiaries with respect to the taxable year in which such Gross Proceeds were received which income Taxes would not have been required to be paid by Frequency or its applicable Subsidiary but for its receipt of Gross Proceeds; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, that, for purposes of calculating any such income Taxes, (a)&#160;such income Taxes shall be computed after taking into account any net operating loss carryforwards or other Tax attributes (including Tax credits) of Frequency or any of its Subsidiaries that are available to offset income or gain, after taking into account any limits of the usability of such attributes under applicable Law, including under Section&#160;382 of the Code, as reasonably determined by a nationally recognized tax advisor, which Tax attributes were generated either (I)&#160;prior to the Closing Date or (II)&#160;after the Closing Date, in the case of this clause (II)&#160;if such Tax attributes relate to the MS Assets, and (b)&#160;for the avoidance of doubt, any item(s) of income or gain resulting or arising from such Gross Proceeds shall be treated as the first item(s) of income or gain, as applicable, in the applicable taxable year; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">any reasonable and documented <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs and expenses incurred by Frequency or any of its Subsidiaries in respect of its performance of this Agreement following the Closing Date or in respect of its negotiation, execution, delivery or performance of any agreement in connection with the MS Assets (for clarity, including any Sale Agreement), including (i)&#160;any costs related to the prosecution, maintenance or enforcement by Frequency or any of its Subsidiaries of intellectual property rights (but excluding any costs related to a breach of this Agreement by Frequency, including costs incurred in litigation in respect of the same) or (ii)&#160;any costs related to Liabilities of or relating to the MS Assets that remain with Frequency following the consummation of any MS Asset Disposition; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">any reasonable and documented <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs incurred or accrued by Frequency or any of its Subsidiaries in connection with the negotiation, entry into and closing of any MS Asset Disposition, including any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee, service fee, regulatory and other filing fees, or other fee, commission or expense owed to any broker, finder, investment bank, auditor, accountant, counsel, advisor or other third party in relation thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">any Losses incurred and paid or payable by Frequency or any of its Subsidiaries arising out of any third party claims, demands, actions or other proceedings relating to or in connection with any MS Asset Disposition, including in respect of its performance of this Agreement, any Sale Agreement or any other agreement relating to any MS Asset Disposition and Losses actually incurred or paid (or reasonably expected to be actually incurred or paid) in connection with indemnification obligations of Frequency or any of its Subsidiaries set forth in any Sale Agreement or any other agreement relating to any MS Asset Disposition; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">any liabilities borne by Frequency or any of its Subsidiaries pursuant to contracts related to the MS Assets, including costs arising from the termination thereof (in each case only to the extent not included in the calculation of Frequency Net Cash (as defined in the Merger Agreement). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Permitted Transfer</span>&#8221; means a Transfer of one or more CVRs (i)&#160;upon death of a Holder by will or intestacy; (ii)&#160;by instrument to an <span style="font-style:italic">inter vivos</span> or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (iii)&#160;made pursuant to a court order of a court of competent jurisdiction (such as in connection with divorce, bankruptcy or liquidation); (iv) made by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (v)&#160;in the case of CVRs payable to a nominee, from a nominee to a beneficial owner (and, if applicable, through an intermediary) or from such nominee to another nominee for the same beneficial owner, in each case as permitted by The Depository Trust Company; (vi)&#160;to Frequency or its Subsidiaries; or (vii)&#160;as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.6</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Person</span>&#8221; means any individual, partnership, joint venture, limited liability company, firm, corporation, unincorporated association or organization, trust or other entity, and shall include any successor (by merger or otherwise) of any such Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Record Date</span>&#8221; means the close of business on the last Business Day prior to the day on which the Effective Time occurs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Rights Agent</span>&#8221; means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent shall have been appointed pursuant to <span style="text-decoration:underline">Article</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Transfer</span>&#8221; means transfer, pledge, hypothecation, encumbrance, assignment or other disposition (whether by sale, merger, consolidation, liquidation, dissolution, dividend, distribution or otherwise), the offer to make such a transfer or other disposition, and each contract, arrangement or understanding, whether or not in writing, to effect any of the foregoing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxe451428_3">ARTICLE&#160;2 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONTINGENT VALUE RIGHTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_4">Section&#160;2.1 <span style="font-style:italic">Holders of CVRs; Appointment of Rights Agent</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The CVRs shall be issued to the holders of shares of Frequency Common Stock as of the Record Date. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency hereby appoints the Rights Agent to act as rights agent for Frequency in accordance with the express terms and conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_5">Section&#160;2.2 <span style="font-style:italic"><span style="white-space:nowrap">Non-transferable</span></span>.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Holder may not at any time Transfer CVRs, other than pursuant to a Permitted Transfer. Any attempted Transfer that is not a Permitted Transfer, in whole or in part, will be void <span style="font-style:italic">ab initio</span> and of no effect. The CVRs will not be listed on any quotation system or traded on any securities exchange. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_6">Section&#160;2.3 <span style="font-style:italic">No Certificate; Registration; Registration of Transfer; Change of Address</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Holders&#8217; rights and obligations in respect of CVRs derive solely from this Agreement; CVRs will not be evidenced by a certificate or other instrument. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent will maintain an <span style="white-space:nowrap"><span style="white-space:nowrap">up-to-date</span></span> register (the &#8220;<span style="text-decoration:underline">CVR Register</span>&#8221;) for the purposes of (i)&#160;identifying the Holders of CVRs, (ii)&#160;determining Holders&#8217; entitlement to CVRs and (iii)&#160;registering the CVRs and Permitted Transfers thereof. The CVR Register will initially show one position for the The Depository Trust Company (or its nominee) representing all of the CVRs provided to the holders of shares of Frequency Common Stock held as of the Record Date. Except as expressly provided herein with respect to the rights of the Rights Agent, neither Frequency nor its Subsidiaries will have any responsibility or liability whatsoever to any person other than the Holders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Subject to the restriction on transferability set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2</span>, every request made to Transfer CVRs must be in writing and accompanied by a written instrument of Transfer reasonably acceptable to the Rights Agent, together with the signature guarantee of a guarantor institution which is a participant in a signature guarantee program approved by the Securities Transfer Association (a &#8220;signature guarantee&#8221;) and other requested documentation in a form reasonably satisfactory to the Rights Agent, duly executed and properly completed, as applicable, by the Holder or Holders thereof, or by the duly appointed legal representative, personal representative or survivor of such Holder or Holders, setting forth in reasonable detail the circumstances relating to the Transfer. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination in accordance with its own internal procedures, that the Transfer instrument is in proper form and the Transfer, is a Permitted Transfer and otherwise complies on its face with the other terms and conditions of this Agreement, register the Transfer of the applicable CVRs in the CVR Register. All Transfers of CVRs registered in the CVR Register will be the valid obligations of Frequency, evidencing the same right, and entitling the transferee to the same benefits and rights under this Agreement, as those held by the transferor. Each of Frequency and the Rights Agent may require payment (without duplication) of a sum sufficient to cover any stamp or other transfer Tax or governmental charge that is imposed in connection with (and would not have been imposed but for) any such registration of transfer, unless the transferee shall have established to the reasonable satisfaction of Frequency or the Rights Agent, as applicable, that such Tax, if any, has been paid. No transfer of CVRs shall be valid until registered in the CVR Register and any transfer not duly registered in the CVR Register shall be void. Frequency shall not be responsible for any costs and expenses related to any transfer or assignment of the CVRs (including the cost of any transfer tax). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. Such written request must be duly executed by such Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the CVR Register. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_7">Section&#160;2.4 <span style="font-style:italic">Payment Procedures</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As promptly as practicable (and, in any event, within twenty (20)&#160;days) after the consummation of any MS Asset Dispositions and, in any event, not later than the date that is forty-five (45)&#160;days following the end of each fiscal quarter of Frequency following the Closing in which CVR Proceeds are actually received by Frequency or any of its Subsidiaries, Frequency shall (i)&#160;deliver to the Rights Agent, an Officer&#8217;s Certificate certifying the aggregate amount of (A)&#160;the CVR Proceeds (if any) actually received by Frequency or its Subsidiaries during such fiscal quarter (or, in the case of the first delivery of such an Officer&#8217;s Certificate hereunder, all CVR Proceeds actually received through the end of such fiscal quarter); (B) the Permitted Deductions reflected in such CVR Proceeds; and (C)&#160;the CVR Payment payable to Holders, if any, in </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
respect of such CVR Proceeds, and (ii)&#160;deliver to the Rights Agent, or as the Rights Agent directs, the CVR Payment (if any) by wire transfer of immediately available funds to an account designated in writing by the Rights Agent. Upon receipt of the wire transfer referred to in the foregoing sentence, the Rights Agent shall promptly (and in any event, within ten (10)&#160;Business Days) pay, by check mailed, first-class postage prepaid, to the address of each Holder set forth in the CVR Register at such time or by other method of delivery as specified by the applicable Holder in writing to the Rights Agent, an amount equal to the product determined by multiplying (i)&#160;the quotient determined by dividing (A)&#160;the applicable CVR Payment by (B)&#160;the total number of CVRs registered in the CVR Register at such time, by (ii)&#160;the number of CVRs registered to such Holder in the CVR Register at such time. For the avoidance of doubt Frequency shall have no further liability in respect of the relevant CVR Payment upon delivery of such CVR Payment in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(a)</span> and the satisfaction of each of Frequency&#8217;s obligations set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(a)</span>. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Except to the extent otherwise required pursuant to a change in applicable Law after the date hereof, the parties hereto agree to treat the issuance of the CVRs as not constituting a current distribution and all CVR Payments for all Tax purposes as distributions of money governed by Section&#160;301 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;<span style="text-decoration:underline">Code</span>&#8221;), which will constitute a dividend to the extent payable out of Frequency and its Subsidiaries&#8217; current and accumulated &#8220;earnings and profits&#8221; (pursuant to Section&#160;316 of the Code) in the taxable year in which the CVR Payment is made. The parties hereto will not take any position to the contrary on any Tax Return or for other Tax purposes except as required by a change in applicable Law after the date hereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency and the Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, from any CVR Payment otherwise payable pursuant to this Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payment under any provision of applicable Law relating to Taxes. To the extent that amounts are so deducted and withheld and timely paid over to the appropriate Governmental Authority, such deducted and withheld amounts will be treated for all purposes of this Agreement as having been paid to the Holder in respect of which such deduction and withholding was made. Prior to making any such Tax deductions or withholdings or causing any such Tax deductions or withholdings to be made with respect to any Holder, the Rights Agent will, to the extent reasonably practicable, provide notice to the Holder of such potential Tax deduction or withholding and a reasonable opportunity for the Holder to provide any necessary Tax forms in order to avoid or reduce such withholding amounts; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span> that the time period for payment of a CVR Payment by the Rights Agent set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(a)</span> will be extended by a period equal to any delay caused by the Holder providing such forms; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, <span style="font-style:italic"><span style="text-decoration:underline">further</span></span>, that in no event shall such period be extended for more than ten (10)&#160;Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed to by the Rights Agent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any portion of a CVR Payment that remains undistributed to the Holders six (6)&#160;months after the applicable fiscal quarter end (including by means of uncashed checks or invalid addresses on the CVR Register) will be delivered by the Rights Agent to Frequency or a person nominated in writing by Frequency (with written notice thereof from Frequency to the Rights Agent), and any Holder will thereafter look only to Frequency for payment of such CVR Payment (which shall be without interest). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Neither Frequency nor the Rights Agent will be liable to any Person in respect of any CVR Payment amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable law. In addition to and not in limitation of any other indemnity obligation herein, Frequency agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to Frequency or a public official. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_8">Section&#160;2.5 <span style="font-style:italic">No Voting, Dividends or Interest; No Equity or Ownership Interest</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">CVRs will not represent any equity or ownership interest in Frequency or any of its Subsidiaries or in the Surviving Corporation. The sole right of the Holders to receive property hereunder is the right to receive CVR Payments, if any, in accordance with the terms hereof. It is hereby acknowledged and agreed that a CVR shall not constitute a security of Frequency or any of its Subsidiaries or of the Surviving Corporation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">It is hereby acknowledged and agreed that the CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of Frequency&#8217;s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. Each Holder acknowledges that it is highly possible that there will not be any Gross Proceeds that may be the subject of a CVR Payment Amount. It is further acknowledged and agreed that neither Frequency nor its Subsidiaries owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto intend solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. It is acknowledged and agreed that this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.5(c)</span> is an essential and material term of this Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_9">Section&#160;2.6 <span style="font-style:italic">Ability to Abandon CVR</span>.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Holder may at any time, at such Holder&#8217;s option, abandon all of such Holder&#8217;s remaining rights represented by CVRs by transferring such CVR to Frequency or a person nominated in writing by Frequency (with written notice thereof from Frequency to the Rights Agent) without consideration or compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Frequency of such transfer and cancellation. Nothing in this Agreement is intended to prohibit Frequency or its Subsidiaries from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxe451428_10">ARTICLE&#160;3 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE RIGHTS AGENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_11">Section&#160;3.1 <span style="font-style:italic">Certain Duties and Responsibilities</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the extent such liability arises as a result of the willful misconduct, bad faith or gross negligence of the Rights Agent (in each case as determined by a final <span style="white-space:nowrap">non-appealable</span> judgment of court of competent jurisdiction). Notwithstanding anything in this Agreement to the contrary, any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees paid by Frequency to the Rights Agent during the twelve (12)&#160;months immediately preceding the event for which recovery from the Rights Agent is being sought, except in the case of the willful misconduct, bad faith or fraud of the Rights Agent (in each case as determined by a final <span style="white-space:nowrap">non-appealable</span> judgment of court of competent jurisdiction). Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Frequency or the Company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_12">Section&#160;3.2 <span style="font-style:italic">Certain Rights of Rights Agent</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent may rely and will be protected by Frequency in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document reasonably believed by it in the absence of bad faith to be genuine and to have been signed or presented by or on behalf of Frequency. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent may engage and consult with counsel of its selection, and the advice or opinion of such counsel will, in the absence of bad faith, gross negligence or willful misconduct (in each case, as determined by a final, <span style="white-space:nowrap">non-appealable</span> judgment of a court of competent jurisdiction) on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any permissive rights of the Rights Agent hereunder will not be construed as a duty. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any loss, liability, damage, judgment, fine, penalty, cost or expense (each, a &#8220;<span style="text-decoration:underline">Loss</span>&#8221;) suffered or incurred by the Rights Agent and arising out of or in connection with the Rights Agent&#8217;s performance of its obligations under this Agreement, including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection in connection with the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been determined by a final <span style="white-space:nowrap">non-appealable</span> decision of a court of competent jurisdiction to have resulted from the Rights Agent&#8217;s gross negligence, bad faith or willful misconduct (in each case, as determined by a final, <span style="white-space:nowrap">non-appealable</span> judgment of a court of competent jurisdiction). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(g)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In addition to the indemnification provided under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(f)</span>, Frequency agrees (i)&#160;to pay the fees of the Rights Agent in connection with the Rights Agent&#8217;s performance of its obligations hereunder, as agreed upon in writing by the Rights Agent and Frequency on or prior to the date of this Agreement, and (ii)&#160;to reimburse the Rights Agent for all reasonable and documented <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder, including all taxes (other than income, receipt, franchise or similar taxes) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement, except that Frequency will have no obligation to pay the fees of the Rights Agent or reimburse the Rights Agent for the fees of counsel in connection with any lawsuit initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(b)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(f)</span>, if Frequency is found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such suit. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(h)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent will not be deemed to have knowledge of any event of which it was supposed to receive notice hereunder but has not received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection therewith, in each case, unless and until it has received such notice in writing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(j)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to Frequency or the Company resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final <span style="white-space:nowrap">non-appealable</span> judgment of a court of competent jurisdiction) in the selection and continued employment thereof. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(k)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency shall perform, acknowledge and deliver or cause to be performed, acknowledged and delivered all such further and other acts, documents, instruments and assurances as may be reasonably required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(l)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by Frequency only. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(m)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent shall act hereunder solely as agent for Frequency and shall not assume any obligations or relationship of agency or trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by Frequency, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Frequency. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(n)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (i)&#160;any guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in substitution for, the foregoing; or (ii)&#160;any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(o)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent shall not be liable or responsible for any failure of Frequency to comply with any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable Law. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(p)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking or omitting any action hereunder, the Rights Agent may (i)&#160;rely upon an Officer&#8217;s Certificate and (ii)&#160;incur no liability and be held harmless by the Company for or in respect of any action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#8217;s Certificate. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(q)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All funds received by Computershare under this Agreement that are to be distributed or applied by Computershare in the performance of services hereunder (the &#8220;<span style="text-decoration:underline">Funds</span>&#8221;) shall be held by Computershare as agent for Frequency and deposited in one or more bank accounts to be maintained by Computershare in its name as agent for Frequency. Until paid pursuant to the terms of this Agreement, Computershare will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1&#160;billion or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&#8217;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). Computershare shall have no responsibility or liability for any diminution of the Funds that may result from any deposit made by Computershare in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party. Computershare may from time to time receive interest, dividends or other earnings in connection with such deposits. Computershare shall not be obligated to pay such interest, dividends or earnings to Frequency, any holder or any other party. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(r)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The obligations of Frequency and the rights of the Rights Agent under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.1</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4</span> shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_13">Section&#160;3.3 <span style="font-style:italic">Resignation and Removal; Appointment of Successor</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent may resign at any time by written notice to Frequency. Any such resignation notice shall specify the date on which such resignation will take effect (which shall be at least thirty (30)&#160;days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (i)&#160;the date so specified and (ii)&#160;the appointment of a successor Rights Agent. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency will have the right to remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date on which such removal will take effect. Such notice will be given at least thirty (30)&#160;days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If the Rights Agent resigns, is removed or becomes incapable of acting, Frequency will promptly appoint a qualified successor Rights Agent. Notwithstanding the foregoing, if Frequency fails to make such appointment within a period of thirty (30)&#160;days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance of such appointment in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.3(c)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.4</span>, become the Rights Agent for all purposes hereunder. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor Rights Agent in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.2</span>. Each notice will include the name and address of the successor Rights Agent. If Frequency fails to send such notice within ten (10)&#160;Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Frequency. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Notwithstanding anything to the contrary in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.3</span>, unless consented to in writing by the Majority of Holders, Frequency will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Rights Agent will reasonably cooperate with Frequency and any successor Rights Agent in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_14">Section&#160;3.4 <span style="font-style:italic">Acceptance of Appointment by Successor</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Frequency and to the resigning or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the Rights Agent; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span> that upon the request of Frequency or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxe451428_15">ARTICLE&#160;4 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">COVENANTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_16">Section&#160;4.1 <span style="font-style:italic">List of Holders</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency will furnish or cause to be furnished to the Rights Agent, in such form as Frequency receives from Frequency&#8217;s transfer agent (or other agent performing similar services for Frequency), the names and addresses of the Holders within fifteen (15)&#160;Business Days following the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_17">Section&#160;4.2 <span style="font-style:italic">CVR Committee; Efforts</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Frequency Board has delegated, to a special committee of the Frequency Board (the &#8220;<span style="text-decoration:underline">Special Committee</span>&#8221;) comprised of [ <span style="FONT-SIZE:70%">&#9899;</span>&#160;]<sup style="font-size:75%; vertical-align:top">1</sup> (the &#8220;<span style="text-decoration:underline">Initial Special Committee Members</span>&#8221;) the sole responsibility, </p></td></tr></table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="text-decoration:underline">Note to Draft</span>: Special Committee to be composed initially of the Frequency Designee, the 2 independent directors and 1 designee of Korro. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
authority and discretion during the Disposition Period with respect to (i)&#160;managing the MS Assets, (ii)&#160;conducting any sale process (including engagement of advisors, upon consent of the Frequency Board, not to be unreasonably withheld, conditioned or delayed) with respect to an MS Asset Disposition during the Disposition Period or (iii)&#160;otherwise divesting or disposing of the MS Assets during the Disposition Period pursuant to an <span style="white-space:nowrap">out-license</span> with a term of not more than ten (10)&#160;years. The Special Committee shall also be empowered with the authority to authorize and direct any officer of Frequency to negotiate, execute and deliver a definitive written agreement with respect to an MS Asset Disposition in a form approved by the Special Committee and consistent with this Agreement and the Merger Agreement (a &#8220;<span style="text-decoration:underline">Sale Agreement</span>&#8221;) in the name and on behalf of Frequency; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, <span style="font-style:italic"><span style="text-decoration:underline">however</span></span>, that no Sale Agreement shall be entered into without the prior review and approval of the Frequency Board (such approval not to be unreasonably withheld, conditioned or delayed). In the event (A)&#160;any Initial Special Committee Member who is an independent director of the Frequency Board no longer serves on the Special Committee during the Disposition Period, such vacancy on the Special Committee shall be filled with an independent director of the Frequency Board, (B)&#160;the Initial Special Committee Member who was designated by the Company prior to Closing no longer serves on the Special Committee during the Disposition Period, such vacancy on the Special Committee shall be filled with a designee of the post-Closing Frequency Board, and (C)&#160;the Initial Special Committee Member who was designated by Frequency no longer serves on the Special Committee during the Disposition Period, such vacancy on the Special Committee shall be filled with a designee selected by the member of the post-Closing Frequency Board designated by Frequency. In each case of (A)-(C) above, the post-Closing Frequency Board agrees to install the applicable replacement on the Special Committee. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The delegation of responsibility and authority to the Special Committee set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.2(a)</span> shall not be revoked or modified at any time during the Disposition Period; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, that the Special Committee shall automatically dissolve upon expiration of the Disposition Period and shall have no further responsibility or authority thereafter. The Special Committee and Frequency Board shall not have any liability to the Holders for any actions taken or not taken in accordance with this Agreement in respect of the matters expressly contemplated hereby. No provision of this Agreement shall require the Special Committee or any members thereof to expend or risk its, his or her own funds or otherwise incur any financial liability in the performance of any duties hereunder or in the exercise of any rights or powers hereunder. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Holders shall be intended third-party beneficiaries of the provisions of this Agreement; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, that under no circumstances shall the rights of Holders as third-party beneficiaries pursuant to this <span style="text-decoration:underline">Article 4</span> be enforceable by such Holders or any other Person acting for or on their behalf other than the Special Committee (or the Frequency Board if the Special Committee no longer exists). The Special Committee (or the Frequency Board if the Special Committee no longer exists) has the sole power and authority to act on behalf of the Holders in enforcing any of their rights hereunder. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">During the Disposition Period, if and to the extent the Special Committee authorizes and directs the execution and delivery of any Sale Agreement, Frequency will, and will cause its Subsidiaries to, use commercially reasonable efforts to (i)&#160;execute and deliver the Sale Agreement, and (ii)&#160;effectuate the MS Asset Disposition pursuant to such Sale Agreement in accordance with its terms. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Except as expressly set forth in <span style="text-decoration:underline">Article 3</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.2(a)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.2(b)</span>, none of Frequency or any of its Subsidiaries shall have any obligation or liability whatsoever to any Person relating to or in connection with any action, or failure to act, with respect to any MS Asset Disposition. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Subject to the foregoing clause (d)&#160;and the other contractual obligations of Frequency expressly set forth in this Agreement, (i)&#160;the Holders acknowledge that Frequency has a fiduciary obligation to operate its business in the best interests of its stockholders, and any potential obligation to pay CVR Proceeds will not create any express or implied obligation to operate its business in any particular manner in order to maximize such CVR Proceeds, (ii)&#160;except as expressly set forth in this Agreement, the Holders are not relying on any representation of Frequency or any other Person with regard to any MS Asset Disposition or other action involving the MS Assets following the Closing, and neither Frequency nor any other Person has </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
provided, or can provide, any assurance to the Holders that any CVR Proceeds will in fact be earned and paid, and (iii)&#160;none of Frequency or any of its Subsidiaries, officers or directors shall have any obligation or liability whatsoever to any Person relating to or in connection with any action, or failure to act, with respect to any MS Asset Disposition. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(g)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Following the Disposition Period, Frequency shall be permitted to take any action in respect of the MS Assets in order to satisfy any Liabilities of or arising from the MS Assets, including any wind-down or termination Liabilities. For clarity, following the CVR Period and following the Disposition Period without an MS Asset Disposition, Frequency may take any action in respect of the MS Assets in its sole and absolute discretion. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_18">Section&#160;4.3 <span style="font-style:italic">Prohibited Actions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless approved by the Special Committee (or the Frequency Board if the Special Committee no longer exists), Frequency shall not grant any lien, security interest, pledge or similar interest in any MS Assets (other than liens or security interests generally granted with respect to all assets of Frequency, and not specific to the MS Assets, and which do not prohibit the ability of Frequency to complete an MS Asset Disposition and, in connection therewith, to deliver title to the MS Assets to the purchaser thereof, free and clear of such liens and security interests) or any CVR Proceeds. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxe451428_19">ARTICLE&#160;5 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_20">Section&#160;5.1 <span style="font-style:italic">Amendments Without Consent of Holders or Rights Agent</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency, at any time and from time to time, may (without the consent of any Person, other than the Rights Agent, which such consent not to be unreasonably withheld, conditioned, or delayed) enter into one or more amendments to this Agreement for any of the following purposes, without the consent of any of the Holders or the Rights Agent: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.1</span>, to evidence the succession of another person to Frequency and the assumption of any such successor of the covenants of Frequency outlined herein in a transaction contemplated by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.1</span>; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to add to the covenants of Frequency such further covenants, restrictions, conditions or provisions for the protection and benefit of the Holders; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span> that in each case, such provisions shall not adversely affect the interests of the Holders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to cure any ambiguity, to correct or supplement any provision in this Agreement that may be defective or inconsistent with any other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span> that in each case, such provisions shall not adversely affect the interests of the Holders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">as may be necessary or appropriate to ensure that CVRs are not subject to registration under the U.S. Securities Act of 1933, as amended, or the U.S. Securities Exchange Act of 1934, as amended and the rules and regulations made thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(vi)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">as may be necessary or appropriate to ensure that Frequency is not required to produce a prospectus or an admission document in order to comply with applicable Law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(vii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to cancel CVRs (i)&#160;in the event that any Holder has abandoned its rights in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.6</span>, or (ii)&#160;following a transfer of such CVRs to Frequency or its Subsidiaries in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.3</span>; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(viii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">as may be necessary or appropriate to ensure that Frequency complies with applicable Law; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ix)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to effect any other amendment to this Agreement that would provide any additional rights or benefits to the Holders or that does not adversely affect the legal rights under this Agreement of any such Holder. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Promptly after the execution by Frequency of any amendment pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span>, Frequency will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.2</span>. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_21">Section&#160;5.2 <span style="font-style:italic">Amendments with Consent of Holders</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In addition to any amendments to this Agreement that may be made by Frequency without the consent of any Holder or the Rights Agent pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span>, with the consent of the Majority of Holders, Frequency and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Promptly after the execution by Frequency and the Rights Agent of any amendment pursuant to the provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span>, Frequency will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.2</span>. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_22">Section&#160;5.3 <span style="font-style:italic">Effect of Amendments</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the execution of any amendment under this <span style="text-decoration:underline">Article</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5</span>, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of Frequency which states that the proposed supplement or amendment is in compliance with the terms of this <span style="text-decoration:underline">Article</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5</span>, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxe451428_23">ARTICLE&#160;6 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONSOLIDATION, MERGER, SALE OR CONVEYANCE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_24">Section&#160;6.1 <span style="font-style:italic">Frequency May Not Consolidate, Etc.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the CVR Period, Frequency shall not consolidate with or merge into any other Person or convey, transfer or lease all or substantially all of its properties and assets to any Person, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the Person formed by such consolidation or into which Frequency is merged or the Person that acquires by conveyance or transfer, or that leases, all or substantially all of the properties and assets of Frequency (the &#8220;<span style="text-decoration:underline">Surviving Person</span>&#8221;) shall expressly assume Frequency&#8217;s obligations under this Agreement, including payment of amounts on all CVRs in accordance with the applicable terms; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Frequency has delivered to the Rights Agent an Officer&#8217;s Certificate, stating that such consolidation, merger, conveyance, transfer or lease complies with this <span style="text-decoration:underline">Article 6</span>. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_25">Section&#160;6.2 <span style="font-style:italic">Successor Substituted</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any consolidation of or merger by Frequency with or into any other Person, or any conveyance, transfer or lease of the properties and assets substantially as an entirety to any Person in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.1</span>, the Surviving Person shall succeed to, and be substituted for, and may exercise every right and power of, and shall assume all of the obligations of Frequency under this Agreement with the same effect as if the Surviving Person had been named as Frequency herein. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxe451428_26">ARTICLE&#160;7 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">MISCELLANEOUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_27">Section&#160;7.1 <span style="font-style:italic">Notices to Rights Agent and to </span><span style="font-style:italic">Frequency</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests and other communications (each, a &#8220;<span style="text-decoration:underline">Notice</span>&#8221;) to any party hereunder shall be in writing. Such Notice shall be deemed given (a)&#160;on the date of delivery, if delivered in person, by Fedex or other internationally recognized overnight courier service or, (except with respect to any Person other than the Rights Agent), by <span style="white-space:nowrap">e-mail</span> (upon confirmation of receipt) prior to 5:00&#160;p.m. in the time zone of the receiving party or on the next Business Day, if delivered after 5:00&#160;p.m. in the time zone of the receiving party or (b)&#160;on the first Business Day following the date of dispatch, if delivered by FedEx or by other internationally recognized overnight courier service (upon proof of delivery), addressed as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to the Rights Agent, to: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Computershare Trust Company, N.A. </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">150 Royall Street </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canton, MA 02021 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to Frequency, to: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">75 Hayden Ave </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lexington, MA 02421 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: [&#160;<span style="FONT-SIZE:70%">&#9899;</span>&#160;] </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [&#160;<span style="FONT-SIZE:70%">&#9899;</span>&#160;] </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy, which shall not constitute notice, to: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">100 Northern Avenue </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Kingsley L. Taft, Andrew H. Goodman </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: ktaft@goodwinlaw.com, agoodman@goodwinlaw.com </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address or facsimile number as such party may hereafter specify for the purpose by notice to the other parties hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_28">Section&#160;7.2 <span style="font-style:italic">Notice to Holders</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Notices required to be given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at such Holder&#8217;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other Holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_29">Section&#160;7.3 <span style="font-style:italic">Entire Agreement</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As between Frequency and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_30">Section&#160;7.4 <span style="font-style:italic">Merger or Consolidation or Change of Name of Rights Agent</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span> that such Person would be eligible for appointment as a successor Rights Agent under the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.3</span>. The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.4</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_31">Section&#160;7.5 <span style="font-style:italic">Successors and Assigns</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of, the Holders, Frequency and the Rights Agent and their respective successors and assigns. Except for assignments pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.4</span>, the Rights Agent may not assign this Agreement without Frequency&#8217;s prior written consent. Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(a)(ii)</span> and <span style="text-decoration:underline">Article</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6</span> hereof, Frequency may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more of its Affiliates or to any Person with whom Frequency is merged or consolidated, or any entity resulting from any merger or consolidation to which Frequency shall be a party (each, an &#8220;<span style="text-decoration:underline">Assignee</span>&#8221;); <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, <span style="font-style:italic"><span style="text-decoration:underline">however</span></span>, that in connection with any assignment to an Assignee, Frequency shall agree to remain liable for the performance by Frequency of its obligations hereunder (to the extent Frequency exists following such assignment). Frequency or an Assignee may not otherwise assign this Agreement without the prior consent of the Majority of Holders. Any attempted assignment of this Agreement in violation of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.5</span> will be void <span style="font-style:italic">ab initio</span> and of no effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_32">Section&#160;7.6 <span style="font-style:italic">Benefits of Agreement; Action by Majority of Holders</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this Agreement, express or implied, will give to any Person (other than Frequency, the Rights Agent, the Holders and their respective permitted successors and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of Frequency, the Rights Agent, the Holders and their permitted successors and assigns. The Holders will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set forth herein, the Majority of Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_33">Section&#160;7.7 <span style="font-style:italic">Governing Law</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement and the CVRs will be governed by, and construed in accordance with, the laws of the State of Delaware without regard to the conflicts of law rules of such state. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_34">Section&#160;7.8 <span style="font-style:italic">Jurisdiction</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated hereby, each of the parties hereto: (a)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware, County of New Castle, or, if under applicable Law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the District of Delaware (and appellate courts thereof); (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.8</span>; (c) waives any objection to laying venue in any such action or proceeding in such courts; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(d)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; and (e)&#160;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.1</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.2</span> of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_35">Section&#160;7.9 <span style="font-weight:bold"><span style="font-style:italic">WAIVER OF JURY TRIAL</span></span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">EACH OF THE PARTIES HERETO (AND BY ACCEPTING THE CVR&#8217; S, THE HOLDERS) HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I)&#160;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II)&#160;EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III)&#160;EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV)&#160;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <span style="text-decoration:underline">SECTION</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.9</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_36">Section&#160;7.10 <span style="font-style:italic">Severability Clause</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any reason determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, <span style="font-style:italic"><span style="text-decoration:underline">however</span></span>, that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_37">Section&#160;7.11 <span style="font-style:italic">Counterparts; Effectiveness</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_38">Section&#160;7.12 <span style="font-style:italic">Termination</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement will automatically terminate and be of no further force or effect and, except as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2</span>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation therefor, upon the expiration of the CVR Period. The termination of this Agreement will not affect or limit the right of Holders to receive the CVR Payments under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4</span> to the extent earned prior to the termination of this Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_39">Section&#160;7.13 <span style="font-style:italic">Force Majeure</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained herein, none of the Rights Agent, Frequency or any of its Subsidiaries (except as it relates to the obligations of the Company under <span style="text-decoration:underline">Article</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span>) will be liable for any delays or failures in performance resulting from acts beyond its reasonable control including acts of God, pandemics (including <span style="white-space:nowrap">COVID-19),</span> terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunctions of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war or civil unrest. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="anxe451428_40">Section&#160;7.14 <span style="font-style:italic">Construction</span>. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For purposes of this Agreement, whenever the context requires: singular terms will include the plural, and vice versa; the masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will include the masculine and feminine genders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words &#8220;without limitation.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless otherwise specified. The parties hereto and Frequency have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and Frequency and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All references herein to &#8220;$&#8221; are to United States Dollars. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Remainder of page intentionally left blank</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed as of the day and year first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:16%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:83%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">FREQUENCY THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#160;&#160;&#160;&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Title:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">COMPUTERSHARE&#160;TRUST&#160;COMPANY,&#160;N.A.&#160;and</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">COMPUTERSHARE&#160;INC.,&#160;collectively&#160;as&#160;Rights&#160;Agent</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#160;&#160;&#160;&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Title:</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_159">Annex F </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Execution Version</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">LOCK-UP</span> AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">July&#160;14, 2023 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korro Bio, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Kendall Square </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building <span style="white-space:nowrap">600-700,</span> Suite <span style="white-space:nowrap">6-401</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned signatory of this <span style="white-space:nowrap">lock-up</span> agreement (this &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Lock-Up</span> Agreement</span></span>&#8221;) understands that Frequency Therapeutics, Inc., a Delaware corporation (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Frequency</span></span>&#8221;), has entered into an Agreement and Plan of Merger, dated as of July&#160;14, 2023 (as the same may be amended from time to time, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger Agreement</span></span>&#8221;) with Frequency Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Frequency, and Korro Bio, Inc., a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;).&#160;Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition and inducement to each of the parties to enter into the Merger Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Frequency and, solely prior to the Closing, the Company, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Restricted Period</span></span>&#8221;): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Frequency Common Stock or any securities convertible into or exercisable or exchangeable for Frequency Common Stock (including without limitation, Frequency Common Stock or such other securities which may be deemed to be beneficially owned (as such term is used in Rule <span style="white-space:nowrap">13d-3</span> of the Exchange Act) by the undersigned in accordance with the rules and regulations of the SEC and securities of Frequency which may be issued upon exercise of an option to purchase Frequency Common Stock or warrant or settlement of a Frequency Restricted Stock Unit) that are currently or hereafter owned by the undersigned (collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Undersigned&#8217;s Shares</span></span>&#8221;), or publicly disclose the intention to make any such offer, sale, pledge, grant, transfer or disposition; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (i)&#160;above or this clause (ii)&#160;is to be settled by delivery of Frequency Common Stock or other securities, in cash or otherwise; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">make any demand for, or exercise any right with respect to, the registration of any shares of Frequency Common Stock or any security convertible into or exercisable or exchangeable for Frequency Common Stock (other than such rights set forth in the Merger Agreement). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions and obligations contemplated by this <span style="white-space:nowrap">Lock-Up</span> Agreement shall not apply to: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transfers of the Undersigned&#8217;s Shares: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is a <span style="text-decoration:underline">natural person</span>, (A)&#160;to any person related to the undersigned by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Family Member</span></span>&#8221;), or to a trust formed for the direct or indirect benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B)&#160;to the undersigned&#8217;s estate, </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td align="left" style="vertical-align:top">
following the death of the undersigned, by will, intestacy or other operation of Law, (C)&#160;as a bona fide gift or a charitable contribution, as such term is described in Section&#160;501(c)(3) of the Internal Revenue Code of 1986, as amended, (D)&#160;by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement, or (E)&#160;to any partnership, corporation or limited liability company which is controlled by the undersigned and/or by any such Family Member(s); </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is a <span style="text-decoration:underline">corporation</span>, <span style="text-decoration:underline">partnership</span>, <span style="text-decoration:underline">limited liability company</span> or<span style="text-decoration:underline"> other entity</span>, (A)&#160;to another corporation, partnership, limited liability company, or other entity that is an affiliate (as defined under Rule <span style="white-space:nowrap">12b-2</span> of the Exchange Act) of the undersigned, including investment funds or other entities under common control or management or advisement with the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), (B) as a distribution or dividend to equity holders, including, without limitation, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution, as such term is described in Section&#160;501(c)(3) of the Internal Revenue Code of 1986, as amended, (D)&#160;transfers or dispositions not involving a change in beneficial ownership or (E)&#160;with prior written consent of Frequency; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is a <span style="text-decoration:underline">trust</span>, to any grantors or beneficiaries of the trust; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Frequency a <span style="white-space:nowrap">lock-up</span> agreement in the form of this <span style="white-space:nowrap">Lock-Up</span> Agreement with respect to the shares of Frequency Common Stock or such other securities that have been so transferred or distributed; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the exercise of an option to purchase Frequency Common Stock (including a net or cashless exercise of an option to purchase Frequency Common Stock), and any related transfer of shares of Frequency Common Stock to Frequency or sale of Frequency Common Stock in the open market, in each case, for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) during the Restricted Period due as a result of the exercise of such options; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span><span style="text-decoration:underline"></span><span style="font-style:italic"><span style="text-decoration:underline">&#160;that</span></span>, for the avoidance of doubt, the underlying shares of Frequency Common Stock held by the undersigned following such exercise and any such open market sales shall continue to be subject to the restrictions on transfer set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the disposition (including a forfeiture or repurchase) to Frequency of any shares of restricted stock granted pursuant to the terms of any employee benefit plan or restricted stock purchase agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) transfers to Frequency, or sales of Frequency Common Stock in the open market, in connection with the vesting of any restricted stock unit or settlement of any other equity award that represents the right to receive shares of Frequency Common Stock settled in Frequency Common Stock, in each case, to pay any tax withholding obligations due during the Restricted Period; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span><span style="text-decoration:underline"></span><span style="font-style:italic"><span style="text-decoration:underline">&#160;that</span></span>, for the avoidance of doubt, the underlying shares of Frequency Common Stock held by the undersigned following such exercise and any such open market sales shall continue to be subject to the restrictions on transfer set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the establishment of a trading plan pursuant to Rule <span style="white-space:nowrap">10b5-1</span> under the Exchange Act (a &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">10b5-1</span> Plan</span></span>&#8221;) for the transfer of Frequency Common Stock; provided that such plan does not provide for any transfers of Frequency Common Stock during the Restricted Period, or the sale of Frequency Common Stock pursuant to a <span style="white-space:nowrap">10b5-1</span> Plan existing as of the date of the Merger Agreement (which, for clarity, shall not be amended during the Restricted Period, but may be terminated during the Restricted Period); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) transfers, sales, dispositions, or the entering into of transactions (including, without limitation, any swap, hedge or similar agreement) by the undersigned of or relating to shares of capital stock or other securities of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Frequency purchased or acquired by the undersigned on the open market, in a public offering by Frequency, or that otherwise do not involve or relate to shares of Frequency Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Frequency&#8217;s capital stock involving a change of control of Frequency, provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this <span style="white-space:nowrap">Lock-Up</span> Agreement; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) pursuant to an order of a court or regulatory agency. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And <span style="font-style:italic"><span style="text-decoration:underline">provided, further</span></span>, that, with respect to each of (a), (b), (c), (d) and (e)&#160;above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section&#160;16 of the Exchange Act or other public announcement shall be made voluntarily in connection with such transfer or disposition during the Restricted Period; <span style="font-style:italic">provided</span> that (i)&#160;any filing under Section&#160;16 of the Exchange Act made during the Restricted Period shall clearly indicate in the footnotes thereto that such filing relates to the circumstances described in (a), (b), (c), (d) or (e), as applicable and (ii)&#160;the foregoing shall not prevent the undersigned from filing a Form 13F, Schedule 13G or Schedule 13D, or any amendment thereto, or from disclosing its holdings in Frequency as required by law or regulation or its internal disclosure policies in the ordinary course of business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any attempted transfer in violation of this <span style="white-space:nowrap">Lock-Up</span> Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement, and will not be recorded on the share register of Frequency.&#160;In furtherance of the foregoing, the undersigned agrees that Frequency and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this <span style="white-space:nowrap">Lock-Up</span> Agreement.&#160;Frequency may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Frequency Common Stock: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this <span style="white-space:nowrap">Lock-Up</span> Agreement.&#160;All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this <span style="white-space:nowrap">Lock-Up</span> Agreement.&#160;The undersigned understands that Frequency and the Company are proceeding with the Contemplated Transactions in reliance upon this <span style="white-space:nowrap">Lock-Up</span> Agreement. Notwithstanding anything to the contrary contained herein, this letter agreement will automatically terminate and the undersigned shall be released from all obligations under this letter agreement upon the earliest to occur, if any, of (i)&#160;the Company advising the undersigned in writing that it has determined not to proceed with the Contemplated Transactions or (ii)&#160;the Merger Agreement being terminated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any and all remedies herein expressly conferred upon Frequency or the Company will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity, and the exercise by Frequency or the Company of any one remedy will not preclude the exercise of any other remedy.&#160;The undersigned agrees that irreparable damage could occur to Frequency and/or the Company in the event that any provision of this <span style="white-space:nowrap">Lock-Up</span> Agreement were not performed in accordance with its specific terms or were otherwise breached.&#160;It is accordingly agreed that Frequency and the Company shall be entitled to seek an injunction or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
injunctions to prevent breaches of this <span style="white-space:nowrap">Lock-Up</span> Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which Frequency or the Company is entitled at Law or in equity, and the undersigned waives any bond, surety or other security that might be required of Frequency or the Company with respect thereto.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any holder of Frequency&#8217;s securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Frequency (or prior to the Closing, the Company), including through any written consent granted under subparagraph a(ii)(E) above, to sell or otherwise transfer or dispose of shares of Frequency Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder or is granted an early release from the restrictions described herein during the Restricted Period, the same percentage of shares of the Undersigned&#8217;s Shares shall be immediately and fully released from any remaining restrictions set forth herein (the &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Pro-Rata</span> Release</span></span>&#8221;); <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, <span style="font-style:italic"><span style="text-decoration:underline">however</span></span>, that such <span style="white-space:nowrap">Pro-Rata</span> Release shall not be applied unless and until permission or early release has been granted by Frequency, and solely prior to the Closing, the Company, to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holder&#8217;s shares of Frequency Common Stock that, when combined with all such other such permissions and early releases, represent an aggregate amount in excess of 1% of the number of shares of Frequency Common Stock originally subject to a substantially similar agreements. Frequency shall notify the undersigned of any Pro Rata Release of its shares on the same day that any permission that triggers the Pro Rata Release is granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the release of any of the Undersigned&#8217;s Shares from this <span style="white-space:nowrap">Lock-Up</span> Agreement, Frequency will cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned&#8217;s Shares without the restrictive legend above or the withdrawal of any stop transfer instructions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <span style="white-space:nowrap">Lock-Up</span> Agreement and any claim, controversy or dispute arising under or related to this <span style="white-space:nowrap">Lock-Up</span> Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to the conflict of Laws principles thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <span style="white-space:nowrap">Lock-Up</span> Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.&#160;The exchange of a fully executed <span style="white-space:nowrap">Lock-Up</span> Agreement (in counterparts or otherwise) by Frequency, the Company and the undersigned by facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., <span style="text-decoration:underline">www.docusign.com</span>) or electronic transmission in .pdf format shall be sufficient to bind such parties to the terms and conditions of this <span style="white-space:nowrap">Lock-Up</span> Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">(Signature Page Follows) </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:40%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:41%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5">Very truly yours,</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="6"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Print Name of Stockholder:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5">[<span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> ]</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="6"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5">Signature (for individuals):</td></tr>
<tr style="font-size:1px; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="5" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="6"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5">Signature (for entities):</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-size:10pt">Name:</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-size:10pt">Title:</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:76%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accepted and Agreed</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By Frequency Therapeutics, Inc.:</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:76%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accepted and Agreed by</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korro Bio, Inc.:</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature Page to Lock-up Agreement] </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_160">Annex G </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Execution Version </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">LOCK-UP</span> AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">July&#160;14, 2023 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korro Bio, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Kendall Square </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building <span style="white-space:nowrap">600-700,</span> Suite <span style="white-space:nowrap">6-401</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned signatory of this <span style="white-space:nowrap">lock-up</span> agreement (this &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Lock-Up</span> Agreement</span></span>&#8221;) understands that Frequency Therapeutics, Inc., a Delaware corporation (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Frequency</span></span>&#8221;), has entered into an Agreement and Plan of Merger, dated as of July&#160;14, 2023 (as the same may be amended from time to time, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger Agreement</span></span>&#8221;) with Frequency Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Frequency, and Korro Bio, Inc., a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;).&#160;Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition and inducement to each of the parties to enter into the Merger Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Frequency and, solely prior to the Closing, the Company, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Restricted Period</span></span>&#8221;): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Frequency Common Stock or any securities convertible into or exercisable or exchangeable for Frequency Common Stock (including without limitation, Frequency Common Stock or such other securities which may be deemed to be beneficially owned (as such term is used in Rule <span style="white-space:nowrap">13d-3</span> of the Exchange Act) by the undersigned in accordance with the rules and regulations of the SEC and securities of Frequency which may be issued upon exercise of an option to purchase Frequency Common Stock or warrant or settlement of a Frequency Restricted Stock Unit) that are currently or hereafter owned by the undersigned (collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Undersigned&#8217;s Shares</span></span>&#8221;), or publicly disclose the intention to make any such offer, sale, pledge, grant, transfer or disposition; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (i)&#160;above or this clause (ii)&#160;is to be settled by delivery of Frequency Common Stock or other securities, in cash or otherwise; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">make any demand for, or exercise any right with respect to, the registration of any shares of Frequency Common Stock or any security convertible into or exercisable or exchangeable for Frequency Common Stock (other than such rights set forth in the Merger Agreement or, to the extent the undersigned is party to it, the Registration Rights Agreement dated as of [ ], 2023 (as the same may be amended from time to time) between the Company and the other parties thereto)). </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions and obligations contemplated by this <span style="white-space:nowrap">Lock-Up</span> Agreement shall not apply to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">transfers of the Undersigned&#8217;s Shares: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is a <span style="text-decoration:underline">natural person</span>, (A)&#160;to any person related to the undersigned by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Family Member</span></span>&#8221;), or to a trust formed for the direct or indirect benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B)&#160;to the undersigned&#8217;s estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C)&#160;as a bona fide gift or a charitable contribution, as such term is described in Section&#160;501(c)(3) of the Internal Revenue Code of 1986, as amended, (D)&#160;by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement, or (E)&#160;to any partnership, corporation or limited liability company which is controlled by the undersigned and/or by any such Family Member(s); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is a <span style="text-decoration:underline">corporation</span>, <span style="text-decoration:underline">partnership</span>, <span style="text-decoration:underline">limited liability company</span> or<span style="text-decoration:underline"> other entity</span>, (A)&#160;to another corporation, partnership, limited liability company, or other entity that is an affiliate (as defined under Rule <span style="white-space:nowrap">12b-2</span> of the Exchange Act) of the undersigned, including investment funds or other entities under common control or management or advisement with the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), (B) as a distribution or dividend to equity holders, including, without limitation, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution, as such term is described in Section&#160;501(c)(3) of the Internal Revenue Code of 1986, as amended, (D)&#160;transfers or dispositions not involving a change in beneficial ownership or (E)&#160;with prior written consent of Frequency; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is a <span style="text-decoration:underline">trust</span>, to any grantors or beneficiaries of the trust; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Frequency a <span style="white-space:nowrap">lock-up</span> agreement in the form of this <span style="white-space:nowrap">Lock-Up</span> Agreement with respect to the shares of Frequency Common Stock or such other securities that have been so transferred or distributed; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the exercise of an option to purchase Frequency Common Stock (including a net or cashless exercise of an option to purchase Frequency Common Stock), and any related transfer of shares of Frequency Common Stock to Frequency or sale of Frequency Common Stock in the open market, in each case, for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) during the Restricted Period due as a result of the exercise of such options; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span><span style="text-decoration:underline"></span><span style="font-style:italic"><span style="text-decoration:underline">&#160;that</span></span>, for the avoidance of doubt, the underlying shares of Frequency Common Stock held by the undersigned following such exercise and any such open market sales shall continue to be subject to the restrictions on transfer set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the disposition (including a forfeiture or repurchase) to Frequency of any shares of restricted stock granted pursuant to the terms of any employee benefit plan or restricted stock purchase agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) transfers to Frequency, or sales of Frequency Common Stock in the open market, in connection with the vesting of any restricted stock unit or settlement of any other equity award that represents the right to receive shares of Frequency Common Stock settled in Frequency Common Stock, in each case, to pay any tax withholding obligations due during the Restricted Period; <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span><span style="text-decoration:underline"></span><span style="font-style:italic"><span style="text-decoration:underline">&#160;that</span></span>, for the avoidance of doubt, the underlying shares of Frequency Common Stock held by the undersigned following such exercise and any such open market sales shall continue to be subject to the restrictions on transfer set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the establishment of a trading plan pursuant to Rule <span style="white-space:nowrap">10b5-1</span> under the Exchange Act (a &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">10b5-1</span> Plan</span></span>&#8221;) for the transfer of Frequency Common Stock; provided that such plan does not provide for any transfers of Frequency Common Stock during the Restricted Period, or the sale of Frequency Common Stock pursuant to a <span style="white-space:nowrap">10b5-1</span> Plan existing as of the date of the Merger Agreement (which, for clarity, shall not be amended during the Restricted Period, but may be terminated during the Restricted Period); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) transfers, sales, dispositions, or the entering into of transactions (including, without limitation, any swap, hedge or similar agreement) by the undersigned of or relating to shares of capital stock or other securities of Frequency purchased or acquired by the undersigned on the open market, in a public offering by Frequency, or that otherwise do not involve or relate to shares of Frequency Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Frequency&#8217;s capital stock involving a change of control of Frequency, provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this <span style="white-space:nowrap">Lock-Up</span> Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) pursuant to an order of a court or regulatory agency; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) transfers, sales, dispositions, or the entering into of transaction (including, without limitation, any swap, hedge, or similar agreement), by the undersigned relating to shares of Frequency Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company, if any, purchased from the Company pursuant to the Concurrent Financing (as defined in the Merger Agreement) or issued in exchange for, or on conversion or exercise of, any securities issued as part of the Concurrent Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And <span style="font-style:italic"><span style="text-decoration:underline">provided, further</span></span>, that, with respect to each of (a), (b), (c), (d) and (e)&#160;above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section&#160;16 of the Exchange Act or other public announcement shall be made voluntarily in connection with such transfer or disposition during the Restricted Period; <span style="font-style:italic">provided</span> that (i)&#160;any filing under Section&#160;16 of the Exchange Act made during the Restricted Period shall clearly indicate in the footnotes thereto that such filing relates to the circumstances described in (a), (b), (c), (d) or (e), as applicable and (ii)&#160;the foregoing shall not prevent the undersigned from filing a Form 13F, Schedule 13G or Schedule 13D, or any amendment thereto, or from disclosing its holdings in Frequency as required by law or regulation or its internal disclosure policies in the ordinary course of business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any attempted transfer in violation of this <span style="white-space:nowrap">Lock-Up</span> Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement, and will not be recorded on the share register of Frequency.&#160;In furtherance of the foregoing, the undersigned agrees that Frequency and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this <span style="white-space:nowrap">Lock-Up</span> Agreement.&#160;Frequency may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Frequency Common Stock: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this <span style="white-space:nowrap">Lock-Up</span> Agreement.&#160;All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this <span style="white-space:nowrap">Lock-Up</span> Agreement.&#160;The undersigned understands that Frequency and the Company are proceeding with the Contemplated Transactions in reliance upon this <span style="white-space:nowrap">Lock-Up</span> Agreement. Notwithstanding anything to the contrary contained herein, this letter agreement will automatically terminate and the undersigned shall be released from all obligations under this letter agreement upon the earliest to occur, if any, of (i)&#160;the Company advising the undersigned in writing that it has determined not to proceed with the Contemplated Transactions or (ii)&#160;the Merger Agreement being terminated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any and all remedies herein expressly conferred upon Frequency or the Company will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity, and the exercise by Frequency or the Company of any one remedy will not preclude the exercise of any other remedy.&#160;The undersigned agrees that irreparable damage could occur to Frequency and/or the Company in the event that any provision of this <span style="white-space:nowrap">Lock-Up</span> Agreement were not performed in accordance with its specific terms or were otherwise breached.&#160;It is accordingly agreed that Frequency and the Company shall be entitled to seek an injunction or injunctions to prevent breaches of this <span style="white-space:nowrap">Lock-Up</span> Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which Frequency or the Company is entitled at Law or in equity, and the undersigned waives any bond, surety or other security that might be required of Frequency or the Company with respect thereto.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any holder of Frequency&#8217;s securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Frequency (or prior to the Closing, the Company), including through any written consent granted under subparagraph a(ii)(E) above, to sell or otherwise transfer or dispose of shares of Frequency Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder or is granted an early release from the restrictions described herein during the Restricted Period, the same percentage of shares of the Undersigned&#8217;s Shares shall be immediately and fully released from any remaining restrictions set forth herein (the &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Pro-Rata</span> Release</span></span>&#8221;); <span style="font-style:italic"><span style="text-decoration:underline">provided</span></span>, <span style="font-style:italic"><span style="text-decoration:underline">however</span></span>, that such <span style="white-space:nowrap">Pro-Rata</span> Release shall not be applied unless and until permission or early release has been granted by Frequency, and solely prior to the Closing, the Company, to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holder&#8217;s shares of Frequency Common Stock that, when combined with all such other such permissions and early releases, represent an aggregate amount in excess of 1% of the number of shares of Frequency Common Stock originally subject to a substantially similar agreements. Frequency shall notify the undersigned of any Pro Rata Release of its shares on the same day that any permission that triggers the Pro Rata Release is granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the release of any of the Undersigned&#8217;s Shares from this <span style="white-space:nowrap">Lock-Up</span> Agreement, Frequency will cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned&#8217;s Shares without the restrictive legend above or the withdrawal of any stop transfer instructions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <span style="white-space:nowrap">Lock-Up</span> Agreement and any claim, controversy or dispute arising under or related to this <span style="white-space:nowrap">Lock-Up</span> Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to the conflict of Laws principles thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <span style="white-space:nowrap">Lock-Up</span> Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.&#160;The exchange of a fully executed <span style="white-space:nowrap">Lock-Up</span> Agreement (in counterparts or otherwise) by Frequency, the Company and the undersigned by facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., <span style="text-decoration:underline">www.docusign.com</span>) or electronic transmission in .pdf format shall be sufficient to bind such parties to the terms and conditions of this <span style="white-space:nowrap">Lock-Up</span> Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">(Signature Page Follows) </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:40%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:41%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5">Very truly yours,</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="6"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">Print Name of Stockholder:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5">[<span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> ]</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="6"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5">Signature (for individuals):</td></tr>
<tr style="font-size:1px; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="5" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="6"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="5">Signature (for entities):</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-size:10pt">Name:</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-size:10pt">Title:</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:76%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accepted and Agreed</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By Frequency Therapeutics, Inc.:</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:76%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accepted and Agreed by</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korro Bio, Inc.: </p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature Page to Lock-up Agreement] </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_161">Annex H </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">PROPOSED AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CERTIFICATE OF AMENDMENT </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TO </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">RESTATED CERTIFICATE OF INCORPORATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FREQUENCY THERAPEUTICS, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration:underline">Corporation</span>&#8221;), does hereby certify as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="text-decoration:underline">FIRST</span>:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That the Board of Directors of the Corporation duly adopted resolutions recommending and declaring advisable that the Restated Certificate of Incorporation of the Corporation be amended and that such amendment be submitted to the stockholders of the Corporation for their consideration, as follows: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">RESOLVED</span>, that the first sentence of Article FOURTH of the Restated Certificate of Incorporation be, and hereby is, amended and restated in its entirety to read as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#8220;That, effective at 5:00 p.m., Eastern time, on the date this Certificate of Amendment to the Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware (the &#8220;Effective Time&#8221;), a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-[&#160;&#160;&#160;&#160;]</span></span><sup style="font-size:75%; vertical-align:top">1</sup> reverse stock split of the Common Stock (as defined below) shall become effective, pursuant to which each [&#160;&#160;&#160;&#160;]<sup style="font-size:75%; vertical-align:top">1</sup> share of Common Stock issued and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the &#8220;Reverse Stock Split&#8221;). No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, (a)&#160;with respect to holders of one or more certificates, if any, which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, upon surrender after the Effective Time of such certificate or certificates, any holder who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a cash payment (the &#8220;Fractional Share Payment&#8221;) equal to the fraction of which such holder would otherwise be entitled multiplied by the closing price per share of Common Stock on the date of the Effective Time as reported by The Nasdaq Global Select Market (as adjusted to give effect to the Reverse Stock Split); provided that, whether or not fractional shares would be issuable as a result of the Reverse Stock Split shall be determined on the basis of (i)&#160;the total number of shares of Common Stock that were issued and outstanding immediately prior to the Effective Time formerly represented by certificates that the holder is at the time surrendering and (ii)&#160;the aggregate number of shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificates shall have been reclassified; and (b)&#160;with respect to holders of shares of Common Stock in book-entry form in the records of the Corporation&#8217;s transfer agent that were issued and outstanding immediately prior to the Effective Time, any holder who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split (after aggregating all fractional shares), following the Effective Time, shall be entitled to receive the Fractional Share Payment automatically and without any action by the holder. </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Shall be a whole number between and including [<span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>] and [<span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>], which number is referred to as the &#8220;Reverse Split Factor&#8221; (it being understood that any Reverse Split Factor within such range shall, together with the remaining provisions of this Certificate of Amendment not appearing in brackets, constitute a separate amendment being approved and adopted by the Board and stockholders in accordance with Section&#160;242 of the Delaware General Corporation Law). </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The total number of shares of all classes of stock which the Corporation shall have authority to issue is 210,000,000 shares, consisting of (a) 200,000,000 shares of Common Stock, $0.001 par value per share (&#8220;Common Stock&#8221;), and (b) 10,000,000 shares of Preferred Stock, $0.001 par value per share (&#8220;Preferred Stock&#8221;).&#8221; </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="text-decoration:underline">SECOND</span>:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, at a meeting of stockholders of the Corporation, the aforesaid amendment was duly adopted by the stockholders of the Corporation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="text-decoration:underline">THIRD</span>:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Section&#160;242 of the General Corporation Law of the State of Delaware. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its [&#160;&#160;&#160;&#160;] on this [&#160;&#160;&#160;&#160;] day of [&#160;&#160;&#160;&#160;] 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">FREQUENCY THERAPEUTICS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
</table></div>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_162">Annex I </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">2023 STOCK OPTION AND INCENTIVE PLAN</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">KORRO BIO, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">2023 STOCK OPTION AND INCENTIVE PLAN </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">1. <span style="text-decoration:underline">GENERAL PURPOSE OF THE PLAN; DEFINITIONS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the plan is the Korro Bio, Inc. 2023 Stock Option and Incentive Plan (as amended from time to time, the &#8220;Plan&#8221;). The purpose of the Plan is to encourage and enable the officers, employees, <span style="white-space:nowrap">Non-Employee</span> Directors and Consultants of Korro Bio, Inc. (the &#8220;Company&#8221;) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#8217;s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#8217;s behalf and strengthening their desire to remain with the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms shall be defined as set forth below: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Act</span>&#8221; means the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Administrator</span>&#8221; means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two <span style="white-space:nowrap">Non-Employee</span> Directors who are independent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Affiliate</span>&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Award</span>&#8221; or &#8220;<span style="font-style:italic">Awards</span>,&#8221; except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, <span style="white-space:nowrap">Non-Qualified</span> Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Award Agreement</span>&#8221; means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Agreement is subject to the terms and conditions of the Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Board</span>&#8221; means the Board of Directors of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Cash-Based Award</span>&#8221; means an Award entitling the recipient to receive a cash-denominated payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Closing Date</span>&#8221; means the date of the closing of the transactions contemplated by that certain Agreement and Plan of Merger by and among Frequency Therapeutics, Inc., the Company and Frequency Merger Sub Inc., dated as of July&#160;14, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Code</span>&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Consultant</span>&#8221; means a consultant or adviser who provides bona fide services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form <span style="white-space:nowrap">S-8</span> under the Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Dividend Equivalent Right</span>&#8221; means an Award entitling the grantee to receive credits based on ordinary cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Effective Date</span>&#8221; means the date on which the Plan becomes effective as set forth in Section&#160;19. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Exchange Act</span>&#8221; means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Fair Market Value</span>&#8221; of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is listed on the National Association of Securities Dealers Automated Quotation System (&#8220;NASDAQ&#8221;), NASDAQ Global Market, The New York Stock Exchange or another national securities exchange or traded on any established market, the determination shall be made by reference to the closing price. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Incentive Stock Option</span>&#8221; means any Stock Option designated and qualified as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Director</span>&#8221; means a member of the Board who is not also an employee of the Company or any Subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-Qualified</span> Stock Option</span>&#8221; means any Stock Option that is not an Incentive Stock Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Option</span>&#8221; or &#8220;<span style="font-style:italic">Stock Option</span>&#8221; means any option to purchase shares of Stock granted pursuant to Section&#160;5. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Restricted Shares</span>&#8221; means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company&#8217;s right of repurchase. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Restricted Stock Award</span>&#8221; means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Restricted Stock Units</span>&#8221; means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Sale Event</span>&#8221; shall mean (i)&#160;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii)&#160;a merger, reorganization, statutory share exchange, consolidation, or similar transaction pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii)&#160;the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, (iv)&#160;any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company or (v)&#160;the approval by the stockholders of the Company of a complete liquidation or dissolution of the Company. Notwithstanding anything in the foregoing to the contrary, with respect to compensation (A)&#160;that is subject to Section&#160;409A of the Code and (B)&#160;for which a Sale Event would accelerate the timing of payment thereunder, the term &#8220;Sale Event&#8221; shall mean an event that is both (I)&#160;a Sale Event (as defined above) and (II)&#160;a &#8220;change in control event&#8221; (within the meaning of Section&#160;409A of the Code). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Sale Price</span>&#8221; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Section</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;409A</span>&#8221; means Section&#160;409A of the Code and the regulations and other guidance promulgated thereunder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Service Relationship</span>&#8221; means any relationship as an employee, <span style="white-space:nowrap">Non-Employee</span> Director or Consultant of the Company or any Affiliate. Unless as otherwise set forth in the Award Agreement, a Service Relationship shall be deemed to continue without interruption in the event a grantee&#8217;s status changes from full-time employee to part-time employee or a grantee&#8217;s status changes from employee to Consultant or <span style="white-space:nowrap">Non-Employee</span> Director or vice versa, provided that there is no interruption or other termination of Service Relationship in connection with the grantee&#8217;s change in capacity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Stock</span>&#8221; means the Common Stock, par value $0.001 per share, of the Company, subject to adjustments pursuant to Section&#160;3. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Stock Appreciation Right</span>&#8221; means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Subsidiary</span>&#8221; means any corporation or other entity (other than the Company) in which the Company has at least a 50&#160;percent interest, either directly or indirectly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Ten Percent Owner</span>&#8221; means an employee who owns or is deemed to own (by reason of the attribution rules of Section&#160;424(d) of the Code) more than 10&#160;percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Unrestricted Stock Award</span>&#8221; means an Award of shares of Stock free of any restrictions. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">2. <span style="text-decoration:underline">ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT</span> <span style="text-decoration:underline">GRANTEES AND DETERMINE AWARDS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Administration of Plan</span>. The Plan shall be administered by the Administrator. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Powers of Administrator</span>. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&#160;&#160;&#160;&#160;to select the individuals to whom Awards may from time to time be granted; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&#160;&#160;&#160;&#160;to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, <span style="white-space:nowrap">Non-Qualified</span> Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&#160;&#160;&#160;&#160;to determine the number of shares of Stock to be covered by any Award; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&#160;&#160;&#160;&#160;to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Agreements; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&#160;&#160;&#160;&#160;to accelerate at any time the exercisability or vesting of all or any portion of any Award; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&#160;&#160;&#160;&#160;subject to the provisions of Section&#160;5(c) or 6(d), to extend at any time the period in which Stock Options or Stock Appreciation Rights, respectively, may be exercised; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii)&#160;&#160;&#160;&#160;at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Delegation of Authority to Grant Awards</span>. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company, including the Chief Executive Officer of the Company, all or part of the Administrator&#8217;s authority and duties with respect to the granting of Awards to individuals who are (i)&#160;not subject to the reporting and other provisions of Section&#160;16 of the Exchange Act and (ii)&#160;not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator&#8217;s delegate or delegates that were consistent with the terms of the Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Award Agreement</span>. Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event the Service Relationship terminates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Indemnification</span>. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#8217; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#8217;s articles or bylaws or any directors&#8217; and officers&#8217; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#160;&#160;&#160;&#160;<span style="text-decoration:underline"><span style="white-space:nowrap">Non-U.S.</span> Award Recipients</span>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Affiliates operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i)&#160;determine which Affiliates shall be covered by the Plan; (ii)&#160;determine which individuals outside the United States are eligible to participate in the Plan; (iii)&#160;modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable laws; (iv)&#160;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be incorporated into and made part of this Plan); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section&#160;3(a) hereof; and (v)&#160;take any action, before or after<span style="font-weight:bold"> </span>an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">3. <span style="text-decoration:underline">STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Stock Issuable</span>. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares (the &#8220;Initial Limit&#8221;), plus on January&#160;1, 2024 and on each January&#160;1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be cumulatively increased by five percent (5%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December&#160;31, or such lesser number of shares as approved by the Administrator, in all cases subject to adjustment as provided in this Section&#160;3(c) (the &#8220;Annual Increase&#8221;). Subject to such overall limitation, the maximum aggregate number of shares of Stock that may be issued in the form of Incentive Stock Options shall not exceed the Initial Limit cumulatively increased on January&#160;1, 2024 and on each January&#160;1 thereafter by the lesser of the Annual Increase for such year or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Stock, subject in all cases to adjustment as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided in Section&#160;3(c). For purposes of this Plan, the shares of Stock underlying any awards under the Plan and the shares of Common Stock of the Company underlying any awards under the Company&#8217;s 2019 Stock Incentive Plan, Frequency Therapeutics, Inc. 2014 Equity Incentive Plan or the Frequency Therapeutics, Inc. 2019 Incentive Award Plan, each as amended from time to time, that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan and, to the extent permitted under Section&#160;422 of the Code and the regulations promulgated thereunder, the shares of Stock that may be issued as Incentive Stock Options. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award.<sup style="font-size:75%; vertical-align:top"> </sup>The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. Awards that may be settled solely in cash shall not be counted against the share reserve, nor shall they reduce the shares of Stock authorized for grant to a grantee in any calendar year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Maximum Awards to <span style="white-space:nowrap">Non-Employee</span> Directors</span>. Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any <span style="white-space:nowrap">Non-Employee</span> Director for services as a <span style="white-space:nowrap">Non-Employee</span> Director in any calendar year shall not exceed: (i) $1,000,000 in the first calendar year an individual becomes a <span style="white-space:nowrap">Non-Employee</span> Director and (ii) $750,000 in any other calendar year. For the purpose of this limitation, the value of any Award shall be its grant date fair value, as determined in accordance with ASC Topic&#160;718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Changes in Stock</span>. Subject to Section&#160;3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, extraordinary cash dividend, stock split, reverse stock split or other similar change in the Company&#8217;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other <span style="white-space:nowrap">non-cash</span> assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i)&#160;the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options, (ii)&#160;the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii)&#160;the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv)&#160;the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Mergers and Other Transactions</span>. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent that the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Agreement, all Options and Stock Appreciation Rights with time-based vesting conditions or restrictions that are (i)&#160;not vested and/or exercisable immediately prior to the effective time of the Sale Event and (ii)&#160;held by grantees who have had a continuous Service Relationship with the Company or any of its Affiliates for at least one year prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards held by grantees (A)&#160;who have had a continuous Service Relationship with the Company or any of its Affiliates for at least one year prior to the effective time of the Sale Event and (B)&#160;that are subject solely to time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator&#8217;s discretion or to the extent specified in the relevant Award Agreement. In the event of such termination, (i)&#160;the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A)&#160;the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B)&#160;the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii)&#160;each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">4. <span style="text-decoration:underline">ELIGIBILITY</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grantees under the Plan will be such employees, <span style="white-space:nowrap">Non-Employee</span> Directors or Consultants of the Company and its Affiliates as are selected from time to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees, <span style="white-space:nowrap">Non-Employee</span> Directors or Consultants who are providing services only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405 of the Act, unless (i)&#160;the stock underlying the Awards is treated as &#8220;service recipient stock&#8221; under Section&#160;409A or (ii)&#160;the Company has determined that such Awards are exempt from or otherwise comply with Section&#160;409A. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">5. <span style="text-decoration:underline">STOCK OPTIONS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Award of Stock Options</span>. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted under the Plan may be either Incentive Stock Options or <span style="white-space:nowrap">Non-Qualified</span> Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#8220;subsidiary corporation&#8221; within the meaning of Section&#160;424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a <span style="white-space:nowrap">Non-Qualified</span> Stock Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted pursuant to this Section&#160;5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee&#8217;s election, subject to such terms and conditions as the Administrator may establish. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Exercise Price</span>. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section&#160;5 shall be determined by the Administrator at the time of grant but shall not be less than 100&#160;percent of the Fair Market Value on the date of grant. In the case of an Incentive Stock Option that is granted </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than 110&#160;percent of the Fair Market Value on the date of grant. Notwithstanding the foregoing, Stock Options may be granted with an exercise price per share that is less than 100&#160;percent of the Fair Market Value on the date of grant (i)&#160;pursuant to a transaction described in, and in a manner consistent with, Section&#160;424(a) of the Code, (ii)&#160;to individuals who are not subject to U.S. income tax on the date of grant or (iii)&#160;if the Stock Option is otherwise compliant with Section&#160;409A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Option Term</span>. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Exercisability; Rights of a Stockholder</span>. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the date of grant. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Method of Exercise</span>. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Award Agreement: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&#160;&#160;&#160;&#160;In cash, by certified or bank check or other instrument acceptable to the Administrator; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&#160;&#160;&#160;&#160;Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&#160;&#160;&#160;&#160;By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&#160;&#160;&#160;&#160;With respect to Stock Options that are not Incentive Stock Options, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Award Agreement or applicable provisions of laws (including the satisfaction of any taxes that the Company or an Affiliate is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Annual Limit on Incentive Stock Options</span>. To the extent required for &#8220;incentive stock option&#8221; treatment under Section&#160;422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a <span style="white-space:nowrap">Non-Qualified</span> Stock Option. For purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5(f)</span>, Incentive Stock Options will be taken into account in the order in which they were granted, the Fair Market Value of the shares of Stock will be determined as of the time the Stock Option with respect to such shares of Stock is granted, and calculation will be performed in accordance with Section&#160;422 of the Code and Treasury Regulations promulgated thereunder. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">6. <span style="text-decoration:underline">STOCK APPRECIATION RIGHTS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Award of Stock Appreciation Rights</span>. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Exercise Price of Stock Appreciation Rights</span>. The exercise price of a Stock Appreciation Right shall not be less than 100&#160;percent of the Fair Market Value of the Stock on the date of grant. Notwithstanding the foregoing, Stock Appreciation Rights may be granted with an exercise price per share that is less than 100&#160;percent of the Fair Market Value on the date of grant (i)&#160;pursuant to a transaction described in, and in a manner consistent with, Section&#160;424(a) of the Code, (ii)&#160;to individuals who are not subject to U.S. income tax on the date of grant, or (iii)&#160;if the Stock Appreciation Right is otherwise compliant with Section&#160;409A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Grant and Exercise of Stock Appreciation Rights</span>. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section&#160;5 of the Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Terms and Conditions of Stock Appreciation Rights</span>. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">7. <span style="text-decoration:underline">RESTRICTED STOCK AWARDS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Nature of Restricted Stock Awards</span>. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of <span style="white-space:nowrap">pre-established</span> performance goals and objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Rights as a Stockholder</span>. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of vesting conditions, any dividends paid by the Company shall accrue and shall not be paid to the grantee until and to the extent the vesting conditions are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i)&#160;uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section&#160;7(d) below, and (ii)&#160;certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section&#160;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Restrictions</span>. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Agreement. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&#160;16 below, in writing after the Award is issued, if a grantee&#8217;s employment (or other Service Relationship) with the Company and its Affiliates terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#8217;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Vesting of Restricted Shares</span>. The Administrator at the time of grant shall specify the date or dates and/or the attainment of <span style="white-space:nowrap">pre-established</span> performance goals, objectives and other conditions on which the <span style="white-space:nowrap">non-transferability</span> of the Restricted Shares and the Company&#8217;s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such <span style="white-space:nowrap">pre-established</span> performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#8220;vested.&#8221; </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">8. <span style="text-decoration:underline">RESTRICTED STOCK UNITS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Nature of Restricted Stock Units</span>. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Agreement) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of <span style="white-space:nowrap">pre-established</span> performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Restricted Stock Units with deferred settlement dates are subject to Section&#160;409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section&#160;409A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Election to Receive Restricted Stock Units in Lieu of Compensation</span>. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section&#160;409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Rights as a Stockholder</span>. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his or her Restricted Stock Units, subject to the provisions of Section&#160;11 and such terms and conditions as the Administrator may determine. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Termination</span>. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&#160;16 below, in writing after the Award is issued, a grantee&#8217;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Affiliates for any reason. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">9. <span style="text-decoration:underline">UNRESTRICTED STOCK AWARDS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Grant or Sale of Unrestricted Stock</span>. The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">10. <span style="text-decoration:underline">CASH-BASED AWARDS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Grant of Cash-Based Awards</span>. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles the grantee to a payment in cash upon the attainment of specified performance goals, including continued employment (or other Service Relationship). The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">11. <span style="text-decoration:underline">DIVIDEND EQUIVALENT RIGHTS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Dividend Equivalent Rights</span>. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Termination</span>. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&#160;16 below, in writing after the Award is issued, a grantee&#8217;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Affiliates for any reason. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">12. <span style="text-decoration:underline">TRANSFERABILITY OF AWARDS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Transferability</span>. Except as provided in Section&#160;12(b) below or otherwise determined by the Administrator, during a grantee&#8217;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#8217;s legal representative or guardian in the event of the grantee&#8217;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Administrator Action</span>. Notwithstanding Section&#160;12(a), the Administrator, in its discretion, may provide either in the Award Agreement regarding a given Award or by subsequent written approval that the grantee (who </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is an employee or <span style="white-space:nowrap">Non-Employee</span> Director) may transfer his or her <span style="white-space:nowrap">Non-Qualified</span> Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award Agreement. In no event may an Award be transferred by a grantee for value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Family Member</span>. For purposes of Section&#160;12(b), &#8220;family member&#8221; shall mean a grantee&#8217;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, <span style="white-space:nowrap"><span style="white-space:nowrap">mother-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">father-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">son-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">daughter-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">brother-in-law,</span></span> or <span style="white-space:nowrap"><span style="white-space:nowrap">sister-in-law,</span></span> including adoptive relationships, any person sharing the grantee&#8217;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50&#160;percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50&#160;percent of the voting interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Designation of Beneficiary</span>. To the extent permitted by the Company and valid under applicable law, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#8217;s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#8217;s estate or legal heirs. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">13. <span style="text-decoration:underline">TAX WITHHOLDING</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Payment by Grantee</span>. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for tax purposes, pay to the Company or any applicable Affiliate, or make arrangements satisfactory to the Administrator regarding payment of, any U.S. and <span style="white-space:nowrap">non-U.S.</span> federal, state, or local taxes of any kind required by law to be withheld by the Company or any applicable Affiliate with respect to such income. The Company and its Affiliates shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee or to satisfy any applicable withholding obligations by any other method of withholding that the Company and its Affiliates deem appropriate. The Company&#8217;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Payment in Stock</span>. The Administrator may cause any tax withholding obligation of the Company or any applicable Affiliate to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the grantees. The Administrator may also require any tax withholding obligation of the Company or any applicable Affiliate to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company or any applicable Affiliate in an amount that would satisfy the withholding amount due. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">14. <span style="text-decoration:underline">SECTION</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;409A AWARDS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards are intended to be exempt from Section&#160;409A to the greatest extent possible and to otherwise comply with Section&#160;409A. The Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section&#160;409A (a &#8220;409A Award&#8221;), the Award shall be subject to such additional rules and requirements as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specified by the Administrator from time to time in order to comply with Section&#160;409A. In this regard, if any amount under a 409A Award is payable upon a &#8220;separation from service&#8221; (within the meaning of Section&#160;409A) to a grantee who is then considered a &#8220;specified employee&#8221; (within the meaning of Section&#160;409A), then no such payment shall be made prior to the date that is the earlier of (i)&#160;six months and one day after the grantee&#8217;s separation from service, or (ii)&#160;the grantee&#8217;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section&#160;409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section&#160;409A. The Company makes no representation that any or all of the payments or benefits described in the Plan will be exempt from or comply with Section&#160;409A of the Code and makes no undertaking to preclude Section&#160;409A of the Code from applying to any such payment. The grantee shall be solely responsible for the payment of any taxes and penalties incurred under Section&#160;409A. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">15. <span style="text-decoration:underline">TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Termination of Service Relationship</span>. If the grantee&#8217;s Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&#160;&#160;&#160;&#160;a transfer to the Service Relationship of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&#160;&#160;&#160;&#160;an approved leave of absence, if the employee&#8217;s right to <span style="white-space:nowrap">re-employment</span> is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">16. <span style="text-decoration:underline">AMENDMENTS AND TERMINATION</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#8217;s consent. Except as provided in Section&#160;3(c) or 3(d), without prior stockholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect repricing through cancellation and <span style="white-space:nowrap">re-grants</span> or cancellation of Stock Options or Stock Appreciation Rights in exchange for cash or other Awards.&#160;&#160;&#160;&#160;To the extent required under the rules of any securities exchange or market system on which the Stock is listed, or to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section&#160;422 of the Code, Plan amendments shall be subject to approval by Company stockholders. Nothing in this Section&#160;16 shall limit the Administrator&#8217;s authority to take any action permitted pursuant to Section&#160;3(c) or 3(d). </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">17. <span style="text-decoration:underline">STATUS OF PLAN</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#8217;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">18. <span style="text-decoration:underline">GENERAL PROVISIONS</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Distribution</span>. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Issuance of Stock</span>. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#8220;book entry&#8221; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Stockholder Rights</span>. Until Stock is deemed delivered in accordance with Section&#160;18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Other Incentive Arrangements; No Rights to Continued Service Relationship</span>. Nothing contained in this Plan shall prevent the Board from adopting other or additional incentive arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any grantee any right to continued employment or other Service Relationship with the Company or any Affiliate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Trading Policy Restrictions</span>. Option exercises and other Awards under the Plan shall be subject to the Company&#8217;s insider trading policies and procedures, as in effect from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Clawback Policy</span>. Awards under the Plan shall be subject to the Company&#8217;s clawback policy, as in effect from time to time. In addition, the Administrator may impose such other clawback, recovery, or recoupment provisions in an Award Agreement as the Administrator determines necessary or appropriate, including, but not limited to, a reacquisition right in respect of previously acquired shares of Stock or other cash or property upon the occurrence of a termination for &#8220;cause&#8221; under any agreement with the Company or an Affiliate thereof. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Fractional Shares</span>. No fractional Shares shall be issued or delivered pursuant to the Plan or any Award, and the Administrator shall determine whether cash, other securities or other property shall be paid or transferred </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in lieu of any fractional Shares, or whether such fractional Shares or any rights thereto shall be canceled, terminated or otherwise eliminated. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">19. <span style="text-decoration:underline">EFFECTIVE DATE OF PLAN</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall become effective upon the Closing Date subject to stockholder approval in accordance with applicable state law, the Company&#8217;s bylaws and articles of incorporation, and applicable stock exchange rules. No grants of Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">SECTION</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">20. <span style="text-decoration:underline">GOVERNING LAW</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware applied without regard to conflict of law principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY BOARD OF DIRECTORS: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY STOCKHOLDERS: </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_163">Annex J </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">2023 EMPLOYEE STOCK PURCHASE PLAN</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">KORRO BIO, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">2023 EMPLOYEE STOCK PURCHASE PLAN </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Korro Bio, Inc. 2023 Employee Stock Purchase Plan (the &#8220;Plan&#8221;) is to provide eligible employees of Korro Bio, Inc. (the &#8220;Company&#8221;) and each Designated Company (as defined in Section&#160;11) with opportunities to purchase shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January&#160;1, 2024 and each January&#160;1 thereafter until the Plan terminates pursuant to Section&#160;20, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the lesser of (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Common Stock, (ii)&#160;one percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December&#160;31, or (iii)&#160;such lesser number of shares of Common Stock as determined by the Administrator (as defined in Section&#160;1). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan includes two components: a Code Section&#160;423 Component (the &#8220;423 Component&#8221;) and a <span style="white-space:nowrap">non-Code</span> Section&#160;423 Component (the <span style="white-space:nowrap">&#8220;Non-423</span> Component&#8221;). It is intended for the 423 Component to constitute an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423(b) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and the 423 Component shall be interpreted in accordance with that intent. Under the <span style="white-space:nowrap">Non-423</span> Component, which does not qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423(b) of the Code, options will be granted pursuant to rules, procedures or <span style="white-space:nowrap">sub-plans</span> adopted by the Administrator designed to comply with applicable laws or achieve tax and other objectives. Except as otherwise provided herein or by the Administrator, the <span style="white-space:nowrap">Non-423</span> Component will operate and be administered in the same manner as the 423 Component. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning ascribed to them in Section&#160;11. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Administration</span>. The Plan will be administered by the person or persons (the &#8220;Administrator&#8221;) appointed by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) for such purpose. The Administrator has authority at any time to: (i)&#160;adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii)&#160;interpret the terms and provisions of the Plan; (iii)&#160;make all determinations it deems advisable for the administration of the Plan, including to accommodate the specific requirements of applicable laws, regulations and procedures in jurisdictions outside the United States; (iv)&#160;decide all disputes arising in connection with the Plan; and (v)&#160;otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Offerings</span>. The Company may make one or more offerings to eligible employees to purchase Common Stock under the Plan (&#8220;Offerings&#8221;) consisting of one or more Purchase Periods. The Administrator may, in its discretion, determine when each Offering shall occur, including the duration of any Offering, provided that no Offering shall exceed 27 months in duration. Unless as otherwise determined by the Administrator, Participants will only be permitted to participate in one Offering at a time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Eligibility</span>. Except as otherwise determined by the Administrator in advance of an Offering, all individuals classified as employees on the payroll records of the Company and each Designated Company are eligible to participate in any one or more of the Offerings under the Plan (provided, that a Participant is not permitted to participate in multiple Offerings at the same time, unless otherwise determined by the Administrator), provided that as of the first day of the applicable Offering (the &#8220;Offering Date&#8221;), they are customarily employed by the Company or a Designated Company for more than 20 hours a week. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated Company for purposes of the Company&#8217;s or applicable Designated Company&#8217;s payroll system are not considered to be eligible employees of the Company or any Designated Company and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Company for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated Company on the Company&#8217;s or Designated Company&#8217;s payroll system to become eligible to participate in this Plan is through an amendment or subplan to this Plan, duly executed by the Company, which specifically renders such individuals eligible to participate herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Participation</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting an enrollment form to the Company or an agent designated by the Company (in the manner described in Section&#160;4) at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Enrollment</span>. The enrollment form (which may be in an electronic format or such other method as determined by the Company in accordance with the Company&#8217;s practices) will (a)&#160;state a whole percentage to be deducted from an eligible employee&#8217;s Compensation (as defined in Section&#160;11) per pay period, (b)&#160;authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c)&#160;specify the exact name or names in which shares of Common Stock purchased for such individual are to be issued pursuant to Section&#160;10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant files a new enrollment form or withdraws from the Plan, such Participant&#8217;s deductions or contributions and purchases will continue at the same percentage of Compensation for future Offerings, provided he or she remains eligible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Employee Contributions</span>. Each eligible employee may authorize payroll deductions or contributions at a minimum of 1&#160;percent (1%) up to a maximum of 15&#160;percent (15%) of such employee&#8217;s Compensation for each pay period or such other maximum as may be specified by the Administrator in advance of an Offering. The Company will maintain book accounts showing the amount of payroll deductions or contributions made by each Participant for each Purchase Period within an Offering. No interest will accrue or be paid on payroll deductions or contributions, except as may be required by applicable law. If payroll deductions or contributions for purposes of the Plan are prohibited or otherwise problematic under applicable law (as determined by the Administrator in its discretion), the Administrator may require Participants to contribute to the Plan by such other means as determined by the Administrator. Any reference to &#8220;payroll deductions or contributions&#8221; in this Section&#160;5 (or in any other section of the Plan) will similarly cover contributions by other means made pursuant to this Section&#160;5. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Deduction Changes</span>. Except as may be determined by the Administrator in advance of an Offering, a Participant may not increase or decrease his or her payroll deduction or contributions during any Offering, but may increase or decrease his or her payroll deduction or contributions with respect to the next Offering (subject to the limitations of Section&#160;5) by filing a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her payroll deduction or contributions during an Offering. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Withdrawal</span>. A Participant may withdraw from participation in the Plan by delivering a written notice of withdrawal to the Company or an agent designated by the Company (in accordance with such procedures as may be established by the Administrator). The Participant&#8217;s withdrawal will be effective as of the next business day. Following a Participant&#8217;s withdrawal, the Company will promptly refund such individual&#8217;s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section&#160;4. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Grant of Options</span>. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (&#8220;Option&#8221;) to purchase, on the last day of a Purchase Period (an &#8220;Exercise Date&#8221;) and at the Option Price (as defined herein) hereinafter provided for, the lowest of (a)&#160;a number of shares of Common Stock determined by dividing such Participant&#8217;s accumulated payroll deductions or contributions on such Exercise Date by the Option Price, (b)&#160;the number of shares of Common Stock determined by dividing $25,000 by the Fair Market Value of the Common Stock on the Offering Date for such Offering; or (c)&#160;such other lesser maximum number of shares as shall have been established by the Administrator in advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each Participant&#8217;s Option shall be exercisable only to the extent of such Participant&#8217;s accumulated payroll deductions or contributions on the Exercise Date. The purchase price for each share purchased under each Option (the &#8220;Option Price&#8221;) will be 85&#160;percent (85%) of the Fair Market Value (as defined in Section&#160;11) of the Common Stock on the Offering Date or the Exercise Date, whichever is less. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such Participant, immediately after the Option was granted, would be treated as owning stock possessing 5&#160;percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section&#160;11). For purposes of the preceding sentence, the attribution rules of Section&#160;424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the Fair Market Value of the Common Stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section&#160;423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Exercise of Option and Purchase of Shares</span>. Each employee who continues to be a Participant in the Plan on an Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll deductions or contributions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Unless otherwise determined by the Administrator in advance of an Offering, any amount remaining in a Participant&#8217;s account after the purchase of shares on an Exercise Date of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Purchase Period; provided, that if such Exercise Date is the final Exercise Date of an Offering, such amount will be carried forward to the next Offering and any other balance remaining in a Participant&#8217;s account at the end of an Offering will be refunded to the Participant promptly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Issuance of Certificates</span>. Certificates or book-entries at the Company&#8217;s transfer agent representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee to be his, her or their, nominee for such purpose. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Definitions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Affiliate</span>&#8221; means any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under the common control with the Company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Closing Date</span>&#8221; means the date of the closing (the &#8220;Closing&#8221;) of the transactions contemplated by that certain Agreement and Plan of Merger by and among Frequency Therapeutics, Inc., the Company and Frequency Merger Sub Inc., dated as of July&#160;14, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Compensation</span>&#8221; means the amount of base pay, prior to salary reduction such as pursuant to Sections&#160;125, 132(f) or 401(k) of the Code, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains related to Company stock options or other share-based awards, and similar items. The Administrator shall have the discretion to determine the application of this definition to Participants outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Designated Company</span>&#8221; means any present or future Affiliate or Subsidiary that has been designated by the Administrator to participate in the Plan. The Administrator may so designate any Subsidiary or Affiliate, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders, and may further designate such companies or Participants as participating in the 423 Component or the <span style="white-space:nowrap">Non-423</span> Component. The Administrator may also determine which affiliates or eligible employees may be excluded from participation in the Plan, to the extent consistent with Section&#160;423 of the Code or as implemented under the <span style="white-space:nowrap">Non-423</span> Component, and determine which Designated Company or Companies will participate in separate Offerings (to the extent that the Company makes separate Offerings). For purposes of the 423 Component, only the Company and its Subsidiaries may be Designated Companies; provided, however, that at any given time, a Subsidiary that is a Designated Company under the 423 Component will not be a Designated Company under the <span style="white-space:nowrap">Non-423</span> Component. The current list of Designated Companies is attached hereto as <span style="text-decoration:underline">Appendix A</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Effective Date</span>&#8221; means the date on which the Plan becomes effective as set forth in Section&#160;26. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Fair Market Value of the Common Stock</span>&#8221; on any given date means the fair market value of the Common Stock determined in good faith by the Administrator; provided, however, that if the Common Stock is listed on the National Association of Securities Dealers Automated Quotation System (&#8220;NASDAQ&#8221;), NASDAQ Global Market, The New York Stock Exchange or another national securities exchange or traded on any established market, the determination shall be made by reference to the closing price. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">New Exercise Date</span>&#8221; means a new Exercise Date if the Administrator shortens any Offering then in progress. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Parent</span>&#8221; means a &#8220;parent corporation&#8221; with respect to the Company, as defined in Section&#160;424(e) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Participant</span>&#8221; means an individual who is eligible as determined in Section&#160;3 and who has complied with the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Purchase Period</span>&#8221; means a period of time specified within an Offering beginning on the Offering Date or on the next day following an Exercise Date within an Offering and ending on an Exercise Date. An Offering may consist of one or more Purchase Periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Sale Event</span>&#8221; means (i)&#160;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii)&#160;a merger, reorganization, statutory share exchange, consolidation, or similar transaction pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii)&#160;the sale of all of the Common Stock to an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unrelated person, entity or group thereof acting in concert, (iv)&#160;any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company, or (v)&#160;the approval by the stockholders of the Company of a complete liquidation or dissolution of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;<span style="font-style:italic">Subsidiary</span>&#8221; means a &#8220;subsidiary corporation&#8221; with respect to the Company, as defined in Section&#160;424(f) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Rights on Termination or Transfer of Employment</span>. If a Participant&#8217;s employment terminates for any reason before the Exercise Date for any Offering, no payroll deduction or contributions will be taken from any pay due and owing to the Participant and the balance in the Participant&#8217;s account will be paid to such Participant or, in the case of such Participant&#8217;s death, if permitted by the Administrator and valid under applicable law, to his or her designated beneficiary or to the legal representative of his or her estate as if such Participant had withdrawn from the Plan under Section&#160;7. An employee will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Company, ceases to be a Subsidiary or Affiliate, or if the employee is transferred to any corporation other than the Company or a Designated Company. Unless otherwise determined by the Administrator, a Participant whose employment transfers between, or whose employment terminates with an immediate rehire (with no break in service) by, Designated Companies or a Designated Company and the Company will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; provided, however, that if a Participant transfers from an Offering under the 423 Component to an Offering under the <span style="white-space:nowrap">Non-423</span> Component, the exercise of the Participant&#8217;s Option will be qualified under the 423 Component only to the extent that such exercise complies with Section&#160;423 of the Code. If a Participant transfers from an Offering under the <span style="white-space:nowrap">Non-423</span> Component to an Offering under the 423 Component, the exercise of the Participant&#8217;s Option will remain <span style="white-space:nowrap">non-qualified</span> under the <span style="white-space:nowrap">Non-423</span> Component. Further, an employee will not be deemed to have terminated employment for purposes of this Section&#160;12, if the employee is on an approved leave of absence where the employee&#8217;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Special Rules and <span style="white-space:nowrap">Sub-Plans</span></span>. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules or <span style="white-space:nowrap">sub-plans</span> applicable to the employees of a particular Designated Company, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated Company has employees, regarding, without limitation, eligibility to participate in the Plan, handling and making of payroll deductions or contributions by other means, establishment of bank or trust accounts to hold payroll deductions or contributions, payment of interest, conversion of local currency, obligation to pay payroll tax, withholding procedures and handling of share issuances, any of which may vary according to applicable requirements; provided that if such special rules or <span style="white-space:nowrap">sub-plans</span> are inconsistent with the requirements of Section&#160;423(b) of the Code the employees subject to such special rules or <span style="white-space:nowrap">sub-plans</span> will participate in the <span style="white-space:nowrap">Non-423</span> Component. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Optionees Not Stockholders</span>. Neither the granting of an Option to a Participant nor the deductions or contributions from his or her pay shall result in such Participant becoming a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him or her. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Rights Not Transferable</span>. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant&#8217;s lifetime only by the Participant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Application of Funds</span>. All funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose, unless otherwise required under applicable law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Adjustment in Case of Changes Affecting Common Stock</span>. In the event of a subdivision of outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section&#160;8 shall be equitably or proportionately adjusted to give proper effect to such event. In the case of and subject to the consummation of a Sale Event, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the Plan or to facilitate such transactions or events: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#160;&#160;&#160;&#160;To provide for either (i)&#160;termination of any outstanding Option in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such Option had such Option been currently exercisable or (ii)&#160;the replacement of such outstanding Option with other options or property selected by the Administrator in its sole discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#160;&#160;&#160;&#160;To provide that the outstanding Options under the Plan shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for similar options covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#160;&#160;&#160;&#160;To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Options under the Plan and/or in the terms and conditions of outstanding Options and Options that may be granted in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;To provide that the Offering with respect to which an Option relates will be shortened by setting a New Exercise Date on which such Offering will end. The New Exercise Date will occur before the date of the Sale Event. The Administrator will notify each Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant&#8217;s Option has been changed to the New Exercise Date and that the Participant&#8217;s Option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering as provided in Section&#160;7 hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#160;&#160;&#160;&#160;To provide that all outstanding Options shall terminate without being exercised and all amounts in the accounts of Participants shall be promptly refunded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Amendment of the Plan</span>. The Board may at any time and from time to time amend the Plan in any respect, except that, without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the 423 Component of the Plan or making any other change that would require stockholder approval in order for the Plan, as amended, to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423(b) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Insufficient Shares</span>. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions or contributions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Termination of the Plan</span>. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. Unless terminated earlier, the Plan shall automatically terminate on the ten year anniversary of the Effective Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Compliance with Law</span>. The Company&#8217;s obligation to sell and deliver Common Stock under the Plan is subject to applicable laws and the completion of any registration or qualification of the Common Stock under any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. or <span style="white-space:nowrap">non-U.S.</span> local, state or federal securities or exchange control law, or under rulings or regulations of the SEC or of any other governmental regulatory body, and to obtaining any approval or other clearance from any U.S. and <span style="white-space:nowrap">non-U.S.</span> local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. The Company is under no obligation to register or qualify the Common Stock with the SEC or any other U.S. or <span style="white-space:nowrap">non-U.S.</span> securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of such stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Governing Law</span>. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware applied without regard to conflict of law principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Issuance of Shares</span>. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Tax Withholding</span>. Participation in the Plan is subject to any applicable U.S. and <span style="white-space:nowrap">non-U.S.</span> federal, state or local tax withholding requirements on income the Participant realizes in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company or any Subsidiary or Affiliate may withhold from a Participant&#8217;s wages, salary or other compensation at any time the amount necessary for the Company or any Subsidiary or Affiliate to meet applicable withholding obligations, including any withholding required to make available to the Company or any Subsidiary or Affiliate any tax deductions or benefits attributable to the sale or disposition of Common Stock by such Participant. In addition, the Company or any Subsidiary or Affiliate may withhold from the proceeds of the sale of Common Stock or use any other method of withholding that the Company or any Subsidiary or Affiliate deems appropriate to the extent permitted by U.S. Treasury Regulation <span style="white-space:nowrap">Section&#160;1.423-2(f)</span> with respect to the 423 Component. The Company will not be required to issue any Common Stock under the Plan until such obligations are satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Notification Upon Sale of Shares under the 423 Component</span>. Each Participant agrees, by entering the 423 Component of the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date such shares were purchased. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Effective Date and Approval of Stockholders</span>. The Plan shall take effect on the Closing Date subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Equal Rights and Privileges.</span> Notwithstanding any provision of the Plan to the contrary and in accordance with Section&#160;423 of the Code for the 423 Component of the Plan, all eligible employees who are granted options under the Plan shall have the same rights and privileges. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">No Right to Continued Service</span>. Neither the Plan nor any compensation paid hereunder will confer on any Participant the right to continue as an employee or in any other capacity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.&#160;&#160;&#160;&#160;<span style="text-decoration:underline">Entire Plan</span>. This Plan constitutes the entire plan with respect to the subject matter hereof and supersedes all prior plans with respect to the subject matter hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY BOARD OF DIRECTORS: &#160;&#160;&#160;&#160; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY STOCKHOLDERS:&#160;&#160;&#160;&#160; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">APPENDIX A </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Designated Companies </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom451428_164">Annex K </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Section&#160;262 of the Delaware General Corporation Law</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">&#167;262 Appraisal rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Any stockholder of a corporation of this state who holds shares of stock on the date of the making of a demand pursuant to subsection&#160;(d) of this section&#160;with respect to such shares, who continuously holds such shares through the effective date of the merger or consolidation, who has otherwise complied with subsection&#160;(d) of this section&#160;and who has neither voted in favor of the merger or consolidation nor consented thereto in writing pursuant to &#167;&#160;228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections&#160;(b) and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; and the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Appraisal rights shall be available for the shares of any class or series of stock of a constituent corporation in a merger or consolidation to be effected pursuant to &#167;&#160;251 (other than a merger effected pursuant to &#167;&#160;251(g) of this title), &#167;&#160;252, &#167;&#160;254, &#167;&#160;255, &#167;&#160;256, &#167;&#160;257, &#167;&#160;258, &#167;&#160;263 or &#167;&#160;264 of this title: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Provided, however, that, except as expressly provided in &#167;&#160;363(b) of this title, no appraisal rights under this section&#160;shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders to act upon the agreement of merger or consolidation (or, in the case of a merger pursuant to &#167;&#160;251(h), as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167;&#160;251(f) of this title. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section&#160;shall be available for the shares of any class or series of stock of a constituent corporation if the holders thereof are required by the terms of an agreement of merger or consolidation pursuant to &#167;&#167;&#160;251, 252, 254, 255, 256, 257, 258, 263 and 264 of this title to accept for such stock anything except: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or depository receipts in respect thereof; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger or consolidation will be either listed on a national securities exchange or held of record by more than 2,000 holders; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167;&#160;253 or &#167;&#160;267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) In the event of an amendment to a corporation&#8217;s certificate of incorporation contemplated by &#167;&#160;363(a) of this title, appraisal rights shall be available as contemplated by &#167;&#160;363(b) of this title, and the procedures of this section, including those set forth in subsections&#160;(d) and (e)&#160;of this section, shall apply as nearly as practicable, with the word &#8220;amendment&#8221; substituted for the words &#8220;merger or consolidation,&#8221; and the word &#8220;corporation&#8221; substituted for the words &#8220;constituent corporation&#8221; and/or &#8220;surviving or resulting corporation.&#8221; </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any corporation may provide in its certificate of incorporation that appraisal rights under this section&#160;shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation or the sale of all or substantially all of the assets of the corporation. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections&#160;(d),(e), and (g)&#160;of this section, shall apply as nearly as is practicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Appraisal rights shall be perfected as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) If a proposed merger or consolidation for which appraisal rights are provided under this section&#160;is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167;&#160;255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection&#160;(b) or (c)&#160;of this section&#160;that appraisal rights are available for any or all of the shares of the constituent corporations, and shall include in such notice a copy of this section&#160;and, if 1 of the constituent corporations is a nonstock corporation, a copy of &#167;&#160;114 of this title. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger or consolidation, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger or consolidation shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger or consolidation, the surviving or resulting corporation shall notify each stockholder of each constituent corporation who has complied with this subsection&#160;and has not voted in favor of or consented to the merger or consolidation of the date that the merger or consolidation has become effective; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) If the merger or consolidation was approved pursuant to &#167;&#160;228, &#167;&#160;251(h), &#167;&#160;253, or &#167;&#160;267 of this title, then either a constituent corporation before the effective date of the merger or consolidation or the surviving or resulting corporation within 10 days thereafter shall notify each of the holders of any class or series of stock of such constituent corporation who are entitled to appraisal rights of the approval of the merger or consolidation and that appraisal rights are available for any or all shares of such class or series of stock of such constituent corporation, and shall include in such notice a copy of this section&#160;and, if 1 of the constituent corporations is a nonstock corporation, a copy of &#167;&#160;114 of this title. Such notice may, and, if given on or after the effective date of the merger or consolidation, shall, also notify such stockholders of the effective date of the merger or consolidation. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167;&#160;251(h) of this title, within the later of the consummation of the offer contemplated by &#167;&#160;251(h) of this title and 20 days after the date of giving such notice, demand in writing from the surviving or resulting corporation the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger or consolidation, either (i)&#160;each such constituent corporation shall send a second notice before the effective date of the merger or consolidation notifying each of the holders of any class or series of stock of such constituent corporation that are entitled to appraisal rights of the effective date of the merger or consolidation or (ii)&#160;the surviving or resulting corporation shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167;&#160;251(h) of this title, later than the later of the consummation of the offer contemplated by &#167;&#160;251(h) of this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger or consolidation, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Within 120 days after the effective date of the merger or consolidation, the surviving or resulting corporation or any stockholder who has complied with subsections&#160;(a) and (d)&#160;of this section&#160;hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger or consolidation, any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such stockholder&#8217;s demand for appraisal and to accept the terms offered upon the merger or consolidation. Within 120 days after the effective date of the merger or consolidation, any stockholder who has complied with the requirements of subsections&#160;(a) and (d)&#160;of this section&#160;hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the corporation surviving the merger or resulting from the consolidation a statement setting forth the aggregate number of shares not voted in favor of the merger or consolidation (or, in the case of a merger approved pursuant to &#167;&#160;251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167;&#160;251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167;&#160;251(h)(2)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of holders of such shares. Such statement shall be given to the stockholder within 10 days after such stockholder&#8217;s request for such a statement is received by the surviving or resulting corporation or within 10 days after expiration of the period for delivery of demands for appraisal under subsection&#160;(d) of this section&#160;hereof, whichever is later. Notwithstanding subsection&#160;(a) of this section, a person who is the beneficial owner of shares of such stock held either in a voting trust or by a nominee on behalf of such person may, in such person&#8217;s own name, file a petition or request from the corporation the statement described in this subsection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Upon the filing of any such petition by a stockholder, service of a copy thereof shall be made upon the surviving or resulting corporation, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all stockholders who have demanded payment for their shares and with whom agreements as to the value of their shares have not been reached by the surviving or resulting corporation. If the petition shall be filed by the surviving or resulting corporation, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving or resulting corporation and to the stockholders shown on the list at the addresses therein stated. Such notice shall also be given by 1 or more publications at least 1 week before the day of the hearing, in a newspaper of general circulation published in the City of Wilmington, Delaware or such publication as the Court deems advisable. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving or resulting corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) At the hearing on such petition, the Court shall determine the stockholders who have complied with this section&#160;and who have become entitled to appraisal rights. The Court may require the stockholders who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with such direction, the Court may dismiss the proceedings as to such stockholder. If immediately before the merger or consolidation the shares of the class or series of stock of the constituent corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger or consolidation for such total number of shares exceeds $1&#160;million, or (3)&#160;the merger was approved pursuant to &#167;&#160;253 or &#167;&#160;267 of this title. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) After the Court determines the stockholders entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger or consolidation, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving or resulting corporation or by any stockholder entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an appraisal. Any stockholder whose name appears on the list filed by the surviving or resulting corporation pursuant to subsection&#160;(f) of this section&#160;and who has submitted such stockholder&#8217;s certificates of stock to the Register in Chancery, if such is required, may participate fully in all proceedings until it is finally determined that such stockholder is not entitled to appraisal rights under this section. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving or resulting corporation to the stockholders entitled thereto. Payment shall be so made to each such stockholder, in the case of holders of uncertificated stock forthwith, and the case of holders of shares represented by certificates upon the surrender to the corporation of the certificates representing such stock. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving or resulting corporation be a corporation of this State or of any state. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a stockholder, the Court may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) From and after the effective date of the merger or consolidation, no stockholder who has demanded appraisal rights as provided in subsection&#160;(d) of this section&#160;shall be entitled to vote such stock for any purpose or to receive payment of dividends or other distributions on the stock (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger or consolidation); provided, however, that if no petition for an appraisal shall be filed within the time provided in subsection&#160;(e) of this section, or if such stockholder shall deliver to the surviving or resulting corporation a written withdrawal of such stockholder&#8217;s demand for an appraisal and an acceptance of the merger or consolidation, either within 60 days after the effective date of the merger or consolidation as provided in subsection&#160;(e) of this section&#160;or thereafter with the written approval of the corporation, then the right of such stockholder to an appraisal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be dismissed as to any stockholder without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just; provided, however that this provision shall not affect the right of any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such stockholder&#8217;s demand for appraisal and to accept the terms offered upon the merger or consolidation within 60 days after the effective date of the merger or consolidation, as set forth in subsection&#160;(e) of this section. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The shares of the surviving or resulting corporation to which the shares of such objecting stockholders would have been converted had they assented to the merger or consolidation shall have the status of authorized and unissued shares of the surviving or resulting corporation. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROXY </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">STATEMENT/PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;20.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Indemnification of Directors and Officers</span></span><span style="font-weight:bold"> </span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsection&#160;(a) of Section&#160;145 of the DGCL empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsection&#160;(b) of Section&#160;145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections&#160;(a) and (b)&#160;of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(7) of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency&#8217;s Restated Certificate of Incorporation contains provisions that eliminate, to the maximum extent permitted by the DGCL, the personal liability of directors and executive officers for monetary damages for </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach of their fiduciary duties as a director or officer. Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws provide that Frequency shall indemnify its directors and officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL. However, the DGCL prohibits Frequency from limiting the liability of directors for (i)&#160;any breach of a director&#8217;s duty of loyalty to Frequency or to Frequency&#8217;s stockholders,(ii) acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, unlawful payment of dividends or unlawful stock repurchases or redemptions, and (iv)&#160;any transaction from which a director derived an improper personal benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of Frequency&#8217;s directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Frequency&#8217;s Restated Certificate of Incorporation does not eliminate a director&#8217;s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of nonmonetary relief, remain available under Delaware law. It also does not affect a director&#8217;s responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Under Frequency&#8217;s Amended and Restated Bylaws, Frequency will also be empowered to enter into indemnification agreements with its directors, officers, employees and other agents and to purchase insurance on behalf of any person whom Frequency is required or permitted to indemnify. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in its Restated Certificate of Incorporation and Amended and Restated Bylaws, and intends to enter into indemnification agreements with any new directors and executive officers in the future. These agreements provide for the indemnification of such persons for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were serving in such capacity. Frequency believes that these Restated Certificate of Incorporation and Amended and Restated Bylaws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors, officers and employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer of Frequency against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in Frequency&#8217;s Restated Certificate of Incorporation and Amended and Restated Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit Frequency and its stockholders. A stockholder&#8217;s investment may be harmed to the extent Frequency pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to Frequency&#8217;s directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, Frequency has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of Frequency&#8217;s directors or officers as to which indemnification is being sought, nor is Frequency aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, from the closing of the Merger through the sixth anniversary of the closing, Frequency and the surviving corporation agree that all rights to indemnification, exculpation or advancement of expenses now existing in favor of, and all limitations on the personal liability of, each present and former director or officer, of Frequency or Korro Bio provided for in the respective organizational documents of Frequency and Korro Bio in effect as of July&#160;14, 2023, the date of the Merger Agreement, shall continue to be honored and in full force and effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, the Restated Certificate of Incorporation and Frequency Amended and Restated Bylaws and the surviving corporation in the Merger, will contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Frequency than are presently set forth in the Restated Certificate of Incorporation and Frequency Amended and Restated Bylaws, which provisions shall not be amended, modified or repealed for a period of six years&#8217; time from the closing of the Merger in a manner that would materially and adversely affect the rights thereunder of individuals who, at or prior to the closing, were officers or directors of Frequency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that Frequency shall purchase an insurance policy in effect for six years from the closing, providing at least the same coverage as the current directors&#8217; and officers&#8217; liability insurance policies maintained by Frequency and containing terms and conditions that are not materially less favorable to current and former officers and directors of Frequency. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;21.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Exhibits and Financial Statement Schedules</span></span><span style="font-weight:bold"> </span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(a) Exhibit&#160;Index</span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:56%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center"><span style="font-weight:bold">Incorporated by Reference (if applicable)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Form</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File No.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">2.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/d651936dex21.htm">Agreement and Plan of Merger, dated July&#160;14, 2023, by and among Frequency Therapeutics, Inc., Frequency Merger Sub, Inc., and Korro Bio, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">2.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">7/14/2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">2.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/d651936dex105.htm">Form of Contingent Value Rights Agreement </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.5</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">7/14/2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519263787/d796545dex31.htm">Restated Certificate of Incorporation of Frequency Therapeutics, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10/7/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519263787/d796545dex32.htm">Amended and Restated Bylaws of Frequency Therapeutics, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/23/2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex41.htm">Form of Common Stock Certificate </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">S-1/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-233652</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">4.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/23/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917dex42.htm">Second Amended and Restated Investors&#8217; Rights Agreement, dated as of July&#160;17, 2019 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">S-1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">333-233652</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">4.2</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/6/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000156459020012977/freq-ex43_875.htm">Description of Frequency Therapeutics, Inc. Securities </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">001-39062</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">4.3</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">3/26/2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Opinion of Latham&#160;&amp; Watkins LLP</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/d651936dex101.htm">Form of Frequency Therapeutics, Inc. Stockholder Support Agreement </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">8-K</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">001-39062</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">7/14/2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/d651936dex102.htm">Form of Korro Bio, Inc. Stockholder Support Agreement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">8-K</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">001-39062</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.2</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">7/14/2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917dex101.htm">2014 Stock Incentive Plan, as amended and form of option agreements thereunder </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">S-1</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-233652</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/6/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.4+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex102.htm">2019 Incentive Award Plan and form of award agreements thereunder </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">S-1/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-233652</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.2</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/23/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.5+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex103.htm"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Program </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">S-1/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-233652</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.3</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/23/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex105.htm">Form of Indemnification Agreement for Directors and Officers </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">S-1/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-233652</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.5</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/23/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex107.htm">Second Amended and Restated Executive Employment Agreement, dated as of September&#160;20, 2019, between David L. Lucchino and Frequency Therapeutics, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">S-1/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-233652</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.7</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/23/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.8+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex1013.htm">2019 Employee Stock Purchase Plan </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">S-1/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">333-233652</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.13</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9/23/2019</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000156459020012977/freq-ex1013_758.htm">Indenture of Lease, effective as of January&#160;7, 2020 between HCP/KING 75 Hayden LLC and Frequency Therapeutics, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.13</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">3/26/2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312522192035/d328479dex101.htm">Sublease Agreement, dated July&#160;8, 2022, by and between Frequency Therapeutics, Inc. and SalioGen Therapeutics, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">7/12/2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:59%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.11</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312520196443/d12381dex102.htm">Registration Rights Agreement, dated July&#160;17, 2020, by and among Frequency Therapeutics, Inc. and the Investors named therein. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.2</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">7/21/2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.12+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312522092065/d309564dex101.htm">Separation Agreement, dated as of March&#160;31, 2022, by and between Frequency Therapeutics, Inc. and Peter P. Pfreundschuh </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">3/31/2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.13+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000156459021016117/freq-ex1016_1057.htm">Employment Agreement, effective February&#160;3, 2020, by and between Frequency Therapeutics, Inc. and Wendy S. Arnold. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.16</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">3/26/2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.14+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312523083653/d491154dex101.htm">Separation Agreement by and between Frequency Therapeutics, Inc. and Carl LeBel, dated March&#160;23, 2023 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">3/9/2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.15+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000095017023021755/freq-ex10_1.htm">Separation Agreement by and between Frequency Therapeutics, Inc. and Wendy Arnold, dated February&#160;17, 2023 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10-Q</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">001-39062</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">5/12/2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.16+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312523161600/d390817dex101.htm">Amendment to Letter Agreement by and between Frequency Therapeutics, Inc. and Richard Mitrano, dated June&#160;1, 2023 </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">8-K</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">001-39062</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">6/6/2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000095017023007140/freq-ex21_1.htm">Subsidiaries of Frequency Therapeutics, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap">001-39062</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">21.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">3/10/2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d451428dex231.htm">Consent of&#160;RSM US LLP, Independent Registered Public Accounting Firm </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d451428dex232.htm">Consent of Ernst&#160;&amp; Young LLP, Independent Registered Public Accounting Firm </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">24.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#sig">Power of Attorney (included on signature page to registration statement) </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d451428dex991.htm">Form of Proxy Card </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Consent of Latham&#160;&amp; Watkins LLP (included in Exhibit&#160;5.1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d451428dex993.htm">Consent of Cowen and Company, LLC </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.4**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Consent of Ram Aiyar to be named as a director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">107</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="d451428dexfilingfees.htm">Filing Fee Table </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Instance Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Schema Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Calculation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Definitions Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Label Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Presentation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Annexes, schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation <span style="white-space:nowrap">S-K.</span> The registrant agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To be filed by amendment. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="font-style:italic">Financial Statements</span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements filed with this registration statement on Form <span style="white-space:nowrap">S-4</span> are set forth on the Financial Statement Index and is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;22.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Undertakings</span></span><span style="font-weight:bold"> </span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a <span style="white-space:nowrap">post-effective</span> amendment to this registration statement: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent <span style="white-space:nowrap">post-effective</span> amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;<span style="font-style:italic">Calculation of Registration Fee</span>&#8221; table in the effective registration statement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such <span style="white-space:nowrap">post-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a <span style="white-space:nowrap">post-effective</span> amendment any of the securities being registered which remain unsold at the termination of the offering. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) That, for purposes of determining liability under the Securities Act to any purchaser, each filing of the Registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15 (d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15 (d) of the Exchange Act) that is provided in this proxy statement/prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(6) That every prospectus (i)&#160;that is filed pursuant to paragraph (a)(5) immediately preceding, or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such <span style="white-space:nowrap">post-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(7) To respond to requests for information that is provided in this proxy statement/prospectus pursuant to Item 4, 10(b), 11, or 13 of Form <span style="white-space:nowrap">S-4,</span> within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(8) To supply by means of a <span style="white-space:nowrap">post-effective</span> amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Lexington, Commonwealth of Massachusetts, on the 27th day of July, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Frequency Therapeutics, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ David L. Lucchino</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">David L. Lucchino</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President, Chief Executive Officer and Director</td></tr>
</table></div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, the undersigned directors and officers of Frequency Therapeutics, Inc. hereby severally constitute and appoint David L. Lucchino and Richard Mitrano, each acting together or alone, his or her true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form <span style="white-space:nowrap">S-4</span> (including all <span style="white-space:nowrap">pre-effective</span> and post-effective amendments and registration statements filed pursuant to Rule 462 under the Securities Act), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that such <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:33%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David L. Lucchino</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David L. Lucchino</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President,&#160;Chief&#160;Executive&#160;Officer&#160;and&#160;Director</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<span style="font-style:italic">Principal Executive Officer</span>)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">July&#160;27, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Mitrano</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richard Mitrano</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Finance and Operations</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<span style="font-style:italic">Principal Financial and Accounting Officer)</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">July&#160;27, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Timothy J. Barberich</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Timothy J. Barberich</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice Chairperson and Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">July&#160;27, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cynthia L. Feldmann</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cynthia L. Feldmann</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">July&#160;27, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Huang</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Huang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">July&#160;27, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert S. Langer, ScD</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert S. Langer, ScD</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">July&#160;27, 2023</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d451428dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of Frequency Therapeutics, Inc. of our report dated
March&nbsp;10, 2023, relating to the consolidated financial statements of Frequency Therapeutics, Inc., appearing in the Proxy Statement and Prospectus, which is part of this Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to our firm under the heading &#147;Experts&#148; in such Proxy Statement and Prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ RSM US LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Boston, Massachusetts</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;27, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>d451428dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated July&nbsp;27, 2023, with respect to the
consolidated financial statements of Korro Bio, Inc. included in the Registration Statement <FONT STYLE="white-space:nowrap">(Form&nbsp;S-4)</FONT> and related Proxy Statement/Prospectus of Frequency Therapeutics, Inc. for the registration of its
common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston,
Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;27, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d451428dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g451428dsp046.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: P.O. BOX 8016, CARY, NC 27512-9903 INTERNET Go To: www.proxypush.com/FREQ &#149; Cast your vote
online &#149; Have your Proxy Card ready &#149; Follow the simple instructions to record your vote PHONE Call <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-390-5362</FONT></FONT></FONT>
&#149; Use any touch-tone telephone &#149; Have your Proxy Card ready &#149; Follow the simple recorded instructions MAIL &#149; Mark, sign and date your Proxy Card &#149; Fold and return your Proxy Card in the postage-paid envelope provided
&#147;ALEXA, VOTE MY PROXY&#148; &#149; Open Alexa app and browse skills &#149; Search &#147;Vote my Proxy&#148; &#149; Enable skill TO ATTEND the Annual Meeting of Stockholders of Frequency Therapeutics, Inc., please visit www.proxydocs.com/FREQ
for virtual meeting registration details. Frequency Therapeutics, Inc. Annual Meeting of Stockholders For Stockholders of record as of 2023 TIME: 2023 [&#149; AM], Eastern Time PLACE: Annual Meeting of Stockholders to be held live via the
Internet&#151;please visit www.proxydocs.com/FREQ for more details. This proxy is being solicited on behalf of the Board of Directors The undersigned hereby appoints David L. Lucchino and James P. Abely as the true and lawful attorneys of the
undersigned, with full power of substitution and revocation, and authorizes each of them, to vote all the shares of common stock of Frequency Therapeutics, Inc. which the undersigned is entitled to vote at said meeting and any adjournment thereof
upon the matters specified and upon such other matters as may be properly brought before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote each in his discretion on such other matters as may
properly come before the meeting and revoking any proxy heretofore given. THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED FOR THE ELECTION OF THE DIRECTOR IN PROPOSAL 3 AND FOR
PROPOSALS 1, 2, 4, 5, 6 AND 7. THE PROXIES WILL VOTE IN THEIR DISCRETION ON ANY OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING AND ANY ADJOURNMENT THEREOF. You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE
SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors&#146; recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card. </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g451428dsp047.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDEFrequency Therapeutics, Inc. Annual Meeting of Stockholders
Please make your marks like this: THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR THE DIRECTOR IN PROPOSAL 4 AND FOR PROPOSALS 1, 2, 3, 5, 6, 7 and 8 PROPOSAL YOUR VOTE BOARD OF DIRECTORS RECOMMENDS 1. To approve the issuance of shares of common stock
of Frequency Therapeutics, Inc. (&#147;Frequency&#148;) to the stockholders of Korro Bio, Inc. (&#147;Korro Bio&#148;), pursuant to the Agreement and Plan of Merger, dated as of July&nbsp;14, 2023, by and among Frequency, Korro Bio and Frequency
Merger Sub, Inc. (&#147;Merger Sub&#148;), pursuant to which Merger Sub, will merge with and into Korro Bio, with Korro Bio surviving as a wholly owned subsidiary of Frequency, and the surviving corporation of the merger (the &#147;Merger&#148;),
and the change of control resulting from the Merger. FOR AGAINST ABSTAIN FOR 2. To approve an amendment to the Restated Certificate of Incorporation of Frequency to effect a reverse stock split of Frequency&#146;s issued and outstanding common stock
at a ratio ranging from any whole number between <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-</FONT></FONT> as determined by
Frequency&#146;s board of directors in its discretion, subject to the Frequency board of directors&#146; authority to abandon such amendment. FOR AGAINST ABSTAIN FOR 3. To elect David L. Lucchino as a Class&nbsp;I director, to hold office until the
annual meeting of stockholders to be held in 2026 and until his successor has been duly elected and qualified. FOR WITHHOLD FOR 4. To ratify, in a <FONT STYLE="white-space:nowrap">non-binding</FONT> vote, the appointment of RSM US LLP as
Frequency&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2023. FOR AGAINST ABSTAIN FOR 5. To approve the 2023 Stock Option and Incentive Plan. FOR AGAINST ABSTAIN FOR 6. To approve the 2023 Employee
Stock Purchase Plan FOR AGAINST ABSTAIN FOR 7. To approve an adjournment of the Annual Meeting of Stockholders, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2. FOR AGAINST ABSTAIN FOR
NOTE: To transact such other business as may properly come before the Annual Meeting of Stockholders or any continuation, postponement or adjournment thereof. </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g451428dsp048.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">TO ATTEND the Annual Meeting of Stockholders of Frequency Therapeutics, Inc., please visit www.proxydocs.com/FREQ for virtual meeting
registration details. Authorized Signatures&#151;Must be completed for your instructions to be executed. Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc.,
should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form. Signature (and Title if applicable) Date Signature (if held jointly) Date </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>5
<FILENAME>d451428dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Cowen and Company, LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">75 Hayden
Avenue, Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexington, Massachusetts 02421 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board
of Directors: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of our opinion letter, dated July&nbsp;13, 2023, to the Board of Directors of Frequency Therapeutics,
Inc. (&#147;Frequency&#148;), as <I>Annex B</I> to, and reference to such opinion letter under the headings &#147;PROSPECTUS SUMMARY &#151; Opinion of Frequency&#146;s Financial Advisor&#148; and &#147;THE MERGER &#151; Opinion of Frequency&#146;s
Financial Advisor&#148; in, the proxy statement/prospectus relating to the proposed transaction involving Frequency and Korro Bio, Inc., which proxy statement/prospectus forms a part of the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> of Frequency (the &#147;Registration Statement&#148;). By giving such consent, we do not thereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term
&#147;expert&#148; as used in, or that we come within the category of persons whose consent is required under, the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Cowen and Company, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cowen and Company, LLC</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 27, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>d451428dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FREQUENCY
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Newly Registered and Carry Forward Securities </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security&nbsp;&nbsp;<BR>Type&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Class<BR>Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Amount<BR>Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Maximum<BR>Aggregate<BR>Offering<BR>Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Amount of<BR>&nbsp;&nbsp;Registration&nbsp;&nbsp;<BR>Fee</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="17" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="17" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Newly Registered Securities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common Stock, par&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">value $0.001 per share&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Other&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">29,311,738<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;&nbsp;&nbsp;N/A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$9,770.58<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">0.00011020&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$1.08</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Other&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Warrant&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Other&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">30,001<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$N/A&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$N/A<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="17" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="17" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Carry Forward Securities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Carry Forward Securities</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Offering Amounts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$9,770.58&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$1.08</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fee Offsets</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$1.08</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the maximum number of shares of Common Stock, par value $0.001 per share (&#147;Frequency Common
Stock&#148;), of Frequency Therapeutics, Inc. (the &#147;Registrant&#148;), issuable to securityholders of Korro Bio, Inc. (&#147;Korro Bio&#148;) pursuant to the merger and related transactions contemplated by the Agreement and Plan of Merger,
dated as of July&nbsp;14, 2023, by and among the Registrant, Frequency Merger Sub, Inc., and Korro Bio. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee under Rule 457(f)(2) under the Securities
Act of 1933, as amended. Korro Bio is a private company, no market exists for its securities, and Korro Bio has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price is calculated based on an aggregate offering
amount equal to <FONT STYLE="white-space:nowrap">one-third</FONT> of the aggregate par value of the Korro Bio Common Stock that will be exchanged in the merger. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares of Frequency Common Stock issuable upon the exercise of an outstanding warrant issued by
Korro Bio. The warrant, which is&nbsp;currently exercisable for shares of Korro Bio Common Stock, will be converted to a warrant to purchase shares of Frequency Common Stock upon the closing of the merger in accordance with its terms. Pursuant to
Rule 457(g) under the Securities Act, no separate fee is required to be paid in respect of the warrant which is being registered concurrently in the same registration statement as the underlying shares of Frequency Common Stock issuable pursuant
thereto. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>freq-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2023 [06:37:33] {PM}-->
<schema targetNamespace="http://www.frequencytherapeutics.com/20230331" elementFormDefault="qualified" xmlns:freq="http://www.frequencytherapeutics.com/20230331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
<link:definition>1004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" id="ConsolidatedStatementsOfComprehensiveLossUnaudited">
<link:definition>1005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited" id="ConsolidatedStatementsStockholdersEquityDeficitUnaudited">
<link:definition>1006 - Statement - Consolidated Statements Stockholders' Equity (Deficit) (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
<link:definition>1008 - Disclosure - Organization and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/RecentlyAdoptedAndIssuedAccountingStandards" id="RecentlyAdoptedAndIssuedAccountingStandards">
<link:definition>1010 - Disclosure -  Recently Adopted And Issued Accounting Standards</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1011 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
<link:definition>1012 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/Investment" id="Investment">
<link:definition>1013 - Disclosure -  Investment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>1014 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>1015 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/Debt" id="Debt">
<link:definition>1016 - Disclosure - Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1017 - Disclosure -  Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1018 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>1019 - Disclosure - Stock-based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlan" id="EmployeeStockPurchasePlan">
<link:definition>1020 - Disclosure - Employee Stock Purchase Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1021 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/CollaborationAgreement" id="CollaborationAgreement">
<link:definition>1022 - Disclosure - Collaboration Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/Leases" id="Leases">
<link:definition>1023 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreements" id="ResearchAndLicenseAgreements">
<link:definition>1024 - Disclosure - Research and License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/Restructuring" id="Restructuring">
<link:definition>1025 - Disclosure -  Restructuring</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/Sublease" id="Sublease">
<link:definition>1026 - Disclosure -  Sublease</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1027 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
<link:definition>1028 - Disclosure - Employee Benefit Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1029 - Disclosure -  Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1030 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies" id="OrganizationAndBasisOfPresentationPolicies">
<link:definition>1031 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1032 - Disclosure -  Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1033 - Disclosure -  Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/InvestmentsTables" id="InvestmentsTables">
<link:definition>1034 - Disclosure -  Investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
<link:definition>1035 - Disclosure -  Prepaid Expenses and Other Current Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
<link:definition>1036 - Disclosure -  Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>1037 - Disclosure -  Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1038 - Disclosure -  Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1039 - Disclosure -  Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>1040 - Disclosure -  Stock-based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1041 - Disclosure -  Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/LeasesTables" id="LeasesTables">
<link:definition>1042 - Disclosure -  Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/RestructuringTables" id="RestructuringTables">
<link:definition>1043 - Disclosure -  Restructuring (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SubleaseTables" id="SubleaseTables">
<link:definition>1044 - Disclosure -  Sublease (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails" id="OrganizationAndBasisOfPresentationAdditionalInformationDetails">
<link:definition>1045 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1046 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
<link:definition>1047 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
<link:definition>1048 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" id="FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
<link:definition>1049 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails" id="FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails">
<link:definition>1050 - Disclosure - Fair value measurements - Schedule of debt securities in an unrealized loss (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/InvestmentsAdditionalInformationDetails" id="InvestmentsAdditionalInformationDetails">
<link:definition>1051 - Disclosure -  Investments (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails" id="InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails">
<link:definition>1052 - Disclosure -  Investments - Schedule of classified as available-for-sale and recorded at fair value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails" id="InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails">
<link:definition>1053 - Disclosure -  Investments - Schedule of debt securities in an unrealized loss position (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
<link:definition>1054 - Disclosure -  Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
<link:definition>1055 - Disclosure -  Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails" id="PropertyAndEquipmentAdditionalInformationDetails">
<link:definition>1056 - Disclosure -  Property and Equipment - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" id="AccruedExpensesScheduleOfAccruedExpensesDetails">
<link:definition>1057 - Disclosure -  Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails" id="DebtAdditionalInformationDetails">
<link:definition>1058 - Disclosure -  Debt - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
<link:definition>1059 - Disclosure -  Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
<link:definition>1060 - Disclosure -  Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails" id="StockholdersEquityAdditionalInformationDetails">
<link:definition>1061 - Disclosure -  Stockholders' Equity - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" id="StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
<link:definition>1062 - Disclosure -  Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" id="StockBasedCompensationAdditionalInformationDetails">
<link:definition>1063 - Disclosure -  Stock-based Compensation - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" id="StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails">
<link:definition>1064 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" id="StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails">
<link:definition>1065 - Disclosure -  Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" id="StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails">
<link:definition>1066 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" id="StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
<link:definition>1067 - Disclosure -  Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails" id="EmployeeStockPurchasePlanAdditionalInformationDetails">
<link:definition>1068 - Disclosure -  Employee Stock Purchase Plan - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1069 - Disclosure -  Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" id="IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails">
<link:definition>1070 - Disclosure -  Income Taxes - Schedule of Reconciliation Pre-tax Income (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails" id="IncomeTaxesScheduleOfProvisionDetails">
<link:definition>1071 - Disclosure -  Income Taxes - Schedule of Provision (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" id="IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
<link:definition>1072 - Disclosure -  Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<link:definition>1073 - Disclosure -  Income Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails" id="ResearchAndLicenseAgreementsAdditionalInformationDetails">
<link:definition>1074 - Disclosure - Research and License Agreements - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails" id="CollaborationAgreementAdditionalInformationDetails">
<link:definition>1075 - Disclosure -  Collaboration Agreement - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
<link:definition>1076 - Disclosure -  Leases - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfLeasesDetails" id="LeasesScheduleOfLeasesDetails">
<link:definition>1077 - Disclosure -  Leases - Schedule of Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails" id="LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails">
<link:definition>1078 - Disclosure -  Leases - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails" id="LeasesScheduleOfFutureAggregateMinimumPaymentsDetails">
<link:definition>1079 - Disclosure -  Leases - Schedule of Future Aggregate Minimum Payments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails" id="SubleaseSummaryOfFutureSubleaseIncomeDetails">
<link:definition>1080 - Disclosure - Sublease - Summary of future sublease income (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails" id="SubleaseAdditionalInformationDetails">
<link:definition>1081 - Disclosure - Sublease (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
<link:definition>1082 - Disclosure -  Commitments and Contingencies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails" id="EmployeeBenefitPlanAdditionalInformationDetails">
<link:definition>1083 - Disclosure -  Employee Benefit Plan - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails" id="RelatedPartyTransactionsAdditionalInformationDetails">
<link:definition>1084 - Disclosure -  Related Party Transactions - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails" id="RestructuringAdditionalInformationDetails">
<link:definition>1085 - Disclosure -  Restructuring (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails" id="RestructuringSummaryOfRestructuringRelatedChargesDetails">
<link:definition>1086 - Disclosure -  Restructuring - Summary of Restructuring-related charges (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails" id="RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails">
<link:definition>1087 - Disclosure -  Restructuring - Schdule of Changes to the liability for the restructuring (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails" id="RestructuringScheduleOfIncurredChargesDueToRestructuringDetails">
<link:definition>1088 - Disclosure - Restructuring - Schedule of incurred charges due to restructuring (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1089 - Disclosure - Subsequent Events (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="freq-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="OtherLongTermAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_OtherLongTermAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Earningpersharebasicanddiluted" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_Earningpersharebasicanddiluted" substitutionGroup="xbrli:item" />
<element name="WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesUnderEquityOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_StockIssuedDuringPeriodSharesUnderEquityOffering" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockPursuantToRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_IncreaseDecreaseInLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashLeaseExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_NonCashLeaseExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromPaymentForPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_ProceedsFromPaymentForPropertyAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" substitutionGroup="xbrli:item" />
<element name="EmployeeStockPurchasePlanDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_EmployeeStockPurchasePlanDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_LicenseAgreementTextBlock" substitutionGroup="xbrli:item" />
<element name="Sublease" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_Sublease" substitutionGroup="xbrli:item" />
<element name="UnauditedInterimFinancialInformationPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_UnauditedInterimFinancialInformationPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="SignificantSuppliersPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_SignificantSuppliersPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PatentCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PropertyAndEquipmentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfRestructingRelatedChargesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_ScheduleOfRestructingRelatedChargesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfExpectedFutureSubleaseIncome" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_SummaryOfExpectedFutureSubleaseIncome" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LexingtonMassachusettsFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_LexingtonMassachusettsFacilityMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LabEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="FurnitureAndOfficeEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_FurnitureAndOfficeEquipmentMember" substitutionGroup="xbrli:item" />
<element name="LongTermMarketableSecuritiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_LongTermMarketableSecuritiesMember" substitutionGroup="xbrli:item" />
<element name="ShortTermMarketableSecuritiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_ShortTermMarketableSecuritiesMember" substitutionGroup="xbrli:item" />
<element name="PrepaidRentAndDepositsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_PrepaidRentAndDepositsCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrepaidResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_PrepaidResearchAndDevelopmentExpenseCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrepaidAccountsReceivableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_PrepaidAccountsReceivableCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TermLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_TermLoanMember" substitutionGroup="xbrli:item" />
<element name="PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" substitutionGroup="xbrli:item" />
<element name="PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" substitutionGroup="xbrli:item" />
<element name="PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentInterestOnlyPaymentMaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_DebtInstrumentInterestOnlyPaymentMaturityDate" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentFloorInterestRatePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_DebtInstrumentFloorInterestRatePercentage" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentPrepaymentPremiumPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_DebtInstrumentPrepaymentPremiumPercentage" substitutionGroup="xbrli:item" />
<element name="DebtDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_DebtDue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_LoanAndSecurityAgreementMember" substitutionGroup="xbrli:item" />
<element name="Denominator" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_Denominator" substitutionGroup="xbrli:item" />
<element name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_UnvestedRestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="OutstandingStockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_OutstandingStockOptionsMember" substitutionGroup="xbrli:item" />
<element name="SalesAgentCommission" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_SalesAgentCommission" substitutionGroup="xbrli:item" />
<element name="AtTheMarketProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_AtTheMarketProgramMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndNineteenIncentiveAwardPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndFourteenStockIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_TwoThousandAndFourteenStockIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" substitutionGroup="xbrli:item" />
<element name="TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" substitutionGroup="xbrli:item" />
<element name="PercentageOfEligibleEmployeeCompensation" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PercentageOfEligibleEmployeeCompensation" substitutionGroup="xbrli:item" />
<element name="IncomeTaxesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_IncomeTaxesDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_IncomeTaxesDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetOperatingLossCarryforwardsExpirationWithLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLossCarryforwardsUsageAfterOwnershipChange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_TaxCreditCarryforwardExpirationYear" substitutionGroup="xbrli:item" />
<element name="CumulativeChangeInOwnershipPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_CumulativeChangeInOwnershipPercentage" substitutionGroup="xbrli:item" />
<element name="PeriodOfCumulativeChangeInOwnership" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PeriodOfCumulativeChangeInOwnership" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_OperatingLossCarryforwardsExpirationYear" substitutionGroup="xbrli:item" />
<element name="NetOperatingLossCarryforwardsExpirationWithoutLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreTaxNetLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PreTaxNetLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsLeasingArrangements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_DeferredTaxAssetsLeasingArrangements" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_DeferredTaxAssetsRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CaliforniaInstituteForBiomedicalResearchMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_CaliforniaInstituteForBiomedicalResearchMember" substitutionGroup="xbrli:item" />
<element name="MassachusettsInstituteOfTechnologyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_MassachusettsInstituteOfTechnologyMember" substitutionGroup="xbrli:item" />
<element name="MassachusettsEyeAndEarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_MassachusettsEyeAndEarMember" substitutionGroup="xbrli:item" />
<element name="DescriptionOfFutureDevelopmentObligations" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_DescriptionOfFutureDevelopmentObligations" substitutionGroup="xbrli:item" />
<element name="AnnualLicenseFeePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_AnnualLicenseFeePerShare" substitutionGroup="xbrli:item" />
<element name="PercentageOfRoyaltyOnSublicenseRevenue" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PercentageOfRoyaltyOnSublicenseRevenue" substitutionGroup="xbrli:item" />
<element name="RightToTerminateLicensedPatentsUponPriorWrittenNotice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" substitutionGroup="xbrli:item" />
<element name="PercentageOfSharesOfCommonStockIssued" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_PercentageOfSharesOfCommonStockIssued" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementEnteredDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_LicenseAgreementEnteredDate" substitutionGroup="xbrli:item" />
<element name="RoyaltyExpensePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RoyaltyExpensePerShare" substitutionGroup="xbrli:item" />
<element name="LicenseFeePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_LicenseFeePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_MilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RightToTerminateAgreementIfBreachRemainsUncured" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RightToTerminateAgreementIfBreachRemainsUncured" substitutionGroup="xbrli:item" />
<element name="RightToTerminateAgreementIncaseOfNonpayment" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RightToTerminateAgreementIncaseOfNonpayment" substitutionGroup="xbrli:item" />
<element name="RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" substitutionGroup="xbrli:item" />
<element name="DescriptionOfConditionsToTerminateLicenseAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_DescriptionOfConditionsToTerminateLicenseAgreement" substitutionGroup="xbrli:item" />
<element name="RightToTerminateAgreementUponPriorWrittenNotice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RightToTerminateAgreementUponPriorWrittenNotice" substitutionGroup="xbrli:item" />
<element name="PatentLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_PatentLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="NonExclusivePatentLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_NonExclusivePatentLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="Phase2bClinicalTrialMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_Phase2bClinicalTrialMember" substitutionGroup="xbrli:item" />
<element name="Phase3ClinicalTrailMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_Phase3ClinicalTrailMember" substitutionGroup="xbrli:item" />
<element name="LicenseAndCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_LicenseAndCollaborationAgreementMember" substitutionGroup="xbrli:item" />
<element name="RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_AgreementTerminationNoticePeriod" substitutionGroup="xbrli:item" />
<element name="UpfrontFeeRecognizedAsRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_UpfrontFeeRecognizedAsRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueRecognitionTransactionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RevenueRecognitionTransactionPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="JointCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_JointCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AstellasPharmaLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_AstellasPharmaLimitedLiabilityCompanyMember" substitutionGroup="xbrli:item" />
<element name="LexingtonLeaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_LexingtonLeaseMember" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseCommencementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_OperatingLeaseCommencementDate" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseNumberOfAdditionalExtensionTerms" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" substitutionGroup="xbrli:item" />
<element name="OperatingLeasesAdditionalExtensionTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_OperatingLeasesAdditionalExtensionTerm" substitutionGroup="xbrli:item" />
<element name="LeasesTerminationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_LeasesTerminationAgreementMember" substitutionGroup="xbrli:item" />
<element name="AREMARegionNo20LLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_AREMARegionNo20LLCMember" substitutionGroup="xbrli:item" />
<element name="HaydenLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_HaydenLLCMember" substitutionGroup="xbrli:item" />
<element name="SaliogenTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_SaliogenTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="ReductionInWorkforceDueToRestructuring" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_ReductionInWorkforceDueToRestructuring" substitutionGroup="xbrli:item" />
<element name="RestructuringRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_RestructuringRelatedExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AcceleratedHearingProgramCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_AcceleratedHearingProgramCharges" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AcceleratedDepreciationChargesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_AcceleratedDepreciationChargesMember" substitutionGroup="xbrli:item" />
<element name="AcceleratedfxthreetwotwochargesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_AcceleratedfxthreetwotwochargesMember" substitutionGroup="xbrli:item" />
<element name="AcceleratedfxthreefourfivechargesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="freq_AcceleratedfxthreefourfivechargesMember" substitutionGroup="xbrli:item" />
<element name="RestructingLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="freq_RestructingLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestructingNetCharge" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="freq_RestructingNetCharge" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>freq-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2023 [06:37:32] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#AccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfProvisionDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesScheduleOfFutureAggregateMinimumPaymentsDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubleaseSummaryOfFutureSubleaseIncomeDetails" roleURI="http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:label="loc_FREQ_PrepaidRentAndDepositsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_FREQ_PrepaidRentAndDepositsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="loc_FREQ_PrepaidResearchAndDevelopmentExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_FREQ_PrepaidResearchAndDevelopmentExpenseCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidAccountsReceivableCurrent" xlink:label="loc_FREQ_PrepaidAccountsReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_FREQ_PrepaidAccountsReceivableCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidInsurance" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsLeasingArrangements" xlink:label="loc_FREQ_DeferredTaxAssetsLeasingArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_FREQ_DeferredTaxAssetsLeasingArrangements" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_FREQ_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_FREQ_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_FREQ_DeferredTaxAssetsRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_FREQ_DeferredTaxAssetsRightOfUseAssets" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OtherLongTermAssets" xlink:label="loc_FREQ_OtherLongTermAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_FREQ_OtherLongTermAssets" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansFromBank" xlink:label="loc_us-gaap_LongTermLoansFromBank" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermLoansFromBank" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="24" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails">
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PreTaxNetLoss" xlink:label="loc_FREQ_PreTaxNetLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_FREQ_PreTaxNetLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_FREQ_PreTaxNetLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_FREQ_IncreaseDecreaseInLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FREQ_IncreaseDecreaseInLeaseLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NonCashLeaseExpenses" xlink:label="loc_FREQ_NonCashLeaseExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FREQ_NonCashLeaseExpenses" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_PaidInKindInterest" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InterestIncomeExpenseNet" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ProceedsFromPaymentForPropertyAndEquipment" xlink:label="loc_FREQ_ProceedsFromPaymentForPropertyAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_FREQ_ProceedsFromPaymentForPropertyAndEquipment" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockPlans" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt" use="optional" order="22" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:label="loc_FREQ_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_FREQ_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_FREQ_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_FREQ_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>freq-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2023 [06:37:33] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CoverPage" roleURI="http://www.frequencytherapeutics.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsStockholdersEquityDeficitUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationTables" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#OrganizationAndBasisOfPresentationAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails" roleURI="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails" roleURI="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#DebtAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockholdersEquityAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#EmployeeStockPurchasePlanAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ResearchAndLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CollaborationAgreementAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubleaseAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringSummaryOfRestructuringRelatedChargesDetails" roleURI="http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails" roleURI="http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#OrganizationAndBasisOfPresentation" roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurements" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipment" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#AccruedExpenses" roleURI="http://www.frequencytherapeutics.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Debt" roleURI="http://www.frequencytherapeutics.com/role/Debt" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockholdersEquity" roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensation" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#EmployeeStockPurchasePlan" roleURI="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlan" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxes" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CollaborationAgreement" roleURI="http://www.frequencytherapeutics.com/role/CollaborationAgreement" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Leases" roleURI="http://www.frequencytherapeutics.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CommitmentsAndContingencies" roleURI="http://www.frequencytherapeutics.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#EmployeeBenefitPlan" roleURI="http://www.frequencytherapeutics.com/role/EmployeeBenefitPlan" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RelatedPartyTransactions" roleURI="http://www.frequencytherapeutics.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubsequentEvents" roleURI="http://www.frequencytherapeutics.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#OrganizationAndBasisOfPresentationPolicies" roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipmentTables" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#AccruedExpensesTables" roleURI="http://www.frequencytherapeutics.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockholdersEquityTables" roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurementsTables" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesTables" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubleaseTables" roleURI="http://www.frequencytherapeutics.com/role/SubleaseTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#AccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfProvisionDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesTables" roleURI="http://www.frequencytherapeutics.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesScheduleOfLeasesDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesScheduleOfFutureAggregateMinimumPaymentsDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubleaseSummaryOfFutureSubleaseIncomeDetails" roleURI="http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Investment" roleURI="http://www.frequencytherapeutics.com/role/Investment" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#InvestmentsTables" roleURI="http://www.frequencytherapeutics.com/role/InvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#InvestmentsAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/InvestmentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#NetLossPerShare" roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#NetLossPerShareTables" roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RecentlyAdoptedAndIssuedAccountingStandards" roleURI="http://www.frequencytherapeutics.com/role/RecentlyAdoptedAndIssuedAccountingStandards" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Sublease" roleURI="http://www.frequencytherapeutics.com/role/Sublease" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Restructuring" roleURI="http://www.frequencytherapeutics.com/role/Restructuring" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringScheduleOfIncurredChargesDueToRestructuringDetails" roleURI="http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringTables" roleURI="http://www.frequencytherapeutics.com/role/RestructuringTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ResearchAndLicenseAgreements" roleURI="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreements" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1782" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_DocumentType_102" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_AmendmentFlag_103" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityCentralIndexKey_110" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityRegistrantName_112" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityIncorporationStateCountryCode_113" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityTaxIdentificationNumber_114" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressAddressLine1_115" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressAddressLine2_116" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressCityOrTown_117" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressStateOrProvince_118" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressPostalZipCode_119" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_CityAreaCode_120" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_LocalPhoneNumber_121" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityFilerCategory_129" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntitySmallBusiness_130" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityEmergingGrowthCompany_131" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityExTransitionPeriod_132" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityPrimarySicNumber_1773" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_ContactPersonnelName_1774" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_us-gaap_StatementTable_1776" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1776" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1779" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1779" xlink:to="loc_dei_AddressTypeDomain_1780" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1780_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1779" xlink:to="loc_dei_AddressTypeDomain_1780_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1780" xlink:to="loc_dei_BusinessContactMember_1781" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_216" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_223" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_225" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_226" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_227" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_228" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_StockIssuedDuringPeriodSharesUnderEquityOffering" xlink:label="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOffering_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOffering_229" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StatementTable_212" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_212" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_211" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_211" xlink:to="loc_us-gaap_EquityComponentDomain_213" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_211" xlink:to="loc_us-gaap_EquityComponentDomain_213_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_213" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_222" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_213" xlink:to="loc_us-gaap_RetainedEarningsMember_224" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_213" xlink:to="loc_us-gaap_CommonStockMember_218" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_213" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_220" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_214" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_217" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" xlink:label="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount_230" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" xlink:label="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares_231" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" xlink:label="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits_232" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_235" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_NetIncomeLoss_236" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_219" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_386" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1565" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_389" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_391" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" xlink:to="loc_us-gaap_AwardTypeAxis_387" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_388" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_411" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_408" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_408" xlink:to="loc_us-gaap_EquityComponentDomain_412" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_412_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_408" xlink:to="loc_us-gaap_EquityComponentDomain_412_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_415" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_415" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_410" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_410_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_415" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_410_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_417" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1440" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" xlink:to="loc_srt_StatementGeographicalAxis_423" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_423" xlink:to="loc_srt_SegmentGeographicalDomain_425" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_425_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_423" xlink:to="loc_srt_SegmentGeographicalDomain_425_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LexingtonMassachusettsFacilityMember" xlink:label="loc_freq_LexingtonMassachusettsFacilityMember_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_425" xlink:to="loc_freq_LexingtonMassachusettsFacilityMember_422" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_430" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_430" xlink:to="loc_us-gaap_TypeOfAdoptionMember_426" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_430" xlink:to="loc_us-gaap_TypeOfAdoptionMember_426_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_426" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_436" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_428" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="loc_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_441" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_444" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_445" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_437" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_421" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_454" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesTable_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_454" xlink:to="loc_freq_SummaryOfSignificantAccountingPoliciesTable_450" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable_450" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_449" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_449" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_449" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LabEquipmentMember" xlink:label="loc_freq_LabEquipmentMember_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" xlink:to="loc_freq_LabEquipmentMember_452" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_455" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:label="loc_freq_FurnitureAndOfficeEquipmentMember_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" xlink:to="loc_freq_FurnitureAndOfficeEquipmentMember_456" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1784" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_494" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_498" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_501" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_FinancialInstrumentAxis_495" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_495" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_495" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LongTermMarketableSecuritiesMember" xlink:label="loc_freq_LongTermMarketableSecuritiesMember_497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" xlink:to="loc_freq_LongTermMarketableSecuritiesMember_497" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ShortTermMarketableSecuritiesMember" xlink:label="loc_freq_ShortTermMarketableSecuritiesMember_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" xlink:to="loc_freq_ShortTermMarketableSecuritiesMember_493" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" xlink:to="loc_us-gaap_MoneyMarketFundsMember_485" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_499" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_499" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_499" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_496" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_491" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_502" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_502" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_489" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_489_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_502" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_489_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_489" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_492" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_InvestmentTypeAxis_488" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_488" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_484" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_488" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_484_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_487" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1185" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1189" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1074" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_1075" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_1075" xlink:to="loc_us-gaap_InvestmentTypeAxis_1072" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1072" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1073" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1073_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1072" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1073_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1073" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1071" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_530" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_530" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_529" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_529" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_529" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_535" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" xlink:to="loc_us-gaap_EquipmentMember_532" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_537" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_533" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_536" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_528" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_571" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_565" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_568" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xlink:label="loc_freq_DebtInstrumentInterestOnlyPaymentMaturityDate_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_freq_DebtInstrumentInterestOnlyPaymentMaturityDate_570" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_572" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_573" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_561" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_InterestExpenseDebt_574" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentTable_559" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_563" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_563" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_555" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_563" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_555_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TermLoanMember" xlink:label="loc_freq_TermLoanMember_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_555" xlink:to="loc_freq_TermLoanMember_562" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_VariableRateAxis_566" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_566" xlink:to="loc_us-gaap_VariableRateDomain_553" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_566" xlink:to="loc_us-gaap_VariableRateDomain_553_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_553" xlink:to="loc_us-gaap_PrimeRateMember_557" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_DebtInstrumentAxis_569" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_569" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_558" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_558_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_569" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_558_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_558" xlink:to="loc_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_564" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_558" xlink:to="loc_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_567" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_558" xlink:to="loc_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_560" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_TypeOfArrangementAxis_552" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_552" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_554" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_554_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_552" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_554_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LoanAndSecurityAgreementMember" xlink:label="loc_freq_LoanAndSecurityAgreementMember_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_554" xlink:to="loc_freq_LoanAndSecurityAgreementMember_556" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1572" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1572" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1172" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1172_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1572" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1172_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1172" xlink:to="loc_us-gaap_SubsequentEventMember_1112" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentFloorInterestRatePercentage" xlink:label="loc_freq_DebtInstrumentFloorInterestRatePercentage_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_freq_DebtInstrumentFloorInterestRatePercentage_575" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="loc_freq_DebtInstrumentPrepaymentPremiumPercentage_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_freq_DebtInstrumentPrepaymentPremiumPercentage_576" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_577" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtDue" xlink:label="loc_freq_DebtDue_1678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_freq_DebtDue_1678" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1175" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1175" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1120" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1120" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1124" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1124" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1124" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_UnvestedRestrictedStockUnitsMember" xlink:label="loc_freq_UnvestedRestrictedStockUnitsMember_1174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121" xlink:to="loc_freq_UnvestedRestrictedStockUnitsMember_1174" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OutstandingStockOptionsMember" xlink:label="loc_freq_OutstandingStockOptionsMember_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121" xlink:to="loc_freq_OutstandingStockOptionsMember_1193" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1175" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1122" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_629" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_PreferredStockSharesIssued_626" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_628" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_630" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_631" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_632" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_CommonStockSharesIssued_633" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_634" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_635" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_636" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" xlink:to="loc_srt_RangeAxis_625" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_625" xlink:to="loc_srt_RangeMember_615" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_615_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_625" xlink:to="loc_srt_RangeMember_615_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_615" xlink:to="loc_srt_MaximumMember_616" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_612" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_612" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_612" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AtTheMarketProgramMember" xlink:label="loc_freq_AtTheMarketProgramMember_1534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617" xlink:to="loc_freq_AtTheMarketProgramMember_1534" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareDistributionMember" xlink:label="loc_us-gaap_ShareDistributionMember_1297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617" xlink:to="loc_us-gaap_ShareDistributionMember_1297" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_623" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_623" xlink:to="loc_us-gaap_EquityComponentDomain_619" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_619_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_623" xlink:to="loc_us-gaap_EquityComponentDomain_619_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_619" xlink:to="loc_us-gaap_CommonStockMember_620" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_621" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_624" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SalesAgentCommission" xlink:label="loc_freq_SalesAgentCommission_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_freq_SalesAgentCommission_637" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_646" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_646" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_641" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_641" xlink:to="loc_us-gaap_AwardTypeAxis_642" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645" xlink:to="loc_us-gaap_StockCompensationPlanMember_647" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645" xlink:to="loc_us-gaap_EmployeeStockOptionMember_643" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_646" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_644" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_663" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_670" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_681" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_682" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_657" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_683" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="loc_us-gaap_StockOptionExercisePriceDecrease_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_StockOptionExercisePriceDecrease_677" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_678" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" xlink:label="loc_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions_679" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:label="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_668" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_674" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_672" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_673" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_675" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_676" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_us-gaap_PlanNameAxis_659" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_659" xlink:to="loc_us-gaap_PlanNameDomain_660" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_660_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_659" xlink:to="loc_us-gaap_PlanNameDomain_660_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:label="loc_freq_TwoThousandAndNineteenIncentiveAwardPlanMember_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_660" xlink:to="loc_freq_TwoThousandAndNineteenIncentiveAwardPlanMember_661" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:label="loc_freq_TwoThousandAndFourteenStockIncentivePlanMember_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_660" xlink:to="loc_freq_TwoThousandAndFourteenStockIncentivePlanMember_650" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_us-gaap_AwardTypeAxis_667" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_656" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_656_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_669" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_669" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_654" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_654_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_669" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_654_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_654" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_664" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_654" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_658" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_srt_RangeAxis_665" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_665" xlink:to="loc_srt_RangeMember_652" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_652_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_665" xlink:to="loc_srt_RangeMember_652_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_652" xlink:to="loc_srt_MaximumMember_653" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_693" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688" xlink:to="loc_us-gaap_PlanNameAxis_690" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_690" xlink:to="loc_us-gaap_PlanNameDomain_691" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_691_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_690" xlink:to="loc_us-gaap_PlanNameDomain_691_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="loc_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_691" xlink:to="loc_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember_695" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_689" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_699" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_700" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_704" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_701" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_712" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_706" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_707" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_708" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_709" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_710" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_711" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_714" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_715" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_713" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_696" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_697" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_702" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_703" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_735" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_724" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_724" xlink:to="loc_us-gaap_AwardTypeAxis_728" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_728" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_726" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_726_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_728" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_726_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_726" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_729" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_736" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_737" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_738" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" xlink:label="loc_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues_1783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues_1783" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_727" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_730" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_732" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_733" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1170" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1170" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1136" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1170" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1134" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1134" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1138" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1138" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1135" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1135_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1138" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1135_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1135" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1169" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1135" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1137" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_747" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:label="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_749" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_750" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_744" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_744" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_746" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_746" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_746" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743" xlink:to="loc_us-gaap_EmployeeStockMember_742" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:label="loc_freq_PercentageOfEligibleEmployeeCompensation_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_freq_PercentageOfEligibleEmployeeCompensation_745" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_751" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:label="loc_freq_IncomeTaxesDisclosureLineItems_778" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_OperatingLossCarryforwards_769" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncomeTaxesDisclosureTable" xlink:label="loc_freq_IncomeTaxesDisclosureTable_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_IncomeTaxesDisclosureTable_758" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_srt_StatementGeographicalAxis_770" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_770" xlink:to="loc_srt_SegmentGeographicalDomain_760" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_760_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_770" xlink:to="loc_srt_SegmentGeographicalDomain_760_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="loc_stpr_MA_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_760" xlink:to="loc_stpr_MA_756" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_761" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_761" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_766" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_766_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_761" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_766_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_766" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_767" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_766" xlink:to="loc_us-gaap_DomesticCountryMember_754" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_772" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_772" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_764" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_764_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_772" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_764_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_764" xlink:to="loc_us-gaap_ResearchMember_765" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_774" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_774" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_763" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_763_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_774" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_763_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_763" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_762" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_srt_RangeAxis_776" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_776" xlink:to="loc_srt_RangeMember_755" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_755_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_776" xlink:to="loc_srt_RangeMember_755_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_755" xlink:to="loc_srt_MinimumMember_757" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_759" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_784" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:label="loc_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_785" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_786" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_787" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_788" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_789" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:label="loc_freq_NetOperatingLossCarryforwardsExpirationWithLimitation_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_NetOperatingLossCarryforwardsExpirationWithLimitation_771" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_782" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_783" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:label="loc_freq_TaxCreditCarryforwardExpirationYear_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_TaxCreditCarryforwardExpirationYear_777" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_779" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:label="loc_freq_CumulativeChangeInOwnershipPercentage_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_CumulativeChangeInOwnershipPercentage_780" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:label="loc_freq_PeriodOfCumulativeChangeInOwnership_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_PeriodOfCumulativeChangeInOwnership_781" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1219" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_freq_OperatingLossCarryforwardsExpirationYear_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_OperatingLossCarryforwardsExpirationYear_773" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:label="loc_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_775" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:label="loc_freq_DescriptionOfFutureDevelopmentObligations_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_DescriptionOfFutureDevelopmentObligations_865" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_RangeAxis_864" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_864" xlink:to="loc_srt_RangeMember_842" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_842_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_864" xlink:to="loc_srt_RangeMember_842_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_842" xlink:to="loc_srt_MaximumMember_845" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_842" xlink:to="loc_srt_MinimumMember_857" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_dei_LegalEntityAxis_849" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_849" xlink:to="loc_dei_EntityDomain_846" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_846_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_849" xlink:to="loc_dei_EntityDomain_846_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:label="loc_freq_CaliforniaInstituteForBiomedicalResearchMember_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_846" xlink:to="loc_freq_CaliforniaInstituteForBiomedicalResearchMember_861" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:label="loc_freq_MassachusettsInstituteOfTechnologyMember_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_846" xlink:to="loc_freq_MassachusettsInstituteOfTechnologyMember_853" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MassachusettsEyeAndEarMember" xlink:label="loc_freq_MassachusettsEyeAndEarMember_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_846" xlink:to="loc_freq_MassachusettsEyeAndEarMember_869" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_CounterpartyNameAxis_867" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_867" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_852" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_852_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_867" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_852_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_859" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_859" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_859" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PatentLicenseAgreementMember" xlink:label="loc_freq_PatentLicenseAgreementMember_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848" xlink:to="loc_freq_PatentLicenseAgreementMember_847" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:label="loc_freq_NonExclusivePatentLicenseAgreementMember_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848" xlink:to="loc_freq_NonExclusivePatentLicenseAgreementMember_858" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_TitleOfIndividualAxis_873" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_873" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_856" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_856_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_873" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_856_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_856" xlink:to="loc_srt_DirectorMember_855" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_ProductOrServiceAxis_870" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_870" xlink:to="loc_srt_ProductsAndServicesDomain_841" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_841_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_870" xlink:to="loc_srt_ProductsAndServicesDomain_841_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_StatementScenarioAxis_875" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_875" xlink:to="loc_srt_ScenarioUnspecifiedDomain_850" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_850_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_875" xlink:to="loc_srt_ScenarioUnspecifiedDomain_850_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AnnualLicenseFeePerShare" xlink:label="loc_freq_AnnualLicenseFeePerShare_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_AnnualLicenseFeePerShare_893" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfRoyaltyOnSublicenseRevenue" xlink:label="loc_freq_PercentageOfRoyaltyOnSublicenseRevenue_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_PercentageOfRoyaltyOnSublicenseRevenue_874" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaap_PaymentForManagementFee_885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_us-gaap_PaymentForManagementFee_885" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:label="loc_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_886" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:label="loc_freq_PercentageOfSharesOfCommonStockIssued_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_PercentageOfSharesOfCommonStockIssued_871" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseAgreementEnteredDate" xlink:label="loc_freq_LicenseAgreementEnteredDate_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_LicenseAgreementEnteredDate_851" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RoyaltyExpensePerShare" xlink:label="loc_freq_RoyaltyExpensePerShare_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RoyaltyExpensePerShare_878" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseFeePayment" xlink:label="loc_freq_LicenseFeePayment_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_LicenseFeePayment_868" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MilestonePayments" xlink:label="loc_freq_MilestonePayments_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_MilestonePayments_879" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:label="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured_883" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:label="loc_freq_RightToTerminateAgreementIncaseOfNonpayment_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateAgreementIncaseOfNonpayment_884" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:label="loc_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_891" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:label="loc_freq_DescriptionOfConditionsToTerminateLicenseAgreement_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_DescriptionOfConditionsToTerminateLicenseAgreement_881" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:label="loc_freq_RightToTerminateAgreementUponPriorWrittenNotice_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateAgreementUponPriorWrittenNotice_882" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:label="loc_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_918" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AgreementTerminationNoticePeriod" xlink:label="loc_freq_AgreementTerminationNoticePeriod_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_AgreementTerminationNoticePeriod_920" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:label="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured_922" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:label="loc_freq_UpfrontFeeRecognizedAsRevenue_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_UpfrontFeeRecognizedAsRevenue_926" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:label="loc_freq_RightToTerminateAgreementIncaseOfNonpayment_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_RightToTerminateAgreementIncaseOfNonpayment_924" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RevenueRecognitionTransactionPrice" xlink:label="loc_freq_RevenueRecognitionTransactionPrice_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_RevenueRecognitionTransactionPrice_925" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_JointCost" xlink:label="loc_freq_JointCost_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_JointCost_928" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_919" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_919" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_919" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Phase2bClinicalTrialMember" xlink:label="loc_freq_Phase2bClinicalTrialMember_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911" xlink:to="loc_freq_Phase2bClinicalTrialMember_905" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Phase3ClinicalTrailMember" xlink:label="loc_freq_Phase3ClinicalTrailMember_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911" xlink:to="loc_freq_Phase3ClinicalTrailMember_914" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_srt_StatementGeographicalAxis_921" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_921" xlink:to="loc_srt_SegmentGeographicalDomain_908" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_921" xlink:to="loc_srt_SegmentGeographicalDomain_908_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_908" xlink:to="loc_srt_AsiaMember_912" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_908" xlink:to="loc_srt_EuropeMember_902" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_us-gaap_TypeOfArrangementAxis_906" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_899" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_899_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_899_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:label="loc_freq_LicenseAndCollaborationAgreementMember_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_899" xlink:to="loc_freq_LicenseAndCollaborationAgreementMember_907" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_srt_RangeAxis_915" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_915" xlink:to="loc_srt_RangeMember_900" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_900_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_915" xlink:to="loc_srt_RangeMember_900_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_900" xlink:to="loc_srt_MaximumMember_903" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_srt_CounterpartyNameAxis_917" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_917" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_909" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_917" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_909_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:label="loc_freq_AstellasPharmaLimitedLiabilityCompanyMember_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_909" xlink:to="loc_freq_AstellasPharmaLimitedLiabilityCompanyMember_901" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_913" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:label="loc_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_916" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_us-gaap_ProceedsFromCollaborators_904" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_us-gaap_NetRentableArea_949" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeaseCommencementDate" xlink:label="loc_freq_OperatingLeaseCommencementDate_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_freq_OperatingLeaseCommencementDate_951" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:label="loc_freq_OperatingLeaseNumberOfAdditionalExtensionTerms_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_freq_OperatingLeaseNumberOfAdditionalExtensionTerms_952" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:label="loc_freq_OperatingLeasesAdditionalExtensionTerm_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_freq_OperatingLeasesAdditionalExtensionTerm_956" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_us-gaap_OperatingLeaseExpense_957" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_us-gaap_LeaseExpirationDate1_945" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_936" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_us-gaap_LeaseContractualTermAxis_948" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_948" xlink:to="loc_us-gaap_LeaseContractualTermDomain_941" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_941_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_948" xlink:to="loc_us-gaap_LeaseContractualTermDomain_941_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LexingtonLeaseMember" xlink:label="loc_freq_LexingtonLeaseMember_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_941" xlink:to="loc_freq_LexingtonLeaseMember_932" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_us-gaap_TypeOfArrangementAxis_944" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_944" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_931" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_931_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_944" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_931_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LeasesTerminationAgreementMember" xlink:label="loc_freq_LeasesTerminationAgreementMember_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_931" xlink:to="loc_freq_LeasesTerminationAgreementMember_937" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_srt_CounterpartyNameAxis_946" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_946" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_946" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AREMARegionNo20LLCMember" xlink:label="loc_freq_AREMARegionNo20LLCMember_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940" xlink:to="loc_freq_AREMARegionNo20LLCMember_933" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_HaydenLLCMember" xlink:label="loc_freq_HaydenLLCMember_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940" xlink:to="loc_freq_HaydenLLCMember_942" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_srt_StatementGeographicalAxis_938" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_938" xlink:to="loc_srt_SegmentGeographicalDomain_939" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_939_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_938" xlink:to="loc_srt_SegmentGeographicalDomain_939_default" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_998" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" xlink:to="loc_us-gaap_NetRentableArea_996" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994" xlink:to="loc_srt_CounterpartyNameAxis_993" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_993" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_995" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_995_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_993" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_995_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SaliogenTherapeuticsIncMember" xlink:label="loc_freq_SaliogenTherapeuticsIncMember_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_995" xlink:to="loc_freq_SaliogenTherapeuticsIncMember_991" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" xlink:to="loc_us-gaap_SubleaseIncome_992" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1002" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1005" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1005" xlink:to="loc_srt_StatementGeographicalAxis_1003" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1003" xlink:to="loc_srt_SegmentGeographicalDomain_1004" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1004_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1003" xlink:to="loc_srt_SegmentGeographicalDomain_1004_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LexingtonMassachusettsFacilityMember" xlink:label="loc_freq_LexingtonMassachusettsFacilityMember_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1004" xlink:to="loc_freq_LexingtonMassachusettsFacilityMember_1001" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1005" xlink:to="loc_srt_RangeAxis_1478" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1478" xlink:to="loc_srt_RangeMember_1077" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1077_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1478" xlink:to="loc_srt_RangeMember_1077_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_RestrictedCash_1006" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_1009" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1010" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1025" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1025" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1020" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1020" xlink:to="loc_srt_TitleOfIndividualAxis_1023" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1023" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1024" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1024_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1023" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1024_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1024" xlink:to="loc_srt_DirectorMember_1022" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaap_PaymentForManagementFee_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1025" xlink:to="loc_us-gaap_PaymentForManagementFee_1021" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1196" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1196" xlink:to="loc_us-gaap_RestructuringCharges_1146" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1196" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1166" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1166" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1144" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1144_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1166" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1144_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1144" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1165" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1144" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1148" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1149" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1149" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1147" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1149" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1147_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1147" xlink:to="loc_us-gaap_OtherRestructuringMember_1167" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedDepreciationChargesMember" xlink:label="loc_freq_AcceleratedDepreciationChargesMember_1197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1147" xlink:to="loc_freq_AcceleratedDepreciationChargesMember_1197" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedfxthreetwotwochargesMember" xlink:label="loc_freq_AcceleratedfxthreetwotwochargesMember_1150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1147" xlink:to="loc_freq_AcceleratedfxthreetwotwochargesMember_1150" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructingLiabilities" xlink:label="loc_freq_RestructingLiabilities_1154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" xlink:to="loc_freq_RestructingLiabilities_1154" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructingNetCharge" xlink:label="loc_freq_RestructingNetCharge_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" xlink:to="loc_freq_RestructingNetCharge_1162" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1153" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1153" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1156" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1156" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1155" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1155_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1156" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1155_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedfxthreefourfivechargesMember" xlink:label="loc_freq_AcceleratedfxthreefourfivechargesMember_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1155" xlink:to="loc_freq_AcceleratedfxthreefourfivechargesMember_1164" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1155" xlink:to="loc_us-gaap_OtherRestructuringMember_1199" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedfxthreetwotwochargesMember" xlink:label="loc_freq_AcceleratedfxthreetwotwochargesMember_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1155" xlink:to="loc_freq_AcceleratedfxthreetwotwochargesMember_1157" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1034" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtDue" xlink:label="loc_freq_DebtDue_1554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_freq_DebtDue_1554" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1623" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_us-gaap_SubsequentEventTable_1030" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1555" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1555" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1383" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1383_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1555" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1383_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TermLoanMember" xlink:label="loc_freq_TermLoanMember_1389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1383" xlink:to="loc_freq_TermLoanMember_1389" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1031" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1031" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1032" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1032_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1031" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1032_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1032" xlink:to="loc_us-gaap_SubsequentEventMember_1028" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_srt_StatementGeographicalAxis_1624" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1624" xlink:to="loc_srt_SegmentGeographicalDomain_1386" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1386_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1624" xlink:to="loc_srt_SegmentGeographicalDomain_1386_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_srt_StatementScenarioAxis_1395" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1395" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1384" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1395" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1384_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1551" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1551" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1378" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1378_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1551" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1378_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LoanAndSecurityAgreementMember" xlink:label="loc_freq_LoanAndSecurityAgreementMember_1385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1378" xlink:to="loc_freq_LoanAndSecurityAgreementMember_1385" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_1033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_us-gaap_RestructuringCosts_1033" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1029" use="optional" order="23" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>freq-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2023 [06:37:33] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation State Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address Address Line</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address City Or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address State Or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Noncurrent lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansFromBank" xlink:label="loc_us-gaap_LongTermLoansFromBank" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermLoansFromBank" xml:lang="en-US">Loans Payable to Bank, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermLoansFromBank" xml:lang="en-US">Term loan, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansFromBank" xlink:to="lab_us-gaap_LongTermLoansFromBank" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Lease liabilities, current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less: current lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-Term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Term loan, current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized, 35,751,956 and 35,262,083 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2023 and December 31, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xml:lang="en-US">Long-term marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right of use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Short-term marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OtherLongTermAssets" xlink:label="loc_freq_OtherLongTermAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OtherLongTermAssets" xml:lang="en-US">Other long-term assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_OtherLongTermAssets" xml:lang="en-US">Other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OtherLongTermAssets" xlink:to="lab_freq_OtherLongTermAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OtherLongTermAssets" xml:lang="en-US">Other long-term assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, issued shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, outstanding shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Beginning Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Ending Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, authorized shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, outstanding shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, outstanding shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xml:lang="en-US">Realized Investment Gains (Losses)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xml:lang="en-US">Realized gain (loss) on investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign exchange (loss) gain</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign currency exchange (losses) gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income (expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit (provision)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Net tax benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total (benefit) provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Earningpersharebasicanddiluted" xlink:label="loc_freq_Earningpersharebasicanddiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_Earningpersharebasicanddiluted" xml:lang="en-US">EarningPerShareBasicAndDiluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_Earningpersharebasicanddiluted" xml:lang="en-US">Net loss per share attributable to common stockholders-basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_Earningpersharebasicanddiluted" xlink:to="lab_freq_Earningpersharebasicanddiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_Earningpersharebasicanddiluted" xml:lang="en-US">EarningPerShareBasicAndDiluted</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighteds Average Number Of Share Outstanding Basic And Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted-average shares of common stock outstanding-basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighteds Average Number Of Share Outstanding Basic And Diluted</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US">Other comprehensive gain (loss):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized gain (loss) on marketable securities and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Total other comprehensive gain (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Accumulated Other Comprehensive Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional-paid in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Purchase of common stock under Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Purchase of common stock under Employee Stock Purchase Plan (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Issuance of common stock, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issuance of common stock, net (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of shares, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Forfeiture of restricted stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_StockIssuedDuringPeriodSharesUnderEquityOffering" xlink:label="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_StockIssuedDuringPeriodSharesUnderEquityOffering" xml:lang="en-US">Stock Issued During Period Shares Under Equity Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_StockIssuedDuringPeriodSharesUnderEquityOffering" xml:lang="en-US">Issuance of common stock under equity offering (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOffering" xlink:to="lab_freq_StockIssuedDuringPeriodSharesUnderEquityOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_StockIssuedDuringPeriodSharesUnderEquityOffering" xml:lang="en-US">Stock Issued During Period Shares Under Equity Offering</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" xlink:label="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" xml:lang="en-US">Stock Issued During Period Shares Under Equity Offering Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" xml:lang="en-US">Issuance of common stock under equity offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" xlink:to="lab_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" xml:lang="en-US">Stock Issued During Period Shares Under Equity Offering Amount</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" xlink:label="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" xml:lang="en-US">Issuance of common stock pursuant to restricted stock units (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" xlink:to="lab_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" xml:lang="en-US">Issuance of common stock pursuant to restricted stock units (Shares)</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" xlink:label="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" xml:lang="en-US">Issuance Of Common Stock Pursuant To Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" xlink:to="lab_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" xml:lang="en-US">Issuance Of Common Stock Pursuant To Restricted Stock Units</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_freq_IncreaseDecreaseInLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Increase Decrease In Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_freq_IncreaseDecreaseInLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Increase decrease in lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposal of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaidInKindInterest" xml:lang="en-US">Paid-in-Kind Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaidInKindInterest" xml:lang="en-US">Non-cash interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NonCashLeaseExpenses" xlink:label="loc_freq_NonCashLeaseExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_NonCashLeaseExpenses" xml:lang="en-US">Non Cash Lease Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_NonCashLeaseExpenses" xml:lang="en-US">Non-cash lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_NonCashLeaseExpenses" xlink:to="lab_freq_NonCashLeaseExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_NonCashLeaseExpenses" xml:lang="en-US">Non cash lease expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Non-cash interest (income) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Redemption of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchase of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ProceedsFromPaymentForPropertyAndEquipment" xlink:label="loc_freq_ProceedsFromPaymentForPropertyAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ProceedsFromPaymentForPropertyAndEquipment" xml:lang="en-US">Proceeds From (Payment For) Property And Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_freq_ProceedsFromPaymentForPropertyAndEquipment" xml:lang="en-US">Sale of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ProceedsFromPaymentForPropertyAndEquipment" xlink:to="lab_freq_ProceedsFromPaymentForPropertyAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ProceedsFromPaymentForPropertyAndEquipment" xml:lang="en-US">Proceeds From (Payment For) Property And Equipment</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xml:lang="en-US">Proceeds from Stock Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xml:lang="en-US">Proceeds from Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayments of Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayment of Term Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xml:lang="en-US">Recently Adopted and Issued Accounting Standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="lab_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">Prepaid expenses and other current assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:label="loc_freq_EmployeeStockPurchasePlanDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_EmployeeStockPurchasePlanDisclosureTextBlock" xml:lang="en-US">Employee Stock Purchase Plan Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_EmployeeStockPurchasePlanDisclosureTextBlock" xml:lang="en-US">Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:to="lab_freq_EmployeeStockPurchasePlanDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_EmployeeStockPurchasePlanDisclosureTextBlock" xml:lang="en-US">Employee stock purchase plan disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaboration Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xml:lang="en-US">Research and Development [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseAgreementTextBlock" xlink:label="loc_freq_LicenseAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LicenseAgreementTextBlock" xml:lang="en-US">License Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LicenseAgreementTextBlock" xml:lang="en-US">Research and License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LicenseAgreementTextBlock" xlink:to="lab_freq_LicenseAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LicenseAgreementTextBlock" xml:lang="en-US">License agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">Restructuring and Related Activities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Sublease" xlink:label="loc_freq_Sublease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_Sublease" xml:lang="en-US">Sublease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_Sublease" xlink:to="lab_freq_Sublease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_Sublease" xml:lang="en-US">Sublease</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Retirement Benefits [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Employee Benefit Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently adopted and issued accounting standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="loc_freq_UnauditedInterimFinancialInformationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_UnauditedInterimFinancialInformationPolicyTextBlock" xml:lang="en-US">Unaudited Interim Financial Information Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_UnauditedInterimFinancialInformationPolicyTextBlock" xml:lang="en-US">Unaudited interim financial information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="lab_freq_UnauditedInterimFinancialInformationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_UnauditedInterimFinancialInformationPolicyTextBlock" xml:lang="en-US">Unaudited interim financial information.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk and Off-balance Sheet Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SignificantSuppliersPolicyTextBlock" xlink:label="loc_freq_SignificantSuppliersPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_SignificantSuppliersPolicyTextBlock" xml:lang="en-US">Significant Suppliers Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_SignificantSuppliersPolicyTextBlock" xml:lang="en-US">Significant Suppliers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_SignificantSuppliersPolicyTextBlock" xlink:to="lab_freq_SignificantSuppliersPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_SignificantSuppliersPolicyTextBlock" xml:lang="en-US">Significant suppliers.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs and Accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xml:lang="en-US">Collaborative Arrangements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PatentCostsPolicyTextBlock" xlink:label="loc_freq_PatentCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PatentCostsPolicyTextBlock" xlink:to="lab_freq_PatentCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Basic and Diluted Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PropertyAndEquipmentTableTextBlock" xlink:label="loc_freq_PropertyAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PropertyAndEquipmentTableTextBlock" xml:lang="en-US">Property And Equipment Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PropertyAndEquipmentTableTextBlock" xml:lang="en-US">Property And Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PropertyAndEquipmentTableTextBlock" xlink:to="lab_freq_PropertyAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PropertyAndEquipmentTableTextBlock" xml:lang="en-US">Property and equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xml:lang="en-US">Schedule of debt securities in an unrealized loss position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xml:lang="en-US">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Schedule of classified as available-for-sale and recorded at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Summary Of Prepaid Expenses And Other Current Assets Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Summary of Prepaid Expenses and Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Summary of prepaid expenses and other current assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Computation of Diluted Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="loc_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Schedule of Common Stock Shares Reserved for Future Issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:to="lab_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Schedule of common stock shares reserved for future issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Summary of Recognized Stock-based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Summary of Status of Restricted Common Stock and Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Reconciliation Pre-tax Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Schedule of Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Aggregate Minimum Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ScheduleOfRestructingRelatedChargesTableTextBlock" xlink:label="loc_freq_ScheduleOfRestructingRelatedChargesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ScheduleOfRestructingRelatedChargesTableTextBlock" xml:lang="en-US">Schedule of Restructing related charges [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_ScheduleOfRestructingRelatedChargesTableTextBlock" xml:lang="en-US">Schedule of Restructuring-related charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ScheduleOfRestructingRelatedChargesTableTextBlock" xlink:to="lab_freq_ScheduleOfRestructingRelatedChargesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ScheduleOfRestructingRelatedChargesTableTextBlock" xml:lang="en-US">Schedule of Restructing related charges [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" xlink:label="loc_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" xml:lang="en-US">Schedule of Changes to the liability for the restructuring [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" xml:lang="en-US">Schdule of Changes to the liability for the restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" xlink:to="lab_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" xml:lang="en-US">Schedule of Changes to the liability for the restructuring [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfExpectedFutureSubleaseIncome" xlink:label="loc_freq_SummaryOfExpectedFutureSubleaseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_SummaryOfExpectedFutureSubleaseIncome" xml:lang="en-US">Summary Of Expected Future Sublease Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_SummaryOfExpectedFutureSubleaseIncome" xlink:to="lab_freq_SummaryOfExpectedFutureSubleaseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_SummaryOfExpectedFutureSubleaseIncome" xml:lang="en-US">Summary Of Expected Future Sublease Income</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Subsidiary Sale Of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Date of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_freq_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LexingtonMassachusettsFacilityMember" xlink:label="loc_freq_LexingtonMassachusettsFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LexingtonMassachusettsFacilityMember" xml:lang="en-US">Lexington Massachusetts Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_freq_LexingtonMassachusettsFacilityMember" xml:lang="en-US">Lexington Massachusetts facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LexingtonMassachusettsFacilityMember" xml:lang="en-US">Lexington Massachusetts Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LexingtonMassachusettsFacilityMember" xlink:to="lab_freq_LexingtonMassachusettsFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LexingtonMassachusettsFacilityMember" xml:lang="en-US">Lexington Massachusetts facility.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xml:lang="en-US">Accounting Standards Update 2016-13</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_freq_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="loc_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xml:lang="en-US">Increase in right-of-use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xml:lang="en-US">Increase (decrease) in operating lease right of use assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adoption Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in accounting principle, accounting standards update, adoption date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in accounting principle, accounting standards update, immaterial effect</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LabEquipmentMember" xlink:label="loc_freq_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_freq_LabEquipmentMember" xml:lang="en-US">Lab equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LabEquipmentMember" xlink:to="lab_freq_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LabEquipmentMember" xml:lang="en-US">Lab equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:label="loc_freq_FurnitureAndOfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_FurnitureAndOfficeEquipmentMember" xml:lang="en-US">Furniture And Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_freq_FurnitureAndOfficeEquipmentMember" xml:lang="en-US">Furniture and office equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_FurnitureAndOfficeEquipmentMember" xlink:to="lab_freq_FurnitureAndOfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_FurnitureAndOfficeEquipmentMember" xml:lang="en-US">Furniture and office equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property and equipment, estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LongTermMarketableSecuritiesMember" xlink:label="loc_freq_LongTermMarketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LongTermMarketableSecuritiesMember" xml:lang="en-US">Long Term Marketable Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LongTermMarketableSecuritiesMember" xml:lang="en-US">Long-term Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LongTermMarketableSecuritiesMember" xlink:to="lab_freq_LongTermMarketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LongTermMarketableSecuritiesMember" xml:lang="en-US">Long term marketable securities.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ShortTermMarketableSecuritiesMember" xlink:label="loc_freq_ShortTermMarketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ShortTermMarketableSecuritiesMember" xml:lang="en-US">Short Term Marketable Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_ShortTermMarketableSecuritiesMember" xml:lang="en-US">Short-term Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ShortTermMarketableSecuritiesMember" xlink:to="lab_freq_ShortTermMarketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ShortTermMarketableSecuritiesMember" xml:lang="en-US">Short-term marketable securities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Unrealized Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Unrealized Gain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Fair Market Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Amortization Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Unrealized Loss, Less than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xml:lang="en-US">Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xml:lang="en-US">Fair Market Value, More than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xml:lang="en-US">Unrealized Loss, More than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xml:lang="en-US">Debt Securities, Held-to-Maturity, Unrealized Loss Position, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xml:lang="en-US">Fair Market Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Unrealized Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xml:lang="en-US">Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xml:lang="en-US">Fair Market Value, Less than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xml:lang="en-US">Number of Debt securities unrealized loss position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xml:lang="en-US">Fair Value, Separate Account Investment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:to="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xml:lang="en-US">Short-Term Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xml:lang="en-US">Short-term marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xml:lang="en-US">Fair Value, Separate Account Investment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:to="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:label="loc_freq_PrepaidRentAndDepositsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PrepaidRentAndDepositsCurrent" xml:lang="en-US">Prepaid Rent And Deposits Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PrepaidRentAndDepositsCurrent" xml:lang="en-US">Rent and deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PrepaidRentAndDepositsCurrent" xlink:to="lab_freq_PrepaidRentAndDepositsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PrepaidRentAndDepositsCurrent" xml:lang="en-US">Rent and deposits.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="loc_freq_PrepaidResearchAndDevelopmentExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PrepaidResearchAndDevelopmentExpenseCurrent" xml:lang="en-US">Prepaid Research And Development Expense Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PrepaidResearchAndDevelopmentExpenseCurrent" xml:lang="en-US">Research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:to="lab_freq_PrepaidResearchAndDevelopmentExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PrepaidResearchAndDevelopmentExpenseCurrent" xml:lang="en-US">Prepaid research and development expense current.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidAccountsReceivableCurrent" xlink:label="loc_freq_PrepaidAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PrepaidAccountsReceivableCurrent" xml:lang="en-US">Prepaid Accounts Receivable Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PrepaidAccountsReceivableCurrent" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PrepaidAccountsReceivableCurrent" xlink:to="lab_freq_PrepaidAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PrepaidAccountsReceivableCurrent" xml:lang="en-US">Prepaid accounts receivable current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid Insurance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Insurance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property Plant And Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and office equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Lab equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xml:lang="en-US">Accelerated depreciation charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Payroll and employee related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:label="loc_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xml:lang="en-US">Accrued Third Party Research And Development Expenses Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xml:lang="en-US">Third-party research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:to="lab_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xml:lang="en-US">Accrued third-party research and development expenses current.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Income Taxes And Other Accrued Liabilities Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued income taxes and other accrued liabilities, current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Debt Instrument [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TermLoanMember" xlink:label="loc_freq_TermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_TermLoanMember" xml:lang="en-US">Term Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_TermLoanMember" xml:lang="en-US">Term Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_TermLoanMember" xlink:to="lab_freq_TermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_TermLoanMember" xml:lang="en-US">Term loan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrimeRateMember" xml:lang="en-US">Prime Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrimeRateMember" xml:lang="en-US">Prime Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs After First Anniversary Of Closing Date And On Or Prior To Second Anniversary Of Closing Date [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xlink:to="lab_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs After Second Anniversary Of Closing Date [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs After Second Anniversary of Closing Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xlink:to="lab_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs After Second Anniversary of Closing Date.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs On Or Prior To First Anniversary Of Closing Date [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs on or Prior to First Anniversary of Closing Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xlink:to="lab_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xml:lang="en-US">Prepayment Occurs on or Prior to First Anniversary of Closing Date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Debt Instrument, Payment Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Payment terms, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPaymentTerms" xlink:to="lab_us-gaap_DebtInstrumentPaymentTerms" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Frequency of interest-only payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xlink:label="loc_freq_DebtInstrumentInterestOnlyPaymentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xml:lang="en-US">Debt Instrument Interest Only Payment Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xml:lang="en-US">Monthly interest only payments due</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xlink:to="lab_freq_DebtInstrumentInterestOnlyPaymentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xml:lang="en-US">Debt instrument interest only payment maturity date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Loan maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt instrument, Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentFloorInterestRatePercentage" xlink:label="loc_freq_DebtInstrumentFloorInterestRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DebtInstrumentFloorInterestRatePercentage" xml:lang="en-US">Debt Instrument Floor Interest Rate Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DebtInstrumentFloorInterestRatePercentage" xml:lang="en-US">Interest rate floor percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DebtInstrumentFloorInterestRatePercentage" xlink:to="lab_freq_DebtInstrumentFloorInterestRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DebtInstrumentFloorInterestRatePercentage" xml:lang="en-US">Debt instrument floor interest rate percentage.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="loc_freq_DebtInstrumentPrepaymentPremiumPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DebtInstrumentPrepaymentPremiumPercentage" xml:lang="en-US">Debt Instrument Prepayment Premium Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DebtInstrumentPrepaymentPremiumPercentage" xml:lang="en-US">Debt instrument prepayment premium percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_freq_DebtInstrumentPrepaymentPremiumPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DebtInstrumentPrepaymentPremiumPercentage" xml:lang="en-US">Debt instrument prepayment premium percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xml:lang="en-US">Debt instrument final payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtDue" xlink:label="loc_freq_DebtDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DebtDue" xml:lang="en-US">Debt Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DebtDue" xml:lang="en-US">Debt due</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DebtDue" xlink:to="lab_freq_DebtDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DebtDue" xml:lang="en-US">Debt Due</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LoanAndSecurityAgreementMember" xlink:label="loc_freq_LoanAndSecurityAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan And Security Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LoanAndSecurityAgreementMember" xlink:to="lab_freq_LoanAndSecurityAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan and security agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Denominator" xlink:label="loc_freq_Denominator" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_Denominator" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_Denominator" xlink:to="lab_freq_Denominator" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_Denominator" xml:lang="en-US">Denominator:</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_UnvestedRestrictedStockUnitsMember" xlink:label="loc_freq_UnvestedRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_UnvestedRestrictedStockUnitsMember" xml:lang="en-US">Unvested Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_UnvestedRestrictedStockUnitsMember" xml:lang="en-US">Unvested Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_UnvestedRestrictedStockUnitsMember" xlink:to="lab_freq_UnvestedRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_UnvestedRestrictedStockUnitsMember" xml:lang="en-US">Unvested restricted stock units.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OutstandingStockOptionsMember" xlink:label="loc_freq_OutstandingStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OutstandingStockOptionsMember" xml:lang="en-US">Outstanding Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_OutstandingStockOptionsMember" xml:lang="en-US">Outstanding Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OutstandingStockOptionsMember" xlink:to="lab_freq_OutstandingStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OutstandingStockOptionsMember" xml:lang="en-US">Outstanding stock options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class Of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Common stock, sale of price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock shares issued and sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SalesAgentCommission" xlink:label="loc_freq_SalesAgentCommission" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_SalesAgentCommission" xml:lang="en-US">Sales Agent Commission</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_SalesAgentCommission" xlink:to="lab_freq_SalesAgentCommission" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_SalesAgentCommission" xml:lang="en-US">Sales agent commission</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AtTheMarketProgramMember" xlink:label="loc_freq_AtTheMarketProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AtTheMarketProgramMember" xml:lang="en-US">At The Market Program [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AtTheMarketProgramMember" xml:lang="en-US">ATM Program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AtTheMarketProgramMember" xlink:to="lab_freq_AtTheMarketProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AtTheMarketProgramMember" xml:lang="en-US">At The Market Program [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareDistributionMember" xlink:label="loc_us-gaap_ShareDistributionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareDistributionMember" xml:lang="en-US">Share Distribution [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareDistributionMember" xml:lang="en-US">Equity Distribution Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareDistributionMember" xlink:to="lab_us-gaap_ShareDistributionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Shares of common stock reserved for future issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Shares of common stock reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockCompensationPlanMember" xml:lang="en-US">Share-Based Payment Arrangement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockCompensationPlanMember" xml:lang="en-US">Shares Available for Future Grant Under Stock Option Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:label="loc_freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xml:lang="en-US">Two Thousand And Nineteen Incentive Award Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xml:lang="en-US">2019 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:to="lab_freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xml:lang="en-US">Two thousand and nineteen incentive award plan.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:label="loc_freq_TwoThousandAndFourteenStockIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_TwoThousandAndFourteenStockIncentivePlanMember" xml:lang="en-US">Two Thousand And Fourteen Stock Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_TwoThousandAndFourteenStockIncentivePlanMember" xml:lang="en-US">2014 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:to="lab_freq_TwoThousandAndFourteenStockIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_TwoThousandAndFourteenStockIncentivePlanMember" xml:lang="en-US">Two thousand and fourteen stock incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Common stock, shares available for future grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Number of authorized shares reserved for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xml:lang="en-US">Percentage of shares issued from outstanding number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Total unrecognized stock-based compensation expense relating to unvested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unrecognized unvested stock options, restricted stock awards and restricted stock units, weighted-average period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="loc_us-gaap_StockOptionExercisePriceDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionExercisePriceDecrease" xml:lang="en-US">Stock Option, Exercise Price, Decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockOptionExercisePriceDecrease" xml:lang="en-US">Underwater Options reduced</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionExercisePriceDecrease" xlink:to="lab_us-gaap_StockOptionExercisePriceDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xml:lang="en-US">Cost related to stock options, stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" xlink:label="loc_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" xml:lang="en-US">Expenses of stock based compensation to be recognized over vesting period of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" xml:lang="en-US">Expenses of Stock Based Compensation to be Recognized over vesting period of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" xlink:to="lab_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" xml:lang="en-US">Expenses of stock based compensation to be recognized over vesting period of options</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:label="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xml:lang="en-US">Period For Automatic Increase In Common Stock Available For Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xml:lang="en-US">Period for automatic increase in common stock available for future issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xml:lang="en-US">Period for automatic increase in common available for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:to="lab_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xml:lang="en-US">Period for automatic increase in common stock available for future issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Options expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Common stock future issuance, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Options vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value of stock options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Total grant date fair value of stock options vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of shares, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of shares, Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of shares, Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of shares, Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Number of shares, Options unvested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Options unvested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted average remaining contractual term (in years), Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term2</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted average remaining contractual term (in years), Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="lab_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share based compensation arrangement by share based payment award options granted weighted average remaining contractualterm2.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted average remaining contractual term (in years), Options exercisable as of March 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted average remaining contractual term (in years), Options unvested as of March 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate intrinsic value, Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value, Options unvested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of shares, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="loc_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" xml:lang="en-US">Two Thousand Fourteen And Two Thousand Nineteen Stock Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" xml:lang="en-US">2014 and 2019 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" xlink:to="lab_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" xml:lang="en-US">Two Thousand Fourteen And Two Thousand Nineteen Stock Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value, Unvested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value, Unvested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value, Awarded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" xlink:label="loc_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" xml:lang="en-US">ShareBased Compensation Arrangement by ShareBased Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Values</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" xml:lang="en-US">Weighted average fair value, Unvested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" xlink:to="lab_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" xml:lang="en-US">Share based compensation arrangement by share based payment award, equity instruments other than options, nonvested, weighted average grant date fair value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of shares, Unvested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of shares, Unvested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of shares, Awarded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of shares, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of shares, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">Employee Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">2019 Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:label="loc_freq_PercentageOfEligibleEmployeeCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PercentageOfEligibleEmployeeCompensation" xml:lang="en-US">Percentage Of Eligible Employee Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PercentageOfEligibleEmployeeCompensation" xml:lang="en-US">Percentage of eligible employee compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PercentageOfEligibleEmployeeCompensation" xlink:to="lab_freq_PercentageOfEligibleEmployeeCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PercentageOfEligibleEmployeeCompensation" xml:lang="en-US">Percentage of eligible employee compensation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncomeTaxesDisclosureTable" xlink:label="loc_freq_IncomeTaxesDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_IncomeTaxesDisclosureTable" xml:lang="en-US">Income Taxes Disclosure [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_IncomeTaxesDisclosureTable" xml:lang="en-US">Income Taxes Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_IncomeTaxesDisclosureTable" xlink:to="lab_freq_IncomeTaxesDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_IncomeTaxesDisclosureTable" xml:lang="en-US">Income taxes disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="loc_stpr_MA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_MA" xml:lang="en-US">MASSACHUSETTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_stpr_MA" xml:lang="en-US">Massachusetts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:label="loc_freq_IncomeTaxesDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_IncomeTaxesDisclosureLineItems" xml:lang="en-US">Income Taxes Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_IncomeTaxesDisclosureLineItems" xml:lang="en-US">Income Taxes Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems" xlink:to="lab_freq_IncomeTaxesDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_IncomeTaxesDisclosureLineItems" xml:lang="en-US">Income taxes disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xml:lang="en-US">Operating Loss Carryforwards Annual Usage For Next Each After Five Years And Thereafter After Ownership Change</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xml:lang="en-US">Operating loss carryforwards, utilization after 15 years thereafter after ownership change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:to="lab_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xml:lang="en-US">Operating loss carryforwards annual usage for next each after five years and thereafter after ownership change.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:label="loc_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xml:lang="en-US">Remaining Pre Ownership Change In Operating Loss Carryforwards Written Off Due To Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xml:lang="en-US">Remaining pre ownership change in operating loss carryforwards written off due to expiration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:to="lab_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xml:lang="en-US">Remaining pre ownership change in operating loss carryforwards written off due to expiration.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Federal and state deferred tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Interest and penalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:label="loc_freq_NetOperatingLossCarryforwardsExpirationWithLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xml:lang="en-US">Net Operating Loss Carryforwards Expiration With Limitation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xml:lang="en-US">Net operating loss carryforwards expire through 2037</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:to="lab_freq_NetOperatingLossCarryforwardsExpirationWithLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xml:lang="en-US">Net operating loss carryforwards expiration with limitation.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xml:lang="en-US">Operating Loss Carryforwards Usage After Ownership Change</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xml:lang="en-US">Operating loss carryforwards, utilization after ownership change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:to="lab_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xml:lang="en-US">Operating Loss Carryforwards Usage After Ownership Change.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xml:lang="en-US">Operating Loss Carryforwards Annual Usage For Next Each Five Years After Ownership Change</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xml:lang="en-US">Operating loss carryforwards, utilization after five years after ownership change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:to="lab_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xml:lang="en-US">Operating loss carryforwards annual usage for next each five years after ownership change.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:label="loc_freq_TaxCreditCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax Credit Carryforward Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax credit carryforwards expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_TaxCreditCarryforwardExpirationYear" xlink:to="lab_freq_TaxCreditCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax credit carryforward expiration year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:label="loc_freq_CumulativeChangeInOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_CumulativeChangeInOwnershipPercentage" xml:lang="en-US">Cumulative Change In Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_CumulativeChangeInOwnershipPercentage" xml:lang="en-US">Cumulative change in ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_CumulativeChangeInOwnershipPercentage" xlink:to="lab_freq_CumulativeChangeInOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_CumulativeChangeInOwnershipPercentage" xml:lang="en-US">Cumulative change in ownership percentage.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:label="loc_freq_PeriodOfCumulativeChangeInOwnership" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PeriodOfCumulativeChangeInOwnership" xml:lang="en-US">Period Of Cumulative Change In Ownership</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PeriodOfCumulativeChangeInOwnership" xml:lang="en-US">Period of cumulative change in ownership</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PeriodOfCumulativeChangeInOwnership" xlink:to="lab_freq_PeriodOfCumulativeChangeInOwnership" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PeriodOfCumulativeChangeInOwnership" xml:lang="en-US">Period of cumulative change in ownership.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">U.S federal statutory income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_freq_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforwards expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_freq_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforwards expiration year.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:label="loc_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xml:lang="en-US">Net Operating Loss Carryforwards Expiration Without Limitation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xml:lang="en-US">Net operating loss carryforwards without expiration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:to="lab_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xml:lang="en-US">Net operating loss carryforwards expiration without limitation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">Internal Revenue Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PreTaxNetLoss" xlink:label="loc_freq_PreTaxNetLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PreTaxNetLoss" xml:lang="en-US">Pre-tax net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_freq_PreTaxNetLoss" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PreTaxNetLoss" xlink:to="lab_freq_PreTaxNetLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PreTaxNetLoss" xml:lang="en-US">Pre-tax net loss</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Current:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Total current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Deferred:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in deferred tax asset valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income taxes, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Research and development tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xml:lang="en-US">State rate changes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Stock compensation deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax asset (liability)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred Tax Assets, Deferred Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets Liabilities Property Plant And Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred tax assets liabilities property plant and equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Capitalized research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsLeasingArrangements" xlink:label="loc_freq_DeferredTaxAssetsLeasingArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DeferredTaxAssetsLeasingArrangements" xml:lang="en-US">Deferred Tax Assets Leasing Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DeferredTaxAssetsLeasingArrangements" xml:lang="en-US">Lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_freq_DeferredTaxAssetsLeasingArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DeferredTaxAssetsLeasingArrangements" xml:lang="en-US">Deferred tax assets leasing arrangements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Gross deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:label="loc_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xml:lang="en-US">Deferred Tax Liabilities Tax Deferred Expense [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xml:lang="en-US">Deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:to="lab_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xml:lang="en-US">Deferred tax liabilities tax deferred expense.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_freq_DeferredTaxAssetsRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DeferredTaxAssetsRightOfUseAssets" xml:lang="en-US">Deferred Tax Assets Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_freq_DeferredTaxAssetsRightOfUseAssets" xml:lang="en-US">Right of use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DeferredTaxAssetsRightOfUseAssets" xlink:to="lab_freq_DeferredTaxAssetsRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DeferredTaxAssetsRightOfUseAssets" xml:lang="en-US">Deferred tax assets right of use assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:label="loc_freq_CaliforniaInstituteForBiomedicalResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_CaliforniaInstituteForBiomedicalResearchMember" xml:lang="en-US">California Institute For Biomedical Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_CaliforniaInstituteForBiomedicalResearchMember" xml:lang="en-US">CALIBR</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:to="lab_freq_CaliforniaInstituteForBiomedicalResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_CaliforniaInstituteForBiomedicalResearchMember" xml:lang="en-US">California Institute for Biomedical Research.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:label="loc_freq_MassachusettsInstituteOfTechnologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_MassachusettsInstituteOfTechnologyMember" xml:lang="en-US">Massachusetts Institute Of Technology [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_MassachusettsInstituteOfTechnologyMember" xml:lang="en-US">MIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_MassachusettsInstituteOfTechnologyMember" xlink:to="lab_freq_MassachusettsInstituteOfTechnologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_MassachusettsInstituteOfTechnologyMember" xml:lang="en-US">Massachusetts Institute of Technology.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MassachusettsEyeAndEarMember" xlink:label="loc_freq_MassachusettsEyeAndEarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_MassachusettsEyeAndEarMember" xml:lang="en-US">Massachusetts Eye And Ear [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_MassachusettsEyeAndEarMember" xml:lang="en-US">MEE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_MassachusettsEyeAndEarMember" xlink:to="lab_freq_MassachusettsEyeAndEarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_MassachusettsEyeAndEarMember" xml:lang="en-US">Massachusetts eye and ear.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:label="loc_freq_DescriptionOfFutureDevelopmentObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DescriptionOfFutureDevelopmentObligations" xml:lang="en-US">Description Of Future Development Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DescriptionOfFutureDevelopmentObligations" xml:lang="en-US">Description of future development obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DescriptionOfFutureDevelopmentObligations" xlink:to="lab_freq_DescriptionOfFutureDevelopmentObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DescriptionOfFutureDevelopmentObligations" xml:lang="en-US">Description of future development obligations.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AnnualLicenseFeePerShare" xlink:label="loc_freq_AnnualLicenseFeePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AnnualLicenseFeePerShare" xml:lang="en-US">Annual License Fee Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AnnualLicenseFeePerShare" xml:lang="en-US">Annual License Fee Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AnnualLicenseFeePerShare" xlink:to="lab_freq_AnnualLicenseFeePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AnnualLicenseFeePerShare" xml:lang="en-US">Annual License Fee Per Share</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfRoyaltyOnSublicenseRevenue" xlink:label="loc_freq_PercentageOfRoyaltyOnSublicenseRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PercentageOfRoyaltyOnSublicenseRevenue" xml:lang="en-US">Percentage of Royalty on Sublicense Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PercentageOfRoyaltyOnSublicenseRevenue" xml:lang="en-US">Percentage of Royalty on Sublicense Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PercentageOfRoyaltyOnSublicenseRevenue" xlink:to="lab_freq_PercentageOfRoyaltyOnSublicenseRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PercentageOfRoyaltyOnSublicenseRevenue" xml:lang="en-US">Percentage of royalty on sublicense revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaap_PaymentForManagementFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForManagementFee" xml:lang="en-US">Payment for Management Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentForManagementFee" xml:lang="en-US">Payment to director</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForManagementFee" xlink:to="lab_us-gaap_PaymentForManagementFee" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:label="loc_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xml:lang="en-US">Right To Terminate Licensed Patents Upon Prior Written Notice</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xml:lang="en-US">Right to terminate licensed patents upon prior written notice</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:to="lab_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xml:lang="en-US">Right to terminate licensed patents upon prior written notice.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:label="loc_freq_PercentageOfSharesOfCommonStockIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PercentageOfSharesOfCommonStockIssued" xml:lang="en-US">Percentage Of Shares Of Common Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PercentageOfSharesOfCommonStockIssued" xml:lang="en-US">Percentage of shares of common stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PercentageOfSharesOfCommonStockIssued" xlink:to="lab_freq_PercentageOfSharesOfCommonStockIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PercentageOfSharesOfCommonStockIssued" xml:lang="en-US">Percentage of shares of common stock issued.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseAgreementEnteredDate" xlink:label="loc_freq_LicenseAgreementEnteredDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LicenseAgreementEnteredDate" xml:lang="en-US">License Agreement Entered Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LicenseAgreementEnteredDate" xml:lang="en-US">License agreement entered date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LicenseAgreementEnteredDate" xlink:to="lab_freq_LicenseAgreementEnteredDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LicenseAgreementEnteredDate" xml:lang="en-US">License agreement entered date.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RoyaltyExpensePerShare" xlink:label="loc_freq_RoyaltyExpensePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RoyaltyExpensePerShare" xml:lang="en-US">Royalty Expense Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RoyaltyExpensePerShare" xml:lang="en-US">Royalty Expense Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RoyaltyExpensePerShare" xlink:to="lab_freq_RoyaltyExpensePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RoyaltyExpensePerShare" xml:lang="en-US">Royalty Expense Per Share</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseFeePayment" xlink:label="loc_freq_LicenseFeePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LicenseFeePayment" xml:lang="en-US">License Fee Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LicenseFeePayment" xml:lang="en-US">License fee payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LicenseFeePayment" xlink:to="lab_freq_LicenseFeePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LicenseFeePayment" xml:lang="en-US">License fee payment.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MilestonePayments" xlink:label="loc_freq_MilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_MilestonePayments" xml:lang="en-US">Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_MilestonePayments" xml:lang="en-US">Milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_MilestonePayments" xlink:to="lab_freq_MilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_MilestonePayments" xml:lang="en-US">Milestone payments.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:label="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RightToTerminateAgreementIfBreachRemainsUncured" xml:lang="en-US">Right To Terminate Agreement If Breach Remains Uncured</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RightToTerminateAgreementIfBreachRemainsUncured" xml:lang="en-US">Right to terminate agreement if breach remains uncured</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:to="lab_freq_RightToTerminateAgreementIfBreachRemainsUncured" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RightToTerminateAgreementIfBreachRemainsUncured" xml:lang="en-US">Right to terminate agreement if breach remains uncured.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:label="loc_freq_RightToTerminateAgreementIncaseOfNonpayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RightToTerminateAgreementIncaseOfNonpayment" xml:lang="en-US">Right To Terminate Agreement Incase Of Nonpayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RightToTerminateAgreementIncaseOfNonpayment" xml:lang="en-US">Right to terminate agreement incase of nonpayment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:to="lab_freq_RightToTerminateAgreementIncaseOfNonpayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RightToTerminateAgreementIncaseOfNonpayment" xml:lang="en-US">Right to terminate agreement incase of nonpayment.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:label="loc_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xml:lang="en-US">Right To Terminate Agreement Upon Prior Written Notice If Insolvent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xml:lang="en-US">Right to terminate agreement upon prior written notice if insolvent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:to="lab_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xml:lang="en-US">Right to terminate agreement upon prior written notice if insolvent.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:label="loc_freq_DescriptionOfConditionsToTerminateLicenseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_DescriptionOfConditionsToTerminateLicenseAgreement" xml:lang="en-US">Description Of Conditions To Terminate License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_DescriptionOfConditionsToTerminateLicenseAgreement" xml:lang="en-US">Description of conditions to terminate license agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:to="lab_freq_DescriptionOfConditionsToTerminateLicenseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_DescriptionOfConditionsToTerminateLicenseAgreement" xml:lang="en-US">Description of conditions to terminate license agreement.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:label="loc_freq_RightToTerminateAgreementUponPriorWrittenNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RightToTerminateAgreementUponPriorWrittenNotice" xml:lang="en-US">Right To Terminate Agreement Upon Prior Written Notice</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RightToTerminateAgreementUponPriorWrittenNotice" xml:lang="en-US">Right to terminate agreement upon prior written notice</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:to="lab_freq_RightToTerminateAgreementUponPriorWrittenNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RightToTerminateAgreementUponPriorWrittenNotice" xml:lang="en-US">Right to terminate agreement upon prior written notice.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PatentLicenseAgreementMember" xlink:label="loc_freq_PatentLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_PatentLicenseAgreementMember" xml:lang="en-US">Patent License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_PatentLicenseAgreementMember" xml:lang="en-US">Patent License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_PatentLicenseAgreementMember" xlink:to="lab_freq_PatentLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_PatentLicenseAgreementMember" xml:lang="en-US">Patent license agreement.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:label="loc_freq_NonExclusivePatentLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_NonExclusivePatentLicenseAgreementMember" xml:lang="en-US">Non Exclusive Patent License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_NonExclusivePatentLicenseAgreementMember" xml:lang="en-US">Non-Exclusive Patent License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_NonExclusivePatentLicenseAgreementMember" xlink:to="lab_freq_NonExclusivePatentLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_NonExclusivePatentLicenseAgreementMember" xml:lang="en-US">Non-exclusive patent license agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Dr. Langer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Phase2bClinicalTrialMember" xlink:label="loc_freq_Phase2bClinicalTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_Phase2bClinicalTrialMember" xml:lang="en-US">Phase2b Clinical Trial [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_Phase2bClinicalTrialMember" xml:lang="en-US">Phase 2b Clinical Trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_Phase2bClinicalTrialMember" xlink:to="lab_freq_Phase2bClinicalTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_Phase2bClinicalTrialMember" xml:lang="en-US">Phase 2b clinical trial.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Phase3ClinicalTrailMember" xlink:label="loc_freq_Phase3ClinicalTrailMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_Phase3ClinicalTrailMember" xml:lang="en-US">Phase3 Clinical Trail [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_Phase3ClinicalTrailMember" xml:lang="en-US">Phase 3 Clinical Trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_Phase3ClinicalTrailMember" xlink:to="lab_freq_Phase3ClinicalTrailMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_Phase3ClinicalTrailMember" xml:lang="en-US">Phase 3 clinical trail.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_AsiaMember" xml:lang="en-US">Asia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_AsiaMember" xml:lang="en-US">Asia</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaMember" xlink:to="lab_srt_AsiaMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:label="loc_freq_LicenseAndCollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LicenseAndCollaborationAgreementMember" xml:lang="en-US">License And Collaboration Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LicenseAndCollaborationAgreementMember" xml:lang="en-US">License and Collaboration Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LicenseAndCollaborationAgreementMember" xlink:to="lab_freq_LicenseAndCollaborationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LicenseAndCollaborationAgreementMember" xml:lang="en-US">License and collaboration agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:label="loc_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xml:lang="en-US">Revenue Recognition Potential Commercial Milestone Payments Eligible Upon Successful Commercialization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xml:lang="en-US">Potential commercial milestone payments eligible to receive upon successful commercialization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:to="lab_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xml:lang="en-US">Revenue recognition potential commercial milestone payments eligible upon successful commercialization.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AgreementTerminationNoticePeriod" xlink:label="loc_freq_AgreementTerminationNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AgreementTerminationNoticePeriod" xml:lang="en-US">Agreement Termination Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AgreementTerminationNoticePeriod" xml:lang="en-US">Agreement termination notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AgreementTerminationNoticePeriod" xlink:to="lab_freq_AgreementTerminationNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AgreementTerminationNoticePeriod" xml:lang="en-US">Agreement termination notice period.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:label="loc_freq_UpfrontFeeRecognizedAsRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_UpfrontFeeRecognizedAsRevenue" xml:lang="en-US">Upfront Fee Recognized As Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_UpfrontFeeRecognizedAsRevenue" xml:lang="en-US">Upfront fee recognized as revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_UpfrontFeeRecognizedAsRevenue" xlink:to="lab_freq_UpfrontFeeRecognizedAsRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_UpfrontFeeRecognizedAsRevenue" xml:lang="en-US">Upfront fee recognized as revenue.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RevenueRecognitionTransactionPrice" xlink:label="loc_freq_RevenueRecognitionTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RevenueRecognitionTransactionPrice" xml:lang="en-US">Revenue Recognition Transaction Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RevenueRecognitionTransactionPrice" xml:lang="en-US">Transaction price allocated to single combined performance obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RevenueRecognitionTransactionPrice" xlink:to="lab_freq_RevenueRecognitionTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RevenueRecognitionTransactionPrice" xml:lang="en-US">Revenue recognition transaction price.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_JointCost" xlink:label="loc_freq_JointCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_JointCost" xml:lang="en-US">joint cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_JointCost" xlink:to="lab_freq_JointCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_JointCost" xml:lang="en-US">joint cost</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Revenue recognized potential development milestone payments to receive</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:label="loc_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xml:lang="en-US">Contract With Customer Liability Revenue Recognized From Commercialization Milestones</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xml:lang="en-US">Revenue recognized commercialization milestone payments to receive</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:to="lab_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xml:lang="en-US">Contract with customer liability revenue recognized from commercialization milestones.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xml:lang="en-US">Proceeds from Collaborators</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xml:lang="en-US">Payments received under collaboration agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:label="loc_freq_AstellasPharmaLimitedLiabilityCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AstellasPharmaLimitedLiabilityCompanyMember" xml:lang="en-US">Astellas Pharma Limited Liability Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AstellasPharmaLimitedLiabilityCompanyMember" xml:lang="en-US">Astellas Pharma LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:to="lab_freq_AstellasPharmaLimitedLiabilityCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AstellasPharmaLimitedLiabilityCompanyMember" xml:lang="en-US">Astellas pharma limited liability company.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee Lease Description [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LexingtonLeaseMember" xlink:label="loc_freq_LexingtonLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LexingtonLeaseMember" xml:lang="en-US">Lexington Lease [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LexingtonLeaseMember" xml:lang="en-US">Lexington Lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LexingtonLeaseMember" xlink:to="lab_freq_LexingtonLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LexingtonLeaseMember" xml:lang="en-US">Lexington lease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee Lease Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetRentableArea" xml:lang="en-US">Net Rentable Area</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetRentableArea" xml:lang="en-US">Rentable square feetspace</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetRentableArea" xml:lang="en-US">Rentable square feet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeaseCommencementDate" xlink:label="loc_freq_OperatingLeaseCommencementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OperatingLeaseCommencementDate" xml:lang="en-US">Operating Lease Commencement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_OperatingLeaseCommencementDate" xml:lang="en-US">Lease commencement date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OperatingLeaseCommencementDate" xlink:to="lab_freq_OperatingLeaseCommencementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OperatingLeaseCommencementDate" xml:lang="en-US">Operating lease commencement date.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:label="loc_freq_OperatingLeaseNumberOfAdditionalExtensionTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xml:lang="en-US">Operating Lease Number Of Additional Extension Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xml:lang="en-US">Number of additional lease extension terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:to="lab_freq_OperatingLeaseNumberOfAdditionalExtensionTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xml:lang="en-US">Operating lease number of additional extension terms.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:label="loc_freq_OperatingLeasesAdditionalExtensionTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_OperatingLeasesAdditionalExtensionTerm" xml:lang="en-US">Operating Leases Additional Extension Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_OperatingLeasesAdditionalExtensionTerm" xml:lang="en-US">Lease extension term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_OperatingLeasesAdditionalExtensionTerm" xlink:to="lab_freq_OperatingLeasesAdditionalExtensionTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_OperatingLeasesAdditionalExtensionTerm" xml:lang="en-US">Operating leases additional extension term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LeasesTerminationAgreementMember" xlink:label="loc_freq_LeasesTerminationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_LeasesTerminationAgreementMember" xml:lang="en-US">Leases Termination Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_LeasesTerminationAgreementMember" xml:lang="en-US">Lease Termination Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_LeasesTerminationAgreementMember" xlink:to="lab_freq_LeasesTerminationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_LeasesTerminationAgreementMember" xml:lang="en-US">Lease termination agreement.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AREMARegionNo20LLCMember" xlink:label="loc_freq_AREMARegionNo20LLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AREMARegionNo20LLCMember" xml:lang="en-US">A R E M A Region No20 L L C [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AREMARegionNo20LLCMember" xml:lang="en-US">ARE-MA Region No. 20, LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AREMARegionNo20LLCMember" xlink:to="lab_freq_AREMARegionNo20LLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AREMARegionNo20LLCMember" xml:lang="en-US">ARE-MA Region No. 20, LLC.</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_HaydenLLCMember" xlink:label="loc_freq_HaydenLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_HaydenLLCMember" xml:lang="en-US">Hayden L L C [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_HaydenLLCMember" xml:lang="en-US">Hayden LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_HaydenLLCMember" xlink:to="lab_freq_HaydenLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_HaydenLLCMember" xml:lang="en-US">Hayden LLC.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted-average remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted-average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of future lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: amount of lease payments representing interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US">2027 and beyond</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Total minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next 12 Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xml:lang="en-US">Total future sublease income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next 12 Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xml:lang="en-US">Sublease rent per month</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubleaseIncome" xml:lang="en-US">Sublease Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubleaseIncome" xml:lang="en-US">Sublease income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SaliogenTherapeuticsIncMember" xlink:label="loc_freq_SaliogenTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_SaliogenTherapeuticsIncMember" xml:lang="en-US">SalioGen Therapeutics, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_SaliogenTherapeuticsIncMember" xlink:to="lab_freq_SaliogenTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_SaliogenTherapeuticsIncMember" xml:lang="en-US">SalioGen Therapeutics, Inc.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Operating lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Security deposit classified as restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xml:lang="en-US">Loss Contingency, Loss in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xml:lang="en-US">Losses related to indemnification obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod" xlink:to="lab_us-gaap_LossContingencyLossInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss Contingency Accrual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Legal contingencies, accruals recorded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xml:lang="en-US">Employers matching contribution vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Employers matching contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Maximum percentage of employee contribution to retirement plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Percentage of employer matching contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Percentage of employee annual compensation matched by the employer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xml:lang="en-US">Restructuring Charges [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance and other benefit-related costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ReductionInWorkforceDueToRestructuring" xlink:label="loc_freq_ReductionInWorkforceDueToRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_ReductionInWorkforceDueToRestructuring" xml:lang="en-US">Reduction in Workforce due to Restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_ReductionInWorkforceDueToRestructuring" xlink:to="lab_freq_ReductionInWorkforceDueToRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_ReductionInWorkforceDueToRestructuring" xml:lang="en-US">Reduction in Workforce due to Restructuring</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructuringRelatedExpenses" xlink:label="loc_freq_RestructuringRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RestructuringRelatedExpenses" xml:lang="en-US">restructuring-related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RestructuringRelatedExpenses" xlink:to="lab_freq_RestructuringRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RestructuringRelatedExpenses" xml:lang="en-US">restructuring-related expenses</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedHearingProgramCharges" xlink:label="loc_freq_AcceleratedHearingProgramCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AcceleratedHearingProgramCharges" xml:lang="en-US">Accelerated Hearing Program Charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AcceleratedHearingProgramCharges" xlink:to="lab_freq_AcceleratedHearingProgramCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AcceleratedHearingProgramCharges" xml:lang="en-US">Accelerated Hearing Program Charges</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other Restructuring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Severance and other benefit-related costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedDepreciationChargesMember" xlink:label="loc_freq_AcceleratedDepreciationChargesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AcceleratedDepreciationChargesMember" xml:lang="en-US">Accelerated depreciation charges Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AcceleratedDepreciationChargesMember" xml:lang="en-US">Accelerated depreciation charges [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AcceleratedDepreciationChargesMember" xlink:to="lab_freq_AcceleratedDepreciationChargesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AcceleratedDepreciationChargesMember" xml:lang="en-US">Accelerated depreciation charges Member</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedfxthreetwotwochargesMember" xlink:label="loc_freq_AcceleratedfxthreetwotwochargesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AcceleratedfxthreetwotwochargesMember" xml:lang="en-US">AcceleratedFxThreeTwoTwoCharges [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AcceleratedfxthreetwotwochargesMember" xml:lang="en-US">Accelerated FX-322 charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AcceleratedfxthreetwotwochargesMember" xlink:to="lab_freq_AcceleratedfxthreetwotwochargesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AcceleratedfxthreetwotwochargesMember" xml:lang="en-US">AcceleratedFxThreeTwoTwoCharges [Member]</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedfxthreefourfivechargesMember" xlink:label="loc_freq_AcceleratedfxthreefourfivechargesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_AcceleratedfxthreefourfivechargesMember" xml:lang="en-US">AcceleratedFxThreeFourFiveCharges [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_AcceleratedfxthreefourfivechargesMember" xml:lang="en-US">Accelerated FX-345 charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_AcceleratedfxthreefourfivechargesMember" xlink:to="lab_freq_AcceleratedfxthreefourfivechargesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_AcceleratedfxthreefourfivechargesMember" xml:lang="en-US">AcceleratedFxThreeFourFiveCharges [Member]</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructingLiabilities" xlink:label="loc_freq_RestructingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RestructingLiabilities" xml:lang="en-US">Restructing Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_freq_RestructingLiabilities" xml:lang="en-US">Restructing liabilities Ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_freq_RestructingLiabilities" xml:lang="en-US">Liability balance Opening</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RestructingLiabilities" xlink:to="lab_freq_RestructingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RestructingLiabilities" xml:lang="en-US">Restructing Liabilities</label>
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructingNetCharge" xlink:label="loc_freq_RestructingNetCharge" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_freq_RestructingNetCharge" xml:lang="en-US">Restructing Net Charge</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_freq_RestructingNetCharge" xml:lang="en-US">Net charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_freq_RestructingNetCharge" xlink:to="lab_freq_RestructingNetCharge" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_freq_RestructingNetCharge" xml:lang="en-US">Restructing Net Charge</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCosts" xml:lang="en-US">Restructuring Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCosts" xml:lang="en-US">Restructuring Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>freq-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 27-July-2023 [06:37:32] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CoverPage" roleURI="http://www.frequencytherapeutics.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsStockholdersEquityDeficitUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#OrganizationAndBasisOfPresentation" roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RecentlyAdoptedAndIssuedAccountingStandards" roleURI="http://www.frequencytherapeutics.com/role/RecentlyAdoptedAndIssuedAccountingStandards" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurements" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Investment" roleURI="http://www.frequencytherapeutics.com/role/Investment" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipment" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#AccruedExpenses" roleURI="http://www.frequencytherapeutics.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Debt" roleURI="http://www.frequencytherapeutics.com/role/Debt" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#NetLossPerShare" roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockholdersEquity" roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensation" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#EmployeeStockPurchasePlan" roleURI="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlan" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxes" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CollaborationAgreement" roleURI="http://www.frequencytherapeutics.com/role/CollaborationAgreement" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Leases" roleURI="http://www.frequencytherapeutics.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ResearchAndLicenseAgreements" roleURI="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Restructuring" roleURI="http://www.frequencytherapeutics.com/role/Restructuring" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#Sublease" roleURI="http://www.frequencytherapeutics.com/role/Sublease" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CommitmentsAndContingencies" roleURI="http://www.frequencytherapeutics.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#EmployeeBenefitPlan" roleURI="http://www.frequencytherapeutics.com/role/EmployeeBenefitPlan" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RelatedPartyTransactions" roleURI="http://www.frequencytherapeutics.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubsequentEvents" roleURI="http://www.frequencytherapeutics.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#OrganizationAndBasisOfPresentationPolicies" roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurementsTables" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#InvestmentsTables" roleURI="http://www.frequencytherapeutics.com/role/InvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipmentTables" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#AccruedExpensesTables" roleURI="http://www.frequencytherapeutics.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#NetLossPerShareTables" roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockholdersEquityTables" roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationTables" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesTables" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesTables" roleURI="http://www.frequencytherapeutics.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringTables" roleURI="http://www.frequencytherapeutics.com/role/RestructuringTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubleaseTables" roleURI="http://www.frequencytherapeutics.com/role/SubleaseTables" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#OrganizationAndBasisOfPresentationAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails" roleURI="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#InvestmentsAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/InvestmentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails" roleURI="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails" roleURI="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#PropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#AccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#DebtAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockholdersEquityAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" roleURI="http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" roleURI="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#EmployeeStockPurchasePlanAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfProvisionDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#ResearchAndLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CollaborationAgreementAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesScheduleOfLeasesDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#LeasesScheduleOfFutureAggregateMinimumPaymentsDetails" roleURI="http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubleaseSummaryOfFutureSubleaseIncomeDetails" roleURI="http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubleaseAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringSummaryOfRestructuringRelatedChargesDetails" roleURI="http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails" roleURI="http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#RestructuringScheduleOfIncurredChargesDueToRestructuringDetails" roleURI="http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails" />
<roleRef xlink:type="simple" xlink:href="freq-20230331.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_us-gaap_StatementTable_1776" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1776" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1779" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1779" xlink:to="loc_dei_AddressTypeDomain_1780" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1780" xlink:to="loc_dei_BusinessContactMember_1781" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1776" xlink:to="loc_us-gaap_StatementLineItems_1782" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_DocumentType_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_AmendmentFlag_103" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityCentralIndexKey_110" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityRegistrantName_112" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityIncorporationStateCountryCode_113" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityTaxIdentificationNumber_114" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressAddressLine1_115" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressAddressLine2_116" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressCityOrTown_117" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressStateOrProvince_118" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityAddressPostalZipCode_119" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_CityAreaCode_120" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_LocalPhoneNumber_121" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityFilerCategory_129" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntitySmallBusiness_130" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityEmergingGrowthCompany_131" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityExTransitionPeriod_132" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_EntityPrimarySicNumber_1773" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1782" xlink:to="loc_dei_ContactPersonnelName_1774" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_142" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_142" xlink:to="loc_us-gaap_AssetsAbstract_143" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_143" xlink:to="loc_us-gaap_AssetsCurrentAbstract_145" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_145" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_147" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_145" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_153" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_145" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_158" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_145" xlink:to="loc_us-gaap_AssetsCurrent_163" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_143" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_151" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_143" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_156" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_143" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_161" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_143" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_166" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OtherLongTermAssets" xlink:label="loc_freq_OtherLongTermAssets_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_143" xlink:to="loc_freq_OtherLongTermAssets_170" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_143" xlink:to="loc_us-gaap_Assets_172" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_142" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_146" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_AccountsPayableCurrent_148" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_154" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_159" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_LongTermDebtCurrent_164" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_LiabilitiesCurrent_168" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_152" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansFromBank" xlink:label="loc_us-gaap_LongTermLoansFromBank_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" xlink:to="loc_us-gaap_LongTermLoansFromBank_157" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_162" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" xlink:to="loc_us-gaap_Liabilities_167" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" xlink:to="loc_us-gaap_StockholdersEquityAbstract_171" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_171" xlink:to="loc_us-gaap_PreferredStockValue_144" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_171" xlink:to="loc_us-gaap_CommonStockValue_150" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_171" xlink:to="loc_us-gaap_AdditionalPaidInCapital_155" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_171" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_160" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_171" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_165" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_171" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_169" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_149" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_173" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1047" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1187" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1188" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1205" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1206" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1213" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" xlink:to="loc_us-gaap_CommonStockSharesIssued_1214" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1046" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1215" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_187" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_OperatingExpensesAbstract_189" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_189" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_186" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_189" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_188" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_189" xlink:to="loc_us-gaap_OperatingExpenses_190" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_OperatingIncomeLoss_191" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_InvestmentIncomeInterest_192" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_InterestExpense_193" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_194" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_195" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_197" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_198" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_us-gaap_NetIncomeLoss_199" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Earningpersharebasicanddiluted" xlink:label="loc_freq_Earningpersharebasicanddiluted_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_freq_Earningpersharebasicanddiluted_200" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_185" xlink:to="loc_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted_201" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_NetIncomeLoss_205" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_207" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_207" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_204" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_207" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_206" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_203" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_208" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_210" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_210" xlink:to="loc_us-gaap_StatementTable_212" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_212" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_211" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_211" xlink:to="loc_us-gaap_EquityComponentDomain_213" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_213" xlink:to="loc_us-gaap_CommonStockMember_218" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_213" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_220" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_213" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_222" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_213" xlink:to="loc_us-gaap_RetainedEarningsMember_224" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_212" xlink:to="loc_us-gaap_StatementLineItems_216" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_214" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_217" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_219" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_223" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_225" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_226" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_227" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_228" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_StockIssuedDuringPeriodSharesUnderEquityOffering" xlink:label="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOffering_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOffering_229" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount" xlink:label="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount_230" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares" xlink:label="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares_231" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits" xlink:label="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits_232" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_235" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_NetIncomeLoss_236" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_237" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_216" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_238" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_240" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_242" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_242" xlink:to="loc_us-gaap_ProfitLoss_244" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_242" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" xlink:to="loc_us-gaap_ShareBasedCompensation_246" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" xlink:to="loc_us-gaap_Depreciation_252" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NonCashLeaseExpenses" xlink:label="loc_freq_NonCashLeaseExpenses_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" xlink:to="loc_freq_NonCashLeaseExpenses_258" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" xlink:to="loc_us-gaap_PaidInKindInterest_264" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_268" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_1580" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_242" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_256" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_256" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_247" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_256" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_253" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_256" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_259" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_freq_IncreaseDecreaseInLeaseLiabilities_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_256" xlink:to="loc_freq_IncreaseDecreaseInLeaseLiabilities_265" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_256" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_269" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_242" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_262" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_249" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ProceedsFromPaymentForPropertyAndEquipment" xlink:label="loc_freq_ProceedsFromPaymentForPropertyAndEquipment_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_249" xlink:to="loc_freq_ProceedsFromPaymentForPropertyAndEquipment_245" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_249" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_251" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_249" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_257" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_249" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_263" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_249" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_267" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_241" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_ProceedsFromStockPlans_248" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1506" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_260" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_261" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_266" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_270" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_271" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_271" xlink:to="loc_us-gaap_InterestPaidNet_243" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_273" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_273" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_274" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_276" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_276" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_277" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RecentlyAdoptedAndIssuedAccountingStandards">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1101" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_1102" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_279" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_282" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_282" xlink:to="loc_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_283" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/Investment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1055" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1055" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1056" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_288" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_288" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_289" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/Debt">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_291" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_292" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1087" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1087" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1088" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_300" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_300" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_303" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_303" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_304" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_306" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:label="loc_freq_EmployeeStockPurchasePlanDisclosureTextBlock_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_306" xlink:to="loc_freq_EmployeeStockPurchasePlanDisclosureTextBlock_307" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_309" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_309" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/CollaborationAgreement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_315" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_315" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_316" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_318" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_318" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_312" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseAgreementTextBlock" xlink:label="loc_freq_LicenseAgreementTextBlock_1137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_312" xlink:to="loc_freq_LicenseAgreementTextBlock_1137" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/Restructuring">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1113" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1113" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1114" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/Sublease">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1110" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Sublease" xlink:label="loc_freq_Sublease_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1110" xlink:to="loc_freq_Sublease_1111" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_324" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_324" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/EmployeeBenefitPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_327" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_327" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_328" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_330" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_330" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_331" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_333" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_333" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_334" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_336" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_337" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_338" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_UseOfEstimates_339" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_340" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_341" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_342" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_343" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_344" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_345" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_346" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SignificantSuppliersPolicyTextBlock" xlink:label="loc_freq_SignificantSuppliersPolicyTextBlock_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_freq_SignificantSuppliersPolicyTextBlock_347" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_348" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_349" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_350" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_351" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_352" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_353" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_354" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PatentCostsPolicyTextBlock" xlink:label="loc_freq_PatentCostsPolicyTextBlock_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_freq_PatentCostsPolicyTextBlock_355" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_356" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_357" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_358" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="loc_freq_UnauditedInterimFinancialInformationPolicyTextBlock_1772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_freq_UnauditedInterimFinancialInformationPolicyTextBlock_1772" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_359" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_361" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PropertyAndEquipmentTableTextBlock" xlink:label="loc_freq_PropertyAndEquipmentTableTextBlock_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_361" xlink:to="loc_freq_PropertyAndEquipmentTableTextBlock_362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_361" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_363" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_366" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_366" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_367" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_366" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_368" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/InvestmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1064" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1064" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1065" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1064" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1186" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_370" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_370" xlink:to="loc_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_371" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_373" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_373" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_376" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_376" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_377" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1093" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1093" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1094" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1093" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1179" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_379" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="loc_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_379" xlink:to="loc_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" xlink:to="loc_us-gaap_AwardTypeAxis_387" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_388" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_386" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_389" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_391" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1565" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_393" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_393" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_394" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_393" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_395" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_393" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_396" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_393" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_397" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_399" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_399" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_400" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_399" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_401" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_399" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_402" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RestructuringTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1116" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ScheduleOfRestructingRelatedChargesTableTextBlock" xlink:label="loc_freq_ScheduleOfRestructingRelatedChargesTableTextBlock_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1116" xlink:to="loc_freq_ScheduleOfRestructingRelatedChargesTableTextBlock_1176" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock" xlink:label="loc_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock_1192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1116" xlink:to="loc_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock_1192" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SubleaseTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_404" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfExpectedFutureSubleaseIncome" xlink:label="loc_freq_SummaryOfExpectedFutureSubleaseIncome_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_404" xlink:to="loc_freq_SummaryOfExpectedFutureSubleaseIncome_405" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_407" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_407" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_408" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_408" xlink:to="loc_us-gaap_EquityComponentDomain_412" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_415" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_415" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_410" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_414" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_411" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_417" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_418" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1440" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_420" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_420" xlink:to="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" xlink:to="loc_srt_StatementGeographicalAxis_423" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_423" xlink:to="loc_srt_SegmentGeographicalDomain_425" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LexingtonMassachusettsFacilityMember" xlink:label="loc_freq_LexingtonMassachusettsFacilityMember_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_425" xlink:to="loc_freq_LexingtonMassachusettsFacilityMember_422" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_430" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_430" xlink:to="loc_us-gaap_TypeOfAdoptionMember_426" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_426" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_436" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable_427" xlink:to="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_421" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_428" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_437" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="loc_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_441" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_444" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_433" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_445" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_447" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesTable_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_447" xlink:to="loc_freq_SummaryOfSignificantAccountingPoliciesTable_450" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable_450" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_449" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_449" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LabEquipmentMember" xlink:label="loc_freq_LabEquipmentMember_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" xlink:to="loc_freq_LabEquipmentMember_452" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_455" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:label="loc_freq_FurnitureAndOfficeEquipmentMember_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_451" xlink:to="loc_freq_FurnitureAndOfficeEquipmentMember_456" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesTable_450" xlink:to="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_454" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_SummaryOfSignificantAccountingPoliciesLineItems_454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1784" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_459" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_459" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_462" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_462" xlink:to="loc_us-gaap_NetIncomeLoss_461" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_459" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_464" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_464" xlink:to="loc_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted_460" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Earningpersharebasicanddiluted" xlink:label="loc_freq_Earningpersharebasicanddiluted_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_459" xlink:to="loc_freq_Earningpersharebasicanddiluted_465" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_482" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_482" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_InvestmentTypeAxis_488" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_488" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_484" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_FinancialInstrumentAxis_495" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_495" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" xlink:to="loc_us-gaap_MoneyMarketFundsMember_485" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ShortTermMarketableSecuritiesMember" xlink:label="loc_freq_ShortTermMarketableSecuritiesMember_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" xlink:to="loc_freq_ShortTermMarketableSecuritiesMember_493" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LongTermMarketableSecuritiesMember" xlink:label="loc_freq_LongTermMarketableSecuritiesMember_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_490" xlink:to="loc_freq_LongTermMarketableSecuritiesMember_497" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_499" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_499" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_491" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_486" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_496" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_502" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_502" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_489" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_489" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_492" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_483" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_487" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_494" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_498" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_501" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_505" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_505" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_509" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_509" xlink:to="loc_us-gaap_FinancialInstrumentAxis_507" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_507" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_510" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ShortTermMarketableSecuritiesMember" xlink:label="loc_freq_ShortTermMarketableSecuritiesMember_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_510" xlink:to="loc_freq_ShortTermMarketableSecuritiesMember_508" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LongTermMarketableSecuritiesMember" xlink:label="loc_freq_LongTermMarketableSecuritiesMember_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_510" xlink:to="loc_freq_LongTermMarketableSecuritiesMember_513" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_509" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_512" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_512" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_506" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_512" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_511" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_512" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_514" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_512" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_515" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_512" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_516" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_512" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_517" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/InvestmentsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1067" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_1068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1067" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_1068" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1070" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1070" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_1075" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_1075" xlink:to="loc_us-gaap_InvestmentTypeAxis_1072" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1072" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1073" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1073" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1071" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_1075" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1074" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1185" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_1184" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1189" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1077" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1077" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_1081" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_1081" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1079" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1079" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1082" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ShortTermMarketableSecuritiesMember" xlink:label="loc_freq_ShortTermMarketableSecuritiesMember_1080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1082" xlink:to="loc_freq_ShortTermMarketableSecuritiesMember_1080" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_1182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_1081" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_1182" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_1182" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_1078" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_1182" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1181" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_1190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_1182" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_1190" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_1204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_1182" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_1204" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_1182" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_1207" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_1182" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1212" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_519" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:label="loc_freq_PrepaidRentAndDepositsCurrent_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_519" xlink:to="loc_freq_PrepaidRentAndDepositsCurrent_520" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="loc_freq_PrepaidResearchAndDevelopmentExpenseCurrent_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_519" xlink:to="loc_freq_PrepaidResearchAndDevelopmentExpenseCurrent_521" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaidAccountsReceivableCurrent" xlink:label="loc_freq_PrepaidAccountsReceivableCurrent_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_519" xlink:to="loc_freq_PrepaidAccountsReceivableCurrent_522" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_519" xlink:to="loc_us-gaap_PrepaidInsurance_523" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_519" xlink:to="loc_us-gaap_OtherAssetsCurrent_524" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_519" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_525" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_527" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_527" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_530" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_530" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_529" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_529" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" xlink:to="loc_us-gaap_EquipmentMember_532" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_535" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_531" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_537" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_530" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_528" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_533" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_534" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_536" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_541" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_541" xlink:to="loc_us-gaap_Depreciation_542" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_1439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_541" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_1439" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_544" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_544" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_545" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_544" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_546" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:label="loc_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_544" xlink:to="loc_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_547" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_544" xlink:to="loc_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent_548" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_544" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_549" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_551" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_551" xlink:to="loc_us-gaap_DebtInstrumentTable_559" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_TypeOfArrangementAxis_552" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_552" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_554" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LoanAndSecurityAgreementMember" xlink:label="loc_freq_LoanAndSecurityAgreementMember_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_554" xlink:to="loc_freq_LoanAndSecurityAgreementMember_556" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_563" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_563" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_555" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TermLoanMember" xlink:label="loc_freq_TermLoanMember_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_555" xlink:to="loc_freq_TermLoanMember_562" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_VariableRateAxis_566" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_566" xlink:to="loc_us-gaap_VariableRateDomain_553" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_553" xlink:to="loc_us-gaap_PrimeRateMember_557" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_DebtInstrumentAxis_569" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_569" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_558" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_558" xlink:to="loc_freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_560" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_558" xlink:to="loc_freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_564" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xlink:label="loc_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_558" xlink:to="loc_freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_567" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1572" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1572" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1172" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1172" xlink:to="loc_us-gaap_SubsequentEventMember_1112" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559" xlink:to="loc_us-gaap_DebtInstrumentLineItems_571" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_561" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_565" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_568" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xlink:label="loc_freq_DebtInstrumentInterestOnlyPaymentMaturityDate_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_freq_DebtInstrumentInterestOnlyPaymentMaturityDate_570" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_572" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_573" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_InterestExpenseDebt_574" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentFloorInterestRatePercentage" xlink:label="loc_freq_DebtInstrumentFloorInterestRatePercentage_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_freq_DebtInstrumentFloorInterestRatePercentage_575" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="loc_freq_DebtInstrumentPrepaymentPremiumPercentage_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_freq_DebtInstrumentPrepaymentPremiumPercentage_576" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_577" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtDue" xlink:label="loc_freq_DebtDue_1678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_571" xlink:to="loc_freq_DebtDue_1678" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1096" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1096" xlink:to="loc_us-gaap_NetIncomeLossAbstract_1097" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1097" xlink:to="loc_us-gaap_NetIncomeLoss_1098" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Denominator" xlink:label="loc_freq_Denominator_1177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1096" xlink:to="loc_freq_Denominator_1177" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_Denominator_1177" xlink:to="loc_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted_1099" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Earningpersharebasicanddiluted" xlink:label="loc_freq_Earningpersharebasicanddiluted_1178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_Denominator_1177" xlink:to="loc_freq_Earningpersharebasicanddiluted_1178" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1119" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1119" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1120" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1120" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1124" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1124" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_UnvestedRestrictedStockUnitsMember" xlink:label="loc_freq_UnvestedRestrictedStockUnitsMember_1174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121" xlink:to="loc_freq_UnvestedRestrictedStockUnitsMember_1174" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OutstandingStockOptionsMember" xlink:label="loc_freq_OutstandingStockOptionsMember_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1121" xlink:to="loc_freq_OutstandingStockOptionsMember_1193" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1120" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1175" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1175" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1122" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_611" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_611" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_612" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_612" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareDistributionMember" xlink:label="loc_us-gaap_ShareDistributionMember_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617" xlink:to="loc_us-gaap_ShareDistributionMember_1297" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AtTheMarketProgramMember" xlink:label="loc_freq_AtTheMarketProgramMember_1534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_617" xlink:to="loc_freq_AtTheMarketProgramMember_1534" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_623" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_623" xlink:to="loc_us-gaap_EquityComponentDomain_619" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_619" xlink:to="loc_us-gaap_CommonStockMember_620" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" xlink:to="loc_srt_RangeAxis_625" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_625" xlink:to="loc_srt_RangeMember_615" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_615" xlink:to="loc_srt_MaximumMember_616" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_618" xlink:to="loc_us-gaap_ClassOfStockLineItems_629" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_621" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_624" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_PreferredStockSharesIssued_626" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_628" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_630" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_631" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_632" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_CommonStockSharesIssued_633" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_634" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_635" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_636" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SalesAgentCommission" xlink:label="loc_freq_SalesAgentCommission_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_629" xlink:to="loc_freq_SalesAgentCommission_637" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_640" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_640" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_641" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_641" xlink:to="loc_us-gaap_AwardTypeAxis_642" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645" xlink:to="loc_us-gaap_EmployeeStockOptionMember_643" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_645" xlink:to="loc_us-gaap_StockCompensationPlanMember_647" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_641" xlink:to="loc_us-gaap_ClassOfStockLineItems_646" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_646" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_644" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_649" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_649" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_us-gaap_PlanNameAxis_659" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_659" xlink:to="loc_us-gaap_PlanNameDomain_660" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:label="loc_freq_TwoThousandAndFourteenStockIncentivePlanMember_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_660" xlink:to="loc_freq_TwoThousandAndFourteenStockIncentivePlanMember_650" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:label="loc_freq_TwoThousandAndNineteenIncentiveAwardPlanMember_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_660" xlink:to="loc_freq_TwoThousandAndNineteenIncentiveAwardPlanMember_661" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_srt_RangeAxis_665" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_665" xlink:to="loc_srt_RangeMember_652" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_652" xlink:to="loc_srt_MaximumMember_653" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_us-gaap_AwardTypeAxis_667" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_656" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_669" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_669" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_654" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_654" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_658" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_654" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_664" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_657" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_663" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:label="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_668" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_670" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_672" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_673" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_674" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_675" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_676" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="loc_us-gaap_StockOptionExercisePriceDecrease_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_StockOptionExercisePriceDecrease_677" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_678" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions" xlink:label="loc_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions_679" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_681" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_682" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_683" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688" xlink:to="loc_us-gaap_PlanNameAxis_690" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_690" xlink:to="loc_us-gaap_PlanNameDomain_691" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="loc_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_691" xlink:to="loc_freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember_695" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_689" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_693" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_696" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_697" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_698" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_699" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_700" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_701" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_702" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_703" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_704" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_705" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_706" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_707" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_708" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_709" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_710" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_711" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_712" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_713" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1734" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_714" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_715" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_718" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_719" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_720" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_721" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_723" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_723" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_724" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_724" xlink:to="loc_us-gaap_AwardTypeAxis_728" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_728" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_726" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_726" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_729" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_727" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_730" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_732" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_733" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_734" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_735" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_736" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_737" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_738" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_739" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues" xlink:label="loc_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues_1783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_731" xlink:to="loc_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues_1783" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1133" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1133" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1134" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1134" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1138" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1138" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1135" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1135" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1137" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1135" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1169" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1170" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1170" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1136" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_741" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_741" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_744" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_744" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_746" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_746" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743" xlink:to="loc_us-gaap_EmployeeStockMember_742" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_744" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:label="loc_freq_PercentageOfEligibleEmployeeCompensation_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_freq_PercentageOfEligibleEmployeeCompensation_745" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_747" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:label="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_749" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_750" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_751" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_753" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncomeTaxesDisclosureTable" xlink:label="loc_freq_IncomeTaxesDisclosureTable_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_753" xlink:to="loc_freq_IncomeTaxesDisclosureTable_758" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_761" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_761" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_766" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_766" xlink:to="loc_us-gaap_DomesticCountryMember_754" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_766" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_767" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_srt_StatementGeographicalAxis_770" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_770" xlink:to="loc_srt_SegmentGeographicalDomain_760" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="loc_stpr_MA_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_760" xlink:to="loc_stpr_MA_756" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_772" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_772" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_764" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_764" xlink:to="loc_us-gaap_ResearchMember_765" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_774" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_774" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_763" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_763" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_762" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_srt_RangeAxis_776" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_776" xlink:to="loc_srt_RangeMember_755" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_755" xlink:to="loc_srt_MinimumMember_757" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:label="loc_freq_IncomeTaxesDisclosureLineItems_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureTable_758" xlink:to="loc_freq_IncomeTaxesDisclosureLineItems_778" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_759" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_OperatingLossCarryforwards_769" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:label="loc_freq_NetOperatingLossCarryforwardsExpirationWithLimitation_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_NetOperatingLossCarryforwardsExpirationWithLimitation_771" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_freq_OperatingLossCarryforwardsExpirationYear_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_OperatingLossCarryforwardsExpirationYear_773" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:label="loc_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_775" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:label="loc_freq_TaxCreditCarryforwardExpirationYear_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_TaxCreditCarryforwardExpirationYear_777" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_779" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:label="loc_freq_CumulativeChangeInOwnershipPercentage_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_CumulativeChangeInOwnershipPercentage_780" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:label="loc_freq_PeriodOfCumulativeChangeInOwnership_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_PeriodOfCumulativeChangeInOwnership_781" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_782" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_783" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:label="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_784" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:label="loc_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_785" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_786" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_787" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_788" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_789" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_IncomeTaxesDisclosureLineItems_778" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1219" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_791" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_791" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_792" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_791" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_793" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PreTaxNetLoss" xlink:label="loc_freq_PreTaxNetLoss_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_791" xlink:to="loc_freq_PreTaxNetLoss_794" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_796" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_796" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_797" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_797" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_798" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_797" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_801" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_797" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_804" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_797" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_806" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_796" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_800" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_800" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_799" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_800" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_802" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_800" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_805" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_800" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_807" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_796" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_803" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_809" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_810" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_811" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_812" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_813" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_814" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_815" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_816" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_817" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_809" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_818" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_820" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_820" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_821" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_824" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_828" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_829" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_830" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_831" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_832" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_833" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsLeasingArrangements" xlink:label="loc_freq_DeferredTaxAssetsLeasingArrangements_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_freq_DeferredTaxAssetsLeasingArrangements_834" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_835" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_836" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract_823" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_837" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract" xlink:label="loc_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_820" xlink:to="loc_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract_825" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_freq_DeferredTaxAssetsRightOfUseAssets_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract_825" xlink:to="loc_freq_DeferredTaxAssetsRightOfUseAssets_822" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_820" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_827" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_839" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_839" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_dei_LegalEntityAxis_849" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_849" xlink:to="loc_dei_EntityDomain_846" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:label="loc_freq_MassachusettsInstituteOfTechnologyMember_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_846" xlink:to="loc_freq_MassachusettsInstituteOfTechnologyMember_853" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:label="loc_freq_CaliforniaInstituteForBiomedicalResearchMember_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_846" xlink:to="loc_freq_CaliforniaInstituteForBiomedicalResearchMember_861" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MassachusettsEyeAndEarMember" xlink:label="loc_freq_MassachusettsEyeAndEarMember_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_846" xlink:to="loc_freq_MassachusettsEyeAndEarMember_869" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_859" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_859" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PatentLicenseAgreementMember" xlink:label="loc_freq_PatentLicenseAgreementMember_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848" xlink:to="loc_freq_PatentLicenseAgreementMember_847" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:label="loc_freq_NonExclusivePatentLicenseAgreementMember_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_848" xlink:to="loc_freq_NonExclusivePatentLicenseAgreementMember_858" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_RangeAxis_864" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_864" xlink:to="loc_srt_RangeMember_842" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_842" xlink:to="loc_srt_MaximumMember_845" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_842" xlink:to="loc_srt_MinimumMember_857" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_CounterpartyNameAxis_867" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_867" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_852" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_ProductOrServiceAxis_870" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_870" xlink:to="loc_srt_ProductsAndServicesDomain_841" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_TitleOfIndividualAxis_873" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_873" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_856" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_856" xlink:to="loc_srt_DirectorMember_855" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_srt_StatementScenarioAxis_875" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_875" xlink:to="loc_srt_ScenarioUnspecifiedDomain_850" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_840" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseAgreementEnteredDate" xlink:label="loc_freq_LicenseAgreementEnteredDate_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_LicenseAgreementEnteredDate_851" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:label="loc_freq_DescriptionOfFutureDevelopmentObligations_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_DescriptionOfFutureDevelopmentObligations_865" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseFeePayment" xlink:label="loc_freq_LicenseFeePayment_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_LicenseFeePayment_868" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:label="loc_freq_PercentageOfSharesOfCommonStockIssued_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_PercentageOfSharesOfCommonStockIssued_871" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_PercentageOfRoyaltyOnSublicenseRevenue" xlink:label="loc_freq_PercentageOfRoyaltyOnSublicenseRevenue_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_PercentageOfRoyaltyOnSublicenseRevenue_874" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RoyaltyExpensePerShare" xlink:label="loc_freq_RoyaltyExpensePerShare_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RoyaltyExpensePerShare_878" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_MilestonePayments" xlink:label="loc_freq_MilestonePayments_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_MilestonePayments_879" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:label="loc_freq_DescriptionOfConditionsToTerminateLicenseAgreement_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_DescriptionOfConditionsToTerminateLicenseAgreement_881" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:label="loc_freq_RightToTerminateAgreementUponPriorWrittenNotice_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateAgreementUponPriorWrittenNotice_882" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:label="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured_883" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:label="loc_freq_RightToTerminateAgreementIncaseOfNonpayment_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateAgreementIncaseOfNonpayment_884" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaap_PaymentForManagementFee_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_us-gaap_PaymentForManagementFee_885" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:label="loc_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_886" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:label="loc_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_891" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AnnualLicenseFeePerShare" xlink:label="loc_freq_AnnualLicenseFeePerShare_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_877" xlink:to="loc_freq_AnnualLicenseFeePerShare_893" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_898" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_898" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_us-gaap_TypeOfArrangementAxis_906" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_899" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:label="loc_freq_LicenseAndCollaborationAgreementMember_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_899" xlink:to="loc_freq_LicenseAndCollaborationAgreementMember_907" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_srt_RangeAxis_915" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_915" xlink:to="loc_srt_RangeMember_900" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_900" xlink:to="loc_srt_MaximumMember_903" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_srt_CounterpartyNameAxis_917" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_917" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_909" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:label="loc_freq_AstellasPharmaLimitedLiabilityCompanyMember_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_909" xlink:to="loc_freq_AstellasPharmaLimitedLiabilityCompanyMember_901" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_919" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_919" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Phase2bClinicalTrialMember" xlink:label="loc_freq_Phase2bClinicalTrialMember_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911" xlink:to="loc_freq_Phase2bClinicalTrialMember_905" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_Phase3ClinicalTrailMember" xlink:label="loc_freq_Phase3ClinicalTrailMember_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_911" xlink:to="loc_freq_Phase3ClinicalTrailMember_914" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_srt_StatementGeographicalAxis_921" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_921" xlink:to="loc_srt_SegmentGeographicalDomain_908" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_908" xlink:to="loc_srt_EuropeMember_902" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_908" xlink:to="loc_srt_AsiaMember_912" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_910" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_us-gaap_ProceedsFromCollaborators_904" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_913" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:label="loc_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_916" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:label="loc_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_918" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AgreementTerminationNoticePeriod" xlink:label="loc_freq_AgreementTerminationNoticePeriod_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_AgreementTerminationNoticePeriod_920" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:label="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_RightToTerminateAgreementIfBreachRemainsUncured_922" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:label="loc_freq_RightToTerminateAgreementIncaseOfNonpayment_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_RightToTerminateAgreementIncaseOfNonpayment_924" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RevenueRecognitionTransactionPrice" xlink:label="loc_freq_RevenueRecognitionTransactionPrice_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_RevenueRecognitionTransactionPrice_925" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:label="loc_freq_UpfrontFeeRecognizedAsRevenue_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_UpfrontFeeRecognizedAsRevenue_926" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_JointCost" xlink:label="loc_freq_JointCost_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_923" xlink:to="loc_freq_JointCost_928" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_930" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_930" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_936" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_srt_StatementGeographicalAxis_938" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_938" xlink:to="loc_srt_SegmentGeographicalDomain_939" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_us-gaap_TypeOfArrangementAxis_944" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_944" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_931" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LeasesTerminationAgreementMember" xlink:label="loc_freq_LeasesTerminationAgreementMember_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_931" xlink:to="loc_freq_LeasesTerminationAgreementMember_937" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_srt_CounterpartyNameAxis_946" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_946" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AREMARegionNo20LLCMember" xlink:label="loc_freq_AREMARegionNo20LLCMember_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940" xlink:to="loc_freq_AREMARegionNo20LLCMember_933" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_HaydenLLCMember" xlink:label="loc_freq_HaydenLLCMember_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_940" xlink:to="loc_freq_HaydenLLCMember_942" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_us-gaap_LeaseContractualTermAxis_948" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_948" xlink:to="loc_us-gaap_LeaseContractualTermDomain_941" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LexingtonLeaseMember" xlink:label="loc_freq_LexingtonLeaseMember_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_941" xlink:to="loc_freq_LexingtonLeaseMember_932" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_936" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_us-gaap_LeaseExpirationDate1_945" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_us-gaap_NetRentableArea_949" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeaseCommencementDate" xlink:label="loc_freq_OperatingLeaseCommencementDate_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_freq_OperatingLeaseCommencementDate_951" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:label="loc_freq_OperatingLeaseNumberOfAdditionalExtensionTerms_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_freq_OperatingLeaseNumberOfAdditionalExtensionTerms_952" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:label="loc_freq_OperatingLeasesAdditionalExtensionTerm_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_freq_OperatingLeasesAdditionalExtensionTerm_956" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_950" xlink:to="loc_us-gaap_OperatingLeaseExpense_957" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesScheduleOfLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_959" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_959" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_960" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_959" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_961" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_963" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_964" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_965" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_966" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_967" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_969" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_971" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_OperatingLeaseLiability_972" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_973" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_974" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_976" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_976" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_977" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_976" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_979" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_976" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_980" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_976" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_981" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_976" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_982" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_976" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_983" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_985" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_985" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_986" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_985" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_987" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_985" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_988" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_990" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_990" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994" xlink:to="loc_srt_CounterpartyNameAxis_993" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_993" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_995" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_SaliogenTherapeuticsIncMember" xlink:label="loc_freq_SaliogenTherapeuticsIncMember_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_995" xlink:to="loc_freq_SaliogenTherapeuticsIncMember_991" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" xlink:to="loc_us-gaap_SubleaseIncome_992" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" xlink:to="loc_us-gaap_NetRentableArea_996" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_997" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_998" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1000" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1000" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1005" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1005" xlink:to="loc_srt_StatementGeographicalAxis_1003" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1003" xlink:to="loc_srt_SegmentGeographicalDomain_1004" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LexingtonMassachusettsFacilityMember" xlink:label="loc_freq_LexingtonMassachusettsFacilityMember_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1004" xlink:to="loc_freq_LexingtonMassachusettsFacilityMember_1001" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1005" xlink:to="loc_srt_RangeAxis_1478" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1478" xlink:to="loc_srt_RangeMember_1077" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1005" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1002" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_RestrictedCash_1006" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_1009" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1007" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1010" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1012" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1012" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1013" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1012" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1014" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1012" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1015" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1012" xlink:to="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_1016" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1012" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1017" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1019" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1019" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1020" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1020" xlink:to="loc_srt_TitleOfIndividualAxis_1023" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1023" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1024" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1024" xlink:to="loc_srt_DirectorMember_1022" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1020" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1025" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaap_PaymentForManagementFee_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1025" xlink:to="loc_us-gaap_PaymentForManagementFee_1021" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_1140" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_ReductionInWorkforceDueToRestructuring" xlink:label="loc_freq_ReductionInWorkforceDueToRestructuring_1141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1140" xlink:to="loc_freq_ReductionInWorkforceDueToRestructuring_1141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructuringRelatedExpenses" xlink:label="loc_freq_RestructuringRelatedExpenses_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1140" xlink:to="loc_freq_RestructuringRelatedExpenses_1168" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_1195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1140" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_1195" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedHearingProgramCharges" xlink:label="loc_freq_AcceleratedHearingProgramCharges_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1140" xlink:to="loc_freq_AcceleratedHearingProgramCharges_1208" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1140" xlink:to="loc_us-gaap_SeveranceCosts1_1211" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_1143" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1143" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1149" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1149" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1147" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedfxthreetwotwochargesMember" xlink:label="loc_freq_AcceleratedfxthreetwotwochargesMember_1150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1147" xlink:to="loc_freq_AcceleratedfxthreetwotwochargesMember_1150" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1147" xlink:to="loc_us-gaap_OtherRestructuringMember_1167" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedDepreciationChargesMember" xlink:label="loc_freq_AcceleratedDepreciationChargesMember_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1147" xlink:to="loc_freq_AcceleratedDepreciationChargesMember_1197" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1166" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1166" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1144" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1144" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1148" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1144" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1165" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1145" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1196" xlink:to="loc_us-gaap_RestructuringCharges_1146" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1152" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1152" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1153" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1153" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1156" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1156" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1155" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedfxthreetwotwochargesMember" xlink:label="loc_freq_AcceleratedfxthreetwotwochargesMember_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1155" xlink:to="loc_freq_AcceleratedfxthreetwotwochargesMember_1157" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedfxthreefourfivechargesMember" xlink:label="loc_freq_AcceleratedfxthreefourfivechargesMember_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1155" xlink:to="loc_freq_AcceleratedfxthreefourfivechargesMember_1164" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1155" xlink:to="loc_us-gaap_OtherRestructuringMember_1199" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1153" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructingLiabilities" xlink:label="loc_freq_RestructingLiabilities_1154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" xlink:to="loc_freq_RestructingLiabilities_1154" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructingNetCharge" xlink:label="loc_freq_RestructingNetCharge_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" xlink:to="loc_freq_RestructingNetCharge_1162" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_RestructingLiabilities" xlink:label="loc_freq_RestructingLiabilities_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1163" xlink:to="loc_freq_RestructingLiabilities_1198" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1159" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1159" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_1160" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_AcceleratedHearingProgramCharges" xlink:label="loc_freq_AcceleratedHearingProgramCharges_1200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1159" xlink:to="loc_freq_AcceleratedHearingProgramCharges_1200" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1159" xlink:to="loc_us-gaap_SeveranceCosts1_1209" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1027" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1027" xlink:to="loc_us-gaap_SubsequentEventTable_1030" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1031" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1031" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1032" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1032" xlink:to="loc_us-gaap_SubsequentEventMember_1028" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_srt_StatementScenarioAxis_1395" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1395" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1384" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1551" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1551" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1378" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_LoanAndSecurityAgreementMember" xlink:label="loc_freq_LoanAndSecurityAgreementMember_1385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1378" xlink:to="loc_freq_LoanAndSecurityAgreementMember_1385" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1555" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1555" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1383" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_TermLoanMember" xlink:label="loc_freq_TermLoanMember_1389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1383" xlink:to="loc_freq_TermLoanMember_1389" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_srt_StatementGeographicalAxis_1624" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1624" xlink:to="loc_srt_SegmentGeographicalDomain_1386" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1030" xlink:to="loc_us-gaap_SubsequentEventLineItems_1034" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1029" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_us-gaap_RestructuringCosts_1033" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="freq-20230331.xsd#freq_DebtDue" xlink:label="loc_freq_DebtDue_1554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_freq_DebtDue_1554" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1034" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1623" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g451428dsp046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428dsp046.jpg
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M P,# P,# P/_P  1" -P J@# 1$  A$! Q$!_\0 L0 !  (# 0 # 0
M      <(!08)! $" PH! 0$! 0                 " 0,0   & P ! P$#
M!@8-!@H!%0(#! 4&!P !" D1$A,4(146,1?7&%B8(B.VUC@905'24Y/3)%9V
MEWA9"G$R5)155V&!D=0EE=66-]BQ4C,T)K<:-76E*/%"<F-$166%=[@Y$0$
M @$$ P$              1$"\#%!P2%1D:'_V@ , P$  A$#$0 _ /[^,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>)S2&N#:X("'!:TGK4*M(2ZMV
MDFW!L-4D&$EN"#2]*N0;6HACT85\Y!Q/O#KW@&'U#L/Y7WCMWR6P6K^DGNT+
MWK>(-_'?15#^-6<7FB@L&>(XX2ZU[KJARLGR/6I&5;(W-4'35KR];$3^ABH%
M)462RQS>UCD$YM3(DY0;W#/(?>5==FPSGN1=@QF].681V_6U12?KV2,](1YM
MF3/;O!?2ERJ>>K$G4"C<8J,N:UQ;M=QE8F<6!,RKSRGU$V+ F'['I0'/FT?*
MOY E4-4SN'7U=)S,S<M="72R3&EJ\X]=*M9G@'DIZFYTH.WNDE5K0ISD(N46
MZMH7%B7IU@Y1Z\IA2J'@[?M$:L$':3R,]V]!<%$<NW\M>F2P*LN&A[JI5_@\
M*9$#S#7_ +F=JK;;4Y*>(/("FU5+S&"V);")%$$Q(UFV\TMY0'&%[-!HW047
MNWN/M>A6#L@RP^ZXG$N@?'37G*#-".<7:KZ9T#R!6+-*/K.>3V7/S6LBY%E.
MS5T%<LH>X)#TM<*&$M@5L_J/2Q5HXG0>KHOH[NJ@XQYD9FU]S7.^J>*8YS$G
MIN)S.O.1B$K"Y=)PRN)H^JY(Y-=!Q[;@]0E3)U2%F,5J0-I9'M&X%J]AV;@6
MNFG3O2M3>)'NOHA+<MI*KTJF.2Y_@$IN"<<*73((8:W,,4&UGI%?(<-:Z7$S
M'*U2DPM$^HU3H$[Y!F[^F&F#H- Y:[ZZ'DGDU*IRT.D&*P*FMN[.Q*KK&#UP
MPT;)J_0DT8D>GZ,PQZ8$08'V3SC<57LL/<2)6X39NE4-E2LTO[J5(BU;48:%
M(;V\QO9/.O4DDD3S86IGSE3W0WDLAEF5HC@<&,<G.(0FS:0YXY0;4KPVQD$G
M3:A5X7BP)U)Y:C1ZY.N'I:,[T#L(1_4G;OF;N%IJ^IH);]O6=U>S<R7/(7!%
M5E4<;HZID/0=;>1SI;FI*\],J;19(RNB-%%P^K434KW"ST[P$*0T\L E6]C,
M"]$C\A73R*S+*L<?4\0:+'KSRHP+A1@\8J>%5::;8%,/EN5Y5RZ7)W!V92^C
M%5C2ZMY2OM-GD:-S*C*=C2 )&VG)0*3L"N?"G9GD(ZIG]<5O+NN;_JY+:_,G
M2-Z/DZG=><.MS/-B:SN)'%ZW=^!=QNJ9.Y20N.Z9%[?8;7/TBAQ;FAQ2JBDQ
M)BA(M"&8L'R ]S0#QI^/MTKKIBWK<[<[?J%;V"[2DGF2&W.Y0F 5SSVSS9XK
M!DJ+GRC=G-5:6=?\FB$/+D+JV*U+,FDJQ08YAVG)T6&E7[YP.I4LLNVS:@?R
M2^3[=I[QRF<\3%MC$.E#MSYT'T:V0ZSUD/FI6V!68KB=RUYJ6L9SB[C6%,DI
M9$J,K2,Q7H0@N38-C=YPJ2^95OA7>5G2AVXXAU1$<^,5AP+DMNC37(+QIV.V
M@<ZRIR;:0B*IS61)R<#4;(!4O)2#3" %:6L-]#,#??*)T%Y &3LN*<X\02F\
MQ2YSX3LJ[() Z8@W*TB8GB^&6XHK!8$\]"O?2:9.?'^?1;>](WTR-KB7DH!V
MC$X!##ZX'ZR;R%7%%N2?->\R:^JY8^EN3I=T<U4"QD&5^%TA?YN.**8M=N*C
MD-=407.;L#+9K\^+DJAW1+SE2?U*.$,HGXP!6^3][=2U[QNVM1%^WV/J'J"\
M*4IVJ)B_-_&'9TTJ>-J(T]VA>%Q0&D_']5CLKDS%&JRA[N(;;(&ET6E*Q)#-
M?&3HX6PA.TO,;T](*MYFOV.=!,E.LT7Y C%C=64\R1>BAW!$K_@MXR>G[]>;
M I+HY/7TJN&FBGNNWAA)BE7REAL1B>-A,4IC!JFM.:%[.+.J^F[N\A/143GM
MV6NMJ.M>S.C*BAT.;ISP3&:G)@\&C6E$,B3_ %4[P@CMU^?4JM>$6W%O< D&
M*-$C,&),2K"(-.N3O[M6M>I^@^)8F[NUAW93]PVKV]&24, C>U,V\:\4Y@66
MY":@2A11D1)SC)NMSD52;=R2MOPF\1AP%&UGM/V&M4%U;TY<<FYJJ^*^2@Z^
MC^P.$+$ZIMJ7TU6_,),KXFL"MSZ3D; &&HT=<2AD::ML]=.7N$C8[";GV0$J
MF@9R=Q+6%+/C"L,:['\@)\3\88W'LB_YZMZ_X%F_8%I[BKEXSJ&D:";[6<R-
MC2P1>2]&TNS5H*NXX*PG?9362!5)E)BW1PU)J9(9HH.@7E+ZEZGJ.S>&*RY_
MN:>QM):W.O4E@3!5$)UPM!9+.)35+?SF5!'YZL;JV*N=)_<B578;@<Y)(\%&
M:XZ6:-2:TF(_@!&_,/7/D#Z!M7@NO6^_8D\5;W/S33/=C];R:N(U$9O6$0H6
M,0",]?4! H \QE4F<HW?=P3F('L+ZY#4.,?97V1:3&'?3M!I(?T$47,9)8%2
MPB92]PJEUDK\UFJW9PHZ9+;!JA4H X+$P1PJ9N+4R+7]LT20$(CC$I.]*-&
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M,@J2Z(!0\$H&;WI/Y_7\DL=(AB4GA,73ML?BKRD9'0:I3,G1L3FGA5+BMA"
MS>]A'^3>]8$HPV]'\VKY9:%Z5DY\TMT-T\KWMOL&4Q)_^DC#*@3KSI6>[PUS
M=FHEN,",TO1(A_4[,*]-!_A!]0J&C\B5KR:."M.N>!>CYY0FR1.+=9*9P@['
M*Y-' @^4,KB=.O#H5,GEC6) [4)M[$2<H*V'8 ;]VL"VL4ZCK6P>=77IRNW0
M4QKMM@\GFP2T1&T+R+4/;'%>^QI>A<!%&L\F0*&PQ(>F4:#M.HU_"WL'\+ V
M*MKO;;(H*&7^A97%M8YK5+5:Z-A6"(&ZH6QUBP)26V*SRA?1C7%IA?%L81?%
MLS?V?9@0,/NJ)ZX63]W@@\F%"5-?([ +@>U36&5;1K7TEA+;1+_F&SZ6?4':
M,]WNT#0/L_+@;#4/1M[V1+&!FEG&MF5+$7I">O,L61V'4T@96XK38)Q;]*&B
M+R5>_&_>AOL3E^PG>RQF:$/6@Z%O08^#]QUO-.N+6XW,0.D;LNLVUK=6U6\#
M1Z9[%2JF-K?WDJ*&$F;. Y1A \IC5*4[7S#3F;-!K8 "] D^*=$L\MZ*N'G-
M$P.:9^IV"UE.G21GFI!M#TCL_P#$'W:A;TQ1@EJ=4V_A\?S;-U[1Z,#[/7[<
M"!)]W4[ L^74WSASO8O4\XK4U,BM1=#7J+0FNZ]>E:<*PF)O%A3!84TK)MI'
MOY3&U* T9&MZT8((M^F@D>#].S:95/:4[7<SW5!9W5*5U^\*=F;8UMK_ "YR
M;6?;X2FKR6$KE42F")T1A]A"M,;LKZC>B1:T/?I@:I)N^:H:.5H%U+'D+U-&
MRTU$/CU<5TR 3 G,LL:8NH&%/6R9*I,T0FD[.\@4DKPC_BTVD1XQ;]NM;V%W
M$:I4>VI5:M&) L.2ISE3>,T!XT2@P !'HQGD^I1XDQF]@V,'\ >P^NOLWK X
M]]5>8J&<K7E+:.>.=+FGKC$4[">HE46*;"H^Y;?F5&]%A;?JM&GF 2%+0E&"
MWO[30"UK7IK KQ_]\(5S^R)T+_\ D7_%8#_[X0KG]D3H7_\ (O\ BL"?.8/,
MK"NGKS@M&-'-UV0EQG1[N0FE,B*:C6!G^YV-Q?33G;9 0'$ICR6T1(1Z]?0T
MP&O3[<#LV4/Y"P#]/3WAT+T]-Z]/7^QO6_M]=8'Z8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# HIXS/Z"/-O^A"O^4[_ (%Z\!@,!@,"F7=W1LQY<I:)V1!F>-O;
MT_\ 2_(M+JD<J(<U#83&[_Z;JJEI:XIRVER:E6GMJC,Z5*&\0C1$ 7%%".+.
M*T,H8<;.>_+[U[T99M6<S$P_GBGKZNF_.E6NO)')(A8L[@+YRW7,0Z*45E;;
M;%VVU(>].<G1VKSB]1.7(M.Y)250%,I*T2!<G!H-=YW\I7DAN%V\<;6Z,7/C
MGKM^H;$Z E*BGN3[QL,VJH+"K6HZKB&5_2&]7,_W"QA4V2O5.DU4#4HV[_(R
MM-!V]C&8$01CSG=Y3&)=2K(E4W-[O+H!&4KC4*"50*XZO8D<LE/DB1<,UFP+
M721V>N%T= Y<Q%.3FZ3&'A9FJ*R!%IK7 ,.- 7@2.\^<+J2SYY#81SW4\.;%
MTNO.-4V[QU51UE=!VW6LE:.-5UXW? )#5D3NREC7N;5;=\>=HRXG%N:%.@:T
M!BK9*D0=",#IWS!?/;\[[XZLYPN"8\O.=2<RQ"C)8(^NJ2M6'6)+@=&,]H.L
M30;>Y-T#.(\R&07\W6@. _NI3][?5?Q04.P>@@ZOX# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8%)K0_I^\>?[.W;?\ *SCG NS@,!@,!@,!@,!@,#CMVA&K5EOD
M0XT9J9M%MIZ<G4-TZ<GF[K &VRT:5K3+*W,<VXR+.CBU)3AN8/9H)^SP[)V#
M?H$?N],#=N\8_8L9\7?2K%:]@H+3G*.L'#3U.FJ&H:^0/.U$F;3T>R(FWKG-
M&V?1HC2RAZ >9\VP>[?IL6]:"KKXT= G]%\&P+M>R8,^T0]N[9/J95U'"E<(
M8U'1D 8DKI6D)M-:_.S\Z'E',ZD]6V[2&(RUC@3\0@>@?L"8^HH[/Y3Y+^;V
MJM[@!1TE#R;<:K<W%$(U-P;0$3Z+A6,VF&4GDM0 KS!EBV?]IA>B_0'Y=X&_
M=XUC:TE\<%M0@<W/ORP&%K99'+7AGC[-&7&Q(U$YXV2Z2,A48B9I[8C..AR
M:;X2M[VH"1[O3Y!>F!/N^S*19>4@=,P)P03ZK&&',[[IIA+HP ?D+*GVW(79
ML*9W)Q;BD3K#41@QJF\P0%.M)1DEEB-V6 84BXN;CK*XM[OL>OFDTB =-6?U
M5.Z)C1(20'"BCY$C(N@4 ;$PS=M:J2R5I4FZ2;]!E[,#K8=;WZ["9^9;KJQ%
MXN*PEJZ=Q5NC\,Y/0QB5+5[VWIA1^1Q.O!QU\8'8@U06H1O2)Y0"3;2C!H\9
MV]!"#>Q!UL*G/3"\Q?\ X?5"POZ!2U.Z?F&(JU"-428E5I .\S9G5'\Z=1H)
MA8]H5Y1@@BUK[-_VMX'2[FR!W1$A-KA9W52:[F-?"VA(QPO5:U[!AL*_:5">
M%P ZQ92<Z/ DJ$L:?XC?XL6C-F[_ (0=8'-UXYR=N@>DO)"NKYY+A]_4U=?.
M]H<]SO0P%B8; :Z+1!&SN8][_CHI-D!6VQU(%_%&)QZ&/UV6' WCQXWF;T+V
MWU[8SK&ET'EY=%\Q1"RH.YE'%+879D)<K289Q'=[/UH:A(@=TPAICO3T-2FE
MCWZ[WO DGQA2V,UVV]&<V3AT:XYT!!>F[KF,XCSXM*0R"6QJPI8HDT+LMM"N
M$0<_QUVC2M.G I(V<$GZ;18]A_@ZV'2>(VK75A/TOB\+GD4E+_7ZI&@F;9&G
MYO>EL5<'1/M4WHWLI >H"@5*4P!B  S>A[T 6MZUO6\#D937-L0:/*;<$/*<
M'(ZKZ8B35U35=8G?".*0JZ^BSW.)SV5-*3>O4&BR(:<I0D^GQ(U+F>,OT%O
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MINUZMTOE#7NRH!IS@Z-0XS5NW,8[I?$&]*/1:I?*$>W'ZB/HTQ@M!,-5A)
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M_P#]/]O ^?8#_P"I#_:_)K\GY?3_ ),#[8# 8# 8# 8# 8# 8# 8# 8# 8#
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M$YXQ0243.)2V\F"3,# I=8>D:'.%A1<_O_W;)B%YC>[NB;Z!-H9IR7:@.K\
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M:2I918SR\*T2=NI^*O,PF86HX2QQ*86%O;W*9NRI2O++(4"*.V$X_91180!
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M%G'[#LY%H.L> P*36A_3]X\_V=NV_P"5G'.!=G 8# 8# 8# 8# 8# 8# 8#
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MI^HV=O7H#V>H@ZI8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M;/FQRC72$M@H5$YLJHJT9J8LS:1:YO*N/P>D[!89$)\AY.AHG0IQ;S@)7<I
M!( /9)>9_(NDCR_\/W?(WA[DKM(':SM*+7DYI4B0-_7;C+8\R52V[DD1#4NG
M?FY?]!\#*[QT'L*+;E"P!@0+BPW:XN7.MGF,T*_5S8<H<+W@O'?0E)*K4E-C
M+8RL8[6L-+3;M$)O+XI&'I5#9>H,+KUX:3UH"W)2B=7% Y!^?Z7ZE.$ /O'?
MD%VM3RF+VI-4 GQBA<;FXU$V*372**,;_P!B.[!#6*5(K<$I6-5622XHP[)!
MNL[6'.:4@9"TQ<%)M J#VQ_F[M*['*1MD]D5J$P1HZ&<BY<ZSZX'ML56<PUO
MWG0\^K^85-"4"-(32HX'4-6RX:58SZ0Z=]/2'Z,]24(@YN#(2+FGR='M$A96
M*W921)"6B7ME;6!^?]W TQZO4T.N^,LM?RR+*$1PIE;,F?GV+.B>;KBUC@W_
M  %FF+BSVP1#D$D2;FCO)/:,721.\;#14>P6G*7!ET19;A,+";&-S4<\OS"]
M2MTF<RCWXUBZ59'IZVG-+R9)"T:1X %.V' &F&VAV+P& P& P& P& P& P*3
M6A_3]X\_V=NV_P"5G'.!=G 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# HIXS/Z"/-O^A"O^4[_ (%Z
M\#DC#@"'WYY"/;KU]&OC7U]/3[/6K9__ .' _7MTDW]2WK_^!O\ HNW[_:_[
MJY5_X<#I957_ ,+ZW_T"A_\ )YNP-]P*R]E6??%,<Q7!9_,='_K(7O#HR4YU
MS2GWZ5'/QT[#>&Q$L2_>9F]"WMI9E2EP^F*V%0N^D^F)$$TX&]!(U&2NQ9W2
MU33:WJZ_-!:LNKB&22R*JT^))-^;B<O4>;W&4PC\0H0@1O7X8>E!R/ZDO6@'
M?#[M?EP.8'DX[BZ.Y.GK/'Z,@0+"0.?!?D"OUS0IB(0!=%9QSPBH@^O;!=5<
MYF<.2N,%B@I^XB=V=O$K=7,)Q7TY(]DBU@4_*\_Q<.ELDCDYIEID<$I:O*QL
M#H"X(W,7EO<85#AS>EZJNR;K*K70$#OHN&RR[VQU2)4ZDU&M8TJPU.M."4$S
M86JY%\JMK](]3MG,TRY'%3S@16D6D\[<'>Y(NLDD*E4KH:N;[;B2J_=6N-2R
M60(Q%8P(WMY;$Q_PO[:IT<4 GUV4%<'CSPRY!%9(Z'<N1:$NM>SN=4/9SK<5
MXKZ[K.)=/T)5-GV]T#1Q,XW4[T-X=PLL6CC?!U):, 92ODPM^Q.%"("D/7+?
M/$]HG5!"(=S"TK+@>+%?X(14-@7&9 YE$RU<_P"'X+5KS:+8174F=8(BG1W8
MAQY@QHU("@Q<_23:[1H]IPG?I#J?O2.]]5I05&QR.O,>9.>.:[RN>& B[$^U
MZA9)M?-LPCH=VD]SR"20B:1E'%*Q@ U$)"T,3BL>) G 4L0!3GCT4$60WS36
M6[E<R#G'.%30!;T/6O)EO(XVJZ/<W&4KX#VA8\C@$!<ZN:E-,,@+*44(T1[\
M4VX$)B%-$H^H"84>K]NQB#4:=\[DYMI+2QI')"=L7=%6RAYRJMG)M%\<EQ%\
MHEW/KR^()Z+\U:,F+5I+:-MF0V="'[?RBD<%B85AB=&:Y%$IPFZR_(]*ZKZ'
M[O4VA<-559!^+BFXFON4Y#%E&K1Z:ABWFYAM]3=J"8D*GN: C1D[D"YG3&QJ
M-NJ!L2Q-P"X%FJ#1#1!!4&\[-CS^ 3BPV;E6 HXU5-?M#W94@?.B#D;(T2F6
M]J6GQ9%7) N::HD#>?3S>\5P*8R:2'*BON&+_4#+(7#)",T)@I/R/]$G\N\X
MSXZ#U]T3:_2/>79O/S?MFLC47K]DKFEYUV!-&1U@TMC=5.:BR6]IJ7GDIJCH
M]LJ%5)C#TAZ@XDP\TW K<9_Q$3BAYYBU]/O*C.Q:F<W3%Q:(G7ZQ.JU]KPN&
MP:9R<@3@P1%T(B5OP@$Z*;ET;D &E6J4D;.0@5%;4!1AIKKYYK+A]Z6A;$NK
M-C4<D5I59S?.*NADW)E5NU#,#>DNAZ#@<JMIE)K)"]1*Q[ L:O(G'EL2^\%B
M-F;Y:B<M'G"+-"<'].->NTL?H#!WV>1E+"YR]0^,NTSAR%VV_HHG+'%E1+)%
M&4;Z)"V">DK$\'')2U>TR?:D!6C/B+]WMT&X8# 8# 8# 8# 8# 8%)K0_I^\
M>?[.W;?\K..<"[. P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P&!13QF?T$>;?]"%?\IW_ O7@?R_^6W_
M (<Y_P#)7UJ5U7!>WI5SBM<:[AD%E<#3UXY2YF>3X,>[Z:GDEP8[.KY24!4W
MNWPG)SBSA!V7L99P=&>P 48M+_A%9W<$S;GUS\@;%4\6TUM3 _P.B.>["C,<
M>&U.J4B=W(22;=33_?XE>4*P1)APQC2[T45ZI]Z"+0P_M38VE.P,C.Q)!FF)
M65K;VE,8=L(CAIVY(2C)&:((0AV:(LG6Q;UK6O7^Q@93 CZUK8K.C*\E=M7'
M.XK65909LV\2^=S5Y11^,1UM^H(2 5.CLXFD)4P3UBDH@H.Q>XT\T!8-"&,(
M=AGXA+HK8$4C4Z@TB99?"YDQ-,HB<KC;DD>8_)(X^H2'-E?61V0&GHG-J=6Y
M26>G/)&,LTH81!WO6];P(QG]RP>'6;7-2N<<E<IG=G,,P>&1#&8>HD*9KA46
M?:_C4SD$H=MZ*;V&-H7:Q64L_P"4S8S@G;$$HP)(]A"$K'[3Y/@#0ED:9^CE
MGMDC=GZ'N;A47X/L I&YQB,DR%8R2E0W/)924P; F)$G(.$+9I6BMA#\?L%@
M36&^>;1R.0E:N*E/Q9#MN\>E(=SV$!D$:U'VR22A_9WK8G33@U$L;5#WA<L)
M.]@$I32N,-T'Z11LL(K*EO%G-47=%R>15C$8M<'1Z-:^N!+M^*4<IZ1Z!-:9
MZVK7I?\ 4OXTTCF*)X;G-&,\9*9*TFHS"/A1:3^@>ZO^NN3K-KI3<R6RJQ8&
M!*M;D$K43:1PAC?8>]'.*]N96><%FO*G3 ]*E<?/TD(4':,']*/V?PB1Z $H
M3Z\J>KHA4O?YA$1OHX&Y3I!'TTCBA4KDD&9"%+@I=V5,[/+6!<QEEA., H&>
M6B^PP7R:T$>]!A07_P LKI<C@!=RT.LG+8^'P%!#@3Z!*9.W2-8K61I5#DK$
M%T&YHW=2Y-)[::@"4$T2I.)*('RAV7H(4E-N<.SJSJ#DA\DK*QI) YI83[7,
M]B,PCKY#ZAE350<V.D\LF3FRR8N/L8QTH)Y0HUJ\E3].E4'!)V2'9A@0L,IN
M'GU2PQ.P5EF5&?')TYB@<(F"J61(QMESVXFK2CH3&'DY=LE\>%9[0I"8UI3#
M3Q#2':$5ZDC]H8@B].7R694K36W1I+!N3%U:M/)FT&+:ARU02K4EP$\0'$*4
MQZ-2?4'Z;M^INR-&F^SX]#%H/T)Z%YE <8@3W32(5#).$D"VA(G\(TH;K&>-
M/92&($I"W3Y2I@YZ9W,!2( ?K#MHE8= WL@_0 C)KZZXY>978\++LRH"$];N
M4%7RB4+Y)7Z>!J)K:)MC(VUF02$3R-(MGY!%<.IKD0,!:HA((!NQ#+&9L >.
MQ)=R#>]CNO)$N3PZT9(B:#+YFT.:'-I6H6-=S_:%02!G+L8#&_)')(^))^],
M#@E;G(D21=IO-TIUL!6RAA*$=ZKYUD;88N*NBKFU:WP9LL62QUSL6#!D,,BK
MHTQYZ Y2Y AD2\MG3I$,L;!'';-&F#IP3"":,"@@9@89@[0Y.DSQ(H^T]#5*
M-XB\N305T0K9JR-)QTH5Q!BGA#8R?>JI$&2:W$I&E6B.;MJB %[,T(>A$'!+
M#>77HB@V,*$3S==4MFG12W(FWZVP(JG$X*WB.M\N:4R()CJ$2H]TBSLD<4X0
M:%L]$K).![BS2Q"",H7W%RM.HJWS]INJOV^O7Q)"U<7G,FET:BS#*-SQD6R!
ME1-0'UW0O"=U*:V\XQ4D7)$:DC10][!L)9@@!(:[I7G9M52]"OO>GTBVOU)2
M*=(C[(B %</7'/6XV4@DJ;;O\[*O'(=?0:(4!+-^LWHGV_(+0=A-11I9Q99Q
M)@#230 -*-*&$PLPLP.A ,+&'>PC ,.];UO6]ZWK>!]\!@,!@,!@4FM#^G[Q
MY_L[=M_RLXYP+LX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%%/&9_01YM_P!"%?\ *=_P+UX# 8#
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M/U<>NO\ >)65^[QS%^CG ?JX]=?[Q*ROW>.8OT<X#]7'KK_>)65^[QS%^CG
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M P& P& P& P& P& P& P& P*36A_3]X\_P!G;MO^5G'.!=G 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"BGC,_H(\V_Z$*_Y3O\
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M&4J#LU@,#XWK0M;"+6MZWK>MZWKUUO6_LWK>M_9O6]8'U***(*+))++)))+
M4444 )91118= ++++!K00%@#K6M:UK6M:U@?? 8# 8'YF%%'!T$TLLT(1EFZ
M"8 (PZ,),":29K0M;UH91H-"#O\ *$6M;U]NL#],!@>$ML;2EZAU*;T);HK(
M)2JG(M(0!>I3)]B$0G4+ EZ4'$$;%O8 "%L(=[WZ:U@>HPDH[X_E*+-^(P)Q
M7R "/XS0>N@&E^[6_88'0M^@M>F]>N!^F P&!2:T/Z?O'G^SMVW_ "LXYP+L
MX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M)Q@];WK SK34M-L*1*@8JSK)E0HI<"P$2)IAD5;DB2>%DF)@39*F1MI)*>7
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MX%Q?ZN+@#]BOES_4;7'\WL##*> ?'2F.VF%QKRV:I"+8!D)*(K]8:4/6M;V
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M& P**>,W6M\(<W:W]NMP=7K>O_!N3O\ @6JAQAB%:Y,RK>M&!V$9/\'VZ$-
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M"X\[Y/C6>XX-PCT;X :54[JR-(N;4QMQUJIGL_A[<?"C$L\J1F?92G/DCJD
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MW*7%W=UQZM8I-V,]4J/,.-&,P8A;#:\!@,!@,!@,!@,"DUH?T_>//]G;MO\
ME9QS@79P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P**>,S^@CS;_H0K_E._P"!;J0L!ZA06\-/\6YD
M;+$8$ BRS#_A",!)Q!AG\2%6268(&]&?Q9Y(MEC]->T00BZ+0^H(S9$QM9+5
M$.C-Q3IO:F>>V2Q0QL33:7M3( @AJ221Y2H0RE8A0@)*" M0(X@.BB_:,>BP
M;T$KGS)I+]0IP.*TW^%K19+>J(#[@_9[1'KBTB<'V_VQX&LZTXRQPT6>+X"2
M0["I3D;V8G:DQX=Z,+^JV$'U+VN)_@Z$'6OIR1;WK6O76S DXLL!)9910= +
M* $LL =>@0  '00!#K^QH(=>FL""NG.:::[#H>Q^:^@HH*;4_:S.E99G&RW=
MX8#UJ=O=VZ0-:A(\L"YM=VU>U/S.E6)S2#@""<0'U]P?4.PW6HZI@5%597-*
MU6P%16M*GA,8KJ QHA4N7%,,0AS.C8(\T@6N:E8Y+?H6M 47LY0<:>;L/N&,
M0M[WL*^]0\IJ>CWRM'9'.TE8+J^=R5Z6P(I%W,F\V)O.>F9PE#%7%I-LU8T\
M48;#9&C;/(&YR:']L<D1H1B3:/3D#"%'4_B$,;J;8*>8K_\ N%"D5L)<N>T\
M!E;JNG;="HO 8G!'=R"_W0Y*6*:QUK@OM$8U*44>6_6^JIG.$B0B("5S/&.R
MH"W8J,V!%4(9A6G0=:3,Y]IIJ?E007O;4YM\Z=0,]-+V44.L-J>)N)$X.!WW
MGI[2H4@Q@3')BAA"WO/G-<:Y]1V2TL2IN6L%@2R%2HB/(HNVQQEC9T0H^HJ;
M,2H&Q >>A-T\&U3IX,,"63L"A>(KVC^+1I@5RNSQU1^Y;(O>:FVF^QF/733K
MC#"($@C38N:8=;C\PQF RB[TJI2X%??*J3U)7L<BBUD-()3&M")87M1Z.1P2
MPB&1>*9/)-6"XFV\PL4BM?2]PFAD1J+\-1MJ?4UQ5A<D425RS-MB%/$/@H'.
ML0(9&U#=%JF1DNJ]0%<@4GB,P)8GOCA@UA4?5M*.;^RH&NMF;HX@ ]0USE;2
MJD?1U=6E"'N2-J"PIW+7QJ.CKG:JQS3%FNJP0O9]*6-,0,.B@CEX\;(&Z\:7
ME4/>FXFN45W+[%N-A0L3%&&E?7$9JFC1P"JDK"D"L"YD;Z;YQBDVVI+TF 2#
M;JE& ?UHS#@E.=^-VJ;$<[]D<H=1/LIO"YXG:29QD34ODC% V!D)YU322!,<
M%=I.?"QZGR3GM.G=7<E$C7JDCCM.?H\E.$LT(4M/Q)1VV@39A>+?_#,/E3S=
M2Q"L@=:-<:MEK:KYOB&]"2@A79X9*KTXR."RF!H&J%.Q+4B-CL>&>FV4J.$2
MH)";^4.-7RC;SO*QY8MB[I'G)M@T9I)ECT>;XVPPTMUBD3D_1\DB431'KT\!
M9[EO)M Z"90J57T0FDO8#1%C+UH.BN P& P& P& P& P& P& P*36A_3]X\_
MV=NV_P"5G'.!=G 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M!:5MXV.NBPSQN9ARS: Z*J$0T.MB]FD(B=%ZT7H.M!9S 8# 8# 8# 8# 8#
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MT 8#]?\ H#_-_J7]QCM;] & _7_H#_-_J7]QCM;] & _7_H#_-_J7]QCM;]
M& _7_H#_ #?ZE_<8[6_0!@/U_P"@/\W^I?W&.UOT 8#]?^@/\W^I?W&.UOT
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M3KRM.A+8LFN:I^JD\?K.&5K*G"RTWR!B;\IM!N5OK(T1<T:707<*!A(+,6J
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M0;9E3V5VE7^N?SPO2=JHMTM0:>(+TTGCXF:OJHKR$KFU(E.NJ.2X)*I:03H
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MA<E_.(ES@%O3#"5\YV]FF^SW"^W>\QK5G'G'_BZ7]9%S9%T/XV'9)%Y>QS-
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MHVA^8IG'M:=ZI0[T1OYA_P '^&+U#/G,;*H6:<5#.UGN&C41^EQS>D-6:.;
MK MQVE0R1'Z-;PN*C1 O=ZE:/,]OI[Q>H8$=<U\:H-5F02&F*SXS^"SE0XPR
M#4'0[X]D_A,TX2'9AD9^'?L^@WO:7V_9[/3 $5U7R8+6!-!8:G QMNF5E 1&
M&0H+.SA6$. 6EK"6A#IO;=+TQ9^B"O85\Q81^WW!UO01#<?)'/\ ?.V3=EP$
MAT Q-;['RB6AX?HHF<XO)R(PED44D*:+.;.1(8T\)H6TE&I%@3B]$H"BP>PO
MWA$%D,!@,!@,"DUH?T_>//\ 9V[;_E9QS@79P& P& P& P& P& P& P& P&
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M="Y3!N;RG-T=2(0Z&!)(T,0"T@A#]NMA]0Z8X# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M+0?47H'8=3L!@,!@,!@,!@,!@8&52A@A$7DDTE3D2S1>(,#Q*)(\*0G#3M3
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M]FMO_J]'_B<!]W-O_9K;_P"KT?\ B<!]W-O_ &:V_P#J]'_B<#[ ;FWW:_\
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MZ:]-;^S ^^@AU]N@ZUOTT'UUK6OX(?7VA^S^P'UWZ:_L>N!\X# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M 8# 8# PDDDT<AK [RN82!DBD7CZ!0ZOTDDCJ@8F!D:TA>S5;D[O#H>E;FU
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M'%4V9&AMD#S#DSXV'REI87E0L2-#VYQXI4)V0-#JJ;E!292:2 D\P@P(!"V
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M[1H$^RBVU!)U"T9FCS @]N@;W[Q:U^7?I@6,P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MZ5KVY('(_=7>9>>4CXMWCQ86O74"HN-SNVE'4#8L<H&VEGNWZQDD-4.]B()
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MP.*,3&:SJ4^GH!#PG**&';3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MDJD4:>(4YPAHA]DK3B8&F"L)EOXF>723-907,DUN:EC60VJ$IJA82):C+4!
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MK2)RTL<0GNM,*%X/C-)]I"XHK>O<6(0@@2T/#@[6BW6!&5]Y-S+&Y#+^@FJ
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M";9!)[C%W0PIR1IER<S6S?50%.'1C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M/9*U2)\8;!:MO]1KD<2TVGP=>F51PQ,8$&DX"2_A$$J23A_FR31Y-'3H4]L
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MJK-\IQ,C>I39,QE3[(8ZR5C)%S.VM2X]0VMQ"HTQ.06>88:(-SHSE2E><3G
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MQ:CM!70D+G,#9W6'='-GE#G_ "):[_#;B>*HGQ#PV*28>-(D7FLZA$Z,98!
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MD_76KZ)<>=HQNXEMB$VV?+D3].&D&K/!'OPFLGJ:-M,I11-%*GZ-Z"B=EA*
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MI*-3.+6W==4/T>NGG*'!54_9+S -/$?N/IND:QFB20$-@34[P9N'R!:0A-.
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MN1FL7K^ZZC5S6D4ZE4F(6QZJ(_!2@.",\A44E6Z4IA&-J="D*7!H$I\O76T
M@M6#E]4\[#F=PUC0%WM$O;I IB]20*)W=3MFV2DK>;.5R6Q534=.C7>L%*-O
M<PR)"4K1FG'DM:A2B^B5A82K.\[@O7M/GFNG!TJ^IHTMF%DM<JYQ02M>]W_]
M&U<IDV.W3&PO@V9$W>J'F3R@!S N;DZ<@\"1$H+6+-JE*5"%9&CR>=<434\:
M33=AK2U%%FO,]55K93RY'-I];QUKZWL&H3W2_5TVGE6P%W;MM!;0C9Q$O\32
M)W \A H5F[$6H."29+Y8.I&ZO#K)3T_230Q:2\NQ!8(Z5-LH;XO.^@V:42-9
M8[[/S;>@=-G4XWM\."C: "E"+[T<Y(W%&.Z?X1:6AK]%^2KJ6=V[)V1O_5\>
M);;TAK-B@7-CE82R63Z)R"6<8-MA(K'@[I!7=SBCOS$"P8O]XNRPDY</21]5
MC^]2%"5,E7A:=;Y,Y$\<93#KV.QF)PV,R&ZH?3]#BL) Z!3N!QRB(02PG&PO
MO66UU'&8V/761+V)*-SD$69MELB<Q2Y$[4AUL*H0_P SMPRUABDJ(CO,NE)U
M5T]+%E-)Y;)5]S6V^65:/0%3RAXH]*TOCHQ+X35^Z:*E+IO0G@L+&):48O3A
M)3N*D,Q&?+U<,@A$45J9)PVT!EC9%I:;TLHE]BF<GPU0_P!$NMPJ><I*]#<4
MSL+H9$L:@IM ^\DP-M2H*P3:%< +.>'MCGD\Z6<VU=+XI4]?QJ-L[)+KKM"&
M7$^68\6&UL!%U537)E:1%0G-;D$6?6YKGBP[WK$@T2-8@*(TA"6H-$E#T<G>
M3'H!RN;FKGZ[G^CI^.SCI9'I3-X.C-#/%$^#/^@VDF.KZ\:IXMD]=EPA+5B)
M"J5FQMV8CS-J]+G9E5)@I3PPBSIA=!+,D\^C_6\ZE]\,_D(N:MI7R<HLE/84
M>'RY#YM."Y<J54,SMC]+:]9:RIR.FR9+(&Y&0L&I:R"=C6!<=(U0>.L_-#;[
M_7E@SQ[K6IIHAB,\AU7,Q]8N)R_[]L/H:F5<LY9CRA'%+&N!O92I?=3:3!W$
M:IT*< J9&V'*$#2:4K2X&=DGD!O0^:I::_%=0U2Y,O7]2P9['(9=-3K.OA'(
M/(T^TA.FCFE"]+3B10^'1:O3R) @.)= I&Q^TGT)J*(3*%0=#J[ZA@\?ZZ[&
MJ*V;\@,<5L$JIY15E=3FPHA'7A'&%W/D2E,J6Q6/.SBWO*UF.>_KUJI0 LXH
M!H#][$'18]!#]+'Z:AU6]PUG%;&O6#UU54ZY/GDDC[9-Y[$XE%I=/4ENU>W-
M#DQ*G]P0%/;Z3''H\LH"4XS>TRG>_9O0@BP*&)_,#*Y(SPIMC^^<8O*'F'U0
M"VIE.))(AUER[8<\N*W:[?4MY@0/+>X1Y R)ZN*;R6M<N9UOXB>D12M4E3F@
M&((SFWE"ORV(+*&VOYMS#!YGJ>4=$85#HQ(KB-M=[5#M7EY2XW6 IZA#<=^J
MA<#593@@0JE[0R*SV)4E-2."U<L^A3A,"+O?K!^NF&4U'HY1J.XI/83_ $ _
M2-]5VNKI=(XP"T>TV!SG[%7"&1$O)*EY:.=6\TM(:Y_4Z-<#$IK@,A.0?@9Z
MAO*;:%OV;S^P.</I2/I;6<Z0ASU2:612U=T0NW:O.J2[G_HFOT9Y29J<.=(.
M_J5# 8:H;A#-TTN!YSDE5D%-AX1W-_+A=)?44VYUJ^,T'(!+;&,JZN7*3+W=
MN<HI(6/L#G_EV2++*C3183G9"] ,BWW%S3;4Q>'D'FM)?W:I>6]1]X!#]);Y
M&.@Y*]5Y6#J_4!3DH;.@Z$KJ9? \3%LFG0BD/D:E7,MC"Y?97A6:(42;8S3Q
MRB2HEX'I4D12?:8Y2BTG(7K@GOL7R L-6W*6BJZSFQ<Z<]UKTHX7Y5[@E>0(
MF.2IF?G\FHGJRF("9M>B(2>[6HE$W/05")C4_5'^YR()3+%*0*SU-Y6^MKF:
MU*R&P+F >H1,*\@,Y<%SY)W%ODSU:O9:ODZ-.T04UO.[,BK,U,B1>BD*\!3]
M)RCQ)#D*97L*LM:B#WA\N?1Z&VXO5:^DJ>7.#.)UCDX4FSYG@*&SI"TW5>E*
MO4MIH,ZL='/B8;$E5-Z=5Z!NBL\<?8J4(C#DIJ<@]:&Q)N]+BZ6\:?15HH53
M?%;J@UCU57(SZ"D*./)?=.)32"X;/!K533:V*_4.3DQV"H;0/[5(7!.G":6H
M5$-BO1[>E"^G$S#?-<%6&P=$RIY;$LYF^G?GJJ[5NADNVY(Y#6"%1A+/@/-C
M(VYI,E:-9-!*7).B+,=QLJ)4#1BW0#BTB0..UV>0?IN. Z@N8EWL2NJ"Z 02
M!#QE94Y/A352;0]\X6-&&MC505ZB[[);)3L_3M3(9E,7@Y\8T(M-C&4%LT=[
M]>\)P(\O=[;MVO*I;:YH>P6T^>%1ARN&'S^.QRJ>CVE;<+;6:E;R\YV7;L4<
M%KG!$R\8'E,VE6 88_DA;RPE)SRW# G#A_MB[9M(N;N;)DW(YO-9M6)%_/=H
MNVW<2QQYJ21-[C+U*7(9>T[?JS4G39:"/_2Z]I'W M+5_#\FO785LL#S06VS
MV?>\#@T9Y\?6V'*)3N$O$CE++#G*-(X#TS#J!E),Y8)C=\34N;\N32<U6V(Y
M*.IRERY)\")0X)SDZLX-R[>[EZ!-Y9Y9NNDK,AE6H+ZYGZ0FS^2XQ^0L#G([
M(8*'2S2N&>N'B3"0O49<4LC3."M,4:B<CEJ$@9I92HHKWB#YNGRL=14?+MU2
M\5%2$GGL/L>X(U*I6FES77%:6(17350<H8(# %=RVY 3HQ8\F8+W*+.V%9+5
M*<UJVH(9U:=4/2$)_L;J_J**=RSJ@H9(Z47LTTFG)4.K.)V!'Y#MUKF.6!4/
M3-B6=8#D"+R1M=9J6ZO5)?=:$.A)$12HPLL2@.RC=&!5:8^;"="B]1?FUA]*
MO\EG51<\22S9"=,&/\#<^VS9C/TJ]3JMK.4S2V*BCC&[MRFBDC.@:W23LSLE
M<'$[9X%!P$R!2$^]K>4B?\S\Y<Y7$T0NL66=VY14COV35O/Y.T.364VPR)P"
M02&"Q&QP6)74*=G4URG92-*K;5<B>%9>@*6Z.NA.E(DP:NL\F?2;,BW(9%$N
M<F2&V>]W4UU7*UZZPDC)3,?ISNB"<A.-E=&.JMQ(;G:&;8+$2R-6-K,8R$)Z
M$:4Y6!,I^\$8819W!:D Y1YOZ0D-I1Z7[.Z.\A8ID^150_/]3V!$JQC_ '&I
MK5M;CD: ^4.54-#E!8^H;# [T:4@;TYARO9(#5>PUR"^8NYEM=J)A(JFK.6_
M26A9=;A=JX=A+V->#GS=<W+>[X8=#I_<D30'H.1Y1('MD0H),^ 62*)G)=JA
M!6%DD!K\/\B-[0._;$NKH.;5K&:+L5C8F>L8,_N,MA\;J%I7\J3;JJK6]\4.
M[_J//5MV<G*0-[H(24E<<K >B0!T$HHG G"(]_69$N/+MZ/DSQ'3)@^]+U=#
MX$VSHH]3 X,&WJ@YTDA<4 >ND]=-3;&61UFSH-(;()/'6_1YH0JW0C8PZ$%1
M*X\IG7-C36M;3-F=(-U<2!?5[PNYYC[%MVE\W1ET/WLI>XI7LS!-5I*HVZ;C
MYU;T,<.)"Z  _'MK<0I7A"I*<@F=!Y8^D'Q(Z(X6CY!LX<:IBP^@Y!9E;.MF
MR.K1LL)HK5OKJ';A:=R%95U19PT0C>5!RWX$[8\(%QK:D4C&V;#YMORP]64L
MV BLJJKGYSL<F6 -63A'* P>E/PXMYPJV_6&OSG.Z+6K$EKL>0*+!6-B=<)[
M4[-0,2ER3,BHS1C:0$@VGY3+]BS;;;4PU'5,?F]#J(27;8K"E9#;&H^3T)8L
M:5<W%1IXD4XK>#2U^<J'.=W!W2*Y2Q(54B2$HTK@1\Q1)P;O=/DZF4,HOFJV
MXD11\<*N#F:Q^CW)ZNU1/X7%9V]U@U5ZJ#SE3R,\MLD6K<MA3-%)K!M2!S/+
M0M9IR9L>="WLL-!:+XZOCM&7!>#U=D5CSS(_*E7U6!%8C$\;A]2\ZF=&0"G5
M5:*V9PEB=HB[D6SN.TKJY)CTH3CCCS=["L&%0$(.B7D\Z]IGFZC$ED1NJK!F
M]ATWQU-6&WW)S,;&:*1Z]XUT']X.W0"NRK)IV'.<Q4O'/9:8I63(XHV*WB4E
M)BR]#2D@<0NM;/DS>*AHBDKBG\;JZNE5O\1=)]")6F53] ZL2B\:BBE12*O:
M?ALOCSJ-BG!%B!F[L<F*;35#BXHFW1J+0M%G[T$-C\F?3;,TIY#+8AS>PQFS
MW.XVNMI0K5V(@8:6::<[C@7(3U8_1#DN<P(7*$Z9K$3R)5MM.92F\Y"-*>L"
MF4;<$80Q1/E<Z%_.-7]2.4=JZV6M\L.>#>+)36#%&Q):4>G'5O14%:'SG$V:
MV;#95)JYIJ*P-$$A,WQN7JW-(G$E-5H!@(5JP_.>^6GI*)1J&(;0BU"H]W!Q
M8&_FM-5[W-R)<CDMBT9:UKQ.,%@*GOYSX:@BA,.1I#943&ES N,$K4&.C H3
M%HS0E">^5:^6*R)% 8@R\OK7Q8[6E&HU5$ADD]%<U4+:YZVYUY?C<@Z!:6M6
M8)'';7:;G42YJ&E1(1[;M(BTPG$LPY9H,&Z>7/IB*7 UTZ\4+6<ID$,F3]!Y
MV*.2N/PS\^;FU=&V;1:H7.39:-O1J5!=HVTP%,[+&=(USQ6<X.A38,:( B'%
M0%H?'OV1+NC;4N5TLRWZ(?FUTK#DA? X=3LJ<U<6A4TLIJZ%E\IK%<7+#Q.J
MBZ&9HC1)+ZF*$4<:G9RU VYN'H],4&M6+Y%[XC5X2'G5NI..*I6FLA]I!#*3
M39<5&]61(7TJVZJ^J&A'\Q$>4<)-4@G+TL+5!^F?V;;<4('RA] H7!^^.WW=
M:URV*V+4;T*(0RX[0_-/- 3(]O05=&^ ^.^AXW&YZO:GD^92F5.;_.W,+0_K
M3"/<<N<EQA:X!1"$ 7=OOK.WH'U%3]NF3B.1CFQNYDYRG4KK>1.+TQLS0KZ<
MZUK&DYU9D\E:1X;HZN:ZFK>3G+T9CDF"@;3$QRDW98!F# &D\_=M6?T-V=%1
M-,]#^:!ZZ'=J^9H[$''Z^"R:#PFO?*,R-K\D4J"CCEA,W5T-%WY0:4=M.:L0
M$C(WHCTT,-><?+=<2.2O,?*WR4:D=[EN2I39("3S8YLX[;ZIZNWSPS6+VD3]
M[$A:8_:+,>!8RDE*(X48[EZ3:5FH3C7%"&7.\OUIQ:-QF0RRDXG*&QT1N4U'
M)JS6S!QBTLI]GE\_YJ26/7*EQ0"5O:*Q>L$\&,82AA^V!3DE=L1XD@E1P:RU
M>5OKEXL:<5'JEJ'8IPT65':.()?9JUFB@$_WTM3?.3I,YK!F&W'BY7^MYL.Q
M5LA8=BC,9 0@ VEZ7N9:_P"M*"UO4O=]Q45=[?3S"AHL;LW13G10",34Z7(K
M)Z(E/05H2"IW7?-<4;GLL3FTT6I9"WV0)C!/"@Y$J"F4'-!6@NI@5B-[HO\
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M08&GW?Y(N?*P5W4V1*-R"Q[%YEEE>1N=MS97TQ"VLJRSK2J&"2UKC\J;(B]
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M-6_GV,7&JFD"PMH2KOEACQ.]_2&*#M@0[]!;.-+*"(>@T"RO'MR=:S2V,DQ
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MT5<_K1-Z\:QV9S@B!I&>2("@,PD\2EM E I( _EJ/$328QR2)V"/1J; ;N&
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MPT>64$5RKR).'+5B]5MMH4D8/F^I[LL6+Q"P:T4Q%"ZI'J/\/Q'M>41135Q
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M?>I(UP0)1UGJ7M?X@#L7N9OKR/J]$_('U#WBZGYO+8(3*CKPK%-&[(JB6WM
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M$$JF,7KR-K).[HV=.^SJ;.A3+$(BUFK32@+9!)7<\"9$E!O9J@X6@ UO>_3
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MGILQU%;X*8*BS,^6C=]K/L"HVV)+#W0MDW6V[63,3(M4LQ03T;?\FDZ<(]%
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MR6IIU"N[^?+LFM>S*7#&>SU=0'12U8Z2!$[J(RR'N3A*H''D[XW(3$"4W87
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M\C%GU7U'Q%(7"3G4E6_#;-/;792Y6FJY5'B8C#X!%:!9(K*8]92=7]X260+
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M".B>M_)92$TZG41:?]!2*+^/6W[EY7-:5+P\.QU\O/D=?.A'[D*RG=4,9FY
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M@0,,?K7I1:E4)?8(Y4[-P1A,"F'L @@F(?\ $/JV"*K2YGSW'8T[4ZO[X<K
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M^KR5B:TXG!B7*E#4I,*"8(CY-:%@:M(/'!Q7)8E8L#7T4P)(;:-8T)3\FC;
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M0QC&+00  '6Q"$(0MZ"$(0Z]=[W]FM8  P&@ :4,!A9@ C+, +0P# /6A &
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M2H&VN+'C]B^37IACN]RF2#\%GR!T U\;+HR\?,C<6T\DLU.Z#$H<1G"$'<7
M8# 8# 8# 8# 8'.+R,=Y+>&(/'9(PP6-63(7=AM*<GQ)\EDHBBTV"TW&D$CF
MKJV+&"NYRV)BTFGA"F/7/![2V(!K21F'&;'HK85V.\K\A6I275BK*CR&ZR+4
M6TM23-,.ER(Y8+;+&.YHY2K]+>B(216CJHJZLQ.\@"O0KFQ0_J3RC6M(:20I
M?$7L#39MYCWV$QJ83H5/TM+(S #5%>/[;!>HVZ4RZ17,7SL\] ENE9H$5: :
MIMSF44T[9SI=]4D7!$4X+M-?P-2@LP,C9?DJN2!V.PI9ZR4#6<.J2Q;1BEYM
MB.\G%ZE$H>8#P?9'41J5!&W:E"9,VTO]<K80E2A$2-Y,4MHS--1B%64$T-.C
M_F.MZ0I;(+0\Q5[IVH&/7?/KQ)=[OE,9TGA%)HN89"O(@30YTH;(3IP^QOI,
MO1;=(4S"4D6,PM'G@ K+^() L#RW2>'MKHZ-=,5Q(Q3"Y952U)P]INQT>K;)
M=H%<LRIF426^ZI8:M<I)74?5N<+,5->FC<B-4*UZ)J4?3+%&AA"?IOY!Y;$.
M7J&Z0WSVXFJ[Q1/D2;ZR43A#I]07X[,#^71U8)'IO9'!M<6>Z+-CX(RC=S"T
MIB-0\-QIR,(S3DY(5"<O*%;%JVA3Q]#M4,C54V9,ZZ;4[Y8,P":FDE8NR7HZ
M/2M^CC&CKLUP9)\"UZ9<&M#I6ZGH7!.U)]!)3C6&&:#<:X[4Z$LGQ]=#N]HU
M]4)]W5?XX*AZF:'ESDGX\KRR4UR4-8\L9W&RHN96L6;6)^)D]3.:AV94*1Q9
M!E*B"DRH1?R; $:A\H%V<TLUP/-IU-7=CU9';3EM6U7JJ9YIL5L$EAO,]'VB
MAA;;&D-3HFP%')U\F=0AD9BQ2])4VM'":Q)@E@ %B+"[/N^R/'[,[DC40?J"
MN1JZ&IRC3$C/)802J5E2/I.FZ[?W:%2.Z88./1+4KB,X4)"#9?'2#&1<,W9Z
M88""E!H5FKWRD754[#;\%L1FCMHSB@W*\['GRVX[IJF)24%+U<S4F^-M;0"=
M4;6RBGK_ .@'EOMXE42G;T,91-GS(V=V, YC$I-"0W;RZ2"47.\4?":"K6<J
M'V=,L?I"0OUGRY@C3RXM74\%YN<WN:!?J4 YMPXI,)66Y_/'TCZF3K&I2WE*
MC5)8%&PG#E;N>SNB^E5:)X;(%%JE,YHL:S8W7<*L%!8]C@<HA>J.L]++4810
MJ,OE=S@LIG7$A9"5;BDT:H-3&&?6H#L"N:CR/=$]!N/,D(JQMJBI%-WV7R=8
M[C)(9;Z.S7ALYKO-'=S\;74H$[4HYL\#OX J5$G<4&D3@@,3*5)2%S+.3&JB
M0VZ\;<L6K9AUB^P7H+\+-]$],<U4[5''1<5HD566O'K>K[F9\EE=CC7YN06^
MLF-FR.Y7SZ!<W2 D*5<<29M.<F(4$&AJZ3RL6#!JX8C(KSTS2R.)B.>:TBBP
MRP%(GH^Q[V03)\C3>XQ.L:.):FNO(?#:^5D .:T>E;@YJFYO2H"PF&J0!Y[
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M0EH FDJ-:".$/F^D+XURV6L')CVIAL1HUQGSDN6SQ6@,36"BXV([ (93GA3
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M[*HG*>)%-3[7TXG-9[*C4D2D#*5-!B99I( 1YI)81J]>8DEU8G&Q:HJV!/\
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M"V5]DQ2!IK5K+IV['YQLJ;0RGCIFEG+E#:M0-PV<EJ7HPJDX5J51I$-0/ Z
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MZ7IV2KV=UD=3UI('./2I5.F!Q>X)%G5>QS==]+];,6=8O:CU#9*EGT)'RN!
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MAD$%C%L00ZWOUP)!1L[0W*W=>WM3:A7/ZPAQ?EJ-"F2JWMP3-J%F3+G=204
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M$8<FL4V4KY0\5VR-U?2Q1(YG''F)2&:HY;#TS/(6V>K8_(%J;[[(4 <PEJ3
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M+-. H.,,T+0QBWL,W%J?@,0>+&?&IC3C7VFH8_Q=I<60J2*&B,Q1!#([$T*
M1(4;?$&5D1#TG;BP:3A/6*S=AV8I-$(,?&>?*$A3<L9X;2%0Q)I<&EW8%[7&
M:UAC"W+F*0)T:1_95B%J94B92TOB5N3E+$PPB)4ED%A,"+0 ZT&Q-565@Q3)
MXL5DKB!L]@R%,4C?YVU1"/-\R?$:=,B1D)7B3I&XE[<TQ*1M3%  <>,(2TY8
M=:]H ZT'A=:8IY]_".GNJ*U>=5^^*I- M.L%B[C^"9(N6[<ELAB/U;6=^&WQ
M8XBV>:K1?"H,.W[Q#V+[<#''T!1"EQ:W=32E2*'9C<GYY9',^MX<:XL[O*7X
M$JD[JUK3&82EO<I'*"@N2\\D0#5B\.E!HAFZT/ V<BMZ[2A3 30*%IP(RH@2
MD 1%F,D*4FO3C%$!*3!+0AT05!U!PS&<(?338,6Q)OCWO>\#=,!@,!@,!@,!
M@,!@5&ZOX\A76[;&&V732>0L$=:K*C9YT&.BX!O\4MB&*(7,(\Z@E$9DI111
MR8296F4I IEB=4D!Z&[)&<48$*VOXQJ9MJ27?+'>:3Y$[7JK)72=(>UU7,XN
ME,(<:K<@HP0RQZWF45?6<TRI&\ TKJD7!T$XTPH12@"8].&\/7!D//JWG>O(
M9=%]UM(^8X\[1&MKECDJBSY:HHO*8B.$31HD#C/X7,(RY:D;'LHPLXMK(/:5
MR)&>WB2Z3!+V$&L?B*H]DN]%>V[7NU[DS7+D\N;RI&JK!X<U"@F\*BZ TAEU
MD**QU<-CI4DWIEL2(-R*1.@VIB,.0)-DA^,P 3W6?#S-4EG?G%AMX7,4@:4M
MBLL"KEU%6;I!JXBEPW3"[SM6,1O1M<%REQ2RZ40[2(M2[N;FN:F=4).A.3B)
M3FE!>+ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
= 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g451428dsp047.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428dsp047.jpg
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M  (1 0,1 ?_$ /D  0 " P$! 0$!           &!P0%" ," 0D* 0$
M                $  " P$!   #!@8 !0,%   %!@,$!P(! ! 7(% 3%!8(
M,$!@$1(5<#$U-C?0(1B D+ T)1$  @,  0,# @0"!P4#!@(; P0! @4&$1(3
M "$4(A4Q,B,'0180(%%",R0E,%!@85) 0[5P<6)3-'47H7.T-7> D+#P@9%C
M-G:6M@BQP9/31)75)E;6EQ(!                    T!,! 0$!  (! P0"
M @$$ P$  1$ (1 Q02!183! 4&!Q@7"1T("0L*'PL<'A_]H # ,!  (1 Q$
M  '^_@
M
M
M
M                            !I".F(9I'#>'B99Z$7-J>9N3!,\W9JS6
M'F8A@&R-V>1I ;@^3T-@08L$UI'";FF(^3P@Q,"+F*;(U9NR-DA/(^34$R):
M                "J"H"$&M/ EAMCP(N:4Z6*V,LB)!"ZRLRSRLS>DB+L./
M"WC1&C/@M,R"CS:%@E<FB+4*K,@N8K4N8AY5Q<)!2/DJ-43TK,CIV.6T
M                  :XV(    -:1TF@   /PCY(0? /L
M             B)_GT.ZB@3H \RV3D8L,DA,RV#^<AN2^"O2SRL"<D./<Z!.
M9R(G29U,8!_.LG9V4=3                           &F.?"*E!&H*J.B
MCY+(*0-<=3'N>A59Y$U.0BO#HLMLI4N0HXOXY;/Z7G(YJB6G8A-@
M                    1 P2;GH>94I 2ZR7%8%H'X?!SV9)?I6I]ECE:GX6
M:?AZ@                              Y .-C,(X5L?T$.-2!EJGL56=,
ME2G3AQP3@CI-RKC=&@+K+?/Z'
M \#2DA
M           !R:74?1N30$>)\8)]'F8)%B;$<,<\S-)H<Y'-I=QV^
M                        #BDK<^2Q2$$$+[*L/LN(KPBQ(RV#F0Z!(47N
M:@YQ.CCJ                                         %5%>F^+Y
M                            !_)D@1?11ANRHSL<Y<.LSETB!?AO2G35
M%YE,DZ($5^9).22%PF$5.?I,S^CQ-P                           >!X
MD-(F99D&Y,8\#0&:8A(#V/T^#4'N>)E&]-L8AKS0&2?IK"X#T
M                 !S<4T5&?T!.,R_B#E8EMEA%%%T'-YTL4V899I6ACG3!
M5Y!#1%TE('L?T5                             *@.<RQ"$DT!8A]F_-
M 9)K#>'N0\PS?ES                                  B)H"$DR(B89
M^EB&40@VIFGF9!59N"X24
M
M
M                                    _ER;LBY>1>9=P
M                           ! 3^?9A%L%4'39UF
M                      ?SN,H@!'#*)2=]D[
M
M/XRG\HS_ $JG4(                                        /\ZY_"
ML_V2';     !C'\MR5FW(P=D%W                         '&Y6!(R#F
M6?TA    /\ZY_"L_V2';
M!"C_ #(G\L3_ $N']DC[
M/(HHOH                                                %-ER'X
M<6D]*G),9A("C"XR&F\-$>Q9) C2'P>Y;9#B.&T/$V)IS))&5\6"0XWI!R?D
M^.=C=F49)\'B=''+IUF3X  '\^#T/Z!@X!(^0(Z0.RP:\_E66(>Y<IUH #DT
MYC/H_J8     #3FX!R$>Q$RV36&Q/LC!H">&G/ UI."#&V) :<TQLB:E$'1Q
M59.#T*L+*/<Y5+Y+2*_/8RRN#;&[(86T0\V1+C#-:7J;(' )(CMP X&-V=O
M @ARF2XZY  -6:$]B6       %'F(<REHDL(J6.: GA7AX'F?9MS1F&2@W)$
M3,(L1,MHRR2$G*;) ;P@)[$^*@-N8YF&Q)"10C1$BRSS,,D1T";,')A)SHP
MY4-N=*  T1S*647:           ?S?)63LH0Z$,<HX$..Y3F@AQ81@EC&004
M]BXCU*<!:!0!;!599Y4I("#E]D$(,20_"9DG*\,4DYHC=$+.Y27
M           '\[S'/LTY8)G%(EA&K)V5X=8G+1T>5T4,3LU!:A79NCHXY8,(
ME!$2=$Q*D/HM,YS)T0LZE*-/,Z".9R^R@26%DE(%Q'90
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M)@                   ^3^;)*CS,0GI5!&RS#O(S0
M                       >)[
M   _"GBXC\.;2QR%'V;4W1#B4$=/@TQMSY/TDA6Y)"'$G/L]#V/<KXEAY$W(
MJ>)F'R9)JC))414BI-C:$;-P9ID%%%GDB+=!PR>1W6#A\U)!"_#K4&,?S3)R
M?9;!U" #G<IT^#NT     ^2FRY@5*:$ILL@V!YFL-<3LJ<S#")R3 \",'N:P
M&$:DMPK(WP((6D8YD&B-<;4P#Z)B; \RO#7DD(&74:HC![%F%G X#)8=H CY
MQ$;<[,-T#'*G.;2<G4AM0 0(J<S#HD       XR(,:LW!9!1Q*RT3G N$T9T
M,<V&K/@V9/C+*+)^:PWAIBRRO2,GP3,J,Z+($?I@%JE1F27B426H5H; M8H0
MKLLPZ=+Y!Q,28ZS .+3='7  (J<KEA'2           /D_FB30W)IBSRC38D
MQ(\?97!TR<QDS/PQSH$K(W1V,>YQ$5@=,E3&^.RS[.'#<%-F,6(14S#:DY($
M8Y\F$;T_#N@V@                   !Q6>I,R D[(@>AO"<$-(J6\4L3 K
M\GA>91!'C;&46$463@U1B$B, VYE&E/PWI'34F>:LVQ;12@/LWIZ'3!M@
M                <0DJ!L"4'B5<6&?ICD9)$1TM$RS8D@($:XWYNSU,0]23
M%1&Q)$0TG)'C,,TVAI#$,,W)(2#FV!KS*+2/0                   '$IB
MDP/4E17)+C%,8QC+-:;$Z )>
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M>9GFM+!,<H4W):)%BWRNRRBFBRRMC'/0F1A$K*O-<;(R".%YG88/X]$E/ZP
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MGB;0&K-H5B6(90          *5-L6H"N3$-*9Y;@!21YF\)$3, $)(L9!:X
M   !\G+!U2#E TQS"769)+2GRY"LR<FW*I,8O4HP$F/4B)>169""4F])<4*=
MG%S          '\N#:G],@<B')IA']!2]0:\_GT5H30ZH.A  <V'-Y]'](0
M                             #AXVAV: <0&U.R@ 0(Y],TZR
M                            (N9INP"-GL;X 'R1,WAL@        #\*
MW+)/PHXM QCR/<R2!$L*F-L9Y(CZ-H99JR(DR/$A)/35FU,PILLTG)]
M     '*A['4H.>S"( 6>= @_#C,WYMB6%V  JHJ\V!TJ     >1S*=/@YT-*
M<^EB&_-^5^621 DY@F,56;@V!/"'@L\CQ%#T(V6.>A7QV028          _F
M^2([^!0AQ@;T[B++!@'*A01.#K<L@ %%E+&.=R@
M         '"1(CLL X7-T=G  A1RR3(ZI
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M)EG49516!:Q;Q8X  !Q*28ZT .+#='7( (H<L%@'20
M
M                 .<BD#.+7,$U)ICY->6.:<KDO$HPV!8IHS1GZ;X^B2E>
M%E$#/DU)GEIE3'L2\I@LD]"*E@D4)$5:6,5L>A8),2KR-$X(@9ICDS-P=,FY
M               *\*H+&*O-J9!%39F[/0BY@$F/4TQMC )85P;<VA@'F1\P
M#<&^(<=3&H/<RS#/L^3T,T\#%-82HU!@&*8Y.",GV;,\#4&Z/TEY^@
M        %#$#)\0 DAX$ )63,AAKCS),00G!\DH,DJ ^B9'H1(DA."HST)N=
M#GT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 #__V@ ( 0$
M 04"_P#L'D25 12&-"Z9^(6]8LEY&==A&SOZ56^"K8M K4#@L62W30N<%+C,
MOCZG6@I/-,@Y*PJA^M5'\4LRKX'N^W*XR'QD7^N;9(>/[Y/@^N0C8M,OHMN5
MS=RVZJ5 ;&_I<UF\YJHTK*Q 8:L#,O6BWKNH<WJCPGWJE%G72?E=I7+50JS+
MP*:0V'BFCT%(EJ#2PPQ2JL0&[YV\IT=OTJ-Y)U65>N\1O2;-:A)#[%N)Y39H
MK!@75\$N:H>[M/2?2M&6Y879K#VG5;A1I7 D4V@I5>ORUK/9$*W++'+6<%6Y
M/#H"38B#G@[!!]Q.X>Z?6;:D4 &Z070!=N'-V)?IP*S_ $B6C*#&P%50"V!6
M*=29NVJ1,<"P^X@M] J<$%S*.P*[)/\ #RLL5^["H-P8E;S%QD#OB6Q-Y+W/
M6?KI0!LGY_E7?NQ<&>L(=8L FBJ^D15RRUS94?X70ZVSTFZ[FM\B+GSMDK%C
M2 R-_P 55&S<.&1#%58;.=NG?Q:1&D84_3;197*N8GH2-)->80#DEL)1BCS!
MKCANYHT2#@J64&!RZ8SLU1*63"\8Y1BMFD-2G%>-N:2=8S"ZL,HHY9SYJX$V
M$IM.>ADUH'D,R#- &E31W#F4@CNYA;3X3$ _[MYMU>^OX7MRIS[88P%0C_ _
MY? PL*-5?E[[YSYSUSUY]\L'_0?VV4<NGY1-=TQO)T_W/LO^!+6M0*ME'=&>
MRID]@M@]%7OW),TI0MKNO$2EG<F4\*(:-I".P9QH)A[9MRR'/1KYI*O]/M+7
M=Q9!89-_<$RVVI%T_5WUPEW1W -A+4=@-N%S]RURRBBOW",'2D;U<Z-DS<GJ
MEO=$K6;"_E+SHFK9DB9D;/L"YLW_ (F6M*<U51J;^T+BYGUC6IY/O<C5]O#\
M@0;.9(>;Y7^C%]1QW1TN-MR)W!DT?-2>A8 $PTY,PI&5Z4HR!\EN"[,V ,%!
M?V@ 4HX)A:GVG9?HV;VGD^V9S99-'DPV,B21,ZTQ:N(^43JPT3^VYOKTQJ[H
M!_8K/[<O:*C%FC8?3A&&:%*0K9<UAM>B_;>4J9[^DMG[7)LW?LX27);G:4D5
MB-X<1-?M^\8; 1&V>,&MT2@L!]]'S@M:"K# %:@/XG'O'GOGOGO?'/HAW"&:
ME76\^*HP,^+8@W^?'^4#FOW(_P#+GWKCOB3S\6+SU?TX =3@VC+!.K_GQ_FW
M-PE+!E6P4'8.I(^/![<)),:^W"&3OWKGSXY[X[^_]@"-;2.XSG0?R0S)S'14
M,IZ$KBVC/]$NAE56/T%T%D+O5LF<O<NZ$^<LEK5D/.SX.O(A'D%&_;M$#C()
MV;G^SF?H_P"F,'NYXUDU^TAL\[ASGS#/G@O*31,SYGS="!MYMHE>K8S5PC7T
M[*K7+!@"Z76:G]$21QS1C1 H-#_P$EV91KVZS>L6>8G!2G\J'@=_JDZ)Q*>7
M14SCJHP 2%WUJ6.:_+0M=Q<M:OW# ZIUJ,SIB,$%=MBM')?>08T^.T1,(A6[
M1%)(\X?5.7JB?!%/7^CX9<REK,1!3M<IJ6C_ - 1XJ#\IQ8+8J6!>%%!=M(Q
MV--BH8-X/]_^-\]VDIY-*ON8O(B!'XDP8AY[/E$,N?VL1L?B5?V^?A"N\1OP
MQ,.9R'7.K^VZ0>">,GZ:1!/#H[Q-'3S:I7:?_);1FST8?VC_ ,E?TDRI@%M[
M^DZK\",V5PI?^@&2=D7_ (;7=X\=-$8;P]4$O94B-\U%W].\.>@TZ*<RE_Q"
MCV>KK;5VP*>7E'IHJ1D&UV%R76KV.4I,V"CAIP-1066]N@"N[,UD!B^YFB3!
M5=V#P.Q-;)[2GTS2&+WK2&\M*Y/[FN1=.AR WC+I:L>9*ZLQ\Y"\:':73IDM
M((E*D!^LKM^0F(^^/8X_?B2M7E^#QA:7!UA]0*]21V1XS=]L3AY.1@6AU"@Q
MJY.A3;5(U!7>T"U7Z;DBP-E>4*K)PW*75P(Q*[#\<L"M9B,M:L LQLR19+Q.
MB9)\1N:3Z-LM:;1J3D%[B;N877H"B 4M6J'5NWQV[)<=P\XJ"G+&UIW18(X(
MC;<YYYX\^^M+4R3?1845JI%Z6,MHNR1%7++7<RIAY6:XECNIEA8:CYFQES97
M"0AF^.:$$:FO6D9MN+*LHDP#))EK5RNL"7;8663,37DA1)<#8.VD7PYNXC-L
M<5[.W:>83TQ]K-579_$VKF)Z$C237F$ Q(I$Z^?3EO\ Q<QS%I3RWWVY-/JI
M1L;1Q##UH]OJK]98(9B6ADP7EW4*HT-TW>^!U5J]8QJN>Z9! YE(6&4JUP#F
M)U;NE*N>:*8!55&#]2B+&EI]:S)I2[W9F83,+C_0A4+1,^DU$(8G[SD7+\<)
MX+P']/:/?L66J/OQ3SBG3J@5JL!D'!/]3W02I!-HDBJQ4Y=7+!(9VITIP81<
M_P!%*-R5;%F*>:!*%J$35A+_ /U##-8>+4OU;<_).=3T2O48WYK&,F>WV8JK
M_P!'M5V^-5[3WJ4DX_1M*GYL,+__ &)ONJ<\HS0S%VG^CWABU8:QCF=\DL3.
MNNUJU9QWB+X]==DB79FO4OP%>Y?(KO\ PE_=/K+YFQ3_ .4NX?&+L1AMS#^D
MOWP_];^/VY_^%/X<WG7L4V7ZG$$N)NH7I?T3I Z[06MEKQ(/C#7 ?>;>J.UT
MS^FM.CG54AZAF_2VO6^+2&YT[?\ !_?#_P!;^/VY_P#A3^D6 <3*#/W%I^XQ
M6J]>>W/A*/OU0'SY_CS_ $CWQQ+POY?GRJ8_J)5)&[E[Y1GV("4LZ%[$K=[7
M_B,M:K;H]>ZC/5O)^B2N'HK6F"G6IZ%:)*,VPV(^/=>'^TJ&P6[W4^O3QUBS
M]+2'!WP]^EQNJWIB539YK'QUL=J$>S/G0 B#<&*%,M;%U!5]U$M%)6U4C/*
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M?HO"\4JA-:6BG)#0P\:H+UH)+#:U!6C@NZ:MU2'FH)<D73I8GH?4$)2[L["
MX@$Z0'M5IM45(KE%X5R JCH5 NSTM,7)I/J:F_EK&GIE:632DR+X):@M#N_-
M,4X^:3NLWQ5;0:!)AJ:?3[N?4E._$HOJJ1B\U-(ZYCT5/FE(.PBE$/>%@G39
M-H#B*W&EJG/JVYC&F]\H-7-69D79+#JR_(OM- :R_7&C$1I_N$FN<*^@F&4W
M\I98H(O?W#^SB9]C*=>7=P@H%LTTCZA0_8TA]YS\;)LMKBHK[7&RM7\/W_W\
M6DWE8C^5].%D/+>?!K@"+':]6C4S$)Q%]-@<WH!*54ZRO92N+=J[GBDYKDJ
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M 5,EL4Z\V2=]CJV-7H.T_,?%7V+*1%$ &QJ2E*%'^B0W\K5$-;=52@M@$_\
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M_=UM'OZY3Q[_ .#W:#^YAGEK[G-2VRB*\KZ?N/E[-&$WBZTDTX%EA@]:F%2
M5!(_QMVVX)F<TXE.LIA\D_=!CF>ZXT!A'EYMG,3MA<G,+YLM133N.@OB]O1>
MX>WM@<5]<.6YIP#>YJHI^U^QQC-Q5FL]PW&>;$W]"Z.FW!]4 5:%Q++#&\.Q
M++5%T]O6O.SB/\C6F_[!6Y.DHXLPQS3+XCC/*\RSEO*X&S]PND%-ZFD?R>WV
MF?1:K\*U,_B]_P!X-_DS'#(4Q>0O6XSH<8S4^/G)A'VQ9NF+-?'>+*69Z@G\
ML6\<>N..;.1RG1P^.?MD2N$7>,GFZZ'*A<QVWL]:$$MAQ5;2S,EWM2M>Y* #
M:L3:+1,1R=!OC+.)D5:RXQM/8S$,;E.[V+L?.)R)+*U-1!II MZCJ]$CNYUF
MUH]H_P"";A,.A1%I89!$K%QDI>.VU+TM$UM2T3[Q/JRV1F9^4O:\DL#-261#
M8D_B2PEABI-Y_MZ=?_(+IJM Y J/-+RM6-$^*Q&9I/<+6=<WT,MVLV&PXLKF
MGO6L]GD@<]O7T7MWL@95LM?:>48T4@N9N6R ;(W=-6YX*@OX35F;DBM8Z_CZ
MS9!R?CQHV;33)D6SG$C3O!OCS1":,3\NT,?I]*=?K^G\?6E5'9RG+8Q+!UZJ
MZ"C%LLM(M:XM&!%O*1*0.W6"=LQTG^ST!;.Y9QI]EFY1++I[N6R9@H 59,,
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M9?+6!:C\#@E62E[XZR&*6B_K208XX$UT$]*U#J;)_A'T\<^6KI9_SW<-%"M
M,:4UDE"%L/Q_K4%,](C!MQ1LV@DX-7?G-:9TTT:'TJ9X#Y[JV/\ '>I%;^0O
MR90\<UD?U$^GUQ);'S$:3MSGN:?RM/NNKG.6Y$O<"\"2OW.5+A]U;7BM;>].
MG\8^Y!X_#P:+IJ \F^@+:T=JR&(XR*,8.?4Q5JCU^[O4H8Y/'UHKTN/J/>!0
M8+F6>M(:$*>JS21653@M+*B+'>!E:U;5* 1*VB:VI68F/2FGLX4,I S%!O:R
MND"K;NU'[<J<^9D6-\,85DS O<7?\CZ"=)[>SK,,SH*(H/)N6495S]D&X"D_
M'6;%;Y0@)D'>X&JS(RA%>/QZ32:WM_6^;J.\A%E/\JY& ]L+)SM;?R<5%GD5
M./\ Q<2W&>X2VA<*D7+/W";"[;=11>UX1OS432F,V%\3"HD%")A>5Q<$X17D
M" SYHC.,-6&S\QL)2#L#MI/CFW]')HSL7;IQLW;FX;(LK+;,C]H<QOO&RDM>
M\O-M:6>;3LI1JGQBD56@??)9K;"('"Y2SD9>@_\ ?3.9>51[:R-+6G+R"RO?
M/Q-"#9"-2.6HLF,\]H_-3MOUF!NK:8:,J-G'ICXVNPWGL+8''ZE4=S1JUL09
M=1DYER"K<G=YJ>,OBH*>/M;;G)E<V_&M9G2SWDL8:M]A/9%F9\'/3CN=H"^X
MY=[-U%,+%_";C'TL/^EEGQ&8^. Q_ L.QF#>(=B>( J_44Q.WI6L>\SZ ,^=
MR%+7B^QI=ZV$B\(XWLA%W#R9MDX_(EH^V['RU>TOQ[7%44L%%-NOKE0JFY6H
M1=[.8QS+86,L(*YN1U09R8 [B/#=L'#8D\G6;=%: P2U@VFP9W1)Y7(39!W<
M]'C;<Y>0R00^/[65G:[K%50_)K'*42MLQ=@(QQ05)!TBWK5%^X"I0,I*<9$H
M>4QJ+:)2X\,Z3X(H$4T,4Y:U9#/6%V:7I7I7I_5XD+BYG O;W,TL,\9JF(YI
M&3-C[CQ!(#Y"0.15B2H4GN+>L=L3[^N;ODY*OG,_MNOQ[MXMN9.']VY@;2RD
M=8OW0F:>1JFTF'K9Z?VR?%# )GJ7WKZR,Q]YW[?J[?[AB,EL8V!G8]L;C&EJ
M9RHN+:R9:Z^INYS0EJM!-3_#\M^G;$6_VLG^$KYI:J])? +R2[17X-&YOV]T
MLU2_2B_YO']/X?T[6D;AU-3"<I=EAQVB \?8E33KA*ET66 E%3N^&.]+FK;L
M6K2W]D0GF<F1XDNC0;+V=E(W7Y5@BSL?L%+M&$\FF8E"[!?!6G;7]2U:5ZVO
M%?6D<A45)Y4FSC>8600#V*C1%/B9T%Z1D_*XRM$2,4#8J.DF+TB/JZ>@2I3%
M53LC8R@$<:>XZFVY\$M%$DT).Q;4<0[;B'2UR^+K->E>OI')S+\>6JH3[NA1
M?)A7.0;-C,Z,MB<A$>:CI7Q)->?U*'\,$C^%XC2TLBV5G$:&30U#!QC9;C=1
MF3I+#8[9ZS;-[FV033K%K$^56U>L$B9S\ASA:/&RZ$-MYZW@SKBN;$\$^U5U
MQU&<8=*U@^WY:DZ=/XC053S\-'9>T%;Y!,"R"Y;@URX'RM, D8345?>7@02L
M]E"S^G$]U9K&AQ_0XDB3S[.+&V3^61G69=U\S=UT7?&#/8)LN4G,O7I2MRP0
M_7_K]0NHIQI[1VT!5\U<0-ZZ2C&6)H2!-&R/Q3FOC5H3XEB>7XU8MV=D>M%5
M+*0M]OT<O*?2QN-7L.&F-U!(8ZROGPHW;,U7AD-45B7"3\8\DQ$ZU+K<=8$S
MH+GT5Z\<EB^R_<S@UWEE*9=R\AGS 8Z,+U8K$U)/=^;TY]QR<O71X_H9D*(E
M45T%Z9[!L%-;<7'\4X45Z4WH\59BI#0.]1Q/28@>20V6RKNLW\V>SD'^-=T^
MH5'IM@80@.:XULK7%2'8$0K-)BO6\>N.!KEY:4ZRR;K:\H@&IQ\"?%'>1 ^8
M["=<V3YF6**^*I/*$9HMVQ2?53("PLCN%I$O"_&S9S"X$@*SHD?7KEA80#"[
MP/J/4=25,.*]>^O4&G;%P 8(]*"JAMQF WKLD/"%87QK9M7_ +L0U8%%*@\U
MND1$=/3LKX:>W'$<-7?4Y RC%KA9<NS>B67=M#O78%\"?+,$I<9J]DT[J6[;
ME8Q\R_!U0Y2TD.NII9I=]KXY*\>R<=59HFDUFW8I2UQ#Z>>>P<6FM^WY<#Q#
M.-*9:MF%^-G:9(NR2 Y680BV44OFL5'L&I;]6M@=.R/'[:!<NF7I,XE&M>U*
M9WC):;.?++HYY6514<$SJY<6EH$D'9@,3W=U8]%%H<;XF-.ZO'R'[=+'W,P:
MO)M-A@:>@4"$0GIB?!9BZY*122?7Y(GK,6)QP.86F>=(O8++^ 18E<^%\ML:
M[*BIJBME?0L>M>RP/8=IKZY#/(<G(1<,_IX+[#.+70-MHY".&YH,O$408O\
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M:6EM@\I%,_23>^B*6@92VL.I/>/4*O@<>?V=;DNAIZUGR.A#3[JT;'@GR"=
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M46T'A:V+M/\ [@L)FG/<"RK7&Y(L//+#IG3B(CI*Z-I"+QT@8J4BEK1$]?\
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MI8PF#,DDC)(8<!9GN502L)F5F0^=6R^6O$AOU%-@UMV]T=?]TLU^\9K-PZ&
M(+:&<,;20.-<@V=>RLFAP\AT3AV/%>U>V*7CN[.ENWUOXYGEGOO.*MQ_Y$KZ
MI:V023>37N\KI[ND$M[5>MWC!\<73Z8CITZ'7CEF>'Y.9R'(=NUDM-+*X^S7
M#)>B)W=R^AYEKX,3Y&SL]*&FOM4=/7&IH^(=,G3TG-H8<\=*\C49W+\G049G
MRS([9^^)<WDGR=]:DKTCRST C_,(/IXWFJ 0E&D?ZRA]F2U>3"%\OR]SV1CJ
MJS7_ +KK:>Z?)T]8^EQJJ.\WD5S5I47S\VRKYT-3=.RZZLSK9J^A(?O)/TI9
M$49Z^2+S:.R>$9YCXR.UQQ30H=1_&#M87^MJLJN!^V#<6!!4AM?HS4MQQTL/
MZJ7F?50GULXJ*K3C2G3 $+0<^[<CRN0Z0=UFCGQGUJ6S?$N.@0TK6U.Z+>*L
M2TZVSCY=D>5\EW,)6F&,TM_.Y:+95CDI@Z58ULLR^>+M!6 $IWUF9[PT]:\!
MV$1Z>L//F[ \>0JK$!RS<Y4\DB,3\.H93E]GP4@+%& ^/RP2;S[7S#\@!X&1
MQ#1U<PX7(O73YB[653LZKQ(IX.733]6Q;]R\6FT]TQ#3>J_AE9;SMA"R^?QN
MB.2O\_CZG'U&ED"/N31H0%IL:W?^I6U1QVUI'5"@M1(<CXNSQ'0MHY'W/_(.
M2E8^CD=75_MVS6R7TDMYJ>]9M69''I7!5=5@Z7)J<D RRAYE[W%RR_)*KL+T
M8%>\R&W@DD7B?[W3^[ZQP):JZQ\;*XPE7L3<36T&^/CY* S3_P!HU<U[_.#Y
M':U>P];C*/K,WB9CUB8DL*^'$XGR/C0)*@1H<$WLM?-JZ"CCS)PU3@,]*6*2
M\UMV]_\ 'T9\&DLL!DK RYOQ=)=*B+>9QE$WAIC;>/,N^3CO?U)WBM!8ZTZT
MBTH9>!GI:@WU64M/2:2S)"G\CF$\D^4.&=11S/<\;%O(P.CLFD5/TZWK3JN4
MVFN\)/5S' >=;38.RGF-Z+PPOP_MO(?*\[W6+KK@K%ZVOV_7TJX9:ZU :&9Q
M?M9:!\L*>CPSE5^0IA84AA8IE=:CMZ6FEHFGB_YQZSOCZRZS6=+A^\:32P]!
MIGD;.[67R9NF@_88ZN7I$T/6]2]"1/XTE#CXR4M5).RWD'5F!=Q))>\BHVX\
MS447)/;6YB3$>W7U1(G(2_&HEGJ"J!+PW2M_+36%OLI7^5?Q%W6[@;GKU\=P
M]/J[NOIJ"MK.MVS.1K1106@.YC:G'E<%0RS.]M;DH."$I^>)@=8O%>WI3K.C
MK;U,[CS#I[I?:1(G12+E'P<'+:8NCQCEO0;L%R9BG<Z89!>UAUCM[=6BHZOL
M,ZF[M14(QJF:+HO-/@4(4I)@AJ5+4/E);WZ=9Z>F.(LN*)WC #CH:2X?F6"4
MV0,3K!E6O\N<8-(A/%3VBP8B)]_?UO2]K9[1]C,W4PV^UNL5SF-I?BP/DB-K
M;.H\:5YXU%NLEBUO)[=L4B/5]6S^>RH)3D2B8Q9'QM4E>1;RF^8FOJ_--&@1
M4X+#IT$/K%NZ?JF?1:FTDK$AOCDJ-+9,+-+H\?W]K8@=2RT:U'&P:\CL2G;6
M+5[NWI/;ZY+QX^K!?Y@P@<<^X*TU/.-%--U-9@XM3;U@2QT>M-AA@ ?[O3I^
M#[6F]@0Z[EVSQQD\9'FI($^Y93U651?.89DUJY->^]RV)-NG2T5I2L#W-+<2
MT1"TA._%ODL=6*@UF]4/FJ?58SP%K9OMZ++@%%J=_;W6GTEQI=<-N/D+F'>Y
M+"F:-I,265JYTAR&)U?N.9 1M4K1>%#4FUKV@M*WO6N]Q\NDK\K;/G'LV%74
M84[\>$?A0VCL[NM=M<WP*U.&I1#N"?%'2([O5MYIU!AQD6Y\H&?E?;D1,;+F
M,Q_IPK--$67"+(^J+6O8QBW),QW=/6;9?6XX4F!;PY%7.(C*%U.Z^NJ0O)K#
MU M:VI ]BTT)0@1P2+V\?4Y/1<<.H#S6-:]=,^2(K<A_^#FO!! --3CM<5"U
MAKMBT5BGZ4=.G?Z,<&AA4T7&^4%=EWCD:&=<'+%\\#<B3MH@+\[.KGQ"Q+DM
M'BM8=JS%O6;QR[\-@SN5K\B\KBT'LR%;?G:&JQ6Q>VYYCI62_P#7'=V_P].P
M+85*7Y-C9;+8N16:#0NF?3O\@J_*@#"T.Y^E"IT6ZSUF];02])OFVY0J1$M2
M,E(3 @>@75-^WM^ 7/)%M$*8TH#%&8%0$6[NM._ITGU1QG0084!OUUPJ?:.G
M>&O(.1<B@#4W;((C%&>0S2I(I6(J&L]O7U@(KI*,8&5OJ\A/O%2SZG_R_&'\
M6$4&*ZUM!-8=S#I57X=JQ]=H/%;=D?[HZ?\ Z/Q]7$K?E0DPSED;ST=1#[@T
M'0Y#R%KE+"!#7K4FU=2$I[R$B\"F_AF"V])W?U.5(KPS@J5$/1RAGC"8T>35
MTB:DKT((FX'$MGU8**?H/'<*>[NMZXF)E?:>WELKDJ&H)9M092-Z?#=W)2/J
MC\P4VQD>(&I)CNB/+,]O2;=+HX>GR$^2#3=E%ZTHZ>O)CXG&RYUV9OIX4'R
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M^?1<"?.&5+-A)X):L%B@;UO';:9]O3))?.M9-9UIM=[+U4'5QY\9MF*E1=2
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M1YQI6IJ\=XA\T>AFW OI^?4WG:?J5>&LQR+1N)<]+03XJM)':8Z6G4XN5C+
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MF1&L'1-F%XT7)IGF!7'DI[BU+0>9OH2O-(KV@J2.Z7195L ;FEK\TU&'F2D
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M\8<8SFB9?(H><-H$7BE<9/.P&]LCKX+Q)^M559CI6)M$=WX].D\EW18[4O\
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MN-1F_P"A\CP]\]W;ZAF^3GW8AJST&LJ*20Y<Z#5VN[MZ^>S.4M>;?CW I/\
M=CU:ML?.M6U6*6K*HIB:-Z,:[-9^G\#ZD>>W]I?J_'TQ76Q\_0AJJ=6/EJB-
M)8S[LE1[K6K-NJEW"R/_ *?);I^,^BC1STTQGJ"AA++" (E%E1(KCL,=:T\8
M$P4%6.G2HZQ'X>J)KX.4)0=QDHM"0/!%PH6RQ3XYI-/T\V\@C^P,]OX>C8R>
M-G+Y3-K680$J*JS%K]D6L<?;T+/0=8^KK]-8C\(CU33^P9,OC^3VMRBO)_\
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M45HF+=)CTULK.#T\].A[$+C_ .K6O=?_ !%P"S_D$8:[OI\=8FW=[>H\ZNZ
MXB.UU4B9)OEX"^=]OL[H;-*6O1?/ +66)Y*6)W#+W5ZQ6_:\M3,Y(1I:GE45
MKA-^?;7KH5RR-8]+17S*A=)6+D)XJU'>I9_2F+^L+944U]47(V83RT\Y'OT"
M,0F^^:A5V2JP#XP,PWD[K1TFG\?0;Z+8,%HH"LSF;C:"&D  O+-RG6^63M'
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M%#]_A: 58WC(0-_$<=A$[#"M0HK]MO:U9BT?P]:CJG'*I41Q'NY/*TM;&5<
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MI9X:PYI%V)JRG>E9KU@DQ]/6/6.&AFU'-E7.,)9K.T1#6:T\R-=7);T+*QG
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M=_*OX-(G6L=L]W3W]:>@RUNJK[\Y\\GQ,_3^-B<GG,H,*OWA7PD-/^5#0)?
M0'G#2*$[JQZR=7-MHIZ.1H\E>HT%@(R/ Y7H-:FKC:G:K%'L:K[,$ *T=P+B
MI-+1,3W?[=I]Z.+Z2[!DF'L(KK2^/OM+%WNYIX2O'12KXONXSA@T:)O*O%;F
MM]-Z))1;C9&E<M9:FZ1S7KHH0#@K?%OL: _A%[L7[F?YE26+6_ZE^HI)TOZU
MBJAXY*+.RYJ6R[G<74Y&%SD:^Z1'>@&=: 5D42*9Z-5M8(^ZLTM:D?<ODXM-
MD6CFL9C%2Z9A8N6$&R-C 3N2HF;Y8*:= 4KU'YP"CN[.E(J+3T39%5!PU;X:
M#5C=K#69FHG**@<'"3'YS(=\]!=_;V]UB6B;>FSO(968HQR/8)H"(?1E[E6;
M/[G+;XXWER*T",*V+F$&I6+GJ6C?3](<VK+P5FL;*D_W,$<C19T?O;7SN1)[
M&7ML+0L$ -?B"*L@0I!BCZDZ=1@ZALOVN9@%QC$#[2GI'535-3C^!D#UTFG^
M/[AAN)GR36%TH-B*L=89K?NFW(MDYT;YVO5J8Z&NYI-,F?JT%@QRYJC*X@AF
M]9"5E^.ZWZ,@''B]<RP6:XU]#E6*KFD;&(A!E.OPY#!\NA<B]#&I&H IH]K3
MVWZ_FF8]/6SRX^#JZG\R4=+FL-]DHZE,F<[%\_V\?DSP3G2*W4/:.EYM4<S-
MJSH!EI%=PF6-7*B7OF5R[6Y%?5T\]8X^.YJ2>?L9O^6+XL_MK!B1XKT]KTXH
MN3/NU.K#IE'W!N(US[:DO$S5&YXU1$';3_#ZY-EQS],!Z=)B567LR^L%#CN>
M"]&2D&;/R=[<TW\:S3N,V-9!]1Y:G_L91VLO%;AD=:QZX3Q[4A5]7 V[:6JH
M\R30793^#OA%GCO\! ;85#Z@8I2RX0P(72*1$5KZ)EM,<?:/?.N&=YEK3/HE
M!'$?L*W%#!(E:MN.BU*T:\LDM/T]WQ_-^IZX<_EQD9Y,"HJD$9@AD\__ #66
MQ>$TK9)A.U$-&PQW%.:S7V_6BDWIZR%N1BXP\GAI<:RU1W(YH_*!@+<P6*^<
M;N<,:[3_ -^7MXZ]\5\=NI+=*^L^@Q<9TE$T$DA9+[&JMFY[PN.\8S)Y&G5!
M:I;:*+V,Q85*R"]ALS,'#>;>J:!==<W:%N 'KH$ 3.\MMKJD(-L!MME%^=&M
MS5JZM3K:_=0O;29XYJ+K84J8XU((&+,08+=^,3CZ^HE)%"1+CC@ S;K-+'I]
M5[=T=+;AQ.9[&59M71PL1PSHP&OHZ^;K<SS-DH@F[<[:+D4@790W;#!HO2:3
MVV-<4X%/E$0881 U<8852TN5L"XK1C0XYLB-B(+[RMU[E5M7RH5KX!U\=AJ[
M)7$CITQPH.E.Z?4TVK"RD$1A$9G(4:6& Z7=-OE67)2(F%1$M:_HVJP7-+H!
MT<=O'<DKDL9PE?W)Y%RS4J&\ACPW>P=>BL]OYYBP[?I^\[6EFBX_/WHF%#7S
M8H%LP,O,VDY[FBXFV"MALNKWCJ EK#%,5L*\5MZA5C5SFPKXV)9=$S&G\=SD
M,_8!\R%H,^.3_9M]7COCK>*V+'W%J;4GKVV^\Z8LB/$@Z#)ST2-,K\;^?M:3
MQ$,F[2Z_1.B3=!]]:"]^^M:4'TKZSF-&G'2BS=E70:;\CS3O*BAW_NM=K:"T
MIX%M=)*;@%%;'_QR1Y*"[:>MO7UVG29>BO@!ID*:CRJ3GVGY=RUV4@2(+HKE
M-3I6;6K>D36T=OM.1"\8$L#7SOE:EV-(;^'KK<@/KZ/(L2*+6A[2V4B#7+Y;
M+3T6'6;7%U'ZR]!C'X^N,<"OI<4T7-82W+KP;8M1SE<WSF/B:.9\\=@4\+E)
MM3I,Q7Q0.QEM3$,P3BUL4[NB1MWSWG#^VT3&%C./H)*"/$="?-*&XJ]UT[&F
MUY?9T#9OQV$]19-1-FS'PZOM(-4#U'C8B51T( DV\*X:=U^L4]Y]8R^?H97P
ME>-+KZV0>SHTW>0C-Q7[I03"X?*/!Y2E@7$['9WQ>WE[+R4M?7'-4=\)2F;I
MF;E$33+:.%FFVS:-\7&6<R+7)3X9II0P"Y<T);I:A05H&NGDD"@'3?RV A\M
M[-)I:!U2!J4;-E:&Z"DL]"0*M^G\/2:.23+I40]6"_<2>"XFFU*@SW5CSC[?
M;\._?-ZT&$\]T>,XND]Q'A&R)TW-'7:V+&9T8IOYC1\1E;C^HQ0$FMFL3EW&
M:.VT#J6;5K?NO6S.5Q\/&DMP^YJOK"AIR<C(1UMEEZU$#%R3$(XDDQV![UO!
MY?QIXX[/2>85!5(:RW6?!K,:Y2.F:;,Z0[3.9G$9(Q:U3W/-8L0QK_3';$V_
MK[V:']O";2S/+^6[2FDORK 3&PGN;[VHK/QFR58#>H&8BT6_CZGE&YQ6>,H+
M\,8P!5+MY>L9EP^VGH1-:YUK>(= @GWM_'^IS:J? K[Z&[RYKD"&@OR;#0BR
MS.3C)0(BKQ*G&6A<ZW7_ )3ZXYN['#K<9S<'!Y4B0QM_(U;LL[A^.76&(&=>
MUZ12N23NM;V]X_J[**\1+#N5H* BT]M9,PH8(HM:?:L3>_X^L#$+^UK!RX^)
ME91#CYEQF!F)GH@4N4<6-W10EA=8Z^_3USG:Y!B_8"\EY&EHIYTZ26H6BJG&
M,'&FY6$)D$6(SFWF*_C%>G_E!XI]HI1E,A-MS>S?C^9O0R<Q$9#TS;1^I715
M@WG'2/\ 'D7B_OQ,:+"W,<W"3R,5K>4T?M^:RMN*GY#R=51YJ6YB*X&<AC!&
M3P>$U[DM-BU^GJAJTY$]F ?_ &S?YW?!MF89 ):"@<::YOR#Y4Z4I=[]^_NO
MYNL1]4?AZ [JSR!FS:^26W\R#XCG J-D!"M,Y$<5HT<_2TU_3:\?TS'28GN]
M+$_F?5#@QQODG)W<=7+P#S-.,%XY$I+'/F7>D;P=$W?^KY.Z8[+4]<RT 9&<
MEN\=XXIR!0/WFFMEE5UD&G<ZYG5E 6HR*J9/*'Q]OM6:DM2\6]:C).,KG^W/
M;2=5P[39FG!<:5&?=>&!3CK4KJ+E.,="%[!?5U+</6O=<].(W.NR;97Q/#LP
M9M^^%O9F(Y9I &65A>D_<X-2B_S6+P.U:CFW;W9QYQ_EYS"8RZ+6<ZVR7->O
MFZ6C.?-"XRR<EK7-FO89A9KZNO@B(GUE8S&9B)+&Q=K0T:)\A'M,"(O_ "P?
M-D5UT@17N7W>EQEJ.9Z]])L.*6)3);Q?MAC[M,H-3:%I+\(JW(S"UK=^<!,Z
MYK\>FM95.R&9+T\O=2U?3FQAY*B=:T07589W$+N$V&$,G:E)?+.K2&T2Y^CV
M0S6\WB>I/#XH\GIO0/BC'KJ\I'P_[975K="VLQIJYRI9V;(BD>??YE+VO*WD
MK[U@=K=(E=#+Q\FHZ;6;C&1)K_X[WC_<-;6%]S^UFK]L^7Q:A!'&+R]H^V1]
MQ+5&1D'$M0Z2V*'0</4A^BSS'&)Y.-*S$9MLKXL![0R:6JD[[=U0VI$V]<6)
M7,S)N]E<GT=C()N!77K3'31=K\?99S:V,4 ;WZ5@-*WM;ZIK2LW]"82P3NG9
M<V5%4?G4$Y>,K[5V%NM"QF.X]=6DV$.A35Z=M*EO:M9!7+PQZ;#J-6)3+M0@
MD@1)3D[.F/Y!L"-+Y%;X$AM0P:6@DQ$T%VW]:!T.(:S22ZK-TF.\X/EOJ#1N
M1(UR9WP!02SDP/P,-'OV?X/6](G&RKXU% :<RH71E]VP0;$%U@VR*C-AJV$\
M.^7]07I09GO^@5^VWK3QQ8%M,:0-BJS2C]Z2WJ8N4+48S+2SFAS1EM4G9T&V
M<U+=.X4=T1ZR-5'% SIZO)/Y8G*OILI"1?B[E2?,9>Q5]!?P45[KC(E0T=W3
MMGVZ@9OQ<8W'\_'U\K.^]':*YG:JN\Q>;?;,)]@;:7\O%DE:"**HK5O8M([H
MJCF R2+,-9E=T\$<'>4\1O+Q=#)>M%!="3IEV?!6L3T@BI_JGL]9RPN+K2QN
MOL)X<?S(*U"#2W#X;K&M(\HA,KL**"#I%3R2LVK]-Z37UEU!QI6Q^1?:F./T
M)R5<8RY^JXVD,NT6N<6<=T1%XF5ZU9[NZ:5M)*6IZ/X>*:1%456?N35#'(%;
M45QF]<BXVQYELH^;;XOCHS\FA"=\7J":=9]:D[>./JRVDE@YZ;]#17:>X_QO
M2S..6=E!>3GU[ZIB0::=!>&]8BU8B?3JDY@F$L7+SM;<=)K+HL!7UCZ:R0\A
M!@/^L,V+E7B:>4$S-JU'Y"3V>B MQ)8SR^&QRA@2W*%SJ4P0Y7W>EZ.UR^A-
M0@JWI\?LK3N[+>617[XOF%X>XQJ*W=*^KFN-:0Q9JBF"[!UF5,4E2.$7Y"+J
M,\+ H2EHD_2:6MHB,D)[CR6)Q%UOM<"OJ)%WM[=Q[&10E<A]BQ++AZC\@HK%
M)[.Z]NV<O43PF\-"-!33T3&\LG?XQ_+?(^2W!F?=,$(;Z)A<?FA>VM@1%H\3
M$]TD$=5WC0(;SEWM36A'D(]!5?&1PE^06.DR/,'9_1(J?LA::"CR=L^3QWK?
MUR??3X_]JU\2BME5]:[],]H;E%#C8H=K*SG+0,+%HM_E^R;U^FUJ3%O3L;6#
M\[S[_*,O!,@Y8A&BY7,$^.@2;14RBL++AC5%%3TADQ8#:9%%K5BPM=)![&Y#
MM:$\=S$R9;VLVGIR\PFQH"RJI!T-(&<BH=^!V7&0@0]+TK/6(RBVX])>S-R#
M<H*9Z<QK)?;Y,;B&@F'(.@0YF$M54EY&2X/TH_ZND3A+Z7'AY4\AIA-HWIMC
M>I3.WL[E#JYFI^WJ0-L1.,7I8,=U>AJS!.L6KZ)?+RJKV>XYJMH:E&R/CS]I
M7AS/*QJLTMDBRS^, HZUJU8WO6U@Q2W7TC4I!$XQ_*UBO*>&GGG>T&7*81!M
M=/+7Y;.;\&H_RV,W3^/I-#D60[MZ&<$MN4[.6F<8ER$VMW/!*BBN<7/L(%,G
MZ_*TM:8_)!+1:/2[ ..6R$_M'(M9RS1VAM&33XP3;S#8U]+"7$9FI*3!>\-U
M_P LTN6D^J5)QD=?N3>CG\>O.]3M>9S>8J<-+;5G[7$8RY&WAFK:OR9\?6O;
MW]M;8SB^&M.QM\EVN+KYQ=T5,P;F$?=&V<NX) \2N0/'RV%V+VO>UJUZ1[S'
M/>2A8R\E%-7(#Q<.FRO9-)IO$0=,QJ-43'^=S2K%2^>ZLTBL]*UBU[_ T*&U
M*J"T"::FY3'R-U0Y:<<!A@^;@V<XTYGLN[$WLS7PR%>9F].H_P!3;SQXJ"FA
MQT1:\@8-R1*$42F9E+/+BF92!7>ZEF+$'>%+#M^E]19BDY>J+(HSFBXKN:>V
MDVU3*U:7PVN+A9T"*WSS$3<)73-==&TUJ4%QDL2G=6(RVHS(2SFV'-1>X'5M
M-W1X]CVT5M$#R,@!]CTC'$*1U\A8_-6UZWI>OK51?XW]Q<J3Y2^9B.FU@I9*
M>#@:#DTTL[$+9MPY]JO94XEPU]^XU:=EK9HV.-54R-/5<SQ:Q=<I/ );D9.,
M#(\LMC''G,-O"F1T8,(-H^B#27]/UM=<.',[$:^U'8KK@!H&V2<:MR9<(,JZ
MMYG-NM-!V9DO=6\VGQ6H.UO2QGU@IN%%6YU5VK/!!:WOXZ-V63D_2O\ 'QU]
M_P#<"FCOLIIR.6*IM,"DA0Q(NYVXK4$0H 5!7J8GM2M?SST]"PS5X@PSB,V&
MLB7.1O3.;:T% FHIWJR 1B:&D"20.>O<:E[?C$^B[FFUF?$@CO'K.F%4]BDA
MNZNACBZ"(=GJVC:"!I%HF0S,Q]/LU&;;AN9=1(>TR5!5!85%$U8?&W\E8-07
MLFBW!^E;3<82=_2*SU]*#486??LBS(')%X1KK7V\G(>1(ZP.ME&"N, M\>W2
M2]E/[:=39/'+\9E'49A5C.ST5@*:1]-)TT5(K58871NHYK$=W2U+U!>O7Z9B
M+PXMQS33S\USD:Z-<=5ZA ARY?/= 1%?BDT"Y8^_QQ,%D/U3'9[^E,YT7&J"
MT6&TD,]I1,E30XVI)O,O9;M0G0T/#%JFBG>S%:^Y.GKS8*G%M'0PP+"&9;+2
M^3GJTNP!6%"V5I>BHBA*.LBGLK:MZ_C$QZ%A+1Q;(V,J6V J!320OFW=SH==
MO0M ""H5S*%Y+QW5L0 YGWK2>EZCKQ$PMS3K9D/VI2?G:0+@.-O07LGW_IWT
M!DJP>L4_S%;1;]2)E3PK<>5T6HOA* =QE4WI41UFLA53ZU?T<\VCES1:LVBE
M[UK6L=_T^M +.IQX^<X]8&@K9>C =%Q@++,DLI"Y/N4,AS"W@U:DH2 6Z6GL
MGHN6I>*)ER,>C:C8E4AT0QZ*ET1PJZ('A .J#EV*BI?N\!;$[>RTS)##MQ$K
M&=D- N2^<I4ZF0O:,]O/ZE5J2@Q2Y K*Q]7:>L=G0D=V0MM,\<TK,]"Y(--(
M3=AR1V<[K4;2UY1);16^/,7\=O/$#GZND>A<Z=S,,2/)15#9W4PUHT=+S=5X
M28%94KCA9HKT\?ZG6@^OY:]?1A8\<<+]GS%S&(BHI\9#*:1L=;_-"#\82Y<W
M0M:*Q;_!-,].EI]:?()7XP:MU&,AFL9*@WGQ(Y@G/M!A'4H>5?MM S^K$ @/
MCF9[.WUA,2IQ?&U+2QG8E85SJN)B&^5"0487!_IU"/EL+I-J5D][#B9O,Q-=
MET/%R-[:J,U>)EJL/:BF\!Y1&ODA0C38]-5$XXK[]XQVB8Z1Z7A'3XV#+SFQ
M71"JL,8 -F6?<"R@L):.MB+JM7@HJS$^,OOUK;U4C-^(O9J["V:."()MKBLB
MN5U2HA?%)$)*)OW-0M8^/0)K7BW;:9]<BT1[%#OA#DY32"8AFMEYF4T'/1QL
MI1-5<=4,QK>\MQUDA*0SW3]'CB!8DY@XT#ES-MG0OF+V/:-CD#&>KHMZ-5AV
M882=>)V5]S12W2G69]TU^O&^FJVORD@E$TA@VR+AT;!ML?Y21-3>LL7@1NAK
M6I>8]ZV]9YQ3Q,K!LFZV<U?/3'VXL :%"M&S*THL@5()O$.;5H4$7FD33KZX
M/7+M]U,YR1@BR^919=&NCE858%J[GE4JW8N5E&'\*G=7OJ6MHBU:UFJFDYEY
MS6AG]WP'F$ES.)=_Y_BLD'8R_=_'MF/5UT^/8BH"PW! K92(!$C0'0+T7&,%
M:VAP(JT)_P!=:Q$^T>J7>PL=VXVH>'9K-38M1R @6AJLE#:88A=45._\W8.L
M?A6/2VLUD9C.HG%(4TCH*F?5@<EFD+MD%8X8I)[S';:.DVG^WU;X.%CI=[-G
M;_%S4U^YNX#K7:MX@UZGLLT0?=^/82T?A,^J"S</(SQBLS88TLU-6@[.U'1N
MU*A#2M9:&&M2?]5:Q$_A'IK)4PL=7+>\OS<U?-3"@W!Z>,T,J##4!X*..V>Z
ML]:^WX>I5+BY159HV*5R9ZEP2-\HSO4D5A32:N&#6Y8_[RU8F>LQZ1"KF9ZP
MLOR3FB FN(>?)AD$64J4'%59*(UZVFG3K%IC^,^FB?:,SR/7H1R_P5NYL@S5
M9'=FWBZFO1FL$B;=>EX[OQ]0HSA8["M0IKU6/FIE! ,XA"YX8%<-AP)(IKV%
M7IT'-IZ=.OKY'\K\>@\+?#@T8V=!84^-9+XL7^/W0O\ "O(>S\OBGM_+[>O*
MUGI,DZ*U\AU0%OT1;J^E'<2EIZ*/4@P_^@L=T>_OZ5>G#R)=1DTI-SFIRRI+
M!BLGE8_A\@),P>][=LQUO>T_C,^OCAXU@"7\YFO +(SQB^2PN1,Y_'5>*^8R
MAK"M;\9'::_A[>C91%AI"-4M/,@ND,XZ,: -1L=:G595(!]Y>I&!$&01Y_Q*
MV]+\5G,5T<5>Q2_$U%5'!&8.V9\S!%Y7HG4EG#VO$4'2@^O2E:Q$1Z86'GHC
M7;'432]%05 R*BHT:#.**>,HZI!H&(M$Q JQ7\(]#4#QK $J*[1!+#R$*@I=
M]:4W;5%"_9%G%)\1?;ZQ_3/MZ0%'&\*!Y7F^V4C)0[<_Y$]S'PJ^#HMY[3UO
MV=.Z?>?1[_9LON94^ S;X"O5A'Q@#\,T^+]5;Q*CKV3]/:.L?A6/3+8<+'$T
MXS5QMD>:G0[3=(+%66"U#!#'KY[_ %6F9^NW]L^J)QQ7CD*":^:-6,3-A>CD
M4@?RJ!A;QU8\<=O?T[NWV_#TFP7$R"L9QSLH')G*7*DPT>6F3J$L&;KE.U;R
M7M7I-B?5/OZMHN8F2UH74(A=YC.4,W=$U+B*G9D@K&LL01;5FG7MFMIC^,^N
MD>T1^'^X%TVM1W/"$6@ @UQ)L@8%I+U7(2ZKP&%_FJQ3JN6:SXNZWM]7IL66
M<CVCV\DNF)TXDEI;Y*LJG<Q60ILE#&9*\'%-:3?OK_YNG&<E37;0T>+7 VCM
M@"J<Q-+[>YG:+C2KHCK,3J"TV;$B8Z]Y>Z)B8],HGY'N&S36>=HH>,V]Z;FG
ME$QW]F[E41L'(=8Y;>&9\-2FM,5[>RM'=3[MH!G1<EMM:HU+"O-7.+/ '2UP
MR0<!/Q4?OU^JI;Q/]WIBV1W-))W SN.9V<[0.>>:UX\/>6H4J[*I%RV=3Y&>
MEXZ=*S%;5Z3'NMW\BVF0J9;.6*K LPC%1.<5:XH?L=E+S@!\9JQZ!'V"AF9M
M,6B>D,DOR+5F-<J]^2CJOF4INC4T+:BP9_REKYM:MF+%I7FDV$6:_C%;5RF,
MO4+W(YRF(Q\L 20SE T'M$T1 Z#\;9RM]O='M6*_AZY.?<TV?Y>V'E6PXJ?Q
MJ08P>*K<?^8PW93YH"BO)9J.A)'::#M/]ZMJ/Z/)]AK6EE<C&K"F.JY*Z@EP
M*A0*HB&^2P(:_P#C!F))8E^^+1V5'H_)WG+\8<IF%)F5"A!G;J\LY+RO[>RQ
M\/Y %$W=>D4(*]2F'-JVZ3$7]8^F7<U= W'EAY>-5@><*BF(OE[&6KG7^(H"
M62"ILVM8]OU+R*GX?5W7K#[7C+FK*7DB.29J'%L!?CD: 7BI697\F>M$R*DQ
M7R3/3Z)FGIJK;ST?)T=?5CMHI:!.ZA\5JENPH+T,-)C#%-:7B8O6;5MUCT5>
MKQXEA?-$Q*R6<B*Q,[DI>3^>BRBPPCL=DGBM^,^..LS-^MO6!EJ;KZKO%W"-
M8FS"V>5@-;KZ&="[*AEKI-CC)TK@F9I%IGI?K%O6SQ]#0U*+[,7[W/.(>DJ4
MN(CC%:69"$=1M6^%YXMV]*EM[1%8B(?JGR;34<TX> XZKG8@^Y#4RL[)T4Z*
MV0(O7Y \D!8-,6-4U9GNFMIKZO&EI,YOW%EJNYE9UU7%M/(#R;3WL5(KS2%&
M%V UT+5.1>!=\$M6/PI>,QTF]J:'V6,D&6%@.:*BV?B+<E402M*J@+GF \F)
MY"V_4O(Z_A[]<$U=)^;8''TN/+]:K?K 2RN29(V"] ]8/8/)26GMZ5[AU_AU
MZJ6MHM0=-)#-%<Z66\'X2F.KC%'91Q0JTD9$F,G=V_02OM]$S6?C U'T_&[L
M:"I B2GXS&I?/(.*BLOX;!1)FC[*=.EHZQ/K,VBZ38+(1E^908EK <MC[ MI
M&]K$%8H)JQ6];=D_56_]L1/J^C#S%['NR=JITLM@EVRET"+LKM&4NPC*\/\
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M]-Z(GQT 5'LWH%G?H#7;CC[_ $5 H %58 =57@!C3$9_DS ?LGWY>@H\,J$
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MC6NI/2A>RB4W%@CP8"QPWUQ(YS#A<X NY@<+& !HI)RE^8E5X(D@NYVJ$/\
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MHXZEF<VXRQ $7(]M=8^X<#Z7F+V!]^K!&(T=!E&E%!O0 85AIL1Q\IH]54M
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MX$P,BI^4AZRDY*+-IB2\8K06'IRCC!J/$0*TI:.C&T;&$_.=4Y*H-/+$'(]
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M*/C.I7'@]J'%7=X=Z%CA"%S+9D^\CMI-:O7G)XF!P7Q)D.1]30$GE(#18 !
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MIM32.(!+LUE"/L,#A&I(D@DU(F5MG(27[ //UA,2)!G83>C*,NAEZ O'D)X
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MT#001Z&<IV.\<NE6I_H'9N1,RBVY4+I?W B5>J^R ^CL$S+WP,T1!,H L9V
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MT?A4<?X2%! H;6F%[[GFXH$:W<FP"2N\64R/3&B(]1CY='G>1J)\/=QEN/\
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M(?\ PD-__]H # ,!  (1 Q$  !
M
M
M
M                                                  "" "  "2"2
M    "  "0"0 20                   0" " 0000"00 002"00"02020
M                    "            0
M     " 222"00 "" 0                           "2   2 "0 002""
M                             " "0020 0 22
M            "" "00""0020                                   "
M
M      "000 2 20"                                 "  0""2 02
M                                        "
M               2002020""2" "                             "2
M 2 ""02000"                              2 020 " 22"
M                      "200  2 0
M     2"2 02" 0
M
M
M                             2"
M           "                                         022
M
M                   "
M "       2"0                          "0    0
M                          "0
M         "
M020" 00" 20020""200020  " "0 " "  "0       2 2"0 2 20"  "2
M22"022 2 "0     "        "2220  00  2" 0000"0  00   "  0
M        002""020"0  2"  0 0""                      20 02 20
M 2"""00 2"0 "                    2 "22  2"020"2 0"  "020
M               0"2202" 20" 20200 2"00                      "
M"" 2000222"0 0" 0200                    00020
M                          0
M    02"22  20"""0"02202002"0  0 20" "  "0     2 02"""000""20
M02 0 "2 " 0 2 0" 2   "2        "220022" 2220 202 222 0 0 "
M            """" 20 0 ""20 0   0                        0"0
M"000 00   020  02"                     2"00202   0"0" "  ""0
M                    " 0 02 0
M                                           " 2 2 0 0""22  02
M0 " 220  "0   ""0         " 2 0 02"202 20 2" 200 2       "
M "         " "2" 00" 2"2022 222"0       2             "0 ""
M  "  0002"  "    0 "0 "20  "      000"0"2 0"00  "202020"000
M0 2  "2   0       20"0"2  00"" 2  2"00"   " "  "0
M"""2 00 "0  0 "2""20     0               ""  " 00   0  2
M       2 22 "0   0     "0"0   "2"2"022"                 2  "
M0                               " "   "
M              "0     0          "20" 000220 "00          2 2
M" 2 0 "0     " "    2"0000200          "0"   "2  "0
M                        "
M                     ""02"  020 "22" "2222 02  " "2 0 0  2
M     "2 "20"0 2 " 2 2"  202   0"20" 0  20       0 "00"22  00
M""""2 2     2 "   0
M                                                         " 0
M  "2"000 000"2 20 "" 0                0 00 00 2 222 0""2220"
M002"                2202 "0  220"20
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+DBP@F(P_P A5>IS.M!*D3.L,69"R!NS^6?@'G59<&2E-,5WM^)LX6@:),0
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M0V3H&]7T,63<A)U(^I=W;TQ\8*KS.B8#<WB??(.&D=!BB4$32&8OU*8^6CR
MCFV=(0_)B&RN5050&V&>H_+7RZH&:,T3UG_6[^.'?]N+T-]FS*L&-E6N28&-
M+TE%)_\ 7]3_ ,E'UD1O=A?NS-FBCQ;LF) &']!X3G&I^R+_ *@!3:P/H [X
M>(P 9FF6<:6WATNLE/RH_C%*,C1;*J/0]@$KG'%2O/Z[+_9P+1-U(\#"IYZ
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M.-%+BB&J%AMCE_C M<2B+G8U&+B^'(6K_P"I-!'P80U//\#<+$&XJX:-*Q.
MX<B93'YLTQNZCCK9SU,>P55TH0D[X.3!W*K0%V ".WJ&9S=W7A<U(A0 BS;G
MD?.B.YYX&ER#?"_I.^(H)="6"%X6)T3JB4-1(/Y2FT^(.>%Y%",953G(4&4^
M%!T@/Z*,VWWJ17)H3<<XI*S" U$]@B*1 \[CK)Z)_$)ICH$O58[%4>[M@O0C
M0 !3*C7*T4=B>_&OCM2L*%N(_P!,O@''2%?*'3\<*R@'MB&M8!\I+MJK8;;-
M#_V8T9UX>V 9=4^2B#H3WF24I2<W3>]]%^K!>DG#4?BTYYM6C \3?EW\K0\9
M"A$#@Z".<A9E8IR4:-6G%?\ U#$ELQ>&>(9%6T*TJNA6/TY8S,)V!4Q*A[1,
M[W=AG,9(#9=8C%\ZF$P3RS?U";2<8'TE"%_2= GV0$J?8]0T.]^*=T"]K4TU
MB6Y4OC/E!D@R:1""J2[NJ&4, $G#0Z_J H]V=YU+T1L8*HDR3*3;9\7N;3 4
M.2$WP"Q\;\;K^!Y>!*,%4XMOQQ"M3.1G#FV@Y*<R["*?+9*3-!P[J?\ $VMP
M'L9!Y[%G*$92+KS!:[CE:L4/]@OMS\$;=.N H^3N,=-P,;FMR*T!"C=!DSB=
M!X3P8DI,=8B,PS@52('NMH*H5CM0)((7F( W\H>C*8/M705IS1 D.>""2!XK
M%J['ZW><"-?((M"O_K(U%&26)A]91<I_7C?-?;@-*<!FNF049D#S2<*AJ=CL
MT,+*&M"_N) *Y7!.*="LIPYFC 9S2)9!O98P#G]20,H!%2HDG"(IN(F@1QY1
M<$1D_L1)_$X[UF@<=X*@21  J3@ I/R30TC2ZHQYDY5#0(9_A;XF?51*.B'@
ML4"SP$K6T2I'3F<#S$'</U,((\CD[ RW&RK>ZV]  DANG2'BBI&)@)<P,"CW
MB3JP8:9"R, 72_*L:BK9OQ<9+#\/^K0\-ZTI)\Q=YV_LF&7KS:K[BCII&-?
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M[B6@9)4$<FV+6T"XB+32RSBL/U;B27OA :K;VHPSR3H(0X?BC8>9,M]'Y>]
M^G]48B%>S8WM>"^&GTJP3TDO.Q*==$2CAR(DSL83(KE1V87QJM<@7Y=W>7C7
M3+GN&'C^+^2=R#&^PUQV\W?_ ,0?V3]9 C_LS*SOYLO+1G'7<?Q<7&W;: U%
M%EX+T&]<4;RB]EYVA)HR/?##[5@CP/K13)?0WW0!N%CQ90'.3.!;,*(7,Z-\
ME(X,H[(C;RH1S#MDDL1\,=DN2F2$D4\\.)'"ZPG(90UF +L38# =UDN8]$D2
MQ;O^.N&V./I+W51:J]B@<#>E=@'OG 45'L0S-K[S1K5CW<K%;.6\AW&X[[1>
M[Z(Y8$@T^L1!21,GYL4'U-G>/$?QWRV:&4[5N( [9J6[6#\M VR-UF+4X)W[
M PUX8-XLV8+77Q-^IQ!O+2/P+V-_/<DEO9>CP*9966 H2;O$5T*4BEN]2G3(
M3%T'?]+_ ';$K'8DL6JF6FP7%_-V_P"\1JB3<J8";5C"Y:7>IP^$9@(-!+[R
M8*.&9FX'Z!4B K5A0'+@(A #D0^8'<HD14)7]/\ /ZU"6"ZR2BJNOO&1CVNA
M"247Z4T992A8))!"Q=Z!R<$X>\IBC3?Z=%V31\9)2]7]>,*7WH-U"\IMOFH*
M=:_N1.@AOIKEK7 B92IN$FS;1AW-KM*Q&9*:/>8$&_:X$YV5*T%,($LJXQMB
MT_@Y@'F,QY'P*YT=U4W;]Z,0CP-+)5F0_$(6B FB!CLI[Z$=<IF<SRKXOH91
M!+WL>,@'UMF^H4"^7"0>L&:'Z2T $ 4,,$">+:X%GKN+!R</G;^,!S,T^W>#
MF*KH?2"8GBGQ6?<E.$$(L[Z=G)G(I0@/931QA=*Y[B$%., -FHYUDINF7>14
MLJ<=+;KUA[3%)?!=9MIE<<F96-E0#6X[)\;TH[7Q5/%'6^Q]SH5$4X\83;SG
M>)@C=8RDS2GG)(WAY7K>G$Q+_<F5QCWB0=/VC-W1XW!1%%"I@**1G,CCEJNK
MDA-1^J&W(.WGWG?!]PIO@]6K 'B6:]A^AAL05B#VDW9!"YET(\0Q80"RFQC]
MK8;9[$RK2A;YA+7)F1^!'IC^CL@2(J2 M5=&SF&1A -=%#:4(Z.9>ZH9E00)
MP<4SH02^/C9@ .,@^AV#G=(#;SR PTC5Y4D,"<" //T7!?VLEMG%E4$P5_KU
M,/J/5<4'V(2X25 NS./VZX,(H*(,4!5!YX6=>!U7XPGI'APC[*_PQGWF4)4*
MPK*Q8?=A]-*%*V%ZSW#YE\"((B/I&C_A/T% J@?=8?\ ;]-*%*BA>H2H>T*?
M]ZNDBI"![46)?6$ H0"(B(]$3B(^%#VAT.H=0'?E(?=\* J@!5> 'M7X# @D
M](!_PE'Q )4!1A1K7Z;\?/N?XE_ZN4$%!6 O5BP^[#]'T_\ .W7X7C1E O,S
M*I;(<5R$-/OY"2$3UW^K"%P>HHC0N9]A$@#\.X=!0RJ&N5A6&40YM85@".'*
M@X[U]#Q./(3&+:0:+S5?W):BV=B%2(N'/\D&BL+K,^]O]*XS(R^Q'8I]-G7A
MK>G3"/I&>X^OU [Z@/6VX[HB403+%&(DDXOC@ " !!*(D1'V)ACT$QX;6I?A
M<4@(;/<C1_5U)<[%L"I6H>-84$ ZIZA0#084C-JIVZ/CDA7CNHI[QQT*B-#A
M@(>'<'CG!8RT#W]:9G3E6;B77$I65>+$VFCW4/T13!W\V/38;3IFM%0$%9%:
M5 FJ8&YZD@DEX>5HSRZJ"(:QD=CQ[X@R0JKD)56BVGN_G3/AY->885?Z$?QZ
M[B$R_2@7)[.#;+MI=F3XR3BB*+TI!L+,;-L]A)35.OQAJ".CJ0P&,:-VV(Q*
M^!8L0739(J9Q&9)#-5ZW(_K4!SX:L3HLT5UU/='O97%#P8" QNC]YH9!-K5O
MB/\ <E+TOB3[$GC4XP!/$-5.JNA!Y*L"6A6 G\O'PK@9CN9/2RU](\HQAU"Z
MJFL<?:)R'HJ".H16#V:"7LKF48(?GS",KIE\T5X_^N^4:)B_991+Q5Z(&/KN
M&7.:):9Y47"O5*WP6T&%SW;O@"<M(45@A=/D!S!8@B4%';%,+\<Y=Z<"#C6X
MHA8L$E^"I6!N?. ,Y:;J-Q[W#V^K7%208*?0?GZ=TV>4W.*\_FJ_K:08,\."
M7.M)^HNY\!RII6=58=^"QW*S]2TO)".PT/K("MPZW\NJ#6-;+;.:?4*Y731A
M.Y36CQ'2'FTG(M',%'=V&J;X#X>UI]*E/:K^KK+_ ."K"Q&WHE4S!'[%R &%
MN^#FP.;),)$=ZX,MH(%42C:\TQ>47)/DN$DA=5.WI_5$P,X)0)YZ6 ?)>AL?
MB=+;-=X/(-AI!76)@5IMA.)QV6GD/-!VBX<!TT /,I]CZ4WZ"UYO )FC0,O#
MV9*7MVY>Y5&-I\@D&Q+,J?A ,(:?,'W=B@")J+C4P,,7&291IZC?MP):;-50
MB0@(YQ$QC3<5V%7-2ELHM;:V31KD@[Q%SZQ\=1G>T%:!F?9O<F@+B8/8-&-)
M/!K@3;J0LT #(-3=R8(#5/8@;.9X6R* XCQ,><3-]F,WU,<\  J=NBQ9_=Y\
M"M\(]>I4CR&7BKL)"3(U[R@7BR'&CX+0D!I6L!+!J:)YQCJ*&&5%C?9I'K:7
MXB '+9^/4ES @QO3UI+A#6&1TW8+XPX2.NF>!.D[;V.2'_X-ZMQ-<GD\0! O
M#-XBG&5.)W4:B\3B$G6TH",D0\H.FP3B/)EH"2_6/G!.D9GOG#TYU\W>XOY;
M['^+.O\ 7T7\LX_X^'_=W^D#W]M?X%^9/J_7[5[7W>]O;<1.:?8I&>UL^SB<
M_<<D^LM"'%WYE&[3G)GFY2Q["W>@OEJ=OOL]X]!.I2@*W%7 R@1\58TX2)S%
M'8DM!ZX!=[@HUG5^Z=7'":T@E9>J4B)0/",%TQ@-RI7$[:;,]$)2JC3 -9'9
M+0 :6[[AUR6X\H=:&<53&A1S/6[&L)3Q^+(]J)8WG_,(;_QR*Z^@S9&O&3,H
MM5J[W"6.-L_QR@9IKM 6$!]A&X0O@CB)M,<66P8B A[%-ZL #%U"HRDV[+>^
MTA06T L+1'X%ZF83\&\BXJ-R%XL;NMSG(-G\A=!>%L%D48<IF$QW6K<R=-M7
MQ$!)* 594]^I"E5<-0=P!#%WXTJ!9(":T%?SV4]1GE5A(69<E<.7^ T#A164
M-$DZ1?\ '3U7?(0B'T;39%KA)MDZ:XCS,]0#LN^5FXH-IC.T<4\F6^S!]#3D
MAA:R92_8+45#:CA^PX4=X'&PA@]#PR'G^E0X2E!9D.,F4"%<[I#?CT8,LYKZ
M&C%3R;3F18)C.L8$8CPC)& /I_-$E7?"70(C@Q,:#\R,.@ #$68PP9Z&H@@?
MM8,]?QIF%@.*-7@$2 H^@"J_X,&, LQ:OPGI%SZ% 50 JO #VK\!G_/[ JIF
M\(% D4T=]LL>< "Y."V4E1^$'!G6[Z^..RE)-,@DWL8#NFP5)"H8(459)&RW
M&/GMY^SX:PQ@>\8'?KHU)I"E"U,4 JB]K!FH&T+"/!B^P!Y%8+Y*]2E9@?GF
MP [_ &R@-=6!"$$'P6$>#%]@#R*P7QZ. &0 / "5L<UI]RR(8\1D8_MTF">+
M[=+J%'$!UH-.5/+*?_%$4-5TIOD^'4GO@''D-H14APHJN:%27A"[)KA;A!*R
MDY*?1D5O:W9M"X*HQV .Q]%LC;&YC#H*9''DZ!/GLNA\1P"H@!#Z%6[ZSWO#
M \(PVH^MP19TM.Q-R4N=3JREP+GZ?PYU+&7FC[B-FL^XA#.%<PGF@EX4X@%!
M_9E=%+FC6GJF<!;Q0W;G]O*FG\W[(,4*0FPIW#1^)&@U[0?*109K\XX@Q%MA
MFTN>O+4!&X+PJ.068+&ZR= HGNE5Z3/V"%IG'JE^Z"#C,N/:9X\2-05TPW!?
M(V=RP86G&Z__ +^O-31M:BM\&(@+ S;2&EAPQ*4(^>&E@CBR-&!;RY(]U,:)
M4>(^_5YP JCC,?#A8T8!FF+3PA <LE[Z[?E+,W"741Y=_,KV5RC-IJ,=S3?C
MKOZ U]N#!1P'X',!F"2&9N<9"K^-CPXT1&9(YC'MQFX!\U0)K @D2H._MK6L
M=0:_FTC&/IZV7!-I8N%ST2A\'23;(8%%5EF+=40WM'-)49#<X)!AC&7P%J-'
MKIP[YXV-9A><<E09(@Z!IIY:F)TURTDJ"G'&2%[98<Y&YR)\]#;T_4016"#J
MG]/35=EM).>-A^^!/:*B&C:E,A/]!0TON@U^;::!DX*HY>-(*D%2'VON)VPM
M($+] :[Y5A^=S2A()9=Y/GAC@P]5] 4 50 ZJP ^5QMR9B%SO;M@F./B%C($
M-Y?$#^COGO-O4FA<&K@D?(2$WT&0!E^@:/2>(I)"Z /1G/ S;A ,:(4X?2@E
MUJ(M40@B,<JJLK565?:ONN5YHBLW8QI 6!^T.@IX<H  JO P+<_C-4P/\#+1
M4A@7V*%@<JX%ER1*4<E=0&I$A0"H E(K:,E8V- Z*?./&2Y0'>@61CJ/0$J<
MZ>%MX+S-8D$=Q%-Z%_IA=$B(C%Z;=;VJ BEFVVH"^P2NE,PX[AB" ',[BN$G
M\"@N*M07T@187[<+G<]>5YS9+INZAIP[T'TK<G'VYEY,S9&W*,##)@6.\S^E
M9;:"WE+_ (8KN(#!<0857UB<9WJ =.;&;HX$=4(!.L,-TO FU(E<0PZ:I=!6
MQ7JL-FBB ?)KQ!)A"<0T2G!JUN16V&^L$Q]"&D 69V8X=Z)#B%9Z.,)N0_JB
M^&*..$4<-\#'4F(C@'_ 1+RN$1B?O ,%#7T,LHL/*DHGN/A%KTA>T2A,5T%6
MT0PFX+1#2UGJ-)^D5$,UHH1%3&C_ %%^9)P0( 4  55> &!\& *[%E4P?A3%
M4-G#2-W+T$'GW*DR$$5E)F(,XD$8;Z;M'5QJFH ?,'HUF8GD?D5Y6=$C,36Q
MPZDK1B_3:<Y 3U)%>G3*V6UCN^5V)5\@/ZPGQB:N<[P?S+TB!6WYU^)24.$8
M[N ;?QRV:74VGLN,5JRD%Q&RZ^#68@GZMC&6<R%I!9@3=4^G&\.7+<B-BTFD
ML]0AM#]<AB)>)AD#  1BN8B/A$P%HSE:I5V2/:QS;QBI@2,"W#1-%O+I1,&0
M/T6?9C>//"^0-=075I"9A)VXOW2QH:"?3KE42TTA:TA3'FCHPQDFP"1L91U3
MK3YRLY3U_E3OMV /',OM<;;G8D9B=O=$P$Y>AA3>'EP2N30U_A(D$_=:V3?
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MQ1/QGFP%]['X>?$<N!VITWIMNPTRX+;?> 4RR%382QC>"^#'.$:0@,$)T<!
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?V@ ( 0(# 3\0_P#"0W__V@ ( 0,# 3\0_P#"0W__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g451428dsp048.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428dsp048.jpg
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M P,# P,# P/_P  1" -P J@# 1$  A$! Q$!_\0 H  !  (" @,! 0
M      <(!08$"0$#"@(+ 0$  04! 0               P$"! 8'!0D0  $$
M P$  0,"!@$# 04) 0 #! 4& 0('" D1$A03%2$6EAC861<Q(B-106&1T3+P
M<8&AL>$S)!DF$0$  @(! P,# P0!!0       0(#! 41$@8A$P<Q(A1!%0A1
M,B06@5)R(S,7_]H # ,!  (1 Q$ /P#[^
M
M
M
M
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MD^V6/RM6^B=XOD%38&.\<Z\J;6-O/9YW4GUMGNI^CXIE:9:(VU333323</\
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ML_7.0E0
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M5,).V+A%VU5RDINBKA-=#=1+?*2R>VFWTSG[=M<XS_'&0.6
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MYG&04$SC;TYL<U4X9*^SC5].6=^C6&C9%5+31GOM).EU7.NS=%,+?
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M]#J"E86?-:YT2W<DN>D5OA[((O5:5TVCR4,_VQMJDHNEHNTW=,UD7*@6I
M         #&3$+#V*,=PM@B8R=AW^FJ3Z)F&#63C'J>BFBVB;M@]27:N--54
M]=L8WTSC&VN,_P#7& ,F  QZ,1$MI-_--XR.;S,JVCV4I+(LFR4G),XG9]O%
M-'[_ $2U=/&T9O)N<MTU-]M$<N%<Z8Q^IM]0R        &.CH>(A\/L1$7'1
M>).1=S$EB.8MF.)"7?[:[/I1]ALDE^7(O=M,9574^Y53.,?=MGZ 9$
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MD-4PGD
M
M
M
M
M
M
M
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
..               '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g451428g00a12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g00a12.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@! @)= P$1  (1 0,1 ?_$ !\  0
M!@,! 0             !!08'" D" P0*"__$ %H0   & 0," P,%# 4(!P<"
M!P$" P0%!@< "!$2(1,4,0D502)1<9/2%B,R4E-488&1DK'3%S2AP=$D,T)$
M=(*#LPH80W.RPL,E8F-RHJ/PX?$9)SA8>):W_\0 '0$!  $% 0$!
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M/W)W"39:8B3+HOF<<HNUDFSR+&2:I2"K'#?X>:RMX[M;BVN[65S$)[60NJR
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MY07?.9/[L6@,$6)53\LG7B@7J2ZMMC,2V22ZE%S!;1V:Q-*\_,%Y9>TT=@:
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M ,U7*(I+*88,+<S9.3%,Z0SQ]H2[ABC*B\ZLNAS%9$(9#KN(WJLDF0A2S2]
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MO(AR8?@4.X_ -8JOKEI2FE*:4II2FE*:4II2O0W;F7/P'8@<=9OF#Y@^<P_
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M22=!(9$5P&Y7V68AF]G>SU#;[FJRV ,-_P!"OL:+;O[Q,K=G6[:QX?O-!)D
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M^-2!KM VN,*MD&D1^!,6QU.RLC5F^1JM'5&*CX"WMZ1X7W(-YF*9H(,G#>N
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M/"-7->L3MP[C''EI$J9%UVQ9IS<D6-Q]K9R7%O<6K7';2*56.1)I6D51IB6
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M6-)$4@JK $ @$ @>8!(%>^IX8Q11+M?<DT^@5BNW_**[!SD.X1D8@A8+@M%
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M@1Y.?UX ?TCZC\ #^S@-144NW=TWLGP&_P ?^?E64D*/#?@/Z_KXUZG#H4S
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M#(X&]'7F>\#Q\?'I5!.Y&BY'D0H)[_'NZ:/Z5-D(QDB0A0:-ODE .?!(81$
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M["(_P#YL/Y&G;R^^?T^E/>C_ /.3_L)]G3L(O<'Z_6G;R^^?T^E/>C_\Y/\
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M($C19)X\=?0RW=JK]$-Y8LR7MGS'H!=6\))Z ;JZ7(<@'(<B B <]Q O &$
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MY"\@M(R1L(9I%1I6&Q[$*%I9#L:1&/A7*<7\2V/!O"_$'%62/_HN'\1?96=
MP5YQ9V[RQVL1(;]]=RJEM -'FFE1='>JT[;%\WW[<WDW+SW+=G@8VAW*M.*8
M^K#^>!@\M,U:R2*85^H(KO6CM0(:$4<(-DXPBBM?B!8HHI*2EAG)R1]J]).&
MPG!6-X=ML4K?M:"\%[:SF-/W4-D83V]P.5E=Y;@([\X/K,YD9V6&VMK>+XO_
M +-G&?&WIKS_ *1<CQ08_P"Z%UA_V1E+-9[C]_>9M;Q39V3JT;0PVMCVD4!C
M*_LVS2VBC26^R62R5S5&9?9@;1<7XCO5[L.5KIC>/J<'(S;O(5SG820KM?10
M.*C=25B6L!%*R: J'0CD8^/=(2TFNL@UCQ6DG"":D"S]-_%1O;<W%CBKFV+H
MLMI;P3P2RKK3B*=[B;LY#U<,R/&I^TA0$5O\I_8=]%TN(O;?$YKBJPR[Q3&Q
MRE]?65_;VTQ<R1&YL(L?8K<VZ#4+QQSV\SQ;83";VSJ]V2Y7?6:_8]Q.^O&5
M:?M;RY?8R.0AH.6E*?;LX.WZ[F AK)( U<EEL7X8FYXS*(4B*T^CKSD=B1X^
ML\\SK;)I71G\46V5](-EEN*X<?98^RX?L9VMFDC1[JZ2WY9[F)[@ >L2V\"R
MRKS@VUM(5@@C>66:<8/1O><'?V:<MPGZ)+SB'+<4<5^D#-8]<FD$\B8;A^3(
MB2SQEQ;8V1G6SCR%^]M;-K60OX"V0O)(;:VLK-OK+AH6(K<-&5^OQ;"$@H2/
M:Q4/#Q31!A&Q<:P0(V9,&#)L1-NT:-&Z::#=N@F1))(A2$*4I0#7@I))))))
M))).R2>I))ZDD]YK[9;N/W'\.G37EKPK2!M\L58AZOM)F<)S[VS9_?S5J<9N
MI];N$O.FE\;L8N[N9DV2($DG(Q4*]1>MZHE5G,JQ8/S/W: QQ'*HI 3Z)XGM
M;R:\XW@X@MH[3AJ.WLUX?OKNQ@MA#E9)L>D'[*N3#%-<1F-[UKM(9)(NS1C*
M4 )K\[/1?E,38X3T)W_ &2GRWI+NK[,2^D'!XK.7N1:]X3MK/B"6^;BK&K=W
M5G87$<\6$3#S7MO;7)N;B(VHE=D%7 KV\?<(KB2Z9(-.4.PBICJIV$6:;_&J
M\SC*SS^1JW5YQ0*?7+.O/M:=7*[87[M5;)Q&C^/G*^E[]?),73QLAK+G@/A@
M9NPQ(M\E:ZRM[:AVBRRP9:SM<5=WEN#?7=FELU_=W5K&@&(,D4MO='U:(R)&
M[]1B_3KZ37X)SW%39#AO*%^%L+E#"MSPF]_PGE\GQ5B\/D'7!XK,2Y*'!8K&
M9.YF>3BY8;BVR&+3]I7"6\UQ#'6RVYC+[*,QNPL&:,9U&%MV;;K0W&77#C%E
MT1CZ>PQDTMD2:TC3K"OC^'M[6>=#'I'3?L6'DWD#(RL.HW57;O\ 7KPE@Y)L
MK):X'+7UQ8\/6&23"(N9L#+?R9=[*?U(7]JN3GL6MD[5@T<DG:1W,4,ZL%:/
M?R>EGC>WLN%H,IQ[PE@\?FO2#G^')>-I9>#L]':8.#A*+-6)S!P>4DX9L,W#
MDIA;(PN8+<V\^.NKVQ>.1TN;KI[ALHGV%#GU5TP3R S9^.:=0@")QDK"QF50
MJI[@G N"+)-F4]2VQK&)03!JV2>F>-"I-2(=&E;A?$#TD#AI4D.,DD"BV:ZW
M-#/-AO718FY4JS26U^_JG4\[M&(Y-N6WV:^D[C%O[-Y])3S6J\300=J<C'C5
M6SO,?:<9C#MG%QLH=(H,E@(CE2H7L8EN#- %A6+5$SFZ#(MTOTK7,29(J8U6
M9W1X\P_5;BP@(>WQB%1L>"IFTV%S'*IN6[6<=M;E&N',=(&?*MBN&A6J@O(H
M%F:^PMN#\788V&ZS>*OA>V_!^4SMY82W,]C,U[:\1PV=JLJLC26\;V$J++$(
MU<JY=>SFY9$T&0]+O%'$'$EYB^">*\*</?>E_AG@?#YVVQMCG+./"93T<WV9
MRDMJZRQPY">'.VDLUK=-<O$)85A;M[+GMY+36C<WE:QX\B*E<\I4['9)''.Y
M]*=O$I4HH6^6K1C&]O,=0E#B(QW(M&D-+3\*K[W>M*\NI,.':B2<,DB42MS[
MNSX0PUKE)[VPPU_E#%E>$&M\=#>S<V$L\OC8\I<Y*>9(G>>"VN!V$<ETHMTC
M!:X+$%AQ68]+?&>5X7L<)G>,<%PL+KA7TNID>(;W"V79<:YCA'B.;A?'\-V-
MG/<PPV-[D\>_KMQ!BY&OI9W5<>B K"W=1MQ&8X)/#&-ZG+4^M154P?M)<0D'
M<)?'E=89)8W2K0@6UPK(W.=BK0\,U;IN("O(X[:O%FMC:$)-$<A(-6@VY'A;
M!7)S^6O8+Z[FO>(N-TGN+&#*74N*EQ]W<&R58K"WFLT#L5NKILH\:O:.3;E.
MR=ZOX<]*''6/3@+A7"WN$Q5GA?1[Z$I;#'YR^X7Q5MQ5;\08?'C-RO=9[(VF
M8G,42R8S%Q\+PS/#EH%2_$WK4, KB<SUN#8XXNF4%\JTV.A(W/V1: C7#1./
M:S9VF/\ '-@O2<@M39:]R2%;MM]<M(Z,*$))HMDW%?A'1HY-2?<+O5M=;\-\
M,R93'XA<-?RW$W#.*R;70FR=Y9OD\K;8XQ+?P8Z)KNRQB/+-_P"HA9V6ZN(Q
M*PME6->CR7I'])EMPMQ!Q?)QE@K7'VGI*XIX:3%&RX8Q&7@X9X6R7$:W+X&]
MXCNH\7F^)98+6TUC[N.)9<7CYVM4?)22W$DE8;@+'5KEN2O,WG>P(PIL6[>[
MG1ZC)4^N*3IF.1(>*03GZ[2+!:(F+A!A7LNWCK.M[Q0KK*2FV\K<GBR<0@DZ
MDR\,6M[8<*8ZVX<M3<#,<3V&1OHK^Z%MVN+GG8VMUD+:SGFN/6(X&ELU$374
ML5NT-A&IG9DUUOZ2\KA\[Z5N(LAZ1\FF./!WHRSW#N#NL'B6R1MN*+&R1<IB
M^'\IE[*TL#83WT5KEY#<Q8JVNK^*]ST[K91I+,<?[C<]Y'7HU$BLB0D5*V#<
M;EO$:]]5JU'M;M6K4_$$;D:->G9U676HSV?;O';N/3D(%^>#6!-HNY9O2I.F
MKK#D^%>&\4N1R,V+N)H;;A7"9M<:+S(62"\OLY+BI8P][ N1CMGC1)3%<Q"X
M7;JDD?,CI+X8]*?I(XKDX?X<LN*,?97N2]*G&_!$O$CX?A_,S/A\%P-:<5VD
MY@P]\_#UQDHI[B:U6YQURV/DY(9)8+@)-%-9;)VZ')V1\&/(*XY(IN/4+!M.
MO5E?I.ZQ''6S9<1O-VQE(52OB]D&YHEZ$3 ,Y,C.M"H_9REA)(+,W$"R,SUO
M\/P?B,7Q#'<V&)R&4:VXUQUI&R7DH'#]@,?CLO%>W0BB<31]O<R0F2[Y8I(;
M4Q*ZW,@D' \7>E[BWBGT>38[.\5X'AB+)^A;B'+W*3XBU+\?YT\0<0<)W.&Q
MAN+F(V5PMEC(;P08DO<P7>46YDMY<;;F W689+O]8NEAKN.7M8ITO<<X;2L7
M/[.K46,T\4A+CMD]ZO'LD@JX9C+R46]8M%H=1PZ2*W(V39*^*Q4<(*Z:7$XR
M[L+:ZRL=Y?P6'#W&V8BLUOI+>-;BQXO[&..%@DG813)*XG54;F+F1>60*R]E
M;\6\2XG/Y;%\+7&(P=]G/2%Z$^#[C+OA+:_N&Q^=]$:7D\]W&\L!OKNSN((9
M+!Y9D$2Q);OSVS21/3MOW@9SB*S4ZV:_U>'N:C[<-62W)['8UJL;:[;B[)<5
M2:8I85,DV"!J$!79*/>O'EF0J3J4M"#ALB[8Q*<:"PJRK'@;AVXN[VZ&,O)[
M 1\+W9L(Y<M>2V5EF<1-D+\6HQ-K=7US=12QQQV;7R0V;*[1R3&;EY=7G/3C
MZ0['$X7%'B7#V&>>X]*&)&=GM>$\-:9C-<(<667#^!;)OQ9D\;@\;B[JVN;B
MXRT>%FO<Q') DUO9):"3M,U,_91MV/8? L&WR+7Z0SR-:$:S=\Z2\9!O(. 2
M84:7L"3QHWE%&]49/;Q,Q:$?%.I(%8EHFZ7!%FJ<6YD> X:P]CDY^)+A\5=9
M"3%6;7>/X=@FN([BY:3(P6K1NT(:]DCQUO,TLR1<LSE%YI%'-S>^^DKB_-\,
M6/HWQ\7%&,X?M^*<Q'B>(?2'>VF/GQ^-2WX>OLG'-!'>/%AK>XXAO[..ULYK
ML26<*32".!F,31XF8XFKSGC/>TVX7RP0<TVB*QN%?PBX4B'5A+.GCW)$! QN
M18!O('=&A'UVB"P#]G+1IO$AE8H[RO*I,Y@R:7:96WQW#?#?&EACK6Y@>>\X
M7BN%.1G6XLVR>)NKF7%731!!<1X^X]9CD@E&IQ,$N@9+<$^+<*W_ !#Z1_21
MZ%\YQ'D\;D(K'$>DVYQ\@X>L7Q^77ACBS&XVTXIQL5T\YQ]SG[$8VX@O;0AK
M%[-I\6R07Q5([RKU=9?,<K,T&!R'/)[1ZQ5;PFM4$4C5AO?Y:Q05YM#*^*#+
M,55HDF'JZHR0;MV4NJFK:'AE6:12E%Q7@3'8^#!0V^3N<7;'C>\O,>5OB?7&
MQD%K<XZSEQH[&0+,<[=!W9Y(%(LH^61NO(].W$.?ON.KR_X:QW%&27T)XC#\
M0*^#C1L1%Q+>Y3'<19B#B-O7;9Y+->!<6;>**.WOG1\Q.SVZ* 9K>96N6&K+
M=]XMX=7ES'9)<U+"5CVQ&@+C,Q-]>V*P83AI>L$I%<A)9%_,I2M@=0*<RW;Q
MK]H"#Q07PI$.*H;3#6&=M,?P)CDQJ2XI+[B&TXN%U86\V.CM;;B">"\.1NKB
M!H[<P6J71@9Y8WYHP(]D!:Y?C'/<"97B'T[<13<12VO%4N%]'V5]$1QV=OK+
MB2XRF3]'V.OL.O#V+Q]ZES?QWN4FQJWT4-I<P=G<.9^57+UVY&RSD4<MQF?)
M."R(Y8[9Y;$5#M\Q76C=3'B(+P+H=S[>PD)*I*>^&CJ^P\='G:0S]NR<5$@&
M5;D.=0EN*PF+&$EX:AN,6LG%L&;R5C!=.XRC<ERG]SWM6,)'82)C9Y91)/$T
MB7QTK$ '+Q3QIQ3_ 'UM/21>8[B>6W]$UYP1PWG+[%P1-PNG:8V8^EV/)JMZ
MC^O0S<26%K:F&PN8K>7!#;QJS,L(DLJ3<JZO+A4D!55]_<S2U<M15HL#R>$#
MT*"D('$DK5B*LJXCCR]/GZ#-*QB^EED9-^NS4AV29F+UXF[ \)ICU!N;U?1K
M#?C"S6=LEM[.4N8KG-PWA$ETV4QT43N;41P*T,2R"XD(EC2RR%XOI8FXBE=<
M;AI/[2F0P#\:V>8R<^2(;AO'76-X)O,.KV^*3A?B*XN(H$RIN;YTN[F2W:PM
MT-O/<[LM?/\ 7Z 5R*4QS 4H"8QA "@'<1$?0 U0D*"2= =2350"Q  V2="J
MKCV!&9077X%42B8!XYZ0X$! !Y$!Z@,''(%,(\\_  UTTQD.NY >@\2?,CQ/
MD/#[ZV,4(C&];<@[/P\AX#X^?W"L2[%EJ\9RM$WBW;M)$AZW7Y!Q 92W!':-
MI")K<@W/X,I2,5M'A%&%OR,VY,WF)A<CBI4-7J3D"S-A)[A;]%:6%CB+>+)9
M^%KF:=%FQF!#-$UVC E+O*2JR2VF//VHX(P+N_TR)):Q:N'\WRN<SG%=[=<.
M\#W(Q]E:3/:<1\<]G%<Q8V12!-B>&;>:.2VR7$"]4N+RX$F*PI):=+V\"V27
M_P 78@H^(H,T+3HM5N=V[/)ST[(O'$M9[;.." #VPVVP/U'$G/S;Y03'</I!
MRJ8H"5!L5!JDB@GJ<GE\AF9Q<7\P<QKV5O!%&D%I9VZG]W;65K$%AM;=!KEC
MB10S;D<&1W8]5PSPG@^$;%K'"VK1=O*UUD;ZYFDO,KF+^0?O\EF,E<M)=Y*_
MN&VTMS<RNX&HX^2%$C6YQCE(')A H  B(CZ  !R(B/P  [\CV_3K6_KX=.O?
M71D@ D] .\FI [GT$A,1L47)P$0Z@$"I!V[=^!,8.?B  4>_RA[:DQ6S/HN>
M12-ZUMOD.@_&H4M]&FP@+D>/<NQW]3WZ[NFZIU>4D'0B"BQTB=^"HB"8=^.P
MB4>HP<?C#W^(:E+!$O<H;XMU[MC>CT&]]>E0)+R:0$<Q3KW*==#X;&CTZ#J3
MWUK%]KAGF=V];%<PVBI/EXVXW!.&Q=691!4Z3J,>7Y^$5+2;-<@@HC(1]5)8
M'<:NF(*MY!%LX(8#)<ZZ'ARR2]RUI Z@Q*S32KT'.L(#!2!W@N44CQ5B.[>N
M>X@O'M,1=S*2)6"P1D;VKS$J6!ZZ(3F8'P90>_6_BQP*YI4I'#BF]*M8EE+V
MRMSU4L3DB:WE+*L_95F0@'KVSVACCZCUBP0<FO*V2_R]3M4C$N:I  #)>/*Y
M1#V"ZAGA!O(!_APO#+&![)MPID#JD2"::6.1$$<(F56#-OKH-X]9SQ3?^AG(
M EN(WAE;1;MV80B-FF=8((Y%D8R3M',^U0<H'M"69EJ%W4OMBM<Y6;!'1=SF
MALT'+2C"-(S?5^V/99S4Y!63K43#U54LQ&1KQRU<Q$=%QTD1@_>QT<@S3,1*
M^+(6%EC6N))5;U*TE>6%.;MV>VC7M((XI'=VE,CQ0\O-L/-&NU+J*J,9?Y7+
MQ6D<9C?(WD*17$Z\MHD5S*W)<W,T42K':)%'/<2SK&.6WMYIC[$;L+@[<,,8
MDR<ZN+;)-S902,7 .UH0%U7[(CR<<^$QA&IA;I&7*T4D7B;N5?K$(SC86.DE
MU5"+F;G#Y>]/WI5](G!>1X<M,0#PAC,ACKV\DRM]8665-_F([GL;3#=I$V2M
M+:)!)!<7*L\4[VKF9)) %1_M3^RUZ#?1+Z1<1Q9?<11MZ1<UB\QC\<.'\3D<
MG@UPG#4UE>W>6XH=)3A;_(2R0P26.+'_ -K%?(JSQSK-&[?4K["G-DI>]L]W
MQ%)33J;_ .KGDAY2ZG*KN/'<J8[GFH3M59JN.1,J6(>A889B!>$48B/C&S<I
M4$2$+U"3Y3*83AC/YRP&-RW$/#]AD<KC^Q,*6V1DC'K'+"^Y(!<1M#=-"^C&
M9R@T%('E>3M,%@.+.->%>%<L<YP]PIQ7EL-@\N+F.Z]=Q-O=2K9N;F +%<]D
MJM;B=!RRB$/H$UO-;S;YN)0,(.4@  ,!^ 4'@?4#@'(CQZ";G]/'KJ$UM&V]
M$HWAKJN_#8\ON\!Y[WDBOI5T&TZ]VCT;[PQZ; Z=?A52LIAJ[$$^H4EAXX34
MX 1$?@4P?)-^CT,/XH:AR0/'LGVEV=,!Y? =?CU'<1XUL8KJ*7H&"M[K$;_#
MP/X'^8J:&*4X" AR \@(?M =8JD=X\1OY_U_7?5C<D84:6>6;WVC2RF/,N1;
M8K:.N\6W*NA,L41%1.MWR$%1!K<*LLIV%D^.21BS',[K\G$O.I8^UL\I)!"U
ME=1K>XV5PTEG*3^[?1';V<@/-:W"AB0R;CD&UFBD4@#57F)AGN$R%LYLLG&O
M(MY" #/&""+>]CURW=N2![,A[2+6X)(VV:CC/+CBR2S_ !YD*'3I668%D5Y*
M5L5SN8BQ1)5?+EN-"E54T??]5=+=*:O4FE,0#Q0L9/L6;@S59[BO+$0HMW:R
M&YQ\K<L4V@)89.I-M=HHY8KA0-CE8QS+[<?3:K*MKHR,8)U$5U&NV0?9E4<O
M-/;\S%GMR6 VQ+HP*OUT37!CQ<D5ZZ@W[*11CW[J+D2L7*3H&,FR/X;U@X%%
M13P7K,_R7;502K-S_)5(0WR=6Q2.A6.963F17C+J5YD??(02!S*VCRL-@_<1
M5)HU;F>+3:8JX4[TP )Z#Q&_:'F?,'7BU*J)32E:#\O;Q<E96WFQN+<93T55
M*=1;\%>1L<Q* R@FK*J>?_I#MTRHJX:,DFB@-Y-)1X+HCI:K19(*-78)6>RH
MS/T5B^"<)@/1]<<09U'EN;W%F[DB1%[4/>F+]F6D;$,=CFA;D*=FEW,;F996
ML[0P?GCQ)Z;N->/O[0F.]'O 9CM\=AN*1B(;IYI3"\6%6Z;B?*311\JE6,-V
MG;*[3S8FR3&V;VT>8RR7^=.4O9X;;]PN097-,]-W1V_NC"*7>'J5JB2UN468
MQ[&.:S;!0\-+*\N8U@V0.1I)&C5"@9=!NFL85=>?X+TJ<3\.XBWPM@F--K:/
M,8'N;622=(YI))FA+)<11L@EE=PS1&79Y2Y4<M>^\=_V6/1EZ0N+LEQGGY.)
M(\IEHK1;Z#'92"VL99[.VM[.*[2.6PN9HY6M;6*%TCN!;D R+"LK%ZT$YQ"I
M[7=UDY0]I657M[O&.2I3%CMRX.6]4V]$4<&9/&.1Y^!79IY#LY%54(V*QY7B
M1J4[)O0B;:JT1CI:'D?0EX]S/'>(@X<3 6AR63YH+F60+-:O"@#&[MK>=7]4
M*#FD>XF>;U;D#VY>62,Q>)P_V=>"_0+Q1?>E;+\?YFVX1X9$5[B,=:L]EFGO
M9F9%P^0O[.2+]J17#<D,%G:0V;9(3&*^$%K;SF[^A?8-'TVQ80KV9V<Q<KWD
M?([1TGD7)F3I!*8ODW-0DN^CI")3.V31A:O36$DV<KUJD4YC$5.'9KIJ-XX\
MDL^?.O%N*\+<\.9R]PER\3FR:+LV@4I#)%/#'/%(%8LW.T<BAS(6?G##>M5]
M@>C+C_'>D[@G"\:8NWN+.VRR72O9W15I[6YL;RXL;F!W0+'($FMW,;QJJ-&R
MLJ@DBJNWX.W3':+G%TR<KLW2-6:"DY;+*-UTA-888AA(LB8BB?40QB&$I@$2
MF,4>PB [/T<(DG&_#R2(LB->/S(ZJZMJVN" 58%3U (!!Z@5R']HZ::W]"/I
M#FMYI8)DPT)26&1XI$)R=@I*R(59=J2IT1L$@]":Q#M^:Y+;]A^K3.WZ3PA:
M9.5MV4$[/1,.6&6RA5W[6*QF$T[O2EA>C(SL8XQ:C'5V=L\,0S9C*0\JV9"*
M;J18N-=Q8</Q<39R\M^)X>(;.&&RPYL\CG;6'#WD;SY?U=,<+6/LK>9,RTMW
M;6EQIY(9X6DZI#*E>(YOC^[]&G V&OO1E=>CW,W=YF^+TR_#O N4O>+\/<0V
M?"0R$_$;92?UO(VDO!\=KB\AE[ &*WO+&]B@)2:YMI:[;QNOR;7[S;(BN9MH
M\\--?;80HE'-4(,T]N"9Y9AZ<6VN(5R@[0?-FH%E75F:DK4:JO%A()(NG2$8
M5FB-,=P7B+K'6<]WP]D;87T?%YR.1%]<BVX8DPD]\;%+A&C9&<F%+-VNY@LW
M9LT:&;G:KN(O31Q;B^(LU8XOT@</9(X*X]$(X<X=;"8XY+TFP<:6."&;EL)8
MYXKB&'5Y-EX5Q5J\EGZRD<LT=H($J8QFZ?.TK<,IK%FZ9&1]67W(1*]!E9''
M#6>JZ6,:U:']#EX2N#.&R=.RZ[ZOL'MH/-0RE;>Q,LN_B6S%BS366PS<&\.0
M6.&4V]_-)>+PK,N2ABRKVUVV7N[./)07%V+<8BW@2.ZDBLQ;SB[CG@6.=I))
M"%EVOIB](MYG.,77(8&TM</)Z5;.7AN]N^%H,EATX1Q.8N>&[RPQ)R+<79&^
MEN,9;7&7-_8-BI[&^DN;.*WMH$D?BYLF>)&Z[,)>U[F6U3/F^B7N:+Y:FUZ&
MJ32<GZWCN5@:>:$D)?W;<91TO.^Z*VI,F5E2O$5U89N5U).$1JEIPW%8<>P6
M7"3WO]W\EC;<<]_<W%\]O:W>5AN;X7$4':V,*+;B:[$ 6!D95G8I$C5;-E?2
M-<\0>@6]S/I;BPI](7#G$5\.RP6*L,)#D<EB^%KW&X(X^[O3:9V\GDR)L<2V
M0,EZ)XY7L(1-=2QU3^$=P%RJL-M)A33-8A*!=*O6X8U'Q\QH9[,M=[+?K?&-
MBS],F'Z%IC*%,L8Y!*/LM'15)#3",X^GB.&2)$0D\0\,V%Y<<;7 @O+C)X^\
MN[C]H923)>J#'VF-L9G-M?P1-9RY*"65FEM,BP-Q UO';%9&).L]'WI+SN&L
M/0GCS?X?'\-9_#XBQ;A[ABWX;;+OQ#E^),W:1#)8"]N8LO:<-7]O:HMMEN'H
MW%A>Q9*YR*R6\:H+R[/=PN8<S6YNK<YRFNX2;H]DL$Q4$);'K6U4*SQ-NCHI
MK%1E7@)U[?4:\U82"T5.K9!BTI-";;QRZ;QLG)$CS:+CGAC!8&Q9;"WODN+?
M(6EK;WS091[/)6<UE-,\\UY=6T>-:Z>6)9K88N8PM;M*IC<PF6N\]!OI.XXX
M\S<;Y[(8*;'Y#A[*Y.]P4=[PS#F>&\O99NULXK.TP^.R-QQ*F,AMKI[/)/Q-
M9QW<60CM)%GB6[%LU'1N1,E)Y3LF/<<3=9QXYR+O/S!2IFQHTF+G%_=M=P15
M[BE*K,'+AHC(6([EH=(DD[7,0QO*>>;/F;8[%>=-BL2</:Y/*V]WE$Q? 6"R
M$%JV0EMU[6ZXCN[%H5E1':*U"."8D78'/V;QR.)%T5GQ1Q8O&&7X9X5R&(X7
MEXG]/?''#]_E(^'[/(2FTQ?HWP^=CO)+:66".YRAFA*+=SR%3J'UB&X@B:WD
MN6EN.R678M$YU55A!R"N5C"R]B4AC&@(8@Y2#'<S?'L$W<$)Y:'B$W-H=,2+
MIQZ3A$P+%3C$U4RZEN%<3_\ 46;AP+<?LQ3)<06HG'K,Y_8W[5M\;'<LN^>>
M<I9I(5,K*PY29BI/6)Z4^+!_9VL_2*[X_P#O-(+?'WV4:P9L;8+_ 'Q_NM?\
M23XV*508;&Q67,3VRR+;))&W.$LT=5LD]R=:+[?\6UV7O$)ERL8\WKXYA:AE
MN!C8>/CK>A,X'O5@FXE3[FU5:T]>U*4?&BW;R&%-)4JR)'*1'*:G.^7$6>,Q
MN8NH,?<82\RGH_REQ?82YEGEEL6@XDQEM;3#UM5NXX[V&,3)'/S,I5BK%"*X
M&?B[+\2<2<(XN]X@Q_&N(X8_M <*V&#XUQMI8VMKFX[[T<\29+(63?LIWQ5Q
M<82\N&LII[ JCAT65%F1Q5J:+N6R;&4[;_C6CV^C8J/8,742;C$SQ^,*[6%9
M&TY?NE?M:LE_2%-Q*WD(BI0)Y&!C<<QD_)N[,X,UF42E?Q[8^[R/">(GON)L
MMD;'(YD6N8R5O,PES%W>"*SP=A=60B_9EM..TGO;D17,V5FM84M%#P.3%*PX
MKA[TL<6V>#]&?"?#V<X=X,;*<'<-Y&T1K7@_%8AKO,\<9W&YE[K^\^0LI#;6
M>%QSW.,M.%K/)W<^7D:'((!<VT37[@]T.57^1(A$+Y5I&2F\PYCQO/[?6]=B
M4[+CFG4&)N"\+?7\DFZ4LOCE/78>3EG<LC]SDJWL:;2):,SID.'-7/!^&BQ4
M[?LZ\BBM\%@LM:\3O=3&TRM_DI[%;C&Q1%%M.4BZGAAC@8W<+6IDF>0$@^E8
M_P!+_&-SQ38QKQ'AKJZO^.>/.%LEZ,HL79+E^%L%PU99N2PXDN;I9CEA(K8N
MQN[V>]C_ &7>Q998+*&!E1A0#7='N4B<:O[3)7.!LLO:-F3C<-7TV=!BXPM/
ML4'<:O772)$T7#P)Q@\AIMQ*2YI),$$9!LJO'-HR,Z6"6T?@[A2?*QVD-A<V
MD%GQ\G"UT9,G-,;ZTN+&\ND8EDC]7ECGMEA@$3<S1.%E::4=JW,0^E_TKV7"
MESE[O/8W+7N7] LOI0QH@X:M+,8/*8_.X?%S(%26X7(6TUAD9+R^:Z01QW4+
MRVL5I::MDK^Y[PK%)6N^L:%E"EQ^,C9?P#CZ-R^DP@YZNT"NWFA6:=N4^>3<
M*E@7ZBEIKZ%<0D)]PO"PKU\L@Y JJ!4BZS'\#6T5GC9,EA[^7+C!\2927!-)
M<V]UD[K'Y*TMK"U$*#UJ,"SN6NVBME6XN(XU9=JW-739[TYY.[S/$=OPWQ=P
M_;<(GCCT:\,VO'"6^/R.*X:Q7$/#>7R6>R;7DCC&W+MF,9'B8[K)RR8_'SW,
MD4VI(@@H"U9HMF.;WG*[TNX0=U?6&O[+:J_RRR85]E7T8*S2F3HV3R W;R,J
M%,8I*I 1!B\EI8E2:/Y)J_=J^ZDQ1-L[+ 665QO#N/O[&XQ\=K=<?WD6%DDN
MGNFN;.'$S0XQFB@-_*RG;21PP&]>*%XXQVQYJYK,\?9KA7B+TA<0X'.8[/SY
M/&>@3#W7&EO;XRWQD>-RU[Q;:7?$T<=U># VR.G+';SWM\N$@N;N&XG?U->S
M-8'W+9>%I1*];LS8TQ;&S#3-\P3-138VN;&SEH#V!+3:B[7B)E_CF-M:\?-/
M'=MC89PJ[=C#E;P:46NNJ P?[I80/DKFQP&6S,T#\/0' :RMA):')QW)O[U%
MGMX\K+9K+;QQV,MPJI&)^:X:8*#6];TL<;]APYC,YQWPGP?:7T/I!OEX^YN%
M<];Y<<-SXX8'!SR6-_<\+6N:>VOYY\W:V$KSS^H"/'I9R2.IL_<,J9ANIK1/
MV[)[2DJW7V?S3*1</3=?BWM8MSY@POSRUUN&K4_( =5:980;RQ2DHS1=V2.K
M4LG&NE5(N$;+AO+'#8.P%G;V.(?(+C_2;)ASG;>ZECO+&.27&1V5W/=VT6E6
M"6X2UAAD*6DMW 9D42W+J>%SW&/'.>_;.2S?%\'#\F>_LS0\9#@;(8RSN,1G
M+BVM>)I\UB;'$Y2Y)9[^WQ\V4O+R".?+6N)O4M)9'L\=%)7/*V8K1:TX^@2]
M]J50A*=>MF,?5\-)UV.2G+G%S@8YN+^Z1<DH]3EF\=$R[A6/0)&-7,"PC8E2
M+D$B2KYJ[)3"X*SLC+DX,;?7UQ?8WCV6\SQNI6MK":W_ &K818^:(1F%I9H$
M65NV=;F26<31$P1NAOXSXZR^:%MPW?<2X3!X_!<1>@:UQ' :XNU3(YZTR/\
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M$L=\58*$65CEUH>*57B"E+$K*Q[116+*0I2E+'*&1$[(I2D(4H-A2 I2E
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MW"ERL\RF0H9")7!<QD&,N0WM%" 4YM\I (T0*M;'8]Q"KV%FZVXF%NK6L#"
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M8/DIF$1^2'S (<<!WX'MSW*&HEO+S#D8^T.XGQ'E]X^/>*R7$/*>=1[)[P/
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MAKA&QNF@N #E,Q=O$;K+R(?8MF:W?E6P;96?DY5>V,]K%;Q/=27B^@X/T/\
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M?T^M*:;/D?T^M*:;/D?T^M*:;/D?T^M*:K2FE*:4JTDG@C$$S=@R)*4*#>W
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MEPP)V+6"24=PZB1A&AWUUUT-;WLUN;?@/B&X',;:.V76PUU-'&?NY%+OOXD
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MYBYE,BZYE&B.FR/#R[M?T:EV5P%/9,-*?LG?V3X#KX'S\"/'?2M.P\^@_/\
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M4.<YCT190W(B F-5#J>82YA#+)Q\;+XE;P-=6@472@F2%5TMT!L\Z!?9$_O
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M.\QD=6T3R$D[T-;CA3)R02?LZY<&&8[@9B>6*3?1 2W02=P4'7-RZT2=_5:
MCT@(<\\ /S#SQS^H=>9=/ ['GYCSKT =&\M'Y=?]JKN(>@[:%.<?OI!\)4!]
M>LO( 80_]\.#<]P[^O;6LFC,<C#>U8[77=K74 _#Q [JZ"VE$L2MOJ!RMY['
M0$C_ ##K^-4)F3'S3)F/9VKKKS;1R)HR<A7E;E&\+.LK)5Y1E8ZV[BI9TRD6
MT>\0FXMB8CIPQ=HIEZ_%04()BBMY##,L@Y6&F1UD4.A213&^UV"0%8MH$'F
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M=-)(01Z$CB54W')S'.!CG5$! >D%>!*  !>0$O?;6\I ZG^(]->8 \O&ILT
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MPZ%926BXROUNKMI TNG78"*0,*3+WHHSCU'RKN2<R,LY6\FU3*ZD5TT$")@
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M@TDXQXUD8Z0;H/&+]DX1=LWC-RB1=LZ:NFYU$'#=PBH19%=%0Z2J9RG(8Q3
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M((%#QS@#'9'AFVQ<%_Z)K^[S%I>R2G/J+%)XQ+._9R!FW.JVT4@4^WHI&2-
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MYCRNFSQ9F9DNDL:UKIUY(8X)6E"J'0\JJ!RJ@)<<PT>4D$;V#KPJUH@2TC.
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M .*>LR^8_**@,R__ "A _P"$3^\!]?\ ]N-/5HO(_F-/69?,?E%<1F) ?^W
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M!^.J?=5>ZOEG]M=NBOE@RM&;<8^(GJE1,<)1-TD'<DW78!D2Q2:!TXZ;B 4
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M_P!WGN \<P)I>S0A?MN-*?(>)/Z>!K/:0=J^V^PAYF!!ZZ[AOIX[W]W=UJX
M  !P < 'H >@:UM;VL!-V>:Z<YD!P*PD*59[FZ8,[$]QI8UY%)G='322C5JO
M137NH6-M+X-O<G:EZ<[H-NN,-[GF)R2@8NO!)2SHXQNRL;:4 WA$J0JW()X>
MS,D9(/-*L,Z]G=)&I;M(XWYP.K!5ZF%=3("+<&-I74MV4@;E< Z52Z'<19M
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M"[O;M8Q<Y"?#XZ:[N5@"B(7%U+;-/*(0BA!*Y[((H4*%&OF"RU9X+='/Y?W
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MTP26*W_#V:Q]]-P5C<W(RRX*ZL[VWX>N[R[QV-C@OH[JRAQL4LOK+6-S=5=
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M2BKT)E33!(.")I]1>3& 3]!"=:@B(\G4Y.8. $P@4-91,._V3H[Z$:\._O\
MA\_G#>Q&P-=X.M^UL[^\;Z;'RK+G:MLSS1O"F$([&$"YJU*8/B,+=F&?;O J
M4:U.D8LJU8_?"!9K"43%*Q@( "*)D4*,Z^BVRY) L.]RL5J.K\TVMK"OB/ L
MW4*I/0D^1T"="H,\<$(*L5YNND4=1Y-O?31&^[K\!UK[1=NN/VF!\54G$"5H
MM%Q84Z)3BFUFN$@:1FWH^*JN;QC\%08QR)UA;1$2T*5E"Q2#.+9E%NT(8?/+
M]3<RR7*HB.[%WC307XA5  [ALGILDD[.Q5+6ZY=1R,6!(Y&/D2>\]!WD@=W<
M!TJ_+]@C(I 41*!P#E-4 Y$ ^D/4OZ/C^C6OBE:)MJ2!OJO@?O'3Q\>F_.IT
M\*SIH@;\&\1W]WSKO9LTF2)44@X  Y,;CY1SC^&<P_$3#W^8 X .P!JCNTC%
MF[S^@\ /@*OBC6) JC7B?BQUMC\3JO48.0$.>.0$.?FY#UUC/<>F^AZ>?PK)
M6*E?P%)I9GF+_D"S.<@5FLN5YO#;"SQ-$DW]&>VLJ8V]BWG/N#:7DI(Q[$LW
M%?<KWI\T/%RC2*<1*:]/B)->8UT#;K%#'V+NH2Y,9D43!".3:%S&-@^T%1?:
M7>SSMN.(=2F1VYPNS&&5-H6^UU"!M=.GM'O/0:%70O44C=J[::RZ/X3.RUZ:
MKBIR@;[VUF8QS&+*  "4PF!)R8_82F[  "40#C88V5K"XM+M!N6VN8+H ZZO
M!*DJ+UV-;0 [V.I^ZM)G;./-XS*XF5BL&3QU]C9&&]B*]MI;61QHJ=A921H@
MCIU%?*1MPJ^.ZAGW(^V7=+4HF>QUD:+M.%,A,)LH(-8F58RK:1@+3&NU@;O&
M3MK,038\!-1JC:28^]&TW%J^.W0 _P!=^D6S/%W ]GF<*[R2VS6F;LEC!=YH
M986BGMV"<P#I%<%Y%;:A[=HGY=DC\EO[-V??T.>G;*\)<6*EI%D%RO!>5FF(
M@AM+ZUO([JPOP9NS>2UN)K$0PE=&6#(1W,0DY45L*%]B.[:B[M;9[*#'^1+*
MEMWSE;*KF:4L:")%(.9PO7!?+M,@21TDRHE=12(EK\]%-%VD79<@URKL516;
MMX)8GS4;JW:!;^2,"X@#0\AV&68GJFCU'7;*2"R(S^):OUB6-BPACDYK:8+,
M)%(93$>H*N-@AN@'*2K'E(V#U^@3>Y4,98IV[X-V"8'C&$9)S4]4X^O51FJ1
M52#IM?4?/).YVY5$HKE&4G!-,S$V^(F,DHC:9YPN(1SPVN[]$UM/!E,IQE?J
MZ8K#8^[#W++RBYOKA42.SM=Z628Q,RB-"2KR6T07<Z5\G_VN,S;9;ASAOT0X
M>6.XXLXWXAQ+Q6$;\QQN$Q\LMQ<9?)*@9[>RCN(XG,THCC:VM\C==IV=A/K/
MS9YB1KAC!\-56"[U6.D9JQ6N)2D6BK%^S@[#)JNZ^V?-%_\ *&TA[B+'.))N
MX*1PVD7#MNL7Q$C&-Q'&V;DSV?GO9A&)H[>ULYVB=9(Y+BUA6.Y>-TVCQ&X[
M58F4E6B5&!T:]K]"W!=MP'P%8X2R:8V4]_E<O8Q7$+P7%OC\I>23XZ&XBE_>
MQW(Q_JLEVDH$J74DZ2@NK$Y1:Y*O5ZH7(F2J;BJNA:;S*K140I*14&T\I$S,
M])R4W./$V$1$1,'7H^5FY:3D':A46S*-CW3@_P M04P234.38XO$W^9NO4\=
M"LTXAFN'YYH+:&*WMHS+///<W4L-O!#%&I9Y)I44=!LL0#SO%'%F!X,Q8S'$
M5X]G8O>66.A["RO\E=W>0R,ZVUC8V6.Q=M>9"]N[J=PD5O:6LTC>TQ4(CLM:
M-G"3MN@Z1$XHN44G"0JI*MU!26(51,5$'!$ET3]!@ZTEDTU4S<D4(0Y3%" Z
ME'9&US(S*VF5AM20=,I*L-CHRDJ1U!(ZUOHI4FBCFCYNSEC25.='C?DD4,O-
M'(J21MHCF21%=#M756! ME.YJQE6K#-56;LODIZNI4A:88>YY]R+1/(TR\K]
M--YAG%N&CCWQ+L'33AJNL,?X8+R@,FRB:Q]M;X#+7=K;WEO:=I;71R"P2=O;
M)VAQ5NEU?CEDF5U[""1']M5[7?)#VC@J.2R/'W"6)RE_ALAEO5\EC$X?DOK;
MU')2]@G%-_/C,$>U@LY8)/7KZVFA(BDD-KRB6\]7A99#=/6GKL::4II2FE*I
M&B7NJ9,JL7=J3*^^JQ,C(%C9,&4A'^9&+DWL.^#R<JT8OTO D8]XWY7:I IX
M/BH^(@HDJ>=DL;>XB]FQ^0A]7O+<1&6'M(I>030QSQ_O(7DB;FBEC?V7.N;E
M;3 @:3ASB/#<68:SX@X?O/VAB+\W(M+L07-MVIL[N>QN1V%Y#;W*=G=6L\7[
MR%.;DYTYHV1VJ[4&MW5#KY)HB+FM-2V>,>JV^QRE1KQXI129:OK)"-Y)S+PY
MWL2F]9L'D82'DTWQ9%=H1L[9JL53E>]+<VP7%9%ENW-I-&+&UAOKH3 0/':7
M#1+!.(YS'))'*9X3&8E<NDBR*#'[5<])Q7P['+BH1E[2=\WE+O"8QK)FOXKC
M+6$=U+>V+3V2W$%O/:"QNTN!=20K#- ]N[+/J,VMOF/]O&0,KQU:O=;B9W)T
MA15I\D<Y0L"2<Y0:Q8V3026 6)F];L$5&6*P-@;0=C._-XKY9=M'G;E=*$W&
M-R7%&,PTMWCKJ>VQ$616V,R-;$VV3O+61P;7M UW:SS6MJ_/<V@C&HU5Y0Y0
M'C^(^&?1?Q-QG:XGB/$V61XNNN'9,DMK-'DT3(<-XC*6T)&3]7,6*R=G:93)
MPB''Y5KEN>XDDAMFB$S+D2  4 *4 *4H !2@     <   '8  .P '8 UR_?W
MUZ@      !H =  .X > %4TE3:PA<7M_2B&Y+C(UV/J3V= ZXNG%<BY&0EH^
M*,F*PM@0;2,H_=$.1 JYE')@45.0J9"2VO[MK&/&-.QL8KJ6]CMM+R+=3110
M2S \O/S/%#$A!8KI!I0=DZI,%B8\Y<<2I91+G+K%VV%GR(:3MI,79W5U>VUF
M5+F$1Q75Y<S*RQB0M*P9V4*JU-J)6VII2FE*:4II2FE*:4KU,?ZXU_VA'_F%
MUCE_PG_TFLD7^*G^H57VM76TII2FE*:4JC9K^OG_ .[3_P##K8VW^$/O;^=:
MZY_Q3]R_RJB;96(:[5>Q4ZQ-2O8&U0<I7IEH8""#B,F&2[!ZF'60Y2G,W<*>
M&<2&\-3I. <E#6PL[N>PN[6^M7,=S9W$-U!(-[2:"198VZ$$@.HV-C8V.XUI
MLSB+#/XC*8/*0K<XW,8^\QE_ P!$MG?6\EM<)[08 M%*P5M'E;3#J!7S65ES
M>_9IY]ME.R;4U[OA_(L<>O30@R*O!9$H2JBI?/1[21$D,_F&#"2=LI>">JHJ
M,W+IRP7=C#OC#+?5>1M\5Z8>%K6XQUU%9Y?'LTBPR-^\L+UT"R07!0-,MK.T
M:O%.B.LL:*ZQ]O'^X_*OAO(\5_V//2IDK'B'&7F6X1SJQ0&^LT9(,YA[><RV
MV0QPG:*SDRE@D\D=U8S2PSVMQ(T?K*V4X:^G^QH^P+V?[K.>0L.W"V9QR;F.
MRNFV-J,PQS:(BX4O&ZKOWG6<0A+S)'[%\Y0EU$ONMMC204/82Q, NUKKAS$I
M)/O*I/1=QM>W$4.3MK+$V%L"UUE;G(6;V:JNA+=!(INV.TV8HFCB VPDEB5F
M9/K^[_M;>AJVQ9N>'<AF.*<]> +CN%,9@<Q%EKF[D'[FQ>2ZLDLH@LI"331S
MW+:!:UANV"1R;!=IN',GW?*]SW&Y^@W,'>[C(Q<JZK+AN!&%6KL*1DYQ]0T4
MG)5W!'K!\TC+E.-Q7;R$$\JE!*_%:4G+.PCG&N=Q%AA\?PKPU<+<8S'Q31)>
M*Q[2]N[@R+D\DQ4JI22-YK"V;D>*XCO,EV7+#;V<DFH]"W O%V=XPX@]*?I+
MQTN.XEX@NK.ZEPTL:BWPF)QP@EX8X>C2422+<07$-KGLC'VL5SC[G$<.&X#7
ME_EK>WVGZ\@KZ^II2FE*:4II2O K%1:\BSF%XU@M+1[=VT82BK-NI(L6D@9N
M9^V9OCIF<MF[TS1J9VBBJ1-R9LW%8IQ13Z<BS3+%) LLBP2LCRPK(PBD>(.(
MWDC!Y':,.X1F!*!WY2.8[C/9V<EU!?26MM)>VL4\-M>/!$]U;PW)B-S#!<,A
MEABN#!"9XXW5)3#$9 QC37OUCJ37@DXJ+FFAF$S&L)9@99JY,RDV;=^T,X8N
MD7K)<S9TFJB*S-ZW0=M51()V[I!%PD8BJ1#ERPS36[B6"66"0*ZB2&1HW"R(
MT<BAT*MRO&S(XWID9E8%208UW9V=_";:^M;:]MS)#*;>[@BN83+;S)<6\ABF
M1XS)!<113PN5YHIHTE0JZ*P]^L52::4II2FE*:4II2FE*\4E&1LRP=Q4Q'L9
M6+?H';/HV2:(/F#ULJ'2HW=LW2:K=R@H'8Z2R9TSAV,40UDBFE@E2:"62&:)
M@\<L3M'+&X[F21"K(P\&4@CP-1[NTM+^VGL[ZVM[VSN8VAN;2[ACN+:XB<:>
M*>"97BEC8=&21&5AT(->I---%--)),B221"II))E*1--,A0*1-,A0 I"$* %
M*4H 4I0      U826)9B2Q)))))))V22>I)/4D]2:S*JHJHBJB(H5$4!555
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MC!+O!L_O+^%=LT"CFN(4_=!I@0^PA)9)<H'14*H00 0,0>0$#!R40$/4!#N
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MT.51WL00-;WT/B=]!K\=:W5?MD"MD4D2B<P)D @&.;J,( //<?3U]     X
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MZ,"JD=1L'6B/CUT?]OA54*@FH I.$TQZRF3 QRE%(_7V O!A,/R@'@2F#OW
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M2FE*:4II2FE*:4II2FE*:4II2O6PX\ZUY[_?T_V]0<?L'OK'+_A/_I-9(O\
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3-*4TI32E-*4TI32E-*4TI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g451428g00a13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g00a13.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #; D<# 1$
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ME):QL[33UB0U8G-T=0DT-D-V@H.RM<'AXN/P8Z+QP__:  P# 0 "$0,1 #\
MI-VE[6=HA'9SL8)$]DM^"Q0O>^WAPT8.W#L.$/'#X6P;#&AP8,.-8FHT2'$C
M--QXT:.VVPPPVAII"&T)3CLFUM;4VML3;0$F"$DF&,DDQJ222N22=R3SKY*>
M><3S 32@"60 "1P  [   -@ #8 <J@C]KWME^*#L1_6O97S-R_U2T_!K?]#'
M]6JO6+CZ>;]*_P!:G[7O;+\4'8C^M>ROF;CU2T_!K?\ 0Q_5IZQ<?3S?I7^M
M3]KWME^*#L1_6O97S-QZI:?@UO\ H8_JT]8N/IYOTK_6I^U[VR_%!V(_K7LK
MYFX]4M/P:W_0Q_5IZQ<?3S?I7^M3]KWME^*#L1_6O97S-QZI:?@UO^AC^K3U
MBX^GF_2O]:G[7O;+\4'8C^M>ROF;CU2T_!K?]#']6GK%Q]/-^E?ZU/VO>V7X
MH.Q']:]E?,W'JEI^#6_Z&/ZM/6+CZ>;]*_UJ?M>]LOQ0=B/ZU[*^9N/5+3\&
MM_T,?U:>L7'T\WZ5_K4_:][9?B@[$?UKV5\S<>J6GX-;_H8_JT]8N/IYOTK_
M %J?M>]LOQ0=B/ZU[*^9N/5+3\&M_P!#']6GK%Q]/-^E?ZU/VO>V7XH.Q']:
M]E?,W'JEI^#6_P"AC^K3UBX^GF_2O]:G[7O;+\4'8C^M>ROF;CU2T_!K?]#'
M]6GK%Q]/-^E?ZU/VO>V7XH.Q']:]E?,W'JEI^#6_Z&/ZM/6+CZ>;]*_UJGGL
MSVL[1"MT6B +[);\&P61E&6U#@;AV'#B-+D:_JTE]3<>/8FV4*?D/.R'E)1C
M+KSKCJ\J<6I6:;>UM3"I-M 3E]S#&3L[ ?>]U6SSSB0@32@:8]A(X&\:D[!O
M:=S[Z@;]KWME^*#L1_6O97S-R[U2T_!K?]#']6JO6+CZ>;]*_P!:G[7O;+\4
M'8C^M>ROF;CU2T_!K?\ 0Q_5IZQ<?3S?I7^M3]KWME^*#L1_6O97S-QZI:?@
MUO\ H8_JT]8N/IYOTK_6I^U[VR_%!V(_K7LKYFX]4M/P:W_0Q_5IZQ<?3S?I
M7^M3]KWME^*#L1_6O97S-QZI:?@UO^AC^K3UBX^GF_2O]:G[7O;+\4'8C^M>
MROF;CU2T_!K?]#']6GK%Q]/-^E?ZU/VO>V7XH.Q']:]E?,W'JEI^#6_Z&/ZM
M/6+CZ>;]*_UJ?M>]LOQ0=B/ZU[*^9N/5+3\&M_T,?U:>L7'T\WZ5_K4_:][9
M?B@[$?UKV5\S<>J6GX-;_H8_JT]8N/IYOTK_ %J?M>]LOQ0=B/ZU[*^9N/5+
M3\&M_P!#']6GK%Q]/-^E?ZU3YISM7VAG:^[5R9O9'?<R2'T& )")$K<.PY#X
MLBYV>ZX"7)XYUVQ+<@S7!10F,7*C*:?4/(SH2G,QI<AMRB:UM1):@6T !G8$
M"&,9'JMR<'L[C(!P?: >8%6QSSE)R9I21$I!,CG!Z^$9':V."1D>PD<B:@/]
MKWME^*#L1_6O97S-R_U2T_!K?]#']6JO6+CZ>;]*_P!:G[7O;+\4'8C^M>RO
MF;CU2T_!K?\ 0Q_5IZQ<?3S?I7^M3]KWME^*#L1_6O97S-QZI:?@UO\ H8_J
MT]8N/IYOTK_6I^U[VR_%!V(_K7LKYFX]4M/P:W_0Q_5IZQ<?3S?I7^M3]KWM
ME^*#L1_6O97S-QZI:?@UO^AC^K3UBX^GF_2O]:G[7O;+\4'8C^M>ROF;CU2T
M_!K?]#']6GK%Q]/-^E?ZU/VO>V7XH.Q']:]E?,W'JEI^#6_Z&/ZM/6+CZ>;]
M*_UJG?KGVL[1%-@V&,2[);\(QFM$=I2+<>=N'8<MAL@(ZQ[>+"9R&I%B<;1,
M%E84,F.DI3A^$0B1ID9;4EAIQ%%S:VHC4BV@!Z^U&1#&-C=0@C9>1!((]H)!
MV-6PSSEV!FE(ZJ<X,CG<02$'=N8(!!]A (W%01^U[VR_%!V(_K7LKYFY?ZI:
M?@UO^AC^K57K%Q]/-^E?ZU/VO>V7XH.Q']:]E?,W'JEI^#6_Z&/ZM/6+CZ>;
M]*_UJ?M>]LOQ0=B/ZU[*^9N/5+3\&M_T,?U:>L7'T\WZ5_K4_:][9?B@[$?U
MKV5\S<>J6GX-;_H8_JT]8N/IYOTK_6I^U[VR_%!V(_K7LKYFX]4M/P:W_0Q_
M5IZQ<?3S?I7^M3]KWME^*#L1_6O97S-QZI:?@UO^AC^K3UBX^GF_2O\ 6I^U
M[VR_%!V(_K7LKYFX]4M/P:W_ $,?U:>L7'T\WZ5_K59O;W8#M_:=W:\U_1.Q
M&]$'+GJ?J0+!BF]ZVZM0"-IN/7/3CJE2")2WB0<&4=L)5Z60)E)L1F01GR)Q
M"7]*^\^K6A@M%@DDDMX-*3798]0CD*ES,-@$+$*HP  <   ;5?)+<&542:4%
MDA '6LHRT2'F6"C).221DG)YUC=S3?"8=?QT@SM;<?8@ &A['MVH"!@7V5*W
M02*VC1$1W;70C!.C;)LL$/:!,>4Q,4))OQ)4N O,^ B5"0X^G,(X;<'$4-NQ
M,:3 &V"$Q29T. \:DJ<$9 .#L<':HR&]B&9))E&MDR)BP#KS4E7(!'<?[JKM
M^U[VR_%!V(_K7LKYFYL>J6GX-;_H8_JU5ZQ<?3S?I7^M4ZZQM7A$]P5U5NH>
M_MXSZNULNCZ@EG3':2941XZ_['BFYM,$$W+=LP&X.A&8U<..)L4QMFMP\CGV
M2!>(^IIIRF1.'Q-HD@@#=4\P46H<F.,J'8:(FR5+KV1ECG93O5J->2#4DTI7
M6L>3.5 =\Z0=3C .#OR&-S4-Q>U';Z87C@V.S^_LD)1%D4SAS?5Z8A9F/R4Q
M&\.%'[>V+9BY?4GRB#TQN VUXY+DE$?&7<6FUM "?58, 9_F$SC&>6C.?=C/
MLQFJQ/<EM/7S9)Q_//C.<<]6.?MSCWUE;IV/[FT"WVBC67LYOAJQ4ZP&*P=:
M$]A;C8QC1<%/D#"+8^P5VZ% )J&B7&>3'*!B4\9.:PF3"ER([C;JL);V<B)(
MMM!I=59<VZ*<, 1E60,IP=PP!'(@&LM-<HS*T\N5)!Q,Q&1ML0Q!'<02#[*V
M*H[A[YWNE;3V)5.P780I4-*A:Y8MEE,]A;7 =K@6VVL91P$] DE>H9DXU,M)
MH4)=371Q9T>N<Q*)-PX*LR<1>&QC>*-[>W#S,RQCU=#J94+L,A"%PBD]H@'&
M!D[5E9;MU=UFF*Q@,YZYA@,P4'!<$[D#8''MVJ-_VO>V7XH.Q']:]E?,W+/5
M+3\&M_T,?U:AZQ<?3S?I7^M4\]:.UG:(KN0!!*=DM^$H3E?V.ZY#G[AV',BN
M.1=9W"7&<7'D6)QE:XTIAF2PM2,J9D,M/-Y2XVA6*;BUM1$2+: '7$,B&,'!
ME0$?)]H)![P<5;!/.9 #-*1IDV,CD;1L1L6]AW'OK\Z6NW>S>XW:Y>F]K=Q0
MAVE=?2=J;!E6/?\ M(:D70X!4<$)'HK<<K/>)I'E# >+('0&WRSF23#L.#*8
M9FNQ<3)8P&(/:PDS2=5&%@B.7*E@NX &0I.3MM@D$C*-[J4.5GE C76Y,L@P
MN<$[$DX)&<;^VM[W<"\)QUXKA2S[4WIOH*/#;'QJX@U [%74]);L;VNJYMD?
M,8R%MLV).KA77UMKUB'V&!+DCE,D4PI+L8E&F0X\(&X9<,%B@@8F,2C-NB]G
MK&B([2 AA(C*5(#9&<$$$SD%]$I9Y9@ V@XF<D'2'!V8C25(.0<;X.#D55I/
M:ON&KS'R>R/957I-64#?)W#M'/I!:7?H%)@^*Q9\[5A__,Y2Q])G#O\ F\X\
MO]W-GU6TW_Y-;;<_N,6WY>SM_?5'7W.WW:??E]TDW_)OO_=7&KMAV^0RY(7V
M5[(HCM/(C.OJW)L]++4AQ"W6V''<V/"$/.-H6XAI2L+4A"UI3E*<YQGU2TSC
MU:WSSQU,6<=_R:=?<\^NGQG&>LDY\\?*YXWJ596RN_$+1HWL9([';TQJDQLJ
M5J,<:8['VJ:2=O<"N8MA /*KL&[R3PCS,$["G+D&AXYF2T1@J@*EH=<6U4(K
M SFW]7@ZT1B8KZN@'5EM 8,4TGM;8!)R#G&*F9+L1B7KY=!?0#US$ZL:L$!L
MC;?<#F*S>U>U?:&)K7J_)B=E-]PI)?4ELF%IC&X=BLO$9C/83=0QJ:2>8L/T
M\V0P-@08#;[_ -,^B#"BQ&\_0QV6D1CM;7K+G_DT!Q(@ ZF/8=1$<#*[;DG\
MI)]M'GG"0D3R@E&R>L??[HXR<')P !^08JR['7KPKY ]&KH3L1M(^06]H%!3
M(KL_>\LUV+VCD(@Z&*G,S3\)Y@3L F]%%,3X3,YJND9L.-;_ %?S);5G6-QP
MH*6:WB48N,:K9.T;7><+A3EHQDD'&H E-6#5_57Y.!/(3]SSB=^R)OYLMD@@
M,=L^PD:L9JAY;LIW0"GB5:F]C>R?I@3*GQ9<2/N39\E6<C77VI;[&6K&KZ>&
MCS=UQ,MK"F%L(R\E>6_\KF\MM9LH86]MI(!!ZF+V\L]G8[\N>=JUC-=!BIFG
MR,Y'62>SV_*Y>_E6*1VN[@.-,/M]D^R;C,J1F)&>1N/9ZFI$K'T?CC,.)L>4
M/2,?2M>-EO*G,?2-^-/^6GQR]5M/P:VY9_F8N7?\GE6.ON<9ZZ?'?UDF/_>K
M>-:;Q[G[1NP^C"NV>VJS.F.N(F'-B]F;7KZH5]EEQ##TNQVFU7,:)#L(DNLP
MVT2'_.IA"1%&P(THA*CQ7:Y(+.)#(;2)@,8$=LDCMGEI5$)/?GD!DD@ FI)+
M<NV@7$BGVEYV11CO+,,;[8YD[ 9JP%-VEW<T[V2VUI7<.^=]0KIK?4?;@78P
M4O=UV/0H5BK75_<!<41@S(UIFC9N(D^*,/@"\)US"'6QY2"\V^VRXBAXK*:W
MBFA@@*236A5A BDJUS""""@(R"592![01SJU)+E)I(Y)I=21W&097(U+!(5(
M[6#@@,I_(1O4=Z=MG>[=U2VQ>:IVPVV-K.DP];L&Q2-H["[/$(#!+98XE2"D
MVT-EIBYT=ZQ3X(V3B)AUZ#F6W-F-,#6Y$QBR9+&%XHVM82\Y98PMO$=3(I=A
MN!@Z02,\\8&^ 81M=2J[+<2 1@%RTT@P&.D'F<[[;;_W5M78 7X37K".AD-S
M;P[ UAR1>K[KJ0-8["7@T0%V?7,.F$[ T0P'MDV'@6\(V%32P8Y#F3 YB"=B
MJAS5O(D,,PMSPVY.(8+=ON<<H/JZ %)"X7&4!R#&X9< J5.14I?781F268=I
MD($SD@J%)SAN6&4@\B"*K(GM3W$4N&VGLAV64X11](/0G<&T<KG-^4I'TD-.
M+%E4I'EH6CRF,+3Y2%)\?C3G&-GU6SW_ .3VVW/[C%M^7L[53U]SM]VGWY?=
M)-_R;[UPK[9=O&V?.5]E^R"(^)"XF7U[EV<EG$IM*5N1OI<V/"/.&T*2M;/E
M?2)2I*E)QC.,\SZI:9QZM;YYXZF+.._Y-/6+G&>NGQG&>LDQGN^5S]U3A)N/
M?5C0KO8YGM1M8EKN!=J]0#K0GL_:B5KK-BMP4U8*JU8:O%N+A(>Q8!==-OPG
M/(==96.D,$6(+R<(S1HL>O%N;6(2%&D7-LH1E1E5]+%,$J67(_Z0(S5FN[ZK
MKNOD*!@IQ.Q92P)7*ZLC(!Q3<':SM%"H75V3"[);\B2"^AS9$J_%W#L..\3(
M-]D^PPIN<0=:L2%S9B!@P:-1*DJ=?3 'P8:5XCQ&&VT-K:F2Z!MH"!.H ,,9
MP/5;8X'9V&23@>TD\R:23SA8<32C,63B1QD];(,GM;G  R?8 /972Z^[ [X=
MF-F#M1ZP[/[MD7DR(LA@*+-[_P!DB4F6ZH#G64S &/*/OXEEVP(LH2AC$)\Y
M))'O1("))%V)#DYGCL;:,RRVT&A2H)6",XUL%4GL[#40">0SDX&2,1/=3.(T
MGEU$$@&9QG2,D#?G@$X]N-MZW$S,[_5^@:CVB8[7[9A43=](V=?M?V%6_P#;
MCL.>&T_+>&7V(0S'ENK$FQ)F.Z#8$3DM2B194&*.Q)P8".$H*+!I)HEM8C)
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M*T2[1*HT09!2VM2I>)EYA3*/#G,86.EW2))J<>6[8&'1R<FY@&<RH,*7.6&
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MZGX5G.$_4U<?*RE.%*PG]I+>GCRE.5)PK.,>/.$Y4G&<_NRK'^G%L7\[<_\
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M0$H_=&P#C\&*;[=$R8,CI<H%,G,U=$W8 78PC:(:[8BCP2B%<AD-ET0>RMJ
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MOPR#\\4]2N_H)/"GV5_A%_P;;X]R)W]^/LIP[\,@_/%/4KOZ"3PI]E?X1?\
M!MOCW(G?WX^RG#OPR#\\4]2N_H)/"GV5_A%_P;;X]R)W]^/LIP[\,@_/%/4K
MOZ"3PI]E?X1?\&V^/<B=_?C[*<._#(/SQ3U*[^@D\*?97^$7_!MOCW(G?WX^
MRG#OPR#\\4]2N_H)/"K.;#Z%>$MJ&]-;;9U%UFWR-M6O=;]4Y]9M8.F/R'@5
MXUUH#4@J:E"9#3\1Z77[6 G"R,&9'D1%RH$N!-COL9>:7K1W_#7@EBFN8"DD
MMV&1GQJCEN)B.6#AD8$$$'!!!!J][:\699(X9 56$JP')DC0>WN8$$$8V((K
M<7]7>&YDQ4BG^LVQW*PFBW/6JJ0KK'J?-$DTB^7Y6T[ "(TSU!]7"S6-BJ]<
M TPL.FD:\;\N2"F#TR)3;\!-P4$MZS'K+K)K]9FZS6D?5!@_6:E^Y]A@I 9<
M!@<#$BO$3L86*Z631U4>C2S:R-.G'RNT.X\L#:HDJ?4/PQ-$:H+%.Z^=DZ['
MU=MLGO6A11=%Q'A5S:IB-6H1"V1(&(>8+KS\.H@H>!DN/("M1&)<5H:B.5*M
M3+GO.$.9"]Q;,98A!(2^[1#40A.<X!=CD8;)&^PQ6L%^ND+%*-$AD7"CLN<9
M(]GL&W+W5) /3'AL:G-.3J5UMVO1%6'952VZ2C4;KGK*I0<WZCM6%BN&(<0%
M1X+(Z+'BVRSPR0*"F/7[%#L!>'8Q9:,0DM.5M/P9PH>YBDTQO$"]Q*YZN0J6
M!+.222B$,<LI52I4@5,1\14G3"R9<2$+%&!J7.".SMS.W(Y.0<FI=U?1/"Q4
M'6NU:X0Z7;R/WVQ0>M(C3]FDZKJ$RGZ;"=9KA8[E4A W6YNH%JV3C.$['+F1
MG?H84B$=5+LI!PX4)SU/4RR<*DDB87D"QJ;DS()7#3&Y14<F17# X4 \\J @
MT@#%B+>JD@-O(7(A$9T)IC$+%E&D@@[L3GGG?)-1&YI[PX$BNR:K-T)NXD&G
M4C8NN2""^A=>ER).G[:VC"W5L484.DZ7+.DY-IVD/B7*::GDI!UDFVM$$G$A
M/R(KMO7<$#ZQ/ &#QR#$\@4/%$88R$#A $B)0*%"XYC.#593B1&DQR$%74YC
MCR0[B1@3IR<N-62<YY'<UR7[3_AM]I)FYV+UQVS<94K9Q/<48B<ZZ:RE$ &P
M#V 'K*7J4K%&0NGP[4Y5J\_:J_6/1-=L4@;A\N*EN3BBIR.;@L6.KN(D'5"$
MA;B4!HUU:5?M]LIJ8*S990< C P9.(N#JB=CK,@)B0D.<9*[87.!D  'VC<U
MF9U \.B4*R3)706WB<N>3WR8)-3.N&JG!Q>?V<#Q@.]%&12: @88B;!&0H4<
MD+)Q)8J#F''=#PASC?E9P)>"*-*SP@ 6X&+B7(%JVJ#2=>5,;$D$$$Y.HFLZ
M>)$Y,;G)D)S''@F48DR-.^H;8Y#V8J&.O'@T?" 5[;P4[8NI.[1(UL)L-J3/
MF4N9'BMR2FN[8.A-J5C&$(5+(S8T1A"4XPIY]MM.,>5C'+I^)6#1$+=PDZHS
M@."<+(C'\N ">^JX;2Z$@9H) ,29.G;)1@.7>3BH.^RO\(O^#;?'N1._OR[[
M*<._#(/SQ57J5W]!)X4^RO\ "+_@VWQ[D3O[\?93AWX9!^>*>I7?T$GA3[*_
MPB_X-M\>Y$[^_'V4X=^&0?GBGJ5W]!)X4^RO\(O^#;?'N1._OQ]E.'?AD'YX
MIZE=_02>%/LK_"+_ (-M\>Y$[^_'V4X=^&0?GBGJ5W]!)X5-VT/!F]_BVNNM
MPP;U(W;-(5C55J$6&)'ILUQ\.3E[XW#88T&<C&?&Q(?"&A)1MM7[U0R$9W'^
M2YCE,?$[ 27!-W" TBE27&X$,0)'>,@C/>"/95CV=T4B @D)",",<B9'(!_N
M(/Y#4(_97^$7_!MOCW(G?WY=]E.'?AD'YXJOU*[^@D\*?97^$7_!MOCW(G?W
MX^RG#OPR#\\4]2N_H)/"GV5_A%_P;;X]R)W]^/LIP[\,@_/%/4KOZ"3PI]E?
MX1?\&V^/<B=_?C[*<._#(/SQ3U*[^@D\*G'KUX,[O[6[Z?(GNI.[1,&3H[LZ
M 8E3:;-99=-6OK7MFKUP:A:L^+,LU83 L/ :_P!+\Z=&83_E.8Y1<<2L&C4+
M=PDB>V; <?)2YB9C^15!)]P-6PV=TKDF"0 Q3KN/:T,BJ/[V( ]YJ#OLK_"+
M_@VWQ[D3O[\O^RG#OPR#\\55ZE=_02>%/LK_  B_X-M\>Y$[^_'V4X=^&0?G
MBGJ5W]!)X4^RO\(O^#;?'N1._OQ]E.'?AD'YXIZE=_02>%/LK_"+_@VWQ[D3
MO[\?93AWX9!^>*>I7?T$GA3[*_PB_P"#;?'N1._OQ]E.'?AD'YXIZE=_02>%
M3=MCP9O?XQ1^M< 7U(W;.FU?2)D#8HT:FS7'0YE_L-OJRLC9R<9\;,MP#809
M9+2OWYA%(;W^AW'*(N)6 DN2;N$!YU927':46UNN1[M2L/R@U;)9W16$""0Z
M8M)VY'K9#@_W$'\AK$4+I'X7/5P<D U_UT[+U805GO%WX8VH2DIBFY%9/TQ\
M^&=?:>D5ZQ/5*T6&MNV "Z-,N!2TP<J=F*YAM,I+WA,I#27%LQ QDN-U#*^E
MOG+K16TME<@'%82WOXP0D4H!.<:0<'25R,YP=+$9&#@XSRK%_L%>%C]4TT3'
M7#L[BF(J+U#36,5PO@(FG2-A1]L2*]@?A?F_HY[9$2+<G6O(\:SD=B6I6<M(
M2G/K_"M6OUFVUZ^LU:AJU]68M6>>>K)3^R2*QZM?:='53:<%=.-M);61C/+5
MVORU,Z-&^'#9GP"D74/:$>3%V2AV^ 0%T*$+FQK%K"HO4"@DD2APJ*_E57HL
MJ731L9:U0TU:;. /1WA<V7%>IZ_@F".NM2"LB$%R05E?K)!@G':<!R>>H @@
M@8LZOB7S)A@J=E4;JNE>0]B]G'+&W*NA7.O/AKJ@LBJKZ+[&@FR-@,6GS0;K
M +&'"3UAI[^OK!.JXQ / ZG8/49]52-Q:G%"PBU>:ABB$:1#@0FH^6N>#/C5
M/;-A53)D.2JN)%#'.7TN-:ZB2&RPP2:P(N(KG3'(,DMLBX!*Z"5&,+E3I(7
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M0& W )RV0 .9&OTGM*8N>TMA:O2UJ<.?IF_BFEA-=GWLHJYVP<*UU7MH3;C
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M#(&NH.Q;2:L.+C%LE;N)MF@8BD:2?"7DW6B $:-$+0";$QQ\Z#*$09C.1>2
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MX^5@XS@TU+DC4,C.=Q[.?A[>[VUMHG=>HCE9N-R&;)IDBK:ZD%X>P3BSX^+
MH<P!%Q..0KH[+?8S59H:$I,LI#.I@28$9:'Y333:TJS$Q2*RH8W#. 472<N&
M^25^<#R!&03M6<C!.1@9SORQSSW8]];)3[W3K_ ($J98Q-CB!S9.LFE#)2'G
MPEE"N(:+UTY#SY,P,>&+<:Q/#E&(A&(EYA;\9"'VE+BR,A 92I(##(YJ>3 \
MB#["-J @\CG?!]Q'L/<:VSD:S3BE.*4XI3BE.*5N;'_$,_\ )-_]A/.)?Y;?
MVF_TFN>3Y"_V5_T"N7D:E3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*5CRY4>"%$SA>4B$*##YI4G-=PM3<0>.C.S)LIQ+25N*1'C,NNKPVA:
M\I1G"$J5XL9M@AEN9H;>!#)-/+'##&, O+*X2-!D@99V"C) R=R!6M>WEMPZ
MSN^(7LRV]G8VT]Y=SN&*PVUM$\T\S! S%8XD=V"JS$*< G JG?VBG2O^?U5_
MW;:OE_GW7\EO3_\ %F]_2V?[371_VSWH&_K'X1_A.,_NRGVBG2O^?U5_W;:O
ME_C^2WI_^+-[^EL_VFGVSWH&_K'X1_A.,_NRGVBG2O\ G]5?]VVKY?X_DMZ?
M_BS>_I;/]II]L]Z!OZQ^$?X3C/[LI]HITK_G]5?]VVKY?X_DMZ?_ (LWOZ6S
M_::?;/>@;^L?A'^$XS^[*?:*=*_Y_57_ ';:OE_C^2WI_P#BS>_I;/\ ::?;
M/>@;^L?A'^$XS^[*?:*=*_Y_57_=MJ^7^/Y+>G_XLWOZ6S_::?;/>@;^L?A'
M^$XS^[*ME4K=6;Y6@MQIIP=9*O88+1(*<$R42H!"&]X\)=9=1G]RD+2ME]AS
M"'XLAMV-)::D,NM(^*OK&[X;=W%A?V\MI>6LC0W%O.A26*1>:LI]A!#*P)5T
M*NC,K GN7@O&N$](N%6/'.!<0M>*\(XG;I=6'$+*59K:Y@?(#HZ\BK!DDC8+
M)%*KQ2HDB.@V+FK7*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE:1L78U/U34"MXO)=@+7A"6<2)3O\ E./2
M9+R(\.#$9QG"GY<R0XAII&,I;1C*Y$EUB(S(D-;O#N'7G%;N*QL86GN9B="+
M[ H+.['V*J@D\R=E4,[*IX;I!T@X3T7X3=<:XW=QV7#[0)ULTA&[R.L<42#(
MU22R,JJ"0J@F21XXD>1?/OL?W\MU(JVH++USTX3W<,VN*+FHUDB0SY,".0'D
M^920&&*Q#E2WK&R^W,<)19,B"H4S#\2H\MQV1B!V/T0]'O#^+77&K?I/Q^#H
M[)P>:&W>TEDMHKJ62;4>MU7DL2+;C"*C*LIE>0#,8"F7SKZ7O3_T@Z(\,Z&W
M_HUZ W_I#@Z7VEWQ&+BEI!Q*ZX9:6]H(O^2E.$VMS/)?.'EED262U6VAMV8"
MX+2BVC_2/A<-;6,F6K'8JED>OYFO0Y#Q>PD9$TG4(DB)Y#:H9IN0*'V&K$B$
MQZ.-"BY, OZ2*R8@EHAZ4GCX<O9Z8>BB?H]PY.-\*XW8\:X5*Z+'VHK>Z<2D
MA#;!9YK>_50"TC6\J2A THMS$DKQZ'H;_A20>DGI-+T&Z1=!>/\ 0_I;;PS2
M3QK%=\2X;$;5 TXXFS6-G?\  &8LBP+Q"U>U,CI;OQ!;B6VCG]2*%<V[_6H=
MJC5JW5<>34MT3#NX7-:/SQ2L(7!,O5N5)<.@&"3*\/,"+6/ 6J#C"FC=>%2<
M?0<ZE=-#%2RL1L2C:E!]H##LMCO4LI^]8C>O6(.H @$ \LC!QWX.XSW$ ]X%
M;GR%9JGW;[K^KM/U\VMU^S;L46-M 0FOSK3@!FS/BH22T(B^Y$$9-U]M^4[B
M#AEEQXBEEC+F75L2,)PWGG+2;J)(9M.OJP&"YTY.G R<-MOOMOWCG7 3KJ:5
M<XRSC//[XU2E_P & @:(M]9H^[<5*F%]W:G[.4S7^=:Y*4;7V^J!)A2+B4%B
M&]@"B$O6&V%,S)%CU>@R-R"(RV9U7MHW$=^/.W/7R2K/%J8120.^L!WA?.D$
MZ"!)'MB3': (93G(JZL;@' +!@,;!ASVS\D\RO?R(WK0WO!_7.V]A]LUH@.#
MZVZWDZKTAFQ3-*J55&"KH:ZV;&O>T#%*H-?&;'=.ZF%XLAL!'5./5>TJE \E
MH,$L\5:18)DA=JL,;9,DX:ZR'9B5$Z+&&=BFF0Z0=@R[X)&.R,=62S<@A$?+
M&Y1F. ,Y SC?'+;.:[R_!3V0A&M";%V78-D+34M65.<4QIG(YQ+.I>UA/M&
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MD529, [#*E@1G'R2!W;#?/@.9VU*Y]K^R-@V")B!C=:%.U[PLY;J\!KPTF3
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M*%BJJ W5LKKJ3&@@,H."O+4OR&93CU>,J$()4!@ 221J!4X;Y0."=P>>#\H
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M ("S>Z-G^$\8/N\1YTR/?X'RIZUC_P" LWNC9_A/&#[O$>=,CW^!\J>M8_\
M@+-[HV?X3Q@^[Q'G3(]_@?*GK6/_ ("S>Z-G^$\8/N\1YTR/?X'RIZUC_P"
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M ("S>Z-G^$\8/N\1YTR/?X'RIZUC_P" LWNC9_A/&#[O$>=,CW^!\J>M8_\
M@+-[HV?X3Q@^[Q'G3(]_@?*GK6/_ ("S>Z-G^$\8/N\1YTR/?X'RIZUC_P"
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M0:V,31AFGCQD51K.5LY64:58R-)H"YC"%>JZX$.9 <E.T.SI*$$/G:A<#VC
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MZ+8=<[OM<J[NR3$,H,N&D-PZLTL<U\NF2Z^R4?,2[AL=X)&8:D*-2;&%P @
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M8+C&GXLNRK>,$A<%B<Y76)UA&3>V40Q2*P"B)GED&I@Q];D@0HK8;!"J>2X
M)(U$*8K*=;J022X"*< @=2DC!B-MBV.9W(QD FN,'WZU ?APR# ZR"DF:AK6
MU5H'8HB15SLS>V#6M:K44UZK-^>R+*)1=]G#*!8CU2E6*)6;H#/!S#,9M^JS
M+0:PF4D90A7E5F4Y1>J65WU.0 I*1&1%?271E*Y.L(%Q&0#N,JK -@,0^@#
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MZ(S;\E"WULQWW4M86IMEU>,(5=PNZCL>)\.O95=HK2^M+J18PID:.WN(Y75
MS*I<JA"AF52V,L!N.(Z3<,GXUT;Z0<'M7BCN>+<$XKPRWDG9U@2>_L+BUB>9
MHTED6)9)5:1DCD<(&*H[84_-W]BIV=_F'H?WAV#_ .6G/5WVP'1#^B^DG^%X
M7^]Z_+3[0WTN?C+Z.?UKTF_X2I]BIV=_F'H?WAV#_P"6G'VP'1#^B^DG^%X7
M^]Z?:&^ES\9?1S^M>DW_  E3[%3L[_,/0_O#L'_RTX^V Z(?T7TD_P +PO\
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M@DA&(TFR'^ 9Z5FFB6XZ4>CV* R()Y(>(=))YHX2P$CQ0/T8MTFD1-3)$]Q
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MF)9F)9F8DLS$Y)).Y).Y)W)W->L$1(T2.-%2.-51$10J(B@*J*H "JJ@!5
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M%PQ0RL,9#-C/+Y7NQ4)">[^RM?6NUUS>.C]BG15EW$4UMUB.:XUO+JEGW+'
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M#4TJ=!"B<TYY:C*<#XT"'-BC\RXTO?M-+1W(:.,F*UDE1F16;K.LA522P.0
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MQN&:17MY7E8J6 )BE6/**T;9+0Y+D$9US8! W.L,&4@*5E55&0,X=2W:(8#
M? 4$5@U[BWFB1<K55Z>2%'YFL>L!T@.MU-K%0V!89DNL[PF;$J+FP!5,LU,1
M<1'H2LEZY"LT8I3(IVQ1*3'GTAK9P<T+R(H,(CN"HENE!1W>-,- (WZLNKZ&
MU,&*X<A2Y#]4RG&N3+%5()2(]I55B<2%EU8*Y&%(SE03I[.L$>F==GOE:^"*
M2HA*!))!A<^1!,0FQI>$_,A,2'HA4<T_*:'DH[CBF9T)J3(;BRD.L(?=2WAQ
M7&L-+, 00&(!4Y4X)&0<#(/L.!D;XK:!R =QD X(P=Q[1[#WCV5F>1K-.*5K
MQVHU2T/!I%FK%>L3]<*-'*\\="C2[P$TPVMIDP&<(1I"Q91EIQQMHA!4Q+;;
M<6A#V$K5C,E=UU:69=0TMI8C4O<V",CW':L%5.,@'!R,@'![QGD??6$5JS6*
MK,]=5:YH:KE(G12;]M54*_FS/DH+"8L(@\>R.R5<G0XJ4QHLM<M4B.PE++3B
M&\83R76RZ0G62: " FMM(!Y@+G&#[1C>L:$R6T+D[DZ1DD<B3C.U9P54ZJ!*
M'C8.LU\,9M4MB?:"XH,.'%+).BQT1(TT]/AQF99B7'B-MQ6))!V0\S'0AEM:
M6TI3B)=V"JS,5484%B0H))(4$X )).!C<DUD*H)(4 MS( !/LW/,[;;UC36N
MM?61>'+%1::?<Q88]MPX:K 0HO%KB T5>+9L*G07U8L,:M-MUV.:\?I)D&A
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MF,;Y.,9V&^#M5Y=1=G3.S-[[JT*5UK'I]DTA:9L*PRE7*2;21H9>O4^PZKV
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MZ/?O^GVU_7;^6&Z?R%&^=N/M?NE7]+]'_P!+Q']W4^WT]&/XI=//\-T>_?\
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MT\\,!%I?EDRA%,QJ6/8R57(;CJ:Q?(BS7\D+*W5H+@1HC8P$CDE14R'PI(&
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M_/\ MGN.'^/\?;#<2_%JQ_6%Q^ST^T!Z/?UD<9_R_8_O&GV']%_G_;/<</\
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MU-K92XM*?%A3B66DK5C*L-HQG"<<JF=*[CY(]A[A[ZX20KUCY#9UM]\.\_\
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MB$%J2)SMF,3G1KT=F )>;SA;SS#3G,P!3U>H@*%#-DC<*N=(R5R6QI R-S7
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MZS5[CK/5>V!!\:]K_7SA /IJVU*QT_6EAOM.79:PZ%*4_%GDU2..#JR93KD
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MW_ >5/KAV-]XOT@%\,XT+W?$^=-;=_P'E3ZX=C?>+](!?#.-"]WQ/G36W?\
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6D O_ &?_ /,XT+W?$^=-;=_P'E7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g451428g00a16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g00a16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4\L:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(S+3 W+3(U5#(Q.C,T.C$W*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(S+3 W+3(U5#(Q.C,T.C$W*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,RTP-RTR-50R,3HS-#HQ-RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$P-#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%A045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T960S9U:D$P9C=T
M;E)U4B8C>$$[;%I15'=25DIR44$X:5<T<49'-7)T,$]6-4UN1%<S-"]',6,O
M:V=M;%=+4DI9,6M3=D9H559"52])9S!)4&E$:S1Y0D9H2S=#<D9.5R8C>$$[
M=79-,3,U=T]J-EAQ55=N5S!7;G@S:G,Y<TQH;60U,VIP=DI(45516DE64W-,
M=E!Y=3@R>2]M575T;5-#-'1Z<61R<5$Q:'!/13A6="8C>$$[8F]5;'-20T5,
M,&MQ04M38V5),S-*>69'2W!J5S93-E U,"MO>79B:CAW-W4R*W)81'),86%L
M<&\Q1G!486A23U),1$YC3VM,0D1T>B8C>$$[53AA=#$K37E-9DI&;S=8=D]Y
M5T-Y83=(*UE&-4Y9>EA$,B\V2U13;$5J9E8U1F530D1*.5<Y27!$8W%'97%S
M9713449!165L2U-H5"8C>$$[-753,C X6#%R*UID>DQ:4E17141O3DMA4U%3
M>7AE;GE,,TQF6F5/1U-2=V%G144W=CEO.%!K="MA:G%(;F4S=DQ55VPS*V%D
M>D%S<28C>$$[<DIB,W-/:U!B0C)%;D%I<TA#66-$13-)17%$>DA7;4EJ-4QF
M;6ID2S@W4S)D-U!Q9#<K661Z9&%08E0R9C916G1(5DDU1&1133A34B8C>$$[
M9VPU26Q:3&8T=451,V%V56QG1$AY5R].3#E2.'E81VQE66]D4'5V>DDQ1S5V
M3$DS.'1Y='1P9U=/3G=J4W-*4DQ*=VM7=3!A:$A6828C>$$[55@P*W5%0WAY
M5R].:TTS;DMB5#<U:W9F>D1%:TYX2F8V9D-F,%5!67(K2# P4F5#45!Z14Q4
M8VEX:U5..$DS2$DU2&@X:S(S;VXU=R8C>$$[*U1V3'--5VPV:')6+W=#64QQ
M-&Q.>F,V>#E7:U-.0F--6$%-37(K;VE2;U8K0TI#4$%6-4%*>&MR>%!837%:
M3WA6,DMU>%8R2W5X5B8C>$$[,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%9!1"]12E<U1VQG-'%#86XP-4XR8VM,2'-R8G,P:VMN6$UF*S=/
M+W="2"8C>$$[,TAR,"M*:UIC,E!,,TYR<E=N=54T4V5O2D96:S1F1S-X>$Y-
M0G=7<F<K;6QF<S<Y<31J5E%023,O651Y-3AH,TQX:#-/,D9W8C,V:28C>$$[
M-&Q-66I.,S93*V]947!L0S O=G5)63 T8V$X:C W-5!X9DDQ*WDK6%!Y-5AF
M4DYO<4,U9W5%3%)/1T%.1TA2;$I!8FEY;F17;U)S9"8C>$$[.&Y#66M.;$)T
M9WI29FYK3&U35EIF3&A1;T5J9V(V-3992W,U-3=,>C5-<DM$.%I(=S=!5G)L
M=G X,&)R<FE0.#=7=E9E1G9,;W1%-28C>$$[<3!$1S@O94MZ9VAM*T%K37%#
M9V\Q3GI7=3-&.5!M;F18:'-0>DYS>$A:-F1$-65T3DQ3,C1Q:T,S3512,TQ7
M.5AA3D%R4BMN.6%*628C>$$[06EP5'(X5TYX.#$S46\P:C@R1U-7931F>2]0
M<61O>$]J6'-S53=Y:%I*<7E*239P2#9A;40T4#-A,5!C.3A.>#@Q,V1*2BME
M16QY.28C>$$[<7-E9W=X=$%Z:2]56$Q)<W!,<7-A9WEC>3,R1S5'3&HQ-C!O
M6# K83=R9%=S9GIV=2]55S Q1%)T4%9*-G=08BMQ5V%!:'A36#9X0B8C>$$[
M8W)Z2'=%8TM$<EAT:41&1S9A841P2&Y1-F=G.#%3-F1Q;&AB2C9L<$]I9G8Q
M=D9M8W!/<UII5DDO=T)X3'<R8VMC92]*:F=*2%),3"8C>$$[36=L,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W%%5%=%9'<Q=D59:W5754\X4SA1-28C>$$[54%+1TMJ96=!07)K67=!-4)&
M2WIO:FEJ<4=!25E!:6]Q<'%$=C1%5G=K03@P<&1/+W="5C%26E9N=#1O2C%R
M95)Y=GAF-%9):F5.928C>$$[:%EN6FU0-TE!-UI4-&-H:W5.8THK<CE&969F
M-4%-84YT>2M99$Q1;%5K37IF>7AQ5R](<&PW2E%B6#4R+W5,2GHW>7-%+T1F
M2F-*4B8C>$$[>$)41W%A>518:$%G.$-(62]G4F@T0VII5D1E-FMW+W956"]5
M4V@O-%IM=SA#3TI9-UAJ;F4X;$$Y:$=0,4QJ=VAE2E)A0S5*3F(R-28C>$$[
M*V@V9G%'4$%&-&QV,49M*S%D6$(K8VAX-%%V13$K:EEY3C5*1#@U1W@T479%
M6$A3-UDO>FXO6G1J=VA(15AF;W$S<%=R:B]:=%@Y928C>$$[4$-&-&DS*VIO
M:#!K;%@O;F\S5$AH0V5)=&EZ8V9:=3=L9FQ)8V5!3'A&97-6>793.'5$.#-"
M+U=U4$%&-&Q66'9L3D)D>54O>6A'9B8C>$$[*TY-94%,>$QH9&%K=E-:5R]W
M0EI"+T%R:G=,>$]E+S%99EI-0DAU:FHO:F,T3T)017!J5F1952]&1D))4$)3
M>2]W1$5Q-$]!<GA"528C>$$[6%AR:&%E=%EU064X8G$O-&)93T5P<TMQ*UET
M3W)36#%)1#1325(K<75#:V]Y1%5,1V9A1V1(2B]:1$-V,V1C5E8X5F1I<G-6
M9&ER<R8C>$$[5F1I<7E784=&96-S:7AP+TTU0VHW>FEQ16TQ<7=J2'=S6GHT
M47%82#-J-&9X=S!T;TM46&(V5&$S=%)'3WIZ3B]W06%R=FA%0VII0R8C>$$[
M0G4T<GDK2V97-6Q003AK-$EQ<VA"<E=/5#=A;EEB:DIC1$AI46LP3C=$=&-V
M3G%&:U=7;DHS85=066=S5D@R>#AT+VYJ=V=,>$EU>28C>$$[:C K-70P;70T
M,&5*<6A'-#EE2DMN-U%R,4=31DE*2TU32E%#1D%!07%",'A1<W5R:3-S-U=A
M-G58161T8F\P,#!H*WEQ24]436%E028C>$$[1TMS8C!4.'I02VUQ>51R-C,V
M4$5.=D9E8S=T-&\P3G9+=U)*039Y3W$O17EQ5F-H9U11:D1W;%-Y2W<Q4%1.
M4E-35%1R=4,X:FEC>"8C>$$[4W9B>4I+16M58F]X47129T0P3TI"2$Y19S$X
M,V55;EIK6%<Y4$QO6$1+3'%';TU64%5Q02]W0WA58W9$1'=3-VM717I7-'1M
M=4=T;"8C>$$[;%$S0V]S>G=H9UA%8FQL4GEV6&EX4F=$-TA)<&1A,TYT9%%I
M93%M4V5%;&Q%<U1",4I2:7)!37!),EE%2#-X2U98:G9G=&%5-U,V="8C>$$[
M3'5"3&DP;FIU3&515E-A2F<V35!%37!)3TI6=3%U3%<W=&\W;3%M:G5,95I2
M2D101W=D2%9T=WES=%%19D59;7=O8FEL9VY4;D)):R8C>$$[<UE::S5O47<U
M4G-58U9(9%=59RM"1TMR*U S*RM.<E1U0D(R*R]&5W5)<'8Q>'188T8O<WAT
M6$9#2VUU-#9$1E9H0CA+*RM&1%)7<"8C>$$[04]+=$UT96]X5E%E>G1Y86U&
M2RLV:D=G='5-3$%C67!:658W3$A)>6HW<3!W8TE4>$9Y>F%T05 S9#,V;$14
M:$MV3"]!25EB-$]"4"8C>$$[17)P<FPO2'1087)*+VQ1=%0O:%=Q8VE91FQX
M0D9W-C59>69B16M(+T%";%%Q4'9&4BM/0VET;W5'-W1*:E-'84]1:G%%64UF
M=T]"2R8C>$$[57EA>&9Z2W=H:D9Q3G=(9C0S4'9X,D$K;DII1$5Y44ET14PK
M<$UZ6$5V.$%.25,S-%I-4D1%>5)#<6%5-T0W<VMH<TQG479O4V%N<B8C>$$[
M:6QC67<V<W)G37)#:D$W,4A3;2M"5W)E,71O1C114G!%:$Y3<4M&1F9'9WA6
M5D,T3%-X5S-U9$TQ;E=.54)N=4QQ>DU$5T9Z<&AI9B8C>$$[,&E(4$9M1$MA
M9D5&66)G2$PU4DEI0E%A;WE":U5L,5 X<V)F4CE#,4-B4F)7-3AW-GA,2&)7
M.6Q$<4XT>2ML1$)/:VMA4E-Q,759,"8C>$$[:$M"=T$T4'=G035#170Y.6UC
M:'-W>30O3'9666131CEP+S5A>5%Z2D=$8GAP<CA99VIU4&AK5UAI1VEM0FIC
M05535E%E3S%/=5I!>28C>$$[:7%-=G-A5$$S.5 R<'1(-50Q3UE.2% K5C=*
M.5IU2DIB:54V*T-!,3)P:G5:95%K3&IK9TA*4CEO5DAZ:GAJ*V8Y:DE24#A!
M3BLQ428C>$$[.#,K43E7,5-E5G)0>4$S<G=Q=&A$<6)A>7)3=EI22S!#<VMC
M:VY"5V%!1#1P07A"8F--8UE:05 T=G-22T8Y4'17,F9L2TXW1UHW6"8C>$$[
M.'%P:&1X>GHR='AA>F%X2D53:S!+3$I)<S!P0WEO-4A!8U-E;DE5<FA-.2]R
M*WAE2&(V9G17,U U639Q,VU/-%-0>4Q:4#5D:6%-428C>$$[3S$Q26PP.$)L
M5U=257!F8T9K1$8V17%O*VHT5U)M1F96=CA!:GE4-&4O3%IQ.2],,U55,$),
M5WDX:$DK;WIX,C Q,6%386I/655M5"8C>$$[-C=%-45H=D95:&954C%26')X
M:V)K83E%6E)F,6)E-S-E4T1J,C5F8C<P1F1F;'0U9W1L:$YJ*UAT=3EX0U5,
M,T18.&]5<DA,261O:"8C>$$[<5A)3C9A445$;3%'1$1C8V-)>6<X-69J-4PT
M6DA)9FHU*S4V6#5'+TQ0>6YO,%=N-C%B-DUU;F$R,7-N<G V.7I)27!*63%%
M<4MS,"8C>$$[<V=(.'9J-S5J-4TP:G1E>F)$1T)U>EE*;%1.,TAX>'17=4%R
M5$<Q8U9P:7%H2F57<TYX2&)V3D=L>$U#66]76E$W,"]L53=N2D-*228C>$$[
M=$9H43!Q-75R>7E3-'5R4G)+66QG,74W8VE!<$E"<E%D8TUW061J84EK:V)O
M>FE.,4A4=&M5<F508G@V-'%T6F9V=V]71E-4:7$P<B8C>$$[:%995DAH:6AA
M5DEW<6]V85<X:VES56\T26]Y-T@X36E9:&M#<DXY;R]02DEC0FEH949W2W9#
M:G=W2EAH4FEQ-$QG4W5#-'$V4DI$1R8C>$$[,W!K2S5"-$5I;T)P<U1I17-D
M.'5V3UE:1G9T8G1:<G=Y:W8Y5$YV=4YG3V9W9&5V8DQC<V=/;$1Z86]E6EI"
M1&115%A%,79'4UI)3R8C>$$[4'%F0V%F1TMI:#9(8G=Z16IM:DM2:4]C5W=%
M26EH<FQJ2G-,:7)F2$962TLV<S5:-6)E2V%/4S1G<#8X4W-#-F-H56-L1S8Q
M.3A65B8C>$$[9W4K2W4T-'$W:G1I<G5/2W5+-'$W:#=9<3%X>%91=G)Y,7-B
M6C=Q-FM%145D3V-R,6]/4D-J.%1K;WA*3D)"3F,R3S)/9UA-,&M&.28C>$$[
M<F=45DQP6')A86AB35EZ2$<Q3TY65#!G4416=5%Q9"]P>397441A3S-K,4-(
M53=S;31!9DPW.'@R-7A12$-H85)S35971F-+=$945"8C>$$[,GA1<TLK,D<Q
M5VQC54Q#=49#,$PX47 T-%9A<#A2*V5+<C%'0E8T1T)+.$1!;&5":6QC1G=+
M=D,T1F(T-'!35C=E4%$U<'!R4WIT8B8C>$$[8E1:16%A.75N:TU:16]A:6EG
M5CET.78T9#=*4TUH,WDV3F1C4$QK:79,.'0W3' S,6DX=6]B;U-U6&AN9S)4
M,'E"469:6&-'=5EE;B8C>$$[:&UI0TUP0FQF5'4K>$U,<F1-,5I',U9G,WDS
M>DE:<F=-0W0P>%8U3C52+TM0>DIO;FU+,S%*<GEZ:F$P4R]",4-0,4IB:3AE
M-THY228C>$$[,U5:4T=Q>&LX>41+-7)T6'!3=WI#2U1+,B],8GHO0GEC969B
M:5,T2WAP-FHR,'I,>&A-0E=S5%A::G%F<3E'2V=&=6(X<3$R<T]74"8C>$$[
M.#,X9DIR14ID-VPX<BMD=DQ/9U%.3#4S=4HT3%,V.6)53&U7>$8S2DIB>79#
M;D9M=4IP5VIJ:$-U>G5$<W)%,"M(2&IJ22]3;VI)1"8C>$$[;7=Q,S$W>E9$
M6F%4<C!N-6@S34=I-FMY-F9$9EA':WAV>FQ29E9196=J6$-K,6%31U-4:W(X
M,"]B559&>&I'>4](8V5B6%HR4$5M;"8C>$$[-7%8;3%B:514-S=Z='%&;%!O
M:WAU3'962#!E,T54+U<U0EDR8TQ1451'4G55:7E3>#@T=4QQ=UDO6E4U04-0
M35)'+VXX5U(T=58O6B8C>$$[.$90>59R9FUB>GA*93)E;2]M1&,K=F%X4GE*
M>C!E,G1Z5DI56EIW635J>59U2E5X=%-O3S8P=S5)>&AZ:CEQ=TIL>6PY:DM4
M-40O3B8C>$$[1#8P8G(O;%EB*W1W36%$.49W0TI63&AV-VM3*VU4=%1K>6QV
M9DMV16@O3BLQ;'=3-R]S6FQO9&IR1G!:96QQ,G!$5DQR-% Y2D5#5R8C>$$[
M=RM'2D5B-$5,1#1N5FXO,E9"<T)L56E#9&A464%E<F5U9E=26DM99G%O6#%9
M+U@K=6MI4# K5SE+02]%5V]&<FMS9%@Q*T-*8VM61B8C>$$[8E%W;'I%9VHU
M;7)!8D%N>&].<6YX>4)*2V%E4"M6=GDR."]75W%L,6U44G)Y1DPT6&YM4EI&
M=EI.4VQU,T11>4YB>4%515!'=$I'-B8C>$$[.4]P>7II2'91454Q;"],:GIJ
M1&90<F5R9FU(9&5L8FA:-V=#3C=/,4-12T]::VI3-5=&55I%4$]I:BMA;T]7
M94Q'<457=F=),TI15B8C>$$[=G%5<WDV6&\R;B]M:$<R<5%E<F%36&$R:U9W
M;#%*8V=Z,C5,4U!*1GE65C1G.'IY<'A&1W)K:4]:361L<SAU2D0V9G%';UA9
M='12;B8C>$$[+TY335<Q=DUR>'DS1VUX869$36Q:;S59<7ET1$A.>3E.=7@T
M8U%W07%$:$E!,C10='1!=G)*5W-Z8T5Z>% X06UP1&-8361L1&)1,R8C>$$[
M6'!7-G=2>GDS4F%/4W%Y*VI,2WDR>GAC1TIE;%-4=E%G+S%&1B]Z;$LO,5AZ
M2VUO;4HO>D9H:'1N9U%74#%84S0W>' R9W-9<#=I8R8C>$$[.$EY<6AZ3VMQ
M<6I-1T1"5DYD<TE!<C9F=#@Q,S<R4C98-4\X*U=6-4908RMD2DPR2DI)9E=G
M:W-99W(R.%)C=$8O94AI>CAX5U5F1B8C>$$[='9554%R3U-*+VA:0THW,EEL
M8W):3&%F15!N:7$R;GA(-315265'-EHW*V$Q8FER47%(-$1K>&%..6MC=%)6
M6#1L9&5/-3)R:VI(,"8C>$$[,RM0>'E11'932W0W:3)N.50P2E5L.4IZ1DQW
M64YX9&9T23%/:D1W>4)"2$YK0T-I0EAT:U=3-59P:7$X1$%L8T)I<31$1E=/
M,RMV828C>$$[2G)E:3-K96I83FQR;D52<E!B=U1X>G%"23-W.'9396]R>$I8
M8V1.<W Q13AS23A735A0;W=N=4YT,4<P,"MA,&5Z:VQN.4-#2T5P2"8C>$$[
M;VM+8VLU1W!R56PR2D)/-V9J;#)02UI12$=05U=!0D9F8S=4.59V26)E2#E-
M,F]G=C9E<$XV04)#4FPK0W-31U!5;F]#8WA.9#)H:28C>$$[=UI/1&,W5V9)
M6%@S=5IP=$IK>5$T=&@P.2]6:W1R27IC;S-B:S8W9SE+<65L8WEI,&A8;TU6
M8G!G4W,Y5TPQ1$AY2$U#<%=U.4U.228C>$$[54Q79%AM;E@Q961'0FI";U!H
M239R44-O<E594T5"5T4X4D1N;"]D;6HW2%DU1FLR,#!A<7)%:W$S46=%-U5R
M6&)T:$-%4$IC=5HT:B8C>$$[1%8W8V-V6&12>4A4-&%E3R]W1$PY3U-!,E)A
M2FIK:FM8;$=W9&9&5%5:1DQD3593-WI$65(S,FHS3G4Q<4PP;&535WI/,%ED
M,%!*4B8C>$$[>E=H1S1Y94]64W4V67I&:'918FI5<FY3-%ID4W126C-:<4AG
M53%!04Y&-VUL4C)X>4%!-T<Q9U-2=6IY36=Y535967!9;FEL4EI)-28C>$$[
M1DMV1S1$2WES2T5-1#%"1TMP5$@U3CAO4E1X>GAA2' X8SA,4GE1>7)A=VAK
M9455:5I70S%":D@R4T]N8DHK2DQV3$AH2&-Q6$AL;B8C>$$[>35C4FU/-#!Q
M>FUJ37-L=U5K=#1M6#%P<2MR2E%R.70V;FLS53DX4DTY-F5%250O04%,-4M#
M4THO:"]4945P1%-,.55G;WI+4U9*2"8C>$$[1&-G<V-0:5,W>6IH2&-J0F]M
M:DMB2FQS3&17,#%3;6Y-26M"=#%:46A71&(Y,D-O-"]$5&)">$9.0D9&8T-R
M0TU+1FQ0:4AZ=V]7528C>$$[,U!Z>%94=3=#,79%5DQH02]"=6-B9$=2-D91
M-D5B<7<U1VA(5$1'6FIY45EG.#!O;'10,&)D=V5P95A+5TY9;5=1>DQ1>5))
M-6Q%:28C>$$[=$=&-$Y(>6QL9#5+;&AT=FPT;'A$:TPY,S0Y=S)A*TAH4$TQ
M*U W4VUT:F-Y2F,O535*1W52>%!'-5!%34=655EP349734Q)=VPU2R8C>$$[
M04XQ-T-M*T=)-4]+4FQW:4<S1%8O2#=E=&YP>38U1GAO05AX9&9X-W9*36U:
M55)N879&45=.05=.0G9S0E5N-DU+;T-,5VYL;&%/3"8C>$$[5&(Q:71A3S!A
M>$MA94)L6DU&<E,O4F(W53=T6FAE,F8Q57A/558V-U!1;71&,S)!<'959SES
M5E-V>F9:+VU"8U0R;SAR,V1N85=Y;R8C>$$[,S%S,TQ5:UIY>6QE3F)E-5=I
M<7)!*U!,=%%:6D%X+VE9>79O;"]L6'DS-3!S=%!B5#EF=6)39E1)3&%#,G-R
M5WE,9G4Q:59O;3-A2R8C>$$[3GI737(Q8S=J235H0V-33R]M=$AQ;71N8G1P
M84QA,F-0*S0Q54TP=#E)-%EH<6MS0V=O5#A)1V$O1FI/;CE%0BLW<7I);CE$
M5T)W-R8C>$$[9$9::F)A:EII87A#;'!U46EV0VQ05&%L4%5(4&EX23=5>2]&
M-$]3<V=I2F(S9&9R,V)2;6QW,$-A2UAE43=Q47A247I4,T8S-GE4>28C>$$[
M,C$S3TMC-#0U5FIC0W)/4E)I2U8X8WHY4DAE,G)#9&U15%1A,4I-.&1V8E)W
M>'%30F-4=GIQ0C-73DXO=EE::DXV-U,W2%5R95<U828C>$$[.'4O<E-Y<T1%
M=DAI13(K2V=Q859*-E9X5E5#4VHQ<F5/3DXK5$9I95 Y-E-E=V)E=&-N-7-6
M46DT:VUI2FHY3DEY5UES45-35DMG3"8C>$$[>'(T.3A'>5AN;7!F;6(U<70U
M8GA94$IM<%AC2WEY4G="64QN;$EQ359346=W8U9344%(6FU)<C!Y,%E2+T]$
M07HX;6$V5F189#-P,28C>$$[:&8S34)T3"LW:4-Z45-Q>6U):T9Y:DLS1G%Q
M4E1T6')L6D971U--160W16YP>&E.:7I-,W%T54%&;4Q'<60K=3-X64YL,UAY
M5S!V,28C>$$[55%14W1#-FA65U5"5TDT*WI!:F9!5&%114@V3W9X8DI08C-)
M+W=#3%5A2G8K0U%U4"M&=TI8,E5L-V175$15<DE24S=H;U-Y4TLT-B8C>$$[
M:6TU2#,T,E%G<$I+6DY+,7-T<'5J1F9R=VHK<W5!9FE+<U9O<%)M:E1I=35R
M;41Q3F1M131X15-9+W0W>'0X,FLW4S)$2T-10T%4=28C>$$[96U:>F,V;496
M1SA3-6$Q;5<Q6E5U5VI944\T<7%Y1E1X3$1W0GA6-'HU4'1F>D4O,TUF5C=M
M-# V5S P<')3*W9D574Q=4E0,#1K:28C>$$[=3%W03=89U9&9TY$4D%P1DYH
M,G5(1%ET:6)R6FMC4V9N:F-A4&)R83,O;'E:<&]+9G!.5&-U-V-O;#14>&Q9
M+U%*3#%F*S<T9%!H."8C>$$[6F9U-R]I665U=6ER1DPK8C%L0EIY-C5E*UA)
M8D=#9%<Q93E6<FQ'*W%+,&1E1%-+<U%K66-W86=,=4M5>"]D;FQX2T]0<E1/
M.6I1:B8C>$$[8TA+1S%$9E<W3G!L:%=E37I/2$M20C$U2#!M0WE51F$O07I!
M3C1%-S5+:TQY4&E'2T9,.6\O4$-H55A!56AC,%5C<V)24V](:F-&6"8C>$$[
M4F=#<DM246=G.5%C8G!.5VQM<U=&=3DS85-.1VE)-WI#-&Y#4G$S>#(U:F]:
M>7EY>&-G<6IL1T,R=T=W>3-&23!F:#DO9'E0>&$U>"8C>$$[1FHX9$5D<&LX
M-6QU3%,T2FML9U!Q0UEI3D]58W)/54%J1'1)06=8:%9W3UA';W)V:TUG1WA$
M2TI027!G0FQ43F-":7$W1EA5=TMP1R8C>$$[,&HK3&I50G1Y=E9A;G)T:%=K
M=G903#%H33%V3F-0-F-.:T=+4G)X4TQI4E$X9V%I9TAY>DAN<%EY;$4O>D]1
M2$II640U24Q12F)3=R8C>$$[;$5/;TIP.79Q9#@U3G5B0D-&;&@R-$UZ1W4U
M8FPQ4#0U8FXQ5T]->$%Y3FYK0WAG44]D5U=454=38EAB67%W*RLX-U173W93
M,E-E5R8C>$$[.5=U,$5J23$O8C(X<GA'3DEG+TI3-%)4*SE,24%$,C5!+T5!
M84I:>4180U-(630K>C1Y>#AF:5%"<FM:8C@O,6(O63%**UDX:7=V328C>$$[
M=FQB6&U73#!E8695:C9H17E&+S-A.'IY2T5C6DYX>'=E4#A!,%IF2FU/>D)D
M94QI-B]X9#-F-RMJ3&)A8WHR,%4U:F5%>6]R;4M58R8C>$$[6%1K2SA804IO
M=S9(9DQW8D9U=&Q':5)Z5712;$U.<$QC2F(O049M5T93.&-)0DQ-=S=,44UA
M+U)K37-Z0T))1FMD3SEH23=*8S-M528C>$$[:$9C859Q0D)R565G95%O;U!3
M=FDQ4'8X37A$<F1R-$UN*VPO2#1T:#1N:U4P<S=N-GIB4GHK;$I"-F=R-E5W
M-'E,+W),53!Z3'AZ-"8C>$$[;V<P4F9F>EIG,D9B8DQ%<E=J1$M64%%I:$E*
M0C,Y>&IA<TAU-VUZ;3AZ5T5,1SAG;71R<U%R8D,X1$]367A,-FMK0CE6:D5F
M<VQG.28C>$$[2UIL9T514$QL,TY"231G>2LK<TQE.%)6;$)6,%!+2U9$>&M1
M*TMS3GAM23-O85EA<%IO:&=R<45+9RMQ:FQ6;BMA<T%Q3CAI069F1B8C>$$[
M5F$Q,4]X=55,4GEQ1U93,'-414(T-F)-2%AQ=D4Y831K,')$+TU6-355:3 S
M53E,:5),,4Y::VMK,4=*;6M-6CE606IK3VA5:EI"5"8C>$$[9W=P,7I787)T
M94=/=4%G>2MX;WE:0E904#102R]W0UAI4E178VYL-DU79'A'67!8:6YU:$U&
M3%)V.$QY5%-F6F%&0T(W539%,7A)928C>$$[,'5B:3E10DAK-#1L2&Q7>DMT
M12]*;CAN-VY4655T3D\K="MG04AN935U5FY:>49$3DIW94]H8C!W84)1;TYE
M24=D0F@W4CA98U5*5R8C>$$[,W=X=TDR5$LU+TIR.'8W:3=G;G5,0C59<E<R
M93%T<E8U-51':7EZ4WIY4%AL-FI/>GIS87,U<'13:$9C=4=E5DTO0VIA>4@X
M;5!Y,B8C>$$[=#=U1S=G,&=X,TYV2DA.1$MT>F1G<3A20E)V-S,Y:W)J-#@K
M.69#:GIP;59.>&Q43DI0369M3WDX=C9F.69V165317EP1'AJ35E02R8C>$$[
M43!'.')X3%0O6EI:1TXW34-A62]99FY*-4YU67I*2CEB=%(V2S-#<DQB=7I-
M:G-%5VEX97$R-TU"=4MF9FMZ9VMO;4<T+WIT.&A'4"8C>$$[,5AU6EDP17,P
M36A-64I8-G5Q33=K2WI%<E-1530Q2F]A1&)!8T5L.%%)*S$O35 X=E!-9#E(
M;SEP<7-C;6]5:G5,8FQ!>7-J=4%9;B8C>$$[:F$T:3E)4V9V0G@W,4Y/=4EH
M3T<Y8F9J=5%:4FQS>4A42'1V,'9Q<TM#='=J=T=347AO<#1.0T]#96]#6&MO
M47I68G!Y;TYS<FQ+=R8C>$$[1V-9,%-M-$=6<VPR2W0P=TLT0W5+5G='2W!F
M-6=76CE,;&EI,#AA;C9P5DAT0S9X:&M**TDX;4E!;TUN:C4X-EEZ-6-R445U
M:7EW,B8C>$$[05139$]T3$\U:$$K<5-0>&523CDO=T)H:%@S-4A-3%8T-7IU
M55)(>$]H4#EJ17<R,D%4<3!&>4Q315A21%A):E54<W91=E%C:4]M,28C>$$[
M8W9X.%A#3TPV<3,Y-TUC=#%B2G!D:7)S5F1I<G-69&ER<U95<G$U:'1B85<U
M;EER1$-P:VM907125D9384M#5'0T65%,3DM45$@U-R8C>$$[=E9.6G9);W)2
M16PX<UAK0D4Q-T,U:G5&9&=E;%=2;&]A8F-E;C-:8T%):F8V=S%%;5(R*VQ/
M-TA4-V5Z=#1962M5;F]*-F%3>6YN2B8C>$$[>#DS3RM5>6M35W=#:U9T9U-T
M27A62G9-96YX;E-T46YT;U97.65&9S!Q2T))>2]T2U-.>CA)>D8Q,%-C375(
M;E1$2CE*95-S>DUA<R8C>$$[4U0W-7A"3'(R<T-S:SAG>51R<C133592-&XY
M665#:6A"+S1+9WIB9&EM47HW8W%.+VHS=#)$-FYP0D=D8S5I:S)+<D0Q=V]3
M;E5O8B8C>$$[*S1T>DA9,VXQ1S0Y4D<Y9C Q;2M"6$)D3TQ%1#0Q0E=V8G)L
M9UE&:7(K5F9Z4&IJ.6%$>G%,;3AJ:&%.27!B0T-#1C-:;5!.*U!Q."8C>$$[
M4V]+,&]P-F8U5U=C8U U<D5#6&5R,TAK+W=$375E2FM4>C)95UIU4TUU;#(Y
M5E=H0EAA4F586'%2:U)/2#@S-U5M374Y:T=G-D)R528C>$$[1FYE,F5V-G@K
M;F)A-E%24GAV8DIB*VY'5EI847-J33!N24U.,DYF8S%Y=55G95%P;4%5>#!8
M>35O96ER2W5L5V-D<#E926%B,#8Q628C>$$[<4M,56MN<%A)17-K,4="5WAG
M5G9V:6QE0FER<U931'IP.5AH,&Q,*S1N=5E98D-E2V0Q=%-!-S%C2G@S2S=6
M9GAY-T)F1E$V=&58;"8C>$$[9F-Q-F9R3VEC<GAL;&MH5WEG4S1V6G)U4FQ%
M551Q>FAN.5IQ;T]+16LW1$EY0C5-9U)Z5$\S=C='-',P=F)E-&EM<W!516MD
M>D<V="8C>$$[17E(8TUR9VQ34&5U44E.,'E"46PS-6LX=3)6,F)/.#%3>G1R
M<T%-8F5A94M/44M14T1W6F<Q0T)H15-E:3)%9$)00F-1<%!"27-S328C>$$[
M<6@T-55)6E=5:6]+<TYI1&M65DU69&ER<U9D:7)S5EEW<W(V;C5S9#=4535R
M8CE&05%81VY/:#E+6716:30K3F$W34)8:C)'6#%W=R8C>$$[,TA0<3%C-6)(
M:WE#1T5C>E!*1$A(8VMC5V1$>4I52%E&:7%N2U-E:EE!<C1%=7A6,D)7:4U+
M=D5B,%-#.&Y%<65N2C9J8S0V531M<"8C>$$[,GIG8W0X4G-58F1B3&UH,5I8
M8FEP1$XP-&IC-4-I:6YP+VLO>3,K:#=&,VU!3CED3GIM86TV3%0T638O-5 V
M.#=,<S=3941J,RMO+R8C>$$[:6Y/>'AO2CAX>EET:6MX=V]5:61X:%%J9C!F
M859R-F4O=T$R+W)K3TES*T5,:%I7=S9**THO<FIX1F5%3FDQ9TA29GA/0WET
M3&A"128C>$$[4#)F>$].<E1F<$HT63)T3CA&.$U&<' S1F9$1EAC4FER9$U6
M9%%9<3!656EH1E(T2$95:S%4>50U6C%454<Q0SET1V4X9$5J:VQ3828C>$$[
M94QK<V1E25I9,U)7<'E055I)4TE24U%Z9FMR*U@X=711-G0Y5&U384I':F%"
M3&E54E!Y:3E(:S-X1BM3>&II3TQ$3%!Z139P:#19=28C>$$[,6%(.&UV>3%H
M=5=U;SE'551U,TYN33EY,WAB-S!-:$@W4E!Z,W@X969E;G<T<VXP6%)D33!8
M5$E.3#!Y2#!,0S%"5T-(:S<X5DQ&<28C>$$[0FY,3E-P,C,R>755:51:6D%5
M:F%$27!D45EQ-F=X5C%":7)Q1$963V4R=#4P-%12<DEO3E%'1F%(>$AG9F9#
M0U%G:%5O34-854=+=28C>$$[;TU69%%9<39G>%9#6&5J-EAE3TAU<E=+6C$S
M1$]O2C(Y.'!Y869(33-+24Q%=T(U:%9I<V)/24MS545C650W0591;TAY<#!Y
M=U%I3R8C>$$[44-A0W V865'5'1.3F5J2#1F:6-B4E12=&]4*WHK2GAT85<O
M53=E=&5(-&XK=5!%5F]0+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P
M+C N," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @
M/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(^36EC<F]S;V9T(%!O=V5R4&]I;G0@+2!3-"!G<F%P:&EC<RYP
M<'1X(%M296%D+4]N;'E=/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F-R96%T;W(^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/G)R-3 Y,38W/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI
M8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@
M(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP
M5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T1&EM.G<^-3DU+C(W-3,Y,3PO<W1$:6TZ=SX*(" @(" @
M(" @(" @/'-T1&EM.F@^.#0Q+C@Y,#$S-SPO<W1$:6TZ:#X*(" @(" @(" @
M(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \
M+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI.4&%G97,^
M,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE
M5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R
M96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A
M;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM
M<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM97,M0F]L9#PO<W1&;G0Z
M9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY
M/E1I;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14
M>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP
M,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^5$E"7U]?7U\N
M4$9"/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1I
M;65S+5)O;6%N/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86UI;'D^5&EM97,\+W-T1FYT.F9O;G1&86UI;'D^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y2;VUA;CPO<W1&;G0Z
M9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4
M>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S
M=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1FEL94YA;64^5$E27U]?7U\N4$9"/"]S=$9N=#IF;VYT1FEL94YA;64^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^
M"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L
M871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L
M;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O
M=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO
M>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R
M;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @
M("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT
M(R(^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM
M<"YI:60Z-3DV-44V-S(P,3)"144Q,3@Q0D8Y0D)#-$(Q0D0P-D(\+W-T4F5F
M.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM
M<"YD:60Z-3DV-44V-S(P,3)"144Q,3@Q0D8Y0D)#-$(Q0D0P-D(\+W-T4F5F
M.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^>&UP+F1I9#HU.38U138W,C Q,D)%13$Q.#%"1CE"0D,T0C%"1# V
M0CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12
M968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA
M<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-4$V-44V-S(P,3)"144Q,3@Q0D8Y
M0D)#-$(Q0D0P-D(\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I);G-T86YC94E$/GAM<"YI:60Z-4$V-44V-S(P,3)"144Q,3@Q0D8Y0D)#
M-$(Q0D0P-D(\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HU.38U138W,C Q,D)%13$Q.#%"
M1CE"0D,T0C%"1# V0CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z-3DV-44V-S(P,3)"144Q,3@Q0D8Y0D)#-$(Q0D0P-D(\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C,M,#<M,C54,C$Z,S,Z,C,K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C5!-C5%
M-C<R,#$R0D5%,3$X,4)&.4)"0S1",4)$,#9"/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 W+3(U5#(Q
M.C,T.C$W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#
M;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M7,=42-=N7EK-QFOK:.EFSLF3&IN?U!2(LLDN>83ND9@V2!I0Q=N;H3RQ_3E
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M:6UAJ5'1@*VTM9+R@?6B6REKA&]9CJ5O[/MJ'C"E2%S*2,P.N-#3W2!,Y_!
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M!4M6JH\"U17B8TY6)HO5Y6E4B4NQ+<FXSLF;,#%<.V<Z^UFM<HZ?()07#\Q
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M+RB#G_B8[/Y72#B)XH%?ULQ\NYD;EVR<N^34 Y %ZK_5ES:XJ2JX%J>'Z3D
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M((*R02I;*E+2HI(05*T/;L"GJA"&[%4-Q<AU4D:=B#[]+^>V- \@ %VL-CJ
M;:[Z;$::Z[&V^,&O#\:>47%8W4/*1I2TJJ89V.X65N--)6 #L [2?KL;,-%
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M =!4BFJI25>70[FA5$=().@5%*E$:!WOK$TTX.7EDGLI#7Z:92;XT$\1%\X
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M0LQ)N&NQ()ON!>P/EUOC)J8<0$EQ"D!8\R5*205)/NDG0*3]#UH"#<YP;7!
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MEM<WR^_D/(;84E*PDH\RPA1!4D;"5$>A4"='7?1/IZC70YB025)VN2NW7O\
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M%N?PP;;:[^7C\O''OD;26BR\M"E ?%.]);^]V (/F*4C78['I]Y1/0W.:[:
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M*DDBX.C7&ECH=??TQ,D&.XA$.($+2"7/C.J0A202I2FTJ<0@@;(_S^8_L@J
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M\PL#Q*L5N+5,R2G1#]@E4MQ1 'WOAR%O,MD'>OAH2.P( /IV145.@!,0+?\
M.<_UT_\ B/+J>>2IE8D9R!V7V?F-?GKC:6VVVD);:0AMM(TE#:0A"1\@E(
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M7]CA2TH=5YPXVCXA 6%)* A9&U'R ND-[]#OU.O*!U3+:]P;C70Z$>>NOZ#
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M>.FIPS+W^O\ ?Y?3 S"D23Y$!02A20?,ORH05]M@$^X'?R DZ]#U(:VIU)[
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M-_AV_P!_J,+<*1'2VGX+BEDK6H-+#S9T!Y"X=!0( [)! T1L[^\4',2"1;4
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M[WC1M/E[^8J_9/E\H3W5_E"O-Z)W^T1][7IWZDWTM;<7OVZV\<0+:W[:>>/
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M-]2;FQ\3?#W5L5QZ01KTT1OL0==]:(!)!['L='6CK1!, @WMT-CYX6M]<>J
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M>'2VH%0(3M'<CS(([*\OW2%:7W]/(22.X[=^IO?WX6-R-R.Q&%(3Z^8'1!T
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MBQX%2MG(EJU:0SL761$8&HIX*61E8)<6AIXPH&@(8D-<@Q9/Z+?PKSZN33Y
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MQ"B#B!XI&IO.2UJHW8M=B@RW.I*3@=)(9'=ZEVE,K2'F1 L9J+^7NVD-M:<
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MTP3B7BS(G^0<OX]X6PSFSC_",3R:^QZ96Q\/YX9CL9C2S'V,5AV*FJ=J#6C
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M'^H?0XNFY\OU&'<G.\CO>P&K>R!UO9/VQ\[.R1O1 ^Z - =M[)K2_P#AXO\
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M;BV-0MKYCE W W]Y[V.NIL0#?"P@#U[[]"0=?C]?G^7;H?\ F-R/Z18^Z]P
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MO4#6R>Y]]#OKOU/,%K@]>H.NVFI/<=O/ Y==SIV%O/2WSPI:3_X=:'HG1 ]
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M_P#*=;T.Y)^8 _D._P AU4M?5<S7.]K>U\=.FN&<6L 3X&V@MMUO[\+#:O\
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M](Z\U<2FI=?("_,J>%M'Q.OH*.83QT'K#25,B<E4AI@#,\JG,08W_!.4,7D
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M1!DN2JIEEP/,18[J]N/\13B'$ZZII6<4U7-%,J2)RW+1PB)>8%9US+=POML
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MAZ #U'N-_7W/UUU\NS,QR+?_ )CU'=1TT&YV U[X^B6ULY\+ VT-M/>;^.)
M &DI'?7?Y#MW_GW^OU]#%5%AI;0G7RMW[=<2H+',VP_*.XN""3]-+_J^VV5'
MRI!)T23KV V2?H "?PW]3USDEO #[]Y-M,:XFI0$ :T=C9())[$C2M@:)UL
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M[W^[^'49B-C;W"WPV]^+!1:Q%_OSO\\'D1[@^OS/I_7J<[=_D,,B]OF<>A*
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M+ "^25.6U[&Y-A89C:'PQ\R/Q[_RZX,=F/"V?8@_F/\ 3IACSR*]AO\ #O\
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MVYHI"7X5S3?K.WGSX;5K43F8UC <>COI6V9,5MM\;7'<>:\KBO0XY>3B$TZ
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M[B3]8VDGXZ,AR;&,@Q6K TN3EE1.Q="?U^R:[KF/"^(A)7-'.$@,JS,4-HS
MB23!NW+CECE;M$ZR_P"&<V.@<1H2T:BJAS2B,Q@.+N)69(RO?.Z/&O>12GYQ
M;&V<,\PX)S]QMCW+/&<Z=:8/E8LG:"RL*J?2R+"'7VLVJ^WHKK-F/.9B37(2
MY4+[2PS(5#>85(8CR"]'9Y:ZAGH*B2FJ%59HLHD175PC,H?+F0E25S96L2 0
M;$C7'325<59 D\+,T4F;ENRLI8*Q6^5@#J5)%Q<C< W&++4C7<=Q[_,?]!Z?
MV=<?C?[%O&_^WG;I-MB !T\/S:_ >Z^$HCE]1""E.AM7F]-?/L#LD^O;WZN&
M!76^EAW-^X['?&;+;2U[[?/3SVVVZ8Q[C8_Z_(_AH=OI]/PZV1^A[7![COM^
M;76^_F=:C?*;DZ6-MQM8DFP(M]](WE5W.B0/70V!^)'IZ@=^WRZT8 [D#WZC
MR'7]?<,00&TZ]/,Z;]M/O?##K?F'F'J!W^H_'YCK+:X(UOO?Y8S5K:'OYV/W
MVQ"6-'?I[*_T/[NW\/;K1&*VTUW4=][WWM?Q'QQ=A<$>\>?Z?9Q.JQN0M0&S
M\!05H=_^\;T?RWO\!OOU,M@ PV)V )L=;_=OIBJ'<'==/I?;W?IIC'WZ?_<A
MNSKTM)_?ZF6\3_?IU>F_P8_]"?-%_;&,_P#BR>+L?>&(QC/0:WZ]_37SU_ _
MOZWQD!<@=\24)V4I^HV._P!23^[O]?EUD]R0!U-B-#IT^/ROCH0@%F-K*+#I
MV^6XVMIB4!L@?O\ P [:.QW] .^_XGJKD* +?E&OF;?V^QBR F[;W-N@TTUN
M#XD]/=B4RG:M^R>_[_8=<_<FQO\ 7O8?[8NYL//3%+<^^'O!O$=BM7B&>R<A
MB5E1?Q<ABNXY9-5\I4R-&EPBR_\ :8<^,]'>C39"%!4;X[:BER.^RL*\_P!)
MZ,>DO$/1:KGKN&I2R33TSTLBU<32IRV99 5R21.K!XU/Y\K >TI%L>+QG@-)
MQZEBIZQZB-(IQ/&U.ZHQ959"&S1R @J["^6ZZY;$G%%<.>(/CGER1E=.NOLN
M.N)?#L_1U3LS/)$>JJKVR@2955CSEK8SI*&84;'S2-3F:>QD.SI=K*JI\PLO
M5K4>3]-QWT;XKP1*2<21\4XYZ4+4RA.&H\TU-%*J35?(BC7,[5/K#1O41(J)
M LT2 B8LGB<+XW0<4>:(H]!PO@7(C)K65(II49HZ8SR.P1%IQ$)!#(Q=Y6C=
MR#$%;I7)L@X@RC$\>RO-,FI:S"YDY]W'+2]R&/BU;;RG&YD*%95-HY,KY$A$
MVO\ M<JE>A3D)G5LP3D-.MK8<:_$_3'^%/#_ $]GI.#>D/!^(\8_D=1+Q!>&
M<.GKZ9Z;B,U(]$:R6IX2]/Q2FJJ&FK*ND AK8(XGJYUJ$FDCA,'Z+P3TTE]'
M(9N)<-XA24*\2C%,:RL2ED2HIEJ%FY:Q5HEI9H:J6"&:TD,C.D4;1Y$9L]-^
M'ZKY_@<JYNFXK<5QCPR*KYAXDQV'!KX-^\%64955;/L>4Y*S)G529LV\&4/)
MDJE38B6(;)2XEC[*C]#/X6_P_P#03@7HEZ!<&CX/6<,<"OI:'GFABDD262MS
MS2/)'5S/5L *M7GFJ"DCSU,K$,WSQX]Z;>DWI-Q/C7I+7&MHJU6-)-49!52(
MKHE,ZQ@+- @@4DPR+&D89!%"@!5>VT)WW([#T_OY?W\^O)1;ZG;ZG]OOOCV'
M:V@WZ^6)*4DZ*O0#L/I_3U[=:XRQ4_-7)5IQ1A@RNLQ5W+E_K6'6.P&9KD-<
M=,Y+R69A^%"G./MB2AF,IIM"%^>0V0K6]92R&-;@!C>UNP/73QL,610QL21H
M3H+[??\ MCDI'/7BWS7MAO#S=-%=_P"XERL?M#I*NR2)]],A5SFM@DB/KMW&
MM#KE,DK$V2U]?RGZG3QQO95L";@6W9=AX#76VFOF<2$X7X[\M!599A7XHP[W
M+:;.CKE-I)] ,;KYLE/E';NZ5@ =]C?3).PN38;;@::#2US;]L5O%K:Q-R?R
MDGKKJ;>/0>':G>:O#ASC58]57^69Q+Y,L7KZ)2P:2'+R&]EQW[9M\AZ)^LFT
M!*5N1&F74QXZ/,%MK4KR-G6;(]KEBQ!M;VB1?S [;#%@R$E;VTO?* ---;>&
MW3'47A>\,^3<9_"RK,LFMX=I*:"T853VLAJFCA:?NJO_ (#OV>TEM@[3%;!B
M1U@^=Z224(TCB*ZL3_I!T]_0^0["Y.V(<C+8D$;;>UH-+=ATN1UM<;X[C2CT
M[:'S^?X?/Y;^GTUUOC, MM[*^'6PM[R>M]/?C2L_X^J>2*J#CN0/2EXRFU:L
M+ZECR)<)O)HT:%.1#J9\VOEPI[$"-;OU]\4Q)#:GYE-!CR2Y =EQI&\%0],Y
MDC $N4JCD!C&2RYF4,"N8H&CU!LKL1[0!%)8$E4(]^7FNZZCF  V5F!!"ALK
MZ$7*@'0D'GS'_!]3UT6'5W7(F79)3M8YP!C%A%L6*H3K^!X;,EMLJXZ%Y<J8
MD6,LR;:T:7E[[#L6QR-JJA(58Q/M5R;;NEXN[$M'3Q(_,KY%*9BL;\1C6.HR
M("%4*J_A @K&7) :R!.)>'HEE>>21<E(C!@ 7%#(TD&=K,S79OQ""#)E%V%V
MS0,C\$6"92+2+<97E<VJRY?&=AR+52)TQ]C-LGXXR7(\E5EOVI=B9N+WF5OY
M//A7S^*R*I+<6-4+J4UTFGK'8J/C%1'E*QQ*T0J5IV"J#!%4QQQ\FV4+*D0C
M!03!]6<-F#OFSDX;%(6#22,LG(,RW-I9(7=^8#?-&\AD8,4(( 4KE*K;HRHX
MU32\44?&)N9-W_AK&JO':V[L(-16RY36/LLQJ61/A4$"KI(\E,:'%8G_ *GJ
MJN XH/N0JV PXW$9\BHE$\TTN14YTC2% 6959R6;*TC-)ES$D!V9@+ LQN3Z
M4$?)BCCS%N6BQAB%!*H+#,$"H"  #E502+@*#8:SC%HY*BN5D]"H]S3J^Q6$
M9TZ<VR?A(? _S)<\H"U E(<V1M"VU+]"FF$B!20&06/<@:!NVUK[Z[]L<L\8
M1K@$AS<'H#U7;>]R-=NF/E9REX;O$-DW.E_:PH4ZQA762R9M1F2;EAFOKJ*1
M*)A-NN_:T3:]-1 6B$NN:CEW_AUMPFI+:VEN?Y\>G/\ !O\ BWQG^*'&*VGI
M:FLAXIQJIJ:#TD%?#'14G"YYV-,)934K4TB\.HV6G-&L1EM 4I(YT:-G^"K.
M#\7GXE)(BR,DDN9)^8%5(B?94C,'41I[.7*+V.6X()^AF<\J<6^'J@QZMR-]
MFEC/LF+2T6/U/G=>:AI:$N1&K8:6V(D5MQU*G''G&4+==\J%.O%8Z_KKTH]/
M_0;^$?">$4/%'BX9#+&8.&\*X10!I'CIPHJ)8:.G"PT\"/(K-)(\:-))E0R2
M%ACZNKJZ'A,4*SMD!!6**.,$D+;,P1;6%R"Q;J2#<V!:K^=*/-Z^(KA^MF\B
MVL]A+I\J)%'CN.E9*0K,+Z?$+=4\V4J6:>%&M;^2V$NQJM<5UN7UV<&_B+P7
MTLI*>I]#1-Z0FI0.[\F>DH^&L204XK5U$2I2SJ0Q]2C2>ND3+)' 8)4F).)1
M5*H.'1M62. = T4, -__ !$K+^&1;_#4/*RZB.Q#'*5_$RKNQB9)RQ;MY[=P
MWT3*JA^RF%Q[BTE)\S;E)B[CLA%E8QE?]UD.2O6MLE8^+ _52%?9D_7TL-0@
M$M9.)Z@ZD1)RJ6'3588B68VVYDK-(VXR7*C>/AYD835\@JI00R19<M)"1:W+
MA).=EMI),7<;KDVQ\Y>0_%ER#9^(S(.*/#=A?'&/W46[N,8L<LO**&;S,LCH
MUR&)<)^P28S#,>RO8HQ['XTA,R9<6\FM^'-8=LF(;'ZQ1^CU''P2#B/'*JNF
MB,450E/%,_)I89LK*ZQ^T2T<3&:=ERK'$LA*$1EC\S4\8J6XI+1\)IZ2&3F2
M0M.\2B6>6.ZLI>P #R+RX@06=RGM N%'8?Z/GQ$N^(#'>1%Y+61ZOD3&;:G5
MD:H#;S55/K+AJS-1*@,277Y$)Y$NNN(\^"N0^A@MQ'6W0B2(\;Y#TM]'5X%5
M0O!,\])7"1X3+E,L;Q9.9$S(%5U"R(T;A5NI*E;IF?Z'@'&6XM#*LL2Q5%+D
M63)FR.LF8JX#7*DE'#H6:Q 8&SY5^@=Q#F3*>UAU<Y57:2ZV=&KK1#;;RJV>
M_%=:ASTL/MO,NJAR%MR TZVXTX6PAQM:"4GY$[&V]C;'T W'7'&$?P;SLM>;
MG<V\S9YR"_YPZJI@RUU%&RL_M--M27+(E@;.C"CU*M?LI1WZID)W)^_&YQ;-
MV%O*W0^7QZ>6V+WQ+PY<(81\-5#QQCADM >6?;Q#D%@%CU=1,O%SWF%D]_\
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M7?VYX)#[H\?-/Q:>/+_9YRE2T%3X=\9FV=16UUG<6/-.)!K*D_;''5M1,?\
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MN1^7Q/Z$8G)&DCZC?YD]8/N/+]3C1;:GJ-#[@!]0<24#]D?G_,]547(&+,;
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MXKS%CJE+,K4[4\CO3P(;63F@)&N0"TI=4S$$D%2"?MW3"S:IJEJY=9>N&ZR
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M2HCT6=$G\#<6RH[K:OA@X](CO-/0K_(8MK1N%4;',5D##4,LTB,K9J-@ZLK
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MK^7KUJAL<I\?CI^F+N.NG;QZXC+'H?71[_A^/Y_G]>M,9XB+2-D;]1L?CO\
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M? ./7%RQCM7*D.P:1FVM7WK2S:K&(R)UBZ[-E)=DK4Z>N8!:.C(4!F29F8
MFTC!<QM<V!L+[ 6VQQPLQFK 6)"F%5!)(&:)2P4'07W-MR;X[@0.Q/[O[_OV
MZXT_*/&_UQU+HK-UV'[W]XQ+2-)'U[G\?;^&OPW^/5L7464>.OW[K8?;&AL[
M^8[]O*>Q_/L/W'JI-]B.HU']0U'G:Q.*.=;=OU&OU^N'D#U._3L/G\]_3_KU
M5S;2UKZFWWKB4'6]P+@?6_S^>'.L\:8?"?*->_O^/]/ETPPM(\QU^\_A_7IA
MAX#0T/\ S_'IA@]>F&'4H [GN>Q_ _Z]9L_0>(O^UCAAP)*CH#9]>L\,2$-
M *5ZC1_#T[$>_?\ /IB?T^7B"#\/'"ROT\O]_36NF!MWN>I_W'SPWZ],1CY6
M^*7]&R>?^8Y?*M#R6SBB<F;J&LLJK.B?N%-/5-?$J$3J-]FQAI/QZZ%&2NNF
M!IM$IMQ]N86Y CL?H?H_Z=#@_"TX=/0-4&GYOJTD4JQ!EED>4I,&1[$2.UI%
M#74A2EUS-\AQCT5'$ZXUL=6(.:(Q.CQF0CEHJ!XB&4:JH&1A8,+YK&P[HXT\
M/7$/%>/T%)C.!XHF714];5+R5_&Z162V[E?$9C*L[6W3!3+DV$Q;1DR72Z$_
M&<5\)*$!*4_#5]4_$:RIK9U7F5,\L[*!=4,KLY5+W(5<UAUL-23CZ"DX914<
M44<--!FCC1.<88S,^10N=Y,N8LUKDWW.@ TQ='D3Y?)Y4^0CR^70"?+K6M>F
MM=M>FNW7+86M;3:W2W;'?^F@\NV-2Q[C[!,2G6%GBN&8MC=C;$FSG45!5U4N
M?M8<(ER(,5AV0%. .%+JU)+G^\UYR5'QN&^CGH_P>>IJN$<#X1PNJK"35U'#
M^&T='/4W;.1/+3PQO*"_MD.Q!<EB,QOC&*FIX&=X:>"%I-7:**.-G_U%%!/>
MQ-KZXV_KV<;8.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z
M88.F&#IA@Z88.F&/D5^D,\8_.GA]Y"P[#.,F*['Z6PQEG)).36=%&N57TY=G
M/A2*6(JQ;>@QXU8S#C.34L-?K%2[)I1>CL_!^-^E>A7HQPCC-#4U=>7GE2H,
M @29HA"@C1UE81E7+2%V"%CD_#-@Q#6^*])N.\0X94T\%($CC>'FM*\0DYC%
MV4QJ6NH"!06 &?VP;@6OTCQO8<6^.SP^XI$YEH\9MLE7$CVF4XA76DB!=XI?
MQG9<*+<Q&HLYO(*!JZ@%%I 2\Z6GZVT1&<<GQRI3GAUR<1]$.-5+<+EJ(J>Y
MCIZF2(/#50.JNT3%D,,QB>\;$#,DD>89&%QZU*U'Z1<,A6NCBDEL'G@60I)#
M*MP)%56$L(D09U!)!1PI+#>W./\ PK\*\4FB7QMCEGA4BBD)?,J@RK)X;V0)
M^(IUR/F"/ULN-ET5U2B Q?QYR8J EJO,-M"$I\VL](^*\0YPKIHJM9ERY)Z:
MG=8-  U+^&&IF%@2T#(7-S)G)-^RFX104?+-+$].8S>\4TRF34FTXYEIUZ 2
MA\HT3* !CHCKP\>G@Z88.F&%)5Y>F)![BX[;:^>^%'R+&B.Y_/M]>F%K[:VZ
M:Z#X=+Z_';7$=QLH.P/N^Q^7T/\ >OY=,1AH@$:/5E8CR[?MXX8:*2/Z_P!_
MW_/K4$';^_O&&$]3OAC\]GC$X!M>&^2[2VA0G5X#FEC,N,;L6FR8L&3,=7*G
MXY)4E/DCR:YYQPPVU$?::PL/-E3C<I#'^:/\;OX;UGH+Z55=9! [>CG':J>M
MX55(I,4$L[O-4<+D(%HY:5V;D*QO+2<N169DF$?Y1Z1<*?A]8\J*?5:EV>)P
M-$9O:>)M="I)R[9DL1<AK<A=?BN/GL'3#!TPP=,,'3#&9Q>@M<RR:GP_&XJK
M/([V6W#K*MA23)?<7M2W2C8+<:.TE<B5)6$L18S3LA]:&FUK'K<%X'Q7T@XC
M1\*X10U%=6UU1'3T\4,;$-(YW>0#)%&BW>6:0K'%$KRR,J*S#>GIIZF1(H8W
M=I&"K921J;$EM@J[LQ( &I(Q^E?C?$6L"P#$,*9<0\,9QVJIW)#8*429,.&T
MU+E)! 4!*EA^1HC8^+KVUU_K5Z'\#3T:]&.!^CR,L@X1PBBX?)*NBS3T].B5
M$RC<":;F2VT(SFX!Q^QTL IJ2GIP;\B../-L#9;,?_<P+:]\;6H;4/;8&_?O
MZ=>\@-CV4VQU)L1T_?$98^\L;UW/I]?;\CUU8SQ"6=%)^1W_ "ZHYL5/8W^F
M)&_N;Z'$-7^?\%?]/XZZH@NP^/E]G&K; =R!C'O'MK\/SWO^0ZZ8A8L;==/?
MO\2,8ZZD^0\@!^^(BCI)/R'1S<CPO]2/T^>*./:4> .NF^MOTPY5G_B5C_YP
MH_\ U1O7Y]_RZ@CV;]2?WQ;K[C[]1]-/CC5\D5_[D=]W]+BPU\^TIWM_ Z]?
MR'793:4\##_TD!'FH/4Z;WL!\CCEG_QI?];?4_?NQJN0WE%14KT_(U,IJURJ
MNM^$]'$L3+&[M85)2UC$0(<,J;;74^OK8$<(4I^=+CM#RE8(V1':3+'N0S@W
M(RJJEV8L=@B L>P4G7&#LBK=R,MU747NSL%10-R68A1W) [7J*V\1O#.*3#"
MNW[6BLZJH58HK9^$Y#76D"O.(2<WF--09%2Q+C?9:""?MK26D-IL@FF!<LXL
MR+$Z1P^JF&9,KJSY<RS(RLW-$0)(:QN["Q.N6[6 (.,_7J>(Y79E9 6 ,;@A
M>696 !4'\@-Q_F]C5@5PX[XD.&8]W'KF)L64&+6XK)*8%!?3[N'F$+,N,>/X
MM:U45F.3DL3+"[Y3QAE;UI8TUG^K+.GO:ZNN,3L)%_5Y'A]8\68@@Y$-V=$0
MPF*HG+EVD'LJE-)HJNN961G64!&N*ZE5\H(/ML#9&9EE$D$.4*J-8LT\>[(;
M%'56C+,NZX7SKQ)R;*9J,<GR;MV=A\3.4MOXK>HCNT$K'>/\P:5*7+JDMQK$
M8_R/@%FBJG? L)0MTQZ^/+F4-_'I^:2AJZ49Y $"SFG-I4N'$E1"; -JI>GJ
M%SK=1E)8J)(R^J55/,X",6S1B76-[%#'#)?50 1'/"P4^T<V@)1PNF4_BN\/
M,I<.PA3;&,_91S95\B1@&25DJ<U*I<2R1;\=<REC/*<?H>2L%M7BHH6(^:5B
M)'DDBU8K^F7A=?E92JDK[) J(W52KRQV.5R-)*>9!I:\+6TREJ#B%$;%;W/M
M*3"ZEO9CDN"5!_)/$Q&X$J@B^8!U_P 4W [>(2<N?JKA=8X]R.:N*O#4IF9,
M[@W^.Y^2N4J7RW"D.6,7C'+[9L39D-Y+%9!7D"*F9=T$>RP_E=>95C#H& I@
MQYQM'SN2(\]KD934Q)H"+LPC+A)"MQQ"CY;2E6RGG95,7M2&+F\PH2 #F$$K
M$W!]D9\I9 VP2O$YP74P;RRRF;&@BAN,^-TJ#BV378KIV"3N6H4E4]*<5B6*
M<@E4O!/($Q3#%?*82[C2JVLN+J-9X=8Y/5.&UI=$CNPDCI^6&DC3,LXI67+>
M5EY8:MIQ?,#^*&9$*3+%9Z^D57=R%,;RYR$D?*T)J%.;\,-S"M+,;93_ (94
M,P:,O?\ @N08IF%%#R?%8Z40#(O*$%ZH=IY\"9C60V=!D-+)ARHT:5$<JLDJ
M;2#*CE 85+BNO,*>:6V^YRS1RQ.8Y3[5D?1PX99$62-PRD@AHV5@;WL0#8W
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MITAB5I4#!$!!)N"$4$;=P<1-!*TLA$;$%B01;4$^>,4G#\H2=_J.?_\ NO\
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MZ#XD=#F8YC<Y&N=NP&NAV_3Q[X<K\<OVI"U.54U +2@%%HC9\[9\O8GV!(_
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1.F&#IA@Z88.F&#IA@Z88_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g451428g00f02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g00f02.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1(:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $?Z^1@8X0DE-! 0      #<< 5H  QLE1QP"   "   < E  $5!I='II
M+"!+87)E;B H0DXI' (%  UP<FEN=&UG<B!F:6QE #A"24T$)0      $&X,
MUBTC,K(Y#X#5PD1/>&0X0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <,
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$1       $     (   )    "
M0      X0DE-!!X       0     .$))300:      -!    !@
M    20   8@    & &< ,  P &T ,  R     0
M   !              &(    20                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    20    !29VAT;&]N9P   8@    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   $D     4F=H=&QO;F<   &(     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3004
M   $    !#A"24T$#      '@P    $   !I    %    3P  !BP   '9P 8
M  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(
M# D)#!$+"@L1%0\,#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            _^+__TE#0U]04D]&24Q%  $)OLS^_AX
M"(!P041"10(0  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03
M  !!1$)%                     0  ]M8  0    #3+4%$0D4
M                                                      ID97-C
M    _    '1C<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!
M,D(R   !L   H@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  "
M.+1",D$R  6W*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E
M8B!#;V%T960@*%-73U I('8R
M
M         '1E>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@
M26YC+@  6%E:(        +5:  "\9P  DC!M9G0R      0#"0   0
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M_H;MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ
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MN7U2DHL9/'W&CO#UA7JJNEW=67J?M$C$IWJSKHNK?'KPJ3V1XGM,I$YWLGO
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MB'Q02H?+AW8T=H=YAP4.^HE6AKO81X\(FY+#+HTRF'NM@8N&E9>7'HH3DOV
M%XCHD+YH4X?FCKQ/6X<3C/\SG8;"C!T.%(@HB836Z8Y*IA7!T8QXHB:L)(K4
MGG.5THEHFPI^YH@RE^IG2X<^E2U.?89ODLPRV88<D<$-3H<EB/_5IXVQL,?
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MDW1@"[&[D95.Z*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&*
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M<'S#>HIWNWT[>Q9<]GW#>ZH_UGYX?%P;%G_1?0_P7'F0A._9.GH'@^C!<7J
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MFAM0.'WYEPLT7GXRE5\.>WZ B<K8\WWSN>K#R'V.M(&MVGT^KS&7/'T8JB"
M(WT>I6]H87T_H2=/?'UGG8PSN'V9FV8-V'W#B5S8$'V%Q5G"ZWT?OPZL\GS(
MN->64'R9LN-_1'R@K6UGG7S+J)5.VGSWI-DS+'T;H%@-4WTHB0+79'TUT1?"
M/'S0R>>L,'QNPL:5@GPTN_=^A'PXM<UF]WQEL)=.5'R7K)8RNGRWHDP,Z'RM
MB+K1P8U1=I*]M8OK=P:I XJI=WZ3?HF.> E],8B7>+)F!8?%>7I-GH<H>DDR
M.(<E>S$,UHDD?'G0/(OQ@,>\?(J9@#ZGVHEC?\Z2:(A5?WY\'X=N?U=D^X:N
M?U%,E(8>?UPQ-88:?Y@+[(>+@%K.XHJIBQN[(8E?B9RFK(@KB#>1+X<PAPUZ
M\H98AA-CXH6IA49+CX4FA)8P1(4AA$0+'H8D@\+-?HF/E76YL8A)DQ>E)H<E
MD-J/S88NCL]YL85LC0MBQX3,BW9*G(11BA4O;H1&B5D*:X3LAK?,)HBPG]JX
M5X=LG*NCSH9.F9Z.@85=EL)XA(28E!YAPH0(D=%)P(.3C] NKX-^CO$)TH/A
MAJ3*]H@ JFBW+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N
M!X+0E0T)48, ADS)^8=RM1FV-X8QL$ZAL84/JY>,=80@IQIVIX-FHO=@%X+2
MGT=(58)8G'4M>X(XFDD(YH)&A@3)+(<#O_^U;87%NF>@WX2?M-Z+H8.IKY)U
MWH+OJL)?9X)FIJ1'QX'MH_DM!(&ZGG (CX&NA<G(D8:NRSVTS85TQ-B@+X1)
MOGJ*ZH-+N&AU-8*.LP!>U8(&KK5'2H&3JM8LEX%>GB8(2H$UA9O"!Y:]=82O
M692*=@N<#9*#=I>'\)"N=S9R^(\'=_-=!HV4>,M%N8QR>:8K XQ.>HP&J8S_
M?)S O)5]?RRN4Y-0?LN;%)%3?GZ' 8^(?E-R"8WM?D]<'(R(?FU$SHMO?IDJ
M)XM#?OH&+(ML@!>_CI17B-BM&)(TAYV9^Y VAG6%Y(YXA8EP_XSJA,9;*(N2
MA"]#\8J!@[HI8XI-@[D%OHH*@R:^;Y-!DJ>KY)$HD)F8N8\WCJ&$R(UPC.-O
MZXOTBV9:,(JHBAQ#&8F>B1$HJHEEB.<%7XC7@Z&]1Y)GG(6JSY!.F;*7F8YA
MEP.#E8RJE(5NV8LHDD%90(GKD%)"4XCDCL<H"(B@CLH%#8?0@VJ\/)&_IH:I
MQ8^IHOB6D(V\GX>"EXP'G$IM\(J'F5%8;8E EKM!IX@\E-\G?(?PE#L$R(;S
M@SR[6Y$YL*>HZ8\EK%^5M(TUJ"R!P(M^I#1M+(H$H)A7QHB]G8-!&8>IFY4G
M"X=5F+X$CX8\@Q6ZI)#/NP&H-HZ]M@"4^8S*L0^!!(L.K%YL>8F4J#!7*(A7
MI-= G8= HMPFJH;6FB0$8(6F@O:Z&I!\Q;JGIXYMP .46XQXNE* 8(JVM/)K
MXHDWL$Y6IX?[K1) +8;LJ,0F2(:!F>($.X4O@MVRPZ!Z=,.A2)V(=4Z//)K'
M=>)\:)@]=HQHL97I=U-3Z)/:>#(]H9)%>0PC9Y))>=0!2I!9?+JQL)]@?>:@
M?9QK?9B.?)FL?6-[JI<D?5%G[)38?693))+2?9T\VY% ?>$BN9$S?E0!+([,
M?]VPNYY&APZ?>9M<A?2-CYB;A/EZMI8@A#-G!9/=@YQ24)'A@S$\'9!3@NXB
M'I U@SL!$8UO@+FOO)U3D#&>:)IMCF",;I>TC+9YMY4PBS-F$Y+ZB?I1?I$%
MB/,[;H]XB#DAE8]*B+, ^HQ @*FNU9QPF8J==IF3EP2+<I;BE*=XLY1EDG-E
M,9(;D()0MI SCNXZRHZGC=PA%XYMCB\ YHL]@)RM\YO,HPB<K)CNG]&*J98X
MG+YWX).\F>5D8Y%]EU=/_X^*E3TZ.(W^E!(@J8VWDN  UHIC@)&M,IM-K*";
M[)AOJ,&)Z)6WI/YW)9,ZH7YCNI#_GF9/;H\*F_$YPHUJFP(@58T6E=P R(FN
M@(>LD)KKMFJ;4)@-L>.)2)51K75VA9+.J59C()"3I<M.YHZGHTHY68T H5L@
M#(R0E:L O8D;@("L%)J<P)V:TY>^NV^(OI4 ME9U]Y)XL:)BGY YK<U.>HY,
MJUTX_(RNIF4?OHP^E78 M(BE@'JD":J1=#F3GZ;L=+R"L:-\=4]Q!:!%=?Q>
M<YU*=L5*O)JH=Z(U5YB^>&L;0)EK>.P  (V>?Q&C,*F6?..3"Z7G?)N")*)P
M?'-P=I\T?'!=VIPY?)=*(IF;?-XTOY>M?2T:T)@U?9@  (QL@ "B<ZB*A8B2
M/Z3DA(6!;*%F@Z1OLIXQ@OY='YL\@HA)>9BC@D0T+):R@BL:;9<9@L8  (M@
M@ "AL*>5CB^18Z/VC(. ?:" BOYNVYU$B;)<59I9B*M(RY?%A^$SH971AW@:
M$Y8:B#@  (IW@ "@XZ;4EN:0EZ,UE)I_J9_"DG]N IR(D)];G)F)CO9(+);]
MC;\S)I4"C2\9R)4MC.T  (FO@ "@.J8BG]Z/[:*)G/-^_)\6FC5M5IO:E[9:
M^)C:E89'H)8YD^4RNY0[DXD9A)16D.H  (D'@ "?G:6AJ/*/9Z(%I6=^=YZ*
MH@9LR)M&GO-:;IA.G%M'*I6RFI,R8I.=FA 94).BD1T  (A\@ "?%J5#LC2.
MYJ&DKA!]])XCJA5L2)K:IGI9]9?@HY1&OI5,H@XR$9,NGW09)I,0D0$  (@+
M@ ">JJ3YN]Z.?:%4MR%]A)W0LHMKUYJ#KGI9D)>&JX-&;)3OJ4(QSI+8H:P8
M]Y*UD.$  (>P@ "5\;4(<\2&?;"X=#=VD*RB=,)E[ZC%=6Q49Z4K=C%!HJ((
M=P,L\)_X=ZP2;J(<=ZP  (E^@ "55;0B? &&'Z_%>[1V-*N>>Y!ECJ>R>Y93
M^Z01>\A!.*#I?!HLCY[)?&D25*"=?*\  (C$@ "4U;,9A"R%C*[#@S1UL*J3
M@F5D_*:I@=A3;Z,'@7] O9_@@5LL+YVT@6<2/Y\_@@D  (@A@ "43K(?C%.$
M[*W/BL)T^ZFDB6!D6:6QB#]2UJ(8AVA /9[RAM@KTIRZAL$2*YX&ALH  (>3
M@ "3N[%3E)*$5*T$DG!T6:C<D(ACLJ3ICM]22J% C80_R)X?C*$K@9O;C*@2
M&YSNBN(  (<9@ "3*K"WG/F#RZQFFDMSU*@XE]5C+Z1!E:U1SJ"4D^4_9IU9
MDL,K0)L+DQ,2$)ORC#8  (:S@ "2OK EI86#8*O5HDMS:*>EGTIBQJ.MG*=1
M;J !FHX_&YR_F7HK$)I&F)02"9L,C#(  (9>@ "24Z_%KD6#&ZMLJGAS)J<L
MIN-B>*,?H\E1'9]MH8T^SIP]H+HJVIG*G/D2!YI=C#$  (89@ "1^Z]ZMVR"
MRJL7LQ%RU:;0KO%B*J*_JWQ0W)\)J7,^GIO4ILTJO)EDG.42!IGFC#   (7B
M@ "(=K_E<U%YX;KU<ZUJV;9#="M;)['*=,Q*BJV>=8<XDZH4=D8D4J@K=K<*
M6*H'=Q<  (8,@ "('K\%>RYYN;H(>M1JKK4\>JQ:]+"K>K9*3ZQN>NXX7ZC5
M>T,D-*;'>X$*GZ@N?&(  (6V@ "'WKWR@NEY8KC]@?1J7K0F@2Y:EJ^/@+5)
M]JM,@'0X&J>L@&PD$Z6!@)0*WZ:#@28  (5K@ "'E[SGBIAY ;?UB1MIY[,B
MA]1:+*Z!AM=)E*I!ABTWSZ:=A=4C\J1;AA@+%Z4'A5$  (4I@ "'/KP*DF!X
MI;<6D&)IA+)!CJ99P*V>C3-)/ZE.C!PWCZ6LBY8CUZ-6C#X+2J.YAZ(  (3Q
M@ "&W[MBFE-X4+9GE]9I-;&(E9Q9=:S?D[U(^:B,DE4W7:33D<8CPZ)KD>@+
M=**4A[\  (3"@ "&A[K>HE]X";7:GV1H];#OG*Y9.:P^FFM(PJ?LF-LW.:0L
MF*HCNJ&8EJ,+G*&4A]D  (2:@ "&3;IBJI5WU;5:IQYHQK!KH_99#ZNSH65(
MFJ=>G^4W%*.FGPHCJJ#\F!T+P*"TA_(  (1[@ "&#;H1LSYWP+3XKSEHMZ_S
MJX-8]:LCJ*A(B*:]ISDW$Z+]I \CPJ!@F"T+\: =B!,  (1A@ ![;LLQ<OUM
MF<6V<S=?6,!_<YI0<[N"="= GK;?=,LO1;,A=60;!K'X=6L#;[!-=XD  (,D
M@ ![:,I >HAMJ\3">A%?7K]K>=E0<+I)>=I F;6'>@TO4K&H>E8;1[ Q>E\$
M"ZXO?$8  (,B@ ![<LD2@=EME\.>@-A?1[X]@ ]03KD+?Z! ?;0Z?VTO4+!'
M?W<;?:Z2?ZL$EZQ)@'4  (,A@ ![<,?HB11M?<)SAYY?%[T1AF=0);?4A85
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MG-,<>*C@DT &AZ7KA&H  (,<@ !ZW,2=KSYM/K[AJY-?";DXJ%M0*K/,IC-
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MKGU0"G2.JDDT8W3]HR@.]'2?BAS6%7\.<;;!Y7\0<LJL]'\=<\^7'W\U=-&
M=7]6==UH[G^(=O90,7_/> @TFH!9>0</6('R>3S4C'U1?'_ LGUS?'JKSGV7
M?'R5_GW ?(]_4WWS?+EGTWXW?/=/'GZ-?30SD'\2?7(.08!(?8/3 'O2AU"_
M!WP"AD*J07PSA424@7QQA&]]_GR[@[UFHGT5@R9."WUV@I@RDWWM@B4-3'[2
M@8/1;GJ&DAB]97J\D!FHH7KWCC"3#7M C&E\JGNABMUE>'P,B7)-"7QVB"$Q
MK7S>AQX,>'V-A/S/\WERG.F[[WFJF@NG+7GMET&1I'H_E)A[9GJEDAQD6WLB
MC^=,&7N3C>$PW'OJC'\+PGQWA_/.LWB;I]*ZLWC4I!^E\GD5H'&0<GEJG.9Z
M2GG6F9%C5GI3EH1+/GK,D^8P(7L5DH(+*7N-AXO-KG?QLM.YL'@JKDZDZGAE
MJ;^/;'BYI51Y6GDLH31BA7FNG7%*A'HAFDLO@WI<F'(*JGK+AS;,Y'=SO?&X
MXW>JN*"D$'?<LS6.BW@GK>MX@7B;J0EAQ'DGI+=)Y7F<H6LN_'G!G4X*0GHM
MAO#,57<>R3ZX2G=1PR.C7W=WO."-RW>UML)WR'@DL2]A('BPK'M)5'DGJ/(N
M?7E!GV\)\'FOAKC&?H@8<(JS_(<S<;Z@DH9R<MJ,&X71<^YVMX5'=0M@7(3<
M=C5(M(2>=U4MQ83T>%((W(9/>6#%1H: >KBRZH6[>NJ?<X4,>QN+!X1U>U=U
MJH/Y>Z=?6X.<? E'NH-H?&DLV(.R?, (+X2J?77$$H4.A/FQJ(1<A#&>7X.S
M@W*)V8,L@M)TAX*Z@E1>48)K@?-&QX)$@9\K^X*%@6X'F(,Y@0O"K8/'CRJP
M,8,6C8V<R8)\B_>(<8( BGQS0H&HB39=-8%KB!)%U8%*AQ,K+(%XAGX'%('X
MA"C!5(*]F6&NV((-EOV;=8%ZE)V'*8$%DE%R&X"PD"U<-8"$CE1% (!HC+PJ
M>("$C D&HX#FA'W ,('MH[ZMN(% H)::5X"KG62&%( XFD5Q''_GEUI;47^V
ME,)$1'^ADK0IUW^PDA,&1'_^A#V_1(%)KC>LRX"?JDZ99( %IDN%('^.HEMP
M/7]$GKA:DG\8FX)#IG[VF2(I47[XET(%]G\_A B^D(#.N-JL$( FM#*8F7^$
MKV"$3G\"JI]O<WZWIDY9V'Z5HJE##'YWH' HWWY>FX(%MGZC@]R^%(!XP\&K
M@G_3OF.7['\DN,&#DWZ3LS5NQGY KDE917X@JG-"DWX'IS H>7WFFUX%@WXF
M@[JW7)%7;[&F-8^><.V4(8X<<A* ](S)<RYLRXN8=%17DXJ5=89 [XG@=J0F
M@8H[=X$#*HHD>;VV6(_A>5.E0XY'>9Z3'HS4>>E_^8N'>C]KUHI?>JE6JHEF
M>R1 "HBU>Y@ELHCZ>_0"VXB$?6FU28Z+@NJD#(T"@EV2 XN2@=-^UXI3@6EJ
MS(DW@1E5NXA*@.,_-H>>@+HD^H?.@+@"E8<6@**T+(U-C)6BU(O+BSZ0MHIJ
MB>A]N8DJB+1IO8@?AZQ4SH<^AL<^:X:8A@TD4(:VA>8"6879@9:S!8Q+EDFA
MPHK+E#B/G(EODBU\BX@ZD#=HL(<QCFM3WX9AC.4]I86]BZ\CLX7$B[D")83*
M@7.R!HN%H!^@OHH)G5F.F(BLFH][DH=YE]IGRH9QE5M3$H68DS$\_H3WD:XC
M+(3LD2$!^8/E@5:Q-8KIJ@Z?ZXEQII:-P(@/HPUZO(;9GYUG!875G'M2:H3]
MF=0\=81*F#XBP(0PE9T!U8,G@3VPDHIRM">?0(C^L *-"8>6J[YZ H96IY=F
M4850H^%1QH2#H/0[\(/.GU\B88.4ES\!N(*-@2FP((H:OHN>O(BJN<*,;H<[
MM,9Y787OK^YEN83BJ\!11(03J.8[?X-DI3$A_X,BEOP!H((2@1FHFYKI;PB8
MCIAS<$&'I98\<6EUL)0\<HQBM9)H<[=.DI#5=.<XU(_"=?0>HY"&=H0  (IR
M>T6GRIF=>">7TI<]>("&UY4.>-UTY),->4=AZY$[><5-T(^L>E X&8Z5>LP>
M!H\U>PL  (C9?I.F[YA7@3N6T98)@,J%Z9/;@&5S[9'E@!QA!9 =?_%- 8Z8
M?]\W8XV!?]8==XW^?_,  (=R@ "E]9<VBD"5PI3JB1^$QI+'B UR]I#-AP]@
M&X\3AD%,.8V6A94VP(Q^A1L<_(S=A68  (8[@ "E"Y8NDW&4SI/LD:.#RY'0
MC^)Q]H_<CC-?1HX6C+-+?HREBWTV*HN,BJX<CXO0BN,  (4P@ "D-)5OG,:4
M#9,OFE&#"I$.E]YQ)(\:E89>=XU:DVA*RHO?D:XUF(K%D,<<(XKRCY$  (1/
M@ "C@93:IBZ34I*>HQF"2I!ZG_IP:(Z!G/Q=R8S#FE-*-HM&F#\U)8H6EY0;
MT8HLDL\  (.5@ "B\91IK[N2O9(QK N!JY 'J$9OQXX$I*==+8Q$H8I)IHK/
MGV0TM(F8G=D;BXF'DI\  (+]@ "BBI06N9J22)'@M5N!(X^NL/-O.(VAK+]<
MJHO8J5))-XI@IT@T4HDPHM<;-XD8DF<  (*$@ ":4J3;;H2+/*&Z;Z][69[=
M<-)J>YPX<?18E9G&<QM%;I>O=#\P<I9E=2@5_YA-=2@  (8@?FF9LJ.[=RZ*
MM*"D=X5ZPYW!=^EIY)L1>%Y7_)B;>.=$W9:">7HOZI4J>>T5II;4>=P  (4
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M!:6*I+UKYZ'DH<Y;^)YBGR-+2ILYG3DYBIB9G*PE\Y;+F7(-2I<YB/P  (
M@ ") ZCHL()ZO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-
M0Y:@B/<  (  @ !_<KG_;6QQX;7 ;FECL;&];W%4JZWI<(!$F:I@<8TS :>3
M<G@>NZ;1<L$%O:<_<VT  (  @ !_,[D?=5!QQ[3)=8QCD;">=>E4BJRI=F)$
M=JD)=O RZZ8F=W4>Q*4P=Y(&(*4A>,4  (  @ !^^;?Q?/YQ;[.??)UC1:]G
M?%Y4,ZMH?%1$*J?"?&LRMJ35?)8>N:.U?*$&<J,V?:,  (  @ !^JK:_A))Q
M!;)Q@[!BQJX]@O%3RJHX@F9#R::6@A0R<J.D@? >I*)B@A8&MJ%_@>0  (
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MT*\KJ59AA*K!IEU29*:"H^M"D**MHL,QE)^/G_,>=IW)E)D'H)O%A2@  (
M@ !RK\5(;-YEI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@
M *LI='L  (  @ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_
M=B$5%:_$=;L #ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<Z
MB+$#>Q(IGJWR>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ
M@4))J+/2@,PZ9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME
M7[P'B,A7P+=%A[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (
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MI()@LS.$7H%\KNMR/("IJJ!??( 0IN]+UW^OI'HVS7]8H7D=GG\-E <  (
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M (WBC!![^(Q>BNEK"(KVB;]9+8FUB+)&'(B^A]PQ68@7AU 7L(C&AU@  (
M@ ":4HZ@EE&+/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T7
M28>LC 4  (  @ "9I(WOGX**AXQ:G3!Z>8K-FK5I>HE>F#U7K8@AE@I$U8<<
ME%LP7H97D_06_X:RCXT  (  @ "9'(UHJ,R)]8O8I>EYW(I$HLUHW(C)G[=7
M$H>(G0]$0(:+FTDOYH6]FBD6OH7ACV$  (  @ "8O8T(LE:)A(M[KO%Y5HG<
MJSEH3HA2IY!6D8<&I)1#U88$HO8OAH4XGQT6:X5(CR@  (  @ "0V)[A:,R"
MUYQ,:HUSWYH";#1CQ)?O;<52AY8+;TD_[)2&<+$K2I/H<;,0;);><2\  (
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M%Y9XD<MP 90\D$!@"I(?CKI/,Y SC6 ])8Z?C&HI(HVVC%T/BX[ B9$  (
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MWJ36<4=GK:'G<BQ8@9\G<Q9(,)RK<_XV9YK#=,LB*YI'=1X(@)MT=3$  (
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M]Y^9ELYDN)RHE0)5G9G:DTU%II=1D?(T=Y4\D5LA%90>D.@(XI,.A@(  (
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M8*W8=QM< JI'=V!-H*;K=\,^**/L>"TM$*''>(08[J'I>%0"7IWY>E@  (
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ML:DMFSM:,J6&F59+V*(&EZ,\E)[LEK4KZYR3EG88NYO&D+D#B993@F0  (
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M8;=F?!Y0A[-=>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (
M@ !I>KHQ@W]=-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X
M )IL@    (  @ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<Z
MA\ /YJ>KAK@  )F0@    (  @ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS
M\:B;C>$CIZ8RCD40(J99BND  )C?@    (  @ !I#;?SF5E=%[.>E^901*]9
MEE5"DJM-E0@SY*?'E+8CG*5>D\P0/Z59BOP  )A(@    (  @ !H^K>/H.M=
M([,3GTE04:ZUG7Q"EJJ;G"4SZ:<+FVXCL:24F"(05J2#BPP  )>R@    (
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M9H&(=XN!78$[>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP  (
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MMGO<HU5\CGNGH&MK=WMYG7)9B7MQFLE&CWN#F,,R'WMME_D9('K$D/T  (
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M"XBR?B1T\H?!?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (
M@ "1,(A,ALR##X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2
M=X3H@X8  (  @ "05X<[C[Z"5(9*CK)S0X5@C7=C(H2%C"=2)(/,BO _\H-$
MB@ KTH+]B9X2'X-GB#H  (  @ "/J(9BF+6!FH5XEQ=RA82)E3EB9X.IDT91
M;8+RD8H_58)ED$(K;X'[D!T1Y8(>C!D  (  @ "/((6\H;Z!"839GY9QZ8/A
MG1MAS(+TFHM0U8(WF%H^N8&REO0J\($ZED81LH$1B_<  (  @ ".OH5%JO>
MEX1EJ%=Q8X-BI45A/X)BHB%06(&7GY@^5H$*GF4JFX".FS41<8!%B\L  (
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M*I"QA =H^(\8@Z%9QHV:@S%)J(Q!@LDX!8M1@H<D.(K^@F<*[8KQ@>X  (
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M$Z F9)5@JYWN9J!2()OG:(I"6)H>:DXPXIC^:\,<@9G!;#\#WYBA;+X  (
M?]!Y_*%!:GMMH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$
M()80<=(  (  @ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q
M=?X<-I8%=?L$4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ
M[)6!>QTOTY0\>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U
M@79/R)83@2U :)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J
M^IESB3A=DY<PB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (
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MNJD;:H]4_:9&:^%'0*.@;2HX-Z%@;E,G/Z Q;QL2<:(M;HH  )<M<VD  (
M@ !M%ZJ!<+-A.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@
M )6@>#   (  @ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<
M>6P2EYXR>/4  )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W
M,9S0?O0FG9MP?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'
MA>1%A9X+A5 VV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?
MD:+2C:]2WY_GC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (
M@ !K)*4/EA!?5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,
M ) G@    (  @ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=J
MEN<2JI>IC)X "X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,M
MNZV,9R4<DJU$9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5
M:C@\;ZX+:V8MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5
M=[*_;Y))7:]R<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (
M@ !@JK1D==A5);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@
M (^_?Q8  (  @ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.
M?)D)ZJ6(?1D  ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M
M;Z5(@H,=):00@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?
MB;P[BZ;AB0@M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94
MLJS+D7Y(F*E(D'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (
M@ !?P:_=F:!4NZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8
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M>G>O8;J&-'A<9'1TIWD49OMA\'G3:6=.!GJ;:[<XBWMF;;\>RWP[;M,  (
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M(&WOCCY_^&\3C/=NS7 LBYU<O7%%BE5)C7),B38TVW+RB&,;[W'+B$L  (
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M1GTY::1Z 7UD:X=ID7V<;4U7[7WC;OY$^WY!<(\P.7Z]<<D6-G^S<;L  (
M>F>6.7K7<+Z( 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5
MQ7U(=H4  (  ??.5!7C$>>>&O'DJ>G)WEWF%>MMG>7GA>SE6$'I.>XY#<7K
M>]PO"7L;? H59GL=>Z8  (  @ "3TW<'@PZ%KG=_@O-VA'?J@K!F37A2@E)5
M'WC'@?M"EGE(@;0N5WF2@784Z7E-@5,  (  @ "2U'6DC$N$J78FBX=UA':7
MBI%E6'<&B8-4.G=^B(-!X'?VAZXMQG@PART4@7?&AJ8  (  @ "2!W2"E8F#
MVW4,E"-TMW5]DGQDD77ND,%3?79LCRE!07;BC>$M6G;\C5,4.79^BQ8  (
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M'8.D<*-M[8-"<=M>=X+S<OI-WX*[= L[V(*Q=/HGLX+W=8<-GH/G=.\  (
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MYWS[F41IL'RWEU]:>7QOE6)*27Q&D[(XTWPTDK$E@GOFDDH,RWPGB*8  (
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M1(KN=JIAWHGY=U13A8D3=_%#UXA=>'LRHX?V>.<>W8A&>.T&?(>2>;\  (
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M4H6^G<M>ZH2XF\90@H.EF:)!-H+"F"4PAH(FE[8=@8&OD_,&?8$4A&,  (
M@ !QKYO87+)E\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<
M ),-:;\  (  ?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N
M;*L6,)47;)0 +Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[
M-)(1<0DJ5I&"<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'
M=65)C9&/=A(ZF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C
M%Y,,>^)6<9&"?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (
M@ !N,I-;@UIB?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@
MX(DG@)<  (  @ !MK))/BR=A]9#5BJ%55(]%B>1'LXV_B14Y!HQVB'8HSXN=
MB%$5=8OCB 0! X??@*\  (  @ !M0I&+DPIAL9 7DC55$HYYD0%':8S3C[$X
MO(MTCM,H<(J>CP05&8K'C* !&H;1@+X  (  @ !L[Y#XFPYA7X]]F?A4N8W4
MF%]'$(P@EK$X<HJQE=$H.8G%E2<4_(G)CC !)X8#@,@  (  @ !E8J976[!:
M$J0?7A5-\*(C8&5 JZ!;8HTQ\I\%9&@@YY\398H+^Z&[91H  (V4;=(  (
M@ !DLZ3,8R=9IJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T
M (O[<LP  (  @ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!
M;Y4,?9QL;P8  (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q
M$9E(=(T@D)C>=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[
M>:T^XYD_>>PPM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97
M<9P6@&%+=9GX@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (
M@ !B)ITMA[]7&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T
M (7.@    (  @ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^
MC*\,B9,EB'H  (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPO
MJY-*DV<?L9);D>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T9
M7JHUG*L88)XG+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-
MNJWB8QM"(ZMJ9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (
M@ !8"*Z2:&A-2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@
M (9G>MT  (  @ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.
M<:L$A*%<<OP  (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,F
MNJ'U=VT6":)==RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=
M?4XT7J(W?3\FDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,
M*:82A!9 N:-U@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (
M@ !6A:?2BT-,$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8
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M9V>F?SQX,VE>?T9G^&KY?SE6QFR(?RQ$.6WM?R@P&FZ>?QX74FX&?O   (
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M)WE27 ERMWGA7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (
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M1VWCA7IM#F[_A0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH  (
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M:'[*8U]FU'[M9;58%W\>9^=("W]@:?(V<'_*:[DB9X"$;,D(WX'I;)H  (
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M9G40BMYB#'6)BA!3I77QB2A$-'98B%TS7':@A]D@2G8[B \(<GC8A54  (
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MK(4^:;-;"X3I:V9-(X2A;/D]^(1X;F0M!X2A;WT9 (69;Z "3H43<38  (
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MUWTOCW)717T CF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (
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M7HR>;O]/8HO)<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (
M@ !EKXM]=4Q:EHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0
M (%.?.4  (  @ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,
M?:,/"X<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@A"] =H94@] R
M6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59#8;OB^5-+X8?
MBR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (  @ !C?(:QE!E8
MK88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L  (  @    (
M@ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800
M (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K49@490P:4)D1
M9;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]9Z(Y!9:$:28J
MZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0.);G;)Y$T967
M;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (  @ !:#)9,<H%/
MDI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X  (  ?RX  (
M@ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$
M (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI+HZE@,X9((ZI
M@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8H
MW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5."9!RCZ-"PX\5
MCLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (  @ !0IJIA5$U&
M8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P  (  <2X  (
M@ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914
M (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A
M9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?
MP)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%
M<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (  @ !-UZ!J=F!#
MRI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0  (  @    (
M@ !-<Y\3?55#?YV#?:(XJYO/?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX
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MGEU#:69\3U_U:UQKS&)^;3Q:/&3B;PE'=V;[<+PS*V@M<BX:NF>1<L\  (
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M>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8N5\YC.T  (
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M4V%H<-=P_F.K<B5AH67&<UA0_F?#='@_&VEC=8 K<6GK=D42DFQ'=@P  (
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MJE>]FY]L@EIGF59=7ES2EPA-15\#E18[^F"/D],I"5_ODV@1)&7OBY<  (
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M2&9S=V-EW&@^>")78&G=>,%'SVM:>50VI&QX>=,C;6PY>A4+"G&;>F4  (
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M!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$A(#I9.T  (
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M;VR/?1-:VFW/?5I-,F[B?7X^:F_.?9PN '!2?;T:X6^(?<($F'@\?H(  (
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MD'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\  ($):F(  (
M?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*:V<2E'^):S\
M (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@VOWMH;\XF3'O;
M<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E<_5$47BB=-$V
M(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<<'5X>F)0B'8>
M>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (  @ !FKG+(@;-;
MRW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D  (  @    (
M@ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$
M (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(A
MCC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O
M&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>
M7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4
M+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (
M@ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P
M (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\LP($G<RT<9X&.
M<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL
M(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0UWU/?I)%F7UO
M?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (  @ !:K'MYA<M0
M='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\  (  @    (
M@ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD
M (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HDSY5W6Q82[YA2
M6Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD
M9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](W)!Y8&<^"H_L
M8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (  @ !2 (Y"94!(
M!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0  (  >SP  (
M@ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH
M (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?
M=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B
M!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%B(92@? ZV(7V
M@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (  @ !.^(4TB3-%
M6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (
M@ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0
M (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P919ZA7-@(IY]S
M75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO7XXFVYKY8208
MPYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\
M958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (  @ !%9)>X:.@[
MW9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\  (  @    (
M@ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<
M (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2
M>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/??@DPY"(?=H7
M0I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z)9#.A/0O\9 R
MA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (  @ ">^U/53=6/
MR%<(4AV !%HB5E!O7%TL6F-=I6 97E%*OV*U8A$V<61C98$>7V.69_0!>WV
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MU5B[6OYU+5NV7DIE?UZ-8794HV$Q9'A"@&-J9THNN61=:;<63F9@:MH  (
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M?D<&APUNETM$AFU?GD\>A<U/E%)^A4,^6%34A-\KFU1,A,0455VBA/H  (
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MM%M;8M]J+5X<96-;7&"C9\5+:6+H:@,Z"V2A; TFN622;9D.$VN';<4  (
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MTDP*C,-DJD^VB[)6=U+XBIQ')U6JB;@VA%<*B2LD-U;"B6(-)6G(AS8  (
M@ !]@D8@EF=Q2$I3E/)D'TX1DS95\U%;D7I&NE0+D!<V,55/CU$CWU50CV0,
MX6H\B+4  (  @ !\E6ES3A-P!FL-4?QBNFRW5=)486Y868-$QF_=7/LSCW$K
M8!,?U'&L8CD',W>V8Q   (  =89ZLV2R5I%NG&:W6=QA@VBI70M36&I]8!5#
MXFPA8NHRTFUE96@?1&U/9PH''W3J9[\  (  >:UY'6!%7RMM%V*F8<E@263:
M9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (  ?5)WDEPN9]-K
MFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'#G03<<X  (
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M+5'MD:):L%3UD$M-+U>"CN(^F%EAC=(NBEF4C7D<0%N>C1D&G733A'D  (
M@ !PT7%S3>)E!G*34:18>'/-555*T74&6-X[S78M7" JYW=#7MD6G7@P8!8
MIW[F8EH  (  >-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J4G-:
M9 ,60W0)9-< SGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=96DZ
M)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4XFB<
M:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (  @ !JXV$C;D9?
MN&-F;Z13NV5D<.U&RF<7<A8XHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX  (
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MW'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@  (  99T  (
M>[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG8A$,M'RL8CT
M (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P^G7F9= @@79X
M9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7:!T^-W&L:=\P
M'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5 VP$;5])I&UI
M;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (  @ !>=F=&<[)4
M!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,  (
M@ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T
M (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,MJV>S@HH=[&;J
M@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM
M2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.JX.63]U#A(0$
M4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (  ?AI7>'].4WQ-
MA'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$  (
M@ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958
M (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHFB'I_:.85TWKX
M:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O;#8S8G;0;6PE
MXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)0W)O<;L^A'-D
M<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (  @ !246YW> I(
M<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,  (  @    (
M@ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<
M (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D$6UDA=L4$&ZD
MA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>
M58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491".(GF5(LWM8H7
M5U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (  @ !*A87Z6&=!
M'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H  (  =H@  (
M@ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX
M (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@
M:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:
M^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+
M=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (  @ !&3W;0>VP\
MZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@  (  @    (
M@ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @
M (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2>9PR4E,#4IF^
M5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81
M;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U.I(95^$K'I(^
M6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (  @  ];XY]6_TT
M4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8  (  ?5@  (
M@  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0
M (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#
M;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.
MYX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ78//=WPG=H1E
M=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (  @  Z#8"J?B<P
MYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @    (  @    (
M@    /__  #__P  __\  &UF=#(     ! ,)   !
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MA\1]PL"?AL-]<*F,A>9]59)2A2I]=7L'A(9]QF/$@_%^-4R/@WA^Z362@RB
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MD!%]_RG0BQQ_Q*]<K5*"9I[4J-F!@HX&I(2 T'S^H%" 6FN_G#* (EI]F ^
M'4F-D\J -CDACTN DRG@BFN!.:YWK&N*GYX"I_>(]XU2HYV'>WQ'GW.&1VL3
MFUV%2%GIET6$<TD:DPN#KCCDCIN#$"GNB<^"D:VTJYN2SYTNIS20:HQSHN..
M,GM[GK&,-6I<FJ.*<%E4EI*(P4BPDF"'$CBOC?Z%;BGZB4>#R:SMJOV:]9QJ
MII:7U(NJHDF4YWJTGAF2+&FPF?F/@UC-E?*,^$A4D<6*5CB"C7&'I2H$B-&$
MX*Q$JF*C-YO)I?V?4HL+H;";F7H:G828"&DCF6:4A5A6E5&1!4@"D3"-:SA:
MC/")KRH-B&Z%U*N>J>^K7IM$I8"FJ(J.H2VB&'F=G0"=KVBSF.^95%?]E.:4
MY4?%D+N033@^C(B+ARH4B!R&I:L&J9>S:)K#I1^MVHH9H,JH;'DQG)ZC'VA4
MF).=VU>PE)68?$>3D&J2[#@JC#6-)2H9A]B'5*J#J4R[9)I7I,FTZ(FTH'6N
MA7C5G$VH06@'F$:B"5=XE$N;M4=ND"^5,S@7C ..@BH>AZ.'XZ+AM_QYQY,!
MLLQYHX,\K:IYN'-UJ)9Z$6.9HWUZK%._GDA[@T1&F-]\AC5*DQQ]YR=_C-E_
MMJ'DMRV!C9)WL>B L(+6K+R #',1IZ-_J&,KHHQ_AU-8G5U_GD/QE_I_UC4L
MDD2 52>\C!F!'*$_MD:)0I';L0F'L()/J]B&37*$IL*%.6*HH:Z$7%+KG(:#
MKD.EERJ#%#46D8."J"?RBW""8J"WM7*0YI%$L#Z.I8&IJQ*,E7'LI?**Q&(@
MH.>)+5*!F\:'L4-@EG&&.C4%D-F$VB@ABMZ#B* LM,>8AY"WKY*5E($9JFF2
MV7%;I4R03V&FH#.-Z5(CFQR+FT,GE<Z)0#3XD$.&Y"A(BF&$C9^;M$*@)9 W
MKP2<>8"CJ=:9 G#NI+J5O&%$GZ22B5'5FGZ/54+YE3B,%#3MC[^(P2AIB?>%
M;I\NL[JGL(_6KGJC0(!)J4R? W"<I#6:\F#]GR66[E&AF@*2VT+6E*N.JC3E
MCT:*9BB%B:"&+YZWLURO&8^-K@RIS8 .J-*DM'!>H[&?S6#"GJ6:^E%QF9J6
M$4*\E%21!33ECNZ+VBB;B5F&SYY-LPJV9X\\K:ZP-'_+J'.J,' HHU>D9&"<
MGE">M%%;F4B8[T*TE!"3#33JCK:-$BBMB2"'497LP?UY?X<RN_)Y4'B1M?AY
M8FG\K_]YPEMGJ>MZ:$SLHZ%[3S[KG0Y\8C&%E@5]TR5TCF]_J94\P2: V(;1
MNQA_^7A%M11_7&FNKP]_!UL5J/-^_$RFHJ=_+#Z]G!-_@#&3E1: 'R7<C9V!
M 939P#*(#X9KNC.&BW?KM"N%.VE-KB*$05J\J .#A$QBH;R"^CZ:FRV"B3&E
ME$""2R8VC.:".)21OU"/+H84N52-"'>"LT^+&6CMK3R);5IHIR6( DPEH.6&
MM3Y^FE^%=#&XDX2$4R:$C$B#3I1"OI.62(7&N)*3>7<SLHJ0ZFB9K'J.DUHE
MIEB,94OXH">*5#YKF:R(/#'+DN*&,R;'B\*$0I/DO?V=785[M_"9W';UL>&6
MFVAFJ]*3DEGVI;60I4O6GWV-P3Y?F0V*TS'=DE6'YB;^BU*%%9.)O8.D3H4Z
MMVB@#W;$L5&<$&@_JT&82UG8I2^4HDO$GOR0\3Y8F(.-+3'LD=R)92<LBO6%
MQI--O0&K$X4.MN6F"G:GL,VA1F@LJK^<OUG)I+.84DNZGI&3U3Y5F!F/1#'Z
MD7&*KR=1BJF&6I, O**QM83RMG2KOW:?L%&F$F@GJCF@N5G,I"R;CDO'GA*6
M5SYNE[J1$3(8D3"+QB=OBFZ&T8F5S"1Y<'OUQ39Y*&YFOFAY+V#LMXYYCU.0
ML'AZ/$9IJ0E[+CG:H3=\3"X&F-1]R2.DC^%_G(E)RRJ 97N_Q&)_=FXOO8Y^
MU6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR Z8DSRAJ'(GN7
MPVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ EM:!_"2PCC:"
M$XDOR1V-OGN)PF>+IVWHNY")SV!JM(B(0%,?K5R&^D8PI?"%USGWGBR$Q2ZY
ME@6#W24;C8V#&HDCR$*44'N"P8"1FFWFNI^/+F!?LYJ- E,=K&J+!48ZI1*)
M*CH1G6"'42[NE5&%E25UC/V$ (D)QX2:V'M[P+:7=VWPN<V49&!ULLF1E5,O
MJZ2.YT90I$V,23HOG*^)JR\?E+F'("7!C(6$Q8CLQN&A+WMVP J=&&W]N1J9
M5&".LAB5VE-+JP"2?T9NH[6/)SI0G!F+R"]+E#F(>27_C"*%:HC-QE2G4'MQ
MOW>B=FX-N(*=^&"JL8"9RE-KJG"5PD:/HSF1MCIRFZJ-I"]TD]&)H28RB]*%
M\XBQQ="M,GMQOO&GAVXEM_JB/6#2L/F=5U.;J?"8HT;#HL63[CJDFTN/-R^A
MDX>*EB9:BY.&8?+/>V-YL-O=>[QYTL2H?!QZ!ZTE?(-Z7I5Q?/=ZW7VM?7Q[
M@F7P?A5\/DY$?ME]-#;+?^E^??"R>;F$S]HM>C2#RL,J>K."Z*O/>SN",I0T
M>]"!JGR(?':!0F3A?2Z XTU5?A" GS8!?SJ :.[,>%F0 MAJ>.6-VL&?>7B+
MTJI>>AF*$)+J>LF(?7MD>XN'!6/D?%^%ADQ]?5N#_C5,?IN"/^T&=S.;,=:N
M=\B7[[_X>&B4V*C@>1F1\I&8>>&/5'I!>KN,PV+R>Z>*&DNX?+F'1S2M?@R#
M_>MI=D>F5=4;=MZB [YR=X6=WJ=W>$&9[)!->1:6'7DH>@:2<F(->P:.EDL"
M?"R*;S0D?8V%G>H$=9.Q;]._=B>L$;T>=LVFUZ8W=X^ASX\O>&Z<YG@?>6F7
M_6$Y>GR2ZTI?>[*-;3.O?1^'%^C:=06\>]*==96V#KO_=C>ONJ4D=ONIE(X]
M=^2CC7=1>.J=<V"!>@:7#$G4>TN0,S--?,*(:.?G=)S'<=&P=2>_[KL0=<*X
M>Z0W=H*Q*XU@=W&I^':;>(.BKE_R>:J:_$E>>O:2NS+\?'2)C.<G=%720=#V
M=-G)F[I,=6K _Z-N=B2X@(RB=Q.P%77T>"NGB%]J>5N>CDCY>K&4^C*\?#:*
M@>*9A!%X&\V-@X5X>+@<@PYXX:(X@JMY9(P)@EQZ#'6\@A]ZV5^ @?![PTE5
M@>)\[#-\@@1^=>#A@HZ"J<Q<@A>!YK<2@;.!/Z$H@66 P8KI@2N :W2@@0F
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MDH-^V)Z$D&U^DXNVCGI^<GB%C*)^>64UBME^I5(4B0]^YS\[AT=_6RTKA72
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MDR-^5R1NC&1_GHR$NFZ"LG\NM/^!QW&IKX2!#&/IJ@* FE8FI&. 74B4GIR
M33N8F)6 5"]PDC^ C"3-BYV Z8Q!N6R)OG[5M &(-7$_KHJ&VF..J0*%NE77
MHVZ$T$A?G;*$ 3N%E[>#/R^*D76"G"4?BO&"$8OON)60OGZ"LRJ.F'#GK;*,
MH&,RJ"N*TE64HI")*$@QG..'F#MVEO2&!B^BD,:$@R5DBE^#%8N7M_&7N'XT
MLG^4\'"AK0&22V+SIWB/R55;H=Z-7D@.G"F*_SMJED>(G"^VD"V&/"6?B>2#
M]HM%MW">C'WSL?>;&W!IK&^7OF*_IN"4?U4PH4R15D?TFYR.*SMEE:^*]R_(
MCZB'PR7.B7^$M(L0MO:E,GW%L7RA#W _J_&<]F*;IE^8\U40H,V5 T?:FRF1
M#3M<E3R-$"_9CS6)$R7UB2V%4HK4MJ:KO7VQL1ZFTW QJX&AVF*%I=N<^E4"
MH#^80T?9FJ&3D#MJE-..WB_PCNN*+R84B.N%T8$-QF1S]G2*P#1T9&?^N@5U
M"UMILZQU\T[<K0=W&D*"I@MX?S;#GK1Z#BO*EN5[]2)%CK9^)8$'Q7]Z^729
MOT]ZIV@$N09ZGEMGLI%ZVT[8J]Q[7D*+I-Q\'3;CG8=] "P:E<E^*B+7C<!_
MAX$0Q&"!L'2'OCN P6?PM^R #5M*L6U_L4[#JK9_D$*)H[Y_I3;^G'1_UBQ@
ME,V .R-5C.J Q8$/PT2(-W1PO2"&NF?&MM*%=%LIL%"$=$ZLJ:*#M$*%HK>#
M%3<6FWV"BBR>D_"")2/ C#.!WX#[PE..KW1;O"J,HV>PM=>*SUL,KU:)+4Z@
MJ*:'N4*)H<V&93<OFJ2%&"S6DS"#YB0<BYB"UH#<P925'W1+NV"2?F>JM020
M"5L-KH&-PDZ@I]:+F$*4H/R)@S=*F>:'=2T'DHR%>R1HBQ:#JH"]P/F;8G1
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M=&F(&KB%=7^&Q*)]=I6%J(PK=[.$KW6_>.*#RU]D>B:"XDDT>Y6!]3-P?4R
MY.$H<?R4C<PS<R.2"+;4=$:/I:#]=7&-:XK8=JR+:G2@=_>)<UY]>5>':4B
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MA75]B"M^A$-^LK=ZC?F"RZ<$C&."/Y7[BN&!MH0LB86!2W(+B#N ^5_-AP2
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M?:6'A9?F?:2&BH7W?;2%D7.=?>&$KV$P?B6#U$[_?GN"]#T:?OJ"!"P9?Z*
M\KB2?'^1_*?V?'^0.9:K?(N.8(3,?*J,>W*B?.2*G&!>?46(R$YB?;6&WCRV
M?D^$S"OR?Q&"=K>&>Y.;@:;L>YJ8ZI6F>ZF6)X/2>]"33W'!?!:0<U^C?("-
MDDW8?0J*FSQ=?;R'8RO2?I6#T+:O>MBD[J82>N2A?Y3)>O*=S8+[>QN9]W$
M>VZ6'5\&>^:2,4UE?'B.'CP5?4")PBNW?BV$_K8,>DNN.*5F>EJI[901>F2E
M1()#>HB@9G!3>N&;@EYP>VN6BDSV? J18#O6?-N+X"N@?=>& ;6A>>RW5Z3F
M>?RR*I-Z>?JL?8&D>A2FC&_">FN@E%WY>ON:B$R6>ZJ41CN3?(N-L2N/?9.&
MUZ]FBSMJLJ!.B?1LJ)!9B.!N?G^#A^YP1VXIAP=R(UR@ABET(TM7A5%V23I
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MB*]]WR60A@I^T)+[F3J"%X7$EJZ!M7@-E"V!4VGKD;6 _UMPCTJ P$T#C-V
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ML$*"<%M1JR^!X%!TI=N!9T7!H%.!&#M0FJ: Z#&CE,: PRCCCL2 MR&CB-Z
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MALB%TGI'A=*%*VP"A.6$;EU\A R#L4[;@U:# T">@JN"4#+@@A^!DR9N@::
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M.7R]F!V6E7&7E9Z4J&7;DN^23EG&D"J/M4VZC7V-(D'NBNV*F#;8B%6(%2R
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M<'B$XH8Q<<6$4W:)<QN#KF:4=):#"U9R=D6"<D:[>!2!UC=T>B&!,"E9?&F
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M-YKZ?4=HOXW3?6MJZ7^_?9]L^G#S?>)O!6&F?CAQ'E(W?J5S5$,C?RIUJS2
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M=>E]'RJ%>:Q^*:2_7X&!:9938EJ!1X<_91F!#W>59]V RV>>:L^ CE=T;?Z
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M=W&"D6L >!F"4UZI>,F!]5(F>9R!F$6I>IV!1CFJ>\. ^2Y0?1N JB1??HV
M6(%A=7J*3G8F=D&)E6I7=O:(E%X/=[B':E&<>*.&/$5">;Z%$CE\>OF#ZBY(
M?'6"LR1[?@N!=(#5='F1P'6>=4^06VG1=@V.E5V4=M>,F%$L=]2*ED3?>0J(
ME#E >ER&DBY!>^V$?"22?:&"9(!L<[>8[W4T=)>6Y&EB=5F45%TK=B61?%#7
M=RF.H$2D>&Z+Q3D0>=J(YRXF>X:%_"2D?4R#*7MYB<%::7#DB.9=S66VB#1A
M*5GMAXYDB$W*AN!H 4&EAC5KJ38%A91O@BL'A1)SN2%DA+=X3WJ;AUQB'G N
MAL%DSF4*AB]G>EEBA9]J+TUBA1!L_4%CA(QO\S7NA!9S$BLC@\)V?"&]@Y%Z
M*7G$A0MIMV]&A*5KO&1,A#9MOUBT@\=OQTS>@UUQYD$,@P9T)37)@KUVA2LU
M@I9Y'"(*@H][W7CA@N]Q-&Y;@JQRF&-@@E]S\E@$@A%U3DQ,@=)VN4"J@:5X
M/#6:@8EYU2L]@8][E2)-@:Y]:G@'@2)XG6V.@/IY9&*;@,=Z%E=%@)-ZO4O9
M@&Q[;4!5@&Q\+S5R@'A\_BM&@*=]X2*&@.Y^S'=&?YM_]&S=?X^ 'F'[?W"
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M?<M^TE*R?@%^^TEM?B%_$4 D?E!_,#<H?IA_7R[0?O1_GR<$?XE_W""=@"N
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MA/V!@4J/A&B!5$)<@Z*!$CHT@MV Y3)0@C> RBL_@9. Q"3;@3* L!^7@0R
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MC*"#?4+TBSV# #OEB6N":S3]AW^!_"Y1A;R!J2A4A!N!:2+]@M&!(!ZY@=>
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M3Y=^<78X5(-^FFCH67Y^O5M*7K5^Y4V:9#A_'4!=:?]_8C/$<!!_MRB>=B&
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M?O]_EA[A?_V  U+@=W&"'DO,>/:"%T2@>A^!OSUQ>NV!6#95>Z.!&B]H?'R
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M@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$   $
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MYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^_O\
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M,O^F0$O_L#E8^;TQ8N?.+6G0X"1_N<\WEZ?"4JF>NF:UFK5SNYBS?;Z7LH/
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M_Z(W(O^?1#?_H4A(_Z=&5?RL16+TLD9N[+A(>N:_3(/AQU.*W,UBCL[(;)O
MOW&JM+=WM:FQ?+Z?K('%EZ>&RI"DC,Z*HI71AJ*ATH2;I="%FJ7/A9JESX6:
MI<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/_Z(V
M(O^?0S?_HD9'_ZA$5/VN0V'UM41L[KQ&=^G$2W_CSU2$V=1EB,C+:YJZPG"I
MKKIWM*.T?+V:KX'#DJR%R(NIBLR$IY+/@*:<T("CI<^ H:;.@*&FSH"AILZ
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MK,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&_Z U&O^=0B[_HD(\_ZI
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MDE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^
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MY4ACK.)-<I_?5'^3V5V*B=)GDX/-<)I]R7>?>,9]I'3$@Z=PPHBI;L&.JVS
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M8O=S@VCT;XQN\6R3<N]JFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\.
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MM%0_W;-;2="L8EG&I&IFO)UQ<K27=WRLD7Z%IHR&C*"(C9&:A966EH*>FI*
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M?XJ[GWZ*R)Y_B<F=@(C*G("(RYN B,N;@(C+FX"(RYN B,N;@(C+FX"(RYN
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M=>ACJ7CF8;)ZY&"[>^)?QWS@7]I]U&+A?<ICX'[#9.!_O6;?@+=GWX"W9]^
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M@EBOW8)8K]V"6*_=@EBOW8)8K]V"_X07 O^9' +_JA\#];D5 M[-# #0WQ(
MQ> F!;O?-@ZPW4 =I-E)+9C543N-T5A(@\]>4GO,95ISRVMA;,ER9V;(>6QA
MQX%P7<:*=%G&E'96Q9]X4\:L>5+&NWI1Q\]Y4<3C>E.\XGQ3O.)\4[SB?%.\
MXGQ3O.)\4[SB?%.\XGQ3O.)\_XH4 ?^?& '_L!0!V,,* ,[1"@#$Y10!N>0F
M"*[D-!.DXC\@F>!'+8_>3SF%W%9$>]I=3'/99%1LUVM:9M9R7V'5>61<U()G
M6-2+:E74E6U2U*!N4-2M;T[5O'!-UM!O3=7H<$[,Z7).S.ER3LSI<D[,Z7).
MS.ER3LSI<D[,Z7).S.ER_Y(1 ?^G$0#8N0D R\8( ,+5"@"WZA8#K.HG#*+I
M-!B8Z#XDC>=',(/F3CIZY51#<>1:2FGD85!DXVA57^-P65KC>%Q6XX!?4^.)
M8E#CDV1-Y)UE2^2I9TKEMF=)Y<9G2.;?9TK@[&=*W^QG2M_L9TK?[&=*W^QG
M2M_L9TK?[&=*W^QG_YP- -NQ!@#*O0< O\H' +7:"@"J[QD%H/ H#Y;P-1N,
M\#\F@O!',7GP3CEP[U1 :.]:1F'O8$M=[V=/6.]N4E3O=551\'U73O"%64OP
MCUM(\9E<1O&C7D3RKU]#\KM?0O/,8$'SYV!!\^A@0?/H8$'SZ&!!\^A@0?/H
M8$'SZ&!!\^A@WJ<" ,NV!0"]P04 LL\' *?J#0&=]QP'E/@K$HKX-AR!^4 F
M>/I(+V_Z339G^E,\8/I80%O[7T16^V5'4OML24_\<DM+_'E-2/R!3T7]BE%#
M_9-20?Z<4S_^IE0]_[%5/?Z\5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^
MSE8\_LY6SK " +VZ! "QQP0 I=8' )O]$ *1_R )B/\M$H#_.1MV_S\C;?]%
M*F7_2S!>_U$U6/]7.%/_73M/_V,^3/]H0$G_;D%&_W5#0_]\1$#_A$8]_XQ'
M//^42#O_G4DZ_Z5*.?^M2SC_N4LX_[E+./^Y2SC_N4LX_[E+./^Y2SC_N4LX
M_[E+OK4" +#  @"DS@, E]X% (__% *&_R,(??\N$'/_-1AJ_SP>8O]")%O_
M2"A5_TXL4/]4+TS_6C%(_U\S1?]D-4+_:C8__W W/?]V.3O_?#HY_X,[./^+
M/#;_DSTU_YH^-/^A/C/_JC\S_ZH_,_^J/S/_JC\S_ZH_,_^J/S/_JC\S_ZH_
ML;H! */(  "6U@  B_0) 8/_%@)Y_R &;_\H#&?_,!)?_S<76/\^&U+_1!],
M_THB2/]0)$3_529!_UHG/O]?*3O_9"HZ_VDK./]N+#;_="TT_WHN,_^!+S'_
MB# P_X\P+O^6,2W_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXRI,(
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MID<\^[%(._N^23K\STDY_.-).?SC23G\XTDY_.-).?SC23G\XTDY_.-)QZT
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M)2;_H28E_Z<F)?^G)B7_IR8E_Z<F)?^G)B7_IR8E_Z<FG\   )'-  "#VP
M>/8" &__#0%D_Q("7/\9 U3_( 1._R<&2/\O"$/_-@H__SP,//]"#CC_1P\U
M_TP0,_]1$3#_5A(N_UH3+/]?%"K_910H_VL5)O]Q%B/_>1<B_X$8(/^)&![_
MD1D=_Y<9'?^7&1W_EQD=_Y<9'?^7&1W_EQD=_Y<9_U8G!/]1,@7_5C4'_U\]
M#O]D11;_9DX?_V18)_]A8B__7FXU_UIY._]7A#__5(]#_U&81O]/H$C_3J=*
M_TVN2_],M4S_2[Q-_TK$3O])SD__2=Y/_TCI4/](\E#\2?90]TOY4/%,^D_K
M3OM0ZD_[4.I/^U#J3_M0ZD_[4.I/^U#J3_M0_U8G!/]1,@7_6#0'_V([#O]G
M1!;_:4T?_V=6)_]C8"__8&LU_UQW._]8@D#_58U$_U.61_]0GTG_3Z9+_TZM
M3?]-M$[_3+Q/_TO%4/]*SU'_2>!1_TGK4?Y)\E+Y2_=2\TWY4>U/^E'F4/I2
MY5#Z4N50^E+E4/I2Y5#Z4N50^E+E4/I2_U<G _]2,07_6C('_V0Z#O]J0A;_
M;$L?_VI4)_]G7B__8F@V_UYT//]:@$'_5XM%_U252/]2G4K_4*5,_T^M3O].
MM$__3;Q1_TS%4?]+T5+_2N)3_TGM4_M+\U/U3/=3[D_X4^A0^5/A4OI4X%+Z
M5>!2^E7@4OI5X%+Z5>!2^E7@4OI5_U@F _]4, 7_73$'_V<X#O]M0!;_;TD>
M_VY2)_]J7"__968V_V%Q//]=?4'_68A&_U:22?]4G$S_4J1._U"K4/]/LU'_
M3KM2_TW$4_]-SU3^3.!5^TSK5?A,]%7P3_=5Z5'X5>)2^%;;5/E7V53Y5]E4
M^5?95/E7V53Y5]E4^5?95/E7_UDF _]7+@7_8"\'_VHV#?]Q/A7_<T@>_W)1
M)O]O6B[_:F,V_V5N//]A>D+_785'_UJ/2O]7F$W_5:!0_U2H4OY2KU/]4;=5
M_%# 5OI/RU;X3]Q7]4_I5_)/\U?J4O97X5/W6-I5^%G15OA:SU;X6L]6^%K/
M5OA:SU;X6L]6^%K/5OA:_UDF _]:+ 7_9"T'_VXS#?]U/17_>$8=_W=/)?]T
M6"W_<& U_VIJ//]F=D+_8H%'_EZ+2_M;E$_Y69U2^%>D5/96K%;U5+17\U.\
M6/)3QUGP4M5:[%+F6NE3\EGA5/5;UU;V7,]7]UW(6?A=QUGX7<=9^%W'6?A=
MQUGX7<=9^%W'6?A=_UHE _]=*@7_9RH&_W(R#/]Y.Q3_?$4<_WQ-)/]Z52S_
M=5XT_V]G//QJ<D+Y9GU(]F.'3/-?D%#Q79E3[UNA5NU9J%CK6+!:ZE>Y6^A6
MPUSF5M%<XU;D7-]6\%W55_5?S%GV8,9:]F# 6_9AOESV8;Y<]F&^7/9AOESV
M8;Y<]F&^7/9A_ULE _]@* 7_:R@&_W<P"_]^.A/_@4,:_X)+(O]_4RK_>ULS
M^79D.O5P;D'Q;'E([6B#3>IDC%'G8955Y5^=6.-=I5KA6ZU<WEJV7MQ9P%_:
M6<Y@U5GB8-%9[V'*6O1BPEST8[Q=]&2W7O-DME_S9+9?\V2V7_-DME_S9+9?
M\V2V7_-D_UPD _]C)@3_;R8%_WLO"_^".1'_AD$8_X=)(/^%42CX@EDP\GU@
M..UW:D#H<G5'Y&Y_3>%IB%+=9I%7V6.96M5@H5W27ZA@SUVQ8LU<NV/+7,=D
MR5S;9<5=ZV6_7?)FN%_Q9[-@\6>O8?%GKF+Q9ZYB\6>N8O%GKF+Q9ZYB\6>N
M8O%G_UTD _]F) 3_<B0%_WXN"O^'-Q#_BS\6_XQ''?F+3R7RB%8M[(-=-N9^
M9S[@>'%&VW-[3=5N@U/0:HQ8S&>47<EEG&#&8Z-CPV&L9<%@M6>_7\%HO5_0
M:;I@YFFU8>]JKV+O:JMC[VJG9.]IIF7P::9E\&FF9?!IIF7P::9E\&FF9?!I
M_UXC _]I(@3_=B,$_X(L"?^+-@[_CSX4_9%%&_213"+MCE,JYHI:,M^%93O7
M?FU%T'AV3<MT?U3&<(=:PFR/7K]IEV*[9Y]EN&6G:+9DL&JS8[MKL6/*;*]C
MX6RK9.UMIF;M;*-G[6R@:.YKGVCN:Y]H[FN?:.YKGVCN:Y]H[FN?:.YK_U\C
M _]K( /_>2($_X4K"/^.- S_DSP2^)9#&.^62A[GE5 FX)%8+M>*83K.A&I%
MR'YS3<)Y>U6^=8-;N7&+8+5NDF2R;)IGKVJC:JQHK&RI9[9NIV?$;Z5GVF^B
M:.MOGFGL;YMJ[&Z9:^UMF&OM;9AK[6V8:^UMF&OM;9AK[6V8:^UM_U\C _]N
M'@/_>R$$_X@J!_^1,@O_ESH/])I!%>N;1QKCFTTAVI95+<^/7CG(B6=$P8-O
M3;M^=U6V>7];L7:'8*USCV6I<)9HIFZ?;*-LJ&Z@:[)PG6O <9QKTG*:;.EQ
MEVWJ<)1MZW"2;NQODF[L;I)N[&Z2;NQNDF[L;I)N[&Z2;NQN_V$A _]P'0/_
M?B #_XLI!O^5,0G[FS@-\)X^$>>@1!;?H$H=TYI2*\J37#C"C61#NX=M3;2"
M=%2O?GQ;JGJ$8:9WBV6B=)-IGG*;;9IPI'"7;Z]RE6^\<Y-OS7.2<.9SD'#I
M<HYQZG&-<>MPC''K<(QQZW",<>MPC''K<(QQZW",<>MP_V,@ _]R&P/_@!\#
M_XXG!?^7+PCXGC8+[:([#N2E0!+:I$8<SIY1*L676C>]D6)"M8QJ3*^'<E2I
M@GE;I'^ 8)]\B&6;>9!JEW>8;9-UH7"0<ZQSC7.X=(MSR76*=.)TB73H<XAU
MZ7*'=>IQAW7J<(=UZG"'=>IPAW7J<(=UZG"'=>IP_V4? _]T&@+_@QX"_Y F
M!/^:+0;TH30)Z:8W"^"J/0[4IT0;R:%/*<";6#:XE6!"L)!H2ZF+;U.CAW9:
MGH-^8)F A664?8UJD'N6;HQYGW&)>*ESAG>U=81WQ7:#>-]U@WCH=()XZ7."
M>.IQ@GCJ<8)XZG&">.IQ@GCJ<8)XZG&">.IQ_V<= _]W&0+_A1P"_Y,D _^=
M*P7QI# &YJHS"-RN-PS/JD,:Q:5.*+R?5S6SF5]!JY1F2J20;5.>BW1:F(A[
M8).%@V6.@HMJBH"3;H9^G'&"?:=T?WRS=7U\PW9\?=MV?'WH='U\Z'-]?.ER
M?7SJ<7U\ZG%]?.IQ?7SJ<7U\ZG%]?.IQ_VD< O]Y& +_AQL"_Y4C _N@*03N
MJ"P$XZ\O!=>R- O+K4$9P:A,)[>C532OG5U IYED29^4:U*9D')9DXUY7XZ*
M@&2)AXAIA(61;8"#FG%\@J1T>8&Q=G>!P'9V@=9V=H'G='>!Z'-X@.ER>'_J
M<7A_ZG%X?^IQ>'_J<7A_ZG%X?^IQ_VL; O][%P+_BAH!_Y@A OBC)@/JK"<#
MW[0I ]*U,@K'L$ 8O*Q+)K.G4S.JHEL^HIUC2)J9:5&4E7!8CI)W7HB/?F2#
MC89I?HJ.;7J)F'%VAZ)S<X:N=7&&O79OA])V<(?H='&%Z'-RA.ER<X3J<7.$
MZG%SA.IQ<X3J<7.$ZG%SA.IQ_VT9 O]^%@'_C1@!_YL> ?2G(@+FL" !VKHA
M <VX,0G"M#X7N+!))*ZK4C&EIEH]G:)A1Y6>:$^.FVY7B)AU78*5?&-]DX1H
M>)",;'2/E7!PC:!R;8RL=&J,NW5IC<YU:8WH=&N+Z7-MB>IQ;8CJ<6V(ZG%M
MB.IQ;8CJ<6V(ZG%MB.IQ_W 7 O^!%0'_D!8!_YX: ?"K&P'BMA8 T[T= <B[
M+PB]N#P5L[1'(ZFP4#"@JU@[F*A?19"D9DZ)H6Q5@IYS6WV<>F%WF8%F<I>*
M:FZ6DVYJE)YQ9I2J<V23N'-CE,MS8Y3F<F62ZG%GC^IP9X[J<&>.ZG!GCNIP
M9X[J<&>.ZG!GCNIP_W,5 O^%$P'_E!0 _*,5 .JP$@#9O@P S<$; <+ +0>X
MO3H3KKE&(:2U3RV:L58YDJY>0XJK9$R#J&I3?*5Q67:C>%]QH7]C;)^':&B>
MD6MDG9QN8)RH<%Z<MG%=G,EQ79SD<%Z:ZW!@ENMO897L;V&5[&]AE>QO897L
M;V&5[&]AE>QO_W<2 ?^)$0'_F1$ \Z@. ->U"@#/P0H QL48 +S$*@6RPC@1
MI[]$'IZ[32N4N%4VB[5<0(2R8DE\KVE0=JUO5G"K=EMKJGU@9JB&9&*GCV=>
MIIIJ6Z6F;%BEM6U7IL=M5Z;B;%>D[6Q:G^UL6I[M;%J>[6Q:GNUL6I[M;%J>
M[6Q:GNUL_WP0 ?^.$ #VG@T V*T) ,VX"0#'Q @ OLH4 +7*)P2KR#8/H<5!
M&Y?"2RB-OU,SA;U:/'VZ845VN&=+<+=M46JU=%9EM'Q;8+*$7URQCF)8L9EE
M5;"E9E.PLV=2L<9G4K'A9U&O\6A3JO!H5*GP:%2I\&A4J?!H5*GP:%2I\&A4
MJ?!H_X(. /^4# #;I08 SK$' ,6[!P"]QP< M= 0 *S0(P.CSS,,F<T_&(_*
M2"2&R%$N?<98.';$7S]OPF9&:<%L2V3 <U!?OWM46[Z$6%>]C5M4O9A=4;RD
M7T^\LV!-O<5@3?_B__])0T-?4%)/1DE,10 #";W@7TR\\&%-M_5B3;;U8DVV
M]6)-MO5B3;;U8DVV]6)-MO5B_XD+ .&< P#0J@4 Q;4% +N_! "RRP@ J]@-
M */9( *:V"\)D-8\%(?41A]^TD\I=M!6,F_/7CEHS60_8\QK1%[,<TE:RWI,
M5LJ#3U+*C5)/RIA43<JE5DO*LU=*R\572<O@5DG)\%A'Q_I92,7[6DC%^UI(
MQ?M:2,7[6DC%^UI(Q?M:]Y$$ -2B @#'KP0 NKD# +#$!0"GT D G^$0 )CA
M(0./X# )AN [$GW?1!MUWDTD;MU5*V?<7#)BVV0W7=MK.UG:<C]5VGI#4MJ#
M14[:C4A,VIA*2=JE2TC;LTQ'W,1,1MS>3$;:[4Q$V/E/0]C[3T/8^T]#V/M/
M0]C[3T/8^T]#V/M/VYH  ,JI @"[LP( L+T# *7)!0";U@D E.@4 8SI)02$
MZ#,+>^@\%'/H1!MKZ$LB9.=2*%[G62U9YV R5>=H-5+G;SA/YW<[3.> /4GG
MB3]'Z)1!1.B?0D+IK$-!Z;I$0.K-1$#JY$1 Z/5$0.?X0T#G^$- Y_A#0.?X
M0T#G^$- Y_A#S:,  +VN 0"PN $ I,0" )G0!0"/X0H B?$: 8'Q* 5X\C(,
M</([$VGR0QEB\DH?7/-0(U;S5R=2\UXK3_-E+4ST;#!)]',R1O1[-$/TA#9!
M]8XW/O69.3WVI#H[]K [.O>_/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW
M[#PX]^P\OZH  +&S  "DOP  F,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX
M$%[]0!58_D<94_Y-'4__5"!+_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M
M./^1+C;_FR\T_Z8P,_^R,3+_OC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q
M_]8RLJ\  *6Z  "8Q@  B](  '_? @!Y_Q$!;_\9 F?_(@1@_RP'6O\T#%3_
M/ ]/_T,32O])%4?_3Q=#_U490/];&S[_81P[_V8>.?]M'S;_=" T_WTA,?^&
M(R__D20M_YLE+/^E)BO_KR8J_[LG*?^^)RG_OB<I_[XG*?^^)RG_OB<I_[XG
MIK8  )C"  "+S@  ?ML  '7Y!P!K_P\!8O\6 EO_'@-4_R8%3O\N!DG_-0A%
M_SP+0?]##3[_2 X[_TX0./]3$37_6!(S_UX3,?]D%"[_:A4L_W(6*O]Z%R?_
M@Q@E_XX9)/^8&B/_H!HB_ZH;(?^M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX
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M!_]C.P[_9486_V50'?]A623_760K_UIP,/]6?#7_4X<Y_U"1//].FC__3:)
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M8V2,]&-DC/1C9(ST8V2,]&-DC/1C_W$0 ?^"#P#_D0T WI\) -.J"0#,LPD
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MH2TY\JXN./*^+S?ST"\W\^<O-O'S+S;Q\R\V\?,O-O'S+S;Q\R\V\?,ON:<
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M$![_H! >_Z@1'?^Q$1W_L1$=_[$1'?^Q$1W_L1$=_[$1E;P  (;'  !YTP
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M6')Z_%AR>OQ8<GK\6')Z_%AR>OQ8_V<1 ?]U#P#_@PX ](X- -N9"@#4H0L
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MQT44;L9.&VC%5B%CQ%TG7L-D*UK":R]6P7(S4\%[-D_ A#E,P(\\2L";/D?
MJ#]&P+A 1<#-0$7 Z#]$OO9!0[W_0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT
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M(S7NSR,T[N8C-.OU(S3K^",TZ_@C-.OX(S3K^",TZ_@CLZ4  *:M  "9MP
MC<$  (#+  !UU0$ :>$& &3S$0!>\QP!6?0F E3T, 1/]3@&2_5 "$?V1PI$
M]DX,0?=5#C_W7 \\]V,1.OAJ$S?X<Q0U^'T6,_F(%S'YE!@O^J$9+OJO&BW[
MOAHL^\\;*_OG&RO[ZQLK^^L;*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D
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M2W]K_TM_:_]+?VO_2W]K_TM_:_]+_UX0 ?]K#@#_=@X ^X - .J(#0#;CPP
MT)(5 ,>2)P*^CS8(MHQ"$:Z(31JHA%8BHH!>*IQ]93"7>FPUDW=S.H]U>SZ,
M<X)"B'*+1H5PDTF";YU,?VZH3GUNM4][;<90>F[@4'EO\DYY;_Y->6__3'EO
M_TMY;_]+>6__2WEO_TMY;_]+_V / /]M#0#_>0P [H,+ -N+"0#4D0H S)43
M ,*5)0*YDS0'L8]!$*J,2QFCB%0AG81<*9>!8R^2?FHUCGQQ.8IZ>#V&>(!"
M@W:(17]UD4E\<YM,>7*F3G9RLU!U<L-0<W+=4'1S\$]T<_U-='/_3'1S_TQT
M<_],='/_3'1S_TQT<_],_V(. /]O# #\>PH WH8& -6." #/E D QY@1 +Z8
M(P&UEC(&K9,_#Z:021B?C%(@F(E:*).&82Z.@V@TB8%O.85_=CV!?7Y!?7N&
M17IYCTEV>)E,<W>D3G%WL5!O=L%0;G?94&YW[T]N=_Q.;G?_36]W_TQO=_],
M;W?_3&]W_TQO=_],_V0- /]R"@#P?@8 VH@% -"0!P#*EP@ PIL0 +F;(0&Q
MFC &J9<]#J&41Q>:D5 ?E(U8)XZ+7RV)B&8SA(9M.("$=#U[@GM!>("$171_
MC4AQ?9=+;7RB3FM\KT]I>[Y0:'S54&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_
M3&I[_TQJ>_],_V8* /]U" #A@0( U(L% ,N3!@#$F@8 O9X. +6?'P&LGBX%
MI)L[#)V81166E4X>CY-6)8F072R$CF0R?XMK-WJ*<CQVB'E <H:!1&^%BD=K
M@Y5*:(*@366!K$YC@;Q/8H'13V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2
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MIT=2F;9(49G*2%&8YDA1E_5(49?_1U&6_T=1EO]'49;_1U&6_T=1EO]']G<
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M-4.[XC1"N?,U0;C]-T"W_S= M_\W0+?_-T"W_S= M_\WSHL  +^8  "RH0
MIZD  )RP  "1N   AL " 'O(!P!TRQ( <,PB 6O+, -FRSP'8<M%#%S*3A%8
MRE855,I=&5')9!Q.R6P?2\ET(DC(?B1%R(@G0\B5*$'(HBH_R+$K/LG$*S[)
MX2H^Q_(K/<;\+3S%_RX\Q?\N/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X
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M$2?U\1$G]?$1)_7Q$2?U\1$G]?$1HZ@  ):R  "(NP  >\4  &_.  !BUP
M5MX  $[P!P!*^A  1OL9 $+[(@$__"H!._TR CC].0(U_C\#,OY& S#_3 0N
M_U,%*_]:!2G_8@8G_VL&)/]V!R/_@@@A_Y ((/^="1__JPD>_[H)'?_)"1S_
MW0D<_]T)'/_="1S_W0D<_]T)F+   (JZ  !\Q   ;\T  &+8  !5W@  2>0
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M-/\A_S@J O\_)P+_0R8"_T8I O]),@/_23P%_TA'!_]&4PO_1%\/_T)J$O]
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M&0#R<A\ YG0F =UT,0+3<3\(RVU+#\5I5A? 9F =NV-I(K=@<2>T7GDKL5R
M+JY;B#&L68\SJEB7-:=7GS>E5Z@YHU:S.J%6P#N?5M(\G5;I/)M7^#R:5_\\
MF5C_.YA8_SN86/\ZF%C_.IA8_SJ86/\Z_U(2 ?]<#@#_9A  _VT1 /IS% #K
M=Q@ X'D? -1Y+0++=CP'Q')(#KYO4Q:X:UP=LVAE(J]E;2>L8W4KJ6%\+Z9?
MA#*C7HLUH5V3-YY<FSF<6Z0[F5JO/9=:NSZ66LP_E%KE/Y);]3Z16_\^D%S_
M/9!<_SR/7/\\CUS_/(]<_SR/7/\\_U41 /]?#0#_:0X _W$. /5W$ #F>Q$
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M06AXJD-F>+A$97C,165XYT1E>/=#9GC_0F9X_T%F>/] 9GC_0&9X_T!F>/]
M_V0# .YQ  #8?   RX4" ,., P"[D0, LY0) *R6& "EEB@"G90V!Y:200Z0
MCTH5BHU2'(2+6B)_B6 G>X=G+'>%;C!S@W4T;X)]-VR!ACMI?Y ^9GZ;06-^
MJ$-A?;9$8'W)1%]]Y4-@??9"8'W_06%]_T!A??] 87W_0&%]_T!A??] _V<
M .-T  #2?P  QX@! +Z/ @"VE0$ KI@& *::%0"?FB8"F)DS!I&7/PR+E4@4
MA9-0&G^16"!ZCU\E=HUE*G*+;"YNBG,R:HA[-F:'A#ECAHX\8(69/UV$ID%;
MA+1"6H3'0UJ$XT):@_1!6X/_0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX
M  #-@P  PHP  +F3  "PF   IYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.
M&'J75AYUEETC<)1C*&R2:BQHD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[)
M5(O%0%2+X4!4BO,_58K^/U6)_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(
MAP  O9$  +28  "JG   H*(  )FD$ "3I2 !C*0N X6C.0E_HD,/>:!,%G2?
M4QMOG5H@:IQA)6:::"ECF6\M7YAW,%N7@#18EHHW5965.5*5HCM0E+ ]3Y3#
M/4^4WSQ/D_(\3Y+]/$^2_SQ/D?\\3Y'_/$^1_SQ/D?\\Y'0  ,^!  #"C
MN)8  *V<  "CH0  F*@  )"J#0"+JQL A:LJ GZJ-@9XJ4$,<JA)$FVG41AI
MIE@<9*1?(6"C9B5=HFTI6:%U+%:A?B]3H(@R3Y^3-4V?H#=+GJ\X2I[!.$F>
MW3A)G? X29S\.$F;_SE)F_\Y29O_.4F;_SE)F_\YVWH  ,B'  "\D@  L9H
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M(CB__R0XO_\D.+__)#B__R0XO_\DO9$  +";  "DH@  F*H  (RQ  " N0
M=;\  &K&! !>S @ 6<\2 %?0(0!5T"X!4= Y D[00P1+T$P&2=!3"$;06PM#
MT&,-0=!K#S[0=1$\T8 3.M&,%#C1FA8VT:D7-=&[%S32TA<UT.P6-,_W&#/.
M_QHSSO\:,\[_&C/._QHSSO\:LYD  *:A  ":J0  CK$  (&Y  !UP   :L<
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M!!;_Y 06_^0$DZX  (6W  !XP   :LD  %W2  !0V0  1-\  #KD   U]P,
M,O\, "[_$@ K_QH */\A ";_)P C_RT (/\S ![_.0$<_S\!&?]% 1?_30$5
M_U4!$_]? 1'_:@(0_W@"#O^' @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_
MP@(,_\("A[8  'F_  !KR0  7M,  %#;  !#X   ..4  "_P   K_P  )_\(
M "3_#@ A_Q, 'O\9 !O_'@ 8_R, %?\H !/_+0 1_S( $/\X  [_/P ,_T8!
M"O]/ 0?_60$$_V4! ?]R 0#_@0$ _X\! /^; 0#_IP$ _ZD! /^I 0#_J0$
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MVD.1&=A"F1K50I\;TT&F'-%!KAW/0;<>SD'!'LQ!T!_)0N4?Q4+S(<)!_B/
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M*Z=+_RNG2_\KITO_*Z=+_RNG2_\K_TD2 /]0#@#_61  _U\2 /]C%@#R91T
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MJ#AN:K<Z;6K).FQJY#IM:_4X;6O_-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL
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M.5QYW3E=>?$X77C^-UYX_S9>>/\U7GC_-5YX_S5>>/\U]60  -QP  #*>@
MP(,  +:)  "NC0  I(\  )V1$ "7DB  D9$N XJ0.0>$CD,,?XU,$GJ+4Q=U
MB5H;<8AA(&Z&:"-JA6\G9X1W*V.#?RY@@HDQ78&4,UN H399?Z\W5W_ .%=_
MVC=7?_ W6'[]-EA^_S58?O\U6'[_-5A^_S58?O\UZ6@  -1T  #&?@  NX<
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M+D:6_RY&EO\N1I;_+D:6_RY&EO\NT7<  ,&$  "VC@  JI4  *";  "5GP
MBJ0  'VI  !WJQ  <ZL> &^L+ %JJS<$9:M!!V&J20M=J5$/6JE8$U>H7Q93
MIV894*=N'$VF=A]*I8$A2*6,)$6EF29#I*@G0J2X*$&DSB=!H^HG0*+X*$"A
M_RE H/\I0*#_*4"@_RE H/\IR7X  +J+  "OE   HYH  )B@  "-I0  @JH
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M$B['_Q(NQ_\2KI<  *&>  "5I0  B:T  'RT  !PNP  9,$  %G&  !.RP,
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M8@ )_V\ "/]_ 0?_D $%_Z !!/^N 03_O $#_\<! __' 0/_QP$#_\<!@[0
M '6]  !GQ@  6L\  $O5   _W   ,^$  "GE   A[   'OT  !K_!0 7_PP
M%?\0 !+_%  0_QD #O\>  W_(P +_R@ "/\N  ;_-0 #_ST  /]&  #_40
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M_R:/4/\F_TH) /]3!0#X6@0 XE\# -IB!@#48PD S6,2 ,1E(P"\93("MF-
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MJBQ]6K<M?%K)+GI:XRYZ6_4M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$
M /);  #>9   SVH  ,=N @# < 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,
MEFI4$9)H7!6.9F,8BV5I&XAC<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV
M7K4N=5[&+W1>X2]T7_,N=%__+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>
M  #99P  RVT  ,-Q 0"[<P( M7,) *UU%P"G=2<!H70T YMR/P>5<$D+D6Y2
M$(QL612):F 8A6EG&X)H;AY_9G4A?65])'IDA29W9(\I=6.:*W)BI2UP8K,O
M;V+$+VYBWB]N8_(N;F/^+6YC_RQN8_\K;F/_*VYC_RMN8_\K_U4  .5@  #3
M:0  R'   +]T  "W=P$ L'<' *AX%0"B>20 G'@R I9V/0:1=$<+C')/#XAP
M5Q.$;UX7@&UD&GUL:QUZ:W,@=VIZ(W1I@R9R:(TI;V>7+&UGHRYK9K$O:6;!
M,&EFVS!I9_ O:6?]+6EG_RQJ9_\K:F?_*VIG_RMJ9_\K_E@  .%C  #/;
MQ',  +MX  "S>@  JWH$ *1[$@">?"( F'PO I)Z.P6,>$4*AW=-#H-U51)_
M<UP6>W)B&GAP:1UU;W @<FYX(V]M@29M;(LI:FR6*VAKH2YF:Z\O9&J_,&-K
MV#!C:^\O9&O\+61K_RUE:_\L96O_+&5K_RQE:_\L]%L  -UF  #+;P  P'8
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M+%1Y_RM5>?\J57G_*E5Y_RI5>?\JX64  ,QQ  "_>@  M((  *N'  "AB@
ME8L  (V-"0"'CA8 @H\D 7V/,0)XCCL%<XU$"6^,3 UKBE019XE:%62(81AA
MAV@;7H9P'EN%>"%8A((D582-)E*#FBE0@J<J3X*W*TZ"S"M.@N@K3H'X*D^
M_RI/@/\I3X#_*4^ _RE/@/\IVVH  ,=U  "Z?P  L(<  *:,  "<CP  CY$
M (:3!0" E!( >Y4A '>5+0%RE3@$;91"!VF32@MEDE$.8I%8$EZ07Q5;CV88
M6(YM&U6.=AY2C8 A3XR+(TV+F"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)
MA_\G28?_)TF'_R=)A_\GT6\  ,%[  "UA   JXP  *"0  "5E   B9<  'Z:
M  !WFPX <YP< &^=*0%KG#4"9IP_!6*;1PA?FD\+7)I6#UB97!)5F&,54YAK
M%U"7<QI-EGT=2I6)'T>5E2%%E:0C1)2S(T.4R"-#E.4C0Y+U)$.1_R1#D/\D
M0Y#_)$.0_R1#D/\DRG4  +N!  "PBP  I)$  )J5  "/F0  @YT  '2B  !N
MHPL :J07 &:E)0!CI3$!7Z0[ UND1 58I$L(5:-3"U*C6@U/HF$03:)H$TJA
M<15'H'L81*"&&D*?DQQ GZ(=/I^R'CV?QAX]G^,=/9WT'CV<_Q\\F_\?/)O_
M(#R;_R \F_\@PGP  +6(  "ID   GI8  ).;  "'GP  >Z0  &^H  !CK 0
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MA (DU)0"(M2F B'5N0(AU=("(-/K B#2]@,?T?\$']'_!!_1_P0?T?\$GYL
M )2B  "'J0  >;$  &VX  !@O@  5,,  $G'   ^RP  -= ! "W5!@ EVPL
M)-X2 "/>'  BWR4 (> N "#@-P ?X4  'N%* !WB4P <XUX &^-J !KD>  8
MY(@!%^6: 1;FK $5YL !%.?= 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI
M  ![L0  ;KD  &'   !4Q@  2,H  #W/   STP  *MD  "+> @ >ZPH '.P0
M !OM%P 9[1\ %^XF !7N+0 4[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@
M#/2*  OUG  *]:X "?;"  GVV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !O
MN@  8L(  %7)  !'S@  .](  #'8   GW0  '^$  !GH   6^ 8 %/H- !+[
M$@ 0_!< #OP=  W](P ,_2D "OXP  C_.  &_T$  _],  #_6   _V8  /]W
M  #_B0  _YL  /^K  #_NP  _\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP
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MKAV22;L>D$G,'HY*Y1Z-2O8>BTO_'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
M +MK  "S;   K&H$ *1K$@">;"$ F6PO 91K.@./:40&BFA-"89F50V#95P0
M@&1B$WUB:15Z8G 8>&%X&G5@@!US7XH?<%^4(6Y>H"-L7JTE:UZ\)FI>T29I
M7NPE:E_[)&I?_R-J7_\B:E__(FI?_R)J7_\B\%(  -U=  #+90  P&L  +=N
M  "O;P  IVX! *!O$ ":<!\ E' L 8]O. .*;4(&AFQ+"8)J4@Q^:5D/>VA@
M$G=F9A1U9FX7<F5U&G!D?AUM8X@?:V.2(FEBGB1G8JLE96*Z)F1BSR9D8NHF
M96+Z)&5C_R-E8_\B96/_(F5C_R)E8_\BZU4  -A@  #(:   O&X  +-Q  "K
M<P  HG$  )MR#@"5<QP D'0J 8IS-@*%<D %@7!("'UO4 MY;5<.=FQ>$7-K
M9!1P:FP7;6ES&FMI?!QH:(8?9F>0(61GG"-B9JDE8&:Y)E]FS29?9N@F8&;Y
M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
MNS,- +,T&0"N-B< J3<T *4W0 "B-TH GS=3 9TV6@&;-F$!F39H I<U;P*5
M-74#E#5\ Y(UA 20-8T$CS66!8TUH 6+-:L&BC6Y!H@UR@>'-N4'A3;V!X0W
M_P>#-_\'@S?_!X(W_P>"-_\']#(  .,[  #200  QD0  +U#  "W/P  L3L)
M *H[% "E/"( H#TP )T].P"9/44 ECU. 90\5@&2/%T"D#QC HX[:@.,.W$$
MBCMX!(@Z@ 6'.H@&A3J2!H,ZG >!.J@(@#JU"7X[Q@E].^$)>SSS"7L\_PEZ
M//\(>CS_"'H\_PAZ//\([C<  -U!  #+1@  OTD  +9)  "N1@  J4$$ *-!
M$0"=0AX F$,K )5#-P"10T$ CD)* 8Q"4@&)05D"AT%? X5!9@.#0&T$@4!T
M!8! >P9^/X0'?#^."'H_F0EX/Z4*=T"R"G5 PPMT0-T+<T'Q"W)!_PIR0?\*
M<D'_"7)!_PER0?\)Z3P  -5%  #%2P  NDX  +!.  "G2P  HD8  )M&#@"6
M1QH D4@G (Y(,P"*2#T AT=& 81'3@&"1E4"@$9< WY%8@1\16D$>D5P!7A$
M> 9V1($(=$2+"7)$E@IP1*(+;T2O#&Y$P QM1=D-;$7O#&M%_0MK1O\+:T;_
M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
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M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
M?S,^ 'TS1@![,TT >3-4 '<S6@!V,V$ =#-G 7(T;P%Q-'<!;S2! 6XTC )L
M-)@":C6E FDULP-H-<8#9S;B V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^
M  "U0@  ID$  )L_  "3/   C3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ
M '4Y0@!S.4D <3E0 ' Y5P!N.5T ;#ED 6LY:P%I.70!:#E^ F8YB0)D.94#
M8SJB V(ZL0-A.L,#8#O@!%\[\P-?._\#7SO_ U\[_P)?._\"T3L  ,!"  "P
M10  H40  )5#  "-0   AST  (([ @!].PX >3P8 '4](P!S/2T <#TV &X]
M/P!L/48 :SU- &D]4P!G/5H 9CUA 60]: %C/7$!83Y[ E\^A@)>/I,#7#Z@
M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
M7T5' %U%30!;150 6D9; 5E&8P%71FP!5D9V E1&@0-31HX#4D><!%!'JP10
M1[T$3T?6!4]'[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+
M  !_2@  >$8  '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T 64E$
M %=)2@!625$ 54I9 51*80%22FD!44IT D]*?P-.2HP#34J;!$Q+J@1+2[P$
M2DO3!4I+[@1+2_T$2TK_ TM*_P-+2O\#P4@  +)0  "@3P  D4\  (5.  ![
M30  <TD  &Q*  !G2P0 8DP. %],%P!<32$ 6DTJ %A-,@!633H 5$U! %-.
M2 !23D\ 4$Y7 4].7P%.3F<!3$YR DM.?0))3HL#2$Z9!$=/J 1&3[H$1D_1
M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
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M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -
M;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:
M  !*7   05\  #EC   Q9@  *FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4
M  YW&P -=R, #'<J  MW,P *=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0
M 7:G  !VNP !==4  73K  )T]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%
M8P  /&<  #-K   K;@  )'(  !YU   7>0  $GP   U_!@ )@0P !8$1  .!
M%@ "@1T  8$D  "!+0  @C8  ()   ""3   @ED  ()H  "">0  @HT  (&@
M  " M   @,L  '_G  !^\@  ?OD =&(  &AB  !>8@  4V0  $EG   _:P
M-G   "UT   E>   'GP  !>    1@P  #88   B)!  "BPH  (L.  "+$P
MC!@  (P?  "-)@  C2\  (XY  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-
MK0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8:0  36P  $)Q   X=@  +WL
M "9_   >A   %H@  !",   ,CP  !I(   "5    E@<  )<,  "7#P  F!,
M )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7  "<:   G'L  )R0  ";I0
MF[H  )K0  ":YP  FO$ :FT  %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,
M   6D0  $)4   J9   $G    *    "B    HP$  *,&  "D"P  I0X  *82
M  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L70  K'   *R%  "LFP  JZ\
M *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0  #2*   ID   'Y8  !:;   0
MGP  ":,   &G    J@   *X   "P    L    +$   "R P  M @  +4-  "V
M$   MQ4  +D=  "[)@  O#,  +U!  "]4@  O60  +YY  "^D   O:0  +VW
M  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9   AGP  %Z0  !"I   )K@
M +(   "V    N0   +T   "_    OP   ,    #!    PP   ,0%  #&"@
MQPX  ,D3  #+'   SB8  - U  #110  TE<  -)K  #3@@  TY<  -.I  #2
MN   TL0 58P  $F3   ]F@  ,*(  "6H   :K@  $;0   FY    O0   ,$
M  #$    R    ,L   #-    S0   ,\   #0    T@   -0   #8    V@8
M -T,  #@$0  XQH  .8G  #G.   Z$H  .E=  #J<@  ZX@  .N;  #LJ
M[+( _P - /\ "P#_  L _P 0 /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@
M6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "=
M .( I0#A *\ WP"[ -T RP#; .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\
M_P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L /< . #T $, \ !- .T 50#J
M %T YP!D .0 :@#B '  X !U -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$
MH #/ *H S0"U ,L Q #) -T R #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P
M /\   #_    _P * /@ $0#Q !P [  G .D ,@#F #T X@!' -T 4 #9 %@
MU0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_
M *4 O0"P +L O0"Z -  N #K +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\
M  #]    \P % .D #@#A !8 VP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9
M ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +< @ "V (< M ". +( EP"P *
MK@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q
M    Y0   -< "@#- !$ QP < ,( )@"_ #$ O  [ +H 1 "W $P M !3 +(
M60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G ($ I@") *0 D0"B )L H "E
M )X L@"= ,$ FP#: )H [P"9 /T F #_ )@ _P"8 /\ _0   /    #A
MT0   ,8 ! "]  T MP 5 +, ( "P "L K0 U *L /@"H $8 I@!- *0 5 "C
M %D H0!? *  9 "> &D G0!N )L =0": 'L F "# )8 C "5 )8 DP"A )$
MK0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P", /\ \P(  .('  #,!P  OP0
M +<   "Q  @ JP 0 *< &0"D "0 H  N )X -P"< $  F@!' )@ 3@"6 %0
ME0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^ (H B "( )( A@"= (4 J0"#
M +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-
M  "C"   H (, )P $P"8 !T E0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4
M (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4
M=@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6
M$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,
M5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [)
M &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>  "H'@  FQT  )(;  "+&0
MB!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q
M$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6
MXP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?)   DB,  (DB  ""(   ?AT
M 'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$
M9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8
M'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*   BR@  ((G  ![)0  =B,  ',@
M  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4
M %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/(
M423_ %$D_P!1(_\ N2L  *,L  "3+   ABT  'PL  !T*@  ;R@  &LE  !I
M(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D
M5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_
M $LI_P!+*?\ LRX  )XO  ".,   @3   '<O  !O+@  :BL  &4J  !C)P$
M7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-
M*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N
M_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K,0  92\  & M  !=+   62P)
M %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED
M1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P!
M,O\ JC,  )8U  "&-0  >38  &XU  !F-0  83(  %PP  !7,   5# & %$P
M#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@
M #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\
MIC8  )(W  "".   =3@  &LX  !C-P  738  %<S  !3-   3S0# $LT# !)
M-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX
M:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@
M (XY  !^.@  <CL  &@[  !?.@  63D  %,V  !.-P  2C@  $8X"@!$.1
M03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T
M/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\
M  ![/   ;CT  &0]  !</0  53P  $XZ  !).P  13P  $$]!P ^/0X /#T5
M #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%  ,4!: #!!90 O07(
M+D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W
M/P  :S\  &%   !9/P  4C\  $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#
M&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M14X +$58 "M&8P J1F\ *49^
M "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%_P H1?\ E4   ()!  !S0@
M9T(  %Y"  !50@  3D(  $5"   _1   .T4  #=&   T1PH ,4@0 "](%@ N
M21X +$DE "M)+  J23, *4HZ "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+
MC0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B2O\ D$,  'Y$  !O1   9$4
M %I%  !210  2D8  $%'   \2   -TD  #)+   N30< *TX. "E.$P G3QH
M)D\A "5/*  D3S  (U W ")0/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;
M49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(
M  !.2   1TD  #Y+   Y3   ,TX  "Y0   H4P( )%0+ ")5$  @518 'U8>
M !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A760 76&8 %5AU !18AP 46)H
M$U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+
M3   1$T  #Q/   U40  +U0  "E6   D60  'EL' !I=#0 871( %UT9 !9>
M(  57B< %%XN !->-P 27D  $5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I
M  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4
M0%(  #A4   P5P  *EH  "1=   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .
M9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )F
MMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=4@  5%(  $Q3  !#50  .U@
M #-;   K7@  )6$  !]D   99P  $VH   ]M!@ +< P "' 1  =P%@ %<!T
M!' D  -P+  "<#4  ' _  !P2@  <%<  '!E  !P=@  <(H  &^>  !OL@
M;L@  &WE  !M\@  ;?D <%8  &-6  !95@  _^+__TE#0U]04D]&24Q%  0)
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T
M  "[    K@   *4   "?    G  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q
M (X -P", #P BP!! (D 1@"( $L A@!0 (4 50"# %L @@!B (  :P!^ '4
M? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_ &X _P!L /\ QP   +4   "E
M    F0   (\   ")    A0 $ (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P
M,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z
M &H B@!H )L 9P"O &8 S !E /4 9 #_ &$ _P!@ /\ M    *    "0
MA0   'T   !W    <P   '  " !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I
M #  :  T &< .0!F #X 90!# &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L
M@@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4 /\ H0   (X   !_    =0
M &P   !H    9    &$ ! !@  L 7P / %\ $P!? !D 7P ? %T )0!< "H
M6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!-
M (P 3 "? $L M0!* -P 2@#Z $H _P!* /\ D@   (    !R    9P   %\
M  !:    5P   %4  0!3  < 4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I
M $T +@!, #, 2P X $H /0!) $, 2 !* $8 4@!% %P 1 !G $, =0!" (8
M00"8 $  K@!  ,L /P#R $  _P!  /\ A0   '0   !G    70   %4   !/
M    3    $H   !(  0 1P * $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $,
M*0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [ %< .@!B #D ;P X (  -P"3
M #8 IP V ,  -@#H #8 _@ V /\ ?    &L   !> @  5 ,  $T#  !' P
M0P$  $$    _  $ /@ ' #T "P ]  X /  1 #P %@ \ !H .@ ? #D )  X
M "D -P N #8 ,P U #H - !! #, 20 R %, ,0!> #  :P O 'L +@". "T
MH@ M +@ +0#= "T ^  N /\ <P$  &0%  !7!P  30@  $8(  ! "   .P<
M #@%   W P  -@ $ #4 "  T  P -  / #0 $@ S !8 ,@ ; #$ (  P "0
M+P I "X +P M #8 +  ] "L 10 J $\ *0!: "@ 9P G '< )@") "8 G0 E
M +, )0#/ "4 \  F /\ ;08  %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*
M   P"   +@8" "X#!@ M  H +  - "P $  K !, *@ 7 "D '  H "  )P E
M "8 *P E #( )  Y ", 0@ B $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X
M'@#' !X Z0 ? /H : D  %D,  !-#0  0PX  #P.   V#@  ,0T  "T-   J
M#   * L  "<)!  F!@@ )@0+ "4##@ D 1  ) $4 "(!&  A 1T (0 B "
M*  ? "X '@$V !T!/P < 4D &P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #!
M !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0   R$   +0\  "D.   F#@
M(PT  "(, P @"P8 ( D) !\'#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9
M!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX $P>  !('E  2!J< $@6\ !($
MV0 2 ^\ 7PX  %$/  !&$   /!$  #41   O$0  *A$  "80   B$   ( \
M !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD
M$PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -
M"NH 7 \  $X1  !#$@  .A,  #(3   L$P  )Q(  ",1   ?$0  '!   !H0
M @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP
M  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@
M6!$  $L2  ! $P  -Q0  # 4   I%   )10  "$3   =$@  &A(  !<1 @ 5
M$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1
M-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(
M $D4   ^%0  -18  "T6   G%@  (A4  !X4   ;%   &!,  !42 P 3$@4
M$A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %
M%#X !!5*  ,56  "%6<  15Z   5C@  %:,  !2W   4SP  $^D 4A0  $86
M   [%P  ,A<  "L7   E%P  (18  !P6   9%0  %A0! !03!  2$P8 $1((
M  \2"  .$PD #!0*  H5#0 (%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L
M !E'   950  &60  !EW   9C   &*(  !BW   7SP  %^H 3Q8  $,8   Y
M&0  ,!D  "D9   C&0  'Q@  !L7   8%@  %14" !,5!0 1% 8 $!0&  X5
M!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@  &QT  !PD   <+0  '#@  !U$
M   =4@  '6(  !UU   =B@  '*   !RV   ;T   &NL 3!@  $ :   V&P
M+1L  "8;   A&@  '1D  !D9   7&   %!<# !(6!  0%P0 #A<$  P9!0 *
M&@< !QP)  ,="P  'PT  " 0   @%   (1H  "$B   A*@  (34  ")!   B
M3P  (E\  ")R   AB   (9\  ""V   ?T0  '^T 2!H  #T<   S'0  *QT
M "0=   @'   '!L  !@:   6&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4
M R$(   B"@  ) P  "8.   F$@  )A@  "<?   G)P  )S(  "<^   G2P
M)UP  "=N   FA0  )IT  "6T   DT0  (^X 1!T  #D?   P'P  *!\  ",>
M   >'0  &QP  !@;   4'   $1P   X=   -'P  "B$   8B 0 #) 0  "8&
M   H"   *@L  "L-   M$   +14  "T<   M)   +BX  "XZ   N2   +5@
M "UJ   M@0  +)H  "NR   JT   *>\ 0"   #8A   M(0  )B$  "$@   =
M'P  &AX  !8>   2'P  #R$   TB   *)   !B8   (H    *P(  "T$   O
M!@  , D  #(,   T#@  -1(  #48   U(   -2H  #4V   U0P  -5,  #1F
M   T?   ,Y8  #*O   QS0  ,.\ /",  #(D   J)   )",  " B   <(0
M%R$  !,C   0)0  #2<   DI   %*P   2X    P    ,@   #0!   V!
M. 8  #H)   \#0  /A   #X4   ^'   /B8  #XQ   ^/P  /4X  #UA   \
M=P  .Y$  #JK   YR0  ..T -R<  "\G   H)@  (R4  !\D   9)0  %"8
M ! H   -*P  "2X   4P    ,P   #4    X    .@   #P    ^ 0  0 ,
M $('  !$"@  1@T  $D1  !)%P  2"$  $@L  !'.@  1TD  $9;  !%<0
M1(L  $.E  !"PP  0>@ -"H  "PJ   G*   (B<  !PH   6*@  $2T   TP
M   ),P   S8    Y    /    #X   !!    0P   $8   !(    2@   $P#
M  !.!@  4 H  %,.  !4$P  5!P  %,G  !3-   4T,  %)5  !1:@  4(,
M $^>  !-N0  3.  ,"T  "LL   F*P  'RP  !@N   2,@  #34   @Y   "
M/0   $    !#    1@   $D   !,    3@   %$   !3    50   %<   !9
M 0  7 8  %\*  !B#@  8Q4  &,?  !B+   83P  &!.  !?8@  7GL  %R6
M  !;L   6<\ +S   "HO   B,   &C,  !,W   ..P  "#\   %$    2
M $P   !/    4@   %4   !8    6P   %T   !@    8@   &0   !F
M:0   &T%  !P"P  =!   '08  !S)0  <C0  ')%  !P60  ;W$  &V+  !K
MI@  :L  +C,  "4U   =.   %#P   Y!   '1P   $P   !1    50   %D
M  !=    80   &4   !H    :P   &T   !O    <@   '0   !W    >@
M 'X   ""!   A@L  (H1  ")'   B"L  (8]  "$4@  @V<  (&!  !_FP
M?K( *3H  " ]   60@  #T@   A.    5    %H   !@    9    &D   !N
M    <@   '8   !Z    ?0   (    ""    A0   (@   "+    C@   )(
M  "6    FP,  * ,  "B$P  H"$  )\S  "=1P  FEX  )AW  "7CP  E:<
M(T,  !E(   13@  "54   !<    8P   &H   !Q    =@   'L   "
MA@   (H   ".    D0   ),   "6    F0   )P   "@    HP   *<   "K
M    L    +8$  "\#0  NA<  +DH  "W/   M%(  +)J  "OA0  K9P '$X
M !-4   +7    60   !L    =    'P   "#    B0   (\   "4    F@
M )\   "B    I    *<   "J    K@   +$   "T    N    +P   #!
MQP   ,T   #4!0  V!   -4>  #3,0  T$@  ,U?  #+=@  R(X
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MY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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ME]Z2G9?>DIV7WNW$#!/SQ1(O],(94NJ]'WS*K#RLQJM5L\*H:KF^J7>_NJJ
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MD*>$SXRFA=")IH;1AJ6'TH2EBM*!I8W2@*6/TH"EC]* I8_2@*6/TH"EC]*
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MGH&KQO^M& 7_K2(6_ZLQ+_^G/TOXH4QGYYY3@=F=69?*FV6LQ9QOM,.=>+C
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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M=JN4N&^KJ;IRI;6Z=YVUN7J9MK=]EK>V?I.YM'^1NK* D+NQ@)"[L8"0N[&
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M:TCOL&Q'[K=L1^ZW;$?NMVQ'[K=L1^ZW;$?NMVQ'[K=L1^ZW;-VO  #%O 0
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M?%'.X']2QMZ!4\3>@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@?^2# #_H T
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M_YE '?^<1B?_G4PQ_)U2._2<647MF6!/YI1H6=^.<V/5AGUNS7^'>,9XD8#
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M@[*9@X3+F(2#SI:$@]"4A(+2DH2!TY"$@=2.A(#6C(2 UHR$@-:,A(#6C(2
MUHR$@-:,A(#6C/]W$@'_=!L#_X(>!/^4)PC_H#(-_Z<T$_JN.!COM3T<YKQ&
M(=R_3"S.N50_P[%=4+>J95^MI&QLHYUT=YF8?(&1DX:*B8^2D8*,GY9]BJ^8
M>HO'F'R)SI9]B-"4?H;2DG^%TY!_A-2.@(/6C("#UHR @]:,@(/6C("#UHR
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M_YH1 /^M% #:O@H T<T* ,OD$ '!Y"4'M^,U$ZWA0"&CWDDOE]M2/HO764N
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M8TG2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8_Z5  #4J0  PK4# +7! P"JSP4
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M4_]=&P+_628#_U,Q!O]4.0C_74(0_V)+&O]B52/_8%\L_U]K-/]<=SO_68)
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M2R30IE0UQI]>1+R99E*TDF]=K(QW9Z2'@&^>@HIWF'Z4?9)[H(&->JV$BGG
MA8AZW(2'>MV"AGK?@(9ZX'Z%>N)\A7GC>H5YY'F%>>1YA7GD>85YY'F%>>1Y
MA7GD>?]J%0'_:QL"_WL7 O^*' +_F"8%_Z(P"/6H,PSKKCD0XK-!%-:Q1R/*
MJU(TP*1<0[:>9%&MF&Q<I9)T9IV-?6^6B(9VCX61?8J"G(*%@*J%@7^\AH"
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M<%FCZW!9H^MP6:/K<%FCZW!9H^MP6:/K</]W#P'_C0@ WJ " ,^N!0#$N04
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M:FF)\&AIB?!H:8GP:&F)\&AIB?!H:8GP:/]G$@'_>0P _XH* -^:! #3I@<
MS+$( ,>[" #!PA, N,(H!*Z_.!"EO$0>F[A.+)&U5SB(L5Y"@*YF2WBK;5-Q
MJ79::Z=_8&6EBF1@HY=H6Z.F:UFCNFQ8H]QK6:#N:UR:[VI?EO!I89+Q:&./
M\69CC_%F8X_Q9F./\69CC_%F8X_Q9O]K$ '_?@D \9 $ -:> P#,J@8 Q+0&
M +Z^!0"XR!  L,@D Z?&-0V=PT(;D\!,*(J]5#.!NEP^>;=D1G&U:TYKLW14
M9+%^6E^PB5]:KY9B5JZE95.NN692K]ME4JOR9E6D\F98G_)F6IOS95R7\V1<
ME_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0 W98  ,ZC P#$K@0 N[<$ +3"
M!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZPUHX<L%B0&O :D=DOG--7KU\
M4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ]F!1JO9@4Z7V8%6A]F!5H?9@
M5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL  ,:H @"[L0( LKL" *K'!@"B
MTPH G=8: 976+ :,U#H1@])&'7K03R=RSE@Q:LU@.&3+:#]>RG)%6,I\253)
MB$U/R9513,FE4TK)N51)RMQ31\CW54C _%A*N/M93++[6DZM^EI.K?I:3JWZ
M6DZM^EI.K?I:3JWZ6O]_  #<DP  RJ(  +RL 0"QM0  J, # )_+!@"6V0L
MD> ; 8K?+ :"WSD.>=Y#%W'=32!JW%8H8]M?+UW:9S58V7$Z4]E[/D_9B$)+
MV99%2-FF1T;:NDA%V]M'1-CT24+3_TU$R?]/1<+_4$>[_U)'N_]21[O_4D>[
M_U)'N_]21[O_4N:*  #/FP  OZ<  +*P  "GNP  G,8# )/1!@"+Z@X A>@?
M G[H+09VZ#@.;NA!%F;G2AU?YU(C6>=;*57G9"U0YVTQ3.=X-4GGA#A&Z)$Z
M0^B@/$#ILCX_ZLL^/NCO/CWF_S\]X/]"/]?_1$#._T9 SO]&0,[_1D#._T9
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M" __G @._ZP)#O^["0W_TPD-_],)#?_3"0W_TPD-_],)#?_3"9&\  "!R0
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M7Q0!_VP1 ?]X$P'_@1<!_X@= ?*/)0+GDR\$WI4X"=.0117*BU$BPH5;+KN
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M /]^$ #_B!$ ]9$4 .B8&0#=GB !T9XQ!\>:0!.^E4P@MI!6+*Z+8#>GAFA
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M7'1Y^EMU>?M:=7G[6G5Y^UIU>?M:=7G[6O]=$P'_; T _WL+ /:("0#<DP8
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M5U^-_%=?C?Q77XW\5_]J"@#_?   W(P  ,V8  ##HP, NJH" +.S 0"LO H
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M'"O_XQTJ_/H=*OK_'2KW_QPJ]_\=*O?_'2KW_QTJ]_\=*O?_';.C  "DJP
ME[8  (G!  ![RP  ;]8  &/?  !;]08 5?\0 %#_&0%+_R,"1O\L T+_- 0^
M_SP%.O]#!C?_2P<T_U,(,?];"2[_9 HK_V\,*/]\#2;_BPXD_YP0(O^N$2'_
MQ1(@_^D3'__\$Q[__Q,>__\3'O__$Q[__Q,>__\3'O__$Z:I  "8LP  BK\
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M2 ?_.U4+_SEB#_\W;Q/_-7T7_S.*&?\RE1O_,9X=_S"G'O\PKQ__,+<@_R_
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M38!K_TR :_]*@&O_2H!K_TJ :_]*@&O_2O]4$@'_80P _VX* /UX"0#H@@@
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M3&QY_TQL>?],;'G_3/]># #_; $ YGH  -:&  #+CP( Q)<$ +Z=! "XH@X
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M+S_']3 ]Q/\S.\/_-3R^_S8]N/\W/;C_-SVX_S<]N/\W/;C_-]&&  # E0
MLI\  *6G  ":KP  CK<  (._  !XQP, ;L\' &77#0!CV!T 8-@M EO8.@17
MV$8)4]A0#4_861%+UV(51]=L&$37=QM!UX0>/MB3(#S8HR$[V;<B.MK5(CK6
M\B,WU/\G-M+_*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4
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M"1K__PD9__\)&?__"1G__PD9__\)&?__":*G  "3L0  A;L  ';&  !IT
M6]H  $[@  !#Y0  /OL! #K_#  V_Q, ,O\; "__(P K_RH!*/\Q 23_-P$A
M_S\"'_]& AS_3@(9_U@#%O]C Q/_< ,2_X$$$?^3!!#_IP0/_[T%#O_@!0[_
M]@4.__\%#O__!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$
M $#G   W\P  ,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!
M$O\X 1#_0 $._T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0,
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M/)%;_SN/6_\ZCUO_.H];_SJ/6_\ZCUO_.O],$@#_5@T _V ) /]H"@#Z;PP
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M8_\]@F/_/()C_SR"8_\\@F/_//]0#P#_6P< _V8# .QO @#<=@, U'P' -&
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M/G=J_SYW:O\^=VK_/O]4# #_7P  \FP  -UV  #0?0( R8,$ ,2'!@"_BA
MMXPC ;"*- 6IB$$.HH5,%YR!51^6?UXFD7QF+8QY;C*(=W8WA'5_.X!TB#]\
M<I)#>'&>1G5PK$AS;[U)<7#927%P]$=Q<?]$<G#_0G)O_T%R;O\_<F[_/G)N
M_SYR;O\^<F[_/O]6"@#_8@  YF\  -=Y  #,@0$ Q8<# +^+! "YC@X LI @
M :N/,06DC#\-G8I*%I:'4QZ1A%PEBX%D+(9_:S&"?7,V?GM\.WIYAC]V=Y!"
M<G:<16]UJ4AL=;I):W7426MU\D=K=?]%;'7_0VUS_T%M<O\_;7+_/VUR_S]M
M<O\_;7+_/_]9!P#_90  XG(  -%\  #'A   P(H" +F/ @"SD@P K)0= *:3
M+P2>D3P+F(](%)&,41R+B5HDAH=B*H&%:3!\@G$U>(%Z.G1_@SYP?8Y";'R:
M16E[IT=F>KA(9'O02&1[\$=E>_]$9GK_0V=X_T%H=O\_:';_/VAV_S]H=O\_
M:';_/_];! #W:0  W78  ,V   ##B   NXX  +23 0"MEPD IY@: *"8+ .9
MECH*DI1%$HR23QJ&CU<B@(U?*'N+9RYVB6\S<H=W.&V%@3QIA(M 9H*70V*!
MI49@@;9'7H'-1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_
M/_]>  #I;0  UGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(
MC)I#$(:831B EE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:
MB;1%6(G+15B([418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B
M  #D<0  SWX  ,.(  "YD0  L)<  *>;  ">H0  F*,3 ).C)0&-HC0&AJ%
M#8"?2A5YG5,<=)M:(V^98BAJF&HN9I9R,F&5?#==E(8Z69*3/E:2H4!3D;)!
M4I+)0E*1ZT%2D/] 4H__/U6+_SY6B/\]5X?_/5>'_SU7A_\]5X?_/?EG  #=
M=@  R8,  +V-  "SE0  J9L  *"@  "6IP  CZD/ (NJ(0&%J3 $?Z@\"GBG
M1Q)SI5 8;:-8'FBB8"1DH6<I7Z!P+EN>>3)7G80V4YR1.5"<GSM.F[ ]3)S'
M/4R;ZCQ,F?\\3)C_/$V5_SQ/D?\[4(__.U"/_SM0C_\[4(__.^MM  #3?
MPXD  +>3  "LF@  HI\  )FE  ".JP  A; + (&Q&P!\L2L"=[ X!W&O0PUK
MKDT49JU5&6&L71Y=JV4C6:IN)U6I=RM1J((O3:>/,DJGGC5(IZ\V1Z?&-D:F
MZ39%I/XW1:/_-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\
M +"8  "EG@  FZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.
M7K=2$UJV6AA6MF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U
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M'3'*_Q\PR?\A+\C_(2_(_R$OR/\A+\C_(;Z/  "OF@  HJ$  ):I  "*L
M?;@  '&_  !FQ@  6\P" %#2!P!'V@P 1MP8 $7<)P!$W34!0=U  C_>2P,]
MWE4$.M]?!CC?:0<UWW8),^"$"S'@E POX:8-+N&\#BWBX XMWO@/*]W_$BK<
M_Q0IVO\6*-K_%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<
M &7(  !9S@  3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"
M+^U5 RWM7P,J[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@
MZ_\*'^K_"Q_J_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0
M  !,U@  0=T  #CD   U]@P ,_<4 ##W'@ N^"< *_DP "CY. $F^D !(_M)
M 2'[4@$>_%T"'/UI AK]>0,8_HL#%_^> Q7_LP04_],$%/[T!!/\_P,3^O\#
M$_G_ Q/Y_P,3^?\#$_G_ YVE  "/K@  @+@  '+"  !DRP  5M,  $G:   ^
MWP  -.0  "[T   K_PH */\0 "7_%P B_Q\ '_\F !S_+0 9_S0 %_\\ !3_
M1 $2_TX!$/]9 0[_9P$,_W<!"_^* @K_GP()_[4""/_5 @?_] ('__\"!___
M @?__P('__\"!___ I&M  ""N   <\(  &3,  !6U0  2-T  #OB   PYP
M)^X  "/_   @_P0 '/\, !G_$0 6_Q8 $_\; !'_(0 ._R< #?\N  K_-@ '
M_SX !/](  #_5   _V(! /]S 0#_AP$ _YT! /^R 0#_R@$ _^H! /_S 0#_
M\P$ __,! /_S 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T
M !C_   5_P  $?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX
M /\W  #_00  _TT  /]<  #_;0  _X(  /^6  #_J   _[H  /_#  #_PP
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M)ZY&_R>J1_\FITC_)J=(_R:G2/\FITC_)O] % #_2 X _TX+ /]5#@#_61$
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M+X5;_R^%6_\OA5O_+_]+# #_5   ^UX  .)E  #8:P$ SVX% ,QP" #&<A(
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M.UM\XSI;?/HX7'O_-UU[_S5>>?\T7W?_,U]W_S-?=_\S7W?_,_Y<  #A:@
MS74  ,!^  "VA@  KHL  *6.  ";D0  E9,1 )"4(@&+DS$#A9(]"7^12 ]Z
MCU$6=8U9&W&,8"!LBF@E:(EP*62'>2UAAH,Q786/-%J$G#97@ZPX58._.56#
MX3A5@ODW5H+_-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH
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M*T*<_RQ"F_\L1)?_*T27_RM$E_\K1)?_*]=R  ##@   MHP  *J4  "?F0
ME)X  (FC  !^J   <*X  &JP#@!HL1T 9;$L 6&Q. -=L$,&6;!,"E6O5 Y2
MKUT13JYE%4NN;QA(K7D;1:V&'D*LE2 _K*4B/JVY(SVMV"(]J_4C/*G_)3NG
M_R8[IO\F.Z3_)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0
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M#2/0_PTCT/\-(]#_#:Z6  "@G0  E*0  (:L  !YM   ;+L  &#"  !4Q@
M2,L  #[0   UU00 +=T* "SA$P KXA\ *>,J "CD-0 GY#\ )N5* "3F50 C
MYF$!(>=N 2#G?@(>Z) "'>FD AOIO (:ZN("&N;\ AGE_P,9Y/\$&./_!1CC
M_P48X_\%&./_!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,
M #+:   JWP  )>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5(
M$_9? !+V;@$1]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-
M\_\!#?/_ 9FC  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B
M   ?Z@  '/L& !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].
M  ;_7  $_VP  O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\
M /__ (VK  !]M0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5
M^0  $O\  !#_"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_
M20  _U<  /]I  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z
M ("U  !POP  8<D  %+3  !#VP  ->$  "GF   >Z@  %>X  !#X   ._P
M"_\   C_   $_P8  /\*  #_#@  _Q$  /\5  #_&P  _R,  /\K  #_-@
M_T,  /]3  #_90  _WH  /^1  #_I@  _[@  /_/  #_SP  _\\  /_/ /\<
M+P'_("P!_R$L ?\>+@'_&C,!_Q0\ ?\/1@'_#50"_PMA O\);P+_"7L"_PF&
M O\)D +_"9D"_PF@ O\)IP+_":T"_PFT O\)O '_"<4!_PG1 O\)XP+_">\"
M_PGY ?\*_P'_"O\!_PK_ O\*_P+_"O\"_PO_ _\+_P/_"_\#_PO_ _\?+0'_
M(RD!_R0I ?\B*P'_'C !_Q@X ?\40P'_$5 "_Q!> O\.:P+_#G<"_PZ# O\.
MC0+_#I4"_PZ= O\.I +_#JH"_PZQ O\.N0+_#L$"_P[- O\.WP+_#NP"_P[X
M O\._P+_#O\"_P__ _\/_P/_#_\$_Q#_!/\0_P3_$/\$_Q#_!/\C*@'_)B8!
M_R@E ?\G)P'_(RL!_QXS ?\;0 '_&4T"_Q9: O\49P+_$W,"_Q-^ O\3B0/_
M$Y$#_Q.9 _\3H +_$Z<#_Q.N _\3M0/_$[X#_Q/) _\3V@/_%.D#_A3V _L4
M_P/Y%?\#^17_!/@5_P7X%?\&^!7_!O@5_P;X%?\&^!7_!O\F)@'_*B(!_RP@
M /\K(@'_*"8!_R<P ?\D/ '_(DD"_Q]5 O\=8@+_&VX#_QMZ _\:A /_&HT#
M_QJ5 _\:G 3_&J,$_QNJ!/\;L@3_&[H$_QO%!/P;TP3Y&^<$]1ST!/(<_P7Q
M'/\&\!S_!^\=_PCO'?\)[QS_">X<_PGN'/\)[AS_"?\J(@'_+AT _S ; /\P
M' #_,"( _S L ?\N-P'_*T0"_RA1 O\F70/_)&D#_R-U!/\C?P3^(X@$_2.1
M!?LCF 7Z(Z %^".G!O<CK@;U([<&]"/!!O(DSP;N).0&ZB7R!N@E_@CF)/\*
MY"7_"^,E_PSC)/\,XB3_#.$D_PWA)/\-X23_#?\N'@#_,Q@ _S46 /\U%0#_
M.!T _S@G ?\W,P'_-#\!_S)+ O\O6 /[+F0$^"UO!/4L>@7S+(,&\2R,!N\L
ME ?M+)P(["RC".HLJPCI++,(YRR^">8LS GB+>((WBWQ"MLL_@S6+?\.U"S_
M#](L_Q#1+/\0SRS_$,XM_Q#.+?\0SBW_$/\R&0#_-Q0 _SH1 /\\$@#_/QD
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M'II'_QZ:1_\>FD?_'O] #0#_1@0 _TP  /A2 @#H500 X54( .)5#0#551D
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M,6EGW#!I9_4N:6?_+&EG_RIJ9_\I:F;_*&IF_R=J9O\G:F;_)_]0  #G6P
MTV8  ,5N  "[<P  LW<  *MY  "D> , G7H4 )A[)0&3>S0#CGI !XEX2@V$
M=E,2@'5;%WQS8AMX<FH?=7%R(G)O>R9O;H4I;&V0+&ELG"YF;*HP9&R\,6-L
MV3!C;/0O8VS_+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD
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M*U)\_RE3>_\H5'K_)U1Z_R=4>O\G5'K_)^A>  #0:P  P'8  +1^  "KA0
MH8D  )>+  ")C0  @X\( 'Z0%P![D2<!=I$T W*0/P9MCTD+:8Y1#V6-61-B
MC& 77HMH&UN*<1Y7B7LA5(B&)%&'E"=/AJ(I38:T*DN&S"I+A>XI3(3_*4R#
M_RA,@_\G38'_)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX
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M'#>?_QPWG_\<-Y__',1X  "UA0  J8\  )V5  "2F@  AI\  'JC  !NJ
M8JP  %6P  !0L@X 3K(; $VS* !+LS4 2;,_ 4:S20)$LU($0;-;!C^S9 @\
MLV\*.K-[##>SB@XULIH/,[.M$#*SQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L
M_Q8OK/\6+ZS_%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0
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M IZ:  "2H0  A*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0
M'-L  !7?!0 4Z0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )
M\'0 "/&)  ?RH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A
M  "&J0  >+(  &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0
M  _P 0 -^0H "_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$
M /UU  #\C   _*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !Y
ML@  :KL  %S$  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]
M   %_P,  ?\)  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?
M  #_=0  _XT  /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO
M7<8  $[/   _U@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_
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M ?\"GP'_ :4 _P&L /\!L@#_ ;H _P'$ /\!T0#_ .0 _P#Q /\ _ #\ ?\
M_ +_ /P#_P#\!/\!_ 7_ ?P%_P'\!?\!_ 7_ ?\?)@#_(2( _R A /\>(P#_
M&"< _Q,P /\1/ '_#DH!_PU7 ?\+8P'_"F\!_PIZ ?\*A '_"HT!_PJ4 ?\*
MFP'_"J(!_PJH ?\*KP'_"K<!_PK  /\*S #_"N  ^PKO /<*^@#U"_\!]0S_
M ?0-_P'T#?\"] W_ O0-_P+T#?\"] W_ O\B(@#_)!T _R0< /\B'0#_'B(
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M#+LL_PR[+/\,NRS_#/\Q$0#_-0P _S8' /\Z"P#_/!  _SL5 /@Y'P#O-RL
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M2[,>BTO%'HE+XAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]
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M(WA5UR-W5?(B=E;_('96_Q]V5O\==E;_''96_QMV5O\;=E;_&_]%  #L3@
MVE@  ,E>  "_8@  MV0  +%C  "K80@ I&,7 )]D* ":93<"EF1#!9%C30B.
M854,BF!=$(=?91.$7FP6@5UT&7Y<?1Q\6X8>>5J1('=:G2)T6:HD<EFZ)7%9
MTB5P6O C;UK_(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL
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M(U]G_R%?9O\?8&;_'F!F_QY@9O\>8&;_'N]/  #:7   QF4  +IM  "P<@
MIW4  )UT  "4<P  C70- (EV' "%=RL!@7<X WQV0P9X=4P)='14#7%S6Q%N
M<F,4:W%K%VAP<QIE;WP=8FZ'(%]ME")=;*(D6FRR)5ELQR58;.@E66S](UEK
M_R%::_\?6VO_'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD
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M3W7_'4]U_QU/=?\=3W7_'=]<  #(:   N7(  *YZ  "E@   FH(  (Z"  "
M@P  >84" '2&$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$
M:Q14@W4748* &DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_
M'$E\_QQ)?/\<27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0
M<(P  &N.#0!HCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-
MC'(32HM]%DB*BAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$
M_QI"A/\:0H3_&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0
M &&5" !>EQ0 7)<C %J8+P!7F#H!5)A$ U*73 5/EU0'3)=<"4F690Q'EF\.
M1)5Z$4&5B!,_E)<5/92H%CN4O18[E-\6.I+X%SJ0_Q<ZC_\7.H[_%SJ._Q<Z
MCO\7.H[_%\5N  "V>P  JH4  )Z+  "4CP  B)(  'N4  !NEP  8IL  %>>
M  !2H X 4: ; $^A* !-H30 2Z$^ 4FA1P)'H5 #1*%8!4*A80<_H&L)/:!W
M"SJ@A0TXH)0.-J"F#S6@NQ TH-T/-)WW$#.<_Q(SFO\2,YG_$S.9_Q,SF?\3
M,YG_$[UW  "O@P  HXL  )B1  "-E0  @9D  '.<  !GGP  6Z(  $^F  !'
MJ0@ 1*H2 $.J'P!!JRL 0*LW #^L00 ]K$H!.ZQ3 CFL7 ,WK&<$-:QS!3*L
M@08PK)$'+JRC""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_
M#;6   "HBP  G)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@
M-K4+ #2U%0 SMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(G
MN8T");F? R2YM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*
M  "@D0  E9<  (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X#
M "3"#  BPA0 (L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4
M&<>9 !C(K@ 7R,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8
MF   BYX  'VE  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,
M!  3T H $=(1 !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-
M  O8I  *V+X "=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP
M@*8  '*M  !DM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,
MVP4 "-X+  ;?$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #F
MD@  YJH  .?(  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\
M &6W  !7O@  2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0
M .D&  #I#0  Z1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@
M])<  /6P  #VT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!
M  !*R   .\P  "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0
M  #U!0  ]0L  /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$
M /^:  #_L@  _\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [
MT0  +=@  "'=   6X@  #N8   CJ    [0   /    #X    _P   /\   #_
M    _P   /\&  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!
M  #_F0  _Z\  /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT
M_P U /\ 00#_ $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_
M *0 _P"J /\ L #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P
M /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *
M_P"F /\ K0#_ +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X
M /\ ^ #_ /D _P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'
M.0#_ T8 _P!3 /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C
M /X J0#\ +  ^@"Y /< Q #U -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\
M[P#_ /  _P#P /\ \ #_ /\>'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_
M#$$ _PI. /\(6P#_!V8 _P9Q /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&
MI@#T!JT \@:U / %P #M!<X ZP7D .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_
M >0+_P'D"_\!Y O_ ?\A& #_(1, _R 1 /\;$@#_'!H _QHD /\6+P#_$SP
M_Q%) /\050#\#F$ ^0YK /8.=0#T#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J
M#JH Z ZS .8/O0#E#\P X0_C -T0\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3
M_P+2$_\"TA/_ O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E#
M /083P#O%UL [!=F .D7< #F%WD Y!>! .(7B0#@%Y$ WQ>8 -T7GP#;%Z<
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M"/\O" #_,0  _S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D
MP#55 ;PU7P*Z-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI
M-+D)IS3*"J4UY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S
M @#_-0  ]CH  .4^  #<0   U#T$ -(W"0#+.!4 PSHF +T]-@"X/D0!M#Y0
M ;$]6@.N/6,$K#UK!:D\<P:G/'L(ICR#":0[BPJB.Y0+H#N=#)X[J V=.[0.
MFSO%#ID[X Z6._0/E#S_#Y(\_P^2//\.D3S_#9$\_PV1//\-D3S_#?\U  #_
M.0  ZD$  -U&  #01P  R48  ,9!!0# 0!$ N4(A +-$,@"O14 !JT5+ J=%
M50.D1%X%H41F!Y]#;@B=0W8*FT)^"YE"A@V708\.E4&9#Y-!I!&10; 2D$'
M$HY!V1*+0?$2B4+_$HA"_Q&(0O\0AT+_$(="_P^'0O\/AT+_#_\X  #S/0
MXT<  -),  #(3@  P$T  +M* @"V1PX L$D= *M++0"F3#L!HDQ' IY+402;
M2UH&F4IB")9):@J427$,DDAY#H](@@^-1XL1BT>5$HE&H!2'1JP5A4:[%H1&
MT1:"1^X6@$?_%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P
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M&6I5_Q=J5?\6:E7_%6M5_Q1K5?\4:U7_%/)#  #?3P  RU@  +U=  "S80
MJV(  *)@  ";7   E5X0 )!@'P",82X B&$Z H1@102!8$X&?E]6"7M>70MX
M764.=EQL$'-<=!-P6WT5;EJ(%VM:E!EI6:$;9UFP'&59PQQD6>,<9%GZ&F19
M_QAD6?\795G_%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8
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M%E9E_Q569?\55F7_%>)1  #*70  NV8  *]L  "F<0  F7   (YO  "#;@
M?7 % 'AR$@!U<R$ <G,O 6]S.@)L<T0$:7),!F9R5 AC<5L+8'!C#5UP:Q!;
M;W036&Y_%55NBQ=3;9D946VH&D]MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J
M_Q50:O\54&K_%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4
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M$<5F  "U<0  JGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\
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M R>EK00FI<8#)J3K!"6B_P4EH/\&))__!B2>_P<DGO\'))[_!Z]^  "CB
MEXX  (V3  !^E0  <)@  &.;  !7GP  3*(  $*F   XJ0  +ZP# "JN#@ I
MKA@ **\C ">O+0 FL#< );!! "2P2P CL58 (K%C "&Q<0 ?L8( 'K*4 1RR
MJ0$;LL$!&['G 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90
M (2:  !VGP  :*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX
M%[L6 !>\(  6O"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .
MP+H #L#A  ^]^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA
M  !KIP  7JP  %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-
M  G*%  (RAT !\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L
M ,W(  #,[0  S/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@
ML   4K8  $6Y   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4
M#@  U14  -8>  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T
M  #>V0  W_<  -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@
M1;\  #C"   LQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0
MX@X  .03  #E&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #P
MO   \.,  ._Y  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@
M "K,   ?T   %=4   [:   'W@   .(   #F    Z0   .H   #L    [@4
M .\,  #Q$   \Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@
M_\   /_A  #_]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8
M   3W0  #.(   /F    Z0   .P   #P    \P   /0   #V    ^    /H
M  #]!P  _PT  /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8
M /^Z  #_T0  _]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_
M $P _P!9 /\ 90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\
MJP#_ +( _P"Z /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_
M /X _P#^ /\ _@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@
M_P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^
M *X _0"V /P P #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4
M_P#U /\ ]0#_ /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0
M /\ 7 #_ &< _P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H
M] "R /( NP#Q ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J
M /\ Z@#_ /\8&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\
M5P#_ &( _ !L /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N
M .< MP#F ,, Y #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\
MW0#_ /\;$P#_&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W
M EP \@)F .X"< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$
MM #8!<  U@70 -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_
M /\?$ #_'@L _QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8
MY0QA .(,:@#>#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+
M#K\ R@_0 ,81Z0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B
M# #_(00 _R   /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1:
M - 59 #-%FT RQ9U ,D7?0#'%X4 Q1B, ,08E #"&9P P!FE +X9KP"]&KL
MNQK+ +@;Y0&T'/8!LAW_ K =_P*O'?\"KAW_ JX=_P*N'?\"KAW_ O\F!@#_
M)0  _R8  /LG  #Q)0, \"$+ .@<$@#>&1T U!LM ,T=/ #('TD Q2!5 ,$A
M7P"_(F@ O")P +HC> "Y(W\!MR.' ;4CCP&T))<!LB2@ ;$DJ@*O)+8"K27&
M JLEWP*H)O,#I2;_ Z,F_P.B)O\$H2;_ Z$F_P.A)O\#H2;_ _\I  #_*
M]BT  .<P  #?+P  V2L$ -8B"@#.(Q8 QB8G , H-@"[*D0 N"M/ +4L60"R
M+&(!L"QJ :XM<@&L+7H"JBV! JDMB@*G+9(#I2V; Z0MI02B+;$$H"W !)\M
MV 2<+N\%F2[_!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4
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M#7E"_PQX0O\+>$+_"WA"_PIX0?\*>$'_"O8V  #F0   T4@  ,--  "Y3@
ML4T  *E)  "D108 GT83 )I((P"623( DDH^ 8]*2 *,2E$#BDE9!(=)8 6%
M26@'@TAO"(%(=PI_1X +?4>*#7I'E0YX1J(/=D:P$'5&PA!S1N 0<D?W#W%'
M_PYQ1_\-<4?_#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(
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M#E]3_PU?4_\-7U/_#>=$  #/4   OU@  +-=  "H7P  G%T  ));  "+6
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M#=%4  "^7@  L6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!<
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M"CE^K LW?L,+-WWF"S=[_ LW>O\+-WG_"CAX_PHX>/\*.'C_"KYD  "P;P
MI7@  )9Y  "'>0  >WD  '!Z  !D?   6(   %"#  !+A0H 2(84 $>'( !%
MB"L 1(@U $.(/@!!B4<!0(E/ 3Z(6 (\B&$#.HAL!#>(> 4UB(<&,XB8!S*'
MJ@<PB, ',(?D!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\
M )!^  ""?@  =G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2,
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M !*H]0 3I_\!$Z7_ 1.E_P$3I/\!$Z3_ :.&  "7C   C9$  'V2  !ME0
M8)@  %2<  !(H   /J0  #2G   JJP  (:X  !FQ   2LP< #[40  ZU%P .
MM2$ #;4K  VU-@ ,MD$ "[9.  JV7  )MFP "+9_  >VE  &MJH !;;%  :V
MZ@ 'M?\ "+3_  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0
M $NH  ! K   -;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D
M ,$B  #"*P  PC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@
MQ/8  ,/_  ##_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U
M   UMP  *;H  !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8
M  #.(0  T"H  -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND
M -;]  #6_P  UO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   H
MP0  '<0  !3'   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?
M%0  X1T  .,G  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO
M  #K_@  Z_\  .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP
M$L\   O3   "V    -T   #A    Y    .4   #G    Z0   .L'  #M#0
M[Q$  /$9  #T)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #]
M[0  _?0  /WT '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T
M  #A    Y0   .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@
M /X.  #_%0  _R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@
M_]0  /_4 /\+( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\
M8@#_ &T _P!V /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U
M /\ O@#_ ,L _P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\
M^0#_ /\-'0#_"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_
M &@ _P!R /\ >@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D
MN0#X ,8 ]@#9 /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_
M /\0&0#_#A4 _P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &,
M_@!M /P =0#Z 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M
M ,  ZP#/ .D Y@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2
M% #_$!  _PP/ /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G
M /$ < #O '@ [0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H
MW0#) -L X #8 /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_
M$@P _PX) /\+# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4
M:@#B '( X !Z -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$
M ,H V0#( .T QP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04
M_Q   /\0!@#_#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2
M VP SP-T ,T$>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(
MU0"[">P N O] +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<
M /\6  #[$P8 ^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6<
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M I H_P*/*/\"CB?_ HXG_P*.)_\"CB?_ O\F  #R*0  XS$  -(T  #(-
MP#   +LI @"X(PX L28< *PH*P"H*C@ I"M$ *$L3@"?+5< G2U? )LM9P&9
M+6X!F"YU 98N?0*4+H8"DRZ0 I$NF@./+J8#C2ZS XPNQ0.*+^$$AR_V!(4O
M_P2$+_\#A"__ X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD
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M!FI!_P9J0?\%:D'_!>TW  #60@  Q$D  +=-  "K30  H$H  )A'  "30@
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M!]I&  ##4   M5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L
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M"D9BJ@M$8K\+1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7
MJV0  )MD  ",8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6
M:C, 5&H\ %)J10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!H
MJ0H_:+T*/FC>"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD
M )9H  "'9P  >V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X
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M<   <G   &=Q  !<<P  47<  $IZ  !"?0, /WX. #U_&  \?R, .X M #J
M-@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!H0,J@;8#*8'2
M RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78  (5U  !X=0
M;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L ,(DE "^*+P N
MBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$BB[,!(8S. 2&*
M\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z  !S>@  9GP
M %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0< "*5)@ AE2\
M()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX %9?) !:5[@ 6
MD_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L@@  7X0  %2(
M  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N
M !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X
M#9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP  6(X  $R2  !!
MEP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N
M+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_
M  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H  $2?   YHP
M+Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10  +D<  "Z)0
MNB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q   O.L  +O^  "[
M_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM   PL0  );0
M !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84  #'&P  R"0
M ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P
MS?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   DO   &;\  !'"
M   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7$0  VA@  -PA
M  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F  #E^   Y?\
M .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP  #\H   ?.
MT0   -8   #<    WP   .    #B    Y    .8#  #H"0  Z0X  .P5  #N
M'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS
M &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@   #=    X0
M .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,  /H+  #]$0
M_QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$
M' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R
M /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4
M_P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_
M 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\
M=0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /< M #U +\ ] #.
M /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$
M_P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W
M '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H +D YP#' .4
MW@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$,
M /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B .P :P#J '(
MZ !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0 U0#  -( TP#0
M .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_# < _P," /\
M" #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X 90#; &P UP!S
M -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4
MO@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_
M! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0
M= #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0 QP"R .  L0'R
M *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\  /(-  #J"@
MZ0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U
M!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(.
M_P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09  #;%@  TA "
M ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$
MJ!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4
M%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*)   PAT  +X6
M! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;90"=&VP FQQS
M )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q 8D@_P&((/\!
MAR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@  M2@  + B  "N
M&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2)6< D"9N (XF
M=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI_P%]*?\!?"C_
M 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$  *4L  "B)@8
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M ]\Y  #(0P  N4H  *E+  ";20  D$<  (A$  "#00  ?D$& 'I"$0!V0QX
M=$4J '%%-0!O1C\ ;49' &M&3P%J1E8!:$9= F9&90)D1FT#8D9V!&!&@@1>
M1HX%7$6<!EM%K 991K\'6$;?!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]
M  #$1P  M4X  *1.  "63   BTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG
M &M*,@!J2SP :$M$ &9+3 %D2U,!8DM: F!+8@)?2VH#74MT!%M*?P592HP%
M5TJ:!E5*J@=42KT'4TK<!U)*]@922O\%4DG_!%))_P-22/\#4TC_ ]1!  #
M2P  LE$  *!0  "23P  ATX  'Y,  !X2   <DH  &Y+#0!K31@ :$XD &9.
M+P!D3SD 8D]" &%020%?4%$!75!8 EM/8 )93V@#5T]R!%5/?0533XH%4DZ8
M!E!.J =.3KL'34[9!TU.]09-3O\%34W_!$U-_P1.3/\#3DS_ \Y$  "\3@
MKE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414 8U(A &%3+ !?
M4S8 750_ %M41P!:5$X!6%16 59470)45&8#4E-O U!3>P1.4X@%3%.7!DM3
MIP=)4[H'2%/5!TA2\P9(4O\%2%'_!$E1_P1)4/\#25#_ \I(  "Y4@  JE<
M )A6  "*50  ?U0  '93  !L40  9U,  &)4" !?5A( 75<> %M7*0!96#,
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M!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&   (M?  !]7P
M<E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"< 1&DQ $-I.0!"
M:D( 0&I* #]J4@ ]:EL!/&IE 3IJ< (X:GX"-FF- S1IGP,S:;(#,6G+ S%H
M[0,Q9_\#,6;_ S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C  !X8P  ;6,
M &1D  !990  4&@  $EK  !#;00 0&X. #YO&  ];R( /' K #IP-  Y<3T
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M 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,  %1V  !)>0
M/WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB< %XXP !:..0 5
MCD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .C?H #XO_ !"*
M_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^  !"@@  .88
M "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL
M"9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?   IC_  27_P %
MEO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [C0  ,9(  "B6
M   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F*   IC(  *<]
M  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\  "E_P  I/\
M *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@  *)X  !^B   7
MI@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P  LR@  +0R  "U
M/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T_P  M/\  +3_
M (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P  !:P   /M
M";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT  ,,G  #%,@
MQD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7
M  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]   &P    ,,
M  #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;  #8)0  VS(
M -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\  -__ '>?  !H
MI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)    S    -    #5
M    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J&   [20  / R
M  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T &JH  !;KP
M3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W    .    #E
MYP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@  _!8  /\B  #_
M,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5
M /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T
M_P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z
M /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\
M$@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^
M /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#' .\ X #N /(
M[ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_
M !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\
M?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .  TP#> .L W #[
M -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P & /\ "0#_  \
M_P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P X@!S .  >@#>
M (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#) .0 R #V ,8
M_P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2
M .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H
MR "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V
M /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V  , Z  - .
M%P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![
M +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K *< ^P"F /\
MI@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#(
M !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L &\ JP!U *D
M?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_
M )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0
MMP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<
M"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0
M_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9
M *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P
MCQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_
M&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D%0@ H!03 )L6
M(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>;P"%'G< @Q^
M ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_ '0A_P!T(?\
M="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$ E1X0 ) @&P"-
M(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![)W, >2=\ '@H
MAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI_P%K*/\!:RC_
M >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<, (<H%P"#*B,
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M EL[IP)9.[@#6#O2 U<[\0)6._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00
MKT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G
M/S@ 93]  &1 2 !B0$\ 84!7 %] 7@%=0&8!7$!O 5I >@)80(<"5D"5 E1
MI -30+8#4D#/ U% [P-00/_B__])0T-?4%)/1DE,10 &"?\"4#__ E __P)1
M/O\!43[_ <\[  "]10  JD<  )E&  "+10  @40  'E"  !T/@  ;S\  &M
M# !G014 94(A &-#*P!A0S4 7T0^ %Y$10!=14T 6T54 %E%7 %8160!5D5M
M 51%> )2184"4423 T]$HP--1;0#3$7, TM%[0-+1/\"2T3_ DM#_P),0O\"
M3$+_ LH_  "Y2   IDH  )5)  "'2   ?4<  '5%  !N0@  :4,  &5$"0!B
M11, 7T8> %U'* !<2#( 6D@[ %E)0P!724H 5DE2 %1)60%326$!44EK 4])
M=@)-28("2TF1 TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_
M L9#  "V3   HDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A
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M CI7FP(X5ZT"-U?$ C=7YP(W5OT"-U7_ C=4_P(W4_\".%/_ KI/  "I5@
ME54  (54  !X5   ;50  &14  !85   4E8  $Y7  !*60D 1UH1 $9:&P!$
M6R4 0ULN $)<-@!!7#X /UQ& #Y=3P ]75< .UUA #I=; $X77D!-EV( 31=
MF0(S7:L",5W" C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@
M (!8  !S5P  :5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82
M.V(I #IB,@ Y8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L
M8ZD!*V._ 2ICXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;
M  !O6P  95L  %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD
M #)I+0 Q:34 +VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z<
M(VN] ")JX  C:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J
M7P  86   %=@  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ
M)@ G<B\ )G(W "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y
M !ESW  :<?< &G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9
M760  %)F  !(:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;
M>R@ &GLP !E\.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]
MU0 0>_4 $7G_ !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH
M $QM  !#<   .70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\
M$(<H  Z',0 .ASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &
MA>P !X3_  B#_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U
M   \>0  ,GT  "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@
M  &2*0  DC,  ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4
M )#Z  "/_P  C_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    T
MA   *XD  "*-   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">
M(@  GRL  )\U  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV
M  "=_P  G/\  )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0
M(Y8  !J:   2G@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0
MK2(  *XK  "O-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M
M_P  K?\  *W_ (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0
M !*H   ,K   !*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@
M +TA  "^*P  P#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0
MP/\  ,#_ 'F-  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX
M   "NP   +X   #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5
M  #0'P  TRL  -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L
M -C_ '"9  !@G@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%
MR    ,L   #/    T@   -,   #6    V    -L   #=    WP<  .(-  #E
M$P  Z!T  .PJ  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T
M &>F  !8K0  2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@
M -P   #@    XP   .0   #F    Z    .L   #M    [P   /("  #U"@
M^!$  /P<  #_+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\
M% #_ !( _P 2 /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H
M /\ < #_ '@ _P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D
M^@#( /D X@#X /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_
M  X _P . /\ #P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X
M:P#\ ', ^@!Y /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#!
M .L U@#J .X Z0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H
M_P ( /\ "0#_ !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N
M &T [ !T .L >@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H
MR@#7 .8 U #X -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P
M /\  P#_  T _  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &<
MVP!M -D = #5 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@##
M -P P0#Q +\ _P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\
M  #V  @ [@ 1 .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G
M ,0 ;0#" ', P !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X
ML #J *\ _ "M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H
M    W@ , -, %0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0
M9P"R &T L !T *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C
M )\ ]@"> /\ G@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5
MRP & ,, #P"] !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D
M &@ H@!N *$ =0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )(
M\@"1 /\ D #_ )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<
M +< "@"Q !( K  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6,
ME@)I )0"< "3 W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$
M"O\ @PO_ (,+_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-
M  "F!PT H@46 )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE
M (D-; "(#G0 A@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\
M=Q+_ '<2_P!W$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9
M$00 F X0 ),0&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6
M: !]%F\ >Q9X 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_
M &T:_P!M&O\ ;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'
MC!<, (@8%@"$&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S
M'VL <2!T ' @?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B
M_P!D(O\ 9"'_ . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B (
M 'X@$@![(AX >",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@
M:2AQ &<H>P!E*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<
M*?\ 7"C_ -@L  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G
M$ !R*1H <"HE &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N
M %\O> !>+X0 7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\
M52[_ - Q  "].@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K
M+Q8 :3 A &8Q*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU
M=0!7-8( 5360 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_
M <LV  "X/0  HSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1,
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M0P  FD(  (I"  !]00  <T   &L_  !E/   8#P  %P^! !9/@\ 5S\8 %5
M(@!302L 4D$T %!"/ !/0D, 3D)+ $U#4@!+0UH 2D-D $A#;@!'0WL!14.)
M 4-#F0%"0ZL!0$/  3]#X0$_0_D!/T+_ 3]!_P% 0?\!0$#_ ;]!  "J10
MED4  (9%  !Y1   ;T0  &="  !@/P  6T$  %="  !40PT 4405 $]%'P!.
M12@ 3$8Q $M&.0!*1T$ 24=( $A'4 !&1U@ 14=A $-(; !"2'@!0$B' 3Y(
MEP$\2*D!.TB^ 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<
M ()'  !V1P  :T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4
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M "E7U@ I5O4 *57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4
M8%   %A1  !.4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q
M6S, +UP[ "Y<0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=
MT@ B7/, (EO_ "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0
M %15  !*5@  0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX
M)V,V "9C/@ E8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :
M8_$ &V'_ !M@_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9
M  !'6P  /EX  #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP
M !QK.0 ;:T( &FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\
M$FG_ !-H_P 3:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"
M80  .60  #)G   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U
M,@ 1=3L $'5&  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]
M  MQ_P ,<?\ #'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:
M,VP  "MO   D<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &
M?S0 !7\_  1_2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\
M_P  >_\  'O_ (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4
M "1Y   =?   %H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP
M (LW  "+0P  BU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P
MA_\  (?_ ()M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$
M   5B   $(P   N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N
M  "9.0  F4<  )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\
M )7_ 'MT  !O<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .
ME@  "9D   &<    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H
M+P  J#T  *E,  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_
M '=[  !H>P  67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I
M *@   "K    K@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)
MNC$  +I   "Z4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#
M  !?A@  48L  $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<
M  "[    O@   +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20
M ,XS  #/1   T%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7
ME   29H  #NA   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+
M    S0   ,X   #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D
M  #G-@  Z$D  .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I
M0JL  #2R   FN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;
MWP   .    #B    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\
M)0  _3D  /Y/  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P /
M /\ $0#_ !8 _P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ',
M_P!Z /\ @ #_ (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U
M /$ ] #_ /, _P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\
M"P#_ !$ _P = /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T
M /4 >@#T (  \@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D
MY #[ ., _P#B /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_
M  X _P 8 /\ ) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8
M= #D 'H X@"  .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T
M ,P _P#+ /\ RP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L
M]P 3 /$ '@#M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#.
M ', S !Z ,H @ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D
M_@"X /\ N #_ +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 .
M -X & #8 ", T@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T
MN0!S +< >@"U ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F
M /\ I@#_ *4 _P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@
M$@#" !T O@ H +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M
M *< <P"E 'H I "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\
ME@#_ )< _P"7 /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S
M !8 KP A *L + "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@
M;@"7 '4 E0!] )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_
M (@ _P"( /\ B #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !
MH@ : )X )0"; #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"*
M '  B !X (< @0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$
M_P![!/\ >P3_ /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3
M ), '@"0 2D C0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P
M?0AT 'P(?@!Z"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O
M#?\ ;PW_ .@6  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+
M%P"&#", @PTM ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q
M '$1>P!P$8< ;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\
M91/_ -\>  #&)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\
M$AT >10H '84,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9
M=P!F&8, 9!F0 &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_
M -4E  "]*@  J"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@
M;QPC &T=+0!K'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=
M(7\ 7"&- %HBG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK
M  "V+@  HBX  )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,?
M &4D*0!C)#$ 8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P
M5"B* %,IF0!1*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P
M,@  G#(  (PR  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ
M)0!<*RX 6RLV %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ(
M $POEP!++Z@ 22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0
MES4  (<U  ![-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6
M,"L 53$S %,Q.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<T
ME0!%-*8 0S2Y $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@
M (,X  !W.   ;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@
M3S8P $XV. !,-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP!
M.:0 /CFX #TYTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[
M  !S.P  :CH  &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM
M $@[-0!'.SP 1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:,
M.3VV #@]T0 W/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O
M/@  9CT  %X]  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_
M,@!"0#H 04!! $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T
M #)"S@ R0?  ,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00
M8D   %M   !4/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \
M1#< .T4^ #I%1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&
MS  M1N\ +47_ "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,
M %=#  !00P  2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230
M-4H[ #1*0P S2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G
M2^T )TK_ "A)_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&
M  !,1P  1$@  #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X
M "Y/0  L4$@ *U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L
M(4__ ")._P B3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)
M2P  0$P  #M.   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95
M/  E5D4 )%9. ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_
M !M4_P ;4_\ '%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P
M/%$  #93   Q50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <
M74  &UU* !I=50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:
M_P 36O\ %%G_ )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8
M #)9   K6P  )5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H
M$F5$ !%E4  095T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -
M8?\ #6'_ (U5  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?
M   F8@  'V4  !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^
M  AN2@ ';E< !FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\
M VK_ (5:  !T6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?
M:@  &6T  !-Q   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X
M0P  >%   'A>  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_
M 'Y?  !N7P  8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=
M$G<   U[   (?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P
MA$@  (17  "$:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E
M  !I9   7V,  %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,
M  :'    B@   (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\
M )).  "27P  DG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F
M:@  6&L  $MM   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5
M    F    )D   ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$
M  "C50  HVD  **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@
M474  $1Y   W?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D
MIP   *@   "I    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T
M2@  M5T  +5S  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(
M #R'   OC@  (Y0  !B:   0GP  ":0   "I    K0   +    "T    MP
M +@   "Y    NP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0
MRE   ,IF  #*?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8
M   GGP  &Z4  !&K   )L    +4   "Y    O0   ,$   #&    R    ,D
M  #+    S    ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(
M .17  #E;P  YHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?
ML   $[8   N\    P0   ,4   #)    S0   -(   #6    V@   -L   #>
M    X    .(   #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(
M  #[7P  _'H  /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !,
M_P > /\ *@#_ #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_
M ($ _0"' /P C0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\
M_P#O /\ XP#_ -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9
M /\ )0#_ #$ _P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H
M[P"! .X AP#L (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#=
M /\ U #_ ,D _P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T
M( #Z "L ]P V /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z
M -H @0#8 (@ U "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\
MQ #_ +L _P"V /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G
M "4 Y  P .$ .P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,,
M>@#! ($ OP") +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_
M *X _P"J /\ IP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\
MR@ J ,< - #$ #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N
M 'H K "" *H BP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\
M_P"= /\ FP#_ /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C
M +, +@"P #< K0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ',
MFP![ )H A "8 (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P".
M /\ CP#_ /P   #O    VP   ,D   "]    M0 " *X # "I !, I0 = *(
M)P"@ #$ G0 Z )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U
M (L ?@") (D B "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\
M@ #_ /0"  #@"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2
M "H CP S (T / "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X
M>0!\ (0 >P"0 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_
M .D-  #/$   N1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0
M@P N ($ -@!_ #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q
M 8  ;P*- &X"F@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4
M  ##%P  KA<  )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H
M '<(, !U"#@ <PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X
M9@R+ &0-F0!B#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y
M'0  I!X  )4=  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/
M*P!L$#, :A [ &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.(
M %L3EP!9$Z< 5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@
MG2,  (TC  "!(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C
M%B\ 81<W & 7/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;
ME !1&Z0 3QNW $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<
M (<H  ![)P  <B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL
M6AXS %@?.@!7'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)
M(J( 2"*T $<BS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L
M  !V*P  ;2H  &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P
M %(E-P!0)3X 3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**
M02BR $ HRP _*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q
M+P  :"X  &$M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ
M- !**SL 22M" $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP
M #HMR  Z+>L .BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@
M9#(  %TQ  !8+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%
M,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4R
MQP T,ND -#+_ #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4
M %DT  !4,P  4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38
M/C4] #TU1  \-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O
M-^@ +S;^ # U_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W
M  !0-@  2S0  $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ
M #@Z0@ V.DH -3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8
M*CK] "HZ_P K.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-
M.@  1C@  $(Z   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_
M/P Q/T< ,#]0 "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\
M "4^_P F/?\ )CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0
M0CT  #P^   Y/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K
M1$0 *D1- "A$6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#
M_P @0O\ (4'_ )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$
M #A#   T10  ,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$
M(TI* ")*50 @2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :
M1_\ &D?_ )5"  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'
M   P20  *TL  "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!'
M !I040 94%T %U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\
M%$W_ (]%  ![1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K
M3@  )E   "!3 P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)7
M30 15UD $%=H  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_
M (A)  !V2@  9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5
M(58  !M9   57 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *
M7E0 "%YB  =><P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.
M  !P3@  8DX  %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT
M !5@   08P, #&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX
M &=<  !G;0  9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J
M4P  75(  %12  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H
M   ,:P$ !FX)  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6
M  !Q9@  <7D  '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P
M6E<  %%6  !&5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $
M=@   '@%  !X"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]
M7@  ?7(  'V(  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP
M $M=  ! 7P  -6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@
M (,!  "$!@  A0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@
MBVD  (N   "+F0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E
M   X:0  +FX  "1S   :>   $WT   V!   &A0   (D   "-    D    )(
M  "2    E 4  )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\
M )QV  ";D0  FZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P
M=@  )7P  !N!   2AP  #(P   21    E0   )D   "=    H    *$   "B
M    I    *4!  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K
M  "NA0  KJ$  *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0
M'8P  !.2   ,F    YT   "B    I@   *H   "N    L    +$   "S
MM    +8   "X    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%
M=P  Q9,  ,6O  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T
M  VC   #J0   *X   "R    MP   +L   "_    P@   ,(   #%    Q@
M ,@   #*    S0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:
MX(0  .&A  #AO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U
M    N@   +\   #$    R    ,X   #1    U    -4   #8    V@   -T
M  #?    X@   .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(
M /F0  #YJP  ^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_
M #( _P ^ /\ 2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L
MB #Y (\ ]P"7 /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_
M ,X _P#& /\ P@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P
M_P X /\ 0P#] $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H
M (D YP"1 .0 F@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$
M_P"[ /\ MP#_ /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R
M /  / #L $8 Z !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 ((
MS0"* ,L DP#( )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N
M /\ JP#_ /\   #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L
M-@#3 #\ S@!( ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N ""
M +8 BP"T )8 L@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\
MGP#_ /\   #_    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\
M #@ N !! +4 2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *,
MA "A (X GP": )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_
M /\   #V    Y    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #(
MI0 Z *( 0@"@ $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0
M (< C@"3 (P H0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@
M  #E    S0   +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T
M )( / "0 $, C@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($
M?P"- 'X FP!\ *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1
M @  NP(  *P!  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0
M-@"" #T @ !# 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"(
M '$ E@!O *4 ;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#
MK@P  )X,  "3"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V
M #@ =  ^ ', 1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4
MD@!D *$ 8P"R &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(
M ),2  "($0  @ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3,
M:@(Y &D#0 !G T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:
M!Y\ 60>P %<'Q@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8
M  !_%P  =A8  '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU
M & ,/ !?#$( 7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\
M4 ZQ $X.R !-$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W
M'0  ;QP  &D:  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2
M. !7$CX 5A)% %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N
M $85Q0!%%>@ 11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@
M:"$  &(?  !?'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/
M&#L 3AE" $T92 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;
MP@ ^'.4 /1S\ #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4
M %TD  !9(@  5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S<
M1Q\^ $8@10!%($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W
M(N, -R+[ #<B_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H
M  !4)@  42,  $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[
M $ E0P _)4H /293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$
M,2?Y #(F_P R)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0
M*@  3"@  $HF  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ
M0  Y*D@ ."M0 #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX
M "PK_P M*O\ +2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@
M2"P  $4K  !!*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T
M+T4 ,R]. #$P6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O
M_P H+_\ *"[_ )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#
M $ O   \,   .C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$,
M+31, "PT5@ J-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C
M,_\ (S+_ )@Q  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS
M   W-   -#4& #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E)
M "8Y4P E.5\ (SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\
M'C?_ ),T  !_-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R
M.0  +SH" "P["P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^
M4  ?/EP '3]I !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_
M (XW  !Z.   :CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@
M*4   "9!"  D0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 8
M1%D %T1G !5$=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[
M  !V/   9CT  %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40
M "%& P =2 P &TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8
M$$ID  ]*=  .2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q
M/P  8D   %9   !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+
M   63@< $U . !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?
M  E1;P '4($ !5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P
M740  %)$  !*1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   2
M5 , #E<*  M8$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8
M:0  6'P  %B1  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@
M $]'  !'1P  0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P(
M"5X)  1?#@  7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P
M8'8  &"+  !?H@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+
M  !$2P  .TP  #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'
M  !G#   9P\  &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\
M &J%  !JG0  :;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _
M4   -5,  "U6   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P
M"   <0T  '(0  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^
M  !VEP  =;$  '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6
M+UL  "9?   =8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P
M?@@  '\,  "!$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%
MCP  A*D  (/)  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8
M !YK   5<   #G4   EY   !?@   ($   "%    B    (H   "+    C0$
M (X&  "0"P  D0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@
ME:(  )3!  "3Z@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y
M   .?P  !X0   ")    C@   )(   "6    F    )H   ";    G0   )\
M  "A P  HP@  *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D
M *BU  "GW0  I_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   '
MD    )8   ":    GP   *,   "G    J@   *L   "M    KP   +$   "S
M    M0   +@%  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH
M  "^R0  O>\  +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@
M *<   "L    L    +4   "Y    O    +T   "_    P0   ,,   #&
MR    ,H   #- @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;
MM0  V]D  -OR $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D
M  "^    P@   ,@   #+    S@   ,\   #2    U    -8   #:    W0
M -\   #B    Y@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0
M];\  /7= /\ !@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\
M1 #_ $T _P!5 /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2
M /, FP#P *8 [@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\
MNP#_ /\   #_    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\
M $< ^ !/ /0 5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\
ME0#< )\ V0"K -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_
M /\   #_    _P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $
MX@!) -\ 4 #; %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#"
M )@ P "D +T L@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\
M  #_    _P   /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !"
M ,0 2@#  %  O0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )
MJ@"< *@ J@"F +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^
M    [P   -\   #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T
M0P"K $D J !/ *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4
M )8 H@"4 +( D@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L
MV0   ,<   "Z    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8
M $, E@!) )0 3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0
MF@"" *H @0"^ (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@
M +,   "H    H    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T
MA0!# (0 20"" $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T
M *, <@"U '( SP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(
M  "7    D0   (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ]
M '8 0P!T $D <P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T
M90"O &4 Q@!D .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")
M!P  @@,  'X   ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H
M/@!I $0 9P!) &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J
M %D OP!9 .$ 6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@
M=@T  '$*  !O!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!?
M #\ 70!% %P 2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %
MNP!/ =L 3@+T $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(
M &<0  !E#@  8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL
M50=" %0'2 !3"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&
M"M@ 10OS $4,_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6
M  !<$P  6A$  %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^
M $T.10!+#DT 2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P
M/1'V #T1_P ]$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5
M&0  4Q8  %(3  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $43
M0@!$$TD 0Q12 $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U
M #86_P V%O\ -Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@
M31L  $P9  !+%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]
M&48 /!I/ #H:6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;
M_P P&_\ ,!O_ )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"
M $8=  !%' ( 0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0
M-A], #0@5@ S(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J
M(/\ *R#_ )DB  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A
M   _(0  /2$) #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1*
M "\E4P M)5X *R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\
M)23_ )0E  " )P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z
M)0  -R8& #4F#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI
M40 H*EP )BII "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_
M ) H  !\*@  ;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@
M,BL# # K#  N+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C
M+EH (2]G !\O=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK
M  !X+0  :"X  %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\
M "LP"@ I,1  )S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U<
M&S-D !HT=  8-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T
M+P  93$  %@Q  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U
M!@ C-@T (382 " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB
M !0Y<0 2.80 $3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@
M830  %4T  !+-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =
M.PL &SP0 !D]%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^
M;P ./H$ ##Z5  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<
M %$W  !(-P  03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008
M%$,- !)#$@ 10Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '
M1'P !D20  1#I0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ
M  !%.@  /CH  #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*
M  U*#P ,2A0 "TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<
M $J+  !*H0  2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"
M/0  /#T  #8]   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0
M#0 #41$  %$7  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'
M  !1G0  4;4  %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0
M.4   #)!   J0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#
M6!   %@3  !9&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9
MF0  6;$  %C1  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44
M "U'   E2@  'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T
M &$0  !B%0  8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP
M8ZT  &+,  !A\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/
M   ?4@  &%4  !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-
M  !M$0  ;A8  ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<
M &[&  !M[P  ;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   8
M7   $6    QD   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z
M#0  ?!   'T6  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^
M  !\Z0  >_\  'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:
M"VT   -R    =@   'H   !]    @    (,   "$    A@   (<"  ")!P
MBPP  (T0  "0%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".
MX0  C/L  (S_ %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT
M  ""    A@   (L   ".    D0   ),   "5    EP   )D   ";    G00
M )\*  "B#P  I!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT
MH/4  )__ $YA  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3
M    F    )T   "A    I    *4   "G    J0   *L   "M    L    +(
M  "U"   N X  +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H
M +?\ $9K   Y<   *W<  !]_   3A@  "XX   &5    FP   *$   "F
MJP   +    "S    MP   +<   "Z    O    +\   #!    Q    ,<   #*
M    S04  -$.  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R
M #YY   Q@   (X@  !>1   -F0   Z    "G    K@   +,   "X    O0
M ,(   #&    R@   ,H   #-    SP   -(   #5    V0   -T   #?
MXP   .<%  #K#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\
M  #_    _P $ /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0
M /\ 6 #_ %X _P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *(
MZP"O .@ P #F .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_
M    _P   /\   #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /(
M4@#N %@ ZP!> .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G
M ,X M@#+ ,X R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_ /\   #_
M_P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3
M %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +<
MK0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\   #_    ^P
M .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L
MMP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"?
M +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V    YP   -,
M  #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8 /0"C $0 H0!*
M )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ". (X G ", *T
MB@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C    S    +P   "P
M    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1 #T C@!# (P
M20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X
M '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP   *@   ">
ME@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z
M $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L )T :@"O &D
MR !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<   "-    A@
M ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W &X /0!L $,
M:P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8 70"H %T O@!<
M .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_ @  >    '0
M  !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &( . !@ #T 7P!#
M %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8
M40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P  ; H  &@'  !E
M P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0
M10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O
M $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\  %X.  !;#
M6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4 30$[ $P!00!*
M D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%
M_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82  !3$0  40X
M % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4
M0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U
M#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-%0  2A,  $D1
M  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+
M #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\
M+Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@  1!@  $,5  !"
M$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,4
M40 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_
M )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P  #X:   ]&
M.Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K
M&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=
M  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>   X&P  -1P$
M #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]# "<?30 F'U<
M)!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U
M(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S(   ," ! "XA
M"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A
M !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_ (4B  !Q)
M8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)   *R4  "DE!P G
M)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I
M;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@
M %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD  "0J!  B*PP
M("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1
M+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L
M  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O   <, D &C$.
M !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH
M##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#
M+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7-04 %#8, !(W
M$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*
M  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0
M.3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@( $#P)  T]#@ ,
M/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80  /G(  #Z&   ]
MG   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T   ^-   -S0
M #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(  E##0 &1!$
M T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T  $2!  !$F
M0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [-P  -38  # V
M   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)#   20\  $H3
M  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]  !+E   2JP
M $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@  ,SD  "PZ   E
M/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@  4 T  %$0  !2
M%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4CP  4Z@  %+&
M  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX  "=    @0P
M&48  !-)   /3   "T\   92    5    %<"  !8!P  60L  %H.  !;$0
M718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0  7:,  %S!  !;
MZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(   :2P  $TX
M  Y2   *50   UD   !;    7@   &    !B @  8P8  &4*  !F#@  :!$
M &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T  &B[  !GYP
M9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   350  #ED   A=
M   !80   &0   !G    :@   &P   !N    <    '(%  !S"0  =0T  '<1
M  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S  !UX   =/P
M '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80  !F8   !J
M;P   '(   !V    >0   'P   !]    ?P   ($   "# @  A@<  (@,  "+
M$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_
M $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8   ![    ?P
M (,   "'    B@   (T   ".    D0   ),   "5    F    )H%  "=#
MH!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0  F^X  )K_ $99
M   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-    D@   )8
M  ":    G0   )\   "A    I    *8   "H    JP   *X   "Q P  M L
M +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(  +#\ #]D   Q
M:0  )6\  !AW   /?P  !H<   ".    E    )H   "@    I0   *H   "N
M    L0   +(   "U    MP   +H   "\    OP   ,,   #&    R0   ,X*
M  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO #=Q   I>
M'8   !&)   (D0   )H   "A    IP   *T   "S    N0   +X   #"
MQ0   ,8   #)    S    ,X   #2    U0   -H   #>    X0   .4   #J
M"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\   #_    _P !
M /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H
M_0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T Z0"J .8 O #C
M -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_    _P   /\
M  #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\ 30#L %, Z !9
M .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D
MP@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_    _0   /H   #X
M    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@
M6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$ J0"N +P K #A
M *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@   .<   #;
MT0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L
M %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4
M\0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D   "\    M
M *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\
ME !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "
M /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F    G0   )<
M!0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!.
M '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S '  T !O /8
M;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3    C    (4   ""
M  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R $( <0!( &\
M30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_
M &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?    '<   !R  4
M<  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@
M $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0
M_P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D   !F  $ 8P )
M &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D
M4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X 20#S $D _P!)
M /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;    60 % %<
M# !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P /@!+ $4 2@!,
M $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\
M0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0  4 8  $\"" !.
M  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!" $$ 00!( $
M4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_
M )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T  $<* P!'!PH
M100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W
M!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0
M  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .  ! #08 0 H,
M #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8
M+PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W
M%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y$0$ .0\( #@.
M#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A
M "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P
M8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%   ,Q($ #(2"P Q
M$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D%%, (A1? " 5
M;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP
M %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8  "P7"  K%@X
M*1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9
M&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @
M  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;!0 E&PP )!P1
M "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH
M$AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$
M(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @( H 'B$/ !TA
M%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+
M  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,  $LD  !!)
M.B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0< &28- !<F$0 6
M)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DH
MFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G   _)P  -R8
M #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0
M$"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7  !"V#  (MF
M+*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \*0  -2D  "\H
M   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ#0 -,1( ##$7
M  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_   RE0  ,:P
M #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+   ,BL  "TK   I
M*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W
M&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   WD@  -ZD  #;%
M   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X  "LM   G+0
M(BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X  #T2   ^%P
M/AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP  /:<  #W#   \
MZ0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO   D,   'C(
M !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0  !$%   11H
M $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0  $3   !#Z
M0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @-0  &C@  !0Z
M   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,$0  3A4  $\<
M  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\  !+YP  2_X
M $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/   %3\  !!"   ,
M10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@  5Q$  %D7  !:
M'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5XP  5/T  %3_
M $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@   M+   %3@
M %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X  &02  !G&
M9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0  8/P  %__ $E"
M  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6    6@   %T
M  !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.  !U$@  =QL
M '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<  &[_ $9&  !
M10  -48  "I(   @3   %U$  !!6   )6@   5\   !C    :    &L   !O
M    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&#0  B1,  (H=
M  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__ $9+   Z3
M+D\  "-3   86   $%X   ED    :0   &\   !T    >    'P   "!
MA    (<   "(    BP   (X   "0    DP   )8   "9!P  G0T  *$4  "@
M(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2   R50  )EH
M !M@   19P  "6T   !T    >P   ($   "&    BP   )    "4    EP
M )D   "<    GP   *$   "D    IP   *H   "M    L08  +4-  "X%@
MMR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K80  'F@  !-P
M   +>    (    "'    C@   )4   ":    GP   *0   "H    K    *T
M  "P    LP   +4   "X    NP   +\   ##    QP   ,L%  #1#@  T1L
M - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<   %GD   V!   !
MBP   ),   ";    H@   *@   "N    M    +@   "]    P    ,(   #%
M    R    ,L   #.    T0   -8   #;    WP   .0   #H!@  ZQ$  .HC
M  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P   /\ ! #_  L
M_P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X
M &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#? -4 VP#W -8
M_P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P   #\  , _@ +
M /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\
MW !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P
M /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R    Z@ % .<
M#@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!>
M +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#< *, ^P"? /\
ME0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/    R    ,$ "@"_
M !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$
M7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X \ "- /\ A@#_
M (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@   *8 !0"B  T
MH0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"*
M %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '(
M_P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X  0"+  H B0 0
M (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!( '@ 3@!V %0
M=0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8 9P#_ &4 _P!D
M /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X  4 =@ , '4
M$0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5
M &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\
M6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $ 9@ ) &4 #@!D
M !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8
M5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T _P!- /\ 30#_
M *H   "4    @@   '4   !K    9    &    !=    6@ % %@ # !7 !
M5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $, 3 !* $H 4@!)
M %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X
M  ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X "0!-  T 3  1
M $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!% $$ 30 _ %8
M/@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\ .0#_ )4#  "
M!P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$  L 0P / $(
M$P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@ 20 W %( -@!=
M #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_ (P)  !X#
M: T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @ / $- #L $  Z
M !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T
M9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q
M %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@* #4&#@ T!1(
M,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D
M!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3
M  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +"P O"A  +0H4
M "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8 " -90 >#74
M' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%
M%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I#@T * X1 "8.
M%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1")
M !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0
M.AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L (A(/ "$2%  @
M$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2%'0 $12' ! 4
MG  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;   _&P  -QL
M #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q<
M&1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *
M&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \'0  -1T  "\=
M   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P;
M !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H
M QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P  ,A\  "T?   H
M'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA
M'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $BD0  (J@  "'
M   AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$  "HA   F(
M(B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A  "R85  HF'  )
M)B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP  )J8  ":_   E
MY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C   D(@  (2(
M !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\
M 2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0  "N^   JY
M*OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C)   'R0  !LD
M   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q%0  ,1P  #$C
M   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\   PY   +_L
M "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@  '"<  !@H   4
M*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@  .!@  #@@   X
M*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   VY   -?P  #7_
M %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L  !0M   1+P
M#3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0  $ ;  ! )
M0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP  //P  #S_ % O
M  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S   --@  "3@
M  4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6  !*'@  2B@
M $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P  $3_ $HS   _
M,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (/@   T$   !#
M    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5&0  52(  %0N
M  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_ $4W   \-P
M-38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2    $H   !-
M4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P  8AL  &(G  !B
M-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\   Z.P  -#D
M "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8   !9    7
M %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4  '(@  !R+0
M<3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y/@  +C\  "1"
M   :1@  $DH   Q/   $5    %@   !=    80   &4   !H    :P   &X
M  !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7  "&)   A30
M (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10  *$@  !U,   3
M4@  #%<   -=    8P   &@   !M    <0   '8   !Z    ?@   ($   "#
M    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">&@  G2D  )P\
M  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,  !59   -8
M V<   !N    =    'H   "     A    (H   ".    D@   )4   "7
MF@   )T   "@    HP   *<   "K    KP   +0)  "X$   MQX  +4P  "S
M1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI   %<0   'D
M  "!    B    (\   "4    F@   )\   "D    J    *D   "L    KP
M +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0  -$E  #0.P
MS50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[    A    (T   "5
M    G0   *,   "I    KP   +0   "Y    O    +X   #"    Q0   ,@
M  #,    T    -0   #:    WP   .0   #J    [@P  .T:  #L+P  ZDD
M .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @ _@ . /\ % #_
M !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /(
M;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H _P"V /\ J #_
M )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ ) /H #@#] !8
M^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/
M &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )(
M_P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .  "P#; !$ V@ :
M -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9 +8 7P"S &8
ML0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"
M /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W  X M  4 +0
M'0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E
M )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\
M<@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H F  0 )@ %@"7
M !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "# %8 @0!> (
M9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_
M ,P   "^    JP   )T   "3    B@   (4   ""  4 @  - '\ $0!_ !@
M@  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\ ;0!6 &P 7@!J
M &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T
M  "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P #@!K !, :P 9
M &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$
M60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8
M    A@   '@   !N    9P   &,   !@    70 % %P "P!; !  6P 5 %L
M&P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X 40!- %L 2P!F
M $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_ )\   ")
M>    &P   !B    6P   %8   !3    40 " $\ " !/  T 3@ 1 $X %@!-
M !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\
M;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),   !^    ;@
M &$   !8    40   $P   !)    1P   $4 !0!$  L 0P . $, $@!# !<
M0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T
M '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V P  9@4  %D'
M  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H $  Y !0 .0 9
M #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7 "T 9  L ',
M*P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"   7PH  %,+  !*
M"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q !$ ,0 5 #
M&@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8 8  D &\ (P""
M "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T  $X.  !%#@
M/0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\ *@$2 "D!%P H
M 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L
ME  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0  ! $   .1
M #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD
M(08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4
M!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]$@  -A(  # 2
M   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P<
M !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:<
M#0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%   ,A0  "T4   H
M$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/
M(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0D  )$*4 "!"\
M  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8  "H6   F%0
M(A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1
M$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3
MW0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8   C%P  (!<
M !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R(
M#!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$  !>Y   7W0
M%O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A&0  'A@  !L8
M   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF
M  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY   ;W@  &O8
M !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P  '!H  !D9   7
M&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #(!P  2$C   A
M*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?W@  'O@  ![_
M %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP  !@;   5&P
M$AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D  "8@   F*
M)C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP  (_D  "/_ %4>
M  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>   3'@  $"
M  XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=   L)0  +"X
M "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L  "C_ %$B  !$
M(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0(P  #B0   LF
M   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U
M   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_ $PE   _)@
M-2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*   "RH   <L   #
M+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0  .R8  #LQ   [
M/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I   [*@  ,BH
M "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$   $T    -@
M #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$  $4L  !$.0
M1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X+@  +RT  "DK
M   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \    /P   $$
M  !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G  !/-   3T,
M $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0  +B\  "DN   @
M+@  &3$  !(S   .-P  "3H   (]    0    $0   !'    20   $P   !/
M    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>+   73P  %Q.
M  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(  "0S   ;-@
M$SD   X]   (00   $4   !)    3    %    !3    5@   %D   !;
M70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K
M6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[   5/P  #D0
M  =)    30   %(   !6    6@   %X   !B    90   &@   !K    ;0
M '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP  ( ^  !^5
M?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /2P  !U$   !7
M    7    &(   !F    :P   &\   !T    >    'L   !^    @    (,
M  "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS  "720  E&(
M )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@   &$   !H
M;@   '0   !Y    ?P   (0   ")    C0   )$   "3    E@   )D   "=
M    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS
M  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',   ![    @@
M (D   ".    E    )H   "?    I    *8   "I    K0   +    "S
MMP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@  S4L  ,IF  #&
MAP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0    EP   )X
M  "D    JP   +$   "V    N@   +P   #     Q    ,@   #+    SP
M -0   #:    X    .8   #K    \08  / 3  #N)P  [#\  .I;  #G>@
MY)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_ !D _P B /\
M+ #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z
M .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\
MC #_ /H   #R    [    .D   #I    [  % /( # #X !( ]P ; /4 )0#P
M "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4
M? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@ _P"# /\ @ #_
M /    #E    W@   -H   #;    W    -@ !P#1  X T0 5 -( '@#+ "<
MQ0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$ K !I *D <P"G
M '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(
M  #3    R@   ,<   "\    M@   +   0"O  L K  1 *T & "M "  J  H
M *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A (\ :@", '4
MB@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!
M    N0   *T   "@    F    )0   "1  8 D  - )  $@"/ !D C@ A (L
M* "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y
M '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_ +X   "Q
MH    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0 =P : '0 (0!R
M "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\
M?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +    "?    C0
M '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5 &, &P!A "$
M7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/
M (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-    ?    &X
M  !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A
M $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A $, < !" ($
M00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_    ;P   &,   !9
M    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!' !8 10 < $0
M(0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/
M #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90   %@   !/
M2    $,    _    /0   #P  @ \  < .P , #L #P [ !( .@ 7 #D '  W
M "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M ', + "( "P
MH  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"  !( P  0 ,
M #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T
M+0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C
M +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !""   .@@  #4'
M   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@ %0 G !D )@ >
M "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\ !P DP ; *P
M&P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P  -0L  # +   K
M"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X
M(  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ##
M !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T  "P-   G#0
M(PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8
M!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \
MY0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/   D#@  ( X
M !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$
M$@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *
M!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A$   '1   !H/
M   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG
M  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$
M @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0  &Q$  !@1   5
M$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,$!T #! D  H0
M+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .U   #O,   [_
M %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(  !82   4$0,
M$A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %
M$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP  $?4  !'_ %@2
M  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03 0 3$@0 $1('
M ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?  (6)P  %S
M !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<  !/_ %44  !&
M%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3
M!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;)   &RT  !LX
M   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_ %$6  !#&
M-QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00 #Q4$  T6!  +
M%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0  (2H  "$U   A
M0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9   _&P  -!P
M "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!  L: @ (' ,
M!1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<  "<R   G/P
M)DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \'@  ,1\  "@>
M   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?   $(0   2,"
M   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN   N.P  +DH
M "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0  +B$  "8A   @
M(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E    )P   "D    L
M 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V-@  -D4  #57
M   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0  "0C   ?(0
M&R   !8@   1(0  #B,   HE   &*    BH    M    +P   #(    T
M-P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0  0$   #]2   ^
M9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E   ?(P  &"0
M !(E   .*   "BH   4M    ,    #,    V    .    #L    ^    0
M $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH  $I,  !)80
M2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;*   %"H   XM
M   *,   !#,    W    .@   #T   !     0P   $8   !(    2P   $T
M  !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&  !76@  570
M %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P  $#(   HV   #
M.@   #\   !"    1@   $D   !,    3P   %(   !5    6    %H   !=
M    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G4@  9FH  &2)
M  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT   )"    1P
M $P   !0    5    %@   !;    7P   &(   !E    :    &L   !N
M<0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20  >V$  'A_  !V
MGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1    5@   %L
M  !@    90   &D   !N    <@   '8   !Y    ?    'X   ""    A0
M (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED  )%S  "-E0
MB[4  (CH "L^   @00  %4<   U-   "5    %L   !A    :    &X   !S
M    >0   'X   "#    B    (P   "/    D@   )4   "9    G0   *$
M  "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II  "HB   IJ@
M *+1 "-(   83@  #E0   1<    9    &T   !U    ?    (,   ")
MCP   )4   ";    H    *,   "F    J0   *T   "Q    M0   +D   "^
M    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%?   PIT  ,&]
M !Q5   17   !V4   !N    =P   '\   "(    D    )@   "?    I0
M *T   "S    N    +H   "^    P@   ,8   #*    S@   -,   #:
MX    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@  Y)   -^Q
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M______________________________________\
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MX.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0
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M_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G
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MM38/^<$_%^[.1B/DW$PRW>=/2<_H5E[ Y%URLMYD@J/4:9&5RVV<B<5PI7_
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M ]#C,@S%[$ =NO%'+[#O2S^E[5%.FNM:6H_J8F6%Z&IN?>=R=77C>'MOX'Z
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M%/^50QS_FDPG_YE8,_^68S__DFY,_XYZ5_R)A6+UA(]K\'Z7<^QYGGKH=*6
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MW()1V=R"4=G<@E'9W(+_CQ,"_Z03 ?ZX$@#6S L S.01 <#O)@>U]3@5JO1
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M)3S_F24[_YXF._^>)CO_GB8[_YXF._^>)CO_GB8[_YXF._^>)CO_GB:KP0
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M14O_OD9*_]!'2?_<1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$?1K@
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M117_=4\<_W9=(_]S;"K_<'HQ_VV'-O]KE#O_:9\__VBH0O]FL$7_9+A'_V/
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M;4S;W&Q-V.QJ3L_P9T[/\&=.S_!G3L_P9T[/\&=.S_!G3L_P9T[/\&?_CPL
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M,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P  )_)  "3V0
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MJ#4+Z:T]$]^O1A[2J5$OQZ):/[Z;8TRUE6I7KH]R8*>+>6BAAX%NG(.(=)>
MD'B2?9E\CGRB@(MZK8*(>KN#AWK-@X=\XGR'?.=UAGSL;H9\\&F&?/!IAGSP
M:89\\&F&?/!IAGSP:89\\&G_9QP"_W49 O^%&0+_DA\"_YPE _NE+ 7PK#0)
MYK([$-NS1!W-K4\NPZ99/KF?84NPF6A6J)1P7Z&/=V>;BWYNEHB&<Y"%CGB,
M@I9\B("@@(1_JX*!?[B#?W_*A(&!X7V!@>9V@8#K;X" [VJ @.]J@(#O:H"
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M=HCM;':([6S_:QH"_WT4 O^-%@'_FAH!_Z8> ?"Q(P+DNRD#V<(P"<N]/QG
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M44CA_$](X?Q/2.'\3TCA_$](X?Q/2.'\3TCA_$_AF0  S:D  +ZS @"SO@,
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M_S3_5",#_U M!/]9+07_7S '_V,V"O]F0 [_9DH3_V55&?]C91[_87,C_UZ
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M7U6N^EM6K?M:5JW[6E:M^UI6K?M:5JW[6E:M^UK_?@D \I$" -:A @#*K04
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M3]):IU'/6;!3S5BZ5,M8QE7)5]I6Q5?L5<-;^4_"7O]*P%__1KU@_T*Z8/]
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M7&>2_5=GD?]29Y'_4F>1_U)GD?]29Y'_4F>1_U+_;@X _W\) /&.!0#9FP4
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M24ZY_TE.N?])3KG_24ZY_TGOA0  U)4  ,>C  "ZK $ L+0  *>_ P">R08
ME=0+ )#5'0&)U"X&@-(\$'C01AEQST\A:LY8*63-7R]?S&<T6LMN.5;*=SU2
MRH! 3\F+0TS)ET5)R:1'1\FS2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'
M_T)(Q_]"2,?_0DC'_T+>C0  RYP  +VG  "QL   IKH  )S$ P"3SP< BMT,
M (7?'0%^WRP%=MXW"V_>0Q-HW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U
M2MJ+-T?:ESE%VJ0[0]NT/$+<R#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#
MV/\Y0]C_.4/8_SG0E@  P:,  +*L  "GM0  G,   )'* P"'U@< @.D1 'GI
M( )RZ2P%:^DV"F3I/P]>Z4@46>E1&57H6AQ1Z6(@3NEK(TOI="5(Z7TG1NF(
M*D/IDRM!ZJ M0.JO+C[KP"X][-LN/>KO+CWH_"X]Y_\M/>?_+3WG_RT]Y_\M
M/>?_+3WG_RW%GP  M:D  *BQ  "<O   D,<  (32 0!ZWP8 =/03 &WT( )F
M]"H$7_0T"%KU/0M4]44/3_5,$DSU511)]ET71O9E&$3V;AI!]G<</_>!'3WW
MC1\[]YD@.?BF(3CXM2(W^<@B-OGC(C;X\R(V]_PB-O?\(C;W_"(V]_PB-O?\
M(C;W_"*WI@  J:X  )RY  "0Q   @\\  '?;  !O]@H 9_\3 6#_'0):_R<#
M5/\P!4__. A*_T *1O](#$/_3PY _U8//?]>$#O_91(X_VX3-O]W%#3_@A4R
M_X\6,/^;%R__J1<N_[<8+?_(&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_
M[QBKJP  GK4  )#!  ""S   ==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K
M!$3_,@5 _SH&//]!!SG_1P@V_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .
M)?^-#B3_F@\C_Z80(O^S$"'_P1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?
ML@  D;X  (/*  !UU@  9^(  %OQ  !4_P8 3O\. $C_% %"_QP"/?\D CG_
M*P,U_S($,?\X!"[_/@4K_T,%*/])!B7_3P8C_U8'(?]=!Q[_90@<_V\(&?]Z
M"1?_APD6_Y0)%?^?"A3_J@H4_[,*%/^S"A3_LPH4_[,*%/^S"A3_LPJ3NP
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M47> _TQW@/]'=X#_1G> _T9W@/]&=X#_1G> _T;_9 \ _W() /]_" #EC 4
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M1F"6_T9@EO]&8);_1F"6_T;_< , ZX$  -:/  #*F@$ P:,# +FJ @"QL@$
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M&3/TL1DR]<4:,?7B&C'T\1DQ\?X9,?'_&3'Q_QDQ\?\9,?'_&3'Q_QFRI
MI:L  )BV  "+P   ?LH  ''5  !EW@  7O4* %G\$P!3_!X!3OPG DK], -%
M_3D%0?U !C[^2 <[_D\)./]7"C;_7@LS_V<,,?]P#2[_? XL_XD/*_^6$"G_
MI! H_[01)__'$2?_X1$F__(1)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,
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M181O_S^%</\[AG'_.(9Q_SB&<?\XAG'_.(9Q_SC_6P\ _V<( /]S" #S?0@
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M/&^!_SQO@?\\;X'_/&^!_SS_9 @ _W(  .%_  #3B0$ RI(# ,.8! "]G@0
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M,4&_NC%!P-(Q0;[N,$&]_2]!O/\N0;S_+4&\_RU!O/\M0;S_+4&\_RW.B@
MOY@  +&@  "FJ   F[   )"X  "%OP  >L<$ &_/"0!KT14 9]$F 6/1- 1>
MT$ (6=!*#%7/4Q!1SUL43L]C&$O.:QM(SG4>1<Y_($+.C") SIDD/LZH)CS.
MNB8\S]0F/,WO)3O,^R4[R_\E.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X
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M"R'_X LA_?(*(/S\"B#\_ H@_/P*(/S\"B#\_ JBIP  E;$  (>[  !YQ@
M;,\  %_9  !2WP  2.@  $/_"  __Q  ._\9 #?_(0 T_RD!,/\P 2W_-P(J
M_SX")_]$ B7_2P,B_U,#(/]< QW_9@0;_W($&?^ !1?_CP46_Y\&%?^O!A3_
MP 84_]8&$__I!A/_Z083_^D&$__I!A/_Z0:7KP  B+H  'K%  !LSP  7MH
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M-99>_S&67_\MEF#_*I9@_RJ68/\JEF#_*I9@_RK_4@\ _UP* /]F"0#_;@H
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M9_\QAVC_+H=I_RV':?\MAVG_+8=I_RW_5PP _V$$ /YL P#D=0$ VWL% -.
M" #0@PH QX4: +Z$+0.V@3P)KWU($JAY4AFB=EL@G7-C)IEP:RN5;G(OD6UY
M,XYK@3:+:8DZB&B2/(5GG#^"9J=!@&:T0WYFQ41\9N%#?FCU/']J_S> :_\S
M@6S_+X%L_R^!;/\O@6S_+X%L_R__60L _V,! /1O  #?>   U'\$ ,Z#!@#*
MAP@ PH@8 +F'*P*QA3H(JH%&$:-^4!B=>ED?F'=A)9-U:"J/<V\OBW%W,XAO
M?C:%;H8Z@FR//7]KF4!\:J5">6JQ1'=JPD1V:MU$>&SS/GEN_SAZ;_\T>W#_
M,'QP_S!\</\P?'#_,'QP_S#_6P@ _V8  .=R  #:>P  SX(# ,F'!0#$B@8
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MEC$%EY,^#)"02!2*CE$;A(M9(7^)8"=[AV<K=X5N,'.$=31O@GTW:X&'.VB
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M.T^6M#Q.ELD\3I;H.D^6^391EO\S4I;_,%*6_S!2EO\P4I;_,%*6_S#F<@
MT(   ,*,  "XE@  K9P  *.A  "9I@  CJT  (BN$0"#KB(!?:TQ!'>L/0IR
MJD<0;*E/%F>H5QMCIUX?7Z9E)%ND;2=8I'4K5*-_+E&BB3%.H98T2Z&D-DFA
MM#9(H<@W2*#G-4F@^3)*G_\P2Y__+DN?_RU+G_\M2Y__+4N?_RW=>0  R88
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M'#?'^1PWQ?\<-L3_'#;$_QPVQ/\<-L3_'#;$_QR^D0  L)L  *2C  "8J@
MC+(  ("Y  !TP   :,<  %W-!0!3TPH 3]<2 $W8(@!+V#  2=@\ D;81@-$
MV4\$0=E8!C_980@\V6L*.MEV##?9@@XUVI /--J@$#+:L1$QV\<1,=KG$3#8
M]A(PUO\3+]3_$R_4_Q,OU/\3+]3_$R_4_Q.SF@  IJ$  )JI  "-L0  @+H
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M P[_\ ,.__ ##O_P P[_\ .3K@  A+@  ';"  !GS   6M4  $S<   _X0
M->8  "WT   J_P( )O\+ "/_$0 @_Q< '?\= !G_(P 6_RD %/\O !+_-0 0
M_ST #O]% 0S_3@$*_U@!!_]E 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_
MR@$ _\H! /_* 0#_R@&&MP  =\$  &C,  !:UP  2]X  #[D   RZ0  )^T
M "/_   ?_P  &_\% !?_#  4_Q  $?\4  __&  -_QT "_\B  C_*  %_RX
M O\U  #_/0  _T<  /]2  #_7@  _VT  /]^ 0#_C@$ _YL! /^I 0#_JP$
M_ZL! /^K 0#_JP'_*BT!_RXK ?\P*P'_,"X"_RXU O\I/0/_)4D$_R-7!/\A
M9 7_'W(&_QU_!O\=B@;_'90&_QV<!_\<HP?_'*H'_QRQ!_\<N ;_'+\&_QS)
M!O\<U@;_'>4&_QWO!O\=^07_'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_'?\%
M_QW_!?\=_P7_+"L!_S H ?\S* '_,RL"_S$Q O\M.@/_*T<$_RA4!?\F807_
M)&\&_R)\!_\BAP?_(I$'_R&9!_\AH0C_(:<(_R&N"/\AM0C_(;P(_R'&!_\A
MT0?_(>('_R+M!_\B]P?_(O\&_2+_!OPB_P;\(O\&_"+_!OLB_P;[(O\&^R+_
M!OLB_P;_+B@!_S,E ?\V)0'_-R<!_S4M O\T. /_,D0$_R]1!?\L7@;_*FL'
M_REW!_\H@PC_)XT(_R>6"?\GG0G_)Z0)_R>K"?\GL@G_)[D)_R?""?\GS0G_
M)]X)_R?K"?PG]@CY*/X(]RC_"/8H_PCU*/\(]2C_"/4H_PCU*/\(]2C_"/4H
M_PC_,B4!_S<B ?\Z(0'_.R,!_SLI O\[- +_.4 $_S9-!?\T6@;_,68'_S!S
M"/\N?PG_+HD*_RZ2"O\MF0O_+:$+_RVG"_\MK@O_+;4,_RV^#/XMR0S[+=D,
M^"WH"_0N] OQ+OX+[R[_"^XN_POM+O\+["[_"NPN_PKL+O\*["[_"NPN_PK_
M-2(!_SL> ?\_'0'_0!\!_T(F ?]",0+_0#P#_SY(!?\[50;_.6((_S=N"O\V
M>0O_-80,_32-#?PTE0WZ-)P.^3.C#O<SJ@_V,[(/]3.Z#_,SQ0_R,](/[C/E
M#^HT\@_G-/T/Y33_#^0T_P[B-?\.XC7_#>$U_PWA-?\-X37_#>$U_PW_.1X!
M_S\: ?]#& '_1AH!_TDC ?])+0+_2#@#_T5$!?]#4 ?_0%T)^SYI"_@]= WU
M/'\.\SN(#_$[D!#O.I@1[3J?$NPYIA/J.:X3Z3FV%.<YP13F.<X5XCGC%=XY
M\17;.OP4V#K_$]4[_Q+3._\2TCO_$=([_Q#2._\0TCO_$-([_Q#_/1L!_T,6
M /](% #_3!<!_T\? ?]0* '_3S,"_TT_!/M*2@;U1U<)\49D#.U$;P[I0WD1
MYT*#$^1!BQ3B0),6X#^;%]\_HAC=/JH9VSZS&M@^O1K6/LH;TC[?&\X^[QO+
M/_L:R4#_&,= _Q?&0?\5Q4'_%,1!_Q3$0?\4Q$'_%,1!_Q3_01< _T<2 /],
M$ #_4A0 _U8; /]7) '_5BX"^%0Y _%110;K3U()YDU>#.%+:1#=2703V4A]
M%M5&AAC218X:T$66',Y$G1W,1*4>RD.M'\A#MB#&0\,AQ4/3(<%#Z2&^1/<?
MO$7_';I&_QNY1_\9N$?_&+A'_Q>X1_\7N$?_%[A'_Q?_1!0 _TL0 /]1#@#_
M5Q$ _UL6 /]='@#Y72@![ULS N=9/P3@5TT(VE19#=-29!+.4&X6RDYW&<=,
M@!S%2X@>PDJ0(,!*ER&^29\CO$BG)+I(L"6X2+PFMTC+)[1'XR>R2?,EL$K_
M(JY+_Q^N3/\=K4S_&ZU-_QJM3?\:K4W_&JU-_QK_1Q$ _T\- /]6# #_7 X
M_V 2 /UB& #P8R$ YF(L =Y@.@/47D@'S5M4#<=87Q/#5FD7OU1R&[Q2>AZY
M48(AME"*([1/D26R3IDGL$VB**Y-JRJL3+8KJDS$+*A,VRRF3>\JI$_])J10
M_R.C4?\@HU+_'J)2_QVB4O\=HE+_':)2_QW_2@\ _U(* /]:"0#_8 L _V4.
M /5G$0#H:!@ W6<D -)F-0+*9$0'PV%0#;U>6Q.Y7&08M5IM'+%8=2"N5WTC
MK%6$):E4C"BG4Y0JI5*=+*-2IBVA4;$OGU&^,)U1T3";4>HOFE/Z*II5_R:9
M5O\CF5;_(9E7_Q^95_\?F5?_'YE7_Q__30T _U4& /]=!0#[9 < [VD) .EK
M# #A;!  TVT> ,EL,0+":D 'NV=,#;5D5Q.P86 9K%]I':A=<2&E7'@DHEJ
M)Z!9ARJ=6) LFU>8+IE6HC"65:PRE%6Y,Y-5RC.15>4SD5?W+9%9_RF16O\E
MD5O_(Y%;_R&16_\AD5O_(9%;_R'_3PL _U<" /]A @#J: $ WFT$ -AP" #5
M< L RW(; ,)Q+@*Z;ST&M&Q)#:YI5!.I9UT9I&1E':%B;2&=870EFE]\*)A>
M@RN578LMDEN4,)!;GC*-6J@TBUFU-8I9QC:(6>$VB%ST,(A=_RN)7O\HB5__
M)8E?_R.)7_\CB5__(XE?_R/_40D _UH  /5D  #@;   UW$# -!T!@#-=0D
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M-UUZLSA<>L<Y7'KE-UY[^#)?>_\N8'S_*V%\_REA?/\I87S_*6%\_RGU8@
MWF\  ,QZ  # @P  MXD  *^.  "FD0  G9(& )>3%P"1DR@!BY(V!86000M_
MCDH1>HQ2%G6*6AMQB&$?;8=H(VJ&;R=FA'<K8X. +F""BC%=@98T6H&C-EB
MLC=6@,4W5H#C-EB!]S%9@?\M6X+_*EN"_RE;@O\I6X+_*5N"_RGL9@  V',
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M*T6;]"E&FO\G1YK_)4>:_R1'FO\D1YK_)$>:_R34=P  PH0  +:/  "KE@
MH9P  ):@  "+I0  ?ZH  '2N!0!OKQ0 ;*\D &BO,@)DKCT%7ZU&"5NL3PU8
MK%815*M>%%&J9A=.JFX:2ZEX'4BI@R!%J(\B0ZB=)$&HK25 J, E/ZC?)3^F
M]"- I?\B0*7_(4"D_R! I/\@0*3_($"D_R#*?@  NXL  *^5  "DFP  F:$
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M#"G-_PTIS?\-*<W_#2G-_PVNF   HI\  ):F  ")K@  ?+8  &^]  !CPP
M5\@  $S-  !"T@, .=D) #7?$  TWQL ,N G #'A,@ PX3T +N)' "WB4 $K
MXEH!*N-E BCC<0(FY'\#)>2/ R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@
M_P4?X/\%'^#_!1_@_P6DG@  F*4  (NN  !]M@  <+X  &/&  !6RP  2]
M $#5   VW   +^4' "WM$  K[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X
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M  #_U@""M0  <[\  &3)  !6TP  1]L  #K@   NY0  (^D  !KM   5_0
M$O\  !#_ @ ._PD "_\-  C_$  $_Q,  ?\8  #_'@  _R0  /\K  #_,P
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M#= S_PS.,_\,S33_"\PT_PO,-/\+S#3_"\PT_PO_.18 _SX2 /]!$ #_11,
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M%YU,_Q:=3/\6G4S_%IU,_Q;_1PL _TT" /]4 @#W6@0 ZUT' .=="P#A7!
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M+FIFLR]I9L8P:&;D+VIH]REK:?\E;&G_(FQJ_R!L:O\@;&K_(&QJ_R#_5P
MY&(  -)L  #&<P  O7@  +5[  "M?   I7P* )]]&@"9?"H!DWLX!(UY0PF(
M=TP.@W54$G]S6Q9[<F(9>'!I'75O<"!R;G@C;VV!)FQLBREJ;)<L9VNC+F5K
MLB]D:\0P8FOA+V1L]BIF;?\F9FW_(V=N_R!G;O\@9V[_(&=N_R#V60  X&4
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M+5-\\BE5?/\E5GS_(E=\_R!7?/\@5WS_(%=\_R#E9   SW   ,%Z  "V@P
MK8D  *.,  "9C@  C8\  (:0#@"!D1T ?9 L 7B/. 1SCD((;HU+#&J,4Q!G
MBEH48XEA%V"(:!M=AW >6H9Y(5:%@R14A8\F482<*$^$JBI-A+PJ3837*DV#
M\2=/@_\D4(/_(E"#_Q]0@_\?4(/_'U"#_Q_>:0  R74  +R   "RB   J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
M --B  #':   O6P  +9M  "O;   IVL+ *!L&0";;"H!E6LW I!I0P6+:$P)
MAV94#(-E6Q" 8V(3?6)I%7IA<!AX87@:=6"!'7-?BQ]P7I8B;EZB)&Q>L"5K
M7L$F:5[>)FI?]"%K8/\=:V'_&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E
M  ##:P  N6\  +%Q  "J<0  HF\( )MO%P"6<"< D&\U HMN0 6&;$D(@FI2
M#'YI60][:& 2=V9F%'5F;A=R978:<&1^'6UCB!]K8Y,B:6*@)&9BKB5E8K\F
M9&+:)F1C\B)E9/\>9F3_&V=D_QEG9?\89V7_&&=E_QCP4P  W5\  ,MH  "_
M;P  MG,  *YU  "F=0  G7,% )9S% "1="0 BW,R H9R/@2!<$<(?6]/"WEM
M5PYV;%X1<VMD%'!J;!=M:G,::VE\'&AHAA]F9Y$B8V>>)&%FK"5@9KTF7V?6
M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
M *9^  "=?@  D7P  (I\#P"%?1X @7TM 7Q\.0-W>D,&<WE+"7!X4PQL=UH0
M:79A$V9U:!9C=&\887-X&UYR@AY;<HT@67&:(E=QJ"15<;DE5''0)51Q[B)6
M<?X>5W'_'%=Q_QI8<?\96''_&5AQ_QGC7@  S6D  +]S  "T>@  JW\  **"
M  "8@P  BX$  (2!#0!_@AH >X(I 7:!-@)R@4 %;G])"&I^4 MG?5<.9'Q>
M$6%[9A1>>FT76WIV&5EY@!Q6>(L?4WB8(5%WIB)0=[<C3W?.(T]W["%0=_T>
M47?_&U)W_QE2=_\94G?_&5)W_QG>8@  R&X  +MW  "P?P  IX0  )V'  "2
MAP  A(<  'V'"0!XB!8 =(@F '"(,@)LAST$:(9&!F6%3@EAA54,7H1<#UN#
M8Q)9@FL55H%T%U. ?AI0@(D<3G^6'DQ_I2!*?[8A27_,(4E^ZQ]*?OP<2W[_
M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
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M /\<(P#_&"\ _Q0[ /\220#\$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL
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M Z\D_P.N)/\#KB3_ ZXD_P/_+P8 _R\  /\R  #_,P( ^3(( /<O#@#K*Q8
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M"()!_PC_/   ZT,  -Q*  #,3P  PU   +Q.  "W20$ L48. *I(' "D22P
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M$F]-J1-N3;D4;$W.%&Q-ZQ-L3OT0;$__#FQ/_PQL3_\+;$__"VQ/_PON10
MW%   ,E7  "]7   M%X  *Q>  "D6P  G%8$ )56$@"05R$ BU@O (=7.P&#
M5D0"?U9- WQ55 5Z5%L&=U1B"'53: ES4W +<5)X#6]2@@]M48T1:U&9$FE1
MIA1G4;859E'+%652Z11E4OL19E/_#V93_PUF4_\,9E/_#&93_PSJ20  U5,
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M%E5>XQ567O<25E[_$%=>_PY77O\-5U[_#5=>_PW>4P  R%T  +MD  "P:@
MIFT  )UN  "3;0  A6<  'YG"0!X9Q4 =&<C '%H+P!N9SD!:V=" FAF2@-E
M9E(%8V58!F!E7PA>9&<*7&1O#%IC>0Y88X0056*1$E-BGQ-28JX546+"%5!B
MX1518O8246+_$%)B_PY28O\-4F+_#5)B_PW95@  Q&   +=H  "L;@  HW$
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M#D%S_PU!<_\,07/_#$%S_PS&9   MVX  *MV  "B?   EW\  (R!  "!@0
M<H   &5_  !=?P@ 67\3 %> ( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)
M?UT%1G]F!D1^< A"?GL)/WZ("SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[
M_PLZ>O\+.GK_"SIZ_PO :0  LG0  *=\  "=@0  DH0  (>&  ![AP  ;H<
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M!"*9_P2L@0  H(@  )6.  "+D@  ?Y8  '*:  !EG0  6:   $ZC  !"I
M-Z8  "ZH!0 IJ0\ **D8 ">J(@ FJBP ):HU "2J/P CJD@ (JM3 "&K7@ @
MJVH 'JMY !VKBP ;JYT &JNQ !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF
M_P*EB0  F8\  (^4  "#F0  =9X  &BB  !<I@  4*D  $2L   YK@  +[
M ":S   >M08 &;</ !BW%P 7MR$ %K<J !6W-  4N#X $[A) !*X5  2N6(
M$;EQ !"Y@P /N9< #KFL  VYQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<
MD   DI4  (:;  !YH   :Z8  %ZK  !2KP  1K(  #JU   OMP  );H  !V]
M   5P   $,,&  O&#@ *Q14 "<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F
M  +&=P !QHL  ,:@  #%M@  QM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@
MB9P  'NC  !MJ0  8*\  %.T  !&N   .KL  "Z^   DP0  &\0  !/'   .
MR@  ",X!  '0"@  T!   - 6  #1'@  TB<  -,Q  #4/   U4D  -98  #6
M:0  UGP  -:2  #6IP  UK\  -;@  #6\P  UOX  -;_  #6_P",G0  ?J0
M &^K  !AL@  5+D  $:]   YP0  +<0  "+'   9RP  $<X   S2   %U0
M -L   #< P  W0H  -X/  #?%   X1P  .(D  #D+@  YCH  .=)  #H60
MZ&L  .F!  #IF   Z:T  .G%  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U
M  !5O   1\(  #G&   LR@  (,X  !;2   /U@  "-L   #?    XP   .4
M  #G    Z $  .H'  #K#0  [1$  .\8  #Q(0  \RL  /8X  #W2   ^%H
M /EM  #ZA   ^IL  /JO  #ZP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(
MQ@  .<L  "O0   ?U   %-H   W?   %XP   .8   #I    [0   .\   #Q
M    \P   /4   #V @  ^ D  /H.  #]$P  _QP  /\H  #_-@  _T<  /]:
M  #_;@  _X4  /^:  #_JP  _[D  /^\  #_O #_$2  _Q > /\,'@#_!"$
M_P G /\ , #_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_
M )@ _P"> /\ I #_ *H _P"P /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L
M_P#[ /\ ^P#_ /H _P#Z /\ ^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A
M /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0
M_P": /X H #] *8 _ "L /L M #Y +T ^ #) /< W #U .P \P#X /, _P#R
M /\ \0#_ /  _P#P /\ \ #_ /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\
M* #_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6
M /4 G #T *( \P"H /$ L #P +@ [@## .P TP#J .< Z0#U .< _P#F /\
MY0#_ .4 _P#E /\ Y0#_ .4 _P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_
M!3  _P$^ /\ 2P#_ %< _@!B /H ; #U '4 \@!] /  A #N (L [ "1 .L
MEP#I )X YP"D .8 K #D +0 X@"_ .  S0#> ., W #R -H _0#8 /\ U@#_
M -4!_P#5 ?\ U0+_ -4"_P#_'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH
M_PLX /T(10#X!E$ ] 1< .X$9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=
M!9H VP6@ -@%J #5!;$ T@6[ - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,
M_P#%#/\ Q0S_ ,4,_P#_(0P _R & /\< P#_'0H _QL0 /\8& #_%", ]A$P
M .\./@#J#DH Y0U6 .$-8 #=#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8
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M ILE_P+_+   _RT  .TR  #B-   VC,  -,N P#2)0H R247 ,$G)P"[*38
MMBI# +(K3@"O*U< K"M@ *HK9P&H*V\!IBMV :0K?0&C*X0"H2N- I\KE0*>
M*Y\"G"NJ YHKM@.9+,<#ERSB Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M
M_P/_,   \C,  .0Z  #6/0  S#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,]
M *<S20"D,U( H3-: 9\S8@&<,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$
MD#*E!8XRL06-,\(&BS/<!HDT\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\
M,P  ZSH  -Q!  #-1   PT0  +U!  "X.P$ LC<. *LX' "E.2L H3HX )T[
M1 ":.TT!ESI6 90Z70*2.F0"D#IK XXY<@.,.7H$BCF"!8DYBP6'.94&A3F@
M!X,YK0>".;P(@3G3"'\Z[@A].OX'?#O_!GP[_P5\._\%?#O_!7P[_P7T-P
MY4   -)'  #%2@  O$L  +5)  "O0P  J3X+ *(_%P"=0"8 F$$T )1!/P"1
M04D!CD%1 8M 60*)0& #AT!G X4_;02#/W4%@3]]!G\^AP=]/I$(>SZ<"7H^
MJ0EX/K@*=S_-"G4_Z@IT0/P(=$#_!W1 _P9S0/\&<T#_!G- _P;Q.P  WT4
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M#F!-X0Y@3?8,8$[_"F!._PE@3O\(8$[_"&!._PCC1P  S5   +Y7  "S6P
MJET  *%=  "86@  C5,  (92# " 4Q@ ?%,E 'E4,0!U5#P <U-$ 7!33 )M
M4E,":U)9 VE28 1G46@&95%P!V-1>0AA480*8%"1#%Y0G@U<4*T.6U' #EI1
MW@]:4?4,6E+_"EM2_PE;4?\(6U'_"%M1_PC?2@  R5,  +M:  "P7P  IF$
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M"TQ=_PI,7?\)3%W_"$Q=_PC/5   OEX  +%E  "G:@  G6T  )1M  ");
M>&4  &]D  !I9 X 9609 &)D)0!@93  7F4Z %QE0@%:94H"6&11 E9D6 -4
M9%\$4F1G!5!C<0=.8WL)3&.("DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B
M_PE'8O\)1V+_"$=B_PC*6   NF(  *YI  "C;@  FG$  )!R  "$<0  =&L
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M!C5T_P:Y:   K7$  *)Y  "8?@  C8   (*!  !V@@  :8$  %N!  !1@0
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M ""8AP ?F)D!'9BL 1R8PP$<E^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P
MG(8  )&+  "'CP  >I(  &V5  !AF   59L  $F=   ]G@  ,Y\  "JA   A
MHPH 'Z,1 !ZC&@ =I"0 '*0M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E
M@0 3I90 $J6H !&EOP 0I.( $:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P
M (R1  !_E0  <9H  &2>  !8H0  3*0  $"F   UIP  *JD  "*L   9K@
M$K ) !"Q$  0L1@ #K$B  ZQ*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  '
ML8L !;&@  2PM0 $L-  !+#O  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8
M  !UG0  9Z(  %JG  !.JP  0:T  #6O   KL0  (;0  !BV   1N0  #;P#
M  >^#  #O1(  ;T9  "^(@  OBL  +XV  "^00  OTX  +]<  "_;0  OX
M +Z5  "^J@  OL(  +WD  "]]@  O?\  +W_  "]_P"2E   A9H  'B@  !J
MI@  7*L  $^P  !"LP  -;8  "JX   @NP  %[X  !#!   +Q   !,<   #)
M!P  R0T  ,D2  #*&0  RR(  ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'
M  #/G0  S[,  ,_.  #/ZP  SO@  ,[^  #._@"(FP  >J(  &RH  !>KP
M4+4  $*Y   UO   *;\  !["   5Q@  #LD   C,    T    -,   #5
MU@8  -@,  #9$0  VQ8  -P?  #>*   X#0  .)!  #B40  XV,  .-W  #D
MC@  Y*0  .2Z  #EU   Y>H  .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X
M #7"   HQ@  ',D  !/-   ,T0  !-4   #:    W@   .$   #B    Y
M .4#  #G"0  Z0X  .L2  #M&@  [R0  /(Q  #T00  ]%,  /5F  #U?
M]I,  /:I  #WO   ]\X  /??  #WWP!PK   8;0  %.[  !%PP  -L<  "?,
M   ;T   $=4   K;    WP   .(   #E    Z0   .P   #M    \    /$
M  #S    ]00  /<*  #Z$   _!8  /\A  #_+@  _T   /]3  #_:   _X
M /^6  #_J   _[8  /^_  #_OP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_
M #P _P!* /\ 5@#_ &, _P!M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\
MH #_ *8 _P"L /\ M #_ +T _P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_
M /H _P#Z /\ ^@#_ /H _P#_$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #<
M_P!% /\ 4@#_ %X _P!I /\ <@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\
M *$ ^P"H /D KP#X +@ ]@## /0 T@#S .< \@#V /  _P#O /\ \ #_ .\
M_P#O /\ [@#_ .X _P#_$A0 _P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!
M /\ 30#_ %D _P!D /T ;0#[ '8 ^0!] /< A #U (L ] "1 /, EP#Q )T
M\ "C .X J@#L +, Z@"] .@ RP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A
M /\ X #_ .  _P#_%!  _Q$. /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\
M1P#Y %, ]0!> /( : #P '  [0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"?
M .$ I@#? *X W "X -H Q0#6 -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\
MS@#_ ,X _P#_%PP _Q0( /\/!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M
M $T Z0!8 .8 8@#C &H X !R -X >0#; (  V0"& -8 C0#3 ), T0": ,\
MH0#- *H RP"S ,D OP#& -  Q0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_
M +\#_P#_&P8 _Q<  /\4  #_$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8
MW -1 -8$6P#2!&0 SP5L ,P%<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_
M!J8 O0:P +L'O "Y",T N KE +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\.
M_P#_'@  _QL  /\;  #Z&@  ]18% /81#0#K#A4 X@LB -@+,0#0##X RPU*
M ,<-50#$#EX P0YF +\.;0"]#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*,
ML!&M *\1N@"M$<H JA+E *<4]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_
M(@  _R   / C  #F)   X"$  -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D7
M3@"U%U< LQA@ + 89P"N&&X K!EU *L9? "I&80 J!J, *8:E "D&IX HQNH
M *$;M "?',4 GAS? )H=\P&8'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_)@
M]"<  .8M  #:+P  SRT  ,HG  #''P@ P1P3 +H>(@"T'S$ KR ] *LA2 "H
M(E( IB): *,C8@"A(VD H"-O )XC=P"<(WX FR.& )DDCP&7))D!EB2C 90D
ML &2);\!D276 8XF[P&,)_\"BR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0  [#
M -TV  #-.   Q#<  +XR  "Z*P( M24. *XG'0"H*2L I"HX * J0P"=*TP
MFBM5 )@K7 "6*V, E"MJ 9(K<0&0+'@!CRR! 8TLB@&++)0"BBR? H@LJP*&
M++H"A2W. X,NZ@.!+OP#@"[_ G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]
M  #%/P  NS\  +0\  "O-0  J2\+ *,O%P">,28 F3(S )8R/@"2,T@ D#-0
M (TS6 "+,UX!B3-E 8<S; &&,W,!A#-\ H(SA0* ,X\#?S.: WTSIP-\,[4$
M>C/)!'DTY@1W-?D$=C7_ W4U_P-U-?\#=37_ W4U_P/P,P  W3T  ,I#  "^
M10  M48  *U#  "F/0  H#8& )DV$P"4."$ D#DN (PY.0").4, ASE, (0Y
M4P&".5H!@#EA 7XY: )\.6\">CEW GDY@ -W.8L$=3F6!'0YHP5R.;$%<3G$
M!F\ZX@9N.O<%;CO_!&T[_P1M._\#;3K_ VTZ_P/J.0  U4(  ,1(  "Y2P
MKTL  *=)  "?1   F#X! )$\$ ",/1T B#XJ (0_-0"!/S\ ?C]( 'P_3P%Z
M/U8!>#]= 78^9 )T/FL"<CYS W ^? -O/H<$;3Z3!6L^H 9J/JX&:3_ !V<_
MW@=G/_4&9D#_!69 _P1F0/\$9C__!&8__P3E/0  ST8  +],  "T3P  JE
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M!E5,_P953/\%54S_!55,_P752   PE$  +57  "J6P  H%P  )=<  "-60
M@5,  '=/! !Q3Q  ;E < &I0* !H4#( 95 [ &-00P!A4$H!7U!1 5U06 )<
M4%\"6E!G UA0<0174'L%55"(!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0
M_P904/\%4%#_!5!0_P702P  OU0  +):  "G7@  G6   )1@  ")70  ?%<
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M!4%<_P7#5@  M%\  *AF  ">:@  E6T  (IM  !_;   ;V<  &1D  !;8@4
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M C-RB0,Q<IH#+W*L RYRP0,N<N,#+G'X RYP_P,N;_\#+F__ RYO_P.S9@
MIV\  )UV  "3>@  B'P  'Y]  !R?0  9'P  %=[  !,>@  0GD# #QY#@ Z
M>A< .7HA #AZ*@ W>S, -GL[ #1[1  S>TP ,GM5 #![7P O>VH!+7MW 2M[
MAP$J>Y@"*'NJ B=[OP(F>^$")GKW B9X_P(F>/\")W?_ B=W_P*N;   HW8
M )E\  ".?P  A((  'B#  !LA   7X0  %&$  !'A   /(0  #.$"0 PA!$
M+X0: "V$)  LA2T *X4U "J%/@ IA4< *(90 ">&6@ FAF8 )(9S ".&@P A
MAI4 ((:G 1Z&O $>AMX 'H3U 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."
M  ")A0  ?H@  '&*  !EBP  6(P  $R-  ! C@  -HX  "R/   ED P (Y 3
M "*0'  AD"4 ()$N !^1-@ >D4  '9%) !R15  :D6  &9%N !B1?@ 6DI
M%9*D !21N0 3D=@ $X_T !2._P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$
MC   =X\  &F1  !=DP  4)4  $67   YF   +ID  "6:   =FP( %IT, !6=
M$P 4G1L $YTD !*=+0 1GC< $9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>
M  J=L@ )G<P "9SL  J;_@ +FO\ "YG_  N9_P"<A   D8H  (B.  ![D@
M;98  &"9  !4G   2)\  #R@   PH0  )J,  !VE   5IP  $*D%  NK#0 (
MJA, !ZH;  :J)  %JBX !*HX  *J1  !JE   *I>  "J;@  JH$  *J5  "I
MJ@  J<$  *CD  "H]@  I_\  *?_  "G_P"5BP  C)   '^5  !QF@  8YX
M %:B  !*I@  /:@  #&J   FJP  ':T  !2P   .L@  ";4!  *V"@  M@\
M +85  "W'0  MR4  +<O  "X.0  N$8  +A4  "X9   N'8  +B+  "WH
MM[8  +?3  "V[P  MOP  +;_  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL
M   ^KP  ,;$  ":S   <M@  $[@   V[   &O@   ,$   #"!   P@L  ,,0
M  #$%0  Q!P  ,4D  #&+@  R#H  ,E'  #)5P  R6D  ,E]  #)E   R*H
M ,C#  #(Y   R/0  ,C]  #(_0"%F0  =Y\  &BF  !:JP  3;$  #^U   Q
MN   );H  !J]   1P   "\,   /'    R@   ,T   #.    SP,  - )  #1
M#@  TQ(  -49  #7(@  VBT  -TY  #>20  WEH  -]N  #?A0  WYP  -^R
M  #>RP  WN8  -_T  #?] !YH0  :Z@  %RO  !.M0  0+L  #&^   DP0
M&<4  !#(   )S    ,\   #3    V0   -P   #=    WP   .$   #B!0
MY L  .80  #H%@  ZB   .TK  #P.@  \4L  /%>  #R<P  \XL  /.B  #S
MM@  \\D  //A  #SX0!MJ@  7K$  %"Y  !!OP  ,L0  "3(   7S   #M
M  ;5    V@   -X   #B    Y@   .D   #J    [    .X   #P    \@
M /0&  #V#   ^1(  /P<  #_*0  _SH  /]-  #_8@  _W@  /^0  #_HP
M_[,  /_!  #_P0#_!QD _P$7 /\ %P#_ !H _P A /\ *P#_ #D _P!' /\
M5 #_ %\ _P!J /\ <P#_ 'L _P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H
M /\ KP#_ +@ _P#$ /X U0#\ .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\
M\P#_ /$ _P#_"Q4 _P43 /\ $P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_
M %L _P!E /\ ;@#_ '8 _P!^ /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /<
MJP#V +, ] "^ /, S #Q ., [P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_
M .L _P#_#1$ _PD0 /\ #P#_ !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4
M_0!@ /H :0#X '$ ]@!Y /0 ?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I
M *X YP"X .4 Q0#C -H X0#M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T
M_P#_#PT _PP+ /\#"0#_  P _P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!:
M .X 8P#L &L Z0!S .< >@#E (  XP"& .$ C #? ), W0"9 -L H0#9 *D
MU0"R -( O@#0 ,X S@#F ,P ]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_
M$0@ _PT" /\'  #_!0@ _P . /\ %@#W "( [P P .L /0#H $D Y !4 .
M70#= &4 V0!M -4 <P#2 'H T "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M
M ,( N #  ,< O0#? +P \0"[ /X N0#_ +@ _P"X /\ N #_ +@ _P#_%
M_P\  /\-  #_#   _P<) /@!$ #H !H XP H -T -@#8 $( T@!- ,X 5P#*
M %\ QP!F ,4 ;0## '0 P0!Z +\ @0"] (@ NP"/ +D EP"W )\ M0"H +,
MLP"Q ,( KP#8 *X"[0"L _L JP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(
M /<2  #L$0  Y@X  .4&" #= Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@
MN09@ +<'9P"U!VX LP=U +$(>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E
M"[\ HPS4 *$-[0"?#OX G0[_ )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>
M  #?'@  U1H  - 3 @#.# L QPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!:
M *H080"H$6@ IA%O *01=@"B$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P
MEQ30 )05[ "2%OT D!?_ (\7_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0
M*@  QR<  ,$A  "]&04 N1(0 +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:
M7 ":&F( F1II )<;< "5&W< E!M_ )(<B "0')( CQR= (T=J0"+';< BA[*
M (@?YP"&(/H A"#_ 8,@_P&#(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&,P
MO#$  +8M  "P)0  K!T, *8>& "A("8 G"$R )DB/0"5(D< DR-/ )$C5@"/
M(UT C21D (LD:P"))'( B"1Z (8D@P"$)8T @R68 8$EI & )K(!?B;% 7TG
MX@%[)_<!>2C_ 7@H_P%X*/\!>"C_ 7@H_P'O*P  W3,  ,HY  "^.P  M#H
M *TV  "F+P  H2@' )LG$P"6*"  D2DM (XJ. "+*T( B"M* (8K4@"$*U@
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M U\Z_P)?.O\"7SK_ E\Z_P+=.P  QT,  +E)  "N2P  I$P  )M*  "210
MB3\  ($Z"0![.A0 =SL@ '0\*P!R/#4 ;ST^ &T]1@!K/4T :3U3 &@]6@!F
M/6$!9#UI 6,]<@%A/7T"8#V) EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD_
M_P-9/_\"63__ ED^_P+6/P  PT<  +5,  "J4   H%   )=/  ".2P  A$4
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M TI+_P/(20  N%$  *Q7  "A6P  F%P  (Y<  "#60  =E,  &M.  !D30H
M7TP3 %Q-'@!:32@ 6$TQ %9-.@!434$ 4TY( %).3P!03E<!3TY? 4U.: %,
M3G,"2D]_ DE/C0-'3YT$1D^N!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5.
M_P/$3   M54  *E;  "?7@  E6   (M@  " 7@  <E<  &=3  !>40< 65$1
M %=1&P!4424 4E(O %%2-P!/4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "
M15-] D13BP-"4YL#052L!$!4P00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/
M4   LE@  *9>  "<8@  DF4  (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6
M& !/5B( 35<L $Q7- !*5SP 25A$ $A82P!'6%, 15A; 4189 %"6&X!0%A[
M C]8B0(]6)D#/%BJ SM9OP,Z6> #.ECW SI8_P,[5_\#.U?_ SM7_P.\5
MKEP  *-C  "99P  D&D  (5I  !Y9P  :V(  &!@  !570  3EL, $M;% !)
M7!\ 1UPH $9=,0!%73D 0UU! $)=2 !!7E  0%Y8 #Y>80$\7FP!.UYX CE>
MAP(W7I<"-EZI S5>O0,T7]T#-%[U S5=_P(U7?\"-5S_ C5<_P*X60  JF$
M *!G  "6;   C&X  (%N  !V;   9VD  %QF  !19   2&() $1B$0!"8AL
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M "!UMP ?==( 'W3Q !]S_P$?<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?
M@'X  '1_  !G?P  6G\  $U^  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C
M?B4 (GXM "%^-@ A?C\ 'W]( !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_
MLP 5?\X %7[O !9\_P 6>_\ %GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0
M &V&  !@AP  5(<  $B(   \B   ,H@  "B(   @B 4 &HD. !F)%0 8B1T
M%XHF !:*+@ 5BC< %(I! !.*3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,
MBL@ #(GJ  V'_  .A_\ #H;_  Z&_P"?>P  E($  (J%  " B   <XL  &6-
M  !9CP  3)   $&2   TD@  *I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=
M  R7)@ +ER\ "I<Y  F71  (EU  !I=>  67;@ #EH   9:4  "5J   E;X
M )3@  "4]   D_\  9+_  &2_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0
MF   1)H  #B;   LG   (IT  !F>   2H   #:("  >C"P !HQ   *,7  "C
M'P  HR<  *,Q  "D/   I$@  *16  "D90  HW<  *.+  "CH   HK8  *'2
M  "A\   H/L  *#_  "@_P"1B@  B8X  'N2  !MEP  8)L  %.>  !&H0
M.:,  "VD   CI@  &:@  !&J   ,K   !:X   "O!P  KPT  *\1  "P&
ML"   +$H  "Q,@  LCX  +),  "R6P  LFP  +*!  "QEP  L:P  +#&  "P
MZ   K_<  *__  "O_P",D   ?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P
M "*N   8L   $+,   JU   "N    +L   "[    O <  +P-  "]$0  OA8
M +\>  # )P  P3(  ,)   ##3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP
MPN\  ,+Z  #!_@"!EP  <YT  &6C  !7J   2:T  #NQ   MLP  (;8  !:Y
M   .NP  ![X   #!    Q0   ,<   #(    R0   ,H%  #+"P  S0\  ,X4
M  #0'   TR8  -8R  #800  V%,  -EF  #9?   V90  -FK  #9PP  V>$
M -GP  #9] !VGP  9Z8  %FL  !+L@  /+<  "ZZ   AO0  %<    W$   %
MQP   ,H   #.    T@   -4   #6    V0   -L   #=    WP<  .$,  #C
M$0  YAD  .DD  #L,@  [4,  .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=
M  #OY !JJ   6Z\  $RV   ^O   +\   "#$   4R   #,P   +0    U
M -D   #>    X@   .4   #F    Z    .D   #L    [@   / "  #R"0
M]0\  /@7  #\(P  _S,  /]&  #_6@  _W$  /^)  #_GP  _[$  /_   #_
MQ@#_ !4 _P 4 /\ % #_ !< _P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F
M /\ ;P#_ '< _P!^ /\ A0#_ (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0
M_@"_ /T S@#[ .8 ^0#V /@ _P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_
M Q( _P 0 /\ $ #_ !$ _P 7 /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\
M:@#_ '( _P!Y /T @ #\ (8 ^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y
M /  Q@#N -X [0#P .L _@#J /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX
M_P - /\ "P#_  P _P 3 /\ 'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U
M &P \P!T /$ >@#O ($ [@"' .P C0#J ), Z0": .< H0#F *D XP"S .$
MOP#? -  W0#I -H ^0#9 /\ UP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$%
M /\  P#_  D _P 0 /\ &0#[ "8 ]P T /0 0 #R $P [@!6 .H 7P#G &<
MY !N .( = #@ 'L W@"! -P AP#: (T U@"4 -0 FP#1 *, SP"M ,P N #*
M ,< R #@ ,8 \P#% /\ PP#_ ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\
M  #_  , _P + /, $@#N !\ Z@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H
M ,X ;@#, '0 R@![ ,@ @0#& (< Q ". ,( E@#  )X O@"G +L L@"Y ,
MMP#4 +4 [ "S /L LP#_ +( _P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W
M    ]  # .< #0#@ !@ V@ E -, ,@#. #X R@!) ,8 4@## %H P !A +X
M: "\ &X N@!T +@ >P"V ($ M "( +( D "P )D K@"B *P K0"J +H J #+
M *8 Y@"E /< I #_ *, _P"B /\ H@#_ *( _P#_$   ^PP  .\.  #F#0
MWPD  -H !@#0 !$ R0 = ,0 *@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M
M &@ JP!N *D =0"H 'L I@"# *0 BP"B )0 H "> )X!J "< K4 FP/& )D%
MX@"8!O0 E@C_ )4)_P"4"?\ E G_ )0)_P#\$0  \14  .,9  #6&0  S!4
M ,<0  #$!PH O0,4 +<$(0"R!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F(
MG@MI )P+;P";"W8 F0Q^ )<,A@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+
M$/8 B1#_ (@1_P"'$?\ AQ'_ (<1_P#V&0  YR   -8D  #()0  OR(  +D<
M  "T% $ L0T. *H.&0"E#R< H1 S )T1/@":$4< F!)/ )425@"3$EP D1)C
M ) 3:0".$W  C!-X (L3@0")%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0
M?1G_ 'P9_P!\&?\ >QG_ 'L9_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H
M(   HQ<( )X6$P"9%R$ E!DM )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<
M9 ""'&L @!QS '\=? !]'88 ?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_
M '$B_P!Q(?\ <2'_ '$A_P#H*   TC   ,(U  "W-P  K34  *4Q  ">*P
MF"," )(>$ "-(!L B2$G (8B,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W
M)&8 =B5N '0E=P!S)8$ <2:- &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I
M_P%H*?\!:"C_ 6@H_P'A+@  RS8  +P[  "Q/0  IST  )\Y  "7,P  CRT
M (@G# "#)Q8 ?R@B 'PI+0!Y*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V(
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M 5,Y_P'-/   O$0  *])  "D3   FDP  )%+  "'1@  ?4   ',[  !L. T
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M 4=%B %&19@"14:I D1&O0)#1MP"0T;U D-&_P)#1O\!0T7_ 4-%_P'!1P
MLD\  *94  "<5P  DE@  (A8  !^50  <4\  &9*  !<1@4 5T8/ %1&& !1
M1B( 3T8K $Y&,P!,1SH 2T=! $I'20!)2%  2$A8 $=(80!%26P 1$EX 4))
MA@%!298!0$JG C]*NP(^2]@"/DKS CY*_P(^2?\!/TG_ 3])_P&]2@  KU(
M *-8  "96P  D%T  (9<  ![60  ;5,  &)/  !73 $ 44H- $Y*%0!,2Q\
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M 2Y9M0$M6<\!+5GO 2Y8_P$N5_\!+E?_ 2Y6_P&R5P  I5\  )ME  "1:0
MAVH  'QJ  !Q:   8V4  %AB  !-7P  0UT" #Q;#0 Z7!0 .%P= #=<)@ U
M72X -%TV #-=/@ R748 ,5Y. #!>5P O7F( +5YN "Q??0 J7XX *5^@ "A?
MLP$G7\P )U_M 2=>_P$G7?\!*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\
M 'EO  !N;@  8&L  %1I  !)9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D
M+60Q "QD.0 K94( *F5* "AE5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?
M9LD 'V;K "!E_@ @9/\ (&/_ 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U
M  !I=   7'(  $]Q  !$;P  .FX  #!M P I; T )VP4 "9L'  E;20 )&TL
M "-M-  B;3T (6Y& "!N4  >;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8
M%F[I !=M_  8;/\ &&O_ !AK_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D
M>P  5WH  $IY   _>   -7@  "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW
M+@ 8=S< %WA  !5X2@ 4>%8 $WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F
M  YV^@ /=?\ $'7_ !!T_P"?<0  E7@  (M\  ""?P  =X$  &J"  !=@@
M4((  $2"   X@@  +H(  "2"   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .
M@S  #8,Y  V#1  ,@U  "X-=  F#;  (@WX !H.1  6"I0 #@KL !(';  2!
M\@ %@/\ !G__  9__P":>0  D'X  (:#  !]A0  ;X<  &*)  !5B@  28L
M #V,   QC   )HP  !V-   5C@  #X\#  J0#  &D!$ !(\8  ./(  !CRD
M (\R  "0/0  D$D  (]6  "/90  CW8  (^*  ".GP  CK0  (W/  ",[@
MC/L  (O_  "+_P"4@   BX4  (*)  !TC   9H\  %F1  !,DP  0)4  #26
M   HE@  'I<  !68   /F@  "IL   *<"0  G X  )P3  "<&@  G"(  )TK
M  "=-0  G4   )U.  "=7   G6X  )R!  "<EP  G*P  )O&  ":Z   F?D
M )G_  "8_P".B   AHP  'B0  !JE   7)<  $^:  !"G0  -IX  "F?   ?
MH0  %:(   ZD   (I@   *@   "I!   J0H  *D.  "I$P  JAH  *HB  "K
M*P  K#8  *Q$  "L4P  K&,  *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]
M  "I_P")C@  >Y,  &V7  !?G   4:   $2D   VI@  *J@  !ZI   4JP
M#:X   :P    L@   +4   "U    M0,  +8)  "W#@  N!(  +@9  "Z(0
MNRL  +PX  "]1P  O5@  +UK  "]@0  O9D  +VP  "]S   O.H  +SW  "[
M_@!^E0  <)L  &*@  !3I0  1JH  #BM   JKP  'K$  !.T   ,MP   [D
M  "\    OP   ,(   #"    PP   ,0   #&!@  QPP  ,@0  #*%@  S"
M ,\K  #0.@  T4L  -%>  #2<P  THL  -*D  #3NP  T]@  -/M  #3]@!S
MG0  9*,  %:I  !'KP  .;,  "JV   =N0  $KP   J_    PP   ,8   #)
M    S0   ,\   #0    T@   -0   #6    V0(  -L(  #>#@  X1,  .0=
M  #H*@  Z#P  .E/  #I9   ZGP  .N5  #KK   Z\(  .S5  #LY0!FI@
M6*P  $FS   [N0  *[P  !W    1Q   "<@   #,    SP   -,   #9
MW0   .    #A    XP   .4   #G    Z@   .P   #N!   \0L  /42  #X
M'   ^RL  /T^  #^4P  _FH  /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0
M /\ $0#_ !, _P 9 /\ )@#_ #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ',
M_P!Z /\ @0#_ (< _P"- /\ DP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@
M=R@  &TE  !D(   6QL  %(5  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q
M 1P , $B "\")P M BT + ,T "H#.P I!$, * 1- "8%6  E!64 (P9T "(&
MA@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?*   DRT  (@O  !^+P  ="X
M &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q<
M* @= "<((P E""D ) DP ",)-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8
M#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q
M  !?+   52<  $PC  !$'0  /!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9
M !\,'P >#24 '0TL !L--  :#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@
M$1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=
M,@  4RT  $HH  !")   .1\  #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0
M&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K
M  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P
M4C(  $DN  ! *@  -R4  "\A   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2
M$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP #!=L  L7?P )&), "!BH  88
MOP '&.  !QCU  D8_P"5.   BCT  (!   !W00  ;4$  &0_  !:/   4#@
M $<S   ^,   -BL  "XG   G(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P
M#A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI  4<?  $'9$  AVF  $=O  "
M'-T  ASR  ,<_P"3/   B$$  ']$  !U10  ;$4  &-$  !900  3ST  $8Y
M   ^-@  -3(  "XN   E*@  '24  !0A!  /'0L #1T0  P=%  +'1H "AXB
M  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A>0  (8X  "&D   AN@  (=L
M "'R   @_@"00   AD4  'U(  !T2@  :TH  &))  !81@  3D(  $4_   ]
M/   -3D  "LT   B+P  &2L  !(H!  -) H "2,.  8C$@ %(QD !"0@  (D
M*  !)3$  "4\   E2   )E4  "9E   F=P  )HP  ":B   FN0  )MD  "7R
M   E_@".10  A$D  'M-  !S3P  :D\  &!.  !72P  34@  $1%   \0@
M,3T  "<Y   >-0  %3(   \N P *+ H !2L.  $J$0  *A8  "H>   J)@
M*R\  "LY   K10  +%,  "QB   L=0  +(H  "N@   KMP  *]8  "KR   J
M_P",20  @DX  'I2  !Q5   :%0  %]3  !640  3$X  $-+   W1P  +4,
M ",_   :/   $C@   PV P &,PD  #(-   R$   ,10  #$;   Q(P  ,2P
M #(W   R0P  ,E   #)@   R<@  ,H<  #&>   QM0  ,-0  ##R   O_P")
M3P  @%0  'A7  !O60  9ED  %Y9  !55P  25,  #Y/   R3   *$@  !Y%
M   50@  #D    @] @ !/ @  #L,   Z#P  .1(  #D8   Y(   .2D  #DT
M   Y0   .4X  #E=   Y;P  .(4  #B<   WLP  -](  #;R   U_P"'50
M?UH  '9=  !M7P  95\  %U?  !27   1%@  #A5   M4@  (D\  !A,   0
M2@  "D@   -& 0  108  $0*  !##0  0A   $$5  !!'0  028  $$Q  !!
M/0  04H  $%:  !!;   0($  #^9   _L0  /M   #WR   \_P"$7   ?&
M '-C  !L90  9&8  %ED  !+80  /EX  #);   F60  '%8  !)4   ,4@
M!%$   !/    3@,  $T(  !,#   2PX  $L2  !*&0  2B(  $HL  !*.0
M2D<  $I6  !):   27X  $B6  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J
M  !K;   8&L  %)I  !$9@  -V0  "IB   ?8   %5X   U=   &6P   %H
M  !9    6    %<$  !6"   5@P  %40  !4%   5!T  %0G  !4-   5$(
M %-2  !39   4GD  %*2  !1JP  4,H  $_O  !._P!^:@  =VX  '!Q  !F
M<0  6'   $IO   \;0  +VP  ")J   7:0  #F<   9F    90   &4   !E
M    8P   &(   !B!   80@  &$-  !@$   8!<  & A  !?+@  7SP  %]-
M  !>7@  7G0  %V-  !<IP  6\4  %KM  !9_P![<@  =78  &MW  !==@
M3W8  $%U   S=0  )G0  !ES   0<@  !W$   !Q    <0   '$   !Q
M;P   &\   !N    ;@(  &X(  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K
M6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T
M #9^   H?@  &WT  !!]   '?0   'T   !]    ?@   '\   !^    ?0
M 'T   !\    ?    'P   !\!@  ? P  'P2  !\'0  ?"P  'P\  !\3P
M>V4  'M^  !ZF@  >;8  'C?  !W^@!S@   98$  %:#  !(A   .88  "N'
M   =AP  $8<   >(    B    (D   "*    C    (T   "-    C    (P
M  ",    C    (P   "-    C00  (X,  ".$P  CR$  (XR  ".1@  CEL
M (UT  "-D   C*T  (O.  "*\P!HA@  6H@  $N+   \C0  +8\  !Z0   1
MD0  !Y(   "3    E0   )<   "9    FP   )P   ";    FP   )P   "<
M    G0   )X   ">    GP   *$#  "B#   HA8  *,F  "C.@  HT\  *-H
M  "BA@  HJ(  *+   "AZ !<C0  39   #^3   PE@  (9D  !*:   'FP
M )T   "@    H@   *0   "H    J@   *L   "J    JP   *P   "M
MK@   *\   "Q    L@   +0   "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z
M=P  NY0  +NQ  "YT@!0E0  09@  #*<   CH   $Z(   BD    IP   *H
M  "L    KP   +(   "W    N0   +L   "Z    O    +T   "_    P
M ,(   #$    Q@   ,D   #-    T@$  -0/  #5'P  US4  -A-  #8:0
MUX8  ->C  #6O0#_    _P   /\   #_    _P # /\ #0#_ !4 _P @ /P
M*P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V
M -T ?@#; (< V "1 -, G0#/ *L S0"] ,L X #) /L QP#_ +T _P"Q /\
MJ0#_ *, _P#_    _P   /\   #_    _    /8 "P#Q !$ [0 ; .D )0#D
M #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,,
M=P#  '\ O@"* +L E0"X *, M@"T +0 S0"R /( L #_ *P _P"C /\ G #_
M )< _P#_    _P   /H   #Q    Z    .  !@#9  X T@ 6 ,X 'P#( "D
MQ  R ,  .@"] $$ N@!( +@ 30"V %, M !8 +( 70"P &( K@!I *P ;P"J
M '@ J "" *8 C@"D )L H0"K )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H
M_P#_    ]@   .@   #<    S@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K
M *H - "H #L I0!! *, 1P"A $P GP!1 )X 5@"< %P F@!B )D : "7 '
ME0!Z )( A@"0 ), C0"B (L M0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R
M    XP   -(   #%    N@   +$   "K  < I0 . *$ % "> !P F@ E )<
M+0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ") %4 B !; (8 80"$ &D @@!R
M '\ ?0!] (L >P": '@ JP!V ,0 = #K ', _P!S /\ < #_ &X _P#?
MS    +\   "T    JP   *$   ":  ( E  + )  $ ", !< B  > (4 )@"#
M "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X =@!4 '0 6@!S &( < !K &X
M=0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B /\ 8@#_ &  _P#,    O
M *\   "E    G0   )0   ",    A@ ' ($ #0!\ !( >  9 '4 'P!S "8
M<0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!=
M 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\ 5 #_ %0 _P"^    L    *0
M  "9    D    (@   "!    >0 " ', "@!O  \ :P 4 &< &@!E "  8P F
M &$ + !? #( 7@ W %P / !; $( 60!' %< 3@!6 %4 5 !> %( : !0 '0
M3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0
M"@  A@4  'X   !V    ;P   &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0
M)@!3 "P 40 Q %  -@!. #P 30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!]
M $  C@ _ *( /0"X #T W0 \ /@ / #_ #P _P"L$   GQ(  )02  ")$0
M?P\  '8,  !N!0  9@   &   0!9  @ 50 - %$ $0!. !8 2P ; $D (0!(
M "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L /0!3 #L 70 Y &D -P!X #8
MB0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8
M ' 2  !H#@  7PH  %@#  !1  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$
M/  F #H +  Y #$ -P W #8 /@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K
M )@ *@"M "D Q@ H .H * #^ "@ _P"A'   E2   (HA  !_(0  =1\  &P:
M  !C%@  6A$  %(-  !+!P  1  & $  "P \  \ .  2 #8 %P T !P ,P A
M #$ )P P "P +@ S "T .@ K $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4
M(0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28  (8H  !\)P  <B4  &DB  !?
M'0  5Q@  $X3  !&#@  /PL  #@%!P T  P ,0 0 "X $P L !@ *@ = "D
M(@ G "@ )@ N "0 -@ C #X (@!' "  4@ ? %X '0!M !P ?@ : )( &0"G
M !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M  !Y+0  <"L  &8H  !=)
M5!\  $L:  !#%   .Q   #0- @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @
M B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'
MNP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W,@  ;C$  &0N  !;*@  424
M $D@  ! &P  .!8  #$2   I#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""
M%PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI  X,>P .#)  #0RE  P-NP +
M#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F
M   ^(0  -AT  "X8   G$P  (! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC
M ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0
M!1#O  80_P"2,P  B#<  'XZ  !T.P  :SH  &$X  !8-0  3C   $4L   ]
M)P  -2,  "T?   F&@  'A8! !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0
M*  +$3( "A$\  @22  '$E4 !A-E  03=@ #$XL  12@   3M@  $]$  !/N
M   3^P"0-@  ACL  'P^  !S/P  :C\  & ]  !7.0  338  $0Q   \+@
M-"H  "PF   E(@  'AX  !8: @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &
M%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D  !B?   8M0  %]   !?M   7
M^P"..@  A#\  'M"  !R0P  :$,  %]"  !6/P  3#L  $,W   [-   ,S
M "PL   D*0  &R0  !,? @ -&PD "1D-  89$0 $&18  AD=  $:)   &BT
M !LX   ;1   '%$  !Q@   =<@  '8<  !R=   <LP  ',X  !OM   ;_ ",
M/@  @D,  'E&  !P2   :$@  %Y&  !51   2T   $,]   [.@  ,S<  "HR
M   @+0  %RD  ! E @ +(@D !2 -  $?$   'Q0  !\;   @(@  ("L  "$V
M   A00  (4\  "%>   B<   (H4  "&;   AL@  (<T  "#M   ?_ "*0P
M@$@  'A+  !O3   9DT  %U+  !420  2D8  $)#   Z0   +SL  "4W   <
M,P  $R\   TL @ '*0@  2<,   F#@  )1(  "89   F(0  )BD  "8S   G
M/P  )TT  "=<   G;0  )X(  ">9   FL   )<P  "7N   D_0"(2   ?TP
M '90  !N40  95(  %Q1  !33P  2DP  $%)   U1   *T   "$\   7.0
M$#8   HR 0 #, <  "\+   N#@  +1$  "T6   M'@  +2<  "TQ   M/0
M+4H  "U9   M:P  +8   "R7   LKP  *\L  "KN   J_@"%30  ?5(  '55
M  !L5P  8U<  %M6  !350  1U$  #M-   P20  )48  !Q#   3/P  #3T
M  8Z    . 4  #<)   V#0  -0\  #04   T&P  -"0  #0N   T.@  -$<
M #17   T:   -'T  #.5   RK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J
M70  8ET  %M=  !/6@  0E8  #92   J3P  ($P  !9)   .1P  "$0   !"
M    00,  #\'   ^"P  /0X  #T1   \&   /"$  #PK   \-P  /$0  #Q3
M   \90  .WH  #J2   ZJP  .<@  #CM   W_P"!6@  >5X  '%A  !I8P
M8F0  %=B  !)7@  /%L  "]8   D50  &5,  !!1   *3P   4T   !,
M2@   $D$  !("   1PP  $8/  !&%   11P  $4G  !%,P  14   $50  !$
M80  1'8  $./  !"J   0<8  $#L   __P!^80  =F4  &]H  !H:@  76D
M $]F  !"9   -&$  "A?   =70  $EL   M9   "6    %8   !6    5
M %,   !2!   40D  % -  !0$   3Q@  $\B  !/+@  3SP  $]+  !.70
M3G(  $V+  !,I0  2\(  $GJ  !(_P![:0  =&P  &YO  !D;P  56T  $=L
M   Y:@  +&D  "!G   490  #60   -B    8@   &$   !@    7P   %X
M  !=    7 0  %P)  !;#0  6Q(  %L<  !:*   6C8  %I&  !96   66T
M %B%  !7H   5KT  %7H  !3_@!Y<   <W0  &EU  !;=   3',  #YS   P
M<@  (W$  !9O   -;@  !&T   !M    ;0   &T   !L    :P   &H   !I
M    :0   &D#  !H"0  : X  &@5  !G(0  9R\  &<_  !F4@  9F8  &5_
M  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z  !0>@  0GH  #-[   E>P
M&'H   YY   $>0   'D   !Y    >@   'H   !Z    >    '@   !W
M=P   '<   !W 0  =P@  '<.  !W&   =R8  '8V  !V20  =5\  '5W  !T
MDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%@@  -H,  "B$   :A   #H,
M  2$    A    (4   "&    B    (D   "(    AP   (<   "'    AP
M (<   "(    B    (@'  ")$   B1P  (DL  "(/P  B%4  (AM  "'B0
MAJ<  (7'  "$[P!FA   5X8  $B(   YB@  *HP  !N-   /C0  !(X   "0
M    D0   ),   "5    EP   )@   "6    EP   )<   "7    F    )@
M  "9    F@   )L   "=!P  G1$  )TA  "=,P  G4D  )QB  "<?P  G)P
M )RY  ";X@!:BP  2XX  #R1   MDP  'I4  !"6   $F    )H   "<
MG@   *$   "D    I@   *<   "F    IP   *<   "H    J0   *H   "L
M    K0   *\   "Q    LPD  +,5  "T)P  M#T  +55  "U<   M(X  +2L
M  "TS !-D@  /Y8  "^:   @G0  $9\   6A    HP   *8   "I    K
M *\   "S    M0   +<   "V    MP   +@   "Z    NP   +T   "_
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M____________________________________________
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M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______GR[>IG96.B82 ?'AT<&QH99#_________________O&I(+1D*
M             #'__________________P                        /_
M_________________T(                       #<________________
M_XX                       "R_________________\X
M          "-__________________\I                      !K____
M______________]:                      !.__________________^&
M                       T__________________^N
M       >___________________4%P                     *________
M___________Z/0                      ____________________90
M                    ____________________C@
M    ____________________O!D                     [___________
M________\4X                     V/___________________XL
M                O____________________\Q#
MH?____________________^1&0                  >O______________
M_______R= H                17_______________________Z'03'RPX
M15-B<H6;M-+U___________________________7Z/3_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________OW\_'N[.OK[/'_________________
M_]FRF8=Y;61=5E%+1D$\.#(M*"/$_________________TLE"P
M          "2_________________X@                       !F____
M_____________]<                        ]__________________\S
M                       8__________________]L
M        __________________^=                        ________
M___________)#                       ]O_________________Q-0
M                    W___________________6P
M    R___________________@@                      M___________
M________J08                     H___________________TR\
M                C?___________________UX
M=____________________Y,'                    7O______________
M_____\U#                    0/____________________^'$
M            '/_____________________87@                   /__
M____________________OTX       X<+#Y2:H:ER/__________________
M_____\)\C)JGML76Z/W_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^[AU\_)P[ZZMK&MJ:>FIJ>N_________________[Z&
M;5M,0#<O*"(<%A +!      4_________________]<%
M        __________________\T                        ]O______
M__________]V                        TO________________^P
M                    LO_________________A)
M    EO__________________40                      ?/__________
M________>0                      9O__________________H
M                4?__________________QR,
M//__________________[DL                     )_______________
M_____W0                     $/___________________Z,6
M             /___________________]A,                     /__
M__________________^(#P                   /__________________
M___+4P                   /______________________I3@
M  D=-$YKC/_______________________YDY0U%?;GV.H+7+Y?__________
M___________________K^?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________KS+FLH9F1BX:!?'AT<&MH9F9H\?________________]A13(C
M& X&                GO________________]^
M    =?_________________#                        4O__________
M_______[-P                      ,O__________________:@
M                %O__________________E@
M /__________________OQL                      /______________
M____YD(                      /___________________VD
M             /___________________Y "                     /__
M_________________[DL                     /3_________________
M_^A<                     -G___________________^1&
M         +S____________________*4P                   )W_____
M________________F"X             $"E&9L3_____________________
M[G\=#!HH-T97:7Z5K\SN_________________________^>@JKG(V.G\____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________?7PZ^;BW]O8U-+1T-+7X/__________
M_______.GHI\<6EA6U913$A#/CHV,B\N,?_________________2)1$#
M                 /__________________0@
M /__________________?0                       /______________
M____L L                      /;_________________W3D
M             -S__________________V(                      ,7_
M_________________XD                      *__________________
M_Z\B                     )G__________________]9(
M         (+___________________]R                     &G_____
M______________^A*                    $[____________________3
M7                    #/_____________________EBX
M !4R4G?_____________________X'(3   !#Q\O0EAPBZC([/__________
M_____________\IO;GZ.GK##V.__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________^>#2R,"ZM;"LJ*6BGYV;FYR@I_______________
M____@F162T,\-C K)R(=&!,."00  -3_________________D@
M             *W_________________S!X                      (O_
M________________^U(                      &W_________________
M_X                       %'__________________ZD;
M         #K__________________]!"                     "/_____
M______________5H                      S___________________^/
M%                     #___________________^X/@
M      #____________________E;0,                   #_________
M____________GS<              ! O4'3_____________________W7(4
M      87*D%:=92VVO_______________________[Q81%1D=8::K\CC____
M___________________________2S>'Q____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________\^_K[_?______
M________________[KFHG9:/BH:"?WMX=G1R<W5X?Y#_________________
MZT\Z,"@A&Q40"P<"         "/__________________VD
M          #__________________YL*                      #_____
M_____________\@Y                      #___________________!C
M                      #___________________^*#@
M      #___________________^P-                     #_________
M___________56P                    #_____________________A1H
M                  /L____________________L4D              !@Y
M78'_____________________Y7L>       ,(3A2;X^SV?______________
M_________[M8*3E)6FR E[#-[?____________________________^SGK3%
MU^O_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________Z[^?AW-G6U-+0T-#1T]G@Z_?_____
M_____________[B*?G=Q;&AD85Y;65A75UE>97'__________________[\Q
M'Q80"@4               #__________________^U6
M      #H__________________^"!                     #,________
M__________^K+P                    "S___________________25P
M                  ";___________________W?!
M  "%____________________HC<                 !2N4____________
M________RV$"            #"Q0=I[1____________________]8TP
M   -(SM7=IF^Y?_______________________\-C&"H[3%]TC:?&Y_______
M______________________^H?Y:HN]#G____________________________
M_________?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________=SL6_O+FVM+.QLK*UN<#)U>/_________
M__________^7;&1>65513TQ*2$=&2$M066:A__________________^G)@X'
M @                !6___________________.4
M   Z___________________T>0L                    A____________
M________GS(                    .____________________Q%@
M           (,5J$____________________Z7\?           &)TMQFL+I
M_____________________Z=)      (7+TIHBJ[5_/__________________
M_____]-U'B8X2EYUCZO+[_____________________________^N<H68K,+;
M]O__________________________________W^______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________O[*JIJ.AH)^?H:.FK+3 S=WL____________
M________BEI33TM(1D1#0D%"0T=.66E]____________________GBX&
M                ____________________PU8                  !5!
M____________________YWL:              DT8(NT________________
M_____Y\_          0E2G&9PNO______________________\9F#P   !,J
M1&*#I\WU_________________________^N.-2L^46B!G;S>____________
M__________________^^=G^4J<'<^?______________________________
M____TMCS____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________V\O#O[^_Q\_C]________
M____________________^+"?FI>6EI:8FY^DK+;"T>'N________________
M_____HY02D=%1$1$149'2U%::(.I_____________________Z9! 0
M    !S9CC[KA_____________________\9E"@      !"=,<YS$[/______
M_________________^6(+P  $RI$8H*FS/3_________________________
M__^K4#9*87N6M-;Z_______________________________2AWR8L<OI____
M________________________________U,[M________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________MY>/CY.;H[?'Y____________
M__________________VQE)*2E9F=HZFRO-#M________________________
M__^=4T=)35%68'.*K];\__________________________^R5@ :-5!MBZ[2
M]______________________________-;SY?>YFWU_G_________________
M_______________NGX.FPN'_____________________________________
MX\[K________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________
M
M
M                                              #_____________
M____________________________________________________________
M____________________________________________________________
M_____________________________________P    #_X4%?:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60]
M(E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y
M+C$M8S P,2 W.2YA.&0T-S4S+" R,#(S+S S+S(S+3 X.C4V.C,W(" @(" @
M(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @
M(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O
M(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F
M(R(*(" @(" @(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]T:69F+S$N,"\B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N
M<RYA9&]B92YC;VTO97AI9B\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C,M,#<M,C!4,#DZ-#@Z,3 K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@
M,C Q-CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C R,RTP-RTR,%0Q,#HP,#HQ,BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C,M,#<M,C!4,3 Z,# Z
M,3(K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QP9&8Z4')O
M9'5C97(^36EC<F]S;V9TPJX@5V]R9" R,#$V/"]P9&8Z4')O9'5C97(^"B @
M(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y0:71Z:2P@2V%R96X@*$).*3PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O
M<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*
M(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYP
M<FEN=&UG<B!F:6QE/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*
M(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G
M92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H
M;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U I('8R/"]P:&]T
M;W-H;W Z24-#4')O9FEL93X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^
M>&UP+FEI9#HX-34X-3(T,BTU,61C+3<R-&0M.#!C-2UD.#@R9#0U,68S,68\
M+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$
M/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IC,3(P-#AE82TR.61E+3<Q-&,M.3@W
M."UF.6(T,&)C-C1D-V,\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#IB,6)F8C=E-2TT,S0U
M+38Y-#,M830W,RUA-F5F,&9D-S T.3(\+WAM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.F(Q8F9B-V4U+30S-#4M-CDT,RUA-#<S+6$V
M968P9F0W,#0Y,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,RTP-RTR,%0Q,#HP,#HP."LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P(#(T+C8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HW-6$X-#@Q.2UB.64P+6-C-#4M.#(S-2TV-6(T-3AF,3=F9#$\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C,M,#<M,C!4,3 Z,# Z,3(K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<" R-"XV("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HX-34X-3(T,BTU,61C+3<R
M-&0M.#!C-2UD.#@R9#0U,68S,68\+W-T179T.FEN<W1A;F-E240^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#<M,C!4,3 Z,# Z,3(K
M,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS
M;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-"XV("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C<U83@T.#$Y+6(Y93 M8V,T-2TX,C,U+38U8C0U.&8Q
M-V9D,3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O
M8W5M96YT240^>&UP+F1I9#IB,6)F8C=E-2TT,S0U+38Y-#,M830W,RUA-F5F
M,&9D-S T.3(\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#IB,6)F8C=E-2TT,S0U+38Y
M-#,M830W,RUA-F5F,&9D-S T.3(\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'1I
M9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @
M/'1I9F8Z6%)E<V]L=71I;VX^,C8X,# P,"\Q,# P,#PO=&EF9CI84F5S;VQU
M=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I;VX^,C8X,# P,"\Q,# P
M,#PO=&EF9CI94F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z4F5S;VQU=&EO
M;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(" @(" @(" @/&5X:68Z
M0V]L;W)3<&%C93XV-34S-3PO97AI9CI#;VQO<E-P86-E/@H@(" @(" @(" \
M97AI9CI0:7AE;%A$:6UE;G-I;VX^,SDR/"]E>&EF.E!I>&5L6$1I;65N<VEO
M;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS:6]N/C<S/"]E>&EF.E!I
M>&5L641I;65N<VEO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO
M<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  : (P# 1$
M A$! Q$!_\0 '@   0,% 0$             !P0%"  ! P8) @K_Q  N$  !
M!0$  @(!! $#! ,    $ 0(#!08'"!$ $A,)%"$B%A4Q0A<8(S-9EM'_Q  ;
M 0 !!0$!               #  0%!@<! O_$ #,1  (#  (! P,"!0(& P
M  $" P0%!A$2 !,A!Q0Q%2((%B,R04)1%R0S5W'38966_]H # ,!  (1 Q$
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M]I;?Q/\ '7F&Q_P/:=[P]EN][UI:ROMKG+XG$9K/GW[LO66$,E3+J]/;78X
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)3T+U7Q>EZ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g451428g00z04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g00z04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>:4&AO=&]S:&]P(#,N,  X0DE-! 0
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!:P           "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$
M)@      #@             _@   .$))300-       $    >#A"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8              *$   %F          $
M     0             !9@   *$                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   "A     %)G:'1L;VYG   !9@    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !3A"24T$#      -)     $   "@
M2    >   (<    -"  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 2 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M5KVW-;^E:YME6$W[3Z?^&6*3 )B? #NMAGU:S6YSL6NS:Y^,7OM:T@$E
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" "0 4$# 1$  A$! Q$!_\0 '@ !  $$ P$!
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MZA@*W0[W:X-TC^L%*2W-CMOAM922.:T5EIU/=+B%I.""*HG,&IJF*5O:<?\
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MC^NI5?"4U55)3>.PJNYCD%(]]JMU.JHB0G8+N#ME88-5! 2>IB(V)Z4H]P=
M4-Z&Z]2T[6D=M-OBNI2 I,P-@@$82XR\I0ZD]RTGMCM4Y875JDO-J)VE@K((
M!R4N(2/'R6K_ !VV! XU:Y*/4(-H _/J"27[_IZ_JYK:K7A/F?F'YU<PXVZ[
M*/4(1J _I27_ !#TQ3"3XGYL?@57+['#7W^)FO\ J4?Y,XP/(?,*XVI\U?3^
M=7?C^/\ 0X]<JR,,U Y3=P&\I,!#I\OD 9SBF,=CT]O?Q]I]E7DC(EG%-R-V
MB)$DR !2E(4"@4      /N?+%*]/%*PQY_:P?;4XO;!B8EJL]F:\FRN46S;H
MBNNZ6KZPK.T4B%$#B?W8J^5*! .<YDBIE(8QPZ3NFY:8=WC+60EMTJCK43@)
M#N DGV;P@'/0 Y\,5'W1DOPG4I&5(PZD>91G(^8D^/;&,UJ;" @(@(" @/00
M'T$!#Y@(?0(9N.J/7S%*8I3%*8I3%*8I3%*8I3%*G/\ !LKRY";KM0I"#9<U
M7@"+"7H!EFH2$@=,#?3VD=E,( '0.OSZYK_7#H_Y@SD9!><(\<'8G/T59-/H
M_;"\=]B,_%DX^FIR<U_5DIBE,4IBE,4IBE,4IBE,4IBE,4K!KQ%=7/\ :7%F
M[MH=FH_FZ8YC+]&,T$C*N'!8!15*8(B4I@,*B=??R[DA"E5,L=N5 B8J*$,6
MP:8F)AW>.5D);D!<9:B< <W!;)\.KJ4#K@ ').!4;=F%/PG0D$J;*70!U)V$
M[AC[@J/B>G3K6J9FX*I-,4IBE,4IBE,4IBE,4IBE,4J8#P=:^NYW%M2TE1$6
MT/K9O *+]OPD7L=FBY!%+NZ_-1.KKF[0 >H)@(].A>M*UNX!!ALYZKEEP#S#
M3+B2?D+H'RU/6!),A]>.B60DGVK6D@?+L)^3Y]AC-:5:J8I3%*8I3%*8I7PQ
M2F*8IB@8I@$IBF !*8HAT$I@'J @("(" AT$/0<4K6P\1SAN32MK7VY06@$U
MI=Y94\C%(E $ZA9GQU'"[1LF0A03@I)3O7CD_B*Q6%9B42-P9IEVGI>]^GL"
M%(43+CH 2LY)?92  HDGJXGLL_OAA7?<34+M;_1W"^T/K+JCE(&.6L]< #H$
MJ_>^1R.V*BWRVU#4Q2F*4Q2F*4Q2F*506P]DU/5\$>?MC_V1L)Q1:-DB"L^D
M'(%[O9V38H@953IT,<PB5-(@]ZIR$#KGFZZAE.]9P.W;))\@/\#SKLE)4<#O
MW/L^.ORX6EW?X@&[4]6Z'I,+6ZK#(EF+]LN^JR+^)JE=*?M\Q:.@SM!6FY10
M!9P42C(.#NW(BLX.VCVSUVV@[A?VH#)=4WD;MJ$DY6XKOA*00   25%1"1UP
M3A)SXMO7)7L"L8&5*QZJ1X$]R<^ '4GV FMUWC=Q[J7&K6K#7M677DCE6/(S
MT^[03;O)Z97*4KA\J@D90K=$I2E19M/.7]F;D*F*RI^]0^L;I<W[K*5)> 0,
M!#;222EIL=D@D#<?%2L#<>N , 6V)%;ALI902K'5:R %+4>Y('8>0[ >9R3?
MW(VLJF*4Q2F*4Q2F*4Q2F*53MND)^)J]@E*K IVFR1\/(/(*MK2:<,E.RK=L
MHJRBCRRR#I*.*^7*1N+Q1NN1OYGF&2.!>T<.XO2X\"8_ B)GS68SSL2$I\14
MRY"$%34<R%(<#(=6 @NEM81G=L5C!D;3'@2[I;XMUGJM=MD3([,ZY(BJFK@Q
M7'4I?EIB(<:5)+#94YR4NMES;M"TYS5D] <EJ=O=I*1B3)]2MF5,Q6U]U991
M!"T51\!A2.(IF(C[TAU52C[#-LTO9':1DSB5!0_DEKFE=96_4Z'F VY;;U"
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M4I>*36]C5.=I-OC49:NV./6C9-BMU %$%B^ATSAT.BNB<"K-UDQ!1%8A%""
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MYG'TUU S_C-6EU_X9W.;E_+JV">A;-$UU98 8P\2*<=",&BIC"1!6=FW,77
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M-JS1-WV?*[9UI8]C1D(QL$' O(=&FR[V%MD=*K2:!V9$X=[%R9?>1%^CSV=
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M)KLF[#KZPGIL^F=LT75*K6,GF8/+0^O*:YVDC'(JQH%:"U.B"(,%E5SNE%"
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M[X1K@V5 -!"(:$LKCE*@5%9R4@'C9.%CVW:SK=+L7(3:\O<:GMR&W+!;5?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g451428g01a65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g01a65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %RR^63(X0DE-! 0      '$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  AR<C4P.3$V-QP"!0! 36EC<F]S;V9T(%=O<F0@+2!0<F]J
M96-T($9A;&-O;B M($9R97%U96YC>2!3+31?1$9)3B!$<F%F=" W+C$X+@ X
M0DE-!"4      !"-)GWT#\N(\(4%\<0./3>1.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0&1"AR         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             6$   /^          $                          0
M           #_@   6$                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   6$     4F=H=&QO;F<   /^    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   %A
M     %)G:'1L;VYG   #_@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    "CA"24T$#      ,A0    $   "@    -P   >
M &<@   ,:0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ -P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M1P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
M)VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@
M6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V
M.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W
M=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @
M(" \>&UP.D-R96%T941A=&4^,C R,RTP-RTQ.50Q,CHU-SHQ-RLP-3HS,#PO
M>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*
M(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C,M,#<M,3E4,3,Z-#(Z,C4K
M,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A
M1&%T93XR,#(S+3 W+3$Y5#$S.C0R.C(U*S U.C,P/"]X;7 Z365T861A=&%$
M871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XP+C @*%=I;F1O=W,I/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @
M(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^<G(U,#DQ-C<\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @
M(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O
M<F0@+2!0<F]J96-T($9A;&-O;B M($9R97%U96YC>2!3+31?1$9)3B!$<F%F
M=" W+C$X+C(S7RYD;V-X/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.D%#1#%&,S(S,#DR-D5%,3$Y.3,P.3@Q-C)#.3DT-#-$/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.C Y0D(U14-#,#8R-D5%,3$Y.3,P.3@Q-C)#.3DT-#-$/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z,#E"0C5%0T,P-C(V144Q,3DY,S Y.#$V,D,Y.30T,T0\
M+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI
M<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C Y0D(U
M14-#,#8R-D5%,3$Y.3,P.3@Q-C)#.3DT-#-$/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 W+3$Y5#$S
M.C U.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z04)$,48S,C,P.3(V144Q,3DY,S Y
M.#$V,D,Y.30T,T0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C,M,#<M,3E4,3,Z-#(Z,C4K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T
M97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I
M;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D%#1#%&
M,S(S,#DR-D5%,3$Y.3,P.3@Q-C)#.3DT-#-$/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 W+3$Y5#$S
M.C0R.C(U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#YX;7 N:6ED.D%"1#%&,S(S,#DR-D5%,3$Y.3,P.3@Q-C)#
M.3DT-#-$/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z
M9&]C=6UE;G1)1#YX;7 N9&ED.C Y0D(U14-#,#8R-D5%,3$Y.3,P.3@Q-C)#
M.3DT-#-$/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,#E"0C5%0T,P-C(V144Q,3DY
M,S Y.#$V,D,Y.30T,T0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M_H=_!MWY+WR*0K@W[X3OXH <$Q6!+KWP4@4,4@J=SW '$"B/=" 8!^N , 8
MP!XO'@'IIR,>L5N9%\S5*Z!86IDW*"A7(-P$5Q;B4X@L"( (K"F)@3 !$_<X
M![@" @ @(" AU 0\(" ^(0'S@. >N=VU3<)-#N6Y':Y#J(-3K)E<+)I?^D.D
MB)@44(GU#NS$*)2?_2$, \!?L05<H"]: LS2!=VB+A$%6J!B]V"SE,3]V@D)
M/XX**@4@E_C /3PX!^3:7BGJ"[IG)Q[MLV QG+AL];+H-RD(*AQ7625.FD!4
MP$YA4,4"D 3#T+X<0] >XBLBX237;JIKH*D*HDLB<JJ2J9@ZE.FH03$.0P"
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M;)TEA6Z[HK=,W?5IZ-I"NR"%_@_CJ*O<2Q<K2$5+'#SIH8(5]&IN%@?I@S?
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M$FXD))"7!E'S$Y5X=--XM*F5;SJ4;57+[%2VH;CR[]GM+)<P*, 8 P!@# &
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ME*.92(<0BM8+&ILXV/A6;9'N37KZJ>=+0Z9YWU(U/=6DTJ9:XL=G%I+B'?\
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MGJ_9V6Y BCR:\LOLUO2=R4_96V3E7JXOL^()^9B!@# & , 8 P!@# & , 8
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M\-L+;+B3CO>%LA("5[MJC),CF7!A[U4!< 174,10"1II*=7[")IVJ7RYB48
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M7%>)'9\&98T;\2FGO1;K[]4XC&*[XOQ*92R 8 P!@# & , 8 P!@# & , 8
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M(AYD?15Y#>J.WY<-UQ7B3%9\'X&6-&_$II[T6Z^_5.(QBN^+\2F4L@& , 8
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M1V?!_#SK0L^T;\2FGO1;K[]4XC,<5WQ?B4RED P!@# & , 8 P!@# & , 8
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MH"]T(B.R5\GUNKAGKQ;+JR#(\/$%AT542R,O) JJ"HJ3$@K(+)]"@3N$E%0
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M)JZ>+9IIYKUPND[%U6.5NPXW_P"-?.J"O;A<16ABIR$G+,UE4TG2"8:]Y(O
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ML[#.7Z97_P 9TJJA+9I:_P ?9-KA6\13*:_3T/YSLN.+[F(^D)G@#OC & ,
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MQ][B(BJI7TWI;;:Z3TCGM<<_>8^0V/\ A8/\J]QE_P"T/=E3_-@??T@.3O\
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MLYN[.^DW;IRN\7#N3+*+J";J!A#"Q8E2? D+1=B-A^U8=G7_ #.]&_['MO\
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M# & , 8 P!@% W)3F1R5WYM21XY:!U)?F%)N<%?Z*ZG8BY:RC9F\5<)!&C;
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MI.04923:;B*M9WDV:AN(N'>=Z6Q>*Z5GD\N$.W=N*2FS$# & , 8 P!@# &
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MD6T)%-V&.+%UN""27GS:RW$N\Q*, 8 P!@# & , 8 P!@# & , 8 P!@# &
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M9MUN@*LY-#O[%),#68[16>M-B4:-&C=ZN1>XL4VE*%G=^W=-82DG&Y+/,2C
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g451428g01a66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g01a66.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1M.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &S*^:6(X0DE-! 0      "P< 5H  QLE1QP"   "   < E  $%-A<F%V
M86YA;B!386YK87(< @4  U,M-#A"24T$)0      $$H]K@#HV+DUN6ACD_ZE
M]2$X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q :>            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$1       $     (   )    "0      X0DE-!!X
M      0     .$))300:      -!    !@             !T    \$    &
M &< ,  Q &$ -@ V     0                         !
M  /!   !T                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !T     !29VAT;&]N9P   \$    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   =      4F=H
M=&QO;F<   /!     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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MA)>-WIT_:6_H?TL-_2)*?__0]522224@S,NC"QGY.0[;56-2 2=3M: !_*6
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MN].O=_@'U_0?L39YH2$I3AZ@+_5_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(R0Q.$%YE[<7,C-1)30Y0G6X0U=A<7BVU?_$ !T! 0 !! ,!
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M^W(C]<JSWE8MG3ZB;!A;OB4336VYU]V'9K-/,O.['#[MT?M8D(!6PJN>[/(
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M4>9$?EAR.(Q&,S*C.O1D(?:4KD4=4CD*,(YE+Q.5(25%=HV:-B.UU#JR%E)
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M995:K5ELUG:!4AG]&1Y:[2*.UTXC))5LY_\ 7%SVT)UH-[^'0QO!WQ4F>O\
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M-Z^/S?U2V]MH3HVG5X96=IIV;8_PT_5*_9M2W #L2F,6X1<7F*M9:P<M==$
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MI>.!_"X8_/GSSQDS_P#K-W _<J'?S-4+\J<A^C3_ /7&_P#97_\ F9?]2?\
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MF"+IK1]-TNENE)I=50AMRZVCJX=36LNRU5N7+=*&M!8J[FS:9IK?>9([4;2
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M)97:221V+.[N2SN['DLS,26))))).6T18U5$541%"HB@*JJHX"J!X"@> !X
M\#QGMN<,Y8XQCC&?C(CL2X[\22TA^-*9=CR&'4X4V\P\A3;K3B<_92'&U*0M
M.?ME.<XS_?SBRJZLCJ&1U*LK#E65@0RD'P002"#\QG)69&5U)5E8,K \%64\
M@@CR"" 0?H<];7J\"J0$-5JN'&5ZMUT7!" 0(:%'&B P<9&;ACA@P?$;:BPH
M,&(RU&BQ8[;;+#+:&VT)2G&.79)))I'EE=Y)9&+R2.Q9W9CR69B222?F2<MH
MB1J$10B*.%50  /N ^_R?M/D^<]QSAG+'&,<8R!7D,']CY^G:UGJU2K/;MI0
M]@#Y<293]A,4$W58K%>LCL<OC!:RUZHV481.MA:P7%7N#>Z:-'GG[0<UG?(P
M#Z$^QF8]+>J\7J/KRRZ[B+JY!@E;_KL:Q5]FZPR!P8S6J]7 K=G&7&YWE@66
MKX@%"K4:'2R8:A)$"A[M9I-*B.YKT-C,8[R=6-J]K0NK:E1MMZ]US1ZY=LV3
M;M2ONH;!LR%NJKQ&HSPO69,K5=O:AL-9H\HY&BG+H*&%I*+W@.$KA_XM0S9*
M_964//T/'\N<C_JCQ14^OC=W57<NV;5LFC;+%5*D4T1K&7L;K/:J3K2C;WWE
MV)K@DYLO5.VV+Q:KBB\[[LPHS::\6UZ".U($ %S:1B1)L<PTQQYY^OR_ED:O
M!YK*JZ9VQYA=6T?\18J5(\CI@&!_%MSN&P[)\@QH[4[C?UB[7\Y9;E9)GN=7
M[R5B/%"+B?:AR4I#:$I97.@#C&.,8XQFAK)V%ID S,J-&A&]P7R$ZJ-,J6M(
M\4U@)+]N<I9N%ID2H=.I/W],J;LQX?.4C.518$I7HVKJUSJW7169-?K(K/4&
MTC/9)1TR)9%9^/"["\[QZ_6CR"1<M12D>4BD/"GO>M]GVYGIP[?>3TND-#,H
MDAVW4LDM+WV+D<OI]7'%-N-W]@;64+$ ;@2SQ#EA#?M7TWWGW:K=5A; O^OM
M.0:R;D&P],KE<,[#F1%S!ZX3RSUYE'*@P3G9;RC"80BJCQT'/QD_4#.<LR6]
M?=;^S[J;VCTZ,>WV>IT$5.P]FOK*E2QMI(S)$8V:ULY+%%9YNW@".O1AAC^(
M"6QRKC<7LK]L70_L4V6TGT&@Z@ZQGV=*.C<W.QV5/IZ&58;"SJM#1Q4=N]:#
MN!)FM[6S9G^ ^A3 >)IW:0UJC3FH-;:L20CELT&F@:L\6BC\"F2T@0/9B22:
M1^)$O,51!]MR6XTJ5)<PX\K+C[J\J6K9W3.F_P!GNG]/I/52P=7KZU)K"1>B
ML[P1JCS"+N?L,K N078\L26)).:+ZWZD/6/5_4G5)KR5!O\ <W]HE26P;3U(
M[=AY8JIL>G%ZHKQLL*L(HU[4 5%4 #:?,YG5L<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8RL3R.>/:+Y 2/6BNV"Q8K>O\
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M,N2XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&4/\
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MK=@/DJM0+FQFQ>CWC^KE33H_L?N\6_8-^T?5E?J=8(EFGXTE^' @VF-6MQ;
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MV6C6U;6SS]XU_6:"#/CM;Z9KQ<("A?@+5L"Z&+'8@50:L\:YW*NUUPJ]!U[
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g451428g01b69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g01b69.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %H:^5V8X0DE-! 0      #(< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  64&%N;F5E<G-E;'9A;2!4:&EL86MA<CA"24T$)0      $,(6#G) O"V#
MC@@']_L0UFPX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585
M  $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3
M &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M      X             /X   #A"24T#\@      "@  ________   X0DE-
M! T       0   !:.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,U    !@             #M@  "D$
M     0                         !              I!   #M@
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #M@    !2
M9VAT;&]N9P  "D$    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   [8     4F=H=&QO;F<   I!
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  Z * # 2(  A$! Q$!_]T
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MGISR[[1D,=8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( +8!^ ,!$0 "$0$#$0'_Q  >    !@,! 0
M            ! 4&!P@" PD* ?_$ %X0  $# P($ P0%"0(("0H#"0$" P0%
M!A$'(0 2,4$($U$4(F%Q%3*!D:$)%B-"4K'!T? D<A<E,S9BM.'Q&#0U0T2"
MDI.U&29%4U9D<W25LC=8UG66HJ.EIK/2U/_$ !T!  (" @,!
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M&L+\/Q/T$+2W6[4KU,6=EB,[%G%"N^4R?HM9 [X3S>B3WJN"Q!!V(/V;Q>&
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MT[D)04H.P'N Y][:<-GZY6?-@V3=7)>[90/\FO?YZ_<QB4$@A1#C;?-R*)4
M4^8,E&1@*5L#S@YR$[GE'$$7TT9\[Y LP9P<GWU,'JU\M?3"-9;*4I64$!:5
M8.P!R2A1Z$X(YDG.-SG<8'!AY%QMD/C=VOGGM #O<6U.0+MZ\(R##:FBM2DM
M!&$^Z%E2UJ!4G"<X&V4J.$H 2%#F)W"ECJ<@2;VWR^)!#<M(89L'W.?ZMHU^
MN4:2 L);<42DN<YP!]9:@5O9P25824A'*$C8X!&QL/S&UO5P0=,FT#F)+.6M
M^CVSOD'YY/&/L[:PYY?N>4%+YG<J2M/./+2&PW[KAV2=U<V^ $E?$%1< $I
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M)->J*1,D[:72R9<H3JI1&)CA<@ *N <("BHC\P!8!PQ *C627PH 41_-8[N
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MDIXI\H8@C/UZTWB3N"(@<$$#@@@<$$#@@@<$$#@@A"N"YZ!:L)50N"JQ*7%
M5R*D.?I7U)&2W%C("Y$MT#?RHS3KF-^7&_!E  ]A%;+@\1%3JCSE/TYMUV1A
M10JLUEK"$[XYV83;J66@1A;;LZ6"00'(25>[PTM"YK]VE2FS(! '4E@'TO?2
M!12C\Y;D+F_1^9RTYQ%DVC77>$@2[XN6=4%9YD0(SN([)(^JTT$(@Q<'9:8L
M,\XS^DSA0S95 5!YTP)L24H"B=PDJ883HX<<]\==2'*9203< G$^1&1#;Z@>
M-PY:7;='I 2J' 80Y[O]H7^F?"LD$*==YG$%1!)2A2$ $$#'*!L)<J7)![M"
M0IV*E#$;, H%3A)W:Q-VM&.I<Q0<W+N0<M>?U+.8:^L>I='T7TGU%U;K\=V9
M2-.K-N"[9M-BNML2ZLB@TQR9'I$)Q:%M)GUB4TS383C@+(ERVEN#D"CP[G$$
M"ZEE@#D5*MHS9C/)S"C"7 )N2^;W!?/D#GXF/(U&OCQ)_E"-;&Z/<>N%!M^Y
M[EJ<2%8EG71>=P6A8#-:K548IEOV/I[;E%@UB.U5I<B6Q!8JL^ )DQME$N[+
MI<D%,MS;*E4]))*YDE4Y@3,7@3,("4DJ4RR E  + 7:WO%R1)6LX4J"=!<W)
MR<ZFV9;5AI%X/R6?C;U:MS7:B>%S6&ZJ[>UG7G)KUOVK,N6KN5^N6#>]"IM2
MJ<2!#N:8_,J$RU:RU1YE!:H[\V?"I]7<M]=O&ETYRKM3\>MI4(0)TD84D@*2
M'PLML*@FV'WB 0S%\G<$0IW"F) L=VS?>SE_S/N,O32 6R$^2E7*5)425*"N
M527% $' (2"GW<X2M2OK$8U8#N[9N_7D-#K<BS#>'MU^77?Y<\KLV_K_ +*T
MNM"L7UJ%7:?:]J6_&\^J5JH+<0RREQT,QV6V6&Y$N;-ERWFHT*GPH\F=/D.,
MQ(;#TAUM*LBGI)U5-ET]-*5.GS"R$)#N0'+N62@ $J4HA*0Y) BBJJY%'(F5
M-5-3)D2@%+6LV3<)2$@74LDA*4)!4M1  )811.R/RB-HWU84JIV[;K52U2FW
M=3;5LG3R#5)J4WBBM5!J'3:W!JDNB0Y,* A)E)J3,FF)ETZ6Q%C3&X_TI%<3
MU+7>T:JX7+XUPOB/ DR>V7"NT--V=E=G)=8%BOGUY*Z"LIZ@R4K-%44R)L],
M[N%("4R'6D54HQZ=X;_9_H^.5/9;CW!NURJCV5]H>P_$.W-9V\G<([H\#H^"
MHP<9X57</36S)0XO15TRGHU4GXY,PK75E")BN'52!T:AI?5'BKG-,M2U,,*F
M-Q'')$=J4IM"I+<9YYJ,X^RV]SH9=<9CK<0$K4VT5% [2EF:9<LS4H3-*$F:
MF6HKEIF%(*TH6I*%*0%N$J*$J4EB4))8>;9XD"?.%,N;,IA-F"GF3Y:94Z9)
M"R)2YLI$R<B5-5+PJF2T39J$*)2F8L *)ORUJP DX.2=@!GJHI .,  $XQCT
M X?)]SJWP=MLNEXJC/DY5;)"D\BPGG!2<E)RK )!*%9Y=SG SOL%*@+$L1F+
MGQL+OX,Y.8@W]?M^FQC82OD;*ARA*?)+AYB.0^8",D<HYDKY0D95AH\I&#A0
MIG"FN' #Y!FU(&COF\, 3<9N[N!^OJVL:UEUU?O%.2$@;!("0/=[;#&#DD]
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MHQ1%FY<4Y-A_H5Y*N5"7&N14=W'*%*6ILND+Y/-1R\8$REE3SBM+5_RAGW+
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MY4E1SUP,@[DGC/3[H 0, 8!A9VV;/:VD8JU+67.(NSNY?/R&7@.4'D-J2D+
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MP41$PK:6^9=[?2\RWIU*I+P>27I,*HQ41JG!<\FL)BS8-5337J2^J>W8FG6
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M:0B6&"=0<^98!R<R2YYM&NF3"HFY)?-^67HP=2C)QN5>_P"ZD9("!DJ.V.7
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M)5=)F(24W8@K2#<%PX/ZP!P"6 L6(8V8MH06?ZM'D1_X:?C _P#S2>(+U_\
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M[V=3+[Q:E$DXD)#$EGF!!86TB_@;.ZP 4H',I*C@$ C;/?)('*#DYV]1[&4
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M0=#D?R.XWXR*7_B)?^_^A453_P"$OH/F(K#E/+CE(4",$'8CWN;(/?=..7
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M !)(V),+ ;"$E*>5#8;*0GZJ0E(!2@ #'ZH"!L 0G) '&Z"@$I2@ %+!*4@
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M_6V^77;YFT2&MD#MJ->1@$*P,(2#MN=\$C?ICL?3Y<3Z]>OG$G+Y%G;T\#!
MQR)5\=DY_>1_7SX(CT?0RC!6/_5J/Q2<@'X$9Z>N!P.!F6B#<,&+C,DGE8L?
MG *4'KS#)ZJ01DD]<CIGXGYGB'!R(/C  UB&TL+GFZ3;Q^)C!30_55G)P<$$
MCUP/4;=^G$Q!LX&?@_2S&PN,\HT+0I6"O<G.1@_5QG.^!C)(QC;J201PP4P(
M(=]\K>A\($EM" 0^OB=;97SR=\XT+90IMQM: XEQ"D*0O"FRA6 H*04D*Y@2
M"#[O+D%)X"$K!24I8@@A5TJ!#%)!LQ!+AB\,"H*2I)*5!E)6DD*20000H$$$
M%BD@NX?I5-?@VT49<U-FT:UFX54U'H-4I,A;CB7J=;HJ#*_.D6W!+(12BY-\
MF<ZE!>*5LICQ$QX:EQ5]8S?9)V00.T,REH!*J>.T=12H$Q0F4W"U3T%7>\,D
M]W_X8_B B<;S#+P=S($JF4N2KN5'MU[?3!V3IZ_BIGTG9CB-'6GNTF55\832
MK 3*XO4=X36 4W>TZ21*[SO#/J#.JDHGIYL5'P&ZZV70XDB)$H%X2)4V2F53
M[:J@]MIS8\M$9]\5EJD-RFY'*HX@+DN1]B\A*"I:.V_[.:?_ $>=C:WLQVGF
MT%+5KX[6\7IZFB545$F?)JJ6@IN[J5_A99352U41*5,J6JF7(EA0F2E)/F?^
MV?257MB]I'#.W?86DXKQ"@E=E>&]GJR@XB:.FJJ.IX?7\6K!.HI:JQ25\.GH
MXFD*EA0G2ZY%7/4A4FH2M'1;PE:,W1I#I[48-X%F/7;CK*ZX_1V)3,INC,(@
MQ8;,5Z0PMR*[47!'<>EKB//1@@QF$O.+96H\I[:\<I.-\3E3*+$JGI9 ITSU
M(4@SU&:N8I:4J 6F4,02@3$I4^-12,0$<<]D78_BG8_L]4R>,%$NNXE7?CIE
M%+FIG)HI8IY4F7+F3):E2EU*^[*YRI"YDL),J6%J,M1BS;C?+C'4 \QSD*.3
M@IVZ<N,DDY.3T(XX;<WR8V#D?',7Z.P8\NUX*K!R2K*@K=62<D]B3WZY!/\
MON2<0R"5;@?MF,Q^HBM2;OIDQR&W0'+1GMR).H(]<$ X]1N.^!D9/7 P<[#A
MP7ZBQBL^OMU#W@F\WR**0I*AM[R3S#L2 <;_ #_CPI#@%B-P;6!VWS\"=6@$
M$7P"2KD 45'FQLG!.Q2D#W0DD]^A&,!(S"5,P9B[$V\7#<\MK0BV<:,"1EIH
MS>>NT6&L48M6DC_0E_#_ *?*XU=7_P 1,_V_T)C.D?PD=#\S#MXQXMAG7_\
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MT*A")2$HEH2B7+2$H0A(0A"$ADI2D,E*4@       ,(Y.&%F#"P =@ 6 PL
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MOON<<,;V?///+PR=OG:) )<@9>.>08N\'$))P._? ]3]F<9Z;[].G%"B"2D
MM8Z-YWNWA\K@& 'RA1;00$@XY4@G&WJ3R]<G))W/3.Y P#&60^@_;I]X"0.3
M_';X[=.4'$(V"A]IQD=!WZY'<D'T&X/"J)#@?MKY@6U^(B&>Y?/5KMRVUYFY
M&4&T))ZC ZA.^ #WW.3T&,DGX[;*[=2+-D!OU+ Z?2 L<O$ODV^N^V=M2#B6
MN;WEXY0#G._7KG)QOW&.^_7!2!@;L -+;V<C*]K9Y7=Q&]/OC;9&X/[2OCGM
MOCXC'IC@B<_ MUZV#'I\8V)2$] !GKUQTV]?L_EP>O@?IK$^O7QC=R$C;!V
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M9@YE+BY"1$29JDNC-_RNY8VM:[$<VRRN3[*(5KT*"E(;I[#RQ_SLI(E.$_M
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M\'R)WO\ OY6,'VF]N8YP ,;9(QG/3J>F,9'?TXKB&RO9@SYN-=C;+,/=C!@
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M^$W=T@Z@Y =+9<WSCV#5^U8%92MU*$Q9W+[DMI(]X[^[(;& \@]"=G$[%*B
M4GCTR2F8Y;"IK*'DXU'GL8OEK*;/9S[IRTR.ASY'6&%3:U<%B3/99+9>@K7S
M+BK4I49X$C+\%[&&W,#? QS##K6<<N%[\DX5#W3GL1R/T^(C(]V8'%B/B.H]
M<C$Y4:O4VNQ$S*:ZE8 Q)C+(3(85^RZUS'E(P>58RAQ)!0I7&0E06''ZCU^U
MHJ4D@NU\B[L1]_O>/CU HBZRW<II%+7<#-,D41FO*I\0UIFC29<:?*H[55+/
MM[=+D3H<2:_3TR$Q'I<6/)<94\PVM+A2@&<LX4SG"5!P"SL[6=G8L\*P-[6=
MSL1<L6WS&1SW?)Q'*=NFWV?$8Z9/V@XP>&+D8F SRW=KOH1YN^<,.?K]X0J5
M0J-;U,@T.WZ33:#1*;'3$IM(HT")2J73HZ<EN/!I\%EB'$CH420S&9;;3E82
ME)5GBP**O>)=1+J)))-[DDN23G?QA/RDVM=@+"V666W.S#.,GTDI!!R 5822
M?=.,\Q!&!G'4$DD'/;,$.]CM9@XU#[7^,/">M((."-\D#!SD'I\/UAV[9/%R
M5. K;W2?@0?,.>OA4H%V&I=N;%];Y;?#71#3BH0?A-C?<7T?[.)F!Y:QNE7Q
M8_6%&8ZB$^:":G4B.OTC,&_J)+I.>FPS^_OPC@IELQ9*>F0'T\.4(W^(IWLI
M1\"6'BS^4;&AG'Q/X#^CQ<,M/#*&A4;3]4 9(25$#KME1]/JC<]L ]>$42 H
MG4L->7GLV?,PZ YRRN]L]/A>_380?91T]3W^0SN?EMTQO]O%46PI-I&-LCX>
MG^\@]SW'"+) ;=X47+_3JVOCH_NFS0=:;)/0Y.,;=CTV^/7J1MPKX0PS+.",
MF^;O\(">8 U/P R(YWT:%%"0CE'52@2!\@3D]!C(P #L-QOL$?[>O65\H ]@
M1?EDP=N6>0T<%@T;TIVZ@'8GMDGJH?#O]HQG/$$C/KD#Z'C#1L2V2.8CW<G'
M09_K_=\4)"E-IXW^P\-/@1\ERXE,BNS:@^B+$92"MQP\HP<I2 !E2EJ) 0V@
M*6M1 2D\!4$BS!C?5F RU+LS[\XFY8"_KT8@RX;\JUR/FDV\R_$@NJ+8\H8G
M3$X(4IQ:#_9HY!RI*5 \N[KI!+8H=4PX4@DG3,G[#UK#A(2,2BWR&W4P=MZQ
MH\/DEU;DE2AA2(P]Z*R00059_P",+& ?> :!) 0O"5\94JG"64ME'-M ?KKR
M=FWC&FU!+I18:G7]/7,1(8&  !@#88Z?+C)8'X-X1B$O?76/N_7'V^O!Z]?'
M7E!!"+4Z?/$GZ/GPIYA2WH$P0Y3$KV.='Y?/ARO(<7[/+8YT^=&=Y'V^9/.A
M/,,TT]13U9FBFJ)%1^'G+IY_<39<WN*B6W>2)O=J5W<Y&(8Y2\*TN,20\94^
MAJZ7N/Q=+4THJ9$NJI_Q$B;(_$4LY^ZJ9'>H3WLB;A5W<Y&*6MCA46,&#S*W
MP3]AXRTA*7]X%^8]>LH0 "PCX01U!'SX9QN/C$Q@XXVRVMYUQ#;32%..N.+2
MA#;:$E2UN+60E"$)!4I:B$I )) !X54Q*$K7,4):$!2E+60E"4)!*EJ6IDI2
M "220 +O#(0N8M$N6A4R9,4E"$(25+6M1"4H0E(*E*4H@)2 220 "3$7VAK7
MI;?UU5VS+-O.DW#<%N16YE4BTUQU]A,=3WL[CD2>&Q!J*8SRFFI2X$B2B.M]
ME+B@5X'%^#]MNR_'^*5G!N#\7IZ^OH90GSD2 M4I4H+$M:Z>IP]Q5)E+5+3-
M73S)B4F8CWBY;F/'?9[VR[,\&X?Q_CW :SA?#.*3C3TLVJ[M$X3>[,U"*FEQ
MFIHU3I:)BY**J5)6L2IA"6 ?QG^.GPXU_P -OBPOJE:ATBO_ .#:_-1;DOVR
MKEI*&VA=%A7/<<BX9=.H%6GLOTYVZ[2BU5=NUN+-:+\:JPV*O)@?0E9H\N?V
M)13Q,D"4"D3I2,.%1=P'"%L&)20V)K@N+6CA*T^]B#X5-<7()%T_%P.3=(3[
MPH5;_* ^+RKL:#6;<].JFL%:B5&HPZ\[&KS%BQ'A$IM>NZX*C1X,&-$LZ@,!
MJ:_(E-MR9#O)2(1F5BHTR#) H4-&F7,4A:T(*):0Z3,-V#$DYGWB+ >81WBR
MH I!.(DZ/MEX?>T>WJWJ)#MJ@4*W*>7E0;?H],HD)4A8<?5$I4)B!&+S@"0M
MTL1VRZOE3S+YE8&<<<? :R@?#TS7^4.2[\R\;ZE2X=4CJC364NMG)2=TN-K*
M<!QIP8+:QZCW5#984/=X5<M*T^\''\IU!WY$7\=Q#A1#$%F;HSY;D7&Y&D1)
M-IE;LF<FHTR0X8W-A,A R@H*AB-/9SR$'( )RAPD*;*',!. N4N2<22Z39P]
MO]3?/+I&0E8F!B&.V^CAQ^T2]:MWP[C9*,"-5&D@R8*E9#H& I^,H[J;R?>2
M??:V2H$<JU6(F!?(C,?4;CY:YB%6G"Y9[6WW;KK\KPZG6QLH;I._IGX@D=?P
M/?8[6@MMDUX2^GF&<D]!<_/0N&3EHP#ND>B3G/IZ8V],@D'OPUA[R3X?,':S
MG7R!,YN&/7)LB-7VT@DZG??N"GOE0/1/IC;?^.!Q8&(!B$[;:?/UL0<R83'F
MBG&1CG3S)Z= 2 1Z9(4-P.G<;\"5 +<NP<78#1^>HZZ1)N#Y=1D?K":^!L1Z
M#.W<8!_@>,@?4D=#?ZQ0?,6/A$XV<,6W3!_H2?N]LD8XT]3_ !YG4?TB,R5_
M#3X_U&'-Q1%D-*^QFU*M_<B'[I\4\7TIPSY99VQ6W]U45S?X:O#^H1 #0/X
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MR/L()^>WWC.W88X9!S&WHP*%P>8\L_)WW8;0EO@G!SLG 23DX2DDI'?J2<#
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M'_-VF_W9/^N2.-34_P >9U'](C(E?PT^/]1AR<419#4O@9M:J_W(I^Z=%/\
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MT%T@;AB2VII1.-\!Y+&W0 DGIPBQ9]OKZ$.@W;?Z>C#3T\EH>@282E@+B/\
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MX"%M,N$A<I23GE6\G"&AL4M%:B/T@QBH3J?#[_:+EG0'K$KN>[S@)2>;8>H
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M#OL?PXM3D.@^40G,GFKS;[0F1SB;$R>LN,#\<NH_CCBW_P!6=\*OK$*_,-G
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M!P$@7)8;F  G($]+Q'=>OQA@+BT4)E2#E!EE)+#1.WZ%! +Z]]E'#0(&SH)
MQ9E2!:6RC_FT'3?Y?7*E4Q/O3+#_ "ZGKMTC*VM.:Q<3PJUS/2(D5Y27/+=_
MY1F(."D)2K:&P1LDK05A)PTRE)2X,16-3J42=WS_ $&C?"T9J5I0,"0SM^4!
MAZWTZQ/,&E4^D0VX5-BMQ(S?1#0.5*QA2UJ.5N.+ ]]Q:E+5W)XE!+MHS^8A
M%C75\_C&:AE)^&X'?^N@^TXZ'BR*X+D;;[#![=R.OV#\#G@'[\X(371@C;?
M_ ;_ 'D_AQ>-[,7-M7.O@VC_ %(3GNG_ 'G_ -RN&38IY$>45I_,?'Q][T(1
M'S@#?OO]OK]O%J?YO]1^D-?%EF!Y'Z O""^1O_UOQ.!Q;+S5_M'B'/UB%NS:
M$$D]+CXQ-%GY_-RFYW]R0?OF2.-74_QYG4?TB+Y7\-/C\S?QAR\419#0OTXM
M*KG_ $8?_B$3C(I/^(E_[OZ%15._AJZ#GJ--8K[&4,#X;_CG?XY) _V\;<A(
M.)V))>X8!K"PRZ[9Z1@H+N!X;V#?(!^;^"]'(*>NX(&/@=OPZ_T<),!*2+[E
MM@7]?:+49^6?I\O5H6XQZ ="K'_9.QZ=Q_7K418CD1%WHPN1]B!MT/\ 6?3B
MB$5F?]!A2:.<9[J.?^T?X8XA61Z'Y0[OZ\?K"LSG!5L!G.P],#OUZ#';)/;I
M4K(=-][O\2?@(#Z\<H,('4_9_'\-N%@@VRD'/4'&-L8QL?Y<*LLU@;Z_OZ^$
M,E+DO!G'[Q_/\<<5H%QX^O,0ZR&(U/W@<715";5J3 K<%ZGU*.F1&>&X.RVU
M@'E=97]9MU!.4+3\00I)4DA#V, +7$5UK5E7+94M=2HRWIU.02KVB.@J<;9!
M!\JH14YYD '!=0%-''.2PHA(08Y9Q).7RYCUX18<$P85 7^?(Z>A>%*DZ@4^
M2E+55;5!?V!>0E;L59QN3RA3K.3T2I+B0-RX.,I%2DV7[IWS!^%Q\&YQB+IE
M DH]X;$@'Z ^7+:'Q%G0YJ Y$E1Y*",Y9=0YCON$J)2?4* ([CC("DJR(/0@
MQCE*DY@CJ(-<3$0.""!P00.""!P01BM:&TE;BTH0D94I:@E*1ZE2B !\2>"
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M[F*LI+0)[,.M(2,D-GA"@'*WK;[-#!9'/KZ^;PQ5V+J'0B?HF:B>PCZK;$M
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M?QA8CTB6G +D?((W"W._7_FA]V.%[Y#NRLB#EX:_:&"27+VN6V9OO"PU3)(
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@@$C?'$JJUK204INX<:/Y^<+W <'$;$'X??\ 9K1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g451428g01b77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g01b77.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1T@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '02^="@X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      /$    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     < 00!0 $0 +0 M #(       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ "4S,P  0 " )3,S  !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             #*@  !R     & &< ,  Q
M &( -P W     0                         !              <@   #
M*@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M*@    !29VAT;&]N9P  !R     &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   RH     4F=H=&QO;F<
M  <@     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P![ND?6$9MV[+8YK+GNLK_:
M :0W>3L=^EW5>WV_R$1W2NK2ZLV%CVRS_E4$^K!:P/8YW^E'OK7H3C'4?2MQ
M*_2M:6U9((+R8]2VNRO8-C/^NOWJP[$Q'&74UN)&TDM!TGU-O'[_ +T_C\$4
M^9'IO5X>WUF@B7 GJLEK06!\^]K=K??[]O\ A4:GH'UAR??C"VUC20_T^J;Q
M,>UI<WZ/NVO7I/V>C7]&S70^T)V55U@BMC6 ZG: )/R2X_!5/G3?JM]:?;OH
MR>VXLZB1/[T-?O0;_JG]=7N>:6VUL(]C#FN<1I^_O7IH(.H4?5J]7T=[?5V[
M_3D;ML[=^SZ6W<AQE5//=?Z+U?J'U<P\'$>&9M1I-Q=:YGT&%MOZ:L/<_P!Z
MY:OZI?6"JVQE^1CVFMFZRLYUK','TA:[:S<QO]9>F?!<ZW(R,ZK%RCTYM.5D
M,)]8&N'V>AEM^R^H?T[FU_Z6VKT?W$A(C1-/,L^JG6GV!K#0_=M<Q@ZC<21'
M\FKW,L1!]2_K+,N961[I:,V]O)]FOI._FFKK\?%SVVX]KJ]CA74+ '@AI VW
M,]I#'?\ ;2UDN,HI\Z/U*^L4$-:V3NVN=GW:3/I^UM/N]/V_\8G_ .9?UBW3
MZ;(@R/M]_)VPX'T?S(?_ )Z]$22XRJGS>WZD?6EQ;Z+F5 "' YESY/CN-35T
MWU9Z+U7IO0\O"SG-?DW66.K+;'6#:ZME;!ZEC6N;[V.70R)B=?!.D9$JI\IJ
MZ!ELH8RUN*;*V"NQ[>I!LNT]^V'-98B'ZO9K" :L<:G=NZCKP]L-T&W:YS?^
MVET(ZT6.QJ!Z]%3*Q4QS7UU5NVR/6LKMIN<QKOSGLL>JN5GU9S\>RVFUWZ/T
MJ['NFRP-<X>YM==3?>Y^WVL0.0^"_P!OS<<?5W,WP:Z. &L_:0G<#[W.=M_=
M_,VIS]7LSD58\$P">I:;N2W_ *K8K]C,<S86$-=_-EG[S8_G&?Z';[?68[Z?
M^#3>M6&O!>RL;.2UI+C/T1NA_M>[V;7H>Z?!/MAHM^KF>(FO'< ';B>H"3N<
M/3</;[/38UU?\M)OU=Z@Z6U,QP7/8:WG/#BS6H[8'\[OV6[=W^F5UM%=S*WM
MAI8)MWM/TI9LVL/J[F[/>YGT/4_FV([;J6ES12TO#F-#G^TCW3ZGIM_SO]"E
M[I\%>V'_T.YQ31D=9&?CXS65W[F#-EP?::VNI>Q]%E;'5,J?7['[OTWTUN+G
M.C8-F-E8K[,5M;W,<TY9,6V#](]M-M#ANK;3N]D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $# D@# 1$  A$! Q$!_\0
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MJAFX<,S),1BKUJ\.OR$EE$;YQK###%OO)MGMKCY^$?AG#8U9GRT2*H)9F+
M#<DDMM7Q849C,L0%D:V-*!1)V[AO>_<+(]>V,#GTK_I&,=_]EGR?Y9SC/K25
M_'R^6/\ :+'S_+.,_)WN5P_]$CZ?OOYWV]>]@S,Y_P *V]55=_7KX?*">A%8
MIGTL'I%\8[YZL^3_ "QG/EO7^V<=_+/?X'G&/+Y^>?+[_@]RN'_HL?=^</\
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MS)&6D$(\V9LO)(ID$$@ $P81Q#60&##M6 "+O%M67E1QE](+D2 2JK:#(O\
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M7FA256.,5OI4-(RGM4MM9!I0,0?@N]%N'/761R]U/JN%>1KI]S]WR%0:JMY
MEVXHL7*Q_)O%&J:KU-UQ%=4F;:K54!I:@L)4EIGGF5)V>YA7Q560>-=T.D&3
MBRQGC02+'(QC]]6(1RVSB9&T$R!#J9 +*@"C1AU*SRO)RV8J64!@4+ZT "E6
M ?2A;8,20&U'8XE9<M^A&ME<Z;\/MZ#QQA0-UQ\4U0NB\RW8XSDWCLW@NJM>
M(6#C9S?FT=F^/WUW;*B@%5Z+JU<0P(*XU4/C5Q!A%5!GF$ F5Y;.2E820QJ(
MY1.XF I%T:8U1F)U,EZE*@BI"8%$NAE6AF%72Y)93&#'U8WJ<D"MF(H@XO0N
M..@@3F?E49@@Z<V?'=9KBG/3N!6^H"!K]UZE_3E'"XMG*;6[=4?%*&G<S;TN
M0K.M4:7KC0@#<VQ'"\6MRJZCT*:9,\88B&S D9SYR6@(Y3Z&TI$$RLK/#K [
M:QRV H,JZFI0(>8^T>D <NI1VQJ%LQ:50KE;[+,O>=!*BXW=%= Z1+1S;R?)
MS>VXW7<,*N1*PD2(N5+C"JM..-+#=78#:Q(;4MYTX@K9!=1K(RK:RN$<O*SO
MVIX+6H\>/5VK8L>UG),VL,7(60SF-F)B34G,5%(5E,$S .Y.@-REH$/*ITW'
M$L)9A(4"!E #, =))MK$B*&4"F-.;/94@[6?-=BZ<23_ $>#D6I\/:\;5VC5
M)+SWOQN_G9<@O):IS58XK\KY,J&;>U9+F#"C87V)(],K*2>V;V]H.H=-J^D2
M)ZJ0KF*X@NN8R-([0<Q=,:AX%,9C?0JD!]2E0S:-(+*'8EU<Q^\$JFD*HD"F
MW-.=09;O=>T-E)LZ6( TRJ=\AQ/>4.JL+G#D?I*Z@*A:.&^<]>D@1]S)1YJ;
M48=.0N,W5;KE2TJUZJ>>%8FM%"F^BU)LA=0LD+2I')TBP6=J^'M%58],65,$
M>:R[K-!YV5A?6UQRJS/JC?GU(07D4.M.&8D %)-5O+S'A=2K\JW6@ RZ0NEA
MRR5N@2K6* ':M.5"L] ;F\OD*6E=-!@%/-Z6$^Y?)_/U_I]:M7&]YI>MCZH>
M2@+/+RU7 G/*G'-L)"JE<IU9*VW6+,,M8./[H_ GE@<[YY8PS/F0S^=,!'!&
MS))&^G*QZ!"S"*5 79WV)HF1%:L-40%B (B 80=4C*"K*#,P)<=I32A5Z $!
M"0<8:D=.W1+R#BDQT^QTAWI>J32./*Q6Y^4V W,CKFQMU_B5 \^?CD%D=:%Q
MIW2>R631;8J$E=)$*F>5U&SL"QI.$LF8SD9?4'&AY)&;E Q+"O#]8]\TA"!F
M@W5]0.S$*1@"0OIHJ=050"P#ESF-)[%E@QB.YTZ?R@"0:?:\C=+G (=RKQ7"
MW$ ?&_*B;A 6 -OR'9QJAS3LAZK+HEO5JKP]3ZEN2+$L$XFH@RA4P'Q?54NM
MM2OK8^23UXY<GUA0YJ?2PGF,D1F-B-=<.K*HT:-KRT:DRN6:^6UH516#6<//
M*CM="!6$?5F"O4QU$:96-1K5VPW!9A5#&B[EA74$?*G)R;C]A"UH:?D*ZJZ.
MT@/T:#LJ@OLC(2M,(6>F<Z,834L(!$1^FV^IFDNI&NV<2]\[4)=HHFD!60QH
M9%JB'*@N"#T(:['<=JQ3>M3A3:ACI([5J'(4[$@[616U>.Q#?YQGS[]OEW\L
M?/..WS^W&._ECMG[_GCQ)_;]O#IAMCP[Z-^!OI[1UWH6:ZX/+'G]GSSC/E^#
M.>_?[._EWSG&/+/@^WV^U8!=$[]!0K>B220-A=75'I8O'Z.'HL_Z7CTB_M-5
MW_\ O*\>>\3_ +H9O^.?Z<;V6_ 1?P!B??BCB?'#K_)$_P#1]U_/?..W3CQS
MG\7TQY.[]_R^_P#5X[3R?_$6_P HD_V(\9&?_#+L#<:#Y6D^?8;^'AC0_P!N
MV<=N^?E_DQ\NWRQCZ\=OK[]_+.YBCU'Q$]*[K)[^\]U7M8H[4SCOMY]O+'W_
M -W&.W;Y_/SS\L?C,'0; ^/3ITL79(H;= >_"GI;TBLVVN/AF1RG=6Y *E8+
MYRAS!Q8RH_?<QR![:$]MQ-IHY(X<YVFBWVBSI)KOG7PC ,I! ((Z$ @^&QVZ
MX4-5'IN#MM1-=/DOU;BP1ONAY(ZFNC_D)SU%75E8..K&+;.5>M9VT07[A)S;
M.7>5TW(:R??I-8<-<DO:(U)X>14"U&9>.TL]QXT(7RZ-RSTMJPUB5XQHLMFX
MURZ!9%*19%0T<ZI%$T9K-K-&L@YS.@TJVB4'L@%*U"VTD3%WM2"T]AHRS.&%
MQ&-BIT!6%D$K6Y(-X6X74?T-7[FEGRUS=?.*+"@L7'73772:%'TW(U6P2%+P
MTSI?**=PP@Z6K@Z.OM7Y!" D6QTFVT-9)Q^=5\H>6BL4*OT>OL.7SL<(BA25
M2LF98/YRQ)+3B2)@#FD41M&3>M)&Y@?5".8TC.YD)<NQ2B(AIY7<(]+"Q"Q+
M*P!4!@-.G2]*%$*:_P Y\!XZH.F#ERX-RW%%X#Z<.#=VZ<5(WU86/E[@[AL3
M1)QX#&:D+$UU8<IIDB@JP,A9*EJKP>QE-*!Q'J3<:"?S7,Q(H62?,342RD"*
M:8ZI#3#I$6;2#KNA08[0AX^;$QLK%&EBFLR(@I.G>XTZC8KOH XD?7>J'IXL
M_4W1.H&+G^V<2A6OI=M/&G40HY)!Y'MEJNO(2?C^Z<(TLBT,^)N.):[<];(@
MVXQY):E94BK!6R%P89IK:H5PI-=LKF%RLF7\W64IFDERYC,2(D9D2>32)90R
M:3S8@+M@RUV22)!+&9$DYA4&,I+J#L68(T8U:$IK&ASL -))W"X0=2ZA>E&F
M=+)_27'<;P<<ZXHY+N#'E)% X7<9P=3FUU77KCAU#5#*0+R7\8%0\5<<<4"7
M$8H56L56VR;DJ(1)FK2-[09I\T,UH0!98D$3:3+YMRVCD!<2&+3JEDFT468H
MHU6 ,-#Q"+DVQN-F+@-HYE@H=.G58"*@8;46VJSAM[=U$\<WWTAG3;RX9:S+
M)Q)3'71#'8#GT3B$)=]S7CC@ZM\J;2+'T,$^D -GJ5A^(D:"^[//<MF,,IPA
M0Y4TJ9>1.'YB$*%E=<[I"T2W,EG:( KM91UK>UNC1%8:74S1L3:CD:B016A8
MPQ!(W'9(-=:L&M\9&VVJO(.F/K X!Y-Z@ 1N5=^J5%<ZKQ(T4<JM](C.,3^;
ME%]G7MEM.9<=K&W(32^(C@C?I$/$R'K\F]A.!P(FCG159LUE,Q%ESR?-FC:4
M-$-I.2R @N)&$81@1IV+=D&VI2P$4J22=OF:M%/^27#;A=%L6&]BZ&H[#"TX
M1YTZ7*;TI[TMC;*'4;1;N!N1^,.3T(_!YC_FA_R;8>H!/;E%WAY4Q3]P2^.(
M>&5">NB4<OD(!5BTINS"H[23XL\#)H,R^:UA)&1<Q'+$QGTPB)<N4:/E:B1(
M9F+&01%M#;/MHPJ/&L5 JI*,K#03(7:0$%6T^CH&D L!8W6^T)&IGGH\N6N4
MTG'D:BDVJAH.(>3+KR7RG5.*Z_46H(_!/)PW-]6+V(5\&=.RH3?D/AI1:N'+
M"&GX_P!)8VEJ0UTEO;\5ZO/#*Y7B$432$NDAFC2*)I6<'GQ<AAO/F"1',RSJ
M6DZ(S!8]3*) <N[ =EE5&+,%TUH?F*?P<8&I 8R%78L!;4"8I]%#WAX]=U+<
MO\IB]/M %"YGZ='@A7)/!RSE.G5>HVJY<K-.1J+2J$#2+GE0,_J@6:XLB55J
M->%N,AAV/K,HZRR([.=6;5EH8CF')AS*GESF)V=4B$<CR%DLJ_:)9B2"U!K9
M6CA*U([:!3PD:DUBB9"ZJH4T"HTT% !47755H7S'T([<6'CUU+P^$B-K[P!7
MQ+;^$')_, ',975)-;*SR0^YI34PEMMQ$IZ>\@U-W4$'*>YA D)]>"X],:EZ
MO/#1%GN8"QE+!U+2I,!"81E C1K"TE"5LQ;J[0D TQD"]G!J@TD:5 (-(R'7
MKYNH.9 H.@1=DJ&OJ MF\?'/'4!TY,^%.JCB[B6[\4@S\AV/IOY05I1.!T@-
M>,<5I)R^AY*X^XDMB;IRXU;08JFUIH1--MMXI7&CF)1)?5HK]@4S>,[LD&7S
M"S9665)3RTS$1;GL6 9HFCDF0YF53KT2:U1Y03RR5&E1&KNFB559-VC?\&NY
M&H.JGEQFE)72Q"G=@#9.I4]._._1))%TXD<\VU"<+Q/P;Q1QO<Z5;^)1+>C;
M@_RP74/;N3U(K)WP/S&U^++JA<J$<$!3)N.-;,,Z918Y82-JO&NG3,09W]T>
M;H099II$=)=#!O-\LD;%1F(%HND@)?FZ=(/*96)!')#[US"*5%4AD!%&24N
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M7/\ (SO+>?\ A4\<_7_O;V;Z\?\ I)G[V/P?N>#[XX>[+2_KI\^Q^C![GO\
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M>Q)4U.T+4U^R7%XBX5J'OOY<@TW*0VQTVU)IC!!"[AV)1F<AF5$U9JMT[EW
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M32!1;, 5'Q$[XZ?<M<<CUKK(X(NK01VU/CH="Y6=V&QW:&*G6@>=,.F.YIM
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MP&(^3*+DMKH5@UFNMR5RDKU;39RFNMF/$K&P$AUC8,%Y2&S+ZKO,K? PJ[*
MX/.+"#'RO(*,5B>[9?FV;$.LG,9Q#(@D9TS#2",L!+[WRF0, 25='*UM; D-
MI";+33%3YMEI%0LA1H5 84%#.7C##J=!461J( 6L8/CFO5B1V^L.4AR<5#$2
M;2JFU!@?'I0]1HY"[RPBN0; ABHJXI(TBN96A'N!;4<.1,J*E3,M](\I%EQ+
M+(0T%"0QIF@5DC6B!*586P4'4%[3TM5V:Q+G7S#PP0!US!,B%I(:".=0/*N-
MB$<C8[A+(W'4N^0H QQ;#L*G770ZHVN%#8+K2*Q5X;BU3:)+!K!8"(*ZW'A
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MM3X&"M?A\Z%)G6+;-:3H:/2"2M+C>,25-&WCW0D $DT "2>X "R3X #"@$D
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M[PZA#X^5XGGHX88H&C;ES\HLW+;0KNS$H9"0#O5T5:E%FL:F9X3DI<Q)+.9
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MDF.^-?+OVQVQH<2^Y_Y2Y1X5S^0DRL\T6;?*91>,Y&+-Y]<AEWSN<7(9"#B
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M;.Z0"(?I)7WWNT4\,13^D:C;N&:FH8GQ8(8(3=)%TJJ5MJM(8"C:R=3G4R#
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M"2,2!']:B5(Y .[M(I]5;X]?#\,QJ!],7^E!PEY_[]>_\&7(/Y>?CUG[C/\
M?;-_F;.?^9R/RX^9O^5:+^YID?\ ]6\+_P#Y=QKO[MZWZ8T&?EG\&/[W;\OG
MX^I\?G96QWK8WU-@&CL:[O5^KWU^S[^?P9S_ (_^S[/!A:V%$'POKN"/'YO
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MO]"UT\_M.<>_X,+?'POY1?W?XY_G?B7JW\\FOY\?L%Y!_P!X_D;_ /I;R?\
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MKMG7.=<[:XQG.,YQW[>.FS.3RF;54S>5RV:13J5<S!%F%1B"-2K,C!6TFB5
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M:67'J8&Q%!&[S>;4#Y_FZ#:BFC(Z2.;))H)\RUZ=#K!LX?E1QMJYYDFD;YU
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MN%2WV/N!_4!0FB%Z>18JM,WK3ZR*U3T117[;6AAQ0P\0[@ZIS;387I;%6V+
MWT&TA/D@R<B,T3&1'S'G;,IE=E=8N6L9Y8EYE[C2%U!F/0BP0F=21HLVH1H\
MLV5E<*JIVF2)C'K9#&QNM^QI&^U;8ZXXXHHO7]E'''[63:67V>FNGM)=L8QM
M)OZN,>O)MC77&V^W?;.,8QG.>V/'3XX'&O'?TF?! ?*&.(G=+YSK%MUYAAXC
M*ULW'4"4);"QL_'M'K_*+;8NPZGJN,K/=^6N+ZRE+8+Q[GG>_5JR,J2NI!VU
MIB+P5C)="-[I/)E@ZY[SQS;ZQ?:6_P"M$Z9%;J:]5V:M.81.EKI87E2JWB4H
MQ8?&,>(6"1N*5-K"6*0-)G6:&334P?;]N-@'@P8M32)11]IH 2F,FN=<8%"W
M"T(WQMMC&=M=F!@(W;3&?6V]<G7;.N,^IKOMVUS%-(\49=()<PP( BA,*R&S
M1(.8F@BI1N;D!H; FAB:"))I DF8ARJD$F:=<PT:T+ (RT&8FMCL-,1%GM%1
M9&MKF/HQ1\S<S9LMC87U?6'%V2\P/Z,J5\;1LG5AJBCB6I:*<7 EN2P6T9JN
MXQK\U@2 ;#-CW)4K2%M#.N1S(\%L_P 4'%XE&2S(R+<-G8Y$Q<-.:;-)F8 ,
MVN<]V.4L"1.8FRQBYCR2+*)-*%<=.O#N!GR>F8YW+'BR\8RP7B@S/%1D$X>^
M2S1;(-PT\ ,SYN3,1KF$SHS(BCAB>!H2TBOC9&"5,7!F6=<8LWQOMI[L=N!O
M/G7&-<XEQLM.8#^IMG.<:XS/B3OKMZT>N/5SMNP2O*FN3+S99M1'+G;+L]"J
M:\M/F(])NA[YJV-J!5\SF(HX9-$>:@S:Z0W-RZYE8P23:5FLOEI=0H$D1Z*(
MIB; O/$V(,,9U$_I<P?MA\1?PIU#Q;R'XW!_#_8<4.*?W/S?\4?I&&R_RY_N
M_7]?X_\ 'XZZ_'NH"J[AM8(WZ;_V#'GV*Y_N_@^WY]^_UX_+/ECP?V;;WOO7
MR^J_C.#"4O7\Y%R[_J5L/_-!GA&'9:O WT\/BZF_B[K!PY/37^$OTC$S:O\
MSLUW^H2C_F\?QP^/3L:GO3%X_F0<)?>YLWS_ .S+D'_M_%X]:^XS_?;/_F7.
M7_XG(X^9_P#E6_\ 5ID>FWE;PO8FK_Z.XSC0;^7Y?EC^YX^IL?G77>0?96_J
ML>'KH]X %+@\_P O[WG^7]_P8+OH0:WKI8&UDGU=;&]5T-ER^$>WW=^ ,?\
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MR6#_ &A=_P!2&7_N4WC(QOXXGA<?Z5&__@0_B_T/7]WM]_\ #YY\??R>@O\
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M]IO?VT+\"/[*KFF]9'R_E3\?7W[<[<68[]_K_P#"?E][[?L\NR:#[?J'CW^
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M-4-8@<_\31A&E(E JZ<H30@C6?0>:0?:2'6;767&FVN-]<;=\>/GGBF;7/\
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M&%X7VIDE3<WT^)JR&#B)TW%!E.%A$TGDS-KG7:>32/&,9[Y[^*V=XY!F<K-
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M-]'A^RZX;_LAD_BG@]S,_P#HDWZN#SF#X5/EQ7\U-]'C^RZX;\_+^>&3Z_\
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MN4)$X8U)6K>,6,Q@CT0#9:IWUAF42BDYJ$&DLB4T224<>.&,;.FYDGLY[>5
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M1%8Q_P!%2=P@E4H12<IH[%DKLRL076+2;4D.>JHXE*\LF=:21(MLJA@,Z*]
M:%!TR-&068F0R!2%"L :-D2<,5&CR\T,7,HROYQ'%)I)UL=8)(8L!J7=B"19
M O"5HO3KS;5QY+G!PKRM$VSKK*4R+X\<M0'SU[.(.N&W3L:.P8 #"*(&0SR)
M1.V7*YLQS%8D$(P(55R^5F2*2<9>9'LGLHH5V8D #+&-G%E@&8454DD:0<3S
MYS)R2+"<W"R,$52<P@,4:;]N59%L]FP7W)-#<C#G]+G '4LJYVXM>)N)^4:=
M7%G*/&;F]?'EEA@C7QZ6U$HN.L:=^/7*WA<:@&VS)\'U;3HH$Q+'9@T(('7[
M6\AE,X\Z,86B$;QRRZG= 2&#.-,J\MAL0%1BQ H;[8K\4SV07+3QG.0YEV@F
MCAY8U*"8F5*(=I-8V4LXTENUTQUH^.MQYSB /6)R[U%<<<M])5>X64-CZI?^
M2P4_(OP[CAG=P7,$W*/"5;.JMDL0"YA#Q<B%X9MW._+6MW-E4Q8><0I5&61$
M!Y-:LAA17V]A^G:L-]PZ#UY<76?J(L)'2]P0WTYPYSWY>#%BZNGH>]>%WX>X
M@XQ^"$2[=,1&&$^"N,BFWOL>@D?L&T ONWM!9)IDW[Q]'CT^(=?CK"?']/R]
M/Z_5A:<K/.NWDCB[DGCN'I2X+4S7V@7&EPM)>L!X7$MEM-=9(XSY!=.EZ#<F
M,/<[4C>#6>':72/,>LFF=L;8+/@?F^O"BMMQU'<3^S]N(_\ W+NO+OG_ &./
M _GW_P"%F^^OZOZ&;'][_)X9I(Z>KN6_B-]WT]/'"DDGK==V]$C;I7>-_E]F
M#[EW7EY_['#@?[,8SU9/LX_#_0R_?S\\?/OY>?@T;[6/DV&^W7PH?:L!.U;'
M>SL;.X/J_9T]EGW+NO+S_P!CCP/Y]_//5D^^O'G_ ,&7^[V_R>$T>WO\/'KU
M'4>WO]6"ZJB.[NKIX^->KK[</QQ(VZ[N,^.ZQ1INE/@MO+7Q2Q]V,75^[$T)
MR2R-/QMJ-OTO3YC]3!>(LXS-OZVVF=^^N-NVL@L"J.PKNW[O$^W^O"'XOB^W
M=BZY'>]=E\K4:"/I2X,6[:62FOLD[]8#LG&=*M;4MED&Q'KTO0YQL9&JV%TE
M]?.(=YM9<Z28TSIM-EYN3-'*4+!&U:; O8BKO:\5\W!YSEY8 X4RH4U43INM
MR-K&W0&\)KV777Y_[%O@WY?LO'?G][^A@_!^6/&Q[M+^C/U[Y%^79>H^WACG
M?O;/Z6/Y(_M?[>V\4]EUU_L6N#?G]75XZ^7V^?3!CPONTM_BS=Y)Y@W/QJ;^
M,#X\'WMG]+'\D?7^_P#M]&)L"?KM=(7:?3I@X+@W;*&2S2??JZ>;ZP;GAS"Z
MR[:8Z8=<[ZQ9EQOG7&VN=\:YUQG7.>^$/&5(KS9M[_PB^OU=>GJ'RVY?)P@@
M^=J:(/X)A=;[=K;X\+*U<_=;'%-1K9;;HSXM>02V7C'CF*.L]63MF=JROURK
M/'*IN4'_ "L$61D"IG816]F8YED^#5T1FSS$3[G[&7!OU'V[?7?S8ZBO6/G^
MK$>NM+B;KYZL*91:JOZ=> J5)3[SM<)33>JZPN]#HLU:QUWW'2"#IJ6[0;^N
M\T*]OM++KZ@^T7LO6DQOKV'D1Y41^27&9.*2Y*3/*^1FR@ACF2!@TTL$@?6R
M2"E$)4KIW+6"*QY9]U[[G>8^Z;Y+0>3V5XM!P>6'C&4XIYUF,I+G$9,MEL]E
MS"(HY\LP9SFU=7,A"\L@J201KW_,R/2&?K<=.?\ ZQEIQ_\ J SX]:_Y\\E_
M^6\W_P#N4'__ "8^:/\ V0.-;7Y=\+-5U\G\WMT\.*W??U.W6SBGYF1Z0W];
MCIS_ /6,M'?'_L![>7^+P?\ /EDM_P#\.9O_ /<H?F_<GT_'A/\ V0.-?_GO
MA??8]P,WU\?[J_M)[B:ZJFB>CI](33N0..[K+Q=TZGPT;D6@7F9?'U(6B"1C
M#2[BEM$R^(C;I]EU'E/B4[!QD;Q2ZP23:S;1R:Z9CVQO*+[KV4XYP3B?"4X%
MF<N^?RKY=9VS\,BQ,Q!#%!ED+ $= PZ]>['5>1'_ "8>*^2/E;P#RDF\L>'9
MZ'@W$8,[)E(N"YJ"3,+$6M%F;B,BQL0U!FC<"O1.-U?W4.NG]B%P=_ZY#K__
M )9\>'7ZC\WUX^P/C^GY.G]7KQIE]*1Z/OTA?I#[IP_:T7$W3GQ?'QA6+;7B
M0FW4O:;-NWWLK5(RB*AG#Z=T^HF@FJG>+>*2.?,NTVN^N^GJ9USJ\,XD.'F?
M5 TO-$=4ZKIT:_&[O7ZJKUXKYC+\_13A=.KJ"?2T^SI7KQJT_.]7I*?_ ";I
M=_MXW3R^7S_F'_WO^W7^^2/?]QR=?ADW'ZG7UFO9BMY@=O?5_4/U_7@_.]7I
M*?\ R;I=_MXW3_,?^7]X^^2.OQ.2_P".3^9^W^M?,6(KFKM^\._S_5N;/><3
MR]&9Z'/K>Z4>M;AWGKE^#@;7CVD1<B1OLTOE2SV2R8S:.+[I4%>5R9CQ76PR
M\8;O@,E^U<B>Q"P01'[>2+0>6AQ'C"9[+\A<N\1YBOJ:16'9# B@H.][;[>O
M$T.5,3ZS(K=DC2%(.]=]UL0>[OH; 8ZP/&'BU@\&#'#K_)$_]'W7_P"MRXXQ
MG\'TQY.\_+SSV^KM\N^?EX[3R?\ Q!O\HD_V(L8^?'OZG8>]*+/\.6AX4=[O
MY\:'L?5]?V_5V\^^._ECOGOW^K';/?&?/OXW,4CW]?DOIUZDUW7[ 1M@\OK_
M +^>_G\N^//.>^,YSC&?ECR^W/@PNXZ;7O5"N_<=!MMO>]@^K!C'R\O/M\L^
M?Y9\L?+'?'EWQ\NQA.MB^_J-AW^K8;DGN.Y!ZW+#I_Z4+#U"<9\]7^NVY*G8
M\)I5+4"FL0&)37D<LRK\D7EBCKI8GKCA-%M-XIN#J"(Z/?#6<0=4+G0LF'UJ
MN8S2Y>7+QLA83LP+@@",!HHPS ]09)D7J*!)/2L2I$)5E92!RP*4 ]JP[;=-
MPJ$]X-4.NU.>^DZT\!4'@JXO;$N>M>9JRXL3.H*E;.)GQO*O2<?6H5+9"B-<
MCF,BJKR;5&IF M-(4Y1)2<S?8X*?U2#-)/).BJ0(650Y(J0%I$++7<'B=1UU
M :AL<*\9C5"3Z:L=(ZIV5:BWK# ^HT,92Y]'[ZD\+\'<S-^1*:(LY7>)4EQ5
MGC6".7A+6[KR;1Q@WOTZM8Z,+5WWCX!E?UWT=4,&(Z0&2")<P/DA@W1,VKS3
MPB-R8E9D8%:GT'3*([*@&.2HSK*C40; WPTPZ41V8#60#U[&K==6Q-.EM8!-
M#H3L7%KWH_WK_JOOG3'ORY2TR_CU)57+OF%RJ>AT[$=]TX\5T6#X;)IJV%WL
MUWY4I5.@R;[MD.5E,V-CA%!(ATC;/JN4CS/*<F1G58 5,EQ&0R$]W9CBDDVN
MP*&Y&'B"Y6B#J-(#%R*4:M&D;[^DP4;=3=5>&\N/2[5J7T\:\VM.8)H[)KR/
M9.&3N*R>,W0;1=RK24]1?7:L&6/=](OT"0KK<+K"]P![-D8$4)&$/MZLF)$S
M+OF.2(04Y:S<T2@@Q.SJC!=%VQ3T;V!&YWPTQT@D+C5KT:"A!#J 2MDT!N+.
MUG885U"Z*(+W8.GVC;\L(Z;=.;N!;9SQH%8T3X\2(-=9>1U]4IM=S7P6&3[
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MY87$2"%/2^8?R0-]Q=]UC$8(H$J]';8+U\!;;]">E[=+L820G6Q)ES*@8T+
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M$72@.F]*C:\.,ZMF1,00JLI"T P H$ :M()-L=^I-D;$IP#TB]R #357[A'
M!?%-4 XYQ2.("@N5\TRGVGBZY\C\@U>\K6$/+,-Y8/LVSEOD QR%8;@YK+@!
M]A08BV 7@QCO/#T)9^?.)6,NN4&+6RRI%&R$<GEA=$,84JBLI34&LFV^<GIH
M32 M)VM(*,SJ;UACNS7;$&ZK88M4'I'N8D0E)'(J7'EEFJO*EQY<:%VF;DES
MM:[%R#7^1:S=P-P">1=E%"0VU7RA9I+(LXE6\?:.G4*-^?O,V40$[C<.A8OV
MY%UQ)"-/*70L;1M&;$=NR&)-+2E]*ZE'98C ,RPT[*=#,]G422P96H%M*@ZR
M2$TV::[%X:'A#JTN7 !#K%(I?')2=US!QCS)M7K&OLCI8N;\2Q<C#U- NEWM
M,+35#&+R8ZBG(,8%VC0A:A8@6,%D%.89--E4G UO("(98=2E5)6;EEV-+6HF
M)>@"T6!4@@!J2Z.FFBZO1%T5L >EL#K/6VVO4"+P[]G](YR[;-N2YFU0I!!G
M)O#07!30PVQ\VOL0T@!/8D(9#-?9^7WBF_V@ 6R%,4UGY1 N[1!8A0K$BE7,
MHYY2(5X?$G+IWJ.8S@!8%N0LK&BL*F-#H *1%%9258$8<<PS:S2VR",]J0C2
M 0"=3TQ[75[(< BKP@#NM&W,>H%AU#$\:\7;/+9Q\[XWY.IV([]]">4$ELH;
M'CFY%6,?>^;V1.RLM;/QK/O2+'4PEC $ Y*"OFU+R9(,F@RXRXDETI(LD3^]
MZXBD@D0+[WI(5AMK5R02"3M1SNV7I;92KKOI8$:#J[1(L&^RPJK &]NBN])5
MR<O:#-L<1\$D3U9]0+?Q'!(FY%B"X6NG&?%%?X:JUGI,,')46[<F"F56LY*5
M\BRWA"2\0K7.RS!$4^A,1X=$01SIZ=9$F.J.YDEE:9UD]Z( UNU&,1L%8K='
M8\Y8$G3'V2K)Z1",JA 4[=GLJMARP+ $@8LJ5Z27FCC]+QW7:U6Z>$GH%#O'
M'7?%CYES87==Y #I43T4>\8Y7Q>./PX&U!0VM*CXGL-"JZFT2N&$"/(;8E;A
M7X=#(TCLSEI)(Y?1@TJ\9?2=')T2$B1D8S+(S)I!-J#A1F672%H!59"2TFHA
MPMT==KNH(T%0&NAT!:OE[J?EY4X>Q12P7&EHM'4'<N=N06;5W9+,#O-/0J=Q
M_P >HTEBNUONE[>? UBZXDN&=P<EL)-W2L08HB$*67:6++"*;F C2N72",!5
M4UK=Y"51$1=1* *BUL2:NL1O*'0KO9D:1B6)WI54 LS,=(U;L2;.P.]1(];'
M?Y]_/'S^6/[W[OGCRQWSCRSBUB/;KM0&V]$]/ ]?C!ZFCN,'Z'S\\=OGV\L_
M;C[/L[?+S[_A\S[?;^O!9L5?7O/7P!%]VX\/CQ3&<=LXQVQC/?.//]S/WOJ^
M><Y_%CP8+WLGN H=.O3<[[7TV]?CML]!MGOZ3CIZ\\9QA=S)]?G^DAR+]7]_
MM]N/L\LKC?\ <V?VP_[Z/%K)?C">/:]GH-TWWH5XU\>/T /'"8V\'@P8U#]#
MQFJWJ9Y=J&PN1]"D7(-C]D($,*!.;IR'6(VISK$8@T\]E.^,@;;SE:^O.#%B
M6*(<>2*#2&,Z&,09CU>@JJ@W'72 "XU=3O6J][QKYZ-O-()6_*9%IMY!4;5N
MQ+:*%UN.E=!B9O4%U35[@-GJESQS>N2W 7%_('-UJ7T7%.@EJO$W&!"$2V6D
MV6Y6FJCLS<%6(*!'64DS!VZW'9;1#CPA9DDT(,JTZZN8D:F6.!"^LAYI0Q1!
MRT<C9269J L=;VPWD"&M+,=+.=.FPJT"3J9;ZB@+)K#8K_2)=.&F; 5;SF=)
M2)9[)[K8#E4C\5X+6;AS%7"3@$M4C=W"$>-)PC=KX><?6A$Z>IAD&'-M)EK:
M$*0\/S'9T!7+!.R#ITETA< L^E"=4Z1T&+%S0%$$M\XCWLD 7O5]#(+ %FJC
M9KJ@HZW8#\5'J9X#OD?(<M9O*\^#BQ098KN0<D?HA%M>6GV94?8@3+"F5!V&
MO@.J3;4IKZNSM5(;RMN%!)L3$"<;2%\M/&8]2$&4A8Z922Q"$*0K$JQ5T(5J
M)5E(%$'$BR(=1#;+98T0 +:S9 !%JP)%BP=[&+_IXYPJO4;Q>IY1K%>L55'/
M9V!(RJ=U!6+[?5W=9=FI6"FP@JF3@ 4S.XD;(7 S,N.=6P7F:R8P3C35,Q V
M6E:)F1R K!T)*,K*&!4LJDC>C8%,".[!&XD4. 0#>S4&!!JB 31[^O0C$*NH
M6RE;\IV]9F&6<3<M97!V(3KWEDI),2!F$:#!#*=X4/N^D(DX6IK3&K=H?I Q
MU7P;KR9[D'/,4:0J&674KD:>SVB=3794B@-6RCV[8L($KM,HWU -N"P.PH;]
M">NU6!5XBVOPK1N++8!")DKUM-D5+8FU36D1YD.C#,M6%(=1TB8/(=V&P2]J
M5(YBFG9B1Q2D;2!N9IGK%%E_.%9:>%"%::166=F&FHP"NH@,=(%D'I>)6=V2
M,6OI6%A#*ZJ.T"S,"$!K<GJ#V=ZQ=8Y#J(QN*M7TVRR"G3D8/>W!^D$KH(:Q
MG/$[FU8.B;4>P,!]L4&;J"OTR9H?B"&P!Y$QE<UI0KB"")S&C!2S%-+6H+!3
M('(/4[ T-UVVQ*L)99)WE"R$@!=32% 0-+N4VH#H2!M7?L7SHERY!KZ-]9HL
M6I/$5.&</4PHUUI6[QY7[RR&*A@*]&YBD-]M 2;I)(=W''ARNCVTCW'(52LT
MLDLT"1QJO817#@D=Q"!2239:AUWON$$ZQQ^]*5E919ETLK:CO0U  ^T"NEG;
M"XY;Y#Y(-LVZ-84E'HZNE3-+$Q#S.98HK.%MIM(/$G%6-1V ^9=)@(P=29))
MMXB-AQCYMP8]J\67D+,TD8.6#%^< PE)7=4B4T#7B03N*Z[MT1<I2&83.U:#
MIY:#:R7&W7P-=YZFD 8+L?NK'F*FW8>[CVI?.KQ,IV$DBV(#F&8+(1DFLD8L
MKW$C07$NTN(]Y1IYI8M(AR-"%U8AX]7*)IA(IMR03RV;\DDBR#L"*/08C<TQ
MCM;#A0;&DFB"UC\G:@1MTWWPF-W*R<$>:=,2:OBT(:Y96X;.YNIJC ?N\QE:
M'!P9J2QP7)L+!'INSDF]W(#5DDSPY\2"0OJEEC2,L E*5YA0,-(4=IB 1OU-
M'P!PNYM->HKNP34RU>POT;!W[MKVVL^)CPO;7=JFT4$3UD[4%G!JT:AKJX&6
M +$UT#VB /4FM%8H$N-%?NL4>I$TPDIXY,V=3HR06+0JQ;6B'F,JC2?2I0-5
M@V":(Z[&L+&H:P\E*2"J $G4!0ON )WW/]7@*$B^DD<\;V?+R=4O&AR_VF 8
MFCJ@]R\[1C%C1@SF"[,<%"F  :%CF2[03,Q!](Q-)$>%955=*LS%6@$DS@[6
M70 (1O>PL6 >X81E*V:.@&M1!HFO'XR:Z7[,8-77'E>MEDL%BP@7P;G@G51H
MP>M)K%+*U^$#-DQQ#DM@BBU=ML"5Y*N0Q:"J%^(IY#2CC=Q(*L,#))FG:=#&
MLJ^;.$,TNAD#,LA?5I-D+I !(!!WNK;9A'C@CAC)<Q5.BJ H8?EGH=+'8$[&
MB!W4YT&168XC=>NT5N#8325F)*VW7,8Y2<S9"V+TD'BSG+$*&'3.C)=/O'+)
MMF7$)FD>FEDA  5"");&MW*JKL;8A9"""6LT % % "ZQ2!*@H;(+GI15=S=$
M&K   [1Z=#B0?!0@L[>TDO(4@[<<^,!6+ SG8$Y#S'(1$61"8&'K >5%OH3J
M+%@[W*#>32(V?22;.M'-2,@TE@JD[N*75OL=??M7?ZCWC X55I-3'O- @=_5
M18V]A/7#O<KN:^EH[LFPSC:PZ@RS00YFBBGD('QKO&0'K+ZV=Y M\8)_T&&7
M?3$??2/>3.FFU:&ED#@;+VF+:BE'=B38) '@173PPQ;8@$>ETN@!9JCL.\W9
M/[<:_1IW1< NA7P8Y;-B?9.*LDLI<'OD$>-%\C*UCYWWKD8@\$I$L6U>@A)9
MD0;X/%*Q,/+KP@R,LB.BQQ'4^E1; UZ(>R21W"Q6_=960E"% Z*-1/2R3Z)%
M6/G\-AB[/#9J/?Y5HXQ^K<D#,(*R(..:/"G<B2. 89TRP+)MMHO/BG/@'CCV
MEFAV#TTV'E(RZ:2,JI:.8KH:,%74#<4I9@HV%[V=@"-KK#(E74"'5 K(&UL6
M)#;;;]11N_'<&L)>HI@Y$<WJKU9%D2/;+.4."39Y(!)SK!-L-"/@S$GKG[K-
ME&HS>)<P#6XRPW6ZX!WVWGK9)806.EM43,J,&+*;LL3^2U$;,*[S9'2YG)7#
MA"#I8(02$W"J I&GM=H6:)WW.W3$F.'-I2>1Z.W-(&BV,CTA& 7P0;#1Z^[G
MZ0:1,C  69&HN@I<1$>T?LB,S:SPC";Q[3$F9C(AE)!<#<L672&U"S0_*((
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MRO?3S>G&L\!0HW#9E#GF0,4YE*KN2XA"F?1<84\DM3VPLJW+U@7A1F$)4:7
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MU-UU-?C9^O"T.E;>&#Z+UG]3J+]Z%_\ %_!J;\YOE.#!]%ZS^IU%^]"_^+^
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M7L3I)YU<F2(8M(X<DD1R22"") 00')W!C:T'> M-7B"+ZG;U(4)[V.U6.E>
M[/CU\>F,*UK(C$JH;RNF48P<LNFZ1:M*8#EKR0)O4$?-9D$\(2O26 >:,S6!
M5*3.$,&824$60 2DI! 8AV!?22*5)*W82H!8TV"M%.MDD@4Z+4=04(GHL"5
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MMI & "/ *-%K^ACABTTQY8\469G9F8EF8EF8FRS$V23WDDDD^.)@   !0
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M*^=FP8>'J?RT6T=2%BI3KEYNE5YA"0W8:--+N"090M .&8HU3-VE86^HVJ:
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M=T]C5.<KH]B>4H(H9F@6/>2:35N"G=O!!LFK>:12X7-UTT,*N%@Q=X7B:@F
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M6;,Z6<T\\PB22<HLN:4@B;?>263??;;;/"9I0F:S*J JKF)E50   )&
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MSFEG52%8 L[ G0"K*;V(K<4=KLV0036,3(+6:X4VM]B =MS$D>V*L-[8"T.
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MCN6[MH)9!0[*<S26,;)Y$&04*QQ/[265# S*)GAWV=+0AQUI&;F563-QYAF
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M/[4'*G_4_P '*;QB_EH?Z3!8]?R'ZL'W5ZY_Q'R9_:@Y4_ZG^#DOXQ?R\/\
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M?;[5CFMZN^X'OV/6R*\!5WTWWL#%?L[]^^._V>7;'GY^7EGR\\X_OXSX,'L
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M;J/D4?;(;#WH>9*'B34_ ++9WEF/[6988LC &C83!&;;D/3&.FL;JZK;:&*
M#?O[L1OGF).EQF&"A69U* ->[!E%Z]B+ZT2;WPB;CP6NXW LKUU4C;(W5CQF
M*3TPPBPJ3::U.+$8S2B>[N<#.PH/4'$8LUY#.3$0&XS9?&TGW6AR66;+G,0\
MR>=692@<\Y!T4A2$5V:PI8#H=AMO,N?FE:.)I5CA$FLEEU&B*;4^[A0!LJD@
MFA5$TP:86IV.K-$%BE75K:0;V%I4LK*$79MF%K(T4Z+W19*\$.TV5XFPG'G
M=D3%AE;!GCY,F&3N-J.7R\<^5D@EB,1ULKQF0!XBVK2I,EDHX(,NE9(Q^6".
MM[,3203"6&1714U K&1&RD$K21Z1L* HJVPW'=*NE)YQJZBWM+Y_55E78D9$
M&^)#BA'1J]2$L&;$2O  !*1G!18;&IM\X$5LL;"D2^T5ZZ[:\,:K BNS*(C2
MKST(*] DC1K&=)&X72R[W5DC&,\K&9FB$<DF8-,5C971@/24LS,&"@=K4-MK
MJ\9>*MZ;EM6Z[<?4!M+)H-(LE7L(FK<?:<QF_&%@4[LX&4,<LX9<K2P.0#/=
MQ!HE'Z*7?>Y#$D:RLG,C1U($8EK3=BR8XXRQ( O59%6-[Q%)+,V@6K-&0Q+@
MLI!H$;@G>AU%&[W[K=!N$J%=J2P+^<J03-<P,WD9UG(?^^,LQLCFV-IF)$H<
M$WL&@4!L, DZJ7,ZZ";2$D-97U9: (3%*% (D$R&1'9C8*N=3J20=)(JMMMK
M<X=RY!@&M1I6,A60CJ0 !6_KLV!>Q.,;&47.<^CA9SY6O!]9Q=3B![.D"S(;
M&&PW5A.=0@!]K65-A=JJD?M5Z\24.-9" 7*>-(O*DC@GD,LD!F>,(#([$*JU
M3$FRK$K5WT!H4,+(5?2.5K*@AA9MC1Z.IU;;L2?S:(K;"-TY,X]L\MBJSK2"
M$Q.[(  76(7'QQX/--E]7PJR1&6NF.*R4J*)&1B9+8S1A:P8@%EU'W)J29[*
M/)/+,(T6)P@@2@[; ; BO?"MT#5G<7L+GF.;*J$3LS(71E="H( V87MIL"V
M&VY'7%B"_P"+F&C%Z.NK#JST^6QGU\YV>:ZM8(\>T(RH8X@I.5R%7X\3LIUT
M:E6L.($59PKK^62K&B\YT,F74<Q5@,F7]\1C&SF+4+!D9EU#;\TG<]V(YDS;
MA4626**8:)HU*(K,I('9#!&4T"=B-1[CUMA>0YAF"ZYG%UV7AMHA; $ID*Q[
M<2%Y\;<N2<TFU^R6&0K'WM%HFAC(64 )@?(LW!(!%@;QU5S7+TM)/ ^2G4-2
M1R22AWV+,^J6U%@+9%4:N]IWRJNO(C$JYZ(M(S2:(8RB]0""%8BME7=MZ&QP
M]Q(X-K,31H0UHJ&H-R5I0;]+8HH9<3K-UFFU;!B8)%IL</OYF(CYQWR5IF3>
M5>1(3#IG32C6)@BPK'+&"&UL9D90HH% %T@[CJ1T(.XH9[ 1M*9$%R**T:2R
MN2I-BP5[Z[Q9'4X?;A8)_MR@@8/[&@+SJZ,P@4J8C@21T^X,X^(&(K IG.<U
M&CV[-&><)=<SZ>PA6BZZ[:>*TPG"3<XASJM76]EV !U =+[KPC-$54QHP8CM
M%@+/A1!)J@.O7KWXD[U!_P#?N%_VV3?X&.8,?WO/Q)P?\9D_B&_WD6,/CG]S
MY/XR/_:V^?$(&/--B@ZN*UP8JLW&C.N&<;NK=<*S* <MY$J16GL]:B4-89[I
M*KLLENE'?RZ4Y=0X&*2NUQC:&EAT%G5B']-0":B&O50(HJ:%D$:=JL=3VB:J
MP:Y 1+YLTI5PP8!2-PPNCV0+ '>Q/6AZL2H_O?9_\?W?J\(1XCPN[VN]SM?T
MB_;6*V#RS_C[Y\O/[WU_W_G^(LCY!X=V_KV^/?V4 8/R_+\/A*HBP?7?S].Z
MJP8<WBW_ &Y8?U,V_P#>AO&3QC\7B_CAO?[Q^[U?;ICH/)W\;G_R<_[R/$".
M5_2%6SAWGWERJV"3B1QQUQGR&72B*($+9%W,J^J@=(ZOJ..YD</H+/8UTU%"
MM)&_'; >#BT# NS5/.(_:N]-4+2E%P]9LO$ZB422QAPY*F$L<V<L(0I12'*>
M^ F4WI:U"]H=,TY1W!*:48@KOK"B$2ZR03V;[)['L).Q=[I\]()7>H"[4?CY
M3Q?9TUANJ*XW&&;=H*>D@H=!M7(O&MFN S"8!268"/RG01J>*M*6*W>X]TJK
MT]<LB), #@S&0:!))#*C*C(E40Q>18Y$0BR 3%(7)!90490Q-'#TG#L%"D$@
MGJ*TJS*6'>0&4"B >TI(&]6_0EUBV+J56NM.16/%XEB,44&V5132,'*R HKC
M0$]SM?&CA>ZM-C-=7;A\APN771J!E-'F%XCF.J]=GG]C.N>RBY8CEB6@TB.9
M*(.B0HDJE54!)M+% ;]%J9AT2"8R ZBMTC +8K4@8J;8VR$TQ%=18!.'FZ4>
M4.5^6%/*[OD1EQU8*W6^7[7QWQE<..Z98Z,#=TE U#KEQL9"6P\C\G;ZCC\F
MAW.I*"@W^!V8%5U=Z0ZP-AXXH<U%%$8EC$BLT*22I(ZN8VDMD74L<6YB*.P*
M[%]-V#A\;,^LG25#E5*@C4%V8T6;\L,HWW OOQ*[Q5Q+@\&#!X,&#P8,0PZR
MNH&W<"@\+8JEJX@H>O)?)K^G/KQS:L;M*56E*/A?E;DZ&66)/?./)1S7#F@*
MJY :0\(B%C<32PJ&IN!1)+N3RZ3F?6LTG*C5UC@(#L6FBCZF.2P%=FH+O0W
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M!X,&#P8,'@P8/!@P>#!@\&#%,XSG&<8SVSG&<8SV[]L]O+/;R[]L^?;OCO\
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M4[LBH =YL0+CJZYFE 40^L;OKLD.S#FY6Y6=BCF!;G.D[&"C 6/:*,P<@J+
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MZ%168^=*SU5O5Y>(C\YE8[Z,3R?:SPG#G1Z2V(LS!*5AA,UQZ4*O48-[>^J
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MMZ#,H'7JW98$@;:A0/3[Z#;+S^@--H742NYKGMERK5=L>2N1)MWP"N_TRF5
M#GT]0VD;'8K_ !X^Y"M"V'C5.KUAK1DH=EFIRT)"-B3=<\L# /ES!I1F6H@%
M)C=W.7#"AKD$:$RL;86@D)8X(2XM9 ]D G5N-2JHDHV:4L1I VZE16'8Z6\W
M*DV&X5CD"3F0HSE6^<JW'C.N\@62R<@:\9<.\6FU#CNOQ6.UVBP/F*QMR@>3
M+R:J4R,"I<CVDE/J,!K528]8LUHD5'C$($4<*2M&JQ\V:4/(Q5$505B Y1(
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MJO!W\'J'P8,.5U6&&BU:B:!G'@X+Y#C@*]P/+ V)'TH]W*P.1('-!O-!@@>
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MDP[?&K"2$;5G)[T:JAE5ZZ[;W1-)FLNC1-0G][):RJN#JTV+%TIH&^A)[QB
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M2F=Q=&-M*D$,1T%K,1\I$CU,@"*"KJNMY0*&ZDLE'T&('9HX=D-[5=A<KD)
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M>1AIH6:KNJ[L]]^RMZZWN=\?I6^C\_H&.D'^MOX<_P  T?CSC.?CF:_RF?\
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M*AT:PFK60:TPF]\JZE6FQ7G7W(]17!:\F50VNP&3Z%3-SN9AS0UJ90X=G57
MH<]WDD4$$@1Q$*J&PSEV8HN^%AB:+8Z2-*J2+_(4*IH_E/N6[E  !/7#P\!<
M.7CA:V6?21!2RQ>8[KRORURQ;T&VJL)*WU84^I<'\=TY'[,4R=<CXH3P+GS
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ME=DX8Y4XHE$-$5*7,QFZXGD09]J!,./ QC4R 98K9"8SH+>4G2#G!S*HEC1
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MC[Y]F,$$/ -!IWSZD46FO?/;Q79F=F9B69B68GJ6)LD^LDV<*    *    Z
M#8#XL9;PF%P>#!@\&##$&]-? 1?,]<Y\DXCHL7,U?CL>R[D<-"(OM$DUB5+4
M+0ML>!H-FP'Y2@PJE[!_HS.3+Y#1$Q $+%AH5.,S.(6R_-?DMIN,L2O9)8
MWI&IB2%H,:+ D"F<M-8DT+K%TU4=Q1NNIK:S9 L"K.'W\08?@\&#!X,&#P8,
M'@P8/!@P>#!@\&#!X,&#P8,'@P8/!@P>#!@\&#!X,&#P8,'@P8/!@P>#!@\&
8#!X,&#P8,'@P8/!@P>#!@\&#!X,&/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g451428g01m30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g01m30.jpg
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M=7:SM=77V!HR5V%TUB,D45*6)E9QDC-BL?_$ !L! 0 " P$!
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MRE]8>V-C^2WJGV1Z/SWN)+_)KW['&]/*7UA[8V/Y+>J?9/H(&P% P%AIDH&
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M-,B! $" ,<]$"@(B80* H]"@)A$P@'0!$1'\8CC>GE+ZP]L;7\EO0?9(L_\
M3>5CH2*D6<Z]8UML[8P2;B,<J*1<>]?+RB\:T=&;"Z)&!)NWTDA&BN+%I(R<
ML^:-T'4M(JNH!I@L0R@L06[X<2  "1G&< #/,@ '@!B2M0@ JQ"C [T\!G..
M7+))QR!)QS,A'F&P=T2^9IGNB;O"7S<][HF ! #"'@].]T$0Z].O01#^7)WI
MY2^L/;(VOY+>@^R1B<]-[*\2?S;.<?N6["/BFHGBW"2+.,BFB3",C6+5NU1:
MLF#%F@DW:LVB*+=%,O0B8")A'%334$*5 )+'OAQ).222<DD\R9)%1CDJQX #
MO3P Y  #  [!(-Z/SWN)+_)KW[',MZ>4OK#VR-C^2WJGV1Z/SWN)+_)KW['&
M]/*7UA[8V/Y+>J?9'H_/>XDO\FO?L<;T\I?6'MC8_DMZI]D>C\][B2_R:]^Q
MQO3RE]8>V-C^2WJGV1Z/SWN)+_)KW['&]/*7UA[8V/Y+>J?9'H_/>XDO\FO?
ML<;T\I?6'MC8_DMZI]D>C\][B2_R:]^QQO3RE]8>V-C^2WJGV1Z/SWN)+_)K
MW['&]/*7UA[8V/Y+>J?9'H_/>XDO\FO?L<;T\I?6'MC8_DMZI]D]"KL$&SAI
MV7VAT'2"S9<EAW*)T7"1T52@;<5W,43)J%*<H&*(&+U .I1 0Z@(9P.ND'4Z
MY!!&VCQ'$?B4G3Z:"+.D""#FIP/ _C&F8_*>;\U_?9)+1V][/RKHLVKAVJ')
M371Q2;(J+J 0M*V@ G$B13F H"8H";IT 3  CU$,O^CA OW)( [FJ<3P'XRE
M*W503:@ $GK4X 9\331(]'Y[W$E_DU[]CG;[T\I?6'MG-['\EO5/LCT?GO<2
M7^37OV.-Z>4OK#VQL?R6]4^R/1^>]Q)?Y->_8XWIY2^L/;&Q_);U3[(]'Y[W
M$E_DU[]CC>GE+ZP]L;'\EO5/LCT?GO<27^37OV.-Z>4OK#VQL?R6]4^R/1^>
M]Q)?Y->_8XWIY2^L/;&Q_);U3[(]'Y[W$E_DU[]CC>GE+ZP]L;'\EO5/LCT?
MGO<27^37OV.-Z>4OK#VQL?R6]4^R/1^>]Q)?Y->_8XWIY2^L/;&Q_);U3[)]
M!!6$O=[L/,E[AN^3I'O@[AQ[O4Y>B/X)OP"?A!T'\$OK_!#HWIY2^L/;&U_)
M;T'V3Y& GQ$1&$F!$1ZB(QKT1$1_&(CX/K$<;T\I?6'MC8_DMZI]D>C\][B2
M_P FO?L<;T\I?6'MC8_DMZI]D^P@[$4 *6'F@*'?Z%"/?  >*4"*= !'H'B$
M "'_ />4 *;J =,;T\I?6'MC:_DMZ#[)\>C\][B2_P FO?L<;T\I?6'MC8_D
MMZI]D>C\][B2_P FO?L<;T\I?6'MC8_DMZI]D>C\][B2_P FO?L<;T\I?6'M
MC8_DMZI]D>C\][B2_P FO?L<;T\I?6'MC8_DMZI]D>C\][B2_P FO?L<;T\I
M?6'MC8_DMZI]D>C\][B2_P FO?L<;T\I?6'MC8_DMZI]D^BP-@((&)#3)3!U
M #%CGI1 ! 0$ $$0'U@(@/\ Z@(@/J'&]/*7UA[8VOY+>@^R?/H_/>XDO\FO
M?L<;T\I?6'MC8_DMZI]D^@@K"!3$"&F0(82F,0(Y\!3&*!@*8Q?!Z")0,8"B
M(=0 Q@#IU'JWIY2^L/;&U_);T'V0:"L)Q 3PTR80 I0$T<^,(%*4"E .J(]
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M4CNRQK194B[XS4BZ)G!6J:HH%62,J!04((R%8@D D+C<0"0,\LGD,^+/.02
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M1GL\?HG;$0 !$1   !$1$>@  >L1$1]0  ?C'(DS\(<BI"*)G*HFH4ITU"&
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MHU?EM5;,Q?)/5V3PLY&"T=H1BI$9%9JX!UX+A*/6532>J)'.1HJH1-<4S'*
MY;'R1L;(QD;3D9XC(QPR.([?%(W+VCQ^,>+GZ/'V29,QDSC,LB55- RJ95U2
M**)(F.4%54T13!8Z:8CWSD2%9(%#% 2D%5,#" G+U1.I(RL7#HI.9:281;=9
MVT8(N)%XW9(JOGZY&K%DDJY4234=O7*B;=HW(85G"ZA$42'4.4HR 6X $D D
M@ G '$GAX@.)/BD$@<R!Y^$[^1)D,D9J'AS,"2TM&19Y1\C&1A9%^U9&D9)S
MU!O'L"N54A=OEQ 01:-P4<*]![B9N@Y(5CG )P,G )P!S)QR [3PD$@8R0,G
M R<9/8.TR)Y$F0-[9JW&N",Y&PP;!VH54R;5[+,&KA0J &,N8B"[A-4Q42E,
M*HE*()@4PG$  >F05CQ"L1V@$_ND9':/2)%T%T7**+ELLDX;N$DUT%T%"*HK
MHJD!1)9%5,3$424(8ITU"&,0Y# 8HB @.8\N<F<+:08/57J#-ZT=K1KD&<BB
MV<HKJL'@H(N@:O4TCG.U<BV<-W (+@FJ*"Z*W<\-4AC201C((R,C(YC)&1VC
M((SV@QD'D>7 _$>R?AI&/*_3BC/F9919HJ_2C3.4 ?JL4%DFZ[U-F)_*#M$5
MUT$%7)4Q136623.<#J$*9@XS@XSC..&>>,\LX!.)&1G&1GL\?HG<R),^$U$U
MDR*I*$524*!TU$S%.F<A@ZE,0Y1$IBF#U@8HB AZP'$3B0>-'*CM)LZ;N%6#
M@&;Y-!=)51D[%LW> U=D3,8S=P+-VT= @L!%1;.FZX%\)=(QF#PX<^(^,9(R
M/G!'G!C]W.<;.1CY#RKR!\S?>0O%XY[Y&Y0<^1R#;N^4L77@G/Y.\;]\GCME
M>XNEWR^(0O>#K)!&,@C(R,C&0>1':#VQD'D<^+Y^R=S(B,1&(G31D8]P\>1R
M#YFO(1Q&JD@Q1<H*O&*;XJIV1WC4AS+M2/"(+&:F7(0K@J*IDA."9Q"<$ $@
MX.<'' XYX/CQD9[,QD<L\1S'9GE.YD1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B);9R6T_:-NQ^FU:M+,FJ^J.06L=S2U<E7+EG$7V$H[B4\KJ[YTV;/@1=,
MW$HSNE9,Z9+L37.H5LCQ6-;G/,1VS;5DI&MO!(JV]6B&4 FFSXPP!(X'!1\'
M.QVQD]Z?*JC.$P1WE17*GDX7/>G@>1(89&-RCES&/1#@/R*@MM&VC"V[7Y8Z
M0VW+;0<UP;!/"O3H*=YA5C?\M1:DU<4*5B9(RE)@Y=<KMT2+9GVC97XMFK2+
M21L8V'=]NU+JF2H"**T@P5<.RV;6XJ.>M4COV P,_P!DHR<][-86]4/O!7!<
MOC)[T&L*FU>](/>@\\ .W#@ 9$..6L.T!L"5'L-UV9=Z<$/-:P7N,)LJP/GY
MW:4*ZX[/MB&@F1&"JUFC[]3:7N*OOVEH9UQO4=A[-D9FI-TXI!@C4HN:M@O6
M(E*F^5J[&I*!Q87'5[CN 0TW>B04WEZ5/:YR3O4DN3M9G9<%<JQSP'5EL<,G
M<JNISC:SG:, 8NNV%IO?;CD]1.15'EJ,:+K$+?\ 55GI$Q9KA$A8],V>JPMA
MB7R+B,K%DCT;]"[LKD=)-4T:X50M*>3+,UH?N5V,.VU*=:@+6I;.*F6:G56H
M%1MM=692,,RDTVH,0>^_# .S&3/9Z=3K5JJ5P R,I9AFF5!!X*W?BH,\OP3^
M%D 2$;+TCM'9.M^)]?>ZOUM;Y>@2^HKKLF6VYN6PGV%0K'KV0HUR24IE[A=+
MVM]L*:)=ZPT=VN2.ZU0-]CZ\$,ZD8N/MS]:%RI5Z5*K=,*M5!46LE(4:*]74
M6H'0]93:L@IKU;$(,5>K+;L$H-T/3=THC:C%2C.:CG<I4JW>L$;<=P[X]YN
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M&-0:G/4RJ2:T8QF8N<@VKA7.C6I4;HU16JTT5%"-0H+EF"*,/2-Q34@$$O\
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M(:O6T@J[:E'=U(*(X=0R&G3ZNI3J*5)12C#=O7 T*AQAL-L".2<JY4/@E2O
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M/+/S=OFD9':/3 J)AWNJA [H]#=3E#NB/X@-Z_4(_P#H/0<8/88R.T>F!43
M3 )R )0 3 )B@)0'IT$WK]0#U#H(_CZAD8/9SY?'&1VB?OB$Z@'?)U$O? .\
M'42?^X/7ZR__ -OQ?\\8/9\7S]D9':/3/P%$Q[O0Y![_ %[G0Q1[W3U#W?7^
M%T'U#TZ],G![#PY_%&0>1''../9S]'CCQ4Q !!0G03=T![Y>@F_]H#U]9O\
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M(!$BT!XJJHHY\0YS&&6O;QQ6#W=TXN=O= :XJL*^P )UP+GK=@ "[]VT  8
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MS,<EF8DEF))))))/$R*=.G21*5)$ITJ:JE.G3541$4 *B(H"JJ@ *J@
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M>M0JKAZ51T8,9I(<BI"*)G*HFH4ITU"& Y#D. &(<ABB)3%,40,4Q1$# ("
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M&1TLK)75AQ#*PMPP8'B"#D'CF?I8]J4I2E!<I2@!2E*[=@4I0#H!2@"X
M    = #U!@6=!0%7K@H   NKH  #   K8  X #@!(;4+EV9W[F9F)9F:RLF9
MF8Y+,3;DDDDDDDDDY,[A2@0I2AUZ%*!0ZF,8>@!T#J8PB8P] ]9C")A'UB(C
MZ\V0 H"C.  !DEC@# RS$DGM)))YDDS39BS,QQEB6.U55<DY.%4!5&3P50%
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MD1$']=;JV")6[Z-,(<2MY6+9.#)"(I+E2,@N11%11,U/KN@Z:MC2.VH/^MM
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MZ![9:+]S5S<_^P.*_P"\QMO_ $>YZ=9\7T_Z3SZL>4?5'\4?<U<W/_L#BO\
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M=MI^7I^F2@OVUO9]>.MY-RXU2#;Q5/)P7U[O45P0[X^$"PITDJ8J@GW?$$@
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MA*MVUDGV;*/KL#)V^?N4I$1KZ.B86.7M4G!PJLB\59/T+Q8><?1_6!+R]/\
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M][[-MNU;5#<D[+5HJ>N,F>5DF-=:ZLU%+MX=NX4*4Q&*,G-2KU-'U@5P_<G
M>J@YR6NVU"UO$IV],4D-NCE5)(+&I5!/$D\0H'9PEYIM:I6MV>JQ=A5902 .
M 5"!P \9,SNY32PC$3!#[(P]KAE??JU9_:3V7.@?"=']"M]TTT-3\"J^>G]X
MDT#<[^<M&(C$1B(Q$8B;YWL;/VO2>^$=LGYJ:WS@^D/PBWR-+ZFG3Z7X(OZ=
M3[4V LHY8QB(Q$8B,1,,.D7>RI[M)-HNVC[DU<=75R;V/#/G-!U#2.//$W7T
M]Y4YZPNTY^SH0=[YC;$54*B,;L"A25HB:#*2*T4ZK305K#9U$RX;?%GESR3Q
M.<#_ +.,>/Q'TYGL3&6A\_X2=L/!_EI%5NY2M!EE./FUG:=GA(NN3$@@SBZ=
M+2LM%$86R(G80[:S1+)]6)!PK&J/V$?,.G\(ZCIMM'231)7F/.)7?3_Y)=7>
M]U2?FU&8D2HN(C$304]D;>V-N_>.U=_:V;.YZ.?![_K-3[%*<WJ_A2_(I]NI
M,#67\JXQ$8B,1&(C$3U:.-_YN^A?>7U;\QX+/E53\94_3;[1G;KR'F'U2M&8
M28Q$TBO9/?YW&@?@Y-_I,OV=ET9\'N?EE^P)0:S^,H?H/]H36DSII31B(Q$8
MB,1&(GIY]FI[7QPL^#-IOYC0V?,K_P .O?UNY^^>=C:^#6_R%'[M9>[FI/>,
M1-/CV4W_ !IX3_T!O_\ O'3V=9T7_OW^&_YB4FL\K?SU?JIS4VSK)11B(Q$8
MB,1&(GI"]BE[5[Q,_JM=_I9O^?.-6^$KOY7_ "K.NLO!+?Y,?OF4O*Z;48B,
M1,4?:LK.$=>:X)(5W<\S3G\[+1<S*ZQO_"?7<%4; [>5-6J3=EG^;+1S2V5@
MD"M9VI5%W""8XQ5EO,-(-%I.<J[N/3)>?,#S[NP^3D_UV9E]7&&2:3/&KCS,
M,'$L[8RNC=2R3)U/RM1G9URT?4&ONF[B:F]?H-:',2RR*I%)*5I+9M49!X99
MW6T$899DF5(/ D=A/+E]/'TRN6)$LKJ7MBN__@5\0/ISYPXD^(><_4LO4Q(C
M$2W+EKR8IO#SCWL3D?L"#L]CJ&MD:VO,0M-0B7-E?%L]PKU+9%C$)R6@XLYD
M)*QLW+KRJ4:@5BBY.B*RY4FZOO;6[W5>G;TRH>J2%+DA1A2QR5#'& >2F>=6
MHM&F]5\[4&3M&3C.. ) \?:)A _VGGAC_P "^47R'J7_ #:RZ][5]^5M/VE;
M^1*_W7M?)K>HG\R/]IYX8_\  OE%\AZE_P VL>]J^_*VG[2M_(CW7M?)K>HG
M\R/]IYX8_P# OE%\AZE_S:Q[VK[\K:?M*W\B/=>U\FMZB?S)3VA>R&^!NI1F
MFT;QTY'L[3,&@TK],1</K)1&QV"JP+"J$D2^6;;**:!6D4F1N1%JQ*H43NEV
MP/7+I13ENB?02E8Z;1U&PH6%M=:[9:3?:G66I<[[NXI:7:VU*I5#4W162A31
M-M((A;?4(-2H[MW/3WIOJ.K:S<:3JE]>7ECT9U+7]-T2VJ4Z 33[.OKE]>UZ
M-(IL=UJ75:I4+UFJ5 NRDKBC2I4TJ%_M//#'_@7RB^0]2_YM9U/O:OORMI^T
MK?R)PWNO:^36]1/YD?[3SPQ_X%\HOD/4O^;6/>U??E;3]I6_D1[KVODUO43^
M9,J/ #M#M3]HE1KY?=34[8M-B]?VMG495IL9G66;]X_>Q"$RFYCBUBSV=L=F
M5NN5(YG+ALN"Q3 5$R?10:N^L*VGU$I5FILSH*@-(LR[2S+@ET0YRIY C&.,
MW+>YIW2,],, K%"' !R #XB1C!'C[>$O[S2FQ&(F&7M^_:N]Z?UFTQ]+]+RV
MT/X4M?\ ?_\ MJTT=2\"K?[O[VG//)SZ%.5C$0 B @("(" ]0$/4("'XA ?Y
M!#! (((!!&"#Q!!Y@CQ@R02"""00000<$$<001Q!!Y&?:JJJZBBRRBBRRIS*
M*JJG,HHHH<PF.HHH<1,<YS")C&,(F,81$1$1S"G3IT:=.C1II2I4D6G2I4T5
M*=.FBA42FB@*B(H"JJ@*J@   3.M6JW%6I7KU:E>O6J/5K5JSM4JU:M1BSU*
ME1RSO4=B6=V)9F)))))GQF<\XQ$WD/8Q'YD&[/A96SZ&]'YP_23P^G^JT_O:
MTZ32/!6^6?[%.;(&<_+2,1,$/LC#VN&5]^K5G]I/9<Z!\)T?T*WW330U/P*K
MYZ?WB30-SOYRT8B,1&(C$1B)OG>QL_:])[X1VR?FIK?.#Z0_"+?(TOJ:=/I?
M@B_IU/M38"RCEC&(C$1B(Q$L>+R9V))\EZGJ>"UPV'7KJ8O%:M-R?3L4Q;-9
M"M+6,D>_B%9)Q&+SZDZM79*,9PE>:2<_&S]5O,>Y@YFMQ\O?Z$DXX?'^[A[>
M';\7#-\.)$M#Y_U9.Y<'^6D I/6BM$6X^;6D1EZ;..:[/IF@*=+3Y&:,JT R
MZ<=+'C"Q$\S /#E8!])Q*X@@]4$$E>8\X^N5WT_^275WO=4GYM1F)$J+B(Q$
MT%/9&WMC;OWCM7?VMFSN>CGP>_ZS4^Q2G-ZOX4OR*?;J3 UE_*N,1&(C$1B(
MQ$]6CC?^;OH7WE]6_,>"SY54_&5/TV^T9VZ\AYA]4K1F$F,1-(KV3W^=QH'X
M.3?Z3+]G9=&?![GY9?L"4&L_C*'Z#_:$UI,Z:4T8B,1&(C$1B)Z>?9J>U\<+
M/@S:;^8T-GS*_P##KW];N?OGG8VO@UO\A1^[67NYJ3WC$33X]E-_QIX3_P!
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MWEJ]5<<WIJR ]Z2#PG?)6Y!0Y2$<0ASG,4A"%LE?,8QC" %*4H28B)C"(
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MCJ7@5;_=_>TYYY.?0IRL8B,1&(C$1B)O(>QB/S(-V?"RMGT-Z/SA^DGA]/\
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M9JM-_P -W&&+\Z0DH@5RP>^;IK=<=+,O'1.4_D\@Q:.TNO=603. E![Y;/\
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MC!51CBO/O3,J_P!V%RZ_FH>5O[=. /\ JVRLFY@=H^GV1]V%RZ_FH>5O[=.
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M:7K5.PMC0>WJ5":K5-RN@&&5!C!.<C;],J[W3C=5146LJ ($P48G(9CG(/\
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M7,AHZZ<26<.LE?E&[6_ZMY176#H#[9Z8)T5\[@U=46=U.1MDJ31K9COUF]/
M\_"EOL:9@F07(!!Y[OFVC.#YQVXDPQ/+:PZVX^<:-I1'&[7U$T;MR3X>5RHP
M\)LP81'7M1Y06^'J+=JK 0VHPJL,^U-&6BIS<E&N9JNTBP(NI.OURZ%L#:"C
M+(@CB1G.,\>W'G[?G/:)DRQ,8Q$8B,1&(C$1B)0[DIO*&XUZ+V3O"=B'MA9:
M_@/.+>O1[A)F[L$T_?LX.MP*;]=)="-+-6*4BXQ:47;N$8M!TI(*MW";8R)T
MD#)Q+;=D<RK5K:[4"C6/5^N)UCLN][8TY&V.L[Q\]1:6W*AI4VV]?ZXEXU+6
M*CV)G-JK0>PZ8E&3(,9>"E:DQ.RA[<-NAV8(QSY]O+F.WZNWG\4Y^.O)*6F'
MVVM0O]*:FT='<;K>UX^56J5S<;1Y$2UPK_';0NZX.BTFO?P4T5O'5B-J>W#5
MMD->:RWFAM07;M& )&2#%%M&>?Q''T _O@CQY)SQY?&1QXGQRIG&C9>S>0-3
MTWR34<P%9TOO3C)J+9\+J@41E[;4[OL:O0UX= [N9(^*1EHJ,A9HD'ZF+<9%
MX@20381)2*(NI@C!(["1GS<)=AB1&(C$1B(Q$8B4)Y*[SC>.&G+%MB2A'%E/
M&S6OZC!5YN]+%A-W/:NQ:GJFAQ3R6,SD?,T4^NMU@&\S-%C912'B5'LFE%R2
MC4C%PD@9^GZ.,MKOW+Z;@=BT;35GU-K&UQ.ZAWEK>M3T1NA*RU2?V[KZ*I\E
M7M,6.-3UD\"&>[0JMBN<A()S1CN:>EKNSM9."G8IPPFW2 /'Q!&#R\7C/S</
M;PG8T#RANMXA-J4TFD=0:KLFG[;:-&ZWUZAOQ'S#:[YK"GUJ;EZZR5#3U<=5
MG7]:B+!%&5GJI5+P]BZY%S+\E- 6,5%S"",8[",_,?Z[?GETN@=F2^YM'ZEV
MW/4IYKF:V3KRI7:3HCZ2+,N*H]LD*SE5X7SP6/B1ED&1W0IM)-6(AW#]IX#I
MS$1;A55@W01@D=AQ*NXD1B(Q$8B,1&(C$1B(Q$Z+*+C(TSTT=',8\TD^6DY$
MS)HW:F?R3@B2:\@]%!-,73Y=-!!-9VOXCA0B*1#J&*F0 1.]B(Q$8B,1&(E)
M=[WBXZUTYL>^:]I[/85ZJM5DIBHT1_,+5]K<K"V3 8JLJSK>-F%H<9MX9*.3
MDB1,EY&JX(X,Q<D3,B= Y\> \9YXF,VB]IC6.1/)O3^D-<ZEJL^G>]:ZIY!Z
M3VC;I<[IM'1^P=.[\FKA+)QZ-;6>URR5@E+=::.,3)#*.@O]T=O#(1E7?UFV
M)EMP,DXXD8\?#;Z>>?FE[.F>0=VO.^-RZ'V+K^OT2Q:LUAH'9+92%M5@L03"
M>X2[*8S\2DK.46F,I1K2IS7)FOI347=DKLD:P)0[EW%66OSD4BD8X9^,CT8]
MLNSQ(C$1B(Q$8B,1&(EJN]^2(:GV;J;4D:PK'I%L^D[SV<K9+]93U"A5:CZ!
MB:4XL[F>GDV$B9DO+S^R:-!HO%4/)("&?6*X.49@:RC6)])QPS\8'SG/L/T=
MLMKE^7]SM-JW-KD-.:FL=QT9$:CY 5Z/F+RI,U^SZ,M.NSW)INZLV!M4Y)BG
M+UG9D%<]=UQO#)2*4M(U(EEC;,P;RAD(E) _!X\\C/8>6.?81GESDVP'.9Z]
MT=H'9DE5=>.+MN2Z<1(JP:UKNU2R$QKJD\O+!38>H6Z5:FJ_GI1W&%M;@J,3
M+1%=C[$M 2BT7/@V33[Z1CB1V9\7/$R(XD1B(Q$8B,1&(C$2V_?&_"ZCMG'[
M7L?&L'EJY$;-L6OH&3G7BD?5ZDPI6G]E;LM]LL2Z1?&<M6-7UE(Q<?%MEVBS
MV;F8Q1=ZQBFLF];)(&<GL&?I Q+9D>5MNV9LICH%?56D[-,W;3V@]YZT<'V3
M_"#JJ\MIN4NZFV!8VMA3%64@CH:WZY@7T-8HJ%D1LP7/7\LW:5I^[.FQ01PS
M\9'+&,8^O/T&0>J\\]CW'AI*<B:YK#4TON576;S=E-XZ!NMVTLEIU?%I(-'#
ME(6] E[22QS]S8V#7%'9LJ7(0MBN*E58KSD6:9?(Q*,=]C/CQG'T^8?5,GB)
MSJHI**(G;J*))G.@H9,RB!SD QD3F2.HD8Z9A$AC)*'3$Q1$AS%$#"D3EQ$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B6N[0X:<=]S2TK/;)HI[+.34E79%_,+6&Q
MLY$Z=3O&I=E0$*FYCI5H=*L,+UHW6%E&LD$(-V_KBA7S%RUF[ WE$G)'+^N!
M'U$B<E?XA:8K4+KZK1R6P%*7JYK#Q5)H4AMC9,C0HVNU=W!OZ967],=VA6N6
M.%I#ZM03BHDLL=+OX4L<1D@_-'.'K-RC).<^/B9<]B1&(C$1B(Q$8B,1)*V/
MKJE[<H5NUCL: :VBC7J!D*U:(%VJ[;)241)H&;N4B/(]PTDHYV0# NQE(QXR
ME(MZDWD(QXT?MF[E) ..(E+8CBQI**9KMG%3/8'3S=\3R0?3%GE9*;EG>[8*
M/A(B'V +EVY%-G+1\16X2,;H1B#&,!LQ$YV)W3M^Y=).3Z!CYI$H7C9IN GM
MF6AC4DU;'MC8;K;%JFY60D9N2:;%=ZWK.HEK73W4PZ?*4.3_ (.:96*L0::,
M(@5C$)*@CY8Y?N7:,GZ,?-G/S\>V3QJO6=.TOK/7^H->1[F(H&KJ96]?4>'=
MRDI-KP]1J$0T@*W$'EYMW(3$D6+AV#-@D\E'SU^NDW(=VZ<+B=4Z03DDGF>)
MD^XB,1&(C$1B(Q$D39FM*3N&C6#7&Q(1.PT^S(-492-,Z?1ZP*Q\@TEXF2CI
M2+<LI6'FH29CXZ;@IN)>LI:%F8]A*QCQJ_9MUTT XXB4YK_%W2E?1KI4Z@26
M>5C=UJY(1<I8)!_,2">\+K&6^&LFP^^Z<"V1E7L=>[0V;L635I!Q*<B4(:*C
MP9LP02<GZ,?-^^0-[P\T#(0&U*^YJ4D">XK9L*\6Z=:W&X1]U86?:U=85#8,
MG0KXPG&MRU@I9JO&,X%ZGKN<K"1(PBC9L1 KESXJ,GA\6.S'#EPY'YY6G7="
MK^KJ37*!5E+ M 5>/+&QSBV6VT7RS.DP5575=S]SNTO/VZSR[MPLLY?S5BFI
M.6?N55%WCQ94XF%(_KL^J3IB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B0.R5R
M)ML*]K\XF\5BW_DPN4V$K+0;L1:.T'R HRD&^CI5H)7+9$YA:/4!53*=!85&
MZJJ1T2V)GP2XK15NC[[7]8*52XP[:LLH.P4V\['I[ZO,:BUV4QAV5;]&K?%H
M5UF9GN'9C>9;PB+!*R$M\D>Q%E%4V*C1)R<8SP[/1[!*U4'3FO\ 6<G99JI1
MLPE+VQ<%)F3L%QNEU? U)+3<ZWA8AU=;!85JY5V,O9)Z0C*E73Q58BG$L]-&
MQ#4JPE!(E3\1&(C$1B(Q$8B,1*-;?X_:DWPTCV>T:J:?\U15T@&#UC.V2KR[
M>O;'K+JG7VO%FZG+P<N>!MU<=F83D.H]/'O%FD1*BW+,P4'(QR,SLJZ'U&LI
M,N/0J.0>3^HXS1$G),G4I'RZFI(8T\I%TEM,L7S>5CHYBM9YMP@XC7C23(Y>
M@Y!]Y0V:*H(S]''^O1)94XL:%4H^N==!0B(534[[4,C1FS.R6]A+1SG0KM@^
MU"64M+*P-[5:VE'>1<>YBX^VS4Y'KK-4SR39\/>[R3D\?CS]/.7!8D1B(Q$8
MB,1&(C$2GFPM543:2=5"ZPJDB[HMJ1N]*EV$M,U^?J=L1A)RLC.5^?KTA%S,
M6[=5FS6.M216KY-O+UV?FH&40>1,H^9KHDMT?CSIG6S;4[6D4**@"Z-U"]T+
MJ=PV<2CB1I6HY$E (^I49+/G[J468.OX+:"=5W(/'DJ9:MM%Q?\ C+/5'*,_
M3QE-I'A#QGD=,5[C^-$FXO6-5:14= LJUM/;M2MS&*@[&M;HF&-M&K7N'VD\
M@V%G6\^-X1]<W,26109.!9B>/8>3).3Z>/'!&>W'*721T>SB8]C%1R!6L?&,
MVL>Q;$$YB-F;- C9J@03F.<2HH)D3*)S&.(% 3&,/412)W,1&(C$1B(Q$__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g451428g02a39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g02a39.jpg
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MENA^2O\ B(XMXFTCB'A^TTG4M;T2V&A-*7LM0DM+?4)9-0NB\ZQVMPK%HO\
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M_P!-.!O]L:/]TI[Y7D/Z\ML_:!*?Q2GZ0..O=AQ+_.M0^\4_0SY)/]-.!O\
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MHI-(W_M/5?1CMW,=Q(?UO1() 4F8^C$X*N58$5M_HN\B!VXX&\FWIRVL"?\
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M@,-F>OJ"_5,_]_IZF_6/=-IOS&Z^UIZN3AKW!:Y_-K#[O3X##9GKZ@OU3/\
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M,]?4%^J9_P"_T]3?K'NFTWYC=?:T]7)PU[@M<_FUA]WI\!ALSU]07ZIG_O\
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M69GAE><8CECC!0K$H9?U@#@[9%8[0A 8C)M&)94$I<2)&H=%CZNCMA@7)!]
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M;=P!#=PR-O:I!ZTBNY(W5F 90(@5Z#*P_P"&,X."._M#=C BL9\Q>1T1Y,[
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M,,,:K'%%%&JI'&BJB(H50% %=RLU;2E*4I2E*4I2E*C7R&_1#]H/W)5D??\
M!_6JY.[X?Z5X YOJ\3N?I8=LZQ.^6LQ$KY4;E:OD)?*24,C[U%E)):5L->2
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M;-DDT&[=!/!%!!!'"R:2**2>.*:222>..":>&..&&&-L<<;8VM:@
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MK5<G=\/]*^;QSL_VU.6'_$/M_P#Y[.5])L/^1L_^[0?^FM>2NO\ F9_^U?\
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MM%-8OMV<WV<&C:H:5B-X0MIM0NH\-N,95*5M):\=BRB38F6(#V&#2++AA=T
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MC>Q9!N(PW+D& ,MA\GW@-H([.WOJ>G1DS4[M*.;CVL[W]+MK06=S1BKI6![
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M-$P9]PV;+FA.*-F!59N@J^;KYI)Y8C)(3DNY.X-DLQ.Y<[6SG.X9.#VC)Q3
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M9 A$C\TQR+)RL*Y"7$"$F3US%Y!&?25'K6MI(%EE=V5%+ HNS<I0OE@"T4C
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M@IT2HUPN-)!,U63PN(?C2KNJ6%46.1)!)'(74-M9"'CV[@5;NPZ,ISU#=0K
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MQQQOE?''&U\\NMG>UK6OEEU<<>ME>W_BRZN../IOZ;]7'&W]5K6I_7MK)).
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M%R"$!P%1$10S=3MC55!9B-S8RQP"3THB)'T7H6(&69F8X'0;F)8@ ' S@#.
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MHRYA$87,Q6)1''9>I[3 TVD<"^H1FX<FYYSV]@Y01;HE!*B[:,K!*%>(D@(
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MWQE$H*CV\D)(,GB:0R+0E5THUM*I"432=X-4BJ[=V.B M%%<A*RS5[@R3;A
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MV> *\UK<2;$?>CVJJHCA8G C;9VMU4,XP=W2?G:!-H60E8YHE#,-K+,22\@
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MM[+%FG*#PB]RE!*^01]D??HD'+A!BZR&D!X/)B+3:C+M0K9WW;O[M^NX\GK
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MCMWG! /3QZ@4Y6=V2#N64#IV&1@0?@&1\-7"XZ,TN8EI8[*)?!9,+([+Y#;
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M6#WA6.L9&F7LL6'CW*;1X[;=P&O<>R;N54T<^TR3RZ^5NKC>WIO:N""6Y#-
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M$=,]",=WOU.7SI$OE$(^FH^U7,P? _P-;V]?'Z#]5/.D2^40CZ:C[5,'P/\
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&'Q_I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g451428g03g00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g03g00.jpg
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M    ! 4#!@$"!P@)$Q02%0 *%A<1&4)#_\0 '0$  04! 0$!
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MY\;\N006/)Y.?9_)Z!FBB:GI T4;!!,%!12%&XX4$?$<#@8]#IFGTXH='O\
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66EK4D'S6KD:*(R5*D3.8XRSDHN/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g451428g08y97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g08y97.jpg
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M 0$! 0$! 0$!_\  $0@!"@$; P$1  (1 0,1 ?_$ !\  0 !!0$! 0$!
M       '!08("0H$ P(!"__$ % 0   & 0( !PL(" 0$!04   (#! 4&!P$
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M-4G2,&W>1;4&@G$7A!F$>W^6'J%$@KW S8R,PXEP.5'#S(U SI>EY0 HI G
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M<LL6G0'-*\]^R..UU&(JP*9<-U1D+C)(X-BQX$;@8<K.9--*'&&PM(!(L<(
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M(INS%8 ++S-H-B1%PX^ @0!H3;\&$=ZBB0))48WCK4-7XKPU5WQH4;P![-C
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MUTR^ VN?V.4>L>R/BW6'P(/00>YB^2L7O^]^]3^\;XT\!M<_L<H]8]D?%NG
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MH<JS%G<@[(U16<G#'"D >4>^;6V6X,A:588H8S+*[>,P4$*%C3(,C,S*H!(
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M1/JI77NVU6UJ&Y >>ZN)AQR)*:<, $I8!FF$%C,& O)&<@"(8LY"#.<Y#C.
MYS\FOF[/KTZ3S*MO %6615#&0D*'( )$@!( &3Y3SK[Y6G1RWDM;:22YG:1[
M>%Y& C4,[1JS,%V':"Q) \@Y5[?!,S=I.?\ *_E]6OI!<^@M_P";_<K(^C-I
M]XN/Y?R4\$S-VDY_ROY?3Z07/H+?^;_<I]&;3[Q<?R_DIX)F;M)S_E?R^GT@
MN?06_P#-_N4^C-I]XN/Y?R4\$S-VDY_ROY?3Z07/H+?^;_<I]&;3[Q<?R_DI
MX)F;M)S_ )7\OI](+GT%O_-_N4^C-I]XN/Y?R4\$S-VDY_ROY?3Z07/H+?\
MF_W*?1FT^\7'\OY*>"9F[2<_Y7\OI](+GT%O_-_N4^C-I]XN/Y?R4\$S-VDY
M_P K^7T^D%SZ"W_F_P!RGT9M/O%Q_+^2G@F9NTG/^5_+Z?2"Y]!;_P W^Y3Z
M,VGWBX_E_)3P3,W:3G_*_E]/I!<^@M_YO]RGT9M/O%Q_+^2G@F9NTG/^5_+Z
M?2"Y]!;_ ,W^Y3Z,VGWBX_E_)3P3,W:3G_*_E]/I!<^@M_YO]RGT9M/O%Q_+
M^2G@F9NTG/\ E?R^GT@N?06_\W^Y3Z,VGWBX_E_)3P3,W:3G_*_E]/I!<^@M
M_P";_<I]&;3[Q<?R_DIX)F;M)S_E?R^GT@N?06_\W^Y3Z,VGWBX_E_)3P3,W
M:3G_ "OY?3Z07/H+?^;_ '*?1FT^\7'\OY*>"9F[2<_Y7\OI](+GT%O_ #?[
ME/HS:?>+C^7\E/!,S=I.?\K^7T^D%SZ"W_F_W*?1FT^\7'\OY*>"9F[2<_Y7
M\OI](+GT%O\ S?[E/HS:?>+C^7\E/!,S=I.?\K^7T^D%SZ"W_F_W*?1FT^\7
M'\OY*>"9F[2<_P"5_+Z?2"Y]!;_S?[E/HS:?>+C^7\E/!,S=I.?\K^7T^D%S
MZ"W_ )O]RGT9M/O%Q_+^2G@F9NTG/^5_+Z?2"Y]!;_S?[E/HS:?>+C^7\E4U
MTJ< 4IIC.XFF+"P"$6G7A+P4H%C''@K!Y."\I\B_4$P19P>5Q8%@(<Y&&]#T
M@;>!/;IL) +1,X91Y3M9F#?NRO;D]569^C*;";:X<R $A9@NUCV;D"E<]N&'
M:!UU!Y"@!_.AQ@19J<\Y*J(,QR3DRI,:,E0G.!Q\8#23@#*&'/ZA@%C_ $UR
M0,KJKHP9'4,I'E!&1_H1\*XFZ-&[(X*NC,K*>L,I((_@017WTJ--*5R^\(EX
MXUP?5_\ =;"-9D7V:_Q_4:V5O]BG^;]35T+[:O%SH'Z%*K^PK#K%?Z[?F;^I
MK D^TD_.WZC4UZC4*P4X0BFU%J4,O>&9&>MD]:*\RYL3IL8$<K:0EA32A($&
M?E,Y#3D3N$LOC.--:"B"0C&;@ NW>XMTGCZ/=,(;6ZE2*PUZ/P;<22$A8[G)
MDT^0GJ&;G%L6;"(MRSL0%R/+7[77<YEZ=]RJ[U'3K>2YUOH5.>D-E##SDGT\
M((=<MPO,OML,WZHH,DDFGQQ1@M)M.J[89?[?3-BO+%+E*8->V"VDMS^0K"(T
M!+BC-,"UKR2.9.+59+3KG)*L0&9*$N1*30I<+7(EO;%OH7NQ="Y.E>@V]Q81
M,^KZ1-)+:[0N);:= +FWD)8%5=HH623#K%(H,HCMWGGB\)_LI=U^#N8=-;VQ
MUJY2'HKTIM8+;4M^\M;7]G*QTZ_@58W$CPQW%Y%/;[HWN8)6%OWQ?16=G<PE
MNDX,:?J]X$+A6WJ+KEM5[BWD#K#GQO;5JB*5\ XPA;,T#VX)B1)FYEBJ8_,B
M;RSAE#''E2%N1X5+TA@1>*;B[CL4G%V1%-:JW%A<A9"P9T"A3S+,Z%!U\^9P
M*^R^FQ'58[6>R/'MKP*T5R@+0F-D242;@.2\-U?#8)ZNOD.JM'F@N#>VK1^.
MX4D,D&K=@"UM"7.4P9+84N.+,5JQD)@<@3G*98[B4N3@8 .$J !ZA4H$B9V\
M0T_&NC?1O7NZ!TBATO2K=I[J[D#3S;6[UTZS#!9+FYDP1#;6Z8 R=\K[(HQ)
M/(BME=T;NC=$>XYT+O>E'2B^CM+"PA:.RLPZ>$-:U)D9K?3--@)#7-[=R EB
MHX=O$);NZ>&U@FE33IM%HUSW0SZ:VU:L6 I-W&SM8\I@#_PTS76D;FJ28VJ_
MIRAY+4%MKR\I(I3,;6D# L,$_P H5)!9#'UQ@/7'=(Z66_0'1]*Z-]'M0,:]
M"=)BMG8<Y+C7;[2I=,Z/6;L-R<>UMI-1Z3WT3AHQWG81RC_XR)6^8W<%[FUW
MW9^D_2/IWTXT1)G[KO26YU"%&Y06?0W1^D<'2#IOJ44;E95L]1U*WT+N>Z1<
M1D7#^$]:F@.W2[IUZ5P  6 !98<   (0  '&,!" .,!"$.,?)C <8QC&,?)C
M&.+7ADDDDDDDDDD]9)YDG\2:^P"JJJJJ JJ JJ!@!0,  >0 # %8$<(3N"N'
M;]7U%F4<; DDZNO==1^W8EWL>./4KC; WVVXO#0>_#8V&3Q%>M4M:M*A4@)P
M\DEFI@JB.2$TXH\C.T^WAN))^/Q"D-K-<8C949C%M.W<RN ""1U=>#^!Q[J6
M2)(S'MW/-'%EP6 #DC. RDXY'KK"BVM_NXVB&7=O36X5]K.$7+1=<4K=,#O>
ME*O>9Q#Y75]EV_'JQ6C<*3L"QVM6@E3<^*SH\L(%9IC<(ET-D" '$QIT3YFP
MV%M<-:36ZRO#/)-#)!-($9)8H6E&)XXF!4J-P_PL\MI^L2N.]S+$)DE*!XTC
MD62-"P9'<)SC9QA@V1]<C'/K'/.E'O[JYUGNX*%L< N%^9]L9<X36S9K7'HD
M* ,\EKZ&=_,@B1 54Y2SCNL8U8&C9W1PA3?#GEY+,;$$I.,#R\X)L)1';NTD
M*M<[#%$6?B%9'X:L?\,QXSS($A=5YE163WRFZ10KD1;M[@#:"B[B/K;LXZB5
M"D\@:MJH.$FINY7"@DC/6U_Q)%N<E4HC%,/MAUVW11GF">(UCFTW.7(1J)4H
M7G0P]H*5LK4^)6]5AT?T1V$B8;":C?E4IM.FA$Y:2W<VR(TRQR%RA>7A!#A<
M;P<,RD\E(R=V5%$NHW,6%D F8K&67 ;:F\L.?U<9 /E(..6";<<.%/H@M%5X
MHW6NX>PI%<LKW$PFN(+7U<M$DF4AD>V21MD<L5&!N)F)"-"F/RY">V)S<'%*
MV#86YR6/RN/J"2$:F0TN<F4-+;QK"MN\DDDA5%6Y4M&<["2>6U@ 3N("AADB
MANX\(0LKF0RJBHFYB86VORSRY\P20,#F1RJ,BN%DCDRMK9)&J<H^W+"K;=K'
M[8<UTC*BR5'*X:\UL\ABSM&.X!\D(3#>*[D")V5W*2J4Y31N*J(Z^QA;*0NO
M,%W?!+)%?---%'+:-$ N_*L)!O#%MN0LBD"' R[AE8+C-0[\#26ZI&[),'RV
MWFI0[2N,]:D'B=BX()S7ZKSA,XO%X7!$L\2W/N&LFX+CW6P:L&2G*&:6J2/
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MEX,ON)PC 5?:KE6>)<*[,JY+. &9E8*A.XX)"D<ZIWU;[=PD!7)&0&/, $X
M4D@ C) P,\S5W3O?YL]K9FK"02^]HHC:+DC!<WKE4UHY%*,OT)&!,,4T4)HL
MR/2N/Q!/TLHM=)Y*0SL;>>%0F7+TZA&K*(C'87DC2JD#EH6V2 E5VOS\0%F
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MW?IK#8MSV9/+8Q',)R$BH_+\_-31S*5>L&WH5)W=!6GYLA:O+,0I#A\DM2L
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M<72-HG\MQB>,D-B?*.Y'J$<EQJ?$G4F5E6SEE>>*,01W#MPED@ EB5D*,
MQ7#]9J+VSK%:[8SA 3,B*CL9&0+O99#MD(((.2< Y'(5;-F[#-T5<4_MZ(VD
M06TUCS:VW:ZMD-X)K<7ULS3^LZ>MBW#YY!I=)6Z$REUAZ9/7+<_S1L:VZ+OC
MNLC<86,+$2<G4IU"0F<5_:R37)NY(L17$%] 81(8Y9XH=DBJ9$#_ .(RH264
M!G!;!!R8O;3(D0A5\O%);R;M@9(W?<K':V $!8  D@$#R$5[;ZX/"QB]RML1
M<59WM(*3E<9VFQ7;38%$PG;7,'RJ8[0<1CC"7&QSJXY/&9O09L<ES$.3C<Z]
M, W2] \.2IQ N<,#;3*6^H1FWB?BVZSH]T]REQ)=()6G=FW!(%9)]R-LQ("4
M*@+@<ZK);/Q77;(T;"$1-&D+;!&H&W<[!H\,-V5^MG."<U>-A\'[93U)]S%Q
MH* +6W@OX5"F[:IZQ,=[G?HFH-A?:S72*01=]-=0JF.-8_\ RQ6]-91S>K=C
M40#5S<M-:VK*6$>H1A;6$W&(!I<T,T?C;..RR!590/&;Z@4D$#)P1DYJ]LY,
MSB/,O?B21MRW<(%,E3GD/K$CD3@9!Y5:%B[&+,:*HX46G*ZV;B03FW=ST"M:
ME[1B3%4[1'991RBZ=NDJ*JZ//J9_02=O#%,PZ;S9RARUI;HRV&E*U1!PWM<4
MF52COHVETR:2\RD5K)%-$[2EEGX%RG%92I4[]Z('!+'.#XHS46MG"W:)!AGF
M5XW 0!H]T9VAL[N15F*D #KYDU>%M<']94DDF[NX6V@"W&[G3A(Z#M.C+"QF
M.8F:6FXV\U4IE<AA[Z<[ 51]C+*(E)SXB+.;5CL)N*&L1+C&EIREC%?QJMG$
M;C$ TV>*>/QMAF990JNN,,V2H7D0,\B,G,WMF8SR"/,O?<;Q-RW<,&+<0<\A
M@/D<B<#(/*L:=HZ^L7??W K+M..%NS3)=]&],G;[)XU7]+29PD]G2N23=&D4
M6A/55IG;A'"'0EACYCG 37S;]$4,/D06-Q#*E+,C;%0<B[XPL'BB8@K8V??"
M,\ZA8D1">%'PA;AW9@) MPY9,@H#D5:@*&X5W7DUQ.(F"QL6<LWUWW\7"@93
M,2A3C#$;:R2X1F%HY_PD<BC*G:>Y[O5KGP6;RVQ>$-6(0>HA,V?;RG\:BEFY
M23M\8D*<#"XO>&@V2L1JV6P]/(#Y"R(#L(UAA6-ISF/3E878M NI@LYX@XB+
M#&SQ9C5CXP&=C>(Y4*QYBKMTNZZ9>"9\VF HV^*QD<!_'*CD3C<#N4$D>6I
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M4Q4%A^XD9%2;JU4Z:4II2FE*:4II2M>"'Y;@N?./EQWWJ<<>/E^7"5#C./\
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M6V\\4#&+TJY_NE@RY >*R:)FR+Y@A4,H!&/:$UH3JS% G)D+ 88]-A6!N#0
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M6.#0M8R$DAPO4NQ2U]4-V&1"SQ@L[)UM(6A9Y;NVNGXXF<!'A,Q1UC'BG(0
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ME,SCECR>H::D=A0\I"1$IV^P&$N\QBY#8/)C:3'I,X-*AZ92FXS.3$!;:M3
M1C$(:;!0A9SF:S7"(T:RS+&^2\:R2!')ZRR A6SY<@YJ)2)F#,L99>IBJEAC
MJP2,C'X&JLY5;2KP1+$SO7-7.J:>/C))YRG<HA$UQ$SDD:&VF1R0RPI4WFER
M)\8#&9G&R.SP%8O:AM3:)"H($A2Y*H)9QLQ)*.&K+'AW&Q6SN5,'Q5;)W!<
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MW;",WFG:1I]UJ<MCQ4$L:7DL""UMYC&R.;9KCOE4DC=H51U8QK#+7V7W0N*
MSRN.(GQ8/ 0LLG(%%G,XX8Q8 0G"]E)$;@>/..,)3:K6F9X\?ZYXM8^N]ROI
MCH"O-?:!<RVR LUUIQ34(%4 $M(ULTDD*#."T\40Y=9Q6;T,_:2[D73>2*TT
M;IO86NH3$+'IFN\70KR1R2JQ0C4EM[>[E;;N6.SN+AB"#CK R'QM\K'../#
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MU>0<B.VJ&>5A@N<?O/QJ5B""4Q0"""P%%%AP$!8,8"$(<?)C&,8^35PG/(#
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ML,$1H <A2"S$<P 5;6FZ3:S^&GW1'4[693C5VR&K71,[3-T;49:!SD3.E5'
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M7$*K$BM+P9VW)(RDEY#&"023C&!RZZ"X,<LN5)7OF.)V+LP7?&,%0>2J&(!
MP.>?PKY2_A5K1\#":YH5'MNC.U2R3;EGJIX[/Y1;[M/;0I>C9+WL1>4L$%K"
MO)6X)#)NH:Y"K=9@_.3-!HF1F/\ .GN2=S.7)9)I47&X+M<L52V$K1I"(XII
MUWLK/+(@(0,@"*&D<EL $ $;Q]F\"(;FE*!V?<Z1MM4A45CXV#EB0J\NO)Q2
M(CO3W973NA2 9TE?,>V>P>"^K_=J.N1RU];YO&F^?HWKND_L\O98"2[^%-%,
M0*H<D0ER%##"H$V-$S2*$4U4K&=-5[*UAM3NXC7,>J/:<78I1BF,*49R.$4P
MY)4OQ"R<TPQHMQ-)-R"B)K-9]N2&&[=DA@,[]WBCF%VC=];E5JUIP@^XMEJ.
M@JZH:H81.74/!NIMZDBD%\7//W)U01V)2IVC<ECYLBQ'WZ03N2.84K2CCQSH
MI9"L+W4U4[.J1K:L)U$I-/MVFGDGF>-?"/>2K!#&%+.@96V[U6-!XQ; ;D,
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M>)!.YD^NZSN/TMU>).]N;DJZ.P-24CI*Y:N/5'\PE()3$\Z:+FB"2B0<DLL
:<6VY$@<@.H#D.KL%7T50H 50.?(  =9K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g451428g11t01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g11t01.jpg
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M 0$! 0$! 0$! 0$! ?_  !$( -\"3@,!$0 "$0$#$0'_Q  ?  $  00" P$
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M<&R)"2IGT&,"&(4LB2BJS[;""QW3LB,V&1F?@M]9NRHMS"S.P15#@EF;&D
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MKUE>=7/A^RRZ>3XDCMTA*PM!*LQ=4!,DBP20AGR=S\(&W+;+IZ'(MWQV:5I
M9!(AC"EL!$,BR$#;'\G3L!USZ,51.S?;^C;ZWQ2=^U72AO6E@K!VLS9];F[:
M:NM0Q5J&W6(.O:!1 T;6M*9U[5J>$KJPL&(Q\O>T19;,A_'ML:3))3;6CP0/
M;O,LJLK@,(BCZY"YDDD8ROS&=FU$^'!&!L0!6:X66591&4(*D@R:ETI@*B (
MNA5 QZ?7USG*Y/Q-39,Z7-.:GC(P6OOB(WER&J]2W6VU]_:#"HTL9EQ593AU
M&J$Q%DX$I32<VU4A<-R/6L8S*7B'#5"*O-\V/A\>1&!^02-(#C5_Q=6",^#
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M3BE.*4XI3BE.*4XI6O'Q9?X-[N)_0R>_O,#G0X5^<;/],OW&M6]_)+C]&?\
M2OF>\^D5Y&G%*<4IQ2G%*EWU&W[4-'7F*8O@<R4#PL&'Q$P W"DD0T\Z.C"B
M^<PIS\)N5#*18(O,A;<YF3&<$Q\,MOMR9+?-.\MWG3$94,=(8-D!@I)&X!P0
M2<;8(8]-JV[6=(6^$!(W*D;E20 VVV0P SOM@=:F86\12L!=86JO4659Y=[A
MSR+-!.V>KMRX*J_-)(DC63&9=U)3U%:Z+EOAV",]TL@HX'@E9\-U9&5 8T5X
M=(TB&0*$(',"-@Y P<>#&&(!( &-1 .V:W&OXPC!"Q??064XP3D9\6<@$C.=
M\ GKBM25CL1RW'2MFLI26:/&YCL\J4G.>ME3);V?-;KBO+"4XQC"4---I0RP
MTA#++;;3:$)["JJ*$0!548 '0#]^IZD[G>N4S,[%F.68Y)/I-47EJK3BE;A*
M5U7TP2ZP=2*Q$!:C+]N^YITW"JD+8=L['"KP$KURW:O1FK;920] @)TC@($G
MUJX6NP/[.--$)\!IKY+"G$,M#Y/(>ZF%S=L3*+2S52QC2W*,RP<^57,AY^I@
MR(O*4@'SBN2:Z"01F& 80SSDA0S2AP&DY:,H7X/"X9CK()QL#7N,>&=I> +%
MWJ-VGN[6IVM6]B-NVRVG^N384]!IV@]CT'3< I5:HC<I!-GB[>V9;2@;7SA$
MY5\IB"H+YM,%^<18"%XE,6:,VJ<WFV\2(MQD%YXY)B';D^$PQ*K285^ITY &
M1LX@ PF?1HE=F,0!Q$Z1Y4:]P[L0F<; 9WR!D8OX:FN=I5W53.N+QC7K&I=3
M=<+7VALYFEO2YXC7?86I]ANR!7L%<6_GNJ&-G:^U'5*'4\:\B+BPYQ.:)')M
MK)&6PHEB'$I(FEYD?,YTMPEJBR !I+=[>V%NG@SB29I'YAR< MHQG&1K.-P@
M1M'+2(S$KOHD660R-XANJ*HTX R<9/4Q:T/X=\G9KYLK=]L@PE,:):5JE5E:
M5D:V[*W2P7_L5:CU8U54R]5U[MR.)I4]IBJVBRWT=9+?%LM6$!,1X]>+SRPU
MMS;GOQ$ $B9GQ.S"?F6J+';(K2N'DARX.M%C*H49FR74*2,$5IK)UN N4"\H
MI,Q:5BJ A7PO0LV6! '3<5D78OAD4O6]3L$\MVCK3EU/VG80;KQ25 :>R6W(
M+I^^I^@JO+EUQK;<S9M9G;0. ;78*W*#:XNM""A:_P"ILVP!Y4C[! QQ\2>1
MU M6T*D;7#ZGQ"7@$[88PB)Q$K*K!I8W9F!5"HR;O9(@;,XU$MRAA?&%D,0\
M/,U@N02"%90!NP)P,7=N.B-1Z_JH$/5>\)^[2=U[![TZY>H):T;UK&?MNDCE
M! 3C-7E*OERR>K!$Q?8]?<)D6J]A@^#+H&H-A<133^6TOGGYAE@$ 2W@N=I>
M;A)Q(P5_@TTN!&6P-659<Z3D5BGM5BTZ).86EDBP5">*,J"5\397+8)V\0/H
MWJ6%"\.'3^L[]F[VK8LK==%T->.VE&[#T^RZYE:]K9*X]4>OYK:%H5KDY#OQ
MPS?==-WI5?U[+-D15",O%9HY] /$0[&;:U'XC++'H2/D23I:26[K()&"7=PL
M2\P&,+'+HU2:09 %!\64.=A+2-'U,_,6(SK*K*5!,,1<E-\L@8A<G2<],5R\
M^%A1;1;:/5;9M'&G77A%2UFW(UQINQ; 07OU"ZR4CLQV3V%M#YV[QB-U450!
M6PQ=*?,5R2R,LMO8;0.U]21,,B_EY3D5'9(N< S2GF3+'B.2ZDMK:.+1 =1D
M,9D <91#@R2,0*DV2$J&?EG 3P(6RR1"69Y-4GATAM)TG!;&$ ZQ%VQT)"ZK
MT'?=B3=O%)FV-25OK/;=F:ZD:X:&T<=%[4 LVRA5"K[0^?$R99]A :B\/LEN
M$*H(H(Q$=+,AK"7R E/R=J*^,MQ'$(@(I6N4BDYF9";5M$CM%H 6-GRB-S"Q
M(&I1J &O):A(6<R'F((F=2F%Q,,HJOJW<*=3#3C&<':M;_.C6G3BE.*4XI3B
ME.*4XI3BE.*4XI7U1^H/X)G5[^KMI/\ 5K6>?,+W\LN_ZS/_ ,UZ]G!^(A_1
M1_X%J1/-:LM=#3_*3_X0FN_U;M;_ .+]F<]SV<_-[_UF3_!%7F^+_E2_H4_Q
MR5U^N=^N73BE.*4XI3BE.*5,OH?V>K_4SL)6MG7*C+V'1G7ZV,NM=BSDP"J@
M0;8U&V(V1"./MNP91,<:H@B2D222V/.0TS S\X3[>@O TK^U:[MVB23ER#4R
M,1D:FBDB*MC<!ED8:ADJ<, V,'9M9Q;RAV74IPK '!P'5\CUD%0<'8[C(SD=
MB'Q%?$UZ";GU1ZG56Q&=V5&\(.2=Z==-@3NU]4M5B)D9 E_7Q_5I2=5Y&MJ7
M;]8V5Z;8IZU6T54)]4'OU=L%;7DU2.!\]P_AM_#,.;&8'0*(+E!:NB 9UK*
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M*P@=Z(!Q?;79^@(VW9V=:Z>TYG?NP-J$->H8M8/74#3%9V^?'XUA"N<^)-V
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M&8D[C4PR/%C&20,9 R,$#++E@ 9*Z3Z8W[4^V(]^D[ZL!2ILA]@QHFMQ\<A
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MH9RM6'$;?F(PM5B N(IV=<,Q$9A9E P-.HQ,%P<*LA4 #4&@VLFE@9B^8W0
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M%8.*:6'.0Z>9--KC\\22K,HV+("JF7*C4"F,H1J8&9+3(\#;Z432_FE4*'J
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M-D6')TC ;UW=;?/J-'K40:3F0I(ER/!J=UA3+.(Q$PS((F*Y.ESC+LM44N"
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MHD] AJWJJT[#D[=VI6ZM8"T&HWPS6JM4IUHJ]4FQ_ERHU\P/B[&LA>XAHM"
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M+WR=!^6_D?$G CY7]F:^4ODO$W.9F!WMGKO8<2\YD^S>J]?GUOI\5%1ZV?\
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MZ[2U!79_R*2$6QV96@T6@1;9LBW1BV)M=HKI[8$:ERPM>)PX]O)@90ZRL =
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M;3BE.*4XI3BE.*5V4/\ )A_PQ]Z_U9ROZTM9<\QVG_$6OZ63_ *[/!OQD_\
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MLU:A%@-@D$JN/=N$*?-:>8K;Q?) 4H",Y/3Y-ONZ?35Z=5-,3NO6A*)IN=+
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M2C+%F+2F!V),H=;B2/!CYIFN5O2,B)[GM$XVX; %_'5M<=U821QVY"Q@1B&
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M,=_9\/::U5DN.5/,C&0I2<Y5Z+:4XSG/HX\UYRG'G[L>>5>_.,>[SSCW_?\
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M4IQ2M/>U^FV[!G:VZ=KJ-*&%*V?[!ZTV1L37+)(A(,W?5^D>OVK!E$G5@:U
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MZ@;F2/!!,X,8P!-%'J*,"KDJ) 8]BI8C((S@Y&G(CAD&E5DD0>,[E'; *G(
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M@[$U]41IB5,..$IIS=:_GDBD9X05(EC$H5M*S7&DL=39 <1K*44$%>8Q&%
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ME+AF661@I5ARQ@;9"Y 8EFTF1@2S,1J-9M"!T?6VP*J,Y&7.^3N<$@ #(4'
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MRP)AN).';5"T4*RQJ96T.0!;=\F5D60,&6$'#+K"G.5+ *9%DFD8D#R,CD(
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MG&2!UVKE$/#!$GP%/%5790FH[GL5QUWKQ-%M$\Z=K#TX?UAJ'97L3="=RB4
M"U61^K:S?PDJ?5TQ+ Z(8KUC$M6.UF)P!4V!Q-E:0O$7A5)).8@4-O=/;6T8
M7F-J,K1L ^0"64E44-@;)6"A'"R,RII))7(A6:5M6E<:%8'!!Z,,DXS3M7>&
ME4V[J^;VAO\ UO9-.@F-C&VUZXFV0F:V+!TGH$3V$W,!'' ]=/U>CDM;UZRU
M>K6F?9#'R<W>"RJF)F$"T9]+,R\1;1IB@E69N6")0JK$9YS;PLRLRLXD=690
M@)Y8UD $9)9KKR\J-&-9&DG+B.,22#(#!="L-63URHR:COU]Z5/;41UY+6G8
M54K:^PVU(U3UUKF4NV1+1<Z57+W7ZEL^Z.6T52;;5* "K;)"PR(I6Q-SYDM%
M+MCT2O3WX <=8MBXO.5W@)&S=WB+R2#051VC9XDT-(CNS879<>>@U#+%<,5M
MKY)9P.:^E$\6IE5PLC:@K*H4$G)SYIV) !NVS="102OS=BF]^:VU_2(U$UGM
M&Q"RXW9]NL&L0?8:! L77FDV5^O:Y8Q9;O>*M)+V*7BNC/8PM7J90^80.FE
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M!!N+-#"LH9BPB9I%RNS.N;<+MG#Y&K.3UQCK67/HFM,C]IV:JS-QR;/4QW9
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MRDS,(M*>>*-2YUEL)ZR2?^&9:=L1DF=4W\K3I,QR>Z6WB^ C&M0C * "H55
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M@-1H,5IA.1(8HL<N-$PN@:5"^$,SZ=ATU,S'ULQ)W)-4>623SW9LMJ\1)\6
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M8C.$7,41?F&-"^H/JTC5K5&C5L]<A&90?0K$>FHYLFG1K;3@KISMAF#$?,6
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<Y/RL-F]8VK$',M8Z<4IQ2G%*<4IQ2G%*<4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g451428g17g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g17g02.jpg
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M>12^]6.E,)Y3^HT?*(O!K_2W;'LGF_S./D_REY%+[U8Z4PGE/ZC1\HB\&O\
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M>12^]6.E,)Y3^HT?*(O!K_2W;'LGF_S./D_REY%+[U8Z4PGE/ZC1\HB\&O\
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M&E*+U"P4 A+9FN,HNP4:[',Q %KWO?:YFZ&C_!O[#LD+N>=WQ$3>J65(Z?\
MJSV=1FJEEI+.U6"[=*;1\SM<,]H4BX>VQY46UTCGM-F;"P9,6C:7CY%NQD7:
MC)R5''6Y1IJU%:!%4OB,+2J$*Y14Q1!1A4 "!BC!U4DD@BX%[S12PC,'-4%
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MBGF"E<W-G.=;*/&(.DI.&K!"Y2P"ER"RA@@8H6RDWMF&7M)V!&L[WJCHFO\
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MM=-021>^H';;737J*T$UZ=Y.^4&X15IB-GUG>6Q->L&#V=C'<4:EZ^5:,%[
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MRSA<.,14"LV522"1N2%9LJWXV4DG4 #7< Z0YMF:,1&(G]17_HN__M[ZH_\
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M@Q9>:E'KQ*2<NWQ7 Q_D;]L5DIY9%+D]*7@PYPNN&HU: 5E'7IULN;/8[C*
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MOVWDR:DL^9K ,_'O&B\4[DT47B*",?X^&7E.3EIU*-5:K9J-?%5A=5(;PO\
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M<Z#0>C2<7DR(Q$_J*_\ 1=__ &]]4?\ [H:?_P#&:F?,_P"IO_;X;_\ 9O\
ML,]GD;_<K_\ 0G_<9_:-GQL]^,1.+FX.%LL1(0%CAXNP04NU58RL+-Q[25B)
M-DN7LKLY"-?HKLWK58O[JK=RBJBH7N.00[LE69&#*Q5E-PRDA@>T$6(/G$@@
M$$$ @BQ!%P1V$'0B:WQ'0_T:0!+"E"]*G3S&H6V,^!;,V::?H236=B/A2/G
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MK@^VOJ%_5C'3G*GTK\##_LQT=@_F!Z]3]<?$1^"K^JX/MKZA?U8QTYRI]*_
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M7D>5]<:VT]/=O[_YHL>.NNQT]-Q?4>FP&AX3V/R)W&(C$1B(Q$8B,1&(C$3
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M7#A11Y(O7CYTX<+K.'+MRNNLJ=10QAMKUZV)JO7Q%1JM:H07J.;LQ  !.W
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M<1&(C$1B) ^;^I?Q#$@[>E?>).),8B,1&(E#>=/^<?\ P'_\]_XX^,@[KW_
MR^),8B,1&(E1_C+_ "F_$F)'$=Q]ZRV),8B,1&(G1]@WJ,UY!Q\W+-7CQK)W
M*@TE--B* *I/MAW:!HT:[5%PL@0K-E(6!L[?F*<5BLT5Q;IK+@FD>RE3-5BH
M(!"5'U[*=-JA'>0I G#N$ 8@D%E73M9@H]IFB6IJS!U.^:/8_P"US9-ZI55V
M7MO3NG*-+5V@0B%+G*14-@QDT\M%E@F#2QW:)95^JS\'6E7JB*CE1]'R\\UD
M91!.0:^A59GIX@\S2IU'I4:]9PU1BZN]-@$5CEIL696< &UBJD"XF= JM3_J
M.RJ[TZ:D+U2H93F8>,+ Y2;$Z$W(GI+GES7,(]0%(L.P]?J5:MP-4GWC^78@
M\3M[Y5DRC8H4G:,C+Q1/@.Q,'EE9H+"6O)S,4ZB6,FLA-N$'2D4@R=)!%QL#
MW[37Q/I4LCF1FW[F2:13QO.MINL3$=89)[*2$T-YM$W'6FV*NXE)1[*T6GV1
MM588AG+MQ+I0B+9:1CH91./)-_C[=+ >\[Z\;:\Y3?8;\3KIL=!M;2W#3:;7
M:JB+9 4*OPEU"").Q+=6/,G6RN B4XYHX50B$D!=\KG.2+(T*NHI^^=8#F,8
MQQ,<T3K6V_Q]I&OV>W69"X'TC_;W8BQ[3[/RC@?2/]O=B+'M/L_*5X'M"/:-
MQV2AQP7CSF[_ .'GD?,/?QW!P #SRCS7.@\W&_F\TMP/I'^WNQ%CVGV?E' ^
MD?[>[$6/:?9^4<#Z1_M[L18]I]GY3\'31L^;.&3U!%VS=H+-7;1TBBX;.FSA
M,R2[=P@L0Z2R"R1S)JI*$,FH0QB'*8IA 9!((()!!!!!L01J""-00=C%K@@Z
M@@@@@6(.]Q;6<57*U7ZA"QU:JD+$UFN0S9)C#U^OQ<?#0D2Q1(!4F<;%QK9J
MR8M4^\2-VR"21!$>P0H#QDN[U&+U&9W8W9W9F9CVLS$DFVER=A.%4+=5 4 *
M   +#4[ 6]DYS@?2/]O=G,[L>T^S\HX'TC_;W8BQ[3[/RC@?2/\ ;W8BQ[3[
M/RD"41 0[1@Y^<.SS_X<18]I]GY35Q/H[T2/5:OUI+UI^[W\.O4M7,[*^FY)
MW&Q-5265.H6&KZRQHN,DGK==5@\D&R)3K,E5B 0BKIVLXW'E'%]'KR873P45
M37RJB!V8F]F<#,1?K6.H.@(%A,O@>'.,\.RDUQ3YD$L<H'$A;VS6-K[6OI-I
M.!](_P!O=F&:K'M/L_*.!](_V]V(L>T^S\HX'TC_ &]V(L>T^S\HX'_F'_\
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M$/N\P>;$Y&[>CW2<3J,1&(C$2I?]7\PXD#CWGV&WPEL28Q$8B,1(+YOZF_\
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M7)L2)GPWA)1O"EIJX<A.;8L"EA8F_&]_1P&TV(X#[?6/OS+-,<!]OK'WXB.
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M;397NGUVIR-%I]/4(WG;-<K9+1IG3E!F_.B^JS" =.6[H3OFADEDI1$/%IJ
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MZS"G)>%5RP6I<$$7J.03;B+Z]_Y:;@D3(F0J9 $"$*!2AVC#P4H  !R(B(\
M'G$1$?.(B.> 3<D]NL]$ #0=W;[3K+<!]OK'WXDQV0^WUC[\2" =#,8;4T[0
M]S0K& OD:ZD8Z-DB2S(K22>QJR+TC==MVQ59K)BH0R+A4ADE0.0>2F  ,4!#
M7@\;7P-4U<.4#D93GII46W_2X(OY]]957H4\0F2H&RWOU6*GT$6(]$P_6^BS
M0=6GHBQQ5=F"2<%)-96-.O9IA=)-XQ6(X:JJ)"Y JH)K)D4[!Q$IA+P<#%$Q
M1]"M_J#E&O2J47;#Y*J%'RX:BK%6%C9@EP2.(M;A,E/DO"TW5UYZZ,"MZU0C
MJ[7!:Y \^_<==K^ ^WUC[\\2>C' ?;ZQ]^(C@/M]8^_$3#>U]!ZTW2,*:_1+
MV04@ >!&*,Y:0C3HE?BW,Y(;R-=,J@',U0, G*)B]@2E,!#J%-NP7*.)P#L^
M'-,%@ ><I4Z@%KBX#J;&Q.O'3B!;/7PM'$J%JAB!>UG92+VX@^:=+H72-I+6
M]JC+G6(&50GH8[@\<N[L,L\00.Y;+,U#^3*N/$J_\.NH4I%2G3*8P* 3QA2F
M+JQ?+O*.-HG#UZJ-2.ZK21>(-@0+@7&P_*4X? 4,.V>GSH.HL]5V%M1L3K[;
M<-";[,<!]OK'WYX\W1P'V^L??B(X#[?6/OQ$P-M/IKU/N2<8V*\P\B]EX^-+
M$-W+&;DHTOD!'#AT1)1%JN5$YB+.ES IXL%! _9,8Q2D OJ8#EC'\FJR82L$
M1S=E9$<$[7ZP.OIF3$8*AB2#5#W L,CE.-^$_+5_3)J/3]A<6BD0TDRF7,6M
M#J.'LY)2"8,7"[5PN0C9RN9 JBBK)N(J^+$Y0*)2"4#F 6-Y7QO*%,4\2U(J
M&SW2BB,3KNR@&VM[::Q0P5##N:E(.&86.9V;3N)/F^R9^X#[?6/OSRYKC@/M
M]8^_$1P'V^L??B)K?L7I/TOM*TOKG;8.4<3\B@T0>.F4_*,$EBLFQ&C<WDJ#
M@&Y%"MTTTQ,1,H& A3&#M=HP^Q@N7N4^3Z24<-65:29B$:E3<79BQ)S*;ZGC
M,5? 8?$5!5</G4:%:CJ/2%(!\\[+JCI[UAI9W,OJ%$OF#N?0:-9%9],2$F*B
M#)599!-,CM<Z:( HNH8YB$ Y_P!T#&[)0#,^.Y3Q?*.3PIT<HS,&%-$:[;@E
M0"0. .@N991PE+#EC3SW;?-49N-]B;<-_1M,U]D/M]8^_//F@ #:. ^WUC[\
M29 D*/G#GG[1]^)%A<GB=YJQ:^C+0MRL<S:IJNRYYB?D%Y.35;669;(K/'9P
M.Y5(@1UXM$%#\G%-("ID$>$RD*!2A[5#E_E'#TDHTWH9*:A$SX:B[!0+ %BF
M8Z::F8JW)^'K.:CBIF)N2M1P-3KH#M;AL/-:95U5IF@Z7BI.&H,:[CF4O($D
MGX.Y)[(JJNDVR;5,04=JJ"F0B*0 !2 '(F,)A-^Z!<6-Y0Q/*#I4Q+(2BE5%
M.FE)0";G1%%R3N3?82VAA:.'5EIAK,03F9F-P+"Q)T%N$RGP'V^L??F*:8X#
M[?6/OQ$@2%, @(<@8!*/>/> _-SSSZL;2" 001H=_/-07W0OT[/WCAZM69HJ
MKMXX>+%2M,V1(%7)UEE>P070B4@J*"!2]H1 ."\B'//N4O\ 47*5&F*:-A\J
M@6S86BQTM_<4OP&Y]L\Y^2L([%BM6[:&U:H !KL ;<?1PTF?]::OIVI*R2HT
MA@XCX4CYW(BDY?O)%<[Q\*8N%3N7BRJH]H$DB%(42IE*0! O:$YC>5B<35Q=
M5JU8@U&T)550<3HJ@ :DS;1HT\.@ITP0H-P"Q8[ ;DG33;:9 X#[?6/ORB6Q
MP'V^L??B)\4G&LY>.?Q,@D*["39.H]ZAXQ5/QS1X@=NX2\8D<BB?;14.7MIG
M*<O/:(8I@ 0Z5BC*RZ,K!@; ZJ;C0Z'4;'20P# J=B"#8D:'SC6:=FZ!NG43
MB)86RD*/:'LDM,B %$1#L@01Y.4"AVBE #=Q>[GN+Q[R_P"IN4U54'@I"BP)
MPM(M:UM21J>^><>2L(2=*HS&YM5?<;::Z:GXWX;34>DU[7=4AJ756JK* @6Q
MVL<V6=.':I$U7"SI4RKAP<ZJIU7"ZRIC&-P G$I"D(!2E\2M6?$57K5""]0W
M8JH47L!HHL!H!M-].FM)%II?*HL,Q+'MU)N3Z9VO@/M]8^_*IW)XX_\ F(_C
MB(Q$8B,1&(C$1B(Q$8B,1/R171<$\:W6273[:B?C$5"*D[:*AD52=L@F+VTE
M2'24+SR10AB& #%$ D@C0@@]ATWU'VC6)^N1$8B,1&(C$1B(Q$8B=6M%YI=(
M)$J7.W5FIDGY=I 09[).QD&69G'YNPRAXL9)TV!_)NS_ +K=BU\:Y5'^!(<[
M2F[WR(SY06;*I:RC<FP-AYSI.695MF8+<V%R!<]@G:<XG48B,1&(G7Y6V5B"
MEJY S5AAHF;N#Q]'U2)D9)HSD;(_C8]>6D&<(S<*IKR;IE%MG$@Z09D6419H
MJN%"E2(8P=JCLKLJLRTP"[ $A 2%!8C8$D $\3.2R@J"0"Q(4'<D"YMW#6=@
MSB=1B(Q$8B<'+6:O0+N#CYF9CHU_9I/X&KK%VZ21>3DJ#5P_.PBFIC>/?.$6
M#-V^<$;IJ>3,FKAVN*;=!50O2HS!BJDA!F8@:*MP+D\!<@=YM() L"0"38#M
M.]AZ 3.<SF3&(C$1B)UJSVZOTYM'.K ]4:EF)F.KT2W:L)&5D)29E%#E:,(^
M+B6CZ1>*@DDY?.S-VJB4=%LI"7D%&L7'O7;?M$9R0HOE4LQ)"@*NY)8@ ; 7
M.I(47) /+,%%SQ-A8$DD[  :DSLA3%, &*(&*(<@8H@(" ^80$.X0^T,XG4G
M$1B(Q$^%S*1C)U',7DBQ:/9=9=M$LW+MN@ZE'#9JL^<MXYNJH19ZLW8MW#Q=
M)L151)J@LX4*5%(YRR 2"0"0-R!H+FPN>%SIKQD7 L"1<[#MXZ=NFL^[(DQB
M(Q$8B<*ZLE=8S476WL]"L[%.(O7,+ .I1BWFIAO'$*I(.(N+67(^D$6"9BJ/
M56B"R;4ABF7,F40$>@K%2P5BJD L <H)V!.P)X7WD7 (!(!.PN+FV]AN;3FL
MYDQB(Q$8B8:OV^M;ZSGD8&WR,FP,1K7GT[-(P4L]K5.C[=-/JY5)*Z3[1JK'
M5N.L$]&2,6Q?R"R;5%9DX<22K%B3RL;Z>'JU5S4US7+!1F4,Y10SBFI(+E5(
M)"@FQ%@2;2MJJ(;,3?2^A(4,<H+$"P!.FLS* @(<@/(#W@(>80].42R,1&(C
M$1B(Q$8B,1&(C$1B)A+9.^Z5K!^=A-,[++EC84;5;WM8BDYAK0J:21&*6M]K
M 'K=XE"-GJ;@KLD(TFY=JT92,HO%)Q4<]>H7TL-4JBZE1=@B!B0:CD$A$T-S
M8:7*@FR@EB :WJJF]S87;*+Y1>UV[!??>P!)T%YTG7NGK-J/9IV&J5H6'Z>K
M!%+V6TU>95D9E^SV(Y6<)N'NNU0DR*1"=O%0EEV$O- _8O[ F:9BFBD]:K3)
MI65:RUJ0-7,<2C9%8  &EO:IIJ4-UIVL0I"DY443E49'&0@4B+L#J<UK#)W[
MM?3307)(VCS)+HQ$J8Q2%,<YBD(0HF.<P@4I2E 1,8QA$ *4H (B(B   "(C
MQB)IGO2>A=I:IO>Q=,[AL<M+:=KMHF(>+TQ:',B1SL*&9,K!!I62'I_ETG<"
M"V8BS0I#]O)0MBBK"Y6^!I)TI#O&F[#J:5:G2KT4"UV0,U=+6I$D,49M%W#9
MULP*#6UP<]4K40LE1KT[L A/C"Q&8#5A;^W8@]QFT].GWUHKS&=D*U,U)60%
MPJA!V$&B4T@Q*Y53CW4BT9N79(UQ(LR(R Q;A;X0C2N2LI-%K(H.FJ.1U",5
M#A[6NRWRWX@$^, =,P%CN+BQ-RDD D6OP-OMTO:_9OVZSL^<3J,1.(FY^&KC
M(9"<DF<8T%0J"2CM=-$7+I0IC(LF:9C H\?N1(8C5BU(J[=* ";=%0X@4>E5
MG-E!8]@'#M/8.TG0<9!( N2 //-3!LE,ZJ*]9JK+:ZL=?FW^N8JSU4DS/0<.
MYNVJ[V^:R4<O#7NE.[@XK$/;)&IM8FUM$ :VR%(@W<IM"^-BGZNS+4PCJZU5
M9159'RJS!*J @YJ53(KE0Y*7NC:^<2BZUP5*L#E5UN0,R$W!!&:P) #:9AM-
M@=0U6T4G75:K%RLCJV6.,1? _F7LE(33@2.Y1\_811IV7*68GDZ_'.FD A/3
M)2S$VWC$I24(5^[<%#-6='JN]- B$BR@ ;  G*-%S$%LHT4FPT EM-65 &8L
M1N2;\=!>P)L-+G4[F9)RJ=QB)T?86Q*IK"KS%LMTFBQCXB'FYD6I54!DY-O7
MHAY.R;>'8JK(J2+Q"+CW;Q1%$>$6R"SIR=!JBLNG93I/5=407)*B^MAF(4%B
M ;"Y ]@N;"<NZH"S'8$VXFP)T'$V!FK5\K+WJTBF]850L&C[AK2Y)!:V\VTA
M)RU1<%8JPX?PEFUO9*O8I&O,[%Y<,#/U"VD>2J=>GJZ]2DZ^Z79>2K:Z;>!G
M/U:].JIR6)569'LRU4=<V6V970A258$,+RA@:^@O3*'K7 + ,-"A!(!TN&!.
MH([9MW4(:0KM4K<!+3SRTRD)!143(661)XN0L#R/9(-',R_)XYQV7LFJD9XZ
M %U0\>LIV3B'&8G8,[,JA S$A!J%!)(4'30;#S30H(4 DL0 +G<VXGSGCYYV
M+.9,8B<)/V.$J\<I*S\FTC&9.V4AW2Q$U'2Y$%G(,V*(F!9\_62;K&;,6A%G
M;D4S%014,'&=*K.;*"3YAL+@7/8+D7)T$@D#<@;\=[=DU$%_5.IIZFX=4W8-
M%OU-IR%NIZ!+ZTIRVP=6;1;./@YHI?=9RUF<Q]0M<S5&@6*-:N6=H@Y:M1SK
MQ!XUPW/,[;/A185*=2D]0HY-,OS=:E:Y%.JJW9%>ZFQ1@VO6 RY[K7ULZNJY
MELV0LC\,Z7T)747N" =ILAJ.J6&CZWJ54M<\XLL_"QHMG\LYDI*:5/VW3APU
M8?#<T8TW.)0K)9O"MYR;,,S,H1Z4G+?^L'3G,M=UJ57=%R*QN%L%X $Y5ZJY
MC=BJ]52;#0"74U*HJL<Q%]22>)L+G4V%A<ZFUSK,C95.XQ$Z[9[=5J5&$F;?
M88:LQ*DA&Q*4C.2+6,:*RDP]1CHF-17=JI$6?R3]P@S8M$Q,X=.52(HIG.8
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MK 2ZSJ6CRPS@FQ&>A>A6(6C5I.24LZOG6Z5,R7%3)450-3E(8:'-*&5:EJB
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MN9#8(K$4*JLKK394""Q85TJ+%AG0A02;FX+ JNX#;L0.<5E(+JSYK%0/5\
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M6N3JS<[:19>D&H88L"Q3G 4-[BV560!Q35B#3)-.M3*L*EZ>(0/J)EM5JVL
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<P!U(S :@, 0& .U[VF7,HED8B,1&(C$1B)__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g451428g17n01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g17n01.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M<9::9,VJ)#TZP3PI,(>-MGHMR@JA$NVLS3HHUPWMR*3..B:LC96B>'ZM7;=
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MO5Q^L>3_ (Q95]/A[U3O&_!"I_+RN_YG3_3)P+X=6_@VJ]##_4^]7'ZQY/\
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MW;5G(^/[)+52K)15?NU4FY-5*[U]=5*/B9U@_>J)HIN1464(V;J&(D0!.H8
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MXZX?4]O=,_BVQWZW:3_G].W^6>_/YF7T<.U=7[E/CKA]3V]TS^+;'?K=I/\
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M_F$?[,NOE#<S\)_+CMEY#X!^3$'U<0"[YO$1  #(\((B(\   PUB<1$1'R
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M$TVVR;<*_>(&8CW$':JC)*5AXT3CW4IWRW8ZQHXHXNC5D4S=(K$E9EG$897
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MKNH.6-;+_P!DSZEO&G"=51>JAP^J5\"-+)DO:I\ZRW-)HPW0/E$SJ[4-602
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M%( FD:4=4:6>/%C%0*:?>@D44^F3.<JJ+23=-2S6 9EZ56-N2])3$LZ@WL)
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M]XO[JEZ*COUP[?\ VK:=N\K\*'FI_HL.UM;[S_:1?28UI]PP[JB"A!':J[
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MRX;^+Q;?KW^3 R<R)UQ(\C"D%H4K8IHUV8Z;X )SKKF"5("S01!02M4R(+%
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MHM>)N*+@A9E,7+CEY0!RF=HF @8>R"!@*5OWQY/UX=7;8\M^L-SXNKL/%O\
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M5N7V)!55+ ,20;'58@$CN P+DC<OONQ/ 7>:M?=#=SCLY<@6>AX6;P.<,C/
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M)O,V9H!L@M)R#6*8$4%*\*'*+J1>M6B0\O+UETP,( /$,DS[-)&"I%E3,02
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M\().F"GA5(($Y)%&B#91CZ%DN54^1Y50Y53,\L=' (WJ)K&HK*AV:6KKZMU
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M .Y?ECRGL4[(VB?G+-,*$6EK%,24Y)JI)E124D)9ZL_>'31)YB*9G#A0Q$B
M!$RB!"@!2AKU54*JJ.2@*/@ L/DQHL2S%CS8DFVPN3<XZ?4XC#3##3##3#&M
M/]L3_EE_K!IB5YCX1^7'ZXS7]S-_YA'^S+KY0W,_"?RX[9>0^ ?DQB9<8U[*
M1^YY&,:JOI1I<8B:B8] HF6D9:NX?Q%/Q<<F4/*)W[^,;LPX<?V[[0_:'N*%
MXT]:?3.L<,N7U---*U@L4-7G>=TLLK7VM%',TA_[O,<\?&LW@J*B+U5NQ(7J
M:RFS^@S&CIHAJDJJS*N"N"<SI*5!W6J:BDB@'/>3D>6+S4=GLE74?5.;:MCS
MT =W6;&5F269-SRD<*T--@P.LU))-4A7;/P9G<-R/$B]$RR(*"H7BJB":GEF
MIID:*>"22"6-QUHIHF:-T9?=(ZE6'?!&/J4%5#F67PUN6U44E/7T<=505L8$
MT,D-5"):6J1;J)8G22.51J4.A N+W'RC7G?5OFV;9%W.8(RKD"4R+<9QHI%U
M>VSCHYV].DY55B\BLAT!F+8K>/BI:FR#M:/J[1-G%14\M$.U&Q5863C9+G'J
MJJF>>*1R[$65C]238AT%K %2>K:P:W>(/YMK>,^,N$\PXCR7,ZZ2OJYD,=-5
M3,=-))*4>*OH4TZ8XI:21BE,H2.*<Q,0##+'+[+=R[V:EVV8>+D&]LE%\[9F
M:-;'='\H4RTO6X)\8)*'I8N' G<INR]4DS;!,)%W=C<&:/#.DX*.6+Z5%3]#
M'K?>64!G)W(!W"[]W>[=]N=P!CZQZG/"?K?RH5U:A.=9LBU%8\HO-3PO[)%1
MZFNP87$M5>S-4,5?4(8R/4+6[CZ-B+)G+=8A+C8:H_=-VB=*IE=NUUEG:YTD
M(:/NTU8J]1H]HV3077EY>RRE0LZ*$>S^RTCL&#=-NZ=ST6@K<L+-&KC?I)&C
MC4;DF-5:0D\E5 Z;GG<FX"G&)8!B.\H8^+42%^&Y5O(-MQB%[#NWJ)K'4H''
MC=2Y(3-4R[>YR5&'NZ"$+!X'ON/J/DZNJ,V%1DI)I>H]2[2"T?#3#./0"7KS
M*"FUX9*X0LTE<E&^ES*=!#PQJH,9+-41R/$US(HZ,Z "P)ZK%EU%&7&!E6X
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MDJE#[Z2I8+O77U;-;:A9*?'MY]Y&. N$2XJCA)"PF1C59-)4*&+1D:#(&NR
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MU$;X%,9V9P_L;^M@A5$LF75NQ7KE9KTC+)RY%+4^L+F-C'#/92!$E:4,UV#
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M/'.7,.? UI5X62,$T\@:-W9RS(DQF19 "$9@QL7"ABNW,:L3T0(<%C:12&
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M57?G!Q8)&.^ 0, M@$AP*[?YY]>LW_"%;]-AZP.!OL,X1YV_B]DWE_ZGR\>
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ML2.\;8]P&X![XOB#*M_MQF_\9$)_R:Q/KIZG^#>'OYKJ?[]SG'SW*/XP<?\
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MV*L""#XP?+\&^+@0P!4@@\B#<'[N/@<[JINQM?=#>Z&1&WR&MCF*P=1<S1&
M<:LD!.YAS3\A;6-&N.4W;%-9)*7D)B=4>##.#'3%*H,(=DW[,NYE%WO=Y72)
ME^7FH*@S20FHD)V.D(72('<@*MK\[N6)[@'-5L[554(0UHUD$2CN%BP5G(Y$
MWN ?<@=\XU5.*PC3=S-_V[[(>Y_CG/.V'+9?JRAF/=/EX+]2X5+&<Z\KT]EJ
MPXM:0F,</5:'8.60R:#[(]@GZS#NW,4DH@X>]!N\.9GIHZBMK^@@F2-NAI8N
MC=C(H98EE+2S.Q!M:-59@#R'(HB69XJ>EZ22-G7I)GUJ-!MK*:50"X^J) N
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M',<R#8VVWVY#*.X>/0>)J9!N\-$6+*V><7P]M'#C:[HX\&@6.RM<,R+V$K=
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M\+!.H^O1#)S"PS-)V@TB8E=LS25CHQJB_?(MV#,R+5!)Z[322*1RL!X,DA#
MNY#$LP+,0S'<EKG<D@7)W-L+ 6L +"PV&P[P[P\6.W)"0R:@JIQ$81422J8J
M$8-2J"G/.T7\XF)RI 823+YLW>2I>/+(NT$7#P%EDB'+CJ;W1[G=/U(LOQ02
M!W@;#"P[P[ORFY\IW/?..L@:73JLIU:Q4ZS7%1BXV$%2!@8N(4&%ANT#$1'/
M'M6YN]<4+MT,;'\>R,>TN.RHI=93FR:1W]N[MUBW68MUFMJ;<GK&PN>9L+X
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M/@C^^/5 Q>62J'$Y0H%OQ[-KNV<=;H"1A%)*-.1*5AG#M Q6$]"N%"*%:3D
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MI::*."GIX8U"1PP0Q*D<44:@*D<:JB* %   Q;50_?ER-^++#W]ZLX:OS'^
MLJ_G;/?^#X>QY62?QZXH_HGP1_?'J@8FG7.X[S$:9(Q#0<KM8Q*Y0RJTE7W"
M[RKVF%E9:KW6HOG2947;RJ7.MO8NS5]5\@0C642C)-NUF6(&C9EO(1JJS12V
M.:2(G0U@P 96 9' Y!T8%6L=Q<$J=U(.^,'17MJ'+D02&4G8Z6%B+C8V.XV-
MQB(B8'RU%G%&"W/7)]'@'!)*_8[Q?9I)N4/V"))6KU['QG"21>!"*R35_(*E
M*!WC]VX%1=2[LB(^VI4!_P"SDE4?#9VD\@(&YL!L!7T+#E*W/ZI4.W>ZH0[=
M\W/?)QO>)O.7I%L_4W7?I)IT\'@Q\\WH8=$_O@\W_P#VP\3><O2+9^INN_23
M3IX/!CYYO0PZ)_?!YO\ _MC;7P7E.31%O/YU9RZ *)JHH'P]4 1(J3FX*'2>
MR,B0ZA>(=(Y02,GY_E-S^;!FAN"("+?]L]_* N)$3=U[]ZR@?E)_],=GXF\J
M?'V[]6E0_P"[K#I(?!QYV3Y\3T9]V?(/FP\3>5/C[=^K2H?]W3I(?!QYV3Y\
M.C/NSY!\V'B;RI\?;OU:5#_NZ=)#X./.R?/AT9]V?(/FP\3>5/C[=^K2H?\
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M,.XT:HWCY8CH5^K9G%MU.D+X[A54D$<PQ*^+&2#0(]LDWCF ,VZ+5JB1JQ:
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M$<49='F:@!0!(0&G< \A"^>  H/#B)^(CQ=J9_",IY6_A[).7>_A'$^N_+O
MN*N=_P"(O&OC_P#9_P ?^;# ,D8_*9(X1E\ R+46*8^*;+?F-1 X"B'&F\!
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MB4/$BA4 1=<6LF^P)N/: ZS>_(8PJ@NYRTZ;V[Q^8 S#9F]OD=GN7]VI*B-
MBSUQ"-PAG%EARTU ]J"ZA)JOIT'1IN D JJ;=J) :2*9^/5'<;,76H,70KH%
M7#2:^D(8F>$S*^GHR+"VEAJ\8Q1V&O1!];:^@><KI&D".01L-6H&[7NO5V[M
M^>,JZ#W*S%6,=S^/HB]Y E,KTRK]T4P%M4LU0D*4T@6%Y@LDX//G=.8?N&UO
M?KQ[/M;-.F3<"D#H7<0Y<RS:637$L6.J^:2RTTACC$3MEU15*X?44:*?L<@
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M^E*NS95F2D2IED)"NL6,&\<K1;)JT2D32@*.D?J$%=SM9BXL>=@Y+J.2L2P
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MDGODXZ<; #O 8@ZK?[<9O_&1"?\ )K$^NGJ?X-X>_FNI_OW.<?/<H_C!Q_\
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M]OEP.C>P;Q7(^7;?X-K=\XTD2F *AU7L88Y7 F<B2+=$*JTXEX(H%-+G%!P
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M@6,BJH9T8(]!/MB9A**:7 %#=GZ8 8.=,3&/S<1 . :8"^US?O[<\ 9R8%3
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MGBS1LQ?.WJ":$@ZD XL&L>;G$7[I\4!,S;,P77=% 3()G !$,51V)55)(N2
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MBNY*Q2UA6E5C58]X9::2,LX8#L;I2%<!5UZFF8D@K90J@&USGT()8D[,LBL
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MY"_^R4P!_NUN4V9Y?1@K29_Q#2JV[+39>D )[Y$6?J#]W'D9AP_GV;NLF:\
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C  "/D#53,SG4[,S=]B6/E))QF %%@ !W@ !Y!CO=8XG'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g451428g21a60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g21a60.jpg
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M 0$! 0$! 0$! 0$! 0$!_\  $0@ _P)= P$1  (1 0,1 ?_$ !\  0 " @,
M P$            &" 4'! D* 0,+ O_$ %L0  $$ @(  @0'"0H)!PP#  4"
M P0& 0< " D3$1(4%188.%B7MM8*&2$V5W9W>+@7,3<Y4521E+?2(B,R-4%U
ML;75&B4S57*6M"0F0F63F)FRL\?7V$=6\/_$ !T! 0 !!0$! 0
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M$[$$)5XRW$8()'(@#'/. <7T,*6T70M 2%AL@[RK<1D<DH5D$#N)]G%?&O\
MJ!LS9]HWG7::7IQ8?H:H;CNIZ\LR+2O7]N$:2#D;%:&:'9V*F]')$R]?&/FJ
MK .LUQPJ.<8>DJ'96I"#DMMI#"EA8+ZV4)1A/$07R$HWIW\@%':HI*L'.,T3
M'<4IQ*2D\-*U%7C;%!L$JVJVX)(&0#C/PX&>F^Z!OOB>*'CKC4:S#T\[;K_4
MDV"=3JB8W6-&$JQ43LV=7QA)%M$>\7H5L#0!,]8>8'+X;>FQF(\F4$MDX!)0
MM7&V-KVA:TLDA2P-Q&Q6 4*) (4GL)(%3&=&>0*0&\J3DI!<QA)Y9W#GN !Q
M@^_K&^:2O=&N%XJ;0]=WB40Y; TV[T(;83=$,QZ9/='F[$ .R@@QZ56F5-ID
M^\YL <IF(^P[.CPU.>7BZV\A:$+\@N)20API2X"L9"5)"CA7=@$\^S-6UM+0
MI2<%6TD;DA12<=I!(!Q[) J"/U&UQ0D:S2:Q88U;FXSF'8'PI)D)+PE_$568
MQ9R,F _A,G.(^<M2%XP_G#6?\9G">3WHW;=R=W^;N&[LSV9SV<_:J)2H **5
M 'F"0<$><'&*V1:=#WFN0=>31Z(MY5L.A5^_-0:'#LAXA4H]HL1VM@ZW<V'*
M_!2+M1&4"5,ACX+I6%-'E [L$G*?E.QH]M+Z%%S.6PVXIO+A2D+*4I4I2#N.
M4#=@DX(4% @8J:F5I",#=O2% ("B4Y) "A@85D=G,$$$$YK+==NNEQ[([NK^
M@*T>IM%OEG?.0!2MHD#-7!^^@ V>4E@"!&" ./!RKS R<Q%25A0X>9S.(,B9
M&E/1VW:2)"(S"I"DK6VD))X02I6U1 "@"I.1S!."3CF 11IE3SH:!2E:L@;R
M0,@$D$@$@\CVCMY=M;?UYT$W7?MR5_KY+)TG7>Y[!MZUZ3Q0=B.W863$7*GU
MYFR$'2\\)1[$";!384F(V&*P2Q!))<N-,:82'=23Y9<GLH95( 6XREI#W$;V
M$%"U;1@*6E6X$'<"!C!';RJXB(XM8;RA#A<4WM7O!"DIW<R$$8([""<Y'=SK
MG4[H#LN\4:I[#"[)TZFN77MM$Z5@G)L_94>8[N@A#B$X"9$5&L'LQJG+%$!Y
M)!Y:_,98FML2A\<@S+A1BYS;;BVU-O;D1#,5@-D<$$I//B^6""-O?C()&"28
MJU)2H+;PI\1QS7]4.#_F>3@@YJ+]@>D.W^NM1,WVSE*+:Z;6>P&Q>KUG/T8N
M;E,5[=FL,.O62HSX5HK=3+2$.P&'R8DX*'D@,^&RO'O)F7ZL54H\UF0M*$A:
M5JCMR4I6 "IEWR5@I4L#G@%)(4"1RQSJCL9QE)6HI*0ZIDE)/)Q&<@Y"3V#(
M(R"._/*H=2>JVT+M:2%42NNUB36M-O[_ -@$[80GCA.M=3) "K1 M%P<A"2<
M_*CH*QU&6!"UH?8SY21<:R(8%Y.3W!D:2Y32$!?C*"GNKMA !+CNXI*49('B
MJ2L*4HI2 A1S@9,4L+4K;XJ2&^*K<<!", @JY'&04D 9)W 8R<5$-GZ6,:E)
M5L59[539$NQNFU)0%E6"?[G&!+//J+IHREVMQ'6H,TP'.H@Q8+4\TJ.%EORA
M,3$@6DA-IY+H44I6 G \8)&24A6U/C<R 4Y)PG*@ HX.(N-%L@*4G)SV9Y '
M;D@I!P2#CM/(\J@MVI=DUW:3%-MHY8L\$?9:EQLK;>9=8EQ6" TC ELJ7'("
M3 N7"+!BD1QV$4%389&$\]$E,NKN(6EQ(6@Y2KL]L$@@CM!200H'F""#S%14
MDH44J[1[XYC((/>"""#YJBO)5&G%*<4IQ2G%*<4IQ2G%*D=._&ZK?G&#_P!Y
MQ>17Y"O<J]!J2/+3[I/I%?K6\\IKMJ<4KHT^Z$KO<Z!T!8/42W6>E',[TUQ!
MR9J1\K6RV84@7<5R(>2(:7"F9BOK994]'\[RG5--J6A64)SC=V!"%S]JTI6G
M@.G"DA0SE//!!&:UUT4I,4E*BD\1'-)(/?WBO#?\:+LS\XK>OTN7_P"T'.WZ
MO']89^*1\FN<XSOKKG\]7YZ?&B[,_.*WK]+E_P#M!QU>/ZPS\4CY-.,[ZZY_
M/5^>GQHNS/SBMZ_2Y?\ [0<=7C^L,_%(^33C.^NN?SU?GI\:+LS\XK>OTN7_
M .T''5X_K#/Q2/DTXSOKKG\]7YZ?&B[,_.*WK]+E_P#M!QU>/ZPS\4CY-.,[
MZZY_/5^>GQHNS/SBMZ_2Y?\ [0<=7C^L,_%(^33C.^NN?SU?GI\:+LS\XK>O
MTN7_ .T''5X_K#/Q2/DTXSOKKG\]7YZ?&B[,_.*WK]+E_P#M!QU>/ZPS\4CY
M-.,[ZZY_/5^>GQHNS/SBMZ_2Y?\ [0<=7C^L,_%(^33C.^NN?SU?GK9&I=C=
MW=YWD?K;56X^PEPNQ899BPVOC-MWQ4V;#J-9+VXXIC#EC0A3D8&#(R6VLK2J
M0ZTB,SA;[S2%6WD0V&RZZTPA *05%I& 5J2A.?%_SE >QVU-M4AU80AQQ2B"
M0-ZOK05'O\P-2W6ICO%M?6>YMN5'L'M9RD:!%5TWM&>4W[;A4P$,MI;("M28
MHN9943S?O<[C AAD*Q/?9F+:]M:BQW6GUP<ZFTZRRMAL./E26@&$D**!N4"0
MG"=J>9W$#'9FI($AQ#CB75[6@"LEU0("C@'&>>3RY9]G%3+7%=[][4H1G9-4
M[&WA58K>O"FV+*LGV<,C2=<UV'O4O6\RSG []NR1'1,V^%('18LAA)*9'3@M
M&A.B58G<BXN"TL-K80%*<#*<1P0IQ38<"4G9@G8<DYP#XI.[E4D(DK05I=.T
M(+AR\00@**"HC.<;@1Y^_LJ+!)?>^R6'?=7!;[VL5+]:ZE=+WM-,+L.?DP(5
M2U_8AU6M!RO%FK>L7;8D,P7%MQ/@],(.E8LYF>+;F0L.OMR5U)*6%*9; DK0
MVUE@ E;B2M"5)*,H)2DYW ;2,'!P#$"22ZD.+)92I:_IJO)2<$@@X(R1V'GD
M8K0/QHNS/SBMZ_2Y?_M!R_U>/ZPS\4CY-6N,[ZZY_/5^>LD%[&]HCI@2#A=C
M-W(F&24$5$7*W%?H\9,DC*:B,*D2%V#*6&$NO(R\\K'JM-X4M7X$YY0L1T@J
M+#. "3AI!. ,\AMYFJAUXD .N9) &5JQS..?.IGMW9O<_1NS;QJ#9&^-W![Y
MKJQ$:K:Q<7=MQ+1X!L6[EF;&9)C+1*'SFVW,>A,B'(>8<Q^%#BL<@TW$>;0\
MVRR6W$A:"64C*5#(."D$9'<0#4G%/MK4VMQP*02E0#BC@CMY@X-<2Q;@[:UB
MGZ]NY'LMLY\/LR'9)U?B".Q!TU88#-6L,FM$D6RLC+E*.TU^00BN/AF+- &.
M'!:FRPG$R OS\52U%4MQL1V]S>T*)CA*3O3N&Q10$KP/**"0D^*<'E5"MY*4
M*+J\+W8PZ21M.#N 5E/L9QD<ZR.G-D]R=[;-IVHM?=AMO2+O?C#0"K0SF^+9
M6QQ U)0XJ$.6:-6F&*A2)[K>(D+VV5':D3'6(J7/->;2JCR(C#2WG&&@AM.Y
M92PE1"1VG:E)) [3@<@">P55M3[JTMI=7N4<#+B@"?-DG'.MN"ZOXB!#9\_2
MT[=6X*QM<9NNI]?)=$MF^[< .)VE>\F44P.WB99<0GAEE= $FQ=G:F+K;J4P
MI3I1J"6%2IMDK@!H/!II3187("TL)4GA-XWJY)SE&X;DXW Y&,@@7 B45EOB
M+"PX&BDND'>K.T=N,*P<'./9Q66GT/Q"AE?VI:B'8:^Q0&E=S#M ;)(N=E+)
ME%>VJ4)/B(E=PRW9ER2D=4^&19<.AV9X%I R?(62Q&8\Y8.02II(905/,F0V
M.KCQFD@$J\G ."/%5A7,#&352W* 62Z<-K#:SQ5<EDD!/;SY@\QD>S3>.N/$
MKZ\B+X>V/MG<#8;5FP1&J]E3ZWV,*VI-%OU@KS%I @;'%!W:9/AH,@Y+4H<:
M1$>KTF1ZXM!;WNTY 31AVW2"VEMMK+K:G6@J.$<1M*MBE)*D '"N122%8\;;
MM(-'6Y;045K7A"@A92Z5;5$!0! 5D9!&#C'=G/*HMJ8?W^W1@O\  [>NV67
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M4XI5U^FW8,3U4M@C=H>?%D[1#[*UXR*"R)5H%1XM""&6;5;IA0B(KY>)*%V
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MM/X<;='[?$VNCVZ[MW2F;!O&LK/K6UU(^(/P040]J$-KP%3HY*WAR-D  :W
M>H\6=F:2"DK_ %-U,E:\J6UL9+)2XE!0MM#J'4*24Y*7BXI9"2$J6H[\8"A#
MK+9: Y)7N<#@4A2MR5K2I"DE)QE 0E.5 J &4@Y(,W[E=V>M6\:CVT!5YR9/
ME;-V3;=G:=LU<A7FC6QXC=-RT:Q%Z5N2L3X\G7M\IR:53H%C$6]R2,V!3[@)
M'T\0R6J4J833;APY#*HBE8'":0T\A10M&&V%I2ME8(<;7Q%E*D8+:T$K)"P
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M[OJ$IZ ;9MC<>STYL!6J_<[=ID?0*->K#+<V;'!]H+B<!=<FK'%!5J4'R:O
M,$4M?L<26V4;J0IRW2@@\0;K/OB?7VDY2K<HH0\5K0D<,F,A*I&TJ4%8;4I*
M,D;=Z@@*)"ML>JN*\9.$I4I&U*E96 \HAK=M!&5 %7G"05$ $9W%2?#I\RH[
M,JMIN>LC>Y[!O/1G670I:J[,=G:^A;IOUIV-\,*O>)D&NRGD%!5:UJW"5!<8
M8P&G;'I,PHXW[6]&B65W#QVE)0XEE+$B3("V\.<!M#>Q: 2.14X3GZX-N  X
M&;B8GBK2I2"Z76V6R%DH"U%>X*(': CL[MP)Y53>3U%W[DX!! : :N2SK^L!
M3IFIC"Y&JUJW;;17$5.AW.U21T$!4[EDE; (0@)-SXC4<H1B8CS)<&9"G2<P
M2V-I4IQ*,!U6%D!2D-;M[B$9*EH 0H@I!Y \L@BL<QW=P2$E1.P92"4I4YC:
ME2L8"O& ()QD]I'.MS2_#>[$-%0(T6[1K.P;KNQ+8Z6K1@Z2@A*YK/:$S2QL
ML3BJJ\<[*CF=J0\TBCHKP8Z_?#4B(BILE8[Z9&+(N$?:I1WHVJ;1A82"I3C0
M? !"BD%+1WN;E)X8SOVD5<ZF]D ;59"CD%1 "5ELD^*"05C:G .XXVY!S7#7
MX>.\$4:S[$Q8=4/5FKANQ]@7+BW.5-0?$=73XNM;&(U:7# OC#HL@6,#XM,.
M1B& -AERH@SWI",$1@V:]4&-Z6]KH6HQTX*,%*I*2IM*P3E*@ 2M)&Y(!."
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M%D.UN_66KW5R]0[E7ZS8K_=R6OH$$E#KC,6BP;T<I<Y0DLX3!N K3.J<.RU
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MJ)4HDJ4223S))YDFL!Z,_P F?Z,\E5*>C/\ )G^C/%*>C/\ )G^C/%*>C/\
M)G^C/%*>C/\ )G^C/%*>C/\ )G^C/%*>C/\ )G^C/%*>C/\ )G^C/%*>C/\
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M'O'?WYKDP^M^DX D=78>OPT>L!H)L<$K#>)& (6)82P$R68#C_.\L;'=EU@
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M7M@:IU]J*VUR)J_9B6)H/5\:KL4PW!G21,J4/LPMZG!)V9BL2QLB5@@A\2Y
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MQT:>^[93 Q3[*H\,+7IS4=/L?GM/$9ME8?>=RV0=G^4^@9'0SB4+A1,*CO\
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M[@*L!SH:Y.G%*<4KQ0_=07RFNM_Z"2G]H![G7:8\B;[ICT.UH[S_ )-_MO\
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MO"LXPG*T8SZV.E"I.1N98"<C)$APD#/,@&*D$@=@*@">61VUR)2Q@X<=)P<
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MDIW;@ H<QVCMKS?I>E]0Z-]53N$E_J4./+X*R E[J]PAO<)1*5@)<V;%$H6
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MDYV-AU$&7EFH&<\P,#/,_P! \Y]BJ$XQR)R?@KJU\9;M[;>KVE*;6:7JL%M
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MF4N*,SZAP9)AN26;"]%]G=B24/9?6_#9KM.,\_/[V,Y[>>1[%1W#.,C'=_\
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M8B8F2\H+PERWW"$5UUAZI<C'.&%)R000M1P-HR.:\'QLG/+*3C /,4"7>67
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M=#M5UZMJ'''",8CA\5Y,FTO30[,4 9"3U!@<UR9/,,M14QX@A=$NL)6#P<I
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MSA#FP!6?J:"20 $BA9"AO.2.1RH$':D<L'EDIR<?YRN\G,FN=0W:3*2#U(V
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MQ&;]=')#:6'$,OJ4RBZEP)9>6AEU6W:V\H-+(<\6ME.\(SPJ+7;HUXN6HK[
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MS3-> .LT>Y6^KTR?.+NFW[+.(86]<1U#M5^H%&"WBIO$P$P&0-T]P'L*"/I
M&RC;*MZQXMY\4^##1/:M'=9]TE:N7;X,R>TVP(Z8;31"8#MRA6RYW&1;IR69
M3<EJ-/$FV..W&3$=B 1>HQ7DR'UA'9Z7L6F;;T4(OM[M-BDOS5SW+K(D N7R
M+IV\ZCTWIZ!?[*Y+MC]ODW"QKMVIX\>P6V[1;J5W47NYPW+?;V"[* FPNFT7
M8MBP2!Z_9HL6Z:ZKU/<B4BT6%&==1-CV:ZVVU%'#5)@$YQB-31E8UMAN>%<-
M$&[&Y(*)MS0DD5EXDBUZ\7:HO"D715Q7;[K*G!=QA13ZJN6F';X4-D1[@ZRV
MPJ>],NV6Y"8[1B!#!@J?:91MX.I>@UK4]S$JWZ;;T\U?M,6RR+8L%XN2?F89
MU3=;]>KS,5/L$:7(FM6.':=+!,B N?)3=5N2T7MN%*EO1D#?>I@1S6TIZN4T
MK"3#LUYV3"(5:Q$"[]V&M[/)!M>C(TNJ^ZX%0LDJ1KBKC5QSY85$#QUERT*O
M&F2DZ3ER;9K:0+L@2Y[*RN);K2XU-BM,)M[IL[3]T?6W-XSL^(A%UF/!49EY
M;ZPPRY+CJ9:1J;=J/H9@+TL\NUV.8PEB[:AU5'E6BZ29KE_BIU=*@:9B-O6?
MJ<>R75UW2UHBEJXS(3$%HSIS%LN+<R0]FJ==>HTRO4V1;5ZZ"&33>K57Z)&U
M78YTNOD\;<:7L6>);Q6"@EN (U)4JZ,'"!I,E%L+]RNITBP_97(XS&//M^N$
M2IR8(NTAB.;R+:M=ZB--R6?4,BU-O'KC+RG7[W.E/.O/,M+BI@6^,TI,0+>K
M/L=_Z%G[98W+TK2]OGSTZ1.I&6M'W60_;)0UHE6IY$-(M$R$B-#T79K7$BPH
MDN6U<W;[?[C);7=BW%'$.;6ZTF3E)LLX)0C\^S6\S=MQK,5NS#ID:5'N-S)-
M5>MQ!E&=&"P!*I0J$!K"XDHT,R_.(2;E4H;V2DK$X]EU;'CW"(W(N49N' 8M
M]A#$N&ZVI"X%O:,R6MZXAY^4S.<N<F8%MQWMK328$UQ/!15FXZRZ*YUPL%U?
MM^G+E)NU[G7_ %TN?:[O&?9>;O=^E-VBU,Q=.KB1+;)LT?3ENM2F'I\0N2)+
MM]LL=PRWZT;0S^EAFQMN%K,^ )5-8FT"-;R)]'7EYV?!>>+4FV1:9'#3JVT^
M6D5<-7K2 ++"QTA[Z>DC20Z<-:DQNCN474#UJL;$-,EF:'H;]V2U<@$I;<2E
MBX0ESUR&Y:DLIF2)4.4R)"R_;(R76G6W2E7GVGKEH2+JC6DRZKMTJS*A7>%I
M9R1I]16J3'4N9I^\M6)J!)M25S';3 MEXMLU<!M,'45Q=B2HTB(AUFPP38_3
MZMY;>GCZ?=T" FMX@Z%/UV:2F9F@Z.LA*VQ5^VUMEALAMS>QL<#(2W?5C!Q(
MZ89\]M+(\Q,Y>3:M=2P4MN3[<7Y%U<=<:NL<EOU2U%$9@J!;E%19L>FX[TAI
MM(*WWW&V-I*G6$>FP-4="-JVK?C62_B' TNS&CR-,3P'_F<Z/KK+O+1X]K;;
M3*UKTB3XEODO+*68,*,_.#J B-.?R]?V;U+K-Q '@Y:H0LUF[:L.PYL37-M@
MXFIU!I&:2;FR&XU6PZW"V7OE0MJS1O(<EQ<!H$Q<*8-D$C\FQ*M&MI<"5%?9
MG.]<MUYC.-KNT)PMF^:A0R6T%<S:7+3IKC*B*W!"R^XV'&WD,Q49ELU9T,VJ
M]VVY0IEDCJM.H-'W%A]C3%ZCA].B= O2DO.I9M&]+&JND8PTW9H-J>9$&.\I
MA^([+N3O S>>G(; 6;F54[PD23<LDY@QKNSR+;;Y(;1)"<D79S16KXBOR-D;
M^LY)BQ-Y)2!-8%UROX#2W0\?!!4_4W7<CK#83.MQ?93$;4Q=(:(,%#^HVFR]
M#CLS"M*+5IF&TJ,>"E^8_+D\=L/JX=8PU#T'P1 D%ZSZ@$*6NZR6YNF;L[>K
MV[!Z/),@1+O/FV@-..ZIZ2;M+1<D"6Y!M,.UVP07U0&^LFNVI;OIMIS:5[V3
M6J6JYL1Z2]K6DR*^5:U[-Q!*-NV^-D.'"6"*LA/&"1HQ$,R\$ASX1^SRH]IK
MEA0)-P>JO=NORDV:VVF7<! 4JX)NUQ3*95=&^(R4P5=8?D15AIMY]UXN,)D+
M:<BPT*A2XI>C.>9Z,O\ H9"M7ZAU5:;"J_-M6!S2E@<MLQO34@1Y:5WMGJ4&
M!<F3)DQ(46(EB>N!'DL7&[/-WBUW-,*>Q9T9M#JK4*U!J%:M%:D5KWPJS$1\
MG7EL<FGRE"Z\F&=>.7,E*JF))>8>WU>[3)(Q42)HJK,B Z KL8)&AE,\@]9]
M:3I;DZ7#EIE\ 1&G$72$EN,S<M4,*N@@-(FE#"(VFK;"0TLH;>FJ??+X7(6M
MD>KQ-7=#UDM,>R6J[VIVU":;K)C/:8O2Y%RF:<Z,Y[>F57Z6]9@[-?N/2-J*
M\.RFTN/P[0W#A)@+:MS3$VN(K:75)V=4HADI5CU7IIK2PEN"WK$M#E&=>ZPU
M:;/W84\ZFH1,.N;CW45=;L3I#.9$*>IF>TGW0Y-L7)^HVM U.<CLS(\V?'O[
MY=-X9<1'NMXO,>+;WTI,Y>T6'3[(5%#?B.-A3:OIX;AU9.KNAU4FRLSY=HN=
MIL4[0<),=&DID=Z=IG26D)]QO\):A9&0M>N=>3%)N:I)+D>3PY" 82Y%T$BI
MHC2%G$%;]6J3J6R-5S7^N8T: :#$ZD%M5KIVO[;?]X5EQ<NJ3@U?G0S=@I@M
MFV6/(.1:Z[5<BJC;)I<@<FQ\6>_J*)(9M<NXWN(J7<[JM;C#[,Z3#A3[I"MN
MG9:>'-1(DMKC19[RH43K"84J:7IT)MAJ,VO:6.'H"[0IFH[58-&75%JTUIAE
MJ-/@RK+ O-XL>FKWJ3I M2U2+,_ MK[,^Y6*&W>;HJWO7>V68Q+)>9$V3/?;
MJ#JNYZ;K]"FQ;N&KYJV7C;E?&FWY=/P4FZ^TZ@ :A7*P5)Q<-H:W8BTRSL.5
MZ*Q)DNAR%,C3\#8V78+\CN;U OTJYMKMS\J/!MUCE/1TMS^"W=+\94=R!%G)
MWJ=,5AN&H2EJ2A+[5P6T75@.)3XIH^^:&MFG'V;_  ;;/O-_UI;(L]Q^R"7(
MTUHA%NGL7VYV9181%3<YSUV;5;66WG509-B:D"*T5L..[1MMUZTS4[<@ QFO
M L90M0/5)0'4;*:FMH:MAIY$F:FRTP)[:U-IUYD0<V":V!N@,CK&H.N3+<^X
M2)6330K?JUOU$=D.W1]8>$F\L2)T1ALDPHZ2ALQ;A(+9;GVY+O5FU2;?(:N\
MX!N G@LQ.LO=^Z*9 UK&MT335O:5#-OT;,M]EN\^0E*+S/6EV0FZV*WA],BQ
M:@=CFYR$VV_V^5I.R+4_>G%2I=TV::V7U-K-J+V?5QRMARL$=V.E5@D-H-N&
M+;(GZT#U/IL>PCX+0$QL0ZHD[M#"U,18GP_*$VC4@9EL<_)U$>TZVEPF(=XC
M2WV7'M*(F-/7."\"U&ER;W?G5'KCF[?.ZM9\!2W/4MEE4=+V74HZV=JKH:M5
MXFW;25QMD"9'C=*+UIEQ--WJ*I,FY6JWZ-T-&:3ZDQ@T6+.+CJX*4TRQ\T<N
M6B>Y$*(KCVLNP>QM#6@#LR)29-2(E6;14@.JR8?7\H+,>U;6AD$ N'+9(U0(
MU6YB_@T-M+!4;,;)S9-LMH P)D1EC)X[<:7M6I8<FT+N")K3*H<V3>6G[HB0
MVF\2W79(6VIJ;(5,;'6W82F76RRVB#!E,/H7QFG>2Z2M4='5WM^K&+ [9I,M
M%WLMOT?+@Z:>M[Z](VJ+'MRF'T2K-;T6IX^I42[-RXDA,R0]>;U;9\)UDQ9$
M:65_9'56)6]1CK.X%L2-=@=/J+B,:_FX]\LS9-PV#O\ %+6Y78T4Q?3)V%0M
M3#3QF1[HA57US :Q>8X3E0<*5:=9KF7QV&)$4W23? P_ZJ-_L=3:(-KTR^ )
M2UL6V/'<N5[>C1D<=R9AB1$(#*7-S;=4]#[-LT5%NRH%S1IBW:(,Z%\S4@=>
M;D/7S4O23#*E6UIJ=J.?<8^F]&Q+C/=$%BS%4Z!=-ZI;K%;*6:U,)U==23S-
M4_=/(W%V / 7,!8[+"CZV(U"PP<_!)^#"=&1;)#M!0:1?,&2HDH.Q70CX=TA
M'E6 20ZRX1[V_>+>TE4WU(:@I==DP),6(XN[-3XCG[-0XX'5Q%PV7FDQV&'V
M7>MR$OAI;<5]KRRQ3]&PM(WZ4MNS?-;*O:H\6VWVVW6ZQV]+2;)<XY]1G8\=
M<1FZ,7>7$E.3I\R',CBV0'(*I+;MRA2;;V[;G5>796BCA(#> E7LEZ:#!Y]$
MLB%GJ#J[K]7];]<*JMPI6VD1Q]CMD8B6/MSU-^YY2I$Z2Q$<4W-G<1!L>LFX
MBF4M2;=(F1+<9$ANY1"(URO.IY-VU7- 9EJ*G8D);3$93>[K" EM"EI!;;]H
MO>M.B!^[(F*EVW4%OM%UU"B#!D:<NB%W'3>D>C:V:6Z+K.5S+4E#<6YWAJ5,
MN2)6SJ+Q<DNMM+V/R<0[;.FLDC*A.3JB@6L_4V([\;7UQ%0IT;7O7V9"&E3F
M!E7:(LUG8V]I<$AL$>-AO&VV C?L0B5!GS#C]Y,'7J6D.!N<7A&FJ6E5T@/.
M-KNFIVUO,1^+,+*IEJTVAUJUO/.)CE4@\1]#C3<9.$N\]!KLIUA4FRB&JY65
MMMQK3-\AQY#6F>C-]B+,N'5+2F4BTZGZ1'X\G4L6*PNX);MZ>KP7HTAZY.Q(
M59>KLG7)3)HAKN%L(_53XLPF!K.U^1!M#EQH]+"FJHE=;EP 0X=JN#;]AP\C
MY(Z:9O5B(9-P!3@>L!X^<]$UBBZL]7:NCEKBS(S[!=N\+>Y#$&XW"1&FXEH<
MDNNWEV#:W.(EUN/;8K75W'DOS'UZ>'=NB1W2\SK\G2\;4USLURASDQM)7DMQ
MKNJ^6"PP)]FW6MZ-;XL;1\>]ZF8,5V+)G:AN<@W&-"7"M,%O=E@V5I_8LFP/
MMN)L.H7K9V -7\]\ K#.':W9EZP<H75+T2+"'%CDDQ O6XU-.@8E,$#,PT?!
MR6!CKN83O/Q;1?;4B,DIZM?$PM,1[9&%SC-O793=X%SUIE$60\Z67WKL\;@Y
MM4U';CQ9*5O)2'1WESU5HC4[MR<0L7/12[STE3M27'YG+E(BZ6;?TDO3G0WA
MVZ0HD5,N%$TM$%BCEYN3/?G7&W.M1'%F.NMN@++UO78[C<]LQ:J&FE=HUN>(
MI)2IV _6(FMWW;?9;6$ 0 ->-08TN:8@4>C(DS&1\L%43!TC6L2"[3"8G5ZF
MB:K$2! LBYLAMBSRVG[@Q-C1ICEV2(,2%(DNR949Q2&V';C<2EM3J),YB,S,
MVL*45^5]'%VZ+C=+Y?=9LV>"_,U=:I,*PR[-<[E:6-+.+O=UO5OML>W6N?&;
M??FQ]/:>2Z^W%?MUDG7*7:N)-0V&;9A:CIFO'1^N[-KJBFK;KK6=/VKL-M>O
M'8;02/4=473;%US=)S=?\V<U<;5>*%JF$ #K+,18%9DD9R8IID0J1Q,B=?Y4
M9VZ0[K<H\&ZW>?9K6H74+5)5.O5OLEO$!I4LAI4"';KE>G)3_ 4MV6EILK84
M]L]G@670MLN,?3%VTOIZ?>=,:3LFL=2I5IEQ@0&[+HR_:RO_ *NR$VW?*1?+
MQJ#3>CF+= ZXVU&M+TF0&9[<+BZ"G;/ZH)2!&(JE2G(-WC65+V#8HVNG(<H=
MK6N:ZA5O:>S*8-2,'L"3=\L]C-%JI$8PHT)51Q1XJ#@'BB</=,U9]:$R7C-G
M-&/;KO<+7$7=4N(=N\JZN2[-:)[W&=4_&ML.+'8FK60P\+@]&9DNQV<I\WD:
MLZ'=MNBBS660)]_TE8-37-G3+D=V-I6UZ88M>L-5V&*(L9N#<-17>Z3YEF9;
MW3X9T_#N,RWQKA+&_"/;0ZQP%%W6Z/52A 9KALD,5!I3B@1W9D?L4"O0"I0H
MQ:' E1JV+T[[QUY:+*<8;FGX>"J)#-B6R$]YY*;/J]P,)-QFLM/753+P<N">
MLQK0O2LFVR9SBV''6URGK]PKI#B1E%N,YP2A40*D<+7N:MZ)XRIBD:?M$R1$
MTNB5$4Q8E&WW'5;72?;M16VRLM36([S5KBZ',K3%XNT]M,BY,"8EQ%S4W;^M
MYQBP=/?.B!HCU3%C0VLP,P#:2U.MYTM)V09BZZ$71-M'? U3!&97TD=JVBL@
M9/PFH\DZ*JL/-A@ L8$OXZHNNL.2%IFO.OW>2W)AL3X,9A-ICKNK]OZBX;@%
M--RBU98<N2CJ=R1&>FN=5<D?3T[%NY]"(4S 879XD6!I2WO6V\3K'>[C,>U5
M/9TO"OWJU%]0BW)>M@DZQN]IMSWJOI]VX0[,QZIQK>.I.QT#O.G0^YED[#.6
M6# " -H S=%;0)L64RZ;"O%=!(&CX# -;D>*(T_'+0V63#09_/D0FXT3V]2(
M3>3*TY/7H*)I=,1QV1)L\F/<B7XN43UVZ7)+KKJI "UOWU3"U*8+Z1N<*W.$
M"X=9;^D*R,].ETZ3576/&M]MU= N&GD(A73:]8F+_;+<F)'C-V]2VV86B&YK
M*$340G"6F RQU@IC)WG2^SVA:6YHX2)*8:IXG=.Z]KG1DVN'9DFBG9M,DU'1
MEF/Q<!,0K%."G2!*]FT5V38I8;$M@,+5/8""H6>=GZ/U+/&HGWVB9[^G]/V6
M,\U*C-HN,9N>W.U%$C+,@N16GXS35MCF6F*B06U/O!HR'EUZ#8>EGHZL*NC^
M%"F!%CA:]U[K*XQ'[7<9#NGKB_8GK+T?7:Y-=0X%SD0;C*E:BGIM;MS>@!YN
M!#,ENWPXYJ-J,W2Z5L^KW.^[+K%V!U"_5ZZ'ZY+&[1(LW!N:;;>M$L"^V$#Y
MF6Z#%#0"3>;6\%"SY[PGSIY1F,4C,=Q?(]PN%GF6^V6B9;Y$ZV2K?&EMNV9I
M4 MQRF&B2E4A_9!<7(=:(A)D2&FTO[6F5+96KQ;15QL5BU;9[[J+55IO]NLN
MI+9?;G;)$75\E%[0_<$.7=^W.)@0E/WIAF#'E)-Z7;X$F2Y"+DB8VU+:;CCK
MM; [PUU=[B=%W:O6NRU;9M^AEH9$W)'#+#;'25FK%VADQC3Y<W@0A^62>AQ9
M4<O%*1"(QY[VQE6,H)ER=.W6W08SUOE0HDVT6QQAQJ.AUZ+"2U$F6]QEU26(
M_'*4-)6M*F%LK:>2GAJ%:Q;EJMVO],:@O=QAW^V7FZVC5FHV)C$JX.QHERO*
MY5UM-_8E1$.39_4DN/REQV7FYK,QF3$<7QT$;VD7_JBR:FHJ . !"1].VJ8-
MD6FI2RQ16V25:EU4 *;FP(4^6IT<\6<OCLY_V"NHLX8>)A3(@IER43YM-LUH
MJ.@SI#DF0J_0VW40YR&&?41J6B9*?+;JVD .I9%M2VGBRC$?<?<;6^H(9]#<
MU)T.(GR!9(#%NM[>A[P]%<O%E>FS#K.5:GK1;8B),9B2\5Q79J]1./NB/:TW
M6!%A1WV82%/2]RV'??6/,+8%8C$:Q8*Z0(VU=;B*UN:&@9(/5ND'M;=?8L@.
MW5A_JF3MQO5VOA";(CQ\AR ORI9 6Z0&D(VABZ9U>'+7,6U,C2FFH0EK%VCN
MR42+SJ(7;4ZT/JFO9CQH%NM]M:;2M76&GLH:=2TZTON;GTC=$Q8U+:6I-HN-
MLE2KR;6R=+3XMO>M^D.C]>ENC1ER$FSQL3KA?-1:@U%)?=:;,*3#V/2(BY,6
M4U5_11GKX/JH 9M28 B%)>XJ$5.E'J<3M!*/K%@Y"S=PDW"Z].:A(;'A8L\-
M-K4Z;.G-'["#+@IC;T*4/[#4;&J'9LIZS-R5LMV&Y,1F1/9ALKNZXSGJ=(;Q
M*;4X2[(6T^B6VVVTJ-%D,26REQ#ODG1[.Z-8UHML36#]N8F/:XT[,N,Q=CF7
M>4WI)NX1SJ"!("K7(;82F- :D07[3)D29"+E<[?-MSZ%L.QK)D FG %.UO;K
MI6=90@5NONOR&TS38DE.LM6"VZ_WO:>2M>%3JFZ[9X5PU%\$JI$$U,V3%T1
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M;@&$(*,HDPB=HK\<16ALW-FD3"::V(A.^X"&U?M>KF"X] ES'^#99<IEF;<
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M<6>);K5:XA<DW.3?Y";A;4.IE"+K?8UTZ\6O9.@9U=KU;!T9-ADF=MC M;E
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M$:KC"9.CE$B2MJ:]#BP84!UV>3;XL-^YOK"9#B9$>.N?%;WMML+;==$4MNR
M0-"[T7W%5GLEQ0[ MS<FT1+M<[Q=[Y%CV1L7ZZ7:#IJ$V5P([D&?.:L=T?#+
M\F<U(B1E71,B+ 4E2IEK_J4=58JK+VR\D)1W7K#*O,$$98BW:N"*GJA_<MA0
M[@@#*!X!,?2G0,J8PXDDL82LP4 3C1#;DZ"/P+IK:.(LU%D3UFXI3%1;G)+"
MEV^4_.O2+!&*>%)9?<9<N DH0H<(.M0Y$EE2XP;<=WNFNABX&YV=_6;@@:?6
MY<W=0L6Z<VU?[5"LVC7-=7,.=9M\R#&EQ; NW//H6)1B2KM MLMIFX+D1XW
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MEG,E#8\])6\88GSGW\3<J5CT8R](:><+Q5;_ *N[*>="9,Q*5F;$9@2VMJ9
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+4XI3BE.*4XI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g451428g28a32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g28a32.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1684&AO=&]S:&]P(#,N,  X0DE-! 0
M    %7R^50 X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "&-G,#(R
M.#<T' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@1F%L8V]N("T@1G)E
M<75E;F-Y(%,M-%]$1DE.($1R869T(#<N,3@N #A"24T$)0      $,P@G--5
MQ7WZ@P:[XSFS@" X0DE-!#H      .\    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     8 00!0 $0 +0 R       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&,\
M(,         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  E,S,  $  0"4
MS,P  0 !.$))300F       .             #^    X0DE-! T       0
M  !:.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             7\   /,    !@!G #( . !P #, ,@    $
M             0             #S    7\                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   7\     4F=H=&QO;F<   /,
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   %_     %)G:'1L;VYG   #S     -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !#A"24T$#      *R     $
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MT? S)&+A<H*20P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ [P)> P$1  (1 0,1 ?_$ !X   $$ P$! 0            4#! 8' 0((
M  D*_\0 4Q   0,# P,"! ,%!04$!0D) 0(#! 4&$0<2(0 Q01-1"!0B815Q
M@0D6(S*1%T*AL? D,U+!T31BX?$E)C5%5!DV0T1&4U9C<H*3&&1S=*/"Q/_$
M !T!  $% 0$! 0            (  0,$!08'" G_Q !/$0 " 0(% @0#!08#
M! @$! <! A$#(0 $$C%!!5$3(F%Q!H&1%#*AL? 5(T+!T>$64O$')#,T0U-B
M<G.2LK,E-56"151C=*((9(/"TI/_V@ , P$  A$#$0 _ /S&)05' &2!G 2<
MGG'GR<_EP>V >O?"UCZS%P?RVCUOMO-O#1461R+3$'ZR8]^!N,(3ZM2Z.E"*
MG-9BN*05!MQ>2H*R0H!(4K!&.<8SD=@,U,QU'(9217J4Z;B)G[TD:@ !%P"+
MFV+^7R6<SJ*V6R+UAJCQA !AM-R3)(((CC2?; H7O:R!S66&]V!](=&[@\'"
M!@\8\C[8YZHGXEZ220<XE.-M.HZB>8 ,@<#GB(.+C]"ZV I^Q,!YK(Z'M]ZZ
MF?:9G?&Z;ZM3*?\ UB8 Y.3Z^>,_]S'C'^0Y&!_Q)TCCJ FP%JGM_E^G];XB
M;H76X/\ N+G_ .Y!R23]^)$D@]\;F^K4\7)&R,\_[0>..?\ =_ESW/GC'2_Q
M'TB__P 1B/\ LU.-SM^>WXF/]@]<!OD:ID_YZ5IM%G&VXX ]<>_?JU.QN2-]
MN7SC_P#QGSW^W@]+_$G2/_J(_P#+4_" +8(]"ZYM^SZ@]0U,W]?. !_J(B1[
M]^;3!_\ G'&XSQE\Y/\ ^Z^QQGC\NE_B/I __$?EIJ6_#Y_EAAT'KD?\C4V,
M'53CZ:]SM<SOZXU-^6M_^(F/'.'OL1V2" 3]QCWY!Z<?$G1[SU"W$"I(W[K[
M?CB2GT#K)DMDJ@N !K0^AF'CW/Y&YU-]6JKZ57#'(\C#P'N>R<]_S _KTQ^(
MNCL(_:)!)M9^(M)7]3@C\/=6-CDG(VC53[S_ )]MO01]%&[XM%"D*-P1L!1X
MP_D@CCGTCQG!_P O8#^W>CD2.IF;7*N=^! B>(L3:>V&/PYU221D#,S]ZGZ<
MZQQ\QVN 5S?5H_\ XAB9SX3)'Z9]'&/RQQ_C!^W>D?\ U)OHW8#\-_?W,6/V
M#U7?[#$[K^[]]]4&3O8VD815?%IJ)/[Q0R#X'S [I'@,<G'C\O'3?MSI$VZF
M=N58[3N8]N^Y]<-^P.J?_D!N)ND1;C5SV.WY(.7K:94A0KL1P)'/^^SS@@#<
MRGCDGN2,#///3?M[I4VS@K SYB" IXLP.]B8C\,..A]46WV#>#NAC< [[]I,
M6VPM^^MIX_\ ;L,X \O9Y^X;&>V3^OMT_P"WND'_ *98(V(V/TYVW[Q,V?\
M8O5?_P A?W']>\';?"2KTM11S^.0O8_[X>^,_P /VSW]OZ(]>Z3N*Z]P(F)^
ME[<[6GU<]%ZK! Z>(,"Y6_8$SMQ[6PF+RM17!J\7CCGU?'(_^C/'<]P.W(XZ
M0Z[TJ3-=>"#:_>>1^!P'[ ZKQD>UM2]^ )D\]O;'C>-J\@5B+P<@;7ACCG #
M9'.#S['/C'1?M[I7&846OM)-[D_/$R=%ZH% /3U-HDLLQ;T@?H'&/WRM4_\
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MU&OZ$]95<J$Y,>F6[=*F:'795-J$AE@MR3>_K;Z84F/G/ZM[2/SBZTK]F?\
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M^62<G/!]_;SP3TL#C;U%CZ0>"">4I/([9)!./<9XXQYZ6&@&/3;"B'G <E?
M!XVI\=^0.>WG.,''?I7O!C]?C[<X0.B"HOMWL3/,VG?%F:3U>="O6@-M/N)8
MJ<]FGS&00EN0Q++D?#B4C"B@K2ZV0,A2 H$8ZT^DUZM+.Y=:;LJU*U.FZB"'
M1F ((/,F)!!B;C&5URA0S'3<XU:FM1J.7K5:9V:G46FQ5ETD'< D;&(*G'<R
MF62!E&[&0"%* YY\$<\=NPSUZ#+$[Q;;3[>YCU._RQY9H6-A-N6_T]/E\\5N
MPD!Y*<GAEWD9']PC)&<<8SXQUU&G25IV\M-C/>%YB0)[R1S$VQ2NSTUV(J*2
MV\23-K1!YF)VG'($*YZQ:-\P;LMZ8_2Z];%TP[AH=2B.EN53ZQ0ZJW4J9.CK
M0 I+\2;%9D-+2H*2XA*@1C/7AF::<UF3_P#U%4[\BHWR_#^_N&6_Y>AR?!I>
MD^1<?2>J_MD_C2KE7^(2MUFOV=4)GQ'RZ;4[L:;MM^D0+5K5)TRF:00:Q85/
MH56ID2D/,V%.=IGX?56ZW0OG8\"L_A)JT-F6(5<J9W\I7<\E23SRH]+GOB:_
MRM'?F?3$;?\ VL_Q<&H5>L0ZM8M*JU7KMYW,9].LJ T_3JW?,/0Z%6)],+[[
M[<=R,U\/6G#M)2XV\W!D1*LZ4.IJSS;:UG4[<O4>J3/\3UC6-XDPT 3-AWPK
MD\1' CD_V^O: 'E&_:U?$G:E_P C4&P+2T(TUFU&X:==-9H>GVE\6V*%7*RQ
M0-7+9KLVKIA5/\8E2;RHVM^H$.XYWXPBIH:G4INWYU#9H-(;BQ!8 $DPCH#8
M2'(-[3:% @BRB9-\+VM>=_I]/;'$NO\ KM?'Q):K7/K!J*Y -TW0JF)DL4E,
MYJDP(-%I,.ATFFTYJISZK41%I]+I\2,AR=4Y\UXH+TN4^^XMQ187Z_7Z^FV*
M8SX &<<>W_E[8_(X..EA8]S]_(Y SSC/@??MG/W[=+"QC/&2.1W&<8Y]CVR.
M?&2!CGD+"QGN<#W&2![Y!QVY[<Y['.?/2PL.S% !RX" 2D?2#R"1]>5#:,C&
M05 Y\]--XOM/Z_7(P^DE0P@SP"3'KL/UZ7QE$0J&X[P#@I(0D@Y &02M([\8
M)SP>W3R+R2/E\^XX[?RPB (F1.UO[XRY"=;25$'  SA.=HP>2>PY^Y X^_3!
M@;;&]N>?T>1])=D<"=)*P"2 T"3 DZ8$BXOP<))CDY4I1#8[J"=RB2,\IW)'
M<8)W' \ <=/A0LW:WH)(M-Q,?CC4M#D!9Q]T\X/D?4>XSC)QQQT_\O[;=\"8
MO%QQ(@_,"8]KX\60D$J5M6!_(4X!YXQ]7D X('?DCV;]>WZ-L$ I4L&N."-_
MG/H;1_7%SV/KU?6G>F6HFD=OJHBK0U1N+3*Z;J;J=%A5.8]5=)ZI6:Q:/R;T
MU#S3,1N;7JC^*0G6)$:J1G$1Y+9;"@IC<J9C3-N\GF?G'XSL0!,&W>Q]_GZ?
MCWQT7?'[1+6B^M0]-=1OW1T>LF5I#8>HEC:>6KIQ8,:S;(MI.J<2[6[ONF!;
M]/FJ#%TRJE>54KE-DLRFJ50:E%I2:'2:? IS$(%-V(@%H!C8#D#W[DG"-Q$G
M<'GC<#M) V[>IQSY8GQ"Z@:<:=WYI=;)HZ+4U'N;3"[+D:GTUF;.56-(JG6*
MO:"X,U92N(PB97:B:DPEM:9[2VVW-H;"B['4%4BR&0#>##"?_P"(_/!6DF+D
M ?(1[7MVQ]$-)/VP&M=H7C?>IE[TZ'<-YRK*^)Z'IPQ:\2C6Q0*+J5\4-:H-
MS7#>]WQIM.KDFNP+&NRV;=OFQ*)37Z3-IEU6U0GT5=EF,XI0_K]?WP/Z_/Y>
M_P#H,4!IU^TK^(73VN0:P*9I;>L6FZ9:0Z8QK<OZQ(]P6Y\GH)7U75I!=KU/
M3-A./WO95R+>J\2M.23'J3\F9'K5-J<"9)BNK#X?T[]J/\5U.J5,K*JW9]3J
M]+GZ<585.J6G$E39U4TNN+6:Z;;J%1=0^RB1*?K>O6H<NLK#;2*C\W3&U-M-
MTME)6&']>(PTJ?[3CXG:M;"+/EOV :*BR;JT^"&K-C)DIMR\M(=)-$*RT)!E
ME:97[B:*6.S"E[0Y%JC55J+84JIN-MK#]_U^OE&+LG_MLOC>JXIJZA6=/W9]
M'U:CZNTVI-VG*:,.IQ]5D:V"UTTABMMVZ]:2M1D?C/H2J,_7FX;BZ*U7VZ0E
MJ&VL.-[^HGM/Z^FU\5=*_:?ZZSK1J.G=5L/0.OV Y2(T"V+)N32V-7[=L&K4
MRNZLUJWKOM&#5JI+4U=-LHUMU"H]%E5EVLTYND52"U,IDV91J7-C+ @ $D&9
MWL-]I]QR>\\8^<+@W$@DE:R2H 825*R5%(S@!1/  XP<  @=--IX_6^"*@'>
M3[#W$&=O<3SVE1N(M92,+"U$! #97NSP.03R>!R,\^W2E>6 [^GRF_Y^F'52
MWW0Q8[*JDDS8=HDV]\&8]JU>7DQ(%1?#:'''?2@/K#:&FENNJ^D*)0VAM:WE
M':EM""XH@!1 M4I+$U%OM)@_3YB^U^V+B=-ZA54M1R6;J:02Y%!]*0"3+#4(
M"@L3: #(PT31)JT.N(9D+3'VJ?6F,Z4LMJ46PX\O&Q""X0VE1("UJ 3A7T](
M5$D>87GD3:+ $B3?C%<9>N0W[FMY8U$4R563%V&T\2+[;X'N1_35AS>%#D#T
M\$]QS]0QVPK&<' Y&<&"#M<?KW@XB9669$1W_./3F8X[SBT]#-;+X^'C5NPM
M:M.)%/BWKIW7X]P4(U> S5J1)>::>BRZ=5Z7) 9J-(JM/E2Z94X:E-JD0)DA
MMMYATH>0X,&;?/#8Z_F_M2_BI<U*TKU#M^IVE8U/T=_LK;M32JQZ),H.C4V/
MHI7:E<6F3%U6"FKR8=TKM>;59346=593U27&+:79:WDJ?4I.HM:ZZ(XCD>QY
M'?TD%89SOVEFMJ;?O.TK/L30O2RT;\%]+N"U].-.%42C.3M2=.W-+[QJL9F;
M7*K)CU&K6PX=SHE+:;J:$3VV4D*:(@0 !Q-SO?N?3C\;WPK_ *_5N+W]L=;P
M_P!L_?"]%M0J=<NGD:L_$O=#5PTBS]9(K=I4RCZ;T*X[[T]U"?1;$%%J/77'
MCPJYI^Q,:M=ZZIE FU>J2ZPZJ-'#]$ELRA@!P&#;3MQA*;$D;J1OM.QY![^N
M./KO_:1Z[W9K;HQKJBV=(+8N'0&I7%<>F-JVGIY$I&GE(O:[K@J]Y7'?DJUG
M)LM,^Z:M>=8<NQ4I^;\C#J\&CH@0(M-IK%/Z-3I<O D@CGD$3OZSQ<"\  -'
MD"&X!F3>W;@^D_.)Q+U?M</C.G4^TV+KO&WK^KMG5*U9M-OJ^+9B5R^Y<&Q]
M6*=K;:MOUBX_4C.U.WJ%J%!DU6GT]UA*F&*Y78*) 9J"PAL/[?K]'&EJ?M6_
MB8LW]PGZ)2M)FZA8"[35"JTNPVYDRN,V-J)J)J=:T&Y6Y%27!J4.F7%JA>$8
ML,Q(?SM%F1Z;4%RQ%:>!Z_*%*R)$W()BE4HGFTK4)G<$6W(PQ&H@G@S B/;:
M8])X&#;?[73XG(M-D4*E6[HG1+?I-O1:!I-1:9IJVW"^'QQJQ;DT[GW!HDJ3
M5Y$NVKBKENW97U5FHUF5<B)=8FM5I,9F?!AO,QQMZ!1[Z5 GYD:H%@28@8,M
MJT@P H@0/U<G%MZ6_MF]8*)JG9&J6IUEV=7ZCILO5*]Z5%T]MVCV0[JCK3J1
MI73-*Y-Z:X39T:XHUV4A^FT6CUBX*32*71EU"K4QF33UTJ0\[*0_O@3IO<<
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MXD<6XWX2(KZ:=!A_AC4=,+Y> F.]-"5R%B4],9VK5(:*R5.E2BXIEM"DI*4
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MP?UQX[CN>ND,>*>!X+[1_EV^?SGZ35'_ !*<\U$!BW\6QF!,W%K<QCA6L_\
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MV3^6,\8Z6%C/L<* !&<>,9P,#/?GM]O X6%AXD.2W=J$+5W^A.2H\ @G'!P
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MLA"D@JY)R,%RBJ XB=P;"3W-NPY]>\8;[4^8?P1#+4:?#"[ $^4 & LEB(
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M:J(I$?\ 6T_H&' ^OI;'"5:YK%4)X/STL=\X_C+\]_.<=AX[#'A><_YO,_\
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MP26QM*BE*SW,@FG8"XCL+?>)@QL+#BUQN'^T,F<HU7=]-):A1@=3ZU<L@EI
M)9I) ! FQL,,*O,FS7E2Y,DK<=6E3GIJV['5J&%;4)W8"<!7@$'(V@]%355&
ME08@_A/-^;VW$][U^HYK.YNN,W6S!+5&U52#!#$F+*-H(FT_*3CPB1W*@YNF
M/R9*"7$>B@.I?V-!89"L)3ES8L.+RI(2,;3DD$2=)V  ^]M!][;<1W)CG )3
MI-FBU3,.[#S@:2?$*KJT20/OQI+'82"#C%[56-5JHS-B6_!MMA^GT_\ ]&TT
MRA$DKC16HSTX"5*EN!V8ZRJ5(1ZZ6A)<=$=AIGTVPV60TUAZIS!#$:FB1))@
MQ>1R>^T"0'ZWF*6<SE.O2Z=2Z>E3+TV\*A(0E5TET#$QJTDL! F\DR3 G\>J
MZ!X4HCSC/;O]CQD]O..K1()) CT[8Q!^HQLRD+4CZ=V7-O<8(X*@3@GL 2,=
MB<<]A-@3Z?U^7X?7#@:CIOJ.WMR?<>_]YLS1HD>*:A4'V66N W%1AQ]_;@_Q
M$@@M((&T+&0O) W8.*S5G+:463)DF0 -H!$2>(M/?MLT.FT:- 9O.UT5 1HR
MZD&K4]"HC3382 [6,VF+:2:A+J*2S'2(\!.$M4Y(VI;0 4H46T@MJ7G!*B<I
M22><=&JI]YR) ,L=S-[$P8D1$?RA9G-9C-J$HJ*651ET9('33 L ^G[A8?>+
M&YCO@&Y3W4K"E!?)2D;P" ?./.<\=L'^O1^(-MS F\>YM\B(_MC/:C5U@D'<
M1)F\1;B9V,X)IBEA]H.MJ<"DI<6D))RD@IY22!W.,X*<X\CH)YGO-_USZGU'
M>P*(IUJ1J(6!4$@#TCYCD'OM-\%9ZG)67Z?%>:C-!*%I"5*2TL@$)!(SD@$I
M QQDCQT(91Y78:F!*BPMR2.W]>^+^=4UU:ID\JXHI"NI#%0\ @$D'<21Z7VM
MC 6N53!$D4UAI2'_ %TSL8?65!0+:RGE2%$!20I(V$8"OJ(Z'PPKZU=K@+X<
MPH"V#*.]KD<'DQA!_$R"Y:IDJ-'35%1<RH"U3Y6!IL08*-,B0"NB!8D%%"%Q
MV5(;&2K;L0" $X^C)([C[*('?MT4R>-]S>>9'K.\3M[8ATNBD)>=A^&\"1-S
MM?VOHW'7*5M?^G!V_2D#)Y.=P[@<Y\?ET7Y]Q\O[\#"6F:G_ !!!!CB)W%YO
M?TOQ,8>I_P!C;6A@*.]"2XG/\R02K)Y'<D?K]N>HS!:]S)([@V^IW-^#M!Q.
M"<NA6ELZ@,!>1=A?FYYY](QD@(=0DX6EP!Q2O"%'^[G Y  )&.^<'&>F! DD
M1P1%XL-I-MKS<6(F#A%%4K!!U@.P!, D[&;@Q$[C&\M"'XVU3CBY"EM%+@^M
M'HH20$J ROC:E*,D#8.<]NG0PQ-@L,(V()OS(%KF-COO&%55:E*"S&IJ4@SJ
M4(H,@R2000 !/W1QB.RH:P\ZK(#?HN%6#P"&SC=SGL3COGQCJ<5)BPXYXY(X
M_&TC&=6RY\5FBPIN3!L(4^XF;>OH<1+/(YQW [9R2.,9(X \^XXSQU)C.QX9
MX['SD<G( XSVR1Y/?MQQTL+"J"HI*$  '!)/Y]ACL/OG!R>".>EA $FP_K'^
MI_G[%8L0;D>KM2E1 PL?SI&3]((Y20D_5V& !WV]"Q@6F?2VWZX_*<3K2%BT
M03R>Q,6&XM<\1L,/Y+:/EO59#38"O3 "QZH41N25(RE6PI& K!3GZ>YZC7<'
MN>_R_.??;$U1$T2([ $WU<$VVV@]Q O@.A *T*>3O1NRXD$HW)&3MW#)!.,Y
M'(\9!SU*2!N?7%44B.;#>W?8Q_H!/M@S2Z54*O)9IL&.N:^Z5*8C1VW'7%A+
M?J'8VA)42&\Y"0>4[OY1NZ!G5 238$S/%S.TG>]^]O2YE<M7S=1<M10U'*MI
M51+$ :IC>PW-SO$"^'D6.8<EE4AI3R(TH*6SRA2FTI2IU*%_W $$9R@G(.<8
MQU&SZMB!(WW$R0+Q%SQ/;G:5*9RU:FU:EXB4:P+TX(D *67:1(ML2#(XC!R&
MMITU9X-!M$Q"$M-%I)*2VM)+@<4=[*BAL!*FMQ(*DDA*SU!4+>07)4B?6S6C
MD7O/-^(QIY=J=4Y^KX6BE72$IE!Y3J!4@[J0H(E1-X$ G!BC+@04-N+9"WD.
MLO(<W*;<265*64-J3E*0XHI*E+"BC:G80 <PU2]34H,+#" )!!$7F)CS  &\
MD]QC4Z6^3R--*[4PU5*E.LAEE=7I,7"TRL :V"7)D$ @@" S*_Q-ER<\LEYV
M0\MTN*4K<X'W 2I1SO4K&2HGDY)[X)7ID*+* (VV(',2!/L8G>;UY'4*5;-U
M"?%>M49V8DDMJ)),SJ)$229+$DWPO4W8\6/':A2Q(2\Q%>E!3*FO2EA"PXP"
MK*G SN6D.H(:6""$DX4%2#%B2I$,0I!GRF\GW@3(FT>F'S]1*%*BF6J"H7HT
MFKPF@I4"^9+B^F6&H'2;0.<)QVX+])J;CSR!**6&XS*FG%%86O>\ZA\'TV2R
ME."EU"O42XH)''4E0L*U/?3!F-N1<#>;7V[X"C3R]3I^=>J5%<*BTU*&8)!=
MA4LJ%5W!!U D#@8A=3<DK8A>HI2F6FOEXQ4D )0A2EE",8(P5DX5D^0H=S:3
M<QS??Y?EZ?GCG<P6*45,Z=&E)VC?Y0-IYYDX /!T#<\,91A."2.RAG:1Y.1G
M@CM[#J6?U^OT>,4M!IBXWD#WC?:\[^GT&&0^^!W\=^!Y/V[_ )?;E8''OSQ@
M^0#[\=LG_0QTL+$RL^T;@O"IPZ+;D%RHU&4J4ZVPC"4,,1&/F9<MYXE"(\6*
MPA;\N0XI+3++2G%J2$=09G-Y?)47S.8<+307D$D[Z0H ,DDPH ))XVQI=)Z5
MG^N9ZCT[IE&I7S=9_*B@!578U'=H546Y9B0 (DC'5-#TMH-DRHD2J5BD5"YI
M\.#+8>J,"8_0*4Y):>>?#2G6U*DSF%-,M,R5Q'X;ZY!<96&$"2O@LW\29OJ>
MM\I3K+TZDU5:HIL!F:C#3"LM]"$-<*2P",IAB%Q]&="_V:].^%:U#+];S73L
MQ\19VE1K97[?3:OTS*&I+M4IG24JYI-&A3544SXJLA@$BP*Q6+SI=5A/7=5*
MC&JT%RG/-OQ9+*)9:IK41V"W#DPEA,9+<1+'R);<2"KTRR<!13C4LGD<UX[]
M/HTR'1Z;BKJTHU16#.R."&>2"Q*P+SYB"?0*G5NK],?(T>NYVK1;*UJ68#9
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M2%,JSZB3N605 A*!SN . .<G(X Y([&\I, \<6F&/;Y\7OQ..>KY5%#4FDU
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MI:=8+2@ :4*(2)@$G5<S)$Q, 1I=;IY%,MT5\FNEZV3=LWYF8O76O575#,=
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MFD%C)N2+#>^T;@3Q&)>HKF*N0R%;.9I31H!THJ:=/4%-5V"L$4%I,R[R5^F
MC4B [)91,6[%BDK]1V,TAU]2$CLVA:VD%7G:I8&.R@>K95U!*Z68F88D+VW@
MG:>-SL=Q@TZ^5JUJ:5R^7HC5J>BBO5( V5"U->Q@MM/( (=^64>NVV\H-G*4
M'()7@X3N1G&> <[B,\YZD13J4Z08!MVG?N(F=X_ 1FUZY7Q::5"*=P#,:@IA
M24O/IYC!VD6P"7)V)*<J<"B0"HE'(^P)'<GD_8GGJZE,L9(@6,"X^<[[>_;;
M&'4S/AJ5+^*23#$Z")(D1>.9,CN3>PIXMAQ*9;J&T]U#?DD< @ D;E#P,@YX
MXYZLZ6 L >QVY-R8VV$7YQE.%6H%S%0*I/F8,&@<Q)WXPVC56-#G%$1E,@'>
ME/K@%H(<:+:E*#@<:2H!1*,XVJPI)SA72--F428)[ $[VB(,&YO /IMB!<[E
MLI78I3\9)(45!"Z2L3IAA/([<]\$43X+Z$B%%6RX4K2^OU@XRI)*>$CTQC=E
M6]2E*W\$)0D8(&DQ/F>8V&F((YWW%Q'K?%\9S+5%'V7+&BSHRU&\34I$V !0
M1/\ $3<V(B\QY$M#3[R5-J*PH%)*3Z8P2"4J!&XD>"#C.3D9S,1/L=[C]"1.
MY'],A:RI4<,"&+S,2+;"9!,\>_ @8?NU'>VD*4@!*4H&U&. O=C@#.[)&X\_
M<\]"$B(D3<^T;BVW/;<GC%JIFRZ!344!0!9!L(/99CD_78X3AR!(IU22\ZDB
M(A3@_B)2LA2PT D*(+BP7-Q0V%J !/8'#Z8=7$R?3?F-_07]K7N%"OXN5S2O
M4_X0U(MAJ,A-B=X8L(FP,[7@+O#BAA0Q@?4"D_2, X)R-V,\ D@C@9 ZLS.X
MBPMOL(QAF";7&WTMA1A*5)4%<*4I 2H Y22%9XR,#C'GG!]NF._I>?PYX_GV
M[.-C8$EE O$3,G:_M(^>)I+>=B4QJD_B,UV)$5\XS3WHZFF$5&<RTW4)#>Q]
M6%M(C,I2ZM)<6AI""VA&X= K%B+#=KS)$>D3/?V/RO-36@OA^,[-"%4-. 6:
MU7S:I\HN+23:!)PR>A0WDQW&G2MU83EMI@(1S@;6P.2Z5_S;D*!*@=W]WIB[
M+(($;;Q$<QVCZSQN'J4*+*AI5":A@L @ !)LH[DG?4!!(OB74MB;#$J*T%M(
M<?0IQ"T;7FU-[L(6HH3M(5DEH;4A24JV_2!U4KZ##,;@'F9G@P>>\^G((W^F
M)FZ(K4:<JKNK.2L,"I)4$E1,$GRVN%)4E;R5##CRI'S#++[LQU!^:D*.]+@Q
ME9>)V(]3DO+4.1DX2!U0+1IAC" P!:;SL+F-AZ[8Z1*!J^*:U*G5J9BHI-:L
M9(8:1J\0P%U7\0DWB;;X;J>;CHD19,1,A27"IM3;A*&FFPXES:IH!2LG#@(4
M$D)&Y)"B0:(7AA4*Z1!!$ZB2-Y,; #8'M&(*E>G06K0KY45F)+4W5M2TD0.'
MC0))DJP(8@A1*F9P%J#\=UQ3L9I;:4MX0E:MY(P-P2O:CA2LG!02D'&3W-VF
MK*NDD&;[$P+D6YGU,GF<8N>KT:U0U*%-TT@A _F!6/, T+NQ, @E18R;X$MO
MET+PXEHMK^G)&"D *(Y4E62HGVSQ@]&0!%I%K$29&WIZ<D;@29QF)6=P3.@J
M8 %QQ,P0=YL=X]L.5/Q$*9D//J@AQ#3<A:4M.*5M;"''&FT!M*@-AV%PEQ:N
M%*')Z(AKC2&.X$Q\CO>#<1 _*5:E)2M6K5;+:O\ BL@5S &EF4>0'RW&HR6[
M##428$9T/1UN/-E60RZ@;@D<%:T)40-QW*V^Y /OTBI(@V;TO'UCCTOOB(5L
MK2?Q:+&LC2P2HH$0(EM)/)D\ D1ZN'H*YR<Q68[)R%$O.I0XM.U;@"3C8!M1
MEP$X2%#&2 %,6"0"9G81L+#@^MO7D\3OEVS0!HTJ5(VU%ZH!-BWDFQ  EAP#
MS:-S27X,F,\IZ. A&]30=;=WI2@.**$J_AE*TDI;&[)6DI*1G'3!U<%;CY<S
M N#8['Z8.ID*^4J4JC5*,*NHTU=7+@#5($E2IN+29$$6.&,B9+FS%O!"U1V'
M%.. IVH9;4I*%[E-I2RRA03](1M2@*!P.B"J!$W(B>3!MS)B?GMBE7S5?,5F
M9K(K$@6*HLJ#I@*H  @ !0.UY(*MI27F0VYZB2RV !M4D$J4VG:H'^49[I)2
M2,@Y(Q)2D DBXD[F;W@[_P!<4<Z5-6EI.H-2$&( DD1O$7]/3:2*)2%J))RZ
ME.=P_E'UJ5MP22-HPG(2<\9')ZF#:0P F9%CZQ?>YF3/J<4H(!!]EO)(WGO<
MCZ[]\6/67X#UNT&-$FRDOP(:V9T92FRT)#S[DDF*EO*F4 .(0H*4HK4G<I([
M#/HHR5\Q48 BI4#*8@P$"7,F3:08M,2<==U&IE*W1NDTLMF:JU\I0:EF:;*I
M0U*E1ZTTPK!E #A#)\T3%L#H44_+-I5DG_>%>.1SY'DX/U*SC![<GHZE19:W
M<1,F3N?J+6CF1;%/*Y=FHH#.TER-AOM\R3?BTX-):8;/\)Q;P3MQM3@ <=_J
M..>_'41JM%P!(-SW GL.+#;ZR<:M*C1IR:55JH!!8A8 ]Q)V$_('O8A_O6U*
M!VYQC*<?4,\DY!P<\?\ GFJ[EMQ'%B?U[S/I&-%0&0%3$B1Y8N2;D\WX&-)L
MA#;;*=P]5"0%J&<'/<$]LDGD<\>>BI4B_H#:=_G[V_KZAFLRE*G3$@U%6&_[
M5A8DCFY^7IA%B8GEY#YCR(Z4.QPELKW+0O*,*!P@I5]84H;01G!\G4H%&0":
MB,"&).G23WO<1: 1(L-L0T<XKJ[K4\&M34/255+2P:T'^$S<:@;W/H-:5.GR
M9+B)"V92TNE];BMJ74.#:\"O&%^IN&$[0  3D'O9&A54!9N % !@ VYMQO,S
MO&,I!F,[6K'Q=%8AV<NT!EL*@)CF1Y=-]Y$8$)AM-.J;6\AU2LI4-PR ,A7(
M(([X"N"1G*L@X.6/\,>YN)^4&+R-]HQF^"M*HRU'1A>3JDA9AC  !M/S]3C:
MH5^*ZXPU!@)C%AA$=;B5NJ^:<2I87(<"U*V.+[+""EH)2DA"23TZ4BLEV\23
MJN!8;@;GV61.]^TN;ZE0JO17)Y5: IT12>H*C$UV$AJK @Z78$ @'3 'EU$D
MH1JNV9#<9QH9&$N'<<Y3D'@ *.1W\G/G/+/2A=2M!W L(D2!.T"_';WP%#.J
M*M.G4IJ0-*MYCOWVDW^LBT&]C3I12VNBPI#$>ERW(4Y]"&RM#TJ.RZTT^E]]
MI,CTTH?=RA*DM%2LJ2O8DBC2#%#4=274L@DP8WBUI,F;;;Q)&.PSKTV=<EE:
ME++Y2LM"NX568/6"E0X>HJOH G8A0>& P';:]!^3$;2S*64K;]5MU2D9SRMH
MH^E6.Z2HE."<I(QAV.H(6!0". -IL;@DF"+7$3BC209>M5RM%:69<JZ-5%4E
M1)$L@52K1P22+Q!.SQ<-*:94IK@27?1+"8J05.K2([I6\C:DI2VR6QO!VGZN
M 0DGI4ZD/30&/./,9'WF%M]S(@P9($8NU,J%R.?S;A?$\(TO $FH0*-0EUTB
M J: &%C?L,42>=V2.YY!X\^XX[_?/Y<'8QYIC<-CZ2225 E/&3WSCD^Q!!)R
M<]+#D$:8$ZOJ/ZV^>"KC18;89;)*W EPI3G&Y:2D!7]W(2 1G&%$8[9Z14$2
M?:.>X]1S'SMB1E=-"*2P8>(;"02"-/M$&_\ 29?%]:6XER5'2VI#2&\I2E!P
MTE+;8#:$H&[8 2K RK).>_56H=*F#S%X .]^9Y_1C&YEJ;5G4O2(TTR)6Q(@
M 6  WY)N1>9P<8CJ"\A"E@*;*00<*&1E*L Y![8QYP 3U6:K*L/1N)B9V)$S
MS>/?&S0RQ5P=):&1@"-P""5/-]B0.></W%M0WY"T(:?4M3BD+25MMHRHE!;0
M4I5] 44[5@<C/(YZKJM2JJR"H7@QJF!.P@R=HF)WQ>=TRM2LZTZ=5G+$$,Z(
MDDE"J[^22/-$D$WFX]Q<A:?F7$*(4LA4@9VY.%*'@;@%).-V?!ZL0FD4PL%1
M$&;D<7 C;L!!MC-J5,R1]IJ+ 9O-F%)(_P Q[ M<&-1;\\*.R8+5,#JI2O60
MIU2&TL*.X*  <4\58)\!)&T8R!DGJ(4ZAJ1H 4D3<6B+#FT< <CTQ8?,Y*GD
M-?VECF SLB"DWFD "H]35!.JVEI41(!G#=BM39;:FI(+[;3*@TMQQ2$H6<8"
M A*<E*5)<&2<_P O9.>I#EE4ZU,>82(!D"1!,_+T]R<5:'5\YFJ34Z\5D2DR
MT6=S3%/8@*JP)$ZHL#L9FPB*&DN/+DS&T! *LN+)WI0"0R4MAQ0+@^A*CPDJ
MR1P>K1D@0LD6]O7CF/<0.TY='0'9JU51IDG43+ 213\H)&L2 ;P#/>6ZZG2B
MZ\TZE;R0GT8RVW$CT3W05%39+B$Y6G:=I.<@G&.BTO ,#:X)_EQ^/SWQ&<SE
M ]160D-*I#?<D^4R1+ "T0.3OA&4A'I-E$8CU$[F"24AQO&T+2 /J2I1V\9X
M&0#VZ7O;OS'I^H^6 JA2@"TMU\GF,D  !@($WVWFQ]," H(<(6"A2@,)QD9&
M2H GL <@#N1SWZ(*""9V]+QW-^/2?>;8H60P05EIB)VOOWW^7>(P17&CH@N2
MQ+<5*;6G#"F=B5(*0H#U2H'(*N $<IRK.!@JFS"J/(-*@F2=R"!$3_KVQ9:C
M0^S-7%=S55@!2-+2I4C_ #ZMP6$#21:UH@)+<]9#""I2AL'!R=I6HD<J(!&[
M&".^!CN1U*!+,1 UL#8"WFN/D+3;%)[I24L6*K;_ .XD][7,=A&W8<AG<L)4
M2 %*!5C( 3])4.1G!."/OW]BB\$Q>)Q#%KR/E]?H;'M,\8[8T3M]RQK;8O.3
M0(]R3[TI5:I=-B-3G$3*+1FWT4N14YL>#ZK\1JIK6XQ'<D&/ZS!]1E9P-WG7
MQ;7^WYH=/3/C)4,EIS%9P%;[16266BRLX$I&J!JDS(@X^G/]D'1&Z!TL_$]7
MHS=7ZCUU,ST[(9=B],Y#*O%!<_J1':*QD"?#&B"M209D+"64N1Q5X[4R(U(^
M91)==!FI?62W(@MML/15J>3+#$A*0_ZSC"4%0#*U(5GA[4WRC5*8-(4C01":
M11#*URQ(4 TRRD, %)$$D X[=\FOBHG612S67R^9:JN<J54^T_::@!K9%::%
M&+4ZZTG&ERSTS!\OE,NIMFS7HL6?<JY$"FLU!^/$CQ%1S)DRY!;C_AJ0J0F0
M\ME2!*?0XM189;=VI1A(7DYOK%)*E>CDDUUC2!KU*JE= 1@?%$(P$DZ)(4&Q
MN3..GZ?\,9O,#*9OK%<4<M1S#_8\G0JP:@KE:2Y-R:C5'%,37C4^G0RC2@&)
M,W;K-+J=9DS&HLQR!3W6HT-Z0_"<FMAEN W(A2HF ]+I06F>)+B4M2O0+C[T
MHN.!60^=J5Z=$%V -16GPPRHQ;405@$*YA2ID@_= ._7T?A_+9'.=2S#(CE*
M&FG1.8=&K4U14+TW/WJF74ERQ6&TW=F-H];DZ?$1 ?@Q'%Q::TNC!VH3V5J$
M-]3RGFEU=*1\@TF4^R:>MJ/ZSC;BVS)4D*2O2SJ4:]>H*M8J]1%K$TJ)"!P%
M(9:1(U&/$\0%@%)G22;<Q\.?M3(Y&A]BRRBADVKY1:N:S0>HU*HU1:BOF5#"
MDB,:?V=E#FHLJ7 P:=I42ANL2V;F^=J%2IE5_$*?$I,24S2%*9?C1&-\F7(B
MO-2OIW/QFBN"AYOTOXZ-J:'VM*J(BY%:?@5$BJU5]68\PU2!24J0#8,8;2;Q
M$[39.MD*E1VZL<T^;H,'RZ9:D%RA-,@PYKU0REO*="@B5CMB-U"CS5N4A-'C
MRZLX^AAOYV/*<0XTB*^\B3",*4E*6T-%QE"E2 TPE24O*2^U(#AT\GG,L:=5
M,TZY>*C5$#(&4JX4HP90;DJ3Y;D:E$$0,+JO3.HE\E7Z7E:N>+A*-3,T<R5J
MT_!9E>BV7J,*8159":CG3.EW5@=16E3Y%);J;LQV#.J3=<8JSZ93,5M +T20
MF0Y$C,,RJ6S$BO3)9CJ"6_66_&=BQEE.ULZ<YS-+]FU4:3432+4T+DLKEEU:
M@LEBJR 3I4$&!,0YDMTKIN>'4GH]1S-'.#-"EF*E*D*:U:?@N::J:E/PZ*U:
MFB0I=RK(&A6(*'=UHPF75O4B4*FPJ8Y3Y,5+2&9*)$>8A3-0* PA25+5'E-3
MA%>E/2&0E;<=C*.KU7I?5*C:/M8\&JM):BMJ9D 9033)8D0"\K(4*1YB0)YZ
MA\5_#>1ITWI]/JKG<LN::@:-&E1HUZE1:CK]I:DQ#4W9*;BL$J5&<"::J643
M.W]9E4A :3;D%]MN8S4H:4&3-G42LRDJ4N?$ES92& [++2&5I7%/IL160A+,
MIMIY65F/A5\QK=<VRJFNFQ;2E/,45V1Z:*Q$?]YBQ-RRE@>BR'^U'+Y3PZ5;
MI:,SFG7I4,N/'J93-U@2:HKYFI24KY 0NA2BJ1"G1B95VZ9EX)-PW*]!%R1Z
M;(K,.IJG,QVV"_#;F04,M(]-F1,+<</*4HJ)0[O#+\@J2,;+Y,9)CE<JM9LJ
M]44:]%:3 MIK%:DD2T:CI"F): (4@X[3.]6I=5RU#.=3^P)G:&3J9W)UJF;"
M^":]+QZ+ :"&J,@%1Y!"K)!<A@(O:=?NZC6U3YU3K,T6U.KL?\;;I?H36'*:
M_(=;DRIL>8ZTN76$B0%0F'&_3+"3F4V$(/6IGLITW,=1:EE\NHK4:)%/Q@4/
MC(NH4P4#JM.%8,PU-J-E)QS'2.J_$?3?A_*Y_/YE<SE,UG-+'*.:B#*5*NCQ
MG\94J/7+51I32B! (:+XUGM46+$B/0Y5/N%$BF_*".RJ:IIVH5:54*<U\^VM
M,:1^.A34:=&ITQ<B(5MEQEP!LQUK+IFO':EI:AKJ+6)50S+2I::@1#&@4A=M
M2:3I*EY^]@^J?LL9#[:N9I9U?LC90:JK4E-?-U'RRM6!.MLP1<TZY8:U84RI
M GB>RX A:T4."4O(_#[\$4L2$!$EM,>K/MI9D-G!2^V4EMYO)#:T*2G<D#/O
MO1"QS?22T,2<L21(N2L[S:8L=MI.Y_/+XN6GEZ?Q%20G2M3J24MB81JB4PT$
M""8!(V-QJ Q](@R2?I21Y(Q_CUZI!FP,7Y('&T;1< 1M?'A_B$;?@W]O]-CC
MGQ(RXVD !2672>PX#:AW.,GQ_3CCKIS>%%F6DY/:-)$SWW$?,3Q0AF-(09%1
M3OL)N3<@_*Y)^6. *Z0:W5L#_P!X2B!C'9Y8_P ,>Q\'.#QX)G3.<S7_ .XK
M?@["/EMCWK*?\KEM_P#@4M]_^&N_J=SABRRMX.)0,N;D$#CE WYP3C'<$@$G
M&3V'5:VY^N)^1;];?.28 _IBVJ+N;I<",]'<:+K9>5O;* Z5Y4TY]02 E>T)
M!)PH=B<8.=7AW8JZD*""0;@B9!O?3/&QWB,=UTQBF3RM&I1=/$!<ED(#DDE&
M)8!88!0)WM$VQ93PDPJ1%AJ8;BN%LOH4%H]5U+R0 L.).Y*5A)"4A1 PK'?C
M#&FIF*C%BZ@A"I7RAAQ!L3,&?4^^/0ZYK97I&6RAH4LN[*V85U=&JU%K*HU:
M@=2JP4KH[@VDW9TE*%;'90<0TMQ"2H)W%())*RC^\$C)(!!)P!CHJTD$4]).
MDP#838@3P2>]KWVM4Z6*1-.KFA42DU1 SJA8J ;N4B655#'2""38&<)UI]LO
M.AI\JBMJRR5I],J0.-WIDG:5*R=JL\GQGI\K3<(-2A7((:&!YV+6 .U[<1Q@
M.M9BDU>JM*L7RU-OW!==$H /-X98A9.HP3ZD S$1J%0;=;;;8;'J-A0*\8*R
M2.^<;?MP /OVZTDH-<O8$VVFPO%_SY@1..3SW4$9%2B)J*6!83+209O.W $3
MOMLC\LXJ J:9#"=CH;6RMU D'>A:PMMK=N4VD((41E(60#RI(,BH Y 6018\
M&+WF;DS!@0(%IQ7-.HV3&9-= RM#4G<*YE3!129*@"";@M$R3B-.+ERE)$=*
MFV@LI6\ZDH"<9)4C?@X Y&,Y/OSBV"B&&[7@$G:TP-_T<8;M6JF45@@.DNRE
M0.;:O3BP.&JJ/ZKZ7')2Y#9)2A2MWU@@X6$JR ,\I(P.0<'MTXJF]H.\'CD@
M7W(X_+$)R?B5%)K-44D!201,W! /F -]UWG:+/I<!J-#3%::2OZFW7%D)6\%
M@*&T+'UI2<@^F0HE0!R3@@!4!,R0;@V(O:+P+1VMZVQ8S65IY=4I!=3$*[&
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M:L04.@M*E/.K0DMLA8<<#9Y5M0-I"6UJ40@ #:5*(Y)),U6'$6G<=X^L1MS
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MDA17A*4@E0"3@I(&=N?8Y./MC- NY.JQN(-MS,7/R]!-L=$N6IT4-(F"6T@
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M9CC<2/&90IY^3(E.-H89:90E2W7G5$I2VA)45D)\YZEKNM.D]5F5$I)K<LP
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MI!TL TG@D>4=YB(V,$D#OOBIX])T%7+N,L]%(-1J>LAG!!4  _?V5R1,VX&
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M(9=3J:94E0@$F20IMLHVM]#+0SV<^(11KY^EU&MGA4(H(JN:67=*U-J:N:S
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MO(W@,# B1.W?UQI5*/AUIU'R$ ^4TV\PU.I7<P\B2;P3CTA"EQ"^2C8IPI2
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MUED,)I,R&E=L#8-9CL-ICU)#ACBG36HI89;+GS3S2OEG'E$H*FD.8W$J6MM
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MLTAI421818Q?>.TG<WW^>,+J4_;2Z+79')-$.FDO3)*AK$@[&-)(MQ&"M)7
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M:637*KF6&F@E1ZB45%@JLXU-R9(FY@;8,Q:=56I42%!,E,B0F"\&&VE%?KN
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MP)A@N2RQ4C4 0#:)O$3><?CW_M-@=<^/U'\/7/B07B?+U'.[B8OS$B9BT3]
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M0"KKJJ:NHS<%;G: ;B"(OP22"#B2LEAQ3:7W7D0]P<?90KZBYP 6T'*2O:2
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MP/YDI(*\*<4!@C%:X>-P P)VB3;]>G$'&PZ_:Z;U8"M5*FG3684()J-=O*"
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M7HU<ODAYUIMX^LV((U  JL:@0##3,S:,;N5B<AOY&.M8IGI*0X4!+8>2%>N
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MWTP$;FTHR HDA0(_E"@2D<' P<].1%_\T$^I _N???MBKER:K:].A0&"J (
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M@D)&Y6U 25%()[GD]1T@1K!%M1Y,G:2-[7[G?>#BWU"HM9LNY8EURZ@B  -
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M]^LDL?&HR8\X)XW-_3]6YQV8I:>FYLZ;BDXVF" 2>^W\R.,<^R02\OP=P)&
M>2 5$9^YSQP!V'72$ 0!V'Y#'DC&22.Y_/TPB%J3D).,_K^0/? )[?;C ('3
M80)$QR(^6)E9EQQZ#6XLJI0D52EN+].J4YQ0;1.@N -R8Z7]CBHSJVLAF2VC
MU6'=CC7UIR8,Q3-2FP4E7L58;@@R/3T/H3?&IT7J Z9GJ=:I27,99M29G+.)
M2M2J*5=3!!!(,JRD,K $&P@[,JLUEF13?46J@SZ@N93HOJK7$:>(]%N0$JPD
MR$,J2SZI 5W!P,CH51(4D?O0I#-R>;P8O>(_UMYG-UJ29BG!_9V9K&IE:!DT
MZ4$C4I(U%U2%U$SN.XQE4FE.3%1HLJI18:&64,I7Z"UJG(;*7?44E2$B,5ES
MTW%*+B4$9_O$C%0 3!;<B]A[1)(W_KP?C9%Z[4J69S>7RQ1?"/[MB]>(\TD+
MHU$PTEM)L+D@M269S;#[D3;Z\)M+DIF>4AAZ+( :,EP*<0<.%]AI*4I=WE8<
M2M*4X$=4@D*X8B3$1*L#,;;D@;D< SC1Z>N:6G5;+LI>BH-5,R1H>E573K92
M5D$.B@>8M(.H# N)'E.U%EQ:_P#>O)+J&&$.$IWH2$(:5E+A.0D([+  SDD]
M&SQ3)!^Z(69CZP/F>#Z1BEEZ%6KG*6IBNNH&JBDBGRA@&55)@W-AR(M<X;36
M(01-?#X,J'-]%RG/(=8>?94XZIQT!O\ A-!K#8=0IQ)RXA+:%@+"7IEB!,74
M$,#(%KP8OR =^=R(KUZ66_?U%J'Q*%<ZLM55D-6EJ-SI,#2 "5E=U"W!Q(HL
M=ZG51Q4FGCTJ;%9F(@2TH4AY]YMH1XY;W.>LP%.H>6E.%.(!0K&3U!5)T!5<
MJSMIU*0"HDDMP)(D"2;&18#&ME*39?..]3*H]'*T!F5RU4$I4=PHITBH+%D#
M.&.FY  M?#"&(,V=4:K48,$>M+:>31V6Y$=M0<=>]9B+\N/3C,L@(+H*MR0
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MX&RAIUZ51/"%.7K4#.G02S-II23X@9-191M!!@=^MLHDQ0V@H/H*)R<JY40
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M;2ZM;]8BU2,F/3$/F;Z!C0'ENL-L,14?,L!3SS,ALOI;2P8RU8.3S>5S^7S
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M4#L3 $3AY&K$B+4I$BG$MX6MM$=0"7&,J*D>A@*""CE0*2"@8"3A((=Z"-3
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M5%"F"JE*=,E/NA25O]T$#4).J!?4251VX;,UI,J-)>:>C+DJ=!>B-?PD);=
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M[(J=#&;:C%A>%^HD@?3G')?$0C-4%*A8RX.__:>W':WN/;$#Y Y^PXYY X/
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ME3+[#TN%+73W9#3\NL-L-RS%BQ4MQ7*>Q":2DNN/../3SE-R]45*=-G/BA$
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M-,8DH3+;2N8F8]AQV,RAMQ]"&FR"&06B0E)2X %#'1UZCT VA/$>H0=(@0!
M+$@7]VO\A&(ND9'(=3;P<YG&Z=1RE&JPJA&K>/4!:I20*SKH) "V) )DB;XV
MJS+CH@1Z>AU^9ZJ&HTUZ5Z<AUG(8CQG6BZXVRALMN$*/]U(!*04GHJ#MYBX
MDR0 2 =S!(!8W]P>\##9_2YRM+*%JU96"4\S4J@5FIKY5I/3#E:84BQ(F(GB
M)7:M7LF% G(KD^J4NN)DJ2RZS3VJM ;AAC^(O:W(CRES%2L))PZP&%DG:L#J
MCG<OGZM9#ETI-EXEU:KX529M$JRP!>!!D[G;&_\ #W4_A[)9;/IU*OF<MU*6
M%!Z>3&<H@:;_ ':M)P[O*ZCXJJI)"SBJ*_5:;4'F%PV)*"VE:9#S[H<$I9<4
MIMU#(9;$4)00DM>H_O4-V\$E(U,NC4Z85XGLNW%MR3[S?@#'#=1S*9NJSH&N
M2=31+&]X@!2>PF)W.(TO;O7Z9RG/''C QW.>?N?Z=38H"8OOC7SG'].Y_/W_
M %[?Y+#XW;*03N^D%)&1DD*.,'&03[<G.<=NEA'#R/->B/L/Q75(=96D[DA0
M).\*!PHD93@'.,]_!Y&HJU$*. 5*D'L009D3VF=M^^TE"M5H5$JTF--T964J
M;@J01'L1]1R,6M3[I@U6-$A5)4A4Q;I962RVN.6W"GT2V4@.E>2L.[_YCMPH
MX(&:^3^S:ZM& L$W)!E>TDB HM.U[&XQV^3Z_2SZ4,GU!G:J["F&\%6IZ7(T
ML2L$MJ8AIWMM:!-:HCM-K;$:,M/\3"@EM:4MMY2-@!5@*!*AN!2>1W&<='EL
MRE;+M58$ !IL=<CN!8>T\VQ1ZOTBIT[JR92DZAW"NHIL- UQI <@ R8]=0@[
M2)Y,HRGVJ2Y4)37J!@@/(6'E,J0M2$LR D_PE*Q_#2L\H(4!MQUF4JX7QQ21
M@&?:(D$ RLB"!L??><=?F>E-6I=,;/YA/$% D5:;^,:;([*M&MI)\-F*^56_
M@((A2"0<BA/184^H.S8C;:$QRB$U*+\F7'D.R4[PPV"E 8<BJ]=#JD.)#K2P
ME04=MQ*X=T0(S-<%F72%8!22#:9FVPWM;&!7Z35R]#.9HYJDE,+3"9>E6%6K
M5I5&J@,46ZA6I'Q QU LI(OB)[8BX;CJ&7P\5I;;]- V;#N+K:^=V2"D#9P0
M5;O/5^ZP"8GN;'UG?W[3&]CSVF@,OX@2IKE44JH@AB0VH?>DF!:1!/; ]]#R
M2T<$L[ 2D'_=A.3N6.Z0@<%)]\>".BV@S$['@_S))^8_*M6%0&F;>& "1(L!
M.ZP"#L+\"1>,;J6AB6S)<9+D9;A0/4*BVM "D@ Y_B;585QE*0<Y''2 D&X]
MI&_SV,7GM[X<,4S5.K4I*V79M())*L+DF1Q8F=O0[8$RY2&I3JDAM;:E+6E
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M\@@@@Y5D9!8J")/(BQO'RVO?OVD3@@VDHP68),R+D$&X]MO6^Q.+@B5R@77
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MV &X.&W(QQC! \8[@'SY[YP./;I8?&<9(SQ^O?OV_0D]@>WL1TL+&/'![?\
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M%MU:T*,Q1(-7JM0122['I518I]0;>CU5V+-7*4EZF1G$I%2BH:BIWS4EMO\
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MOF45Z55#3J  $D,"# !D,-U87!C3>,:'2^IY[HW4<OU+IU9LOF<I5IUZ3I4
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M^3,>,B0^M065OOON+<<<<*E'*U*42#A1X ZZ:G32BBT:5.G2I((6G3"A% V
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M]_(SC'18''CVSR2/'Z@_?[9[]OSZ6%CP.<Y[9X_3_P LX/\ CV"PL>Q_7CG
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M9[+ME<UETKTR9*N-0D7!CN.#(/J!.-+I/5NH="SM+/\ 3,U4R>;I2$JTV(8
MV((OJ6-P0186!"X^A-@UVA:\0IUS,.M4#4^D6XY'J%DVG2UL&XF:9%;D*NJG
MQHRH<7ZBA3L^'",J7"FPFI283C+NYCR'K&1ZA\+.<I24Y[I&=S53,KF\RVM<
MIXK:SD7<%]*4@0M/7X:FF64.&4@_8?P-\3]#_P!H^5J]2S>97IOQMTKIJY&K
MT[+G11ZG3ITPM+JM"G*$YF"KN U0K7IBH5A@!4%0BU%ZNL4ZO7+*>7 D/0%Q
M'4LRT*5$,?TH;CPEM"3#*&%-OE*6TMO-I3A3JR!T=*K1IY&K5RN4I('H4Z@J
M4B5!UAE+@!3I*DAE@O*F=@I/$9RAG\UUC*Y#J_7LQF$R^=KT#0J(M;5X9R[%
M6<U:9JTZBHU-Y5(=-RS$+85MTR.^%QZ'5(M!%"JR9$6NK,1F;4G'VY,-%+BT
MQI'S4^0X8BG8]3>"!#=:6XHM./1B_B9W,U* ->O0.??.91:1RVJH$H#4M4YC
M6Q<(GFAJ0"@!E @DX[/HW3LKF=61Z5F'Z53Z;U9LPW4*K46^VTP*N6;)C+JB
M>(X"%DKMJ;53)59"EHG<U(KK5?C5&53_ ,0H%ZUEE-!NZI2%K>E*,YR34'I#
MC?S;"[A2HQTU$)#TIIQ(!1(4]N5L].S%(]+(%2K1S&2IUFJY5:9*ZE6%0&=7
M@D,=/W09$!5$8Y+K^4S=#XEIE\EE\[TOKN:RJY#/"L%K-2\0FLZ* U-<XKHJ
MLVAV! #:R3CR*ZS%IMT4JYWZ(Z]29"6J6[67'6D1E-U!R(Z]3(;J6FZK*=B%
MUYMV:B.MEJ8^4@/,,H;"KE:ISF2S&0IU!3K(WVD4%!-0E4=14<2:*BI$JH;5
MX:R #AQU.G]CZUDOB.KDZ=7(YJBN0;J54@4E1ZE)A1IZJ0S#>#J<.=! JOI,
M@+BKKMU68I<R+4+3K#M9JZ&A'7)J<,R6HP1$?IJ5LNR5I29"H28XPB._&+:6
MG!)#J5,IZ#I_1B*3?:J?A(:CNJ(1)U.'"N?-J$EH%B)@#8X\^^)?CK+T,PIZ
M%FQU%Q02A4S&<HNZTF6DU!FRWB%8)0*-05E8*C%I\IYGJ#ZI,E3R\EQQ(4O)
MY*C_ #94  #N)) "><<#GKIPJJ%"[ #]?K\HQXZ[O5=ZCMK9V+$Q%R9B/2<,
MOL,G'<GMXSG/?([<8YX^RP.)SIJK;?-J*5D[*]3C]N'CX_Z>3P>.+_2__F60
M_P#W=#_W5QG]5'_PW/\ '^YYF_KX1CYV_N,?0)#Z5DXV@ #DJ]_TQXY'<<=^
MO3/D+W@V'-Q=;$1[Q>+8\IF!SW,6]@3';C8S;:[\(P\" -NQ:1_^K'' Y' Q
MX!\ ==O2DSJ$CPG@G<>4P.;3V/H?7DLMJF01(*[[S(])$7F]YMQ' EJV#7=4
M-3J;I_:Z:<Y<]WW.JW[=CU.HQZ7%J%=J,M<:DTHSYBT1(\JKU%R-3()ENL1G
M)TN*RX\RVM3J?G;.",WFA$1F*UA/_6-W_7RQ]%9/_E,M?_H*/8?P+^>W<^^W
M0NDGPK4RM?$G-^&_6JZ9=B7?'J\&S40;23:UPO(U#J%1I5-DVU4ZS6KFMZTZ
M.;35-J$NZO6K+LKYR@3K7I#$NN2HJ4UL6/G_ %_4>GSP\T3^"2[M7]0Z];3M
MTVW9]FVYJI5-(I-XW0^NBRZU=].I]SU@4*UK9J1C56H5]VC6I/J:Z3-33C#]
M:%394E-7FP($I87;]?K_ %PZ>_9X_$G^Z]DWE3J!;58M^_I%*BT:?3;IIJFV
M':H_2([KLY<WY-G\(HCEPT'\<N6G.U"V(/XQ#2FLR7$2VXZPK_A'I[Q_?;%(
M:Y_#GJ)\/CMF,:AMT-B1?-LP[KHK5%JS55Q2I\>-+C./.MM-,NMOQ9T1Z-4*
M8NH4.:''6J?593\.<S&6$)Y_#;\\4)SX'(X(SW'V)[GC_///2P^/ D8&<9(!
MQD9(P/'?_+^Z?LL+&2XO&TK4I*3DC)QR...QX'L!G';GIY,1)C#0-X_5_P"I
MQDK5Y*B#CN3QV&,?88 '?C&.,]-A\;A]T!02ZYA0^H!9 5[[AD> .",# P.E
MN9-SWY^N&@8PIUU>?4=6L_\ >4H@X& <%1[ XSP<<'WZ6'-S)N>YN=HW]K>V
M-?4<(&5*4$@X^HG''W]P<9 Y'/8X"D]\(WWO[W_/&-Z^Q62"1D$GG &,\G<0
M, 8S[>W2PN(X[<?3&O8GL,\X)YY_KY[=QG(QR.EA8SQ[>>1@=^.3_K[]L'I8
M6.S?AR^%2%\0=DW#6:9J11*/>M,U.T9T[IMB2Z+6Y,J3"U;O:)9?[Z56MB*S
M0J=1*-+G--M4YFH3:W4I#4E:J=!B,-2I*Q(HD3 W DW%R1)N(''N)P:O7X18
MU2U1TELK0:Z%W=0]:+&O*^;4JFHS=$L&;2XFFU?U,H5[FZ%IJU5HM/B0F=*Z
M]<D&2U/<7(H\RGPS&-40MEPEN8/R]?0VY_4[8%@!!%YGF-C>18>T=Q',EZQ^
MSHUXH7S4JH5C1]%"I<4RKANIG4VANVU:R)=-T\K5N-U^H!M3T23=])U7T_FV
MW'CQI;KZ;B]"I?A<FDUR/3G81VVX.UYOO<]IF/08&#WGU_L(_EB7)_9JZKOZ
M1WW>%/>;FZ@:6UV:G4>SXYILBW[7M&)=^JFGG[RNW@W4%Q9"YE]:45BW*338
M<>8]7IU:MQFDJDNSVAT&%^OU^OYSS_J/\(.J6E=:T_H-TU#3HR-1[WNC32F3
M*3?=%JE*H5_6/5;;H5ZVQ=\]A2&[<EVM6+II,*ISY>^AN;Y,RFU.;38KLP+#
M<[^W'OZ'Z6$X/6S\+;EM_$:/AV^(6H3-/+LC)@TNI4.WOW6K=>A7K64PS1[(
MJ50K=RV]95JU=I<UEVXYMR7'%I]N,1)T.=FJ^G&2T^5R9$"02-H'\[F^'CO?
M:8/)'>/U'OB6V/\  W=5[_$-?.C,6]+8M^T]/M=J1H?7-2+JD"V(L^M7%>%9
MMFW(]$HE5<;FRZ_7X5N5NM0*.\J-%9C0'DU"JPTNQ%24K2JL+$B3?OV(]/0<
M_)Y(V) /K]-M[$_HX:*_9Z_$;/M>AWK:]%H-U6]<TMJ#0_PNX(C-5E2I5:LR
MD1X(IM0$7YR:A&H-J3ZHFB2*S$HD.=.359T>51:O&A/^OU^.!CYWGV_K\_Y8
MJK73X9=5/AUAV;*U!<MT(ONFO52AJMRO-5UEZ$TW"D(D-S8K2:;.AR8M1A2&
M:C1)56IB7%OTR5,BUB#4*=$<$K)!()$$C<C:">?GAR6[F.;\>\[;S'I8QCFU
M+SR<8=<&#QA1_P"1[ X\<$9^_0P)F!/?G"-Q!)(WB3OWQKZSQQN<<44C:/J/
MT@Y/!.,9R3_^U@Y/3X4?U_7TQGU'>WJ+QE)."0"1G'D#C)_(' Z78&\;3?\
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MM_)B"5(I,FZ*%=MO?A$. Q5I+L^I)I,AN-/9D,,.&8&02#M()F/KMA<GUO\
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MIWMS@#=/QV?$=7]0KXU A7FU;;]_UYFMUV@4"E4V+;KD>)#OJEPJ":>Y&?\
MF*(W2=2[VA3(<M;HJRK@F5"J?,U-N-*86GU',W['B!VCUP_Z_4X.Z_?'+>FL
MM4T5JU(M>A63,T2KUU7O0IYBV_<4^KZ@7O4K5K5PW+<"UVQ2J9<#AJEGTB1%
M>N:EUZX9RQ*E77<5S5&6[-4-^2#<[3M\^^%,[ @1SO/;]?Z5+&^*S6\:B2]5
MZK<]-NN^*M:\6SKCJEZ6K:EWQKOH$)B%'B,7C2;@HL^F73.8_"Z7(36ZU%F5
MM<ZE4R<[/7*A,.A!85@#9MQ,$^W;;8&>>V'@W(BPY^G?\-_6XP^L[XO]?;'O
M:^=1:->,67>.HUV4Z_;KJUS6K:%W(EWU1JI/K-#O.%3;FH=5I-(N:A5"JU5=
M%JU+@1)-,8J4R)%4W$>+(8   #88:#<^P_7H+?7VQ<-I_M$OB$H4F+/KE=;K
MM1MNS;QM^RY$.DVO;*Z9<-YZ91-'9EY71+H=O1ZK>]4ING4:+2J6Q5ZF&H\R
MDT"I[R]3EID/!X]S)XW,=_;^F%#"9BW;];Q%K]_;FR__ (@-3]2+&L?36Z*O
M2W;+L!Q^7;])I%M6[;J'JI*I5+M]ZOUMV@TRG/5^X7*%0Z/1G:W552I[T.FQ
M_7D.R"_(>6%$_P ]MO7>QQ2H;0.?K.0.-Z<\9X_E)'GO]N3SE84'Z[=_7F?P
MMZX]Z:<9._OQ]2?^('_A[ ?UXR.,!84-Z<_@))W_  [<XU+8X W'/@%.XD_]
MX #@#&/? /?I8>#^4_,$CYG;]#&-G<X.<G/*>..,#' YSDC&#YY)6$%/T'S^
M8N>V^]S88\&AV*3P"<[DC[')X!X&3@GCI?K];_K\7TF>+;W%AB661>=?TZNF
MA7I:DIJ#<%M5.-5*3)ET^G5:,W,B+"TIETJKQ9M+J41U&YB73ZC#EPYD9QV/
M*8=8=<;)*VDR)FW\_2]K>F_:!$B\W&+1N#XE]8[ENZN7K-N6-$K%>L*/I=(C
M46W;>H5 I^G4-JFQX-F6_;=,I<6AV[0H35(I_P M$H\"'Z;K3TE2UR9<QY]B
M9))BYN!;Y?K\<(D;R+_01:![ ?J^.D-#_P!H?JYIG=%3NF\8L?51YVXG[^H]
M+K;=MP:/ U$7=KM]"Y9M.?M6K0YGS%ROORW7J;'I%R4R,_+BVM<MN,5">F2T
M@;SMM])X)M?;Y]\*&/W8-[S%@9]K_P O?%:V_P#''\1U#N9==9O9]4*9<1N&
MK6Y$@4>!1YZQ2K4H A--L0?5IK4*BV1:\6@28#C4NU9M"IE;M]V!6(C<U3$
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M\^NY-EVCN2(^4]OIMZX\\726):+WWCGO\_7?ZLW4I6I2BDE92"/<D)XXW#/
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MK@IM:I<2\;@7&95331G'*%3P:BM-4:GJ9ZJ:KTJ:U&2FBDU% =69TJU1YUU
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M>._N.GX!.POWVGD?GZ7(DC# 7L+]]NTV(CY1:; P#A-Q9&-IRG'/90[^2?\
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MA51A=FVO6J75H[UXW70(+=$DROFVI#0JSD41X2'T9'4<X*0-,T0Q6IE06O)
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MMPZ"W/>BMN-+E-0ESTO/1FE>J^TE;;>Q:@M-<VI9BVRM8&VV^XMR=[;X#=J
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M%R7;\A;MFS;FD2:;26RW2WVD28D66@QUDG5*5+R51YF$2" 98$1ZF!/.\>N
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M_I:/[X?Z Q(WW N3/;B9(WPB72,' VD=R?/MP/;GI7X!/MA [DD ;2Q@$^D
M[1;T]9Q=9&[E0S@\C^8DXYY[#/Y<'L03UV!OO?WO^>//+F;B_<Q8S;?;TPDM
M&"5#A(P,9';&3C&>V<CN>,\],%' '>PV&Q]ML6*;#2LF]Q?_ +QY_O&&;QV;
M2GZ?R\D#S@]LY_S'0. (@ ;_ ,L&201!B">=X B8VWYV%[89K!4"$CDXP,@
MG@GN?L>^/L1T$[^]SW[3])B?RQ,L<WO&^PCWV,\";6/!;GC.<#P<@_Y>W/W\
MCCIL/$$P3>]B/0R9FQ[QZ7F^BP3D\G'?)' )Q^?)/'M]O"_7M^O3$R-YHDV$
M#?<1MS;VO-L-GDI S@9P<G [^.>^>!CVY'VZ:/:.+;$;<_R^>+5,D\D@"-[1
M.P[?0C?#4 */U<X^V3C_ )#W_3[GH8!,F#VW-A]?F+W,S)&+8 ,B%W[;'TM/
MX7$<QAJZE!2K*$XSP,#WQ[8./.!Y[CD= P$$0.(!O$&))%M]QMM!D1B8 0(
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MWE4K5!%S:IVY0I%D&Y:!>UUVO2Z#-N-.HB;+^'BJ_#W#TJJD2IUJ' CVA?\
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MGL&%6G4=:ZC2E4.RU$U>5@KCS*I!AE!@@D6WQ&N=6'E1I<@U%*AM<1IU"(+
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M,_$A D7-&TY#$1FXI"W:@B>PU.PI7\!,B=-HHCTX4&H-!B"&IZ0-#;^6QL;
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MT!@3<D;\"_,A/.$@G))"$(.5*.[Z$ (3DY^AL!M).U " .K2IX:BF!9!I O
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M?([YYQWSGC/OCCJ5@64(6,6DB),#O'M/M @8K/2&ZE@2?X?6?0GVX'M(*Z2
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M?OY;TABW+4HJ*]^$FHU$&M52I34-1Z54IHS&J%9M5,B5C03,R )(,$$DS?O
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MT3RKS@D<9_+//GN/(XR/ '3?KZ^WZ[8<F+CM_3@VGZB^]IPT>"0%XXPK [G
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MSX]NPSR10 D:1W-^P_IO?ZX;Q&_SM(N 1P9]YN+ V%^^,+<4E.=@SD?WN/\
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MQ,G3*$<RWK[$[QOPLF6X2$@ CV' [9\DD#![<G/?/3AVF(GN08V$FU]_Z^F
M:)DN09M(DR8' CMOSC<2EG/TIQ@D E7;//; [CMQT6J8,$B8[7/]N9B_'%>H
M]_O$B(-MR!/8$[>WOA1J2K<?!"3GL<=O<?U/YXXXZ$/WFP/>YFUICOS[<8 >
M<Q B2W:-)@\>WSX.^%OG%>^>/('^/'?\CCCH]2]_SY$]L(4R8M'!B+0;@>G?
M:<9^;7[>Q[)Q@\?GC],]#K]?J-S/H#$#\XFV"T">=X$$V@7$$@7@WB+3%[;(
ME*6L) ]^, 9 ]SX_3I]78R?;ZDB!P-@=S'KAC3C:UY];G:QO)L9M8'TPN'5[
ML!7&1S@?<G@@=P,?H#[=6$LIO^787VWP*D7&]XF3(@WWWM],;I?.?I&3M/!.
M..YYQ]Q_7N?$JC4=)C38[ ^GN/E^,G"=;;B.#?:)V]C-N3&TPH9#A2<H2/ Y
M&<<X''&,CL?^G1-2 !L(@SZ$';;@&)YGBYQ$4$3/%K>D]_3TPFJ0X#A02GG'
M'.3G'L>!P>_Z=\UO!6T6(^D 'CU'?Z[88!KB9 /$B"+]]_E'YXW3(45<H&T_
MWL@G'?."//D>>B\!0 2-^9[@\3\QVL.,1&JX,38';V/UN  ;WQYQQ>1M(2G'
M; .2#]_!XR.WCSPQI*; <'\+\>G;_4T=VN;W]+3P)^9[7^FA>=0<J([8&.3W
M)&.$X'G\_P!.EX($DC<^F]YWGM[8<ZB=(^\!,3:-@=XM(VO'K?'A(5G.=VTC
M *4X..<D$8\9P<\9]QT*T@L&! N;?A;Z&_?<[HAF5CV$"^T"1$]K?/OOC!F[
ML$\[>P(! SP<)(V>2,[<\\<9'1FI2!/DN;1P3< [?(=@-A;$6AP1)/EN;S8G
M;ZD'F>9OC82UX &0,E2<'!R0=W. 1]*CP?IY/<XZ?7F/X-(4W (78F!O<V@7
M)._!PM54$PT1*GG[L&.9VD\<6PF90YW(22K .1WV@!*E<'*T@_2HY*=RL'DY
M%J@$"L 7L9'^7C;;F(N(P2FJ1(-KJ)/>UA_;G'DRDI3A("<#.0D'</Y1NR.2
M!@I)Y0I*5)(4E)"_=5I14N/-VVM?8'<6_M!%JR %F,3&\[WMVV.T3,'<SNJ8
MHE14I16L'<2 "H<YRH#.2,A1[J!P<@E/3&@NF8WV)X/ISP1['GD15=C ,$R+
M "3<=P!'Y@7V@M5KGN*XOPU5P5VN7$*/3V:51Q7:Q4JNFD4N.Z7F*92DU&3)
M33J<RM14S"A)8BM;E)0RE)*37'3J2N*P$&VY),;B\GD[#BUA;$_C5W4T]6]Y
M 59.TD 7,1)OR1>^!T6O5BFLU&+3I\^!%K$,4^K18-0E1(U5IR)+4Y$&IQX[
MK;-0A)FL,RT1)B'F$2H[+X;#K:%BQX"FY$W WM['O'$B-MN UU0  UH,&)()
MF2)/E-@)%_EAFF8\G  "=@7@9S]*TE*L]@<I44@GE*3M04@ !>"H(,<2-K\6
M[7&Q'SYP:K5=9U^F^X&TBVQ]>=C&-!*<22H(1W)&W"<*5DD@< ;@-JL<K3]*
MCM)3T@*=,ZBDS:\2.9$#F(-]A&V$R5@)+D\;@ V,2!V.PDB;VQJ):L8#:,;0
MG'@_4'!D8"20H;P5#((3@C& ^JD_DT7;R#L+SS8&^_TP :LID.=@2>;@#?<W
MGMO<'&ZY+JR5+0#RK)R.%*.5$ =B2>=HQR?')8T5!VW$@DS;VC^8/IWD%9R/
MO&!)L8B+0! V]_F=L)EW@'TT\Y\\X\_;(\=OSQTXHKP-A)^7/]1SS?>L:S'5
MS>T[@;QQ)VOQQ'&?5'(*<9!['W P<?E_KD]":*QL)_#Z6MWWG>)MA_%:=X'/
MY^L]^W&P!QCUD^QSV'\H'Z<$@@#@YX..>G\%?U,_6?U^.&-9Q8&Y)[P1R(/U
M^?<",EX>W?'^'/@_8GG/MQSEO!4; 3^<Q[QMZ[#;;!)6+.JR88J(]R8[#OVY
MGU36_P )^^3V^_!\<X_SZ<TE!B #?B=HM,W )M(G?OBZ$D;\GC>"1/IQ/RWQ
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g451428g28b32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g28b32.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1?\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %^"^81(X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "&-G,#(R
M.#<T' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@1F%L8V]N("T@1G)E
M<75E;F-Y(%,M-%]$1DE.($1R869T(#<N,3@N #A"24T$)0      $,P@G--5
MQ7WZ@P:[XSFS@" X0DE-!#H      .\    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     8 00!0 $0 +0 R       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&-&
M/8         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  E,S,  $  0"4
MS,P  0 !.$))300F       .             #^    X0DE- _(       H
M /_______P  .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              &0   #S@    8 9P R
M #@ 8@ S #(    !                          $              \X
M  &0                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  &0     %)G:'1L;VYG   #S@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M2P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6TZ-K7OQQOACV=K;_K&6V(@T2.E_QC@0>OD(& +U(@* /X9.!23G$F/D@_=
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M$/'ZKU7T/_E&$?;*<^2 <XXQCN?;I_VBI6_V?,1,']^O2UROQ^/)PO[&5/\
MS="?_=/T_P#>7OQ/EYX-_P!)&@9'_52K 9&1^)P0<X]?]7^X).0/8<#H'M(H
ML:#1.Q%,F)V)(DGJ8WN=[!]C:C _[70DQ_P&B\WM4'E)D7]!@7^DG;HX-IUC
MC&<5.#\PQR ?AR/FQ]^W?J1]I4M.78[_ ,-+8WGW7)//3$?[%U?_ #>7G_W#
M\2"/[PV/ $>L&<;_ -)6WAPFTJP,CN:G!P<>AS'P.?4X[<#N>@^TB&(RS3Q*
MTR.=NF]R//T!_8NH;?K>7C?^X:UQL#4C_2VUMGQ*6\>3:=7]O_*<+T(_^Q_M
MGT['[P_M)'_!.^^BGN)@;_U'&'_8NI'^^9<#_P!R>O\ GYW-@+3@?^DO;V"!
M:573CN34X/IV/,;OV!/'L>01U%O:$-?N6L#LE,?&\#[VC$#[$5"1_MF7$=:+
M3_\ W/, 1Y"T8S_28M[Y0+2K!)QC%3A<^F>(W^/ICV'0.WT( -/,@QLM10.;
M*!L!P!TQ$^P]0?\ ZZ@+@B*#6W'%2/C/'GC!XF;?/RBTJQR2,FI03W[#F,<?
M<\>G&<=23VA1#/<5WFT5'6I?W@7F;CBT&;+^P]2?]\H'<?W#CTN*HL(CT,;8
M+_TE;?[FTJOD=S^)P,9(XP/AR#D>Q[#MGGIGVD!,C+D#H4IP#\CTWO<SYL>Q
M#@?[YE_7N&.XZ][)$ \G>/(B_P!)6W\?^:=6)_\ SE QCC_[&XP>V2.>.@^T
M?_[=AUA*8];S(^_/ ?8>H3/Z[1%N*+\7_P":/G/O(QK_ $E;?''ZI54@Y!Q4
MX143] (X SQW'?/)ZK/M"&(_<MN8 2GMO?J1TC8],!]AJG.>H_\ ]!CR3_S3
MUF_,=)&?Z2EO'(%I5?GNI53@\9R  3'QD#/T/OU(>T4 #N28@ Z*=ST_EOQ;
M"_L/5_\ /4?7N'W@#_FV]?6YO@'^DA;V,?JG5L#_ /*D#W(.1\-ZY'!'Y^I?
M]HR9F@T\>"E\>L'W1YX9]AZN_P"O4;C_ )#;6X[S^1M,#&CXD;>Y/ZIU;O@?
M])P#WQ_]C<)P3G\^^#T?VC'_ "#<1^"GN9N.MYB(V XPO[#U?_/42/.B]]]_
MWG0F#O<@8"?$E;F#FU*UDDC_ ,H0L<8XX8X /L0>?;I?VC /]P8_R4^#,7)/
M)Z^>('V(S!L,[EX$;TJIDCG\=B;3%NFU@_Z2-O\ 86G61QG_ +="[#UR6"??
MG@GZC'3/M$+_ +ANLZ*8(W]?CMO8X:^Q.8$_[9EC, _NJO'_ *N;;_/? #XC
MK?4 ?U3K1&0?^W0>.^2<L<8&<_SXZK;VADSW/_T4_=(F.-MM]^9CV,KBWZWE
M9(-C1J'?>"6DVGBW Z%J\1= 5VM:LC'  F0._?C#([GM]N_4V]H@1'<MO_RZ
M8OZ@[Q@'L76&V;RVW_*?8[#\1])B][#D'^D30N,VO6!@ G,V$.#G&/V7&<#'
M!YSVZK';X_Y+'T5/ZXD/8RM!_P!KRQ]*#$0>IU>A%MX]Y?\ I"T Y/ZKU@%7
M.?CH0'(_^U8'&#Z$#Z=1/M 1M1MYJGTO/YX8]C*H(/ZYE@8M^Y;@;$EAP+W\
MO(%J\05!)43;-8!QC_ML+Y<\?^KX!Q]C^8(8]H.#2V-X"?<^LV/QD?8ZOO\
MK>6OUHO/  C68&_2;8!_;]0#P+9K)()QF=#.<#_[5R,@\\C!('OT?M_K2/\
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M>6)?V8S/.:RVYG]RY\X!UFT[>I],+8&L-M393<:53ZC3$.*2CXIU<=]ELJ.
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M.0&_C(Y)X.$EX#C!4GN(',]H( QIY-P=@*U5=SR>Y;?TW.QXK;.YX#4M#)L
M8TFK54DV&_=&)%OPR!-C$8W,TL14([J[8N"FU>2U'26Z7-0[1*T^OC#,.,Z_
M,A3GP,'R(\\.K/\ LVEX/37M84R5S>3JT03I[^FPK4%V\=1AIJ*O$M2 Y,;8
M8[9[LH,[DZF65CI-:BQS5!1$AZK@)4IH3(+-2T@W) Q4$^FS*6\N-.8=B2&G
M%LO1I#+C$AEU&"I#C3B$+0L!8^52<_D<GJJRNBU*;+4IN 5J(0R,#>Q&_P"?
M$C'81EJ*KHRO38 JZ,&1@>C*2#A90KFN.UY,B7;-?K5NS)4&53),NAU2?29+
M]-F(\N93Y$B _'=?@S$#RY45U:X[Z $.M+2".GB6%5-O6[Z+6)-PT>Z[CI-?
MFA\3*[3*Y4X%8F"4M+DKXFJQ934U\2'$(<?#KZO.6@*<"E8/1@P<Y?=\/2!*
M?O&Z797Q,>:9+MPU=R1\9$D3)D64'US%.?$Q9=2J$J.^5>:S)G3'VE(<DO+6
M8/O[^_7'1MY>.GQ1WUHW8V@=;U+3%TQT\E6G.MRCVO9MB615E3["IE1H]E3Z
M]>%G6Q0KONF?;%/JM4:I4VXZ[5);;U0ESW77Z@Z9?1]_?W^>#',TRZ[GGRZW
M4)]QUV=/N5*T7'.EU:?)F7 VY)9F+16Y3\A;U5"ID:/+4)[CX,F.U((\UI"T
MF"/N3]_SYP;^N-W%F%%_6FX?AJ:RJ+3HYK=3\FG1UQ7X2V(3?Q.R(RY"DR(:
MVV$(;5$?>CE):=6A1A?EP/IAV1J%J.S+A3V+]O)N;31%8ILQFZ*XB7":B18\
M"$U!?1-$B*B-!BQ(<5#"VTL0XT:,T$M,M-I(,3QSY>OW&'YFTB;F_''&%XK6
MJE3@5F Y<5ZR:3<5217+BBRJ[6S3:[6&5%YNKUIB1*$6K5-I:UNHGS$29:%*
M4I+N23U4U:BITFHFK_"&!,](WG%+YB@A@U4)Z!I-^@WVOB^=/O$9K3IC%U ;
MIFKE=74M3=.*SI/=LR9$I%Y5US3RYHT:)<]L6]=MY1:S7+)1<5-C,4.NRK+>
MHM0J%##E$DSG::X[&75WU5B5I4D"&Y:K8Z@8#!0ID'J6 (B>(I;,5G,4J("
M$:W=@P;_ !=V%((M-VVX&^*(B+M],]*6*"I:70EI+E0ER%H2\$JPXMM"VD<
M<).4@@92>08NM<H2:Z@@R>[102MK7#'>) %Q))M:#KF33.O,!3.HBE34:A>
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M^8]T@I5I7#75%-%I%2JN&]ZU084J2VC/)2XXTTIM!&>=RDX!!X&"*:V8R^7
M.8KT:,B5[RHJEAY F?OIBBOF<ME@#F*]&C,1WE15)G: 3-_O<8E-/TZJ+?SU
MR;%HJ"^N.[&=S)J31;P5K,)O&UH9X6X\TDD* 5E( RMVC3)(H4WS)*!E=3IH
MF=@*AL3;958B<8ZG:=.2N7IOF#H#JZPE$S( %0V+=0%: 9@X5JLBE;G S5YS
M[;:E(#B:6AI"TC&-I54%D9.?EQ@G)SQCI#.5H!>A30D77ORQ!/$"F 2.3.]H
M -W^OU@!KRU)20I(-=B03UBE C??>!$BRN-8E#6A2)M7J-,=^0)=>I29$=D$
MD*5(0S,;DA)!3_LT+QDG"L!)B^=S (-.A2K*)E16T,T3^$FGI)%S=UF+XKJ=
MH5U\5&A1KK<PM<H[0! 0E"A)-O$1,6C#!<&GU<I4,U2.(U7HK14EVKTAQ4J,
MRI1 ;3-;2VF13U+&W:):&TD_*E9(P;:':%"L_=,&H5^*5<:'<1,TS)2H!!NA
M:!<QBZAVEEJ]1:!U9?-,I;]7S'@J.%_$:<DI4T\Z"3U$7Q7X!#@2<Y! . <=
MQC!^Q]!SZCC'6X\_7;'1&XYO^?OQW%9#!78UKD!.U5,CD $[@<.#DA)X[]N/
M?T/7K\O_ +AECP HW!OI;I[NG&/G7:"M^U,ZP($U&W'$CUYG@8YGU1_\J4WM
MS2D GZ&2\?;M[GCMW]>L_M4 ,_0 _P#)T?F6QWO97_<*_GG*OK^%/OUG%9#D
M?7C)[>V,_7GZC^G7F,>FQA'![\#Z9(P1SW^I[?;)Z,&,^_(R2,CMSZG';_ G
MN.08,:P03]L# _,8S@<<D\_0YQGHP8WD 9)(Y]N?7N/KR<X'1@QGKD#U'I]#
MSG[?4^V,GHP8P#. ,\%(].XY /\ #T.,G^)@PN;ILMSA,9Y0VD;BE38&!D$E
M6 1@YQ_>SP>#TBRCD?'$2ZBVH3:P(G?[MO&V%JJ(IB(9+\IAM0.U+ 7O=7P"
M2$ ]AG&2,$]B0DGJ.L%M(!-IU#\(,[$GT.V(=[+:0K?YB"![C_*?F,$IB(<#
M8C>8I8_VBE$(3D'!V9 (!P1E1./; R9203)$#IN=O7K'OV-L3U:;L8'$3\C$
MW].G7$QB0Y3<(MI9BL H'F.LL9><&0,+<6KY@ >" ,DE0&<GK*S+K#:FF?\
M%80+$ #?TGX;Y'="]RS0; FP-MH')^7D<)6Z<_L242Y20@DI&XXW(.TIVXSG
M=G&1@9(Q@=6-46=EO$S?<#K'OB1[IQ,U0/X%FWE$QUO<[C8Q:<()C4J+)4IU
M*4N#(*5M!0 4!^\VX%)/J<@9&/3J2D.-0/A,@WO;_JB2.#/SMBQ&5U!6^YU
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M(0ZO:AW8?]J<D(<XSR.Q'8@]\=(5'0N&$D"2MICJ(L8V(O\  QA=Y4IZB03
ME@3/AY8$$VGW1L"#.$<:0N++>8<AI6H M<I(*@/W5Y )SSD#UQW/?JUU%2FK
M"H1L3TWV,F-OB3 XQ-E5J8(?2+$7!$D01&UP8O\ .,+GV&G<NH1Y80E!)0I2
M5A[D_+SN!!Y*@,#L/3JI6*^&=4S$@0%V/R 'ODF#BM'98!,L9(D!@5G:#(,
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MM\!BMZIL0?# %MY%@+"PL.(@S;&W6(R T 5)4% A9QGM@XP.""<9R#A1)[]
M<G5,FUQ]"?+J;^^,(%R"1!D3'2#]R>LSYF/Q08Y6THE144J00< ) 4'%GM@J
M)'&#ZDYYZ2O!XCB/?M?B.9M8<X2L14AA_"""+R9,#J!:_%IP4]$5#::?D;DM
MR DM?,#N/N#R,#@)R/OT*_>,P6"5WGB./*\^?$VQ,.M0E%B1O>8$"Q-C%S&]
M^>,)4N!2B0[N"3VV@8S@YR.<D9]"/KDGJP3T@QUM-^!\??Y8>D+N@N/SVWV
MCK8 1;#;-4HH0DY+8<&[.<[25$]@,G)).1[<YSF:V,@2=[[2-S!G@;?#%U(
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M2FS)EX0F8L7)9PPDP5*SN (Q/8*Z^\V(SDER%&*213Z8A$&(G*2G"V(@:2M
M2!EPI)* -ZCCKGU%RBG6$6JXWJUBU5R1T:H6(.]@=Y@7&.=5_500505&!'[R
ML>\J2"((=YW@P 1Y1:%YM KC/.--AN8\D(W.!94I>_:XA6Y1"2YN.U23G *M
MH3WI':(%10QFFLDA8VTD@B +"+VMMOBL=H!64,=5-98BUA$@R!<"+@B+@"\R
M]P[">$9E(7#<*@C*]R00LN!M2#A6U26U)4I3@5ZD$*2,]9JG:REV.FH 28&\
MB"5-P"-5N(])QDJ=IIJ8Z:BB]K[1J!N 9.P6 /3 95M2U%]*H[3ZPWYAEM)1
MD(#:OV*DE2@O=M(2<E1QE(SA*53SU+PD,R L%[MB3?4/$" "/,1 N">3),V@
M"D.R@FZ$F)D$-( B)N-@?*,09%%K-/FRZC2'&8L&)#4NI0YTAIANH1G5)2Y'
M6Q)PB0EQ"R"VEIQ>5;D)!3E/5.8RU:G3HU@S5'?]R]-68TW$PP9+H0;R6$@&
M;3CHOF*&8ITZ694UJM2HO=5*2LS4ZB@Z6#(24(@$L6 M<D$SSU=\./!NBKQX
M; C1$3W?AXR%EU$=E:@IMA"U94XAM"@E*R25)Y)Y..[E'9\K0=VUN:2EG(TZ
MF NQ'$D21QCT>3=ZF6H-48NYIIJ8KI+$""2+021)  B=L=H:?H'ZAVJ5''_1
M4?@C/_K,<#Z#GD]^O;Y<G]GY<0!9;@3)"MT]?/YX\/GK]I9T_P#M6CTFWWUG
M'*VJ/-4IN/\ \5H]^ )+X[<9X]QSV]3FCVK,Y^@0;?J='ZMCM>RO_A];_P",
MK>OX:?V/7WFL?7'/(/IQV [C''T'J3SVZ\QCT^,''8< X ^F,Y]N?RYP">C!
MC#WSGCMV/K[G/;CZ#'?@\F# @E1X'KSW XR>QXQ]O;@>_1@P-+#JP5!"BD'E
M8'RI^BEXQMSV/OVY R3_ #PB0/Z7^F'""S$"UB6'7  <)CD$I5A1Y4X"DY./
M[JB><8&3U$S_  QSO[]M[C[YPB6_AB1>XF>(CSX-MB=KX?J=*D,-OIIK,1K>
M"VZIV,U)?<0K"5*:6\TLMJ23D*;PK!&W'.*G16(-348,@*Q59&Q(4B1Y$0;V
M/%3JCNI?60I!A6*"1.X$2+W!,7@VP<\S4)#J$R)3KR2V$^8I9:2D<[04;DX"
M1A/[H! 'VZ:Z%'X0""9Y/69,VGS\\0#4UG2@6-P!J)@]1,^=]@<#-$44A+J-
MK@1YC2R2I+B-V<;@I7L22#C)SC.28]\#^$C>#S!Z[;[#WCRP#,"+&9.DR 8!
M$ZH,\=!Q?"BGTYI!_:%6XDDI.[!4"2,$9X_O=R#V/<CI/4)VB+$P>O6]]A!^
MF(5*I) !-]F(D[@@0VPO/6;XDI+R6F@$)4&E'RTA*/F"E<!23\RR , '*DI(
M/(P>L\ EC)$B\D\;1TYG@G?F<Q U'5,O&IK\"T1MT) O$S,83%*E*)(6VLN!
M2VP A06#NX2K: HD@X[$<CN"96 ,$$Q Y]\WG;K-S<$8?F+@" 9L1:.AVF_^
M+X8(K[#2=OQ2FGEN>6[N9Y6DO<[%JX*7$IP'$@G81C/H70.H&)M8S %HDB>)
M @[F>F)99V+0BM30:EAB+A20&%R")D@F+28@6A,D-(*DL%Q(QN4-ZR%.))!5
MA1VDX/(R 03VX/6L21!O;>1:WE.\V.Y$G&]03XF F=QTCB-^A^8V&&.4G8^Z
MV2G.X<HSM.0#A/YGGM]00.I R)ZXL\SOA/CW/KDG')/(]^/3 '(X[=/!C!Z\
M<YQG)]_<]^1Z=^ <8ST8,*FHC[RTM--J6XHE*$( 6M:AP$H0G*EJ)  "023V
M&.@D*"6( &Y)L/7RZG8<X1( )) "W)8A0!N3)Z#$_H%E$N%^OA<)I"TA,%20
MF3*)3N*5*41\*V,@+6L%T'(""2",-;-P(R\.Q!E]T0;3N"Y/ !@G<Q;&&OG=
M*QE]-0L#+CQ*@'2)U$\08@WB,72W6YM%IBJ91) MNF/NAN13*0'(K\A' 2Y.
MF-J\^4. I2)#RTD<I0#VXPRR5JO>5P<W4525K5R'1"?X:=,PB7F(40>>3P#E
MJ->MW^8IC-UU#,E7,Q4II?:E3,JAM&I4#<&U\0^;3?-"7&U_$!3A05K(4I3B
MB5).%D*R!\NX]\\J!4,[TJZ3##20MH $*(G:US> ;8Z5.M *D%(74 L@#^&;
M$CW1/%A;#>Y&BB&MS8526%%2TE03M2 $I*=QY4G*LD9/H#GJP,VO3(%-IX.^
MYL.H]Q)G8C%@9S46\*X@$SXKWU$00(WG>/3&10L80VI(2Z0WPH'G;E.Y!(SC
M) P <^H  Z;V$F;"9OU$QOT_H>%4TM),RID"#,;&"-HW(YB\W.'P(>F(3'0K
MS'6&G'EG>I(;#65J!"AM)V)!3M/.#CG&<Q(3QFP=E46W)L+C83O.WD-J"RT_
M'I(U,% B2=4 '>8F)V]<)9Z*>8#+Y6\IY*"5-+\SE\*!40%)VJ:(P3M.21V.
M3U92-456!"A2?Q"#X3,;&=0N!O:W!AIW@J.D+I)L01.F"+D'?<">3;J=- >3
M!$);\F6I#S[D-"5D1A\J@X#@-[@0?]GG:-P/. $3XJG>*J4Y55J$K+S:" 2T
M>IWB,,GQU>\55ID(H>5\43(WD\'Q#TYPK14XK[F\)4[,V--/N@';%4M0",9&
M/,&3M'S !6TY2.H&C452++3EF5;'7$S/1;7YM;IB'=.@*F!2!8JI()J  DP/
M\,6&U_,X=JDJ)'BHRZF3*3O#B&4E""O?PI1*=BU@#*DH7P,85DD"FCWC5&A=
M%.!!)D@1MR0)Y/PC&>CK:H?"$0B S$$@;P)/A!,[@>@%S5-PS%.T=]@J6D">
MPK8I142H)>&Y/LD!020>,G)''76I(!4# "Z$3 M<&(]1O;8WQV<LI%=7/_*<
M:H_Q%2%(BY,7.WR K-?!.>3]NY//MDX!/;CD_7&S'0QHC/';).<8SCMSZ\X]
M/Z#DP8$EM2R$H!4HGA(P3]$X'U(V\'D\ YZ,&)92:"V2'ZDEUI*5(4F*C ?>
M'JG(SY22>"5#OZ \]4O5X0@DV#;J"?KY &_PQFJUR/#2 8C=B95?./XNF\3U
MOB:L/2(;)BTT&!%=&QYN,2TX\@@82^Z@AQY(QG8XI:20% 9/6-D1R'JP[)="
MXU!3R5!!"GS !X)C&)D2HP:HO>NI\);Q*C3<@$&)DW$$ D7QJ-%;"E9;<PO.
M%\G*LDJ*B>><DY!&X9'/;J3,2!82/A)-N/0#;KB3N\DD@Q$^$0%X$"(L(Y \
MSLXPXK;,Z,F2A:F5.)WM(44%8P20"5!(7C."K@9S@C@UU&)IN4(#!2 6!('
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MIA0L:0/>3ZDCZ^_$FT!555@#B3$3R(O/KYC?#15Y:Y3K+1*4J0/VKBB2IUP
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M+/&=S@^8;U# VDDCMS@ #OGJD(02 (U0/+@@#DQ$0)Q4*<%FTQ(WB(,BT[D
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MLQ N>!Z=3OMMOTQ2S%R465 'C?;2. )B21(/^'J2(PO1!=DOJ7*!+BL943G
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MB ;X2($J-5!+,\2.-O,VXGKUN)=)"0[&1*IT3#T%*6YRU@(0?, VG.$D[MP
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MXB+V !!&_GYS@UI+Z6TJ#@00TZ\A3I2CY4?*K"2#G'"!QDJ/(3R.D2LG<C4
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M28XC8]0,=4NM- [:F8E9TC43)B (/,<"#:0,,\R,PVT J47W0"@E(("49QC
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M/^Z 3R0>>/4'HD==M_+"/WQOY^0DVOB9VY#?>F&1'#1,1"GG$NJQN/.%(.,
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M(!(!DC:! U0<.=.8IRG&R]469+OPIEJ=BATMJ0X$(2&O-0A*EA#@<X"TJ<2
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M@X?VAP*4/,"E#@X((QD!/ .",C@Y]908,%($2HM;PV]X@Q\2;SCUN58OI(F
MAM$@&()L#,P8N8X(Q7]QY34U-;B RTRWL402A?E J222,X41G)X)ZVTO[L$7
MF3Y&_$>6W\L;LO>F#RS$DB+F;'^OOWOCOK39/_W.K..1@T6( =Q3Z+]R!DC&
M?Y9Y/7M,M/ZAENFE?^S_ $/OZ[?/^T78=IYU=4#OG//4>8ZG[VXRU5 %7IIQ
MC=3$JY(]93WN!R"<G';Z]A1[5*4SN6!B?U*EMM +#UW!W^..[[(_^'5O_C*@
M.^^BG-X$W.^*M XX[_7W'')'UY'/VX&.O+X]5A5%C^:ZV3PV%!3A&-P1DJ5P
M0>< XP<$D#VZ1, G[^6(L8ZWM;KQ[_C'.+&I<1E ^1)2%8V_+RI*4X&<X/!_
M+DX') R5&/41!F/63U_GN-CC#7+;&P&_Q$\W$R?=P<6W;G_0[=1<3&@R%5.!
M\(LR]^YE"\(#C2@IML/C=\KCH6$?,0D*P>N-FQW[4@7J+W-36-$$,1!@S)(Z
M@$<<&W#S0&8:B-=1!2JAP4CQ1! 8$$E1,F-)ZS)B,RT/N27C(3GR7%I65;3E
M(.Q(WI*@O:0$A0)XP3^\,[*90(HI_P 0!$6O^(R($6,F;#;C&U2J*IIF2ZC2
M "O DFQ@G?Y>CE"KL.''DMOTB#.2['6TVM\NA<-_(*9C1;<05N(&4!MP%LY)
MP  355RU1V4KF*E,JP8A0(=!,H;0 ;0>)C?%53*U'9'7,5*1#:B%"PZF9IL2
M"8ON(-MSB*+J;SFU:W"E#:U;6PK"$A*BK:D8!QMP3@# R/4GK8*2B8$S F/$
M3$3,WO/6_.V-?=4P%&F20 6,$\7),@F]C(.TQ,8;EU/R4NI"4D.N)6M24_*@
M$E*MQW#Y2"2K 5GUR>.K.[F-Q"Q?>?(=;"#M<WWBY:6H@M: =$\Q>X-IFP /
MSP=3J37KMJ,6D6M >JL]Q,B0F-'*DJ*(;?G2BI1VA+;2$;UJ+B<8X)&>E4JT
M,K3:KF7%) 50E@9ER0L $DDS:%(%Y\X9C-93LZA5S7:%:GEJ"&FC5*A 536;
M13$Q)9GA44228 &V+YM+0G5G45YJ\:=IO4)-ORT4ZG!IA4&GR:HXT&H;LJ!!
M,E#TE@NA"I,I*/)!>4\M))P>%FNU^S>ST?*-V@HS"&J^M@]1*18LX6I4 (!
M\*K<^ +( QY#M+VS]F>PV;LK,=OY:EG4[VNQJ&K66@&#55IUZBH5IN5M3I%M
M;6  -A=M*\&-7ITIAFYYS-%9-5J;\[]N)+D((B,JA(8;CQI"9"GI'F-.%Q2-
MC36Y: '-HY53VJ-52U!%J'N::I*V?Q'4QET@:8T@203^+:?'YO\ 2WV=5HLW
M9U*KG:@H9<43I-):S=ZZU=;LZ%.[0*P 5B34 4D@G%(>(+26KZ>5&BLN4./
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M7K%.CXX!: !,@:I 6T6XMM&)<S5XZ:%4X/G2&YLA"7HK("4MJ6TI2E!PJ(*
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M2\VABFK6TZA+;(F2'&T.N!P*2D*PD(1\U-'VDJ5"]2A7%8/4*Z*E/0M( ^-
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M(I*0QM!WGB!>;<V$$[D8*>BL3& ZEV4NH+=#0"VP4K22D(5YB5*^99)!22G
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M#.F*EO%3NQ*7%@K"0=Z$C((0<8!SV)(&#VP.6B@* -HZ;'RF9V%XWG$Z:Z
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M&Y!9;D(;FLK_ '$!UUH*6KS'0" G86&RE3G992#4F);53B[ %D+4W!NQ56(
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MP>;Y"6R259"5'<$J64[?EVD*!('8Y/5Q2F0KL!(,:C'J!TGI%M_3%X6AX&8
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M1YLF74DJ>?67 VI!=42RE "$IRM9MK>RF92D7R^?&8S.K54J9I"IJ29E5I&
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ME-EH"/YBG6F!AMPNKW.$I'EI4A(6%C)7J5U$99:52H""ZU*FDZ"&)> K-N
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MV=+JDHMK=<>D.OJ<?D**UJ*5$Y4YGD'=G*U'))]=V#T%1*:#2JJ H 6(&QV
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MDL,QDES]BPL-...+\Y"U)24Y:>3I5*ZYNH*P=$:FE/O6"!2Q)+(#I<M(NPD
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MW-P?<.)&*^Q*QK5L]J8%N\RIJ!1 FIE5,ZC^(GF.!%L=8Z;[SIO992>/P.$
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MLV_4J6RZ@*6!(>9;?;0I8.6T/-Q5!;ZA\I&5@(RH<7MJFSY%:BQIRU>C599
MV)4PI$$^.0H(MM>V.+V[3-;(4Z@ 9<MFZ%5@3 @,5+ ;$C5(7F\&8QTFZVS3
MJ3'C(EIE.GSE/$M ADELE"6GPDJ65$@$$@)4G&\=>1!:M7:H49 =.D QJ@@>
M)9L )L!\9G'D59ZU=W-/0/ $!8^*]RR>$ #?F9)C%0S&WDRY4K("GMZ7%I<4
M5.$8WJ.PE(W$#/)"CS@E)V^CIE>[1#$*! ($"9,"1-AM80(X(GT%,J42G&P!
M (F)F )N8'386(VQ%_B4O+4DNMI "TEU0^5.$D9)4@\@C.0 <]OKLT:8(4F8
M@3Q.UC\B?>-\;0FD @3' @VG;T]YM\X'6 U4 S'@+<FSE[_-PM0"@VK&T!W8
M"D(&<9'H!C..M]*:<LX5:8_#Y6Y@VO%MO/G'1R\H2U3P4P  (%YB#X2=B>8O
MOU!--9#$5IORU-J<&YYM0Y#A_>XYVIR 0.,  9].I,06+383!\K[7\QQ\9M"
MN9J$S('X3Y6(GUO%SQ[U$N.'FMB7O+)(*ED$_*"-PR2.^.<$'L<=(-!A@=C:
M9)MQ ]]YOZ8*3:23IUR "!X;W/RPRS82([*]J=Q)"MY62<%2,CG']T#&5 <Y
M&2<]35M9B9$_&...D7VWZ8TTG+&0-.PTD>0))-YL-KWY%P6YA+SJD-M[RXHX
M&"D@\9  *222#M( .2> >_5A(63((\4@^9-A;KN3TD8L8 "\" 23U^8._E\I
M&)*[2ZSL14:DQ(>$U2$-+7(4\[+4EM!SY7F..N-(;+;*' CR@L.1TJ#S#B$4
M"I1([NDPE)U!1IT&^]A<[V/1@(()SBM1GNUJ+*@Z@%C03%BT0#L8F=CI(-U!
MCQ%LS9-/>>8%,@0YDB&&_-8=D&2A.75@M)98!*2.7'$KVI2"5!0B'=717 />
M5&4/,0NF5MXBS6.T"#)M8Q#,K4TJZ&6O4=%;44(IE" (!)+3)_A&D$V  PEJ
MD=R#$IBIS$=I-7I3DYEUMUI:EMN/OMGS0PI904O,K2EMX(=0V$.*0E#B5*=-
ME=ZJHQ/<U>Z8:2 & !%R!/A93(W)CBSI,*E2L$<DT:HI.K!H!501ID ?A()*
MV)&\R!$(T0!!D*2E2$J4@)*E!2\#)6D<9"3P4I)^;) ^4GK5SO\ 3X>^YMP#
MC47!.D S$[3,^XC:UXVB;SAU1'0D@HWH=0DG )  '*5*4?E5E) .,>QQW->H
MF!OZ]8V]./.3)O:N3\?0#:.F]P+>G(.'6WHJ9E8=,5"P8D&5/<Y20E4-I1<7
ML/"@ XG=W) VI';JK,.$I0UM=1*0W!(8D =;VCS!)-SBO,512H /!+U*=,>E
M0PJ[2#:Y!D$"3:<2JTV?C=VPH:65.N+W ;5N*4I3@& <%9SMRK9VR4^F7-OW
M8D@G8 6M%@=]A$F+]//'GCW>XL-.F\D  ;WO'\5IZ7OB93C&:2TU&2[M2A"C
MYN2%+(]0"<@'G!3C QD]^L=(.Q+/IW(M:Q-CU&T'X$6.,%/62Y>-X$'CW<'U
M\@.,1:5)*UX6<D C)2.1D\9 !XQP#V(&T \];$4* 0+GSVM]>ICKO:=:)&P*
MS;<D3UY$W'''GB)U5*GD%U@*"8Q29"P24C*BD%6<'&<8V@GL3C 5UJI"##1X
M@8_+8R3?F.3;&VB8L=V$ 'T-K7F/?8[89J*I67WA@J<<VAQ03O*4@< X/!SZ
M'N<D<=6N/")@#I)M:-YO;GCYXNK@$:9V$C?K Z'IYCG$H;CN.I*TI^5()5R
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M64U/P9W+"EF,Z*#-3&9RJ9/-_JM#.9Y!3>J'[U*I"T6:E(.DZ-0KNL5-N!=
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MBM+4I:Q^R2.R4(4<+4#D;$\*]> >LS18!2-3$ 1SS)@1[XV.]@,3%21 C4Y
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M)VZ@>6&81V77TA&Y:U\;>0H+&-WS9VG *BE6W 00",G/5NJ!,>$3?_I'PO$
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M2G"TX32@(73*ZB 3N;BLR@M2'OPN0)#\TNQ5>:EM28C<<AQ2L+0HE"0&VV\
M)4XM9(R$JQP.T<TR@54*(FFH-),U"\ ;$7W9IN !>Y&.%VAFF4=^A04P'!!(
MUEX$6, F[$S95 !-Q-P1:;3')-.I3CB&RVR6WF&@M93R8R0PXA:7'2HN!T[3
MN;"RD%./DX!J58J5A)UL"',;R&E@9$VVYB.D^?>O75:M55+2TJS6#6UG4"L*
M!!43()!,$6-,>*^C,T-[3 ,)>\BH6=/F,*<0M*GE&LR([[N74^:L%V(K)<<4
MD< $$J!]/[)U!4I9]B067-4U8 ['NM0&D& -+*0(Y%HB>M[ 9Y\[_:(5=/>9
M7MBG0*H58+3&5I554Z3IG14F0!Y\8L?3M:T:=6=L!S^#0\D\@_*YZ)*2/H>Q
MY^_7U_)D+D<L6N"B@6F#I'W\<9>U Q[3SNF_[YYD&+1T\H^..0-6,_BU+SQF
MDI)__FWR"<]B/SQ_2CVO_P!^RW_P:?\ >^/0^R-^SZY__>5";$?\.G-N8-K]
M.HQ5 4.^,]B1C//IQ]?0]N/0]>3QZO"Z',<B[TMA)4X4E*U DH5R$D<D#;DG
M(3DXQA0RDQ90PO)B;#GRQ%EU"#]?Z&?N^'Y<M+K<=9CMB4A14](!65OD8(2X
M.$< >F#VSU65/BAC'\*Q8;[1?XB)!$[XK5-+, Q*D#P$6$$;1>8)/2^PXE%.
M6B7$><<"D.A"/A_+1EAQ>0%-/*/.$ J4H@K6".$X..J*G@919EDER2583R(M
M)@"#'Q!&,M5=%10I!!/B'\2B#<#;Z"YL8."7FW929$4-H*D@J;4!D?LQ\RAG
M( *02,@ ''S!1XF"JZ7X-FWM)-N.?<9B#AB$TN2;D@S ))L)G<B;D&+==V2&
MVK"7D[D/L2$!"P5;D)0=Q4UD^G;)SCN.<9M:YTVTL#/%[SJGS XG?%[F/"P)
MU*21,@^1B;0>;@SYXEU6=9J<D24O274)9:;;,I25.[4L)0I*BVE"$H0X%^4A
M(&QG8#\V3UDHJ:2:&5 =1)%.=-V)!&HDDE=S_BV@$1BHEJ*:2$4LQ+:0=BY,
M@&9)$2>3) C#/)C,!#!BN/[PREN070V2E[)4LLJ3MS'41\@65.)*2"58"NKD
M8DL& $$P;P1T.\-?@Q8'&A'8SWA2"VJF$),K:-8,PPD[") ,##:\LMM*2^9#
MA+B5I(&6DC8$A)2/_29W#?\ NA&,X(YL!EHL)&PWWDVO:/7:(@XN7Q74*%@@
MC;F9]UI]VX,!O;*VUI=9.PH.1DYVGU"AR2<9([;SQQGB9@ R"9WY'D?E>WE!
M$8D3_"VW,$G<>>^XWVCF8P\1:8[(^)FH"):(C460XTZ^VA+B)R_+93M#K:EO
M;BHNLLA2F=FYTH0#U6752%8D:R0  ;:1,F1"C:"8U&UR<55*H32DZ"Q8!E!,
M:0"284@".6W.U\(!#9:GHA/^9%9<&4*= 4O&U2DD@9 !   SC@ $D[@]3%"R
M0=)ZS,6(,#UVCD@8F')I!E(8@\2!:Q!%R8L#R+'C!:8C\62V$MH6XA0<2EQ.
M4+.24[@K^XH?3TP#D9Z>I64R=[6WO>WOZG@$P3AE@X(!\#6F+\]//Z>N+Y\-
M=F5.\];[!A,18SSIN6'/?9<<*&E,Q70^\DJP=K:PV6U )*L8 258SQ/:#-T\
MIV-G69F -!J2M$Q*D:A)%^03;S$#'DO;OM2CV3[)=MYBH[HB=GUZ:N@+.'K4
MS26!R9,@VB+R !BVOTCI7%\8%^>4TU%7&I=@N--120EDL6;1%HV$X/F(4G][
MLK!4>_7'_1W#^RF3EFJ*U;/ZF?\ &P.<K F((O-AP+8\U^A/34_1MV-  #U>
MU-2D&/%VIFM4@F06F6DGQ,QGC%35B3(4S3ZBZ\X_!K].CU)EUM9VN.*:2B5D
MG_TS<@.M/ CY74+2>>_4RRH#4I*H2IEJK4BI )5=4H+WTE2I7R]+>ORZ(QK4
MT4)4RM5Z+*X *@$Z8  E"FEE.\$&]\0R YY<M?EDI"EG(SE9&<$'';.<'T^N
M1UT*@U))X&^P!&YZGW7,\SC?54Z/%!, [F!\+P+[3_-XGO-M-J:;C['7EC]K
MD>6C;N*LJ)5G..,C)P01Z"FD&)#%I"BX&YXF/CYB09MBBF"Y!+>$ PLF3)@$
M_ D[7Q"W'I0DJ=CEUW8TOXMM'EA"/, "",C=NQD[05 X]/7<%4* T D@B9D@
M>?UZ;\'&X!33AB%OX&O)*F3[K"]CO?"!]'P[[#C$E^1#>;2%+>\M);D@$K82
MD)1PCA R"%>Y)&) ZE;4JA]1@ D@J+ WD_&/*V+E)=2K (ZFRB8T\--[D3(&
MQ/,3A;(2V^N."MQL!E1"G<*"5 \MIP"4I6HY  X[YP#U!20#$$R! F2+R?A;
MX6OBM&9 WX6@@6W@ [=8]T^X8;W6*8Q56/C%RGH&P%T1@TF4 D'(2%A2$@N;
M<Y*OD23R0!U,,Y0Z O>3X0VK1>P,B]KB.N_E=-5Z3&GW8J RNJ=/Q!!VZ;GR
MP1$84XEYQM*4MQTEW"UI"T)4XELK )!)W%L'YCG*0,8*DS8W$S>VQ\[<V$;F
M.>=Y.T$*;R"+;2!MN/,#F?CATBMQPL^>%+"D+*@G 5YI2=J\D8("Q\P(R1Z@
MYS6S$"Q&XG>XWBWES(_+%#N\&%B"!,W@F#,G<@6)$3<VL2*E(9=;*6&FVUAL
M ,@AQ+J4)\IQ12I2EI6M6]?!&U1 1P$].FC*9(U3)DCJ21P+ $3.\7.^)TD8
M$EI@DG6;,#N!8 $"W2VY."6Y3R:0Y&6F4]%WONIIZTJ4U'D*BM(%20D$);64
M_*Z]DK*6VP  #D(7O0WA+6!8?B8:CX/,2-MI/.),H:J'0HKR 7'XF4-J*$WD
M-L (N?2%5.;4S#89"&RXXWYH6O(*&]O(2L*'S':1R%8!]SD1<ZF8B0 8@0?4
MGW&VTSTG%56#49C( M87+ Q-]A,D7C:QPX18[WENF7+D;9#GD>6WL47"1NCA
M*-F\H20 HA6X93W.2(.R@C2J^&\F;7@DGTD[=?0ULTD!4 T^+49&G:238>Z!
ML3MNVS:>XW0W:@Q'<Q J,.-->6@I;C5![XUYAE"P,)+S++BT(40HE"N"E)/5
ME.HAKBF667I56IB\L@"*S$ \,P&\7ZQ%M.JK9@4FJ*6K4JCTD!\34:90.][F
M"ZR=AJ W8 M\RM.,RE%@#"B"5A6 3A)6,@D':>!QP00>V#-*0TW,F(B)B)V%
MS?BXZG%BT$98:Y!,;;7B8X(B;;\DX,76FY"CA#V0DE8PI22<9'S9'/!.,_3&
M#DKN](%ATD].1%HMY8BN6(D%EL1!Y'D!M\1Z=0LCU545*YD9:V'V3N9<3@N)
M*0<'!R!DD[3SV.1GCJ+4Q4.EAJ5A!4[7F9^ F.N]HQ%J :$=141AXEN5(-CT
M-]][V-R9Q&9,B1)ENS5%:GW/F4Z/WE*5\P4.!A9 P0D $GD8P!H15540#PK
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M$[>OH'*ER)32WW&%*0^0ZSE>4N;%)4E2"DE6Y*@I:22<I!P.">H5%0Z002L
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ME-MD0SO" 1'5N!^3"G"XK<I 0KIJI%XL2?#'/^*.)._ XQ)5(8L90DR4)!6
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M P,1!D@ D;>HZ'F_K>]^F-O,L(9;<2^CXCYPMA(4K: K"%)7DH7GD+0D)*0
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M7 78:XNTNH<2I*0=P&4A94=J.QR59^;V/ P>#$,+$$=1)Z7^0]WNPT(9B03
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MH2<X"DJW;$]]H!/OU&DTDBJR:C> ?X=AQT@&;;[#%]"H2-%=DD@F >),3,<
M"T3>W."(KK[Z AXJWMX "V_+4$G!^8$D\'(]?[OOQ-A<;$&]B#L=Y@02-KB
M;21AOW=,EE,ACP9B."!Z^?7C&2W5-)!W;2@IP<%2P,$# )&2>V"?;[F5+3J
M95<$&QL#%Y$<C<<$GUPZ9#"1L($$;<"=^>=A'E>:VY4+7I5-E5"MVU,N6JOB
M$: K\8-.@4E;<EIV9*J$9$.0NL!]I'P\>&'X:8SA4\XX^,-]8LS3K5BU.C7_
M %53J%0A%=B ("J6/@(!/B%X((%L8<TF9KMW-'-#*KXA4TTE=G!! 1"6 2(N
M\$G81.)9J/JE7M3J30J$[ IM%H-O;FX:&U&1-6Z\4@/5"4X6U/(C*2&X;##,
M9MAD'>'5GS>LO9/9E#LRI6KFM5KUJB1)6*:J)\*("2"2=3EBQD " 2N.3V/V
M!D>PZ^=S=*I5S&=S]377#J*=&PT_NP"54OO4+!B[WD"V*HAQ9?GAL2$K24@+
M>\O)6VAP*2YE2CM&_DE)RD)V\CKJ5'!$Q<DG3$03[]X('$V]<=^H4"_ATP/P
MK# &+C82;=!>Q.'R0'84J.VZI*O/;2R/+3N4XPLI<;4I7<*(W<\%.0#SVI4=
MXCE;:#/B)%Q(L-CQ/TQD5E=6/B$%B000 5D&TP;P?,?ADXE5CVY/N2X_P>E1
M'B^^0E#3J_):"]N]*U*(5PM.4G(VE6T?;)VAF:>5RPJU&! L HEC?20 2+G?
MR YWQD[4SF7R.2.:S%1!2I@%B!J8 $R O4;VO-Q8G'?OC0@RJ5X6[0@R64,K
M8U(HJG"D)2UA-"N%(((2 EU6" " HA.>!CKQOLFRM[05F!!__+ZE^036H$WV
M(@38[GKCX-^BK,T<W^D?MO-4GJ,E3L7,E=4ZP#G\BTF23 $1>.#<1CQV\P?$
M>8.R5 X4,GCCMVY()'T[=?3B9)/7'Z><R20)\C\\6[2Z(JN6[^*,@*\DK9EI
M02E32D@*;SA) #H/;@E*58YZYE3,+0S(HN8U^)"8AN")D?AM/ D>F./6S*Y?
M-=TY@N-23LRVU 3%U,21U$[P6"DK9BM2TRH[3R4NI"D+0HD(2%A6[;C(YR2,
M=N1R,:ZZ$]VRF)#7'G'OMZ<GSQJJ>-D",5,$@BT[09\@!-KR?7#4TTFH/3/A
MTQD)0%*:SN/F% R5-I2<C>0%%)4?W0#G/,]6A1/OCBXGIUQ>Q%-1K=V)@ Q(
MO:29\["+\[X(7$6T0I:TH#;VQ6"<@C() (S@GD ;N,8SWZ X(@29!@_06^9-
MP=_*0(@D F3P9XM/(GDB?,\8+*U*6=Y)44]P.Z02E'  P=HR>?E)QZY 8CWC
MDG@38#^$0#U O>#A;R>1 &HP;?#WB1U-R(*4QY@?<\UEL-@*"%E6]S?G ;1P
M..ZW"<)'!3ZEA@  9VW@VYO$W/ O;C $+7F/4[@QY7W/(^1D+00EB2VZ' XL
MLF.H'+86A2EN*<3C#B=J<)1E)\PIR2.B=41L 9!Z;?&-C;UWQ(*58:B.3:&N
M2!\_7Y;Z;/DI4E:=I4YN*LE1"AW)!YSSV&Y/. 3QTHDQ-@-K6VD WVY]PYG#
M:&(@1:_G?Y1TO!CJ<*%RHJV6&&X^U\K5YCQ45!Q2MH:2EO@(2,J*TY.7,+R4
M@CIA2#);YV FYN#Y?=\+29O!$^@ ](,;7WM:Y./2GPM:86]HI;Z/$5JW(M)J
M#'H\FH6=;U=J4=VJ2C()CHE4VWMWQ-3JSQW)@L/H1 ::4Y,<<66DIZ^>^TG:
M=;MBLOL_V8N;9N_[K,ULM384U*RQ%;,1%*B/XV4FH6"JH4&<?$_;_MOM+VGS
M3^PWLTF?1WK4QVCVE1I5$H4@K([4SFAX%I !158:F9@:842QQYTW_.B7#>%T
M5VC0W85*J=8J50@Q7EAU^-%DRENM,NK;0 I:$E(4K"0HC.W'7NLFCT,KEJ-9
M@]6E1ITZC@0I=4 8B=I(L,?8NSLK5R>0R>5S#K4KY?+4*%5U!AWI4PK.)OXC
M),F;X9*;&6N.XHH)4H_(K)^0$8^Q/&,9R._"ACJ]C<7%A<?7CD=/.+V.ERJQ
M/N%K^H(^$7N?>^4,EFHL)7'=<"CM(0D<[L#(]<@Y/ /J>H5AX&,@6B2; _T]
MW)L<45KTW.H*=)NQ@3,SZ"=N0#;<8]>?#U8U6M[P>^)*X),=ABGU32VZVX8;
M0H2WUR8<A;BYFXE)#+:&/A%HP,.. IRDD_)O:#.4J_M3V!05B77MC)FYL!2<
MB$YAF)# SM,BV/SG[8=LY7-_I2]A,A1=GS&5[35JX:&I4T9  $BX9B6-00+Z
M(./$KC QGZ#MD]\<9QSD8P.>/0=?8,?I?!K2PAQ*C^Z,_NC*AZ# SGW'&"!G
MU Z,!^_Y>_$QIX3-82MA26GF=R%K4,Y2$C:5$C@$@$GN.V>1U74<+$@]1 Z>
M?!_*?+&=CW9$Q?:#S(D#H8N, G17(JTI<5E:TI)*% ME2O3<,?,H]@H?7<3U
M%'5MC:2;B_,WF(&\C>X'3$E!92P @$<P1T@^=N;'C"->] ^'6R020LD]\;>,
M;20><]CC')'(ZG;<'B+R>9Y,_P M]AAP!?UZS(/29$<W-@"1,8.;<4IMY"FT
MOJ<VAM:TE2V<#T"<#'.#Z9.>W1$$?P\D#8FW ZQ;>VUY&!B)&HZ>#,1;IOYP
M8OMM.&]5/F!QY!4EHI0%D+6 I+92%<\$E*@,@9.2,8'H]4 &"9Z7YCF/G$\3
M; '!"P#$W@'SL/+H-C$8.DTY20V''@ETQVRXE+9!0M)VH8R"0K+9;<+A(SO)
M(P,D5@VWG[[Q.) @Q/2+\DF.@F>HXF0,)$L!EE07C<5K"\'LWM&W:>Q5G((X
M_,9!<W$;FPGISZ6^M^<2$,P$D 7(&Y $G^4&+S[NNO"K<NGED5NZKUOZH4A+
M=$M:1&HE.DP!4:E/JU3(@J_"J>]&DQE2([*G5.R'U-AAH^<@[TC'FO:>CG<_
M2RF4RM&H14KJ:[([4Z:TZ7B_>5 RD*Q_A$AB(.^/">W^2[>[6[.R79W81:G7
MJYZBV8K"J:--<M2.MM=5;@FQ"[M  ,[59K#>5O79=3%5M&A.6[1(T1J+%BO%
M#LQ1W.K=DO(0E*$_$N/*6VE)4IML;%J4KD;>R<C7R>6>EFJPJU7J,[%9*"R*
MJ M?PZ1)')D <]WV?[/S_9N0%'M/-KG\TS%GJ !$,@ *!N0L7)$DFUL5VMOX
MAJ*A.]:4$K674E 4HLEO>?F.3N[).1ZD]=( WF-N"#>QCGB1(Y,6..P'*,Q8
M ";!3,7,#W>7Y6%.AEV+'CHW(4I]#;:^?E/KN)]" >.>3GH4P23%E)B1,;'?
MSYM;YTTZOC=IL%)/4Q[[@\WZ=<7)HO:1O75.P[>8CHVBMPDR0"2M:&GDOR#D
M)REM2&U+WG(2HI;(P<CD]LYG]5[,S5=C!-%E3?=O"3UD B+<2+8\_P"U/:8[
M)]F^V>T7:.ZR=>I3)B=?=,$L6'\1  DSO.^+O_250X\+Q-U" R$-HBV#IVRE
M"$;2E+5L1F]JN?\ ;!1"EYY*MQ5A1R>)^CUS4]GDJ,9U9_M,F?\ JS;FQC;_
M  V@ + C'COT&U^^_1[DJM1@SU>U.UG8J/"6?-.;28D$PUX+AB2"8QYX=S].
MW;VSSSP,'[]A[CKW&/KV%32T(&XJ6% )3@ '*2#NY)[ D??';T (D3M\?2VW
MWL<.2#(C:#_/F?+;YP.K=#ZW3;AIDZTYKY15*>V[-I <4$"3!:0A4B V3RN2
M5)4ZTD;E+!7M QSY+V@H5:-5,[1 %)H2KS#R=%1H%E A3/,"\R/%>T67J92M
M3SM!&:E69*>9*B=%0DJE9C>$40&-@+3O>S8*6$5"3+63%4P1F*,"2A\A.W8C
MY5.(V!6]60 ,J[=<>KK:BE,14US%3="HD&3)"G5&D#R],<FJ7[NG2 +JV]4_
MW;+O$WAIBV^PPY2JH].B*3'C/LB2VXIM] #J60PM*DY:4I;K@>+F4A&T%!4H
M9QQ13HK2J_O*B-H90R&5+:@=F@!0L7F\Q,6&(K16FXU/3;05U*Q*E]8/\4:5
M*@$0=C ,;X1L46HST,L.J6I7PX:2%_L6R6B?+_9K3O;5A7J02I*0 <#JULS1
MI,S( "7U&#K8ZQXH(.EA((Z09Q8U:C2+,@72&U2+F\:K@@1,#G<[3@52EU]+
MJZ(F)&JCL*)27+;9(>0&S"JS<JKI#D9;#H4\TEH.J*U.>4-K2PM*%)G0&694
MS!9D5JM=<V;-(J4"*$*T@C5JZ;F8O@H+E549IV:D*E2J,VY((;O*#)1U!M2P
M&D @ 29,2<,E;C2*766*8Q!BOJ<$2:VTA2WV5*D+>5*@1M\9<P?&O3W66@\M
M^8CR4-K><!01JHNE>@]5JCJ STI AA 0I4;QA2:2TU8P%23,$R,:,M4%>A5K
MO5-, 5*:SI5PJWIU7\80]WW88D 4VU$J!&(=<UD7)$9FU6?2$0Z%&GJ:9G I
M:8?F-K^6 E:5;U.1V.764I=<:QO=2A9XZ.3SV6<)22J[UG0:D969E73+/<:?
M$VQD DD+88Z62[3RE3N:5*N:V8-(:Z=RRH5G7!$>)@-+>$$$1((PGI5TS*!
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M3<F%*$%!$D&)' D0>18P0"9)G!5$99,@^6A4<AI:FTH 022VK/FI7@I!!)R
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M?D ZJS>7IYBE^L4BI+PH=9EFM%I U':=YW%R<59G+T<S2-:B;OI&NG)U&09
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M])?H0R0R78'::JK**W:*U)(,M^Y63?<#;4.DGSAME2PW8EK-XPH4R-E1!"2
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M?V=O(;F+=<.5/P$I!Y6D*+: $X6%+"BLD\X3W(SN)"?W<XZBTZ3[OO[\\!@
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MN(><<4T6'PM9W)=>YR5G(*0H#DD_4R$:-I $R3/F8).WPMM?%A5&&JD R@&
MHM8&(F?*3STMA[D4:+'83,>GM.!QK.QAEQ+F\Y!:=*MJ,%/=;?F9&.YR>JEK
MEFT=V/"?Q$@ZHYD':9 ) (/SS"M49R@ILA!@DLH$=1'K-XFYQ#I4O#Q$4.):
M6"/*"UMJ6H ("UH21N4D<)*AD XZTP+&TW]T[_'G&M 0#.Y&DF=QL1\O0P+8
MV*U4&8C\)$MPLO\ R/-A2MJAS@8. 2G)R3[DCD]0-.F6#E%+#9HN+0;^?.(B
MC3+*[4U+K.EC<B8)CIM'/YX:%/NK2$J<44_,<9S\QQDXYR3ZGGV['J?Y??W[
MN@Q=)B), S&"O3"C]>_U^WV!XQT86,QS^?J3[\^V#S@=\]L8ST8,:[GD#^N3
M[$?S('&?FS@]&# DJ*3E)(.2,I&/8$GD$CN#SCG!ST8,'HER$+!2\OTR,DYV
MG*00,>_KR>!P>>F"1MYR.#._QYPP2 0-FB0.8V^?SQV1X5M=*K8&M.G4R]KR
MN1G3G\88I=S055:HOTPT.H-N07A(IOGJ9D1H2WVY2HRFUIVL?+GA/7E?:GL:
MGG^QNTER.3RW[3[GO<G4%)%J+70AUT5 I9"X$:A)\B;8\%[>>R61[8]F^VZ>
M1[)R-7M=J!S&5JKE<N,RV9IE:H[NKI5A5J:64$NH);Q, 3'J+J=2JK:B*<['
M_ [GM%UHU"U[AI;!^!KM/D+\Z/4IZVRIQZ6 MMN8HJ"4. IV@ GKYMD*ZYFF
MY9*M',(P3,Y:L9J9>JH"M3B8"D@E"!#+XK3&/SSV!7R/:.:S-)ZF?[/[69CE
M^T,FY%-\O4IJ:52CDP^GNZ$*65"#4$:98W-?434!<VN2J?5'_B'"@-J89=6C
M86@E8:A.+\U+9::+:VW5,N(2I!25':0-K4R$E %!!(,2#)B2!$S>5U GWW[?
M:/LS2RV2RV:RBO3%-P[57"FH58@%JUD+%F)!"D6((43ADE5:V&YM+I,^)#<9
MAOS9[M.G."3-<,B2E3;#R8^UYA*RXZIYU64O%92?+"\=2TU"K."P$!-:J=(8
M#^$D%2=H'$<\]:CD^TQ2S.<HUJI>NM"DM6B>[HJE.D0U1!4E7("A558*D2-4
M'$>9H,:]:E*9O&VZ*FE+D*<C3XH2S(=:A(4Q!;3*94I45#24%AU4HK2$I2H[
MT@XN%9\O#9>NZOH(8084L?%8R&!L1IB3O&YU5,Y4[%R]-^R>T,ZV9 05,K58
MNA:L>\KN:3@&JSEM2BC!U,8TG$%1;\.BUIVEM27*A0Q(DL+#:VGYD>.\@JBK
M<6^V[#?# 2E"4-H*M@0H*SE*;'K&H"[ )5@$,HTJQ$!B "&4M,DR9,R ;GOC
M.ULWDJ>;[L4,Z:25!3J!DI&HI&M84K54LQ()),&Q# @XK:^D4.B-NPZ>ZQ&C
MA+<9Y#ZES/BTMK6Z9:4I0VTR\0I+95Y:$I*2% )P1T\AW^9JJ[*[LI+*ZL$*
ML0%TDF2RQ<*#(X..UV4V9S&FKF%9W::BPJT^YU!0*9\1+*""8+$P22<<VW16
M8=.\MQ(1,8>7YD:,^<J=2TI27-[;+C12VD[N0$)4,["H@]>MRE-V!+>!D@.P
M)(F%(W!))D7\C(!V]CDLK4="22IG2T<64D+()L+DF3/IBD*C/?G/+DN*VI5A
M*4))VH;&2E(3W  ''Y_8=A0%  L!]>OKCM4Z0IK VG<Q)-[_ )3[AMA 77%;
M4J<41D8![#D<#Z8]#S[=NI$DV)G%DDP-X-A_/Z>F.TK..+-MT$[2*>R#GYCW
M=P#Q]#Z\=L=>TR3M^H4/$P%K#CPGT]_TG'AWC]KY\S ),6D&&7C;<D^5Q>;4
M=JV@(K%,2"<" G]X<Y$B2./R SCZX'/5'M=!SV5F/]V7:/\ &Q^9]X$3).-?
ML:^KLVJ8_'F7<F-CI4VF+7CJ?/%//\NGZ[2<<8RD8]N.^?7GN>O(F9,[R9^/
ME\OGCU@_K\<%<'MCU]/O[=L\\_?WZ,&,([=^_H,G(]3G_ =N.V!T8,:R/8\#
MVQ@<>^>1P>!CM]^C!@6??@^_'O@=_O\ 4<\$^I@P-+F$J24Y*L@'<H ?PP#^
M>?7(/(!A@B""H)X)W'IZX5Q))85O:+C.,;EM*<3QM.4E22%)2H#D9V\$_*03
MTB =P&$BS;;V%OA^>$%4GQR1:) \_+X6,7ZG'4^FFN= 1#@6MJK;C%S42"B4
MBE7  ^;AHB'$J<;0E8>":C 8=*UMQG$EP*<VH6 D)Z\WVAV([&OFNS:U3+9B
MKH+996 R]5@P!G8H[+(U+()B1<D^*[=]FLZ]2KG/9_.U,AF:F@U,MI0Y/.$,
M@9JBFFS4ZA0'QTW )@L#).*_OJ_HDZ=6V+>2XS;\R0]$AM.H,=TTX)2EIYYO
M=AMYTY6I"BH)) "N>NAD>RZE&A0J9F#F$ +D'45<R2 QB5 , @"U_/':[.[,
MJ9>AE7SA[S-T@&J1!'>&YTQ!TK901Q<[XHG R3Z>^>,@CWP<D >P[=\]=7';
MQA/^'/IW'.<_4\>H'?'1@QHDG(S].3P2.X )R.X^F<_0]&#&_P"HXQQZD8'(
M'M@8';/.>C!C./3MQSZ9/''I]\8[]&#&<\^O],X_(CT[9_CR3!C0''ODYP/3
M\_Y<#(].C!C/R!]^1WXSE.0 >_8GHP8WQ]>,<#CUQP..,G[?PZ,&-8V_8DYS
MC[?;![^G''?CHP84&1NQA"$D**DE)4<)YXP3D#L,9/;&!ST"QG[VYZ\^5]HP
M@(V)%H\YM>>O^@@6Q)J#>E<MN4B51I*H;NPMNMH4I3$A)R"'V59;<.U6 5)*
MQ\I"@4@]49K*Y?.4^[S%%7$@AMF!$&5874S<D1(L9&*<WELOG%5:])&T"S0
MUB3(800;Q(.V\XG J4F_6Y$QWR4U*,RD/QT'8Y+0WDJ?CMDX>6-XWM-@J ^?
M;@*)QK23(!*:!S38F";A"396,'PV)#-Z$[#'/%&GV>:=.F*C4ZC,=1&I:9@
M*2 2JP =1L#:"2,,L1MR-(7%2RM20TH^<E#J"VZOL@Y2.1ZG.1Z=@!IJ,&4-
MJ&H$6M, ]..=QZ6QH)5@'9H$_@#"XG>.2(DW/'IA:TVGX<0WI#B'5/80-B@$
MI4"KA:A\V2.02<#[9Z@[%SKTC2 ";R;6GJ!O\>F(HQ5S45-0TF;B#/D"+[^4
M@'BQ#E-KK+3\6*AR0V^"%%*7%%62,**@=I5C)0?8?-G Z9K4&;6WAZ3IE1?<
M;^=^LVN<3UY9F4O4533B!.F8'(X]('YX8W:!-:#9J<E$-+79#[N]]022=K<<
M?,D<=EIV<DE8(XM%=&CNP6$;_P (VB\1[A<>N+C7IL=--6<V!=02M[6>PM$;
MG>\[88*DXPAY*HI4M7SA3KP25%601M2 $IQZ'@C &3CFU=4>*)\ML64]C/E8
M<<W(WO/TPT*45$YY)SR>3R3CT(X/N<$GG!ZEBS N_P!<YY(''?[9'M]#T8,:
MYSZ8[8'J#W!SP0!G_EDCHP8ST^A!X)]..?7C']>>C!C#GUP>!D8&>.?MCOW[
M>G1@P-IPM+"]N\)/(R4Y'90)203DCGWSZ=%^"1(BWG@]\>8PL1/=1@A)!"E*
M)"U)*PHI44G:1M22A!P",E*=V=H/2@3L#$0") B?YG ;J$,%5NH(!@FQ(M-Q
M8CD1M&'.96S4&V%25.N2&6'6"ZXHK4IHN+<;;WG*UI:*U#+I*SP,X'  JSH4
M*IV4?A6>F()36FS%0 K&13  0$B"8YM$R>+ '#<W*+9;=22A2%$#82DG(SGC
M)S['/?GTZ14&?,S?@_7RWVQ(F0%(L!QS>;DG>U_F><.=3JR)[;3JV]KZEJ\T
ME>]*F@VE*$XQ\NU2,JSR=QQD="KI$ _?]<5I2"" 3[XZDDB!;W7].&?S@IO(
M!W#:?9/[PX'!..Q R .WKU+$M-]SR!M-QUYYMOSYX4-EE;BWI:UJ4IE3@4"%
M%3V,- IQD)*N"3S@#'<Y(M'&V&)DWCW0>-R9!Z<SP>BB!5G(DIIYAIM+J!M2
M5*.T*.,N'&"% #/J#QZ\]5M3#*5),&/=$_SPJB!U*DD [P)_GQ(]^'.77U&7
M(E%*);DE)2MT!Q/*@ 6U%?SX2>1@XR<CCH6F%4+)@?,W@GXP>MMHQ6*(%-*:
MLRK3 "Q M?CI?F+B=\,B)ZBO:6D[<G"0I0V@GA.[O\N2!GDYYSU(J"9^7G._
MY'%UPNF2>2>;"\>9V^?J:FLRV$.,QW%(2K<"0I04 3@H!.<@=SG')],GI&FC
M;J"9!DB^\QZ??6454D%D4D Q($WZ^<GSVPUEXDY4D$G<%?,4E15GN4GN<DGO
MNR<CG(GP +1R-_Z^_$MMK>GI'TP4<C)R>!ZC./7OW(XP>_OG@X,&,!_PX'..
M^.V<9P, >I]>.C!C,\?<]NQ[X/J/7[<G)[X!@P<RZ65E8&24*3W4DX4.<%)R
M> ,I['G(Y&$1,>1G#$<J&'0\'K@0D+2<A*?8]P2D# &<E1 ],G';[F1N9(\H
MO$>GW\,$S:!$SY_&_P!@8LK2[5V\M(;GCW99M0,&I,MF-(94/.I]6IKI29=&
MK,%PJ8J%)FI"DOQ'TJ3G:XVI#J&UIP=I]G97M;*G*9VF*E,'53<>&K0J#\-6
MC4$-3J(22K*9!)W!(/([;[#[+]H>SZW9O:N43,4*L,C2RU<O66]/,9>HI#4Z
MU)_%3<&QD&5)&+:U,U,M'5M'XM"M*E6%<*Y3LF52Z<7541YJ2VRAPP'I!=>;
M+;K)=##RW%$OKPX2 >N7V9V9G>R*G=MF:N=RS4U5:M4@50RR1K00A!5B"4"V
M46Z<;L/L7/\ 8*KE*O:.9[7R8IA:&8S049I=#LP%7N@J/(?1( LBR.K!=5K(
MI5OVW+;J3$IF92G5E"2ISRGFSRRD)*5G<2%9(QG.WU)LR>=[[-9M#29&I5@
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M_$^WT[8Z,&-_Q)[@9[ Y.,9QWS^9 Z,&-@X((SW[]L8)_H<#W/UQT8,*A,<
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M:0PTMQEM#B$-,_#G("$%8!.XJ.Y1P$]^MJG*:4IBHHIJFHEO"Q8$EM< R0#
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M&$40=X32),@")OU,^ECL(6';BCCR)?J2?C%GM_X/I]CGGH'85 D2&]2W-_\
MIVWOU/F,(]MYW_"!Y:>3!-IGGW6F;R/^S^W">696,#($UWD?3Y#G@<GGOVST
M_P!@Y>;ZH%R WGL1'&W3U)NCVWG(,@;Q^ [6W\1$R;[$$B>,'BP;6.$B)._*
MHO$#C(*L,\#D#)&!GG@'JW]@Y#_$W)$5 >.+<R0.GPD_;6=N-*1(N5,#B8FW
M3X[0<;-@VN"4F--^J?Q)S@XR1_LQ@ Y)X],]\ +]A=G<LTSN7N)!%A:?AOY
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MLO@&,[4*:Q3#-A-OA2%M./Q6VW&E)<96ZE;96CV)V?$EWB3!!: 1O( D0)W
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MF^7!:*:5,@MN+D/)7(=V@V((-C$6/N)!&Q,B.")!C&*H8(@CFXD W%P&D[?
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M0N223),WC:8@D"-Q!XF2!&.?5\-1E1I0$:"22"")!@F=/B\)8DQS:2U 8S@
M8SGVYXQ_A^??U'24 "T"=XC>+^_[C?#!/.\";W!/D18[DCB-KXV,IY&<\]_K
MC/&>_H1Z ^W4*AE>HD3U/(Z>1WQ![K!ZWF(&]]MN18[03.-AQ8(^8\$?U_S]
M.LYC@&;23-S!'!-YO\<5$  ^$;= /K;"LN$X"E9^YS[\?O'[Y[ >QZB6:]S?
MTG_ZI\S-N,4[FT"_/KT)_.#;;D.1ZJ '/KDX[#U/WSC/W^;I$G?<^M_]?AZX
M())B^T2/J0(%AO/)F<8%@C][.%=^<'D\#&#QVYR/OQU;3)@[_$;CGF_P-[0<
M...>(.]X^%C%I.-[TC@'&3G^IS]>?X9^AZGP0=NFX)^GOPH^_OW_ '?&EJ20
MK)S\I!XR<8(.,\'([#U[>O2*A@1L2"H(L1(($'B)]W0[8-KW$29'!%Y'G-\>
MWNG?CPTWMJ\_!I:<B[=085D:/Z!Z;LWK<-.UXU8IMA1;TMWP]W90Y=KT[2%B
M&]:%K7?!OFI4^G,ZB4.G3ZO#K:?UB@K=>><=1S_U&K AR;"1)])@0IDWG5)B
M8D#'>2M1J5**Z1>D7<&FA[RX.IF,'83%P9*DP3%HVQXW-+KBH%P5ZW-3Y%NW
M/<NA7ALM:)2]4?%1KGIUK%%N*PM0M;:GJ13-0/$M9--1>5_O4N5<]&J5HH?7
M!H,^P:A;-+^ C3[66DY&IU4)1P9!B]1C%O%#1,7 6WB\1@ XF[T&8!(*AG8:
M*2 :2P"^ L$!E3J,@H2I!;85QI#JI9]P5+2I*/%/I[:.A]FZ$WE9.MGA:NJ\
MKF1#URU>DT_5%R]GUT2JTM=C:D3=3ZU5+5NVBZSWU4&IS:VH$=VLTNMVQ2X[
MR&M'0%"VJ(\1@#Q2;\,8)(!+<BYFJIW+TZCM4T&G&D@*+!J>C\)+!E$J$)TJ
M(@FQ'"7A[U2TKTFN>YD6K<]>@T74#PL:P6+?U2U&L^S4U(Z@5W3.Z6*3;-C5
MBB-URM4N@5RYW:+$-01)HE4JSJ6V*ZL04%OK:5[Q%44Y,2&@3,$ $D*8D@F;
MB#)@8QI7H-5-,'8ZA=M( 8:B=18%@HM @+.D:CCT-E^(+0^^].?#K8]H^)BW
M_"\S:T'0V#;=ST&Y]0*C7K#9HN@=[6?XDJG7M-9S3MCZ<7F_=TPP]-[HL9BW
MJO==:O.5=58N*<Y(G52D5-2==4DR506F0!K!(5N0K"8NVDF)@8U*48B*88@U
M"T@:7,HR#5:S%6,-*K.F"HD<@W'J]IK>WBYU?O#4^Y[1_4FLZ"O:>T&JT"\;
MDOR'<9IMG69:-ML7;?#-,I%8ON^[AI%&?F:A5JKPFHM4N5ZH!]+L)J&$UZ:D
M"YB"MR2+Q$2!)*B# W/(N*JA5:H4* 14#QI"W\18@*Q"@.P*1,""(-L=!6EJ
M-X&Y5?BWE;5O^%RR=2[;UMD)MUF[+9N.C:9,:#VEXB%UB+70P(,Z ]J7-TB3
M2FK:KRXKUXSZ1"J$J#(1=[;;3U;(Q%K'4"054+O9@+C4%$J3%XZ8TAZ 9@SU
M)T:& 8DABN@I,SH+-#"(-[[-A?7ZA^CVN*]M4-3ZM<NB%<J&H5?9G:?4VOQ[
MPE.MZH-U#Q7S*S<FIE)%(2BG:>W/>%9\.]1N*3+5)BUVVQ$280IT2OQ&PJYF
M2T%9'X;,8G7:88L(TR#!F!<SI?JI'X[JQ4$DGPQX0AU033"-%P9VDSBOJ35?
M M!TMNMR_;=\-M?U2,FZVM1X]DU2MVC:T=;NE-@4W3I_1.1^H]RUYYR%J@S>
M]9O)G2']6K9EW&J=3'6CIL[;KS4&INH0ZC,F-,#2+^%(4^$D!1H(V),\V-4R
MY)"'5J"R"&\9W+/+1J AO'-F@1:&ZX;_ /"UIAXX?!]J]I1/T:H5BVO<D:Z-
M1Z/9]#76K#L!$"^;@5;LFH5V'1Z9"O=YBUY5&GTRN/V;;M^4]J!2DWM37[KC
M/U!Z]:;M28DD %VE=AX-6H>$$&6!!$D*JG?5C,U2D6"LH8DH(<&2 Z@J99I6
M%/AD*9(4:=)+A"OGP83V*5J!J%#T%O25*HMD75;,6K0+HK.I-Q:H'0G4>;K7
M'\1)(,^KT.L:[/VLY;C-3JDZ XXFB"U%Q;:-<'4*%-GU%N5 _P 1DF6U$V@7
M XOM%QIK5:*A0JV5F! A55?"%-."/$1<P 9_%))PS6#JQX)/PO3^E7=I=X<#
M\3_HS1+WJTC3JH(J[,:]6M2_]*&H?%0VTM1)EKE%AQJ&["80+-4VQ)LYOXB3
M4Y+T6H5]<S:)C0!!5C,$S=(4@1;5S;2"K2T1'B!:!WC$$$+IM(D5)(:]](#!
M9O;])N?P)6+HU<D"S;E\-<[5"X-$KEL:V;@G6-(0E\W3H7$EU@7$S-IESU:'
M<!U1HK]%AW)?=<DW(BX9;[UN0+4LBJ4N)T^[KJK!:8>5/B8&"Q( #'<C_I8$
M3>8 P@],,DIX5<'3X?  26* DJ#$$%3N1(-X;+ANGP 7#?2KAK-1T3N#3"JU
MQ4R[:I6H]Z3];ZEJ:YK[0'J3)8J4EAZO2M'/[$FG8E<"9YH\BEJK[58AN7JB
MFJ(XS((8KW:M,LOXY:P4'3/=MN1<$@2-P9TGH*I5J26$A  J #D &.\U$08U
M $$'G'FMXFKGTCO$Z5W%I=;M@6C5G[=OJ!J#;VG-$G6W0(TREZL7O%L*4[35
MD1_Q*9IG^JSTJHL*+]60B/*K3DBKN2U'5E^^D>-H!U$*($ST7DB223!VC8##
MF2I<LLQ(TF9,0-0DDFS0 .!MU/*\M0+8\PJP%I(Y]2E7_/W^_5_:#L4_&1^]
M3_L>P/(YGD863/[PMI']VPDBUW0P(^?28WG$T6[O2 K;@'.?K@CWP>^.,\]>
MSZ&Y^!Z]+>5M\?/[?E^4?EA.KGGMWX)Y'KVSZ]_N?MEXL6Z S$@B]NOP^<W\
MH#_G_/\ 3I_9\_O^5K8M2P:3&TP9Z[3)Y$G:?,'#>X.7""4G<<GO_>] 3W/(
M/H..HU1%,G<F(MR2/46W'7$PTD6 BVPD"\CK[Q$<X) QQNSCG)[D=\>N0,>H
M[D\>G6:9B=[7G@GF+&('0&PWW( D@VFX(WB_,GF]K7.V"'<8X.""/7TY/./O
MR2/KC'4Q<W-O.>-^;^0$8LX^,W^8MY]9YM@H=O0YR>.!_G/'.#W]N@R+'[^_
M@.(QIIW1?E)B2)F)D;QQ?8DF^ .@$ G(QQQ]<=SZ #/Y>GLU69\MOG]\8F ;
MD&T>MCN)L38;;WCSPD<45#U''L3QV[X'MSW [9[=9:K&2H V_K^5K[C I,WZ
M@;B1>UNH-P"0?2#"UD$-(_[I//KRKT.1QCGT&,9SU!3:_ $6MQ'OZ#K.]@-"
M"^PN3L1/H)-@+DF]O=@K\O\ /K_S^W6/YVV^,GT&_&_,&=1YB #!/(@@]"6Y
MN>@'3"=Q(*B?M_( '_/OWSU H"3]9Z??GBY&&@ 0;FYM>3)OQN2 >0.D%+;!
MQR?7\AZ9SZ #\^WKQ T@VS&T@[<V-OOZ8M4S>-KB_'7R \S/',A.H *('IE(
M!//W]O4^O<\=+N02!J)/H+[\GX1MM;%R(H(,D<^8MY _'RWZAQWQZ?GQ]3W/
M;OVY],\@H"]R8/0$?6X^YZW:1:2=H$_R/TL;=03A?38C=0FT^ [-A4YN=-BP
MEU&I./-4ZG(DR$-+GU!R.S)?;@PT*5)F.LQ9+K4=MQQN-(6D-*&.G+L-Y4CR
MB;&QX O ) $W C%:>%E4;;R?DH\VF%O?8D;CONY? ;K-#DPJ/8&M6DVN5T5?
M1&5JI3[/T>NC4BXKEEZ/0G*2(A8I]5L&AM.4NK/U)A-)M\2%H"X<IZ5%@,1F
MW7..E>FH*NB@B")8%FDL3 $R""A ,R6X(ON-.(*LX75!)6 K'3-RTS^(,8!\
M)W!!Q454C>+"NV[9NB+^FFH\23:%VW'J! @4JQ;B@ZBW'>]P7)!T[G79=M5+
M3EPW)6J-<5&B:<6W+>6@4*8E^WZ>RS4)\QJ1HI5<NP<,I$ $:9U&QEFDR2(T
M@@@D$+T&*W2JC!@RG58RW@!!!"H ( ,EF!F8U01)#8G23Q>6[;2:$_8.OU)M
M>!J%!H\6B-T:^6+?B:FNUE%)ID*-1V/+@L7>]<3T:FTY^.Q\:+A?13F'&ZH?
MA59*C9<2QF;VTP!/H-Q%N0;0)Q/17,$1Q/B63$7+7\.\@P-(DSN)#+\/WBXJ
MC5H63J!:6M%J69)N"!;MO*U&HVHK.GE"K%4BU*?38T:$:9468)F[:DB%^"T=
MUQZ29<1+(69C+->NC8!?*=)B\D@\7X(&\"UPLV:JZZ20!Y$:C< 0.HFXDVO<
M03$Y&@GBSB4:5?,G2;7N+0'+;AW1-NF3:]Z(AN6G0HM.K=+K,NKICAM5'H]-
M32:W3)+KX9@4]N#683J8"(TIO5WN6(LL7BX/6-Q8:;^A!,BQ%NBJ#&H'8"#O
MOL+F\[\[$ VQ,O[!O&5>TZZ;HN6V=9F)-LVK1-6:_<>H"[PC3E6Y3+EMNR:-
M<[<JJEZIU2=0:A>](##$,O5BCTV=+FQ6&([;J7LSU,OK8A2-A!DDV$7/XC-Y
MU2#,<S$TZC$2^\B%.QCQ$ ; @="&L+VBO+UT]\06E<!5S5FG:E4.RZ'>52MF
MBZBLQ[WI]F2KDM>X:^=]M5V>Q3#YC=9A5^JTTEF',2_^./!#5414D):&E4U0
MNQO.P WTWX(D&-N29PUINHC69,$;$D$'@ F3,$2+QN",=,O>#KQ!7)6K3@U;
M7_3*?KG>MS:7L5_2BOZNW,O6"S)^MK=,MZT:Y>PJ%)73GY3U,J5OQ;PC6O<M
MR79:E%JU.BW12X4-B6B!&:8&KN_"?"2S B^F).X)4[P28@2NDF;*=M9.YLEC
M<DZ; 0""8/A),B&D"AYVD_C&K;-G4";9^OM?@UN@5BAZ<P7(=]5*E5>T(B*=
M4JI3+9:D*+#=K/0C1:I)A,1XU.?@JI,XQG6O@W.HBI0@ #<6L3-^)(@1_"1L
M!8\+35O>\C5$:@3,FVY!$2"2.H!.*EN+1_5BSK=9N^[]-+YMBU7ZO)M]NXZ]
M;56I%'57(4B?"ETDS9T5MINH1YU*J4)R*XI*_C:?4(2-S\&0&Y4\Q2J1N)\C
MTMN !Y@W)MOA5*%1)) /2\GY<1>=@(/48KL#(!"DX(!YX." 0",G!'8C)P1U
M?(O$D$0)(GY<1Q,>L1BFXL=X@P;3S[O]?+&L?5/\?\,9Z-ND[S;Y<>D7L<'W
M_K;YV^>,VGL%(SZ9.!_3_'_FU&HQ($^8&W3I_*8P8"HA)P7&\@9(!R?R^_I[
M?7TN[I1_%M?Y@7'EQS),=0??W^7YXM72?3RX]1I.H$NUJ]&M^7I?I7>.K=0E
MO2:E%E2:+9HIPJ--I4BFI4ZW59R:HVU%6^IJ($^:B0ZA"N:<P8!BP$DF\^&Y
MB#,[D$^7GBRFY4@  EF"B=@6V)M<2+[6^4YL+PTZ]ZBV_:MXZ6V?<EX?CS-2
M<;?I:TT=-*,"Z%V- C&MU^H4>F5&5<%=)I=)A4:9+EOU-YFBH2_4Y3,)VA:]
M-456IJVX, ;@WLS*"#/NY,D SBJ[%^\T6!OJO:8$ G8 7ZZ@+$A3$\*GBGN2
MCTRY8NCVH=6@UJ518\9\-QI-4>=N6K/T>@N5&ANU-ROTJ%6ZO19L2BU.MTRF
MTJ8JD2Y\&<N!2Y2H$'S%&5'=B"+$ >*> )D7XA5 ,V%A,4JS:OWA)7<2?#&Y
M+1!@ SI)8SX@3&JP9\WQ6-6T/"1>'Q-JTF)9E4U,;I#5I6]4ZY=5D6/2;DU9
MIH&H=FPJG<%ZZ>-5"B5*OT#9=%7LZD59E58#P<ICTNFS#4- )&DB/"X6(WD1
M((L((8Q8"\Q45JA_"=0,^)68WG2;'\)@PQ*@M$QL&'2? YXMJI6+TD52R*]:
MU\V=:DV^&HEQW)2:?6ZX_1=1; TSN"BQKD%?<I=#NZUZGJ!;\VNTFZZK;]2I
ME+?2XZUNF4U$J'>T/^5#*00OA$R1.DAM,BQ.IAO DP#,K4_Y@8&TG60MB02N
MC408,:0PD"2 #@R#X$O$Q<UD3KOHUKUBI7% K%%H52TZJ+4NAWS^)7'=>K5A
M+B0F+H=ID"NSH]RZ0UJWIE/I,N74*G69\&@4BFSJA'G0VK#F*$'336!:/#(
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MB'C156@W371$O>9<4%N@+N459^GHIG_2C=!1<"6Y[>?]192"8*J-(.OQ:?\
M+! /%R>2>@T/F@Z%9(+-K$*" T%29!G2!!-MSIGG"*POT@%>LE5J Z>4^L)M
M6T=.K38;F7)56TOLZ?ZUZH:SM3 I#*C'75)^ITNC26V4[4LTUN>E)?FOH2ER
M:*>3X0NX@@$F3:9XY',8J;,.TBPEV>8ZJ%@>+@"9D$S$VPXL_I&;GBS69O\
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M]6J!2T4:EVE4(%F13)K,6T+;K]F6Q2G+M8M]=6O-BSK8KUQ6Y:T.M52OLVQ
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MDC^7 ]L8XYZ"R\$6YD7L/SG_ $ Q;24K-M,B (CF#TCB-]YB=TR\$K'<G.,
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ML$$@]AZCOV_^:+J-V'Q'WP=^><$&T3(B9FWNM O$S;WW#O2H$@@ G &1],'
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M'"=>G]^;S_U&O$<]S:];R,#ZP1SQ[?3Z](U<L1>9VD P+6M$VVMMO?8S%+,
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M/L#^']_3'&/RQT01LK>5F-YOP3>?.>-CAZTY=(ZAU/ISS(VZ\P<!_L_O_O\
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MQ[][_#^O\\:]S]",]A^7\>P X[\9Z<#H!TVG;Y^>_6=H/LX$GN<_8#^1Q]L
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MY/T/^>QX]1TBH):>1)VL;1\.) L,!$6D2/7D@VO'F9CG?<%J &,>W^3W/?\
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M9]J!69=$9D5!E]V1,5*L:BH0..ZUZ2-6M05!86D20)4%A-SOB??,4[MHT23
M%0R6+$L07_%).EAM)'3'.5OVEJ!:LVMU"A:B:2P)5Q6S<UHUEQK5:Q'3-MZ[
MZ>[2KAIRT/S7D(14(#[L<K;"5LI5^P4G:D=8R4!\5-7&DJ"E0/I!$-,JT2#
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MKDHIQ5.<IXCN5&>M]Z<L 0%HB8B*@@=9'),Q)DCUN)!G4 &HY W)#AB0(&S
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M3^\_^;_M7%1W]R_08,'=7W_P'6C$1NWK^0QOJ:[/Z?D<!V]Z_48)_O)_\/\
M0=,?A'^5_J,-?P#_ -/T.!([#_O'_P!T])]QZ?F<([KZ_D<"3W/^?[RNHMN?
M4_7"7<_?\38%T-N?4_7$L!/[P_+^B^EB)_$/=]'QL]T_?_ ]&&=U]?R.-#]X
M_G_1'1A#\1]_T3&T]A]A_3HPUV'H/IC?1AXSHP8"GT_[J?\ 'IC9O3\QB*\?
MY5_/!S?K^7^/5B;'U_(8;;'T/TQM7[A^Y_\ >ZGB/\8]3_VK@?1B(_$WK_\
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E@.R_Y_S.")/97_>;_P#=<ZSYW\(_SK_V-B[+?B'^1_\ O7'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g451428g28p69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g28p69.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[17T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %=B^59(X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "&-G,#(R
M.#<T' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@1F%L8V]N("T@1G)E
M<75E;F-Y(%,M-%]$1DE.($1R869T(#<N,3@N #A"24T$)0      $,P@G--5
MQ7WZ@P:[XSFS@" X0DE-!#H      .\    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     8 00!0 $0 +0 R       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&>,
M@R         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  E,S,  $  0"4
MS,P  0 !.$))300F       .             #^    X0DE-! T       0
M  !:.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             5X   2F    !@!G #( . !P #8 .0    $
M             0             $I@   5X                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   5X     4F=H=&QO;F<   2F
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   %>     %)G:'1L;VYG   $I@    -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !3A"24T$#      +)     $
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MX_-&E*2%M)7$U.0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M29.EJK;Z04GGTTU5$$E#68;32(T!4 "(0+:,Q3DY02?:48 -R;6 XG%+3_\
M:;'_ ' +[M#\_ XK?TYJ?^IC<C_UF7&.WS;F<R$@'; <3K&OV _?/^G#J7[_
M /B3-C]@1V[_ ,.(X+].:G;YF.VYN=&_.8;?AN/> CAUC7[ ?OD_+^>'4O\
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M ,TCN./L#B>N[/\ [L1%Y_3G?_\ 3MW"/K?S?M3^^%_],C_N87Z6KF_>U?\
M>"8\OZI//'/OMQ/7:"__ )8DS_\ /5.^P.3N^?8_-^T_[X7_ -,C_N8*M6[D
M !$5BJFFD!$1%032  &XB(I<! 2(C ;CMD:*V@_NQ)L!^N5Y_8U/-X.'YOVG
M_?"X[:9'_<QT)-9GIP2D+D#I6M1*RJ3TJQ&N2JDRD@RGVBCDZ@E-64<572(5
M4F%UU454Q52//@:R@!@[+2D@F1UR@>X@MV[HX]^ V?M,W&V5D<13(_[F.\-6
MKEYJUG]X)Y;_ /)/+/K \/7=G_W8G0#]>KQ/V-3QW8?F_:F_;"_^F1_W,/\
M2U<H1_.E7JH*\OW7[L[<!6T$_P#NQ$#_ .>J;[B<F[M&D8?F_:?]\+_Z9/R=
M&$&K5R_O:P/_ +P3/:?YI\>)Z[06_P#+$V_^>3/?['.Z)P_-^U/[X7_TR/\
MN8IENLSRW(U*]P=JD*%&28I6+5B](E2)4Q- UFGJ%)Z<LD@DJ@*JS#3:Z"Z*
M &JNH  1XR%90*("=EI),  /*)/< B<QXW.)^;]J"3^>%V__ (R/?^DMBI_2
MU<G)8K\_E!.=H_Y)W#F.X<8BMH!_^V)/>^H__A[^_P +^;]J?WPO_ID?]S#_
M $M7+^]*]_VY/VI!^WZYOKNS_P"[$Z0?TZO,>QKYVMA^;]J?WPO_ *9'_<PO
MTM7+^]K.G]8)CS_JOT?#AZ[06_\ +$6U_3*OI_N=F^=9UP_-^T_[X7_TR/\
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M#L5I1XAGBD]LMPIZ<&>Z"-*!76@2G5&-:Q2WN!EP@6G0I"!35/*HNA"<G6
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M6W5-54H:>S(4@*9+!40XH%2R704YCG2E*BD8S!6H@ K4@*:NI&4@^WUD#(#
M]@@Q8DWC&+Z>.5[V7IMI/:#Q>OB!M"TD!VL*+4JX&2Q'RX[Q9]1&AW; L>T4
M])VGSXJ*M1T;ECZ^)W1L;%[0]NZ8AO%_**4 C/S=#;CS[B6Z5Q9%.6DJ=2A"
MFE)/6+/Z5$K!"4D*4%)!)"9OC!!4E*$E3H3^DSJ"2I05/L#["I21F,@$$C[4
M0,;&: &Z[W;>[>[:LW'>S&GMS1#19U4VB#*S,MO7!?\ =5&I2:]%3Y6+*:JJ
M=4"9JMI2N8&ET1)V1Q4IZCT] 5E$5[6J]60V4L(;45U#X#F92E(:1U1;"/:
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M6VR(7 A[INNY+*1,EN&L[LPJ7!8:<O'<)986Y4J=%. 7:B E2)2 R5-+S]>
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M)0I1"@2DJ4I94;B2)!&4 #=.,VNLZDJ65*60HP1H1(   WQ.A))\,0];:_Q
MD^YNFNYM14*&V=0_"Q9;;IPDM-E0VPML^\M-]&B-4UZA,%JB[5$MSO=5T*#%
M2%>D;[2<V)66!:<M,N3%ZZQ2GV,C1*VJQPO%:BX%MNO]2)SA/M!"1]F7$JB=
M,8 NCVI7 4RD("1!"DMA9C+-I4;$!)!D6(Q%[&MUGT]M-NM)@>]34" ==_$!
M3J8\7 ENY(K8R3[KNIYTS+:WIJTBU 5 P7<@<*+@6.S*QN#8I<R6YN5.[.6X
M5-ZG74&'5J6I+*B*:E+(04'-"$)>E*GVAG;*<@2I0*4E1"5$!6,!UB$A(*P.
MM=S%05(E1*(_1JLJ29 B8$[L2(].?BAKM?5Q_/OZ]ZKDL3PRZ8N]GI+2LZA%
M;EVZI7+;5Z%W2^EM+]9B6XU[DE5H6-?1:U*9G-9G$XLIR92?>EH2M%*:/.R@
M-MY':MX.%:Y6VRA2,B<R'"A((4H%8*@H#V5F"3D2]#ASJE+*,N5-E.*2J3!3
M)O!B!!-Q>!EVIMZ:JZ0*]2;03/VK]Z'..BUDGZ4/U%EJ;L6KM1*[NU!HO=2I
M<;2M MB:E+<UK+.-4)W<IO2$,B9*8C*/K)55F8LML5 9<*&&XJ' ^GK V UU
M;1; 2XYF4"0Y=.8YB02 1BK6MO.)<5+:<A""HE<JS'V4@")3(.41WXPMHO[5
M2\]5+@MIGO[5AS64^(#6/3]]M=+9Y26P+=T<;&&["T#PBO/\S2T)=Q-%QEL1
M#4LJNI8Z5+S2V8UL.3"9.:FF6V$K+3('JM.ZE9</6JJ%*1*2CK)*%(*LPR!(
M S!0-\0*<4LI"ED]:XDIR@(#8"H(44W(,#4R=T7Q%UO/^O=M:0Z"6E:%R:@V
MPV(M%G=&]OUUL5\EN+-K>RTVPV);6<TC?HM?SRX,MO$_+U+.Q'-K<SW734YE
M%W&Y&MY)5&JM-*M^I<<0TLFI24H0MLA5,K.2L$U+20I<I"EA2BV<OL)F<8 N
MI;:"2M*>K()*52%@I$$!M1@"2! "H,'$HNSKJ;<FM%FH+W>=3S'^W/$G:1I5
ME->GSE1I$FTT1:>@:DO0FZ*[/]@FI5<*Y><>N6W?2O(<%!]O+&H@I$%).BD,
MHIW"VAG*ND7^D4Z"_P!<73+91GW( L&X*1G"O:QFHK+B0HKD/)(2$*ZO($P%
M!0'$F941>(L<;VZ-/C;<FFMLOC/=[]?K8Y4.BA!=US-Y#6\/:87MRH*4'(TS
M6SD4I"@H^2-:DEN)+7-2=$NHK4TJ/E9_&OI4AU:5(0TI, H0<R4G*)OF5?>H
M9I"I%M!N6S*$D**@9(4H02),6 %N%KB#?7$G?7,[1B<QB-L8VXTL9X.O3X;"
M,^FWGWX88SBV?ZD=,P"NO/F22(1RZ]!'TSVO8-Z5V;Q4*CL_1M'G?)W;^D])
M1_XUD\:9$_Q7@/</=C(A^$[>70?3;&9D1XYLWOP^R9M?=X^/80<==Q*FE@0O
M=?\ P9..?^G'</JXX';\=33Q^U5;3^IP@&V@QV?HS^OJO^$W_G.(3U6__?\
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MVVW8MNLMQJ*G6JIU1H*"E"87U4"U[^;Z!&HAK!X644J70&TI+2X'4@8J VH
M'C574/.)"%N+4@!, F0<HA,\<HL)F!IC (0DE02 3-P.,$^<">.)+XTN?IC/
M!PY[\,&?K_R^C?B6^(CCQY\\,*!F<8G8<B.W8.7?;?BX8?I^.W3Z.&&$/88]
M/(=M]N7?AA@VY]1&<X#\!_'/##!S^SXR/KPPPQQ^.T\OAPY\K?'#&V=F#_\
M95BYB+>2&!ZSR\^^V!#,CRC7ZI'^$8X6H_7.?XC\!_+Y<<GY1SV@=X@,B/(
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M;R2EM2@%N(6@D))2)7"I$T-NA!!1F.7* 2FQ+KA*A*@"4H4%02 ; &9BY$Z
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MP 4@ 4AG ! "/+=    6 T TC&R))))N23)WSSP^&.>-H#ON(A&XA Y#G_D
M<7$YYY^6 >0<IYX"9YQ&8B>@3L/##=V?/GRGM..7>9FJ0R.TY#;KVWC<8#AB
MQ,Z?7N'/#6!CJ)_T)0X""RXC<1]FG>0 -_H =]^,EGVE'_>)]YQBG[*3Q ^
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M_1I,'A]K=[N[#^D[O]D;_BJ_T8/S7($,K# _]U3Z_P"URR.!D<;;"_,#1_\
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M /B5VT]A-^S[7=Y@X?TF=_LC?\57^C"_-<J0#Y69ZET;1O(UAGU_R#8#9_\
MB5?N)UO_ +UXBVG'=A_2=[^R-_Q5#_\ ##"UR?WLP.0?R5/ICVI"9",9#RCA
M^8&QK4K&[]6F#:=<WAX>&'])W?[(W_%5_HPOS8*_>S.X>ZIQ_P#-P.P6P)]9
M7?09$GPG-<WW",/Z3N_V1O\ BJ_TX?YL%?O9@9_94Q'G[8_0'D/%_H^W_:5_
MPT_ZL/Z3N_V1O^*K_3@_-<J<*S(Q/\E1\?Z0=.>P!Q!L%LS_ .)78Q^K3/>1
MGMOUW"</Z3.S I&_XJO]& +7) /ZX8'0!*IYB./Z>( .@!Y</S C^TJ_<&O#
M7DVP_I.[_9&_XJO]&#\V"OWLSE_Q5//_ -O_ #[;P_,#>OK*X$_[-%SI]_YC
MXP_I.[_9&YW?I%?Z<'YL$_O9G_PZ?\7W=NG#\P-"9J5ZR?T8,;_O=T>Z^'])
MW?[(W_%5_IP?FN3(?SPW?$%4Y"?_ $Y]('@-@-FXJ5QQZM/N&;OX;O!_2=W^
MR-_Q5?Z< VN2(C_.S>8A_)TCWD8K$!'T$)Z</S WIZPN-QZM,:"(]H3OTG3#
M^D[O]D;_ (JO].%^;!0?\K,'D/\ )4#_ /F@?OX'8#<7J5CL+:1_^<;N,'0X
M?TG=_LC?\57^G#_-<G][,Y8$JGZ/UO7,=IX?F!O^TKW?[,#7_FYTUP_I.[_9
M&_XJO]',8 M<H8_GAD_[JGZ/UQ^&_GQ?S W_ &E8X#JT_P"JYXQIA_2=W^R-
M_P 5?^C -L$_O9G_ ,.@?_S!]W2>,3L%L6]97?2&T\8WK&_OT.'])W?[(W_%
M5_IP?FN3D?E9F!C_ $5.=X_VMOJXOY@;C_U*]\#JTWC_ )M_#7LL</Z3N_V1
MO^*K_3@"V"9"51HAC %T (XV 9$ '/08XHV T3>I68.F1(]^8P? D<,0])WH
MM2- [B7%$>643YC&0I4I*(FD@D/9HH$1$1@:ZZQF:ZA@)$8">0! !@  .8IZ
M=NF;#+:80F;DRI1)DJ)C4F^HC< ( X"JJG:QY3[Q!6J! LE*1HE(O"1NN3,D
MDDG%0 ;YV",?3,P/;S@)#'&ON-B+6(N>.IN;VC7CK;;\\\_*93TLCYP=8_<B
M)\_?C_#OOQP&W_U3%_\ :*M-_LGM.Z-?=ICM'1F.NJ8_9(GOSGMQG*Z?EBF/
M^F,\HQ("(C]D!MGCBV?U2.X<.[=Q/>?ERU1^N=[51\..*/;</CGKO@>81&!^
MD>-7&CY<_#F<,=Y$! ><[0.)@(&<AMSG;AAA1M_E'7:-H$!'$[SV8;N?'XCG
M1_JSSP.)B(GR'$SZ=\<+\C\<7CR/G._ZG!U&=QCG'60WVC$;8X8AWQI//;A2
M$ $3@?/G(>7PP(CN,@PX6^-^>S#^W?8(C ],Q(P/(<SOPQ8T[1Y?CV=L:X0A
M QD(R,9' 3/*>VT!W$>'OXXG/-_IAA(S !D1B0V"0 (C80G(]N'RYY_EAS?D
MX?7;8-PQD0WQCKG,#B($. YGGZXI[N'P^=S?=$1&./P 9&>D8$,#RZ8^GASS
M_.^[$Y\\,=\S&W7$@/,9'&\AB0QL' SNCQP^';NY[!CSS<_%W?-I+F"^[I;+
M!4:*79K!KQIDW)&HI]2:C-+%H<SZMN;EJ$:O5/2VWKA:5->CCZ<M0$--O4M[
M0[-CD6ZJQ)J(6[Q-.E8*$E?6I;:<),9"72T B(S!0ZT;S)!$8QS01,1)';:;
MZZ3J0;"^^!E+?XRF]J:7UMN&QKX>KSL9-HVR/S<WMUH6\_7=>>K*BQ&AHHM6
MPG*^UKRD9%CU>9A1;RJ7*K63FVW=2 NZ%]3+2J78FFDI(6@)672#*E!*6\Y5
MF6$!)(" 2![1S).43:YA!["!I!DV&NDS_/&2.GC(LFWFY6LN.T[N95+:[ZK-
M+HVU&VVX'H:M%],Z=1;_ %U*EM?52)6WM*NNBPJ5*)0H Z\C2DH #<;0X58B
MF62 %),AL@^T)ZQS(@73()'MF19/;;#-K(-IG307MPG=OOIKC&?_ "O[B>KJ
MT_LJV=#KQ177<FJ;+9=S6_=SM9"-Q8+7=-)G75ZNXPJ:[R6H:%Q-O-X%*&E2
MK!>V+@^1+D'RMQ925V7JP"5K4ZDI2V5I*0KVE!T-1=(,9CJ 9'8%$3,9 "9T
MF=P-]QF>_P"F.BT/&PQ.AMJIU%G7J_,]T':>.!^H2)IM9@M>W6O7-_NH_2IK
M<6]9?3B].+BDLQL8WJXE3$G<PH8W))=BQ(S$N M*(JE(S$*0"G.,F91)+03U
MAG($@9B0D*BX*03$F@SN)!B\$"\QOW[_ /\ $Z2CI+XG&75A\<6Y)8EYVJTD
M:9L6K[1<MR&VG\W/NGUV.+PAM-Y+1,]R.STS'OZ>WG=V3-=Q-K2O3-R6FM:0
MG4FBEHP<8+8!*TJ)66RE.;V5I *A*DA)RDA)*21)U(O@#)M(M(/9Q_G!Q&+'
MXZ&!_1,E2+1K5DJX;O3Z3.%A6DIIL,M[O!HUC"\3;8=TWLWG6WL:1*WV'<;V
M\T7*M:5*!A3%NPD5$F5TE9FD4DG](WE3U@6N50DM!&8'V9)E:4C*#*K3@%@@
M$"+"QB\R-Y(O$ZGB-8Q8]1O':5;UEW:]VAI)>+LZUV5J@\:2+'==9Q%M:CW-
MIE=EKZ=/#830@NXVX$#23?%X-")*Y+FYNHN5O(5FVZ:J/6,9;I44A*DA3B8S
M-AP#-*$N)4L$DI"9R(-I)2?M  &(56WFQCA8"_=IPD"VXF_NWC?MEJ6WHPJM
M/;^!TTZMJZ5FH+HUH[=?F6RKHM/3RJ_75@<S$-S^Z-I*JJ(M9(YT+*&5SO$[
M\W4+L<82M5I8*51"%9T0M2<@)4%*2M>0* *?^8C4(]HC=BY@)M,:]D GCOB+
M7FUIQ=K0\9%IJ;AJM:]&6XK7;6@V_6!UU<N2BU+9T]=;ETF-M=IO\Y&B_/!U
M?&II(N&YD[.E6KB#6NAY*/8P=E*LLJL^*IU9<R2E1.0AM.8K"7,Q0)R@*.5,
MVN0<P$:7-NF!?NM ._MCSG%R<?&58;?>A[!1:]VN%EH[I368=JVW&VJHL0Y^
M6:)J=>R2VZ;CIN)U0T6&EJ4K71O8CT"%0H1BH/I1G&*DX4RRF92%Y<W5G-FR
MAT,R;90<Y@ F3WVPS#M@6G=)!.[LXZQK&F/4^-MI(96U\==%M5F=/5;.G5]7
M6E6FZ? XV'9&K=P4VSIZ]7$A+O8PXYRN%T(>0IM!CI=+K0)F);6Y-*4]6SI7
M*^JF2 ZV3F6A,9X4MM)4L).31(RRHPDDB";D3,-X.DG2TS$W[--=VN+#7XY"
M+?2OAUYZ87)2O<M4]6K(TFM^UEMNN[S?MN:..1]N7;<-!(7!722>FN9#6V)$
M8@0J>5+];B-G0+##5RHF^JSERN)(#;:W5*! ;4X,R4V3]TS.[*HJ(M+,+V.I
MX&;QWZP-+R-,5C]XW&>USKR656+?]U)V8^^5%-OMK1:; Y6LQ:1:>6#>6IKQ
M<+M<5])6XY*U.-]H[;$#*&M:1=217;9+>MJ+)<U9-*59?;0F<@S$K4"IQ:TM
MI2$H)DA)5O!209O 9OP[(N;S$2;]N)'UE\2K7I4LLA2<VW(XI'BPKIU'6VZT
MVZA<7]X;FUWTYLE@MA$8MN9E^9[J?;XU9M1$SI:D#P4[&IG1N,-;1*!9QIM,
MEP+ND95I1)5 !4%J),)5*4I;43=,"#<8$Z:Z>),CNX[_ #MB-EOC6KI>K7HH
MTNN!CMQ"Y:_5ZS.%R.UH?*-.K8\/9;2WWF_)JV>[%R%[)1/MS, &@T'O!YB8
MIY;4Z*IY3 27F*:ROTB22&>J"0KVU/$E*3*1E)"5:Q>#,'$F_G/9'\QSI>[=
M\:[+=9-J@Q:/ZJK'"]KKKMZU4)Q%HH271N36(OU >+K!X772G9"F&VVU$6UW
M(:#@8>UW(O;V("E*]2!5,-,4YI=;A"95&<D$K" F,LDDF1;[()MBYIL9WQ)%
M]28N=X@]NN.EN\;]M.RYN;T.E&IAQMVL-HW)I?32;8?O]2VK4*Y%MOV&I:$G
MYYBJM^BY4C+<=V%FWD5;Y*&T+?<G9PK(-*^1!32*2"2XW[*E)<^W[!0D*6"<
ML*RE03""HE2@!,S@%"\"Q%I@:FUID$]O:,4KOXJ;U3W?J);KGIFZ6"PVI^@*
MUDUSNBBS;I7-^I^K5QHR'JW7EC9;^((5M[%:MQ6Z^?+F]PIH2HD-R.IQZTD^
MVT#E$L)RH4%A2E=:K*,Z9;:!@A2D&ZE!28.I(%O:(F;6T1'#?V3H!J>P\+]]
M/CCM:M.@.HTIU2--NMJTZN+2]O(+LH]SU+MK4Z\Z;,M=W9D)5X5&,(J#JP?E
M#=>0V\X$6]0I<#4]%:%R3HQI5WAQOV2M+DY@$*;05J!.6%:904R"JV])-S:6
M)X1PF..EY,Z#Q&,TL?Q86W?%TZ<VBELFZV9XU#27DI3@_+[/0)$!]B7===FW
M$W(%GYS&$7FX(G"T'-T4)+'KN$]/:ZALN)106WKJ*Z<54ZD)6K,E01EF HDA
M:4J22 GV)"@)5E&>4S(PS3WG2>_C,:"==+XL57BJ?$.HNIMF*=)WYW3L&K=O
MZ(:7A;SQ:1KKJ1?RC2Q'J_<R2GYTN= A9FZW[(4J[A5.3M6UI$:)C=FXXU1<
M=!3/QD*<%"%=8$RVIU94%0A <ZI)LDDDKA, &Y!TOA.[6"0/CO/ DC3SUOCS
MXNK"9=)].]45+'<PFZGOJNUK6LJH&2FXC;D:?SA%\;5*NEW,MT"&FBUGLRIQ
M1O"Q"YTD(RV0QS4.C<2I@IUEQ;8*3U8S*6)RY3$&XS7S"T2+D@ '"=)WSX1.
MO='A;%L;?&"P.-X6K:=>ENJ346_GZ>M;N]O2"VVM)9=T:D6,\:@M-I7$V*KD
MHN&M^:;<9Q670G:&AR(82ER(]:>6G-J,I&F(2I76-G+G@ JE:6UI05).6,I4
MJ$R1FN ,3-V$7'"Q(F#>;#6T<,1UI'XWE-TV<S'7;I?>5.H=TI=.7FQ;;:"+
M614:@M&MCQJ6JTY%@J67D>2S?(;+TVN"XKB47@M8#/F%E5W$G1TEJR&XK4<I
M<JE0XC(DN!:B5'(6@@+!A(F5N)2G(%"2 3-\ J8D7,:[YG2^Z">X;\7A#X[+
M55-]J+B-)M4CD;TVV4[/"@H;%-)M)GU"UH=-";(6NIY-YF$NE5SW4T*W)H1V
MP8^J5MNDGN1%%=1-9 E4BLRQUC<I4L"<_ME#?6K .2V5)$DY?:MIK$*]E-CH
MF^\3[-S-Y/9Y2<=M_>+ZU$EE)+M46#?%%LW-=X6OI0_5G6=0GU2<$U=R XK&
M%'^= N[0SD-=LN[XG77.W,X.K0"$QJ*6+'!(B-W- VINHRE:2>K/6)&:4?9*
M0HY0DG,0"$DP20<;/:+76TRAH4+2M)-^(5I>,I.HM%M^,)U UUN9JMG09ZL_
M3^Y%K]K%>#*@KL-W0MK;=S:P#9-S7S<!+@0ZOS0TLCFVH;>H1K%KBZU(FTY0
M%1A:HZHA.=S< %5Q $VDR9@'B9[;S!QUQ#:27<RTY6TGV@3!5F"01 )()-H%
MP)XG&(,'B[9[K6V^JM"U[MNH;WM'3ASM"Q4C=;#2^_.EUV4\ZHOI[I<SS>J-
MA2I+?L8VUJW8E46D1I5SLU?-#Q<8W"02W,I!N1:03>(%MUC*C: =^ECC)3&7
M,%*2,JE!2I,0%! @93,F8WV)( 3>D8O%TGNBY&S\T[3>KK9KVL;29UT_M5N*
M9VZ\5MRWS:EXZF7$6^N+Y<#=;+0V6UIVAM->L YP"LE>ZT)R#W"MS0$T@B!?
M4:G="2 G0223-H)\+XI8R@A2@DI4L*.J80I*!$225*S1 \HQ=VSQC6B__F4I
MM^P[\=F6ZW'2UB<'R@;11H[1N'5JE,K8&-W3K;H(<'1:V,JHBX;B,MA&^)&U
MD/3+J%"DLZ*!0;R1,&!Q ,;H-S8 JN;QPQ+)$A2D@I"S !DA$@D0D1<$#-!.
M.FV?%JRJ[4=KM6V[=;Y:=LVXJOR]KX;FNW&=JL^WG]&]WC8K$I95-Y+WNX+B
M46/1;=1M-LDNORPZX&%R.3-53T8U-3+X&8 ,@DVG06$S(C6;6O5,G,$R I2L
MJ4F25*!"2H'*,J2J?M&T*$F)->U^(]\NR\;5LALL)ZLFX UD)T^O5LO$RVW<
MY*T)M&ENL+JH:E%GW0\H/E1+:X62WGG*%50(%K^8F-1G')J@"Y0!,@B)$ R+
MY8N-\$P+D#6(P+(2DJ)"AU>9.7,)/6=6)S '7,=+@ [\=]S>+RR+3N9S;7.V
M+M_-)F==06)PU'(_-RNW*'?2VTEMVWVF3ME3_1=JTAB!'7;AK@EMXQ";=-7S
M,4>)E'O*H!-Y%P+<)TW#743P/AB&%$ R)(00F^:%G*DZ!(G6YTOBA?/$Q=C)
M=UG,CKHQ<]KM"ZQ]2]3;W5W*^6+4Y6U86GZ2UJ3'LM,S7FN(&NMSO!M3JV\T
MPUR#Y(Y$$(JO<BJH  _UA<@"Q&NZ3J#&X=W90T(40L*A2$I@+@J5/LF4@Z).
MG?.+(?XO&EGLQR3O#9<=>H5OV\^&/Y)=N-">I X,^F>GU\4/AUMC>9Q1;:Z.
M>JM@6PULU-U&J%3Z_%(0= ;R%3R4RRJ9  T),W48X;H(/9H(Q0P2H0?8)]F3
MK[2TQ.77V%&<F@)C<>YJ\69K(IO0W5"S'&WK38M0;[L*VKV2J&0Y%<"C2[3Q
MQNB[U"QM3W$X+T2U4\VI=R!H1$D&4UU_-+0)A[D4XFT,N\&20#$$1)@3(OK.
MMI_J@X%B<H0944H4I)U25KR@3 %@4DGO/9B3]0O$"BT_:V$\VP;R?KA=]/KA
MU0<[0;#[51.MJ69:"%F574Y7 N?[B:&,LYH5O[6STH4+FM4N+F?72AI-2)U*
MLE&ID 2 =2"3IN,3?RGC."&LQ/MI2 L(!(5!4HF( !-X)TM%XQB=DZWWM>=\
MZT/)=O W:-Z56\U)VNI2F:"WZ[KK66-;^IBP[YU.NPL6-,GM>[&!*2V.-N$$
M%JCU9K@^IC2*T) B !>5$FVD20!IQM(,D[AKC)3:4I;!/MK))O[*4A9;%@F_
MM)49!TB!&(F8_&)?I-6E2^^=(7IJ07)I18-Z:A-S#7;[@IM-XUCU&MZPM,3Z
M5:J[B_;:UZFNXQ,9$Y#G=*BE/\HJ0(:VY4D.I0(C-)"C TN 3P\9-N),XSZA
M,+"5@D+4E*C(S!""M=@.%@3">VX.-@M*/$=;.L=V/]OVA;-W&LC.C=E26_%"
M)$%I/%;+<%-NGHDJPA><I1KW!1[UR9$;DE3*7)B3FNX%$):DXGXD$ G4S%B)
MB2>!T&L#6W=IK:+8!44DR)2#?VA/C: 8F#(U!Q![9XVSTU@O-[W1I!=?\P2Z
MSWR2V6V[V2H,)T9TAN@^W%E\KE;K=Z%'4J7G E3MK,F4?.5PK*E1S WJ6U.*
ML;D!@2- "=Q40+ 1P@$B,LP8)C&?J\D +2+MI.8*'MN"<M@38228@;R#B5#_
M !/)@=7AH0:5Z@N:A'?Z32E@,(/LM*3>6H]5L);O?+=8:G"ZDM=)%I,=-P*+
MC?W2AO8DQMI7 C2+EBY.0F40IG^L![)4;DPD6$B#!)BT3/GC'J2 "5I!R%:A
M[1*424@J@?UC  %X4"1!QB5N>-BS+K5V,UV_I]J,ZO%ZH[==3V9"DMY<X6PR
MW;<[Q;; \N]*&X%*92VGDLJJYUZYI4."%HM4Q([+E152Q(F/RRF\D2)%Y$P!
M(B\'001K-M<4TY&<E2822D&" 5)@D"P)-\HF"5>R!;&2VCXD7)3X?JM=KZT[
M>V<M:]"1;-J,:ED>7NZVBX[V(MG3JIG+)?3TE3I<)#LQ$&I5S@A"IU,6&)RR
MFXQ$:9"GVLOC)F! F\]UB..XF<8J:'6]6A0( DJ.XA,K!@2<I!B ;>.*0GQ<
M6_6M);%>GE[MR]O(U8<K]I4*;--0:;V]HR\VHUWA<-R/".Z%+:M0>[NU,K:D
M]MJ'MT<1:WI 6@I7M:L@H$F)!$&,O;K"=(L=(T$7Q>I_WT_[.("I47 K*$@@
M'^J9)@21N@XQI^\73R)*!HM71F\?S\<[KT<0-]JW0XV:B.6VEJLJ>UR=^+4-
M]W*4:-Q)MFT+L/K8G-<B<VE<F1*G5(#4)YW$"=/:!'M28),@7U%R;SK: !K@
M&1JIQ.7*X2I(484@"WV;B5)N+$&Q&.[_ ,L>V+J;KC_,=AN^A.6XLELVQ?AE
MO-KY:[I<]R:DL>EK4D)1%W,T'&''/KV#JB;G!>SJ76V&]<]IAH3BB!9<L1,6
M,F^[+,S<FUB8,]TXH84"G,1>5%()"@D(*YNDB(!$B8-B)L)*TD\1S)JY=2NV
MFZRKRM\BJVW"\&!]N"FWZ6RY[:;[R<[)H=T!#4^N;JWI75>VFN#"+V@;:WAG
M&M<CIKH).IH%.4<;WB;0!;?H!I)DVWXQ6T4#,5),*"2!FF2@+@V M,*@G*1V
MB=C.0X#.1QG,C\,2 #'J&>,= .$CA$"P,^1&IFW;C1_#=W^[ZX7WR$<ML_1@
M-Y^G&;P-+&1:)U-P>-H@X8!&1^D0SR]=OJD0XRF8M8Z=XGCNWS$Z:Z!SS'\L
M'/IGX9^SB1H( X@WL<PW1V_,X88Q.P &,9&/6/7F&0WXI .D7,]AXS8BXWQX
MWPPM_J  QO\ 9YCUZB/"=#K,:$=LWUW3VD#MPP;8QMGGOF?AT].( 9D:;[F_
MGK O(@'0:8<^>#\<O,/\QF>7*.*9ONCL!F]B!.MM_AA@^/TAR&.V0'OSR #P
M%_ DB!&ZW#C<;SOC#GSPQ 0#//(;=I[ARZ3UQE<R)O(T$0-#<@P;DZSPB<,+
M8<<AYY^K?TX@@:: [SI<"-=(&_LPYY_# (1Y_C\;2&T<4"";R;3I&Z_>;GY:
M2P#N.>8\@F.O+T#KM'$BXDSJ;@<;\->,'B(PQ*FE@RX.O_@R<\_]./XS/;C@
M=O?J&/\ B'A]TVMVS)WDGN'9^C/Z^J_X3?\ G.,Y7_UM1.P&5<^<! B'F,=?
M0..+9CJD=P'T'X?&9/+U'ZYS_$=/#7X<WHXSM&=A'?;&WT#O(8'GJXT</U@=
MP >0[R(]<#$\AWX8O9S-I.FA]WQ43(!UQD8F>LQL(!(AGSW8'APG?R+]UX&&
M&>O(,<L;ASD1 9CE.\SP^&&[\?EY7[([F$Q$9[\LB&P9"!YP.=X@!X8=GG.X
MR?+Q^F">HYWD.0R 8#:-YB?:B>)/#X]D]O-^]QGX[_(R.9TE0([2,3B<;Q'*
M $.4!@,=KA$Z3SQ-HM\/)1VY\Q !@.G3F [@$=L,(W?3=\NW3RPY@?7&1C<=
MHY0.,#Y0/#"W=/;,:\+V^6^<$R.)  B,@ 8C',!'<0D>&&OAIV7]^O?Y8)';
M?88WQB-_.!  #X<.>?+">>.ECY;HP0(Y&0Q$!/PS@ SY<N&&L=MN>_&MC=X0
M_#VVMS^TEV*K<6ZXK<O&T%B:XKZU"NJANMG4(5=5\L]JU7-=;N99*2[ 6JJ7
MVFS*V$QP+K I15644471K&H>)!S@0I"O90A,J1]@JRI&?+NS3&)E!F-""(DZ
M1>)-A;='<) QE!?AXTEINY3?)]MN+E=*JX&VY0='J\KX?A0.30].-P-I+(B>
MKD7MMOL:1]=%CN7:[$D;K8%P^2*ZVBHYN;ZTN(><RA 4 D)*8"4 D$ ',<N8
MJR@#,3FB1-SA G30CB8()C6T]T []^(VU!\&6C5[D7RI0M*NWKFU"3W(U7!<
M0/MX/19;#J#<C"^ZJ-+';R^ZJ&&V0U%)912/*NW4;490M6&O(%GK /H5:B*E
MU!1>4ME)2G*@>TA)#9*@G,K(3("B= +#$RC=O)F)[)M:,W$7WZXSIK\,NBS,
M+*<W6R[)W!BNAWO-(^C?NHA]SK+C?F$BUW9Q?[J578;<EUTJ[=2(62I#=#J[
MMQ3:VM:9,D)+:T )L"^Z9!((4D((*&\H2E68 )"<J?:)5* +E4FYD )^<GLG
M4WL-#X7Q4-OAQT>86E"TV]9+:W)FARMU\92%"Q^=$"%XL[2]-HW:2@]&J>H7
MH6/3U"D8R&=0=2W&&%UO1A7YR'&O0B^X3*EW(*3&4$A3A=4 8L2LDR!.[[(C
M"!NB]K]T7G='UUOB$--?!@GTXTZUMM-MOPE-<^L=BHM."+G9V&Z/FVQ;78K5
M>K9M9$P,U\ZF:@W(<4P!<+LM3)55^@WD^VB;VE$T-Z @D=5=3G6THH]EM97E
M)3*U%04K,4-H3?*!.28U),G ) !&\[YMW03-N_L TB9+"\,>B^F]5M*K:M11
M\Z6DXHG9E>W>Z;QN)V3+VZRGG3UN 5UQ7 ZJ3&IJM"X7UF8K<--,MVW2'16:
MQ-3>I,!0&DMYU<@J "A"DA*$I(*@LV2D7*D@E7VB0,Q(MB@ 1;B1<\")/<-V
MD#3?BV4^$?P_ @N5M"Q5/R2Z:#"UA7YZZ@#6S$GWFBU%/2V,?5=/RC39&IOI
ML:KK/1:=FVNC/?&EH7'$5FM;>*>^L/2DYKI_W47.4HE8RPX<I*05YB 2!8G$
MRIX:C=/&8OIQM:?=?:O#?I!4;>55=OOE:34&@VB\F6O4#46NV7PY14UU+7 ^
MU!NS\VB'ETK9D-3R^HFI*\O=5*NIU7+*G%Q%7.O<]GV@"C[)R(S#6 %9<Q D
MY1)"=P&&47L>T$G4=D\=3KC*K<TATZM)V;'VW[:)0.[01?9#:L^7NRFM,7J=
M=**];ZK]A:X*2CE%PW,W(G)0K4%&J4WN 1(#DK=48DKQ4XM0(4J0<LV$_HTE
M"(@3"4DB!K,W.+ $:;](WF2=;$G6P]YQ#K1X0-)A<-0'R]T*^_;@U'?M4W-Z
M6KWZ\&YJ1MVJ*1PMA>B8K93W4<P6^^(]-U*73LV^&!&U78X,28\NER0IUQJ$
MO4-2Y"$I(2EL-@ )222B%23EE22N5Y%2D'<3<P) DQ,W)$@7L#PG<3J8UQ)+
M_H!I'=%ZMFH+W:-*JY6E+:J0@PM]N1"QK";&=%[Y9'S]9Z!Y2VA<Q]GO3FM=
M[65W&QNJFWG$[Y8TGHU!))A>"77$I*$JA)S'0$@K "H405)S 0H)(D6-L6)O
M\/.XL.T<+D:'%A_\F#1:DYK4IK=N!L5LEQ7E=#.O9M2=36-Q;''4)S2O=ZHD
M#BSWBB7)K7N1Y0I'5RLHD^FSC'!.4LI8J%%/O.,NO=O[0.9*4F4(((0(23*2
M,R08"OMQ(G$R@1 T)(\3)\YTTQ<7'PXZ+NJ:YT;C9)2E/>;/J.PW,76^W/3\
M[-.KEP-MT:C(SC"WJ@PFBZGMH;5*TQ)60<00B3MR Q&V%@D&!]T%,+C*I"DV
M%BVDI01;^J"8F=\B;X0. [>V=?./IC*+ITET]O5\1W)=%N%.STAHM<M(M.<7
M=.*<JS+X9]2;<++)2."9+[*"]F!C?S*1($' ]K0IG/Y8@(H2!BEQ:1E28!S2
M(%\R"A1N#JDE.M@3!G%(XSNX[B"/@/"VEL8@O\,^B+I4 KK)I445I]6T2M-7
M<%UTH75%KH[G/^JR!^;Z'VA%<"&[GQ28ZGHGM.X)6Q=2G4,1+88E2B3EU[HT
M7?\ 1D63(ZD96\IB1E$"Q$BRIP@6UW]UXMV]W=B^6WH?IO:JBW5C:V/JY7:3
M?=#3;RVZK[OV]US8V7G0Q%7&A+6WI<[^K.3KB;:9222U1QP-Q"4TEK!&4M<*
M%44ZM6:2 %$%65"$ E,P2$)2)]HWCOT&  $&)CCV[@9YON!Q'37X-O#FRMQK
M:TV.[-]%=-BEI7%-J-JB7<3.FTT"XR["16W=5-Z!<MJMMJI;ON5L:FRVG=J0
M$M#PL9JDU;572BIS-2\3)6/ZY(R-Y25QG*DY<JBK*"2H$R)F;XF4>^0).[3A
MNX<(B(QF9?AVT?H>%C[5:RI2O7N]HW O+7W9>2]K7/UBVH59%L/:MB77$>R*
M79#:R9&T*W(YOK6/)3<U*'LUQ6-+:H2X]<[ &:P"DB$I!"5JSJ 4!F@J),3
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MVEQF-HURCL$0(Q(0 (<@&=I["'T\HWX"">R (U$@Z21X#>=8T.,/*_NP;0.
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MWW.6Q)'8>'B1/8,3Y>[#P.^,\LAGUQMRD.V,K&QCA%AVB;GANUX1AB4]+/\
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MTYZ_'F.8Q/PPP^7?Y>[#C.1B)W$<QRF Y0 AOVY<,(^?N[X_##D=A">L ("
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M1#GMD1F('X["$;(@DG?&ND6WG0CA/<-"'/R]V#O@0GM@<Q(1MV@ 'AI.EI)
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MSG(0 ;S <,3GGGSP@@/(9 !C(8#/+J$?$(YL46UD>'C/PTW<-YR@?3GN&8V
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M&>.\:1?L\3&IMV2+9IWG7X%AB.\8VC;ESWP/,8#?$AS6TM!M![.%X[+#773
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MI8,N#KL'\S)P'^^^'^<\<#MZ S3C?UBO ! MJ>?,]GZ,_KZK_A-_YSC.E_\
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M6U %0A2 1[23(OIF$2F;@!0!.['W^>-C%@>_=%NW\8Q(8X#,  9',<LC(_\
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M>'PPAQ <LC$ST#(]<".V!QG( Q3;=%YCLW7[+C2V_@' 8CE$CN/GUQN/,1W
M B&!C=NY]W,"  !$0Y3.X\PR @.\B$[;QL'##XWO//;WSCK)&"2H_9T1W$*
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MMTK)=#G-H.:Z_CGIJZ%[1Z6]&Z=>R6U5&T=C53E8W1I/MU=.XT6ZEID&RJ@
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M+(44&IR_<?H]]).P/2+LM59LAQ5-6TX0G:6R:E:/7:%Q9LKV2!44CAS!BK0
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M(N)M76J@<2$;<9>3:S/+$I7.K8D;C&Q^4F)6Y:O<SU="!H3U&$&U*C'10D!
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MJ=J'MB5^VZENGH6E!MJCVI6;);IJ9;E8V'GGZBE2O,]ZNVEMS*GK'<K:M?\
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MGB,(>_E$Y".6X],8$,^7#MX\WQ,&?^U@,YS(YZ;8GGCZ&+>;S\X_EA@$=AP
MR//V@VCI&T@.?46 \HO[]W$]EL S@1Q'J.! !W&=QVY>HCPPOK[YO:/'\,(0
MR$8VVG<1&(\^6P!L(@/#"+[OK_/MB-\8-ISM ?>,A B "&-^6.&)C@2(B03
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M3KR+@I,@*2I)U2I)D$2 ;B00"(,''?ZNDIZUKJ:A&=$A0N0I*A,*2H001)'
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M2I5:EN/4EEF&'EJ#2"## KHI TP**:30JJ^2?E75&SC5=$*-/5G:S+&TWWX
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MIJ-VX<>S2<_/ ,1,^DY]<>LCRQW 2!''?<[O?NU@S888E/2P?Y^ZA_YF3_\
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M'<8WB1'<1])V'/#$,;O?@S 9',P/>._01$)' #D.?#W<\^6 Y_'2,<"LE%"
MA %ES.X?J!,C&^( =]H@! .*K4]Y^.(G[*=\H2>.X:R!\-_;CLD P.0D0'/<
M,XSR^SD(C,9&WPO&[GY7QUF5TET&&5C!9=%1E0CF*:?UA'?D 2.\>8<4 J(
M$DD #MF![],0J"0I1L "9X 7/NGCB"%!U2@\\\P?USS33JYSDROVACO(B'IR
M'CM3:0A*4"/90E.DF$0GB1H +7F]HQTIQ1<6MPFZU*6;_>,_/37'1M,1Z@$]
M>_\ G]64@$6!-AXZC6XN;V.NLB,8<\CF<//;N =/3$!OCS&8P,C4B?,Q&E@.
M!F1 D'48MY]W9 [MV\GQP<\=,8Y<IV =I$1QC,Q'%C72)\XG6Q[-9TFQQ.>&
M(@UQT?8];M/G2RW@:4JFJ%S \ 6)AK*]IRS 2K:*1S608!AB5<0 T^_1GGT4
MC29[LPO<4U0JE=2ZC312;@+03)$<1J#$@B\ XS;64*"AX]HYYB<?.4_LCA;+
MZ\VZZT4DN;$Z.#0O+H'VJ:%C<J-2*0HJQ[5('%5 %7^U3%4!,<=P0M*TI6DR
ME:0H=Q$C'(@@C,F;\;:B?,Z=A-Q8#%J^@!Y?'X\P^OC+%CL,"-^O=>WR'$FR
MB(YA.<YR$]X^$;ATA'/Q\]_UP@'C$1VR3I/9IPN9.N#I].!"._Q'81X<\\>^
MV$"+6B)XVF;C?H=XD#<</GG(B/H$\]^4Y\MN7#3X_P K7^.(3.^(F)B-.PWL
M0="03PQ!NK.MB+31?;]LM["ONV]KL.*3V_;J*ND@#JU*NAO25*50EG5EBI6F
M 0E)(3GG**RS0J$BD ,'9U56&"E 25N+ RID 020)/:1! \#OQKM,ER5%02E
M-RJ\<3 DB(UF-)&/H.\)G@R06':3;=>MS5;ETZDO[(EK<[;K;"G.U;-K6>[5
MG-B(MVH5U.3NE#V$*UZ,I)HJJ*/+0)4Y!YM1W UM>Y4I"("4))*B@G](I,Q<
MDD( F-ZB9,>R,<:\_F5#14E T,PI7$F(@'<(MOOC<$=%](/_ .EFGG</S,M[
MZ9;N?XB0XX\YN*AOB29]K7??N!(&NL'1ZQ?WU?O'LU^7"-V%^A?1_GI9IYR_
M_@RW<[__ -NZ[><QRX3[7VE>9BW'7>#J=Q\;UCE_;7)[29GLGN%M!CY M3])
MKM\,NJ;YI=<C866Y60L/2,2AZ:D+DV73:=(G)+;NU&C<DRMK<6Y\::25?L^Z
M4TM3J"QH5"2\-"LE/^>7I$Z+;3Z(=*]I(J:=1I*NMJJW9=8ZPV]35=-4NN.I
M$K0XPM]@++3[2AG;<2',@0MI1_I'_)P]+'13TT^B/HR_LO:3:-L;+V'LK8W2
MG8U'7O46U=C[5V92T],\8IWF:YFBK%L"HH:IM?55%,Z6>N4XW4-HE[P7:*W1
MKOXBK#1-""L66U;J8;[O9W)2UD-K&QL+P0\^Q76CI)3HECRI0@U,*2@2_>*S
M1-*(K0MZX2.S^A;HAM';W2Z@VXJF<;V1L.I-=45906F7*MM*E4M)3J24)4X'
MRV\M")0VRV4N !QM*OF'Y<7ICZ-^C[T-=(N@Z=HL5'3'IWLS^C^S-CAY%37,
M;)JUH;VKM:O;<#SC=,*!%12L//E+U16U#:V%+4R^XU]=?Q !_':<AQ[FMI.D
M'M,<?*"9[#&_\ \&!P&/HSD><^6^<"/$.X2+1.X"9B1KX2-V+',B+=NGOP;;
MP.\\^FT0'P'X<6TVC0?N]AM&[?V@3K,'TAUZ  Q&\>G<,YX1<=A,:\ (,\;W
MB_&3>R>)CY#3&I?C5\-U?BBT+=; ;%J-KO%G>&Z]+ <7(3:6LBZV4A>BI1N=
M1!9QI*!]8G=\MQ0N+3*S&JEX^=R4:T] 6E.ZITUZ+L=,NC>T-@ON"G55-H72
MU&0K]6K*=8=IW2F4J4D.("'4I4%*94X@&Y./KWH)]+.T/0GZ3NCOI!HJ4[0:
MV8X_2[5V8'0R=I;&V@RJDVC2(<*5H0^6'.NI7'$*0W5LL.*!RX^9AX\)/B>8
M;AKM=ST#U4!VH.,)]ILL]VN%G,$L:?Y4BY;<3NUMJ2#*:Z#"S4[L;34 U4#[
M)Q1Q1?BRI]#7I$IZTT2=@+J@5%**REJJ-=$XD$?I.O<?;ZI)!!"7T,ND2 W(
M(Q^YVR?RU_R;-J;!3MUSTC4FRX:0NHV/M39NUV=N4[JTJ5ZL=GLT-0JJ<24E
M*G*!=72@E)+X2M)/H?IJ^6;^2:T:N'6?Q#D4N6NNK1"5CL'1!D>D%=Q&LC4I
M%6?2O7$_.+>U$5K3BEEQOM!;@@:TZ1J;4WS@]JA;:_5WHH]'[G078;S-8ZT_
MM?:;Z*K:"F94RP&T9&*1I:@DK# +BENY4]8ZZN 4);./R1_*T_*!:_*(Z?4+
M_1ZFJ:'H5T3HW]G;!-:A+=97.53P>K]KU3*2HL+K2W3M4U(7%%FGIFU.%#KC
MX%O=?$M9?BP>'+5VQ5RHYA<JD3<0SN=%!#S;%2!O2T',;NBH-.I2K23JC5%0
ME&FI%E*D%R$\](H*.J\3^GU.V?\ VG;?<VO3OT[:_5D[)ZT'JG=E,T[;5.[3
M+E25-..)><6$GV'UO(6E*PI(]??DT-;$I_1!T9IMC5%/4/-BL7MPLJ'6M;:J
M*IUZJ9JD66AUME=.VT5)&>E;86@J0I*E4?U<OJ_'E''QG'WO!OOGU'K,^<^G
M4!GAAA#CZ)CT$0Y_CIPPQRVQN,^><QB #,AY" XY<,,*1B/H .P>4R(9^.1X
M88 S@)'RZ>7KU^OAACU<\$EL&M&F+K<"@H2Z[JN$XU-4(" FMS.32@),"?\
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M'8$;#S@ #S@9D/J&8QO'&.+'?/#C//PUW6&YE/R5F6" @%9X FH'$#[X0IK
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MIY]944H3HAEM,-,M)A+32$-I 2D#%YC;G,\^0=^N!ZAMQR(M!B).FX38:Z0
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ME2)"@0I*P2DI(,A0-E!0(!!&^-!CS@U#\"U\L3^HNVU$%OWVUNAJU:X6@TT
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M[AY\.>1SVQAY3Y:CL(%N[77@29B R 8Y[2'8 C?;OV%S\\3 &.6!#/, QY#
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MIDI;>$.,..  E3;;Z&UK N4I,7C'S2GNU[Z747SIQ<+2XV:[7.@;6.Z+=NA
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MY.0G<"D:AA0+ZBE]2)A%$M]HU\HSR#02+'46L8C=X_+&J:1!(AQ28#I62G,
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MAU#'[%K^&CZ8/FYO_<4?]V(_P<.O?_;._P 1?UPZAC]BU_#1],'S<W_N*/\
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*E*4I)' P!C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g451428g37a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g37a02.jpg
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M*#YRG;%7((&6#,C[C,OV#,U!0* % "@!0 H 4 * % "@!0 H 4 * % "@!0
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MK4FU\0FC.^G&?.+WCDOB2_#"X&^$_2/Y$#4%%^>KVE>\Q8=01"@!0 H 4 *
M% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
M 4 * % %//F[X\YSZ6X1Z#V=NO7=II..7>;.F-H:+-WE<VCWZ#SE+5CPU@<L
M.BLD!B9)Z)*'1QS[NEK$\)O[N]3=A=!V^2<A-M1DHL'C)D1].99&>/$E^&%P
M-\)^D?R(&H*+\]7M*]YBPZ@B% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
M * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * *8_.9S/)MZ<-;QGH+I
M/?.CF&@>=>F)](()J*7+QR';Z'IZO7*7@>Y1B.>.$FARB49<C,QBULL+CY*?
M1^KZGF7UA-L\*3R(\J(N?=SZESZB1WB2_#"X&^$_2/Y$#4%%^>KVE>\Q8=01
M"@!0 H 4 * ,/RK>,#A&PV6NI6]4 N7.M91M5S*2RXH=#1$8B)^-1TI[X,/B
M;=9B\R>RE@LV])CFPNU1=YN'[=7!!%Q\&;J2LKK9JIG.'%6Y43;M4U]3#->Q
M#@2H<1[M$AUY"FW#<G-&C+1M&A*S4ZE1)2K+ZK1%[=Z>>U#5,)GMM:DJ]+-U
M<1$J3<R[.V@6=C%['#8C.(?9)FKD(<P^3Y.K:2VPX@UK;\,>Z,T!+3(F.1;=
MFJI$?//R8L(%"3V,$RI8B&3LL39#V#,FLY=N6:-[+JI()9Y70O9?"V:5[9U&
M+JS2\Z0Q$A:BI)<J4Z\S&CQK.&\\^['+>>;:;;>4M:VT_"-*2,S3\(LIYB=A
MLZU]4PI=C::*U575\!B-)FS9U#9Q8L2/,5N17I#[T9#;3;RR-M*UJ21.?W:C
M)?P0&=&: -IGE0^[-5$T8L.8&)(LPGT7=(@111RV9#R1=9$GFFP8NWCQFU2=
M.<DT;N7C1"^=E7*&*AG5FEY)2CCZBI'DPF6I$Q35G#6F*P^M#;+SYI>,FFW%
MN-H2M9DG><;29D:TD:3L[U]#5 3+T5JJ,NTDR(=:A^AM&ESY45MQZ1&B(7%)
M4A]IEEYU331*7PV7ED1I:<-/D:=#:&?%(F$9;EU@Z,3MNW=PL8A.(XJ^E+9V
MZ<,F2X)M@1NJ23?O6CMF/R:XJ6?NFKENT]<L@KAA5&JM,NO08S>H*9<BS2E=
M>RFRB&[-0M:VVU1D$[O/$ZXVMMHT$?%6A:&]Y25$47=GVNV(MM->T;J=J'1.
M.-74IRCLDL5;C+;;SZ)[IQB1%4PR\T]()TT\!IUMQ[<0M)G]7/=6GDQ+,\IM
M+7R80C&"4T8%\Y>!P&O(@&?,19:3-GN3^S98$-)DQPYZ434R9MG[YHS56Q<+
MI)Y7SU#0I8;E*NJHHSL-ZQ:D'/BDRY CN-LOS$.<7<5&9>>::<>(S;0ZXAM2
MB6HB/R%HS5ZI;T!.E]0*G1[.-2OQ$U$]4EFWF,/RHE8ZR3!N(G28T63(9BJ2
M3SC##KR$&VA2B^$0Z1Y]$@@LH*[MU4-CLC2(K 33^>1EH-,)AR3$.8N-=."2
M:3O(05),1Q;!'+/,:\=)-WN*"E[XV\KVKM+1XT>:_J.D9B2TO*BR';.&AF04
M=YJ/(-E:GB2YV=]YII\DF9LN+2EPDF/?'V<[0)<^;5Q=%:JDV-<J,B?"CT-F
M])AJF1GYD,I+3<92V2F18S\B(I9$F2RTIQ@UI(C/WD-_:-= 9+*&NX-:.HW#
M2J(.5G6TUCK@3'S3E3!%H)*OD2&;9F1>+YXMV3-53%P\<W]G;)JK6OA:ZC5&
MFW(TR:W?4[D2O?3&G246,1;$60M1)0P^XETT-NN*,D-MJ,E.+^"@E*Y"PYH+
M6[4^MJW=(:D:LKF*N=50':6P;EV$)M*ENRXC"XZ7'H[+:5.//(2;;+9<1U2$
M84/7)=$Z##IQQ8KNG5@Y*8,Q9"*J/9Y&&V$C'FGCP>*?A<E2>%B3)^^'OV;=
MVTNJWS<LG:/K+*-U<<(/:KTQ'3$4_J*D93/;9=@F[9PD%+:D..-,.QS4\7&;
M=<:=;0M&\DUMN)SE"B*Y&V>:]F*L41-%ZIDKIWI4>U2S0V;BJZ1"99D2V)I(
MC&<9]AB1'=<9=W7";?97NFEQ!J\NN=\:JVO)-BQ""2\4=DFJY*O%9D(;.VN;
MY@0;(-<U723?!?-9P)Q=N%P]BF.&+6YL49%>G[6,=)X2J=34EY,MH%9/8DS*
M28J#81T.-FXTZA*#4XE"5J4MC?6J/QB+<[2Q(8SQ&5I*&HM"ZITI7:=M[VHE
M0:[5-8W:T\MQETF'X[BW4I:6XIM*&Y9M(;F'%-1NE"E0Y6[P9+2E<7C/46F"
MP2#/I-L" P&0S]D(> X9(-D:^>FW%CY(L)!XLG$>DI<.:3+O@A)L/=A")!FY
M=-7#/!?VQ!9NGXH>L]//QJUV9:U=9*M&H[D:OE6]4Y)44IY]B,3:HLQ]B03[
MD=Y#3D=UUM:T+;)7$2I)?4L]F&LHDZ\8K:"_OJ^@?F,SKFOTYJ!F"WY/C1)<
MY3Z+"MARX2HC$V,[(:FQX[S;3K;QHX*T.*]O;>_&.JI=KV!M]=;$V3+MECYJ
M5 !M?IPBRB ^ XQO(\Y)NYS-X2P0M:TI&W9IMG3M9?T'7I)I>J3]=<O-3M4D
M^JJTU5M;S[AJQ?BQZM-=E+564,Y2WG+*QKFD>FL\,D+<4K#F23A.]9TGH-_5
M53J&]7J'3NFZG33]+%L)FH%W>XM^^.R* W&:HZ2[?69G5R>,IQIE#>6L*5O*
MW/BS/JC6$3V#"M6-S :0["E)YV#,PP7*XQ^DT&NVU_)I]@\E0O(IE=@W6;1R
MPRZJZZ+1!R48N5GF+11-17S6&M::#:5U*B1'E6LV4Y&D5[,Z%VRMW*J;:DY-
M9-X^$E2(?!-2EI;2X\TM3A-F2C]M-LMU/;:?NM4N0YM?I^K@-3H=S*JK3R9>
M<2_K*!3-5***12'$.V1R=Q"%NN-Q7VD,F\E248X>]]Z#8"G*3J3QIK/VT"@<
MZMKI]L?5HUX_QV"TL1$Q\/,2,T:P N::B\D"[[%E)5&>(@@&(-W*Z)D=Z_Y+
MFU#2[3"TKFPT6J*RLL_)+MO2LN.E:MD\Q%CV#M@BKD2$,FE]PFYAM\!V.ZE:
MDR&=[(F=@NO7Y3:VJRR=H'+Z^HSU$QIS5$EE@]/O=GEV$RGCTSM_$A.RB7$8
M-^M2Z<N/,CN-MKAR.'(UONW3CN8N->-=J:\<3QGB8S=PY&8 %),TM'[+9G+.
M0N+^Y!OF)3;N5B&"R&&;5!JZ76QP1:N,T\M1J/3[E@NJ1=U2K-LI!N5Z;"*<
MQ!1=XY._&)WBI-@D+4Z2D$:$H6I1$E"S+7;FB=8LT[>H7=+:A;HGCADU<+IY
MZ:UWR@:$P3:FFP4=Q,M3C:(ZD.&EU;K2$&:W6TJ]J [@U3M3,NGK38\(GRD?
M]AN<3A\G#R%01B4LZN+S(X"W;K)FD3Q8O%!RJ]L$WR3995KDJFGEE:=7?TEV
M<@J>WK;0XO"[24"9'EFP3Y+-@W28<6;9/$VX;2E8)PD*-!J(C,6K[2&JM+)A
MJU+IR[H$V''["JWK)E>F6<7A%*3'.4RT3RHQOLID)0:E,*=0ETD*41#(U?6&
M.A0 H 4 * % "@!0 H 4 * % "@!0 H 4 4Q^<R+]AG^&MXD.:=G:G@>L8]S
MKTP0ZB ;$C+X[(]@:OMK!956/ZV?M!1!$!),@K68M<2#QP.1L[*"5?:+8M5,
MT@FWN[Q9(\[R<8[CSW^H2.\27X87 WPGZ1_(@:@HOSU>TKWF+#J"(4 * % "
M@!0!#/I3EHMO<W(2P^7#H]@;YTV3I!-%X+<OLD"$ZE$*D+8_GF@Z0MFS'IQ5
M9LNRQQQ76S>)*)K88I9XY:^UAHI_4\B4\U/:B%(TG<:<)+C"W32[9S:V6B49
MI<1EMHH*D*;Y*4;B3)1$1D>Y-F^U&)H6'7Q9%1(L3A;1--ZV4MF4VP3D>CJ[
MNO=@));3AD](5:H=;>,S0A+*TJ09J(R^8_Y!NML0O.!YR/#4G_1^FMX-63>/
M>I79!M6:M9:^7BN#A!9/'%8F[2?DVCE/#!JS0?KHYME55EL\[+N@C5;2+)F5
M%92[J[3^I$-IB;JVX])2M5:H)*2HBWGEI<>0LB)MM+JDFA1FHS]$?:YP].Q*
M21!L)*V-G.L=$.O.6&^V]-U3JA_4"+4VUH49HC-+CQG6U&;KSD="R=2E"$IB
M9K#@W:\RTH$#[+/1&%$&FE#>JXY&&D,<HEQB,IV_'ME'G.Q7R<B?LI"Y1M%$
M& I$4BQ:K6+N";Y--Y95-?"*?9G=V&GH[%O*@U[J-.R:2)"1 6E]I,Z^B7$E
M=LX4MUJ4M/84-,)80VE1/K>=(G-XE;9U/MWTI3ZTFS--0+>ZCNZU@ZIL;-VY
M;7#DKJ](V&FX#>G6%5L=^O;7Y56_*7+<?=0<1N,PI3)H4W*/87(<DEFQYR2"
MS&)!=:;4F>B)S-!2\2>K3<&^T.N#6$!X&<9FF8@:,D5HX.Q=+OQ2ZX11\>68
MH.[D\L,,RM-!RYUM9NL3X,>GN[#3-E8,*@N*L8SNF5QU,,5DE$AMAAF5V1HE
MK<86J,IV4MM+AO&1:OT_M<K:K3E'&FT]M-U+I6FUU1TLI%LPBDG,:[;G(ES+
MZ"]"?ER9-=Y2D&TVQ*;;FI8@(?6R44E*QN^\>SUT/W2P3V8DBWDQ@ OI)FF,
M,,6FKHN)W84W\2ASUP$/"#+T>>FY)%FJ2"%@Q84+#A'(YU@^&-;)_)=V5N.,
MZA:*X)*)DB*O3K9,OMHI83&HG]3NU[BX\IB0XS*LGDMJ>COQWV&&(RF5\1A&
M,C8_X@66I&C'U::4MRLAST:U>5*AONZHLY>BHV@8MPRW-@3(;,B!21EO(CS8
MDV)*E3)S4AHV)+IJY!_T./'C%3)V8B(TH1UMTY%3-FWZPY@FZEW08^'#<9BH
M=V7,I=*'[X<C%W&9M5<DVN3R(98M&S*^3M5UZO[-W'&\N2(++SM/K&#))'E6
M>ER=JIN UV]4FXL)\UUQI,)1R#4\CC&Z9-H:^&:_G_VWLLR")J';28L?4>S*
MTA<4M/4ZFJC9_(N9)TR8.FJ:IJV&)*[1!0DHC.%&*.1O./$32&O2DW!Y@DFN
M[ 3T8$)#\N7R4>;,6LIC;%4QSU$9Q#WR1,K"I+&Y0-9R9E-,G TA'"S$L =B
MF"UE'N"5D;VIFS-]XE+C6;,=UH]&/14M(FQ&U2-*P+& Z3S]=,B3643&K U,
MNQ)#;\9;#1[SA)W1?K-NL.,IMJ?0RIL:06TZ-8./NU=B\F'M!MZ2W85&BW5;
M95DEVM?IB1)CV,1^)/:E/HW635OCPF.!UBD0ET>9G8A'UI/SL9TVV29CYB?9
M!)$?W!)-LDY2@5FTKDTL?H.GY_ZG>) ZJ]<E45""&;!I=H,94D;,5/0)\1N3
M BJF:4DT"";:L)3<>7+OIEX]-2]93ILYU*W97P^+*4XM]*G4FTWPV6Y0]O*(
MMO4V#T"WGHK-H<+6+BGI%/7O3:^!I"NTG&K'(M)55E2PMJ/ _N3CP4LMQ5IC
MK)]TGI3\J]2ZEDFL]@[T.+'8^5B&V9XTV.+9("'[.3ACR\1B\4-,"1'(DL,?
MA_5Q1H]&6;CFSS%=\]]K6SMBGC?-J.CET]KJ62J3%?@7MFW;L-)8=;F1Y*H$
M*#(:>=-Y3+K&(+;C.XTAPE.N;ZC(DYU9JS5E=J6@T-"1!GQ;?2E"[IR4\N6P
M]5S(#=O:6L)^-&*,B4Q,WK9YF4;DAQDT,,\)"3-1E$0=X_"S37I:&N)Y'G1%
M[HG4^H&1G.-.;W8/-=;@DNT'QI+'-]FO@T+IF6 ])FDM@JB\&X/%E5<<44\,
M#:V6OHJY$!=G$6Z[IJCHFWSAK/A.5-_,N7)"<N;Q-R$R&FDH2HE)<:)Q1J(D
MD6W).W^(]J&)<MT5@U'8UUJO5[T(K)HBD,ZBTA6Z89A+-+!(-V(J'(?6\M"D
MK9DJ90A)FLU9TZ9YH*[PG>GIN-2U&8PU<.V.P7B>YH(_GD5+J3NT+]E))CV!
MD-DV(@LHFIFU7S54_P#)]Z6-L?5Y6SR76.CW]26=!9,IHI!4K-NTJ#J"M=LX
M3ZK/R=N/$TU(CFAV,<%1H4:CYN$98W3S@NS3:5%T11ZPI)*]6PSU0_IQ]%KH
MV]8H;6(FB.ZXL94A^%,)V-.3;)2ZA*4<F,&9[Q8QLGQK/;;*2D:VP(*I#FN[
MMF[S;L\(05PFRI_;.N3T.D 1S),Y(JQ]P!2)5%R&0L)4=O!:#1H]>(Y!V>*_
MR"V?VGE<I:K2M.O1J.YU(ALJYXK%4J]J)5?*CKEG+-LHT=U]+C"284XXRE"'
M7$FPWO9(K;%0GIM=<B@O$W#NBM,Z'<>.[BJI$0-)ZB@7%?-;K2K4/]OFQHBV
MYBSEI99E./.L,K*8\;?&'/"$UQ@Y"!C]B0^PV2<O:?T-(WK^*EEB2$@T^_*N
MQDF JH&D4$11A,TZ2?CWS9P]1]E:V;NO144]5XU[,[$JYVL:M8'!EZ+H-,2W
M'83ZGDRJ!UY;,R,:9"4I8D%(63K3B%N)-#>XY@SQ]1K;K2G>1[Z1IZW[36[3
MM7Z[KF&+6(B,NOU?'BLR:R<A<):U2H:H32V)##C;*^,Z;C64)W_M;(X[DV8B
M=26,D@YV4J[:Z(W8(!I"VK%_(<]HZ+E&M@<"N7*.?=Z#I,L48++DRGUA\V^'
MJW#9-/"^=O1<:!F*8LID-Z/)F'>:LU$Q&2PAMV6=UIJ;3QJSCOKX*5I??;4I
MY_+!I+=4@B+)>+3NV"M*915ME&F0*M&D]GFBI<Y<IU]BO+2^N:O4DZ^[)%:[
M0XTJ)%?0B+%Q,2XK>;<4I6#Y!P=!=H0,%/F&R86_"YN_U=7'S$_D29RB7N@\
M+;QH@)(1\G/=@J#A,#'A (($3;$QK(^FL]=(AT<D%7CWU[,ZVYK(UHU;USL<
MUE4\*PE&\W,GKCUZ8;K#D5ZSM#98K&H\:-%=0\RW))3BTL)-"G'/G[=KS3%[
M.H7].73$U+/Y1$_3P"C/5=0U,N7+*/+CV$:AT^F1+O9$V?.GQG8LAZ I#+2Y
M:R<2RQ/RMGC0@4 * *E.U>MMSZBWZK XI,GVG=.P;003<.S-OK<6[EZJC0I>
M2SF;1_+.1'-<S&%@M>1V#1V $9++'9=Z1(X"S+(QB/3"#BI!H$B(C+/4\GRR
M1'R+/?S//=@N?QCX$F[2VHAUM*8F1VDTU3S9#=L<_:O#S,EQIMW8VO=IO]G0
M?6$N7SRZC$SP!JO7#>=239#35D-*.QTD' 94DW4.*JYE0+(P#'+U\^\BQC/4
MNO=GNY#._>O3<TY_*\]1N-34%J\)MV6;!%2O9#C4LLZ$E@)&$Z\)S$0*B6D(
M 683*18R!^RNG(Y>S'G0T-$,,FA5FP>RH*<%A0BSG\<=Y>K'NYF77H)"<@;?
ME&_^7="[JFH^-"Y9L[6$4F)]G#B"1*+XDC(Q%RNN#62*G+M1[V^5GJ(AP:+O
MP/M%P9(F_(#W+I4!E@S+P,2/H*!0 H 4 * *9/+X)GI1+F#WQ&>N)OQ^UFNQ
M5.K(=Q&XE&.[RRRD/:):5=$1VOR(G8AC4XJ59'EYXRBK]*Z+]6)DB6"R+%%.
M[_?^_P#?(31RSTWO\.<8\#Z\L^&1F/Q,C]T#>7C2&UQV^PD34W;M)?FN/]3N
M73KHV/\ ,BC\=^K0/M_,HX=R%&1-'F,FN)8R=X[D V&J1@>^<JXM4<J"BL9Y
M8Z<]TC(L^K_QR\!3?Y2]P[L>]T=/)DE]T_J*XAY$T?OUDTTOUS(^6I=#6D@V
M 7<[#W%  (Z$3:);RVGZE@A$ L9VLQ2URSCH,\)S50D\A%9+A))%NETRI1IY
MD1D?(L>M/7J7?CU8XGL'>^US_54_ZG#;FW.SGD#\P'$'(&K=88;%F ?7K_ES
M;6NH<I)(.5TLV*-H*1<[6:RHQ."ATE&7,A9R .B2"$AJ;!9+(*D7(BQ_@6H^
M19,RWL9/F?(BZ<L?&8E)Y6NJ_*(UT/W]JD;XP19+EO+2G0D.4Z@OU=J=JZ3U
M$[UY)1Q7;?ZIU<OTLR6%1Y9Y(+0VUO?+S)G8:C_^2OA0$)1E)[_/)?!W3ZYZ
M9Z?2+0O$E^&%P-\)^D?R(&H(+\]7M*]YBPZ@B% "@!0 H 4 85Z V&\U=KC*
M6L7_ +M7QFVKX[[5^CB4J_\ 1FFRHG#ET/="TFB2=[.43N:&;_WSBH)34S)H
MCRRS1,8[QW5-LY2U!SVW>"HK&EB;_9$S3W;&X@UZD\!4R"GX:9)H-WM&6"4;
MR69"FR9<S30&GF=4:C*I?8[2V=+J>QX7E%55\.FTU;7#:^UHK+91<-<%+A,=
MC-,I22C+D1$.JDM8YU]UU$-A;+8:W:038X'WX;VY&(S,9 PC"45DDBTD>S"3
MH6,R%RDH=2LWP]42'OR8,>P?M\UFJ;C FR>,D?DU6NX%K<-5#=9;1>TR;Z'#
MGRFH90I<O3DHXUDRT;$U^2G=+=>:<>CM-NH-2"43S:VRR+4&R2WT_II_4;M[
MIR?V*%I*SLJ>O?LU6E;7:U@%.HY4DI55%@J-P]Z-(8C39#[#A(=4V<9YIY>$
M=N=B[(C)/?8$#JPZ,_4OM?0$18R+*\4-XRT7LB4ZY;%A#</A*?;49#) ,J(O
M(=E=LDQ2&Y-%#[X!(;9!L,<O=?6\-W4\:+22F3T]>:7@-RS[#)*>Q;SJAM]A
M$<IO$3+EQ9SSE>9H2TEDVU2G8TK,<LVTEL?TY91M!SY^J8,G\M-*Z^MGJXBM
M8)U,K3=5J)R)+<F*J^"NOK9]7'9N"XBGU22=3 8GUYE,/D<E\A^I(C'V9*1Q
M.;!)+<_M"/'($:):Q!2"./-/+C4)M@Y)F]B#H@:=6R,BL8T)BTE.F96L^Q1"
ML'%VS[)I[)>U6B@Q6W9<&QC3#DW46362':>-*AKH%-)L=]Z3:M0)"\R&"B,0
MIDF1-4Z28[2S0[N?.K?^'O5EO8/1JZVI)M:4#2]A"OH4;4TZOL&=8(DKI#;C
M0M.R;>$UB'*.REVM;!AU2&37-?;)Q@G<]3GHB/15AJE2.1.9;-.[J0</]>1.
M&(QYH9+!1\9QF!<VY<S60Q($,8C 2C955-^80>N'SYB/:-5UU\_59-9:KBPF
MJ0XD&?<2M0I6[50:\HC<A^.U#*?(D+78RX,9EMF,I"E$Y(2XMQQMIM"E*/=P
M.CV>V%J_JI-C:T^F8&BUMQ]0VMRNQ=AQ)LBS.HB0FVJ6OMITE^3.2XE)L0UL
MML,/R'74-MEOX^=]HZ]&RER*+Q#80B&,YZ<U2[VJ^8QJT,;;.C44?S [#EF+
M:4.)MBL/'BB8[,UC$\P"Q]@Z&-R2N*=G67RU[0JIF:MA^!:L5[=G)I'+MQJ'
MY/1<PX+D^37J;1,78$IIIEYDY!0CBJE-+90\K&^,@9V,Z@DU;<N);Z?EW+M%
M!U4UI5A^R\LN:8LK5BG@W"'W*QNE-$B1*C2"A':E/1 ?:E.1D&KA%']_V[+S
M<@-E1D9E&LH%GJOG*<11&;PR+R.2&D]Q[[_0)&2M1X+9+1K[@D,5("6R*!*0
MCC,9?I%'[D$^<LD1A'%W=HT^1*D/,PYE/6'2Z3L8*;&OARY<@M0:G.L1+0U&
MMVT=DEPG6$I2[*9D0W2?<7&=6VEE[/F-B=1"KX4639UFIKY.J=HM):KI+FTK
MJV&K1V@O+[E:[(G:;=>[?7VD>6XMR-7R(5FPJ*PW.8;>7)C9@_Z\];-G4BR,
MP':P./@Q>]7["5O0\8<B)4[YU)+L=D"8ZW%RY^9R=MDDDWHIT9&!Q3])19#,
M@V=,7J*'WO[3:A"Y9R*N[C1(S.IG6ISD>&MB<O2;RVK=B(AF<[(-:4I)QA<A
MF.PZ1J0;J%M.)3B']A.I'6JXH=]I6=83I6A8[]4S,LVY=4UM$C-OZ<EV+LJH
MCPR9<6M3,MJ')F2HZDH64=UI]E:\D:ZZ>CNPM>;9V0G"Y='PVGW,B9GT7Q'7
MYS,R[B\5:2\NC%R,*FTH!%<4!K]DWLZ5*LV>1)?-E9QZQF_]E^M5:RB6E3>6
MY5T^+'H%RVY27'JJ2<A<*$B<^F$]76,V,^267&TDM3[;9NJ-O>RV[N8YJ+9C
M8Z?U#I/3AW5183-8-USU>MB/J""F&U:6KM1$7:1[JDK)T4W)+#[AM(BO/%&;
M)\V]UZ/Q<+G_ "+:DB3.)/)=#9_$[RR)#]C(CY(\UF',LM:G#. 6.S'$.\V(
MF0/W.JV>D&D4B:!^:MA DH\)QYBHDT;/<>E;6**"W!<G5]I![=!:MDM2W*>/
M(;IY,@HT2P[.Y;$[)[4KB.MP8295BAAAYQZ*VI+:',R@?\/&K+9ZW9J;B@M2
MJ;:1IU<BM9U+,AOZD@PE3;&G.8SIU3$#L*>#'=M;9=?3.RY<5J-8/I6ZXSX=
MD]VQL=^N:+Q&-S1D=UK$MQFLYPJ*@$H!#5M,$V4<E+Q["?UJ1R8W0O)B8\3'
M6QIK&\9/[38J/<W MW1)*-QM+B,EJ"'!AV+<FG@Z@D'9&Q5S8S*M/.MQ)KCE
M=Y;AV&[VQYIB(B0B(4W?X[2^RI6\5S3>PNRD_D=:6UE2OP=26VCH::1,N_K)
MTE&LHKUE5LLW?Y+65.2_)D:1+L7(3MBJKX79)#13W&8R\FY=A0MM,4XPO$)\
MYCJ>Q,-,N=J-V$82@^6W;1:TISAN ]279S3#+)O:XSWU^C2T=2/Y8BLC.>..
M3RWV#U]7(L"A*@6BHB;4M/KNTM0TUIWW8NVG7DT<X[ C-']SVCLBHA2CX!R#
MP;@QDMD%R[3G9MV]"W8JT\>LF]*N/V:[LM(^4_):;A4A-0FE41.8D]B*R38J
M@$<LH:3,F1]70O5\4WX70#"8-L2$N"NM(YMR+J3EE&6Z,I@DC(N@J1<9>.2B
M29M<F1IDNQ<,S& UTNEDU),4G0YTDXO?TSK>#JA],=BMMJY3]/$O82K)J&A,
MVMENKCI?9[)-EF@VY#:FUMR"96I)H=;);2TK/S:[V4VV@H;DV7>:>NFXNI;'
M25FFC?LG%U=[71VIJXDGRC5UJ72>A/MOMO0U26D+)V,^IJ0TML8LE_=8-I&I
M82B.M=@/+KQ7=Q'4$L*-H=A#=F&]&HD4YFF/1PG",C'# ZHT@6LI)!4=6D $
M*84C_M9'%BQ>?&G[2H[<2<[!I[5S>A:C=H9SR(!5]Q)TVEXK FDE9)ELLL&R
MZ^2IC$14N-'D'%WW2:;<R>GV&3GK*IC6VI*!DD6FB8^KJF*Y<*N--0M<+C*I
ME2%JHUULF5,1)CQ#36RK%%?/F0TS^%'-]]B27.TCFDPTAK.6;#R=93&31=D>
M-9/!8(*K=0MDJ_9WP&QLU(1#=I[N7:>P71*K.EV/LSDFW'%%GHYIENE)=A/T
MY3SK7?.PF0FY4CB,1HRLOFIUO#,23+80CA*;X6Z^I:F]Q;R6GE.-(USM#KJ:
MGUMJ6IT^314];:/0(9,RITU!)B$AAXE2;*%7S''2D(>)\EQ$--O\1N,Y(BH9
MDNYGK(1A@4 * (8=$<N;'W63G#:+]-SK5VO=OZM3T_MK7B4:"S@8M&;J2= C
M)M1N)"]2;ZDV8? R\M&I%*?=,R"EAS"+/%XA8Y&F)7(*YQCU'GW?@,9;!XPL
M_5Q@)CI"7C>5#$WU#,W//1D&/D+UBKI2\!=QS7D#VF4(KGH9IHN;UM%9!,(;
MB"+$UB+J3I@)G%1\I=,DZD1GT+(&HBQG!'SP?Q^HN\NX^A?L&2MD\P;'FLY@
M6YXQT(K&-S:Q>[P"P25%-6QJ51%#3>]BD**FM6'H0V,QE0YG'E]:Z]=1V=M)
M0&DF3V-Y*&/>PTT8$O*!GN[CQ\>2]>/6?_O!C,_.VD 7.6FX;IV.F3,D91;$
M\]?R60V'X&9+)IA)S4WF4D?MA#,<''JGY=(SA?$4''LA A)ZF,%M&[!HW2P
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M"1-TJ]?.LTT9BDCAFX=+JK98(III8Y9WQ3PPPM;&SLDO]6D?P7/^D5\JUO\
MS"!]:C?]8\EML>.,['VZG)^W^?Y,[;;*U6CL'*%[5SD;=E"G4M:6E.3[-E("
M5VA2\/3DRL>P6NDV<$4+>W648).O1<"0WYS+B,ERWVUISCPR19Z_%SY]PFB7
M$D9-F3'>W3(E&R\TYNYSC>W%&19P>,\SP>.ACQ&=Z^#ML8*MCO0G)34VW)/D
M#+9_O=LU?-RJ3I5,B@\;9S%/-N[1=XK)N$,TT\DEL<T\L,+XWQL*)*,LE&D&
M1\R,F7,&7CYHB=G7),TJGP4J29I-*I,<E$9<C)1*7DC(^1D?,CZ\QD[67?'B
M$TXT*L=:=@\G11H;<MG95%IO".N\7CAHDHBW5SR)R-[GA=))53"UDLD\;VRO
M?+'*]K7L[)+_ %:1_!<_Z1'RI6G_ /4(/UN.7N<&3O\ NN^-'_[V<M?QEA7]
MVIV27^K2/X+G_2'E.M_YC!^MQ_Z@F]#)G$]BQ&,SZ!R,/+X3,P0N3Q.51Y^W
M*@9''3;-$B'-AB33-5J_&$V#A!XR>-U,T7#=5-5//+#*U[^<R,C,C+!ER,CZ
MD?@8]Q&1EDCR1\R,NAEXCDM "@!0!K0>3;7CGG;9FRNB-WZ@\3?3_-<UE;?8
M3+4746$2YYZ5;R9M H?!S.$"VC*F$H@6UCI)C#V*2;B3@6\GN,;@8TU<W'!T
M+XA<3SP1&LCZ93DRQDS+D6#(N9YQGQ(LF++?$MN/FG?7'X/9G*7+[_DC5IR9
M2.RFJW<#C,"8N92W9A,34NCR$165!R>.FTLF#8;,&Z;10Q88JDNQ:*,;I8A%
M9&2L*/>/QR9_1SY_0+,J"(4 50^9WI70^C. >I('MS:$7@,PWYRYTS M-Q\^
MZ6;D-AS'/4Y87A'H\FDW6P<$<B$F M+)JYHX^M*-;>G]665\0F@C-:<$9X41
MGZBSWC*'B2_#"X&^$_2/Y$#4%%^>KVE>\Q8=01"@!0 H 4 * % "@!0 H ?_
M ._^/^* *=GYY;0NUNCW@W:>T\<X;M'2&LM9,M@;#V'MN.L<]H:C&RDXS<Q_
M8^\8#!LW;TE<B\92?8$P9BXW_P"QJKDK=@P6T&Y)5IB\U<XS=7>] NM.T],W
M:6UK>Q&SN:%F;(;7%MM25=:;CCW%6U,M9[;$,SPA1GPFE=@,0$:\TKLY9D:6
MTN:;C3&M]2ZF>T_I[3VDK%].F-6R:N$\W/TYH>_O"99C=G9>K-/T[TJRZNH)
M)/OHY)$^S-\S2*A)<.3U<-9 N4]B="S1J[C4@)J24QKV;SJ$I  *X>9ND  N
M09Q\:6<O4U9<J-M@Y:CLBR3Q%VV]4':#J>PAQIS14K+<;0]MJNP0Y#E/'+D5
M5E95Q18JH]@M,9F4<5E]3B3G*:PM#)ODXE:/G6VQO0E+:S:F0K5$EZ=M4T[L
M^I76K*!&36Q-0TE'=JL)Z)=,TY/E5Y6$F(VRI%2F3O-.R"B*96TYQ)AW#O=U
M$8Z:1-ZH,CI]M!>%1V8B!>NT<(\P!ZIO-22<C'ENFV$#'&Y%,<W<;C;&1;2C
MS[*-Q@B;:"S120!AC?Q-;1]2+@Q)"9-)(:M+I==$GL,5*2BLQJ3RBZF6T_K%
MJL:DRYYN1(C<NZBNG#ANR&V)#\J.RCZLC8CH5JWL82X6JX4BATPW<V%/,DZA
M6JPD3M5>18ZJZ1$V9OWLB%74Y,V5B]7Z6L&"LK*/">E0HL"9)<SYS9M_<<YZ
M)DXO9L^U^-8&.?M$[!$ZF!>[S3?(I)V$OQDI;7<M'3PP//!&!47FZ-&Q321#
MR@PQ$V:3T9F'4)23)](WVH++5<UFXLZMEI_2VF;1BCC<*2@WYC=@4Q^JGLV;
M[4F.V^P:Y$AEN6T\R_!;2XR;"GI>![2-(Z/H]GM9*TS0W\E^'M UWI^7JR<<
MB$X46L?J#K8NH:B310Y$&<_$E$U"A2G:Z1%DP[9Y3,DIB8U=AZ']"3ASV&RV
M*\?[._45LO:4YYK (D&Q7]3">$>'AQ$!EL7>9K^YUY;*-M0K8@5VZ1;8K+")
M",:XN<[M5$<O@5^JK)>OF[9;MS^35Q=66D(J7D/_ )/$41IABKGPG#5P%SYM
MY76L9Q:6]XX\IE&^?#-(R^XV?T;>R!_3K,?3'Y<Z:TM1[2+!R.[$+62E6$B9
M,OZFT:)';$5-7I*ZT[-9:6X:$2Z^2Z;1<5*RMWK>XY("@!0 H ^89-!XX)(G
MI 5' P8AHN0*F"[UL-%C6+;"ZCAX_?O%$6K1J@GC?-5==5-)/&U\L\K6M]=6
M9$B/$8=DRGVHT9AM3K\A]Q#+++2"WEN.NN&E#:$D1FI2E$DBYF8],.',L9<>
M# BR)TV6\B/%AQ&7)$J2^ZHDMLL,,I6ZZZM1DE#;:5*49X(C,5U[B4V7W9"2
MT&T9D0UAJ'-3$BVZ&DF<H $YL7&8K*CF.JHF)?@C)"&/W-\&)R<2K)$(_%.7
MWZ, #KENT)HZGOSM]I=:_6Z;-VFH5&3J-5RSF17K%]DE*9;I(+#L:0]7NK,F
MY-E--,9UE;A0XLE:4/(Z'T@G36PR[B7FN"CZGU<23CN[/JTJR?%I(DHTHDO:
MJM9<>=#CW+#>7X-)5$N:Q*:8\ISX+3CL9>I)](0T<.YWFG$VL&CO(L4%\]2M
M_+I$JHLLXDTS*; R=2,VLX<WNZ527?7NU&8NLLUF@9H-899Y8M,:W]L+TVUI
M2D<ID.&^^Q%B.3Y:C4I<RP>4\N7(4M>5J2ITS0R2S-3<=MEHS,D$.,?^,'7$
MG:'J:)J=YDHD6586<>HKDI0ANLIHK4-JN@H;:_ND*0P1.R3:(D.S7I+Y$1NF
M->&M\#C4* +3/&3LG4^NB6Z%ME;5SUTX,1P"T#LWQOW($+-$LC]RQ5)3-)1)
MW*X_DN/QCJ6.5GZ218KD/9D;JN;-,4U1%ER4P2C1.TDAUPUFEOB+29\/<09<
ML,NX5Q3/X)FA&\I.",]K;+K*HK7KI5I;JK%/16$,(6_V=AY)&^;SI*P9*EQC
M-OLR2/B$3KO#0YE1)K1E*H]:3R-822(F12IXNJ,+F+Y7+%1ZA!QDR)%+YXXY
MW(OFUTW3V^>..7M*JOI8VO\ 7:LG:)1--DM*4+)M!*0CS$*W2WDHQRW4GDD^
MHB&L)1MJE25-../-*?>-IY[)O.MFXHT..YY\1:<*<SSWC/(^#5P6 H [2[Q:
M_AL<%_"+S]\L(U7-LCTA_P"6=^VH=_0?0H?S6/\ <H$\JLCU!0 H JMZ#T9X
MFN8]QF^V.M0?/,2V_MF1BVK3:_1AMK(G:YR-QP<*&C]9@M@$# :+N P(.V67
MOK\ +=(W4<$23C)9^JNL$BWU%NEDR+N+I\9_B?Q"=6A^A]&=-P;+9'/6T(=M
MS7Z)I_&<I5!BB)<&F<$H,ER CVI"UD\7;)N08J+(6M]::;E&_P#EE:@H9&1X
M,L'ZQFB@H% %9WEZUGJ:=>._LH]L37^NYC)(!R5TT?UJ:FD4C4A-PJ28ZAD+
MK$U!B)Q@\?QLYB\&"7-B(!9D_LY'CEK+>M:-LDPD@SWD\_\ $GWCD?B2_#"X
M&^$_2/Y$#4!?GJ]I7O,6'4$0H 4 * % "@!0 H 4 * % 'RW80*_3>(OQ MZ
MB1S;J$$G;!HY3?J-+)V:*/,%DL\76;6R*5F^:]L\D;))V3OC;#'ZK+D:.Z3B
M76&7$O&@WDN-(63IMXW#<)23)9HW4[AJSN[I8Q@AZFILR.IE;$N4RN.EQ,=;
M4AUM3"734;J65(6DVDNFM9N$@TDLU*WL[QYX]+M=PR<122PF2 &;N.2Z.EHH
M?9-?6"UG@ XFXP*#\'XM1F0:)NKNG"V6;-T@K@Y5R<X9XKW]97DGU-?909E=
M+BMKB3XC\&4VC+*G(LDE$\T3K)MNMDLUJ49MK29+,UD9*YCZ%3J&YH[6MNZV
M>\S95%C$M8#[N[*0S/@J;5%D*8E)>CNJ:X3:"2\TM)MI)M231\$<,@&@-9:Z
M;RE(6)?'G,V=!7<L*3DP2FQ,[G&QR8F.HO7,C</\;-08Y+%L-:MTD$$/25<7
MPS=+KKJ?/J]+T]2B:3+#LI=BN.N<_92';%^2<1HF(B7%RU.%PXS1;C*$)2E.
M5+P;BU*/[-_K[4NHG*M4J6Q :I6IK55%HX<:DBP2LI"I=BMEJN;8/BSI*C=D
MNN*6M>$MDHFFT-IRS@*%INF[Y,:P3>M67NUJ\P9M\738=?+#.[!NXQ3LJBR]
M-/#/V5//%#TL,,O5_7C:]ON$PR2TNDRT3B&^"APFT$M#62/A)61;R6\D1[A&
M2<D1XY#$U2I2FG&%27U,NO=H=94\X;3DC!EQW&S5N+>PHRXJB->#,M[!F%A0
MRS=NSL-86:-%TW35K9FWLW;.D5KN4G+="R?JD5TG%[KIK)XXJ8+7NKCE;._I
M4X#.XEO@M<-"B6A'#1N(6E6^E:4XW4J2OX1*(B,E?"(\\P[5)XCCW:'^*ZVI
MIUWC.<1QI:.&MMQ>]O+;4W_=J0HS2I'P#(T\A[]718"@!0!@W;V_H;J143'U
M6Q>;;-E6"EH/J6$MDR\[E:F%\L,G:3"ZR+8''&>>.69>72)R,C@E!);-R0NO
MBFV5QN^U17T1L130_97,TC\FT5<@G[.<HLD:TM;R41HC9D9OSY:V8C"$J-;I
MK(D*SC2.@KC5J95@EV)2:9JS2=WJR[<5$HJI)D1DTJ02%N3K)XC),2HKFY-C
M+<6@FXY-FIU&* V@YIN0L.G76#L66:L7:)6(\YQQVJ^U+#'"6>*S%]-W*R3?
M/;TV8VQP])\9:HPP2\NYO'X[G>Z17/XD?3%C?OM66MW&'T-.)?@:3B+4Y1UZ
MTGO-N6*U)0=]8-\LN24)KV'-\XL0SW7SRJ9KRFT=$D4>REF5$=?97$M]HMBT
MAC5MRVLC0^Q1MH6X6D*5_*B)B&ZNYELDUY0L4X7%3,?##!/#%-/''###''##
M##&V.&&&-K8XXXXXVM;''&UK6QQM:UK6M:UK?5:L^(B(B(B(B(B(B(L$1%R(
MB(N1$1="&GC,U&:E&9J,S,S,S,S,SR9F9\S,SYF9\S,:/7TJK[SG+'[B)7\P
M5*V1L[_/VGR47[;XT)MV]"TW\ZL_N80U9JVB.<0H 4 * % "@#M+O%K^&QP7
M\(O/WRPC5<VR/2'_ )9W[:AW]!]"A_-8_P!R@3RJR/4% "@#6@\N/9W*[#I#
M1P>/]B<=ZCZ1Y /;*0F<2ZJT;N[<(1(9N: 0^U@347!P5PB2KT4F&D#DNT(>
M^VBK4,T%F1[)Q*1)D+B"5@S)*C)7+X)XZ'XX/PQC'CZA:!XM=XH]!<R.9ZAM
M7F?<6">RY6!_2[E#5FP-/ZMPN.'1U>XE6);*44D>4H9>W65+EL<O=SULZ&I-
M;64:N*"*B,CYD9>I1Y/]N"]PL?H(A0!39YQ>,.>.G^%M\;3W1"WLHFW*?.73
M&U-'E6LKE4>2BDW2U<Y-X%78Z/&!@Z1I6)0N.K^[I&U*#KXLLT;M;HNW>"P3
M;49*+!XR9$?3F61(7Q)?AA<#?"?I'\B!J"B_/5[2O>8L.H(A0 H 4 * % "@
M!0 H 4 * % "@!0 H 4 * /$NNBV16<N5DF[=NDHNX<+J8)(H(I87456654O
MBFDDEACEFHIGECAAAC?+*]K6O>HJ4E"5+6I*$)2:E*49)2E*2RI2E'@B21$9
MF9F1$19/D)(0MU:&VT*<<<4E#;:$FM:UK,DH0A*2-2E*49)2E)&:C,B(C,Q#
M4EO&?[V?O8CRDDP2C+9TN-D_3DF'9$-?AE45,FSUCJ8&KDW_ %MRAJI@MC8H
MFLAKP2Y1P]N+&U%/=F6OW=26FIG7(.B$M)A(6MF;K&8R;M7'4DS0XW1QC-!W
MDU!DHN,2D53"TEQ'Y!GP3W'&T10:%CLVVU13Z[-UIN35[,ZV24>_FI6DG&']
M63D$Y^256ZDT&<4T.:AEMK/@1(24]I+,VH-#0?3B19\'L5DLYE*B;F<[0F3W
MW]L*;O4[8VP4.'EDT\DAS;T<<!<=$HCHX&1QLD+%-;74RSR&ATS6Z?2^[')Z
M7933)=E=6#G:;6R<+H<F4HB,FD=&8C"6HD=)$EEA',SPW5VN[O6"XK$OLM;1
MU:5-T>F*9CL&GZ1A1GE,& A2B7(=R9RK&6N3935F:Y4MW"23FFLA&&!0!H\?
M2JOO.<L?N(E?S!4K8^SO\_:?)1?MOC0NW;T+3?SJS^YA#5FK:(YQ"@!0 H 4
M * .TN\6OX;'!?PB\_?+"-5S;(](?^6=^VH=_0?0H?S6/]R@3RJR/4% "@"#
MG8W:6MN/7NI6$MT?T%O"3[N-R@!"HOS?I]/<$Q<D8>$:R O[> ;&!17%# *J
MN^279HO\$V@LFN[]D;M/69A4BSGF18\1C'C;RC<\]B3][J>$:TZ-TQ-< T[D
M ,'T%I(GJAO,VVK98(@FU6L0)W?EPI>0:SEIX("G<;S?M9%'GS]--X-M9L^N
MT"II,N>2/GCD>?67[2Z>.!8T<D ",,/>LE."(\+LZ8L;DCA)D)8>W%'B X8S
M]L?KMV_M1$@Z;,&+?UGKG;QP@U;X*+JIX9!$>JM+HHWDK2&.)/'D)@0'+%V$
M46-#4I*]$M\\TURC0%FYQ*.1R"B:F"SU%KFV3S3SQS5QRQRM8 J&\Y7.VP-T
M\,[SF\.Z:VYHD+HWG3IB<36 ZX<HH1KH +AJ]<E> [-34=(9+QG-O'" O)-)
M-QG[')R]O5_7E:V83;/"D\B/*B+GW<^I<^HD9XDOPPN!OA/TC^1 U!1?GJ]I
M7O,6'4$0H 4 * % "@!0 H 4 * % "@!0 H 4 * ,2[;W9 -+"6+^8D72Q8Z
MZN,A\*CK%<_.YV;OC:Z0.&Q5A;,F;(*99)XJ9I)ICQ^*N#DL^8,_3<X_#O=1
M5>GF&G;!U:GY*S9@5T1I4JSLI&"Q&KX+67I+IF:249$331*);[K3>5EEFD]%
M7^LY;[%/':1$@M%)N+JP?1 HJ*%DR5.N;5_$:%'21*-*5*5(D&A3<1B0]AH\
M!(:DVAT@NB;Z4QRA&J[JINPG,D<,>T6,HIY8JLW>^9<,43QE3B^=L7.6NHZL
ME"F2F#9,R]E2R2ML<7117.KE)DZO(ZZEWB7&T=#D;W:$D>\AS4\YDR*:O.%^
M2HBTUS9D@I#DU25$6>.:LTQLY0N%LW,KO5))4U-VF64/AG#4HC2\SH.HDI4=
M6WC+9:BLD+NGDJ=5"8J4+09S+'#AX=@R%"6#(6+&M4&(X:.:H,F#!DU3Q1;,
MV3-LFDW:M6Z.&"2#=!--))/''!/#''&UK; 99:CM-L,--LL,H2TTRRA+;33:
M$DE#;;:"2A"$)(DI0DB2E)$1$1$-.R),B9(>ERWWI4J2ZX_(DR'5OR'WG5&M
MUYYYU2G'77%F:W'%J4M:C-2C,S,Q[E7!9"@!0!H\?2JOO.<L?N(E?S!4K8^S
MO\_:?)1?MOC0NW;T+3?SJS^YA#5FK:(YQ"@!0 H 4 * .TN\6OX;'!?PB\_?
M+"-5S;(](?\ EG?MJ'?T'T*'\UC_ '*!/*K(]04 * *1O,(^:L9)R&KK7_K/
M;]@X'=U+<\D>+(WK>62UK$4XI%<-Y([" [??L->D("Z&K0:^:))7WMC(VX)<
M1EBD@2P5":<X/IN\M[>SC//'F_"\>G+Q'L>,#C$%'78+J6; .SXAN0(UWI$2
M,6[!,Z^4E$EF^])Q#MB;BZ <@M<+E(\P,;#O%8+!A" LHR&BHCKUJ/7"NR?U
MG%@*5G)?!P>/-ST+."YD1\O67/KX"MOSX[1WS(-GQR,R#1W3;7F?FW9W)DTU
MW+=>0IB2UANW>TOW)K]<^^F4J=2,7E@S@4"?D=8ZNAC48[_2+;\X-$#I$4UC
M\?54"J.A\RR9*(\]<;I].7CU//3Z<8$VJ7C1_NC8\F+#&P+OPIYI^ W6EPLG
M;CQ_0@3E KJ.(.EPK(>FY=2)EI]M W,R;;3:"7#B")ODE;29=9ZF/6N$BZ8_
MP\-1GX;V3ZY[\DGP/IW'@6!^5J'>:'/0W?QD/MSA!+BVVD^A'RT1>QO:V6^;
MZ(PUY)53@7 DE%,HI;8BT5Q(-A[JY:P; PHV46>8-K9J8TYY[L?'S_9C_440
M:,I+"M[>+GGEG/ACH+/_ !)?AA<#?"?I'\B!JJ(+\]7M*]YBPZ@B% "@!0 H
M 4 * % "@!0 H 4 * % %7O>&]NC>;'&.VP,]B836+,UJ2,PG7MM1RB7B)H:
MD$Y9BMI%NC-UYMF40YSUX,C18<G#9N1D4<!!2;,H:DA67*NA<!R"22SR^/O+
MPSTZGTZ%_P"_8W3M?JG5&^=5M\]FZP-8[DZ7B&N=8\IQ:$+'#9_FWUP!MM_<
MTHGKIP-EH*7ZLCCJ4;1.EF3#]589J-B>KUVYZ2RT;(GX4P1_077U]Q?Z=?7W
M8'SNSMK):VZ?T2%SVOI?DUK.-,;K-D>JMK0^(G7Q$AJ\YKO*,Z BYV=&H_%P
MB9UKL*8;)D[!<AE))!'80^:1/!AFW-R )XCKH!V!6IPXQV28I0DSU,H.4B(3
MBW>SH?,C<0R;BU+4A*B2I1Y41X+'U$7-N5.O3Z+*<5(N?Y3<J$27DU[E@;+<
M?MSL1*N"[)2RRVRAUQ"E-I+"#3O'O2LXMWX0ZAY5T9OPR)9A#NR8(/,2$8,;
MDF@IM)&B[D-(KAV9G+,PR#.#8Q^Y$,BZBI1F-6:MB*RSQ)97/VCY9E@S+P,2
M?H*!0 H 4 :/'TJK[SG+'[B)7\P5*V/L[_/VGR47[;XT+MV]"TW\ZL_N80U9
MJVB.<0H 4 * % "@#M+O%K^&QP7\(O/WRPC5<VR/2'_EG?MJ'?T'T*'\UC_<
MH$\JLCU!0 H H7\H$9W-O2<ZLBP?E3J@S)-6[,GZ^BY/S/Y M!<I3F=AW>KX
M2M*MB!DI2>:2]PQ%Y'Y) G(1NFV."&PXX7))_HW+1JC@)IP6<FDLESRDS[SY
M<BZ\B/\ \D)E>+MC, W.TBCT_$;\CTQCFX)F%D$=Z4ZXA79^U03]L*BZJ@PM
MM6"F#0P*T1Q7QS:Z^?N&YJ.YJN'SQFBD;:Y*A177NZ%T+=+]AD0L*, PDA9>
M[CX<6<'V<LWMF!@>T)LK/!SI)\/=^RO45T/:6+U!!XS7]7ZULZ12<(9X*IX9
MV"(^4X@\*=RQC/74/BSF="QJP89-'$?$K2P<(<W5R<"F,C4:9&&@U?)=;)9B
MW>)M5;K*WS2RNIG]8!4=YR]S]":PX9WG%M-<K$^@H5M;G3IB*[NV(PVC'H"W
MYSA.>KUV.>Q2$?-!2CW8;=,<:D):\>!NA+[+"**M;.[*%&ZB 3;(C463Q@RQ
MR,\GGIRZ?2)&>)+\,+@;X3](_D0-047YZO:5[S%AU!$* % "@!0 H 4 * %
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M63(L&1EZSST(2.\27X87 WPGZ1_(@:@BOSU>TKWF+#J"(4 * % "@!0 H 4
M* % "@!0!H9?2DOO[Z:^$*#_ #FWS6SMG?F6_M0?=+'/.W?S]+>S=>^J&M96
MRASZ% "@!0 H _,O\K_[7_XH [7;A+[C_&WPJ<\_**(5S./T)5U/XS]XE704
M"@#1X^E5?><Y8_<1*_F"I6Q]G?Y^T^2B_;?&A=NWH6F_G5G]S"&K-6T1SB%
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
9% "@!0 H 4 * % "@!0 H 4 * % "@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g451428g38a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g38a01.jpg
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M(597EM35(C$9(S)!4@HD)35"6)6T-'2$_\0 ' $!  ,! 0$! 0
M  (#! $%!@<(_\0 0Q$  @(! P(#! @#!@4$ P$! 0(  Q$$$B$3,04B411!
M4I$5%B,R89/2TP9QE$)458&5T0<D,V22-&*AL4-7\'*R_]H # ,!  (1 Q$
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MG$'2(R=G- 0[QR3L"M@?FL\T@I262XM#JD2."$TQ,>2H 6I3E#&0<4:$.RS
M"W%36ZAT*.C<JRE64CMD,,@\\<&=;>I*MN5AW5L@C^8.")@?0HOL:7\.5^3)
M8'H/D)S)]3\S)-E='SF$UU5-L2>))6V W:3-5%8OWKH^L^<I-=R/YI3 >VQ
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M@+;74MBT'F.Y.4S-:]IDDV9%LDBB0#.H7!>'-$^L;<L<D+XT(%[$8G*#[3D
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MU'L[(4(HK8K6+AG(9BKMA5/4(R#1K37T;!FM6.J>U%KM6SJAMP-CC+%..P!
MR2-O'$J\4RBJX-0W-;W!7_CN+U<KY0ZN;>@'^;.U.,_2F^IWB-VJV,[0WKW]
M4GMTD:^+G,[?&DC4($16P%4])UX35*J*A,KUJVV7ZE776-:-5I30J"YM-[*K
M4DL0H-/WPQ<GSBP#& &EFF*+705- 3H7"PL4%W6(8 #/G[$  >7;G/.V1XL0
MTG7'AW2%R5S7F*R)A&.?^7+BHM:5 ^-F]4WVXV657RJ>19OBS46[] 6'*8\B
M4*H[=AUV)U+)-=JG=(HBY#8>K0%3^WL\0"A-56C:C4TWC?K2#2U=@K<N<:>M
M#]Z@4G-?E(;(!D?(FE)+4NRU4O4=M&-ZLI8!1FUF7M9OX;X2)96W'>-V+W?T
M]>*BW>2%L/3Q+G]^I5"TLO!\HD]IU!)'%2FG4E<9O=*A0Q1G4(5HG;Z1%$E0
M+KD<HF?%VMA$CC21L$HS4J]>ATM JU8??J!<2=<BU7* :U"4 .PL!'3"D4[]
MQ;+EL6V$/J+K-])4+4:P!IV9T/WR6L)5=I!W9!L*X P )YG0ICY+;/&NG;0M
M+I '.Q-M7.;6J5]51P_GG4I/@TL75*C=S2C3(H&O@V4='R$Z(!GS<(]E"W'%
M@9RSB ^G8=6?!JR.O[1TJ.IM#^T;18@NQ_;ZG3W9/WNY'FQ,:B@>(N#T^EOL
MV9QTMVT[,_V=N[&/=G'NGHNADM/2-SXPBW44@Y(<+U@_-?>9;1%ZQ?>:=5/'
M>H'VPH>[U@D<D9>W#F=FGCQ&%3ZZM@I4A'7:VU@ 4+"E3F2>#7F[;D]M?2KJ
MQ0^HT&7L74]5M,M=@M(/&I**P4':>H*N!@$36"A.G%S4=5:]5@(:]@N+H4XY
MJ#%<D;AL+<]Y7:Q[:I>L6+MFTF:F.8XKT!!Z5XF)B;%./V3KMU);9';4KC5F
M68P0ZI@.=.()D[0%P9WJ:12%M.DC*YHDTK?&1&<>ET1IKJOM?15-=JGT[W:T
MNR>U4;:NDC55,]N+B@L!"/8<L"55B!DTNZ5KJ'%=(L%>FP&Z-FY^HX=]J$H&
M*X+*O (!(DDWU,N&YQ..LZ[F$9Y.C5#4_P!:>'M(*X<*CC5<1J2.E?6N^&KN
MM5;++(7[,LGC0!I4KRY A;G!S;H<G(;T*%$TEMK4G2U4)KD326(VJ>^[2>()
M9U6L9194O_)Y5_)6Q(&TD ODDELL3.QM.S7HZTBJN_2LI0("5L.;N5\S 9.<
M$[1@<8$W)6#G\NVZB1]))>#P!%XD4?\ V:P5$#FD3'KB<#++@+=V495^Q,HJ
MJ-'N%?(.KD'N:'2/UQB@.TY:K88CK]*XZ;V_/T<WM'5]HS[;N3 JZF&ZN.IN
MZ.4"[0,$R9Z6]!;[/QJQT=G2'_+X;.\* -G;E^2WX2#(+:5(6.5R/9;A27)T
MOL:-7!VC6*J 0L[F>D%22JFZ,QDFH)"G:[) 15<GDU=J'A<_50.V4#RGEKBU
MJ"=K7-\6*G,S195?5[56+]6E;5:*T6/[5?FW>_77-1ZJK8%"W=$J4!'"J )4
MME;]!S707#ZA=J]*LA0 *SA_(S+DE.ID-@Y).3,I<\S:6?ECQ!*"JVY>6K8-
MB?1U2SER=5$+Y0KUSD-52*DW$%BN,59V!(CATDL6$3(U+!U$@ILYS?$\E(>E
M<+&V%R@](?"E"=3H-1;3JJ=^GN0+OU5@6Y;EZ:N6)=:W3+A;MJE=H?.P3MC#
MHZFI+*7*VUL3MI4E#7ER,>5G4^4E"3N!VXS)"?)I4<W[7[ 3UT\\:5_6O.BZ
M%(*<B$)J?BI.HM&*SM^:5]HR-GLJ_ #KKY*BBA.K>YVZH]/,G)9G4,>A9;*W
M 4H]P5+J]%I#:NMLMU&\W/9=K?LF16%2M7019Y^%K7RKN 9R3@F19&U%X4T*
MM)7IA4H!=68%R'L\N !ECRVW(7'.>&YI[11U,]A496KUS&FHB%^)E$)G,(LS
MET8D<"N2I="UAL]E51F+2BWQ_>D,L<CH]%'6L#7*>19E-,B,4-;8P QM"IJO
M%^COM74F]_#71';K$>V(_P!FEV.%4H,L+<5L?,V6R9UVKZ=]:FD5+JU9E^S!
MZ#(-[)G!)R<*5\P^Z"%XF2OM^YX8;NIHE@YKYCMF)M/5,@>Z4=2+HX!A4.E5
M"ZJNQ --?M#=#1H%!L91KTT-FD-<>F$"[WUEMS9"WEY6KID>C4\H74&FXMJ=
M54S:55O!H\0L==1U*]UA:S/G(+HXTQ&*B74 (&BUJ@]>*JK +R:_/IE4U]-L
M(-I'ER RFT<N I.3/.>>IJ]KKQ?^979!;L&F,41WER+,)7+$+-2$$;( =\Z8
M(Y22*3Y90_HZ+4RFO2"#$,\F,*.#'G!P2+'%8KVM X&Z]!.I9X1J5-+HYT^L
M1$S?8;/)8%:L7YO"V9S6CC< 0 ,8$R-L37TG>K+OI9FQ6FTY7*N:\5EE'WF7
M )Y_$W&@W8'-$_[>A?*J2OHJR\S-W<'4W15H3R]K-B%H12Q;&?ZVL^'-;NSC
M<HI%H%$:S.'M.Y1ID,W(S'!T7LBX;\J<DP%;ACLTFI30OJC8[:DZ+2Z>JNBI
MZGKK6VMRK89K'M]SMY< ,-N#Q>M]+:E: @%0U%]KM8X=6<I8H*@@*J'@J.>2
M/?R:^E4:\UKX;48A%!69SLY33JAM:+?ZVFR_I2C8M)HI6[)[MVJ_G1LBS_/&
MZ;FF(Q'CF]HH$$>"X'2?22(!^6B$)Z%/IZXM\19[ZM0$TK-3I$&FO='L;RVZ
MDNM93G[E1+8"9?@D$U](II E3U%KPME[&VL$(.4J +;N,Y? Y/'/(&M>)16:
MZF:'I7GRF)U2DJY<H_;:ZR.50.^J;ELMO;I2P&C1L[MMVKN*SAUG2=@8B"=P
M&#A>F#WT7C3<>!0MTF>2/*7AU@NONU%U=R:J_(5;-/<BT:>LXKI6QT"%C_U'
MVMYF/;RR.L0UU5U5M6:*N25L1FLM?[SE58M@?=7(X'X$2ZH*\@D(\/>%MT;J
MFM):]2GAZNK#M.*HX3RF;8=:0^260>[W'U>)SG3K^UL\O:NJ5_S0;1L->FPB
M,A5-4H@4V\FII6)\0L=_$'+6VHJZZRNIR^KZ=CK5BG2XK'L:J+0;/-9U&P4>
MO#$'0$5-*H"(Q;3HUB@4[T4MFRWS?;$["5&%VC *MD R3;74<@);\YV8B:SY
MJ64*;VE2*FH+313GBO</:Z0TRO!4BBJB'5Z%+;K[7CRF);5TT<N@4KD)EF:1
M,)S>?7NY!:RNGVOH:@]34C4>Q7BVHIK=[7EAM??9FE;!R*QI\;D. ,+Q8_0Z
ME0VTFOKH:WW:?:*]I!4*OVC*>"QM['![R#*UF_(%S+^6I?<,<X[B\KBU_P#;
M=9Q!H3QBLJ_K4UECU:-KER\DN=D90(T;U7:2P5"5*RR>=!7HW=3L07IW<P.,
M@4+K[4U=*ZI*6UCHU&BL=M]EENYK"-4:&;.VPU\LE>"O!4#"XK4T6-2U@H#+
M=J$4!41#@?8BP#.5W#@MP?>3SF6J9MB,5O;?.['/'?C6-=H6+R?VM"+Y7Q%O
MY>*KA1(EI"Q9RE'YE(H.E%1#',GU*C<VM_2MC@A+D4651^.S?2](XI6\ZFZM
MK*M0R#6-HJ]7HK* YU75" @:ID5S[0R*2&4L#M;<U>""1.MU5ZU8Z==0]&H6
MPKTMA;.:0Q4=,$C(./O#AN, UJA8:/=^([3Z_LJ%TCKH'D5CZ3Y2DL4C<+K9
M1$+)MR_)BUDT5:3<U0UL%6SZAK9HFMO@:7%J+6(U:*$L;DP':;&=&>/39UQK
M:M)6]_L^K;3ZI'9[-]=6G0F^HESU5-C)3D-@@V,&Y)$I4UG3V7NM?5H%U#(J
MKM9[6 K?"^4A0SX(]RY!XEF^IH9SY!:YO!CNV+\@PZ@E=%\7.-3MU=M-2,_3
MVKW>T53.-A.1K?&"2K?3J5L"4/[F^FKTQ,86PA4RK6G1ZQ;*C3\VF?4/92:'
MU;WB_6BTV-<=+T%-RUC+?8\6!0NWS!]P;&%Q=>*E6T6+0M1KHV[0@NZIV%B<
M>?[I))/&W&/?*C>+&JH9+4[FS5A6E-&1?=\L2SG>UZQG7(0MI*>'#),4?$&&
M&4=I+=#M"7 *9B=7AZNE$O<V.9)R25;\)Q? $+=?A8U!M!MLN#=!O::K*]6,
MW;UP[/?FD6#+ +00"G90JS/KND*R$6L@6KTG1J.*]IX5:R+"IP"38"0WOSR9
M,H^[J9>*%X3YRL3?-K_7\FX@[7(M!=.VFMW:<0^8-;]=,GK!G2SA^$=(JS>=
M2!$TO$:;6=8P.+RY.:=;[#DI+8C$%5]%POUNHK]I6Q=;HC4$-@1T*TI:VQ<+
M8NTD.S!@H4C@;LSJLK->FJ?I%#IKMY8(6# N4&X\H<X( ())_E.15#N?6CP^
M7ABD\LY?M5V#2'),\J$W2/DFKC 6 JL^ND=I1!"Y0U:'I97(&=D='&,7C-+;
M7HRG#:MY<B6EJ()4EI6_4'7AD755#KZNN[_U=OV8JL-3D./9@I8!Z$J!QY1D
MF=VU#2E2:7/2H9/^B@+;UWC*GJY':QGQGD\B4F\6U!7ZJ34;,X<Y5M$EDU9I
M^I>.=82CY@=%G.[:WR%I3QU@465RNG*C5AP1^2GK5=9*)EH^?-; U+!O1QYS
MO[>]OA1L"WUV"QQ6Z!=2YU(]H)4EFZ>J):MU\HL">0L>,;><VNV$U,I5=P8F
MH"HFH9  +U9#*0"4W>8*.>3@>G%BP_EM@A](1R83?EBRCX-W1P\9#9RP1_CF
M",TBHR2+]@M!<TQ*FU2J8DTLJ"68GDY5]N#LYK53.:[/(P>Z.,UYE;ZIFO9$
MU=8LT.MWHS:RPK>H'2!>X!.N/[/050 <#.9LL6H+6"U+[-1I]K**%!K)P^ F
M6Z?N/4).0<\3SQ[TG],6ER],')@CG.,:G=4^)#=-05>FIB*5Y"7M1R\C@@'.
M,*5B2&EIG.:1<^3$>J13M[V[^O=5*K1;R:<K/"9OT%=]6J0,VI:NWPVFZTW/
M8ZC5&S# %\A&"GFM=N!CR@"9-4Z64N0*@U>LLK3IJBGH[20?+RP) .XYR??S
M)VBDMYJKVKVB<-#'RX_3N+^#;!'UI;)?&ZKEJ8[I9'U$N'ZIVC#N2H3/]N(&
M#2)<J;'E(O?EK*E2$/K>XQT1R%14Z:FRUD)U2UOXNZL4:U/^6.E (#J05J+Y
M&00H;.TAN1<K5+6& I++X>A 8(WVHLSR#W<#D@Y..X(DPN)E*R1WZ"GG-*7B
M)'UW.Z"X.G<?;;#3\[-U5H RB%*%G56X#'K2WJEX_,?E4#'\_P!I.3)G]N:#
M70;604\+W 9] %RKIJ]3[;[+7?KD8U^T&WRN!I.HU7V[)@MTR,J2%SP!)GID
MVM3[.+WJT[ /T]G(/6VA_LPV0-P[CG@$YD;5Y9'*+0\>&'4%M,''OT9SI;:$
M@ZIEK)$JU6[,F$3O"W!U&T2R;ITYRZ-5:!\.8Q;0N!C:T/5=NXBY*-PB!"(E
M#;97JROB5M3:SJITUTJ,]@\CTU=5D0\-;MW $9*V#R8<G,5>D'1UNM&Q]YN8
M*I&Y;'**6P=J9V_S0C/&,;X\-->2F_:W3KVRAJ>N" T%T#(#Y0X*_#9LIXZ$
M6IIC CZSB4?B\7/;^7JXGS2T.$N30^;V&Q$R-Q@C6X!2-CBL;"G%/6#8M%IS
MJ+J;;Z%V@>)5+I\I9U79W!U5E;,$WI6VT6$98!B)(A#:G_22Q*;?,?96-I#)
MTPJ@]%7P2%9^2ON.,R4 L_+COTITG'X<#EN Q&QZPYLD#YTVUNW#4R8*<D95
M/.#A8R5QINQA&PN65[8,C&$VR%7/*9J>TTM;T0$QA@7="5JO=JAIM,7]KL>N
MS4H-,5UJ-<O6 J/6K&]+*TST_:,J4[XVDF>*3;:%%*!TI)M!H8(>F2P*-Y61
MCP_2&<]AR#*Y3 [EAD\/B,)Z^KVHK*ACKQ<W()J^D3CDF)S&"=?#<3U<BGC@
MFF(&_KYXL-IDB<I"Q1:/K%D-D-;.*!J;67T.U*@K0GM3:]NI9=6XUI**:]6Z
M/I, +6"F[1K64.69L.M@)+!N#2W0&E7:M;J=. Q#4@K?SECN(NW[ONJ 5(.!
MD=I9[2E%71_D?O\ AU9O_'+304NA_%V^.&2GG:GDUR2^!1ZQ*Z<9R;-4,14A
MLI[5-+XH7.+UJTR39$ED(I4N9P!:@/)X:=&EK:O0/:-8VH1]9[8URW&A':NP
M5],N.DH*X"]([2NP'G;)ZED&GU*H:!41I_9PA3>RAE+[@IW$@G/F!();GO//
M&G;0K"O> :08TT;YX=+&L_L^<PFT7N:PZOI1:+'21D?I]?[I.O?B%3U%(PO=
MTYQP)#LDC1!S8K3-3DC)4O9"[T+:K;-?>Q;4"JO25O4J/8M+7!K1V4A78 \K
MSWRP)VD9:W1-+4 *B[ZAD<LJEQ60AX)Y S[_ .8]YS>"SF[GZ00'Q+H[%-<X
M5#%FFY>HIC!+JCRCD*<H+);$30W)(108:]DX5%W0@"Y80,ZD9U0FTK02^OZY
MT"B4JVA2<9BK.H6WPUG]IN=J-(ME##5H:CD[[S8OV#X__/7J.2JXR,C&EQ4R
M:L+TJP++BM@Z+!Q@!:RI^T7W&MJN,\^XS3_%CDE 6-4TXDE!R>EWFPF*=<WE
M=)KUCE!Y%9LOCYG+=0L=2N-*2;U1RTNLH@\()-%[1B<1$JD)-@;^590>3'2"
M4B6?A:7UW*+UN6MDU/LP =:E;VJUK1<N,=1U*/4[84UC"Y;)D=<U;HYK:LL'
MJZO*ER.C6$Z9[[000X7G=RWEXF;X]*YU24%RFK="^0#^7#:NZ&,\1 VS?H..
MZ!^DG0YP" I&@N8;%>A+D%*"$?0L53H )AKAGJ'#6UIVS1QUAU/7U0!U8U75
MTWT?TNO[/TOL^H3L_P"7Q]_K=?G& ..)W3]'I4?^GZ.RWVK?LZN_!VXW?:?#
MLZ?XYE%/$-OPJS^<?#BAR)TJQTW'.82%LJ30J+UPWR&-2M'8$]CQ+"].$4:D
MSVPDCCZ1O<U,/5*$;<J=59TJ4-1KPY'N1^_P_3]+4>(N1: VI\A=K"K*:ZV+
M*&.UL,2N\ D ;,X4 9=7;OJTJY0XIRVU4!#!F&"5&0,8.W@9.[&3F6(['CR.
M]G'GWKFJKII19S/6W*-,1!_K-?><+B,\@.JYBQ358W/A51.#XBF3F_3)20YH
M&UJ8X^O9)7I^ -6O RG!<!Y]&QH%^DMIO&IMU5[K:*'>NSJ/FO4=8*4"H"I)
M9@R;<8S@2Z\"PU:A+*S0E-:LO4"LNP>>H(2&);'  PQ/IS+8/[M'H1W_ -,^
M(Q)^D:0F'(D^I:UBHDG9[KA;Y,K;9YY38HC!^?D=-)7P^PD+PPR)2T$.3'(H
MHULL?U%QKERI+I*:,C(%9M!IO#TTUZ:NNZDOFAU2IJ[B[ZCKE>D0RABKH[,P
M? !R1+R0NIMU;6UG3O6P7%@+.&K 6OI@EQAN,$  KGCB5JZ*[;J*DJ6H5CK6
M*BL6]+8\(2J>5Y=/TMN-"ZMZUA4R-E!$TB[I5K'&E+BJMMI].K%HV13I$F8B
MWEH5&172A$(3IIT^BNNNO:Q^G15XM;JDK-1%ECIMV.+6;'1.>RH=VTC=@\46
MZFNJNL(NZU]#727W@HBL#D% /^HISW;C/;UM%9\F@M7]7]*]ARCH.BEG.=@<
M+-=3HJZB]W0&;3B^)>Z<NPFM&ZO U-$I ]2,HALGB(U6XO,K9VMH9"FO3@8K
M C/,4@S(MENFT^C2B\:A-<UQM>BQ*Z$&KLM-G5=54DUX "$EMV._$O<JEUE[
M6U](Z8($%BLUC&I5"]-23PW<D#&,]IY^^$<R0(@NSYU+IY2[?ICL2CFR05_8
MT5Y97R!XK)>Z284]E!<OZD&-%'*U9T&BD=@MM5-R^Q)"<LCI20]L$B;A+M_B
MQL/31*[CFJ]ELJ?5 +: FQ-FE^]8QR:S<14N&SNR1,V@"8=F:L8>L%76HDH2
M=QW6]E ^\$&\\8E\8#->1ZILZLX!&HMQN[0"P_%.[&JR?+IA%*?FAK3RNI?X
MTAB"%#(9 !>.+URK0&D'1N3$'IDXB&E.G9'DMK4O:-TP6)K+*[;&;6+8GAFC
MMK"-<F[5[27)5<![ >&3!Y/F7(4C2K4(]:*NG*OJ]0C%E1L4Y& "?NJ?[)[#
M''&0=FX^?*5K*%<[.U5R'C6,T^BKKM=FZ#D\X?J<1]$E7JXI;<CE9((^]R1:
M"UO<N,*5QYNB^XR?N*.%=+I-M]&:I6LHS8ZU;[7U(L76-:;-&VG5%N.FZ"FI
MK254=+(?)?=YQ8$V]FG:"B)44-"ILU M+%!;U2'"@$^?&, ;?+MSGW3RI\.-
MYCLCH+Q">;FNQX15-\]#U34C=3,FG\P:JZ8Y"WP.R39':-6 G;XJ;F=H7V3&
M%"-J3-SDY(D+X%(:E6&Z2$GB!ZGB*LM^@U)K>W3Z>VTWJB-8RFRO95;TU!+"
MM^20"5SP,F8=(0:]52'5+;405EB%!VL2Z;B0!N7^0)')XP;/<J5C4]21R$P#
MI&7<RS6PF#Q&^&TSTJ.L2K+43,5.*&.9J)C$E$N"X.[0=!6+WB-+/&MI=7"$
MM2[92%V/]42,HK-JK;KFLLTR:I*V\.UNT=.VHM=OK".$P&%C<],D!R,E1CF7
MZ=$K 2UJ68:K3Y\Z.!7AB1NY&T<;@"5!QGF:V\=10$BC_$!L9LKCCI/9,>O>
MH:@H)F34]49Q+!3A9MX1YT=:YC)J$_;THU%%:-K=9N82^*SB%C:[N*\QY2LC
MHCD--9UM!6;-8:VHNMU!-UV6NQ0RBUL^7S@D)Y1D, -I93PWKTM4X6@.MJ)4
M B8"9<$HOO\ *>6Y/8YR 99CI&[.=K@9>G:TLHSGAW@U>\J^'_*H#-XXT5V*
MWULX3G4DRV>6P64W[-FDGD+9!W%^B[E%$;FK(96-F ATS(30O)Z_/IZ-14VF
MLJ]H#V:KQ!;*V:SHBL]=JMU9\B(SA7#D99FSN/EQ=:]5@N1^EM2G2E6 7J%O
M('PX.XD*""H[ 8P.<YN]#*%:!6'N70K@6>5HDZRY75>'#!J\DW-\3/FE0(IB
M>HM:/V=-H@?\XF&MY)7Y+:USV0=#GF-Z6=+C%BP*A&6C *%(O(KV/KZ[#I-5
M](V6)J6V7&L=)JD<;6L6PDHNFY-8&,'F=LZ8+;ETSIUJ/9%5JEW(&)8.R\A2
MN QLXW>HS(]Z(9.=B3.NGMQDG/\ (I7+.2J1>X963\W<J1N14W+E?6#:)QJQ
M1,N<](JZD\E1PTXXU3-XTH33LBK%K0AENTJ!H1CW9ICJ?^54+J%5-5J ]JG5
M,MR#2'%H34YL5#9V1LUFX,4Y8R-HJ!N8FLEJ*R$84@UGK#R%JO(3LSYE\P3A
MN!*=>+>BKY8JH2;0U35\'7RQ!8GRES5 "N6W]11#4U+8JE8$Q-I\N$$M5A5U
M*0B7J*U%8NOGPTHFMY4*#%.GI4:'9X4;!UT<6N%->-39[4O7)#ECTM5S78AP
M+.G]FQ*X V@3-K@OV3*44MOS4HI)K VX\]/#(?[&\[NY]YGC?GKSSXQ$8B1C
M(?\ YPL__P __P"J1E+_ 'C_ )?_ $)LJ_Z:_P"?_P#T9_2(C_\ 35^(JF2)
M4PG_ )B$).F(($+5HS?6A;**"7L6M;J3SUK>P^>O/]_EO/%'\1Z  #9J> /_
M ,:?NS4?"-023OJY)][?IG8^K8^(I]^\Q_%*;_I)G?K'X?\ !J?RT_=G/HC4
M?'5\V_3'U;'Q%/OWF/XI3?\ 23'UC\/^#4_EI^['T1J/CJ^;?ICZMCXBGW[S
M'\4IO^DF/K'X?\&I_+3]V/HC4?'5\V_3'U;'Q%/OWF/XI3?]),?6/P_X-3^6
MG[L?1&H^.KYM^F/JV/B*??O,?Q2F_P"DF/K'X?\ !J?RT_=CZ(U'QU?-OTQ]
M6Q\13[]YC^*4W_23'UC\/^#4_EI^['T1J/CJ^;?ICZMCXBGW[S'\4IO^DF/K
M'X?\&I_+3]V/HC4?'5\V_3'U;'Q%/OWF/XI3?]),?6/P_P"#4_EI^['T1J/C
MJ^;?ICZMCXBGW[S'\4IO^DF/K'X?\&I_+3]V/HC4?'5\V_3'U;'Q%/OWF/XI
M3?\ 23'UC\/^#4_EI^['T1J/CJ^;?ICZMCXBGW[S'\4IO^DF/K'X?\&I_+3]
MV/HC4?'5\V_3'U;'Q%/OWF/XI3?]),?6/P_X-3^6G[L?1&H^.KYM^F/JV/B*
M??O,?Q2F_P"DF/K'X?\ !J?RT_=CZ(U'QU?-OTQ]6Q\13[]YC^*4W_23'UC\
M/^#4_EI^['T1J/CJ^;?ICZMCXBGW[S'\4IO^DF/K'X?\&I_+3]V/HC4?'5\V
M_3'U;'Q%/OWF/XI3?]),?6/P_P"#4_EI^['T1J/CJ^;?ICZMCXBGW[S'\4IO
M^DF/K'X?\&I_+3]V/HC4?'5\V_3'U;'Q%/OWF/XI3?\ 23'UC\/^#4_EI^['
MT1J/CJ^;?ICZMCXBGW[S'\4IO^DF/K'X?\&I_+3]V/HC4?'5\V_3'U;'Q%/O
MWF/XI3?]),?6/P_X-3^6G[L?1&H^.KYM^F/JV/B*??O,?Q2F_P"DF/K'X?\
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M]6Q\13[]YC^*4W_23-/UC\/^#4_EI^[*/HC4?'5\V_3'U;'Q%/OWF/XI3?\
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MGZ!DK6!;1Q'.+;'BW5X;V6'T\7L&U$5@:-L7(OF4-S$D8]NKY'#&]_7:B<.
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MEE;+%F5B&W(:R. 0"ISQ@@AAP0?P,J_PEU/;%^RIY:+%<V@_W-00F=.C89"
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M7OJ#3T=/6!BS[ZUEESD@J<GRXY&*GU5QP4<J6TM5R5BL6;['+97[I8 X [@
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MRR'6&-+BK*0'+)8[[0I &/!@*M0K/7I;+*R;>G8]^U-K&E;]B/8%48R2:P[
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M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)I1=;5T4M=W(J
MPHMQ?R')*^N!<58@+7M*];%MX3.ZH*#1[D0[;&/;D2L,.+7;&+:H)NQ;\Y]6
MS"CJ/A2"HWMA2OW2HS@$>[&,>Z1VKSY5YSG@<Y[YXYS[_69CYK1C;\5*MQQA
MW*$[=MH(DGR0W_+Q+3L>S-M93QZ?Y1+;MF"$/:("@*;8][%[KVM[WG-S;=NY
MMN<[<G;GUQG&?QQF=P,[L#.,9P,X],]\?A,"LK>*+K!26:H1&"E*:"O=<*#-
M';^3W:*/CTROYB!Z;A!$F<QMCBS#&RGJ [&V$ODD((_Y3VL"*0L<5FH'R&Q;
M.W(=59<J>XR&\P'<JI_LB<*@L']X4K^!4D'!'OP1QZ9/J9EVN'1!D0-+4RQ6
M-M#6PJSU[&VM;&V($#,N4D+4RE:THTB4I.W*U"9S<4YZE&62<:0X+2C!B+5G
MA,B7=BQ9V8L,,2Q)8<'#$G)&0#@^@])T*H  4  Y    /J/0\GG\9TTM>0!#
M'W")(H-#T<5=C3CW2,I8RRIX^Y'J!%C4'.#,4B VK#3QDDC.,4IC!FB*+$,0
MM@#O73986#FQRX& Q9BP S@!B<@<GL?>8VK@C:,'N,#!SWR.QS-A:VIK8VY&
MT,K:@9VEO( E;VMK1IV]N0IB]>1:=&B2%DIDQ!>OW ))* 6'7[@AUD22Q)8D
MD\DDDDGU)/)@  8   [ < ?Y3OYR=FDHJTKEM-<3VZ 0E >\%"(=CD458DIK
MH2-44N&2XF$("QK2AK2"%@BU.S0"5$E*-ZV:6 >IFVP@ V.0OW078@<8XYXX
MXX]W$CM7GRKSWX'/\YR*:]A![PJDP(I'$<M4EJ _/%&PLQ,L3FJ$(VT2M._[
M0#< *P(A[3EG".'Y$ZT2((R?,O86.%"[V*#^P6)3OG&W.,9_""JDYP,^N!D'
MU![YG)7\%C580:'UQ#4&VR)P2,LD2CB 1YRHU*RQ]N3M;<6H6*!F*5JKTJ8L
M2I<J,-5+5.S52HTT\XPP2QVM=['.7=F=C@#+,23@#@#)X X X'$*H1551A5
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M4EAT]H0X2L6&L/O%9MV=0H&\P5F*@@<8 $=)-^\##9+=V*[B-N[9NV[L<$@
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M3HZI9O:*,QR*^9L>E[8X.:\YG+..=B&,91OHI$>V$)E*EP)853D:C2I52E0
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MHIL4+&Y3I.X 8$FM)G'U;+:Z'T^I0U>PT^(6&X*-3U!J+48%R+U!94&&V59
M(.-Q[8U1K5MJ8-[19I5%98U[.DC A<UD@,2V"SX)!'8=[,0'DFU9Q7'2<A=*
M8[N;[W%X:MR<JQK71,KY.*KAP<'Z.)PQ^I*O;:88XS(9 W%R0H]1%)5*A-S
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7(Q$8B,1&(C$1B(Q$8B,1&(C$1B)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g451428g48h62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g48h62.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4J,:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/D5L:6YS/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!46#,R-&$N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#(U+4IU;"TR,#(S(# Y.C W.C(V)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#(U+4IU;"TR,#(S(#$R.C W.C(V)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF
M(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S
M92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C
M97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#86QI8G)I+4)O
M;&0F(WA!.R @(" @(" @("!#86QI8G)I)B-X03LF(WA!.U1H92!F;VQL;W=I
M;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @
M(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP
M1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C,M,#<M,C54,#DZ,#<Z,S M
M,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y
M1&%T93XR,#(S+3 W+3(U5# Y.C W.C,P+3 W.C P/"]X;7 Z36]D:69Y1&%T
M93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C,M,#<M,C54,#DZ,#<Z
M,S M,#<Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T
M;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#
M<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @
M(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG
M.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z:&5I9VAT/C4V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K
M6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML
M3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&
M:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='
M0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%4
M17AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(
M>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G04]!14%!=T52)B-X03M!
M04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%1
M04A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G
M8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%
M1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I2
M5&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P
M5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7
M-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E
M66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"
M455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO
M8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X
M9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-
M5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F
M2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K
M<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9
M<3=&6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA(8U5R5#-X5C1(8V9M=C4O
M<S-A0C5';&MS;&XP5SAC=WA$;')-:C-(,5=58U5P44I%:&]0:$YE;5@X05E7
M>B]Y)B-X03MX<4]U42MA=DTY=')/=E0S96XK6&\W4G%343)K84U,:3)-,')V
M-DU#4U51:C111S9D95=6:T-H5$E-5# O=T1--WI*4'!/=G1Q1W!F)B-X03MO
M<39M<T1R1VA46&1O255I:3E6,49R2#9Y=W)-5U5X0D@K345T,W!42FU!4F)R
M-S@Q9%EL8E(U-TQ56D1P9'):,E@K23<R,71K;E0Q)B-X03LW-65%<D=C4E-W
M479B8D]&86=,9D-686Q-4D%,8DYF>7$Q4%<Y5C!'-#%$5G13;'8U;74U-V5.
M6DDW94Y9,'0U6%%&4D)&16%S2V-U)B-X03M24%1A;5%M04-K33!Y0UA9<3=&
M6%EQ-T9867$W1EA9<3=&56XQ4'IB;U=M,UET3'$T075.=E524GE-65I3=TPO
M041P,$AX8FIB9DUB)B-X03M,<3AC1%)/-VU99$)L>5(T;VIB-R]W069*0V5B
M=DUE;V%86C)6>G!Q5S@P9#-)27A.37@Y3W)G1U!D4T12:%AF9DLY6'%*67=$
M1VIB)B-X03MB;TY*1$Q+55HR1$5D3V9M;4YR<7)X851(96%S171:1TI6,5AK
M>3=U5E1J='E.5F]E;C-:9$A,54]+97IJ>G=8:TUC9G%(-T5266%P)B-X03MP
M*V]2=$I:>G)-<3!$,#))<C!Q<&]26'0T-5!(;&I0-E1B6&QW5'AM<$-K5FQJ
M57!85C-A5V1U.7AD>E(R.75L3V,P<D)%5W!!1E=9)B-X03MG0W!.36I+46E,
M2F]--%DU5$Y20DHX;5!8,S5G-DQB6$-15SA.,7%$<R]P=3%T14]#35-!;DXU
M5VE7:C%Q:D$P23-R5$U3979X9S!,)B-X03ML-W8R,#=$1C)6;&M,2FI$,VXY
M5CAU=E9U,S@K-F1*.&,Q:F4R='1X5C%U;FI34TIU8F-50V96-4IM8W-4='A"
M.&5H1TUD9$4X>$E$)B-X03MV+W-T12MY-6I94VA+6&1:0C@O<4%R-'!M4$TO
M;&]V=T=R5UIF<'@K<U)6.$]N3#-Y+SA!330O-3!F;4A'+TI:=69"3"]3;%AT
M.5@P)B-X03MM-750<3EV97=46$9#,V]X>6\W,%4X5U!%16Y9-TA*4GEW:V%"
M0E!V834V9DI%5UEK1#-&1C59,4]X5C)+=7A6,DMU>%8R2W5X5C)+)B-X03MU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMO2%=D4T9H6D=284<T;%!P
M5W%.,&%69V5.96UW<%4K=S(S,GER3FPT23,Q-F4Y)B-X03MV,"M(>$I6,$<U
M.7IZ=E=.0U,R:"MV:VAP,%!/935E<D9M95%(=C9J03 V;79T43$R,&U81%$T
M=79E.49P.51X2&<V9$(X4&@K4&-N)B-X03LS;7EA>E!L1%0V15!#<S!54VA7
M54QY:E(Q2R]'0W!O54E(255R5'1M6G%P1'=9*SA/0F]9>2]-4S<V2BMD9'EL
M-79U-4I.2C!+=W0Q)B-X03LY4V4W<390.%)J05-(,#9S>3=G8W!L3T16>G5%
M26IM9C%F=%IA1$=":WE44$M0-C<O46Q+=F0V0F17='I#>FU+2#!L=G916E9J
M9G%0)B-X03LS<UE6>61J6&Q4-6(U:D%Y>$5%9$]D9G!C<VE/94II95IV:'9N
M.$0K:C4W4%(Y4'9R92]S;W)U,TI-57=Q2S!Q0T11<6%61E9);V,S)B-X03ME
M4$E*>$5H,65C>31J:FM9;FU'35=T*VUU6'E88W-N*VHO1RML,C0K>5E6-&HV
M=U%D*V)R278R9T-Q='A!*S!Z64%Y94Q+>GDV9G(O)B-X03M!0GDK+UIZ>$A"
M2&A!,S(T:C4O>F9C2S9C>4PW9T131WII:E9A:WE30E96-6U#:#(T.3(T:%(S
M2C)&375%04A';&M*6&U#33ES4$-')B-X03M015AL9FQM,W-V,')O,#A%06UH
M=DEP94U4;4YP,T553'%!5C5):3!E0FQ"-&IL<U-X3F5/;'=22$A%,7IV,SAV
M,F9J<#%/<VY,=S5G)B-X03MM:D5J=G)C:C0X<%AZ3F-G3RM:879O+VQE83EL
M*W5W<DI-9E):,4Q61$9J-E-&;VM.4U8U1#0S6%E%8C!',F1L>%EI9"ME,S9U
M5' Y)B-X03M0<4TT:4]%-V(O<C5N-V=E;DQV32]*=7(S3C%.9#9E6FYV<F)4
M9VM3-F<T0DIK<7A-8GEG,&M:54M#;T9A9SAJ56I-;E(U6E-*:GI%)B-X03ME
M=C0U+VDS1C=1,#A9:4TV-%I4,S1F3'9R<'9F-D]42CAZ;E=/>%8R2W5X5C)+
M=7A6:3,U;&$Y<6UI95=8=DY-64IC3DMK4FQ+:'5#)B-X03MT5W)!3E56<4%.
M>&U$,FAM;&IX,TAN8G1/>4Y,1$YN-%HX<70T1S)S87$R;R]P23-C=C$O;'HK
M=&-Z-FY,+U=Z;69%;'AC5BMR=F4W)B-X03M';G@X2$)W:F@W=6I+3E4O33=Z
M9&5A2F$R,W)',T)$>%A&,T=!<GIL869T069$4E=&94Y->DUN84=754%,<GHW
M,U=997AT4$1+6E9F)B-X03M51'4O2&UX,U)F34]S84QE0S<P-C5E1U%K1U)A
M,5)X5W1(53=-37AC5V%733-%,#=$56%42&UJ=WI&:C=V8VIV3E!N8E@O34TW
M:3AM)B-X03M+5UEC=$9:2CA-841T5VQ/4DAI,E=A:E9Z>6XQ2&)U84Y&,F1I
M,#0Y23E896XS-5=E8CE8=$YD=$Y(95HU.4YU:5EH035*15IO4T=3)B-X03MV
M5&-B:G!M5#)D<7!X;4E88U,T4&)79WAZ>%-Y059/3SDY+W9E-34P<GA$<U9D
M:7)S5F1I<G-69&ER<U99>F-8:T]P871,=V]6<T=E)B-X03LS43%.4WA).55K
M1VTS3D]),B]:<411-6=4;4IZ+W$W9G(O2&LW3T=--#A9=BM09CE8,D<O:6\K
M66)6-4Y*;4-!,51H2E98.4UG2319)B-X03MS1V]A54%R,$]1>G@Y0EHV4V1:
M0F)(+W):;G1.3S!:-UHU-$I:4DUJ=WEL:5=I05=247%+,W<O14=99VEH3F%J
M<4U4:G5-6599=3-9)B-X03ME2'=Y;&QU:4)7-#<K6% U93=P,%9*3E5K;G5R
M3G!%93%E>DLR:'0S0E%+;UIM;6M8:U%Z254Y345S05%6<E1#8W!*1C=6="MV
M.41%)B-X03M90D=-<3E81C9R*S1E*S<U9#=)3'5Y4S1T>D4Y94IO9'5T5DY2
M*W)-<6-,1D]V:&M-5%E54$I&-EEB>2LP5F=W4T0Y.6%L.3)+8VI')B-X03LU
M2G(O041R541J*W9(47IO;4AD=4=F85=/-'AY.2MX*SA)2'EZ8E<K;#)6<%E8
M0VU#+U-:-%=!37),2DQ!:&E:.2M(=U!(1T=534]0)B-X03LR86(P>7)4>$5!
M26YA5BMF5&(W;2]75$]74FU.-%9F5%E(9C5G;F5T*V9M;6QT-6PP<35U5&%1
M>D9R<%574F]H2$I52W@T,3-58D)T)B-X03MM+VQ05VU84C%%0V%",RM,:E0P
M95--94EJ,"LX9G(O=#9+.35Q559P03AS;%=+<7A32F%C,TMQ6#1)0U)6:49/
M,E-N:T528EAJ=VU2)B-X03MO9C)E.35B-6)#=%!#:DU,5S%J.6,R,W!U.# O
M3#%/0T=.0UI!<$1437-1-%9Q>F9A63<V8D)U4C!'+W8O1RMZ,4=S,D(O:6MA
M=F]/)B-X03M7.6YB=3E7+TE$:TAO6&QZ>6%H.5-B57)664Q!:R]69$992WEB
M-TY09#=U2G!7<#A)2DE552]A*WIT.5!P3W-H=#!J*VLY-2LW,W90)B-X03LV
M=G1!-T-"=5A79C9).'%(,RLW;DPT65E9255H:%)9;UDQ0U)X;T%Q<7%I9U91
M3F=!33)!04%O3VYL27E.;F-L2F(W6%!-548S3$1B)B-X03ME5S=I-V=1,&IU
M5G5B4D9C94E6-5999E--;E$W,$M(*TDO3E@O57 S6"]36%DO.$%68D=H,W$W
M+T%"2#5Q+S9L3S8O-E,W2"]!2W)9)B-X03LP3SE89C1J.#%F.$%5<#-8+U-8
M62]W1%9B1V@S<3<O169M<B]!2VQ/-B\V4S=(+W%T:E$W,5-0.'1V3FYM6%9.
M5#%B4SE2=%I,:7@P)B-X03LK47)"<D1.069J2C-T<$1!>&EK9% U;R\Y:T%C
M;$])0T%75F5A.4IL,69Y-68V9$-613%X159I-2]:-6=H;'(T8FIR;4IQ<U)Y
M67I%)B-X03MC>35M:'IJ1FUJ33AG6&=M<6533F$P9$]E<G1B,DDO65(U;S-K
M8U9P5DDT>3=K9E)N35ID2E!(.61$-&@W<D(R:FIZ1W-D>2M"<C5L)B-X03M/
M<C9F42]-2&PW4W1",$%'1R]S2D<T=S-F0T9R;'!2.%1*2GE:3U1-4'-S,W-/
M;5AZ34UK27=H.5$W*W1U2&EJ;'=:<#5C=3A:1"M')B-X03MZ=S$U5F9X4VU4
M>7=M:#,X2CAY4WAP1VI+,"MN,CAI5%A,1')W2V]E2V-V1FU',U-U56Y"-&-H
M-&YY2$YY>')02&=F0D(X<$562#EV)B-X03MY4F5P-F1,-7HX>C-&,35E:E%R
M8T)'*W%33DA"2D5%:E9$.$1.4F@X3F%P6#9-;FMG8RM1;D=/9E193D](2TY(
M9T5C>#5D9'E$=F8T)B-X03MT;C,U8F9L=&0V1F5387!Q,W!T94)42&%X4FYN
M-EEB6FY,8D1K4G1T,GIA84112$A,:6YZ-D]I-U@W6&IN:4E9-S1E=FUZ9E9R
M,B]T)B-X03M,6EIB2%0U3E-M3&A40D9*1D51<$)*9FQ->4Q157 Q<G9M,T1Z
M>55F-&HX,68Y4VYD9CA!4UA9+SE6<TY$=E8S*TDO3E@O57 S6"]3)B-X03M8
M62\Y5G-A2&5R=CA2*V%V*W!4=78K:W5X+S9R63!/.5AF-&HX,68Y4VYD9CE*
M9&HO=T)6<V%(97)&=D]0;FIZ<'!D+W!-.7)O,#A-)B-X03LX,'!T>&\P:S%P
M3CEC5G%&=4%H9#5K84U#=DU!<5 R<VQ'24M#6'!C3'4X4T\X6FED;$)A2FE#
M>6MI<%5L4WDQ2'-C<E-P,VPQ1F%7)B-X03MK.3%,+V17.&)3=E-G4$9!5U R
M:4(R-VY)>FM)9VLY1V5/0FY)4DA-;6YN+T%*3FMU2F11;FUM67,Y>6IZ>40W
M035.2G4O06)F15-2)B-X03M8>$(V0VUA8E-%;5)*-C=U+W=#,$%"04%D3G9S
M-S)587%L=2MN6$-8179O=TUH5U=4=49/>' Q,U!16FY:44]%,F%$<DU"26U/
M15=5)B-X03M(-41U5G59.5%N:F17:&MM1$EQ,7%V26,V35-45G9I;V9L=%5B
M-4114W9I4&TS9'%1-%1%2&Y3:G%J4GDK8UEA249%04M'5FHQ8WA")B-X03MI
M;T94*WDV8C!(:'9K33%(3U!,.5@Y:E!!0TY-9E X05@K=W!U,&9W-6M%3T=#
M:V5L>#-&<C4T0D-Q.%8S8G5P96EH;%9+1VTR-2M))B-X03M$<B]$35A#1$A0
M-W<U,F-I5VPX-'E5+TUL<&-V<F5O,G1N9'1$8U1W,C$W1T<U.%9L5FYI24Q*
M>$E2,6=55416-FY(5E%0:45!-VM!)B-X03LO;R]1>3!E441&1U5O,D%:4BM'
M>"M9-&HY:D-B3R\Q1TLO1G9A-F9-4$U%>G1#-5IV,W-N<D-34W%!0DEV4U=6
M5UIT9TM5<61I4G)9)B-X03M3;'A50C9Z*U!D5G4V>5EO1T9Y:U!#1R]K2V]E
M*S8R2%!E,F$R+S5B4S-J>'DV+V9.4#9:64Q"07I!:$-X2'!M9'%33D<X455/
M0T]8)B-X03M+<#4W;75Z:C)C6D<X:'8S9G(W<2]T9$Y0=&=10D='3E@Q4#,X
M4$MW95A3=C1E5$Q,2%%T13 K57I71VXR,7!->3A':V=H:FI9<5-$)B-X03MX
M3$M!859!>EE1=W=I8FE!4&<V;DQQ8W515D]5<$1Z2DM/>7AO9&ER>C-2+WIP
M.'8S,78V<SEP8S(X<3)S1C%.8DEP;6M26FA.27A9)B-X03M+0CA#47=,3'DW
M<30R<FQH>&Q!2TQM+TXW>79%=G%.0F9M17%*0DU,6FEH46U52S%A.40Y5VQ)
M.6Q/1'=Y='1R*V%E:C-E;UA&;G!C)B-X03M:=51:>#,W6$Q05T]J,E-)>3AD
M;41,2GE)<C%&3VU0071Q3G(K9$AK>#=:-4QI4V%&-$M*3U!38W V+W!U-6E2
M-D1K>$U4<793<$AY)B-X03MX.$UR87I4+T%--79,1CEQ36--0WIF57!J0D1(
M9$=.;$EN;FMD47)Q4E%*>%%.>35D-E5R=&A/37)A23%$>B]O*VQ85G9O96DR
M0F4T)B-X03ME.5=X9VE72F],5V]L0UA,27EQ469295%"-D0W5%E"1SEY=',S
M>4-8:5@U,F%D3$0U:G1R-'9Y:74W8TMQ,3-6;U12:%1W;W=0,S5Z)B-X03MN
M83)/<V=094AT4%HS2TI95$AR12]E=TMW=&)Q-W993&$P571D5%-+:T-R<V5B
M1VDW.70X,7-):VM!8S-E-5IX:D5Y;#E)1S9C*V9.)B-X03M,=71..#%8,$YZ
M2TIP6DA%-6M"2G(V=S4Y.3EI85IF<3A::&M)4% Y8F@Y;5IO-4U%5$553UAY
M5F9Y-G-R*S<X-6%93$]O84-66C4S)B-X03M&449H43%K<5(O379W+U1K=$1#
M57-S83<O<UDY<EI)4C P*TQQ2TAV-F9R9E)M9%DK95!0;2]/4%-0<39E;EDS
M3#-Z5'=1+U9L475R)B-X03M'831I:5I)-4%0:6M%8S--3%%6-E9Y>G<P5V]N
M.#8Y23E7.&M&;$MD3W0T4%9I=7AY4$IM5TUX<DMV1#DQ>F594C$S*TQ(=S%T
M3F1()B-X03LO3DQ19%%N;'1:24QM,'5O63=M5C!K4W%-=&]32D1'-%!X+UI0
M8C4P<4MG=TLR:&XO3VYY4D=W4U=3-6IM155K.'-,44](:E-/37E$)B-X03MM
M4#A!3%9A<E0V85DK1U9T15AN-7)E6$Q457)Q>&UG=D].;3-P>EA+=SAO9R]Q
M5'AS=%$Q9'9Q<VI6<#!".$UE07)A6#9T*V)0;$\Q)B-X03MJ=3<P5TTU,5A4
M-U-2>#8Y=5DR:DQX;5='1U-7:DY'2C9*4VQ2=5!O26=62E1(4V9Z2G1.5CAZ
M=S9,85=C:4DV=C8P<SE9-5DU22]6)B-X03M$>'1%5C9Q,% X,V9!655,5S T
M.#5Q-RM7-WE.9'I*-E-507)S,'%+9&@W2$U,5VHY,&9H.3=N9&Y'<S!4-R]U
M3$=.16MG2$-Z3GI.)B-X03MB>4EV,6E#-4)J2$I7448Q24-'1FQ&1T9D+W-K
M-V)(3F9G23574C%V.&)/>C%)4#%51#!),R]89CEQ85-E6&UM=D1D5%A62'%'
M0FI3)B-X03MH0BM%365,=$I(.&%,4G9G.$-+15IK2%0R8DHO2#-F631O,612
M-%%0>#A+3S-V.$%F870U3FAU;TQR53=E4D=7,VAD1G13>DTU369+)B-X03M1
M<4]433)W5VQ".2M4,%%)36@P-F9A=S=1;$=5645C>GHY*WEZ>D]M;3)M<3)C
M.'=-5%AJ16979U173U9/0U)L4E)V=#AG<D-L1'18)B-X03MP9S%1:D=92C8Y
M9DYL;VI/94]11R]$,#=X=F9Y-6A.141#3E$U-4]!3U1!57%A8FUL5%1,:'EC
M53@Y;4HV-W%:=$YE=')H035J<V5*)B-X03MU4VY*5%-6:'A(24UV249L1F1U
M;%)V56I.9FUY.$]12"MB>F1T<'-02&E)4#A83#1-;C$O47!,=35T=%)S*TLS
M,7-':F-%065T03E#)B-X03LP6F5H24MS039D<3=B8VE2<TY29S1I2D0V:#EO
M+TA*,65L,5%G1$-8,'DK=SDO-D0X*VQ)6'DW-59E>3%7.#%7.5-%6$5P0S)S
M8TQ3)B-X03M-155!.'!'-495.5(V-SA5,D<S23AJ:TY0<&5'4FQ+<C9F:G9B
M9%AR:%!(2$A'-DA/-BM89E$Y+W=&0FMU6G)R6%EQ-T951'(R<7)P)B-X03M'
M:&%J<7I2;5ID4'1:<F]X03A3-&AJ851J5VAP6&I40T):579/8D1Z6BM6=7$S
M>3)L,W!&<&)7,$YN84TQ>&-2<'A794I#17-U4$AD)B-X03MR94YY<"ML85I9
M67E#3FQB4U!/6&MJ5CE,,#8X8E%O63E0=7AE4EAC:F5I-E=W<TE*<FIG=UAD
M=555.&I#9RM(;3-F17A)5S%,>5@U)B-X03ML.'5A>&9P3' S;&4P=')E.70W
M>35V<G5/4DI*559(159W:&EI:6)M6$I39U9V:54O4FI)16160EA79FY4.&]:
M6$9V86%52&UU;6AU)B-X03LO<3AD;4=:<FQ*9E1G56AA:C%1-U9(658V,4IX
M-%I,<V]86&UV.&].4&I25&]01U-*-7!B944R25)I.6LX:3AH>6]A97%(:E=V
M8T5')B-X03MG1U!$3'97=W(S2&XO=T1,6DHY4C%#>#!D<'1F:5@V=WDO5DM3
M3E!&0S!X-5-!3GA-46I0<4XW8F-S945R8C!Y>G50<DYP0F-C94AR)B-X03M2
M<DIX<E=N2E%A5C(X8W%3;$AM:GEB;W9M5T]"9%)6=SEU4UEP66TT=4$Q3U$S
M1$-H;T\R63)P,&M-,6-84GIT1C)H;#!X4$(Q-S!0)B-X03LU9CA!>3@X<C9&
M9$QD,E9U>EAA2U9795IY-T-U>$E'>6=N>$%Y1T11-#A:<T1D<S%8875F4$AH
M:V94,T):-6LO3')Y-35G=GAF,W%Y)B-X03MP8SA1:G9#-%AK1C9C9U$R-#99
M3E)O36576$5B=GE4<$\Q<S)#2$)'<3@P9#5E.&XK6"],+W%N4S=B,'!*<4-3
M4FU:,DE(4599;6<K)B-X03M75S1.3&IX9E-':E9A+TQN<FI.,&U6+V97=6XR
M1GIF,V(K;F$R:U1Z,T5L0V5-8V%L,V%G,S)56FM!3T<X>'-V4"\U64YD4G4R
M;%(R)B-X03LY<S@Q<DI95&969UI48U!)-CAZ1W%K<C9B,GE52S%05$Q41U-,
M56@U=B]*,2M%.#)H3$9B24EK:G58=$DK3F)G4$56;W!,9D-S0C5B)B-X03MD
M=D59.$UU.61K>3!J>DXK53$Q-6=T;W),5#0P,6)6=E9J-6963TQ!3U=J65,W
M9D(V;D)H.2]+;%1G26Q3,D904W9-2#5D86U*8FPO)B-X03M,-DIF45=C.#=!
M5WEU<F]L<D<X<TM3:TM(9C9V3DA5140W5DU30T]Q<&19*V10>71S:V4U=E!,
M>39C8F5S5VY!,G%U,'-B2D9)-F<P)B-X03LT.#%.-59L2C9'=%180UEY-S%S
M26QP4'ET=%!-33!5*VEW<D%M;5%3,F)#2&MJ=UA*9C%+>$92>%EI64$Q,TDX
M2UDK<6Q41%,O4&XU)B-X03MB>6%X65!:-F4X3W-A=$U&=#).<4DU:6)G3$M*
M;5DW.%A7-C4X9U-A16YP9TU44S)'838V55A3<#)C9TEV0FE4,$9(53%Z1C%(
M,$9Y)B-X03MD3&9I0W9X<WAZ54Y0<W(O045P1$4V4D=+4&Q$3G-%0SA4<U11
M+T)4=C(V:DU$2FIJ3T=Z<V-75U=02G9V6C,O04(S;U=4>EIB,FUN)B-X03M2
M471):W0O>#1)5VQ49S15165S6'%F:%!(-'4T3S-H5THQ46I%1"M,,R]A,D11
M;6-Y87%(=5!Y<$\O2D9T>#!K,W)U6EIB,3)C=659)B-X03MQ<4U66%HR8G<V
M,$924V]Z2S!-4%)X9GIN0S=3;BLX-&51:6Q0-7$V6&4S96M7,7IB<4=I<S53
M,7HO37-B:FIY564S96AR;%!A;4M5)B-X03MO06IP>F-V<U!.1T=1>%!/43(Y
M-DMS=%974%)5;FTU;#=E3&I/<"M**V-9-'508S%'34UT47,Y1W)*9W9*439N
M8C1S3C%1,V0P>C9G)B-X03M"2VQN2DUK359U1TI"5&1Q.%$S2#145&I2:4]6
M4G0P>EA:3&PV=6QU-7=C3692='A69"]J-V9+;G(K9$DX9S=&6%EQ-T9867%P
M,U9T)B-X03MB,V1T3&$S36%Z5S V3D9.0S1$2S9/3TQ+=U!514=H>%9"3#5C
M,$)28VAD3W0Q1C9S<V0S4TY2-G%Z<U=L1#!(>$)Y8718<FAS<6]8)B-X03LO
M:S-Y<G%&>#E9=F1+=')I87!*:V5.4U-41W-2<C0O=30Q6&9S35))<E-,6%).
M2%<U;G5L<V]"8UA19&)M6# Q-5-#44ER:'I4-&=W)B-X03MI44=V:&IA<&%0
M25!K;THV63!3>C0K;C9.4%)8-TA,;E-T3W9,97981'A&858S.&YE5DA%06)3
M3%%R8D-68F1F4E1I:7IS5VM#<E-G)B-X03M$335.4$4T3TER4V<S-68K4T=J
M84YT1'-I:FA!=TU+1V]I6&EV8BM88C,W-&5)<E-F26E):6]I:%550E964E%!
M1%E!05I&5SA69&ER)B-X03MS5F1I<3)A1TMA2C1::U=31U)3:VMB9TUR2W=O
M5EE(66=J1E5J2&M,>5=)-&\O,$I:8TE'5F]G655.0VA:;#9J9F1Y9#AL>$9A
M5VXX)B-X03MV+TI$4GAX;E),37!%07%!>$QS1EIM2&(K6C)0,#0X4E)327-V
M2C-L5WAU3&4T<SE*=%E,:3%,;3-L:FE65U%Y9F%O44LY+V]W8U)3)B-X03MR
M,B]L=GDO8D-K1VY7,%DT<VQ&:5%$:DI':U1I;% R;S1552M)04=.;%5+,VMF
M>64Q;W1O,FHR:'1K<45J35-K1&PV9DMM,V8P238O)B-X03LV;W<X4E=L5SDX
M<&573#)73U<W,'$Q;6MI.4U2=3A317%)9U)'0G0P6&QS34%K5E,K-B],:GEJ
M8V%V<#)Q:7E%1C%P6FHK<F5H*S=7)B-X03MK25%206=$;V=I5E)3;G<O0V%J
M8D1X;$9*>G)6<F-896U81G9B:T-:=T]"871.:41466IR5$M-.$1+0D$U=5)P
M-6E%=U1Y64Y$-4XX)B-X03MZ,V-Q43-,;3%T:#AB=C9V3F=3,4=O47I-1%1C
M065(,G$Q2C%59$9L:V%/=SDO-"](5C-C=3!-15)C9E9,,V9J.&1%,VTO3$A1
M8FE7)B-X03M.-VEE-6M334M04C52<6AP4W!,0U Q4&DW+TAM4V5Z35HU:R]J
M-$]*2'1N3$5%05)(;G8K=79S6EAB5SA.=&)X5S!#.$E955=/2D)5)B-X03LP
M5E)11&8R>E!J15)&1&M(5E1M6D5Y4$UT6&-";G1:;T$S07EO>4(V5G!Y1DLP
M-S1Z:EE)5&IL=WE"-VU%-G U6#AZ46-9=%!-5GI")B-X03M,23!T>#98*VI-
M4S,R;&9M-VLX<2]A5F=2.3)A=DQP8V\R:G50;"ML,U=$5S1*8GIS14-H9G$K
M-&9O54ET13@S>E)P8GDV9DA!:65M)B-X03MQ9DA$-F$P25!-0E=A;D1J,$,Y
M*VAP5$E$5#5J<UDQ.&UY5W P-$YI4E!0=B]6,68O.6L]/"]X;7!'26UG.FEM
M86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C
M(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#HU-4$X048U0C U,D)%13$Q.40U.$4V
M,S8U-C Q,4)!03PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#HU-4$X048U0C U,D)%13$Q.40U.$4V,S8U
M-C Q,4)!03PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y
M,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I
M;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E
M240^>&UP+FEI9#HX1C<T,C!%-3 P,D)%13$Q.40U.$4V,S8U-C Q,4)!03PO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^>&UP+F1I9#HX1C<T,C!%-3 P,D)%13$Q.40U.$4V,S8U-C Q,4)!03PO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P
M.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#
M;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @
M/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.CA%-S0R,$4U,# R0D5%,3$Y1#4X138S-C4V,#$Q0D%!/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S
M+3 W+3(U5# Y.C W.C$Y+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O
M<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU-4$X048U0C U
M,D)%13$Q.40U.$4V,S8U-C Q,4)!03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP-RTR-50P.3HP-SHS
M,"TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T
M;W(O,2XP+R(^"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL
M93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(" @
M(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O
M<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*
M(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A
M;G-P87)E;F-Y/E1R=64\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y
M/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@
M(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C,P+C P,# P,#PO<W1$
M:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#$P+C P,# P,#PO<W1$:6TZ
M:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET
M/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM
M<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R:3PO<W1&;G0Z9F]N
M=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A
M;&EB<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z
M9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R
M:6YG/E9E<G-I;VX@-BXR,SPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M
M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE
M/F-A;&EB<FDN='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D-A;&EB<FDM0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O
M;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y"
M;VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXR,SPO
M<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FEB+G1T9CPO<W1&
M;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*
M(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A
M=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N
M,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y
M(#$V+C S/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !L ?P# 1$  A$!
M Q$!_\0 '@ !  (" P$! 0            @)!@<$!0H# @'_Q !"$  !! ("
M  4" 0D%!@4%   $ @,%!@$'  @)$1(3%!4A,187&2)!45F5UR,D87&1,C.!
MP='P&$*AL?$E.7BVX?_$ !T! 0  !P$!               ! @,$!@<(!0G_
MQ !*$0 " @$# P,!!00'!04&!P$! @,$!0 1$@83(0<4,2((%4%182,R<9%"
M5%6!DM+3)#.AL? 60U)BP24T4W)SX35$18*BLM'Q_]H # ,!  (1 Q$ /P#W
M\<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<:
M:<::<::<::<::<::TCV5V+<=0]?=T;7H%9CKE<-::TN-]@ZI*D%B@V$FHPAD
M\[$N/@(68ETP0 AD5 Z?<>+4PSA2/<RM->M&DUB&*1BB2RI&S@ E>;!=_/CY
M(W)^!YU3E9DBD=0&9$9@I\ E03M_?MJIOLAXQ;VF_#MZO]S:CKBM6Z\]BCX*
M(QKLV<DQX6$-CX&SF;/('D V')(L"I6&K/P+"W6T.8S(B$F_[IY"O5KX?O9"
MS3:1ECKAF[@4$D%E$0(/@%U;E^7@[?AJREO=NK#85 S2[#AN=@0"7.X!\*5/
MY?.YU)3=O?NT0UVZ$Z]Z]T"L[+LO>"OVB_PS-EGSX@.NZ\K>MX?8:9APR,&)
MPA<B',8:'*):4(E$:>KVG%I3A-M#04I?DLR-$M)EC8HH8M*TACX[$CP"/.WG
MR/.JTEDAJR1J':P&8;G;9%0/ON 1YW __P!U$-'B&^)VYVD=Z>IZ<=;/STLZ
MFQNI8&=[3F*_BC9G6Z[@G$_](^-F1^INH1].]OW?9\WO5Z<>7+O[OQGM?>>\
ML]DR]G?L+RY\>6W'??;;\=4/=6^\:_8A[@C[G^];;CN%^>/SN?C5[L7('LUF
M.E;>U&P4HU!"2%H8'/P1$0QZ(]LF;:9DWT#X?C8\C!*&SWFV,.BLI(<0UZLI
M3X9 Y$)NPY$+N-F(W^G<#?R1MX&_GQKT1OL-]@=O/Y _CY_+5-_A]^+-+]R^
MQMSTY;=2@:RJEBH]KVUUDMGU.1=-VSK*I;2G]:G21@<@RTRW*+(ABR?8C_0A
MIV LZ<M.#",$*]C(8I:==)DF,KK(D-E-AM%*\0E !'G;8CY_\2_B=M6%:Z9Y
M6C:,(K*TD+;G=T5RFYW\;^-_'ZZS[L5XCNT].=S.O76F(ZR6(?6FW-TU[3DA
MO?89WY/Q-CEY<6NR,JK45>$6])62+K0%D":D+=*?%A2IYN0@ A7'(Q\URG6Q
MT4U.Q9:RIDA@>801CD5"\N/><^%+%#L@W8+LQ/G;4\MJ2.>*(0GA)(L9D8[
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M \:MM]M8^<>YCRY;XJM(*5\EHE]W6,<(::,,6'=4A@6W3R1^]MXU4NS)WZP
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MS$/#4LM;F4-&H;=K4<IF=%6(J)E*=&S_ &?,';QZ24;>2I22J%IW5LC*HX9
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MSY3CH= =<9BP_:CZASN'Z1CDVVW#UY(;L?,AE'^P9^S;C!4GNT ZE.TSKW=
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MHR#A&&JYLT-E4G)*9?%LD2J4%E#A<GZ5]1\ETY']U]<>YL4J\J58\\$>Q9I
M\%C.9*(IL4I.0%7+1JTTA5TM0F1)98\4ZY]',%UU,N<]*O8TLO>JS9"7I$/'
M1Q^7:/O26!TLLLKBEEX%C+Y'IB5Q6K!TEQML59:M>6WL<@<P=@L1]HD4IEH@
M8EAQ#K! [Z$N,OLNMY4AUIUM27&W$*4A:%)4G.<9QGG02.DB+)&RNCJKHZD,
MKHP#*RL-PRL""""0001XUR')')#))%*CQRQ.T<D<BE'CD1BKHZL RNC JRD
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M2ET<H0EIU@AEQ*5M.MK0K&%)SCD)X)JL\U:S%)!8KRR03PRJ4EAFB<I)%(C
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M145B*\-:-ZT22+VXFA':IO)&LD:#L=J1-X7B=YG!"X2TG[>6/+&/O_[>6?\
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M_ET_1W[V_BB=X_YEJ;^G7'WC!_9E'_#+_J:>TD_KEG^:?Y=/T=^]OXHG>/\
MF6IOZ=<?>,']F4?\,O\ J:>TD_KEG^:?Y=/T=^]OXHG>/^9:F_IUQ]XP?V91
M_P ,O^II[23^N6?YI_ET_1W[V_BB=X_YEJ;^G7'WC!_9E'_#+_J:>TD_KEG^
M:?Y=:1["]>I?JUK&:V[NSQ<^ZU1I\/EL5E3LCJ@J8L4V4AU495ZI"#ZY5(6*
MS2ZV7$1T/',ND.);?+?R/'B&&#UZ]@6I1%!B:3N?)^F4*JCY=V,FRJ/Q8G;X
M W) -.6$PH7DO654?JA)/X*HX[LQ_ #_ ):U7X271?L3KO<>U.YNT=B;@U[5
M-WK,+@^O]]=J>+W?X\UK&(K978R,KM<AZO 7ASU.SL;!UR)#M\6?)ELV>SO)
M=GHZRU<M>KR0Q4XHX9'@V#6(P_;C(_>CKEF+LG]$LQ*, "J?NE9:5>5)'G=Y
M%63XB;CR;QX>7BH ;SX '(']YOD'T'\Q_7IZ<::<::\\7<'8<??.TMG8F1W'
M'-;RHE>K"RGB'HMMFNX5(F@+!'4VE#SAL;9U/%K<'68BYBA/F)5%1.!^0O4;
M,)E.M[Z6%)^YYHZ=(NS-"J4]II8S&C+LS316RSDJ9!?2-I (82OT,]'^GK&!
M]+<9)3D"IU)5ER&46)$2TTF1(K03K/(&+(L%G&!8@KK V%EF2%A;MF3?VBJ4
M67L6$2RL9;.M77%1![SHKY4MK.TQ[DI09A(SCXT@_'_$5+5YF2#)>! G12(X
M>(0%$R27LCZ8QCMEJQ0HRXAF,$K,C-/A[D338N?@629H^!FK++&[11V4:)8.
M$,O+ NN<U#%T[>+K(K]2*HMP(LL<53J7%V%J9^H9%26O'8[HJ9!ZTT:3ST98
M[,EQIK59H[&TN-,(4Z^ZVRWZVV\+=6EM'N.N)::1ZEYPGUN.N(:;3Y^I;BTH
M3C*E8QG<&ZHH+$*/I&[$ <F(4#<G;=F(4#\20!Y(USDJO(Q"*SL0S<44L>*J
M7<[ $[*JLS'X506.P!.NC5=:;D0HW\J:ZL,,,R0+(1,1[C(X,?Y?.,=6@A6$
M#">>,/OY\FVLJ3A2L94G&;3[RQ_!Y??5#''')+(PL1$)'%_O)&V?PB?TF/@;
MC<^1KT1A<P98H/NO(B:::&O%&:=A7DGL?[B% 8QO)-_W:#ZGV.P.QVJIVUV
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M5L!W7MORKNC(+C&4O2^7(MD<1F)\0U6>I,M+J&-,E1<QS0WG3'6ECQUV$QB
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MUA*L@^@RQ';+?9&'BY2MBS<(P]/01-FG+* 1)1<\4/7[(T]/2TP8W(24$<^
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MX);<.\YE"[AD<RIN(V0 QACX<L>9^DAM@ ?D$;$:UBK_ .ROUD__ !_Z!_\
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M15J?687"FDMH^'#B8RC+F''%TF=W"!F)$:<$!_HIR9^(_3D[-_%CJ8*JEB
M6/)C^9V W/\ < /[M91R34VG&FM0[[TW7NP6H+WIVTE& 0UXB&P'9$##:S(P
MX$\.8AI1AI[^R?7&3,='G9%=RALI(ZAEN-I=RM/@]3]/U.J<#D\!=>2*ODJX
MB:6+8R0R1RQSUYU5OI8PV(HI>#;!PG D!MQEW0?6.0Z ZOP76&+BAGN82VTZ
MU['(0V8)X)J=RK(R?7&+-*S8@[J@M$9!(JL4"GSRRW@B=B6+ X)![/TY)5G)
M'I8FY,RY0\OD3"_++I->&J<T,R7E'ZR16+ 6QE7DA1R,?KXY3G^SCU8MHI6S
M73\U/G]-F:3(5Y^WO^\]5*-A Y'D(MIUW\&0#ZM?0>I]MGT\>@LMWICK&MD^
MWO)2K0X:Y4$VW[D>0ERU*1X@?!E?'PR;;D0$_2=U5[P+5HDHEVU=C$D1"7&'
M9P"OZW4'(O,IRG)(<5+2-Q-&'<<3ZFV9(N%)2SG*7EQ3^,98SD53[-1$T#7N
MK0]<%39BJ8CMS,H_>C@GFORHA/PLTE=PO[Q@;]W6%Y#[<8:M;3%>G1CME76C
M/D.I!-61R"(YK=2OAX)9%4[,]:&[&7&Z+:CWYB]#5VL:5IJA5K6FO(9F!J-4
MCTQ\5'M*4ZYG"G'""S327,Y>-DI(UX@^2.?4I\PXE\AU65.9\NE,+AL=T_BZ
M>'Q5=:M"C%VH(E))\L7DDD<_5)--(SRS2-NTDCLQ\G7#G4_4V:ZQSV2ZEZAN
M/?R^5L&Q;L, J^%6.*&&)=DAK5H4CKUH(P$A@C2-1LNJ\O$$\.A[M[-5W8U(
MNL;4-D5RMIJ;HED%,>J]BA!I*1EHULDZ+;)D80Z/,EY3.368N80:.2T.L4?(
MK;R]4^J?I*W7MFIEL=D8J&7J5!19+B2-2MUDFFGA#20AYJTL4MB;>18; D1U
M4HIC#-T)Z ?:)3TCI9'IW-X6SE^G,CD3EEEQLL*93'79*U>I9:."TT5:[!8A
MIU=H7M4S#)&\BRR=UD%<M+\#_>$B4\G8&WM7U,!*<_'?JHEHO)SSF//_ 'H,
MG'4,9AK/V\G$R;[GX^IA/ECSU+COLW]22NPRF>PM&,?N-2CNY*1C_P":.:'&
M(J_&Q$S'YW4;>>B<U]MOHBO$AZ?Z1ZGRTY/[1,K-C,' B_\ EGK6,[*[CSNI
MK(OQM(=SM//J7X3.ONO6P0=HWZ\JV[:*X2V;2@/R836:W791K/FQ/D@NS<^1
M-302\)>AW'2 PHDK^^I#+D6 #0=G="^AF*Z4RL6:R>2.>NU'$F.B]F*=2I.O
M[MIXFLVGL6(SLU<LZ1P/^T$;RK%)%HGU8^U?U!Z@]/S]+X'!CI'%Y&-H,U/]
MYG)Y+(U7 YT(ITI4(Z5*8;I<5(YIK<7[ S0UWL03VY<WMKDK3C375S<+%62%
MEZ[.@L2<)/Q<A"S$:3A2AI"*E1'@9 $A*5)5E@L1]YAW"5)5EMQ6,*QG[\BK
M%6#*=F4A@1\@@[@_W'4" 00?((((_0_.M;9T+I[,9:8;.OX'Z7=M45[1MK"]
MLC#,YJ6IA6V.KE$-Q@CU9A(@&]V\85MM39&&YX["R%YRUENIWYMU;N-NDK3H
M?'TRN4+./'RQC0G\/I'C4O;39AQ&S((V_5%Y!5/Z ,VW\3K]2&B-02L7>H20
MH$"7%;-&K0=]!=:?RQ:!J?%1\)6&9+"7\*4B%BHF.!"PTIKT,B-85E:L*4J(
MGF!C82,#$6,9\?078LVWC^DQ).^_SM\:=M-F'$;/MR_7B !O_   :Z.Y=8]!
M;"$F0+KJRKV,6?V0WN"5:D1R%Y(VD/1&-:!WYMQLEMT.TQU)$$A(J7"6.5$_
M##D8U8LL(,>U%+,\>Q25UXQ]D;'XB,AE,?ZH9"6*GP=R#N"1J#11MN&0'=N9
MWW_?X\>7\0H !_#8;>1KM*?U]TO00Z&#3M=U^!8UE*VJ>I&0VB,DPL]>19,*
MYSV37R'C).=M3$S*YGYF8(D)*5?D"BS2GBW5/\@]B:0R%Y&8RJBOOMLRQE2B
M[ ;!4*KQ50 -@ -O&HB*->/%0.!)7]"P(8[_ "2VYW)W))W/G6O'^D_5LBO)
MJ2]00;=61-6B<37192S!0N'KLW&-6Z(^FASC F:A8VH:+;EZ)EK-*-0"PEZO
MJPG/G5]]:Y<^\W,JJ\B%+;)OP.Y4GFNYXO\ OC?PVI/;P[;=M=MR=O.WGP1M
MOMQ.WE?W3^(UO>:H-,L+M(>F*Y%FKUM8F+90\*8]IJK6(6MSU/&E(AD=33([
MP]9M$_"LH]M3#04H0VAI.?;4W;K(Z\]F([BE)/QY*65R#O\ /U*K?GN =5"J
MGCN >)Y+^AV*[C^YB/X'6N+-UET1<(AZ$G];0A(CNP)S:K9(CTI$34?L:S)+
M;L-RA;'#2 %A@9V:8/.#DS824CUF &F1[V%@DOCKJ+9G1N2R,#VUB(.Q4QIM
MQ1E(*LJ[ @,#L0#\^=2F*-AL5'[Q?QN"'/RP((()W()!'@D?&NOLW4[KG<HJ
MAPEIU)5IZ+UF++Q],%DFS2/IL58G1"+-"&/J,^18("TD@ E6N L;TM#6<L,4
MJ>!D2!VG$16W80R,DKJ92"Y&WDKOQ8#;960$A&79D!(4@$Z@88F"@HI";\=_
MP!.Y'YD';Z@=PWX@Z[@'K?H^,/U+*1FNH2-D-%U%F@ZI+CG)$%ZI4@8".C1:
MFPH4YGZI7A!HB,4)$SF),(4L$:1'9;D&\%<@;,Y$H,C$3N9)0=CSD))+^1]+
M$D[LNQV)&^WC41%&"A" =M>*;;CBNVW'8'8C;\#O^?SKCSW670]EUQ0M2S&M
M8)Z@ZL8A!]:0HKDE%D4%%=A7*Y#.4^>BSPK'720Z^^3!_,BI84LB(+,CBGWQ
M#"672VITEDF65A)*6,C>#W.3<CS4@JP+ -L01R (\@:&*,HJ<!Q3;@!N..PV
M'$@[C8$CP1X\?&M/7SHCH^\V?0*WJM7(C6.@:EM^N5[6,1"%13/U':IFOS?R
MFA+1"3<1,5::B7J;++D9(!!,O:'+?+KD95GY$EB6K)>G19SS9I;#Q,TK,&.T
M0D'%E96#*>8V!V50B@#XVD:O&QC'$!(PX" 'Y<J>08$%2.)\^2>1\_G(>LZ5
MU/3'JN_4J!6JVJE:]*U15&X6/;CA8#7)IL/)%U&-#%RV(/$$'P$.6XTEC+BG
MP6E^[YJ=]RW:>5PX>1FYR"5^1W+2 , Y)\D[,P_OU4$:#;90.*E!L-ME.Q*C
M;X&X'\M8T/UET(+""5P?5]::@P:'JS6 D:EHO([% TE8"[5JFK(PHK*OIE(L
M1YDM#(RK+J2R'%$ND(\D8F-F<L6[K<C)+*3XW,DZA)F^/F10 WX;? &H=J/;
MCP&P5$V_\L9W1?X*3N/^.^MZ\H:J:9SY8SG/X8^^>--55:>A@)&DT=U(L>Q)
MC5Z+DHF0<";?^FS!\<,8\>EI#@KCB2#7/D'L()8S(?KI>>2I?N)YYP,$4]*B
M0D:3+6BG@E:,/V9Y8EE,H *%N<IWE0.O=W(9O.XZIZON3ULWG%:6P]63(6JU
MRNL[1^YIP69(5KEF654,<"]NN[1O[?Z>"%1Q.;]@-,O[/JXTI6,Q\?LNM8;)
M@)E0S.'#AV<NN%5LMUUYM!$5(^\_C$;(OJCE/.95AZ+D%#6"*]?JCIYLS22>
MGVHLO3V>K.47>55+,]20LRAH9>3;13,8N3$AH9&6S#XW0'64?2^4DK9,6)^F
MLERBOTQ*Y6"1PBQ9&)41FCMUN$?^T5HQ8"* 8[4 DQ]J+'7R>=C=M,.S3:ZU
M*.&'1]LK9!6(Q04E),YCA7A&RLQZIFM$3+@Z 8I0J3JR8M A\<.:"3@7"^E+
MA@SB^Y!IV"[QWJ;OV>W+,O91D#F(V*;V"G;A*"6E(1')&LD;K'M#U!H+9Z2D
MCI$9.J(8+&)R4<7NA/7K.+$B2M&+ IY*.DDC3VQ*8,G"K306'AGB,EF9QP<:
M(0>>2P&&*WET@DEU#+#+:?Q4XZYE*$X\\XQCSS]U9QC'GG.,<W'+8CAC>65D
MBC12S2.P55 _$EM@/R\GYVUS+7KS6IHZ\$4DTTC!4CC1G=F/X*J@L3L"? \
M$GP"=5>[[W9"[#M-8C]?2Y+L_7Y.T1(2?CL9BG7I:&CB@[<4[)IP.F+K(XQ4
ML>AX)2Q1VE'MF#.B-M%:2ZHZCK9:]4BQ<SM9JS7(8P%40L9X(GCNNTPX]FHJ
M/-)R0\%!D#J4 ?J/H+HJ[T_B\G/U!3C2AD*N+MSGNR>Z2.I=LQ38F)*Q,GNL
MG))'4@*3!9798'AD65FBM*ZLZ\3KC3E=CUL/BESJ6[(4*2*B/?%8)CHZ,@1B
M8YMII,<>/5HF!:E@L(QAB81(83A*<X0G??0>&^Y>FZ4+*Z36@+LJ.@C=!)%%
M%6C>(!1%)'2@JI-&  LZR[ ;[#EKU3ZA/4?6.1L*\<L-$MC8I8Y6L1RO%8L6
M;TL=AF8V*\F4MWWJ3$[O3:OON06,BN9EK7>J?O%>2M VD26%#X);,N8R6RR?
M88=&D7J<"4UZ,Y0@AU_+[ J&UNM82DE:TN)<2A2>>_7=?'3+@IS#9- )'"J5
ME;')(-OZ1;=$ W ^LD_ UU_]E$J9NMXI!+VGAPLA:&/N.LM9,S8B8D;F-$[<
MDI8*Q)B"E2I8&.GAE6@YR5VW&N*><;DU1EID%DJPMP9\IU8L=C+;;Y"1<297
MY4%J:4YG)!+!);>,,.(PG"O2"](9\W >1$O9N2E_)5V)2,;!F"]U_=N1RW9U
M:0#BVPV-]IC&0)5Z2LKVT:JMC%0",;)*D2++8(8HAE-:/[LAY!=HXY(XFWD5
MF-N6#L9_\R?^'EG_ *<WD)M_R'\1_P#<_P#W_#7)1KD#?Y&_X%3L=:#WEL6M
MTBI-V"65)H()<7B+#$BRLOS1X Q1D9#RV<LLDC1#LK@1XYIQX5MUA+F#?.'S
M+*QB_4F7J8^DMN<3<G)$,:0/RL21*\L,$VZJZ5S,(VD5F0,O(2?L#.=9]T/T
MYDLUE6Q]3VQ1%'NI9;,?"E7GEBALW*@YO'+<6J9D@=$E99"A@_VP51JG\RV$
M"UNZK(D<$JG9YFAP<J/'Y?=:;>:#NFU)]MIUL9;S!N"M6PA.,X;7(*?="<4,
M0\0B/T-+=9*60+2AS:LC'5YTB#$!@F0S-A0>#,L@;$P,/'=+E"48LL?74.)C
MDR>%6.L8UHT7SMZJ]@(K,C38;I:@S*T@22#M=478S]2UQ&LZB2..-K$X>LG9
M:4TQK?-8/C,R1,I+IM.7"'LY>8:F:]7L#BN90\5YN-L"MK=];RG</..8?2V]
MAQM&S^ANLI^G,(:,D0F::S[W=R2RBQ3I\4)!?R%0%MVY<B>0!W T;ZF^FM7K
M/J3[SKVO:Q5:AQ82-.*2-3R.1,DJ@I%LK22LJ;($**I0LG%C=KSIG7%.M-;E
MZ_:@W_$QL/MBFBV=B%)?+A#FY"8@9Z%?*;2R;])L=<D(B>CF3V4-M2(HLBT)
M(MM,H-8(2RUA&/=0]*X#JF"&OG<='=6L[25I!+/6LUV<!9.Q;J2P68EE4 2Q
MI*(Y0JB1&XKMF71OJ!U?T!;LW.D\S+C'NQ)#=@:O3OT+J1,7A]WC<E7MT+#U
MW9GK2RUFFK.SM \9=RW*U+H?4.BXHF(U31(6HL'K2Y*G#))/GYMUO*U-NSUG
MER)"Q3KC.7%^PN7E#,CI6I#'MHSZ>3X+IC =,P/7P>,K4$D(,TB!Y;5@C?B;
M-R=Y;=DKN>'?FDX D+Q!VU2ZMZ[ZNZZMQW.J\[=R\D *U8)3%7H4E8 ,M#&4
MXZ^-H*X5>X*=6$2$!I.3>=;;Y[VL2TXTTXTTXTTXTTXTTXTTXTU!?Q#IK:,7
MH"#B=-[%EM47Z_[_ .MFJXN^PC03TA7Q]G;OH])D2FV9 ,\5YG(4T\DIAT5Y
M) V76%(4AU2<W^.6(V&::,31QU[,IC;?9C% [@>""/*^#OX/G5O9+B-0CE&:
M6).0^0'<*?G]#J#78CNGMW8G7_1YVH[+(:MV3$PD)M;L_F"0"X?2S*9MZ Z\
MV/3)"CAS4 KM&])"YBM/I821(5G3=P#2X*D]*\WM>E#'8G$RB6,EHJO+?9P\
M+65F&Q!/"!4W\[*\Z'8[:MY;#M'&4)1QQ>78?N[2"(H=QXWD+?AN5C;XWU9!
MM_N%IW5NONP-N39!9>:Z]TBT6FTUM8LK&K5)0C3HD97VY*1!#BWRYVR*CZ\$
MH0Y]M1L@/GW,-*]S'FPU)I9*Z<=A8=55MU/AO)8@$D!5W8[CX!U=/.B+*V^Y
MB5F8;$>1OXW( W)\#S\ZB]T,V_L#9%%WOU_FNS%1V]NK4I52DQ-\5@NG;'C"
M(+<]("M(LDR#79!J -<HVRAMJ4:(ABR%LB0=2JRY-)XY?M$W5^&.-X+"UGAA
ME#@P.'C(:%RNQY L.Y$8G8CY9WVV(W%*N[,LD9E61T((D79AM(NX.P.WTOS4
M#?X4;_KPZ1V3N.H?#?V9N>^;#)NVQ*7L+M-K>I7C91]?C7K!<8SMCM?26E6[
M8<#'0-:C@4R35+C)8@&)BX>+AQB"&8\4$3V6XO62;(Q0)&(XWCJR.D08\4-2
M&><H"68G;FP!+,6\;DG4!*T=5Y&;DZM,BL^WEA,\<?+8 ?/'?8 ;?@!J+\IM
MBZV7I)V8(A.X-[N>XND5ANE7#V_JC8E7=B]N5JW9J]^U;=;BJN RT#/%A4VR
M-TLG(+X:1[14[<T0R@GW6V[GLHEVL&IQI#=1',,L;[PO&'26-.1#*"Z\_.Y*
M.GGX.J)=C!*1.S/79AS1@0X8AD9MAL?I/'P?!!U;;9GYGK'U]V%9H)O:O86;
MH==LMPC(2S3Q%FOMK+&&R4S7V).*KIDCD-"FOU&XNLSDL.'@G,9#39_QHTGR
M4"V;$:L8JZR,J%E7C&F_CD06 'ZDLJ[_ "5&Y%Z=XHV(YRE02 3NS?CMN!_R
M4G;X!/C45;'X@^(2I:35'-Z M%TW=);0S"S5=W-=)?3$+6]2M0&+4;,VV-TJ
M9>AK@/+VRLUA_7[FN&C(J9-D52\R&U#OM/7:X_D\^YG1(!%N'AC69FFY% J&
M<1\"JLPD[NQ '%3R&J)L[+'MVV:0OL0[% $VWW(C+\MR!QX>"3N1MK(:;W3V
MEN1S7T!I70D"9?)C3I&Z-BU_:VSYO74358AK8=DU?%UNJS0&J;=)VZ3MUHI-
MS,K,W+5BG0:ZI$QE@D5"KL L8-*]**'N-/8;@LPAC:&)9"Y,:REV!E0($1T#
M*&=N;%1OQ)U,L[N56.,<BA=^;E0!R* *0C%BQ5B"54<0#^.VNMNG>V[TB.[,
MWV6TO66-1]>=FA:+!L!6U3F;;L+;MHG=6UZEC#5@/7$G'UB@NR>TX86UVR0L
M)\U"^T83$4ZQ"A9<*BE!'-6-9G,UB(SE1$"D<*K*S_5W 6DVB;@@4*VX!=2=
M2M991,Q10D3]H'GLS.2@7QQ("_6 Q))&Q(4C6I[9WH[#6>&K8>JZ#JD:UQ7:
M31&J[).+V#>7=6WJH[74V^ +4;1/Z 9GF273696KWM>:@S*4C((4Y!/67$T,
M$-62C61F[LDI0U9Y5 CC[L;Q;[EU2P5/CBZ#GLX)5N.V^I&LRD#@J;B:-"2S
M\&#[;;$Q@_.X8\=U^1O\:V1.^(:9%;CG==!:XK<U$43<6N-%WM$7=K>;L@BW
M79%$:LEFH%-$U._ V"@:X/OX")H^QW:GV&7B("XS8->$:B(86STEQX:%93*R
ML\4DR<D01A$[G%9',W-9)1&>(2.10612WEBLYM;.5X \76-MBQ;=N.[*O#8J
MI;SR920&('@;X9<>S.Z=K73K+8ZS28^E: GN]LUJ:)N<1MF83?KH%JYG>-"G
M,7;6[%-B(8:B7*V4J9.A0$7RQFMC05=D9R!9>EO17YUK0Q):5G,EA:*RLC0C
MMQF5J\B]N0NS&1$=0Q[:#ZF"ML/JE:9W,+!>,9LE P<\FX=Q2&7B!Q8J2-F;
MX&XW)VMKYY.KW3C33C33C33C33C33C33C33C33C33C340.U7:ACKL;J>JQT3
M69.Y;AF[0!!$7FR3M3I$!#4F 3.V6=GY>KTS8%B?=0LN$AH>&BJN2Y(R4TTZ
M6?$QH)IK=Y4J&R)G)8)"$+<%5G8R-Q55#O&GX,Q+.-@NP!) U0FF$7 ; LY(
M'(L% 4;DDJKG\@ !Y)W^ =1IIO:2R;'V_I[:N8]VAQ!'23NQ;)[7%ROTC5];
M9NVGNP'7RDM6*6M<O  !M5!2P;$35=J2]'8,&UW9W+#B"#8E3HA=R]5(X9HM
M^X??4461(P\O":O9?BJ!B2_E0T0?8R+QY;@'5)9B[QO^Z.Q.2K,53DDD2[EB
M/W=]^+\?W3OMY(U](SQ%Y\ZF[OD1==:ZM]BTY/Z-'+G]8[,NUXTYBE[QDI*/
M:V'8+<QI@&ZQ==URW 6*1NC\/KFQAJAPHV:8D@XJ1DBJ[ XY0\ ,LB+,L_TR
MQ)'-S@ )C5#,4+2<E$8:5#R)4C<*&B+)*R'@K%#'Y1V9.,F_U%N'+9=B6V0[
M#8[[;D9K3NQW8.[=HM4U2%!Z^SND[IUBDMNS$I2MS2]LBBGQ;]6J^_;J/:&M
M*!HLXX[4H@*$B29:O0TO&R)DM)2,5)1(H!TCUJZ59G8V%G2T(55X%0C]FS<)
M$[YXD[;D@,5(  (8D1$LC3(H[1C:$R$JY(_>4<E;M^?G8#P""23N -8? ^(I
M8)%[<,4-K76VT;%0M$G;TJ(/7'<5BW%#V42*M U3EZC*3;>GJX4F0BBI.)EE
MS-$@K^U)PRIGZ3#E2D2''3<[8Y1V2998EDG$#FS"L)4LO-75>\XV(##:1H]F
MX[D DK 62>8XH[+&9%$3F0$ \2I^A3N"0?I#;C?8>!OV5D\0E4/ :4#AVNOM
MJNVY@MKV$&>@MU724TG#U34<E5(6<>*N,/I*5NV;D5/WBMUYVCO:Z%=K\BBR
MJF)I*J^V)+03'\FG+&PB0F)>+0QK.S3!V7Z&G"!.,;-S[IY#CQ4\MU&T (]N
MVS2<R"'8QA4(!W81EN6[*./#P=]SXULK9?8U5D\/RX=E4U>^TDDK3TC<2JE%
M6I^D7J DP5*&DHN'NJJ\<_'.,2(I+<39TUA7U&,R-*-Q+"#4CM4XZW'()6#Q
MR 3! Y0/&P^02G+8^/E.?AO!/@ZG:4FL9>+*2G+CR*L/T#;;C]#M_=^&L:N?
M=79-6OFVT#:0K1VE]&=E-+==+]?"=KE!78X_=D7H=R,L=/UZSKPZ//'J$IOF
MN_E*#-W:"R;$#.D5\J0D,%1X<R4HF2+>=A-/5FLQH(04 A,^ZO)W 1S$#\2J
M-LVW( >3*9W#/M&"D<T<3,7V8F01[%5XD'CW5W!8;_@=9[VCVOV U_M_IW4-
M,0NN9B&V]MR]T^[AWJX2U5S+C077[<&Q8^':,B]7["*B &'J4NRYGHW*)-^:
MKT+478W,!:9N>@J=6*O)#<>9I%,,,;H8T#[%K$,9;8RQ@G9^'$^.+,^_)%5I
MIGE5X%C"$.[*W-BNX$3L!X1B/*[[CSN NVS$B-^I.RVYZ#>]BC6JD@VW3%D\
M0N]Z #O<MM>6)V!6Y"[3XT536JWKLFGR4/G75>G'(ROE,/;!@Y,;ZJ?(1-8S
M'1#2YRYFK0R1QE'*3+CDL&,1 1L(U+.6D#@]QEW8'MD'B 6W8;4TE=&;DH*-
M9:/D7/(%CLNR\=N(.P/U#P=P/'G.].^(4G;^W:948C7\,[K[8^PMG:[K$W"6
MNTS6Q*\YK@6\E!W;9--<UI&U*MTF[*U_*AQ1,5LFPR<(;.T@6:!P58)0:L23
M8_LPNYD/<CCBD965!&W<,8*1N)2[.@D!.\2A@KE3LH+3)9YR!0HXLSH""Q8<
M>7U,O *%;B=B')!*@CR=OWM7?]ATEVG[!3;C4K;:W#Z,\.R'C*,1938N CYG
M>?;SL3IJ>M8 RAI4 *7:CI6#D))X>,058AZE#0IIP[ X98"*NL]2N/",9\@3
M)Q!8K!4@F"D[@D;J0-SLO(L!\@RM(R6)?E@(ZH"EB #)-(C$>#L=MB=AYX@'
M],XVYW+GM>3NWZQ7-3#72?UQN/JUIRO D7M%98M\QV;-J\9''&2#]8E&JT-6
MC[.PV1YM37SQAW"4Y%<RD;-.&FLBPLTI19(;4S'M\N K<R0 &'(L%W_H[$[?
MKJH\[*9 $#%'A11RVY&4J!N=CQV+?K^?Z:P.;[X7"GQ$S7+YKK5=*V[ =J(W
MJW,OV#=9\9H.(DI[00W9*OWN3VO)ZT G H68H1P%=CX8J@#R9>R3@*PE]H(U
MJ;3.M%'96CDE>%JIM#C #8(6P:S1K$)2I99 6+"3B(@6^1QU*;!4%65%<3"$
M[N1&"8Q*&+E =BI VX[\SM\>=2FZJ;FLW8/1M0V_::?7Z07<'9]Z.AJO;Y&]
M0A$'%6&4@XF?C;-)4^CNRD99AHS$_"F#P> 3H*1BY$,PIDQ*DVMN%:\[PH[2
M!..[,@1@Q4,5*J\@!7?BP+;A@5(!&JL+M)&KLH4MOX#%AL"0""57<,!N"!L0
M002#J0CWG[+OE^/MK\O\_3GRY;-\'^!_Y:KK^\N_QR'_ #U35KW:$54FZ95Y
MIEV,RJMU]0LHXIU^/+8>C8D.-;&6,,MQR1DY1\R/&CG6QG<XBBR<JPE^.:-Y
MBQ69AH?=]2PI@_V2L5F)9HG#101Q!&5-S++.SQI$P1B(9')V:)9.R,_TQ;R[
M9G*4G6UMD\@)JJA([$+I9MS6FE62556O6JI#8DL*\J;VH8P-TL-!+"2V?6JY
M@7$[() 0_&R\H@A;;JQL#00K1I^,N,I<_M\!K<+''2E;I+ A>6$+4SE.<\ES
M5.H$]S,(@\,\P<JQ3A6022^5W^KMEG5?+.L;A02-M:KK=,9+)&7V-8V&CL5*
MQC1E60R7I&@@/!R $,ZK%+(=DB>6(.5#[B-N^+'1I]^KRXE*38Y260RS7;O5
MK)$1EV:6I!33;<%&-R49-RSL>^]EA\8E\-EKY)L2MT91[^',2ZFNXVV].=,>
M+<TP45<E2MP0Y$;JZ@5X1+!:G,3-P=)&C50\L)9&D;?8_0F.S="/)U)<T<;5
MJ,\F1PF4QUJSA&53$Y:_::O9HU%L(@D22*.9V$4-M4D6!"L6]R]CI*M5RHZZ
MN[JW*J3$CV"JW*OP]><E":<I"0X%5FK4H?56*A8H; Z_8F!$JB#R0I&&>J!
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MT.=37[) V!RJVBC2:6BW@I$,F-G*=<[-798 P AIX*5<>'R+(#AFC2PSM!W
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MF.@3)BNLPZPKC[4F%)34> 8^$76JW1&ICE)4"OV(G6%)PH-GW+<XI'17W8L
MW+=/!"DC<4Y8"S<T\DR]QU,C1DGM=H<7125V4 D;?5M\C<[R@ZST3:>N=3QU
M7W#;V[A;F;!<9$=QJP2US16:K,6B5DZ=1,7RPPM;LE_S2JT3&UY5UL4!#S-@
M6"HLP!C.4XS:V9(I)2\*<$*H#]*IR<(H=^VK.L?-P6X*S!=]@3JM$KJ@#G=M
MV/@EME+$JO(A2W%2%Y$ G;?;6_<X\\9QG\,_;/+?537G N #7U(JKV")E(&Q
M0'HK!DBEDTR':F*H0JE/G2XX@K YZQA19!F,PX^8QY6M3"BAW@&WQ.,<E"$L
M34;4$U:U48TGEX.\*ST7;'M+82-%64HB2K#NSH/?<>:LBM']&L/._MXLIC[=
M2_C\ARR<58O##<:GEHQFD@IR32O) ))9J\EDK'"Y.*$@AD2PR38C+WNSMB'U
MZOESYWMC(K(T8ZQ)'J15D%E$N/&_4!FHN*E2 &RT,&J<%<R-DQ;T;&ABN$"^
M=/DK:I)5K/:DV45%B832D4^;N6D[J"&O,\0?C(61NV9"T,4<9>/V:>"QC2U\
MC?AQ\')VR<MI)*T"G*&**)4A]O*UJU5CG:%GA"RJ)!"J6;,\JQR[1U'URW]9
ME"W>DUQZVMBH4W$FV2?9B*EEHR+*0C"7WSA/JS :I4ELX6L-DB$R6+!%R9<>
MDQH]>0]/]&=5Y )D<;2>XL8VKS6[25Z15X9 .,CR1^X5#,PD6FLD32^ZAEDC
M[B2G%^KO4?H#&"7!YO()B3*>5N#&T'MY</#:B8\DCAE%2245(C!+DVCFBK?=
M]JM#8,4D"YBQX8/8W8%C)L>S=EZ\AV3VP!'! A9"8E10P,N+%'898 %@F (M
M3^<1<*(\W&L_$CW&4AD"?)>]:+T3ZOREIK6:R^)K!Q'&5C$UF=(XRQ141(8Z
MRQPDCLPI(L8"1[!&3DWD2?:>].>G\=%CNF>F>H+CUVL2K+-+7IU)9I^"RR.[
MV);SSVE3_:;LJ-9?NV%=I8INVD_^LO0'4?6N0 LP,E/76Z1XJQQ9J<6R)&1[
MCHV1'RHB %RZD0@IE3BWU&R,HE)+SI(N!7,,X9VQT9Z4X#H^>*_'-:R63A0I
M'9LE8X(2R<'>O53D$=U+%FEFG(=F=.#;;<_^IGK]U=ZDU[&-GK4,+A;$HDEH
MT0\UFPJR"6.*Y?EX&:.)PH00UJI,2)'*91S+SLYM#6B].--.--526[5FUV9Z
M:@I_7=IL-=B]@&72(EX,$&=;N#3,H=-@D$8$E&\QAS\QAN;D1)45]9;Q?P6<
MI?0HG//V2Z=ZA6[;KSXB[;J1967(06*L<5E;ZBQ+9B=N-@&*5I]K$J3HQ=G[
M8/(<]=5XGJGI1Z%*]0ZAQ>/R%KI^'"VZEZ::B^':2K#2GBC[M5O<P)3+4:\U
M25%B2+OO^S/:U$?9G96VO2$9#0B9;642XEQT^3DF(>2M)3'N#"K6/4V'EXCT
MQ1[JV2DR=EBCFWA2AR(,UIUI.-?9?JZ\98:T'N,3"=S)+*L$MUUW5&(I!CVA
M#(2KB:W#(K(R-7E! UMOIGTVQ,=>U=N&IU+;4JD%:M)=K8J*3:655DRTB#W!
MM5T5XC5QMN!DFCDCO0NK'7=:VV%I6@RS0-76<7)S4(ZW8;_:A,E6B1D6"U-Q
M@D\9A+)8$/&MAR+F8X842- '> =%$9'4HI5?$Y; 8R<14VE>6Q786<E<0O<E
ME1]HDLOLLD4$*QRDQ(J0QJT11 I+&RZEZ>ZTZ@J//E1!'6I75;'X#%2]K%5Z
M\D(-F:A!N\,]RPTU9?<R2S6IY$G66620"(?*4W<9/224+(BS]73\ ^7+%GMJ
M8,6\L<\>4@8!U+\<_@0CZ,7\5N5%S,-M29!KA8X: T!R3=0O9F 9H9,-9K,\
MTDH*2%N,B35ZI!B8HQ@?@LR=X"=Y#(L:H$J5NB8:%8D1V8.J,?D(X:D-<B2%
M462"2K?R"E+$?=3W<)E>K+[-FJQPK%+,TQFL;Z:58"SZD)M]KAXF4,M=K,EP
MG71!2&A 68&N0RXL5WVL-J;BY2)D@2%L(;:?D6#B$HPIY7GNOTUQ\5SIUK]^
MM!-)?ORV(R\4;B.):U.L848IL5AGKS1N5 5I5D;8%CKG'UER<^,ZMBQ&*N7*
ML.)Q4-295FEC>:=\ADKJVI5YE@UJK;K3QJ[,Z5W@C+$(-3CYM/6D-.--.--.
M--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.
M--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.
M--.--.--.--.--.--.--.--1ZV7U;TQM69_*>QUE85KSGU*LU>/)AI1Y>1%1
MZW3665.1,H^['KS'NDRL8:2N/2@'+WQ4):QB&;Z%Z:S]CWMVB8[^^YNU)9*T
M[GMF(F54)@G8Q'M%YX9)#$!'RX#CK8737JCUGTK3^[,=DUFQ7@#&9"O%<JH!
M*+"I"[A;=6-+ ]PL56U!$+!:?AW6+GIJQU T=7I-B9D*Z3=I(-&&HY5X,1,Q
M48REKV?; JPXT=4!U*1]UDX@%&.+_M'"5+_6Y;4/3OI:E.MF2D^2FC\0G)R"
MS! NVVT-%4BQZ$CY?VID)\E]R2;S*>KW7&1K/3KY&/"5IB6L#!Q-3M67+\^5
MC*R2V,Q( ?"Q'("!5^E8@/&I.(0AM"&VT);;;2E#;:$X0A"$8PE*$)3C"4I2
MG&,)3C&,8QC&,8QC',W "@*H 4       ;  #P !X '@#6LF9F8LQ+,Q+,S$
MEF8G<DD^22?))\D^3K]<CJ&G&FG&FG&FG&FG&FM);)ZZ::VRZHN[4@ V34O#
MRIB.(/@I5XA#/QV7S380H!R4<'8_LA\2V#FV6\J;;;PA2DYQC-=&]-]0,7R>
M+AEF)Y&Q"\M6PSA>*O+)6>(SE%^E18[JJOTA=B0<VZ;]1>LNDT$6$S<\%8*4
M%.S'7OU$C9^X\<,-V*=:JR/]<OM.PSMLS,6 (A!NOIAI75E4.O->"ERS(U)&
M0X>65 N0;*RWW"7WTM1M?BY-)+A+[Q6242J",E.**RYDG.7>:QZF]-NFL'0D
MR5..RTD/+MUYVJFLI=B[,%BJ0S<RS,W/O\PQ+!N1+:W=T3ZS=:]4Y>O@<A/5
MB@M&,37*@OK>=846.-"]G(6JIC6-%B[353'VE$7'M ((!]>->U#<>]H;7E@A
MV8BLDI40^S .OYD7510TA((;5,V)VQ2N&C'DY0<A):?=96I+.6%X0XG4_2.'
MQ_4/55?#W(!#28L[+59N\QKB60 V+1M3<922LH#CDIV4H0"-^^H?4&7Z.Z#N
M=18^X]S)QD1(]]8Q61;;5H&84L:F.J<X58- QA/%U4N)%Y*WHQ@("&JT+&5V
MO1X\5"PX;0,;'BIRED89E/DA&,J4IQQQ6?4X\^\MQ\AY;CY#KKSCCBNQ:E2M
M1K04ZD*5ZU>-8H88QLJ(HV &Y))/RS,2[L2SLS$D_.F_?N92[9R.0L26[MR9
;Y[-B4@O+*YW).P"JH\*D:*L<:!8XU5%51__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g451428g48h63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g48h63.jpg
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M9G&V):""1(2>849-[R")9'XH[O(Q>1VD=L<G=BS'  &68DG   R>@ -7E55
M%50JCX50 !^>@, =]ZNKD.O=.--.--.--.--.--.--.--.--.--.--.--.--
M.--?QSFL:Y[W-8QK5<YSE1K6M:GJYSG+Z(C41%55541$3U7^."0 23@#LD_
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M-QV'<(=SVF=ZMNLP]P(XRJQ]\4J'"2PLN%DB<$./V(4+>=]V?9?+-KN[!O\
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MMCOZ"KIBX_AF8L5286 ^>1S8_P!Q"]T;9<RK_6B0SQBUL<8K'J4U[C-.I/\
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MHDD #MR?]590WM>-6VD\X,EM<ZC=GF(+&1"4^PF!IX!R%<L$Y+TO@+>:.19
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M,]&-\L0)3ACDXKS0A1Q16Z;/MY/DJ ,^_MCD@=="12M2;A/+ "1&RE_YLK*
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MB2)K5(C2!H@*H;=5_E.\-B$>G?+Q/)_,?[159958QKQYY(8<2O(#'0.9)M3
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M$N 3WGH'.LU=&&6(?:3(K<."KJS:/6SD/!J5:;I#JJPIHY*VK'=,1#+..1%
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MJG\_Q_<O_N3++D!6HS+D$ 9P!V!@D#. ,@$#)ZR/S\8#LMSU-T0/@HV<?YC
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M"2E'/.^N#93 GUEK );+,KIS*_ZD8<\;&0GM(<.&R(,^91BEJ)6Q$&STA#$
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MQ^GED#&I-,ER_3*$#"WD=M?#"#NU>EC6)]G+*Z)IL66II27M2!KG.^VHKIF
MU5;_ /76J.DG4(4BE7U;+Y#E(<!XXXR0S+G)=W_"YR %Z;X4GLBWS S+[H\
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MX4&M[/,/-.MKRUKJH 0,6<@DPR"&.-7/Y,3<=PD8(DJLQ#''H5ATJEF))B
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M>H]&Y$5S55O??D0J(YKE8Y%5.V?\M<BM<G^4<BHOHJ*G)?\ %+W^V7_D5_\
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M!!&G*(?Z+[(HGN]%]/3D2[EN#LJ+*&9F"JH@KDEF.  /2^22 ->&K6 )*$
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MWI0O(&J/M'ER$GD"=<5]*5;EQ6HQF>#<&Y\V1F(<LO\ ,.53UJ\RQ@E20JF
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MK.@L<V4+7X_2:&IT]_?"Z;4MLZL +,&FR4)U/7Z2US]57ACD60NQ7B5'3(O
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M') \H'DGWMG[[/0W6&NK(_LKN3JFKFIQ,1=Z#+9[(:3KKQ%K=H[/:YNIH)*
M"AT'9W8NR%=)GNP'FQYK8+8Q5%;E]!<AFK0,K%9% CAE.2ZJ[.LEQDY)Q;D6
M6*)#[H\<TQR+*I"60$94DLZ=!20%*PAN+9&,%G8##$X.< ,1YP_*/O9#$O+R
MO&KJ0?':0$FEINBM1? ']@U^ZZ\IX[3+Z<OMJ@%O<5246X<59W%[88!\85#J
M['3T^*L,Y>TN>]-6#'%3DEU8,9T4B(I(>+H(F*R,T?0429+($,@92SUI,@G
M&""!&Q'+D@RK<QE0'[)X_I8D+@@?1OE]WM_30MF5U/*-;6.'ZLT3Q!>O="<-
MC5T]OB:?:W&]2U[!S$]-/4$:2T,J<+,HE>W/59F@+[;+_IG<56<\^T@Y$>KD
M"25<F11SX"1D$>(VY!@HS(#GD>(A'*,OYZTF,\/E4(PC'CR*AN677!&3[3CH
M$\_:P6?W7EU>Z3 XG0ZBM#I]+>Y+.W&@J:Z:8@"MN;*H$,LP09B6L)D$&,FF
MA&<0U)UA8SYD^3W<H)%59'5"6178*2,$J"0"0.LX^<=9^-5*DE5+#!(!(!R
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M3V?+_M^_U_Y?D_L]?3W_ -OKQ_\ 7_UG0?/_ ,\X_P!^._\ AWK"7C5'9Q=
M]0QW46AAM6X+/H=%K*_J^JT;)_I1JY+>MZ5?)U0$7Z*BN'P3W9V-JL:$OI[D
MY1[?R^QJ\O4Y>@G(2K620''8=:G_ %92/C$'\O\ ;5SWGA_%=P],PE/NIN)@
M>Z\..1_T;[D!>9?_ &K0]8G);6;^5FK9IQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIK^.:U[7,>U'-<
MBM<UR(YKFN3T5KD7U145%5%145%1?1>--6SD\1C,%72T^&R.8QE3.6X^>KR=
M!59VNF.? .*\R4*G$#&D+>*(*,XA\2S.@&'A5ZQPQM;$[O(>4CL[8QEV+'&2
M<98DXR2<?N3KQ551A5"C]E  _P"[5S\AU[IQIIQIIQIIQIIQIK7?^3]7IXM%
MN9Z>C>Q,"]Z.<K45L=I+(WU<C7?RV1D;F)Z(CI&L8KF(Y7MU9]921X'N./\
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MA7$,ER=%,=.N"S<II%B/<S@<-F.L<1D>NL7614^2P^=I\KG*R'^6A4]&#!7
M0N>J(Z:9!QV.((D]9B9W2$3.?+(]R]C4ZD%"I6I58Q%7J01UX8U& L<2!%']
MS@98GMB23DDG7S)W3<KF\[E>W;<9FL7MRMV+MN9OF2Q9E:65@/A5Y,0B+A44
M!% 50!=W*G5#IQIIQIIQIIQIKYS)ZQ2HK4<BQO16NC^5KO5JI[71(K5D1?\
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M 5U;7 P2%'6%@<5)$,&$&-%*0443+' /!')--(R-CG)Z 6(5069B J@$DDG
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M1/;Y6?V&,P-/3Z,0&MVF'"ZYL&LO)[2*IQ-=G@C"7651G1#AR6WCX1!5EKH
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M I8'F/38P2JA"08\D.2ON>-#WP'QZ@P1D$9) Q@VSL_R V46%WUQF^O:;/G
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MS<-TLPT*X8R2B0Q0\!(6+%A8MI<F+2,5Y2,"1D#5'[%\:M#?4'8^CH+^M?\
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MU4RR0.M>)&_YTC:R\>0;'?EEA\GVN:LVY1TJT$NWUX6D^\<H@!9Y25$0)SS
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MNS<5PRY&$OQ=7?E)V#K+_M3;]Q5EMU29N3D)H-%IH[NZ ,&B*7ZE57$3O?G
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M1GI*FDJ(UNCF@:,^D&7FI8NS1EK)E0L>.>8M2*IZX *?<V6,)@(5B&]Y!XG
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MTXTTXTTXTUC:3ISJB6Q2WEZZQTEJBVBI9OH*YUAZ7>^$[3N&?<6#['QV79
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MU,[6FESU6;:9".4VA"KFD##2H^"/7FZ7%O[A;N)'Z26)GD1#CD%/2\L9'-@
MSX)',M@D=ZRZE7-6I7KLW-HHU1F_!([.,]\03A<_T@:EQR@U5:<::<::<::A
MIY[X*/<>-FJ.2"VG+ZUN,QVN*M#)%%=Q!X:X@/U4E2^9\426+L-+J8 VOEB8
M\B:.-\C6.<O,'^H= 7/&;,^)2VT6:>\ P$+,L%*8?Q!HBV )/X7)>502 2P!
M."=;8^BN[G;//*5,M (?):&Y^+NMH,:TEC=ZK+LZ6.&6]'^/0[2\I4%E1&91
MR UK0[WSYG6'0^STN<U!63[0V77T4=1%V8?6 66+HM+8"-LX;$2!;AU*:X:,
MH>&O *(K2Y@YIXVO>TR;F [Y7DVW9;EBO8DJ;C:HQA8KK)'-2BE,7.+"!RLI
M0XPK.C%2RL0.]R>'WE\@\NVNG?V]+VQ[5O#-9;9H)9JVZ6Z44Q22-Y67UH(W
M*MR=%=4DC5U5G %]>$7COVB:;V7N]@[K72=/]I9['C4(1U8<<3>EU>=8(9JZ
MYD\4(]95WDUE8)/#*+,\YS&S11#P2>XBX>%^/[M++N5^Z*%G;-RBJK&C+*TK
MO#7$1LP^HBB-''O4#)?.>3 8U:_JGYGL,,&P;1M1WFAY%L-W<GN2H8H8X4GL
MO+'2E6,LSSU"#&1( L07BRY&!G/K?Q5ROC*=7;*L%M=K<4T.BS<UY:[&Z.B&
MH]C9Q&/!LJYZ-KUBJR8X!:Q$K7LK@42*.87W.<Z\;;XM6\<*7(8WMR(;5?UY
M;3E8H[4HD/*(D1_RSB-&X#@G(?+<M8EOGG^X^>03;7*]?;Z]C[*Y#5BH0QM+
M;VVKZ#SI.JFP6M*&>?\ FL)9VR JCAK"OE;W+W[V3@M/U5U)\&')J=C%0:KL
M'83)G*=:6N@K+.8_.VSF2,-%B^W"KY71QFD/#*$A'DFAE22T^5;SO^Z4)=KV
M<"F4MI%8O60L,:U3'&_JPO+B.0*21T&Y_I4<N.,H^G?CGA^Q;O3\E\C#[I'+
MMTE[;=HVWE;G>P'DB6+<8DQ-$Q9HR3%D1LZO(57D->/KOL;19'&>1D/7SINT
M.T,1TYC8:PL?--$%VVAK4M@7GB U3X77)#[,HLZW2$AQTTI$+'(YT@\+:?;-
MSLU*N_1[>QW#<*6T4XX@E952Q812AECC4<9"S-SD !/N(SR)(G;UL-2[N7AK
M;J5V/9-S\EW,R^M<+R;;3L&"6.&Q+*Q-=2$XJ9.(X @8 SK7=O\ IH_L+I#_
M %)T-MGL1Y"%D5&EO<:+84]71.NHAY!2; ZA.1WZHHH)HU9;!Q6*5-@9%8P$
MB2I+/!+@6Y;,^X;*NXSSP5-[]1+%BL#%"BR D-SB()BYC#2*Y)60MURUN?9O
M)HMD\L38Z$=S=/#88K5"AN,\,]BS'4'!JM1)X0#85+'JSB6% \<3QD.I'+5U
M]#S83I_HO0Q=A7S/ZN[ U:769I:B4<TZWB(H:RFN2/JBG%A"1Q!@1,JV)-#
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M[8=>=6 XK)G ^-]Y+KPK*NN@)H+/K(-67Y!M3>RQ^^>M)IY"'@L61B#W1 $
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MR6M37FP"3VF7L-9?V%'9L9&4,>8*9.\DBDS\E5/CL2QJJJ5]CET)52REN(8
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M#3NS9]DXCQ:Z5@LSLWD,]H='W+V9H0B@\-FRNWS$O:F$.TD?)(;=9BFCJY@
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:33C33C33C33C33C33C33C33C33C33C37_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g451428g62m07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g62m07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X488:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/D5L:6YS/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!46#,R-2YA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C$Y,C$P-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,C4M2G5L+3(P,C,@,#@Z-#,Z,S$F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,C4M2G5L+3(P,C,@,3$Z-#,Z,S$F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0V%L:6)R:2U)
M=&%L:6,F(WA!.R @(" @(" @("!#86QI8G)I+4)O;&1)=&%L:6,F(WA!.R @
M(" @(" @("!#86QI8G)I+4)O;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($--64LF(WA!.R @(" @(" @("!";&%C:R8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(S
M+3 W+3(U5# X.C0S.C,X+3 W.C P/"]X;7 Z365T861A=&%$871E/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R,RTP-RTR-50P.#HT,SHS."TP-SHP
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(S+3 W+3(U5# X.C0S.C,W+3 W.C P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU
M;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @
M(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XX,#PO>&UP1TEM9SIH
M96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'
M/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV9$<Y
M>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"
M24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%
M0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=1
M1$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$
M03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!0451
M9T%5045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!
M04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!
M028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-
M0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(
M:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)
M2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q
M>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM
M2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U
M<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E52
M3FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y
M5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG
M<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B
M1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L
M2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#
M15%-4D%$.$$U=#E5=78X069-;B]!04HO<&UD8B8C>$$[:C W-G!D9C<U:R\T
M12\P>'1A9#E5=78Y.'EF.$-F-EDR=$\K<5A8*RM:4"M"4#A!5$<Q<#,Q4S8O
M=T(X>68X04%N*VU.<E1V<6PQ+R8C>$$[=FU4+T%)12\P>'1A9#E5=78Y.'EF
M.$-F-EDR=$\K<5A8*RM:4"M"4#E-8E=N9E9,<B]F36XO06XK;4YR4V8X06Q8
M+T150S-C6&U05"8C>$$[8G$T5V8P,70U<F14>FA!3$=29W!:07I-2TM+.4]V
M86AJ2RMJ265B2FMT4'E79C9Z36)F5V\T;S4T5F=T;4$Y95-%<51+-$MQ,%E+
M=B8C>$$[=%)N2'<Y3CAJ8VU60DM99BM695<X.7I+=6YA<&-!47AF56]:=VY(
M,2]2<$PV=D5J-&96,T908G1513=O,E99-&9Y="]28T%E>C%R.28C>$$[2U5G
M1G<S1TUW9R]U:&-&4E5-9CDR;%!O<FHV;&],3#%F>3)J=DQ+5%1T4#%75T-#
M5EAV23=P5G!/:7AL:6Q%8T9!,&]#,4160VMN<B8C>$$[:G5U>4I7-2],5S,U
M=$AO,35D3UDQ14MY>'E+:4]J4U9,9U1L;DUI3W1A34%'6%E5,G=B<#)19&=V
M-65T<$51,4MW,55A<W!54T<R5B8C>$$[0D%55D]84FIY-5!)3TYE=TYE,4-4
M84YK8DY,*U8P9'I&2F)A5G%S<U546$-.2$MQ+TA%.$UW9V-K35 S:7I.1V9$
M:4\Y2T5E<&1L3"8C>$$[5$<O3$\S.'=14S-E;6%P8V%/:TUN<E)-;TQV3S!Z
M0DM+2%-I0T1J5#1Q.'9(0V)P9&Q3938O3$\U,'=#5%).4G1T46AT;VMI*W)5
M128C>$$[56LT:DMY3DE86C(K,$9)<#<T3C W2V0O1"M6-S-(;S9B6C9T1$)*
M-EE.>F1G1FM*=54U;6M24'=R8D)Q9D-X<65N9D-/2D9"6'8W8B8C>$$[.&\T
M-W T<E,Q,6EA15!26G=">$MI6G%-<7-%66AO=4Y1441G2$5T0E$K<F9L:$IP
M<W-N,6)626(P5W),1D-F:7)C;U5#=EAJ>'!)2B8C>$$[1THK2VEL4#AO3&@Y
M4S!%<#@R,C-L0G!)4#A+5S)P2DA75#9Y3#E62G!69E,T96Y8+TMR6#)W>'9Q
M9VIU62\X059,<B]!2'I*+W=!0R8C>$$[9C9:2S).3RMQ6%@K*UI0*T)0.$%4
M1S%P,S%3-B]W0CAY9CA!06XK;4YR5'9Q;#$O=FU4+T%)12\P>'1A9#E5=78Y
M.'EF.$-F-EDR="8C>$$[3RMQ6%@K*UI0*T)0.4UB5VYF5DQR+V9-;B]!;BMM
M3G)4=G%L,2]V;50O9U0O5$<Q<#,Q4S8O,WI*+W=*+W!J83 K.&I7:'!S97AZ
M0B8C>$$[8VAJ=FU842].3W!7<T57:S8X9$IL5#%05VU70EI3-&11<3E3=DAJ
M=61V-%I+2D$U;U-I1'EP*UII5$=75'IK<DTT:D5G*V]W;&8S628C>$$[,S1Q
M5'A8:U-A:T-V5$1X4C=L9'%(:S=Z.60S1C9Y96)J8E%856EY4DQ&8FQ416=A
M=G!**S@R1DMF2#%08V)N15-(8W$K6'DU*UDP8R8C>$$[97!06F59,%-36FU/
M;E<P,&%Y<$929VMF3UHT,V,O=5)59TPY=F9F9FLR3S56:R]L;C@P;6=C2C5W
M:6%8:UAJ2#%'1TUF0R]*1DQ!328C>$$[94I'>F)(1S0Y>7!T-5DP<GIP85A5
M<S)V-C5(<55$>#A9<E=/,VII16(X>658<4MQ1B]G;T]G=T5J;W)).&EL,DMU
M>%8R2W-A.'5E8R8C>$$[8G)73F(Q3%,U=$9U.5!';C$T,V,V+W5:44I7:BM"
M<4%64$1K2T4O:&MJ1V=I,3)P83DU=70W-F%'>3AR=F97<4=K5C),,C)I1&EG
M3B8C>$$[941N:TXY=#A10C-P5G9+4&U7-#$V,79P3&Y4,C R-'-,>5-X;71M
M;%-9.#1K4FEE841J+T%,<W Y1TUH4W-7:R]/+U%9-4=1,D8P4R8C>$$[:$MK
M+W4K>' O3FUM4&$X4#5P96E(<S5L279I:CEQ3#!8.#-D1S%B5F)85%EB2S5J
M;'5N16%/+T1I0V9':D4U6FDW56I/46E!9#)R528C>$$[9&<U35=->DUO,4@S
M<S=Z6G5I9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<B8C>$$[<U975#-%1G9%,#%X26M-2V9A:VM9
M2V]Q86)K,$=+<G=14E5B9SE$:7%L0F57:S=Y2D)02$LX4G!+<4UR1E1V<W="
M,C9(1E9/5%4Y3B8C>$$[:F-X>5AC2T]P;WET26])4'5#8V%6:E U9'E2>4XU
M;V5.9S9.<G0P5EI30T-05&@V15I/9E)$=TLV+S-Q;2\Q,B]78S19.#,Q3T@P
M:"8C>$$[4%!Y+R]W0U4P,&HO04II1B]58WE.2"]F4CDW:&1Q9C1T4#A!<79P
M1$]U9D]N67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E='9FY$<#@Q.2M83W-2=TQ-.#!C
M87EO:T)K-4AG-FQQ<D=6-7%&<5-$560V8EI01R8C>$$[9#!(:WE0>39&2&PO
M5$%P<6]T24M'9T92-F$Y9U-0>'E*-7!14&QN>5 U8CAS>EAS=6I7>E<W-F=9
M>F1C<$I*3UAP8W5(.31Z57 V:"8C>$$[=VU24$Y&2W0S-4LX;3-L>DID6&5G
M-F1C6$UZ1C5:-6)30C5(63E3>DUH2E!Z=V-2-S%O2DXK5V1N85=A95IB87IG
M:G1R84Q88G!9;R8C>$$[25573D9!:6A!0W%O04%Y52MI:#1X<$]J2G$K=%,R
M:C-K3FM#6D<Y5V,P53AA;6<Y.#0S0F@X4V1722LY.4DQ5W%/1$5*0TIL>35)
M>B8C>$$[>4Q'22]03VQX:#%K-%A16&UH<7)5<4MQ5%1B2F%15FUI4#946#)J
M3&DP<WI66$AQ.58X,BM:3F%S3EEE,W1,:C T46E-1C12='52=B8C>$$[=7EK
M-71D6G%S:TUL4D\S=V5B-U P5TQ*:31P0WIF955M+WAP-6TO-6)0.$%K;D8O
M>E)M3"MF>F0O=T)G8S<K5$U(.#,W5"MT:V9M4B8C>$$[=GI#=61.,'E4>7)*
M84I02D1Z=EI,>C=*6F=N1V=65SA72G!N431*07A";#-"-6)02&AN241O4VQT
M:D8K9'1U:VHS13)K6'-J<D59-"8C>$$[-4]C86]3:#E69C-A<5=02E8S-54S
M3W@R>3 X3%9U9U9F+VY)1WIH95IO.4@Q2U%&9TQ91FMQ1S1H4W O8S=Q45-E
M5&IV-UDK:$<W,"8C>$$[2U,U=EE/0FUI:4U294].<$5K8FQ74F=G25%P5#=4
M1&)L,'E$2E9V<C8P<TQ74S=V2E9G=&]G1$I+*WEQ0U%"6#94:TIZ15):,D10
M2"8C>$$[:6Q/46I%5U-H279-,VQY5F]K5%9,57E4,#E'37I2:#),2&E!14I$
M5G%+57 Q,GES86Y'9C1H=C5T,'1(;48S0U<S:U=P4$TO;'A%6B8C>$$[:G%D
M<S-%,$MP2VIS5'8X04-&56QI9FA/=TAB0614:D@X42MA:E)::B]"3#5,669.
M9FQQ6DA:3E5T9TDR6EA$>7%H0E)U0G%(2VUN3"8C>$$[=C!/,4]U23%722]X
M1#5P;&]C=S5W;#AM<'9.=FQI1C0P9E9,8FQ*6&E6;%9G2T%%;&U5:TM+34XR
M<&=/<7A$*TE*:F]--49I179K;28C>$$[3G1D,G0Q1C9T<DY(4$95<C9K5$(Q
M-4MA1595:U9'6%)M2D-W8F-E94]55%5G469.5GE40C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>"8C>$$[5C)+=7A69R\U>7E4=RM32G)M15=B=&)44E-T1'%#
M=TY$26]*2$%#-%9O>7AR=#,X36YJ-6]L>5ID<%%),'5Z0EAG9E%J<6=14E4K
M028C>$$[8F5M2VA0.$%6-UI%<%-0>6)&-2]34R\O04U74S)C<UI-9C9.*W%!
M:&=V>"MP-FQ1=2\R2U4Y.$UQ-DE&<6PO0BM9:'9*:EE8=6M2,B8C>$$[6EDK
M9VLY<&-V2T8W0C)3-5)39FMO>$9,=6QV-5E,9G)$-6M';U!&2F5$6$QR,6YG
M5F\T:3-P43$T<3=/=T9F1G--*VEH-%!D9C<Q5"8C>$$[9C8W9G)/8TUE8C9N
M1#91;FXU9B]!4$MA85(O>D5,*V\U:V%0*RMJ-S-#-U4O=T%7;B]696DK92\K
M56AK+W=#36-F-G-Z=3!0-S!U:B8C>$$[-THO=5(W>7@W348R8C),4V8K3U9:
M+SA!1T-0+T%)9TTV;D(Y169C2&ED4B]E4R]R2#<P5FQR4S=&541R6'(O55 S
M2$@Q=E=T+U0U,28C>$$[-#AV6%-N2VTY34E6038Q3'%O,&Q)-61):3%I85=1
M0V4Q4U)5:31R5C%F.$%E9R]T2TYV2$UF56LX3D-02#5/6&]X2&IS>CA/=74O
M-B8C>$$[1TI79'IQ,79A>#-$95-B965'2VLP1%=B4D5C-F9#-E5-:#)B*U5(
M63$W54]S:$M11BM%0U!,.$8S1U-'3U5I4$AK0V1J>%@K>CAF628C>$$[2S K
M=T5":49R-4]T-6).<&Q.=&52>GA-4D123TUX6G5B=CA!8F-G9SE",'EE3T9C
M<U%Q.6IF5'8X,G9,;#1R-',X:$MT>%(U-S=D028C>$$[3U%55V,R=&UN3'E6
M0D9A6$-X<E Y875)96)Q=%-O67E$:U-I>&AZ>3,V+U!!5'=J*S9!0C=Y4'@U
M<V=/2U@Y*U1)6%924#9/*S8R5R8C>$$[,CEL9#-5.%A$>5)9>#(Q=U5P8VPT
M2E9J5G502GIX<'IP=CA!6G!G:D%Y3S)+3D@S2FQK:D5'.5)/># S1B]Q6E0U
M4G4U2DQ35S-K,"8C>$$[>4A35VE9<VQT1$Q(24=$13AP3TMD4&I$3'8S0GI/
M,&LW1F-):39Z6#1W2D%I6FYF56<O3&9Y5#=-='=(67$W1EA9<3=&6%EQ-T98
M628C>$$[<3=&6%EQ-T9867$W1E=(+T%*=3-K;&XK6%=T6$UA>$Y*2$A(>$4X
M2UA%9%=M4F9I:61*1F(W6&1D=754>#@P4S5-:3!&,VLP3%1P2"8C>$$[041V
M87=S=U5!0W!J56UG5V<K-TEN;6Q,4$M8;G)14$Y46'DV4S!J2%0S4DQJ,44T
M0W-G2E5Q86M-1'A/-'=Y:5%G1E0Q1#AX=DHK;B8C>$$[,W,Q;&0S<VMD>F)S
M56Q15S$P-$1$+TM32FQ0,$A%44MB4R\X<CE1=$Y19SAY6&QO-6MT-3EC=6YI
M8W%Y17%9;U-0:&-+=RMK65IJ:R8C>$$[9U!(<FYY;#5Q3GI+4F\Q.%%866=I
M,FTX9CE83TY/;7DS.4UV:U@P;4=U=V-)+V51+W="344T.&HK5V9-9'0U=#!U
M930P<3AH9VIN5B8C>$$[<$I:3&5615553S59<4%-=C!M;GE$3$5M37%V=4QI
M9'!A>D1,5'I!;D5M=C5W6G U-DE(;4IY4E5E;DA59$LW6FLV+RLK,SAN5F1L
M9R8C>$$[*T)T-7!.<44Y;$Y/1W1)1&)X.%%#:&)L56=B;DUF4$]%:C9246-V
M5%DX:TDQ3UA%5UHV-W)(;DQ4=$PP9V57.4=45FI,8FHV>GIK128C>$$[65%G
M4G)'2VQL-C@R2D\O5#=U:S T2$%,-V<X:G%F-WE8.5DO96QC;FY$.#$T8D%!
M*U1&=4Y16716;S=Q3DE60W-!3FEZ33-)5E!59"8C>$$[=&IL+T1(=F%B2W9O
M;FY0.'=P3E-S<DA79DM$,CAD-4M%92]I;7)&0V=1;'DV<4IE:%A9;&Q"<E0U
M<&E/.6):;F-7=#%/-%9P:T9U2"8C>$$[4U1G27IZ+V1S2$$U.#9D5B]L>4-5
M2')F;%A23F)K:6LQ1T9P6&A"5TUH,U-G8G(Y:VIR;4YM,'--<'518W9483=,
M:$)%1%8K4T%T=B8C>$$[>38X<#(P,&,P3G$V>5)(:V@Y855G2&E6,D)A;E$U
M5DAS+T5$64@R=#@K,7,X:%)04'E#,E X=5!+.$XQ0F-W4E-W>5<X>7IG3$LU
M1"8C>$$[36A:;$1":3)W6G$W54]!9&XT9U%297@W,&YT9D]9;4I)3FEU5')B
M.'1V2T9T23!K5F\T6C!K:F%S,')F1$MJ4G8Q63E68VI$2',O128C>$$[3U$K
M,')0=&954T9%.3-19$XQ.% U9"M5;VXU4C):0C1.2"]E4T556E=5:T%T<S%(
M,DDY:C%X2%HK161%4S=7,4(U>2MW2792=DHK9R8C>$$[84YE4UAE;C(U:6YK
M:D5435I(9C1"4V=!66M#;D5D37-W-E1(:DYX1S=4<4YF;'I2-%IM=T1F24IZ
M;5,T8G-69&ER<U9D:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-69&ER0V9Z;3%#
M,G-V>3DQ13-+0U-'8WA1<W!91#=59T]W-7A&=G,Y1F%U5'AJ9$(U37 P5&@K
M:&)$9T9#9E9O928C>$$[25%%2T(V67!117-A9E-C:65A559$8C(X04MW>$I%
M<#-)4E%O2BMJ07$O1E=*9FPO+V4K868K,CED+SA!2G5(2E,V25IB:U5U>%8U
M<"8C>$$[-3<O-5-'5"]!27AX+W%Z;BLP4#<P=E4Y:R\S23DU63EM0S=.-T9P
M4"](2W,O=T1J0D@O>$%:,4]$-DDK-%!%-FHK.&PO5U S;W),5R8C>$$[;#)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9+3F4K=E=7
M;BMR<$9G8G4U36E,.5A357=R>$I!6G1M56)!028C>$$[9C5N2V-L9V5K5S5/
M1&AL2W!Y;V0Y5WAM6'I4-7AJ:$1Y955:5E!%33A:,5I&6D9*-#%E;T9/<&]E
M.5!L;$IY>D@X4"MY8SAA5$%4428C>$$[>6HO4TEA5'ID-39T>6LP=FQC4U=C
M<TU4>'I$53%I47E017-R3'I:;7)1<S9I:3<P2&)"-'-X=5)T-S)9,&5N3W=Y
M*W%Z+T(U,2MP1B8C>$$[4V599GI!16QW13AO>6Q9-5-B6FIQ02M/2U P-C%&
M9G104G50:#1(97!/5$HO3BLQ<D=N,#(S-S!C="]2,3,K-61O4&UB>D1D875U
M;28C>$$[-FYP0S)I2#1:3&LS>E)L0W$X1T%G8W1+-6515E%J67%183E#>FIY
M>4IQ47(T;S%';'A2:'AW;F9L=R]P-6-U9FXY:V<Q:E1.3#%I>"8C>$$[=4Y(
M3V]45SAL>7!6;71R;6LV:%<K3&E'3&HR3E9Z2VE9,WHS.3=R:4I69&)E-4<V
M9G!59&Q:5SER-C@Y>#E84DEX3DY)5$DO04%C;B8C>$$[-&-&<6%B,%5$0U%W
M-&HK06MN;$AY,35J,'HV-F1E,7E45GI/,%IT;"M/35%H5F\R-&)F;6%(+V)W
M>4%02E))+V="=2LX:E!D,V-T=R8C>$$[=FU,5W)94W-71G9"9$MS4U8W24=J
M63 K;D-+6&E0-'!,9GEY,#%B84QZ2$$Q>F-83%)A,V-P-C@P<D=2*TU55S=L
M94%*4&,P>&U/4R8C>$$[0DES>BMQ>%9"-5-B8B\S:VYT+VQE,RMD8VAW<#1Z
M*T%(9E9)<54U4V1+9C-S;GDO;7@T46YJ4&PX9V=R=GDQ;VPS35IR;3,Y5U5I
M:"8C>$$[9'!*0V%B+S58=FQ5.4YJ:V))<W0K4%<U64-O;6@X1DPO0TAL>B]L
M:5AX*S O=T1Z5FM0>5=,*V%Z+VQ(4"]/4F)W,E9P1$=L6D9J528C>$$[8T56
M6DI.9T%"5#=89TUT26I%3D%-<&MN<CA&4#9X<"\X,#,O04--:SDO.$%+.3AJ
M-&MF3FXT8R],-T5:87E24$9727-60DDK26MM=B8C>$$[6'%35#-Y,DI"1WI4
M3TI",U9C:W=D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%#,7)2
M=% Q<E1*.4TQ0D=K<S=K2TIK5B8C>$$[,E%K2W=91&MH1&16>4TT0U%O='5$
M3DQ&351J.5%99"]Y;R]Y06)M4V0W935F;4%)-'ID5$)9-E9*-$971&9%5%4X
M:69A;5DO-4]$<R8C>$$[+W=#6&145E=0.4M.,%,O-4\K45AN86,R36YQ<WAC
M:UA%+S)I4V$P-2M,2$0K57AT63=:,49662M16$@X;U!)6G18=%1:4T='4C!K
M9"8C>$$[9G)%.65587E)=$1Z<4YP;7)4<FHK5FA3+W=!<V%I-W-8-V@U95AK
M<%1F:S$U16MA3C%T<&]N:G X4WIY35=!2'=Q,TUV<T=!8C4Y828C>$$[,4Y1
M9$A"23=A,4$V:C5F:C-+<VXU4RM5;FID2UA+<WEC1FQ766@Q2'!,1'-A8FYJ
M1T16<6UU4#5/2&UG9'(U9V5N>3@W4F9L-SAT=B8C>$$[2VYL-U5V,&AP545K
M3352:V-.3$I)<D9I5'I):TQ(:T]4055.4&E0=%-C3E!'2G-.5W W5'I:;V--
M>4-08WEJ3#-!4W9Z3W9M2G1$=28C>$$[5CAU4$)(<DHT9E98=7%M169V1C4X
M<4$O-W(U53DX27$Y,4M886AR9FYA1SEM:7,O3$5D,V%O>$5.>611:6E,<C)B
M9UEY5BM68TE!-R8C>$$[,54O24=N83-A5RMS5&%X6G)9,T]O-G!097@R-GER
M3T)(3$A'0CAA54A65#)X:U%G37!Y2UA9<3=&6%EQ;UA6<71W<6=S5C1M=3)1
M;B8C>$$[1&EB3654:%$O=T-I22\X069H*S1:6#1!-S)Z.'=E-497,75)22M!
M4$E6<E4U8D-00TMA<'HT:F%R:VU$<U9D:7)S5F1I<G-69&ER<R8C>$$[5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%782]O
M54]T5VMD=$Q03F)E;$MS>5-W349C36]91&-G-R8C>$$[9D9L1V]W1$E+2DDS
M-D]4<&138TUJ24%'>%<V6&56+TDY:C5E;CE7,G4W;30O9$Y#<V,W2U965V-3
M2&E&5F%(:TUQ,#)I:FE.9VLW3R8C>$$[4G)E,'!A9U9+35)V93-Y6D<V:#!:
M5'-'0D)P-S5L:U=(6&<P56XP=GEX8F%F94,V4V536C%J.4U#6&EA3%%!54Y!
M9&=O1UEU2%-#128C>$$[=4MY6$YZ-C974U!#44)V97EC-6QU0W!F5C$Y8C%A
M-S%R4V<X2UI(:#-T;G@W57$U2F<W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-R8C>$$[1E@O+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.CA!-S0R,$4U,# R0D5%,3$Y1#4X138S-C4V,#$Q0D%!/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.CA!-S0R,$4U,# R0D5%,3$Y1#4X138S-C4V,#$Q0D%!/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C@Y-S0R,$4U
M,# R0D5%,3$Y1#4X138S-C4V,#$Q0D%!/"]S=%)E9CII;G-T86YC94E$/@H@
M(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C@Y-S0R,$4U
M,# R0D5%,3$Y1#4X138S-C4V,#$Q0D%!/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R
M,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.#@W-#(P134P,#)"144Q
M,3E$-3A%-C,V-38P,3%"04$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#<M,C54,#@Z-#,Z,C4M,#<Z
M,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.CA!-S0R,$4U,# R0D5%,3$Y1#4X138S-C4V,#$Q
M0D%!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(S+3 W+3(U5# X.C0S.C,X+3 W.C P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @
M/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O
M<CI3=&%R='5P4')O9FEL93X*(" @(" @(" @/&EL;'5S=')A=&]R.D-R96%T
M;W)3=6)4;V]L/D%D;V)E($EL;'5S=')A=&]R/"]I;&QU<W1R871O<CI#<F5A
M=&]R4W5B5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@
M(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS
M=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C
M(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R
M<')I;G0^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @
M(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G
M.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA
M>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T1&EM.G<^-C,P+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @
M/'-T1&EM.F@^.#$P+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @
M(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$YA;64^0V%L:6)R:2U)=&%L:6,\+W-T1FYT.F9O;G1.86UE/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y#86QI8G)I/"]S=$9N
M=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A
M8V4^271A;&EC/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@
M-BXR,SPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FEI+G1T
M9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y#86QI
M8G)I+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A;6EL>3Y#86QI8G)I/"]S=$9N=#IF;VYT1F%M:6QY/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z
M9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/
M<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#8N,C,\+W-T1FYT.G9E<G-I
M;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^
M1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&:6QE3F%M93YC86QI8G)I8BYT=&8\+W-T1FYT.F9O;G1&:6QE
M3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R:2U";VQD271A;&EC/"]S
M=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0@271A;&EC/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@
M5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXR,SPO<W1&;G0Z=F5R<VEO;E-T
M<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS
M93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9I;&5.86UE/F-A;&EB<FEZ+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%10
M9SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'
M.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E
M/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP
M9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \
M<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$V+C S/"]P9&8Z4')O
M9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^
M"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME
M="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_P  1" "V ET# 1$  A$! Q$!_\0 'P !   ' 0$!
M 0            0%!@<("0H# 0(+_\0 3A   00#  $!! 8$" H(!@, !0(#
M! 8  0<("1$2$Q05%AI7E]4A.':V%Q@B,3E8=[4C-T%1<Y:TTM;7"AE356&3
MH]-25EEQE=0D,C/_Q  = 0$  00# 0              !0$" P0&!P@)_\0
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M"@&%6'B\P^*'2RXIB2)BRIK.$WML(X)3)[%R4$)"L2QD*JNP%)4 LH8L %)
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MS;Y[S3R)\UNE\A?[K2Z%W[AO3^:\NBZMA4A=P]JLL&N,U$]<#17H10Q''AR
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M2<\#" $UQVRY<M3A\8*^7(ZS8V:.&TA5$5S-+;3O K%9+*?VY9)CP3@^HE0
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M5)90>  !&V90^]D=C$9 /?LD C1)&.:,RIX>QQ)]HGWZ )&NW<\^)^CML@[
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MU/\ &7T!_M=@_P#XZ/[:D?\ $;Z7_P#RYZK_ .53_93^/5X>?UCN4?ZU0O\
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M2T$*17GID,498/&CTW'?VPMX80)H'C2>-9%(?PC+%"&E7BJ/N21)"P#<D#L
M2I4+H-;R^([GA(KM&S*05YA&;2'98:52H'8!N(V =D[/_%GF%DXKXV\*Y%<"
M<,O:>;<IH]+/SQLF7,%K*5ZOP1LN.)F3V8TZ6)@NQU0!4J9%B29 ^-&>?B17
M5JCMQ=U*LUS/*@*I)+(Z@@ Z9B1L#8#$'9 ) ).B1WK;B0I%&A.RJ*I/O[@
M=C]('N!^JJL[5R>N=WY%TKB]OF&QU6ZG2;'0[#/K<N) L$,/9Q<D20D!IL^
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MO/9#L6C0C2Y8(YHV(9=J$/ EEV&)!X^R=$G_ $SQU[(TQ'OQYM]0]6.Y>/\
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MUN?"DRZ;92U ^!-?(Q8=&<AUH:S"@"A2(6Z+^8</9A(2(0A3$O$Q JP1E]Q
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MN))H>7-6'"*!6&N0T0#%6O3G4$SXVY7$Y&X7+S7%KC9H+"[,5_/;B43PV;)
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MYN>!+&),^9B]7XP,6LQ*+-E =8V03BX#!IU965G-L6&Y ?;]D<650-%_$)D
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MQ#C:?EOMQ8K.WY#C;6G9,EYJ/';VKWWGW6V6TJ<6E.Y!F5!R=E5=@;8A1LD
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MI+?V44BAXY+NVC=3[F1YD5E.N^BI(/ZZQL^NUJ_[ZE_^C_[6<!\VR7^MR_\
MV_=KM7R##?ZA#_QD^_3Z[6K_ +ZE_P#H_P#M8\VR7^MR_P#V_=IY!AO]0A_X
MR??I]=K5_P!]2_\ T?\ VL>;9+_6Y?\ [?NT\@PW^H0_\9/OT^NUJ_[ZE_\
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MM_5/V4\>#XT7S$^VLP(6MZA1-;U[-ZBQ];UO^?6_A(_1O.THO\U%_P"[3_\
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DF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g451428g67a27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g67a27.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1B24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &':^8F(X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .\    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     8 00!0 $0 +0 R       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0("=(M         *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      !  E,S,  $  @"4S,P  0 ".$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!$0      !     "   "0    D      .$))300>       $
M #A"24T$&@     #00    8             !,8   T8    !@!G #8 -P!A
M #( -P    $                          0             -&   !,8
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !,8
M    4F=H=&QO;F<   T8    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     0X0DE-! P     #AL
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MV@ , P$  A$#$0 _  .^K'5M[Q]JPI827@Y;?;!UWZ>W:G/U8ZM6]PLR,/\
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M<QS0RJ2"!^G/_D5ZC4TMJ8UW+6@'X@*:2!D2FE*AUVC)R>BYV/B G)MHL92
M[8=Y:0S])+=G]97TD%/DV/TKKA%C7N]=[@&U%G4F-P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^+__TE#0U]04D]&24Q%  $)OLS^_AX "(!P041"10(0
M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                 0  ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
M@ !U1*[TA>%H?ZM8A2Y;!:?/A(=,MZ1M@_,]<J%D@X\LD)\R@VL8V9[W@[\"
M[9H[@?L  (  @ !TY*X3C8IH**IUC'):KZ;CBUA,7Z-YBE@]'J!HB9HL7YX8
MB6@8TIVVB8,#(YBV@A\  (  @ !TE*UEE3UGYJG!D\I:;J8CDD-,&**MD-X\
MU)^:C^XL,)T[D <8VIR5CED#5I=J@D(  (  @ !T7:S7G0)GL:DMFSM:,J6&
MF59+V*(&EZ,\E)[LEK4KZYR3EG88NYO&D+D#B993@F0  (  @ !T+JQ^I1=G
MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
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M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
M@ "4T8\,8Y*&\HV=9?%W\(QY:"!GGXN):B=6&XJ[;!5#/8HJ;>$N=HHI;T<3
MR(R;;Q0  (  >D"4$(TM;'J&*XOW;?YW#HKE;VAFRXGT<,!568DE<@M"D8B3
M<S\MWXA]=!X38HI]<ZP  (  ?;:3,8M?=4>%'(I-=@YV&(E(=L1EU(AD=W!4
M?8>?>!I!UX<3>+DM28;N>1\3 XA_>)H  (  @ "2+(FX??N$"XBR?B1T\H?!
M?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (  @ "1,(A,ALR#
M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
M?4:&U9;]:XIYSY4?;0)KF9-I;F=<19';;[]+O)![<08YOH^!<B<E>(]V<L@+
M+I$8<D4  (  @ "&()5(<]MX[I.(=*5JTI'9=61;>Y!1=AY+#([U=M0Y+HWZ
M=W0E#HW4=[L+'([(=WT  (  @ "%2).P?!9W_I'\?$QIS)!=?'-:IH[:?)=*
M2XV,?, XD8R4?.4DG(Q8?.8+ 8R\?0P  (  @ "$;Y)=A%EW*I"QA =H^(\8
M@Z%9QHV:@S%)J(Q!@LDX!8M1@H<D.(K^@F<*[8KQ@>X  (  @ "#NI%'C,AV
M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
M@ #!$V<57^VNTVDY8K2;[6L^96"((FTD9^YS:6[X:FE=MW"Y;-%&QW)%;Q L
MSW,F<-T*!'8J<12_(&0E:M&M2V:*;(6:CFB_;BR&Z&K2;\MR1FS/<6!<J&ZQ
M<NM%R7!)=%,KZ'#Q=5T);71H=6N]26&5=:>KAF0@=DZ9!V9]=O.%<VBS=Z5P
M^&K2>%Q;@6S0>1%$RFYP>:\K#V[9>@H(Z7+<>BV[=U]+@%VIN&'U@ ^70V1L
M?\B#[F;!?XUOEVD!?VE:4FL8?TU#SVR^?RDJ0FSD?NT(=G&S?H:YS%U5BP2H
M(& 7B=R5LF*FB+6":64,AY=N4F=BAHY9-6F0A:="YVLYA,TIB6L9A!H(%')9
M@C^X<5O E;.FU%Z2D[N4<&$MD;6!,6.BC[9M+68#C=18/&@WC!U"&FGCBJ H
MY6E^B;$'P7+EA3ZW7%IYH&.ES%U6G9Z3:E_UFKJ ,6)PE]YL/63>E3%7:F<:
MDL!!<6B[D*\H8&@7C\H'?'-9A1"VCEE_JPZE!5QBIWR2G%[^H[Y_7V%VH AK
M;F/GG)E6K68LF8] UF?)ER<G[&;BE2('1'.XA.JV"EC4M:RD?ENUL3^2 UY$
MK*5^NF"QJ"%JSV,=I -6'V5@H'Y 36;PGA\G;F7(F5\'&'0#A,RS-V[L7T>B
MF7!/8C&1#G&G9.E^:'+V9W=JM'0_:>U5Z76!;$T_O':D;G<F G=:;_P$,GL)
M<1*QPFPL::NA>VW/:XR0 &]0;5!]:W"];O]IPW(@<)]5#G-X<C(^^'2@<YHE
M5W4/='@#X7ER=<FP,6FU<_2?S6M^=-^.>VT@=;A[]FZM=HQH>G P=V!3[7&A
M>"X]_G+)>-PDAW+F>28#F7GK>D:NDF>"?A^>)FEF?BV,VFLA?BYZE6S'?BEG
M.&YI?C!2V6_N?CL]''$7?CPCTG#A?A #6WI3?BNM$&6?B$><LV>8AXN+;&EI
MAKIY+FL@A>%F$VS1A151UVYLA&<\2V^2@\<C,&\&@U,#)GJM@8*KUF08DGV;
M@&8?D/R*06?ZCUEX#FF_C:]E!6MZC!I0]FT6BJ\[E&XZB8@BH&U=B1\"^GKY
M@@.JW&+<G+6:B63LFG*)2V;+E_YW'VB5E85D)6I<DS50-FO^D28Z_VT2CX\B
M+VOJCMP"U7LW@>JJ(V'LINV9S&/^H^F(A&79H*AV5F>?G6)C8&EJFF%/@&L4
ME]$Z;FPAEA8AR6JJDY "MWMJ@=:IK6%%L1^91F-4K5N'Z&4BJ4UUL6;<I45B
MQ6BBH:1.^FI*GK8YZVM*G/HA3VF*EH4"GWN3@<6EI'<57L.6>G>O8;J&-'A<
M9'1TIWD49OMA\'G3:6=.!GJ;:[<XBWMF;;\>RWP[;M,  (  <F"D>'1Y:(V5
M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
M>A^,'7,;:K5^O70);'EP>W3C;AU@Y76[;Z)0,G:/<1(^&G==<ETJ"W?M<T40
M/7D0<LL  (  ?;6*U7"3<[)]:W&H=,!O*7*A=:U?Z'.-=H=/3W1Z=TL]9W5/
M=_LICG6]>&D0 W;L=_   (  @ ")DVYK?*Y\4&^9?19N"W"I?5=>N'&E?7I.
M77*>?9H\BG-]?;HHW7/&?<,/H74E?9X  (  @ "(B6RDA;9[1VWCA7IM#F[_
MA0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH  (  @ "'LFLLCKIZ
M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"X<2?;4
M ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58
M@XD/,X4A@T<  (  @    (  @ !CWH> C$59#8;OB^5-+X8?BR1 /X4LBCLR
M+X1GB; B-H0&B@$.Y8.@A_(  (  @    (  @ !C?(:QE!E8K88ADWQ,RX5-
MDE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L  (  @    (  @ !<X)[Q5=]2
M0IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800  (.C;4D  (
M@ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K49@490P:4)D19;0&WYC=9>,
M ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:'
M:K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0.);G;)Y$T967;<XX:I1A;N,J
M:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (  @ !:#)9,<H%/DI4$<UM$,).W
M=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X  (  ?RX  (  @ !9<Y2W><A/
M!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$  (  @    (
M@ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI+HZE@,X9((ZI@.L'4(P<@.
M (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUS
MAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LH
MXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (  @ !0IJIA5$U&8JB85M([3:<-
M63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P  (  <2X  (  @ !/QJB46RI%
MQ*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914  (  =?@  (
M@ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X
M (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _
M;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?
MC)RE<?8.P)W9<8X -98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH
M=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#
M?YV#?:(XJYO/?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (
M@ !-))X#A%E#2IQSA'$X@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L
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M[EHB<E]ZKET#<X=J>%^V=)U9"&)%=:=&=61Q=J0R866%=W8:*V4[=[8  (
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M[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&E8TOR5P3E/L865YFD'8  (
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M\EZU>6EOK6$@>?Q@8&-9>G50$&5L>N8^1V<7>U$JT&=H>YT2-&IZ>V\  (
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M:G*65O-JI7.S6GA;I7387<E+7G7W8.<YEW<.8[LEF7?Y9=<+NGK$9@(  (
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M-V0Y?YIDW&8;?ZU6<&?0?Z-&]&E4?Y@V!FI??Y@B]VG*?Z,*WW 8?\<  (
M@ !]O& HB"9Q7F):A\ID#V1,AS15KF8-AH9&/6>8A>LU<&B3A8(BI&>DA8H*
MRV[/A$,  (  @ !]"EZ1D.5PLV#4C_9C9&+0CKM5#&24C6M%GV8>C% TU&<*
MBZ4B+F78B^D*LVWJASP  (  @ !\BUU7F9)P,E^HF"!BVV&EEDI4A&-DE&%%
M*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (  @ !X_7GN4OYM!'IB5H]@#7L
M6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$A(#I9.T  (  >2!WLW9@6TAK
M]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'9^H<B'L%:/$$FWXI:;(  (
M?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M N7:_:[@OQ7=];34<$'?+;=8$
MG'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/;OY/$'-%<& _XG0N<9HO(73?
M<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H2VZP=3I;HF_>=AU.!7#G=MX_
M/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (  @ !S#FL8?)YG;VR/?1-:VFW/
M?5I-,F[B?7X^:F_.?9PN '!2?;T:X6^(?<($F'@\?H(  (  @ !R.FDSA/EF
MH6J^A.1:%FP*A)%,>&TEA"(]NFX0@\0M;FYU@Y<:F&V(@]X$FG@X@H,  (
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M;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*:V<2E'^):S\  (  ;WH  (
M@ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@VOWMH;\XF3'O;<*$2.7R/<$@
M (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@
M=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<<'5X>F)0B'8>>M5#FG:=>R4U
M?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (  @ !FKG+(@;-;RW.]@=M/]G1K
M@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D  (  @    (  @ !F$G%)B9I;
M-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$  (  @    (
M@ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(ACC81$7,_BO
M (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI
M7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>7E4\]8C$8+PN
MH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4+88Q8IA(UX87
M9*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (  @ !=L(-H9\E3
M,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P  (  >%L  (
M@ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\LP($G<RT<9X&.<V,)88'C<XH
M (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H
M>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0UWU/?I)%F7UO?K0Y1WUD?K<K
MFWU/?KH;T7TD?L0)C7W2?S,  (  @    (  @ !:K'MYA<M0='OYA<Y%1GP;
MA7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\  (  @    (  @ !:.WI*C6Q0
M!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD  (  @    (
M@ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HDSY5W6Q82[YA26Z@!@I2E78T
M (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G
M8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DC
MY(^O98<2FY&D98X"!HW+9V<  (  =N0  (  @ !2 (Y"94!(!HW(9O$]*(U+
M:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0  (  >SP  (  @ !1.8O(;%5'
M1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8  (
M@ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?=8@"1895>$H
M (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E
M>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%B(92@? ZV(7V@=<O#(5P@:<A
MFX41@:81+X48@<,"88,1@74  (  @    (  @ !.^(4TB3-%6H5&B4 ZN83S
MB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (  @ !(6*)Q3E\^
MWZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0  (  <'H  (
M@ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P919ZA7-@(IY]S75D  ([<9'X
M (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.
M8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL8
M1YCM9P8(@)A,9U\  (G>;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98
M:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[
M2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (
M@ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H
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M E1M8]=SF5>Y9E!D EK/:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH  (
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MLD3*CZUMXDDPCDI? 4TFC/-/ U"5B] ]RU+<BODK+5)'BL84*EWKB9L  (
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M%U=Y:T)HE5IT;0M:%%TP;KI*/U^@<$HY%&%5<;0E^6#(<KT-N&EX<L\  (
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M2$I3E/)D'TX1DS95\U%;D7I&NE0+D!<V,55/CU$CWU50CV0,X6H\B+4  (
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M7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[==8=N&+[=CT&YW15=X0  (
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M!G*34:18>'/-555*T74&6-X[S78M7" JYW=#7MD6G7@P8!8 IW[F8EH  (
M>-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J4G-:9 ,60W0)9-<
MSGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?
M:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4XFB<:?='WFHV:[TY
M1FN$;4TH\&P1;H(576UN;JD \WYE<98  (  @ !JXV$C;D9?N&-F;Z13NV5D
M<.U&RF<7<A8XHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX  (  @ !IQ5X#=H!>
MR&!V=U!2YV*6=_]%]&1<>) WS66C>1$GV66J>7@4KFB:>6<!$GXP>_0  (
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MJ';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG8A$,M'RL8CT  (  :D@  (
M?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH
M (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S
M;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5 VP$;5])I&UI;KP]+&Z+;_,O
M>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (  @ !>=F=&<[)4!FD9=*1(OFJ<
M=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,  (  @ !=F&23>WA3
M2V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T  (  @    (
M@ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,MJV>S@HH=[&;J@K<+BFY<@GL
M (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4F
MB2H+66T^AJH  (  @    (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$H
MO(6 60(75H>)6EP$<8?56Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@
M67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,
M5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (
M@ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\
M (  >"   (  @ !4&G0Y:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$
M;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)0W)O<;L^A'-D<J8RH70&<V<E
M-W0]<^L5!72'<],$8GE#==\  (  @    (  @ !246YW> I(<V_G>*D]Q'#V
M>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,  (  @    (  @ !1IFPG?W1'
M[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<  (  @    (
M@ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D$6UDA=L4$&ZDA;@$47BU@NL
M (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=
M5O8  (F*7#0  (  ;*T  (  @ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=
MF8N86VP,.8T56]8  (9.8-\  (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:4
M73PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H  (  =H@  (  @ !)C8)47T=
M%X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (
M@ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D
M (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&
M<(<  (  =E4  (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:
M<GKG=A,*U'PV=FP  (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\
M>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\
MAW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @    (
M@ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH
M (  < T  (  @  _-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"945
M63\  (&N9$   (  =0$  (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0
MH)3#7!\"TI#/7BX  (  :2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([5
M7ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS
M=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (
M@  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L
M (  @    (  @  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%
M=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.
MHX1)=Y(";H,">BL  (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L
M?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @    (  @    (  @    /__  #_
M_P  __\  &UF=#(     ! ,)   !                     0
M          $   $   (   (D!!T%V@=I"-D*-@N%#,<-_P\Q$%X1BQ*W$^(5
M"Q8R%U<8>1F8&K4;TASO'B4?62"'(;(BVB/_)2,F1"=F*(8IIRK'*^@M""XH
M+T@P:3&),J8SPC3>-?LW&#@U.5$Z;3N)/*4]PC[>/_A!$4(I0T)$7$5U1H]'
MJ4C#2=U*]TP232Q.0T]94&]1AE*<4[)4R57?5O98#5DC6CI;45QF77A>BE^;
M8*UAOF+/8^!D\68"9Q)H(VDS:D)K4FQ>;6=N<6]Z<(-QC'*4<YQTHW6J=K%W
MMWB]><-ZR'O-?,Y]S7[,?\N R8''@L6#PH2_A;N&MX>SB*Z)J8JDBYZ,F(V1
MCH:/>Y!PD6226)-,E$"5,Y8FEQF8#)C_F?*:Y)O6G,B=NYZMGY^@CJ%\HFJC
M5Z1%I3.F(*<.I_RHZJG7JL6KLZRAK8^N?:]KL%FQ1[(VLR2T$K4 M>VVVK?(
MN+6YH[J0NWZ\:[U9OD>_-< BP1#!_L+LP]K$Q\6UQJ/'D<A^R6S*6<M$S"[-
M&,X!SNO/U="^T:?2D--YU&'52=8QUQC8 -CFV<W:LMN8W'W=8MY'WRS@$.#T
MX=CBN^.>Y'OE5^8SYP[GZ.C!Z9KJ<>M([!WL\.W#[I;O=O!5\3/R#_+J\\/T
MG/5S]DGW'O?S^,;YE?IA^RG[Z_RG_5S^"_ZT_UK__P   >@#IP4L!H0'OPCG
M"@0+%@P<#1X.' \9$!<1%!(0$PL4!!3\%?,6YA?8&,P9UAK>&^$<X1W?'ML?
MUB#1(<LBQ".^)+@ELR:N)ZHHIBFB*J KGBR=+9HNE2^1,(TQB3*&,X,T@35_
M-G\W?SB .8(Z?SM^/'P]?#Y\/WU ?T&"0H5#B42-19)&F$>:2)M)G4J?2Z-,
MIDVJ3J]/M%"Z4<!2QU/.5-55UU;95]M8WEG@6N-;YUSJ7>U>\5_U8/AA_&,
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M?\Y_6,V9?ZA^S;3:?YE^>9P4?Z-^98-,?\9^A6J%?_Y^P%&_@&-_/3D @1*
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M06#6@<>+9$H8@9>(:#.B@8N%!.=<A(NHH-%L@YVD%;L0@M2?NJ1;@C>;E(V
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MC.Y^("QJB3M_T[VBHYR#<*OBG_*"?)G.G'.!M8=NF1^!)73%E>^ TF(*DL>
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M=W&I^':;>(.BKE_R>:J:_$E>>O:2NS+\?'2)C.<G=%720=#V=-G)F[I,=6K
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MBC6 /*JCB/1_T99:A]5_AH&OAM)_96SHA>-_9UA A/U_>T/,A"Q_NB_N@VZ
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MOCN P6?PM^R #5M*L6U_L4[#JK9_D$*)H[Y_I3;^G'1_UBQ@E,V .R-5C.J
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ME-B OHJRDH* 7GHZD$^ &FERCBE_\UB9C M_Y4@2B>-_XC?^A[I_^2D(A7^
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MDKE^BR(,BZ-_CGD#O0."D&U<MX&!N6&AL<F!#U7GJ]> HDH\I;& ;3[EGU*
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M>N)Y9&H&>ZEZ0E8.?(E[,D).?9=\22\Y?N=]D\CH=H* W;;E=TF @:0Y> >
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MGVR  &X@G!)_OV$@F+)_EE/BE4U_B$;&D=A_CSHWCD=_HRYEBJ!_RR0(ANF
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M*EC"G\1^+$RYFU5^4T#IEL9^DS6]D@U^Y2MFC3)_5"*/B%!_TGMPJU6%27
MISR$BF1'HPB#TUA=GK:#)TQZFDJ"F$# E<^"'S6WD2F!K"N'C&>!22+;AZ6
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M@+]Z+U9:@*U[ T9H@*I[YC;;@,U\Y"AK@19^ :*;@!B (Y1(?]^ ((53?ZZ
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MB'A^,"+5A:1^_WX$FG:!P7*QE^"!B&;OE3V!0EK<DHV ]DZSC]F NT*6C2J
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M\RZ%E0]V<"8HCXUY*!\VBC![]6E;L(1PPE^3K&#_XO__24-#7U!23T9)3$4
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M:0R'&H_2:QF&/'[_;2J%4FW>;U^$;ER/<<>#F$N@=%6"NCL7=R:!SRNE>D"
MR:YO97Z1?Y[J9[*/X(Z\:=&.&'WX:_F,.FSP;DB*6UO5<,J(?DL9<X"&F3K&
M=G>$CRN.>;*"4:V!9%B:^9X!9IJ8?XW7:,*5QWT?:OF2\&PL;6&0%ELW;_Z-
M-$JL<LJ*.CJ&=>.'$RM[>3N#J*S08WBD0)U/9<"@YXT=9^R=.7QH:BB98&N
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M@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^* A665?[. 7E@<?Y2 .TIM?Z"
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MV%72CE9WTTIAC%%XX#\2BDMZ!S19B$1[0RI5ADQ\HR&[A&U^$W6FDJ=\ &M
MD-E\86!ECOE\LU4[C0=\_4G_BQ1]5S[-B2]]Q#0\AT9^/2IFA6Y^R"'^@[%_
M6G43D7Z"_&JYC[Z"SU_IC>.">U3%B_:"$$F9B@Z!JCZBB"^!530KAF2!"RIU
MA*Z P"(U@Q2 =W2;D(:)RFI#CM2)"U]WC/V(#%19BQ2&YTD]B3:%PSYGAV>$
MJC0KA9^#FRJ(A F"@2)C@I*!:G0\C]&0;&H(CBF/*%\_C$J-=%0>BD^+?4D)
MB&^)DCXMAK>'MC0#A0:%Z2J4@X&$"R*(@BB"-7/RCTF6UFG!C9Z5"%[UB[F2
MFE/9B;F/UTC3A]B-(CX+AB6*?S/VA(:'["J;@QF%4B*F@=."VVU"HF]>L&-X
MGZ1A@%E:G-9D8T[FF=IG8D1,EJ)JASG1DT%MXB_UC\EQ:2;/C$MU0A\'B/)Y
M5&RIH/QEO6,<GC1GXED/FU!J(TZVF$1L@T0VE0QO"CG8D;QQP3 <CEMTGB<?
MBOMWOA^(A\)[ FPQGSILC6*9G(5N'5BLF:QOPDY>EJEQB4/^DX5S<#G%D$]U
M@3 QC0QWL2=AB<]Z%!_WAKE\BFNUG7QS,&(1FMAT.5@=F!%U3$W\E2)V=T.T
MDAEWOCFBCP%Y(S YB]YZH">5B,5\02!7A=5]ZFLXG !YPV&<F6QZ2E>MEJ]Z
MS$V-D\M[4$-VD--[[CE^C=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]
MF$R 4E=8E9* .DU DK* %$,VC\1__#EHC--__# \B>N ""?>AQ: &R#MA'"
M,&IMF>F&I&#SEV:&+%<7E*J%=$T!D<F$GD+YCN6#TSE&C .#&3!'B2&";B?^
MAFN!OR$E@^F!%6HGF2J,OV"REJR+PU;6D_"*:4S&D0V(WT+'CBV'7CD5BUV%
MZS WB(2$CB@>A=V#*R%2@WR!U&GOF**2LF"GEB*125;+DUF/.TRRD&",W$+%
MC76*F3DJBJV(<S!0A_2&9R@VA6^$6B%V@R6"<&*LJ\I>&EE]J'-@UU WI.-C
MO4;1H/%FT#UIG*5J&30XF!UMG2NUDW=Q32/ZCL=U11V5BE1Y56(5JI!DP5DO
MIR)FX5 $HV=I,$:]GUQKKSUQFPIN8C1?EHYQ2RO\D?MT6B1HC6AWHQXMB19Z
M^&&]J-YK)%C4I71LO$_%H<!N>$:+G;AP:CU=F7=RAS1ME1-TU2PQD)QW0"3%
MC"QYV1ZPB )\<V%PIQIQ5EA]H[QR<T]IH!5SJ493G"-U"3T[E_IVDC1MD[5X
M/2Q7CU]Z 241BQ5[YA\@AQ5]Q6$CI9)W>%@XHD%X(4\IGJ)XTT83FKEYE#TE
MEJ5Z?C1LDGU[ABQVCD=\G251BB-]RA]_ADM^[V#=I%U]DE@*H0Y]RD\&G7%]
M[47TF8U^$#T-E81^2C1UD6E^I"R5C5%_#B6(B5)_@A_/A:-_\&"CHV:#>E?J
MH!6#04[PG'6"T47@F)2"3SS[E):!X31UD(N!B2RTC'Z!126YB**!!B 0A1B
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MQT1[>,!SF36S>P5VM"@A?9-Z,9P::_5M%8ZY;;QNUX"W;W)PBG',<3-R-&*
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M;Y.$^G0-</R$>6:D<G6#V%C_=!>#-$M3=>Z"F#X@=_6!_S%_>CJ!7B8Y?*.
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MA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6> WT>^BVV ICZAB7: ?C78AXV
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M/JB]56=I@)G]63YK@(K$7/]M?GK18,-O@VIX9*]QEEG\:-5SP4G>;3=V##I
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M=?5]^"<^>@A^WHZ/7,:!Y()27_*!VW5W8PF!K&@)9C&!9UI9:8R!(DR9;2N
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M=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@. S#*&>VB KRF0?0* C2($?I^
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M?+2$KU)Q?/N$*DD^?1R#>T (?56"X3<&?;^"6RZT?CV!ZB<7?N^!:R#'?[6
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M2*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F -$2W9C> /#<5;/J 4RKH<\V
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M>B]\UD35>R9]+3V&>^!]@C9 ?(Q]\B\Z?5)^>"D#?@]_#B-O?O]_EA[A?_V
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M@5)^VSU5@9U^YC<Q@6Q^^3$D@0]_,"M4@,I_?"8H@)9_T2&:@)Z &QX%@,2
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M1$'_I$92_:I$8/2Q0F[KN$%[Y,%"AM_,1HW3SU*7P<1AI[.[;;.KM7B[I;&
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M<\*&J7/"AJESPH:I_[0D)>S*%B/-Y1,LN?8;1J?Z)EN8[C5LC.5$>H3>4X.
MV6**?-5LCWC2<9-UT'65<\]XEW'.>IAPS7R9;\U^FF[,@)MMS(*<;,N$G&S+
MA)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$
MG&S+A)QLRX2<]<$5&='?#!B\\Q,QJO\>1YK\+%F.\CQGA.I+<GWE6'IYX&.
M=-YJA'#;;X=MVG.):]EVBFK8>(MIUWJ,:-9\C6?6?HYFU8".9=6!CV75@8]E
MU8&/9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/9=6!CV75
M@8]EU8&/TM(*";_H#1VM_Q4SG?\C19#_,U2%]T-??O%1:'?L7&]PZ6)T:^=G
M=VCE;7EFY'![9>-S?6/B=GUBX7A^8N%Y?V'A>W]@X'V 7^!_@5_@?X%?X'^!
M7^!_@5_@?X%?X'^!7^!_@5_@?X%?X'^!7^!_@5_@?X%?X'^!7^!_@5_@?X%?
MX'^!_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4
MA+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JL
MQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&
M_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$
MDXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5Z
MK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y
M(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNV
MPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U
M>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<
M1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/
MNL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&
MM7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_
MFE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+
MDKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JL
MQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*
M_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^
MAY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5Z
MK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU2
M6?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_
MO8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U
M>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?
M5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8
MP;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&
MM7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GM
MH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!
MF\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JL
MQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=X
MXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[
M?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5Z
MK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^=1C;_FE!*_YY16?>@4FCMH59XY*%:
MAMN>9)32FVZ@S)AXJL:5@;+$E8FVP9&.NK^,D+V]B)/ O(27P[J!F\6Y?J#'
MN'RGR+)[JLBP>ZK(L'NJR+![JLBP>ZK(L'NJR+![JLBP>ZK(L'NJR+![JLBP
M>ZK(L'NJR+![JLBP>ZK(_Z X(O^=1C?_FT]*_Y]/6?BB4&CNHU-WY:17A=RB
M8)/3GFJ?S9MTJ<>8?;'$EX:VP92,NK^/CKZ\BI+"NH:5Q;B"FLBW?Z#+M'RG
MS*Q\J<JJ?:G*JGVIRJI]J<JJ?:G*JGVIRJI]J<JJ?:G*JGVIRJI]J<JJ?:G*
MJGVIRJI]J<JJ?:G*_Z X(O^=13?_G$Y*_Z!.6/BC3V?OI5%VY:95A-VE79'4
MHF:=S9]PJ,B<>K#$FH*VP9B*NKZ2C+^[C8_$N(B3R+:#F<RT@*'/K'VESZ9^
MI\RD?ZC+I'^HRZ1_J,ND?ZC+I'^HRZ1_J,ND?ZC+I'^HRZ1_J,ND?ZC+I'^H
MRZ1_J,ND?ZC+_Z$X(O^=13?_G4U)_Z%,6/FE36;OIT]UYJE3@]ZH6I#5IF*<
MSZ-LILF@=J[%GG^UP9R'NKZ7BL"ZD(W&MHN2R[2(FLZRAJ31IH"DT:"!I\V?
M@:?,GX&GS)^!I\R?@:?,GX&GS)^!I\R?@:?,GX&GS)^!I\R?@:?,GX&GS)^!
MI\R?@:?,_Z$X(O^>13?_GDQ)_Z)+5_FF3&;PJ4YTYZM1@M^K5X[7JE^:T*AI
MI,NE<ZS&HWRSPJ"$N;Z<B,"YEHS&M9&2RZ^-F,^JBJ'2H(2CTYN$ILZ:A*?-
MFH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-FH2GS9J$I\V:
MA*?-_Z$X(O^>13?_GDM)_Z-*5_JG2V7PJTQSZ*U/@."O5(W9KER8TJUFH<VK
M<*G(JGFPPZ>!M[ZAA,"UFXG&KI6/S*B1E<^BCI[2FHFBTY:'I<^5AZ;.E8>F
MSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.
M_Z$W(O^>1#?_GTI)_Z1)5OJH263QK$MRZ;!-?^&S48O:LUJ5U+-CGL^S;J7+
MLWBKPZQ\M[BE@;^OGH;&J)F,RZ&5DM";DIO3E8ZBU)&,I="1BZ;.D8NFSI&+
MILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+ILZ1BZ;._Z$W
M(O^>1#?_H$E(_Z5(5ONJ2&3RKDEQZK),?>*V3XG<N%>2UKIAFM.];:#)N'6K
MOK!ZMK.I?[^JHH3&HIV*RYN:D,^5EYG2D)6BU(V0I=",D*;/C)"FSXR0IL^,
MD*;/C)"FSXR0IL^,D*;/C)"FSXR0IL^,D*;/C)"FSXR0IL^,D*;/_Z$W(O^>
M1#?_H$E(_Z9'5?NK1V/SL$APZ[5*?.2Z3H;>OU6/VL-@E=+$;9S%NW.JN;-X
MMJZM?;^EIX+%G:*(RY:?CL^/G);2BYRBTXB5I-")E*7/B92ESXF4I<^)E*7/
MB92ESXF4I<^)E*7/B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/_Z(W(O^?1#?_
MH4A(_Z=&5?RL16+TLD9N[+A(>N:_3(/AQU.*W,UBCL[(;)O OW&JM+=WM:FQ
M?+Z?K('%EZ>&RI"DC,Z*HI71AJ*ATH2;I="%FJ7/A9JESX6:I<^%FJ7/A9JE
MSX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/_Z(V(O^?0S?_HD9'
M_ZA$5/VN0V'UM41L[KQ&=^G$2W_CSU2$V=1EB,C+:YJZPG"IKKIWM*.T?+V:
MKX'#DJR%R(NIBLR$IY+/@*:<T("CI<^ H:;.@*&FSH"AILZ H:;.@*&FSH"A
MILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;._Z(V(O^?0S?_HT5'_ZI"
M4_ZQ05_VN$%J\<%$<^K,2WG@VE9\S]5>C<#,:9NSPW*HI[MYLYZU?[N7L8/"
MCJV%QH>KB,J!J8W-?*B6SGNHHLU[J:;->ZFFS7NIILU[J:;->ZFFS7NIILU[
MJ:;->ZFFS7NIILU[J:;->ZFFS7NIILU[J:;-_Z,V(O^?0S?_I4-&_ZQ 4O^T
M/EWYO3]F[LA#;>/636_5W4Z!Q--9D;7)9I^IP7&KH+MYLYFV@+J4LH7 C*^&
MQ(:MB,> JXS)?*J2RGJKG,IYJY_*>:N?RGFKG\IYJY_*>:N?RGFKG\IYJY_*
M>:N?RGFKG\IYJY_*>:N?RGFKG\IYJY_*_Z,U(O^@0C?_ID%%_Z\]4/ZX.UGS
MQ#QAYM%#9-G?0W/(W$J%M]!7E:K'9:*@P'"LF;IYM)2V@+J1LX6^B[&&P86P
MB,.!KHO%?:V0QGJME\9ZK9K&>JV:QGJMFL9ZK9K&>JV:QGJMFL9ZK9K&>JV:
MQGJMFL9ZK9K&>JV:QGJMFL9ZK9K&_Z0T(O^A03?_J3U#_[,Y3?F^-U7JS#I9
MV]T[8LOE/W>[V4B)J\Y7F*#&9:28P'&LD[MZLY"X@;B,M82[B+.&OH6RB<"!
ML8O!?K"/PGNPE,-ZL);#>K"6PWJPEL-ZL);#>K"6PWJPEL-ZL);#>K"6PWJP
MEL-ZL);#>K"6PWJPEL-ZL);#_Z0T(O^C/C;_K3E!_[@T2/#&,TW?V390S>4V
M9[[D.WNMUTB,H,U8F9?&9Z22P7*KCKU[L(RZ@;2(N(.WA+>%N8*UB+M_M(J]
M?+.-OGJSD;]ZLY._>K.3OWJSD[]ZLY._>K.3OWJSD[]ZLY._>K.3OWJSD[]Z
MLY._>K.3OWJSD[]ZLY.__Z8R(O^F.C3_LC,]]\ N0N32+T'/Y"Y5O^\S:Z_A
M.WZ@UDJ-ELY;F9#(::&,PW.HB<![K(:^?Z^"O(&R@+N$LWVZAK5[N8BV>;B+
MMW>WC[AWMY"Y=[>0N7>WD+EWMY"Y=[>0N7>WD+EWMY"Y=[>0N7>WD+EWMY"Y
M=[>0N7>WD+EWMY"Y_Z<Q(O^L,S'_N2LVZLPF-M+A)D'![RQ:L.TS;J'A/7^5
MUTV,C=!>EHG+:YV&QW2B@\1ZIG_#?:E\P8"K>L""K'F_A*UWOH:O=;Z)L'.]
MC+%SO8VQ<[V-L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ<[V-
ML7.]C;%SO8VQ_ZDN(?^S*BORQ2(LUMX<+</M(T>R^2M=HNPV;Y7B0GV+VE*(
MA=1@D(+0;)9^S'.;>\IWGGC)>Z!VR'ZB=,> HW/&@J1QQ82E<,2'IF[$BJ=N
MPXNG;L.+IV[#BZ=NPXNG;L.+IV[#BZ=NPXNG;L.+IV[#BZ=NPXNG;L.+IV[#
MBZ=NPXNG_ZPJ(/J]'R+<V1(;Q>L:,[3Z(TJC^2Y>E>X\;8KE27F#WU:"?MID
MB7K6;(YVTW&1<])UE''0>95OSWN7;<Y^F&S.@)EKS8*::LV$FVG,AYQHS(B<
M:,R(G&C,B)QHS(B<:,R(G&C,B)QHS(B<:,R(G&C,B)QHS(B<:,R(G&C,B)QH
MS(B<_[8>&.30#A/(Z1$@M?D;-Z7_)DN7^C1<B_%":(+J3W)\Y5MZ=^%D?W+>
M:H-NW'"&;-MTB&K9=XEHV7F+9]A\BV;7?HQEUH"-9-:"CF/5A8]BU86/8M6%
MCV+5A8]BU86/8M6%CV+5A8]BU86/8M6%CV+5A8]BU86/8M6%CV+5A8]BU86/
MZ<<-#,K:"P^W]Q(DI_\=.9C_*TF,_CI7@_9)87SP56EU[%YO;NEC=&KG:7=G
MY6YY9>1R>V/C=7QBXG=]8>)Y?F#A>W]?X7U_7^!_@%[@@H%=WX.!7=^#@5W?
M@X%=WX.!7=^#@5W?@X%=WX.!7=^#@5W?@X%=WX.!7=^#@5W?@X%=WX.!R] )
M [KB"Q.H_Q0FFO\A-XW_,46$_T!0?/Q.6'3X5U]M]%UD9_)B9V/P:&IA[FQL
M7^UP;5WM<F]<['5O6^QW<%KK>7%:ZWIQ6>I\<ECJ?W)8ZG]S6.I_<UCJ?W-8
MZG]S6.I_<UCJ?W-8ZG]S6.I_<UCJ?W-8ZG]S6.I_<UCJ?W-8ZG]S_YPX&O^:
M1BW_EU%!_YI33_Z<55[UG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0
ML,6'E+3#A)BWPH&;N<%_GKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]
MNWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_
MEU%!_YI33_Z<55[UG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'
ME+3#A)BWPH&;N<%_GKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBS
MO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!
M_YI33_Z<55[UG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#
MA)BWPH&;N<%_GKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MX
ML[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI3
M3_Z<55[UG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BW
MPH&;N<%_GKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[
M>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<
M55[UG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;
MN<%_GKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]
MNWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[U
MG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_
MGKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBS
MO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[UG%IL
M[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_GKK!
M?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MX
ML[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[UG%IL[)M?
M>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_GKK!?:*[
MP'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[
M>+.]NWBSO;MXL[V[>+.]_YTX&O^:12[_EU!!_YM13_^=5%WUGEAK[)U=>>2;
M9(;<F&Z2U95XG-"2@:3+CXFKQXV/L<6)D[7#A9>XPH*:NL%_GKO ?:*]OWNG
MOK]YK;Z[>+&^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^
MMGFROK9YLKZV>;*^_YTX&O^:12[_F$] _YU03O^?4ESVH%5J[:!:>.6?8(7=
MG&J1UIASF]"5?:3+DH6KQX^-L<2,D;;"AY6YP8.9N[]_G;Z^?:*_O7JHP+QY
MK\&T>;#!L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JP
MP+!ZL,"P>K# _YTW&O^;12[_F4Y _YY.3O^A4%OWHE-I[J-7=^:B78/>GV:/
MUYQOFM&8>:/+E8*KQY*)L<2.C[;"B9.ZOX28O;V G<"\?:/"NWNJQ+1ZK<2M
M>Z[#JGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNOP:I[
MK\&J>Z_!_YXW&O^;1"[_FDU _Y]-3?^B3EOWI%%H[Z55=>>E6H+?HV*-V*!K
MF-*<=:',F7ZIR)6&L,22C;;!C)&[OH:6O[R!G,.Z?J3%MWRKQZU[J\:G?*W$
MI'VNPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL.D
M?:[#_YXW&O^;1"[_FTQ _Z!,3?^D35KXID]G\*A3=.BH5X#@IUZ,VJ1HEM.A
M<9_.G7JGR9F#K\65BK7!CX^[O8F5P;J%G<2V@J3'L("JR*=]JLBB?JS%GW^N
MPY]_KL.??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL.??Z[#
M_YXW&O^;1"[_G$L__Z%*3/^E2UGYJ$YF\:I1<^FK57_BJUN*VZEEE-6F;IW/
MHW>ERI^ K,69AK2_DXR\N(V3P;*)F<6NAJ'(JH2IR:& J<J<@:S&FX&MQ)N!
MK<2;@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;@:W$_YXV
M&O^<1"[_G$H__Z))3/^F2EGYJ4QE\:Q/<>JN5'WCKUF(W:YBD=:M:YK1JG6B
MRZ5]J\&=@[2YEHF\LI&0P:R,EL:GB9W(HX>FRIN#J,N8@ZO'EH2MQ9:$K<66
MA*W%EH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%_YXV&O^<
M0R[_G4D__Z-(2_^G25CZJTMD\JY.<.NQ4GODLU>%W[1@CMFS:I;1L76>QJA[
MJ[R@@;2SFH>\K)2-PJ:0E,:@C9O)G(NDRY:'J,N3AZO(DH>LQ9*'K,62AZS%
MDH>LQ9*'K,62AZS%DH>LQ9*'K,62AZS%DH>LQ9*'K,62AZS%_Y\V&O^<0R[_
MGD@__Z-'2_^H2%?[K4EC\[!,;^RT4'GFN%:#X;M>B]J[:I+-M'.>P:MYJK>D
M?[2NG82\IIB*P:"4D<::D9C)EH^ARY&,J,R/BJK(CHJLQHZ*K,:.BJS&CHJL
MQHZ*K,:.BJS&CHJLQHZ*K,:.BJS&CHJLQHZ*K,:.BJS&_Y\V&O^<0R[_GD<^
M_Z1&2O^J1E;\KDAB]+-+;>ZX3W?HO55_X<%>AM; ;([(MW&=O:YWJK*G?;2I
MH8*[H9R(P9J8C\:4EI;)D)2?RXR2J,R*CZK)BHZLQHJ.K,:*CJS&BHZLQHJ.
MK,:*CJS&BHZLQHJ.K,:*CJS&BHZLQHJ.K,:*CJS&_Y\V&O^<0R[_GT8^_Z5%
M2O^K157\L$9A]K9):_"\3G3GPE5[W\AA@-'#:HW$NG"=N+)UJ:VK>[.CI8"[
MFZ&&P92=C<6.FY3(BIF=RH:9J,N&E*K)AI*KQH:2J\:&DJO&AI*KQH:2J\:&
MDJO&AI*KQH:2J\:&DJO&AI*KQH:2J\:&DJO&_Y\U&O^=0B[_H$4]_Z=$2?^M
M0U3^LT1?][I':._!37#ER59UW,YD>LS&:8V^OFZ<LK9TJ*>P>;*>JWZZE::$
MP(ZCB\2(H9+'A)^:R8"?I\J!FJK(@IBKQH*8J\:"F*O&@IBKQH*8J\:"F*O&
M@IBKQH*8J\:"F*O&@IBKQH*8J\:"F*O&_Z U&O^=0B[_H40]_ZA"2/^O05/_
MMD)=][Y&9>S'36OCTEAMUM-A>L?*9XRYPFV;K+QRIZ&V=[&8L7VYCZV"OHBJ
MB<."J)#&?:>9R'JGI<E[HJO(?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZL
MQGV>K,9]GJS&?9ZLQGV>K,9]GJS&_Z U&O^=0B[_HD(\_ZI 1_^R/E']ND!9
M\\-$8.C/3F/?W%EGS]A@><#/9HJRR&N:IL)PIIN\=J^1N'NWB;6!O(*RA\!]
ML([#>*Z6Q7:MH<9UK*S&=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>F
MK<5WIJW%=Z:MQ7>FK<5WIJW%_Z T&O^>02[_I$ [_ZP]1?^U.T[WOSY5[,M$
M6>':3UK4WU%LQMI:?;C38HNKSFF8G\9QI)7 =ZV.NWZTA[>#N8&TA[U\LHR_
M>;&3P7:PF\)TL*;"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)R
ML*W"<K"MPG*PK<)RL*W"_Z$S&O^>02__ISTZ_[ Z0_VZ.$KPQCM/X]5%3M7A
M1E_(XDMQNMU2@:S56X^?S&:;EL9PI(_ >*N*O'^QA+F#M8"WA[A\MHN[>;20
MO'>TE[UVM*&]=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^
M=+.EOG2SI;YTLZ6^_Z(S&O^@/B[_JCDW_[0U/_; -43GSSE%U]\\4,GG062[
MY49VK-Q.A9_36I*5S&><CL9QI(K">:J%OWZN@+R"LGVZAK1ZN8JV=[B.N'6W
MD[ESMYJY<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@
MN7.WH+ESMZ"Y_Z,R&O^C.BS_KC0T_KHQ.NW*,#O:W3(_RN<X5;SL/6FMY41Y
MG]M.AY337)*-S&B;B,ARH83$>:: PGVJ?,"!K7F^A:]WO8BP=+R+LG*[D+-P
MNY6T;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M&^Z
MFK1ONIJT_Z0P&O^G-2K_M"\P],,J,=[8*RW,YBY%O?(U6JWN.VR?Y$1[D]M1
MAXO47I"&SVJ8@LMSG7[(>*%ZQGRD=\2 IG7#@ZASPH:I<<&)JV_ C:QMP)*M
M;+^5K6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_E:UL
MOY6M_Z4O&O^M+27\O"<HY= A),[D)#.^\2Q*KO@S7:#M/6V3Y$=ZBMU4A8/7
M88Q_TFR2>\]REW?-=YITRWN<<LI^GG#)@:!NR(2A;<>'HFO&BJ-IQHZD:,61
MI6C%D:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5HQ9&E
M_Z<L&O^U)1_LR1H<T.(9(;_P(CBO_2M-H/@U7I/N06R)YDUW@>!8@'W<9(9X
MV&N+<]5QCG#3=9%NTGF3;-%\E&K0?Y9ISX*7:,^%F&;.B)EES8R:9,V.FF3-
MCIIDS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:_ZXD
M%O7!%Q34WPX0P.\8)K#](SRA_RU.E/DZ78GQ1VB!ZU)Q>N9=>'3B9'UPWVN!
M;=UPA&K<=(9HVWB(9MI[B679?8IDV("+8MB#C&'6A8U@UHF.7]6+CE_5BXY?
MU8N.7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N._KD6#=32
M"P;"[@X6L?P9*J+_)3V4_S),B?Q 68'V36)Z\%AI<^Q?;VSI9'-HYVIV9N5O
M>63D<WIBXW9\8>-Y?6#B>WY?X7Y^7N& ?UW@@X!<X(6!6]^(@5O?B(%;WXB!
M6]^(@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@5O?B(%;WXB!U,@) \37"@>R
M^Q 9H_\<*Y7_*#N*_SA(@?]%4GK\4EIR]UE@:_1>9&;R9&AB\&EJ8.YM;%[M
M<6U<[71N6^QV;UKL>7!9ZWMQ6.M]<5CJ?W)7ZH)S5NF$<U;IA'-6Z81S5NF$
M<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;IA'-6Z81SQ,T( ;3=" ND_Q(:
ME_\?*HO_+C:!_SU!>?]*27'_4E!I_UA58_U=6%_[8UM<^6==6OAK7UCW;F!7
M]W%A5O9T857V=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T
M@&51](!E4?2 95'T@&51](!E4?2 95'T@&51](!E_Y8S%/^50R7_DE$W_Y=3
M1?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JI
MRWN>J\IYH:W)=Z6OR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^9
M5U/]F5M@]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>
MJ\IYH:W)=Z6OR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]
MF5M@]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IY
MH:W)=Z6OR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@
M]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)
M=Z6OR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA
M;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6O
MR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5
M:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6I
ML,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NR_Y8S%/^50R7_DU$W_Y=31?^95E+]F5M@]9A@;>V69WGE
MDW&$WY![CMJ-A);5B(J<T820HL^ E:;,?9FIRWN=K,EYH:[(=Z6OR':JL<=T
MKK+'<[2RQ'2ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6Z
MLK]UNK*_=;JR_Y8S%/^60R7_E5 W_YE11/^;5%+^G%A?]9M=;.V99'CFEFR#
MWY-VC=J/@);4C(B=T8>.H\V#DZC+@)BKR7V<KLAZH;'&>*6RQG>JM,5UL+7%
M=+BUO7>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AW
MN+6X=[BU_Y<S%/^60R7_EDXW_YI/1/^=4E'^GE5>]IY::NZ<8';GFF>"X)9R
MC-J2>Y74CH2=T(J+H\V&D:G*@I:MR'Z;L,9[H+/%>::UQ'>LML-VL[>^=[>W
MMWBVN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR
M>;:X_Y@S%/^70R7_ETTW_YM-0_^?4%#_H%-=]Z!8:>^?777HG62 X9INB]N6
M=Y35D8"<T(Z)H\R)CZG)A)6NQX":LL5]H+7#>J>WPGBNN<!WM;FX>+6YL7FU
MN:QZM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6Y
M_Y@S%/^80R7_F$PV_YQ,0_^@3D__HE%<^*-5:/"B6W3IH6%_XIYJB=R:<Y/6
ME7R;T9&%H\R,C*G)AY.OQH*9L\-^H+?">JBYP7BQN[EXL[RQ>;.[JWJTNZ=[
MM;JG>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6Z_YDS
M%/^80R7_F4LV_YY+0O^A3$[_I$];^:539O&E6'+JI%Y]XZ)FA]V><)'7F7B9
MTI6!H<V/B:G)BI&OQ8.8M,)_G[B]?*>[NGJPO;)ZLKZK>[*]IGRSO*-]M+JC
M?;2ZHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2Z_YDS%/^8
M0R;_F4HV_Y]*0O^C2T[_IDY9^JA19?*H5G#KJ%Q[Y:=BA=^C;([9GW67TYI^
MG\V3AJC%C8VOOX>4M;F#G+FU?Z.\L7VLOJQ\L;^E?+&_H7ZSO9Y^M+N>?K2[
MGGZTNYY^M+N>?K2[GGZTNYY^M+N>?K2[GGZTNYY^M+N>?K2[_YDS%/^90R;_
MFDDU_Z!(0?^D24W_ITQ8^JI09/.K5&[MK%IYYJQ@@N"J:8O:IG.4SY]\G<:7
M@ZB^D(JPN(N1MK*&F+JM@Z"]J8&HOZ6 L,"??[# G("RO9J!L[N:@;.[FH&S
MNYJ!L[N:@;.[FH&SNYJ!L[N:@;.[FH&SNYJ!L[N:@;.[_YHS%/^90R;_FT@U
M_Z%'0?^E2$S_J4I7^ZQ.8O6O4FSNL%AVZ+%>?]^P:(C5K'20RJ-ZG<";@:BX
ME(>PL8^.MJN*E;NFAYV^HH6EP)^$K\&9@:_!EX*ROI6#L[R5@[.\E8.SO)6#
ML[R5@[.\E8.SO)6#L[R5@[.\E8.SO)6#L[R5@[.\_YHS%/^90R;_G$<U_Z)&
M0/^G1TO_JTE6_:],8/:R46KNM%=SY;=>?-VV:H//KW*0Q:9XG;N>?J>RF(6P
MJY.+MJ6.D[N?BYJ^FXFBP9B(K,*3A:_"DH:QOY&&L[R1AK.\D8:SO)&&L[R1
MAK.\D8:SO)&&L[R1AK.\D8:SO)&&L[R1AK.\_YHS%/^90B;_G$8T_Z-%0/^H
M14K_K4=5_K%*7_6U4&CKN59PX[U>=]F[:H#+LG"0P*EVG;:B?*>MG(*OI9>)
MMIZ3D+N9CYB^E(V@P9&,J<*-BJ["C8FQOXV)LKV-B;*]C8FRO8V)LKV-B;*]
MC8FRO8V)LKV-B;*]C8FRO8V)LKV-B;*]_YLS%/^:0B;_G44T_Z1$/_^J1$G_
MKT53_+1)7?*Y3V7IOE9LX<-@<M.^:8#&M6Z/NZUTG+"F>J>GH("OGYN&M9B7
MCKN3E96^CI*=P8J2I\*(D*["B(ZPP(B-LKV(C;*]B(VRO8B-LKV(C;*]B(VR
MO8B-LKV(C;*]B(VRO8B-LKV(C;*]_YLS%/^:0B;_GD0S_Z5"/O^K0DC_L412
M^K=(6O"]3F'FQ%9GWLEB;<[!9W_!N6V.MK%RFZNJ>*:BI7ZNF:"$M9*=B[J,
MFI.^AYB;P(27I,*"EJ_"@Y.PP(21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21
MLKZ$D;*^A)&ROH21LKZ$D;*^_YLS%/^:02;_GT(S_Z9 /?^M0$?_M$)/][M'
M5^W#35WDS%A@V<U@;,G%9GZ\O6N-L+5QFJ6O=J6<JGRMDZ:"M(RBB;F&H)"]
M@9Z9OWV>HL%[GJ_!?9FPP'^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_
MEK*^?Y:ROG^6LKY_EK*^_YPS%/^:02;_H$$R_Z@_//^P/D7_MT%-],!%4^K)
M3E;BU5I7TM%>:\3)9'VVP6J,JKMOF9^U=*26L'JLC:R LH:IA[=_IXZ[>J:6
MOG>EH+]TIJV_=Z&QOWJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^
M>IVROGJ=LKYZG;*^_YTS%/^;02;_HC\Q_ZH\.O^S/$+[NSY)\,9$3>;23TW<
MW%=6S-5=:K[-8WNPQVB+I,%MEYF\<Z*/N'BJAK1^L'^RA;5YL(RX=*^5NW&N
MG[QNKZN]<:JSO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6S
MO'2EL[QTI;.\_YTS%/^;0";_I#PP_ZTY./^V.3_UP3Q#Z<Y$1-[=34?2X%-8
MQ=M<:+?387JIS6:)G,AKE9'$<9^(P':G?[U]K7B[A+%SNHNT;[B4MVRWG;AJ
MMZBY:;:VN&VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VO
MM;EMK[6Y_YXR%/^=/B7_ISDN_[$V-?N\-CKMR3H\X-I$.M+B1TS'XDU>N=Y4
M;JS96WR?U&*(E-!HDXK,;YN"QW>B?,-^J'; A*QROHJO;[R1L6V\F+)KNZ&S
M:KNMLF>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1G
MNK:T_Y\R%/^@.B3_JC0L_[4R,?/#,C/CU#@PT^$\/\;H0E*YY4ACK.)-<I_?
M5'^3V5V*B=)GDX/-<)I]R7>?>,9]I'3$@Z=PPHBI;L&.JVS E*QJOYNM:;^E
MK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM
M_Z P%/^C-B+_KS H^[PM*^C-+"C5X# PQ^DX1+GL/E>LZ45GGN=+=9+@4X")
MV5Z)@M1HD7S0<99XS'>;=,I]GG#(@J%NQX>C:\6+I6G$D*9HQ):G9L.>J&7#
MI:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H_Z$O
M%/^H+Q__M2HB\,8D(=C=(R#(Z2TUNO(U2:SQ/%J>\$-IDNA,=8CA57^!VV&'
M>]=JC7;3<9%RT7>5;\]\EVS-@)IJS(6;:,N)G6;*C9YER9*?8\F8H&+(GJ%B
MR)ZA8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA_Z,M%/^N
M*1KXOR :WM88$\GH(B6Z]"LZK/@T39[W/%R2\49IB.E0<W_C67MZWV2"=-QK
MAG#9<8IMUG:-:M5[CVC3?Y%FTH.29-&'E&/1BI5AT(^68,^4EU[/F9A>SYF8
M7L^9F%[/F9A>SYF87L^9F%[/F9A>SYF87L^9F%[/F9A>SYF8_Z<H$O^W'Q+F
MSA$-R^85%KOT(2JL_BL^GO\T3I+Z/UR(\DIF?^Q5;WGH7G5RY&1[;N%K?FK?
M<(%HWG6$9=QYA6/;?8=BVH&(8-J$B5_9AXI=V(N+7->0C%O6E(U;UI2-6]:4
MC5O6E(U;UI2-6]:4C5O6E(U;UI2-6]:4C5O6E(U;UI2-_[ >"^W&#@C-VPL(
MN_,5&JS_(2Z>_RP_DO\W38?]1%A_]D]A>/%9:''M7VUJZV1Q9^AJ=&3G;W=B
MY71Y8.1X>E_C>WM=XWY\7.*!?5OAA'Y:X8A_6>",@%C@CX%8X(^!6."/@5C@
MCX%8X(^!6."/@5C@CX%8X(^!6."/@5C@CX%8X(^!\[T-!,S/"0&]Y0P,K/\7
M'I[_)"^2_R\]A_\]27__25)X_%1:</A:7VGT7V1D\F5G8?!J:5[O;FM<[G)M
M6^UV;EKL>6]8['QP5^M^<%;K@7%5ZH1R5.J(<U/IBW13Z8MT4^F+=%/IBW13
MZ8MT4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MTS,8( +W4" .M]0X/G_\:'Y/_
M)RV(_S0Y?O]"0W?_34IN_U-09_]956+\7EA>^V1;6_EH75GX;%Y7]W!@5O=S
M857V=F)4]7AB4_5[8U+T?611](!D4/.#94_SAF9/\X9F3_.&9D_SAF9/\X9F
M3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9FO<L& *[;!@2?_Q 0D_\='8C_*BA^
M_S@R=O]$.FW_2T%E_U%&7_]725O_74Q8_V).5?]F4%/_:E%2_VU24/]P4T__
M<E1._W543?]W54W_>55,_GM62_Y^5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!
M5TK]@5=*_8%72OV!5TK]@5=*_8%7_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4
M_9-B8/61:FOOC7)VZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3
M;ZF?TFZNH-)MLZ'1;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLAN
MQJ+(;L:BR&[&HLANQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B
M8/61:FOOC7)VZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?
MTFZNH-)MLZ'1;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(
M;L:BR&[&HLANQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61
M:FOOC7)VZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZN
MH-)MLZ'1;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:B
MR&[&HLANQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOO
MC7)VZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)M
MLZ'1;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&
MHLANQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)V
MZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1
M;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLAN
MQJ+(;L:B_XTM#O^-/AW_C$PN_Y13._^55D?_EEM4_95A8/:2:&OOCW!UZ8MZ
M?^2'@X??@HJ-W'Z0DMEZEI?6=YN:U72@G=-RI9_2<*FAT6ZNHM!MM*/0;+JD
MT&S"I,INQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$
M;\2D_XXM#O^./AW_CDLN_Y51.O^85$?_F%A3_IA>7_:59&KODFQUZ8YV?N2*
M@(??A8>.VX".E-A\E)C5>9J<TW:?G]%SI*+0<:JDSV^OI<YNMJ;.;;VGRF["
MI\-PPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*G
M_X\M#O^./A[_D$HM_Y=/.O^944;_FU92_II;7O>886GPE6ATZI%Q?N2.?(;?
MB82.VX.+E-=_DIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QR
MP*JW<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"J_X\M
M#O^//A[_DDHM_YA-.?^;3T7_G5-1_YU87/B;7FCQF65RZI5M?.21=X;?C(&.
MVX>)E=:!D)K3?9:?T'F=H\YUHZ;-<JNIS'"SJLMOO:O%<K^KO7._K+9TOJRQ
M=;ZML76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZM_Y M#O^0
M/A[_DTDM_YE,.?^=3D3_GU%0_Y]66_F>7&;RG&)QZYAI>^64<X3@CWV-VXJ&
ME-:$C9O2?Y6@SWJ<I<UVHZC+<ZNKRG&UK<9QOJV^=+VNMG6]KK!VO:ZL=[VN
MK'>]KJQWO:ZL=[VNK'>]KJQWO:ZL=[VNK'>]KJQWO:ZL=[VN_Y M#O^0/A[_
ME4DL_YM*./^>3$/_H4]/_Z)46OJA667SH%]O[)UF>>:8;X/@DWF,VXZ"D]:'
MBIO2@9*ASWR:ILIXHJK'=:NMPW.TK[]SO+"W=;RPL'>[L*IXN["G>;RPIWF\
ML*=YO+"G>;RPIWF\L*=YO+"G>;RPIWF\L*=YO+"G>;RP_Y$M#O^1/A[_ED@L
M_YQ(-_^@2D+_HTU-_Z126/NE5V/TI%UM[J%C=^B>:X#BF'6)W))^DM.,AYK,
MAH^AQH"7I\%\GJR]>::ON7:OL;=VNK*O=[JRJGFZLJ5ZNK*B>[NQHGN[L:)[
MN[&B>[NQHGN[L:)[N[&B>[NQHGN[L:)[N[&B>[NQ_Y$M#O^1/A[_F$<L_YU'
M-_^A2$'_I4M,_Z=05ORH56'UJ%MK[:=A=.6D:7[>GW.'U)A]D,N1A)K$BHRB
MOH23J+B FJVT?**PL'JKLZUYM;2H>KFTI'NYM*!]N;.=?;JSG7VZLYU]NK.=
M?;JSG7VZLYU]NK.=?;JSG7VZLYU]NK.=?;JS_Y(M#O^2/A[_F$8K_YY&-O^C
M1T'_ITE+_ZI.5?JK4U[RK%EHZ:Q@<>*I:'K9I7.#S9QZC\65@9J]CHBBMXB0
MJ;&$EZZL@)^QJ'ZGM*5]L;6A?;BVG7ZXM9I_N;29@+JSF8"ZLYF NK.9@+JS
MF8"ZLYF NK.9@+JSF8"ZLYF NK.9@+JS_Y(M#O^2/A[_F44K_Y]$-?^D14#_
MJ4A)_ZQ,4_BN4ESOL%AEYK%?;=ZP:7;2J7&"R*!XC[^8?IJWDH6BL(R,J:J(
ME*ZDA9RRH(*DM9V!KK::@+>WEX&WMI6"N;24@KFSE(*YLY2"N;.4@KFSE(*Y
MLY2"N;.4@KFSE(*YLY2"N;.4@KFS_Y,M#O^2/1[_FD0J_Z!#-?^F1#[_JT9(
M_ZY+4?6R4%GLM5=AY+=>:=JT:7/-K&^"PJ1VC[F<?)FQEH.BJI&*J:.,D:Z>
MB9FRF8>AM9:%J[>3A;:WD82WMY"%N+60A;FTD(6YM)"%N;20A;FTD(6YM)"%
MN;20A;FTD(6YM)"%N;20A;FT_Y,M#O^3/1[_FT,J_Z)"-/^H0CW_K45&_+%*
M3_*U3U;INE9=X;U@9-2X9W+(KVV!O:=TCK2@>IFKFH"BI)6'J9V1CJZ7CI:R
MDHN?M8^*J+>,BK.XBXFWMXN(N+6+B+FTBXBYM(N(N;2+B+FTBXBYM(N(N;2+
MB+FTBXBYM(N(N;2+B+FT_Y,M#O^3/1[_G$$J_Z- ,_^I03S_KT1%^K1(3/"Z
M3E/GOU99WL)@8,^[9G'#LVR!N*MRCJZD>)BEGGZAGIJ$J)>6C*Z1DY2RC)&<
MM8B/IK>%C[&XA8ZVMX:-N+:'C+BUAXRXM8>,N+6'C+BUAXRXM8>,N+6'C+BU
MAXRXM8>,N+6'C+BU_Y0L#O^4/1[_G4 I_Z0^,O^K/SO_L4)"^+A'2>V^3D_E
MQE=3VL9>7\N^9'&^MFJ LZ]PC:FI=IB@HWRAF)^"J)&;B:V*F9*RA9::M8&5
MI+=_E:ZW?I2WMX&1M[:"D+BU@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU@I"X
MM8*0N+6"D+BU_Y0L#O^4/1[_GC\H_Z8],?^M/CG_M$% ]+Q&1>O$34GBSEA+
MT\I<7L;"8W"YNFA_KK1NC*.N=)>:J7J?DJ6 IXJAAZR$GX^Q?YV7M'N<H;9X
MFZRW=YNWMGJ7N+5\E;FT?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT?)6YM'R5
MN;1\E;FT_Y4L#O^5/1[_H#TG_Z@[,/^P/#?]N#\\\<%$0.C+3D+>TU5*SLU;
M7<#&86ZTOV=^J+EMBIVT<I64KWB>BZM^I82HA:I]IHRO>*25LG2CG[1QHZJU
M<*.XM7.>N;1VF[FS=INYLW:;N;-VF[FS=INYLW:;N;-VF[FS=INYLW:;N;-V
MF[FS_Y8L#O^7/![_HCHF_ZHY+O^S.C3YO3PX[LA#.>/54#?7VE)(R-)97+K+
M7VVMQ65\H<!KB9>Z<).-MG:<A+-\HGVP@ZAWKHJL<JV3KVZLG;%KK*BR::VV
MLFRHN[%OH[NQ;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%OH[NQ
M_Y<L#O^:.QW_I#<E_ZTV*_^W-S#SPSHQYM!#,-S?2C7/WU)'P=A86K/17FNF
MRV-ZFL=IAH_";I"&OW28?;QZGW:Z@:1PN(FH:[>2JVBWG*UEMZ>N9+>TKF6S
MO:YHK;VN:*V]KFBMO:YHK;VN:*V]KFBMO:YHK;VN:*V]KFBMO:YHK;VN_Y@L
M#O^=.1S_IS0C_[$S*/F],BKJRS<IW-T^*=#C1CK%XDU+N-Y56JS97&B>TV)W
MDL]G@HC+;8Q^R7.4=L=YFG#%@9]JQ(FB9L.2I6+#G*=@PZ:H7\.TJ%_!PJAA
MNL&I8;K!J6&ZP:EANL&I8;K!J6&ZP:EANL&I8;K!J6&ZP:EANL&I_YDL#O^@
M-1K_JC$@_[8N(_#%+2+?V#,<T.,Z+L3H0D"XY4E0J^%.7Y[>56R2VUQWA]AC
M@7[5:HEVU'&/;]%YE&O.@)AGS(B;9,J0G6+)F)]@R:&@7\FKH%_)N9]<R,.B
M7,C#HES(PZ)<R,.B7,C#HES(PZ)<R,.B7,C#HES(PZ)<R,.B_YLL#O^D,!C_
MKRP;^+XG&^31)A?1XBT@Q.LW,[?K/D6JZ454GN=,8I+E4FZ&XUAX?>!@?W;<
M:89PV'&+:]5XCVC3?Y)ET8:48L^-EF#.E)A>SIN97<VCFES-K9I;S;>:6\VW
MFEO-MYI;S;>:6\VWFEO-MYI;S;>:6\VWFEO-MYI;S;>:_YTL#O^H*Q3_MR05
MZ\H<$=/@'A/$ZRLFM_$T.*KP/$F=[T17D>Y+8X;M4FU]Z%MU=>-B?'#@:X%K
MW7*%:-IXB&39?HMBUX2-7]6*CE[4D)!<TY616M.<DEG2I)-8TJR36-*LDUC2
MK)-8TJR36-*LDUC2K)-8TJR36-*LDUC2K)-8TJR3_Z$K#?^O(P_TPA<,UMT0
M!\7K'ABW]BDKJ?<S/)WV/$N1]T18AO9-8GWP5FIVZUYQ;N=D=FKD:WIFXG)]
M9.!W@&'??8)?WH*$7=V'A5O<C(9:VY&'6-J6B%?9G8E6V:.*5MFCBE;9HXI6
MV:.*5MFCBE;9HXI6V:.*5MFCBE;9HXI6V:.*_Z@C"?VY%@?6T0L#QNH0"[;W
M'AVI_2DNG/XT/I#_/DN&_D=6??A17G;S665N\%]J:.UE;F3J:W)AZ7%T7^=V
M=EWF>WA;Y7]Y6>2$>ECCB'Q7XXQ]5N*1?E3AEW]3X9Q_4^&<?U/AG']3X9Q_
M4^&<?U/AG']3X9Q_4^&<?U/AG']3X9Q__[$5 ]3'"0'&U@H#MO<2#ZC_'R";
M_RLPD/\V/87_0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN
M>&Q7[7QN5>R ;U3LA'!3ZXAQ4NN,<5'JD7)0Z95S4.F5<U#IE7-0Z95S4.F5
M<U#IE7-0Z95S4.F5<U#IE7-0Z95SUKX' ,7+" "WVPD%J/\4$IO_(B&0_RXN
MA?\Y.GS_1$-T_TY*;/]44&7_6E1@_5]87?ME6EKZ:EQ7^6Y>5?AR7U3W=F!2
M]GEA4?9]8E#U@&-/](1D3O2'9$WSC&5,\Y!F3/.09DSSD&9,\Y!F3/.09DSS
MD&9,\Y!F3/.09DSSD&9,\Y!FQ,(& +;1!P"H[0L&F_\7$Y#_)1^%_S$J?/\\
M-'/_1CMJ_TQ!8_]31E[_64E:_UY,5O]C3E3_:%!2_VQ14/]O4D__<E-._W94
M3/]Y54O_?%5*_G]62?Z"5TC]AEA'_8I81_V*6$?]BEA'_8I81_V*6$?]BEA'
M_8I81_V*6$?]BEA'_8I8MLD$ *C9! &;_PX'C_\:$87_)QM[_S,D<?\\+&C_
M0S)A_THW6_]0.U;_5CU3_UQ 4/]@04[_9$-,_VA$2O]K14G_;D9(_W%&1_]T
M1T;_=DA%_WE(1/]\24/_@$E"_X-*0O^#2D+_@TI"_X-*0O^#2D+_@TI"_X-*
M0O^#2D+_@TI"_X-*_X(H"?^".1;_@4@E_XI/,?^.5CW_CUQ)_XYC5/Z*:E[X
MA7%H\H!Z<.Y\@W?J>(M]YW22@N1QF(7B;YV(X6VBB^!KIXW?::R.WFBQD-UG
MMY'=9KV1W&7%DMQES9+49M&2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2
MDL]HTI+/:-*2_X(H"?^".1;_@4@E_XI/,?^.5CW_CUQ)_XYC5/Z*:E[XA7%H
M\H!Z<.Y\@W?J>(M]YW22@N1QF(7B;YV(X6VBB^!KIXW?::R.WFBQD-UGMY'=
M9KV1W&7%DMQES9+49M&2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]H
MTI+/:-*2_X(H"?^".1;_@4@E_XI/,?^.5CW_CUQ)_XYC5/Z*:E[XA7%H\H!Z
M<.Y\@W?J>(M]YW22@N1QF(7B;YV(X6VBB^!KIXW?::R.WFBQD-UGMY'=9KV1
MW&7%DMQES9+49M&2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/
M:-*2_X(H"?^".1;_@4@E_XI/,?^.5CW_CUQ)_XYC5/Z*:E[XA7%H\H!Z<.Y\
M@W?J>(M]YW22@N1QF(7B;YV(X6VBB^!KIXW?::R.WFBQD-UGMY'=9KV1W&7%
MDMQES9+49M&2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2
M_X(H"?^#.1;_@T<E_XQ.,?^053W_D5M(_Y!A4_Z-:%[XB&]H\H-X<.U^@GCI
M>HI^YG:1@^1SEX?B<)V*X&ZBC-]KIX[=:JR0W6BRD=QGN)/;9K^3VV;'E-EF
MT)3/:-"3RVG0E,MIT)3+:="4RVG0E,MIT)3+:="4RVG0E,MIT)3+:="4_X,H
M"?^#.1?_AD8D_XY-,/^35#S_E%A'_Y)>4_^095WXC&UG\H9U<.V!?WCI?8=^
MY7F/A.)UE8C@<IN,WF^AC]ULIY'<:ZR3VVFSE-IHNI;99\.6V6;-E]!ISI;(
M:LZ7Q&O-E\1KS9?$:\V7Q&O-E\1KS9?$:\V7Q&O-E\1KS9?$:\V7_X0H"?^$
M.1?_B$4D_Y%,,/^543O_EE9'_Y5<4O^38ESYCVIF\XIR<.V%>WCI@(1_Y7N,
MA>)WDXK?<YJ.W7"@D=MMII3::ZV6V6FTE]AHO9C89\B9T6G,F<EKS)G";,R:
MO6W+FKUMRYJ];<N:O6W+FKUMRYJ];<N:O6W+FKUMRYJ];<N:_X4H"?^%.1?_
MBD0D_Y-++_^73SK_F%1&_Y=94/^68%OYDF=E\XYO;^Z)>'?I@X%_Y'Z*A>%Y
MD8O>=9B/W'&?D]INII;8;*Z8UVJVFM9HP9O3:<N;RFO+F\)MRIR[;LJ=N&_*
MG;AORIVX;\J=N&_*G;AORIVX;\J=N&_*G;AORIVX;\J=_X4H"?^&.1?_C$0C
M_Y5*+_^933K_FE%$_YI63_^975KZEF1D]))K;NZ-=';IAWY^Y(&'A>!\CXO=
M=Y>0VW.>E=AOIIC6;*^:U6JYG-1IQIW+;,F=PVW)GKQOR)^U<,B?LG'(G[)Q
MR)^R<<B?LG'(G[)QR)^R<<B?LG'(G[)QR)^R<<B?_X8G"?^&.1?_CD,C_Y=)
M+O^:2SG_G$]#_YU43O^<6EC[FF!B]99H;.^1;W7JBWE^Y86#A>!_C(S=>961
MV72=EM1PI9K0;JZ=S6RWG\MKPZ##;L>@NV_'H;5QQJ&O<L:AK'/&H:QSQJ&L
M<\:AK'/&H:QSQJ&L<\:AK'/&H:QSQJ&L<\:A_X<G"?^'.1?_D$(C_YA'+?^<
M23C_GTQ"_Z!13/^@5U;[GEY@])ME:NV6;'/GD'9\X8J A-N$B8O3?I&2SGB9
MF,ETH9S&<:F?PG"RHL!OO:.Z<,6CLW+%I*YSQ:2I=,6CIG7%HZ9UQ:.F=<6C
MIG7%HZ9UQ:.F=<6CIG7%HZ9UQ:.F=<6C_X<G"?^(.!?_D4$B_YI%+/^>1S;_
MH4I _Z-02OZC553VHEQ=[Z!B9^B<:7#AEG1YVI!]@M&)AHO*@HV3Q7V5F<!Y
MG9Z\=J6AN'.MI+5RN*6R<L.FK'3#IJ=VPZ:C=\2EH7C$I:%XQ*6A>,2EH7C$
MI:%XQ*6A>,2EH7C$I:%XQ*6A>,2E_X@G"?^(.!?_DT$B_YM$+/^@137_HTD_
M_Z5.2/NG5%'SIEI;ZZ5@9..B:&W<G7-VT95Z@LF-@HO"AXJ3O(*1FK=]F9^R
M>J&CKW>IIJMVLZ>I=L"HI'?"J*%YPJ>=>L.GFWK#IIMZPZ:;>L.FFWK#IIMZ
MPZ:;>L.FFWK#IIMZPZ:;>L.F_X@G"?^).!?_E4 A_YU"*_^B1#3_I4@]_ZA,
M1OBJ4D_OJUA7YZM?8."H:6G4H7!URYEX@<*2?XN[BX:4M8:.FJ^"E:"J?IVD
MIGNFIZ-ZL*F@>;RJG7K!J9I\P:F8?<*HEGW"IY9]PJ>6?<*GEGW"IY9]PJ>6
M?<*GEGW"IY9]PJ>6?<*G_XDG"?^).!?_EC\A_YY!*O^C0C/_IT8[_JM+1/6N
M44SLL%=4Y+%>7-NM:&;/I6YUQ9UU@;R6?(NUD(.4KHJ+FZB&DJ"C@IJEGH"B
MJ)M^K*J8?KBKEG[ JY1_P*J3@,&HDH#"J)* PJB2@,*HDH#"J)* PJB2@,*H
MDH#"J)* PJB2@,*H_XDG"?^*.!?_F#\@_Y\_*?^E03+_JD4Z_*Y)0?*Q3TGI
MM590X;=?5]6Q967*J&QTP*%S@+>:>HNOE(&4J(^(FZ**CZ"<AY>EEX2@J)2"
MJ:J1@K6KCX*_JXZ#P*J-@\&IC8/!J(V#P:B-@\&HC8/!J(V#P:B-@\&HC8/!
MJ(V#P:B-@\&H_XHG"?^+.!?_F3X@_Z$^*/^F0##_K$,X^;%(/_"U3D7GNE5+
MWKM>5-"T9&7%K&MSNZ1Q@+&>>(JIF'Z3HI.%FIN/C:"6C)6ED8F=J(V'IZN*
MA[*LB(>_K(B'P*N(AL"IB(;!J(B&P:B(AL&HB(;!J(B&P:B(AL&HB(;!J(B&
MP:B(AL&H_XHG"?^,-Q?_FST?_Z(])_^H/R__KD(V][1'/.VZ34'DP%9&V;]<
M4\NW8V3 KVESMJAO?ZRB=8JDG'R3G)B#FI64BJ"/D9*EBHZ;J(:-I*N#C*^L
M@8V]K(*,OZN#BL"I@XK!J8.*P:F#BL&I@XK!J8.*P:F#BL&I@XK!J8.*P:F#
MBL&I_XLG"?^.-Q?_G#P?_Z,[)O^J/2W_L4 S]+A%..J_3#SBQU5 T\):4L>Z
M86.[LV=RL*UM?J>G<XF>H7J2EIV F8^:B)^)EY"DA)28J'^3HJI\DJVK>I*Z
MK'N1P*M]C\&I?H[!J'Z.P:A^CL&H?H[!J'Z.P:A^CL&H?H[!J'Z.P:A^CL&H
M_XPG"?^/-A;_G3H>_Z4Z)?^M.RO\M#XP\;Q#-.?%3#;>RU(_SL994<*^8&*V
MN&9PJ[%L?:&L<HB8IWB1D*-^F(F@A9Z"G8VC?9N6IWB9GZEUF*JJ<YFWJW28
MP*IWE,&I>)/"J'B3PJAXD\*H>)/"J'B3PJAXD\*H>)/"J'B3PJAXD\*H_XPG
M"?^1-1;_GS@=_Z<X(_^O.2CYN#PL[L)"+N7-3"W8T$\]R<E74+S#7F"PO&1O
MI;=J?)NR<(:2K7:/BJE\EH*F@YQ\I(NA=J*3I7*AG:=OH*BI;:"UJ6V@P:AP
MF\*G<IG"IW*9PJ=RF<*G<IG"IW*9PJ=RF<*G<IG"IW*9PJ=RF<*G_XTF"?^4
M-!7_H38;_ZHV(?^S-B7UOCDGZLE )N#622C1U4X\P\Y63K;(7%^JPF-MG[UH
M>I2X;H2+M'2-@[%ZE'RN@9IUK(B><*N1HFNIFZ1HJ::F9JFSIF:JPZ5II,2E
M:Z'$I6NAQ*5KH<2E:Z'$I6NAQ*5KH<2E:Z'$I6NAQ*5KH<2E_XXF"?^7,Q3_
MHS0:_ZTS'OZX,B#PQ34@X],_'-C>12;*VTTZO=-43+#.6UVCR6%KF,1G=XW
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M4];6BU/6UHM3UM:+4];6BU/6UHM3UM:+_Y<D"?^I)@K^N!P)YLX1!<[C%PC
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MT"@'U-\R"\G?/AF]VT<LL=9//:315DR9S5Q9CLEB983&:&Y[Q&]V=,%U?&W
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M0_^154+^F%9!_9Y70/VF6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5A
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MASTX_XP]-_^3/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0
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M_Z5*.?^M2SC_N4LX_[E+./^Y2SC_N4LX_[E+./^Y2SC_N4LX_[E+OK4" +#
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M,2W_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXRI,(  );/  "(WP
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M6SC_=V-!_W!L2/]L=T__9X)4_V.-6?U@EES\79]?^ENG8OA9KF3W6+9F]5?
M9_16RVCQ5=UH[5;I:>-9[&C:6^UIT%SN:LE=[FO%7NYKQ5[N:\5>[FO%7NYK
MQ5[N:\5>[FO%7NYK_V0C!/]A+0;_<#(,_WLX%/^!0!S_A$DE_X11+O^!63?_
M?&% _W9I2/]P<T_[;']5^&B)6O9DDE[S89MA\5^C9/!=JV;N6[-H[%J\:NI9
MQVOH6=AKY%GH:]I;ZVS/7>UMR%[L;L)?[&Z^8.QOOF#L;[Y@[&^^8.QOOF#L
M;[Y@[&^^8.QO_V4C!/]D*P;_<S ,_WXV$_^%/QO_B4@D_XE/+?^&5S;_@EX^
M_'QF1OAV<$[T<7M5\&V%6NUICE_J99=CZ&*?9N9@IVGC7J]KX5VY;.!<Q&W>
M7--NV5WF;LY>ZV_&7^IQOV'J<;IBZ7*V8^ERMF/I<K9CZ7*V8^ERMF/I<K9C
MZ7*V8^ER_V8C!/]G*0;_=RX+_X(U$O^)/AK_C4<B_XU.*_^,53/\B%P\]H-D
M1?%\;$WL=W=4Z'*!6N1NBF#A:I-DW6:;:-IDHVO68JQNTV"U<-!?OW'.7\UR
MRU_B<\1AZ'.]8NATMV3G=+)EYW2O9N=TKV;G=*]FYW2O9N=TKV;G=*]FYW2O
M9N=T_V<B!/]J)P7_>BP*_X8T$?^-/1G_D44@_Y)-*/V14S'VCEHZ\(EA0NJ#
M:4OE?G13X'A]6MISAF#4;H]FT&N7:LQHGV[)9J=QQV2O<\1CN77"8L9VP&+:
M=[IDYG>S9>5WKF;E=ZIHY7>H:.9WJ&CF=ZAHYG>H:.9WJ&CF=ZAHYG>H:.9W
M_V<B!/]M)@7_?2H*_XDT$/^1/!?_E40>_Y=+)OB64B[QE%@VZI!>/^2*9TC=
MA'%0U7UY6L]X@F'*<XIGQF^2;,)LFG"_:J)SO&BJ=KEGM'BV9L!YM&;0>K%G
MXWJK:.-ZIVKC>J-KY'FA:^1YH6OD>:%KY'FA:^1YH6OD>:%KY'FA:^1Y_V@A
M!/]O) 7_@"D)_XPS#_^4.Q;_F4,<_9M)(_2;3RKLF54SY99<.]Z19474B6U0
MS(-V6L=]?F'!>(9HO72.;;AQEG*U;IUUL6RF>*YKKWNL:KM\JFG*?:AJX7VC
M;.)\GVWB?)QNXGN:;N-[FF[C>YINXWN:;N-[FF[C>YINXWN:;N-[_VDA _]Q
M(P7_@B@)_X\R#O^7.Q3_G$(:^9Y&(/"?3"?HGU(NX)U:-M:5843-CFI/QHAR
M6;^">F*Y?8)HM'F*;K!VDG.L<YIWJ'"B>J5OJWVB;K9^H&W%?YYNVW^;;^!^
MF'#A?I9QX7V4<>)\E''B?)1QXGR4<>)\E''B?)1QXGR4<>)\_VDA _]T(@3_
MA2@(_Y$Q#?^:.A+_GS\7]:)$'>RD2B/DI% IVZ%7-<^:7T/'DVA/OXQP6;B'
M=V&R@G]HK7Z&;JEZCG.D=Y9XH'6>>YUSJ'Z:<K. EW' @99RTX&3<]^ D73@
M?Y!TX'Z/=.%]CW3A?8]TX7V/=.%]CW3A?8]TX7V/=.%]_VHA _]V( 3_AR<'
M_Y0P#/^=.1']HCT5\J5!&NFH1Q_@JDTEU*14-,J=74+!EV5.NI%M6+*+=6&L
MAGQHIX*#;J)_BW2=?)-XF7F;?)5WI7^2=J^!D':]@HYVSH*-=]Z!BW??@(IX
MX'^*>.!^BGC@?HIXX'Z*>.!^BGC@?HIXX'Z*>.!^_VH@ _]X'P3_B28'_Y8P
M"_^?-P_ZI#H3[ZD_%^:M11K<KDHDSZA3,\:A7$&]FV1-M)5K6*V/<F"GBWEH
MH8>!;IN#B'27@)!XDGZ9?(Y\HG^+>JV"B'JZ@X=ZRX.&>]Z"A7O>@85[WX"%
M>^!_A7O@?X5[X'^%>^!_A7O@?X5[X'^%>^!__VL@ _]Z'@3_BR8&_Y@O"O^A
M-0WWIS@0[*T\$^.R0A;7L4<CRZM2,L&E6D"XGV),L)EI5ZB4<&"ACW=GFXM^
M;I:(AG.1A8YXC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_
M@'[@?X!^X'^ ?N!_@'[@?X!^X'^ ?N!__VP@ _]\' /_C24&_YHN"?^C,POT
MJC0-Z;$Y#]^W/Q+2M$8BQZY0,;VH63^SHF!+JYUG5J.8;E^<E'5GEI!\;9"-
M@W.+BHMXAHB4?(&&G8!^A*B">X2U@WF$Q81XA=V#>83>@7J#WX!Z@N!_>H+@
M?WJ"X']Z@N!_>H+@?WJ"X']Z@N!__VT? _]^&P/_CR0%_YTL!_ZF, GPKC$+
MY;8U"]N\.1'.MT4@P[)/,+BL5SZOIU]*IJ%E59Z=;%Z7F7-FD)5Z;(J2@7*%
MD(EW@(V1?'N+FW]WBJ6"=(FR@W*)PH-RBMJ#<XG>@72'WX!UAN!_=8;@?W6&
MX']UAN!_=8;@?W6&X']UAN!__V\> _^ &P/_DB,$_Z K!OJI+ ?MLBP'XKPQ
M!]7 -A#)NT,?OK9-+K2P5CRJJUU)H:9D5)FB:EV1GG%EBIMX:X28?W%_EH9V
M>9./>G61F'YQD*.!;I"O@FR0OX-KD=6";8_>@6^-WX!PB^!_<(O@?W"+X']P
MB^!_<(O@?W"+X']PB^!__W$< _^#&0+_E2$#_Z,I!?:M)P7HMR8$WL,J ]##
M-0[$OT$=N;I,+:ZU5#NEL%M'FZQB4I.H:5N+I6]CA:)V:GZ??&]XG(1T<YJ,
M>6^9EGQKEZ%_:)>M@&:7O(%EF-& 9I;??VB3X'YJD>%^:I'A?FJ1X7YJD>%^
M:I'A?FJ1X7YJD>%^_W4: O^'& +_F" #_Z8E _*R( /DOAX"U\DB LK',PV^
MPT <L[]**ZFZ4SF?MEI%EK)A4(VO9UF%K&U@?JET9WBF>FURI()R;:**=FBA
ME'EDH)]\89^K?E^@NGY?H,Y^7Y_A?6*;X7UCF.)\8YCB?&.8XGQCF.)\8YCB
M?&.8XGQCF.)\_W@8 O^+%P'_G1T"_:L> NRX%P'>R!$ S\T? L3,, NXR#X9
MK<5(**/!43:8O5A"C[E?38:V959_LVM=>+%R9'*O>6ELK8!N9ZR)<F*JDG5?
MJ9UX7*FJ>EJIN7I9JLQZ6*GD>ENDY'I=H>1Y7:'D>5VAY'E=H>1Y7:'D>5VA
MY'E=H>1Y_WT5 O^0% '_H1@!]K$4 -G!"P#2SPL R-(< ;S1+@FQSCL7ILM&
M)9S(3S.1Q%8_B,%=28"_8U)XO&I9<;IP7VNY=V1FMW]I8;:';5VUD7!9M9QR
M5K2I=%2TN'13M<MT4[7D=%2PYW56K.=U5JSG=5:LYW56K.=U5JSG=5:LYW56
MK.=U_X,2 ?^6$0#_J!$ V;@* ,[$"0#'T@H O]D9 ;38*P>IUCD4G]-$(I30
M32^*S50[@<I;1'C(8DUQQVE3:\5O667$=EY@PWYB7,*'9EC!D6A5P9QK4L&H
M;%#!MVU/PLIM3\+D;$^][&Y0N>QO4+GL;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO
M_XD0 ?^=#@#:KP@ S;L( ,3'!P"\U@L L]\: :K?*P>@WCD2EMU#'HS:2RJ"
MV%,U>=5:/W'3849JTFA,9=%O4F#0=E9;T'Y:5\^'75//D5]0SYQA3L^I8TS/
MN&-+T,MC3-#E8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(-
M -ZF! #.M 8 PK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S
M;^%8.VG@7T%CX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(
MX<992.'?64??\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M
M! #"N 4 M\,% *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6
M-V#K7#Q;ZV1 5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ1
M0>_,4D'OY5) [?%10.WQ44#M\5% [?%10.WQ44#M\5% [?%1U*4  ,2R P"V
MO , J\D% *#8" "7]!,!C_4D!X?U,0]^]CL8=/9"(&SV2"=E]D\M7O=5,5GW
M6S55]V(X4?=H.TWX;SU*^'8_1_A^043YAT-"^9%%0/J;1C[ZID<\^[%(._N^
M23K\STDY_.-).?SC23G\XTDY_.-).?SC23G\XTDY_.-)QZT  +>W @"JPP(
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MI#H[]K [.O>_/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH
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M&B/_H!HB_ZH;(?^M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX  (O*  !^UP
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M9'5\\V1U?/-D=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8
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MKDM(Q;]+1\;82T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY
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M+S?ST"\W\^<O-O'S+S;Q\R\V\?,O-O'S+S;Q\R\V\?,ON:<  *NP  "?NP
MDL8  (;0 0![W04 =/<1 &WW' %F^"8#7_@O!EKY. I4^4 .4/I'$4SZ3A1(
M^U461?M;&$+[8AI _&@</?QP'3K]>!\X_8(@-OV-(C3^F",R_J0D,?^Q)3#_
MOR8O_\\F+O_C)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT
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M5X)O_5>";_U7@F_]5X)O_5>";_U7_V 5 ?]N$0'_>Q, _X84 /:/%@#GEA@
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M0$7 Z#]$OO9!0[W_0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT  ,:;  "XI0
MK:X  **V  "8OP( C<@& (/1"P!_TAH >=(J W+2-PALT4(/9M%+%6'04QI<
MSUL?6,]B(U3.:2=1SG$J3<YZ+4K.@S!(SHXR1<Z:-$/.J#5"SK@V0<_--4'.
MZ#5 S?4W/\O^.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,
M )B\  "-Q@, @L\' 'C9"P!SWA@ ;MXF FC>,P5BWCX*7=Y(#UG>4!15WE@7
M4=Y@&T[>9QY+W6\@2-YX(T;>@25#WHPG0=Z8*3_>IBH^W[4J/>#(*CW?XRH\
MW?$K.]S[+3K<_2XZW/TN.MS]+CK<_2XZW/TNP)\  +&G  "DL   F+H  (W#
M  "!S0( =M<' &[H#P!IZ!L!8^@G E[I,@58Z3L(5.E$#$_J3 ],ZE,22>I;
M%4;J8A=$ZVH90>MR&S_K>QT\ZX8>.NR1(#CLGB$W[:PB-NV[(S7NSR,T[N8C
M-.OU(S3K^",TZ_@C-.OX(S3K^",TZ_@CLZ4  *:M  "9MP  C<$  (#+  !U
MU0$ :>$& &3S$0!>\QP!6?0F E3T, 1/]3@&2_5 "$?V1PI$]DX,0?=5#C_W
M7 \\]V,1.OAJ$S?X<Q0U^'T6,_F(%S'YE!@O^J$9+OJO&BW[OAHL^\\;*_OG
M&RO[ZQLK^^L;*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D  '33  !GW@
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M2))@_T>28/]'DF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M@QT
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M2%&8YDA1E_5(49?_1U&6_T=1EO]'49;_1U&6_T=1EO]']G<  -B%  #)D0
MOYL! +2B  "KJ   H;   )JR$0"4LR(!C;(P!86Q/ Q^KT84>*Y.&W*L5B%M
MJUPG:*EC+&2H:C!@IW$T7*9Y.%BE@CM5I(P^4:.80$^CI4)-H[1#3*/(0TRC
MY$-+H?1#2Z#_1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\
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M+3S%_RX\Q?\N/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP
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M"1S_W0D<_]T)F+   (JZ  !\Q   ;\T  &+8  !5W@  2>0  $3[!0 __PX
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M_S^"9/\__UD. /]D"P#_;@H ZG<( -M]" #4@@H S(02 ,.%) &[@S0%LX!
M#*U\2Q2F>50;H79<(9QS9":8<6LKE&]R+Y%M>3..:X$VBVJ).8AHDCR%9YL_
M@F:F08!FLD-^9L%$?6;91'QG[T-\9_Q!?&C_0'QH_T!\:/\_?&C_/WQH_S]\
M:/\__UL, /]G"0#W<0< WGH% -2 !P#.A0D QX<1 +Z((@&VAS$$KX0^"ZB!
M21.B?5(:G'I:()=W82:3=6@KCW-O+XMQ=S.(;WXVA6Z&.H)MCSU_:YD_?&NC
M0GEJL$-X:K]$=FK4179K[4-V:_M"=FO_079L_T!V;/] =FS_0'9L_T!V;/]
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M1%]]Y4-@??9"8'W_06%]_T!A??] 87W_0&%]_T!A??] _V<  .-T  #2?P
MQX@! +Z/ @"VE0$ KI@& *::%0"?FB8"F)DS!I&7/PR+E4@4A9-0&G^16"!Z
MCU\E=HUE*G*+;"YNBG,R:HA[-F:'A#ECAHX\8(69/UV$ID%;A+1"6H3'0UJ$
MXT):@_1!6X/_0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP
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M.$F;_SE)F_\Y29O_.4F;_SE)F_\YVWH  ,B'  "\D@  L9H  *:@  "<I@
MD:P  (>Q" "!LA8 ?+,F 7:R,P1QLCT):[%'#F:P3Q-BKU887JY='%JM9"!7
MK&LC5*QS)E"K?"E-JH8L2JJ2+TBIGS!&J:TR1:F_,D2JVC)$J.\R0Z?[,T.F
M_S-#I?\T0Z7_-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(
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M&C/._QHSSO\:LYD  *:A  ":J0  CK$  (&Y  !UP   :L<  %[- P!4U @
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M:@(0_W@"#O^' @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8
M 'F_  !KR0  7M,  %#;  !#X   ..4  "_P   K_P  )_\( "3_#@ A_Q,
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M.FQJY#IM:_4X;6O_-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL  .MG  #9<0
MS'D  ,-^ @"[@@, M(0) *V%& "FA2@!GX0U!9F"0 J3?TD0C7U2%HE[61N$
M>6 ?@'=G(WQU;B=Y='4J=G-]+G-RAC%P<9 T;7";-FMOISAI;[4Z:&_'.F=O
MXCIG;_0X:&__-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P
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M-EA^_S58?O\U6'[_-5A^_S58?O\UZ6@  -1T  #&?@  NX<  +*-  "HD0
MGI0  ):6#@"1EQP BY<K H66-P5_E$$*>9-)$'22415PD%@9;(]?'6B.9B%E
MC&TE88MT*%Z*?2Q;B8<O6(B2,56'GS-3AZTU4H>^-5&'UC51ANXU4H7[-%*%
M_S12A?\S4H7_,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD
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M*4"@_RE H/\IR7X  +J+  "OE   HYH  )B@  "-I0  @JH  '6P  !LLPP
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MC04JW)T&*=RM!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T
M )BE  "+K0  ?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8
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M 0?_D $%_Z !!/^N 03_O $#_\<! __' 0/_QP$#_\<!@[0  '6]  !GQ@
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M+GI:XRYZ6_4M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9
MSVH  ,=N @# < 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.
M9F,8BV5I&XAC<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>
MX2]T7_,N=%__+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT
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M+61K_RUE:_\L96O_+&5K_RQE:_\L]%L  -UF  #+;P  P'8  +=[  "O?@
MIGX! )]_$ "9@!\ DX M HU_.06(?4,)@WM+#7YZ4Q)Z>%H6=G=A&7-U9QQP
M=&X?;7-V(FIR?R9H<8DH97"4*V)PH"U@;ZTO7V^]+UYOU"]>;^TO7V_[+5]O
M_RQ@;_\L8&__+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(
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M*4^ _RE/@/\IVVH  ,=U  "Z?P  L(<  *:,  "<CP  CY$  (:3!0" E!(
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MD14ZJZ 6.:NP%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0
M *Z/  "BE@  EYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0
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M B'5N0(AU=("(-/K B#2]@,?T?\$']'_!!_1_P0?T?\$GYL  )2B  "'J0
M>;$  &VX  !@O@  5,,  $G'   ^RP  -= ! "W5!@ EVPL )-X2 "/>'  B
MWR4 (> N "#@-P ?X4  'N%* !WB4P <XUX &^-J !KD>  8Y(@!%^6: 1;F
MK $5YL !%.?= 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD
M &'   !4Q@  2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\
M%^XF !7N+0 4[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *
M]:X "?;"  GVV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)
M  !'S@  .](  #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=
M  W](P ,_2D "OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL
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M'HY*Y1Z-2O8>BTO_'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4  /]-  #E5
MV5D  ,]; P#*6P8 Q%H/ +M;'@"U7"X!KUL[ JI:1@6F6% (HE99"Y]58 Z<
M4V@1F5)O$Y=1=A654'T7DU"$&9!/C1J.3I8<C$Z?'HI.JA^(3K<@AT[((85.
MXB&$3_,@@T__((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T
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M(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<  +MK  "S;
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M(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D  )!Z"P"*>Q8
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MDAQ(AJ =1H:O'D6%PAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT
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M#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((  *B,  "=D@
MDI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P 1+$G $*Q,@!!
MLCL /[)# 3VR2P$[LE,".;); S>R9 0ULFX%,[)Y!C&RAP<OL98(+K*F""VR
MN DLLM (++#L"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T
M 'VC  !QJ   9*T  %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3(
M,[T[ #*]1  QODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(GOY$#)K^B R2_M ,C
MO\L#([[H R.\]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8  ",G@  @*4  '.K
M  !GL   6[4  $^Y  !$O   .L   ##$!  JQPL *,@3 "?)'0 FR2< )<DP
M "3*.0 CRD( (LM+ "'+50 @S%\ '\QL !W->@ <S8H &\V< !G.K@$8SL4
M&,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS  !<
MN0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB !39
M*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@I  -X+@ #.#2
M  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0
M1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +
MZ2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #K
MT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T
M "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X
M /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP
M^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<  "'<
M   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^$   _A0  /\:
M  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2  #_H0  _ZT
M /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H _PY' ?\-4P'_
M"U\!_PIK ?\*=0'_"G\!_PJ' ?\*C@'_"I4!_PJ; ?\)H '_":4 _PFK /\)
ML0#_";@ _PG! /X)S #\"=X ^0GK /4)]@#S"?\ \@K_ /$*_P'Q"_\!\0O_
M ?$+_P'Q"_\!_Q\C /\?(0#_'B$ _QDD /\7+ #_%3< _Q-$ /\14 '_$%P!
M_PYG ?\.<@'_#GL!_PZ$ ?\.BP'_#I(!_PZ8 ?\.G0'_#J,!_@ZH ?P.K@'[
M#K4 ^@Z^ /@.R0#U#ML \@[J .X.]0#L#O\!ZP__ >H/_P'J$/\!Z1#_ >D0
M_P'I$/\!_R(? /\B' #_(1P _Q\@ /\?*0#_'#0 _QI  /\73 '_%5@!_Q1C
M ?\3;@'_$W<!_A.  ?P3B 'Z$HX!^1*5 ?@2F@'V$J !]1*F ?02K 'S$K,!
M\1*\ ? 2QP'M$M@!Z1/H >83]0'D%/\!XA3_ N$5_P+A%?\"X!7_ N 5_P+@
M%?\"_R4; /\F%P#_)!8 _R4< /\F)0#_)#  _R$[ /\?2 #_'50!_1M? ?D:
M:0'W&G,!]!E\ ?(9A 'Q&8L![QF1 >X9EP'L&9T!ZQFC >D9J@'H&;$!YQFZ
M >49Q0'C&=4!WQKH =P;]0+8&_\"U1S_ ]0<_P/3'/\$TAS_!-(<_P32'/\$
M_RD7 /\J$P#_*1( _RP8 /\L(0#_+"L _RDW /TG0P#W)4\!\R-: >\B9 'L
M(6X!Z2%W ><A?P'E(88!Y"&- >(@E 'A()H!WR"@ =X@IP'<(:\!VB&X M@A
MPP+5(=,"T2+G LTB] /*(_\$R"/_!<<C_P;&(_\&QB/_!L8C_P;&(_\&_RP2
M /\N#P#_,!  _S,4 /\S&P#_,B4 ^C P /(N/ #L+$D YRI5 >,J7P'@*6D!
MW2ER =HH>@'7*(("U2B) M,HD +1*)8#SRB< \XHHP/,**L#RBBS \DHO@3'
M*,P$Q2GB!,$J\0:^*OX'O"K_"+HJ_PBZ*O\(N2K_";DJ_PFY*O\)_S / /\R
M"P#_-@T _S@0 /\Y%0#Y-QX [S4H .<S-0#@,D( VS)/ -4Q6@'0,60"S3!M
M LLP=0/),'P#QR^#!,4OB@3$+Y$%PB^7!<$OG@:_+Z8&O2^O!KPON0>Z+\<'
MN##=![4P[@FR,/L*L##_"ZXP_PNN,/\+K3#_"ZTP_PNM,/\+_S,, /\V!@#_
M/ D _SX, /T]$ #O/!4 Y#D? -LY+0#2.CP S3I) <@Y5 '$.5X"P3AG [\W
M;P2]-W8%NS9]!KDVA >W-HL'MC62"+0UF@FS-:$)L36J"J\UM NN-<$+K#74
M"ZDVZ@RF-O@-I3;_#J,W_PZB-_\.HC?_#J(W_PZB-_\._S<' /\[ @#_0 ,
M\D(% .E""0#E/PX V#X6 ,Y )P#'038 PD%$ ;U!3P*Y0%D#MC]A!+0^:0:Q
M/7$'KSUX"*X\?PFL/(8*JCN-"ZD[E0RG.YT-I3NF#:,ZL ZB.[P/H#O-#YX[
MYA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]   #O10  X4@
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MAD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P  SU,  ,95  #
M4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B63F,*E$UJ#)%,
M<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*UAE_2NT8?DO\
M&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@  ,!9  "Z6 $
MM%8) *Q7%@"F6"4 H5@R 9U7/@*85D@$E551!I)46 B/4E\*C%)F#(I1;0Z(
M4'00A4][$H-/A!.!3HT5?TZ7%WU.H1A[3:X9>DZ]&GA.T1IW3NL:=T_Z&79/
M_QEV3_\8=D__%W9/_Q=V3_\7^$8  .)0  #05P  Q%P  +M>  "T70  KEH&
M *9;$P"@7"( FUPO )=;.P*26D4#CUE-!HM850B(5UP*AE9C#(-5:@Z!5'$0
M?E1X$GQ3@!1Z4HD6>%*4&'92GQET4JL:<E*Z&W%2S1QP4N@;<%/Y&G!3_QIP
M4_\9<%/_&'!3_QAP4_\8[TD  -U3  #+6@  P%\  +=B  "O80  J%X" *%?
M$ ";8!X EF L )%@. &-7D(#B5U+!85<4@>"6UD*@%I@#'U99PY[6&X0>%AU
M$G97?11T5X<6<E:1&&]6G!IN5JD;;%:X'&M6RQUJ5N8<:E?W&VI7_QIJ5_\9
M:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90  HV(  )QB#@"6
M8QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU7&L0<UQR$G!;
M>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:_QME6O\:95K_
M&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4  )=F#0"19QD
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MDQE4;* ;4FNO'%%KP1Q1:]P<46OQ&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P
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M%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH  +5U  "J?0
MGX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB< 6(XR %6..P%3
MCD,"4(Y* TZ-4@5,C5D&28Q@"$>,: I%BW(,0HM]#D"*B0\^BI@1/(JG$CN*
MN!(ZBL\2.XCK$CN'^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P  F8<
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M R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D  'B>  !KH@
M7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD *K8R "FW.@ H
MMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV
M\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K
M $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@
M&,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0
MQ/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[
M   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T
M  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T
M =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#   J
MQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?
M,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G
M  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T
M%]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0
MZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #T
MR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6   4W   #N
M  CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2  #T&   ]B
M /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L
M_[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\
M<@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[
M /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\
M_QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_
M W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!
MP@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP;
M /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W,
M^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F
M"<T Y GB .(*\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>
M$P#_&Q( _QP9 /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W
M .X0?P#L$(8 ZA", .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>#\P
MVA#A -41\ #2$OL SQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B#P#_
M(0\ _R(4 /\B' #_("< _QTR /@;/@#R&4L [AA6 .H78 #G%FH Y!9R .(6
M>@#@%H( WA:( -P6CP#;%I4 V1:; -86H@#4%JD TA:Q - 7NP#.%\D S!C>
M ,@9[@'%&OL!PQK_ L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8. /\E"P#_* P
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M"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(  ,Y" 0#)/@8
MQ#L/ +L^'0"U/RP L3\Z *T_10&I/T\!ICY8 J,]7P.A/6<$GSQM!9T\= :<
M.WL&FCN"!Y@[B@B6.Y,)E3J<"I,ZI@N1.K(+D#O #(X[U0R,/.P-BCS[#8D\
M_PV)//\,B#S_#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@( ND,,
M +-$&0"M12< J$8U *1%00&@14L"G413 II#6P.80V(%ED)I!I1!< >2078(
MD$!^"8Y A@J-0(X+BT"8#(E H@V'0*X.A4"\#X1 SP^"0>D/@4'Y#X!!_P^
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M$'%+_Q!Q2_\0[$,  -E,  #(4P  O5<  +18  "L5P  I5(! )Y3#P"85!P
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MDQ)>6: 475FN%5M9OQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%
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M%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H  +QC  "P:@
MI6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P 9'$V 6%Q/@%>
M<48"7'!- UEP5 57<%L&56]B"%-O:@I0;G,,3FY^#DQMBA!*;9@126RG$DAL
MN!-';,T31VSJ$TAK^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(
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M"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X  (-_  !W@
M:X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@ 0I!  $"01P$_
MD$\!/9!6 CN07P(YD&@#-X]S!#6/@ 4SCXX&,8^>!S".KP<OCL,'+X[A!R^,
M] @OB_\(+XK_""^*_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP  98H
M %J.  !/D@  1I4  $&8#  ^F!0 /9D? #N9*  ZFC$ .9HZ #>:0@ VFDH
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M 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@  $6L   [L
M,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X $+TW !"^00 .
MODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]
M_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L
M !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD
M ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0
MS/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(
M   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_
M  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN(
M?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2   '
MU@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J
M/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H
M &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L   />    X0
M .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@
M^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.
M'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_
M /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D
M[P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_
M#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /<
M@P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6
M .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0
M_PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M
M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L
MY@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5
M /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$
MX@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,
M"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7
M& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V"
M -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/ ,,0Y@# $?4
MO1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@ _Q\- /\=$@#X
M&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)%'< QQ5] ,85
MA #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8X@"S&?(!L1K_
M :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0' /<A# #L'1(
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M!X(W_P>"-_\']#(  .,[  #200  QD0  +U#  "W/P  L3L) *H[% "E/"(
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MDPMJ2)\,:$BM#6=)O0UF2=0.94GM#65*_ QE2O\+94K_"V5*_PME2O\+X$0
M ,M-  "]4@  LE8  *95  "<4@  E4X  (Y."0")3Q0 A5 @ (%0+ !^4#<
M>U!  7A02 %U3T\"<TY5 W%.7 1O3F,%;4UJ!FM-<@=I37L(9TV%"F5-D0MD
M3)T,8DVK#6%-NPY@3=$.8$WL#F!-^PU@3?\,8$W_"V!-_PM@3?\+W$<  ,=0
M  "Y5@  KED  *)8  "85@  D%$  (E2!@"#4Q$ ?U,= 'M4*0!X5#0 =50]
M 7)310%P4TP";5)3 FM260-I4F $9U%G!F51;P=C47@(8E&#"F!1CPM>4)L-
M75"I#EM1N0Y;4<X/6E'J#EM1^@U;4?\,6U'_#%M1_PM;4?\+UDH  ,-3  "V
M60  JUP  )Y:  "360  BU0  (16 P!^5A  >E<: '97)@!S6#$ <%<Z &U7
M0@%J5TD":%90 F965P-D5EX$8E5E!6!5;0=>578(756!"EM5C0M95)H-6%2G
M#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T  ,!6  "S7
MIUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX :ULW &A;0 %E
M6T<!8UI. F%:50-?6EP$75IC!5Q::P9:670(6%E_"E99BPM469@-4UBF#E)9
MM@Y16<H/45GG#E%8^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P  HV$
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M#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD  (EI  !]:0
M<6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T 4'!% 4YP3 %,
M<%,"2G!: TAP8@1&;VL%1&]U!D)O@@= ;H\)/VZ>"CUNKPH];L(*/&[@"CUM
M] H];/\*/6O_"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M  !X;0  ;&X
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M!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$  %*%  !)B0
M08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$ +)-* "N44@ J
ME%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@D/H"((__ B"/
M_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@  .I8
M #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?GU4
M'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7
MF_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC
M   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8
M !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\
MEHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;
ML   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W
M6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$
M (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3NP
M#KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4
MQ%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>
M  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@
M  #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X  #41   U%(
M -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@
MK0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "T    -0   #7
M    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3
M  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@
M1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0   .$   #C
MY    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X
M5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P <
M /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@
M^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I
M /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\
M(@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ")
M .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /
MW@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_
M "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4
MBP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y
M ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0
M_P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6
M (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,(
M_P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I
M .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@
MQP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T
M#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*
M+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z*
M +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z *D2_P"H$_\
MIQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X V0X7 ,\1)@#(
M$C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q%GX KQ:% *X6
MC "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;_P&<&_\!G!O_
M 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1 ,(:( "\'"T
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ME@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4
M -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF (T[,0"*.SL
MASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R
M.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"
M  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5 +0""0#< ?T!
M 'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$!&P_D 5K/YP&
M:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%W#X  ,=&  "Y
M2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![130 >44] '9%
M10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#C09D0YD&8D.G
M!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$  ,-)  "V3@
MIT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23  <TDZ '!)0@!N
M24D!;$A0 6I(5@%H2%T"9DAD F5(; -C2'4$84=_!6!'B@9>2)<'74BE"%M(
MM A;2,<)6DCD"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@  HU$
M )=0  "-3@  ADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV &I,/P!H3$8
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M"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D  (M8  "!5P
M=U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\ 5UE& %9930%4
M650!4UE; E%98P)/6&P#3EAV!$Q8@@5*6(\&25B>!TA8K@A'6, (1UC="$=8
M\@A'5_\'2%?_!TA7_P9(5_\&P5$  +)9  "C7   E%L  (=;  !]6@  <E@
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M!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8  %EH  !2:@
M36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D /7%1 #QQ60$Z
M<6(!.'%L C9P> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q;OL$,6W_!#%L
M_P0Q;/\$KV0  *%I  "/:   @6@  '5I  !K:0  8&L  %5N  !-<0  1G,
M $)U"P _=A( /7<< #QW)0 Z>"T .7@U #AY/0 W>44 -GE- #5Y50 S>5X
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M:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<
M (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P  "V0   EDP(
M'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3
MF', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\
M  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::   >G0  %Z #
M !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H
M!Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !Q
MA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN
M!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q
M  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@
M79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y P
MN@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^
M=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\
M $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(   #$    Q00
M ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@
MSWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T
M   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0    T0   -("
M  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\
M .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   H
MP   ',0  !+(   ,RP   \\   #3    V    -P   #?    WP   .$   #C
M    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S
M  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\
M_P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T
M ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4
M_P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W
M /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\
MZ "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6
M /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /<
M/P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0
M -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\
MR #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I
M $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L
MD@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_
M +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\
MU@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\
M )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#
M_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1#
M ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$
MKP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@
M#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-
M1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6
M *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\
M_Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I
M%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1 )88
MFP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T
M .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">'D0
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M G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(  ,DY  "[/@
MK#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4 ?S,^ 'TS1@![
M,TT >3-4 '<S6@!V,V$ =#-G 7(T;P%Q-'<!;S2! 6XTC )L-)@":C6E FDU
MLP-H-<8#9S;B V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@  ID$
M )L_  "3/   C3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S.4D
M<3E0 ' Y5P!N.5T ;#ED 6LY:P%I.70!:#E^ F8YB0)D.94#8SJB V(ZL0-A
M.L,#8#O@!%\[\P-?._\#7SO_ U\[_P)?._\"T3L  ,!"  "P10  H40  )5#
M  "-0   AST  (([ @!].PX >3P8 '4](P!S/2T <#TV &X]/P!L/48 :SU-
M &D]4P!G/5H 9CUA 60]: %C/7$!83Y[ E\^A@)>/I,#7#Z@ UL_KP1:/\$$
M6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2   G$<  )%&  "(
M1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F0D, 9$)* &-!
M4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#K0150[\$5$/:
M!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H  (U)  "#1P
M?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\ 7T5' %U%30!;
M150 6D9; 5E&8P%71FP!5D9V E1&@0-31HX#4D><!%!'JP101[T$3T?6!4]'
M[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+  !_2@  >$8
M '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T 64E$ %=)2@!625$
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M T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$  &)2  !<4P
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M< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$
M )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L  #IN!0 V;PX
M-' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E< *G)A "ER;0 G
M<GL )G*+ "1RG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64  (YD
M  !_9   <F0  &AE  !>9@  5&D  $EL  !";P  .W(  #1U   N> H *WD1
M "IY&  I>B$ )WHH "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ??'8
M'7R& !Q[F  ;>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y
M:0  ;6D  &-J  !9;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$
M$@ ?A!H '80B !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:!
M !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@
M:6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3
MD!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1
MC0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4
M %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X
M"9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<A
MG)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"
M  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0
M  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X
M *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^
ME   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R    LP<  +,,  "S
M$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7
M  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8  $*<   WH@
M+*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@   +\&  # "P
MP0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)
MGP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4
M !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P   #- P  S@@
M - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@D0
MX*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##
M   (QP   ,H   #-    T0   -4   #8    V0   -L   #=    WP   .$$
M  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0
M /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_
M %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X
MF0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_
M .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P
M]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A
M )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -
M_P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1
M .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )<
MSP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#"
M /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L
M5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0":
M +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\
M_P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#&
M %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +(
MG@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8
M /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$
MM@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C
M *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.
M  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92
M *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$
ME@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6
M&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/
M4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J
M (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0
MNR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0
M%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:
MM0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H
M *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U
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M 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH  ) X  ")-0
M@S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4, :C%* &@R4 !G
M,E< 93)= &0R90!B,FT 83-W %\S@@%>,XX!732< 5LTJ@%:-;L!6C72 5DU
M[0%9-?P!6#7_ 5@U_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@  ?3<
M '@T  !T- L <#43 &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@-E,
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M/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4/TT 4S]5 %)
M7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"Z ))0OD"24'_
M DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T   &A   !C00$
M7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL 3D-2 $U$6@!,
M1&, 2D1M 4E%> %(184!1T64 45%HP)%1K0"1$;) D1&YP)$1?@"1$7_ D5%
M_P)%1?\!ND8  *9(  "42   AD@  'M'  !R1@  :D(  &-#  !>1   6D4+
M %9%$@!41AL 448C $]&*P!.1C, 3$<Z $M'00!*1TD 24A0 $A(6 !'2&$
M1DEK $1)=@%#28,!0DF2 4%)H@) 2;,"/TK' C]*Y0(_2?<"0$G_ D!(_P)
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M<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390_P$W4/\!KD\
M )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(! $93# !#5!(
M050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH -E=C #57;P T
M5WP!,U>, 3%7G $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q5?\!J%(  )52
M  "$4@  =U(  &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9"  ]6A  .UH7
M #E;(  X6R< -UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA "]=;  N77H
M+%V) "M=F@$J7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_
M50  <E4  &=6  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3 #)B
M'  Q8B, ,&(K "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8 )F2&
M "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60
M;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II%P I
M:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !UL
ME  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T
M %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH
M'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3
M=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB
M  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T;
M !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT
M"GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,
M:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)
M&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI
M  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=
M/'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4%@
ME!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@  E8X  )2A  "4
MM0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY   _?@  -8,
M "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.  "?$@  H!<
M * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0  **9  "BK0
MH<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   XBP  +I   "25
M   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L#0  K1$  *T6
M  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<
M +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3
MIP  #:L   >N    L@   +4   "W    N    +D"  "Y"   N@P  +L0  "\
M%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\
M  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@
M!KD   "\    OP   ,,   #$    Q0   ,8   #'    R00  ,H)  #+#0
MS1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;
MN@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^   $P@   ,4
M  #)    S0   -    #2    T@   -4   #6    V0   -L   #>!0  X H
M .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP
M\+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L
M7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B
M .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\
M_P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M
M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@
MI0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P (
M /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T
MW0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#%
M *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\
M  #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!>
M ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4
MM0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]
M    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H
M7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K
M *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J
MX    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J
M %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"< )T F@"G )@
MM "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH
M ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D
MG !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+
M \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0
M  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I:
M ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<
M?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A
M%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (40
M6P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35
M ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@
MDAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y
M&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=
M[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(
M (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@
M;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@
M)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD
M  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925:
M &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@
M6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R
M* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK
M7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__
M %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8
M:"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4
M,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT
M_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(-
M %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6
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M<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X__P$^/_\!KD
M )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX% $X_#@!,/Q4
M23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH /D)C #U#;P \
M0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#
M  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E## !&0Q( 1$0:
M $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W1WH
M-DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""
M1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)
M(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R&
M #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2
M<4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V
M3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2
ME0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L
M &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$
M+E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C
M5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/
M  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD
M "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$
M&UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !2
M4P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD
M)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q
M !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P
M1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4
M;2D %&TP !-M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MM
MP@ +;.  #&OS  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\
M #EC   Q9@  *FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R,
M#'<J  MW,P *=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !
M==4  73K  )T]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K
M   K;@  )'(  !YU   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D
M  "!+0  @C8  ()   ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L
M '_G  !^\@  ?OD =&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E
M>   'GP  !>    1@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-
M)@  C2\  (XY  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?
M  "+[@  B_8 ;F@  &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A
M%H@  !",   ,CP  !I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P
MFR8  )LP  "<.P  G$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":
MYP  FO$ :FT  %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4
M  J9   $G    *    "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X
M *HF  "K,0  JSX  *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0
MJN@ 9'4  %=Y  !+?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G
M    J@   *X   "P    L    +$   "R P  M @  +4-  "V$   MQ4  +D=
M  "[)@  O#,  +U!  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=<
M7'\  %"%  !$BP  .)(  "R9   AGP  %Z0  !"I   )K@   +(   "V
MN0   +T   "_    OP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+
M'   SB8  - U  #110  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P
M $F3   ]F@  ,*(  "6H   :K@  $;0   FY    O0   ,$   #$    R
M ,L   #-    S0   ,\   #0    T@   -0   #8    V@8  -T,  #@$0
MXQH  .8G  #G.   Z$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\
M"P#_  L _P 0 /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I
M /$ ;P#P '4 [@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\
MWP"[ -T RP#; .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_
M  0 _P - /\ %0#^ "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0
M:@#B '  X !U -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U
M ,L Q #) -T R #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_
M_P * /@ $0#Q !P [  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0
M &H S@!P ,P =0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L
MO0"Z -  N #K +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P %
M .D #@#A !8 VP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4
MO@!J +P ;P"[ '0 N0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K
M ,@ J0#C *@ ]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -<
M"@#- !$ QP < ,( )@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D
M *T :0"L &\ J@!T *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$
MFP#: )H [P"9 /T F #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]
M  T MP 5 +, ( "P "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *
M9 "> &D G0!N )L =0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/
M (P Z0"+ /@ C #_ (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @
MJP 0 *< &0"D "0 H  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2
M &0 D !I (\ ;P"- '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (
MY0"  /4 ?P#_ '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (,
M )P $P"8 !T E0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\
MA -D (,#:P"! W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U
M"?0 = K_ ',*_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(
M#0".!Q4 BPD@ (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@
M '@,9P!W#&X =0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/<
M:1#_ &D0_P!I$/\ T!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%
M#A  @0\: 'X0) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X2
M8@!M$FH :Q)S &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_
M & 7_P!@%_\ QR(  + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T
M=Q45 '06'P!Q%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C
M&68 8AEO & 9>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>
M_P!8'O\ OR<  *DH  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1
M &L<&@!I'2, 9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V(
M62!K %@@=@!6(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1
M(_\ N2L  *,L  "3+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B
M%@!A(A\ 7R,G %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H
M %$F<P!/)G\ 3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\
MLRX  )XO  ".,   @3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:
M)QL 6"@D %8H*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK
M< !)*WP 2"R+ $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$
M )HR  "),P  ?#,  '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@
M4BP@ % L* !.+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#
M,'H 0C&) $$QF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U
M  "&-0  >38  &XU  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$=
M $HQ)0!(,2P 1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@
M/36' #PVE@ [-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  ""
M.   =3@  &LX  !C-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U
M(@!#-2D 034O $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F%
M #<ZE0 W.J4 -CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@
M<CL  &@[  !?.@  63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^
M.28 /#DM #LZ-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^
MDP R/J0 ,3ZV #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT
M &0]  !</0  53P  $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B,
M-SXJ #8_,0 U/S@ -#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M
M0J( +$*U "M"RP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%
M  !9/P  4C\  $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H
M #%$+P P1#8 +T0] "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$
M)D>S "9'R0 F1N< )T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !5
M0@  3D(  $5"   _1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)
M+  J23, *4HZ "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ
M "!,QP @2^8 (4OW ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210
M2D8  $%'   \2   -TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D
M3S  (U W ")0/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1
MQ0 94>0 &E#V !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD
M #Y+   Y3   ,TX  "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP
M'%8S !M7.P :5T0 &5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 2
M5^$ $U;T !15_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/
M   U40  +U0  "E6   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN
M !->-P 27D  $5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH
M#5WP  U<_  .7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P
M5P  *EH  "1=   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG
M,@ ,9SL "V=%  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I
M  1D]0 $9/P =U$  &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@
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M  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y8P
M,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@  (,-  "#$
MA!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&
MI0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI   R;0  *7(
M "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)  "/#0  D!
M )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5G0
ME+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$
M   1B0  #(T   :1    E    )@   ":    FP   )P"  "=!P  G@L  )\.
M  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D
M *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +
MEP  !)P   "@    HP   *8   "H    J0   *H   "L    K00  *X)  "P
M#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ
M  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #IP
M *L   "N    L@   +8   "X    N    +H   "[    O0   +X   # !0
MP0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-
MM   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q    M@   +H
M  "^    P@   ,8   #(    R    ,H   #+    S0   ,X   #0    T@$
M -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0
MYK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4
M50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9
M -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\
M_P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E
M %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P
MG #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P
M /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %(
MS@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y
M *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\
M  #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3
M +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H
MJ "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H
M    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O $< K !- *L
M5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"?
M )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3
MQ@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P 3@":
M %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H
MIP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,   #! 0  M
M *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T
MC !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![
M +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(
M  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !.
M '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T
M;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+
M#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%
M3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\
M &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%
M?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I
M#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0
MU@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@
M '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL
M7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1
M%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;
M  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA-
M %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L
M21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@
M'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>
M40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z
M $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P
M5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%
M(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG
M_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$
M $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%,
M/BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X
M+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ
M"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9
M #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\
MF2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!
M+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R
M8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$
M (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T
M.3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M
M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U
M  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0
M #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH
M)SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M
M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]
M%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V
M "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P
M7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004 *D(, "="$0 F
M0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%
MA0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\
M %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @210
M'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 3
M2Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"
M  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7
M !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$
M#5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$
M10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8
M&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?
M  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@  $A(  !!20
M.DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (
M8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?
MK@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5
M "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.  !H$P  :!@
M &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0
M:+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;
M   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q$   <10  '(:
M  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD
M ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7   *F   ")D   ;
M:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^
M&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*
M  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH  !MO   4<P
M#G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T  (H0  "+%0
MC!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-
MW   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4
M  ")    C0   )    "2    DP   )0   "6 P  EP@  )@,  ":#P  FQ,
M )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP
MGN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &D    )0   "8
M    G    )\   "A    H@   *0   "E    IP   *@$  "J"0  K T  *T2
M  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X
M3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP   *0   "H
MK    *\   "Q    L0   +,   "U    M@   +@   "Z    O 8  +X,  #
M$0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH
M #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,   "W    O
M +\   #!    P@   ,0   #%    QP   ,D   #+    S0   ,\#  #2"@
MUA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@  XJT _P " /\
M  #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!>
M .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8
MTP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_
M    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D
M7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K
M ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^
M]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60##
M %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E *\
ML@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T   #N    X@
M -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P %D
MKP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K ">
M +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>    RP   ,$
M!0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *( 30"A %, GP!8
M )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0
MC0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'    N@   +    "H
M  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\
M5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#
M 'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@   *(   ";  4
ME0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"!
M %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$
MT0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$  ".    B@ (
M (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %(
M<P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E
M .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!
M"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2
M &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0
M6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q
M!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(
M50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU
M %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@<
M9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5
M#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2
M_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$*
M %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4
M2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"
M%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7&0  518& %05
M#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA:
M $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\
MFB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+
M&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>
M8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,
M (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\
M0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T
M(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H
M  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202
M #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D
M+BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M
M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H
M%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU
M "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@
M7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M$P N
M+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q
M@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$
M %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I,A<
M*#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =
M-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630  % T
M  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<;
M "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$
M%SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&
M-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]
M'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B
M !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0
M/3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 4
M1"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%
ML@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP
M #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX
M#DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $
M2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%
M   J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B
M  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\
M %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@  -$,  "U%   F
M2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9
M)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5
M  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD  "A,   B3P
M&U(  !95   16   #5H   E= P $7PD  & -  !@$   810  &$9  !B(
M8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@
MZ@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3   <5P  %EH
M !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(
M &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@
M:O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   68   $&0   QG
M   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC
M  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\
M5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P  "V\   5S
M=P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<  ")
M)0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8
M $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT   "!    A0
M (@   "*    C    (T   "/    D 0  )((  "3#   E1   )<5  "9'0
MFR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@
M   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1    E0   )@
M  ":    FP   )T   "?    H    *(   "D!0  I@H  *@.  "J%   K1T
M *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK   N
M<0  (W@  !E_   0A@  "8T   "3    F    )T   "A    I0   *@   "K
M    JP   *X   "O    L0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?
M  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G@
M'(@  !*0   *EP   )T   "C    J    *T   "R    M@   +D   "[
MO    +X   #     P@   ,0   #&    R    ,L   #.!0  T0T  -84  #7
M(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\   #_    _P )
M /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0
MX@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#(
M -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ % /<
M#@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C
M ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W ,@
MM@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X    [0   .4 "P#=
M !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@
M8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#;
M *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP   ,L !@#$  X
MO@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D
M &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0
MZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<  @"O  L JP 1
M *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L
MDP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$
M /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">  < F@ . )8
M% "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !;
M (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\
M=@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  ( BP + (@ $ "&
M !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8
M6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y
M &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P & 'L #0!Y !(
M=P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H
M %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T
M_P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5
M &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@
M70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4
M /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0 &(
M%P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)<
M %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\
MH1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8
M!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*
M8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0
M (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X( %,-#@!1#10
M3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!
M$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:
M  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7
M $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D
M.!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N
M'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5
M&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES
M # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@
M7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W
M&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?
M@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4
M %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH
M,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D
M(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H
M  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(=
M "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\
M'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&
M*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G
M(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R?
M !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+
M/BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >
M+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0P
ML0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX
M #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B(
M&#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .
M-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^,   .#   #,P
M   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F
M !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$
M"CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L
M,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^
M*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7
M  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P
M(S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &
M1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I   1+D  $31  !$
MZ@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY   E.P  (#T
M !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL
M $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0
M2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&
M   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O
M  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*  !1YP  4?0
M63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P  %TH  !)-   .
M4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<
M-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(
M $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,   Y6   *60
M!5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G+0
M9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&
M  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@   "8P   &8
M  !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(
M '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [
M2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K    ;P   '(   !U
M    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V
M  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P
M*U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0   ($   "#
MA0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6
M.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9   O70  )&,
M !II   2;P  #'4   1[    @    (4   ")    C0   )$   "3    E
M )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<  *DC  "I,0
MJ4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X
M   ,?P   X4   "+    D0   )8   ";    GP   *(   "D    I0   *<
M  "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8  "^)@  OC@
M +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(   %
MCP   )8   "<    H@   *<   "L    L    +,   "V    MP   +D   "[
M    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5&P  U2P  -1
M  #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P % /\ #@#_ !4
M_  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9
M &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\
M_P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ;
M .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &<
MP !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L
M /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2  X S0 6 ,H
M( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G
M *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2 )T \@"< /\
MG0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P
M ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H
M9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_
M (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 . )\ %0"= !X
MFP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ")
M &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P
M_P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T $0"+ !@ B0 @
M (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &
M> !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N
M /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D
M(@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B
M &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\
MM    *    "1    A@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K
M "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T
M90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $
M )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\
M7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2
M &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+
M  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @
M %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &<
M1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T
M$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!
M(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P
M #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%
M8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$
M"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,
M?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@
M %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\
M/ TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N
M$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;
M  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A
M #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P
M)Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !'
M'@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4
M(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F<
M " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$(
M/A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F
M&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>
MK0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(
M #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20
M(!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5
M(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^)   .20  #0C
M   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H
M !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L
M$";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M
M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H
M+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7
M  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@  "\H   K)P
M)R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0
M+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DN
MZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H
M " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\
M"S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $
M,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO
M   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T
M  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*   XY@  -_(
M7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,   'S$  !HS   5
M-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _
M.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]Y   /?( 6C
M $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8  !8X   2.P
M#ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120  $4M  !&-@
M1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU
M  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_   /00  #$0
M  A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T
M $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ]
M.   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +20  !TL   ).
M    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$
M  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [.P
M-3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40   %0   !7
M6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A
M3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4
M "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X   !A    8P
M &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10
M;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+
M   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M    ;P   '
M  !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT
M 'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   4
M6P  #F    =E    :@   &X   !R    =@   'D   !\    ?@   '\   "!
M    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7
M  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .:
M!VX   !T    >0   'X   ""    A@   (D   ",    C@   )    "2
ME    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E
M8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X
M  "$    B@   (\   "4    F    )L   ">    GP   *(   "D    I@
M *@   "K    K0   +    "S!   MPP  +L2  "['P  NS   +M#  "Z6
MN7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F     B    (\   "6
M    FP   *$   "F    J@   *X   "P    L0   +0   "V    N    +L
M  "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4
M ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S
M "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X
M<P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_
M *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D
MV0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W
M '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T
M_P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L
M +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T
MH@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P".
M /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H !X J  G *8
M+P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N
M (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\
MY    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D DP A )( * "/
M #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X
M;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP
M +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H
M?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M
M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0
M  "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J
M &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T
M7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'
M    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$
M*@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S
M %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G    (D   ![ P
M< ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5
M "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $<
M? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H
M %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8
M2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ]
M (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.
M  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F
M $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4
M- "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1  !+
M$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#
M*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5
M "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%
M0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q
M"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-
MIP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18
M #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2<
M*@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =
M$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _&0  .A@  #47
M   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J
M ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L
M%Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O
M&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4
M+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2
M !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P
M*!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7
M&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;
MZ@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T
M ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$
M$1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,
M'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >
M   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W
M  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$
M8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0  (2$  !XA   :
M(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H
M/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(
M %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,  !LD   8)0
M%"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !
M+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX   +/  6B0  $TF
M  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L
M  \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(
M #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _
M*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2+@  #S    TQ
M @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*
M   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L  $8L   \+
M-"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P  #34   DW @ %
M.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&  !
M5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\
M "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P   4^    000
M $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P
M2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ
M   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&    2 (  $H%
M  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\  !12@  45H
M %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A
M.   &CL  !0^   000  #$0   ='   "2@   $T   !/    40   %,"  !4
M!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG
M  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD  ",\   </P
M%4,  !!'   +2@  !4X   !1    5    %<   !:    7    %T   !?
M8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H
M=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$   620  $$T
M  I1   $50   %H   !=    8    &,   !F    :    &H   !K    ;0
M &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0
M=X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   05   "ED   )>
M    8P   &<   !K    ;P   '(   !U    =P   'D   ![    ?0   '\
M  ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP
M (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80   6<   !M
M<@   '<   ![    ?P   (,   "&    B    (H   "-    CP   )$   "4
M    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B60  H'   )^+
M  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<   !]    @P
M (@   "-    D0   )4   "8    F@   )P   "?    H0   *,   "F
MJ0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "U
ME@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/    E@   )L
M  "@    I    *@   "K    K    *\   "R    M    +8   "Y    O
M ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+C0
MRJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8
M.P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!]
M ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\
M_0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#&
M #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P
M?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P
M .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O #<
MK  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7
M (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T
M  #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W
M )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L
M@P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O
M    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (,
M-@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"
M '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";
MCP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q
M #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &(
MAP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D   "*    ?P
M '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C "\
M8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4
M )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\    <0   &D
M  !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O
M %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L
M2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P    9@   %X   !9
M    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H
M+@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7
M #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@
M3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!
M "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0
MI@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H
M $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W "H
M-@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L
M +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,
M   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L
M "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E +(
M)0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0  .1   #8/   S
M#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$
M+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;&
M !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$
M+ \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @
M"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,
MX0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3   J$@  *!$
M "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3(
M&@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1
M#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3
M   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y
M !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$
M8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5   <
M% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \5
M00 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8
M %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@  !P7   9%@$
M%Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +
M&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:
M  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9   7& $ %1@"
M !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D,
M!!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!
M'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<
M!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--
M   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^(
M-2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@!  -
M(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@  )ST  "=)   H
M5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(
M "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,   TE P *)@8
M!B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D  "U&   M5
M+60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD
M   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)
M   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V
M #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C
M)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'   U
M"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO
M   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P
M'2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(  #L%   \"
M/@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!
M@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T
M !0O   0,@  #34   @X   $.@   #P    _    00   $,"  !%!0  1@@
M $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P
M2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;,0  %30  ! W
M   -.@  "#T   )     0P   $8   !(    2@   $P   !. 0  3P0  %$'
M  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T
M %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.   $3P   Q    '
M1    $<   !*    30   %    !3    50   %<   !9    6@   %P#  !>
M!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D:P  8H4  &&?
M  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8   9*    3P
M %,   !6    60   %P   !?    80   &0   !E    9P   &D   !L 0
M;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !P
MKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7    7    &
M  !D    :    &L   !N    <0   ',   !U    =P   'H   !\    ?P
M (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0
M@KP +T   "5$   <20  $TX   U4   $6@   &$   !F    :P   &\   !T
M    >0   'T   "     @P   (4   "'    B@   (P   "/    D@   )8
M  "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\
M*4D  !].   55   #EL   5B    :0   '    !W    ?0   ((   "&
MBP   (\   "3    E0   )<   ":    G0   *    "C    I@   *H   "N
M    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0
M !A;   08@  !VH   !S    >P   ((   ")    D    )4   ":    GP
M *,   "F    J    *L   "N    L    +,   "V    N@   +T   #"
MQP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8
M  #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$
M -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T
MM@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H
M    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D
M1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3
M *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9
MR0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B
M $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T
MF@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@
M *4   "?    G  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P
MBP!! (D 1@"( $L A@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X
M *, =P"Y '8 X !U /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\
M  ")    A0 $ (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [
M '< 0 !V $0 =0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L
M9P"O &8 S !E /4 9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W
M    <P   '  " !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &<
M.0!F #X 90!# &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F
M %< OP!7 .H 5P#_ %8 _P!4 /\ H0   (X   !_    =0   &P   !H
M9    &$ ! !@  L 7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8
M #@ 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L
MM0!* -P 2@#Z $H _P!* /\ D@   (    !R    9P   %\   !:    5P
M %4  0!3  < 4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #,
M2P X $H /0!) $, 2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!
M ,L /P#R $  _P!  /\ A0   '0   !G    70   %4   !/    3    $H
M  !(  0 1P * $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S
M #\ .  ^ #X /0!% #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,
M-@#H #8 _@ V /\ ?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _
M  $ /@ ' #T "P ]  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8
M,P U #H - !! #, 20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#=
M "T ^  N /\ <P$  &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P
M-@ $ #4 "  T  P -  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M
M #8 +  ] "L 10 J $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4
M\  F /\ ;08  %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8"
M "X#!@ M  H +  - "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #(
M)  Y ", 0@ B $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ?
M /H : D  %D,  !-#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)
M!  F!@@ )@0+ "4##@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V
M !T!/P < 4D &P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0
M8PP  %4.  !)#P  0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @
M"P8 ( D) !\'#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&
M/  6!D8 %@92 !4'7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX
M %$/  !&$   /!$  #41   O$0  *A$  "80   B$   ( \  !T. @ <#04
M&@T' !H+"@ 9"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2
M"T4 $0M1 ! ,7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1
M  !#$@  .A,  #(3   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X'
M !4."0 4#0L $PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8
M#0Y1  P/7@ +#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  !
M$P  -Q0  # 4   I%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0
M"0 1#PH $ X,  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-
M  @26@ '$FH !A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0
M-18  "T6   G%@  (A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /
M$0H #1$+  P2#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,5
M6  "%6<  15Z   5C@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<
M "L7   E%P  (18  !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD
M#!0*  H5#0 (%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950
M&60  !EW   9C   &*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9
M   C&0  'Q@  !L7   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*
M  <9#  $&@X  AL2  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(
M !UU   =B@  '*   !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A
M&@  '1D  !D9   7&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,=
M"P  'PT  " 0   @%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R
M   AB   (9\  ""V   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'
M'!L  !@:   6&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@
M) P  "8.   F$@  )A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   F
MA0  )IT  "6T   DT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP
M !@;   4'   $1P   X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L
M "L-   M$   +14  "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0
M+)H  "NR   JT   *>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>
M   2'P  #R$   TB   *)   !B8   (H    *P(  "T$   O!@  , D  #(,
M   T#@  -1(  #48   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8
M #*O   QS0  ,.\ /",  #(D   J)   )",  " B   <(0  %R$  !,C   0
M)0  #2<   DI   %*P   2X    P    ,@   #0!   V!   . 8  #H)   \
M#0  /A   #X4   ^'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK
M   YR0  ..T -R<  "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P
M"2X   4P    ,P   #4    X    .@   #P    ^ 0  0 ,  $('  !$"@
M1@T  $D1  !)%P  2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"
MPP  0>@ -"H  "PJ   G*   (B<  !PH   6*@  $2T   TP   ),P   S8
M   Y    /    #X   !!    0P   $8   !(    2@   $P#  !.!@  4 H
M %,.  !4$P  5!P  %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0
M3.  ,"T  "LL   F*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#
M    1@   $D   !,    3@   %$   !3    50   %<   !9 0  7 8  %\*
M  !B#@  8Q4  &,?  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\
M+S   "HO   B,   &C,  !,W   ..P  "#\   %$    2    $P   !/
M4@   %4   !8    6P   %T   !@    8@   &0   !F    :0   &T%  !P
M"P  =!   '08  !S)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,
M "4U   =.   %#P   Y!   '1P   $P   !1    50   %D   !=    80
M &4   !H    :P   &T   !O    <@   '0   !W    >@   'X   ""!
MA@L  (H1  ")'   B"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]
M   60@  #T@   A.    5    %H   !@    9    &D   !N    <@   '8
M  !Z    ?0   (    ""    A0   (@   "+    C@   )(   "6    FP,
M * ,  "B$P  H"$  )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   1
M3@  "54   !<    8P   &H   !Q    =@   'L   "     A@   (H   ".
M    D0   ),   "6    F0   )P   "@    HP   *<   "K    L    +8$
M  "\#0  NA<  +DH  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7
M 60   !L    =    'P   "#    B0   (\   "4    F@   )\   "B
MI    *<   "J    K@   +$   "T    N    +P   #!    QP   ,T   #4
M!0  V!   -4>  #3,0  T$@  ,U?  #+=@  R(X
M  $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X
M.3L\/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q
M<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JK
MK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/D
MYN?HZ>OL[>[P\?+T]?;W^?K[_/[_________________________________
M_____________________P                     ! P0%!@@)"@L-#@\1
M$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*
M2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#
MA8:'B(J+C(Z/D)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]
MOK_!PL/$QL?(R<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V
M]_GZ^_S^____________________________________________________
M__\                      0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B
M)"4F*"DJ*RTN+S R,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<
M75Y@86)C969G:6IK;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25
MEIB9FIR=GI^AHJ.DIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/
MT-'2U-76U]G:V]W>W^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________
M____________________________________________  $" P0%!@<("0H+
M# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$R,S0U-C<X
M.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)35%565UA96EM<75Y?8&%B8V1E
M9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/D)&2
MDY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKJ^PL;*SM+6VM[BYNKN\O;Z_
MP,'"P\3%QL?(R<K+S,W.S]#1TM/4U=;7V-G:V]S=WM_@X>+CY.7FY^CIZNOL
M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
M     0                    $    ! @,$!08'" @)"@L,#0X/$!$2$Q05
M%A<8&1H:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C]
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MAJB'SH.HB<Z!IXS/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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M@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
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MAJ.(U(.CC-2!HY'4@*29TX"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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MI+5EO*"R=+^>L7_"FZ^$PY:NA,61K83&C:V%QXJLALB'K(?)A:N(R8*KBLJ
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MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
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MM\*1CKG C)"\OXB3OKV$E\"\@)O"NWV@P[M[IL2Z>JW%M'JNQ*]ZK\*L>[#
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MK9&[=K.0N'^WC;:$NXFTAKV%LHB_@K&+P7^QCL%\L9+">K&6P7FQF\%XLJ'
M=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP?^N$@'_
MKQT-_ZXH)/^X)#'JRQHUT.(70[_P'5ZOZ"5UH-LQAY;12)20RER>C<5JI8O!
M=JJ)OGVOA;R LH*Z@[1^N8:V?+B)MWFWC+AWMX^Y=K:3NG6VE[ITMIVZ<[>D
MN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN?^P$ '_L1H-
M_[$E(_/$%R?4WQ KP>\72+#W(&"AZBMSE=\Y@HW73(V(T5V5ALQJFX3)=*"
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
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MNK*0A+JRD(2ZLI"$NK*0A+JRD(2ZLO^/#P'_DB &_Y,T%/^:/R+_H3\N_Z=
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MOZMFL+^L::J_K&REOZMMHL"J;:+ JFVBP*IMHL"J;:+ JFVBP*IMHL"J;:+
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MK$<[]J]-1.VQ5$WELUM5W+!E8<ZH;''#GW2 N)9\C:Z/AIBEB)&AG8.=IY>
MK:N3@+^KD8'!J8^!PJ>.@<.EC8'%HXV!QJ*,@<B?C('(GXR!R)^,@<B?C('(
MGXR!R)^,@<B?C('(G_^"$0'_@1H#_X8M#?^6-!7_H#D=_Z8\)O^K0"_[L$4X
M\K1+/^FY4T;AO5Q-T[9B8,:M:7"[I7%_L)UYC*65@I>;CXVADXJ9IXR'J:N(
MA[^LB(? JHB&PJB(A<.FB(7%I(B$QJ*(A,B@B(3(GXB$R)^(A,B?B(3(GXB$
MR)^(A,B?B(3(G_^#$ '_@AH#_X@K#/^9,A3_HC<;_ZDY)/^O/2SWM4(S[;M)
M.>7"4C[:PEA,S+I@7[^R9V^SJVY^J*-VBYV<?I>2EXF@B9*6IX*/I:M^C[JL
M@(W JH&+PJB"BL.F@XG%I(.(QJ*$A\B@A(?(GX2'R)^$A\B?A(?(GX2'R)^$
MA\B?A(?(G_^$$ '_@QH#_XLJ#/^<,1+_I30:_ZPV(?ZS.BCSNT MZ<-(,>'+
M43?2QU9+Q<!>7;BX96ZLL6Q]H*ISBI2D>Y6*GX:>@)N2I7F8HJITF+>K=Y7!
MJ7J1PJ=\C\.E?8W%HWZ,QJ%_BLB??XK(GW^*R)]_BLB??XK(GW^*R)]_BLB?
M?XK(G_^%$ '_A!H#_XXH"_^?,1'_IS(7_[ S'?FY-B+NPCTFYLU')MO33#7+
MS%1)OL5<6[&^8VRDN&IZF+)QAXRL>9.!J(*<=Z2/HW"BGZ=LHK2H;I_"IW*9
MPZ9UE<2D=Y+&HGB0QZ%ZCLB?>H[)GGJ.R9YZCLF>>H[)GGJ.R9YZCLF>>H[)
MGO^&$ '_A1D#_Y$F"O^A+P__JRX5_[4O&?2_,ASIRSH<W]E$'=':2C/$TE)'
MM\M:6:G&86F<P&=XD+INA(2V=H]YLH"8;Z^-GVBMG:-DK;*D9:K%I&JBQ:-M
MG<:B<)G'H7*6R)]TD\F==9/*G763RIUUD\J==9/*G763RIUUD\J==9/*G?^'
M#P'_AQD#_Y4D"?^D*PW_KRD1^KLI$^S(+!/>V#<0T^%!'LG?23"\VE%$K]-8
M5J'-7V:4R&5TB,1L@'S =(IQO7^3:;N,F6*YG)U>NK&>7;C)GF*NR)]FILB?
M::')GFN=RIUNFLN;;IG+FVZ9RYMNF<N;;IG+FVZ9RYMNF<N;;IG+F_^(#P'_
MB1D#_YHC!_^H)PK_M2(,\<0@#.#5) G1X3 4Q^8])+WC1C2RX$Y$IMQ64IG7
M76&,TF-O@,]K>G3,<X1KRGZ+8LB,D5S(G)59R+&65\C.EEN[S9A>LLR98:O,
MF62FS9EGHLV89Z#-EV>@S9=GH,V79Z#-EV>@S9=GH,V79Z#-E_^*#@'_BQ@#
M_Y\A!?^N( ;XO1@&X]$3!-#A'@G%ZBX9NNDZ*;#G0SFDY$I(F.)05HS@5V*
MW5]L=MMH=6S:<GUCV'Z#7-B,B%?8G8M4U["-5-C-C%7+TX]7P-*16KC1DURR
MT9-?K-&38*K1DV"JT9-@JM&38*K1DV"JT9-@JM&38*K1D_^,#@'_CQ8"_Z4>
M _^U%0/:R@L"T.$. L3K'@VX[RP=K>XW+J+L0#V7ZTA*C.E/5H'H5F!VYUYI
M;.=E<&3F<'=>XWQ\6>")@%;>EX-3W::$4=RXA5'=U(13T-J'5,;8B5:_UXI8
MN-:+6;;6BUFVUHM9MM:+6;;6BUFVUHM9MM:+6;;6B_^.#0#_EQ(!_ZT5 =F_
M"0#,S@D P^L.!+;U'A&K]2PAH?0W,);S0#Z+\TA*@?-05'?S5UUM\UUD9?!F
M:E_M<&Y:ZGIR5N>%=E/ED7E1Y)Y[3^.L?$WCO7Q-X]E\4-C@?%'.X']2QMZ!
M4\3>@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@?^2# #_H T V[<& ,K#!P#
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M@5RFWX%<IM^!7*;?@5RFWX%<IM^!7*;?@?^ #P'_C@X!_Z(- -NU" #.P0@
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M%P6;]2<0DO4T'(CV/B=_]D<R=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?>
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M, ]1_S<32_\^%T;_11E!_TP;/?]2'3G_6!\V_U\A-/]F(C'_;B0O_W<E+?^
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M>6V,Y7AMC.5X;8SE>&V,Y7AMC.5X;8SE>/]N$P'_>Q$!_XT0 /^=$ #ZK!$
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M#Q3_H! 3_ZT1$_^Z$1/_PQ(3_\,2$__#$A/_PQ(3_\,2$__#$I>^  "&S
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M.O]"L#S_0K@]_T'!/O] RS__0-Q _S_I0/\_]$#_/OU!_T#_0/U"_T#V1?]
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M_TC;3?](VTW_2-M-_TC;3?](VTW_2/]3'@+_3B@#_TXO!/]4, ;_6C8(_UY
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M:WA\\&EX?/!I>'SP:7A\\&EX?/!I>'SP:?]@%P'_;A(!_WX0 /^,$0#_F1$
M\:03 ..N%@#6MAP!R[0P",&P/Q>WJTLEK:94,Z2A74"<G65*E)AL4XR5=%N&
MD7UB?XZ':'F,DFUTBIYQ<(BM=&V(P71MB>1S;X?J<7"$[&]R@^UM<X'N:W2
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M9F./\69CC_%F8X_Q9O]K$ '_?@D \9 $ -:> P#,J@8 Q+0& +Z^!0"XR!
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M*2W_ZBHL__\J+/__*B_Y_RHO^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@
MG+D  ([%  "!T0  ==X  &WZ"0!E_Q$!7O\: E?_(P-2_RP%3/\T!TC_/ I#
M_T0,/_],#CS_4Q X_UL2-?]C%#+_;!8O_W<7+/^$&2G_DQHG_Z(<)?^T'23_
MS!XC_^T>(O_]'R+__Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(
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M ?]T%0'_?1H!_X0A ?>)*@/MC30'Y(T]#=R+2!;1A50CR7]>+L)Z:#B\=7%
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M6X-O^UF#;_Q8@V_\6(-O_%B#;_Q8@V_\6/]6& '_9!$!_W(. /]^$ #_B!$
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M6G!\^UIP?/M:<'S[6O]?$0'_;PH _WX( .., P#6EP4 SZ ' ,JH" #$KA,
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M  #=B0  RI<  +ZB  "SJ@  J;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E
M$G7(2AMMQU,C9\5<*F'$9#!<PVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&
M1\'J1D2^_TE%N?]*1[/_2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1
MD   PIX  +6G  "JKP  H+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S3
M1Q1ETE ;7]%9(5K18B=5T&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J
M.D#-_3X^R_] 0,/_0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F
MN*,  *NK  "@M   E;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<
MX$T45^!6&5/@7QU/X&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?
M^C$YWO\T.=G_-CK0_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@
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M$Q[__Q,>__\3'O__$Q[__Q,>__\3'O__$Z:I  "8LP  BK\  'O*  !NU0
M8-\  %3G  !._P0 2?\. $/_%  __QT!.O\E C;_+ (R_S,#+_\Z RO_000H
M_T@$)?]/!2+_5P4@_V &'?]L!QK_>0<8_XH(%O^;"!7_K0D4_\,)$__C"1/_
M^ D3__\*$___"A/__PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X   4>8
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M0/<M[4#_+^L__S'D0?\RVT/_,]%$_S/+1O\SRT;_,\M&_S/+1O\SRT;_,_]
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M29-@_TB18/]'D6#_1Y%@_T>18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
MR'XK L!\.PBY>4@1LG93&:QR72&G;V8HHVUN+I]J=S.;:'\WF&:(.Y5ED3Z1
M8YM!CF*G0XQAM$6)8<=%B&+E189B^D.&8_]"A&/_0(-C_SZ"8_\]@F/_/()C
M_SR"8_\\@F/_//]0#P#_6P< _V8# .QO @#<=@, U'P' -& "0#*@A0 PH,H
M KJ!.0>S?D80K'M1&:9W6B&A=&,HG')K+IAO<S.4;7PWD6N$.XUJCC^*:)A"
MAF>C1(1FL4:!9L-'?V;A1W]G^$5^:/]#?FC_07UG_S]\9_\^?&?_/7QG_SU\
M9_\]?&?_/?]2#@#_70, _6D  .%R  #6>@( SG\% ,J#" #%AA( O(<F ;6&
M-@:N@T,/IX!.&*%\6"";>6 GEG=I+9)T<#..<GDWBG"!/(9NBS^#;95#?VRA
M17QKKD=Z:[](>&O=2'AL]D9X;/]$=VS_0G=K_T!W:O\_=VK_/G=J_SYW:O\^
M=VK_/O]4# #_7P  \FP  -UV  #0?0( R8,$ ,2'!@"_BA  MXPC ;"*- 6I
MB$$.HH5,%YR!51^6?UXFD7QF+8QY;C*(=W8WA'5_.X!TB#]\<I)#>'&>1G5P
MK$AS;[U)<7#927%P]$=Q<?]$<G#_0G)O_T%R;O\_<F[_/G)N_SYR;O\^<F[_
M/O]6"@#_8@  YF\  -=Y  #,@0$ Q8<# +^+! "YC@X LI @ :N/,06DC#\-
MG8I*%I:'4QZ1A%PEBX%D+(9_:S&"?7,V?GM\.WIYAC]V=Y!"<G:<16]UJ4AL
M=;I):W7426MU\D=K=?]%;'7_0VUS_T%M<O\_;7+_/VUR_S]M<O\_;7+_/_]9
M!P#_90  XG(  -%\  #'A   P(H" +F/ @"SD@P K)0= *:3+P2>D3P+F(](
M%)&,41R+B5HDAH=B*H&%:3!\@G$U>(%Z.G1_@SYP?8Y";'R:16E[IT=F>KA(
M9'O02&1[\$=E>_]$9GK_0V=X_T%H=O\_:';_/VAV_S]H=O\_:';_/_];! #W
M:0  W78  ,V   ##B   NXX  +23 0"MEPD IY@: *"8+ .9ECH*DI1%$HR2
M3QJ&CU<B@(U?*'N+9RYVB6\S<H=W.&V%@3QIA(M 9H*70V*!I49@@;9'7H'-
M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
M *=L  "?:@$ F6L1 )1M(@"0;C$!BVT]!(=L1P>#:U +?VI8#WQH8!-X9V<6
M=F=O&7-F>!QP98$>;62,(6ICF"-H8J8E9F*V)F1BS"9D8NPE9&+_(V1B_R%E
M8O\?96+_'F5B_QUE8O\=96+_'?),  #?6   RF(  +UI  "S;@  JW   *)P
M  "9;@  DW 0 (]R'P"*<BX!AG([ X)Q10=]<$X+>FY6#G9M7A)S;&45<&MM
M&&UJ=1MJ:7\>9VF*(65HEB-B9Z0E8&>T)E]GR29>9^HE7F?^(U]G_R%?9O\?
M8&;_'F!F_QY@9O\>8&;_'N]/  #:7   QF4  +IM  "P<@  IW4  )UT  "4
M<P  C70- (EV' "%=RL!@7<X WQV0P9X=4P)='14#7%S6Q%N<F,4:W%K%VAP
M<QIE;WP=8FZ'(%]ME")=;*(D6FRR)5ELQR58;.@E66S](UEK_R%::_\?6VO_
M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
MAWD+ (-[& !_?"@ >WPU G=[0 5S>DD(;WE1#&QX60]H=V$3979H%F)U<!E?
M='H<7'2%'UISD2%7<J C57*P)%-RQ213<N<D4W'\(E1Q_R!4</\?57#_'E5O
M_QU5;_\=56__'>57  #-9   OFT  +)U  "H>P  GWX  )-]  "'?0  @'\'
M 'R %0!X@20 =8(R 7&!/01M@$8':8!/"F9_5@UC?EX18'UF%%U\;A=:>W<:
M5WJ"'51ZCQ]1>9TA3WFN(DYYPR)->.4B37?[(4YW_Q].=O\>3W7_'4]U_QU/
M=?\=3W7_'=]<  #(:   N7(  *YZ  "E@   FH(  (Z"  " @P  >84" '2&
M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
M^@"Y /< Q #U -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P
M /\ \ #_ /\>'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(
M6P#_!V8 _P9Q /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U
M / %P #M!<X ZP7D .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!
MY O_ ?\A& #_(1, _R 1 /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\
M#F$ ^0YK /8.=0#T#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J#JH Z ZS .8/
MO0#E#\P X0_C -T0\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3_P+2$_\"TA/_
M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
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M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
MKQJ  *X:B "L&Y  JQN9 *D;HP"G'*X IAR\ *0=SP"A'NH!GA[\ 9P?_P&;
M'_\!FA__ 9H>_P&9'O\!F1[_ ?\B  #_(0  ["<  . J  #4*0  S20  ,H<
M" #$&1( O1PB +<>,0"S(#X KR%) *TB4P"J(UP J"1D *8D; "D)', HR1Z
M *$E@@&@)8L!GB64 9TEG@&;)JH!F2:W 9@FR0*5)^8"DB?Y I H_P*/*/\"
MCB?_ HXG_P*.)_\"CB?_ O\F  #R*0  XS$  -(T  #(-   P#   +LI @"X
M(PX L28< *PH*P"H*C@ I"M$ *$L3@"?+5< G2U? )LM9P&9+6X!F"YU 98N
M?0*4+H8"DRZ0 I$NF@./+J8#C2ZS XPNQ0.*+^$$AR_V!(4O_P2$+_\#A"__
M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. #U_&  \?R, .X M #J -@ Y@3\ .(%(
M #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!H0,J@;8#*8'2 RE_\P,I??\#
M*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78  (5U  !X=0  ;74  &%W  !7
M>@  3'X  $.!   [A0  -8@) #*)$0 QB1L ,(DE "^*+P NBC@ +8M! "R+
M2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$BB[,!(8S. 2&*\0$@B/\"((;_
M B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z  !S>@  9GP  %M_  !0@@
M1H8  #R*   TC0  +)$  ":3#  DE!, (Y0< "*5)@ AE2\ ()4X !^60@ >
MEDP '998 !R69  :EW0 &9>& !B7F0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1
M_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y
M #64   MEP  )9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD,
M$*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -
MG?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>
M   DH@  '*4  !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%
M  "N4@  KF$  *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\
M *O_ ):+  ",D   >Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <
MK@  %+$   ZT   )MP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\
M1P  O%8  +QG  "\>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_
M )"2  "#F   <YL  &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2N@
M#+T   6_    PP   ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@
MS4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9
M  !WH   ::8  %JL  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0   LD
M  #,    T    -$   #2 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H
M .)*  #C70  Y'(  .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !K
MJ0  7*\  $VV   _O   ,+\  "/#   7QP  #\H   ?.    T0   -8   #<
M    WP   .    #B    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z
M  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@
M3[H  $#!   QQ0  (LD  !;.   -T@  !-@   #=    X0   .0   #H
MZP   .T   #O    \0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_
M.P  _T\  /]F  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9
M /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ ((
M_P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #]
M /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\
M%@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$
M /\ B@#] )  _ "6 /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8
M\ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_
M !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /,
MA0#R (L \ "2 .\ F #M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^
M .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !(
M_P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D
M (8 X@", .$ DP#? )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T
M_P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6
M /8 (@#P "\ [  \ .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (
MT "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\
M /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D
M&@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0""
M +\ B0"] )  O "8 +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\
MK03_ *T$_P"M!/\ K03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4
M !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('
MA "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_
M )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8
MP0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E
M$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7
M_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,=
M *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;90"=&VP FQQS )H<>P"8'(,
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M O J  #<-0  QSL  +H_  "L/   HC@  )PS  "8+P  E2X0 ) P' ",,BD
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M/P  O48  *Y'  "?10  E4,  (Y   ")/   A#P* ( ]% !]/B( >C\N 'A
M. !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J07 #:$%Y V=!A 1E09$%8T&?
M!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU _P-=0/\#74#_ ]\Y  #(0P
MN4H  *E+  ";20  D$<  (A$  "#00  ?D$& 'I"$0!V0QX =$4J '%%-0!O
M1C\ ;49' &M&3P%J1E8!:$9= F9&90)D1FT#8D9V!&!&@@1>1HX%7$6<!EM%
MK 991K\'6$;?!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P  M4X
M *1.  "63   BTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG &M*,@!J2SP
M:$M$ &9+3 %D2U,!8DM: F!+8@)?2VH#74MT!%M*?P592HP%5TJ:!E5*J@=4
M2KT'4TK<!U)*]@922O\%4DG_!%))_P-22/\#4TC_ ]1!  # 2P  LE$  *!0
M  "23P  ATX  'Y,  !X2   <DH  &Y+#0!K31@ :$XD &9.+P!D3SD 8D]"
M &%020%?4%$!75!8 EM/8 )93V@#5T]R!%5/?0533XH%4DZ8!E!.J =.3KL'
M34[9!TU.]09-3O\%34W_!$U-_P1.3/\#3DS_ \Y$  "\3@  KE0  )Q3  ".
M4@  @U$  'I0  !R30  ;$\  &A0"P!E414 8U(A &%3+ !?4S8 750_ %M4
M1P!:5$X!6%16 59470)45&8#4E-O U!3>P1.4X@%3%.7!DM3IP=)4[H'2%/5
M!TA2\P9(4O\%2%'_!$E1_P1)4/\#25#_ \I(  "Y4@  JE<  )A6  "*50
M?U0  '93  !L40  9U,  &)4" !?5A( 75<> %M7*0!96#, 6%@\ %991 !5
M64P!4UE3 5%96P)/6&0"35AM TM8> 1)6(8%1U>5!D57I09$5[@&0UC2!D-7
M\@9#5O\%0U7_!$15_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6   >U@
M '%7  !F5@  85@  %U9! !96A  5UL; %5<)@!373  4ETY %%>00!/7DD
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M S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C  !X8P  ;6,  &1D  !990
M4&@  $EK  !#;00 0&X. #YO&  ];R( /' K #IP-  Y<3T .'%% #=Q3@ V
M<5< -'%A 3)Q;0$Q<7H!+W&* BUQG (K<:\"*G'( BIPZP(J;_\"*FW_ BIL
M_P(K;/\"*VS_ K%A  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P  2VX
M $-Q   \=   -W8* #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E(
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M *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^  !"@@  .88  "^*   GC@
M()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &
MFV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!
M  "'?P  >GX  &M^  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T
M !&@   ,HP( !J4*  &E$   I18  *8?  "F*   IC(  *<]  "G2@  IU@
M *=H  "G?   IY$  *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""
MA@  <H8  &.(  !5C   29$  #V6   RF@  *)X  !^B   7I@  $*D   NL
M   $KP   +$&  "Q#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=
M  "U<   M88  +6=  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@
M:I$  %N5  !-F@  0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y
MO0   +X   "^!@  OPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'
M8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X
M %*C  !%J0  .*X  "RS   @MP  %KH   Z]   &P    ,,   #'    R0
M ,H   #,    S0,  ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5
MWFD  -Z!  #>G   W[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS
M   [N   +;L  !^_   4P@  #,8   /)    S    -    #5    V0   -H
M  #<    W@   .    #B!0  Y L  .<0  #J&   [20  / R  #Q1   \E@
M /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   M
MP0  '\8  !/*   +S@   -(   #7    W    .    #E    YP   .D   #K
M    [0   .\   #Q    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=
M  #_=@  _Y$  /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X
M_P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_
M )  _P"6 /\ G #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D
M_P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C
M /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L
M^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L
M /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\
M*P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ",
M .H D@#I )D YP"@ .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#: /\
MV@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X
M #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "& -H
MC0#7 )0 U "; -( I #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_
M ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P
MY0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#%
M (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4
M_P"U /\ M0#_ /\,  #_!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q
M ,T / #* $< Q@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D
MLP"1 +( F@"P *0 K@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E
M /\ I0#_ /\-  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X
M-0"[ $  MP!* +0 4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"-
M *0 E@"C *  H0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\
MEPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N
M!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,
MDP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_
M /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S,
MGQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+
M%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:
M  #D(P  SRD  , J  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX
M )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>;P"%'G< @Q^  ((?BP" 'Y<
M?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A  #;
M*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S (<D
M/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![)W, >2=\ '@HAP!V*), ="B@
M 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI_P%K*/\!:RC_ >@H  #0,@
MP#@  *XW  "A-0  F#(  )(M  ".*0  BR<, (<H%P"#*B, @"LO 'XL.0!\
M+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\ <"]Y 6\O@P%M+Y !:R^= 6DO
MK %H,+X!9S#; 64P]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.   NCT
M *@\  ":.@  D3<  (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T,SX
M<C1& ' T3@!O-54 ;35< &PU9 !J-6P!:#5U 6<U@ %E-8P!8S6: F$VJ0)@
M-KL"7S;6 ETV\P)=-O\"7#;_ 5PU_P%<-?\!7#3_ =PS  #%/   M$$  *)
M  "5/@  BSP  (0Y  !_-@  >S0$ '<U$ !T-QP <3@G &\Y,@!M.3L :SI#
M &HZ2P!H.U( 9SM9 &4[80%C.VD!8CMR 6 [?0%>.XH"7#N7 EL[IP)9.[@#
M6#O2 U<[\0)6._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00  KT0  )U#  "0
M0@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
MR0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\   #[
M  ( ]@ - /$ $P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T
M70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D
M +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D
MW  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R
M %P L !A *X 9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P
M\P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V    YP   -,   #&    O0 #
M +@ #0"S !, L0 < *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4
MFP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ". (X G ", *T B@## (D Z "(
M /\ B0#_ (< _P"% /\ @@#_ /,   #C    S    +P   "P    IP   *$
M" ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4
M (< 60"% &  A !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /<
M> #_ '@ _P!W /\ =0#_ .8   #+    MP   *@   ">    E@   (\ ! "+
M  P B  2 (< &0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '<
M4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_
M &D _P!I /\ :0#_ -(   "X    I0   )<   "-    A@   ($   !\  @
M>0 . '< % !V !P =  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H
M %0 9P!; &4 8P!C &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P
M_P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 ,
M &L $0!I !< :  > &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\
M6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1
M /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$
M#0!? !, 70 : %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2
M %  6@!/ &0 30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\
M1P#_ *P,  "5#@  @Q   '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7
M  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"
M5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_
M *00  ".$@  ?!,  &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P
M3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _
M"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3
M  "'%0  =A<  &D8  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T.
M $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X
M-A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""
M&0  <1L  &0<  !9'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1
M$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H
M "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'
M;1X  & ?  !6'P  3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X
M%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:
M=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$
M %PB  !2(@  2B(  $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!(
M,!T8 "\='P N'24 +1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @
M'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD
M  !/)0  1R4  $$D   \(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5
M "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)((
M&225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,
M)P  1"<  #XG   Y)@  -28  #$E   N)   *R4  "DE!P G)@X )283 "0G
M&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4
M !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@
M0BD  #LI   V*0  ,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =
M+!T '"PD !LM*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XN
MIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP
M #DL   T*P  +RL  "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H
M%C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (
M,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N
M   Q+@  +2X  "DN   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<=
M ! X)  /."P #C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4
M 3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O
M,   *S   "4R   @,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H]
M(0 )/2D "#TQ  8^.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0
M   \\   //\  #S_ &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M,P
M)S0  "(V   =.   &#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$'0
M1"0  $0M  !$-@  1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"
M\   0O\  $+_ &@V  !8-P  3#@  $,X   [-P  -38  # V   I-P  (SD
M !X[   8/0  $T   !!"   -10$ "$<'  -)#   20\  $H3  !+&0  2R
M $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P
M2?\  $G_ &(Z  !4.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!
M   31   $$<   Q)   (3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C
M  !4+   5#<  %1$  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\
M %'_ %P_  !//P  13\  #X^   W/0  +SX  "=    @0P  &48  !-)   /
M3   "T\   92    5    %<"  !8!P  60L  %H.  !;$0  718  %X=  !?
M)@  7S$  %X]  !>3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_
M %9$  !+0P  0T(  #Q!   R0@  *44  "%(   :2P  $TX   Y2   *50
M UD   !;    7@   &    !B @  8P8  &4*  !F#@  :!$  &H7  !K'P
M:RD  &LV  !K10  :U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(
M  !(2   048  #='   L2@  (TT  !M1   350  #ED   A=   !80   &0
M  !G    :@   &P   !N    <    '(%  !S"0  =0T  '<1  !Z&   >R$
M 'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'
M3   .TT  #!/   F4P  '%@  !-<   -80  !F8   !J    ;P   '(   !V
M    >0   'P   !]    ?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD
M  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P
M-%4  "E:   >7P  %&4   UJ   %<    '8   ![    ?P   (,   "'
MB@   (T   ".    D0   ),   "5    F    )H%  "=#   H!$  *,:  "C
M*   HCH  *%.  "@90  H($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$
M "%G   6;@  #G4   5[    @0   (<   "-    D@   )8   ":    G0
M )\   "A    I    *8   "H    JP   *X   "Q P  M L  +@1  "Y'@
MN2\  +A#  "W6@  M78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW
M   /?P  !H<   ".    E    )H   "@    I0   *H   "N    L0   +(
M  "U    MP   +H   "\    OP   ,,   #&    R0   ,X*  #2$P  TB,
M -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (
MD0   )H   "A    IP   *T   "S    N0   +X   #"    Q0   ,8   #)
M    S    ,X   #2    U0   -H   #>    X0   .4   #J"P  ZQ<  .HK
M  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T
M_P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z
M &L ^ !R /8 > #T (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T
M_P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_    _P   /\   #_  8 _P -
M /\ % #_ !\ _P I /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4
MX !J -T <0#: '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[
M /\ L #_ *@ _P"D /\ H0#_ /\   #_    _0   /H   #X    \  ) .P
M$0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C
M ,  :0"^ '  O !X +D @0"W (T M ": +$ J0"N +P K #A *H _ "H /\
MH #_ )D _P"6 /\ E #_ /\   #Y    \@   .<   #;    T0 $ ,H #0#'
M !0 Q  = ,( )@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@
M80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_
M (L _P"( /\ A@#_ /<   #L    W@   ,D   "\    M    *\ "@"K !
MJ0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1
M &$ CP!H (T <0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P
M_P![ /\ >0#_ .D   #7    P0   +$   "F    G0   )< !0"4  T D@ 2
M )  &@"/ "( C@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H
M? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M
M /\ ; #_ -H   "_    K    )X   "3    C    (4   ""  D ?P / 'X
M%0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !:
M &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\
M8 #_ ,4   "M    FP   (T   "#    ?    '<   !R  4 <  , &X $0!L
M !< ;  > &L )0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T
M70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_
M +8   "?    C0   '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@ !,
M7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1
M &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!
M  "4!0  @@<  '0(  !J"   8P8  %X$  !;    60 % %< # !6 !  5  5
M %, &P!2 "( 40 H %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T
M1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*
M"P  >0T  &P-  !A#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L
M%P!* !X 20 C $< *0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D
M #P <@ Z (( .0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@
M<A   &41  !;$0  4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!"
M AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&
M<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,
M %\4  !5%   3A0  $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \"18
M.PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K
M#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7
M  !1&   21<  $,7   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8
M #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(
M(Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-
M&P  11H  $ :   [&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2
M'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161
M !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0
M0AT  #P=   W'   -!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G
M&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:
MHP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R
M #D?   T'P  ,1X  "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T
M(!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0
M'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B
M   R(0  +B$  "H@   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A
M !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0
M"R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O
M(P  *R,  "@C   D(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G
M)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,
M  8G[  ')OX "";_ '$B  !@)   4R8  $@G   _)P  -R8  #$F   M)@
M*24  "4E   B)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .
M+"D #BTR  TM.P ++48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)   L
MZP !*_P  BO_ &TE  !=)P  3R@  $4I   \*0  -2D  "\H   K*   )R<
M ",G   ?*   &RH  !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28
M"#(N  <R-P %,D(  S).  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@
M,/P  ##_ &@I  !8*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K
M   <+   %RX  !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J
M   X,P  .#X  #A*   X6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT
M #7_ &,L  !4+@  2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8
M,0  %#,  ! U   .-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^
M+P  /CH  #Y&   ^5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_
M %XP  !0,0  1#(  #LR   T,0  +C   "DO   D,   'C(  !DT   4-@
M$#D   T[   */0  !4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&*P
M1C4  $9!  !&3P  1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T
M  !+-0  034  #DU   R-   +3,  "8T   @-0  &C@  !0Z   0/0  #4
M  E"   $10   $<#  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\
M $\\  !/2@  3UH  $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'
M.0  /CD  #<X   Q-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*
M    30   $\   !1!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV
M  !91   650  %AG  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0
M/#P  #4[   L/   )#X  !Q!   51   $$@   M+   %3@   %$   !4
M5P   %D   !;    70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F
M/   9DT  &5@  !E=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\
M #!    F0P  'D8  !5*   03@  "E(   -6    6@   %T   !@    8P
M &4   !G    :0   &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0
M=48  '19  !T;P  <XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(
M   @3   %U$  !!6   )6@   5\   !C    :    &L   !O    <@   '4
M  !W    >0   'L   !]    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P
M (A/  "&9@  A8$  (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3   8
M6   $%X   ED    :0   &\   !T    >    'P   "!    A    (<   "(
M    BP   (X   "0    DP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$
M  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2   R50  )EH  !M@   19P
M"6T   !T    >P   ($   "&    BP   )    "4    EP   )D   "<
MGP   *$   "D    IP   *H   "M    L08  +4-  "X%@  MR8  +8Y  "U
M4   M&H  +*)  "PJ@  KL\  *WU #=<   K80  'F@  !-P   +>    (
M  "'    C@   )4   ":    GP   *0   "H    K    *T   "P    LP
M +4   "X    NP   +\   ##    QP   ,L%  #1#@  T1L  - N  #/10
MS5\  ,M^  #)G@  R+X  ,7I "]I   C<   %GD   V!   !BP   ),   ";
M    H@   *@   "N    M    +@   "]    P    ,(   #%    R    ,L
M  #.    T0   -8   #;    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50
M .=R  #EDP  X[,  ./4 /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_
M "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0
M<P#R 'L [P"$ .T C@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_
M *H _P"E /\ H@#_ /\   #_    _@   /P   #\  , _@ + /\ $0#_ !H
M_0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4
M '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P
M_P"8 /\ E0#_ /\   #Z    ]    /$   #R    Z@ % .< #@#B !4 X0 >
M .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L
MM@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+
M /\ B0#_ /D   #O    YP   -\   #/    R    ,$ "@"_ !$ O  8 +L
M(0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J
M )L <P"9 'X E@", )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\
M? #_ .T   #@    T0   +\   "S    J@   *8 !0"B  T H0 3 *  &P"?
M ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8
M:P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_
M -T   #+    M@   *<   "=    E    (X  0"+  H B0 0 (@ %0"' !T
MAP E (0 + "" #( ?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q
M &X ;P!Z &T B0!L )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H
M  "T    H0   ),   ")    @@   'L   !X  4 =@ , '4 $0!T !@ <P ?
M '( )0!P "P ;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8
M8 !R %X @ != )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B
M    D    (,   !Y    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &,
M( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L
M %$ >0!0 (H 3P"> $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4
M@@   '4   !K    9    &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5
M "$ 4P G %( + !1 #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8
M<P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,
M &H$  !A!   6@,  %4!  !2    4  " $X "0!-  T 3  1 $L %P!* !P
M20 B $@ )P!' "T 10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [
M 'X .@"1 #D I@ X +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*
M  !8"P  40H  $P(  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 >
M #\ (P ^ "D /0 N #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H
M,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2
M#@  2PX  $4-  !!#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@
M(  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@")
M "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0
M11$  $ 0   \#P  .0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P
M!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('
MFP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,
M #L3   W$@  -!$  #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\
M*0LE "@,*P G##( )@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9
M#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5
M   S%0  ,!0  "T3   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C
M ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+,
M$1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P
M%P  +!<  "D6   G%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3
M)P <$RX &A,V !D40  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*
M  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;   _&P  -QL  #(:   M&@
M*1D  "88   D&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6
M&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8
MYP )&/H "A?_ &\8  !>&@  4!P  $4=   \'0  -1T  "\=   J'   )AL
M ",;   A&@  'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D
M$1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $
M'/@ !1S_ &L:  !;'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=
M   >'0  '!T  !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N
M  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@
M "#_ &<=  !7'P  2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?   <
M'P  &2   !8A   2(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G
M,P $)ST  R=)  $G5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_
M &,@  !4(@  1R,  #TD   T)   +B,  "@C   D(@  (2(  !XA   :(@
M%R,  !,D   0)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,
M+#H  "Q%   L4P  +&,  "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C
M  !0)0  1"8  #HF   R)@  *R8  "8E   C)   'R0  !LD   7)0  %"<
M !$I   .*P( "RT&  <O"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8
M #)"   R3P  ,E\  #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,
M*   0"D  #<I   O*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P   XN
M   +, $ !S(%  ,T"0  -0P  #8/   W$@  .!@  #@@   X*   .#(  #D]
M   Y2P  .5L  #AN   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+
M/2P  #0L   M*P  *"H  "0I   >*@  &2L  !0M   1+P  #3$   HT   '
M-@   C@$   Z!P  .PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  !
M1P  0%8  $!I  ! @   /YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\
M #(O   L+0  )RP  " M   :+P  %3$  !$S   --@  "3@   4[    /0
M $ !  !!!   0P<  $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@
M25$  $ED  !(>P  2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q
M   J,   (S$  !PS   6-0  $3@   T[   (/@   T$   !#    1@   $@
M  !*    3 0  $X'  !/"P  40X  %02  !5&0  52(  %0N  !4/   5$L
M %->  !3=   4I   %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F
M-0  'C<  !<Z   1/0  #$$   =$    2    $H   !-    4    %,   !5
M    5P   %@"  !;!@  70L  %\.  !B$P  8AL  &(G  !B-   844  &!7
M  !@;0  7XD  %VG  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A/
M&$   !%#   ,1P  !DL   !/    4P   %8   !9    7    %\   !A
M8P   &4   !G 0  :@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O
M90  ;H   &V?  !KP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH
M  Q/   $5    %@   !=    80   &4   !H    :P   &X   !Q    <P
M '4   !X    >P   'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""70
M@78  '^6  !^M@  ?.<  'K_ #]$   S10  *$@  !U,   34@  #%<   -=
M    8P   &@   !M    <0   '8   !Z    ?@   ($   "#    A@   (D
M  "+    C@   )(   "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P
M ):+  "4J@  DM0  )#Z #A+   L3@  (%,  !59   -8    V<   !N
M=    'H   "     A    (H   ".    D@   )4   "7    F@   )T   "@
M    HP   *<   "K    KP   +0)  "X$   MQX  +4P  "S1@  L6   *]^
M  "LH   J\$  *GN #%5   D6P  &&$   YI   %<0   'D   "!    B
M (\   "4    F@   )\   "D    J    *D   "L    KP   +,   "U
MN0   +T   #!    Q@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(
MD@  Q;,  ,/> "EB   <:0  $7$   =[    A    (T   "5    G0   *,
M  "I    KP   +0   "Y    O    +X   #"    Q0   ,@   #,    T
M -0   #:    WP   .0   #J    [@P  .T:  #L+P  ZDD  .AE  #FA@
MY*4  .+& /\   #_    _P   /P  0#\  @ _@ . /\ % #_ !T _P F /\
M, #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_
M .H B0#G )4 Y "C .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\
ME@#_ /\   #[    ]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R
M #, [0 [ .D 0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D
M@ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_
M /H   #Q    Z@   .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P
MR@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L
M (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\
M  #C    V@   -,   #&    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M
M *L - "G #L I !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D
MD "' (X EP", *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0
M    Q@   +8   "I    H0   )T  0"9  H F  0 )@ %@"7 !X E  F )$
M+0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !]
M 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^
MJP   )T   "3    B@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z
M "T =P S '4 . !T #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &<
MA !E )8 9 "K &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP
M (D   !^    >    ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8
M9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6
M (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@
M  !N    9P   &,   !@    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F
M %8 + !4 #$ 4P V %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4
M2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P   !B
M    6P   %8   !3    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H
M)@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2
M #P J0 [ ,< .P#S #L _P [ /\ / #_ ),   !^    ;@   &$   !8
M40   $P   !)    1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _
M "< /@ L #T ,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #(
MH@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208
M $,%  !  P  /@$  #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ",
M-0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H G  I
M +4 *0#< "D ^P I /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*
M   Y"0  -@@  #4%   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D
M "P *@ K #  *@ W "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A *X
M(0#, "$ \P A /\ (@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S
M#0  , P  "X+   M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8
M)P E "T )  T ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#%
M !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0  ! $   .1   #,0   O#P
M+ X  "D.   G#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?
M!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%
MY  2!?H $@7_ '$.  !?$   41$  $82   ]$@  -A(  # 2   K$0  *!$
M "40   C$   (@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D
M&0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -
M#/4 #0S_ &T0  !<$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2
M   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P
M !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0
M!P__ &D1  !8%   2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =
M$P  &A," !D2!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3
M-P -%$  #!1+  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_
M &43  !5%@  2!<  #T8   T&   +1@  "@8   C%P  (!<  !T6   :%0
M&!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )
M&#P !QA'  485  $&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6
M  !2&   11H  #L:   R&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<"
M !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@
M AQ$   =40  '6   !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/
M&@  0AP  #@<   O'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(:
M P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%
M   A3@  (5T  "%O   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0
M/QX  #4?   M'P  )QX  "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .
M'P0 #"$&  DB"@ %(PT  B00   E$P  )1D  "8@   F*   )C(  "8]   F
M2@  )EH  "9L   F@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$
M #(A   K(0  )2   " ?   ='@  &AT  !8>   3'@  $"    XA   ,(P(
M""4%  4G"0  * L  "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L1P
M+%8  "QI   L@   *YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D
M   H(P  (R(  !\A   <(   %R   !,A   0(P  #B0   LF   (*   !"H$
M   L!P  +@D  # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(
M #-E   R>P  ,I<  #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G
M)0  (B0  !XC   9(P  %"0  !$F   .*   "RH   <L   #+P   #$"   S
M!   -0<  #<*   Y#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@
M   Z=P  .9(  #BP   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P
M(28  !LG   5*   $2H   XL   *+P  !C$   $T    -@   #@    [ 0
M/00  #\'  !!"@  0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;  !#
M<0  0HT  $&K  ! T@  /_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H
M !<L   1+@  #3$   DT   $-P   #H    \    /P   $$   !$    1@
M $@#  !*!P  3 L  $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.:@
M388  $RD  !*R@  2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S
M   .-P  "3H   (]    0    $0   !'    20   $P   !/    40   %,
M  !5 0  6 8  %H+  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX
M %B=  !7P   5?(  %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]   (
M00   $4   !)    3    %    !3    5@   %D   !;    70   &    !B
M    90   &@%  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4
M  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[   5/P  #D0   =)    30
M %(   !6    6@   %X   !B    90   &@   !K    ;0   '    !S
M=@   'D   !]!   @0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !Z
MJ@  =]8  '7] #@]   L/@  (D$  !=&   /2P  !U$   !7    7    &(
M  !F    :P   &\   !T    >    'L   !^    @    (,   "&    B@
M (T   "1    E@,  )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0H
MCL4  (SS #%$   E2   &DT  !!3   (6@   &$   !H    ;@   '0   !Y
M    ?P   (0   ")    C0   )$   "3    E@   )D   "=    H    *0
M  "H    K    +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0
M *7E "I/   >5   $EL   IB    :@   ',   ![    @@   (D   ".
ME    )H   "?    I    *8   "I    K0   +    "S    MP   +L   #
M    Q0   ,L   #1!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+
M ");   68@  #&L   %T    ?0   (<   "0    EP   )X   "D    JP
M +$   "V    N@   +P   #     Q    ,@   #+    SP   -0   #:
MX    .8   #K    \08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\
M  #[    ]@   /,   #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ]
M /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$
MX0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R
M    [    .D   #I    [  % /( # #X !( ]P ; /4 )0#P "X ZP W .8
M/@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6
M +H J "W +\ M #H *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E
MW@   -H   #;    W    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"]
M #T N@!$ +< 20"U $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$
MG@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@
M ,<   "\    M@   +   0"O  L K  1 *T & "M "  J  H *0 +P"@ #8
MG0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "&
M *< @P#" (( \ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0   *T
M  "@    F    )0   "1  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U
M (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T
M;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(   ")
M    @@   'P   !Z  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M &X
M,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I
M %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +    "?    C0   '\   !T
M;@   &H   !F    90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !<
M #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T
MN@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-    ?    &X   !E    7@
M %D   !7    50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L
M3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _
M -< /P#_ #X _P ] /\ /@#_ )0   !_    ;P   &,   !9    40   $T
M  !*    2    $< ! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K
M $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8
M- #U #0 _P T /\ -0#_ (@   !T    90   %@   !/    2    $,    _
M    /0   #P  @ \  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4
M+  T #( ,P Y #$ 00 P $L +P!6 "X 8P M ', + "( "P H  K +L *P#J
M "L _P K /\ + #_ '\   !L    70$  %$"  !( P  0 ,  #L"   W
M-    #,    R  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K
M "X *@ U "D /0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "(
M_P C /\ ) #_ '<   !E!   5@8  $L'  !""   .@@  #4'   P!@  +04
M "P#   K  , *@ ' "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H
M(P Q "( .0 A $, ( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ;
M /\ ' #_ ' %  !?"   40H  $8+   ]"P  -0L  # +   K"@  * D  "4(
M   D!P( (P0& ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N
M !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\
M%0#_ &L(  !;"P  30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?
M"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$
M,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_
M &<+  !7#0  20X  #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$
M&0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1
M"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-
M  !3#@  1A   #L1   R$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$
M !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D
M# U%  L-40 )#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0
M$   0Q$  #@2   O$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0
M!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!
M  803@ %$%T  Q!O  $0A   $)P   ^T   .U   #O,   [_ %P0  !-$@
M0!,  #84   M%   )A0  "$3   <$P  &1(  !82   4$0, $A$& !$1"  0
M$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (3
M2P  $UH  !-L   3@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%   /14
M #,6   K%@  )!4  !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D
M#1()  L3"@ )% T !Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   72
M%U@  !=J   6@   %ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8
M   H&   (A<  !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(
M  D6"0 && P  QH.  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4
M !MG   ;?0  &Y<  !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F
M&@  (!D  !L8   8%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:
M"  "' H  !X-   @$   (!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D
M   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D'
M'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@
M(0@  ",+   E#@  )A$  "86   F'@  )R<  "<R   G/P  )DX  "9@   F
M=P  )9(  "2O   CV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P
M !D;   6&@  $AH  ! ;   -'   "QT   @?   $(0   2,"   E!   )P8
M "D)   L#   +@\  "X3   N&@  +B,  "XN   N.P  +DH  "U<   M<@
M+(X  "NL   JU   *?L  "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=
M   4'0  $!X   X?   +(0  !R,   ,E    )P   "D    L 0  +@,  # &
M   S"@  -0T  #81   V%P  -A\  #8I   V-@  -D4  #57   U;0  -(D
M #*H   QSP  ,/H  "__ #\D   T)   *R0  "0C   ?(0  &R   !8@   1
M(0  #B,   HE   &*    BH    M    +P   #(    T    -P   #D#   [
M!@  /@H  $ .  !!$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB
M   ZQP  .?@  #C_ #HH   P*   *2<  ",E   ?(P  &"0  !(E   .*
M"BH   4M    ,    #,    V    .    #L    ^    0    $(   !% @
M1P8  $H*  !-#@  314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%
MOP  0_,  $+_ #8L   M*P  )RD  ",G   ;*   %"H   XM   *,   !#,
M   W    .@   #T   !     0P   $8   !(    2P   $T   !0    4P$
M %8&  !9"P  6Q   %L9  !:)0  630  %A&  !76@  570  %23  !2M0
M4.H  $__ #,P   L+@  )RP  !XM   6+P  $#(   HV   #.@   #\   !"
M    1@   $D   !,    3P   %(   !5    6    %H   !=    8    &,
M  !G!@  :PP  &P2  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P
M %W_ #$S   L,0  (C(  !DU   1.0  "CT   )"    1P   $P   !0
M5    %@   !;    7P   &(   !E    :    &L   !N    <0   '4   !Y
M    ?08  ((-  ""%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W
M #$V   F.   '#L  !)    +10   DL   !1    5@   %L   !@    90
M &D   !N    <@   '8   !Y    ?    'X   ""    A0   (D   ".
MDP   )@&  "<#@  FQH  )@K  "60   DED  )%S  "-E0  B[4  (CH "L^
M   @00  %4<   U-   "5    %L   !A    :    &X   !S    >0   'X
M  "#    B    (P   "/    D@   )4   "9    G0   *$   "E    J@
M +    "W!P  N!$  +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   8
M3@  #E0   1<    9    &T   !U    ?    (,   ")    CP   )4   ";
M    H    *,   "F    J0   *T   "Q    M0   +D   "^    Q    ,H
M  #2    V@H  -86  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17
M!V4   !N    =P   '\   "(    D    )@   "?    I0   *T   "S
MN    +H   "^    P@   ,8   #*    S@   -,   #:    X    .<   #M
M    \P   /0.  #R'@  [S8  .Q1  #H;@  Y)   -^Q
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MZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
ME:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:
M_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'
M?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y<K"_^7-A+_H3X:_ZI&
M)?^P4#3_L5I%_[!D5_>L;6GLIW=[X9Y]BMF6@Y?1CHFBRXB.J\>"D['$?I>W
MP7J<N[YWHK^\=:K"M7&NP[-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S
M<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\'_F1\%_Y<J"O^8-1+_HST:_ZQ&)?^S
M3S3_M%E&_[1C6/:Q;&OJK75]WZ-[C=6;@9S-DH:HQXN*L<*%C[F_@)2^NWR:
MP[EYH<>U=JG*K76LQJMVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$
MJW:MQ*MVK<2K=JW$JW:MQ*MVK<3_FA\$_Y@J"O^:-!+_I3T9_ZY&)?^U3C3_
MMUA&_[=A6?6U:FSILG-_W:AXD-.??J#*EH*LQ(Z'M[Z(C+^Z@Y'%MW^8R[1\
MH<^K>*7/I7FJR*1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FL
MQJ1YK,:D>:S&I'FLQJ1YK,;_FA\$_Y@J"O^;-!'_ICT9_Z]%)?^W3C3_NE=&
M_[M@6?2Y:6WGMG&!W*QVD]"D>Z/(FG^QP).$O+N,B<6WB)#+M(:9SK*&I-&D
M?*31GWVIRIY]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]
MJLB>?:K(GGVJR)Y]JLC_FQ\$_YDJ"O^<-!'_ISP9_[%%)/^Y333_O%=&_KY?
M6?2]9V[GNF^"VK%TE<^H>:;%GWVTOI>!P+F4BL:UD9++KXV8SZJ*H=*>@J/3
MF8&HS)B"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8
M@JG*F(*IRIB"J<K_FQ\$_YDJ"O^=-!'_J3P8_[)%)/^[33/_OU9&_<%>6O/!
M9F_FOVV#V;9SE\VM=ZC$I7NWOJ&#P+:;B<:NE8_,J)&5SZ*.GM*9AZ+3E(:G
MS9.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+
MDX:HRY.&J,O_FQ\$_YDJ"O^>,Q'_JCP8_[-%)/^\3#/_P55&^\1=6O/%96_E
MPVR$V+MQF,RR=:O#K7RVN:6!O[">AL:HF8S+H962T)N2F].4CJ+4CXJFSH^*
MJ,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJH
MRX^*J,O_FQ\$_YHJ"O^?,Q#_JSP8_[5$(_^^3#/^PU5%^<=<6O')9&_ER&J%
MUL%OFLJY=*J^L'JVLZE_OZJBA,:BG8K+FYJ0SY67F=*/E*+4BI"FSHJ/J,R*
MCZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/
MJ,S_G!\$_YHJ"O^@,Q#_K#P8_[9$(_^_3#+\QE1%]LI<6N_-8G#DS6B&T\5M
MFL6\<ZJYM'BUKJU]OJ6G@L6=HHC+E9^.SX^<EM*+G*+3AI6FSH:4I\R&E*?,
MAI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\S_
MG!\$_YHI"O^B,Q#_K3L7_[=$(__!3#+YR5-%\\U:6NS28'#@T&:&SLALFL"_
M<:FTN'>UJ;%\OI^L@<67J(;*D*2,SHJBE=&%HJ'2@9RFSH&:I\R!FJ?,@9JG
MS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\S_G!X$
M_YLI"O^C,Q#_KSL7_[E$(OW#2S'VS%)$\-)96>C:7W#;U62&R<QJF;K#;ZBM
MNW2THK1YO9BO?<.0K(/(B:F)S(.GD<]^IIS0?:2FS7RBJ,M\HJC+?**HRWRB
MJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,O_G1X$_YLI
M"O^E,@__L3L6_[Q$(?K&2S'ST5%#Z]I76>/?76_3VV.%PL]IE['$;:>DO'"R
MF+5TNXZQ>,*&K7W&@*N"RGJIBLUVJ)3.=JFCS'>KJ,IWJZC*=ZNHRG>KJ,IW
MJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,K_G1X$_YPI"O^G
M,@__LSL6_[Y#(/7*2R_NUE!"YN%65]SD6V[+WF.#NM%HE*G';*.;OFZND+AQ
MMX:T=+U^L'C"=ZY\QG*L@\EMJXS*;:N9R6ZLG\=NK)_';JR?QVZLG\=NK)_'
M;JR?QVZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\?_GAX$_YTI"?^I,@[_
MMCH4^L)#'_#.2B[GW4] XNE25]+H6FW!X&* L=1GD:'*:YZ4PVZHB;UQL("Y
M=+9YMG>Z=+1[O6ZR@<!JL(C"9["2PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6
MPV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL/_GQX$_YXI"?^M,0W_NCH3
M],="'>C52BO?Y$P_U^Q15LGN66NWXV%\J-AGBYK/:Y>-R6Z@@\1QIWO =*QU
MO7BP<+M[LVRY@+9HN(:X9+>/N6.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.V
MD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"
M&=_?1RC3Z4Q RO%15;[R6&BMYF%WGMUGA)+5;(^'SV^6?LMSG'C(=J%RQGFD
M;L1\IVG"@:EFP(:L8K^-K6&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYA
MOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZ[_HAT#_Z8G!_^W+PGRQS@-X=A!%-+F
M1BK'\$Q OOA04[+U5V.BZV%PE>-G>XK=;82!V'&+>M1UD'32>9-PT'R6;,Y_
MF6C,@YMDRXB=8<J-GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?
M8,F/GV#)CY]@R8^?8,F/GV#)CY__I!T#_ZTF!?N^+0;FT#0(T^(\%L?N1BN[
M^4H^L/Y/3Z;Z5UR8\6%HC.MH<8/F;GA[XG-]==]X@7'=>X1MVW^':MJ#B6?9
MAHIDUXN,8=:0CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61
MCF#5D8Y@U9&.8-61CF#5D8[_IQP#_[4C ^[))@/5WRD'Q^P\&;KX1"NM_T@[
MH_]-29K_5U2-^6%=A/1J97SP<&IV[79N<>MZ<6WI?G1KZ()V:.:%=V;EB'EC
MY(QZ8>.1?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#C
MDGQ@XY)\8..2?&#CDGS_JQL"]\ = =G<$@''ZR@*NO<[&JS_02F@_T8VE?],
M08W_5DN#_V%2>_UK5W3Z<5QO^'9?;/9[86GU?V-G](-D9?.&9F/RBF=A\8YH
M7_"2:5_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?
M\)-J7_"3:E_PDVK_MQ4!UL\+ ,?J$P*Y]RD-K/\Y&I[_/B:2_T0PA_]+.8#_
M5$!X_V%&<O]J2FS_<$UI_W909O][463_?U-C_X-48?^&56#^B59>_HU77?V2
M6%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-8
M7/V36%S]DUC6Q @ QM0) +CW% 2K_RD.GO\T&)#_.B&$_T$I>O]),'+_4C9L
M_UXZ:/]H/63_;T!A_W1!7_]Y0U[_?41=_X!%7/^$15O_AT9:_XI'6/^/1UC_
MD$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^0
M2%C_D$C$QP< M]L' :G_%@:?_RH-D/\P%8/_-AQW_SXB;O]'*&;_4"QA_UHO
M7?]D,5O_;#-9_W$U6/]U-E;_>396_WPW5?]_-U3_@CA3_X4Y4O^).5+_BCE2
M_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*.5+_
MBCG_DAT$_Y I"?^--1#_F#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!
M=^>.B8+AAH^+W("5D]A\FYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_
MDAT$_Y I"?^--1#_F#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.
MB8+AAH^+W("5D]A\FYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$
M_Y I"?^--1#_F#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+A
MAH^+W("5D]A\FYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I
M"?^--1#_F#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+
MW("5D]A\FYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^-
M-1#_F#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5
MD]A\FYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_
MF#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\
MFYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_F#L7
M_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\FYG4
M>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_F#L7_Z!$
M(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\FYG4>*">
MT76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DQT$_Y I"?^/-!#_FCL7_Z)$(/^I
M32W_JE@\_ZAB3/^D;%SUGW9L[)E_>N21AX;>B8V0V(.3F--^F9_0>IVDS7:B
MJ<MTIZS)<:VOQV^TLL%LN;2\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQ
MO&R[L;QLN[&\;+NQO&R[L;QLN['_E!T$_Y$H"?^1,Q#_G#H6_Z1#(/^L3"W_
MK58]_ZU@3?ZI:E[TI71NZI]]?>&6@XO9CHJ6TX>0H,Z!E:?*?)JMQWB?LL1U
MI;;"<JNYP'"TN[=NM;FS;[BULV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^X
MM;-ON+6S;[BULV^XM;-ON+7_E!T$_Y(H"?^3,@__GCH6_Z=#(/^N2RW_L54]
M_[!?3OVN:%_RJG)PYZ1Z@=Z:@(_5DH><SHN,ILF$D:_$?I>UP7F<N[YVH[^\
M=*O"M&^NPZYRL[RK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MS
MMKBK<[:XJW.VN*MSMKC_E1P$_Y(H"?^5,@__H#H6_ZE"'_^P2BW_M%0]_[1>
M3OVS9V#QKW!RYJEX@]N??I/2EX.ARXZ)K,2&CK7 @)2]O'N:P[IZH\6W>:O'
MK'.LQJ=UL;^E=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE
M=[6ZI7>UNJ5WM;K_E1P$_Y,H"?^6,0__H3D5_ZI"'_^R2BS_ME,\_[==3ONV
M96'PM&YTY*UUAMFD>Y;/FX"EQY*%L<&*B[N]AY3 NX6=Q+:"I,>P?JK(I7>J
MR*%YL,&?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\
MGWJSO)]ZL[S_E1P$_Y,H"?^7,0__HSD5_ZQ"'_^T2BS_N5,\_[I<3OBZ9&+O
MN&QUX[)SB-BI>9G-GWZIQ9B$M+^3C+RXC9/!LXF9Q:Z&H<BJA*G)GWRIRIM]
MKL*9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZR
MO9E^LKW_EAP$_Y,H"?^8, [_I#D5_ZU!'O^U22S_NU(\_;U;3O:]8V+NO6MV
MXK9QB=6N=YO+I7RJPIV#M+F6B;RRD9#!K(R6QJ>)G<BCAZ;*F8"HRY:!KL25
M@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!
ML;[_EAP$_Y0G"?^9, [_I3D4_ZY!'O^W22O_O5$\_+]:3O3!8F+LP6EWX;MP
MB]*Q=)W'J'NJO*"!M+2:A[RLE(W"II"4QJ"-F\F<BZ3+E8:HRY&%K<60A;&_
MD(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%L;__
MEAP$_Y0G"/^:, [_IC@4_[!!'?^X22O_OU$\^L)93O+$86/IQ6AWW;YMC,VT
M<YW"JWFJMZ1^M*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FP
MP(R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,#_EQP$
M_Y4G"/^;, [_IS@4_[%!'?^Z22O_PE [^,983O#(7V/FR&9XV,%KC<FW<9V]
MKW>ILJ=\LZFA@KNAG(C!FIB/QI26ELF0E)_+BY&HS(>.K,:'C;#!AXVPP8>-
ML,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,'_EQL#_Y4G
M"/^=+PW_J3@3_[- '?^\2"K\Q4\[]LE73NW-7F/BRV1XTL1JC,2[;YRXLG6I
MK:M[LZ.F@+N;H8;!E)V-Q8Z;E,B*F9W*AIFHRX*3K,:"DJ_!@I*OP8*2K\&"
MDJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>
M+PW_JC@3_[5 '/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!Y
MLIZK?KJ5IX3 CJ.+Q(BADL>#GYK)@*"GRGV:K,9]F*_!?9BOP7V8K\%]F*_!
M?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!?9BOP7V8K\'_F!L#_Y8G"/^@+PW_
MK#<2_[= &_W!2"CVRTXY[]-43.;96F+8U&%WQ\MGBKG#;)JMO'*GH;9WL9BQ
M?;B/K8*^B*J)PX*HD,9]IYG(>J>ER7>BK,5XG[#!>)^PP7B?L,%XG[#!>)^P
MP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,'_F!L#_Y<F"/^B+PS_KC<2
M_[D_&OG$1R?QSDTXZMM32^#?66#0VE]VP=!EB;/):YFFPG"EF[UUKY&X>[:(
MM8"\@;*&P'NPC<-VKI;%<ZZAQG*MK<1RJ;# <JFPP'*IL,!RJ;# <JFPP'*I
ML,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,#_F1L#_Y@F"/^D+@O_L381_KT_
M&?3(1R7KU$TVY>-02=GC5U_)WUYTNM=DAJS/:9:=QVVCD<!QK(:[=;-^MWJY
M=[1_O7*RA;]ML8W!:K"7PFFQI<%LM+*];+2RO6RTLKULM+*];+2RO6RTLKUL
MM+*];+2RO6RTLKULM+*];+2RO6RTLKW_FAL#_YDF"/^G+0K_M38/^<$_%^[.
M1B/DW$PRW>=/2<_H5E[ Y%URLMYD@J/4:9&5RVV<B<5PI7_ <ZQWO'>Q<+E\
MM6NW@;AGMH>Z8[60NV&UF[QCMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y
M8[>FN6.WIKECMZ:Y8[>FN6.WIKG_FQL#_YLE!_^K+0G_N34-\L<^%>751A_:
MXTDSS^M.2<;M5%VWZEQNJ.)C?9K9:8J.TFV4A,QQFWO(=:%SQ'BF;L)\J6G
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M/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSZ]Q04
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M1/6[7U;MNV=IX[5N?=:L<X_*HWJ=P9N I[B4A["QCXZVJXJ5NZ:'G;ZBA:7
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M+$/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBVQP@$
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M!O^-)@?_FBT*_Z0U#_^L/1?^LD4B]KA,,.V\5$#DN%U1U[)D8\NI;'/ H7.
MMYIZBZ^4@).HCXB;HHJ/H)R'EZ67A*"HE(*IJI&"M:N-@;^KC8'%I(R"RYN,
M@L^5C(+/E8R"SY6,@L^5C(+/E8R"SY6,@L^5C(+/E8R"SY7_@AD#_W\D!O^/
M)0?_G"T)_Z8U#O^N/1;\M44A\[Q++NK!4C_@O%M1T;5C8\:M:G*[I7%_LIYW
MBJF8?I.BDX6:FX^-H):,E:61B9VHC8>GJXJ'LJR'A[^LAH;$I8>&RIR'ALZ7
MAX;.EX>&SI>'ALZ7AX;.EX>&SI>'ALZ7AX;.EX>&SI?_@AD#_X C!?^1)0;_
MGBP)_Z@T#?^Q/!7ZN$0?\+]++>?%43W<P%I0S;AA8L&P:'&VJ6]^K*)UB:2=
M?)*<F(*:E92*H(^1DJ6*CINHAHVEJX.,L*R!C;ZL@(O#IH&+R9V!B\V8@8O-
MF(&+S9B!B\V8@8O-F(&+S9B!B\V8@8O-F(&+S9C_@QD#_X(B!?^3) ;_H"P(
M_ZLS#?^T/!3WO$,>[L1**^3)43O5Q%A/R+Q@8;RT9W"QK6U]IZ=SB9ZB>9*6
MG8"9CYJ(GXF7D*2#E)BH?Y.BJGR2K:MZDKNL>I'#IGN0R9Y\C\V8?(_-F'R/
MS9A\C\V8?(_-F'R/S9A\C\V8?(_-F'R/S9C_@Q@"_X0A!?^5) ;_HBL(_ZTS
M"_ZW.Q+TP$(<ZLE)*.#-3SG0QU=.P\!>8+>X96^KLFM\H:QQAYBG>)"0HWZ8
MB:"%GH*=C:-]FY:G>)F@J769JZISF;BK<YC#IG66R9YVE<V9=I7-F7:5S9EV
ME<V9=I7-F7:5S9EVE<V9=I7-F7:5S9G_A!@"_X<@!?^7(P7_I2H'_[$R"ON[
M.A#QQ4$9Y\]()=O233C+RU5,O<1=7K&^8VZEN&I[F[)OAI*N=H^)JGR6@J>#
MG'NDBZ%VHI2E<:&=IVZ@J:ELH;:I;:'#IF^=R9YPG,V8<)S-F'"<S9APG,V8
M<)S-F'"<S9APG,V8<)S-F'"<S9C_A1@"_XH>!/^:(@3_J"D&_[4P"/; . [K
MRT 5X=A&(-/82S;%T%1+M\E;7*O#8FR?OFAXE+EN@XNU<XR#LGJ3>Z^!F76M
MB9YOJY*B:ZJ<I&BJIZ5FJK2F9JO%I&BFRIQII,V7::3-EVFDS9=II,V7::3-
MEVFDS9=II,V7::3-EVFDS9?_AA<"_XT<!/^>(03_K"<%_;HO!N_'-@KCU#X0
MV-]#'\O>2C2^UE)(L-!:6J3*8&F8QF9VC<%L@(2^<HE[NWB0=+E_E6ZWAYII
MMI"=9;6;H&*TIJ%@M;.A7[;%H&&QS)IBKL^58J[/E6*NSY5BKL^58J[/E6*N
MSY5BKL^58J[/E6*NSY7_AQ<"_Y$: _^B( /_LB4#]< K!.;/,0;8WC@/S.5#
M(,/B23.VWE%&J=A85YS27F60SF1RALMJ?'S(<(1TQG>*;L1^CVC#AY1CPI"7
M7\&;F5S!III;PK.;6L/%FEN^SY5<NM*17+K2D5RZTI%<NM*17+K2D5RZTI%<
MNM*17+K2D5RZTI'_B18"_Y89 O^H'0+^N"$"[,DB MG=)03,Y3<1PNI#(K?G
M2#.LY$]$H.!64Y3=76"(VF-K?M9J=774<'UNTG>#9]%_B&+0AXM>T)&.6M"<
MD%C0IY%6T+625=+'D5;-U(Y6R-:+5LC6BU;(UHM6R-:+5LC6BU;(UHM6R-:+
M5LC6BU;(UHO_BQ4"_YT7 ?^O&0'TP1@!W=@1 ,SE)@7![C<3MN]"(ZOM1S*A
MZTQ ENE538OG75B"YF5A>>1L:7+D=&]LXWQT9^*$>&+BC7M>XI5^6^">@%C?
MIX)5WK&#4]Z^@U+>TH-1V=R"4=G<@E'9W()1V=R"4=G<@E'9W()1V=R"4=G<
M@E'9W(+_CQ,"_Z03 ?ZX$@#6S L S.01 <#O)@>U]3@5JO1 (I_S1C"5\DL\
MC/%41H+P74]Z\&96=/!N7&[O=F%I[WYD9>^&:&'OCFI>[I9M6^V>;UCKI7!6
MZZYQ5.JX<E+JQW-1Z=5S4>G5<U'IU7-1Z=5S4>G5<U'IU7-1Z=5S4>G5<U'I
MU7/_F! !_ZX. -3!"0#)SPD OO 2 K/Y)PJI^S@5GOL^(9/[1"R)^DHU@?I3
M/GGZ745R^F9*;?IO3FCZ=E)D^GY58?J&5U_[CEI<^I9;6OF=75?XI5Y5]ZQ@
M4_>U85+VP6%0]LIB4/;*8E#VRF)0]LIB4/;*8E#VRF)0]LIB4/;*8E#VRF+_
MHPL UK@& ,;$!P"[U D L/P4 Z;_*0N<_S45D/\['H;_0B9]_TDN=?]1-&__
M6SII_V4^9?]N06+_=41?_WQ&7/^#2%K_BTE8_Y-+5O^;3%7_HDU3_ZE.4?^Q
M3U#_NU!/_\-13__#44__PU%/_\-13__#44__PU%/_\-13__#44__PU':KP(
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MC(:,H(B-D9J%E9:6@IZ:DH"GG8]_LYZ-@,*>BX#,FHN!TI**@-B)B8#;AHF
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M.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3C!LP  LKX" *7, 0"9W0,
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MY'B"@N1X@H+D>(*"Y'C_<1H"_WH< _^*'0/_ER,$_Z(I!?RL,0GQLSD/Z+I
M%]V\2"7/ME(XPZ];2+FH8E:OHFIBIYQP;)^7=W68DWY\DI"&@HR-CH>'BI>+
M@XB@CG^'JY%\A[F1>X?+D7R(V(E]A]Z"?8;D>GV&Y'E]AN1Y?8;D>7V&Y'E]
MAN1Y?8;D>7V&Y'G_<1H"_WP: _^-' /_FB(#_Z4H!/FO+P?NN#<,Y+\_%-C
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M7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7$KC\USYF0, U*P" ,6W! "YPP4
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M:E>O\6=7K_%G5Z_Q9U>O\6=7K_%G5Z_Q9U>O\6?_?PX!_Y,+ .&E!0#2LP<
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M_U*F:?]2IFG_4J9I_U+_6R "_V<< O]T&@+_?R #_X@G!/^.+P?]DC<,])1
M%.R521[DD%4JVXI?-]&$:4/*?7),Q'A[5+]T@UJZ<8M?MFZ39+-KFV>O::1J
MK6>M;*IFN&ZH9L=OI6;?;Z5J\6BB:_9AH&SY6YYL_5:>;/Y5GFS^59YL_E6>
M;/Y5GFS^59YL_E7_7!\"_VH: O]W&0+_@Q\#_XPE!/^2+0;YES4+[YD^$N>;
M1AS>EE(ITI!<-\J)9D+#@V],O'YW5+=Y?UNR=8=@KG*/9:IPEVBF;9]LHVRI
M;J!KM'">:L)QG&K7<9QN[FN:;_-DF6_X7I=P_%B7</U7EW#]5Y=P_5>7</U7
MEW#]5Y=P_5?_7AX"_VP9 O]Z& +_AAT"_X\C _^6*P7UFS,)ZY\[$.*@11G7
MFU HS)1:-L2-8T*\B&Q,M8)T5+!^?%NK>H1@IG>+9:)TDVF><IQMFW"E<)AO
ML'*5;KUSDV_0<Y1RZVZ3<_)FDG/V8)!S^EJ0<_M9D'/[69!S^UF0<_M9D'/[
M69!S^UG_7QT"_VX7 O]]%P+_B1P"_Y(B OV:*03QH# 'YZ0Y#=ZE0Q?1GTXG
MQYA8-;Z284&VC&E+KX=Q5*F">5ND?X!@GWR(99MYD&J7=IEMDW6B<9!SK'.-
M<[ITBW/+=8QVYW",=_!HBW?U8HIW^5R*=_I:BG?Z6HIW^EJ*=_I:BG?Z6HIW
M^EK_81L"_W$6 O]_%@'_BQH!_Y4@ OF>)@/MI"X%XZDV"MBI0!;,HTPFPIQ6
M-+F67T"QD&=*JHMO4Z2'=EJ>@WY@F8"%991]C6J0>Y9NC'F?<8EXJG2&=[9U
MA'?'=H5ZY'*&>^]JA7OT9(5[^%V%>_E<A7OY7(5[^5R%>_E<A7OY7(5[^5S_
M8QH"_W,4 ?^!%0'_CAD!_YD> ?:A(P+JJ2H$X*\R!]*L/A7'IDLDO:!5,[2:
M7C^LE65*I9!M4IZ,=%F8B'M@DX6#98Z"BVJ*@)-NAGZ=<8)]IW1_?+1V?7S%
M=GU^X'-_?^YK?W_S97]^]UY_?OA=?W[X77]^^%U_?OA=?W[X77]^^%W_91@"
M_W43 ?^$% '_D1<!_YP; ?*E( 'FKB8"V[0N!LZO/13#JDDCN:13,:^>7#ZG
MF61)H)1K49F0<EF3C7E?CHJ 9(F'B&F$A9%N@(.:<7R"I71Y@;)V=X'"=G:"
MW71YA.UL>8/R9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1
M ?^'$P'_E!4 _I\8 .ZJ' 'BLR$!U;<J!<FS.Q.^KD@BM*A2,*NC6CVBGF)'
MFYEI4)25<%B.DG=>B(]^9(.-AFE^BX]M>8F8<7:'HW-RAJ]U<(:_=F^'UW5S
MB>UM<XCR9G2']F!TA_=?=(?W7W2']U]TA_=?=(?W7W2']U__:14!_WH0 ?^*
M$0#_EQ( ^:,4 .JN%0#=N1< S[HH!,2W.1&YLD8@KZQ0+Z:G6#N=HV!&E9]G
M3XZ;;E:(F'5=@I5\8WV3A&AXD8QL<X^6<&^.H')LC:UT:HV]=6F-TG5LD.UM
M;8[Q9VZ,]F!NC/=?;HSW7VZ,]U]NC/=?;HSW7VZ,]U__;!,!_WT/ ?^-$ #_
MFQ  ]*@/ .6U#0#5OQ  RKXF [^[-Q"TMD0>JK%.+:&M5SF8J5Y$D*5E38FB
M;%6"GW-;?)QZ87>:@69RF(IJ;9:4;FF5GG%FE*MS8Y2Z<V*5SW-FE^QL9Y7Q
M9FB3]F!HDO=?:)+W7VB2]U]HDO=?:)+W7VB2]U__;Q$!_X$. /^1#@#RH P
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M55"Z_E50NOY54+K^55"Z_E7_A0( W9@  ,VF @#!L0, M[H# *[&!@"GTPH
MH-T5 )G=* 20VS<.AME"&7W62R1UU%0M;=)<-6?18SQAT&M!7,]R1EC/>TE4
MSH1-4,Z/4$W.FU)+SJE32<ZY5$C/SU1(SNM32<[X4$K+_TY*RO]-2LK_34K*
M_TU*RO]-2LK_34K*_TWGCP  T9\  ,.K 0"WM ( K;\# */+!@";V0H E.4:
M 8WE*P:$Y#4->^,_%G/B2!YLX5(F9N%:+&#@8C);X&HV5^!R.E/?>SU0WX5
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M,P8Z_SD'-O] "#/_10@P_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^
M#1[_C X=_Y<.'/^A#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O
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M8/] NF#_0+I@_T#_4B$"_UX= O]I&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O.
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M6WB"_E9Y@?]1>8'_47F!_U%Y@?]1>8'_47F!_U'_91,!_W4. /^##@#_D X
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M4F&8_U)AF/]289C_4F&8_U+_<@L _X,% -^3 0#1GP0 R:H& ,&R!0"[O00
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M(3CXM2(W^<@B-OGC(C;X\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@
MJ:X  )RY  "0Q   @\\  '?;  !O]@H 9_\3 6#_'0):_R<#5/\P!4__. A*
M_T *1O](#$/_3PY _U8//?]>$#O_91(X_VX3-O]W%#3_@A4R_X\6,/^;%R__
MJ1<N_[<8+?_(&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4
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M_V$4 ?]L$@'_=A<!_WT< ?^#(P+TABP$ZH@U!^&'0 [6@DP9S7U8),9W8BW
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M3HET_TF)=/]$B'3_0XAT_T.(=/]#B'3_0XAT_T/_71(!_VL. /]X#@#_@P\
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M1W*$_T=RA/]'<H3_1W*$_T?_9@T _W4' /:#!0#<CP, TI@& ,RA!P#(J @
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M/$3%P3Q#Q=\\1,3S.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP
MQ9H  +>D  "KK   H+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ EC
MUD807M90%5G56!I5U& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5
MPC$_U>$P/]/R,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$
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M$2?_X1$F__(1)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0
M<-,  &3>  !8YP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P
M_T8%+?]-!2O_5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_
MP L:_]8+&O_?"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X
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M,+MB?36X8(4XM5Z-/+)<E3ZO6YU!K5JF0ZM9KT2I6;Q%IUC,1J18Y4:D6_9
MHU[_.Z-?_S>C8/\SHV'_,:-A_S&C8?\QHV'_,:-A_S'_4Q4!_UT0 /]H#P#_
M<!( _W<6 /M\' 'N?R0!Y( M ]I_.PC/>DD2QW54&\%Q7R2[;6@KMFIP,;)G
M>3:O98 ZJV.(/:AAD$"F8)A#HUZA1:!>JT>>7;=(G%W&29I<WTF:7_)$FF+_
M/IIC_SF;9?\VFV7_,YME_S.;9?\SFV7_,YME_S/_51,!_V . /]K#@#_=!
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M.H!U_SJ =?\Z@'7_.H!U_SK_70X _VH& /]V!@#D@ , V8D& -*/" #/E H
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M1U&;ND=0F]%'49ON1%.;_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ=
MV8,  ,B0  "^F@  LZ$  *JG  "AK@  E[4& )*V& ",M2H#A;0W"7ZR0A%W
ML$P8<:Y4'VRM6R5GJV(J8JII+UZI<3-:J'HW5J>#.E.FCCU0IIM 3:6I04NE
MND)+IM%"2Z7M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD
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M)3O,^R4[R_\E.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=K@
MD;8  (6_  !YQP  ;\X$ &36"0!>WA$ 6]X@ %?>+0)3WSH$4-]$!DS?3@E)
MWU<,1M]?#T/?:!%!WW$3/M]\%3S?B1<ZX)89.."E&C?@MQHVX<T:-M_L&C7>
M^1HTW?\;--S_&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X
M 'G'  !MSP  8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'
M/>U8"3KM8 HX[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L
M[/X1+.O_$"SK_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/
M  !@V   5=X  $[S"@!*]Q, 1O@= $/X)P$_^# "._DX CCY0 ,U^D<$,_I/
M!3#[5P4N^U\&*_QI!RG\= @G_(())?V0"23]H HC_K *(O[$"R'_X LA_?(*
M(/S\"B#\_ H@_/P*(/S\"B#\_ JBIP  E;$  (>[  !YQ@  ;,\  %_9  !2
MWP  2.@  $/_"  __Q  ._\9 #?_(0 T_RD!,/\P 2W_-P(J_SX")_]$ B7_
M2P,B_U,#(/]< QW_9@0;_W($&?^ !1?_CP46_Y\&%?^O!A3_P 84_]8&$__I
M!A/_Z083_^D&$__I!A/_Z0:7KP  B+H  'K%  !LSP  7MH  %#@  !$Y@
M//4  #?_!  S_PT +_\3 "O_&@ H_R$ )?\G 2'_+0$>_S(!&_\X 1G_/P$6
M_T8"%/]- A'_5@(0_V "#O]L @S_>P,+_XL#"O^: PK_J ,)_[4#"/_" PC_
MP@,(_\(#"/_" PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\
M "S_   G_P< (_\. "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!
M"O\^ 0C_1@$%_T\! ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@(
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M1((5]D.,%_1"E!CS09P9\4&C&^] JAON0+(<[3^['>L_QA[I/]4>Y3_H'^)
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M*K-1_R>S4O\DLE+_(K)2_R*R4O\BLE+_(K)2_R+_2A4!_U,1 /];#P#_8A(
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M+(YE_RR.9?\LCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9?PP
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M_S'_7P( ]VP  -YW  #0@0  QX@! ,"- P"YD0, LI,1 *N3(P&CD3,&G(Y
M#96+2A6/B%,<B89;(H2#8BB @6DM?']P,7A^=S5T?( X<7N)/&YZDS]K>9Y"
M:'BK1&9XNT5D>-%%9GGN0&A[_3IJ>_\V:WS_,FM\_S)K?/\R:WS_,FM\_S+_
M80  ZF\  -EZ  #,A   PXL  +N1 0"TE0$ K)<. *67(0&>EC$%EY,^#)"0
M2!2*CE$;A(M9(7^)8"=[AV<K=X5N,'.$=31O@GTW:X&'.VB D3YE?YQ!8GZI
M0V!^N41??L]$8'_L0&* _#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9
MY7(  --^  #'AP  OH\  +:5  "NF0  IIL, *"<'@"9FRX$DID["HN61A*%
ME$\9?Y%7'WJ/7B5UCF4J<8QL+FV*<S)IB7LV9HB$.6*&CSU?A9H_7(6H05J%
MMT)9A<Q"6H7J/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8
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M-4F@^3)*G_\P2Y__+DN?_RU+G_\M2Y__+4N?_RW=>0  R88  +R2  "QF@
MIJ   )RF  "1K   AK(  'VV#0!YMAT =;8L F^U.09JM$,+9;-,$6"R5!9<
ML5L:6+!C'E6O:R%1KW,E3JY]*$NMB"I(K94M1:VC+D2MLR]#K<@O0JSG+T.K
M^2U$J_\K1*K_*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4
M ).L  "(L@  ?;@  '&^!@!NOQ4 :K\F 6:_,P-AOC\'7;Y("UF]40]5O5D3
M4;Q@%TZ\:!I+NW$=2+M['T6ZAR)"NI0D0+JB)CZZLR8]NL@F/;KH)CVX^24]
MM_\D/;;_(SVV_R,]MO\C/;;_(SVV_R/'B   N94  *R=  "AI   EJL  (JR
M  !_N0  <[\! &C&!0!@R@X 7LH= %O*+ %7RC@#5,I#!5#*3 A-R54+2LE=
M#D?)9A%$R6\40<EY%C_(A1@\R),:.LBB&SG)LQPXR<D<.,CH'#?'^1PWQ?\<
M-L3_'#;$_QPVQ/\<-L3_'#;$_QR^D0  L)L  *2C  "8J@  C+(  ("Y  !T
MP   :,<  %W-!0!3TPH 3]<2 $W8(@!+V#  2=@\ D;81@-$V4\$0=E8!C_9
M80@\V6L*.MEV##?9@@XUVI /--J@$#+:L1$QV\<1,=KG$3#8]A(PUO\3+]3_
M$R_4_Q,OU/\3+]3_$R_4_Q.SF@  IJ$  )JI  "-L0  @+H  '3!  !HR0
M7,\  %+5 P!(W @ 1>42 $/E'@!!YBH /N8U 3OG/@$YYT<"-^=0 S3H600R
MZ&(%,.AM!B[I>0<LZ8<(*^J6"2GJIPHHZKH*)^O6"B?I\ HGY_T))N;_"B;F
M_PHFYO\*)N;_"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<
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M 0#_R@&&MP  =\$  &C,  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P
M&_\% !?_#  4_Q  $?\4  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0
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M0),6X#^;%]\_HAC=/JH9VSZS&M@^O1K6/LH;TC[?&\X^[QO+/_L:R4#_&,=
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M'J)2_QVB4O\=HE+_':)2_QW_2@\ _U(* /]:"0#_8 L _V4. /5G$0#H:!@
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M.6YJN3IM:LXZ;6OK-V]M_#%P;O\M<6[_*G%O_RAQ;_\H<6__*'%O_RC_60
MZV4  -MP  #->   Q'X  +R" 0"VA $ KH4. *>&( "@A3 #FH(]"). 2 ^.
M?5$5B7M9&H1Y8!^ =V<C?'5N)WET=2IV<WTN<W*&,7!QD#1M<)PW:F^H.6AO
MMSIG;\LZ9W#I-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@
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M7'KE-UY[^#)?>_\N8'S_*V%\_REA?/\I87S_*6%\_RGU8@  WF\  ,QZ  #
M@P  MXD  *^.  "FD0  G9(& )>3%P"1DR@!BY(V!86000M_CDH1>HQ2%G6*
M6AMQB&$?;8=H(VJ&;R=FA'<K8X. +F""BC%=@98T6H&C-EB LC=6@,4W5H#C
M-EB!]S%9@?\M6X+_*EN"_RE;@O\I6X+_*5N"_RGL9@  V',  ,=^  "\AP
MLXX  *F2  "@E0  EI@! )"9$P"*F20!A9@R!'^6/@EYE$@.=)-0%&^15QEK
MD%X=:(YE(62-;25@C'4H78M^*UJ*B"Y7B90Q5(FA,U*(L#11B,,U4(CB-%*(
M]C!3B/\L5(C_*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(
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M(4"D_R! I/\@0*3_($"D_R#*?@  NXL  *^5  "DFP  F:$  (ZF  ""K
M=[$  &JV  !CN X 8;@= %ZX+ %:N#@"5[A"!5.X2PA0MU,+3;=;#DJV8Q!'
MMFL31+5U%D*U@1@_M8X:/;6<'#NUK!PZM< =.;7?'#FS]!PYLO\<.;'_&SFP
M_QLYL/\;.;#_&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@
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M!1_@_P6DG@  F*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW
M+^4' "WM$  K[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9
M\W$!&/.! 1?TD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P
M_P*:I   C:T  '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0%
M "3[#0 A_!, 'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$
M#/]O 0S_@ $*_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/
MK   @+8  '*_  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_
M"0 6_PX %/\3 !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<
M  #_:P  _WT  /^0  #_HP  _[0  /_&  #_U@  _]8  /_6  #_U@""M0
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M+'U:NRU\6L\N>UOL*WQ<_"9\7?\B?5[_'WU>_QU]7O\=?5[_'7U>_QW_4
M]5D  .%C  #2:@  R6X  ,)P 0"]< , MG 0 *YQ(@"H<#("H6X_!IQL2@N7
M:E,0DFA;%(YF8AB+96D;B&-P'H5B>"&"88 D@&"))GU?DBE[7ITK>%ZI+79>
MN"YU7LPO=%[I+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P
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M+V1L]BIF;?\F9FW_(V=N_R!G;O\@9V[_(&=N_R#V60  X&4  ,YO  #"=@
MN7P  +%_  "I@   H( ' )F!%P"4@2@!CH U XA^00B#?$H-?GI2$7IX615V
M=V 9<W9G''!T;A]M<W8C:G)_)F=QB2ED<94K8G"A+6!PL"]><,(O77#?+U]Q
M]2I@<?\F87+_(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8
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M(E"#_Q]0@_\?4(/_'U"#_Q_>:0  R74  +R   "RB   J(T  )V1  "3DP
MA98  'Z7"P!YEQD =9<H 7&7-0-LEC\&:)5("F244 UADU<179)>%5J19AA7
MD&X;5(]W'E&.@2!.CHTC2XV:)4F-J29(C;LG1XW4)T>,\"1(C/\B28O_($J+
M_QY*B_\>2HO_'DJ+_Q[5;@  PWL  +>%  "LC0  HI(  )>6  ",F0  ?YP
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M%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(  %RV  !0N@$
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M 1S?F0$:WZP!&=_$ 1C>YP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@G
ME*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP  *=D  "'>!0 >
MZ X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW !#N
MB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L
M 'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL
M%/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P
M_8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]
M  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,
M  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4
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M')1(P1V22-@=D$GO&X]*_AB/2_\6CDO_%(Y,_Q*.3/\2CDS_$HY,_Q+_10
M_TL  .E3  #>6   TUL  ,U;! #*6 < PE@5 +I:)P"S6C<!KEA$!*E73P>D
M55@*H51@#9Y3:!";46\3F%!V%990?A>43X89DDZ.&H].F!R-3:(=BTVN'XI-
MO""(3= @ATWK'X9/_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\
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M)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D  --B  #':
MO6P  +9M  "O;   IVL+ *!L&0";;"H!E6LW I!I0P6+:$P)AV94#(-E6Q"
M8V(3?6)I%7IA<!AX87@:=6"!'7-?BQ]P7I8B;EZB)&Q>L"5K7L$F:5[>)FI?
M]"%K8/\=:V'_&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E  ##:P  N6\
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M'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL  *9^  "=?@
MD7P  (I\#P"%?1X @7TM 7Q\.0-W>D,&<WE+"7!X4PQL=UH0:79A$V9U:!9C
M=&\887-X&UYR@AY;<HT@67&:(E=QJ"15<;DE5''0)51Q[B)6<?X>5W'_'%=Q
M_QI8<?\96''_&5AQ_QGC7@  S6D  +]S  "T>@  JW\  **"  "8@P  BX$
M (2!#0!_@AH >X(I 7:!-@)R@4 %;G])"&I^4 MG?5<.9'Q>$6%[9A1>>FT7
M6WIV&5EY@!Q6>(L?4WB8(5%WIB)0=[<C3W?.(T]W["%0=_T>47?_&U)W_QE2
M=_\94G?_&5)W_QG>8@  R&X  +MW  "P?P  IX0  )V'  "2AP  A(<  'V'
M"0!XB!8 =(@F '"(,@)LAST$:(9&!F6%3@EAA54,7H1<#UN#8Q)9@FL55H%T
M%U. ?AI0@(D<3G^6'DQ_I2!*?[8A27_,(4E^ZQ]*?OP<2W[_&DM^_QE,?O\8
M3'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0  ?(T  '6.! !O
MCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3BV@24(IQ%$V)
M>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&_Q=%A?\7187_
M%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94  &R7  !FEPX
M8Y@; &&8*0!>F#4!6I<^ U>71P55ED\'4I96"4^57@Q,E&8.2I1O$$>3>1-$
MDX450I*3%T"2HA@^DK,9/9+)&3V1Z1@]D/H7/H__%CZ/_Q4^C_\5/H__%3Z/
M_Q7%<P  MW\  *R)  "ACP  EI,  (N6  !_F0  <YP  &2?  !<H D 6: 4
M %>A(@!5H2\ 4J$Y 5"A0P)-H$L$2J!3!4B@6@=%GV,)0Y]L"T">=@X^GH,0
M.YZ1$3F=H!(XG;(3-Y[($S>=Z!(VF_H2-IK_$C:9_Q$WF?\1-YG_$3>9_Q&^
M>P  L8<  *6/  ";E   D)@  (2<  !WH   :Z0  %^G  !2J@  3:L. $NK
M&@!*JR< 2*LS $:K/0%$JT8!0JM. D"K5@,^JU\%.ZMH!CFJ<P@WJH )-*J/
M"S*JGPPQJK ,,*K'##"IYPPOI_H-+Z;_#2^E_PTOI?\-+Z7_#2^E_PVVA
MJHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@  0;4& #ZV$0 ]
MMAX .[8I #JW-  YMSX -[=' #:W4 $TMUH!,K=D C"W;P,NMWP$++>+!2JW
MG 4IMZX&*+C%!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0  HI0
M )>:  "+H   ?J8  '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 MPQ(
M+,,> "O#*0 JQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?
MQJL!'L?! 1[&Y $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH  (ZA
M  "!IP  <ZX  &>T  !:N0  3KT  $+    XPP  +\<  ";+!  >T H &]$1
M !K2&@ 9TB4 &-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1V*0
M$-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !U
ML   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C
M$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K
M  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0
M6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '
M\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #S
MK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD
M $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!  #\"   ^PT
M /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F
M_ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(  #+9
M   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_    _P0  /\)
M  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@   _Y4
M /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*-@#_
M!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F /\
MK #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\ _0#_
M /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I /\.,@#_#$
M_PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP _P*B /\"J #_
M J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W _\ ]@3_ /8$
M_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5+P#_$CP _Q!)
M /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ? /\*I0#_"JL
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M"+,RS FQ,N4)K3/U":LS_PFJ,_\(J#/_!Z@S_P>G,_\'IS/_!Z<S_P?_-P<
M_SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$  Q#Q- < \6 *\
M.V$#N3MJ!;8Z<@:T.GH'LCF!"+ YB FO.9 *K3B8"JLXH0NI.*H,J#BV#:8X
MQ0VD.-X.H3GQ#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ_PG_.P( _SX
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M&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L  -U3  #.6
MQ%H  +U:  "X5P$ L50. *I6'@"E5BX GU8[ 9M51@.75% %DU-8")!27PJ-
M468,BU!M#HA/=!"&3WP2A$Z%$X).CA6 39D7?DVD&'Q-LAEZ3<,:>4W?&GA.
M]!=X3_\4>$__$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\  -97  #(7   OU\
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M%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH  *ML  "B:@
MF6<" ))G$0"-9R$ B&<O 81F.P)_940$>V1-!GAC5 EU8EL+<F%A#7!A:0]M
M8' 2:U]Y%&E?@Q=F7HX99%Z:&V)>J!QA7K@=7U[.'5]>[!M@7_T885__%6%?
M_Q-B7_\28E__$F)?_Q+J40  U%P  ,1D  "Y:@  L&X  *=P  ">;@  E&L
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M$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@  'IY!P!U>10
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M$T*#G11 @JX5/X/"%3Z"XA4_@?<3/X'_$D" _Q% @/\00(#_$$" _Q#&:P
MMW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD 6I 4 %B0(0!6
MD2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM C7\-/HV-#SR-
MG! ZC:P1.8W!$3B-X1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT
M *>&  "<B@  D8X  (:1  !ZDP  ;94  %^7  !4F0$ 3YD/ $Z:&@!,FB<
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M B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'G
M>J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T (KT5 "&](  A
MO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V !3
MTP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH
M &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L
M$,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (
MSN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y
M  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;
M  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X
M .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]
MQ0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P  XPT  .02  #E
M&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1
M  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@
M)-(  !K8   2W   #.    7C    YP   .L   #K    [04  .X+  #P$
M\14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^
MR0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4   BV@  %]X
M !#B   )Y@   .D   #L    \    /8   #V    ]P   /@   #Z!P  ^PT
M /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@
M_[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\
M7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U
M /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\
M^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_
M &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T
MN0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_
M /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\
M_P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4 M0#S
M +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_ .D!
M_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H _PAF
M /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#_XO__
M24-#7U!23T9)3$4 " GJ!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_
M -T,_P#<#/\ W S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\
M_Q0[ /\220#\$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F
M#J  Y ZG .(.KP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3
M_P'*$_\!RA+_ <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU
M /4:0@#O&$\ ZA=: .8690#C%FX X!9W -X6?P#<%H< V1:. -86E0#4%IP
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M!*(L_P3_,@  _S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL
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M#8D^LPV(/L0.AC_@#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/
MZT,  -Q*  #,3P  PU   +Q.  "W20$ L48. *I(' "D22P H$DZ )M)10&8
M2$X"E$=7 Y)'7@6/1F4&C49L!XM%<PF)17L*AT2#"X5$C0R#1)<.@4.B#W]#
MKQ!^0\ 0?$3:$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@
M --/  #'5   O54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"
MC4U3!(I,6@6'2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U
M2+P2=$G2$W-)[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3
M  #!6   N%H  +!9  "I5@  HE(' )M2%0"64R0 D5,R (U3/@&)4D<"AE%0
M!(-15P6 4%X&?D]E"'M/; EY3G,+=TY[#75-A0YS39 0<4V<$F]-J1-N3;D4
M;$W.%&Q-ZQ-L3OT0;$__#FQ/_PQL3_\+;$__"VQ/_PON10  W%   ,E7  "]
M7   M%X  *Q>  "D6P  G%8$ )56$@"05R$ BU@O (=7.P&#5D0"?U9- WQ5
M5 5Z5%L&=U1B"'53: ES4W +<5)X#6]2@@]M48T1:U&9$FE1IA1G4;859E'+
M%652Z11E4OL19E/_#V93_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P
ML&(  *AB  "?7P  EEH  (]:$ "*6QX A5LL (%;. %]6T$">EI* W=9401T
M6%@&<5A?!V]79@EM5VT+:U9V#6E6?P]G58H19567$V-5I!1A5;058%7(%E]5
MYQ5@5OH28%;_#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68
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M$%)B_PY28O\-4F+_#5)B_PW95@  Q&   +=H  "L;@  HW$  )IS  "/<0
M?VL  'AK!0!R:Q( ;FP? &ML+ !H;#<!9FQ  F-K2 -@:T\$7FI6!EQJ70=9
M:64)5VEM"U5I=PU3:((/4&B/$4YGG1--9ZP42VC %$MHWA1+9_423&?_#TQG
M_PY-9_\-36?_#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$
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M"SIZ_PO :0  LG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$
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M B>>D (FGJ$"))ZU B.>S@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0
MH(@  )6.  "+D@  ?Y8  '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 I
MJ0\ **D8 ">J(@ FJBP ):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VK
MBP ;JYT &JNQ !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\
M (^4  "#F0  =9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08
M&;</ !BW%P 7MR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /
MN9< #KFL  VYQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;
M  !YH   :Z8  %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&
M  O&#@ *Q14 "<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL
M ,:@  #%M@  QM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !M
MJ0  8*\  %.T  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0
M"@  T!   - 6  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2
M  #6IP  UK\  -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@
M5+D  $:]   YP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P
MW0H  -X/  #?%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #I
MF   Z:T  .G%  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(
M #G&   LR@  (,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $
M .H'  #K#0  [1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA
M^IL  /JO  #ZP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0
M   ?U   %-H   W?   %XP   .8   #I    [0   .\   #Q    \P   /4
M  #V @  ^ D  /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4
M /^:  #_JP  _[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_
M #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\
MI #_ *H _P"P /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_
M /H _P#Z /\ ^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H
M_P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #]
M *8 _ "L /L M #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /
M_P#P /\ \ #_ /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!#
M /\ 4 #_ %P _P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *(
M\P"H /$ L #P +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E
M /\ Y0#_ .4 _P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\
M2P#_ %< _@!B /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D
M .8 K #D +0 X@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\
MU0+_ -4"_P#_'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X
M!E$ ] 1< .X$9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%
MJ #5!;$ T@6[ - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_
M ,4,_P#_(0P _R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH
MY0U6 .$-8 #=#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(
M#JX Q@^Y ,00R #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83
M_P'_)08 _R,  /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/
M ,X560#+%6, R!9K ,46<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D
MMQFT +4:P@"T&M8 L!OM :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_
M*   _R<  /XJ  #O*@  YR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@
M4P"\(5T N2%E +<B;0"U(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O
M :<CO &F),X!HR3H J E^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+
M_RT  .TR  #B-   VC,  -,N P#2)0H R247 ,$G)P"[*38 MBI# +(K3@"O
M*U< K"M@ *HK9P&H*V\!IBMV :0K?0&C*X0"H2N- I\KE0*>*Y\"G"NJ YHK
MM@.9+,<#ERSB Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,
M .0Z  #6/0  S#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U(
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M2@  O$L  +5)  "O0P  J3X+ *(_%P"=0"8 F$$T )1!/P"104D!CD%1 8M
M60*)0& #AT!G X4_;02#/W4%@3]]!G\^AP=]/I$(>SZ<"7H^J0EX/K@*=S_-
M"G4_Z@IT0/P(=$#_!W1 _P9S0/\&<T#_!G- _P;Q.P  WT4  ,Q,  "_3P
MME   *Y/  "G2@  H$0' )I%% "51B( D$8P (Q'/ ")1D4!AD9. 8-&50*!
M15P#?D5C!'Q$:@1Z1'$%>41Y!G=$@@AU0XT)<T.9"G%#I@MP0[4,;D3)#&U$
MYPQM1?H*;$7_"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54
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M"EM2_PE;4?\(6U'_"%M1_PC?2@  R5,  +M:  "P7P  IF$  )UA  "47@
MB%<  (!6"@!Z5Q4 =E<B '-8+@!P5SD ;5=! 6I720)H5E "9E97 V167@1B
M564%8%5M!UY5=PA<58(*6E6.#%E5G U75:L.5E6^#U55VP]55?,-557_"U95
M_PE65?\)5E7_"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP
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M"$=B_PC*6   NF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L
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M!3AXD08W>*$'-7BS!S1XRP<T=^L'-';]!S1U_P<U=?\&-73_!C5T_P:Y:
MK7$  *)Y  "8?@  C8   (*!  !V@@  :8$  %N!  !1@0  2( * $6!$P!#
M@1X 0H(I $&",@! @CL /H)# #V"2P [@E,!.8)< 3>"9@(U@G$#,X)_ S&!
MC@0P@9\$+H&Q!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@
M )U_  "2@P  B(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ<
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M !&EOP 0I.( $:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0
M<9H  &2>  !8H0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0
ML1@ #K$B  ZQ*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2P
MM0 $L-  !+#O  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(
M %JG  !.JP  0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(
M ;T9  "^(@  OBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@
MOL(  +WD  "]]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P
M  !"LP  -;8  "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2
M  #*&0  RR(  ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,
M ,_.  #/ZP  SO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   U
MO   *;\  !["   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9
M$0  VQ8  -P?  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z
M  #EU   Y>H  .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@
M',D  !/-   ,T0  !-4   #:    W@   .$   #B    Y    .4#  #G"0
MZ0X  .L2  #M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #W
MO   ]\X  /??  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4
M  K;    WP   .(   #E    Z0   .P   #M    \    /$   #S    ]00
M /<*  #Z$   _!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J
M_[8  /^_  #_OP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\
M5@#_ &, _P!M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L
M /\ M #_ +T _P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\
M^@#_ /H _P#_$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_
M %X _P!I /\ <@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D
MKP#X +@ ]@## /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_
M .X _P#_$A0 _P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D
M_P!D /T ;0#[ '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L
M +, Z@"] .@ RP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .
M_P#_%!  _Q$. /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!>
M /( : #P '  [0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X
MW "X -H Q0#6 -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_
M%PP _Q0( /\/!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8
M8@#C &H X !R -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S
M ,D OP#& -  Q0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8
M_Q<  /\4  #_$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2
M!&0 SP5L ,P%<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'
MO "Y",T N KE +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL
M /\;  #Z&@  ]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX
MP0YF +\.;0"]#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M
M$<H JA+E *<4]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C
M  #F)   X"$  -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@
M + 89P"N&&X K!EU *L9? "I&80 J!J, *8:E "D&IX HQNH *$;M "?',4
MGAS? )H=\P&8'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_)@  ]"<  .8M  #:
M+P  SRT  ,HG  #''P@ P1P3 +H>(@"T'S$ KR ] *LA2 "H(E( IB): *,C
M8@"A(VD H"-O )XC=P"<(WX FR.& )DDCP&7))D!EB2C 90DL &2);\!D276
M 8XF[P&,)_\"BR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0  [#   -TV  #-.
MQ#<  +XR  "Z*P( M24. *XG'0"H*2L I"HX * J0P"=*TP FBM5 )@K7 "6
M*V, E"MJ 9(K<0&0+'@!CRR! 8TLB@&++)0"BBR? H@LJP*&++H"A2W. X,N
MZ@.!+OP#@"[_ G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\
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M!69 _P1F0/\$9C__!&8__P3E/0  ST8  +],  "T3P  JE   *)/  "92@
MD40  (I!#0"$0AD @$,F 'U$,@!Z1#P =T1$ '5$3 %R1%,!<$-9 6]#8 )M
M0V<":T-O VE#>01H0X,%9D./!F1#G0=C0ZL'84.]"&!$V0A@1/,'8$3_!E]$
M_P5?1/\$8$3_!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD
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M!5!0_P702P  OU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX
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M!41=D 9#7J '05ZQ!T!>R = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@
MM%\  *AF  ">:@  E6T  (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!2
M8R4 4&,O $YD. !-9$  2V1( $ID3P%(9%<!1F1? D5D: )#9',#06-_!#]C
MC@4]8YX&/&.P!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,
M *5J  ";;P  D7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$
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M B=[OP(F>^$")GKW B9X_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P
MA((  'B#  !LA   7X0  %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  L
MA2T *X4U "J%/@ IA4< *(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&
MO $>AMX 'H3U 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@
M '&*  !EBP  6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4
M()$N !^1-@ >D4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3
MD=@ $X_T !2._P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1
M  !=DP  4)4  $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD
M !*=+0 1GC< $9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P
M"9SL  J;_@ +FO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4
MG   2)\  #R@   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J
M)  %JBX !*HX  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD
M  "H]@  I_\  *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@
M/:@  #&J   FJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0
MMR4  +<O  "X.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V
M[P  MOP  +;_  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$
M ":S   <M@  $[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P
M ,4D  #&+@  R#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y
MR/0  ,C]  #(_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]
M   1P   "\,   /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49
M  #7(@  VBT  -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8
M -_T  #?] !YH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )
MS    ,\   #3    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H
M%@  ZB   .TK  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A
M  #SX0!MJ@  7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@
M -X   #B    Y@   .D   #J    [    .X   #P    \@   /0&  #V#
M^1(  /P<  #_*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_
MP0#_!QD _P$7 /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J
M /\ <P#_ 'L _P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@
M_P#$ /X U0#\ .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_
M"Q4 _P43 /\ $P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\
M;@#_ '8 _P!^ /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^
M /, S #Q ., [P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$
M_PD0 /\ #P#_ !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X
M '$ ]@!Y /0 ?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4
MQ0#C -H X0#M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+
M /\#"0#_  P _P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L
MZ0!S .< >@#E (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0
M ,X S@#F ,P ]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'
M  #_!0@ _P . /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M
M -4 <P#2 'H T "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,<
MO0#? +P \0"[ /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_
M#   _P<) /@!$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4
M;0## '0 P0!Z +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8
M *X"[0"L _L JP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0
MY@X  .4&" #= Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U
M!VX LP=U +$(>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-
M[0"?#OX G0[_ )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H
M - 3 @#.# L QPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@
MIA%O *01=@"B$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2
M%OT D!?_ (\7_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A
M  "]&04 N1(0 +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II
M )<;< "5&W< E!M_ )(<B "0')( CQR= (T=J0"+';< BA[* (@?YP"&(/H
MA"#_ 8,@_P&#(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&,P  O#$  +8M  "P
M)0  K!T, *8>& "A("8 G"$R )DB/0"5(D< DR-/ )$C5@"/(UT C21D (LD
M:P"))'( B"1Z (8D@P"$)8T @R68 8$EI & )K(!?B;% 7TGX@%[)_<!>2C_
M 7@H_P%X*/\!>"C_ 7@H_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P
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M ED^_P+6/P  PT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$
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M TY*CP-,2Y\$2TNP!$I+Q01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20
MN%$  *Q7  "A6P  F%P  (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:
M32@ 6$TQ %9-.@!434$ 4TY( %).3P!03E<!3TY? 4U.: %,3G,"2D]_ DE/
MC0-'3YT$1D^N!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54
M *E;  "?7@  E6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424
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M S5>O0,T7]T#-%[U S5=_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;
MC&X  (%N  !V;   9VD  %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^
M8S4 /60] #QD10 [9$T .615 #AD7P V9&D!-61V 3-DA0$Q994",&6G B]E
MNP(N9=H"+F3T BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',
M 'US  !R<@  9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$
M-6LY #1K00 S;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G
M;=8!)VOR 2=J_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY
M  !M>   8'<  %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T
M "QT/  K=$0 *71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==(
M'W3Q !]S_P$?<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G
M?P  6G\  $U^  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^
M-@ A?C\ 'W]( !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O
M !9\_P 6>_\ %GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP
M5(<  $B(   \B   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5
MBC< %(I! !.*3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'
M_  .A_\ #H;_  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)
M $&2   TD@  *I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\
M"I<Y  F71  (EU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]
MD_\  9+_  &2_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;
M   LG   (IT  !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q
M  "D/   I$@  *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L
M *#_  "@_P"1B@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   C
MI@  &:@  !&J   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q
M,@  LCX  +),  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__
M  "O_P",D   ?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L
M$+,   JU   "N    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P
MP3(  ,)   ##3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!
M_@"!EP  <YT  &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X
M  #!    Q0   ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8
M -8R  #800  V%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !V
MGP  9Z8  %FL  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.
M    T@   -4   #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD
M  #L,@  [4,  .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ
M6Z\  $RV   ^O   +\   "#$   4R   #,P   +0    U    -D   #>
MX@   .4   #F    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\
M(P  _S,  /]&  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4
M /\ % #_ !< _P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '<
M_P!^ /\ A0#_ (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[
M .8 ^0#V /@ _P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\
M$ #_ !$ _P 7 /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y
M /T @ #\ (8 ^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X
M[0#P .L _@#J /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_
M  P _P 3 /\ 'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$
M>@#O ($ [@"' .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I
M -H ^0#9 /\ UP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D
M_P 0 /\ &0#[ "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@
M 'L W@"! -P AP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8
M\P#% /\ PP#_ ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P +
M /, $@#N !\ Z@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0
MR@![ ,@ @0#& (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S
M /L LP#_ +( _P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .<
M#0#@ !@ V@ E -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T
M +@ >P"V ($ M "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /<
MI #_ *, _P"B /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0
M !$ R0 = ,0 *@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D
M=0"H 'L I@"# *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_
M )4)_P"4"?\ E G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH
MO0,4 +<$(0"R!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";
M"W8 F0Q^ )<,A@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1
M_P"'$?\ AQ'_ (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T.
M *H.&0"E#R< H1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W
MC!-X (L3@0")%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\
M&?\ >QG_ 'L9_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6
M$P"9%R$ E!DM )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS
M '\=? !]'88 ?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\
M<2'_ '$A_P#H*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-
M(!L B2$G (8B,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E
M=P!S)8$ <2:- &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_
M 6@H_P'A+@  RS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8
M?R@B 'PI+0!Y*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I
M+'T :"R) &8ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N
M_P':-   Q3P  +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX>
M ',O*0!Q,#, ;S [ &TP0P!K,4H :3%1 &<Q5P!F,5X 9#%F &,R;P!A,GD
M8#*% 5\RD@%=,Z$!7#.Q 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT_P'2
M.   P$   +-%  "H2   GD@  )5&  "+0   @CL  'DU! !S,Q  ;S0: &PT
M)0!I-2\ 9S4W &4V/P!C-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!63>"
M 5@XCP%6.)X!53BO E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/
MO$0  *])  "D3   FDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C
M.BL 8#HT %XZ/ !=.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\
MC0%0/9P!3SVL DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@
M *Q-  "A4   EU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@
M6CXQ %@^. !7/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+
M09H"2D&K DE"O@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0
M  ">5   E50  (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N
M %-"-0!10CT 3T)# $]#2P!.0U( 341: $M$8P!*1&X!245Z 4=%B %&19@"
M14:I D1&O0)#1MP"0T;U D-&_P)#1O\!0T7_ 4-%_P'!1P  LD\  *94  "<
M5P  DE@  (A8  !^50  <4\  &9*  !<1@4 5T8/ %1&& !11B( 3T8K $Y&
M,P!,1SH 2T=! $I'20!)2%  2$A8 $=(80!%26P 1$EX 4))A@%!298!0$JG
M C]*NP(^2]@"/DKS CY*_P(^2?\!/TG_ 3])_P&]2@  KU(  *-8  "96P
MD%T  (9<  ![60  ;5,  &)/  !73 $ 44H- $Y*%0!,2Q\ 2DLH $E+, !'
M2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P! 36H /TUV 3U.A $\3I0!.TZE 3E/
MN0(Y3]0".4_R 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$
M (-A  !X7@  :5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4
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M 2=>_P$G7?\!*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@
M8&L  %1I  !)9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K
M94( *F5* "AE5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E
M_@ @9/\ (&/_ 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(
M $]Q  !$;P  .FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T
M(6Y& "!N4  >;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8
M;/\ &&O_ !AK_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY
M   _>   -7@  "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA
M !5X2@ 4>%8 $WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\
M$'7_ !!T_P"?<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X
M@@  +H(  "2"   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#
M1  ,@U  "X-=  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__
M  9__P":>0  D'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC
M)HP  !V-   5C@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0
MD$D  (]6  "/90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+
M_P"4@   BX4  (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<
M !68   /F@  "IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4
M )U.  "=7   G6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".
MB   AHP  'B0  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD
M   (I@   *@   "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$
M  "L4P  K&,  *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@
M>Y,  &V7  !?G   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P
ML@   +4   "U    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]
M1P  O5@  +UK  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L
M &*@  !3I0  1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP
M ,(   #"    PP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@
MT4L  -%>  #2<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I
M  !'KP  .;,  "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\
M  #0    T@   -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P
M .E/  #I9   ZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [
MN0  *[P  !W    1Q   "<@   #,    SP   -,   #9    W0   .    #A
M    XP   .4   #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^
M  #^4P  _FH  /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !,
M_P 9 /\ )@#_ #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_
M (< _P"- /\ DP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /<
M_P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4
M /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y ((
M^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G
M /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\
M' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@""
M .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\
MT #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0 _P - /H %@#V
M ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0
M@@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_
M +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  ' .T $0#H !P
MXP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_
M (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L
M_P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\ # #6 !4 SP B
M ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L
MK0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"<
M /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L
M)P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\
M )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\
MC0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J
M "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $
M?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_
M ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"="2,
MF0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""
M#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03
M_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G
M (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX
M=!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@
M)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:
M+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ%
M &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+
MPS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q
M(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826! %\F
MC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD
M +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P
M9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6
M+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"
M  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ
M %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z %$QB !0,I<
M3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@  MD(  *E&  ">
M20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:,B4 6#,M %8S
M-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LVA0!*-Y4 2#>F
M $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4  *9*  "<30
MDDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R( 4C<J % W,@!/
M.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$.Y, 0SRD 4(\
MM@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94   CU$
M (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8
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M #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@
M954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W
M2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-
M_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL
M %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$(
M,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G
M4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>
M  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5='
M "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\
M(%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&
M8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?
M3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_
M !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P
M-FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  6
M9U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E
M_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(
M "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X
M#7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";
M;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\
M   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5
M  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P
MC'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2
MAP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(
M70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,
M 'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -E
M!I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "650
MEF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-
M  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?   $H    *(
M  "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL
M *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<
MF0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K    K0   *\   "P
M    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B
M  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@
M0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@   +P   "]
MO@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,
M:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K
M ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L   #+    S0
M ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E7
MYG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\
M   /P   !<0   #'    RP   ,\   #4    V    -P   #=    WP   .$
M  #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,
M /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_
M #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\
MCP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_
M .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L
M_P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R
M (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .
M_P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R
M /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D
MX "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#(
M /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q "  [0 L .H
M. #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@")
M ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\
MM #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D VP E -4 ,0#2
M #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8
MB@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_
M *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ? ,( *@"_ #4
MO  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C
M (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4
M_P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X
M *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8
MD@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T
M#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H
M.@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+
M (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P
MUAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+
M!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)
MD@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,
M +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34
M? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I
M$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N
M  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X
M &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D
M7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D
M-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<
M.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F
M %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/
MECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;
M(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PG
MM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD
M (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D
M4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%
M+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#
M  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\
M $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@
M/S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X
M1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q
M0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H
M #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U2
M:D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^
M-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[
M^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@
M %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T(
M.#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P
M/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)
M  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!(
M #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\
M*T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-
M2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%
M3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_
M "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+40
M0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E
M2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+
M_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4
M #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%  "!120 >4E,
M'5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C
M60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:
M   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E;
M !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P
ME68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @
M80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA
M9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT
M (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P
M$VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 "
M:W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W
M  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"
M  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P
M '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V
M@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0@@  "H(   *#
M!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X
M  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@
M8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@   H\   "0 P
MCPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/
MA0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+  !DC0  5I
M $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T   "=    G0,
M )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P
MGI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<
M   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J    J@   *L!
M  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@
M +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   C
MIP  %ZD   ZK   %K@   +    "R    M0   +<   "W    N    +D   "Z
M    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4
M  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0
M#;0   .W    N@   +T   #     Q    ,8   #&    R    ,D   #+
MS    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%  #A
MGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y   -O    ;\
M  ##    QP   ,H   #/    TP   -8   #7    V@   -P   #?    X0
M .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP
M^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\
M10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7
M /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\
MT@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_
M $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P
MF0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_
M ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4
M[P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5
M )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4
M_P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!(
M -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0
MO@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_
M    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,(
M2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7
M *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_
M]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N
M $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@
MFP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(
M -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T *$ / "> $0
MG !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"'
M *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0
M  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!%
M (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P
M=P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S
M&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X
M10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F
M &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P
MH2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P
M"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-
MM@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD
M )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$
M9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4
M$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM
M  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9"
M %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\<
M2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]
M+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<
M1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F
M $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0
M;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !(
M(D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH
M^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8
M &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0
M02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W
M+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V
M  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ(
M #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\
M,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10  94   %L[  !2
M-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q
M3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_
M "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !./
M13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N
M-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX
M_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT
M #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0
M*#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H
M20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0  #9
M!0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!=
M "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30
MFE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'   J
M0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&
M:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@
M (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$  "].   F2P8
M($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3
M374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB
M  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(*
M !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'(
M#%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^
M:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:
M#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN
M  %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![<
M<G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@  $68!  QE"@ '
M90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !D
MCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@
M &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$   9Q"   < T
M ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@
M;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^
M  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/
M  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH
M 'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"
MAP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*    B08  (D,  ")
M#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K
M  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0
M*Y$  !^2   4D@  #9,   24    E@   )<   "8    EP   )<%  "7"P
MF X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7
MO   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL
M !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4   "F @  IP@
M *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP
MJM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG
M   !J0   *L   "N    L0   +(   "R    LP   +0   "U    M@   +@$
M  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$
M +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S
MM0   +@   "\    OP   ,$   #!    PP   ,0   #&    QP   ,D   #+
M    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)
M  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L   "_    PP
M ,8   #+    S@   -$   #1    U    -8   #9    VP   -X   #@
MY    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #T
MQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5
M /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *(
M] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_
M  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /<
M6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F
M .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_
M_P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C
M %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D
MJ@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_    _P
M /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %,
MR0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S
M +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4
M  #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4
M +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D
MG@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9
M    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !- *(
M4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P
M (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%
MO0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1
M %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P
MNP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@
M *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P
M@ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L
M ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.
M  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!,
M '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0
M7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+
M$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#
M3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA
M %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P
M>Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:
M#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0
M^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X
M &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@
M3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#
M%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@
M  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=,
M $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\
M/!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9
M(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<
M4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_
M #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4*
M3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W
M(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F
M_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@!
M $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0
M,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L
M/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI
M"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ=
M "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P
MG44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R
M+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q
M:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD
M )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P
M*S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >
M-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1
M  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]   J.0D )3<.
M ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W(
M%CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""
M6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^
M$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&"
M !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  " 70
M=EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 5
M1!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'
MDP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,
M &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$
M#DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !
M3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI
M  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43
M  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W  !5BP  5:
M %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6
M;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1  !?
M%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR
M  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P
M0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL  &H/  !J%
M:AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !F
MR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH
M "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-  !V$   =A4
M '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !RQ
M<>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#
M   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "##0  @Q   (,5
M  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,
M '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-   1
MC@  "HX   "/    D0   )(   "2    D@   )(!  "2!P  D@P  )(0  "3
M%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S
M  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<  !&8   )F0
M )L   "<    G@   *    "@    H    *    "A    H00  *()  "C#@
MI!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK   I,D  */K  "B
M^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC    I0   *<
M  "I    K    *X   "N    K@   *\   "P    L0   +(   "S!@  M0T
M +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!G
ME0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O    L0   +0   "X
M    NP   +P   "\    O@   +\   #     P@   ,0   #&    R ,  ,L+
M  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0
M3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@   ,(   #'
MR@   ,P   #,    S@   -    #2    U0   -@   #;    WP   .(   #F
M"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P !
M /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &
M_0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L
M ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\
M  #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A
M .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L
MU #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_
M    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#< %4 V0!; -8
M80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#%
M +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U
M[  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^
M &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@
MU0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /    #E    V
M ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H
MJ0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3
M .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/    Q@   +P
M! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9
M )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J (0 O "" -P
M@0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^    M@   *X   "G
M  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8
M6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M
M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  ,
ME  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V
M %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &,
M^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 '
M (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %(
M9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8
M /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!
M"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3
M %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\
M307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G
M!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '
M50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_
M $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4
M60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%
M#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1
M_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$(
M $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8
M/!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O
M+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84
M#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=>
M #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@
MGS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \
M&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=
M9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P
M )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X
M,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F
M(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#
M  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1
M "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W(
M'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#
M20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G
M%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR!
M !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30
M>$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @
M+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,Q
MDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(
M &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4
M&3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .
M-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5
M  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8
M !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*(
M!SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>
M6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_
M'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T
M  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&   &9@  !=7@
M45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &
M1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'
MS   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F  !99   3&
M $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1  !0%@  4!T
M % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0
M3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID
M   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA
M  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND
M %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H
M:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D
M)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z
M  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @=
M%G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P'@
M<"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I
M_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_   7?@  #WX
M  =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B
M 'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P"
M?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /B0  !XH   "+
M    C    (T   "-    C    (P   ", P  C @  (T-  "-$0  C1<  (XB
M  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0
M;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0   )8   "8
MF@   )L   ";    FP   )L   ";    G    )T%  "="P  GA   )\7  "@
M)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<^0!PC   88\
M %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,   "E    J
M *D   "I    J0   *H   "K    K    *T   "N 0  L D  +(/  "S&
MM"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;
M   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T    M@   +@
M  "X    N0   +H   "\    O0   +\   #     PP   ,4'  #)#P  RAH
M ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   L
MJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##    Q@   ,@   #(
M    R@   ,L   #-    SP   -(   #5    V0   -T   #A!0  Y@\  .<>
M  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_  8
M_P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V
M &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0
M\P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\   #_    _P )
M /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@
MXP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#(
M /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_    ^  % /(
M#@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G
M ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /<
ML0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O    Y@   -\ "P#6
M !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +,
M9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *  RP"? .X G0#_
M )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP   ,< !@#   \
MNP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P">
M &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z (D
M_P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4  0"N  L J0 2
M *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X
MBP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W
M /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@  8 F@ . )4
M%0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!>
M 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\
M: #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4    C0 * (@ $ "#
M !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L
M7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_
M %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W !(
M<P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!=
M &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %
M_P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4
M &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P
M4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X
M&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D
M%@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A
M $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@
MI2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,
M!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*
M:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P
M )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!##!(
M00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q
M#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T
M  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4
M #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$
M*1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%
M.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4
M%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB
M "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@
M>3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I
M&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=
MD0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(
M &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1<
M(1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5
M(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$
M  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A$  >(14 '"(;
M !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z(
M$">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@
M1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G
M'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU
M  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P
M4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1
M+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8Q
MRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2  !=4   4DP
M $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R
M##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR
M-N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;50  45(  $=/
M   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF
M  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<
M #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W
M40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#
M*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y
M  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T  #U:   R6
M)U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*
M2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'
M_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T
M !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;  !4(P  5"T
M %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(
M9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E:   &F8  !%D
M   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS
M  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@
M?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<   $V\   QN   $
M;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J
M.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD
M '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H   1Z    >@
M 'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@
M=T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!
M  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&    AP   (@
M  "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@
M (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-
MB@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3    E0   )8   "6
M    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":'P  FBT  )H_
M  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP
M,Y8  "27   6F   #9D   &;    G0   )\   "A    I    *4   "D
MI0   *4   "F    IP   *@   "I    J@0  *P,  "N$P  KB$  *XS  "N
M1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\
M !>A   -HP   *4   "G    J@   *P   "P    L@   +0   "S    M
M +4   "W    N    +D   "[    O0   +\!  ##"P  Q14  ,4E  #&.0
MQT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK
M    K0   +$   "T    MP   +H   "_    P0   ,0   ##    Q0   ,8
M  #(    R@   ,T   #/    T@   -8   #;    X P  .$8  #C*P  Y$$
M .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $ _P * /\ $@#_
M !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\
M= #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_
M ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P & /\ #P#\ !@
M^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6
M '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L
M_P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T # #H !, XP >
M .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T
MO0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A
M /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #. !  R0 8 ,4
M(@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M
M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\
MC0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T LP 3 *\ ' "L
M "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0
M; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_
M 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0 )X %P": !\
MEP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"
M &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X
M_P#=    R0   +P   "Q    J0   *$   "9  , DP , (X $@"* !D AP A
M (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &<
M;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#-
M 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\ !0 >  ; '4
M(P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I
M %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#
ML@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F
M ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %(
M;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8
M )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X
M6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!&
M '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?
M  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ?
M $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '(
M.@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  ")
M)@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $(
M( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^
M # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0
M>RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X
M!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,
MCP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$
M &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P
M+@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?
M$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS
M  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q >
M "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*
M%Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A
M-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3
M(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS
M !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0
M534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9
M&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=
MRP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH
M $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2(
M$QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )
M(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[
M  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G
M  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4
M!";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _
M/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI
M+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV
M   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^1
M,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P "
M,#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O
M_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-   Z20  +T4
M "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(
M #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N   #7U   U_P"-
M4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U3@  *DL  "!(
M   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ
M   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P
M@EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50  )5(  !M0   2
M30  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&
M0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(
M '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH  !57   .5@
M!U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P
M3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L
M  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@   )7P   %X
M  !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM  !9.@  64@
M %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H
M<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ    :@   &D   !I
M    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D-   9$,  &13
M  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0
M47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0   '8   !U
M=    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q
M7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X
M #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,   "#    @@
M ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!5@
M@6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*
M   @BP  $XL   J+    C    (T   "/    D0   )(   "1    D0   )$
M  "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X  "43   DV(
M )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4
ME0  "I8   "7    F0   )L   "=    GP   *    "@    H    *    "A
M    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I0   J58  *EO
M  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP
M *$   "C    I@   *@   "L    K@   *\   "O    L    +    "R
MLP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  #
M?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG    J@   *T
M  "P    LP   +8   "[    O0   ,    "_    P0   ,(   #$    Q@
M ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@;@
MWXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_ !D _P D /\
M+P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\
M .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\
MKP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4 \P ? .\ *0#J
M #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H
M?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_
M )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  : -< (P#0 "X
MRP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q
M 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$
M_P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P
M +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8
MFP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X
M    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E "$ H@ I )X
M,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X
M (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F
MTP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L D  C (P *P"*
M #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4
M? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP
M +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z "L
M>  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D
M ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"
M  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K
M &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L
M5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5
M#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!? !\ 70 E %L
M*P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$
M $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P
MA!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!.
M "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P
MD  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD
M '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8
M0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q
M )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=
M  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F
M #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V "H B  H )P
M)P"P "8 R0 E .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D
M(   6QL  %(5  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\"
M)P M BT + ,T "H#.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N
M !X'Q@ =!^< '0CX !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@
M6"$  $\<  !'%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E
M""D ) DP ",)-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,
MQ@ 5#>8 %0WY !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<
M $PC  !$'0  /!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24
M'0TL !L--  :#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0
M$.@ $!#[ !$0_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH
M  !")   .1\  #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I
M !40,0 4$3H $Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%.,
M#!3Z  T3_P"7-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  !
M*@  -R4  "\A   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4
M+@ 0%#@ #Q5"  X63P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU
M  D8_P"5.   BCT  (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,
M-BL  "XG   G(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,
M&C4 "QI   H;3  )&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<
M_P"3/   B$$  ']$  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(
M "XN   E*@  '24  !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S,
M!B ^  0@2@ #(5<  2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"0
M0   AD4  'U(  !T2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT
M   B+P  &2L  !(H!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\
M   E2   )E4  "9E   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10
MA$D  'M-  !S3P  :D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >
M-0  %3(   \N P *+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K
M10  +%,  "QB   L=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX
M 'I2  !Q5   :%0  %]3  !640  3$X  $-+   W1P  +4,  ",_   :/
M$C@   PV P &,PD  #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P
M,E   #)@   R<@  ,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7
M  !O60  9ED  %Y9  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D
M  @] @ !/ @  #L,   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X
M #E=   Y;P  .(4  #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M
M7P  95\  %U?  !27   1%@  #A5   M4@  (D\  !A,   02@  "D@   -&
M 0  108  $0*  !##0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:
M  !!;   0($  #^9   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90
M9&8  %ED  !+80  /EX  #);   F60  '%8  !)4   ,4@  !%$   !/
M3@,  $T(  !,#   2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !)
M:   27X  $B6  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L
M %)I  !$9@  -V0  "IB   ?8   %5X   U=   &6P   %H   !9    6
M %<$  !6"   5@P  %40  !4%   5!T  %0G  !4-   5$(  %-2  !39
M4GD  %*2  !1JP  4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO
M   \;0  +VP  ")J   7:0  #F<   9F    90   &4   !E    8P   &(
M  !B!   80@  &$-  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0
M %V-  !<IP  6\4  %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S
M=0  )G0  !ES   0<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N
M    ;@(  &X(  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&
M  !IH0  :+X  &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@
M&WT  !!]   '?0   'T   !]    ?@   '\   !^    ?0   'T   !\
M?    'P   !\!@  ? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !Z
MF@  >;8  'C?  !W^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<
M  >(    B    (D   "*    C    (T   "-    C    (P   ",    C
M (P   "-    C00  (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D
MC*T  (O.  "*\P!HA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3
M    E0   )<   "9    FP   )P   ";    FP   )P   "<    G0   )X
M  ">    GP   *$#  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(
M *+   "AZ !<C0  39   #^3   PE@  (9D  !*:   'FP   )T   "@
MH@   *0   "H    J@   *L   "J    JP   *P   "M    K@   *\   "Q
M    L@   +0   "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ
M  "YT@!0E0  09@  #*<   CH   $Z(   BD    IP   *H   "L    KP
M +(   "W    N0   +L   "Z    O    +T   "_    P    ,(   #$
MQ@   ,D   #-    T@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6
MO0#_    _P   /\   #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _
M /  1P#N $X ZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (<
MV "1 -, G0#/ *L S0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_
M    _P   /\   #_    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H
M00#5 $@ T0!. ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"*
M +L E0"X *, M@"T +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_
M_P   /H   #Q    Z    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"]
M $$ N@!( +@ 30"V %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8
MC@"D )L H0"K )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@
M .@   #<    S@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L
MI0!! *, 1P"A $P GP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0
M ), C0"B (L M0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(
M  #%    N@   +$   "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z
M )  0 ". $4 C0!* (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L
M>P": '@ JP!V ,0 = #K ', _P!S /\ < #_ &X _P#?    S    +\   "T
M    JP   *$   ":  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\
M.0!] #\ >P!$ 'D 20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2
M &@ HP!F +@ 9 #> &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E
MG0   )0   ",    A@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M
M #@ :P ] &H 0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D
MFP!7 *\ 5@#+ %4 \@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D
M (@   "!    >0 " ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #(
M7@ W %P / !; $( 60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!*
M *@ 20#  $@ Z !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X
M  !V    ;P   &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q
M %  -@!. #P 30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *(
M/0"X #T W0 \ /@ / #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N
M!0  9@   &   0!9  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4
M,0!# #8 0@ \ $  0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q
M #( S@ R /$ ,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@
M7PH  %@#  !1  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y
M #$ -P W #8 /@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D
MQ@ H .H * #^ "@ _P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$
M %(-  !+!P  1  & $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P
M+@ S "T .@ K $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @
M .0 'P#Y !\ _P"=(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3
M  !&#@  /PL  #@%!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N
M "0 -@ C #X (@!' "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\
M%P'U !<"_P":)P  CBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#
M%   .Q   #0- @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#
M,@ ;!#H &@5$ !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR
M ! )_P"7*P  C"\  ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P
M.!8  #$2   I#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5
M"C< $PI! !(+30 1"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-
M_P"5+P  BC,  '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT
M "X8   G$P  (! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30
M#@X_  T.2@ ,#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2
M,P  B#<  'XZ  !T.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?
M   F&@  'A8! !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\
M  @22  '$E4 !A-E  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@
MACL  'P^  !S/P  :C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E
M(@  'AX  !8: @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,6
M1@ !%U,  !=B   8=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\
M 'M"  !R0P  :$,  %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0
M&R0  !,? @ -&PD "1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1
M'%$  !Q@   =<@  '8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&
M  !P2   :$@  %Y&  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD
M ! E @ +(@D !2 -  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\
M "%>   B<   (H4  "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O
M3   9DT  %U+  !420  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL
M @ '*0@  2<,   F#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<
M   G;0  )X(  ">9   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40
M95(  %Q1  !33P  2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #
M, <  "\+   N#@  +1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M
M:P  +8   "R7   LKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<
M %M6  !350  1U$  #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4
M #<)   V#0  -0\  #04   T&P  -"0  #0N   T.@  -$<  #17   T:
M-'T  #.5   RK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=
M  !/6@  0E8  #92   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'
M   ^"P  /0X  #T1   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH
M #J2   ZJP  .<@  #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)
M7@  /%L  "]8   D50  &5,  !!1   *3P   4T   !,    2@   $D$  !(
M"   1PP  $8/  !&%   11P  $4G  !%,P  14   $50  !$80  1'8  $./
M  !"J   0<8  $#L   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9
M-&$  "A?   =70  $EL   M9   "6    %8   !6    5    %,   !2!
M40D  % -  !0$   3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,
MI0  2\(  $GJ  !(_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D
M "!G   490  #60   -B    8@   &$   !@    7P   %X   !=    7 0
M %P)  !;#0  6Q(  %L<  !:*   6C8  %I&  !96   66T  %B%  !7H
M5KT  %7H  !3_@!Y<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O
M   -;@  !&T   !M    ;0   &T   !L    :P   &H   !I    :0   &D#
M  !H"0  : X  &@5  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<
M &+A  !A_ !W>   ;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $
M>0   'D   !Y    >@   'H   !Z    >    '@   !W    =P   '<   !W
M 0  =P@  '<.  !W&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3
M  !Q]P!Q?@  8W\  %2   !%@@  -H,  "B$   :A   #H,   2$    A
M (4   "&    B    (D   "(    AP   (<   "'    AP   (<   "(
MB    (@'  ")$   B1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$
M[P!FA   5X8  $B(   YB@  *HP  !N-   /C0  !(X   "0    D0   ),
M  "5    EP   )@   "6    EP   )<   "7    F    )@   "9    F@
M )L   "=!P  G1$  )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:
MBP  2XX  #R1   MDP  'I4  !"6   $F    )H   "<    G@   *$   "D
M    I@   *<   "F    IP   *<   "H    J0   *H   "L    K0   *\
M  "Q    LPD  +,5  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@
M/Y8  "^:   @G0  $9\   6A    HP   *8   "I    K    *\   "S
MM0   +<   "V    MP   +@   "Z    NP   +T   "_    P0   ,0   #'
M    RP   ,T,  #.&@  SR\  ,](  #08@  T(   -"=  #0N
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
M04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY
M>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&S
MM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL
M[>[P\?+T]?;W^?K[_/[_________________________________________
M_____________P                     ! P0%!@@)"@L-#@\1$A,4%A<8
M&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!2
M4U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+
MC(Z/D)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$
MQL?(R<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^
M______________________________________________________\  0(#
M! 4&!P@)"@L,#0X/$!$2$Q05%A<8&1H;'!T>'R A(B,D)28G*"DJ*RPM+B\P
M,3(S-#4V-S@Y.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!14E-455976%E:6UQ=
M7E]@86)C9&5F9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$A8:'B(F*
MBXR-CH^0D9*3E)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:W
MN+FZN[R]OK_ P<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>W^#AXN/D
MY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$   $
M               !                     0    $" P0%!@<(" D*"PP-
M#@\0$1(3%!46%Q@9&AH;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3$R,S0U-C<X
M.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)35%565UA96EM<75Y?8&%B8V1E
M9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/D)&2
MDY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKK"QLK.TM;:WN+FZN[R]OK_
MP<+#Q,7&Q\C)RLO,S<[/T-'3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN
M[_'R\_3U]O?X^?K[_/W^_P ! 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.#P\0
M$!$1$A,3%!05%A87%Q@9&1H:&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK+"TM
M+B\P,3(R,S0U-C<X.3H[/#T^/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B9&9H
M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M____________TEH"         %W,____________________________J#4
M         %S3____________________________?0T          %36____
M_______________________N?44          $34____________________
M_______\JF0O @  !"(W25C.____________________________Z:1K02@_
M8W^5I[K:_______________________________5LJRRS.3Z____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________ENY=W8LC_____________________________
M____VYYG-@H  HS________________________________(?S\%     %[/
M_____________________________]F!.0       #RJ________________
M_____________YY,         ".0____________________________W&\:
M         !!]^?__________________________KT@           !O[O__
M________________________A!,           !DYO__________________
M_______L40            !7WO________________________^X%0
M      !(UO________________________]T%              XS_______
M__________________FB6A,            CQ?______________________
M___?FUPL           -NO__________________________[[%]53DB$0<!
M A$BLO______________________________W[^EF9B:H*R]VO__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________X[Z=@'S[
M________________________________\K>$5S . !VL________________
M_______________2BDP5      !R\____________________________]9_
M-@        !+R?__________________________^I$^           OJ___
M________________________P%H            :E?__________________
M________C20            (A/_________________________G7@
M        =_________________________^T)0              :O______
M__________________]]                6_3_____________________
M__TK                3.O______________________Z4
M    /.'______________________S ,                +=G_________
M____________F8IA)P              )]?______________________^V^
MB54G            )=S__________________________LJ==EU*/#(M+# Y
M1][_______________________________WFW=;2T-/9Y/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________OU+O6________________________________
M_^>XCVI++Q5O_______________________________DH6<T!P     \R?__
M_________________________]:".P         2E___________________
M________[84Q            ;___________________________ID(
M        4.'________________________L:0              -\G_____
M__________________^S+P              (K;_____________________
M__]Y                $*?_______________________(T
M     )G______________________ZD                  (S_________
M_____________T8                  '______________________WP
M                 '3_____________________EP
M &K_____________________S@                   &/_____________
M_________RDB 0               &'______________________[FC@%<W
M%P           &C___________________________K3KI2&?'5Q<')W@93_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________V[J=@FEIT___________________
M____________R)-E/1D    =GO___________________________]N.3!,
M        ;O__________________________VWPL            1=?_____
M____________________BRH             (K3_____________________
M___"1                Y?_______________________]] 0
M     '_______________________^<V                 &K_________
M_____________YT                  %C______________________T8
M                 $?X____________________Z0
M #7I____________________E@                   "7;____________
M________O                    !C.____________________ZP
M              _"_____________________P                    JY
M_____________________R<                   JU________________
M_____W                    VY_____________________^"<C'!50C,F
M&Q0/#0X2&B:_____________________________^>38TL[,R\S/UN#\____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z].\X________________________________]*IA65(+!(!A?______
M______________________&K<3P/        3^#_____________________
M____U7\U            '[+________________________C=1T
M     (G_______________________^0(P               &?_________
M_____________]5#                 $CV_____________________XH
M                 "[=_____________________S@
M !?(____________________O@                    2V____________
M________G                     "E____________________N@
M              "3____________________W                     ""
M_____________________P                    !T________________
M_____Q,                   !H_____________________T(
M          !@_____________________WH                   !=____
M_________________]$                   !A____________________
M__\D                  !F_______________________)K)F)?79Q;&EG
M9F=K<'J,____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________XL6JD7EA=______________________________=IG=0+ P
M    ,<3_________________________X)).$P           (__________
M_______________2<!T              &#______________________^YO
M#P               #?B_____________________Y8<
M !3 _____________________T                    "C____________
M________K@                    ")____________________G@
M              !R____________________O                     !?
M____________________V@                    !-________________
M____^@                     [_____________________PX
M           J^?___________________S,                    ;Z?__
M_________________UX                    /V___________________
M_X\                    &T/___________________]
M        RO____________________\K                    R/______
M______________^                     R______________________W
M%@$%!0,!       !!@T8R________________________.OAV,_,S<_0TM37
MW.+J________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________':QO__________
M____________________\<:CA&A-,A@ %:O_________________________
M_[E\1A@          ''________________________7?"\
M #OC_____________________]]D"0                RU____________
M_________W0#                  "-____________________Q14
M              !J____________________F0                    !+
M____________________M@                     P_?______________
M____UP                     9Y___________________]@
M           %T____________________PX                     P?__
M_________________R\                     K___________________
M_U(                     GO___________________WD
M        CO___________________Z4                     @/______
M_____________]@                     =/____________________\V
M                    ;?____________________]\
M    :?_____________________7#0                  :/__________
M____________<                   8?_______________________U \
M1DY465UA9&AL<'9^B?__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________[]6[HXMS
M6I7___________________________B_CF1!(04      %+\____________
M___________WG588             !?!_____________________^5L%@
M              "-_____________________V,                   !>
M____________________G0                     U_/______________
M____H0                     1V?__________________R@
M            N___________________[@                      H?__
M_________________PP                     BO__________________
M_RT                     =O___________________TT
M        9/___________________V\                     4O______
M_____________Y0                     0/___________________[P
M                    ,/___________________^H.
M    (O____________________]$                    %?__________
M__________^!                    "_7____________________("P
M                 NS_____________________7@
M .7_____________________R1P                  -K_____________
M_________YT!              <.%\7________________________5N;S!
MQ\[5V^'F[?3[________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________XW\______________________________
M[,:EB&U4.R$' #+>________________________UY)9*0            "@
M______________________^)-@                !G________________
M_____V8                    R]O__________________E0
M           #R/__________________IP                      H/__
M________________UP                      ?/__________________
M_P                      7O___________________R4
M        0____________________T@                     +/______
M_____________VH                     &/___________________XL
M                    !?/__________________Z\
M     .'__________________]4                      ,__________
M__________\D                     +[___________________]4
M                 *[___________________^+
M )_____________________+#@                   )+_____________
M________5P                   (;_____________________J@H
M             'G______________________VT                  &;_
M______________________=5                 $7_________________
M________:B,K-3]*56!J=7Z'D9S_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^C/MIV#:4ZY________________
M_________^RR@UPZ'0(       ![_______________________%;2D
M          ! _____________________X,;                   'R___
M________________D@                      F/__________________
MI                       :O__________________W0
M        0?___________________PX                     '?______
M_____________SD                      .C__________________V
M                     ,[__________________X4
M     +?__________________Z@                      */_________
M_________\L                      )#__________________^\6
M                 'W___________________\^
M &S___________________]I                     %K_____________
M______^9                     $G____________________2%@
M             #G_____________________6                    "G_
M____________________H@                   !G_________________
M____]58                   3______________________[LO
M          #X______________________^K*0                #/____
M____________________R4<     !Q,@+CY2:(3M____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________]-7)____________________________^M*PDG==0B@,  !*____
M____________________Q7U%%P             1V/__________________
M_\10                    G___________________H@P
M        :/__________________E                       -O______
M____________V@                      !^S__________________Q4
M                     ,3__________________T@
M     *+__________________W4                      (/_________
M_________YT                      &G__________________\,
M                 %+__________________^</
M #[___________________\S                     "O_____________
M______]8                     !C___________________^!
M              7___________________^L                      #_
M___________________>(@                    #R________________
M____7                     #?____________________GP
M          #,____________________Z$H                   "W____
M_________________Z 6                  "<____________________
M__]Z @                !W________________________>@L
M      5,_________________________Z)7:'2 C9RKO-#G____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^WC___________________________2HWI8.BDC
M'!8.!@  G_____________________^L4@X                 :?______
M____________Y$,                     -/__________________>0
M                     ./_________________S0
M     ++__________________Q,                      (7_________
M_________T\                      %W__________________X,
M                 #K__________________[(
M !S__________________]L#                      +_____________
M______\J                      #[__________________]/
M              #G__________________]T                      #4
M__________________^;                      # ________________
M___$!P                    "M___________________P,P
M          ":____________________9P                    "&____
M________________HP                    !R____________________
MXT0                   !<_____________________Y$&
M      !!_____________________^M?                   =________
M_______________*2P                  ________________________
MRU<   P8)#$_3F!TBZ?'___________________________7Y_+_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___KU,W'PKZZM[.PK:FHI?___________________]U^4S\P(QD1"0(
M     -O_________________=@                       *?_________
M________N@                       '7__________________P<
M                 $;__________________TX
M !K__________________XP                       #]____________
M_____\$                       #;__________________$9
M              "^__________________]$                      "D
M__________________]K                      "-________________
M__^1                      !Y__________________^W
M          !F___________________>(0                    !3____
M________________2@                     _____________________
M=P                     K____________________K H
M       6____________________YT4                     ________
M_____________XH                     _____________________]9-
M                    _?____________________^G+@
M    U?______________________F"H           88+45@X/__________
M_____________ZAC=(&/G*N[S>+Z________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________GR[>I
MG96.B82 ?'AT<&QH99#_________________O&I(+1D*
M #'__________________P                        /_____________
M_____T(                       #<_________________XX
M              "R_________________\X                       "-
M__________________\I                      !K________________
M__]:                      !.__________________^&
M           T__________________^N                       >____
M_______________4%P                     *___________________Z
M/0                      ____________________90
M        ____________________C@                      ________
M____________O!D                     [___________________\4X
M                    V/___________________XL
M    O____________________\Q#                    H?__________
M__________^1&0                  >O_____________________R= H
M               17_______________________Z'03'RPX15-B<H6;M-+U
M___________________________7Z/3_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________OW\_'N[.OK[/'__________________]FRF8=Y;61=
M5E%+1D$\.#(M*"/$_________________TLE"P                    "2
M_________________X@                       !F________________
M_]<                        ]__________________\S
M           8__________________]L                        ____
M______________^=                        ___________________)
M#                       ]O_________________Q-0
M        W___________________6P                      R_______
M____________@@                      M___________________J08
M                    H___________________TR\
M    C?___________________UX                     =___________
M_________Y,'                    7O___________________\U#
M                0/____________________^'$
M'/_____________________87@                   /______________
M________OTX       X<+#Y2:H:ER/_______________________\)\C)JG
MML76Z/W_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^[AU\_)P[ZZMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<
M%A +!      4_________________]<%                        ____
M______________\T                        ]O________________]V
M                        TO________________^P
M        LO_________________A)                       EO______
M____________40                      ?/__________________>0
M                    9O__________________H
M    4?__________________QR,                     //__________
M________[DL                     )____________________W0
M                $/___________________Z,6
M /___________________]A,                     /______________
M______^(#P                   /_____________________+4P
M             /______________________I3@           D=-$YKC/__
M_____________________YDY0U%?;GV.H+7+Y?______________________
M_______K^?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________K
MS+FLH9F1BX:!?'AT<&MH9F9H\?________________]A13(C& X&
M        GO________________]^                        =?______
M___________#                        4O_________________[-P
M                    ,O__________________:@
M    %O__________________E@                       /__________
M________OQL                      /__________________YD(
M                 /___________________VD
M /___________________Y "                     /______________
M_____[DL                     /3__________________^A<
M             -G___________________^1&                    +S_
M___________________*4P                   )W_________________
M____F"X             $"E&9L3_____________________[G\=#!HH-T97
M:7Z5K\SN_________________________^>@JKG(V.G\________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\
M<6EA6U913$A#/CHV,B\N,?_________________2)1$#
M     /__________________0@                       /__________
M________?0                       /__________________L L
M                 /;_________________W3D
M -S__________________V(                      ,7_____________
M_____XD                      *___________________Z\B
M             )G__________________]9(                     (+_
M__________________]R                     &G_________________
M__^A*                    $[____________________37
M         #/_____________________EBX              !4R4G?_____
M________________X'(3   !#Q\O0EAPBZC([/______________________
M_\IO;GZ.GK##V.______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________^>#2R,"ZM;"LJ*6BGYV;FYR@I___________________@F162T,\
M-C K)R(=&!,."00  -3_________________D@
M *W_________________S!X                      (O_____________
M____^U(                      &W__________________X
M             %'__________________ZD;                     #K_
M_________________]!"                     "/_________________
M__5H                      S___________________^/%
M          #___________________^X/@                    #_____
M_______________E;0,                   #_____________________
MGS<              ! O4'3_____________________W7(4      87*D%:
M=92VVO_______________________[Q81%1D=8::K\CC________________
M_______________2S>'Q________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________\^_K[_?__________________
M____[KFHG9:/BH:"?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40
M"P<"         "/__________________VD                       #_
M_________________YL*                      #_________________
M_\@Y                      #___________________!C
M          #___________________^*#@                    #_____
M______________^P-                     #____________________5
M6P                    #_____________________A1H
M      /L____________________L4D              !@Y78'_________
M____________Y7L>       ,(3A2;X^SV?_______________________[M8
M*3E)6FR E[#-[?____________________________^SGK3%U^O_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________Z[^?AW-G6U-+0T-#1T]G@Z_?_________________
M_[B*?G=Q;&AD85Y;65A75UE>97'__________________[\Q'Q80"@4
M          #__________________^U6                      #H____
M______________^"!                     #,__________________^K
M+P                    "S___________________25P
M      ";___________________W?!                    "%________
M____________HC<                 !2N4____________________RV$"
M            #"Q0=I[1____________________]8TP       -(SM7=IF^
MY?_______________________\-C&"H[3%]TC:?&Y___________________
M__________^H?Y:HN]#G_____________________________________?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________=SL6_O+FVM+.QLK*UN<#)U>/___________________^7
M;&1>65513TQ*2$=&2$M066:A__________________^G)@X' @
M      !6___________________.4                      Z________
M___________T>0L                    A____________________GS(
M                   .____________________Q%@                (
M,5J$____________________Z7\?           &)TMQFL+I____________
M_________Z=)      (7+TIHBJ[5_/_______________________]-U'B8X
M2EYUCZO+[_____________________________^N<H68K,+;]O__________
M________________________W^__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________O[*JIJ.AH)^?H:.FK+3 S=WL____________________BEI3
M3TM(1D1#0D%"0T=.66E]____________________GBX&
M    ____________________PU8                  !5!____________
M________YWL:              DT8(NT_____________________Y\_
M      0E2G&9PNO______________________\9F#P   !,J1&*#I\WU____
M_____________________^N.-2L^46B!G;S>________________________
M______^^=G^4J<'<^?__________________________________TMCS____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________V\O#O[^_Q\_C]____________________
M________^+"?FI>6EI:8FY^DK+;"T>'N_____________________HY02D=%
M1$1$149'2U%::(.I_____________________Z9! 0          !S9CC[KA
M_____________________\9E"@      !"=,<YS$[/__________________
M_____^6(+P  $RI$8H*FS/3___________________________^K4#9*87N6
MM-;Z_______________________________2AWR8L<OI________________
M____________________U,[M____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________MY>/CY.;H[?'Y________________________
M______VQE)*2E9F=HZFRO-#M__________________________^=4T=)35%6
M8'.*K];\__________________________^R5@ :-5!MBZ[2]___________
M___________________-;SY?>YFWU_G_____________________________
M___NGX.FPN'_____________________________________X\[K________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________
M
M
M                                  #_________________________
M____________________________________________________________
M____________________________________________________________
M_________________________P    #_X4'\:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E
M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C(M8S P," Q
M,38N9&5E,V$W-RP@,C R,B\P.2\P,2TQ,SHU-SHP." @(" @(" @(CX*(" @
M/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R
M+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS
M=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S
M;V9TPJX@4&]W97)0;VEN=,*N(#(P,3D\+W!D9CI0<F]D=6-E<CX*(" @(" @
M(" @/'AM<#I#<F5A=&]R5&]O;#Y-:6-R;W-O9G3"KB!0;W=E<E!O:6YTPJX@
M,C Q.3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A
M=&4^,C R,RTP-RTR-50R,3HR.#HT,BLP-3HS,#PO>&UP.D-R96%T941A=&4^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(S+3 W+3(U5#(Q.C,T.C0Q
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,RTP-RTR-50R,3HS-#HT,2LP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z
M<&AO=&]S:&]P.F$Q9C$R835F+3AD,3(M-F4T,2UB-S)D+3DX-F0Y-39A8C=B
M,CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E
M240^>&UP+FEI9#HV938P,#<S.2UA8SAB+65F-#<M8F$R82TR.#)C9C1E-V)A
M.3,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^=75I9#HV.#0Q-3@Y."TX034W+30P1D4M.3A!,BTT0T$X
M0S9",# P,C(\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.F(W9#$U-S9D+6%F8F(M9C(T9"TX9#-C+3<X9# S-3(W-F9D93PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,RTP-RTR-50R,3HS-#HR-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P(#(S+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IF-S<W-CDP
M-"UB,S0Y+60V-&(M83=A,2TT.#0S,S0U,&$U-F8\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#<M,C54
M,C$Z,S0Z-#$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA
M9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R
M<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HV938P,#<S.2UA8SAB+65F-#<M8F$R82TR.#)C9C1E
M-V)A.3,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C,M,#<M,C54,C$Z,S0Z-#$K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.F8W
M-S<V.3 T+6(S-#DM9#8T8BUA-V$Q+30X-#,S-#4P834V9CPO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^=75I9#HV
M.#0Q-3@Y."TX034W+30P1D4M.3A!,BTT0T$X0S9",# P,C(\+W-T4F5F.F1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^=75I9#HV.#0Q-3@Y."TX034W+30P1D4M.3A!,BTT0T$X0S9",# P,C(\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D1E;'1A/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A
M=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA
M=#X*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A
M=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I;VX^-3,Q-C0R,"\Q,# P
M,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I
M;VX^-3,Q-C0R,"\Q,# P,#PO=&EF9CI94F5S;VQU=&EO;CX*(" @(" @(" @
M/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*
M(" @(" @(" @/&5X:68Z0V]L;W)3<&%C93XV-34S-3PO97AI9CI#;VQO<E-P
M86-E/@H@(" @(" @(" \97AI9CI0:7AE;%A$:6UE;G-I;VX^,S,U,CPO97AI
M9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N
M<VEO;CXQ,C(R/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @(" @/'!H
M;W1O<VAO<#I(:7-T;W)Y/C(P,C,M,#<M,C54,C$Z,S Z,C(K,#4Z,S F(W@Y
M.T9I;&4@4S0@9W)A<&AI8W,M,30N<&1F(&]P96YE9"8C>$$[,C R,RTP-RTR
M-50R,3HS-#HR-RLP-3HS,"8C>#D[1FEL92!#.EQ5<V5R<UQ$96QT85Q$97-K
M=&]P7#0U,30R.%\P,3)<9FEN86Q<9S8W83(W+G!S9"!S879E9"8C>$$[,C R
M,RTP-RTR-50R,3HS-#HT,2LP-3HS,"8C>#D[1FEL92!#.EQ5<V5R<UQ$96QT
M85Q$97-K=&]P7#0U,30R.%\P,3)<9FEN86Q<9S8W83(W(&-O<'DN97!S('-A
M=F5D)B-X03L\+W!H;W1O<VAO<#I(:7-T;W)Y/@H@(" @(" @(" \<&AO=&]S
M:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @
M(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^52Y3+B!796(@0V]A=&5D("A35T]0
M*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M-*21L@U+P79P9U+DSNB,A>GN-.:<A4!+&*P.=Y;%2/+@R*G<6.+'AL<9W7@
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M;7KYIZ>DN&>UOAJCZ5.E3]T_%9\U?4IXV?%01 2&+-D%*0MP2V7(#%.#L $
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MVLO8^N.>F32<[W5R;;CG $-C>?<MQ2+X]=1<1/6;8O/&-HP8R,;P9A''N/\
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M]K7M>U[7M>UKVOSI]45-W"?X/YZ=!D^[9^-Y%Z!.OH?_ 'FR@%I!DS=:)Y$
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MS[$/*#B^&'6H:>_%,=-/]%PN?&G1I^YGQM\J_D?!GXH1A]U1FLTA,4B#< E
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M-EB!:;BV\^[6DO+76LJWNO&XAP%B0""6C(V )+7$'KL,SD#FHC1_<[=$,(C
M6['L?7*VW&4>+<WK*N,)VVSF0S5ITFBFS3^_R2/1&3M+ QG2&7@DF,S(TT6"
M!HD3VWG$K#3XRIC$D[CJ.CYQUY' &5WJ89(RQK'5KZ9K6N>TN.ZS=DWG>N:#
ME9V\WB$LMAD,@ 2YK@XD0B0D@$ 7(+;=9'58Y&AXA^3I(NV*;D;%CIG6PN+/
M$<Q)#C#Q R#),U/,\A^(\>-82CI@N<GR-#R#,6=OF3DIQI#R(XO?F!K0JI*D
M&8]JZ3A\313DND(>X.F?;U#86QOED(LT .YMCBP"1^\&N)#2-U!4.)D%F@@6
M8W_.+R0UHS=F-X@.NT6OJ1FO/@[59ZU/<M@L:2?RQSN/XXF&*(OC7*F6R)5,
M%4\4N<=TUQA)4C&N5R6-HE*N,+L@R[*K\AE,Y8_+W(I.8B:9,RHV*<OS-7T6
M"J$$K=UCI&2ODBB+&",!U7(TD;KB-X1LB:6,=S;6W+22QKHYQ\1D:;N#2T-<
MZY+LHFFUR!EO%QNX;Q.1R<1)"5;#93>\7:6Y$L^0A&^Y#-R=-I8A@TH6)\:2
M*4PG6S-$[CV+7*3M#G*%!T:2RIB3J99=N<'FRM= UX" *T(34!W7;3Q-EK8]
MUY;&(V,+V#G&L?4P1NE#7!H#BQUF!P;82"]B+KD+W%L1NVYWB;$[I+6/(;<7
M)&\,[7ON]J\AA^Z&S\V>(09&8DW"=,D1;&+&H52K'\B1XRB<D/>=\@RV4L\?
MC<QD+@[(A_2!QPD)<$N9GV.2IFD3"ZLK@RD/K>K4<KZ*F8)-YYM&^0C=D:9'
MMM0[C7%S&AN51(;&(.8YK@X.W2%0)I"6V NX &[3N@WFN0 XWONM_P \@@BQ
M%U@:[?\ SUE^T@A[&TQ3&JU+"<-2<UK;#%Y&5 R.1MFK4X?F"*E*)C9^>2D)
M.6I^TS-*?C!L216/0]$:9)) HE2H$=KZ#!$&O)?)=\S;D@QAK34L:Y]F6;?F
MHRP\X=][R UH8-Z.?D>"  T@,)M?>N>;<0,[FP<[>]38 :FY E+K9N1G_+WT
MUU4CUX/57A\G9&EOB$3>(:P3B'$.+QDQN>$>0&J69/5K%]HXDAD:4V>$33%9
M)(UDJ6I&7%8FYA*>WGKU-'3P\V&U%MYKB7/:]S'D-B+3&YD0 W]]V1+FL#07
M2W=NMY(Y9';UX]#:P(#AFZ]P77T .@)OZWBHBQ'?39@*:5Y!=+0LE'-DV*E"
M5R?,>9?/Q/B%UO@C(V1WS%MXX!Z12==/W:=LK7B!T?R'Q"U>7!.<N,C1;Z-#
MCPWMOH:8;D8+[L,UPV2+G9F\_%$V4.W=T1B,NF:T@G=-@XMO(.(32>J=ZG/<
MM<.W6^H<XMM>Y<39I(-K\+C=7HDRXBFR# FG!1>%F-K>FV1X7;DZ93'%[VP8
ML9LB0B4OK\HRK*EN5(&WG21KF,9+@ZN-O)6("HX:_,CXA><AMJY/<_C9AU,[
M<//DM+9B2' .E=&]@;S3!$\[I8_G YO/;VZYA$;@5)J)!?U !NWA<-#FDG>.
M\ 2"+$7;:X(+KB\T=3\D3R>S788J97/+3I77!4H1LOD\;)FB"2#(>N6,I/-,
M>1IZ&(12I@9WHT,D1V2V+3&&S!0N3DDIUY)0>E51QL93[FMIVEVZ&F1L=1*U
MDCFZAQ;ZDWN;, ODN:)SG.DOH.;-KW +HVES0>H&QZLU-6NFN9*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1%A4[QMCW*#2F8<D0B*3QE1. '9$URY@;)"A1
MNA:-:W!<4B9T3*BDRWR.<G%N$J("6<-O<5Z$8Q)5JDDVN.22)V]&]\;B+$L<
M6D@D&Q((RN ;=8!U 5+FM=8. < ;@$7SS%_$2/"LJ;V] TH$36UHDC:V-J1,
MWMS<WIB4:!O0(R0)D:)$C3 +3I4B5.660F3$%EDD$E@**   0AM222222222
M23<DG,DDYDDZE5::+^5[8VNA:<IS;T+B4E7(G-*6O2$+"TSDVJ2UC<X)P*"S
M DKD"PDI4B5EV">E4E%GD&%F@"*P$B]B1<$&Q(N"+$&W C(C0C5+ ZB_'P]:
M^VH18Y+(?%)ZP+HK-XTQ2Z,N0D8W!@DC4B>FA6:W+DSFW''M[@2H2F'MSFB1
MN3>?<OMR)P2)5R492I.2:"ICWQN#V.<QPO9S201<$$7&=B"01H02#D2H+0X$
M. (-K@Z9&X\1%U\L1@$%Q^ANV02&1:&-]R4J<:.+,#4P)C"47;NY"S2FM*E
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MF-+2KUJ<(K%*CP&29)"7N+W%T@(>2XDO!()#B<R"0#GQ /!-UM@   VVZ
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M#"USJ/$<+K-W1CW5-+*_L:'0RQ7_ 'TS1VA75A?HMMB:ES&8K@&T>%EY =)
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M+=RRQ7Y!4FAM<=9XPGE9V1Q)K&U53/A-00 Z*NA?S6]E?<JJ?GH=P'1TQ@)
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M-<T@':@N[QVKI5O:\LQ2::,P*4*%#VA"3N1LKL=@^RM(R*C@9+6NC:*O$I6
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M#B 3J0UQ SL=%+=W>&\2&W&\6@.<&WS(:7-#B!F 7-!.1<-5BG=D[_BY$O\
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MMJZB)1$HB^)P;R'-,)(I,6EE#$ 5QM[DXM*FUP"L(-@K6I4B6 #>]N0P /"
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M-P\0@54U-S7-'#JTR&\._OA[/7!NYE<QI^N\;7?<^UZ_!>2/TWJ\_P!0R?\
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M=6IM<EIFSNS1(UB]"F6*ADI,]Y%2)"AJ%!1AHBTR0@A(G (=P$IR2B"[!*+
M$.V>P>SNSU9LC@=35X%@]542TKW2U%1AE#/-(X5,S=Z266!TCS8  N<2  ,@
M %YG\LNW6V^&<IVV%#ANV.U.'T--B<<=-14.T.+TE) PT=*[<AIX*QD,3-YS
MG%L;&@N<3:Y-\%\JL7_BXP_@AO\ _P#/U\/?M5W?4ILO_NW@']#X=_RRQC^J
M3RBG_;W;33_>G'.O@>F^'MRME=<>5B-6^PM'F.Q8OLA LTH.Q$,'0 0@]S\K
MB#89E@BO:]PV&.UO\*]KVK5X#L@W;7 Z X+LTVHDV8VHJ>A>EN&-FDC9BFR+
M&S]&YG?>UEYF,EW"&WD:'#U:OBBVXY3G\G&TV*#:_;MU+#MIL31^F/I_M :>
M*67!=O99*3I@JS$R21K:>1T'.![@(7N8;,(Y\JL7_BVP^G_<ANO_ /I_>\'C
MJZOJ4V6_W;P#L_Q/AW_+JR/U2>43/_+[;3L_RIQW.^?M_.W8? !9=))6-E;(
MY('-M9VMO<6]D=5R!>A;TB1:A6I$)YZ58D5IRBU"54F/++.3J"3"SB30 ,*&
M$80BM\7:/9G9N'9['IH-G\#AFAP7%)89HL)H(Y8I8Z&=\<D<C*<.8]C@US'L
M<'-< 000"KKV#Y0-O*O;C8RDJ]MMKJJEJMJ]G::IIJG:3&9J>IIY\7I(YX)X
M):TQ2PS1.='+&]KF2,<YCVEMPM["M.%ZI)1$HB41=8]$HE#,[$.2PQN;CVQ>
M2O<"5YC4<A1&)30*EA3H4:0:VF)2!&'@7EG$F(Q LH :6(NP[$6JHY:N9LQ?
ML,6.!SC;N78O-VIU0R)AC:&5\7%U<=6FK6V5R'#MS85E'&\SSF?D^=R7*CJF
MR!%X>P(8G(V[*<@F,721"0@C@%+4 BVOJ(E$2B)1%0AM0C4+^/SPU4R5U7LI
MP]0MO+A<&TML-6$V 4E&()8'AM=D%[&AM<HSMR$T5@#%<H19E@F!D$ YM#NP
M[UN_ZDM/OV[$\-O%\H*NY\JK[]TN;?ZACCYOZJWF]S9XY/I%%CUGWO(GE5??
MNES;_4,<?-_3>;W-GCD^D2QZS[WD6KGQ&VE>FWGRT0=)WQP-! <-B$M5IXV!
M2;8;$]7" P""/(D=@DVM<)=RDA8[V%?MHS1=B(.R'(LTR8'BQ;(^$#%A=L8C
M(<>AP&YYYDIN/_"0,M%H3Z+2>.+;#9EKZ2GJ2=FW'?G=5-<T>F==ZD=&J8&V
MN+W<QSKD^JM8"&WD>K_Y\=.__F6;Y'\/I]/166JU]52P&6"+$L2E! %+1G"(
MYW!Q +@_$'T5, P9N#JAI(!W&N=9JU@P\X?653*>I&!X1$]KW.K<1^J22E86
MM+FM>S"CB=87R.&XPQTCVAQ:9',9=ZXN@5\NA[=+W],EEM['0T7[WJ]-^_WJ
ML+;+%>4)VR^/#8?9K%&;6G#:@;/OQNIV..%MQ+=_8#6"''7/+-=R[3'SO-B4
M"+G%ECDVP?D@;M]LF[E1VKP!_)VW'*([8,V9IN4@8Z[!!*.F-P_G]G61\Z0
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M6+I[_BY?JHIN,K<=. [3POKF,^]=.OC]3KZ?I4\_/SS[V:6ZLA\NF?'(:9@
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M+:CV,[1>X6+Y\?L?4?I5X<G?VP-A<_\ ;'9@=9SQNAMUY'B2<\M"MYRM'%[
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M-^CC:7MNPOC(>ZVG@O?;KVV^];K'^-FS%:[\M_V8P7W-F_*G+>ST(?L7VM/
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M[EJJ^%M1[&=HO<+%_P WU"O'D[/_ &@;"Y?[8[,Y]7^.Z'P]_M&BWG*T<7L
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M1*(E$2B)1$HB41*(E$46=L,-Q'9;'H<!+<JFXLR(XN\1S-C!]8/*6]36/RC
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MCY^0[ E_!U\?36GW*A[.L=[^'?FB@MY^)>HWH=/M-['6M_M!I_*G&_D5O56
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M=P7W6P[\LA5K[<>PO:_^2^T'YIJUJ[6Z_M\'J_KK>DYC4\3<?HUURMU+QU/
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E0^[DH;HA.).E9#"U",QO4NJA189MA7*N1>O41*(E$2B)1%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g451428g94e51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451428g94e51.jpg
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M3*$X"(RQ.[^VQ=N<5H%"HD\TI4_.[<W  B*5'!-4A,,* G+-.+H=(QCHV.<
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M>S1U$ZN?DJ!S=#TI+6V+UB>T^:*-[&/>&ND$A8"#J(FYY'$@$-:UMB7.(%R
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M2R*H-#30&EG+J2K;42QN:P-GB%1*\LC+G97N >U^1V4'+8$G0R71"IEEZ8A
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MZAFRKDDZ\HS.,]MROAJIB7.5)/:+KB"I*XM,$7KA;7KC13TY1.!0>(.R"2V
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M#$E\[B[FL88H@7.<0F2IEAV&MUR3EQNX-#HVMN12&I#<V^<QSLX,#]VYXC>
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M6899!A=)LW0UTKHV 9Y]Q@^V4-:6PW!<\/$;<PW@((5 ^_*Q'^8UY_[WIS_
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M,;G&VN9EOHD[*\')%+@A,8),]196 \]",:8T!RQD4*$XR]ZV),<3LTLHWOE
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MWJUBJY3DC+++ */M!P@ "$1QIS]HPT00ZULPS1+V45H8]Z[PM%%%EZ%O?<+
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M5Z:.+F?/O[[CI?=C*3;><(\F4;Q>KG;*#]A1NQV^V@ZI_LBNQS/U0CZA])#
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M,3FA 16Y]T)0?OX5!_67#/\ G6$5M+N0-9[5G;;+WX]@0]H? "NL!@,5ZUW
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M6SB>]Y0I?]0?V%_(;\@S?UJV9O\ 8WZ;]E?PDP/]*4J\^Z,/U(^BE_)SMO\
MW9Q-<9^?0Q? 5,(F$3")A$PB81=?G2\]@K1G]&ROI?G^?@/HB_3SM3]^*O\
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M<NQI>QJ?V"'Q;5LNS"5],(F$3")A$PBC]RKLZ:TQQTM^U*[9&^0S2"0QPD+
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MX9V AN4;4N!AC& I(&MCW1PM;-;_ %OP^-25Z;,];+/)YNSUG9)O'&R2\Z;
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MG.CI4*5O1 V2F-%XRI045K8=!V+M%K6_S91R,AJZ:60V9'/$]YL39K'M<XV
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M94^]5=3GWD./_P YU3Z&,?MB*;^"D_\ 3$?^&I_L_:[_ (ITG]3YO\RK%AG
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9(F$3")A$PB81,(F$3")A$PB81,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850367806400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001703647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Frequency Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2324450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line</a></td>
<td class="text">75 Hayden Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Lexington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">315-4600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line</a></td>
<td class="text">75 Hayden Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Lexington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">315-4600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">David L. Lucchino<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850369354944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,853<span></span>
</td>
<td class="nump">$ 51,954<span></span>
</td>
<td class="nump">$ 79,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">25,797<span></span>
</td>
<td class="nump">31,143<span></span>
</td>
<td class="nump">51,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,643<span></span>
</td>
<td class="nump">4,396<span></span>
</td>
<td class="nump">4,041<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">69,293<span></span>
</td>
<td class="nump">87,493<span></span>
</td>
<td class="nump">134,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
<td class="nump">5,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">28,350<span></span>
</td>
<td class="nump">28,980<span></span>
</td>
<td class="nump">31,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OtherLongTermAssets', window );">Other long-term assets</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">101,501<span></span>
</td>
<td class="nump">121,238<span></span>
</td>
<td class="nump">185,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,715<span></span>
</td>
<td class="nump">3,114<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,567<span></span>
</td>
<td class="nump">5,891<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Term loan, current portion</a></td>
<td class="nump">11,667<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,037<span></span>
</td>
<td class="nump">21,026<span></span>
</td>
<td class="nump">11,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">26,215<span></span>
</td>
<td class="nump">26,761<span></span>
</td>
<td class="nump">28,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Term loan, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="nump">14,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">48,252<span></span>
</td>
<td class="nump">52,043<span></span>
</td>
<td class="nump">54,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized, 35,751,956 and 35,262,083 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">334,485<span></span>
</td>
<td class="nump">331,023<span></span>
</td>
<td class="nump">310,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(281,208)<span></span>
</td>
<td class="num">(261,665)<span></span>
</td>
<td class="num">(180,085)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">53,249<span></span>
</td>
<td class="nump">69,195<span></span>
</td>
<td class="nump">130,824<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 101,501<span></span>
</td>
<td class="nump">$ 121,238<span></span>
</td>
<td class="nump">$ 185,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OtherLongTermAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other long-term assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OtherLongTermAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373961184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">35,751,956<span></span>
</td>
<td class="nump">35,262,083<span></span>
</td>
<td class="nump">34,611,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">35,751,956<span></span>
</td>
<td class="nump">35,262,083<span></span>
</td>
<td class="nump">34,611,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850366989744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 11,355<span></span>
</td>
<td class="nump">$ 13,781<span></span>
</td>
<td class="nump">49,418<span></span>
</td>
<td class="nump">60,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,156<span></span>
</td>
<td class="nump">9,477<span></span>
</td>
<td class="nump">33,584<span></span>
</td>
<td class="nump">37,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,511<span></span>
</td>
<td class="nump">23,258<span></span>
</td>
<td class="nump">83,002<span></span>
</td>
<td class="nump">98,099<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,511)<span></span>
</td>
<td class="num">(23,258)<span></span>
</td>
<td class="num">(83,002)<span></span>
</td>
<td class="num">(84,031)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="num">(961)<span></span>
</td>
<td class="num">(764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (loss) gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">753<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(19,519)<span></span>
</td>
<td class="num">(23,374)<span></span>
</td>
<td class="num">(81,582)<span></span>
</td>
<td class="num">(84,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,543)<span></span>
</td>
<td class="num">$ (23,386)<span></span>
</td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (84,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_Earningpersharebasicanddiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (2.33)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighteds Average Number Of Share Outstanding Basic And Diluted</a></td>
<td class="nump">$ 35,324,053<span></span>
</td>
<td class="nump">$ 34,810,676<span></span>
</td>
<td class="nump">$ 35,075,924<span></span>
</td>
<td class="nump">$ 34,351,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_Earningpersharebasicanddiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EarningPerShareBasicAndDiluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_Earningpersharebasicanddiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighteds Average Number Of Share Outstanding Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368041616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,543)<span></span>
</td>
<td class="num">$ (23,386)<span></span>
</td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (84,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities and money market funds</a></td>
<td class="nump">134<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive gain (loss)</a></td>
<td class="nump">134<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (19,409)<span></span>
</td>
<td class="num">$ (23,620)<span></span>
</td>
<td class="num">$ (81,716)<span></span>
</td>
<td class="num">$ (84,775)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850369421664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional-paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 192,491<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 287,829<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">$ (95,399)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,964,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">21,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock, net</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(84,686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,686)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 130,824<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">310,936<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(180,085)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">34,611,213<span></span>
</td>
<td class="nump">34,611,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock, net</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares', window );">Issuance of common stock pursuant to restricted stock units (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,386)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="nump">112,670<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">316,402<span></span>
</td>
<td class="num">(296)<span></span>
</td>
<td class="num">(203,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,976,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 130,824<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">310,936<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(180,085)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">34,611,213<span></span>
</td>
<td class="nump">34,611,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 19,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock, net</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_StockIssuedDuringPeriodSharesUnderEquityOffering', window );">Issuance of common stock under equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount', window );">Issuance of common stock under equity offering</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares', window );">Issuance of common stock pursuant to restricted stock units (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits', window );">Issuance Of Common Stock Pursuant To Restricted Stock Units</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,580)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 69,195<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">331,023<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="num">(261,665)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">35,262,083<span></span>
</td>
<td class="nump">35,262,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares', window );">Issuance of common stock pursuant to restricted stock units (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits', window );">Issuance Of Common Stock Pursuant To Restricted Stock Units</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,543)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 53,249<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 334,485<span></span>
</td>
<td class="num">$ (64)<span></span>
</td>
<td class="num">$ (281,208)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">35,751,956<span></span>
</td>
<td class="nump">35,751,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Pursuant To Restricted Stock Units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to restricted stock units (Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockIssuedDuringPeriodSharesUnderEquityOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Under Equity Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockIssuedDuringPeriodSharesUnderEquityOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Under Equity Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850364238880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (19,543)<span></span>
</td>
<td class="num">$ (23,386)<span></span>
</td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (84,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,431<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">19,831<span></span>
</td>
<td class="nump">21,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="nump">2,766<span></span>
</td>
<td class="nump">2,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_NonCashLeaseExpenses', window );">Non-cash lease expense</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Non-cash interest (income) expense</a></td>
<td class="num">(112)<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,051<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(697)<span></span>
</td>
<td class="num">(429)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="num">(2,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(479)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
<td class="num">(1,816)<span></span>
</td>
<td class="num">(396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(413)<span></span>
</td>
<td class="num">(1,352)<span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,132)<span></span>
</td>
<td class="num">(17,343)<span></span>
</td>
<td class="num">(58,237)<span></span>
</td>
<td class="num">(76,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_ProceedsFromPaymentForPropertyAndEquipment', window );">Sale of property and equipment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(1,978)<span></span>
</td>
<td class="num">(20,786)<span></span>
</td>
<td class="num">(54,222)<span></span>
</td>
<td class="num">(92,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Redemption of marketable securities</a></td>
<td class="nump">7,570<span></span>
</td>
<td class="nump">8,136<span></span>
</td>
<td class="nump">85,338<span></span>
</td>
<td class="nump">29,233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="num">(12,662)<span></span>
</td>
<td class="nump">31,133<span></span>
</td>
<td class="num">(66,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of Term Loan</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(833)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(2,468)<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="num">(577)<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(11,101)<span></span>
</td>
<td class="num">(29,805)<span></span>
</td>
<td class="num">(27,681)<span></span>
</td>
<td class="num">(140,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">53,653<span></span>
</td>
<td class="nump">81,334<span></span>
</td>
<td class="nump">81,334<span></span>
</td>
<td class="nump">222,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">$ 42,552<span></span>
</td>
<td class="nump">$ 51,529<span></span>
</td>
<td class="nump">53,653<span></span>
</td>
<td class="nump">81,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NonCashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NonCashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ProceedsFromPaymentForPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payment For) Property And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ProceedsFromPaymentForPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373616464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization and basis of presentation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Organization </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, and Frequency Therapeutics Securities Corporation (the Company) headquartered in Lexington, Massachusetts, was incorporated in <span style="-sec-ix-hidden:hidden84371168">November 2014</span> as a Delaware corporation. The Company is a preclinical-stage regenerative medicine company focused on developing therapeutics to activate a person&#8217;s innate regenerative potential to restore function. On February&#160;13, 2023, the Company announced a restructuring of the business which included the discontinuation of its hearing program and a downsizing of personnel by approximately 55%. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and capital resources </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has funded its operations primarily with proceeds from private and public securities financings, a term loan, and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of March&#160;31, 2023, the Company had an accumulated deficit of $281,208. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources and the cost savings generated from the restructuring announced in February 2023 will be sufficient to fund planned operations for at least twelve months from the date the financial statements were available to be issued. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements are consistent with those discussed in Note 2, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of significant accounting policies</div></div>,&#8221; in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K).</div> </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited interim financial information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated balance sheet as of March&#160;31, 2023 and the consolidated statements of operations, the consolidated statements of comprehensive loss, the consolidated statements of stockholders&#8217; equity and the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March&#160;31, 2023, the results of its operations for the three months ended March&#160;31, 2023 and 2022, and cash flows for the three months ended March&#160;31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three months ended March&#160;31, 2023 and 2022 are also unaudited. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023, any other interim periods, or any future year or period. The consolidated balance sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December&#160;31, 2022 included in the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Lexington, Massachusetts, was incorporated in <span style="-sec-ix-hidden:hidden84371167">November 2014</span> as a Delaware corporation. Frequency Japan was closed down in February 2021. The Company is a preclinical-stage regenerative medicine company focused on developing therapeutics to activate a person&#8217;s innate regenerative potential to restore function. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and capital resources </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has funded its operations primarily with proceeds from private and public securities financings, a term loan, and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&#160;31, 2022, the Company had an accumulated deficit of $261,665. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374626432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of significant accounting policies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards</div></div> Codification (ASC). </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan through the date of its dissolution. All intercompany transactions and balances have been eliminated. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. Net loss and other comprehensive loss are reported net of any related tax effect to arrive at comprehensive loss. Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the years ended December&#160;31, 2022 and 2021 consist of unrealized loss on marketable securities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Segment information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, view the Company&#8217;s operations and manage its business as a single operating segment, which is in the business of developing therapeutics to activate a person&#8217;s innate regenerative potential to restore function. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2022 and 2021 the Company recorded $5 of foreign currency exchange loss and $16 of foreign currency exchange gain, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2022 and 2021 consists entirely of cash and money market funds. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has $1,699 of restricted cash as of December&#160;31, 2022 and December&#160;31, 2021, which represents a security deposit on the Company&#8217;s Lexington, Massachusetts facility. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketable securities represent holdings of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable securities mature within one year from the balance sheet date while long-term marketable securities mature after one year. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are reflected as a component of other expense. Interest on securities sold is determined based on the specific identification method and reflected as interest income. Any realized gains or losses on the sale of investment are reflected as realized gain (loss) on investments. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of credit risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">restricted cash at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of short term and long term investments. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Significant suppliers </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div> (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Quoted prices in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of lab equipment, furniture and office equipment and software recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of long-lived assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2022 and 2021. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs and accruals </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, preclinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for leases under ASC 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>. The Company determines if an arrangement is, or contains, a lease at inception and, if so, records a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) asset and a lease liability on the consolidated balance sheet for any lease with a term longer than 12 months. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, the Company has elected to account for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, such as common area maintenance charges, as a single lease component. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC&#160;808, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative Arrangements</div></div> (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (ASC 606). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> clinical activities are recognized as research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> agreements that are within the scope of ASC 606. The terms of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (Astellas), as further described in Note 13, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration agreement</div></div>&#8221;, of notes to consolidated financial statements. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this standard. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC&#160;606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a)&#160;a good or service (or bundle of goods and services) that is distinct, or (b)&#160;a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> research and development activities, and/or manufacturing services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-09</div> which identifies areas for simplification of several areas of share-based payment transactions. The Company treats <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> The Company believes the fair value of the stock options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> is more reliably determinable than the fair value of the services provided. </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses the fair value of its share-based compensation awards to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> on a straight-line basis over the requisite service period, which is generally the vesting period. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2022 and 2021, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 11, <div style="null;text-indent: 0px;;display:inline;">&#8220;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes</div></div>&#8221;). </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss per share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2022 and 2021 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,075,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,351,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Recently issued and adopted accounting pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses</div></div> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted this standard on January 1, 2023 and it did not have a material impact on the consolidated financial statements. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850367942160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Adopted And Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Adopted and Issued Accounting Standards</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Recently adopted and issued accounting standards </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the JOBS Act). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, the Company will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses</div></div> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted the standard on January&#160;1, 2023 and it did not have a material impact on the consolidated financial statements. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850367800080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair value measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy at March&#160;31, 2023 and December&#160;31, 2022 are summarized as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,844</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Silicon Valley Bank (SVB) was closed on March&#160;10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. The FDIC then reopened SVB as Silicon Valley Bridge Bank, N.A. (SVBB). At March&#160;31, 2023, SVBB continues to hold the Company&#8217;s term loan, deposit and sweep accounts, and security deposit for the Company&#8217;s office space under the existing terms and covenants which were in place at SVB prior to the receivership. The Company is actively working to move these accounts to another financial institution. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair value measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December&#160;31, 2022 and 2021 are summarized as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gain&#160;(Loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(137</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">111,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(89</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2022 and 2021, we held 14 and 18 debt securities, respectively, that were in an unrealized loss position. The unrealized losses at December&#160;31, 2022 and 2021 were attributable to changes in interest rates and do not represent credit losses. The Company does not intend to sell the investments before recovery of their amortized cost bases, which may be at maturity. All investments mature within twelve months from December&#160;31, 2022. The following tables summarize the Company&#8217;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than&#160;12&#160;Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850463280128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Prepaid expenses and other current assets </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Rent and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Insurance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850370552960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investment</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Investments </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the Company&#8217;s investments, all of which are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and recorded at fair value: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s short-term marketable securities were held in investment advisory accounts with SVB Asset Management (SAM). On March&#160;27, 2023, following the closure of SVB, SAM&#8217;s former parent company, and the creation of SVBB, the FDIC entered into a purchase and assumption agreement for certain assets of SVBB with First-Citizens Bank&#160;&amp; Trust Company (FCB). As a result of this transaction, SAM became a wholly owned subsidiary of FCB. Although the accounts are held under the terms in place prior to the transaction, the Company is actively working to move these accounts to another financial institution. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the appropriate classification of investments at the time of purchase and reviews any investment when its fair value is less than its amortized cost and when evidence indicates that the investment&#8217;s carrying amount is not recoverable within a reasonable period of time. The Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the investment is compared to its amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to a credit loss is recognized in other comprehensive (loss) income. The unrealized losses at March&#160;31, 2023 and December&#160;31, 2022 were attributable to changes in interest rates and do not represent credit losses. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At March&#160;31, 2023 and December&#160;31, 2022 the Company held 9 and 14 debt securities, respectively, that were in an unrealized loss position. The Company does not intend to sell the investments before recovery of their amortized cost bases, which may be at maturity. All investments mature within twelve months from March&#160;31, 2023. The following tables summarize the Company&#8217;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities in unrealized loss position</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities in unrealized loss position</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850371281536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and equipment </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment include the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,747</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,444</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,496</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized $1,000 and $726 of depreciation expense for the three months ended March&#160;31, 2023 and 2022, respectively. The Company accelerated depreciation of $360 on certain lab equipment for the three months ended March&#160;31, 2023 as discussed in Note 17, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Restructuring&#8221;.</div></div> </div><span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and equipment </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment include the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,496</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,184</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized $2,766 and $2,775 of depreciation expense for the years ended December&#160;31, 2022 and 2021, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850371077936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued expenses </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payroll and employee related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Third-party research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued expenses </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payroll and employee related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">767</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Third-party research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374500464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Debt </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2020, the Company entered into a Loan and Security Agreement (Loan Agreement) with Silicon Valley Bank for a term loan with a principal balance of $15,000. The Company made monthly interest only payments through November 30, 2022. The principal balance and interest were to be repaid in equal monthly installments after the interest only period and continue through May 1, 2024 (Loan Maturity Date). Advances under the Loan Agreement would bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in The Wall Street Journal, subject to an interest rate floor of zero) or (ii) 4.75%. The interest rate at March&#160;31, 2023 was 9.25%. Interest expense related to the Loan Agreement was $284 for the three months ended March&#160;31, 2023 and $178 for the three months ended March&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2023, the Company prepaid the remaining $11,667 due under the Loan Agreement. The final payment of $150, which the Company had been accruing over the term of the loan, was also paid. The Company was not subject to any prepayment premium as the prepayment occurred after the second anniversary of the closing date. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Debt </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2020, the Company entered into a Loan and Security Agreement (Loan Agreement) with a commercial bank for a term loan with a principal balance of $15,000. <span style="-sec-ix-hidden:hidden84371525">The Company made monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continue through May 1, 2024 (Loan Maturity Date).</span> Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Wall Street Journal</div></div>, subject to an interest rate floor of zero) or (ii) 4.75%. The interest rate at December&#160;31, 2022 was 9.0%. Interest expense related to the Loan Agreement was $961 for the year ended December&#160;31, 2022 and $764 for the year ended December&#160;31, 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the term loan is refinanced by the bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will pay a final payment of $150, which will occur on the earliest of: (i)&#160;the Loan Maturity Date; (ii)&#160;the date that the Company prepays all of the outstanding principal in full; (iii)&#160;the date the loan payments are accelerated due to an event of default; or (iv)&#160;the termination of the Loan Agreement. The Company is accruing the final payment over the term of the loan. The term loan is secured by substantially all of the Company&#8217;s assets, excluding intellectual property. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373659664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Net loss per share </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the three months ended March&#160;31, 2023 and 2022 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net Loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,386</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,324,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,810,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,642,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,165,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,610,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,242,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,776,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374500464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Stockholders&#8217; equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of March&#160;31, 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has authorized 200,000,000 shares of $0.001 par value common stock of which there were 35,751,956 and 35,262,083 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has reserved the following shares of common stock for future issuance as of March&#160;31, 2023 and December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,742,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares available for future grant under incentive plans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,690,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">988,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,290,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,730,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Equity Offerings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;10, 2021, the Company entered into an Equity Distribution Agreement (the Sales Agreement) with Oppenheimer&#160;&amp; Co. Inc. (the Sales Agent) to sell shares of the Company&#8217;s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $125,000, from time to time, through an &#8220;at the market&#8221; equity offering program. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issuance costs incurred related to the Sales Agreement are classified as long-term assets on the balance sheet at March&#160;31, 2023. During the three months ended March&#160;31, 2022, the Company sold 12,767 shares of common stock under the ATM program for net proceeds of approximately $50. No shares were sold during the three months ended March&#160;31, 2023. </div><span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Stockholders&#8217; equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of December&#160;31, 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Common stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has authorized 200,000,000 shares of $0.001 par value common stock of which 35,262,083 were issued and outstanding as of December&#160;31, 2022. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has reserved the following shares of common stock for future issuance as of December&#160;31, 2022 and 2021: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,742,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,830,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares available for future grant under stock option plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">988,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,552,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,730,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,382,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Equity Offerings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;10, 2021, the Company entered into an Equity Distribution Agreement (Sales Agreement) with Oppenheimer&#160;&amp; Co. Inc. (Sales Agent) to sell shares of the Company&#8217;s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $125,000, from time to time, through an &#8220;at the market&#8221; equity offering program. Subject to the terms and conditions of the Sales Agreement, the Sales Agent may sell the shares by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made through The Nasdaq Global Select Market, on any other existing trading market for the Common Stock, to or through a market maker, or, if expressly authorized by the Company, in privately negotiated transactions. The Company or Sales Agent may terminate the Sales Agreement upon notice to the other party and subject to other conditions. The Company will pay the Sales Agent a commission equal to 3.0% of the gross proceeds of any Common Stock sold through the Sales Agent under the Sales Agreement and has provided the Sales Agent with customary indemnification rights. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issuance costs incurred related to the Sales Agreement are classified as long-term assets on the balance sheet at December&#160;31, 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368051008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stock-based compensation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock options </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes stock option activity within the Company&#8217;s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares<br/> in Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise&#160;price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term&#160;(in&#160;years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> intrinsic<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,742,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,969</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(166,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,789,470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options unvested as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810,618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock option valuation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2023 and 2022 was $3.58 and $3.55, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total grant date fair value of options vested during the three months ended March&#160;31, 2023 and 2022 was $2,874 and $5,097, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Repricing of stock options </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;17, 2022, the Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $2.14, the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022. Except for the modification of the exercise price, all other terms and conditions of the Underwater Options remain in effect. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option repricing resulted in incremental stock-based compensation of $2,505, of which $170 was recorded as expense in the three months ended March&#160;31, 2023. At March&#160;31, 2023, $705 incremental expense remains which will be recognized as expense over the requisite service period in which the options vest. </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes restricted stock unit activity within the Company&#8217;s 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average&#160;fair<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,101,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Awarded</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,666,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(306,775</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(819,050</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,642,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, total unrecognized stock-based compensation expense relating to unvested stock options and restricted stock units was $17,610. This amount is expected to be recognized over a weighted-average period of 1.72 years. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Stock-based compensation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&#8217;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December&#160;31, 2022, there were no shares of common stock available for future grants under the 2014 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2019, the Company&#8217;s board of directors and on September&#160;19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (2019 Plan). Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries. A total of 3,100,000 shares of common stock were approved to be </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">initially reserved for issuance under the 2019 plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> term of the 2019 Plan, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stock option grants are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&#8217;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock options </div></div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise&#160;price<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">&#160;(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term&#160;(in&#160;years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> intrinsic<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,816,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">171,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,357,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32.76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(642,314</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(701,873</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,830,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">221,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,299,113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,742,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,579,486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options unvested as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,162,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,043</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:8.3px">(1)</div> On August&#160;17, 2022, the Company&#8217;s Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $2.14, the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022.<div style="background-color:#ffffff;;display:inline;"> </div><div style="null;text-indent: 0px;;display:inline;"></div><div style="display:inline;"><div style="background-color:#ffffff;;display:inline;">See &#8220;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="background-color:#ffffff;;display:inline;">Repricing of stock options</div></div></div><div style="background-color:#ffffff;;display:inline;">&#8221; section for more information. </div></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock option valuation </div></div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of options granted to employees during the years ended December&#160;31, 2022 and 2021 was $1.58 and $22.39 respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total grant date fair value of options vested during the years ended December&#160;31, 2022 and 2021 was $14,219 and $16,304, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Repricing of stock options </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;17, 2022, the Board of Directors approved the repricing of each Underwater Option to $2.14, the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022. Except for the modification of the exercise price, all other terms and conditions of the Underwater Options remain in effect. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option repricing resulted in incremental stock-based compensation of $2,505, of which $1,630 was recorded as expense in the year ended December&#160;31, 2022 and $875 will be recognized as expense over the remaining vesting period. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted stock units </div></div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes restricted stock unit activity within the Company&#8217;s 2019 Incentive Award Plan for the year ended December&#160;31, 2022. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average&#160;fair<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">626,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Awarded</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,576,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(551,450</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(549,850</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.06</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,101,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense of $19,831 and $21,750 for the years ended December&#160;31, 2022 and 2021 respectively, is included in research and development and general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, total unrecognized stock-based compensation expense relating to unvested stock options and restricted stock units was $19,537 and $39,112, respectively. This amount is expected to be recognized over a weighted-average period of 1.55 years and 2.49 years, respectively. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374626432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_EmployeeStockPurchasePlanDisclosureTextBlock', window );">Employee Stock Purchase Plan</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Employee stock purchase plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the ESPP) which became effective on the date of the Company&#8217;s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten years of the term of the ESPP, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31,832 shares were purchased under the ESPP in January 2022 related to the second offering period of 2021, which concluded on December&#160;31, 2021. 24,754 shares were purchased in January 2023 related to the second offering period of 2022, which concluded on December&#160;31, 2022. As of March&#160;31, 2023, a total of 1,553,394 shares remain available for future issuance under the ESPP. </div><span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Employee stock purchase plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (ESPP) which became effective on the date of the Company&#8217;s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten years of the term of the ESPP, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s first offering period of 2021 concluded on June&#160;30, 2021 with the purchase of 7,064 shares in July 2021 related to this offering period. The Company&#8217;s second offering period of 2021 concluded on December&#160;31, 2021 with the purchase of 31,832 shares in January 2022. The Company&#8217;s first offering period of 2022 concluded on June&#160;30, 2022 with the purchase of 44,774 shares in July 2022 related to this offering period. As of December&#160;31, 2022, a total of 1,225,527 shares remain for future offering periods. The Company&#8217;s second offering period of 2022 concluded on December&#160;31, 2022 with the purchase of 24,754 shares in January 2023 related to this offering. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_EmployeeStockPurchasePlanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_EmployeeStockPurchasePlanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374547520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Income taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s total provision is based on the United States statutory rate of 21%, increased by state taxes and reduced by a full valuation allowance on the Company&#8217;s deferred tax assets. The income tax expense for the three months ended March&#160;31, 2023 and 2022 represents state taxes on interest income earned by the Company&#8217;s subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at March&#160;31, 2023 and December&#160;31, 2022 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which no net tax benefit has been recorded due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Income taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which the Company has not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had federal net operating loss carryforwards of approximately $174,107 and Massachusetts state operating loss carryforwards of approximately $141,318 which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,399 available to reduce future taxable income through 2037 and approximately $151,708 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2042. As of December&#160;31, 2022, the Company also had federal and Massachusetts research and development tax credit carryforwards of $8,177 and $3,556, respectively, which are available to offset federal and state tax liabilities through 2042 and 2037, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Code, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382 of the Code, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a rolling three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-ownership</div> change) is limited under Section&#160;382 of the Code. After the limitations under Section&#160;382 of the Code, the Company may utilize approximately $10,800 of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-ownership</div> change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-March</div> 2017 ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> rate. These </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">carryforwards may be subject to further annual limitations under Section&#160;382 of the Code in the event of future changes in ownership. Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO. Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section&#160;382 of the Code. The Company has determined it will be able to utilize the entire $46,123 of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-ownership</div> change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section&#160;382 of the Code in the event of future changes in ownership. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2022 and 2021 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $77,288 and $50,931 as of December&#160;31, 2022 and 2021 has been established. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss for the years ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,586</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,624</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,582</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,671</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s provision at December&#160;31, 2022 and 2021 consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total (benefit) provision</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S federal statutory income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(0.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income taxes, net of federal benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">5.4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">2.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">5.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">3.6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State rate changes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">3.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation deductions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2.8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1.6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other items</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(0.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in deferred tax asset valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(32.3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(28.2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effective income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s deferred tax assets at December&#160;31, 2022 and 2021 consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">45,512</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">36,590</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">11,163</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,026</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">10,042</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangibles</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">478</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">392</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">9,507</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">6,554</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">107</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">357</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">176</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">282</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">265</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,735</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,269</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">85,076</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">58,379</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(77,288</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(50,931</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,788</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,448</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(7,788</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(7,448</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset (liability)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374532688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Collaboration agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensable,</div> nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GSK-3</div> inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322,</div> outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80,000 in July 2019 and has agreed to pay potential development milestone payments up to $230,000 and commercialization milestones of up to $315,000. The parties agreed to share equally, on a 50/50 basis, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;11, 2023, Astellas sent the Company a notice stating that Astellas would be terminating the Astellas Agreement in its entirety on April&#160;14, 2023. The Company agreed to the terms of the notice and on April&#160;14, 2023, the Astellas Agreement was terminated in its entirety. The Company was not subject to any payments or costs as a result of this termination. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement was a collaborative agreement that is within the scope of ASC 808, Collaborative Arrangements. Under the provisions of ASC 808, the Company determined that it would apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company recognized the $80,000 upfront fee, which was initially recorded as deferred revenue, as revenue over the period from July 2019 until June&#160;30, 2021, when the Phase 2a clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202),</div></div> the Company&#8217;s performance obligation, was completed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company invoices Astellas for all joint costs. In the three months ended March&#160;31, 2023 and 2022, the Company invoiced Astellas $14 and $193, respectively, for joint costs. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Collaboration agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensable,</div> nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GSK-3</div> inhibitor and an HDAC inhibitor (Astellas Licensed Products), including the product candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322,</div> outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These parties have agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">age-related</div> hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collaboration is governed by a joint steering committee (JSC) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&#8217;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80,000 in July 2019 and has agreed to pay potential development milestone payments up to $230,000 and commercialization milestones of up to $315,000. Specifically, the Company would receive development milestone payments of $65,000 and $25,000 upon the first dosing of a subject in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100,000 and $40,000 upon the first dosing of a subject in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315,000 in potential commercial milestone payments and also tiered royalties at rates ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-</div> to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teen</div> percentages. The parties shall share equally, on a 50/50 basis, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis until the latest of (i)&#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii)&#160;a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#8217;s material breach if such breach remains uncured for 90&#160;days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue associated with this single performance obligation was recognized as the research and development work was performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurred over this time period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligation. The Company determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and continued until the completion of the Phase 2a clinical trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202).</div></div> The transaction price of $80,000 was allocated to the single combined performance obligation and recorded as deferred revenue in July 2019 when it was received. This upfront payment was recognized as revenue over the period from July 2019 until June&#160;30, 2021, the completion date of the Phase 2a clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202),</div></div> using the input method. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&#8217;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statements of operations during the development period. In the year ended December&#160;31, 2022 and 2021, the Company invoiced Astellas $392 and $885 for joint costs. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850370569712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (Lease Termination Agreement) with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARE-MA</div> Region No.&#160;20, LLC (Landlord) for the Company&#8217;s office and laboratory space in Woburn, Massachusetts. The Lease Termination Agreement provides that the Lease Agreement, dated as of August&#160;14, 2016, by and between the Company and Landlord (as the same may have been amended, the Lease) will terminate on March 31, 2021, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May&#160;31, 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;7, 2020 the Company entered into an indenture of lease (Lexington Lease) with HCP/KING 75 Hayden LLC, for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (Lexington Premises). The Lexington Lease commenced on December 11, 2020. In the second quarter of 2021, the Company began using the Lexington Premises as its principal executive offices and laboratory for research and development. The term of the Lexington Lease is expected to end on May 31, 2031. The Company also has the option to extend the Initial Term for two additional terms of five years each. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s rent expense for the years ended December&#160;31, 2022 and 2021 was $4,802 and $4,960, respectively. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other information</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining operating lease term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.4&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December&#160;31, 2022. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,534</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: amount of lease payments representing interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of future lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,021</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Noncurrent lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future aggregate minimum payments under the noncancelable operating lease as of December&#160;31, 2022 are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,534</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027 and beyond</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850371267936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_LicenseAgreementTextBlock', window );">Research and License Agreements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. License agreements </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Massachusetts Institute of Technology </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement) with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-month</div> prior written notice. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, the Company entered into a second amendment with MIT, removing a patent and certain patent applications from the MIT License Agreement which were unrelated to the Company&#8217;s hearing and multiple sclerosis (MS) programs and which were not being utilized by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;6, 2023, the Company sent MIT a notice stating that the Company would be terminating the MIT License Agreement in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-months&#8217;</div> time. The Company is not subject to any payments or costs as a result of this termination. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">The Scripps Research Institute (California Institute for Biomedical Research) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of MS. The Company also has the right to grant sublicenses of its rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> licenses to other nonprofit or academic institutions, for any internal research and educational purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment. The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. The Company may terminate the CALIBR License Agreement at will upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> prior written notice. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;29, 2023, the Company sent CALIBR a notice stating that the Company would be terminating the CALIBR License Agreement in 30 days&#8217; time. The termination became final on or around April&#160;28, 2023. The Company is not subject to any payments or costs as a result of this termination. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company entered into an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Exclusive</div> Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss (MEE licensed products). </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering the MEE License, the Company made a $20 license fee payment. The Company was obligated to pay certain annual license maintenance fees between $5 and $7.5 per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;21, 2023, the Company sent MEE a notice stating that the Company would be terminating the MEE License Agreement in 30 business days&#8217; time. The termination became final on or around April&#160;4, 2023. The Company is not subject to any payments or costs as a result of this termination. </div><span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Research and license agreements </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Massachusetts Institute of Technology </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322.</div> The Company&#8217;s future development obligations are: (i)&#160;to commence a Phase 3 clinical trial for such Product within five years of the IND filing for such product, (ii)&#160;to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii)&#160;to make a first commercial sale of such Product within 11 years of the IND filing for such Product. The Company also has certain development obligations for a second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fails to cure such breach within ninety (90)&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent applications, and its rights to enforce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents are subject to certain limitations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, the Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-twenties</div> royalty on sublicense revenues. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-month</div> prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90)&#160;days (or thirty (30)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringed</div> (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, the Company entered into an amendment with MIT, removing a patent and certain patent applications from the MIT License Agreement which were unrelated to the Company&#8217;s hearing and MS programs and which were not being utilized by the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr.&#160;Langer, one of the Company&#8217;s directors. Pursuant to MIT&#8217;s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr.&#160;Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr.&#160;Langer has received $11 and $6 from MIT under the MIT Policy during the years ended December&#160;31, 2022 and 2021, respectively. Refer to Note 18, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related party transactions</div></div>&#8221;, for all related party disclosures. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">The Scripps Research Institute (California Institute for Biomedical Research) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, the Company entered into a license agreement (CALIBR License Agreement) with the California Institute for Biomedical Research (CALIBR) under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> licenses to other nonprofit or academic institutions, for any internal research and educational purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR Licensed Product. The Company is also subject to certain milestone timeline obligations, which may be extended in certain circumstances as set forth in the CALIBR License Agreement. In October 2021, the Company entered into an amendment with CALIBR which updated the milestone obligations to: (i)&#160;initiate a Phase 2 clinical trial (or equivalent) for a CALIBR Licensed Product by December&#160;31, 2023 and (ii)&#160;initiate a Phase 3 clinical trial (or equivalent) for a CALIBR Licensed Product by December&#160;31, 2025. The Company does not have the right to control prosecution of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent applications, and the Company&#8217;s rights to enforce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents are subject to certain limitations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and is required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 is any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 is any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursor cells from <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> studies and/or are active in animal models relevant to MS). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-teen</div> percentage to 50%. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and CALIBR Licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Product-by-CALIBR</div></div> Licensed Product basis upon the later of (1)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&#160;days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&#160;days. CALIBR has the right to terminate or reduce the license to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company entered into an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Exclusive</div> Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss (MEE licensed products). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is obligated to use diligent efforts to develop and commercialize the MEE licensed products. The Company met one of its milestone timeline obligations by dosing a first subject in a Phase 2 trial by December&#160;31, 2020. The Company is still subject to a milestone timeline obligation to dose a first subject in a Phase 3 trial by December&#160;31, 2024. The Company does not control the filing, prosecution, enforcement, and defense of any licensed patent rights. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering the MEE License, the Company made a $20 license fee payment. The Company is obligated to pay certain annual license maintenance fees between $5 and $7.5 per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. The Company is also obligated to pay a minimum annual royalty payment of $15 per each MEE patent family case number included in the licensed MEE patent rights after first commercial sale of an MEE licensed product. The Company is also obligated to make milestone payments up to $350 on each product or process that incorporates the licensed patent rights. In addition, the Company has agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEE License Agreement at will by giving thirty (30)&#160;business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30)&#160;business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45)&#160;business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60)&#160;business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374718000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">17. Restructuring </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company announced the topline results for the Phase 2b study of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-208)</div></div> which failed to achieve its primary efficacy endpoint of an improvement in speech perception. As a result, the Company also announced that it would be discontinuing the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-345</div> hearing development programs and focusing resources on its remyelination in MS development program. This restructuring resulted in a 55% reduction in the Company&#8217;s workforce. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expects to incur a total of approximately $4,329 in restructuring-related expenses, of which $3,970 was expensed in the three months ended March&#160;31, 2023. The total estimated restructuring charges consist of accelerated depreciation expense of $360, accelerated hearing program expense of $129, and severance and other benefit-related costs of $3,840, of which $3,481 was expensed in the three months ended March&#160;31, 2023 and the remaining $359 will be expensed in the second quarter of 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended March&#160;31, 2023, the following restructuring-related charges were included in the Consolidated Statement of Operations: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance&#160;and&#160;other<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">benefit-related</div><br/> costs</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated<br/> depreciation<br/> charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated<br/> hearing&#160;program<br/> charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At March&#160;31, 2023, the liability for the restructuring is classified as current and included in accrued expenses in the Consolidated Balance Sheets. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated&#160;hearing<br/> program charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance&#160;and&#160;other<br/> benefit-related costs</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net charges</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability balance as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850370634816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sublease<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_Sublease', window );">Sublease</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Sublease </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;8, 2022, the Company entered into a Sublease Agreement with SalioGen Therapeutics, Inc. (SalioGen) to sublease approximately 30,040 rentable square feet of the Company&#8217;s office space in Lexington, MA for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> term. The base sublease rent per month for the first and second year of the sublease is $197 and $203, respectively. In addition to base rent, SalioGen will pay 49% of operating costs and taxes payable under the Company&#8217;s lease for the Lexington, MA office space. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since commencement, the Company has accounted for the Lexington, MA office space as an operating lease. In accordance with ASC 842, the Company concluded the sublease is also an operating lease. The Company recognized sublease income of $1,186 for the year ended December&#160;31, 2022. The below table shows the expected future sublease income as of December&#160;31, 2022. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sublease&#160;Income</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total future sublease income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,754</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_Sublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_Sublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373770528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Commitments and contingencies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contract commitments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also enters into contracts in the normal course of business with contract researc<div style="display:inline;">h org</div>anizations, contract manufacturing organizations, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by the Company upon prior written notice although, purchase orders for clinical materials are generally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable.</div> Payments due upon cancellation consist only of payments for services provided or expenses incurred, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> obligations of the Company&#8217;s service providers, up to the date of cancellation or upon the completion of a manufacturing run. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Guarantees </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Guarantees</div></div>. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office space in Lexington, Massachusetts under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> noncancelable operating lease. The $1,699 security deposit for this lease is classified as restricted cash as of March&#160;31, 2023. The Company has standard indemnification arrangements under this lease that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Legal Contingencies </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-49 </div><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#8217;s accrued liabilities would be recorded in the period in which such determination is made. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;3, 2021 and June&#160;22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company and the Company&#8217;s Chief Executive Officer, President, and Director, David Lucchino. On March&#160;21, 2022, the two lawsuits were consolidated into a single lawsuit, Quinones et al. v. Frequency Therapeutics, Inc. et al. and on May&#160;16, 2022, the Company&#8217;s Chief Development Officer, Dr.&#160;Carl LeBel, was added as a defendant. The plaintiffs alleged violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#8217;s Phase 2a clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202)</div></div> for its product candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> in the Company&#8217;s public disclosures between October&#160;29, 2020 and March&#160;22, 2021. The lawsuit sought, among other things, damages in connection with the Company&#8217;s allegedly artificially inflated stock price between October&#160;29, 2020 and March&#160;22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#8217; fees and costs. The Company filed a motion to dismiss the Amended Complaint on July&#160;15, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. On March&#160;29, 2023, the Company&#8217;s motion to dismiss was granted and the lawsuit was dismissed in its entirety. On April&#160;27, 2023, Plaintiff filed a notice of appeal to the United States Court of Appeals for the First Circuit from the order dismissing the lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, <div style="display:inline;">no</div> accruals have been recorded as of March&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;21, 2022, the Delaware Chancery Court dismissed a lawsuit brought by two purported stockholders against the Company and others. For previously reported information on this lawsuit, refer to Part I, Item 3, &#8220;Legal Proceedings&#8221; of the Company&#8217;s 2021 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> On August&#160;16, 2022, these same two purported stockholders of the Company filed a similar lawsuit in Delaware Superior Court against (i)&#160;the Company, (ii)&#160;Computershare Inc., and (iii)&#160;Computershare Trust Company, N.A., entitled The Gregory J. Parseghian Revocable Trust, et al. v. Frequency Therapeutics, Inc., et al. The lawsuit alleges causes of action against the Company for breach of the statutory duty of care, negligence, conversion, and unjust enrichment, based on allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The Company intends to vigorously defend against all claims asserted in the lawsuit. The Company filed a motion to dismiss the complaint on November&#160;14, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of March&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;30, 2022, a purported stockholder of the Company filed a shareholder derivative complaint in the U.S. District Court for the District of Delaware purportedly on the Company&#8217;s behalf against members of the Company&#8217;s board of directors and the Company as a nominal defendant, entitled <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dewey v. Cohen et. al.</div></div> The complaint alleges (i)&#160;violations of Section&#160;10(b) and Rule 10b5 of the Exchange Act, (ii)&#160;breach of fiduciary duty, (iii)&#160;aiding and abetting breach of fiduciary duty, (iv)&#160;unjust enrichment, and (v)&#160;waste of corporate assets. The claims are based on the same underlying allegations as the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones</div></div> case (described above). The complaint seeks, among other things, monetary damages, interest, attorneys&#8217; fees and costs. On September&#160;27, 2022, this lawsuit was stayed pending final resolution of the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones</div></div> case. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company&#8217;s board members are each party to an indemnification agreement with the Company that may require the Company to reimburse the board members for certain expenses and other costs related to this lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, <div style="display:inline;">no</div> accruals have been recorded as of March&#160;31, 2023. </div><span></span>
</td>
<td class="text">16. Commitments and contingencies <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contract commitments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable.</div> Payments due upon cancellation consist only of payments for services provided or expenses incurred, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Guarantees </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Guarantees</div></div>. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office space in Lexington, Massachusetts under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">ten-year</div></div> noncancelable lease. The $1,699 security deposit for this lease is classified as restricted cash as of December&#160;31, 2022. The Company exited the Woburn, Massachusetts facility in the second quarter of 2021. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Legal Contingencies </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#8217;s accrued liabilities would be recorded in the period in which such determination is made. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;3, 2021 and June&#160;22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company and the Company&#8217;s Chief Executive Officer, President, and Director, David Lucchino. On March&#160;21, 2022, the two lawsuits were consolidated into a single lawsuit, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones et al. v. Frequency Therapeutics, Inc. et al</div></div>. and on May&#160;16, 2022, the Company&#8217;s Chief Development Officer, Dr.&#160;Carl LeBel, was added as a defendant. The plaintiffs allege violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#8217;s Phase 2a clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(FX-322-202)</div></div> for its product candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FX-322</div> in the Company&#8217;s public disclosures between October&#160;29, 2020 and March&#160;22, 2021. The lawsuit seeks, among other things, damages in connection with the Company&#8217;s allegedly artificially inflated stock price between October&#160;29, 2020 and March&#160;22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#8217; fees and costs. The Company intends to vigorously defend against all claims asserted in the lawsuit. The Company filed a motion to dismiss the Amended Complaint on July&#160;15, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;21, 2022, the Delaware Chancery Court dismissed a lawsuit brought by two purported stockholders against the Company and others. For previously reported information on this lawsuit, refer to Part I, Item 3, &#8220;Legal Proceedings&#8221; of the Company&#8217;s 2021 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> On August&#160;16, 2022, these same two purported stockholders of the Company filed a similar lawsuit in Delaware Superior Court against (i)&#160;the Company, (ii)&#160;Computershare Inc., and (iii)&#160;Computershare Trust Company, N.A., entitled <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Gregory J. Parseghian Revocable Trust</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">et al.</div></div> v. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Frequency Therapeutics, Inc., et al.</div></div> The lawsuit alleges causes of action against the Company for breach of the statutory duty of care, negligence, conversion, and unjust enrichment, based on allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The Company intends to vigorously defend against all claims asserted in the lawsuit. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;30, 2022, a purported stockholder of the Company filed a shareholder derivative complaint in the U.S. District Court for the District of Delaware purportedly on the Company&#8217;s behalf against members of the Company&#8217;s board of directors and the Company as a nominal defendant, entitled <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dewey v. Cohen et. al.</div></div> The complaint alleges (i)&#160;violations of Section&#160;10(b) and Rule 10b5 of the Exchange Act, (ii)&#160;breach of fiduciary duty, (iii)&#160;aiding and abetting breach of fiduciary duty, (iv)&#160;unjust enrichment, and (v)&#160;waste of corporate assets. The claims are based on the same underlying allegations as the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones</div></div> case (described above). The complaint seeks, among other things, monetary damages, interest, attorneys&#8217; fees and costs. On September&#160;27, 2022, this lawsuit was stayed pending resolution of the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quinones</div></div> case. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company&#8217;s board members are each party to an indemnification agreement with the Company that may require the Company to reimburse the board members for c<div style="display:inline;">er</div>tain expenses and other costs related to this lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of December&#160;31, 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850370577760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">17. Employee benefit plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees of the Company are eligible to participate in the Company&#8217;s 401(k) retirement plan (401(k) Plan). Partic<div style="display:inline;">ipan</div>ts may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches 100% of the first 5% of employee contributions and vests 100% at time of match. For the years ended December&#160;31, 2022 and 2021, the Company made matching contributions of $550 and $723, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374708416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">18. Related party transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As disclosed in Note 12, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and license agreements</div></div>&#8221;, the Company entered into the MIT License Agreement in December 2016. The patents <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr.&#160;Langer, one of the Company&#8217;s directors. Accordingly, Dr.&#160;Langer has received $11 and $6 from MIT under the MIT Policy during the years ended December&#160;31, 2022 and 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s lease for its Woburn, Massachusetts facility, terminated in May 2021 as disclosed in Note&#160;14, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>&#8221;, was with an entity affiliated with one of the Company&#8217;s directors and shareholders. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374706848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">18. Subsequent events </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through May&#160;12, 2023, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows: </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2023, the Company prepaid the remaining $11,667 due under the term loan. Upon prepayment of the term loan, the final payment of $150, which the Company had been accruing over the term of the loan, was also paid. The Company was not subject to any prepayment premium as the prepayment occurred after the second anniversary of the closing date. Refer to Note 7, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Debt&#8221;.</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;4, 2023, the Company&#8217;s termination of the MEE License Agreement became final. No termination costs were incurred as a result of terminating this license agreement. Refer to Note 14, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;License agreements&#8221;.</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;6, 2023, the Company provided written notice of termination of the MIT License Agreement. Pursuant to the terms of the agreement, the Company has the right to terminate for any reason upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-month</div> prior written notice. No termination costs will be incurred as a result of terminating this license agreement. Refer to Note 14, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;License agreements&#8221;.</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;14, 2023, the Astellas Agreement was terminated in its entirety. No termination costs will be incurred as a result of terminating this collaboration agreement. Refer to Note 13, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Collaboration agreement&#8221;.</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;28, 2023, the Company&#8217;s termination of the CALIBR License Agreement became final. No termination costs were incurred as a result of terminating this license agreement. Refer to Note 14, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;License agreements&#8221;.</div></div> </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">19. Subsequent events </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March&#160;10, 2023, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows: </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company announced a restructuring in which its hearing program was discontinued. As a result, the Company reduced its workforce by approximately 55% to better align with the needs of its business. The total personnel costs related to the restructuring are estimated to be approximately $4,000 in future cash outlays primarily related to severance costs and related expenses. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368282384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). </div><span></span>
</td>
<td class="text"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards</div></div> Codification (ASC). </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements are consistent with those discussed in Note 2, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of significant accounting policies</div></div>,&#8221; in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K).</div> </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan through the date of its dissolution. All intercompany transactions and balances have been eliminated. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. Net loss and other comprehensive loss are reported net of any related tax effect to arrive at comprehensive loss. Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the years ended December&#160;31, 2022 and 2021 consist of unrealized loss on marketable securities. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Segment information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, view the Company&#8217;s operations and manage its business as a single operating segment, which is in the business of developing therapeutics to activate a person&#8217;s innate regenerative potential to restore function. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2022 and 2021 the Company recorded $5 of foreign currency exchange loss and $16 of foreign currency exchange gain, respectively. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2022 and 2021 consists entirely of cash and money market funds. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has $1,699 of restricted cash as of December&#160;31, 2022 and December&#160;31, 2021, which represents a security deposit on the Company&#8217;s Lexington, Massachusetts facility. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketable securities represent holdings of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable securities mature within one year from the balance sheet date while long-term marketable securities mature after one year. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are reflected as a component of other expense. Interest on securities sold is determined based on the specific identification method and reflected as interest income. Any realized gains or losses on the sale of investment are reflected as realized gain (loss) on investments. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Off-balance Sheet Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of credit risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">restricted cash at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of short term and long term investments. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SignificantSuppliersPolicyTextBlock', window );">Significant Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Significant suppliers </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div> (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;1</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Quoted prices in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;2</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;3</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of lab equipment, furniture and office equipment and software recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of long-lived assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2022 and 2021. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs and Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs and accruals </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, preclinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for leases under ASC 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>. The Company determines if an arrangement is, or contains, a lease at inception and, if so, records a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) asset and a lease liability on the consolidated balance sheet for any lease with a term longer than 12 months. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, the Company has elected to account for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, such as common area maintenance charges, as a single lease component. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC&#160;808, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative Arrangements</div></div> (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (ASC 606). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> clinical activities are recognized as research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> agreements that are within the scope of ASC 606. The terms of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (Astellas), as further described in Note 13, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration agreement</div></div>&#8221;, of notes to consolidated financial statements. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this standard. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC&#160;606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a)&#160;a good or service (or bundle of goods and services) that is distinct, or (b)&#160;a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> research and development activities, and/or manufacturing services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-09</div> which identifies areas for simplification of several areas of share-based payment transactions. The Company treats <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> The Company believes the fair value of the stock options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> is more reliably determinable than the fair value of the services provided. </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses the fair value of its share-based compensation awards to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> on a straight-line basis over the requisite service period, which is generally the vesting period. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2022 and 2021, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 11, <div style="null;text-indent: 0px;;display:inline;">&#8220;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes</div></div>&#8221;). </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss per share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2022 and 2021 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,075,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,351,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited interim financial information</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited interim financial information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated balance sheet as of March&#160;31, 2023 and the consolidated statements of operations, the consolidated statements of comprehensive loss, the consolidated statements of stockholders&#8217; equity and the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March&#160;31, 2023, the results of its operations for the three months ended March&#160;31, 2023 and 2022, and cash flows for the three months ended March&#160;31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three months ended March&#160;31, 2023 and 2022 are also unaudited. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023, any other interim periods, or any future year or period. The consolidated balance sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December&#160;31, 2022 included in the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted and issued accounting standards</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the JOBS Act). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, the Company will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses</div></div> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted the standard on January&#160;1, 2023 and it did not have a material impact on the consolidated financial statements. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Recently issued and adopted accounting pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses</div></div> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted this standard on January 1, 2023 and it did not have a material impact on the consolidated financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850371281408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PropertyAndEquipmentTableTextBlock', window );">Property And Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of lab equipment, furniture and office equipment and software recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text">Diluted net loss per share is the same as basic net loss per share for the three months ended March&#160;31, 2023 and 2022 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net Loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,386</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,324,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,810,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,075,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,351,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850363672352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December&#160;31, 2022 and 2021 are summarized as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gain&#160;(Loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(137</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hierarchy</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Level&#160;2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">111,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(89</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of debt securities in an unrealized loss position</a></td>
<td class="text">The following tables summarize the Company&#8217;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position. <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities in unrealized loss position</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities in unrealized loss position</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">The following tables summarize the Company&#8217;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position.<div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than&#160;12&#160;Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373681680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of classified as available-for-sale and recorded at fair value</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the Company&#8217;s investments, all of which are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and recorded at fair value: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of debt securities in an unrealized loss position</a></td>
<td class="text">The following tables summarize the Company&#8217;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position. <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities in unrealized loss position</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities in unrealized loss position</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">The following tables summarize the Company&#8217;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position.<div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than&#160;12&#160;Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Market<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850473860064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Rent and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Insurance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850370596688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment include the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,496</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,184</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374541440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payroll and employee related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Third-party research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payroll and employee related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">767</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Third-party research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850371234000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text">Diluted net loss per share is the same as basic net loss per share for the three months ended March&#160;31, 2023 and 2022 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net Loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,386</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,324,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,810,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares of common stock outstanding-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,075,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,351,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share-basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,642,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,165,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,610,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,242,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,776,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373578864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Shares Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has reserved the following shares of common stock for future issuance as of March&#160;31, 2023 and December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,742,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares available for future grant under incentive plans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,690,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">988,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,290,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,730,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has reserved the following shares of common stock for future issuance as of December&#160;31, 2022 and 2021: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,742,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,830,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares available for future grant under stock option plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">988,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,552,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,730,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,382,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368361152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes stock option activity within the Company&#8217;s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares<br/> in Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise&#160;price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term&#160;(in&#160;years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> intrinsic<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,742,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,969</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(166,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,789,470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options unvested as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810,618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise&#160;price<div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px">&#160;(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term&#160;(in&#160;years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> intrinsic<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,816,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">171,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,357,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32.76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(642,314</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(701,873</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,830,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">221,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,299,113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,742,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,579,486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options unvested as of December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,162,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,043</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:8.3px">(1)</div> On August&#160;17, 2022, the Company&#8217;s Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $2.14, the closing price per share of the Company&#8217;s common stock on August&#160;17, 2022.<div style="background-color:#ffffff;;display:inline;"> </div><div style="null;text-indent: 0px;;display:inline;"></div><div style="display:inline;"><div style="background-color:#ffffff;;display:inline;">See &#8220;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="background-color:#ffffff;;display:inline;">Repricing of stock options</div></div></div><div style="background-color:#ffffff;;display:inline;">&#8221; section for more information. </div></div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Recognized Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Status of Restricted Common Stock and Restricted Stock Units</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes restricted stock unit activity within the Company&#8217;s 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average&#160;fair<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,101,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Awarded</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,666,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(306,775</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(819,050</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,642,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below summary includes restricted stock unit activity within the Company&#8217;s 2019 Incentive Award Plan for the year ended December&#160;31, 2022. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average&#160;fair<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">626,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Awarded</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,576,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(551,450</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(549,850</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.06</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested, December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,101,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368371248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Reconciliation Pre-tax Income</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss for the years ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,586</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,624</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,582</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,671</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s provision at December&#160;31, 2022 and 2021 consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total (benefit) provision</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S federal statutory income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(0.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income taxes, net of federal benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">5.4</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">2.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">5.1</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">3.6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State rate changes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">3.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation deductions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2.8</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1.6</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other items</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(0.7</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in deferred tax asset valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(32.3</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(28.2</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effective income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s deferred tax assets at December&#160;31, 2022 and 2021 consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="visibility:hidden; line-height:0pt; color:white">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="white-space:nowrap">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">45,512</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">36,590</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">11,163</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,026</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">10,042</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangibles</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">478</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">392</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">9,507</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">6,554</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">107</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">357</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">176</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">282</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">265</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,735</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,269</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">85,076</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">58,379</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(77,288</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(50,931</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,788</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">7,448</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(7,788</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(7,448</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset (liability)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373787088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other information</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining operating lease term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.4&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December&#160;31, 2022. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,534</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: amount of lease payments representing interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of future lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,021</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Noncurrent lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Aggregate Minimum Payments</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future aggregate minimum payments under the noncancelable operating lease as of December&#160;31, 2022 are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,534</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027 and beyond</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850371073952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_ScheduleOfRestructingRelatedChargesTableTextBlock', window );">Schedule of Restructuring-related charges</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended March&#160;31, 2023, the following restructuring-related charges were included in the Consolidated Statement of Operations: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance&#160;and&#160;other<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">benefit-related</div><br/> costs</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated<br/> depreciation<br/> charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated<br/> hearing&#160;program<br/> charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock', window );">Schdule of Changes to the liability for the restructuring</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accelerated&#160;hearing<br/> program charges</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance&#160;and&#160;other<br/> benefit-related costs</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td>
<td colspan="4" style="height:3.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net charges</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability balance as of March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Changes to the liability for the restructuring [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ScheduleOfRestructingRelatedChargesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Restructing related charges [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ScheduleOfRestructingRelatedChargesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850370591488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sublease (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SummaryOfExpectedFutureSubleaseIncome', window );">Summary Of Expected Future Sublease Income</a></td>
<td class="text"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sublease&#160;Income</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total future sublease income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,754</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfExpectedFutureSubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Expected Future Sublease Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfExpectedFutureSubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850364302000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2014<span></span>
</td>
<td class="text">Nov. 30,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,208<span></span>
</td>
<td class="nump">$ 261,665<span></span>
</td>
<td class="nump">$ 180,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850364275200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange (losses) gains</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">$ 1,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Increase in right-of-use asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">Accounting Standards Update 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember', window );">Lexington Massachusetts facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 1,699<span></span>
</td>
<td class="nump">$ 1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373819680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368334656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,543)<span></span>
</td>
<td class="num">$ (23,386)<span></span>
</td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (84,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding-basic and diluted</a></td>
<td class="nump">$ 35,324,053<span></span>
</td>
<td class="nump">$ 34,810,676<span></span>
</td>
<td class="nump">$ 35,075,924<span></span>
</td>
<td class="nump">$ 34,351,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_Earningpersharebasicanddiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (2.33)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_Earningpersharebasicanddiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EarningPerShareBasicAndDiluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_Earningpersharebasicanddiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighteds Average Number Of Share Outstanding Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850361819952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="nump">$ 25,799<span></span>
</td>
<td class="nump">$ 31,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">25,797<span></span>
</td>
<td class="nump">31,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,928<span></span>
</td>
<td class="nump">$ 111,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">63,641<span></span>
</td>
<td class="nump">61,792<span></span>
</td>
<td class="nump">110,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">37,844<span></span>
</td>
<td class="nump">30,649<span></span>
</td>
<td class="nump">48,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember', window );">Short-term Marketable Securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember', window );">Short-term Marketable Securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 25,797<span></span>
</td>
<td class="nump">$ 31,143<span></span>
</td>
<td class="nump">51,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=freq_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=freq_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=freq_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850364145040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Schedule of debt securities in an unrealized loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Fair Market Value, Less than 12 Months</a></td>
<td class="nump">$ 8,407<span></span>
</td>
<td class="nump">$ 17,303<span></span>
</td>
<td class="nump">$ 44,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized Loss, Less than 12 Months</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Fair Market Value, More than 12 Months</a></td>
<td class="nump">9,943<span></span>
</td>
<td class="nump">9,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized Loss, More than 12 Months</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Fair Market Value</a></td>
<td class="nump">18,350<span></span>
</td>
<td class="nump">27,230<span></span>
</td>
<td class="nump">44,710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Unrealized Loss</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember', window );">Short Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Fair Market Value, Less than 12 Months</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">17,303<span></span>
</td>
<td class="nump">32,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized Loss, Less than 12 Months</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Fair Market Value, More than 12 Months</a></td>
<td class="nump">9,943<span></span>
</td>
<td class="nump">9,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized Loss, More than 12 Months</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Fair Market Value</a></td>
<td class="nump">18,350<span></span>
</td>
<td class="nump">27,230<span></span>
</td>
<td class="nump">32,991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Unrealized Loss</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (213)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=freq_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Fair Market Value, Less than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized Loss, Less than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Fair Market Value, More than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized Loss, More than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,719<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=freq_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=freq_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850371059360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Additional Information) (Details) - Term<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Debt securities unrealized loss position</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368315616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of classified as available-for-sale and recorded at fair value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="nump">$ 25,799<span></span>
</td>
<td class="nump">$ 31,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">25,797<span></span>
</td>
<td class="nump">31,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="nump">25,799<span></span>
</td>
<td class="nump">31,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 25,797<span></span>
</td>
<td class="nump">$ 31,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479808/944-20-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480078/944-80-55-17<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850364096880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of debt securities in an unrealized loss position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Fair Market Value, Less than 12 Months</a></td>
<td class="nump">$ 8,407<span></span>
</td>
<td class="nump">$ 17,303<span></span>
</td>
<td class="nump">$ 44,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized Loss, Less than 12 Months</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Fair Market Value, More than 12 Months</a></td>
<td class="nump">9,943<span></span>
</td>
<td class="nump">9,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized Loss, More than 12 Months</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Fair Market Value</a></td>
<td class="nump">18,350<span></span>
</td>
<td class="nump">27,230<span></span>
</td>
<td class="nump">44,710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Unrealized Loss</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember', window );">Short Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Fair Market Value, Less than 12 Months</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">17,303<span></span>
</td>
<td class="nump">32,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized Loss, Less than 12 Months</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Fair Market Value, More than 12 Months</a></td>
<td class="nump">9,943<span></span>
</td>
<td class="nump">9,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized Loss, More than 12 Months</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Fair Market Value</a></td>
<td class="nump">18,350<span></span>
</td>
<td class="nump">27,230<span></span>
</td>
<td class="nump">32,991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Unrealized Loss</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (213)<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=freq_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850364064480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PrepaidRentAndDepositsCurrent', window );">Rent and deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PrepaidResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PrepaidAccountsReceivableCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 2,643<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 4,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid accounts receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidRentAndDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent and deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidRentAndDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850364102096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 9,276<span></span>
</td>
<td class="nump">$ 9,235<span></span>
</td>
<td class="nump">$ 9,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(7,444)<span></span>
</td>
<td class="num">(6,496)<span></span>
</td>
<td class="num">(4,184)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
<td class="nump">5,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">5,747<span></span>
</td>
<td class="nump">5,706<span></span>
</td>
<td class="nump">6,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">3,238<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368063968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
<td class="nump">$ 2,766<span></span>
</td>
<td class="nump">$ 2,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation charges</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368533360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee related expenses</a></td>
<td class="nump">$ 3,831<span></span>
</td>
<td class="nump">$ 4,216<span></span>
</td>
<td class="nump">$ 4,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent', window );">Third-party research and development expenses</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 5,567<span></span>
</td>
<td class="nump">$ 5,891<span></span>
</td>
<td class="nump">$ 6,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued income taxes and other accrued liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued third-party research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368789056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=freq_TermLoanMember', window );">Term Loan | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DebtDue', window );">Debt due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument final payment</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of interest-only payments</a></td>
<td class="text">monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DebtInstrumentInterestOnlyPaymentMaturityDate', window );">Monthly interest only payments due</a></td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan maturity date</a></td>
<td class="text">May  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Payment terms, description</a></td>
<td class="text">The Company made monthly interest only payments through November 30, 2022. The principal balance and interest were to be repaid in equal monthly installments after the interest only period and continue through May 1, 2024 (Loan Maturity Date).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of interest-only payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DebtInstrumentInterestOnlyPaymentMaturityDate', window );">Monthly interest only payments due</a></td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan maturity date</a></td>
<td class="text">May  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DebtInstrumentFloorInterestRatePercentage', window );">Interest rate floor percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement | Term Loan | Prepayment Occurs on or Prior to First Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DebtInstrumentPrepaymentPremiumPercentage', window );">Debt instrument prepayment premium percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement | Term Loan | Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DebtInstrumentPrepaymentPremiumPercentage', window );">Debt instrument prepayment premium percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement | Term Loan | Prepayment Occurs After Second Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DebtInstrumentPrepaymentPremiumPercentage', window );">Debt instrument prepayment premium percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement | Term Loan | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentFloorInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument floor interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentFloorInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentInterestOnlyPaymentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest only payment maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentInterestOnlyPaymentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment premium percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=freq_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=freq_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373821392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (19,543)<span></span>
</td>
<td class="num">$ (23,386)<span></span>
</td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (84,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_Denominator', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighteds Average Number Of Share Outstanding Basic And Diluted</a></td>
<td class="nump">$ 35,324,053<span></span>
</td>
<td class="nump">$ 34,810,676<span></span>
</td>
<td class="nump">$ 35,075,924<span></span>
</td>
<td class="nump">$ 34,351,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_Earningpersharebasicanddiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (2.33)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_Denominator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denominator:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_Denominator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_Earningpersharebasicanddiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EarningPerShareBasicAndDiluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_Earningpersharebasicanddiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighteds Average Number Of Share Outstanding Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850375630720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">9,242,253<span></span>
</td>
<td class="nump">8,776,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">3,642,165<span></span>
</td>
<td class="nump">2,165,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsMember', window );">Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">5,600,088<span></span>
</td>
<td class="nump">6,610,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850362392352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, sale of price per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,751,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,262,083<span></span>
</td>
<td class="nump">34,611,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 1,298,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,751,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,262,083<span></span>
</td>
<td class="nump">34,611,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,751,956<span></span>
</td>
<td class="nump">34,976,409<span></span>
</td>
<td class="nump">35,262,083<span></span>
</td>
<td class="nump">34,611,213<span></span>
</td>
<td class="nump">33,964,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ShareDistributionMember', window );">Equity Distribution Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, sale of price per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SalesAgentCommission', window );">Sales Agent Commission</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ShareDistributionMember', window );">Equity Distribution Agreement | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=freq_AtTheMarketProgramMember', window );">ATM Program | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SalesAgentCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales agent commission</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SalesAgentCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ShareDistributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ShareDistributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=freq_AtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=freq_AtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368347008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">7,290,493<span></span>
</td>
<td class="nump">6,730,269<span></span>
</td>
<td class="nump">8,382,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">5,600,088<span></span>
</td>
<td class="nump">5,742,053<span></span>
</td>
<td class="nump">6,830,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares Available for Future Grant Under Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">1,690,405<span></span>
</td>
<td class="nump">988,216<span></span>
</td>
<td class="nump">1,552,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850362674288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 17, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 17, 2019</div></th>
<th class="th"><div>Nov. 13, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,290,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,730,269<span></span>
</td>
<td class="nump">8,382,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 22.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total grant date fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,874<span></span>
</td>
<td class="nump">$ 5,097<span></span>
</td>
<td class="nump">$ 14,219<span></span>
</td>
<td class="nump">$ 16,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Underwater Options reduced</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Cost related to stock options, stock based compensation</a></td>
<td class="nump">$ 2,505<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
<td class="nump">2,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions', window );">Expenses of Stock Based Compensation to be Recognized over vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,431<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense relating to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,537<span></span>
</td>
<td class="nump">$ 39,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized unvested stock options, restricted stock awards and restricted stock units, weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months 18 days<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 839<span></span>
</td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">$ 19,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="nump">$ 2,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,550,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of authorized shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance', window );">Period for automatic increase in common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of shares issued from outstanding number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Common stock future issuance, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses of stock based compensation to be recognized over vesting period of options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for automatic increase in common stock available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368403296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details) - 2014 and 2019 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Beginning balance</a></td>
<td class="nump">5,742,053<span></span>
</td>
<td class="nump">6,830,037<span></span>
</td>
<td class="nump">6,816,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">27,350<span></span>
</td>
<td class="nump">221,176<span></span>
</td>
<td class="nump">1,357,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(2,969)<span></span>
</td>
<td class="num">(10,047)<span></span>
</td>
<td class="num">(642,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(166,346)<span></span>
</td>
<td class="num">(1,299,113)<span></span>
</td>
<td class="num">(701,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Ending balance</a></td>
<td class="nump">5,600,088<span></span>
</td>
<td class="nump">5,742,053<span></span>
</td>
<td class="nump">6,830,037<span></span>
</td>
<td class="nump">6,816,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable</a></td>
<td class="nump">4,789,470<span></span>
</td>
<td class="nump">4,579,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Options unvested</a></td>
<td class="nump">810,618<span></span>
</td>
<td class="nump">1,162,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="nump">$ 10.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">4.66<span></span>
</td>
<td class="nump">1.78<span></span>
</td>
<td class="nump">32.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">1.24<span></span>
</td>
<td class="nump">2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">18.04<span></span>
</td>
<td class="nump">16.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">2.36<span></span>
</td>
<td class="nump">2.35<span></span>
</td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="nump">$ 10.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Options unvested</a></td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding</a></td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
<td class="text">7 years 9 months 3 days<span></span>
</td>
<td class="text">8 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Granted</a></td>
<td class="text">8 years 7 months 9 days<span></span>
</td>
<td class="text">8 years 3 months 25 days<span></span>
</td>
<td class="text">8 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options exercisable as of March 31, 2023</a></td>
<td class="text">5 years 3 months 14 days<span></span>
</td>
<td class="text">6 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options unvested as of March 31, 2023</a></td>
<td class="text">7 years 7 months 24 days<span></span>
</td>
<td class="text">7 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 9,114<span></span>
</td>
<td class="nump">$ 6,987<span></span>
</td>
<td class="nump">$ 171,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, Exercised</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">11,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">9,114<span></span>
</td>
<td class="nump">$ 6,987<span></span>
</td>
<td class="nump">$ 171,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Options unvested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options granted weighted average remaining contractualterm2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850362275392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">79.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368355616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details) - Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested</a></td>
<td class="nump">3,101,650<span></span>
</td>
<td class="nump">626,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Awarded</a></td>
<td class="nump">1,666,340<span></span>
</td>
<td class="nump">3,576,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested</a></td>
<td class="num">(306,775)<span></span>
</td>
<td class="num">(551,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(819,050)<span></span>
</td>
<td class="num">(549,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested</a></td>
<td class="nump">3,642,165<span></span>
</td>
<td class="nump">3,101,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Unvested</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 9.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Awarded</a></td>
<td class="nump">4.78<span></span>
</td>
<td class="nump">3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Vested</a></td>
<td class="nump">1.17<span></span>
</td>
<td class="nump">9.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Forfeited</a></td>
<td class="nump">3.85<span></span>
</td>
<td class="nump">5.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Unvested</a></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">2.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues', window );">Weighted average fair value, Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, equity instruments other than options, nonvested, weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368778960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,431<span></span>
</td>
<td class="nump">$ 5,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">$ 19,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="nump">$ 2,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368569808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Stock Purchase Plan - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2019</div></th>
<th class="th"><div>Sep. 20, 2019</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PercentageOfEligibleEmployeeCompensation', window );">Percentage of eligible employee compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,730,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,730,269<span></span>
</td>
<td class="nump">7,290,493<span></span>
</td>
<td class="nump">8,382,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PercentageOfEligibleEmployeeCompensation', window );">Percentage of eligible employee compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,225,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,225,527<span></span>
</td>
<td class="nump">1,553,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance', window );">Period for automatic increase in common available for future issuance</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of shares issued from outstanding number of shares</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,754<span></span>
</td>
<td class="nump">31,832<span></span>
</td>
<td class="nump">24,754<span></span>
</td>
<td class="nump">44,774<span></span>
</td>
<td class="nump">7,064<span></span>
</td>
<td class="nump">31,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfEligibleEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfEligibleEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for automatic increase in common stock available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850369259984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">111 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Federal and state deferred tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,288<span></span>
</td>
<td class="nump">50,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PeriodOfCumulativeChangeInOwnership', window );">Period of cumulative change in ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange', window );">Operating loss carryforwards, utilization after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange', window );">Operating loss carryforwards, utilization after five years after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange', window );">Operating loss carryforwards, utilization after 15 years thereafter after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration', window );">Remaining pre ownership change in operating loss carryforwards written off due to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_CumulativeChangeInOwnershipPercentage', window );">Cumulative change in ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_NetOperatingLossCarryforwardsExpirationWithLimitation', window );">Net operating loss carryforwards expire through 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation', window );">Net operating loss carryforwards without expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NetOperatingLossCarryforwardsExpirationWithLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration with limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NetOperatingLossCarryforwardsExpirationWithLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration without limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards annual usage for next each after five years and thereafter after ownership change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards annual usage for next each five years after ownership change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Usage After Ownership Change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsUsageAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodOfCumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of cumulative change in ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodOfCumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining pre ownership change in operating loss carryforwards written off due to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850364293632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation Pre-tax Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (81,586)<span></span>
</td>
<td class="num">$ (84,624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PreTaxNetLoss', window );">Total</a></td>
<td class="num">$ (81,582)<span></span>
</td>
<td class="num">$ (84,671)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PreTaxNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-tax net loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PreTaxNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850367958144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">111 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total (benefit) provision</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373595984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal', window );">State rate changes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.30%)<span></span>
</td>
<td class="num">(28.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368359888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract', window );"><strong>Deferred Tax Assets, Tax Deferred Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 45,512<span></span>
</td>
<td class="nump">$ 36,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">11,163<span></span>
</td>
<td class="nump">7,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">10,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">9,507<span></span>
</td>
<td class="nump">6,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">7,735<span></span>
</td>
<td class="nump">7,269<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">85,076<span></span>
</td>
<td class="nump">58,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(77,288)<span></span>
</td>
<td class="num">(50,931)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">7,788<span></span>
</td>
<td class="nump">7,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DeferredTaxAssetsRightOfUseAssets', window );">Right of use asset</a></td>
<td class="num">(7,788)<span></span>
</td>
<td class="num">(7,448)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset (liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredTaxAssetsRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredTaxAssetsRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities tax deferred expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850363962912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 06, 2023</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Dr. Langer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForManagementFee', window );">Payment to director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DescriptionOfFutureDevelopmentObligations', window );">Description of future development obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s future development obligations are: (i)&#160;to commence a Phase 3 clinical trial for such Product within five years of the IND filing for such product, (ii)&#160;to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii)&#160;to make a first commercial sale of such Product within 11 years of the IND filing for such Product.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PercentageOfSharesOfCommonStockIssued', window );">Percentage of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate for any reason upon a 3-month prior written notice.<span></span>
</td>
<td class="text">The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90)&#160;days (or thirty (30)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent', window );">Right to terminate agreement upon prior written notice if insolvent</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember', window );">CALIBR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_PercentageOfRoyaltyOnSublicenseRevenue', window );">Percentage of Royalty on Sublicense Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company sent CALIBR a notice stating that the Company would be terminating the CALIBR License Agreement in 30 days&#8217; time.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&#160;days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice', window );">Right to terminate licensed patents upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember', window );">CALIBR | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember', window );">MEE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company sent MEE a notice stating that the Company would be terminating the MEE License Agreement in 30 business days&#8217; time.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate the MEE License Agreement at will by giving thirty (30)&#160;business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30)&#160;business days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent', window );">Right to terminate agreement upon prior written notice if insolvent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember', window );">MEE | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_AnnualLicenseFeePerShare', window );">Annual License Fee Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember', window );">MEE | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RoyaltyExpensePerShare', window );">Royalty Expense Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_AnnualLicenseFeePerShare', window );">Annual License Fee Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember', window );">MEE | Non-Exclusive Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AnnualLicenseFeePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual License Fee Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AnnualLicenseFeePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conditions to terminate license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DescriptionOfConditionsToTerminateLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DescriptionOfFutureDevelopmentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of future development obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DescriptionOfFutureDevelopmentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LicenseAgreementEnteredDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement entered date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LicenseAgreementEnteredDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LicenseFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LicenseFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfRoyaltyOnSublicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on sublicense revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfRoyaltyOnSublicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfSharesOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfSharesOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIfBreachRemainsUncured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement if breach remains uncured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIfBreachRemainsUncured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIncaseOfNonpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement incase of nonpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIncaseOfNonpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementUponPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement upon prior written notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementUponPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement upon prior written notice if insolvent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to terminate licensed patents upon prior written notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RoyaltyExpensePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Expense Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RoyaltyExpensePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_PatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_PatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_NonExclusivePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_NonExclusivePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850362496752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Additional Information (Details) - License and Collaboration Agreement - Astellas Pharma LLC - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received under collaboration agreement</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_AgreementTerminationNoticePeriod', window );">Agreement termination notice period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RevenueRecognitionTransactionPrice', window );">Transaction price allocated to single combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_UpfrontFeeRecognizedAsRevenue', window );">Upfront fee recognized as revenue</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_JointCost', window );">joint cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">Phase 2b Clinical Trial | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">Phase 2b Clinical Trial | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">Phase 3 Clinical Trial | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">Phase 3 Clinical Trial | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones', window );">Revenue recognized commercialization milestone payments to receive</a></td>
<td class="nump">315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization', window );">Potential commercial milestone payments eligible to receive upon successful commercialization</a></td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability revenue recognized from commercialization milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_JointCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>joint cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_JointCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition potential commercial milestone payments eligible upon successful commercialization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RevenueRecognitionTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RevenueRecognitionTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIfBreachRemainsUncured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement if breach remains uncured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIfBreachRemainsUncured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIncaseOfNonpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement incase of nonpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIncaseOfNonpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_UpfrontFeeRecognizedAsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_UpfrontFeeRecognizedAsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase2bClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase2bClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase3ClinicalTrailMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase3ClinicalTrailMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850363743280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th">
<div>Jan. 07, 2020 </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,802<span></span>
</td>
<td class="nump">$ 4,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=freq_HaydenLLCMember', window );">Hayden LLC | Lexington Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable square feetspace | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OperatingLeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 11,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OperatingLeaseNumberOfAdditionalExtensionTerms', window );">Number of additional lease extension terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_OperatingLeasesAdditionalExtensionTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LeasesTerminationAgreementMember', window );">Lease Termination Agreement | ARE-MA Region No. 20, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseNumberOfAdditionalExtensionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease number of additional extension terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseNumberOfAdditionalExtensionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeasesAdditionalExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases additional extension term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeasesAdditionalExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_HaydenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_HaydenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=freq_LexingtonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=freq_LexingtonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=freq_LeasesTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=freq_LeasesTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_AREMARegionNo20LLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_AREMARegionNo20LLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850374701520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368535808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount of lease payments representing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current lease liabilities</a></td>
<td class="num">$ (2,088)<span></span>
</td>
<td class="num">(2,021)<span></span>
</td>
<td class="num">$ (1,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent lease liabilities</a></td>
<td class="nump">$ 26,215<span></span>
</td>
<td class="nump">$ 26,761<span></span>
</td>
<td class="nump">$ 28,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850362640096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Aggregate Minimum Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2023</a></td>
<td class="nump">$ 4,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">4,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">4,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">4,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2027 and beyond</a></td>
<td class="nump">22,340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 40,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368558864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Sublease - Summary of future sublease income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">2023</a></td>
<td class="nump">$ 1,779<span></span>
</td>
<td class="nump">$ 2,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">2024</a></td>
<td class="nump">1,383<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">Total future sublease income</a></td>
<td class="nump">$ 3,162<span></span>
</td>
<td class="nump">$ 3,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481295/840-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481295/840-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481295/840-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850367843088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sublease (Additional Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 07, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=freq_SaliogenTherapeuticsIncMember', window );">SalioGen Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Sublease rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_SaliogenTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_SaliogenTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368766624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Losses related to indemnification obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Legal contingencies, accruals recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember', window );">Lexington Massachusetts Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Security deposit classified as restricted cash</a></td>
<td class="nump">$ 1,699,000<span></span>
</td>
<td class="nump">$ 1,699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850370700368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage of employee contribution to retirement plan</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of employer matching contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employee annual compensation matched by the employer</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Employers matching contribution vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employers matching contribution</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850373688064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Dr. Langer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForManagementFee', window );">Payment to director</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850375530400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_ReductionInWorkforceDueToRestructuring', window );">Reduction in Workforce due to Restructuring</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructuringRelatedExpenses', window );">restructuring-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,970<span></span>
</td>
<td class="nump">$ 4,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Restructuring and Related Cost, Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_AcceleratedHearingProgramCharges', window );">Accelerated Hearing Program Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
<td class="nump">$ 3,481<span></span>
</td>
<td class="nump">$ 3,840<span></span>
</td>
<td class="nump">$ 3,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AcceleratedHearingProgramCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Hearing Program Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AcceleratedHearingProgramCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ReductionInWorkforceDueToRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in Workforce due to Restructuring</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ReductionInWorkforceDueToRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RestructuringRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>restructuring-related expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RestructuringRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850369387216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Summary of Restructuring-related charges (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">$ 3,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">2,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreetwotwochargesMember', window );">Accelerated FX-322 charges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreetwotwochargesMember', window );">Accelerated FX-322 charges | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Severance and other benefit-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">3,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Severance and other benefit-related costs | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">1,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Severance and other benefit-related costs | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedDepreciationChargesMember', window );">Accelerated depreciation charges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">$ 360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreetwotwochargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreetwotwochargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedDepreciationChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedDepreciationChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850362232400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schdule of Changes to the liability for the restructuring (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingLiabilities', window );">Restructing liabilities Ending</a></td>
<td class="nump">$ 3,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreetwotwochargesMember', window );">Accelerated FX-322 charges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingLiabilities', window );">Liability balance Opening</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingNetCharge', window );">Net charges</a></td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingLiabilities', window );">Restructing liabilities Ending</a></td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreefourfivechargesMember', window );">Accelerated FX-345 charges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingLiabilities', window );">Liability balance Opening</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingNetCharge', window );">Net charges</a></td>
<td class="nump">3,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Severance and other benefit-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingLiabilities', window );">Liability balance Opening</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingNetCharge', window );">Net charges</a></td>
<td class="nump">3,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_RestructingLiabilities', window );">Restructing liabilities Ending</a></td>
<td class="nump">$ 3,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RestructingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructing Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RestructingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RestructingNetCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructing Net Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RestructingNetCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreetwotwochargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreetwotwochargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreefourfivechargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=freq_AcceleratedfxthreefourfivechargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850371063616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of incurred charges due to restructuring (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_AcceleratedHearingProgramCharges', window );">Accelerated Hearing Program Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and other benefit-related costs</a></td>
<td class="nump">$ 359<span></span>
</td>
<td class="nump">$ 3,481<span></span>
</td>
<td class="nump">$ 3,840<span></span>
</td>
<td class="nump">$ 3,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AcceleratedHearingProgramCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Hearing Program Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AcceleratedHearingProgramCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139850368763040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_freq_DebtDue', window );">Debt Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=freq_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=freq_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>d451428ds4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:freq="http://www.frequencytherapeutics.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="freq-20230331.xsd" xlink:type="simple"/>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2014To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P09_20_2019To09_20_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2019-09-20</startDate>
            <endDate>2019-09-20</endDate>
        </period>
    </context>
    <context id="P02_13_2023To02_13_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_10_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="P08_17_2022To08_17_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2022-08-17</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_StockCompensationPlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:LexingtonMassachusettsFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_StockCompensationPlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:LexingtonMassachusettsFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MAsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MAsrtStatementGeographicalAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandAndFourteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MAsrtStatementGeographicalAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">freq:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">freq:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MAsrtStatementGeographicalAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2020To12_11_2020_AREMARegionNo20LLCMembersrtCounterpartyNameAxis_LeasesTerminationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AREMARegionNo20LLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LeasesTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="P12_10_2021To12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ShareDistributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-10</startDate>
            <endDate>2021-12-10</endDate>
        </period>
    </context>
    <context id="PAsOn12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ShareDistributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="PAsOn11_13_2014_TwoThousandAndFourteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-13</instant>
        </period>
    </context>
    <context id="PAsOn09_17_2019_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-17</instant>
        </period>
    </context>
    <context id="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-20</startDate>
            <endDate>2019-09-20</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To06_30_2021_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2017_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="PAsOn10_31_2019_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:PatentLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:PatentLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_NonExclusivePatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:NonExclusivePatentLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2019To07_31_2019_AsiaMembersrtStatementGeographicalAxis_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase3ClinicalTrailMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase3ClinicalTrailMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_EuropeMembersrtStatementGeographicalAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase3ClinicalTrailMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase3ClinicalTrailMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2019To07_31_2019_AsiaMembersrtStatementGeographicalAxis_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase2bClinicalTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase2bClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_EuropeMembersrtStatementGeographicalAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase2bClinicalTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase2bClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:HaydenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">freq:LexingtonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-07</instant>
        </period>
    </context>
    <context id="PAsOn07_08_2022_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-08</instant>
        </period>
    </context>
    <context id="P07_08_2022To06_30_2023_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-08</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To07_31_2024_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="P02_13_2023To02_13_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_StockCompensationPlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:LexingtonMassachusettsFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">freq:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OutstandingStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:OutstandingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AcceleratedDepreciationChargesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">freq:AcceleratedDepreciationChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">freq:AcceleratedfxthreetwotwochargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">freq:AcceleratedfxthreetwotwochargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AcceleratedfxthreefourfivechargesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">freq:AcceleratedfxthreefourfivechargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OutstandingStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:OutstandingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_03_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="P09_19_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-19</startDate>
            <endDate>2019-09-20</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To01_31_2023_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="P04_06_2023To04_06_2023_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-06</startDate>
            <endDate>2023-04-06</endDate>
        </period>
    </context>
    <context id="P03_29_2023To03_29_2023_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="P02_21_2023To02_21_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-21</startDate>
            <endDate>2023-02-21</endDate>
        </period>
    </context>
    <context id="P07_08_2022To07_07_2023_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-08</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="P07_08_2023To07_07_2024_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:SaliogenTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-08</startDate>
            <endDate>2024-07-07</endDate>
        </period>
    </context>
    <context id="P01_07_2020To01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:HaydenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">freq:LexingtonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-07</startDate>
            <endDate>2020-01-07</endDate>
        </period>
    </context>
    <context id="P12_31_2014To12_31_2014_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-31</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="P10_31_2020To11_30_2022_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-31</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">freq:AcceleratedfxthreetwotwochargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AcceleratedfxthreefourfivechargesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">freq:AcceleratedfxthreefourfivechargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">freq:AcceleratedfxthreetwotwochargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703647</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Term">
        <measure>freq:Term</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2023To03_31_2023">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2023To03_31_2023">0001703647</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2023To03_31_2023" id="hidden84370518">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden84370519">MA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="P01_01_2023To03_31_2023">S-4</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2023To03_31_2023">Frequency Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2023To03_31_2023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2023To03_31_2023">2834</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2023To03_31_2023">47-2324450</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To03_31_2023">75 Hayden Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2023To03_31_2023">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To03_31_2023">Lexington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To03_31_2023">02421</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To03_31_2023">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To03_31_2023">315-4600</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">David L. Lucchino</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">75 Hayden Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Lexington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">02421</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To03_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">315-4600</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2023To03_31_2023">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2023To03_31_2023">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2023To03_31_2023">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2023To03_31_2023">false</dei:EntityExTransitionPeriod>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2022To12_31_2022" id="hidden84371167">2014-11-30</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2023To03_31_2023" id="hidden84371168">2014-11-30</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:DebtInstrumentPaymentTerms
      contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      id="hidden84371525">The Company made monthly interest only payments through November 30, 2022. The principal balance and interest were to be repaid in equal monthly installments after the interest only period and continue through May 1, 2024 (Loan Maturity Date).</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">51954000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">79635000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">31143000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">51072000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4396000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4041000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">87493000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">134748000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11719000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2739000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5522000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">28980000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31350000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:RestrictedCashNoncurrent>
    <freq:OtherLongTermAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">327000</freq:OtherLongTermAssets>
    <freq:OtherLongTermAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">320000</freq:OtherLongTermAssets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">121238000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">185358000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3114000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2748000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5891000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6101000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2021000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1747000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">833000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">21026000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11429000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26761000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28851000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermLoansFromBank
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4167000</us-gaap:LongTermLoansFromBank>
    <us-gaap:LongTermLoansFromBank
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14167000</us-gaap:LongTermLoansFromBank>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">89000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">87000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">52043000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54534000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">34611213</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">34611213</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">331023000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">310936000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-198000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-62000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-261665000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-180085000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">69195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">130824000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">121238000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">185358000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14068000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">49418000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">60923000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">33584000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">37176000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">83002000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">98099000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-83002000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84031000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1327000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">397000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">961000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">764000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-23000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-5000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1056000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-266000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81582000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84671000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84686000</us-gaap:NetIncomeLoss>
    <freq:Earningpersharebasicanddiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.33</freq:Earningpersharebasicanddiluted>
    <freq:Earningpersharebasicanddiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.47</freq:Earningpersharebasicanddiluted>
    <freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD_per_Share">35075924</freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted>
    <freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD_per_Share">34351274</freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84686000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-136000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-89000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-136000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-89000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81716000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84775000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">33964000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">287829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-95399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">192491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">21750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">7064</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">60000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">60000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">642314</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1297000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1298000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">2165</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-89000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-89000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-84686000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84686000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">34611213</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">310936000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-62000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-180085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">130824000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">19831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">19831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">76606</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">196000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">196000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">10047</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <freq:StockIssuedDuringPeriodSharesUnderEquityOffering
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">12767</freq:StockIssuedDuringPeriodSharesUnderEquityOffering>
    <freq:StockIssuedDuringPeriodSharesUnderEquityOfferingAmount
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">50000</freq:StockIssuedDuringPeriodSharesUnderEquityOfferingAmount>
    <freq:StockIssuedDuringPeriodSharesUnderEquityOfferingAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">50000</freq:StockIssuedDuringPeriodSharesUnderEquityOfferingAmount>
    <freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">551450</freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares>
    <freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits>
    <freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1000</freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-136000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-136000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">331023000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-261665000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">69195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81580000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84686000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">19831000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21750000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2766000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2775000</us-gaap:Depreciation>
    <freq:NonCashLeaseExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2370000</freq:NonCashLeaseExpenses>
    <freq:NonCashLeaseExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1066000</freq:NonCashLeaseExpenses>
    <us-gaap:PaidInKindInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">396000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">347000</us-gaap:PaidInKindInterest>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-16000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-681000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">173000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-677000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-2292000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-14068000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <freq:IncreaseDecreaseInLeaseLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1816000</freq:IncreaseDecreaseInLeaseLiabilities>
    <freq:IncreaseDecreaseInLeaseLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-396000</freq:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-208000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-398000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-58237000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-76059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <freq:ProceedsFromPaymentForPropertyAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-17000</freq:ProceedsFromPaymentForPropertyAndEquipment>
    <freq:ProceedsFromPaymentForPropertyAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</freq:ProceedsFromPaymentForPropertyAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2914000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">54222000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">92445000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">85338000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">29233000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">31133000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-66126000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">60000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1298000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">196000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">60000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">833000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-577000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1358000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-27681000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-140827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">81334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">222161000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">53653000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">81334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">914000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">703000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Organization &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Lexington, Massachusetts, was incorporated in &lt;span style="-sec-ix-hidden:hidden84371167"&gt;November 2014&lt;/span&gt; as a Delaware corporation. Frequency Japan was closed down in February 2021. The Company is a preclinical-stage regenerative medicine company focused on developing therapeutics to activate a person&#x2019;s innate regenerative potential to restore function. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and capital resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has funded its operations primarily with proceeds from private and public securities financings, a term loan, and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&#160;31, 2022, the Company had an accumulated deficit of $261,665. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-261665000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Summary of significant accounting policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Standards&lt;/div&gt;&lt;/div&gt; Codification (ASC). &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan through the date of its dissolution. All intercompany transactions and balances have been eliminated. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include but are not limited to management&#x2019;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. Net loss and other comprehensive loss are reported net of any related tax effect to arrive at comprehensive loss. Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders which for the years ended December&#160;31, 2022 and 2021 consist of unrealized loss on marketable securities. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s chief executive officer, view the Company&#x2019;s operations and manage its business as a single operating segment, which is in the business of developing therapeutics to activate a person&#x2019;s innate regenerative potential to restore function. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2022 and 2021 the Company recorded $5 of foreign currency exchange loss and $16 of foreign currency exchange gain, respectively. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2022 and 2021 consists entirely of cash and money market funds. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has $1,699 of restricted cash as of December&#160;31, 2022 and December&#160;31, 2021, which represents a security deposit on the Company&#x2019;s Lexington, Massachusetts facility. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Marketable securities represent holdings of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable debt securities in accordance with the Company&#x2019;s investment policy. Short-term marketable securities mature within one year from the balance sheet date while long-term marketable securities mature after one year. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#x2019; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are reflected as a component of other expense. Interest on securities sold is determined based on the specific identification method and reflected as interest income. Any realized gains or losses on the sale of investment are reflected as realized gain (loss) on investments. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of credit risk and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-balance&lt;/div&gt; sheet risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;restricted cash at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of short term and long term investments. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has no significant &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-balance&lt;/div&gt; sheet arrangements such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant suppliers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurement&lt;/div&gt;&lt;/div&gt; (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;3&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of lab equipment, furniture and office equipment and software recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of long-lived assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs and accruals &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, preclinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development if the technology licensed has not reached technological feasibility and has no alternative future use. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for leases under ASC 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;. The Company determines if an arrangement is, or contains, a lease at inception and, if so, records a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (ROU) asset and a lease liability on the consolidated balance sheet for any lease with a term longer than 12 months. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#x2019;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components, the Company has elected to account for the lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components, such as common area maintenance charges, as a single lease component. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaborative arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC&#160;808, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaborative Arrangements&lt;/div&gt;&lt;/div&gt; (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#x2019;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (ASC 606). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&#x2019;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-development&lt;/div&gt; or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-development&lt;/div&gt; clinical activities are recognized as research and development expense. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company enters into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; agreements that are within the scope of ASC 606. The terms of such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-license&lt;/div&gt; agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#x2019;s ongoing activities. Such arrangements typically include payment of one or more of the following: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#x2019;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (Astellas), as further described in Note 13, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaboration agreement&lt;/div&gt;&lt;/div&gt;&#x201d;, of notes to consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#x2019;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#x2019;s accounting policies in compliance with this standard. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC&#160;606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a)&#160;a good or service (or bundle of goods and services) that is distinct, or (b)&#160;a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#x201c;customer&#x201d; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; research and development activities, and/or manufacturing services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in the period of adjustment. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect revenues and earnings in the period of adjustment. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#x2019;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#x2019;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Patent costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt; (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-09&lt;/div&gt; which identifies areas for simplification of several areas of share-based payment transactions. The Company treats &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees.&lt;/div&gt; The Company believes the fair value of the stock options granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; is more reliably determinable than the fair value of the services provided. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees,&lt;/div&gt; the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses the fair value of its share-based compensation awards to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; on a straight-line basis over the requisite service period, which is generally the vesting period. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic&#160;740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2022 and 2021, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 11, &lt;div style="null;text-indent: 0px;;display:inline;"&gt;&#x201c;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income taxes&lt;/div&gt;&lt;/div&gt;&#x201d;). &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net loss per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2022 and 2021 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average shares of common stock outstanding-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,075,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,351,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per share-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently issued and adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/div&gt;&lt;/div&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted this standard on January 1, 2023 and it did not have a material impact on the consolidated financial statements. &lt;/div&gt; </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Standards&lt;/div&gt;&lt;/div&gt; Codification (ASC). &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan through the date of its dissolution. All intercompany transactions and balances have been eliminated. &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include but are not limited to management&#x2019;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. Net loss and other comprehensive loss are reported net of any related tax effect to arrive at comprehensive loss. Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders which for the years ended December&#160;31, 2022 and 2021 consist of unrealized loss on marketable securities. &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s chief executive officer, view the Company&#x2019;s operations and manage its business as a single operating segment, which is in the business of developing therapeutics to activate a person&#x2019;s innate regenerative potential to restore function. &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2022 and 2021 the Company recorded $5 of foreign currency exchange loss and $16 of foreign currency exchange gain, respectively. &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-5000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2022 and 2021 consists entirely of cash and money market funds. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has $1,699 of restricted cash as of December&#160;31, 2022 and December&#160;31, 2021, which represents a security deposit on the Company&#x2019;s Lexington, Massachusetts facility. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2022_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2021_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Marketable securities represent holdings of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable debt securities in accordance with the Company&#x2019;s investment policy. Short-term marketable securities mature within one year from the balance sheet date while long-term marketable securities mature after one year. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#x2019; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are reflected as a component of other expense. Interest on securities sold is determined based on the specific identification method and reflected as interest income. Any realized gains or losses on the sale of investment are reflected as realized gain (loss) on investments. &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of credit risk and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-balance&lt;/div&gt; sheet risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;restricted cash at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of short term and long term investments. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has no significant &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-balance&lt;/div&gt; sheet arrangements such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <freq:SignificantSuppliersPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant suppliers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. &lt;/div&gt;</freq:SignificantSuppliersPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurement&lt;/div&gt;&lt;/div&gt; (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;3&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values. &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of lab equipment, furniture and office equipment and software recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <freq:PropertyAndEquipmentTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of lab equipment, furniture and office equipment and software recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</freq:PropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn12_31_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn12_31_2022_FurnitureAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of long-lived assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs and accruals &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, preclinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development if the technology licensed has not reached technological feasibility and has no alternative future use. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for leases under ASC 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;. The Company determines if an arrangement is, or contains, a lease at inception and, if so, records a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (ROU) asset and a lease liability on the consolidated balance sheet for any lease with a term longer than 12 months. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#x2019;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components, the Company has elected to account for the lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components, such as common area maintenance charges, as a single lease component. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <freq:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</freq:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaborative arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC&#160;808, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaborative Arrangements&lt;/div&gt;&lt;/div&gt; (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#x2019;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (ASC 606). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&#x2019;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-development&lt;/div&gt; or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-development&lt;/div&gt; clinical activities are recognized as research and development expense. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company enters into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; agreements that are within the scope of ASC 606. The terms of such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-license&lt;/div&gt; agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#x2019;s ongoing activities. Such arrangements typically include payment of one or more of the following: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#x2019;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (Astellas), as further described in Note 13, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaboration agreement&lt;/div&gt;&lt;/div&gt;&#x201d;, of notes to consolidated financial statements. &lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#x2019;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#x2019;s accounting policies in compliance with this standard. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC&#160;606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a)&#160;a good or service (or bundle of goods and services) that is distinct, or (b)&#160;a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#x201c;customer&#x201d; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; research and development activities, and/or manufacturing services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in the period of adjustment. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect revenues and earnings in the period of adjustment. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#x2019;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#x2019;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. &lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <freq:PatentCostsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Patent costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. &lt;/div&gt;</freq:PatentCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt; (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-09&lt;/div&gt; which identifies areas for simplification of several areas of share-based payment transactions. The Company treats &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees.&lt;/div&gt; The Company believes the fair value of the stock options granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; is more reliably determinable than the fair value of the services provided. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees,&lt;/div&gt; the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses the fair value of its share-based compensation awards to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; on a straight-line basis over the requisite service period, which is generally the vesting period. &lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic&#160;740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2022 and 2021, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 11, &lt;div style="null;text-indent: 0px;;display:inline;"&gt;&#x201c;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income taxes&lt;/div&gt;&lt;/div&gt;&#x201d;). &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net loss per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2022 and 2021 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average shares of common stock outstanding-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,075,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,351,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per share-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average shares of common stock outstanding-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,075,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,351,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per share-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84686000</us-gaap:NetIncomeLoss>
    <freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD_per_Share">35075924</freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted>
    <freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD_per_Share">34351274</freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted>
    <freq:Earningpersharebasicanddiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.33</freq:Earningpersharebasicanddiluted>
    <freq:Earningpersharebasicanddiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.47</freq:Earningpersharebasicanddiluted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently issued and adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/div&gt;&lt;/div&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted this standard on January 1, 2023 and it did not have a material impact on the consolidated financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">2023-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December&#160;31, 2022 and 2021 are summarized as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt; Hierarchy&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Gain&#160;(Loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,649&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(137&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,928&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hierarchy&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,116&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,072&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;111,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At December&#160;31, 2022 and 2021, we held 14 and 18 debt securities, respectively, that were in an unrealized loss position. The unrealized losses at December&#160;31, 2022 and 2021 were attributable to changes in interest rates and do not represent credit losses. The Company does not intend to sell the investments before recovery of their amortized cost bases, which may be at maturity. All investments mature within twelve months from December&#160;31, 2022. The following tables summarize the Company&#x2019;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&#160;than&#160;12&#160;Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December&#160;31, 2022 and 2021 are summarized as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt; Hierarchy&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Gain&#160;(Loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,649&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(137&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,928&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hierarchy&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,116&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,072&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;111,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">30648000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">30649000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">31280000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">137000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">31143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">61928000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">136000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">61792000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">48160000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">48160000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">51116000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">51072000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">11764000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">11719000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">111040000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">89000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">110951000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="P01_01_2022To12_31_2022">The following tables summarize the Company&#x2019;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position.&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&#160;than&#160;12&#160;Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">17303000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">9927000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">27230000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">17303000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9927000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">27230000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">32991000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">29000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">32991000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">29000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">11719000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">11719000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">44710000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">44710000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Prepaid expenses and other current assets &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Rent and deposits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,084&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accounts receivable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Insurance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,396&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,041&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Rent and deposits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,084&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accounts receivable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Insurance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,396&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,041&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <freq:PrepaidRentAndDepositsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</freq:PrepaidRentAndDepositsCurrent>
    <freq:PrepaidRentAndDepositsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">470000</freq:PrepaidRentAndDepositsCurrent>
    <freq:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2084000</freq:PrepaidResearchAndDevelopmentExpenseCurrent>
    <freq:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">858000</freq:PrepaidResearchAndDevelopmentExpenseCurrent>
    <freq:PrepaidAccountsReceivableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">449000</freq:PrepaidAccountsReceivableCurrent>
    <freq:PrepaidAccountsReceivableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">144000</freq:PrepaidAccountsReceivableCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1608000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2384000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">255000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">185000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4396000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4041000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment include the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,706&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,177&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,706&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,522&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized $2,766 and $2,775 of depreciation expense for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment include the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,706&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,177&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,706&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,522&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">5706000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6177000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9235000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9706000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6496000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4184000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2739000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5522000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2766000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2775000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Payroll and employee related expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;767&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Third-party research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;840&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;525&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Payroll and employee related expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;767&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Third-party research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;840&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;525&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4216000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4375000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">377000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">767000</us-gaap:AccruedProfessionalFeesCurrent>
    <freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">773000</freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent>
    <freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">840000</freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent>
    <freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">525000</freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent>
    <freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">119000</freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5891000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6101000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Debt &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2020, the Company entered into a Loan and Security Agreement (Loan Agreement) with a commercial bank for a term loan with a principal balance of $15,000. &lt;span style="-sec-ix-hidden:hidden84371525"&gt;The Company made monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continue through May 1, 2024 (Loan Maturity Date).&lt;/span&gt; Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Wall Street Journal&lt;/div&gt;&lt;/div&gt;, subject to an interest rate floor of zero) or (ii) 4.75%. The interest rate at December&#160;31, 2022 was 9.0%. Interest expense related to the Loan Agreement was $961 for the year ended December&#160;31, 2022 and $764 for the year ended December&#160;31, 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the term loan is refinanced by the bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company will pay a final payment of $150, which will occur on the earliest of: (i)&#160;the Loan Maturity Date; (ii)&#160;the date that the Company prepays all of the outstanding principal in full; (iii)&#160;the date the loan payments are accelerated due to an event of default; or (iv)&#160;the termination of the Loan Agreement. The Company is accruing the final payment over the term of the loan. The term loan is secured by substantially all of the Company&#x2019;s assets, excluding intellectual property. &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <freq:DebtInstrumentInterestOnlyPaymentMaturityDate contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis">2022-11-30</freq:DebtInstrumentInterestOnlyPaymentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis">2024-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <freq:DebtInstrumentFloorInterestRatePercentage
      contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      unitRef="Unit_pure">0</freq:DebtInstrumentFloorInterestRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2022To12_31_2022_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.09</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">961000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">764000</us-gaap:InterestExpenseDebt>
    <freq:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.02</freq:DebtInstrumentPrepaymentPremiumPercentage>
    <freq:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.01</freq:DebtInstrumentPrepaymentPremiumPercentage>
    <freq:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMemberusgaapDebtInstrumentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0</freq:DebtInstrumentPrepaymentPremiumPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Stockholders&#x2019; equity &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Preferred stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has authorized 200,000,000 shares of $0.001 par value common stock of which 35,262,083 were issued and outstanding as of December&#160;31, 2022. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has reserved the following shares of common stock for future issuance as of December&#160;31, 2022 and 2021: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,742,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,830,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares available for future grant under stock option plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;988,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,552,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,730,269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,382,667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity Offerings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;10, 2021, the Company entered into an Equity Distribution Agreement (Sales Agreement) with Oppenheimer&#160;&amp;amp; Co. Inc. (Sales Agent) to sell shares of the Company&#x2019;s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $125,000, from time to time, through an &#x201c;at the market&#x201d; equity offering program. Subject to the terms and conditions of the Sales Agreement, the Sales Agent may sell the shares by methods deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made through The Nasdaq Global Select Market, on any other existing trading market for the Common Stock, to or through a market maker, or, if expressly authorized by the Company, in privately negotiated transactions. The Company or Sales Agent may terminate the Sales Agreement upon notice to the other party and subject to other conditions. The Company will pay the Sales Agent a commission equal to 3.0% of the gross proceeds of any Common Stock sold through the Sales Agent under the Sales Agreement and has provided the Sales Agent with customary indemnification rights. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Issuance costs incurred related to the Sales Agreement are classified as long-term assets on the balance sheet at December&#160;31, 2022. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesIssued>
    <freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has reserved the following shares of common stock for future issuance as of December&#160;31, 2022 and 2021: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,742,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,830,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares available for future grant under stock option plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;988,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,552,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,730,269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,382,667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">5742053</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">6830037</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_StockCompensationPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">988216</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021_StockCompensationPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1552630</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">6730269</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">8382667</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P12_10_2021To12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <freq:SalesAgentCommission
      contextRef="PAsOn12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      unitRef="Unit_pure">0.03</freq:SalesAgentCommission>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&#x2019;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December&#160;31, 2022, there were no shares of common stock available for future grants under the 2014 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;17, 2019, the Company&#x2019;s board of directors and on September&#160;19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (2019 Plan). Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#x2019;s subsidiaries. A total of 3,100,000 shares of common stock were approved to be &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;initially reserved for issuance under the 2019 plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ten-year&lt;/div&gt; term of the 2019 Plan, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#x2019;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#x2019;s board of directors. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All stock option grants are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-statutory&lt;/div&gt; stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&#x2019;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&#160;price&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px"&gt;&#160;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; term&#160;(in&#160;years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,816,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;171,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,357,426&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32.76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(642,314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(701,873&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,830,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;221,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,299,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,742,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercisable as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,579,486&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options unvested as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,162,567&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,043&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt; On August&#160;17, 2022, the Company&#x2019;s Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company&#x2019;s common stock on August&#160;17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $2.14, the closing price per share of the Company&#x2019;s common stock on August&#160;17, 2022.&lt;div style="background-color:#ffffff;;display:inline;"&gt; &lt;/div&gt;&lt;div style="null;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;See &#x201c;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;Repricing of stock options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#x201d; section for more information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock option valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average grant date fair value of options granted to employees during the years ended December&#160;31, 2022 and 2021 was $1.58 and $22.39 respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The total grant date fair value of options vested during the years ended December&#160;31, 2022 and 2021 was $14,219 and $16,304, respectively. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Repricing of stock options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;17, 2022, the Board of Directors approved the repricing of each Underwater Option to $2.14, the closing price per share of the Company&#x2019;s common stock on August&#160;17, 2022. Except for the modification of the exercise price, all other terms and conditions of the Underwater Options remain in effect. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The option repricing resulted in incremental stock-based compensation of $2,505, of which $1,630 was recorded as expense in the year ended December&#160;31, 2022 and $875 will be recognized as expense over the remaining vesting period. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted stock units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The below summary includes restricted stock unit activity within the Company&#x2019;s 2019 Incentive Award Plan for the year ended December&#160;31, 2022. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&#160;fair&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested, December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;626,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Awarded&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,576,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(551,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(549,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.06&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested, December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,101,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Stock-based compensation expense of $19,831 and $21,750 for the years ended December&#160;31, 2022 and 2021 respectively, is included in research and development and general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022 and 2021, total unrecognized stock-based compensation expense relating to unvested stock options and restricted stock units was $19,537 and $39,112, respectively. This amount is expected to be recognized over a weighted-average period of 1.55 years and 2.49 years, respectively. &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn11_13_2014_TwoThousandAndFourteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">8550415</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2022_TwoThousandAndFourteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn09_17_2019_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="P01_01_2022To12_31_2022_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis">In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#x2019;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#x2019;s board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance contextRef="P01_01_2022To12_31_2022_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis">P10Y</freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndNineteenIncentiveAwardPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2022To12_31_2022">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&#160;price&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:6.6px"&gt;&#160;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; term&#160;(in&#160;years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,816,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;171,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,357,426&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32.76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(642,314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(701,873&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,830,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;221,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,299,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,742,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercisable as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,579,486&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options unvested as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,162,567&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,043&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt; On August&#160;17, 2022, the Company&#x2019;s Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company&#x2019;s common stock on August&#160;17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $2.14, the closing price per share of the Company&#x2019;s common stock on August&#160;17, 2022.&lt;div style="background-color:#ffffff;;display:inline;"&gt; &lt;/div&gt;&lt;div style="null;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;See &#x201c;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;Repricing of stock options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#x201d; section for more information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">6816798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P8Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">171415000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1357426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">32.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P8Y25D</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">642314</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">11652000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">701873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">6830037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P7Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">6987000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">221176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P8Y3M25D</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">10047</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">37000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1299113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5742053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">9114000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">4579486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P6Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">7071000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1162567</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P7Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">2043000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="P08_17_2022To08_17_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.14</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">22.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14219000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16304000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="P08_17_2022To08_17_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.14</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2505000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1630000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <freq:ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">875000</freq:ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The below summary includes restricted stock unit activity within the Company&#x2019;s 2019 Incentive Award Plan for the year ended December&#160;31, 2022. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&#160;fair&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested, December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;626,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Awarded&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,576,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(551,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(549,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.06&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested, December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,101,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">626300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">3576650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">551450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">549850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">3101650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <freq:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.8</freq:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">19831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">21750000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">19537000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">39112000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To12_31_2022">P1Y6M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <freq:EmployeeStockPurchasePlanDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Employee stock purchase plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;20, 2019, the Company&#x2019;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (ESPP) which became effective on the date of the Company&#x2019;s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten years of the term of the ESPP, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#x2019;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#x2019;s board of directors. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s first offering period of 2021 concluded on June&#160;30, 2021 with the purchase of 7,064 shares in July 2021 related to this offering period. The Company&#x2019;s second offering period of 2021 concluded on December&#160;31, 2021 with the purchase of 31,832 shares in January 2022. The Company&#x2019;s first offering period of 2022 concluded on June&#160;30, 2022 with the purchase of 44,774 shares in July 2022 related to this offering period. As of December&#160;31, 2022, a total of 1,225,527 shares remain for future offering periods. The Company&#x2019;s second offering period of 2022 concluded on December&#160;31, 2022 with the purchase of 24,754 shares in January 2023 related to this offering. &lt;/div&gt;</freq:EmployeeStockPurchasePlanDisclosureTextBlock>
    <freq:PercentageOfEligibleEmployeeCompensation
      contextRef="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</freq:PercentageOfEligibleEmployeeCompensation>
    <freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance contextRef="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">P10Y</freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2021To06_30_2021_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">7064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2022To06_30_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">44774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1225527</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P07_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">24754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Income taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which the Company has not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company had federal net operating loss carryforwards of approximately $174,107 and Massachusetts state operating loss carryforwards of approximately $141,318 which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,399 available to reduce future taxable income through 2037 and approximately $151,708 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2042. As of December&#160;31, 2022, the Company also had federal and Massachusetts research and development tax credit carryforwards of $8,177 and $3,556, respectively, which are available to offset federal and state tax liabilities through 2042 and 2037, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Realization of future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Code, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382 of the Code, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a rolling three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(pre-ownership&lt;/div&gt; change) is limited under Section&#160;382 of the Code. After the limitations under Section&#160;382 of the Code, the Company may utilize approximately $10,800 of its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-ownership&lt;/div&gt; change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-March&lt;/div&gt; 2017 ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-exempt&lt;/div&gt; rate. These &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;carryforwards may be subject to further annual limitations under Section&#160;382 of the Code in the event of future changes in ownership. Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO. Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section&#160;382 of the Code. The Company has determined it will be able to utilize the entire $46,123 of its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-ownership&lt;/div&gt; change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section&#160;382 of the Code in the event of future changes in ownership. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2022 and 2021 because the Company&#x2019;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $77,288 and $50,931 as of December&#160;31, 2022 and 2021 has been established. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; loss for the years ended December&#160;31, 2022 and 2021 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Domestic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,586&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,624&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,671&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s provision at December&#160;31, 2022 and 2021 consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total (benefit) provision&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2022 and 2021 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S federal statutory income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State income taxes, net of federal benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State rate changes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock compensation deductions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other items&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in deferred tax asset valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(32.3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effective income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s deferred tax assets at December&#160;31, 2022 and 2021 consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;45,512&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,590&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,163&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,026&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,042&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangibles&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;478&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;392&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,507&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,554&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;107&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;357&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;176&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;282&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;265&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,735&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,269&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross deferred tax asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85,076&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;58,379&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(77,288&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(50,931&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,788&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,448&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,788&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,448&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax asset (liability)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P12_31_2014To12_31_2014_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MAsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">174107000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_MAsrtStatementGeographicalAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">141318000</us-gaap:OperatingLossCarryforwards>
    <freq:NetOperatingLossCarryforwardsExpirationWithLimitation
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">22399000</freq:NetOperatingLossCarryforwardsExpirationWithLimitation>
    <freq:OperatingLossCarryforwardsExpirationYear contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">2037</freq:OperatingLossCarryforwardsExpirationYear>
    <freq:NetOperatingLossCarryforwardsExpirationWithoutLimitation
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">151708000</freq:NetOperatingLossCarryforwardsExpirationWithoutLimitation>
    <freq:OperatingLossCarryforwardsExpirationYear contextRef="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2042</freq:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-3"
      unitRef="Unit_USD">8177000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2022_MAsrtStatementGeographicalAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-3"
      unitRef="Unit_USD">3556000</us-gaap:TaxCreditCarryforwardAmount>
    <freq:TaxCreditCarryforwardExpirationYear contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">2042</freq:TaxCreditCarryforwardExpirationYear>
    <freq:TaxCreditCarryforwardExpirationYear contextRef="P01_01_2022To12_31_2022_MAsrtStatementGeographicalAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2037</freq:TaxCreditCarryforwardExpirationYear>
    <freq:PeriodOfCumulativeChangeInOwnership contextRef="P01_01_2022To12_31_2022_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis">P3Y</freq:PeriodOfCumulativeChangeInOwnership>
    <freq:CumulativeChangeInOwnershipPercentage
      contextRef="P01_01_2022To12_31_2022_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</freq:CumulativeChangeInOwnershipPercentage>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn02_28_2017_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-3"
      unitRef="Unit_USD">12400000</us-gaap:OperatingLossCarryforwards>
    <freq:OperatingLossCarryforwardsUsageAfterOwnershipChange
      contextRef="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-3"
      unitRef="Unit_USD">10800000</freq:OperatingLossCarryforwardsUsageAfterOwnershipChange>
    <freq:OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange
      contextRef="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1600000</freq:OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange>
    <freq:OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange
      contextRef="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-3"
      unitRef="Unit_USD">180000</freq:OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange>
    <freq:RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration
      contextRef="PAsOn03_31_2017_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1600000</freq:RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn10_31_2019_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-3"
      unitRef="Unit_USD">46123000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">77288000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50931000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; loss for the years ended December&#160;31, 2022 and 2021 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Domestic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,586&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,624&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,671&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81586000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84624000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-47000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <freq:PreTaxNetLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-81582000</freq:PreTaxNetLoss>
    <freq:PreTaxNetLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-84671000</freq:PreTaxNetLoss>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s provision at December&#160;31, 2022 and 2021 consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total (benefit) provision&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2022 and 2021 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S federal statutory income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State income taxes, net of federal benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.4&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State rate changes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock compensation deductions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2.8&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other items&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.7&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in deferred tax asset valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(32.3&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effective income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.054</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">-0.323</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.282</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s deferred tax assets at December&#160;31, 2022 and 2021 consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="visibility:hidden; line-height:0pt; color:white"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;45,512&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,590&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,163&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,026&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,042&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangibles&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;478&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;392&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,507&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,554&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;107&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;357&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;176&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;282&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;265&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,735&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,269&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross deferred tax asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85,076&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;58,379&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(77,288&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(50,931&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,788&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,448&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,788&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,448&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax asset (liability)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">45512000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">36590000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11163000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7026000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10042000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">478000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">392000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9507000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6554000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">107000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">357000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">176000</us-gaap:DeferredTaxAssetsOther>
    <freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">282000</freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">265000</freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <freq:DeferredTaxAssetsLeasingArrangements
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7735000</freq:DeferredTaxAssetsLeasingArrangements>
    <freq:DeferredTaxAssetsLeasingArrangements
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7269000</freq:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">85076000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">58379000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">77288000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50931000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7788000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7448000</us-gaap:DeferredTaxAssetsNet>
    <freq:DeferredTaxAssetsRightOfUseAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7788000</freq:DeferredTaxAssetsRightOfUseAssets>
    <freq:DeferredTaxAssetsRightOfUseAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7448000</freq:DeferredTaxAssetsRightOfUseAssets>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <freq:LicenseAgreementTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Research and license agreements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Massachusetts Institute of Technology &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-322.&lt;/div&gt; The Company&#x2019;s future development obligations are: (i)&#160;to commence a Phase 3 clinical trial for such Product within five years of the IND filing for such product, (ii)&#160;to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii)&#160;to make a first commercial sale of such Product within 11 years of the IND filing for such Product. The Company also has certain development obligations for a second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fails to cure such breach within ninety (90)&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; patent applications, and its rights to enforce the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; patents are subject to certain limitations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, the Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-twenties&lt;/div&gt; royalty on sublicense revenues. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-month&lt;/div&gt; prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#x2019;s material breach uncured within ninety (90)&#160;days (or thirty (30)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-infringed&lt;/div&gt; (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#x2019;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2022, the Company entered into an amendment with MIT, removing a patent and certain patent applications from the MIT License Agreement which were unrelated to the Company&#x2019;s hearing and MS programs and which were not being utilized by the Company. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The patents &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr.&#160;Langer, one of the Company&#x2019;s directors. Pursuant to MIT&#x2019;s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr.&#160;Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr.&#160;Langer has received $11 and $6 from MIT under the MIT Policy during the years ended December&#160;31, 2022 and 2021, respectively. Refer to Note 18, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related party transactions&lt;/div&gt;&lt;/div&gt;&#x201d;, for all related party disclosures. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scripps Research Institute (California Institute for Biomedical Research) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2018, the Company entered into a license agreement (CALIBR License Agreement) with the California Institute for Biomedical Research (CALIBR) under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; licenses to other nonprofit or academic institutions, for any internal research and educational purposes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR Licensed Product. The Company is also subject to certain milestone timeline obligations, which may be extended in certain circumstances as set forth in the CALIBR License Agreement. In October 2021, the Company entered into an amendment with CALIBR which updated the milestone obligations to: (i)&#160;initiate a Phase 2 clinical trial (or equivalent) for a CALIBR Licensed Product by December&#160;31, 2023 and (ii)&#160;initiate a Phase 3 clinical trial (or equivalent) for a CALIBR Licensed Product by December&#160;31, 2025. The Company does not have the right to control prosecution of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; patent applications, and the Company&#x2019;s rights to enforce the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; patents are subject to certain limitations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and is required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 is any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 is any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursor cells from &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;in vitro&lt;/div&gt;&lt;/div&gt; studies and/or are active in animal models relevant to MS). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-teen&lt;/div&gt; percentage to 50%. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&lt;/div&gt;&lt;/div&gt; and CALIBR Licensed &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product-by-CALIBR&lt;/div&gt;&lt;/div&gt; Licensed Product basis upon the later of (1)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt; prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&#160;days&#x2019; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&#160;days. CALIBR has the right to terminate or reduce the license to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2019, the Company entered into an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Exclusive&lt;/div&gt; Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive,&lt;/div&gt; non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss (MEE licensed products). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is obligated to use diligent efforts to develop and commercialize the MEE licensed products. The Company met one of its milestone timeline obligations by dosing a first subject in a Phase 2 trial by December&#160;31, 2020. The Company is still subject to a milestone timeline obligation to dose a first subject in a Phase 3 trial by December&#160;31, 2024. The Company does not control the filing, prosecution, enforcement, and defense of any licensed patent rights. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon entering the MEE License, the Company made a $20 license fee payment. The Company is obligated to pay certain annual license maintenance fees between $5 and $7.5 per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. The Company is also obligated to pay a minimum annual royalty payment of $15 per each MEE patent family case number included in the licensed MEE patent rights after first commercial sale of an MEE licensed product. The Company is also obligated to make milestone payments up to $350 on each product or process that incorporates the licensed patent rights. In addition, the Company has agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEE License Agreement at will by giving thirty (30)&#160;business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30)&#160;business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45)&#160;business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60)&#160;business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. &lt;/div&gt;</freq:LicenseAgreementTextBlock>
    <freq:LicenseAgreementEnteredDate contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">2016-12</freq:LicenseAgreementEnteredDate>
    <freq:DescriptionOfFutureDevelopmentObligations contextRef="P01_01_2022To12_31_2022_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">The Company&#x2019;s future development obligations are: (i)&#160;to commence a Phase 3 clinical trial for such Product within five years of the IND filing for such product, (ii)&#160;to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii)&#160;to make a first commercial sale of such Product within 11 years of the IND filing for such Product.</freq:DescriptionOfFutureDevelopmentObligations>
    <freq:LicenseFeePayment
      contextRef="PAsOn12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">50000</freq:LicenseFeePayment>
    <freq:PercentageOfSharesOfCommonStockIssued
      contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</freq:PercentageOfSharesOfCommonStockIssued>
    <freq:MilestonePayments
      contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">2900000</freq:MilestonePayments>
    <freq:DescriptionOfConditionsToTerminateLicenseAgreement contextRef="P01_01_2022To12_31_2022_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#x2019;s material breach uncured within ninety (90)&#160;days (or thirty (30)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#x2019;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
    <freq:RightToTerminateAgreementUponPriorWrittenNotice contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">P3M</freq:RightToTerminateAgreementUponPriorWrittenNotice>
    <freq:RightToTerminateAgreementIfBreachRemainsUncured contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">P90D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
    <freq:RightToTerminateAgreementIncaseOfNonpayment contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">P30D</freq:RightToTerminateAgreementIncaseOfNonpayment>
    <us-gaap:PaymentForManagementFee
      contextRef="P01_01_2022To12_31_2022_DirectorMembersrtTitleOfIndividualAxis"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:PaymentForManagementFee>
    <us-gaap:PaymentForManagementFee
      contextRef="P01_01_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:PaymentForManagementFee>
    <freq:LicenseAgreementEnteredDate contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">2018-09</freq:LicenseAgreementEnteredDate>
    <freq:LicenseFeePayment
      contextRef="PAsOn09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</freq:LicenseFeePayment>
    <freq:MilestonePayments
      contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">26000000</freq:MilestonePayments>
    <freq:PercentageOfRoyaltyOnSublicenseRevenue
      contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</freq:PercentageOfRoyaltyOnSublicenseRevenue>
    <freq:DescriptionOfConditionsToTerminateLicenseAgreement contextRef="P01_01_2022To12_31_2022_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&#160;days&#x2019; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
    <freq:RightToTerminateLicensedPatentsUponPriorWrittenNotice contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">P90D</freq:RightToTerminateLicensedPatentsUponPriorWrittenNotice>
    <freq:RightToTerminateAgreementIfBreachRemainsUncured contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">P30D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
    <freq:LicenseAgreementEnteredDate contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_NonExclusivePatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">2019-02</freq:LicenseAgreementEnteredDate>
    <freq:LicenseFeePayment
      contextRef="PAsOn02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</freq:LicenseFeePayment>
    <freq:AnnualLicenseFeePerShare
      contextRef="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">5</freq:AnnualLicenseFeePerShare>
    <freq:AnnualLicenseFeePerShare
      contextRef="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_USD_per_Share">7.5</freq:AnnualLicenseFeePerShare>
    <freq:RoyaltyExpensePerShare
      contextRef="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">15</freq:RoyaltyExpensePerShare>
    <freq:MilestonePayments
      contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">350000</freq:MilestonePayments>
    <freq:DescriptionOfConditionsToTerminateLicenseAgreement contextRef="P01_01_2022To12_31_2022_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">The Company has the right to terminate the MEE License Agreement at will by giving thirty (30)&#160;business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30)&#160;business days</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
    <freq:RightToTerminateAgreementUponPriorWrittenNotice contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">P30D</freq:RightToTerminateAgreementUponPriorWrittenNotice>
    <freq:RightToTerminateAgreementIncaseOfNonpayment contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">P30D</freq:RightToTerminateAgreementIncaseOfNonpayment>
    <freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">P45D</freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent>
    <freq:RightToTerminateAgreementIfBreachRemainsUncured contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">P60D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Collaboration agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-licensable,&lt;/div&gt; nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GSK-3&lt;/div&gt; inhibitor and an HDAC inhibitor (Astellas Licensed Products), including the product candidate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-322,&lt;/div&gt; outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;These parties have agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;age-related&lt;/div&gt; hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The collaboration is governed by a joint steering committee (JSC) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&#x2019;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80,000 in July 2019 and has agreed to pay potential development milestone payments up to $230,000 and commercialization milestones of up to $315,000. Specifically, the Company would receive development milestone payments of $65,000 and $25,000 upon the first dosing of a subject in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100,000 and $40,000 upon the first dosing of a subject in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315,000 in potential commercial milestone payments and also tiered royalties at rates ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-&lt;/div&gt; to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-teen&lt;/div&gt; percentages. The parties shall share equally, on a 50/50 basis, all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-of-pocket&lt;/div&gt;&lt;/div&gt; costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-licensed&lt;/div&gt;&lt;/div&gt; product and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&lt;/div&gt;&lt;/div&gt; basis until the latest of (i)&#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii)&#160;a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&#x2019; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#x2019;s material breach if such breach remains uncured for 90&#160;days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-development&lt;/div&gt; and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Revenue associated with this single performance obligation was recognized as the research and development work was performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurred over this time period and, in management&#x2019;s judgment, was the best measure of progress towards satisfying the performance obligation. The Company determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and continued until the completion of the Phase 2a clinical trial of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-322&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(FX-322-202).&lt;/div&gt;&lt;/div&gt; The transaction price of $80,000 was allocated to the single combined performance obligation and recorded as deferred revenue in July 2019 when it was received. This upfront payment was recognized as revenue over the period from July 2019 until June&#160;30, 2021, the completion date of the Phase 2a clinical trial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(FX-322-202),&lt;/div&gt;&lt;/div&gt; using the input method. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&#x2019;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect revenues and earnings in the period of adjustment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statements of operations during the development period. In the year ended December&#160;31, 2022 and 2021, the Company invoiced Astellas $392 and $885 for joint costs. &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">80000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">230000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">315000000</freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_EuropeMembersrtStatementGeographicalAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase2bClinicalTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">65000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P07_01_2019To07_31_2019_AsiaMembersrtStatementGeographicalAxis_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase2bClinicalTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">25000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_EuropeMembersrtStatementGeographicalAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase3ClinicalTrailMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">100000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P07_01_2019To07_31_2019_AsiaMembersrtStatementGeographicalAxis_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_Phase3ClinicalTrailMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">40000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <freq:RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">315000000</freq:RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization>
    <freq:AgreementTerminationNoticePeriod contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">P60D</freq:AgreementTerminationNoticePeriod>
    <freq:RightToTerminateAgreementIfBreachRemainsUncured contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">P90D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
    <freq:RightToTerminateAgreementIncaseOfNonpayment contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis">P45D</freq:RightToTerminateAgreementIncaseOfNonpayment>
    <freq:RevenueRecognitionTransactionPrice
      contextRef="P01_01_2021To06_30_2021_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">80000000</freq:RevenueRecognitionTransactionPrice>
    <freq:JointCost
      contextRef="P01_01_2022To12_31_2022_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">392000</freq:JointCost>
    <freq:JointCost
      contextRef="P01_01_2021To12_31_2021_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">885000</freq:JointCost>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. Leases &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (Lease Termination Agreement) with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ARE-MA&lt;/div&gt; Region No.&#160;20, LLC (Landlord) for the Company&#x2019;s office and laboratory space in Woburn, Massachusetts. The Lease Termination Agreement provides that the Lease Agreement, dated as of August&#160;14, 2016, by and between the Company and Landlord (as the same may have been amended, the Lease) will terminate on March 31, 2021, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May&#160;31, 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;7, 2020 the Company entered into an indenture of lease (Lexington Lease) with HCP/KING 75 Hayden LLC, for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (Lexington Premises). The Lexington Lease commenced on December 11, 2020. In the second quarter of 2021, the Company began using the Lexington Premises as its principal executive offices and laboratory for research and development. The term of the Lexington Lease is expected to end on May 31, 2031. The Company also has the option to extend the Initial Term for two additional terms of five years each. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s rent expense for the years ended December&#160;31, 2022 and 2021 was $4,802 and $4,960, respectively. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other information&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining operating lease term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.4&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,273&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,402&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,534&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: amount of lease payments representing interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of future lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,782&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Noncurrent lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Future aggregate minimum payments under the noncancelable operating lease as of December&#160;31, 2022 are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,273&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,402&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,534&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027 and beyond&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseExpirationDate1 contextRef="P12_11_2020To12_11_2020_AREMARegionNo20LLCMembersrtCounterpartyNameAxis_LeasesTerminationAgreementMemberusgaapTypeOfArrangementAxis">2021-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:NetRentableArea
      contextRef="PAsOn01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="INF"
      unitRef="Unit_sqft">61307</us-gaap:NetRentableArea>
    <freq:OperatingLeaseCommencementDate contextRef="P01_07_2020To01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis">2020-12-11</freq:OperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1 contextRef="P01_07_2020To01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis">2031-05-31</us-gaap:LeaseExpirationDate1>
    <freq:OperatingLeaseNumberOfAdditionalExtensionTerms
      contextRef="PAsOn01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_Term">2</freq:OperatingLeaseNumberOfAdditionalExtensionTerms>
    <freq:OperatingLeasesAdditionalExtensionTerm contextRef="P01_07_2020To01_07_2020_HaydenLLCMembersrtCounterpartyNameAxis_LexingtonLeaseMemberusgaapLeaseContractualTermAxis">P5Y</freq:OperatingLeasesAdditionalExtensionTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4802000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4960000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other information&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining operating lease term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.4&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022">P8Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,273&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,402&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,534&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: amount of lease payments representing interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of future lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,782&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Noncurrent lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4273000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4402000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4534000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4670000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4810000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">17530000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">40219000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11437000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">28782000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2021000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26761000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Future aggregate minimum payments under the noncancelable operating lease as of December&#160;31, 2022 are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,273&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,402&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,534&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027 and beyond&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4273000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4402000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4534000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4670000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">22340000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">40219000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <freq:Sublease contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15. Sublease &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;8, 2022, the Company entered into a Sublease Agreement with SalioGen Therapeutics, Inc. (SalioGen) to sublease approximately 30,040 rentable square feet of the Company&#x2019;s office space in Lexington, MA for a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-year&lt;/div&gt; term. The base sublease rent per month for the first and second year of the sublease is $197 and $203, respectively. In addition to base rent, SalioGen will pay 49% of operating costs and taxes payable under the Company&#x2019;s lease for the Lexington, MA office space. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Since commencement, the Company has accounted for the Lexington, MA office space as an operating lease. In accordance with ASC 842, the Company concluded the sublease is also an operating lease. The Company recognized sublease income of $1,186 for the year ended December&#160;31, 2022. The below table shows the expected future sublease income as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:14%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sublease&#160;Income&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,383&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total future sublease income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,754&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#160;</freq:Sublease>
    <us-gaap:NetRentableArea
      contextRef="PAsOn07_08_2022_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="0"
      unitRef="Unit_sqft">30040</us-gaap:NetRentableArea>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="P07_08_2022To06_30_2023_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">197000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="P07_01_2023To07_31_2024_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">203000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:SubleaseIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1186000</us-gaap:SubleaseIncome>
    <freq:SummaryOfExpectedFutureSubleaseIncome contextRef="P01_01_2022To12_31_2022">&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:14%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sublease&#160;Income&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,383&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total future sublease income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,754&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#160;</freq:SummaryOfExpectedFutureSubleaseIncome>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2371000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1383000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3754000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">16. Commitments and contingencies &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable.&lt;/div&gt; Payments due upon cancellation consist only of payments for services provided or expenses incurred, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt; obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Guarantees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Guarantees&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#x2019;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#x2019; and officers&#x2019; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company leases office space in Lexington, Massachusetts under a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;ten-year&lt;/div&gt;&lt;/div&gt; noncancelable lease. The $1,699 security deposit for this lease is classified as restricted cash as of December&#160;31, 2022. The Company exited the Woburn, Massachusetts facility in the second quarter of 2021. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022 and 2021, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#x2019;s accrued liabilities would be recorded in the period in which such determination is made. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;3, 2021 and June&#160;22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company and the Company&#x2019;s Chief Executive Officer, President, and Director, David Lucchino. On March&#160;21, 2022, the two lawsuits were consolidated into a single lawsuit, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Quinones et al. v. Frequency Therapeutics, Inc. et al&lt;/div&gt;&lt;/div&gt;. and on May&#160;16, 2022, the Company&#x2019;s Chief Development Officer, Dr.&#160;Carl LeBel, was added as a defendant. The plaintiffs allege violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#x2019;s Phase 2a clinical trial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(FX-322-202)&lt;/div&gt;&lt;/div&gt; for its product candidate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-322&lt;/div&gt; in the Company&#x2019;s public disclosures between October&#160;29, 2020 and March&#160;22, 2021. The lawsuit seeks, among other things, damages in connection with the Company&#x2019;s allegedly artificially inflated stock price between October&#160;29, 2020 and March&#160;22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#x2019; fees and costs. The Company intends to vigorously defend against all claims asserted in the lawsuit. The Company filed a motion to dismiss the Amended Complaint on July&#160;15, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;21, 2022, the Delaware Chancery Court dismissed a lawsuit brought by two purported stockholders against the Company and others. For previously reported information on this lawsuit, refer to Part I, Item 3, &#x201c;Legal Proceedings&#x201d; of the Company&#x2019;s 2021 Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K.&lt;/div&gt; On August&#160;16, 2022, these same two purported stockholders of the Company filed a similar lawsuit in Delaware Superior Court against (i)&#160;the Company, (ii)&#160;Computershare Inc., and (iii)&#160;Computershare Trust Company, N.A., entitled &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Gregory J. Parseghian Revocable Trust&lt;/div&gt;&lt;/div&gt;, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;et al.&lt;/div&gt;&lt;/div&gt; v. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Frequency Therapeutics, Inc., et al.&lt;/div&gt;&lt;/div&gt; The lawsuit alleges causes of action against the Company for breach of the statutory duty of care, negligence, conversion, and unjust enrichment, based on allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The Company intends to vigorously defend against all claims asserted in the lawsuit. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;30, 2022, a purported stockholder of the Company filed a shareholder derivative complaint in the U.S. District Court for the District of Delaware purportedly on the Company&#x2019;s behalf against members of the Company&#x2019;s board of directors and the Company as a nominal defendant, entitled &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dewey v. Cohen et. al.&lt;/div&gt;&lt;/div&gt; The complaint alleges (i)&#160;violations of Section&#160;10(b) and Rule 10b5 of the Exchange Act, (ii)&#160;breach of fiduciary duty, (iii)&#160;aiding and abetting breach of fiduciary duty, (iv)&#160;unjust enrichment, and (v)&#160;waste of corporate assets. The claims are based on the same underlying allegations as the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Quinones&lt;/div&gt;&lt;/div&gt; case (described above). The complaint seeks, among other things, monetary damages, interest, attorneys&#x2019; fees and costs. On September&#160;27, 2022, this lawsuit was stayed pending resolution of the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Quinones&lt;/div&gt;&lt;/div&gt; case. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company&#x2019;s board members are each party to an indemnification agreement with the Company that may require the Company to reimburse the board members for c&lt;div style="display:inline;"&gt;er&lt;/div&gt;tain expenses and other costs related to this lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of December&#160;31, 2022. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2022_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:RestrictedCash>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17. Employee benefit plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Employees of the Company are eligible to participate in the Company&#x2019;s 401(k) retirement plan (401(k) Plan). Partic&lt;div style="display:inline;"&gt;ipan&lt;/div&gt;ts may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches 100% of the first 5% of employee contributions and vests 100% at time of match. For the years ended December&#160;31, 2022 and 2021, the Company made matching contributions of $550 and $723, respectively. &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">550000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">723000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18. Related party transactions &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As disclosed in Note 12, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and license agreements&lt;/div&gt;&lt;/div&gt;&#x201d;, the Company entered into the MIT License Agreement in December 2016. The patents &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr.&#160;Langer, one of the Company&#x2019;s directors. Accordingly, Dr.&#160;Langer has received $11 and $6 from MIT under the MIT Policy during the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s lease for its Woburn, Massachusetts facility, terminated in May 2021 as disclosed in Note&#160;14, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&#x201d;, was with an entity affiliated with one of the Company&#x2019;s directors and shareholders. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentForManagementFee
      contextRef="P01_01_2022To12_31_2022_DirectorMembersrtTitleOfIndividualAxis"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:PaymentForManagementFee>
    <us-gaap:PaymentForManagementFee
      contextRef="P01_01_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:PaymentForManagementFee>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19. Subsequent events &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March&#160;10, 2023, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows: &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;13, 2023, the Company announced a restructuring in which its hearing program was discontinued. As a result, the Company reduced its workforce by approximately 55% to better align with the needs of its business. The total personnel costs related to the restructuring are estimated to be approximately $4,000 in future cash outlays primarily related to severance costs and related expenses. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P02_13_2023To02_13_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCosts
      contextRef="P02_13_2023To02_13_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4000000</us-gaap:RestructuringCosts>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">40853000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">51954000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">25797000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">31143000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2643000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4396000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">69293000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">87493000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1832000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2739000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">28350000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">28980000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:RestrictedCashNoncurrent>
    <freq:OtherLongTermAssets
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">327000</freq:OtherLongTermAssets>
    <freq:OtherLongTermAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">327000</freq:OtherLongTermAssets>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">101501000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">121238000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2715000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3114000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">5567000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5891000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2088000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2021000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">11667000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">22037000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">21026000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">26215000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26761000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermLoansFromBank
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermLoansFromBank>
    <us-gaap:LongTermLoansFromBank
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4167000</us-gaap:LongTermLoansFromBank>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">89000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">48252000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">52043000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">35751956</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">35751956</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">334485000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">331023000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-64000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-198000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-281208000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-261665000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">53249000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">69195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">101501000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">121238000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">11355000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">13781000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">9156000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9477000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">20511000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">23258000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-20511000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-23258000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">523000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">95000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">284000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">753000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-33000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-19519000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-23374000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-19543000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-23386000</us-gaap:NetIncomeLoss>
    <freq:Earningpersharebasicanddiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.55</freq:Earningpersharebasicanddiluted>
    <freq:Earningpersharebasicanddiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.67</freq:Earningpersharebasicanddiluted>
    <freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      unitRef="Unit_USD_per_Share">35324053</freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted>
    <freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD_per_Share">34810676</freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-19543000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-23386000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">134000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-234000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">134000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-234000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-19409000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-23620000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">34611213</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">310936000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-62000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-180085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">130824000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5266000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5266000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">31832</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">139000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">139000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">22764</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">310600</freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-234000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-234000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-23386000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-23386000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">34976409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">316402000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-296000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-203471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">112670000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">331023000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-261665000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">69195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">24754</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">2969</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">462150</freq:IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares>
    <freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits>
    <freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1000</freq:IssuanceOfCommonStockPursuantToRestrictedStockUnits>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-19543000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-19543000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">35751956</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">334485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-281208000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">53249000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-19543000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-23386000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3431000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5266000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">726000</us-gaap:Depreciation>
    <freq:NonCashLeaseExpenses
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">630000</freq:NonCashLeaseExpenses>
    <freq:NonCashLeaseExpenses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">593000</freq:NonCashLeaseExpenses>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">112000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-266000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-2051000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1385000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-697000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-429000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <freq:IncreaseDecreaseInLeaseLiabilities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-479000</freq:IncreaseDecreaseInLeaseLiabilities>
    <freq:IncreaseDecreaseInLeaseLiabilities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-412000</freq:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-413000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1352000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-14132000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-17343000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <freq:ProceedsFromPaymentForPropertyAndEquipment
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-7000</freq:ProceedsFromPaymentForPropertyAndEquipment>
    <freq:ProceedsFromPaymentForPropertyAndEquipment
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</freq:ProceedsFromPaymentForPropertyAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1978000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20786000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">7570000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8136000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">5499000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-12662000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">61000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">139000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-2468000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-11101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-29805000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">53653000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">81334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">42552000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">51529000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Organization and basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Organization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, and Frequency Therapeutics Securities Corporation (the Company) headquartered in Lexington, Massachusetts, was incorporated in &lt;span style="-sec-ix-hidden:hidden84371168"&gt;November 2014&lt;/span&gt; as a Delaware corporation. The Company is a preclinical-stage regenerative medicine company focused on developing therapeutics to activate a person&#x2019;s innate regenerative potential to restore function. On February&#160;13, 2023, the Company announced a restructuring of the business which included the discontinuation of its hearing program and a downsizing of personnel by approximately 55%. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and capital resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has funded its operations primarily with proceeds from private and public securities financings, a term loan, and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of March&#160;31, 2023, the Company had an accumulated deficit of $281,208. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources and the cost savings generated from the restructuring announced in February 2023 will be sufficient to fund planned operations for at least twelve months from the date the financial statements were available to be issued. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements are consistent with those discussed in Note 2, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of significant accounting policies&lt;/div&gt;&lt;/div&gt;,&#x201d; in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; (the Company&#x2019;s Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K).&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unaudited interim financial information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated balance sheet as of March&#160;31, 2023 and the consolidated statements of operations, the consolidated statements of comprehensive loss, the consolidated statements of stockholders&#x2019; equity and the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;which include only normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of March&#160;31, 2023, the results of its operations for the three months ended March&#160;31, 2023 and 2022, and cash flows for the three months ended March&#160;31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three months ended March&#160;31, 2023 and 2022 are also unaudited. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023, any other interim periods, or any future year or period. The consolidated balance sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These unaudited consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto for the year ended December&#160;31, 2022 included in the Company&#x2019;s Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K.&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P02_13_2023To02_13_2023"
      decimals="2"
      unitRef="Unit_pure">0.55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-281208000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements are consistent with those discussed in Note 2, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of significant accounting policies&lt;/div&gt;&lt;/div&gt;,&#x201d; in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; (the Company&#x2019;s Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K).&lt;/div&gt; &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <freq:UnauditedInterimFinancialInformationPolicyTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unaudited interim financial information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated balance sheet as of March&#160;31, 2023 and the consolidated statements of operations, the consolidated statements of comprehensive loss, the consolidated statements of stockholders&#x2019; equity and the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;which include only normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of March&#160;31, 2023, the results of its operations for the three months ended March&#160;31, 2023 and 2022, and cash flows for the three months ended March&#160;31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three months ended March&#160;31, 2023 and 2022 are also unaudited. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2023, any other interim periods, or any future year or period. The consolidated balance sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These unaudited consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto for the year ended December&#160;31, 2022 included in the Company&#x2019;s Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K.&lt;/div&gt; &lt;/div&gt;</freq:UnauditedInterimFinancialInformationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Recently adopted and issued accounting standards &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the JOBS Act). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, the Company will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/div&gt;&lt;/div&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted the standard on January&#160;1, 2023 and it did not have a material impact on the consolidated financial statements. &lt;/div&gt; </us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the JOBS Act). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, the Company will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/div&gt;&lt;/div&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company adopted the standard on January&#160;1, 2023 and it did not have a material impact on the consolidated financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy at March&#160;31, 2023 and December&#160;31, 2022 are summarized as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt; Hierarchy&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,844&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Investments:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt; Hierarchy&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,649&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Investments:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Silicon Valley Bank (SVB) was closed on March&#160;10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. The FDIC then reopened SVB as Silicon Valley Bridge Bank, N.A. (SVBB). At March&#160;31, 2023, SVBB continues to hold the Company&#x2019;s term loan, deposit and sweep accounts, and security deposit for the Company&#x2019;s office space under the existing terms and covenants which were in place at SVB prior to the receivership. The Company is actively working to move these accounts to another financial institution. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">37844000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">25797000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">63641000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">30649000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">31143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">61792000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Investments &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the Company&#x2019;s investments, all of which are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and recorded at fair value: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:75%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:75%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s short-term marketable securities were held in investment advisory accounts with SVB Asset Management (SAM). On March&#160;27, 2023, following the closure of SVB, SAM&#x2019;s former parent company, and the creation of SVBB, the FDIC entered into a purchase and assumption agreement for certain assets of SVBB with First-Citizens Bank&#160;&amp;amp; Trust Company (FCB). As a result of this transaction, SAM became a wholly owned subsidiary of FCB. Although the accounts are held under the terms in place prior to the transaction, the Company is actively working to move these accounts to another financial institution. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines the appropriate classification of investments at the time of purchase and reviews any investment when its fair value is less than its amortized cost and when evidence indicates that the investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. The Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;this assessment indicates that a credit loss may exist, the present value of cash flows expected to be collected from the investment is compared to its amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to a credit loss is recognized in other comprehensive (loss) income. The unrealized losses at March&#160;31, 2023 and December&#160;31, 2022 were attributable to changes in interest rates and do not represent credit losses. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At March&#160;31, 2023 and December&#160;31, 2022 the Company held 9 and 14 debt securities, respectively, that were in an unrealized loss position. The Company does not intend to sell the investments before recovery of their amortized cost bases, which may be at maturity. All investments mature within twelve months from March&#160;31, 2023. The following tables summarize the Company&#x2019;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities in unrealized loss position&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,407&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,407&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities in unrealized loss position&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the Company&#x2019;s investments, all of which are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and recorded at fair value: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:75%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:75%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">25799000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">25797000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">25799000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">25797000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">31280000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">317000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">31143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">31280000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">317000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">31143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn03_31_2023"
      decimals="0"
      unitRef="Unit_Term">9</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_Term">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="P01_01_2023To03_31_2023">The following tables summarize the Company&#x2019;s debt securities in an unrealized loss position, aggregated by length of time in a continuous unrealized loss position. &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities in unrealized loss position&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,407&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,407&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Market&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term marketable securities in unrealized loss position&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">8407000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">21000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">9943000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">18350000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn03_31_2023_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">8407000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">21000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">9943000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">18350000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">17303000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">9927000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">27230000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_ShortTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">17303000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9927000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">27230000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment include the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,747&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,706&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,444&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,832&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized $1,000 and $726 of depreciation expense for the three months ended March&#160;31, 2023 and 2022, respectively. The Company accelerated depreciation of $360 on certain lab equipment for the three months ended March&#160;31, 2023 as discussed in Note 17, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Restructuring&#x201d;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">5747000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">5706000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">9276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9235000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">7444000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6496000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1832000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2739000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">726000</us-gaap:Depreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">360000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Payroll and employee related expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,831&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;550&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Third-party research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;457&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;525&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,567&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Payroll and employee related expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,831&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;550&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Third-party research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;457&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;525&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,567&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3831000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4216000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">550000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">377000</us-gaap:AccruedProfessionalFeesCurrent>
    <freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">457000</freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent>
    <freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">773000</freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent>
    <freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">729000</freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent>
    <freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">525000</freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">5567000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5891000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Debt &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2020, the Company entered into a Loan and Security Agreement (Loan Agreement) with Silicon Valley Bank for a term loan with a principal balance of $15,000. The Company made monthly interest only payments through November 30, 2022. The principal balance and interest were to be repaid in equal monthly installments after the interest only period and continue through May 1, 2024 (Loan Maturity Date). Advances under the Loan Agreement would bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in The Wall Street Journal, subject to an interest rate floor of zero) or (ii) 4.75%. The interest rate at March&#160;31, 2023 was 9.25%. Interest expense related to the Loan Agreement was $284 for the three months ended March&#160;31, 2023 and $178 for the three months ended March&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;3, 2023, the Company prepaid the remaining $11,667 due under the Loan Agreement. The final payment of $150, which the Company had been accruing over the term of the loan, was also paid. The Company was not subject to any prepayment premium as the prepayment occurred after the second anniversary of the closing date. &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPaymentTerms contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">The Company made monthly interest only payments through November 30, 2022. The principal balance and interest were to be repaid in equal monthly installments after the interest only period and continue through May 1, 2024 (Loan Maturity Date).</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="P10_31_2020To11_30_2022_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <freq:DebtInstrumentInterestOnlyPaymentMaturityDate contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">2022-11-30</freq:DebtInstrumentInterestOnlyPaymentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">2024-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P12_11_2020To12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_PrimeRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <freq:DebtInstrumentFloorInterestRatePercentage
      contextRef="PAsOn12_11_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      unitRef="Unit_pure">0</freq:DebtInstrumentFloorInterestRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2023To03_31_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2023To03_31_2023"
      decimals="4"
      unitRef="Unit_pure">0.0925</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">284000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:InterestExpenseDebt>
    <freq:DebtDue
      contextRef="PAsOn04_03_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">11667000</freq:DebtDue>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="PAsOn04_03_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Net loss per share &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the three months ended March&#160;31, 2023 and 2022 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net Loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,543&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,386&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average shares of common stock outstanding-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,324,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,810,676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per share attributable to common stockholders-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,642,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,165,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,610,663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,242,253&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,776,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2023To03_31_2023">Diluted net loss per share is the same as basic net loss per share for the three months ended March&#160;31, 2023 and 2022 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net Loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,543&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,386&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average shares of common stock outstanding-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,324,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,810,676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per share attributable to common stockholders-basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-19543000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-23386000</us-gaap:NetIncomeLoss>
    <freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      unitRef="Unit_USD_per_Share">35324053</freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted>
    <freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD_per_Share">34810676</freq:WeightedsAverageNumberOfShareOutstandingBasicAndDiluted>
    <freq:Earningpersharebasicanddiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.55</freq:Earningpersharebasicanddiluted>
    <freq:Earningpersharebasicanddiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.67</freq:Earningpersharebasicanddiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,642,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,165,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,610,663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,242,253&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,776,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To03_31_2023_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">3642165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">2165350</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To03_31_2023_OutstandingStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">5600088</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022_OutstandingStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">6610663</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      unitRef="Unit_shares">9242253</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">8776013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Stockholders&#x2019; equity &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Preferred stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of March&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has authorized 200,000,000 shares of $0.001 par value common stock of which there were 35,751,956 and 35,262,083 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has reserved the following shares of common stock for future issuance as of March&#160;31, 2023 and December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,742,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares available for future grant under incentive plans&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,690,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;988,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,290,493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,730,269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity Offerings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;10, 2021, the Company entered into an Equity Distribution Agreement (the Sales Agreement) with Oppenheimer&#160;&amp;amp; Co. Inc. (the Sales Agent) to sell shares of the Company&#x2019;s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $125,000, from time to time, through an &#x201c;at the market&#x201d; equity offering program. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Issuance costs incurred related to the Sales Agreement are classified as long-term assets on the balance sheet at March&#160;31, 2023. During the three months ended March&#160;31, 2022, the Company sold 12,767 shares of common stock under the ATM program for net proceeds of approximately $50. No shares were sold during the three months ended March&#160;31, 2023. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">35751956</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">35751956</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35262083</us-gaap:CommonStockSharesIssued>
    <freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has reserved the following shares of common stock for future issuance as of March&#160;31, 2023 and December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,742,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares available for future grant under incentive plans&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,690,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;988,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,290,493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,730,269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">5600088</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">5742053</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2023_StockCompensationPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1690405</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_StockCompensationPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">988216</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">7290493</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">6730269</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_10_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P12_10_2021To12_10_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_ShareDistributionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To03_31_2022_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">12767</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To03_31_2022_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To03_31_2023_AtTheMarketProgramMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The below summary includes stock option activity within the Company&#x2019;s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; shares&lt;br/&gt; in Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; term&#160;(in&#160;years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,742,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,969&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(166,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercisable as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,789,470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options unvested as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810,618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock option valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2023 and 2022 was $3.58 and $3.55, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The total grant date fair value of options vested during the three months ended March&#160;31, 2023 and 2022 was $2,874 and $5,097, respectively. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Repricing of stock options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;17, 2022, the Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company&#x2019;s common stock on August&#160;17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $2.14, the closing price per share of the Company&#x2019;s common stock on August&#160;17, 2022. Except for the modification of the exercise price, all other terms and conditions of the Underwater Options remain in effect. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The option repricing resulted in incremental stock-based compensation of $2,505, of which $170 was recorded as expense in the three months ended March&#160;31, 2023. At March&#160;31, 2023, $705 incremental expense remains which will be recognized as expense over the requisite service period in which the options vest. &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The below summary includes restricted stock unit activity within the Company&#x2019;s 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&#160;fair&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested, December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,101,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Awarded&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,666,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(306,775&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(819,050&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,642,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;839&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,592&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2023, total unrecognized stock-based compensation expense relating to unvested stock options and restricted stock units was $17,610. This amount is expected to be recognized over a weighted-average period of 1.72 years. &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The below summary includes stock option activity within the Company&#x2019;s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; shares&lt;br/&gt; in Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; term&#160;(in&#160;years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,742,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,350&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,969&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(166,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercisable as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,789,470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options unvested as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810,618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5742053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">9114000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">27350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P8Y7M9D</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2969</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">166346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5600088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P5Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">4789470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P5Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">810618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis">P7Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="PAsOn03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      unitRef="Unit_pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2023To03_31_2023">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      unitRef="Unit_pure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2874000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5097000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="P08_17_2022To08_17_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.14</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="P08_17_2022To08_17_2022"
      decimals="-3"
      unitRef="Unit_USD">2505000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">170000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <freq:ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">705000</freq:ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The below summary includes restricted stock unit activity within the Company&#x2019;s 2019 Incentive Award Plan for the three months ended March&#160;31, 2023: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&#160;fair&lt;br/&gt; value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested, December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,101,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Awarded&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,666,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(306,775&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(819,050&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,642,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">3101650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1666340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">306775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">819050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">3642165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;839&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,592&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">839000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2592000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2965000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3431000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5266000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">17610000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2023To03_31_2023">P1Y8M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <freq:EmployeeStockPurchasePlanDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Employee stock purchase plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;20, 2019, the Company&#x2019;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the ESPP) which became effective on the date of the Company&#x2019;s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten years of the term of the ESPP, beginning with January&#160;1, 2020 and ending with January&#160;1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#x2019;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#x2019;s board of directors. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;31,832 shares were purchased under the ESPP in January 2022 related to the second offering period of 2021, which concluded on December&#160;31, 2021. 24,754 shares were purchased in January 2023 related to the second offering period of 2022, which concluded on December&#160;31, 2022. As of March&#160;31, 2023, a total of 1,553,394 shares remain available for future issuance under the ESPP. &lt;/div&gt;</freq:EmployeeStockPurchasePlanDisclosureTextBlock>
    <freq:PercentageOfEligibleEmployeeCompensation
      contextRef="P09_20_2019To09_20_2019"
      decimals="2"
      unitRef="Unit_pure">0.15</freq:PercentageOfEligibleEmployeeCompensation>
    <freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance contextRef="P09_20_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">P10Y</freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="P09_19_2019To09_20_2019_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2022To01_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2023To01_31_2023_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">24754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2023_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1553394</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Income taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s total provision is based on the United States statutory rate of 21%, increased by state taxes and reduced by a full valuation allowance on the Company&#x2019;s deferred tax assets. The income tax expense for the three months ended March&#160;31, 2023 and 2022 represents state taxes on interest income earned by the Company&#x2019;s subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at March&#160;31, 2023 and December&#160;31, 2022 because the Company&#x2019;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which no net tax benefit has been recorded due to uncertainty around utilizing these tax attributes within the respective carryforward periods. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2014To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Collaboration agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-licensable,&lt;/div&gt; nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GSK-3&lt;/div&gt; inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-322,&lt;/div&gt; outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80,000 in July 2019 and has agreed to pay potential development milestone payments up to $230,000 and commercialization milestones of up to $315,000. The parties agreed to share equally, on a 50/50 basis, all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-of-pocket&lt;/div&gt;&lt;/div&gt; costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;11, 2023, Astellas sent the Company a notice stating that Astellas would be terminating the Astellas Agreement in its entirety on April&#160;14, 2023. The Company agreed to the terms of the notice and on April&#160;14, 2023, the Astellas Agreement was terminated in its entirety. The Company was not subject to any payments or costs as a result of this termination. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Astellas Agreement was a collaborative agreement that is within the scope of ASC 808, Collaborative Arrangements. Under the provisions of ASC 808, the Company determined that it would apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company recognized the $80,000 upfront fee, which was initially recorded as deferred revenue, as revenue over the period from July 2019 until June&#160;30, 2021, when the Phase 2a clinical trial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(FX-322-202),&lt;/div&gt;&lt;/div&gt; the Company&#x2019;s performance obligation, was completed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company invoices Astellas for all joint costs. In the three months ended March&#160;31, 2023 and 2022, the Company invoiced Astellas $14 and $193, respectively, for joint costs. &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">80000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">230000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">315000000</freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones>
    <freq:UpfrontFeeRecognizedAsRevenue
      contextRef="P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">80000000</freq:UpfrontFeeRecognizedAsRevenue>
    <freq:JointCost
      contextRef="P01_01_2023To03_31_2023_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">14000</freq:JointCost>
    <freq:JointCost
      contextRef="P01_01_2022To03_31_2022_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">193000</freq:JointCost>
    <freq:LicenseAgreementTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. License agreements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Massachusetts Institute of Technology &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement) with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-month&lt;/div&gt; prior written notice. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2022, the Company entered into a second amendment with MIT, removing a patent and certain patent applications from the MIT License Agreement which were unrelated to the Company&#x2019;s hearing and multiple sclerosis (MS) programs and which were not being utilized by the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;6, 2023, the Company sent MIT a notice stating that the Company would be terminating the MIT License Agreement in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-months&#x2019;&lt;/div&gt; time. The Company is not subject to any payments or costs as a result of this termination. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scripps Research Institute (California Institute for Biomedical Research) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of MS. The Company also has the right to grant sublicenses of its rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; licenses to other nonprofit or academic institutions, for any internal research and educational purposes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment. The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. The Company may terminate the CALIBR License Agreement at will upon a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt; prior written notice. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;29, 2023, the Company sent CALIBR a notice stating that the Company would be terminating the CALIBR License Agreement in 30 days&#x2019; time. The termination became final on or around April&#160;28, 2023. The Company is not subject to any payments or costs as a result of this termination. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2019, the Company entered into an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Exclusive&lt;/div&gt; Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive,&lt;/div&gt; non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss (MEE licensed products). &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon entering the MEE License, the Company made a $20 license fee payment. The Company was obligated to pay certain annual license maintenance fees between $5 and $7.5 per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;21, 2023, the Company sent MEE a notice stating that the Company would be terminating the MEE License Agreement in 30 business days&#x2019; time. The termination became final on or around April&#160;4, 2023. The Company is not subject to any payments or costs as a result of this termination. &lt;/div&gt;</freq:LicenseAgreementTextBlock>
    <freq:LicenseAgreementEnteredDate contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">2016-12</freq:LicenseAgreementEnteredDate>
    <freq:LicenseFeePayment
      contextRef="PAsOn12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">50000</freq:LicenseFeePayment>
    <freq:PercentageOfSharesOfCommonStockIssued
      contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_pure">0.05</freq:PercentageOfSharesOfCommonStockIssued>
    <freq:MilestonePayments
      contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">2900000</freq:MilestonePayments>
    <freq:DescriptionOfConditionsToTerminateLicenseAgreement contextRef="P01_01_2023To03_31_2023_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">The Company has the right to terminate for any reason upon a 3-month prior written notice.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
    <freq:RightToTerminateAgreementUponPriorWrittenNotice contextRef="P12_01_2016To12_31_2016_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">P3M</freq:RightToTerminateAgreementUponPriorWrittenNotice>
    <freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent contextRef="P04_06_2023To04_06_2023_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis">P3M</freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent>
    <freq:LicenseAgreementEnteredDate contextRef="P09_01_2018To09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis_PatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">2018-09</freq:LicenseAgreementEnteredDate>
    <freq:LicenseFeePayment
      contextRef="PAsOn09_30_2018_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</freq:LicenseFeePayment>
    <freq:DescriptionOfConditionsToTerminateLicenseAgreement contextRef="P03_29_2023To03_29_2023_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">the Company sent CALIBR a notice stating that the Company would be terminating the CALIBR License Agreement in 30 days&#x2019; time.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
    <freq:RightToTerminateAgreementIfBreachRemainsUncured contextRef="P03_29_2023To03_29_2023_CaliforniaInstituteForBiomedicalResearchMemberdeiLegalEntityAxis">P30D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
    <freq:LicenseAgreementEnteredDate contextRef="P02_01_2019To02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_NonExclusivePatentLicenseAgreementMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">2019-02</freq:LicenseAgreementEnteredDate>
    <freq:LicenseFeePayment
      contextRef="PAsOn02_28_2019_MassachusettsEyeAndEarMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</freq:LicenseFeePayment>
    <freq:AnnualLicenseFeePerShare
      contextRef="P01_01_2023To03_31_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">5</freq:AnnualLicenseFeePerShare>
    <freq:AnnualLicenseFeePerShare
      contextRef="P01_01_2023To03_31_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_USD_per_Share">7.5</freq:AnnualLicenseFeePerShare>
    <freq:DescriptionOfConditionsToTerminateLicenseAgreement contextRef="P02_21_2023To02_21_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">the Company sent MEE a notice stating that the Company would be terminating the MEE License Agreement in 30 business days&#x2019; time.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
    <freq:RightToTerminateAgreementIfBreachRemainsUncured contextRef="P02_21_2023To02_21_2023_MassachusettsEyeAndEarMemberdeiLegalEntityAxis">P30D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15. Commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company also enters into contracts in the normal course of business with contract researc&lt;div style="display:inline;"&gt;h org&lt;/div&gt;anizations, contract manufacturing organizations, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by the Company upon prior written notice although, purchase orders for clinical materials are generally &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable.&lt;/div&gt; Payments due upon cancellation consist only of payments for services provided or expenses incurred, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt; obligations of the Company&#x2019;s service providers, up to the date of cancellation or upon the completion of a manufacturing run. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Guarantees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Guarantees&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#x2019;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#x2019; and officers&#x2019; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company leases office space in Lexington, Massachusetts under a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ten-year&lt;/div&gt; noncancelable operating lease. The $1,699 security deposit for this lease is classified as restricted cash as of March&#160;31, 2023. The Company has standard indemnification arrangements under this lease that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2023, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;F-49 &lt;/div&gt;&lt;div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"&gt;&lt;a href="#toc"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company&#x2019;s accrued liabilities would be recorded in the period in which such determination is made. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;3, 2021 and June&#160;22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company and the Company&#x2019;s Chief Executive Officer, President, and Director, David Lucchino. On March&#160;21, 2022, the two lawsuits were consolidated into a single lawsuit, Quinones et al. v. Frequency Therapeutics, Inc. et al. and on May&#160;16, 2022, the Company&#x2019;s Chief Development Officer, Dr.&#160;Carl LeBel, was added as a defendant. The plaintiffs alleged violations of Sections 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended (the Exchange Act), due to allegedly false and misleading statements and omissions about the Company&#x2019;s Phase 2a clinical trial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(FX-322-202)&lt;/div&gt;&lt;/div&gt; for its product candidate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-322&lt;/div&gt; in the Company&#x2019;s public disclosures between October&#160;29, 2020 and March&#160;22, 2021. The lawsuit sought, among other things, damages in connection with the Company&#x2019;s allegedly artificially inflated stock price between October&#160;29, 2020 and March&#160;22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys&#x2019; fees and costs. The Company filed a motion to dismiss the Amended Complaint on July&#160;15, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. On March&#160;29, 2023, the Company&#x2019;s motion to dismiss was granted and the lawsuit was dismissed in its entirety. On April&#160;27, 2023, Plaintiff filed a notice of appeal to the United States Court of Appeals for the First Circuit from the order dismissing the lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, &lt;div style="display:inline;"&gt;no&lt;/div&gt; accruals have been recorded as of March&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;21, 2022, the Delaware Chancery Court dismissed a lawsuit brought by two purported stockholders against the Company and others. For previously reported information on this lawsuit, refer to Part I, Item 3, &#x201c;Legal Proceedings&#x201d; of the Company&#x2019;s 2021 Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K.&lt;/div&gt; On August&#160;16, 2022, these same two purported stockholders of the Company filed a similar lawsuit in Delaware Superior Court against (i)&#160;the Company, (ii)&#160;Computershare Inc., and (iii)&#160;Computershare Trust Company, N.A., entitled The Gregory J. Parseghian Revocable Trust, et al. v. Frequency Therapeutics, Inc., et al. The lawsuit alleges causes of action against the Company for breach of the statutory duty of care, negligence, conversion, and unjust enrichment, based on allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The Company intends to vigorously defend against all claims asserted in the lawsuit. The Company filed a motion to dismiss the complaint on November&#160;14, 2022. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of March&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;30, 2022, a purported stockholder of the Company filed a shareholder derivative complaint in the U.S. District Court for the District of Delaware purportedly on the Company&#x2019;s behalf against members of the Company&#x2019;s board of directors and the Company as a nominal defendant, entitled &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dewey v. Cohen et. al.&lt;/div&gt;&lt;/div&gt; The complaint alleges (i)&#160;violations of Section&#160;10(b) and Rule 10b5 of the Exchange Act, (ii)&#160;breach of fiduciary duty, (iii)&#160;aiding and abetting breach of fiduciary duty, (iv)&#160;unjust enrichment, and (v)&#160;waste of corporate assets. The claims are based on the same underlying allegations as the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Quinones&lt;/div&gt;&lt;/div&gt; case (described above). The complaint seeks, among other things, monetary damages, interest, attorneys&#x2019; fees and costs. On September&#160;27, 2022, this lawsuit was stayed pending final resolution of the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Quinones&lt;/div&gt;&lt;/div&gt; case. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company&#x2019;s board members are each party to an indemnification agreement with the Company that may require the Company to reimburse the board members for certain expenses and other costs related to this lawsuit. Since an estimate of the possible loss or range of loss cannot be made at this time, &lt;div style="display:inline;"&gt;no&lt;/div&gt; accruals have been recorded as of March&#160;31, 2023. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn03_31_2023_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2023_LexingtonMassachusettsFacilityMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:RestrictedCash>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="P01_01_2023To03_31_2023"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:NetRentableArea
      contextRef="PAsOn07_08_2022_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="0"
      unitRef="Unit_sqft">30040</us-gaap:NetRentableArea>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="P07_08_2022To07_07_2023_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">197000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="P07_08_2023To07_07_2024_SaliogenTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">203000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:SubleaseIncome
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">593000</us-gaap:SubleaseIncome>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1779000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1383000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3162000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17. Restructuring &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;13, 2023, the Company announced the topline results for the Phase 2b study of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-322&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(FX-322-208)&lt;/div&gt;&lt;/div&gt; which failed to achieve its primary efficacy endpoint of an improvement in speech perception. As a result, the Company also announced that it would be discontinuing the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-322&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FX-345&lt;/div&gt; hearing development programs and focusing resources on its remyelination in MS development program. This restructuring resulted in a 55% reduction in the Company&#x2019;s workforce. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expects to incur a total of approximately $4,329 in restructuring-related expenses, of which $3,970 was expensed in the three months ended March&#160;31, 2023. The total estimated restructuring charges consist of accelerated depreciation expense of $360, accelerated hearing program expense of $129, and severance and other benefit-related costs of $3,840, of which $3,481 was expensed in the three months ended March&#160;31, 2023 and the remaining $359 will be expensed in the second quarter of 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During the three months ended March&#160;31, 2023, the following restructuring-related charges were included in the Consolidated Statement of Operations: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Severance&#160;and&#160;other&lt;br/&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;benefit-related&lt;/div&gt;&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accelerated&lt;br/&gt; depreciation&lt;br/&gt; charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accelerated&lt;br/&gt; hearing&#160;program&lt;br/&gt; charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,932&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,481&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At March&#160;31, 2023, the liability for the restructuring is classified as current and included in accrued expenses in the Consolidated Balance Sheets. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accelerated&#160;hearing&lt;br/&gt; program charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Severance&#160;and&#160;other&lt;br/&gt; benefit-related costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liability balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net charges&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liability balance as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <freq:ReductionInWorkforceDueToRestructuring
      contextRef="P02_13_2023To02_13_2023"
      decimals="2"
      unitRef="Unit_pure">0.55</freq:ReductionInWorkforceDueToRestructuring>
    <freq:RestructuringRelatedExpenses
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      unitRef="Unit_USD">4329000</freq:RestructuringRelatedExpenses>
    <freq:RestructuringRelatedExpenses
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3970000</freq:RestructuringRelatedExpenses>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">360000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">360000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <freq:AcceleratedHearingProgramCharges
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">129000</freq:AcceleratedHearingProgramCharges>
    <freq:AcceleratedHearingProgramCharges
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">129000</freq:AcceleratedHearingProgramCharges>
    <us-gaap:SeveranceCosts1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3840000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3840000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3481000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3481000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">359000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">359000</us-gaap:SeveranceCosts1>
    <freq:ScheduleOfRestructingRelatedChargesTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During the three months ended March&#160;31, 2023, the following restructuring-related charges were included in the Consolidated Statement of Operations: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Severance&#160;and&#160;other&lt;br/&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;benefit-related&lt;/div&gt;&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accelerated&lt;br/&gt; depreciation&lt;br/&gt; charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accelerated&lt;br/&gt; hearing&#160;program&lt;br/&gt; charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,932&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,481&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</freq:ScheduleOfRestructingRelatedChargesTableTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1932000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_AcceleratedDepreciationChargesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">360000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">129000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2421000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">1549000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1549000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">3481000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_AcceleratedDepreciationChargesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">360000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">129000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3970000</us-gaap:RestructuringCharges>
    <freq:ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock contextRef="P01_01_2023To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accelerated&#160;hearing&lt;br/&gt; program charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Severance&#160;and&#160;other&lt;br/&gt; benefit-related costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liability balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net charges&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liability balance as of March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</freq:ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock>
    <freq:RestructingLiabilities
      contextRef="PAsOn12_31_2022_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">0</freq:RestructingLiabilities>
    <freq:RestructingLiabilities
      contextRef="PAsOn12_31_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">0</freq:RestructingLiabilities>
    <freq:RestructingLiabilities
      contextRef="PAsOn12_31_2022_AcceleratedfxthreefourfivechargesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">0</freq:RestructingLiabilities>
    <freq:RestructingNetCharge
      contextRef="P01_01_2023To03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">129000</freq:RestructingNetCharge>
    <freq:RestructingNetCharge
      contextRef="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">3329000</freq:RestructingNetCharge>
    <freq:RestructingNetCharge
      contextRef="P01_01_2023To03_31_2023_AcceleratedfxthreefourfivechargesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">3458000</freq:RestructingNetCharge>
    <freq:RestructingLiabilities
      contextRef="PAsOn03_31_2023_AcceleratedfxthreetwotwochargesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">129000</freq:RestructingLiabilities>
    <freq:RestructingLiabilities
      contextRef="PAsOn03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">3329000</freq:RestructingLiabilities>
    <freq:RestructingLiabilities
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3458000</freq:RestructingLiabilities>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18. Subsequent events &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through May&#160;12, 2023, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows: &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;3, 2023, the Company prepaid the remaining $11,667 due under the term loan. Upon prepayment of the term loan, the final payment of $150, which the Company had been accruing over the term of the loan, was also paid. The Company was not subject to any prepayment premium as the prepayment occurred after the second anniversary of the closing date. Refer to Note 7, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Debt&#x201d;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;4, 2023, the Company&#x2019;s termination of the MEE License Agreement became final. No termination costs were incurred as a result of terminating this license agreement. Refer to Note 14, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;License agreements&#x201d;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;6, 2023, the Company provided written notice of termination of the MIT License Agreement. Pursuant to the terms of the agreement, the Company has the right to terminate for any reason upon a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-month&lt;/div&gt; prior written notice. No termination costs will be incurred as a result of terminating this license agreement. Refer to Note 14, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;License agreements&#x201d;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;14, 2023, the Astellas Agreement was terminated in its entirety. No termination costs will be incurred as a result of terminating this collaboration agreement. Refer to Note 13, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Collaboration agreement&#x201d;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;28, 2023, the Company&#x2019;s termination of the CALIBR License Agreement became final. No termination costs were incurred as a result of terminating this license agreement. Refer to Note 14, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;License agreements&#x201d;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <freq:DebtDue
      contextRef="PAsOn04_03_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">11667000</freq:DebtDue>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="PAsOn04_03_2023_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>132
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<!9QG5\ YU=*V=-.?H-JR6WR'U!+ P04    " !PB_M6+<C[3(P&  #N'0
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M3+YR2$)D=MBU0X5&LK&K'DWPV]#DE=Z(;:JP_-B2U.0LEV;*RF#GY!0V><V
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MJ S\\'+Q<"+9OGW==L>D9%5[N*-$V=,"]?V6,?ERHM_@=:]XE_\#4$L#!!0
M   ( '"+^U:7M><8$ ,  -0+   8    >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULK991;YLP%(7_BL6F:9.Z8""0I$N0VJ!J>Y@4-=KV,.W!A9M@U6!F.TFW
M7S\;* LI28C4/C08SCGV=^-+/-UQ\2A3 (6>,I;+F94J55S;MHQ3R(@<\ )R
M_63%14:4'HJU+0L!)"E-&;-=C ,[(S2WPFEY;R'"*=\H1G-8""0W64;$GUM@
M?#>S'.OYQCU=I\K<L,-I0=:P!/6M6 @]LIN4A&:02\IS)& ULVZ<Z\C!QE J
MOE/8R;UK9% >.'\T@R_)S,)F1< @5B:"Z(\MS($QDZ37\;L.M9HYC7'_^CG]
MKH37, ]$PIRS'S11Z<P:6RB!%=DP=<]WGZ$&\DU>S)DL_Z-=I?5'%HHW4O&L
M-NL59#2O/LE378@]@S,\8G!K@]O7X-4&KZ]A6!N&964JE+(.$5$DG J^0\*H
M=9JY*(M9NC4^S<WWOE1"/Z7:I\(YSR5G-"$*$G1+&,EC0$L3)]'[!1&0JQ04
MC0G[@#ZBM\A&,M5WY=16>G:38<?U3+?53.Z1F;X2,4"><X5<['H=]OEI>P1Q
M8W<[[%%_N].VV[ID3=W<IFYNF3<\DK=4NF)Z_RO$5^B.YKINE#"TX)*6^_GG
MS8-40N_J7UV5JK*][FS3ZM>R(#',+-W+$L06K/#=&R? G[KJ]IIAT2N%M6KJ
M-37U3J6'"]WR((3>B'K;QX]7J" ";0G;0%<-JZQ1F67>;ML0#S#6W^UVOSB]
M5-$Y50MGV. ,+\,A&Y5R0?^:.T>;J,H,]I;BX.KO@*RO,.HA;/'Y#9]_&1^5
M<G.2S7^QDD.HLXKHE**%$308P648^M=1*I(G-%^?8 G.LIQ51*<4+991PS(Z
MR3+G6:9?/GW:9]2K?7JIHG.J%LNX81E?P-*K=\8OZNGB[N;IK8SZ*%M\DX9O
M<@'?V=Z9O%B'YX]\9^('!VA=0C=P\=@[(.L0#@/'<1VO&\S!_\\4^ *T?OU4
M1_8 [%1V$G8INQ'MO1.4.>_JP\J:YA(Q6&DK'HST:T=41\AJH'A1'JH>N-)'
MM/(RU<=N$$:@GZ\X5\\#<TYK#O+A/U!+ P04    " !PB_M6"AOV^K,%   *
M&   &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U8;6_;-A#^*X17# G0
MQ*+>E3D&$LO; BQ-T;3KAV$?:(NVA$JB)]).ME\_4I)EFSRI*> OMB4_]Y#/
MW?%XY.2%5=]X2JE KT5>\MM1*L3F9CSFRY06A%^S#2WE/RM6%43(QVH]YIN*
MDJ0V*O*Q;5G^N"!9.9I.ZG<?J^F$;46>E?1CA?BV*$CU[SW-V<OM"(_V+SYE
MZU2H%^/I9$/6])F*+YN/E7P:=RQ)5M"29ZQ$%5W=CN[PS1Q'RJ!&_)G1%W[T
M&RDI"\:^J8>'Y'9DJ1G1G"Z%HB#R:T=G-,\5DYS'/RWIJ!M3&1[_WK/_6HN7
M8A:$TQG+OV:)2&]'X0@E=$6VN?C$7GZGK2!/\2U9SNM/]-)@ V^$EELN6-$:
MRQD46=E\D]?6$4<&N,_ ;@ULW<#M,7!: T<W\'L,W-; ?>L(7FM02Q\WVFO'
MQ420Z:1B+ZA2:,FF?M3>KZVEO[)2)<JSJ.2_F;03TQDK.<NSA B:H&<AOV06
M"([8"CUM:$54-#FZ^%*2;9))S"6Z0E^>8W3Q[A*]0UF)/J=LRTF9\,E8R/DH
MUO&R'?N^&=ON&=M!CZP4*4?S,J$)8!\/VV-[@& L'=%YP]Y[X]X>9'PDU35R
M\'MD6[8#3&CV=G,;TC-L'M/EH/G\[>9XP!E.EQI.S>?V\'79H))AQ@I9B%)5
M(784/91+5E#TU]V"BTJN];^AX#?L#LRN"N -WY EO1U)8DZK'1U-?_X)^]8O
MD.//21:?DVQ^)K*3$+E=B-PA]NDGNJ/EED+>'S3\4>^?DRQNR+R:3.UCNZDU
M&>^.76HBL&OY88<Z\977^<H;3.>VG)5K1%_E-LLIOX'\YIW3;^<DB\])-C\3
MV4DD_"X2_G>REE-2+5,DMPVYJ>]DM[)1=08*AV^F G8\[S1A9@#*"4)\BHH;
ME'^$<B,7AUKRF2C?BM1N "5?T$D.!B7_1DN9?7FMF"1R'\]4X50]$B0Z,*80
M8<_7- ,@-P@TR2;(<;S0U20#J  '/BPY["2'@Y(_,R$%,V/508)#8P*VY6$M
M?C, Y=B>%K_81(6.9=F:9!,5A584P9*C3G(T*/D/QCE:5:S8RY:]$R0W,@:_
M@O1",$ P (,40S#7<C L&5N'!M(:%/U0"BIKA)#-H&H*P#;0,L;VCE94HQ8
M1=HZCP$,=FPMZ>< RHF"'IU'C3)^F\XVD4&A& B9OMQF$ H'>E@A5.1C72N
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M";K [-VN;*/Z B!LZ^)-D*$;XO%Z1!_Z1#S<*'Z@ JGR ,H+C#971=@U\AK
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M^WX<GLF2A 3(30FT+#D0@3UCEK(^B!#"B.@YZ]MR[A[QX+T5% % J:EN20B
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M!9#?;SAO7B_4 XZG3)?_ 5!+ P04    " !PB_M6;$-6L0P(  !H&P  &
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MPQ8C+SHS\*:=&8I$V-1TDU:;3D_((Q>#%T,&K0IJN6&^/\["%6$$3\D[/,0
M:'[%5!F"H^D(]Y/C&3HV!:\9+\APFD1W_ /J V@UI6)7"3KO"\UELN]@X^ 1
MP?Z#C=US@]_U0.";C1]_Y4")O7^/&;9;$)Z]W#Y"&'\_0_A]SQ#N1?CSCA%.
MYN.3DU??CQ&^'R,\=(SP&W;]\^1;[OCWG0U/!Q\S2F&7X1N/8V'/$+]K=$^[
MST@7X>O)M%\>OT%A2EA*6*#$ J2SR4^O1LS&[SKQQILJ?!I)C?>F#)=4ZX2E
M!7B_,.A&S0T)Z#ZNG?\/4$L#!!0    ( '"+^U8F$PDKH!\  %-E   8
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M:\B.8P#]OG+D?_0#%@C_CLK+_P-02P,$%     @ <(O[5I-9C+_@ P  !@D
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M\5-+G'A3AZ\5,^.]J<*P%!P/(A+ _L+@K=E,Z(#V>]?5?P%02P,$%     @
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M3JQT):M,2P-S/NC0D.)C,<@WW$^$!XW!1^!U[2P@R?!8OED?P$&Y"QDB8ES
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MS)CU/6O8U:62.Z)P-$C#"^,;,QNL$37NXMM&P5L!\YJKMXTL/IRA(TKR0FX
M')JA?R_/&Y".8\X+)^FYE10>D!215[)NUIJ\K$M>3LQ_<7Q^$!X1< YF];:%
MG6W/PZ,27S'ED2B@)/3#:$JAX]._YT4_/3RB3M2[.C+RXD.N7C/%SYX;5[]F
M=Q *#;E6BM4K;J[_=GVC&P6X_ON4\ZWL:%HVQOJ%WK*"/YM#,&NN;OG\ZKMO
M@M1_.F7X5Q(V<D/<NR$^)OVS$'=4TK2>@>^1X1+%8 G[@L@MWFCR;LW)#>:Q
M+H<141=56W)-]&"@336BN8/0;-:B)@W,0\U9???=-WD89$\U8"2(G?B?Z@*V
M$Y(3>5TQF%V7^'8Q>'Z]8ZJT;R$/&WG-6G%.-C8 . 8  ?@6ZQZ_%[.?V\T-
M5T0NR6\F.<&0_N)ZM5)\Q1H^^Z5M= -KBGI%F,;1@&-N9G98)@G-XI#Z241.
M2.A%"4F]= '7"QH$\>Q'@"3*##,:)3Z)O30EN9<&Q!@;/IV]_,A5(="YIR%=
MP,PGQ/?\K'L/@H(9Y-@E%RCF-$A3&L4IC J]T.]'==+V%1X;#MJFOD_]/+?:
MIB3Q4M0\GOWB-I);A=A-Q:=%Q#3+%S3.?",B]D%$N!B):.M;KE'=R?EYX-,T
ML H$$<F\-('KS@+$$>LV ##4* %5KB"WK&HY2M,CV E-"E85;<7<>KC_I5@N
MN>( $8!DL^/<PLQ9QLE6B<+(PJ=C>0@P?+ID0MVO.052B 5 F)MND2?U0W'-
MFC5DS<H':VL"@<)Q"JN_8#EO%'MFG@U)XSP- 3A<?B"-M BT1D)M;KB""LC-
MVQ6"]*Q$AX\5&1NS<EB&^7RSK>0=Y]9AI5! )*32!(PRJ%G*"BS4E)A<8F9A
M[,-[%V/LEBL@-L@:A+Z8]1"9O1'ZP]D2XQ?V'J3IABA4+/)2\BU$RQ960AU
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M'\':9N\=UZ 3U"RB@1_0-+%,)<MG9E60"P\-CT)"!H]_M=GS-/)3FF4)D*O
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MV3:M<K[1T\O!5K^%4NOVVA1@R$Z3NW33,;![AHZ^E",)BTX"AH/1:2TK6'?
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ME\J2I/G' AF)GC.@^5PIVPY<@.Y?D_E?4$L#!!0    ( '"+^U:A\RLH!0P
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M,UYB_+5^7%D(JH?A'I+0H":_'98=I-M[F+?'KU!;C[4TL<FH?\)LX\--+O=
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ML:Z^AOFY7!DKV:DW:ZL48E2_G-803H],DR#HM1>T.")H*=Z8LMXX\6V9JO3
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MB/'C$'P@CFTM,CSM4\=;-+?8GS]_%D^BUWL(IAW!=!_ZGM+O]XO3(;3)?51
M9<-J@0;B4+IH *Y N-!5+=0&4#DTF(-43H-0<+8RB'2H'-"!AB]HJ*>$/Q]Z
M&5#)*H>ONFR4HU,*GQMCD"0V;'!CL)(<^$4PW?7OD ^IA5T!9Y_>OKP^8XI_
M"-4PU#00W,M/4BCE&H,<KO1!*-:=5"M',7S4%O_]Q<WHS\L/O\/T"-Z+#;G!
MU=7%P.?%$8(SH8BZ-OI.T@G&<@.3>#".IG3ZB1+"DN<>V5"*3BQ*2IXF&Y&
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MORSH\HJ&#>C]4FNW?>  W75X_B]02P,$%     @ <(O[5BQ$PFB^"P  *3(
M !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL[5MK;]LX%OTKA*<[2 #'
M=NPD?4P2H$U3;(#)M&@ZNPLL]@,M43:WDJ@AJ;C>7[_GDI0LV9*;/F:GLRA0
MS%@V>=_WW(>=\Y72[\U2",L^9&EN+@9+:XMGX[&)EB+C9J0*D>.31.F,6SSJ
MQ=@46O#87<K2\70R.1MG7.:#RW/WWAM]>:Y*F\I<O-',E%G&]?J%2-7J8G \
MJ-YX*Q=+2V^,+\\+OA!WPOY:O-%X&M=48IF)W$B5,RV2B\'SXV=7)W3>'?B;
M%"O3>,U(D[E2[^GA)KX83$@@D8K($@6._]V+*Y&F1 AB_!9H#FJ6=+'YNJ+^
MRND.7>;<B"N5_EW&=GDQ>#)@L4AXF=JW:O57$?0Y)7J12HW[+UOYL[.S 8M*
M8U46+D."3.;^__Q#L$/CPI-)SX5IN#!]Z(59N#!SBGK)G%HON>67YUJMF*;3
MH$8OG&W<;6@C<_+BG=7X5.*>O7PKC. Z6C*>Q^QG&<$_@CU?:"'@*FO.QQ9,
MZ.@X"@1?>(+3'H(S=JMRNS3L.H]%W''_:O_]X^D> F-H5ZLXK51\,=U+\9;K
M$9L=#]ET,IUU";3_^DL1U=>G>\29U1:?.7HG#['X2W&/1"K(UNR?S^?&:L3U
MO[JL[HG.NHE2KC\S!8_$Q0#);(2^%X/+'W\X/IO\U*7Q5R+6TO^DUO]D'_7/
MB;B]!+O%/3X9U<1Y39S=<F-XM"R-L'BZR8V5MK2"J82]$]$R5ZE:K/$^'!.)
M;"XTO'Y\-F1V*=B5R@J>KQD("2UB)G.KH 03'Z*T-  C5G!+CDRW^;*#VYMW
MN[H>(M?MTM%^F%Q$YG#(2B2&9JNEC)8MP31DAAAQ2Z@AX6@: U7P4JLU3^WZ
M: X/R'Q12PI%(J$M0+_201/\&?H@]B$Z!.J\!XDEAZ(9)VJ0=LB R.D0<B80
M":?]8RHXZ0\'RZQ0VK)"J[B,0/ @6"%F;\);A^[<AI%[+(2F"D7W(F&,V+KH
MWSL,-I!YI#380')GC[0Z:3>F S7WF46IL\XG,&TL#0DZ) II&9-%YJ5EN2(?
M9M(*)Q==0V#=XY(K/!!/PW^QY.X9=):5.94Q(_:NX1*>&@63&4?$V90H+C2'
M *:<!TD-$9&P3K"Z=["+BZZX&;%?"S!V<4AL72#VGFX';\$EXH,].IW4SD\$
M1>[:&<6YS)C2:T[TS))K+Z J-8M4EH$URE+TGHG?2I[2N=._T.=667I<BOP(
M[8*QH$721;R0](&[T[:.A,8@(K5G!R'J,.1Y3L0K&:D?05SR/'+RFN#Y##?F
M@D4@4'E+EWE.;'VH2QR-2V<ELH+A&4[S5.0QUVP-M\'W"9BMAU444I2S0E$2
M2 B0R51 \KPV$;Q3T+E'T^'3R821'Y"X;#NL&>)M.V*]\IU. A*D*845Z8Y_
M OD$(B6$<"9%/A=2AX#3C,\AK<JK..:X&[SFT]<X;1+(7KW#>%' F(Z":63(
M$E#FPVV;.>$,=$?H"HW&@Y-]8;!4"MWVXDYXUQ=<UGEDX@:2EQ2VG,V.,JKP
M!+.W<" 0]NE^A(77\CB8"?=@00A7Q% F^#66J5P("H[:7\8S!R!%:E-H:O^,
M/'>J0U37]_&O2'1) :.I>Y*"UW;&R2TL;9D^T2KK3]80URNPA_FU2'D#A()X
M/_[P9'K\^"=3PPZQS-"VRB)%B$>IT,H@M0YN[PX)0($VF0^(!G'"N+F@VR5"
M3/X'7.;K)I<1>YVSYX5&_)WYUJEM(T/2D@Z<:$$/)'CE$&Y;1U>J3&/*TRHP
M*K=UFP"&"Q%B@JHNW.XB+8O"L+I_V%3)@RN>2K@[E[SQ+OG_A52$U$CY^MXA
M>?Y.%+:N[T_V>G^GF@_![_G/-R_>=E3TX::D?XI,-<G_>77_A*+>6<[;EFA6
M]2^LS;=W7[>2]KEL5'T26L<M!J7Q3@--D2:^2.P*D*O\:-,&]E3G/@G:T4=>
MH )]/)Q,.FMT,$L/,:K7J 8 +&19*79J2;..^,)1,5:PX2* 5"C&=0UMNX*J
M[@;C]ZG&>*AL%?)/CF)<?EU#[]->: DDOP!=>H4B@)DP"%+CBY69\#K61"#O
M7$34+R1X3EDHO%HAI (N3I]XZ7>:&@)7Q.2_R>RN@JTWW8.B)LI0A<8_"CH
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M(?9;W!5OX6UKO_MYFXFN]>KV=Q/"5X&P1-D/YH0>L3(^M/U,6Q4$&M!J//3
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M:!+ _VNE['Y!#KJGW?QO4$L#!!0    ( '"+^U:\  ]/.P,  #4'   9
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MD"8X@:?*!Z%M=#R?9M"MB!AIB3\,GC<^*.$*L6@"] @!N1O+?KP@;TF?B5*
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M%X.HN2%EWBY0U]JT)2U77<-%K-RBLYN4)$,C3QYE\#!NWZ*^;A=16Z C 8B
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MC8='!U'=>]N%TU6X8RRTPQM+>,34XJ<&">#[I<9#VRS(0'=+G?X-4$L#!!0
M   ( '"+^U:>T!'M1R0  &:)   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;.U=6W/;1I9^]Z] >5)35A4DBY1O21Q7V7*\XZP3:ZUXIJ:V]J$)-$G$
M(!K!13+SZ_?<^@:"H*315FWMYL462:!Q^O2Y?N=TX^6U:;ZT:ZV[Y.NFK-H?
M'JZ[KO[N\>,V6^N-:D],K2OX96F:C>K@8[-ZW-:-5CG=M"D?ST]/GSW>J*)Z
M^.HE?7?1O'II^JXL*GW1)&V_V:AF^T:7YOJ'A[.']HM/Q6K=X1>/7[VLU4I?
MZNYS?=' I\=NE+S8Z*HM3)4T>OG#P]>S[\[GS_$&NN+OA;YN@[\3G,K"F"_X
MX7W^P\-3I$B7.NMP" 7_7>ES798X$M#QNPSZT#T3;PS_MJ._H\G#9!:JU>>F
M_$>1=^L?'KYXF.1ZJ?JR^V2N_Z9E0D]QO,R4+?V;7/.U3Y\]3+*^[<Q&;@8*
M-D7%_ZNOPHC@AA>G>VZ8RPWSF]YP)C><T429,IK66]6I5R\;<YTT>#6,AG\0
M;^ANF$U1X3)>=@W\6L!]W:N/S4I5Q1^*>5KER1O5%FUBELE%HUM==?S+HPM3
M%EFAVZ.7CSMX+-[\.)-'O.%'S/<\XBSYV53=NDU^K'*=C]Q_/GW_;#XQP&.8
MKYOTW$[ZS7QRQ)]5<Y*<S=)D?CH_&R-H^O:W.G.WSR?(.7-K<$;C/=DSWNLL
M,WW5%=4JL6Q._O/UHNT:$/+_&F,XCW<V/AYJ_G=MK3+]P\,:%[&YT@]?_?4O
MLV>GWX]-]IX&BZ;^Q$W]R=3HKT:E;6S&D\.,$^G&KD-)_G6MP79D9E.K:HLL
MSTS5 M=SU>D\61:5JK)"E4D+UVNP5UV;K-653A9:5SA2K1JXKJAHD":'JS6H
M;+>FS[**<&^5JR9ODQ8,\6*;=/#0=V[H8+TOW95O#/R7/'KW^O+-T0E1B7_B
M &VRTI5N5%EN\2&Z1D*#I]5- >/6)4C-HW][_?KB"!ZG.GKF.4\S69H2['6;
M="8!"]PW.BE@6#]9X$%>('M2,,TM6$#B&_B*AIC6IF0:,M6NDR4-!$P@QA5M
M!RP"PH QI@'"3I)/>JD;#6RAQR%!2=&V/=!L&8'S @;"WZU.*M/QE?C3X;7
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MI8+O93?24-Y;H\\65CTM?IIW;#L,2+9A/PE2UP*A(]^H/TIB.Q\D;AX.^_'
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M:O>%7>,[''B0;;2150NF""HNFI6]MG4X "3!&X"H!40N[D;(17G+#$LG2NY
M66]BLQN7JD-3<%S81WDRBFXYX4RZ4%@SGL/=*SVS1@U,Y/#5%*C@9J,4"@,S
MK=%H^/C,EB7J3Q/?D*Y%^UFK,6\THC<TP@@>I#"%ACN18_X_@4\!=U%'^ZCG
MT4G&6\PN8!#V(0JBZ 3?H*O"P/'%[ZO"01&:Y/M=,7[.EMHH^I=^':M#HS(X
MKF+[:ZQKEN'4HP;2J+;HI>=GX2BX/I%#W.40GV)/GYJV KF"=S_JL1Q.J^RI
M\9!:.NJLI6;-_Y))ZEQM,+<1D0.L9$DC@(OUN$?OA]62,/8-#XW>HV,@SAQK
MJ3GQ?(#SLR0*HVO:Q9<!>6AD*BM:KRW-E;JRJ"ZDJ!\D,23#I#?+,KD11*)(
M@V_M#PQQ? 5A'/?NA=XH)C*$L#\*$D(-DKC75"D:#B%,AKUG:5AI=?N#JY%;
M@S@\]E;^00=6J-9NSM@:D'K3C-UI-\IF30?_<V_FX -3:RXTE+@B:'!Q.?1
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M4\Z]L4=R*&C#S;W<?85]/0.+ETFNW4AVK6^"&;-&&UGM@]&NF&AG^K*_AZ.
M<?A.0+P/B!WO-I%C>4,-36=*[HBRWHAF%ZY4%XWDF+"/LC8*3QG&F72E\'V5
M>254Y.3+4\-JO'%#+A[HAH.^G 4&DUC7(-L#+EO ^!W *"9W4IA2DR\BA_PM
M0(#L.HKQ@>(R/HMX ]D5Z4<^B<,X/H/7[TKN.[SD/R7[9,4IUOJV\M^+C38*
M?Y8_IVIOD?NGD:V IKJF&<P]5(@&]0Q>^NE#- P_G^&==+R3<^CI&@69-QR(
M+,CI9SO%^#SF&QSH+H&)C#<Y$%,"*21'Y3*QG?;P):#:@'*O<6STOM/-4?A'
M,O!'X1#GH1^-1KW;1@EF&@4NC2P*EL&1>]^/^^-V[*UE8784/>-)9+_>@S24
MDPD>#G!$U-XBRYJJX=1 COK#B\X8=0J_&/K)9$@NR47B1^.$7/9.E^<3 99D
M[(_Z$T=V</K'"HYT58':NNZA228;85J)=;M=@UJTNOSGWG:W.ZJV3&C"H<#0
M\&HT\(AJ.T9K&%D[E6ZD0<V[98E-%I1UP/-"2G,P;(*N;:=_ 5!+ P04
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MXPD2E>TNUSYH4=MU:",T+E?V6.#Z"]((X/>MP,(X/!@#W4*]_ )02P,$%
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MX+23EC73N)3\:YF;8NZE'N2X80TW]W+W$3L]8\N72:[=)^S:V(0R9HTVLNK
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MT+?-$ "++AFYJ\/NK@X?>U?;9'B58P1_1,L^;"SK7^*:;'(&M-K6E!NA8'S
MMJ?00]?SJ!+#5=)B2D.A[$>EYV2RQJPT$OI_(U2%O17N+K96[,9GU\&+U@J@
M%]6JE'="-#C*"P4^ETH3B'6_LCK$ZK:QG<-^:SUOK;]&Z_<GW8TRN2CTQU=S
MO.XA)8";-D2A8KX;D1=06E8@"74 ]<D>M!MW@BO]$C*4;C=O)&1)4>)]D$+%
M[-/E<$WDT$&0NT*4.=[,Y 49NJ.>X'WROW7_'^#$9@B9V,J%U\!()-!GU V_
M$(\'8Y(T7H]3-_EB:(8"M).T49>TT6.3]D)D<E$7_X#,AZ;"H7P<YW_5"[/:
M"M ] 5E_!.IURSS+&D(L:QF$6I9%;LL\W'G&3DGVAI$K"%I;O7O-RY5MCON3
MY,2V91C)R07$W^:6!8JX@89^9>>KYR2Q=QIT%I1-?A(U\"[M*9X#,@MM4!:T
MXW"#I8 (:&7#R94T< BN;R?P&78'CA=%0]DSZJLGCE)Q%^EX-!)@,MRE%E)-
M%7Y?%V:PPH[R^=KI\1LQVS$YZ4Q.OO.@G7Q+5WTC9CNN2CM7I8\?M+E9ZZ8B
M=) Y:]J/!CF8#H^'T[C@D7E:;44T)7\-(AX[6/\7H_/D?=O;.@-MK>\PBG-'
M,R[&R<1*M>-,9(=9G(IA^4/3'>_Y%(:A.+1# -OI^Q.60K].8<=WD[ 3.CQE
M^@Z.0<S.EKX;ID/ &HW R*7]'>*"]V0;CWLN=K\N)#"Q>>!WB@%)W3#H N+#
M'!/92,&=S;J A"&,H=;M]G0O(&&0.HG="5T:?04*$CJ4FK/>Y]I*J(7]BHT=
M_KHVS9?;;K7[4'YBOP_/ML>;K^P A@7,1Z04<R"E;@S]F6J^7#<O1J[LQ]]K
M:8RL[.-2\%PH/ #[<RG-Y@4%=/\^./X74$L#!!0    ( '"+^U8+@(1Y$04
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MLO2H>G-+7S&HG0.MYTK9X\!MT'X7+;\!4$L#!!0    ( '"+^U8%=$E2+ ,
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M<VAE970T-2YX;6RM5FUOVC 0_BM65DV=Q,@;9*R#2!2H5FEM$:S;AVD?3'*
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MT-LVK>A_]$UC##5U1YE$)=G"4MY@""<JFF:SF2B^-]W4ABOHS<RP@/Z<".T
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MK54@S_X<X$?H+ NH52".+P<[]7K]H[PU"Q3 +)08S>_RS6^XCF:NJ8&VS<(
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M(4AC@/NQ$/IU8CJ0NN,,?@-02P,$%     @ <(O[5JTJO93U P  &1(  !D
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M<D-2G29RCPE,%<C[*TK%RT#M2MI=:_@74$L#!!0    ( '"+^U9QN]?KA0,
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M;_?\[4"R;;,+OF%2[:F;PPV0#+@&J.LY8_)^H#?6_9>7Y']02P,$%     @
M<(O[5AHLCKG8 @  4PD  !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&UL
MK5;;;MLP#/T5P2N&%NCJ6RY#EAA(X@SK0X&@7;>'80^*S<1";<N5E$O_?I3L
M>$GJ>AV0%UN2>8YX2%K4<,O%DTP %-EE:2Y'5J)4,;!M&26047G#"\CQRY*+
MC"J<BI4M"P$T-J LM3W'Z=D99;D5#,W:7 1#OE8IRV$NB%QG&14O$TCY=F2Y
MUG[AGJT2I1?L8%C0%3R >BSF F=VS1*S#'+)>$X$+$?6V!W,NMK>&/Q@L)4'
M8Z*5+#A_TI/;>&0YVB%((5*:@>)K U-(4TV$;CQ7G%:]I08>CO?L7XUVU+*@
M$J8\_<EBE8RLSQ:)84G7J;KGVV]0Z3$.1CR5YDFVE:UCD6@M%<\J,'J0L;Q\
MTUT5AP, \C0#O K@G0(Z;P#\"N"? GIO #H5H//>';H5P$BW2^TF<"%5-!@*
MOB5"6R.;'ICH&S3&B^6Z3AZ4P*\,<2J8"RPYH5X(S6,R>UZS HM D4]D',=,
MIY*FY#8OZU$G]C($15DJK]#D\2$DEQ=7Y(*PG'Q/^%HBB1S:"OW2['94^3 I
M??#>\,$G=SQ7B22S/(:X 1^VXUVOA<#&@-11\?91F7BMC'=4W!#?O2:>X_D-
M#DW?#_>:]+3#0XA:X;/WP]V68/AUB?B&K_./$KDF\Y1B;1Q7RJ_Q0BJ!__OO
MIL27S'XSLSX#![*@$8PL/.0DB U8P<</;L_YTA3T<Y*%YR2;G8GL*#V=.CV=
M-G9,-Y)&K/P]88<-1$)3*DJ6KF'1W6,3N([C#.W-88A?&_6]WK%-^-K&Z_=.
MC&9-1OUN;72DM%LK[;8J'4<1-AA!%<38"PY41PD5*V@\>;JO_/![IZ);=_W?
MNCHGV>Q,9&6T[8,ND0$&3+=G22*^SE5Y&M2K]0U@;!K?R?K$'4S=AO40;PQE
M@_]+7UXW\$!<L5R2%):XE7/31V&B;.'E1/'"]*@%5]CQS##!6P\(;8#?EYRK
M_41O4-^C@C]02P,$%     @ <(O[5H:\JU3T @  %PD  !D   !X;"]W;W)K
M<VAE971S+W-H965T-3<N>&ULK59?;YLP'/PJ%JNF5EK+?TB[!*D-F[:':5'3
M;@_3'ASX$5 -9K:3--]^MJ$H 1KUH2\)AKOC[FPPTQUE3SP'$.BY)!6?&;D0
M]8UI\B2'$O,K6D,EKV24E5C((5N;O&: 4TTJB>E85F"6N*B,:*K/+5@TI1M!
MB@H6#/%-66*VOP-"=S/#-EY.W!?K7*@39C2M\1J6(![K!9,CLU-)BQ(J7M *
M,<AFQJU]$X<*KP&_"MCQ@V.DDJPH?5*#[^G,L)0A() (I8#EWQ;F0(@2DC;^
MM9I&=TM%/#Q^4?^JL\LL*\QA3LGO(A7YS)@8*(4,;XBXI[MOT.;QE5Y""=>_
M:-=B+0,E&RYHV9*E@[*HFG_\W/9P0+"]5PA.2W#>2G!;@OM6@M<2/-U,$T7W
M$&.!HRFC.\046JJI UVF9LOX1:6F?2F8O%I(GHANDX1M($5?GN5"XL#1)5K*
MI95N""":H<'E\Q@$+@B_D,#'98S.SR[0&2HJ])#3#<=5RJ>FD+Z4NIFT'NX:
M#\XK'GY@=H5<^Q-R+,<=H<]/TV-(.KHS0H_?3K>/Z:8LLVO4Z1IUM)[WBMX"
M[_&*R*ID&4U_F'#TYW;%!9.K_.]8/XVB.ZZHGOP;7N,$9H9\M#FP+1C1QP]V
M8'T>:^L]Q>)W$CMJTNV:=$^IJR89)407"65-Z!Y OFH(%G)%0KLBQ^IL9'TM
MJ]Y[V\B=N')NMX<U#4&>8P?'H'@$Y(9^!SJ*Y76QO-.Q&,V J_<F)BB#\0B-
M1'!P8]^W>@F&&#<,>P&&F# (Q_W[G7__I/^'O&#I98V9V",UZ9@EN9ZC%+9R
M&ZGEIB!.3H\_\.3Y/=_S(28,W5ZV(6;B6>/9@BY;<#+;3Y$#&_,<#/TXUSW/
M0XSO^#W/0XQM7X][#CO/X>GYH *3,<_A8/'Z?M O>@0TN>X]*_$0%-B6W;-M
M'NQ"ZI-!OM;71<41@4S2K*M0\EFS#3<#06N],:VHD-N</LSEEPLP!9#7,TK%
MRT#M==VW4/0?4$L#!!0    ( '"+^U;\H0L!^@@  /]D   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;*V=76_CN!F%_PKA+HH98#;6AV,G:6(@8XGD
M )MN,)EM+XI>*#9C"ZL/+R4G$Z _OM1')%.1:2LX-XDMZWTH2\=ZR?>(TO5+
M*O_,-D+DY&<<)=G-:)/GVZOQ.%MN1!QD9^E6).J3IU3&0:[>RO4XVTH1K,J@
M.!H[EC4=QT&8C.;7Y;)[.;].=WD4)N)>DFP7QX%\_2JB].5F9(_>%GP/UYN\
M6#">7V^#M7@0^1_;>ZG>C1O**HQ%DH5I0J1XNAG=VE=\8A4!Y1K_"L5+MO>:
M%%_E,4W_+-Y\6]V,K&*+1"26>8$(U+]GL1!15)#4=OQ50T=-FT7@_NLW.BV_
MO/HRCT$F%FGT[W"5;VY&%R.R$D_!+LJ_IR]<U%_HO. MTR@K_Y*7>EUK1):[
M+$_C.EAM01PFU?_@9[TC3@EPZ@"G$Z :[@]PZP"W&S Y$#"I R;=@.F!@/,Z
MX/S4%J9UP/34%F9UP.S4%B[J@(ORZ%:'HSR67I '\VN9OA!9K*UHQ8M2$&6T
M.H1A4FCW(9?JTU#%Y7-//.;D5W*[6H6%EH*(?$NJ7T2AK$^>R(,PRCZK5?YX
M\,BG7SZ37TB8D!^;=)<%R2J['N=J*PK6>%FWN*A:= ZTZ)*[-,DW&?&3E5CU
MQ/OF>-LY!F!F@'-N (S5_FMVHO.V$[\Z1J(GEF?$MK\0QW*LOCUB#K\+Y!EQ
MJW"W)]P[/=SIVY\G;+PAG)X>;O<=#'/X/]-G%6X=;)V;PV^WZKM;;M^NTXZD
MV_P<W)(W,?T<OB59+G?J!)V3__RF5B#?<A%G_^W9NJ\5S>VG%7GG*ML&2W$S
M4HDE$_)9C.9__YL]M?[1IQ(DS$/"?"2,(F$,">,@F*:\2:.\B8E>*2]LE/=%
MJ3 7JIF<R" 7?=HS\H9JKX+95DDK.CS/<^O,NG3.K\?/^[)"-NI7L,M.FWJ+
M%-DB0\(X"*;)Y;R1R[E1+HTZ_)^J&YN)+Z004)],C)RA,JE@YWM'S+F8="3R
M?AU[=J&OX[]?YW)J=P[\^W5FTTY;#/GE. BF'<]I<SRGQN/Y0\B8_)8&"?D?
M>=@]9N*O79%__.<R"]V)^%'(W@QDQ X]O$B8AX3Y2!A%PA@2QD$P38*S1H(S
M:-]GAE0>$N8A83X21I$PAH1Q$$Q3WD6CO(OC?9_5KK>78XP<JC(DS$/"?"2,
M(F$,">,7[_L&]G0Z:[*Z)I_+1CZ71OF4:?-V+84HSEM](C+&#Q41$N8A83X2
M1I$PAH1Q$$S3FFVU!3,+FB9K'$A\4)H'I?E0&H72&)3&431=@GLU6WM(K8 \
MA47A=AN\'CK_U3SMO'MNZ6.IA;G1P=)"TGPHC4)I#$KC*)HN+:>5EC,@EPX=
MC)KA@\]U2)H'I?E0&H72&)3&431=D&U!WL96Y&UH21Y*\Z T'TJC4!J#TCB*
MIDNPK<S;@TKS)Z1;:&D>2O.@-!]*HU :@])X33O4A=*EU5;Q;7,9_UVZO9=A
M+,CW Y:/F3986$B:!Z7Y4!J%TAB4QE$T78&M[V!/L?D5:CA :1Z4YD-I%$IC
M4!I'T70)MKZ#;2PNSZDL!QC+5Y(^J3Q;&9N_IDGT^I9D^RXS^GJ$&A?7^$2O
MO:J#N@U0F@^E42B-06D<1=-5UWH.MMETN*OTT0B.:(([9$<<@3:7,QVZGFEA
M!@S6'M2$@-(HE,:@-(ZBZ=IK#0O[!,<B#O*=#/-7LCK4VS-#[H)70BR[TMJD
M5VM0JP)*\Z$T"J4Q*(VC:/JEJ:U?X1B+T>^'&,VE)GV:,\.&=N^@- ]*\Z$T
M"J4Q*(VC:+H 6[?"L:$C# =93U] :1Z4YD-I%$IC4!I'T70)MJZ&8W8U[F68
M+,-M$)''( J296^ZK1F="H_5M<G,30T6%-25@-(HE,:@-(ZBZ8)J70G'6'*>
MWU?#!**&#G'VA:Q$MI3AMI@STZLL,^S'1I!%&F^#Y%5U"E>"Q.:A2;Z1Z6Z]
M(6JP45IQS?R),U*@MEVQDR!9M:P7]8_D*7D41(IM$!8?$34 5^NW[69Y$$55
M:\&3"E1MBN[F"!FFJY*]5'%ALA/-EA5=TVI*R(1\*CL@=V^=74]U=C^?]9ZI
MH5X+E.9#:11*8U :1]'T'U;KM3AFK^6#M2 S=7"? >JX0&D^E$:A-';DV!ZN
MR''4=NBJ:VT8QVS#?*P6= 1ZO!9D!@S6&=2 @=(HE,:@-(ZBZ=IK#1C'///C
MM%K0$<CQ6I 9,%AK4*<%2J-0&H/2.(JF:ZUU6ARS)S)\DJ$9.#BQ5K3N-,/)
MK#O-$-JL?VJS%-HL@](XBJ9+I[5+'+.SH2F%/$5I*HLAP%+)*%CW2Z<":M,[
MNV-IJ!D"I?E0&H72&)3&431=6:T9X@R9OK%?H"ZOAQ%U-XS\OESN9*:Z9D1)
M[UX-/F4QC*6A5**\39+P6<@LD.7 81&E69BLR\%FKS2A$T*@- ]*\Z$T"J4Q
M*(VC:/I](UJ;Q<5."W&A1@N4YD%I/I1&H30&I7$439=@:[2XPZ:%;-MSIWH9
MA[OX2,:N^9T;,CB=I&W>BL%:@SHJ4!J%TAB4QE$T76NMH^(.G"=B3MJW91'Y
M:*XNJ\F_ZPG^02Q3M71@AC=O_N#3*]3S@=)\*(U":0Q*XRB:+OF]6T.YV R/
MK,LOH#0/2O.A- JE,2B-HVBZ!%MWQ!TV$V5XAN^]Y9+=S?!0_P-*\Z$T"J4Q
M*(VC:+K66D_$'3@UY90,_\%D#9W6 J5Y4)H/I5$HC4%I'$73U=NZ*BYV6HL+
MG=8"I7E0F@^E42B-06D<1=,EV)HM[B"SY0/)>G:T@&[>A,%"@[HN4!J%TAB4
MQE$T76BM->.:K9DCF=HTH=1,'GS:@]HY4)H/I5$HC4%I'$73U=C:.>XE-O-"
MO1@HS8/2?"B-0FD,2N,HFGXGY=:+F9BGO'S@7LI6[Q4"=N<"@86YX:'R@M)\
M*(U":0Q*XRA:):_QWM,38B'7Y9,T,K),=TE>-+*WM'E:QVWYC(K.\H5]Y=D]
MRWW[BE;/XFCQU:-![@*Y5CHED7A235EG,S5HDM73-JHW>;HMG]WPF.9Y&I<O
M-R)8"5FLH#Y_2M/\[4W10//,D_G_ 5!+ P04    " !PB_M6T4+W.W4#  #?
M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RM5EVOVC@0_2M66E6M
MU$N^$TH!"0C5KM2/J[)W^VP20Z*;V-1VH/OO=^R$+*0F>Q]X 7LRY]AS//;,
M],3XL\@)D>A755(QLW(I#Q/;%FE.*BQ&[$ H?-DQ7F$)4[ZWQ8$3G&E05=J>
MXT1VA0MJS:?:]LCG4U;+LJ#DD2-15Q7F_RQ)R4XSR[7.AN_%/I?*8,^G![PG
M&R*?#H\<9G;'DA45H:)@%'&RFUD+=[*.E;]V^+L@)W$Q1BJ2+6//:O)G-K,<
MM2%2DE0J!@Q_1[(B9:F(8!L_6TZK6U(!+\=G]D\Z=HAEBP59L?)'D<E\9HTM
ME)$=KDOYG9W^(&T\H>)+62GT+SJUOHZ%TEI(5K5@V$%5T.8?_VIUN   CQG@
MM0"O#PAN /P6X/<!T0U T *"EZX0M@ =NMW$KH5+L,3S*6<GQ)4WL*F!5E^C
M0:^"JCS92 Y?"\#)^5=(Q<],"/1(.-KDF!/T@#:0C5E=$L1V:(E%D:(%S5!2
ME+4D&>H@APZRD)(7VUKB+8 D0RM659 %&\G2YYR5&>$"O4V(Q$4IWL$"3YL$
MO7W]#KU&-A**0:""HB=:2/$>C##^*V>UP#034UM"F&JS=MJ&M&Q"\FZ$Y*,O
MC,I<H#7-2&; )\-XUQL@L$'?3F3O+/+2&V3\@OD(^>Y[Y#F>;]C0ZN5PSQ3/
M,#PAZ2!\_7*X.R"&WV6<K_F"6QE75X1CR?C$=+0-UC=CU:,Y$0><DID%KZ(@
M_$BL^9M7;N1\-,EZ3[+DGF3K.Y%='4#0'4 PQ-Y=>9/\#3+42%5BCO,']T,8
M0-(>+X4UN'F^/XZNW1*#V]@-Q\ZUV]KD%D07;%=AAEV8X6">)80R>#!O9EIX
MSTR[)UER3[+UG<BNCB#JCB :S+0?NDR33*#%$>[\GB"X_%NH&M]V;>'X5DLA
MX9DOZ/[W2F,ZM>BW7/%#WPN<L)^B!L=@[#I1W$]2$Z,3AQ^\H)>F)D8_=+TX
M,"=JW*D4_^]]+,_U5%=#A'OU-&WJJ;BHIP];+1=HA[+;<C4KCR^OEC,*PYY6
M1J\H[@EE\/)&?D_WM=$KB'L2V1<="Y2#O6X5!<194]F4DL[:=:,+W83U[$MW
MLG(-]@2ZUZ;9_(^^:7VAFNX+*E!)=K"4,XKA1'G33C83R0ZZ7]HR"=V7'N;0
M@1.N'.#[CC%YGJ@%NIY^_B]02P,$%     @ <(O[5J< A3M% P  7@P  !D
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MZQ]D=L_7H$RYW>%#LM@,;3V1>\YT9^T<!/S;4ST26(M[U'"/_HLRB(XIV)'
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M>OZ)\G6O<D/Q3?&VT1-7BJ?%QS6C$1-Y _W]DG/UMI$GV+UT-_L/4$L#!!0
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M'8#C,\[5<T??BINOIO _4$L#!!0    ( '"+^U8K-/)>UPD  !Y1   9
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M<<P/:$AY1G)*5K<PJR=&FS?%2,&I@9"S#+%2%(+DL;JS/C\,GW7!04&"9E-
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MG.KCFA)Y@:D"\O=GQL3^BW)P>"7B[?\!4$L#!!0    ( '"+^U:6ADSNQ08
M &@E   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;+5:6V_;-A3^*X17
M#"W0V"1U[Q(#L:UM!=8M:-;M8=@#(S.V4%T\DDZ:?S_J8LFB:%IVG3XTLO2=
MCSS?.:3.D73]G+.O?$VI -_2).,WH[40FP^3"8_6-"5\G&]H)J\\YBPE0OYD
MJPG?,$J6I5&:3#"$[B0E<3::7I?G[MCT.M^*),[H'0-\FZ:$O<QHDC_?C-!H
M=^)SO%J+XL1D>KTA*WI/Q9?-'9._)@W+,DYIQN,\ XP^WHQNT8<0NX5!B?@K
MIL]\[Q@4KCSD^=?BQ\?ES0@6,Z()C41!0>2?)SJG25(PR7G\5Y..FC$+P_WC
M'?O/I?/2F0?"Z3Q/_HZ78GTS\D=@21_)-A&?\^=?:>V04_!%><++_\%SC84C
M$&VYR-/:6,X@C;/J+_E6"[%G@)T#!K@VP$,-K-K 4@WL P9V;6 /'<&I#4K7
M)Y7OI7 +(LCTFN7/@!5HR58<E.J7UE*O."L2Y5XP>366=F)Z+_+HZU4A]1+,
M\U3F'R=E!*_ ?94[('\$)0K\L2FOW!:QC<6+G*E8@S@#&"*[AGS,(IH5H0=W
M"9%ID"V+J\'>^=MGPI;5U;<+*DB<\'=RL)*C@9>7K\"7^P5X^^8=> ,F@*\)
MH[P8[DL6"_Y>GI3'?Z[S+9=F_'HBI!J%3Y.H]GQ6>8X/>&Z!3WDFUAR$V9(N
M-?9SLSW"!H*)#$,3"[R+Q0P;&3\1-@86>B\UP)9N0F;S!8T:<ZPQ7PPW1QKS
M<+@Y-(AA-8EIE7SVH<0LX@UF_<2\98QD*RHW*P%F+V ?=T=>RM-5COWSFZ0$
M'P5-^;^Z]*C&M_3C%QOT![XA$;T9R1V84_9$1],??T N_$D7FDN2+2Y)%EZ(
MK!-$NPFB;6*?_KY-'R@K=I!J^;X',[J*LRS.5G)[EXL\HKK(5*1N25K<Z9ZF
MCF=CZ,A%\;0O>A_G^A:$EM?%+70XY'J!W\6%1F?.E,III').E.H7F>="NS/-
MG)Y#V+,<J,BC06&$/%=1IP]#5J&W@@N-\S]3';=1QSU1G? ;95',]?JX/9>N
M<. &BCX:%(+05K-' W-M;"%;T<?HP9GZ>(T^WHGZR#+JD<8'\L?3>.ZZEJV$
M?*[#X2! 2%F)"PW0@\CW%%QH].),C?Q&(__4',J61W8BO[\3N1!"7]DYYAJ<
M;L=:]'':'2O4X;H[5D>"H)$@.%&"JJ;C@%;+B3PD6AV"WGQLSP]L3]UR-#C'
M"VQ?W7.,TSSU#G<ALHZB"+8%-#Q3TVWV1/F!%5B3[BOE(^@B-;$T.(1<[+CJ
M+F6>Y:F27HJMJ^E>4X*,FOY=]G>RHB-/E,E^=9>>%&Q8'-&!940]B+]_ QQ;
MCJIP'^7T4 L-"L$Q0LJZ-?MUKFZXU0U_GVZ&FJ*F1FA_\8Y=]9:@@Z&QYZMZ
M:6 6'JO%1VAVZ%S!VB8#&<O?XX(9RXR:O.,D'$,/=OXA54&-%1IC6U50 \-C
MB%4!7Z.^1VV!C\P5_E$!C75(38YPQT>L"F9K!//'L*>8#N>.;;7,-[MTKF1M
MH8_,E?[QG#M:EM0C*+EA]=:J'M;;VYP!.V"H075WP*X<;66/S*7]43D&EBCU
M,$HNV:HD0U +\Y1/OIF^1F> VM8 F7N#P0(;ZQ5/<R]5VX"Y'H55=2_4!=3J
MOD9/@=JF IF[BIZZC!;/YXL%'.698"026Y( 05D*WL89>*&$\7=2]*W@@I0K
M7:NW>52GX@$>2*MGD,@#2_*B>PPZ/T+EUE3^CLH_Q+0XPN353,&.R3K$%!YA
M\FLFIW$/:ZBZ$6M[(&1N@LZ-F*EV,H_HJ]$*#@=K&).U8\+.X6@-HSK,$)H9
MSEQ:N.VLL+FS.GMI]6\8@/"B0_M$6+0V/6*?'9F2H^J/[(.A/$*U6W=V$TIX
M,)1FJE-WS$NQ=</:-G?XQ.;NQ+#N;E/#8VJ>CZ>N3FR(Z3 J!!NNPS&]4*M8
MQ_0U&D_<-I[8W'C>KE:,KHB@()81C#,>1^"))%MZ]$97$SM[)4. U&>K<PW*
M#7SU&8@&A3QD([64-3MSKEAMTXG-3:=!+&.[6=-VG@6I.O4AO;<A.AKD.FIC
M:7;B7)':QA*;&\OOR*C^ZYY>.O4A_:1;U"ASTH4:E))T707:/A&;^T23 L-:
M(MQ_M=-3H@_QH(=4)2[T[J=6[#7>).&VX<3FAG. KJ9.J&;?C[?Z%%P#P=!6
MWP68IWFRJ!=M,B=[7Y2DE*W*3WFXO#]O,U%]T-"<;3X7NBT_DE'.S]&'L/KH
MIZ6IOD&2]^V5%!\D]%%2PK$GY6+59SW5#Y%ORN]6'G(A\K0\7%.RI*P R.N/
M>2YV/XH!FH^KIO\#4$L#!!0    ( '"+^U;V9<O;&P,  *<)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;*U6;6_:,!#^*U8F39TTFI! :#N(!*1[
M^5 -%:W],.V#20ZPFL29;:#\^YV=- /F9E75+^"7>Y[</6>?;[CCXD&N 11Y
MS+-"CIRU4N65Z\ID#3F5Y[R$ G>67.14X52L7%D*H*D!Y9GK>U[HYI053C0T
M:S,1#?E&9:R F2!RD^=4[">0\=W(Z3I/"[=LM59ZP8V&)5W!'-2/<B9PYC8L
M*<NAD(P71,!RY(R[5_% VQN#.P8[>3 F.I(%YP]Z\BT=.9YV"#)(E&:@^+>%
M*629)D(W?M><3O-)#3P</[%_-K%C+ LJ8<JS>Y:J]<BY<$@*2[K)U"W??84Z
MGK[F2W@FS2_9U;:>0Y*-5#ROP>A!SHKJGS[6.AP D,<.\&N ?PH(GP$$-2 X
M!?2> ?1J0,\H4X5B=(BIHM%0\!T1VAK9],"(:= 8/BMTVN=*X"Y#G(KFBB</
M':U<2J8\Q],DJ4E(A\RKDT#XDGP1M%"=E"H@GRD3Y(YF&] ;!DZ^EQHB*S,D
M0OB]$1S'XRT(/#]D0B63Y"P&15DF/PQ=A=YK']RD]G12>>H_XVE ;GBAUI)<
M%RFD%ORT'=_U6PA<E*W1SG_2;N*W,MY0<4Z"[D?B>WY@<Z@='D/2P'T+/'XY
MO-L23="<A,#P]9X["6LJH#,Q)V%&]WBU%1D+S.@*S/CG>"&5P'OZRY:[BCNP
M<^O:=25+FL#(P>(D06S!B=Z_ZX;>)YMN;TD6OQ'9D::]1M->&WMTR^1#9RD
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M:E"C!F]$E1O&%M(1VJ!/$>*YU:N! 3O/G8=CM&%-&_[$@@W[L^N[MJS8#NR
M7:>P6[#S&G8^"?M-[ZKRZT).P.0I 6U)RM")9$>8YBYEPP://0O"#G3?:#[S
MG'GS;Q@?6Y?=TKH^@(G55\EBW(!S^Q$,F3DS"X]@-S9Y?#WV^$*L5%LX>(:#
M+O6 V?_-O'T)P;X^A,D%6@EWDAIV2W[(S)M9_@CX9>_%D_O5]35?Z88M;&_>
MQ7;ZV*VUT<:^[(-X>B.\'GM2]ZUG@4H-.ZWPNM&9C0-P#FRG[P4<Q?18B/(L
M7(_6=X\[?>(V+^;EQ44>W79IP5$&6^EJS0*Y(;+R+E!V!#WHX_03%?)PKIM[
M>7\"I@SD\RVEXK6C7E#?R*+_ %!+ P04    " !PB_M6HW/%.XL#  !:$0
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MO'+M+6,XWQ Y( IT]XJ.XU;XM6R^W6,6HS]_E4@4"I+QOUJNYZ[*;[7G5Y.
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M;INC]?>Y&::317GI$<VG5,MDO<J+OJGBS53;BH=J%*HQJ.9!-1^J<:@FH%J
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M/JPZFNFV#U4?3'*!:!*;V@9F_WVOG9!A6&- R@LDCL^Q[_&]U]<>[;AXD2L
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MF(6$V4B8@X2Y2)B'A/D@6,./QAL_&BM[D@?^6KI*GK @3&GJDK1V*4I(7U=
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M.!<\$*D\@7Z?)DF^_B(5O"3I]_)R;OX+4$L#!!0    ( '"+^U;]J"TQZ 8
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M]E2^DDS<L][\^^^LR>!GG3Z0, <)<Y$P#PGS0;"6RD8[E8U,]/D=_5)I2K"
M*1F%9*N&$D&"UI!,'X=DG7ZJ"L9E!<7LY7X^':B_B_[]OC",S>@J#"3,1<(\
M),P'P5K"&.^$,38*H\G".1-J\E )(>6YRMLD8R+BNH1U;89.!B2D7W29>F$,
M[*H/),Q%PCPDS ?!6OJ8[/0Q,79E^>)!<KZ3!VM&"1*MR%*]W 0;-:P4[S12
MC2K!5FCG.-?F>F;')6,,["H9),Q%PCPDS ?!6I(YVTGF[']()@W46R'A*S7&
MI%F5E71J,5<Q&A]5BS&PJUJ0,!<)\Y P'P1KJ66Z4\O4V)5[<UB2B2+KT#CF
M@5)-6&A(1NDZ9FJ>DBQ58%BDI/)%,U4%^3*.UF7"TBG(6&W7^2X2YB!A[O0I
MTS(/6:4/@K7D,MO)96:4R\=L)=2[,%DQ5LQE^3J-OBI9T&)F>\_2+=-)8?:D
MJ:NQXJY]C(2Y2)B'A/D@6$L*UJ QI@9&,?S-(R6%@$MM"C$'=QT!:MJ^B*Q1
M6T&.KLQLV"[D0IOE::H<SNQVE;ZFT'0ZWA5JW_T]6] ROU-NBDQN+\E"G8D"
M&I,/(E*__Q)W*WBF?1+-R,Y]@J0Y4)H+I7E0FH^BM85C-\*Q7X;E5;<#I38D
MS8'27"C-@])\%*VMML9?M8S&VOQ=-2_8GRUD/%=:*L:J4)V,>59**XEB)G.N
M%)4]NF5J EH;9EIY515/]H;5R?AP7F%N7V?=0-U2*,V#TGP4K:V;QC&U3EBF
M1]/;E8RH5@](5W !I3E0F@NE>5":CZ*U9=/XJ=;XA20WI,>X@-(<*,V%TCPH
MS4?1VFIKW%GKA#W[?,EM<I#<;%UR@[JS4)H+I7E0FH^BM7736+26V4"MDMNP
MTZL;TG)<0&D.E.9":1Z4YJ-H;=TT9JTU?2'9#6K?0FD.E.9":1Z4YJ-H;;4U
M7J]E-GN?,;O-#K*;-=!XPN8&=A8.U!6&TCPHS4?1VE^W-<:P;3:&CZ:W8Z]N
M9E[7X09*<Z T%TKSH#0?16NKIC&T;>ME)#<;ZH)#:0Z4YD)I'I3FHVAMM34N
MN&WT/9\QN=45[R>WD2:WF=O763=0/QM*\Z T'T5KZZ;QLVVSGWU+/T?)-M%V
M/-)_74!I#I3F0FD>E.:C:&U]-+ZU/7HA60QJ=T-I#I3F0FD>E.:C:&VU-7:W
M;?[4]QFSV/C0@!SJTAC4N8;27"C-@])\%*TMG,:YMCL[UP%/$B8"I9SH:_4=
M>G?1'+K60TMC6YL;UUDT4-L:2O.@-!]%:XNFL:WM$[;U;FAIM*(3"8NC=;2,
MV9Y:R#93@I+;(&!2KK;QH=JT>CH[_+Q*JR>HG0VEN5":!Z7Y*%JEI_[>(E?5
MM^MR_;)4/;U-\Z*2O:.[-=)7Y<K@;XXOK'/'TASWK'._6@'=X*L%V;=4K(L%
M$#%;J:H&;\Z49$2UQKG:R7E6+K%=\CSG2;FY831DHBB@SJ^XTG:]4U2P6VD^
M_P]02P,$%     @ <(O[5D!X*V@\!   6A<  !D   !X;"]W;W)K<VAE971S
M+W-H965T-S8N>&ULM9AKC]HX%(;_BI6.JE9JR87K3 &)(5EU5DPU8MK=#ZM^
M,,D!HB8VM<TP(_7'KR\AD%%(07*_0"X^CX_?-W&./=Q1]H.O 01ZSC/"1\Y:
MB,V-Z_)X#3GF+;H!(N\L*<NQD*=LY?(- YSHH#QS \_KN3E.B3,>ZFL/;#RD
M6Y&E!!X8XML\Q^SE%C*Z&SF^L[\P3U=KH2ZXX^$&K^ 1Q+?- Y-G;DE)TAP(
M3RE!#)8C9^+?1'Y'!>@6_Z2PXT?'2 UE0>D/=7*7C!Q/9009Q$(AL/Q[@BED
MF2+)/'X64*?L4P4>'^_I?^G!R\$L,(<IS?Y-$[$>.0,');#$VTS,Z>XS% /J
M*EY,,ZY_T<ZT[?8=%&^YH'D1+#/(4V+^\7,AQ%& Y-0'!$5 \"H@:)\(:!<!
M[=<!P8F 3A'0.3>@6P3HH;MF[%JX$ L\'C*Z0TRUEC1UH-77T5*OE*@'Y5$P
M>3>5<6(\ ZDR1Q_1)$E291W.T!TQ#Z R\ET( J<9?X^N4$K0US7=<DP2/G2%
M[%TQW+CH*30]!2=Z\@-T3XE8<Q21!)(JP)5IE[D'^]QO@T9B"'$+^?X'%'B!
M5Y/0M#G\;TQ:R.N;<+04;]_X_<$G]!587C>Z,W)IFUP"].TQ1.^NWM=@HO,Q
M?CVF(E6[M+FMN9V3-G,.@+3;* 0>LW2C_?UO)ENB.P$Y_UZ3[JW!MNNQ:A:[
MX1L<P\B1TQ0']@3.6.K8\S[5^6$3%MJ$199@%6\ZI3>=)KIY!1$\R[E?_O]"
M5W4^-"(N]<$F+#2PKH:IS]+3N#/P@J'[=*QO3:/KGE<VJNC6+77K-NKV&;\D
M0-!L-I6BS> Y)2LAGV@M9YV$C;1+);0)"VW"(DNPBB6]TI+>GYEF>C:]L0D+
M;<(B2["*-_W2F_YYTTS*S*<]P:+V/6G$7.I%<T[W^$5_[>3GKNW7J6\SE\@2
MK*+^H%1_T#C2.1"!%QG(2GB+&:"E+-AT;W+NVI<>=68T4B\UP\!Z1[-PSV][
M_>I<'=KL,K($JVA^76I^?<83']-<+FQBD#_BY#/?"+I4YN:LRJKU5-D:VDPF
ML@2K&.![A]6%USC8+]M\ 0S1)<*']456S$2B6&\*67%S^1Z<J+QOF_NXU)V"
M=OP6O*I60JL=1K9H50N.%GC^6?/^L=JU*C=B+E:Y.:DN>@',ZE>1-O.(;-&J
MX@<'\8,SQ%</=DK,5W>R8F#FHE]H,H\^WD_0'%;JSA?:DE/"!U70UOK3V-/%
M_MBDA59ID2U:U;/#4MG_0VMEW^IBV2HMM$J+;-&J#AT6S/Z9*^;?E;*_X=QC
MUMK7GT%=_3EM!EQL@DU:9(MF3'"/]A!S8"N]><ME];0EPFS)E5?+#>*)WA9]
M=3U4&\=Z;_* ,;O.4NY52KC\_B\ETFOUY5*5F8U<<R+H1N]4+J@0-->':\ )
M,-5 WE]2*O8GJH-R.WW\/U!+ P04    " !PB_M6%D_J-"4"  #+!   &0
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MK'/=MTX_L:KUY;I3%HO?#VO\VH!V ;A?*67/$]<!X_<K_PM02P,$%     @
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MU/R6,?DTT+?0]M\4J_\!4$L#!!0    ( '"+^U:LIH:=>0(  &(&   9
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;(6576^;,!2&_XK%JJF3MD+,5]8E
M2&VC:I-6*6K:[6+:A0,G8-78S#9)^^]G&XJRA28WP3;GO,][8OLPVPGYI"H
MC9YKQM7<J[1N+GU?Y1741%V(!KAYLQ&R)MI,9>FK1@(I7%+-?!P$B5\3RKUL
MYM:6,IN)5C/*82F1:NN:R)=K8&(W]R;>Z\(]+2MM%_QLUI 25J ?FZ4T,W]0
M*6@-7%'!D83-W+N:7%Y/;;P+^$%AI_;&R%:R%N+)3KX5<R^PAH!!KJT",8\M
MW !C5LC8^--K>@/2)NZ/7]5O7>VFEC51<"/83UKH:NY-/53 AK1,WXO=5^CK
MB:U>+IAROVC7QP8>RENE1=TG&P<UY=V3//?_PUX"QF\DX#X!.]\=R+E<$$VR
MF10[)&VT4;,#5ZK+-N8HMYNRTM*\I29/9]_!E*30)[0RVUVT#)#8H-M6MQ+0
M55E**(D&=$<YK=L:+<F+V1"MT/D"-*%,?4!GB'+T4(E6$5ZHF:^-*2OMY[V!
MZ\X ?L/  O(+%$X^(AQ@C!Y7"W1^]N%?&=_4-!2&A\*PTXV.%_;K:JVT-'O_
M>\Q:)Q&.2]C[<*D:DL/<,P=>@=R"E[U_-TF"+T<,AH/!\)AZ9NH-QSQU6;'+
MLE=JFT4X-9';$58TL*)3K&B,U64E^ZPHP..L>&#%IUCQ&"L^9,5A-,Y*!E9R
MBI6,L9)#5I(&XZQT8*6G6"DR9QRMX47P8@R;'F Q#J,WN-.!.SW*?1":,'OU
MW0UD]EBCIK^'8R:FA^<GP)//_YGP]UJ&[;YW1):4*Z._,7G!16H$9-?1NHD6
MC>LB:Z%-3W+#RGP$0-H \WXCA'Z=V,8T?%:ROU!+ P04    " !PB_M6T:$-
M8EH"   U!@  &0   'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6RM55UOVC 4
M_2M65DVMM)$O/CH6(A70M$F;A$J[/4Q[,.&&6'7BS':@^_>[=D($-- ]["7Q
MM>\YG'.=>XEV0CZI#$"3YYP7:N)D6I=CUU5)!CE5/5%"@2>ID#G5&,J-JTH)
M=&U!.7<#SQNZ.66%$T=V;R'C2%2:LP(6DJ@JSZG\,P4N=A/'=_8;]VR3:;/A
MQE%)-[ $_5@N)$9NR[)F.12*B8)(2"?.G3^>#4R^3?C.8*<.UL0X60GQ9((O
MZXGC&4' (=&&@>)K"S/@W!"AC-\-I]/^I $>KO?LGZQW]+*B"F:"_V!KG4V<
M6X>L(:45U_=B]QD:/U9@(KBR3[)K<CV'))72(F_ J"!G1?VFSTT=#@!^_PP@
M: #!OP+"!A!:H[4R:VM.-8TC*79$FFQD,PM;&XM&-ZPPM[C4$D\9XG2\K%8<
ML SD/5G6%TE$2M)*5Q+P:IM#5B0B!W(]!TT95S>8_;B<D^NK&W*%A^0A$Y6B
MQ5I%KD91AMI-&@'36D!P1L W*GLD]-^1P O"#OCL,GP.20L/CN$NEJ*M1]#6
M([!\_3-\7XU?17[>K926^(W]ZG)44X3=%*;OQJJD"4P<;"P%<@M._/:-/_0^
M=OG[3V1';L/6;7B)/3Y3\VF-&EB4F0/;V!^-/D3N]E#XRZ0@'/EMTI&@?BNH
M_YJ@?I>@&C4\%!3>AB>"7DDZ$C1H!0TN"GH0FO(S_= E=/"B**$_#$Z$=B2-
M!OT3H>Y!4YN!BHVR884B'%*$>;T1XF4]I.I B]+V^4IHG!IVF>%<!VD2\#P5
M0N\#,SK:?XKX+U!+ P04    " !PB_M6? (O1] #   5%0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970X,2YX;6S%F.]OHS88Q_\5BYVF5CJ57PGA>DFDM@3H
MM&I5N]M>G/;"@2<!'=B9;9J;M#]^-E NM FEDJ6]2;#Q]^,??'ELGOF>LF\\
M Q#H>UD0OC R(7:7ILF3#$K,+^@.B+RSH:S$0A;9UN0[!CBM165A.I;EF27.
MB;&<UW7W;#FGE2AR O<,\:HL,?OG&@JZ7QBV\5SQD&\SH2K,Y7R'M_ (XLON
MGLF2V5'2O 3"<TH0@\W"N+(O8U^UKQO\D<.>'UPC-9,UI=]4X39=&)8:$!20
M"$7 \N\);J H%$@.X^^6:71=*N'A]3,]K.<NY[+&'&YH\6>>BFQA^ 9*88.K
M0CS0?0SM?*:*E]""U[]HW[:U#)147-"R%<L1E#EI_O'W=AT.!(YS0N"T F>L
MP&T%[EC!I!5,Q@JFK6 Z5N"U F^L8-8*9B\$MG]"X+>"VBYF\SCJ9QE@@9=S
M1O>(J=:2IBYJ0]1J^0ASHJS[*)B\FTN=6#Y6ZP+DLT=G5VF:*SOA MV2YIV0
MI7-T%H# ><'/T0>4$_1[1BN.2<KGII#]*XJ9M'U=-WTY)_IRT1TE(N-H15)(
MC^AOAO6V\Q8@>@,P- )3KERW?,[S\ET[@\0[S"Z0:W]$CN6XZ,MC@,X^G!^;
MV3#FEZJX0-:LQDP&,,%XS-!H5F]AB)R4]28F',8$D'1KXPQ@HA&3:C%#:Q./
M61N_'<U&_/R3/?,_#UC [=X@MP9/3H!EU"SPFC*L@C"Z8@R3+<C@+I!\2WKE
MWT0&#(D,$]07??U5,M&M@)+_=>RU:@;@'A^ VMPN^0XGL##D[L6!/8&QE-/S
MK,_'G*@3%NB$K73"0IVP2"<LU@3KF772F74R1/\1[G.2T!*.F:T!3&N .O@\
M+:>?W+GY=.BAP4[>ZR&=L)5.6/AZ*6S;]_IK$>GL,=8$ZWECVGEC.NP-7.0T
M K7% \,[J$2>\(_R,"##^-<[*-? CD:G0>I[HY-.6* 3MM()"W7"(IVP6!.L
MYT"O<Z#W?V^EGDZSZH0%.F$KG;!0)RS2"8LUP7IFG75FG0V&RP?I0RQW4_FY
M76$&:*,2#?^>.%DVYAL$OM=\.F&!3MA*)RS4"8MTPN(&YAV<#ES+FEC=\:#G
M*K]SE3_N@,94F-O)(%>J+]9C;AH$O==-_JNCCF.]./4%K]O8GV;]-JL1;4*=
M X]&##S6U&'S0,V#9$L);%LGWCA*:$5$DSCH:KO<WE6=TGI1?V-?ADV*[@>F
M21C>8;;-"4<%;"32NIC)Z;$F"=<4!-W5*9TU%8*6]64&. 6F&LC[&TK%<T%U
MT&5"E_\!4$L#!!0    ( '"+^U8S)!.Z80,  .@,   9    >&PO=V]R:W-H
M965T<R]S:&5E=#@R+GAM;+57;6_3,!#^*U9 ""187OJR=;21M@;$I$U,3, '
MQ ?/N386CAUL=]W^/6>G"^U(LTT*7Q+;N>>Q[SG?Z3)=*_W+% "6W)9"FEE0
M6%L=AZ%A!934'*@*)'Y9*%U2BU.]#$VE@>8>5(HPB:)Q6%(N@W3JURYU.E4K
M*[B$2TW,JBRIOCL%H=:S( [N%[[P96'=0IA.*[J$*[!?JTN-L[!AR7D)TG E
MB8;%+#B)C[.)L_<&WSBLS=:8.$^NE?KE)F?Y+(C<@4  LXZ!XNL&YB"$(\)C
M_-YP!LV6#K@]OF?_Z'U'7ZZI@;D2WWENBUEP%) <%G0E[!>U_@0;?T:.CREA
M_).L:]O#44#8REA5;L!X@I++^DUO-SIL >)]@&0#2!X"QGL @PU@\! PW ,8
M;@!#KTSMBM<AHY:F4ZW61#MK9',#+Z9'H_M<NK!?68U?.>)L.E=ER2W&T1I"
M94[F2EHNER 9!T/>D9,\YRY 5) S6=\R%Z[7&5C*A7F#)E^O,O+ZY9MI:/$\
MCC5DF[U/Z[V3/7L/R 7N5ACR0>:0M^#GW?@XZ2 (48A&C>1>C=.DD_&"Z@,R
MB-^2)$H&;0?JAF? &GC2 L^>#H\[O!DTL1UXON$>OG,P!H"< ^8%R< PS2L?
MO1_G:$G.+)3F9UO8:MI!.ZTK1,>FH@QF 58: _H&@O35BW@<O6^3K$^RK">R
M'3F'C9S#+O;T7*&<!FN=H!9R8A7A>.U*R1><U5FAK@5?^J%ID[6F'WEZ5XYO
MTF@:WFQK]:A%UF6QX]6H\6K4[14L,;?9=MJ_Q6K,](H*YRQ3NCTY3SMYGWM+
M:K)QA^<];;<CTK@1:?R(2+>HCL407U!C*"M6!BQ6S(^4<<'M79L\G8S/E:=/
MLJPGLATE#QLE#_]/33KL4\X^R;*>R';D/&KD/.J\F)\KT-1E+A%>40NZ;%.O
MFR6.R!U0W5:TYIW(YTK5$]F.5)-&JDFGDU? 5AIS%;O"2AEN"1.8RUB\L993
M5^F,U9RYRLZH*=I$G/Q3>^/Q9!)%#ZOX$^VRSO,^5XUPJP<L02]]+VVPL*^D
MK1N@9K5IUT]\E_I@?8YM?-UU_Z6I_P&P.UIR:?"J+9 R.G!=LZ[[ZGIB5>4[
MS6MEL6_UPP)_14 [ _R^4,K>3]P&S<]-^@=02P,$%     @ <(O[5I'; Y$%
M P  <PD  !D   !X;"]W;W)K<VAE971S+W-H965T.#,N>&ULK99=;],P%(;_
MBA4F-"1HTO1SHXW4CR%V,:G:&%P@+MSDM+&6V,%VVNW?<^RD6=>E 0HW;>R<
M\_I]CAW;HZV0#RH&T.0Q3;@:.['6V:7KJC"&E*J6R(#CFY60*=78E&M791)H
M9)/2Q/4]K^^FE'$G&-F^A0Q&(M<)X["01.5I2N73%!*Q'3MM9]=QR]:Q-AUN
M,,KH&NY WV<+B2VW4HE8"EPQP8F$U=B9M"]G0Q-O [XRV*J]9V)(ED(\F,9U
M-'8\8P@2"+51H/BW@1DDB1%"&S]+3:<:TB3N/^_4/UEV9%E2!3.1?&.1CL?.
MT"$1K&B>Z%NQ_0PE3\_HA2)1]I=LRUC/(6&NM$C+9'20,E[\T\>R#GL)[?Z1
M!+],\ \3ND<2.F5"QX(6SBS6G&H:C*38$FFB4<T\V-K8;*1AW,SBG9;XEF&>
M#J[2+!%/ &0*'%9,DT5".?E )E'$3)UI0JYYL5A,U<_GH"E+U#L,N;^;D_.S
M=^2,,$Z^Q")7E$=JY&JT9<3=L+0P+2SX1RRT?7(CN(X5N>(11"\%7.2IH/P=
MU-1O5)Q#V"*=]GOB>[Y?8VCVY^GM!CN=JL8=J]<]HG<+FDG I:]W55;D^V2I
MM,1%_*.N8(5>IU[/?-B7*J,AC!W\<A7(#3C!VS?MOO>Q#O8_B;U [U;HW2;U
MX(8^LC1/208R1'[<%XA8$=@MNA#G7;)E;M>6%K@M5)7*<!W6E:88[\*.9[:H
M3>"U+D;N9I^XT=.)Q+V*N-=(O*@CE?C)ZC!F?/T"N8ZO]XJO?4#7./Z)=/V*
MKO_W=$ HYSGN%*%(\711Q59AB2$BRR>B8Z@J4<?<KYE3KW> W6CL1.Q!A3UH
MQ"YW2:GJYY%L0&G3^;S,ZS 'OYW:1A<G,@XKQN&_,-8!%8*]/:!>SSM >ATS
M\#M53.'4W3N_4I!K>ZPK'#[GNMCUJ][JYC"Q!^9!_Q1O%,4%X%FFN([<4+EF
M7)$$5BCIM0;H2!9'?-'0(K.GY%)H/'/M8XRW(I F -^OA-"[AAF@NF<%OP!0
M2P,$%     @ <(O[5N.>!.UY @  K08  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#0N>&ULK55K;],P%/TK5V%"FP3-HP_0:".M+8A*FU3M 1\0'[SDMK'F
MV,%VV^W?<^VDH1MM!=*^)+9SS_$Y-_')<*/T@RD0+3R60II14%A;G8>AR0HL
MF>FH"B4]62A=,DM3O0Q-I9'E'E2*,(FB05@R+H-TZ-?F.AVJE15<XER#694E
MTT]C%&HS"N)@NW#-EX5U"V$ZK-@2;]#>57--L[!ER7F)TG E0>-B%%S$YY.^
MJ_<%WSANS,X8G)-[I1[<9):/@L@)0H&9=0R,;FN<H!".B&3\:CB#=DL'W!UO
MV;]X[^3EGAF<*/&=Y[88!1\#R''!5L)>J\U7;/QX@9D2QE]AT]1& 60K8U79
M@$E!R65]9X]-'W8 \>  (&D R4M [P"@VP"ZWFBMS-N:,LO2H58;T*Z:V-S
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M]J1*J]WK]4/5#PY, BK@G&V2O7]_8R <R1*ZD?B2V&:>9\;S^&VF!\9_B1A
MDI<LS<5,BZ7<W>NZ"&/(J!BQ'>3X9<-X1B5V^587.PXT*D%9JEN&X>D937)M
M/BW''OE\R@J9)CD\<B**+*/\WP=(V6&FF=IQX"G9QE(-Z//ICF[A&>2WW2/'
MGMZP1$D&N4A83CAL9MK"O \FRKXT^#N!@VBUB9K)FK%?JO,EFFF&"@A2"*5B
MH/BWAR6DJ2+",/ZI.;7&I0*VVT?VH)P[SF5-!2Q9^CV)9#S3)AJ)8$.+5#ZQ
MPV>HY^,JOI"EHOPEA\IV[&@D+(1D60W&"+(DK_[I2YV'%L"\!+!J@'4.<"\
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MI2"- 3Y?"J&?-L9!,^;&?P!02P,$%     @ <(O[5@F</@O" P  BQ8  !D
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MWW*.X5M-,JRZ$5MN;9:G/,.WG&B8_7JS-&<'-2)+(2M$[MG&G]ZF_4#Y3@&
M!+?*WAO,5&-XM?-9%23+R[W #9.2I>7E'FF$7%=0S[>,R>>"WEYL]I^#?P!0
M2P,$%     @ <(O[5@\=P_Y. P  RA0   T   !X;"]S='EL97,N>&UL[5A=
M3]LP%/TK41@32!-I&TB;T5;:*B%-VB8D>-@;<ANGM>38F>.REE\_7SM-/_#M
M@(=1IJ6BL>_Q.??8OB&&?J67G-[,*-7!HN"B&H0SK<N/451-9K0@U9DLJ3!(
M+E5!M.FJ:525BI*L E+!HTZKE40%82(<]L6\N"IT%4SD7.A!V&U"@;M]R09A
M.SD/ R<WDAD=A'<G[W_.I;Y\%[C[T8>CH];=Z>5N_,0"IV'D%;UX@NA9JX4+
M XB))T\3WZ>-27>WI>WP8R/DB,<8K>>AF2QK)G0P<NHE;U 18K?UI'78LPQ6
M.*K+9-C/I5A72QRZ@,E,"AK<$SX(1X2SL6+ RDG!^-*%.Q"82"Y5H$V9&BMM
MB%0/#FZ['E1PK5,P(97-[3*X[W$]? =8]< @X[PQV E=8-@OB=94B2O3L8-M
M\!$4U.W;96D<3A59MCL7X9I@;R;)6*J,JB9-.UR%AGU.<["CV'0&=RW+"$"M
M96$:&2-3*8CUL&+4#2,[H9S?P./](]_27N0;>VIW5#1-8ZAN.AG7 ?U--:>]
M*7O^(MV@9/=2?YZ;Z0C;AUJAUXKF;&'[B[PQ@*FW<752EGSYB;.I**B;_),3
M#OMDQ0MF4K$'DPU*96("5(7!/56:338COQ0I;^E"K\IID>.>._\]_\'SE JJ
M"-\T;6K_>8[_;F6\V'']/GR-5;:_5G8=>TW&W</W6)\!#MUD\A9,OHGM[AV^
MR3@]?(_U>?# 379?[5VTUV14GX0VCEM;AZTF&L"A=A!^A^,S7R<-QG/&-1-U
M;\:RC(I'9RXCK\G8_*&VI6_&9S0G<ZYO&W 0KMO?:,;F1=J,NH:%J$>MVU]A
M>NVD.5&;7$QD=$&S4=U5T[%M!J9ALM87$':1*WOY$8SC,#\"&)8'<X!Q' O+
M\R_-IX?.QV&8MYX7Z:&<'LIQ+!\RLA\LCY^3FLL_TS2-XR3!5G0T\CH88>N6
M)/#C5\.\ 0/+ YF>M];X;N,5LK\.L#W=5R'83/%*Q&:*KS4@_G4#1IKZ=QO+
M PQL%[#:@?S^/%!3?DX<PZYBWK G&$?2%$.@%OTUFB3(ZB3P\>\/]I3$<9KZ
M$<#\#N(80^!IQ!', 7C D#BV[\&=]U&T>D]%Z_]>#G\#4$L#!!0    ( '"+
M^U:7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] A
MB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:
MU;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]
MVR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::
M1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$
M%     @ <(O[5EHN<!EZ!@  13H   \   !X;"]W;W)K8F]O:RYX;6S%F]]S
MVC@0@/\5#2_7>\@1C'^UTW0F3=*[S.0:)F3Z>B-L$32U+2K)-.E?7\D.R0K,
MSKTL>0)L8S[6DKY=6?[X4^GO"Z6^L\>Z:LS9:&7M^L-X;(J5J+GY2ZU%X_8L
ME:ZY=1_UP]BLM>"E60EAZVH<G9ZFXYK+9O3IX_9<,SV&'Y05A96J<1O]AF]2
M_#2O^_U'MI%&+F0E[=/9J'M?B1&K92-K^4N49Z/3$3,K]?,?I>4OU5A>S0NM
MJNIL-.EW?!/:RF)O\]Q#WO.%Z;98OKCC#N1LE)ZZ$RZE-K8[HCL_=XP;X0[N
M/[56?9&5%?J26_&W5NU:-@_^-.Y?C,'?Z.*P?>V#^$'_GS"JY5(6XE(5;2T:
MV\=1B\H#-F8EUV;$&EZ+L]&%V@C-9OQ!^#_E?N6Z[/^@=60@7/J#=#OT==DQ
M4O(T1E6R=+]>LL^\XDTA6!=' P C!#!Z,T#V;L8!Y!2!G!X1<NXA_!<,4TMV
MNQ8:0,8(9/QFD!>J7@/(!(%,W@9R;E7Q?:4 9(I IF\726Y6 #)#(#-:R%O]
MP!OYJ]O!>.,[CY$=XTP+ X>?'(',:2'G;5US_>2IYO*AD>YKO+'LO"A4VU@)
M(-\CD.]I(>]$X0ZHGMAYJ=;^DI^[:%X;T_JW10$'\E-L)#^EQ?S"I6;?>-4*
M]J_@IM5]JX1XJ&B(3>-:W9K+DET]NI,88;HV>6M73H<7K89CY 33S838-]?-
M1ACK#X)$F%LFQ')Q.9=SB'WJ G;UHY7K73I,*A-BJ[@.H'U'V%Y6R(5Y9$(L
MDDNQ"&*$Z6)"[(NO[KPWRA@V<XU]ON(Z2/XP1TR()?&LU:H4VOS1-2[[!-DP
M-4RHW>#93A;<N-;E$Q37O+J#(!]FA0FQ%J[J=:6>A.AS$S9K=;%RL&SF<E28
M.V-.B(B=<-T4JA;LGC\&/3/"1!"1EQQ5Q1=*]YG)^8,68F= B]!Z@U@ -\Z=
M8;"PP3\B'OSO7*K&7</J!O\;]QTWQK[&+,#$+! 16\!A6MT6MM6NL(90F (B
M8@7,6_=[/$AU(TP#$7G94-?2]J6"OYRNC+ N7*(I9-C@,"-$Q$9X&=4^BT8L
MI=T;SC E1,1*N/,;G0YFW.=#]YH[)72S44'X,"E$Q%)P;<Z('ZT[B%UM=GKH
M%#/!E-@$:#GX7P0Q,3E,B>6 %H0A)B:)*;$D#M1:[-T]=R#!14>GI8CM\5K,
MO*#]"=DP94R)E8'6@^&5QB0R)9;(</4U&$W,+5-BM^R688. F%>FQ%[9KX$&
M$3&[3(]1<.P40X.0F&"FU((Y4!4]@\*I9DPW\1$+CZ$8QIAD8F+)]"G^(!8F
ME9A8*D$2/4B'N20F=LDVFQX$0V]K$(L$SVRF$!,324Q>C6"938")B20F%@F.
M&4-,3"<Q]<05BIE 3$PI,;%2#N6))VSNSEY"3$PJ,;%4.LQ-AUGO80:Y6())
M)2&7"DAGS\M2^B-XQ:Z;[G00$]-+0JP7B/E\H=M*^*9:5-S XB#!=),<[4['
M+F8I%I9!3,P["?GM#ZQ.@.-F@EDH(2]G!NN$;6 A)GI[_6W*F1/6=R>(B5DH
M.78Y$S90B(E9*"&VD+_)]!([.!3U&3G$Q"R4$%MHH/:"\828F(428@L-8OH:
MI[7^8+CV [-02FRAP3+QM1% 3,Q"*?5,VC#F]K)#3,Q"*;&%#M:S?40A)F:A
ME+KZ.8SI4U&(B5DH);80BADD<BEFH92Z%D(QH=-3=)D7=2V$8L):*,4LE![K
MELW C6B'"C$Q"Z7$%@JFA/:E"3$Q"Z7$%MK!A&G'G2B@A3+,0MDQ)]A"3)?C
M;2 F9J&,O!9"HAD,2!EFH8R\%CJ(>2F64)899J'L+5<#A-'$+)21KS0>7.&Q
M[?00$[-01FRAYVG@0_D[Q,0LE!%;Z 43MLKM%/9ET#;1Y<;$%AK$]"-F4\CP
MEFB&62@CMM @YI?6MMKW)+AV)<,LE-&O(^AGV_O\\GFJ<]ES&CB=D&,6RJEK
MH9>; H-]"&)B%LK)EYPA*V_8"<3$+)036VAP[<WK^ 0Q,0OEY!8ZM JG8X68
MF(7R8ZY)VV^@$!.S4$YLH1 SZ.Y^%\3$+)036V@/LUAM1\^+5;!"+,<LE!-;
M: #S9927#7Q6(T<?>R%_[F5GF5C8/B$F9J&\L]"X.]A\^EBZ0:,1Y5?W$\9M
M+WA5S#3S+_Y,DRA._(+I95M5%V[;;7.C>+E]"G+[!.>GWU!+ P04    " !P
MB_M6.&5KYYH"  !R-   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
MS=I-;J- $(;AJU@<(+BKNJO:HSBKV60;Y0+(:?\HMD' *,GMQW(6]H=F,9N(
M;X4:1/&N'B'HQY=R;,9#>Q[VAVY8?)Z.YV%=[<>Q^U77PV9?3LWPT';E?+FR
M;?M3,UZ6_:[NFLU[LRNU+)=6]_<SJJ?'^YF+UZ^N_,_$=KL];,KO=O/G5,[C
M/P;7'VW_/NQ+&:O%:]/ORKBNZL_C[?107P_AX3*Y6CR_K:O^^2U4]=Q! D$R
M?Y!"D,X?%"$HSA^4("C-'V009/,'.03Y_$$9@O+\02L(6LT?%)8HXY(@:8(U
M@=8!N0X$7@<$.Q"('9#L0&!V0+0#@=H!V0X$;@>$.Q#('9#N0&!W0+P#@=Z"
M>@N!WH)Z"X'>,GG9)M!;4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;
M4&\AT%M1;R706U%O)=!;46\ET%LG'TL(]%;46PGT5M1;"?16U%L)]%;46PGT
M5M1;"?16U%L)](ZH=R30.Z+>D4#OB'I' KTCZAT)](Z3C]T$>D?4.Q+H'5'O
M2*!W1+TC@=X1]8X$>D?4.Q+HG5#O1*!W0KT3@=X)]4X$>B?4.Q'HG5#O1*!W
MFORL)- [H=Z)0.^$>B<"O1/JG0CT3JAW(M#;4&\CT-M0;R/0VU!O(]#;4&\C
MT-M0;R/0VU!O(]#;)IM-"/0VU-L(]#;4VPCT-M3;"/1VU-L)]';4VPGT=M3;
M"?1VU-L)]';4VPGT=M3;"?1VU-L)]/;)9D$"O1WU=@*]'?5V KTSZIT)],ZH
M=R;0.Z/>F4#OC'IG KTSZIT)],ZH=R;0.Z/>F4#OC'IG KWS9+,W@=X9]<X_
MJ?<P?AW+<.OY7L/S5S])]7BYM]P>?UU^GT2<5U><Z_N*X>DO4$L#!!0    (
M '"+^U:GD>I9-P(  -\R   3    6T-O;G1E;G1?5'EP97-=+GAM;,W;36[;
M,!"&X:L8V@86+5(BU2+.INVVS:(74"4Z%JP_D$SJW+Z4G 1HD1H)7*#OQH)-
M<KX1!WAVOO[^.%F_.O;=X+?)/H3IHQ"^WMN^\NDXV2&N[$;75R%^=7=BJNI#
M=6>%W&RTJ,<AV"&LPUPCN;G^;'?5?1=67X[Q9]^.PS9QMO/)ZM-IXYRU3:II
MZMJZ"G%=/ S-'RGKIX0TGESV^'T[^:NX(1&O)LPK?P]X.O?MP3K7-G9U6[GP
MM>KC+G'LA ^/G?7I^1*O]#CN=FUMF[&^[^.1U$_.5HW?6QOZ+CT5O3J?'.(-
MV]-G=G'^4N9<8-QYZ\;)QXDY^_ZXYY',I]=3+&1=:,^_XDMB+'WQ^]EYVHUM
MWI@=K_?GZ [+/+Q8'I??\>\S?JG_SCXDI \%Z2.']%% ^M"0/@RDCQ+2QP=(
M']F&T@A%U(Q":D8Q-:.@FE%4S2BL9A17,PJL&45629%54F25%%DE159)D552
M9)44625%5DF155)D5119%45619%54615%%D5159%D5519%44615%UIPB:TZ1
M-:?(FE-DS2FRYA19<XJL.476G")K3I&UH,A:4&0M*+(6%%D+BJP%1=:"(FM!
MD;6@R%I09-44635%5DV155-DU119-45639%54V35%%DU159#D=509#4460U%
M5D.1U5!D-119#4560Y'54&0M*;*6%%E+BJPE1=:2(FM)D;6DR%I29"TILI;_
M4]8?XWCXQ_'+,^VK=GC.%\O_6FY^ 5!+ 0(4 Q0    ( '"+^U8'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ <(O[5B'SE@7N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ <(O[5IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !P
MB_M65[K"J7@$  !^$P  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ <(O[5BW(^TR,!@  [AT  !@
M         ("!NPP  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( '"+^U:7M><8$ ,  -0+   8              " @7T3  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !PB_M6"AOV^K,%   *&
M&               @('#%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ <(O[5IADH3MR P  @PP  !@              ("!K!P  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( '"+^U:N>PPH6@D
M )%1   8              " @50@  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !PB_M6^1EC20\(  !Q*@  &               @('D
M*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ <(O[5FQ#
M5K$,"   :!L  !@              ("!*3(  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( '"+^U8F$PDKH!\  %-E   8
M  " @6LZ  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !P
MB_M6DUF,O^ #   &"0  &0              @(%!6@  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( '"+^U8_R_62IP8  /L2   9
M          " @5A>  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#
M%     @ <(O[5DK?O_BA @  !08  !D              ("!-F4  'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !PB_M6]"USQ]X&   @
M$@  &0              @($.:   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+ 0(4 Q0    ( '"+^U;OKNL6D ,  -,)   9              " @2-O
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ <(O[5D=*
M/2S@ @  OP<  !D              ("!ZG(  'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6Q02P$"% ,4    " !PB_M6B/.C)+,%   2$0  &0
M    @($!=@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M '"+^U9LX"F(V0,  '4)   9              " @>M[  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ <(O[5H0[1MED!@  'Q0  !D
M             ("!^W\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !PB_M6]'$V\" +  !R)@  &0              @(&6A@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( '"+^U:D1<%=Q@0
M $$1   9              " @>V1  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ <(O[5J'S*R@%#   G28  !D              ("!
MZI8  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !PB_M6
MAV\I]SL,  ##)0  &0              @($FHP  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( '"+^U9) E0]^00  !H+   9
M      " @9BO  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ <(O[5BQ$PFB^"P  *3(  !D              ("!R+0  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !PB_M6".)?&R@$  #F"0
M&0              @(&]P   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( '"+^U:\  ]/.P,  #4'   9              " @1S%  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ <(O[5F,/*@@W
M"@  HR<  !D              ("!CL@  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !PB_M67%KT+TP"   N!0  &0
M@('\T@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( '"+
M^U9*;BF1=P(  )0%   9              " @7_5  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ <(O[5CX..MT2!0  L0X  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( '"+^U87;M@BKP(  .P%   9
M  " @44/ 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M<(O[5E4N,W&> @  P@4  !D              ("!*Q(! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !PB_M6P$ZA9NT"  "L!P  &0
M            @($ %0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( '"+^U;-#Y8#-00  %P+   9              " @208 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ <(O[5E#I3><8 P
M(P@  !D              ("!D!P! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !PB_M6$=" 05('  !*&   &0              @('?
M'P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( '"+^U8+
M@(1Y$04  'L-   9              " @6@G 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ <(O[5AF)*&FE P  (PD  !D
M     ("!L"P! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '"+^U809';<E (  %H)   9              "
M@2H^ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ <(O[
M5FO=R0*+ P  _0L  !D              ("!]4 ! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !PB_M6O$>HO*@%   Y+   &0
M        @(&W1 $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( '"+^U8T*GH8L00  +L;   9              " @99* 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ <(O[5FHPVO@^ @  *P4
M !D              ("!?D\! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !PB_M6^,&]7A@#  !]"@  &0              @('S40$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( '"+^U:M*KV4
M]0,  !D2   9              " @4)5 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ <(O[5A%<,'8& P  P0H  !D
M ("!;ED! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !P
MB_M6<;O7ZX4#  "%$0  &0              @(&K7 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( '"+^U8:+(ZYV (  %,)   9
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M 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ <(O[5J<
MA3M% P  7@P  !D              ("!?G,! 'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6Q02P$"% ,4    " !PB_M6Y9WB,V@&  " -P  &0
M    @('Z=@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M '"+^U8^5 K;-0,  $$-   9              " @9E] 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ <(O[5BLT\E[7"0  'E$  !D
M             ("!!8$! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " !PB_M6EH9,[L4&  !H)0  &0              @($3BP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( '"+^U;V9<O;&P,
M *<)   9              " @0^2 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ <(O[5I\-S02S P  G0T  !D              ("!
M894! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " !PB_M6
MHW/%.XL#  !:$0  &0              @(%+F0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( '"+^U;9;F6G0P4  (XH   9
M      " @0V= 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ <(O[5EAUP@WB"@  \8\  !D              ("!AZ(! 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !PB_M6HK\?+9\"  #I!@
M&0              @(&@K0$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( '"+^U8173;.U0,  '@6   9              " @7:P 0!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ <(O[5O>2#$,>
M!   CA(  !D              ("!@K0! 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    " !PB_M6O1^WUB0$   A#P  &0
M@('7N $ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( '"+
M^U:QG$4'#@\   *I   9              " @3*] 0!X;"]W;W)K<VAE971S
M+W-H965T-S0N>&UL4$L! A0#%     @ <(O[5OVH+3'H!@  =3X  !D
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M=#<Y+GAM;%!+ 0(4 Q0    ( '"+^U;1H0UB6@(  #4&   9
M  " @0SA 0!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @
M<(O[5GP"+T?0 P  %14  !D              ("!G>,! 'AL+W=O<FMS:&5E
M=',O<VAE970X,2YX;6Q02P$"% ,4    " !PB_M6,R03NF$#  #H#   &0
M            @(&DYP$ >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4
M Q0    ( '"+^U:1VP.1!0,  ',)   9              " @3SK 0!X;"]W
M;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ <(O[5N.>!.UY @
MK08  !D              ("!>.X! 'AL+W=O<FMS:&5E=',O<VAE970X-"YX
M;6Q02P$"% ,4    " !PB_M6>69E+Y<#  ###P  &0              @($H
M\0$ >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( '"+^U:7
M4Z*1XP,  *X4   9              " @?;T 0!X;"]W;W)K<VAE971S+W-H
M965T.#8N>&UL4$L! A0#%     @ <(O[5HL X/-4 P  *PT  !D
M     ("!$/D! 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4
M" !PB_M6(T_S+A\#  #R"@  &0              @(&;_ $ >&PO=V]R:W-H
M965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( '"+^U8)G#X+P@,  (L6   9
M              " @?'_ 0!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L!
M A0#%     @ <(O[5@\=P_Y. P  RA0   T              ( !Z@," 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !PB_M6EXJ[',     3 @  "P
M        @ %C!P( 7W)E;',O+G)E;'-02P$"% ,4    " !PB_M66BYP&7H&
M  !%.@  #P              @ %," ( >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ <(O[5CAE:^>: @  <C0  !H              ( !\PX" 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ <(O[5J>1ZEDW @
MWS(  !,              ( !Q1$" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     &$ 80">&@  +10"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>219</ContextCount>
  <ElementCount>391</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statements Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure -  Recently Adopted And Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/RecentlyAdoptedAndIssuedAccountingStandards</Role>
      <ShortName>Recently Adopted And Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure -  Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/Investment</Role>
      <ShortName>Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure -  Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Employee Stock Purchase Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlan</Role>
      <ShortName>Employee Stock Purchase Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/CollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreements</Role>
      <ShortName>Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure -  Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure -  Sublease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/Sublease</Role>
      <ShortName>Sublease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure -  Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure -  Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure -  Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure -  Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/Investment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure -  Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure -  Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/PropertyAndEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure -  Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/AccruedExpenses</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure -  Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/NetLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure -  Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/StockholdersEquity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure -  Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/StockBasedCompensation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure -  Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure -  Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/Leases</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure -  Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/Restructuring</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure -  Sublease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SubleaseTables</Role>
      <ShortName>Sublease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/Sublease</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Fair value measurements - Schedule of debt securities in an unrealized loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails</Role>
      <ShortName>Fair value measurements - Schedule of debt securities in an unrealized loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure -  Investments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/InvestmentsAdditionalInformationDetails</Role>
      <ShortName>Investments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/InvestmentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure -  Investments - Schedule of classified as available-for-sale and recorded at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails</Role>
      <ShortName>Investments - Schedule of classified as available-for-sale and recorded at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure -  Investments - Schedule of debt securities in an unrealized loss position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails</Role>
      <ShortName>Investments - Schedule of debt securities in an unrealized loss position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure -  Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure -  Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure -  Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure -  Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure -  Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure -  Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure -  Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure -  Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure -  Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure -  Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure -  Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure -  Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure -  Employee Stock Purchase Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails</Role>
      <ShortName>Employee Stock Purchase Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure -  Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure -  Income Taxes - Schedule of Reconciliation Pre-tax Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation Pre-tax Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure -  Income Taxes - Schedule of Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure -  Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure -  Income Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Research and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure -  Collaboration Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure -  Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure -  Leases - Schedule of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/LeasesScheduleOfLeasesDetails</Role>
      <ShortName>Leases - Schedule of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure -  Leases - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails</Role>
      <ShortName>Leases - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure -  Leases - Schedule of Future Aggregate Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Aggregate Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Sublease - Summary of future sublease income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails</Role>
      <ShortName>Sublease - Summary of future sublease income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Sublease (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails</Role>
      <ShortName>Sublease (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/SubleaseTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure -  Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure -  Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure -  Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure -  Restructuring (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails</Role>
      <ShortName>Restructuring (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/RestructuringTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure -  Restructuring - Summary of Restructuring-related charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails</Role>
      <ShortName>Restructuring - Summary of Restructuring-related charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure -  Restructuring - Schdule of Changes to the liability for the restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails</Role>
      <ShortName>Restructuring - Schdule of Changes to the liability for the restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Restructuring - Schedule of incurred charges due to restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails</Role>
      <ShortName>Restructuring - Schedule of incurred charges due to restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d451428ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Subsequent Events (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.frequencytherapeutics.com/role/SubsequentEvents</ParentRole>
      <Position>89</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentPaymentTerms -  d451428ds4.htm 24788</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-4" original="d451428ds4.htm">d451428ds4.htm</File>
    <File>d451428dex231.htm</File>
    <File>d451428dex232.htm</File>
    <File>d451428dex991.htm</File>
    <File>d451428dex993.htm</File>
    <File>d451428dexfilingfees.htm</File>
    <File>freq-20230331.xsd</File>
    <File>freq-20230331_cal.xml</File>
    <File>freq-20230331_def.xml</File>
    <File>freq-20230331_lab.xml</File>
    <File>freq-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g451428g00a12.jpg</File>
    <File>g451428g00a13.jpg</File>
    <File>g451428g00a16.jpg</File>
    <File>g451428g00f02.jpg</File>
    <File>g451428g00z04.jpg</File>
    <File>g451428g01a65.jpg</File>
    <File>g451428g01a66.jpg</File>
    <File>g451428g01b69.jpg</File>
    <File>g451428g01b77.jpg</File>
    <File>g451428g01m30.jpg</File>
    <File>g451428g02a39.jpg</File>
    <File>g451428g03g00.jpg</File>
    <File>g451428g08y97.jpg</File>
    <File>g451428g11t01.jpg</File>
    <File>g451428g17g02.jpg</File>
    <File>g451428g17n01.jpg</File>
    <File>g451428g21a60.jpg</File>
    <File>g451428g28a32.jpg</File>
    <File>g451428g28b32.jpg</File>
    <File>g451428g28p69.jpg</File>
    <File>g451428g37a02.jpg</File>
    <File>g451428g38a01.jpg</File>
    <File>g451428g48h62.jpg</File>
    <File>g451428g48h63.jpg</File>
    <File>g451428g62m07.jpg</File>
    <File>g451428g67a27.jpg</File>
    <File>g451428g94e51.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="969">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>138
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d451428ds4.htm": {
   "axisCustom": 0,
   "axisStandard": 30,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 969,
    "http://xbrl.sec.gov/dei/2023": 28
   },
   "contextCount": 219,
   "dts": {
    "calculationLink": {
     "local": [
      "freq-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "freq-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d451428ds4.htm"
     ]
    },
    "labelLink": {
     "local": [
      "freq-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "freq-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "freq-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 605,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 6,
    "total": 7
   },
   "keyCustom": 81,
   "keyStandard": 310,
   "memberCustom": 33,
   "memberStandard": 35,
   "nsprefix": "freq",
   "nsuri": "http://www.frequencytherapeutics.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.frequencytherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure -  Recently Adopted And Issued Accounting Standards",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.frequencytherapeutics.com/role/RecentlyAdoptedAndIssuedAccountingStandards",
     "shortName": "Recently Adopted And Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.frequencytherapeutics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure -  Investment",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.frequencytherapeutics.com/role/Investment",
     "shortName": "Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.frequencytherapeutics.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.frequencytherapeutics.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.frequencytherapeutics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure -  Net Loss Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.frequencytherapeutics.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.frequencytherapeutics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.frequencytherapeutics.com/role/StockBasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:EmployeeStockPurchasePlanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Employee Stock Purchase Plan",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlan",
     "shortName": "Employee Stock Purchase Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:EmployeeStockPurchasePlanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.frequencytherapeutics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Collaboration Agreement",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.frequencytherapeutics.com/role/CollaborationAgreement",
     "shortName": "Collaboration Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.frequencytherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Research and License Agreements",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreements",
     "shortName": "Research and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure -  Restructuring",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.frequencytherapeutics.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:Sublease",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure -  Sublease",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.frequencytherapeutics.com/role/Sublease",
     "shortName": "Sublease",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:Sublease",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.frequencytherapeutics.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.frequencytherapeutics.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure -  Related Party Transactions",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.frequencytherapeutics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.frequencytherapeutics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Organization and Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "31",
     "role": "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:PropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure -  Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:PropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure -  Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.frequencytherapeutics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure -  Investments (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.frequencytherapeutics.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure -  Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure -  Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure -  Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.frequencytherapeutics.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure -  Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.frequencytherapeutics.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure -  Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.frequencytherapeutics.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure -  Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure -  Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.frequencytherapeutics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure -  Leases (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.frequencytherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:ScheduleOfRestructingRelatedChargesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure -  Restructuring (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.frequencytherapeutics.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:ScheduleOfRestructingRelatedChargesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "freq:Sublease",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:SummaryOfExpectedFutureSubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure -  Sublease (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.frequencytherapeutics.com/role/SubleaseTables",
     "shortName": "Sublease (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "freq:Sublease",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "freq:SummaryOfExpectedFutureSubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Organization and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:PropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:PropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Fair value measurements - Schedule of debt securities in an unrealized loss (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
     "shortName": "Fair value measurements - Schedule of debt securities in an unrealized loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2021_LongTermMarketableSecuritiesMemberusgaapFinancialInstrumentAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Term",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure -  Investments (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.frequencytherapeutics.com/role/InvestmentsAdditionalInformationDetails",
     "shortName": "Investments (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Term",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure -  Investments - Schedule of classified as available-for-sale and recorded at fair value (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails",
     "shortName": "Investments - Schedule of classified as available-for-sale and recorded at fair value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure -  Investments - Schedule of debt securities in an unrealized loss position (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails",
     "shortName": "Investments - Schedule of debt securities in an unrealized loss position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "freq:PrepaidRentAndDepositsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure -  Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "freq:PrepaidRentAndDepositsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure -  Property and Equipment - Schedule of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure -  Property and Equipment - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure -  Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure -  Debt - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure -  Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements Stockholders' Equity (Deficit) (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
     "shortName": "Consolidated Statements Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure -  Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure -  Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_10_2021",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure -  Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure -  Stock-based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails",
     "shortName": "Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure -  Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails",
     "shortName": "Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails",
     "shortName": "Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure -  Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails",
     "shortName": "Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "freq:EmployeeStockPurchasePlanDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P09_20_2019To09_20_2019",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "freq:PercentageOfEligibleEmployeeCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure -  Employee Stock Purchase Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails",
     "shortName": "Employee Stock Purchase Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "freq:EmployeeStockPurchasePlanDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P09_20_2019To09_20_2019",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "freq:PercentageOfEligibleEmployeeCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure -  Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure -  Income Taxes - Schedule of Reconciliation Pre-tax Income (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation Pre-tax Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure -  Income Taxes - Schedule of Provision (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails",
     "shortName": "Income Taxes - Schedule of Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure -  Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure -  Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022_DirectorMembersrtTitleOfIndividualAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentForManagementFee",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Research and License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Research and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "freq:LicenseAgreementTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022_MassachusettsInstituteOfTechnologyMemberdeiLegalEntityAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "freq:DescriptionOfFutureDevelopmentObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure -  Collaboration Agreement - Additional Information (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
     "shortName": "Collaboration Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P07_01_2019To07_31_2019_AstellasPharmaLimitedLiabilityCompanyMembersrtCounterpartyNameAxis_LicenseAndCollaborationAgreementMemberusgaapTypeOfArrangementAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure -  Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure -  Leases - Schedule of Leases (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.frequencytherapeutics.com/role/LeasesScheduleOfLeasesDetails",
     "shortName": "Leases - Schedule of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure -  Leases - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails",
     "shortName": "Leases - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure -  Leases - Schedule of Future Aggregate Minimum Payments (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails",
     "shortName": "Leases - Schedule of Future Aggregate Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Sublease - Summary of future sublease income (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails",
     "shortName": "Sublease - Summary of future sublease income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Sublease (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails",
     "shortName": "Sublease (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyLossInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure -  Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyLossInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure -  Employee Benefit Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
     "shortName": "Employee Benefit Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022_DirectorMembersrtTitleOfIndividualAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentForManagementFee",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1084 - Disclosure -  Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P02_13_2023To02_13_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "freq:ReductionInWorkforceDueToRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1085 - Disclosure -  Restructuring (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails",
     "shortName": "Restructuring (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P02_13_2023To02_13_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "freq:ReductionInWorkforceDueToRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:ScheduleOfRestructingRelatedChargesTableTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1086 - Disclosure -  Restructuring - Summary of Restructuring-related charges (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails",
     "shortName": "Restructuring - Summary of Restructuring-related charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:ScheduleOfRestructingRelatedChargesTableTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "freq:RestructingLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1087 - Disclosure -  Restructuring - Schdule of Changes to the liability for the restructuring (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails",
     "shortName": "Restructuring - Schdule of Changes to the liability for the restructuring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "freq:ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "freq:RestructingLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserveAcceleratedDepreciation",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1088 - Disclosure - Restructuring - Schedule of incurred charges due to restructuring (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails",
     "shortName": "Restructuring - Schedule of incurred charges due to restructuring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P02_13_2023To02_13_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1089 - Disclosure - Subsequent Events (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P02_13_2023To02_13_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d451428ds4.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r878",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address Address Line"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "freq_AREMARegionNo20LLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARE-MA Region No. 20, LLC.",
        "label": "A R E M A Region No20 L L C [Member]",
        "terseLabel": "ARE-MA Region No. 20, LLC"
       }
      }
     },
     "localname": "AREMARegionNo20LLCMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_AcceleratedDepreciationChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated depreciation charges Member",
        "label": "Accelerated depreciation charges Member",
        "terseLabel": "Accelerated depreciation charges [Member]"
       }
      }
     },
     "localname": "AcceleratedDepreciationChargesMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_AcceleratedHearingProgramCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Hearing Program Charges",
        "label": "Accelerated Hearing Program Charges"
       }
      }
     },
     "localname": "AcceleratedHearingProgramCharges",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_AcceleratedfxthreefourfivechargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AcceleratedFxThreeFourFiveCharges [Member]",
        "label": "AcceleratedFxThreeFourFiveCharges [Member]",
        "terseLabel": "Accelerated FX-345 charges"
       }
      }
     },
     "localname": "AcceleratedfxthreefourfivechargesMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_AcceleratedfxthreetwotwochargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AcceleratedFxThreeTwoTwoCharges [Member]",
        "label": "AcceleratedFxThreeTwoTwoCharges [Member]",
        "terseLabel": "Accelerated FX-322 charges"
       }
      }
     },
     "localname": "AcceleratedfxthreetwotwochargesMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued income taxes and other accrued liabilities, current.",
        "label": "Accrued Income Taxes And Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued third-party research and development expenses current.",
        "label": "Accrued Third Party Research And Development Expenses Current",
        "terseLabel": "Third-party research and development expenses"
       }
      }
     },
     "localname": "AccruedThirdPartyResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_AgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period.",
        "label": "Agreement Termination Notice Period",
        "terseLabel": "Agreement termination notice period"
       }
      }
     },
     "localname": "AgreementTerminationNoticePeriod",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_AnnualLicenseFeePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual License Fee Per Share",
        "label": "Annual License Fee Per Share",
        "terseLabel": "Annual License Fee Per Share"
       }
      }
     },
     "localname": "AnnualLicenseFeePerShare",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "freq_AstellasPharmaLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas pharma limited liability company.",
        "label": "Astellas Pharma Limited Liability Company [Member]",
        "terseLabel": "Astellas Pharma LLC"
       }
      }
     },
     "localname": "AstellasPharmaLimitedLiabilityCompanyMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_AtTheMarketProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Program [Member]",
        "label": "At The Market Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "AtTheMarketProgramMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_CaliforniaInstituteForBiomedicalResearchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Institute for Biomedical Research.",
        "label": "California Institute For Biomedical Research [Member]",
        "terseLabel": "CALIBR"
       }
      }
     },
     "localname": "CaliforniaInstituteForBiomedicalResearchMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability revenue recognized from commercialization milestones.",
        "label": "Contract With Customer Liability Revenue Recognized From Commercialization Milestones",
        "terseLabel": "Revenue recognized commercialization milestone payments to receive"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_CumulativeChangeInOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative change in ownership percentage.",
        "label": "Cumulative Change In Ownership Percentage",
        "terseLabel": "Cumulative change in ownership percentage"
       }
      }
     },
     "localname": "CumulativeChangeInOwnershipPercentage",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "freq_DebtDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Due",
        "label": "Debt Due",
        "terseLabel": "Debt due"
       }
      }
     },
     "localname": "DebtDue",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_DebtInstrumentFloorInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument floor interest rate percentage.",
        "label": "Debt Instrument Floor Interest Rate Percentage",
        "terseLabel": "Interest rate floor percentage"
       }
      }
     },
     "localname": "DebtInstrumentFloorInterestRatePercentage",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "freq_DebtInstrumentInterestOnlyPaymentMaturityDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest only payment maturity date.",
        "label": "Debt Instrument Interest Only Payment Maturity Date",
        "terseLabel": "Monthly interest only payments due"
       }
      }
     },
     "localname": "DebtInstrumentInterestOnlyPaymentMaturityDate",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "freq_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment premium percentage.",
        "label": "Debt Instrument Prepayment Premium Percentage",
        "terseLabel": "Debt instrument prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "freq_DeferredTaxAssetsLeasingArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets leasing arrangements.",
        "label": "Deferred Tax Assets Leasing Arrangements",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets liabilities property plant and equipment.",
        "label": "Deferred Tax Assets Liabilities Property Plant And Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_DeferredTaxAssetsRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets right of use assets.",
        "label": "Deferred Tax Assets Right Of Use Assets",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUseAssets",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_DeferredTaxLiabilitiesTaxDeferredExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities tax deferred expense.",
        "label": "Deferred Tax Liabilities Tax Deferred Expense [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredExpenseAbstract",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "freq_Denominator": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator:",
        "label": "Denominator:"
       }
      }
     },
     "localname": "Denominator",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "freq_DescriptionOfConditionsToTerminateLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conditions to terminate license agreement.",
        "label": "Description Of Conditions To Terminate License Agreement",
        "terseLabel": "Description of conditions to terminate license agreement"
       }
      }
     },
     "localname": "DescriptionOfConditionsToTerminateLicenseAgreement",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "freq_DescriptionOfFutureDevelopmentObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of future development obligations.",
        "label": "Description Of Future Development Obligations",
        "terseLabel": "Description of future development obligations"
       }
      }
     },
     "localname": "DescriptionOfFutureDevelopmentObligations",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "freq_Earningpersharebasicanddiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EarningPerShareBasicAndDiluted",
        "label": "EarningPerShareBasicAndDiluted",
        "terseLabel": "Net loss per share attributable to common stockholders-basic and diluted"
       }
      }
     },
     "localname": "Earningpersharebasicanddiluted",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "freq_EmployeeStockPurchasePlanDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan disclosure.",
        "label": "Employee Stock Purchase Plan Disclosure [Text Block]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanDisclosureTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses of stock based compensation to be recognized over vesting period of options",
        "label": "Expenses of stock based compensation to be recognized over vesting period of options",
        "terseLabel": "Expenses of Stock Based Compensation to be Recognized over vesting period of options"
       }
      }
     },
     "localname": "ExpensesOfStockBasedCompensationToBeRecognizedOverVestingPeriodOfOptions",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "verboseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_HaydenLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hayden LLC.",
        "label": "Hayden L L C [Member]",
        "terseLabel": "Hayden LLC"
       }
      }
     },
     "localname": "HaydenLLCMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_IncomeTaxesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureLineItems",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "freq_IncomeTaxesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Table]",
        "terseLabel": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureTable",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "freq_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in lease liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right of use assets.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets",
        "terseLabel": "Increase in right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_IssuanceOfCommonStockPursuantToRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Common Stock Pursuant To Restricted Stock Units",
        "label": "Issuance Of Common Stock Pursuant To Restricted Stock Units"
       }
      }
     },
     "localname": "IssuanceOfCommonStockPursuantToRestrictedStockUnits",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock pursuant to restricted stock units (Shares)",
        "label": "Issuance of common stock pursuant to restricted stock units (Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockPursuantToRestrictedStockUnitsShares",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "freq_JointCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "joint cost",
        "label": "joint cost"
       }
      }
     },
     "localname": "JointCost",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "verboseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_LeasesTerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination agreement.",
        "label": "Leases Termination Agreement [Member]",
        "terseLabel": "Lease Termination Agreement"
       }
      }
     },
     "localname": "LeasesTerminationAgreementMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_LexingtonLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexington lease.",
        "label": "Lexington Lease [Member]",
        "terseLabel": "Lexington Lease"
       }
      }
     },
     "localname": "LexingtonLeaseMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_LexingtonMassachusettsFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexington Massachusetts facility.",
        "label": "Lexington Massachusetts Facility [Member]",
        "terseLabel": "Lexington Massachusetts Facility",
        "verboseLabel": "Lexington Massachusetts facility"
       }
      }
     },
     "localname": "LexingtonMassachusettsFacilityMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_LicenseAgreementEnteredDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement entered date.",
        "label": "License Agreement Entered Date",
        "terseLabel": "License agreement entered date"
       }
      }
     },
     "localname": "LicenseAgreementEnteredDate",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "freq_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Text Block]",
        "terseLabel": "Research and License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreement.",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_LicenseFeePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fee payment.",
        "label": "License Fee Payment",
        "terseLabel": "License fee payment"
       }
      }
     },
     "localname": "LicenseFeePayment",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan and security agreement.",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_MassachusettsEyeAndEarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Massachusetts eye and ear.",
        "label": "Massachusetts Eye And Ear [Member]",
        "terseLabel": "MEE"
       }
      }
     },
     "localname": "MassachusettsEyeAndEarMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_MassachusettsInstituteOfTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Massachusetts Institute of Technology.",
        "label": "Massachusetts Institute Of Technology [Member]",
        "terseLabel": "MIT"
       }
      }
     },
     "localname": "MassachusettsInstituteOfTechnologyMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_NetOperatingLossCarryforwardsExpirationWithLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards expiration with limitation.",
        "label": "Net Operating Loss Carryforwards Expiration With Limitation",
        "terseLabel": "Net operating loss carryforwards expire through 2037"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardsExpirationWithLimitation",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards expiration without limitation.",
        "label": "Net Operating Loss Carryforwards Expiration Without Limitation",
        "terseLabel": "Net operating loss carryforwards without expiration"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardsExpirationWithoutLimitation",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_NonCashLeaseExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash lease expenses.",
        "label": "Non Cash Lease Expenses",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpenses",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_NonExclusivePatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-exclusive patent license agreement.",
        "label": "Non Exclusive Patent License Agreement [Member]",
        "terseLabel": "Non-Exclusive Patent License Agreement"
       }
      }
     },
     "localname": "NonExclusivePatentLicenseAgreementMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_OperatingLeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease commencement date.",
        "label": "Operating Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "OperatingLeaseCommencementDate",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "freq_OperatingLeaseNumberOfAdditionalExtensionTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease number of additional extension terms.",
        "label": "Operating Lease Number Of Additional Extension Terms",
        "terseLabel": "Number of additional lease extension terms"
       }
      }
     },
     "localname": "OperatingLeaseNumberOfAdditionalExtensionTerms",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "freq_OperatingLeasesAdditionalExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases additional extension term.",
        "label": "Operating Leases Additional Extension Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "OperatingLeasesAdditionalExtensionTerm",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards annual usage for next each after five years and thereafter after ownership change.",
        "label": "Operating Loss Carryforwards Annual Usage For Next Each After Five Years And Thereafter After Ownership Change",
        "terseLabel": "Operating loss carryforwards, utilization after 15 years thereafter after ownership change"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards annual usage for next each five years after ownership change.",
        "label": "Operating Loss Carryforwards Annual Usage For Next Each Five Years After Ownership Change",
        "verboseLabel": "Operating loss carryforwards, utilization after five years after ownership change"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "freq_OperatingLossCarryforwardsUsageAfterOwnershipChange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Usage After Ownership Change.",
        "label": "Operating Loss Carryforwards Usage After Ownership Change",
        "terseLabel": "Operating loss carryforwards, utilization after ownership change"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsUsageAfterOwnershipChange",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_OtherLongTermAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other long-term assets",
        "label": "Other long-term assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherLongTermAssets",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_OutstandingStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options.",
        "label": "Outstanding Stock Options [Member]",
        "terseLabel": "Outstanding Stock Options"
       }
      }
     },
     "localname": "OutstandingStockOptionsMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_PatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent license agreement.",
        "label": "Patent License Agreement [Member]",
        "terseLabel": "Patent License Agreement"
       }
      }
     },
     "localname": "PatentLicenseAgreementMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_PercentageOfEligibleEmployeeCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible employee compensation.",
        "label": "Percentage Of Eligible Employee Compensation",
        "terseLabel": "Percentage of eligible employee compensation"
       }
      }
     },
     "localname": "PercentageOfEligibleEmployeeCompensation",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "freq_PercentageOfRoyaltyOnSublicenseRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty on sublicense revenue.",
        "label": "Percentage of Royalty on Sublicense Revenue",
        "terseLabel": "Percentage of Royalty on Sublicense Revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnSublicenseRevenue",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "freq_PercentageOfSharesOfCommonStockIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares of common stock issued.",
        "label": "Percentage Of Shares Of Common Stock Issued",
        "terseLabel": "Percentage of shares of common stock issued"
       }
      }
     },
     "localname": "PercentageOfSharesOfCommonStockIssued",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for automatic increase in common stock available for future issuance.",
        "label": "Period For Automatic Increase In Common Stock Available For Future Issuance",
        "terseLabel": "Period for automatic increase in common stock available for future issuance",
        "verboseLabel": "Period for automatic increase in common available for future issuance"
       }
      }
     },
     "localname": "PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_PeriodOfCumulativeChangeInOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of cumulative change in ownership.",
        "label": "Period Of Cumulative Change In Ownership",
        "terseLabel": "Period of cumulative change in ownership"
       }
      }
     },
     "localname": "PeriodOfCumulativeChangeInOwnership",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_Phase2bClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 2b clinical trial.",
        "label": "Phase2b Clinical Trial [Member]",
        "terseLabel": "Phase 2b Clinical Trial"
       }
      }
     },
     "localname": "Phase2bClinicalTrialMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_Phase3ClinicalTrailMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 3 clinical trail.",
        "label": "Phase3 Clinical Trail [Member]",
        "terseLabel": "Phase 3 Clinical Trial"
       }
      }
     },
     "localname": "Phase3ClinicalTrailMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_PreTaxNetLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-tax net loss",
        "label": "Pre-tax net loss",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PreTaxNetLoss",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_PrepaidAccountsReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid accounts receivable current.",
        "label": "Prepaid Accounts Receivable Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "PrepaidAccountsReceivableCurrent",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_PrepaidRentAndDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent and deposits.",
        "label": "Prepaid Rent And Deposits Current",
        "terseLabel": "Rent and deposits"
       }
      }
     },
     "localname": "PrepaidRentAndDepositsCurrent",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_PrepaidResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development expense current.",
        "label": "Prepaid Research And Development Expense Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date.",
        "label": "Prepayment Occurs After First Anniversary Of Closing Date And On Or Prior To Second Anniversary Of Closing Date [Member]",
        "terseLabel": "Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date"
       }
      }
     },
     "localname": "PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Occurs After Second Anniversary of Closing Date.",
        "label": "Prepayment Occurs After Second Anniversary Of Closing Date [Member]",
        "terseLabel": "Prepayment Occurs After Second Anniversary of Closing Date"
       }
      }
     },
     "localname": "PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Occurs on or Prior to First Anniversary of Closing Date.",
        "label": "Prepayment Occurs On Or Prior To First Anniversary Of Closing Date [Member]",
        "terseLabel": "Prepayment Occurs on or Prior to First Anniversary of Closing Date"
       }
      }
     },
     "localname": "PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_ProceedsFromPaymentForPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payment For) Property And Equipment",
        "label": "Proceeds From (Payment For) Property And Equipment",
        "negatedLabel": "Sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromPaymentForPropertyAndEquipment",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_PropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment.",
        "label": "Property And Equipment Table [Text Block]",
        "terseLabel": "Property And Equipment"
       }
      }
     },
     "localname": "PropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_ReductionInWorkforceDueToRestructuring": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in Workforce due to Restructuring",
        "label": "Reduction in Workforce due to Restructuring"
       }
      }
     },
     "localname": "ReductionInWorkforceDueToRestructuring",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining pre ownership change in operating loss carryforwards written off due to expiration.",
        "label": "Remaining Pre Ownership Change In Operating Loss Carryforwards Written Off Due To Expiration",
        "terseLabel": "Remaining pre ownership change in operating loss carryforwards written off due to expiration"
       }
      }
     },
     "localname": "RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_RestructingLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructing Liabilities",
        "label": "Restructing Liabilities",
        "periodEndLabel": "Restructing liabilities Ending",
        "periodStartLabel": "Liability balance Opening"
       }
      }
     },
     "localname": "RestructingLiabilities",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_RestructingNetCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructing Net Charge",
        "label": "Restructing Net Charge",
        "terseLabel": "Net charges"
       }
      }
     },
     "localname": "RestructingNetCharge",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_RestructuringRelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "restructuring-related expenses",
        "label": "restructuring-related expenses"
       }
      }
     },
     "localname": "RestructuringRelatedExpenses",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition potential commercial milestone payments eligible upon successful commercialization.",
        "label": "Revenue Recognition Potential Commercial Milestone Payments Eligible Upon Successful Commercialization",
        "terseLabel": "Potential commercial milestone payments eligible to receive upon successful commercialization"
       }
      }
     },
     "localname": "RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_RevenueRecognitionTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition transaction price.",
        "label": "Revenue Recognition Transaction Price",
        "terseLabel": "Transaction price allocated to single combined performance obligation"
       }
      }
     },
     "localname": "RevenueRecognitionTransactionPrice",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_RightToTerminateAgreementIfBreachRemainsUncured": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to terminate agreement if breach remains uncured.",
        "label": "Right To Terminate Agreement If Breach Remains Uncured",
        "terseLabel": "Right to terminate agreement if breach remains uncured"
       }
      }
     },
     "localname": "RightToTerminateAgreementIfBreachRemainsUncured",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_RightToTerminateAgreementIncaseOfNonpayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to terminate agreement incase of nonpayment.",
        "label": "Right To Terminate Agreement Incase Of Nonpayment",
        "terseLabel": "Right to terminate agreement incase of nonpayment"
       }
      }
     },
     "localname": "RightToTerminateAgreementIncaseOfNonpayment",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_RightToTerminateAgreementUponPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to terminate agreement upon prior written notice.",
        "label": "Right To Terminate Agreement Upon Prior Written Notice",
        "terseLabel": "Right to terminate agreement upon prior written notice"
       }
      }
     },
     "localname": "RightToTerminateAgreementUponPriorWrittenNotice",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to terminate agreement upon prior written notice if insolvent.",
        "label": "Right To Terminate Agreement Upon Prior Written Notice If Insolvent",
        "terseLabel": "Right to terminate agreement upon prior written notice if insolvent"
       }
      }
     },
     "localname": "RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to terminate licensed patents upon prior written notice.",
        "label": "Right To Terminate Licensed Patents Upon Prior Written Notice",
        "terseLabel": "Right to terminate licensed patents upon prior written notice"
       }
      }
     },
     "localname": "RightToTerminateLicensedPatentsUponPriorWrittenNotice",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_RoyaltyExpensePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Expense Per Share",
        "label": "Royalty Expense Per Share",
        "terseLabel": "Royalty Expense Per Share"
       }
      }
     },
     "localname": "RoyaltyExpensePerShare",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "freq_SalesAgentCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agent commission",
        "label": "Sales Agent Commission"
       }
      }
     },
     "localname": "SalesAgentCommission",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "freq_SaliogenTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SalioGen Therapeutics, Inc.",
        "label": "SalioGen Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "SaliogenTherapeuticsIncMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Changes to the liability for the restructuring [Table Text Block]",
        "label": "Schedule of Changes to the liability for the restructuring [Table Text Block]",
        "terseLabel": "Schdule of Changes to the liability for the restructuring"
       }
      }
     },
     "localname": "ScheduleOfChangesToTheLiabilityForTheRestructuringTableTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock shares reserved for future issuance.",
        "label": "Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of Common Stock Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_ScheduleOfRestructingRelatedChargesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Restructing related charges [Table Text Block]",
        "label": "Schedule of Restructing related charges [Table Text Block]",
        "terseLabel": "Schedule of Restructuring-related charges"
       }
      }
     },
     "localname": "ScheduleOfRestructingRelatedChargesTableTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractualterm2.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted average remaining contractual term (in years), Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "freq_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, nonvested, weighted average grant date fair value.",
        "label": "ShareBased Compensation Arrangement by ShareBased Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Values",
        "verboseLabel": "Weighted average fair value, Unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValues",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "freq_ShortTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term marketable securities.",
        "label": "Short Term Marketable Securities [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_SignificantSuppliersPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant suppliers.",
        "label": "Significant Suppliers Policy [Text Block]",
        "terseLabel": "Significant Suppliers"
       }
      }
     },
     "localname": "SignificantSuppliersPolicyTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_StockIssuedDuringPeriodSharesUnderEquityOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Under Equity Offering",
        "label": "Stock Issued During Period Shares Under Equity Offering",
        "terseLabel": "Issuance of common stock under equity offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesUnderEquityOffering",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "freq_StockIssuedDuringPeriodSharesUnderEquityOfferingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Under Equity Offering Amount",
        "label": "Stock Issued During Period Shares Under Equity Offering Amount",
        "terseLabel": "Issuance of common stock under equity offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesUnderEquityOfferingAmount",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_Sublease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease",
        "label": "Sublease"
       }
      }
     },
     "localname": "Sublease",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/Sublease"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_SummaryOfExpectedFutureSubleaseIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Expected Future Sublease Income",
        "label": "Summary Of Expected Future Sublease Income"
       }
      }
     },
     "localname": "SummaryOfExpectedFutureSubleaseIncome",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubleaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of prepaid expenses and other current assets.",
        "label": "Summary Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "freq_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "freq_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "freq_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_TwoThousandAndFourteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen stock incentive plan.",
        "label": "Two Thousand And Fourteen Stock Incentive Plan [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenStockIncentivePlanMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_TwoThousandAndNineteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nineteen incentive award plan.",
        "label": "Two Thousand And Nineteen Incentive Award Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "TwoThousandAndNineteenIncentiveAwardPlanMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen And Two Thousand Nineteen Stock Incentive Plan [Member]",
        "label": "Two Thousand Fourteen And Two Thousand Nineteen Stock Incentive Plan [Member]",
        "terseLabel": "2014 and 2019 Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenAndTwoThousandNineteenStockIncentivePlanMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial information.",
        "label": "Unaudited Interim Financial Information Policy [Text Block]",
        "terseLabel": "Unaudited interim financial information"
       }
      }
     },
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "freq_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock units.",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Unvested Restricted Stock Units"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "freq_UpfrontFeeRecognizedAsRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee recognized as revenue.",
        "label": "Upfront Fee Recognized As Revenue",
        "terseLabel": "Upfront fee recognized as revenue"
       }
      }
     },
     "localname": "UpfrontFeeRecognizedAsRevenue",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "freq_WeightedsAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighteds Average Number Of Share Outstanding Basic And Diluted",
        "label": "Weighteds Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding-basic and diluted"
       }
      }
     },
     "localname": "WeightedsAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://www.frequencytherapeutics.com/20230331",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_AsiaMember": {
     "auth_ref": [
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]",
        "terseLabel": "Asia"
       }
      }
     },
     "localname": "AsiaMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r364",
      "r391",
      "r616",
      "r829",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r915",
      "r1005"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Dr. Langer"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r427",
      "r651",
      "r691",
      "r729",
      "r730",
      "r791",
      "r793",
      "r795",
      "r796",
      "r801",
      "r821",
      "r822",
      "r837",
      "r849",
      "r855",
      "r864",
      "r944",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r427",
      "r651",
      "r691",
      "r729",
      "r730",
      "r791",
      "r793",
      "r795",
      "r796",
      "r801",
      "r821",
      "r822",
      "r837",
      "r849",
      "r855",
      "r864",
      "r944",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r258",
      "r653",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r824",
      "r850",
      "r863",
      "r886",
      "r940",
      "r941",
      "r945",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r258",
      "r653",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r824",
      "r850",
      "r863",
      "r886",
      "r940",
      "r941",
      "r945",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r410",
      "r427",
      "r459",
      "r460",
      "r461",
      "r627",
      "r651",
      "r691",
      "r729",
      "r730",
      "r791",
      "r793",
      "r795",
      "r796",
      "r801",
      "r821",
      "r822",
      "r837",
      "r849",
      "r855",
      "r864",
      "r868",
      "r936",
      "r944",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r410",
      "r427",
      "r459",
      "r460",
      "r461",
      "r627",
      "r651",
      "r691",
      "r729",
      "r730",
      "r791",
      "r793",
      "r795",
      "r796",
      "r801",
      "r821",
      "r822",
      "r837",
      "r849",
      "r855",
      "r864",
      "r868",
      "r936",
      "r944",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r364",
      "r391",
      "r616",
      "r830",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r229",
      "r428",
      "r882",
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r259",
      "r260",
      "r722",
      "r725",
      "r727",
      "r792",
      "r794",
      "r798",
      "r802",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r825",
      "r851",
      "r868",
      "r945",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r722",
      "r725",
      "r727",
      "r792",
      "r794",
      "r798",
      "r802",
      "r810",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r825",
      "r851",
      "r868",
      "r945",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r229",
      "r428",
      "r882",
      "r883",
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r915",
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "Accounting Standards Update 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r20",
      "r862"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r45",
      "r174",
      "r675"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r30",
      "r86",
      "r180",
      "r671",
      "r699",
      "r703"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r3",
      "r13",
      "r30",
      "r529",
      "r532",
      "r610",
      "r694",
      "r695",
      "r898",
      "r899",
      "r900",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r83",
      "r862",
      "r1006"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r719",
      "r909",
      "r910",
      "r911",
      "r982",
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional-paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r216",
      "r217",
      "r218",
      "r220",
      "r229",
      "r262",
      "r263",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r331",
      "r468",
      "r469",
      "r470",
      "r496",
      "r497",
      "r498",
      "r499",
      "r512",
      "r513",
      "r514",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r567",
      "r568",
      "r569",
      "r570",
      "r587",
      "r588",
      "r591",
      "r592",
      "r593",
      "r594",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r655",
      "r656",
      "r657",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r58",
      "r59",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r463",
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r119",
      "r175",
      "r205",
      "r238",
      "r252",
      "r256",
      "r298",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r517",
      "r521",
      "r565",
      "r668",
      "r751",
      "r862",
      "r876",
      "r942",
      "r943",
      "r991"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r169",
      "r182",
      "r205",
      "r298",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r517",
      "r521",
      "r565",
      "r862",
      "r942",
      "r943",
      "r991"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r268",
      "r318",
      "r667"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortization Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "auth_ref": [
      "r320",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r269",
      "r318",
      "r662",
      "r916"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r265",
      "r318"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r172",
      "r265",
      "r318"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r171",
      "r827"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r35",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r34",
      "r95",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r2",
      "r95"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r162",
      "r163",
      "r262",
      "r263",
      "r300",
      "r301",
      "r302",
      "r309",
      "r310",
      "r311",
      "r331",
      "r496",
      "r512",
      "r513",
      "r514",
      "r523",
      "r524",
      "r525",
      "r526",
      "r538",
      "r539",
      "r540",
      "r543",
      "r550",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r587",
      "r591",
      "r592",
      "r593",
      "r606",
      "r655",
      "r656",
      "r692",
      "r693",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r152",
      "r216",
      "r228",
      "r305",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r237",
      "r389",
      "r390",
      "r391",
      "r393",
      "r396",
      "r401",
      "r403",
      "r708",
      "r709",
      "r710",
      "r711",
      "r849",
      "r881",
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r142",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r344",
      "r345",
      "r811",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for future issuance",
        "verboseLabel": "Shares of common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873",
      "r909",
      "r910",
      "r982",
      "r1004",
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r82",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r82",
      "r739",
      "r757",
      "r1008",
      "r1009"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, outstanding shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r82",
      "r670",
      "r862"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized, 35,751,956 and 35,262,083 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r31",
      "r187",
      "r189",
      "r196",
      "r664",
      "r682"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r76",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Off-balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized potential development milestone payments to receive"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r887",
      "r908",
      "r980"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r887",
      "r908"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r495",
      "r506",
      "r908"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r887",
      "r908",
      "r980"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r203",
      "r360",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r376",
      "r383",
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r79",
      "r80",
      "r120",
      "r121",
      "r210",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r590",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r68",
      "r70",
      "r361",
      "r590",
      "r845",
      "r846"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal balance"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r25",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Frequency of interest-only payments"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r210",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r590",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r158",
      "r844",
      "r983"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Loan maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r25",
      "r210",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r590",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "auth_ref": [
      "r24",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.",
        "label": "Debt Instrument, Payment Terms",
        "terseLabel": "Payment terms, description"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Debt instrument final payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r25",
      "r50",
      "r53",
      "r67",
      "r68",
      "r70",
      "r74",
      "r106",
      "r107",
      "r210",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r590",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r132",
      "r323",
      "r838"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "negatedLabel": "Unrealized Loss, More than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r132",
      "r323",
      "r838"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "negatedLabel": "Unrealized Loss, Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of classified as available-for-sale and recorded at fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r130",
      "r321",
      "r838"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "negatedTotalLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r320",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r129",
      "r838",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of debt securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsTables",
      "http://www.frequencytherapeutics.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r131",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of Debt securities unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/InvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense",
        "terseLabel": "Cost related to stock options, stock based compensation"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r908",
      "r979",
      "r980"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r975"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Federal and state deferred tax benefits"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r908",
      "r979"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r7",
      "r114",
      "r151",
      "r505",
      "r506",
      "r908"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r908",
      "r979",
      "r980"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r62",
      "r978"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r62",
      "r978"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r977"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset (liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r977"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r62",
      "r978"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r62",
      "r978"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r61",
      "r62",
      "r978"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r62",
      "r978"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r62",
      "r978"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employers matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percentage of employee annual compensation matched by the employer"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Percentage of employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage",
        "terseLabel": "Employers matching contribution vesting percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum percentage of employee contribution to retirement plan"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r7",
      "r44"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r429",
      "r433",
      "r464",
      "r465",
      "r467",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r9",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Summary of Recognized Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r231",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r207",
      "r484",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S federal statutory income tax rate",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r976",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r976",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r976",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock compensation deductions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r976",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal": {
     "auth_ref": [
      "r976",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent",
        "terseLabel": "State rate changes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r976",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized unvested stock options, restricted stock awards and restricted stock units, weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r973"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized stock-based compensation expense relating to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "verboseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r14",
      "r164",
      "r191",
      "r192",
      "r193",
      "r211",
      "r212",
      "r213",
      "r217",
      "r225",
      "r227",
      "r236",
      "r304",
      "r312",
      "r405",
      "r468",
      "r469",
      "r470",
      "r498",
      "r499",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r547",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r610",
      "r694",
      "r695",
      "r696",
      "r719",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r555",
      "r556",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r555",
      "r556",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r374",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r556",
      "r624",
      "r625",
      "r626",
      "r845",
      "r846",
      "r852",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r555",
      "r556",
      "r557",
      "r558",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r374",
      "r412",
      "r417",
      "r556",
      "r624",
      "r852",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r374",
      "r412",
      "r417",
      "r556",
      "r625",
      "r845",
      "r846",
      "r852",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r374",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r624",
      "r625",
      "r626",
      "r845",
      "r846",
      "r852",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r554",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r10",
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r324",
      "r325",
      "r385",
      "r401",
      "r536",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r681",
      "r838",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r929",
      "r930",
      "r931",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r654",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r780"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange (loss) gain",
        "verboseLabel": "Foreign currency exchange (losses) gains"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "verboseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions",
        "totalLabel": "Total future sublease income"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next 12 Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubleaseSummaryOfFutureSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r903"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r90",
      "r761"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.",
        "label": "Debt Securities, Held-to-Maturity, Unrealized Loss Position, Fair Value",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months.",
        "label": "Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value",
        "terseLabel": "Fair Market Value, Less than 12 Months"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer.",
        "label": "Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value",
        "terseLabel": "Fair Market Value, More than 12 Months"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r7",
      "r43",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r0",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r206",
      "r507"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails": {
       "order": 1.0,
       "parentTag": "freq_PreTaxNetLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r1",
      "r87",
      "r123",
      "r238",
      "r251",
      "r255",
      "r257",
      "r665",
      "r677",
      "r835"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r206",
      "r507"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails": {
       "order": 2.0,
       "parentTag": "freq_PreTaxNetLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r330",
      "r336",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r336",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r479",
      "r485",
      "r488",
      "r493",
      "r503",
      "r509",
      "r510",
      "r511",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r138",
      "r157",
      "r226",
      "r227",
      "r243",
      "r483",
      "r504",
      "r684"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (provision)",
        "totalLabel": "Total (benefit) provision",
        "verboseLabel": "Net tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/IncomeTaxesScheduleOfProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r190",
      "r481",
      "r482",
      "r488",
      "r489",
      "r492",
      "r494",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r652",
      "r902"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r69",
      "r126",
      "r194",
      "r242",
      "r589",
      "r767",
      "r874",
      "r1007"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r92",
      "r380",
      "r387",
      "r847",
      "r848"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "negatedLabel": "Non-cash interest (income) expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r197",
      "r200",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r91",
      "r241"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r721",
      "r723",
      "r724",
      "r726",
      "r728",
      "r790",
      "r792",
      "r794",
      "r797",
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r721",
      "r723",
      "r724",
      "r726",
      "r728",
      "r790",
      "r792",
      "r794",
      "r797",
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r127",
      "r128",
      "r161",
      "r264",
      "r266",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/Investment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r988"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount of lease payments representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r986"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r205",
      "r298",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r518",
      "r521",
      "r522",
      "r565",
      "r738",
      "r834",
      "r876",
      "r942",
      "r991",
      "r992"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r85",
      "r122",
      "r673",
      "r862",
      "r907",
      "r933",
      "r984"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r170",
      "r205",
      "r298",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r518",
      "r521",
      "r522",
      "r565",
      "r862",
      "r942",
      "r991",
      "r992"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Term loan, current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansFromBank": {
     "auth_ref": [
      "r19",
      "r121",
      "r735"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.",
        "label": "Loans Payable to Bank, Noncurrent",
        "terseLabel": "Term loan, net of current portion"
       }
      }
     },
     "localname": "LongTermLoansFromBank",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r25",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r346",
      "r882"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Legal contingencies, accruals recorded"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyLossInPeriod": {
     "auth_ref": [
      "r939"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.",
        "label": "Loss Contingency, Loss in Period",
        "terseLabel": "Losses related to indemnification obligations"
       }
      }
     },
     "localname": "LossContingencyLossInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r88",
      "r97",
      "r124",
      "r168",
      "r185",
      "r188",
      "r193",
      "r205",
      "r216",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r232",
      "r238",
      "r251",
      "r255",
      "r257",
      "r298",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r549",
      "r565",
      "r679",
      "r759",
      "r781",
      "r782",
      "r835",
      "r874",
      "r942"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
      "http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Rentable square feet",
        "verboseLabel": "Rentable square feetspace"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r152",
      "r153",
      "r159",
      "r167",
      "r214",
      "r215",
      "r218",
      "r219",
      "r229",
      "r230",
      "r305",
      "r306",
      "r500",
      "r501",
      "r502",
      "r533",
      "r545",
      "r551",
      "r552",
      "r553",
      "r571",
      "r572",
      "r573",
      "r595",
      "r596",
      "r611",
      "r658",
      "r659",
      "r660",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RecentlyAdoptedAndIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted and issued accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r238",
      "r251",
      "r255",
      "r257",
      "r835"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r985"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current lease liabilities",
        "terseLabel": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion",
        "verboseLabel": "Noncurrent lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfReconcilesTheUndiscountedCashFlowsToTheOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r598"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r604",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r603",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "2027 and beyond"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesScheduleOfFutureAggregateMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Sublease rent per month"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r115",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r181",
      "r862"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r14",
      "r17",
      "r186",
      "r189",
      "r195",
      "r579",
      "r580",
      "r585",
      "r663",
      "r680",
      "r898",
      "r899"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r5",
      "r12",
      "r116",
      "r186",
      "r189"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r183",
      "r184",
      "r297"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities and money market funds"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r840",
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Severance and other benefit-related costs"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForManagementFee": {
     "auth_ref": [
      "r901",
      "r989"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Payment for Management Fee",
        "terseLabel": "Payment to director"
       }
      }
     },
     "localname": "PaymentForManagementFee",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r917"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r81",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "verboseLabel": "Preferred Stock, value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r81",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized shares",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r81",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued shares"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r81",
      "r739",
      "r757",
      "r1008",
      "r1009"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding shares",
        "verboseLabel": "Preferred stock, outstanding shares"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r81",
      "r669",
      "r862"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r897"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r828",
      "r839",
      "r935"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Payments received under collaboration agreement"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "verboseLabel": "Proceeds from Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r168",
      "r185",
      "r188",
      "r198",
      "r205",
      "r216",
      "r226",
      "r227",
      "r238",
      "r251",
      "r255",
      "r257",
      "r298",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r516",
      "r519",
      "r520",
      "r549",
      "r565",
      "r665",
      "r678",
      "r718",
      "r759",
      "r781",
      "r782",
      "r835",
      "r859",
      "r860",
      "r875",
      "r900",
      "r942"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r146",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r100",
      "r173",
      "r676"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r666",
      "r676",
      "r862"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r146",
      "r149",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r683"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized gain (loss) on investments"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r762",
      "r763",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r714",
      "r715",
      "r716",
      "r764",
      "r765",
      "r766",
      "r787",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r32",
      "r711"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of Term Loan"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r478",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [
      "r478",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r478",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r77",
      "r477",
      "r999"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs and Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r895",
      "r904",
      "r1000",
      "r1001"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Security deposit classified as restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r139",
      "r896",
      "r904"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r332",
      "r333",
      "r335",
      "r338",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r7",
      "r339",
      "r340",
      "r937"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Accelerated depreciation charges"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r84",
      "r108",
      "r672",
      "r698",
      "r703",
      "r712",
      "r740",
      "r862"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r164",
      "r211",
      "r212",
      "r213",
      "r217",
      "r225",
      "r227",
      "r304",
      "r312",
      "r468",
      "r469",
      "r470",
      "r498",
      "r499",
      "r527",
      "r530",
      "r531",
      "r535",
      "r547",
      "r694",
      "r696",
      "r719",
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r239",
      "r240",
      "r250",
      "r253",
      "r254",
      "r258",
      "r259",
      "r261",
      "r406",
      "r407",
      "r653"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r760",
      "r823",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock, sale of price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Computation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/NetLossPerShareTables",
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems": {
     "auth_ref": [
      "r137",
      "r865",
      "r1003"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Separate Account Investment [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": {
     "auth_ref": [
      "r137",
      "r865",
      "r1003"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about fair value of asset supporting separate account.",
        "label": "Fair Value, Separate Account Investment [Table]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Aggregate Minimum Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation Pre-tax Income"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r762",
      "r763",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r478",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ResearchAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r430",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r15",
      "r16",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Status of Restricted Common Stock and Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r106",
      "r107",
      "r108",
      "r177",
      "r178",
      "r179",
      "r237",
      "r389",
      "r390",
      "r391",
      "r393",
      "r396",
      "r401",
      "r403",
      "r708",
      "r709",
      "r710",
      "r711",
      "r849",
      "r881",
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r259",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance and other benefit-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringScheduleOfIncurredChargesDueToRestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Common stock future issuance, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares, Awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value, Awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, Unvested",
        "periodStartLabel": "Number of shares, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average fair value, Unvested",
        "periodStartLabel": "Weighted average fair value, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r430",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of authorized shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock, shares available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, Outstanding",
        "periodStartLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, Ending balance",
        "periodStartLabel": "Number of shares, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Options unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of shares, Options unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of shares issued from outstanding number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationTables",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r429",
      "r437",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareDistributionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution of shares (or other type of equity or ownership interest) made by the entity based on a contractual agreement such as a partnership or employment agreement.",
        "label": "Share Distribution [Member]",
        "terseLabel": "Equity Distribution Agreement"
       }
      }
     },
     "localname": "ShareDistributionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Options expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Options exercisable as of March 31, 2023"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Options unvested as of March 31, 2023"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total grant date fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r804",
      "r805",
      "r806",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfClassifiedAsAvailableForSaleAndRecordedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r28",
      "r164",
      "r191",
      "r192",
      "r193",
      "r211",
      "r212",
      "r213",
      "r217",
      "r225",
      "r227",
      "r236",
      "r304",
      "r312",
      "r405",
      "r468",
      "r469",
      "r470",
      "r498",
      "r499",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r547",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r610",
      "r694",
      "r695",
      "r696",
      "r719",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "verboseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r236",
      "r653",
      "r706",
      "r720",
      "r731",
      "r732",
      "r733",
      "r734",
      "r736",
      "r737",
      "r739",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r760",
      "r761",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r783",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r236",
      "r653",
      "r706",
      "r720",
      "r731",
      "r732",
      "r733",
      "r734",
      "r736",
      "r737",
      "r739",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r760",
      "r761",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r783",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
      "http://www.frequencytherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Shares Available for Future Grant Under Stock Option Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r108",
      "r708",
      "r783",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Common stock shares issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeiture of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r108",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Issuance of common stock, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited",
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r28",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Decrease",
        "terseLabel": "Underwater Options reduced"
       }
      }
     },
     "localname": "StockOptionExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r64",
      "r66",
      "r164",
      "r165",
      "r192",
      "r211",
      "r212",
      "r213",
      "r217",
      "r225",
      "r304",
      "r312",
      "r405",
      "r468",
      "r469",
      "r470",
      "r498",
      "r499",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r547",
      "r579",
      "r581",
      "r585",
      "r610",
      "r695",
      "r696",
      "r717",
      "r741",
      "r757",
      "r784",
      "r785",
      "r808",
      "r875",
      "r907",
      "r933",
      "r984",
      "r1008"
     ],
     "calculation": {
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r204",
      "r388",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r405",
      "r537",
      "r786",
      "r788",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r602",
      "r861"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubleaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [
      "r586",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r586",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r586",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r586",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r586",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r618",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r385",
      "r401",
      "r536",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r681",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r929",
      "r930",
      "r931",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfDebtSecuritiesInAnUnrealizedLossDetails",
      "http://www.frequencytherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails",
      "http://www.frequencytherapeutics.com/role/InvestmentsScheduleOfDebtSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r216",
      "r217",
      "r218",
      "r220",
      "r229",
      "r262",
      "r263",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r331",
      "r468",
      "r469",
      "r470",
      "r496",
      "r497",
      "r498",
      "r499",
      "r512",
      "r513",
      "r514",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r567",
      "r568",
      "r569",
      "r570",
      "r587",
      "r588",
      "r591",
      "r592",
      "r593",
      "r594",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r655",
      "r656",
      "r657",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/CollaborationAgreementAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/LeasesAdditionalInformationDetails",
      "http://www.frequencytherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r334",
      "r335",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/RestructuringSchduleOfChangesToTheLiabilityForTheRestructuringDetails",
      "http://www.frequencytherapeutics.com/role/RestructuringSummaryOfRestructuringRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r480",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r141",
      "r143",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/OrganizationAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.frequencytherapeutics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org//940-320/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org//942-320/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org//946-320/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481295/840-40-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479808/944-20-55-15",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org//250/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org//808/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org//320/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(4)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "50",
   "Subparagraph": "(a)",
   "Topic": "405",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org//420/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org//715/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org//830/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "47",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480078/944-80-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r877": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r878": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r879": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>139
<FILENAME>0001193125-23-196280-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-196280-xbrl.zip
M4$L#!!0    ( '"+^U;\3_D1W@(  %$'   1    9#0U,30R.&1E>#(S,2YH
M=&V]56UOVC 0_EZI_^&4:?U$"+!NK2!$ A)>IO BR-KUHTD.8BW8F>VL9;]^
M=@@K:Z=.D[9^27+GL^]YGKN<W7$T#3UW'/1\[_S,C291&'C!9[OUKMYTG8.I
M_4X5 &Y_[M]!?S28A_-EU[H=3Z+ @E5T%P9=*Z,,[13I-E7M&1<[DED>G)_I
M_0-D"H7G^I.;8_ ]353:OJZ_I\P"DM$MTP?@1EEEFL4Q;$?$EC);\;S=R%4'
M*GO-E>*[@VO#F;(E_8[MYJ.](3N:[=L1W:&$&=[#DN^(SM0+)Z-9UQ(&I.6Y
M?2]X2.F:*C",P77ZGNLL#.7?(6BV_B&$N-2DQ##@3&H+^ 8F+,$<]4.;2]Q2
MJ6,P@46QSF@,O3CF!5.4;6%(Q>Y5\'JW"'$%4'%0*4(A$2C3GU16( 51E#-8
M*:)P5U)A,.0&X7 ^BW[6/*4*;9F3&-N,WPN26][*OG0=$^09^D.!7PMD\1ZB
M%/4Z%HK&LJ9EB>MFG1<"!.9<*$ATJN3\;$I$G%ZPM<P[S48-6HW6NYH.R4BI
M4@78X.<9+;? AC+"8DHRD$>X\D^Y:T#R'(DP9Y;,$1:"/^Q/&!.6&)_,,5:%
MWJ;)QBEHA7(BRM*^(%<=7J.*))/\:2D%;G2#L1B-PZB[,7U5Z 84Y7J*)#&D
M+]XT+Z\ZP4..0DEC7'>,$++0'%]6XCFW$]R&VI-?_!E1RSN4UQP#9DCU^F$
M@R ,5XO>8#(;=:V&5=J+GN\?[=N)'XV[UF7CK07]^=(/EJ6[@G#PV'J,A;W%
M*F@?/UX4\:GB9E3I864@+;WJPS\F;C9T9OUS1KYY+$]"CQARLD5[+9!\L2F3
M-,$V^<9I G^)H4I[4XT5+:/E.=*!Y6H*GU:@57D$\2N DY-.#AH'D]$XT@0^
MG,)_->A]+A5G-9@2*4F<ZE&CE#R54;], WC_[Y+P/A;9_M!SK:O#2#GVL*-O
M, VDNL\.%77,G:B=Y57Z U!+ P04    " !PB_M6<XU? V("  !4!0  $0
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M_NXOXNLY+T<9CS]R20S@P9N^+8=V<^+MP@4X>MM^Z#5'OW&Y<?WDR4R<RS_
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MW1BA6;TQ;QD@@("&KTSL^QPN:]29;WK&%T9C2F4D'$'CNS&XB%6:I<ZPB%4
M;Q(8*B4\)&9HS.Z0FH%$IO!8N92O5I$?9#.4)-]=[5Z@I>L:M;9T:2,^OX9V
MUW)LN:-S6UYER9Z5A@]BZTG7+!-K7W%;8"^9]^V5\[5.PMK6W?2&Y4RL', 9
M7 .TX^OGM^C56+ZS4.7>L:X)UOF"5V&@L<__3(>7]E_W_@-02P,$%     @
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MZ]E6CMR72;Y8*)QO$VF7ELOVX;QPL0+GTM7IY?%Y'KTZX\;1CJ=Q'@+T6W1
MRL:(KBM_\Q!H.E<T4M%[:?3^PW8<FWPQ[*!(?@\IV[ 8^0.V?VJ:I/VW#ZI
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M,,F8"WQ1HLRBPD+3*<&,)DXGDQ/I0^ S9$R*IKACQEF3"-U(]WGV_/BR?J\
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M> NJA%@))H;S\G+")8!N:^X)S.\3ROLH07 T]FZ^NX3NKP#E)JAJ?'.&K9;
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ML!.W@)[O^4 :T$LXE=R83HTSC11#C5KX0.IBOVHRLGTQ;T2,O-EVB&8XFC^
MH0"!$)4]/!N>(2WQ0IA=;)0OAFGB^*C6-^ ).M[/O[,UX,\)^0M> 2\%68%Z
M16\.'7\V9;HC/F!Y ,9;'PA,'!@6R/:G$<Q,,WUL9D-PTRWF/W,(/3,WQS\7
M/@??"UZ/?3V@H_172(3T=X*E8]\R]G/LB8!*4#['OAZ""C/^)3 7)CF@8Z,-
M&E@%WP-SY$_8T%PSAJD?D:P6>Q*-S85J 41^L1U=+)EAWX'5QT$B!,PSA940
MPG#*Y5Q .;R74(SP)Z0,4(FQ5CP5,&DEONT1$,.>[?!V73U8F5P2Q*Z(K5X
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M ??F2[<0]W$.,0;%B,F>,&1V0JHH5N1;T0T?#&3FA.,8$'OLO$B 1\/@T'I
M=4_CKH6XS()Y9HM +LLPSSP<+M7^]@VDC/1+<7)F[J$?D@YF?B&R)="&V2N&
M0-S0>9SQC(_"J_)6J9EUWP3:QD B/ 0RZ6PA,H]+UA#6?,_D85#?I"F!G,SK
M=VS?DD0#I@B'$M%AHPYGQ2@7O+B%C\\QMX!,!05HS?)T(Y=UP-[W G=]Q/\_
M*1[5X:7]F<B#]]-CPCM%+N-,%ZK4FZ].5^5(74@]$@(K)GRBM2=S,[GL<]@
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M8@A"^%](G4@9BM7;@7)JHN2C5=QD- EOF$N61NNQKK_4])LSJ7<JC+#]R#!
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MMF>O7N\]7QVK.]A[L7/X<O] *VX8SA\A/N3_F>@1E=]0\6W5I4@9&U/M9'8
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MQG-$^CE##63!,&YBJRY!E9&.;AX.FW# 0[M698 %OS@5 '4,"H%JBBEX)I)
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M3HQH"DSDJ(A5WM&Z[ONN[GK50TYZR,F#04YN$G,,XNBO/^39C(MY_N=56ZK
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M#M,PV+H23;E97#I)P<ZA>J^?&$[O,.$VJ+VQU9^F>W6%2-A'>19&9/3D2K>
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M/4*:=/93UI!--"M813Y'F&M ?=CW]M=:3IU+?.[*RI!:O?_Q329MS)GI;<8
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M_MVA,8E=M/P%G2<L+.HHC$4"(#T2% LB\A-P.(.?7'!/LUUV<1/0O/E)!&N
M>T1XQWS Y)N+J;%)7..B66V>&T6[/#_4<*7[!R\N!A0S$+V;HS&30OL)!K)
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M_/R>]GPPC841BD9]-&[9K*E.[$8+0!V?E/G)N4-C<A0L:_=NS)WE)_4:(!:
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M:7[?,^VG$0@+F$<#< ;TM'>V!4W-L$VG.3\SW76U;FI)@*(_,MJGIIEA$LD
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MW-8$:9P)/44MMT5>CG5E0DV4_Y2=?20CBV;;CI*=+U W)/(CN7JQ'8L618]
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M+[I3@C,NE"X(R\58+Z=40I7;FH$ZI=N5-][\/EIW-EMU17%7 G*" NB%_!7
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MP89T*_@$7D\=2LK,4?V$FOL(RF&%T7<>G(D-BIH'B5LQ+M"X?]'\E+RC4JA
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MGVG/DY2 IPNS!,*G+#JTAH.L\<UK/@WGH%1A/!D1UKE("Z/2%YMK#+KI!.!
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MF$J(0'YR?C1;_>!FF=_S3=/M"\*IO!8"\9]^>/,ZBS8/F<9@,^XLWVW:\L"
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MT4V5EWMGAK_,_&6U)],A3[(&$U"?F'JW) ]NQGB!&60NP-Y;H$]E78$##UZ
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MD77OJJ+[3%7$17\^N9>=U@3C,KHYHIO"^/0"T=H^&D@=/AOP!LVZ*]H;RRX
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M$I-2#LL4"(+J3(HWH<1>O?E(R10=7^;Y9)&E:H'',E&/5=6/"M#)X5@1HTO
M&C=M%SE6QK2 ,),RJ#&&-[K/J.D2+1<"G/ L4H42M6CS2*\6WU;-[M!["M*P
ML\;G&EE<,>97[I1>?RN$725>NF;KBG5<;^%AD-/"B%S%C_H<Y(^^2&DE1)I2
M;?$BEZ.8\?JG7UM*5+4G,'ZJ4G)U%S;&#P3DU5\_,,NLVY9T-U8/J2"EXQJY
ME*<$"_\@:!S]A2[#/S0;V,X[6H5,YI:.H0R0N&<DS30:\@&\-F2?AT%&BY)0
MW!+3KXW^".OK&(,KJA=B^C-A>QCX>XLGT FQQY!P.L:6X>NX)DOYB<79,O.^
M5*M[1\ZP. R1KE0^D"]ETN(^LTANC9(.858$3;O='0 +S$KOR3#);'C%^;RT
M+X;A %[G*1FR+<H\B^19"U)-MW[I>F38 O@E#Q_A:>"XA>>.5FT"?6-C?$_C
MV-;=,[FH@KJTF4@D;1O.'3$KJW \ /S@J]\1'CI ]S%J;U9LYJ:J!X&K[V\H
M<:3V34[M;KK.GCC9;:]C&4_O:>/A0=;MKRSDII'@'T_2$-GK6!M#(J-F/VU\
MV^<7?-N3LG=^/]7R"6,\4@,WP9NKVVO&BC3DX(9?]=="HYO5;Q.#3?UP](6E
M,0X+!S_, J&T1\88<_;6\7V_[-KKGOQ*83M6UDV#LE!JHQL(6^Z@=C3S5SV@
MJ\4_Z,P5[!CKHBVUZ#(9/8TX/FE4#,8CDX7#[U8-([2"[K^I&2\<--Q="%7#
ME^!J$'(X?'I)'QW" 0Y?1V:ERO+;M#9!]3%J1_4 T;I/'E\A^K1ZO=AY?F]B
M-*4A7<UX8(/)4/$=^1-;3I/'V0-1E4KK<?8\LHU7BV^H[IY \X:;[GX@B#.<
M/HH=PL:O'RPB1_ORCV$[0:&'M:)G9J^0;L6L]3FRR[D.+%YG*]BKQ>NXL4&F
M'I@2ZJY[5XOA\IM)C% 'N!'5XKJAM]/KDY8UIULD71%P]#=])W90"3-FLJX^
M>$RHC5VWV'7WB*Z8HSL9Z1V.F RN&L).#%M F$DL 3(7Y![3"JJ!*GO@ -9E
MQDR".[,GY!P/_F<2"GIFX7K0^.'H!(@C#LP,P0K7O2<7TCZ;],U] X%?@](;
MO[ FB]W#B8Z*,V_&\1OPC?=A!SFL:2'3)]2,&FO+8S''/J[@?K=D%1'$\4'F
ML8_5.TUW?7B0W/?P:9H4XVL--N.#?UNF,)M._9BHR7"DPE'9/5A Z,:[ORHR
MPD^5<SK?@1UPNE/BINM'-<JA*Q<C'0N(EM080U$66.-Z&F2XZ+M=S?P[3*2O
M#=UYU$['G]48!E%$G2]:"RM">8[O3S[&U+CR3(:@NKI-;<VXF1]*.BCH7%L/
M#<<L#BDLCL8,4B$XLFN:*,!M"N]YM7A+WNFL'3W3IP\&_YE6PXP'?)M&+:)H
MF^"ZWS$ -KQ%(QDU'#HVDPVP7^3@\8'"3D3;E@;$9-Q[LM =+3;+C%TF"";T
MI3&]LD> AC+2D.A%H3XKJ(72(DCZ9TTNA )H]P+M9CJ1HV[%G(K[T KAW\/J
M!$5 .4X(!,\D.C?0AFD<!.A:6*226..\]-C%Y=DW"DN$O2+7)\%! O[-#A*F
MD2)J90>H(+MF*6CCP*2*3H,[0@E'0&17LR&MVQA#\H'S>X^^)W4BQ<>S]\EM
MU<C#J@#9QWESNB<8"%R\$(#SG2:>*@^\T.<E27W8DQ,>UF.HP]=)61@+K+_M
M4(\V*H?G^8"9<GU3](7TD^F^],RW7XW"KA\?LWHPK](NEP^H4A-!*0U,CZ+<
MPE)(<&2PB1%Q'HG;R9$;R??&*7U&CC$G2!AZ,J G4MZ<"8!85[#62EPRV\,4
MN1>;6P][,AWV;D+Q4QA5,G6%R NL:'FQ3+HY)!'0&6T7;(!:V&FN8B8M:VXS
MJ.XV'!4,(S>"$C$$?!^7,&CZ@3Q)FN.[KC^\COGVT). W^+$]X==K5Q.@$L@
MAQ;^7?6;:8Z)&V"",&.M1UHXFAA!AFE=$<=16#+P\-&!#?+,9S]N+TWH# 91
M!RP(QY117Y0?A@S(KGDG'4<?=JW\@#>CF]$6C$G:$L'U65J7ASWM.4*BB-I;
M2QYLCP"S,EN9)CF5C7<1WO0FE5*.(HF9M\LC$C'N)=>0G>4J4P(Q F&MS#8
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MW;L@HJ3R\)&7;[X;& L=/($*9%5WX5(VT9543PH/3F6L;J\KANNL*2^RCK3
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M\15+*'NTB1WG\2!$V?R/ANQ!4V$ "[(FP?=9+GX8JQOZU:[K@Y'FYWO5W;,
M%\Y2=F3X?0KGB\+@+;)"(*\9@]-'6T;<;+GIUIWP'1LEOF29O:5CV9*:N(_>
M4O/;;G?->@H"@PZ[QY=NJW=UHG:D#@\>;@DU*-L_%MS9^0!)_$X]Z_(O* RK
M"&VHFC:"RCH*8RF.8O_5D56 ?UIR  6$;DK8G" YCE3 9G*AGVYQX8M+<>%)
MARD>ST$@&9LXD8E;?D9^8&(D?)(@\1"#/F$<*9_#;WY8_*5NH:V^IFN\CM=X
MXW)BX0I_^?KUFX++2-7^\."??_;\#UK:!,6,0,\G9M-YN# =/O.=YA&X(JS8
MUV\HJHI8?%0+:0Y]?N#I,?/$BE-IWGM 3!3,MW<8H)'[;G481I]T\:DVZE'+
MEGM2(H@V"] )O'E:T0]7.>R%>NJ+WWWYU>>?L6X(\K,3GH<OX[PX-)YI3:0G
M'7R(I%[NPC*U&:,,*4:DT9>DG:_A7/3I1*D4[&"+IWF#(6U12W?*":A]$?^F
M5$T<8H!]@BWB9$C=QKJ]..A! X?G(-?'+2A%W>BX2@LC*>0EL8E?D23^[;![
M0,0B1@8C1,.S_^U QL60?82:)J?U;_0/;6"YP;  CX^444+5/3/P6*(^70E)
M4=%5_R5(J9'<) ,.5N3IWP4=M9%D&_5;BJE[>]-0DUE.UY8B-^-6V"$#C1R[
MZ9/!-71]@3)JJB\!T*QW%3NXX:9O7[X<TG&0,KOLA[>X65 15*FABLA&W%-W
M,FA2RRTC7MJ-#IUB.@?4<O2MZR3_\!4M=WW' 4:03[KHR<S0-S\\^^&M)H%$
M6_$2?MN'@.*^Z]^!&M5$S<^,6M4/75L<O"I3=\(6Y<-:PT)^MQZ[5=WSV>1A
MM9_3[[]I;\A#"%OPMMJ&]T(NE;8PW?>WX=JDR5Z%9PCG^AH36%X82O,J8OJ1
M8\GAHCI'%NZ59+94P$AZ[0,LY#OUL7D$W6=\\L;@U06+$&6$<E%$ T"!J>9]
M3- @TR9M06'0O?<$UQRR[+,$'2J"UJ_4M=D)(7;UGH;RD;O>#"EE9Y*)$_8#
M>CV22BT1"NG!4AD-PJ>)=I&)K:95D&D^;S@01'M2UEJR9< <*+UV,O0O*;DP
M.;LTLOU+/N^#:LW6>14GCLPH#>7D1=  E9P.=.+Y1P/S(&>9;"XS,D@X 0V!
MU"RL&(8)3[YG^1!R<"/^%GW,-6&3]C?(C.\Z'01$,-WK7D!I"BBS5C4_/RC'
M$ISE6@L6X0D3>%#=A>CT^=)U!N ,W52;4G0!LX<])+_-J?U_"Y(98AIQFJ0D
M_L._J1/%#0IC=UWCZ-CUD!8)7P^?S+TQXO4C)PLX H)%Q0<(FQV^8"<8DR._
MC_=;W#9]3WASA*9P1R*W'3]0<U5?+?5O>VMO9Z>!=G[&2?DU_?C%5\]_?_7;
MA?SN-]%S$7>%>,<I2<,/59P=6E@YQ=FG34_,9*ZCB(J#Q@M1HZ 4;!RTTA7D
M$Z*S1SBKCH<$SH8"_6ZOP3HUA!] '+ +1YM6NB9D*A()X3:IB@5VM-U$/R)[
M"LW4QW*.W(6NC2M#22<#((*/<6!04M"]G->Q)+26OE.%D[6.'<4?1RUZ MC,
MISZ=-F'C*9ZP)KRC"?#77CF2[W ,Q'4"S[!,P ! B65QADWP3O^VE(1$&D 0
M3MF@]H+,1*%G ZJ#9<+[#O4#+@Q(!DC\,4A]&)FG& :!1P>V=;+1+'H=*T.]
MD2:*> WH*_*1F*V9O(9B=U.+X^*S]P5P"+S".II26L\[;AQQ,V.243"$L*E6
MA,3&W^RQTSIRMMG"N)2.]]+0A$S89M-SZK%0LP A9T_;J6#80XLXAS8KS[QF
M7@BN%!-::1^ (#:F<(T9ZYI@M&?PV4>.VQ^>=O93ED>LV[NF[Z3,J&RCO/#!
MYYXMDJ8H,X?AX"D_,.1QO7$YUYM#I1PBDBVAZI('2K(*Z#('#0BR+\[!_UCF
M,Y4G 37H H;Q8BSZ6/,P/"DI2;<^?N-ZRS*PA&$I?]*.)<.1ROC*>6Y,(>3=
M$7:! )=:)5S"4<6L$J22FR'LO8XYV8BKC*!5LS$5G&ZB;Q!RV^I_@FJGMU((
ME*"%X@!:^T.$;!+',?,345,'U-$-QCNO>:#2.L3831L<O[990X)(2]#@I7"V
M)[]D5UI^=+F4X#UT/X:/QA(+:<=.YHLO%Z;]'CQD#9 Q.@*2*E_MNFX31*YO
MJ3H23&*X_Y -7"3E7%:5Y;-W'$C!#J;I8VNJ^+1SZU]><NM/FEM_(>Z'#D;6
MP(TG@;)3%)E$A\A%G;25(&=,U7\4= $\\,H^&HRFI1Q%.QJHUC6<T@B0KN=9
MU<56W'@9C[L35<66ND\.:=1"A"LIJ![J@?T)2G?!I-UAM2SK;77(')[G*JM2
MD#CT9]M,[;M[;].YC$F,-?2X5)I%RY'R VN,Y"4\^T_&*=?G9LZ^JPU$= :H
M)9\;WS=A:QZLG>@#>DJ+9O.OOPJ.^I>_??[EYW_XKR\^/^T[O0G2.GC&N:GE
M;Y![K#DN,:[[G^R7_+*^X*LLIQ8S:3H*0$?F+C7SYY%29,B$3U6C=AU!'7Z^
M:85#KC7^TVPB=2.M_.NP2I&U/[^DC=)M!ID_ CH#1G.BF*<!(9,@4_*%[:$F
M"L2R![<)-'C_4\\\7M17]'! U:YY>(Y37HJ8<R%$;+_;/1RYZ7GK(J<D#SCX
MA'P<WJV\KT ^H8C"HEW70E393GHU& [,7JZ,8$[!=ER\*)V<#+M\WY*O5\O
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MI[QG^(H)#M2H.W?%/,A2U[04VSB7T5W-K"+S8*8^C/M8.AULR?;;W# MCCL
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MAV<D*7: Y0W.PZ9VH;F86T5N<1#DEY-A._ NEE;2F*S,E.FV%$1\<,2A0;Y
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M#!P&,"HL8(7"BVPZ( $Q[*8PZ :LS49O2]IQ.:,4@>0SIDH_74JEZ3VUYGF
MY4?5H1\35FGB^[FBA[1T**%<G(+E<BGD=R2I% <>.]$'_/2XGPF'Z>P:0.U@
MV&QO(Q;1LI/[8',.3,4%J+X>1D5[<;];^-+/H)>?]%Z?Z+.GQK[6=O"LFZ^[
M9_IY<]62!M(3ZXG73V3&PB,.3Z6#GUM'4?OP>*9MNMZ)"XPW)2Z$3N<>VV@@
MU]%>II:]6OP]@L%EW]N:@AV,&>^,O4AZ003X8B)=.!SYP2AP;V8+I)/;)D?H
M"63C+'Y?K*PR%1@P2H>=-C$K(Z3']+'I6+M4Z0!H1,@L(0([-C52V57S$(67
M#J]HF+,#1B3.!]_<BY%B$DMR,IW*V Q^7FJZ)B(NR;JXMH/S^@DQXU4G1\EJ
MNFE140KM;%PM7K16S2:_YKH3-H=?- _RT=NW5]F^Q=2&=LR,-^G<.\V"CD-^
M?A*LK#A[T]8FX[DB6KWZR5B]7J5GD3POS^2%V9-NPM,921M7CJ &^S@A(YT,
M*#..DO5T+GC&FG9H+<-\=MDEQN<NV1C/A&_)=#,,E]/$66'[?+LJK=GD@:<O
M.[VK?RYI^5^2AX\X3MSM[CR:_: $UD%!'GH;'W!B?8'SM!Z^&QV'Y>>UWD8]
MBIY7;U_[/7DS=>K9Q($G TAXJ%TU_\3+-]^Q@>;T=!RH6O>IX5Z2^FD&RY$4
M7*:K7-:P< ,OV^3=6\^<ZQ)! W762O-FNCS)6^N"ZO,E8V5IC-ZXN#Y40,,5
MP\]:B'[P<'G2'[>CF%2X7"TSSUFM'E>XJ39N@Z9"ULU)%Q%,<EC-WHF%T)79
M@J%>>&0V!\AYQ81;V"%HM9K!\A%*P;X%WI^SYB1K&[0UL4 ;T=)) #_0FRD]
M$OJ^[1B @<6/+M7B2/(TK@^26PYYJ#DW(\A>-#OP):'#EM]],[DXIN,F%VZ&
M2#2TC.R%$KX&+?P,LG1K[?-HL#F,:U*V,$".@C-K589"9M;/!1<W%WZTD#;B
MI&0ME$(FT:&6'N&?.+3Z@[=S?K/@[+DNX53@E%T$7(/WG/PWMC-4=7@*&]?3
M(EX^J+BD3Z\0$!7H.)@QMHN.F^?W6D9F&T#^N+S.LQX/-$J39MR%C4 0P?P:
MS/F<S&?VHVS=<#R<SK1=XIPUB>)",OUHRW&\8]K<"M_C ,)U[7.(_L9'[(/9
M2V)U*=<C"1XL=EO=UK$H$:=1JA!3_BJL8'M<S:P.#>J=M]9,)QV_V%;.+PV*
MQ4!$GFBNF)947^]H0_F3IC#L67L:0<&&B%[FT+I?N*6V.<Z\TLJNH",#,#A=
MQH(OA8CY#MZ9S' (:I2N"!JSX /@=YQ<Y-.P2L@+23-#X''S$A/(#)=N4G6F
MHS\K+,M)H;^MZ\UP1 RJ6^(Z_)2+&5]>BAD?N-O7SUC*,GYQTOV\?@G!^0C?
M8$@3Y8!H$,]6<BCUC+*\ZX0FG^I.IO/4FT))@F5_U<,YAK.L?#4\E(H&<E4;
M\1"L'MEN#P/WQ!\;,&UK$1\Z>>:49%'R9"LP0H\8&F=%9:7P2355<1F$F#0&
M*#0P,^8(.90\YTI7B^]LX"<I M)>RTEZ9P8!H3=P_H&8K':3*ZFP[^$:Q-LR
M44&K:N#R_O'+G&/KU)5QTY2G9"K'#-C4E!0XD#@"\0.><M(C1PIX9%V,"<E-
MLC&&J;-(MG0Z33K[F2\07X]0,_*LA5P6-TD6LED?H^]TK+=:^$$U;=V@[773
M(SU%C!WQI-X0$/7).JV_QV *BC<Q)Y!Q+WX,!$F<T!:<2^2F'#9N.I[-##_Z
MC4B^Y%*8>K*F+N<QOY".!3D_/B5P+,EDG%X)!>>E:?,"V_T)L%WG#22UFCI.
M589[DN/-LKP=PR%(]G$P5G7=.H8/G75T=':C'K_RN#G86H(P&LC^TMEQ.0*/
M<@2D_@O2C5(.QH\WK7;!;VNY4RY!DU ,>V"QKI/TC_^0,LZZX/9GEVF/6:G+
M$;D<D4=JV2,7*8XB5@CPSYP"FLP%FN$]3^,6FH'Q?@<EGA,V2&R^P%Q%YHH"
M6-1+$D;OR\&Y')S'.3@I47Q>^ O!FT]32F![4V/& "B9N1!C)+.[VE?/LFGB
M/+C#TK"#]@.Z9-%%L"^"_6A-W--)\90<(< '\<V"U)^'TKAADK%Y.V$MS0<1
M;;IZB.'$=%@@4EJ'0;'$L2X7]'E/-HG)]%%'C[=T*.ND.J888120*YXCR4G8
M?_)0 *73EJSLY11=3M'C1M^*$:E;H!,881"CB".>$K+.;&9<E3NG[18"7YT\
M+NETH7^KI%DSGX^5I&HS(-?E"%R.P(<Y ADUM:]@3>'%"<=T1262AM4ZS;PQ
MM*^4JI0 /6ELO6L@>(6>F_#I,H5U9&,MIFDO9^5R5C[ 64DEV;L]7'?+Q=E"
M8*,W.^R[-FG1U>+J18(O$OP!)#@C%G?UZ:1\GC9'EMT3*HM7205X"*]=\UP?
MM N2NR1LZPD=Q$RHWMVWW/NBY9'ZQWW37W3[Y60\^LG0*K(U! N&1O+[$P"W
MT897O:INDIF+9%XD\_&8G7*/0-H/^ML$(G1A%+O(W2^D$=<W'24V0#,C< (;
M\D:H@1[$3@XVHWB"21?,^W>(\90HA[?'$Y%WH>-!LP<R4 ,RD+-]ZT_-?_;V
MAA%OOL\'31.#CH25+HFGH-/_1&'5O[W JC\@K'J*A5PTFW_]5=_=?OG;YU]^
M_H?_^N*+T^C(-\WP+L&>%M"LL;L1'=0*W;CNN_OQQJ"RKJ7Y)V,D/Q!3QQ2'
MR-"704^RPX$3/Z"41-X%?1!><NC:MMXIV4HUHEUSJ1\$%K(;FSL"P_QWT'H\
M:<F^]^0-+X1FN FK!I"/ 'X6DOS E*.Q&:Q3+GC<08_MJ?Q3WZX$=,[EH:27
MWG6UCG5U2\WT.\+[7-_DO9X0IJRG- 2709&&^+(>1T7=<3MI.B[']9[^B*'G
MU %*>7MTR$XFP BXUS?#";.;SI[AWL@FJ)&ZOVN A>;$*[4:?'BRNZ35GOKC
M2""Y7Y-B=5GZZ;O3)T@XW4G-I-A&9AX#XQ)9PEA?/^0I!VE;"&O4=(?!]<E]
M>^C)(::'(_G?[^ @EAZ09"1Y0JWW6R>H@8C'ZEW-*6MA2:+!6]W&H,DV;X"'
MO[8'DDON%8GST6T<V.80WNHA#M,D>[+A.7##NR8XM<+79].]9)+2QA5,EXMK
MS$XJLBZ=QUGE5Y2&JTNJG)LI;VARDU(.#O9F^Z[;@6*#Z**&NM0=G#!-TF7
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MAP)[2 K' (P\A&64JR894-_9/C?7/$7%J)Y1GM0M37S<#]EA32=*S-&P9J$
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M,D@N1=43E%8?+E!4Q[386X+HY:&8F71D_I6 P]%OH8GXH52_:I+3DZ*5K-3
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MKRA6.^#I+XG,W*W>.9.^]>@%E4C8?J5SG.J\A.49E"7C-71C+6(@Z#><1S_
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M!KX%ET5H]-@BZM_V![+1G3F'Q%^SJ!3CMBRL,QR%V#$@<GH)E80C2U]:E5$
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M^Q]L%VF0=NQR&B+D8(+&A^#)4#<34&^ZS*)W!T0EP8>09F)TI\1($MX]C$
M<9=D^C% %$<3!!0VY%L/\",MDK,'T9Z;F$6 &-"C61ZJ\:#31&96\)'['-[Y
M&4M>+(2 SJ=_0OH*C4-'+WGQP ;I-3^RX7ZT5N+6S-C;E#DV6^?J]^PGS:<L
MM-+1E>43!#9.XJZNT/(M^.32%$!Z*20V0H-==/LI@&<%Q)DHS'CLJZ, Z>3_
M;#O3ES=?S5KE6*7^@>K/F^UXP(#0=:E!NA3?-#T529[*>>T"VZ&?"OFA:EAR
MI]+.T#E^W"I CZ^2O$KR@[%=E+\#P,E)<L?NU9+^#"*9!Z&D,2B*./+-=>X$
ME"(4=T R'<:/-X/M *B:/UA&P)V_YI:6*\19[FP'TL0'7P[QG]$;)8[KQ$]$
M#$[+ D@PUB6QS6H9UOOTCN_39#X@?8_RT?G@G7L0!-\2?$E\2XB'7;DK.W*6
M0@2,"I!@_^&C\*/X:J&^@T]'3!AX"DT <)Y!S)529I"'UHY#L@*IEXS;^EV<
M/?:<ZS'3\C5%E/4X\&K:F\;Z9&Y)#$&[19ZH6^_9>L_>\SVK"3N"?G\NAM9+
MP /N7(B<7X=5>E?I?3#I]:ESV^Y!OU ?AA2H0NP--^V385]1V5[^2JP$C<P-
M-2ME!K3@EH94$(+K0#T#5"( KC22S27EX&^Y'^$O>9C 9S/E[MTMMQ4W-?HU
M"DRW[H%?[U_7Z[9>MX=)4CF)W5>7E0Z%1LJ=A= %*S<=35(TC%5) %WL_.Q:
MFI]/?8;[$BG5VLB]D[8 &N\XEJAN$9"V@1*W4<IJ3E;Y?FAS(E@,0 1/B."L
M*D,=4E1V++@.+"$[,89T[JN7(W;!C4WW"F9^NAPSW1[).?686_*_LPH0I1OH
M0OIZDF'II$G_MN?[YVNVVBL6@56ES<W:,;Q>R0=C\+M&/$_XSH ]:K=E$:9S
MXWM(@,JV%9&:/KJ">VZ)&JA!-V;@G10"S(4\6BOW(( XR= FFC+&8\O&*EJ#
M,B6(JHBNI2\7,QDAA5-Y )/QH;T.N33$DLF-T'U;5]MJ\#?4K>MWX9?@-"+#
M$?#G?:VSO7$&NA8',GHUTZOJ7HR:$[C!66#)3$G:5U _A%9D'GXT3C.G4]#3
MB8*  :G@^GF <4!"]K)$4X>\[9&(&"RK'FK>(6N41D66]HM+TK-'3&AH.^(M
MF X3H+1+@:9=$$#@%?5'TLT>T?IX)()O_WT"S29?93"RAC(_*!*;V2W,R7<C
MDRE'O0HT;L^"T'ODK8FM<%%+G3.\-72^H"0PGJO]\DN **".DX2F6WKPY'52
M0',?<Q_B\[4/\8_V(3[<&,/E#!:Z0ON' F5B-$K[?2:#XHS!%ZHR<0P?M2$^
M?_JY.G[?_>WEWT.EA6,H0+8";-']HB5UC8X=FI-G#)EG7_Y'NMN7X,:HOQ]%
MF7;P:38V'=H<Q^,"EYR&@STT;#R@%@@D"P;-0%!BIW@,IK$H]!5A _@5Q/P4
MR5>@EUU:M.<EH(?]A*:IL'2!>>S#2(X R7G )7>Z#;4Z?W"M:G^D<>E<"JF0
MVAZ%TA28[#!L,7:,D1S7(=TQ2RM7H*#R+-[":W3BF4#F$2I2^C^N7K"EG?Z-
M.CYS)O \-*IM_NDB!X1286&>K#R6T(^MW4R.0OQ2+],1*&*/^BI='IHZ#O.<
MO<TR4O*C%L9'?X+RA[O119C.QQ7&O8!9X0[-R0:'BR])%NA)+_?D.0=TE=>#
MK-QW,LY@QQD_?2X]GSX3<!-R%=QQTUP3V@6WVM886*<VEX"$\ZB8E^4^KW?9
MYM/GYAGR00) %)@WZG^J^-O(L#EQ0RBZJYP;7!%&3#%2)'O#;PNRK9TPE_@8
M6,+F/@N-EGZ6CO;P+,.R6^'G=UEAWE4]XS@'&%3Z@#<$L<Y_2X'"*]RK?]&M
M_XOY^@%5)<BZ&8^F99NR0>B?^4#$%T$![&=2!G<3_O;6PA"^ZM,O[[*_4P/K
M<=SRW2ZO.D (#AU@T7X#2,Z=UYG)W-M$P,/!>< _/\*')?6&A80"BH"=%1[U
MS]&)!362^R3*EN]A)]^B8P1Y<\];FLDSC,F]QQ6/T:X4=YD#VFC1D_#DMD)&
MK.\>5MVQ'MN5!<A1G8%PQ[T=U,C)J_[68+8";XQ>=@ MWE%/7I:+AE+:9]IZ
M#$N4Z3*">8X%%EXD_8D(LZB&9<PSQ>]9D$#!&X2%C1(+7@$8^WK9V6L#2SNQ
MK])$CAF#WICA,W97[_(=M>I"@@.L/B0G(]Q<XK#H+;*FCB DOL52!(0YZ B%
M/0HAR74N$IN1OB?LPNPHX#3L4,8I8G!NPA4G]5X)$PC>!X_.8D:%"L)(M#+"
M;P488.2=-@WUZ29O)7,>S%='NXAL!AM "IQ+Q-?N7*]DU*F3,9">=8D9/I8+
M8E.T<F7 M10+E$_[\BNJ!(L[6+=;7';2.I/IYC#*<^DG,34WC.D;VJKD>NV(
M29#%R"RS>FQ3 XX1*0YMGQ@QV^,LTXYNB9*#F5TO/P;F1X+4<=T&P\%)B,C"
M>=HZ199F&\#\ X9Q4^'& 2G6]IR\88^0$VN-J#[<.MC!  ^F%33QGV;7)O-6
M1<2X4E*QY1>F7%ZN<(]WM^B*%&)6!S(]O^DUI)S9N]1^!*MW4S+-\#M<H5O.
M.?MTQQ?PDC\E+F,R$Z,CE(6F;[<<*"DI;5L#'\)L19 R:V G8=2,7\M2%64Q
MEX<:97.9VEV@/3H_WO=.HM]-5?SGG[KV\,67S[YX_O7__?S+V^/AOPG9^2N:
M2_R!YQ+?/LA[M['[JYP-N3U_(77""!;L/KKUY+*<5U@9'1L[,<B$^(/C$T7B
M).;LH!G"AN;&]M)?J+6*H=SNF[9NKP1CU%TDJA.8JL9C1<Z_ 0(!UX! L '6
MS!P'$3(C@8$PE=^$>TDA *8WD6^"Y)N)D:L!C*0BC^=1ILA="R&I5GC0/F,,
M3[E0^ &GZA40@!W,RU%<N(X&8\*,KIJ+NLXO1??0R#R2Z%=$M5 S%AG_M9,>
MXGRA)]L'><=)2 3L'*KWT ,Y&GQU<3O%<R57%E%08 ;;.3=S2K\2;UU?EF]2
M,BSXW,$(2^W"JQJ&K_7O&)6(W=O32<4SKY<T\WH]YW(CN]F/Y-I5(#P>E4C-
M5@\HON$"3&#U(HJ$CSSE__F:\G_4E/^O;4#4&::"V>6@ODU<#D]I0*%J7I=6
MI\!MCK&! SL8!\T@C9\TOGHG,W1U(ZM1DDNA23AN_A9:A$E#.@6-AH9,'!1,
MJS(EI_>)!%_6M*IS$TN*S5,L2PI_WGO:D7:)%2GSR_G6>MDC_VMF/-01_DP6
MS01-^5576IQ</WK;7A//&3%[40PL50PUGEQ4C&)@M*;X-'BNCI:RRL*+ZR:6
MG-XBTR*EGCK(NMR?H+6@[0PGI"> G- LS"6(M9O*SUU,!KB-Q!9EL2$"NV[2
MF,@H:-4)N]_<9$Y8?HPS :(=DMUEKR*#;-:4HQDYN'%*>7#!A^AHL=/T/F5^
M6'!"Z*=7'3@ \1*"AP")]G4'099*QX(3Y@?&$>.SZL0[$QX/23[0M9Q6PA5"
MI.INA^NY]0^*_.24U1/W/][!8DB?P"9GTR&S*S?W$8T@:Y\+47?F'5<)W0;2
M9*_NKN$\M01V"T[@CXM4&1#<N=S>[)U1)]^J+&Z1)S2897Q%,P%40<>,P%N5
M\P5%BP_VGG0.L9 [0_)O5F%RIA]R/4^WQ)#829H8&6MS+TVRT.,YF-2988L2
MTP*\#XJ+X '>=&US1;G,$\\+<=8.$(2%YR,99M ONZERB @!R2,[^V#*;UPQ
M !U :(@67LV0NT?6:7/?&=)TDB"4K0AO'G_UH>H-DU A#UW0./HXV $[$'4S
M,>;HAT?]$_'539-^XF.%1C])N6JN 1:D@1EE@C@@GV( *N5CQ0:I=] H>&4@
M'L ^=P*Q+4>&-Z:J6M5Z-7^R\%\A7:@ ),X>::M8Z$\SOU@,.J1YRMTCIU)@
M-PO0,S>2WMU HTIS'M7?QDNJ&] 4JJ:$0\'.OTO%SW(GR>E>JFLDT5_X2]@@
M< RU5;XY>T/"^$2T!O^8D(4QPW^&](W%MQRH*FF>>[%Y4=/TTY5-ISN#KCQX
MP)JZ10]DLZ.7S++B0RY\-VW6K0;LC?O'DWU[HW:+<DBTP8IW775,3Q<QB"9L
MP5SQX:W83;6'-5,\<VVS</,C0!NKAH*'NW &?P^Y?%DN,VW2'\)V[6AB1W.K
MO&9^B_</DA7=(F:"Y-1Q I:96D E-<3YHC/&9*8^]FUH]( '[BN8D5W>I8\#
MXHO>],AS)[B2J\;G/A<_:D2I\@TGHULM+J<S0]PRA-YWGTAMPC>QND!%A$S:
M":]#W/!Y<(KZI:^_S5"DZ(_3C^+79>\K;((BT!^L1^N\OMV3\$;P\O'6W-F@
M0=[L8B$U783:BMI2+ZQ3LR[2[&]A*8_BD&=>/Y@-/=_#JBY8U->^-*;]N*QY
M ]^<LLDQ$JQO"SF7ZN:,Z3S1+9SF74LAWRU>XKNYL=:KWKG8EFN%;D'FL/E4
MYK5#&!1_XZ4%&6AM;<.:K,@/+G29Q7,UTXM+Z)863PWF#5%W7'"XV[&HE:?B
MM(<=/;:"7S;9_=?+]UZ6XP?>J>Y9L&SG1I!G@+O^ S;@\)UD$DQR7,>IYO H
MP27V 449A[8G$RD9'!E^H+F\ 740Y6!]7DT7(G<;RV$4@RX9CD=*F(Z3)[JG
MW0DEUO<#7*AI_GZ68:W(4[$:<UGHY-Y'@A>5N&/"1YN$#XSI@!9$1L)T$@TS
M;O@)5OD'&K%5O<FN&_?%%L3-#K']%$&T?RX%9N^%F,]$DP2/%6C\*#R=>>\"
M<Y,P!+:8[U+Q58V%U]^#D(LF.%'RGM:C ]IFP+?.E:MRP@3JIR$$2M O29#:
M 5)*/5DR8X=;5I<$#QJ[H;YG.PYCH)#B4"<L#QJ/$GO.46S(L!JT#0Y59'T"
M>$FIF*H12&ENAOZX*Q!?K!6(1ZU Q%5/\$PV8/T>.RD9]MJR1B53R75SB9!=
MUXBA_!+N>BN, 1RZ^"8K#]=)[E1-W?;N(HB;B#9*=RN(Y+-"0UL6Z@KV"=+'
MJMTL=_+5%EPU5J)4K]T1&</%YK\F3/?NUE]75VW'&8VY^2)&SBB91&[S9,FW
MF[*HO8@Y10O.EP2^C6#20F9V0+CO014\^7OL476':'\F>1':]K&1SOO!-VD>
MY47MQH<T"^'%\XRQ;5"+7[@N<XB 1>LEY<7OAX2LVB3?Y<RJ[@.TT@2)'"P5
M6+T+&E*CU\GK$]KQB+?3$E-31%7UM W8JV/5Q'F=I=&]R6YPJ4T@D]T^CH=R
MSKS\&';\U_W=H)PQMK2K1S9OTC#M2P@LNLP\+64VV=G6FN*PSZ#N<#<VOR0,
MGUE/J!'SG7;@H_U//T^!^19HN?::O^W99=&7.F$O**19#$6CGGX*@I 4:J3-
MO9(BISM5> G],!8*&!ZZ#E23462'"U:6@V+ON:_3IIV=?^6Y2-W(D,R;$EI-
MQ,AMF.5B]\K7;]W6Q19<_^P$%SW:?EV0GI >:]O$ 3NWI1I>=PX=J[ZZ]/[-
M$''7L7AYS4:_'SL-$L*(JGU%LBCQI4%>X4/E*K>7R?NC:0T1^CSW[@OJ4P2%
M_MB*X&W7/FE9QOT<E%J$O-Q)>[5[X$^D/]AK_?Q9MGG^]/ES :IP\G27M=RX
MM7SR_.+9<[J(XFOCJJ6>_3F)*S[Q].++I^$3J=R<E<.JUWN&R)]&H[FQZ3)@
MV$M/L@GA0@@0;("(L=.DI%,\>+I,8 M+.-0P8E[W7>VAVBJ[PL:S]UZ6I];#
M^6.(?N(2<)(7K25X$7EJI3UQ-?-"F9B%#M/8^&RICH.4@#_G>>SCI)!036YY
M:;P)/FL"P+%Q,9GV@]/< ,$B='!-!B8U#FU;0>U>;+[MVKRP&^?MCVX<TB[E
M%68_XMZ4VZ;I,[$8M0R:HB^$#<+":CXXO?0Z%V+O//); [OC[5 $XMN[]]R6
MQS#4:1_7XUL$[W_K;'X6Z?: F)!J T*38%T_EO9[=SLD+55+>R/0#G>21),M
MHABKZJ8]2MQO<:Z]S'CZTD45)TI*\Z)S:G84A_NV]C4='N:ME8E-.V'/J&O2
M7;NNA"JE.6_W :0Y%<[1=V!):^B.6W/H#B)#B(U=FGK*, ]^9!<6&7&I$NO$
MN(P<!ZXLM R[B%"G EZ-;BW/OOCB_&"5\+2AAN2W:R[2JJOM/#I8ARJ\$BD[
M?MFRL,UGY8Q$SWC0%)_-@S^R>=WYLS-?;(R475HXL9^/4@,)/WH5%O<:#Z6I
MN.@O?@DJT/Z)O%G942EP%QIR/'XN[W2B84';&T50JX;R-%0M0,<N+@.GOBG]
ML"GKZLH#F,AW0.K-V])()?,MT1R''K7_CZ^>/CMS[C]Z3SK<H84-S^6:A'@
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MS L>I="=8>9J.J'U8HHE[]<;SD XM.N^%1R[4SO2*@%WB@FU#FB(]"GWJTY
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MW!\).)5>-D:_F+N :JB".B.;;&!!T SE$3(N)NF%AD>GJX$NNX2'9/;GP"S
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M8H5-292N@?NFFIOL0@\4UVF6Y6.N7_QEK5^\Y_I%$$ !Y4MAM1D@-BU$Z]T
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M%8\J8\0_N=YPO)I.<7O\_D_L)0];H5M[;A:1TF\0M;X>>*LD@C/%WYBK1<#
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M8J)\+0TY0-U LIEWG4]SGO2,0]B0,L&*57"P<B,]9/#(2E,!MX*RS&_RSE-
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MF>IT& EMT,HI>ZC-P-(U%E5-/5A<'E%,4Q#Y1$$744NM/;PK%<, &WELCPK
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MF7YNVNZ-U +CSCX#5NK^:]_V1RK>]IXJX^6KGWO-CQ8*H[3JYE7<WPU(0#O
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MY9'.O0@?**?*"_?Y"D,@V[3'9:;L=#Y_2]A-^QXC,@>"8YUZB;B,\X#0RZU
MD8>&>-"$+@Z^R,T@:7:CRYS! )\ 4/P\KN'TE40!=HTZU@P?2[1%$J*--(5Q
M5&8/%7^G7XI*&& L8%QY6^)($V87Y7)R+T<8H2ZAF*/=QS N6B.@>/Q1>6&7
MU5,8["98MW[3 *.LL[SA$:X;VNC[&Q%6N>;L*AKIQ!PK-CH#N!,-D# 4+3&
M]UE/X'[YQ=S=^\@3N/U=EX47[(;"<JU$'R&?9'^ :U@SD#O)HE,_71XM*XTJ
ME%#4*7I:K\-WCKU1+/,^R6C&O7XFDI#?&^SYN*6*LZ8=9XD<6"KG8')F)EDB
MK4T>)CO7G2'4,Q$-3)I&_I>)Q,>2\RI^ -Q(:>@SQL$(?Z,$)LC;0C#T;'/$
M]$G)-&,ABB,ODD:NN\@E=VCJG<XNZ-@MLQK;DIQ\-%<T?]5SNUB\XR=M4CNO
MKVOB@I93'/0I]K)%<@XK\0DF>],A% .RE]+X&..=*VQQIHR/)#HL&!]F4J,S
MA^=QWT]/>'K'3O"!JS<RZY:R-,)0A0I$3?53:4V7DC0*(L%0@N?NPM>5>Q"[
M=S*%R-5P2%8YUI"P&YN3-(+;?2WS=Q-]*WH?^VV]\B/Y^YO3&+Y4=WAK89\\
MXWVRKT\41'&@W8U$EPD?Q2]3YQ3TD8P.DU[L3HBKW*TF'"2M8V4!47@<GZ1R
M7G_BH&8JYI60<K4IIUI4FYG0%(7[OVT[B</1/:BW.J1P.,FR3IZ<"A8KLE<>
M$1X3!KZ<6,]3L[2[)?&Z4S[Y\0^>GZ=TIG$M9-I>CDI?M.>I'DW<\-BJ '!F
MG\I,R;_.S?RY??GNVO.TZUOX:;$PG#?[@Y:U2G*+E3@+8?2KW3"FKW:I#)9Q
MF[D/$9,%ZA7->@:(S[;\:+:<"!!VA*'B(/>R[IZ52$7S5OPNF<U$C' VU]E<
M'\U<F5E)>Y9"'7-> JL>_3QZB6R)!S]'$6=0X0>OTQB9(72T=K;HV:(?S:)#
M-,I<D972(W2BW<'3N4)C +H,-_@[V^!L@X]F@\Q]SV/>MTTG:B7D8VN!@Z2,
M)V<][FR5LU4^FE52JA_66]OU?N) RAN>MH *4$//4@<3@Y4<JQU$!+'?-HSD
M839&)ISA?KEG0A"ZFMGOSA;^8:)9F?A1?ZH%S04UWXU<"KB*V>YFNWN\I#_3
MP;JFJGUG!/B3DC(W[(GX$]F2=O^2@O%LH+.!/IJ![@>:D[C. LTQ$TSW:3L%
M!<6D?1Y>FFWS@SI/;W81@.7X1!49:Y3(96F4=)")"OZ^-8GK6:_ $C8A3#-R
M-6YZCDJS1C.[\4X^A:FC,DT[P0T@D^JU% ^) KUT^.AWK'L:VX"F)<Z]]#L9
M$(Z@#5:55 9/R,S1WZE/+YQF$UEF3XU<)BIVLMG)Z J(XQ2$DBJH@F_ 4ZU/
M*00*4TU7GQSN@F9ALBY],(ECR+@@0P+3'17[VQ!CWFUS"<2HN!3;05N9FVO>
MMLPUOAZ.U\'4*<^+ G J6 .:8_J+0QV48?8IIBN%P70G_A4;,-?M^$1 C/=9
M9)[$J_?MFOZ=#!0X:M"^,Q8XNR)]?MGV#LI@>)\J)-HAVMM!IRJ\A<-1 $8Q
M8*0+7(<MI"@/8>04GG',W+6W'"R*7-9GC?;\<D9[?FRTI\/P\['(JG5R0&0C
M2UTPS*ULXCB1LLL/W\0),;NQ:(_).4$G+OY9=DYY+$)V'>%5"!0X(TKFF/+=
M8\H=P=E4(M'.?@'0F8=F00$WHQ \>Z834Y,T 6D0L4:'C(8H*.]4^;U2)0W^
MLNI=U*V>JT^SL3^2L0-;;-AI-T*.Z5S$RH)J%J9,1L0^2"VGNCS#&Q5]O/9V
M!J5NT'/(8Z1Y'\S[X%'WP3D!IHBJ1NV_N:4&%%&+L%@83;2C]45% 9?JS'8Y
MV^5CVF4J=-9T-OZLG HBOLFAQNBT3+D5,)=<9XM\)(MT0M&WS40,NJ!453LY
M:QG&)FE',#S82!?3%4E%PM<V/H4::3:?%H*51FL]L=)#E M4ZG0%*^9EV ;K
M6Y^R;8N^G9X<4@2=SI-HQASK:\8[(H5(SJI->=OSOO#03*JES@0CG%./,N%<
M> 8,#\7GX/GZ.(AU51H$J5.A"M-+X^N0CXK%7QK,&]+T1ZNS,AZ8"*U+A7_;
MJ!08CX]6Y?5Q:R-EPTB80)/XYVDNAD8GQ9<JFNF*_= 2"V^<'\@/#%F-M (>
M=B )L''$,B.L=LPY\NK'?KO.ODM*,4@B$\H+IR<?2Y\?=P[H<IW%6UP_9-7<
M!):>Z[^Q&GPXJTBY]<Q#.W:(\WP-%I]A3-1U'I0[+2JBS 6A^<1[!)Q[REOC
M.^*Q$Y@WP-4;SZ#UV3P?W3R!"X:3U5# F:2(7R;*)]JX1ND'Y77^8M3?8D2G
MFO,]@,[9F&=C?NQQ3L1)JWZ/RGFI?*CAGR,ZFNUPML,/ RQ2( \9X^6*-<@_
M/,W*;)2S43Y2,;!=S6)ZLS5]D-9? BF_::_!54@Y]\CG;P(MG^O)LQD^EE.K
M#\R$/3*R\E.J]YZM>%$V#X"8U0 C<!%#[:Y )<BH=ECX9DZ75+E2<.L#-+(]
MP%"7CI&#@GF](D7[^!']9;IYIJJ]7&5<],NQAR)[B+&[OO._Q] XP'4!@8'G
MD&R2*IY)_RFB!](5*<^K7BU>'[$,<;D=,;8(RQ>60\B>FFPA52Z9E(9V84]S
M,1A>#3S&A'8X$!^HDMT[]HWF;;,ZTO,7L,2?*/R7AS2HWCD>>9PR<>J)#Z=.
MX>&(-Q42^^TIMB;,*H '%A[BJ\7W(1B&@+@1]:*HS<3/<0;IPB\F;%H7J,RX
M0F;\SOPJ2:O^D+\CP:"+%I;>-XM4K 841;)O&%MA1E'X]+S>UI0!N>'Y55R>
M2A1C2IP8+%0I-NGU4,+BYW0=;V-P+>$XA!^@18D%RK2CY"KP.14G**0CYL>U
M<ZX6SU>K'E,#U-8P5N(IL[+<.;-/AE]8$DT-C_M6B[#*-XMUOZ-AA!5W@L!Y
M*U55HL&ECPGW6U[*4J)Q^V4O3AU7;%^WZ,")J#PLNB'07Z-\X6LHS5>*03J9
MJ S2O6"7I)?F:'KY6]R.\F#9BHDU^6?MI>+'_<!?U-RN#*RMBO=J%MCAS> A
MWE.CN%HH&6/\WJ@\<VOFP+)=_UFCP+^:4> ?&06>^J1Z1UQIGI^3$HA%TX$<
M'IV0;7^74BE&]EI_CNB@H2.3/?0F9%2G_.#!D70XGPEZ<!LNR+[G(8RY1&]_
M'/&3#YBEA4N\K)$@%.SY'I1=1AR7 N%-#JM<98$]I=+FGJ<AEC '>I2T"M6Y
MR#&C%),#DYZ>Y +.W4MR G]\YLE?*+JF-^<[QA:*'$["#[%68O@'Q3N7 IV.
MCYHI<S]=YGK;+^F@N5K\+"3_!4KUY%!*!L@&)>H'@\5Q^5<99XB9=S*\@QJ/
MLLQ[_RZO3@KA44.K ,40&B,*@&@OA>#X)OPO* !!>8.N'A92] ;#48,@>51T
MQ80MOEE\]VNU>!&.M77M[B@2) +M3K3++=3BP@'>,8'^_GB VBB=5GI.ZQ9G
M+M2(C%>&U]$(9<_E"#\%GTQK5B5/2?$,!>JG;!JJR,E:%1^V'%_0D%H-=(.(
M,+BSG@,,<GP0:^=;3T=DPM<Y>(6-)19JF<C4VU"W+4:T#C8$$K7(71N>X62.
MES.Q?C R67-GX:GMTN>6M1"+]AX1KB].7^C(F6[7-2!3CL)&*FH@@SIG:%]%
M8T'P._26^KMZ6%O0%5>YRBVZ[3;;H\K6JE)*Z26K)4V#NSPT8^?/P*%@-=OF
MNAV5A(FG2D,*A%, @)7;-KP?(5=?':')H-@LUZK:#/6NN>N'-UAW;_C)"R>F
ML6:!,D\(G^[)]*89U#>2FN(?OOKC#S&6?&7.0O[V4G.!5Z+]\J.YSA=JF&$#
M_8*E?(FE?,D)QM\7D@XA[EW\!.":S*WP?X28^N]=4,M?^(>L$I X;D4"ZBO[
M)KSAQ8NA'^5_OKYIFVVP_C_1X$T=W%$X&\+_:PZKJW\@.PKWB55^J9HG6,\O
M_ZAYW3W+JKH^GUQF_^/&4Z#WX*(G=*!F:@\2<#3P%%6J=L&M(6$@QOM#<FR<
M%MANA2S=YKY--^&L%.Y4&9+GKH\$S'KR1-L7'O[*G@L9HD4 $;JX;_J0XT)5
M5"6UQSBY6'G5)68/6H[-P7]1'*+[4G(QMZH3J5)#-.(B]ZK\5>FD@HWO*V@Q
MSO/3EX15'?6 L(G#TE!0HC/;.M&#4PV^C_-KN<0Z4B3R4=/<!G\OSCA]VJO%
M<W.I=)(6"G<?AV=@? >B 2R9MP+UF>7PZ+OC$,(]MOEF.S9W"%Y1)$9Z<CS(
M0H<,2'<=WY3N%/L!KZZQ:RQKR6SA824T [("3AO/3EDSYK?W"I7A"]>U4 >/
M=/23O!>"$]%(*"<8CR0 ^PDJ6?S'3;MM?"89E<W"<?U& ,)U1&&?B7,L+/K^
MV^=Z (9C%&^7J@OA(@F\)=9_X@B29QX)*QM,/E*,Z(%9+S8UH;MR251F-$/D
M0N]V*YIA[B># =[<U< ?D^T*7JSK2=%4SN=L2AN!?E(/E)HP;L:O3*88UTA%
MJN\8:TV-A(>J>"&5"K=#=S_YG5QD)5.I\5+(MIBVA.$."C?^=!P3[VXI/;E!
M"X4GIGEIO,T#W8-+[(^( CF2E8&,.LH^:RY]Z8K>6L.K'U@]V%#Y$S#X,02)
M!QM_Z!JJ.0C6WC^(AIMDYL$IUJLW<'.HU!UN!JXUL<1W(BH^QNF"LWLG1OY(
M_VJ7T917O"+)$L=->7EK*?-&#_I@&B-L[JX6?PHG M+8#[#O+L2&5XO7'RG=
M^"Z<<VN<EM\ZZZ&U>(4EH& ]*C9_2X,5LNDD>)<N!FR*A)9X$#X)%3(KN5JP
MWYXN"%?(&KFE*5G%$%6)Q&M*=AW+-Z))YH(B8]7G]98+Q,I[?'7\HL8S;RKS
MAQ?$D"X92GM0L4CS=NTP]7=7GW>U_^NYVO];J_V_E3+,#V&EYRX:]8B/HE1W
M\;3@&3")BZ)2GW.C<3N*$T4%[F\A]SQ,?>DOEW<&G:@2P:(5(:6ILH3@F>29
M19H@8BRJN??<+(*5_%8E4Q#_0/<5?E7NBCN4#XS&\.&0<^Y:*3_!_VQ;(:JU
MYH%.&0(L7;.8;F...1G"XSM,7*%>1@,OJ,A3%A7<X9*JRCB#Z;+;K:_,-N=T
MX-;%9:OXK*+JM/VTYJ'TSMLA!K_ML,,:$AE_2%RL :T)M(9_XXTNJ?PE!8?0
M$"JZQ>&07P_U'5MJJ@64$KJHX,]5.+[H65#,*]F *7/77/G&NCM;NVSN6')H
MT1UQZBR%!WZ0ED=-P8_%*_',^>C*E#ZPE^28&@7I[H$OH*VCDG('C'%2F/OR
MU8^\,U SI* "QA3^^:?O%N/JIMDU%PO6<HWX8>5@6^?1+,UL)J<]);J4$=,K
MGX:?FIM2#3U[2>,8 H,L""83I:(X!8/H71J*(?Q.%UZ.\A<V0^.*>3 ?CBB%
MX:>T?W<U.DX6WB[H!!EPOJ_9'ZV/0Q/77UUA2Q:XN#[6V+C!3]_$:+,N8:A*
MJ2LV"H9AP_)2?:.];B4;P<\EJ^_]FD.4T5[(7G[^55V;-1#UJKXUL-:!?VTU
MOZ9@*O1PVQ#B4V>L827M1NZ/NYVK8%E4):I,P#.>.,EM2U%)W4!W)7_V%[,-
M?3;TT]7S#FTM+IQ?1>:^#9'B8D$0GKF?E6!.J2ZCUYXZ:NY.7 B5^:%T[NN[
M7XM]BH_7B8C_8&W5DG:ZI -:S/_TJD2_=E&PD3O%BR9XZYXX&EW.^V!@Y\5:
M&D= A6K:IU-5+].HKM213+L%:-ARAN473+Q$LJ2*__)_B:LD#!-7B^<LU"/5
MZ1Y>8AW?RKJ_ZQ@S0=LG)OZ3"P8/@C)_SCA;+V[KH6V8;1B$OW387'J548W]
M+N0938>X:P=NV?N )1D84DY#!^D8:@!8XW.LZCT9)[G4#J>91&U1$@["AWQA
MB=N>X\;HZFMF]J*&NJRY ^#2N&>1Y(-<[+9%J27$<&,X(TZR8-RNY0]0Z7D<
MCGNNLC^/(3BE7=<],X+0CX&4]_R"9KB'L%B(M3H[8J1P#=&2D,I% 4><+,(%
M$;?I%BV(C.M7^@X7]K"#%$?4]2?GH"XLHYQ\_!R\$W?U:N@+#LS;\*:I@<LF
M0$ZGYW5<N)&ZXRN@ Y@:MT*_7H*@L%_8)&@..21R@^$N;GOZS+:9KGSE0"<1
M!D2IP;(Y]=)K%,C,$S$#/U]1L,Y1.]!H_1;I 9 ?#<&70PX3'@>LCYN:7&2U
M2%Y=,-!#\XPF3YI_[?J[H=[_W?_J^NZ92(Q3X* ]:JH783'$%GV(I&58/E_B
M6TGY@L,^[D8N<L+M'NEUB-![O'QLRBOOROF7K&KIESYBA33R8UP^$BO"CP['
M'72BEZS&?M+5M+;BFY;Z+W9["KT5SG5T5>5&]U0BUJ)O0AIC:1];V;,[BCSL
M[9 ##AYR)V"/YFU-*&=D-S^A$O[5%U]]72U>!^\;[GSQ[]1)/RV^J;LWX=\H
MB*-?P'_2CX>/A?=S3;[EA3CE%_VPOPK.ED:O:LK?[VC*/EBSY<?#>-/NM5WY
M??#>=#!^VV#((X%K#/L^55.BDVD\=93&'!!-_7KU^BHDZ=T;>@>;(_6&_\?7
M7_#"+TG,B;"3W>+[=A@I0A.2:+I]GO#:ULS[0\4&XNR]"ZD<8W%>W[7!?[S@
M3(0?6''%B__Q^]]-?@+ )-H&O1"QA]Q\.#RC@\@M_J9>R<@LO: 7 P6[B]?'
M\%/-XH>0 .T7SW_@KF3+]9?#H=GM%2'*J?::5\H$Q^OM3AP6)?=8#3YGB'W&
MYHV>=KK(3YTXNO7AF(V>?( HZL)VO0KFS7I;Z:&@BN#O$=+><X;HRQD;^H4J
MH?./)TCAZ !T:5N.O $S](?&@P/$!P1^_I$NOM=)E+8)V2@HKO-Z&OS;-%Q[
M<(PF40G@6@MUZ<<]511N^ETRZK77?G9N:9]Y@^!W<X/@(X\#_!BQF?%$)RPJ
M;>G@,3 ZQGMQ&?XC'/"FLTYSD0;V60Y]344:$??C.IS]=3R-!X@?0#10X,2I
MTW#-.C@&^4PBIV#QB,+4K#JE()P'.#6#R5B^-0&]X09B#HS:C-U>V,_;PPV*
M>HZ=#]5%@/+DJ9A_)WP]! 6CJ",:8*]KZ!YJ#KZ0(^Z'-CC%BG-$NT/U-<I5
M3JX,$QMC! C3QUI%QNHS40_1T^=)6?2O?.1(0&7/6\KW4[$5\DVHY"]/=HSX
M<-56HLH.)Q^]>IZCC'#=DU&N6P*U<:SYD.!576E8''E)GV R]PK5AE=Q_.&5
M%?&JQ9^;:ZT[OM">R"\LJOW>2=&'?9QO&D;-)^,Z;G"X#VZN[XZK;=,?J!2O
M#1Q&WF/^'F16.4W5:ELS-9MHU%@95G!P5$&%[JCV98)# DY.6N^Y)CGJL((H
M2B>3!'Y1H"=Z0HF: GSHWE2S>?N,T@5-,?T#J9P,$BRWTIK;NA$!;,US;XUS
M,9G+Y1H_95=OD17[\1X>C>BNZ5H33+V4OA78=F\!3; 8XFL5AQ=RBB/MH+L0
M!PWUYK"X#CD(O-^Z7QV-SO;;X&&! PUYWY?R[!2L]HL?__*M:[X* ##\9LB!
MCM*<H8+4")+8;$6<'@H'HE09:Q LUJI[LFTWS;/##60H$.J14SI0=&KP8\*,
M8,'-7#?AWF5BAU-D_O--.#3AYA+B(B7UYT$C^:JD!O_[&*X=GOFKL+>R]:$A
M(OT]F8A5E2+>D [5,L'8;"9+X0=_J@0FV;)4&U!OKD(A=DB[\=0<XDA?P[/,
MZV:#D2;P(FQIHV*,EFH=*ZYMT).$$[3C@U /6&QF22/\+1>>JO@VN1NI*=BV
M7KU!@_#>6R#X*QV0^/ULXV#'W+1H6Y&M$$1 S%_K V&MK!ZBBQ7"?'HCQSAS
M[5L]+>DI3&1W&* ?S/G@F_@/^0GZ9HCM]GVG\W@8@XH[8ZDO!>$,6OF\OZ:
M329,MCKN&OAQ@@]R6W5UDUX@[>-[1&%87:G[%DSP(:W/#+:ZE(/J8.#NI9N=
MSK0%1SE)#EYC, [5%]KCL6D(6@6T*:T@5#I<)FC7AL.!=;,+2WX PX'VC//#
M+ <CG%,\-)'#?.R!^4MYXH#>6M_19&.]:5)ZU+!JQP,3(ANTS>DQ,@Y>M.2T
MD7ZU^/XXT"+3IRO>GY00A:U>#W:04ZP'.NUXG'N!LYYJ2*P2DDX> @3$D,[1
M5*5L"#[B_FP 3W;V\SAP-^U8&,MP_D8H_;GP"MTX[I32N C<O(0J+-I(\FQB
MM/1H\BIQ7JW$L5$IA.<0P@+N=<0T8GH9S<()&OV/'!?/ "/J90_\/]DO8+<&
M=T@Y"ZH\A%)D'&\VWCLB\5C30=4NC]*\IO]8V0T*">]=C9)1,K'(3\<5!X\7
MDNJYK[STU$1P3F:Z02Z%=4 <-WZ0UUT:^*4([E  D[G/Q'OA_<O8.^.0K97_
MW$]XENP*$&!,XB0\.V)0B/C$?$QTD<-71+GA3YN6/Z5X@/"SQQC^!EOL*5KL
MPRG&3I9+3LVG1WSS7<>]*S3OM,(OLYN@!,]B3AM^<92."3&->_T.IN.PC-/=
M>F;P0_L/;A0?T]WYR3<2H_[39 O?J0/VD'6)6?S\5S8=ZR8[W3RZNIA&7HDP
MV9#Y[#$U&(R1)Z'A*;;UJ;S!'GI"3SK >^H8R$IOVS?!Y=ST_;I:2%\&#9V#
M! '%1^!;QCNCWC_/E!6L"L"!R'],0<M*YEM:;/3B<#E]"_YS2E&!T(X=D]+S
MK&ON;+@B>!/?EO,C$F=[C@E0-6>?B:$H92K9[\.[RR^;4W(O!YE:RZ0XJ?%N
M^Y&/J\)F44PZPE@*[11 *?&]^:5Z=4,5+<_*H3X*%?0RN(G!2H!BR01Z.&7"
M.A[:PS;\QN.CF,(C1=C2.R"3/K H2<'Z"7BQ8SHN.IV))X!)E7NMK6IJX+@,
MP&BWRPT=$U/<4T!"H\78Y&/4/LA"9C[Q"G/T3L6(*I;]J'(H9, TVM52FOE9
M-R!^/S<@/G(#@JST^8L0WH?05,Z?/#Q<A<-@;&Q\D\=P:T2N4BK?\S32!<PQ
M%Y/[18A/<?*["MMPW+*7SLE1.(0&OA];DU&M-9*+BOM_74WH6HV_K0W(@-6:
M?P79-&WI(U/VT)T^8?,ZY:N3Y4]&XGD=IOYE%V(Q=(/LL%TVMODS@1\I+DC_
M%0= L*I^H*ZT,:DHTE>+5RY0H58N2$5*)#1Q:$K2M%A-S#F"KH0& T!E/)?2
MTD%2B*LB,(Z$>X9)/V[1DN%12XO5DXGLL=_?M""YHS50#776,J+R''*G">L,
MQ^YDTZ:ZKHD:_(/5EK@=1@%%L[;<ULL5VARD8P(\&8"960'K6(D9\"Q:V=#O
M\JV<*>4SW _\.0?!A&2<-Q1J&9&(94R>0T1G!5.CJ",.R%]="&^$F$MY])08
M[Q<^U+;X;5/713+@R9',5.U^)N:LA J(;]W3XV>7#>(A":R,>U(H-"H"L$QB
MG6HJHW1N_N%C;_X_N\.<26QBTH"3G++G>+KSY$(O;C8;[DG"4[X8)_O"@2:M
MQEVO8RY4-HJL)V?T8 M) 9+UH;&->YGD)Q)I\B'"G(WR5:H?)?Q;L2C.4Y9#
ML(-#K5U*OA!?6"\DOC(&5-@]^N/BG*:A=*XS- $(4SV.76D6AL42V;@:PFJ%
M72BU8Z##7O3=]2 Z1I-9O+PLAF0U:>AR%B<L(-@QDUM/S@0MFR39-O,G'Z@G
M(?L<CVA%(S.>>'&27]4_34LKGV#C]KY.9ZD6JPBM)B30E+%* T@G8%)8,_<W
M@P,)N4^L:,76W .:H.'="]O;3\]]S:I(.! IQ[@_PO,WW7K?MX+9+#52>802
MU&3ZIV!%P<U208^XLW5\@,\>*S[K/ZLVGV<PJ<-6/OWGDS'X_N@J]CH>"CQG
MB1A7LZZ+,Z="R<):83+1K05^[M%0]W&4<R(GB' S9(SM*K\_[)Q)E7.U;6J9
M4>J-(^<,Q>\WL2?RT.=)28JZGMCOR*R?$=*3][6B=/(Z0WCKQRXE68_BXO&V
M<>R>8U-YP N"][3W>7$%_!TF[\@H=>1VTP U[A&X_O?;?3;<:^*(!!)L.^FK
MV_:G;4*,Q<PMBNHY@HW(S_?0Z6<4I1/OQ<R18+4,^92TQ>W9'65(D2M$FTL6
M1KZ+,UL<$8?F82RWK^_ _Y"4G1+2-%HN)NU+751"F[.M%6ATY@U@JMO9")MA
MR4KL>3@;Q_3/8SO>U,\Z&\O:O%)P>0='_/<AS-U2>0W]A4.(4S  JK/6&.QE
M^JI_R"(/QFWH#%!<F_I0:\#W$)_^<4-<[;!INQ"#GYO6SQNYH:=L>S//5P0(
MA14- 1 LGDM<Q:6N2I50^OU[,3LAZ'HF.5ZS5N2.>_<T*KYN0GR'W4Z$_YQD
M;ET4MVJRGNN9"=[??F-Q(%>>E]U"/-RMUWCLI)8)]X;8&M8^'HP$+1J7A:X/
MFZ89VF RI^EBN6VW;6Z!(0B&RIDB$"F$K4;(QZ/&GCNJCM._1*$V\DR8 ,2U
MPT87H:<&? /!DCIG?0X)^%"R?<O)@:B.CM*]8Q@$O!GE+&5=O*O%SY?\APV*
M%YE\31]$DVIV;X>QU#@??<0'AX\E>_XNC)1ZDEE44$M<X "[4BAZ(P %[RA\
MT1O<?M;4RR?'NS6G6\N1*$2P.6, 45S&OW#*OK#@)$*5[/D,BF 5HW.MG_#O
M3!5XM?B/L)3R,04\AQ^2SBPNNV&N4R K:@/:14["I$ZCR6^DNPU'W?\?<EZN
M?__EZM^OS&?]L#V%2[ #?KYL5KN:0Z9O@K4>^NWBIQ.I"KP.N=1RR7#M[;%9
MTBC!DE"Y @$4(H_/ND;_3W.-_B/7Z,^Q7O1#H6R@A/J-[)K@VE\$5Q2Y;L2G
M7BU>1[B55X%ADE6:MF;PD.1"$,"%9>,#-[7@IL"[DO'2 22J'A-S"DD1(L:C
MGV#!X4=B)VDLZG)0E#PG?V@B4 SM:;0C!YZE6ME\Q@G2:J009"/L>MGQY=D,
M!Z5:P_ETU]J+5;6K6SO^\T0QQ K'I,HG&C"#SQ\B/E!T;*";1"T7:9QN)>/4
M!$OE;JH)H#"'@U@UV<O-9&7;IZA3?,.J7?',.[?GSKP3Q?-Z<O?WLIGDA1U1
M<1<I(6^P^1)COI7&^NCWG&KAM,"48B#+YAA>_ WQB)-,FEU!:HHA4V,=,V 8
MDVB#J5JXSZ3=@PH,7>1H"%Y]BLXFF@P^[\2TT"WI=>B )OMD0@H :<<$F#\=
M_5*_@GT+@<Q!]1/XYCE>==,,?DE]T33<Y/8TN;XC3I7 2L),K*.D.^$_>3 X
M^[:"QRG(W_G@O,[34]G;.KX4S-7B.!K2L>3SXZ=_$?KL%\ZG;I*_XET%(R2\
M"@UJMN(G;D-R8?P&KAL @ ,EM6#%_HG>79RN1WPK?1.,=ME@W'1_":"1ZOGJ
M2WNL(/I(4X>?W+N\9@'0=]35V +O&LR/:U<7D6_G;NHIV] Z*1""JFV]I(EX
M5O=P/1'G]T,$W:!Y?"0848@7PAL4EH&UJ#E3!SC!^U9E!+7B(K,&2,[.(@#@
MTH+F;;XS'E6RY;(KM?'C?\W?P:R^.JNOWJ^^&@.A@?@HN,I'Q99P_AWS"B@W
M*-F%XR2<M:AG,WP4,XPF5BU^?/6-@%0[IB@ 6=/AAI2AR&&VAT/CZN":2_K>
MJN"W6!2NO6;;]?V<24@"9\S!Y>1O%&N94@%F5_#/(0V9Q=CG#?#!_# !R^IV
M*XTU_/.BIF(^-Y(3BI#,8@$;JU>'0KY/AGSH5_UV-&49L^L7KWXN!8RP]'$V
M]=G4'\74W[?^I"4GWSI2@6]K$H5H>$R*0RE5(%^'U(LJYM*TR,:/JWD:BCZ>
M"ZZDE#\"37:$7^H[>XQ,6L"D-!3%.&^G>3L]SLD1!]I,^8691K?;9XH?+DPY
MBOPB BL^,OR<NV&S29F1!IH(:^LH9I*-(<<$SI-:,<L+XO#D3)D9[#VU&>.6
M(IVY"ER%[\P;8]X8'W1CY!L!V*A&,2ZQH>TFI7V)CNNC3<<;C,ML,GYJ(_Y4
M+L708?@5 O;W@TZ;*JFYXP: *'O?4ST6 Q_AX_UZW@7S+GB477 H:QG:C/SF
M-W0$?41& H?AUIVN:!RQ#\%.T]$QI!#8\2CCYPGS&O=9QTG;P_,'+?4[(6Y#
M!^.&*%B[:S Q9-P;@VIO'P1S!1J29AUW=8)G/-#M*U\UE0]V!".IU[<$DEI;
MX*8X>R[],M?!Z+0=DR?_H^-5X!AS'4Y0B$):QWKBC^A$O6FO@>'A)E9A06?W
M,+N'1W /4U2CUWG6.H(F2-KM1VOS-,''YB/G),PA32.]$I%D]\LMU>04H-[*
M&)>0H(;;[J@!9ZI"LZW/MOZ416:M"F10ZF*->3R.=#'@DP#(QPR^.G@K CS"
MF4N'W:WP,],T3\;1W_5=Y&RXN%%)R)( SB@Y;A""CBV/E$"51:E8#2![[%2^
MF$Y?VM3- %RQ3$<;O90_VS'XT0AJ"B/_-$7=N1(F3U:*G@9M_@T#M8C[<]\8
M8FCJL/)*?F0AI;MY0 'S<T4P_O.,8"P@&&>'_M_&H3-:GK'>#_>G@J?(DI=K
M,&U*#._A)7/,/9OMXYNMZ"&%$^IO1!?+D@+O% #8>4QP5;;YR ?NJK._=6.$
MEQX9CQ$P*6>XCS=2R%3&ORG PTJGH3 >EG#15H)JVI( RJ6UR.Y18,41]48'
M/0VX,\D8)MV]#H)0AR<Z"#3"H>E)2AJH<$VDZD1NL3EVS$8X^X+9%SQRW_^F
MAF"4%8LB*MJT,X7:I(Z8E:&!4 D8,6@X(792[IV&V_1$2?3LN/^C#L/-)CV;
M]*/W]\4E4]F3*?VY]"DV//O1V>@>Q>BD@2<\3L88D,[!:R4G:CX1,%RIMO1+
M_9+T02+1)U#[K8T9QY%VF@28#7@VX$<Q8(SU# "G4H.LX<J>"CS*C$(]COVJ
M!9T @RW>)6&P\7J:0)=IC^,!0X4VWV@Z3#+=/IOW;-X?S[S;SB6I/+JW:Z*8
M#PG1L- K&3RK2(D2Z#[D9/TPLFSE;+*SR3Y&'!N)M\_U.,G:C ,P"3&"X4I+
M91#.KH,R%D7U'$5B7]UOLA]\HBYA))?>5C)3MV#.RRBM\#!<+&]0'3U]<&%'
MA)VY[*(TK2)#M^7&=!/R8R- ?,"]QV'N2",F4$3DV8]V\\JP/N6H&1MW<;IL
MI&RUL78*.<%32[WP?AT^1..Q[J]\9;*QP8:;572QNF\APFW.DX*S.WP/=^@0
M3PGW7HE&0%B4SS @G"]H@_'A[ 3R# >9#?HQ0U(VM,1J?XLB4D$':;;5V58_
MB*TB^_\PJEJ^J[?LWU*I0?XR6_-LS8\52CC]-)=G4<1\5Y\22N%V-*VE9G:I
MLQ$^HA'>(Q18X)82\LWW4@/4--)7$&9KGJWY4:Q9B#G/D(4?;M9#?5>)OAHA
ME"LI^6?T3N9U*1;>$5 W"Q=X,B:))U2G@'8/.KNOOOOI-2.!68!VUZ\1CZC,
MLA=^I<_.FV#>!(\75U"($(QO-JG9I![!I#QG:+TCLL7@P*8S"$.S/S+5WZ=0
MRW]9X*!@%E2P;8/*W$1Q[R^>EWE3[ZV6#_?5"1.U)I#,4TGE3=??1;&F;DI2
M*8SAU\RC24H-'<DK)1(<2SFWCH0O5?$E%622@C_8QL?53;,^;ALW;W:U>.TR
MZ)RZDA< 2\@,@&,X9XD($JT!@9,PEV!1[YUIB8G^_:UQE= $@]%3/9 .T'H-
M?!>L+U@8C@D/&U9=";"6@Q,;&IT$.8]\@%Z]5R$-OC))5;5#SFN8MU#>_;[I
M8R%<B*.]I.B%GUF*_FH%-M!N)8Q&JBOA6BIQUJ=2P3#,"BDCY><ZV?.'>;+G
M(W*3OQ^[=JJ$R?YQ5/^ FIO03SC1A70*WJ"^4W=:L8($D8?N#ZSHK-#^@E3!
M*%LU'4H71M)F??4TA-,O"H,':(!/G(,;L<S7J'9R*@4> U^LM.6\N^FY-QJ^
MV<#A&9>\4FX4-:M8U$B*^"90Q))"/0\S\Q'7!.-MQ1>JJLG5XA4K/=C-^2>A
MVV$9>(:M@"F:N7N39WB0CLF+G__]QV^???DOBMN^WO9+*C>0ENV.%4F;X(^O
ME42.]<MI6+06:;8'_T2EOP$T#GEWS1,GG1%F1J^O58)#_'7VA9$_QKS5S+P2
M8CR9?Y&W4T7^%-69]'/EEJ@"/%'I?[TED8Q3LJ^\QA=@R'*/MW6[U;,L?-Z(
MB2(14:0[CW(P>G,JZ%*R OM:NI^O%M^>]0L%:\D_1332'$0)A9^;K+TPA%-\
M5DV\+5Z+ \Q<M8IKP,SF46DUZ@8BF*P6 -$.29AY@!=PX\]B CFIYM4G)YCP
MW43W2 -%%OR)'OB!--O0.<JTV4-<VPD\)&K[367XK"HS#0H+;DL-TKXEDUMH
MPX=]%)[GKO&]S7S(D?3;GDR7X&4BI.9%%"Q&G(:UA?@24@++)@KQB,PIZ2[M
MC\-XI$T,NC$Z@TA\VTLEXJ7\A738BOH]""[=150=*4EJHNRB_#3)N<''F4!Q
M6>WB>,"D_>1GF<U?U5<IWKV4356+\$YNSM]_C4YUE>@;L.U 62F*%S![NAH3
M(=_QL\1RA01)LH-@0L1V#TFE0]V)%B#K.!WW4'*B,Z=AQW/FL#N<]DTE.^UM
M*S(-$(#BKYT1EPQ.J]_>DL;[]Z*<<)&[GG?"=.=@^T7F=HX3O!WJ;4Z^>I4-
M$-(F-UTDOWTEOQ)++DOX7M3=:#FU_&M(*<<UUV&G/^YS]+;SB$/8GTB&R<,D
MIIK,C%Z7UX^S*]L:O%QG;Q=>9D*7 >U@%B]EE2IW$T6M3Y.V#+NMIZ,MQ "K
M-ULGY"$2>_6H<(N/KT/PNEEQJE\P.HE:1A'/6)IVT<;IE]PC,Y&^O)9$"W96
M1[\@U *R8*]7YIU_L):1BE+M>%,V[JAP.)5.N5I<>F;412X\N'^">DFS8/X&
MDI%@\WN'7I5%/ ](^MGPORC$:3'\J]*3I=6Y>N!A$H50+#HTXB^#9@XL%!3C
M1RA9H?IQ"]M%L<<SJI#"4&<YAN=7(:K9M\&F5?](A/E2@I5(RPF[.:X3TO-+
MD#RG4!'^)P3EG*,CG$A(8,KVA(=P3A[JJ2$D=;V?B5(XO2_FSME (K@7LFKD
M(R3/2B[-N0!=.>;FS7R'O2CL"21I+BF$;S?[B]E"THF-N\RI>=@J2Q"7Z9>>
MDW)1]D:Z&3L9X<'/;F:MB3K-D$I>PD7M]%1<TAT^']O//?<W]"Y!V80JCRV"
M>0<1<DS)BV: \MRJ>4]:#0KVR[+H%]24@S\#KWY4EA6=+VZ"L\R79;+W$5#-
MF([9H!^9F[$0%$>-N^J<MN+[[(=*9VV*WEP'3C0@E*A'X?Y>(8PYWAR<>MX5
M\ZYX-#?O6H#G) R5>W2QI>KD)?WS" -T%:-W.D1\"#K;^6SG']'[7_+7$J L
MDIR$,YZH7I\R $C"#Q+._W)\F?\R=]5GOLS_SB[ED3*D:0:4EDC0RJ7JR*0H
MHASZ!0+D^=R<C?S1C!S61R!&!EQP6V<*1WG74K"K.KI9D&F5N^ZHE>BJN'&S
MN0^VG6T]W]SA[GE_J2M<;/%1U7\[-G=$#3!OIGDS/=IF<KT59/A1'B+V8)K!
MN%53R&NB1$G=@2,UAI18E8C6VA7:(D-]%YEL*[_KE&ZV/']UKJ<Z4P'-V^!1
MMT'L<?5;.@1&)R#I^T+O%6"YF6T6->JN&Z9Z93D4D>&CWM"%^C/WQ\XUQSZ%
MR80)R.KBR1OE8PJ-:$?N6,+/GF\!FV\QYA_^C:$A8CQM80KRHJ!*DR;FZJ0D
M-3]_:E\MGL>&I,"$N47*^#J$#60\S]>W[4C??*$Z)#&2*#P178%UK=?C_<#.
MKN^>Z1TIMI/E29,AOWC324LT??3I7 BN]-=&KN.A0/'1K_NPG;N=@Y!0,(00
M39"JV^:Z';>1@%.FOP=6>N4"-]Y$F:$K+@QVZDFG,8 TP( &0*+3&9EJ*L4E
MR+K4-#Y^^_5,9QYH"WH3@GDK8IS0:*79#O2;TZ(\ P&I_AG>/_=GP^.><$T9
M__1L$KB"?#.;^F24H;]V9;P1=%F:\P2<;;RX+2-#:[.JCQ8.<Q3QS-^Y2-H
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M\0S7V_6\9?;A(,=G')ZH6Z<S^U2A&X[78>^\:J_[@;A8'XQJQU;NW(J6;-F
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MWU5&KRNT8Z8RU%.#Y B7$U9U\RRYK;_7?;.C_1M2TD;T$G"5?U#'TH37W6K
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M.:Q[R%9'BN.P:PKYEBDMU]+ZVY%.@\,IW[HT@<H[IT'%,NYMZW/KZES(*9Y
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M\4AEH2WWSX2>^JAYK*![O'%O>RZC^8F2"!N*&@,6I7[_[?-*JW*$7V T]R#
M+XZ:U9,4IP'B0QN&GK8+_T<K_8U4G(>Z@#(Q@>KK-6JFT$D0H+04NW^FY U1
M](],%AV60) MFHM^2]ALZR_^*>8R?T)EYK6,6U0<"GDUR,KU!.D&0R['L7'%
M'0LZ^L)?['7$LX!6(IP0E?@%S"3?L/ SM"712F2X7\,<D&7NX G>&1FT.3Z5
MLRB2"F?G&]M DU4(BSS['HA'8T5REN),&)H;HC6[;=P;<E3>2E/!]6+A]/'
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M(!S_8:;<4T"8*U(6?6\A&9]]N,[ GS)>EX/,1'M ,H?%BY0'>*R[Y*QDZ@@
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ME@?P.%(U82OH!$(4.<I&"XD8P>&/OG*CX.,C,THS#)+_6^TC7> -LM[[>QZ
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M!M087L1MD&V!:N&WS$<D@-4<LYSR'7C<KG0L'812R?5"3#0<6WX?-U2?*(
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M[DO$)9_%W=?D8*"VB_$OV%?F6^ZY>LV=Y2Q(K!S9^3=$T*_#2#9'\@U\\$L
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M<5W"@-XP!N0P(,7502#[* :L6(Y9WB-3/$8V<)DG&WBHY9YO'\L]=UCNN9%
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M8'^X;=-7RV-Z'".!Q&?P.L9>O $0FLYB%P<8A[%E_N6^RJS=]68XP*41+,U
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M5T$Y;SW$ 8,IK+X*M<9(*.:-F6&<*HW<[WC#8: ;9 NV&DN#C^ \U;HGW]H
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M%KZU<V?]G5<=$%9QGVHY5-*.$#]LT M]YWGQ"+AL1F[AYK3Q^_B Z+,G1']
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M8&YWV5Y" OV"V:J<:5 ("Q#08B06KD8@(O'HC=%O!N'AO)JAO!/6:2,PEY^
M2'BRB+N]B9/=.%=<C?&X'3PPXT';DT+8^N@SX&R!JUN*TB57+=$J0JA_OO G
MO-Y$4W=U$YY!YDG0,M$UYQI;NZW:#&1C2R*:AN0NU:Y+%N*\=_1568YK4Q&
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M/V_[P^9GD[BRA[ -,-___$(L8\%:4/WD? ,>&?QIU<Y4O9TXYX"B"B!P_]J
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M" P-B)U% H.M))G!:<KGDDV@G";]?#N<,.H&LR%B+ID;:E9[L/(N/D[,% 6
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M"2,PNF0* ,V00I0&87Q5ZFD68$O)C;]HITDBQ("=D6>\P@Q2SRAW2F^]_GM
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MO!:5/Q&C^'SYF I^W'NWM/="NM^H) %Z!;U!97-%TB[-(ER8!=&',C$]'%,
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M)%(87$S!Y/,7[*>-ZKQJL@&I.BUY3\ETA$S:!XK4>RJNTNW%]1Y3[6&%"U+
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M5!"-O"D0 UT115^\^4LO;,Y'*^0=* -1#UF!]E7;T.C$7HV\X8(Y9UG2 34
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MX#6L",D$:$Q,DO=2R("4-P,?W)F_F591KFV.ZKK0KKYJ^>,2N#,B=.46"H?
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M]TM>+@ BTZ[A5/@)&&'<XRY.7IWDUN5+%S_/)Q_\.OP%W$AH!L:519-"GBM
M1*?@:1E+^R):3?ESVGAJ\>%Q_&G[6J;M57="O\(Y\PD3\Z0^#C'GG9$F'YV
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MMGO$"I"&#RD2S>_M=H9>19$_L81ID9 SY1HX'0+ED*-/X'<[4LVW667@]B<
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M6:D1*H3S'^#B9]*L .!HTP6"&:L*<F=CG\[79([F,EC.RF":D^I>,*G."V5
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MYV-\((Z;S9+D;AK [?113M>0*S?X$>)<8 T+,MNA$Q5HYX:H@,)]##HK8,&
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MX&N,OZ"1<%^>1%[TP>_9780I@J8["1>R=C%*FY/HN>(]&_OLBM7E-9D\O'Q
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M!=RLO+A,+,!@D^_>+.R@$UO1?)@0-A)[J4XSJ\^%>'4L*Z+>*;QB>^)=F3-
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M$K@1NV$BZ1SYAD_859N6MT;9>ISPJFHU2]>\0ZK!JN*9Q+EJ+]_0T$II1/D
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M?&???AQ(UTIC<)[<W?^>35D-SL)Q@'(&0CXG/"BXNT&%T,H;RG_&(I&5(0P
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M-_)"[\PP*NG0M?Z@NA&% ;:7AP,6%>SKI:"&PW 8"?P;]^AE/W_W;[':5.I
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MJQV&+17N1W$.=%:(,D]K-M,MP4A6YD8DNQ1D.?((@^XQZ@*A#TP5%ZK?24"
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MOF-J+-&(^'[(PK4+(<4W4$7!J]A'$#)5+,S)Q2HY9S)L(A.+<DPMSU)(?]M
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M,5A_S]T!&P3KD$GFGZR0OK;-5Z5I8"F>)SB_13E+4G3"2,I!F-4>LW5G+9=
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M,N+B9@ XLR+,298=,)!&Y?2*69RODZQ84,$\5)BC-:BS;)9+G;>#BP+ FR0
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MI>7<=?$&E4[J?,()Q*(=R-FLA^[=F&7#^WT29801\_J0YLT\*8NF,EL(RD8
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M)A(QZHRI1R""9L&27$QU3_BI48<1!+ZN\2J88:!SN6+<?^R7U\5]J&F7AF4
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M2"":S_;Q_/!26WHU\^(]\SG4Y,%LM1#W,>%F0-18QKZNX"H,6C4NBF@6:S"
MGG;-\*A60]>1Z=X"BZ:$1]9^\F^=-V4]39LT/$L04AX'QZ 8T+'#47[(IT6Y
M*$I[B+B!KB'9_AJ^<&:G/K(.,7_0]J-L<[]?K(526<_Z*LG0Z;,E6?AO6&ZF
M3+2-[,^22V@'3V\_%V@^[(0XF6811 ,2VU?>;8ES1^1Z-.6"1B8EH[!)7NBJ
MK]=OR%UW[W4/C7DBAD=ST E6X.Y3T<2Y^6?#02<O<D"U-U_0G[>UZSW]5-?#
MU*"HH?4(LV-21\>!RL#;]?=?*MAFTC3K45]Q7PP*,T'[N)+ZR$6:/[GKA:<S
M+T.XBEM3)@G-PHBN7T!<RFH/>D2NPBRK9]O(7P5,>@U2WFL:%17SS]+D6@K,
M;-5_6MO>\C8T9D6@@=;P*:MPX@5H!8[ZAP6JU35= ;9.\_0H^%=3E,V<XW 3
M_.:*F_6IPFXU(#29U2B<$GW2G 2OQ]SJ/7,2#)RY-IYO-O:>B"M$GBV=^F1)
M95C[G8@X"[,S9.B"N)E2H-V1'6^D"7PJ76/.U@O.9$3QGT53YB'55WY.O Q'
MU4SA_;AK^1Z.LMH;)>K:SG?V:NTJR KZ[U::3.I>90RQ>C\6@0H5.OS?Y250
M =.37[T 0P]<UY*.O)[#!K-,JS[N_@^.4VLHK+,,((.(1#>[M ^Z@7VT0G$P
MW:R9D?&%>7/HCNYI44A[$,^$TODNR@O/HS1SA?W#QBDV9704/[9H41*>[4RG
M+LL^Q3K'<W>+V*[J0Y3(N<0E.DA@> ?H]F-VCTR.#O)^-6&#-MX!D@ZBG*7S
ME//C:]@>U $U8U81=T#V?P/Z'F;<YDAN_/)D;>6?)]PS",ZIER^_A2M_2#*J
M]#?_"?%]Y@[PFG%![+&._C.9-#%/A-@6F_@X RZ..Z6CZ>>\N#&B<>DET^V4
M@]^6RXV@'=*R3*X+-J?S6$$1];RDBL< $ZYP1E24ZYW+IT0I)"IGPAU.-L'P
MO+U]V9TW)X DGFAQ&'&/ZMHR$D.E>KABK'XI18X BU@]>=THA-!FQ93"U-55
MIX2$5S"M1>WJI+B;(9Z\-B. FK0!RYZ?SW*!*W@3"?.%6Q)K+D9+[;DAY[XE
MVX>W<;\4/G1)Z^F9..BH+)=PMS[+!+JY&MU9E/1VTE)WM#7!+^)FTS +"FC@
M;MI80SFWTF7-^(E+X0EX^"+^;YZ]-T=88W9\889U9)L$W'-TZ401$DMJ&7<G
MK#9& ,LIT;TJV5!B,3/GE=_LD,A$0DKJ%OFP;Z^MG1X.(N>O<A4_A:6P0] "
M7X_ =;0AXV+:D*FB/#"-%Y@D.%*DNE-D'[@%>T9?=ZYD-,5E8:0(K2! %33U
M55&F\IP6"\AP"(M+ROIYEQ R V-0T1'SXL@R>+2:/&#;97JH1?CTCU+'*>!-
M&CN19=S H1.72?WE(T9KO+ ;9%#L=C 6:AO-+7]XI$J'(U@,3=W$[&(STHL2
MZ.^.(5U#?=A8A?P ]E0M.N^_FXJP9FB5]LY*X20BLLW:U&&ZX=AP/L%,@G.J
M,):U6?\DAZ&B)6 V-SS9' 5E0TVP83J,64&OM,)A.U(-"$^O"3[P5&8Z>WCU
M]>VS]Q^,RIGG#JH"D_P!HELH#[ \/]C\%_SM$YP-#Q! 7X7EL#)X8KT$N-_\
MJBR:2SJ>J_0++DD.)PBZGJRTNE&CUE.*J7$SJK"U[WH!58(- 1P;3>O21=^-
M]3#/P/<@YA[REF^N"K)';CC=R8[/8&7L:GUKKH,G"KV5=Z?_6:'E&RRHW1JM
MJQ_"+E2102BJT3P!^(<0K511^-,X:>G<3%%60&\B:&\43=*,6\'%T3RZA'_\
MV<27J-]#*&!BVCQU( &5'O1IJ?A4 +1MCL]3<#?>PY:UR/+OQ6DU,>N4\!O,
M+0URPPSXQCCDD#,K  >"T\ZHS&E" 45D6#366PV9&KQ$0AW3]#J%?C)E"L2!
M '>,S3_8C:6TF[H3DM!1F6(#SJ)!W4?@/-MHJ& #$$,@[!*(^*00%)"5*=V"
MI:CQ;A1KY.I5U,Z<^Q+HYU36%'? ^4AB*S)8G W*V9[TOOS .83:-1Z\9*,M
M@Z<6$LW-FFP&/W33?=XYISC<<8Y -U,^C0P,7TK!)NULM]#NLSO=,8^7Q:^F
MDOI6!YBIGS1*O:01K,%D:?R.5CJNXRCYYPGLCFLX2N3@ETW-.WS:9 L;4I'0
M-C%7EO.D5. +XO+GP\<; F5A2AL:-R8/],X%Z_9*4@^W_#8.J4\X)6BIV6C/
M&!,VB< >12M&<)" CDR_!,LD*JO!HPFA)$\Z'O]FC,??<SR>D4<H[I0.8A 2
MAE1G"<?0)=9@NY"2P)LO3>,&G%.C[T2[KU1W-PG&E&3+Z<WHQS^;'.T:0FMK
MZD)%AXJN32MS>;'=QAP^/SC3&/94(TA@=@>OPDBI>Y=2H!!HAAFP?+@/I!8Q
M P%@H!UKPOL_R;8R+G"= :./N5:9&[$0]0S)[\1 !;]-?)T%1L'!W&0CL8T?
MB)QH<$?UKC$>!A@'5A&7Z#I*,_*Z^\I/L*H(WC<%OQ*J-3"&7@53XSB:N2B7
M>+K\=G!^0*J>FT224&+"F5HDPUJG=1/5K=+? ^/.61>[,VO8+)?B=8NFG!J[
M"!(-<GX)1@7+J'!^ED+8W]N1,?EBS&"<&)'/6RW"<OT*Z)F7U? 6XOZ=Z[7=
MZ8\A!)!77%MA\:P?X"C*BNGG2IQO1%N=0AQOFK(:8)S./3O='_I#W;T3'O8J
MS57M/]/**Z@TYQ@HRWDRG[")QP]TDV9!P <!ACSIVM67ME\SV:!K8D1;C:4?
MNGA V*]8)D(%RC5Y_"G"!0\3Q%H6^EGP%*U]VUF3)?3 P[>3YZ_HG\5,GHIG
M>J?)N$N#=KJ2PVHO$ESR@2&)BRE76;?FLDDAR)Y38NQC5,71OPZ"CY@\UTQ<
MM,#]*TTY &("YW/)N)F8"*DP9Z?7K+_'P,!*<ID<\V"C'02.G$[M][R<0RRN
M-K.@\0CR:!N1'1Z;S\.%(=5$ \L?2BNU0GZO7KS%!A^O@M,LHO,>?SHY/SV]
M[Y#>Z2KCTT=/]-5G8^  ,K9X[< W,6VPV0)@.7'AX 2P:U.J9K01.Z]]CA=Q
MP)B"D1A87$R@"DHU"O)&A'D3J"I  QIS1*-90"]N%M!W9NF! K0)NS>$(JVV
MA)'B*8/A<0^"X =W3^SNL6%>#[K'N%.<7413 [(4MJ.Y ^9>C -X%H]KY^\]
M84W, S@5JP7>[Z-9]P]L1DYVH2\E]C<H_5H ^A.CG#B.G/V&.54Z#1_!UOY&
MX\Q?OSC<^[Q/'WOOL7KTAC33 *=F;(JN;8B&RM0C*\\6Y()ZQ\I>K2X\"QS0
M)ZJ>4_T]M/U=J(K(O50.]&"181.1"'$!2(X1DT( <(E+?JM"7,8HR RS:!T7
M,=G1.38EHU Q0&%3,[R46D 27@+[0]DF8R*,"#H2FP^\/6:#F$19A!VH^':(
M4P80XPBN,6?XX'+W]KMG[UUK A=X?+ L^%""],K3]Q 5Z,^&V]X]7GF#* S*
M FZ=%T8W3!G3&)ZAIJ"JDX,WQ+$Z>*P<NT7EV%RJAF;&N<XO-<(",0G<D':/
M6OGLXY^Q8HA) @">X?[:PE^@[I([\A:\8@ 9M?5>&2N)QZVPDZVP(?R)BS10
M#PO\3&V (2R2[?FXIW&4B /P"_,*M@2B*:7HK16TO[,M X^UQ$;R,L+Y"'D)
M]!V#:Z:T@<G>&K?:N-7N<ZMEZ8R0+6G^9Y.3U!L7[2J=I*ZX"QA3\+PB!KA)
M1("$6YXE*ZA7GVKN]>V8>_W+\DR.VF9WV@:BM!7S?:B<&Y6-)JXJW&L?.P"N
M>PR$5J>M:O8N '#8]S4&OH0ER,,$SDPH6V.'%DIX*V+9'!W/<5-^%6_]-K4'
M>Q$#NFT"/S)6 J61S6ZD'%30Y'6:]0&I&&W/)GR[Z,<^J /I4'0(\I(PV)OP
M6'S>28UAD4NY/E R"@#U-S?Q:".?_@]3#U)*(T.J-^2WF! MQC"EP/:^ L^9
M0\;P..AM3.U!J#8>[;M@;\I3HS\<X,F .]CD^RW[ O$F4?3^W/A)=CS\&+_.
MT:/"[,;G5Z)9 /SI<%%#;R;]IR@_-II#?K&[XCR9EDG-P'*LRY1/L#](^5:H
MIHHKIM'N&DZNDQ6[%V\HGL&O4?DYJ<TG&&</TLO!F\/#%U#- VS%/MTJK:=4
M/5+,B"I34R3U%'E593Q6E@>DUNZH#<[,\6@9CY;U1\M)I*J]MNGL#$7SI27*
MU?6&4)YPR:@W+F7P8-S,VPE0+,TK9[0"H_;[0C"WTL<'P6E?:JN%KFF=KFC0
M6;@GIRWJLJ!#,DYF ">DTRFIZ\P"#6UY6?]<4'<Q+B6ST\D\[6VR9H:R"3O4
M$KO1"(&X?UD/$?1!^Y-<P1JU5G=/L) 54$ELI#,AMY4&G6VT X>S+*VPB,)G
M6([-89 5"TL/W3I8PW7S-&JV4;/M6K-1\EF5:+"B0!G_5V/NFBV])M9E4I27
M49[^.Z*:>0)?]$.^)&G]ZNVWQN+626O&TBGMBN4,R(#UQ1$E4+UNX#H>9$MG
M@^J>CI0"5X^S-,CF0:F8W BH-L\W-E-3Z@1\NZ5"Z_&,-7>UOA[ ?*@ZL\5;
M;F=0VA1L,8&'KPY?=6;0@]@FK>G<T!&RZ@]MYR7W.\?S+9WI-)O4*EG2!YA+
M "DR-!A+R2#GD);39LY8)U4UX/>TR-+/8,/C )B-WKQPODAB+_V-.IV%4(!0
MWM+@:M;FV?4MHB7W@5/XY@5 <&T0B$_;XP&DWH. %W!]K6_CRMI:GHQ")+A]
MT$(M#%LA*S@GD7_.!])0"(T)3HHR#'S?8P';1RKM_;07!>R%U@&Y,) :*NF2
M%?26HPQA*$.LEU /<=!+%^,;0UCC:7R+T_BC$3VS40KD+P388LE5NKA8&/7)
ML.RW7'(9KWDL<EFZ=)9E"B!^)=:J#AG<#35O'\%1/9:P7)PC1$P?,2V:$L\Y
M(AV &_YLC!T<IZT1#IR6PW=2Q;9DE%DE6<H;U6AB0B<^9+^IL/Z*V='X'O,*
M[GZSNTDQ9RWD"T?3?%0&NS;-U7ZSJ ]R:847J<V&-$KA*(4[D4(HDEV3UE $
M.FLS"BZETCY#K& +TG7K[(32RFW>[;4G6%_6(=A3QBC6\T#HQA&;2R'&_AAQ
M'K?='6R[M95[4+7YO%E(I9[7Z8_+TM.\$5K0(0P>%SRD\WD20R,[C_.NF_(<
M%/&GBF;Z9D0SC6BFO[NN&6!"]HY)+/UQ=5* =YA.S8*Z_@!U+[%/'U&RYZJI
M8Y;39 OV7C$H8TFQJB3ACJ7JDC[:Q(&OL26[]-XDM\V9QH3*N)EVLYG:K+BX
M=VC3),)!E@,2A&,-JE=,F<P2Y(RSYJW[HV?XZJ-Z!85.SPX-A6JCIRM-IS$M
M15!UC@<REY8E50]^W#[C]MG96:03]9:C)BI+(#0EAS!94VK9/A/BQI=C[+]J
MUBN-2@S_#\EXZ**2M!DF*36=R:.Z*5<08=JL(#)32UENFIN-B*V$ 6'0:E:/
MYU%=-@EOQ!) '[B%D5V(@0/\4=4 %TTOULZV3.H\G4.J [PV0ZDI>]17T3SI
M=2?2&57J><_'%"*^8(]:W;9R.?CW-6N/&2(S 8BY@UPF%012Q3;7+S<9]J6
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M_D1H\B1$B#WDH<:BZ<S72@H?Z*I:B=ZFN,;V(=PNY75(_/VZ3F!15%6*I=6
M:D"4%S5#AOZ'[3(%JY;WWP7KSAEY!)\EX=H;KHH;H!RRUW-=/S1%$\X.QT[?
M>VQY#0A='RF*SG.%.8;%;7VN3BA &;AK* NAM!RXY:4EFE3/\@W^T0D%%Q"Z
M\/F)!J:?.+ @\#XT#%C&.JT;<!NC #:)*]\=8.S<]6JP[^*OALOBB". 4A.3
MM+U] 8T'*FK2P3T,,,FE SXL4%0Z;ZD;SD^.K2#'R32+X'!VT%TZLQ5&MK(8
M63"S@"_K_/EKK'26OL34PN;+TEWZG^9G#$(UV)J"4ANA^ OT57BS^>/+-\&D
MJ:"QC^IQVK^<H_J^/_4]_8NH[VB3FN.!:N,K[$^/-6010O0RQNOESXT%FT2D
M]"P<'=A$<L41'$D_A:AV]=B9J]ZNPB#)_RS2O/*HMRWK<*65D.-]<K&PD;[^
M$6^@^$EL(-4KE6V=:#9+RSDU#$>(*HN<M!K2#7#>OOT/&R6Z F>MJ2$J%?MQ
MQ4$<>P@OP*J-"EL[YI<9D(Q%P**3;] +SVS#2BK<"#J/LA]5@,[*DZDY4B!$
M#">][<;5F]?@$L\VA0F&":&S,F?K/?O/%J4R*<\,)LR>9'@Z\]3<V7$*93<.
M-6'>O[6IN$O+3REA2"@ICC2<J:I+6B9A@%$MW9]:2IZ$6MK,+7-_UE(%W;%@
M5U@'XRK)%(X@J1E5T'MWQ?2%=)3SH4]JT*\BQYZ-4-9N0U(.H41I4B0?I"#:
MVL%"0'Z:-;'4U=I&?BM+W%4ZP&L&UQ_;E]"_]8G:G^*I-UOUSJ9$_VS=PC=%
MC:/Q6T@KMD[K^'5):>5J"448E%_'E,MUBY]@8,%OS&>CWVF_==!9[$26;N%;
M>MT<!QW-42'>ET*</0F%J)2?#LI[("0KZYZ(>;+NR]ONE=A,.RF*_4SQ_0F
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MK8,,&%3^6HIWX+\Q5B8<M%02C'6(F;2;AM[LI$S['\WOE\U?&TF#B_"\!FH
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MDZ17-X\UNZ.,[BZ<2RZE<WIMWJX_;8>2>E,T6>S5D, B@N4MO1=1+W- RR8
M>[-UYG&V(76OIPN .?O4 =?:BR7[Q\AC* 7^0^!3*HO9FA#X?"P,0;!69(;P
M)^&L^%+=6I/"@6NJ.4'YJ-0L!6!6+6V(QS' >;B&3BZ&'MRT,'+?JN #/_<!
M.F2V"R"P2LKB?#H35!?[[4HL8Y:8/T%>V^^F"09"[3'<K=DD'7F765%U)EA8
MXN!/G2Z;7?AVJV=<T5ZI!^N-UB[' K#+/$+=!A4##'M@--X,(=/08A 4 .F?
MT'XQL#W1R:< U@Y8K5UZVRUQH_8 !UVLA@?E$)5-#&Z/#DGR"97SJ8L//B(
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ME!4.L54@OM%'!2TE/*J!%\\F VQID!:JXP,PN Z>W^2%06_G50W&U=4M"8*
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ML+GS)&PC\7K<#SCAZPEYR)S*E% 3NCTR&RA+ "9RW6):>[J/\'2_JLP5I8Q
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M'U=".EW1.6I[B\IWEV?GM<:*W]2QXI<=*_[IN!!:/5D,K391#\+_]U&[X2]
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M5_70:VK_BL&OU)9*='5$."DCI0$$XQ5G90UGI)9C8!6[&P'"%\)CN&^#FJQ
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M 'Z%)V5)#\]:.C0_FOV'8+J6["69KWA2_"4&0N58R/->]UW5Y;4+]<)>%DY
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ME7:FTR &'W>B@&__GS^9_@)6!.;4AH<5EJ[96KC",EYN;&B)$WIA@Q$8<D9
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M8ST(= _'&BD%LA!O 8E395;4$2:I,%D?2O74YG,N],?.6HB2L2=O3F159(,
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ME5/#M$44%S".-=_N>%3M-:-[.0WH9870B;E+RVX+ON5II70LBI#[@V_XWV2
M25 <S43$/)H;9Y>,>7.9DT%$?&DXBQU8MW#K-J?@9X=P&+PN:\QMYP:TN)]]
M/CUOK*HQT(G PF7NZVDH)IC%VZ?"#+:K%@QD,&<=A-0JF 8T/4K/6R189E3"
MRD7202-XW;#Z;X_KI, 6DP+E1_-S0ATS:7B'6J-OF<=;]T%SE'"=SV==6\6+
M6I+YM_#VEU7Y+.<0+YQ,MLCA.K/]!KX3.(6//.#@ATRIE 7YZ)CJ6 B'.1E
M9@#S>Z@$S$TB#A*MNO5PE8^Q["$,&TFA0'<6K1$^.WX3'+S1F.[B6*EX8W.X
MBPA'6XQW'5O'^^N*#'+-4W8E*[5MP5/#*67;3<9C<&*E[LRF;&*V3I=5V++Z
M2@(DX!28:),3P*@*8V*<.B # S0_U0/HA'# HJAO)Y&K56F.*\5Z4YW+=\L0
M2BG!]2F!,87!72"&>6XM%TA^8;5"+0(+:Z4M-9-O(VL&'G*#R7CC>HB!;1%0
MLR-F7Y0[$.\F;,,!5@N!;Z%J.&E5KU01I*D%W+)T=X.(-.A*K7&9'+(A\.;M
MP?&[DS='!0T"ZG8\UM6*K5-E(V=$81DE&5$8TBG)AK,LLVHO K,@IIK*ID-X
M2+VH/!X^B+9U&+O%P#,J6<Z(MLK9E$F "C#,)L3-:_'Q*J+=:F85[9:0G28W
M$GZ8"5M0$TR2F=!E5M1O5U5 LHT.@U<^V5"TT3!,A^#ZY%@9B8EKXH_!O!+/
MSV+G<J;)LX$Y1EBN>7-+QU0SK2:I7&Q2O$V6I$H*-JR]4LMA& U-:;E,98+R
M+ZM"H7GD7*03' Y)Z:5$: J[Q?EA&FN>(\^\KJVC(:MH"GE#_I"$BA+):1*Y
MVG&/7*WO/F8N&^CZ3S$,D%.87Q6@B]_G<%KKRE17 ?LJ)(1/144Z)P]+&'@4
M\Y[0=RC-BYD^]$TM\2ZQ(XB ,,;)"J6/[]&RITQJ9B)(YN%JQI8QL%]@9%R\
MGA#$@5S10OE@.QXFL*N2A<)322=(O'']K8]S<ONE[)[=CHR<?7VF-"]UJ9CU
MJ;C"?*^!1X$.-!*$-V2#5MM=>+(X%Y0&L#ZZK$(\+/:VLB .6:KT12 [XI8]
MJ#)E%3F\2S@K*>:;"O 7J\I'U".@?2^4-3B!,SGB' 24H:ASRR3>)/TPR\(!
MH -6"+N)4.E#+IL4R-@R*0S!/$/DS_D6-0=H45I>(,6QA,0D X?5X_>*_QUU
M/VN AGM"B+)*_H!^]A(E8#BMRU2UMB'5**0V'5^-)OE:\4(.Q(!42:Q75THX
M%G[Q>O'Q MR)\3$<XNV#TME':TGE[*O6:#?M("LHRQJJE4!8[9VLT;(T/7,J
MP^7)9X.XS_YR='AT=%P@J?;+NRETQ&SD#?TIVLF8EUK4M'C[(A4 ?7+@1]2Q
MD-T& ;:PY$S0R>2HE>1M*A&GV&;#V"*B5>$C7-9ENT<JW1P"RY!Y.LL !@AA
MGP]D(0KL8#[+F57?I]F.^5")%00_Z<AC<6FIDHQFSSE+6S_*4DO7F*Y]U;4.
MC?(-/T0_4F0%^31A6)A3AG,+-FE6-EJ33L9\C_R=,QP5264KVG!8Y@>A+D"W
M*A=7R'!_^>9PH@3Q-UTN,,V;F]BKJ(JPI O/H3,.ON._ PE$H*ZZB<GDQ"!$
M/)?\H:R7GY)=M5:^?@?:ZP+=.RSVO#[LP=H&( GP0YLWL>]_]TZM95MV,& Q
MZ!%?UJA/WWJ9GHE-6=Y1B'N2S283Z0>C8(^S'&-9#I'I')9CN(GE<'T0A\6.
MO(%4%1#X)'A1@!8*Z)AY%O+=!W(U33![B$/%88F+QZ?:\O?X%#B3P8^CV=E@
M]P,K%3EE@3KM)ASGUB<4Y;E%/DV?;<#A'B+_]#J4A<@3CB-0BDP]7B>'M$M9
MPA]?NG-ZM5YU^/VD#K]ON29?MQ>!2)<>9N/[*=-HQ@8'K6A#\I;HR^2F,227
M4IDJ5;#'I0<-=<-$X01SJRK_;P(J3PPN6@SKW8"M>GGC19#>(),V-4:!0L?[
M$%_]&]EZDA/47Y?//>IF./VM2S?IREM E$%#!=PIW6 SK5L/W&]8E-@JX3_W
MF)04-S&6%5O6P;H+5RW,"O>-IE2EJ268NT>? 5P7!(2\(6<790_L4O!\;W@/
M-8MWP_L#3!9JS1@%0^WQ(RGY;!"%8 V/O'2&78WLR/JC21A+,>P=A0EBL&V&
M(B.RP.UNCVP]2J$/87P4]PYC'8#1GZ0B)QQ,,E:1!PFW$7$JNLVJ@AW;2+!
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M;F%5I"+C[GD?.\WN&99AG+6[K=,^%J3 ?SL7%ZW+LQYX)[]U^BT5W?K4Z:J
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M)UZ5_/O*X0B8D9X3>O#K;3CU@,A*'7W 8:IE.SDL&2L2PF7^/8=I,.J13!4
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MBO4 !AJRT\T>D6#03UU$@HUO--\Y_.#6^(,7C_B#GO*?W<?RGT?\P<WX@T<
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MI3%O"@IUHTK_R,MIHR'M]?$@-]B>F-"F T'?HB):<0L/OJXRVO9UME)[&[^
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M1MFXK:5O %@"8^$[G[=UTZ:PPK #W&'<H^Y[U@Z1H%7#&S9TI2%>N]P-ZXN
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MTO9.+^XP:87?I8 @0Q'KK*JG:9G_6PJN8-SIG"XF\QML&NV 2@-E5<)<E?Y
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M>^)<KDIOGKK+-K@W!"K N7]2NDA%0TI-44AZ2=FXXC8F#P.@@YW*P%$"W#@
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MAN:3TX-]OG_3T86U)3F33NGSC$.8]I/NFL<@6^4)&#@9-KHHLM1QQ=#,R-C
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MM2V2Z-'AM$H*NT)P.T-)'7IE(KF/[@L#!?2+T,)Q;%'IT$ /892.]67>>/0
M_08;>.55X8+36#B>!]-,N:O+@DGWB%#/[P./G&-X_2K3LV![YN &Q#'\ JO=
M6<IJG?IFH7E:<'K/L23@=^&7-&S>9HEO<NR>ETN"5DI6:/>5,@PLD9[UG;;
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MQTIL)A\.N[B%P<@Q@>AMZP9F#J.K2F_AS:3*5=A0V2KJ5$=D#YVH4>EEPKA
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M5I-U9O"_]JHQDZ6 ,K834N"^?\=(6AV1E=QC$"G'O#P@YHUQFB,(O]C!=L>
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MMW2]JH#("@\MZ,Q[D^R?_\Q^_/D).UD5,Q;01#+I(:?#,*E7^$,1$4[<'G%
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MI<YAVLFOOT7C?]3F?>B7WM7!A@-EV;C>5)A=')OZN@+C;Q5VAV#@+3K\A66
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M;VNUI84@&.^KNB7$+&B =Q7Z.&$2NX;NBK0%D/7O,ZK?7;,)'T8[(8;'8_^
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M^_URM_TWY6Z[8U9E9V$.(#FTJ!G88"S@%-.>GJL^-T^C=UY[>*QRA9S#BV6
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M%E[\^"Q6[HJ=1S\S]2!4*VXL^6+0A?G<B_.]./\FXKPM]P;Q"CH7(2HE/90
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MI]!WEG :"A/W) J"#;\(XN[%022 !]5G4HW'<IP_SYR!K ).P@>&>]6B]OF
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M+"NE4/(@"TWW[F.K['.%?##YI@0FM ;^B,Y[RIW?"_.],/\FPCP*>A"\46G
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M8@&CZ=*]U1FZ(]P,P#["Z"M-8S/B(MY*IO&^?W%V>IIBK<DE?OKT[ [PF"X
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M"2YU%E#/GK(*\7 "5^$#*7^$-4!MI28*JWPS80GXJS.7W(-"K5QV,9UY,!T
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MGE, RA2+ F<!@JV."!CS@W[DNR /U'!A?&A]>6C[)A'EPR;66JF;I](<!Q>
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M;I50Q4?ZX0PLP2W-V!6"D9Y"6(MHG)$%1/"]&^R%8&W(L[!Y_T<BOQ?RBYG
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MCG!7T++\ETY;5<K,*P6(UF_LY(J7?:=V9<,(OL$:4ZMJ'I&,AS$XJF'B6UV
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MO6Y:OV"P7DZ,_E(K7ONSC>Y;L93T]O(S]DI5^D^O*U-; Z[1>!*K[.$J3Y7
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M SKL^-?Q;RO\F\QUS$&%!G683 U3KIC*A&75V"169.OP&[55S+ ACHD=$[?
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M=F5]P)@AG4IB(&//SNUSK-X:JP?:>QOI]JNI:A&F(V&#QH6&V)M"+T.K!_L
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MH*8BGL?% 0;::6GGRR@#AP3"U)H'4UH7^HQA,I&VYZ&F^ <NQ;]3C*\:TM"
MT'#V'TD(X9! (69J:M[#+)'=6(F_E\9\2R>RF*%BQ]$K&V(Z/=;\6EX-3YK\
M<0'^2KB]%HYO-0$@90OHKE,!O,Q?.EIV9(%,JBIE*L'VL_Y/+SCH7/V^$DGG
M%W]M,@%6)'[UWX=W8XJ_;Y0H\3;>,#I6-ECOBA3+RNOKOP*%CD+]]Q?=CL[
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MD(,M-BH8< YN%)C797D[?\3N9 'H$% AHR0NI @MW1LE9G#@(.V**,<'X_O
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M=6^6.$H7#="$&]EF^U?YO(?&V;J<Z6/89843W=114N[,)B23+"M4/VRI8XG
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M<$&TR$(ZFDV.!>P09LAJ:92=G5=5G+*G,P"SFCP^^!)!P<G],[?,<OC Y'1
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M*4>'#9,X8?>=%. ?I]>GW@0C>6F%0R</?@Q#G/1/NYYNU :9.[O\25$L3S!
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M.,QD"0IAK<W5Z@-K[,XK=4^:6R'ONTRB"[L\<N8J01CY#"]-VIH# A)O3$E
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M^702\;K6K."%D[^_ "X:#+N#WL5_=_N#%V\^A?\JP@F2#&GQ-IBCN'C?1);
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M9RB'_P'_SG"[BHS.=R2(VE.@TYC/QI5B^210IX8.L&;8W>_23H+S81X)>)^
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M:!I.A<A$S(Y 32&G'BNRL/(4'==@)[ 'L$<Y>WQ#N51D-PGS%,AIT&H[DI!
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M4TS&%81FZ/-];,HV#E)1>T\A@T2<FIY1APU 2TTSF2QPC8*3& 0863>BT-%
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MR)S8O?XRV(/A/>(HO5#T[I>846#6F/G Y>-0&.R2_0CDQOL7%+"L*Z7E? A
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MFR5*7C+4"?;"2KL7[)CCZ,$80L0S)QYNGT>I>]#D +J-!4.G;46A]2!MND0
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MO]=QG6Z[VUV#O>X%$>PUSE. 9NHZ_*?'@6S)Y4$ U@X0QV<9>UW=L;&=;L$
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MQ[D"*PS@TZ,>+FA\(7>LTHBP!:S413^ 0H(54B5-LHNE6A6KF];\I5=1YJ:
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M& XV2F?WF":.JZ2.&+<>Y;@L<E39ZCN7P_4 YAX*%3TN<A$8J/'P)1BD#X/
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M(V;;!A'I511J3?@-6/9HOFM?@,Z3Y?K(L3PRU7;)4K (U#/:J? 68#7T*)C
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MM\)_()T%-$;*SX7.MEN7-N8<+:HUNJS/P1A=A>@AE&A%49A=N98OXD+ CLU
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M8&:-=7SPT@>OY24_27](@!AF&$T>OUG)QUA+'H)NG"MQI >=$B.]2%.4T/,
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MNUMFQVX2 6U=_@"?-@<7U;L 'UB!+TN+.4]3G"WO\VS1=?P@<_H+\$A<OIC
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M+]&_Z149K%.E9/H)L\$"^F3[31E"8LGC92?)ZGH5)=*_^D.<&6AOG7XT+>5
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M9I*$Y,5/&%UC!Y#1KAP4&(1Y0%B-3+=B;1^TSB@;SF=<(WWYI$$7X*]2G^9
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M.]Y)!\M-HD*\#I=T?4(^M#!&A$>5U<,*SJC0X#O&Z:'1&\G$'1F2C %?%E7
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M+/$4JB/T1Q7WM=C/P PFV<NRPC QDR]BR?>",2GK?\EWJ<#G9B%,(TAUQ6Y
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M#:*]-K$G'  G699_&OI$!_5DKJ_L$D6^\MB945XL3$%?A/W*D'RP'U2$VZ6
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MISC$K7OJZ?&_"'M>;2I7I+IR5\+6+A[L@:0;A=>!)#'#.H6==,"I)(<RBC?
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M%WMU+N<G52B5@H4EN(#R'PY76+%>'#HCIC39U@'UD1+";F'S8#3-8-DJIP^
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M(0N47' 3B14I@LDK&8CAQ['KHC=5I,)SZ44:D9&8#"GRE(3?@7"I^"X3=1,
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M;M<EIN&/T>W.31)B?4-J7HR<+48;RBBW3+F%HHA/M<B"(P%0HY+GZ< V8EO
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M:UQE*HX6"3)K0?,O!L8;AP?C[:[9;?=6!?%^KVZVNOW]!'"K70'XC@&\>7@
M#A#;::] DB?,56'FRNIO?*)9C>\!]I,1H"8"\BVK8_9[W?W!A0I WY-5^8
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M%HPE$NDK(-HK(#HPS_O:_-#4F.$3R:-I#MPR6PW,?5PA<V2K@,]G?Q3T'V:
M7*,*D"L(D-O9'61+\A=<BN&,_OHJ\*>MMM5J]'ZW6OU7[Z^_77XYO[P^NS)N
MOG\]__67KU= 6F^,KY^,\Z^?/UQ^N?B('Z[/OOS;*(<AJU&R ;TJ!]"_]0IR
M7/"TD'M,]S#"&1LZ8Z1[[MSP_(B-3%+"QK[K^O?D[/8 +*8VXBEW2P-"^I@K
MDOH%J$=D4TB=@YDRH+W- O]A#INR([*6O(&_<;(H#HV1#RN"R8Q;+ G"QF,,
M'Q9I*O#8S ]AG&\,R1$##1!IQLW,=:+:DY_5]]11"&[)(C(/11-@8P'N.G42
M ;NU V1T"U-X5HM =*93-L)$.+@<>XRF/SCG,)Z*J<18O/$.:/I S\G+SR<H
M>]#PA\.8Z#C\DB>8N+6W!L,T)EK$!( >7F(/>'D\3.I3P/Z(F3><$T D5)ZR
MIHA4XVS9[>,JID!A>(V&]D]+C\*/(P ?C\XRS>MH=;Q(3+(PFMVP#8^:9.1*
MSI1-MV0T&5Y1_KI"BB7;44./4CT]BFKCJ&HX3P_Q'XJ %M!YQ"(JL<TQW!X.
M0<RSO2'GQ+3Q(':3"-N;"Q[$(H)H7,PS&[KQ")ZX\R-B_4A 5.K.S+]G 1\+
MA(>9( A)HEO-^ VE!A@;B .?RBQ&,#4/QK8*600.%$;C0@:N#@['N7-&&&H(
MRR C[MR8P%.AS\4.>F\DE\H7M\J",]EY,.(]2+ITH<EJX(A26 [X$"U>%ATO
MLB"<PQ[^$0,$K23[B\P_DINH212?48I="-9$RFEP'F81JBQ'%,?T?,@40N+E
M9E,D.74@*LZQ"6D')TAX:W)6:5J?Q<',Y\M"7(DC2;MFO/T1B"99P@D'Q8>&
MRX_IT.:T3&0F$4@QB%YVFG(\>C:\,7XZ?,J:(3BG'7).B9L=^WZ$?W R$,:#
M_PA(P!N./;Q Y&C )^:&:]^'@NW:,^!G9+0U2ZGI@+D.PS#,@1UR8LUA)&$U
M,#* "[\>^&UJ)J D*FAQ"B.=%)PR.GP@SLQ@$O\>8 S(#\&^@'A\;2FP(]%+
M 7(XP3Q9.RP'C.GSL'"^5Y>TJ^3HBV]>G3:F#M2[+;/?%DI&"?IF6(8.>U*Q
M*F?9Q-1!#,*GTX+0=<!.SUT?XW^-3XX'M%9>S$QVW2M\;[$ A:?AQ3*L4.RH
MX+H4%5U$LW3&N2*9,L7(ZG06$RB9=8Z02$QCC  8!0X=N%0G'8UTY5XO?A[W
M19IE.85;BW",4Z\^)MLD"T82:\(X.62D>7SA2/">=O%^<&M[SO\1&*^W@SPA
M%1KL82K@S4H!WU0!WXB@7^:4(IVB)MQ4R&%SKL"0,(;%#[2W9_GVI<(&E0 R
M<;09*K/.E+_54YK+ZBAO(D)B9E3"WC/+TPFC& MP=S@A;B18=B%+,%=8<K_Q
MB#5SB88_@J;")>O(+2.0)?NRBZEUK"7+&=HS)P(I6%#SLC/5Q2VAB9,.S*F_
M=J)<6D2:Z3I3AZ]/ Q5%SCP6P=SA1,#*4.QQP(C-_H&".<SUYT:[)D0"@%#7
M08KV/2-1T3H8U2.,- DN/V5*YDOH*C\ 06[%<OX6P^E9+5-X\D&\Y[::$4:W
M:"!\=ALP'J%R;X="OY1V'?8PQ#H$P*=Q9%3LD+-.[81LJVVF;ZU1ZW:;5E80
M2K MK:!O*J(DB\HL&'<$Z +J,IVG;8QC$%I.1XX;DT1NATZH'9?P#K>$-A33
M==JP2F<6NS3^G>W&+&VL1MD_M?<_MUJ-6C]UX\9)@JZE*/&:;C=U3 5CUW/
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MZZ )!1Z<<:.Y/1SZL1<AO1X[P=3$5=$61O B3N4$\!;Z9GE N(\##MUX)!\
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M'P>P.!!;D$O*6['=T#?4*K*6$W/5XY(,S@>^YT;.S"VY$=M3=Q%[5#03)?R
ME]D)HR ><IM48I47PNPH05N;&+S,?"@@1/9M@!P8%B-6CRN>SB(7! LR+4N9
M&/D!/QQXDT*(@3NCT3U"^_9,Z7Q2-0ORYP-7*=Y&QX-@2(4TT1"J!L40C-0Q
MP"LB'$ >;S(S0EE"\N[)($\;8B.0Q<;&W(^->S^&>W.='XQS5B[Z%V]$'XXL
M$@X?0[ZE[@[>D4!6.GYVL9G181B0084@+B0=[8+'6(Y=JAG\?$U2YIC+9A,?
M!5O@$KU.Y_5R(:C3ZIWVK&93BD&P,1B)36W'19B;V4"N_C^'ZHX J1"VEK V
M1.L#]\@!NDEZ<8[PZ+O&EYC2BM4ZX9P"C?$>N!^AN\"/\/Q.!,U!\/] 8YJY
M]OPM (G'_M_[OS@/;R>@C[" ?W1&P,OH(_P.=P9X.02B-X7)1LQY>X$)>?-+
M;^@'(-"3!/01D.+K./45-^+SL7JM9M>R.MU71)G@[+ZQ\5]?7=>MW^&_Z(7\
M[EN-WYO\\ZOWC;K5.K6LTV;]+V]2B]C!FGIE:VI^]^M-L:;FVFN*P]-;VYZ]
M_<@&T27A**+PM3W'?[X#2P]S:VDWVIFUP)E8-'^=SD=\_OW*M[TS;W3#Z['-
MSY RX["?R;T;ASCQ]_D,-G\6!*BPX(]G#T[X.TZ,;^M/7OG>+<H8N%)\"Q_D
MCF99.8FT=&"XT<35"K<1 Y[Q#2'##/SX=F)\\>]XZ0 11M7(YGX.;)<T827<
MX%CWZ,7D/H$ 2*Q#7@$@]VC\4_,";W1=(<",(Z&3998#-^!S55@Y8>7*/H/P
M; F;VPD> E8;H ,T$%)>UW+W^B:-"R1L  -BX?N_  W\\38<3H >PE49#_1W
M!*?WUU>A QH2>R6^FP1XDV/@7:<(1_5FTZH]A"-"2'H _V\ 1'WM87Z?!:SV
M,'7E(T!?X;5)%,W>OGF#TO;#('!K?G#[IE&O-]_@SV]T?\U5,K$<P@Z&N5'N
MFS2&!;3E#3V%?GYT" ,O>R,7#P-,72]\2P\L?ET^FGLRO=QDY,T/:L3&ZQX4
MO.)XSLLZ)M<>K'M,\ IS7\X)#6UWW1."5X:Q>V@(]R9#[MYH @*7;(J#$0PN
M#+TK"D<P>#R"H3].$0E&/@ AW<"$?R7&S$8&-%\M6$=*AC/^YX_8C]YE1#G^
MI2[]&98N(:*49A2(C/1=>I^YP 8I9CD>6GJ+GG[<TEP&FE9P*H+6<2D/<*Y\
MH0_O\M->?OEX\2_C^U?CT^67LR_GEV=7QLWWL^\7GR^^4%1C(JNN=+O;.M4B
MZ]\A'>NY'JWU245KW:P0FBFB\J3;\=\4;7=!=OQED9J+KTO?5&,#,-:'6/=<
MI *FJT BNV-)[D5:0Z+Q!3T0F1ST#8B]0)@BTGO>&8*ZH)JS$63R&;"9F6O/
M0OA:?E(_I0[@U?M4FH@V7/)K)CO$Z'?66>(KGGQ0-) %XV1R1 Q^H1N.?S@O
MRP9!F2N0(RS(#!+WG4_L,2BS)WMWV7,&P,\@C&[_-4XMMLXE/([OI-DCS8BX
M=RJ4?U#K@ZGM/A]E_(MM</GI3R!&2U9-/7^$ Q"TKTLMY/=;$O(KJJR<)9&F
MGYQ@^I<W=IKDY>"G!!T*&F:M<+OK/*W;@DB$R4H_FG'-$ VPUC[03Z>-53>.
M:S**)LTWLZO0YW#0IY&1-SX(.\K-A+$HK/"C6>''B\:/9@8_TE+X5U"@>61V
MA2FM"E->-*:T%F(*&OT#-F%P$W?,N/+#"F-.VQ7&O&B,:2_$&"TS*!2A3[Q(
MY+S"G$Z%.2\:<SJ+>8T=4G?,^XK'G'8K3'G1F-)]]1YSP2EV;:ECH4*7W@[0
M15;XT9<[=)D=8(?ZR;NI_2 A2#A-*F?9ZE?VFR=+06S/;?8=L(@9GS%"2'K/
M/MO!<))RG36EZZQ1N<X.V'76KEQGE>OLA<H&O<KVO]CV7YDT7S:"]"OC_ZJH
M4MDR7S:J6/7*_+\NSE16S!>.,U;E '@L[E1VS1>..]G I<H%4(HKNS!J5KAR
M0+C2U)P :QA,*]1I]BM_P&'Y U;R F2K6%?Y,I71OS+Z5T;_%R$,M/2$F2I;
M9KV(S2H=X(5C3S9FL_*993"D\IF]< Q9')N9.,U(E*[\ @4H5/G27C@*=9?X
MTCPZ:53DKE6IRAO5#;'(;_"1C;&L;(5<[<KI]L*1*QOU5#D.2G&E<AR\<%SI
M5]D#:R%,Y2XX/'<!T(!PU?2!,L=!E3%0.0\JYT'E/#AV@:!1+R69E2$TDTE8
MN0I>.*Y8I;A2F4371:;*J_#"D:FQ(C)5QM%-T*SR/+QP-&NNBF:5F33!FLJE
M\,*QII4VDZYJ4:I0I[>+-)Y'&DQ+C'$I:V>^K991TE?+X(VUDN&3QEHI8Y>$
M:VRL9?"66T9P.SBQVDW3D/_W^MVK-Z7FO6:MT<.74PNM=;H%:Q5?IQI9&F2/
MU0$;)*17[[^3J8\+5%$&6!>;EC. LNTF'7KE[RW@_Q&UXWAD5.<JQNC5>8]^
MG@6-3<O.\VE.Z#MO7*[K *04X)<??&S1"X?W43217EXO:*4CV\"W4M"S]I#@
M\>O,\:B+,6\<6>A3>3FP]T_&&Z7*["OJCCKD36*I*_M0%Q=D.[N0K*E+(9&Z
MWD78QW< \IYHZGL2)<WV7F/S4P3NQ5DM)N_]S5Q:1&I%84K^]Y7-RJ1&MXG!
MRO6QIVY8H&8SREWF7?10?1BC^J!<:'/*O8FP1S0UGC<59LKE>%+$PB]3:QLK
MT-)6>8*^']Y='IO)4M/[@N=>U^ (#6P8ZG-X+7_4$'WNC+'M!#BFXP&;=U6+
M6=GO.,P.,?-#1S;TUBYEU3M)#B*,77[^>-E^VFZ(7ZUTKKSS.':RQ^N@1LUV
MPA)$2T7L''W+/)C!=>?X.YOA28L6X;]YCM():3UGU-O0KFCB$BKPP0X=?C>2
M.KX<"OB=V@X7(I:-?3HYA,\ GIV!XR)LIM%%]7^'1=F\^VC-^ J(FWG+(2+!
M'F;4L]GV)&)+1I0=KG!%V+..>@DC92":'=8,H.&X4MN8<4E*0YLQ2E)!(FNI
MIO9"Z)(HKPE?7T''"1%$A>QQDL*JU\;)]?G9UP^O";EQ6M& G;J2#[!%:2+D
MY;JM:T0&B11,&HR(H="3O]5N:L:8C1"[C9#W>T6.X=KWB4!DSV:P<%(#>"-Y
M_ %V*-H.AO)V;I+W\8F+A^$$F\/B_%,G#/'@Y9"TH15IQ'K ODX<RI/Q>Z"R
MHYBZGR= 5'0=U&D\@D,"*%#'*L[JNVA?+W\50 "/V-C?UH!)^?D",T"2SJ\.
MIT(X\ >1[6!?=COT/;I*.PSC@'?*'?@Q##%A\$90SO,0\L88W0+K4HP.+U8^
M8JHQ1C%UVV5!0,W:X358"&_4JX Q1#:> F64BDRTZ_!VO; GYMT"?M./8E<F
M-:.G70GF1PUZ/5@*]:3W7<._PP[@:@<!*4-P4S7C#!BWS16CY!Y,G"B+5>*X
M8*[80\D%3QTQ%>=<=3YC *>*>Y0,>!8',[Q#&$30)'PJ3Y;8>,RE%0_)5@GI
M6V?;!&78^7U.FY4$T?-!3!Q.Y/0O!!V_ZA@X=&,,T1+ Q:4>?\A&<< %3$ 2
M/"GB2$[X(RR%?7E-19BS!"],'6NS2T#DYEQMQ,DY A MI6;<X.5I#ZOML <X
M20^&,A&D;"/"_M4#%#A,@]TY(VRZB@3<)JC@A&**S(@3;CBR(0CO8LS2;7&6
M*X[2=D-?6\"=[<9VI 8O%"ICY*LX'[ ^SQD#AX%CA)4Z4Y(EJ2GX8*[Q>!/%
MY'L&<C;\FYD"H1\E<+T!]:([(18^8*[#[@0)U2@SG"F>$IR<1B\'2F#35(07
M@C-290U9<(>7%A:2)#H].!\@:P!?C;K5?2''\R9\8WR[^6S\=F-<75WO8L]K
M&"2?2'WQ0;$'#?DS4$A[. %<CK)&G"/=N1;.:]5%..\*\;N]#3:FC;!Y].Y:
M\> '?E>?3@LCK"O7SAZ[=G:?JE &IN]23FX>^)V'&^,O\GQ2Z]5]T\(U/;"'
M/VX#D'Q&I_S2R6NIH-0H-$%I^^;;+CIJ?M+:HW3.^2/-'_RK4K@O]</GSG+U
M:U@*.<O-<^OY7=)^P<:K0@0ODQ^>>:<+@JA+&<P!7. )J1!^'(*HC_K' QJ0
MC7!"]C.N^,B_N [R>@5V2G>H;;Z>_"FV#M^DN=^Z62L?OG[[>/'M]/SKU=79
M]<W%6_DA?7P+&"2=-<=78@,BZ:4N%OJV+A!R[<R37N^GHIR+3*"$B!#AKS13
M;RS]N-TA\V%,^;@D"DLR5C[;'M[N*@$RAKCI!"-J;9)(5HV!66V<W&A \ &F
MO+^^2FB0R#L2 UBU>AWQ #'>^%.=_O.N^+QS+"&#@VM'+JV%OSFG%/^ GJE'
MA2P]T8V\L+NP=G87.\!>HHPYZ>A/PR%CX_%BO(:C?(0(DP\E+(MG?!R;7#$P
M<>'=GH4AI4NM<8U\CVO& ,J7GO'!_5CIC@#[>.#WG&?FDA$\"M]60'FX0/E\
MU+;Y9-"*$2\JI A]>7>VRXT:6X1;/?!8Q!V7C//GQ[]<&'/M/, [WJ? 'I)O
MP[.G,&(<GM[:]NPM;O[,&^$_%\G.SZ)S.P@PINP?MANS5^0KA*&_H0GH^BS\
MZEF-WYO6[RC+O3)BS^&_8/3![[_=?'QEC-C0@=,-__KJM FR$ZP3YH1/Z*FR
MH[^^<AZBMUX\/1WYT:EX]M7[MF7VL?A?>L%%Z>\KG^6:N/G2+L_:WN5U^V8'
M6SCMYO(.E>4^&1&[F?A!= H:Q!07\(-QBT42F/-,M&S3$=;'B;,[VW%Q\Y_\
MX 8@-XDM^L@&4?*7D%&>B+2!QF6UFH=-V@[Z+K=(Z8!-U;N- Z-T+T".NP[8
MS'8PB&6&V7,\),6G\)EA2B%Y,;10G,@%/Q"0%+[B:7![P=/2OY;9['<J\O>D
MU[=%DM<RZRWKZ2B>1KIF#XL)U".U]75U]G4IH# 3<[?A[$%8B-%U7S<-_._K
M,BJ6CKLXE/5M"QWW=7_[OKYCT)7:3R4H?/<C#']^F3+!<W#_7M=L]2OM9U<W
MM45&;S5;9K?5JY2;?7.I7/G>;67>6=TD\,7WAKND<6/G@8U._X\%/IY"KV$U
MWN609M>G?$RT;JO7NDV":)E=JW]@]/!XR-YU@"GJ(N4?77,SGL_CL>C%D#QY
M!M>N[45GWNA"'L,7]E0"7,/L-G>&!,=*TQY[;]LT59OM1F6IWCNJ]HU2]OTQ
M9C*^-/U3E"KV;J^8'3(ZB:_CWT)&VLY3D;.>V>_5*WKV1#>W18+6M,QF>V<W
M5XECRP@7"Z/ H7H4&"SU8HA6LF^,M=FU;IE70LQ.OQ*_GN#.MJDX[O+.*M'K
ML12,7*B&JZQI+T3Z&@?LC[>T=S0D?H>=<^OR4X4_-;H5^=K=36U3P&H\H715
M^?D/V<]<^?DK/_]>!P1R/_^S<O@G30=X4I9N-2RST=R9I_@(LS6>E(];O;;9
M;#^A(_^X>'D3:/7(CZERZ5XRDZTL<)^Y^<N[@4JI?YI\^2O'IC+/LMQP43^W
M"RHT7^74/]E*#U68??*<>C>!WBJQ_H A\P4D9(E"]5@[>XZQ72]"!Q-[ON9;
M?N(L4].RJOSY75[6%C6TQ@$&6A\5;0IBEB2+'KT'2(-YW+@F!#\MC6J;O?[.
M4@F/S1FTT:5MD59U3*O^A/F?E8#U_[/WILUM(TD"Z/<7\?X#PC.]845 &AX2
M1=D]'2%?O9YU6WJ6>S;VDP,DBB*F08"-0Q+[U[_,K"J@0("7!)  6!V['HDB
M"E6967D?6Q:%8"*6:A&8254;S?#PO:-A:]GD-'E1%OOE;3V3^BEJWK8?S)6:
MK7-Y7EF*@E;&-@7J,!/']2WO>/F73/; <J?],JUNQ^QT=#)TM?@JD54-^Y55
M4K<]JG=L&2)UB^D=&_Q;9]D<J$6'8N$<CT)P* =-KPM6C.[552FZRBU0/^\U
MK="@/6'9 A>,QZBV\U@MF17V_-Z+IGH#\W*@O3'[Q%Z9T;&A.;S0+N?:\3O%
M57/D?$YZ +X ,,)/@3][9WE_[*V=:G>@*ZJJ1EB96EJE&--:VHY5G\=H4/*:
MPO3@>U?(AKJ$?2\H*]/7O$>6I5W-379U:E>S=C4W-/A,KN9CU @4R;*OY+^>
MV=%C<"K"4YE] \_-BWYEF>1:]K=+]FC9WTK9WQ[SOZC"DU&%IRZAV\=.6Z><
M[K'_-9LPL/CQ+$##IO'WC2.C^/>)Y&^MX":XBZR(V30*])8%=U,KV'F>ZX\Y
M"WZ()U-]XO/73XE"T=F@4%2]ZR+=Y^6[[IQU"LL>"OO\SZW >,#]OC5V.2UM
M,+R.HZD? .'8.^$FI(?W@91=MIE#QLNVR1-45R2I%J*"O\^PDMV:ST#)YS",
M*T3':<C&>-9'4 Q"YCT'&YMW^"),E+##FS@*(\NS'>^^SH#<<IOE0M/S-Y/S
MC@3O$$$8?F#XZ8D,*S(^L#&;C5C O]WOF@9"G;I?%/X)_H7UY@S>\<#<Q=%X
M1++$4>'L<ST^YI!X>[ZGY$!XTQ;>INXH_FP&5+&=DLR_W"@-^85;;I)ZK!RU
MMKKQ,_=8LF+<ZU2O&>=.6K%:_&),[$/E+.B\<F'V!CVS,RP*;A1B G6OTD%?
M,H%5 _J2-]D_-P?=KMGK;@WZK+9,4^*UNOP<M4NA@ IUY8++IB.(U2&JS&;R
ME2%*>Y2?W?C(MAW$A.4:ZHY5+!@"#8;+HH@%]"EP1MSV$VR2'^KI;;ZSYMQR
M;-@_YW_&V)H[D>4>#3=,(7L+</CLO>?GWQ=3[&/=GLZMJ!YII8XSZYA7_<J*
M+;7;8',7N'@6NVA+&S[EB(_]V3Q@4P; >6"&ZX=M2@=[O;'+F(0&91Z_5V'Q
MV0/0L"\ D*\LNIE\MY[*8VPA;!(^VQ0'NBJW7>))*]C;_G"Z&]_;#J>#<J?3
MGF@5L62N:+.),W;:-&Q[PX7YQB(+H&)_M (/E-Y0 <8'#HM]\[W>H&L.!N6:
M4D?!^UZ&RBK877?8,3O#ZE"I,VO;E=FI,VMU9FT#^C2%*_-K6Z0WK)<U:HHQ
M'QX#RK4;8T3AEC=&N(ZBP!G%$7::_^YC*2? /O!= .S]9Q!" 0OW58D[N#*[
M5]J)7CL4E]EPH-\QASU=PJ,%G58T:KJ_5L>S#E>^2V'ZVFDD>YUKHQ2,7GMV
M7F[I$;$M1)P>'EL7Y>'X1I?637TX/@S0G8)_T/18M;5N+[^U5 :G2L-:#4/A
M:6.&-DW!^%7Z.=G^SFDD*];#N+PSSG_]CC'#&F/@UO(6F,'G^1$+SXSL]%;Z
MMQ@N>.8<5 P5+$/TV620L'JE"@#\Z;2__6E(S5K: WZD*)0C!NP?%$KWT5J$
MK^1RTX0="U7QBOY[*Z@12/;MHV-'4SA#YZ=7_RA $ZEU9T/4_=(-&:#IG0TN
MT\_XIM*/U8F]!HWLA2U9QC1 2?8WD(&@Y"%98[/)]RC^O"C\^1_6+P40X8E'
M/TOH9+:HWBQ!F3GMF,190F%&(45NN  <1,.S"R>#2M2*WV8T9"N.?/E)P ^/
M'SV#L;Q IU9V:/#3[#Q.^5, BC7SQ@OC^Y2! L!BX):A:7SVQDMW$)=U;%C3
M\<XONN>]X0]42?('+>)3=3@I$!_9?!08I0J,&=(BTJ5HFPM?R!^Y.:A\[7A&
M-/7C$$PHP"![&C-@A)0N3585'%+^-J/!F2<K3ZMPO%[*7E=RVRQW1>E&-W[,
M7'=NV>ABHT1P_%V($?I=O.S=S;</'[^=OK_Y\N7Z]N[C&_G#;K9RRMS><E']
MIB,V^J8CKN8*I97DV)+:*OC \*>M556Q@7[FB8T_EKMD!7Z(X:9XAR'V:@A,
MIS?B[&(>O=U:<]QRG=QJP/J!IKQ_OAHD!"54-;% ]ZR#"@'W]_RM0_]MMO@*
M[^"+5:&U]_?_F!48'SV;V3^/@G_\DB]6V&F@_2YX.6JZZ36=;M#M4QEIE+M.
MJX#>;=)]/)+DMV_L@7GQ4<RJ%T?%5NAH5^&7_M>)IN_C$)9CP<<G$=V\#D,&
M_V?G\T,[W1\=[C7^[NNN".U$;5=!;;D=\3L#[6+6\=%&.IB/#?Y-383;WX0)
M.3?)8$]SY@%7U:TE]['3UBFZ>TN<^,9"9@7C*7GV;- 77'^._LRC2=F4 +CV
M[ _I\3_RZUNMHIL?Z'1EGG<;GBG1$ Q6I,\..N95=>77396_>^-FOS(/!+!+
MS,RR9X[GA!$*Y(=#6?+[OPT"!' 9KC, . Q'Z_?-BV%E^<=MY6C/Q&%%/*U_
M:78O]]B=0-OH3;81M8W>2AO]"$PAGD/NYTSXHU$=$N^%D#/+<X:J5A:&?;/3
M*;<5Q!$H"UMCK2+UX&IH=JXJ&^JIU8-VB2>M'K12/6B/"Q_[(!F3P)])3<#W
MVJ0!;&B6D@B3M"E4^4K =EU2*M &CJ+?S0XH?+Y&L"4*S\U.OZ@W?#DH;)VI
MLS<F)]L0& [12(OXV_J[\=E[@%-C>(!?CA7M&*HV=+IFOU?93/7F,K9R<5>5
M-_2J,LQIW6Q;MB5<,RWB6QN$NCSY8:(X5X/JA'ASV54Y**N(35T.RHVZ:;VK
MG&P;V/-?S#;N+<<S7F-CZ1,#*,=)9%N;;,U-:1L<%JE<_Q6 $J*]LG?/LVZ8
MOWM7U6=@KVI[L^3,FSWPO/:PMD]^ !]Y6"X\M;Q[)KD;<KH6\;0-UT) X7T<
M!%@,_SVPO)!_$:\'WHYWU'6ADB*:[2Z);B&]JZ0J :E5E<\T;6C($>AX-&!!
M.-:,U\)2/3$-CQU/4C7!X*OO^5E?]&&LUZ[9N:CLGC27YVT*(SP+A95K>(-R
M,:G;YK<WU*U3#72J0:TU!4HUX%W8I+X064^M2CC<Z".5(6I9H^YX,<B:M)$6
MUZSY][XC<#X^18$%5.MX5K#X'+%9N%6']?VE+73-BZ%.6V@"*>PA_6%PJ=,?
MZL=X@7J [WILXD3&ZWG@/S@A(.:D17QWF[L&4!#:_#L.BT.Q3)WR_3QFN34"
MJ_(^Z1%FVA;0MEA=]Z=ML1U4@J\L.N2<YY+;@FT0'W#8&N1WHZ'4:;BA5$.\
M[<.J&>[3"ZNMFMU86-J@^W1DA<Z8M_9QW#AB=JO9VR1@?[X18WX!!@0"@@
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MDW_D!Z_ ^;+A3O4O]42>JI!6$2/LFIWJ!)?6X^K*(1U1FG,T3#+Q<E(Y^O\
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M[J.U"%_)Y:8)-Q9:WQ7]]U80(U#LVT?'CJ9PALY/K_Y1@"72T,Z&F+V<;L@
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M'3!APR>>9<&_4.#@COA:]%UE.4-(?WGAMI2L],+\?I,=V7$@W&[B>Z1\4,7
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M*A6'6N@]&-&4G@^$5NR!R'&1QO@!@6G.BB;)/L](N6.DSWR3ZE;U;+&-MHN
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M2VH)IC+ *B'/U^%))CDX<.T$>29Q11L?(]<FMT:XAQ*,M)6 A.]O:?:$)!O
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M+MTD>-%E,'Y+]YI1UK%>$_=Z8F(U!NAF#HAJ]"E%8  PT)6!QRE%(E/@Z,@
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M\J\$<=4G%502"A7=)$UZ\SNFJ$'2L<I)ST>#:60GODR3OVQ31 QNC^6(E22
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M$?@II" (#^@!>Z"<-6SN-2<_!R(?/Y4Y%,GW^)%4[5TV*9F(C'B!%I[Z)TP
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M$UUD0)F-O2>&C]B6,GM+I-OGPO<\UIQ[,9")KU2ZJV9)0; W@8.25;$Q5XA
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MRF7)YH/3O!;6V*= 5-IES3$X+'???H$3;VEDQ9[#O_$[_/#C][L/KPR;C1V
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MT7)@QO6;%?S!(HX<SL0:).J.I/KD-YJT.B-,&1,XZ*'*5*M(X_Z"MJ[H7-_
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MUB8@>NQ8KC&RO#\HV]*"S0<SP\4GQ-?F@>.-G3E]R\7!@9C@MC'%=!1]]D+
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M0D++//!!^[4)$_$<T;,Q;9$_\"GP9U)1R*0Q%)0M==)2V1<!_3?KR9G%,_Y
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M(X5/C9DGFXQ0U!A_0^,M.5 6;\CBHU'K3O'MF8'1"6M&PTM!9T?82K2L"";
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MQB36/8W2TBIOPE+7M,%K97_K)%K)307>C-Q4Q\VP9*#T,X1C(T2!1L [I<.
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MI_S3( H><#\UIX9SZM!_T3$7B^4W%L9)>)'$(Q,U*?T!+YCN#_IQ?MAD::T
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M[GS7KIV=5]G]Q3Y>.\N?1[SGT]BJ(?FB8(1;M@KC6A:8^;(B(U.5WEP%1I'
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M'@<0)I%-<%2?$:QL#*!.4 Y!;.1.@9E&EH'SD^EH&4+0 $41;G5)%4AU "I
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MG'7^=M;A_8ETRLWO?N\E-PR.W?'QS!W]P8)$XF/D^@+I,B8:FG/QJNS/CE*
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M7%G+NZ5\<C)O0.>.Q".QVE;X2@!9/)KE4L$G74V:1K-JH[#+?T+SF9=0O@J
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MU!_GB:\L^A5^>,D]*3K5HNSH!^/%M4RM-"#(T%FT5TUL5LN-' I<Q='?DS,
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MI50T;6S9\(E9*+09A3&$[XVQ>+(AI!+__>3Q1/ML\= &K!!Z,A+"XI=A_63
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M4^6 D(J<)@5K@RO'_D ':0J>7EQ40OZ<:4P-X?N C' XD<:^0,87BF@*,SG
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M*@#8FGU]%=W2YJ'L[R[8L-U>E+O;<@3C0;:J0!$-GT#/6KD"JD)-)!473,O
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MILVZIK"60X-5L7JM6G^?#)OD]^.$L921K&TPYE?'N=Y3<MH-?=[;A_T<,1Q
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M7M>&&UCYA86]!V9V+%93:GTSGP4$QK@=8H;BGO>&N H"SQJ& ;;S?W+Q+BK
MWW-M .[S+>@OC_D;:V/>UWNG[6SQ74)S$T&K\TN]>[G9:'YKIAR2>FS-E-W
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M&8&@!2X.8YR"0%9[<1\/#=\:\9X*EAT&<;>F@[0>QA[[\X.88 5P(C 1!
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MT5E*.ZVN6EM[<#HZ!H #LTMN _\):,;^,/\#P'+MW4B@#!.8[*T^JVNV.CH
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M #1&#&ZW;>#; W@.S 77>I LTWH,&"DD6:8TX0PQ#I!U!OA*NH"@L(3P8KC
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M6OHDP,91\LNF^*8K!E[1/$EJX"1'H/'&%1/_V3/X=!8G,"8.3C1$1//&&'(
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MC]@I##JY:!CJX?_K;X-VJ_\>.[MCU_@->BP:!4T6=WV(?$((_OR+X8#6Y8R
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MO\>FMJA;3#L6HY/;;>/9"HV_[[+#_4*XF/[X$8Z8T-^+"*R$%(-.XSR?TT*
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MNBU!3"R<A;K):1C^$) 3+I2D93N<K,6W\O@48[AQC#T;CX$P]R;416@YO9G
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MS_M>M-ZWNS_4-'TRNN[G,Y&GO]^$O@?F^L]&&$]A\3F*3+PLJ'X4H,.P!&!
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M_S_KM-N24##2!]I..GA=\?IQ9XVD=) "?@&Y<P+"[_.P-BA(?N0(7H% 21^
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M3M6%-/^6>A]-@$LBHA><5*)C3"P(A&QM87JBBYNN93*'JG'7,#XZW/Z&%>)
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M"\ E$@39+>(V2E#2$5"D*Z]$(E&*^ M0"6(O2@%Y,DDAV92'%[$-ZH['E$F
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MB2Q91V!(<'&B3IXB16P/0_(38/DB3J0V2.E4GI]:F Z9UY7OO\@S%IR55*9
M"_,\QE'@1U3UP?$@.9]!IF0L\E;* T2'F(<M!GBR X"%5!>"V3DR0N!14VQ;
M@ITF8 M^S(KI!]>C+Y6K='4%717ZN@1LU'NK%]5R*4'SN$4I TH1P*#H,D!J
M,J>0Z"JXJG<EC4F*'T%=\/5TE4+%SPN-57B2"AWBI4%8GVQ3)M.B=@/Q0D8?
M<_"C,'#EG,)\^UHYC$QTN^<'*7^-_32(G\A)J+V,GP?#)"\Y/0VH-/+G?3Y:
M9,_=!JKGF\QS?4(TZMW!&@91$' M[/&#+3OR;]JH#H=^7L7&"8;ZWY'[9*AZ
M:)]1<TY"-FVN$6K7\HW4C(-,_)"KPBA'NB2W\T%)R;*9+<HD=3U9J#^FFK(E
MQ6?%&#%),\1%4"N O8=<UB>K]3+,RWJ/"5HC.G@B5T8.HI(FB;XH2;X$6B 6
MF=EE<=\D5*]&F$,FT'2!+_X)2]T09A7R6)\*A5L:J9X"L%SUX:G+3!504%=[
M0'LF<#WB:Q3UCN_PTOQD[DVLHRV[$$X!3["!#IS/9WF$)ZY8&Q38RBN7:0G:
M G<R-PL9'_S(W,PG?12+\@(?<[ID8(143,GO"*5:H%[*M6"S>M>;D?8Y<RJV
M-_.;X:PP>7Y>#=OF($@"3TE;M3F5 C::V]:X\$$G5I8HIS2 SZ4)!,@)K"G(
MCNC1$K0F<L"/N9!%4)%)$U#JQ15#['#MJI3J$11[DK=(AA[W[4"TXX033G+5
MDV*4LJ&5EGIN'%/2Z9W*?\LS2Z;N U$BIY\@6J%"B JV_$4FF&BY6C</W#4K
MSP9=7+Z(?RC/F^17H5*^Y?1A59"L"M71ULO;DV *)-Y<E)3T"5JX97W43N&7
M5"3.LV0]"ED:J1'%A9.BI'(QO>@V9+>EGHV6Z$DZ<%[6BAX[J_@NB_#3I&2L
MG!YY?=5EVR^:;'NO4H[W2V E$4G)PH2[T0HA' LE'T>Z@$3*6-;A3)U-*=NH
M5<>AS"-6?Z%5)(\'7$(:UEPEZ<2/1QQ@)!^?YX[ //7H75NW_\(H/ <!./93
M%0(Z\I;(%XX)^-6X#'DKL3B,( $A%V5!R/BS -L!)&^PT8D;*\TY;ZQWKNH#
M:':;KHSMA*:T4<&/555@<H-'2OA8<(6 M!&VOS.?B!U;2LB]S;6L8 >.8E5S
MQ20RO8>M=%E,IA60H!I;V&1@B<&>@L*$4;ZA!)-.<9@RX"QP0!Z:-[HCXV3F
M/C ?Q+5NHV@DRU)8:Y?.%-4;@QK'8@XJJQ5KF5(Z0R=5BNM*Z0&MK9<LAD,=
M.RZ>XPT5-9UYJBZ<.$^RRI^69R&= ACX?M*4$[T=OB6OFMN-"EU9>ZSNMMR&
M8ZZ]G#(WN-6&K"-:WO,S+S"BC0@7GI$%LE8R$9SH#N#Y&/):7+K')B#20WDK
M194.65SH_%&^(+2&5'&EQ!>%*L5]*@=4'C/F]I=2%:2]2O<F;9371EO?3W)P
M^N%=%-R1$H%J.K5>@>]1H7;L>LJG+*,QG)%-7?:FTRRD_H?HLT-)3V7$J!P4
M[3]UIV(9[[62\@(]PTIWVHV8N,&8E6@&F+KY_-P*Q(N@ 3TVDN8O^5UR?44E
M *JOYJBNMVM1%CUM%"'E>TQ&1/_W6 <+CW!FDU*<N= )7U;VJC#T,3&-P[UC
MGUK:<"EX!J!^4!&2 BT8KO!1?D"P[M$F4*Z0OQ 5*9M7AG.QA1;>JQL_\.O)
MZR'+[:N@N[BR/"='X[BN%-0ZH ?F9/D]+O(5A3,( *!I.$<42D8U%1(<!8%R
M3Q\TW3"9HZ0R8N"DXLC4U#5O?!R*6X"]]$;<H4_X2"8F*C !KSQ7/Y?B%'RW
M#[):#B\@"]%^S-DPV9C$9<J&\CTWQY1EG!J-N3ZS@>^*A:J9K\I)EI8,=O3;
M8'2#&*T_*BHF3\_P^PA<+<!L!D3JW/%W(*M/YR>Y* K$K60XB5XVBD$"5!AF
MLT"VJ4VD&^!!1;^D_7>=@7#@[\]E:\+SL@4)ZTDCC-&@QXU<MOD.M%2GDC#6
MJH5+S3ZDECL?6#M%]+K6U.EWNCI].,3*.Y,0M]?VERNT%9UJBJ+/@3,\>-&G
M#DG9>I@ O1S$>@DHG"#OD7/@@Y3V2'K;;>8SV/-D2<RMJ+HFW2J\C5U)A5QZ
M'LT*0H0UTMCW6$6B*0+TC+WH4<26,C+"L@5R+Z4_^C'OD=O.%;Y&8 H?%!KF
MNZ8GI?H^G071 VG6.[%\\_5UT4Q)-LDRC8H[B6,Z#EF849RWI_0U[4DJNXL/
MKS(1*D&4&R(ZD+0(R=O !=RX]B81=HKB/Y^KO'[*[648+\&#2FCOSGU77*@R
MZI\(#?<>(5N  <R3&"M6/'XN=P?,I>&6O.#DU QD2R\-) &'Z!X*NXAR&#5<
MG6>9FMXJ44 ^<2?G-A3=S!>5,2*_Y%'7"X8BW4 %*)9"IV)_U&US+I0FFWFI
ML!RQFP0N63>V_$=C;=O/9%D3!_PT*=\98P(&6&8\K@2_4R2\<^10SBVI$' 4
M\XG=J;B/XK\4?LCV:B'U7$ ?'OLJ,9&7]*<OV0VP==7USU6-\ =OK&_HJJ(2
MRR^H_B,\K_S1P07G'WK/DB^Q?P= "A[._RF"T3)5Y-!2L0:J!J!EC794)^A@
M*DYJ@+.L$9Q*1ZS1INH$H(_44+A&&ZH3<%R#-8\;?_JV6M8_\T98JI!,=_9F
MJ2^3LU0Z)6D*J$M2XW5.4>5 01IA)I,@[J;ZIDB/L]2_<P6;](J\Q=#G+[_F
M[87T-H8IVG;E]4!UP:0,4+*RA)TRG :E)YRC8@1+6BF6(,PI/#*4N'3.A$OY
M5T%N54D%N.)HZ*-54PYM5H=4N9TJP*_0H;&F(\&LM 2S'HN$$WEFRF2G,_)7
M^)PR>[KT2LU7G>=ORUPAS%E7'<< #K8T2C4HX,W*4U"3Q+',WL$RIW)5!K9J
MB?V;C.?=1*5L[CP39L%$6 5A+OQR)3[@WP2Y:642$P5\5(I=/CB4$H5L&C\@
M>T&BOTW<@A[)0R\P91CTSEL18R6B2C^2$4N/=%/&7Y7JE.]4 XM/1PG9/<C&
MG1O':)J[*4^D'JGA5O!U/K$*F>@+[47]?X\T6*FJJVAN\EB70S6VH<I@+PI-
MN5QN^5(J=NQ:84:==-'/088=08YG;ZI?QZZTY\OS 6.N@R(&<_3I*1V3GF+J
MT;= X;KW SV<@EP0,S:?56MJK8V:+5,"?,E."^FB)'J"Z="KF#.Y2;3<-(YS
M3G,+71:5Z/VP^:UR3(HLM<J9>KGL,1&A'+=9Q7'*<EJ3!GE$W_\+0#")N"S$
MQ5;#=^2^F!<4A9Q GNW3 !$)M@B;:U(\/R;)T2I-(E#)MG*'.I=3N2BEC@"J
M9V<1D^3NG12.+-RUC[J8\S.+,E,?T7P^/ @'K"AG=P^RY6,QB.=1S]EC5VDO
M];=:)7]KX;M/53="BLG*X:2:#-&N19<C9_XK9ON<P,M)]%)6\YPE%.E:!G^%
MS\^&5?1E<([P^1C+<"F1 TN_8[H3>$Q_+E^?;Y)HT+J+< -Y0\0S_Z[J&W"/
MF XRLAY\$8S*Z1%9(L&1^#@5EMQG4G=V*5M%%83?/%C7[]]A?^OQ6)^G\38+
MP+"@<G'9V]YI#VAHCBHRL$J;(?",UXHMJ/3IO# W$IP;0A%VK5ZKU&E7*LC4
M^9*+2?#T0,):OUQVLM(0(<G"M(RDA>W.E0<KBR2Q5MQ?H9F[9"50"7_1M )G
M#"2RVL//BYYY-K+T>BY'* 6TEO56>"YFNJ?:1"C)AE1C :D\/DH__'TWUV7E
M%\[S]L0:D*E*9LH:K(:""/**KB$KVR1KA*.M) T:[97Z']%&03D]HZ0T.F[P
M< X28R0]]#R'FR ): VV!A4YH,,7.#.\VU/3MD0PUND[24$IDH.U%V8<2QD1
MNS.1X?!X&CNOQ^"!>N""/%^HX@D:^*V;O_HI*LIP%DH2:61TB .^4K$.8I0Y
M306AN[(YU0)3P&7^*^)HGN0H&PM'JW$NB_H26:WSKGX;/0U,I'XJ=\D9$0^K
MOYCW.U^8(K?W*$<I" __/Q8RUQ^1;DG EY.P2"$H?0/3RTXQM^(CE;A;W]SO
M>T_4D:].Z=6E*L75N1.]PS?,UJ%6;I/-$DK*,<;,D=*I^:1%C*VBI;WRII79
M@1;?U!=;UDY.B9&<]\B$:?P*"B\:0RK5<5E9-I=OJE?]KY4^3!61L'PLX$TH
M['Y98Y]<>RD%]%Q/:*4X>Z+<$'CQW<SKX2TLLLICD?37,>!%Z#(_QMWR.(40
M<X*1_RG 46\2/]0LIF([14ZY)U4@G-X98^+?E::J4TDZU]]2FXBT\N9\K0#4
M!^E6 @'S@3QG-O?#">+.V&#:YV1S; 1&QM #9Z2CUD47FB"2HB^,.XO002IV
M04G3>3G@@9HOE)AY%BH]'[>I2@%SVME^5@7"\)QAR$T4 !QY;H5TT<HJ:R9%
MIF&RVJ* S,XE>V9*UL;YP$4L.YZ>9['H&>/1'O-C/;2"4-)KW'M6Y+169W3W
MI1>E[E\BY';E!1[?"/FYW)>D95Z.*03-+4"9-,C7!<TP1=^OEKOAPFY3;)IR
MSS\6Y1;D;2_V.Z;4>2QJ+27H:OF9;FG?>[)UI6' M42A&\#&42&]I7ILZCEG
MZWOT=3&6=W4O)XC.]4!!@,I8QQ>4%(DJ"M?74BU43-+HDQ2;WT"V?HIXSI5U
MC6.O]ZS>X#!&CX9U!VH;-'U[SIBXD?HV30=2#P-1491%34/6%7 5;9$M'!FH
M8G3N8N$V6$2%UUU]2\[\SE*D,.Y&4 SU41E*O_A!AOO9:,.XP-XVK:0S[U@W
M!;D16, CQI0LQSJ'%;Y-N[1VR50O_^F>ZG694674ED8LS0?=N]3D 0EL!FY=
M**;WT3GQ,2D)I:M)EK%@5Y42TA8(@S?%MR3M+9YZK"Z59XI@(9C42,@IRZ(Q
M[[(L)[J5FE%IU\)B=5]'QAAPH5?KSL2CCTYU372JZ<73T7@9D5)\@?!=8[VD
M^"PE0^4PI'R/W%$T$K!*S&5NKM8?;FXM6%U&AJA>*\\FP*IB-\;69LE^"3L/
M,DC-J["RE@@PUI.+8FAEG*X#.];MR9'-B>[PXIG4JB58R)RD(F,-N"[5++HT
MA99V69:$8+>/V&S7X-FR?I-7+GDG==C,M[TDYC8G(]6A54G4*"H\^MC&,V]R
M2ZD@K"M4UZ>&^69.41=]AVVIPK286_D.0 R&T5<_^6LW50*?Q^/SMUQS+1'^
MFBJOZ8W[U8,_5+0!ESK +$*6ZU.U+UBB45+*/6$2U"#'3(I!AY$<C*O![F1K
M:-6(%OLPV-QFJ-1S.2QUEY9=F?/!S;(/&%J:@B>D6&,QXL'B.,2#.@25.YKG
M_2@J!XO+^E2;0M<($UOF1U6L2_;\7(,YU="6@S#K'8KWC1VUS['* 4WN)5N&
M+]J%+S!=B/[DPRO)C43><LX&*Y<78ZGC% LKBTLIG:*(8%6UP"9#E=K1HR-A
M28=M9BI2[5[HLXT N,5X3,BNP%L1>G/=MZNV,]]PMK03"N3$!+.9.Y,]++67
MZ+F%[S1L9#2@JNR<Y9.#;Y1YR@T@,P.6Q,E+34>!TQ )$'*P"Y [4^G0H"P.
MGH.L-]R,U+1CU9U<VQ)%Y!!'U*U)5-F[[<+- TH=^[?.!R/@@S<E/L@=*.C"
M5%H(JJRPB6*<7][7P5:I"46GAWSPJ_K61(QNR0C5VCJ=HI#[*CSB)-;5"("&
M3?6*O(,O<11&Z/4\3/]UZX.XB3/L?M!I.Q?,ZCY<7;]5=JFVTVNT+UVL[/]]
M1MDM1='K[WE2\M;1%+=UWNZH<KX#1[>H569BG<D!M;W.JZH85U%;R[TRA51>
M.5*U+ BC1GZ6^L&@/EN,<>?>ER5G\13YQ5^H@>;.@E*NSZ(?P54-.;^1B^K>
M2N3%%MFP+KP];YI/3Y.$GN4M.N5&2*BZ>0#?Z<P-E*",+-6%AV&3@P3KWFC
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M2PK)[X?/V%$AXJ*[ '*2O)N1HB1L1X7?4GP5UHR%'"2M/"OSOAG5=5\>\4:
ME*5%5,0Y#'D</3; )Z[%[@8Y^$9R46*]+A?UJN1:K9\*3[^C6B(?23L4.&>C
M72&#=T/5G?9YNU\3JOZ*R198(X*AB7>Y1DGRY1U<:#1%9XLD^HOV!7/>*E[P
M/H_&_D+&)DJK=S*D_%Z2_3QK (D@HR]%+%=='"%L+B'O73W/)%J&"(F&,NX8
M.ZR79ZLX?9JMXD@K%07#M @+<"K>\Y;N<,=V0/! TB92&VX?3-T@D)PPW5,V
MP])<2E<IQ$S2G,$]I;YS-BI$_W)#5$[ET>1 FJ(IPS0:<2 9*#J.<H^A2A5:
MR#ERE7-3Y2O$LJZ&QVSG^E5:@(Q:^*F$754&A#$N5_9=*!BF[E#(2PVXJ4,U
M;UU@K<E:[0AIEWD+SX*E)R55YT:4EZ]*&P-)47:MD#(A@CSQ018UJMQROH<9
MMQQPY40[3)08^62]<!??_#*EQD=5>FKV+K);6Z+?O$O+?U4,*Z*,#=+LYA0I
M-<MB[M* B<Y_?=Z'4)X=Z"8\WD.."^&66+YTU.>+:WT,8TH8P@_P!9HJC@GN
MA!Z)H M&CW(H]ZYR&W"ZCZP36"P?50"OU(05>P)PY7A(HE#VU2 !R/$#3:(C
MZU)RDCS0977^<=5]+WSA=^GP+\BMV/9\'Y-IA.U%48F1^EG.AZF()'=7<E]4
MS ,OJ?&E60(2]U532/<F\,'<H@N8T^:/H!\@Q4?.H_%YEI3G%<F!NV/K9:=U
MR;0*UQ!0_5/528\]7MLS\5I33;@%KJ3-<L]G[ $1P4V4B(C+>Q?I2/MZR/2G
M5B%-CIG<RVZK.T^205!JQ5\EPG*Y-/]22I'#:(A\%; [G'0%LF@BW-%_0(G"
M7$02]L 9[]F_C#,@O%6&4J5-M.BLK^#>>W.9<YH/@<R5N4P)!R^L))M.T;.I
M=CDWO8(B_%59TP&W:1!3@I-+)H'(!P-7'-8Z(XT#1 V@1 )&R+)&%G2N3L%*
MEW+6,B?%^?1T.$\$P0SK#</;GU^T7]#O4D[0[_)E;S]__>7]U_-WGS]]NOIR
M_?ZU^F$U4YV'/1/I9>>'-S?4MOEU6^[S=5L2(>XKKN!N**?XKZ,RQ?<Z/[S@
MJ>JE/U(B&NB3D@TP&!0?[9>^\NB/1[ F390OP4X3.SY-;7GMWD7^R%K[PDCX
MKMJK)3=K2?0I0BNM_DR?2__(F==<9V$U$!V J.'/+YP"31FMU I.JXTJ!1D_
MUM_:]-^;:H@O2)<YZ?-L9\7*Z%"535H6L-N!H<&5SK&CRA>P\J5?)HWRBF;^
MX4K*D1+JW,0_[G%[T5ANY?H=_P"R;&>8;#!EU56PVY(/F%]+%8:8*]G7E5QG
M-S(':(&"#TBS"BGF4&4?%+P#642*YH*%^3?/$V(\7BVE *)+S4"KP@XL?<;6
M)7D!",G\$.>,O+;.Z:.G9YI8N@&M@B<O_OZY84ZE-9&+(;^4553L5VYWR3HO
MG_YEG9?0V0BUJ;7[MG:W)F.M.5 Z]B6JLP8,VP/#COAF<]FCELMCSSO/#.NI
MV-VQ@\.Q^X.!83K;!(-1UI[*C7[1XXH-Y3^7W4M#;F?/A,*K9H!A=VJP47R>
MH_A4!P^;P7^,Z54!E*[=Z7<-&+8)!J,%;4D+:C(SNKPPRA H0\^#@E&&UF%%
M\ \F<NP^+:8J2V4$;*YH4H#]R; @*5!I0-&J;EKKC63,,YV7+4'%SC1^N-Q1
MD">-ES/9NS*VOJ\^WNKM6&!UN;<J#.?RW*E+=6.IX^E9WE/TU6OKFKMJ/ZC$
M>ZTL%._QL::? BNU0ZK'4.W]\GK"O(?\?+T5O%EO)D>Y5VJB#G>$2[&),1?>
M8,O&?#",:O-7S/G Y_/>1%@+I7>FHV*+N3*,O)6^GF -"%QJ$JE7;W(SIZ)*
M/;H/19Q,_%DQ:T;K%6_O%)U4/;=JA9[/B=?OC'O'E\[,U2_<2T+KG8@G=>^)
MNN.\@8,^V$#-2%&M_7?0A3))Q>P\F\F3R01_V=K4IQW?1M$(ZSTQQU$?=(N#
MD?*J'BX>.*J:'3_1BW6^513/4(E2J9"W.'!5LI*=]P!?D@GZ>$_;1Y) 4_T&
M3K?B?WF=OU0S_BU26:JC.@/LO?Y?UAU6UO[OB$5=G#O=FDB\H@//QZ(#C[P<
MV<#D$S>*DN*PV[D <?AKN8-L^4D@@<IER\/DOI7J"K6)'L!)9?<1V:**6@\C
M0Q&CHD-VWIU6/B0'@[BRRLH-)7\G@VWN*:Y2S7/% VJJ/V*N@!WO\X*8))=7
M<)(EI<.ZB-9ZW<C!V_5/=,C;FIV#;#C'03>E=(>1N-';VJCI=1+XI8NRYVI%
M84>E*>O<]%KU2=,ZNH-L<T=<ESS*/*5BN5.4(?^E-II)SF4+#6->SB$GC\",
MX9KBK<J\]BJ9-P:\@*51C7]L.:G1.TMK4S5!]Q$GL=Q5*N1)GIB%C7QVKIVW
MCYE7V7 %-(?9OY.*VS]E4QY5->WT7]GK5E/7I7"Z4^IK4(V7*4VF6?:>9:K6
M0G7TTM)EZBU"7]U4 >OFK#8OZ%131E13A;+YOCLQ+#&;SK*!6Z!*)SP&-:\+
M4@E'<OU!([DT*9XLG4"[;96KU,B.-\#F67E66$7/M[S_/9X=Y[;P^#HJ[294
MXZ?9LX+],<DA5>K)]E%O[D9]8^1$RO4;NQ7]:VBO@.H^Z1SY[F)6?6F,T?Q8
M.Q]-Y+G=1O'"R>2QY0%Q"=D<1V^3>/3EJGU3KMKT]L+4'HK(0V_E1Q/[4!SB
MP-P1]SRAS@)Q'-U0T285&T:@Y<1W!"5)$#R8[!OUV8YC<L9Q42-JX6/91*!J
M*$*IIU@BO6'8-G,&@A$'8J'\"54_ ]ZQ"O5PIRV[F$(R<Q]H4U3^ZGDQ,8'\
M^^BA^YX/H .6IDUWM*T1]Z;@OVA-"4)W;V.RKKASF.2](VSVH;/>D!P;>'BN
MA47ODDM,J-H[S:T&J%4B]YLWM:!KUH)V-ZX%O=Q^V6;3EC3U@@]'7'+T+0+;
MSY1['03V_Q_IGGS +Z1Y\L_^(2LTKTA7YHW\R@HS_P(B_(#;^JBL"UE]1B+U
M@/LY^X0#3BWGE:&=PY1*%MHMG_(SJI '1(C/N>[,^_E(*O?A,;1C,/3@&'I
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MUL6@^(PW57RL)S=;E-T,6W*M22S&/[_X6QIY8/A3$1E<\+L(R0QS8MT**%3
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M[JULAK^\=/IS67V6FUKXS12 8\UB'_/8HB4SM5O6M_G74Q);DMTDXC\9_!H
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M]Q;^?BL[4/6P\'*N^'(5H+%1FM8>#2LDEE9;SI=_SF)QYT=9$CP UXJY71\
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MO!%)S?ZC+0>IJ>!CNP$V#DL@Q+FE*/P%;I9T(]4XP8H\[K?/V(K=&.'N1Z!
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M90Z;6T&+V7]X>+/UMG'_I#-I!O-+6^%4@30T$CPVLP+%-#SO>>YZ3X8WJT,
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MQ)2]39MTNMFWS4)"*3[T#*!4&$BO6=F$IR?86H+#6<@0?_AHQ/4@?];D\0/
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M5=S#N<)&&SMET+$?<%B'(Q10GG?_D?$>!@O7X].)877$/'V.VIY>SST/19M
M(GLT+!N%UTF0M(]#C]M#@,20O OXX1+.[%D @>3JA?<IN <%SV@8>P_,WW(.
M11N7J-Z\#MU9_>X[>!%T%!X4K'7.8XA05!P@O)AC(B)WT;[#\Q\DKX/Q9]!4
MZ)XR][="1I.N\CM;NH3DWSR4+Y_)J[.S35( E/W)]),#//^,5-G-4B4I6(:7
M=^Y0<-?Z!!L/<,TG 1A=Q?'ILE/%[GF\5IMFN'I6>FJ_.U+\_X2HS>:,T945
M^-.%U[C>,V] .I^CIX.BPN@6*U@>N/[.6$X]:_; U*S\XM>.4D#C)1PE_!+]
MG70)_T?H,,ZIVH XM<L%4#CU0;[#64%F<4_SVM=[755<=+Z&GA\:7$W=WM\I
MX_X:7/$ZY:&6#2C%$]NR1TU7R6O777<1HJ#;Q6.GP5HV]^YR-5=V\":(C:JY
M[<L_[Y7WH663KV'8[?XTZG;/Q6^WX0/8#H>Q'#XFV*[\: 5,I^FJ-ASLR75?
M'*;\$R@/U>T]?W(#U^4V]Q%PA#&#M)^.*1LP4L"8A@.O?>;TKD?TCGM%+S50
M.."$6Q1,6!,4#EI_4G!*/^N/B.U>W+<-B\)]!!:V K0D? 9*&0,>,T9V3&17
M 5<N$70&<FPVCBB(DWRL9!1'$9&UO<:2P""S.O L<H:8AL^M:[ '[!#_CEN!
MUT8@)8=+Y36WCNM<D_T1C8D0 0Z!M4T1/NUD5N\&HC%LW\VB,L*OP"3<55$N
MPU4 OL39*!LOT3O]M7@P^<O!5@&;FIQ3"1H3?_%&L-#6T#^>?JV_+J@WG(HN
M%RF:X;<^N =Z ;W>C9R;=LPY:L0Z^$TZ._Y]1C8T>KSC;^?W16\#LC C(>3S
M4,.E:HQ[3"HYBX[X8@8NT!.1T:Y*PH]V6ZXGH@/%FH'SAD-N7DZ34\L-F+EP
M7-M]>*8+,+XUT2"&DPX #K#/X#[J1(C/M%Y(]$$,[[P&$  1&F"PAP;X'=T5
M&<;LH1/&QG@4;H7 YOM@9<$ES)I;:](#;Y5XY00 P[WT'Z$M=$GDXDX"R!2[
MI5>#J)DE:\<'VAA;V:24DBWNHY5TJ94N6VI]0$+T(_<._@FH:TIQQXCWSGSG
M%)Z0A+Y%V#1SC*Q]1A^Q^&2<9TWN.,K&;7+Q4'(U,IM'^#)J,GOW*W+2/!F)
MTY+>8_Q%CL3 <VT1^5X3C+VNGA&,Y+ 2MSZ2I6!XD%6A==7>9)C^[A;*10CG
M<*"DD0"4O1;E.9IG^Z; *__Q>C3:G:8*0BLED14>6"F(J_ 8PM\F]-^-"#5@
M7(7'!##>4AY&Z8RQ=T6R(26.EF0VE7R\/8:R*4C2FHA&YBJ;Q-HWFRO&DKLP
MMEDJ)9(J:[AD+FPIT1$]P[?"DYA@*_,YL+Z?,N31W.5J$R\")& WA6N'"=^5
MLF&6[3 QF"C!9+:]0O'@//SRJON*?A="G7X7[WK_Y=MO'[Y=WWWY_/GVZ_V'
M=]$/FSEP'6T\.?I=-TW]V<J)?$$4U4.M55#PQWMO;M;RMK$L:IT<>?6'/BQ(
M;1>[*%IFYQJ8XE?NG39^0)0Y'16GUY>DEW\@*D-GVSU;!2FS)*-6N#&<,KN(
M'V8\(P>_L,T@Y]$M,*LPPB4>GH%R,M%'&:^29H:84Y+,A$V9ZI+L)=GO0?9X
M=UG"PXN(ED%]/W,GBPA:@W98SPOE$AAC7TMWQJ]>,>E&O%'D?8Q,P^+\+LLG
MOG"GL.O(S;)$<RUKH47[XT[W-1>>\). @0>W'3(T4^JES(K&2YYD+LE<1V&N
ME!\AB@BE79-%N1I"+<1^?*+?/#?%5(QWG,@^R[A0"N_7/4GJDM2/0NJ; S,%
M=G[LQDR)]RH"-]PEM_U[F(;UB%5'-FH?/TQ<^YL]&\APF>"RB<$(VV8[VFCI
M2W2!,VO_*UV9.TJ@YZ#.L*GUA'>K: @IV@I4=D1)W2*"?F+_U*V?L2?<*2;4
MH4?4I"*&[5&;V-6="?5:@; G9E%=$CFD/)8D\24>KLCY328*!6_(?Y0 :!5Z
M0->8!/0U711@S%R>R _TQJ&G\RR\52HQ@;_FP3"?E8?0FE$$3+AS-^<L9+,5
M',IB] SJUHLHQ'(&RX]L.,N/HD[<[<U55LS *85&>8\8OXM?-$N/K8_J(S)Y
M>U/#IGW["\:B5(]\CL6";8[[4>%6_#);E%6A+R:JC.-*D>)M4>U4^?>YOQ&S
MV@4*,@#S#&3AYZ*@W4DBJ!^%W9"605E$^Q8\:7CVWBA/XY@R35<NNKTP\R03
M #&B!,\MQH6(AI0OM1Z$+?(-D_Z@GPB)W  ""@(,6CY([B!EU\>">JVP-> E
M!.D39R ".M:D\BD$#8C^I>#MJ"3V=N59=MH!T%OS*Q,T1&PM,>H*G,*H9)86
MCF9&MS-;KNQTI5T:I^?.;Q012U$WM;0<:QDNL[="GPH*N9#?(DRCU-2LYL2+
MH^$+SYVO7)%V!PT,W_;?;G;CT?F;8(ARRV\T?).8I'R?[[K"O5O6#J6;;X?"
M%QOJ;W9H8R+Z,@@#-OO(IA_S+5I*+&5E9T!0)&.GOBX"+8G%VAFL@A=TX]N\
M3FXUTT4"<'YYI<?8%\TIQ ):IXOA&=Y2ZV]=^F_=EA?OSH4##FQ7L5\L\B/Q
M*S_@[YQI^2_"\XX_?A7L^Z(^'[N@Z @DQ"]UZP4G?P-CCLWGFXF+[EA[7Y/R
MLV3*VH:]*,9<<G-"Y_*.".&[W=:2)AW %_'[DG4*>DGM^G#QQ*?1:'+(?HY/
M3ZTBF]Z9R.;0%8IH1U=[VJ#>M',9LJC?(J+2U.ZP8)9V1425HH[5C\TT$*U7
M$53+5M^7R%[>/C1;B=R4_;5!P?1.)0MX*_.-E\%VF"T#51L63&*14N+PGGVG
M%Q.5;'"GEH"5>V8J*$%;:['VXA*T/=TZVQQ7+8YQZ*>/<6138PM#![D*JL+<
M6.Q_:&63QYL^8S J__>P):3KS)(BO%3#IY@O]B9S'F'R> 30<3$R@(V>5D Q
M/%(IVNH4N.B9'UA+XC'1N,FCF ;P,8@OC[(8^7*\M12U[S,4_]F!14!*1A%+
M43."VWNVF UG#3V*>!CVLV_Y'>5]\CAOT2#^DMU-Y/ZF)C[H5:?F5_1^[/75
MZ4[>$)2PX^F+'+W<BUY$@R=OM0![(Q\_\WV6[+0L&8AB0?P,/+F)YZBK40R0
M!Y-$4"+]#0#C3'0BC+L3*3Y;&0152CG'7A:K-2E??XZK?$$04-=:]UH?7(\[
M>>F9IV!"'3(+CX@V/L=^+'/LRW+L\]0@6Q.5"CF4,"8J[C@10$H4;: 6$-%Z
MVQ:1C\$;0N<E.>D WNO12 >;V0_+3^KZ_5CS85_7Z'N&X@"&UEH [& Y;-%+
M6?5-G9X:95*,.N/1FRBV3MDU1:UU6)R$/Q//K>/F5#'R77*&\4KEE^=9KAG;
M/+MY+26EI* [4]>YZ\UL8YEJ#T@P3K*S186-&1TN?W7D'.BG<N6R"7*%%0K4
MX,RT06'SI/#]2E&_>F L6;/H2LO9RR5[6I22[EY$>AHK<WNOJ'US*<K([8+R
M)H;C"O,FQL.]\R9&,FWB(M(F;JF^129$U#$(>:[(=L61!5T=ZL>++#0C7G4R
MLOG,?/^=L"!1+4<F*/!IBT+:5Q/]D"WM.D:V#;$J&=%NN,8Y<:@[&R=X;HL*
M&NC'R\EKE\"0P>U3!K?UDN#V>O?,=(1;6VOU1RX"G!Q&E]7\][N=T<LBXOKN
M?A=U+?"UN673+A/C/+8T+">! /F:=JAC1]<B7+_$$(W+:Z)U%RZ7\$5?^6IX
M?YVQ">!'-O4P[%D0<G]Q%\#BLQ5UBAVK6G^\9Z?8[.J6H_Q?=QIZ3F%?YA(H
MYUO_16 0O?]Z@K&H. ^GMJ6:O<;=^9(RLCM>+ 6[=ABOT(U;![$?S S3?OGB
M+64AO[%;++DFRRJ/D\E0N2;/)_$R?EVK $5(^_L<_4DTJL]WUO!XN"!V2/(9
M%Q--F1G/OF+,@ZA%1S'.\\6NY23[#;]SEW[@-W@@Z2W\;6TKG$1\T* 4"7#B
M25-8R\N+/!WX'\]'1BL$1O$;&^@8+H'^!?F$*ZVE&X_W]@F/I4]8^H2E3UCZ
MA ^_D/<UZ1&6U4PO<N5H![E^+\B1(SV_#=<K)_;\)@Z76M4Y'4.(#%&/2O4C
M Y*5!21U&9"4:DFJ)1F0W%$!=66MK0Q'MB,<F6\_O3$<*487&<X!TR)S@<EB
MY_"A8<8RES-%&(=\<&\+IIU,9"56C:>=;&EHW,@8];"K?+0\/U#N P]CL^>:
M98KM+?>*3V\*3A<>JB V/>BJ_4%OS[%S.\TK7=]!\>S28N#SOJ08;HSBF5'C
M6A2TU ':>ALU&_4#@_<TQ8$>=J85:114CONX8]F5,HV21M8*?!0+%LU,QXLE
M_)4?FHNH!^]F(.\=48V/J.E\[D,4/XPJDG9\S8Z;W!SU5>,*NN*WKJ4)<"#[
M&&J.0[Z:WBT6F*/!FQNEH)WZ&D?>I-11IX=68[ 018/4Q!8>QJ[['@?6%EB5
M19RKB&WO]JX$HDF/D/2;XQ;&:65?#'QD431>3&%L3)GR>C1<2ZC*==TM72TU
MYC7;IGO7,:]:[QS)%]O[VN\^VK'?&6SN1Q^-=L02U2EC3GN&.NHH@"T_WX&?
M6&'*>/=M3FBO>^M9?E1ZNEGXKL_0R)-37*Y+\P9?Z^NVNZAO17%F82GC=A8L
M$8TUR3")"71A\+X4S[#E&;/Q5*Q8ZL;YA+F!C%1F#D0258[&1;_KC?'+^^!'
MVT!;@+JP(SH<MP'EZIM;SJCK?AI4[F6WQK7+6XG:(VY/.!\0#4ON?$,LJO2-
M\!7U*!$MV!42:UB1G'!27M!N;<7_TBK<5F:A?@;0/_!V *<UZ].JRN(9?P9H
M?H_S,WYJQUM3T2U#+ DR&!0+7 3Y'&3N^\#YX:)/4O),IH72)JPCM39ED*_6
M[RC]KG;UUUOEWGCD+@^0G,HYD+:(IEI@<O<U=0RRICS1U1=[6]DT]!LS ^_Y
M/%P.>G$$P<*?OMUE;D?BKWBP[(4H]0>0V*CND+$5'%+@/C/8Z=/"59:,% ?M
M*@Z0&@\\U5U,FH]F[":*UN!)B4A_EFG!^0*:P$(S.) N,T+'PC&\3B@T.TA*
M0:2@\_^-T3,<:1\804B71-M: F_B%[ W!0/P.V(6<&YHP]KM=FD$Y@).A9X6
MLLF<^*BQX2! DH:^#[8!L1 L\(-.#\_VWD303ATQ7L4'T]Y[SAQ O,GCNTB?
M(I7J"9@CUQU>KM;W/F,%T\%A#[0>0B"[9Z%BTBB>@84JKBX[:)'O!7I#S.-[
M+GOI'F]HAG@8X.V-Z^RO)$J_>P:0I\F/>Z:N?[<!7(,%K2GNDP-\N[!69:;P
M/?-08M\S/(,7S<"Y#USS+S7ZX^WZ7XB'Q1_?YQ^C'20CD'P:XC6?@W9(]6V)
MS<??LE3A;W9PXYN3:21)LT)A-L;M0;9XU'&9W*<J0G'%>\R@;92RQW!*$<"7
M:C&X4/.3&]_T.7=" L%&/_O:"5#;1D,U,<&;&!3;Z:17+2@Q^,,E<1 _2WG?
MQ0L<8(LUP%T_WF.@V*6YZXL;IQ5X\)7"M&I^)(4[\0N&_N6]]FNA<?JH0+J^
M;.K@+D& FTP@GF?['VCYOVRS^UX0M"'P-%[V7!!>*[3D%NAKVTS:F?UM2) H
M &"!!MH=@*<!R?=%:I@[^0[0YB4]A';E(SIA0?(MC$?&'6/LAW [Q'.'TP.]
M*-G*#E&P.P!H.P*T3X">,M,(J5\6VITB/XO/\YJB<1-8U_0T.F)+:FHV5-8H
M&?_.X12<7G1?L&8C[B\IXA&U-KB^X'I1AD.?"&<@"<H;1<@0K-79(P$F1SLB
MPP 6M8V5#Q]'/\5_RIR_"(A[EP0I(_W-35$RB/CS,!]+B.H^=BT,.M*R)4DP
MNT@*,J_S&5D*I62MPZFN)4?#5]M6SI0BB82QM7R5[%<$<K04,8J_",\0Y<C=
MG+E4Z?\#0YJ#Y0,:T_S'G.5WPE*FRZ([_5+I+@V8]+]XQ2C[V]&H4*+XQ"C6
M3H[B P0-MR=*)8V2RR,FW.G=/ER8>V/X9S!XNTT>84I!04OI@OS@X]V$"NH;
MBC,PSV3=;W! O8AL]DS&C:FM*!BXOS@I6J5P^%A/'8T+<IV/NKL+!<WQA(1D
M_ZK8/^=B;C'O][OJN#^6O'\*T$@#H3H)(5BU\@R:]]>:\$J7R(!6D;BNJWI1
M5:3D_NI!(S7_>?E:OR"^[JO]R5"R]0D@(W5ZXZW^/YU'YF,$+IVWG@KLM=CZ
M'TC+OU!(C)MA]DOF/YCYOX0!UFI0W1L/X_,1M7Z+N7ZBZN.N9/P"R(S57D-L
M?FD=G$% /!F>9[RPZV8S&$ ;2F_ \>&RJ1\,]C;:-;7@16S 4XM.@Z63MGDZ
M).Q\0&BX%6>4]"#I8??F:!=[?^G5SCRA_FLM-D@F&(0;29ND&#0]K6!BEC1+
MCBRB]^PFUTP]5)-#2HJ0%+'%-"EJPVC:S/"P=^3B9FG\B#976LJRN8CIY59%
M:6%P<TO"1AULLNBS_X387./#(Y4[G:]]1/H]N<UBFP*^'?9HV"'5S_K)YAG?
M//:.P"8F#PZU(J%R7.R ;;L^#CY:A=[*]:D5E.>&#XO4##!]1 6K/5X]&W48
MHYXR#MGP],:YY1B.B<V L#. :#Q I;&6[X=LUE$^_##9*HC[IBP-Q(FOS)AO
M>M84BWJ9[3ZMU^CZZSUM'%=QJ9^2.!@NEZX!IZ*TN*D-/2*:(:3/*[I!;3U"
M495N ]F&?H[%UD$M?%+KB98LN:__G3E BD![MW%[PK*RV#/45'YRE-\-SUP(
MHCZ3B"GO\L@+[*@'8\2H &5J5U3<[C$/[KC7(S5#B_]^;UK8 \I7_KZ<_H]R
MM?9XND&DR4=:%O8O^/;'K8*]PJB% #,7CFN[#\_95\5?MJT5MJHP')>WY;!9
M^AEJ0/((;+^B8ZY<+*.VL$T2;UCE(3?RODCT6N1[8\5"6(CDB&&O%L:U1D6B
M@?>\\H&ML3,*G?.YH_R3/:>XF@_J2YI[%)"ID1GA]JZ,4@M+2S+$\W_6Z.;_
M1"23943ZC#H4P__:V-@'A)-?\G?36*W_*2I0[W>[>1*,ONEZ "4''M6+2LES
M',(_(9F*S?)P':!8+"=%D. B3V OK5$Z[&3ZEP6/X;-^X+E_L:BZAOZ^=BWC
M&RN)[@P&%-@1T1V^G1GVWR*&N X6EOF70\,<+%1FN-+Z=P282_\N7A?_/<7.
MPUV=)A58)\/S5!'OOM>=2:IB<JD/96PH?RXIE8XH7K1PT(9TH)>42N_@311O
MT?N=_G \QC<5^1=S?:"1BD#:#XLF$42M)[3!4!^4K;B[$Z/D_2_K,?TRW9P7
M>O7R;JZWE3*P'>9:;U+1,A959JRWK+0EPQMFYF;QYI5<)W?C/-H%4^I)J2>E
MGI1Z4NK)5NG)M,*BAM$>LY;3T/-3Z@:O9R8<T;"<RGRD59=+5+Z@&U)?XI5K
M_L6"LLOC(2# 6S+VP;\. *6I7DS ;7[@)TWYC&R#0NP*2(8">?WXC9O?=['S
M'N\@NV(>RB5X>-,-N2/-!FDV2+-!F@W2;)!F0S.NU\EU&1O=!E9@\P:S'C,9
M]A2,A['$O0LCVR8>06&8"XN)3ON@3K%CK36WL((*WH'8P,ZU#]CN,)J:E+BO
M%3@C\P/@6E\5 T+0<Q[[NI45AN7RWT[V);I=.XKQ &KX@0)P-$T&^]/VNSE/
M 2COE>?.0C/(>M4+-[7C:P:C3C?S&NE%D.: - >D.2#- 6D.O,P<R.AE^+J%
M/)72RQN37CSWV;#IWBHNQH$"O^'5%]0?]NC#@1A 9 PG=T4C*7C21VW=$4L+
M&!>'.K'K&8 C\-5JG0<X_W"&<SGF(2J^:,0'MF3V#5MT\.>9!K/(@O"C468T
M;]%T5VR'P,(QC8&C3I3#=*.58<V2P[W6.V,EGKMTI-PH/B5PD1XS19.?],X@
M?C?(>8_-040C1-4X'"2P4^K@B09=)?E.,X[?S ;C;=%L*SXK"W.IHEPM.#AC
MT7Q*/BR"!Y[$,(->Q6E26Z@\1RAYNI=I6_NG;=T;?)S!R;O3U#@[#*E_ <C"
M3$4A^,JFL( 2BX=S/AFHP2*.LS@WK3__>WP'N[-=%/S$O>P'7M%X/_SDNSCF
MQH0/OB'Y% P C/:X"F'O).>UH=H;#M5)=\#[[/OG0:U!4\\\2TP-U3NC<=+[
M/SO42"C^6>H"BKJ)IFN".C(9F_G\SCM8O_.*J[M%DYX*)SZF"&2\ZYUCCX$
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M+S!<\BW"RQJ!ODP_[IB4OQ&UM[X/*O[=7GCDA]RS95WTT!F_6(^='HFRVT/
M=UCQB+ZY+&E*HFP>49Y/W/9.1JV8S$0Q*?PA*>#U*Z7;=$Z72.DJ6>?URQ\N
MZM8[&JF#7N^0#>U)X+6#0&^H]BJ#0%.%_\G8Z7[A>EC7XBWARHX#SI9GY*5#
M5R@<R:%.BL9TU9B?C@*%L3K1!O5FJ@M07E\]1M41HJB )U=$T;2T%=8B!M15
M;505Y368 =5Q[WC\EV*DU8_-[/)"@WE?LWE??GSY;)-LW*\I^ZN*JNMZOKKO
MKPU&XN!4:HNFQ[170XTU=5@T[?G"5-1@I';'-;]X78 _^:N']:,!3^U!_\:*
MY]<Z24.T%O"<!O>R2<' I@OCN8DZ'E8E>9JJQD[&6;>S1TJS2/H5N=3HIX#=
M6L1IE#VLWQQ[BXUBNU'->>X"U-P7WB3!>5!LAF4[]>]-2L2#W4E#GZ7CM^TS
MB#5U,"D89'QA0D)7NWJ_WG*B1>* G*"5\ZR#+;+XO;6MS-I7QWWI7^W#%?YX
M=U?I7VVR?T_Z5UOI7SV?D7QBQ^M955;%V1U:MZMJO6ZC]%75*3X]==2ORKR6
MNJI=LE+JJE;JJO9<U/9+=_]L&5/+IODH:M1\@-K4KG?3H,X[J5ITT?- #",-
M9+Z\3$VN/6M$B?1V0O0RF[[!)-N>O$/L=DIEN2OC&0MCVW&7Z*L#3;ODFX2N
M#KLRJ;<&S.5A)Z8-2;TIC= BS[.N=B=5!4B:ZWGN59C?+!79GE%C.W._$-RV
M<CWL9-0J3NOILHA%5R=Z5?I>^LW:Y;>1?K-6^LTN)L;3;DMQK$X:5M1\'"B,
MNL?37\VP%,^67YBQ%'$JBCMOL<&H=65NO=Z=2&-1&BO26*S%_J2Q6)VQV$XC
M<:)V^\U*##J2J:Q5!05I)&Z+V+K+I<5;WD1S3OB@![-JUI*A6YEM4''G)CZ)
M\I[Q6;1EF36J\KK;Z7:U5/-EK:>.QEHTV\,(@X7KP<9F:C13A )8J7$[1J!D
M6\/2E GZ6JY5*?Y)5ZZ2P4RV]9\0^USC; &^-^:(69;:4-6TP?[+OVV1UM,&
MZJ2R,J/FJKU*P2#UWFZRXW9/P='OJN/^N :"8Z*I@V[WL@7':*2.>K)K2:5@
MD-;(@1+E"'.Q-5&XN9^HTG55!W%R?E$U&*O=2Q=5 ^#1KHS_5 H&:>.<32+I
M+Y-(8#P->WF)M+]HN(G6PJ_TU?YD&*U:E6Q3%5AMQ2?VV<][2CI8];6FO\Q
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M<.YC,8-$*?I\P!?(LK[+!!@_N[Z?ATES('!E+'G?5LL!(>R&/AP1KA?LA\E
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M\HKC!G1/0Y\)J*: /7A@;*T,C^JX@P7SL8@;^1B+!^ GBM\8&/46#GSXNA_
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MHH\ [$D2E0"?BU)HA<7>AHT8LUQ/$,@2^P,!Y?^78$SR!VYTXD ;H++D 77
M> I IK%"-E+A,W@&8)X@&;WRG@'D!C@)/1Z!3V"4$,"UQT#:<;EJK&(/34?Y
M\,C@ DI73B4ED[71C8]$1[@NP E=7?W0-$&OS4/8FA4@UX01+RM/"^:HN# \
MZZGIY:/3(W08_"]L(&0\5!F]T#=LEMQII1 M$Z)_=Q&A8/D"U)WSB<ZOH8=]
MYTA8)I;W+<\.P1V"$>[,#&_F*^]=^!_E2A@!'V_OW\<60.'W[]P9\0;)P>BQ
MV_N[^*GO[@HT?>7"0.\.KOM=M>".?08T?T4)Z01&I R*;C<B&)"AB#01J&A>
MP1?1C =&%<*'Y#U&V<$Z!8ZE5DOX#R/^1@>4E>@(Y%24QNB-LD#0<_,'.=MX
M> ")"%M!1C= NQB6S\A@ D0&N-&9&TY!O$U=4(3Q1F)!P^71,Y>=2 (@$, $
M,T!C<4N0$S@J,1SXZC#E&32&8LP#OE\%%1%_-?Y6Y"&C V%_1#;;*ECVXXL-
M-[ZT3;&  TT9"%N^.W3DH<BS*)7*9-0]#G;ON>'#0OD=]2%WP?4T%2Q+O8?J
M!5X"&XR_]5H;=";\6[!Q6U"'DVI"PEO614,Q^!L10BA@\;NB;>4]XTY&\N$6
M-)C,6.[I9[[&W[O'[T5<J2JO)UI'KV)KM_ONZW;#I@:CSJB*31VAS:>VO<UG
MT6F/N),2,)(H>#T8=[HUA>0.#5-/!$E],R1/)X?.=/]?NU+A!2BY*^ E700.
MA0VH4LZH&?@9/0#"$9[!KZ4-Y534T47U153IH Y"NS?Y:YR^PJ<'D79P49TR
M<K+/P]AJ1OGLN*D-&H^&9=.W?#?T3)YVGKH)W>(ET5P4VK;<LB^^0?V/^\1M
MXJS5S<UG>M_F.]C:"]W0GH%BP6.97)_/&&!!A5V +0VP\!2&UTX'521JF]+K
M%G#M@V<L"98_P6,>/.? 20""<+\):6MI2BK.XXNN\+ 1?%OJ8HSO6^6NCW0W
M(MV,X =;)/3HQAIK\PQHI^E;!TU_)T 1>81S( X+3Y+4N+B4I0S:E0.6><LL
M=<WARHK?PZT*J@'KIMR+4W&H$J2$@;ZM<"6\6V AT;V-6UB1+R!8LR/0(((+
M,:);0(D#L,SBPM.]T,8BP?V/T'[FTEX?<6M$39M=>P8KE2>VNRU6QTO>::2G
MWE& ."P2.YD; /+1?;A<HB\(-6E*+*;N4%\!!V:)1TTZ[4MN6N4 3\)+^,FE
M>?)S^0O[L+M!$"VZTB!@?P,3$=WGF3_I*J]5%"H;+CR,*4LXQ<+'>G]X4]ER
M_.&% 5*4;EM@^:T,<57%$WBSQ!^*2WNAS?RT3X^NNSP' XQ4,YJJB]_X\,-<
M&,X#R>(ER"_R2:0MR0]W&2N9FS@VVA*D@]@L*IE!$&ZD&XZL\3IA[!&V3:VP
M+[:S%<#K^]L:E=Z/UO<XTFEH_>,U3J':SM\979-/0U%*\E 4GHAR4Y")(K(S
M,./D1HG2[C 31>$Y*E2^K0U ^4;_O+TI3TW1>AU]C ]G-LJS4-;W*CX^-#OE
MW*DH;2+#%=QY3&ME)V&F/QV*'9'/CT34[1*NKJ81^T7_?GO[-1% >.,!ZS9Z
M^O;^+A)KZ'8EV;I5BJ=R_CMD7'AH+=O/9/X]@XU)ESH>G@$- 0:Z>$7J02')
MW8#GO,6>Q^FS@AL6&UG"28-BUUU'^<2/X*[ TN>N!H T<!;^67V! 0KD;&-P
M#S?,+0OT5(AKIC'[=RB&IRM/"PLO2AX&Q_#2@287[M=0YH:%PVBSCMFB($JR
M@97K6S% X,G0YI&>[-U#%?HRK?]X;QL_>A^:S=_W/K2_B*Z*((Z(+."9?X<.
MCS'&"G$'?8Y7;9Z @Q</<:& 6QA6?=H^>^+7$<2914&D'\_)XS_![S[>\L,-
MMZS6>4'2[! C,>+,O6PI(AV;OB!R2,NLJP--*.Z."&=61&YE^YP:-IE4_H*Q
M0&RGV*B+!,5,00K!("%\&ZZY60^A>.<F6Y)NO3.*-V!D?>8R/R>(,$_$=OW0
M8YD ,@%-?9$4N@AJ_82JVEK&\FE?^D%1"9B(Q"6&*RQG1A&\1Q;)R&AQPN/2
M>$:AQ'U_+*'8.2 0,$!>",:]-(5D!82.$ADSA;@WCTO+"\'7!L8L9*"(10)Q
MHXO2#=9SM5 06*0!7;C 7+M/*-W1OV3-+-""JGC@=\/W4]<D_K J]":R-_/1
M]6:!<"!Y%V$0$=?M<#S>VC:EP'M1QE?@&8YOF$GD48@8/W6OBWV:D29+;N<R
M!VM';\=A3J36.SPRB3D)3%813"@F[@?6DNQQ,>6!VVOD=,B8A7LI>1!B,^:;
MGC5-UERW*W=0DVG]'XE1MMGC0GE@:=M.3=G L?K>S\KC_OV$=1U709!YN&?N
M4/'+#KD-!;.03/;=%924#3O*AC]]TM8?8OJ^1 FPQL<E"A4Y&LU[C*[0-8H,
M2F%A^JFK*L9>EL9?+"4UJ&..[X=+/CV06T3&?$ZIIZBB14(@3]]+I$'IY2!?
M9=91ON"54W$='NF9HH];+62WU%89A?QPBV@%)!OFTD!( FY^1S9?.KEUO0L0
MSZ#&Z/?UU.!2<(E_X; 5W\JF:4^IU5?V[?!=D#:!ZU%&)C[F693\BLN[E+X$
M-/07W$-0^J#D0-N0_P&N37 H%"0I>%L!R"3;8H^\G(1?CGV7QV%Y.BM);\LS
MPR7&UDP$Z"T(-IZX2F:L21?KF05H\Z)[C.NGT"RESJY9X<SDP??;F4O^\K0M
MXKF.BPFFI=4\IY%'GQSE'Z'#,-U_J";^-![/5&[O_SQ&-J(VO-9Z-4E'3-(/
M/SF8>9S./[SSL'Q#^<R3,JYX=F9/'[Y]I_P.C 77LZA4(_M-8.S"9=.81?&
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M9&!$/+*,"!#K!D+!ZMRBB%@;OFMYL*[M!M&!\_<A8BJ@1B"7Y(B;WU)SV[Z
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M9U>G67"D11(W.%WA<!=@B T3X;G<1!,*.L10=*V3;/;>G#)%%*W75\<3_9Q
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M46[:MIA\R[W#\A8'-1![=OUJNXNOM8L33;O41CZO<5?;^:T19>Q7(D(7ZY4
M ^="6W97:"J]X_KU[E9G;_]M%R6_F:5I42SJS_['#>+][<W._D+ARMJE>07>
M;YZ!(%EUX9')C^M=&3:ID 'OBL1[O4X/+>*6^Y>_-*WF?UV^[C6)KT%U[2ZR
M ^W[69KMSC8F&KP!MFZ>4G\EL__;(^&7=VS^OW'<NF4MR\[;,/M;WI^;]\^K
MPK7OF.G? <;_LI;FH--;*-)_:QV\*PDALS;>LVS8;=T!RU^7"K'0]G2H92NY
M)LRQI8>6'JKHH3W U+AC]346)[]G@V3SH+/96Z3'[OVLS0%&*/=:N^3%]5!-
MVC U8I(M1;04\8AM\C2XC=+J@+:8:.9BHMZ&=97V8_%GBI5<IW=4/#)ST6Y)
M;5!68T_CZD[4W!>FDD?@N[5C:H  \T#DM\ 2V-)"UZO8OF_%V7 %#]<>)+(P
M)@WLU/4XY%-:M-:W?3MPA!7?"I%8^%U%JP9=</?/U!_S3[T]HXL#WPM_Q)4%
M<AF8NRZ5DW4Y7ARGPNU@Z0_<AS7MR2TB 3SY:8R]([@[PRCR<$RPQXX?TE-A
M:G*)D'4LH^'$]-*^TG=5-M#M4-F3?!$WG @=B=V7;98_MOIIPO,/PF3J8$QJ
MFR#9W$B9.LO&NU&9=B!MI8D'?PV#=34JE$ RQ6"2WJI)@VJ[XG0(+$$SZPL_
MO-<],MZV0**_L[K<N3/^^7D>''@\IZ1P0T0WP-1&<P4R ^SAZ!"3/M9/@,31
MB?N9MQ[^F@5OX'V709X'!DEVMTUI5=[T(C"[20 /7X!P)";GQ3?;74SNA]GL
MXG-$'.*,L109F$ND8+#$'>LL<#9 /%B?A&_?<]UC-%(]-E0K#'VS?B:.)7ND
M?#6HJ4<>B+?=WX980AG>!U+Z>*YG1V.<5?;$U?RDX,E9&XYO"B"-.W#@,^$Q
M_\'J1U@R@A.!M\4#1!O- ,I1=GE<_^R*V(F\?B;7BDO7,6;$D+-]80WQ*Y=7
M$]])&_2O,(I"ZZ,7JHG3SX5O87C1G7>GVCK)9Q-HZFR+8>PRC2+*%N,LP)F!
M1!UE-:-X.6J;$"4UWY"G,=N/PV)W%7PYK,J(]TD3'<U'(NM:"+V Z6)PPR@%
M+6/'@FM1=4VO? ..K[MW&.>K7['N/(?TIA\"BM$1DTV,?NIV]S:V\D!SYF*,
M0,PX4LP,E)C)UN8E6UF5"9FK/%5FY&K0HERW20KTAD/A>KP.L#Q8LL^/X4)?
M+.HE5%[Y@*$4"')E3O5%.#^U)!U+V-QL*L@73E,]\2Q;N)IA">:^9WLIPR[D
MFNW8(,CB8PN5W&1Z<#6TXI.R%TB&77B^HD%)TJC0]+2F)8 L1%<\@P,AUY )
M'&5;08J%<(38J%DC)T G5U75?/,$;0?Q(<@()NXKHX]'+98EDO5U^6Y.<B*"
M:Z%P@C\)A$+*?UQ-,C_S=*UNSQ%TQQ3M3@K+-43QJ*[-&&F#019F$T22F$#\
MQ*D=: 9]2:I:)%$]A9B*A&3QJ<;*"XS\)E02FU%_O6"<@$H$KR<Z,8JQC.4C
M>M7(VOR\?K#78GQ587Q- _%J,;R6WHE(&BRH$=A>+5,@-D&D8#M,AF'!*S3J
MT2!,(Y!H?Z9@E;)LS+"6Y--! 1GZ@XS+.QO$[IB/"2@OP0!WP5(IZ(W" <=&
MMQ#(:_2P$!;4-%5D B[G##9$NR(C%W&;O3B1AZ(,IFG@^>J$@3=>G9[@7.')
M@>"SC/Z)<+WX@ -G %,7>-B3T)9PEGP0&FL#?G*P%BA@;R!G-4P3Q&TLN<J6
M/B%^H$>NL6);#OP=%%K8)P0TN6'24YC3)M<E!@T9"C#$6(\5S64@!)HW\<[T
M/2KNNTDV?5PP06.2K2K0.,6>K8X](O_&?_D])0KSV\;5AO7;\?'%(^>)5A?6
M6N2 +MROTH5__8OUU[_\]2^_CDH48HD^K%"'K U7CH!,1A@XR;0AZ[R_'= _
MAU(=HC9DS8%:<L7ZY8@'4;Y+O$EE>H?53A%U=U*_3&HA#"Y;I9,NV<^G!@T.
M)_R7D[.Q//?O*U$XW-[I;O?V_U]W9WOEZ!ADW8-U3(M8/KBRL\I"1T=+!$N-
MD"Z5_M"5HU/= N^[/.G^^@O><E0]]-[VRRSLT?%OEZ>GOY]^O;:.OWZR+KX<
M?[7./UN_GU[^=GKYFDNKQM=GX6W#J>7F0QT&]/GR]'^_G7X]^;=U_8_3R^.+
MTV_79R=7'>OLZ\G&8;T&*'?QZMO'&@T/=[,&P_C7^>7EN?7Q[)R7I@Y#^J3,
M#C!>_OGMR[_SOG^E+(K:J%5(KZ&0CJZ//WXY15%Y<O[U&L3G59&"C!<B 16&
M.#'"S X;X6H:F(4F1F$1PU"^Z^/YY:?3R_63\R]?CB^N3C^H/Z9/L[@FV98>
M2LC#33G.#YMZU8G@?J5D-*L$X&_G9PWC9TW+>Y%I+_*5ZJ:R)^[O+^"1T_^F
M5!4KEUTWF1A+>;'6S"NZCULZPWAS>74UNG[R+A.ZCNX Z2"M,_G '.C<A^[&
M)E"5S)C^VR;]<UCQSDD+RF"_E:,+V UM,CUCWC)[4M%N"8M.[I:4=;OP2S;U
MK5)"+;UT>V5YQ-7=?)2Z0-#DQVV()BLOC*Q2@6F*8=Q*U!SF(6U=??FD_*#,
ML68'#[8RY\$,O00K"@3JF?7I]//9U[/KL_.O5V22GH%XO;RX/+T^OC[[?FI=
M7)Y_/[NB7]D)-WHR250R1$EBR5-Y:N9'*!:21XCC];U%#:B$X&8E])F)N_>F
M^& NVM]:&.UW-[K/(==9KS^<I)9YN7YG00S>0]C/ 8'O4P%WR[>S\6WC&*37
M4 8!_7Q.?O6,36R?'!]G:&&-(I'8%'*]B,([+WYO7)0S_\IVZ7B]MUEM +ZT
MFFSMP>7:@]N&/7B&;K;,']DLFN_6A^9;TW"9FJ_76--PAV/\'.1M^;LU(>=E
MI*::D+LK1R<J@;#EHI:+YN.BK89RT1X<Q*(;.Y!I/G (^Q0Z*16A'5J?O$@X
M21AQ:O[Y8. Y(FK<0:QEM\6SVW9#V6T?E%:N_H-3\YO&4KV6I1;.4CL-9:D#
M8BE52?/=]E-A72(I-HVIMEJF6CA3[3:4J;J;^G2%6HJJ=G7!V#5USA:1]3$,
M?S1.=VVW;+9P-MMK*IMUL10:.^RZ7*;#Y?$G7+0HNX*T[-6RUWSLM=]4]NJ!
M%LLW#<?F\R=V?-LTMMIIV6KA;'705+;:6CGZC 6F6*5(A99-XZ;=EIL6'Q#>
M;"H[;:\<_>$EMUANW<!HU@OP4IOG5(\\I^Z.F>AT9EV>7ER>7IU^Q51WE?[^
MQ_'EY?'7Z[/3*RPVXJJUEB7:-*AWJ?6V&IL&U=U=.?J4"LL,/A\2FB_!_'G-
MBXFU-N7BN:NIN5'=*6D=3>.KO9:O%LY73<V6ZNX#2:7);1AYR?C0^N@Q2.A7
M.Y&(Y1JTJ>6RELOFY;*F)DEU#U:.OH>)L"[%GZD7";=EII:9YF6FIJ9']39G
MH#GL'H%)5)&-32+P*"8I$ % X]9J;%EP$2S8U&2J7A?#T"::9M.X:;_EIH5S
M4U-SIGJ]E://NF?2E>Z9U#2>.FAY:N$\U=1$J=X6D%0?##UN-7-R:P<WC?/
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MJ@/_'ZY1V40HS;D\\I)9=U2;C38*7N:TE0W4QEP9#9'Y5H[,LT1K-GCQ4V1
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ML6,6 R/C3#@R!NB]Z,#D/4*"P7"6._0"7-R(^8$,(O)AQ\0(3/GR"=*XB;.
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MMR87E1.RC"YL6/^" @^C'M3V4K(U]HNX0\_=0()U%.]\#*T'58_"27 2)1-
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M76]*QG%1D6CL:<[BP3$IE!INM@KT[64]ON6*(< Y301GA/Z%VNQHF&!NW(4
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M-YE(EAO9 Y*[^$IEDJ%Q S?8H,"]F0\G%:>EDJG@PRJK(EEX"FLJL%ZVV'3
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M. HZ>V[U@/M?94!2_-<+$I2#H D59WL Y7>W4HRK&S;KX&FXXL\NW :D.-P
MX[Q9?W>(\]^.RL!B$/:Z Y@,DUM^]_XF X_ZF]L,7VXBR/I>#M@#\O?O9Q#(
M&[^A1;#GI!+9Q7U2]+$WD!C(> -@<H1?3[PPVZ/T88@3,CBN#]36N.?FI:<\
MTLXX..[K!3(%[X/[ C<"KO,_,4R-?,8'162]WR8TF)5'T<N8ST@T%/(<"K90
M57<? _UDFYC:'@$?2]F2TPGZ; 438+54,O@$CP-S?FE$V+L"&O>VUYZ=#1\
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M.B0+%58NN U9 UDI[=6G9N-4#?S.7<)L\N[D\@1Y3TQUQ(^= GK\,P7TG5-
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M<JYW8/IW9_B.,-]H\(J<'!9U4M+KHF50I('GFBKW=(1FXC%5;W0:+-@N,X&
M*+.45GFI^A*[)AC'2"],PJ@)H:9'""?Q.33*..U<UN.))RWFF5PS#4?O6,8
MA9#YX:&+J\/45SH+24($)AMC\Q6MY#$0C8E646RR#:D-<E:#V,^0R/.'$*M4
M@B"6F&S).L4^9>IN=3;^2(6*GHI![!<YY-".O.I'VFZB(_P=] I:$$FCXB0L
MM[ )-AT'+^[=V:#0&P$33*YMBW$FN3-\YAC\@7I))^>=D"C:V75!G%]2;?I[
M?MMF0:7T<AG&DR@Z$9P3C]V0//WQ82H0L3O<SD/ 1I1X("G-"L>$V=@@<\YS
M)?FX \:N]4D!N?[9\U/JS9).(=J8AH2R@NN%$;NY&U$U]YWKMH\$[ !T KE+
M&@2B$=?I7S'N["9S5 \UWO0LI!SM/ _3TJDNZLP8K"P60P?\L+A]90.U)>6*
MK(FAHR0[$4C24(;VD#&[[8D?.Q?VY&<N[$MS85]<3^N4N^WSX^3*LI24CY<<
M6]0K^=SP1^[,02WX4GU(=@O<([P4(V^(]+]P'Y-J;*S2)N*--A20V+]S,W5*
MCKC H'V$-08CGH:^$B2V?E&$0 T6*L/#1W3.(:+S?'P(6<K(2)))*/R@D9QW
M3@$A]HEBC$45I;F"&(_;.;>/:XP":ZI-^9';B#<1(\57=3V?+'(X1KW\S]Z0
MXTOS_F'VY.-L)'VR'PVBV?GTFM3KI-5.,.,'F4!I24.9<)R9)L&D0IA'H/T=
MMSQJ'[3E:WEL8JW&$IL[ZX/;O@'RW&VL28S-BRXOER8BIKA4O_MPD9UYC5LW
M"^]!8I9?MMSFGMUOMMY0',Q?!Q;B/ODS&.!KVU]SDF@%,'*<SKM?Y](^C=,9
M4:)5MV)V71:+R8+J@IPH9MI&5 #E@D&$V%1W\*/BGW4:#8,^N7 AE^;3:'?Y
M7J+RY<!4.^[S-R,EJV]#I9?PR/>4(O9U$D57F(QJ.ZEL=6X#MM8]1AJ"*#2C
M\ [/T .MOSX["V9=,(Q@9]9\FL\^/]JLQ885H =W6'6S<_^_V*!)3OLB :XM
MMY@HG\O%K@'WMY-7.*\ZP:)MJK983M YTIO9H<B'OZ.38O[B' ^W+00#V7Z%
MHF;6_:$$W6(M"\3 65>F"NTZCHBZATF^>79R9H+70?VTB+%DZ/4P0>Q_E5!)
M["[CS3!<)= &)+H0C(.0&XY'4@O0?73,!^SMZ&1E2A\'"2#M*J]Q'6=RKJFS
M\YT2PPQ<''LN ;]/<T'S8\(=OOEHDZ!PU\'72)K&1V-QKZ]Y:._PF?W44(6-
MX\Q'Y+; 'D(H/*4I)Z:%-8LOZ!)'BH7:9Y 49;.:78$UDED#DLYCV.H1"W4H
MCCB,G<5IPN"<R,& '5M 5L70=FE?#H[3"&?#I,: VOCI3SB>I\.X&-5_,3E0
M&((S9S@:+P9C'I^!B"KZ 8HUY[8X>6$9'JLQ2QFS)>]2;XE^O)Z;!DP&QDE*
M24Y<#YJBS*E]6F/H_=)F)JU_]K(N!PHO4F#XX8$?)N+Z5D*/)AX>'=3H@M[K
M9N#9B?N!UNF.6W0>UIQJS01F[VXUM70VC9&P=L&TSC8:+!K JBCH:.0=,(UT
MD=N)!P:[+I/102L ;4R+U1$C9:KBRBT(U>JP\_J(P[KV]"2=%8&^L<^+7TN=
M22(G_2XW8JA:Z,&=T@)/Z<C#DR/%IW@'>VS9T'(\>-S$<\_"BY$XD+BW<4=Y
MNA=QZ""ZZ%%%!]EW82[?+W2B31:L[#'?]9"DT-TGY?+ [#@KY=U.OEZ%H(,6
M%,#-BW6!1VJ2;^9E1S5BII1 "@PF"CX+444IL+&A%*0UN,]KX@ 7'KBO$-?R
M[O)O9;/JF9FQKRP"U(:LX&W1<S!!^)7]W'V\VY@=(]8#&^PCMUI!L2U7BZBE
M[*QV9V2TY&<)R":>'Z)L/A?8F2:\]K?&$0JO"QC36&:!F$6L UO2G3[9,E2@
M\H01$:P?F&+7;GA ^<I46BQ]!_:ANO-MN)MBR7R@^-E-Q=II+JJI%:D.W9TW
M+27!D32R]5G1Z!41=15)8?CW+TB/-=M%697XP@!5E0""1&"3"<%#]>$"K%[0
MW#/%BN KA'_+(YD/OZ-:PJ3HY[8CL6!/+;5)JJQ*L\RAF&HW4P;HIW=LRPL]
MR7CBY",0@S% @R,3'A?Q;X*L27H5?NRLX\7/K.-WKL"3+@-RY-"PQ),T+4F3
MU<F*.X*]/603]5,/@^FN3WX7Q.2US1,9_AM[?5?@)#2V@EJZR3Y0"[#P4#28
M.Y4>(3O;&FOZ=PK"G'@\L%9\L-12G'FD@\% 4X.KIB5LZC9Y^3>@_0FUF@.I
MOU,5$"\EHF-]@I1_4Q8<RMD3ARHM1(_='/)&;<RNAD3V^*'Q!Q3;*;.49(\6
M>.U:W&G=5(7&YQ5J0H8E;%'&#T/R27Y62>QL/JX?]9 <RFX.L:^O@3MBOD'*
MT%YOY(=^FH<JQ6!B)*WVUKXQ92K8&9I/XE@J\F#_& N$V(C"NE3)%1F4I(&$
M>Z"S-05:G*!*R^L?"^=F=C%5- "8/_1Z&3..D606?$FI=26L%1.PIJ_"MM0H
M(<!C)XL[:BT^)%.@2!><($Z1E"BXAF(!/%($#>]W!LM%?ZQNU["YJ ).4N&,
M;6,_/.[G,>!^7HP^?+]QM=NE/8,GF"')J4D" H^'"T\2?13*-J$MTVSY5*7M
M4Y?@KA5MV4@D;98W\%MQTX8M.0H2 T7LEK?AW02-3_D]=P$ "4U<A37V-RB%
M"GPNE852!ED9\)?O]*#)">DTB1]T&Y-?,2!V<##> $83Q!:I>TN7HPLE]:[
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M/G\#!)<)).2AQ<H3$"OC.QX:L?*/RBO:W]EEL@U'WHTN1D<^VNINHHX7V%'
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M.%C<7T<)\'I?C;Z7\A<2 O$A+.&.8,A>RTM*'*(F><G]<^!7$U^K-S',GM.
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M<%PSDQO,V$"F1'.01K;Q)]Y<XSXQL[G$)0;!XE;N^M2KXJ:SF*] : 8,$A+
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M@M5[5;>PKC=U@TWFRAD*<R^L(])M:XY[UB&P_E_O2]+2UL[?* F5(NI3'_D
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MM<"(+T%Q%Q.8SH?"6585-[<#^N6PR,1^A")7<&VCNEMZ,.5$8I.LU)K%*/(
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M=>B6(;WT I<@=FFAZ#$".0DP0X01'DL# !IX^O6V5'0V<]<6"0A&:#G#D5)
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MJ@H^]HN7U34<=$9-G 7"-+$S"5>K'-5Y_/MX 8Y"_UCV/X,U2@[X872Y0NB
M 2\@-"=)%Y6A9+)1HE?**#"*4GY3@Y!:@%KG/X2&W<6H?6.2MI#"J+\43/4!
M] ["@=/DR,F+_X4<<-VR<\PG@D;J_&^*2D@.)]>LNN1]@QW4 !<6^L[0JV+K
MKD%985X5M& IOBV"1AV)K>AKHSMVT<^^+.LY _6Y-!9+F&$B?2?J7Q]0]@*N
MK+*QL!>X.M& D;.,/B$[B73(ZMBE;56"72@3=BRS!3NWQHV-P=%PW7],47],
M#3 8U4:>#5;3=E.M@_QBHH0TG%..&K(XW]%AFTELPL/(:9SOY(/9&Q6>AYTE
MOR#WR@>0"2@PH/2Q9>;.K1:7)18 <*;= &Y$IHK1D<CD,C-;=^,OQKO"NX3T
MB2"I#H7N8XQ BT:K##Z@-AD-4]- 3+CSS)9L;(RE,1N;C$@Q$$J/6)#K!%VN
M7R ^R9;/_]C.R0>F?1H&]:2)H_4&*>/-(S:Q$)G?UU4%=:VQSQ45P.V< 1*O
M+J_8'KLU]37';A>D!_,YAN(K/FX1?H*GG_[4[/@;2'92FJ]J6FJ8Y-\>PXW1
MG,7)$[O2&," '4":,J'%E'=*$GQ>F$5(9@Z[!MWY6V1F?4ET#TLL6FWC$S(E
MLX=FFN+(*  :-IM3AB\5#7N!LTMX0V>)Y_O270;M39*:YC8G:IGPLE0]+U'5
MFM1%3Y3V&.ZIG7M,=>L$/NS\@<)%)I+<906:)E44;)5<40^BIGL XJ_X *=6
M$BZ-I%CS\%5&YZ!AJ_A#09[!'=OA$\Q3AP>/^."1>X<,ZY^-"X;S5K*%'AA4
M>WPJ&C'_;VP]IAP\4?3!"9PQKH$!PR6SKP?G,F3RER7CRM4&-3[ _S,?HZ^<
M ^RIBFH<[\-8VRO9SP[6'U_S$EG.Y!C<\Q736(YD^B6NG^"K)+D0-07K7/&<
MFL^#_&4L0I7BR+^__'OE?BVGGGHO#,?L//A9&Y5$.< N_T-1N[[%O_EF+KOM
M=<*Z+5[):\;<X]XEP_!1CW[(L!UL!R/Q7I1"5<TE32YZN)'C<S2+6G8\-X$I
M+F..F;N"9 $.*30$.UFQ-+?N(@W1B_@(;ENLRP7$K\6B@# 7N:DO\WJU1)U*
M1.J4JRD)N">9;:/*5?H8#?4AXN 4[R.P%70OV&P^[(+(Z6-!Y#L3!99-T&@W
MQG?,N+P,-7V.[8*NOEL44JY0N;#9KL25T<(_E!;<YKHH0C\4J]F:B*=0!6&7
M<!NE-,?0JV4D1:"6GJ^#;4F='SLW7"#1TK]UN<& N7/@M39T"9]SJ^KXZ>MB
MA4KGY5H"WW&=4-_ST/VR+^X#2.]MXL6;4A>H$!NV8 P$$*2J49F7C-HI(09<
MO<Z745=@ED->%5U5B+JSH ND]LB1 !-B<W \OR;D8Y4!R<4,-@98]\%#*!03
MGX7,'<JW87"L@#Q:JB:N"PNKN8INZE"%L/KH5.E[+,]^VT*K18%]H/ 3^<:8
M O@*NP= &WR<R1M$O:7Q?3,?H79Z&5I4 7+G^Q5LS+<"8V9QL%X&!,AVP=?-
M1.PB0,!-7S/&A= * !<U(O;R.J,"91)(L6T646Y)NGW1LG@UIFQD&WBUVKA
MQ/AL(F?!G1J(2R/'QZ@DUY3380L1EG&E\,98?5GCGF;(_>:"6:YO#-;2?S:Y
M=BA\] W([M9NO]%2YY4UD99ISXQN5.)X3^'2I?O#)L)5Y\7L?6BZNZ&NW\\W
M2W9,;'MH=8MGZ($_&R] IP[RGG%"9FBN8:Y(LMY>Z:\JCO%LKQ@9R(D:+@>#
M?'+8WN/'$/8",W[M.*VM>%';KXAV!%LK\^CYT>(PNK;EX4)MF)$A';4ZH4>#
MC"QDT>_\++%0S?U@#^CC/Q3UH-P,Q63J[BZ]I=:+XW2\_14*_7%=43-]2,?G
MSGMT;*XK2*P SF96TO&&?ZW<+=;<T/+F'@S1P!BIS"LV\,F;$R#*]@![(X[L
M&%$+,QAI]M-I'(DO R> D1W2K;.&2TR!,P-/S'63"WP0SB72!/\_SUX\S9X^
M?7HOQFY@\!+XKG-)I"9>OBZ8FRV;L"HSP<4 O)I965P_CI(9T)8G2 D316,#
M@4G0"FNH%ZPWW@XI.]Z'(;[J'V%4YL3:3\6=2KH_%YK#47>ZGEQL<Q3G)##N
M?CFG>S 4 R-A>N(#'0JE-0OZW(!.9EZM.M[[ %$9[7F)#N"\A4]:X41V<?VR
M%QP&^O7F[CT,/T6*WR=!3SJ"AW]5-3",5U6-,I/E#.VYM]<13;YU[3WK&T03
M/^U+]]14+H0I"04DKHA>\CXLH0%[I0MGD!E8"($M\M2PZ@<<P?W)$^KM^['W
MAO[JEH"8'V''#1-AS;T8^8&AMX9LEF]*0+]"H...5=@9HNTI'5AJ[[T*=X\[
M&AZ<IT_QX Q:O6"SNUO5V $%A*_<'MTR8H%(.+A!PCU1O@0%R_LPG"/'$T?'
M%O*9G-K7]34SROJG8@F3:FN4'&D97V%)NHA9)9B?]/#OFK4W#SR]?_:8WK]G
MY$=?Q_M0JZIN+ZAEDNX']B>;+*M\C9H8C%:9N:.U;$T-+_/=EZ:PUPV=&"3A
M"=KBO3H%C/$UJ_:MJG5QP\E*9^9YP_+-T[NK8GH)04OI[@[H\E*Y5-G^":\(
M7Q_]DV+:!FKL!(@@2AOZ!+/:A!>Z!R9S<!%$1POG0$/YG/T.FQ>C#ALS^W\+
M7=? $_2>_1$WL]W(_'*'(_4@)UTYX%-TOD84(AAS[7V^A>>%)&@7N9JIU>+>
M8N;\8!=>8&RO/UNHMB%F"+%)@?\Y+_(E\2'Q&T.%ZX_*G3H6>)XOEV6.P$;Z
MTQ7M38BP-6.<A01=W;R%QY=K <J*&H]F5H'Q+M?;D-B^B5A>Z.$MQ-W%L<7L
M<NVL],6-\=\SN9U_T"&7\,[/UE_3H^0T%)G  YHJ^JJ/3F,G69*-("S"P-.L
M"H0X,QBJ4.=4 !.)/UF<F&U*"Y@LJ8Z%[$\QM!_[]P-V&IJI(IPU>0(P"68"
M1X:/_"?[^@1OU@7?X<4)[A^(98R\:>R<%9[[+Y7A?7C)@*]C,D\2@H?XX44)
M/)_H\,Z=X0-K,ZVK+V""%B5I!0!RN&GI),C77[K471DGK_":=)4;;SN#<R/1
M]7C?DTY?AX*+_2R2:4L@P*:/J+6JQXX'UK_)$O$WO;G&RJ3O:4$.QT82IM;,
M 4Y9SW VK/@A#4J@@CMHMY)^U?V8%2@^!F2SX-<AS>WDE\)M]'OQE%?PD+I<
MN&N60'&8YPVDL8,__Z70AO>;Y_X-OLK!%\O5L8&F#%2IP!UA  DF\=E+.4)S
MNJXD,T/M-[C1CSO^2>]1B?5\920+38PJL+/,S*;=Z??L#!1\KH[TK#R^1PAO
MQ1^@JC5%@D29OY[\GS.J_R2@ G!(&5NX9\32=]T@5RD3$O/6VU2X^N-1,)G&
MP$0HN\/H>O?T 9,;GVP#]FV_5$[FAF#G@W*X$S9_=:O%@5L"709N2N9\1)$P
MU<GD,[(]0;M8H/'2O9CG8R-0B?8) 9KL)'H]]Q$O[]FM,/B&DMV:]<*T& M;
M#3VL"#-!8*&=-IA;0+B8"-1ENN>@]XG[G80#;.05#*$5Q=NXKR"M+*LSS)AW
MGA6&$C<IT]8K^GZ#&@.I=Z>\,<4*HC"E>WUP6-Q7=EV\*8HO;C)6D*%B;^C;
M-?">1YYK:K]F(Q9%Y#DF!K41JFN6APLYKUGY)MD>F<7DA^_"3CYJEX#918)0
M+ID@G\6ZN'"+B%E%*Y(1RQG(9^-MLUIVKP^8<"Q79V&V+5\YC[4EL8'*$_\'
MXYNJV73O("=72)J'?))5'29O=ESJ@:L*O'CVF%B_:V+]FP+ZGB/F[/EHC_@M
MLNR >7S#&BTNV/UH(* '1>>-Y @MV6%T[HXS3/\O=\%E?4-[XC2;G#T]>YJ9
M3CRC8SC3M^<$!9SYGOKGE_R:3!;E'MB)T_;H9@L*:;[UV3V$<QW<KWZK S5:
M(;[CKIX>@F1 K!<LS+E;N;*]1+YJ9'.+M38''&MQ7]!]#\%C^-"J#8KD#Z.R
M"73B*0">^R-W]6+C"8@X+D(Q4B_S93DM!9<EDP2)883J2JY(W5JO C$V 4<L
MA.E*ZT82KB-C%,&6"_.0Q9Z,O42:H,B"^/&4U$%<EE] K\?TG.;L+\@PKA/.
MHYS#2).T HDA:9GEUH9)@,L)(A9I%(@@I;4%] \^8SS'!9(QPV9Q'GU^@S^M
M\B_('(!T \NPWT::EY5]<3!1=YA(Y=TXZC-D7V69(TZXI&S!_TAU0,*'.*XS
M:/Q%%.C%S_#/HKYPT^<>HX\,Z^CNJ%L^-R*H[<E(Y._]S-T\WU.P?D#>G(;G
M9.PJ(77GWB,J\(3#Q^)YP!.K0S1SV^-%$KP0Y334X7!5?2G0YP?!HI9,-,+I
MX)?-!GM30P..340WD2\LX_+==^SL. SBX[&Z[4'<+<FJAK).IV_D&WW,\#3_
M]/8\FWSXOY_<?W_^Z1S*:5MAC\[GU:8-J#TR-9,U;.\Y7I+EI<[C  ;(Y]WI
MM]HN+]"@@I\R^:G>7H!R&MP$"BGG2+E_(*WA6]M7'?<A0PMT..COL8.6?O6(
M?3 Z^N]HAIFX#*)?=3^S+C25.9LZ*I1,^((_-^Z9<XA]E_D4.) OA%7&%N[!
M:VA+^D*(:H"!];1QA',Q+')]CR^T,+2 A3X.F#J!=!G$(&]ULO!UWNIUHD-F
MY!GS#0XYLQ[2Y]T>C2[K*LX\=:[NXY4CW\\)AA<,LK,S\SJ_7JN]A=\J9W.0
MYIJSK\;7H&Y.)DXVN9%,'4E*JL7I216*C#FDR[4]H5@W(:;E:_S1-32@!//<
MMX<[&PS[AHB:-#Z3WT-Z?[L6=+ZB$WKL 63BZWD'WYXP]=0(:JC!V0TW)Z0G
MYN$D$ILPV](RM%QL/0";*]UBF?&>E?4"TTP+IJ$P-N#_"GJ!358K;@#>\22'
M$?P^=ZM.X4XM*M9F 1RJ:5UH'@B'VM^ 76V,4\RJ9NZ0+B[SY4)ZH[%MOB)E
MG:A@G01[>!ZT(9-&<1*DD\M9"< ;V.(%,1J[RRS<DT)=C7V2#+T6Z@WV#[SO
M-C1)#NM(\$&67/#AZ(59$E,WR129C2XA+ZZS4UJ:;T]^/OEX,OF0 W72"[<_
M7SQW_WOI_O<*+_[L].QD\IMO6 0E1N6^J>YK-?JY6X+[Z7;OSU0Q8,@:*%+6
MQ.HP)Z)!-6V!26M&V#1&769C?%]*IPB@RX7C4!;P^_"2^&(A?\!--X9&0PXH
MS@/0_J+3C-(1\<Z]R^X<2.'<89L>AAYY;_V3<:2XE +B^H8!X-4[.!XZ Y5-
M2FI@EJ(0GQFWBZF"S"M,ECP(OZRM<2LVCT7%($R*H;[L]OT,G/C9Y%_N?;<%
MB8NI*+76:'ZFDO"/H U6WU"*^3WGJ/[AS %I48NJV,\EJ/9]@&ZKFY"PZ\7+
MR<^P6MQV.YD\?WGZ^G1R]*EP$1O07TQ.G14\??WZE#@,<$MUJLY9&+"%QC=!
MJOJP:TK/'VM*WYF+J;J#ZH_\[9L8#T9+KUB-@0\8H#<5 3,5D,_$IQ;5L2^=
M#UB\;60[NEGRI"4QS"#"9LZ61;_W?2Q*=GOK(/R9D;'OA5U]OX/"KZH.E8RT
MKV3:MT^@[0M\<0V.W8-<E23J0*?,K"Y7A6<$T$!74C5&?,I2M:BK/"^F>:VL
M M2ZH540X&XX.TWJ0SY[]B+'.'OR_$P^ '_YX<WN+MW39V=/\R<_9 ;0:.F2
MQIO]#MGLCM>"7!;)*V7LQS6VGLG^D3F FV@7T;0E=P[J4.J1/UBOO,5Z#)RU
M/VE-EKAY!Y;AOJ31(1V\H%TP6$?>J*@[Q$-11'N7JF$744=;!BUII?/B XJ0
MAG@B:T;,C6H55ST9WRENKP>\&;"$YB '6&![7=LNI2(XQV&J/ 6$Z:]3BMX5
M<5T/5L(/H[]QC@&SR:I:R*2-/83::FCK28*8F2\P0AFF%=ZIPY18JL-P!R7*
MAW/CCBF#"!-A89+Q<0A5AGE>SXE!A'/%R-L<#:]4[T/0I<U+: (LHG%U)CC(
M(YR=/L6W/#L]98MQ6=BS!.ANW&MM\,/"S!85/'I5GG"8W/<I7MRV;LK(!PB$
MB0^C5_%K1?P]%,)CTLZ.<%.V?;KOMSKYUU7R!@OD*TH9WZHVSY?M;XN/#,+
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MY*1CK-ZTRB>]R1L@;&I:1)',U4$[#(C[%KX$O,5EL23X(BY++_BNVK_]J97
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M8^2#5C( HES2^)Y/.6=!]1/C0V=9;HH<(R+A4P/G*/EE,(Y^U@$-C%4M]^+
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MT=/C! _&FD-X5NSY/LDD[GJ6]^JJ$'@5^M$1\>'!F2\!G'GZ=/0I^HZJH6\
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MU.042$Y('!&SY^N2F@(P9%@P-Q?4@%?4J>.6#; F,67//\FEIT4'O4< OY3
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M5NYHYSP$ G!DK^FVN367]S8W!()W;LRC]) ?PD2*:'($N9#,IP=W^*&<:RH
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MGN6FTF&""I_>5H3U%N5]>E#6!Y_#UZA$<S9>B>:WL$.=88>?MM/$1&(@&)4
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M09KT\4+Q2>8I9@E4NL8K)'B06DWF1ALUUN"['QEW.ZU&9N;$+V!^7Y58")1
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M=Y#XL6E)A2&F4ZH?7!\.EH-1L0Z\I:V&":2P1L;51$T5S:LTAWY+/=KX$"A
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MC_YP-#&>358_?^3)H<@<;K<_M?5/_$?J"_3AXS^ .F_3P?<7$%4W3@H+.DV
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MF= FIDP%R10<3C%*P:!'"*+)KG6"THMRJJ$NAZ&XN,^R?9TACR1BUPT<SIG
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M4P+>VS)W/)^#([EKG_;[&_NT__.FQ-Z,(-CF)4_)D/A?NXOO^HU^N/$;O9-
MR_%T3:&YA'37.E!]],JDQM(MZF\TS2BEDU/&8VX$#H0.3;&&('!5;0L2H+MI
MDI-//(@'D<UGD:Q3D,+,4D(@+(;CP$V6?6[HR 'X+^D\7>+A)?L"D;E*]XN
MQYSI+HHW";W'4993WKS@$J"V.B,HC,TB6]/. _<T7/1.:JW'@S36=+87K@CQ
M[/GH(I>WQ!ZAN3GI,1*:=NVRO]#<K8KL5*I4HH@>=$*\ZZWQXXVWQBE.^P<&
M QU%'\VY -'VZ+T+_+GM8D$)#IQAO0NI@- U#Q9DQ,K6-:B%=#)U!*)0L&Z;
MB6L,OXRFW;SCIB?.8*,B@6EA' MH&3NC1Y+\X /UW06$3!E+AE@QK@J?3'87
M/-SEA6R<!DM-..5)P@'RRP^QN@+\?2SW"'$NZ'&1!20\*5S%S#1&6"-FAFR^
MQ5,G3>; -$5!6RH[&F8_5:ZQW]_0)^_,F,#)M14-P-U:L&JB1B2 V6%J^K5;
M<=HM68I-D2'=BK<QV[986II4ZS'PNP89Q]"J_JTK+:&7^U>C ]+\P-"+,>:7
M,7EV[+8LSC$^A& .CJFGS(A1&GBQL#531>A_<D89C@<7!KL*4V_'\^0"?JJ+
M =B:H+;%N>MR)#:9)[0V"]X"S00X:7:RS&RRZ,(F0NF]>V5S^.C&VL9U^(,E
M.>4N2J)?Z%Z?0B7'D+ D"/F 5L(&/$>-]8T/<08JN2\'9;?P-7THG<FL2MI\
M!-(S"M*L. .HD[AWU C!)P?+/PI#.[?DVORA4AR'^68YX%A'V6=+<\\%,J[7
M]"->EX!)O=*<&!C69I+.>1\$R\KW., $B70O>56!CV/&"/?<)["MAMJI&94E
MLO/JSZ4H4*6B82 5.E[^N9]C!>B016XU99:WO&L&0ZNGGG];ZT6.H,WE<==<
M2(90?02F"Z->K_E>M0DV1-_X/9!0Z?KCQ6QRFWP6J;(T?F.S0]QQ_5T4VS'P
M@.TXMJ K;TZ-;)R6TTNILG_#<4=?5;ZK^D[MV-YR)A5D<"" R7O!J;YEB,.D
MNE1U_H!H3R5QJ;Y!N-]XR.$@.@93D'-;[G>8$3-#K^;&V+#=HU%DTD&?6TDP
MG;-9"4"3"XIXY^22 "$.73]T/_H5CA;&0QVI=0V=63X$W-$$0"!G 52K$"^.
MK<JQ/</-A=1+G,!NZ3PO06-X*+ %!K$9<"T.68C(V:4'2RGQ@YOJT0FU3*!X
MP4<7J^</(<6CUOO!_<Y+/701VRXSX.'-B4X_.83N!F:A"\!A%8QK1%!6T<Q8
M[7BLHV=@25Q4C\)^K"YLYWA SI@C?6Z4M''MC0( "3,6<B'5^##.P /T M.U
M5Z$?@L\<V4T;KZ4>.J=NY%<,ML;2+4TLMGN1\3FT;/JP(D63$49Q[$0T!TR>
M"4DR=7\',\1QV B6=U8G'09\Y /P^Q%.@IW1!]#WWM,<*Y&2F6W%BPYOSMWY
MFJ46.C13R=!X-!5GFAMV(IX?I@%I@ .5P,1WJVC3P[6,7'"<. I16!H>E$.=
MI@S7;EPMD4+9#ZAES#U<%@^J^A1,3B>]\3PGKBPLT!-V8XAH&8<0Z:HDIC!>
M>3Q>Q3/*\[T%6;DYP>2KO)D6E9&3;%Q&_)07!H[&F2E@91:=T9<--=I*Z0&9
MV#\(P:/@C+ .H9.*5FG7 *K8)?.78>CT2%!Y=&4LGDU07$[TU.-0:(//XQ2S
ML\G8!TXY8#FLL+<>/ECCK=S#,\@52@##6[:C]7BTP+(@-K%?Z 4W\0@01V"=
MI _=N09O/[B&>,2^G.>3W(8(>JO&B4Q9,_*37;2,T?*"%QY%(2.XQ9M)N6*E
M#Z_1=Z[$[>2E@Y^$5C$>."RC\D)]EU29(9T0U&R:I,%IGPSK5NNV*]D!H 03
M9EG"J]@9#5@<F#E59'@OS1X),PLJ4E9G08$*SK%4T(YB@H#(&1@!&)HE/4T7
M>9EO3EJ/<[Q:CDG,!,"T43T3;NNI^:8TKS"U@L"\&/0EO+R9"2Z-T/%;FL-
M&YM17;+>>!(SRY%D<5!;44/:]@0V*L7M'UP<HV&H4@C@L\<F1>(8[51(T 9@
M OMV7V.Z)YEB&Z/#<_29\?B.6=>"^^BJ4[9^CEE7V.M7SG$VG-H>12 G0E"[
ML#7.H#D[3_QMQCI-E\* BG"[@#([='6?AQ $WZY90P;.W 6P2%R+Y;?)19(7
M>&^I9]$J23VZ #VO*N+ #\!4,#+"--LX_F].<_4.JSI=KPJ:U'R:::/,V].Z
MCM4&KA3%GUL=%]!B=-=,Y84%EE-P8IST)<9I$$L-&1WH6K'G&GN:ORJL-Y',
M]CXBWV?)%+D5V)J3^A?U0T@UYK6B%E+7[7/:T>BX:5M7)235KG6;7CM1;:W&
M8LHBIR014L2A[-X.NFP_'GQO?;:QB#HG^ 8= =H!!MVX!'BD8#(E 7P0?[#Q
M-#L_=\=I(*)>ZTXZ2#@NR!0%_/+HM;*'FZA$+*=*21,5^>>,]^;^%E3-S>MP
M/B(%'GGN3N&4!-%B@W(\4V5;1Q'-3 5@2LT9P_9GD[==(JD)^,#C?7.GANH
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M=)$LT8%WW7^'54-N#U&N&2\[Y8@KE!>;NS1M]*ZZ0,XP#E@^C:/'CQX_\<
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M3!@V5A6D!"7L[=H8'Q,JI<<%/K$\;8%I]7[6RS"$B UN4R>-FBHWC-#]S[J
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M[+_)8@'D \+T:!=2DXAPQ\[S3/<<A-F!1_-'NR^[3WS9Y3H+(OI!5<FE\"2
M23L@"#.VRK1C+M<D^F<'S)?7,DWNJE1N[+_8RPS7<-9R+:3U5\Q[$H]:0$'%
M8 YGV(A(-W&%#U.JZ^7.6DPUH[>H^]'P.[J-[>VU;[ZXH .)"9]6BQX6\P4)
MO:$RI"WHH&\J'*BFURVC67)!O??VCH4EUCW1:2U]\W\PM2#R#KR07V'CTI9F
M$SNW0"\ZU6 6R;! ^=!@9LD4NF,DS/NUMJ1Y+0?<D4=T2X6+X_I+M+ JYU.5
MT;8EHWXCG_D>;W&Y^B5CH*;(4NQ49FX#A4],]&Q6.C$Z6;1^C#U>S7D Z=K*
MK\:&U::*[&*I&3U!=+JY:O*UZ2RJ]5U=(-X,J"7 KB;V0&'[QNE$IX[.,WV6
ML<F9"?5S$L$C:MQI,?#+HIK!0C$HY%+T7R"FC77JD[1:#-]2GU2EV\%P2!(Y
MFE;F.1&]'X3;@F(?26S,C.UA(Z&7PV-2.GG:HGDT-)O65OLSMP(U<MQ"B?M&
MAM[&G("^OG-=QE;7P5Z',"/\*)\5#AP6JEI.S*^HX+*:&KF6A)U/=GEBV8L_
M80-N>S)09ZR$>W%CEVYN*#@0)JLZI8T6M%IT/4.O:"N#@U]D]*-?WKQYX]JL
MTDFCK8S8\4^BP G?QUBG4N3YP3?.4J\YR ,"XPY;NH3B4H/C'<^/<@HG!5$2
M,0L+M8-GEDTA:8G'N5E BQ;%P,S7KF>_O^W*/M!(Z)&J'33OVLXH=,N<Z2[T
M:9[@YK(_MDX>-,Z\>&-?-Y5F ]J.V,S5)>+UD=2(M3" >0/X%#*CU(B(P?,6
M'0.]]Q2*H#:A?B3J]/.86ZPO8W^\*M"[Y_J#\TG_9;FOK.55+%C4W''<RT<2
M$GQY)B6P7?*8XG$8-?;5I*-3B(84!MC1]BR?M;&T.,,/<]VJ#]E/:2&:1<$G
M/D2*C.(!DF9J,H;=%";V+9%\DEV]*QYUSE0?Y# 4^ZGME;XYS:GEIX5 ./>D
M,"]"MM524<.FRH.X^PTZ3GQXJ\&H#QFP$?3#4:^O[>NM:B0_UOG=VB/&7@>&
M'&P@Q][%#&US))B)_?B"D35PLM$/6R_=:/Z#@ZXD\ZTQG.]##.*9L7'\,,2^
MWEGLE[D-HXRX-,-\4.]RY093X%\465MW34N-8UU60+Y,] F(U,40 E(,['VU
M2@HU]-2*>WHZ14E.T"6W13)[J"ZS?HL V]+84:+Y6WM?F8->7F.IZ./),8K9
M<9'W8?;.57SRH6@@";$6:*-7L+^G%5Z_'R(]AV37$N_=1'[[HJ#%P+-4>DX9
M]2I%9WPN7UEB1]OTEVDG7=,]O;4=E0FG3HQ>J+N,9L.(LTR-S:4X[D3S'#A5
M.&AHIL.8:K8=KWX&1ITX*16ZP-J/FO98Z/A\$^M8O;QY8R1SN\BKP@L'6*_4
M=I9UQTW9%<0%B>C2=1BN9!)19DFW'H'5M0+E/2^@.H'_$-=F[U 6D:4*"<2Q
M7PDU]*L6+HD#70><I+E?0&@@P_Y,WRZ*I,3.TA*HQ+.>K"#L%A]N\2OLXG+/
M#-ROQ](,*+CY PLUM%3V)#S'4DP*<&F7>_"+?1YK!J</QB^P_>TJ\\G.0\P;
M=&PO2GBPTJ 1F#KRDS&*RZ9,F;ENQ>*#HYG4'_ ^!HJ3)4ZFA&CV'"TDFW+F
M#8CPYPISQ]$FN\F_9+J#H&N]Y:S%S6]N5O>)1#W]WGPYIJXQ4 HA.>/@E&9J
MS_,%3"MJ+J,4BESZCD\%(9/8=<"H1$F1.[,%V*9G_\S=$K]'7LP^>)H;BP'"
M9C8SCZ&@ W;0C#4X*':'&JWW"8X:E5==86;=JGH\$ZI2OB.-[Z4O0;4-IX(>
MT7^]Q %&ZF7L^#K9LZ7]3K2T"6=*],K9348($\*D!0YC[,^E>SJ*3QQ)2FSO
M*:\B*A.G$7 @&!H:Z)#"Z!#M%4/FPJ@U)%E-H<%XFT^Y1QWY&KPBH=0;> C0
MD=EHU+8M;(,>([?/^FJ--F<3W)R-A)_$:P?UJ%PTC#XJ,DWS)_ (H\<&H6)C
M.^32K-[\VE$(X[#=/^T2^OX+9A=</R!2B31YVO%3/_=5B]<5:@>-S*?FD'&1
MMKKJSJ[<J>QNAOELWT(80%@0NAK49[@I228F2?FY[A8M)'7!7*9?HEP;*9^:
M#9;5DI4V@I)" S1G6=3<KA!^M!_WCL!HC\XB<#X1TX,Q7R&,]_DSI4D"?.;N
M8#LQ2C]4_16;)6A))/I7^WQO,&4D $H0,L_N5BZR2F*8;[#K(6EY4=0Y#X5[
M282LJ+C?1@5ZFN(4 WEVA)W7B?(;CTMHCMJW>20XHZ8PIRZ0B1^P86P=?.-:
MV>H>*Y$+"/]6$<G;MEH+C1/7W]1;_^#9Y+1 OY)5SI&O(= X$&0CM15+0QW(
MNW4MSBU,';KAHXSSU2K4SD9XG6TS_([]]TW JR';AJP$E?<-79=V&,PX2TH
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M7_1@>:Z35XN;[I%S#MQZ%RP:MFQ7)OL8S/'RO,):4I5@4XR>?F\-MK"0%C:
M,.X]G%,-T$87Y=D60)D[X8>R#1L_AA9Z"54]Y9:F%WM3+SNXJWICM=R#6HE&
M50*[O' _F-1?-,L\';Z)AI>7=F/;;_A>^O;<60 S#>&!JD>XVV]A:VY6E;#Q
M@>V%7(^BORF?<.WY3=@=W)ETAKB--@QTT0']5C'0$X#;_.-55@##6A9S)76!
MJGKF?H '[!QCA"XW1T\?AHY]]EDAXL-_P,W0[U$ 2",>@\*@2=9> JVPAB&Q
MND_,_$B6F:!;?K8IP-[@WT&W=K=E<TO.[-D^DKCY7<DZ]>N8YY3Q(;M4:C$\
M-QZ[A670(L,J,?;[7Y[#4M3+T=F/7)**C=Z03XC.N&3,N/5Z'WR?11\1]E75
M[O'X:?"1 WS_JYS!QO1CR?O;CSV)@:JJ*\;VN A+=X&%8Q^)8'O<2H1U&!<4
MNQ7.,RA<(J0$13"RU*T1*?)^Y-<\$3)W>]=\@6O2FW#$\D=KO6*;@VN- #5E
MPQ#GWSA+#^&9!($8)(<2F%LSDX[PS*PY= +++VYS4+9FG.Z/A1X)=XHWX\2.
M]D;0.O3'TLJ)NK>[0..X4XJ[1%QSG%K^FJR^X%9LG&3JETEM.HW.@;)MUO.9
M$(;JXOX;IB%8BIYY>0+?:$5X"0]>*3JKU+!<?_#>.7(*H/O0M?@GPP1J(//.
M,:ZI5V3F HE,XUMS>.IZL+G>]A #S)R]I5@<8(N"4I*DV8Y6?S]3QO98-0B%
M/%PLG,APQ/3!M>-ERM0**1-,YD4W&_/3N'=O(CV^W9*I7ZT]:(RC9?0)A-#C
M:.@%'1A%A7K(>1AXM!)L$9,20QJ?-3:)0)K(5>V9(7V[@U#:3,%J_0P?3@7C
M9/A5RC).O :AOC)\#37)N/,%O?72 +<#?D9NA!.>(KNNP#QF(T809LC.S&Z7
MEECSBB/XLO25=%Q'GD^&D:=U,FL#Z:$X'+>'(T>Q0%>U7W:077#U0*+8C<<I
MU_U6PF+0!F)D75E(_))X(FQ;JS90FGU.[J]1@Q!" 2VHPYTHPF[W@Q?[+:!?
M\-RD_@Q8G"#8"@?8\^QW+]]DE'M6,W,I+H5K3L77*.=\/%>]&@9F6Y$$;Y K
M7YU;)LDDMCJ$9ELX#+-D8[_?5O^XQ[=;.G!B5MI85 J>]-*US6N.+ $N!@)?
M"WACS,&T'#2MUU8@?+Z'B =H,]*8$N^V6(_29"F1Q%&<L4>(X.,K8Z94YU@D
M1AUK)"-&)8"[=-19#+'']'PGCBI8_0H0]=YT<!Q8JW'NJJ>;$S;.V]0M$U60
MH[S?6;CO'K)P=YR%,_;V&4()A%FB)UOZM"HSNVT;H$IT8'\RDC*AP,9$")!
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MO7^7TLOX^"H%(_TB'NL+GH^XOV[%_9[$_=5JB/O;%Q^ZTH1[DGG=?I"&8(V
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MZV\KQOJNU_W:.]K'(OOG9JVO@CRWUOJ#'12[JV*M;VU8S9<+[P]I'82-UB2
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M^5#0^ESY.V!6VT4=*^"$5V%2-)32  /4F1MU538>K NEQJNE#5YPCDC!R?*
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M)U088($0_+MR\*)2,,FNX8(9L>K]&G>./6/4#NAZ\T,&'(8[R6[KPS\Q9&/
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M7;5N8#^?7"ZF-B,6=>0_,9T]Y 2RCL:9%)B-H %]GA38GTUA'PK-DU-]G8L
M!Q^EU,\M=+N4<V7GNL*=/5'<W$Z+FVO S3VFDUK3S*\JCO3K%7"DOQZ<[O7
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MDXEN38//&>EY=%/D-QV@#NLSHGNJ<^8J&\QY8&D#1=H%._XY:716AQ1KY$Z
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MR)S",VU?_>HBDN;7ALI#:6V*+##9 V$4[7G@D*1:7&&BM2 TNB3M.VS'1"+
M5"]E/RPH;GG_9E)JE?C3+:TH5\6_,Q>0H4&<$8["L<$5,#OT2"?]QM@@SKGJ
M:HM:,+U.P;+V\*JE7I^WN;A [\R<Z*NB2KC4JH1[!\0^B !'&66D>,48-J&0
MUV3A4%9<RX!OY7W5@8EJ:07C/-M6PX)9-I42<O7&ZB2UZ'B,76L2@M'/<6SE
M\!1+7HQI#!7>0T+#"&P@"4K"[8BHK31<]G /"Y1C4_MR'MZR"AM@/=J:%>,
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MPOF6BN"99J(\_0VST[%#\G=I9'XW#]$M,4Y)\&<9V(3>[\./8?#8JP$9/&A
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MHYM584JY@QW7Y:;(\@!1);#?37*?])HJS3??*,76T&32H:12UE\_3EW<FD8
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MQ)R+.<VNU4G%A@>^70A6@*\*2=JY<1E&:'W8$:W-#: 8""<>52&&2W/_O'D
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M13IQJSL67TA-3_1K%6%XBQ+Q<2F".PH4$A2B=,#70-A25V4Q@FEDE\#.-P>
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MPNZO*JJN>.FNVS&<TU92VEXEMU=I7'*4)TF2MP#L7#M+^(Y'"&[#)M9:_N
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M!]33KASO/E>.[[ERO(9.A^3,48"RHO]V\3U%-C2*3!<-Q]N"+)8S6$#*;C?
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M^<R7-)$*53(MB"/7I5?XGFM:ZBPW0*AQ-";.[;)9BHC[40EY/\#<^;,GYUR
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MU5*+F#^&CEV J-7&T4LD(7%\B&%@NCCVVDD7"7K^VI[TI4>VRS2ZV?B*7PN
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M*F($<Y%R7%V_,-YB48V5_ELJ))& ,&9X&;L:*L=?16J53Y))1:FGA<S.'_$
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M=LQ<(#N$=+OBR17>3E],N?EX/3@;$8EXZ-BI)5VWA8"8B52B_!KF+JO<57.
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MM#*$_HKGSD>9Y!&/T(0J&:HFV5>)J]*^2W0LPMV#IE;X<5+NWS(3T<#@((E
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M!N0QM=2J>Y?A=)D=85AG[5#LMH&Q1 &6(]V>G)HKH1L&^H-BXX%ZM-G1&&E
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MG+/I0S"O[6T.:=5TP4&<1C\&?+U8P='5&Y>YI,VHB'*74%KC[_D57_RHX)8
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MEUW.QFR,BB @!2*,"I^'=7!>KE)&RNLKYK06GC?G[<3_0<3(/\@2G.Z3Y#5
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M61Q[?.?5+%YEZIC?+/2 -$<?ZALS0L\ *Y[*%_8P1CKD8E:.O?'?]:CB:GY
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M=GE5(#_2>4K!?*J52^2EV&Q3JUB7H;0 VE&@G&B0>X25,@$K5-Y$UM())N>
MT3S"+,G+UG?_B+[[ M=RHC)-8:;+"F;%VJT'(%W5=-:@PT)&B;CW0)6)7+;=
MR*$[]9Q (,I1_7103?-OK1GV!E$I,E39ND!4%+/YL%,WA<\GV$[9UYDU0.I
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M>W,.=)4/*Q AAVD) NJHX=W;?S7S??4+=5Z@!U;J'_P(@.S>]@\[^[UG?A#
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MJ2W$;0S$'1^=/0G$'3O!, LXO^_,#_\:X*2D%O#:I6[D4EO VQC ^W3R^4D
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M[<<A=( Z?8W)?@2JHN[NP%<&_PN5L=WW%=.HP]R>KZ/X'<J?_P]02P,$%
M  @ <(O[5J*S2 Z,$   9/H  !4   !F<F5Q+3(P,C,P,S,Q7V-A;"YX;6SM
M7?F/X[85_KU _P=W^K/7<[1)=I%-X)UC,^U<]7C2!$51<"3:)E8F'5+RC%/T
M?R^IPY9D\9 E2]1X@2#KL7F\[WV/]^/C]S^^SKW>$E*&"/YX=/+N^*@'L4-<
MA*<?CP)_TO_NZ,<?_OB'[__4[W^&&%+@0[?WO.I=7%W?]7[Y-+KI76/F ^S
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M^52&-T1=&I9MX2='<!'/->XGZ?CM"L;D63K.F1R8/LIDORV/T/Q;\U<!GS'
MX71*X90/';<(HWF0+ I9VX_*LTB\O%3*@+7&);3VBH!4IK*/<N@+LB.^AQF7
MZK<']%@M\ZDT%/\:CWF%\%<(J%&4JS*E'0#[6<"6W88PQG!% EJ;!:0*.P@#
M2.&US.W2' ):UM<#I H[#/XW>"U[$]L0PIC/U""8^)!6IS]=U@&PGX9K[-;9
M])P[=E5,W'TVD^_<#\W/MO?Q>E\SDE_.%QY903B"863O4@@,\K;[%+".E7QC
M,0!DV>0XABB<"B!CH5!7L(3U23-VBS@=FGKGLY)S\UB(\0Q1]P%0?Z4,>ZK@
M*#Q;WK6T;A!7"6*]LU,UFZFH(>O+9B4Z^S3.<D5UC\=R^(RGF$W/,HK<-S93
MC:)?FY]O2%T/U/Z.ZFS-'E<4"_*9:AT!E1E;;34FK!0<6"@!V3??V#P"L[GR
MP#][,-0W=H=S$=?C]_#[75R*ZJNB<\90'W3SB]!-=Z^/P;,GEJ*/0H]TE9R<
M)%_O&.BO>K#2],(X$6;$=0D\)IQ"PN7S,W"^I&)LJCJJ'<MK,CSK+A**R[H(
MW^-PHZAN^+G"6VV^E>QA*TQK#=JP;""H &G\0G1[M+64_M5^,NJH%.MP(.1Z
MYK7\\']02P,$%     @ <(O[5@Q5#DF#0@  W!T$ !4   !F<F5Q+3(P,C,P
M,S,Q7V1E9BYX;6SM?6MSX[B2Y?>-V/]06_NYNBR_W3$]$RH_ZOJ.RW+8KNZ9
MW=A0T"0D89HB=4'29?7&_O=-D'J0$EXD 0+TK8@;?5TV .;)Q"L3B8-_^;>W
M>?CA%9$$Q]%O'P>_''S\@"(_#G T_>UCEDX^G7_\MW_][__M7_['IT]?482(
MEZ+@P\ORP]7-[?V'__CR>/?A-DI2+_+1AZO8S^8H2C]\^C!+T\6OGS__^/'C
MEV""HR0.LQ0^D/SBQ_//\/??BP]^>#SZY0#^"3\=GGWZ>Q8N/QT>'!Y]^-\'
MI[\>G?UZ=/1_/OS?AV__[],G*D&(HS]?O 1] (FCY+>/I6^\O9#PEYA,/Q\>
M'!Q]7A?\6)3\]2W!E=(_CM9E!Y__X]O=DS]#<^\37L'8U*+-L.H-+BXN/N=_
MA:()_C7)Z]_%OI?F.I3*]8%;@O[KT[K8)_JK3X/#3T>#7]Z28",7E G2S6?*
M#9Q\+O[XD:J+Q"%Z1),/N:2_ILL%^NUC@N>+D"+,?S<C:/+;QPE!_\BU?G!4
M?.A_7L;0'QZ\*12DC7Q_O*V HA4RZ"/+= ;=88' LGYA6%KZ<ZGVY[9RT(Z#
M ]KEGE+X+^U<R5,:^W_.XC" +G3]CPRGRRLTP3Y.OT=>%F HVU#LIA]KB3+_
MQ!>P=W 9SQ<H2O)N].R]A"AIA$3<8$MI1V3J1?BOO,EA%,!G<#*:/!"4@+J*
MWP:@%_A_+[R-)C&9Y[^\0JF'PV9XVGZRK7VR^=PCR]'D"4\C#,;WHG3H^W$6
MI3!'/D"?\3%*M*/6\=E.D-/I,\A"-)I<)RF>T_'S/4&3++S#KP@,-4P2E";F
M55%3CI:ZN?$P^=T+,_0->4E&5K/%1H0;',%:@KVP^.JJ4#"*'I&?$0)BY]VX
MC58T2V!6'U?H)7VB'X;>BI);&,??(X*\$/^%@KLX,:D(Y4^WU,!M!-TLW?GX
M9>@E"719% R3X2M\A\["-S%Y\D($<QG8(B8!_#'=@&BC"=TBF-"(S!P/<8+;
MSIUZ/MP2_0.)%XBD2] QW3DLJ#A;:5A_;0.YQ==:XJ1ZU;[ZR1MM*?4]2G.C
M(_(T\PBB.Z6LV$Q 3\'@K:!@I\@P30E^@4(P?)YCJ#"/H_+VL U<@]+HV)U6
M-L#Z=SHU/Z$=46FNW.HQUW+R")M,\HH"F"]OLA06E]LDR:B7J!=P*PF,^!]F
MK%SS,T:0;7>3],^C12Z&G^)7L,,?.)W=1H<'@^/\C[>@9MACOJ*'T*.N!_SA
M8O.[X0^/!/0/^K5B3D33&O72#+;:T&=A=O+3O-BZ.^=[C?7O\]]\CW!+Q\"@
M.&8U17==X,O\M?KT7D&#6E'^=$L-7$.A>(E0_I6'C/@S^%+>2W5/+0V_U'IW
M"P*@9^_-@/.OW'9+#'1Q\4!?,!CN,$P:"1I."2H\*.V@FG^L=1PQ!*<G)L6*
ML_ZF=GQ-/M,2V1UXO :ZGTJSK6-+L'&%KQB(FZDTW+I'S>>X<#"A-U_&>2 *
M9#(1"&S\K=9S0TAC: \>^(W/Q(/5P<^/< S,"TT^U'[F2TGFPX8:M%E:&TN_
M7<EU"=OP*6JU3VG^,:TH_=G*QYAYT(.2Y_AYANZP]X)#V%>"?P'_K%30![GQ
ME]O/,DDN9GK]:F1-J_<!C>=A7[R0.H%/,X32IO,*MS4CYW:CR6B!BL4Q,7%4
MQVG?$!:Z8R9H!KL8\+-H8,8,)-%G3"'SDME-&/\PA8C1O/$S24/GCAV=L!D\
M-#-S[J/O&$=#%!XM/!Q<OU'_%M$=U(A^_C(CA&[.\[.QA@%WE88-G"%H.QYH
M+1UT)Y*AC0H:";;7AH;3B,8G#@9BRYH"Q(;B41KC2^;B17IC0CKC/FUC.X8B
M&QJC%YHB%"VB$"9]==W^N+8Q\ 5%:(+3UKV_THZA>(!6GU^[QZ?%J^M@A]IJ
MKU>G^0[V4RUR%^LT;V!OU4IR?G-Z]UDMA.2TI'W7TS9[E=E8)[Y6&\EK?<"$
MW]5">&%[^G9,+21DM*+I#**5S:M-=)QQ2V=Z'V:<[C.6+$EJ8,[7'A.N_Q&]
MZ\-6Z3M_: .J]C<ZV&=L^J!*X786-26,V2R3K["S3J]@H[V9W2LI14G^=YH3
M_@?"TQG\-'P%^%/4.C>]$[GTK4J51-E7G.C+WA"U;$)^FMP#KFB(5\FCWY]N
M$$R@7ICG0J4Q66ZJ/8+^M:-L^GT3NKA"$P1C+H!?MY\":G[!O&UAFH&_%P4-
MFY'Y*2UQH18[KVH#6J39XB_^W3Z%AMNB9GG7]@*%S-#W*,!)OA.#Z7=]VI8?
MN:\.2*-I7E\GO'8":-9&D2<]G$X)FL(D\PU'>)[-'[QE[M3HA*WX)4U^RF;]
M+#Z[_G7[.:#>!TQE,3QX=(,T0R";%^I-:=AI6MN]II:WDW3>L&KE6>^UHD\N
M [FQBFWKO2&DXUZ/;IE:V)S3DE[Y7 A4F!:I]:D*O:L1+H=!O*".3A30^SWP
MPR:6 COG*/!(T/2@I4;[FM:I5FN0WIS']KF+>N4QD52OVKKF7-+5,(+- 8UL
M;#)7,Q@NQK)(:W]3_WFLL=LKRM_0:<<6*PBS'8/W4;3?.5E)"W]>"[SZL?R-
M#;T.CM+/ 9Y_7I7Y[(7A1RE"#M'/FJ>',OR<Y,#SUMJ( S_3)-$X^A2@B9>%
MJ4;A&&UK$C6>>S@R(^FJZ5:"YFU\FJ/Y"R(ZI:RVVT;$&4A#_.P%?=I UR@H
ML_4VXD9Q.M0Z;M8-YD)![P0'G,Z5=]!4Y2/H+4510'.-B]]2:9J16N5,9+%?
M:3VDW%\QV<>0K)4Q\9*7'$66?)IZWN(SG?8^HS!-UK_))\(<T^H7XTW6-*!!
MM_!CLOY Z+V@,/_LF%]X/#@[/UQIIK[ "?)_F<:OGP.$"UGAAZV(\(_QFNWM
M&5ID"+9;9#PX.-RSTY!4Y8)^LFYJU64:CM()B>>*"EI]/Q:)G24@2+PHUN2/
M'RAA"OGMX\"@=H<@0$"%N F]*4>]E3(@Z%%/],N0FZU@D]WW&IR?='D)4A"Z
MS0K0V[^C)4?1S++CP>"@)PH7R,]6_)%QQ3^B*8;]HQ>E]]Z<-W^PBH+8?9E'
M^.*SM7YL7.LTDDL6JR3?',DEC0*0Y64<B(T@K F@^C+W**-AF^C$N(GH25M
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M5;/5D'<GOH=.58EOA7<;QRA'("BW5[ITA#PK?WQQ-,GE4XDT,,N/3SL^1'J
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M-GK7%I8HPH5T]I)W=.DM<.J%$B=)+9"GUA:HP<48!-\#:(C0N4O ^V/ C8O
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M_8MYZZ-90S $K-(O=)77V$0K!GDJZXES VK;NT2VN7S&)4S1^A%0R?N_6F)
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M7P<ZSQ8@"D;4?!(UWZR6_K(]^^S*KXJN;@>.?J<:E-*$%)0DI.5PH'A]L^-
MZQS:+,)?:3 O<(*WT@+QPA[.;<48UP(])TWK:@;ORM86EVNS"NK&W!,%(RK'
M&J%W^RQ]BW*",/ONAJ;OKL\_?0VFQ3RD?=1AEU]C>5=R^QVJAQK>N DU=-PP
M"=73B5$AT][81XDIZ;5S:$#Z'(X!M^LBC#\V"8-H'>[I/AAF/P+&G:;YTN'O
M;H0_ETH_JD%]51]5GQFWC<LW+8@'PXZ?GX,\"H-DLXGB0S&:(J35R]4=9"7W
M@U1SWJ$Z8;N@'<Z3S17O ' MV5B"2I.:M%@4],Q4V#HH+2O<GS'"K K*9EQ6
M9W>:]1#7N=[L$&Y:-YT7A-T,5?X-T\J<>).?$Z,8O.!/!_J0UGK+/MG*Q^A]
M7:3CD\FY4O[I\O:GIZ:$2E*(TT+K+4^3:"=.(48/G=/'RL#,AGW9SX)2]#+]
M-MUV[$@[4\DC8S(3\QTKXP/@M<R/E\!W=.+_AI,#KL(O-./@MZAXO3P0C.YP
M=OVU?,&%WOHG_[>1GW!.HN8T.V"*M,.S=D:EB7=2.N@+(80J2BM4TT(5,;B#
M3ZMBPZ813$;K,+E@,E3=5J@O(Q ZKQ1)^D!4IA_A7%R5OFH,7J=[&OM5/530
M>MU*S CKT(L XZJH'":2T@*,5T0KXY0]":$^!U?T<UM>3BK!2)TVUKY\H+?N
M46D!6*&YZ5)LFA[ 9>?46!JI/:<&DA-5^ 4G1"-CPLCY9A<E$=7&(GK32 I1
M]G2H#FHI^E J>S D=?O JL0\28).'TBUT,157S$T007C$)DX0K .D);C W,(
MHL,K/]!+![Z.5ZZ.MHL# UJMD[S1UA# E9[L--#MG.T!XU?*,DNW8=OUM,XL
M\0*]ZN,I"28<I;94R?>< :U<.E$7I\DM0KZ'^2'UU0_>=K5@+IJ.UV'$._]3
MF44&FV(A1\HPQT(.$T?PYA]5.]B#ED[!W.=2B /K[K)I5I8VIWB<4[>0'9W]
M(5)'I][5]>O^U<!/N%AOY8%X:2^WUZTEW(_<1QY>_JQN#]%C^G1+@^@KK]*(
MYH@XEL#C^+:U"EPCMZQ5R(+6"XU(N59O/_1$]E3D/'T!#[5/DYI?O D[LK=N
MO8)&X U0::!8(%%Y-LPC3'U.LO)>[K^E,3TAJV[1K9/FS<'S+,K)GZ[(/UF2
M3I1N-%:MY3[I^DK<,N,VT(3+VQ72>LVS^3@JOSYZ-?=\\Q\'[I*O4+ E.@QW
M9NUP&%N#T[L]/_IT* OM[M($'\N_H^TAV<#&$Q;6U='K@@LJ*JB!H_Q6#-VG
M&0T6M=?/IY2OGA/LF#9E#\R5_BB,K\_:ODE)W"N?WOZ@E#%TN>OBHPDQU 9=
M2V&H"JX+-CVV,KWI@Y#%T:Q,DZP_3'$FJ432DDSMGO^ >%__2C*I9TQ2B$D]
M76X!R'F@:D/<#/H0Z==(=FZDZ <!.($$@S1^CJ:F'0$6:0FT'YW-/=1E+%/&
MS\/PL#O$K'ZA>+GV0K-EJB#4:)D>.-'D'@-7Z8ZL\A(-%K1WJ+DBCE681[_S
MID J.Y5M2&Q+P=''M!09;AYV;(R%R)O[B.D=!PF^#6BX?![20+*!"5U?W@KC
MJKP7D$K,DLK[A<$8C8/W*TVAZ"@'NB!ZC3?EO<9<J5&B#DZSG@4\#Q.%>4-4
MM036$&W&V^IPA;=1.*R^X3:Y60:285:S#"&N:X<K 3W2%J8NN! -EZTJX, (
M-F77DY+><L *$>#&S=EL(AJ&"N+[(-K<)I?!/BJ"6.W:R/NY=&<4$@RL6]T>
MT0YG48+*+M >S&1!SO:D VH$ ?54=  U\$YTT.0H&$7TD+\PTSZJ8?7TKW?[
M.#UBS(OM$PR\!CF^)W,B#5)-HN<T>#5-XF'TE"X0G!#BE! GM>*O1:Q01:Y<
M3"J"B%*$BGW9$;X6I5_NX)!LR';"1'"W\:89:!_&H69 '5*Y^4LS0A;E,>B)
M%.$57$-J$Q6O7G&601VHJ)B] 9BAYKX\1SQ3!S257E<!P-=T]K?UGMV-N?Z*
MLS#*I2\:3J %K^I222>LX[Q)20O5Q+S2;B.9:7?V9GA/K\'KFD^&KLGB+,4M
M_,)L246EQ.!U5"[K0$EIZ[.+@!;8H:%<G.0!SR?*,OJ6!<MB>#ZB=KO[X,A^
M??XER(@NEU]9U?J;TQTD9\8K338;&:DJRQ;AZ3*:W16R(F597HO(F%=^E\@*
M>V"N-/38R*_PW& ]X+S(HK H'[)D^G:39EL<C9=)M$'4%P.FDGW*EJ*A67H>
MI06KZ7JIRJ8C4?[MD#'3E34R\QW&*6P?M(!OI.E:J)]1ZU3Z\<]T4\<S$=;;
M+:9_'M'>B71<53>=(*&^CE;O07_FVU^>;5)1 BAG:D%8D?]0;O$QES$M"4"K
MY2P0=ZJ6@B)8JURI'TAV:&S.=^EA],;%+&J^&IY:6DN3ACC!$[!"0LG-;-')
MV)\NKF=9H05 O8@M<@#N&8:IPMEZVTI&N#]D]+?%4]ISPCXG49%SYD2V:09!
M5^9ICLS:>KHOZ=$LR8%'?Z TT;M'8.]A]N1W%-B/F=?289\1X%:9+:JQUPHL
MF[CU%G4RW2I*Z"D=!B 8M5/26%NZ>A):NMPT>W-#6Q)%U.ONV5WKD2DSNE -
M=05MEFS=&]'059%,8#?EOK/CM-:JI$?^E JR"Q_+-Y?PIGV"]D!W57E4X$><
MO44AYL[X P[3EX1184>F$OU;_M-.DVL7'\=!6NO][>5J_."R.=NDM2K##-/D
MFFU*K41>H!9MJ 1>YX/%UJDS1H^9D_H<V(,R@ZYT<)A,[$8!75=GN SRUYLX
M_:+S)HJ\&TPMAC'^I248: ?$>OA7>$$X&9)Z"\*9<',KB7R=_C^-)+T%,56/
MQN&E?SA/-MU?M%H2:\L?!KJ*\GV:!_$O67K8LS?!\I _8(XWS?OE$F2Z9</E
M72JWXSNX]T0(KKC*M.AV#L]Y$UK'J_?+;H^:%U0Q@Q@W_-F6%C^H8<CZ@KOG
M\=0BR K5LNO%P(=T&'%[&.EHM2(^K$%0H&?\$B7T9B*U</MELJTXV>M$F<!P
M6D.'R:^%@^;T;A^ *1U<&P2PHZX>@*?<WF?I6[3!FXOC9^*EW2;UBP#G81&]
M\9)Z:C]H"C&W3\F;RSKVDC.SXA49FOCYCE)"4?(=:AZN:*B!U\"U(C@3>LO\
MP_8K%T32H.X.6A=W.I1'GFN?B&//=-:*KGJJHW9T$Z;VXVPIV2)]X(*-:N)I
M*.)\!73\D >/@EUA_M\61V6D0V.1-"'B]/D/ ]F&[VV4X<%W5??O*# ;A:OO
M_ .OA+.DO'RE =&\IW)YC@M>KSF.@N<HAE\(S6$Z?(S$%*-SCM ''[NC_[EK
M1E-X8J[1T]D!N8X40KVI>J';!+%^J-41(*ENDC2<\5C,N+LS>VU(=8_HW>))
M[T1^%JXV%:Z(S8K[T_.]\\/VH3#G89B1W:]<V<VZ@RZ:H_)H+I=E7SC5GRE6
MQ;\/;W>:($V]^HEA!J0VEVG"EM_?HN+U\I 7Z0YG%7='(PU24 )5)I64FGI5
MD4%?"!U4$5K5>G;T1<M,Y;W"6YQEF(9OWW!R '[F;A)&U;JG!5 @-;S/,"T&
M5LU#^7;?><*K?IZSK8&1-NH1!%5*39DU=;.D5CTIR?91/%^+4X)[8]*2W)6
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M;]ZD&?GM'F?%D2@TK52RI[\6G5694'!U@F4DE7"]HKW1NRK.2 A\ARH2B-!
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MHN_R46-+(S)X&;A%=X4ZE-F!3YLVQ71-'37D/7DMT2IH!B\.VT2,_SIT59\
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MGH48!XX2[Z,=^[8R>6W0TFEJ?9_+X<D>:5'B%#37S(15V(3YT8D?9LB/SCI
MS$VQ[H\U!HNX"9;309@*</6?PK _\329#R!& @!J/P4[M2\@[@*&X [?"EBL
M$&T-[!_,9=\?; \A(T?X$"]SBW,=*=EU&!ZR_'Q+1O\FRO+B/$FB-S(3 :W@
M>1FG>92\7%$W.]FLDW5&%HHT>TH?,9%Y(VHKCW*X^;;3(F'+C^1HY2+V6<2_
MB]B'$?LR:I&C)2=*@NB*U;&EQ\,)6F>(<8">4L1YD/8"C/MX/\)I;ZP"/L)I
M-<+%Z CW>L%65W-D"H85VD[)#NA7>?OFT6JU2&1_M*PO+B>P8EB>]A.TZ,N/
M@-<6UZX9/2';Z'S>E[)=+2,NM?=F!LR4*I05,Y9>/:$]+U7MVGIDTA88CK2[
M2"M7=F_LVS3%D!HY0*V89.D\@ -T,N6=1J4]80^P -F=I/S<(,Y[!UU%;QG>
MX6)D \S(0V0#P # _)YK*<VBT$=ZMQ,8V'N\*P.J97O$.OB >(4 %;\TQ2M?
MH0W.PRS:0U>*4^-'COHQ\   _X:L>P><A&1!N\=D5=I$8<F9MAK(2( IA50N
MI8K4O=DKM&7_2G%\4!DC\3K21 GY',Z+LS2)CZCT3D"OVIH"4JY7:C3.V#QV
M/W5;#N6:C&3YC>J!;.JZB?:*AD1<;0U-95/Y)A4%1$G4BTY%9'2OXV#'-U=*
M]H(YD:=2(]11([0YP&W@)H&SLU^#0Z;6]LP*0J,&H:-SB'850C<>;+\4]D2G
M$]@2;&8O5I"F89( ++.^@Q9_5E&9JNN#!@#P%T$>Y8_[# >;==).OWRO#7\9
M"3!ED,JE5 W6&_'N-(0D3:6%4!5S\:*6>+6KD'FE1&HLRE5*#42(#5\0XO,=
M?9=,?X/7Z@*WH6OSK=[ D=:(-_=!/:3,WV=1$D;[($;/00S]6)@*+(K-UP I
M3A!>V8^R6@KE20+NT=8.<3W.[?#IN-(FELU6[&HF)#0DH]Q'A62(K>V^;^(T
MS:H/4:M*MOLAW4*\:.Z\I01@=MURF50[;M:[64S9?8N& /AFVTRXCD^ MDRT
MO5 8H$VV!@8E&VQ7 )RPN9X Q-;&FL]6U)G!9NYL97+TXNGU42OY:1<==J;F
M0$H QAS(95*9@];A<]G=)VLP0;86PO:-;/M2-N^,@P8B)<;!%1PG&(<%IPXZ
MWM8[,F"G<Q=!3.Q94OTJO<#W0;31/R4V( EWAFPBM_J$N7=BQH^::1B#4:Q_
M7:3HF;@HA*H/F[3Y8]!> B-:Q78_?F((>$YMC&_%*;8QN&<N^%<'Z7+._NQR
ML>;\C*+A:G@6Y&B5E3 %?4#5FK_!XF=[\K27-OU)=+(DT1I&Z^UYEA%N,!5
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M,,[>:N(NUM[F:QBJK?\*,H6BH>N%N)<9-\TP]Y3Q<[/ZER_=K+?G21%MHOA
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M 52GG:J0\1L$32?06NTMWG7JG5>6W*L7"2;)X%?E]CZ$U+7;^_@!Q/Z$=PJ
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MS3@1<$,BD&VZC5A,X756=$LR>E\8489(/7V4P=&;U;_OOM,65Q'I2 ]9HF"
M!$-CIR8/KI[&XS%=<4?VL:Q=^P,GL)Y/&",BTRY(Z GJIFP8PCZ\:U,WIBS/
MNHKAC:$8#Y5A\U5:EZQGAD$B_W2#((X6TVLYWAL"@S'ADC:K/I6/)NVGV[IJ
M\C/?(/MN%52*,,4:J+3 &ROP5!6]RJN:03/U?XR@9YH_*O-TG7^JJUNM4$7P
M!'1=:Q0Z); V30DLYN?S9YJ\7_7%$)^BV6)\>Z73;*OR0KRR".<=8V1!O26T
M/=1TV4C,5/J:]'$DW^DD#(#)X' )Z>:^? /E)#1?J0A3C8!2"[RQ!Y_29(,W
M!]+L.<;EX<7C:Y#ABR#'F\MT1W_#8XQI+CM56^)CGED,X[&:;D(ZGZK.]X@A
MH5\[8Y]#]\&1K;;G6485COY\ H9E]A@^%FGX!PI;#5%),$V\-SK3M&V*%9JF
M:MZ8I77QBK/Z5\G+;8%W>0GNF49(3MHSDZ,8A^D&AA%&+<J(D3X!"V(X)%S0
MB#;RW3KH@'Z*+=!!O-.<G?IX\BX*G@E+!7&3/F&=G!UA3X"<';$4PIR=YG2?
M+/$8Z%#/G'_Z9L;(>?R[N.QX'"0<0:3N*% E2MU10 I&,<@/U>_*Q=O@2I$6
M%4B%D4JGI3STY_H/5?J;^+X0*!S5<ZF$IGHB86#Z2YINOD1Q3+:WMTE!9HUZ
MF_Q/)CB5DH$$JEP^+:16)%CXIR%2_ATVD7FBG$T34)=J"AJ5FJ8!15]6A/8F
MCK!;IISFDZ(WRWS.KS5FRGA-7HQ6J$V-*7_UP6X8I].,?M43D[#,^ VC-UY9
M$(M*-F%-GZQAOE@D>NJ5O>&<,'\>AMDAB'/V7[QI^=;SK)#F)_RR/+KC,L/:
M5)]@EJ;ZR J5GT&M[WAK7Z:.4B4CYF3\\DEF*LD$*V*D(3"6HWMKQL0@]'M"
MZOE "BWU[=W?\D0;]67)^!L97BG9.)Z4NC,.)AB58#%:$TTH.T J0,6S%NY9
M8T_0+F)\E$=09'=@H01T!Q,SRH#+0J/W&7T]N3C>DY$KR!IS_;=#Q-*^1L [
MAYBKLN)39=4 ?=OK0A4MQ(@A0@W5Y #>3[<E]DWTE<@<C :SG%4VGX773@5T
M>+!J54JW#MKZ4"='<0NT^PJT>P9:NK? %3GW3Z$/I+Y-B+ ASNMT2R)NZRU6
MD^5420IRH57+J;4$1PDJZ=2YR*KG:X$6:'.!+X-]5 1Q]'?FH@H2D\,TATU)
MGHI@Y<JO"5\8-34\V@<_SS<[Q*>W6D:NZGMRMF]RH.^7:I@<W1N>UVN[O3C(
MH^2EE6$I?!1'KR^<4SLJB98/RWNVTTP=AQ#G2$1;X=JE.7KDH8JAI7!(%\;5
M1/_3#%]M=[/$5]#JZH%K^4LV_@*6J@-HMD(V_F[2>%Y"YOR-+&/&V>]'%BJO
MUJD.4M3Y!6V8 (4:>8&*Y(4^LW5)].ZX3;,O0;8QPKN,"FA04B:=7J2RHH H
M"=2AX<G^R$A(YJ/6,M&'TU HDPDVX*D$ISH*JD0FV'DYOQW:X4GC:K4Q)>#3
M;[F4VH?<G$Q7_YI;U)YHHK&XOM^:G@A;G8-J#<S:V;VUHJ%&B=03Z0#LZG0E
ME"I;^WC",*':[8YOMK14MUIQ;9"'&&:!5+0G=(]0T_VA[;EC_ZZW!&7.C_&&
M43<"]!"]O!;K[>=<G-6NVQ$L]C,B@T[@AW5#ZRTB':UGJ__,!4GP2U#@C5GD
M1T,>SGNZ10?".]B6T0Q2\K#/HGB:%O,QP54KX),-Y@8@WO,8ON+-(<;K[?B!
M22N018LY4!OUE-[CC/@MNYLT8XD6Q)X]Q[+L-9L?<>C26QV;00)X29P"0'0(
MV2UI4'T#%2DJOX+(__"$HAS]SKX$]$*4FZ%:MX;J7#Q4S4@]-2-UHQPIEYL+
M^VK7WW?8USEC>Y3C\/N7].V'#8ZX*2(_-!:(_..O=V39BZ^3(BJ.YU^C,:=B
MM)4#&S#.W?!4A;1 O G9))!&CO7/G$T(U$NFNH*M9)X7P!W_R%6Z"Z+!,E_R
MVVWB"'$]O@95+4J@\08 4-/B#PIA8Y/:AM?8C,[8(ET&<42,91(%MTE.*!\*
M3.SF193N\"8*@[@RNQ_Q[GDTHWD2%5>;)V/IAGE(%0%44V"+<$.C6<Q_YV0@
MHBOS!3V_N[UX -M638-A9X\%B$&M#=<R6-R.8]%6!.4CV=$%X2O9VQ4T*ZW\
MZGK[A,/7)(W3EZ/<,.CW=V42#"3J3T"G:VL.B$/?](:T G-DNWT"4WY3D'74
M'@1A6@J_ -+2-M(6T?'K(RUN>1UD!GH]Z .BRT/.Y:-*VO-K&T'FC<YJR'!]
M[8>>"H BULTE46*NCZ9HP4=>\9>LKI;"FWE6M$*;Y%_-YH[\XZ^7Z2$AZ-D'
M67'\%.RP(+(@;NI "25\#IR75C-$VX$$&N8P#*%V*B!4VJ9"P6(H?<![,D&O
M08[/7S)<QN&Z? CC$X;]'>'91"(-D(,$.:S+ 85]8WBU%<(86TZ.JF;$L>^B
M!+-BGY)#*COD'1Y/61H/:5[6Y,,H^@5>21?H1&KIT9ES_B09')>'4#85JG_\
M9%.;9N6QY&$6[5GQW^W-H3ADN,7.^CF.7H3/;IH2<)?7HB_3, ^A[DN#+[QW
M!\>M_B"Y;G9DHP]L<=G:F:6I6#:':3"&B.REPT# 43,MQM'4V8K>G"?)(8CO
MHI FSMU@3.P0JS G,@7B]JXT7\+QH!88:XK*MH@TIBL1+[@(H-<+<>Y,:U58
MZ2BI$Z!HZ>0"PSY#X<I*^\$+34I)CT%<'-?)XX%H=LCKM;&"6B+UT^WM2AFU
MI1EY%;;LR'*_>%=$+%_3&3V,%Q=SH*D08CE38S,$=I0: 'Y:*FYIOK)FOO)F
MOLH:=^[34LLWG<B>X&.0!'S'0$R29/LN[.%P1R[F>C#XY9M5=,O<M*56%V:W
M;,XYV?=OH@R'9.XA][ *H/2WI0J4S%C<6!+X4_J$LUV4! 4N%]+-/?DY*?+/
M^S2YSZ(T^RV+"O*;3VD1A<*U;B(Q5TO?5%G';R<\I:BF5/D?]%4W1@M18HA1
M0R4YQ.D!K(UVY28:5-1RQY7<^U+N Y5[S^3^4LJ=C,KM;/&<A?#.6@H/;ZVE
MU8OIMK7;;?L)S*G/U]O+=+>CSW"GX1^W>7[ &QW?6](9PO66R2)Q>=9;OK7)
MZ4^\+^(U^7EO8,][HE3$D<NY5.2GD$N5,ZFB4:E '&\E^H1^MQOH&;O="TV6
M+<TOS59]E'=-#_+PYHI8'I&^2[NXTG(YWX,[#N66I6Z.RO:(=@!0YVGL!S7[
MN&1_,\*^,[W5P$Y'6UT!1TM';<Z +64LM^CEM6]5R%G4VIFC+^)VX.*4X8.J
M8 )DK-D^T^Y<;"DZNC[T\M#0<Y*MCO;\98Y&N?DF7[&XM1LZ7M(Z/(KL$(O
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MKZZ*.O<@RX(T?1 X.]8&N.LH/]L0%>WE\VATM4)2AZO^8&1%5.=3X:SRJK
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M4,N8C+&B-L+&!I]O10LT]=^+%E#R1 2F0;O4/48[..XU%.Y0=_%* :7>(G(
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MU/)(+= =*_]1FYW21[@W9A(O!UK_3Q)5/\-Y8I>F)*>'^L01QB5A\MB?4.M
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M[@D/G=3]L7#)\# VJK,,"_;FU1WNG7!>"OK0'<##U\RTNG8B_3)< #<:;GW
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M'G28C7Q^;9<S@_01ARMM48_6[4_36RC4VC,P_U'_B?W'.BKHO_X/4$L#!!0
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M(:=O9 ([IMLBARTR\U]C_L5V ;?J02>6SVZD;/B93I!M3\WLSZ/7LAMA3M]
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M'7G?=["O:/(AFUYQ76R5=%NWB:-V0J_]=L7OU3Q(9^V6Z.8?LXHRG*^LQ/,
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MVK=24<25@!+DR^%F:J!"Q!>R\4-5>(8#ELN[BNQXI-F?5]!AFK-_R>T&HEI
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ML+5Z_$Z2&0RT.8",!&=\:7D@ "G#43-1[8I; YJ#'E,JV9+9/ASA$5U:'@A
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MI*L4FZ\1*4453U8I&<K?"PF1Q4Y8^@0("MU^WT:9[/+@NU^8$-Y7TLB8!M6
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MOVV]!YA_3Y+)=QI%5680.#$Q:U#U)Q.=D30#M"&?%+K2%R5HOXVW&K35K83
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MW>Y"JS$@!SEI8:^SA0$G H7!-2<:[IGNIG=QED1O358698OC3Y?'?(!I2XQ
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MR\QDEDQF2R:^MFA;%-Q <4=;<5^HHE8K+G47$;56Q:7N6\5=^ZIMK:__>9Z
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M<6M,RZ.37+H;+)M=4RO$:U#&'PZ9:+"9$BI^N^U3S69''^;IIH+!+6M=3*U
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MS4<5FZ5U=Z*T(EXVQU9+44GA,-SB:#Z1**01/NV&R9V>(V:B553#&) I"<.
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M?%D_ZQAQ1^UO8O1"-H"E;7\/PIL\H>C=4@-I(*VP4DR07JQ7UAMX 8T D8I
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M/1Y%Q)Z =7-"5&M1A" DV$ FTX$1CU;*XFVJ*2&4-UIL]/=M($9/)BTB6V/
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M9.C"8X]=])9GT?GT],_VV&?%TOE_PM\?<=>5R__SD/FMVYE5Q_QAQ4E[CIA
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M6-RQF*2*=:TN0PE[FT=])P/S?[+FN_Y6//9G7M,-ZL<,R/!C8H2W^-E-FE)
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M\IK0AP4!-6[&Z!LC"7>C'BB2]\3^FI9Z\[?H]_F1CTX74FLQW2 %[@1Z_;4
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M#A%'J;X4GU';+_#GVG<XW,Q(#L[_7'=#C:C*OHL"LUI"P'7\&50- K_P++/
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MAT3.BM*H7UUV,5%^>;QE#A,6E]TT7_EI)*9+Z":!)?^[C]SV:8'2CL?GA0*
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MWV&'Z^"*6_1WH'B=6/FV\1YZ;!ZI!=QY][%+]I$1^N3YX7+Y\/$C("5'M.^
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M1G('Q<VV:UN15[0U:G"E1L7WZ^UF37B='+WEW="CH<&0#XE2.0!$3O!?S4_
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M.E;!DH*X8*$^(3PITC'BX1!K_W3:>>0:,RJZS$4:OU&=?+E94"B_E@9%>,(
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M9/:L.9JR,+Q#G+-;0'UWLG'Z=*9'7!X/S(X8UWAC_<KZ1A5$0BN;5\6)'T;
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MP2L-)&5^3&>[0QG";48WUR1M?PFKKZ;95+O?%#^MP<Z>5.YZ15+@ %(Z<9;
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MRQV\][?+A(+F[AN)W]37LS6!]RV7A:42O6[,V-,6QLPTS?,$S44V-KFQLY:
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MOBU="Y7,)\]8#KWGZ:C*YU$^^UG+_V]-_<<K(C )F # 4Y]4(/I*.>Y?JF
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MY?EV7R_GK.@KJ$,E(.) ?QI)!QOUZ_P?W(OIQ5&""?Y'IM^35^HMUBP_90?
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M6GB1^F67HD7RWD[!DF@"V!.V.=%Z*6.;AW73+0P*[7%&$/B9I99%>>.EB49
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M,B33GB!A#!G,%U6[3!.[B2#!F79/*BN^20EU N 1\_UG7=3<B>F1:=;R\C8
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MES]BL,OEM374U\7GMF2C;%N)2@[R51 '>9M'2L9REYR9^DN/Y:1+[3$6__D
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MJS<LOCK&>/KF5*"L_-"Z8YZPNSK"*2+'-O>TF-B.1,3H )"M;(3:A.,%TF-
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M5/"U,P35ZXY9L#^P!=A'#_;5K>NW2B>"5#[WB'N;)VH7,>*P_D9Q4>2?;I/
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M. LQ?&)T_T&G#:]+OG*/B O/DY['=]*%#77^W,N::+N<+KKJ2I>*G7D\;;W
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MT"/06$D>.5IU24PUAQ=6>?!:WB-2<;4MSKIR_;#[>G?-X/5 8^0M6Y8<^5.
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M#9QBO/3MTT.PD9$^=(O(R<:\&PH9L;B]F]T7E<M?HL86OQQ*W!3\R7^?S*K
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M=-E)S7/7?PC!^;AW^8ZZ$+/Z5X*_$DV]T_TSCJQ7GP] SY^:%^__'0=HJRH
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M/#5JDWV8L3]UUDX;]_.WYJ6VZ;]M?#IX&[5(.TW!DVC&VD6/S;I:'5IT0,'
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M7).T6'?FKJ1.TX0MT>*U/O<BKQY<1)SZH[)=#KGGPLP,"2=1\6CV8!OZS2=
M^)]=PK +U2XOER8$7A9:W;S6P_.]Q+RR$:*<5)GH,R!T&-^#;+FQ<:HVI7[_
M(%!2E_OZ!W X'CY$/02Q56<W74,_&T[3/4E3 ITB/)S6'77>%:_/KQW!'E$"
M#S$N$ M&\U( ^%U3R5)(I[08>*D9?;AKV[+?G+ERD)"2EK8Q59NCX3H\?J I
MJHD\E"1*6(7=>ZPVM+ BX'XXAJ!:UMNHNM\0.$ ]24$A5"LVD@1^NRENDH&6
MA$]3\&_08%-7*%(9H!V)YJ-RCZ;=U,4[5N.T @N+:6!\X6#/309KJFZ.BW][
MRDHJ#F]J+'-XV!AMZG>>B;=W1JI^I+2[9OR]$5O4Q'Q47,T12E.AYD4LYS>;
MI\%8BT+8SC" [G*#G4A')$<U)]NK2ULSX?G:6<OYGL\_LH+:* %5.>\FE+HY
M).K52JQG<9[?>H;K^S4@LK\TA484AM+"=_D4U*=/R>&162?XN4/!Z,M">G=X
M@U2CX3O?\/7$K#.=3H);'(KJ"5T"OMY\<5R+98[2=JBP:)C ESI=[G)2G@53
MER4\GZQ5YIK&Y%U8?EEM/PE4N,_;SN=TRQ= ?)Y&UJV!X6WP5Y)!%0CK,9^V
M=QS^0T+ D>=7T$"R^=JA=K>N5D\H.Y.[]9H&PKPNUR@96IV3J3OBZ!P2_3XA
MMY=1G&06@\<0N[3L9^R(^9^R7&XCI$9UPWI;JP4;;;?]?V#<6RA=N$WC^*O-
M3[BE4P';L6*5&+NKMKJKFZ(*X=SPT'"B7EX]4"F241ZWCL91%[6_5OKJ<0ES
MUM4E=-?^3LUHIC 4%4V/]B@)1UXK3FZ:IYZO%Z%.4IJ61%RZ^ZNT@0=RB'Q_
M$#.Q@7C%A75"\?H"PI.48ZY.<O1)!Q8Q"B1JJ'VY3^??KOCC;!S,XPQ':(/2
MOL%UF<F!00$Q\^$OE)!8/[:S82 3\@$YLP  $0  9PP H "$N'X3TK0G/"[^
M]G.O3-^LY]GZ\_B\8 \Y-U9WK02URX=1*F140!M"E_(;!> =,M?2_&3[V97,
MBY,K_\';G?!:).973*8CX]Y^*$_$BY$W7#,J&5Q(II<#./3$PM1R@CJ7RAYK
M:4 1^Y>T=,3C&'VZ3G/R%/5GZ8'\=TM%<!Q;@1_91.LLBUZV!X)GME-OZ&0/
M%H;L%?012D$]!+\*$G>(*$()\WJXSI.GU_TTE#<A3?96&/8W =&A>!<^;8[?
M\@V>$Q6-=)SX[&DN"E%J:6*X4>W]YVJ64< _Z@2CDMW-]D05:FM*3>;@WL3(
M<G&MRN(#N<HY<EH9)L:]6/[!@@P(S!Q365W*1/\W_$:)/OI!48C>V.YY>4W&
MF_$CS;10B):DWI=*_L$>Y17Z2=@I%3"LZI0%O3K#O!_^^BW&&K5H.%<PPW>I
M7IER$+79(> $,V<\3%=03YB+A4!UCYM]=IA=D!.X'NFV9J#X8O:+K'&6D%<6
ME4]KGQ$1G)$/51\ZAB'/(F,6KT/N!?V(<STVL7DMC8)\WX4Z%MN$[U.@'3[,
M_U :79L*G4[&N"2^N2NOKZ)WL8NDO]:<;2N =!IA+^5 L]K%%U[[-D:@5B,H
MV>Z'X7?P1<UR@8-ZY*P\4>U=3^6,,K5!H>9L^"@B>\ #J5.@7B;A6HJ"4:OG
M0I#ER AY$:6/*2#]YZ9"5*UAGZ.5(W()LCH+)X6N>>Q#M$J93&C-@YV"07^)
M]U/$;,K#5,=V)>_D53)48 4[]RM?? JN3^S8/G.%97MKO?_DXT(%T_F]HT-M
M2/2FET5FD91^U@AVOZ;?P\JY8-_*[ "N5(.XS&Y$_>P(QP]I/2F$TOKU^$$Z
M]$@+,ZERE_)]0UH3!NG9:P5]7A7X!028+<:-VO4M'&_*R:N-\A4&_5!7WE-W
M&V9@('=36^,/L)Z-O>$!*@9$"PE"@3FA1Y29EO/19M@'H&$(\H_,Z,K5IE;O
M99!G!#F%_MYV1TL,>=CPQK#XD(5M4CBA5?2%!U#LTWE2N2L/(YN!O#/06=C6
MK'TG\F:](9X'7T?\:C#_V'IDS=X]X?<=T$J?&5Z@4GH3?IT!A^]H[^D;![%>
M?*H:A.1 _7&>$>-*[;O&=;NQ:Q6Y276YJ)\GF^(M_:\=1H##_?+I9QTW2N.@
M)4/!5^]'8@]BS+SIHX6I +)>NO0P?-#XGMDJ-7VK[]LHXTJC##1 P^FX9TX,
MJUL2H)0SJH(.^!WWB3)<-E\G)^H@:8H>1, 9+^!%3\LXM W!%7AXN#J)X%#%
M3-;0^,WKL+DEF9?L!P2@O4YNA.@+ E3:\J>XQ7;F<LT'1GPYH<Q@*WSJ/(T\
M<T/96H=>,>U^;)W"D=VRN+8&$FK(/#6RW& G4<Q<.%KX4PJ]]1%@[)"CP 0:
M.!D8+!U/%7DB04&?+(9_=/ 5T9L[RCB=+K*QL:F]>7BYQP8\75 QOP2^UC?H
M&$UIDO?:E JWS(2PUN(VHP\<QG,OF:S6.$F0T]DFV^AE3?L9'NYG$<_)Y9X1
M]#"^/BF/G=!"*=V?W5I2_'9MMMSN;5DA5]J]4GJ*(,@9;1SWJ6*BUT >IGT.
M9(.6=;P;M<&TS0X4MTD30Y>VB.=]7O_QV]WP_"LK"WOJNN_3B^W9C\S,0;VS
MY=WMUI9@A%J>,D>N-3U=$&79^CJ2K==OUE[B?I7AU_9215<U;P2ZQH4"RUSU
MFO9H5];9SOP(=L764/,=V!@J0BE\8_]V5Y#2ST:79R#R"AR*BI2F3.Y(XCS.
M$I/#H^FFJPU1"=1Z:#[WL6#X%!$+J]&$A1O(+;(:K&&)*![/;)?,QXYN:O0^
MPIZP.N8'RU69;?!]446>B&-3RM(<%T.OCW-Z@*E7VB1:URQJ7:"8P]ZXI($N
M*^M[69^L3GG\=34KZP1. !,'ZWV[F[DM$&F^KFDJDS;!LF*6Q1U'5QPMY\1X
MT<?6-F)DMZ$^4#\];<,L<!-^5;<@+CJ),@I*H(WDFP:&+XSX\'[-DP]A>Z'6
MPQ)A5,VW"T?'RZ+PQ=G93?()X!(N)KL4L@Q_71M]#*8Z9Y*B^9PN-GRI7&QX
M?JDEW9PJ%R(L15A&+A7?OWZVTX63D5% E0.QJ730NO]Q*+;8##1)=M!TT#Q!
M<G0\Q0@A0UYI*W_LZ%$W>VWULH6Q&#0&/%ETTI1&64D!O3JN$ QO?BEKG2K[
M28\<$QQOHD$$'PQY83K%QEBHEQJGKAE(CFQC#80$:H,VS(\H/,G$**RUY+:I
MJ&3J9W)VY$1R15S73\N-)Q=JX\B=0G!7960\.JDM8L<!J?270&)GR1/'VO97
M=]5V^KKOI[X&ZFZ(N2SR7(.P:I<W&=GY&MJCZ7+BY6UZ%>(F,&MAXA#2;3_]
M\T.P1&']CO@+GZP/T;@"M!P#AUUYQGH$;_%^AHR@N%"0.TFG+FR_[NVC8FJ=
MS&A@M!&O6"T5_QBUA&538W-;HIBM(]?X>"U_GR-6@IP:[:JN#HB@+BD:Z 4T
MYHS+$T KE?D1.[QWS5WED]A5.[@" J(+;8J?( EH)!]ZGE?D^42$48:9-[?\
M9/!$:[:Q2N;-^T19FM98/;^:&'F'IX13S:%*;B$H^SO,"!_'A->3<Y.&)'_$
M5,I1V#IQJS0!<SC(V1(43KT\!CE$!\=39N#=TG[OU:&BP!2U9$%3%A$8K.I@
M=7#V?9#*!MI@(T?4@(66.H<HF==<FFQK!?DO'<DZ6YZ@KC)%ZRXN5 VDV)Q2
MCSCHVJ\>22TCK)BR(\"K<R\2I*N5A!WQWYH;38T/B-6YO'W7]W#%8-PC9*&A
M/>96C1NNO#?'T'R-6(BW[DE#L4(EID\''Q>7C(I-P#0,S-6#%V\-9.)&.(#H
MLASEK#GQ-KIF6A;1M M9LO!(!'26Y&)<B"^4,0.]*?@"+XQN&.OZ*T-"]_,X
ML2,>7NQKJWKY*1C2,<[N ODX5PSX5FF+O$F9@6F5?]6QD;MG(R%I^ !8RXC8
MC$*]_1QB>5)^3]"E^ !@B\S3=RY6-OY[I;KT1,!GD;?5@"?WFL8/ +S?^>NI
MH>L[W4O*LR8/'0TI CXE!^,U_%-Q,"H5<*N5EWHETM?'G;C#<T?L[.>G=(K2
M4R(?=':\ON,2IP&F_AHQ:'O&.9DX"0P4JWA=/*!S]K45&#&O/Y8>9F.CX4?!
MPOW9]9KNBOZ4AX<KA\N H[T]IJ*S8,5Z31^&8#S;46G^DU9SM? #D$<^SJ50
M9+"<1++>5BK-3Z&I#+DN]>=\8.[.#Q?I<11U,74AW=XHH!$71B8,4<;"43*S
MONC(ZAE)7G\&H)TXLL_\9HIH@EH<[[)<:T?+IW@I7K^XP@NI.)+6T\S)*Q!5
M[Z>D;6KYN;_QG>/Q<P?K-0V^TQ9"GU &N!EI+ /'_OI6WBRJ.7'*/K)Y%#R"
M29B<4-W6_*T[Z@ \N+RV+A'5/K[O?LI6_=G:4)'/+ITP4>C6.1K7)7"S(IFY
M=/-@07$XTR3&Z8:=+7T))8$F7?'G+5WY.2NEBH-',(.0]W>2^ [<S51G3!,_
MHUZ5V)#VWKU@?AB&@G,MOL)X*G$OY# H: &7DZ\=OBU^;^DB#;#XCLVM<U$P
M[]XKA>VL.T]+H>FA51OF3.2-\;NCDZN[LDD^FDT_WTC,YX42%"1A=^P_KWYJ
M0;K_D;7,7ZSU.ES_!\WQIN->4V?1&<H%-#PL_&U8]>I+/R&UQ1YW-*\VFZ:>
M&J)O&159EDR])A%(X/AF4Z#'::IJ?>/*C2=^65?4:C1"= GO:$P1BVW,0@"?
M1,#T!ONG]N_&+0;=VZ$./_LCTO .*HD^WK+/BDO-;<B+_L]VS=S("5(QN^7Q
M(!MG+Z%.HQX,/+UKXZ#ZQC UQE@IMU$*@W9IQ:N^>M]>:J[$C-K;6D5=;H=W
MFS$M!>TDSW@@9<H)>Y18'6RP6S6Q(^,,]+0H"@(U),P)*>.U$">W&W\F*D2M
M+/\MC65G8ADE5*L=C(VL9AD?"7?_3PP5-B0"%/8>1KK..@4J"'B)I._BA] D
M\HSI$L+'-XQ_?GA,ZG.3+[(HNO:LRUMJ.ERKZZ6$'[K?I]EGPPKP$AQN!P%/
M^/*^R8<^K@JWF(%<L)ZS>.9P\PQ&!5.CZ>M'\ST\3VEX3PV2+ID&]9[9FN\I
M5D?55Z:\3Q&:E\IZ%N7#3'_HB7GO6AG_GO,MQQK7F%6-KT53DY,<KH]3$G8@
M[_DIU]<IP)7,(*LS),5A _\(F=ZHA&AND!O_E0K%_^\L98;7'&CKRLEFT$\=
MMLN^-IFSG<5&4>)I*4Y"IVU#$3O<3[R4K6ON_$S5[.M^G_E'S\C0K')U] 2I
MH&%85\:DO:;9FD3LTT%^]X"[/;GN=BQ6$OHW;)D%ETSF4YLV]5.6?>#!]7X\
MZV+#&(3@)D+D:M0,N)Y!GZ%XGN&F]OI\@U-+BYM>=J^YMOT+:KRH%NT7]T.2
M#P"I54QG6S1M]JCD$HZ<@WW6H;S368330QB#H01T='3U&*=J_@!IG>4!5WZ?
M<S!4* >16%#_^OK&YE7'NN?K?!!A? 2Q8ZQG7I:"+Y]-!>6@T9:^%">JEZV%
MA^"#J:>?"24SC('0E].B_W6JB/B.;YE*?&7%EWA.4W";'S@$TK36_W%RU=Y1
M\#N6=1#L9.1RE:'?F5$;-!XW:O+Y*,)KA5+-D)'YSV.[78QT <+RJ&%V$*F5
ME06IK2O+I2'?N,V\=,:LB LE25+>Y#4):? <+K7EV2JU%5_$SK@-SB,/24WJ
MA/+)\IHX4TYJ+S/UPZ?^70%K__DYZ0[;!=>FI2-L >+-Q:>9AM(,SA^!8-$*
MPTX.WN+&40'O[?)ELH/3!& @B)5LH76LF Q&D0-/E,OB1]2DTL,2J05>\L7#
M+H.M=42^J6RA4UQ.O);,-(XQ7V82R(M,R^[!$;]/QZ *S=+A4R$-DHE[_/!Z
MJ%4SJ^Y*_]RZ'%ECM&U8N'2DI-, ,%(Z29:_BECO3;.E+=/,($[WY>=J[+%"
MG$R)Y]T:B3=V9C MNC.P)]T&LB4TUOKH1+K\G'M(0T^ 'Q5#L]5CT\R1$6-5
MOCB9LPVS'EH1NF"@H3^YSA6H)M"OYID)2#.S O##1B5%$X$P3.KF]NVO/=0,
MQL)]L+JTZSH;=-*I8II&=4/WVQH#&>*8HN8Q<1J\%BG>(B>(CJZ9S(JYVO^[
MVRIM,D8R2K$\,4+A/?:.4;,E8DFG^1L2V9.$^M$_ "(A?@;EFD$H5QY_QU2,
MNV?M!5O9;SM%SP&MNV0A*W(MX&DMR+HXCYQ$>YBHPB)W TTFCZX8M&_+@O),
M3C%.I5,/#@LOA6:UC=MO2C-$R:*!VW9S ZU+OU_Y<]49UPYJW&L;^K[Z7_\A
M;:W F789^$5FED:@I*8)^3L#T_@SVN'B2-%!H-+"9_.1?F'Q:&O*>;E-_>+.
M;R-<>PD5L.=G\KV(A0$(%#]YU@=+R*P_ #UI/CK* ;5*:0C3#WGV.;>+?R#I
MAXE:D_S <5FR<$,]G;\)[*/3@9Y:Z@)VZ?588LK=*KDDF:..:AG"9E@2L8O8
MII%X;O1@U%O2F*C/% CH<<%]G_Q0/T?I#\RHUHZ254,HB>W=X<$UX_&1;!M?
MD/)D/_Z.RJUM#3;*CNZ"VD6]?](6892FV1<XA'ZG?))Y&0J(PZ[*//+A=FY\
MIKH^CS<R.4#< "69CBKMP)&LS/]((*&]FBPL<9!K#:- Z1ZMO*GC;!9B<G])
M*1*T?:AE)D01\UX,[T'E$+[[GJ4B7?\!@!0$*9EL;>C[2HU?N0+:K]@S@_F1
MR+<8JB1J^>UL]2X73SDP0!!G>9!ALA?(NL$UYFBIAVS1&G,*GYZD69]NU!]L
M'D\2<X8RTZL5VLGAM94-$@L7HE=/['W4)BC]@;^F:4G\L%"*Q!OI:PWDL,6\
M@ Y!XUE%%U#MSQY+@[_K&0)2SB_,(11)/36="E1O/@!.>*^G(6HA+.%;%XVK
M6D,X4^?LGR:-R?F7K S-:W+SL'5&965'[YO'9.P2DRV\#,$WG^XN'M#.;.!B
M%&L L0)EMB^<@^WE4)E1U1<70G !8MO>OK8&L%\$0R$$KH2_"CZB[4T+ $**
M?3=".IL"146A]!;;[MR\GVTKVWFVEB9SQHQE7P1FA'X;Z5]^ 'Y%63FL^^6M
M]:Z^@%7J&;,NP,G]B.F^ 7$J7).%&P  9$.DXLMW*X9S.8@;_<4B\O2OH:G'
M1 HFG/+C%C]VF(!B0('UZ@3,&LJ.>GR=R_ZJON%Y<%.<^VA^#''U4P#S)?,'
M@'Y-"NH]MGV6:=H^D7NRY[86+?O$-")V*<(NIUM8-[9*A\%EE$(5[1DHE-/]
M%172&?!;3VLG5O;,$27L0;(&9^GSKIN#P\6%3KJ5GV ->S/-\A'LR):'H<>W
MO,>[)\1VAZYCN)W<>JCJM4TEIR?Y-\.#G\4CV:0QRKPQOW3DITQXXB#VNI3[
MI'9LUCX 6_9_F>]"V,=S)N ";JQ*(BRCLD>BIC+]]A4UQ.AD$#GO R"#Q#[)
M:5A(T9-HYY_[U7PNM66YP(5P/M1!%/=+K[!P E'@ 6H/7!#C^J<I-;D0>SNF
M)VE 3Z5#0:PUB4R2"=REI8U7\"N(3N03\5"R33C)!!:&>Y.I=.L3H"@@NNW5
M5KGEU,TG:'V^5AV_C$;GPOQ+40PI=%G@X/PN-AJ;E$YXA@IG%8C9-%7&0S$O
M]-K422J#%J*RBM3"+,I(7]XS]FD8@4.XZ2$?& _W%0+D><%/X!-ZX8"R'UL-
M)892CQJC%#36Y;>%J457]=..'LD]6704;:24MM1\0"-J2.T+ @JQ3?KT2'I\
M#'&W>QTSWN/IV+B=;6'WZ6NK=?AW^U\@/WZ2O+Z<"V&XKLIZ$8(_" ^:+RJ_
MS)JPSQL<*$SZ1J$*]"7V&']0Y$83S23QR"F</&C#PN#H_32!),>DSXY93[UK
M\ YHR5'T_@!@]OORU]UN[<U(;A@=KO@4$LN/83S) -:RC[8QLEF-7PS\YN.B
M![?C@_)=V*!C;C(#X(_S-A$6&RH<S3SU!0;;!@>C;9.A4Z77]$ "+]^'$=AO
MJVPOC""1PE$05]9@#FS9&1JMO:R-_9>CQ;!(:ETF9<MXBJ^?Q@L6Z9T9D7OP
MO@D*KI?11U]YLR+#B:X"_388+-QML><M#%",42FC[X7V0/V8FP+M/MU<?0X^
MCKGG^KC=IGJ,9N *TSE<5Y=].ZU+)K"VN?SF@RPY#"Y?AH@F15PKG,M^S?51
M7:28&=D,^?Q+^M*PW*/2V<$P 4TN[18][?11]N/=EG_K8E*VK3$%99_OZLG&
MFMDUC2%<BE%@+0G7UTX759[G[W#]*OZPK![TAB%OS'!E'P"/K&U!5T@;'TYR
M_[4HNAL2X'L6;-VJV&KGVAGYH;'8:>5.9Y; UL;&8B4  '""Z(;+ALNVU==?
M[59<.6QU38/H+@?2:?FD%R*?*3L71'EAI6T0<\9'Z55)<5WDF-FS!#FZ@ N.
M)X^X3R-Y6@YI@-FFISU4C$=[A+4UC8E0GI(EB$UD623C(_ADMW+5DQV9L](%
M;3)[_D[\U9HG)H8*7R.<S&P,Y<%JL =.*$GR.>M2Z:("#)_N$(>\.S5&ST@V
MJ\7PBN#0C1SUJU:8P;3\7>$Z\"/:1M?-^KJ+:Q4C:^)-\1[ S4\E<N*-,922
MW@ Y,JZF8(5")7BL9)L+LH8?ZP"YNB%;^ZE1P"'=RNW3G4-19\X!RW:/"<L-
M!PT0[Q1I_$<O:$EUM8=I8X@Z\%*>\.:.4+ #8L&W8J9)5^G'Y*E#'MC#1Q[9
M1Z^=I+^,_]4M\7:$<**X-$J\@)"8P(5VE:_=78>8W^6HW^R114*NN2P&?5Y=
MJK-I[\BN63F0O,>4R017%]YX0/(L+WWA?&&_O15LK#$Z:"-#J(7+<V-0S BD
MN2E[$1#!\+:\V_,9S)!/:K?S0%4.&&B*!:Z&?C:W:*KOW\W5=$]BFM?3S6,?
MHFCD@$+AUI+)0A...EI1MFIIPFS?4#1YIZ@SXYFNHB[WDC/J@)V1>?HS"JNF
M2)A7\M0XIW+)4$)&]L#<FVY5,T#Q>?] 4?I0_9#4:'RU5*?@01KK>W7X(L-8
M4AB!N#R>J:SD%W-@_#"<\ CPHDN)9B<:MZ,UG<JUKQFI;:TATF"?IF^OL*U%
M!S+TQ\!\XX1@+EHXFMSO6O@<\1\$SX%C6IY,,U,';]WGIV@CNT(QVLR?:LZ2
MLEAO8G'L^XT.$)_[4IMG. HOG,&4+F&(#8,DR3HK7O"/-=AIV,N"C<R+4:<9
M;![]1!;ND3M$D_Z63<%P;4D($AQZ:WA=+C>E#@]'D *X;38X9+4&)#.YJBSC
M1HFLG=%==>^$84(L3C$ G2Y,\\KL =WAG$D!XOB1B'C'G(9X=1Q2DO&0Q;W^
M(8='%SQ&LWL=!XMDT@(1*[_CBEOKY8(Q'6N"#\#Z&#X]?_5]*%@%S:ZWA/J$
M+;8F-,IZE"N4/QSH\QN^6K3BVUS2N!$*/5H&2[X@=A?*M8,RL361[@52F2IE
M?62-H1C1^(^-S&40@SQ!?4A&*>3:%MN]R-G+T J+K'"XIV/8K3)12]%;3M28
M(K(LM.NF&<L%DU1W,.UN('=+@[YM&F63&*0\0[Z)>*)>DR]ZU2%W29H9)>7&
MJ+#'YVC%=A_8,F'PD?@(O&MAA/1Q:6TO0NQO-IFT[_#J>!+YT.)3H#HI.'QC
MRY\Z.^$")?)C#.7600O, ,8+30V[KPB4)5"=5>_3R2D\[\'--[.SJSYC:=?)
M)=@5]>P&RFQO93&6.CMA1K*HM*::&B]D\9R?;-5I]B*3*/5:=L(0*\*^<$^7
MQUVP]>VR^AZEH(T\!Z=V\JJ&HF,CT+P1[VHW+M,,F2)"FV0F3"!2*S>5[]PT
MIU8Q<EQOKE:"HAD/#,JE=::7WX=[S-7I@6M0J.<&ZUJX; A<JS=HZ;"=RGLH
MV+MCY=(!7R^<GF5Y?::#M5:5<)KU]=-2A-XN]S*0,^@?^BF1NBZ:8)1_#JZG
M&_=.3W;4J'6P]#>:3,&N&YSYBX" E4%>0OU:*<5K1)VIH1[DJH,/7F>FUQ7N
MR(:?R^;+YA93/7MGS56&P7PO=G(1+\O0I^7&A]L]3LL[^EXNCF':UIY&UXYV
M\;PT,E6UB^ 5S\WC6UP>CR6M1?5Q%[2_0W)UT*GCVVS4'Z%'8F^0<.(-3@8'
M*?8(EH=_(AO[CJO:^F>="=?O.PJ-\M^M(G!QX?:<\12,Y#G,+'G]+X1I1\WK
MP"PTE24VQ#\$%\HG]8)7:Q5JL_PRZEA2MDGVVXCN;61T(QV_^ 1?FCE%E FD
M#EW7S# EQ&&;+BJ$*8.6-)V&S8S(SD?I&:@VD:F&\/%9U[GLK9L9BJ^Y&Y=,
M=[<8S-/.K*N3K\E&Y1DG9R#8<6QM' )'UJ2/(O/TL7A>;4V.G)F>^F:5))AH
MB,RL=L<K01A/+Q?8XU/=[5(OX#E4K@\ \NKJBF2*U-F^ID)4)=-^T[WL;I8D
MN.BS^:>!/%$3,]P4D$<Q4ZV#4)D/>X/&X/AAC]HZ$95#QG%?8@Y\\WA',2A_
M;PRH$<;^*X(1'(WBR*K+ML>K>^.R&GI&.61P[8$HL,JT<R_9T+F3'M%V)V4;
MF+LIL"+G6F/FX&6"0?N@5+H7UD%'@[QF@;SRW!Q!?)0RF\]VL(4<PL(MCW#,
M0QK>H\PX$J,KY/T;P9YH(QQ:_OYW!ZN,3*RVQXO#/MN*RX(<]>]XIJ1BWU]-
M24 6+2#RJ@M&E%^1TNA^$_HB?;!0FA'%IX9*;EB^L=8W=IL!?F[=%=TZ*?'G
M[_=/8\Q8HT14=P]X980MUT0J%(.KU3X^D='<[ZM$<F.V 8E-NA<DH_II& )E
M+^Y=/Z'99;IO2&+"7(V2/ V<"S'&A 9T,S1C<+U9?;(H1B5-AO>>/,)8O0@G
MF9*7:()V?)X9:ZXM[=D::R<BN[=D ^L[,L20%03,6\%YG\])IL;;Y8%/^[9(
M?\!R]G!T&*.CA])J\+4W=-HZS%XG%@1?>NB(B31R%S.II+D8 !S .K=U[.46
M?65+MF3_!"?+V;4'PW+MIY3F8"\F#%H'!;3T$BS]S_OVYR;):G-(9GYT#>?(
MR.H)<3[(0X\I+&]I3QOL+90#NO(9N#A2,>UU3:-C[E[1N$LV$8VQ^TX&0@$)
M[0T-&G6^X3M,F-1D^LO)JGP_Y7 :?*=&':AD9/4%?UA$PDI&Q(3F=$KOE[NW
M(1=(F69C=.E%#F"XA]36QM.W)[ZT)(^J.E#0I+)\CC4C) J7=*]N&W(:O2IN
M#IYE:'%P5I?GEJ8TIJZ9(DK,\]!VM<QIC\8SU=EY2T<A<,]:E6H-ERTP-?O-
M1@0ZINN@%19^9'$/;1J\5LRLB/FT/I#I8[ % >I+KAB+'-!SLMBDV+VYN9"/
MF+K$OL33'3.+;_2U6.@HR+>N6P%[U3G'E.D&BA>Q):]AVXFIUXD567!&]4[H
M#\L>\M\A]\&,[Z'O#>OX(-#/*OD?'2T$-]*?PFY+S<:Q>GYW[$H(>=)B:"?R
MF#8A3>'SL7$]R8SZ4;#)N%U9:;]OI+"IMNNC[H7A72E]?>Y0X**9 Y>2_KUI
M[P,@I\U;R=?<N^5<SD #95+[-)/,H[O>R! V1+3GO-0XR]F.WON PZ?9MS'R
MHAW"AF[!!J[YX=8JO#KD41?H]1Y&GHH_>W-A'V\?XM3(VJJ^J%E/5)J2WI_T
ML"F;6"[76)3$5R^/HK$B\#48Z$)C+-,W#&P>:E1QRQ#TM*+$050(1@W)L;L(
M8#'QS;DPP3MSXUW#A-(+Z:+>B'R)8ZX4T,)(DU0(!.F==Y"SY$\2->^%LA(Y
M'D->",-L,Z--;>=[.B]5]!M(N/>G-73%T$YO+[B@1Z UWIK9X2QRV#5&N<03
M6F>,8SBG%M6FKVKXQ;^)5:Y[1*1N_RXJF:Z)4Q-Q<FZF:!% *75Q+(M'#M^8
M?Y%*XZAILSO82M,4Y_!'U6O@\)5RTEKVO,%8-6/W !,A!38W-78U_[3NLI'O
M]]":*PD6:,YG3JZL%<KEIR&#E6GC\;=1'1G2969MZ=:W\$P)=O::4LIPCQG>
MK]9YD1>HNC@HRLLPDAY8O/B-[>Y D4X#M=:3])/.ZCPM'BG.&9F:,2!EBF]@
MGYJV:LVE8#7P35 >G\VVA;B\'P.[Z5L&,S;/$E%@9@"I7K(GZA$VIVZ=HZF0
M,#Z?MOE/<;'9&*.6\&.3G4X2V5L>+5X[?SF.G\E(#!! 7";PKXU3PN$SMN!3
M.DO*L]J4\ANNXJYF5FG[52#Z8,)SP0<@/T#&5>?*DH5K4%"LSP.A!^SQG'$[
MX!<=@<MZ%Y+9N_Z;-\TY@RW-:V *>4<-CW*T$:7'X;?^4V6AS85EW>3&U)H=
M]HLT4;B7Q_ =(Q<;=H#>J?^@LU+!&5S]0'\OR3>,/W+,_T796T7% 73=@IW@
M[NYNC;N[.P1W:!P:=Q(LN+L3G.#2T#06".Z:X!(:"^Z$ ('Y_OO/O7?FY:Z9
MO9_/JI=:NZK6J;-W)\B'?-+<7.N; D6+)MLQ,2N/@8S"-_QO?H/$0BN&06L5
M8_ VD].@UD2;I"FM-#,,T1H8F>A>C&N/0H&*J'LY.$C=3)%#I:)PG4;QR7(&
M=-V5@@CY$A=8'_.(_[04SSAWS8)FHAF2Z39252)Q]3-Y9*N$@U.PJN\ZE\&S
M.+N.6>UD6]S1,PJ2B<+9U>GYNRT^O@M$V:\Y\0:XURS=9K\G-Q"@YG::T>;N
MA-4]FWVV$_N\5FX$&>)+1/M-@AQA?3 (UO/4X\ OI+T3IZ;9]<]P/N/-XWB1
M_K/"DM+[;=SJP=5YZ#AY3-/[@5_R'E;L=I1AY^Y=?OA!+UK59#KVJ&BG$D<-
MS=W&O@0.%AVX#KKC'#*7CQOT? 5H<UFE7HADQIVUIAVYTW[?UTS*#R$%QJA3
ML(VN3]%/9P(>U)&TN.]/]Q5/?9OG0)/C5I2;T(7@E.H:W*P9\A4LGEL"63-#
MG12V-CSO,Z<;O1L>3U2^?#DYI@:" (RH>[HO_9BD4T6@QPNLU)^>C<EFV)QC
MFI]6L#S2VV"1$C]G$B([KS41NU!W8T)R LG9M@\6Q'F]"/V$X[V*5.V&+?,N
ML/63*N"BD.UX6,H28@Y'V-!:P\>[3:+DF?$I+O23V8>=V*9+KNO5U5_?4DXF
M*=WTIDXY[7S\C&1P8.)<*HYP^X8YB\^0BR4A6Q1=SVE:G?BH89UK_0=2-)6H
M"?U]8J=K(S>\I,3.'M_?C:O 1*<*^C:0@:8H):]C0F8N6G@/K/U7$_4LXPK^
MEL0?LHG#CH[N&"^B%[7K.K4E3>NXHD6VH B]#_Z )\TI+W/*%]<Q6.\GLR6C
M2FR4@MG!#3*B'.E(8(.WB83]0:;%KZ;*&'\85%U=8O]6@Z$SG0X"\C5R(4=A
M/H#Z05<H8YH,_5]9G(V&MS0,.))706PA6=B'!'5+!0P\P>WQ:Q-S0P()P,ZX
M[_X5V ]*XPU!$;S!FLFS#&A,&ZNVH^0B1WMNSBK<X'4-$#&)!+,']U;9_7C4
MD+OGK3]YNE5G"H=BE@=$##. ^+J=]"ND5VO37G(FM<R2P<2CY?'K.:S@CV3*
M70LLE! MU'.%$^M0:Q"#J>\0FL%@)SEKJFXW"2963/?!=FV %X4NUX1-"P,3
M*1*R>MC\.4(8L<!3/EK_&(ON39+%GTCR\OM4# NJ _^XG6<2P@B=SO98QKV\
M_PTEJXY8/WZZ%,P,V01C#Q%Q@>Q6J&:<O0*<K;U:"ETGN-\ 'K+(8AR=],;[
M;5%TWFMHS!TV$_B-KB+U*8%O +SOH?S8)/&P(\D1PR+*M3_P=]CZ% E3CKGQ
MX"6&V,Z!-X G]^5CPBD1>J')^:U1KW1R:FPI9*(^O\DA:]:QWK_N07LV?/1G
MSL_6FAX--B</G8_8155\0[+M:O!#KH99B9^<0RA1V!RJ"J-=R85N%U1)&/:&
M"@8IOH_7YTUG%RTO(B#((&?MKZ)_A3O*HC&O*RR.R+8?();J]SE2.SEL!ZKN
M6RP9!S_-<CXD:4W80DB_<=\E<$(H7?X:W"T-D,6UY!)CA$1.>FY;WGYVKYZ:
MV+"VAQ:MWFZ9F&JZAA$^"*VNFBR5+)O%U-:O"4M*=K83G@?9+*N96GFYWS(+
MI=5U>Z3RGHOUX_@(<634B^HU;!4&H'?9JQAVL5!) V_6X09KEE3K2L8$\7YQ
MN[ ST%8)$2\'"CH4A8/H1$J?)<Q/,O8\KQG74B"E##3>^$-O0RZ'#=,>T3&W
MT",1OJ-*<%C&P#^:Z66>^RUK;Z^)L'M(G0;3<Q2#S+Y$@B(@-K]E_CMA,V<_
MCA#[S0I3D)#[I2.!P,FLX>6YJ8< 2QH;IL>*1I17S'B(?H6]R8V%W2KC8D?&
MUFR.F!PVGA*N+E(\O2Y&6E.91?%PQJ0P&1N1N9C.:4QJ4NF $#\#,]\0B8U7
MXIY$"OGJWD%Z9<\P4U<.1_YP)W]^IQA^+E[T9Q0\A:\)]19S95,7DEJ, V;7
M7&'Q$*B$YF_7V, IQEY95[<T. RZQPCM%'E&@8X9)S*EC,I [ Z=P96!_\#'
M^_D%:JM#_SME/<B\?U?Z2?.C/,EC[6N9P4.'7_O__%7N^O3W#7"Q] 88:DSN
M?)2_]#@R/?URK;W9/]DR]8D;M.J.(BD29^)+59(%_"ENA_:!=((M#G8\G$2W
M,V")]R.2*VK>]&L+#D#BM/?.AY+O>@P+>-)(.A[[;G3,E9!?'1S\!L#?9-3X
M<H2QLV5)]:^"I1=Z1W/,;$:2S2(A=B6N^/!/[^1F<86VY@UP,)%:<"+:_ZHO
M'? Q=&P 5'SJO@?.D9QVN_ 'T'KE*+%>&!;!JU!<\G(KR:GQ9JB#-<F,.S.<
MYFV+2^X&AX.+JH+! HS:$KLG9PPQ<I"3D@+ %_'H]E[ND^3$#'4J?GK.#0N5
MSE)<F2!3QM9YSTF  8 _[0T@]@:P,;YNO9*FL#15I#F?NU1L)S-R.$J_YH6?
M[P\#"JB2U/V$'.M*@LS'31*&$_(_YDC6YA.LHVAO-"T]L)N@:_EL_O2=O;WO
M8^C!V^BSE5SZW?/#E>SS.\CG32J1?.<,$WQB;UEU'W,U/,;&7)6;[X])_A@.
M2YL6X==FT'+M-X"Q[3OYBMUS@.SJ$=:T&AWG']VB23Q:L2#"7/#K1'#LXRT6
M%76L*4,]EJH'A5N#.XW_L],@3,&>J,GNPU5VU=[8_JVVY3J3-P;IJ>:H+\5=
M]G['-UW27'RUN.I\M1NQWG$SN>'A=N?+32S.AM=$6(KZ>&F*^AO@$JG,;U'5
MNQ5NZ?2AQRW*@P;,0"4'U&35NSCH%_DHA3D5YO)%.8HB*,@/&^<Y(E<]"#/#
M='?XQ80H>TKQ?2<WY]WAP";L("2^J2)B4YG0_(M.\-^"?C4.@\ =%,?UF&4O
MI(_##S(!UJX9K1A'L DE ]:LZ_M/-#PUW$[BSB*H7Z<P,TEXF,6/06X$MZ";
M2-\%E<\$3,V@*2\<+"NO%.\#SM9XE\>B?:^#X=PE(:V34 )9!VJ.VNJ.&(6N
M'YX=C1U=YP+&&>^:DV'J"Y>5#21EWY!'IM+ASMYI7D:(VEZ#FLCX$R*.%'9C
M&"%Y3LV\4/]\\1[GUI$F#WV6S'%N:Q,[F<HJ<_<^FX9T62&?)CW\H#B'(L<-
M@[B<PBT7,V:#9I%9/=O!A[S%ZHQ\(<+S_=56?T7':D,VD$9]SHQ](NL=DLJY
M%<%1JZCTQ?FR3+7WEHC+Y(^UO:;=H6V[MOGOKE3/VRW#YB@QJG;TZUL!N 8!
M$66I:[EU=W8#149#CHO,'+&+GU#[,Q<-75F[2AB&M[W -'$PM8<W )M/1"QZ
M\L@R%M%61^_N3<#-UVYGI@2.A2"I[?69+QXKZ*$CW08:/AG5K47;%]R0->Q"
M+<CLOT4+K\#YA!3A7(=Q]_3Z*1FE'7OJ;_E./Y_X,BI5RRIUTQPQQY,Z=[9#
M,)Y#2)'U"9!-=R)YH;"IYV?Q,(.Q0VGGG"E9QI(*]B$?+C[2O4CEY++/N7@"
M>N8JH%V<"HT+]&?1X$W.D7QL@O$G-[A;+J%UBTEH[+GY&P"5FF)_5_TWK6B/
M*K<7M%<Y0'#DCL><Z0!>B7PBG@>D-0N>P[$^^\[D,Z@TR=F&P#XB36//]AC3
M]D>TT[YQ56\Z/1-F^OZE@;.8P<R>H_U ST(EB(T,]1Z-N @4.17UCM;UME<^
M,F8H#IGJ.L-B>_]J>4F"]-GWOD<_HF!'VB>9A-@-:-/=CV086)Z@8\^O4+\.
M[GS!^GV;?'&[G;J11 ]W#57"B D<8K+'>@BCXQG97TDYYY- 2H(;M4RSS6S!
MK[3:!).W?OYL-5-L[TH?:37-!&MQT%5E\FS),\!@A_?57M!?E.*?OY\QM9HN
MLLC ]COLK58R)E(^9*N]]Y*3,!B?$T5,V>W9C1;#:U(TH621 L+Y.Q^S6G8/
M.J<\)ZO&\%21G6TQO:NO;;O=Q% U9UI8ZSAUTIIQ85A\+CA59E*L6L!?YC1$
MZL5WD7]>6([Y3%I?4]V; P4O\E$PN*@NO.)'%CO@>VW8$(F=]DK4Q2%/-TS#
M3)**AO;D%5G=1B*4>\HR/]@^9_?Y-E9Q3I<TY840Q&\LDZ_I!IV8+$!(2<M,
M"Y;B^Y.@+UY.,T2]/%7M0L4^5\NO6C[RPELH=\'*YOI!Y!L;O#"WO0>:(PJ^
M_JL>J$^\W,)4&;<\P2>*-SO?6(#7(?>^F-CLW?$7JJ&U4*I9@L3;O[,L=Q:_
M^ZF0S0@R.@J6"+[L%CY/P HDBL_6S()LQB><!5C_$.MN3>3E49LPZS/6BLS\
MX$A6I@!WLFF2T+=V3EVPY[]+67$,;E&B,C?BR+A*_*%3PZ?VL9V2'J)?.]FA
MY81GQYA7RHG]MSV0O2 O,(S)YF/.KU[!KA%5.Q3TG<T#0PWW]C(?'GA@I)#K
M7ZSZ3?/&OM:(F7Z!5FJP%\54.8O7&P#+T;.([?A+$O<8D=D1=Q_KK]9>;J9^
M/% CV:/0;:(DC39E("D!$[$X]5_,N+YH[F?QD"K>!TXOHJ]^'AR4SMDZ5Y92
MHR;?-2%L)6>9*9[IC?C8-W$?<D>FX38@"WJSB4,+ P1VO#MX1\:&H8Z$0C61
M[7$G>JUO?BB_CS*U66PL<0IY>Z<6[;U()L[I5%Z&:UQZOR.&;Y^('16L]YZ)
M>J(3G^$,D_B%:53WP6?3,[=2Z$[M-<-[C:R/IFCFQXLU3YMGJ) AB7XIG+F_
M$./?C5E2HBVR^RI)RK_SJCB4H&Q7\HOWR,INWCY$#>G@DG!?0SY!<?.H8[4J
MI4R6W,,C>OO*YODNK,AK$[YX&50E'S2M(;.RL_F9O9-:?$40*$V(H[<3<W-D
M9/Z[7T(;M$MKD>.4=2_FX0\=-CI&4&DLA127K! +4^9];/B&N?&<H[AZX%9&
MNP83/%!_T5+H:(%JZY4EX38("!K</L4HZ(;U#=D$?KI-\2;#X#C]QM0"#W$&
MPCIC14!VO_HUDE.\QSAMJ*!4Q!?&%Q4N>\YY&X(K;>G5-Q4-,:.3Z_ST_/U4
M6^['Q\*=;=!V:J.JW!ZI*7_6B3&\AG%%Y^-EKQG0_/QL96EE1!LK+;;@BVO.
M[G,##W2(F4]=J9"(63CC@BYM3!DI<<P/,*;\N:-@S3XM/70ER*S5RS-M<]@B
MORN86^Z%8^QQED<4F[<POO&F9>U:@5)ER;8)!^>::.3"A2/)_JQ(UF?TKYE&
M%C2-U@W?-M ,WXWWUF*OZ3/O&/F$LI47E_Z73;*J@]9MG58-Y8L='"M:/@)7
MNN1$./0-@"AHFT3OJ6:JZWAIS%995<F87Z5OJBJH.#W>CXCI(U:8/&/3"+.6
MQ=;'<44L(B@>,X=OS[T!E@BN!>>:PDZPQML<S\"<27CR#)8-BG(;<8E.RJ5P
M2_0]RMS*H8\A@R]6V=^@=QL#O:I)\$#ORJOHW H-YR&$5'.?0[NH%=Z5XX\^
M 8B!)ES9TYVOK6LYSHVW&FRP>+%J=WM7CXRM?5$WJR^_6/86&\5,JS)!#9?F
MM6HZX$638!=Z>W_.E]1-=;%#D08.%$JXTGN-QGF%.MBZZC E)]$ECBIH->_:
MTT'$X7#=L%<V)"YA49 ,P'MMW5C3:4+3_J^,:=GP&FROTF1[Y$ G6A^F_)IY
M<;6=9CT]-I+II7B)\J0^NN^>2R2^&]A]R>O#86WU\&^'$@3TV.^,,WL#!/P:
MN8+2:_A5KAAOE!&J-#(M%)>"F>M>KS-/!.M#1Z*H#\S9[*KU,;AJR;>.V:V?
MMB4F!'^/LJ2AWM(NJ]Y.$&4:Q^.)BA!MTB*;*QPM;>P_FCY(^-,_7(QBF%>3
MQ'%R7TXC?*%*HY0/R!K>TJ2-FR2#)XA$6-K:=!G8DI2>M9D+'\OC^ Q+6$0-
M'W'?A/*.FK_+'OBE> N4D!\Z__U,,$1IE-C1Z9KNOC;DY^7E1]]=JC[MEC%*
M+@\M9?&DAM-7\MX1]F[K^FY1:BOJ,1_KQJ1_4_UQB]%C/M/#W/4K/XIJ;*6R
M6%--0)$#*45L#H/. )R$KFR]+>FO)>2_J3ZXI)C5%;.#G;36FS"3VE<"=#/*
M(VR+',.-#00V=.I4XHZ;+B^:J><U4S49JRTV)$Z#/E($ZT!@NZ'N%\I)S E<
M&+NCK7.[0'!@RBW&&+]#\VVHF5!NBHCI"EF X+]]U"Z)JB8K&I_H! D7BL#S
MRLZ, W->K&WTU.Z&[?N?W01,NCZ2]<SP%8B1R9WK+&^)='K#3J&"0 19>F,%
M@K-J=#F;'2Q5<_";SX!G*:_Z5*&^7>'8YGZ@<&R%.D62EO([Q[AI98]4J&O5
M% C>,]I[8Q[<W]@QDYXQ:X_!IG@V1'MNW.<7M(T*Q_3 "0;=17L)^=",A(J/
MY:=P_?I[^1C%1,UE2;!;6*2,KVB'++XRRRX!MG&'$'L+0.N!Q5TIAO?V>)2P
M]40,4ILX\8\C1D<=!T&B9WU"/V\[L?OF_M&K-EM'-[<S1)$:MS<OF\L.I4<J
MJA*?M)E5$2;YX(J4".0L/?R;28X<!K8LF%F?;S,JG+\![ >AG21:.B[*W3WJ
M\=.5$+[Q'@< P?FG&/>V_DW@)Q^Q/YP%>^*]N13[=+ "DX_*SPL!S-HT2=%,
MXM!8LKA<*EM.73V1RL[,' '@!]"G+K5[T__*UO@B+W65Q)E%D^9U0GL]'O&-
M"?L%@$,/WKT2'I9!IIH.>Y61PGH=^Y>ZJ\]9^0:X;GUL>@/HONY=-XAM%@EL
MHX^W/,^7*:FH*7Z7$:RXR,E'W0KPN B4S#Q:],K'YN*M4ZMG\AOP]O9>CDF>
M5[DA>'PP?39UP[8G;*2/8<HM($#X8F\\@28]<&1^HGJA2N@6\>+R.3"*S6ZS
M+"O<V!OZA%"J]DI[1X/L$>TPC7DF6(Y//V&1G5H449)DQX_!3WA.<IW1JJ>9
M$43#0'W?^@-\GKE<S[A;G_5!3)V^C%!CE"U<283V#V[ 5EU?5BW[0#U".>H"
M8B"N"Y^NRGB@ T\\MGP6XL$+G8H&-5W0WV%IQ,"_S)?'LY 1_I&9R9 QKS6*
M*['5BQ<7SI&VN:EOT2JGKQ9G*7L[NP>WS=I_!7QL /B,"4S8" ^ATJBC/+=C
MM4D,UU0FY^/;P&G5:VF"1T.KK2&:2'J<6*TOM9*OC)FF_0]I9^MF(:O+S-1=
M83E59DZI5EKZ\!+)X-"/=AF>/QI'.F;):@U$S1,8=5$3^06HI)L1Q@XTDS*-
MFDPYVCNLC-8 Q%[G5-@VS4@L/3T6OZ@+;^OV^,M'SWK3@3EM=96)DWUU7']F
M4W_$H)RSDK.K+#^MC)48#>6+(VQ9[15-:>14KN>A31<&"<A,,ZT3R3.JNMRU
M43."[L0.V;ZCB71BFZ%-^GX0I:QL8SO']Y;9MQ8+E;U\Y>JY/L'9:2:_ZQ%L
MFQ@Z)?:NK&TAK6<%V:(=@-:LM\0N:X:^UH?R;IFCV_R@$:'H#-/>N$.Q^='1
M9<7C"V!*U;R[.%A^"=6.+39CYKE\X0D9/WZ\W]GM[_>;YSW:#V0+E_+"B0VS
MW$P]^R5M6<7XRPG;LIM\[<2OZ?P5(>0DI-<%,P?% C> ZHSG[WNIJ(O:(DU+
M.;\GWM:O1 $<1(.E*!;([@O@A>YF:@G_\_6O J")3*73GN#[C<_D[2Z1320&
M IFBD3(P5K&O[&)I8I?!R^%46G<"R'^N!9'- P\<6+6Y(M!13P+*5LH8/:YH
MT!NTY:+BP$90#E_ON"YCG51730%WJ.KW!3:-\X!&;7YLW(;"O&/ZA,M9C DN
M+U*H-AGM^;/KXEGK>R:]H7J?C/! + _S_62"J05E)=J[KWS&,>MQ&[U.V6*2
M8O?DMU*6IK?9VA_TDY3X]-A.EHC^5AJ1_F6JF*$\8'%+4:@L9\R/RCW/5^,5
MBQ/1A3BS'%.+OMC!N0!W>&H:PDI:]OX//T[37',MD50?XJYV+$M3^N 4>W=C
M^2A!E^1BV[VJ*U:GC2K?6\@$,A%1]:M6?I2BA4]&#","?MFA!6H@5);*9893
M*Z?CPO74_ =:)-<14XK_#87<[.CKFE&+':/$KU&]*O?LP;'\@3)T:NQWS!^6
M$*,BF;_H!O&&:\_+^7VE9YCXL7^(#="@U5G6Y;E\T$IYPFO&?GT#Q,X=89TI
M#:P$BNUT0/I[/:K')MN.7#;X9R@&\^3$266ZZO7RI!@P_&V^@*_8=1NUTA/9
M?Z;NH!*[HBF,<)"B NCCT^623G]#IS)D6BZ]6TU3FF>$H"W-<5? +;E:230I
M99EB]"@)3SGT5DMPMR*5<J;'1P&EY^X7%--GQ8TF:>>(:P,67":G=G-C_7+]
M!'<'F JYDOOOQ[HF#](7(F3>\6(;=SS\^2I[#,(H$:@]\3FJS>W4O3#?A/?7
MN(N1;8%YJS@# /9N6[!;AM;LB-[R::[N^$@$0WIJ.DOO'=5^Q-8FBEH_]RH#
M?1JA0JDGMOX'A'3 D_R/_HJ])\'F!,-X:&7$M_I?GZZ7QL:J7TY\KQJ.RY%?
M*(8#_H2>]A4*Y--_T,,&(&12I&;YI.X6#5T3X(3E(81C#Y!7]*B,%/:^1@W@
MA-?#DVUEZ@3AGX!^4&F"NGM2T7?8@?N(HG^[<"SL),>JGZA+PM GC&NM!O2<
M'8(27V4@HN-$!5/9AU<;&!*:^)K_R,X;:I/[$H/F8$*Y&1F\9^K"1'\XMK\(
M2)A7J-3@L35KQV5:VED@@%OE:6PORK@T'!0)$!DRG<Q'A7#:B4C6+<YNH7MQ
M?FSI&T5<TS;90M'?5G0B.I9JVD/F9,N,Y.X)D]=[G!NZI3_/3ED6-+%[1WQ[
M6';@G;:=! "R!JU5)U)7U< # "9<;"'2-=-!^.(Y\@&T*_(W0E,S8BT[MT6R
M.T!\]>33R:*CV][,'A\LW[B!3,+O04B)8C7A8=W,A-*I=M5$E9PVI5@QM-)]
ML#GEA.P/PWFN;P=K_IE?>OFYB#X=3R$K[3*S05*],RF&AFM'1,^HUOJTK) $
MX@^7Y,J\YX7V3=-OXKZ -X#%DR)$PF+@(:B(HS=C0[ :/&&'M.UD'UU>LA7I
M S@F^AY$!"T[7V<Y6&.X,7L6=MR9/ZIQ:T;SLJVJ-$&:O+(T=(Z+I% _-1N_
M:.#^7@@)X@0SM^(.&BD9\^%M#C,>*+JQ6MF*0\LOEM?.2L?^XD_F;-UFM]7G
M5P&=Z!5I#SW[/*VXEFA5J1@GXRT4Z9F:YQ0%+"HM<FE7V,\,B H[(XV_"%+4
M^T=X["=AQ"'(C_N3.;#4.=U3^4^J ./FX*;]QCE"0+H4+5?GR&E&/3(-Y:_L
M>]8QOU'8V,>RDJ-6?A.$9&/:)_A?1OFC1>R1*JG.:'_8._VIY))N0'O<<4\C
MD=FUD:U0WJ6DYZG)SROT&)^4$;?N6,1%1WFU?O&/P$P;69]MU.CD.&'([F)H
ML^TFL? T6B%E=B78A)F7GS49C?W&3('$IRKTR[\F?J$U,.5NOX)(D!T,/BL,
MIU0?L:&XI003T  [2<A",TH=.]M2X")%,ZPI0M#.\2W_XN+/3W,S);9*,#N4
M(0-CKGOC8[)ZHB8F-N*$UD^SV$/,]=W/CC,D;P!6=[H+^C&1#/"O2L]UQ2'H
M*<FPRJ@PWNA:%__:WTL'O/B*S@Y(<;E?AB@7IXWQA:6P9L4P6-P@/BO;*9N4
MBORA7VZ3Q'T@%,GN<YMS<M:?O^9]24:XO23$CR]5^YE[9; $J^TQ;][7>J9U
M-<1:/\9C5JX&+5W7C&:C.A)Z4!V8O2FZ^I:]_8-<1KJ.NT2EQO1=4=;FWO"J
M@H+"]Y6* X>#RGVJKQ_,^))3?7^] 3AE-? UY3/M$H=W#L%]VE3H,R(QKK%'
M!1A.MIW0I"F)V\TM=:Q>W!'RG"#F;$)?"J",Q"6AEP-*%*\=[[!1JJ/MGQSC
MWR$8'"_96]OR#&(;QJMK=JW^*_D8&SVUFXR&#SD0E>TE(M24*5,ASTSH;S$%
M+=8N118T]%KV+5E56R*%$05*/*8%:=FH1J9,S0\S$X1TV/J$M&)9_DHK?/P<
MSMDQ/])\)]5:5G]/JJ7_P!=;?F+3<ZHHD +/&B]^.%)._LNH,S5#F9"AM,Z0
MSZCH*VYD8"T#U>^J)S-LX#<PZ>'.*&FJ4C&UB>TZVDQ4N!&8FOPGL&U39!:3
M(GG-]7U)B[RI9>S1NK>4SZW<E<;=(WS*8GUCVVS=/V=%F;9%=6.#Q<G+\-CO
MDR@HWR($E5'YX6>(Q8W\N@B[*#"5QC.'A2TL9MR^SXHI28LFXVGCA[?> ]J(
M\.T>CW)'Y*PQX_WIJ7,9/1NC4&^YV9Q1=(Z\[WU-T^A_.V+7DC-=U&:RMP:X
M:#1_JR=@H#5>X[&GHSE4XM(\$_]UX]U(VJ\^D)X:N).]7HD>*,4N18_.6'L$
M:NV$):ZU_D7]:'FSJ6 ?VYY@*2O .T=S21=$#W:J2OZ7*W9XX,Y#ZRSB$W>U
M:1(#@6/3]/XKB^L7IE\\D_5Q7R\4[SH#*]L$8?5-^@<80D:>Q_4+,XM%*T#^
M]1W(G7[RS1E.<5V-@IPEO"?09\HJI=[ *L)\EZ<)U&W5Z5[1[>'J^T*4],^Q
MF9K7(",GI=FUNA'][$MU'S<2HG3['A]G =O198K3,AY<"?]<+/SO(BD^E!G*
M;"4$9/'FW2IMK+S/!G.J_WEB4,*^*EDN!LP<<%WEC;8Y]"?L<=I0_>B$<DIF
M;,IZ2):V]JA'^#%R8,Y+]K3-?9UI_&;WKQ>$V4QEVK<,=_3VC29ROE$6E1O(
M\,DB'TG.E&4*-\[O W\G(K-M$4*>]^?O%T[X:[^A7-QEP:HY*LPT0CHMT!EX
M6GO>B@<R7)U.=M.$:MTL*R.OM&,%N$HL0YOG?)P8R),-#K!UJ*7C'AT7P@B\
MBIM8XJZ%3*BYNG?7^-1=!8($-&*QX'PY\^F9]S[$'"R.SED3@W1C!Z8'71>,
M&10.<1I3Z;0 G?=9@"I6 &$I  !X-P  ^ , 9P"J<,&I/W]6O@+^"^0 7P#V
M+Y1P(DTFS08ZKY P-;HN+C[!U:?,M7DQ^/&(-Y>2G*D4ZT3"X"JN.P/KOP5L
M!?2N+&]K7?VTVK2,]=?S!KM1@3,WV^Z<!W%W;OHM34(==1Z)WI<Y0EXZI(1C
MY"RJS#H-8F:)@S'\JBSUHNZ1#1O'\9A,:":)HY]?B+O#AZ[/RD0_#Z8GITC3
MVAO(UN3J?JS'F_V_,@[O>5]A*__*:/Y&+XN&#8;=%4S\_^E ?2VTMR4_-VK5
M;]!4>T#^B<)FF>]D31L5-Q&CWA*<YY=VP#:]-5A"-AQS]>-8!(4)RPUX<=32
MT_&MPX=JIGA86$=%N+T C=AXHPPQ_$3H/Q!/=H:()&*^,K!%3<IUBFR.2MV2
MA2$ %* !RS=FYBSMI.\7U+Z;*6>W#WTENC4Q\0EY<#[:L!=G_K'2L_N22!E\
M-Q]%WXR4SJKVM3;T+D05CY'_;PPF8W%;;F1P'3N_]_$4TE:2^!YFY\\@BE"C
M:FKB#MB8A:)C[AA$I65\I[>ESQ>#D00)00,*:7>YUHH[!3HUM3Y<O^[=-,?<
M2!C]2Y5D!S4$QI(%Y>Q2GHR\^P914N'/"PF:AJYA>A:70S+9K#,GJ'XF+0Y)
M-@XGTS0T9NTVUSR32PWT?;F E,@-=6(X>$UTI4P>0X4J>,:$XA*CN2GJ+K?]
MBN3P;QD_C=QF,?U0OX"N+LK*KZH3 'I,3V-YV1B?)ROO+$97.O'D,Z%MPZMF
M[U=,S(JB"]?JFCYWRM(70L4U\\J=X ANC#E,#J"GU\MGLV!RZ$AA"=6X@TB-
M9.#[/9@^6<2T8DY73]JGPY'][C9UULA).4T!GTUHA*LQ>)71VXW$&>;#LG73
M-^?5]80U376QQT#"?M*V"\.+-NU!5]+RNL<B+,H.0 S^?JLRE;7G9='[F6"R
M"K%YQ%EU2ASUB/S(BY@T- S]ZN?@IAWOM2:^)0?UXL/%K_$NB4PB]BK&Y,,6
M*%@Y 2X^G6L_A=57E.$BB>')3>(8.!0GR?:D/J:> K>D[89TYV(!73BO\HH\
M(RU)=W\OZC(F>B$-"W6=)7UL,!)Y+E+&I@A?R?WK&O*QYG2<X_3D?^[?*PXB
MXMY$T>@]8TY.ZJT-)?P$"+@RD3@#&>QXGO]-S,%[K6=)P,71J;R6P-MA9L2V
M2%>[AGZ&;X01 YB(V) *Y&! K0R,BMM6^;[OGR3^V0&Q-." (>^"?VUMP@_I
M+@>Z:+D^(B&TDHJH[>>!-1&W.80T1)=#VH2)F[^7_).)9QB$::<9<I]2N1*I
MQ<[E7):G,=J28VU?T,7/)N2^T\X?PY4>/.$CY%OP-6%ZNU-VPT ATO\B37%0
MB;X6]V *<\D,EH-F'RG35*X"<MH$QBV,E\W7>_>ZC>\%@QP,D521!;>*BU^8
MUY^6UQ\V)S"KMR]0FVSX-J9SB6](JY63)I"&=;4QL@\3G!8_L/]ND'P:T7.N
M8OM?Y!AA(J/@^[[Y83B$S+CS-Q7D]QISG)3U?5O98D6 VQ9S?0 K*U5*QD0Q
M?ZP=H;P)?8$QDVIICHI#?-084&MABB+E4!6WG@$'60_U2I#Z8G'Q=3U$_-0U
M9$,\;YVB4!UF!X/"XD=+V'[E6[+9V2QD*-C;S$=95BYI$BZI,HYGJ.+65F;8
MLQ%H\A&B*RS1R:#+X98BL:D!]++^2QH1#/&-<VS5\549,U190!G!&=IZVGJN
M?'7E=?1U]*P?%-\9&,B@UY4"ZDK_AY(B&/R/H7^V*G8FGBR9_W8.H)5 10UX
M]P[[%ZU8&2 2=54250 QJG4^H<%NB_E?:\8'@-:[^7); "WC,5O0+QD9-;""
ME%&SY^68V/(47G+'=DW=EX?GL9?E63:%!!P?["0I*;M?85HG WD17JWU>496
ME!-G1W2K6L%%M9,V]E".^^2_68;Y7*6 *HK("X@VDJE;77@FIJMKFF'EU8P+
M/]'0P$GUEQ^56,)O &<ZVNE/,^U)RJQ9?QCQ"<I8UI+#<4JGFB(I]/.C1[JL
MUI<72)S0ED"E2?B7R'.7W+L6$)F* CCAOWGG")R6SSFJWA$+.G6X,HB8LON(
MF)19,O(_$,7#8VVP=S?,</Z<2.UMAI$OAKX!<)6U>;]=S]]3B9'GJBF3/2F^
M9P7]T% 8OOP#07W %0VZ7!6GB,"_D2JE)Y\@W,JD ;785)1]^X*P>WU\Q]MD
MS?_U79?*SJ<[?\$5BZ>KFYLZ.I !N+2R"U,1H-P2:X<RH$9+22JR!_N(,'!#
MOL;!D6)/%YO2BZ-UO2W^$H:UG&-<PLP^*4,U_(<F3DHZYG[/,(3/VDT11E[>
MWC D']F[,FM/Y)94[Y/^HEZ%CL3_FZQ:33 _/ T_JXKD:FZUA\^:]6OK/.^B
MX*]LB8&T3]3285_"4K6C'=O[NUNS'3KR=_V.VVT1L**J+>MD:0E:^R*6VV5+
M_L5"KA-[BS:HU=V9!S3*)_:F&[P\:%?#F75T8OOD6W4KKJG5HICULW]_5^0C
MM%S=+-* MJ$5AM!ZS,CL[/7'QDE'!U-SIS+,IW*XJ2+BF(3'K)ZV775R"%O0
MV*_4BC^Z&'&Z9TI:DVB:.109@2J$T@,K0T%[6>MJADS4U06)&"K/$@Q=(B3<
MF%M,YMGQC.\N<S05HUM5"B)-V/Q*-P[$::E\;;;?+:S,6:7*?KND"HJ;CB5]
M;L]>""H@:,]C^TTZ^@M?>&<2U;)H?7NZ#1_+B/ /WL\C(JCWC?:^Z;JV*(-I
M[*=>' 6*/ '; T[L_.JUTF_N'$=+X?[;BN-Y7Z<CKVNL\\%F5?@^PL+LX4;*
M=HXAVU!MK8+;E;CZ"UZP/1*\0,4@ "^%C$F7E:6(;S IJ&-JTMC)HVQ[(+<F
MUEU-N3M'H\./P43,860/#@*&.KB7J##>.W#F>!*'JS(55U#^53K.&^&K<H)E
MH0P)XR_1X2ZL8:U4IP8$A#^GANWHV+?'FT&<#I1LI@DWS#FRJ26J.2-: I;V
MKIM-B?[XU?UL_=S;3C_#G->B)H3--8+DB'2XD)?JG]65&9&>[8K? +(+8MYC
M/E"Z-%12N.94ZQ$59:!+,X]G5-*,I,C/.W-78;#PU9H@1QBG>:=S. KIOE$X
M\"\K+L_@*8VJVJB[E993BKB0%#]IVMA>A%2?N!'@BCA J._[G$@__EAWTVO\
M=4HTD,U?/H9W.X0W'-7)E3"Q'L\;G90=MBNLJ]]!+\VMQS@.I/7!5;T 4(.+
MPW"P^Z2I3^8/*B$CB"2*4=+2#JU?'25B-7P_%F-?U,Q]ZTSOE+;U9Z\6M7'<
M=&]=!GV1T?4V-:?W<"7=*LRXLE&3V3<'/L!+:]5 'RRV7'@GY7P9Z^?P>1/$
MUMH@*MH@#?5&;A]A+3C:[YK=2;^FY*TFYEN>)7?.!6O-W](\YVHEUTMK%->2
M;X#+[E7R\T\U6%26#?**1AQ7YQGV!&@HU(O,]+P%=(N9*H_+J*4SA:"A5EQP
M@G-N.BXK:EQ*"Z1+8MHD[RQ'W$$*5%)Y=^*J8 XA!C=L,&:$AKQ\>@,\U&47
M!5_.4J.BZ9U@=TPCS%N6#"+=$5"DA "N$,;H 1*GF)E R7WBA<5(M!/4T]VE
MVH7+GRJ1VZIQ\P>ZV\.X@GUW4BP?D?NI7/VLH#*-Z:KX\=-H::C(HMU)M AS
M7G?W=X#_LO4"  0;'0YMUQ% Q=CA'I.=7LWTT8C%[W[V_-?4<K'^BGJQ*XUA
ME?ORL<-\"^Y,]-3*[&<XX+TW?93#.*,!I>2G^\FOD)04AXS+2BNNK41&$M]N
M51JFOMX5?49<I45UN@,#JWR@5C:1#%-QG(&..NX[057[%-1U$W-ZUC7;T"=
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M5JPD3\KQ\!'> #9CB^6R;X O'^[C^O;^:B_6KZI??*KX^U[[_DC;5^63_!L
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M+)2XO4,@T=9 5IN]I@ 62O93:[8J2'NVS7QE_SQH+_HXD^"-,<,6*UX/H9Z
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MG3.B^T]\_K:EX#^/D*OQ_P)02P,$%     @ <(O[5@VY 9*OB $ %]\! !$
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MU6;<H3(E&4J>S+9GZ>@;#JNOH([C^$+DJ>/!.?+3TE4:9+:2N5G6(P;*]+5
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M3-#R($:IM-' LP">>+ ^F# ?XBF(T5=),]/7;, )@>6$)VW&W&(8A:;2";H
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MY<AQ]5&: P6ZDQ4@3Z3: 7%OHAB7$2[6!PBP< GG:6<=X(Y6;Z&FUNB$R5%
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M8A67/6W-,XM1?50QMA:>1D56:-8\/Y$STA'B"P'?N%T_QJ#@SA5^/]L[![(
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MEDN<X29^& :&#-3J$CSI^"ULD^][ NNZ:5&UB1"6PP2DZOEX!$]+*UJ!AWP
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MO<D37MBLJ68F)U5G7X1R,;2C,=*(X(PNS.*(U H8%J('GXW1(WP@@?-*%<[
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MV0A40UX!IT,O^_9-BPRO]^;;FDW@<I@FN\=  '!24Q&,E'[H]Y]>7B';!R^
M*C4*,<,Z7DQ) 6)#/U,7=W#*V5@R?B:F+J%DA_LWW;&OG2[)UCPVM<7)!S!T
MJ/>#/%X922JT[4Y IW2J5XB%P5I$V"YM"M3R*%SQQ*M-IEB*]GIU^H@-4W@
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M)3Y?018@H9VW=/^QMKR;&:VDF8/U FW8[XA6V?Y(NB0\?^PG)(U"K^LRVG2
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M?-+T?@XDY,#3T1$PL%B')WT]N1735=+$J\8"%VZN(C[C RJ&CW;$[LHO!X
M;VJ#M&]E)-P\X*VMJ(K&;G!8CYTC\]_J7>5=Q)[=+58H!TZ[KVH*=,A4:TWL
M9I/75ZTO;Z%!":X< <RL5M?!(XZ?_K(FY22>ER&OJFM(V)XU)NF+A0M]\S<<
M -#[T-,-#<=!7U>A2-#8N=CIPA@@0-2UJOI<DYSA.*\_A@Z:QCLE8!*<9NY1
MIM'+;+W5"4%96+=:?$@XE]0K5(RB>[TJSDO>'%G_(J5//0\-(\JIK8*<;!\0
M=*9F?OWA- "=QYDG]Z/LG%S":^Q4X5 P%CKB3LMZ 8'/V@D@^9AC.3CP7 D;
M8S*;,=YC$I#-#0[EC]&1A]7+:[Q\!<-*&TOTZE6>BP)5S^,(^XF]TD9B! BF
M5-!?Q%>.<<7X DERE9_.[X0'D,*^L$Y24H"77AL5;!GE0*.2Y.FTJ@1&^KL\
MJ#@T;>,35L2D?=+EE[%_6405?V;S=^;4=1'TGB#JL9*?5@T.5<$\O7%#S ^C
M&E.OST^+U@=NJ; %[B0@/X:S31,$-%@4S9+PS+KROJ3J%AP:Q2L=-3\"I$J%
MP.9V$XX_KV,.1CBE?>;3+;1%HZ,3+;;L<'5H4;[><E776#ONCD>NSN#WCL50
M_<R(3.+7*VV!B,J^7R(U]%M_6"=J^+,G='(WQ!>6KY#8Q!8?-LGC$RY<WW2:
MU&Z I)JA-@>Q(#F6S[ESB9U-279B!7,"T!WD,3_]W&1X\.3\0D*.) A#>HVD
M8:\-!M9+%\.H[IWGPDG]*9=C  (::,AH3+9K->WK\2*W(@.E+$F61XUH06,+
M0^>\:_PFJ6BLUJL[_92WBO*-+'/Z+]H;0]F+W9W*\D0+6GC?GX<_-5KH6A%]
M+BN[]$K8N$[(-P5,0YW].5Y^Z$UUMIP5-MS-&*_1Y<^4OY5Y8L\L!D9T-+=^
MI(IU+3?JZVI)=Z( <-@T#(=@/7PB0.8(S"F3O"1]-U;L.(0*E?\F@L?TT:!7
MUY+[S\TW<><#/4/P7I?V'*QK;@A?SIC)IX6AZA[RXEN\<ARAJ("L"+=VT#Q;
M= 9'[B$/O!X*P2!9F*L7_G, Q[8B;M+/_G/.C5W/QJ2$1]N<[X(D!H;,9H/9
MN$S,@-V8Y1%6>%) +!FF!OZ&7V*!8F4P(LP>W,)6HZ5(='=.MWO;/W-:0D?D
M^<WR0HM_/45&M#L(S[YKZKK<MLG<7)Q.*[QCIBD26$0RG=@R?2A8SXM87*8_
M !K;SW<W\,&Q\@%2:A#M?U0!=ZD;TN,K2-(B6*5L!/]E*T*M94OP6T/)@=A>
M)@7-"1I[.SBY26SF$4JF85C48G2;?3AG)6EO/_>"L+M:AG#&3#SK=WV+V_>#
M*BF#;7@E"Q)S,9W5@0K);I'H^$,.IXF4$P-:S[A2?YAB!A%L6K?XLR'OE@TF
M(Y=D S1WNGXVN^'V5@_*Q4 >#X]+A>0NDZ<N7+1+,;2X5[[^:AL@8];OK+*1
MVHF?^&$4&7(KVT^K5)+6I;/Y1-M?K3NWB6+*9+$Z#18[QZ@%]GV>.%A$8-VG
M2:.?S499KC[O(Q,L^H6R6'^&^SRY+)O]%:F8 R4K#W@>UP'GSHS.G3M7.I%8
MA&L.)J2JXL&I0TH4E9(7 \-*-HI?B:R$;O%MMLMP>J':RQNR/ERN,/L6-=['
M])D\9!J9BOE7PY,-;2(*\M:="UJT85^#G,I&(&:Y:J?&)6P:Q_,/\R >4;UY
MS:'TM7OS^^6;^<I(-MMTFEBX4=QZD8"IEFF?'=,ZAB<!;]UMF65'4=GG=%\,
M;&>&"Z/6QI?H@<&[OV_O+;<_CCQ]2?OV$4!K]?;MU;3((^ JV?D1L%#8^W+I
MV<74PX#T5M3OU?O\EX@ADQ8;H_5$P__?C*/WGJ$Z&UY^%_%]!+Q+O3FA^&_[
M[$:'!\]GYQ)_MAI^+J :_GU(:6>R>0280;S^R-S^?#@;;/V?7>\1@:=3AO_>
MN_W3O5&]>@0T+M>\73W_>?]ED',IZ&W1X".@Z_D=>[/5\[FHA]I'P)\%@QF+
MD.<=H4(&5&X-I2VQVA,>F:OFOX*]I"QZ/ I !MN!U&.3;$)IE2U14T'8+/S%
MZ?G]5K&+P#0UJ);?-):Q3QA-9Y;WC+)B,.%1)T6V[89(BG9]PGK&-D1J.7T]
M=OM4;WY>#&RG%]8"<B7UF76E6R8])K9G4Z]^Q]#3'B)V.2[1B:X6.Q13[=W+
MJ"'%XY]3YMZJ:0:M2!'$S<W\,1OH^6[F90'#7S ,CO)MWRQ/TC=U6!>C::50
M>MF8M^V =HB/5,6:UFO1D=)DN&DO=>.%8]#5%PJ#T"%3O.4.=(;%? PO/K@L
ME,>UQV-)U>,])6 JT<I^+6?H_AZ&0V#1;?QJ3R+N&7X#<JE[D_>9^WAQB-:M
M""!QRCW$HT H(_WDB.0IU$C2@4-80RO"_SXG'O<Y=6*YHR-S(ZZ0974C,5:=
MDYIB55IF73H^8&6#\1-O(Z4>1:3@4XX\QFM)8^:?C-"BBV[_N+$9+;%7=<]V
M&7"C.OQ5)[W\-UV\;_9375UG+J1_UJZ'LD@;[3+QK8_Q3-[,&8K1%U>!3LZ3
M-7M(^TW,M2+:F)&UBNCX@<HF_7>^DU!7Z:E18_A7"V)>P"*;WF5*S+BP^&0V
M,':)B#O01 U-H\@(G\/(#8",9[%ARLBG3_0A.)!2J,)[YSKMJJUFX\NQD<!&
M17A"#C#.CJ:*8)/"[H*!)IO0 !"OOK38--2@%!5'C/P3'8H=6EKZFZ821R)S
M<\AQHD.L+R5U(9)-N*39Z+/^.OY=NYV";[6@& ]Z1'^C7D^Y.OQ41UZ>L?=#
MN,-RN,1ZL?7B_/!_OU+B/ASY%?T(N'M^LXHH>OD(8(A[!+@^U*/,SD>B)$8V
M2V8",%>L4*J7(C;ME_M-011!U-NM8SQT0^??,*++WQ7]?JY<3*A$63F8MG<D
M4!YTOWTBOJ<QQM^,:#F F+)"<*:5\#?(PSXETQ?=!FJ++K:!C:LS(K#LB.!D
M/Z/T<K=M#I[\9?!*\^5\^\;FUC#N#1#O<V+C1LM#I"YA6/8#Q=NQGE\_60-_
M'IW7DOX5)ENAON$=*<L<+W5\&VWSU6-8;K;X_M<=]\0(<=3W*3F-JR]L7VO_
M]<D7\]Y7$\Q_O^D:#/XAD.6^-?FE\@C W3W:2_CX,:VC2.;K[$M9P__WO14.
M C\M7=T4>FUKF_S)&-1,R!+/V0C^6M]IG?P]W24[XSMYG-!=1]VZW6SBY<NU
MN'P?X/W9"G=4 I)/@_Z27.%UY)',(,4AJ=MVTV6!(H0 ?RU*.JR<^ADF?IW:
M>>O7I >2WIE^JI$1@?^,UAAE\E:!,^;%_", ?^33[NO0#)F[;_^9W9#LC^_5
M#W0[1L:?_Q+_^/18Y^%O6-;!QUB%WX<EU8$_*(,,__7-9XZ2@0?I;X)JZZWN
ML4NH[WC_LCX"HCR^72I?7<ULZS#]<GA6POU_G#O#G.JOSH$_Q,@ZH^;].0-&
MB]U6R\)-6.=JECR.."IOE5IS F/E5?V.WE@8H[8/T:XO1\A5M$,? 2K9OOE!
MV5'J,)4];+;S1?_4^3_=X\=WW<*M)\RA;LCSRT@=8DK,51RK_@Q1_HA'0$/5
M@[P;R7^)<F'X/^K"^/^B'TTC?O,(&"O\B#HY_X8U!-X?+P>O6>5B3M9G;3=U
MG!7J6@9TVPV($2V_-LMQ&K6$QI.\K?Z]7ME1>ETTP]5W""&ACQF,SI#KA$K^
MYO:C$OJ;6)9YB=L<NWQFF8D=3E=K-=-=GF'T-I0<[]T&^W_!2>[]?T38\'\/
MTGF682]B@C3=&-8M/(I5-CVNQ1&M_B-&GS<]H&=ILT$T1U8N)& >-[U\DI<4
M9_YWI@3CLV/Y3Y55YB,$L)%7[;D%UEV!?\4^Y7"W0+G9>FTS2NDK<P[MI* '
M&1'8Y-X*V/1#%ZVTCG!)!QP(91,>!_A]:&@>N0(=,I+7YZU)D*?#%+CVSU+[
M7A-'DM]F0Q5O4TBIJ+IHTLEO"YU1_!21C6<F1&(IB:V66%I\TJ[TWT8$P-Q1
MZZR&7J/:8PK\:"&T0(?[3?[ DNLS([J79O5O/B.A5;B6N'A8E+R3.M.TO-69
M:L9/4_AV9M=KG_%VR:3QD32PU=^035 INT5.R;069[;,('9A)3?E*D]4)H.,
MEQKLQ-PHB!S ='%Y N_^2L=S!0$%9,.;E>TL(;$54@;-6OU7DDKY1'L60CDL
MV-'#%^0;BE1%GY[89\3.,9P+F8^]&5"<XEIER?"N[/@,!&V?,_C^-$HGTPJ"
MN?GIZ%3[][JOTMAN&_,/:(@QM(3,5^-)H&0@M+RQ+),X:I&S7]H/=_F^SF%&
MYMW<4<M@! 4(.5:2P]>SN_X"Q^/Z$[6%WLD/3;:$]!/F8'?"U;FBA1:XC7F,
M(@PIOM%P:O'E^[ 044/=+#^E+N\M[Z7J*,S5!YJLRO(9,;EWNT=+6[U+^PC3
M"UD#Z6Y7H0:BY]\4$FRZQZ2>&)!+6!36T39G)A_(,/9G%/^A,V!A,AKDQB.E
MYI33->0KXE%GM0W&G*XY7HPT(1'J5U'C4/$>/9"7O2YC7@-,Q?<VP+&\6'Q9
M*(H):H2(:/6K(DG/=8(_O\[49R@(G8A@'>1HE%#T/%2H-1 7Z&>._//$.I=5
MI[2G)YD?T:Y*+:V3RW<F)5Y<]8)]WK7^N(K)H=!=F=*'Y24K;\_-'OF+=EF,
MJ!GFR6L<,FI5NEGY P X0;Y<\2AOF01BF$!1-<."8Z5CG\8FDT!'5<LI(.90
M]#EC;XO]3O>7QRW<Z;/=S0QLSU%C>_(GM1VG]%E3-3E&&QD4KZD:9="NJGCV
M]4+'N'%EI_$F37D+9H![<'U8W2]940LJC)Q*;3ED8]*+CNG+PDWQ=S6YN)UW
M@S9M.^(!DHF!DDE1#9SV3;,$"02D/O!!6[^(= #>CH18?K'\UR]9O&QS5CB]
M"0LENJ_SV#:6^]QJ\9Z4;H]^"[]2 5(78.+2);2I*L8PIG?XL"=&Y?GLD^'[
MI?PV&\V-Y%KK' ?0?K([M(QPVRE;\S_1@JECD^OH5+A+!V5("?7/I1?-/"7(
MLM-*D4$QV*??VI6GO@L2?<U,<_&.^B*I7J8+O#D.$Z]:R=?,?\KKJ^$^"/VB
M76\Z31ZC"1(7527/.B(,OMW5$3JQ9QQXPPY=)>_USFP0"?]4Q!<_<_T),Q35
MYR$0'5%  )C,EPZ84\7*#9:LD_D_2(ZU=Y7^8?3#'73S!.X-*&")Q10!*:>E
MRSCKM'PM)15ZY(VT5RA*=IZ>C!NGI]3O0=PAB*.=?1XT\TZ$OLE@L(])>(>O
M<1M8>F(+8:H%S8+D/J4YFMX&JK!B$A#@CR;[<J@Q/[MD?E#22_M7JK3ZS\]J
M_5_%OC[HK2B9D>[!LVO.@<Q!Y;',RD%IC 1#UTXSQW7(</=%P9"W&VW3KTX^
M1/1HVU?Z1X#F]UI5VY<G4JGZ/I--]&)$@02LH4ZC/M<&IQSVOVD4./=(+$B*
MU_HY" !".H-I[DJL=0^WS&3!_S67S_]WY]+^GUP>4;_I'GVRD;(K[6$#SL>R
M2Z$O%)M1RG_;MHN:G]V>FWX-6_ FB08Z=+5^S%-A&7J(\YEG/81@:L(]#S ^
M0PPL [(L+%K4!@W:_I8A.LSV::+QV:3MU@*.0[9)R7Z2OV5I4B&J>O-$SI(Q
MG>3MELX"(IJFY%O@04J=AH9=88;92ZW7OYQM7,]HT%0(7I78GHMPHDJM/NJN
ML?GBO!;;KGG-#U3<).Q3G>1"\"-_XM;J85^TB@=_]BP>373O2#)YA@:&U'2Z
M]ZOLV67O5^U .DG)%9ZIAS%KVI=&Z\HSEC(RB78\S_763:>\AS$YBD&V:KN4
MO,AG,;]'*DNV*5CWBMUGOS4=![#7FRV -?S0?WDA(V8]6ZU-B#JW+41>MW-)
M2(?A'5OB3*.-ZRI"NQ;GU9$'>W=&\C5BYV^W2*7J+^_M4D"5E=(.Q?'4-E?
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M93=OQ);D'"M7=$O3:4KL-XOW["0S1<U!^G54?0XS\1>/A9P:#-UT+%6KQNL
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M, H@%JU'5XO@DI,N2/BP,5HPVI;-9+75$4T%+]]>1:<YF9EDUB??EF(<,0W
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MM%.Q-K0JD]<MA:U(T#%2:T(+%S<>E4^EV.KM:PJMB-;M-ZW=!"M9V=)2[(3
MW=%23AN;A3H5)9K:Z!#(2$8;AG.!#,^$%JA,*5UGIMC;$HG[/Q*G2*Z3 DBM
M._"E(6-+BRQ%.3ZO@F'FK9V3\:X1>#&@ZWKCL,D?#L0,2L++E+6:ZP_A$5K%
M))DDG]O8;E')EF,9N$1/^-CDXO IU7KJ,:\H2B8!B+J*ZUH8I-:!48*FB"G!
M()']<&1OSL II@(YR%V[TS6\:"<"@O#UOB/S]]6^K1V<X&M*A.7@H$0MP20#
MP1&CXRWABP;<\-W1Y>>;S\(]3O/K,+1^+QX,,L8<0B1KL];8X?!F33F\"URF
M!V=Q_WL_$&7B=ZX2U('+4V7T#@9X$BZ"M$U31"XO!::4<G/V<CMAT>:V<GO$
M#WQM >1V(< TU[:1\YX]FU#/[\VBMVVJGM-[<V!6.-@Q$T9*9W"Z_M6P45((
M38RD.SBKYL\O&98P.>23$7\Q]\I%9=.)==7C9!GX;E0Y $(,UO).S\ GUA9(
M\@>?;?PIE^KZC=;;,N.T?#LP%.[#,^9^BN*TI[W3*],.\D4+5)!<J$;#356R
MN?WWMT;A5XKI3?\V+&7N#V]+^D:[6;B\1AD3#JH\UFI%Y)A<LK)FGC.=]0SG
M.@SZR_3&NKQ5Q_?-M5Q9PC2"J!. >^8"DZ9&1QO?*WLWVENI<@KH/CC_2/+.
MH"&WU>]_3A%Z!4L;SIL-[CI/NE976B=[M3AXI07K@G3\DZ-CWP5=Z0VKV 2G
MX9A-8F#DA-'KHY%-X BVU00M)#A;CF^#8<V=2%59Q-FZN.2'\BFRWX$7<V87
M53RI$EGVB$QH[H^UV@R;E+KH&)@E-OK&S9$1C5)60H#\-BF$'+*_S"W?N$)4
MK5T>6ZN'BKYY'N8:J?N'7I="_0<&6U="G-0[^AN:S$U*;2C-.AU7!74GR!E?
MI\=GC,DA,N2L4YLU\A1]?FS/AS8#R-%,!O&T-D,B5D+DX4,P*:;&9B)_C7[[
MM%$XV^IPK9/P,7__DZ8]X6GEJI 7'Q>]2JH8J(MNA<P5=&Q705]]'=^=KG4G
M,59)3]JDS&7B2<[?Q9\SDC\C"8GSN)N[!)=PRJ[=%?<@+D6X?LGK*6$PAP(!
M2($!Y?XFGX9GG]3F5^?&/]&(;HP,,XJ)#F"2'Y?_YWPL[!;-)H7ZQUXUJEJS
M!7D+@;D.OV_5]NXBA[C>^62SE>@2D_A&H#Y"<D0%[X=+/9++_65S$I].S.F?
MCWIUOK)CU?%Z+03UZZX,%<1UHL[Q3D(X^A]S*)R(XU2+#26K2J)BEI5!9IF&
M6YAU #>'R.-\:[WC?@%VO.)IE4QFA)8XQ%27- T(4"?4M ,99.0INKV#:2[F
MO"PXWC7/?<K!NPO7PG\@<86O(-'A)%\6KY; M5:',Y[B4:&<D/,4M1"#R:8>
MWLY641ZC[E1333<^AS]L!*M:(1A$^*1+E[7.>Z06Y:"C$CE^R<3$D,E&.!0.
M)\9+*MKC NS%]OX^,*J$B:6.^^MEY)GG+P('YKA2IE)A6)._OZYD0I/I)=2P
M\IH, 9<W^OM$\(RJE:NIG@BIW^B<K("3#;ZR=S)0J7RKR( 8+H)VL"501"]4
M1H1O/#;P1$;RL2;]?K5R%;N]9FSW6*BQ<<#^K<28)"!RCW]UK/;Y\TZ4_6[K
M1#]=M(^Z^ZE?%"\=L2^,0YO114*[E:[0[R,:08D.T>R<5 Z\=B2GHJ]*D5MY
MN?(H67(3ZBHRIBDTKGZ 9#%XPX9]^MA!/*K-9]RF'&0TCCH:MS G<DWOF/9[
M?:RK?2K['6#':?DFZ/,..#SQWL)Y"Y[ZM^;^KY,]Y:CO@9KT'=#5D?J'8>6G
MX=RBR3\_]M?\()51\<"Q5.&Q%.,[9BKQE^]!<S_N;*DO9C];GN]?X[1OB\Q[
MA/2<9?]:JS!,LM1WVW=ZM#.1M2-4XM/"(AEQ^X,\M^YWFH.#5RO,FL7.'8_R
M[=H\QKX3>BFI8MZDF:/50#L12;-/L!ZJ.E37Y>SH,QR8T-Q!++2&;!KRQ:PU
M),35@W4,2O7$1>/::5/X#HCQZE:%&SJ1:6M2#/65\YFZXIFX!*4!4V6W3>-^
M8J=6$L/^4 ]PX.W^>_&",E*^ _ .0TG/&9/%J8[B]N0';3IA^^;,%T)$1V.I
M)I,PH%@2"&UP2-W>\UDTT*]SL[NN1$%GI[TWT=>UP'> D<(\=\3^,VY.8PU&
M+)8LHI0R*W25I(=M>B+@2HO=D7:%QQSDM&",="R_E9KLVW7H0=/&?O5CZ+;^
MD&AP<77&PPJD>L<X9RK^C27KKL.IQ8GHWK0[Z*/ZDK0GNE3#J)FOXH)\3 -\
MF!#-OC9PES34=UNZHQW_<-'KSY^D,&2K@]UJ:S>NRC!<:J54(M"S!:'[8$=,
M'_(?DNRU7Q!+51R*2M$LA71,W=5S:D4SA05.B_JNV7[[4Y6-DQL;PI>&O"0#
MM<6@5**\DG"A')@V.K\KY73ZSVV61\_B2>R\D6&&'#?[F8W]^1WS6J\V@]A9
M20RLI?KN79(#S%]_&;LD3$@I;P(_LUVA]U9I[,9ZO" 2I8QQ/OZLN(@YPSS0
M45PTVODHW++#TW4 5AZFVS\\O*I)B@@6.ZARS.0\3$J\V^JT"AE+JKTBCEA4
MVZ0"I^-,-(QR?[WF,7?X*5%]X%)^)N5>+JA"Y,C=7<]5B9H1"8%5)_2YTT[(
M;&#HPCCY(C659&9TJ_2[0KROU]2'*GC,+$8HDE5E:5/B</IZ( PQ@.2?LUBL
MM-"/[G USWOSQ!L)#$\7C =IN_%'J;&*BQAVG8W[OP*(#@C,I:]PVZGVS<AV
M;VY/F("+DMFF;$_^%.2)W"F.KIN,N0IY]0:7$!>AO/QU"/00#5_T6B734E#6
M)<F6GJ'[IB(\]D+>U:$@HY*>PQ=]^J$3&)%%DJC(24UP:. Z=GO[0^=/G-?+
MCK#OSR$WF,4NN:K5,Y@!?03*^1(M9' H\7%U*HBPC<S4$.4$*BJP<,OY43K0
M$GU_R<LB#7AQD)>Z8;X#)(Z*\HH:"8R2'?'XU@M&-)-\!X3O_.P^RRG$=W4?
MA HG!-X(YV.VZ4AN7H%%[M$F8>'H++'V(S;E:43#=,T6V5T@TSQ4,CF5"42%
M,*+>E:[>EN$ZU6S2:#=9M=&4TY]GHY83GQ N]'@X>#;-MC5)4G8?=XRI3;M2
MRYZ?F0[](/=T5\P$1^(V-_.CH+&8K6;)3GK@)M!W;L%O93C;!ZA!;FWOLR9+
MC$S!E]RP#B(5T@Q,)3?%0*,Y()8AY7SEF_\7__/KR=5)HL"%Q*L\22)&O*E&
MN2M7DYN(W[J-4OG&>AI9=A!PR(#MVMN!<55 3O[T4\5!(@XJD#/%?KUL5!2V
MTC1HNX:<)6DAK(-*M?L_Y/KWXX'VCC*_PN[&B=U!O^FF.8G[XD.*$L)7JJ#C
M+"I"Y\&3#%2NDX+;;Y&;Q!T)%1X897\)'M47G0/U! ,D^X9IVI2[9&9"1X3-
M @(>O$"Q_<%]%NVPIO;6[@M%P@OYGO+87S$F&_*#]9Z!*=>?)4_<#3I7QIPN
M5E2==?E*,3HUOI]B&=1Y9=;3U.HM5U3?I&?9M'QHZ<9(M9^0MG!%3Z5MBRW5
MX4U LOF^MV*ANLCRP\TZ4B@O;FRH:VIKRJDN96;G]PINK##7+0UHF0OOP.A*
M9C&#IIRK?I6":6OA[8T\Q<+23-9YS$-4^O*-.MIR!UC4M,T>$=[.'B#P"_U@
MK1DHZ+UDI!0^PE91,]V1=4]LBFYIZ4?@] LCLXA;G^NN\8:FM:?<KKL) ]$\
MF&D&&B?3,8TE2@XL_Q#)_73WAR"(OIF8CS4L%N5#=)D6.M_]SSO)?%7N2!*(
M!^U0AWGF'"$L5Y*2L/9.Y$:X#F:D"*2(666U;SNH=;K@ZFV(]_N%)Y=U/QC"
M^U 6%N/N;O%\?QHBB;2(G7X'HE[PX'$6HNX\U'ITF$KRM5G= ZG; CW 4WZ>
MSL/!\LSXB::R..;]H8IQ0SY"']JZU3GT/"H&8)$L1U'V<>J@T3)K]<QU2.DP
MI79#!+N1"Z_\FC%$*6Q<!'L8<RA5$S@_)?CQ0V\LJ@@#R'/ZKQ!D\?0#H_)?
MG673;=.A0?!QUNOI*?G@7[\-HXH#P463[:V8>(P(3R'3&M.,Q+W(EJ3YF7:"
M@U_)S\T;(-81LG= W!W&;/H,)E$^?NS/K5D\, 87$61GR[<V7GI$./1*8$K9
M9EMF:678?UO2%$K;O$AYJ<XUS'N -X<9D2O'5E LIFBSLTOLW.( <5@WP.S7
M9F\8 86'T#7B97[0FU#!XNUKO+_[G/.D8K9$EB\?[#G,Z= 4HIB(3<_XE'^Z
M\^(]8^\@'$W$W676L]F=5T@8!/S/9?M!DW(.8PFE]O5>$86SGWI^#/XPZ[L'
M%3O2RB] 5!30E> 0US>B[F6,1(*Z[\BP[>'G>:!9VFC^IPIQNJ'P 4?^&VO@
M4+"&R<M>(1;_VB/62/U*_1AA9L?A<FN]\5VUJH5W!:OQ.V MDUUD]C^-O4'D
MS $  & "  @=6.$-PGQ\S7QXT\/-/"(<P\>0T'*(LL13UU4HV&\Y0(L<PZ(H
MS[1M]?2;$RPM,Y7,YW"2.H$SYD#[#*N 4D..3M344[8(ZZQTTG[5W(1O[,X#
M?^AE#Z?SX+/.IE@W>\>TCRS-V8VA HG324IX8(4,3)ZNM@P9L/9IP2/C[C;F
M[I9RT2/YCO3%D/1 -^&&:Y^>9K\N;88<@7*D?MB^I*LUQP(CGO(PDY0DZJEG
MT>)&I]M'Y<YQNC;$I1TM>==I_8LDQ]%HK(1C7:CH"IV?C6\,+9M*UF,_'Y44
M+"D .X7!=+@P+90:B!T-Q'D[V4/L!O>. 2D_9?9H/"AA4!Z[H"$B@4X%^&20
MF6)Q-G&D"@M?<+X5(KP#OAZ8\QYH*;Y9G;\#C(#)=5_L.S2-1E5!^$!:0*1%
M&*58?<46MZMI[=3(;'>#E&[B?P?#Z%UR\K_17N[$4%J5;/AVFR)@2[XI1E#;
MN#K\N-3A46=L1G3O-LDJW0\)TB 3@VIP=D8EBTSSN:>4&>]J2"_X3MD&Y%K+
MPL'IKK^"'=,=DG/BQUF /6</7Q<AK46!/$#7)_DIKETYL"(5[3%@(<FU^KK#
MDKSO:%LU80IALL?'JTK8/O,[+X>\VGRYN,N],HT#.ST)K%-?H.:)>;"L^A%X
MD[JDL>1B]O2AW9B%\;H5?J0.>%W\7,#5BK2$Z(9@D4QAF+_C<53>'8!!UI.'
MR#Z92"R54X\/&K^74%]$;0A<^]!U%&MIFI=H,<5P7J.WI<J>EK7/,QZ[(;,%
M+8[E3X'3^MY3.0_%'>RB7@A#6M"@B.2B[@^4+\@LKR3M!I$8UO6FD\Z,O-4S
M'E^33J=KLA-Q*/.C?&%V?X;$GD5_NU#'JO3+&MP4V PP\;W6:MPWOA;X6N8N
MI_#,[)86ODCLNHY?!)5/A39:3T2Q(^@])4)'&9H-6M.NBQ2\3.XT1% 47GI6
MUG /MLGC+(#2KA)3$T,EG<KU]"'6'L=CE,7X$PSG$7*+$10#99# O-E/@TGQ
M>Z^?SIEQ+RJEA;^@[9MS7613[>\0'IK3-![\-'V$_(C;-@&*V$(P7NA-$P(+
M:X4YZRLSR[,V5XZS-LHZVYMSJ6NH>K:2+%LDOW87^7RD:+N<)(P?^CWID\.(
MJ3^J4<0N*4,NX\.D>SL^B9?,^+TSPW8L^N5AV9P>%A?G&P7R^@-,"J'Z.%Q/
M0WZ#U7.\("?$<!U?YJVQM58>2@5,FDU[1"D1#XG_,2R\)M<E-N()TCN]?P=$
MFYB;M>GKA^BJG,&*,?<!;%9G6):V^F(M(:?$)@*T?P<U&F7VQ1EK+0R.X?!D
M2!8A%ANF;+5U(WU8]ZC3A ZX>>$;D,V,-SF6$'RB!))0+-Y?(JYH!1#N >64
MKWAH"'+VL\#> Z5URKM6+WS![+0TS1W4_A\?(^9V VJ,77Z6+5P(= _4,D$;
MQXJJ;__XQS4C#K2LG7'1I@B$KNI=4;$D3 %3=G)H/CHC=233BO;H(&&:D1YQ
MC-:.F9-)AAVNB_'"T1W*I1PQ*DU.0D2OGIGN,D:-$VAJP! V7KA\D%S4;VG
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MB!1PR12X*= GF(3:W\>G$"_W@:\;Y.">+3N"60&5?8=1L  W3B0UZXW!P8N
M<?]%J9QF[$8K<9;$(7A'* .2GFD/5>5PF1\,[E!##[LJ8"QHQ5V]X"*=0DA&
MB*JTEB:"#(NE>*[BKH]ZE2$TI:%JH<X""WY5+9;,SSC*0OL;])ZQM["*JJ<$
MD]I($A4MK4 3I?F?OQ>+] X;=,SX9J::J312^U@:(\&AZ^GY5(P0?M[7P5.
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M;G4II\C;VB]!NK^[4_E4="(S9QT;(O&K71^YD:*=?H^Z/#;R&7$>%?VRA,%
M,-CD0C:1W"%ZSE^^H;ZMI]&_.@*3ZC3?;<XV9L8R^;;.!3^Z:8??@L=K('+W
M4U6N< (U65D^\M5/Q/BK1P< DRN&+4(AGP5=Y4 *21G1"JS-[9A;??9KZD9$
M['*/.7AK^VK/T.P3W<(E8#5U<@/83C]\V.T5^\^_7.5HA:FA2DVY#C:3XS>!
M%SW!-*7>)\@_L9&3O9/'.59RI>.\M$HI8:F?C'/ZY+)P'Z91?_=;+$8T/?^"
M=#9,YV&4[[[SR.4-X:I2KU:[.BWB\K7CQ>0?EI.Y#KZL1B<V8%,_UV\1#&]F
MN'J%?*A=/SQN['0W)ZA> YQ(3:]G,&LG^(%\:["L5J>:Q1%:#HNQP1;D*F8_
M(@N'@P$J=12X:S?6_;/=*%(]&^]OG_7]5T+1%@AX^&H%I_R6''55UK189NAF
M;+<@%Q773>[%7)&"MOJJ2/^63$O=R"[Z-=2@A$LR?E[S<^MN*K&TN-M(!$CW
M0&1O4IDRY'&OA#JN+%FJ$K+F,N0;-+7H ^^@=%P/!>EM*JN. 1$482XIFI26
MB[%8#FF/;C^W Z$9XF(I&A,3@7LFW'2F\TX?_1J04O/5!+[E8RPQK[O.'*_[
M5[??(OX>'#[C5&#:^Z63Z> (/[KP4AG 6CB!^RK61] <D\4$14NX"%R"'ZG(
M(E_;:[8816KO,^587YC?&\Z:1IUAHKX&PEID=&X%N!,?FDW5_5D':+[NR./8
M(Y,G45V=X438-7%BQ$'8# (W$ @>C3 F>?O,239U@Z,0:&D'8Y&D4:06H['$
M""W&K6,1W(Y<4)4&T.%(QYQ#NXMZCS6.O9G#_/B)7,TIA?1A7RG$,R-3^4O(
M(A*L3[XK=/*O.[<>WB-.ZFE6Q,.D4=5(A<Y7HL<37_. ;/?:&:N,_?:84EX(
M</G<B-R((5Y2]!V)<P9;%)@@\XJMC3W]&FJ-8!UA8YHT_B?_#][[5OKQR?'=
MY8&\[#9M"%M:4I\$G""D3D:A<;1_C +=:+\AI@=-@^0<B+[Y 'N^IJG-I*DB
M1*2-B,)\*D58-YAS*.X#ZOS(;97&.%PLC&<E#<.>NG?YB8V>U0OE%Q_DJ&W:
M)LR15M9/Q3RE_8M6*DZIUF"E&DF"8C^9]*9Q6:34QME3&:N1IJO'S :\C3()
MNL#$,DKZ(;9*""1I@/W([E@ O @%]D%$=#JD3,RSVJ=I?,S5C>KV8==56U$[
MV&'=;(U\N=@4(3>N2OC#YFU*OT=F2L1356(W3YH\)XRP(.:P52%R4FO:1LF3
M9W'9/\^:[^GBH1;J=KF6CWEU^5IOR5QDN#'G)YKZRCY%S1KD*'RVUZ.>X0(J
M6"WW9*PJ+C$8=ZM52VH]E4/]]I!'";/E;.)_7"VW?C:E%>%DW)@=\9!DFM)=
MJF"\@%"'3EKXI]$$<-!K)8#O];RUVVFOJ08:-V%T],( N^/G;)\C'>IZJ;X4
MR^/*=T#,L4##E_[?!L%MM]3YO;Y/5<1WM6\9[X"?WUTMW@$1]Y4&.T,/V;/=
M_IFN>4]2*TR'0R@NS^$P&2H<+E([;BFWEPT;/;]NRBR[Q@I:XRD=F][AJMD*
M/'K)J9NVP\ ==XJN^4Q?[\FAKS3YE,]WFYW@BC+T_C0M>.ZMY) 8.<&_^E!U
MO;H6M@TXJ1IRA?'KFWVN 6.89<&&?J2^GIZ;5"XD\$H)FB-(X>?K4L^>'#(=
M$_=@ ,]FNX"6TL1%(CJ^F7.H)J4?':J+LEH?8[%82RSJW>DPX69'P<N*I# P
M:X=DW,K%G\8;PA".'-!/T8G[9JNO9>=)_GS45&0S0K2-H(>*J_&9$,)]^1M+
ME^U"7/NBEUXSHAEW@CQO&+Y'LI9,7\=KG"]J9OC-P8+OBH,&1(BDPE_>*\W!
M.(\.&BTG41.DQD;#Y&FUE7E*/F/X$,Z5!7!:B0P8V$F@+&BC!^9.3RQ+^'Y=
M),LV<M%,)S@6^/XV508Y481IC[GJLA2)^#1S0RKFHS&K*S9^3/C3&.':R)CY
MMN0?TIU:3XR3ZB9SP1GR<B%S \!)^U9$#&GJCK7)#[KC(,T.-H*S/C; GABF
MP21>6?G5T"V=0F34>7W4A\\8C8,\H%QJQVC>8MX(/-9 A489_F\\JIAL[8RM
MK<>SQ/#\0>OIL7>%\M\R$WE\:GA5<&-85'/0=(IQMVR&.A/H2>MBI$B0-GJU
MV(:%[+A0:8Z= ;8=>KY[%J)U2[ADZK0Q2N%&I!U,5,Q?P [1,NWFV1JH55EC
MDYT.*41(HKY=D<@P8P3SZN\UT_&I""HT3&'MP/1?ZO'V[!7\:=,4)_P7$U[4
MPK.]\Z+M54_:GX>F*9XGUIW)'T8+9_F2W9,-SIY\2H""OH\ ^QS$AM:4(C[<
MW3:%Y)O['$LLO5JC='3QK ,^%D:';DL$=#'<S7 PS=" F?P8.1;F6$,&0.":
MWJE=G[G6GVL*@C;$QT?YD&6;GY[CE,IP0<]!LB\\Q8)>Z>8-@+L&H ^M/<Z9
M7$8-)4!UD6,)S5N'NPQ'I9^JP?T@'*L6[6HL%#P^ B-:8"J%E;X*AIH^4HM=
M#4I,,H3WY[/)J3^'B8QJB0(#)BP?O^J(,4&?XZS--[FIOP[U" #X"M<*%]M/
M\X%G&\",<1\@YFFF_Y=U-;?J<CWW1)(&N'R$AZUG,P#VMN]JF2!4%2#%-/1)
MZ#22&JK^)>;N1NGK4F9X-<@16P)/(E+*"SF .MJ,E#-TQ7C+G(3;?V[;^<85
M/SW&,5UC!$%"!$(!:D@B)%AM(UYBX096@'5X+V1U/T47+'8%M2,3+W5'<S?D
M:KJ+E23QQ)N:20(%=@'_ZN5!!=8+<72!7'N'9B(L&U;B1.QF: EN5YY@H+57
M_,WQ]O@+/M\$J?=M<4VS2Z@'PKE-21&7 OJ5Z&/6;B.]_(1T14L,BFH:-W\U
M>QHV\O9 _RA0QZ ]3G[5M_]Q'G+43A*<,)?[2/,Q :0R9/-1<LI5&*QE_0UU
MC8/(^V3V$S*>-C;],:4-&RYEVWSN";C"WW]6 S#!$*./GI3>N5A#S.R3G)L+
M2"1P="N"*"@SI(<+3C"\ T(]J3K60HL;QM/> 6B3E\94[P"$$TTSU]YYPV.E
M+]&'.?\'%\P\32[O2?W%$YQ#X[9,/S;^O)B%/7!5L@ K3<T$:$>W93)B2IPG
M#?)/V$:!^4<Y!O;V]C9UY;PP"*D11:P.MS0B/*H("E +;)M)Q:IM!Y)S.@;)
MK4+H(Z&@Y IC4F4# T1NA@_251\OF:NHQRGQ_^)7?JZ<*_LGXMMW5UM>U"!<
M>:._5C3^#BC]=-F\L/:;NLRRZ^()?QGG&#OA7\)2K^[1R\GB.V 4"@G[?EC4
MJON;^E'QKT&PZ#N _M'UE[ED:7#$6\3"IP71@,G/7RBZ+%]6%C77\G6?:[[0
M_XM_!]3,*5H>AZ6$754N:VI]2A-E?F76^*V9>I2M^@X@ZU)^?4@,6]$\_K)
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M.W7K2=6M^]ZI>N]<QLS<=$M%T#TH;_QG]J&FEH!. B(]H#HZ6U?'':,:  @
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M]F('G9P(I\6G\/B($T$^YM53TKF(KFQYK\5Y['\^Z7[:;F_(>/KY8=Q%_2^
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M<.&#+VQVN#@;#*UHCE2\9@P%$QR_KTGT_?+5\M\,F_[7P=[_"7NZ]@+/_R\
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M_-*^?D^@#:XIME-:(_I8W;I3<N6R!UW;E\7&@;;-\N?S3'.V1$ I?#K_XZC
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M;&#,$1Q"&'THS DG7N.2I&V7'$<EPZD BLSP-#W&)]PFC#RD=#X>-&3_!5C
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MJ2BKGQ/!IJ9 1;J\K.1U2;\/M1A$Z=@DA1%+:5L05HNJ1KQ(H 0,SSS8'0^
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M=U-JHJ*0AM4(MSR1\9>E9SB6@?WP$>Z5LK9AJQ<09GM:\$C^ J]K=T>C#45
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MO&3M%\T<R U9BF321,<0*R&YBW0]?S5)="592SE_QOFT.K6&8%<RP VHJE\
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M/8]T0X:][AZ=?;/"HOFKB#X3&SL.W/+9L>J[8#"] =Y1/EHV3MYTZ5L*4=@
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M<R!78,#CG^E5MX.\V:_\&3JEM6HV?($E6EMVF(*E7"M?V%A=T[]-+N?^7%K
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MA:#A&HVO\KP\UR@UCF#>%A5_T.O2"T?Q/HO-]ZSW?J1L;(8=XV"K%1$U/CO
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M.%13%+SH'TV11^YWHTAQSTW-_6)_F/[(=*.6@K1KG)G1TF99,=J*%M =LR#
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M5:D9C/%=@PU?O1B8#2NR,G,!1;KLBH( ),04KU'W5G<0YJ;@J#L& ##!4 8
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M6<H@9"H(.CX%=(H3%9%9.P3YO?5*:Z-01[?) S.^W) USZFI$_@5N=VKI@N
MW=VBXX=2;^\[+8KA$F.W+B-[365M?E)6CP+W 2 @P-PSAHVIY$)@CF51V3*!
MPF#-63.ZGRWGYV,"887"F\,L)MGDUSFPE9/D/6>")+<N,<G Z!!=73($04^.
M#;J@_L](B! LOUB?(KG)9;WR%,( Z\9+N 6$VJ6-$1E3J+5RS7>T'/RBDWXB
ME69M/%>\,Z4)WR,V/O.T\7)'31:>TP7R]8$9C/$83'J1D"+#4B2J';XA26!
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M $Z']SMQT6[OV=/JX^8?DXX 2ID_FPG_U4/EUL7YA(,,9=%!-]_G-Y&-]\X
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M6"T6)MQP1D:7)86J/QAG]@/.%OH3-!]@SN!:Q-_M!NM(NR17,%9,)!=512.
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M#)%/]UO(S6W<Z'$_=R%@0P2S8>FU:<S]:IQ,['.'S+,>Q+!Y91C6X@- Y&F
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M9@X>Q]>UB>[4Q']H>7NTG6"53Z(T(U;5L4::A7Z90-TZ('!(I:]Z8$P2ET,
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M]+9B>T'(Z@[G>5Y&L[JQ7;QC&RA$YR/O+7=C@+R)67Y.WCX51,2\#[/6_D6
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M%5')XD+@AA!8^@9D)1SZ)U!+ P04    " !PB_M6!K0<L17\ 0#Z(P( $0
M &<T-3$T,CAG,#!A,38N:G!G[+P'O-O4^3]\$S8$RDH@-$!(F'$26Y9GF@1D
M6;(MRT.29=E.&)(L:]JRAFW)96\(*T#"*+3L0@@9[%!&(9! PBI[E3:L% J4
MI(5"&7EUKZ%E!-K^?OW_/^_[>:O$NO>><Y[O.<]YGO.,(QUO>F'3[X=VQM ,
M.C1JU.A1[BAW:&C3NL)4R;;;,_S^EC6=K>N<,)W7FWZ';?N!Z0'_T,Q#G3;+
MJX(]D1-$N35KTI]^==^DB7)]UB0FG ODVK @R>F^*5#]?(GOJWR\/NG0V=O/
M=&8XS793L-F)3E-K63.<69-&P&=XOP\7^R=-'&EBJ[,F0<,5$RNYXD18-X6)
MX>G@-#X  !,CD>E *!R) %,G!@- T!_P_D>F :$9X<B,8'3BE]>DV=M[]YEF
MO3&#3*)?=N?]-6O2EWSU>KWI/7"Z;HI^(!Z/#\,$@].\%M,LMV6SSK26-7D
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M A(1B((2&0A*^J,$9-$IJ5M/Q?ML*M[+)'.=' 2%"%7+0[X -'(E(*_]\(5
M!TYVH)] Q#"Q=Q%0PN\+04D55;D@ID&ITH"@X>>@C%<I$D@"HI&$2*,)44TE
MB"H&]\140A3Q)*1GX9Z>'0%,)J!<$NH-?X@D%"HB4*R03.1*:((H(4Z/2SD6
MGW9BC;]_>D@ZT>/S22A0]7JHIB2:1$E]I&X$\!N-_\V//^8Q2H@0Z[$+]1!R
MP#*4(2$B1WJL(1 [PGT:&N:.0*!_7 0*]3(I;UK2,*1Z['EU8B;Y[79?SB$$
M>]QZ\\)G8$+'O6K8ZR )B03LE7DSX@&U<IZP<J0W_VB&S#A$&4DA043FJPB=
M:Z>DA,,XA%Q,C #2=EK*.34Y!I.NV$4THD^65"/K5L$BG*>)EAHI]/-2G:ZE
M2\E )Y/!]!P&2V)-PKRI,ZA V<Z7LPG3#?F+R @@4"@%:A4&U5@&<.H5+<[4
M@E*;;=H6QX2[59 $ZJUZ2*BTHXTTX&N !42JLFDYT\S*(3>OZ#Y8#5-EK2U4
MF[410(-K84&A%<XJ[2S3;$?DMF%T+).-='72FU^/_4PR07CJ0E01V%,(;GC.
M)"29@!$J1R,H3>:EC%ASQ!KBC@#J7+J'YM)DB,K#:!F3^2[2QY)D4I18BG89
MN1K%X018I/("AHA.G59[X@C+F%)#4W)=K:,T&#,*_9XKMD<  [YB7\(HU<Z5
MZ'"1U.I5IMSF*B@@5 !2JS7K.LNT32X%=+C@/V-_!-"7U#"&T<)RK=GN\*U:
MI*$:!;7-LBTCVS2,B&N;AJ_K9SU%2PYK!#*L8LD8%*=#1A0MPY&. @4:4;M%
M=@9ZJ-6(4H\L8R8!Q60F9*"IL&D'"N5PKI5DP) _!?!^56QJ3);$JH!*=5&)
M+B=H?T8,9(IR4@VY"53*1F$3S3,C@)UN#@##O8(2J1@TTV("3,L!%2MNX5*S
M'@:5=A=+$S11RY0I"^\6W4XLZ/J;=,=N4G#([AMUTR  J5U 8F5[!)#3:<TB
M800/J :4I7@A X*8VTAEVPH3H2+%<,"GNUU.B?6BG:#/K"1-G&6UM@Z@[1(K
MD0423^;Y@HHGDG9_H-@QU@9\.3?7P% ]6ND67 9VV6C:5T7#^6J_D@SZ(]D2
MI2%*HQQ&!2J1Q.),/--.\D9*,"S!IKQEB0A:EI)*(X#A#A4,Q"J Z:O5^WB-
M+#%(4L]G68J@7$=HN3B(-VI"(461/59$D&@WKL>*JNUC%2/=$L N3C,:Z&/K
M?<@R1@!-C .M@EKD$D&D!<E6&J[R203,($:RGV::&26,-YI*/1N+4L%ZM&C4
MH[YJO5]GBUPIV(@0-3M=SH23=2(7HP92%K5P1JOAC5 '(4"V2VMB,NTR_CP>
M)V-N):4)5;U>['3[&2 5[N(9,&:[7B@A,H5\3Z$LC,2QGLIT JR4+K.#.:P$
M?!T$=H9!U!S8RG*E:%CM-OI)1,T[6"/2@!L!&JJ:OG0@0 HP4>PC>(F7'97.
MQS)@.A-.2S$U".JM<&^@V*4N;N48+2*997\/KN)&2,OW^8@39U0JG^!S%2B7
M,WVZ3.IE'XS!1:@<AC!'-9UB)6?4"DXYF.U\>1L!_,>?WWOSW!6!,>&4)H8,
MF&T%POD@K^)IR^2L@*JV*KF&+UKP]Q+I$4 P;09\F%KC@T4<S)LFT^K0(4K0
M,;2LAAHIT''RN42/,45?4VM8T;@14LI$,0/ZJR4W')- W)' 0A#M<6!$'@$,
M:;FJD@<CE$^O$FT-#OB[G4PU$.+9F!*(AHM.(P/X7%^EZ(8K#3*O&W!8[" X
M64A!^52:U#"(D]U6G=%)JSX"&&O!536O)6RQ3S9:*MZDRK4&+A$ZHHA<)!RI
M9JUP.(KWPSDSFXS5TKTH5#:U;CL6X$Q3+L:B3+<LH%U<MY'PP, &DJF87\CV
M1:GI@]2< 8LZD.\S'1"-%YNM>D6RBOV\Y:1KD7HR+-AYG J&#!4&<R42Q)EX
MA<U#)NEKQ5FL.G!2<KMDQIB\$P- 0@\HL6"*8H10P_5[2JP[!:5B6734E6J8
MX6*92#L=89O)4!%D@2(?CXV0U3',)R":&Q^,T!+$GF-#?=E/5_",U<8-BQ5=
MW@6#J7 *5X!(0/=4E8V:=<9J]+L=/\T$@"1I%\M8I%?D? ;#0I)#52+.P.OQ
M9M\+!OALTJS8<A)-15@VV4ZWB(@HQ@ J4C<TB<,B6KL@-[I %VWR[8)5D\L9
M3TT<O.?I#R_X,47$TB2.CP#F1.U?4,7OW S$LR+U'M!%JFJ'H0LQ*D8,A$)#
MV516$40(,M5J#PHGT&Q?5V3%2$&9*B3K1MM(=D-(N:="L4"[/JS 98"LE5MV
M2,< 4R#=KM,(E3.*D!=& *5JJ]8L1C-0M%8*\9+:R?.8SXRC0J,1AG)LWG8]
MZX(3&JWF^@W7,1A_NJU%,8*KA(/^#H[UHZZ%^),-C,<&UL9)E%(&ZY8J$B3&
MX'35+Y)2"%;D<E*(J#U_EZ[X:4KRAVK-7@PN8-5H16D),0V*2ZDB@"L]2<!(
M%@YC>2XX8-DG11I&J@BA(:T+H$T?4*\D?+SDA(@N OB4JIL/8\E8.#524$E3
MT:J_W_+7; \JC50:N@&V&5/Q"BKQ <M%& W)H$_1I8"J5?PM'2RE)5C(V'*?
M;]0Z4:VA97@!PAU4L,INEXIUDC$PX6<Z(V,H5[I:/E%W:;\KI0;QH2^?&VZ.
M2W56[5(UQIOT6L(/F4H/=PJ"'Z@V:KE$NJ,H?H4/%1)%I*V4ZU7:CZ*)3#%!
MN?Y>$C%"!<AT$O0(8*5B2JQ@5SN0$.,,?XBK%I"VE35\5;M@4A4@DPQ1&=)G
M=&!5=Y,TGFJPJ7H:\]>2<!>L\^5RK%R736OD-@+H_6:X#)M"!=Z2G;8_%X:5
M:%\VD"9@])1TSZKU0X1128-*J.'T K:>+56X2(D%;3)5Z/?S_A[$FET)\>0(
MCP F.B'3]64;3%@K0C$UE#$L*6$RA5*4;54Y!>.3:9E0 _EHTN:[>0-5&::%
M@2Q3K(I6.1UT8K:_I?1$W,ET!M&7$O"%[4#3#@4$S)!2H;B 95M1P@12%)K!
MLCD*(V#4"W>-1, AK(XI@U:482.="E*W.3T0"$@^U\@42CE6&(3$J:S%!4JQ
M?M$+C=R2&0$C123?]28@ZBV%0+Z;[9$8%'$+AA]QC3(OB25"2?8TRLWV@&(I
M3U)4J61VX)@B\\X((-7E7"R+J#2G.X1-BLE  4ND\X0(Q$"!;M74"A,OXGHE
MF<6-E)XK%VD#\IR90_/=9+)'154&Z3,AN]E)V=H@^B) 6+?Z/4FL()RF>4NS
M(CL>;C2=:==9,&_7"5D FI1G\#3$*B4 C)1-*-?.!*M(&G2RY8K2%6V6CE*1
M0;"$=Q*X'&@I'5P@RA2+B9%<$?':%[!R!^C@3-36HTV@.5Q?([%D,=6KI\MV
MS[5L@F@@U69/YV1-;)5:B8PZ FA5:VI8)WIATJ+Y<KK.T*(OD<J:OB+H\^7-
M4B>1"/K\*-/)M+N 8U=XU&]Y/U XV^R$(DFT+"5B69\/39+,("2&"ED[9PNZ
M4R:$ONVR333KBR@IT>[D<(BOMFO5<A1/9UPE:@1Z?*;DH&Z?M:$B6 <C6K(D
M9;NXWS-TW/ J&@%$S+:I^=-VD34QOT;8);_$&+Q<134G@?8BX:K;X! U[8<2
M&F$4NRCI*\"RK7=241M3J!1;(!0#J>8:O4)BD#S2+NLT^MF>I*!&OI=NA,!B
MUPE"OA8F)Q&7R-@([FOG^A6D&X/R&0H,U7*D5T'"AB>(9-12)0L7B:Y.L2US
M!%#6^&HO8IEBSH05* JDJ:8OP9@"8.MHB"#;B)2GC"R*-E*B4R[#(9QR&+!3
MSP$M)D\G6AW<Z.>2#-IO2_+ V@3D=!%M)K-L T&KG)C&PV1&3A"L[B946@.*
M,8MKD'$8@#G22ZUBO8B#ISDFKB6-?,CU:<E$0559DC* 3C4P< '91,]+DWLB
M%(81.QYO\I+5\S(WO%NNUBDTWO:'69?H8ZDDY[3-6%54.D5)92IR2FXF%!ZB
M*4^:!:#0J4&#M2P;N:[%EB P7@RV[72X!!2J^7315XYB\5H'PSB9COA@" BV
ME4Y-(%1<4<4T1L;U<KJO.(JO$5<R9-&;7Q] #&(;T$?$&8 2RF;1A4"S9]A2
MTN!8UZ2Z-3(;@"V55UL)SYLG0VW(27!\CJ_6H&*H:Y%9+UJQF6!#R^:CJ5JT
M,@ TVE+=Z?>#ML/V60=#*#60Q;&,%6C#KAY.0SPEM#*T*>7B?M/G"&DNTK 9
ML!BN1@RP60A111>O%<-UF<T-1E@ @(P6B"4TAB'I=H-'U20:00S=IX08LHDV
MRIZZ*&XI)/CQFA'WXR!-!Q(XX\:DC$_O.\$  + 4JQ2J='.05D2B2!B1NB@M
M-6@2("NFHW(J&T=J9 /@A"@H4$DE&&YPT0!:;VAV6+0U*:_X*G8G[L T#B8K
M,9TVTWBFKDN#8*F2R4=8 DDV@50RR?-\QA5CX8:7381JZ8SWTQ>.5,(I/UYT
M6[J7MT4 +I+KM-@@8+7,=B3>SV3:7A*(&%EKH#:6F(YUE6A8"><"BBWTN60J
MT>E7,:V4!]..8S,=R"QY&62Y+1L2)C!6WDESW7Q*<W)P56=J1#3@U^AH"X.Q
MS B@C4I$P AW3->E0AV3-+-5300Z45Z&VIF$2=3Y7 ^J*VQ&53F]+^>!=,E6
M:5,H<DXD9-BU1K>G,RA5DHW 8.E)Y6HY+<D26\[T#+W+,C%5MF@]E-'=:#J6
MDZN2"IOYN.XO8AD^(4L"VLMV8:77PRH2*1LA7*0Z<,B(>+8R-<@"VFHVG @A
MLIYH6R49L>JQ3K=0K:%=F[-K9L]5N_%2OMO)BX5&KRYT.9RWQ(*6[+.Z4*LE
MO*2L5$& ;HJJ90J#4,1HP*R7S<I2),WU^HC25+*D7."9'I*1)5-3, N7S48:
M+6>S$2M<"W-"EBU0(;$=B5$6'.$EFM=2$2 >*P\2'['CRW9"7KJOV++9*60[
M6>]W*5HU ,>SN5W3!2RN%C4B*H(@]0)O GJ!A)582=4=+)](Y/E@(5@0*[F
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M0/]UTB_+_QDQ+\S^=J<CA3],-\S@[.';1.#KE"/%WT_I3??P J1L;\[%V8&
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M;[GFIH]_']WKC%TOXR?>,#]XRJKERYZ\:,/;US ' %=->WV[JZ]-K%@Q_Z7
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MJ*2;GE=;5I1%"^Q"OD,$B\,9BVT,(2 -6AEX.N-):\@7W1-E\X'5K9(4@"*
MN!PQR5PWJ("R) I@X+N9O\CS#JC!I#K6ARV:,ZQ.B:\6OC7A^+T#L$_#>[=>
MJ[\\Y+N?4J'\>WP[SY]:K?2Y):IY!W#<=IB8X#R-5KAOW?;(7%V_&H@+)V<O
M[UF.9RLM$@ZYT_V&3N=,MK=[IXL9K/Z72R;\.1Q,%#=53RM/J'))D5+]#GD3
M(A?4-B?CZ)\>Z<7,*-V5VEIIQ33N?ZB4M*+YAA[W:F!:T2LE#ZMH?55C8PUA
M+M_,8[(L38F)W/]B;6M)IPI!<G!P5.@0-*VM5ET>J*?_0 07Q*\!=I00&/.<
MBS$]#!>$#>W3[XGHC7KJ++'Q_ET_':5S'2$MM;WP7;O2).WJ9*TM:6L-: D5
M>%4BA1YRT2N,6P^TUA5+(:8SUA43-UW[,!6"+)EWD'#'GCI&W2+UM$]-0=08
M!2&P/34O$N@NWM$'^A3;DDBDH$\#=P G>6IGBX9'M'= -#;Y6JOXX"<MUX',
M/3K_N%T1LARE[1RY>$%GXJC\SHSODOLY/Y+H]KS)V_%,9TT)7BZFV4:5S1XU
M%(E?FXW%$]?U%0VS*GXLXL]_CB[Y*+L)^3Z4 %2V&->!'U)#BA&6T%<Z\"_0
MT\24%6AOQA[_Q(=(O%2NHSHT2.,R=( O3^ H$PP7-6\1.-%E_?VA:EL$A6?T
M.S3^"$:SN:&^D^T8@ UWW1Q63%Z%'K;9\.(<<U[%]M/,_;+K%\VX>ZW[:)P'
M\:.TD[KIWXK*UH:Q [=EZR@YB=FQ.!8DO>U8SCP FF#%%&T].PF!17"M6W8[
M$,ERJ%E&7HOV,RAN+9@\?;*0A::-$-B4!5AA;* W(.33V5H=10J0RQXH_B>
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M1PO7! UARSI27:]QM\\_-"E5G&TT5WD]:K91>  U$K %DNL8XI4*/+F'J4H
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M^?,++1GFIQNB64M'HXJ?DTO[SS43T* N77T[+8Y_DF0"W"U$ J#(04$&_L'
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M#J\\#4FL^QH:/VJD%1*S!.,$!+&YSQR7W2.,XGU@T*1="5$Q<!1YNEG+X:1
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MPKI<7?96)V'O0A7_UHNG$W=.,QK=:LP&7[:HQ SJ](J'+#\&L2%=IF7U2/;
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MJ2G'@9&,;Q&O^7D..FC/,.IBE&B%EW>8RFE@TA2O!]LGO9Y?GGY\W1=5 )?
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MJZ.':K*[L5-RM.A5>G7H8?7%#/54,1S2+(1@.@B)#19:40&IR.H?X#!RO$(
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M).=^O$&2=#;@?] ,-U)N;=-@]"_0N:U[4D^WY=WRN$%;OY'@B5W0Y.AOCN2
M[((<#-(5]4JW7*C-V4P\T,;FJO7WJP2I<])S_GL;%E%#>3R5SM ;MM_EM8+
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M]JD+(<]2==*$B,5)3DZ0J)I6C9\WVE=/Z,:./M^)!<>.5KZ=#HQH;MK8H [
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M_,/&?0-OVT*\'E9=_R/ZG!(SDZY3P] G>0D[65(_OBVOZT&;E%?[]U-[@J0
MH:X7:\)7%M4AEA@1]'UH*"W:.X&]MSQ,B!R%";G)<=QJGOAM&DG[',<_UCF$
ME\"DC.X11E4R[XF)=/MX;>K/<)BE#B\[$)='98<.V,$C.&T#3V$L7K -J&_=
M5?V((?&N[I4N4?S<WV5\M<_W:(*0D34OVKK=)$R%01=PS1+^WKQ6147GM^6$
MX'$'D4^\5#4U*R(R2>2>M8;Y5Z.4O-^PN9CGYM%%%:U(HY5Q0&<IL!SC3T23
MU!->>SB4L5M C;\B6K$YWP8L5C#4XLI1G7T<7]YW\QMT[QK>ZU0<.8X[\;+]
M/N%H <>>N5V(DM_%01AV3O6T-?R \BFZ(^?^][ZDJ!-=W!:OM%2SAI,ZG$'K
M_O8DEJ\J+$4U>3E_EX!F"SF6"[Y'T-;8JB2UD-E@$V-P8)-*J,2[XLF23!G%
MZ/MR7HCK<I1HK4W.*U[NJTT *;$[ 4?=OW:$479<L7<(")<@9,'9HQ(5XQ+J
MX;H;C<QA.'71!#G\;$;RG+4C=K /8O)O1-;KKR4S#)<-#36AB<3C!*4UE]G8
MD[/N^?GYQT7T JGJVNJ:^N**3,:F^4;Y'^-E1:9L]9F$#.RL]1)K>OEJM[5^
M*&,X.[/&E 7ZZT=Y_E&0+V-DIDA:4ARR?XT"$'PNM5'[\* ,#S05C[W7Y=J6
M^$:_E2(W?<^*-15@14%4#]<0A@[PYT^+CP9$+*[4I[ZP_:63&^?Q^ >8-ZW"
MGEB:<>)Y=W[J^-MDNUC3_GDC;Z^N(@8FW% 54^1?HT*64_(3[1<+ T8??E>1
MR.Z^[ON/W$D)]ZVCPE?5"QQ.>>S[)L851>Q.W TTJ.P&;XY=2;W8W_JIM0&J
M]=WW7*!BN&_A+O&6K_TAE.NX?T[@].-?D^KVM8UQUX((FIJBTYH35\UL"?3^
ML!]/?>6*C?][(V\XR+VY?_,#QU>"=3THDIM"X"#N#<NOI][<!2.Q%F6^&CD.
M)3I?E)VX2?X@^5=;+IA6KITBGSQPZ)SX\H]3I-F&9X4LUV#V+>NV:4K$275G
M$S!T5(\0,_M6'YKH3QZ>Y"S[E,.8;GD*X=GD5+'1\+5ZV4;VOH ]@=9NJTT$
M.9XZ'2HJ?=:+-)#1,=%"< &IPQH8<-SH8)GQQKC]IZ!T]E=I 6&'HP/KE7!"
M-,]CWB7$IR*J$+66\HSJ*46C$M[Z%! PB$= !65^OZ<?SY5S,@RD0:"^M3-D
M*+G3H0"3;L1;:Q+YSO7CC L\PG7ZVR;3Z@:98F7(M5*GP$SW\_+ICG27QNY(
MOR&^%::A@!S/)=M9;"8 Y&LPRL@!C^BO.-R,$WPP]768\RKBPWV>0':11D"<
MC4FH)5]Z*K<Y[VMO_39'DK[J>4]@_"JSD'V<$E,&5%:5]/?4)VBM2RD6=>%!
MLC.$?/3)JI&IGT_!DS7*J(WXFX;DR"YOZ+[3!B1R])?_\"GJKERC62)E/?:'
M6M(_A5SZR7BGN'%7D,W&6.+I4=*_B$E6[+U?%'5PSVVJ>!YZUDS1R*JB7,ON
M',ISZ-CAF!PF9UV=AT"R?XX_</^RO])(*Y;OROI VAJ"&R\S><;1TM7$(?W:
MAY[0HIP'=>M--T$8:DJB\(^ ?X#8 $C>^^!IUS *G+I,U>'/0CS%@Q56)!YU
MMD9K"!9?"TW=F%%7&P*5OJR?D-,*G3<>@3/NE"?YG;CCKY^DH#DI_NAX_+&U
M^4:X1TQ[*K[1&]9Z$6]X9G;$IGG)&,K3F%3)[+C4]71:!QAS7NE8=HW<.7Z*
M8P8<#^$O'7.+[J]P@]JK2[VHQ]Q-BQ[C1"[RMZQ%@TD7=MUY3>\[FTUK>^O1
MH5]Y!AM/['0^"H0&..OW<>>-U.^)6[UE\<O3!5V/(;"MB]B.C]GR'?+A C-D
MEF,#]Z4Y0@2O<RA;.CCX(M=G].+S='/@H.L9_;A=2E,EP1^&9I[C)#7*AEKE
M5:VJA.W*$+#,S&RJ&]L-[?<'^F+7CJMP/X9DL:>&YQ0Q1#.UV])+.Q8V4FYU
M\A[R<"/QX\7F:I U>..D^!\@AU:'!EM6OS&VD4^[!Q4G?AD0F-E#Y@>X/0V,
M5+P3N^D\>Z25V:P6 <,\%6!4B2[/%J9"1O\ 0ADHDN':8ION@BT-D+67H&,O
MBX=3 M5$E%W7T-O^E':K<VKDET+WC'$<1%::\F)?YXRX9!OR1O0S(=K14D1C
M3OCJ>ER[UM -TPIR4[,0SI@3"0[Y@$?GQI$-UQ,JSX+(M+R:C1='=\X\Q@\_
MG%XT\YM=Z.TZ#G1T)_ (%CP7/L;?$*<.EF@?"HN,-"!M%!J9/5*9;MN4IF=_
M'+I79F[W0?D3!<OWID =A'5%M1]BOAU53WZ(ZKD]:;=HN%RQ$2KGS)6HHTT+
MSV:K?_3;B'G&OVNXZ.N^PL\EIYA?<\:\A7_@7DHDZH!)Z*IH9I=EE2H;3$Q(
M&['"<GQ:2(XQVZ$O.Y4^/<\-WN=<Y\_!P7"+EZVPL-[M6^3J8#"!0.^QD<Z:
MR3A^9'""K&]F>59 RKP0*>A4<.]8CG&&#%8>U2&,]/>#BS0)S?'.^(C]5V+5
M!$A;896S!JCQ5^%;KPRM&DK""R,)-F[$%QY]&-A9M7R9)W=L'GS;8M S.]$#
M(&[B-[W/'CMXI1KE4A6,O2]VZ*?):"4"!#4S&UD^9[]SU0%26_#9%:3+5MQ$
ME0_M=<==0,@F7C6@#9U8AU163S$>4,S.<"*?3"P..9JWG1MMNWZ@7_Q%E![4
M/AFV.AKV6IOFU[9J; >=@AJWPMB>8E.WG2?DA..XPF19'*_B"<N9+JF?/1&%
M)[HIMEQL95=D=2QN]=CJ<K-Q (E%LKVM5!9M(@(RR# F%S"4FBWYR,R_NL*
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M6#*2UTLW9-3K*Z2F5ED2GGIN8HLYBJ>49-AE5\\$3JP4A2& 09KCGS-?T<W
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MUO"?L:GBKCC..2+2NB+2B7/K\&QBTR>;"BN.)4EN1*C5;K##BT+2AUQ*E(4
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ML.AE)-CI;8]#[M#Y82DH3Y@ML+VDIT5*3Y20-*'E([CY$$'9V-Z/4D$[-;W
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MO^ORZN% Z6-K:?8U\=,:@ : =M; 'X_47\</):/O_P"7I[>OU[ZV/;JK2 7
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M<E_:Q8<,I!31T@C*T\3K+#&LDH,,B2<U&AD$@DB*.24Y;*$!*J IRXKR_P#
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M<9XD%C7UFZQ&D*!H:=]:%YI*7,7B8ORGGF;VRW,,C\W.#;$?RKAUW8P.I<5
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MD'YA0T-Z[#\='_KVW[Z'%:_M*<K#7*.O2^IN1;IO]<=).7V7&9#;VOIM];@
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M42HK!)]=^_Y;_OVZ%@M@%-M!L>ON^OQP#CL!X7)U]X/U]V$_#5[%/KK6SO\
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M>AWW]M_GK7?\M_3H P_JOYC];_VQ-F NI!'8$7^!_7PPI2@G6O.5>_F 3K\
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MJ)^2@>:3VUBAAB0LBM+43R101!GC0R2+G9%NPPJ:F*CIYJF72.%"[&V9CJ
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MJE4(7=4L29(XY,SF^4V*+[14C6UL4'P)X\>%^=<^_P!E^*U>48Y:KBS5XO\
MKZNK8E=>Q:B,N2_&@IK;&:J!):KX[TQB'*::;5#CN!+R7T",?7XQZ)<4X11?
MS&HEIZB,,GK')>1Y(6E8*K.9(T#J9&5&=68YV!L02P\[AGI+P_B-2*.&.:%R
M&Y/,5 LBH"2%RNQ4A 6RL![(.MQ;'<121ZI_,;_\OH?R]>OE 0=C]_?[8^BT
M.FG>Q\.NOV>F$%"2/<'?MZ?W^ ZG$%%/AY806SWUH_0_R_Z],1E:U@00.A^F
MVWO&IPV6_F"/P]/Y=^H(!WUWMT^F(-B1F4H-KKL?<??L?CA'D(/8_A['JN4C
M8VOTM<??CIB MR2K#3:YL?A^V/?OI2%* *5; V1LZ]=C9.OJ1W.^_;JP8J+G
M6P&EM+'?PU.]C\+X@D_U"]^NQV'7K[^OEA/W#_X3^7?^7\CU-T?<6/<:$>[L
M+^/:^(L#L=>QT^>WQMA*FB?D?KL[]_;6C^>^G+8#V6#"][?>Q_4[;X:J>H^_
MGADH4/KW]/?]X_\ /J VMC=3OX7&VM_G]<7#@_F'OW_O]<-E"3[>4[U\@/Q_
M?O?6H?;:Q/?IYW/B=?I@5!O8WMVU[]![@/?AI23K1&P3Z_7ZGV]OX=^K@@[8
MH01O][_MAHH/?R^_M^_T'[]?UZG$8:*0$J"4GSJ('?1&O=(!3L$G1!!!'IZ=
M4*[VZ]+#Y'I^_P K!M1?6Q^'CX_V&N^(JD?31_@?[/OWZS(MH18XU&NH-Q]G
MX^Z_>^ED+0CR '?GWW]->778I.][WO>TZ[CN>_5@<HT[BXO\=/=O8[VOIBA!
M+=1XCM<[V^&_3OB,ML >NQ_$'_I\_?JZD7NNC;[G?Q[COBA76VQ&Q.E]?=H>
MU^F]P,1G&5#2M$ ]TD@@*'IOTT1OML;'L>MED!T) .OEXZ^%^H&U\1O8$6)[
M'0Z=/'PO>^@&F&DDH)!)2E8"5Z"2HH\P)"?-[]AZ$;(]>QU9EN/'IX=_O7#0
MW![?V ^^GNPPXA*P=;]_*2-'7ML?S'MUD00;'[\<97*&W3[V\>^(:D^57WD@
ME)!T02" =Z.B"4GT.B/7V/4AB/(_'MH<::'7<'#3A"U*)2E.SORIV$@;&@GO
MZ #7?9^>_;=;,MKDGHQZ^!O\M/GODV9&S+^4V#+II?KI\;^/CB(M![I([CW_
M "UH]_GKL.V_?JRL;Y3?,+VOU .NVE_L^,%0/:7\IU\!\=;&V)E2G_B5A0_]
MT*.O_IC7RZB?\@_U#Z'$1"TATTRZ?%<0LD&\BO#H$"UL1W^DIT['\1_>NM*:
MPIHSU:.,?!%'RL?NV*3_ .-)X.WU)_7$%I&MJ/;?H/D/Z^H/5AK^F,CI^N%/
ML,2F78LEAF3&D-K9?CR&D/,/M.)*'&GF7 IMUMQ"E(6A:5)4E1"AH]2K,C!U
M9D9"&5U)5E9=0RLI#*P.H(((.H.&0."C ,K JP(!4J="&!T((W!T.V.-%R^<
M\7Y%Y0N.6,DQCC;PI8O5?&QN7CCM-762H3+T&/ C(EP8DC)*O[2R[*:M@S]@
MGF>J'$Q=Y'Q$.*^[R^CM7PS@\'!*.JXOZ:5TP%4E6M1+$)"CM-*R2R)1S<LA
M6@+"2/EYY*Q2$88^6!XO3UW$).*5,'#_ $9I8V,+4YAC<H'18T5HT:IC+AB)
M N23F95I2I8''2G%V>8-GV-P[+C5^3;86U%:15Y"F)/CU4]Q+CS4J+#D6X8L
M["9#>9<%I)7&<;;FJ=C2)B[)J;'8^4XQPWB/"ZEXN+!(N(N[&>F,D3SQ@JK(
M[K!F@BCD5@8$#J3& RQB(QL?H>&5E%7Q*_#R[T,:@1399%BD-R64-,1,[H1^
M*Q4@/=6?F!E%8\#\ZYMRWGW*5!<\2VV'X9A=HY Q?-)4F0Y#RY#%E,KU&,Z[
M"8A2OM3$5-HS(II-A"CQ74-.R%J<CO2/4])?1OAW!.&\(J8>-15U?71!ZR@1
M%5Z(O%'+=PKM)&$9N25J$CD=[E57*RKP<$XY6<5K>(Q2\->EHZ5V6FJV+%:@
M+(8[9BH1RP7F PLR*I"DM=6/5Z4A(T/Q/X]?%@7.FW?P_?PQ]%J[::=/(>/W
M\L+ V=#W_O9ZV  'E[^_AN;_ *#&H%A8??4W]^OWI)0WH=_^I_H/[^O6+2&Y
M"^^W347TM?,/>!L+F^&^@\K^/AI]GOL)B  #YDA6QH>8'[O<?>]1W&CKV[]P
M>VLBP&@W'73?6][@Z_[:8LJ]!?3<]SI?4=?'J>EM2^D%0T2  =ZUW/IV! ^1
M]"=#7L>QIO<DZ^_[U\NFXQH!8Z7-O'O?<:;;]]=MK.)1OT[#_7J0I;R'W]_V
MP9@OF?OX>'[WQ(0CMV[#W)^?]Z^GU'6H  L,9$DFYQ);2D>A(.M;"2KM[D=Q
MK7Y?7Y2?=[S;],1AP-I !WL_+6@/Z_\ 7Z;ZS+]K?/\ 4>[Q\,:!-KW[_P!N
M_P!+?1P))'R'UW^8ZR+@&VK'M^F][Z:^[ L!>P^@'RWM]G#R6SZC[OS/<D_/
M0._SZD*6U:RKT'ZC6Y-O<?/%"2W<_?AAS2$[([D^YT3^>@!Z>WY=,RH+#<;$
M[^%ATVT)Q-E&YN>P_4_6VN&7WBTRZ\4N+2RVXXI#2"MQ0;25E*$#NM:@-)2/
MVE$ >O5;LW@.^Y_M]V.&IV%AMI>VO<]>E\?.7!_TE_'7)>&8ER)@'AG\<^78
M/G6.4N6XCE%)X7LPFTV1XWD,!BUI;JIEMRO)*KK2NE1ID.0G0=8>0L=E#KM;
MA[1NR//2*Z,58&<7#+HP86T((-\<J5<3HKK#5,' 9;0FS @$$&][$;==L=D<
MA.4.7<13QD-!8"HS3'8*%XYD$1^IN8R[N.Q*C0[6%YA+JKBH<6A^5&+B9$&?
M 6W\0/-!77SOI!P3AOI#PCB/ N,4ZU?#>)0/254(=ESHQ&5XY$(9)(W59H94
M(:.1$=3F48VE@CJX'@FC')F0*Z$68J;&QUN&&AOH0P&V.=.%.!^).$L@^TP[
MM,GD"[KE1V(=]>U:[*' D+0^]&J:IEN&\H.%EI#\Q3$AYP,J2TXRRXZVY^9>
M@7\*_P"'/\,>/22<-XLU1Z3\0I7AIX.,\5X>_$(*.9EDECH*&&&CD(D,48DJ
M#!+(RKDCD1&E5_!HN%<-X;4/R)"T[C*BS31M)DT)R1J$.I&^4FP.MKXM6ZY5
MC.3Y>.<?4\GD7*8CBHTUBIDM1<9Q]\>J<HRYY+M75N-;\SE7#%ID! VU3+3M
M8_4AQVEGJ9*3A@/%*F%RE0:9@:.D<?TU==K!'(-2:>,RU.FL-C?'3)7#.T-)
M&:N=2 P0@01'3_'G(*);_(,\IZ1G&@Y/X>&.8ZQR/S_>/Y:RXHR*[#\7D3\9
MPS%YA:<::GP#'?1=W]W%:>>91<W\QV/Y'7Q$HZ]M]UI7U/"N)\1X;**F"9%J
MBI5@B PB,D%HLLE\Z$A;DV8Y5(R%1;FEX5Z\A'$I.=>Y6" M%!"VP92#S)74
M$C/(Q!N;(MS>G^2N(*+PZ<)R,4X%IYE/89[F-!17=M^L9$K(K-,]$YF,TJTD
M.I=;2X^EBL9:C"-&C,V$PMM-N2I#R_YE_P"V?Z:^GR?PLIX/1JKJ(.*>DGI/
MP;T4EEX<XI*F#A_%UK"\-)*C*\+\1K*>CX?/.CB0P5+Q,ZHP*_NO_9V]&O14
M^FTDG%X(7HN#\&XCQU8ZL&>&6KX>:?+)4(ZLLBTD$M15Q1E2O-@1LK$6;5,[
MPK%\1X[8/$>0XP]RIP%/JIF47&)RY+N4Y U;/-P<T=ODJKHPG1*/+G8L2LCH
MFV\5G'4R6I/P?C+85_$WI9Z+<"]$O0JFG_A7Q[@7_P")G\$ZWAM;Q_B_HM55
M#^DO&$XC+'2>E<O&%]1IUK*7A'I*\%-00+5<4IEX'ZQ#5<L3R0O_ $CP+C7$
MN/\ I'-%Z<<,XG_W-_B/35E/PN@XW3QKP?AS4:/4<#3A[>LRFGGKN#)+/53&
M"BG/$N3)"7,:R#Z$1657>/P47<1+;]A60W;"(01]FEO1FG'VT'NI"XTA2@VH
M'S(4@'9(Z_U<X+)55W ^$U/%*44?$:OA?#ZCB-( ;4M=/20RU=.,UR.14-)&
M"?:&74WQ_#'$!#3<1KHJ.?GTL%;514L^GX]/'/(D,IL #S8@KFUA[5Q;3&2X
MTLI33EOB-@ZI]V@6VNN?63\1RL?.VT'9/W6 ME2!LA")"64GR,I'6;JT;NE]
M 2-MQT-^Q'SQLI#JKVW (UV\-.QQ;/6>+X]T=ZT=_+WZ8C_;;[T^6%^5:NY[
M=M;(UZ#L.PZ8G $'7L._KL]A\M:Z8?+[^^_GCWX>N^]CZ=N_[^_\/W],,8^V
MLZV@JY]U;2VH596Q79<V6_LML,,I\ZUE*$J<6LZ\K;32%O/.*2TRA;BTH-XX
MY)I$BB4O)(P1% N2S&P[ #N20H%R2 "<4D=(T:21@J(I9F.P &IT';H!<WL!
MK;%>TF>7/ZKAV658G9MQ9\6%,BWN)1U992R8TJ#&>0\B)22+')6P\ZMYY*S2
M+@1XBV$KL7E)<>5VS4<7,9*>IB+([HT-2WJLRLKL""TRQTYL+ @3"0L&(CL0
M!RQU3Y%>6%PKJK++ /6(R"H.BQEIK$DD'E90"+M?4Y$<AUENI<3!HJ\VL6S\
M.1]@<^R4=.\0DEK(L@D-+BUDED+:5*IXS-ED[+3J'TT#K)*Q4T,D7M5C"D0B
MZYQFFF%R+T\"G-(I((69C'3$@@S@Z8L:I'-J=/67!L<IRQQGM+*PRH0;9HU#
MSJ#FY)&-"=M.0>-;>_N[O%XV9XSE-E'O[:7A#4A-MB\YJDJ,?7%_5%E*==NJ
MQJ#25[BK)MR!Y5)L;"6S"9<C5S'8L5#7Q00PU+4E13HT,25A4QU*-++.&YL:
M@0R%Y9!RR'_\N-6>SRGE:2KI'DDDA%1#,ZR2-3!N9"PCCC(Y;G\1 J)9P5U$
MCN%%D%L8WF=#E;M@S3JF!^J+(G,3ZV372&/CRK*&T2S,::</F>JI8/;:"CR.
M>1U+C;?F34TU.$,H3+)?(R2+(K65&-F0D:"1#OJ""-"+]\4T4I;)>Z_F#(R,
M+EEO9@#J48>8.-;LIW*K<B7%KZK&EE<N8[63%?:G8J:UB3;M0VK/XLJ%\*?)
M2[C3LA,53Z6X361OQTO2VZZ"YS$MT WW\.UC;X^.F-K>-O"VOTMU[],;W<FY
M_5DL4!K1<E+282K1MYRN2X7V@ZN2B,XQ(<;2P75)2VZVI2P@>8 GJ3>PL->O
MV#]+^_#&F8+?9A<(2_D3&+R(DJ,X(T_#ISMI71K.NL+&)<PITN26P2RI$.+$
M^SM+4N3&L_M(CE+;#=5S$W-K>8^5K_>Y-AB387MW%O(]=;;:>?3$#D/,$P[+
M&\#IY%F,LRNRKG6E4;<5Z914,*>U*LKVP3*_X1NO6S#D0@S)/GGMJG?96)8A
M2F1ZE%2EXZBLE6/U:FBD!,Q8+-,Z%8X8RHS&0,RN2NB')F*YU..&JJ KPTR%
MS-,ZFT5LT<2MF>1KW 0A2FOYO:"ABI4Y!@\BT+##$F)0YQ&C,,-N3(#\C&,A
M>^$VEM1_5UH[<4]E,=*2Z](>R*@84M2O*P@:'69%#,Q*M/1LQ)"NJU-."23K
M)$L4T:C8*M/.;#<G%E];B #"*H"@ LA:&4V%OR/S(W8WN6,T*WOH-L8#&<@O
M>6:6'D-+._P;AUC\8,&*F--S:>([[D60U(DO-RJ+&/AR&'H[S<)O)9C[*@]%
MM*:4A)&T\,/#9F@E3UNJCL6S9DHTS*&4JH*3U%U96!;U=5.C1RJ=,HI):V-9
M8V$$#WRY0K5# $BS,0T<-F&H43$C4-&V@G4W'<C 8<>!QM8"'0QUE2L.R63/
MMZI7Q%%4ARLOWW)>1TLQ]:O.M<E_(*E/E*(]%'6ZM]-)JX5C-)7IGF(_\53I
M'%+=19>; N2"90 ![(@ETNTS !<7CI6I@%HVRQW_ /#S,TD9O:Y25BTT3$WW
M,J=HP22%8AEN89%, GX=$K:EJ<]62[2/D,6P#4VO8M8]PTW':80XX:[(*]%'
M("RTIN2MU2$R6&OM*HJ::G@7V*EY)"HD6-H6CO&[1-$Q):WXD$AE6V:Z@9BK
M'+B8)YY6]J!40,49Q*KV95<.+ "^25.6U[&Y-A89C:'PQ\R/Q[_RZX,=F/"V
M?8@_F/\ 3IACSR*]AO\ #O\ ]>F'WWPD@CU!'XC73$7\_@<>=,3C5LIP?$<V
MK9]7E>.4][!LJZ742T6,&/(=7 G,O,28[<A:#)CA;;[OE<CNMN-+67&EH<TK
MKIIZRKI'22FJ)861UD7([ 9D(*DJ"%.H&A!! L01C":F@J$9)HHY%=&0AU!]
ME@01?<;DW!!!-P0=<</8/X2?"]X-;VQYVM<LN*UFL3*@U%CG=U >K<<-RV[%
M=CT\>NJH,VRMI4-R3 C!W]8S50W) 996\79'7UE7Z2<?]*(4X/'2Q2&4JTJ4
M<3K).(B&#2M)*Z1QJX5V(R+FR@FUEQ\]3\%X1P*23B+SN@6ZH]3(K)%S RE4
M"HK/(RED75VRWL"UR.R^/.3L"Y:QYO*>.,JJ<PH3(<AJGU;JE?99C24..PYL
M9]#$R#+0AYITQIL9AXM.LO!LM.MK5\S6T%5PV<T]=3R4DV4,J2 >TA) =&&9
M&4D%<R,PN"M[@X]NFJH*V(34DR3Q@E<Z6]EEM[+ ^TK"X.5@"00P!!!QO*DC
MMYTZWKN!HD?CL#]XW_IURC_E-QXG;W6O;WCK8;8Z2S"U].]NHZB^VOAALM@^
MBM#Z_P! 21^_\^IS$;BYOL =NIUW^]<2'!-CH.A_3K\?#IA'PU;([:^>QK\2
M3KM\R>IN/+P._P ,6N#MKT/WUPVIM.R.VQL;3KV_=K^_EU.(*J>EO*P_2WRP
MV4'V^]]" 2?W:UO\-?3IB"&&QN.QW\MC][##:T@Z^Z$D#1T-;[[V1\]'UV/0
M=05ON3IL>H^ MBIRDV(R'M;3W]?O4X;TM/U'TV0/Q^7X_P >H]M2"#?X#]?W
M\<19@.XMYBWZ>?P./=I5^T-'Y_\ 7V]3Z]NK"17T<=/?[NA\!OUMIJT/@?';
M]Q[[X2IO?U^OO[_G_K\NAC(]J,Z?Y3\Q]!XW[8C5>MO([^.&"DCT[@$^O]#Z
M_NWO74!K$ C*PZ=+]]S8Z#3%PX/YA;2U^X[=QAI2 ?3L??Y?3M[?C_#K4/;0
MZ]S]//S_ &U@I>Y!'QOWOL/+0>.&5(]E#_R/N/\ KUH#?;%"+;X84CMW&Q[$
M>H^6_P"]?GU! (L< 2#<89*4@_>25)^0/E/YZ.C]==9%;7ZCH>WG].VN-0V;
M30'KOJ+=-NOC?3$=2='8]/Y?3_KU'6X%K:][??\ ;$D7%C[CIKOTU\_VVPVX
MC:4D*![$>3N= :[]^W<D_='R^O6@(;0[Z:]SW'C]BXQFPZ$:"]CKMK8>>FAO
MH-<0EM^X_=\Q_P!/[^O6R/KE;W'H=]-OS'MUZ:[UZY6\KFUCL+'6WZ'Y",00
M='^_PZT87'QMY]/O;"P.AV)\?TPVM 6/J/0_Z?AUB18V/WX]??;MX8R!*FQV
M^]1]^&(*T$'1[*'H?P_T_OY]6#$;[>6NVG;PWZ8TW'F-O.WSMAE0V-:UKMW]
MOF/GHGVWLZ/IWZW/MB^@9;W\1:P/38;_ %VQB?8;*VJM>QU-CX^/EMVT&)=4
MDF2OV/P5^OI^VU_7JDC9D\0XN.QL=O []-=>NEE3*Q!U 'LWU-KC_;R T[X_
M(4$Y'=Z][>P/[A+='^AZT@-X(1VBC&__ "@W^!'TQC/_ (TO^MOKB&.WMV &
MC]2#K\M;ZUQEAQ ]_P O[_OW'4$CKL!<Z:6ZW^_EC55-M-V(Z[#H?O77?&$R
M[#,8Y QBWP_,JB+?8U?QA%MJF9\4,2F&WFI+0^)'<9D,NM2&&9##[#S+[#[+
M3K3B'$)4-N'5U7PVKBXC0SM355,Q:":.Q9"5*$975E(9&9&5E*LK6((VSK*2
MFK:=Z&JB6>"8*)HV+ . P8$E65E(=5<,C!@P!&QQS+R_X49>9XKQA@7$W(=C
MPC@V!V4QRQQS&69ZH]W6SG&'5)<=:M8C\B<PM-@M*K5=C'F/6TJ1-0XZ#\;Z
MW@?IK'P^MXQQ+C?#(^/\2XE%$(JJJ:(-3R1*XL%:%U2)@8AEA$3(($5-"+?/
M\7]&'JJ7AU%PNM;A5%1.YDIX>9:5)"I+9N:"TBV?64N&,K,Q)WSN<4?-M#SE
M@>7PN4\*P7PVX[31(&38Y;/5]6Y.GE$Z,81$NN;B*7-4Y6MUK[=Q!;KFX[@C
MPU.I4W-Y^'5'H_5>CO$J*3@U?Q'TKJIY9:6JACFFY271A(#'(S@1 2-,IAD:
M4L,[Y2&CM6P\7@XQ1U*<2HZ/T?@BCBFAE:.#,P!4HP= A+?AB-N9&(P/96XL
M\7CEWGY?+7)O*F:Y]CZO#A)I[1_CRA=99AO)A1'HRZN_<U6(F0X"H,6PDN6#
M]C+<N69T:7%A"*Y$^SZ\43T:'!>$<'X?PVI'I4D\"<3J%)D'-D5A44UQ*T;R
MB5HT$*Q**=HS&\F<2!Z\/?C?\QXCQ*IK8?Y 8I6HHBH4-&A!AG/X8>-#&K.9
M6D/-5U<(59,N.X7Y.\2M336L_P 1V+8[7VV8YI64W%%#5%J \F',AV,^P7>K
MJOUY*B54*.Q$$(2X4G)ER/M3$R$I2V2C\G_CY_$+T*_AK'Z(4GHG3U/'N-^E
M7&8_1>AI*FIJJ7A\O%I8)ZOUFLKX>'<1J*>FIZ6CJY*A^'<,XB\LCTD-%2R&
M622/[+^&O /27TJ_G\_'VAX;P_@W#SQB>:&*"6J2B1TA>*"F>KIHY)))JBG6
M%:JKI1&HGDJ)D"*IZQX\R^3FE/,G6%&[CUG5VTBFL*]4UBTBF0PQ%EMRZRUB
MH1'LJZ7$FQGX\IM#?=:VEMI6V=_%_P +_3ZK_B!P"NXAQ'T>F]&.+\(XU4\"
MXKPQN(4W&:+UF"DHZZ&LX3QJDCAI^*<,K*#B-'/!5QPPD.TL#1AH2[_3>E/H
M[!Z/<0IZ:DXE'Q6BK:"'B%)5BFEH9Q#)-/3O3UE!.SRT593STTT4T#O)8*KJ
MY1QBP4IWW/I_/^_[^GZ+CYVVEAT'[]NM]_WVDI2-@D#7;[OH"/EL'8_G]>M
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M2%A*EJ2V@:0VVAQY]PH99:<><0A6L,#S2QQ0QM)-*P1$75F9C8 >?4Z "Y)
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M$J* J(%091U""P%]R0+=>M\1Z;+,=R&?<UM':,6LC'WV8MNY"0\_"B370X3
M-DAHUST^.&C]MA1Y3TJ!YV1-9CE]D+RX7Z0\%XQ5\3H>%5T5?-PB6.#B+TRR
MRTM/4R9_^%]=$?J<M7$(SZU2PSR5%&3&*J.$RQ9\TFCF:0(X<Q$*^7503<Y<
MX&0L/ZE!)6XS 7%\1;<<XGD-M+N,DK4Y(Y(@JKH\"]5^L:BJB.LEF8FJJGDF
M'#D6"2HS9X:7/>!#0E(CI2R/E^,_PP]#?23C5;QSTJX:OI/)4T#<,I>'\?<\
M2X+PBCF@,%:.#\)G!H:&JXBA)KN()"W$9@!$*M*=5A7Z[AWIGZ0\'X=3\-X)
M6'@J0U0K9JOA2^I\1KZB.7FTYXA7QD5-3#2-;U6E,BTD1O(8&E)D-13.#^$N
M)H60<E5N'5S<_&:JQOH0N;N:JMC3*^*]*BML&WGNU\-;LEMIF-)?0M45U3:V
M%H6E)Z^#]$O^S!_ WT5])J?TAX1Z'01<1CJXYJ.6NXAQ?BE'PN8S!EJ:6BXC
M75-(LM,UI8)98I9*=T62!HF1"OT_I!_&O^)/&>"5'#.)^DC^HM3NE4(*;A]!
M+5Q!"#%45=+30RF.4>Q(BR(DBDI(KJQ!^=/AA\:WB&Y)\0F/8EDKT'(L8R^R
MF19V.P<?@P6\5@HBR9)LJZ=$CILT,5'P4*E&XF6"9$5+K:UB4XT^C^QN.>C/
M!J#@TU33W@GIHE:.=IG<U#$J CHS&-C*3E3E)%E8@CV05/\ ._"..<2K.)Q0
M3%98IW(>-8E7DJ 3F1@,X"?U<QGNH.8YO:'V9PM(=Y#R9:=E#--#8<4GT^*H
MP5A))V-^5*DC_P!0]NW7X[.V:5CITOI;^D=MM-]_/'Z7$,L86UM6(/A<[7OU
MZ=\76 D?Y0?EON0?8_7\/3Z=98O;X[7ZX;>>9CLN2)#S4=AE)6Z\^XAEEI ]
M5+<<4E"$CW*B .H) W\L+$["^*-RSQ-<%867F[?D:BDRVMI,&A<>R.7\1)[M
MJ32-3FF'!HC4EY@!792DGJ"RCK?RUQ.5CTMY^\VM;7;I<^6.-G?'EDRN1IM5
MB>%)SK#K6?$9Q2"["FT68R/CLL-.1F3$=MXLH&>)2(?FK52'&@V7U(<#C:*<
MPWTM;Y_4XMEL;:[:D;#6P.PT[_VQ]+,?EV5I35MA;T[N.V,R(U(ETDB7'GOU
MCS@\QAORX8^S//- @.*8);"]I!.M]7#7Z'78V_;;]M<4M;0]/OIBJ^6J!-W9
MX2QDLM:>-&[E*LFB,-_[F3=EV.G%V\B4M7E.,/S2Y#E+\JV8]C(KU2F"AYJV
MH?7X;.88ZPTZCU\Q6IW;\RPV;UGU86OZR([,NQ:)9 C7!BF\^MCYCTPE8BD$
MGXR@"S2$J(!*3_Y):ZMT#E"1M)#=:6D)2E*1I"0$A*0$I"0-!( &@ !H #0'
M8=>2<VXL1UO>Y^'?'H6Z6\+?IBDN-V71R=SHZMMT1W+S$$,.*2L-+<:QU9?2
MVX1Y%+;#C/Q4I/F2%M%>@I&_6KF!X?P8"V80U9.NH5J@9=+7(-C8D6WVUQYU
M*&]=XD;'*7I@#K:X@UMTO8B_NQ=_E2/8?O\ ^O7E8]'%?8/*9FWG)[T:2W+C
M?XY@-QG6'DOL?#'&_'[BT,+0I;?D^TN/K4EL^7XRW5$>=2R>RL0I%P\,"C>I
MN6!%FOZ_6@%@1>^55M_RA>E@.6G.:2L(8,/65RV-P!ZI2W .ULUR;:7))UOA
MN_RFL"ZZS@/394FGFN/OU[=;:MKLX+\5^%+BM+=B-QOM+(>;GPP^M#+TB$W%
M6_&;DKDM>>2+BQ)U&GQOM8&^@QVA3U  L=3;33X_MO;#TSD7'45[<F)'N+!^
M8GR0X!QR_BNN.N(44HGF75-IJV$@$R7YX;2T@*2A#[ZFH[L7  .9B>U_K<?I
MKB,IOMIWZ6O;PO?H!J>F-4H,NXWXZ8P[!D.M5D[)IDUB S58O9PJV=D#@3.L
MBEJ-6H1$3*>D.+CK=1\)IAM+3\A 0WYP(T )UML;:FP/37:_OP*DDGM<B^]N
MG<WMWWUOB<W3Q,+Y'L\EEP_MD/D!<&O3D3H=?FXW;,,1HL?'Y+A4IN-C=]]D
MC.5TA#;/P+]I%9/?DHG8ZQ ]8R-54$=.KY7H0\G(!"BHB+,[SJ+?B5%/F;.I
MS$P$R1JICG9_/$:T]6\Q7,*K*O-():)U 41$ZA89,H*G0"496)S1!=OLL\PV
ML>$23D-:]8K:0ZU4UKINKQ]IQ/G;<C4=0B=<2D+20M*H\)T%)"@=$$\R4=5(
MI989!'<J9I!R8%8:$-/)DA4@[@N"#?&[U,"'*TJ%R 1&AYDI!V*Q1YI&!Z$*
M;XJ_PVH9K^,:?&YKB6,AIW+)VYHI"7X5S3?K.WGSX;5K43F8UC <>COI6V9,
M5MM\;7'<>:\KBO0XY>3B$TZ M3RB,0S*0\4HBBCC8Q2H6C< J1[+DBUF -P.
M/A(R4<4+G+-&"98FN)(R[NRB2-@&0D:BZ@$?E) !Q:>5YIBF$1!-R6XBUB%-
MJ=8CK7\:;*2A24K7&A-!<EUIM2T!^0&Q&BA:5RGF&MN#SJ:EJJQ\E-"TEC9F
ML0BFQ-F<V0$A3E6Y9B"%#'3';-404ZYII%06) )NS6(!RJ+L0"1F-K*-20!C
M!\6)=>Q-R8]$G0!:9;R#=18]C$>A2_U==9[DMK6/.Q7TH>:$J!,C2FO,G2V7
MFW$^9"TJ.W$2!4!05<QTM#$QC99%SQ45/'( RD@Y)%9#8FQ4]C;.CN82Q5ES
MSU4@#J5;+)4RNA*M8C,I#"XV(MIC:<GLI=!CMY=5]1,R.?5U<V="H:T*$^XE
M1V%N1ZZ(0T\4ORW4I90OX+H05^<MK"?*>$FPOCJ N;7M?2^.3?\ VX]/3'RY
M_P 0<P8,H?\ >.SL8^TPVC[E;[[U:\6T]OOHBK)_Y-]NJYQU!^_[?'YXODOL
M0>G7[_MKC>:#Q<>'S(2AMCD*%5R%D#[/D$"UI"@GV7*G0VX .SKM+/?J<Z^7
MN_:^(*L.E_+[^F+QH\KQ?)F?M&.9+07['E\Y>IKBNM&DI'<J4N%(?2D)_P W
MFUY?<#IF7OBMCV.%8YDV.YC4L7N,6]?>U$E3K;,^N>0\RIQAQ33S*_+I33[+
M@*'674H=;4-+2.W5@0=L"!>QW[>6Q^>^$Y+C5;E=+-H;1VW8@3PR'W*._N\9
MLT_ D-26S%N\<L*JYA?[UE <^R3V2\UYX[Q<8=<;7M!.]-*DT8B+I?*)H(:B
M,YE*G-#41RPOH3;.C6-F%F (REB6:-XG+A7M<QR20N+&XRR0O'(NH'Y6!(N"
M2"1CB7Q)>!FKYFX^1C6+\A9Y3W=9;QKJH&<9_G>?8PY(8CRXCD>77Y'>7#T-
M;L>8Z&K6&'9D4I+8:?8?>;5]7P/TMDX96&>IHJ.2%XFAE-'145%4!2RN&5Z>
M&(. R#-&Y"MO<,JG'S_%O1Y:^E$,-54I(CB1!45534PE@K+9DFDE*W#'VU]H
M=B"1C5_"AQYQEX+*7(\%Y!YNP:7R!F-S7V5O7)N(]=7T[<*(Y%K8C3,]YN6T
MX\F2](D3K)FN,E#D9M$9+45+SWQ/I[_%_P!!YN,TW#^(^D/!.#U-,AB2DK^)
M4D=8&G9&S58$A6E5@$Y23.H(NX9@VF/!J:B]'TEIJKB5,:JH=7>,R*BH%!"
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MFO$WSMFW/''_ "965F3<MX#R/Q?;XXUCN+6,J#$L[OC'.KFDK',DL:!3]R]
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M[$M'3Q(_,KY%*9BL;\1C6.HR("%4*J_A @K&7) :R!.)>'HEE>>21<E(C!@
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MR6U,R([[#J5-O,/M+6VZVM*D.(4I"@4D@RKF-E='*.C*Z,K965E-U96!!!!
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M\G&V+#XJ)C&+2)"5U:5H>'Q41W7OMDFO2H>4US\13.HZFAU_<G_9]IN.4O\
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M\,*"$_(G]_\ 3JO,/0#Z_MAA75;G8&P\/N^&/0"KL!O7?MTN?*^_CY_'RPQ
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M4K$%96#T<JP\U""64R'+H#8M?\^0CYY<(M_I.N,^+N&.&ZV)F^-85BN">'G
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MVFFTI0A"4I0D) '7Y26+$LS%F))9F)+,Q)S%B=22;DDZDZX^^ "@*H 4
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M1N4ID'/[^5TZP0;>F&U[^'DR1R@-A\PE'4L4H_5(;4/%5 B8+,.N?,&5U&&
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M"-Y%H-ODK[B#_'PW*YN=N##.4W"D[C?2B K'!N751ST37ZP\3<41TT"5V=/
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M8,1>TP6G$X:'X>43^;$.'*.DN"!6#0K,".*FHU< Q5B,#Q^0)9X3OT*4,+"
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MI51XC:F"2K?U-\?0HSKK_Z2L&BCU+5C8P9GM_K])^_\"7A?_%U!+ P04
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M_0+[\O)KIS?<MZ_>!WW0?M+_O/=+U=>/W]U_('YVC>LF %;W>=",.86)&/'
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MT'>0RR>CH83DVD$@=%_4S)Y+4)1?4X< .N9JV&($VV/SL3$?5FOXK/$J8AL
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M%6\Y*:4&Y2GH? 6]=$K&<9F?XMW>+&FP?)__*E%CH< Y7E!4.&->B*"4MQ
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M0(U<"K'1,,/I>W!O89LO,E&A2$Q?(RH7":\ZC9(@D:*?J#XD!Q..>H?L2+F
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MN^G721S]0)2,]$RWP#N3A-<, VZSQ!Q3]TG<@?519CR^LFN&. #_N*V7\(N
M:XZJ="*Z-4Q-#R >JZ-$_B %6ER\7A%IM>\!QUB;.*+N$ES"U@+3:]S=33*1
M&E_<6TDHPE_ICJS $TCMW+0.XMR639$,(K])Y$4F=!N2 %M9YSC45K;P2+6[
MOEDXHT;*-PFLD(.X.$$R[%S9D& "XN2:-_RWJ-YPKL ;DS(;)*SX=Y[EK"7M
M;#'SAY!\71<_$3V.Q^$]QB"Q2WE-V+VEAWAPO/T:5UX1(6;I?AZ3&#GK.!]-
MK/EW=J#M:)9SKY$N:6NX$K*<"^3&4 (P4[AVE/W _9Q;U-S5D9PKU/M+QW#>
MT=;-BN#6T0+_5:SHIAJ..V>^)I1]DS.7X\KNXMBAI[*I[%LEU]G5[(.I''8-
MNR^,PF:Q:V>>9-]AVQ)'8PQKDY2IGL=B2LZRQ[(RQ+^0]UD!8H_BRRQ/T>H4
M+2M$: G=S(H73IH9Q2H43AQ1#0E,C>ZE:AX3I#6PQC.C-<Z(MTQW%;GH ]-)
M\3GY"M-=/A ZFSE/=M/]&..;K&9$69F,]5:PLI AJH,RES'RS<$(7T:8X7Y1
M&"-8?R(YC!&I&Q_2P0C0^KICZ<=4_R7Z!_1O'>\4@_0;;;D,%;VK&0XGTZD-
MN$(I'5MW(DE-YYL/A7C1D:8O[MZTPYH?-L6DL_N;%%'TREX4_3M]3O<UV"W:
M_8[8@I^T\ZT>2>ZT?YIG+NFG'6UH<ANBOM5L'U&UY]03JW2BM\H&T!OR:P45
MX@UNDDMA?GFS9+L0TU<MD_DC[P239 O1R5./*^K1T_[TUXI:%V40@B8*D']"
M_B0[R1Z@(36GI.\Q^W,+I?-Q$^*U$CT^+NBVA$GPG%HI8^)[_Z3L0?T2>1DQ
M63A;ED9R(KE)4TB'01<EU61,#E/<1)FY\HIX*F5'4*KH)=5KJIV$3:D;>4)=
MH'2(^4TP0;*9-8_P5GR M;3ZJ>@N*R:[1Q3,2EX9+.QAY0:>$I)8.5-VB)I9
MML2A72Q9*QKF.XNS1?GX[R*X\%#5!Z%.Z)'U07!-P%UA%90()@86"[SY^Z:0
M!8_Y(EOU(%\<H][+RQ&M5FW&KQ*6*\E5<P5"A5_6//ZP['7<6WZ"#!!PGO=#
MVCC%BP^61-OJ -VB2O,V;IV08G+%"0520U0EF-^C3\I$\MYJ97&Y/) F/@#-
M_:;QF/R YZEPMREOX>Z6O=QQ@FM-1NP3_IV&617#O/=U\HQ+O AST?(=W,W&
M]_ZON='&I,F;N9/EMIUBU5YAXOI/'), U)V/K>)7=B16Q/$J6^=D%'!-3>;E
M>=SQC2#_>HZJ?NED+"=1?FI$B1GFAJKI-*C1#"I$)-3> U-*[NBKH;BUJ3IG
M>%ITN-8;\6'^-6TD:M2$6+T!2?C37TFB2\8?<!GUK,$+.1INT4-1X))$[77T
MOC6[-72L0]1>-1?G-Y^B)N&.3PC6NN$21^XE\C:DX*]37NHEA [8>>TU8G4Q
M79-)\EPS4?6!=#$J6/F53)COI+Q(WC5AMNHXF3FBA"GZ38P9Y)_:[XRUT&$-
MD($OZE3]S3"M7J-4,/9':A6UC ?SK(H"QL,)HQ2[F;:W4H#6 06%9'_-@& L
MY+/:C=]2>%19QU^2VJU8R3L1.4:>R1//BY3]Y(''OY"]X;ZTU0%V:I,5QTDX
M=;?\%21.Y2Q[7^BFD$J?I3K(@R4_(JRR^9)BGV?2_1+X^&M2L&B:3?EJ"(8$
MXAO53?UK\&YEC*ZR0"3OUAQ)@<O2U)"(:=)XE=FG4;)9=73\48F'.-56!QA0
M7VXX0R2IXJUCP-$*D^55@;WLHVDX^:E4;YP9KI8H#'"?,/&3VNGC!\4NXN4V
M5:2N[A009RC/M!?7G%*XMAS+U\K 38N2!9)/#5GAL>('5LS<E^(H4^-X@RA)
M;*M]T32M'948U-1FWVI#^8:&ES7-6=[UCR"R^((Z3UCZXKOFG_!#L[F6 X@X
MN]OF%L3>?Q7[+^KWEI4P.K*Y<1A^MSS,RD:NS-Q1!T09XD>9.>CSB]M,JS$7
M9]>8SF+'VGL;7;"VW78JO*D55X!XV1"/GU/64/<>_S!SCOD<H7<ES_B6"%F<
M8!@@_IP=;AQ#_&:?I3]"3AM1E,.-+C0/1$C]+EI%Z6D+A6;-8)@*:#=6/#=P
MZ1Z++M3&TM?-^E0+IB^Q)VCW,];:U"SK/NXKN*0.Q]U1ZFE>RB6M.VZ<R@U:
M :D-XWQ>5*U[Q;DQ:YON ^>JO4K]@],PHLBB^IW2V["O%KPT$J@W+980UT4;
MQHG[XN[JYXK'+G+7[A -S%)K&\0S[+M5)+ZO34VNNZF] N.8&S6'@=.-!6I1
M^L[: %5*'%*W0ID>?%AS4O%^ED@#4K3;'U,NY,?8J@=;ZA(MSV!KS YF?LE-
MPT;CJ72\OL(P,<Y3"])?#JY2?].?G[58K= NL[^DF,VWO2DDN.5R:P!LM$G9
M3"^1&_P:2])GZX:M"<O/:P[7NP?[J==87L\:JSJM2[*_*L_B)XTHE$-?5(6^
MTFX]L$J7&]VU'<1/AG;$@/,CT]H\()_\PEM=8;.F^+>SH5V_4]L%5.6(0O)[
M7:!Q%3M[9L'4.3\ZD^!WDE>T-2/](R-:RE'9?G'-2]"SIF!;@U"RWZDM" ^U
M*=?U7,R6BJ@N/1:?8V[?BHM(NM5JAQ\5\:)I!WZGWZQ&'"%XBJYY*MX, !B:
M*8M'%**E^RG%L;R_TXZ2G?VC+9!B38(UTRBO(J2-H=25OC>M-ZB(*:;&$,H'
M *!V,:/*IA9T:=B(\LCV?G9&-K?E&CL@\5Z3+]L^8HGU+]9[WX9Z#.OM%)U5
MQ+H' .@>_Y<KX7LZQ:*W9=?:.D3D[/G-QX3W$X6-$X09X5?K-P@>^*+K%@@N
M3='5VPE^YV7MT?^IZH[M*F:9MO6\LC_K=M,CQ>;$Z 9/^:YP4=UN^2S?&,M\
M^>HI'99NZ>\LK[G^/S6OP]GH4I;3ZEO[(<O:%*IO2GAG+=,5AJ^PO-=NF?_$
M7*'=/85G[E/P?RN__Q3L=7M+P[VRO)9V:W>6I=%<]RGA:GVK)2\\U.)J/CO_
MNPEF?#1EO:E'T0B8H)9Q'$=4Q98A1KDT]_TV1F56:LMF3;5;;$7_(="AH%U]
M"O#\V;J^!/"08\G&=C < - 7X&QG#RH6;]>"K^<>V[H..CI5-S =%AF+WC@!
M7A/T8$,3HGKVZPWC$3L=W_2.0_SN7YTK&36BRI\.3D ]SR5OWH?6I0+[<9C$
MV%6]F=BQ09=[SF"[/*;UC,&>&%?2TX']_69I[M Y-K5^:S7Q:N[\@9DD]Y0?
M?7^1*F+MUV\@[0Q:W^U-GN#AVA5"=AC7W44C1P( ZGWL&38%V?R!<3[G27\O
M8U_*WEX@HR]F1T\8PQJDZC0P6CW<.U0,R[BG'1+F[UE2=>"_-BP/'OB;_R;G
MV$8NWY32MF$>WS^FONL-[T 0NB.%Q_>8W^[":Q[OUS;,BP( E/?^4V4_-GV7
M3\O9UJ>4,5/,Z[VDNV/DG7>DCD' ]B6208^ UEM2[_&@UM4BR6\5^C]U;5.^
M+BEG<^\I+2O%W).B(<4(.[ZHI4%KVE:J01YN+<]5N\<S6KS$K@" POH_=:#_
MIJ4Y9U=OH'E/2ENWUL2-$7>$&05!6:U(8Y!':,LH??IX7?-<\>]Q1@'X3QV8
M"IY>]F+C!6A4Y=;Z%_#EH'+)7.0\\$L\%/49!@5NQ^Q G$LZADM$NP2>Q?MB
M;HZW)_ECI^WSKIX/.]>WID:&$-:I(/M0@:+'L//H4[@DQ%EL>4DW:@#W+/$$
M)I60'? 8\X8('(<D0(CP/:D5!F+7!E&U-RG=,K:&27HGQ$.VD#LPGV'G*27%
M7,1?U,D))U$8:G^ ,^H:;;SC$]P-6M N<MD:#K!GJ.(#Q]FTJAK!/LY_67.
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M)^@$V4O2^HI;TB_DG&RA="KYS:HK$B"%'M(F_DAYY'E3DD1YX< 0ZZC[;'6
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M1QS5,0C;_4=K-Q"#W&MULXESQB[1^!-O_1EG;/_=HA!?NYUZ?)V#GDE;M6I
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M";18'/FWO<:;I_#O.ZTWD_ETP#:-A4/__]7:-PT+Y>I5"^IKY:+(:LM?<L=
MD=E%IO*::GPGZW>Z9O*4) !NJL$<X_^O>LX4/<WNL?0!C^4S)._*1<5+R1E5
M@:7#U=V@G96K,NY IH,,,0>A-R%M/O.A&-@3NT=4,.)4U\&\ME)O\[3"?\I_
MBL4E+ZN.DB:57:VA5'$JFZ NZRZ#YL*5T1=J'B'_F@L"744C[(Y3K5APQXVL
M88C2F)R7"\,+OQ5V(=82#"5'4;,K0\IVH6^G#U:68C51#ZK=\-/G#%0.$-SM
M^J@G295M7]9EXV[6TK*]\7\+8O-:"!?Q7H5OB,?+[P"GD7:E6<K^(G='C:I@
M4"ASQI?;4[[8&:AO:1]:0]:N8'KH_LE(82;P]F9_9T*P_?E(IJCL<-$6YOJU
MC4 )\VID=-D<UBAO&O $R\..2YO&NMV\*;5=7*B5I]T4;>)J,W<(?V$:<M.%
MZ:6'"GH$/6NN%DL%GA%FX"3^%N]1Q>_YS788VF)>0!,I&:N5:2AK+F@F<1K7
MG56)T8>SV<KQP$]Y;^3KU_@57I61(F86KY"JO=J+B%*C724MA9?:*$CLK6]7
MMZT.MJQE_Y,>9WR-GIGYJW8#,#^7K6M:K2I :&Z'UQ?N4&_RRBU<H;IDET<K
MX<4WW$THZQ"IG5->MZ:R<]/&-4U'U6><L<XH>9:3;<&M7IH?9TH)7U$ -7I[
M_BQ(T/VR2Z/!>;$-XDK?;(ZJO1J47\#Z6&,H=D!%0[:72DHJ8$<J'J9F(GI
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MT!?6!3G91;Y;$K+OP-26K(2O@?V-""!V)C"+4)"TY$+8X=1]:<N*7T4L!,3
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M&^=G^F\J;^%O9][QOVOVS^I_/MR;OC_\H/HA]E'\8]LG*Y\\?7KT6?ESV(N
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M6*"YRVWTSE9Z =#:#"F')[0Z(6SC=PGG-QZ#HCCGZ\J@414KJV>#!W-6F@9
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MJ_E)UAZJ@WYCW$KZ)E66[T-FBW2#DY(3B/?N$A!R=CZW["C]M_=?O7UY1@>
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M[]-7IIK4(*LP>H-Z&M<A\ .^56#E<1UGB,,=4#Q2UFRIQ7U4HZCUV%MF;OD
M]I!=E"?&AKB$E*^8AB^+CL RA2L#-V+.XK<>)[%ILF*'5=@"Q4O+.U@XH*\Z
M@AP1N)6]0QX(E^7N1^Z*)Z84(L<ERJ@[R&[9L$#1W]_2$H^=R&-EAL,AU J8
M:^6"LL%[5=.A3[+W9>FPO_QRKB^<J5B9? TN4E*C5#!3%1B8 S<!EAZ#\$UP
MIL,])!Z:9<5 =L$3*5*0 H&E.\$3T/F<C=!PZ$<R![*&IT;905FP5Z 3U 97
M>IR%/L)+'4?!!OBFU6+$%9E$_@$XJ>^4,H'-ZH$< ?!#[9(< 2[ 55%CP7SL
M7N!H< ]6ZK$9"D>?.\Z&WJ LJR/P%N01N4/E8OJG=++JN#$S9R%@:YB7] W(
MUO5'W@":M?D!;\%)FED>&\ >_+FC'23'!JV>PH5H4\6#1GW>M8(E#3.+&C/&
MU?654?_7=Y<(Q+!19HA2XSO#=)3^W>6$<1:GS39=#PLU"QUT"V1U%6/K?I3B
M^5]J#U<,ILMJI*21<1O,HZOXH4=-"L:_ON,,S]E773[K*?SSMGW:WY()"P<T
M)Q3YY44U--+,_'@SA7(@[45U. V/"S&^89)"08.90_%YJ_?@-[M.T5X3/;']
MI%DE8ULXJ+N5[\LVF'[0&_(Z35;,;6FQ1@OVB]BC^A^\@%!7W5'!<I^3VDZQ
MA^M"C5)ZV<Y+K5*LM##CJX&JLHF&Z[R1>2,,#OP5J8/Z>&%\;*HN6O0NY(76
M7[+;9XTF2+;*U4Z=H%AF1\1EJO46#["SX+I2B7Z\A)BKTD%2(#51NT.FCWFC
M.2MO#NE1WU5L]5F*_U%^=O7& X$H.P/6"M99NF+SH9,E[[4ZE3EWHM82<$QY
MI1$!;3&]ZD[@=P@7/P#*?#38;VBL:R*6#JVR6X]>A<,L::@&WE.BTR2@_)QN
M]2\43:E5T]&\F#)\!3HMQ ^[A3SRR<("D>.ND6@C<M#N!NJ#K+=L12<@QA)?
M=9(N*0=5.VI?I"CP'NV_,978&?7'$!+Z0SW)9QE:@J>[ L@=K-ON%[(1?6XY
MA/2CGGDW%VGS;---'26%5^)_M%F5#D18-J^KW!O@T/";,LN#4.=/W^ 8;^9P
M *LWQI-"X_SS>DC6D3>J(ZR$F7:[+;=\57Q^BPMQ7'A7XW;*$O]G]9/I= ]B
M33F;[:@Q;>$W6Q,-D>(O"S@Z*T5.+MBZA]"4EM;\DUP2=ZWQ%S4\/+A^%2/'
MO[_6FFWV**ENY_UP'#1:BC36^W4W9:$+WFO>*._ECFW.H:Y,/=8X0'\9EU%_
MEI4==K-V->>ZO]"<Q3=Y9!B_BRH=;^@W25-LIFA[%/D+*>IG0$*.H=&9W9V:
M4;^)*XY]4ON:GQN&FV\+X_TS3)O$%(]D@TFZPO&+3B9_89.EZ5 E+#RD'@>B
M.1/K\X0K4^[7C1=]C6VI(4M2PM*K&=(>?T]CGMS2HU"?K!ARFJ,EJB@V&O5F
M<*+%+#P+:LA>7GM<+DG1U_0KLF/SS/.54\(6F/R49_S'&P)4?1Y9N@1@N5.H
M1@3VV&S!WT/++(JP05B1G5*C@^:F1)O-D#+6LGH:M#STE]$?VN'W31\/??0(
MTDK@>*<@]0ZXS^86G@7_L:C!0I#@[*EF&.],F5B]# =C/IK"\6&ACPPLC.7W
M2P>C/SVR-;O07J<\]7R48?,+.X=:66Q'KR"75O@7=&;V-3XL<<ZSU<24[REJ
MDRXDRLO'4W55=**NX#"C@VJ;2.6.8WX.D@FO\]U=CLA^2$<M<\H^7KRT(3W_
M>KD7?J_X)6&'^&7%'$IL%4@":!?SG]-L69J$W>R)/%K0/$&1:)7+&>ES.7M)
M>KJ ;*IKS/Y&=<(X!3+Z 5%KZ7@6B5)1>8D[*7\TY3G_:L)"9ISH>.!1_C#9
M>)<KDJ_*#8MDR3@GO^9^!L#[![F<6\3?(<PK2A(*R4GE"G%0GB?IO71V?#5]
MDWQF(,*]J,QTN2VQ 4YW;([_+?UA)J029,=@+&N1O%,P+_^N@D/BE%*5J;D@
M,5(5%C^=5@I$!L9Q+H!,EP=B)C34[A+S&I%6STT:0*H@>484DL</R[V"Q!!7
M%Z]"_')^5AY#_.(&J8%(6.!,]G<DU^6IZ!2B:+T?E688,DU,(.KW@UUI$;IC
MO/J<^=ISQ,E%WIJ;.7A%L_IYG+@J&O\2\($=B_UT>2E*07^WW(FP;-AD#(Y3
MUAT&?J6TU-SE3<Y:8QY)6%'PW>2:8UG>;DB+<Z. .E+ 5=9:387+&^%M/+7%
M*4S2:6U8$CNL+11 DQ.;F=R-F=J&C01B_N^ZD=D?RXZ88^-&D:\860$[67XZ
MILM[H5Y-;*645V7^-LXE$/,8 (<L*CK'#:7VE@=6+F).(:[)NL792HV/,0C:
M67/\-DMN\@N</)4TJ5>SLNA(,5-_I"RY[(^JM/(4H9932F91+"KNTT)I6[+2
M6!DL;HP#;SFOR,\D+A*M=DI39,K!QAUY':23NCE%#56XXG490 ]@3R2 S.?E
M)RF;.'V90H8WWQA=RWDK:O!+$$V4OG2JDA<J>QK&9IUG3]' ^3Z<EW)1L8QW
ME/FL_)R@J^P\B24R9FRAI4I,T3/8'-D:ORF"Q\JQ3BH9"/342=,EDD#U@APO
M::3,M^"T+):QKU0ECRT;2Z KTC.F5W4IV5']+ O54M_'_*? -Z<:Z3Y(46N;
M4@.%89\R6R&!-"@/ASKH3XLA:*@TI6(+]"B]@Q($+XPJ9_R!2;X'^5/@0:<E
M4FMD;LWDI!FZ\=CH=+*6+N'DU&DVTD,+3ZD_E6PH3U2'ISN0Q^'F*#O&!.R!
M[SI>,>;OM$:R&%6;@Q,FU)K0U-3&FBGB$UF?JQ6T304TX]62T+)9AJBT7:09
MNC61=^@IVEF^B[@'U%RG+1(O;&?UBCAE:PNR+\6U.4F<D;FYX0PM.3^U+J/X
M1:FU^4::EIAHHD8.T/KTSWP!;H8VVVFW^!J^JWHWI3R+C/"IQ_(&13L8><63
MJ!![>#F]Z#;W*O%2JKW@*943?E?BS8KTMI=?X2/V>X$A:9'Q9>778A]X-NE1
MV5%A?=4-0DF5COZ4_+IH"MN.5I^BY2UAE89+13F\(N_ALDK15OMWJDZYR9!7
M^HXT$5Q5F4NY*@!)O;1EE'KJ5":],).QFA.9_)VCY@>$VPD6BPJ]7DC'2X\[
M+% N4K;K]A=E,T\#GF4SV&?XTROW<L^0E620?ZJ 0),)+R4GL3:*OX=MXCO)
M(KWVBU\H]CE$*W8!D+8H?YY(K'Q8["Y>SWU2[BIY0&(20V13\_NJ<'E*TC;F
M;$5;6#GWKO*GUVK1*\#@0)3_A (T+CFYJI^**P5K 3'G9\E[X"JQHS(%],G[
M2KX.-B2ET#= _X3-YQR ]%Z-HAGP0@>5O!@>4@=D?E&GRW_E5:M'<,**)^*-
MA/?E7?B,/ I)C"U.O$738SZAK]AGT?->!F$I*G2HEYU#I^"*C-'5>?*\G%.F
M!/:R0M@X@L JB]>ORGU!3-85)HJI+=HIH6O94]1GO6#!01QW6"DC85[8QS2L
M\:/L2K:PP8OM6)!0-ZOR9ZFG^59N,Z'0M#$QI.J$H2Y4R1+J^%Z5@FQ-C,,&
MV3C<$IO/JLDZ(-W*X>3]9K[F\8MC*]8(:LN;<B:)3A-_QU=)(ZBMP6'R.RRF
M^UK5>?Z K0KZ*E4A)!JQ>)A$P-A6UL"XPYY/L"\_S6TD[\DN%WC2N'$/Q2-8
MB4%O9&-XN>XKE<6BO;9[P9/R%N@-V41,$L^D9E!LZ6<8XZB_RVZSKC!N9JWD
MGF2?CB,(?O$>!/5("");]P[%O](-MC^! TH3J"=,9!B$^\GNK-6T#FHHYTC9
M)$8![WGF#W:7<%;L>[ZKF! D$CV4GG3OE-U12.V\5;>  B"D[*=@@Z"70!/-
MI3:3]XJ5I1-H#I++F<G,O;+(6 IWL7QOD*6P2UGDKI<^!.;:E:MF@9]4CB6Y
MBIW\M>6_E/RJ+<0VU:22A*HXU;*,+H8U$!;[]QD"KP*?"PS@@#LL'0MI[# E
M#R8KDXHFH36\1Z5OT;JJD97[47IQ+WDUZIZQ@+87^1&S@CT+N1IXA-^,''1'
M)&G(9KOEBH?(,D5G@8=A+B^Y)$K/I0@J(G50L3,I6\M/[Z5V:K@Q$2Q'M2*P
MEG<1KW,'Q1NQ978[%")TK<(B;W-="O=RT:N:7^3?Y9/,\46[B5$F0GI^U1J#
M(68,LURW+Y# "]2.<">+H]01=J<5<S"CC"T:G?T/^YVX,-^5M$!RLIA2<$F6
M7[XA-4;^EK0P<J-R W7(;P!H8[6Y%$('^7>M*>AT:;OD*F].T1#K#/]261K1
M0[BD\G[!?+&(K$G9*B718B,+Y!#+RT^KW,?+=&&#<:(3UD/P=?EBL8XE(&#,
M)DX#F4GPXZVE%N1'"\XQ4E,FB:>SBR(>2+6\:K],A;7PI8M$]5[:8C,..JI4
MB=+H%O1@!HW9P)14SF9_8V_) W@4[H]DMN"G(#=")=XO.N%G+5LGK7*!E<<4
M03;IX#7 4VA9Y<Q[0,^A/1*(*JR8=:)AN2LX,6)3TF>^A=0YPD7D([OG-TI*
M5:QWJ5,<5/7::, )X*# FK1()J5A5:UR8CF?#BL"<[ZS^,I1215<@_)V^#G!
M5=5YWTN25."J2YW\,?C>9@M @"?S<PDLZ#SU$'D1/+?L"'4[[)]3Q;@+1R7>
MX7C#A>$*_A88\]TA+H2'7-KE3O OFYNJ<T@0;WU%N^81U8_X16,NBZZ*5K_)
M?DMO5/LFRME3<76X->\8]L37+&K&BEV6R8SH$9N?JG+4AQ=<;E?=5W6$T&?:
M4WJ9,LM8E5U#T^MO)'JP['6$L ^\89IOOC3A5_52EQK9;#S!=J9J&/J'?5YY
M*GLF.46ER_<HY@"D8D*F,QA?/A#7!;F3[$.\8'?J):]\)(6UVS$([1!,LD3P
M4=*-++K,LBB?%"</*WU4U*RHJ,0SU$J,[!_GJ=I$^S?X-3B*-=DK!1+R$AWI
MR#319<N7Z![Y"F:4:%7E,J*[Q)+46KA3:JIJ2S\L^TA?'=NMX+,N!W>HIO$\
MO;R L\*-CD9HNU1EE8PL5[(83GPE]0YAH3"<$52P4_2*U9H^4;*$.RIVJHS.
M-P2'*PI%WEX3543)=\?EH%G^U:H=[@/&T>TX7=SQE;Z\7M[A_(>"=@&6EB"J
M%L7&=$F:)7."/LA.RR9Y?E;.5\QUW %H54E6MZ$K($ +9;E('"HJ.1QI7+X[
MKUV6ESHH."@GQOB+QRC H%-2H7*[YWOY=V"TXT75,I!J/1NRA_91 <888&KY
M 98.:,M;PWD"?$U-X$>#J=&GA5O ]4%J21[DX?E0_@^TV_&)\C:<:9T -L!7
MJA[2PK'MY<&,UUA_GB<;P,I2;G-_H^^CI8)%Z**@$#$3+?/<*XM!/1P_*2.1
M']9L<!ZRKTKX]S]Y0=E9>I<>SSW!*M(A*3K.#VUN=!!_4!,:-%O4K0[U[)5V
MXVF.[Q1'L4IK$[ #14AJ[&;6O>*/V+N\+]DS<*MBE\0+>&HY'E&*<TD3_4?B
MG=3+;NGX#=95.Y(Z5N"_\)+ZH/0(,19F%@X6CX1OE69F)2(I%3\2 Y ^TL'P
MC^A8ZE:_2ZB*><>M%!O!"[+KPS:(;EODX )Y-R$66%A15S0!N$=<DJD&ZRC;
M$VHA#]K+< 0ZRXKU:X.KN<?<2I RH=3N/IHI)5KLQI*5I95YBDE5%84VRMFT
M:QG=JI',ROBWJH?L[^%C@-.\C7YYX'EAO5L&]$Q2:S\162#?:;D 358]J>!+
M,]F6!1FR-N[H] ?R?;P/\0F*FX+G8=VJT>)A?K.!#&F 6PRX4H[:>\%3E<\M
M60@73"SO%CT4GLAOE;#%UNF)TM,2;MQ^N;5T7UBT I([^7Y7?E2L<XL'4%6"
M?2[D!#RS7 L/0LJRCX)CBKB\]Z):Y=BT08F3<F-<AG2-JCCTN=P?F.%[5G$5
M>.Q6KM* Q^T58"4T8/D MH21,BI_!%R=IQ>.@8^DT43GX,-Q<R4B>&/H$=D"
M>*=OC_PE?,LM1KD/F6%?"^Q"HJPF0UU(6>E/;IVF(\^.OT>3EC9>N%F])/:,
M6(Z?"VV5AN&VOO5R9ZS6+5QI@TVV[P1BT&HK'R@&G5QD-(5D$;.^&IORT.1Y
MQF%%NZ-N&2K*78,$^E7$"UX^NM?4?4Z+=3&LA]97M5L%^0L(VFSIM4*![E?!
ME:R9NFTE:%*:KJ0B/BI">Y_D$31%6T1-\IJFN<)<XK1'0^59V?AKYHON+WBE
M?B=?5="FOE2>G!FJODJ0)"Y2;R-OBERMEM*F!PZHG9B+/)_C3[E%3I?P[<(
M&Q0?D"8LI.&[E6GYY]%;Y($,*;:0FIMP$PMDC(FTQ?Q85P.S,"?N&<\]F)O@
MI=-=+%)B;[,;$\K1A6>QK:HC^5-A9^;$]'WP&K9#0C#\FYL6T8IX\[' <0A1
M>,^S$^F25#H]13[*7MN\0PG*>@MG]"(X.Z\2.,@O35\(&@7/XS= LT7*"'<(
MD,P,V W=E)[RU,/I\E5.'^#S2I/M D0,B"U$Z&PH-/>0<I-4D=:DVB9#XF,
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M?"!-Q^LNL++:$7;FB_WO7/[$1E(SOI[:BJFCMR-KRSK@M=Q.>"U_R8!AW9?
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M,CGH'CHY\!XV92F :/W[0+C_:\ +W S*@UV!)#SXF20Z_KXX(>>Z,!UVGE=
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M#V<V2.?2NV4S&:.RD:Q164_.B+PU=T31E/=J+QO(S@:FRU= Z/4#D/AN ])
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M!G%-7H^X$C(N-A6,BW6%XV)UT42YZA4 RMF 6?\WP-KZ+R!YL?_W?P<T[NM
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MQP?_9,H[GQS&:VZI]QB[EO>"V>(SXK77[RG]L'"8=L;_">V6Z#[]A>BJUYN
M<XS7X@'6:_$1]JN@0]Y_!CPT W^;(H2ISX($O860;K82LNTW0K;K=LCRT/F5
M1C/YDLBQ_2@58MZ&A1'&@N(IHZ(,YE/?0LYC7J7@ :?![RZ[0W2+>3#P.F-
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M5 ?*HAW 6*P&W,5;P6^)"HB7;H*(91LA?OEZ2%^^%O)7K('2/P*BJCRX:RL
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M7TL;CFMKP774W6GMWXL@34?0^><0)/,F@L0.R2(1L$ F %;(\F&C/!-V*%%
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MG<S2.,(BA;,LDKB;10)/L8CCC9^L)F>P>3= V5&2_PO)OPH00/)=[@'8+S&
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MJ'F>N$T\(=X27T2_:*'(DA:*?M9$,4)\.=0CV2;J5+30H**E-@VM#.EH9<.
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MCF,R1QTWR!YVV")WR&&OW &'4_+['&\I[')\H;C#<4EIFR,J+Q!;B2W+H*,
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M)[BTS]SGU#KUCDOSY%<>S1/(^Z.-_0!C:\@9(/-OF@<HVP:0M0<@[A# BN,
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M#&!]#<#@)H#Z70#%5P#RWUA!!KE!"@5!',5!!&5!")5! #6!#PV %\V!&^V
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MT8P?#-*8WND7,+_6JV1YJ=O ^D*W@^V9;A_;4YUA]L<ZX^R/=#:P/]39S/%
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MQ&:'+9(;'?9*S3F<E9IQN"L][?A&9ITCRDPXHNPX>5T.'4BV&^F]?J1_!W'
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MWSW[EQ:27[Z5/ .[ 6(. P2<(OL_!V!V"4#G*H#2#2#W"2#R$$#P(R/P?^8
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MQXC/-:;U/]&<MO1/S:E]G-;4WG\Y,H-J0!9H/>GW4]Y=I#UK@/S_2B!W-9!
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MA]YVZ=3>7D6[)4,RVR7[Y5.67)%-6?RC;$K/[_(IW9S2^^RK?7,.-4C:B[N
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M :-+@,XU0/5C0/8I \F7 @AOR<"_I0+>;6V0P0+NF %?V0!?4X/ZC0\U1I'
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M$[Y-&_#M!H(&^O9ZX XE=H<>=N<.\>UKFMZ= 5'-HP_0'#Q*^9\$K$AWS'E
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M#)NZ7,:ZKI*QK)O-3JSK8<?7KF,M:O<15UB+F@>L1?4?/(LJCF=1^88ME.=
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MU%S+4F/"CTZ<M)(Z7^KSO5*6AH7,2YZ[*K+=])#I9@*9NS72W)V1ZNZ%9/<
M)+F'(]$C!E*/1,1[9"#.LP"Q7I60>#4CQKL?T=Z3B/*9@=AG'R)]SR'"]Q;Y
MF,]_(?)9=E%O)<N,4<6N4"!S0*KXO)3O%3".7,:82=*]=9#B;80D;PLD>#M
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M\A??I^^FSIAB'XHE:+W?_\?>>\<W?27OO^/>)%F2>^^]]U[ -LU@>N^$A$"
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M4TB65 A)*+@(X-T%W\H@=%30ME*0#S)2U1XD?  B>1X,A?>#,GI"48R(=2V
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M]H&<]2:;[_V-E-/&]B OSWPO6@+/(VES$&[T@;*[=;+4?[K# 7NBNP\@S&0
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MJ>Y_4NVSZ%3Z9EF2_SH+"5$;P=ONS7FT'J+J%&OQR09B9+.Z>9T8W:K.)V&
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M(YB6R )9S-6%IJJ,.JWD&T++? 9&%9@%U#F@:@^(NJU)<?"=IBZWQ78-<HW
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MCQXW]'BC)P ]H>B)0D\\>E+1D\VS8E.5*):>C*$_HADQ4593)=)J#A:O WO
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MN7P"!#D!TI3 :IQ 9A!/+AU/@AYW!&!#[%?23>V'4O>!@>1P\QZ@</2$<#T
M^  /7ANY[HIH;30<*-9:[./MQ#J1A2:)R3R9B2Z5B2:-P9-&IZ7QI32X55I;
M+082DT8VD$8^GTJFD@HA22%S3,:&Y*^EL]H/A>ST1VI 86H/$CK]>/3DM1&]
M>BBT-A[]4%C[9"NQ3F5A36>AS6#!R6)AR<:.7*-Y@LD-,A>6<NF/7,A[;E<
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M4:?)\ 2J"H.>JI*(4TMJ,S_<01S3/+J!$$E(IWAB\A!35#;$E A.,D32 89
M=NQI&S;<\[T_^1_/A.6W'-^FG##.9C<J=ELBZH..4%6J)V#(J_48BR/#MQA&
M->%HI9+0IU00^B4RPF"YE'B<)2D]29?03E*EG!,TN72 *I4=>]K^]K_QVM_^
M]R;]XX4,SF]2CAMGL1N5NRR1REA'R'C(76O)_/_O('JDT,P_?'_ D1,&&-#'
MA"*C'"?)RHZ3Y.7])(7DV--VUS_FM;N!=R?=\WVZ_%;-URG'33,X3:IH2X-^
MI[W>%EOCM68\V$$8J@AMFDI\IUR-.RI2X7IX%;A>YK_W#Z7]! 6M'Z=@'\,I
M^7U/VYW F%?OU(Z==-?_R?);KB]2CING<IJTZTV-U@W6.M=.E]V266=\L(/
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M'_<W^ZZV?))\=.C-8G?;%^)*_SJ+O.: 6V+/\HNLB%HA-/]SS+AZ:/Y_<']
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M,1.[T:Q#1['LA*-X3GP7D7.PD\P]T$GGC;2NT NCVEM??MXS^.('VOMCI@K
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MC\X(.;&"5@-2TZ$LUC5+T,:P$&,.EI=8 WRLS<?%.CP<K-/UI!X89,.&V>.
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MJ!G>#;;DZJN;LEVF8*[/5)/G,YOS?69]@<^D+?2;U$4!8\43 A3H9SDZ9&!
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MC&9ZT!Q.F"IBC3FB9I 3-X+*"#UHC]*&X1@-F(]5A8VD,AS'*8(U7AZ<"8O
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MYPM=OJ\Q_O@ML_E[KCIH;KK MEI]FLNN.1[H7W0X(BI]?WQ27$=&5OCNXL*
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ME\5V#@FA_Y?A3__/I6M1M5@<*S3&H-%P4O\:\YD?U]HMZ%KCJO"TT4OK5FV
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M^$J(/X2()T8R7#".88LI3'/,%C*"C+ N%$0TH2ZJ"ETQ11B++X:EN"SL)1;
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MF*@*P5)-&-;:HK V%H>-_1A8<R;"(F@Z3.-FPSA;&@85,M"KEX-N\V+HM"E
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MJC9ZQ:DW?>[>8OZ4O<7R$6NO]0/74[9W7>_9WF"]L[O,&G XXP;'P^YPZO"
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M\I02YOY4P;SO:O\%/1FZ!LI,Z"DQ84AS&&D*P]! !/K68M!CCX2._UAH"29
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MYV!H=,^OH3'=;X/G=F)07#L&)K2@?V(3^GT-IG#A=0G =>K#^1Z@&23W7,;
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M#.M?]%]N>-YOO?%9WTF3T[Z'34_Z7C8[YO>'V4&_MQ;[?-%RCQ]:3OJCY>8
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MQ7<,NLZ=OW)6]/P='G/FG_>8T_YXUIQV=(]J1=>8)G2);42GV(8OF9J%.X4
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MU'$KE#YNB=)'Z'B8WO\+VM#>'<A[G83IE!8%]*3U>%)//'7@S2P+YJF;,_/
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M[/)OB><F<\K0B#"(*D7]Z!+4(W3_Y7$4P(]3?: :[*5;SRV4OZ898+25\ML
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M_A^HV1_HY/IPE'A$(/WZE\RG_$K*SZ*^SZ6]!U*V,V5;_$BUOP&@?(OV?A=
MY \ @>< ?!\!N,@&DOQ_GC]($+*$*J%+F!-._WP'@RZ&2.O [G^>/= &\3[Q
MX8OG,#4T>SG4^]A3E'^)\FG?YI2M?1M X1Z ^$, H2>4^P+H]W\-=]JSD*FU
MR!'J_SP'L2-\B5B";@B0ZH%4#]Q+?$_\^C^@G!&@O#ZA!RAM""AF!B@X@T'V
M+ 8AA(@C<H@*8A[112PDEM(R5A#KB"W$+N(0<8;XD;A/O"0^$O^?_Q0I7UD'
M4$F;UJ$+*$EK$K&B=;@PR!?((#>&UI/!(*N$J"?:B7YBF!ACD%D-R$P0VXE]
MQ GB6_K)=XCGQ ?X0"O^P"+8! >9#]PO057*5R?'55,'5-&DNDRM@VHA[LB@
MB"^#PK,9%$QF4""?J"*:B6Z":B&PA%A!K".V$+N)(]2>"\1O\+? 4_A+X#V\
M%D3FM1 RKX3_ ^MK4(/RM<CWM<AS->BH0N^5IOHS U#&@T')4 8EJ!]B640I
M0;40HUJ(]1&+B&7$:N:CV 3S06R2>2]VD'DG?I9Y+7Z#>2[^F'DB_H[Y4P)9
MCR21]5 2V0_^#U"'<O7D"!E G2GHO0[-AB;U0\V%^A3 H&(4@_*IS"?Y N:#
M7!7S3JZ)^4NNBWDC-\"\DAMA7LJ-,\_EUS'/Y+>RGLCO8SV6/\5ZJ/ 3ZY["
M(^:VXCO6;XK(_E4).3>4D/O+/_P\#320!S26),0_8S+UGFIA9 *H;T_K\6+>
M:X4S;S03F!<:V<Q3C5+68XTZUB.--M8#C5[6?8TAUEV-9:P[&JM9MS4VL6YI
M[F;=U#S.NJ%YE75-ZR'[BM8[[B5MY+FHC;SGM9'OW!1:7X(F4G1*DWM;D/M:
MB0!:TWMKZHNE+KPWMX*7IJ[PQ#B0>6 4S=PU2F7=-BI@W32L9-TPG,>^;MC)
MOF:X@/.#X0CG.\,5G&\--W O&4YR+QH>YKE@=(GGC/%]WA/&?_$?-4:!P\8H
M>- 8A0Y,881"^Z>!YK1W:R% &_).>T% 1UJ/@S2\M5.%I[:&<-_&#FY9>\$O
MUN',#]8)K&^ML]C?6!5S+EC5<,]9M?"<L>KF/66YD.^$Y5+^8Y:K^8]:;A8X
M;+E7\*#E&<']5K<$=UN]%-YAA:+;B*U6*+:%V$ROIX/6M/<9E._( G3A 705
MA/>NHO#8609^=]2 ZS/-X8J3*UQP"F*=<8IFGYB9PCTZ,X_WL&,9WP''.H%]
M#FV">QQZA78[+!+>:3\F,FF_7G2;_0ZQ+?;'Q#?;_R2^P>&IQ%H'E%SM@%*K
MZ+B26/$9B7_!&>3^CI^_XO;:@_S?DP6WR,5_=Q.&']SEX8*'$9SR<F2.>OFP
M#GA&</9ZQ//LG)7!/^E>*+C5O5)XLUNCZ(3;?+$-KOT2ZUQ')->ZK)):[;)%
M>J7+ 9EQE\LRRUP?RBYU_2 [XHJRPY^16>2*TM-!!]J[,\ [3X"[Y)Z_!))S
M!7#@6U]^..<K!<<"=.% H"VS.]"#M3T@F+O%/YIOHU^RP#K?'.$U/B6BJWQJ
MQ,>]FR7'O+JD1[T&99=XCLDM]MP@O\ASC\*0YSG% <][BOU>[Q1[O5"AQPOE
M";GNS\C^"SJQ_O-X^Q'EWP@!^#:<?"><@5.A7#@:(@Y[PS1@,L*2V1SNRMH0
M[L]=$Q;)MR(D7F@L.%UT-"A??"2P7&HXL%YF**!=;L"_7[[??XEBK]\:Y6Z_
M295.OY,J\_UNJ[3Y_Z72ZH_*+?ZHU!* "G24GPZZT.74BVI E]L?(BF?G.=8
M-#G7'#;LF2T"VZ)48"+:E%D;/9.U(LJ'NVQ.&/^2V3%"BR)3Q 8CLB46A!=+
M]X95RW:'-BMTAG0KM8<L4FD-7JG:'+Q5;5[P4?6&X!OJ=2&OU&I#4)50)I0(
M14+A7Y N]\_H\G:3]O\-99\@YSE E]Q==-PV5Q VQBG Z@1#6)Y@SUH:[\%=
M%!?,OW#N'*&^F 2Q[N@,R<ZH IGV.>5R+;,;%)LBYRLW1"Y4K8L84Z^.V*11
M&7Y0LR+B1\WRB!<:99&H1J@2RH02H?@O2'/X)\W =?+_LY1[F-QS=PKED_ML
M3.2#5<FR,):B!R.IMJRA%'=N?W( 7T]BA%!'0JQ86WRJ9'-<CDQC;(E\W=Q:
MI9J85I7*Z'ZU\NA1C9*H#5I%4?NT"Z.N:!=$/]/,CT8-0JT@&E4(94+I7Z:^
M>GH_E.:0_/\DY>\G]YS, )@@5J=Q82Q="D8RM6$PTXK5E^'"Z4KWY6M/"Q-J
M3HT1:TQ)DJQ+SI*I3BJ2KTBL4BI+:%8ICN]1+X@;T<R+6Z>=$[M'.RON&YW,
MN"=:F7&HD16':H0JH4(H_\L[ZL/OY-Z7J/Y'4ZD&6>2].>3^Q%@6 XNSQ6%A
MK@;TY9DSG;DS.6TY7KQ-V<&"]5ES1&LR$B0KTM-ERM+SY8O3*I0*4AM5<E.Z
MU+.2AS4SDM9HIR7MTDE)ND#\J9V2A)J$>FH2JA(JA/*_O/"G6: ^G*,:'"3O
MF\RC'I![K2 6T^N! C'H+5*%CB(3IK7(@3VOT(.WMB!0L"HO4J0L-TZB."=5
MNB [5RXWJU0Q*[->)3VS0STU8T@S*7V5=D+Z#IWX]+,Z<>D/M>/2/VG&IZ-Z
M?!JJ)J2ARG2>!M$LS 4X1378ETO.5T0UH%O T1* A70+UETB#//+E*"EW)!I
M+)_!KBESYZDH]><O*0D7+BR.$<\K2I;*+LR6S2@H5DC-KU%.RFM3B\]=J!&;
MLT(K.F>[=E3.:>TY.7_0\:-F5#:J1V>C:DPVJL1D_2^/PCX_DSQ&-=A52'-
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M@!_' _^> ?S&A?(?G)3_Y(0LS7_@+,@M\B[Y\2_FG]+M :7Q1^'4]F2=I[_
MMG^5N?\78$I=Q7W=+_3[(-_K]V%^TN^)_$K^,&!Y9OKS(/)],4[0/1M$/@LB
MQ\&)0!K0QR$_$^0??R&93]+Y?9,)]/I\#_I,S"%^)(9DDM+_L?\P2(;(;G*0
M'"?GR%7R.'E1?Q;DA^%]CC_U^QU__@\D2WGO@Q[7; S]_3A^,Y'(>S%>)(*D
MDD)2\\#^0Q]92S:1[60O.<SR3N$/7,+ON(7?\ Q^8>/]FXG[F=_\Q-_X\?]
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M,+BT$>I+QZ"Z]#A?/X/!10F&%\AY"4;G=&RC'5['7/=0=SYU2ZF;3MWH(T#
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M<)^WV0^?8 XN4_M$)K!3WG]A+"OX>0GCZ$A28F&R)>:GC$5CZ@S4I[FC)BU
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M_(R?/N6?_%BO+>^(R$_$D.\2^<=P#/*.A#%TIR'D'0EYET0^H2(_L55^:FP
M]:*IDTJ-/'R+,I98BR_HP#]'.\ON9KF];)8U;)X-K-MV-M=^UN\DF^X*'?5=
M_),_?8G9>$&_"R+S+'E*OSNATU;H=R04PS']#CO6SY&:+LR;%_5"V>SQU,C
MNVR3MU#.;EB+UQC'RXSC1<;Q#_2QNZ[%,]C$KKN+Y1_F)7.>W?D1/,IH;C/Z
MFRQ=YF$]\BF-:\,Q_.=#>']B3%^Q?3YF+M[%5.9L+K7\J!-)C226G\E6+F3\
MY;Q$:ZG0C%N,XR;CN($5+',=:[\5E[$/%YF+\_SF+&M]ABURFK63[Z>2.?4
MDJC3_D/NTOIN_A9,J6F+>YA O9G4\F0]@J@1C:M(9OE9'*8*<8%QG&,<9YB/
MTXSC));B!%;A&-OD"':R=Q[! 4:RCQ'OY<6TFS7<-=QS_Q/YX<,<*88?!"3O
MB+P\/ RHF3]S:HZDWF1JS69=O!ES*#5BV>-2F>EL'$01-2JH44>-!=18Q#*7
M8P?;9!MSL75X?^0,6^<VHWJ3O?:[X2MHG9X!/7_P4OZ&0_Z[\@V)%L C'&*N
M&<A#L3%UK:@YEK691CTW:OE1)YPUC&?/2\.0D(,M0C$VBY78*#9@@Z(5ZQ7=
M6*=<A;7*35BMVHM5JE-8J7X8?8:OHM?H&_082UAF\I_\1-V/1G 8XG!RB]/?
M>3M./QSZCS"60P9FV*>RPTX#1PP9N6"SL2<VF@1BT#0*ZTP3L=8L ZO-\M!O
M5HJ59C58H9F/7DTGEFOZL$RS 4O,=Z/;XB066SR,3HLWT&[Y UJM)"S\+[ZF
M_AN<9NY,HA.>2.WQG&H9SW9^/V2IQ%:-!398.&# <BI66\W!2FL?]%F'8+E-
M#);9)&.);1:Z;0NPV*X"G7;UZ+!K1=N(96@=,8 6^QV8;W\,S2.OH6GD2Z@?
M]2WJ'"34RHSZFX^I^3R7']<YQ1SG\+[+"=C,>-;Q^S6,9?4(4ZRPMT//*$<L
M<7#&XM$>6#0F .UC(M V-AX+QZ:B95P.YH\K1O.X:C2.GX^&\5VHF]"/F@E;
M43WA,"H=+Z/"\3F4.7Z%THD22F0<]4R0\,X43D>NS,%L8/\LZKM0F_%P>88>
MQK)TO"$6C[="A^-8M$Z<A@63YJ)YL@\:)P>C84HTZJ8DH79J)JJG%J!J:@4J
MG1I1[M2!4J<5*)FV"473#J!@VD7D3WL:>=._0,YT"3G3'L!)PJN<4A[ETN<D
MV>G&^LN[(8RGVYF>B[&T.2G0,M4"3=-&H6'Z9-3.<$7U3$]4S0Q A7,XRIWC
M4.J2BA*77!2[E*+0M0[YKJW(<^U!CNL@LESW"IFNYX2,64\*:;,^%5)G_2FD
MNDH8QD7'\]2[P6G^R#Q@"Y<=J[@$ZG;G&G<.?2?STL2\U+F8H=K5#I6S)J!L
M]@R4S'%#\1Q?%,X-0<'<:.2[)2'7+0LY;D7(<JM&IG8!TK5+D:I=)Z1H=PM)
MVC-"HO:.D*#]6(C7_D$D(=Y-SUQ)>)IZEWW9#ISF!\ER;WH=QC2?L=0S-S7,
M2X6;,4JUUBAR'XL"#R?D><Q&KJ<7LCT#D34O IGS$I ^+QUI7OE(\:I LE<S
M$KVZA'BO-4*<UTXAQNN4$.WUJ!#E]:$0Z?6[$#E/TN$I"5'D">J=#V!?Y!2_
MEBSALG@A8VI@+%7,2QDIFF> ?"]+Y'@[(,M[,C)]7)#NZX$T7S^D^(4AV2\6
M27ZI2/3+1;Q_&6+]&Q#CWRE$^?<+$?[;A7#_$T*H_VTAQ/]](<3O-R()(;XZ
M0GTDX5%JG@ZF[^92>!7I#*3G9$S5C*>4>2D@.7Y*9/J9(]W?'JD!CD@.G(&D
M0#<D!/D@/B@8<4'1B U.0G1P%J*"2Q 17(?PX XA-'BE$!P\) 0%'Q<"@F\)
M_L'ODE\$_R!)\ ^4A "9 $FX2<UC7 )O)KVD+81M0,H93P'CR.;/:>^1$FR&
MQ!!;Q(>.0URH$V+"9B,Z;!ZBP@,1&1Z!B/ $A(5G(#2\$,$1-0B*:!4"(OH$
MOX@M@D_$4<$[XF'!*^)MP2O\WX)7F"1XA4J"MTR()%RC[B$N?P?#>1V2%E)-
MBL.HS_RD\>=)_!P788R82"M$18Y&1-1DA$>Y("S:':'1?@B.#D-03"P"8](0
M$),/OY@J^,2TP#MFN3 O9I/@$7-8<(^Y+FAC_B5HHW\FDJ"-D@3W2!V7(X%]
MM$5KHX#%4;I3.151\OX/_0YC2^#[&/X\,L8 8;$6"(D;B:!X1P3&ST! PESX
M)WC#+R$8/HE1\$Y,AE=B#CP3R^&1V QMXE+,3=P@S$D\*,Q*O"JX)KXNN";\
M)+C&2\*L.#VQDG AEN,"647:21TI(=DDD43'TW/0,@4E*>"?; ;?%%OXI(R%
M5^I4S$MUA6>J!SS2_.&>%@YM6@+FIF5B3GH)9J4WPC6]&\[IZS$C?3^FIU_&
MM/17,"WM1TQ+E3 ]11*F)Y,D23C-9??6_X^M\P"/N[C6_FO)DJSJ5>^]]]Y[
M[\WJLF19MN3>>\4V!AO;8*H!FX[IE] [A!!*( 0(D/*1"@F]A=Y"V>\WNRMP
M<N_#\[*KU>J<,V?.S)SW>&;^X$RP!5TKP,(>>PVH:Y[4W ?O(B4N'Y9*1CQ4
M..JK@M$PY<^/4][\=.7.SU?V6+FRQNJ5.=:AC+%!I8\O5.KX:J6,[U+2^%$E
MC%^C^/%[%3?^LN+&/E/<?*OB1\&(50G#5MV$_ N@9'O!>K $C(%^/F\;A'.@
MNV(^W&\<_K_019F3/DJ?#%3:HDBE+DI4RJ(L)2\N4M+B*B4N;E;\XE[%38TI
M=FJYHJ>V*VKJL"*FKE3XU-T*G7I!88L_4?@D&>M"JR(,)JRZ!GI\MF-WT&JP
M"(R 'CYO1G?5 JD8FI2[&.X!=4Q8[J[8%1;%K A6](H81:U,4>3*'$6L+%7X
MRCJ%K>I0Z*IA!:^:5M"J30I8=4#^JT[(;]7M\EWUK'Q7?B2_Y5;Y+W-@J57'
M:=^98/,8L0@6@ '0CNZZ2;CG%/P?BI2^ OVKI:AULQ2\T5.!FWP5L"E$_IMB
MY;<Y5;Z;\T"Y+)N;-'?S//ELGI#WYC7RVKQ/GIN/R6/S+9JSZ0FY;WI;'AN_
ME^=ZJ[P,UL%.%MEOZ5D'IL HZ.:SQFGZ8)F4OPK]:]&_08K<(@5OAP/NFBWO
M/5[RW.,GCSVA<M\3ISE[TN2ZIT N>ZHU>T^[G/8,:]8>C-_#'^PY"DXR\""M
MNR%JN[]B022+W6G'(;ZV#:S$SY.@G_>MI@9$FPO7P_\WHQ\QD;NDH+UPP/UP
M\ -.<CWDH5F'X+B' AA4X8 $Z B+\!$6FB-,+$=Z[-N?CI@C4'#N(_#,PQ#H
M0_#,LSX#Z#]HQ^GHVDA;EYF=.;SOHLUU&QD#T.2LG?!O]$:>(06>A?ZSX>#G
M2K.AS[J(9/B8%R 9O!BN?0D)SZ4D')>RT!YG$3YNBO $]7&<>7RW_9'(ET+F
M+X$\7_PO@/YC=NS<Q-R,SDG0AZ^;=C .]S &T)N$WLASI !T^EP,!X>CSZ(Y
MT#F12#.Y8<>UV'&=V:428/]GL1NQXR:2HIM8^&Z&]]],8-U,1]YT"%P+'N$[
M;S(YD\W?8+7M4ME*6Y>!D=.(P],9!P>)0?0FHS?R$O2CTP>=;J;^<A.@*23Y
M+'3@#K-+!4)P-\GY/23G]\+Y[Z-?'L".ATA,'F+Q>XA)YF&"ZV%\\1 "'[H3
M0.0?HC\>M-JPEOZ=H+MZCS 7G,<\P-?2KK#OB@F\4?*^57(QNNYQU%YF:B'F
MI,YCCIK($[.D)R$$3Y&,/PU)>#;4?G3]!9*/W[( OLA@?Q'>_Q*.?9'&O,@?
MO?06^!I8M93^':*K6D_0!_@W"[VQ/R/^"!^?!R371QRZGG#474P=Y'E'76+F
MI,[O'?6)/T/:_NHNO4JLODYB_A9VO$V2] Z+S[O$YWO;I/=1]CY.?/\YZ0-8
MW0=?:N)*YB-,J\/'!7<1 P]*H;33YW%BS]1?GG7H?.F4FLO_.J&CGW:*_,OL
M$C%/L<$GWT!6ODN$2!*C/Y@3,@PZ*QUNQ='6>P$-LK[AJ#_,=<"\GSD5DBW[
M+2'-8)ZC_F!VAYB;2C?*?DIF+S@@<VOJ#["Y[W4<WGB-_@T;_)K.^PI&_"7L
M_PLXMSD-,W,;A]D18G9DO"+'K12VVH>GHP;AZ;##W%AB;@DQ.U3,4VLZ;+48
M^^F4)?H&GOL5//<+[/@<.S[%CH]UCC[21?H0%O@!/-.<3GD7AOPV3GR3=V_P
MEZ^?4GLQM0]S(N09FPVF[F%V0LQRO!J;S$Z9!-J5PU^6HZ\)^WO0,8+\A<A?
MBNPU=,$F9.] [E[:=1#91V&VQVCYE83'383)W>AZ0K^E\U[ 6J/S-PX\Y:A%
MV$Z%R.D_Z@_,Y.CTQWM1M"D-?87HJT%/F_Y&G_P)WO\'>/_+V/$B_GB!?GD.
M.Y[%CF>PXU<PZ2=AW(_3)X_I9PRAA]'S(A[Y4 _BR0?08F">[W.W[,_Z.57_
M-[:0<L%W/K0IA/Z*1U<6[2C%]GH]39\\J7Z&XWS:,(GLI6A8C>R-R-RA>[6/
M*#BDNV#Y=] GM^M&>/L]3"F_LNV9N9$H^>]=&=>=8H.Y .<]V3=AO4AL/ /O
M?YRX>%0IZ,E'3R4ZFI#?B?P!6C@?^9.Z!3MNPHX;L>-Z[+A.I^M:8O1J7:RK
M\,45Q,5E2#E.BR[!NV9?D\$EIV!&_]NS[,/\U[;I8#;^\L%70;0EEG9DH*<(
M^ZMUDG%RC;J1/X#\^<B?U GLN)3XN$2;B8;=1.8!/'&^SK-50V[&H@=TA-@\
MQ. ]B]XVSQTZ%=^8!V-YV2^G?H+7^YEB[G R4[([.BVT*8P(2T17#GI*:4,M
M.EK1T8..072,,2(6H6.Y#FL=,K<1%?MT)IK/X"].QSM[Z8_3\.SN66]KE],W
MVNG,.C7[)WR"[K^S[#T%[F'9N9FI]AH^NY(EX#)G+]KFS\B/TGFS4G6.4[X.
M.U?HK-GU.N#2KC-=>[7?=4BGNRW07K<I[9FS2KOG;-*N.:=IA_LA;7._6%L]
M3FJSQ]W:Z/FT-GB]I77>WP+6B%/P#E/9BU$L'9'H9]F[(HSEE,_.8_DYU\=9
M1SU\=,@S6 >\XK7?.U-[O8MTFD^5=ODT::=/I[;/[=,VRZBV6":UV;),&RWK
MM=YWI];Y'M0:WXNTRO=:K?2[2\O]GM8R_[>UQ/][30=8[?"WX]4H>PWF#G U
M:<A%L:0;T7 NEK_]3/FG^\W1'E\_[?*+U/: %&T)R-6FP#)M"*K5^J 6K0WN
MUIK@0:T*'M?*D"DM#UFM9:%;M21TOZ9"S]/BL*LT&7:[%H8]J07A;V@\XEN-
M15@U%OX3S.FDGZ>Q+*>28H"S4]#-9[OCX'W8LBW<65M"YVI#6(C61L1K=62F
M5D86:GE4I99%-6A)=+NFH^=I<<R(%L5,:C)FN29B-VH\=H_&8L_1:-SE&HF[
M54-QCVDP_A\:B/]&_?%6]<?]A.?36?))?:X%%X S';6/+=BR(8G\!M^LCO72
MBKA +8V/UG1"JA8GY&I18JD6)M5J(JE%XTG=&DL>U/SD<8TD+]%PRCH-INQ2
M?\IA]:4>5V_J+>I)?53=J7]75^I7ZDRUVI%B51=X)L=^,\OEX&RPE]1C"Y^M
MPY:5V+(,WRQ)<=?B%%\M3(W0@K1$C:5G:7YZD48R*C6<T:"AS X-9/:I/W.^
M^C(7JS=KC7JR=J@KZRQU9%^B]NR;U)K]L%JR_P*^5',V*V$6R+2J!3Q9P#@L
M),T#!\%.L('/5F+/$E(R*(PF,ETTEF71:':(AG/B-)B3KH'<?/7EEFE>7IUZ
M\UK5D]>CKOQA=>9/JCU_I=KRMZJEX$PU%QQ38\$-JB]X4'4%?P2? ZOJ\D&>
M'>:?G6X$%X+]8"M836J\A-1CDC1H'%M&\IPTE.^M_H) S2N,5F]ABKJ+<M15
M5**.XFJU%S>IK;A+K26#:BZ94%/)<C64;%9]R7[5EEZHFM+K5%7Z@"I+?Z>*
MTL]446)59;$#158]7$XL@'/!'K#1U%_*3.T%_=@RC"W]O/:6>*J[U%^=I1%J
M+TM46UFF6LH+U5Q>H::*!C56M*NAHD]U%6.JK5RJZLJ-JJK<IXK*\U56>5*E
ME?>II/(E%5=^JN(*JTK*'2BSZC[2WRO-[B"PR^Q_ 4OX; $8QIX^[.GFM:-B
MCEHK?=5<%:JFZC@U5*>IOCI/=35EJJVI54U-JZIJ>U59.ZJ*VBF5U:Y32>T>
M%=>>J\*Z:U10=X_RZEY07NW'RJNQ*M^@VJJ"*JON)/4] 0Z";;72*K"(]_-!
M?S5\ [3QOJG610UU/JJK#U)-?;2J&Y)5U9"MBH9BE3=6J:RQ2:6-72II&E91
MTR(5-JU1?M,NY3:=HYRFJY35=+<RFYX#'RFST:JL!E!OQZU0HHO!?K )+ ,3
M8 CT@!;0T C_;YJEJF8O5;3XJZPE0J6M"2IIS5!1:X$*V\I5T%:O_+8.Y;4-
M**=]0MGM*Y79OD,9[4>4UGZ%4MKO5'+[L^!#);=9E=(*6JQ*;;;JQB;I?+ '
MK /3I@8$^D$'5*FA!=[71L[=#O_N<%=AIT7Y72'*ZXI1;G>*<KISE-U=HJSN
M&F7TM"B]9Y[2>L:4TK-,R3U;E=ASEA)Z+E-<#RMPSS.*Z7E?L=UDK%V@TZIX
M< UI]]E@!UB%KDDPW&:O ;6BMP:J5-X%]X0^YLZ;K<P^;V7T!RBM/T*I PE*
M&<A0\D"^D@8JE#C8J(3!+L4-CBAV<%K1@YL4-7BF(@8O5?C@K0H=? J\J[ !
MJ\+[09]5$?.LNJR3M:'3OA=H&1@'_: 3O8VDXQ6]\)X^] _ OZ$J2:/NBI]O
M4=S\8,6.12MF+%G18UF*'"M6Q'B-PL?;%#8^H)#Q206/KU/@^#X%C!^3__@M
M\AU_'+PMO_D_R'_4:D/ B%47H6,O6 >FP CH!:U0M%IT,^25-X+^^?!?J&/T
MI+/"%GLI9,I7P5.A"IJ*5>!4J@*F<^4_72:_Z0;Y3O?(,CVNN=,KY3.]6][3
MY\MK^GIY3#T"7I/GXF_DM<@J[TD[SJ%].\!*, $&01=H&,('Z"X8@_]#D9(6
MH1_:& J-]E_I(LMJ;_FL\9/WFC!YK8D#Z?)<4R"/-56:LZ9-;FN&Y+IF6K/7
M;)'3FL-,?%>!^^AP"-FJSS1K)=GT"JN<P9FCC >P!(RALP^T\+YZG#Y8"/=;
MC'[H4?0*]*]&_WHXV"9G>6SUD,M6BV9M)?G92N*QE<5_&XO,-B:T;0RF;030
M-ARW;2V Q&\SUSY 7+= VC9_#,@B-]EQ&FU< Q;Q]1'0R?LZVEQ*FW-H<_(J
M]*^30C9)?EOAP'!TTB0Y[9TC[8//[2/Q.IU$8S^)R'X6VC-8\,Y@4CNCQ7X5
MTAD(.6,7N)#?W\)W(9#[((7[?B (K#9L1==R<T,/[9W':S-MKEA)#&)^RD8I
M!KTAB/#=(WG!T5T/DO3B6IWM#$@^SR'Q.XH=YV+'>=AQ?C))@-F:RN1V@;D>
MBT9=@* +(/;G0^;/AT2?]R;?_XZ_L]JP'GU+S T]YG06OJ[&UP5;X/^T-V:O
M%'RF9#DD>9X#!SX?W<? I0#7Z@1V7(8_+L<?5V+'522!5V/'M20?U[( GX3W
MGR2X3II'A2'L6LC]-1#ZJR'/5W_)]ZTVK$'GQ ;&PF;B<#OS$'[.H/MB:6OP
MN>B'JGN8^LL5COK+S%X44P^Y&>!>W4IR_C-/Z78+R0CQ<1=VW$/B<0\+WSUM
MCI,Z^.+>HX _O.=7TMT?\CVK#4MV,"_O9BQ"R2OP<S9?BT=O""9;"&7WZQRZ
M?N:HN\S40AX #SIJ(J9&\2B$X#%\\CA]\Z2YM00[GLF L+#X/4M\/KL$T*'/
M7@;XXV?_!F VSUJUX #KHKFA&#_GX^-D](9?3___#_J-SGL=NG[NJ+F8.L@S
M#C)DZB'/G5(/,7LU?N\B_0FB\C<_Z1_88;81OUXGO4%\ODF0O74VP!=O$IMO
MOLW[+S5(FULN,T]HH@]H;S1Z_1G&GH\X=#[ET/>\?MH/\F='+>3'TSF.6LC,
MJ1G;DW4A*)\3(U^3&']#C/Z;<?(M\?D=CO_^$G [>!J\H9].A'@YWL^<"IFI
M/Y@;.CIE?T+)A.Q/2EDC^]-S31UD'^SMH+Z#;?T;!O8-_.XKN-47L,3/Z:3/
M8,R?Z /;7:DSMW.8.L3_DWT/Q+,VOFEJ'ZZ.VH/9"V'V8,SL1S$G9"IMM9@?
MU*MO-8*.27VI9<A?@_Q-R-^!W'WP]8-H.@IOOECOP$;-Z937Z<A_TGFO\>Y5
M./?,$U',B12S_^)QV?=!_+3_0HXZB/%) &V+H5WIM*D(7;7H:4='/_+G(W\1
M4I?I']CQ*G;\%3O^C!VOP#9_#PM]F<'[6YCJ\W#NW^"+7^MW>AI/F#T?3SI@
M]E[<YZA!_/<>C*_PQ<?XXGVX[MOXX@VX[C]4CIY&_8$^>0F^_0)V_ 8[?DV_
M/ WO?PK>_P1V_!([[#=D7(".RPGE&QE"]_+?,^AZ2W?AR3L==0^S]\(\[_C&
M4VPPIU+,H:LWY80^;RP/H!W1]%<:>@JPO4J/T2>/J$L/8<?]V'$O_7+WC_LP
M-B)WAVZ%:=\""[^)R>Q&)I3K&=0G\;BYN^1J>M \9\CLNS"OYGG#ESEL^,Y1
MTGO-,<2>PA>/XHL'B8M[%8^>+'04(ZT&^2W([T;V ++GX_&%R%Z"S%7(W(C,
MG3IA8_U'B8P3-DLNQ.+S&<3GT9MFS\714V!^-OH_<@RU7SNF@7OQQ6V,DYL9
M(]<K$CW)Z,E%1QE2ZY#?BOQN1L$ \N<C?R'RER)S-:-C,UXXC1XY1'0<TP'^
M^DQZ8#^>W$?/[B6JS<ZJO:?@<Z:WUUAZGF:*N]^-:9<EX ;;M.Q&F^:B+QA)
ML?1P&C;GHZ,"'?5H:&4D]*!C@%;/1\<D.I8A<QT6;-<N/MV)9=NQ?!L]M 7/
M;F94;*0_3'7S5)B'D_^6:?Y!<#.XDJGV$J;^"UD"SI.GSI8O^L+0E8">+/04
MT8XJ[58#>MJ)@%[T#&FKQM$SQ2A9I8VS-FO]K+U:ZW2.UCB=T"KG6[32^6$M
MG_U'+7/]1,O<F&5.P:M,[4^P[-X&KF39NY EYPC3[ 'L.</+2?M=O;77.4"[
M7**TW2U%6^?D:/.<$FUTK]$&]R:M\^C06H\^K?8<T2K/2:WP7*[E7ANTU.LT
M+?$ZHBGOXUKD?;,FO1_60N]7M,#G,XW[6/\#OX^PUV"N8VH_QNLA?MX7!O?%
MIFW^P.*JK=YSM=$G1.M\XK1F;KI66?*UPE*NY98Z+?5MU1+?;DWY#FJQW[@F
M_99HH=]:+?#;J3'_LS3?_Q*-^-^HH8"'-!CP!PT$?J;^0.M/"&"NC+/?BG)%
M/.D(V&=J'['P3FQ:&TZ.A2VK_;VT(B! 2P.C-!V4K,5!V9H,+M;"X"HM"&G4
M>$B[QD+G:31T5".ABS04MDJ#85O5'W:FYH5?I-[PZ]0=?K^ZPE]49\0GZHBP
MVM!I$&[5$^9D$JG/Q<GV_2<[D^VUCU6DA\NP90FV3(7/T:)P7TU$A&D\,E[S
MH](U&I6OX>@R#477:C"F1?TQW>J+&5)O[(1Z8I>K*W:3.F-/5WO<^6J-NU8M
M<?>H.>YY-<5_I,9XJQKCK&HRB+7JD33Z(9T4"YS.<K^%U]5\MH049!&V3&#+
M>-QLS8_UT7!<D ;CH]6?D**^A!S-2RQ63V*5NI,:U974H8ZD?K4GCZDU>8E:
MDM>K*7F/&E/.57W*U:I-N4LU*;]1=<J'P&I#3;(=]Y,*7\42?W:VM!NL!\OX
M>9+/Q[%G%-\,X9O^9"_-2_%73VJ$NE(3U9F6H?:T K6EEZLUO4XM&:UJRNA5
M8\:H&C*F5)>Y5C69NU6=>8XJ,Z]41>8=*LM\!KP/K'9DV'$7:?!EN=)9+/';
MP6HP!<;Y;!A[H'+J!=V9[NK(]%5;5JA:L^/4G)VFIIQ<->:4J#ZG6G6YS:K-
M[59-[I"J<B=5F;=:Y7D[59IW1"5YEZLH[W85YC'KY[T+K"K,=2#'JI_E$PL%
MC$-2T,U@.5@(1OBLG]_U8&,']K3FNJHY;ZX:\X-4GQ^MNH)DU11DJ;JP2%6%
ME:HL;%!%48?*B@946C2AXJ*5*BK:IH+B0\HK/J'<XI\IN_@I\(ZRBWY03J'5
MC@*K;BXB[09[H28;'/M?3/UE$/3P>3NV-&-30Y&S:HN]55T2H*J2"%64)JB\
M-$-EI?DJ+2M325F=BLK:5%C6IX+R<>65+U-.^19EEQ]49OEQ993?JK3R)Y1:
M_I;2RKX'5J676I518M5UZ#Q*^KNKC'$(%H/1,GO]I1,T\?LZ7JNA+145GBJK
M\%5)9:B**V-55)6J@JH<Y5<5*Z^Z6KG5S<JI[E%6]:@R:Y8HO6:34FO.4$K-
M)4JJN46)-;]40LV;2JC^3HE55B55VG$5L@]7,!>1_JX $V 0=(-64 <JJN!=
M4):BVCDJJ)VKO+H@Y=9%*;L^45GUF<JL+U!&0X72&QJ4UM"IE(9A)3<N5F+C
M>L4WGJZXQF.*:;Q)T8V_4%3#ZXIN^%;1]5;%U%D56VO5">2?B?Q--=)2, ;Z
M0(>I_X"J6K@W]+&@$>[7Y*S,9F^EM_@IK25,J2UQ2FE-57)KKA);2Y706JOX
MMC;%M0THIFU2T6UK%=FV1^%M%RBL[0:%M/U<P6VO*:3UWPIML2JLV8YCI-U[
MP3KT+ ;#CAI0*ZB#)I6CN[ 9_:WP_W;X;Z>[$KHLBNL*4FQWI&*Z$Q7=G:&H
M[D)%XKR(GF:%]?0JM&=<P3TK%=2S2P$]Y\J_YSKY]CP$_B[?[J_EUT7VW$G6
M",Y%Q\XFN#^80-< Z 1-@.Y5,30IMP/]4,<DJ$I,G[,B!KP4-NBKT,$0!0_&
M*&@P68&#.0H8+)7_4)W\ACKE.S0BR] RS1W:+I^AL^4]=+4\A^Z3Y^#OP>?R
M&B!S[2>3[[/J+-JW!3U+P7S0"W"GZDT-"MWYZ&;J$5.@8@?A/R-2X)B;?!=X
MR[+ 'X3)9T$<2)/W@GQY+:B4YX(6>2SHUYP%B^2V8*-<(%+."RZ3TX([Y33^
M'/B7G,?(Y.=;Y0+VH6,=6 2&0!=H!E7=Q""ZL]"=#$6*'44_M#%P(1QPL;.\
MEGAJSE*+7)<&RF5IA&8O39#3TDS-6EILW^"U%"%+QP!$>BE\=PED><FMTC2\
M9AKN/T4&-T4FN1B6,H_QT,><,,]^%JP=U/%S*70Y9QC^/Q_]T*.P15+ -/J7
M25XK9\EU#<G76A*>M20;:T-H"'QJ'9/Z>B:U]0RV]?"J]3AN/3QS/61Z/01Z
M'61Y+>1M+81L#3:LMMJP$3W3M',4]/(G3:8&1)OS:'/:I!0WA7[T!JR2?*"+
M'G#TV5M(]K;!*[>1<&W'CATD&CM#F61B6'18['8SP>YF4.W&%[L7 /YH]UG\
M_AKP$-^%'.[X-W^+#=NL6HVNA;ALR.S#X7T-;2Y<3 PNA7^O1#]Z_:'M/ENE
M.3LEI]/0#T?7_EE,\"1\9V+'@;DL.-AQ"#L.FW\(2K?O23G;',:D84>6 _KC
MR'''?I17^/Y7/^Y'688^0D>]H,&< ^/K66ND!/2&;4/_;LE[G^1Z)GH/@7-D
M$DTF> <NPA_'X+>7X(]+Z9<3],MEV'$Y"^\53'Y7$-B7F^N!<-YED/O+(/0G
MR.!/?"P=QX9+K9HV9Z% *[ZN7$\,\-7$7<0?>OT.TO=GGU)_,;67F5J(;2^*
MHR9R/3ZYD:3\9CC_+7#MGV''[21DMQ,;M]<ZSN68QV73D-OXP]L>Y3MOD<1_
M9[LU=@%ZNS<1AX1-X1YBD*]%HM>?-GI=*CE?X=!U@Z/F<INC%G(GN-M1$[G/
M41-Y:+;T"#YYU-Q:0A+X1()]LZZY1OY)XN(I.O2I"P&\_ZF7^-VGMB?F#-+F
M9OJWC)#)('1C+B;^T.M]$OTW.W3>I9_VH9@]*(\[,',FQ]1$9O9JV,[*F-M;
MZ9N_X(^_,5;^SJ+W*A/<:P3W:V=(_\ 7_X!-_8/8?.US=1TA#FES'GY.Y%<A
M-Q%_F.EBZB\/.70^Z= S<V.K^4=ILS'_%4<]Q'86Y[]J(>^;)_EBQ^?$Z1?$
MZ)?TR5<,PJ\9(]\04-\0%U\C^&MS%L93/YW_F+F9T_YDD)^>FFN>6&OV@IB;
M0LQ38\R-J6ME;@OY 3;U'<SG6YC=-S"QKW2)OB!@/J/C/L5Y'\$@/X1S?\ W
MS*T<[SMJ$*;^\2M'#<)>^YCA_BZ.^H.YL216]J>DF!LZZO6].M#1CXXQV-IB
MY"_7Q]CQ+^SX #O>8\"^P\!Y&_;Y!JSTGP3K:P3.WV#K?X;)O\)?F;,O9N^)
MV8/Q2T<-XO[_H_Y@ZC+?P^^^4;B^A.M^CB\^AF-^H"9T="%_T'%+Z&(D+].?
MM ;9F_0R=KR('<_K,#HNI.NNH)TWT8WWH^\YVW-C9LZ>&-SCJ$'\SW_98!Z"
M_"F^>$\^>E-!M".6=J3#R8NPOQK_M1!ZW7H:.Y[$CL?AN8_!MQ^%;S\">WT(
M]OD =MP'*[X'9GX7 _@.W8ZN7^IG2#/WR)JZQ\VR[\.XQE&'^*G^8C^#\E?9
M]V \BR^>PA>/*Y&PS$9'"?)K=2]VW(4=9A_&;3_NPUA"BU<Y]F'LU$DX]S4Z
MBOP3>.-&^/L#O'N1Z>4CVPDJL^_"[,,PSQVZP&'#EXYP?MDQW![&%_?BBSN(
MBUL5C8Y4=.0AOXRIHHZ(:]65V'$Y=IP@3B_50F0N81I;12]L0NYNIM*#6'$A
MO/T:O'('/?044?L6GWYKV\UTT 'S_FO9+^1YWE'_N-LQ%9W$%U?AB\L4BOWQ
MV)Z!C@+D5R"_'OFMR.]&=C^1.(J\A<A;@@?6:+^V,E+V:0\3^VE(V(7$G7AR
M![UJ[MLU)\Q.A2EGON1$V\&ML^Q3XF7@8GQQ/F/D' 70CDC:D(2.+'04T>.5
MVHL=IV'';NS8A3]VT"_;Z9>MC)?-6H\W=FD#?[4>26OQX!JBQ.PB6L5(6HG>
M4_$JR][C3/.W@2O!A?Q\-E/_6=AT)G/&/EEH3S 28]"3@MTYVD)L;&+>V*@&
M=+1IG7K0,8B.<71,:07OEF'-4BR>QG-3],=BHFB2N6*AW@7?V4[>S>!%IO;[
M6&:N9<F[$)S%^[TLQ;N\6=[=9VF;LR?M\D5?&+KBM696NE;-RM<*IU(M=Z[1
M4N<F+9G=H>G9\[38942+7":UT&6%)EPW:=QUG\;<SM6HVU4:<;M#0VZ_TJ#[
MVQKT^%8#'E8;!L&O EG"S-D;IO;#8 _OMP21]I .K,&^U=XN6NWNK17N 5KJ
M$:EICR0M]LS2(J]"+?2JT(17G19XMVC,NUOSO0<UXKU PS[+-.BS40,^>]7G
M<ZYZ?:Y2C\^=ZO)Y1IV6]\#WP/HC'@FW;_^\(-+^ST%;>5W+S\O#2/^P9RH
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M<M8I(V>OTG(N4&K.]4K.>4A).7\%7RDYVZH4@RRK+D?/05+/+;G$8IY]_\L
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M@Q<B9"$\<R&D>B$D=B%D:H(,:0*R-@$96H -XU8;UN+;24P>Z+"?!6MHM]>
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MBDQ49E2&TJ/RE195KM3H>B5'=RHI>D@)T5.*B]Z@F.@S%!U]B2*C_T?AT4^
MM\'W_$R&$,7<C8[-Z)R&%HPD0'L2[?676MY7\%D)*.3W^7PO)V:6LF(]E!%K
M47ILH-+B(I02%Z_DN%0EQ><H,;Y$\?&UBDMH4VS"@*(3)A69L$[A":<K-.&8
M@A-N45#"+Q68\":OWRDXG@P!G&GV(R78ST$-FAH0@+ZJ"I3R62'(Q:8LOI/.
M:VJBFY*3?)28Y*^$Y%#%)\<H+CE9L2E9BDDI4E1*E2)36A2>VJ?0U F%I*Y1
M4.I>!:1>)+_4F^2;^IA\4]X W\H_Q:J 9*OV(G<-^B:@ WW0M-8TXH_7<E $
M\O@\"Z2!)'Y.2)NMN'0OQ:3[*CHC2)$9D8K(2%!X9KK",O,5DEFAX,Q&!67U
M*"!K7'Y9J^2;=9HL61?()^M&>6?^'+P*OI%/!MD2V(7L%>B=;_8!.6I U: 4
M%/!9-D@'2?P<ET7>"Z6-R'%76*Z/0G/]%9P;IJ"\6 5B;$!>COSS2N677R_?
M_"Y9\N?+AX3=.W^'O/*/RB/_6LW)>Q#\"7PNCURK/,%6Y"^!'@XCO]-1 ZK@
M?1'(-?4?D KH;D7GD?N3F@87NBB@R$M^Q;[R+0X"D;*4)&AN289\2@KE75(M
MKY(V>98,R;UD6FXE6^12<EC.)5=I5O&]X'=R*OY$SD56N8"-R%^$_'[;&2QB
M$92" I"=8^I/<%]TQZ [O C]4%G_,B=9*MSE7>DCKTI_>5:&RJ,R5NZ5J9I3
MF2O7JG*Y5#7)N6J>9E5!8*H@3%6LQI67 PA()?RFXF-@M<&<2QLW9\$*Z =0
M56#? Y3'9W2ODGD?A^Y(=(>420&5DJ7:2=ZU<^1>[RW7!E\Y-P3)J2'27LQL
MR#2'N4 M@, V0%H;((P-9 ,-$*7ZVP&DH X;ZJPV+./KP]"@#G34ESAJ0'R6
M U)Y'U\*_X<RAJ#;'YIBJ8.#-,[2G&8W.;>RJ+7.M4_H[::@S !N)\#::5@[
M?] !B>^ X[5#7-LAC>T7\=U; >2D%=[=:K5A$6WK1T<KJ"FW[P/*1V\&KXD5
MQ$ U_),F^3>@OQD.CM@YT#:G;OA+#XM\#WR[EX5O'A-Z/Q-9?[R]R&DN&>IO
ML!]NZ8= ]T/D^L]E\)&MS2-KG?<A?V>U80P=W: 15%71#XX:4#)MCH&J,O7*
MO]74?^" W9(K(DD6I"&2G6&2C!%/\X\+#"P6MG$6GP6F\&\.7>;:+QTR#WU:
M *$V!QS&(;#C)YF0(8;SW^?OK#8,8FH[NNKQ<85C'U!JHQ3;(H5!S?Q-_0>]
M'@-P0#@Z"0SRP$*P"#L6NS+)XH\EV+$,.U:PX*YD\E^9:B_XK438RD$^7P'@
M>,LASLL>EI:^;=N'HFGR*72UM)C[@/ !OLYH(P8Z&0.]Z$>O#WKGT(Q9A#>I
M$7\+S'Z45;+O28$O:P/]LI%D;#/]LA4[=K# [62QV<F@VX$O=M"0[8L Y'8;
M&?-62.SFUT@8O[/M1^E"7[.YCX?7''R=U,<<!#WV)YR]T>NZQ*%SIOYB:B';
M9=^+8FH3>QP)\'Y\<L!L2"9.CV#'4>PXRC@YRN ZI\%^&? 1A!P^F\3U%KX'
M63[PE72F59V]]OMP"FASZBAC8,)^!LH;O2[K'#IW.G29FL3,O2@F ?_O>HAM
M?P@^N0([KL:.DRSZ)\W]) 3X-?CB:@1?C<%70NRO("8N@]F=L*H)7Y?2YDS:
M'(N?@];8]\"X['2T[Z!#W\P^%+,GY,?])[+70V[0?][9>B?)\#W$Z@/8\:"Y
M0(_)]P&"[GX:>2^-N@<6<<^]?.^?D*KO5$T?YRYG'.*F$(;/W#V..V!,&R]R
MZ+S:04!FSN.8O2>V>HO^=RUD9D^(N3S@!0_[4WQ?9KR^Q%A]D<Y^ 0<_CR.?
MQ>#?P*Y^\Y&*&3*I$(K(O9(O0V?.^0Z]USA(GZGQF#K(J?M!GCI%S\R=)#-U
M$+,?Q-P38OX!V6SD?P]_O,]8>8^%Z3U\\1Z#ZKT=?'8<T(CW_W *[S=W8+C)
M?@[%[,$PST0Q]W&8NU'-LUG,DW/-,V+Z9,[$?,_@-'>3_AL&]#7!^B7,R-Q-
M^@GL\R,Z[@,Z[%T<]Q8.>ATF_RH\T^PZ,7LPS%D0\U34.QPUB/]K#\;,?1Q6
MN*ZIQ7P+E_D*/O49/.8CF,L'V/$.+.=-F,_KL*[7&#A_@P'^&3O^B!TO$[2_
M)4B?T[4PS+MPVZ]QWX=ZS%'_,+IODOT.SFM.L<$\B\2<0S%G(3Z6.WI\T1.J
MM^$S;\*I_@[O_Z.J]!(,Z7G8T[,PG6=@6D_!OIZ C3T&&WR4R>(1['B08+Z?
M0+Z'3KU3-Q-"C^A6.N<6?6?3;6H?Q_73.1"CW]Q#:IZ%8FH0YBZ*E^"9S^*+
MI_'%DXJD#4FVLR@/PW/OA]?=@S_NI%]N@VW="MN[!09X$XSP!CCF2>RXA@GD
M*ECZ%0S<$VB\E&]?C%>.T5-&I]F'89[L8VH1Y@R(.0/S@2.,?NT(;[,EZ79Y
M,-0LM"(8^3&$9PJ>S4%VB2[''R?4@.RV4^[#&$7VI,[%CG/HER-,*N8FC(.P
M^3.1L!\OV>_!L-]]L0OL!-MEM5UK8QX2_4O'D+O!,?POD0NRO8DN/YT'USU7
M<0S7-&3G(KL$V56V?1C[8;+[8)U[6,A.PXY=V+&#?MD&Y]["IYOYJXU8OI[!
MM4XO,MU^:3O996">!VUN_?VS8UB;K6!7.J8\9E/;UKS3B8L]<-W3X+J[X;J[
ME(#\=&W%CLWTRR;B=(/JD-^"S$Z6CSYDCC)2%F'%*I:6;8R< RPSE_#)+5CW
M.*/I?5ZM/V*AK59GGP(N<TR'^QU+P5;;\N""[5[(]D5B,(A"?B+R,Y"?B_QB
MY%<2D77H:$%>%R-E@"@=)T*68,T&1L]>.+NY/?4DOWD0;_T=? OL.[X,[G-,
MN^<XE@3SSP%F.63J1,HLY+MCKP_R_9$?RK(=@X8DEO ,=.0Q,HK148F.>N2U
MXHD>1LPPT3I)I*S"JAV,HL-$\.5$SYU\XP7P&;#:8)Z3;6HPYACHZ2QYF^:P
M1,ZQIP3FGVE,JC""+X;PQ2#QV6^K/X2C(PX=*6C+1$<^O5""GBKT-"*S X_T
MJQE+FXC/!EI53\_6$L$U1'D-GJ_6>[;*;XT#5Z/SL#F6R]*_RORS$!@% WPV
MCY2@!WNZG>:@RQOI?N@)1D\4;8A'3RIZLM%<@*XR>J26_UJ0VX-%HWAG2A7T
M1QF154J$ES"ZBAD?1<QL1<P(YE:F8G I^O;[V+?$3OO:4[(^WG>!-CYOX??-
M'LYJ=O-0XVP?-3CYJ\XI3+5.,:IQ3E25<[HJ9^>J8G:QRF=7J<RE4:4N72IV
M&5*1RR(5N*Y3GNM>Y;I>H!S7ZY7M\K"R7/ZF+-<OE.EF518XW_SS#WI7L;Q-
M!-!^T 5:^+G!C]R"W]=@2XVWJVH\O%3E;E&%>Y#*/2)4ZA&G$H\4%7MFJ<BS
M4(6>Y<KWK%>>5X=RO :5[36I3*^U2O?:HS2O"Y3B=;V2O1Y6HM??E.C]A9*\
MK4H&YBZ8K>A<&F3.W9#FDOZT\EH/JDF5*_A=&=\I]9VETKES5.+CK6(?/Q7Z
MA*C )UIY/HG*G9NAG+EYRK:4*9/D/\/2KC3+@%(LDTJRK%6"9:_B+1<JUG*C
MHBT_5Y3E-47Y?L5[JV+  71L1-]BZ,%0F'WO22.O-:"<STJPJ1#["OA>OM]L
MY?EY*M?/HFR_0&7Z12C#/T[I_JE*\\]1BG^QD@.JE130HH2 /L4%3"@F<+6B
M T]39.#Y"@^\7J&!#RLD\._@:X4&6!4&S!5Y:\/L^W#Z2,O;0!VH ,5\5H!-
MT%IE8T\6MF0$SU%ZD(]2@_V5$ARJY) 8)88D*2$D4_$A!8H+K50,A" JM%>1
MH>,*#UNIT+!="@X[5X%A)Q40^I#\0O\B_] O>6]58(A5NY&_TIR!,GMP8H@_
M4 U*^;D Y)**9?+[=.Q)Q9[D<!<EAGLI(<)7<1%!BHV(5$QDO*(CTQ05F:>(
MJ#*%1S4H-*I+P5'S%12U7 '1.^07=8Y\HZZ5)>H!^42]HKE17\@2:94OV&'V
M(Z%KA%2\T]2 0 4H E!Z98$T;$H&"7PO+L9),3$>BHJ=J\C8 $7$ABD\+E:A
M<<D*B<M6<%R) N-K%1#/2(X?EF_\4EGBM\DG_HB\XZ^25_P]\HQ_49YQ'\LK
MCDPEUJHMR)TRY[#,/J $>PVH#!2 ;#Y+!RD@ <2 2#X/3W13:)*W@I-\%904
MK,#D* 4D)\H_.4-^R87R3:F6):5-/BF#\DZ9DE?*)GFD')1[RF5R2[Y3+LG/
MR37Y [DE_: Y25;;N;2%R.V#GK4DTP_)9N\-?0 RDTSMAWP7Q(%(?A=*JAZ4
M-EL!Z9[RR[#(-R- EHQP$">?C%3Y9.;).[-<GIE-\LB<ISF9"^6:N4ZS,_?+
M*9/D/X.D.(,L(>-]S4K_3D[IK)_F3!JRNY'="#VK (4@FY_303*_BP?1O ]/
MDX*AL_Y93K+DS)%/KK>\<_WDE1LL3P+' \/GY&7)+:]8+I!&Y[PNS<J#..2M
MLF_@SH.$Y+)"YSX-H7H/P+-RK+8[D8?-63!S!LM1 \KC?29(Y?-$$,/["#X/
MAKHQ!&7)<Y)/@9L\BKWD5FR12W& G(O#Y52,4XOY@Q*X50G$N03B6&(>* /W
M+V$U+H:D%-],L+%:%V%#$1EDH56+#4TW9\',/J!L>PW([ %*S\0'( Y$\GD(
M-#H T99".%#Q+'F4N<FUW%-.%4RBE4QB50SR*@9159)=D-E,4@6)K8*D5T%B
MJL@&JN#^E1"&2DA(!=E3!3:46[6 =O68LV!Y_)AGKP%E\5DJ8A)XC>*ST +T
M0Z$MI7# <C@X--:EAL6V%@Y3QX)2SX3>$&"?W)KP11..:RHTE_L"\Y ?"&33
M1GX/MVF$F#4\QM^\ WZPU6&&S5X@OEX+2D%>@;T&E,1K##^'E:"?)EG0ZUTC
MN==)LZ'S:H;/M;#@M[' MN.+#A:=+B;W[@A[H;6;1G17 /JC&X[791YT0G;6
M"6GK(&MM)X-NQX8V& MM:P95H!A]N<7V&E L/X<C(K#:7O_Q0J];B^2$2!(&
MY()>DHQYV-&/'0/8,80=(_3)J)EP"+01G#<"YQXQ#W^&S X3ET.0N$$(XL#K
M_!U]T0_WIWWU9A\.^@KQ<P:O"813!&X,-/4?]'JVX_LNHU..&HPMN;$G.>-P
M_@4D&0NQ8Q%V3)E-J"PR2^F3)036$G/X"Z.G%P)B8LKL1R%[GOP;?\.XF""?
MHHVUZ"NCO3GX.@E*&$4H!=)>"WH]YDG.@^@:-?IDK[^8_2C0>%L]Q"1]*TG&
M5A,?:XF/#=BQV2S&YFP.\;G%7 J%P$T8O0EBO?$(WV%LK'N>[\,LUL#]^76-
MN8^'US3:'--A/X-E0:\[>F=-.'3^]UZ4S8[$U]1#3)W MC^$&-E/8G: .#U$
M G*8A> P\7D(7YQ%YQU80L*^3SJ#F#@=\KSO8Y)8;,#/9>C-XBOQ?8Q!AK,%
M:NP^Y6BCT6G^D6^;(^$V-0FS!\74!\RYG)F](><YB(&I41PG1J[ CFL8*U>S
MX%S-8+N2CKUBOOUNDN-\Z3B<^V*(^;$?5(VO\P;,7<C$('[VQ;_NJQUZ9^H@
M,_M0C)Z+]-/^D\OUG[60F7,RABS<28S<BQT/L.#?3Y_<1Y#?VP.)6R'==4BZ
M@R_>]EN^^X6*F4K3)XD!<P_Q.N+/M'>OHYVF?:;&,W,>9^89.;?JI[TG/Y[#
MT4_WA9@ZB-D/\AO'7I"7B(T7B<_?TNG/T[F_.0UB":-ZYE'IJ7>5C;_CT1VT
MW7X/S*PC#I\:TG.M0^?,N9B9_2!,,3_60DX]'V/N"C'G8F:>'6,V$;R#/]YG
MS+['HOL>$\V[#*RW":@W4?(Z#7C]]_]5>S![04X]#V/NXTB7_=FP58Y_$>VR
ML:/O&)C_AL=\#1/Z$N9H;E/\E,[[B&#YT'8OZ7&]1>>\#K=Z57_ K*\PSVJK
M0=PE^QV<9@_$M?K/>SB_L\&9]S//APG3]W#,;Y2%CA)]#'/X /[P+G:\Q43Q
M3P;LJ["OOS)07V'0_)X!\R)V/ ^G>186_C0,]@F<^!@.^SD\<Z;^<9UC#X2Y
MC^*8PP93^_A<]KM 31WB/;C5V_"[?\*K_@&?^0><ZA7XY8NVYZ+4X/YFI';2
M'7UT_S#R%R!_BA:OA#MNI-MVP>K.0OLQF-5U=.<#\/F_PCB_M=V]8?2>ZZA!
MF+T0IOYASJ"\[>C"WSJZ^)?R0+ZO'E$(\F.1GX;L/&27(=NPMB9D=R"[%]F#
M#(TQY"^V[3*X##N.P]8OAL%?Q$\7V$[&/$T/F:?HV.L>I@:QVU&','=0O.8(
MIU_HIWLP;L 7U\+OKH'K7@W'O IN=QFQ<2EV',,?%\(8SX?AG0OS.\KB<38Q
M<I@8.0L[#N"/,[0%AG<ZNB[ FI/H,C>6_,-6\S![+S;(?@;$U"'^Y@CK^QS#
M^PK'%' 4SGT$7QPB/L^B3PXJ$B0B.P/)>7#T$ML^C)TPVNW$R#9B9 LQLAD[
M-F+'>MC[6K2:DS&K&-PK\-YR/<=T^Z7MIM]IV<]_F',@_Y^]]XZ**NG:1XL,
M$B1)4$1!Q82*8L:LF,"<,2!!<LXYYYQSSCE)E(R" BKF<8PSZIAUS%GK/J>[
MG7F_]_[^D)FU[OKN^CFN9^@^W:?V4[MV5>V]NZK. *?;Y7*Z)+,\S8\S/+E
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M@!1>B^.Z&#X75D$,CFKR3L,@KXK)9:80>S"=C0%-';I0AR[4<8/Z- #MH8[
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MU."\BPE!Q6?B@TH&AXN_.&2I2] R<#@*#FW:ZK1[U]K/)P[JO.X]8OW'<8N
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M^NZ#H7[EX"B?^027J0@BX4,L"?\^R=7Q708%,YGK9O>VA&KSMH9F]:;9XV^
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M@%&9U^?95-!+[RXZ23U;U$0]GU?G,9Q>Y3F26.%U,^9/  ]UX*(.X;MF@^C
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M5T7=I.OQ':ZWHYHI]P7U;H^YM>Y/_&<"?%$'[^U2P-LQ"Z+WSH$DM/4R5%9
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M&R6 L%L*"/*SP>W(7*"K+ 2&SG)@FLL"$[<%O#QV 9U[$*A1"N"6>@Q<"U2
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MI \N9RF3SE>H+_'W/<8<G]'O.KSTN(9]2QG&?7 YC_^,GPEP1QW(J ,#[9L
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M>/WUW^(M=WZ,P1]^$^ZN]H+G8SC&#K(>]0['W?*()UUS3W>_[)KO,40J][I
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M:F0X,R$LCATC2.5&!N<'A_*J!'Q>>PB/=S&4SW\4R.<_]>4'O_(,#G[K/AU
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M.;#3T^G :>(1^?4<PW4&G1G[T7$I;ZL!KG>1_A\A_;V% MMW+?P,  W6S[)
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M3B&]3QN$=3[M$-;^?$I$Z_-#$:U/[X6UWO\B\%^FR1EL(O>PE[P/&HZ2^><
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M:I?W<>MI[^O6VWU>6$WYS9M.!:#!UB#4V1J,FEM#4'TQ="=S \G\:-+=*0*
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MC&_F<AG<K.#6N]7*HWMKB%?[U@X^K=MG^+1N/>73_&-NN>8-Y->X_F\[%^X
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M:WP7&:SVZ35:Y3,XL=][Q&2Y][Y)O=[G)RWU?F2RQ/>CP1)_HML30+00C9Y
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M? X$^I<$H'TM!/C2C.!%]AF;^_D\\@3YC'SY+\V87RX\ QL#B,*Y^YP!L+\
M,!VSC3!;$[,5[@)(/P+@?03@$A9P"!O$"0]$B PPB")01!V Z"&3$$O$ ?[:
M(!*\(0O_0:*_SAYP' 0+38XC=_]!)>9G87XT_I+O.0"[RP#3,-O@%H#:/< Z
M8S8.G8WY8@2 A= ( _^L&,)!>(@,HHAH(/K(%,06\?C^+ C>$$D#L@3!14]V
M_0.BCFZIJ?<--0.**$RBB)0%17@.%.'X4H0=11'Q=!H1*T9JD5:*B'4BO<@J
M9!VRF2*BH\@^Y"?D,G(/>8%\ K3:;X@1ZG^BA:ZO@WXI1 O'H6)$$<%4BLC.
MQK%XX5C":82;@A0@5<@\I!U9@JQ !G&L&Y"MR![D*'(>N8T\H[YR/E(?.83Z
MP/V;]_^"Z&H!F:#^#5U-()H3L+VF%%&VP9JX440^F$9DXVE$.ALI0^J15AJ1
MZD1ZD57(.F0S,HH<1$Y37Z2N4Q^DGU!OI-]3KZ0)]1)Y(4UHSV7^;X@!NKZ1
M,H*^;:B"[<1Z",^#=*RP/T[8'S\:48FF$27LAV(A4HU@+12Q%HH]M"^*RVF?
M%0=IGQ2':1\4M]'>*X[1WBK^1'NE^#OMF>(CVF.E=[2'2H3V0(G0[RL3^CWD
MKA"EOR$3,7N2/)#)LOB*SCT9ZS') (CQ-(H8VE%D@B<-=S\THIU(^ZR50_^@
M549_IUE'?Z/90G^EN9C^4G,I_;GF2OHSS77T)YHC],>:N^B/-(_2'VA>HM_1
M>DB_H?66<4V+,'[7)HS?D%^1_R"7QT$F8^X4*2#3T+>G2P.Q$)[)Z."/)U/$
M;";U9;(+]=XX@/9Z8@S]N5$Z_8EA(?V1817C@4$CXYY!&^.N01?CMD$?\Z;!
M:N8-@PW,:P8[F%<-#C&O&%Q@73*\SSIG^$;DC!$1.86<0'Y"CAL1UGC(5,RW
M0/>V1.^WYN$EA6.RP5K,-( /5M.IE^;VU.-IWK3[4\/HMZ<DTF^8Y3#^,"ME
M7C&M85TV;69=-.T0N3!YB>BYR?VB9R>O$SL]>8O8J<E[Q4],/BE^S/2FQ"'3
M%Q+[S;Y*C)D1\3W(;C,B]F^(!>;.1/>V%0-BC^-PQ'HX*, [>RUX.LL$[MG,
MH&Y8NU!79@;2?ID1P_C9*HUUVC)?Y(1EN=AQBSKQHQ;S)0Z;+V(?-%_*.6"^
MBK//?)B[UWR'Y&[SPY*[S/_#VV[^F+?%XI/D9DO"W61).!LM"7N#)9$8#YF!
MN;8LS$7W=<9QN'+@@PL?GC@KPFU'7;CB. W..SI0IQR\Z<?LPYB'9B>([I^=
M*;YW5J'$;MM*SDZ;>NX.FU;>-NO%_"W6O5*;K0>E-UEOEME@/28S9'U&=IWU
M/=E!FW?2 [9X!=D2WDI;(HEP5\[Z&V(CG#]^7+D O/.@P6,O%CSRE(#;;CRX
M[*8*9]PGP3%W&^J FQMCCVL@:]0Y6FR;4S)[9$XV=Z-C,6_8L8J_WJ%1>JU]
MF\R@?;?<@%V__$J[(<$*NU&%Y7;'%7KM;B@NM7\EW^- 9+L=B33"1WA=XR"S
MF7\]8O?.$]T;/^+_\*?@/_XLN.0C :=\%>"PGR'L];.B=O@X,4:\?40V>(6)
MK_.(XPRZITD.N.7Q^UU+I9>[S)7M=9DGO]2Y0]#CO$RQRVE0:;'3%N5%3@=5
MVIU^56ES?J:TP.6K8($KD6MU)3*M;D1J/'_=7EP!'F+^M2" 7T(!SH0RX&20
M"!P*DH7=(7JP-60ZM3'(GK$NT%-DP#](O-\OBM/GF\1;ZITIW>U5(-OI52&_
MR+->H=VC57&!1[=RB_M*E6;WC6KSW/>J-[J?4V]P_U.MWO.S4KT7$2!RB$R]
M]]\(:_ >:W 'O?-2.,!I=)ZC430X&,&$W>%\V!JI!<.19M1@A"V]/\Q5I#?$
M3[PG.(S;&13'[PA(E6[SSY%K]2L1-/O-56SRG:?<X+-(M<ZG3ZW&>[U&M?=.
MS4KO4YH5/O<U*GP_J%3X$<4*?R*/R"&R/Q"N@Z?H_]=P_C]'H_>B\^Q'_]P=
M2X.M,9(P'*L.@[&3J!4Q,^E+HYU8G9'>XNT1P9P%8='\^:%)TDTAF7+UP06"
MVJ *Q;F!#<J5@6UJY0%+-4H#UF@6!VS7*@PXKET0<$>[(/"=6F$042H,)@J(
M/"+W ^*&?0@ ^ W]_Q1F'TS"?/2>;?BZ(9$#@TG*L")I(K4DT9*^.-Z!U1;K
M(3X_)I#3%!W!JX^,EZZ)2).K"L\55(25*I:&U:@4A[:H%81T:^2%#&CEA&S1
MS@XYHI,9<E,G*_2M>G884<X.)XJ( )'_P1?A6D3W_@6W&\<Q=PS=<T<Z[K7Q
M=4VJ!*Q(4X"E:0;4XM3IM+9D.V9SDIM80X(?NR8^E%<5&R-='I,L6Q*=)2B*
M+E+,CZI6R8UL5LN*Z-3,B%BIG1:Q62<UXJ!N<L0UW93(UQJI440E-9HHI443
M!43P@S?> +?0O7_&&AQ.1??/1-_)1M] 5F:*PM),>>C,TH.VS*FTY@Q;9GV:
ML^C<%!]V17*P9&E2E%1A0H),?D*&?$Y\@6)67(5*>FRC6FILAV9RS KMA)B-
M.O$Q^W7C8J[HQL6^U(R/(ZH)<40I,8XH),83P0^>"Z]'81^P!OLQ?T<NP$;<
M?@TBO;E,Z,R5@85YVM"<:TJKS[%F5&?-$2W/])0H3@_D%J1%\'-3XV2R4M+D
MTU-R%5.3RY23DNK5$A(7:L8F]FE')PSK1"6,Z48F7D9>:$8E$=7H)*(<DT04
M$84?/,;KX3=A'[ &>W'+M16WH>N+ ?J1KD(*VHKXT%RD ?5%)E1UH16C+-]!
MI"C/73POQY^;G1W&S\B*E4G-3)%+RLA62,@H48Y-KU6-2EN@$9&V3"LL=;U.
M2.H>W>"T7W1#TIYIA:81M;!THAR>3A01A1\\" &XD(!]P!KL+,!U@/X[6($U
M0!:B!\XKDX2Z<E6H+I](E959T M+[%BYQ:YB646^[+3"$%YR0;1T0GZ27&Q>
MIB ZMT@I(F>N:FA.BWIP]A+-P.RUVO[9NW3\LL\A3S4#LK^J!F83940Q*)LH
M_. V;CG/X'6P'WNPK01@J!+7P5STOAJ 9G3AVFH.5,Y5A-*Y^E1!]31:3K4M
M,Z/2632EPDLBL3R0&U<6P8\N39")*$F7#RTI4 @NKE(.*&I6\RWJUO N'-3T
M*AS5\BP\BSS6\"K\HNI=2)1\"HG">*YA'WY"_]^#/=B,^6MJL0:X!6Y':I'R
M!C$H:I2#O$9=R&HTI:4US&0DU3NRXNL\Q*+K_-D1M6&2H36Q4L%S4V4#JO/D
M?:LJ%+VJFI0]*CM5W2I7J[M4[M!PKCRMX5SQIYI+Q6=EUPJBB"BX51#!#RXE
M8A^P!CNP[L.8OQ(=O!NUI*4%H S);V5 Y@(I2&_3@.0V8RI^@04MIG4V(Z+5
M522TQ4<\:'XP.Z Y6M*W.4G*:UZVC'M3J;Q+4X."4^-B)<?&52KVC=M4[!I/
MJM@U/%*VK_^D:%]/! [U1-ZA[F_.I'\[#QS!^J]!%5G6BC5 #Z_O0/=;C.Z'
M/IS0Q878;B6([M:'B.ZI5$B7-3VP:P[3O]-3Q*<S0,QS<03;;5$"UV51)F].
M1[&T?4>=[.SV#GG;]I4"Z_:M"C/;3RC,7/A0,+/MH[SU B*'R([G*-9@%'LP
MC//O1P?OQ.QF].#*'H!<=-$XU*.P%6(0O$(& OLUP;_?!'SZ+2BO?CN:^PI7
MALL*7Z;3BA 1A^6Q8G;+TR1L^PJXUGTU/*N^A7R+WA52YKU;I*?W_20]O?>!
MU+2E'Z6F+2%2TWH(?_HX]N%U,()]7XWY2Q<!M'7C.L#LPA7HWP/HGVO0_U"-
MW(>XX#JD""Y#>N T9 :.0S,I^R%':O:0!\UV*(!N/13)M!I*8EFLSQ6=OKY*
M;,KZ!1*FZY>S)Z_?S)ZT_CA[TKK[;),U'SDF@X1CLOJ?[, UL![KWX?YBW#N
M#7WHO^C!F6L!8H<! C<!N&X!F+6=!=8[^#!SARI8[= 'R]$I8#%J#=-'Y\"T
M42]JRF@(93H:1YLTFDDW'BUC&(TV,PU&ES'U1S>R)NP\RIPP>H^IM_V#B.Y6
M(J*[A8B.9Y/P' SSNU %FU<(GP,"R$8/CM\,$(PNZCX*,'L/@/D^"DP.B<'$
MPU)@=%@5# _K@\$1,] _,A,F')T#>D>]0?=H&.@<2P*M8P64YK%Z2OU8-Z5V
M;(A2/7Z04CUVAU(Y\IZF?(C0E0_^!>,'JQ=]?Q:J'Z :ZYZ[$2 1LT-01SW0
MA6<?P/S# ";HQ+JG&*!Z3AR4SO-!\8(B*%S0 <$O)H@ER%^T![F+7B"+FQ"9
M2ZD@?;D,I/ZS /B_#@#OMSW(->!=>@6\7PCP+A"*=_YOEF'^0LROP=KGX]R3
M<-ZAF.UQ$/./ DS_"6#B:0!M='+E2P"R5YC NR4!O-M\X-Y11+2 <W<BL.].
M!XE[LT'\GB>(W0\'T?OIP+I7!<Q[BX%Q;PAH]XX =0]%_OX'!.7]WM]T8'[=
MNF_/(27CW$-QWA['L/\G ::>!3"X *!Q&4#A=P"IZP"<VP 2+T1![!471%Y)
M ^.E(M!>:@*\-$#0^5_:(+@I>8DWXY=XX;_$B_XE+O17&Q!\X]=WD;?(I__2
M@/G%N.92=N,U> CS3P#88K;9+P 3?@50_0/G?A- \@Z ^ , YBL ^A<*X+,H
MP"<.PD?D\,>JB"XR">#+#("OS@C>C+X*OP\%QT%P' 07.<%)$GQC<N>_E&)^
M&JZY\", GF<P'^=M^AOV_AJ TBV<.Y:/_0BSGP".&2'C^7$6PD6D$,'W<Q#A
M\R#3$4<DZ/LS*54(?NB1P>_G,7O^"U'2!:*,KJV(R.H!X4T$(CX-"-,.".5%
M$8A 4I$"I!JCYR'MR!)D!3*(#"-;D%W((>0,<AUYC+Q'"'SY?T#4M! -(*J(
M GXMK8_3,@7"ML4INE-$)(0BC$2*T'.1<J0!60"$UHDL0U8B:Y%-..8=R#[D
M!/([OOLC^ QO_QK%.QI")_"6\1WFWQ!--4092XBHXM<"83U,L+0SL";..)X
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M,7D1TO$W.TNP!CC_?IQ[9QOZ/WIX)>;F+,4>]*)_KT#_6PG@," &LP>DP79
M#6P&#,!Z]128L=H:K%;/H2Q6>U+35P?1IJZ.IIFM3J-/7EW,,!EH8$X<Z&(9
M#:QC&0Z,L0P&KK$,5KX1T>\G(OHKB*C^\K\1GD.MQOPE./>V3O1O]/""Y>B?
MF!N!6N:#/NHX!# #E77J)C:8;98%T\T:,'FS(9ALG@K&(]8P<<0)C$:\P7 D
M%/1'$BF]D3Q*=Z2&TAY91-,:&:1I;ME#T]CR.TUCTRNZ^D9"5]] &&K#?[.^
M^?NS2#CWAF78 \Q.7P,0A;G^FP"<T<>MMZ$#CZ*#[Z:#]EX.:([)@L:8.F(
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MO3G"9U)P'*3E^S,I6'2R^[\0.2UT??1+*82+WL\R  +HNS +\4#"D"0D#ZE
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M)[C'N@IW6(_AENA'N"%.X)H$@3^$L E<'0?10OO7X@'1X )1Q5=5 8X05XW
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MA?G' (QPONJ8*X>YDI=Q[L+<Z\(3&>3N]].1!Q1NR$5P0\H!>,('%#+<(&L
MO#($>(N;Y7>X27R/-X,/> /\B!\\'['A'['0'S'DXQ7D^E_D"4^%L%4!6',G
MS+; .1N> U"["""#OXUS_?N)S(^3$>$3(MA25&W,0MX(3TAHF"6&[\<%^"*-
MLH U(1.0:?#M7TS%<0C_UUVD[OMWR Q]_\Z8O7]!^.IHW:IHW A# WU=#Q&>
M2%@C;D@P$O__>2*Q&=GY_>F0L\@M^ K/X0M\^L<IR,=_0630;Z44@7 14?P:
MA..8B%@B3H@_$HVD(05(Y??3F6\G$L*G5+[""LP9A,\PC!G;X .,P7LX >_@
M*I;I,9;K_5^G'R^1%\CS?T'DT?5EY; >LE@+>2!,%?S9"<@TQ [Q^GY"E(AD
M_U6+SS 7Q]^$[]R&.9V8LPQ>PTK,68L9F_%]=\)3.(SIO\ C7#@/\7?<QS]Y
M#[G[/R"*Z/H"/M:#!T027SD*0,2U<2S8#\KZ^PE1(,XU!G/3\-WR<3[EF%.+
M.<V8LQ#^A"[,Z<.< <P9ACM8BUNP'V[ &;B&B_@J_HDK6*E?OY];7:*^0_O&
M7^<>RARLAP36 [U?!NO!5\/>& "1,(<OH@[PGN4-KQEA\)21 (\8F7"/7@AW
M&)5PBU$/-QCSX1JC _Y@+H'?F2O@5^9:N,0<@0O,/7".=0+.BMR TZ(OX(0X
M@>,2!(ZQ"1S]%T2##40=_5^9#D1%'(@2CDF _9'1@K?\2?",:PV/N"YPEQ,
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MYZ6T+SN!FB]6"W$QAHB),454C TB8^<B/-838;$!"(T-1TA</(+CTA$47X#
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M-'-]HD3NHS1L:P>J^#J7TBB!=H7Q[]ZT<2[]8U4I8%:%#F94&&!ZQ4P85UC
MJ,*!<(=AI3\,*B,PK3(9^I4%T*NL@V[5 NA4K8)VY6YH59Z'9N7SQ%?0JO@3
MVN4B=(B=+'^C),\[V0[=RGTH3:K[4-*[V!<[Z /:Y$;;[%JH/VFK<;,"^DVZ
MT&LR^G]LG0=X7,75AC_UNM*N>N^]]RY9Q99D6Y)M2:ZR+??>>^_=N."""]B
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M38UI@:I/M:DV+4K5:8FJ2LM015J>RM-+599>H]*,9I5D#%-Q9J^*,OM5F+5
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M<(N4PFLDUX,1'X1D\@<QGS>AQR;TV(0]-J'')O38!,_=Q""SD<%O8SM",&W
MH!MV.,]'64?FO)9,>@V,9K5=6\R9M%#0N81,'[2\D_ =9)[)LY<80**08,3'
MK#VA&B3M=.PNN6) \,L5OEQ#CP/H<0 ]#I*0'63@/4A<', 6!PBL*ZCL%1#]
M_<3EON=H#!\C=JT'=R&8D\$82;G-A^@+KI0RH.?11['_]^>@R+G^Y+1K/N3'
M8N9'SF"3,\3I61+C:]'CNC3G'XBNH[.]#EM<2Y!="]#9\PA$_LQ?'7MREE"/
MJ>#V@#D8G(I3],>4&4V9P6<DKQ^O0;G%-1<R((X].:ZY$7->R5UN)*A^KC-*
M2$KO)3;NQ2?W,1#=BRWNQ8'W4)%[Z*ON^1WRB690U]$GZ"K K0(OFY")N9'Z
MWR1YWN(J_T[77,N]+A+T@'ZT%T?./Q /S(>8-1M/^D"<T./7).W/,/ _2WP^
MQT#P/(W@.9SZ+(4_BRV>_8O&@3WT.OH!ZIA'O>+ #,9=G@-S+P/[<1[5#^M!
M?N42,Q\R<#;)"Y?-A0R<G?HFOGD7/=ZCK?R5P?]]XO-OM)$/B(L/J/B' 'WX
MBQ]Q?[,>Q.P!,<^*,6>2FOTPYCR.%IFU(,Z]*'VPI&GZ$J;Q!:SC<UC/9S"@
M3V&1_X"-?0RO^@@6^@$.?!\#OH>!WH%)OPWG'CB'XT77&HQ'7',0_ST'8N9B
MG.M1_@V?^0J.^;GJ*;^5LD=0]AC8\T2]BQYOH\=;Z/$F3/)U6-^?T../<,Q7
M8-8O._:BW(1Y[H5E/LV_]QUS'V;UR^.N.0CS)-_;_X<.7\J+.@7I[_"JO\%U
MW\46;ZJ2\ALI>ZA^JY'48XR>1X]GT>/7\+I?P2\OH<<3Z/$+&.E%&.JC<*M'
M8.D/$JSW\^E>2KC'L5/(.?]AUF"8YY"<O4P',P= :W5L;7I= ?J]0L"* R<#
MC"+*KZ'L9BP[3 ^CQP/H<3]^N4]3*7L692^@[&4PVW6@;J/)7 %W/TE3.D^3
MNE?7$3C74K.!LT#-6@QS'L:5+AW,.2!_NVP.XBGBXJ*"P8K$9DE@Y%!^*=ZM
MI2FV4/902AY!V:.IRP3*[Z<^,RE_/AY81OGKB8B=8!S6$:X>1JN#-)HKB(C]
M1),Y4<:(67]AGKK\F9S+F5YVA;II7O?)S;$&XU9L<=YQ#D8J&'F47T;-ZNBN
M6BA_*.5W47X/Y8^GVYQ,^3,H>SZ1N1P--E+^'CQSG&[]1C[=AV8OX*U__,<:
MC)6R.^9_7G(U.]/D[W9U0]=AB]/$Q7':R)7P_H/X9#^\?X_*T;].._#+-K41
MA9U@=(,Q#HS)8,P$8Z%6\6^Y8U?*02W&%@NIU0(\.H^6,I=HGP.VD;F(.6;H
MES[.,T!N]W8>#66ZWF..(<$?3"OUB0(G21MH)^O@_:O18R5^6:$F+-^F);3;
MQ>BQ$#WFXY>YQ,=LKLYTK S90^2>T!3'#J*'-4FO$<U?.)X"U>>2IQEF'J1[
MOX.AYGI>3_#Y$/HPA%!/+TJQ@!E"G6+ 2:8N6=2ED#J4@U,+3A,XK>!T@-.-
M!N/!F4K9\WBW4F,I9326['6LXKE/H_#'2*+?[+X;D,?"G(]#N]$L>R05.D1:
MMAM]-J/+:NRR5+[4+0B\,+P=2^DIU"<;G$)PRL&II?9-M))6L#K!Z463B90]
MDV@Q%C*[=@X0/6?53F2W$?&M]!6M]':M<NX&?""688?A_BQ#[=$4YQZ8+>BS
MFK1H,7:9PS XU=,?3"MX$6#%@Y(*3@XX1;2.<K!JP6H"JQVL$6IS&ZM6MZD:
M[+Y +>YKU>2Q5XT>I]7@>:?J/9]0G=<[JO/Y$K$[Y*?@GF=H.T4:>!#9P?OU
MJ=2?+GXN]ID:0FYG\5"/;Z!&>-G4X16I8=X):O=.4YMWCH;X%&FP3X5:?.O5
MY-NB1M_A:O#K4;W?)-7ZSU&-_RI5!>Q69< IE0?<H;+ 7Z@T\&V56KY"["I#
M[@3S.H:UXZ0;^PO-<V"P 7Q_(2GR#.PS$9OTXJ^.8&^U!EK4$ABBIL H#0I,
M5$-@NNHLN:JUE*C&4J4JRR!5!K6I(FBDRH(FJ#1HEHJ#5Z@H>*<*K">5;[U=
M>=9?*M?VCO)L7R-VY2.W@7\&7GV$5&,W7'\CKROX/(]4; KZC2-5'H&_VHB3
M1IN?:JW!JK:&J=(:JPIKLLJLF2JUY:O$5J9B6ZV*;"TJ".E4?LA8Y85,5T[H
M4F6';E-FV'%EA-VJ]/"+2@M_2^D17RLCPJZ,<+@_>*?A]X=(,W:2"J_G=2F?
M9Q=?O@9$:H$^U$9ZJ3S,HI)0FXK#(E48%J^"L#3EA>4H-[Q8.>%5RHYH5%;$
M,&5&]BHC<HK2HA8K-6J+DDG*DJ)O5F+THTJ(>4.),5\J*<;ND!NH]\D:UUZ@
M!E+->N<2[9GP_3Z&_&[T&(H>4#E5);BI*-I?>5'!RHD*4W94C#*CDI01G:GT
MZ'REQ90K-:9!*;%M2H[M5E+<9"7&+U!\_";%Q5^IF(3SBDYX1%&)?U)TXA>*
M2;0K-L'N.)?W.+C[FUSGP2(+27FFUT%-T&,$*7HK,5)/O):3'N8G^2@SWJ+T
M^!"EQD<J.3X>25-20JX2$TJ4D%BK^,0ABDL:H9CDB8I.GJ>HE/6*2#FD\)0;
M%);ZD$)3_\CKYPI/M2L".0O64?#WPF4WDWJN1!;P?AK7QO)=)SH.QE9U1? =
M8B0GPT.I*0%*2K8J(3E<<2FQBDU)5DQ*EF)2BQ2=6J6HM&9%I'<J/'V\PC+F
M*#1CK4(R#LB6>4[6S <4E/E[6;,^X[/=(==0YROA];L-#1CF6H<"UY^"+J/1
MHP/_M."K&F*D&-]DX9ND;#_%9@8I.C-$49E1BLA,5'A6NL+X,C2K0B'9C<AP
MV7+&RIHS2T&YJY']LN1=J\"\^Q20]P*O'_.9K"V7<=R<#0SF3JCAAB[G.A3S
M9^K)</T>J-HPOF]&SVK\58A-TK%)?)&7(O(#%99G56A^N$+RXV3+3Y4U/T?!
M!:4**JB7I; =&:W HNGR+UHAOZ(]\BV^1M[%%Y!GD _D4_2M?(OL.D']#Y!V
M;X?;KX-/+X7GS^ZF34!+NM%K*'9IQ";EQ$DN-DG!)C&5;@HI\U-P:9""2D-E
M*8U&DA18EJ6 LF+YE]?*M[Q5/N7=\JJ8(L^*I7*OV.$D#A6,S!5D"15PBXJO
MY%9N=YY+8_8CD7:O&4>;@(K,-'MQ1COWXK1AESIT*4;73&R2@'\BH$[6.A\%
MU%CD5V.3;VVDO&L3Y%6;(<_: KG75LFM#NY?9WX,4:^#/-=M1<BEZR BM?#N
MVO<0^&8MN52W\]E$F^'SJR;1)OC)=%XG\+F+Z\W8I1(;Y>.?5/P3@]]"L(ME
ML+=\6@+ET<*@TL+@TD)'UD(#;B%P6^CL6G!@"Q5LZ4/F.Q\LVT)&T PI:B9;
M:2)K;"*#;++KH-F/!.[&J<YU*/.A0M-X'<OGH>A2/P'NR3V9V"4!7X6C3Q#5
M\^OTDGLG UH'G+LC5!K.X#*< 6\XG<EP@G>X65B%PL/'(K,)+#C%,+C_4+C_
M4(A0.]E;^Y>.>9C]_<0"N.MF.]>AS)U'//(Z<A9J<[T27?*X)QE]HJB2%5_Y
MHY/'6)*?L7"Z,0SRH['%:&S1BRUZL46OZ6#I<'MI<+THWDM!/:N=&RNZ(7&C
M(&4CX?XCT6&$77O WCS?M0X%2CH3&<O[80NP =>+T"=]#CXP^W H*@ ;>4XC
MP9D&KYQ*@C$%6TS!%OTA/ZQ)F8PM)M.Y3<8?DS':9"HQ:1E"9C014M<'29SP
M.IW@OQB0[(Z]0.9,6G,>ROQ5W,;KB!6X;#EM <GBNWCT"H4F!G*O)Z(!6>".
M^#C7I,Q'C_GH,8]$:%Z*<^'C/!K17/PQ%X?.I5)SMM/HR!1GW4=E7V%@_MRQ
M%L7L!;I\'4KO!OIFI!K)0Q*Y%K:.&$0\$5TN:XU@CS788PUZK$&/-<3&&@;\
M-0S^:XB+U4W.#8!FPFT5!:X\3D=(^US^O+3L'XYS439MY/(6U*/IC-N&#U"U
MCJ9<L),80,(1"^)AUI[L0G;+F6SN<;W_7CP1XF,W>NQ!CSUQ"(/,'CJVW70R
MN\V#N3"L.0!U)W&Y@_:Y_4.2UN^TQAP?0]D3*;-SGS3(/)/G(.WP$/T 8B&4
MW0?6GQQ%!N9#?BPG!@3?G"1.3Z'':=K)Z7SG'P9.8XO3!-8I*GGJ6NZ!S)\P
M>W*^U$)P^U%MI'DN,ABEE)=&61$GP:=;<QLX!V5@+N1&UUS(P*MC/XZ<ZT0&
MYD=N\W2>47(7>MQ%$G07\7D7'?]=V.(N@NXN@.Z"]]_Y'/=]K*G4L8>Z#0:S
M_!HIPYR% I;E\C4H9J[E#OUP+HF9E[A\+\[EYY,\/# ?0IS\DAAYDC;[)+%Q
MB;;Z%&WD*6QQ"<=>@LE<>@3YLT93US;J6<6E[)N<ST2V#,R]_'@>9& OSA,N
M8O;D97,BO_[17(C9(V/6A+R!/=ZD_WJ+_O-MXO,=VLB[-+QWJ?P[5.R=)W[$
M_<UZD($S20>>D6OVPS3 SMI=>U'&ZG,R_<]@-I_"J#Z!^7P,X_H(-O0!W.Y]
M&*?YZ_Z[L.NW<<Y?J,#K*/<:G-NL_S!BS@(U^T#N<\T#_/<<B)F+"=:W\+LO
MX1&?P>T^417E-U/V,/CI*,H=IS?0X\_H\1J,Z__H+'[O.-5@/=QU&Z;8#^IQ
ML*['1'>[GHGR%ES^&\2.NWZ8@[CQ1SJ8=1#_Q!8?*1"\4'Z5 %:6_J@2_1:>
M^X(&ZUF8S-/H<<EQ)N@DRIX&PFS<M) P6$'YZPF+'=3^(&X\1?C<C!8_P[4O
MZG8L9_:@W'K9&HP3E^E@Y@#,8X_?D)G6\M7S\*JGL<63<+O'E:M'X%,/JE[W
MP\[N08\+Z'$WK.LN&-\=,,#;X+FWHL=-Z'$C[/@<G<EU^.0L#>H:[CI% )V
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M7H_0M>WU,O,?\#ZY@QL II4Z18 3#TXJ&#E@%(%4H<GP_DGHT:=6HJ(#2_2
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M-83.-MT$<[V1P+T>6US+K\_ N<W<QVDY]Z <=*W!&)A_,=AF#N)YASO=<'$
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M$-N(@\!0# 03HB @$0%QMPC007@9=1Q[+BX(1[U!Z.&,/1,6?,S 1Q?$]\I
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MVJ<1Z"L-09!H "** TL_]J& +@SM"RX#?VM[@]L+/L) 94XOX - KXW8]W#
MY:B5'^Q"$W!UG+TI:. ?3NM_#("<Z%$H1^ 7CD(_#H)R ([E@#U\)@Q4%@35
MMB!XM7D+ZK.(\@\ 60)7L0*?_>"C##YBP: =@ \C^#=E("C_^WLW/S\KW\<)
M^/GQ7_DA^G%FK#_0PQ_<$__M/QZ&?L"A?8'A?/U__&:Q-VB?F#;@B#,H+S"
MM06J'01-5Q5T(9+'@0^< -TM^%""?Z_!G@/[ZRS8<-2?^1#$^S@HW'=U3H/V
M$D']8Y$L G3RIX$M3@/G/@V,> ID$ X"^Y/5(.]QE /(WPA[E ^X3B82M,.H
M'^?!4H'/FIB?@WWL/I.5<R'8LTEPWL'Y^=VEGP'"KW-+$H$>B:"])H)[D@C:
M2"*PQ37@4-= I:]= Y]BP+U#F0(WU0)ER8-R!$ Y+* <:I#_FE]GH/PZ#_;7
MNSB_WKWY]3?.>SBH/W,BO^9#\H%_Y-/_/)L$=&Z%P!:%P D+0*$% "YH0.F
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MYA4^&8$$SG&N=%I'9 $J.%ZM@5B(C<1U>\'7,""-"S# DS6/H*:W!AZC7(,
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MC),(X#XN<!L!0!,M]0@ VK VOAD&0J!J*,* *P2@8< 4 A#!G"8$M,)*R$#
MLC$$[("!FQ"P!0:^&N(":V!@N10*Y^ 5J^7E3!RO1/2D0&K5L0EDM&R"BOI.
M)U;974R0%3+5@7\/Q7SKO3A_"V5>"NQ/5R/D68CJGU5[%$TWE%RY'W*')-ST
MFXBQ/132(L;=*$E< #&[B"*#!KWP% <*!4W5(H8'J)NX@"\".(X+(,(D.'2O
M0 !0@/&!"@84(5/"4YPH/@B FR9B$ .'#RA2",A": D!O1PP, D1YC#0!P%)
M, !ORQ_:"P%05[N\? /JI9#C@R!B' #/Y'W0RDB)5!L)+-\T<O(Y$GTMLZSY
M+]]^)LAO&<6[RMJ:$F0LNX.3:3/E6N2 =#E+'_?Q#;6; =SU3R#BN !BW@Z%
MPM6B$0E "[7PVB(*!2T&ZR( :/'P. *0Q07R$  3+O"2! :((4/M1&0!1=9(
M+2&_]4$ T.LJ5Q$ M)Q4208#V;C 9T0G=06JAB,,P %&"@S ZTW]\#2).00L
MQZ[%!> !X_*(%2X #QB7E^NT< D$L%P/(B4*1BX1I7V'?,ZDXWU'JNL#W#L2
MY+\@(^V-U4\?E=S/OY=]YS:\^>!UZ $E8<XM-.M_]_BX"WM^")]&X>ZQ1.Q>
M0*%\<8M .#U*#1?8AP"VX@)1R#)P%TF>( '<:DQL00#0[ #<*E"H5%S !0%
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M@4!K( M2"$ 45TO$-@TX^(=?54.TB_)M?P,,(H,UR%2(5588.$?\-T Q/PQ
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M%C ;6!# &1Q@ ?$B"?P6QQ$$ $4@=Q!#$&BQN!G1SW'B E^=8( ",M59.IB
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M:XRW/;:/5.#XU4ER("[ 7O.]VY:UML4^_Q2]K?WL[>2%<+Y;_2(T\F;^8P9
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M6UF/@4O,R*O-.CYA^06*@@043T-"@U)"S5L^]MW*<G1 U[]J*DPJ*$SZQ?Y
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MWT)]T[#1PS[S8 )?WLO)HS</"A8Q5[:1J4[$7Q$?XU897D:M>]/U8$F*K7[
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M24<_*_#.ZBICNZF1Y9[_!U!+ P04    " !QB_M64PE1I/UT    Q   $0
M &<T-3$T,CAG,#!Z,#0N:G!G[+P%6%3;]S=^AI"0+D'I#ND01FD0&.DN06)H
M!AB&%FD)43J4[@:E2[H1I1N#$$F5#H$7\.K5>^_WE]__^_S?YV')F7/V6GNM
MS]IKKQWGS'A.QD_> WB0VW*W 1 (">0&<@. D[4KSY0M[!!VCA9V]M2\'%R
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M/H*8O^N='DBB7X _^?CGEZ#O,P\*T7GIK$-1S\MG]0%L^C\"E@J<S3\ Z#T
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M3QO\X\'"/^7UOY\N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y
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M;Y?X+U,Z<H[&@V/<"EE6$&]-\<+)(0(G*^>'3I5VO%N' J^_[ 6,ET^N]AE
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ME3I1+7=5]-+DM]]]^#C6?:E,8)[G"47Q(U-"&JD.%>@PJUQX%C-&J EY.S,
M! 5M 2N)60Q6$(+3/3L#W:O<][C1SS:=AKF&P@138R=M8>Q2W@3^]'E2D6(
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M8>K<;(*DGVM+ZO02L<4V9"LOV#!F .6]14(*FFM+0E'EHK!SF6-%E1W)V(
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ME$Y'HR7R3C-#BYN8W26ME!A,J@_^EPX7S0)1E@GBHLI("7B5@<"HRD=$*#"
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M5'+VTF[M0DKZ9F'>=N#MYB2!KJJ$L9B']-T<#S!,\\'1Z'(*DY-Q_0@*6Z9
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M@[_RJNU2IU^W9*M59N-J>-8GKV>C()41X=H%Z148?J'14X_W?!3+FDEVB#I
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M;R>]TEI68I[)%,A-"N.RI_'E$M/"??SF)A[),Q6N/64?:.7ZE>SV@<=^<%C
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M%UT*6W:S,L']#C.>7[D0V,%>7[7>NZ5?]MT6*QF572<9Z]ZB IA28V6Z\+0
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MLC-#OJMQ)6P]!G/*Y\7EB\O-/7W$] IR1(+%'QAN,!?,5WW?'A]W>(1I&Y)
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MO[C8:RA#L"!4%A<(-_M](F+9$RO4_M0UK7]6F=D'D=PQ=#%+]^SAKY6.I>X
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MP*ACP*\9H$[D LV(#^S>Z4 $I!-O*Z[0?05 /V0^F&N-%!S*)FYSF7J3'O;
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M:?V1LDO.1F"=N,&")9A"PG"Y1#B)*X_ADV0I!U[>MRW O(UZ2@'[J:!>#J(
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MA]N-+++1L5%>;C_OJRS(#S;ONHG=X;HBC6?F?&LKZ.-FM8C!R#8S9?'B^_;
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MPI6,H<#NHX3V+]^^75U':$!,EK2Q-,\,M*869T  P/=GE #,/RY6X 0 $+X
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MN:_1] A09SAWK]2L%2&1T?R()@3S>*]QRDW)2(J/:2*AV0@G220VKSIPRFK
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M,-VT [PDLTSC@.@2*+>GE<JMR=N1Z_$I(<IM8->^I3Z>)9VC+B]M$5@/:G@
M(#$#RWC<4QD$/8E&6JINZB*2<SWFS#M0E]H=/H5$6N-E%K('A"12^SW!HOH$
M>CKRFLV!FNS((,8L=<;W,FM)02&U-X(?KC4L_3L+XYL*W8#YE9V#XM7VB8QV
M>4Y)^I>FFA3=GF%XR7LSY3UQ#'OD&8?$W%S'V4!#S9^<G*06AEQ;,S).[ZG(
M^2^(K;;:%AQVB#D*+.;/6I3?V4X\ )2V4T;HTJ0:!CD85 4=/W1"+IK<QJ*Z
MR4AQ>PN3PE;6B/H%;WR)L$V92"L:LW!;"HZR8Z*;3[Y?$&Y.2/&NP]\N:>7B
M)R@KF<&XT^A+(U=HJ<TVQ/O&P_(,XE^<USJ+7+"W",P!H;*N9S+9]NW7SE#\
MLO$9+P(,\$\OZ\!=_8T;R G##0?"M,=/UZJ-DL&#UN$3T&+38<N2-U#@5"Y=
MY%0U[UR\3+J6FMY>-2B']&2!9@M7N_2>U.#\G#!]'=)*H>)<O6"NS(3CD"KU
MO.Y\!]K6M)#L$)C+;^9D<^4&0X ^*_96G39F& ,*.Z3ALGN?G&OIA5?U0+>]
M.69LNRX8"44ECR@\_DNIY*_#_ESE3Y2BFZ:%H3-7KO<Y7#MF2@,YP@<YW#=^
M!X$--S0F3_3B\\^>A%I_$80O^T2(H)5J3]G^ &B>;P-WJEM6V3+:TVYO^W*8
M;,I9?C*7(*9%3J\5&P44O"*PB^(3D[MHC]EZDIP/%PHW;M[AS]HP:<G)5<B^
M\/TC.H*B(!HG],FK5.*W!G!\*F@*77"<? 7B? H8'X(^\5'QW7%]!\!!$W@F
M?EU<B.1R:+7CA#)?[EUUMD8QF$([LL;FK#9G;(E?^[FWSF*C8=1 %0&15B"[
MDCHRF#0#22 FE_(+7%OL[(0^94;T.D&<% FE/FGBHO($I^D+/]'$\5?'.AG!
M6OX?OR3IV.[H$ '<(X=MO&F\S8"P\PIMFE4+Q?V!%W0OWI)>>)J:7%BKYC8&
M4&B]SC4KN Z*9E1JC?J,[N*'(I>\@507A\2>1E!*S0TS]-X@<U2_*[R^%Q8Q
MKW>DMHPD&6HMQFL@%HOM\+.*#2B@+<>$$Y*W, 4_YPL$RF,1:>I*/GU)G2+0
M@(<GA4E'[MYOH#+#/A.';$A,^J:_FU>TJ#(JS,EW$_4UF]:&4>EL?I'S"]SO
M%]2D&;T\"!F!N7SN=<\T]L-G>"$+%)56#?%ZELF"BEM:TX03^[*A#N<+J6;M
M5HS2QV>%'X^J\V R_<'-HO1ON&VF-^&?F"5_WUJH.+66FML[VG=21U(Y=]DJ
M"N+^L-)$?V"5M&[2,^J$RRWSG">S(T@POW-5SJQO?208>W]D!;T_OYBLTDZ:
M<A.#T:NV:#U+49-H]9GT0AZAH3JI[H<W7'X&^)&< )],DI^L0"&'\94]6_+2
M-+HDT\UFFP;IK@G]V$84M@= F,>.3W.=AI")7AX1!>V0H;S8Z(N YO60'XJ^
MU;T['-/Y ^'FV9%-!H4HDB/R:'-,U'1:F;[52H)1;DPYC185G-4;>Q/R :U!
M"DEF]C107"R,\#/MQ@@6X("XP6XLQ!-L=6',Y2 >&V$VNY(S,*[14SN:##NF
MC!$40B.)ORY$Z_?)U&P;1 @7?*G_0IP:$TY >P:?9PI5I'-LV$:;2\\L15);
M?!M:?1[$XC!)ULK?=WG5BZS>SR.BN*BFYK@0KZXQ64FDE>0-SZ7JM*^66F@7
MRRV405L!DY?T3PUOI.]LN=7YPD&BUVA!PZS9L./!I1G'$SZ&/6#JOS*K8QOR
MJ@4GZ_+S0B VGHL2+1TWG;C9T-MTEL3'HVI;$&S(W\8 IY-6.$6^9594O%/!
M0O<"EX1.PV$= P'E?;86J^J\^*X/Y<6$"JU/L'/V316JC5:<6O;(U<D1 MGC
MT05<L6S$SY1 N:+3*VO[!N.+0O8N?;R,WH?C=1^+;.",K#FXU5=LJO 80MI^
MPS2"2X1:OB>H UNWOL>H6X_I7K!DU[O5;4- VQITLNQ[?4L(NK7AF=B_#8/O
MFMH\<6E][8[R<OY\"V/HZG\K@;P"D$!_H[];RC_3Q1R\<*W;9@D9I*YJI_:\
MR#&R(B+FV@D^W!\.I%T$V&4)X32Z-G271MM(V0GOSX\N'C)*G1;#Q38:K;%[
MHTRPV.>_<9"5X:E.',85:Q_\3ZD]"LITNWM0(OVW5GG\R2,?RR-L;NWA8=A>
M@C4H/@ "JQ+*+BHT33_\*\\[0]2QYD]'E:Z&@\]S9/O>=&@-G2Q,[U/WJ[S)
M-*L.GE(OI!8$O_WJESN1HU?14%XU4:_P[V[;GWIG"&@UT J;!^ZYU.B.3BD]
M_?0UC&FK,,]9KJC]#YY=*U&J4$I\W".3X%$)DWY:^8&5G4I\ #I!DG6 ;/CN
M7>Z!2;\SD5LI3&+P.W^)8"7-.>0$<9LZJ?,!0'1 '=\HQI^OM<TJO+F#/_)4
M(-\1)6,JWQ')H*Y5AZ[H/?7Y$&R_SUI<$75F2LAHCZ!P:W5(Y:#.'2(DFE 3
M[J@4&J&H^%32$=-H>@>O8XUQV,&O^T-$J"0QD'+3[LPSEZH&RQ/6,I_'='*)
M_@;^NZ!0(-\1X(/I\A4W_FY7D%O+)-E@?4MI1:OV"\;A:P!]\ ( 'P OM_?Y
M-UDX3_+QCVL#PBK,I1*+H[/NQGA68])C<S7-W>5^4WKW]L//^Z:S X=FM-,(
MX6O(P2JO5>*)91D2T/O%3_#<W+&[(^0G2U!*K$)^0]%$_Q#;:QMDA%NOB]7;
M10_KQ+(235,:-3G7G8 Z*37K&3.#,WNK]P?@ UN/P%KGT<R3G731+?_3PU$N
M[8+*J5MNSJGJ@U/"9)VUB/1#8&_K_%JZZLFG34@<F*DE/B7MJO5LR_-\-SW#
MC<X;MH#V &C7=BVY3:6]('#/\5@S/YMYR]-*>'#DY0'55'3A6$,6I%$EH]=(
M0O9L;FZZHH[A'$YJ'#8]+\IW?#J^MW)\OHHZ^DKEOJI\6#M7^0'P=K0P@RY)
M[0% :#"[HMXI3U4V]O/>OG(MY$"/-S)Q&>7R#^/^I3UJ# [R,^NU#1'M#+G*
M.=:S86'2I&.[CZ)D>[&]< &N9C'^M10& 8$E= @H9T8CH1J=ZN2E;*H-AGHH
MF!CNE&>U+G+VW$58ET<&8UZ'Z.A6]#H'82$S5;US^($1.)KYUS.YKFA2<77;
MFPZ<S>\242R1VE4G:B?0ZL%T3L,?)F9"/,-SJ-6H:I%F1]]M]N;_*(]4#24N
M+902&+UHB5K%3POCC(-F>9$Q7V0N>%[GH26L_J(]=LG]_> <#3PV14$<_A(=
M5:PHCFA%++D@)X<),?X7TDE!*3D<* )PWW3@,?GX$%[N!L.>,>_R6*K&3+V[
MEQ;JZEOW\R<OO#JI.9?NDG6VQF_[8+/1WX]<5!A<6AFH*(#;KI_2;HVJL6AJ
MF2>\1N]>>3#![^O,6Q>P;1=7[PQ#Q!0QG[MV<;L4*?DI\OV2\\N74P!!HJXW
MF_W)AKS@ Z#IX"QU9,W1;?ITK29&W^2<+E79BL)N(5D!CW+)3#W*RG'D$_,D
M)V*.C1"S'&._KACSJ&10)%^.I#^ 7AD9/-EH5;#5DK,K5,$^2EN$QK0W$$\I
MH3".DHB4Z30>KH<I'54KW,Z>JXN2^SXEK@JS7?;H13"Q+'3\J0 CHTM:64>#
M!.(J5T\EM]P:GA]H:]2.X?(L9Q$8#7+9$1;_M%MBK:8Y!GV!4%@*N]DRS\\*
MM,8OK<J3QI1UG)"53UG+^F5N62FICJ!C$,DD3-&JL0!I757T:ZWL(R@Y7A/K
M$R>&$G-%[ZZ@H7_[=LFMQVMQASHR;7.?,4*HR';\!M=6D8J.I@^6698&1;YM
MF2R[3*AZ +AT%72:5T@Q*@EW"KG[O,P63WV>:2C__45_4@ XVQ#Q^<XSCFC)
M'H9/F+TD\X'C1ZM)>^?B.VY3<H>X%$/*J4-VK>F$5\KWFU>ZY#7)R3%Q-+N<
MSZ*<BKX+GFX_0TJ@YG'WQ:,G@T?T^/YY]]B(_<-:A[_N%0_(7Z5S[0BTT%!1
M8*NG4L$VV9T#?EUU8])SH-(5V]YE]!7+[&4*;N$&R.@ 4Q#I?>+D)S)\\N!<
MBD^<@C;UB+KHL8H KHR%"3'Z6CRF%-(3>?0XIUAZO.P86K*AQ:WT$!AO4#/H
MR[.]C54.<8!<O$+5DYC'D/-$3P/PRXV"6P:@ A!\@>S0:F@J-7"6=<D;;?M<
MNWW&6P9A02C0N-^"UZ8Y1TL[I>D4YG5'7^K^ .#OV5L,3<TROYP3;#QQ*+-&
MR+W=,C\'HL(A8<3&?/J8&0HZE7OO3)4-ZGE!SG>"Z4?\12Y0%H8)W\Y+"V6N
M;C]VD+M1"J$N7I5)TBJKOGMB90RAHYB"/  8G,^\4_LF.K#:4P_]!3=0';4\
M:\0>PZ<;#7UC+%*5?ZRF/,!9O#ACXO,"_'>X<%O&P.\ @"/:-@!N%9I(*?ZS
M6A8V[-S)48%RZ^GO;;<6]@"XF")J-5T82D^[5H82Q-YIW]J,Q49\&N&UKKQN
MF50/L(=\_Z,]<&X^9Y/9\P%@(P+M=1?RR9*<VS/%.C.JKHI9)S=^^[/V6:3Y
MV:34=(C_&7[ =$#S%%SEY@)2\@V31$JH9"B6FUHI%#]!+LB_I5IQ<TR<X9#D
M9.FMNY):RI*5%IO" \#$^1D-> A[3&OW$KFBGSG?_2U^D78=0[D:>,UIR*AM
M=KQN6@G= 1851&U/;DWV_G9O,*^M,%&HESI4=J)+DTRH:%%NM@KP]UT9Y6?W
MAP@'5U6V>9QV$4RS (]%!D+?O%X>7FVVJ7%.'9;4?=4)Z<0+ 9"VM55Z?(?/
M.T\M(.3FEM>[!=[G8JYC1K*.V2"-^M;U,$+PUNG.9KT5?/%/?/)O#4_6_][P
MU,HZ>Q?1V>Y@!W%;(XNS50WL)O&N=2%YJU:%=3X4(T@W1@WH9 AS*Y";J4N"
MFC@_3V,@'">D."0$G9SNQK)Q3)J  J689%]2"7]=4OYKB=!B_+5(]IW#(?#O
M7/6V%HG[F+4+\.7O(H1X(.',WOWYGYKXP.D]FS"O!P#.U%2NVPZ'^YR9J1E;
MFEN=0_:OZB#!0BW<I!)=S7II8Q91>/)]_(*V*:H4Z-NZYVE+VN#%JZ-D>=R8
MTHT6<%:"^S1OLL;?J1%/GLK=<%5/B%O1=Q#9S.'T*4UQ=6UV'NQRR*AV=R0V
MI91B(_L=U @5MU22J7LNI4ZDXH^I!B 6^N%"Q3@[>;Q02.@;5T1A%SXH-H&A
MUS3!^,7<G1,I+E.O&\#:Z8$>1E5)%4^:B@)(>!C*:T?1Y?BS._V2A^_WWVR*
MY6M[7'Q_OGZ \3[(KWM.W-'KA]:DWLNF*@_W8^716)%SQQ&M!5ZK%HL%WPF-
M6]4R_"L&G$WG;N-X[:X35,CJ[E45B7;:P*W4KP3M#8*'I+/N,[+>7(8L\ ;5
MLNUX#+\LK2M#W[3?8HLYF>NY^.ALO!+P[6RKS#YG.R*;DVWR%VEFDWR$IP&$
MK7[;ZNG?36YV2JBH-F*DK:+KX*E59T1"OL6 8%L?GDL6J-JLL6M08;34],$W
M3-5W'1/,/ #$0WH*+8G2,,9:1?>5;Y(9.MJ=.1&&CNXLO,@> ,;O;U"3$%@]
M:NI33YO7+\JX#L$3)UO;7L'I,PM86DX2L>H)BH[#5&B)6PW*PZRMFI?$3,:+
M-84EXYWB6R5XAG4_/^08#I-I<>&;U=&VL7"Q>S37^9[Z3&H1WN7IIK1*]NP-
M@[!B*Q,';BQCZRXUKMT(AYTT;#T'148QN%\L_5.0_#^W?O59/P!Z)<J68R-.
MN>9U&U:;/BFJ@5:+5*]Y<Q'6;O#"=R];9'2&-@.:DTRRULI<([W*EM8>L4[?
M5VMN'MBLN0_JP?FM=NOA,CHDT$OT5O6:PQ15R3%TY-?8;"N5RTTO<"/S!D-B
M[Q5OBZYECDFFR*;F;JI.M87O"$<PO?-_;.)/$K[2E-,L=5V,NO4$GS'>;>K(
M6%M;#Z2;Y2@;U52WFQ8H2=<HR6;K1;W>Z.@?79BT39:K^\#X2EDU9-'2;+AZ
MHOCKJ<1>ZDW*O.BI N1TL-O+>JS%=;3U#M>ZL]--*N*H5GNL[4)6M_XX&36%
MP50Y?HN!AUN[Q?N^3CGW5T*XPQTQR;H1?P ,SUJG;,9ZH+5!6SD>XT+'#WY4
MX!+,BZ'LY+)I9NQ$M(\:2D\>7KOHD=NR!!RZ.<X3WT"A+A$<TS <->2?9[YM
M6?*>@YWVQ56@<0RD*23*QYGI.$/W:&[B\1Y7N*4>^4;ZP.+V8K3RCF@T[_8Q
MG*?Y9GHL&9YY%H.1MM+Y_@")<,?_IZKHZ]YPB.^BX!)J.NR2VVN)XM,5DVW.
M8N*%ZU+GK_L'3@*EFY]RGA'NWJ9Q(SJ-NI=M,0W,=>WO;[;Q<ESE!>5I+YWI
M5.P=?A3!\L"%>"#T_2[8>EL_-Y\UA$Q;MBDLEES=]ITD#0;_7RHKSR=C>WS7
M5&.J]\,1[Q\ UCUK?:(PS^KA*TYC$< 89']K=PIRTT1@G=1EK[:!P3PB?4T%
M82P#@\$'W06"TM A,N7L&@QUI8Z6/)W#^=Y10O^YM:G:3@CDCO$T0NRZ?_),
M=FG;FW7&INL"AO-OC:-TU_(1,U!OX7G+7R3/OZK:FY5^F/I/94DV]ZV0M-H(
M![NL(?>81=D^9I16[ZW;QQP#7NS+2KG(8TYJL-^?)_!NO>(F3,9V"%V=+$.Y
M&W]>KU?%Z,8AI<6^8>I8A3!F''0OP6UV"I=[IZG,=+SWJ[-I!^D!\%MOT]^5
M."INI,!?.JV7/P"N<SX?G4$?  M30NZ>*X3II;^S-)=-Y5>RDPXG='14&U-#
M*[MC96>W2]Z'ETPDR*=--F,K[5EYVNR!ZU>\1W=>WEU?N4#[4T.5FWJ6%S"L
M!FYXF%1%BPS"+20!=NE=]DRKLK!ALHGJ@-Z<U]Y6AJ?)VY["\?Z-B;>6VP6G
MUK=KD2Q/XPO;/X4\%5[KY(Z;5B\OG]E8-Z[U1;!ZU1:+!]R=U^,>'GY+U4H[
M&9O5I,C0+]QB#=N]\VZEL(ZU0DG)48);,)]?O4*U>*3A0EL3K)&05U!(ME.K
MO.&EB_06WU4+84E$9^O>.J'N"=\_R%?Z;7I'ZL4NS-/U&B?S/F([B/HV1LJ<
M 3O)^1_L:ZDS-&O_Q 6!$ZWLZ2((HX7*.&>B^MV*@+16_19UA1<][8N"F8Z-
M_4[";.R*.V/=%(@D9&\X9GY G=(IYOR&S:0PZ9Q01N!J>""<H?[;-;_Q%ZZU
M?S288;G.K L,1F26$37+SAVO/$8WL5^PXV/WOY<]<M ] *Y>.-ZB5]P'NH>R
M:2A_HRZ3NU4T!XJ,0R9ZE[J2(>G>:8>ZD3;(P'P/0E#>VI&G%S=.Y<6)RJ5<
M1]X2+'!B]?I>!CCTE1N38MC[HYK-81]A"%"$CFAGN"+IUPSD&X8=0WW_(Q8"
MA4[UP[^.F#*<>:;8!-GO+V1R'XK>\\Y=)]R??"#W#*(07X3U>/-8YSA$6,,>
M ( !1JOI0)-^_6X()S)/8,<6;&5#(^? <G+ =Y(J$V&$J=+YP-Z69$0>.,;T
M]JI5^FKK,;"=6K9BH$%9@7_@XH"M_X&+#P4\<4=*A&H<[VO'0"6-FX'_A,6(
M]@4@<S7GP_ZPP]"RXU"M)L/.9L5-.\VA[#'X%T4G\4P<G<SS=8ZFU#^X3IVP
M[@;"V1X 2QH!=WG.K%[N4.UL-TWC&_6[%&[4_XE<_[\4K*B9(P/IH6Y?&=1+
MAR,O;>#$,LPC<RP0W#BXQ.=Z7W$E\MW=M8GHR_&!&I67?7W98AM[(DGP$H'[
MV@@0WUO]'PT>-NKI_W<O2BT@WIF'AL-L5DV G83:-5]1H4]QHK ]KKI426=L
M;F[K_C9)W%$Y/CEQV)W)U5?[,6<M!)4YNG29@&L/4=YP[3BAW V&D5QJMO"X
M6VC</@!&'P"BI^G%+3M<=ZB;<_2HAWKT&!QYHXX,%U*M_?_6R(:;#3UV![:&
MI.L.G<875%Y/-Z%-+,$\TI9">JZJ)B&A)S9SV4!&!SMA-G&_U;(6LD)M\<W\
MYRH*KC7&XDHD$K*3ILR.J-:MT10J@9(+:2'VRW7PT*K.!P!9&HL;8,RKM"CQ
MRNF7!W#VW+OWM[I>R;]<RE!/S]"!2)?\-^(2N,R<.[!M__A>H[=-N;6Q_">0
M/>+S%<+Q R#B,R'OR[O@JPMW#0&YY<Z;PU4&ATO@V6.H:O" :)?U?"FM*]V2
M7OT3,-->"0C\!S!S8YOT=D8[<8 D6[KHWEQ*^]=?HR@H]LD>>)HJ+K0$B?UX
M2R9LVC^?H5I=M9(-0WU<\"(L?R9/YB7A$UF>+P<UOVE#WG]H0WZG6[]I0[?<
M%/;?;Y=0)WLNTE.:<_Z 9ZB_P[.F7_#LP"MPN^XN=<1DZ9S:W59I/-BH.B3-
M/?OV-UW(/L.JO]]T-"K-J8^E_MUSJ9U#-LQ :LIH?]R,#1TIZ6$&!JOW=[^;
MWYMNIL"99NJ#9.I.[](9)?;FB:%ZWK3 D]1X/&U[M%,_","Y^W?'^)'@2*G4
MV%V=Q.W-,%E5Y47@TR8[E:B!)0?8[3;:NXE%V3X1XRO&*6Q(D?;KIW11"?(A
M<O3C%Y2!48VW&$NN)W^V3VD1?#C^R V9(=^OCW0+2*NJQSY(%*TU?C\DE-"D
M3SZP)(5&ZR<8:M&!9HM#VC47#%*)&2WJ3"B^!#Z1-%D*DN+9!FM[%73J_U(A
MY*.7'E-9O'8;#>&V<]TO"]RGL(;R 9!98KSY ! 9_W%T";QAP[UH*1M('GI[
ML7[+MM';"V3XPHW/K478O Q]_"'L^>I2LC&9LE%75NZI90.[\V( A@(9(N!;
M*:QV-XQG]+4/SG>O/ .?7EZ%0RCC/+B.158A(P.B;E7%1J&_LFFSJHU@6*_\
MIE#_(?6]XAW%%=IN]&YZIALK\/-VB&8 BC35IEYC!-<H,*+V/A?8-/@BW4Y\
MEGS!H9C!TARDS!Q*690PH@7N4'>":OSH[$A3"O+X:.LB93 FG;4=/\-UP5$7
MM5V0#DT,O5W*\SC)\;YF70KZ=II,N&+1FN=[D-EAO\%*R*XU6L8PK.7FTNH5
MK\SS ,C0?@"\'2F*FXPM.V_4Q*G%6EX^74K9]^I9629"<20:G? #C8RHT10;
M[#H34N4]4A+N>VOKY*U!^9"CD/YS0=MJH;92U21#JL726LOF?5C)1_QKKI?W
M&SVX#X##4@&OL<9D(,]IV2@^S77ZY0H/@N!5R\#.C:K56PCO[W=#,BJ-+C1T
M2+"5<LXXQ9W%T-D#X?CQC>2L;VZJYRAA:WE"(0:G(^45%J-,!<E/(YG] JP,
M)D"19D+1&./)Y<0]?[EJ1/F_1U8O,\&E3@)@Z['+(^%,9GMG'!X_(#UR<=?<
M!$QO^]HQ=$^ Q=*&S'D/VUU]1+GT<-$N1;"M%AX,V%3>C?:_6G%V_D\MPA0B
MM!?@R?K:'+!0OP);(Y6O#R-*0\V<5H_%"EB1'M#54#H'+:TYRJ'Z;'KE58:P
M?GU?7,%$-TB&7B0V.=,R5R?04O8;3 3^!A.[()!FAE_WBTQ[;6*T_KRWK%P)
M.5S]+X$UQUO">"FL[./HXI^= ,TVZW#FXIR8VOS,@DX14A?XS3[3PI'S(F?#
M4BAJS_[^564C&XT?5<E.;)'7YU3 S0QU_M[)))TZ"R-RR=!_L_N?X!QBI\3+
M1ZGA+Q;2KC9T%8E5U.<NJCWA#%=NQ@LY/9=WUJN)73.&>2.PY)2IAL8K?70H
M6VCX5*BGJ-@GR!'4KVFYU.CUQ3_6$GG67F638':CWX$>H0DT.ZNN# 4S^QXS
M1(I6^)L7[RF_@G==IWC5>8;'8TOO;E>BI)-M[C"+%81%DM-ECT9QT*[8Z*1Z
M,E]%YJ#9^D3^#N24_0 HX(5[I++T@MX&2#$3YPPNI2'@9>$@.KI95Q+GZ2G9
MJ7ED,4U_HZ!*!@*\T/6W8R%R--JC)D(FH*^KMI+;(202XJ+]J:220MKYTXAZ
M;-3]FQ79T25L#*Z^[3".S &V/9;[9S<RP(D+>.]LX_</@$HGK8:1"_>^<;>2
MJ9-5/:G7$2:'[UGP26PGSMB0WK]GL WI[Q:8JX=KSMJS0.,7VC.-BC7&[[I2
M$F7'2BC,$%W\-/(,(UOW,XK^ZYHUL2Z/$WSAU?[DVUMI?;<U;].N19!M+HW8
MLI^=TG6-3WFQCT; ^BO_MQ3 U\>D![U?+[.CE+GT&K&^!<6*8C("?#( [3JI
MCED'%[$Z9M6VIFF\KB#XO>0:BCNQ(]1K63N2F_=&#68W.$W##?1+7]%=.WK"
MQ\+-;5LV>DS5V)ZRW.#ZU1 HJDMZ$W/ ZSAUCA=5/QLBE0^V[T+,5J;U*1?4
MR1@\([)*!K%3*7[4B;I/"QK%$83B\D:6-UD;S:EH'PSF-AO,*?^<JIUI+H5@
M#]4$%D<G)@2D9I@6B!!>L2]DM.Y2!  /29P?<U7Q(7!40^8!D!\G>UQ*'''%
MHNB:CK"W=-EZ?BLI;-4>[HSAGM6S4@?[;/EJ1X0KM&K%?5Y;3^B+N9VI.#?'
M8UB'TT;T#SU&Q7!+_A",+?!&"(?Y"_UG"_/[:+V@.UDAFP< =JWWT63)X:#7
MT ,@Y)&[=0YX_^LK$#I?MF9-39T9/ #$&-7/%-]Y%*W=IEX05GFO/@#F8&6V
M=OAI30+[3,O8<970.C/P,U9]=8+AI!DS&;%C>.])#19;)J5<)51T8627DH])
M^6#I%%![(U,FOD"K+!J?/U\A30=T@<IA,2HDFYO!"*;;%EC$X[*CJV)] PX1
MHO5L1 9-[TT.*Y$FVYO75W/94CC/L)G)7(.6"4\SUT7.^2#122U=AVS*0K-W
M/1JI ]-8LQ1U;.3+<P>E*;0^CK7GW?VSX3IS^W3K5TVX81%.*?5E2+X;[)LS
M(KU=-*Q.+WADJPSQ<^=+41;@\ZEP?CI82[>$C9QSH4[$L52VC:NDC15-%MF_
M>A72*3%XR=J,L,&:4!MABF_,B(&;<U./=F)R_N1D2WZ7+J1Z\U!#)-9_,D;"
MZ4="R)?6 V?Y2EF'V5O_\$]^-,IN6+XB'R'O1&@7.1KS!N>*88+RFG,.@X9!
MS5Y1M6MG0LKWM$K>>7DI8=Y_+"I;0WP]=!^N;L*<=1,7/G!P6LW\9RVK%*D3
MP:ZP4)%8[^2H97*K&#Y@!3/M?4@F*90Y7I.87CZ6)982;LA[5*GU.H3A;*A0
M_%XLH,!=>MMK2/O7J/$OSJ,Q(C3]4C-GX5W-+&?[9]J+F)J5/4L6DZ=2+2VW
MWBP:FNU%HY.&JWVB9V]2C+8*_4+J3&JRW ?GMQS4R15UY6:<NR2Q/:<5?LWY
MHS;DY6ZQIU%#W=$:6%;R3 \Z><732.![K"[))52]ZV@4@22Y8JZ,4S]M_M<C
M9?S\U_OBW=ENU*[K5_,Q3SXL?2K@M6M%K9A/^)R7,[K!U]ERX.P'^:M%+V0K
MT5=YA#755%G8.ZVM:>_ZE:4:_3P/NI8\@&[RRM/Q-<&;\18W:-25F+_=Y(EQ
M9#MI\K9AOD%$B[P-C0R!TL<LWR=$1())U7?\6Z4P=7ZJ\# 6D:)DERP3(EX
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MC5#^Q^RA]0I[*<MWZ,]BU2+$%YAG.TW3"#CK%3:!3$7EC%M1'IMR?'N9Q!R
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MOBP_@;FI!#45[E9H8<+/39[#2Z*L %@P>N0:N[.SLIZ2L9,1$[S<Y82K%/\
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M_ZODHG(UY *>LHFX4H9[QM9)4F'+L-!>J4$! ?"S$.NCHT,U7KJB1T)U !?
MKQW)4UC.N)7"((YKD'8I<$ANW+(W00A]GDP<L%VOJ/2&HM<#O7+,Z5S+('>K
M%S-C^(G2%11'HEN"K_VS,:*&$2G1\J$$'M"<98N(?"?&B%5VZN7UIZ/%?5-'
M*QWN\5Q*T(34^X=F-_&AA52;:2*K*()';-NRB P!2/[@)&.MWIG9L T99Z]@
MRYB>D.;S[O5T3-HJ'^<6'7#)\&$#S,2IDH);+V<BPJ>&_$%_?WO_OW-\BJJA
MQ6(3ETVBN8FNCWW7!XDONTO.D9,3$C%NV-R07\9Z:]77?O,J<45\6T"C1RG6
M-)@3$H7A]NEAOAMX.O]K_52/9[<BWQ":C' -#H6H_#@!_^4L,2;OJ@/?XK@,
M[HH;OB+/4-G?8;&:"X0S=6&P<GB); _PJ@:*J;/)B/5W.??=6>+\\A;O5?-0
M:_W3PBW9[;"8O6[@!&Y0PY$0]\+?#E$@PC3Y?K>]3U,.DANM/8I//MJ"M? Z
M8<,KEKU*@&XM.E;H)LK]MT%?1<L74VSR26:\]0HK+7G<EDMAX"O+=RW_*GR6
MZ.@2*PN(B+4UJ[]IO&KEK6KF<R*<Q>>T14S142[1[MQ1B5%QJ],) +,+1C.:
MW\/P,F'2O:%5T\'ANC];[@G3*E'9H77$KBEB=K8)GNPA)@_UT2(%;[\G@,#[
M,^9A*.BE]YO78MPQ>9@V[9,SS3W$-C!']\PU6.85]17]TJ7I#UZ\21QN?#B3
MZ%3"F$P*5]*C^EZ*F&IK0G_%ED!#FL=37?HU5/X),WHYLQ%3DFXFD$>$70!7
MT%B8]M=]2N"!9:EXRWYG]*-'^76Z4QY'W$7-M8D(F4?^$UE9NZ_,H;Z(2>B-
M\";-31@4OY) T*^C&_8.\DD/<9$D2O@Q#B#AS_'UHF!IW%-7KTB!TVF/Z@K?
M;41D _"Y?V-H&[(3MMW7E(!VAB6$=KX<;;P*I^ 5Q,_*Q=RL>)638BVFAG67
M+DS5^!+F\8%0EC]M6TD%K'1VBQ>]N?EO_-O/\ PXRORR"/6BXB&D)Q5B4C_*
MG*)(9ZR,]OU#BAX&U:/8:ZG@B66QBT+!)KS."J>%(D83N)TY;#9X@@9Z7G?Y
M6L5?GV0Y,7+L'V'39+;Y<[Z./-FQAK!SZ760_@ N+B6G:LI<!6<'_R)IE;K-
MH*/P:DH:1X"LDW:8$;MULT3]5 &5T+;SK22S"BF[F:-[9D[ *Q<SAQ6D_LVJ
M_W^&-_Y&^P]02P,$%     @ <8O[5D'/;'O=T@  C"@! !$   !G-#4Q-#(X
M9S Q838V+FIP9^R\!5A4Z]<V/K1T(]V(Q(AT@W1W@X##,'0.,Z08("C=J" @
MW5V2*MU(MT$J*4A(_P>,H^=XWN_W?>_[K^MB;=BSG[6>>]WK64_L/7O/M4_'
M3]\#")3EE>0!2$A(@%C$!CA=HU+7M'&&.;O9.+O0\UZ[#A"25E)#104@A(JG
MT=;BKR* DQK)&(!"Q:) C0P (/ZHD34!!#H@*,@=Y 1RHM<!.=F#H-3(:  4
M'2#?.8[E'$>@+%X$^#A>PU]C XXYR=QA.+>)G-L6SNR(?Z3S$K8+U-8)I@&'
MN<!AB"+:F4[3#:9CX>SL<%Y#R0D&@3C!'7\<GWW*.$#/ROCG6!U;S[,:TK:P
M,\Q?/B%0=9 C1%?.4/<GV3> )M39V4H' H.[:%C8@1%J'( F  IP1FQ6 'J
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MK!#.YQ0N]AG\4W=+\DX!?4Y!9>W/'CDR9#49;E*=!":2CH[$\Z2 BVW;W&Y
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M9OUFS+)PX/?T)K6NSI',ZV.PJ"OP35M#=PQ. 7)#\<J,=FO/)\PJ/>6N1G/
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MRC/*WA^?P]:E."OY#PY<F/L/V>;#%2KU;2"D,=SBL[K<#P_)FZDR75&<NL9
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M<2L.J:E.;(5/+6^5/!=[Q$G494&_Z$U<,:E3!@@D'7U,&!U"@']U.X%OZ];
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MPBG@A/Z#:7=JGW*YQHAO<F/^6GSC_=&&%Y1B#Y9.1BHT;NG;2E^?/)F0*2:
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M'U'B5HJ^7-EVS\(I7_,LE"]?;A"_? VD5L/^E$WON!/N6K @PR(WZO>L.4?
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M%<Z!:^LXEF/23O+6K7LHTJK\D;1$MTIN2;JY.5F6ALEI!FF*SXKB:AH )
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M"S#HM30V!13U[^W*FYEI.,9LH6$+]5Y;/WXF?+3U&@E*BM[)%(<:/.B2S_5
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M2L,_T/N5>33H-$&JDO[L*9#MH%ULU67L].)'Y]A)45I;]3:KF'1P6Q;U.)E
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MQ$41&->+R>6TU9Q+D_O+%6'UJR.!P=K]!U#]W,,/A9&A1\*HZ%%LNAQ"WF<
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M\Y@'$Y/NZPBW::)T:0<Q9AKN!M<=Z@<E"IRFS\!G@ #ZO#N"HY7@(_YQ09J
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M/X?'F$."C%%1)\$N%?J(6?;.L.O)2\<%P^?W6:U0YWX_$9BS'QWB^8/)G<J
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M3)4=C*E\E:X V,G,-)XL<X^LC=79#0#_MC;US:F,MG]$ROA /<_$<3_J%*N
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ME$UG.Y<MN;_5>9W8<GMIKCI0=<P$P^#Y@4]/X@%4RWE:WID=T)5URP .RX*
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MM\V(H"9ZLIWS?BHVZ3W$@9_*O"N<N)7T0>*2E-$DWK/-ZH#?5%HL^@R2\I)
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MOL$#;$?YP4ALBLI'Y[?IP?EC.CS)GZ1E <</=5C7.<VJ6%(8.+L5,?G\14V
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MZ%3ZC+,E7:&,HG?6$^79;6I>#(OT@!K+LE!CC<PB2(NK+H:H-'RKZ-D'HH8
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M $;+M&GVU@*6),/TN*.M2YQJK*-:EUXG"7=>X\P/TCU>?:GQ79=,>C^*D,;
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MAZGS0L)>DDIQ(L@ZUJC<LC_>N_@4.O/*;_?71%IV7U+5K34F1-W&;H3A\H-
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M[FR6UE<U<+F.36^MA()R4:6/RC,NN0[?-&Q-H%I%6\A8O"PS(CZJKO"16.'
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MD [['J=R=LXW^? 5$!\+ <V\B!OLT0UV'S'T)];1FI  5S$$DE.,)"@4X5G
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M!2J*^I298DRU"9=)F+#%+)-@&L25 $X2P9M;,E#$J58EV#NSYO8G)]LP8]3
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M??7[^0A22SC#A /,"0%$*.<E)R,@@@^\G(SC!R1U4D*&$.=+6R&=\AHXZ")
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MVRH!62D E2ER&#CK;FQV_7F KFS!P<^GK[:B-7E'T)QV!!R<_O[;8Z>N>+
M+ALO)OAX_O#1#\O7+3.GZXPO#Q4+A:I6JU8T]BZFV_;\]*HS5R6R_6;EHDQ-
MO3'%>34*Q1W;7GSJK10I%0;H[C=6B-3(,2L/4PPJP&WNNV)@ Y%@2-2 6R=B
MPM$<OW+,Y\_EO$Q+;'EH!P-E$E82"7$K4"$Y2' @)(!YB<N$;#.T!P;%]V>X
M+9N6?D]G)8O$QI+(!4" 5<I4I25<X"24^\@93S*2<A7O$<I.4IY2KB0O 0!^
M5\F+W'[/G<AQ$,#?SR.N^6?+FXAK5^R;/N_F3=%LV]7TN6Y<=JNFMTF%4@[;
M=V(@&YZ"ZF8T\E5*N(4BE-5B 1[+444Z$B6TZ(S>)QK072HI"EI58D,I+X38
MCWDXBRM'LVL81K?2^Q8$>+.=];$Q65CP.:'M56+5V$W3#EP[JE7=!:C7.Y!C
MPYTRK.UF4U'3&BL>S2),]1\ZZ&GF[]>A>13'KN728[4-K(-2L%BQ24A))!)+
M)"4YZ9,FR!<A+DF*E(=F!;EH7)T<VR)SYM:)0O+PXZ,W?;CM#G610J<'[8@6
M0Q.M^F4^F5&G6E2%ON4BC09+49:44VFKESD1:1*9DTL1JC5(+L!RGU2H1I:)
MGS024K<!1F,HG-5G-[DD!R&-@,V84D!@VC'PV#"P\07ZPE4#PSZ'6W3'*<UI
MU;E84]3F:=/K-Q4B!7*_6HT>=;D^+],U24P773'FV=9[\%EL,0J8BT;2B4F)
M"I]M4&)3V3/F*_G(4#DDE*0"% L!;)2P=\2G))4\,/OSU^;? 9,&7'M"=&GI
MZJLYI983]1<B&*Y4E6E1U2VXIE+E/LEU40*7S2)"W"YS>:4NJ;YTMO+09[R9
MEWBA<LG$2"6S;1P+_?.&'^46MEO]=G?X0PM??#C8FNN@M]:"38K%KV]>,67)
MARJ+!CH30+N_.)-ZTRZHU/1[.P_)CWFS'KU2C%Q@5I1G1I<A":A(<*":M*T+
M!.)"@057(";)20;E.$ '.U@1$Y#(9W&[@@YO=R^>>FWFAA>#W\HQX9;@N*U=
M/])8E9=KPJU&INIME6GI;?,M=/K-)FVU4YUFZ@W#29%_:5HK-$J4ZF3E+D6)
M42Q(==<1^CCSN-Q^*HZ@(,[&E0(/=$SB@J!"@Z9?^', 4 4F8G0%AE" *#A*
MDZOD%9$6>XL3D=<R&,=1_P F+^3\NSPSOW#K)K6Q A:JW30%VG0K/IU2A5A%
MCVI)GP*K6$UFKTUV51YUQU^ITBD(=10YE1IU'I=+2W&K,Y^MU"- QJJH[]0
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MO_A/N1B&B#R&7+?FT]NG18;4B94:A3H$>1-9R)7%E*6D34(1++E2DE2B&22
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MH8) +C-FS.3OO9S'.7\I0U6+KN/36QZ$FH5$4>AUF\*^Q"@394>W(4FH0Z1
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M2+#,:_NP#_7G!EMM1R, =$E).#D;Y QT'+@Y)P3CN!PIN1M<VN,PV?EY&T-
ME2X5*A2ZE49#,2GPHSTF9)D+#;4>-'1YS[KBM^5"&D*.1OC.#D <8]94T]'3
M3ZRKG(IZ:DDS*BHJ)IPRY4F4@KF+4K,)2D$E@3:P)(=)BDH0I:E!"$)*UK+
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MV),+ ;"$E*>5#8;*0GZJ0E(!2@ #'ZH"!L 0G) '&Z"@$I2@ %+!*4@ !(!
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M1-(I*!-5,6H8OX6!(2"0^(K(47L0D6!!)#I=Y:PL.4D"X;$'=K'\OY0<\GN
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M#"&U?POU8'8LQ;8VC0MI2,[[D*!(.#@[>]@8.?G^._$NY!-VZ> Z1+$%[%K
MDWNW+/,"XS@DMLISMD;_ !P.Y^(^XC;/$L"?=>U_VB7NS'[P74G<J[?9@8QU
M]1W)W(SZ#ATJR!SWT/CO?T8@C:QOEFQ?(=<AEFS&\:%-Y)Y@<#<A*0"!L,CM
MDG).V-R>AQP_3S@"K:;"^9^QYW=QF(3W4$'/7/XC&/0X 'Q].W +-I=[![[M
MUS\X:"BT[%)SCJDX!WV[_(8QZ>FW%H+^\-O>&XT/V^#YQ4I+$#<V+FPV\_6B
M>ZC!((QU^P^G]=CP^?.$@BM.?Q!'WD[_ (?=Q4H82XZ@Y_%[6^6;Q"@XYB_C
MI;X_:+ V.,6M2AZ)E_;_ &^5OQJZ@DSEDY^[_2F,R3_"1T/S,.OBB+89]_#-
MHU@>J(8__J$3C(I?^(E_[_Z%15._A+Z#YB*X-)!P.Y&VV>HW^[J#Z#C<J]T7
M+9C73;=R^F8M&N (-[ ,][,_U-^ND*3:0 ,=ML>F,8^?KGX\4)#GS/3TVNOP
MM2&#G,W/CIO86;K!YILJ]T8Z$G?'3L,]]L#U].+C8&)A1"2-B .;WSCI@^@[
M ;@#&W"8@Q4^I2-L_6VUS<N$DMH&-_(CQ^Y&P,MH!.3L!\.WJ?A^\\5.27//
M7G^GAE%L*+:,C!&$E05RCN0".O4X!4,DC .W<\'KUZTA5%KZL6\G/R^6L'$H
M(3ON"<G?;(. <==LCMU(SD;%%&]AH0^6[A\K-\\C$!B7/@"SW&9ZA[-< &-P
M9.,D$;9 QC '7.<9QM]7L1G!V"C"_O'(EWUV)SYO?;Q;$/6N1MOGEG!Q#1(P
M <=<?AD?9@'MC[>%)=K :6'4P'[9Y?J[@9MU8B-P"4D)&%$[8!W'KD[8Q@?C
ML.O$0MW899$Y\FLS9 EF8WC=R%6Q.Q_53@  >]DG .-B#@Y[[;\02W3H3\O#
MT8G#G<W+Z;O:T0+XJ+VEZ9>&'Q$ZA4V6]3JG9&A^JET4B;&=6S*8K5$L>N3Z
M.J(\V4K:F*J;$1$5Q"TK3)4T4J21GADI*EI2,U*2D#;$0';7>_,/>&!PL<\+
M&X!RW!!!Y@@@Z@QXK;8_*$>."RXZ6Z!XHM8'E,H 95=%RIU!=/)NA"CJ-%NM
MIS) !+S:P0<*RG;CE*N&T:G_ ,%CNE<P>6(CRC$[Y?\ FM_I'KP!:/7?X"]0
M+LO3PN6!JCJIXCZ7X@:[?\3Z>?NV':5GV'2[=?Y$0ZCI\Q1;7H5NNR:I:%6C
M3Z3<$VKTZ+595:CS5?1-'C(8IS/%I^&7-F)P&4$J($M:BI26LV,L"2'-K7L6
MO&6'(#7MF 6-S< N1MX19N?J=;\=2A%1,J"^Q9:#+)/]^2IMP#Y,J'ID<4&<
MD?EO<Z$>N9\MG"#R$(*M6"HD,4!2^N"JH[YVZH1 5\<@+]/EPG?JT2#\8G!_
MS>6GQC$ZJ31A2K; 2!O_ &YX9^/,8&V?E\L<3WJO\A\_J#^]XC /\P]>,9IU
M;0 ?-M]:,['DJ25CXX"X#9Z=/>"LG&PX!/W!\#=WUR!#<ATB>[Y^7ZPHQ]5J
M$X0F3!J4;/500P\A/Q/*\E9'KAO/[N&[])T(\'MX'/PB"@Z'PW^(^L.6%>EK
M5#E#=6CM+.P1+\R&02.G/(2VUGY.'O@GAQ,1H1O\7/QW\84I4-#Y0YDD.(2X
MRM#C:P5I4E8<0L8 !2M)4%)V!!22,'<D' 8%_6FAY>.MH1F<N;W;1_F!],WC
MX4A>Q'(0,X)&,8[*&W8]COC(XGI\OH6B>MF?Z:Z=#KT@LXS@GL"3COMZ$X'-
ML.OW\2E1 R%\W&WC]X@ C6Y-BVV0.3EGOZ)-;8&Z3D'J.N/PW!WQWVSTWXG,
M." 1=@&;Q\^6D2"_IQZ=^N8@NMOH/4 @@YQG!'3/3IZIP<YX=*GL6?+K]/H7
MB"&N-/1VYN^>C&\%7$>[VZX(P<@^]C!/PR5;[G V X?UZ^$ +^>S'+QUMN+P
MGN-X)]#_ !Z'IV[>F<8SP M>V8+]'S+Y'(PV<%5H*@4X!*02-MSD].+0190R
M)ODPY_*^HSNT4D,2#X=/0;2[-9X37$8R.XW'R_GM]_#\MX6!!0#4('QG12!Z
M8?;.?O[>AXQE^Z%<@?&Q/A;K WO)(SQ!^A-^K9_&"%11FJ5,8ZU"=]YE.?B.
M+T_PP0;X S'_ );_ $;QBM=EFW\Q/1E$G(.Q#%R#;>,VT@8P#L,)_=]_[]^*
MTN3\WU 9Q\OVADY/J;GZ#?+ZPHMH01@ Y^8QG/<8SC&W7L2>PXN]9>N?QAH4
M$[@@Y(!!SL?>SC/0'!&<CIZ[@<5'W?>)8J!L;-8G/<6;(FV46( <_:V_CI]'
ML8.-(&"2,YQ@D[ \P^_([;??CBL AK]==&;Z_O%D'VV\9.PZ*/3/O8V&>^_7
M(VR.P!"1X7?PS?[?K"DNP!;XA\_B-21RW<'$ # "<G?8[  =\YWSOG([8][)
M'%;XC?[ <WWRMJ6<Z 9AGLY_30"W0/EG!I"<)P$_6.22!S8W&QS@)WZ8R3C;
MB"HY Y/<'-SZU,06_,<M!KGF+[M?;XP:2@-[GWE')Y0-]SZ=AGL/MZ'A8![M
MBZO EATT'S\(V\A5]8D#?W!L,'H#C!/QSWSC;?@AF??-VM\",CYGG&Y*/=R-
M@/AV^ WSCIG8>I&=H)8A]==/&)C-*"H%6.AWS]N"4@';UWSU(X4J+@6+A]1\
M#K\+Y01Y7ORB'Y/3Q+:O:Z>+WQ3TBDTQBUZ?7[$1I_9#\CVR_-5Z#:VEMB6O
M=57LVE0G7/9V:#)HDQ^GTRI)16+M5&J$6@P%O)HJK@VU%Q*52HE2)@8*6LS9
MEV1B+)(#$J&14=!D^453)*EDE)<@6%]G(Y%W W.;"YXU:"Z\ZD^&_4VW=7M)
M:\Y1;HH@=CNME;BJ3<MO3U,*K%J7)$;4CZ0MZMMQXYDL$ID0IT6FUZDOP:_1
MJ14H6[J:>762<"CF,4N8EB4DBRDG4$6(R4#T(H0LRU>2@?M>XZ1[*_"GK-9?
MC%TKI.KMJW X"\ZNDW9:\N4*A<EDW5%99<J5MUU2BA*'&D/L3:7.0U[-6J)+
MIM8B(0Q-0VWQ!=#-ES%(G* 4DL0'42,PH$L&4+@WZ."V89X88$V.I9AR8$Y'
M._S!BU;%AT%I(#B),E7=3LA2<_\ 5CAG'RSPPI961)+:E3 MLV\)WRWT;8#Z
MEX."SK= (^CTG/<ORB1][Y_KUXL_#2LF1_U*^;O$=ZNUS;_3_P#Y^;QI59-O
M+ZPE)S^Q*E#\%.*!X0TTIV )Z*)B3-5HH]"$_1H(2-/J&L$MN3F#N1R.MK _
M[;*B!\U?'A32R]"H7W?PN(E,U9/\IZL,_$.WJ]X2'=/I<5?GTBLJ;=&[96EU
MA8(WVDQE*4#D;8:&/4[GBLTI'Y%_$-YC[0XG/92>MQX6+?/3G&*:W?ULDJF*
M<J$-&>94K^WM$#KF4VH2F=M@77$@?LD;<(H3I>8Q#E<>+-S^ND,#+7E8D6&1
M\-#X/#TH>I%&JBDL5)'T3+40$J<7YD)Q6_U9("2UV]U]*$[A(<5PR)J56/NG
MR)Z_?XQ!01E?Y^(^WE$AE?, O*7&U@*2X@YRDC(4"G*2/0@X(QOUXMBLN+,3
M^^_+FUM;7+2$I;;6]A:TH0IPI;25J6$)4<(;2,K61S<B #S%7*G.W! V3WN=
M6>^;6?++)G9XYX6+XN;IBZ0:=>(_6=FR*3HWK'+IRZ$U9U-K":QI'3Z]$N*;
M;SNIEQ5FZ)M/NCVYVFT.U:A+MVVK9-)O.OQ*>:;.IY=J,?.F4Z539DF5B,V6
M^+$1_BJ3A"N[ #A Q[] 0Z0/>4'4ITI))!($*%V"E, =G]T:.7Z#(.3:P@I;
MOC=N.K5FMTN=X?KTARI]TZ1V;IM0TW'8;->KER:J:1,:O"B7.N;=+-+MR11;
M;8KE1F3%27X:68#-,07:X^(/#FF"4I)G(+)FJF*:8R4RYIE8DLAU8E%( L;N
M63>(*KE@7=+!Q<D/>]BPW;+5C&J@>/RRKPG6\Q;^FNHGT+7I.FU&G73.-FLT
M^T[FU;8N*/9M$K%*1=:ZY4G1<%L56B5B9;\*J4J&&$5!JH2H+[#S@:5:0HJ6
M@%/>,/>=0EL5*3[K,R@0"0HW# AHGO 68$NU[!BK\HSU(8Z"&3IOX_(50MG1
MNG7?8UQ73J!?NA5)U&J2=,TVU6E3[T1H3)URJ=I4VS(US2KEI%0K=OTNILVK
M3JXU$FU*H.4UF.P[1JC"KTAS2E*II0M*4)FF6.]*A[G>]UB*B,)2E13B*20
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MY&JFJ5,U"T\T'T1=O@6'J[9]QWOI_>^J%"O^HZ@V3;E@)U*:U/C7"UK)*9U
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MN_AQ@3@Z%'_E4/(MTO;QO#)S'4?.$^>D_2U2]!/FGU&3)=Q_''RX'(1+ LZ
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M>+*@"D$XB3H^V7A][1[>K>HD.VJ!0K<IY>5!M^CTRB0E2%AQ]42E0F($8O.
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M)7\-/C_48<W%$60TK[&;4JW]R(?NGQ3Q?2G#/EEG;%;?W517-_AJ\/ZA$ -
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MC<I1."1,E352Y-6?Y2*2?[QF@*!I)L\H!QI,</X;4KX=7*DSG1+4ON9X.25
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M-16F Q^;E:MSZ=1'KDJ>41>WT5.% 1@#E*DE6(@@XRN4O\K8I2E+:_O)5AL
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M?]E:&ZQ\BOCS$FMQ'+'F T;4W^+O]L3IW^,WD!$W9SQVWT@^6IV )D/>-%^
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MJV"HBV+A &0 6@!Y !#UXCT#_JZL!8?!;&Y!D*[.-ZUN@U%L E0W. "&>MD
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M1@@(AO"">'D%(38@'N$SH+\:^P>0BA,""7(Z_4U0$L7@M$>!\(D(@05M;"!
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M.G5$HGX^E=RG=#:<Z3/M?-.G?9*(\>.U7ZK#WLRNK&:*YOT%WXF8B<F2M84
M>M3 (X9[+QP7[S[]?*4YV?;(VM.VZ>.!R^32+WDDE]SM+GEP+.MA*(;'5+>V
M8WDXOJ82E+;E>7-K)6).H57*1LR_QK]8I/WSGOO>'TG4V85*(N^$L>H)V[(4
MK\3E7>UO7UG %?0!(IIK;R=HM]>Z3*-'V:KK=VER2D9-96OA"0E57%8\(J)
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MIP&KC@BPWV#EOH'^@ >;+ $GAAB?H%5M48'RX/;PU N>2[=FIQ0HH-VZ^/S
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MEP$)OB6%7RT:WREC&'OD>?6YD0Y[LPFC,RC1X7:@<]8PM @$+X,<3D"N)ZK
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MW0&B,>ZQ)N(>Q5*YOG"&"2$F?LPKMC=AZG+)MNNV5&L1::E^XT<IC;UKT_3
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M53TBGL01 7]HOQJ?U\/!=!--0<OUFKAV;-">:F^B81(W09ZYLA$SM3V:UKR
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M)C-40J.(3=.TOC%+(.$E(:9,BDZHDP'KI$\G,4NH9HGUS:$C*' $/Y1_<JL
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MFW[A%@G$U9[ X@XQ3_I*F> .VYH@/W3C#O&X742:1+:;$'5I/G55_^LF?P#
M[CG#>_YW<-:5?\7C)<FJ.X&]?4<W??0NMG_.V\1?2KN._VXM_@-HW5D>AGUG
MR:>[(KO[+<?U8F<S2&#DG:CLS<?J4M#=M(^[PQ#>$&M,LF/D58JM!8FZ7W7Y
M_^"!;SK4L4SNU?'O;Q=NFOA([X?\+GPECS@OUP6P=]\>+N_\64DZ8S:&5V/^
M/P!O4_9>HM]>-/Z2_=;I*^7W?.7_6/O+]\K\#9;Q6N:5ZA^U?;@+?3+;?OYC
MJG^3ANM'LC0^_C9=3_SQ,N+S+RZ'Q90G7>*C/F[>OQ3?;0_\>+E(D12H-E#6
M?.K(= P1Z!S2Q_GWSH0GD;N['_?\1.U.Y[;V6?X)CS[R1[!_4^+5FSOA]6$/
MM?,/@,K F_A?/GKUEKKQ/EQYO^7-P:/*\A_ _&WF.V!?,K_.K/\ SOG'H7X5
MW7,[_^Q[-7V+N6C^ZTW^=V]V@;M]'[I?5AX,_AU0YI5Q.6CCP9_?8$GAT/#E
M(D?2H-I"V:#KQ>#-]J\T[7^3*N%)(;W&.POV2.9I]&5"A>1=D:^1)KK.&LJ<
M[[H/$5SY,4>_OS(MP_^2HNNMU,<_ZIG$_%\)\@= 2V.@3=A&@OW7G,%/=ZZ4
M!W\ J]%,;Y<W+#<O?O_)$0%PW^.W=Z,-F0B\=C</!OU;"<G7[HM_.?-_:G8#
MY\^OGW1"N=R<XA&;1?>$^N1P0I%#0R0\RR61<<[1Q9,^S)*XM*1*>S9T85;2
M7906PE2<3VW65,-8BRVY=3IB>VI+8<=@%J1E&-]E$V7.^H5?;_>KNF!>&F0(
MOI:F6NN'L8@:MZ[77P_7C@-GY W?*F>,P6Y?55P"LJ+7]USXF:\<X/25"O?B
M/:;C."]!?N@1M]B;,N.VR)>M&A'2,'!O%#_]-@R\[QG][G/<[N->N^ON]+<8
M#=:L'W)20$YJUYO$5=4B,.4%&FHN-OW(1J5:]HVT.$L5:GNI,5.C_=M=W(,)
MOWS[;X<$@@5XWTBNW4[\'@4&!9;]^X;\6_MW_#1[GS1?NW@$>*A1_'?"J5>?
M),[N_P .%"Z/>N]'WVC?VM^P(?H#3IC/_(-P-I\O-9;?LVAT,.?!>/2UX/;%
M_[+XSM/?N]D?=IOL%?75_P4$&?IUSF3I%?4/H+O8UZ?E/2[J^4#"^)O([=/;
M^^Z#FZ>N^Q^_?*_]O_N_/W6A01M_ &^U#_'=MUH/ES "<0FA) RU9H]NKT#V
M:8?>[<3W-BIG-^>L>^?'/2=QW?WVCZ&WK27:QU6:;G-0]YJ(0??-Y9B^O\9T
M]^KU<-I_ &-^>?H#0-Q[0QU>V>VBNSK[OO>(Q^EO#LIZZSXDJ<YQ2/$_+#Y:
M/YVV?T/M4KA2N-W^59-]A)(YKS,S._<'</'Z>1G&_QV)P*_!A&>)L_<62"/G
M1N7R^CU_?/X#QY"0O[N?Q/ZK_X7[C^%KEB][;[CQOJEO1D^/)EW^[^R]%_V8
MHQ_/^[]&[U\^OS VE\.V]MRF7B[7GK_W..47C09G+U%<:Z TJBR;AD5F6)0Y
M5_Q?^VOE::E!\:05A0;1&CWQQ$PAV$R'4B@#?5RB_81MP[QM/W-\C"\GAG+A
M8+,Z\8$&=#U 1.*\G>![7C7G*$V@Y4K<W%#;I8#U8.B1Z<[[VV<.S/:_)JG>
MFQ)(STGQ[]QY%W[@?0[Y ^C[?+Z^_NU>H+B;J-N#G]1;9_F"<T3H)4IJC\$P
MT[YQ#:6PH2=V5I>0BY<^#:T>>&![#A&3S(XYFK+?SX($'@0&FN8[\<\>>OJ^
M#QU0@4[&@P&>2X+L+I[J#,%??W OX6R\EF?;.(P0;0K0^\<L[SJ0/*YR>KN]
MZ6KYO-3GM(1T/GL>W<X_OW;#!C_O_P%@_@'H_0&@PO_T:#]\T:W5V^ZZA;SH
M?5R5[#(8#Z=V6!-0:.X^*WQ\?SAS@BX37E1>W5] Q$>H(10K.3A'ONU-O?^)
MSJ\Y?$)2_3C_=IGRWXVT.S_>N]\_ )'N]NOG]B[Y#,.7\TR!>FR%"Y+JU5M_
M=@'&;/_.[>;_[J=^SPF%4]>N9GE>_F'8(]/=Z1=FTW<W;0D8#!YEJUP>W RO
MYL!N4S_D/%T^>/!-D2#Y*Z+FM3\1_$7QUY,&SR,V.3DIRV.>EX^^K?\U>G#0
MQM6O[M-A=^FBGR=[!EBF[S,VA7(OWDR#S%*[Z/GP0A2L<74HM?Z7)VS>/BPP
M#/S8KSAB<#CO[G15O$VX>+8E\#8_P9<#-=$H)"$!"K_&K$:2 X3;WO6WC[WT
MV3-4.\:9:SMM'Q(@&1GMCWDPECJ(7OGK1O\+A?.+F-Y(#_YW\8?E3Y[O_@!.
M[/F9N]U0G8,U.-]R[][<PP6L"V[J'/TFM/P,*ORR#01 _NR,O4<WT[;NCW_/
M_5,M>G]^6=_V\KLYN7CVU<EYMP;K2W2%KL0$H<+8PVF?1.L>BESN-6//37]Z
M57_FW"=KT(K*%6J;4BLD4A=.P+5%:TJ<;Y/%O=6K@EF#BJ?05(AFQ[("!Q?%
MXE3;4J%]J_'ISPH/ S_"-$!5S"2U"+UZ $,JNY<J0]O7ZSV'3K."@V8DCSTO
M+W[[!L<-K"E]_*6@XBV1C"B'=B<9*+C\G6$D8FB?O28H5?4$H@&3;_TG<S&&
M%EI69HK& 92T?NIR^1\4+SY(:F-$I<9DD(!8\0)@N #.*Z0G"ZHLI5"SC4S&
MZD%)$.?B:P1*D$+4RIJG=,<8B A04=9Z#MFQ78EGR=Y)ZPRK=7Y#[09TO[Q?
M;5V1/U&I>/1;R&'D<\U_]U5#)(!6OZP)9<T7E&WA+#LUQFYM $^M29&@3'*#
MO=1469WZDISR#N80H5'.L>;Z1KQ@;%2MJ[0]OIK7FS+DV[E:Z9!B%RJ/+4C?
MS^3W'0W#7+MK4[4<R,"2*^JMT5I[3!V9Y99GEROF)3C45[HV;/!GQQ FRX&4
M,D9YG<'R7'CN0)B$8VJR'*PO+-C5N+TP>;R>I+4@)VAG<E"HR@B6]/,-'\/W
M:/D)W?R-D5X3TT!S\?25NA6$03&Z4]([MOCE-;UU33V0C5%-X_&\7\7#:N#/
MCZ?6,F)Y6W7K5:1.<.<F^V.;27A)]FR&"Q:$W^?9-5Q-XJXK W]CJ>=U"L;5
M:K"K^=+6YQ>>;[E.>8)SIY/A N.0U,;,[)P"1$VT.P=**V^C9T#BQ7-PHJ52
M9""[,)L%N$*JE5DH+FM\2P1 +",2"5'4"8QHX=T"W26#"LXJ%_&!<V#IU!T4
M[\)IBN[WY?E%CC01/9>6Z\7>,_8I2Z<;:MHU1TC# ;DO,Z>#ZDH+ ' [TC4Q
M\42^>/C84)@!0Q&T&VVJ)Y F-C^PSLE81J64-GW4,%+?0W_$M9D*3"Z.6,8.
MP#B7I)]P;B%K B!SQ^?=?EUJM$FXV-!Q%?9&[%0(S0S5*:/?RXU<C^4RZ\HO
MVKV/EJJ 668O.^-8$OU4V6RD!3L<.(K92)I0X=8XW>@YNI\-3.: (#;4B@0[
M[2IJJ^FY5O:(JPISA5H RQG09%AJQ;''0D)RY*9&O>1[;LU78?-Y!".!C&[1
MC6W88N.-:P]+V!L"E?.1L;\N*;4BE9Q 62E7J"CJ]G*VY^>3VPZRZIN+<NM0
M2G&::7:!4\L)763DZR)MM)%9&/OUDQ\YDE+!DVPV5AIL%_BYBAU]6 N?;>MR
MPP*53"%PQP&&GX5R*9AA'?%I03)$I'4),SK8[>9Z*BBWQJ>TS<Q7/ALN@^<5
M%WILO][4/_-7DP?W2EB?XD2EN-)[T 6;T7H%+W.GX-15K:B2UO3(F'K_.,@O
M,XG*H&?(9] R2DG%3F!G+S$<.!Z7=IJ]P5XI&,/3BCTQ$HU;)5<V96B3V@*2
M#R+OZYN@6<+ BT*V< !X(C_#<['.)7]O:C^AQD9UJ!4H+\Q94@^*ZIVK]G!4
MW8617:R+T'F -"[5L"MFAF8EE!V,BV0I46KBYYL?!D:1()ISF]%@K=C/$2F5
MRT+@$)TYCI(J*K)KPOR:68V%+C%6)0J, @ECH-K:HM1Z9X<6&@D,L#M(JLE/
M#UOIH[K7D&,^.6<%M*Z)$.>G+,"609SWK]N[EDLEWRM-G%?A9QX@)>JIVQ;.
M4$.%!9T:_L!*>_"NJ"C$*NVA"571&CN9)2 5.[\Y#@Q9=H.("F,%E' (YKLR
M5?]:7D,NN1QO1ZY=L:L+>5B?8^[F6CW/F]>/TBM1GZJDQ@XMI)Q$Q%IWC0"7
MGC>E8W)X*XN_)(R6*B,N&"5Y<!'GIRGWG94N][1K5@ KZQIA4?;S4_#3@I@3
M4@GKJARD1_-PQ=!-DI''W(SQHN)S2^1-=-"*0GH^@)68XL=M$9D(UQ:@T0"8
M<L7X3NZ%?NS4 Y]Q+EOCU3QVY=:B,R)[TKMK05#1,XI2?K2.2X-^-"SYW/UH
MIDQEY-^\,507+A!5#.IT]<EWM$.[WG2#Y,9$;%W6E:TBT81_$H6+6Y"E*;&;
ME[O\U.L1E(ABR$=T :X"-!$DH8N*)60]F1,[Q>5&5GF:.GYDP%.0<RA6H'_;
MY/LBI N&EG43RR%M%&QMB)8.("/E[ VT*^_9I?-!/3M,MA7GW4XQ"/BL;1O#
MF9-H($E4#TLW"H@#+STD8PRGE5?5ZEEZ;W@UK/)EFW=6S';(OG<'5QRH,$C$
M2+B\N$P>3(:_#'M_] ;U!L$&P?R/96,LU]<%!6J7SOD">=5=.J#&<R0./KNW
MH%Q5:T.)9-QK@)$MM@3\G*8U,);[%C^19>.C;27#5I^7TI0#U,<+PB$D<92<
MMJ=3G?B*ES7H%'!$N=G+ERC(I*2Q4Y)6N4<&V7H==/NF^VR7]F5+Y]8&U?+1
MQW 6Z\:>A')V>NO3>3E;I,&H9Q'$J]>N' WIVUWE%<_F)"[WPFSBH^CDTI^H
M1N/'+>-QD%4<@7$9QME\7>I[=3)5?:OV\+2M-0Q1@7'3H1S*PW.\-6/G.0SO
MC0BT6@QJ]<7.,].ZH]AXU1UAZ? /)U3"%:RK5GMM"7\;(\C 8#PG/CIU89Q8
M8&*T9HWFM4_3B(W1<&ZXID3-P<=+I1X.().)?\2S?_E1G]'" 0^J:M)9<&\*
M]D+JICIB4NW2693S\.Z<K*(TU)=D6YBQPW;WM2VLGA H::ZJ?*%&T<\ZEL I
M_FAAJZ!S9D_EYEL!ESSAG4X^(IBUYFQKFDAQFO2DE [>NA-MC9%/MYO/NGTU
M:9@*MJ3D09O90Y_$T+$Z<B@&92F8_#6J+RX>KAC^3[K]_R\/I5YD[BPQ4KK2
MC_(*S%M0?4KT,EEOFOA16[''/%#Q/;:1EL+@J];LE:%3DHAZ@+F)D;G(1SC>
M%@IK\S))5-DTX.1H:CQOQ7BAR 594-UQKZ[3(E<;9MV)N2'!8#D12$N? $:<
M<,KO U(YFAXLJY,-4N\MJ(AI4"F"(0#028H_9$9#G$)6Q\GAYEJ4NE#MQKQH
M^(8&J3>PD%\;8@1WF-7U/$Y5_#6KET;H54TR9EVKBZ%'LU#S=6%%3A2FB D7
M,JFK? (:&6$U\#>?6Y/4?8>.*N_@NN4A7K(, ,$\LB* N=[&U<1ZA<8 [T0-
MW[Q 76D)UP:EYQS1W?[!6RABP!/.Y(=^(BD$'9'D4#US9#/R3<M6[<PITE;;
MK*'6P6Y W<%UB?HSRS@;9?E2D&#]TL^2)PZX/A&2A/LJGX$ -'M@!*O@O<JL
M'7\^_&W$VEGTSN_\&$M[1HKXRD)J%NM1D4+O+UX9;AE['AR#3M(/?<P2G'A+
M4L9D%=-#G^U$MS29B0_$"%G,"/CKU.V@XC!XK(TUB&RMQ %?&PD6W/M9;7K2
M29VBKR8@&BA81FZU)2V@ M=7Y@!\^PZA7Z2;];^TU:=;T)#SD46L0JJ+(<M$
M)\8F]E.2UA*EGQEM_-Q/XCYGR?VP:3UC'JJ%:,T#?U5UK:>9D49K.X^[0JP,
MHBE$R1/;.*O!45S5724P#I*+918O3Z2EJ3*-8JN(.46 HQCXR6TKSEX^XFOG
MZBWN.\KK(T$OBD-]Q>JHR9O+4N#H3'U)QY(K:/M4YJVK:N81WY/=#Y$@AU$[
M805#-H 8OPL?P@.C>V@G;\WIC.",)[&PZM,3JCK+! 72#0MB1E@;A'964[<A
M(N2E)Z,SL^!2=EKMP7)&GTQ5"Y2A&1)+NE4TL\[OSSMI0H]W/5E&'RNOU+HF
MK^)9?)"H5R7SL9.T5/$Z_?;TV?!FY121-[S;;7'1.%EW/ ]T-_X;OT4VC8-F
M_6CUFORP0\L\U484W1DXWZP&,8;\-)(;?>61U*(!*V\93>M,1:Z4*7LE4=54
M1.UD?>RS*++G+VFA:DE7B+&=3/"YKF_AU0V?>UGA=*]'I@J=G%#M1VRJ^=2M
M.?^5J Y6A/2"DR9L@,E$+1X4Z%Z&J<9:BRI9^"<H,CZ@;2J^]AL&\22D]>>7
M(C[BCH^D-UAH0$>0M SK$3SC.-)=[X!)HPND>M;(NK<%<=Q659G&<Y1L1#B*
MB;8Y9M%*EP"8,Q(;Z5>V&IX/)7<+Y#P9XS8"NKP*_"6U J?2.=)@F*)SK4>1
M$^]^JU5J+ 3ZB D4O$LYR#9N:!(<2O"UK-_6^HJQA9!.-Y-UB$UR;)K<.4>%
MO)V"&X\2T?&8@VT6"9PU6+CI)<I]H:MSN^U"B9MEP\'32(B0@O/9044Z@QG;
M^2/T]T[45KJQPPBVWB;#KRF[8M5H%66QU/@*ROH40Z%,SOG18,$UD^ M]JW?
M!:0U<@:L3>V SP.U7^2A7FK(DX8"V=.H1>.%/[FBW8$!O@"TKT9M&#])?X?>
M2I^_S@N-O#CU2ZG%_\0FJX!X?_<0M3Z>+GEB#OE\,64.ZZ.<3&(:PP^KAF(C
M<L'QP!F-$&W[<E1?S]H7;[91AFU1I5M#]%D%5CAF6PH3^DF]'7 TV>OA0T]8
M36QEKZX'%4Z1QO#UVS!534%+0Y-@G>W)8/2KXVV8[U=DZ]+)B!S":]QSID,4
M^CVM86C<57V(H<S>ID7:Z>*Z%9BJ,]%RD=^-B;9 '"5P-*D39_U1H1$2WO&6
M.8RZ2DIDZFZ,%?RG$:(R4-EQ?*PWC0UL:P<'V^%T_[[HISS5Z50]#2_-$ZN2
M17P4]Y6R2_WC3HI7D;P&;\2HME632@Y1W%YVO8'$I'X(4RMT&,8-Z(AOUKTI
M9=AG8M2X-34XYJ;2LL:BS9:-2YH/D;&RL^8#U_0EZ",U0.NH70#,96[=[G-[
MC51/77U?3"*>JPOE@4J:&R4(^5.5$MCO@8:_PI?U;+U\1R_3?HG U_^[G""/
MR_*ZPD<U=JI/\:/<;LQB9=P\BIT%UWO$_0PQZHRDE#HL888XEP!.<JJIHWAW
MI'J1),N)<'YS+.5"+YJY;_'W$JHZBF47FIGTWQH0QBA26.I 3@?+K%1)L.7Q
M1%+Y I0!V%*PUL-'<_!+3OCQM,1:"TPV<67J,I"<5H:VJ@CG"OIA3%J:[9&W
MQ/@;XPF0S'=F3"N9 3+^P6CAJG.1"Q)265-P.S-JV9T/N8><W6+IK!^@I+?5
M-I/P:=+5=@@_':6)VF+6 Z7-R3"'</1:TU?B^Z5/C<6R=YE*(^9PIKYP5&.<
M997EJF<W,A4?P(OF)2"S*R_#"#;5,ZPEBP38QLP+POR\]FI'*<F*MT7S9I[0
MYH3C# H5]=D%'&8%"LL"$6=.!0UMH3F^19S,9?P45ZT(9D&1IN[,2V"O,EG,
M$EXA_50#"! DZLDDP_*2\2JNKF\ UJPOK,E^=0[$@?WN:V46#+*A%@"D 2G4
MDXL:[5=]=%J3N3<J;M$%\3,Y#VUXKZQ'/"IF)T$JWL\PE( #T9%.I50K/<NS
MM<;F.1#R&>K$%Z2T0/@"+=)%,!-H#A@IB52@<D-N9C_=!169P=T7P8^-*NW^
MF>*!]\PA1)-^5ANH/OO0(#TO3!2+/BH_*_S)4:Q< DJNG#+K+<XP&6:=+5H*
MPA../(8>?S6:?\3((V<+'%=@;CE>U;A15A-%*WBUX.JG=!)^_2;;3\U%^0T8
M-T )&#FY]&7G9!U= _I)(4"[>5^%T,^9+,K*E\ZC^UC7)"SQUJR6(G.F??BR
MIX=]8Z5-9/*1QKEN:M*W-Y%5AL Y&65$BBQ[%$ P]@7U7H7#=)SF)F .7 VD
MPJV@F<U;N(:F:5K0ZN';9-KIX72+'#;&41K?GTI+DX_'#%=+R :E;,RU*JI&
MI=>T4E1N-0R9YKOR3BIX&G"9*VA67EC$E&G8T$+:%H&^D3^+L21=4)F.AO=
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M/X=(W;E.JF;GQE.3. %[SQ*M^0.@*$*DC-0G'ONM7#QA#(0SW.DFP4$5V2,
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M:C1P"MX3HBTQD.DCY0<ELKBXD1C6[Z)[XV<B;.FVA:GGFG$_I#CM4"&">:9
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MEB)J)AZ-KI,>_Y/WR@)-ED:8SM"5P:5/GD9U3)GW%(-2^KQ+\M*$I!2/#\-
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M>!L@:]K9)WE@>>XIY^[=PF_[F4+*@ZE,=K%73!K? &NIM$+#M1<_^^<Y=8T
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M9F*_5(=<(B?$UK@3PISL%ZS-,CD/'D%#'\ $Y29(.L%S?^S&U)@S>7-%H83
M+>8*\SGOA/RXGZ/-?1Q;U%EJZ_ S[9%DFC(7P60.F IBA8!M!P[.2>N*=)([
MYI,/4N_8)'!ZFU=1UU#<<3<T.%P^:!*4=,'#8,RGUZ5I O6D.EN=3I%@3%"8
M%2FM(\L''9;;WCS474JN0QA^8<CCZ!!)-^9-2*L[$$PUI?"SEJOU32=]J<*X
M HD]L@*> 0MU2*-]A'WW""YU3J8^TNZ"<BH+<D^,)>D$4GT1W81V3O7E.S*1
MR4RDZTN+&_7E+,G24MVP37*"B>D$?7*'WHNJS#+EB.Z6A^4+#>JIAKZQJK6;
M&@W*V,=58M0ZTX]@FEV%[+"IYD[92*++8X@N=6TRJ@)M$?ND2DAE%:;C*LFQ
M<JZ48\\4;/+(*E5"4S3UCN^3G(UO)05KJ;/MIH"2H-K=.]SQJ383V1I%>0R$
MO^X;2W_)TR2V=J:5FJTQE;S!/R9($&ZO1*_%.HTQY2.D^$R0^Q1=VC!TE'!"
M@)! IB8]BBM+QI8,+%1%@\L;&C]628*, I![)=")O+[8NS[92X]_'>(0%AJ2
MKV";1*UFLETO94*'8@<(2U(Y8A&QY/0&;1%QI&N9)AQ2Z^L9DPA\-%S49W>K
M01^'Z898GH]WLQ),XI&F&C)H&WXP.?E&R_OP22?D#-Y_%U@+R3:?OE/U;77/
MB-6A@V=H\'6'52*9H>BLW3L R[]R,-BPTF&ESMZ<3O8K>I"3>:+,6=,%3RBL
MIO41!;:/IQAT:ONM+92JPO/?1(CILY*C%C8*>KK/AJ)!R=9!_C33<HS8^G34
MK@_,Y<GFK4Q>[HX8]&M[0N-6DV\G!XY^M&)E$LB73@B@*#71U*:91?0:AOFJ
M?LS0Y^[I*+_+=Y.?/+%.EL%;B\PPF4^KG\@[:R/+E:_6X[_M%:_3K=:)(_?3
M:,11)N$GBOIF6&/JCD<(<1A+.T_ Y.YIRL7[3%8G%TH_I1671WR%6_0N*6//
M[V0WDHF4_W!F O2C;;;^8K@H.1GWWE.G2C8'7FX3?E VJ0 ZDJ"/L,9R1QY1
MYW"405=G<G*6A#+$M @S9YF('VBS"%$K^>Z/0&^+#57;2%/E2&C *.I#&U%B
M1:>A>M'<KMI-0R\(_$2*\ H\X="$<32')>L*Q-&.XTRN=;K4?C9#"'8JN#!Q
M>A+%JT*KL4G7;?JH\#_L$7+6#A=^'4^T\QPET&AVPC!$WG<%+>BN1$K=L=1;
MN 8298,,$>.*^Z%W^A^],G0F;&I&(Q24\IYU5BXWL26_RJ5I9'"RT,*<U1HX
M=X>Q4:QL5 V%0' "FG([5(](JQC-Z')L2V/_:"3>>SID%CC[P?"SX([?LVQS
M$NW@)=D,W<"J2 ++G]3@5 7*:%XO3Q>\9<EH9SD)MWXX],'J/N/D0F=L8:7=
M^6Z1.N$DX;S>*1,KU$43-8XZ<4)*5:A 0N63<*<F<=<[%6H0K(R;5EB)M'HB
M05L"4"V[L:KG4-1KC%&CO+@F+TLC$*N''Y/>5"Z"QZD3O[4K[X@L<G,^D1X>
M^2G.;;TY@O5S5%,,+#A)Z4_(V$%%S5<A!!O+HMPPX?>S'/,B\5%6?5DV[Q?Z
MQC%'SC/8C])W(%DKI]EN(E(K?"ID%?\E-B+>^9I(1GN&&P9I/NY1>KC4L#[@
MN%G])ZH3$(K:Q*BAV;9B%LJYU+#WI2PQ9^5LXK*[A)DU>*23O;RO_L3P,W[W
M.NC2($5&N3A%RXY7PC,N6-_O),RZK48"Q".RK-SCH3IWN!AN.PX9EJ.I%V8=
MQB+4!%/&;KT^[BU ,:7)UV( 7JYHIMGD]26]8 TE9(DS%=U^$V(G02W%;]2O
M<3_:^B\U:B]DEFTD?]1,YGTFF?NE;S40[KQ?RZSL.R+1A26-']+<F6!DCD5X
M>,4=$X6C03C%HT00V^9M-/RN#$M_61%>UF]H;G'ROG0/;4^KM4F:=/!DF*52
M-U9&UY4\N1IEC# 5LY+H<\U:5EJ]P<.V>EE(":N8W'0>N!^"44[#37HK7<J,
MXE]\_E[4E>:+,Y4*/**S(_ >OTZ6F:'?UK8167:(7&LF'0&O$S?P5$JOE1FQ
MB(7/6<]JIGS+!#@J($\YJ1";\F6G%N:9J'!EL4Z6:)SI3G*UT6'.MX)Y>W6N
MZF_DZ<Q315#YET/42SQP9](,H@UHN&LL2ZV-8*G^#]T&N9BKQU1RPS&,??"F
MQ9'?7ZP2N4KM>:#8B=#6/@=5 WQ+7YYWY53MZQCDLE\-<0;8=6+H0@(T"D0R
M60BF&KBUM-VE2'H;NT ']/@^Y-T  ,GC%B>] (WYY>?:!.;@DB>$,89GN@2!
M5O;2D!KY$;.!5-A2%)9]BZ^1$(U2*F-%.U]'47S.9X4\\NBY:4P8&0<6!@F8
M4-2MQ[Z(<-- C*Q\^<VO$W4,<^L\R^-QJ5E(JHXX)A!LQ1##6A[9?^D4;_3-
M&/60F,"QQQZARA4A6E6;3GV//V".SF\XVBNYKP1Z24^7DAKLM)$:V9K&Y:9)
M5,>:9!@BFO4[TLX^<)S62&/'>,MZY0X5H;-=/@@G=*K-DZL._=KH[C%>9Q'&
M17"D1,MNTY;25*%)J)Z<APL*)L098\2.J&PHY5>OJEG)7'-.L#+72C)^;"+!
M\>N>^YFHM9QH6&/UR/A5*4UW&A3+*!0'2L$@$$V =B5%<7N4&O6P3,DH (DO
M21T@GB58V _(+60J&T6L";E-^B4$WW#L$=R)D]:#O))K"LNAV<DBW2*ZH#,?
M@Q^2+GH5HZ[E>"95D!O'F#=;]LNFXF+:2"YFCB/[UE4L=5H=6MVZ"Q9^F4-7
MV>H43M-Q#X2=S;=R%[/54.ZT8;ICIG0Y#VQI._J-YJ3*HGE^MU6R-F!VS)P>
M#R,')\A];9^[%*\2>>E]E14+9I)"2E4VC@CSD[+AEG_\Z?#*MTAZ\M&\$U 6
M!*9C-&!!P6L4II:2>,B/XVM_]+Z83(W=2YQ!68HH?-7FHI5"2R,7)DZ=-7E0
MP)/)U0J+-A#*P2%H]B!,OJW+C ^3UCO TX_BX9=3CO0<R$8ESUTA5<;VG^3P
MIW&K4K!?DM"H$6@38;S9L)QT]>6T(/R5\F)U__K'?^'+"Z-GT?-G$^R/+NVK
M%@[_?W\F0^]F_H!O;)3O%XD3=2T._6OXXH@\G^6-W*Q!D<^:<UL6R3*#&9S7
M]IU"\Q?*3XGD+J6N^X$(D/]ES< 3(^'^<_FX:WR)#8\2UA$I?2I)="2_C,^2
M: H]6LH;M$4O?51D>8%#M8PMU></0UIQSVK#61&NISP:5EK<SXY'MOSVMD>9
M3#(0\C;[ -_;.TY+$LG"2#/%,+S)7Z6>[E8IEWPEZ5'3?/=</WO\QLQE-T2^
M;")")&-%'Z:_7*5:]O'=7FU0-!4-]QW_U3RD))HYH)N8X86T3UA_B#^PF#I>
MH<X*_.GF#D07#)Z\ 3:OZ6_Y68P/9.?1&,NR-$U?FW9_^7$>(P\+(AJUG+%V
M3[M>[4C"2QL/^L2(O8L#YYES[?O 2++WG(\FZ(,Z<=P1WG1P^US/^'7\\"/G
M"^IZ?1/*B^J+>!0]W F1:;W%__84.WF^DP%<2O!&*?@A%AQQ;[5@WIOON='>
MT,:39$K9Y[$-&W\6RLNBIOS"EZV<"XEO?[MG]Y'@-HU^L 46!#Q4=3WX#?OZ
M:>CNMQIK_NYHW!%XW,IRYO#V3B57@;L(UX(9+\#H'V#S;?#0R!WY1T9BRY@C
M]T#IB7P4NIZW8T%BA^^PI]T:.A^QR=40/>WH^Z($P6ZX>/"_#QW^^:PCY3O/
M%P^&K$-T4=' P E?!A_\JE.^4ZEMVVHMK5474V 'Q*'UE^^G!&?S&)YNZ>!D
M^N"6"KUHF>C,>-10S?%M\-OASMP8VCCC@U'+O%N4B9_ M *QO)WY@?0)&>M\
MZ)25U2&\%2N%TN[ O\E?)SO_PN\*_;7M,^)WX1Z,_=V@:'64T'!'ICGW&JCZ
M.E_DK;"?BXR%\BA6% =%L@2W BEN1.3JZL?$3Y05_P50 L)B*I8B")7=+IV?
M1MT6\TZ60E&640RQF.UADE/KMM$Q\ ]QMPWP[N[FZ\ FW:Z1T%S&7#/$O38>
MJ.^>Y=J?+-^X;Y@D2R?J$#L"<B&,&>8QWT\A%9">_@PC1],R'D:)^)0 LMKY
M;PU=^ZN;SL)%94E/!\'_Z]7?Q*0"QZ IS?Z,M"/"+LD"BMNL/WK:AC#MYH-T
MYB"5?@5B12BTKLN]1F /R1DQ[][_Z35U>",_<O/G>PW)5/6F_.KG#X%J)J=]
MPZ.BZ_+DBUY:UGM*%\@NH0_D/8==QW\D1E@-65)RQGI>D1WXVFJL'5&QHQ+/
M/)NLC3-<<;M71KWN+#\,IW]2>#DVEBF8($^3,6HJ@Y(OT1]0Z]X^4D[,$!M6
M_7G::X)?"FINFR#I$68I5ZPGM.=FZ?U(+*HKDI7S>F,UI$SF/S-UOST58WQR
M=/5<\ ?O90WN\;MJ4_QQFBO74N@U0R?@F&3:>YIK^S#^,G?_?#HH"&GV<]_W
MTATQM=8_@K!\; ::)'UFEX=$1CX!8OVXRJTL+E,K9/A;+)XC,D!<:$STE%1A
M$M9ZSOK2_1@J?H9710#)Y&RMQ;1L#MK8TE0P8B]05QR(W4Q>0#BC0(XC?-AA
M@S-E \UE;_"/V8^WEKDL/4UTG)3W8@AC=IK&Z#_8]^MITW=CQQ@L*N"&V?'\
M<(D[>/+68FY0.>)A^?F\S2_1W],9F&]9\D;7VHRV N5ZPK^!TVTJ(4"!L&BG
MC_7U:V&EIK#O4:QUP/N^6JU3-3SP,L*K=VG])&6&&$=\QD))@!D3_VR$[1^
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MX*;(:X%-8@!B^TI@@N/.<5MQO_LUX<MR4G(_9>X7!D=_A*/]XWK7+\:AH/'
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M\,PB"4B7X(^) 3C-N!OXCJO4-9K1AP!E,J-3>7V/Q0HU(2'34$S>B,7%R+X
M)L;S\_SDF<3>*2ZI4R3*3R'F=:WC7HTAW0DK1M#_9";!X1N%?YEQ4,NU]6!D
MJMEJ)U;9&A;NG7V/[?K#S_B4;X&]7]HW+G_M)YP(>WTTC>9;Z.ZFH(+JW[3Q
M3N98.EY=W-3[K)#9!)Y><I5S;7]OR+[)^V.R^4?9?[/7]!,:P?N6TJ0%QO_;
MV_[];]4FTY>X]K"W43.W!6OZ.5O_[X3)1Y&K6O_+OE>'\AR'MM>K-K?ZKO-Z
MGKRV#<<'.-_*_W*X'Y/ N7*/!\+P;K.67-1ZPJUQC+52=7./TTS6'3S]GR=J
M;4%)AO-GKMN@QE.CQG+M:R2),I+Z)3*YN 'M$:SU#5EH#CT,M39N( ;KOZH-
M0G^-_$TGIW_U=OD-='^7!'F-_P?XW/(%UE+PG)NTX5)\<_?I=XW+7R?W_PB*
MHZT/.Y^>7$AO-AHJKQ+0?%\*+MR>ESYO$/P(=!ZM=6FJ^960?\W\'/AW\A_@
M^NK^8>8+W$SL<7.^!X 2M.=#(?+0R!3%$1[8N?$?B<WQ)'&M*MI7^WGY=-ME
MZV;L.>#/T;/L7Z>OIZ9)QZ/EG^%MKU5^[Q8)#M&T^E-.\__TTPRLOUY8-KM\
M)-Z_CR(/^T(W*'-S^Z@P-\K;=)HO<*AR5Y[J4@_;/A43H/S/#;DZ6K=!\I_Y
MW87]3T^/9Y]JL=#4N:S_>]TR'%UH5Z/]B>?U"/8I;89,TJ GWW/&P\,^[(L_
MXSE5XK;I"_N??X /)S>)_P"=29_R13U_1#M<<Q&<)[QY#?C4LC="X;(UU>N3
MZG!X+5[SU)3L).C6S"-CTT8OUW(9<=<RS_4N_0N'ED4487%4K&D^3ZV,0KE;
MO%/\>>ZQBJUK1TO2T&T"G-M(@&T$F\6CT?4X<%J.^7&QT^X.Z-@Z/_Q&2P'5
MR2J6"MG3]WMGS/!=57^+D3S?(.H%-S"1&55(E9K=U"+A*^+00ZB#)OOK&XM)
MQ5+ ,A:A<=7+NUA&%X5158T+F5<[JI[QVARH\5W]R_D .:R/JZ]SHVT5_G+>
MQI5K0[)A['VY;61#Y'OAQB"W++AX5T)<6?C+J180T&3*- G=C"'5_ZE6<S[Z
M94OPA_U_(3/!T5_W,HG)F$'-KT$XOWZB""$J]Y?,NYVT3M)+R:R>.@"+8+5!
MI]N883T7A8YL?>%BO (O)37<_7*_D57EG$1CI>RE_4_VT_Y/5X(R4_D/:.Y!
M]X8N[*"Z&Q?RJ!""3=MF(2B6A%E( /C"1Z!UV)GODQTR6D]BI1!HL\4^M 5<
MI8(AB<X<#A>O.N7:_2O'F&.?Z/L*$SP^P7&JG2-^R6+[%M8;UFW\%#I-F$')
MPO /X%+'67.K0SH8OEH;HQ=IBX=AIN^GA)[FEOIP313T/6TIHJ1Q?<9G[FQ[
M(ZI[;BK79NX?8([2;;O-7_7T4? J?E^L943'9/,F?PT>]. 6OW]8\ DK^%Y\
MX=<^_9);[=NH!#A.B=<LX?W/D9.J%B((Z^;<>"MI6M=>Q);OWI9*>Z*0][:*
MSTQ#@MM_]IOKQ:ON;P^63WO4%PE1M?OM%CR1#9[+[?V'^FV03SNDIZG@'T#$
M\GCC['E?K&E["(7L2ASYX71[L8"R3]![*X;/T'-[53A8)5E-)>(R/(]'%YD^
M'X<]2X!T;\!Q8UNI0VC+Z6%K?MOIUX87/))]:UKYLM[[07Q!9#]PJF_>1FCZ
M8UJ3NV!@4[V_,U7?^<TMC]9XEA_ITS$>@YB?K5EL"7\UJG]6";X$2N7M=TZ/
M0!.@8<1AAY#HVW$=(>Q<2$>1>I_R=7*S^UUG[K*E]@1JK7*9H6[E(K(J!:6H
MQ4Z0_MYGR\:U%KPLB#2G!>@!.8)3@24SQH>D2,&:<T029A%I:BUJ>!ICGFCL
M=DF[XN23GKJHLE(S"-^B\'_\-<KN;VH<03$:].@#'95PJ-IP6!>(X9RDQ"8)
M%5.ZF:&\%:"Z*<N^K.5C=;??YM$H.L#K8/O3YZIQ^Q:XSO0=AZ%_HD_*NCHB
MP!%S@B5RB*_!,(<9SZUPZF,S#>X7H4,.W+$95&"T;U?,NM5=^(X15+F6C3CD
MZCE\+'M6^6=3?W_SY%'Z$L&2ZQ5M1SOAA V/G_(,P#)-N2>*D2/]K]K0, ]K
M-L=3OJ(J76?\ *+4B=T)#^5PG[14HX.R%]T-69QX_]S^(#"B@>'-6/M[EY#O
M.@8'>*R6Z$GQ'2LQ;TWZUL:\ _YD+K3MNU5.>C-?7O8@FKWOTVG9:_6(./"W
ML?<#1>)ER7_SVWE [$KLS*?8U81A"BFFTB0M[H?["+!T:)>FKH5.)06;MN!,
M6H_I^._A-7&>S"3J/(1B(]2=^]B=HP Q=CJE4T!+#%7^0077^:: 68@=WLC-
M4+6PKT>27;[A4-^YX;AO[ 7WWG!JB7>H[Q@-/!::R>2*]SL6NH6+WNT,1/[X
MJ[5_.?Q5)S //DN1:_?S[J,M6#_'9F5%Y%4#[DTX;\GE_W)Z1D#LE29\E7M9
MW[E@7<!:P"6(D-$,FHXJ8.-MPAEP<H-?=QN@+6BRD5J:O;= W."^;Z&>.BI.
M8^?S(.#(1TCSX+!5R#27GK2^*-G'7$HSS8/-Z_0"B>:\\/+,F1]4Q8C[/$1D
MJI$_9OF-3_D1+9_IQGP=ZT4W6IXT0!BN_Y1M?VOC25P5Y1RRF<TJ6L'D'L2W
MP_,\"==+/* ,HDX6RMZ?=FWXL6;"(PH)_.DBT#_L![K"&;]AM@3"-@0R4D%P
M=UXA<,(9^([^YBR7E39KYIECA&K"M>=I7(E!?H("\F,[#68$=XF\OHA*=Q+
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M31'A;1 WEO=N?>5KIX81!+,*?+0ORZXK.Q!13APVPZ^8UIUV:>4^/,A_/U'
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M$R.Y,IV^6[ZCF!O?M(RQB0RY&IHQ@6)=1JC%M*L-<P\JM,!KL/+6!<PP]T-
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M_HTGS>[3>D-)'^![MW\3^0 88,!] %!<M^KV[]Y%JD8I]Q\>LO?QGAH=2OU
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M,B-U'=4S#4LRLKW3+7-39WRCO7\'MDA1GJ3>MG;S#_VICK>FJ'OS2>N-Q#X
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MLL//XZD=D9S1S7VL^LIJ+;WUMWZH$9L,PE3ZD*9+6RS4P#;:3#(@Z"."WQY
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M^=K5VWGGSX* #KX0)LH]V<%!C U&[K5V_B-S^W#T 2 )F('MUWW9*ML0@'P
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M. 5_U-?+\G34_^EB]R+C^DO$M$_-4#4%FJ3CSAJUB9S(K9<^M>?ZF5YCY@^
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M(N&8=$VS^<==Y@JARV,#\=1:,F0&?T?^1J]*/X$-H4(VK$2:_U.KR5OK,MR
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M#PCM>LQ[?7CY_^$CBO]%$BW]!/S+$GWX6-8+>?9ZNJ_[M\Y;\#F#V_ I-U[
M\A.0YOBN8^;]"?#K9OKYW!;G=N_YTE#8[:?_$;#]1M2U\?K^YB>?,)V(7+5?
M!RE\NF7RWNR]UY>Q\];G<?['KW=G*>RJIZO:QWM'_^6;\:)GH&S:H.#//D"
M'O*7M]ZZHS:%NYF5N]LWPX@VDO_J:TGTW.AHJ?[@Q_6WKWWEW=H+<<5!,(4
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M_FLW8UY^__9,% UPH2QITU7>3Y![C?L$+!<D+AD1"J;RYO]L.]]968X'_=_
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M3.*0GUTVMOZA-LX\.\EAB@B;%/@7(GQ=.7-1).*D27F@PE+MH&=?J"U?@*;
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M.*WWK/0<O7]^I\B#CSERK_5GFS'*W? 4+NWV;?5)-O7WOVUE<)\D@/E%OS$
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M8N7K^9Z#51B34WW8$[;CNK P @.DJ%IQN1??*'*-_M0U06QSU='QO;#[[=N
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M%;X2S1_H'G()'=RG;9^S$:J<*T3O^&YM!*"59U.Q[#\P$U>A[!<,6"TK.@/
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M#A(H]&E*M<1#I?,P?O J![OFSO?!CJKDE*T+[D04^%MN]<L#45&@X=B5]2#
M L3!$9I7VNI(,H_EE/4DVB5_MMA5"9&\0"KSZZP8$D#F^'>_M'0H$NJ;=!1E
ME$!*8[KW6>?TGR0D>$;B7(26RJ1H3716 [74N^H("4@ZR;,N"U)08/ 4C0@)
M(H'=3"G7XD\_F^MNR69BS[DM^UIXE1>B\CHUGFMI:H8S0H=HMG_4U$3X"'3N
MB&F [-<*=.RJP.&:I@J5$*"#,ZC<M5G8G: 9BIF3BT<5H2LDP0U)HI"(7P3@
M2&]!X^* .Y5-<M#V$J//8Z4JQV527C:8HPK\K*,NJ-H0FO;6T'UY$+I?;G]
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M>];U,#,X<Y_HN409#47ACF ;<%&I_$#R#-/I9J4F!>ZCI$G%@HV5M:DGAS1
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MO__.DDAT5]##0-?XE>6IV=58[31K[1E<@P""2035 :&79:<19&5WLVO<CYL
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M2<GV32];^YJB9B6#PG7J91%_KAIUFKD"I^ S$Z%AC:.QOW5,'-8/;G4#4N9
M8OWP &GR$.W]'>WZ_YG.E#=&Y6>)O,\]_2?][\6=+!_%0,@YCYDS9XQKP2_
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MZ:H>Z1'9J; ;SSC9[3H9%'>/[^!X&'^C4I=QVB+?*;;JV?$B([VN$=KYQ5M
MO\82]3!1T4#GHU2*4;%2H5U#X^3"$4E^1EJO^X4#CU:UC5Q1FG)1ODX;NR$Y
MS6EX4W"8>J:0]L%^1A0.XOG@1V2T:#K3D?H:NW]T='%6$V"TVR//?0_NT\$G
M4'?I,JO[#%-\B+XK)U.4NR/EF]D'&?Z(!=WM4HT'+A+(&2\65-#I$2#PG"4M
M9\)'$%V,L&<K(<.NY'X&*=(569&K;TU<B3;4X^-'65=0)/?T-"B5J[BH$9G.
M@@,Q=FR+?DWX0VNWH@G0G(U=O.2OK9(A%@Z7:2#7'?VSP#*M6[3@^2QTD2Q
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M%()I.\_B,SZ?A^D4=H#E9D?[?!XR3$PIN5P3()ZP^9L*)IGUU>I.KY1=0;5
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ML>W9D HL+.L"8S19,A,_4,,#FF4NCH;VK_]_2_#?,-ZL1Z*]\"QW(E!XUJL
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M5C]R\8G[O2FA&&IG%O]D@X$^P]],IQN1X8"D>'7EMYTP'C47*MDNH U>K3)
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M_-T*47_3H#360,[ 5>%VHS;HQAP(*=[ U5/M;JZ;N!VUM$./;% ]J:2+RBM
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MS@Z0Y<7)(QRP[#&! H ,^\=UCEA:-LCB?M-(,9RRJ9Q]4?#R_(C8GL^60P?
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MC?LZI\E_A>T'C*R&[Q9&W_6-WQ<[C08DN7C3@5IXNN.3?3X0 U [VI?K&TJ
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M:>JSVB(&DZ.-PV!(<2Y5:J'#))L;>O3I,OD*(YCGG)HDB":S'<X^$-ZBW*'
M4#>CR1;K@I4X"X^:A*LGNM83W] 5 +A C.5/)/-9HUOH6LV+4_TII$@LL+82
M^,9N6,QO!>@UYRG!Z"C=(;8"7>UN,;ADT#/,8J1:E:";H47PPM83.]"RM3:?
M3L41I1:R2\'AU.K&M&17:_X4<O<V:O6<N(C/HXU6P#/+]4$4D22)(EVI<8.
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MW37BQ N3KB,3K&\(8Z;A" B6!<IHT]IM2P0-5/CM:M)(QPP_7#+7U=>J\$;
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MCOW?)4?GIW.92S6)+=I,U#C"=&.DY3:<S,1W/)H;R@91DH5L]&'BW;<\%X)
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M0K:)!N.?<T16L-2>0>=KK)9&<C?;A=WJ<.Y')&[JQ[B\C,(X<C!J*^<';H
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M]&2-)J6(I0EB%G'T58L$9.O@Q.LPY/DN%>7@OE^H4N5B1&76%S</:%Q\]WM
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M/OV9YJ.=>K')^-W7XZGTLM55K698[7.S-7C1X*P\*/6[Z"_ <<O^[N"^GKJ
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MSE<ZL21Q$C=9"0#$LFB/5LJ@L62<P'&CC3N->+$S'2Y$]8\7,@B/=IB>UA1
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M+A.XJW&7M>NW$\%;>>CJ WQ45"MF;,I#4E_4JKC52I@NN./FTJ)NQ/70\B^
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M3;ECTO=#X;Y/PZ*M;K^;B!,%F8KC6C*KTW]9E?Z]T84(52]<[QP%*L9D":3
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MC$+9=HM"$X&  OJYMQ56+W.P@F7E'IF>C[GHQ]=""G.76JR^5<"&JKEJYU\
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M;T_)%;1D.C?4)34W\EE^O^,<8T  +D.0&SQ#7MDB;,'A30(9#V1TL!NMC'!
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M$<(BHP196-/W4>DLE""BS\(FW6*0(@6L' 96+7CG_@1Y?"]GC1#P)T\2=-D
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MSKKR"1 /?LS(IG3]5SOG]>_;Y$>Q(^"SY?[@WGBEL&BEU[_R<6_:;0>CPH'
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MCADI>>4RP']$R)H2C":9&H*/2K@O2\@V#)RV;K\V)TPW+W*>M=H:<<; @36
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M [_+ 80,[&8%:N$0:FB5Q)5IPZ6H_7^90';T6DHB)(MX)<1+:XZPQS[UL8*
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MQJ^G5_O">Q2ZS.^7S%WWCY:()"1-NVN^QENBE<\KE8>VVU["UDXGH=ZKMA\
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M:#L621"CY@M2SB$Q841;\!AVC/M ])4A?[=%CM:91]*V:M;F]-#;DNP@OMR
MM=7=I/>0KJEI4^?:%R45!.\ZBH\&G)6Y_(] KB_+TAT5]MI[1A%6<M^HFH90
M>.I1 N5,C/=S\M1A^F!/Y<+X8O?B!X&G-LJ$/ />[D.;&_V^'@_C;\6R]C"Q
M(38*.Y4\]R(7 Y)*C8M=9%K3W8^CYGPT1/M=^GKI'7M#1BW@E#Z]3E#'E9*
M*9[<7__UM_=WQ@_"91 _KY\L?HWUX3K?!JJ_+U?\;.SS/CWL'T".\$T\'^X2
M'KVHO#;'#6\3-YT;49CCC9O[66/QIE77 NOG[[_D/4@>9,($RE_!/ATR$;(U
M"FN':>__8?J;8Q#3;3$?D[INCB\L[D5_XN#?GRKU5&GC,%R/;_<IR2;J=M!-
M>O@P61Y%^+-8;:G*P++<#.5B9!3T6AL[[ZC(UBN%L=KHW"MM.'QE))XN3P$@
M4U2$5C>AN<TKER%D HFO[6E;>WMD](%)D2-I-C)1+4UX<(CTT_N-LV/Q_P!,
MKXMGXAX_G/DS5O2'H_UCT)^^[3C<WW1\V">EHT_JF*?:.\2BF=VTA1G7[G!S
M:S(SL+9+SF"#(^M3L4N>T81M/NN:@V4OS:,P!W^A^DVNXJ:.!8?(D?.JBSLB
MW-9^X2H/;'L=!1HM\D4P,"NMA?K\3<N\6X)+4&[3L7HK>C$9N40)&8$1I.K<
M?MHX*A!2%E8B;,/E]6C=:?*,R[X+1Q>)GC%%YMZCM)&HN>>@(JY!ERE>,0UV
M9XL>\6=,EA*2A"(T9 ?\9-C[#%.67MF\B>WS\;\%$Z]=9A/G?H'HKCIP^=W^
MN&,Q(V*NGMX=>\Q5P%X Y7ELOFF(+.%F(+$#P]E6V9E2R>B-%Z:SO+-]G]^>
M?.8 >JWRE)-PL<,9<Q[T*T"OZC%,[1P08!B-"<=7?4<M$_KE)F.<3M'=V[ P
M:S[Y>I-1IRHK9K,]8H7_46]>_,)'8M"5[S+WC3$/"[W/ZI<-GX.;1::C@YB^
M>NR[X9B^(U#N\3\ R-3!4IV)0_N&^E,C-'8]S*^] 01C:Q/2%//@U9;CT&MH
MVY]S"43VJKY(FM\^Z+-J68IIMWY!@(7D4PLLYW!6?1-N&47XU]WE3^QX)X.1
M'WLM8SFM\.L(<_\K7&$F;$/Y/W\-0W29M1*5ABD<R*S>/G<%X/.*L@<B1'9&
MX74%,D)&HI;'!NZM8]RKH&(HDBE*Q,N<2A,OKW*;(\R,Y\&_QZY7]5.S04!4
MKZ0!'>IR[)QU+56^6.LG]_YI!S% CGDU3_DQB-'+.R\5&HR9=29#*'><XX+?
M?M!/&8! !H7U1=#/(=S!Y]+ECZY2?93R0>]+S8>4A#/(FNZZSK4RU&8W<<%F
MO'!%O]^5OJU61D^-9T,L-=R@9Q9Z>X+G!CW"'J(@* E_))1_<QWZ #+X;#"G
MCN/ ,R*1*)I$-\:53]NY94O>.OF9(LNH(*1F(W A67#/3 @RK&[R0?KK5>GL
MZ&W:6=80F@)'&96K)\S)V7B1X/HAS+_"  3';;6Y)VKTYW=]I1]>BE6-ODIR
M%J]C\Z&:]OAB/#%\M^ODGLH$8P<W0CHS;^O'C0&Y%X5("[OSZ#SS5D[<^&5=
MDE!@W;5/G(]R//,X64@Z Y_P&43^6?N<*UZCO^D;$\WY<%L7?7?J:G\D\Q>^
MM,50XL7/)ZMLB\!.[5!]X/G2(1.YMF';Z4L("PVVI^Y,'NYA!Y'VH@-176?N
M<J%R1T'2VY$>"KR/6AM?:M-\ ?N*FSJF6/ENR6)>ZCPIXU_2@46N,/1,4*;
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M9+TWUMXME7EO5K8M_ @B)DXYW1KDSW/7D.L=^""D"9['V)MW5^^8<FNLJZ!
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M;QHG7P&<D__6]/;!9X'A[_]5Q[#SM),S=!<CV7GZ&"0FL\.]BY>/]!RT T?
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M&L@5+6W[ )KM'EV \8WR8.KP.$\ZTN;-GZ>4=_[_3/-_P0_^6?T/4$L#!!0
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M(R* JC+EJ6<<99%E88#5]3\O4:Z4C;=$S!4T;8CE D4:S9"J565I459\1#H
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MO6@CSLG%5*.,\40T4_+"H ME':ZZ'_+3E%X"2C"(J7!54>V@:JU"$$9;6=E
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MIFPQ10MI+Q8SQQK.8*Q6\=?\NE$UJP";F,]Q@M];:P2,23Y19IR)1L20%(!
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MHT.G7G@;;.073EX\F6];\];;:?]<;PQNF=AWAN.E=NG^KJ9M/Z#03SMSU4"
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MZ9U2T,/P%L.321_P#P[4F;?N%UTM,WN/T%E0:.-J,RR\V4.(M;+:D9W5VU\
M@62<[C'ET2!!QO!*2 -<'[WP@$8DRTG,T5%.+V;N_P'8(ON0+BYP\JFRFL%\
M,B-J:<"QZYZD9>FJS+X!KD(F,A1*A06@;9(S4&7TVXM QV'A8K580=.#.+*-
M(?9'8(A)@3JE?, 2DSJIO<AL "$KIT@RJR.MVM^BN5;$D.[O?)/F><W[,1/2
M$E)Z\X-KO/+KSK[NS\*["[\^^>K;UQV23S-WZK]I_C>J#2L&S75P,8?ULDEM
M3P>:YR)(;3\S]-AAA]+V[6=OX]4%)V(MU>%*_=.(Q\:_6*TH3M R8$14BXM/
M1 *4(D3FU @Q6>TQ(RKGRSC)A2,",<C)?SK\VR \F_11_J;5^@>@?^A8SEIE
M,=OG:.5YF4SAS<985V4=MC:%$J)?6"@BJM# +NI<U-)(W!^M2BYN/4J9APFP
M(NIP\_E5N?F5O;_[ 0$$=&.^@#E1 %X$;68[/@!!5HG5)X\;D&K=HCT.U!X7
M8V&V;PI6ZW<IN$KH'7HFI7"5$($-&&)^9'"G3':^]%:9[+=UR>FA4(-"B^3[
MS)WHBXR$.?V+MQ2O)&?]?N1>L.T7)NRCV9.D)VH2A)-3'%9ZP98M=J.%!%+0
MF0KN3G71&U8[5GM&\)*12@X@<[R?45N&/=-?6WXR4UU#AG<\XB\6P$< %H!T
M$+B3-A>6(/3%XT/S=.<_>VUB_:]!UVXP_S_Z_V'G_YNH%0A[L1FDW3?"R^<#
MHV;R.%[[)RSX9BR R[Q&@T74)NM Q64.\;1]2K+92JIU^*Y8C>DPV8]D&IOR
MFN3?LTL4"_%;J_"!1[58 []%:AR_E/K,O K/U-7T"7O*>](*W=LLG]0/]--N
MX14L(VM#EF'ZL:K+1)1Q<A/T!&(( ]*,B=^?[&'^F@22'M6/?'Z27,T',]*O
M U"$+N_BOM 7U[IY&8;6?I5E^RLUZ,<_F<95JOEG[JUAB\*3TCN*9Q_7WCNF
M_'/4F_\W48=C4\7T[5S(3X;%?<JJ"MN]8@SK,["-_TWP'O FA@GOL^[Y3[*3
M?^]=AAD1;\C):;4CR9DKV.AOU-1>T<9_5VS^%WK,./EYUY7Y!\#9]^-?:?,"
M>*$.X+$_BBC_<&*4]@+ S*.4& C0+ N) ;#\ =QE VK.,);^!X5[W N<*$Y>
M_P=5_4=-_'?KLTZ:)#'Q:=.7.(1A !''TFPE;&QL@#+9$W/\B#^ ,TR@8OF_
MA)47#_]1:.+#IQS!=T]GB:D1P93Y3#G&34OH2#-XPFHD$E'!L@P8 YPNA_[?
M#CVV]L5J/CS=C8]@!/OS$B<99C;VPEPR$)1-:$1:EZ;$HP/*?DI&689Q!B#^
M%ZAWTT&"GX*GO]KL? KH/;K;WCE^-7(5^#DT^(7A3X-/!B5_ ,.G.[<'H<\]
MSA]Y>KWBZ,/;4-3 ?#'$ZF81C?];A/:X@NUG:3-EZ&\A4ZE_!R3K9EX2*U\O
MQ#TK/Q0F4EF:/SPOBV=,J:99!@"$_@&0!?Y+!P0[%%K;51W4[%E:L'*R/A'/
M2LQ)\>%$:4AJ1YWV./R*'AO1']9,1E=EQ<T:&4ND6XCR%J#\LU6(3(!1$\K8
M9#KIRKO*>)'8OL"OF=1EP%A?Y0D@8_1)L1!K0UI)3^@[QDBSD,-@7:HJ\GP)
M'&M>YVS<"_,6S]%"0$ \ZTI1('VG84]6($@KAL5)%(![NRLRVA(2E*G-=<">
M=9 .F61'.!67WJ2^(J-](AX_6/K5*IW.3;)UH25BX8"RRB@YX' F_>6"!JEZ
M5C5]B8N@P8RS5<UMP7S(M@0IR9KN.[;TL2)B$1514B)B"E(-#=^0Z\&]4E&E
M.E*5#E^-H.+K75^_X=?$J:)$_\Z6_BTF_+?'V?^745F_= 8[1[7U.,ZMH3 >
MGL<(4Z;4!M%)/):!&I<Y,+X&B! ;WQ+H ?Z:-_%]1^78[\^I-DM6EVWG2&DK
MJ^B!6_'?$WD-]S]HQU+9V4O%T^P61"R6UF;)W19:U$]W(,-Y>/J4)J3ERV>,
MU7_OX<]K,+@ %(9 7.W[F'5V4O;=H (B@9HF/Q?0^JZ>.R6M;!J/\\'(,XGL
M$*WOX_P#C/C=*NH/"<UV+4PW._)&*44%ZJD@XDMOA7/?V1!F6CJ9O6&LA M&
MO>34A?$\\@-IYJSA.;:-Y((Q/E8BJBYXOK2LJWD\82Q.<J(+"R6X'O:I0)0)
M/ $#5( *5"B',/TCWK\]GW> ,:-&Q^H&Z>@XB:ES0LQ/VDK?>:]H\V!5M$8)
MVQ6><;JF$4?#5OE,=RN.U*FR,0D>RR0!'Q=C^HKZ$@Q<*D0?B!)@T0&==EW'
MPO#<=UU?L>K%R16^3@MGH/UM*9*=/5E,P:JP]0WY1J>D "37,M9F 1+\/J/5
MP^EK6@_GIG)*KJ.D!";'.A  TKO02NS$7R8_BNW/R6!'*+%C/L<,*0X8N)XH
M52L0ZNU8,9<V+CJ7",]JLY(.;34+,$86L\^4-9@9+"N[LH-3BNA:H[JL1[$S
M**EQ2(VU?J&CFND(1USI !E9$ZZ,'YU(G4+5\L7HQ.IFE6,2J$$*YYJ3G8&'
M2;%TW>H+9*&3)L#KPC&E8UZ#0D'5BL/N$02P7J^PB@7%00!,M4O^6YR8-:?#
M'(%?9*Y?_,KZG"ERIF@I(#4]Q[G1(L2H28["?;%=F07/"M85YQD=TB_FCIJL
MZ%[BU2FATBI(=IH%# Y(2[-'^ UD3&--L;$I/J>C&],(DW^9L$4.P" G P#(
MR<E/ !CGY.1/C !X!XP)8I]?LU:Q)A3#.<MU I=9(C[*D (<&..X$_1,*)5&
M1=24!H! 5JSX$J=GS;Z)5U9];KU!4W+>AT."QA#J*[952.L-#?BUJ#O_Y! 1
M\)*#V*3#@@ID7B7KRFV ?X0_B[\WS:QY?!TTINGCLS"W</"FH;0ETVU316;+
M[(*9M2C7QT):>TE3?X6;B6-+1NF,M8>73&D2GC&MFJTT*AP1L1M%@$VFB8D_
MB-<4C9+Y4M+PC]4&+OWLY!>%4"3C?7$4=[?OI+.%K/*FVSN7^O2@!9,R&&%1
M+H)LHDMIG[#L'QW+,Z#$'B43)?]"0_HODN3HB>/1K]\,CM0T_J?-$?^34.S!
MG^0$\=T#IWM'Z?#WG'.#,]0I$[D@$(AT=D)5 :%C7?DT*+WZ,:T20)/Q7BUO
MRJ^.KM+LL-UT>O2+H9G3Y]:,J(5-\L0,.JK"+CQ;HIC*58AX:5W&K$9BG=H:
MY;1_Q&'S%XVQB3&-I8Q2-C9&4>G4#Y0I4YOR+T7VCT^NOVEGB61)3[=P0,2)
MX<XV(.X*K?Q#'(@^N1ZUK'O\W:Q:K%.D*B5V%94)%C[!U,KC>C8^&M)$ ^>J
M?/5.BRT-_*Z,D.U,WOZ7W?3-3IF-8&T)IC[_"J]-*9985Z(Z-6.691D=40QO
M (42>P3! */VWCY6@B(/=N1TY/&>W#V%DZ@&E)EQFD! @([ZN>9?C-3J/TPU
M,C(#EAG&F_AR0#0^>61DZI6^QD-]>%T%/:1:IC(#7%A<@&*,Z6)_K+;/Z5JT
MDUA_%70*T6W_<"FL,!?D6!>;# ,Q QZ4RH1SY:(5MY&2%^ HZ #LC5D1,>;1
MXTW0 >93#OD!,$[33>55FIG*'O^H<@I*T\H(I%%'<7=[MA@P=&E+S-O@X,/Y
M*NHQU'+5P2,CQASX#B42^(YD'X5I*X! F31!?U<B=]Q'D-!H*203DOXCW43%
M!HH//KA;EE0&O15/#6CW%RB6\L47)(!S"R9NSY& :!>5:2?8_I;\23JF2F#R
MMV@ZO(S#@9^:+2_I->3?+B6*'3EG6U2\74P1R\9X:#"RX#SOT\]_@R)=H%I3
MQK'.$5&7R-46*R8M)W0A%8M./I#>*PV9X]]]G/!O?H>>R%)\;"R1Q5K/K0XR
M*@M<UAN5=66)KM=3S5:KX8E>Q>6.QP\=\'N<@)?"6'?).5O4!8F.<+D7I]&&
MT,E1S^Q@F3GIC8D%8\YL:2I%#:BKM]:<1[[@6!3)EY<.V%<4R115]-4LIOV%
M/F:0H;U_Q/L%;_K#<Z+1@])[AFS&>\9H[T_9S;#=XM\&U^]?E,HYAR55?Q"*
M5[F+;DC7$,6?F)@84_ZHZ:;0G/Z<\7O_RTGTQ#_,/W A(\WW^J/_HX*W+(P:
M<"T1=13A.X>B?7B09LCR:]%+K<_Q_"XUUC%\417UF8^C7,F*R3" N\=XC*0R
MN]^O,TJGQS3YKQG'79[_)VZ6X%6<N_0MI?=)S0I"5Q3:7_>1NAF]N#)I)F@Q
M\LR>^XI#OK'Q?LEE+I)&#ZTCUF.J=YIYH1]09SIQ;;YZ+#\2--/N5.7A@YW8
M<>L69T10,Y<LC)V*A_,$3XZI.6OG#6_=[&/LX!PJ5*D!C<+I[G,*6B='_U3K
M,06RW:>L91T+'<D"O<]R956]IKSP) :;# EO3GAV[$VE?K935ZV,$IIR:J%
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M:PX0W57GHV+)2A C_I0@ =\@?)RNZP-*_U7KYM8ES; :E(^DU\4+K^<0.7\
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M0T_V&0_(6$=XN\]7G)?1OFD+4X:+]U!U-X=O(,X+=1X]<L4H['1:0K5)WN!
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M^=:O0??_^$BN1YCP.@P>0WIR(V62+5?Q-)[D_!;_#^!$ 8]6(4Y43K,&1VU
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M+=R/G"D C\("M+I-1;Z*<$V&G?^8&?P1C&_YRA1[W;(VZ#895&:5-'9EK,L
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M?7GLNA8,<]Y*L P<P(']NKHT%-OD@!-ND5VV>S>>;3>B%BPLOXHV'+F\Q7.
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MLHR[%/3=_/,FG[P-I&W1D\RR'MCGD'U<@]1QJBDE",IH=O0M"3%:,_5";V%
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M98&W_AMPXPX4),#EE.FY?_[ZM6GB,($%F*953;R!O-?<REH_-TC37%9#D,*
M^1/K]+7!M$M \H<9=:;',5%ULD<2C;GHD]"XC)KMTT#Z_I8US$TDP]99;B#U
M8G6%6=A6>04LJ$Q@7X+%Y'J4N3#XAVK0-L,)U1OMF]+T<_J7W0$&6Y7N+FNY
M=_3>!9I&/>$J)3\V398\K:HJD*="M6#=:$/,#:@)PD3\+@=NB3J3TJ&R76@
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M0TK9$Q7"H/"R:H)G&=?AYD)X]KMJ(!%_S"E<ZOQYNP[AX*)VO2I7P8ZM:O2
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MC$MT[GK!^&Z+7%@FC1TK&\))P%5??AQW^@B(L,27RKOY&BOU;P7W-.=1_N/
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M\]#+^-[]*H&XAK.HS72/"9QA09 U_M7 <A(H/\M=J,2E$.^2'"4A_&6_+"5
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M<PI<=]^VE!DWI@ C._3K[7\A]]W@4)E][7R:9.!KJ*'::54U:((@.$[JLN>
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MS3+::TI6Y@!%]:IXT "Z2N-V#[J$705)0_4:D *WXD#Q9Q+<E,I M]V?.DQ
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M@80C[5 *NV_8&-9^TZRS"0YT&PE>)X7"*F9NY,?_E>H[!SN8T=T5M-[C5_^
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M/52S9W-YV)A;#[T*/S6:[H<B68X8KTMS*&\!7SHT_,+* X<K?><ZKJ"E*([
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MLB6#=AV82$GE^].BX&^>_8;QZNN/:9_3;O I/"?O-^;[Q0L82IHAZ>'IWQ@
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M=)@8V,WND?60-7@/,?4,")43(:.]MPI+1K3F.;!*/777[/&*GZ'1$PFW[(F
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MC:Z@RD@ ?C1M$D=UI02TO!:A/5-YEQ4FQG 6W1/V[UH<-/8[#A2 7BJYRB^
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MM "6$,2B1CL)<IQ6+2 ZP%NBT3(2BVIE/9 ($'FZV;25R(:9 ^,>0D^&:I#
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MIPN<K>:,<.X"2T18OQHME?Q13=,JM*T$B%Q4R]&X*QP.N*Q"G0@1B60<38J
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M'#-DXYJ-3_L'Z'[8LN)J9/GS,XXLSBSGEYY9[75$.^M8AI,O=.E]VIZS-\_
MQH?'7MGKH\5C>V_=,&EM69BW=#1X;*^M"WM.>L_?Z]*;O[FKSQ./I^'N/:[Y
MX(1S-\Z=,?L>R'+WT3<^<\K])S^YY$;F=71L[:(C[YK^^".%W. =8[WO#KQQ
M8E_N[]M5??#\Q[Z>//;' ==?>_X]P5%'3?*O.O[(R'M*8</B8K_-Z-&?]* '
M#[HW:S=7>SI6'4T*P\:[^;=75Y'AJ^\Y^D%^M+QNWI>?1RX8>*:;.J6O?>**
MN\[QF\7ZD#%7-*\6HDGPHL6]W]Z\DGHE]^[S'\]<4K[OL!$KQL[XDZ2?]\TW
MIS%!XO9C=KZ^HW'^EVO[/GE+84K^T57OQ=]RK5TY,.M]U;SNI3>LKN';CC]]
MZXVVT[?=X)EKY]JO6#GIO>#Y4T][,O,!.#RP<>Q=S?EW;C^+>_D#2]?M)XO\
M=VO6D!]__G'7(ZC>Y]XU\<59A\?/WSIL_7O,R4?&>J"/]QTQ]X:SY2"Y@'W@
M._SZ?I%Y^@>7?$?,O7;&BR.PS AARO#;=K\\L++M^&W4E.KP+9LON^RP6^XT
M^F+\]-.N8D]RW.SKB;<_VG8Y.>88N&ZDN=NN>6[0+J,W?VSZIU,G^NMWE?KM
M$C_#<N>A\U^[[[S7?4>LZG_)]IYK1UWXT,Z?TG<.&'#2YE!SR"FU.YAW/EOX
MX)/$3:\NQHZ9=[I99\[Z9//0A\9-.G'-CP^5AV_?\>&LAZN6/5.7[%#?B:Q<
M6_ZDE_SV[0^-?&LG</G-:]<6'N_[;.'3KF.<?<XUNO/;=W^]U>@'P0<\=I1\
MLM]%;]ZXX(T_O5H>^?)VV^BG<VUOKWGWVEX[OW]$WOF%>]R2%5N/WA28M;#W
MW@N(.QK)/V^;EMMR57'0)PN'S?_RQ1&?SQWQYBO??C0;7SKOS:<>_F'7GNF)
M]YPO3"(+R\;PY^Z9]LC";7^);E8_YF_^X(2KU@[L.N4Z[.^6/7W7+;_T*W#U
M36.B[F%W';OU@H$?OW5G^XG+KY_Q]*8N=(_[>W9I+P[--+\';GG\B<CLY"C_
MEMVI?LJ,T.RW-LIW,Y\-GK[S!-=GWSQQY]0%$^]9^-:'RGKL>:0XVW'6;0N7
M?G7_&DT:\*;V5F#-*T.^>K>H>_\_=MXR.([F6_-L@27+8F9N,5G,%D.+F1DM
M9F9F:J&%MIB9T6)F:#$S6@P6[/_>G;WSSL3<C=V-C8F-F/UR/E149OZBLO(Y
MY\G**/K*'8]+^LKCRM]&.$K2C.S2-W[[L /S*)@W&L8@#.H4JVPV$VTS3<\]
M*UX?V/BDD9'0</.X96CTR$)#-^?NC9(2BZL8=R90E^X\;?9:O07ZE%QLA^H[
MY'4HG\0X2]2>[0[8.X5/=L:1.O2D:W@[/<9M^#YW'9"?++WU5U']SK3%A7@@
MXKX+ P$*E/'"RD-_H(6N&Y!_10%OST,XVE+"5(GP :CC"9C/?&'E3&%X29#1
M'9%.6V)-;XV-HD I)"CBW9<"KNQ"N'WRG)IZ;_4,ZD<G#O7"6? /RTNW+ZIE
MDH:F" [K$8MB0FLRM>FCR];X#W/=A]+WIK[%DB?'>/Z"C03&=M>5T8+9M,6C
MVIW:$!EHS<? E5 CG$VD21\ RGE\\6\*GG"JL,4(H;[<^;SAYFKNX4K-A<.T
M($H7PIV^=E8\(T7-?PJ_V#\%O>7_2=8KRL/U<-\#>QU-$*H:$UX::%_F,GP5
M^ "T/R9\]8CO[^Q1K;_H@/4Q*-%L/$\^\_;.>/DVO)\>W9JE]KK]6C1 ,/DO
M[AM-FJE[AHYX3>Z;=/;TR=1F%UZGJ[6X-5S>589;EE=)+X'M;Z2O4Z\1O9WL
MA5Y;1Z@Y_O*SKG^%>/;]Q?9=.C<_/V?GNJYW/:],)MMS<_D%:IY9O]O_]]\1
MVELEFYNU:QBOJK3D,\CR^)Y%8]?PVX3-L3WJ53.:&T=?#<E$Q;?[,,XCU*5G
MZEL3>0;SM"G"\JJ.-3IN77C=L_LBWL,<&HR,(Q]R@EHPTV$@Z&$TI0!7(GRN
MVY)5//]VN4NR%^V[R-]X>@\P8'@KZN(+9>4B.AW]D^</P$%=?<^[7UG D5/3
M_)S0D>H'(%CQM;BL]0/PZ0/PYP-PJ!/HRTY[9.G"'@!Z;@V)("8G\,=YLP>>
MX%-R7)3VBX:)ZV''9<[99?/J(QC?XPZR?6[7G9'<(Z[Y:NXL)6!WIVNQ__G"
M6-<@S;GV-BKHS=AYV3PEOIR_W75D;<:(H^"NV(7E:?R=X'W$8#?G!^^%8$_K
M88U!M '=GXAD/=9T^RGIH1W"/$^%@S611\HC?N&J7-GM4'!2UF7&KO[:4D+3
M?6JT$9]VTLX9(MG.J*6]&D.RN[Q._- O)[=/8X.(',H4PR/20]B]RMFQQ.]I
MFE8C>,1L(-Y@GOT$E_)_)3QC^TH4Z5ZF14?692FG*1LU-NCZ*&XX#BPL72G"
M"ET1/@VSS+7X_.*:K];<QC9J!93Z4!',<NGJF:PA!^/=%AU%=L;]]JX%LAM<
M>Y<;/<*?=,NRW\NV%+6IZ=E4Y"?P:_FU14/BYP-]7LZR,PH,8O/W\Z&]L8@#
MDW-SI$?QACUD4CH](8-'60R%9TXQ"R\=X7$<FDB/[S$KZ^H0BV@^"A6]#X"!
MS(T-,P7?Q.H0)*YTFZ%R+1L&3&G0\X7<Z9S(2&1V3N>61[PV<I1J-.T0'[SS
M^[?262H\58L;OL8I%%END$1=M8'%ESI823$"L+-3SG!^+/JR\!.\5<1JA+9T
M\S)*?+5@W=Y2YA[6FI6,RO+J?-:8]/HOSE5*<A608#1R?5VSUW;H:!L2?C,"
M$9A_)"MX[]=(HQ(;!AQSV@I8(G9SPB+-+4Y&L'JVF>VTE<;C?(_7_"1XL\,*
M6X5Y!_IFCFW9F,N[>1X,![B+O*2I46BK$<X6C1]H4Q[U3R;V&Y\U>2B,)QW]
M*I??;FK>*'PNR51&(5\HW\38S(+"$)U?6:=TL*Y__3")[=Y@&7MY,D6;/8[;
MZ1.\]$>KJXXU(BA&)@)ICI5HT(+8#T/0WIODO$9^X&[5W!&/,>3+V&?$H,9[
M&-ZSA>AZU[1"_&%_O=MQC6,;QN$HL5WO9",F%(NWPG#"FF=A/G68;[&PPLY'
M^+IP]4D.UVJO$FW*4TAQDY6\R<67L##6PY-.$W7C?<YZ>GDO<A@KZQ(I4:\[
M59R$-C$\Q>%6%Z8=X3ZMQL&ZACS1LB.%X$U\V'FZ;_.C<S*=IB5B7][+3YED
MIDR N;@MS3VS]XB"HJ>(63ZZ*XR6C76Y/AT^MS9.<#E.2)H0I:9&C.@U0]QB
M_'.NORB.SUQ5L=G?<.%'D/ 6I-5_U":PB_,:9Q20)56Z852R]ZH5/0MU8,9B
MD"Q+6?.(,ECNMV*JVEEQYFB82U_:5U]HF 5O\OMHQ!/R+*WNKC,=G.D7#0#9
M3JGMU1=D,73MPS>T7A(8".C_+&1S_]1MG-,Z>7&[U1WU\&"ZN'-9MU8%^5BZ
M3Y=8)9W<:*]#)^17M;;.7Y+LZFZD:\;'T%=L:8Z4_;ML&;"V"Z=$'DUW:^IP
MK(JO9SJWDF!2(7<1G,24D;;)L3!JQ@$'8R26P_[HA1:Y%R[Z_QV8(^O*>53/
MXA:[;GF5C^D=6.>P]+%H%N"3!P^ &8_S4JH'=D\V5GGQ)I/1HR@1\;_L9-C7
MG$J]?LF"V?\;(U&O7W6\._B:?PM"U.4GIAY9S>*07M+JZPW+EKO!29^++??F
MQ&*XE?#?_C=9+4Y !5X$L>]_=W5WE)>G_W$"NS<3I;PB-N+B"_Q\(6_K9E&U
M3_EG<@]7!AI%7\ZGJT,=#%*KLMG+U:CY^0=[5U=J,.VL4O=[>GL$"J(^W\/A
M_=T]KFR5%3=CE!L>"V'6=QI*!PUU\W/J;I:#"-FT=P<:[H1^W$[MHN_K]JOA
M+45:)XYG&%RYKRP#[G2,F7Z]:-,86_JK=(?$D>?QTF0$.5->BOESI+44SJ,9
M<:&XI@>#DX+=14BKW;_#1^PI52YX-L?7Z]9E$KY_!\]$592*'$9LHMI+]^+]
M.>*2>4J1L'U/>;7J-R'6&'IX1U;9TGB=G.')?.!(,E],0T;4;EQ\"IY1Q-"3
M6W7/?W&;\% 1!4\S5;(T1J5F[2@_,^X5YT7<Z]-(=NZ<;1*]T5Y'0)TX3R+J
M_ME/]]7M6TU'=K3/7VK!6-&E;LD?K%J6+>EWHFK*Z?[EA.[PPO"S!G6+2"O0
M+NZWT>&2BC!-P(5Q^ZYX)0D?M09C>"Q4&7YOG%?5+*^<VX0"+RU8T8!(+J-9
M)5]35:=%&Q!?*XL"L6"FVNYBT864M"U-+A I5DD4ZG/E6'VZ8W?<J(X@R7(Y
MFN:\*-!:-=@X=7!N$,.^&SCY/&I'IMPANA<D4&;S2M.'HR% W^ZWE?R.U;8K
MR.LV*7DET]ZRE_7.F*Y7_YJ,W)Q:.EQAK6.0];/?9*E%]42CPQ,LO=\5E9T2
M101*[G>+,= 1)3JG=0<B%"'"(##__9ZS2'X8)<$E,]X#Q/'"'1M<:=)B(V'<
M@HM>P[#3 ('?+*;2:I!_0S+]X[.=BKLK2J(L]+^M*;2F:[7-VMU_JEM<*<K<
M4JT7>)JM@N0&<PV,]'&-\6LN=59994YCRNYGZ25$-(6W--E9?P!T&T+"SGFJ
M;R7]-,/WI)EJ7(F5"$&%LL.W( )UZE4UJWD,\=0L<MTT&MP@*Q6PO;!$CLVQ
M0=A6HGQ'$>'8]$B,[:AKO7ZK<WQ4HR .<SCNM:6*]*\!:O@ELQCJN&3J@OT%
M"2*7.S[_'E/S8L<[2+:BV8M!7K^ 8K%-IT!Z"[?+&>XCY.6Z,60"ASO<B7]C
M1:_ZE^MLI5/^A#DL[3<:G>T-735(ZQQ$;AM9A9ELJ?4VL&D3?4^;HP*9;S[<
M-8X!M -5NI&C?Q1].#]I,M^DB\_A)TCC59Q4%8I4/6C'391*@/5PJ,#29@B/
M)!9$4,R)(TQ4V[KTY=)HU@X:_:\RTW*["%9Q_X_ Q"_:-PC%$C@AA@U7&B("
M\]TIV?K871 T1"9_:::#&\O\E96JIKL_ ZNO.'JL#HR.0/MR3KR"IO:P0B4J
MM7"M\0L5ANI<>7L66Q[6)@7DX)N'K7$(MK5.8?JJ?,YDGZ/=8=GP8_/-QJB
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MYJWLEZ'^J3=U0NG6LF+1EN%)&G=ZN_D8WB7'WXX8K:*VNA^$5&9-.9OP^-_
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MC%D?  1:F$JC=K_ 8]L*.6FRZP#D96"8A,2QGW[#/0<&61 [(59HY;+N\,-
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M"Q$A<_SAU"SUC7!LKF[<3^-RBR&F7I$4[*3$(X<ST;ZYRXA9F#+]GQC]2"7
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M[O(LU;4H)U";36'-SH[#N.\A.K-"FVCLI3JM!'_=D 5\R*D[;;E HL)!5,%
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M8FH($!8>Q_^;B.T-EWU^(Y1?\MGA K=7?TJJ+I4TM>J([A:J-O:ZI"=/5^+
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M_>)MPG\KH(9O\(KMMNR5Z220YV?P&J7S]!] Z/WQ]J=,U>R$EM+G@))>K3\
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MT.>G Z%0!6GT@GU(>#2730RHW8#%;0VDV%+2%B4&2+4=]#"?Z$#^N,J\'PQ
M.)=1BD4R/Z+M&!>1 !? \3.(G)08_Z)^B]CY^5R'9;TA(^>-W%S8!4DT8#!&
M[_-;XC7^N@3#H_7; )%E1X^Q<[VJ+E(E^YV:DT.N[L:E(6UJBC*I&:J<^2=^
M>2U.-C+.#J"##UID+4= AF%H4NR"C%E]Q:C$D-<1&HYH,/^HX1)U]NUH2I?P
M9VI+#L<34) $7T8\O8+W6C8B7!9;#4_IY(E>'E=DVCNK9^7MTB?+/NH,!QPF
MG.F%507[K>\>+D[1C(Y + 8Z8SJOR"V4GR=^)>4Y%51)/]L<0^&^&.9UE!."
MNR.H."1Z$,5 #F-7#WW6;;U-]%'?(+1M)XSM[J%GV,^&! ST?,,[TN*X%-,%
M%7\ 3#3=D)WD[4U(![,('P4AG #:BN+(G$6E7/&!F,;+3\?PAHF.&K.(G9-W
MQ&-Z^_Y0'<0\8,Q78D];D-_-=S0+(:XREW$=<@Q=6H+K:RKPTT.%0/M/*4O]
MPS05#P\7JZ_I0R0$:1(Q8#/H?.-:]XKHB+MPD.V!;#ZA'=8!RQ&W]]/^H>MG
MAPQX09[SN[ C0D]21RFOZ,>W%?:Z<-=EA4;N XH@M/@%<2OX5%HSBE3E8NK'
M6.PER!%6^,^'BQ\0LB.*U,]2]YFWY/QS0'H.)]&1XVPY!B3+G]=J7]8[?2<0
M\+[Q==(;G3C6RJL?Y71&F-4:4EM*8"%S9\H3)?5<D>E_>_A5.D(^5#6ECK[0
MN2\0O[(I*!LDMMOM%4%KRW\1C,T"+E=/(M9,#@)NQYZ09P=<;QQB=O.9Y47)
M]RY1MD>W;"(*P/#$HF]BZ[%$I0Y%)[K?S'0J_+!%2T:*QHE&B\"9PGO/P&@:
M@JT5WFJUG87<)@\335T.M.*<Q*HB6O<ZBE$^<8L?80?M/C3ES!%P6KN.6Y$V
MY036QX<][GE0/)B5[W)UX#;Q0@C#)KR48G2D/4:&9J.V^KWF.8.(E=L.!-N@
MX:U)#W*]>%4ZH::%W ZT9N%>,Z=QX+S%B_)M0UD#/ ?>N4(5;?@X5JN#30'S
M!G<J[%J8F6^@1HJ[R0\\<9=ZB <<6QV(@$FSVX ]WA A(;]S7P^+:94KQF^'
M&S-/]UWVXM;N,LQGNA1]63*EN-,!Y8?/A.B4Z5,WR/R2IV^?W1/[FK\2G7&.
MK0E;YN@&"C K=Z2"EGK5266)PL&>)BN-+,S<GQ&2W.3,L*@5X9:CKH?UB,<8
M7*GRI7!0W@FAT/;$JW!P< BY&TC4D#06(F$'S(CL=+P<32I?,3U]"O$K>\G;
M<Z;LSM["U7NV3GQC7J$U-=;[$?\'8(M^+3GJKW#U??_7RK)QR=2ZY5>K'<G;
MQ^OMMEQZR$GIU?K(3L9H@ ?WKW_\!NYLM#["-6GH.&H()I[]U*.YT^$Y]Z_2
M9JW(Q;AC,=<N+IYRXC3^$9MTU]1%NB;,2=3,DQEC:TTR)2[K,M+ZP:!V)"6Y
M][" 8M#8V*/5T!CC*&%&GV>AC^F#2BS!/"6?0^9+LAC=FI8LLH^Z@D(9J,'4
MRVD3SRSA"["E@G5&H*C83T,B.YB-6LN<&%,*@-U%[-5WGVK'9CUN]/C&F[$X
M-IO O=;M?<1  N=F91LJ0X2UIJ9<-Z[,4N.1H>GS[<-4DZK_F6.IL^ED'KQ\
M8:RE_GV]%*%RUV>BDZ9O<W"L6RW'6YM;+8T6261)!LK 8]^3!URIAM(#MT;$
M$5F%CD9?[&NA+VG47##+J<=QM$B_5_A8UWZ54)EJS1W$G. ZIK=["?LY*5MF
M^1$RVU^!"5)GW3*.:2 X@K_00]M)"^[HC-_%XR9OS#GZ;M>9CH5YL?ZV#3F6
M5@&G$Y=YP$JC.>*P/G]3F,CF_:P&_EPFT2^J1RTBR:\$1VKU+&^=--B0L$+3
M9$VG6D(UJX9RKP4)9UOB&+JI(5G_-VN$1B]U[ZE/1C,)RG2H V;[YB":A<P8
MC>@P=X($#)RK_2@X=V3]BUA#27C##_*W1$=-EEC#6@WC2JXM)R1-<M$Q/>M+
MS%A$7#@ #4S)Y$7$PF.)!G"+!-2 OP^N8NQRV,YH<GWP2A(3)Y^J=<O9X]8$
M+)]WYOTBTENR<^JHL2?E]/U(2&2&O?K+ ,D"(F?Q_9O'8@N169<7QY5,_X$Y
M.@=3NI;;T(P2-C?O?'ENF A#"I<9^.PTRO!V.0*3GC>=-!B_["Q%#>@*G/(Q
M_:H[%WPF&B5-&BDB$(O+3[5R.-0V7-Y0XT)UU(K^N<DY6+:J^'B?5=TIRSO1
MZQA^7GPP/6UDAM (3T->6VM::G$0K6%D*\1-OH\8N.>%T1,JP$\>2M\F:WJ1
M%UIQKOHUZ_L*"_=__Q*-<#);E&S)=D5^K.AR0K('1+X34%"L$IP;#>[\RM,U
MG^PL<5C][F,=S_;Z8>,%[/#>S\*:%HZ!%HYX_,=HH+_0J1\FY.N^OI,CC_^)
MFI*7&-OW5H6:GE9N<\)!;QC')>5,6?1%;'I+LC7-T/&*X'U.@46A"4A8GWDT
M=:(1"VK,461Q68TB9L J(WP%KB36D<RL#\U0,4:E/K>)OC%7([R(N]#78C!5
M'/K0%Y=;"OOP8,4GT_VUQW"S3AGR^<K[+0RO^>H!X=B+=FZ/V+6\<1I$>H
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MLCW1YK-:5I3G@6W/R*FZ >'UHWM!W/DT,20E=#N'2)<O9A^/;I@PW> 5]*2
MO9;)UF;:[W%03/2Q,S- 1VN:P>+V)&=CMRDOW@-!<\R,(9KNK1@EI,3C5DP
M+#+$_PPL] FN4<0:T'0B+K%V!"J+A4&0C602D$/4L29/4<IX_X:A![40OJA4
MNV@>[A'\Q]JFB3K!"J+=2Z9,:.J%.BQB]VU>6-?&$WF:7"8)ZG;07TV>" 0X
M%TE&=R=9*;''L4*(\3Q0ACD7'<)_T+6WM2>Q^MO@R"=/"XPUP1KJ9,VD([*D
MO*@0BL&L2K7.CHS&MKZV"CQXO-,36A^-T.>5^X"7;RI,&[JL2A4[CZGP6Q_Z
M#WKJS:Y <C5";G5'_>-V&ZM5GB/*<LYC@;SJD[:>A,WTZS7?.'5Y+-%;G#M"
M%.?MO$+N!!+1.F-VL.30DW)+JUE;CY#;X$95GJ9-S#@9CR+6Z2J6H?DL:5Y[
M E_J"53_4SA _TRH2Y*5X:5\9M:S5-5<M:DF[IAQ/)8-@0YZPFZG <M)7I+I
M;T<P:'>?,^RG:%W9,G*[DC["(8H_C: KXFM<;&XJ.J%H!*T(+IG/+@FVF1V,
M-&GD0(L"&9,JOO?92+W,E4]'T8A6(4:=17Y6S*/PZX/T=.?V1'QS7@F]2 D5
MM1"I5#,'!&@O4.#!/*K?M24]$(F-7&1,2);/73%,NU,M3K9TF[R8SCY4;C_\
MNL'$XZ;K[71E*N@KF. ?Z#7P,%)!8$3GQGO:/K^:;X &6882AJ/G,(I+2,GS
MY/OI26--L.ALG@L,3L5HSBJI-XPS1P3/]>@TL)T']PF".V$YV9(U*D9+&\Z*
M*<YW3VKE$.9&RUB*.=*)A 3 > A=L44C0#_!/6.+/,<!\WG*R@\SESAKKIR<
MS0W'(?X2F%-H['.VY@_HR',=K=\2-%C[1K\SAM2 0K%W@B:1Q/06 ;P'].I6
MG"1"%BT?54. BQ0*,N2;[4SX+J3IKM\!B?=1R$9W;DJN_CYJHYP<N_@:QW0[
M").9L%IIJ'HCB2<#N9T> +U; ^;Q&6K(XJVQOBS^ Z,"7M:XYJ_X)#C^(HK:
MH'Q>T=L;3E76!@C6F=0:B4WRKQ,ZQ 46 $2[,_=1F>W\^L\Q73CGBUFBXB"R
M5\([?J4H:!%*ZF%EOC'=)RO?8:K,#@AETK?SF!#G'&?20Q55CUMY*R3./TP*
M I"9 R,# M0CR\"0#O;*L1%EFEH10ZL6[ETE:2XO'G$QB^]IO?IKQW"V<1T<
M5.E:ZG"$R/#<P!32;7JS5);UI(:5]R_&.)>W\+HE]FV)+&&WW*<7;^WS/\Z'
M-XI\9>$+7ZUW+VZQ\3Y+FG,N=L_7FHT=-;\YVUUHUS:;^/A?#[$KMD>\1?!,
MWV=QN>AJQ/9ON3G$9>N'W<W!@#(#MXL-X&D!!W)C*R!3)=_+H9^7@Q]L:'X.
MY]I9=@MEOG:Y#? A,GCA;X%]U"YZ9;OUU^J(4<AS_- T,-& #-!0L>_5NB]]
MW6V##3UAN*\T3(HGOV/652W[Y#^M>/Y_+W1]\%(1&?E,WW-T?@?J[QC*,PVZ
MTE<C>#;Z&#IO/6XO))@R8CTM<606/&_@NO5&/@?A02 [LS!*L40_RW,=]5RF
M*;#0WHD21R7>3S:]PQ;L8D96M!T"]ADY3)K*OON.3_S*96+O_CFC/ ZVYQAV
MMN#/+Z]]%-]RW9JN1MW_ON)/_E%46_O]_?'>T^*OE<I_AYP?FW,'?-EYOUU&
M^@>@I[?K^]N<.._UMF,;L6O*D=*F[D2/P;?]GC^ ;C66WQ65'V_^ZGDN_KYK
MT85ADWTLN:T\S:_V8M#_#P">J?1+6S=X]\GOE?<?@$_9FE2;)O*YJ^9_O'G9
MST]W7X+.?E^H-P2Z?&!^M9&O?]!>3_CYUX;E\V\*ZO^N+,?B8?V5?'"K9/6P
MNSG=[,^6@=?G<3G7?P"3_??E/VO_'>CN;QBWTR/RX;MCQ/ME"I'M/X",\,^:
MWTW^]U3WY:OV C.V3L*^,L>+K+/Q-:7-0,M/\*]_D<T),DW:1?A4(^0Q6+DR
MDHWE35_:0)F92^0S.YRT@;#I[I-9$Z83'[O,[=]-8%EF:4!J!PN/+\:$[H9R
MOU: ?4/<;KM19S 8)L*P%B*UO37X!S#3KK L=ZCWE/.^UFSJ4^/;A/=-]9M4
M;2+CO\5]M!Z77]GM7NCR71H>/K\L6^MM_*AYNU@5/5)Y+_P'8)+UWNH3]1^
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MX:YSVHO1SC79+Q N<;[ZAOB\948E*%S6))6*-O^#?-S#H+N)M8WO!<!<-%0
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M- HPED28EI9A<2/&!DH,&6]?O@LN<]RX-#F^^G:YWS)^U"6<_C:USN;^Q8C
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MI\<3+5_L;T"?B%-\_<RL1]WR&KKP.XW5+HS+] 1JFGA<\\9 8: ^K(GP\ X
M7;D60 R]Q#HQ4TR!1Z U+DS)KW\D )Y,-&_,7%VY\!_VCV/I;UZ8T0[!,J>9
MNWY2ZA234G9JE'[9HQ269^DKSJNA/1_3;XZ ,#'C#&)=!Q9ZYY,S+)^VQ2.L
MPW/DR7)=%%,XZ._F-QTLE+<C3SU*OB>@RXB*1@M@^?*K"6AWIMHD$.4%*8-&
M*\9H*-8]>UIR1._/G'L'JTV&,3^PD+.S>398*2M%JP"%/!Y;7&]+50^$"F__
M?F=^\A+1G$B;Y>9H(E-P')=]C(R811B-:AH1B>)QG ":$2]$#P6PX(=22SG\
M_9F/R./AZ@ROHD7KX,Z@852"BJI"']KJ$!50$CHV=$^+X3  +\(_P3L[+&D\
MD(\7DS6<F?MHJ/'W]G,@[?FX)/<FZY;VVY;!Q:@X_9'3([,HRTYJ6\-54N02
MWQ5#_V[<F+?88&4_8#^T7RID[RM[A^]W0S373Y72O *-V\5U89W"KE,.@K!%
MA[GCR;%U>G]J/X"5)FY1\;TK.#Q&*3?..:X>(3J\EZ;5_U-_<X]D8IV;/('"
M5P!G%$]/U#IT7H5D74H8L=X_C5\P\D918SX=@X<(AT9*68I?_'.YJZ_'^L8R
MU#B&@0Z/./=$G'NTA&2*-022%H:]SOPI(3-I+7**@&)-S*T]IM<N_-7X !=\
M6T'WHY& ,JF-0$=BTC(LL3&GWY0.>AJ D9^ZDQ-W_:;/IFZ_@YA,$/$ZV,0!
MQIU<5UPUN>G^1OC@?VOGK)K: * %'2"X>[ 2G *E$)S@[N[6 "&4XH'B4+RX
M:W&7 L7=-;@6A^(4;W&H[=W9F9V[#W=GGW9F9_8'''DY-N><CSVD=;[L$,?I
MNUK#$MR59'R1#R]'XTA>7_BD54S4B5M$.* 3=%"M L_[DEYQ]$#7BF3?-JC7
MTK_D$J?::(/*?M?BDW@GL=K0E?UB\V*KQ[VKC69&(*']XG/\\LIR/+RNZ$50
MQ!?)=Y(_H?TZ&6,2IY]E!]<_>57KEL4PZU=&5>RCN!HK6=>H%&@DW3I?,;#V
MZI*J&4B_>H*'3*UN0%1U3VP93$@WED*Q==XISI%U9;H!+U!;<_!GL5EK[ >2
M=[-LJ#PC=M[LE48WE0+WJJU+A-F\:0 N88P<U81X=_KB*-.6.@G5+@5-J]N6
MO@_]=8R6CJDAO)U050XT93YA_E9IG8TDVTMUDLC\+3 <)2:VT18D;2_)Q6Z
MP1IW_KH)><6%Y4>X>GXU\^UY]<P0QQ[LF3^8/@5.NB@@$!,*GK)P?'+2K#JB
M2L+-:L)PX.ZWHJH>[PS:+8QCY#FTCNY!Q :GR#YU-.",WY?4W]\H1;,,GZ:
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M^AG!PL0!#HO<%K?OJC5)N>1S*<-W6H)YM/M4EE[Y16RH,?_<[+:H1[$UDS-
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MUF ^8M&R<S42")4M6JBJFI()^VJ&$,X'8W!B>I-'A'UT#!D?;>/RI;=U,/T
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M9F8BN6MR1D-K=]Y@O;]9/K_?NM7ON.G/?FFH2?]+(W7R2WIG^_9VSGH[..-
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MLQZ'<_%,P)T-E\(M"1:-1*N@!-1PEG&;B*_A8GU RZ7:@W*U!D ^$F&J6(B
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MN65#E[NKW[_Y](+\NQC]MMS7-6)(U\BN.0/ZC>CJ/Z+?@!']MCS4-;ZKJ_^
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M1\R7ET@?D4BO,J?-&L-@SZK6&0!BOC\WYFS_]>&9__*?-^9_99Y?PN?GR=Q
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MY(F+*!WO[KY^Q C=WO9\$9M4&-_$ZXCXFGUSZ[OBLG5EFN6,99WO@*K02GA
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MT+H%9^2B[4G7)SM!;<H9>#,J*W*BZVNE#,][BT-D&ZN:=W>.9Z3;0Q $B7,
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MW(SAY,QP+("X)(%-*:TU%:* 0OL@\QB#!92QKS*^:.0J=BR432R78S.ZMV6
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M)-5&2Y)P/S4S*-$?CZ8>GW;_RJ7+#]6Z)*!(%\L$J520_92,ZK53N=61.>>
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M#77B'$ZY*Y1X&QBPM7 HS1YC^S%%&5"(J:>;J8T41L0_#WO?*T; %5'=K^#
M<X& GG@LCLGP0*Q,N'_AN3C0GMO&IQEAO?:3]4%F)<+(?9&".#ZR$'A-L53?
M#]@Z)A4P'+)T OUYU;[,6*7EM%FGL8#JH/;I*+A;!C=.=$-&$V*XRL1#Y$&F
M4=:AQ,GT_4\E-89)-M:=GN+<F^"27^#&#)7+L:NP6U,EG"I_LB9-D8%-)!3J
M?&[<P3N0TO/+%ONT'!A@M#VJAVA\L2I]7-OTB0R#PN0^!$GOUT2=H>!2Z+U?
M3\CW=9.:"#VUGT#<DZA-6R?7"?+95H^;EK1P$ZVE1.[#XT00=#.C[N=I9B;;
MIU^;L<AXCYT1O<ZTWT9];SH4Z GW%AT-EIVL>1?U\4&:WKBR5,O4XMK#F\3.
M1)"&L4H=L7V47.31X+!!")Q_9/IQ4@DVO0J21:TET9CHB: X);[(HIK.XF!P
MS$.L2*1"I>/$Z529NBA$H6[_BIJ)[ARDWFNL*>>3MS?5%$)YE'O>-2FZU'NU
M3DA*S-<BQD'E87;><J!@19IQ[+R<XN-Z6 Z7SOCP3$7DW1X@T]0K&=$R7P5
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MH#"#6^TQU)]Z4\QO@Q%JR(:@('PH@AGGR66$014X3)1,+.>#0@3ZT *%4:K
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MKM;O7\7ZJLZ0H_^C3IA!%DS@]S=^M-6?F6EH,>W?L-6?F>DKX+]CJS\STU?
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M"5K$.N_0HMYG-S[YM!AB!E3-<$LN4=>X\(X:DZMS[[L?NV.KBBY_9/1+>]1
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M4_B<020%K1(=/+RX<GZ<[[ 9JK*[V1.>FT\8L%@Q^DQZL6($JG;BQ,=7@LN
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M<]+9:T%+VCXOH)2,]TF^_>[8C;(+A90C$4M 767)0EF[^C-SX/TB^]J7-E\
M9S\_\$F_MNC>_7=+7+S'PN)R-@\<R^]X9'1^2_5G^1O7E\*.9^.GGG[G>J>@
ML++H"R#OX]'->(]%1L=>+*FE%",WZVH^+VBE&)ZY6=+S<=^#E[]ILVABY8=3
MS0.? W73A+W3YSQ8 BIK-]N,D7^\W4=_>+;LEL><_ 'Z;^7PR8IX;[:D^PM
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M7O*=6-N\/,FKR8&W??L22R)PV!-O*>P-PZN)AV,?10"&10X3K   #"P PYK
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M/E(5K-8]>\',-N1M/-!X+SAE\BLU'@/3"B,Z.=P+E>HQ0UW:/ITB"SZ%C@=
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M>,QY1V2FTZ#HX<)!WP612P734<QW.:P&P7&CZ/G'&QL+H#^PW6*EJD537[
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MZ7D@N'_5WO[YE_PF\ZE;>=_"U7I)CO0X3#(R/VKL3MC]:[Q)W]UP^UAD9O"
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M]=FCBX9%G_9_]5:U#7^P!]O;<$QOY12/M [A8F&=J! M\99\N;_0TY;7\G<
M>+9-+(6_LQ&0!QXAE"B)1[WE>1 [^RKO.T='K$@HN:&?@ZQ.3F!: Q9V:P;%
MLW:&AAU#Y! X%#7''R[/9UW6D<*%^=".F+Z$;,]J1^JTD.-0YG(N=Q^4W;2<
MER#RT8V!1BZ*W)I::0!U6;9T1WE692+KO!3(IJ,D<U(^4EL:RIKW:32?4I#1
MWMO+4L*:<R@X*]@$=E6[RH\M(52O;1QR\]PGHN.](Q?.F?C4RS)>A1EGMS>D
M;\;Q#6WCG.K=Z%5]\9<"]_5?L3KJJ0.7?5Y;T1<8/N4O,YNZJB>CDW-F*3.6
MT!;1[^LHF)L;THLB^D!WD8,:WRT!="6<&4FQ$44*VF<$=K_-Z;[BL9_MP*6,
M)K3SY@KD=G6 6%T]LTO;(>7GCL@R#"EZ_7X2'N)&>D":SGT]VE@HT+Q@F5=^
M^V;I^_)3=V]>=!L/IUT,'K1W=8!*7"@*B%HR_1[^S7GK:(\\!^_U7X"3-G]H
M)NKB4O: *Z4N09&%]JNB^0;PX66"JX&[?(*VCI7^XVJ70/MA6H'SFXS/X%.<
M.DYICI@N!G9)(B6K76WXTS%"<YR+"Q T[R"R?*<[_V*M[T8>GJ*4)_VDE+6L
MP AL&5+-"BG-_AZA26A93)1WG&-DLN[8_699V%L>4YXHTV!91TR1B&00R9D(
MKM>SB<(;DDBXH)#R!_/HI]KHT;1_Z2#T-^)=-%1?AGQ*+HZH,M:\39]^?HXQ
M)Y-F@V'%&Z!!6P=JSM9!QQX^9;<?E$8<LV.$_L;Z=$KWR1L>Y:,CNU"R+9DH
M>YBIIY1%3"[V"ODD+03. /^X[-[Z^]6*$%;O1:"KR(_ XF_$#SW;ON:G=+R?
MF4F-SND6ZNJZ!06'5=6FEF'=!H$U@W/@X&SK.3%@J4O05O'L%9^B [7M=::_
M:< H)5_B\@C")O$O0.W-7D./31)6(\&?4[W_]SSJ_]MJ\55WZ/\".,LQP]%*
M8UQ>7(P!*%Y,96WHDC<DFM800QY?,YX5 X6)V0^PH<+S1'C700TRQLD.6K !
M9(%)I0T2MRR V^/)U!G1^J[%8D/W8UTJ[<,0.JD.A-0%D 4+C8/++7.TY.OR
M7Q]B*?KUV=%TUIQR>7.P#O"/D=CQ+K ,O.5KLV+&4/%NQJ FS:"HBX]5;WHM
M@I'&ESI%CX7'.SC2<W+TZ>TLTGG(=#Z+,!?8&?K2GS@@6]5[?9*\AJHBMH -
MP!CB-CX^8.CQYX,/2/XJ?I;.I6CM1MQI;:HJ8HIRZT=S%S+#15)FH=/VA9"!
MUH@W\9WC9LGN>,/S;F$1H:>^7A=K"X?7(HP$PIS9+[*851LK'YNZ^,HX&)PR
M7J0T&C>FIW@<1(HUYZWIXO53!F RZ=%=J;TP.?GD<Y68X*%J%_[BE\T8C?GI
MO%BK>L-S3&/H.H*L5\W=(U2%D7%? VG&?>+OX[XZ4V%;\-A&V='S[56R])/A
M(/5/#D3)&W+?[]EU[/H1*!ZNHDZ5=?P<.5@:U7$J/T-NYZI$_6:=/W^GL?DH
MY<Y9J>2TK5<DP:N?A % MD1"D]L6G9)6CWUS0WUV\[9PG#1'8UTN\"2[J1!J
MB#3P2]G+ED\JMITYQ(CS('".W$]&0>&^YKX((*%'B[O36]K8MC"!,#DG3.]8
MX:2W,QM_ =_OKX*)4UU_OSK)5+[LEG=KLTTM:7(RKL_VD9.F/GWRO:Q$S0V$
M+I=VM<JV@CXQR6['>6XWT'TY_C5J5YZK;?RC%F&U&1&94^WBR63I1*[!"]:#
MN2ZH]:1U/*]M/;]^HY"(>-^KD-HRC!JRG&#8SWSJJ\#/\+U#,:WYW^^&=$^?
M=CXK.]6/'_D2G%"6JM'H9S(E\U4XGN+@JXGQ&N4>18*\2L2^V:NK[<WH[_5[
M]Q)7')_[7$KZ<#_:O% *DJ]LZA!NE_22K3LG*3GMYL[2X?$L,S([HTZH;/I*
MIA)CFS-H%NJZ[G:1ILM%%#N5YVA\_OW%C<U91FNU^[LTB4YRK27!SHO/O0 /
MMU=*)LJL(^^F>S%\;!N,,9U^4^B.+;;QJ-SKGEZ.PAJN]E2*.,YTUC<L2OG+
M1LH_V#GUGFS2MG5&9,$I1Q,%_S1YX@O=!RV.Z>XQ9[M[LM2^=N#>%S+#F!.8
MB)Y']HH]+;M+B.?:3&L7R^BH<78C^%93$129/U>W&'\N>>A4XF...B&<$B[V
MXP"C@&T/Y^+OR[=$-(0..\<$R-@GISR6XMUB?,J#M;I,T\<K5:T7X@?&Q[-3
M(RCU=>*' ]?Y?!AIXN=L3),K%;8P:DBM.6B#SG*1T+U5LPE9UM@E43DHKF/^
MG\)D/'V:1 8/:8F:!3ZS$39-X?H[[LC/E;X6M7I=X1T3DZ3GM;M:-LNQU*8?
M%C488[.RTRO<_8.T6&T@955!K:<4I7('>]8[)3)UVGHGNA6JE7L)DF(+T>08
ME*7)S[ 5&1GEX$:A[$4T8$QI!ALP)AXX4)I>&;U12&8D11N+[F>II'_3HA=6
M.MLR)1(&)HJFS2\2_Q6F["ME5<I;@U^L]-W34BLY[7,E. ]\)=NOE4>&'',@
M?)(8EVOHS=YO6^_QKO'<O+XI.7F)O8O."(@%MO7"K?SS!56UGS\P84#G#K4C
MYWK3)Z(G-TLL]YG"*Z*$DSE2U9<WP_*X=8_54H!%*!06R"E-_R0I'C@5X!XE
M_A+_;GH^\G&4GN=Z1,?KYCH3]:MW]/7F^B/'B6@O9X<M@EFEY,E''@_3N<@T
M]TMI/^.3E:S(!+4JFH@&0O).X5+=;.T#VQ1!MN>L#'=/,K1&8G17?G UM8?@
MNU4 R*3 ^U1@DF=I8>P]F2(;T$",Y!1%PU$S&]#T_2FC#+?16]NB7S>>11<1
MZ?+16+5)1<.+M,.CZ%10[%,G%F[-]NCR*//'G(T7,!IZ7<4T".,(OTYN?/'S
M]:&4=AWW2,@ZH("?TTM9?3#4+)29]Z*LG82\TC5)"1"NKS8<;,N6300'V4GO
MXX"?/3;BT41+[+<P-SN.]7)FZB(45?8.7_%XZ4]&9HU^3]G4EV!0R@[Z7HH<
M-(ATIDUF-$QV;@6G",)2V%4+]T)@AT2&C\)K)C:7 #ZW"D=M)>P\2TQIP!T9
M7LWZ?X[J#?+# %ZR?^&;);!J2T;6Q[NI%/Y,IF/*%^':+S:TZH8RN;2,!F)#
M9[L4,_.(:O%$]^>C'OPOWA:\F^]('KAN2I C75[6W>A:[_(/[ +>^2YO_G)Y
M&N^]FCIA0SK)PLA4<O/XN# [66;>Z':BF[_YQ.EG,V4#YS ;\4MP&P= 8#C&
M 9=AA(+N8S6_;9)0E2B#;8+4+5;V!>U969IOX\O>T.7%90L]KY5B7/#D>>GU
M@?JYAKLRLLIDWMD!XFS6WXLJ/4W**R5(E)QL[^#K2-&2Y7.DR8SE52.0!W*2
MHL$<)/PIY#MN*"_/4 3BNZU#K8[7,4V4.B\4ZKTX<3TP"F=/<TLWIXBUH#T"
M6R7).6\PQ\XK42_6QH%DM*(Y7DG%LI>DMT:$C0G(#L[AOSS!$R&63^ RB&2)
M_4/S%Q CI5J%,7:VIC0PLZN[T?MHM7<+M\D0#WZ--%PL/ZCL\2NUZ2O,<+5"
ME2>50W3>3,T:[E42X!]A%Z?VL*2GH??Z>VV AD,N>T*'/_''1F>[VK!C)E+6
M-8A0^$Q6['>%-&./NN4[0PTY*:+T;Y#RD 0Y,HXPY,+HR,M1/[S7H8#EU:U+
M>X>V8M_DY"[V\E4S=[863V<(K<- ^',!(QTM7*;@0!V0^H7V,?E566='06RL
MMX(FN2"!Z7QT.KJX?^KY1)<TC(R;='/8WB.PDD !AU?:TGOAJ2X:*Y)AI^;5
M7\ +2\($N=2\)"]1&\!M%5NQ 642A[>[94KC*QZ[<:G>8L= N)?^' LFM R'
M=IY).Q -;1."%C%3 &JK0$"! J/W935V1E*<M44MK4E2(N<#H *)SK,J3'P&
M$B64%$-R0>UWAS$+"ATE+S9JUJ Q6R=P&SJ4'1[/_M9% ^2A"LABK)1#.Q>*
M5C,PLL[BS9%E&<H89:.;0@A%L+W*!OFDT8W:NO2#*_U_F'/3Z,JB]A>@T/?1
M9H$CK\,PY5A#CIH8)@!63XBYV4"\MM*",#-&/FO;\0U1[!'L]P@I:"ZF0,,U
M87_H+^,&8K6>[Z^&\H26UB<:4"C1P,!%86Z_*[/-;."=@^ >TVSM0J6/4LY(
M6*7N:*11D*I<]ROGJ#>,(JWG7B<P.";?)WQR6BV"YEKPKB@J0ZLW%,$X%:#]
MHR*:F89&'77=,NEV. /*&C43KGA-%^CPBO<PH??V,)''[NW2RN*YBZ<[,3_:
M)EAZAF64P->$U49YPS62/3RYVIK+\SQ>53AM?+X@[7MC;OIP)<,>$0-S&F]4
M&!O^&LAKW=\2]+P5$87B_W=OJTEM'$>%%8CRXBN8_OAIL(\,>$#-% 1N'LO3
MYBV;Q*5:*Y!E<K"3[&]]+$BR9LK+8.8SQ#L,+P!B\$*\AB;0@8;[G/"=-$5+
ML?$JR]?O,$8(65%&"H&()*BX@MJ[)M&(..FM)'M2U_'N9SX/J\.A%5#BHUM)
MEFXZU.#'DV_T_XC?#9^/R-F?'ZX#I]V_M:DE=OBAUO/@:W['(BA/Q'$&_[+>
M1A=J-\\!"!R%BUW_6!)@WKID8XLNS]7%5>)AKC5'ZA*>.>]B0C>94MKF1C2/
M7XPN/'>@\ER):NIFU+>._O[Q-.4JICX;R'7-P[EWTS-NYY7J%O+UZ6 V#&.!
MP:-:EW>K/Y&BJ?7&K2*Y99LT?2.WE%8+?T6T!KZF@@,:P1WG3U[,&9M4M0:F
M' %C==WYB<"G/V-WKUN@I@P'EM.Y&=SIFZK@H]MP,77M6PG$CNE'C8E:L\2.
M=ZC5//=_HFCQX_LP)!CL=0Q7N.JU=:#K/&\8A/5R#:SR$^"_,7/9&SY? MLI
M_5DH6]56*!MM%V-7W5!NJI44=TFQXSJ?84TF1WIYS[&2.A/P-L:)F(U0<4MM
MZ$:. ;%$4$H,H8>TOZI#T_)PM -OL!V2!PY_T"LV+LY4+E25<9CCO9\F_/![
MJ^27G-C1+\7?M!9)?P$*]1^7_E'OS]]=_WYB\6MEJ3A'N^OM+MDUJO-5PY]S
M*^K)^(OE'W]*3#C>-VG<OBNOC_R^N'<L]9M [[V5H6_<7X#9)_[W.H9D;TL_
MY'_2JFK0JM11UL-1H42JYE#PJA@"#VKC94.JG=["E4ZVWK]X"995;BR)'8L\
MEBA&]O-:R>X!K?&:$/O0(<U/<U<VO?/NW*[<>Z()1W.!7$?JG\&QZ8U!V=YM
MT4QX=?IM18Y]H/GC.=_?'.I+K1/)L1>"*B(\=9#S 4=N,J5[;J\$<C%ZY_[;
M&J:.%<HURE(_XSAQ/B1@U 9;:"6_Q$:1&LK_G(5W(+*M657&^H;O&=4T 0!
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MXMO@-C7UX+\!AUN'K*%OS!2:F'H$,B[!SI"(#I:U D8&'%&(,Z$[0]0&GE&
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M3PAEUALZEKI'J&QMA$.<%N=%K!MF"%,B[J]30<(8$J5;G0CFBV5Y6QLM[RW
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M8H^D^#P)8UIBOW1Y+7M)@]5*/J5<F 4]%%>F,F6M-:80^2(0-BWQ,;NG5N1
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M4^2=+<4NIPL?V+#,Q24KY5_YYC3 )1?''/=U4&@:FL3K0DW1!0OEC8:N]2)
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MSSUSGKGGGN>N?_)WHQ57_%$KCIW3'DI*HO[)S9/16N^5=)\5DFST07BRH)+
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MZ/[IP*NC2RDXITA'V_P%-CE*_"I:J7G*5'V%.^FD+V[+X@^@(MH/*+F30\%
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M]4C5[84!BO:5#D-&NQ3P^& .O?I4$+(N[FQPEE6J2X/PD+@H[G 9CM64[A[
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M)W88JBH_[MB%S&_O$(!%"M2?IT34P!8EXG+5MKEK-*7 TQ'V^_<ED74J=_-
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MJS-CK!UZ!<^OV"-L!I"G($,B &5<H?MFL4R&HU)(DS4U"^4SSB K67E+3%?
M=(]G/#<,S$HBJU;HKM2. U6%@N+%2'=$':'!48Z; 61&0M#Q6KB-02:A$MFA
MCEO=@';'.E=QRTF@P0P:>=4JUX%R4HNS#L.!(5S4)*UF$4IJ4&KGB&:^"[/:
M<%"< 6PT*TX-2\G8F"UP#F,I#<ZM=&,^W#*8LDQY-89/ ^4FX6"Y7JNAXB.@
M+ M:/4D*QI"0V6%8][P&6,D5^8PR R@SZ900ZKH*V&.ZZ$'Y(NN!M* ,5895
M"TB#&=;+R C"._F\U^DP.B2D.HR?0:5R6(KEL$K/2?;Y!(JG4)B8 23HGELI
MM>S0R=@^B ^DI@^TXB0B-8RP6B%K2%DV?!"N&$T2&#1!F^B/2X',QFF85)N$
M9XF*78W)='K ><T90%>L>G&JJH##LL-C5J[1D]I!T6KU"(&+XK!(IBJ>@-V,
M-@A](>[6S52_ .JY9#(<IRC4DE-.+B,,?4AG-6D&L!!4680HB[X"=Q2W%7HX
MA@]@&JIFW%9+K#?'>4M+B$R@P!B"-!,(9^4P;V0B-)G.J88#65Y/Q<5"KU^D
M_(EB,QJ,MRBOTP0,O5ALI8QRT JZ$#7(84G)QS/LH.(0C7HOU2)9(V9Q)1E$
M<<%"6!&I^VV>CZ8'UUL<;]3LB?M2)2*C4'02%7.BCTEQVJ9K*N(C;1 O=IF
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M$(HJ(R:F56)QL.YG4)A68E&$UL(BFU>1:G^RJ8L#>M-O2U T2JF!!+03K=T
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M/:L5/WY? PMXE/^XR/T&H7M WC!+IJ_'E!.ER>,'VD.ZRUL;0&NTQ\9BY@,
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M2BD4.Q497Q%S5"[9A)/)&LZ$O%\;BZD:Y%)1("H< $R; Z4S[9J3V4^MP'C
M8+&"1['""QRN[1I%DVB]>]V&2%P7H8D2%PFY2JLW_\9XMO]%6JUW_W?PSO]W
M"==@6:4.>!I[_L4$C2R"QU(F#T>= "00:5^J02=)WM\$R47W ;,ZR2NE@@2.
M G@KA+9GQ;>V8)B>V.J2[KYR9KM\*;H[JC*HA#*IL?1)L4 /"-R@*9((5SH<
M,YY'9B.<T(;H*V/[-\$++I_8OP!6;P6WJP]?Z,GQ JJ%*F]PW@>NEYL*JZYW
M74A'3R(Z+PTJI(WHK5CD5->HTBG7RVHO)9>]*(RWE<W<V9\*BXLP&XQL\EBW
M!Z ^ [$Q:(R _5@1$%%1/M7]CC[X];$RY!JLS%<SRU\[SX=$.4(=U%D6\F]E
M\?O?ZM+D_O_^POP_NB-U(Q[3NU</#CZ$72Q8C]&@*V.%(M"=)')14\K&F 0%
M/!GNK=?S4_%]*!/YV4%5-'*+1P+;C5P<LGJQPOHNV)WCK?JHA':QX9@CJ$X[
M1*UDC)0CJ H\].&827>8.T3=FDZ*,QT_NA8ZF[X+O0VI-'NES2"KU_B#^FJ;
M8+:M@H(3TI1V'I<[B<79X%!)&QJSA%!22!+#A-=<]B5YB$#5#>_\U:S4 -M1
M:^@HCO."2*D%]JC)T6WG0ZOU/Q9=F6!$#*+J1_:4"+^)YG<M%:OBT"K#")/*
M9;%\YF6SCEUW *>&3C=_=/A.E]SLU 9YJ4T6!]_>AEL:<.+=O!5_XX+ I2^Y
MS/>5F0"UL9M/#>$J](FQB7W[2U,4< >(AQZ2J,RFE^=:?4+;2,>.$^XL?BX?
MY:\3#&KRAV(U/:%,C0$3 [,S/&65!K&FCXWO_@*TV4Q*=>KSG-U+-*;7O-LY
MU_/W$ZEB'9^S31;/<O.";>Q+L6QCK:.1<6ELR,N\& ,I*O*T8"@J8M&I6P[>
ME9"<0S,F:>BZ+0:G$E-NW)QJ@L<9:5 <&:,I>V0Z6MP,>%*26:S  C\4R2BS
M,>Z 7JJV]NPK?K/;]%-_RHJAG=I8Z5-![EVYY25Z5R /0VC;MOKY]-NFGG$:
M:"J>7Y,36CS(F7.^Z-R^:"I15,2S[YLK# 7*)\UG'(5:^H$ID]Q@E!B0IH@"
M"DOI\W+N)_0BI]3S18W,24-Q&D;--"T@UI,1N5AKV=TBB/L\%921_SNPWX -
MW8GO*_/KUE4_)7OLI4E*/"LF(U!M^.[L/IK&NC05%[%!HTNIYAA+"CR7I[SO
MLXTXGSCFUA1R3ZK/  H^60K/R$:4G::B-!S79DWH6W.A['Y;);Z^7":(&!^R
MEX+UF"*AIX"G=DO==(45V$)&TG/0=8LVKT6;B9[>D].7.B("IE J$R+%'&&[
MG<1;F+JW5DEY"- ,*I-<3K3&.T"HTRQB&JOP$R* ?+*:CF *;0],L8C$B(_&
MH=V6LV%NJ#'U42F\DR-3B+VDUJ5>=P-QY:-95HB:3M\2-!_LW4Y1S-S8#U+G
ML-KH1+UXV5_B^TS52X)C\K5631(N*Y>LS&$\,=FVZQ/RBRZU.3H1\"3-7E9#
M@(\,_S6YXMZB).Z$/M)-O7)P8S_FV6L5Q.UEY-,JYJ;\0V.J6SFUG]_'/\>%
MRZSJD;5IT!?':/TA[-RVKT0_7?<JCD/']W>@7J9Z97%TH(UI\YUC3V,TXUMD
MP(7-DC-A94[>BXQ'ED*'L#EKCXO7'%M/=VJU@2+^4Y@/=.1(NQ5D.=9"E:?F
M(HUB8'H<X$X+E"&M ;(/U\V;:(>3AA]WG*'N<:=^5(N2=\VL"3SK=>7C?K'7
M?OIH8W($CT/:IETWO4J@#$G? W))TZPLA8$&AK]RU:J-AH[FQQ!A:UNW;>D5
MV#N!&QC,B-0<J6P*V4#LO1+J*$CI9Q)JS@-^?$+5R7XN2%F*+"@E9TL-=/_&
M23;_Q:?U_[]OL__7LOE0-3UAUPB:*[P61SIUTIB\H-+!V+(MDTE)GS>C%HSP
MJ#BEF.=//!2Y/YTE^ ]IF_)5TE+/34'M?[2>:LD;<53O<@Z3C*@-H>:/J+?1
M5Q"K1_%2LIJ&,>5'O\S0J$6*;!6%\>-..W+(9BUY--@+L<\D*<_4H)N&"[)]
M'9.0>2#JE*8_1:6AH2'T>*^X$JQ<WW>A*G"X(++-V;:U"UO7S]IRK%K.[#E,
M?B,B2RW+F\GE-$^<<<BN[YEH+]YLGBGHMM($H[Z!9AE+E* -#8+QP(2K#@,H
M<G0JMSDY:]1YX&>BNTYX)A6$>OKFA#)E)EZ=^( _7U3<15_!QC)%+TR;!RI&
MET%T'Z'9T,!7P2.!2?^APH!KF\LS#E(J'L3![RS'2-4J[]- ?@P@D  9 %IK
M+D+PXRD%D6;J0,^35IP9"8Q59N;T4S-JG+(I#7)I=1X>L[R99MU S4E*('"-
M+;5G\E\+"^_P]])[U^\55_5$VLK5DUZ[L.&JQO!&V\IGDYT<03*IY!QA<41?
M'%4<G^@<'6#9><;YGIU,#MII#?8\_[*?TN]%M*+"4-]AUEXL]90E8HD1H,J2
MTM@$VQ)&Q8U60X $_/(I&:P5JLJQ%[-VFDLI57@,=,N/+9/RF?C*U*FT:Y_8
MISV&:X=%Z"/"D3 P@@AE,)8P@=::F&+AF#LV--?XF+_E"=\K.OV.--6B9"HE
M8)8,&B;9(O4%L;56*F%KW5JK\PBTXXH>EML/$$Y&X,GE1-N(<-8L8;KSLB@$
M+*("H/0\TVF8N'P&P#5!#F[()BH,/30B!1-$0_,Z!K#W,QE31#*<0,Z<:3:V
M.3G-XE:K%'5TS"E'<^!KN:*\2K,P;:52ON":-6_,6U@5]4Q3.4[ VK9&WEK&
M4=VL; VGAG1)6K"%L  (*4T:I98%Y4Q0^TCW/_W)_PF]7'LA4\<\:"O!:KY>
M]/ O/LX-%J)X"#26$9.L**_!@=!60'I;;4QETR(QEC O-,Y+]R6Y8\?/ER%9
M./GXB.2UKDP*O&:R:8G]C7@[F^&4BRT*KU4Y!2A)++<RV9FU3&AL0'V*<?Z.
M,XE8#M2\JT<4F8Z'U#&Y6)(HY@1"$\><WOK<X-?9WNQQ[3(]XFZ7;C/C6/7<
M^I73URP^DWWN^$HR7=LCS-S?>NH;9^^Q]X[73[7/8&!V*GX@XID@XD=1#L?A
M1;=RV;,.T3DYY3>6_,HFWIV['M[C$#9$0_0/SK,OWM%DG8/:$LRP;TW/FP5O
MIM725X/&'W2.#L0/]D/$)*0TY@K^ N!_/I3_^0LX/9VXI7GLGP"NX@>NU\]/
M (]_V4]I_07\S*'V^/5]\)<!Q;442\S=4'\PRW'S!.V6BI-3&="<:]9$=P>W
MEWT\:\A6J!>O/[?724@WWXD\B["*\B&RTC\E4R*QD@;).G/%;?C(]J;E=*#
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M*H<R;1DXO'TFO_3'49?U72B4!7** 0;3\N8T_J9F"K(KQ"U,*]:/!RK!#L+
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M M_T;:?3Q@O1M!&;)&>3PRG:;/LR6L::F)0?(\3QY]DISQ=3A0AM3'3*9R.
MN"VU5PSK%"8ID\/OY,%JI2>%MBJ6QY7<78<!\^11UMAZ!O]M'O]OL_D8.[GX
M;F<8LZ#1D9#=2/9;@7/-8"H]+;Z,7C5W/BH=N)FY]HA-::Z1- 86.&M[U.L^
MD.<PU>^@@(3&D"@1_H7@]3H&!J8HPDN2E/Z+2"-UBMHZ/H-K+(E&5DZ8:/(%
M#_HG)\J4 LX>O%C<&(#;FWEG_4>35XQ=/)V;\//,KL8)ZP%A(N?K;"BG6A)]
M ^LXC4O:7JIK+<JXA$"&X35"11XTYA#8CB',)L]8JR5EZFOBE]/EW/=Y_WR1
M"_S*YK.29GA.H$-H%UM:BB#M@DLGURTO$G9.ZSV]9G+B3%+O18EJ"F]N0[<$
MLV*,[M7%[[^ D.MGW]KF<0612ME N:SM&K8G"$>)D$(,"W38W6S7]?Y<X-V*
M3,6);!K3Y(V3GZ$.YP$O">XDHU6OJ.DA]XRN]EYH$XU( "%S@UB'\P<P(73S
M7(@[ F-)S@4#(D8EU&"KR[L@.R[]^*VRFX[]\?$=PZM=>^]4!K+]PO>HDHK7
MQ7V=#Y]8HB%1J)J%,"C8HFE32Y*7)4LW:#1<<:RM[\J#E%Y*I'1<@KE)(M4W
M\(U*#QQ=;028CAJ6<<JLB#T-*6S!(1WC=;&5*X3V[>[W>0V+'LGB"V%78] 7
MA$MCC )0[0'(2_S*EVWHCW&#>=PY<FH[[%W$>XG.I H@ 09^JS0)-;TJM%Q2
MC_M(E^N%<$FR2*@(<RE%4>CH"='D,YB_VALS6D'!DYV/HR&?II[D8^15(FT"
M;;0Z?U@>"W=E_%<+*,==TFW/PRDMTOS8\::&H+.@2*7G"0M''!N%ZQM;K2_J
ME,:_C<VF\_1YM@H>TK\R+4@IJ/QS/P0;5'YX(ZG\/!;D)HSXIT>\"W:J?VYL
MD21IW:!-AE^%!GOJ5_7$MOZ\BT$:;KEPDZW2.^#N$TG&^0#H&=YK*VE185:%
M9T2S06<IX)[<^LPMHZ #E1]^:_42VTY]?99 5:H#NY,^KRW3R8F<Q4SMQ#^>
MLO45:7T07N,!"5Q?<E9+%:\LWTG7P_1\&C1+F2DE.9%,1D14NHZS'E[-*?/]
MR:#;__$'\G\.^GD#TD%B_2S;:BLDUIJ!6,WL#_M;&N_/4C)>S-"OTM_-B#4W
MF33K;#1EXOPOK+U56)S!LBX\6' (&MS=W36X$QP&=X>!X!;<W=W=!O<0;' (
M[A \6'"W/VMM._*O?<[%>>KNN^BN>KJ_DK?>[C9P,@>3S42'%KT#I'R?%%6+
ME.O@"Y8B@MBD/LMKL2 U@DGB96GW^^#WA.'KYVX,_!1GUL*KEW*!.FVZDNJ_
M'.WN+?]8"3Q6RZ."K<>8^!^C;6NDJW'I:VUPEZ9DU!;%YML3JQ?N$7#)<:)>
M4AN+S5/A_>[Y?FP=B#H#W&I;0%_^-32F19W%L=%ZXC%+1S4_Q&D,#$&8''0)
M!)])SM$G&D9G,NV%=-BZPAQRI%'O!ZK1R(\[F.1\WYR@0F 9YI!B)A*C8%%3
M5,$?K TNU"9(V7?9UJ;E$^!E4-I"$ZK09UJ"':4\2B-:5>PL,%"8\*!-VU4X
MBLP%LU<8^2[6'E_J)854VDXGJ>94ZKY$*G/F'+YF0%R'&/5^/H.J! F;.V,)
M#?N78[NPP&G\*L+&2SP-07B?GQR6KW3C129&'A=42UU6W DC )=]5A,\@T4%
MH2GUI<GH5:"EO=<GXA,+7XV_"R0"/M';WD$GL+!@3,-'=.! URHW_]J1:=$,
M[A\7\ZK\AMZ%'T(C)&-/'E5'Y.N=$672RW7E^C1<\?9(6HV#=W,C2EM^>/O6
MV1;@XI+Q#N DE#Y+:WH'S-)9]DRL!W".EI21"/5^RMCWZ>Y^N3[,:13-$G'Z
M=&;U?!3\LGN#[J8M?OST.P@C5CG!=-X=<WZ/8C%R)#OQSWY+TQG%@'@,#YC"
MHP+T-\I286,J#WO]/E< I6/'1 KSP,R+J)R+ULR1Y)5XJYS'_ZF)_0>YO4YH
M\ E$3;G@_0Y0YCRZ)<D#WFXFRP]7W69,<6S57-\("UGAJY0>>>V.)_5(/ZP[
M+1'>OFIJ;>B8:6D\N,:<S8G$W$P7U2J!8"A:]E'TJA\KZ1PXZJ$T]9-T<Q9=
M48CP'NOWNN($MO7#Q@-HS9,V0*X]V:LI._-_-'/N'>J.]Q^[7SVP>$7%XG.K
MI(4V=7XH6[K]!L!-Y4O97OQ^U!>!4,*[L:^LR6QXA3F>%6$;RG E6>SMID]0
MI<]5).<L'$YZK_^O_/S_=U(Q]W=5$+[7O0-F-K9^@7(TGM"G1 XJF?\1"OZ5
MZ+A;L\BUV=G8U _0!4+LT?E,Q14_)^LH1D561&8#_"T:DED2@:,H+U^'LS,2
MRP4DF#DC5I(6YYDC6#]EC=;QA3/1E&9C058-;O)T%%VAQHXM$)-SB E3F#T&
M\A.2(@[::2S3)8"VS9G<)=Y+.>:T2=H*O[4YC&WFF3=>&PWG.K6MSGBPH)1_
MTH>=R<GQ75/W&<)*ZI=2_TZ@DDAE99"P56 'YO!S&(W;"\BZLO!SQ^IMUC.C
MN[7:&_#7G=\GBO4M_\&)T))+L$LJDX>/H 9W%-**.2>IBH=%07VUT293N2F-
M]C8K+ND\F<$]7J R3CRN802[QS7UGKX5\DHNIP"K$Y^QC-UN-&I_,$6;= @+
MG/;]K<03]F@JFV4)9$$?<+NI6?K(D8!>&EZ*?#M%9;S8U8XSH$HU,@ZM?2LH
M#7P:,[/BA(;T;[A8>\2FDF4%3531ERONP,3"\82(WWIYZA@E@B$6K?IJ&C6^
M;Z\S\90(3AYVLE7]X'J=H>."TD,\""C%"K-TU&EF.H\S9[N;=9+O2HO],&9A
M9ME$3W;*M1('\>;L(N(D?B&W\W9R-Q&C<6:(K8^ R@;ZT.$:.Y%'1GP'<DB6
M8SJ?WWZ34WS[^ [XJO0E)<9ZRB^+9K@,@L^LCA=-+,HH9F(=IL!$.^<"W]I\
MWM";VDNXT)'**'144YIT-V;X.HB5T&8N1=0P#%LF&2L:(P9&^,-OG!:>53OF
M8L#50-.%NRZ-U^Z$]<WY.Q99AP\<YR3*[ 8PHB3+:,>#U65.SU46&33R]1 "
MZW*L"N@H/J\E&DLIYZWK2(\I'T=(]"JEIO]KW!$MNV%,K\(X_G!26LFCE>C!
MXZ,5,6R4%%5SXPA[C, @X%&&A6[*CS")]R@'8S3).@< %D>$IR[V&J6$-YO*
MTQPNMX G<XH)]M"\RVOJPO@J)6@\>R:E$W)$&[9DWQ<S;>V##HFZ.:1 SZ3X
M3-Y$8\_W9U3=TZ*M5-K&KG_+AF%$G%B<5-AD1!B!V]^%P2Z6G4^?WWI</@ Y
MYLFE'^<W\RE]Z>X"M2?$)97_\#>UH>Z-:X[5N(A^ZG7ZWU@N_.%595(3E&(2
MY%+#QD-K!A;\XV_;W%*"';/$!54!PU(5>)-5@ZUY./F%?J%Y$ Y:0&R2HFSE
M"Z+)Q2;\2%99ED9Y<>U+:TQ'RJ[PKEU7I[_M=-V.^R'#;]T6^>&LRN12\REP
MAX X#"U.]4""U, IY4?NBKBI!;BF7O:S?K'H$2\$(D@X4:LOJH6"L16.CZMA
MV[]?"0!][]%1[EVD(A96>URM/)#<YE[J6&O,_*'8EU.O6J-<C^%6KN%-OV)I
M CVZH2;T#WG1SV\Z%I$D\MB$-NG4H^X=>(C[LOA3#^^ AX"NI>?$<(&C'6:7
M93]-QN5Q_UCPZ8-;T1"G!>.BU6\.V^#C@19B>,=4OK"[MZUR^9P-?@^UIQ]/
MC$.G)0<;MQN9IT'U=?*, SC4SMZ[A],U\6(B-6^]2O;E0"-H!V$/\96%$A7;
MCH9*-[M]O\88;NQL$^9?OW3@R&*TJ!0LN6[$*(DY\2PUTC(3PPD=)4:4B=2J
MW*F\JV[^N\(B"F]+0$"IAAB39W]!9>-TV%'3>X,_-U3-?<ZX\22U?;.O'K:^
MH#,:AU\*5 YL1PS&>+PM;=Y1' XI6XJA#SY^G98?>_G?KG#X[Z58>?J%XJGK
M'2#C$1 ( :G_%N5[SBIIP\'^+ZWBSPF5@VOWH*+=&MA0GYE2A['#R9.SXS4F
M9B0L4JE^+:L3PND325Y@[#O0X@JTTH!^@D=QHLG =WN5^ED?(!6G%U&-:E93
M3# </5GT-MS/'^FH52L:K-AD8>Z@*))-H7BHEF<_K(C[%AO1S66J[KB U[X'
MI?I<RH/^4\"G TTL&[5E.XU->-B6/]Z42XJV:8HCN;%4OZOJW%32<09U)'[3
MB=O1CH@BCSR"?")$@LRSEB$/'2+<#G_<MT:=GA-R*!!]$<8[."9QCR4F:'8T
M6_KKR;OP.]3UV?,S5/6.FS/Y0Z$&NS?T8VG)%;,@QZ@RWU]]:Y94[FLN*A$Z
M"AGH&IAQH5%1\!IN!V#0<!U<C @,TJD%F'PA!6(N,)7,_* ADY&QC$RFX\6'
MY;C>ZEH+_X[.T\TNZ_"RP7#\(V^@CB +"@?&)'K<:10;MVPD=HV5N20S:FFM
M/5@\?"M>.*1,0;ESKE(OE=A6<+GSNKAY<^;H)=>HFOYKA^TI=QD+;1@R?A'3
MH&N%7[;-PQ?9[O1RR5!FU95T 6Q=E*$\!=;4C/&]_?&TJW+:,O=;;Y&X5"'/
MBHK8]8 ;W.A7FL%W +31H_EU^,ESK.;+W-/W2U74=:&21[9=I?II$ENWU.Y\
MF7$1SYN/U_@0UWRF;<,\4(P9WXWKX6'T"!5C1"Y&TZ+LJA3DD4!+-L[;J1K&
M+\Z]1OKCX%22; :?3JF.#H\THE68LS0'TF_8)+3"(-0VGO8CS"\C$^0G#1CL
M.'C^NBF!$^.A[.HZ9&D$%.&<G(L6J)VEW:TD%F5ZH% 3_IOV-B$"A?%E)Q8G
ME*!U8(;]HVMIC@=N&[,KZLX0\0Y_QZ(F%2NE%-678<+!STF;:>/-H(L_A*X#
M-0^>H76K9XY\W](6E2FY2V^S5O2=[_,,22F0.?%L*#0B:<.\+-/X^YQQMRTX
MDFKV[XO;\UG=\6-VD?J[+\_'TEFD.>-9A;SYY%T/<ZQF[[VL&@BF$ ]&D>MX
M,'Y<?G3A95K"#&+/;0Y.0G/ONVYLJ50E"_-<$\QT-,N4_[4'IZ"#P-\WKQ\#
MS9431!6N$;"DL#7C-_"B7?O(X2UJ]*1)>?-6?UN;XDIL7L<UN/V%FI8.M,[
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MR=25H&RO8GA^#SN78D!NO_)9KWBH8&(.2F*0+(4D4UOK+!A"&<L*TRI+B.]
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M5M=V3:>IE\?E?5O#IBB-\8G1OIXT?B36J]XI M2E4I0-#*G+Q$>R&H>'BA)
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M$!C=01G1N5:8MZXW>-6^7SSITH 2GOC3'&T)OF'[T_VZR'3$962[D(=' M#
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M7C-OGT;6H4HLV[-;IL3UVTP]59>G@"_LM#7X;DW5;OZ&J&]1+;QSAZYLOMS
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M!Q8Y2S*H7T9I;]6[Q]1T3Q.1LW=BQ4:X?H=F!X(84-6!J*C@B@S%BL(DH/<
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M?L_L4C^9<^K2.:M/ #3SZ"= Y"W@T<_H6-J1.B(IT 6#6D3>T)J@7;=!Z00
MQY#CH)WN==7&)S[2U;V&?21^>+<)#GY(FI$_DD[VY9119,8U?%;@_NH38-&U
M^])W^?:A^6PR1Y(L%& G1"02V.F2R :LA#P.QV 51DR,]@GM,&1W(4K'=YL
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MUNA5U%EQI\?K"^W&G4):<.M)S-@B5MB8;'!2-)E)4[4G3>;&Y6X=(M=Y_03
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MDA16Y4G<*\S$\MAG"%Y!E'GKTVPNW%_.XZCI^)"P:/G9?*ZK&]'(F#PU3*_
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M]R0$5O]:R,(Y30D;G=U9ECP;AIJ191P9H//JBM.FE/WM/3LIN8)M&3)YL#P
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M6 [6AO>&Y9I  J\'%H?^H/?0I$Q;7\O2.4)J/9_5 0_&FR5]XR[H]!BQ3KP
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ME:ZA <A'D0$(82-I;$8,$1'+$7F#\6'Y@3IT#^,>IO$,'>G>)\YYKYU%^O\
M**Z2<=,E?"?DVKT_=:=F,5N[TYO>.R6*ILB8>GWNMQ;.0B!+0_:0(^KV-)4;
M&<:B/Q#5=$!PQ&!AI$"4/#!X[L92!(_$9W2VU(_(CUQA0C%064*Q=<$[Y5B6
M!Z@DD'<Y=XFTLO-?2^2RYV;("G(^50 1TP!ZJI59[+]@*;3@>OJKN"_ *56"
MALS7:T+L4Z*+"$K) GC3L@6PVYCV))2*4)>UQV%(C.29TJ?ZG$YY<G-FMX'=
MI&BC9W"JS%02P4@J#Z\$#'IV Z5"S2JH19&"J20 < %L@X^?)_6<]:#>R_8
M.[>7A>X+]!=V75*Y1KZJ-8IS?SKJ=/ ,52I@RZ<.>C(AUFLQFJ^ ]R7A ?+P
MZ ZQ$D2&G1MH#R\PQGE,SQY4'0[MK=A\K-XF/I;Q') -!-*->)&&L!7P<:@H
MPH/]$;#U#856K7VZ[/WF#%&7#?.T;(/A5TU4H<0Q;BTUF+6K(/K8JPAHZ7I"
MO50CL"H5M@PVCT<DODMEV8IYYV2X]5;6V0DI!$I+!R50 EE+%22!DE2[8STR
M0-JDW$Y&#*Y !4 L=@P4$?K"C/S9ZYJHG^Z/;&U&DV*R]A=KG3:*[<*D@B5M
MY2<^BM;!:'-W@,GVAY;:8-K6(&2SK>$8R1)P8Q:0I9-I,OD+9VJ+I6WB5=2-
M@( -49)0[#JFHA?4"5&VU2;F=CDRN3AER3Z'QJ'_ -6!GUD9ZU:97LKOP\J7
MDYMJ]%T$(USA$&IUA(N-S8.Q8=;&WR$_Z#[:_9K>,I]7&'FVEMYGC@(N$XKV
M>&PVBPMH%QIAC7!0C"@8,98QD;?R"[%?468]2:J9Y2<EV.S Y/4-@,#C!\05
M03UP!OM4B]L^(QN_<NW.ONVK>"H\ASK7;8EXH%(ES=JVVISK$BW!+F7EVTEL
M7:%TV*<;LQ.N XQR.F^PV'!PYMH>@?+D3ILO7BX?###<0HS@7*%)' B1PI1D
M 01Q)&ND,Q7X,X)WR,"LKW<DDD4C*IY+!E4F1@3D$EBSLQR5&?$-A\^< [+[
M3=B=Q/V)[9FX[]<4VJ *$G8IJPSY<*>)!V.9<! M<1Q[+"8$&UD)ME;CH1A+
MI^7(-2<ODWW92]B.UMX=/*AC3025*J 064(2#ZR@"_T0 -MJQ//-)G7(S:@
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M<4IQ2G%*<4IQ2G%*<4K_V5!+ P04    " !QB_M6"F-Z7 NR  "YZ0  $0
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M*H^%6$.!060RK49'P(S32HL+O,^;]Q=9H;NPN3*8/I]A7"CL$$N3?@41AQV
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M-Z7 HMJ@-X+&X)6)NR3AU7G\O_@H/3*]Z@:42<FD/(BP<H6N@'B#)!DS2@#
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MF?9^7;?]VYJCUN*"+8K%WQZ<N7N_5-OM@_TA:.66;S:,Q78>@R:-[7PZM>Q
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M@FP.^T[,+C]+? A[GA@YLM$;-P_?9]LA.G'!^_VNX!LCV^NE394/^\J?NOW
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M5(P*[YU3=)>=5*%VF>0P94W9Q86K8#>Y5V*L^<!IMI2>Q2A"CDPS'^#@;\=
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M@%8\%0W:N=6R,V"8MB'@D- $E;)J$-] 6FE>%/5$RN?U#H%9-BQH! 4B7@"
M2&#M_,([[6V+%>.O6HXD]]>8-9X '_S;G=\U=.F,;*B8VXC#$SBA50S4G ;/
M_LZZI=\IDP%3_M781.0L=U2MWGQSUCRK3/0;L>CJA;$97]>FTO:]VGUSZ'DC
M"&Q0.C-VDOLRW2@.;T OM\VF'1#SH&=S@!Y=SJ]2SK^5%#Q/:IX+>6TH"< T
M*,.+J[;Q OG"Y<^+<56,6C5,81S+92E 4'7'._'IOKNK&(T@-&PU<'U!J^DL
M"(/.MM?*DRXYWLV3$&-S::81F %N>R$M5MJ:V@7$7I",CE4I ^<!4#CF1.0*
M<HWMHH<(@?,?:U\EGJLV]AR3:0$C\GF5BJ;5RQ'9D@&[!MT12]'0<IX\63_+
M7 &35A^B>VZ_7XQX>3T#? 4WHK_>SO!$KQ('/6'<)/QKHT!B0LC.AZHOFKK%
M<RSS'[A][_X9T&WH(&#R#(AIDZ-6_)TN/E7O$9^'0=G*>([],B?,R(R@L#I1
MF473[719$7EQH:#TL-BWT>K2;T<X09&1G@N'@.)VB8I%C?I .4@Q184=%OB7
M#J#P&F,N8U(_?'_DGN^OH"'AR3[[P_.C.9%<3R24<N(T3-WMU98Y/?(1^571
M5FK75LSE*H%>MB1/[!!)M4-#.&OS*$K$,^N^=MK\>,3C<#)R5%$VIS" ;[E8
M&0:^/,?&J[0(Q"W=.^X#0/#; :2_3)>$%#>8E4J;P8-P:Z 3!B=,I$:,:_][
M1>=SHO,_Y0R@UJ'T\'PB4G2>^<Q3\_QUD^/B*\GU9L:Z$^:C845P3GW,7'"-
M*$>,(K>R-'+(<'R\U5+,!G::2+O9[*U#7=SK8 A>SI7:7;RE<,G$7L67[]0\
MDMC5\\80_%+"2.P[NS%Q.,^_-'1 1B%43(CI>H_04388D_@#KP$8$HBZKME9
M\ETJLUA&EV^BVVP[HXB.'G/)R\89/%Y00 *_LL)#R1%*,>.P;!(P0SBC",?B
M"J]MR&]ULV\]X'^D<R/FL[M^2JNT<5C '=>'O6Y*2=D<=Y1"H2"ID-"F O,#
M!(#-32FK=28=DTP_)2QQ,_I0_"#U,UV]KOCC,6.X<]!Y@AC07G#H/VH,!2Y)
M,XU7&,U3I*$71I2A0<18]0RG0.M4/2 IFD0XEA;DLB# \,";:FCN&%N^E\+A
M!MA(?H8C&L;%Z>QOMV&\FM#C36 9>(QL'K/4"#TD4TW0U/8/ZVTK'2W")'U%
M9H(:@4]S-J!)6QP?;DK%D.B-DQ04EXFE#%(2L%COY=SQ%9JX\T!]Y_]B=?H*
M_?SDVK+RI/%,B4V^^!VA>M7\+<]!DR/C#'Z N>9ZLK56?^HTXQ+7&T7F@#(T
M%2FZ(TM^]G[19&.W) 1)[AGC&\FC:^NO%U'?YV+$2OBRH2WSNMR[T*L6%E9L
MN4:56YIY<A<_7D!WN@S-M]6>&66-X;AOQL?8E7/99DLG@3HJUR+>*GH=**H,
ML!V5&D"Z=&C +L[:"GS17?DZ>YR&2R9K2.EY+_II?9G9E?#AF\V3^WU[RVW'
MXTV8U>^D7V$_X9O =0C$8"H_Z?[W;P)W@L0VU.0NL_6ZZZ\QEK)^66@BM5#7
MT,7]WG9[-%3[^XL8(5_7]3"H\96?H8+YE]8>>+X*VE,*<(I:<)RZ] Y]JN2;
MB'F7$Z[D@ *[M,4ZHH#Q[>M!BU5AII57WDJ;6U\$VH2"Y('/M9FT)2V>)0@9
MQ"S)E@+B,E$0UT<UQT-NW.8I)2A L,(>(I7"@[(I(U?.:[P7^[[)MQ$1O.K\
M*%)MP-W9UNZUQIJ4C,Q%.5"&X/'HT&\B60SW31%M#[H_0BQ0&D:^KXEV3+E"
MO%(R3ZO$A+;T-5F]@6+9YO)P8;3-2(D?]VL_1YM9GMY*X_P(G8 %J*K17*I]
MQ69$.V+,9':!ME]N"4X CGSH?$/ ?NC.[6S[=!\#MK?E=_T>+AO.#T $YT?,
M_;KFP1[#_I<3HP1.0@Q"W/==A AVZ^_OHSP)]%Z@^D*%P04WS7DXK_RCCD^<
M/:,-;[]*Y([R5K2_;(](-/KIQW8M/-M=L7&#[5L4A(.9#Z@W*4.__:."^WG0
M=Q?425=?P<*;L_WI2=)!7U<W^XVX/E?BP ^_S2*)!ZN/5U8 JY_EI3O@<SXD
MI$",G1W!=8R=D=F&+U_;11$L/JPAG)[Y$2'H0^L-K]F-E.\]KBT81#81R8#]
ML?U5.Z%5:QKQE:W^.O+GRNH=$A<&.Q9+HY2@ZN27BN].R#GN-%/K@9J53@YW
ML'HHO9UOQX;&A95 ^SAAQO7*)$&J^B)\D[1F(?JEHRDAW^EHN)1@9/L2F9BD
M8V&&<!I+OJLJ'"<6[0"7:>#,>H>CNNV'0_;1+T+O'/=*RO\X.5:,U_;W >=<
M%/:"O1OO?B%9'AEZ]T7GY:M&<UA%+E.6NJBCF3K9<5)"?)YZ[-DPGT<_;.&S
MM'H?DU-"=K*AM)$7I6$@63E8E(-$;',\L&YL:3 8RL1"W_\0%7+4#A72E@=,
M,%M*6Z,9]%+9D E[)#,PFH0SC$ \07*S85_;0?-343+7$YCVZ[V:UC%.\NMB
MT[*VSOC+K /9M]]R/0247X 4-$N-4YDQEOMF*?"RU*(R)0NGF^&;N$N4,8>-
MT&,X[)@_7YHG]9#/U1NL11&&&LHU<XT!W^/Y"_=+1[.:;]9O88/S7F,M6]$=
M% 4UC.;B 6Q],+TOAO"^-E_$F#I])_]9B0ZK1GL$'KW(+F;LI&+CS'69Y];H
M.QG.KU1)LU5"2%QK0ZOPBEXK-Q053,*U0<<FG]+>AW[(A<\O9XD3*U[H-L2%
MS,QW<!.4'O!W'N31$<6<^T0S8N.U+:,=61Y1:&\= '$[5TB/F;@S(HF#O.L<
MG*$5\Z+F-MSBOU4TOT!=$PHFD_LS2'#AJ_1$&@9G*WW?]R=&T]ANR=\./J6=
MDYQV/@.@F/_@SG_GP3,9[@_4]VAY0@(Y[@M&1#ETXMZE]4>8-<^,+8_)(J9\
M.E5A0%(ZHY+MRSEG$S-D>/4,Z.>5X%,H7,Z@J259:AR"!B^YBW]\8';D-12>
M,IG3UD;FR<CNJ6R99/?0K-"E37ET0LF]MG95DZ_-%O<O:BX_<:Z_'"N@9F%+
MF&:T=(*GV?N&$?GT0LST*V.^=E:E#V>;C?+;N+B/*H^R6D72((\Y/##6/IL^
M6+'<JT?*(M*J^(Z5!(?/QI9-$:DJ!?M-[+*HFMH;SAH$F(ED$FUU+0=&0=E)
M*NM_ !C)9X#"8_]/ .X-M>H[VO2K2XSY.8DCCIQ"'B5"#6/'\/C<^A-#@0O]
M4%);L&' X@N*NE(.T!"%!#U%.+@P+-IIEG<$ABB!UAE%4G8TLZH"9YL5<"K<
MV7&1/)Y4M\H9K77B:>XK^U&03<89G;_8(CX+-/<%*^K+SBQQ$RC+B.F;2QJ1
MRIY>$32K W.*RZ8803<&Y^CWH*./9+=JT$"?;DBI+P-,V/9(+" ZE=[W;)UB
M(V/6"RTD:!"K(K2]!"*%*#1D\Q1KE'5^O88KJS[UENRGQND_57/QA&NDD0A6
M?-ZI3D3%$OU%<4-E^#C#1P043LH4J3IIH:0$N_F(-W2[3EK%IHC%RE5@*:RW
MAU@%=!7'V"(F1OK@%Q17 $[V9&,QACX8R)UX .'.%T'V9 N74WBUJ(GP@U92
M%;$9LO1 G=K>@7RG1?E8$&;B$RL[U@#I^_6Z4+]6=&AG8 ]^0/>UG6!-D58%
MS_G4)^NHB0S-@?6$PZ'?$2J)6<#U.H;J[!EPB4*!&O:G[$O%OK9R^;0TSP^E
MV?^I2K-._$PUN8I]J>WRSM[5PC&,:E"$]G#,OPPL[E AJP]J6X_/[,#O!X?[
M@Q+:44%F:D4:!Y3.Q9OI2?(8N?CEMGFG?*?P4_.::>52!^6-;(?"3N?)#^(%
MGQH'LQWPZI+/M"TUL2$>!V9KLF<.L>]ZV]<WOSFHX0>$2C9-'ZD??WM!$48T
M(4NS-EF8F<1VLR]#9W\"'Q9,/X==/@]NF F?*SUM2.@K?A4!K=,&1@X.$*D)
MIS%7*@%F@1/%E!4[3.D #,Y\3??9MY_8RJQ^&NW:E83?9S>B)]ZGWM"$WR":
M9$/_;/LZXAD0RM]514$<>AWVIS%C6;5["",H6LOGO3@XOZKYW?K"*Z&PQ#QW
M?IQ?=6$@.I@C5^XXC:PBY_@!_\,4Q?I2<>[+J'=JZ)!LO-B+(3TW( )CQ= 2
MT1Z:2NVJ'LTFB_ TVC7\FLZGT0/VA>JQ3NR]Y=O#(*:N)8<$Q[T;J'4NBM<^
M3]Y$-F?U[0][\E;3O]R\-+S/K<0SH,5N.T:RY.(QT_V#C\^8!''S)O-OVEE2
M%.H;:0BU6#Q7AUR<;LU?PN.S3+ T2]8[ZB:E&P;>4R@5Q%YA&1/V/) ETC?P
M,^*-1E"^ ^Y0:A=/!ZM9C(X'<V*Q4RF]#P'L4,P=+G'6ZVGIKHR4H]%F+HQ(
MJK88(B0L$.HVGGAJQ2P+3'Y)0L9^U?3%+GU/K5BJOG^!H?82VSRI*B_KTW10
M0-3+,#@T5<(<6FI-PP)#;/A5Y8% FUU#A@:%S/ V>D</MU.OJ=)Y<0:=V"Z>
M)0.Y8Q&%44FX.8O< [N7)^X)*+3[PL5A4TO@>08K!BL]D8%[HOM7QZ=N"5.Q
M1EAYPX$($(-D!@# CAO*^>D9.@"U&9U$3I@(NA_B!,(-$X!J)MH LYVSA78&
MN AU?6\?&@\)"2 A(2$=@D<E(3V 0-E$>IOY[RH_G 45R#KJ:X)\Q^G6LS;'
MUIA*#%J68@D6%C]TM9DODY)*I*@->,3[?>4UOS@">[!&QXBQ15FF&/@$ T"P
MB[;H5_6=E6,C"\$MQ6HN.4ELK&)>1(Q$FZ [5B6@8SRB2*X23K,1+XEUT52<
M3A@('%K3LA^48^\R6R^I;#8I+;1&%G60US_RM,)4<]:*$^AJ?MU38L-RI@-=
MKLKVUGM7-I/B(6:9TT6MK HQ-STSD:=_LWR3E;/F!BP>Y&$C.F.I8P,%T3H%
M.ZM<O'>=97 X6RZ>,5,V0:*05R7%Z[3PV;FC$K99P$1C[-O-#U4V/)DL:G15
M:%L9+G7EY&-[K#P9KI'N5TEEKV-)8-#.X$T]!XFC:'1('N^2+PN*B$_$*41P
MDUS="^:G'[\F:\*I4\O=R])\EV@'01(K/@:_=([1UA#?R%6DH$.@\9X"@[\'
MV@/I&)W-*7QV"6B,3Z\1DFRN2W>YPH:A.&X\K!P .TW;'EGM+BR9C<$BD"PP
MB69A8AU-D^LLZ8A6,* Y050?;#>/XI$G)WOLJ-Y8M[>PH[MW#:5 PDE!+R5=
M!L]6U,VE15O3^5W0WY5@2^-/"ZNKK N]SZ^YJ'/OSUA1I"0^RN;+A%^5A%2?
MS0?6/P"3 C7C+N4<29+?0VV#XD_!3]1]]LG^1X+L^W#]Q',S])<QI)]-OV<
M;1>&H03ZFO?1GT8KM<02=^FX.QPQ-\/\]D"=*QTR)<=2.  LWT2X AN%=Z)H
M5P=-SZ6$ SOQ*;4$.WP<N[_-DNE%H2>M,J=Z*0E:$K'NB--*'N$.+:3=*1HL
M2:R&FMR"?L&*29B%Q1BAW&W!TC.@<3S!HPCDHKLZV^80Q:B3^X94)K-0A0OI
MW>RH6/*+ !G"%<HDGW(A.$W086CIKL3TMXOQ=\9H<B+5>:"T@RU4=NDLB2+Q
M3E-DQ8CR3BX([&A-*XVD3("U(5BX)6V*KE'HD)^N?;:XD%FEU)@WU>UC]RY5
MWQ?@4';\?@KG&/D<#%EOS>5=DL4:LI+W]JT+R3F_YZX&6U0X5E8!.3.6_/MC
M62(-C=R:Y([,,>729#9+4JY-.&DQDN$9$5Q\J$\-BWUW*G6\<1D^>U*%R@,7
ME<5'F.@+KZCKXC%%W1N @YK6X>UA4A)U#9K><8VJ+X,=3OK:%$*;-,7Y7KW=
M'N:^N7>J(;KXT&%=S0N\PC_G.ZB=LK9F[ 46+UJ41KR#0>AZX0Q/)M?7K"HP
MO##RF4PYVFQ3A0Q#6.=;ZX1D'0?=(>W]OCJ*T<M!3()IOH75!^]"RRM/YS1$
MO^\Q5]>&#)[R]=^BX6:$5M=#:T]>3XZH^9W 7T4-OLL;A-F>L'D&;.['_4@X
M"'NZ 1<C HM\J-SXMQTS:ZB%OLWMZ$8KWCF)=J_CGC:.Q6+,KWP4N^\D[CUK
M<01+EF_E>V;%)S-XWEU"Z]2[^(_K-#B%,^'S66VR4[2[PC.(%M8A4CA2@:71
MADM%7X;0AAM Q$J2^(M HXG40EO DRN(+/57P?/YPY/X&:)<XRS8@T;F??(0
M"37!;_H6+&/'XXU0]:K[!WO?O*U]^UXE;:!_H,EB.$+EOB]JE23^+3I1#P+4
M@$S[G.'EJZRE]:SEM-2K>E:*#','%\P@A680A# " ("(+->MM<P[\8OWS(GC
M?SX('N(?T,O6A6RPX5Z(%E(1#>WD)>]M;_WD$\$O7I75,+^<O8T!E5\6=IK?
M=S[P73)J3XS<V4BM60%!E$E\0<'5%;7YVQ39S3JJJ!3X9,H5PZ!0:+*JK(IM
M^UT"/8EJ*EQY&&R@%SB4,#5C.1.I3Z_2J)0/$B9P]+.;8^37X\)%K-M8&8)<
M>U);JP6N#PL?$LS_4&207O&_HY7FL^\>\3,@YH]XRA!("%Z,V5RXQIAF7\"?
MKRE<P+FN$3[>Q$(T[3LN=^=PO[+YM5$8UT^I24 =$)^<]JE?Y9CN$OQ5R$(7
M\+[KSP#*WTLD &$ ]  Z (!.-$D^."& &RTQ^2-Y5^ D%RG.RIIQ^TT.Q=*_
M;/-?NJ*$!+5,A*3_(]\%,),>T814P*$;[1*;[E+_![W\.XO>Y(^=2Q%$L\</
M)7LV2(+O582[:5.E"?U8X&QCT2%H0B':J5#<SCZOH9(.D<]XYT (R<$]&:%^
M6GX&P"")G)$?WP3\![+^JL) IT-\!:OU!J LT++KE(_@NTZKV@>MN;*W8C(H
MHR4BA3?&C85+DFG,Y$$U"$,1)5+NDIC#W=B&^XG]C&[:8G@$-Y5!VO+\DK-O
M!M9&UUA*.033;!B<<?@R]OH4*U6F.&IA0[C5!(6QB)S9DFBM.1=9%E;7"!EK
MA:$N4B7N<!]PV8 "W-\/GMY]_??4_554-"2"=3%F:RXH!':Z<''R';ZNV:)^
M@,_"_(.QZ-N!$?A1<H/UXWLIOX\MX5]$X5O]NOHK1-CKC,<< #DZ7]96B-1R
MDKNT7%^9FBW';5T31;_N,LI''TC9B@WN6#/4K<(IA^$I3J_I^H$G7LR;%,9I
MG=<C8;$]ZWQ)M#QEP)6,RF]MK*JXT/CHADPOX!KPY31 /:H*(Z[0VN:E4[=[
M5(N/E$[M8(;CT[;!DBS6ZI/S T&1H.RLRD/GY3VS89("#>B5D?Y^3@\_/2Z0
MZFD/9<3V-.AMT@G:'LVZ\JMP<!#=%KV*J&7YG(FRD;T=,"JZ\R*H0 S>N#B\
MUQ +ZFH\:&QFZ=\,%37\[XJ_[S!M9M<[@$Y3@A)J=W[>K4O=TU?.+'=:-DN-
M2&WM>+E[X*!\U;8$,6WU,@L>#<5,</NWNJ3,5$@X!4DREP.L@ZNF;19@P$M3
MB^^62""8"IP(4XYZSKJY*8U*HSY"3RH/[(76\B1"WK8@?)[&H9GMXZY"(G;#
M"X+I_QRM_S+7N4?<XOL+HOT,P-O;.3!C"X-'Y Z7\AW-3WU.$T:F!Y;9L246
M])6C>NSEBYR8:ALR*DNL>217.$,38O<SKZ8DN$V<I1-^ '?#AM&%W3O1T>\'
M#JKX"78M!"STTN"M\H4"N2+-) MVS2*^P#TM>G1#GJACI',^VD^$6KAZV-H!
M(-T@.F<==$7AP[:3%H"62,M\A6# 9$;VVF^TX(OA.R'T?6YPT!W.^>SF_Z2S
M=/,,$ K^PWHLQ(;!V1G:?4?/7M^.S4;,WP9P>&)YKG,,FC_^8]::.>,NXQF
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M'BR40,5VH$R1XEY0+NI>0$U=3<'VZQ&AD]V.\.P24^$\>O"Y*,3+Q53'?XP
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M_;U+MZ@0C4VB1RCY17SKIJ9](0,Q( ,D0'HY)K5IFRI+Q^_;AB1U7*U-R:"
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MUXX2<4_D'M:QGBR4IY@5AN%4Z!%)@ C_$#6-Z%ZI$5>&A6O*&Q'5"_* @7/
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MTN+$_^SMV!8F^<2KWB7GOH)/W18:<UW.H1]>_1C0::R9#Y9:OF?\('S>WM0
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MA)NKW[7,[G!DOI@9\@MXJG3=;7-K5R:IEW8YMX%2.>.I3<WN/X")93-T((O
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M8*HC($U;@N?Y.JU0G&3[MB*AO:$-O'2?TRM#Q)]+9)NG93Y[SQO$;R!<G\A
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M_Q,<:FA)7;HX0K$IVW*)4$4N8[,AO(=0%U9UK1)'D#C6SL]Q<;[61-"4I7W
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M@>&'7D[C.K;-^[;BKD5P_SEF:=\#1?B&>3AZ'*?W%, FRPP&"-?-;Q]S0GM
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MP.>+&P*X*?&-N6LO789;J3R4VS)3X0VB;?9+X0R31O0EBP*U'@F@S9HV, /
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M-T/1")/>:6IX+_?=70;D^PZIY.E3?WB6TR#S?)@,U17BX6ECG/T,"3=F^>T
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M-7J[77S%V4UH&%_67@U!9=W[2AGR^!KXP[1@AZQM?$C?L6J ,CV9 ?1P ;+
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M)1D#C ';XC+@+@.FRXN'OZ6 *:B5!>TZD,&_RRRP+8/7PAD>_/VXC^$6_<C
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M@AEV(6(\RM*-36!1<*X!8*&[?P@,)@B&43G!YISPGY,#Q(X<[.X3X&CNX1'
M#P7#,/QYG0B/HK,E0#@;[$3 ^)"<?>A8-@$69@M"\>VA0<( .PH,'VH79.[
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MQ_%GX2WP6"[+Q8X73#9VI- L+6AP?XI3N"40;RDAN\_OE)Q1YDY@#PN>Q$&
M%@4R(&X229!$)/FISMF%$.F^=N:V?#H;XX,AV1+A8$28L2A,C!7YVA.@CJXA
M8'2@I0L4!\0X.P,E+B'S,A;R0EGVV(5+ A</((^T\+89$<S^Y2X *0821>%
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M&EGSSX3Q/__]A\E_F/R'R7^8_(?)?YC\A\G_44P4_AZ;FQ7(M-8-U=UJ,_<
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M]H-I*],(/?7Z=9NJ'=WOT_3=.Z#>S6\BM1.>XV.N;S[X,>+LE3G J6\M+^<
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MW Y'GF=/82G)28&/34#(U5-F!*OEZ^K0EI#"B1?[27BU'#/R:O*&Y5EQ:V)
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M4^N<^5=[^P@VWAI-+BYD,^\<_+(6DT-><6.TO'NL]CN&SDPU-5UNM'BHZE'
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M8MJNU^@O8QTK80KG[]U>*9K V9ZOWIZG8%9R>XE.LE.AW%,T1*G @+?LJPE
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M6P7% 37;PH.[## X!!E<@CL)$&QP&YC!@@=W"9;@P65P)S"X#N[N[BX)%IP
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M-;\I7ZG11,[]DY44C1T6%)L=?-@RO1]%&\"Y*:9'P^ 3'FBB5+P\O1D-9D<
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ME.4X5./G$OM/KP.^T5)T_1B7\\=/.\6/4,"UB1)=(FN0CF(UB">*S9SWTT^
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M>4.CE>4%6_<IW@7;Y:;96_T%%9'IQ<GF!:%!L)??0M4D<4HLS9 DW-Q 7)U
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MJN4P;-O"BEQ^0>K+*!S/Q]$C>!.5N.=Y1=1+2A)'*R,[81XO.?6C;B^XZRP
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MCWO?)SY99EXT)ZPWB:(QU0EW*D0GX YI^9[85O8*?: 3O*??-H-_CUJ^!(,
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M\R)_"Q@]WJ_NYGHTUU=)F(8->U;LDV?[Q<E-Q2:X<]G>10ZN'6(%",:<!ZO
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M,_\)%"W)%YRNJPI'^:0ZK0*Z--"9#2]8"!_EUB<4JR \=#YC:JRKJH-S"-P
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ME;1TN;+=@JO8TK&[!<GCNR40E[/O4C^RQB4&D&PM89,;/2<8Z37I>UF90/X
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M9)I4LTOC6Y6>3%D<B2CX4.A74I% A#(MX!Z&G>"^$3"H"9QJ1MCEQ61RDW]
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M-;7R+"LI*R/\L$"9 T"W&$O'!G95/=%AD+P-!([IG_7!<KOA((9\S:TY4KM
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MD@4JP$$@ID'1]_4_TDH8NNP1DY"1_4_)H[Y.TS7>V""+=2G8(^>%:XS](!N
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MP?4@ +2N\C: Q15*R?EPZ9++*GVV0D[NY4Q#T#1YD1.-EB:#'C.?\LFS1\
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M.ZPW\^Q+KUNVWQ/HG<7E3[%<&OP; +QQY$V=F&04KV_VE/[1U/CF'%S5SXF
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M*+^)'[^08!9^[G <[0DX)LX)[2T\22VGOI()%83__Z3_-Z1C>['DQG]1]7P
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M=7Q[E=@SM/@ O CM<2/+Y,,ELXQ^%M>P0E1'&\9S\\H,P 0C RMS0B%#. H
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MY&0#*6JQ67T<'9I&@6RF.8/K+;DR&0 6H/HK;O3;ILCO):Y%XT6IAW>;SV*
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M0(1U!%$#:A/L%SIS/4F/U5K"&I% \1C 6G=7)3AZB4ZIS_8NG!(43IX;L4\
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MO<M(0(8I'XJ;O?L1VY>,WEO8#X"%@4]!1U[(N[['Y)@/Q(T)2E4$]D4VHC&
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M>L BBE<)/8E>[">2K"ER#A?>KX76.%(W.CXFS>9D'1&FH-^AG=$<2]PSC*C
MI"#*Z()MP;Z8+LL"C"7[WO)#!T  +MU?CLJ9R("@@"D_%=0GAYN 9D&9Z,1H
MWW$4S\7%%E+>+K-%8ZT\INC VO:JAI+HD*(#^VC1I!WVU<3&@XG?T<H528@Y
MJXI/$S7V7''LE+?SI%LB#'9B&/52WNC.^M"KT\#Y&&UBOBA(.D-8;8'67.^3
MGC1I/95VL)V-$KZX,D,J8V8Z@0$<I14ET8KND7$#@6.,A=+#T <@]?,9=*OS
M_TNUX"&^W=,2M(Z'X_)">+E-HRK?$HP,CHRDQ<CZ>WNM\G(1".HFRA+%"RJ
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MHTK(/7&XDQW22^I-:*Z1]UU,9RQ'"O,J* EV*UL4L&.FE0;TG(4+U3HP<IM
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MOW,.\W+9&DR=W!1_MM&14SYOBSC$K8TT7)W?81*D;LP$:SW JB]?+"0\OPB
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MTLVV/QFQ%:#CDU["<#<O+=E8?%;YV4J2FU@ -,E,Y8]J3GZ7<_ORMT%0PC\
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M;7!\@2I9N1 <.(3U7AR!P?Z0_.XWM_L&54[\U%O0@"/(SX4YI,CN/E-2WXS
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MG2&28;.*(P(G_]@J$DZ: =K%]AE__OTXW'%]VM(CNDS/%L"VT,C@CYQR;1V
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M22ZPL6%F)]<YLG! JA>@;]E1&D- (,3NUAF!+5-P$Z46@V06=C6Q8:DEK9D
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M0+QCUZ<1,V.[*"= O:T$>LW.YONL$/N.7=\Y?#=0R^_>-M- @*Z^#,1#&MX
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MFOX)X^9VV![H8'&BXI"DIL(QJ]PT6#UQM=8==(*=*Y>VDIX@=XRB1JURI1E
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M-PSZ1'\=9P%H';( 5/6''#2HP-QHQ))K/3VZZJ[7K9Z_RA%PEEZ2S78SRI[
M"T%"ANG*7: N":LMK;ID4P$W&LWI?OO4%&_1!07;AX)OJW?KCJTQA%%FJ&)%
MT^DD3,4&3YV!E,5PQ1;2=<1D7P%;TQ3_P,B1J/VA[9*;A+]BOVP<N)51',7?
MO]XE=+EYFSX\5*\6,Q"Z%1J^ZAB<\6T8&7^^7N._;ST$5C0!LMU*+-![&O;Q
MR/M&M$Y'#Z"./L[L+]>FS7C,O8F!3KI5^U<B,[/?2**22<P&*1++U*GZBJ%#
M^\:"[HDH9Q[-C$4WLC[W.KN<N.>U_@ '-LM/$$&ZS4%/11I&BRN.O05+^ &-
M/)GDXTOJOBG<V!<CIK'!&32#CJI-#E(S4WSK23>3S&9LC(J;Y:EJ\78DTD="
M9!&XZ.]S_N;SC$-\S&EUF[#2CQ .+;H8>&R9\V"$R1>S%B>4O;&SA[6C?V?'
MD%>A[:HQAE;_)LJE<T\PI&QPW3)'MLN[<N7KV8DF9MUT+.D(VJ4ICW"T:.@H
MKQ\?VSP>V;D),\M1[_/FFIFCS\X*)=#&GHF3U,P\ BOU[&L!MZR[,H2_(VL<
MX^?*^$^7AW+ DC9Y//&:(S.1I3,G?[7KX[K,?8(D#![ZLQ^2(/"GAJF,#!9+
MPVR _>3MB[R9&^KXCTX=E.VY.MD3LA[#CS'TK"02P#M! E@+*Z+LT3P3J6%V
M*$=)V%ZJ+D7,?1Q('QRN.3K8)%X8>)QNZO,FVBA^]8;=Q*G]6<>W3-+K!39I
M6FEB#UMP/52XF^[GM"+S<=?P;P&^6Q3IR=.5D_DKIJ_M+ARO9CQ2GBE8W?2S
M%]BHC&"Z'"F*;&)CW#-X7>)<- ZE4IS"PI/4Z#+8!?>;'W.]*O"5+!;-C';>
M#%P::WY3P9QHK*<($1NS#Z'0&6^DY9:6D0%DV4,(S+(6)GF)OU9&DV8"Z*49
M>G>4I!G"UWQP (_7']^-[B;>WCEEGV_Y=,J$O'7%;IQ#!SC,L?HP2?['?3J6
ME85CLDIST.9NZ&#-*K=?.7FA-V$?1#V)L9XDOVIT0QC).]@XX%Q] .4 SQIQ
M-XY'+CW ;O;F%[(GQ\L7!9VC7E%  JJCFYLS/Q(D,A;Y/%[+.N[&4HA-M-+0
M?+T:O.+I>A#(9V:_Y.CN\ZLI7YZ/!S\_1G<V#N$MU2&'\XHIJF/YJ\<JB,#
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M4JG\ 4P\SV?Z].^\E/(OUN+YS\II_]D8/%[]K4GMW+913(TI&_K[/IUN)C2
MXQF%%&<.@-AA>5C&=3Z&C!>04P.( P#^_KB,).3FCR8W?G*E9J9[Y^"HA0,"
MPP'!A/(;L/B1/RO_!5!+ P04    " !QB_M6UE/"AAV. 0"4SP$ $0   &<T
M-3$T,CAG,C%A-C N:G!G[+T)N.QH62=^;W<#W:TB#8T@VQP:D"5V9ZMLE^Y+
MIY94DJI*I9+*4A$&LE9E7RI))<7S(.NX,]#=( BH\$=L1!A &G'&V1Q@6!0%
M'1101QAE=$!$'1D=&?N?<^IT]^W;MQM0G/_\GR'G5CWG)-_[?M_W+K_W?;\D
MW[WS=^[\@S,/XQF..7/V[&5GV[/MF3-W?M;^V*8LLW,@F&QO,)W4<F^PTQAL
MS R$;X# ,S<^J\E,.W3+(\M=^\E-U_W9O_JWUQWYSDW7:=@,FF4#=^.S^\*5
M]\+2WH<VY5SWK/-7W]B<:^(L=DOSJ(FC9'NNN>FZ$^;GNM^/3X/7'9TT*<.;
MKJ./+QSI,_%HD!;N$78#>KT-P? 1CM\ ]S <A[_W"(%@!(2Z?_CU<.\<AI]#
MB*/3X[KS5W??-Q:.=TX:,J?==7_==-WIO':[W0T[](:T6(,P15'';!#D^J[%
M]=LV*<WF^F3[I .3N_@,W:U=^%GII\G1\=^FE5;E3====_71!<?IO.+L[HXN
M*<#[(1IS\?J!"=>@'Z_!NP=V/+:.[MR@<,W2'7:?\PB$H-=#Q/4(L821<\=R
M00$(.X="-X(7M;P4C[18IFET_B!\+HJJ;5D<GST:R/C1TS0_<=+=]ND7L#HE
MN(C7+'5\K[V?\?0N',\%+2_FT1F$8Y;FU\7EPK87\5ENJMA*3#_:GK^7U$^4
M2D?EO<_>=2'R3Y2<F<767;:9>]-UDKM-J\)VK[L/P6E/Q]H[M_.=<G,>P?"3
M@5UPZH&(-JZ_WI3G88B\A^KTW .1>6D1F^5Y7AR-[Z$[/?E ='YLKMWS(!6
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MXD1 .LC0@YMC:K5+^EPQ)J@)W@6=61FR(->(> ]@IU67,0YK=B]7QZY(;O#
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MN8M:&"*!249EEP' +"SF;3UO4U'MD8#,X3F(,&)#0UPND!=PR).H7H#=$+H
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MW"-Z $$H9<"&B_VV*/)-@$G%F-O3S4H!7;87Z50*TI-#;M.O8:04 Q4<4D5
MFU._H(@]H^X("EQX0ZK:Q23;5:<A4_,&GO1%FO1EGLLY3$F;19OK ,).U $I
MR;7''>[1D[:_6X4LZ04Q:HBM(G/Q6!GI#NQ-30KPII&,-!W<3R%QR@I65T:/
M#42FAU!EII(TJ)FH'V(*OBX(]@!?FW@&+AIV#S(SFX>8<#S75+)2 55QO?T
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M2>5DD/^!('N<Q!N-R>94%&=C*#)-6$]*BISM<W].!/>6QND A0?D.4"PE<@
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M/URDJ741<6R/=*IF'8)WIJTV3Y6(9)^OO8A<M4)5=ZSFN8@HZM 1JNS2,24
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M6L?NTV7;^.J!RB["J4QU=,E4I6DB4W7MUBYB-U$)]61'NSJ>HW\6(ETFQ?S
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M& <FD:3T0*P\&EW2VBDJ K9R6\<"*^"K1(-T[;#]*:4!PY"G12-!3<MG&9=
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M["U![T83*^T+%*675'.SZO W,2%"6#=0=2L:L7V66Z95135KL)#:<W 597+
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MESFZD_CF,NK[K#D<_PIX5Q=7Z[7WA/#F:L7"/%O?$Q,QV&1Q8</3WG##J7=
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M NQUZ\EI;+=I6]CW''V6\N8':W([=4ED.![/SMO!5R/*?5')K#N&^%HPVT/
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M:*'5:97 K5_^ ,;3@#AM"?;P-%719'#*IJOI6G</&S,TTC)HPE;S+7L3'\=
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M?1B[:-?:4X4M1WGGJNU"<.7RP?H[ 6^_]U&?4Q+PG[=%?URS1V,_UNZQ[H%
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M%">H9];D+4R:Y ?^TXA%GI]6R2S*-%(,4@VT%!/SV&[<<#BL\VH#7LNV4*^
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M'5Q ,Y13)R9R2CU#$<K9"- KU.2S:;48$G8?G];AS/HYR\DD<;88X-RCE=Z
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M%9X!0,:5X)V9[J?WI(W*PF?/ "4/OBJUR"/24X&O AX6N(\IQRFWS#DKRW_
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MH$#46;_E_DR'/T;569"Z1U>/3=2YKCB_7<4'3F:1W6NO,N ^6>9;:K/9'4Q
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M:ZW&VI ?;>'ZUS6OOM$>R"@ZWD\L&0EN' A)U;HU(%;=MO20#C0LC+#)F,Q
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M4!= 3$GOJ"CX@==QL/C!0/N(>Q-#RIRR]O)B)A&!#,.^1/?7PZ7>M9E/K8N
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MA62](OVFJ>@E?25VE!L]A_8R\:Z<K>G8<8;%5<,BOW]$;O=IKEYQ N4U\5"
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M!O=S\B5-^0'ME ]U<YJLK @ C[7YJXX&/LC+L2AG./AD9II(A,,^(Y&8BU/
MPHY9@VWLV\$>00%]%05YTWQ!@%1Y3I$NL_Q<@_@(I9YW=SK3 0E;6:ZU"QKZ
MJX+/A&VX?Z(UK1&CM0WY:'NMZ >1)'\!]7TR^[;]VF%_[6#-%?] ,9YVG#&=
M7BA1@K3PL8)^*:D@ SU]#('%D]8J'N2=+2OGY@WEPLFM@"2?\T33,L_H1.(Z
M$[NC/-V[- I'.@*55^WJZ'3V;&@'!*\4XKR0O'!9@4ROBM3'1Z4*RM/5G_;$
M[3D^M>48N_ !2K_9 '-G"_.9%*,H%+4&D Z"@-$R@$U*=@%F?N97A>:_QL\=
MH>M 3YF*EKTZKO<9@^IJ&X)%=PX'J<X0_D_&1,2"'5&S$,E8#%[GHC<?$G._
MD7#\E];]AD4U--M[XZ :]S)@%OKW/F,2J4CG<MH8F/X.5F&2.F@@W'4S*U8.
M7]2":7B[ @@*:L5&(@ZLE2RIX-G<(<%M]%AZ*^W;C>H @G1 %HPJ'0L@QPSX
MS_.(KS:^-GZ-#U]9L[=6"SXN4-1L68',7TF<-[#1PS=!E%[U'MP.S)AJ''KQ
M 'DF[.G:(=$A+912&JOI=B9Z+ <Z.8%Z]89,#K]=_E:^<C8'WX9K(H/FIL5<
M_?VF;SMQ5!01"E1N/WCL4Y.ZN'G%R<WH<_'H*VE2>:%Z-Z"^/BH>L=6:'B7Z
MP\<4;G4L[P@.+*E:J4>M(*T**M%7M3Q[GYA/^<MF)'@UXCW'HE=I'0(<:?@_
M^I\D1]Y"TMO%!A7CSW12_4<P]H3W\)PA%]@[:S(1OH1,Z1%TEJ;U6.,V84*V
MX^!/3J0?@D=LE3S%? P0>O'7^;^1\(X)B@?'U4]JRS!=-%HNFDOAE00+%ADA
MW2TQ$KN#(&9M2R+B_;A, BR]6:9(U^4/ W$#1A??]C?NLD<.Z>$T6?L$0A%9
MD'/O'.WC@XZM<*&]#)JL],HB';RV8@I7M6/3\9\WUYPD2"5Z@4EKU[9,&/$N
M!=O<BHE22K6X; =O55B%+SWBYYBH:7C8D2XF_"NQ!L"T!DQ]@],==0%=(B?9
MQZ:V^>'MJ^7T#XPM*^\[Q<Y/$O?R,N'FRFOU2ZK^., [.C:!/>(X;(/,%V'%
MF!^P<[PK-*%5PK@F 0\VK3(6*1B5IBGHYP4!L$TSR'.>*;=*P"[)D4,_Z+!$
M;[]K<0J#RIM#?*0;NE?Z[-'3;]ERPR4)L?9O^&!(#8(VR]CTM)W-U[9 MOOY
M;T8=VX^QAQX%&9QIYRF.YE/]R!35V0&Y+>CLDIG@ZJ/(\J^;H3[R/0>5T>?:
M!PY>6Z (P(+V,(U$D'5'3$="WC@(7AI33T.YGA7-I19!K[ DE  P8%8!DY>G
M*\5_:5$EK"3*D4LC+"9(0G6T1&V_8-E $]!M]<!<-EL#VPXJJ%CDF-3LGA]G
M2CFH+%0RS4(A=DW)CMI=T?OB1_V_$I_X$DTU\[E,SC*_,8Z^W&F8@AZ(>6WB
MQO$D\/2TCN,Q^BP%,S.MRN(,1 V8'>0F(=RH"F[-]R1E0G9=+CG9^6R:,BN/
M-/4I'?LI&=G1M<>"2B +6&8?T5;(OA0%YG\[9SQY-@B//E*=B2IK;!_Z>=O[
M*[/N=>GBP,NKZ.//,RF_KA;_>=_^L?S\ZL9>Q)/5;R1U_9.VKU'/)>*/@F5_
M=;<]'Q<>_>@:>Y)9?FTK]GW.S_^^H[@/^F'!X(E;BN[7B78$[LFGJTN9[\?!
M'WA:9-+:5=>T9?QH:,(;6+_ OMQFRR2]P93M>E4<)2'ZW&TM?BWY1<'WQ.@&
MG/S$7ZSB?U4]$HX]0ESP)*CT\V)?;$;P5X$SQ>CGV=<2^*D1JZ\>%NZV-W\C
M'52%<?V@&_54T\8?G-4\V1D0>/DEL,>7=C@L_&;F)L+2(?RU:UI30=B)A,2S
MQ9M/&I]..<))BPC^\F.5?>'G^1#0$BVE%B:'-O*2KV%'1(3YK4\R<K:L\3F;
M]W2"/-8>L8[& AL>7"D$D,0BK&_'?K)6).$GU7E): WJYO;3G0>?A\/=O7<L
MC!6)=):/ON[M]YF!ODZ>*D]!"KEZ)OL1*,8#_@C^=B KSYL8WNADD1)I7O,W
MB=,3[(4> =H9"^ZB,@1@%D(HUJC?ACX'6RZ^A<(S.@B+WX'_0^)DPANAE_%_
MQ<=4;D3@7CQ+)ZWMD%%:=]R)='!?M. 3VL@9,86^Z/EK/*@3R#^""YPU]!V3
MF1*K#E",]^0#SWLJ-]W[=TNI]2CUM/DG;:^GG*8N%*>77WLD;$'(%7:"%>DK
M,BM)]=YJ62,>M1ZU+!_[8*Z;[;-O#U2*[F253X-[R#R(\F.0$2'P7-_8@_74
M=B(&DACUS#UR!^YE& :IQE!C7__8+(&Y'R&ECL&ZHCI^?OV= S =4SY\K)5>
M(_42CZ>9A2NVP/;> F !7%G96(QA%1M>Z6(^6;[/"T]"U6ZY<?&'FG=;&6W6
MBZ7#MQ06?=CU2&/0F>72R]/E^^O4K4BL"-,=U6,$+<>3>*B^*&=3_.0NVXB0
MRKEBKUP+AIU^A&\[+K$CJ'2P%1;*JU P&\@^27T1/5Q1G;^O>L::+/X3(WU_
MQ\C#$Z#N7^L-,_Q$P$O8'?KF@\':_28G?T(D#OV<1)(E% 0627@D,R-HEUOU
MW&7F0@OG4TB;":\K+Z^.U^S;(RZP!9R,EE9Q )PV2I3TUL'T6.#PKB9#6JHP
MH.?;RV6F5I+&"K7 ,4<T]F$F C=/]Z]97TMZZ4>YGDIO_$'51H_X/-NE?D-+
MI?X;<@FNT3"517QD@4.VNR!"W]&<K]RCH&%F.7N3:ZIK=##!TN.SP_-7-Y!J
MQ+!PH6D]33QZKD/>2Y)% <+&K+&1 TCX.^]587?F/5Y1K)X:P,*.)V=I0S+!
M00#4,1GJF%W!Z=IKN7"030^3:1N5[T*7TADP^#9HJ\S-K$U-]\JD_E'G$2 Q
M]9W;C3,IXU(=&*BZ.?^DZ[Z9?ENNX.B[K9W'%@]U$MM26:;7BF.JQV6"&A!X
M_48*N^GY!#5]K;I1=L'*^^,?N33PW\CT-WW!.YZ3=6EEE[KWK](*,52MW1*>
M3T-_,K_Y)P:MN';O">Z]]!!&Z33<9*V#H*16ORM!/MMV,JA[2-_8,?>F4UC]
M,AZNU;*8)AZ[80R9])#X8-C&;C*:/6^M0F#?S0&""*E-E;.O$WF*!IB"F*(C
M$1:=,"QT)2:'Y*KHY$QT9W,I-BEF3_U]LXNGB7V_3DU3#R:<B/0%7Q9U+WIM
M=BZ5M(J"X '('(*D&</-Q6PY&J9DV[KGOQ/])"TYH\U7Y\P^XW]5=<M);J1?
M4"F++(T]6I?-NIBF+2TV(RU3X)S[-TZ]^8WT'U$X^:'X)VPRV^8G:01!V(=?
M"K[%?S<:\O/DSQ20O?I20'@9]:8O<"=-A>2Y<_S.MV ?^^>L_YLR<6W^;'N*
M1ZR3&>\85O'1+_O8HY4/UZ-_8+OX/V [(O,>3R9)%E/*^3CZ2#SYQ]3)EH,]
MXT/W=D:QN_'H/Q-B]!]07SD/W,5X4/#]ZJSR&RG0U4+_PPX3,OKSQ<Q@1R+>
MQ?)I+H?JF_,Q>S#1-G7!1'D<R]@J:!24+\0'.S+>,D]0SXEB':?)Q54.'K(5
MG(<J"]">79A][F4,JQC$LVY(E3!&=T<(([=9 B9*.NEC#YE0[.N/YDX4(.F!
M C^8PM@NKT-N+[5"XW!BW,,FLTN%)@DSIT^K/4T+]:].H]MBKZ;D\GXV W1>
MK2<PG\!6UKW5!X:NZ:^1BL2:XR6#MN;I"+$&80RN/QWI@IS& 9J$DYS"-2C[
M+S6_UVBJN4+VQ;*936R3Z[>>>OKZ$B4$@"OD/J,TB ,HFI-Q4 _S.GHY&0TN
MO#;''%;1;YZ/ F<<,<*0Z'<>@ ZH:)J"[<]-OPP@7I!X068R%CR&(W/?8%X;
M"B@(+>0E,O4I<I&MO+T9$MDY+&Q/^B?MB8?^DQZ-6/\]N2Z^?7U,=^]2*5JL
M/=ZB";(QD:GG+F[<.I!6FJ)P3%M''U1WG4)T^;:]Q9MP$F&[W_M],C/R?;#G
MGIH8_=SFI485";F;F'ITZ3\NA=[-'^-X,\7[%&!ZG,%(]R>E30_?M7=2.#J(
M8;N%>GU-_EK5-F1P7E':MVE+?T((Y8F(7>1G+%5>V?%862&^3>'9M#V];S[+
M$DF,RJ0CY"ZOD<C<C?GY3XJ<_0>!&Y;^C^7U_UUMH<7_R9HHQJQ45S>T1SRP
M: A+IWH:6(,*S_6>P+%96RU;W5S%X?K&&@NF;I-"$%K-"=\[M9^K^.-S6M^T
MG^17\QR 5JX]@-KTXT>_D7PUF=BAV31+#;K=+XC,PSD<@TTVS@PVFIKD=M(P
M9[&C@IS?L.I:+_^5'G_5;*\2L^C6([75 =IBJ*^U\VO.VW/XZ%]=1]P4U$RM
M%.T(@SE340U)#@%<Q.%!H2++/&U\Y7+1[OSMM%UAY#?ZUP7]A$*M9I=>#,2Y
MR<[\=++TG3[\R8<0:*J5M?(VJ2ASAX<9?:EY78.BKG%85X5&\^93V653;96_
M.^+N"L:,^72(/>PVX#;@_1SZ$"#LN'UN8.K^,=O731D8R'U=J4:1AO6]:A$[
M>0HQ*F(O=F;EYZM HB?T$#CT4ZGDA5:^0UT_@W8<+3NE0&:IOD;3H%XY=A*Z
MQ*) ,2NMX(5:!C(\FSWVM>-QGJ(''&9'FQ;R&K>3;J@MEA+(VW&]!$5:=&<'
M*%B9%]5>: #,#*([U!2RLIG8TN764XM_<!NRQ[-WNV9K9[-[V2N^486C S*$
MX7,WZ>NI0B7!ZUHM^QZ=-)CZT_!]-S,4HTP;O1^:W;LH!CF""%M,7UNU$*8Q
MG[N1NC0.IJHK]ES"\M&0Z#B3],$J\S<"9P3[VO1J9GKEQ^3K9:4R*5L*U)YO
MX/L>S)R@(<M&3H6Y)N+L$O5.XFH.=70.M$A,NG2WPM"![@$6R9G1C$8'?OHX
M:L=[VH4-Z<K<8!BQQ&(]KS8SJ&-CH5QL8X$X!B4;29YD"F=/<0_9GAV7)M23
M2L(EJ=,AZ.W3!]-7K.(7]!Z'5>FV.K39S%,B&UL3%$#7 8+V8]H:WP+SC'E5
M%5T*'Z5:ZJ#Y#:K"\.?A78BYMARZA[@O@ "+#@6&G(D!)(EX^4< IBR8$W#G
MK82/^&5#]A6BROT*.GU(B6!9_#0I0OLS5?0<N@""4J)LMF04U4]D0]9##"X"
M<)=0FQ]YG\512RFD1NI7/&))N+H.X!SL*"ZKW^.(U(4'<W((/P6_U+A7-[7%
MMQ-<5S+^0W]X8TZ,$).Q;&:>!BE'*X_3\%L^(BMSS?Q*PB$!TLBSS,PL3Y4]
MT4I1BJ_%7R$9*([+*8[> :N>/IR"5]RG>"P=?#MYE?IXN0*+%4FXTEQ-OY&,
M@*-$^[MQ2>HZC@,%/%+:S[,%^^0[F;X%Q_/)]E9GR<?BLU_LR1^Q'GV+'/Y?
MJ;UZRO'Q7\GJD!*4$?BKPR0>!_^3$.;GX+0T+O*1IA5%[.1BDJEV%D+D&Q?<
MR3@>R6I]3]7T18^V'D=.!=_D?8C]K>Y\%IP23#I*J^F\J5&G9G<=% S-,YF@
M!JY<N2K&Z]#!7'35J?L96HZ#]![5-HX "(N[MG/_@5=7*KDO C(6O%F4,B<2
M:=)8!)] B)Q@6"24TA_3C!C;(%V%\\ ZX64\\K"VG&6/>]<(3H%[ILH??I%6
M',1QFV4R\[&;HYG2C5K[C40CXOOHP67T843F[-5C4&AI:G)9[%02=0#JK"A-
MZ=W>U[4 Q8FU2;SLK<7>8\,]^(9/>VVFGA;#WP/:PHW^N-)Z5,.D_NH0,T]5
M?9S__9 JD<$Z<J%0RY3:].,W)O%VB.Z^6%NJ/YW@'SP+N8Q ;_IY?T+98&B?
M3V/'6ME^0>=+P_]"79Y+E9W1$H$UCHX^F*7C%R9[K$4^,:8"&HN(NTD<5>E]
M!<BZ8%M9(V(1H.$9<OKIYZ,(M!T2>,J:X(%]A%B94?B;!\"_16G0SY+"]7L8
MI3BX TY6DR"E?1_;IOCU28\%%8$Y]P^K$I(+NR)+HWY=]M7K&>0A#D91!>J$
M5 85F7 ,HI*__BD%15[_0V>W62M71K_>QIKM+Z3ZN=UX2LLJ?>IMHA@ZH;?2
M^$TG);C&H.Z)O^!X+FM>L.")/_GXJ_U#<\&WN%+:5+GQQ2JD +!_+Y+TC4]-
M&HXLIC+!JP6<\J*/0C.I3,]RP*T5J_X]X3T<?5Z>#RZ;JFZ5-J&RB%C1VO;T
MEO16#DY!^PH'K+87CBKF\TS-])C!Y;S<4AL_K16:)_F[.$Y&W##!^..T!LZ!
M7@>J/=L[CM-)^F[<7=O3:B: N7*B;,).)N=LIZT>MC!F]T4K^/9=X<"Z5\K@
M.8'S*0TKD8//#7??7,3?@9.GM^Z/T(,29!-S<XQ@-F;*,,K0[;U %3!V+Z)D
MF*5UZ-H5?^HV58H,H?N>]%K")%A/^-D],XDH5+L_@X%RQ[$ZN9?$;?"B*UJW
M(;&++_R4<+U%)?@Q48&Y9?GH"L'(O3)87W++<F0PL;*0N4?T&9"UD=F$;8!5
M5XS]$LM$E_NFPHTS6<W8Z5/(*H]V^H*[:D<KQ:%*^BU9X:*Z$MPT,V;4?X48
M/O?L(0##H#+3C_F72,FX>7]R?NDM&\[[5WDMZG^#9WWV@B /2[$.=B].6$7Y
M]M3H>0F%&QHR<IH86'&R150H2GC'$B@H!HK3CVLFU6<$]A:3]].ME0JIA!$)
M-L#><PVU3X$]9:%)8HK ;5\J2.LX&X5>&AV>E?- XP"/NI_JJD\Q5\L!-$I"
M7TW"-'5LZ^;J8C%QMV4AS)G&BN#=- "E7#?TYYZBF VC3@#ZBHV;?(]1+7/I
M:1?:.P@G99&2WVK_&V<+'G;?X/1S=QN=!X<WDS/T=?SG]>PS'$\")R6(\E&?
M=63$[NBYSYKEKR-HZ="&X4IY6VV3.>%]9(-@M4:HO&035GV^#)$,<2:#>>7H
M$G3U\_85RB(P9R9FT6.HRQ)[80V^6<ZHP9Z+0-G+7(NC\!CGU-,=W)*32GH=
M]@-P.L=(@K#\TFX+-B;I<*@+T4O$1T.PJH(YL!DU6>M+1\-]&0:A+!QFWJX9
MM%S0W(%-VV460@F1$TAHK1->WR;_T<!DBM*2*#O^>Z%R^@'X>C>W.E[]R%S+
M>Q%V%T"30;K'MA1##T>=]T9NR(<S3BG5I0F3;+\YLX!/-(=JH-4R6.7AJ9&9
M]YN6P9D6@E)+$-1"3L_<E%R^Z$^$'KVGX6!T+V(1:$2/A"CP"0>T9",AG>KO
MXR2)38VXX*0*<)7ZVJ8F_QBE\% ZU=T3@(T%PY?3'Y3#R54#!'G7&05N1XFG
M5 IZMN<NH#H+?WS7IN$4^V$)9,L?Z,X&:V-W169G<MM[U D"S*1XY>*86C@.
MM8UZ6*X8@.C+=]) B;>0DE:&T,M3F# A%-8W9%00KE4R_E)H KO FUW,^I^2
M,?>?:-(4\:_BD-C?Q:'6$^T;<,&38+&*\%7U3#C6B$'=+VS6+\QB$ZW%.R-_
ML.6K_=^R4_9OV1GRY>(WTC>#)ZX?=+/.:MJTB\_K\[UO'8IWOG@=A2>.Y_WM
M*AI>99$.(E(B^3&X65S** =-\9@)WPAL0;Q9B"=0!4PFFW<<[YO.U2>3NS:K
M;TN 1NZC)V5E[.ZE2N;4P5SBW;$W9$F#];RNB23-(U>N"O!Z#O5^,3TUJ7X2
MJ.3?GF*=?4V4VTUF6SCR[0_Q#57UH:QQ[[:NMQ?!E$!$/B?0Q1O91?MH)3L9
M)E=@_:_JQ:=_S$/SOR2VWF/X\S43'?%R)OK3I4BO>0)*>/RMEK!<)CDN416P
MWU<3_"<-",:B\\/CZ-3RGG$G04=0&@_F(4<3'C_@O*0>XU# IJ>'07O7EMKD
MAZUY!HUD$N:C_9;:)N_#%KWW9U2 K'5 Y%MVL6W^7?I=#1:TYW*0:D2&>WLK
MI=;,WLB?5/B(4,W)XF"\@2%@V;2, IG[KLD7<52*I][80  VVFCSGOZG&$*U
MZ"N]&JY.E[?O@E9"/C 92X]Z#7IEX!!3CQNT]Y6WQ(^[\;(OV[:5<<[P3S46
MBJH4,/Q&JN+ZBH(#^V+XA9IN35W7J_.LZ./;= /CPA*Z3&^S_EW#74J'"H)5
M@:EAJ9SQ>*&B# %#>@V\"@D32L]$*_UH$4BD6(P#$ZOWL#;_]BPQNH82FBE<
M'US@OE\5O9,$$^?66J&,O\L-2MYIU=^I]Z[^:B%=K/_+66FLD_%B+;S1W")$
M^B1,Q)*?F[X\9YR'4W<+U58?>Y& )+]#VY&T@# VHLC<Q"UBV?X]C6R06?7M
MB-:J(0< [&5F7UDVB5W$WL:<O9U%J0WF9%C))5SVOO[+)FY=H$-^R>,).1 \
M=#1/*K4Q76N_5J+I]E()@J.BES2<-5' M6"91A?1FKYXR3Z'83Z8PJT^^4Z#
MD>(N3G-0 #R_JL2W C\<;%?V;M&#'YQ)1N$HO+55YM1 ^%4SL6@Z$LB)I?=?
M^/?.(8+D@TPMUUV5*ZYK>#(^R7E#+[=IUUA:;EP-EN(H T2R_/'I:K:]U/2(
M]0Q17##XK?'V]P*_#&6&-^=14]UM..XI;( 2W4'"\A%+WW9B([E*NIY#=I4A
ME:H="9>[_(+G V:.K L#34<>C67:"1O1M6#(9FC  8JA=.!SGBT3\\!$(HSC
M@IS<CS35XN SFPS?L+W@[NM=+89O*1(C91^DJZCU]+83ZG$JMGJX-6P "KKN
M*A!! V,*]?1T<F9--BF!=>RJK=](1#M/B85"IEISFD#^E@,Y!HF(]N6Y8[E"
MO,-1*+:[.C'I@3*4Y'[+3BEP$W1$J[#ACV5F4.#8/L^J,BNR.;5&Z0_5B3/S
MK^T]'-D&#<70CZSDYP+FVM++N9E@ZG21\B_:]<(X?C#LCD4P]09R<'4T2E)J
M O]P#3^#4"QI19'MO>5B@C<TUYL#M%( ,/KC";CIY=X-_8M!9?_A9XTB_L=L
M;_M-\:N^6WMRH\"" E;Q&;ZZ\VW]DQG]D]O]_ZP#G8Y6DO_\HBTM^R'UCP^G
MO@^;J61L"ZD..2R:_8WT[S<^,_3]G_EV/<H/\7_%IWR><CWD=5Z_7*'H\-;I
M-Q+FZ92R,S-5L0C6C<59S:SX$)NO;71D[FBBP)_-*38B+36<.^^I##\YS_9J
M'8PB:4'-=++F:<Z1UQT([+F;QZMD3=\J 9MSJD:O1F__\C7J)JWOMFKPC(%P
MKQ22P:X$B_#*ZQVKTF\'%Z@QU3A,%1V8Z:I-4(6CP7O G1.?UPF\ 3-)/)PS
M(V!*[<YE=[44^ICJRIQPJ OPW^LD9B28[,!8RI.R!3!*D=J8:X.YF/&LPIA=
M=- Y #%C,<QRD=DH\F@$WB;XC\:/BDW[R;V-Q8Y'1O!"X#9OV:9W)96N8DK'
MQNUG/=(_'K!$CIT#C0"3H:_XGVN:^<_"R,M_3O%21^-?4FKR^.J^YM@'3'IY
M#1\BE=KN>V-0)Q ##("*/=C8JE93UOI(/(?*AVSQM+"/-"(V7X I%,>ZD;,J
MX<3J?LVTJ\@/ S#6R.6GD_WN]QV+^BI#EH"$V/.+=D[4>\E4^&8W:5M45^X?
M-%;W3&2974*,Z4QPIR;XM,GDII&+AMAIU@I,7IWZP;.V2P>@+&L&):O[*N&/
M/49Y9B/$Q0DO_QHH=YT"[=ME.ECXVA%K&)^SL7-0FC>V$C==C+\73BACZB75
MT#U6N6'H.0B<VZS1UQCPH?B;X] _#Z=*CDA.I#ZZ7@=YM=)C 2"#W3S.L=^(
MVMBU&G'4]-35T)Q1C/_>TR DGEEIW4V8IRS&G%B0T!;+1;\3BW4:Y@668Q'2
MFFN75'-[.@Z+[.FTZ+SG_Y=YX/WGGLS0?Z/>9(C0SB7&,I?Q*V87814FZ4.G
M.0ZW<.+?\U&4$Z:/:?SQHD*TD<E*.N43P,K#R-1 F<6#T;G0\7M<>9*DRW@B
M;[IE1[GS:/*$M8\$,88PW?8KCSW6<3;L'9S0\TDAJ9. _5H'R29+DM)&W;;G
MI(_<%H[=+X0>S/4ZZ6]/H?X8R,$X&L/HF:_Q#)/KMN_:,)Y"K9(<WSI!RVDD
M.Q\XI^6$A"M!Y9ZXQ9*FBJIH2>K <N =S5]*^#^X9A+EEH950$LJ1A;6G +;
M ?Z45WJ[W;2[5?J4_;: @M1K@CP$!Q?0U<"YB$MDZW15,CE:?-!<-Q^'KLXF
MQ+]2!^ARY4?O[GI.Z1\GQ[/;<#>Q2!MFP'''JLMPZ-4&ZTX62\AGT$J=K&B[
M);._BW78>JT/-'')YC1S2SKD8;4*@-2;EMQ.MI\[GNNCI5)$V63QC-9QZKIK
M9U3Q.+K8VF48HZQS?' )H4H>3K43^XVD*+!BX'72>'FULG[EFB]]H!H0WK<-
M[.:;"KI25ISGN:%.A%2B:0;'&E%')^@L?-9;&2BXSL?M.EN<. 4IV]F7<5N6
MD\@()_[A=V&C['R>?0GIZ1.H);.KTTFUB,)=#=.X)H?PX3EH>X0XUJQ@*8Q^
M62.))/LB5Q*JMJIR7U1HZ+#;I17?]SZ_O&2-2 D<ZW1F>J"$0>^@VRA\8BO]
MT<QO%&5"D=-+0Z>FRDG J)/?'[/)E4+[9'W1D%9Z@)-LY0XG0X,K_O(3)?!A
M(Y[Q4B-38A(/SL3HI7$X#M,04RS4Z#HN>W;0SN$RBKT2Q4%?\$C\2Z[9APA6
MX_LDH-FAX[!M*!FRALAW7_UD@9$9V:%F-Y,E@.6?HPEJMB9<Q6POV-8@6WM(
M>>1X:+;'"QE&F1!)4R&4-A1KYD97Z")#.S:[1'"2DKTPE0TD?-#%V)=Z;J54
M&0Y0?W/6/GDG'<MM="GP$[Y4J4\REKKEP=O&4N^UGIY+3;HK_XX,7V26I$%0
MS4P/LN3'?4[E().4VY9_L;Y1IN.7]E+G+':OTS<M(*GR]H)=96+2.#C=&+5>
MK<>J$<%7]662WY'<QP+H9G[RAK(S8,F?QG^=M6HQ937MPL8OW%NA>I-EHLV<
M4>_ !&U#!(@B\E$H<5K:K5B@AEH3\S&1QVP06DP"DCA0UB@6-WH^.&\ :PUW
M?"O=*+?@08@WY2N):72P<'Z]Q!/$UAJQ^$JIM+KC;;[CF3JI@<8<2MGJ_N&D
MFR?G5#<D1'E@W7N90.@7=#' ;?)JNU'+Q*)SH/ML7*]1Y!R]9DPS[N*K[:B+
M,.&A?#Y[C$@[GW4VW']:T KI7"@TNZ]1LUBLN^)3RPQ]3*\WC6*[=16Q#2(Q
M?^BCY@NY;>F/H=B83W)4;)L<.\U[.V'ZGP>5[NMI5L(7C!HL^W#'+T4^IN:
MA!1L)'UBW#NW',PKF7.UQEV%KEG6]A$4_#3Q:%9E) =CX;8T1=!F8+ZG,F;?
MSJ4(.^^TQ0-/"Q/*X3>>PIXS:='*]]87#1IP64^P5W/#=O7^:).YQ[P'+% W
MM'/0YY.G33<;5E,7B,QNK4F-]H-3$NEI0^W2 X,>-RFQLZ72VKU;/7Q)=] @
M!^V8/$6+PF1ES2/(&(_ 8^0@,@$AQ)1A&I3)'7(=4-7#3J9L8>S9-5% YAU#
M_%1S6$'31RRB%!I5!Q^H[!6XA!RP2*K0*;[ +@9F@3Z?6469+3WP<WRJV%R<
MMFX;;AF#<Y$E948X42R+FM^=W?#K7Q#"QO*64VDJ-=#&WG9^T_<WSYP/]2"N
M]E21^Q220S@-8C\[%*IC&FRU"M!D('$C1/FR'8MH'7^Q6L:H4?/<@*XPSJ'2
M49MBX7L8H_22QG%2H9'2H?Q4W >4MR'73:=1-#&Q9U[/(RS"J<FR<]K:]G/^
M#B&:?/$8K[QBWZ^;&^Q9QS>9N5\-R:A&N,K$VO!J2'5;IMICV5U6^1L$&R65
MYS98[U4: ]Y5V(G<%5>/MEA:!FJ8,4 :!.GYT<LD?$DGDWR9I/,J+4-2!'JU
M,D!679@.BR'MQB<9[9:I?EW?I4 CT&;G!$^2R$CSMXQZ!K5E&)B4FEGF. ^<
MU0M<LHX^8E/VLXCS:$!!#L,E??S1-^Y:RS-&K7'G)0%NK9Z0?5[VU2^^,*GS
M68&%O0KT/D& IARB5F;TKQ/39\>4R86VWKZPV]-7U11NJML.LNY9PJ6&U0>*
M:FV:T?%SMY9YJT1<;)F'[;X!SW]UC(,"[;9TA\3;NQ8<#EDFQ9@Q?SP+]TQO
M>M<->TQ). !UKT0%M S/O5_H%I)S(7-D<1!0#NP!A 1Y9^A9#O5B[P& H?UU
M?_>@!\R4L4X5#^H7W/<$0QT>\'(>]-XR ;.=CKCBK*EC'A\G= 3-9;U0SBN+
M-^@D3OMU79R%7DV6UHC3R:S\]BO_WTB6/.$-7RCNK3P>(OYH@*4I2XF.#.X6
M]_G;PZZE"MIB@DX&#<0F5R NXEQE;O;4-I_*@[15!BE;RPZ$(MR3<.M_>.S<
M'[RWE.]@YN"U6 N2,5.V$ Y90&H9&%4+/3UE5,<O$*[F[Y+,LI2[JQD9$AIW
M^L,-#P[M/LCLH"%84C3SK$7L8357A4."SJ$ $]<']V2HF3\"8'B\$7)8PG"6
M A0XZ_:K%2BQW 4Z,P'O2&HT_7F<BGO:[5S1\O6,^3<U<1SW-H6]J#1IE+T#
MF*H6&.A7W/FTTA;/=LQ#@I["MU%0W(*B2MZL.F7FYKX_.:?G=#=\!H$@5/0(
MT>;FCV,:@<O)U&JGL6'W"V,WK\2#1>K]N8CA!\_>$<K+HQ:NY]20GWI+NA21
M[\VS#$R;3SN^J ';(A&?O.$BF94FJA4?EVDP-^#UCRL:CW&H&JV44BG\4AB_
MG"5DNB9[VH+NX9N:]6X+3(^0[[Q<L!R^,EDQB;?QB\63J_>>>N>B!!A1D"J%
M::?+6OS!_%<6FS9[KOXO,O+4.UNH4HP&ZP?60P\5-EI5OE%#R9#?:UJP1SD0
MR;(,U:K H2@&QNL%7RP05O9B&U=S!=SY1R6*S&TD4QL6;:<- J6<7@J35R+4
MH -!$@K(M.G<=,T#J%,AUR&U5OO]_ /I:WM-J[*XQ5(_G(7,FVJG^5XNUX:,
M9*'M/+SJ(R7R+^QQ>Y(\!U]018L*8C^:=F;K]S"IBW*!<_@;+KYQP[_3MZEC
MC9,Y"QDUQC>.K5,]S:@GO0IFIM.RL?3Y\'9A^^5K-!)9??^MU*8US7/O\*PA
MD*8E?2DNL6S5AGLOOJ0@]D*246[L0ADMMG7.CTZI@,&SW16^)6F,?@(FLKJG
MMPJ0[CK(T6E^*Z)VLRE$"DRGU#V;[X(G=E5]RG+)3<:$Y2'?-MB^B4:VC-S7
MX@:'=9_""S:,>\%FL)JCH1"-C14P0Y]A?:@H 4#DLD]$,0[+)K'EU0@6)3_!
M5 \1]:/JQ;>R#3<(,98H1DWO9N.$5MXF$.I%0%P;Z;%*/.%HK/*8G-5O;!*A
M9!B;'_Q@Q<.7BP,<:YJKTMN#EHD?A0C\1BI)K[>N\C>L&*B] 9E0+T PN%NI
M%O70@H&6ET6P%^CC8!9--5T[YH3S=[0:9%2MTSO<@4(#1<.%%&T2M3KU\E5&
M]235)(UA'%-*887![C[ ;UD\/3G.5N*^S!S5"<Q'M)^,NS4S^7497&I:&5#?
M<S9'JL3J2T6MA ,ES,&P04AN&#)A):%?-&1?T&<9E^.$3B@!ALL@D@<?4-1@
M YW6A'][M(BISSB[%@Y47-'0#&6N^>(:L,227Y<S"TQ:.+"H ,XD'R,J#",@
M=SF2PL]I:AN)7R\J%O;_$/)@= Z.Z];B*[?X>M@RJ[-!*06[D;1Q1=["@'GD
M3C,WOFYA:)TPL/7!]HU$7K2FQ-'^MK*EQ] I[I$2^YE3J/J#(MC=HKAJ8TY8
M?.QB*DTD+/3Y<#'(<4BU:X>7?V_S$T#S\)*41F;,0.=3_+ZM5NWI;H>_P]E5
MG"'+Q-3W@*3"BF%)^0%-/R![QDYAA1\DO=C[PX!93$9Z^WEA,+]Z9XTZCRIX
M,/VM+8_RG%IUJ5!,@;SYG2NXVCW%6/A79PHE\ONA,WF045? !_BGAQC'X<D:
M;3SK0MSMR!SN?,<TN@.S\W:+Q*I-%BB=CWN8Z9<SMDR*]LF.G3T.RYFS]H[!
MBQDP/O%S.:='(:2(>DDM<V-?N>A;B=(Y5@P',,2/9<U5T&W#9/<$IXT]+W79
M9AYJ8-:VDN-8M?AYHN5CSPY7B.M#M81<.[<>U^Q'>-_4<W8B56!^:?T7RTN(
M/=%X<(:(YL-FE43#<<7Y+7NSQV[M43TTI=.:$O3=[P=Q?F/;&1)EC$^308&%
M2"S"CEM@9C#[I$X]\\2'>&SQJXB(9>2/U*,[E)\<1QN7LQ-I+[;MLV[]$+*1
MVPL_'%5]T$S'=RHUC:AB2]A= 43/QNAMEB;XS#+L95_R*-<K7SO]1GJQ*7/S
MUPIDK'4K8HQY;-&,GO3TPMHCP)&4D$14?-8RW[ =LN.OX["6E\[09C28>DD%
M6JT7U$?0H5(THHSHM*,N,R,ON5=4P&/K8XN4<JM;%E%"W?2!J[D$OC9Y:U3O
M!21&WI^#N6<[U++!6MB?:LWO"-?QMU^;!*GW-#/XJ5 Q#:1FQDZ91T>N>X1W
M\MPY+;-\HJ_M^4SUM@B'7V)R^[DT%]5L!*&T:'2?C;MYZSX9#ODBHZ"7-'4'
M6\?J6JO?O1UK=L6PSR^(WO2\_VZF/=8N&^*M!]L6 =9#ES:FJWJ+C:GKXSC1
M NUA1EAX[S=CN5M8S^7N9/)I!V1PY#3=%6N8KN8&EH9,BE].O')9>I?K[OO-
MG_!28L."A7Z'42,<2KL0G[.X*L:+L@3T\0P\-@C9ST?,G*V$H7//ZJT[ZB[<
M6P(DUC=J2VH-]T";ZA:@=!;5E(6DE5QOH>TS#C#+H2OB9!N/HOP)3"YDTIJ4
MVH"MK]E\H\ICQMI)4,J9YL;3?P'"<T%M9=!S6(K/=IK70ZT9CUO]%CD5:K02
M*X_4X;/.:("Y[&'W"P^OK<G ?61\&NP.?\O'HN287"3I#;LT@U#G*UQAYBUR
MQ(EH'59>Q:=O>!)M!ZB9N[JZQVBZ^R-LV:'F7/!X/D>^)[(1X(Y&>;WN_/+.
MIUKR)DDG,#=9*/<'U<FHBB)$7R^C:Q+M5L5KI5KA7M+*M&I=GNG)!'I!)NG@
M7G/G 7\PJ1+0\2\'?R-F3]W4U@[2H90 C#=5'<ENWSL>)@4=MD3P?R,1MW=:
MIA /WXZO&7!K"EWGTI[$&-Y-O6@.3GV5C8%M6&G:X'B]9J>D[P<.PY4]*_NK
M>6F#;N-V\C.6ACGIVO56I]5."@5U((MM B$F+FQZ&F%P*S/=JJS<S8$^36FW
M78I[8BVHAV'EH;@ZK;&@*0 S-W,-*"OV3JNX===(?E BY1K6?V\I6F->9S1A
M6J_):FRI+C6M__"&T3L Z2L9'ZDD%]O36HK"((8L6G$4UGR&>_HE^HN,L/[,
M4@#^L!_C[C8]K>%;=?R67=K[GWL["X:B2['O8:L.'\&DC$G=PC*,Q:TZ^^^6
MARQ$K(#\:[;WEN<^1(] T'!X(U?SF_FFMI0GO<W6L)6)WAHI<]#]IG_7J*>&
M>HO%?K%N81J--T47?R"42!]<.14G( :7\\$NAU].$.=[>FP6&D,=7<JBW^Z@
M&%Y *Z(PBI5:Z)VK)+H;EW]ZKF+7;+&; PE'URXSXB$R6W>B5\& # D-0FI]
M7V=O O>0\8Y$1VYUA%HNT9:#FL<A0?PJYTPE.&#95\[)++$P 0O$3Z%U=8Z)
M!<(VDP=]<.D]UXY_W<U@!]OT1^^;]U]BBWJA4M!%'T@C6AXB @=Z)-4=^G*K
M*WI[!,;"-#L9C&9*KWTTZMMZT\:')-U/ZS(%2L0E2M^YR>K;25ZWWPT9L,^W
M?[%V4J T.'IAN,$P[6SO"?12<R?<M^T!P5%$+Q28Y8OY]A_ &%:P<C&J BO"
MBFJ@X0+JC$AW127(D_]U$E]+-:1>),ZLO><F(=60[OJU8HHHA9A&SRWE1:6)
M03Y;;&UV-GS+3?,3_6CZ2N[)]#W#5(>_!L"18;'Z22E"JE"#E!.G@[D[)*2'
MK$PMY.!"S1!:V^(_KIE'W[#KSGBGOS?%\J*U_3L!"-_"Y;:IHB;!TL,"23'.
MM4/D9]Q+QH/4/*<[.WJP%[H8;1.MC.^\<")/W5U 0ZK9WE3R,_IF#_>5(H&'
M*!9AQ9X9=>8Y FJSL;7'O+*_:=>^O!7,.Q4>$A3HD4"S<"/QHY"72M_B8I7-
M%TRE;J7AW7#69\+%Q[J.,-M)\4RB4AWM/7/"-;8;+ZSR\,$;$6(>:.OW## 1
M,2I>:W%_"=]SEX@Y=[;!LYX-0VF:H:E?A]91E_AKS#,,4)L<@ EXS5.T)%XP
M\\E-#:KVC]O8-QR]ZOEAKGR_%#_.?K8Z-+!(>)D1,R/H:9FU_=GBKD*75'$&
M8AUR<=TAWJZEZB%ERFX^KN87")4V+!661+ 2-/O._YG@;$D]BPAG'CV&4Z=/
M"QJ+A7B[F^5L&?H\Q%K<!"9ET'RP]/=5*M]Z)6\GB7./MRUWO0&2*;/NPS6Q
M><8N*\?QY5G5:R]7&-P"MQ'K(%LD.50KX1="G15TNB=C8/Z,;_T&FC2,9D.1
MEWPYA585"35#:@1<2?GT<*YO&Q&?A];F*\0#U**(B!-XQK,IANGA-!U; '/]
M*K!X_-34QD"6\6$XM647CZC&X8-IJW/DCVE+5S#V(,^T;Z>9R<(,SX-_K_EE
M\^5*YW5^^/?FV_LBC48$R;-_IO^$96V",%XL*,<L-;>1YG7#Q<99HNMF0WNA
MK.N%R&HC3>R<VAV-KM\FF<4VJZCUC;.P=[L5FUD% =(YUY )22Z3,PM[A1*'
MZBL&_U\&SA[I5PBVKQZ(X'LWLY@E;CU#B3O/%O.A%]E<L=DH-%V'(3[Z/]"Y
MUX' %CCQ_:SS.\<Y^&1R.'_ PE-(^+$F4)*E>:G:*-?['7(W3_('-\[?2+4M
MKT"?V,DF1]XOAH@G^>%W;.K6\ZJG4Q1M\?!$%K8^O<]Z1YX( _C@[0AG\]JL
ME;E5TD_0U+OEG9%X B\F;):2:3^" R>ED^==RU7XRA0,58F#JL0P$EE?^DV;
MWI4(6 DZ"]EO-CS@6"AOZ^W1=$]T=?),NQ0]4"S+4F[B<P6PU#OP?>V0ILCE
M&75FOPFF;"W9AI^43CNFLWZZS8[2MUA?Y%$-$,EN/XWE#ADT7+.+;\Z/\EHR
M#BW_#G$RWY:A6/QZ)<A]W4 T\H-Q4['.B]ARY>1.+_J%6^PXK@&E?B):H)/J
MA0[G''86VW#)QVQ*.*_V\ZB5&5<EN0?P,8@C 7<-,O8F^*!BMG8+EVG+J65Q
MU5#@J\_GHE;*N5Y.EDT6WR3;47.+RL8MSG*QC"SSY&.T$EV4<J_V*]>=A'T.
MNXS*RU=,2@LGV82:)EF@!QJC5?7[2V502\O2"F//<@-/G$#;\-ZE=-M8)Q\+
M\Y#%TO:'^F/R)K^'F7A*QF5^>T4W/D&D#0W]^F,-]?47=N<E9$K_#VMO^=:$
MXW__8R$A2(E(**W$A@P8)4AW-PLZQS8<I2 8=#>C!,F1(Q<P0NE&.C9 I)14
MD%#1U_O[^0]^=W[7N7VNYYUSG>OQO'5H^N$LUM>][&?T$50I08^_XN4C*I)U
MM\$\=,UO939K@92^3.[\1I5_:\8!KLWJM[PX?5,[ZL[_*_O2=D-^I6P>R]_^
M:.^YJ%Z87Y'MR -SLX&.]UI")A]=0UYDN/@:OUR@]>\+'&W*'MJJ%<DP_=N;
M<[9("G B,:H,?O<EJ^UUOP_YPCH^5(O!;]:H"ESKW)VZS/<XD,,Z/+Y*1Z6;
MF(9J%'); PN9CN'7WY:O/V9!ZR>*F \!6+ F\O?^_F8K3.&DS<6;;HW.9BV6
ME/D&]6.6.9 G[BL)KX"6:B&[ <8-E!HZ@/]GF]XY'/,NWSNIP&CF.$?_7:;A
M3V:Y9EFVP6F\GU'S4T#>4(:8(.I90M*_EI6\C$U%?RN:%W<\VN^1SIS6,VS>
MK>8%)O>'H3.7:J6^:)\OPD:NM2^*9BGG[=-9?G%>AF5%A299EM-8]^-GG&SU
MUI%%@D;GJ#O+8 G79L";WGFU-Y&EWD7OR\^DCZO?1Y1Y?Z@Z_8>5FS!*I@)E
M"XM7#G4Y0..16W;ODV?MEG8@;F6:*/-.7M!]>!A+7&5Q:KWDM_^X)-YR*T$N
MG/:EDO4/G]]CW=U/.G]8W_4 WF :S'IC4H<ON0:2&(9"KZR]N8^^+B?6$:ZT
M4XZ0"Z+8_5_*OG< FT-N6GRP;XC;SQP\Y)!>X2M D?$<'[N7-'[GHZ.XY*^:
M[BS\L&C]VOEPLM@R;T!$=L599 7('8J]]"SS[-;9]Z@+]T5U>/E:,&-&7<N,
M;(7^I<-@<1!A#H__^_(_$'$V)+M&[FE[OCM)=LO?*4FV$/_S?6 %Z?_8>80]
M.#S;:>I?#RO\,UDICRW[WVZLRU!V5AB\^WH^4 MHD$>SHJ*5]HE-JGUP^-%#
MW=6ZA0X U.MS*3969R6C3QH\9.A8=]?'8U#^=^ +MKCMS#!^1\NQ 0FV^*'B
M\T';Y)+\@*##A55ZN87?%F6F!"B_ZV!YZ6)9K[&E.'3%<UXL_F] MGP.7M(5
MB:_*+.:-\>/>KEUM/!TLZ5IQ_7R86X@OMT. Q64EUP]\<J5&M^$HQ7,Q'>TL
M[S/1MK^50YX[.ZVR^;+\S@+7_7WO_E?=@D!(TJU?87Q@1L6Q9/C6&$M;0CUR
M$' ;.MS.QQAU2!'_L;=,ZN3K):GJUMC[XES#D?D!ENHH\(1/]3>Y"F5QK<8I
M6C#;5Z'8"!T$1-PHG+1'U6"MS$ 9^VZ,RC[ 7/!!]QB\IU;FBEB%P]]ZO!F@
MK*W%=:K=&1O(V6UE;<U!A$VCXA-D\S*/8?9>C99*EV5J>$4'=E?]B#P#ZYD+
M0%S$6=ICT@TW6=Z!2(I&"C&X+7%A)_9MYFV[W9M$LK/;,.NJP^M:C\/!LY!N
MMD+A)^%Q@C*C6 UH!7UZ2FD2+OA%P*(LRB1% E?*Z'?7YVA$)VFR["[*C*!>
MT^CUQ(=[/X*(FR$&QQ:/\@8#5&8N"]\;K')R*P J:\!)*2TV=2/$EB#"+](%
M_H]V^=DN.N5>  ?RN%GE2_@<),K2,&*A\'%%W])I?%(6M[7M:]U[^^M_JJ\4
M6KDPQ(@=2;);5]ZOXB1PI-4[*#,K/LMZ1CG=*15J_N+VB05,5$'N3CQHB@(R
MN?MK93]MFD,BXKQ&P\97<EI68[?ZO73.75LZ*)O*>T&QQQ)$)>,6[MEO6!J*
M4#WM(2O6DLOV/3/HI6JYPT(2TM3E7WM"FE^**FA3-D0Y-]1T5_R(?;+DK:#D
MHA")(V^*-^/&I4D^AX?P=B!Y@JP>TW3@)ZXA_NZ*V<+Y?J6WH]8-=/?^"9_)
MK)NA6<M\)*WQHJLJD_C%NA;=X1WS;,[Y>FW&];F)K+LZ&C6/#Z^X++.,?VPP
MK;F[:]W0A#HY.C*,0K83O5.=?=M:135(4&0GHXRBDCA?NDPL<GNX2""W07<+
MR!\GK.^?LI?IXN,7G&;L])U4]/#^ZLNY,(198W%>@ <<Q283EF;I=PVTS*2;
MCX;G=7UKM$0>]+9\RKUK+LY7O[JN1S%_7;-Y14KS\(+[MC-]50RAL-PB;M(E
MY,-[7@5US[$F4#WTUK'PC-_T&YVX>A\=/^H?QY9,Z!7)1C#R-/UA'I[U09C!
MW()@_EUES@JMM(!V"K6XG40T1]/GZ4!MO/)T*@TA1Q?@2CA?ZNBM"E,4+@GY
M'=B1X&^OKS)O1-ZM!CLH)L6^G\UP1@,+TF?M]+]WB;8'SBW>"Q0@*: 0ZIFS
MF7B*[WXTV1H=,G6:8)@A38B?QH3\:UT$Y$CNNS=QU?:2! CG3#0''SQOWYN>
M(HR""NE-@\,\M';24./.WCL_U^-Z,MNF%8 CIH_4RF\= ,T-8\FRA5CZ)]W)
MKXOAY<Z+D36!E0<GT-V;#7Y27>:QD 3R-(,]FJQNYRGCO0_C("<JO7C>Y3G]
MJC;L7W"[,4&_<P7]3\P);SH^>R%+SYS(#7VJ1QHK)3IN,8;LPW,*)P9%?!$;
M-+)W6?-+5+5AL,R/00CE]2-!7<X<+4[PF,N\&'"ZW(_9KU\J3X9P$-(U6GOD
MW)B7*&^*+N'.,:B:URT05C%%-MO/"SO6[%@4IFDM&F2(1"<53O0GA;FM$)T$
M8RM_2$\+.:@L+%LN_#SY^O19VV3!:4B1#LG!;.XQC;Z^K_-4]*S[)O2Y65]&
M4/NWW=SS@AG[G!'BV:I[8)=?#I09NXS7B_%KT6CRO10K%OTM"R>:Y!&5_OZ6
MFY++"&FTKM2R<_/*UPO98LVQ)<DK.F##8\(^1*R1_-!+'Y<Q>_YRF38 NP&O
M*%Z?94:LC1 HL=%,"!!?IK\I.8:W^#JK9M&&NUX8O604=M0+R9*D50GUMF"@
ML+FZ*$R7)'S"M#.2!G+T,$+AYLBK2PKU*GQARM)\W,7PDQN1TZ%H8%;>02&*
M;'D:%]SEIUY[&>+-OG"ZDZY;9R;_5U][%C"#XX,ER)#Z'U'[6NPE1T83K(=J
M+?10_Y(((8:=RBHEZU96"F+Q10]<_*##NQYNMX']]Z0_-<W6CH;QLMD5[53.
M#1KD6?XFSSP3UWO7[S/[+FS KQ4B\J5F)'U4!N/81@,N+%J,I395L>'*/N43
M/5J?\DC)M%&V_EAW4]'<CKE\*=@GIJB:LY":]Q3=' O/CK*& ,)_E3.46+F9
M_!1EG(!.84[J5!6/0;X;,[.QE@C+W!IP?*_\FD+%2ZYX\HN"F<):O[V;*HUN
MT!MTLM9=!VKM]G3]7V[UO/4B^OO)(_[2;(9*MCQ=63(:[J73^D$I88>\T_[P
MG#M29.#W9UU&'-!\+D"^9"&*N+0]:FU>,R34._ML4:P-5;DFW0O)[C6"W Q?
MJ/L66DVQ[,A*<5Z:(:D)H&R[=<MV<#M02"L"8(Y'<2]L:>GX+/I],LCUPG]:
M<PY03O(U\J!^;<OUR-Y?]"^R<R+A!B;,69"O74KM_$6%%WA@-V/&ZU?V%_WH
ML$ZH^.-ZA<&$*TU]DI-R3\XVY!_:C?;'V^QVZ- 4\CI@=Q=;?3=A."@41A2;
MZUQIX\ ?.S^2A&P868/<VD:[<^ZOD#FX[H>#/\MWZ4Z=$/ I[RU)B&)\%4HE
MUMHN6U)EXZGO!ZC,A9)I6^PRXBM"IPXUD1!/;SIFH2" T/JB"1+U_%YHW$"W
MB?(.7GW@\*Y@)(P(M>C),'\"X:AE(*[6QZ+U'T*D;/-!2:ET T!LK %HI$Q)
M3&(C4[J:]W<H-X"$<A0+\5A%*\9/U"2TRJ0*!]EQ/^2Q^Y6QKH?F;_?19AVQ
M[?W27BFI"N,2R]:1$8OVVA-PG@YNQ[MTR5:=Y@R<FA(@\C;/D<\EDODD_14O
MZ_>W>W779GV"=YM1^"6DA YN6MT"^S.+G\*0:AHBL0A=*"MAHBSBL>)NRB0"
M;J'>H;XMSBV+N]ZF&O2LVO9A=%\EA[CNP7+)C=9L2<$"S=_6]&0Q1#YTU&-G
MKS#X9.>LV^91K4,+@EEZ.(,YPZH]64XH%VB=>9E%]<T^T_?0]LS-!P70!N@4
M91[-GKI7R]L5QKTF.:%30%W>)<$YN.V0O0M]1X))H7_VX+L699:D6^T!6/1T
M";QR/.H1=/1!?%QB,='U<U+I/Y_GCL&;3O:*/(_9SU#"LUXM9K8O/4NR+I^[
M02O, ?1,KM968_61U\'98,VY2=]W&FRZTTYG!>-*U[&_%E\L1E@'Y;IFB=D7
M1C_"\'(<WLA>.K2PFF55[B\VLA4W7KQIS4.R@4=4='WT-<;4.C= [#8K_H!F
MP5V!_F2%BJ!_:X?!Z75>=295"B1<EZHX\L6NVR ?!'#^B\30 -/)!HMH9;9%
M!&@C]7)[5U4Y'9"IDYIG]3%%^\]F*9DY]S7B8]W4URH6-2.MH2*WN'X]BR>X
M)F[J>S?UE?^K5>;HYXO/Y7RH'CSQ%-$)(41]:+['V[RT.!:9^6<)(WX1G"$<
MZAL Q0PF!X_)%EI%=7#- NXR/#K&G*WA9B!5E7F_VR?L=3. *C+FA"UQ[\<;
M\G9Y4?[-.)N7X;$\V0D3U&E,YBQ:=U-!TB,;Q)5K]F\;OKQJT[]O<<T(;U\#
MCLAJO,++;GGSI<8E?7FU^0?D73N=#ENZP??19J?63HNW1BZD^9(1E4!6]]LM
M/)[[RJPAMN609U\,4\5&V[0)JZ)#KX*2?$,43@)#QAQ8'M><B%0.HNI7Q8;T
M'0*N[L!@:P=Z3*Z*W\ 3T*D?KX[1Q2CPV V:K6]A^"\[XU?E[$=ADB,B5@C;
M6INY9<%/F(2P6*<\XN3SN7,9/%6:_9<ENC5]>\VL[7;3GRGG97JXE"V&08Q8
MIV&$K;4J@FHKB)RIS+OM8]#H*]&"Y8^R&(K*/O#K^B!7EBM,Q N6XLTNW\3.
M7SHUN+2=,@8^6%_V'/7,)]-QG1W+>9F0/P+R0;SLH_Q>_)5/ 0O]\J7%I,L$
M#LCV%\2K1"^LFS,*'&^84X^RV\U"+MS)UIE&.Q[:%9Z=<=SHOEYISMH,_(Y&
MW*F5^Z^V[2^!6M+4C,XB<K;\P=,%3NGD+@J).PQ9[BZ Z(@*D?H==0M%GSV4
M6[UN!DWPT43%"VOZ9B2:1,?/D-PNNBQ9D!$([M/]R3RJ0F%#Y5 >95C''BU7
M1A2_N,?O:'%Z8' >I)YW >2]=4F[8#PJ_;#4+-IZ+SNV%$RKW1^L_?;JB:U^
MG*J)1M@NG_DR,!-%!6Y]24!V^EWB^^R>W@@\_1^=P+3K=!/A7Z)<X]M "JUR
M1:S&ZKO,2/(*?+_*G($3LUQ/CU 8IG)CSGWC5@*R=1;=FGS>]J@_4W0>$,XJ
MJ2V7.J.L?_!Y[RH2\BXKY[Q"7O/J3]T/</E1*VJ%Q#.1# 'Q+SS,49:$1GN$
M',WC^I]RS-PL/ <([6$90*PLITD8 NX2F;M/A20ABT)MIL3PMALP =W4+>*2
MI_GN$[.L9W'=:U7T[YM.,=X):")DXZ[HRM;G+?$O*.V:;.']B)2@_8%&CV_W
MYJEG2(%[X'OB(4L?B>T:=O*>41A>X+9=P,^KG%Z.]?NZ,7=YHN\:@,ERRFTG
M^:EYY2XH@-T_:Z;9FL(<25A20F+\N7Z%L4[ZSVFD[!(GY,KB'0%KX(;VOF\_
MH43)T\!J=#4P=^YB+;F1MZH\E'O,L^%SU<#$\I\9?F;HPK9.0L BYT[MA)">
M*N.[)+-L&P:487+[(RM*+R24%"4K\OH9BEWPRJJ=W7FU+CJB4>6K7E8#+V-(
MMA8#'ZHDD/O1QL.R#WQ0,G!JA>'8Z=U9X[+4:<]W6;I0U2M"U?66P\8!9L7Q
MR!9U[P.\1AMNSP.:/IOITAML:7?I974TBF;'^!G[QO3G/ N26'1,'*O-MP,>
M#)+]:"W!,1]V]AU&NGV_!K4 +BXJ9=%=\ UR()HK ^5M+'9)<2?T;BF_ $"1
MEM@5GY:C@#+QV0(<*L59^^#MF.IUAS0&\12GIK+/FWU8'1?3-F:M^ 7WD$B1
MU*3'A1L>J[KL<FSQQS\3!E/M9(=_K.4\8-Q.BLD\#IC)**VIE!CAC7<"V@TH
MQ3IE>635.'=T>4L&HUIRIZ^<YT'-*+-24.;4*HX8K]8#E4^&OMW9:$6O+1*-
M^[^TG K"485OW+8.>=_XN?[CH I3"+:LY93LVO$J1C(05#;P"FIJ@GCY?]#H
MT/C5&HF7J&Z,"!?,ZD\:? "E'GX/Z*413&\G7 J*X=)+Y].]EQ[DRQ7B)"E?
M:H[=%*[7Y(!FK3D9W-&*T-5R"V< I;3\'I;[H$-H%OFDVG3X"\1#N^W8<R2Y
M2HM7[L]2ZLR*=7T3EW&X?KRMO%?ME(J4Q:FOA")CH&,28H%QEP,IO_HY4G0O
M[VZ*NAL5M<BENS&LFV W8)XYRY &PJ >_9\O1EP"!SZ$U,A@:"-+ZBQL;RN!
M7&I\%M;<C'LN_R@<-7@3A$,IQS5-8<F"L&]&OF7&G-^-->-V*A\Y&H[Z*UHX
M[)CJQC++AFV:(1CN G15@[PB-WJ>F5LC4%^G+E/4U!6Z<)O$H77MU-C?L9";
MYJ4*E<7CY^W=1NUA.9+J4=V^1VGU,7>5Q3IRCI2;A<[7XAB7V+>UFV'^,Q5F
MV=5:GFN!+8]S3#(KAH(+J28]!0G, L,[W6(0MI6.\'_1B%E$/?+JVXIH4[-6
M)[[ZX.PQ7:/V*\UK[2'C=\$_-TL^1C+$&\9[P<+K*,',M\P0T@R+8,_N"DWT
M0K^2-2!YV"0*#*M"7P1I%P%FCGBD904D@H=@F;/?Q(C[\K6$6[L+CHJJ!_\4
M).<9;Z]M(4(OD@:JK$PB3Z]X$6C"NX"'PM\]B8,Z%C4U1:"7J7II]]4HMEVG
MX,N7?8W"@T?PTHX0],<D\RX.1?3MQY9\=<!H%E>RPSG?<V%W6&)Z2(D-#GA*
MG6]C16*7 '82)CEG/YR4=5B,5XYJ(O99WIM# $GO48@G#VD1=6'1^>PN_<2\
M6Y2<LW@K-!/9/)?>W";R2_XS:Z5UB<RCM?_1E2MA%";QB]1&*Z+''*AJK52-
MU?8W\6-48!?L#.3?*HQOM/[.O7_M^>6=VC/TF=69 '<2<Z F)P2;5_K:(")F
M7F@F&+EK"[')4^*%_(^.0#]<SR_H:/\E*L15B;)P3<:VA5= :] CAP.G8&$F
M<'58]C$KNQO!,RIKS/#2B1"LB)T&K\<IU5,/CG >7DO<0TX$4$='K<FDRE?=
MU(G1P!6#Z:U:XTD]3ZO-!E43:%0-Y7[R47KZ84'_ 88;73$_S4^ B9K:E2=P
MVAE[&PUJ8U]5#&3NJS@5M0S('BDR!]K]PAQQ%!(F$>$)'^#%V_/B=)"J^2$K
M9CA?/>)//'C$^O"JWZQ(E0U'3!/RAXZL5?H@<I=J73J>]3B:<BP^$'E/4'8S
M'QM1?B?N&D321'Q'%>-U)?]%D2!1A>^DT+)+?KN%+ZTAP';NGQYJ<"JV,'.T
M.//$.87/PU;6F'A1NH G)W#'4UZASL I(IYD'#SSF&GI#WU*S@-K>+D6>G3_
M51V+LU#NVBOK\Q'#.'3\=O?F,QE8EHK/7??3#=3)]./XB!#A*ONE8(M3[/"^
M*M/QB_F>_?X5XGVQ6VK(,K: "T2-M5"C6.EU"7,\[#"S1S]\_],.N.O2K!--
M8R%5P)T+0?,*EV\1W[G"WK]X92W,Y?4N Y U?]B$6^'GORDJIPYC,!VV<A?C
MNVA2,-?\M"?5<5*R&V_GIX=K[6D2M\MNKT>P"-'3 /9)V3@A"$Y,D47_1:N#
MHW@@F]?2H2)M;&'G71M^C2O\OT_[]A^WW>2"QH*+T^J#=1')CXJX!EYU*65(
M_JN=;J]H9[HANU"US$>]?I7!]Z?<5="V8XU5W>(#Q"OKI-$4[_FNUU)RZ]IM
M:S)61^9R&#<;W#+"YE'(]9L"Q5PKVMX(XVUI12$M5RTQC:5L43]@6$?9!XMA
MSPZ6O>]5I]A4PNZW@-._EYXM.NTA8Q.?89UMQTA)M.DT;[=N-P=_\;\NIM;*
M1=3SJ9]I-9 '[DL*?AUW[64@;!6)]/P"GG6:OMD2HK46>.&U"\;VUFLY-?6K
M5 *"C?TB7*/)GBG;R[2-&.!>T7I3YFL%8; SR78+3FWK$OO->8<E]LC'*S!]
MS=PQE>;?K""+/]EL%Z-A0J1Q]ZQ<6@&,W@FDSI\V*Z=1!>\-&HV&F[3)O62J
MY?-<$3-5R;'[WUD^65=U_[V'=5?_'QWB_?U5WO]$5@X#Q<%G>Y[X"[%@M,32
MNGEPP:LA9F3#^X0:_HK6ZRN[8';H?3497]C-@E@+*;=O\FTOK7H,&Q*+U3*_
M;HXO^2&&8F^F-3"7 "X\K\X;IM05$ VB)$'?$]HDA@]Q4@N5,.D?\-1-$/.B
M5.3!-)JC&#4O>P=%[4EH7_3L"F0P$CWCIJ7I@H)-F"=:-@:3P/1+;88AN[=M
MR*[S%\.S2[E7V.6W8U+< YJH&P;)"8OB[^=&=:<4>0$-]PN!-;0@>P\X<3I%
M?1^_5)TKL.SY8;G>WI@W>#EC0>M.W0GB_-Q-WN,-C[";(R+D"]8 ['CLA'F1
MYG)Q1V=ZM*7*^"5XUI_2'$$WT/9Q=AJ0(0S=X*MX[J8 7%X4S&5F,<*<]1?>
M^);:C_(UD$I9\!Y*DP='[Y[I_H_.Q&R:"8(."_O=V$#)_![T 4Z?]YYW5WR^
MYD;9>:RUNBWE"1A-\ELQKG]9'PMS9($-4(;4-[U!HL P^KZY)07$&W^KNN]*
M83E@PZ_(X,+0LM#/LE<=W#W$4O+F'TA0WW>CG#[3F7#8)18E\/Y)X]^0Q(^2
MO$;JL^Y"E<%!R1/K[2_W4@:30%PAL04!.K9G\8DV!SA_^Y@^S(5CG(H$!6;+
M/VXEQ% D0/HZ->ZGBV4T+<<WEW,&9P10((U9V_<S',DKR^#+.E/'$.#$8N-5
M$Q],Y>H!67ZW[BI0HK5R?X2"-@;^VB] 8OV>29FZY'\$A93S[NC\<_/T_9CX
MJ@B'N$_23V%"/66[N0Z9]OZ@G2#49GEC65##S;^=)_#VV%3_+*1Z(('>1#EY
M,#,)U%"-..:__^3R]/*H'K*"?GYG[?'CPR2,V-#]^,TZ__I'U\DK<!7=;Q_A
MP-R.".JLY";JN8-"Y;O7AI,6)LSB<<T^Q8E4A.JY_&"RL#3\C.^64MY!'T4_
ME?9/DXGUPSUOMZ!OOM:)UO*%_%X[DFH1RY3AKTTO"V(6\UTC1=B=ZT"GAGPO
M@PI]2O]'IZ.CZ/RJ6P]JRI3\2SO-LW:^4<#M,5.;KB-2T@)]_"!A 0@IO3T\
M.BMK"$&&,&SG=2N#K,4J),P!()&'-FNX;UK28V^MD(IZ,[_12^V\1NONP2S*
MTX53@&_K[3XH9#L^>.O4I*V8SI0XAJS*C$<I^[=)0<\AI?:+8;GPJ\P6)7H
MM='U.H4WB-5?'MS+IB5O_%WL/2NJV7^F:JN%*&D-'XX+=>@J_QJY[5S'X8)\
MV*2-JJ@RH3@#6SS,VO&Q61+?,$77J@UBU+^*V8T82(]@JH_TR$.(1^3A%-8P
M;N<LV4H5PH]V= X2FR);=MI%8<DR):H8'68 %Y5J[>N:_,$ 9;1>);$S ;O4
M4C74]OD(!*SM_M@&/T#+YX%I.KBR)L)(&?]IXN^-=U;_WZHX+4@H_#=8I]M
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MI(J4_@96!T/EZ&%GW?L^* 89T1_O4^^N^3E%-I"*S,&?<:M>IC%Q#1A+E<T
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M,7;BK2 LZ@GG%):^(6:4[_=?I8!M8IT,LC,]^[E3TVAGSW7/>#)B/;&X^G7
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M9M>1A+%4+:C5O,R;,=_ 5&JJ3FHTD<9Y!V7B%Y1454=.D9\@/3EML*E;S;S
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M0U@RGY"34_S#33,'\_"4OW%\W"&EYFV'V>>%2ZOH3D23Z"=HRG092676'T<
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MHDV2(O6IT>8[9;:V\U+>>0J+&ZB$B$\^P[+2W8[;E@*7TM8; +/.[.S6W+O
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M %/.^E0;_U8%0/18Y@ .W455>FP P/S38^L!A&!; 2$A"7$1>FP\0$$;!D;
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MD8X<,:;_?CY/^J<A^[]?3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y
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M@Y"THV?]DN;H?5KL TS%>YX? A,T"1VWVY@R?.G!JRU,DP0+HU&'0'?BMY&
M??&M+4'P)KGQV+R@=.$B>JL'7V=3+.JVL8^Y'=O!BA+S-I. =)H'"<)E<G6E
MRV]XALHIP^V+V8)T_.92Q4:#7^ULRH&"$_L,A9,HLG]AA_G+'"SV@N)KBMJH
MCKWYM2!@^*W'5/)4&,E:A_:>=[KVJZ 7PE^9 S)#!:3[XR,;R*28C"Q\;WE(
M/PNOE5X:U+)PX-V;@V%ZT:E! N?=P/0B'>U"S.X>ZA HJ[Q\"&28L5J+R>NX
MC;W1&C@$K#>L#H$+_BYH[[HA'[;<SF[]CLD'59%[XTMAAP#YD"RZ)E76.VV1
MI]"9Q=KO49FTN>^U=<M<7+)DYMH*BTW<#\/>%D2A;[M-\0O/14AN^"#D=X5;
MD,-DPQ%22@7KV<+7/9@'T=-1V_0$\V2YS:HE)?Q^0(+,YF9+^*3=*IXU/P&S
MHP<XPAD'@KS54=01AK(JJS2EO4-=W:F]J-M!Q7%E-E!!5E8[5?-24Q6S7V"S
MO$^^X2%0S1)Y"/@@T702\ZJ[G_V=U@L/ 8'D1M*]I:&]S3K&\![R0^ NVZHK
M_Q>FW$FW0DU]OJ<%)6< A%&A41C)%F.<YV>WSWO@J-S>7<-L_>NX(>OL5\JF
M$];G;W0]=Y4U;<,]!$J)H_':">FT\ZF$2V[5>9MC0?TC+M='J))O,4Y^:B%8
M.O U1N=VUI:"B' J(M_RVWLYN%$>M,PJRB-:$+@AD]X+&V4?7/;68)'H/9R*
M%O3S)#^'@ZH]]Q;M/20K?*S0SV/]\]*<[(=%*7']E&W^P94VZ2>F3&:,B;9;
MLUTX]^?I5SW(R709T"0['3-CI<JN;QZFC/&#M@H<OT%T>P7I4)9I9BE83Q.&
M"4^[555'L[.-^NZMV?'LS'T,E@;WT3-ZRD66"DY'$"U><XUX? CXY42SB.,,
M3J[L)!%]&]%3H#58.[!^*5[2(9W\D7G09=)[D"/*,MC9QVO_@?S!/8; #X*1
M$I.IZ/S.X W#+_0^D5O3/9&JLW%AD=W/^B,7^I>:!3%H02[7[X8](%C9BXH\
MF);/)*#WK80/CG!:-5FX)1_4\'E4GYOWRVY6]J9\O=>^Y%G,4&5\9<<V+:EO
M/&F'L=2_*<6:8+I5)B)R<UJ#:J\G<='V"^MVF)G*<&L].KSGDEP]V?"S04=*
MZ85UP3OR_@YK+9,?ZR293/. EL!]BGE\P18'MX:#D9F4C>S2S=#XG>;>_I;W
M?BVS2+]D+(*#IO=5?DBVCG:03>%K<2_B AI"(A.$TC3.&HFMG'Q'LI?-G"SO
MTB0S"^M*"'T*O-!%EBF['QWT43Y$[I$0;E/$2#.)_TTQ^4,@Y"E]!-9.@,L'
MZ986G,BYJ76.G/6:W5GD^[J#K:W:@^;9VV.L3]7+(T%EGHLND0O$K<1,NRVZ
MILRQV)OR%_U/R1&UKB1+J>:L9Y5 -CGBDX></<6^]K-^\DJ>O+3FG]+15X56
M82"]4O1"O0+6$.F^,I8T'C&<,M?A=W>S4"MENSAXK$G^[C=5[\_R8%>K@Y3M
M+/F"H5U'6Z[N1%).8+A[/"HLD(>C S-(MZ;WO?P'GPC[,R;M14A;;?3?T%6<
M3>OHO]*^6+HUV3F\6U>_,.MZ.P")5&B3E->*VN2(PR<O:I;>V[!^='5&I X_
M7TB=P 77K3]Y[-UIHVW_G"**!_C4ETS?A$:SDTYLZ\V&!_GOZ>+4R&L%UG(<
M FV2+1$"/M,1:>BR3HX#*$QWA2-^01 X11.S5K),,#Z:IX"3&=I^7=87XO[D
M,VEK&&=O#FR77%R+/LN1@-(EVAFY3Q]F&TW .#"9RH!,8\*L3."JIR%,.F[K
M->WR#;X6+EW=3UI&L $A:X]]M?[^<7".N8_T=9&N%)K8SYB!'5=+L+^'TXE^
MW0D^$+*T)EP$A\*ID'!K!1_IGH!#X$L+^.!J<O.$:FM@:V@2@V'7F[3$ZL?X
ME[FX'D5UL-Y["KF!3%II84/5.*T_D-\)-(1SX@/S)%<R ]Q*+UK=W<VBV).@
MH=BGY*B)WX\@9;C69="/O9"1Q4,0R#\#D)#0-!"$1:A-V<8T8"9Q?8>)GK)1
M&*[7979W.BO/>Z\QL\XN9BK295_#3?->JA8!FXA\)LU8R.!@K;Z(E31-@(YW
MWX]P]E(M0#TO0:U3%2\S6Z5LU)8UC)BJ'P+CF\.1%X8BDZ<C#D(/ ?OSSF(I
M8\0FJK)?5B)&GJ_MDL6[?H@MB]1 M^U#?"J8DEDPJY2!_(XS;A#+&?<=AB6Q
MJN6-?$C7[4R[0N*KG]="/%;ZXQO::#]XXVSR8 ;9O1487#IR9N=*OLQGU099
MTX@G5?,&76U4; =WEFLVFS*4D9Z&*JJLZ-RU%G3\]&Y*QS-9^W3=?3LKUATS
M+[^RO#$RUUHS?BTI2."6$SM!<026=*!$!T:.+6KOBQ8'T_*[*;=%E@.E:,*.
ML0Q,7FSG:QX"@F6'0$/+K!CAOG0?6X=60L -YL336A1OS+S4XNMO715YX[_Y
M(;%N,L1O9">THVP;'.0E/U3%/5:53I>X=L,C="P\/_@0(-WH.(B'' +#4<.1
M]DAO,%>O-G_K(=#'#:MC9'=K8<,ZL[>R ^[0W4.F,^V:*\*%Q,6D.]H52J:1
MM_WHYFY3[ F&!?$_96KXN#2SZ/S9GC&>\<JTQF=DL38F\9I=IEF+9#;.+50_
M.@2N)5I.V%;OKRW<KQFWK/(_H.FCJ-P==L3GI6\K<\B\BJI!:!2:*WH>6+/O
MS!/L,:K*8O9>9"F;8YIE2]E/%EAP6VK&.;[AG]LV+<3";)C,3JU>DETJ^;#?
MZ'('LYSX7EKDMU-?Z-B#;]\Z[;OONY:T7N.P7GX(A*LE[[[N2)\8]AXGOU.Y
M$3G?$F7_4'S))I32SWHOR4[TN2;R$.BP4U1-VE^9#G,/]K<<2]'Q&M.@/INM
MZVMR< AP#87Q+Y=9GD/'-RO3WO"&<Y1'5?<U3YJ+Y)WV]\UF% X4(=D+L"9A
MHM_S1M4XHHH. 6V5&_/#OGS>H;K4]8? *=<)U4. !'1SA+=JPM$/7KP+,LSW
M,CT$)LWU]LYH=[!-TMPG8)I+ON=:$,^[>=_"V<BQ3;9]R?%%37T*A0,"IZL]
M95!L<@?,-.3T,.SK5AJ)K;S6ITB?0^"EO^7=S3%,8L]2O.@B41R[H7R/_G*_
MA0_K<IE5_WHON*W[T:!V8CG=J/C&)Z^N= WFC*TTESJ))QU^8_,>FQ*3'#4!
MI^=\><(ZC8OMD!3?1"WYF5LX[#%1VMULR"C"[N)IVCM@>D3';UZ<KUY;!9/\
M',%!LO9Y/P4\R7 PPMI;>;W&7]./<'K:L6RSP?^.UQ:#X.U;^YK#SF2CT?(9
M(;V^/'3^&X.18QS8GO/^!^W1NICMCM4%O\$9%7]_G3W:_:^]^[[+D?4CGH'Z
M730T@9=>$.)JO5_R76"CYW-]I;%,OE3%S[$@@O# ]7_IC;,_[+LL957J98KV
ME=]OV/!3[3I]"-R68SWM5]\E_S6SNIXL?V+T(*[>:D@G-@;3G^;ZTZU/HKUO
M'0+@%C9DBL-TA/)&<D)-I.X;._JF>^=*EF;J)*S&R>^ERMLF-U\EEU[TG2+W
M4Y%%%\-N=AQ4=E[^G!3R9B^9!3)9[:_C.8/)I([=6=NOLKR^I2G/0NKE"?<5
M+HU(QF\9%"VP+7E6!02*2;3V/N$Q>,'OI2(8E?)$78:)G9/A'O.JLV 8LNN@
M?\9_8SUBA<V!!>\SZ1)%S:>:^NM^X$TP&M:^V^!8LKVK:-^#YM=GLURW)A,0
M;V,()F1NF91!E^-.<V3(@C-@@>;)+0]LB]49A^"L9')GYFIO[8FVTQX0CM:_
M!RU43(8)(TV+WP7Q:\C3<LQ%*TQY".ZO2FQ)+G3CY*'&=J>FX QEHWXQ<V]T
M#VCFGMZ;R1>2G_V\5"N]+$]I(Y"R^3KCFO]<+)-D"_<#9]FZ'9]8SV9RR0_>
MF,ULJ93K(>"K91'$X@BN*F3B6KKM1SN7YK]:[ZUNH.JGLM+QSN5V4D^5B/[$
MZO-IP%]X4B8)N7HP0$^2(CG38C;3:%DBN$9=[#@<+YN_6IL2+#5_"*SVO@!4
M;@D66S9ZP06T="A,\F>> @?;!KI1=^1<:J>^RKFTKDQMRX@O1"3*KV2WX)Y6
MV5QTPYQ[<C CR'54"D1)^DQ\*IHH!38T1MJ3:^Z0JO:&2\$#,YMB]JN/Y,=3
M=NZB7W7=\-M,&K7UK^\:@I7VNRS77#L$9O*8E]^-^K?+2B_,W&;H\96\JG[.
ME4LU:1P>61./6=.&AM+W;#,LMHK1&7OJHVRMH>9;1T-WH[]&Q_-SL!*=_R#@
M*[8SSC:;D>QKM3N@.:\B7I7LC?RVO12&;'&ZNYFB6;22]8YI#8N>Z#3K7A1-
MDH]@'RUX$WG5^^F\.VY;U.!*^7AEB9*NQJN] 4T.YI3\M=9FR77!%A\/@J$,
M6<,,TEP#>8D*M)_$A>6Q:Q:,CR&TA\!SL<%.:_E'U:)2*9GQ\KL#&JTX3(W^
M0_+HMND:G*%FA.F"3L(A<!VS#HAOUC'=]1HF/SBO'1!_N23-<B]T=((U3-PD
M S9N\,K54%+&%X[3[RS4)K^SAZJQ6_^HNI1=RV&S5$$'7Q6N>F&_O&3Q OW8
MNG=UV;'=I>FIRDH8@V;7_B&PEI. B?T;C[#/_CMF!+7,27X>,X> W=%@P)QF
MNT+1XHV9XZ-EK)AEF4HZA7=RNAT)<A"7BLW,^>"4 R+@(+*8FDJ6N#0I7[CQ
M3==HIF:CN^R-0(IFLMSK"<P1T@)SL(T3# \A<G)+OO+U(P%U@[OH^3J>MWSW
M;] PM9<%+D62).^L#"_[+>T99B#-$R+W%-?&'*L*ET+/5#/.-OF@I5;5V0KJ
M2<Q];V#+.M)<]@JU?B VO/[J#MX-B4UD!RM)3!TS!5J"_I6K4](+@WQ)?'?<
M?L<7TBF9]C<PRZ:O?@@3B)-/":O=0?D>'5U*'&D7CXC7O"V[00Y%#DGQB\'A
M^ZG?'.L]E"HTC#ICPY[W$)$QI5>]_7SMVJ*5S)DN5^O;IR$)7!ZEGSSZ^^$2
MF8FMTU+(=*GN^_=OO>=V>R!Z;>?.=@)NAX3;HER2-Y-\'R::EZ9K_-(\HRB8
MKWR5L^+<JF!\<:ENE",^83IDK";306%2;,!%DN:=CAM;4'Z*.H<,;M8="/@V
M>O?; WPC-M\IME$B*8@;W<),7>.EHJ?A[P*Z6O$WV;$"@$"G/>M7GWC9<O=U
M]Z]<-6<E6WYJ?HXL^[I5A4FZW=RUWF\JLUG%^])RHP\7A&02!)]4S&6G#Z[O
M, :"[H>;L*Y1TU#2ZX:Y7FKR:?87V$AZ=;[]$3:@RQ) S?KVJ;,C6XS$9G7B
MH_38UB]9GQ0>]D;'XT;QB]+'L:4(OZ)B[U0( ,XUC@UDKJ@ED@U7+0RQ7YG*
MKKRYF&49M\%\+_:)9+I:MM78ZW7NW+.9L()AT]@&Z$Q56W:4HZ;DXR\(WN N
MU[8'=/;=O!^-2#XS&B=UG-93%ROO\?<M\C=46/-5&?*%^"Q\8!_,WN,Z8!=Y
MN?8ZWZX*Z_&"7 +DFJEO#&H@7][-P/7\E8(J/E%[\RC*^_-OWV-/1(@BWO%U
M%62=R0ZY8I=P0=#T?*&N;Q\W3J\>B6&^03S^92FDMLJ5]E,([:H;XZ%4UK93
M\D\79N[=/00N;C79._.9O<SC;+=:E^[0O;3MY4+]^G*^"8^2'N=@OKE;#6.5
M8IY1/O%UEK;(YV6/^9MZYSY>*S'5?ES9'W#?9TP'F/LB'JR11_=)9)BPO"+R
MX8=GP>6399/HPKD([IXG'-T,Y-5SCV$YU-WO--;+Z(.Y49[O0IF?W7\BQ6L9
MHW=7"F=UIL1<VSI*ZJQYI%F&UB.MG"YVE11\PT\IL";J<W-K._ZR58*8$;5)
M?RL9JR. D.$-N$[&C>'2)6_$MJ2)CGH;?50__?8D3@W#'NI%48J^$@<'#B-!
M&""@(MB,M;_268^&+Z%=GLQN =ZX6)^]R20[9+9I,>1F\4N?@URF)0\!^LT]
M)H2\7!RU /53%2-=21W"O:V%CDB'E:78.^'1$YT2K,,,S\QP6B]RMS $NT1U
MUH\1^S14$#CC,FV?]MEDTA'PC@H#2S+P]W61IKG1?9"!RK:.ILA^'$N*J56;
M;*E)H2]63T3K?A&\@U,VM^?L,4ETUR2F;BDI64 P++F%<2P>K=E&1],0ZJ#;
M/?FZ&#Y._*''*IC!:#LRVT?+C)JVD[N*.-!UI@?1VGT_O&X[=A5M0IU$&)O#
M@ TMS>ISU @Q"9ZO><)91ANZ5H)ZEOD8+[XN@VVGK**?DO0><P _#LC%AV>K
MS$D6O7FP'6VG.K];A5GCS*MIUVUBLC;Q]FONO_8;K!19W"A+M>R^3W5&.F*[
ML-^ZS##=4JSG-;+(J4QJ,,<49MRMWT?VI1C7/CC.I/U! P(PJSQU]GR>QU5V
ML8E5.#'A&(E.E+7R:>_!53[/1/\+$K T)CPWM\*;[)ESN?Z4N[XW*]+%C?$[
M\LQBO3D,N44?IYOL/C%-A]W/-K:3Q;Y>7=[7I'+'$,37%E];VAD\EN]%VJK2
MI(>ER3?UQ+C-(!I*?#\<H=UXH5Q,2%9 ::D[LI*/2"ICEL3I,EL[[;EB^-W!
MGCW^ X%UL,$B@X2W%OL8?BPB9RAUN%<Y1]LNQ$WJ:Z8A*NC,8TV73'DYZ1A1
M_ JX1:0AM\MXS[<NGG5!BUNZ-MFDTZR1_MD-FEZJZ$]RU4_*:S&1^K ]49 3
M\-@R6-=C^"&L9)?9;;YK.\B77=:+(1__IM!BG#ZM.&^'7JC#5:UW@F/53KBM
M:8.7>C,;XQHX+>(.@79?65_9Y=WP";E;3Z84UK]NP^%^[_DCI#.ZP[WT4?CC
M?K>$J%X-&CT>2='*B=-;^$0;G%3&;7I&.DAF,%^C]0UG,3=R/4VGH(]WL(DZ
MZKRC"M6GSC69C@X_/U_T4G!,.WQ 58S.7P>+[O.NO U!TQ=?<J/U+6UVR]XT
M.[RB:WZS;L^=!A[H\>RZWK!S-7[85)5;S+7*,DC=FS;80Q==VN[.);*KW&T*
M48O4O+A>M+.?N1(ANV"_$ER37G6WNPE-D+$W_CYPC_- JG"NX);=JV<;TOJS
M'W(X5$=S1GOL+E9I/AV>V#R/Y,NU(NN(,@FQ4:C>&A2"JQ4GQ'4]NF!W"]]G
ML#&86>H0*.S;; CP3K@7-;@*#E47V_U\T7L3OJ][.?U\50F4>SE0\V7FR-9U
ME12I1QK/]:_=<K>[\C31+_)JN1VJ]=P7M]3%N)$2.YE37+/O%?.UTXRM,FH?
MOF>WSR_43=(M';L]_J"(S1*WY8UV -!:7C4O/3F]8WA/8J&-ADMMX8%"[0?U
M#[J!3T8JS?P+99+]^V@VZ!?6T1%4+=N0Y$, 7C&=?B<\-)>+U;DEZ9GDYK@R
MMMSP9 8F">J;JW.:Q7)QVHC4V>@CMY$?/!;)HVHQ.P"+@]<@W3D?*%^Y[MJ3
MM)W)6VTKM:TT<J/[J!?Y;\B?<GR!ISDV<PS",\N:"ZQ,2A_#JEX;O.%_-UJ"
M/5S"FZ,)F@VW*3'P%1ROOT]O0*OXL.01HY]2WI5PAK*TM[YQM"[=$D K\W[:
MY=U( YO>^J$-M$M/-U, _[V2?96;A0W7#P$8@\AKT;>O; SSS=%N1EX+J5Q2
M@5<?72Y9+.,Q055NR&E7&2?H/O[";23I=,#+$,-.S!2VQH>J)870*:I5I6%[
M)PQYMX6&OQB/O]*ZM3X9]6&LBP(MNLW21VI7/'N.+V9H:92*:S?&<V;^L;*_
M1B0VCPG>P]>;<Q73(V6X.5=>::=_<MSLDWK:H_*,=ON%.0*9+AB=CF\1X,ZF
M?J!/KPP*BR;92NEV&=K%NH6LL25O_L(>Z'ZMAQ3K=7Q&?T_E1I7SJ[6XO9*'
MNJ5SQ=XFK]ACG$3-Q/&:KMQ%]'U[2.5L43Q80K3;9'!13O;*@"8OOC6N3KOB
M_H<Q0W@R@ZLZZQWVH7OK0F1;8B\VF]QS:@C]*;R8LL3DXF8C$DP<YR;UH2IW
M(/J3'<]-!RLRU<H9BX<S#&9+>S1>:42995R_).]DRIEZ(T<O-T]:*[<AE/<4
MY#0@B'M*Z]Z; +];(8Q58=4O#2Z/@>DIFM)2'B:<JY:R-92'<C2E/R\L8PR8
MV< >ZCM?4@,;$(^O0DU,I I;&W_K6X#.R4547O&;2U0(ES+=C-0M@#T(KD^*
M95]_]B%=R4ZIZ4%Z ,O$GI_\76'_>@%[G1K(5B-T1EIMQM744=K:K\Q@O;X(
MDCY[^_&DWJ3=DYXL:E\RWMD-0KE$J<+MWA1C6I'94"B<3\LC3W+->?:]X9?E
MF?M>K;C!6'GJD=A5AA64JL%O%J],J."%X +N:#?Y.>&;35S"FRX^-U6UO^V=
MI[+RP[L+-RRX7Z6(9].=;9BS;I?^RKC*6KW(3I!G2;';M@:5)3JX7^F74H4P
M>FK(&6LZK72?:[6S6[KN<\X#/KE5KJT8803X7F-!Y0UE3UO/9/:U5I85SR3-
M)?(![Q5?\+?WYTQS'WO-,N7T%%#;S'1KW.%^ED6]4.&D7SR1*S93?M.90P,1
MQ=33HVF0R'U+^%/EMU7VB[M5U/2\JWKYZVCDPL9&$M"O.S=V:\<+?&<#O^T-
MJG3G=?$@.DW>T7+S8H-)<<&<EV$48X)2!2?5]8S>;*IS%#/Z!VZ)^F'[ZN$E
M%SZVQUV_^:"8DV!WK6V:$)"([)N#7U/RM14.>A:&LY_-Z#%)*R>Y-3E_KF_6
M=JZ:B8;'=,UI*FES,N4&@,:76":X<R<2+U\VMHV5MJX%US9J(29BE$#S%".?
MA/\;7<EY?()9X7F7NLT6#=;571"XS;PLZ/F4OP NF%5RDJ-HLM^]#C?O0CGF
M6-^0Y.X6MT]G )<ER9R+2_-1G&$/[.3/C=2;?T^39G=)\X/%;B)J!EJC6 X/
MAA@M>/N]TB[B=+[RR7%H_5WP5Y>L$LV,%TV\&71AC8-AUE LHY 8QP]#E/#1
ML2>%=PV(7%CJG0B$L5FDD? ]?9H'L^3S[[>SB\\7FC@.4;Q7>;GPSE\GMT2Z
MM,^-5>!=Y9V,2E@.)5?Q6UD[8ZG) FG0)U&[-J>#1-4,W8S!^E<Z6;WI=9FZ
M$;L##_%!WI3BK."EU:7@1(NH5H9JE^W/%Y?V1 [$119QO9Z,/"OA-A*?6Z>#
M\ESINM$=U^0T\08Z,TSSBC9M1'@DJ-M^EZK7&/%,4G F;J$SXZ;K@-'@[6 S
MWC;QFOSJ> /PM'RNM]K^Q)P&&G-(HSLS<+;8I/CZ+!LQ:0=X4'BN1_-E4XC3
M:]/NFV(;EIW&E&5[C>7GM,5<R>;+[#NYXU[U9(GL7M2^_W!KLF4T8W"8X=[4
M&F-9HBJ-@6?X/3&F!X? -;-SNO//M]\\M535<9QC/XOVZEK47.VON&!1XB7C
MC0C7>UDB]BCM/3?>DG-WELE"?6C<6KY!5K$-#&$J8SS=E/HAJ G4192)K4;I
MMX5L \(GR%J(]\Q"0P/;G;QWAZ8$WY];JB=H#(Z'^?*;%XZPE_/F"^<93^C'
M%W1?$16ZH)/UKISY4\RU9Z\$AX*'[B*TBYW*>ZMTJC0#=2L>.?8VD1DM-:13
MWPLX7]N4[XV&>X\_+QV=]GRRQ?0!WLQ/RHY^<OYY[MB9 A^>+K[7V",5,]1G
MN?>K"RV2T\42P+ U5SKJT=?7GET_>[')L(A[_MHY;0)MDT':2[)>W9-*H(Y'
M5WTY [+U6P.U$ZR74?'L6U4!U/O+YCZM6 \48SY\1B(=VU+BL*\RO?*?)-X,
M9"S3_A3RR;&,OTW*G:_B6L&0B%KQ4%!*MDCXA0))@SOZ>:^NARN5NI*-/[5P
MO^B]G-[%&9-[YNMT]4 BC<3L?<M[['BZA,VI+QB?*9"HXT91X 64#X-".NFC
MI$RR^^E2"=C)$B(N%B>$#-]P*_,Y9??A]BQ>:$8?4@]R3=QWR.MJU]3'9\;<
M<57XKB&YH@S,>494B)?USTPXK=Z(M$R=3V(KO1=>SM5UNDD_03#A+-;C>& G
M^_EPXIPH;O)*AB[@@(6O78M7R]+#X/N4BZZ.V@E<,<D0DBM?1# 1J3'8UYN0
M;^8^ KY2\DH=)37T;/!#3PU%[^Q!H6'^;CC[JTS\;+(4"I0Y71GTM5J!6FX-
MJ2!W#Y4NFUI$<?;ZVV=!;#4N4DJT;[ !2@5ITC!:FC=>N@QI:-E#($-",659
M<N6J\0ONP<Q3:MQ?ZY];N%7UHEUW[U204GTK>VC>..3XEH0K5L5.G'XVZ91?
MB;XV=2!EYE5K/"GE;#T:$)?Y76S\@S5XX;1P\9X*^_--1Q_[@I78&^*IPE9O
M4LVC"\\Y-O.%XLT6CA?OK,%$SVM2F%72&X6^33#)[$@SRJ-I>C>(9W+FOL];
M',K'O+&[N^.J7^@QD\S2W"TC\H&4%?#UTM3NFE?<N>)7V@A4<RJ1$($-EDQG
M*Y%P%X3N(H,Z5Z8)8^3-IORZ".YU)<_S+ 6<.F]R!!ZPR,XDD9^R0E<QCVH%
M*$3JPH1G;/ )Z1;5)[KL/S3+/_D@8CK?MYV_?J%6)>FMS5(B(O7A>R+D-]*/
M5/:O,SA[2C=H%W01+Y^(V+R[GOQ*5M2V(!C$+H5[]R(;+Z%>,<$GW-.5::)Y
MJL)S&Q$N%^N#6)K%ICWC-[#Y*7Q<PKV:*O-E%;)@Z0-:QC7N'Q>-S8UWM9:N
M.!GDNLQB)_")9++R;C+LP*1O131Y?EN\<+%UL7Q L;L5YVQ%,+-6\LK8ND"G
MK]RMOJ[>D?*6@9S">>D>*:?2D<?4![D^(^]NS+SOR#Y'GR5/5D,!OQ\N-5)]
MR0)/</UKQ$CPX][<QA2+ZDGY;?0=LE?*@9H96BE"8(>J<[W,MQKX!7P47JA'
M$X50W5QJI8'%E]/[47E0O4#K\"1V;8K9:R> -"MK_!WGJLM8KSF]!TINNI'>
MS1'WS;U>G?]$KW0]1\8\(Z\KW^6&66LY'UUJ,N>\I:NY\A<NRANM8>_5'[%>
M?-P8:2#?1WRT\ZTIFIC&]&!A#;#AR%"4TS>:;(>^M7).]:4H; &KIQCF2[T;
M*JWC&B'*76B.'A583/2*85DLS7FQ\/K9&9Z)8:7UQZ&](_H\D:1%M"W-3=FW
MWHD^3>C$FECSMGCSY(7=R]CSG94W-GMR[U754@D166XFWRR;+^A]XO+41_H:
M==-D^KOP%6+7@J>-7MI.OG.F7:'NEQU"O?7X:<5'6%H#KR503B<H5L!:G\/F
M\=-'\1TJ'>RJI*)S;NDPA^&?8EK'S^NP-=Y);'0'R=W'2K-TLL_GB5PS="M)
MQ=5I;*5P4.)/&9AV'C W76'-TNB5Y<L=9CJUY5!)G3H38_1>Z^FH<Q98G[,2
MI%YNA5Y\F;^K?3[?>=CU6]=-*==K"63[B0Y=<ST;^A8A*M%2V+7<=.]H-JJ[
M[)&U)0OXM*8=>I07SKS@L"=C/P3BI9$<TV(36,U4$;I.'A+S6(LZR+$U!FJ"
MF76T7UF2 P,*G$2QR2B$[R&?[/F!/ EZHX2B W 0HP-?Z$E90LB,$X2M?"!'
M^^Y#GX_-.C?&5,O.<I*<)5GUCY5/8)NLJ5CK^-+5,JM#=SZ61_(#>4W19[>%
M@[M^<:<%?1P8G4G@S8+#9--!:BTUR)3E.AZ\_-<'.+M@[4:T1<72#B0I:=D7
M_6995Q,GO.I*9!HC(<?#M%5IR ,=V6:/248OLYOXLF+U]SQK$::U!.'9*V,/
M)!>F)>I:_&*7\.6M(LLD%+X%I>ZY%PFW#[HW):1M>'XL-,=QE)LPR^ZP21%\
MH&CQH/'EE(_$PS#.I_E\I0JM!MB!-'.Z:7VYFM*/S)W>EO 89LPRWU6Y0<B\
MQLYVVMI),+:/4Z\=-3QIDE%R/L*RQ-S6)E,?5F1RG8VAELW!FCC)72@!$OC0
MJ5GA@@9.L@]%!\-KDHUO0HU+U$.Z9161AC7O&*\^ X/$OM1T=7U9:W*J5_#D
M:AM_Y$G+-,S*9DL/EA/LT\]4-W=;[0++CGN&8'NWT3<.G2GHT'9C28T>:HP1
M*[[\U=HM"8'+DUQT<TS Z9T7>+URHPC54'[3E3,B[HOAW!FI7%=NR+<Y!6+-
M%?8F&R5-C:#H"<JG*L)]P3:/D5=C#H&-LSK[]\-7]^5KRJ$U7[XA?,Y;QDQ=
M\^7(.1B0#^?^8C5!67:U<*"'*(5B=:9$NBACH6SF-*]Y#X=6!@SW?-,=W6?&
MV5%<Y,(@';>$;5_CRI%3T^#:O -*NX\#<1=,N6W]N:YW7%2767W>.5W-7O/V
MTUC">J/C(3#8L>)L=]:K4:HD5"/7>*[L2;MM5UX6J;Q._IC NM19:U^!ZKV%
M%H2P%;FY\\)%/K$U9XARKI3>K%V'V&"OJS1B@S%;>%_7K%<\1. C[ON[/CPQ
MC:K8DO)#<X. IPHZWXK2+?T08-5S.*6I*-+KJ#*>>5WT,6,*S,?"^LZUO"*%
MGG<VK\4*XHWEFR^JO\D:',LZO2@Y%L:2$9QID%@VK3?PM),N]+09H"X0$="O
MAB!=$+N#3?@R),:'W][2?==7MJBQ\A HZ&MIC,N]MEN75: @KOTQQQI2I*[U
M-5N ^1-,X!OJL:-D3M)NOO*5S,Z9%=8+;3V2:Y:<_)H/]Q9YCYZP;>SN.MX'
MRP&T+8QC.][@50F)&1!X&+T?H= AT1&XM9"$/GJP%K82+<G0[!+A&^D0X0,)
MC/ \=8IVT5FV68UQAX"A8N&#-_UTA^8ILG8]K'<! 1JJG>3,41M?E&ZV-E_6
MDUSKTI[8TYW;:&V8N:A$*%S+UE+0L#'C Z4@#IY\@Q,4?3J:3($6-Y^UAH9#
MAG%$)K2-]<O:HL3"_HM[V.S*"_"EL JBWDZCR[4X$CIN88SJ\Y)[#R3VUNL"
M2YLWIU,^3?E>'* GZM2H90OXR%8;DX$;&KKL' V.B>52%I/.XD"$L,ID(E1=
M@MSIR0&7KG'%]X.C06K%PUI^$MW%DEBV3*BU6U.^JN4?A%Q:&.17#X;<:^/?
M7'-A(6\GBK2?;'KP0".VY(;_!1VLZ3!?2P4)9O>I2!NTMU_X"P4N@[H""5;_
MI%TZU8VF#C!F2LOT@F8]5H7GW,M5,G+B%:ITRIA%F1E+1AJCDK.OYIG+LZ]W
MRW0)TB5:9AUP$?6RJ>2HN%!,E5H0$X,1&6"MH3?)MM-,8?,*5/@C\[X'?BF1
M/JCK*WO*):F[W;*BW? 1!L:74!CIW:PXL63S2I<;S:\<0F%2F90+3DN5-RS6
M=W)(K@OEF,8:5&A'MV=D&YU_:&YP$_78AQAY.E"[_Q[>4YI^,H6M1?5Z<0H.
M9\])9VEU'*?13/H=:Q_%6?PDV,A.>F_;\]3N;N]$+;YW4=GKO38?C,%J.:[W
MJYZ6"YL8E(>Q0-U2[;0NEF1X:SJ6B077AQ9UGU5[20N,D@BD' +W]I=-HJVG
ML%8I%KS=6CZ1LJ%?G.^[:2D^FF&Y_LV==)K[[7;RW4P2\Q7.WB;LT&RK,Z(Y
MI.^=1[=\8,6S4X_G3YV?+W4<^MJ8:FB5]C[CNDD/T;KQ@(WP?;V#&JLQG-W]
M \M#X)N@ JQO@6?[3M?@U/G:#)CC''5BAKE2AF#^N]W&2&>+%(ZGL1O7S2^[
M5>EJ]>O(>P^8LHSF-N9+LK5DR[-#O'K$,K$A\05Y<DQ=-7;R3:Y2Z5IY.66V
MW;/K%;LN)F>ETC,IC09ZM/G*2Q[/E,Z>/:>WQQG%M3M:94=?^;;!D>7Y&JJY
M>TB[<T#=#(3V"!/)/NB*#!DL>1$J9[&)E9K:5EF\?2%73 B2,?RF^*ZZB.++
MCP^@L1FFB^SWS>;K'Q5+4F?UF*3V&^0XB0TV;*']JO5#7_HOO-P>S;UO-WOV
MB;R;+Y/)\]D%L;213*[G9)E,QE'Y07W:%^X/N<WU1I?0,H7M4F9U]"4&3WS+
M-QU*NYCEF"<Q>I#JK3LW4[)BJH'.W)V3^I0U,V+2\%$*'?"%1>24=5N%2*FH
MW\@+N^ZWBWF]^7/5GVZ9Y&@:FFJ_#'?LYI:E-H8.OI>LO&)PRI KQD8_&PF^
M1 A07DX8;?#-'$9X=]#LU'\>5F.+S8M^BD]IE!=[)NPS'E4M3A@]0,@@,NB!
MA@=Q8XWJOM@Z;0MWD=F,I;M7\C#L$J\R+C!@.;\LB;OJ01^VMM 9^R5@:68U
M\< OWM5@#"4(?ID3K=7O%B*V51>_F6]IJ:5V]ES#39<67T[R/+'@QQ8%N3/$
M%TF?E>1_8<AV).3C##BC4**A2:4/+XZ7UXVO[EL(#>GRNF/,JWHQ,3N-<DK/
MEPN(N21*2'R*ZB;0VJ#\B3V?K#P8PBNXF;V1(9Q^J32=NB&2G^YTT#AING)
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M2@S@Z2RTQR3-PL;$C?@Q;&0W365(;E,++Y!2LL80D<_0I+@40LD'E/TX/G/
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M0D05@ 0ZA]>D Q%X@D8CKJ(M4D.EY);G/*66OEV/0;4ZO*@T$ A"6MQVI2@
M@;>,# EU-34!!(_BDR0LW-Y.KGB>^V,YDHYUV%4%<PVHJ$2%-1I($ @!23 B
MXD0( Q"WH[S+JVEH]-;:BE:,H^D@\I(!."/./UQQU:7S#4+K$SL/QQDNC4V*
M.(=20PW@C<6G"+B%(4I*OI4G(P"".V>X)'MY\>^,+ @S<8UR3V^W8]\<\\<
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M1"%804$$$ B?E8846M3L8R&WR](4^L&,XA94I&Q*_6<=(VD!6$)"E;P ,@)
MZD4BF+!5' *@F?>#Y1VG>\"Q+&:JO4UU*E1JA+4WU'^%26DRI!VW//$89K#R
M2R&V_1?>VCTU)*$JWGTPIMPI#82%<$[AY/'3$ZB6G@B1P.Y%B#MMV[8BEU8
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MIU"DJCBY#P+AI(O88#RFGGE,Y 5L"FW"I:=NX*7N"E%6/T5SC!'< S33'W;
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M#P.EA8\,#([ ]AYX'.,9\8QSG(STL+#UMI3K: EI?U9_B$'"?J.#Y'(P"/\
M+OTTB_-MAZ>GO;#JCNP %OG\[V!'\[;WP:C4R*T@.2'%N*6@*0VV$G:<E)WD
M@\<CA()X()'8@SD:8B2.=QS:T<'Z8NKEZ2@-58G4 54"?>8Y$@['8[8D+:#$
M^B J* XRVIQU*'"I"E)25LDNI0I+B<E+BD'83G *0.HB=0,ZC)XY@F"-Q'(V
MM:+C&A3FE>CH65)UP2TG<7 (,<J1%Q<1CQ#@^M4\E13@MGZ@C/<?4<G)\#M[
M#H)'^2W![S ]O:]^^T.34-VS3 D05EK Q(OW[ CUD& CZ:=F,=U'CR><\]\@
M=AVP/)P.I/UV_&?UZX6D1'']YWP2A)VK!0@)(:4 L<'<2>#]N.!C'!.>,=05
MMNX,2)^5AQ\_7%S)J16!00WAM!'!DP3Q'T]\/W::)+"G7W5-J4"0D !"P,$D
MI*2-V0,'_A)!R#GJO2JD$* -([[R9L#.UR?EVQ<J=.\2@]2M597)9P)A2LWE
M;'5MV^FPQAM,1YMT)"@AU#GU!"V<A0V(4A8*"UD94E64J&000>KA/D.^T7WW
MCZ_SQF446A40D2JNMR 5)$0#-M,\;$2!Z#*JV)%0]3+;8>*B5(0E#0<*CN2V
MVWA"$@DA"4A( &, '/4M*R=MNY^9O/N?Y#%?.!:N:U JH8S( TR22850 !)A
M8]\/8DB)$A2$K67UP2Z4@C"4K=9<;V@J"@$[E)[YP,\@D8B<,:BF##?U!B^\
M=QB2E4H4<I5I,?$?+EM$B;NA6 >/-!O.P@SBNG^75D8//8<?5C"@,^ <]N^,
M^W5O'/R3<Q>]K#T_#"7/'<]OR_,<]L$^"2>Y[=+"Q[[]_)Q@#&/.?MD_EC/&
M.EA8S['"@ 1G'C&<# SWY[?;P.%A8>)#DMW:A"U=_H3DJ/ ()QP< $D@G'/?
M'3>OU_7?_3M@D348 )]KG;Z\$\\]\'6J7&0J/OD(6L*:4XRSD*(4OELK5QZF
MTCLC8%<$Y!/49<@L(VV)]N /PG\<7$RR JQK*6)#>'M$F"L[R0 ;"+^^)#5X
MTE$4R(]*52J:F6Y";D!E3CCJE)5N9>G<%V2EH)>4RHM;D.*6TR$A.8UJ7 U2
M8G?@1N(]8M,&).^+6=IU!2$91<M3!*!H.JI?^)R9+ "8@&#91$XC+Q<*_3]$
M@NAOTFF]QV< D)*E>4Y^E1XSP!VZE"V),=AQ,V!,6^D=[XSJM.K-, F2  )F
MQ$VVCY0"+X*06#Z3BY!CAQN.\\A<E3KKAPA26XVQ(4G*^/3)3Z;:TI4I>  0
M)F(]-A$D?KT]AB[1I,%9JFG4$9@6DDP++8<Q:1 [W&-(QE1'%29$-QQU/H.I
M+P&$I<!+:G$J"PI+J DM\I!X5@ X*)$P+"_)VB\;;R)W/ .V'H/5IS6>D'*D
M-+"1?5&H7!# 1QM[8W;J#DMYJ,\C?$??PXT$!Q26D+^IIL!20D(*U+(0I(*N
M2<C!<HJ@.(G<&PD]S;L.?7O&&^U/F'\$0RU&GPPNP!/E !@+)8B  )DS@O$I
M!A25T:J-R:89F\N+"E<-M!3C*"RD;E!;GIG<5J2-X!!(),?B:E+*0VFVW/S@
M7V@WMVC&AE<BM'-?L_/A\G]J)(J $DA5+(-*R&U.%B\202#!P&EQ9*7@W,/*
M7#'0<K+G\!1) 2G9E6% )W*2GPK. >B!D ]Q/'($1Q]!_:C6H5UJ%,P""E0T
MDN=1%(FWN 0+D"!?OC*I*H529DQVT! <;4A4EH..;FR#O5OW8WGE:1].W@<<
M](@,I#<@V&T\C:Q[;<8$U#2S*NH@ @@D7,$0=K>H!('&(_,<5)E2GU'*G775
M_2%! 45*&U"2<)2#R , A0S@=6:8"T].T  2=[;?+^=\4:S&K7K,QDLS&!.Y
M)F)V$]SZ ]A3BMZU*(.3GC/W&>^"?] \\=-B'M^OY_UPF1^><C&,#/;[?;/G
MMX\+"PHV 2K/'TGND'/@'Q@X.<<$8  'E'#CGT!M:Y^<>_RQ(:917ZF'"RD!
MB.T7Y;Z]J4M-)X4K>X4H*N1P"I1.4A*CQT+-'J??;WY_6^+63R-7-L[+:E34
MO4J$@*B* 6,L8XV$G8 $F"I+8I<-24QWW92L!)6L!#2B <[4[ LA/;>>_/MG
MH 6:Q&D[^H^OR-O0[X.NF3HDBC4;,D >8C0I,28!O VD@8$*<+CCFS*%@@ )
M4$I*?<=O?C).>,^YD @1P/>=SQ^IX&*18ZO*"NL_=!L)!@#;O XCUN2;%.DM
MKC(6TZH32AM)"MJ5>JYLRM9!2D9RK*E)."3@DY(LP@R0")C8[1Z'T]K^^+BY
M:HCT0R,?M!51YA'F:),B-[2=OD#A:KH2U)>B*90V\T4(64*2IM2DC8I64@;E
MJ/).\@]\="DQ))*P8F>\B/0"V%F,O3H5GH>&59#YB&U+Y=X@;R0!YB ?P%-0
MMQ#FU12E;>Y1Y"<G&">YY//' X&>QD.QWV-^W]^V(EI"00+2#S $Q?\ ,Q\K
M8D),)+S&([+J6F]KB$^J$2G #A2P?3Y!.<@@?2,\8ZAD]S^>]_Q(X_'%P&C*
M^52%!#"_F,6D0 /<>H[X=N)C+982(K:5--!"CM)+JEJ*PI1W$$H*MG(&$A(P
M"#TP8B2#L+_*1MZ1;\,6(I^&D4U&E8!C5),F3(XF+\#ZIQ@XT3\N&TH47,E8
M'\VT HP,$A92,8]O?'3DSO\ R'OQ^K]\#2+*3X86)()83#$ '> 0;3O:;[89
M3!)6X$O%22RDJ;02H@(W%>ULJ.U#8420  ,G((P>E:\1M<]S]1Z<'8>^*U85
M6J -(T@D&\  S D6!)F1!]=@&"SZBU(6LH*VE%3ROJ 2E!.W:C<O!(V\A(W'
M.X 'H@(CDSZ=X!D3L2)%_;DTF+/48D\-OZ @^O8"Y)Q'"#G/)&> 2./MY[\#
M_,# (EQ'C;D>P\;1@?J.V>X_Q\]+"QG'D?I[<X';[> ./.1GI86,>>?/C[=S
MR,^< @X'Y^5A8RD94D=ANQV\$@?XYS[<9\<K#BY [D8?IA)422M*$@'*E9QP
M#P!W/8XXX![X/3 S[<?K;]>EY?#! BV]S%]N\<_SCTE4*;;[%)?AO4M^75WO
M22U5EU%UIF%'0D[V44YEE*7W%X"2Z]*4$I7_ +A2@7$Q,M0M.H!0?ND \[EC
M) B\  "#/&+:5,E2RM6F<F<SF7^[6:JZK2$S:F%@\>9F(@V4$3C1BX*HDL0H
M$E<$(*4M+8=7%2LMY4%K<:4D*6G8G:I12L$'!P00A14DEA))F]_SXWM\YPZ]
M2SGATZ%%S1IJ-.E"5DW,L5@$Q D@F -.\X;2/4?;2M#KCBU -R-[BG0IY?J%
M;J"<%.X( "%;E;=VY:@  ^D"2+";1:#<Q!(C_0CG ,699-0U&;RE3R3)+&Y/
M$7W!))(M@I'W2H3460LH+&YJ"A",[UK6XZVE>WE:5.+65;SGLD8& 8V($L8_
M[1[ "9[G;B;W-SB]13QJ"4:S%60%<NJ+.NIJ+(IB)4L38S-MML*/T]SYF.7D
MH3M0$*'II"D*1CAP# P3DJSR2 !C'("J"#%X,B]F&QT]SQ-@.<%7R3^-2\8A
M! !$7!D A^V\FW'>X)OLL1I,7>PQ/2E.U2B5%K"@,AP-[%D ]L$'C QDYC6H
MS!B)4C^&)MZ38$"YW@S.-"M1I9>M1#(F;70%D$Z "(\P%R5,1)N)&!,B,TA$
MH(6%)4=R?H4D<X)],*QR2/YB.RL'D$]3(94$B# M,GY^OS]_3.JTD7Q0C!@6
M+ B0),3 )!;;<]X)@8C[L)X+W*42I;"70I103Z94E0(*5E6X$9R$G[CA74RL
M-@ /222>\?G$DVVYQE-2)>0T:1K)M, _B?:9L1MAI5%LO/J7&$D-)98"P^MM
MY9>0PA+RO50$I#:GDJ4VD<MME+:MRDJ/1Q$>EMX_ 6F?UQ@*S*SDAF) "WO<
M"\F8WOZ3 WP'X/8GSVS_ ('[?GC/?)/3XAQ[ (_/!/C(!\X[]^X^W/2PL9.>
MX_YGMXP,^XSC/GMP>EA87C-*=*D)RD!.<_8J3Q@8Y\G\O/?HE75-X@3^('\\
M";0=S, #<G@?B;=\3VUK!N6ZY<6GTFF37C.D,Q4.IC.>F#(<2TE9.\$HRH'<
ME)R >_6?G>J9+(4:U7,U::BBCN?."80$D "?,+[#WB3CI_A_X/Z_\29G+9;I
MO3,Q5^T5J5(5O#9::"HZIXC,T#2 9L3(6U\7=2=.Z-0:=*9<A/5JYV"J0VZZ
MO9^%HC2'&5*-/#;J)3'K,+5))]12&4<E/.[F:O6,UFJJLNFAD&&DL-6JH64-
M >1H.AQI,1J,3%QZ]TSX$Z/TWIV;D5.L?$5 &H$\E).GK2K>%XK9<K5.805*
M9-32Q(IW.@D S6EN5JJQ%;VT/?[>4NN;%J:AN5-*4*>:AQDK?]%"F@8[#3.Y
ME*EME"2MM/6=FO!6NH9R%**4%@U0H20"Q\MQ]]CJ#$+IF",==TA^KU^FU-&7
M2L*55J=0U/,F5.8IA7=*:$U-*Z2:*PK4E9M034"8(B89?KID)C-B-+9=6XTE
M2RGU-Z$NLX4'EO;D;7$!)<00A;G\I2=H4U0+HUPR$1MM!(-B MP09B) VQPX
MSIS7C+F%RU/P<S2JLU-&: X=5J4RI#/4)$. NL$4V<D C$EH2X\F/5Y]3C0U
M!RI"+'<:CL(D_,QVG1M#2L1VR]'6MYLRMZG'8ZUL+#H*54,X<S3?*KE9*P6K
M:F8@4V61MYB0T*0@(@W$ G&_T5<KG,GUC,9ZE2-:IGDH9)UI4D<YFEK9ETOH
M5=='4:9=C#JQ1@[*ITIUEP)*4U2N30H(:]-FE.25B8J2ZT]Z<DI4R8R8ZG4-
MMN(<D-+0IQMQ1#0"2V;ZO6ID4*%/4[-YJFF$6G8D@B#J D^4'5<*)B'Z;\&9
M;,@]4ZSF:BT:-%A2R;U3X[YDA@A9&4HM-V"SK9=)*LS!(D^BF6NJ R7YIE.J
M"/DZ>AE]AE-0=2PR!$3]!;$="!N>4A*''VW@4. -K<SFS_5/&J*F7140,6K,
MP;]V):6@F2VX!,D%0(&W3Y7HOPJW3<J<YGJN8K5*J+EL@BO2T9FIX5,BBK"$
M6GI&IP I=7)#-IF7U.5"EUBC6Q7H\:B1[=DN.2*4S36653 VN''=ER998,R;
M(G,M>JVDMK$(B0MAI+;Q:%/*+6H97,9RE4;,?:'8M5+MKHL\LU-1)513>5.H
MPT*/7&QU"ITS-=:Z3TG/9=.FITZJ&J=,.6ILN<I4ZBK3S+UB$:I4S=$AU"H2
M@\1HB%PRJ,3YEN5'KLN!3:--I4C\"8;<]=Z.M+T81W'XD4)+$F1$=<?ANSDQ
MU2F4G+I>V(+984J)H9C*!\QF5KALR6)4L)/BJ)&K2C@!ENJ[@%02(NJT1FFZ
MADNJ5J/3.B5LO6/2Q3 JK2JED%.HZHVE:E2FS-1/E+*-(8.0IK>BU27&FFF2
MI3\AJ2S)C1HNZ2F--8#3C;<=YMK<H*F%15(PMOU$E\!39.X]%G*>M5S"HJLG
MA%R-.I"SIK8,3]U ! [Z9DD$><])SE6A7K=)S>:JUZ.<I9BC0I$5!2JT42IX
M 9"'AJSZ6J& 8U@%;S2MD,*;U6MQI:/3+=V1 IO&"EP3W$J3@CC8I)&,9PG]
M3Z'T8@YOII!F6I0?0^WXQSCYM^**>BAUZF?)X29Q2L?=(%21$"-,1L/>Q(^@
MZTI&."<Y[X\8^WY^_MXY](\Q@KR+^\WW^0^7 C'BY""9$B=HVMWGL>UYW-\4
MTEM25-J."$L.'@\YV'(YXY&2.<8Q@]=2YA5XFFP$B1]UB?I /\N,4FJB*1'_
M %M/Z!AP/KZ6QPE6N:Q5">#\]+'?./XR_/?SG'8>.PQX7G/^;S/_ (]7O_G;
MO?\ ICW3+F<O0/>C2_\ 0LX&>>/SYXP<^..<\Y]_?JMB;"C14%C9P1NQC'?;
MV[C&<D']?R*PK<VPZ0%OY0I!<4"<=D^Q.03DD@8QSP<=-MSMO)_&]_Q[]L)4
M=IT@ML)W_*.-N9W.V)'2J,@J$JH-*4S]24QN4..\\':>0GR"<'. 1R,QU:F^
MDB^YO;Z3_.2?0XULEDEM5S2MH'_1;.]N-C%IFV\<@8.RUO.[6&V@Q$  ;8;2
M$I3A(1R$82>V23NW$DD<XZA5A$DWO.U[D^_^N+]>H]55I44\/+@_NZ0&E02
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M1O[@3[Q!QF?8*RYEJ1260$B-K*"9)CB)X!XY)9EESTD+#B<*2<I"CE."00K
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M .<=$:JC:3YM-NYM?LOKS^<*97,5 /%"Z?#+@E@-2K,!=Y)V W-^)P48--5
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M*DXC+HJ^G9Z41V6(K&4*!OZ*3A(?'2QD1#)8WW7B</.-%I<MTS]+$%F%\.)
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MTQPF<P-&,#O:B,B\!7(1)0<[/?8ZPB0W%74IKD<]Y%N;HMGPK$(%Y@M]EPK
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ME!&ZB!*E=T^</[6\>&/]T=T_UW?K_@X\RPJ[N7/D]^/DYDF_Z0?5?P#5RG^
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M-W7_COLKJ:YI-^MD#KD' >VQNX]M.>6_ C3//0L?U(KI6"X,8PC;-@I\G^#
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M>0W-U?TR3:HA@)=O-+LH>VA@)_K5RWJK:5BS*7O&W%3^&U<&A]QU)A"),:.
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M[6YU>KH)IO,HL[AKC/KW8)3 (6;2L@G:3)63PH.NVW>./V@$5EP:EHPG87<
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MEQ60<)!QDG!P.W![G(Z8H&L3%A8""+6'.UB;D["PWE3-&A%4@$J84OL2?2W
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MAF\&DSU::TQ^]:JL)6+0K!L&*LU0W(N8:8],CNN)>;EQ1.5!#T)MQM^EKBS
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MM4;Q"[L90^(#<%UA@3(8B84D$,E1S/1\]6ZD/B&IU*G3J)5SV5HT7R].E0I
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M4*ZHV#6 )48-4JI*MN!4$I98+]1A!+2W6RIUE(<2X'8JMR"VZK:IM93G+6X
MYR>J>;H)GFIAKI1J20-B1_";$18&2#OMMC;Z1U.M\-93/FFBI7ZEDM%-G5M2
MTM1_>46!4AF\RG2=@+DB,1N35)KT!*7B0"XIQ:U(RXM9.%*+A)6LJR3A1P2
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MTV(51J*E9)!DXC*JC)+:677,)QL2%9PD*4.$C&<>,)[_ '..KH123I'&P%S
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M(WB/F+[C"%6 #J5)45$I6I2CG"LA2B.Y.X'C)SR#]0[=,AO/:(,7DD\_./\
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MQQ%C_._\^<4"2/" V-59C:"3($WWB;>GICY]UX_^FJKC'_;Y/.>/]ZK&._!
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M0)3+D@(6($BPB(F(-FN2"<:A+<YM:P4I*G$)20E;CF]066TIV@( <4G82<.
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M?@=MHFV]KWM7>D4INS K6IMI8$0R%94AN P8!2([B 0<!-V]9RDI&[<,X'?
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MM^D< A:O)Y25P?5N5NM6.)C[Y%=<YLC1.?I  8  @$'&,]-_@)8F#N>+<RK
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M]M*U[([:<:IK";,%@HRJ5:5 3-78K'PG4. ^*D-%J1"%[<?U*'X=GGR!$/Q
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MJBPI%L$-MVUME_#R<SPQ";5B90,II=@YJ"7<.<Z?*?UW]:_8]%^^^*+H+OF
M\+,F\X!Z-%[/&O P,"4I7QU [9?XHW@Y-8!X^HA6N1 1S"Q:B]E"7Y?#]!8F
M;N%^3_8>--8RAIJ'V;[HS<DWO2N)C#-V28R-TY2\C]3JWU<J^.!8]<%TR*.R
M J<\T9CI9=FJY,(_5+$>( =2C0<4#@3;HE[R4?:;+V,-^1$<!-A24XARPUN;
MZ/CR=E3-8%MAWLV8[/'O#X>LO,@$S/</.YSW .#(A>7Y]_=DV5^<HF%&LQUT
M?D_F$N1OC3J^[HA15(K]W0O4W"XEV3&,W[MSL+K.?WK&#U6%@GTIE=/P^TIB
MW"W<HB[T_EN<3*N#&PCF)S-(.P&EJC&O.6,C6U]P;TU7K?NH_<;\["#45A-I
M"(<+C/O_;3;L+(R[*5/X^\>#&_:"61EL:K6(YNOLVX.FT!DX;:0S*<[7E7TA
M2!#A/>RU'_A<[LI&O>T32+-%-P.S01W[#_#X[0901S;&>@HAX<LO(?:5J\7F
MYNR4IXP]#Q1_K_@B@A=;/>Q=7\ *$@*JL;4,B+SZ5D)$)#ND)*65AEI;U6G&
M[9?F %MTE[.JH4Q!M8[N9P]K]T--76AJ>*B3[HE1-7'M>W^7D )PCZ\+*7DT
M3<R&4XXF"L?M\_T?RKF_OB_J+V>]A8%_Y48BGF79T/K^& 8]JQ:+C7M\Q!!<
M2^_[#_ R\E?V\V>+O2+:WE)WICYLWLS^P*S</)OJ+"!V/M('RANAD3Y^GZ43
M/@[RF%[5>_KTR8:)N(@K:#QK.>]-3][IFA#B<=>^1XB?'YT+&#$YY\MZ3D,#
MB%W.??$)[,S),:G>VG"SH4D@SB)9&2YF @#\+(&U<.H[MX7W>*5;=]9<(K"%
MKR#'^I:EXI\/NF8H&]1Q^?EO3(@0F1!),(*)IE2_%>9 RJ7[+;G1?-"2ZD:G
M"Z1U'NGHWISNH9Y\FGSCXT%I^[(I:R+S.SEGLJ+::0 1:"&OW+=%8HX>,)-G
M<?R<27]/J&QHV<^^P%$8ZJ7",@;7CPTM\@H=]KO9'T37Q&/+TY(#.Y"^61#5
M4BZ11E:A-K:DRP,!WCX>Y_2%J:CP?^NYMO]+M^?.C1]\(<JSP]=J'8MO9!P-
M,L^ R4;$6OKB7L<<X5\1K"YHE,-6WS-L_I)QZ$+Q/\#$H-./J@8_O)ZZKT^7
M#MS-"M^V$-2B6Z30PO,46#T.III%*<KF$ZU\K(OQ<27ET$[QUH D.0MQJM2\
M;#NMP8NTE]8-,^*0Z=KSE9%QJ235?;3AIGT%56W-3"*CD>/\?I!E3M@"<59B
M3I3=SLLB63OL5KER4Y'=9PV8I8/X0LABVBN!!WP@Y4V7!^+SFU&-G'C<W#[C
MFI_YH_M<J'>59FG5<^Z]3Z,^I2?S#"7=2J$.EW.^>QJ]ZA"5=1<U@B)W9GS,
M?C&^L^^$QP47CU5,C4G,1ED5?D2FF^&:1&6!<+0'8;)]PZKY[@:KX/+T%^NV
MY$+,EI,/\G9>FW ;><@]!6.?SY]3.'V;T&]RHQAI$A&S-'$SF;A#MMMWJ71L
M]"B9,YLQZH@ZS7.;41U-2W-)H?2M--D]:)J[N-*894!=!$HB,O6K[</G"75$
M6X^RO#H[$B%(Q?2W]E=+V2\5IT1R !4_=801OV71+)I;@?%#]U:4STF>0C9O
M5_IK7_G: $5!HH1D$]^'B9;%X, 1;.UG$_W_K'#5L]K]Q:BK6]K!+K(.=I_G
MP6)T2<R#*TWL?H: DO$][@^-=U2*@@O<;B+*+(=L:N<;++1FYU_X%K<*#52?
M=Z$1&.0-4^;Y4+M$Q2_7X-[]^ET^V2S/FCJR'?PI>I%AE?TYY)*=$CKI[3ZY
M$?>4<?-@4%*I<2R'2<88N^P<.\W<2?$/Z,ZQC"EOI:F1 ['J!3F+O5/0LY-6
M,?N-@HEAUJ/S)V#1Y+ER,.IF\?@<R4T="_U3.S0V[?,94(=R$%3MI_6__CTY
M@45'DTVA=H5]^1N\ 27^EJ[//J 36G/J2[:+F\48W\6W2N6)DP.#3'''DYW@
M1:[;D?*\%9DI9A;;^_[DF4ID!1E8D(3=XV44=;0RF]<U.F2ALV<E^^;5L(9W
M!E??KIK]$.$:*3TZ^[+0?=Z_-<K!U+[B &EV2S"]00T/V^,-4"].'J7F.Y[/
MDYSLV(6I+O61S+U1QT3E:G7CEQ3_*.6:?NP5FPH$68B8&@6N1-3N"+A*)K0\
M.IN=#GBJG\CEIL#U_RE@[+ I"_,7?B9Z^F9+>)[FR>&<\(>!Q>[M>P5.T?,H
MB.,;#UP),2G]XZ2]ET</\K7M_($=Y#6S*_K=XRA>=#R@M6J)%.XZ4,1NU:"F
M8$EGOTY@,3VO,<\YGI(<S=G\5IFG)==R\F,IZ($P:KK<:%;$T.7-K8./X]MY
M-S[[53L69_22'.VT>RVX;% R_C,@WCA#[=N,VU]\M6\[3-[)>D+66$*S#B%Q
MBH1TE+^26;43ZP%*J1*J62-0R/DY3A%8)YI)_Q*2!DNWM>*=)ZA^DN?*V?:X
M^0'!$A:N]0\@4\M,FK5@PH+E+>SYRE%W#4?IG[OL:Z6IYI9]*::(N#LZBK+<
M-3+53K$:]'4Q C ? KUJPI\SA=>7(=[)&C[ AFDM11"%\_QB/W 5DN0]\OVP
MROH>K[]$1-6H:0?9.3@#9O<C:Y4_66/'-?8*Z";"%:AOEXFZ*31_*@F>EAA"
MU_2B;$V1E7;9#O$GN83+]<D<<-N[2F9KQX 77BB(ZW\HDKDXYMXT(B*Z/BHI
M4,G692^99Z_.+HPU!DVD)5$>1?EL!^Q&-3##BT?\>\0/L-H1@KLW-M3$I\($
MA(L<(X@M$Y:#KKRQ?A&^ 7,T;/:;(M?\EG/W'/V6 U:FR5C"D9)-HX.%U4V+
M<FL'OHSQ\)&';:>U^W.%)[=+N&81./DNJ:%=BV2JQ7H3^1]ZYMJ+C96Y$]L!
M^- \7F5*H@'.L3W;R2/6T*F_LKK/.Z!"K4]UN@CR6D'/[?,_0-)QN/(MHR0_
MZ$ST#T116MH<Q*'F+HIGXO;U@4?USLK#8/0O5][BBST+*1'YJ_S!ZD84!?WP
M$Z(4TM(9MCN4JR[_1LH]:35AUFZ7J?4:8:3XE''.21+F3RU&T"T=B_#)VF\-
M1.U]<B41'D!*QYQXH56SJE\H$TA&.F_7(@2T6-<5ZS!';KUE0 N("C:7Q4;O
M6"@4$UM!/$/M8>,M5$$!1CVU8.>J;EYD#7=T-#C"Y+?#O)[C"OKY\M/A=KW[
M-G-PAT\.J\E/)5S.@'"64ZS;I[)D0,3Y_=[8Y_Z_1>,M;R"^-/46>G;*O4*J
M 0S44[M-5D,O?OZ=]8SXD$UYSN%^D>,A/49Y\%]J^@E0RGOZIH%%1K#3_&.]
M7N'2TEWIR^<?]9[ 0&Z/V][_HOEZ &3:W.W0>+5Z_N?9S3$>*&>M\#VPN)NK
MG4[,IFCDM]AE@6\9CP[JZJSV95CX:HZE6-&Z@T</5W^S_0A_?2%NLA?A\SBF
MX8D0]])JDIE^A!/0U+ON2'J,YOH_P*UG%];Z"U=7$2=_[W$5C\=WO+2_GM?T
M1_01_R6+S!W9?,F_505_$]_Q]5ZF_CU:98\$B2[P#[_/^"DMXI1^G3+^]V4Z
M+4PC^^/^_9NC@=1NV499Y85*.4 !Y/E]&'QRI@G@ M<"5.>59NGTKE/#J!\O
M1-U_'W@^-"%X1$''VNV1,VEC8( _4_:&?G+>*T7OVGI-_->>6;9V%<'N*GM>
MVN6/4JL456.U2JE93 YA(?4XXBDX51$0 \J)_ ?XKW4SDE\&8O*?8\-&8).
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MJPD69?/O"R3QD)FC5NH4H5,(:.<MB*.C&L"P)$6[UIY'I<BZP#%3#/<_Z?]
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M*K.,YQ"578WUNT+JZ;UAO8H,!_=WLZ,X;L<RURH\#$1A%X_@E*+B!J2 ^'O
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M"XS;-#[MZ9'G9]\BU^DJ_MX_HQ-B'8Y;N*U9?0WXCSNKL\^<[[\_#7\(;M<
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MUIAA-D]U_MSU00+%JW>/.U>DIPJMJ[BTS@O)-TGFR/'I7^MA?YG\/P 8K2U
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MEQZ"OO@%(KW"?":I.'+]R;,@Q^_1+J7B9>KF1(&T4Z'4&27*RY_HJT&I0R8
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M=.VNT+_[28$/RT0,-(02XJ;03I,W0D]WW_-]__7[YA/+4#F7ZHA[#U<[&.!
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M=$IYDI9FS'HLZB-S@=%[N&"<PRV5J\'OLU\1YI/5J:W'=-;53/2,)OW.GIL
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M=ZO)(R+XGGL0$FO,(N[7":X'<V9QK:<U*<_P2/?H9?V$D8 HQ*HK3PYD #E
M )@JA#S:]OTV_W?9-W]D@CO:$NIM;&@L%& X]N+B:YN<54:;0I@4N##EHTAX
MH^-T FFP9,YQ;M]'5[Q4W[PFH8/R0Z)V<G_C5!8HA%V21HRQA=-.S'OH.//Q
MW8IZ.T8'D+*CR!KA"B'JQ]+00K&CF].[Q?,/<"M,.ZG-SO<F3.*ZM!N6S\9?
M;NHA'H/]!PAO%&/\)HF[(A @="H$R4NDG^[!;884<6F,%^K\:Q(YIH -^U9?
M,'_,,I<)_1KW]Y)A:UA$V%HFP[SP?LJ7ET%^TUKGSP&3#,004 EA(:8)0ER6
M"G@2S58^XOQ8)>.N_^6-!VB1]\G09$CY\\.;,&5QFK1O&?_%Q&KO[S__ ([O
M]UJNWK:AS+_5LF5GH_4R98-0%MUBJI/^^<RC4^>.R;]NC8>!P_)JOX(M@=]H
MJ6B!;BI4*HLOJ+)Q]5:T*A10U#,FW2+630^_7R<BM&N><&A'X6JHFYN$/RW*
MX!GS)6\ZDO@+RV"C"$:(@.'C?79V4ET]^]VT42QOP(QY>PWJ@]>9V^([,<77
MVNT^]4:DP_> 7(XKX.CJU<XO_G);>S=_I&XLIR\IPPE?0(G?$?BC8,562?(N
MK&#=,S]/5F2UNEEC*[?\ZF]3<9%.C'1W;D8TNY,X2U4/6[EQ4&GH4]\9F]E.
M&W( MV_8U%>*I(YS7ZOC/T)UYL?3N;7'?"-]J;Z*#$&U5 )DHIIAU.K@<M,:
MT ^\#%Q$Z9B2^I;@HWWY6FFPB3RIQ??<AA<,DAJ5"23=?.ZPIMN3;-G1'IM"
MNH"9J5C*R?=/)Q\6'9DA"TQ]_S[2T-7)MBFYFB@1;FODWH1\?Y-ZC1B,CA4$
M WE369<?6>#4E87]JN1F!)7$!T4?/&6<-O\^ZH0A21*J?ZU/T$]A[&C)H^#K
M9NEY;$ ]]YJB*#3!B0W-@'7?8CCQ=;I_I!1\H5!44UR;.[)*4X"Q1=3;Y!D1
MR-CL<3:UD3J3EE*U:1_%NH0^]!QS16K8Y&]=+"G[JJ<U-I>]$:AE*&5"O%R\
M_[6%)N6K;Y3'B^>K/!OGFY[T@\DLV%XXC""0"%2N^EE;R)%-_F/HY]*9B3%Y
M>PL+ZL7;^+VOME]1,<.0GY.Q:M*5<^:3<;^GQ0ZT)=82=+Q*_LM(@S02]092
MQI'?-+?3_3%5*;[30>@]MQY+3;WJS252-$#UK^C:HP=N("I5WM!HE+]F;<#Y
MQOAA]P"OG.F:6B=(TNU-1RQ$8F2OB->V:&OI)$9^7Q!OCA?L[,)(>^D N[+1
M+"H:O(RW2G>B]A#"S_P6G2W..>YLL1-LK H)>DVH=U;RK2SDVUM>MT49?YF)
MLZP3(M:[4<E5%\;V=#+44];X0 7!_9.+(AJ!K@3U;A%5L+!*HTWVXSQ+\-L]
M4A*AE<>:S1E_B\I<9^!*$MGZML:SP^(.V;$(N7U8XS[YNQ\CX)Y/CY)J%A+@
MY0<BL;A+RDK%_->4^E;YN4WD(YURJJ8SMC!TTF['GF7^^G?45B,93E$Z66BU
MW2)0AMR4AXO7N=R#(+GL#20ZA]&@ZFOQ +T4+9\4.5(AB&C+E :O4T[,QN/3
MGR<5JK_[NM-YG0X%?DX8*?P#)/$^^Z[]("$A*V1:(%R8K%QE(6JQ94*[V82.
M3K:V"@HC6M*RQ[*B(1-4I5$"<4,G[Z=M7J64A(^<. <\D0M8WRUK"2Y!(E0/
M[O--0KN[!X-;-M%P&DXRHDG-,>P!M(W&BIRUO++> &'$P$I.S7,'\GZKK*M+
MQDUAK0T!P]R.ILUG,JJD%ET).":/=>4:'^2:,7L"#D^=AX6Z5[;UO<Q:3476
MFN;N?G)6.U3L[#H#XC$<_&$]!&1<A@BFD=9J[OOG_2'OOMN+M/KF52]DF25<
M ND<C48LHO+G7/O:B:8$=XGF-_KN=%:K.XC@(4%";7VBDV(K7$XRG(K]%]/
M [@[?DTQV6UBJ3;_IX0>-!9&0A;XCG(_&FR^3U+*V)PO7:53!F48SA#[YO?N
M5"OV:@_OADP].%?+T&YO%W :M4;<(M,I%+:DLE0G VRQYDWW(.M&&F@6I@W#
M6?#G&/5.9XM9=?9#T#<0Y*^ 7^W8$U<1'8Z6FKPP0V0:O-$88FTX3/IQ',P(
M'': T2-?<Y2&KEG :O*._N@JF!3]>FZ[/ <7*OE/,J7]=N2;A=B=,BVC5MF-
M:'5F<[-@9GOPTS<QH\>-7?:Z-';[:W@0!%!*SQ^4[A2&;6!70D&/HMG#^(A9
MXCE/M;==<O'&?W;VB[+MV@%EILFQ\_)[GRC#2_RV1V=*E?3#Y Y<J(WLK>GT
M/[W#HK'HO"I#"61L# WY3NPM_]@TC*%47WPBTPQ\(SO0L$GLNFB\](==6Y/X
M?>Y,--.*$('#C4(0E;<'+N'[/B/G;W*QL3SR'OUK4 J;.?=[Y/W&J)D@L*<6
M+Q&@OL+>;Z\77E?M!"LA>M+&6<DK W*^/G_VG.W3?,0U5/( ;U-9S<0$"7<B
MM ;+&%B<C3=;=EE[P#[+^<BN6;ST"E-2DBYPDX>/&CLQ63-+YQ6ELS?"=$.D
M!02!9#V7J;UU"P>>G<K2N:X=-9)RE&-S>D>4P >G*A=J?^[<75*[;_7+3\ZB
MV7+!J':N$5YG>/CGK5>E(*&I4^E18@S6XAUGS"AZS8SN+@U_CR./'X6Y0&4"
M>X/ !QK8.D"8ZX:VEW,AP5#Q%JHI%IA_UJ(@:SK=O=B[Q=M(VW&^<_5..TM,
M3\ #AH5XHME3F'1B6@]9)2(W&VAA=.(7Q0FR/:OC#/4KZ%^"+7G[M.2YRJ3V
M@5]X(#04!L5Y''':*3@%HJT;Y3X)$5*HGA65U6V!GO,X>ZNI@P6MS!Z$8?0X
M8#6KBA]>Q;,@=&@AI$ :+Z6U+UO3I2MO@S!Y0XQ^^BE!?K=ID_VV7PA/#U\R
MF>_MT/.K+4VA0%T?OY G9W>DI)E/?N_EW'TN2A_28??V09<#/_,HVQKN",_*
M2'.>,?Q^0'+;92'J>ABX<^M,9;%"*Z(W,X1_>%A"^[GZK=E%__^X+O]C@GB/
M#2<.$B.O_P=X [(DX_T'4-9=' C>_I6L;KQXNG68Q-$#9 XC?>>'-1ROC B4
M"SEB['ZGIAT^T7>B5I\.W;2OX->7,DF344L-&9":$!F_SL]G%I6JT(6F@;![
M]RZK-!_]UO_^S?RJ 'BM\=>!_BD>48>7$!ZVHT_/P,2QX_IB^] ,.YF'.R^R
M;KX-13EFP8^XC@F\\0O[!-D(+@+%VF:)<!)W',X55X.4CY7&W2'8?!WP^CG&
MT&X1O!]G%&=9UU0[#V,-F%=2;!598^_93G(7C1+IYL.#PSI6-]AZ<T3G369=
M>QH'J,JN+!HCA8MQ;[S?I!()W"_<&Z#D6*O[T#8A<D)D,@WAG9(2-H$"//G^
M'X#F'Z#S5ISV9K,9MJ@U;^;0LP;[#-LCU&CP0MJ"I"B_J>[T 6BV"3TWU(;>
MP'[;@BKG>??S*1:=O^VJ9Z*?D5;4*U(.6=IG<C%FVC-Z]-[J_!C+\]EO_HLT
M/@/T:&(]0B:G%/]:C3%,TFJV]*]C6^IU62B^J3+R<(SH*BYL2:[O;12+??*U
M>V5U)R K@AVJVO#AR&ZN,PRS*K[<6!1,35E85T"G]<33P_C#6++0<']':@J.
MOW_>!V+6[#_2".[]G)I':=_V<49;]E<N+HLSH[@4'^P\_3P/[$_NV2AX0<.R
M;7-)OU!TRN^":=]7\"QZM>9;.;/?B>!WQ>*2OY*Q0HM!!A%]:>WS^;J39J<6
MOU2G(ZT+9@[5?.X?.6C?7;M3[Y&@T6EQ9[P1V1DQU?$F;-W]L3M434] ?G,'
M=/BL82&XC6 JSGK$ZI<B'@CG+<:=\:?W7%PM/2@A?9"T9QP.,0GH2SQ0(VH7
M1S$H<4@Y\WRY0>XO6+7[?WYXTI';9JU'7,XK55O%$:A0<QL*GK"A?,ZS.RF$
M0_OZ.J/*WE<)CAF(-06_^Z.-CF704#/1><MPJ7JDC%UJU>,,$EMQ+%YVI!KN
MO8R=SW:HUZ14^%Z1VU7:,^WL,[=(4)X.#_TY%V O1Y\[4)P6H"1=6\38'=[E
M(O^1L)^:&BH?0^!.[IN7W=0.@V1&US@0CP16:>%EPKQ?'9/T*R^V"+2-#S6)
M=R0&W>8UU4)#(HQ<QAN+=)XO+5P'5U:&23J4.>BXCVZ*N"?YS];/A!NRN*IC
M]66W:ZP_,T@'E7K#REE8_MA(I:9[6=T6*7#NZW6;9-G.QZ(/."3=SXKF+GD;
MV1^L1!45#R83D:658*3K:@"]Y"A(C1-B8\TB]PP3)I/Q_>]C):+C('1NY9BV
MZ%%^33FFJ!Y:A9<N82,(-+U)55NOKB+0D*P-N>FGV]V.<M9(:V2\9]:L*3">
M0UIOG64>$06:.F/J"\PZ%S4PY@FR^JBVRU(U#ZT:*YX-0J>8:^4<1VF+6V/=
M-9#7!K/'=; $47SU2S4O\4^4-;^AT+9MO+N@SFBD]'K?6]__+O\JV( %KM/I
M31\7X4(^X6S?FTRWLUU)S;,E#\'U$ PM]KK>F_+HO8KU:H+7T_;"/P=:ZQ/Z
M9IEK5O@RS&0?FMQ"K4I9[]RF=AO<P>!]5>KD!.D6V+590; ^M^!1@=RT/VVI
M!800^+'-J5>KS?HWFTH!+71D_ M&=37B)P_/T//BXX?=DG"W^M5SR(<5S/(Y
MR-C(:[U?T#QZ=N6IMY>EM:0E.[!C/-L3P>/]*;B"NYD2;VVB4&%F"8VS+P.-
M:4L?Q#\1J@!MM!.W41=>;8@CEKI<#$8KFBO*1&H^YY>+%3Z_!MD4H[-:#R$'
MU'::06M9J%TMM8YB!=(C;HW:_49?AAT10WK]:\J@]/\ OC4E567SQ?'HF+;0
M(XY*N*RD8[T\>FDH0Z7DN'$6PVWB^9+Q*Y$;W<Q3O%[ZH+LQ(I*[S)W=*TBX
M2:-OTV,^"$?:]0\P5WC9H24J6)WB7D[+D@3ZK;YR\_[!XDIC_E'HI,F,AQ=K
M\1PB DY8@L;+6PE:]F !-I551%W ,)/VR;W=P?B_I)^XWN657:741YH1;]R=
MLZ=";T+/GZ:J$BZ(F,BI4UY+)1HG!?90M!.[<^WNODB.4E%$C?],VF>1I*:-
M8&$:"KK(KKTUZ6Q!"-2R3@_,*$VMQ]: %]<S7[YX#790_5H:+2[Y4":_L%U<
M[E[F]E_;WY-72;)O2BML",!BXGE886M^(G'"5Z2C2/M'D]S[^FS!)_O"Y#'Q
M,:B@1< =SKTG/[\=/^<Q:U GO=?]](Z.W*[[706?\&\:]ALD=TJHKV]YW-D.
MV2"5V]E]SWOZOCLR'-Y(\/M57+(1M>#787$A[!\B W[4<2WSN,SD_"LDUL#E
M(.'Q/X ?(NH?@+DHG>S#3]IG]*Z\/S08Y9]^/O3=BVI6XHFJ[O!]<<33V7IA
M;O'76OH?(,;XOXE V5^!3SCY&16V!B].)P<1K1Z<JL(YW[9ZA;]H9FE.W*+*
MC+"U70AZ7^I2^GCQRI6%^FO05NE%2^NW7HW=;B?MSXOHH)61T8G\6":V-G2T
M+LV(.0WP\5<,:[F%+]G0D<'4Q=[OFDO>$L,II8EZ"7RR>MEPG,##9]'.N[?#
MZI2+0I;V8,?L'(_6\9XF'4K3MM1XN>/<J;H"MF#BV%?]5EBUY0U/6$?9AU<?
M#_#$F=>_#($>E3_F*&"A&@Q*4O12WFOJ 8%R1P]O'<KWO\#^G5PXL+Z[%JP_
M=A16#S<P'><*K\^]:YDRQZ&XX*#/\IU(9*V-9NPX9REU[DG)MMSK8GJ/G;YD
M&7&$/@S$.!9/F^C@!<5HA?VML],D+HZME8)/(,DV+4ZN*!U[SG<3SWM&YE:;
M\^<T&1N*2GOPCF5*#&;9'=*&C-]G.+,8SRH7]HK&1Z.(OFH(EB+:!8)$Z]%B
M%,K=BJL._!O4ME*U4"+"BA$^K,6;_R9*1QOK6?TV5HA9#"T=A#66+]@L"EMA
M;5.=UM9,B^19BOCAM#J49A,'IA$5XV\M/F26+:EQ&'^XN3:OLA7PG6T"6S4E
M5]'V1PZWJZ-NEH><;A7I #HBV&X,O;.#A6ILX:!3(?D^4X3R;@OA><G4>PH*
M3 S?>HR,X<622T, ](>39/TE[O[LZ]EBQ7FD^3EBZ2D^EOZETB5E:_"*GS/-
MI';^,1=CXVK?FM1KF.^ >R(2O2?>EE,PGX!+^G+Q>]@*'SN!PO91BQJVK!4F
MYT#*N*Z_\UP#*T6ZV:"U#"F/KVB%O;O(8KKOC,WH 'D)#5[NGIUJB =$40?*
M#GT@@RL==<R!MK G/+CCW$%26V_0<GKY%TLE5,E$R70Q5^67'"W\*.M#EJJD
MK#  U"W5%R54959ID<_@3M;1]YGET40A7ZJ('(BF+HG[Z88_?J-1I6Z7^BPP
M-LM2N9LE #XK;(-\DULG'F85N*0K5V^7K:X7)W1W_AKJ8)@C$.R@H%2Q9LNV
ML(RC,'1&6^ZOF73*<:==6^8+3,<DK[EKV'907]Z36,"^^J/[R:16G6&"US]_
ME0'4%[LO%6V0E+\7OBO2\M%R^"E4/$@368<G'(DS,+7QFYCP1$L9T.5$S2$/
M.=_<T)F 3.[=E[M_TBG1+YR/RS"OK(XVM)'1)4F)I_!G*ZO\.$@G,1,W ]8B
MV=WF+06$_%BXI17B/G0R26KQX?F]"6:US.7YS?66"L?P;J_;KB'?#E47%-YK
M/=NM<'Z6[D&1.-E&%9E^^KX<</)5_?Q;:;"Q"1T_U7LM'<YOV[_HPR<4)LO_
MV]>?_D/75&CPU,*S']J%JB>+)G2<WRIZ-/;28Q:YILXS7YBK'#UR 6:7_Y6;
MI#J9U"ZWN.)E3TCZ K9VK"#*LJG 4NY 8[AX?YQ1"\3EN;IR2%#G3*7Q3,[Z
MO!_T8HUEJ*VA* 3.I:%T>WYLK?]B38L5"8X)&PHN@\?0%']*X6?@Q_ _0+H&
M_O)ZA'VM1"EOBT3/2NJGPK8>%/!=.CP+!CLB7.?<CD6\?2=EQ$[8QI4?2WHN
ML15HS#&Z9EH\S5F\>-Z+?EY6/FU5M3:S4K5R/M(OA9%VIOHU'8;4\4)0O%FU
MYW+G2+XHO*0SKY'0>*TGD9M4ZD7M-N&A$]HHH5? K6^NSF\/U5N!G4N&U<$&
MJWPX->V-ZDJJN6Q +0R'])D:ZWE.7*89R50K<FF.F0$??N\C50GE_"]$D85+
MT_;2<+@1^4I#.I& 3:1P+%'+$X/$A%9)APB].@VB%0\"7>O\<H;F8K?542NQ
MN2[*M?&O7K$)!_-LEOU18#7+!1C\ [#Q*0N-C4^3#\E:R(?'IM%>E(V"G)8_
M)/$+ CDEND7(F&A0 ,%GAA\,L<5*G0;93*-9,L_$">9)CADL4G84,)%A;U\@
M6.)Y%467M>#T+<5-ETD&*9PT!'#^IKA3@6M[7NSUA\3O1\398S4W?79W"%PM
MF=1?]R,PXAMTVNWFL<Y1;VF)&^B0L*):^O<^/KV3#1=&Q.9Y8L+9?5;8.M6S
M:4S%/:.@/7$V]41"*F\X0JAPL( @/:W@5&!_N>DG5^@'P(RRFTFU["7F;C&H
M[39+0T,"L/%';L%YGM5":[@9T,@5>LRT)"?0(.8=Q=[TY)VUB$&+14WDVDTX
M(GFAH-%:>N\^@CHZ$6:5/:/>A*HJ.ABAI)39[;2OD*.WTO\^=K\(@Z>%*Z:4
M#QQ(L!8RF"A8"B?QA%7^=JYC>W.IAQPY*68?L@U1BR\<*$LFSV8)!S*SOKL.
MBWAM^& K55,--9O*V/M4\/9D/C+,)TOA_EGKZT,=4QX*9LY<4$.#5H59'7?"
M^=T^_2G3%!\&*0,_>99E:"$R']TULF7EYP2"(&D;HD_)\=R-Y&#*9SPWFUN_
M'BE8$3LI[I",JV5^F??.H]JFD7/IP#O?<QF.USHN#3MDZ\C#FTALZ@#P=NIZ
M3\@TZ.FC-.@SZYBH&@!:#RV6RR;D'6;EGK[,42:E-U\20"YI\\J>&:F3)3@=
M_KG5"LRY_N D]\W_6F5W:_J0:VCQ<C=]%Y.0SAJW5?&"ZUOZZ2[O]:[J!.W(
MY*O= 8O(BBX+P ZI7/K?YW^DI-R I"2\%"%;72\>:CR/K/@&:&FY42P0>I6$
MJF1;Q2&I+;?98J%@856:7?)HE;W#*C?ZAL0/,91OOP3<2?H05WL"Q:C-/,*W
MN D,DS/I\E7&I#E7.68_-ZHK8N@@=(J6$E6F8I._S!3GJK1MOM7W,LEQ8W^9
MH$+Z_O[WGTX"S 7Z$F5*QQ0,.^X22OKR5G0,V _PH??7NWV+E\A!3MC,GRI$
M7Y;IM-7,LFE+G?F EU=.51& 7?*U2&6Q4SNX,WJ"V9:@KI/""#'P$#2YALM_
M77>D6(ONF+)/T4N=V(&^A?7+!C(J=(QSF]B]A??U$,& &%)RK[*/0S3*<EUD
M/YHM\<MGO6IK+&FNYV(RN<>&W''V)JD3E392-+\6S%'..IR1\2:UVG+B3V5F
MW'KIH?8RK:KQF GX9GZ1U.W=GC*")3262&(%L@G6:35>HCTJ@%7.H-W-TG7*
MJ1:D@I0$[XN^*8#NREEYKD$G2D2=T938^U:$<A$A@#-[)[5(]1F H/C)LI3:
M&I0[:%=0!%O);=GN4,DK^P3C2)$" 2@4:T]LSF>^P]SGK!_KUZ(444M@65U6
MW!T0+X]NVH3"C>/CNWD-]399F9'( .-I0K$-([426TTCU-6H]A%E@%P:M/8M
M)L R]P^2G*N;P<^$.HY]<BLG )/0\BE'3>@10?++FDN?J;OE,7UHK?03%?!H
MS8_?ZQXC1HTFTOF )WG,L0<TV];N$F-5[4J7K"X\-QS^S:,.8EA$Y#^ V:S[
M33,L!^*)T'NK0<I)K-?+NV>$_)""-(!]G\A^0FX3QH//\:5[I.B>7SMS?X;X
MX-(&-P=:.F\8\\3)\4Z%4<OT3MN2"-0^WC)M3Q]N\NY0NN DLV1R!<O>ZY%^
MI%7*']($TZ3[(1_:)THX,($MLHSG9SM/%(,<:!H[VF7EG3)JV->7_F[LRVWJ
MZM"%/:,<RL/E20\U4,3$7>3T,&^A[S+TBE74GIQGU&7*3;'XR-=\PDX[AP$X
MZ7* T7[?CA*PB+?!PJ&X-+]"JUP,*E=Y$S/0]'6@@YP ]HT5QNQ+R><D#E$8
MX#8#!F=<IS>UT PM")\RTCQU:S"*XFWS@4  #\V&<1,)WDU])I^CCC1&.!.L
MD<YB1/.%>E?E:Z M 2)Z%O7C.C)E@Z1'Q6]JDG.8;$(].O+Z6RFC9I]MI >7
ML,;S_E\__M!HQIQ\^:]:.4^'3_X![O(^U=K^ZR E]81Q<D)U:GKQ3^2=HRRW
MA/28/#$Q %YU)QSHOTB6'I1)2:45N!ND#BX5'/K]#U NFM\_+_$.?;,[4$7K
MX]=JE7*<OU7!51 W[49,\'-<.PFJ[L")>$%78QD?S5L]F!<U =E)/"V4U>GX
MF768\3QM[7.HZ<?7U1I0]F1,28ULI^<Q17;"!_,/E4?W.ICC"DR?WM7ZXUB^
MNB*N9%P:H?XR_[-O@N13M\EH<>M&$7LVN%[*7E8]X0WW, C#/48_SD9]_,CV
M"."#V*[WE[[]GOL_*+@1X',VQPZ:DO>,%]WYNQR&O=/,'-*D:3O9=.K!R@5K
M]&!@FFU9LTVM3M7Z:U6? K$E$WBRO[1CFK]XS7I@1AK)&$:$9I-E$.=4[\EG
M6#I+K$>F8/98N.MQY\QB,RY!TVCCW;1_@%N76@791V4.YY4'YWXZ5D?7QF*C
MR$SMIS:/<N&&OUHIP9YR3@M"V:*L[!0F;Q$(!/-;+"8A AJ="W*_/X>NYK5^
M:7>1JO(/\ 3C)*)IGF9G8HW0NA-OD0PIT\F2HNXZO E(IU2E'Z<?"#I^,<B[
M:1V9;&NE4Z]@HP2\OLS@#IV?Y;'G>(M<JI$SB+M/(#)#9"8Q<-LZ(D^$)F*C
M_3X($E'$-58+KZ["X=\KB?P'S\P-/]H%(TVI=;]Z.,:\()6]B&Y5$.WD,$5E
M0!K9%GZ/-<!XX<(\M?\>J&+A\#70L=RQ9_8^K*A?VBK&M(^%T9F=S8?$H 40
MDEH?!L(SRJCHK21%/3F7S\77M220'L,30"H\L=:]+1REAZ5A#3;U0C6RB4R?
MN_/IA\E#!FM___Z3"<U\5"'-6%V)-Y9WXO95;%FG!NJB*#$]+*;IPLAZ;>E@
MX7;!URLWJ+VD;1M8KUAN 5MU)S.Z!M4&GMC-+,]W 'G)ME7BDG_5HD)/ TQH
M6N)4GM<1'\I_@Y:%$SHYE9#IKG""Q7MW>?#E&G!L@6\R 8S9G.H1>= TWO>@
M495%I!;4IB=B9<5,>X^DZ38YL$W"L5&SAR1ORCK[79"Y"(FFG))C3[7\\86&
M[*)=F<ZMN]1,:66"$,%&',_PN+>DA4C>+Y_#\OP7$R 38.[&YVI"_'VE."8V
MHG<R&PBXJKG+G)HQ;EG,.[J?VU 381!;^?%[2S?;  NZ&5=;F@N,V8[UI>\G
MSU#,<T(*UJRLG@&V#E-[FYK+YMNI"#MR^><HKI=%:47WM 8%8 Z,_G:!?>&\
M^-=D:=L-K@D@-^@0)Y6&!UDYQI94,49H2<#QX#7@]-7B3(A;8;MZOA @!_@+
M(G]WL$Z%.UCWUR[7Z<_O(7\"7PQ_WSC].7E]1YAO,=(U: ^M]9F.<T'=8WKR
MA;_<@ERY>OCPSZ-'C\8B*=#5E,2]<!)C#3&)3?7@H,-T%R!(Z".0[%7XY?LM
M1GIFK]M% B0N[[^/H6,"B3AV6W9OTXK\"EK[8&Z8B3=8NCE0;X3('<5(G\1E
M:VTND%^JAX+GZ1;/6BVL1 ZXL1\A],TK 2SZI/0 5]FWM@\X5Y],))D</_V:
M00S^8U)GXSO@ ;(IBS#/ YRO.@WIM)]0F%?.[@O&"-^QE7C]1])!FI:RY\V9
M"/SN2_,DT[0&;C\+G"CO9W<1(7WXOLT)M:^HZ<27U!SI);&FIG%-HJ4/NKQV
M-@R+(-?\8/<\I>C*'N\^P#=O'7JDNIDG>5'>XZ4$-9=H#3+6+D2EE=<Z?/*L
MMRFY7VN#473F=/GR->_OLO%D_QW0*5138I#S0J1.7W5Y5;;><<"02>3^U'[T
MZ5N[5Q*K>GEZ&6;9I:0;A$,?K;K11.(/S+QW2#?0;MFIDU)#7$C=*X61*R)V
ME;\THX&<:R:/;ZQ?D-AWEKM[+/GF8>(-HX\\8(F8(W11?S]#M\@$8KK0*&X2
MJU>E3$ER;[QT\9?NU6O,158GY7PFINCSU/6#&FOO  LQJZ,G(&LA]GHXXOXR
M'(X0+)(!DK#UU9O/OJR<:1A'2/3*,<_-K 8ZIG9O1WC\#VY D;_-HDO-S0AA
M#L=A^+&W):@M.0<QRVI3JW7+O2:;9?I==,DZ9BC0:L*=+6K-805'ALQ <HQ6
M['4-4D3C$^+,TF;^*<EF.K4<ST_.=0IY09CJ+4*E&GKU@N&\>G3I@T$JT5J,
M_A@4ZCTRLM=G?%.HSEW,1K>?_#WZ;+51Y+L:&)5'CRFV4!RJ,K94JF1JC*<$
MM\&)*)>6T%-A*5!8L]*S6:7IKUNHJKAPM5:9<)F7IR  P_XCTA 7S)  DF^,
MSXOZ;T/-?$65I_#50Y8T8R5>JF6:OTJCF?"UMF%KJJY2AFJ@-5SX=0NS1Y8F
M&]+M.S+GIZ*1,K9AUNDOSIE977YR*8V\7 V9SE+34'H<;\3C/)6ER,A4B1,4
MZG8DH1M)YKJO5\C7.9R^2%?)UZ")E_ 4U=),Z?$-)7?2RQI) 4 '<G =.^%/
M@7KV0I].SG7&R76>GYBK7ZG4S\Y45AY37&3^TO1HM5I.6E4-1V#S 2V"E;ID
M^DV[2Y=ITB/&C/5)VVI%3EK8B.5N25QDFGRIRVVX\8?A\AA]B,F1,>;67WDJ
M4PO":F3SRYS,UDZB:CBFIS2I2IU*OA0"Q*I3U&0RZ2I4&ZF0Q$:/Q-TUNB=.
MZ=F/AC*Y2B2Z=,KG-9BAEJW4AJ"*E=JQI@*]-BZ$,XD-I!46B%1J5QH=B4Y5
M.=I-+=FR40Z6W(]=+"UR') @-%?RS3XB#>_*,=#(=#S:LYDD=;5++=/<YFO2
MJ>+4=5+.\2(IJH+,02K $( TE2#:5C'(9OK/7J%7)Y2KDDZ7EW>H?LN6*^&Q
M>H[FD GA)5I)#U*AIE5J4R@#,',5Q6]8ZM1'I])MN/3J/-8J4J2S7XQWU!A;
MJVDE,1QT.F.XV8[3K<E#RGV$I])I12LYTLK\/Y>N:68SA:NG@(GV2H1X(TC[
MT @$GF1>9,&V.(ZO_M.ZIDJ6;Z1T;+97II^VYBN_5,N1]O/BD!D2J02H&A2I
M5B0 5!B,4+5ZK,JKTF=49TFH3I3X>?DS'C(D/K4%E;[[[BW'''"I1RM2E$@X
M4> .NFITTHHM&E3ITJ2"%ITPH10-@-( BY]S./(\WFLQGLS4S69KU\S7JL6J
MU\Q5>I7=C$ZG<EC<1<G;@XD.F9Q?EH'RFX*8>,?_ !!P#G\_S/@#MUJ=)C]I
MY"=OM="?_P#HN,?J]NF]0_\ V6:@?_VC^N?Y#Z$ASW'&/ Y_7G_QZ]5U+/WA
M/N/Z_JV/) HYGY W_#;Y;S/&-&Q_$''!94<=^!@9]CV)SC]>>NL)\KQQ1J;_
M /=)CV&VV.:H??'JP';8B;;['VOSCYH5S'XU5NX)J$O.,_\ Q#F#D_TX_7/C
MYTS7_-9G_P >M_[C8^B<G_RF6_\  I?^A<"^WW/DC [<\^!QQ^OC/4&+.,=^
M?.,?XYXY']1QDC!XZ6%C//C_ "[D>^??'!]N/8]+"Q@?_LXQR,]LGMW(\\<<
MXQQQTL+&<DYP.?L>.P_(8[$8.3]N>EA8>Q''&\J;(0I+S:P<D'>E+FT@A2",
M#*L@YR ,<'+'S>0DZ6W%HW%R#[X)69/.KE"I5@R_>#"=,>FY/J!BU8]R0;AI
M3%.NB2XS4H33:*95T(<<4ME!&&)@Y5@)3Z;;R2HI3D*3S].8^4;*534RJ!J3
MEFJT1"J2VQ6]M[CGB),=W3Z]D^M]-IY+XBKU:>>RB+3Z;U-1XA\)&!\'-*?,
MPT#33JJ00)#!@!A-ZGPVHX<CW!"F!6"&2I*5)*22H87M&U0P,9SM!Y'AUKU2
MQ#9>HD&)(FQB(@?7<;6Q6K=/R]*BM2CUK*9H$2*1(##N"&(B;@$@G?@7U98I
M>]<^;/8A!MLJ;ALKW@N8/T@(W#<I1QDG QV)QT;"NO[I59B6(9V)VWGU@>O\
M\*C2Z>QJ9W,YNEE552]+*TB6+,-D"@P"3RT0#<3;!-NZK01';4MFH/S5MJ#[
M"FVF6O41]*<.[G"M"T8424)/'Z]5CDLYK,545=0C<D"(Y( OZ6];8U*?7_AE
M*".^6S];-LC>-3+4Z5(.IA#J*NQ0H ;!3N+"XC+]WM0B_P#A5)9ANR-P,QU?
MKOH)/"HZ"A+;2Q@8<3]:0>#R>K?V%B5-:J7"@:5 A3'^:Y+#YCTB\\_5^(J>
M7\8].Z?3R]2J2QS%1C4JK'-,%52F1:& +@6G?$&FS79JG7I3CCK[B_YG%;CC
M.3D@]SDGMQDDY(SU<50H"J  !';Z8YRM6J9AVK5ZKU*I,RS%N )),G\?PP/_
M .9[D8QVP#Y]\$]_UZ+$6/9QC/ YY))^PS]\GW(&.EA8P,\GC_$#C(/OY'].
M_C"PL>QGSDY';'&.<_KSW\X';GI86,_?\_\ #MY[#GC(YYX/986/ GD8P.,=
MNW./?_#^G2PL>[9[]NP)/?//;(/OW]STL+'N>._'CQGG/)Q_@/; ]EA8<QEA
M"L[2HI6%)^I0((2I( PH8.>=WN.WGIB)/X;;W!C\/QP\D?=!U2"&!B(X'J9_
M"U[XE+]>>J8IK%02A28$=48O,)(DOLA:UH3(6=PD.,A9;:<4-R&DH;_N)(%5
M*%BFD-#1J$@DJ.T7,0/6#QB_F,ZV;^SKG"7%"F*6L?\ $T+]T,3(<K)4$W"P
MLP!BP8MML3J9;$>T[RHU1K5:G2X[]N.,R*'4J(\A;;$9=0K561!H;D:I,O*+
M;L2K.-,!I8FB.O8%9GC.E:JV:R=2E30+IK ^/1=2=Q30:D(83=20+R%.-I,O
M2J9:@G3.IT*U9V<MEFI#+5J3:=('BN^EE8&+, 3L"3@C5K'K<2UZ5<M7DO.I
MER*W28[/S<145AVC*C(46IB)4E,EI*Y"RIAIIIM*,>FZXET*$=+J% YNK1IJ
MLC2[,$()UB1Y-"Z8\H#22;>@&IF>AY\=)H=1S>9-1T\2BM(UT*TUI0J U/%>
M5/FBF@%@1%QBL'8\%4&H+D50,RV@%L1&V'7$2U%U 6RIY"@S'4TR5/)6I"DJ
M" UPI6X:JDE@Q!$[V(_"-A8=MC..49$%*J7S(6H3/@JI8$6D:A8&#(D>^'$2
M30&[<GMOI?%>,J+^'.H;064Q,K^<4\L2$/>LE.Q#;:8[S3B2O*FU)&YJRU35
MHE#^["MK!!DG^#^&-P.1;N+X*G5Z?^S:].HA;.-4I>!4'W412->J\EB0.(L(
M](M)FR94="'WEN)C)+3#9)VM-E>\I0DCC*L'P<Y!\CJ4! "1]XGWDQN3O,#%
M!ZM2HB!W)6F-"J3L)!@#:.2/G@4<CG(!Q[=LGMD9/&1QYX/OT^(<9'8<;L9[
MC)_3.,\?;G'CMTL+'L<CN./OWR?<<8R>/N>V!TL+'OOD]@<#L<8]_?\ 3/L>
M>EA8]W.<D8'/@#GV^_([G&/?I86/=B>QXR>WMC&<_;R,=^EA8]P,GVQCGCMQ
M@9 \_P!.>,YZ6%@G3IC].D-2H[SK#K(0ZV\R2A:%(Q@YSN!*N21MY QT#JM1
M65@"I!!!V/RY'S^A&)J&8KY6O2S%!VI5:3!D="58$$$,"""#(&V_SQ.J1.IU
M6J<1^IK4A_Y@*4I_^+!DN[@I)D9^I&[LM0SO3]))/'5*M3K4:#K2'[N#]PQ5
M61?1&]I(D""($XZ/IN;R/4.IY:KU!Q3S'C(SFO+92O4U"'K@W$P Y!\R_.;
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M-FNE9A6I5*!8@46<:5S""& =".1#*")O9W4:,B$A,^&RY*ISDY11(0VOY5Q
M"7%,I>0"E+B4J!]+A22H=P02J%9G4+4\M10 ZD^8$03M&XB3SZ8+J'3Z>6)S
M&57[1DZF8+4ZRH?#90 VG4H^]!@J;@@[C#".S&D2I+JFS!2XZAZ+%'J.J6@J
M)3&2HDJ2I *E)<<"B?3((Y&)VJ,!"7!!5HL )N;V@:1:V\3C.RZY>M6JLX-
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MC4%96"HQ:?*>9Z@^J3)4\O)<<2%+R>2H_P V5   [B20 GG' YZZ<*JA0NP
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MK[\MUZFQZ1<E,C/RXMK7+;C%0GIDM(&\[;?2>";7V^??"AC]V#>\Q8&?:_\
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M"1%O3D<")]_2,,E:;6J4D"/))SSE]0&#P1D'V.#['(R<8(_X8Z7RU8<1;_\
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MI CB#.FXF."/O"=CVY$3B/[DGC<GGCN.?RY[>._N.GX!.POWVGD?GZ7(DC#
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M1Y*VDI:7(82WZ,A;:0VMY"U(0E)2E.]0#&E3.XT ['D?B1S:.P$3C)950E1
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M/!L<$:%5:E P9="09,"#JO8!CL0MP?7;'/4+X#OB8J5>AVU&MBU9+\R+;K%
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M.YI+<34.FR-3[8JBK;J$Z#*5&J$  IE3XH,?VQ$#99<N&1FD'_,.)M,W!DF
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M-BKJB[.7SE&K4%*H02;#48&\1>Q)86"B3N ;R%3*5%I/5286Y*#43"A[@"0
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M,SC E)_,<\XSP<<_;/N,9XQ[=*4]/I_;\_EA_$!&UV/93' GWD^W &V/?-(
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M*%'/'!!([#@*)&1R.0 >W;DS,JLK+I!E2((WD$=KSB-&96!+F 09DR#(B;V
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M_2(0PU/47 $M/D )F(!X!!))@DL; 8JCJJ(_E!(34B@*3*PRJ22Q!;S>> J
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M?G?L(@P%$^8D"X!D1,7D#V_UDE?<K:%#!SS@\?;QU.J:E#=Q-XCGY[ \^Q&
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M--CL#Z>X^7XR<)UMN(X-]HG;V,VY,;3"AD.%)RA(\#D9QS@<<8R.Q_Z=$U(
M&PB#/H0=MN 8GF>+G$101,\6MZ3W]/3":I#@.%!*><<<Y.<>QX'![_IWS6\%
M;18CZ0 >/4=_KMA@&N)D \2((OWW^4?GC=,A15R@;3_>R"<=\X(\^1YZ+P%
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M]OOP?'./\^G-)08@ WXG:+3-P";2)W[XNA)&_)XW@D3Z<3\M\?_94$L#!!0
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M0HF$62Z*]L9KH540I#^7.*U6;[:$&=$ZK$T5L39HNK^_O]DJ/VXB?$=KPD@
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MGM![V5#I>!018"MNFCD7&_?[KF^N\)T/5K\D+OT>#M)-*+&(??G*^>'GDV#
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MSX3HM6DX7<]^-C+30B_%H80Y.3UX* 3-35MF15N:0O-<WR+Q5\Q 6_.SQ'A
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M;A*2HQ/G0'RQ_JQ3?-WIC,//0G945%2ZHB?-.EL,@ F_=,A@G'("9W$ITV'
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M[%. =GX62G:(S69?Z.1):F2 7ZCC.>4 F,!!)+ #9G0$X:$*)K2?X_X\W&\
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M:3-W@?>M.K,"@'EJL=LT97H7M;/_K(48("Y7Z(YG\Y[' I6.>J*I8*+)$L9
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M3KKOV<J]W.LP1)@E%+K)(I69AKT=_NH$+ ^BN]3XB\RZMQ^J! Z.6]S[LG_
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M@[GHM33G#NH0 W K-ZK22/,F/(WC^HXRLPPD):A=(6P<7:;4=M7$G"J/OK=
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MT98.[91 23A&%"UQ4TOWEJ!H\X,=6?&'D4/5#T#07/[,9AH-37\^*AW09TJ
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M=%K1T9-G@C>3D1OA=/T!PRL\4<7,5C?9+E>/9%KIHJ<W,F)M%^(Y\>[P!'I
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M7.WS+!W9+XC:\%Z6;.M;R=\TYFB+QMG15>1GY@"/$KG>V]RL9M='*X:Z,B+
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M-\J=C^1MA6DJ4IJ^N72PQHA\;@O&;BTJK*21D.CO\R%*00,G7<6O"B,R9I_
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M7R\O--\_J]262*]\GA\2[%+%958=A1U#,K/V?X81L_W(S4-6G2^54=GZ""[
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M2NF^Z[;R_RAKO "%W./-<6O_Z&I8+ 2%3L]7(S&=8!\FJKB1(U!99%ZR0I;
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M8&D0I<6)B6<*1D1_H8LX#J6!:"3!,65\?&X&0U.9NS%A01^?V]#C-V!CE'"
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M"-><&-&"U7M5.]E2<V/=.B1$HW%BMX+W=!(/&,@2>ZJ6M4S)V)6K\2)TY!\
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MK0:0VD^(&)(!-R+[VM:;@[8^\]G9^AG\NN;RM05*=9%=7!)1U90596B8(O/
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MM"<A2OV:2#EL$DX">.!@?0^H9N>))V.PZSY]00#.PG#-RLCKO,DVVVZ[V&_
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MP;Z@-XFWG<XB4F2O:K*,AI8^96"2K<5%)!_>3G@\<I.,D]M*K$GCSM&T#>Y
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M=0=JU:J0ZZ2-;LT0-A/X8 MOCZE^C3V?S/LQ[)9/LS-ZC6%?,U:D@0K5:SO
MX "QMN02//D@Y./0G(]<C/8^_;OG !P3R .O1X]]C!P#CGG!]3GC/L.1R?;D
MG/.#!C/MW'Y<GZG/WYSSC/1@Q*+0N>M6A7H-P6_4ZA2*M2W4RX4ZG27(TAAU
ML@@J4URXT<%*VUY;<;.Q>Y*E TU\OE\W1J9?,TTJT:JZ71UU!@?78\J1<&"+
MXRYS)Y7M#+5<GG*%+,9:NI2M1JH'5E((F&$!QNK;J;@R!CV'T'U4\,OB?A2+
M:UNB4C2W6R0DLTV]Z8AFBVS<JB6VVC+C@J@1ZF^23)9DEAF05*+#B,;#\D]H
M.RO:3V<J)F.Q>][4[$'BJY*H34SM #4=5-_Q,BBP(#L )(-H_/GM+[/>VGL%
M6;.>R^;SO;?LXIUCLS-N<W6R&HRR$*AS1RX/]U5I,S41:K399<7M?'@-O*T*
M4Y5K8JT*Z;>8A/2'WZ=*:C/L0=A>\]<8NJ:<1LRL/QW%X3E9;*>O-9'VT[/[
M0S R]85<KG&<(M/,TF!>H;:$8@ G58JX6\C' R/Z4:-8*>UNSGR;LR*7IG]<
MHBJ2$\5146I2!D1K32"8-12<<DW!I^EARCJ7,5\%273/)0"ZZQ((0&XZ,%*W
M6E+2XIQ:]H2"0A7.%>LI9ID[X  FLHIDD  K)+'8 ':"/*>H]YV=V^N:3,!:
M&BM6U40&.D-24W=B9"L RPLL18GJ+'N2R:E7+?H\R,F-"G1VUNNQ9)Q$=BE<
M:6CRE1V6Y'Q#2F$/!+)84X'UIW+V$&BG5%-FU:F5K2FX\++%R5 (8B2&-IYG
M'E^S.WLID^U>T,JYJ5<O5<)3JCQ5%K*'I,&#NR:&UZ S%PIIJ1I# 8JRNVC(
MB)9<82'$U1YY]3#\U2#*<9'G.1&7 MMLK2$N/1E2-J9"TJ9=2I221?3K FYC
M0L!E4>&3I#'PDD7TDK=001O!];DNU:55:JU#!RP6G*TI"*YT"HZW91.E7"!A
M3!#J=)Q6$VV'VZLY.K,B12/-,AR1 GS44YR:J($QPTAYMF8&79&UUHEMPI3O
M"H[?EY2>I3S4TNYIHE4J!IJ)3:H$#$L3I;1.DE2 RB8\;3!QWJ?:%-<M3IY2
MF,V"::K5R]'OUI"J0Q=@S4R425>X)L=9),X0O-K8<IE5DIE"73F"S*DO>; C
MRV'7G*A(8J+R@Q-FEY;[Z77RE:GFI++#;P0VTVB:U"PJY=>[9*K331 '=3I%
M-6I@336/#I!:5TEB+R=*N'%2BNC14([M$TNZE0*89 LTU@!8#'P%"2MS+H5&
M#1ZI5R*2U3FY6UM%,3%_UM<9Y#;.\1V7&W6O@UA)DSHY;5-+[J%_%*"TU:>]
MK4: -8U2@![XOX-22Q =@P.L2!38'1I!!2QS$=YF*.7FLU3NQ+5=95 ZD-=V
M4AM8_!3<,$*@C1(Q7]5U.J%N1([MOR7%P9LU56DQIC;BYD"<F0GRXZIB5>7*
M;$9I+J'([3*4)=\HH"VE*/6H=DT\RS+F1IJ4T%)6IE0E1-)\>C261@Q@AF8D
MB18C'0I=AY;.5&.;0=Y3I?JRLI44ZM$HTGNR/ VHE65V;4R@L8( >*QXN+O@
MP%-0VV69KL)QJ-)6E]Q<<NI"5N)4Z^LN>4,^45 *0Z4K&0C'3H^R])F5JE5V
MIA[J-(U#IMX9($[B)\SCG4?T;]AU:PJ5:8:F*B/4I@(BN:9E5*JH D_BTP&$
M@WC'(%R7;6KJEIJ%=J$RHS%%TI=DN*6$)=4I:@V.0G)4K@$@9[XR3ZO+93+Y
M.GHHTEIJ8LH(VL).Y,#<R3'I'T;*9+)=GT5I9*A3RZ@ $(@4  0+"+@>$=0+
M[G'5EGN!5EVXDY^6GL$GN#GS0  3QV)XXY[=?1<A;L_+D\@0) B5OO%K#^NY
M\>ZG]K9^)-]H_P"NTQN;0?EBA-5L?BU-Y.33DC''(,E_(]?E)YQGT SSU@]K
MK9_*V _V87Y_$P'R(^/EC?['W[-S.]LXXGR$>'TMUDQZXI]X!+I ' VGZ<I!
MR3S@_P"01SGQ_OG'J?Z_#CY;X+]^""?7 Y]<#..?3)'ISVZ,&,]LC'.>,#G(
M[\GO]SG[]&#&9([_ &/UQV(YP 1G/;D=&#!H><R%%:LD8R3W&">>XQC[]^C
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M'<CHP8P>F0<C/\?X <\\GCCZ@DP8P%23P<8X!!Y[X^F.,@^_/T'1@P<B0\V
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MZY(98=8+KBBM2FBXMQMO><K6EHK4,NDK/ S@< "K.A0JG91^%9Z8@E-:;,5
M"L9%, ! 2()CFT3)XL <-S<HMEMU)*%(40-A*2<C.>,G/L<]^?3I%09\S-^#
M]?+?;$B9 4BP''-YN2=[7^9YPYU.K(GMM.K;VOJ6KS25[TJ:#:4H3C'R[5(R
MK/)W'&1T*ND0#]_UQ6E(((!/OCJ22(%O=?TX9_."F\@'<-I]D_O#@<$X[$#(
M [>O4L2TWW/(&TW'7GFV_/GA0V65N+>EK6I2F5.!0(45/8PT"G&0DJX)/. ,
M=SDBT<;88F3>/=!XW)D'IS/!Z*(%6<B2FGF&FTNH&U)4H[0HXRX<8(4 ,^H/
M'KSU6U,,I4DP8]T3_/"J('4J20#O G^?$CWX<Y=?49<B44HEN24E*W0'$\J
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M/8]*+B\1,QT^7EZ7Q-6(4CG@\S(]VVUA;B<%K="L *(&[&T[E82<\G*B..>
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M*:X+>73:-"FTI-8:E/S;G1#DM(N^N*1<EUIK-P-MU-'CK#[ZG\SCV)N;].G
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M+=B4=T1[[@7O6JH_(GN7!<=90^VPT#UGX?E@@]".+[@_3[Y&.7[UUXU>U(U
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M@-Y[$1QMT]2;H]MYR#(&\?@.UM_$1,F^Q!(GC!XL&UCA(B3ORJ+Q XR"K#/
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M<$<]S[_PZJ:S&(&Q@;"W3;G^>---OW8@^DP#<F?G$QZVPG=Q\O?'/&>V<>W
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M5UWQ'T_0G]4;BN2V+[CU"-J>[Y[EP3+>I%0C1"'$6VS5V)JA530V;;\(#:2
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MMRZI2;A9CNPH-RS;JJCK%OUJ9^"VY/;CP4A;LV$9CP*VDD0I/AB6@66X(F_
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M&V]X\\)'%%0]1Q[$\=N^![<]P.V>W66JQDJ -OZ_E:^XP*3-^H&XD7M;J#<
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M%'57(4B?"ETDS9T5MINH1YU*J4)R*XI*_C:?4(2-S\&0&Y4\Q2J1N)\CTMN
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M1;E>LRX[_9NZMU)ZL_A=KTEFUK8J-QO-75.I4]=OE-=2RFD-F>M#.*C,5IB
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M<T@5!B1#:B,Y2 BJ'4L (\/A8$6)+=6\S8C< 81R;DG0WX>6#"9&HD *Q!4
M"6@2>DQ"J=X1_$Q4U6ZW$T<NG-TV^+KHYF3;9IB#;BJ?1JFU5JW(JM=@L6?&
MEP[CMN13F[O=H<JILW!2%4YB8JH0TR%^M4[DAK-! *2=IW<1<Q<@^7&(_LZI
M(&I1<S(?PD;!B$);8B:>H2+Q<BA9U-J%)GSJ758TBGU.F3)5.J5.F(+$N%/A
M/+BS84EK)+3\64TXPZV59;6VI*MI! O4Z@&4R(G>#Y^^W$XRO2--V1IU"QZ'
M;RF-H\O+"=!2,[B1[#N/3)[#V_GC/'5RV!'GTN+;>EQP-MN,5,(CF;DQR+?
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M^BHUSIE:1;WZ]Z72Z\S=C-FW!2G*G6X,RW*G$NFQ;4O"KO,3*2I4VQ;$<O\
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MI37&Y+][UBJA"44B28@DU"B59=3,";_PG23^$$ 0MO\ ->Y-S@[\AE8>$@*
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MYI3E0G0:G;-;?@2P9,6%/CS7**3X#+K^$@Q8[@-!86@$7F0"1L71S;!*J,2
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MQZR4_JXY46(89$8+/QJ9F'$E4]GU*!I(I4Z@;(0 (B (LL;"+D[[8J8YGO\
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MMXDS;6HV@\WX^N+B ^G<9]B ,8'] ?3^/7O<?.]K>NWR'WTPW/C#JN#Z9_\
MW1QR,9]?H3].B1,$B>!-_OXS[[6+&D&;3ZC<@@#W7Y$GS&"^"%8[@$IY^_'V
M_GGUYR ,!_$-QS\>=XM<$7.)JX$\;09WCZWF9DW/F,)W&TE 4=Q4,'CN.WU[
M<]L>I]NB03$J+=>F\VMM)/K,8FM1B0-ST\@+1O .]K387W1KP,C[<$C/KD8[
M@XX/U.>.>F=(_B!$3(((G;Z_7$UF;C?R'4$>EY/!/F;83CO@_<?;/KGUS]./
M3'64E;PRB]QJ%NMP>FQ^/!-P!%])( &PW/PV.Q&YW(X!"R-R@2,9QWQ_+MCO
MSR3]#@!RL?B ,7N.)B;[^0M!F=\!4Q928@[&-H.XO,<\V'7 4X[Y ^GYDC^7
M ]L8XYZ"R\$6YD7L/SG_ $ Q;24K-M,B (CF#TCB-]YB=TR\$K'<G., >F2<
M'U/)R<#U[#M55(*-##W$==OF/7C<8M69B(&]IO%P9%AM/$].BADGRTA7]T$8
M[<?\?;C[]NJ%(@'5>(B5X-NGUZP;XT*(-]C>X8&2;D_&\2+ G 4C.[ _NJSZ
MDCCN!GCV^_.<8ZRCW>1ON1^74#<"\8T2 #?DB3<Q8@Q%Y),2=IM;"4@@GN#@
MC<0<>^<[3[9]?RYS0X.HD*T& +$K,<$ CYG;RQ,1 @SY_$>_K-KBXP!6!M&?
M0@<C@>O/I[>_.>_> ' !/V?N]_GBZF1!'SL  =[^@BXYML)2N?*K '!R3W^O
M.3V]NPSG\NJW4SL>>#\CL9L+=!)Q?2'BMP?(R(.^QMO] #@'^?\ E_D??'2T
MM,P9F2(@";W.\#G8"]^<708B#)V,6@>7Q.TS!@F,9_G_ #_SZ-)Y4_=B3;KU
M@6B<*#%A-]P+?2=^MC>TC&$ @CG!!SR01W!P1R/H>,9&#V/05:8TL8$7!O<C
MBXW$1:=C.&!U'G$>8ZP+Q?R$8)6D)(P!G//<GL /7C"<)' X'.5$DJ&&X/&X
MOY;W^'IB0GDF/*?C,\FYB?6, [<\]_<]R0.Q]/Y>PZC44Z&M8&-C>2.8B_2?
MZR'GO?@7\[=;3/(P'*4Y[CG/^' ]L9]/L3@=9XC$H)X)^>"GC\HYSD@XXXP#
MQW^O&?X]&+5$6B.NYZ7X%_O8PG!P0?4?;_#WQS[^O2GR.W3^4_#$L#\Q6,<8
M]L=^_')^N?OT\*!/.T>@]VVV_P#3&>8H=L?P']<>O8_3MTIX-NGW\ ?/R(D@
M??'6(N)\OK@)))R?\_8=/#QKH](\_O[_ "P8SMTN),><;'S^'K[\&,Z>#&9]
M?Z\=(F-[><P/3?!@E1&[&1DX'<?7/IZ?7D?TB2.3:#M\(Z3\_0;F-<>GK_+^
M&,_P_GV TQ,3O<VYV-X/K?!C#@]^?H0#_G&!@>G;[FH7 /P,?6W6\_T#]_8^
MG&V,SD[O7(R>,G'Y\^Q'T[\GI:EY,VCGRD#:) Y)N=^IC./0_4=CD?EV/^'M
MV+D7N#[X$[[;>\WFVJ=C[^]\8,8]_P#AZ8/YG^7!QT2"3?;8&]^H\K>MS$2)
M,;!(SC'IW_/_ #_#HD'F+'D>5CN0?3ZV!C96?H#GGMCV 'W_ (D]CTY,6%K;
M7//7?C?DWF(P=/3\^/*P]^,WGZ _EZXQG[??[]NG^>_! C[\Q-O)W!Z&WE_I
MYX,QVS_GM_PX[= 'QWZ"8^7OZX6-_P#+_/\ P]^B)&_U'QB,&-I44YQQG_.>
MG]\Q_3!@U+N58/!X&>0!Q[C@>G?(_P 5/E]_?Y6OA:1&UIZ6_P!8Z7F_)&#=
MR<]QG([X'IZ_7//H/J,GIX1!O[HVVYM<SP;7M[M\$<$$C)&,CZ\#U]_H>.W1
MA"W,0-K3ON;\^5^!L)WGM],DC!)R.#C!Q@Y/TS^8Z<'H?.V%*R=K@">LCIMT
MX Z],:*MW !R/H>WY?7[]AGOT@>A^&&8&^Q.Q,><WCGCSO.P$%$9'HDC'&?;
M'?U/I[9/H>7!W@_#W??GBHQ._$]#$>1L./*!M%C$G ()./IC.>_\\8[?P'00
M1N"/7"YMO:?3[F(\]\#&<#@CG )'\1P >W/'KW/'2P CR)(XW/$[\<?G@27%
M !(5GYO;&?0GMC/;'/;ZGHDQ'OCSQ!DF=]O6\>>XXZSQ&!%:CWP!CVYY]\Y_
MP[\GCE&;V-IX(F(']/,XS$=%/E ,_$S\ !)/D)-3R,\9/\,YSV^ASCV]_4R&
MTDWYF=R/=S.\;;<86G:)'NO;I]+ 18'><;!!SCTXS]L?Q_QY^_0!Y$QT'^OT
MPB")!!'!W'TCIY]=[XV/0^GMVR/^?_'/IU;2@/)$"+$V%]A]8.YMM@Z6YVV)
M!B!M-_4_S,X.<#../R]^<^V /N2#G'6F1U'Q&)DB]A(M!Z3N)F=H'G)(,QC,
M[.PQGG)Y'N "/K]OOST]0F=0YY'/\\(@; 7W-YXB+3R;S&WH<:4M140#W_+^
M?(SGZCCGK%4C6T0;[CG&9EAF !W_ )3)O) N8DVQK>KL.!_A[?X]ASV]A&WV
M?NWU@P<(),F#UGKL(ZQ:\=!8['$*PK(., CGD?4<'O\ P^ASU92*AN 8,G[/
M(GIY;&33Y$VL8F>#YQ(W^(O@TK"D*3D#=D'L, \9SD8Q_O9^N1CJ]F5D8:@)
M!&XD$R!R8XO/G;#7PE3&Q!N//ISU^7(GW/H_C9TOTHT&L&_8-^UFX=5ZY1?#
MQ;J-*+&OF1*H>FZ]"_#]JQHL[<5,M>H46COZ>7 ]+NRWK@JE055ZO#K];D52
M;:4R1 0F2QPGIU>_#%B2%"F-A8 1TN), S8@VOUQ77NRFD* [,"P'C#-)#$
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M:\@04DXM>NX)QW3_ *ADIXP"0-V,XP>JGJ4)\6\C5O/!&\3R0??(D#&H9>H
M L0)(((O?;?@\F_K P V%?(/S61>2?;_ *K5WD#N,? ?7G([=1[RA$SUM,^G
M\I]XYA?J]7I>.HB+C?\ +!*[%OL@C]1;SP>Q%L5W."<DX$#Z9]NI"IEQ_$#U
M]_3?;\H.]II1JA@8)W!(.TV-]6YFUC)^.&]>GU]@_P#F->)&">+7K?K]X(.1
M^?OWX#[ZAL&&_GYC@=/7I<;WA'C:;Q=EDW]; ><1T%I*_L_OKUL:\NP_^EBN
M\XSCO![>O'KWSZY.^RYFXW_PM:\_X=^IYF_&+>ZK@@2=A;4D'WS<6M\1'"=>
MG]^;S_U&O$<]S:];R,#ZP1SQ[?3Z](U<L1>9VD P+6M$VVMMO?8S%+, ;KOL
M:B]3O)F_4[;X+&GU]D@BR+O &,_]5ZV!Z\Y,$_X_?//0:N5M$V X.\W&PV]0
M,64UK+JE%J$D1XU,  SLVQMOM<B#."U:>7ZG*OU(O @<8%L5O/)X_P#H'W)]
ML^Y/'5=6I0-,A+L8T@ [:AQY\P3OYB=%)2:@'<A)G]X7L"!/^(7-A'F3YXVW
M8-_ '_J->/?C_JO6LD\=\0<#^&3WZR2(O(/32=Q'46D7\Y\A.KN!),KS;6#<
MP>O))L1  !/7 V[!OU"B38]X\I4,&V*V!SC_ .PN?X=\<'H!C:;@[J1:?.U_
M?R(YQ%J (NR;S=Q8 7V-_..> ,)UV'?*=R?U*O'..PM:NXYP0"?@>/S)]STG
MKZ*96]IL 2+WX!WL-OG)Q<E%1<%6N9\0!MSO.T".3S$#"0V%?V3FQ;Q5[$6M
M6^V?_P!1&<^G/IUAI9B[2#'AV!ZMOZQYWOL(%O= F=:0>CKOUWWOL($[@X)>
ML&_P4G]1;R'WM>N=CZ?]@]/L<@^O/4OUDR"%8QOX20#MQTF#O.W!Q;255:[T
MQQ!=0>(,[3\Y\]DYL._ 1FQ[R'M_U7KG<=OWH [<_3W!])#,&-COOI;SYTVV
MXB=YG?067_'2W(O46(\_%OM\=ASGZB7[D?\ 4>\<=O\ S7K>?IG,#TQZGC@\
M<=/]8-['H/"?K$\;&1TPM:7AZ9-S^-8]?Q=#)C>_NV+$OP$?]1[QX()_ZLUL
M=C[_  /MG^7?OTOUDB/"WG"FQX,VVO,;?#!J6\O2L/\ $O(&XU>G7IO@M5@W
M\HY%D7>,GUMBNGZ\;:><\_;OQG'$6KDDB&CS5N1M;T^8Y-WWB;ZTC<^-!<"T
MC5Z@3[K7P%>G]^I3G]2KN/N/U7KXYR/>G<8R>?X<]JZE4LI6"9\F.Q!C:.+S
MN1;$E=2P$H>?QTS:#_U?+T/3"5>GU^K.?U'O#(& !:U>( [XS^'#Z_P_+K.0
M3NK6VL>GE[Q\.HQ<&0 ^-=S/C6TB8DM<\6Y(ZX+5I]?P&?U'O'OZVO7@/L#^
M']_3'&/RQT01LK>5F-YOP3>?.>-CAZTY=(ZAU/ISS(VZ\P<!_L_O_O\ J+>)
M[\BV*[COV_\ )_\ G![=*#T;R\#?#;X?TN]2<.D':74'Z_8OC7Z@7]QFQKP'
MWMBNC/?@?]'G..,]OOT0Q_A,<^%I\HM])(GWX-:#>HD<^-#S'^*_$X,&GM_8
M_P#,B[QGD?\ 5BO?U_#L?;OGIPT_A/G9M_*U^?\ 6V(]X@/XT]=:Q]?IC7]G
MM_\ K9%W?_TS7O?'_P"+OS]_;G(Z(/1O_E8\3]BW3?#UI_C3_P"9?Y_9MOC8
MT\O[C-D7?Z__ $L5[_\ YW_(>_8=$$<'X'KY _U\N U$!NZ3SXT/YSSST.,_
ML\OX?_23=Q/_ .S%>Y/?C-.^_P"7\GI/0[]#]C;T]9NM:'^--I_&E@#R=4#[
MYC&'3R_P"?U'N\^G%L5\X)X3G-. &\@I3SW[@=^D0>C#_P!)/3CC?D3[AAZT
MMXT_^=9OP?%-HG@S:YMB%ND(*D+!2M*BE2%)*5H4D\I4DX*5)(PH'E*@0<'L
MBNNP_GM:_P!.!U.);??\L$;@/R/'\#V /'YC^6,1- ].>G-NA-C%S]9P?<<?
M6<85)^O/<#_'GV_EP>EW)WC;:WOOTW\[^8P>X?/^>-;T'OQZ9/V[9SGMS]N>
MF*)VB.=N?D/?OY8/3IT_U^^!; B4$=P1GC'KZ^A/MS]??T!0(^Q_/C;Z8/G.
M DI_AQWP.!]\X^IXY^_1W)^=[<B\[Q[_ $N<&-Y3]O3V]>>WIZYS@Y/UZ.Y;
MXF]N1'V#86]8<V(Z];]>#ZXS* !@YY^O'H><GMS[?SZ#1/V/3H?(;],+&P0<
M<CZ#@GU[^N?Y_7'6A:7@$BX%X//I_3Y84Q/ V)D1?@_9X.-Y ]O?^/K_ #[]
M2-,;1SY\'SX,X-5_EN#?:(OM;TGB,&AQ( '/H!R#SS_7!QVQVZ,E?7585,_[
M]@%60FF0+DE!&FF64%(6D$9 6A!P::1<$%!"&J0DI4/J(RDML:!TR]*U+D@O
M++6[+]_?^]_,-3/GF7,_]]SS/'.=:TY[C'@ %[7!RV^P9<<W=[[)"T!;SG(.
M@KJFFZ5&7CO=?_A('AXJ#HS;HY$MJ_F)__P6,;RLZ+V6W[4,1<Z@?A\JMJ5@
MRU +<?K-W$@48KX9%IK'ODHMQFGCR0V!OZQC4JOQ(5#TVPQ!L(!@7N"07)=N
M'YABZ,OOT<N)H-,.7!@/$GK$*(N8H8%_CH/GIAT..KUE7O-&M'0+U-]<HEA\
ME-9L].<ZZ%HZ^FT6B*Y8$_YQ(X:O(%H0CDQ+5K7G($<>$ >Q_#!.R>GTLO4>
M10OK/@TK(DRLEFM$.PG)<<H?J!RFQ,:FML46#_,^0Q]([!U.YW@J^1,E=:4<
MU8K1A$D%-@YU;66_O],I\5])[C4'DOUB<^\V(W(DJ?BBI%$SI4SB&=U.R>0]
M BA 79<2,P9)6-@8 ?/K5O#_3COF!< _G.D_UG,ODYV=2AUNTD1ML>9AR< 0
M4C"4(YK%*%G[$LYV3I(4BL7V[OZ(/AK> ,%7!Y<E^&CZ"8A6PQ[($![/$QI7
M\KA:] P2C#/=])Z?X]C\39(^KVAT7GB/V-893Z_#?^>2B?(TKZ^"_P/+8S@Z
MX@/&@NUB&5G/NJ_6U2)48QM[5A0N0\[%Q4.WO#\2W23Y+G&L3M_X]21<;FYY
M<OX-E*O%M%&+4"OW*@)BQW)D9H%+VO)KCO%.'#IP@9O3J0-_7?U3;^2.%B\S
M+BOYY3?^X()'_9!+#HV6P9]IAZNK)VR;MV3JBRYOW^K%O GE&CSEUFEYMEO)
M&\R*J%O-]7G+K1M#(F2^XP-.\EUM0"O?7(%(Q"GBK:G$+)1=:H[U,V1BN0:O
M]WM/$B.(R4\-$]FTO"1R<POL*&'=T:M4K30WAI[KDOP*6I\)1:($6QZ&WI3
MM#@":9[KRS[T(279I?+  T-OM[ *E-9:F38I'-8+L:<G?*\EN-2R)4Z4K=/8
MU8/(!5.)V9BYO'NO,)P&UI3]P6CR'Y"A[HJDL%Q_)7MZ[QN!L6E<UA]2SA4V
M'Q^?L)3KX% 8^\_W (\WK%,VYI)(IK6?.9L49%&Y!9T2.$Q28M49]$:03&!P
MG=$>VFR)P;!?!*V$N+<IC#0>^<;=XO-<5MF$=K'-DSZ>XF#O@N]X8([*P,#
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M/$FVK$JDC]+D\XN$BC2&0X?$G=4&9+^Y/I-V-YGX\/[S+O@?]><U7JJYX$)
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M9[+2W8RVFB]@5(*[%.3UQ)+DO+&\@JD@0@B%WL4[:U5&:HD'615P[/87XI2
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MR=$HMM/;),F]NC?42BC3FI39)\]IZXL' .7N-[X8%+-,]H;VRC3TIB0FCD[
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M$Y<4DQ 'E%2#_9Q<O% XB#.*>#NMS/>FXP8?!.VJS'=4QEC"V$\3Y8'6"PE
M6828(%U"O%P47/E45:B5@A6#??Q\4#@G2+"/MR]6,5B9;U>Y(O%\ARS.!]D=
M@O-2YMN]?8)8&YM!-#$!*(B"F 3,14)"$B*G(.8B 9>0=H8?AL EX%+B$G!Q
M"068A*PB7%914AKRO?&I4!,_E0)<W1016CK?\8@]9;[OC@4%!8D%28EA MS%
M)144%';4P.$PX@@8]H0OSBD8YHOE_Z;DAQXM%-8E +W[$!6RTW=RQN!QRGQ\
MU)!?VC<@/U>WX)](OX5PAT.,H93XG\2(KO]9ZD?@_P7K7Z'^%<G5Y:>,'S[
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MF!U?7(E@;O(H!5EIN"2,".,&DW3;\47.60HF)2>E )=U<E5PEI?Y ?$'-?^
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M+;\\=?GV2$?\^S,=%6KB!/YXH/2G-?N_W_9 ]D#V0/9 ]D#V0/9 ]D#V0/9
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M)+17'Y\Z1M@&EA5?O:8;+O^ZL4$N+Q\<:S1B+M0N:#2I47Z7:YC[VA<^^$
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M&,'^RSW^7 _>5SY'#Q^ACAKDT4!U73R6-FPN7!.9-:A1GV1JB1ZHE9P7+KM
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M0^K0L$PLDI#3JRG;P(9\*#Y2B%AM-M]>G_T*#YTM6W>DLVT[??)H\\S7,]O
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MRFU08( 5,3EI6LL+(:FK<1?II=97==6_5B'_C!USXZJ1F&;YRWR\)&*D^Y5
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M 6';$37<6'1H5@V#IB>BWEHK(Q?Z1#,&!2%060PBL\(#8O79^9[4@/)?.)I
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MIS""EN_S"E#&N[C9/ P[*Z"[V>/[+Z5>+AYP^E#Y?+!? 6+5.P27/+*TOJ\
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M3C(W!BY=_&K#2O<93=\]C$T=;#BIG6T&!PP.5J3^-9Z:IE)GAM(04D(F0'[
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MA1=W]>7O,KBJF.-3@CM[4?KDA>B5!T;C(#[40(]52YHH#Q?*3,LH!08O)+'
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MC09M1.W_+O?NT#^#8["&#UV.0.(KDKOX/UV+I,S N@8UWT0L6T-""4LH*J5
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MD1X^OB;AUJ*V"OE&N]A:Q1Q5=2)2@V]5=,*KJP!M%X!*R4@62DS^RCBE1[]
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M5I3WU2Y+64XH@]D4MIR<DPNR> U!BPN-+QQW=YN3&)UK@F"!*DJLE &9/V2
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M6N069+<-UJW!2@M!U_.)E8&ZZ#KE+NBWDZ"X4K*XMBMM=P,9B6=,WM1*1.!
MI 405*L2H$ V)TUN+G61KV[P2ZL+4NQ4I)3)"8]H0201!D$@@BY,G3&1LF@^
MDMNMCBS-=FI*6UWM-YL=X3+7!Y=@=[:N-X>'^Y$CL:[.2XYS67(]7 \.5Q/:
M\Q0^/JQ=6<[.2RHLCW3.K=NO$@&;01 T&@@QPW3%..*.8J,A04" !!  $0
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MGG(!(]\C \MI#+##C<1W':<[X#D \L0'38-W///9AQW\^_GMP;CO@)WZ!$3
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MX1@G? !.0GEY>8=N@XCB7U,Q>Y@1N!B"9.\P!?2!AR,'W<A]._J'3BQ;@/\
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M N=]A:#.HC@-1-YPY[SSWX @!#G SVQ^-_HX6 D>9OJ=)$[^TQJ9PPX#G "
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M\)O_ #G&<KQ_GBBGD-=7I  /4>8=-@QD<\8S^J1_A'/UX8Y>H_7._P"+Z8I
M )W'MSQ@ Y>@\L1SXU,://A@',AW 0#$0'(('?.P?$1X8MO&>X1SV8)Y"$3
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M[9 1$ VR([=)[7G>+_3SQ,(1]8QM A@8#H'T[2,A <!V\\]P[L,$<Q$,#&V
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MD^L0IH ZXV(GVSVZNH0 35S/2H1U559;$!!=1@=;VET74C,[LY16+DT[A]L
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MH3A$H I/K-FKCY.]Z4>GJZ]5<UTKVZRK/F0S^<'ETHCC1J/J1G^LD4R6[D!
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M7GQ96W9:8ZS-,'1JN_55S5?-*)(DK!<TVV:(5@J<GI67*(PYNHHK&ALI/K,
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M(@@B-V[>"/=C9-J+:PM,2)M!BXRW (.A)F0"!,'&07%J;=]R 84I<JD**L!
M4#8%2),- [TFU45U*%%(AN"@\T.P;<:3-&PR?91F4/ZRX4=VDV'@+1.^^;C[
MK@A:H3<D)G0;I%SVB2+&,8".8ZC,CU&1SG<8R/*9XW4<_3AX8T#;*8BUQ<1
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MY&_A-X_$1B6RBRB"Z"22RR"2:*2RB2J*:"BBZ0]FB@LN@ HIHHH"D**:0II
M   "  .-.;^_DX<]D_#RQA96F>G!-QU7>5I]9)=V5U#75=!5J,5%QU#[P3!J
M%[I04N8B)@C7[0J9]L1JGVA$>$"9@3$3OCA.L=F-8OO%L,EYTL)5F#)<66@K
M3,&Y"02#&: 3I.,Y'<1 !& $)Z;Y^/E <HB6-+O%_AK:/K<#3=C"'K3;3NY'
M9(_W%8-E/[ZBCY$]/=KL3J[)("D!!*Y+D!ZQ-BFD ]T=0/ZM/_1"+)XFVG9C
M$H2I25*2E2D_940"4_X21*?='8<9G0%-%(4T4A1312%%%-(  4T@   4@ @
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M"7%J'KS:4^N6PXVY\Q"!ZAZ#TVW$./ON/+>FG\CW^_#QCK.<B&>HB,].H#V
M>&%A&L^4'GA![>"R/IB9GF&V8Y@'3GWX8G/''(1VQ,A(!O']+I XD/+,9#AB
MD^7?.ZT]T\!OB#)PH$(D) 9VR/F&.^)Y],<,3W_A[\*,\A@ ZYQ(QOWF<9V#
MABGP-A\N?D,,0S$SB0#J/;EGE&^V^>'/S^7(P(OW@<-2)MR.&&(S$@/<-IS
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M&W!;:HL^WWPPP  LQ<K;Z7N@F:43NBK]DRD"9.A$\-#?0C2 9O8FUM!EF/\
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MN/X^SC@=O AAC?\ I57XG)\N[2!NQV?HQ^OJO^$W_G.,Z7X6*!#?W@]>@?&
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M1&95BK%[\$R%0X^*C1HE,%0UE7(K75>R/]%.V,+LXJA& _H_)TIOM]I]F!$
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MW1_90K:-7YOZ-T^SJ=MFJI&6WPM1IT,%EX=73U!=<J"IQTH=4XI:U**O;/\
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MP6ZND]NL>T+:M!"?6262)J*V69$RI31*IJJI*$PA#14)=-=042-(#4 2/I.
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M0GAQCO[>X?+B94S&(#;R]1WWG.TAD,\,/G;F?/LG=AB(B(A(=@G8 "1G<?\
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MIME#;:.\D^GM;H@OR_;WO!E072@ME$ZL%87&1;[;:KU;1Q;?;I[>KN)T>71
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MI?4+":UJFJ!5](\%[PBB%STJJ;@E]?8XSJ:R3.RM!3<D8Q5"9I(UNZY=1XF
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MX@-\XI/,%*W %10N\"55S$-G9DC"J-2'*-V !8X=-/N0;=AXK8CK"&<[9JL
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M/5L+#BX]8BM*HMA$9^R C&7(7@<0$(^5.S0XRS)]JK9K-;L]"Z'9I-(=3Z-
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MZU5@=6P*#!I$JH%01\\C$=V:Y=>M/"^5.J&QW#_T2C!H5UAU ,,L#@X@/IW
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M9\8"* $^"]E62%%T4K$82DY[Z;B]/#6KC2O^K#XDE2J#,+UR#^W&=B/K6(@
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MA\TT0HX, FR"RTW='AA,BY:.MXL4B'I /UDC!2IU0ETE-':@PTDC,W"*Q8I
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MB\O@=PZLZE:^[%9K/1!*DHMOV2=; P/PZRUTP$-W],3XTCL*,8=FYZS8- &
M#7GOY?R%(6'83UL5UE3P&&1'2_$X6("6UJ]D>UH@Y)R,]A/C$Q*_U&X83:W]
M*A#++O'L+]8 8_H>^W][L)'8WOKR*5)A?Z$7CUY8O:, 7E8OJG9$MS(JVF*F
M)GP&D)H2 \9: BN&5+]9;>4HKK!5#[PO5HN*L_B&\V0!5:]%]?+Q+]9/,*N<
M7>+VFL'XEZ!N]\-$T(!KFK1XP0.:>S1ATI0*S6<VO-@SEB+_9WE^K& >>]"9
M/;9V06:@8)#OA[V:6%BE)F;PNP;)TU3X>YE\$D-:D]8GM79P9B;IX(#3W%V:
MTY"6EZ7%KF-AD^(X'X[!F<_+9:WL"K<R.0^Q2BF598*AFQ"Z!B>>R#=>M*IY
M9,E-8C1RZ;$, %X<GLS26HWHD;PTN\<_ZQ\TMT5Z5A(!>_&/EAXRWW$]17F]
M.$7L1&FWUN[>/F'Y3OEKWNK,Z^L3]_ S$<ZP..6A<%_ ,Y[!6A+=#+TQN!*5
MI!5;T,G)88[/MS4/\0NJL=]"[5Z%.2;.0RUJF;MFJ6@W[73DT^@?',\XBVM,
MA&*/$\6HJ'Q,U%\7'679VI$7N401%Z]\XGY<AY+CHA*%B"\PUG8Y<6UHP,<(
MWA[\;YVD5W&8=[/$'[)K',PNR>G>O_K/ZYJ?#R_-%+RC'<\Y/.QX?JP<:<E[
M&DD:1JY=A@P_'?V'XYCPHD]=)Z+6:LZ4H6;2/11/1/L08E*QLZPKVQKJRI;G
MK"C&9Y.NL9FN3]T)]3V/\\=67E5-'>, [S4DY)D@K([WCV7MBHZ&E_+02^D:
M,*<(9V38U&*UXXZ.FCKA#\%3'K+]%S"?-9BC2L0=F/$'<_MEI>6 )9QO2ZE0
MBX)U&33)66EQL)_KY 4WJ+S6G=)4*=ZF&)_79B5$H\ QZE/=576-G6V_]]+U
MTLE2M;:0!V8U:;[2H"3&/A+K S;$8SHBB0H^O14IX(!S9LBC]/W!6^+]+#H>
MYE0,CFUN$FI5*_;3) R=Q4A14!&S:X04 8K1/>Q@Z4V")!9#[1;I'$Z543^4
M/D^J:A0S6PONAI2SMX909>6(_3X'=BDO+2^^E*N!Z,TSE=IA]E?NIZ_ DEFX
MSO4L_(W9$F.?2 5AP/W+(P;5<>Z,.1);9 22F'A?QYU)J1KA%F$"&+3_V>^@
M!HCR#^:H!XIN5,P9-XQIZFIK0HB]LK(CA0N"]%F62M46^FOFW("6)M\YAET:
M>)BWG825J=R468M:PZ9];1 %VPC,JL8=$LX_#,F')[&2+E9M:_RJ6S@_?+6X
M&*;G++),)8K"^T>P_3-7CA<PLHS/4Z@M+ZW>#3H[/G)/'S,_;JQHA><PT5![
M7 NT[D6HK61Z(.W"EP9C!4/D8ZOQX-;3B[+1&4[#<7,4CO=EX1'5\>DJ1@TS
MD]._>#;AA-%/XXKQ+!T 9Q^@8P(;3#^<_,OPE0N%6/J+6'9NM;(=D)XF7/9-
M(0N'0^$%U-<S*6ZXGLIVC-&J/1@YF:^J^9F95IC(YG=[(>ZV=A1.-1FG92)B
M9781@*V7>2[%%=7:IDOZ4A&O58Q^J@=9<-)%?Q' (9?1%DK!O695P88-LI0I
MG+*DG9,DI?3/^.T<JK1X+1B6I+S4$)S1NR:?G;OQG,&3;)@(;=0=LM"D<7_6
MFS@Y5CR9_-*WH7#1:%G_A7J"8#'HEF2N3VD0L/-.S[)0L'!86?F?>U=OP0:Y
MV<USBF ]ZLK*0O\9M-JP:!\4:7@Y[0-(T^>4[AKGQBWYY+?+D>8,WY:2_"EE
MP;_4Q:$46DH"C'VRILV9_EN1%C: 5A;0CI644Z]28UC60U^7S8IH17B-<I3?
M(?:;8]2-J?]B#;I"$USPHJL68R,XRJ/,9W@;7]>_)Z&TY2_3I%%Y/M!]3A[U
M3&RA82HK";JGT!'+AHBR4"[DBHD^*"O]=?1$D$H+0[?RCG)Q*@8X:H7_9EU8
MSS4J6D]WJPG_EQ7T$-+O (5#<V2VYN3 (XT9'*J]A76.X]4 +^F#.^*\(9MG
MR]S.N<MKRD,*C65FO]J@\P*%0APJ^9%;VD+/(R/;U'7U15A'=+64<KN0J>$)
M2QP>1[G#/FOP/P_!O_)@Z20CD(*9)4FKFN+TE5EQX/Z*P46T2"A_V=/K]2S[
M-R7O7FED][A?F:Z#6K Q)N7EJMKUA3IX<)2&MT]Y+(-I6U6.[H*.4DUPXP]X
M<2.C+.(@"[[\TC$%\F#3/$%<[\53I<PZXL]&FY0<'0/@=?!'.N*9*N)M3A7#
MS%D5PG63/KVPQ$=NV6.3TJ@+C^9;7,1B;"=#I*M)9H3 JW"%I J&3V"/H5)6
MU$+ZLKFJ;K)"235>HPV5^;W:'I25SU%XX1]71H#[EF(1AL=T+B+'_>P;D,_Z
M';*4T'81X%R1HY<UC>1RY"[G9BOWE)#O#-UH..IK-,53%91/()=LF09,?(SM
M%"QJ/BR$M-[#1^R5W6N(&I?()%;!)8TLS\4YH:6:KW>/UBWKRD3T7"LS<X@^
M+QVD:C@R(Q3:@-AI<53*?I)RU2KC9=:A+1STMO-$0S*C,;YBD91!W8&'PBR,
M]1'/',Y]R'RAM&'1@_/4QUS)MGUS*>ZKXWIRZ?C2C)X,+%%]YR/HD]A2X[EI
M*O=A_.O&NOTEO\YA'46&RO!\$Q_WV>G!=5C1*3>^U'Q\"9U@*]Q-+@ D/=U(
MJEF=-V0;N\2RC5E5_FV<+O[ RKANP A1K:^62T9HTOL7R*H)&Y]GRA(/0=D7
MH<-"\CX&;0Y?IMHGK#':AL<V']GV>U6QM>J<V0B]V]..@C^YCS$,@14V([O]
M,8_$IQN6!M+BV_TN$=4Q\SZK:XSXMC6L7A,([K&#3XV.+SG>1WJDZ<)Y65NX
M"Z7#6"6(<-'G6;)J\[4S2+UZKVW ;$.%]=+Q,',2M4E9PX;\;*LNM6CI,12O
M7-O3>=\([801(T9S61D:%5_6\[40F*K$]Y)GJ!#'(V5Y!!AKAN[]+AOMFJQ8
MVT)LQ"9J7K?_>.]#)$&L=+R9=D1KD;U\XJ12C7?K="J1]YG?[)8MZK/RH[H3
MU^_PO MXY5A+:!%$0C;88]N7=W@X8D%MLN(N*Z?)V^5;_VHW\*XW\%^'J";*
ML;6]-$%&'4UJ7\'YI)'3[R\6;W8V)"XI2CUKXBDJZ[WZG]MZ-UR%];]8E"NB
M72M$^C6"Y$US&*OGELSAC9]>S3$V?)>G2_9Y(#/_JEQJ[?%ZYH-DK>L#SL%.
M?C"B<94KY"C9T(^\L6)9MYB3PS3X"CL+YLK!O'_7W[3BF6C\>BM^QI$E#;["
MIF/KPM"CZ2[P_9=1F-D!1)U^G+LA_*3>I;S82:S,D1E(?6HGKRKV,@]2B%C&
MLP @^L%G\3;M\NV^M,]S:/?)U>-:OWL6]9 R"9MKU@W4@TD7&EB*-^LKCAK?
MO*'MU/BL.ULC4GWILQ%HEJ$B[OZUR\)QPY/L5\P>H>@R,AD"T7:G;(X=502R
MM."U4 <%C. 8OG:FT4@17'%%HQ*3;]')/O9&\0&^Q[6'=JE?IP8K8'?N5[.+
MPD"M>0$'SYNXC>1TKD/L!=4HO7+X"(=#TUQ8,T2,*_;0W@TD+/[,TT@:CX].
MB)B4EH#O14.2OM"<DFNHTDOK](JR3Z7(5&'G9+&*K-/T-*-?VY^V/Z$-200T
M\OM#NZD-(NA21XN4A=C3+1H:%CD4QQ249)1F/X_^RA&@/NC_G*&"B_8@2QJI
M2^/\7)2'"^-,Y+\>] ?+N")8U)H+E$GD$ D)%$P,MAU/^YEMSX^<M7?<?W[W
M9)-UI.-S5A7K]CFK2A#_A_2+O;&B="_F*[IO35AW68YN;2S)E-9=_7G7U<7P
M8D"(":S$= *WB7:UW\=>ZSP[;96YW]5GP@2?%QQ'"7=GL DT3 .L>1&21-?:
M@H7*  5,( &F<9#A 5_ X_QG^[]8M_7)7=&U-2=S'DB51R/%,Y._6(6^OTN,
M_V+Q!UTW_\6:)8Z?5_813:#B?B,TO1+ZNWO:993\<_&#>7H<+JEGQ?QX/80J
M4FDC(TRE'&7 E.Y@E?RQ3Y+O![I_?(CWVH&AV^-/P@=.]%^LT3?^CB*/5D.P
MNJWH(__6S)RF7W]4CU'#<_9'M'F?],5HO#5*M-#)",R#L-83?7NMLRO,\$"M
MT;ZPJSS^)R^$>6*-_/?X]<R1\"'W=9C#N"1(/KN+0MK_AWT*B0(DC7]M%<1"
MPRNX<^(1<]Q'1?[O$@AT;^7%$6<=_CRN"ZR*O6)C$1)>2<00H (ZEH4^KY2K
M):E&OJ2QXU<7/IGZ&#G4+"LX,\12-R99^^-NG08/4 !$.& KCD:G>6";2=M'
M+,X#QCASGG."TR&<B;0(!9-HA+*9TN O*@:0='N_&MKT?)-439!SP,C[)9L\
M-8W[XJ*.D<N+PW8S47MX>).^9,3@VF[(-%B7KQ$^).D"K?E<-WS3>'0$_XNE
ME_";XNT^\461PU^LZQ=OC6/-=K'5_F*UGL8P_+EQGS]/?OVXE 7_<##]-G#W
MD7%;?/U7-$/5P)_<C,FA3'7+7BN!/=IHR4Y2@6<\ZJ1)BCE-G-B*=,)C)(QC
MH8 9(:,N2DA0,#W(9U5URG559TY=LG9XOBMS<' TNM9F</ ^X8[REC@A6>GB
MWYFV4OG$JOS'DR;L!GI(XU:V]V(&5[[(E]QSD9G?\T))30NJC12:%B2[V4DN
MK+ G8=VC&T^60,4DX>1H<7"T5"2X.?&;"UMS_T\KB,F*JR=ON(FZ)#'UX+V-
M&*A?=23!?+ EVRV'!)B*7"=9CDO_.,\0M)A9-'+ZBUDO,TWIJ+CBX]/H[ZDM
MB"9;4E*MO0OBUTDX;+$9*JR$H:,TQ5.RY)3E*G7V!31%X?+6UI7LMW$#K &*
MT@'OZCE?A&#IODQ;2YJ\%_CJ!\=I$@XV>\JWGMDRP\<MPB"];XL1IAV04C,P
M(]Z[<! QQGGFSLCZ9'JH(EWT?CH&MO]H:/-9QIY9J.2970AQ3FG]&BCL?^0K
M9/\K7_FO%RLX?[%._[S=_,JQ^&N[@0>]=QODG3TS(.H\-4T]8@A:H'EI<=Q\
M2'L36D##(3HV&F!U2DE (^("-HGJU_+_QF?+(_(7JZZ\A<N;@'S2&:R7VCXW
M+N#UL>/)H=K,C(@#S.D3<7U+GBTT=)Y\64L7G1$KU6>LS6V'ZA609%3XS)JT
M0/!.H7VZ3<Q6(7EZ)R.&O^J:I_B3^OZQ5&'E![74.:3CAN3*HUC>Z2ENLI6W
MMUGES-6I,O+@ !?PL(=)D!Y=%U J!;MBKEW1[UK4+3V!4Q7-LU_3X=K4-R[B
MP858>!L[SO%8/.\S/SO8\6KKF90NFV^7'D4!SBE@'1K>065'C/V94UK(%=A+
M6/G1*XR8.FW+:ST]W3YRSH(%;OXTA)NAOQI@EZ.2FR #LZD7EP6KZ\!5<1(N
MEFF42RF!::L=W2>A*W,5(%"(+%C1NP)W+T5U)G%;/RDX-099J%.L=JDVR!YI
M Q/K3?U(=.M%')LNMU8*$O=OH A1M&5Z?MC@&L>'4^XB!,B,]G7.L'A*ZRS/
M/[;B+-POWU P@8SI?Y%A#YP"8UG$_(; &+1X","XB6#&"I6B>;GLGM<<[)7]
MA1=19<DS]WWE_84CV<YRX2MMI=69HLZ#L(B7P['#TI4QX7MZ54<6/.05(4QA
MJB(>%NH@M3RC2H#:G)E\;/D^L;#MXU&X[BQF+"EJ[MZH.Q")C,/=U\C_GL8R
M^FLL(\!MW(]5C==VHO$.C2WV('=$+)Y*T38F,EB8%=Q%Q0'[R$TGR2=YIO!<
M?F=OJ@X"D!TFX">U39Q*"]- )+)-BRP%CNB.V6Z.5R7G3"_93D6*KG"PB^R(
MF&LSE&>/91R#8Y>/J#%*-BTPR9$S8Y7H##P_,YR&&.:"O9M/AERJD^M#7^@G
MA=9R4BK8:,/5R(P&#HA0/'FEB?)$<E03O0B(3 C'TCZQ=0_*5W6((R+&-"SO
M$5?48P&*XAIXD+A^C;Q![*9_9WI?]V'VAX]B6!CQ/\E]:[9=+?/)P\*S7);/
MO??)%RIK(U[T-[>,'^LH\G[[4%Z94I.!,FYZFZA/H6<DPVDF^Q<KL5>3VB*R
MY2Q3R)5"&K;M56E'GGP;*UFLV?E90&GD1#A 86V08:9R8(8A1=Q)1?.8J7OP
MI)?;NLA *0WTIW@J7Q$J#S&#M\[4&SHX4Q/S=*H43[EI(9O\UK;@_\7Z7J9:
M3_K\A+,5/E=\BLV8C\%+Y;FNG;(R0/TX$/5Y?.@C=IPJQ]WZ/&?JI0V6A'VN
M'T8WS>M9*\41AUD/^Y=.I<+4NAAO7XT &P+7C&-;-XH(\P *CEH(,-..K13?
MQFA="CW!"R0;)/F"N2^,. 6@#'\H!Z!&"$!)K8<5FG"-90<MA%T@,[_IIPA(
MRFH\?!)&E4!H4>JA3<+=2@W.S/U'K,XMM;)T1[R<E>6.&< 8M[*.S<9&4IGP
MXK=VRGH!%E&+\V2Z>/;OXYL4HT?G#!&'4AWK R&3^K37AQ2++!S)^V]JCQQ>
MZK?6LV(6(8+]7DG-&IM#1AH7X@Q*;! HZ(1EIYG]/D>?1$VB3;J*<^C<@4E9
M,%]EJ1QMXCNYM5*[]B$(K*.2WEN<>I%YQRUZ9', O@H6=#WYF.XF7&M_RM3W
M_'*VZG>K7'D4<!,BP%$+\F(6K@\3:2O2,KT^F;7E08[9?DLGM$CVM9RA7E_&
MGX$Y*"MRQ&]T/A!;BDD;Q2B;C. @+K8'M>:3RC@]QPC@H[,KWHOVHT//1 ?^
M\'GU9N4=V*=G[2@##/7(W0ZXX C&UF'[*EG'5CP:IX="#@)B"< 2DVR]&?P7
M,4VQT$;5F>@L^Y,92>NC+/7J".<0E-[<A*DH/^V320F1_L?!5_5RR+?N?5K:
M@@CP2O5;^-9Y;%&LWA>X?"1&*HVF?&>,'Z));H+H9I^2 #/.$]HFWT6!<UZZ
M89O4CC3KDTW\3,NC&59[,>$$;1W.;SPL,C(NKU.7MR!@=+GQI@?3[%P65E)Q
MFE@)/X"4[H+5VGIDTS19&VPXXXS4F0W 3*SRG#ZM!?BIG?I ';]@6NO!!)7=
M6+&5J)UYR,SROZU/RN7W!DM_L4PKV.P1$&$590TD[%DA\ZA,DXHO^P#W;#98
M.I^QDH7&,8D%(KHUQG$;4Y(]U'YHNQE#))']6;X$ST/R-OI"FM"$_,E7"95V
MHS\TM!1G41/K0&;=,:04XU^LY(_'I1^O&&3"+@W^8KE_DRP?O/Z/H&:%WTL%
MG_0=J7X7E/@L@V0OZL]B0I3CC-.5!0K)YI09,X"#1_W6,'#A&0%V5#/!"PF;
ME,XN+.YI$<UN$C60X7U%)0GW-?F^]6!;5$E_0,1O&2_[+V%362+8(]8>Z,DP
MV-B7B)+SS"(-R_ 4[+1N=I#)USA'&;0Z!30CWC)_T&C=R*%%X2_6=E(IN[6U
M#ZC[OM\^-U?CN9VO']HOW6NK"QD'A014[X"4<%@\IQX='1W(8I0@/PI3#ZCP
M*R'OPS/-SW]#=WBQ<3TLWY!;_QE7C#4:\4/'(%4!05*8R[]8)/Y;"7?_0UK<
MN_\=!C_'^MQD\:0+LLG;B^\70;M<^IX-2BT&N8\!9J6S7SZ'3U 8-B(Y##N=
MEB43D.!%B2TH_WUE"[5$X::I10K)>>Z:2@RC]7Y33(\K(I$E742[V7'\9-^*
MDO' $3IX8 -500QO%?4.&&O1P5199C1;DW5""I=4BALS@H/ P-FJHU-ZGZLV
MTQXV8C"05>F?C&9,J[@1NW_B!P-NNZ]$K%M/@LZ^<"M84[,>G&1R)T-7WU03
MZ0Z-4VUV/-KXLLW.+[Y/,^7A<HJ09CZS$8Y&EC -L9".D59F.*-4A,H48%6L
M*@*&5%RI]Z_%0W=BT:@3U*?111V#WL:O#VW(^-$[3IBF-4<$V$^BW"EX"9=7
ML"'#@74V4;&;%O1/KE!RJPN'DD'*0.98UO./0 XQ/F6HZHE;W5!$;/[U:$S/
M;^@L):8.*E3A&?_^)5B?HD=$I;HU1[I&968VWP'4@TRQ;#[,?$2$03_ W:A9
MF5CZ1K1#>J*GG$'!+!QJ.NTT45IQ1^N'QRJEF14Z9=!WCDEE5;KR!6'4<" )
M,K[,F\NF?&=!&KC/*6+=NIG<N,$-CRB>7'(??Q)2O-^&Z:^%'.J9'3M>8L/.
M/1>\+GHD:IVWR([*@1V"9Q.+VA-D4D"^D;E'GZ6;A^ >0$.K:H,:8R<>+>ND
MBJPA\P:+M?&0"T"Q60$\1+P5WSO'J97N%@+V5VV]M?=*DMQHP$13N:U YYJ;
M:@MX.,/G@T!KW:D&&B,BSN,]!H8%\C.><U5I3?7>XPE&)UKNJ_AL!PFF;!2M
M^Y79HF6!\ZW-V]#3?>VOXYO&/QM[9"+L%0EIPHUT.Y.*1%>5X5W!RDS,+)^9
M)"^)YMC"MU;S_G!5E968;HGUNA45A*)6S&XNEK4#5LOP!)03S@AB),.Z].6_
M_KM'S5<[NO):$S3YKXTI,J"+>GA&+\LLN!-Y)9+*0BYZV!SX6@=1.+1VV6*V
M9J9,[B!1EF?)8T/X-9&PI/[31GE_XCJRR<>DT>FWK%/Z;W+J,_.'J*?1%YK4
MS+8*+A/)*$N^X%+T?F4$WKA@;&#S7%F2>8JEED-Z/7CU8*3I-4ED&:N<]70A
M"3GFD"U\B)^3*R/1BKLO-R,6DIZEP$Z8NY,17[L_;R!!;EA!89\4?IGIME33
M".3_8;A93S'SD0NP+M4A; 5UO<JA<HSF4QEI:?\BD7628/('X,]O]>5!SVBU
MGT%6C>6.6HUI=IO.;_K36(ME(PN.O_DZL(4%M\9B[#+JU837Y7"QTS",CD2>
M?M@PB7A^T43%/W^A(50(-N+$+'NDB0II-I))^ET:$>Y<O6,,F$< M4/Z5 =Z
M"$A[R&8&:/EZ:%U["/A1HA:APBC1K5C1)?0 +<S)^-]JA&ZL<O+7J[P+_\\2
M]4S.Y%^90$PA0^TS.FM;1)4>/?I?R@2KK=V_,BWM4H!:RI^SIGT7^&63)8!/
MIRJAOFMBZ3/B ^IN,L/[BEODLN)M2["0;56^6.]_'C;_+\[FIT8O>:2RAH_$
M915QXF[8Z ZD$S!/ESEP,U7*&YQ/5AA)J%IR7ST8D&JZNNJ_@-?(LU*_P[3)
MT#_85VB,/4^C'^HM!,<W!^H1#'&"]'D#??:^B+XEL**7SK.GY_X8*?5\--:N
M%&9FMV+ AMPV#U!ID=6#$KZM<&W>F)H[83%('M8$TVN%FJW:J"0/\'Z4@NXY
M0F VU,VYD>&#OQ)2RA03'YMY7>ON_^5,VG:99GR[L3D;L/.&6SGNHWS8\.?M
M&1IMQ20GKB1%>"1D>FX<\E-W8>_\6U"A@P&"1[RKK1"F3-0)K%<X=HYJ\@&2
MPA24@?0@:\69-&NE#__G%)G_-5/G:6_K'DK>CD</W.:]S]X6AE\6J)0;:6 J
MKV>HRQOI $BFW$Z/M$O^5^LB(UQ+Z(X#3BV-)&Y'Y5>(=$01%0N'L@JG%L*'
M"4Q,E9:60$RN'@]_U:07NBR3Z=;'0H@*3D<W5@ZQRY# A3B4->%:B(3TZ,'P
MZ%%9+>/^@(Z<CO +N"I)-,JS>?&M&CC,6O9#J.YK$/0ZMAB[&O(7R]@]M-P<
M)<R>/NC4S:/9LQQ%HZGN;5.S.IN<GC;_9B^X(57):#&CTA;D/#>@I3JYY>D6
M/?DQ4<,Z?XLD0>?'M(DBANI,W:U_BHR:7$)X64?[L-ZK&#-W-(X"*W:E)Q5F
M6CP:BCW;Q209EPE2]0F*E=J@ZG_*!2-NX*-+0;+OKS;E<W#J#($[6OG.=A(R
MUK?KRWC.UQ)64#)17^N9(<:Q#EI7"CJ2\+V?UFY(F3ZAQMD1R= P5?3^5>>1
MNY\I8H9ET=1 ; D&S>0)8]4*CTY75+#D2\Y7!),86M".GJV:5I]<!V[6\2+1
M4W-%D*G]2%L)[)Q""P5?5<H76A'N=$.9%51.B39"MDY)W"N Q'0G1DIS#>PX
M!N6*4[$1AN:(#Z.ON:R.3B]O<E@HCCL%>58[\"&_#R9.+ @-*^QCW?Y3QT33
MI^1=H0//?S-=WHZ\F/. QBD%;&<].-(]XDSF_4:_7<E5YT1*O?]W3P1EQ2P9
M+<>9'>B1K#),&O]0;XL9QI+)_[U>,K-"2@&PV* >Q'_PP>Y__KJ/X$EY&R;%
M-NHWJ3TP_>0QH4W=,%4G2FQ'/HXXVF=Y6$3R!O!X4A+LI!8S0VKR5 V#U7U%
M#F<KIQE==EPT#V>=<WK%]G'[1TJ\DYC#SZ\E;NWKC0F*.6\A(D$PVXGJ24X'
MT"Y<V@?C>YURS),M2B[H_NX)7\\:4CN0^<?1?A0-7!0<GTR_HKGY-%3@9N"P
MR>583DD<VAT58'B8U>X:I'?'WEJV$2_G5Z&2'X.I8HP%G&-8G^$ 38,UK62U
MX!TDZY(S)@7O#%MZ"Q(&V=-3@=?D+2AUP<L!(;<1VBISO-#+I/'EIYYGXY<9
M/:U.SO;QK2)9XI9N0E\/P]CSJ/>PFAVOA\R>UFMK3E/Q4HVUNWYM3P2+4#W0
M9G9T?)A/JDJ%U/]('(SC9-I=G2CS. #8_3\*9/SW#C_/\FH\(9 EZE<$A0JY
M^,$6XUGIX>N)\5W;TYCJ>%&H;D@]*S0PS3J;TQ;N$,<0V2P&_!7T%C+^ENA6
M4W=_A]J[>Z[L%Y>PN;Z<@U;E4:%Y'74GOJ&?2K$M7#.!%$(2X=(ZXVMHDZXN
M_^%0S*5.G:Y0+G *W-Q:Z_^*O33/>DB[&O:AUUYS6JY 6:=(*=Y>VXTR_H9:
M\EEHX1+=FU;6>VW:/.KJ@^(C-I BP2?YZ/QL@_*QM5\I!)J2-FJ\674>R:VQ
ME0@.>*JPZLBBUA 7U,U3T^1@FU6MAKFZ:(VE?VH2X^(=G'#*.*8NELB4WK[Q
M13F\85[8.C >,\<B9[B57J\*W<8/J??@ZM ":VM[I]F\#'6=S1=L'P\JA2?1
M&?N,V)16QK>5P$MT<2,1W-@>0->-C040&4L0HV5_X_OPC8+TW*$@;(AV'_GH
MH@ T';+4Z!Q+"0CR)(4 $@=H27MHW1JK:JEL2H^%>PB%1PCRN 5'V%5@@DLD
M8%D8*E#Y53 @@D-&"8Y(("8F)I1@4HV TZ=PWQ8IPP_C!A,9Y_XEK%F:5?/9
MOG,< Z9NMDYN?64J1M&S!0("_">ZW=;_*I%:\G^"M;C_#FMM_]]A[4E"^P]I
MQW[PH./AA_L)EP51NE45CR%Z8,RAKW5CI;QHH3XA)O;'TZ;UVOG"-SRA5=B=
M]G#]M87!Y4 3!8/";\#7N"6BTAGM34WUT9<#&6?M?N[G] /11/S/Z;SQRVR_
M2T@SMCP16DL@X7?N%JA!(,"V#]-N1 L94;FT@?/XB#@^_MK3UX'=P6^ !8SY
M^>+7I=<_VMBN,PWP]-P_X.#$B4CAB_)8*XZ@3>[O\)8OMQH^C@;9#3"#".EF
M8+XY&=X?62%"*TUF,JEP-$W3)Y5;UBZ3AWU$V6RTF8' MW<Y"6CQ5LI9JZYI
M[BY1P7?[Q!"K\VL=O(*\2V :>YR46ZN_F,^UY-6]VS?A,I^I/WL+%Y8]-$].
M?V0[W!&B4_#9G"4#9)YM/VF-?;/O6AE6O#T;D9P#>^H!@C4LX;INOLC )#6D
M>6472SD%1Q6_[>G1S F]4:_^= $^D\X:^&;^12]OS=YC<O6WM?3*QK-FU))Z
M'@,W\2>:I467C+UH(4R2]C=7 $*;O0C%-&6B)$Q_L%U)\Q1/6-,N51CE:*7F
M>S(P,'%C]2C_RGY8!6]MC<=W._/.*K?^7Q[UWQ&Y/!____SYR>M/:S3+!;YU
M_1)0@AM64H-ZH3)FOJQ/,$7VE/!TZG@UP\@E^58!KYU%A&SF]<_!*8NA'EN,
MM>;W]^!Z=D<E/9.*/%?:0##PXNYAI$=*/$<MY"]6EY7G\9>R.9I=W:8)V\.G
M!B=J*>%.65;#;O8R X0Y.^LF_Z#65Z8C#DN>VN06W2-%#S0;U)*M>Z[UJ$H7
MLFM,6_:!#="(.^UG >^]KF\I[O\5YI]/QI>&G)QSIA@]ENX_)!J-"_8?"BN6
MHQJDF;S.2:C;=]J&!7*9=NT4"LY=([*<:HMI6-6ZW:G  .(%V9T$24K;E96O
M;.&'N73?C#)%!ZQ3BW %9H>)M)A(HS[6YUTRNQ%D1&G-!I?"B^AU% ,'9N7'
M6K1KU/.'W;1X A KI7(IB6;;WY K7U:.Y"H"CQ#($6C>_*LB8?@/0HF!#B[1
MIB^O#NAUIS+.!I,MB(Y2WUR2$ ?1P.TY&A+R3V25JNG2,NOY!@6"K!A:7@VV
M1B)L_[7%\,KZWF3]M_:_; T$>)^2? G\]E_B[_\_8FU> #MQUE@'FS@2R) D
MGCN:J'<T='_/HS[ZYUT#!8>:G<7JP9WR=%4X%0=X!WY+((_Y G[B3MP*BWT!
M%=UP!_^)&5$H_<F:2>[N $R1+)QH_^7.TQ[^%^M"QL:GS8J/<'R:_>JWPN\X
M5:N,0%OR]W3[:LTAWE_FGCW6EK:6$W WFA<3$N!-T>H/"+?^>@C=*6@IW[CL
MMR^$52N'O)YOR_/DGGX,E0.R?^>#DYN=2-,:=M^XCQVG4M)/9G!)TNZS]:P^
M<,WJRRX9=+S'B9Z__M)87ZCE&NK#F4VUP"2M'2[)L5(7?3TK#=SQ!#IVAT)H
M%7NK@+2,8W-#WXM!0M36%KES%Z;09,O539ANZ_"Z(+(U[='\-=TNK\<5:^U&
MUB[YC$FE>FZ>L?&_L,O5AF(F+*#_VK0KJN;7X2UVI$5\^5Y9:@$V0^LH8W3^
MTSFX<^1%?A7T9)C,.?\?X<$8^<1^@KK!";;LS%9_)H7_FW]]_B<+?"$QN6+^
M%RLWYVCR])[9I??JY%=(^'S;A K1L. 7?HZ(.*B29C(?R#V!)>J @@:/3W=4
MQ:HYM"S03N[G2JGW5$LU#TNL3*'/;JS-:.LU1M3D8V0Q]5^LXI(.)MYJVY@7
M,,-HK^Z%S" C!P&#C4K+<4,3^F\1JA.]66.6Z4.)V">NJG(FS7.(>&HQ$3?X
MY9-35># A]N1L]_OY@:CGO\T5<DYW@FXWY/EAL8Z+U[V$[].O9;NCQEA*A9V
M;,EZQ)Z]P,*V2ORE#'IQ^81ZKUU1%++="OOZ'4M(>*#7%+-IQ,>SJ9Y9!PXN
M WT=\O$)X!UH[^@1W:]2?S4E7F*VWXS'.Q7FI)1JX(.?_"E-@"<-VS;Q@R\M
M>[4HI\Z^3:U.&C)R([ PLNW_JNXKH^)JUG0["H$D2 BDT83&W3TT[I*0X!:T
M@<;=.[B[NUL(3N,2 L'IAN">T+@&#PTTEW/.=[YO9NZL.V?==6?=-3_WVE6U
M:S^OU?/NVF^YGRIQCGA7?,C+]D@=</X'@9"-*5(_SUR+69"J6L=)JCESN[A4
MC8\X6R8EL5T**L:X0,XY@C]/ULL*!/T!-I:E6X1AMXD_AL#C<BW0JKE!MA!\
MA+B&/\4$;+[!0*GVW] G:5/FW@YN%;=&1U  670_-QT\<::SK'<)ZZNFE02M
M.^DZ#-;.O&4UNN]-ZL$R76@767S?A?#^D-3\@YC8"* (-0N=)(L7?71*3.0+
MDF?CP%48ADM3)(<:Z0;KA?@CE'3=0BW..F(<R]Z?3B4&6]2LN3W^,3:SRUT=
M[,:D)B\\5N,M-V)*MFJR(@".?V[U\; 29;MH_@L$Z.96F\F_P'TCK>^9]B.T
M.?E@]);G=IZQTMTR+**A#?9J> JO/>)XBKOI#,$#*_48+^8-[O2Z%]":]!'K
MI:9F)1E)Z_TZ-^7QT+[=;6-.O8AFY4%7JYE\3-6V25;=HP89*[;,R)@T5&>>
M>TZI'/)?Y7(/:"Z8CG6K1&QM9WP3DC;#>K_3LTWZNZ;+@M2:?CU\K$62/+PB
MAZ->XQI-SK+'C]]H.Z$O4B,[T6:;S=?ASNAYZ4+TK')0O)L/NX!,:@/X#72\
MH#RR.,$.SM!PBG3L=1HBF!2:RI$C)X0K35+XR?,)@YZT1P]]63GD7X*XO<YK
M'[:#X" XM*OPX-!B,-JC 1:&G[.7= 9[>0 >P=IY"A,S-IR7B;E^CIQ(O0&T
M$[C< +*JR&BI7M,I?F/HZY%K=;R^G%:PDLYL\SRT7A!R_FF-2AE17V#+CV"I
M=.M08,S67O-:.F\'_SF<YJ7E=W!!"SJ#ZKQ R)**U;L&GCX\/;;TNJ1EU)O'
MRT2-SG.3Z$6W!],LC<1>'Z.]<@^])>D _.1.M8/_+%B19':ESHO[1.-8[GLR
MOG+]8(+>6%O%U(#:>QGW+D;9MC&C1TLJ1\WQC@:@;8T]NO1#KA1=0Q@C1_I*
MA\UTGE>A5V_P>#.C%U) 7KMAFI8E]C.$O!KK^EC$TO!*SST'OR[B!A"^788N
M: FO@-T K,(-&1:/.CPVMLQ2BKS6M@QN /H'GB<8\258.MX4.>;C!6Q>)>Z:
M8GIBYA8;8(;.-:VMU+CQ<L DI6B1SJ:@&N4I#1<%T_3+%QVTNYOU9^?*(0_$
M:;.\F)W)T*>< ZIJX99H@VAB>$ZL6\YZP&D(.)?QNG[KWO;DP W@2@FV%!ES
M5E'?WHD1F0?WA&J>#?K^^6"8#2GX1!.L9H+Y97U:=*9+,5;B(KKR@G/T;:N)
MCCB?UB]DLG3W3Q:(@Y%:< "E@!WT96LQ]G/E\J!8>)RZ:=V(L.[C&KB1B4T.
MB.L7D.TCT9V"ON^?+A&.??O4FL</%&8NA:^N2P:D+^VB<!OM),9A0G67J9(:
M5G.@S']6S+M7W_JMZF=-%PR[[?KH*Z_>/.@[U07$=RX$)G[" ..-.6=X-O@Y
MYLVMKC/P]_<Q6E[7M?$:BFU&/4!%%#:<%<[+PF\ <I:L1PTE(?V-]S<@T!<[
M%.\?&E4?ARGTM\UQY,IS\#^:)N.QY.LS(>3K#8HZ^Q$G*Q_XW5S*U#P?Q*:U
MKH44U6:3\6X&.NTLT<J&L2KL*!WO3X7']V47!.>XB.['Y8R3]XHW9^F/%$>\
MQH*@'X$LG^+7"!(Q\S7XO*J+DXQ[?'*^.<.GG-\E5O#QK6P":&.T.>?=Z?DE
M$D6<=,OO<*J/0:/I8&7WRYT7&E-SL3X^K(MM%>,<6=(423G&Y V]*9 RY:=?
MA0G,]_2(>0SIC_!M6$:*F5A=!FM4QTXRZ:&!HS)0%6PD#@C\%M)F2O6ONH.'
MP88*B@<'Q1WXN3< P<81Z[VLBV3,!)5S#5+8[?BDL<[EX!/IE,8@.9KH#K,'
MLH:OBA,W->0C3SB!"4>KIB(] _'%=0^)^:)KZ8OGK@^DKVU])&96ZHPU7KZ&
M-D"]TW5F6,TPRDD\BM+5S3@>3";NH7,Z[SJ"@, \KWY#EA20RG8$?9#36O)6
M!<2N*#USQ-%88&%%(E$M73=X:*1(7G(XPQ;^:X"IJV@)I+"H\K;_F%A?4'\G
M!8^".1Z155F7P@PY];2J;$ECJFWVT8"WTQ(A68[0%5 ?M\Y)J$Y'&0%-&(T6
M31P!B1_!AXC-5^&L"CJ)\+0RQ;=E"J+%1<"T-/3P\+ [4S[HF/VH\](0PW /
M/A_8@;JR^56&!#/D/Q]&G=#JJZ+ [DG.1#B ,=26NL^&H,DY ?.%?Y&U3Q;&
M=WPU_[JQ-VB^,<^R,TO[>OA5.:\- >+/(C-S^BO3OV9^= 8:^%X8D5;:Q&WA
M7=5UVDAVYJ*)P.E]EXF/UC1D2__& WN=#V@N.&7+^1]W2CJQ%<X)%6[$^D+W
M2P,;5,=>GEX4/.51B0W8"3K=V>P.W8+<30<R8?LWRR4ZER>'_<B6?^":WE0F
M;M_X."$)"*09*E9,*SV>:),N_MT[WOZH#!XCGK)5^MA$:W=Q;T87F?\\0 K"
MTL"AM:E?E&ET?*=TZ$4M:1HML/F#>*4"P^OXB^)P:.DDE7XT,7;I$&W   $!
MY 5&8N"6A=S1ZOC@7)PQ9R!RB:-9QRL*GXF/4AYHYV6>C!<<)N5D$:XH$K#B
M/JB)%XO()KZ^$CMCEWCH$>9^Z;?*Z4QC$B%0^YET/5;YH6GAC^$. J\^EG^Y
MU*.%V4EA!P8-_8F#=YSA/86874ZSVQ,_5R0_;H2!%;WX#=!Y%6;6><B\?_0!
M<]T F&\ MR:_\E%8OTEQ']R[C)-Y?!3^2@\!EE"?P'"?AVF*B^4^H11-TEQR
M2@8[$':F,FGTS2YO[(DJL,][6^BW>A)G7$SF+'PEK=,8(U_YYY0HBI9884^B
M<7]+;QPD$WQ:GZ6,O0$,"9]-"*/Q\B0O/L.:Q;+533W];V6O_3I@V8Y'Q,ZN
MJZ=KE13ES4.UZ[WKY"+3USBF.XH:EBV-USDWHQ6*V@EXQA=%T5GMPUQ]9ILU
MX\3(4/\QW#HTWZ:P\1&A4_01DHNM"/GE>BV>[09P)[$)]\.I2M]XK>1K,V(/
MJB3.V0>!.]_73RT6J5@S=VCR?YV/T,;OB8(<#H(YN&:4^U6,=[7I:Y9+;?E)
M'S!IO9'&TT_Z^)D@643P&(&7P_*C;@AK/-EA09#M_ #!M_XZ"#@IO)/'BZF9
M(9P"*>)&]V>#:X>_IG&[;P8<A0QKB9!@1R<)^^?+RIG'?'S@>8'%.@]6EZED
MB7T3#QFM\SM!N)'0]+:PJ-)F+7-P9N';KJA1?=9K=S-NQA>E[?K]F\2T&I+I
M;EHL\:2VV&2,RQPXH!+1PMX3[C[9[:+^\'$_$LM_VQCK8GAE\=F$"&^;:_$\
M 0C$OD;ILA557J(7F$P:70/D4-2LM,.2E8FPC] &D8&#[B!0"C]:%0L3$NU"
M<O>@IH36PXF9;J6A%P3G:+3/W?^J5.=?:L;#A58SA/GP_@K"NACI@$*L#X8;
MSW(OBZ(]YCMSBMHSJGS>3-4VO-D8_4<?JC18T@U@[@9P*$91N4![3H6R"U+Q
MN)#&KX10Y3%MPX"7/>6YN?^MK+ TC3V&XAOO?L'K.SR++]>N+E_%"E+#U >&
M[ +V578:=:+1U[Z.W*41>WV9\;+JC)SM#9ZU_)Z"EM][:VH5A)JA:_1-<DG^
MO:+9!D<L-P 1SZ!@BP[?*;UE8L;[$Z"HOI<QA2J%QGFJ1=_3>,P)W *"8@P$
M*Z4'AE(4[CWLYG2E^8I%W&\MQLE%NWC_L3 A<Y%]7K;G#>  142Q-F_^(,VN
MA-P^A]_6'9&[\*;IU=/UG47V?F&0G35K0H4QA#.VZP)FH,A[@M]@A]O9 17B
MYXY/\231N<,AG>@0D";<V.WXJ"#.SC2R?S@^X2TQ7LK7=;-+W++335#PR 29
MC4K]K,@9E?R^=(FNW; JD6M'Y6P4W'36QHH]A;?G+O6Z+!>LX34R4TB@HQA*
MQO[PU3/>EU0,S;5[_F&$E_,D'7?4>K<H%>.)$MBT!])KAFBS"SVZ4D"B[33(
MI$K 3LD<J+/E04EBI1^PU/Y[UJ-:I[7$EU^<I@<E0J #C"4M(:!F!0>8Q9A1
ME&:,X*O]\F;EA&\:W[(]4*9'.*_DE^1MB1VE,W.BN:-S^G6H_HO?:/[ZL"+)
M7D1[?CYNB/T&ECF_WN"*N!J"6>&U:&UDM5Z@=6=;SB>?0)G-GOK\$5<N4BX,
MKZMN +<19N^KH0.&[_?[C9S$MSCK#FC"RI+#G#:%%IQ;KWEX\JGC.+/F,C3I
MJDNM011Q P!;'KWUG4=)[,V/UB\C/F/6\2?3&T(W_IS1'MLA]+>UO>%7=K!W
M=90F7_])"$9[N2%O>=0'AVK$Y'KP_E$Y:.(ORRE6%0P]RV_C;7-<Z],[65:G
M1;1SIFC1-]=DFO$Z?8*I[RR^/XE:B4IY%CF_X#[B\/5H#9_@@!RUK).=CZSZ
MJ-R^N(+P3.:,;CY NO70V/VKR>__N7"!!3.67:Q42)<XKO6'N)_< )XO>.^,
MXU_75!>\N_,V+W.'"*GY&?PZA.&%&"<_H9]EC8@U_%NT,^/(6'B;!**=/XSA
MHYYUZ(0V%PL0Z(E\C?WOR]Q1_[]9Z/T#X__?2Z(_VBME.PGS*QZ3/+%CU:TG
M2C-BVJZ\#0C:GQPBNP?EI3>8-+58GI$IR,?T[JVL7+=8$$\SR)S9F-H>0I='
MS2ONS\NGAPZ1)R:(NA_L$_+_V[(;./][V8V_'IJ7\CW^\G*K*I !C+ YUA6&
M^)IUPK$669P0BU?7K+N+7MO!\*3:$-$_LA170U=5F.E;+@?8<_W)WG0#(/-F
M<D(.,@0Y"5P_TGSW&[E$J__@-L:XH]4-/1!:UST*F ]ENE006$[]!4.GS6&>
MZ]ZFCMV&!LP)VVI$5\KISQFYIKC#K_@$V'^2Y'1HR91GF'I*W@!8#N;?'&R*
M!N&MUV#6[GJHQVW_)6OU\U2?C:)3_AC;MM"])S65\(5R>\<092E>*4<H5TRO
MBG6:@6?LSF.0O9$Y59T7HV "*D][A86)W6!QP*A_EDKKM(/I_JB,U=^)A B)
M!/(=.?+_ -H=W-9L.][P'0KH"__!Q^*/]K,3-MI)C9TH!CYQ:15RF^S&HHH/
M0'C9<,\)J<0V];LU6A>[<P+V@#:_M+R!R[$ EAJ<E*;(&X"16TQ27_PC]ZT-
MXTT/HBGM&I.%@P[JN"@'UNR405E>!9(:P0TE6[U\KK!W@=6TC%Z$B:J%48&9
M G7=@ST&O5HDOM(S5P,B=\X]AW+VN @V-!,6TB$MO#*?,O9LI@4#]ED%FW%2
M9LF4/HM4EB[/Y^JV.XE$UVUHB7 L9.U'V'W.56DP<0*8IHK='42-Z.CAMV?*
M/1OX\:L*I/HYLMF=1&2CCS[21&!C/+9A$/L/@8\.;<G[7)],?R6BVN"[J,BJ
MZ^1:G@O83Q;<L,7X)I_9MI]*Z@S.2N;\P5Y]S3":-P#H#> ;P+75/F4!%M7Q
M7'!CC4BB.=,WL+SL"G) 6.GO]]_[,>@?R1]'1>\")RGN,K4UB<]\+7V$<SK'
MDMGSJ%PFD5$'UM,&$X_!TX[D>&MRA0]K]6@=ZCVV@3KLBY?6AG'&#&-=IG7:
MG^ZPCO=Z.".$AR/B<H*Y=WZ'/#LFR>/)7CH\G#JF*/GTD@Q'L]A#M;A8)UF6
M(P(K%CAU-,S[ZNN+_I^FCWCMUX6@)%_N"O>$PLF$ZOQ 4[79&>_M/JK_G1#4
MYH.Z3EE..!'>\KXO])[\RBF$43_,S;\Z]5(X3ZW>_@?R^#"K?<S]38:"$6'^
MK24/OHG#_L'NOKX6H:</S;GL2!+#XL41DI$RYL.T  B!1^D'"'5/EY"UGO='
MI^<Z:RZ<+=I!'BDB0,]#%";DJB]!_ZN@I%:-*35S2V)/]77NAI<2HG,S?M5<
ME\[9E=KX05P[XJVV6Z,JJA*D3$A(S<RB//S2T5[ 2NQ.39]A[_@S/2J_W^>A
M!P2H-'<2U?.<#63.VV!X(7^?&Y]"@5/]V:XO=B2^=S:H"+#O&VDPMZ'FG\H4
M4"9'04:8@R"*DIK#M^[*7< GFJ9^VY_A;'1XY2?)W4\8()_,O<2DL+PJ/5[%
M!IE.0U6]_3!W; FE:"'HR7AO;4&'C*JG:])4>^+!'C-REX]KLHZ_4JJ)F>RE
MO#_-?!WUZ[E=(H>(0EU1\Y8PXX1$)X1? %N1'V+S?W $X$V>6Z":+A8:,K?Z
M(F1I/$?EXJ&PKOJJW.7ALR8RN05N_>W0>AN;L,JA'DHJ6=-E$Q/&D-H'C\1$
MM%+O2D9[_?R9%Y4J*O^R28$%(L E7D+AE""*"922/4S&+4W1/?YBA^,</3$[
M[V7V?'.-9MY1QDJ5G1S+LU_RF[HW3.289M3;@0_*84JKR)BN]:2!J?$;>66R
MUD;0 33HD14+ =!QZ]>[ Z[^;TH=49K11B-D'!^@GV:YS,-MTGDLQ^*#*W3Y
M%<D^Q+/.-QJG8U-G$S<P%L:[T_]]1Q149RK7@63%L"7GBQ?8?+DO9H]*^P;
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MI.=0Z9ROKE*T8WQAE?OLO.$)?21&A>)ZJ^5W6>U<=%=K@6P#0\4*C8ZE8A?
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M1/C)J$$%A:F@UH]:(MRTDHUP4$@:-P49<YB.RWS)+$/*O!B#8Q!;&DK"EFQ
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M6\9)IGC9@#'.QYP\<8@( :Q7]K$_>L+#%MP)8<@AHF@)%S #4GF*DP5$ZBS
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M6U&^&,QD FY7QIZ@E7XA8J8@K4YD#>%2HS1H#;H>/#\,)P0:-O]C@PH:!7Q
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M(M<9']&ZV37_6\[W1C.^*H;^ET<LH["'7-I.5+#/\=G\?/UO3,#+]Z\X%1^
MLJS_4H#Y:;S<N.Y,OW( F!Q3K=\G\2#MQUTJN=ZKV-[RNT'@90!FU=_SIXZS
MQ%KS \;'&XY7S=SW%/,+\LA7HL)IM9W$$AYR4F/>-XY[!W\9T;=CL1BMKXO*
M >:_/@"A6D^V+\UWLJ4_:X]_5/PW!"36!9+_LOO*(N;U[_#_?P%?__X=(Y#/
M*5U!.^8ZICQ-QU*:^.)'[DM[.6TU;Y\=>RF8@JDL7',OK2Z48M/CJ#0*Z"<H
MF"_HAI6VB3.2INZ.CO_+U%G/MN'<F=?IC$XPLC=890LNDGX6WTM!8#(S'^U;
MI?)N+F_XF!J3$*-C;DRBI.M?Q<'_IJ:E_TSIU/\LSFG$O\#](Y2T2>5P+=R+
M08+9OW5BJC1T_)LJVMP/".#P56CU3#WV=&OUDH.&P<DIQ:95*3C%"M$I:<6*
MH7&-9S<HY_?/!@E5C67D%=FX&;O: 0T ELF?]##TP?1W5JV5B^=K2SO]3F"X
MYKA".H5Q&/I$CX.65\ KB)51OF+5,796\TE]PUQC043  &N>:8M9)+B;A<AY
M76.I6OZ1A?D3RTP9RH[?0DH:C/"P&F9$8MO?#T"$9@^P5CVV*]>FGJ-KO97,
M\5HOY2LV^GY.#['[AA8O]&%J'L, "<4EO(A5\'_#7N%_[BC*?V_H?X?_[_#_
M'?[_"_C9-5U?SQ)^$QA!CDS3W'X;\.T\ 70\3L'H/0PM'2>]VGW@VW7A#X#W
M6\=1>L=OM+ 423N.OR4P6Q^ AZ\OF941NS7XGM:$[TM^DV*H[Q\ KH/*+H*H
M$5DJ#LRH?V0=->;_KHGP[@5:9XQV1SPI&NS;9+$0;-Z:7WYY-M-*&":.EPWP
M4/I&7#%OIX9;-@O?D)?Z<7I*G!,4EVAJ(%[UP@9X)U_^$AG^MZ)R VO8$;K_
M4\L8B"7 JZ"ZEL9Q0,OH82AS*C3=L6\L5,*J5*6ZM:S.J+?;RPS>0><6=W+@
M4M=U8(YP+_DT%YSKOF7N/BTY<LW">HHET,Y/PTY/:[3=*V"WP*SLPM>4DZ]I
MKBB<"M,;9AE'M?K:4??W4:Y^MP>G/+V5NA254Q"KK@Z=HA8:\1%3.$*S#A2,
M6E8+,PA+@B%7)4P(+M\1C<&WD:N)-+ Z5W_BTF>3@?>T=VA8X_BN'#:29X6.
M3!202X,^D?,0#:5B*3))H)>=.D%F_OVZ=DM;M-TW'JF<3<N M=(.EA6I"6=W
M4-QA#=*N( 3*2M=A0M1BM/=JDC+,-AN41Y9RA$L0?H*!(:1 34(BQ#:M>$8J
M.4S5G[];>4N%2M:.I8I?O.,Z_ELL@W?";B4JO;T</4O,G@TIN(Z.5'%F4T%H
M4#Q>7J.-95-/53!.RK%P6FH#:N4"/3L%I/0=]HEM:00ID<%,E;!8#5!3V<M-
M IZ;4UI0'7#7P_QP^A'B@]0"@$1],2L?"S/Z?-+XE>:IF-&R_=/*!.793QG"
M=BKV[9QTVK7K=3/00;6RO\\FN.GC \,,6C92H\:Q-?'@P!1P#+*T8LE?1]A^
M]N('?>G_M1:I>Y!IVU YQNW[@[12.4-4&#=CX/Z<EQ'5D=:!R(/NN%XJ'7DE
M\[>_V@BV2F!*LSN09=*J6!W[ =:-'"9_9RBN'=X%ZO,S_-C#$JV5;5)3H^KY
MQ/-V]$[Q#,7;@2[\&LY1K70S_VM;,U8Q1WF.T6,]R@99;]%%H._:^::C"M$,
M#U$O2W5@+DC%(%YD):\<LAUKJ4/Y6%L*1!M'2!8)\_34E45-*$Z/I$R/D" /
M1N DU%JXKQ%-5I@ZG_-5L>D$R3LNPPA42<2R)/)/T&K<.2+]>'N?QFGZ+6GI
M#,<>S:XB$!R^,)\:QX)<A-UI6R=H7D.L(KFD<#)+P,1AUOD26A7;(\P%\(LF
MJT'Q%;YA('$=A&T:"V0#DOA"!RQ)6U_*TPQX+?"4$2U <#3;[6I:7)15*FC"
M:(4Z*-U$]N^K/3;M,1P\8K@$N/G'24BC/V-#_J;-TTF60Z#=5^)+FP5EUVJ*
M/24WIS,%8!MPPN0H)TP&,.-[)YR9HWK!@:/>ZR_$-C"P,"E\G"%%(9SH@<,D
MDP79;5G.1.VX3C*Y-"J8U;<<;O"P;A5W,XE2UIH^>TXN DRTUU%AT3N4,D)<
M]=(';=BYG(=H"CA$^?J2.WS:RP9W79HK[:L,;EVD8RYH$OO!@ A8S&2Z!&89
M%T143J[!\2<L@6N!*YK+&M7_16^<Z$JUO>875K)'^+0,R"H2$BR=&TO7*%AS
M 2??S'+T3"@$6T$GRT ]+3_*(@<*D0C3;W> P]Z7.Z<68A#3IHV+MZA$Z0'&
MIU7,*PVI'R;;V[O=5F)J.VMV;"2>3^D),IV@3G)#AWTLH+U'@)*A?N1AGS2>
M)M%;;\C&;.9:%(-SR+9P'<R'M,7L3+CI'!B,6UQHG JRM.F/9*6;FLWC7Q$>
M8<3>_8!Y9UD&[_?1.K6J9FSM0^(EV\ VX)1I7A9+7-Y5C436H@BMJ6O8CD6;
M;SKC2^=$F\.BV8)!%1C\5@.:1:;R8IN$$X\6%L_-LFX[AG,15?HPL$FJP/6D
MIBZ@?XJ@4%JU(&6*4P)CE\:!DQ/_$>SI EPOIULL8KL$;89LB%$?^JBPM^'!
M'FO=4C.+GX9=2?=4!JQ)=_PU@)]X(_I:07@.'=30KP/HL(+!4Z^JD1#XZ4)(
M359V0B@\(:\NVFK?>_WB2?M5<GJ[D+JVB)LY1,YS-GNZT7XL0RT]:]V08L+&
MVB78_WF)&4L(M%/B>J[34A$%H5T*]OQ)EVGYHXQ;0Z'E#GGP!E32NMR<BSHT
M_.6@^UL;O#),;Y-@?"+0<6B:W-&:VM'!P;1-\A"ZEVM:C"7T5&"3)GG"\ZH5
MM#8VS*+G_T]7VL6G350V@T'7$P%ME]5N)PBQ9,[,JE=J*V7C:NX^W*D;6[G+
M8I2.5CPDADT57O+3BNZU*QN@=H3J2\NQT?ISW'I0$8H!);Z!'MRUO":8V>V[
MQ:FN#--YT8FKR5%LC]MWV9$Q-1.NX"!VV';]%$.>[#R9'#_<P(@)\:HQ!6+7
M*R?+8H/R+KU%AE6(C5:#K*EB2FZOO='D" $,S =@D<6*#7/>]E5+JN;7E5XS
M9'/*('94IY>7Z$<$DJ.E@^R=I8E<Y]15/6O]N8NB8+H)DE;H#UB3Q&/ZZ'S;
M05?$M.?\'1]Z-TN;]I.%YT$M][^9"FDM/0*P;Q'24CGC&"Q&B8L8& 3S14-C
M^H>G"FMAX424]+?.OV]>F7^]H<=\ - *D59W*I;^/L:<"6--><KNV)\U=NH-
MZV5NN;1L/MM"SK9#2"64)-N7GYPQ?\74]JC,>\DL;Z?A^J]K)#X,XTVCHFDG
MA_#S\Y,5:7PN!-V>#^WL&Z04O%KH==:FQGZ/7QCDO-M]:S9K$[<2$,_)30-^
M7LZ7A01ST%8 9I0+Q54Y8+ZV?T7Y $!_(?^5&_O*MT6N[0$L[KY2;7E)6=Y1
M2?BI/.MQU[,EV;]!%0:7S!X6?6,K+*162EFS:UP!M+(V([!4$$+:+$M'".*8
M("&$\O@*W&Y],1KZQCC)C<5FS;/VVF>(^ 3DV+MS:&<1$CS78I:L0"3.P8GC
M0,I764##*#MNKS;JO-TQ4M;>3JH8H>M\CZY8T3($+;CU:#NL^$DV<*[\,$K3
M4<\@\^A0)3DA )CD);&V9UK;8U2Y0.ZFK2/JK]CRT+YGX/ZCDY(XJ!40<+?G
MLU3"=;4,&@]Y1E,^ .)CQ_%+*$0@Z#1E1KO%<B6\E@T22^8VR)T-+>]E<3[P
M<]L$ PFZ6X2B56V,AT,:BW@Y2VU]Q7C#5G>LHU*5!Z.!(.WJ3G<)9IUR.9."
M1'*DP3@3(D^^4$VW+J0T9R78+6ZEQ#1B+S[D:MCU4<DD1/IN%IZ1]X#9-$NF
MY%<V%&.<8@L0):4V<W1#JTS35P<2]P=N_B]6^F3[HB)VF%Z)\E%'@>U,&5ZU
M(&=FS2WS5F^[T'K9H5"5G)DXL[[4.M1.\N.L'#WLGKWAENP1<B"N4-!)'&EM
M <<UP=7?F1Y*VO]EZH]>1<G==VFA6B\8JXUE+.KA'EDSR>=4C2 @."]N28DP
M6H5 ;)X:$0.>X@-0Z;?;[Z5@N,Q9VQ))X%(G;GHZ0,+^BB9]2@,-18$9\L\X
M#9"[S?\>=_@?;Z&:TWY\_U/>[!!Q-2M8'J^8"%+&2$0;?N'+8B!! A7-F7+'
M<HJ0VD1$ZNR+>'_RK6'*#K+J6-/S296Y:CWFN ?_>D/?1)%_<KB!P#J4'Z3*
M"34X,8$ ZT4M$G5/,GNL+_1_1"L31(_ICQ*W<FN49[<H;]#;-(?Y,>S PFS(
MV@CM#E@%F2 TH4P8( ZPL5':^TD?CJAV(2\R$J6D,JD6+5O[6H8GN5K%,\6G
MZ6]2RJ-@A$ELT2S&/\J>PCS*9EBW7J(*_9"G)H2U3D[>]DW4F[C/*^8N)C"5
M8&\FT@EN54(<;D59R-F=W@A:?:"P\45L_Q1K\  AO10-!,]*O_QO0/_;;R0@
MQ):JC6P4,X%/+!?C(-; @D]CPM+177$"T4$^&<VKGG\!'UK+HGV;)TTI_X"9
M?HKBV=]%/+M0,TVT8\)H+I+'7GUWU/N"2=E1,B/5,-RN*U>(T6NHQS&@*(/)
ME=TNE!AM(;_;V^&H@S[?[3Z<FK64YM-T"F".J\?<H_7(]45\IH17F",&G>P4
M,61#N#CMN9RTRTHG^HM<01UTX9[C@UO&J64V-<IA>K7YE@!=AT(^A0R]11B3
M\IV6!G*741;X\K[7R;#*)69H246'U*L8>=T.?FK-K@GV2":L]<D;<Q72" IE
M #4K4%L]JEG7MQ3/K@F8)@_C[JNZH+W-XBUG-8SU 1%PX:2 U:!QT^G]VDSN
MTZ-,X=\B^AIGS]!2(5>XG9K/0W2:A(M99]%PM 45_@)^DA!4S[#?*.F^,;KK
MIQ"?2T5[)0 _#F7W58/XR\'J%#R"HP5 PAXC>O6DT8R<J37#:&1]1_!/U_OL
M8,2XUZP$E![974?E95H')(=]RV;4H(SCNJZJ2@?-D">&W[_=6F..R-Y2\Z*(
M'LCEOJ+XLVZ)L"UO@\)L _> H-QFG\S7QMU+^?DR+\<@'GFLDFD3W.BH<XR8
MJ;,:5MG^G4.ZJC:@V$]"L]2&VOZ>  $06UNG%;ZM$>+4VG<-PQ4B7*R;I'K6
MJ-[ ^>[WZ_E4J4"P'/9@5HWA(A??6=6E7=J:7VS<B5@&K:"\NMA&WY".<;[&
M#@QT1VZS$LX*.G)]*#\%I_*D)!B$J\A%V9XZE,MP>^X)D0"7-#9SI^%HV"6"
MX_:SL%1]].WN'M:%9S]=I119IF];_(2-B\O+^TF! 1C112A,\WP3=I=SD? 5
MZ/TJ\UO:HT>$FD9\[*U< [X]#4ADZ7(D%47P/E*K**_Z1J:Z#7\7"J.Y'/&-
MPL/5T#$]N;*.R&$)LW*U7SX3X;V< IK$>7.XNUE . 0*(*'G^?D&+-&JRK<O
M_]*8FB[DAN9#,&[&B20\V6.WAXK,,-4P:>&5Q;_S^Q2NRWF43.#-4 9;CJ+"
MJEU(M!J%Q6!_=3#A^R%FN\Z70=T8&3QB9+E\#C%(C]B4B=-%UR7(D^!NG:*X
MKB:#*-@]O0LHXMM^SU?2PW6'6!USK8G+#%/RN GEHK>.N^/K!W^^$:D2O15!
M85Z=03BXK9B:G>]U58VY@K/9,A!;:%$C,W.-_>45),.^K[WN@$\O(;BB:*17
M^-GRG+X5/Y+!'6;Z.+?J;I;C>><W7>9D81EJC*(M,+JD^OD2:*HNF!3W9NKI
MJ)IG@!NDF@.XK,W]M<J&7+,];/2S@B_D4%N>E#.!&5),D;$];D,3\P?CCQ(:
MO7 EI/[+$'%Z$M?Z:X;.@LMJW#D=)CZ1X7E!+>,6YW;!\/HALSM&%\YG7Q,P
MC6,W-8W5:3R@:C2N5)/FJ^"^&4<C2DEU/,N2A6S%&.+!4?=6;4V[I07U]_"L
M;M[<FU7)_,0)GLN>L3W5NUM&R6AP#P-E:] Z =4LC/M4GA(%\'DWP>7U^-S5
M)TC1&K/<[3 >VXL>\?"8*8<L84J4*68X.Z338UO#O=X;C7V#M&@!U\O9DOB;
MJK2BH6Q*?OMQWNZ<EKUF$K.T25@IO-R/Q5U[U:)=O/$_R]]1X#SI70EY[S^K
MKUKJ!U.P4T;LO$CQ#G<P]5DCBT_PCW>CNUY.UBLJ7X]XMF4U]EF7L60Q!PYU
M4L=A@E#(J-K3C8[)4[ %!I#IJ(YHZEDM[X.=4*AMB)=>OS?#KK^GJ6G<&NIL
M<RO8-C3KEVH%\/)X<+BVG4/<9")=E&SQ]CA$??^@K0X$]R9Q.>.!P%7V  2F
MTR]PLHN@*3>QEK_"":[?1=A69;;5G\>\*1HHEZPD_OQVLY%.OJZ+Y)Q; N^9
MN7>D<U>D"M*U%*Z.:0M- 6,R0=TF-+H"C=S2]=Q9C_>.,YJ.O*DE#SKM@GQM
MN,TZ:W;/M.&4,8T*4G!@UG.+L%;&5AN60<>MH6:0Z>(45@QY(,K;S\ZK2>F-
M0LZGUCP4Y]D/@-C-%.>P6U<E[<06B[=2!'2(&'D\[\CBT %J:BU>,[0'FKR*
M^J_K/Y<CN\'NI:TQ,WA*U5+$@GC+PYA4XU5G"P%F.0\YX;QX5JR&F]U7AV30
M$30 !/-)SO,.?3"^PPTO \"$*<*"@#I%'I!:\-8L7.)PNI7! )]08'!"X?VE
MW*3&G^?8%1O5@(ZOK]BZ@5:S@S")6'5]4KW;=)%YN5=Q_=1$#4ME0KM\L3Z%
M3P-E1=#.6- $!^7'&4W@=^Z*4?'L.Q4A8UM WA5":'2<P46L LUJWX1<YTY3
MROI5JHWBF\\)8+JA,HWQK[7L;^5/JW0;3)H_YC)N_:N??MKCL>7)VSX4V,>-
M'+5HJ6ER](AVI-@GG^7A^QV)\ZSXA+#+,O%+C5]Y\Q;JFW6)>W*G@09PZ\>U
M+V-/R\(GR$*,%^K DNF?8@II#C,8%P$%/M3T_77WQL+5+?\3)<?)7+1R1]U>
MWK2Y2I>.VF=QW(%:/YV)9NM;V7OG/U8,H]YP[ADT]G6EDN+M@GV&])^W>7M[
ME +:;2Z^]AO!/R) E4*)1D94I,RHV-: F?' (-!J&%.KOHFDHT,$8M")G=MX
M7'#>\0IQ1H6=/D9-3RO[)'*-*J:+A)F<UQZZ*Y?'K[/62ET^='>>2JL);<63
MI9C>_#\@:NWT7JS,2$L$(-2TJN)R,HPK'0%6<#$4%?>13^2<S(7?[J-QU(JA
MX(X*B'5J<;&J*#6(8TR!Y@.0S=6M:\]]UY/_?0*%#%YACA^ GI0QI< <*P4.
MN6%+&3^(I]+49.]6( -GY8;5[1%P:H;;EZ15MY?-8[E,4<M>+@$T0@#>12B^
M$U#" (4[&"Y9\6M7;K%-Z,AW+^VO6)3]Q^X]Y/O.KVHOJA:^B5F)_U7 M?D=
M[P,P\@& _"N2Y]=718ENA7Q:.6(UC0DFN]0S&F\)[T64<0!_>>A=#Z]W$+]]
M\.ZU]ULK:(MO_-4Q\4^>98#<=]6JZUE/;CC M%LZ.VR5:ET2FA\\ ;)V6A-.
MNH($=ON=0=@HGK[M+!K$E#8#@$<1!K7:TSX7_D0@S$?Q2#XQ:QF@^P&(7G_V
M/KEQEGJVK QHRJ.E)%\D 6XA!V/1'(A)/IG/R2$&(P83U[_XT4BRF3WP-=WD
M&N\[JXZWNR?L?OL "&PW5CU%_^Z9*QBI SZZ:H&-H&'34+Q-AGCKD&1%B&@&
MM3J^^F/!6D%,HN?O]"+KT4W7V^I/O/HXVG[G_40@O!^O^S<8)L8>A*8/*-UV
MT(/'''Z YF(3=(C)"!?<9?B)P2W!"&5BH)$901BESXW?[M-_)N[?,IOQOPJ5
M,Y=H;BUWFRD\!AZ6T/]R4P+N./@!=P =)F']WJVH&X&S;9<.@Y>B1O/?7OX%
M_V;87>#H [#USS(_GVU/R&7]O!=GZ/_X%N>8E8F)[A7$*T1FWZ@1GO6!'NE1
M?WJW?L(,PHCC"EQ_H Q\=6P5&#[TXG=X_0G< B:JTE-<OWNSV\Z0]BK%C80[
MI$6@?47 6$RAQ*+$RO/S6H\&FJF*M^O[(?)2(>W>'^OQXJV=3+T^[MV^OOEE
M33TWDO:XBL%XNS<!($5;D"8E-\**S@S".V)Q(].CT](X@T]"-DP1K@8+5G%O
M!-0HJT$BEX*KS>VSPHUC',.N">MWX]W>P'.!FXF\0Z/7][20E(HNV^4S!6::
ME*Q8+!P-.!S "R5#B=(7),L,C L)1  I+.7;YFI;WN9)]W_I("RG=V_5.):S
MJ_//88#5.UB:N;TC:OAVJYG=D"RT01K!C9Z-W-7@1BZ^YILW\.YMC\.L5U^
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MR(P/8\L;O&"+%YTYD\0F\_-6%#(5R.G85#7=+8B]85KP2V,,%NNAHI*>G?Q
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MRC.H4WF@"&5/6V+8J6A2E-B6U[Z<Q/Q-9Y3MT+>\6Y5BL;2K5P*(6Y]1$1-
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M)/Y":\*N"D=_2PNW6AQ+F934T8PU3IE?63@N=$ZI-E)7L>"4!) D: K4FP,
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MLP9^LX31XN.4W)SL\BQ,(:T5OQM$2B;#)6OXYE/%4QR\"Q[/V@-YOJA6! J
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M@GHI:2.SJ,3[\(6J\RXG")H?3L+KKQ+UP"D[2N\]U!<#0[)+Z#9^NC':4%M
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MQKQ)KZX++CZ^K>4)P%E1E*VSU0-PL(W2:^G),.TS?1UW03R(&%]:Y]AFS_@
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MYD5I"K)WD@]#ZJ/,I5 ^X4C4YURK&+TAC72T<FC6[ \_NKC:N'C/G[R[J)X
M5O]>?_OR^K6)Z9E^>WR,UUKP(7A+]TEJ4_AU<Z.K2R_HF@-#0CH3SDQ68M27
M[&R#_"1#([_A<X 2<DUWB7H_FOMMS !DBG_2) C["YBJ_[GHO$H:!*5K-S.A
M/H]F+&H/TJ&SJ;-U"!,+?YHWMR(J@W#_(]VI&2G79KJ@(5;2)WM9]-X\ XYW
M/,Z%BVH 6!7:".6 E 30 %9EW=+&F63UDE#@S6&6ANS_A4V]3[8E,R 2#SW
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M(7NIDE=R^B!LQ8P/"]/5E]3'+AL>P&.I@^7YKC"3VVG&2?^>\DAV8DL2+_9
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MR^Q<QIC=7 6*=]1P#Z$7-MPB%XH?;%.9'@F&B%M1XV<5.DH;9MOM5RM5==6
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M4K#@NF^7S B@'@#%\.124\ [:D8@W//9+#1H?IPG]@M:UK2O9_'XC:U-571
MSM$_K;X)2&D;9)@>W<RC,F2$=LEL;9CJE-UW83G/%:;-N'.$:^=F>7B.,0V
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M]=]1<38BQC4 B<+J4E]:N$JB?BNSG-Z.F?P?/_/N9_1[[F\H^W74)1=82\;
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M\W!?D?%B90_^;X6(_XJ8/W/_!%!+ P04    " !QB_M67!%./ #R  !;&0$
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ML,N+:3&Q7%0$LQF]5LHF@OJTC7;&/8(&P<A\240@)@B7>&?!8E"6B3"JE&)
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M"P >H\=O#'!XE*']?E=*C 7T!D;RNEQ$<!,"+V6X5(Z *KMSO@SD]V&I$NB
M"PYI^.)Y&BT$*'>"$?4>+RB+EN,"FT- TH'H0RX-G%'*O:PK#P@"FI,YU<J<
MG8I9C81@-%3V'!01(N5PYHS:.*>+QD@TYT:3&A*R:%.&K!R$E 2M]"8MYI!"
ME!4-<JU%+Z,=(5$'8(2H#.J508//&K*R9E4NYJI,"FP-&/6L'; %#*A6IP^H
M[&J'GDJ[$9:PH[13BF^I0C0>XE,("()V+>C1RD()KT%>M)G2^0C/5[:Z+;R*
MXRN[Q/:4E/.642821X0(GRT9]3Y-BL+]5##%ABB_V10)%#Q12SDBP_*<6E31
M:M;&1H,*=P:'E:48RI:"!&2VYO((6#ESP!-ND971>"0<%LUN.NI#/*$TA1E<
M"JT^ZLV&#4B^1*"A&$60VF QYX!X*ED,Q?.!@)XR)V4@HTY82XZ@TB6&@,HN
ML3Z/EQ*L2XK("(7 $P9!)P(%/N]!(2B @5:LF")),LJ$(%]2BG4"<I1R6..8
M2<J\,GY]-A*2X@ \ #)Y)E7Y+D#.25[)'N%I*.%/!J3^*[TZ# QC6B54TD1<
MN6PHQ!3T63="H?XL8O=! !LEK"H'2AK2>E*?$K,XP8%4L!"S5K* I!VQN K!
M(J\&,U(&Y8I !E1I+BGBK) @0]JB*,></C=B,RM*@,_H+L%>"N'<DD+D""LO
MI=KE/,*[65,L1H 5 XOR4(D/9B OCJGT,<Y'@PPE1K,%)N@QQ5&L:,C[PFR8
MT>2-2H]7;3&GLAY56,4JI$@M%D++@DV5HA4EQ*34*2K9*" %X:)>SVMM<5=<
MA>7+(=R)!8F(J#/G2PZ[F,R4C*+=XM7H(SE+/*<,X?D$ J;2";_:% '2<A<O
M D"R4$JHN8I?9F-Z+U4P:T)IFS:6]*HTVK ;S<)$,&2-%D0_ZU'F5&;09.?T
MBCA Z#.RD-PEYS(^753!0IS9)RF<R@%ZL3"3E%42\*#&[:)*"9^=PG"Y*\-3
M;@6#R1/!?$9E*R?449GD:-/^LMI*FPDXAM-J/*E6!2)IH\>N+^4*B!P(N^-H
M7D6CJLJV<TZOY"5WG,"2$7\,<6CU93N7YK51E2A%,HC?Y;?[7($44)!#2IE5
MKTJY;%&'(TWE0X)#YHXF$2N695T)<\X$5!+P>,$:UL-Y0SPM*JBR6Q90*H&D
MD.5=?HU"&<4*& 4D,(_+Z E289\N8=)F3"F#W$G[DP[:I[(AO@(, G&<@:)T
M99?8I842WF!,KS,&Q3R?I7F[/N?TI9U@0EMP@P&K18?!/K.'8R67'$>DN"1-
M  7$)6IC42(7S!A57%Z1BT(VAS992< U>J4;P&A(:Q?\(7-8U$EQ!LU*G ("
MPXJ C"SR1H;Q^E11,YBFBB$HH726;&@I3(:-2LF..,,RCO9;?'(D USQ*7@I
MC$2TA-Z3PP78)JC<G ,@HTF7$V+".GTHJ 7T21]NS;!)V.]3V7&M-A#RL:I8
MTE$PD7Z%#0PHRS8EJ+!5U";N2I#F0BE7*@?<2(Z7&ZVLQ:I%[4Z$MKAS5K/>
MG_-[Y29_0:6E8 M$41Y[.1<+!H,(5"A$U'*C29T-^LN1J(JI?%N!>@5'6I"7
M-(Z@--":@)7(A;B$9/TT>8U'G0I"DH>P6F0NM1Q76;Q,3,0Y,(^(K$<.V822
M(JWF\U(^JU3%\D0E).8X& M%5-&B5F%#?=FR4P$C:"E1SIAUOHQ,KR&\)(T
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MY0*A KL9<.,0X!8_._.O]'%KQ CC G10-9#4<TJCZ)S5GSQ5"7A/1%Q?&8Z
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MC/G9I_DYABWL"C-^%-6R^F+;HZ' 5Y?H0I-(=?']Y.(M)[[ 0 G\SX5RQV*
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M[BBQ2WR[?KX!8[-5R"C9Y%8H44_%IRQ:@R_/%G6/8[ZQV':[Y.(X_+-<OHN
M!C5T8D9MM:I#(-("U32B6/212G;\DP\')SR=A]O[X>D*0^YYA]M-'B'8<Q1!
M@QT^\Y_6A?@K\8#O1S; /$O)*FDW\2(>W *UU8^JY@FN?GM@NP\QD;&MT)H?
M4;THNV-[+UH?':%2..=)C^L(.DT+-=C"U++";IT8Q([W#X!L_P<X%@@Y0C>
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M:"VC!0;#W[E8O-&#D/Z8^[3YIM'Q!Q,!U8+=M-P9:E1@J7TV(UIF;.<MQX?
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M+.-GY*S);^<M\RHL.R]9O"1:6Z5=FSW '4#=N3HKE],)<:,HKNFA61W@^#^
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MF_"V.ZRW'"]C,\?:!B[.I.LV;\-V[13HH.X,<4HPE, F>S'4^#8HO0R%2 4
M'\5U>ME/ZJ+JH1.EW#4F;0NU*R*-9G$)7V+Z[P*5"Z,-$AU11%Y2)M_Z:&*:
M4V:S-B ,DTX,SL>GY^8P-YH)6O=@4_4IKA6G;+GXB[%]G#&BI.ZHGA:,:3GN
M89WS.;ZM@7>]4BYMMZ 7,[RZX]>YAM.L!$.KLMG);>B"[,*M^?J%WWWA97*_
M=IEMW]JY[,FO92<RZ-37*#(9B*>,<69"5!VIR?FYE0=[^H8Z6Y:YG$>P9_%;
MUY&1]SBF$X$QC=:%R*59=$[H_HL5%.9Z1;KC7TCL)3KQ0%_^HA/A]5W(^EW^
M]9&''[6\,CQQ_V2O/_L*AH)P/6@%T.KT:/]*=JR8!0Q"8NI;0_B.K<5)+('[
MQ5' U"'''7KOI/3OH,85L4THT#3E;>OH4+C\!\@FA]T!I8WU?/IYA/94\FC^
M?@3P76^^6IAFP *O3F"8],]F)$1TV!C\[WO$,0 9T;[7V%3OW]7]GV*UL&"[
MR28M*>^6@1Y3A&L4\1):ETVTY++(D"W:WNC[O<&Y1T@1Z?+]AYPTRI"V#QAI
MXN<[<)F@8-U3#7%*WX6SI=QXQOWA6K*K/PTQ+EN!/(O1)9]^'][3QORXJ*-.
M1W3 FKQ9USX)Y@W_'5T@^;AL(L(_;SIJ[\S+\FW#3. _OB2J& UH:+G7MS7/
M8XEFY9YJ5F1-TOC(W=O['Z/TOD7;JEIV0UU]X@V,^EM\G*Y]FET5OO@7F6@"
MP#5FQ&5,C07I1&:B_!J3%.YS)DGA4&V4VIKU'HF!+N=)REM>_-R]EL^G^XC>
M@\.*3$-&Y'R8:M+Y'K<O[2>Q-*F]FS)-N2_V5JQP4L3K:GZU[>^KO6^"_69W
M-5DCX["3*B#&@GI"/K0A:1A3R;Z!-J/.;7A?@U@=4$7YR47B:K98PO980.R+
M$V-2U0B0(^1//?#"L"U2LPTG8HT,FX2BV<B!\H:?%4B"Y<%Y5M8VX0VU-9>9
M%=G%& GY871FA]=2QT4A1]9D%.U)*2C=XKGJ8G#*G"B%+0!?7@]A0&=K:N0;
M9VKSO1.;=FAZS=C\S.54]Z/_EK96$K-,HJ)!12)$[*:E$]:]U""XZ^P%G@,G
M&6/UHQ*.ZN3.F9S2>N[U">G]+MZ3]SNF!(X  %$0C62K<HFP81+HU_BJT>C@
MD76GECT.TS@5CR2)ZU)M90FX-)9 LSI0GL016R)%J9^04#%E9H@C;#\%K7(5
MCFO$VFJO%_[-T19N[40!_CB()9 RR42/!1NIO1CMTU)^6&G;*O%)S%H*ED*1
MK1MMBB/L5U Y<T&C]0MWO5<;Q9LJFO Y:%A-H-SO H$_/CAJA<KHGW<XH5,8
MSN5'_-KPE=OAV&,?*MZ #4J:+)]=^C*MZV?K3&E2:']6M "MB^RB],/V8:_L
M?UM/[!V6N!N^Y8T;>26&NP@&^-+W,\511I+9!C2BREM [62:-IL9_>US8>.6
MB1C6J313M[4^%>)$TDBW3P'I3)=86EU>#@2\3%UM&#11[/QN34_X J4=DU,=
MJ1T+=56<$">5'[6<%#.<AH!9 --'^WB"$(S#7KS2KR^(?X!KX>?$ZI>M<6A
M0\U9PLGCBR:]^:E4U*BIN"97PA>E-G,P@FQ87&_KS93.1F;<JJ!VH;6#C4"-
M^C<'(WZ=*R*%G?22LASV&\SCIX ZCGL#G65/(>=$1#'8N0& #T^8).5_T$0*
M784U;LUV\QA@:&%4#_(>U@['86*:#^*&$3X_,A1\KN^:[?"%MJP'_SI3:$M=
M89AS.KJE.O H0C@3+XMS[4KV5_G\:M;B%1J;3'"3C.]87RQZ.ZS::=K1R6BM
ME<4#L+89H[+GQ"$:E.D)EV6*<TQAJJXFS9:IU2HAWXP:]F? _JTL_D643)6/
MW8+#$ERF#,9QZD!/WMMY  D7P/9F+R&:B-H<:S'.#\T-;,M_+^-QWDF23?)C
MV^1^X=V3$,')YEAR^RS?)?KT)C*L#FUT5+Y_2M?:]HK8/#%P1W*_M#\ZC8QV
M_T(I(=K!5J>Z#R>_G["#CKT+>?ASX^9L 4!^DIQ1A!,[3-I227P)'4K3DY?8
MAXRTIGBH,5;GCEOU:7W]RP=3TZ6*<^>WMN).16\08;JNOQI>%+)69.O3 I]I
M<:E)*4CO!^%#AI>WNG4I@T1!ZID8HME_2J-LS87"V7:S%KJ  :U@"M4*KOR)
M$H5YZ,R.ZS1U!"IR9.JC+B%3\\B7+[S@JS^[T$UK9J.W4HMH;Q*?:*.?!0\K
MM[[UE'E_K@DT& ])ZE@!M\K6=<?YA=BXB=M/USA9Z:&(=:F/?";MC.HX(QC+
MH?HX>3=1+]%<S&A$$*0=YAH.@7E-OE'F7H^Q89MX9OS<"P/5FT5A,LGH\)%4
M)K)0\VX[":]188-.436,1#C'M]O,DSU0/;6>&K=#-"1")1K&%X_/$G^N^61N
M-7PN*6_=LA/'[+$2S$E_"@ZQ7S!"JQ L;<<;-Z\F(\.;,^666U8J&BH@(%Y&
MD_E*Z39,\E%)BAA@;!C%(A1_RK+TTTF$B0/N(<'[T=[.$OT<PV;4XQJ)R<;"
MT&.-,&W+&-G34FG7!G8/(.S\*XT2G-0OZ4N(D7\,I5];R89%/QB_:^7L"=2N
M@>10Q54Z<,-&#<7FV "?-0QNB1%BA+\F25==]-6/&?>AH"']X,I)?X8$MB],
MU,B_=1J>E%5Y8BQK.!2N:P/?%6J2Y;0@:H.,D)D,//7<)+[*S;Z=ST$^5$YN
M*G(O!TI4>U&3[7=?#.%+20KVWOP#V G'G^^9S=TS ]'-9R=OO3P@W?'LO/;#
M2JVNRX&Q-0U6A[(D.1(K/SB@U2WSW"JU^4%30UBLUB6:\)[WJ!WF/4N%1@<I
MY$Z 5APE:1P15>RQ"27M\;D^C?=OW$"1U EZB<:J'%V1+.10:@)5<!C2HSB:
M[F12BBA ,\&)N_U"<MPM[WBY9F-FMEIN_N[3%XO2[?MW)F_P!LZ8VES"!._/
MG,/8SPO"@':&XN!3F '13CEF8DT1J:=LBK]Q_H$+P7(4-F^MA@4XOG5>%WB]
MDQM^35LWMMM-BH-D,T7XU%6&TZQT)6J'=:MC\+["3>X1<?K;]P%$W)XD)?;H
M5#\!?7(XW<HXM#\J/FWO/=7:7N^;&CEQ<8WTTEUP-NDB^RD,(%%^LI1Q7PFL
M6C9Y+.PR2W/CR**;[L=$/IS2\W<;<5X"IER2Y)64,417I<FJ7'(R6,O)*< B
M+:$X9IG/Y>>5HP(7:>.\48T]]SO#VOHHA.T\QCG)B(E(I-X@6NB2Q?R=E[WI
MS5UF:-[\XNFW\,W-/"^XD'+VZYQ#W;BRCZ+ECVIMH4V(PLAX)(//^D"CDK5S
M@ZAWIGTK1Q48:&]%&A0ISKE41S3)#YZE*F.WB5:J[C--V"AM@B+NL1+!E:*X
M[=JS/K&3G*GO;0RXQ)I)0<38U>%Q4_0,>?WNZ)]8$T>U=.XJK'U??\UU Q,L
M%[-/G4070I8&-RI8'-M<EH JBOK0\)B&6+$L(ZH7 Q@>WKEM)?8[.K6Z)KM5
MY]2O12TQ5<)O,JB:ARUZ^$>!DR#)ZQI@3:T;F4D#P^&(,&JQJ [R6U;JBT("
M6\-TQ83%XN_6ED-5=LS,^LSO[1AXS4?.H.B0F&M>6OBWV&VQ$8-'1HTZP](V
M0W4)]O]$$:PS,\#,'[<!D2,1=DM*9M8\U[#LTC#\E&PLQ[,@&J*@OB8JN^9-
MR%0>13=4S',V2=K3 J!M6^=P1CD#2.3\M?![H ;XLAB#+IAXM;#[-604GB[^
MT%<$WZU"]D9>-8YF&KKSR;[1BBSHL9)26SK 68VM7[TW\'YDI&51M2P,HM,R
M4LG''Y7G>?O3C,)9I2BI.AX=1XG<.TFB%),G*RDSUF=905!%@UDW0N;LM3BH
M:YV\XSP[,#!%8K\V2C!_BI#B*#(B9W#8#EQ9ZO(-O%KXFK<R8G*F_7W^EF,^
M W0,6JY92Z+%TI%+Z8 SFY"YQI%RO75P4;LVQ++S#O85=''=BNRBEL^*178A
M&:]1BR:,AFB5F@!K&5J9-#M+6Q@]9O.H:%2<4.M@I32U,J.#J++U, GGS(Z2
M9/@")=F(N@7[ZR4<:E2(?;Z^+U1L7&GK7W\E 9='W[PP$,4588P"#M>.#\QR
M1I>M=!AYI=;-*ATZ69]J.N6:)Y&[T(L;3OZ,5PN>D+9W<1 F\'>)SYLDMT\@
M$B/X J=*'*VT4,]*JE7#YY,/!.R:_]!Y"N5Y_.4/X>F?$5A@[BA(O*-3I=09
MO7;?9Z[M629O]WB,I10%RZL,K :$,UJ.T PEL5E7-O%5CRF2;7 ?!'FB)&_G
M>=$*9_;+:HSHY*;NC5%."^:.M(&4L-!A.X:^D9H>(I1"^-W0R=_6_/L-=PXO
MGT[_ 3Z\^I^X]"]G;UXEWV$QAW-\C$BB_CT'_%/CP<6$%1%<U18\*LE>7Q0I
MADQDH4"Z^YNCX&%\\#72AN+$KV9]!!$^&!FMT)1BQ+;579>V\3OYBHL 3QLG
M5_3CWS:QZ0#@] 3E5' UFVV3O?.O(M44[I&;W,J+OO+WZ9C1RASRFYB;S*(H
MT7Z!>G3AD6NZW&E_/KJF"OIP_U3R:6LVAG5(3JI+KJ<B,LT$SJ@O1):#*YIV
MZ=U%(2-_)D*2]];KS#;3O5BAP\Z6*1@?')B/] W0;;X%ZN>F40N=]#4RN9N>
MHV>HK@0X9P^N\BQWP]B'8;FVI[M,OMZ6E"H;10&"AG_WL&P@6:8&O-.C]=Y+
M"GXY1LSL4'5V2)B/I9K\@*N35IGIP*>NR96),I;.TT%G:?<:UE45IS;"2]0H
M3)Y.*Z5XBO*EPG?.S4*2]VJV'/#8(<'KZ](]2QWGAL2[G//FWFL$3,XF-<A"
M,8^*))FNXXGO1UWVR&T]\"_F\7KW0II]]=#K<KD,>&X<,D:1#.6]XE?:8.%3
MQ-%G3IR"";5__W"WSWU<&6+VF6Z,^&TK-:W$ "QJ G*(.KY*.)(1D?YC3D='
M5QO%<E%(92N)=X4@4C1]X?*F+:!!Z\?3A,@R)Q@8-7\FBR9W\9$A]"1973#V
M>!-I4IZ)0'C5,J30.^TB=BIX5.+<.D4PAP2$VJ*6]-:FIQXSIJS=I)4S!:JJ
M4&5-8F#9DW@_F37S3M)H].>#_^NLU';NZZOM<&H(TU//*<HRL5?VE)Q5-6;A
M;(Z:U>C(()$;BO&OI$%C]HTZ,,F355R*@K*=$-.QG1S>LFY&C!6>/R4G$ /$
M6^NY2C )UA+(:P8.C^:XD:XJY'X1QMA0Y3@?7Z3YC*VXN1KIX%18[CKX)@?6
MOVU$%:( 0LIG6W<B$Q77%IC+(!SK^YVPYA0E'6=Z>$YPD!QV=GTW&9S8STCC
M=<E@>1O)YTU$$:\:Q\]%3NO\S= ^58.>"6]7S5[K5%4+5N2UL7LJZ<2ZQCT-
M?:G1&6821AW2:B8&FW6>@X0]!5GW*>\O"G%*P=IW:O@QB7@9V55.O&F\1O%N
MDM\RF33.-C6SBB3<'2LC! P\C"0B&<G=)"77%>TLF9L%EV[JO4[S@FOKW$1^
MOI\V,^+?FE@\H86U3*QF0C8Z]B8GYG%60T+:\PS3/0YW_P'69U7_.KAL>D<2
M*;_%S8WW1-M.:6FO:*M6YNJ=,XX/^>/WK-'1O)PM.;J(DZFO%QM@Y/LE%(G2
M9?=DK]06J[)'/98?TL3PG*88!JJ]'8N+=.O7:<3XO ,A2&E=:S1[8AC+*OR0
M "/U?WH$A8[[UQY-SE)\R)=\GG;3:PC)JQ8J(5KJ-@E(MY8BDK9FB;*5*ADY
MJW@X-=WC$^9Y!(>8TK,W?"(/*%=(/7WZ@2B3@+JHH._:9(,^2O%66]>M[0>\
MN'X]73[T$Q'%"G+&*]D:OT;[UMCZ1T.2AZP)SV?I#>7;W,06X\S@N0ADB'MX
M_$_1Q!#-+!U36F983EGS5-I6JOF&FWQH;+TN65D*9^U!_,?I)SZN$CZ0 ;8<
MWF9;1G.3T<16X:[SW\]S55RK?'=JE#TDBM^3CR\*[919AT:1V;*G>4"Z\2D"
M*<:_HH^LOG<DUOINWQ$\X?O7.N<1@EXGUDKQ]/P:?^!)G@NU[%<C""</\@>
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MBX(TL(8$*^AZT@\(98Y#"9<^>Q%E-AZG2V?9G^J4G=Q7>SO)_=6"JD* G_F
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MX33/C0SAF!OATG28]%2G9YL:IWD3'%\PG1;3G'Y]LP?W!/,8LTPS'<,-6.6
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M:?QTF9)<I02F\KJC3_4,KO015[TX&6G?(4VAC3'7]CI?I:!<B:1Q-F+?Q6R
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M(&9O2>Y\G9-)1\<5\V[3O8%\5@IE\^VL@UTF.X4?Z0)^O:G@ F]-Z'#F9ZS
M*-)7<NG;1.@G+!?CT.'7W_M%C=%HA G<))<RRH*PWCOL$VNW(JN %DHOWB['
M$[#&B^;U:0"E) $349Q,.LA>B3+9F 5IR[TLZ;A/JV&.>3(B,F&?W6V;)W.
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MNZIVW7?=JW8E8NI^OU]VU9:$")H  >)@'!,3#0Z0:(+ :!25/V ($*(@RL1
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M%$/>\;(?__I"_G/F$/7UQZGZ'B)@"-P_TXA-X)4OC.RC5##Z-C^5;\,@C+P
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M]R2H 8)>@!*05 <D[JK>&Q!ZH["[/GAY/5G2 3?@/L757@WYG8$4)UW?%\7
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M*2R/8;NJR(]"4@F#UJQ$LF]Q>QO;QQ8!##5L)XXM"U)X0" >T'3(-IK"<4]
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M]2NDR">FQC)URCO,U(B=P!QAEJOYA<,:D3F<8. "(LY)M$.AEL?SX\2ZW6=
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M>N![1W\G;(-"#TC<EB4?(>!ZLT&U.XP[DCP4Q./%(G+ JSN3/;]7Q)19-&-
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M<ML $ TYR5 GQS&]TTN^)9.[-FVO68#>T4#;W>H: 1AAU$;.&I9C=!]OPFD
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M/<;W"KZ[ /&/R9Q]INO[1<\9_/^=.7N4?GCYO;>6/[)<?\EB>O9^WU\?5C]
M\+C.[(.-^T#EN_KH]>/4*GT39V7T4NFS>G-5GT+Q"7)>7>^E3_[KKP3[L,R/
M4/\C@#R&\AGWM(U FWP"ZJ&RZKL!*QM95#_=4CA\ NAAZN\*]##-$];YA/OF
M/NNRN8]BI*W?[[+>8&5#YI?198[Z]FE*7S)>.43/9OE)%)\FQ^B]>MB\450'
MZTNCGUXGZ4,T'Q<F*QM.'EY"W^%\5?!Q2LE;GJKT[!Y]]YADFXQW;R\Q!'P'
M?/X\K>5'V>LHTY<X]%'*]+644YV-+Y5F&Z#A/<+GHH^L]8^T^S6]>IKEU]UO
M=_227ZH8L-G;NT^74#[=!_KRU0V23XW^4/FGLS)>E97KZYA?U7P6>Q"]U*)D
M*KW^P\S!9VE^ZN++RY9SOGCZ[8/,SS6?S#P_K@K5Q\V*DY>O+@Y]@;T#(^\)
M^3#%)TMZNO&S&;(Q>F^U?+3X,SJ_N<?G(0X>H_?..,8?&H3WZO]18X'7V<'S
M):/_+QC#1]7^_](2_%^D*3Q*/^PION-V/NI8WG,X2NF-STI>YW4^)5MX>5J]
M^K-,\J7D/:$J[S/IKM'3G;6?2?9\%^WWB*\^L9/OC8!^\\8@/??-U'Z/8_"]
MWRSZ;O*DYGE.J4?"]^*A_L6S_L=^T0>(/EW.LZ&#'V1ZK>G_0PS8Z\;DEPQW
MM>$G;!=M%1M>03Z,5K;"=S=4&4Y!U+\"C K%O'A:,5Z_/E_[O"W<#U%]:H,?
MI1K%O/SJUMWWKE)_W4C_TG^^K^3[2KZOY/M*OJ_D^TJ^K^0?*R5???]_QA+5
MX3??NKWUK9??_N_>.+WQYB_R\R3D%ROCS6__F3>^]I4W?N'-O_;Y-[_VQN>^
M]N;GO_;FM__<&[_QC3??>/.+SP1OO/I\Y8M?^O(/?/4+G__<F[]L(SC^RJW^
MC<^]^87/O?GYSWW^"U_ZZN>_\.;G/O_%+[WQY:]\[8=^U:_^@1_^3;_F+>C7
M?OU'8?*K/Z)Z"&YW_\9?^W4_]N/_M.;WM^5W_.1_]!]O,G[]D_ OOZ]A^VRB
M-C5?>?,'MFIA:\^FX,W/?_YS7_C<E[[TY2]]>=/PA:^]\<4?^DU?^E5O05_^
MU22L_O#7C]Y7.D33_Z6?_-=^S8^>_IV_^G,_MO?[G_FO_^ZO_7%T&'_VU]'&
M3_^1_^ __/9_^\8/?O[-K7>?_]H;WWKCY__F[]O_30G_.7G_<_]0O_PWOX+\
M=_]R^&=__W]A_O1/_Z6_)@J?^UW_X(M_XE?_+!_^I+3W&?-W?_ZW_+WP7U[_
MI_"7_V3TVQ3IZ\Z__[O_SE__UZ__Y=>NOQ_Y5[[X^[_UV]Z0T;\1J3_UF\Y_
M@7LC^3]__K?^GN(_EW[]^&M_Y'_]/7_J[_R!GS+^R;_Z;_X9@?\??\T/_-9O
M_.TW_^!?QG_N)Y __Z/P'^[_T^"G#G_AVV^<?^8O7W[DROW@'V'__@]^Y>O_
M]\_^_&\Y_>#O^,H_^-DO_/8_5_S]?^%?/)?__!_\X1MJG=4_\&?^V._\XS_S
M*__LW_Y+?^!;/P6]_>7?D/WX'_^Q7_CM_\E?_&4A_)]]Z^>+'_[3?^6+SAO\
MO_KK(NX+G_M6>_F+WW[C[3>_C+_XFW_H=_[=WQ[\7\7__LO_>_0/_<2/_=$_
M^4=_YO?\X;_W=_ZW'_W"+PA1]6_=T<L?^Q/+W_N+_]5?^8'?\.=_XFC!7SK_
MR?_Y]_W;?^O_^&'O]_Y[/_+&[_T=\*_XV1_Y^U_^N^?S+_S!%__+%_ZI'_HG
MOH)__6_]QO^'<K<*JH.)N@4/'"1(< BN!X?@[NX:W-TAN+N['"PX08*[N[N[
M^\$MN)/[S:V:AW_FUE1-/^SJJNZG77NOM=?JZM6$T:5*3>N'2/4']^%'3F39
MBN%OE(P9.N_/#T_(T 'E+F>3:4,A6LSD 7LQCF#Y$*7/R?$QH9:DR&)0$%9H
M-0\@5A9B9F9*05&7EU2#E ](5T;M8V .F.A^<%/36SBA#V_-;ZKJ+.4 .;JG
MPB.9Z^D:9XH<J<0C:@_GD)/C&269I)Z,%8"IO07B;83'QV7K4XUO<=$D)25%
M^O"(_@'2NF#0$T7@=T.2_@'0R]/Y5]J=_F1;E^!;#V?^GS<5P$8^.> ";DSW
M\,44#9Z\OS?<E*F=]^BUYOA]I'(0FN<1Y_3DZ69?Q3G]".@NRH<,U\O,F9J&
M2V ^?$K2;\2E@4C6+3VE008,IXB-CL4V1E&'1*A2(7TA6@YVJN@>JKWZ5&A?
M7'/G97,@2%W9@[42#1:&S=4V<ZX3@9%&3E9B*V(>KKSE+:76R:]X7[IW6C\.
M]]#^6?9ZA1G\I6OP<$EK<V7(F!\X9&T<66P?LU?Y[=A:@S%"7&%TEV/PJZ)=
MS]_W118_IYL7+E#EF\4ARO;%Q+NL&()9'ZGT?5+&I#CTX A[LI&QL>7C>8'E
M/P 2L2'.]!/YCKL<7[_4V==,,F/RE-UD&-WL?N[/O4CT_+1*]<F('0OND;*J
M8=7-):NRLT8LJ1A;&2^=KT,"^:K-CA?E%^&1O:@8%G3-QC$X5I'!&C5--](K
MU'\[MYBGL"--<A%PM"SB**/5R,#21<HG9P,%U46L>:.DYQF5RW6*4]'NO\%=
MY0UR.I,893+&N?!6?Z+%!2I&R.MY<P>@48=;QV[GDPTK[YA&F7]6/_0KD#C:
M0R&/F<%-5WHK5Q_6EJE(=H/9,7!+U9A[@UF_V.V)<O@I)T[<#'$1>&5K'-W6
MD.K&L5=F->U]*Z-(3,3+7I%^P<#A"!PY+;^!\@QDN[EO.&V::D]?Z$&S85:+
M(QEI+ODE@3\"2OM<P]D8GZ,R2[V,BJWNS;6[ID"3(8+_I"KL"!E&,J[2%-Z5
MO,RQXUF:BP_\E?JU>*Q,14R70(=##\UJ^17!9LA&RM 4;U_IS%>2B>MXGLS<
M5RXN/#75@R]&:WSR^'+0K1:M#40^<UY#N,OM%%0M^E]=HBH:EM)32I0G4 TT
M=\VI*S-M-:Y$6B.&'=,OOFD^X%I(KW/"E/VH/(=$9&^A[W\T.?ST,O;RJ*K#
MYZ-E_35[=L%83DOI4Q!_]3>F(_N#4MEY<GF0YE"W?O$P"1RF)SP&NMGA+SR#
MC_>,K5W>8E!B'$N1IE4)U:Y/K"-5H,N@D"X$$9-!,+AA"R7535@"8%XEC@*4
M\QL\3"LTNC>T,ZDVGW1155.6-:-LFC*Y[11,S)&1PVGP<=NUB^/6L.N%Q+SX
MYKME%@CL%S?0JZ-+7R]GC^*";>(L'%1U*I <K%#L)$7Y:^QJ$ZSHOLFZ'B2C
MX4CP6\_SE22\* X=8J\/3WGSB?)[_V5MY*Q(FX99.D0B+R,-2X2+&J^5(8#'
M(6'^RT3W5RY*:<R]S-K[_7-^G57KMZND%)L&A.'OZ"AB8V(#963J[!2R[PK/
M4P9*[<?_P/.5R'.ZL]$T'XK^FJ J35[3Z$#IS.5_@'2&Y#$"]+)_ '7U>Z77
M6_@D"CP/<1(>=T1F0449_ Q"ULE-XV@9W8-8J^DU(2 BPK4&F<#8(IEL+=YZ
MC@-H2DTB-&?8!$%%\YU\A+&0.+KG7D+)0)7SN/GWP!66VN>40WO>,Q[4TA1_
M@'^2EU2]PRW3ZUCSIML_0'2_9'6[@*2E$E+DU$EI(T43NKX 49=?(Z/$_;VF
M+!0,"[K?CSGUT9BSW.S2\"$?(+,2\JZ[/&M1"$FWRB^;\"GZE%7*\32;MF==
M9CD@R:VV"NK'>O6M>UGC_Q^JXZC\!YB MS1ZG1@2I5IV"S!TSRVT;9MYN%:!
M7\_QT%\C"@B_Z#+ZYK;OWORG>H&O%+^YI-IY>LDJNM9<?C"[+YT#]2: 0N.X
M<0C4W"L#BE+!EXE5Q85X)I:QD"$791 $!R7"GWWFJ&ZZ2?M(N%L@D; ?E5]\
M.9)$@6:B KD+D_J>C=WD:6;=V Y-=\ /=TYC-OHRG,87;EG[L'5^V3IWUB_P
M/Z 2G%%?-5>^'\N1MN-E=6U7"6>%E^F<J?5R-5=;TN F?+!E+&Q,L%C,<YZ7
M<+=.,@U9D(JD^+5,NH 09$#C&)"VMH_ 8QII0H[[8T'=BB(N9FPL]86)'")I
MRM_&%5#FKPC5"V^0"Y^P202$4,+EC7W/WGDPD+HEF/,K*[RRS\GMCY\DTO11
ML^+:%D&JC/D06%@_:Q\J<%TQL>9]+:B^1?X35W]DC:=)\#-8D*;ZVP<!]IJM
M F%-BQ*&>'0LHO $D;_0I')],KLM!>N='LM,8YSJ\C%AX 1!P7K<NJ@6X2B2
MS*BCR=B%N_ 75>Z$T=Y\-U17<R=B#'_1=K'!W5BA6I^(J>VILQU"%I[UBO*"
M;P00OW"A:F:==1\!?@YC*!TJC0YC'T,/-SMVHYG,M_1A**1<&PEV#(&M;I]?
MZ$.R/'8=V!0Y1K?2L9A)H#H),K7C-"S,Y<BSIHN1+_RY'EHIT*AXLN6UAT&!
M/)PRYT3GJ [>=L@!4;G6SVVKVPS?F23F]5L.6IP\VU16.7X1+VSLO<J-UI!Y
M_VFIK6_-N9*U-S>Z/SB[XWVT%I\Q$+VCXXB#>[:4P*,8X*!B<D@MK?*.8><T
M;IQ[39*\6ZZBC=OF^N*%948_YHAH[L:0KV49MH=H"J8.998RC]?^D:AA(/8
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M%L^@J,5K>.E]Y;/1>AR?'<"H*='!I1O.3Q3M#_(^2;BW"3D \EP#62UM5UR
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M,E.1Y\7F%[<Q^^FN+NCX>7#%_8RL!_ !0>U ( BM4AH\H-XV&^9Z'O^O)T(
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M4RI@XOL@9<F^H^3] ?W$\G9UE$96>:)8M/*00'SMW)J-*NVYBF[)[6P\\S\
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M[F$9G(M6[IG80,"'[F0B9J=0M7VKH."1$(5^%F&69'9TV4%6KE7%049%"W(
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MPE,TX/'ZD[PPP NF)G!T*/!+VA)4XO FPRY?2/(']2NHZ\[[*2*@B+R.A#&
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MQ+EE&M$<I..//>1$Y*<[B;4FWU(PF \)DREF FD(FV$2$_^0Q3R1P$O?I5Y
M:'?.<+>.)EA':+*3_'"<IX73PNB)E;8BKJ:$(_DZYR0K)VL8B/N75'2(65&6
MEIURWI11!YV8J(OGD\P+X/B,$\$S&&]"_7WM+\_2P2!S**,REP&F+[/I#W5R
M"=?]!QKK&$G92'I^)P 3\/OW77T[K.C:N2,VT&'=CQHN*T)'D4.$V$:$=SGD
M]>NH4/"W,!972T=6PUO&X(01Q%!-(YDBK*2G>N<^29,XDCD>5#-I]8%@D<9J
M*YM50 $3MI!D"*%\XQW;4T9,GZ7U"D"R[8O;!Q.>D-$N2%-*9SJR+##>S^5O
M:W:3(>1E=DRKS>0SS;IB@+^SAH>UG"1;RT)VY(M^0&6 ^8CF6#"2?[M7A*!8
M,H#;Q2K""9N;1F? LG($:/L0(9AY+L,-V$#:?\4:3TO.P;?(6BZ5?\P *G9X
M,P8J:K,=4AD/(2;7&@^OKNDC+3G+L[#\-K2X[0#F]+>,AOJU&PG.(+E)[2I'
M7".3QXEOZE_TL=T.TP":@=Y-@B/3LA)ZR$$KW]AWPHVWK\% V@BW)0K*N,SX
M7Y&'*ITQR0M7O1(2]\-Z@FNH@_+&>>R?Q*IB*W59(&C($M67MT=[PN_C:HFA
ME-[%Q2KA?@Q*B!QY21045B#"=P(-'T"#8VP_W"?+K'5LZQ3DP^&*A@/[Y!TR
MX8V2@BGSP;K&1HWZ5E:7RIQ'37S"=1LIOWV"H'#2L0:C#B([(!I"*(14Z#O)
MA)&,IB[:L2!@<"8')!34U5>\@[4(T=C&0]"BKCW%<25O6<DPG&OO;Z%##;VI
M@I;)A)2U#UCX+9Q\Z]9N&D$^'_CCWE:[4-]6+W'45H$^QM(V_HCD8/<R=%Q.
M@M!_N!)/VA*;CQS9'[1*TGW?)R\*[\-FZ"?6_LJ!DU10#6\==;/]J,9Q!8_V
MP5.*RG;S'.Y"S\\:OA-J$C\L0TV.Z6V:KR)([G\:4-R,:*/=];%!EHZFY$"H
M7.AKZ%\1A<_O?\%[%%O;_UCJ5S6.B61_4+:&M+A&0S!%&"Z$8."&>";6J#DY
M$"?<T\H+J7(?]:XL-5K%$\O9@-<"2"ZKR^%_3,$FEK%*;512#%!H]B>_;5)D
M@:Y^R<%O2+:;P=D!NO=YS_3F<1C7>$A-S%]Y(^-> $E!TU%)+6B15GJ0H02T
MH!5_?D6BE,5RA/!OTT3Z"*3L,-?<&*3L&$&%_Z@P_&XB K@<MF:>91S;EJ,!
MM9,C9$" <E8^E_7]$)*D+I*N)&8V ( "  @#<(-HD"HE;&QMO/XUT%A?'1_/
M*!_/, @,1("!VS=556*SPO]5-V%>XFL5VDDY;KU$R6=W&BMSO==CJY?GV)XC
M!@EM(4 G%,]\IJZ%<:856#>QQD ,-.8=3X6#?NS$/@!#Y]]J4U5_A>FN#0L%
M.!'J*&N!!_\$QV 9I^WMVJ.7QQ7J?6R@X?[!_J!P<LU.:YMHBC 85.^E>_>+
M8T.JXO@"C__(<=3P,!L5VV (V$L?(3@WN=VWXH5!SJA4WL<SF /Y7&H0S4(/
MT'T5#00@L6HT&(X(\>+SHATE7BL"/@@!$9+DCYE^=6O0?VM6UL;DJ:<>E2FO
M7#U!O#XW"61)^Z";^&=*_>6&'<NPO%G^[(XI2\BKN./PH%OV>,_!P1K;XH(^
M%D^OIZ6;5+;PGR<DY+7H"[D5%DA8,'EY8$+-PW-G;(![9RS>X$!MAY_*#63?
M*8CR0C4]X]O#PC"YX6B;2_(:70':HKI]-]-W_;S<QO(O8Y:1C))K@N[X0-@D
M0Q-7-SH.1X@N!$^ZZ< #MZBXDZ/K>4ML_2J[S"!"FI!7WA\<H ,+K/HK15G!
MNMG:3:*7Z\$2K;OZ G!@];_#+SV-]:^ZSO6<O#@VVWC^?E[UM^/K4&",Z0O
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MC#[;*5U$8E%.TH%A'W0WH-Z:'8BZCB^%AB8\]@*XT?7^9]]:FK<O -HOT2^
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MBOY6'Q>-S5"4A. 9->EW<DT=OQ8!!\^%"B1KFTA9?YO2E[*VUQ2J3]Y0-OD
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M%0O:'-=5JG&$IJFL6<PG5R.5[]W^3I9Q.0>8L9('-P.QW"Z<WD.QRAG67N^
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MP.?CD&(#1-QYR;WD'TPU1#D0K]\!CH8/V13]GAB?>S3/"W=,?:O0!2ANO[7
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MKDU!&SF)*>:PNV7GZO9@,A>0[\@3,OY-"D'ZCT6.'= \U6DT>GM@VIX"XX]
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ME!!<[4SD7F9F9(3? ;V,1+A\>7:W(?*AI%=@.YU&^&"?G<KNCZ^&$?K,+N\
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M%J?UD/S9P:$KB"V^_&^7$IH\3C@LB=-2-(;K#0^KY+A_9 ]YUN<,0Q<61FP
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M<STK4UAFH(2%GN98&>C#_ZT'7K$ZNH+'G6 $*K^@NC!4,PF$)80E#5(/'E8
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M7'! 8'C29M./?OIGJR]ET, S)<3.IWLMEFY%7V@D"P8/EKJE(F'4M#2J$IU
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M2!S;WOMDD/-6AUC?%ES[IMUWGY5MXR@AT9$IW5[2YN_SR1?I+JZ]OV6N&U"
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M=0YC_""9V.H_N*HBE%&H=TU]]5[_8%)UA QW-B71@+IFUXL;%3J!F*9UKSJ
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M76"U!ZLVG.BF46FCPA+T20_-<K2J02+H9R1\0G/R<"E$2 8'FNQ"M.G ,08
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M99R%GY4P*'_@SW809R\;Z_GWCU%SH"\&ENGNZA?-K\?U'XMEJ3"(%&F>Y.$
M/NKT5>B*QJ7O-";I=009%P9$TZKD5?0&=!=48O(/^(J0"T<X>X9TJ2ICN_G
M%^@VPT9CQ9:GNE-H7^(MO4*/2;R",6.%HOR/M93#3[)&C GLR4KF@U\W^U;E
M''Y3>O@Y0!I<ISJ7W'F(;%R<DL&P(ML?F-(GR2,FT@LKXL+SHJ0<&,^E;A'M
MQM2TV@(V_DJ]EB:%H:1T74#&S) V(XCE<M??/_0X0/ULZFCO)O%5%HK M G1
M07%;^\SWY_YQ3EBO1MN)>V&%Y?"E#/+:4%N7R71(!>_7U("\SOL$"#(*IMAH
MS9Z^'N6YYHIF\\+R:1NL>$FCJSV+JZ3YS0]*QYOPZ_R8_8W223L^^\U;%61M
M69UP2OB+>^BG6==A1OME%-+6^>7#49&;V49'?/LD?2POD7E?BZUW$.D RZF[
MWQ7X*R+?UP\C^T(EPOF]<EY;1U%%M6*.:8'WQ4K:'1@\P0\!C8JBIN+>,L9Y
MV5D3'90-G+J$AW#9N25X2EKBIYM>5-^<JZD/A=*+5A:#P99?ANO[B266BB*[
MEIPX?XNQL4] ]4+UMT0W7FU@6GA3N$=?W%?R,"^/PBYZ'[(&MPP59%_O[NDS
M,AOJ+-!RGS.],RI3^?4S$*Q_1)(S#V=, >G9N&@P[3IP*B3X%R;)0PQ9<5<S
M08JRRL,;6"A=A,K"DC?C(E-CRKT[U[J7YW=Z2+977+GTG3]3^S8E5C.,8$Z9
ML,DIC[YS-AKKWD]=5Q.<P[6B2_"NU,0GGMABX/W27L8O^TM3C<T1+/Y8Q 6<
MH4Y-=8GU#%]@5\EH%;0_M:@R[*G^JN)/:,#I!#:/(U]\8=:CE^!A_IZ\4VP-
M'&#B]B\)?S9<@L+L>\I'J3.F_@&D%^%*B4$AQC_.*S=4H<M<2X<F># K!G#C
M^L6G(/3WMO:+7P)$&K/1OE;YV!\\*D:1C&6]';'>RPD?;(:";0QVGC$^HM-U
M9=LPB^ HT]PD5.9CV''AX#@FP8]V8C;>9TWFRQ*C? \Y%Z3O3;U=\<Q-60U>
MP<?O/@L14S]R_?[*T$RW,F]\P-Y(GHH^>AQ9:D<'Z3@_Q\R73^L*&XHX<;Z]
M3;(T]Z[)?US&?3O /D+2<\4-BS4$=)&P;5?1]0M[61G?*FM* %=#PH0=TU/N
M)GBSQB4HX*<,Q9,0(I]%/J[T_NV&MQAN?H^JRBD1JN<GHWAPU R8:7C\!^ P
MKNK&R]OX!VAAH[9<7[]NCM1W+DM.Z6Q]9C,E.A18$9%#S[NX:(O*OQ^O'@##
M3SM$*(+T59$A+XGT/I %(C^*#$L2I^2LU+#9["84- Q"Q A#C)$<[>)5) 9D
M>@G+HOW.6TN.UNWP\C7!-:C!#L,B%-\]!7;I>B\4](W+^@1Q7"?)O+&B!M2R
M<'K.1[J 5H/[B#_N-EA! !.IF8(W0S->D#+^D\6$/[HO6WJ0H-K,/!(M>P%W
M8O4M<H*DPEGOYP^^F(FI%GC9KCWN*3AV K^L[3%E^LM-P6+IQ0#*R$U].;^R
M1C4#+!4:M\TZ,_@S-M&G68Q"7(B[^J@^@ZZ%\_F+)E<9ZQHV@:'%[O0W8G.T
M-'9J&L)U&D9[RY!;^KB:@4F@#"E27ZV#/0+I/@U*&G=H^@3%;\170VIQ'R+?
M/^=@>L1O?QN-]T&6SML63L0";3_":VI<7-#/0J]M;5I>/%JOZ-K:L[)+KM11
MC!TXC67T/!R^-+F6 !>77B5_+I_=$NL:K[O5U9H*%,TJ!W=%H8<BYR?@C9.#
M)U%E8F/LK2>_\#M^G<ZDZ][5R@3X6/%JKJ$"F"^^EQ\+^T3LX)!8([!YB["C
MV/LUN_!<(54WD,LX$,YLP,M15M;[Z7VU6B6#EFEH9>.MF4V:(C8^?+*1A [.
MMVDGZDT5/W0TZP"U]'WGF3(07K]Q:CX-_"<5])(C>'W"&3#APR%,U(=9[\&U
M=S,A_P-*<.F3][V0U76 J 3EAUF_Y172L'Y0_=OA>W?%BZ"M0,[3*P5-F5:B
MM-2OOGV-P#7UPP/?03]C$]'I,W??X9GA(E!LX+Z"@<&$,]I>M5QP/"$#8[SX
MCO6LP"7PO0+BDWG3PH>CB%X-R%HA8OQJV\"+[5KR+>P/R1!#H#4,Q?3X@\5H
M656HTO4%WY.UZ<6%AZB+JN_?:+H>2JATYKS+Y5W0?$@:H:FYMUO7 A67YO'W
M,!>>7 YD]/"M$01LM?0-A!JC@3SF^MR,6".^/,K$5#D^GD/878[5YQI,9!$<
MG[4TR1_PR5:1,XJ:U/.B?_8M$(;?_LY1#<S8<YHO9YUX\'9A]I>'..8..T/"
M4WB6MG3(;5_*TCB#NAV;^:$ZA3I\H]V7/:5&.8N%5;].=H3H*1$=)O3][5-,
M%/X!0)D@9"]  3\"$QMZB1-JPDE,W.>(,64MHQBFA0O\Y(.QD8?;@X <C@#_
M !E_HI[6BP?^I@1APKZ2E:(6-6WSA)IS8XXR['(QVXJKWU&N7O P=[ZT.<KO
M=9NB_KK=)=*<Q<-2=Y"[S5!AFV8R>=R$*Q9:*UR[_?S=(KO=C_0>9BJVXE^K
M/8>.5U+R;R41ZJ*,&L)S;K*1)(818]_2Z*1" U_)1T./7<Y";,X@]N:)]1OS
M]BV_#> <?5>'G*Q&MT];\Y>Z$,QU]:89,06%9&:"DD?(S#D;!@C!G?D*>=UR
M&>NI##&RQ#PMS8P&=#\4%#P825Y28L3MTI&UO)!#?I4Y<@(1TA$H.\55"2>L
M (#BY6#/R><9]-=1R2683@.7:_FDNJ;"8F=8^;!["]D'04=#)1/*#IV35\'1
M);_GO 5*K/5_@'JV"M "4J?G?9^'+242!XZ@[MEE_1[1GJPYX3#_'%]YK2@1
MG7U"$-$;+JB*57?+&((GC$1B'DN2C*AGH*,?YV2T@Y5$0"+>]YT30)LP_4:]
M]*K1NZ;Y)CU%6#[[R=/ 3X%QS([;F:V-+6[-?Q<^7]"*\3]8N?(:DM(!$;6M
M*J+^ 32K$,3!^G"(:5GB-70A03[.A]E?,D=#Y>/H\R_!9SMX0=[Z'%=,N(K)
M]:MFJ+_@S "!+>\ D@%6[V2[=%'**0N=,___=&.)HW^  ]L1SW%_):[&VY*6
MPD2'HY&S7DF/'XGGQLTK^#J#C-T%A2(EF(L&X%3\P=#1_[(;ST/3;$#WA=DZ
M&Y$&<'0X_>P!TNG$+=U'.)OGVZ9*&N^1;D1.3HCKV:>2["<V$P1P+7^OAMKM
MGN'ARK;T>(^SLT9Y=9':1J AB-!0].W] V13?CBRU#CNV1_'&JR_"&OY->U$
MMQ'-D6+=MD+H(TAN]AX;>Z+R.OWP8)<I7[ELNA*O":41@X-)..^0J"6UUKL_
M4M5/%)"FP^NE#V;_5"UG83W9W/V:D2XS#(^X#K7JP)LQ'\EH5Y2FB9+4_QJA
M'W> (SI(B:/VY?!CU7]?PQMY(I.L:/6/L=&L*?AW\VAQV[6G"/**T!#F_DN)
MSB?[-,[NH>"Z>BPP45W[+4IYP6B+1=LN5=[I0 DN^]=273G"+P,=&90R-+)\
MS(65 C8<Y1M-Q 1^WK%1NT2C/'$?>DS"3WZ8(%3:"/KF!B^QXS%U0_NGHG'Y
MTP1) [N6O0,?%+(%!X_B+VZRBU!_PK?>_E3Q;QU&"BX23MX\5KE-=9]^WL@U
M*;7]/>P*?(.\;FQ).!_RNG./JB1-+.#Z5ZX9.U_IBM"(&<!R?XG+UFR4MKUG
ML'53[=]<"\'\-8DJCV"?N%FO.SYN!AB5XGSIV%C79]KT1V^"FZ+MO,9"/3!?
ML2YQM3T%VBXY4Q_F%C,%AM@O%:$LD^!RQO?/H''G$IW3&6@ORCK[I1M&FC%$
MO.U;$8&V$PF;HYAS<$UYNSZ^^S2RW#G>D#[VQ;E_;R%E8Z_C!]V,9+#W)^BE
M&)/)-M7L!24#1XKE,HN"[J]/":1TK6ZQ66\Y=E8$KJ8R=1NIQ8C=-3%SHJ_9
M>N)K5=GC26Z<4;H0B,A&BU&?%>Q]MS?O?KWDNK8:-PR#P; #5=CJ6T_P0TLE
MZ])O'-]B=LM%^Y')\NA@G(FHVHF@[Y;?=+2.UL6))RL+0[;:53^XN+RFL>E7
MM)XYI%0JIE<K24OP(P#*_&Y'TI+CSJXCY Q'>C4A_C<=VEVM2EC+G>-MTLU0
MSXX"X<P@1GFD!B(X\WH^8D1F:>GI,O!)6-U:DE+_K:J7*V_$%J:2Y2\Q:PDD
MQOSA(0(;,_-!RWMR%Z,Q1#.]@5D9 2E0)F\BF4Y\P'"VX'#;1B)&OX+[X0]P
M@N#+T38JE5:I"1"7%*&))L;L*T^,52]X'-!XN"73/NGJ\CNEN'.#(3+7O^>O
MJ)A0'1,+Z;E!L5_^^3"#1Z-PM!)3-:E(_*!<S-_X2XJ?">:5RW'+QK\H(U?W
MZ\].8HA$D.;'K!EEQ8R  THOYV0B;(>> S(\(R&.]='*%L<$ST6VMY30GXD>
MA6;-0(*O'LOY="D$C)%,M7^0((B9W74TEQA(^SE_;+/^:*9MOR3MPQZ<:5J0
MS]L]TE=;^)I=QA C3125C:F<+D"U"#<9MD\E5E.1E?#==U-] H\E+=<OVRVV
M<X]'F6M\4'X-3M:S17W(B\O"V9%=C:"/L0,J:]2/%X1\J8E=K-P+E=3%EE^W
M8K%CQQP?1O$_%>@2M*W@\M4XZOM9T[,S4FICX58P$S*P<V]J8CW=O\1(=%C7
M]%W87 T:])@V>M5"Q'T9>&;8?94BW$:9,RH4L08U>>.+DDK&.9B,SL<@?CD0
M7/^MF;!;]MWND(3&<-GL8,&LDO8*DURM676TK^&?-4..:63<W*+RY( -L4#W
MBII5)AB32:'Z"W[#V0HFW?3A&R +N9$.2,JXYP0&'4R4 B%(*&3MSY7J[\FY
MO5^<-ED@^Y-MA1 5@MJ6%FF(0U_>(=%$>TX165.,%1XK=J=B1HO1;!JYN,7J
MGU_[/\-<!'>BL6VW,CI''[I;(<KV.;P():0<W<AN7IA(G\'@!2AXA%KQ*V'5
MQ&T8B8VKKR;E35V86+-G1\- \Q4?^=+C74Y*,X/NLG%)AJ)127Z@I3#+D*(C
M2I_ZL61X^_-*?F H90/PX^JI0KN'Z2--E%'&=Z<.I$B'A)$%8*Z 11<7A61F
M8^49*8;1ML=5X_!%93M$]*I%B*]F[:$^L!LC('D/1O@)C!",&UOM%LW6Q>[@
M+2\9@'G_097JDV'J0>E(S9X 0XO9Y:UASNP&XNV+.[=3MG4!T]>/1)Y&;,HR
MBGL+8[*X=3 EI)(:TR(38JF4I&S!F3/%>O@I.ON\EV6&5,! FWT,0*MTJ;LB
MWT-^W<O,/Q:?%YE-;LNX?_2B>/K<Y&V3R1@HG8F@JYOQW6BO%G+N4GR6I- A
M#I>(!9J(QIJU_O#5+NCV<SO>-*Q>I6FEQ+\Q^&I7>BTU([*/Q(#@&-/91H3H
MHS]NJUMMU9(5%H*@NJWAS=N*5XEWZ=Y*NT25]5;ENN,M4M\IQ,$5BNF]NL%L
MFJYN[,K%_:C#HLU@$XM:II8L%EO5<HOP<<QXX'Q&3R);9%/?([;EL!I;5A_G
M85?SEC^^D%!6Y;..[%C3R?=88R+-5/Y/1.K]+!WK-OAGDTY7G/>,0=K)SK0D
M0%S#!-QN[D^LPME:4]S R:>@TM^;HY61_2N>_P#EDU1/^C96F61;("@5I[Q*
MO0-1S'X0(\M9%ZOP5^T>ZO'<5+V(@+30( H:/H.%U@E13T)-5$_0K.0Q-L$G
MB2^-<TLBR;&H:I+=HLUI>+@F=VJK7VB:5"FV.;=?PIOIKU^OTU%']&HG8)(P
M>$7Z"%BB,-UF_2A9)'6[,I+383QK N,&[5ZE\@I_J/,=&]IN/^W.K5J[$(9W
M"<N6NQB:$.HC[)HQC6J=2X-T,]^VV'3!(/L GN0Q1+L'35$(=V:TP7(Q12!1
ML&\<2@)A4YL=.M*>0F$M2-K-SU^T@$(=0$2_39X]0:PL[#7GC L913]!T[KK
M.1(_AJ::UK]MAK9%>Q Z5/!V8B:E6T85JU0T[6GB&/&@DJHVD4C+\2#T22_0
M99+\Y:+_)6SQ[H5*NB>-TDX3@0:%8YK"BIIUOOL=(V?":?,CBG1G2Z[83\X[
MNV+YF3NLK/#%QX6V[>NQ(ZC785G+TJ&TGNB7)T=<8ZCC)J"TLOK5%+,^AW&M
M)[F#TU$@2DA2@42X%=2@(9Q\.SB1>S:&*DPA_68TCB-?&<LS8?N+)MF1B61B
MJ3=*I<@>$U\-,59G&SK*=_Z)WV$%(LPDO89C^ODQ&N="-ON7<C)GPUZG+7+6
MEDB4'!\UN3.6=EJ@O13K0'+:%#@3^Y%568KF+$!-4I1^)TIJ#Q4Q/(.L!IUY
M$%/8&AL0F8 IA\[<-"8\C(U 3L&-C:ANIS6,Z>[FK4!.-K$*;4M1+&.B9<@$
MBC"!-2>ENE:Z7V_^%PT[&SS#)2UC&M;_EDI5A+"-OX\.'XG)59VU=F%0Y#I1
MA^BF+QW<^PL\X13IAY24+62I5U0VX_Q0X='+@@M#B@9R%*DM>2DXY_[YF6&X
M%G9$[C7U>]4NPRZ"'D@17^DU<1&9$4D9AX3^C>U.W(U\ZQ?G_LDD8CQ8GA1=
MQ8B>#<>'5,[;GN9A'!/;K5?1P7'7]*:Q[*]%8(2ELL?3U\W(-;&&F?[+V<&F
MJ<J2>WV!A]D EBQRD8R"'=$>5=:I,S-WLQ%SH\4E<GLGZZFV?10 #^_F@>F0
MI^%H7IE3:2)A%.Y'"0/]@/3>2%769F<2) ,K JQ)AK-&)QC,H]8Z8WB2(84M
M>P[)IC92+QT-0,,8CY@9/$ &ZV 7[?[_0'*A>W9<*N3PUP_!K^KOE9B,J0$G
M?@L8&7UOAN3]4>D9%S4,_FP ?O/LR1)5L*STJ( R1!F><J(>$1^)"<"RPQ/=
M.LF743_*)\,5#27G!9TB9"2Q3C#!#FP0_>6D380]C$+=N7Y8J+>ZP^+>J&X'
M[&[4CS:=';.+HBY>0;3E5=W%M(47WZ36K[G'1-25QYT8'OVGM*DLN:$[C^.!
MAW=4JKK;)@>\V6+?$;V\3TR_OV;;](OT &X_51E- 9E6#<DI'Y@ANA+NU>7#
MS)ZQ/_<#!-VA=5>OEZSO,@2+2XT?EN,5[Y1XLK)Z3+*6(;'&AGA0JUX*)-SR
M&NW-D&6V,)Z]PLHYS (0>>5I>]=EZT^7AU!BY4#W^4J"V$YM_-+8@Q2>@H]X
M%5>I8(JWE)$'#XPVE-NZAE=JF?;R(3WC(]^'[.8^9?$5."<$UNL<_N?!4$9O
M7E&7(\.R0G;,QY^_%D2ZD-!#[-G.#T+<3SU6*E(H>.1YZ-78>A78D:F^2U/3
M8(FP5O7?15_!&M.O7C&+4?K<VMIAA: ;6!M'K,+]3HBW,KOV2!K%>TNU@G5.
M<O-45F0=.4BT$:+)EN-O?-I:9H-0&90W\<FNB,A]I<G)&:_)!?$S#J4%+D$Y
M@0@N9C.W/;*Q0X3-S.?,>?<0Q^P@3UKQNV%%_@^&2U]1*YS<%''UB1.222*Q
MBR>Q^ 9V/5X?W^Z?3N=G3$P_%X)RBBFG%Y+)8[,,LHM .8KX0,I>?H]I9=GF
M],!H8OV& )ZZ2\[8D]1#[,]*3ON?_+,)?C0-J)W7L,[VEY@:&]IZNMNI3T-I
MDN= X@W/>'ND98@^=OGT7UTF:Y>ZNMQ,B>YSPQ-UBYV^^V@M9-CE7["2,MBR
M95!8L23'[,=/<$0QLVUM,%](&A]N\7U<(4Z[RO[>9D-LF.8/9#-(C+X;):"@
M14A..*>O TQD-0&>Z$0[>L63QTYGFL\.9_W'9<[YM59_#5C9 _RPA!OC?<AX
MY&/YY=9U-I8MHD[M$'<O)I)=[>VJ77\< 3L\J10T1F;:\P(D,D=.K V3D-O"
MW)(!64@6(@1EQQ2)>&BSR,3]@1W15Z:?M?^SMZ<%A6T"=_H8@^0AMKZQ_!G1
M2:2,NSF]#T79=D \H$H7"KH#],X4/ .E[IT*W%P)+4<2,#8U-2^\.F5N'"@:
MGJ',JCU!G#$K='43T(KH-B5[BA'(F\-T''D>,[CCZW%Y<"K>M*0H[22,J0<Z
MVS=^^/XM%)CO&DR:J:\O0<^2!<!T-7 G]U_Q<?*OGYMY,B]0):)?/[\\1X*T
M,FK)I!QOI'Q-S20.8S-QLA-F']*CYF;K__S.I11!+V&]'+ ,#4XBVVLA>K(3
M53%O0'8;-$ER[,6Q@A_GH1E%YR#5'YE]16&,KAA18;X;D43Y&30\(SWDW\-C
MU'HSB0G.N;_4=3)1VA].*[NI1H= <NGTK%<2+Z]Q7J0^J%^ZCQ_HV]7+DMIT
MZ(![!1]G5J[+8,YUXJ!3)ZGW7O!WIT[YB=#9KN&WK!"HR.Q0W4W(!,>/./!+
M'*T:BJ_SU1-1W,?8=G/WH Z!/"/W.L?X<:3\2LYV@)+=;'I\2L87>08>:0:#
MRZG93>1=I;&G.K[-=;:5)+\"8RI+"Q8/.<J*!@M)3CQA^QC=!$2\J<YQW/3
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M3B$P,BCD##*Q@H&GT7Z"_ _T1.+OZ#45TT[1@X$@-O??N$CIM(I^$0R'@F@
M0'V!/Q 1:>F$=$(%B2  ($[(FH+&D-^+90.!%(X3"* 51!4?W;IUTSK!%"0
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MG6*-&Y5I=52E&K:9#'K$8N0302-1#9L]-A]@0 (6 3%D(?W=]"L <5Q8;##
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M2D8$D6N" :'!+N&2&#8J5EKC(4^ SW&HX!C-+P:=1A,,LP-:*H(5WA:SUVI
MB0J*'G'S0Y5JH]$Z1/$XWA84LJ@,FDV/AV,<G1 K98UJN<4-N8D"/F)TL@TR
M)UGCL 28;E? (_<0@C(D5+X2 %WJ9/.X>IR&A5;F-C$: R$1"%:"W$^+J85N
M)Q/0.820GL0&O"JJ7AC$\[@F(0EEX(B8'U!C"2^'I&2$E!*&G,BV1M2:2,S
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ML['ML.#);B^*AT$RSF9U1A!*',<2VO4BOXZJL4GLY* WAO=$*2JO2PDS'(Y
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MD<*BD^*,"$CE&X@AD0C'4HKT 1W5PE%R)  2I[B @-O#_5A%*Z?\SY\/^@T
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MGE5Z>$;_F.#&ON0Z:<6:?N"LAZMH1[LC!YX*+TUNNHDV_G[60IIQ 9*0)$J
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MH"'D')&4*ZW^CI=QK;=QZOY&CRX19K\.7[\^MI:BQ[U!P!MJ:>C+D9VKO%-
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M%X739F</.AFM2SM[6$W=\;*D,;[17=,/P.9ZK84[!"D=E<W=V;B4JMN&18J
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M[EK?8)<_;_V]91=QR8_(\1]SWA_802IJ-_O\MBWQX^UR63\<3!:-//WP9-F
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MO%<F2RO-; 3Q<,G]QO&(][\F2[1P>$L" Q!DP0!WDWKWI.,C1P</B,C/)C!
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MMP%P_BM/#NZ$Q]7^9U1@#=85( 0%F^^N'\RQF$O,O +.CQZZ"L;K=E_ ]J\
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M$+LEW V579X!"0J^\X^ M>$H1U**1FW%3.>Z"R:O-?>LZ.B45M:YJ>G#8."
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M?X\0FAQ$K+J^D15#SH>Z3]N5*V1>8CA89.?^]=!&L3W^*^],]WR./RBSNN.
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M /IOS0>KI_E_LP?%IOZV^V?'NH7_;9X5FYV1&984KQY<]7@EIR?^E;$9DXY
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MV\69D"?L36=/E[[=., \+)UF%<*<*[P!'*?68<@UG(+G;8>E_A*CQOO4G<*
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M^8Z=6*)=EHC*D]-*=%*/2[WE[_>G2_QD$3M6"YL*^ XQ_,*"6?/]^27<A0!
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MR\E3V76\OA993C\GM; 1=(ZUFV0,?L3(36O*_40;"%Z=]XZZV/D7I(G<;B*
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M>V6L.O:@[GGFXO[WXHFL%5T;,-W9>YM_)#W/P=<A_:>#6"H?QUC03^7*&1]
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MNUCC*_XA-K31B?94-4/QG)I5+F+V4V8JC6!'2-<4A8G:Q$LR>.!APL_\BUO
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MA!#>_J$.-S]5/LRX6L\J]H_F5&^5GPHD59C+JCQJE >DF?:R(M^">Y8)<H2
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M;UN6]X-ZOMDST8/Z5^.,Q?W4(W4-[D.4M^KM(ZKFG&IBI5;X5E$'?$-Z+:>
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MA#?*F[K7H-V*&&U%GE#6J3Z\!B9-48$CIDGBE":?>O%FY9'Q1\2>HF1;'6!
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M.61$P9LZGY(=R_K;[<B9F=]; LG61&@CE?PJ0E(?2EGE>]-Z@P*?8JQ?0OX
M -2$T"MM:D&'F@4OBVSM9Z5E<IJNL0(2[C7XLNPC%EO/,M_[UM6BF6^G:*U"
MYCT 0/OXWUP)^Z-=)'Q;>JVE34C*G-]X5' _05 _09 6?K5V(_^!+\JR@']I
MBK;6CO\K+VN._*>JVK8K&:6:YO.*_HS;#8_DFQ.BZV;+=H4++;ME,WUCS/-E
M:Z>TF3LEO[*\^OI_:EZ;L\&E-*O9M^9#AK4A5-<0_\Y:JLT/7VE^K]DR_XFI
M7+-["M?4*^?]4G[_*NCKUJ:Z>Z4Y3:W6S@QSO<GR*?YJ;;,Y)SS4[&8Z,_]O
M(]3P:$JWL4M>#YB@DK(=1U3YEB%ZF23[_39Z149RTV9UE?NR\OZ#P(-!NWKE
MH/FSM+WQH"''HKY6$ P T.5A;6</RD.V:T#7LX]NW0 9G:P=F Z-7(;JFP"K
M#GJPL0%>->OUQO'PG8YO>L;!?_6OUHV$'%%E3P<G()]GDS;O16F3B_NQZ(1E
MJWO2,6.#+G>=QG1X3NL:@SD^KJBK#?/KS5+?H;%MJGMK%>%J]OR!&42/-=][
MSQ++E]EW;R3N#.KN]"9-\'3K6$)R&-?9025% @"JO2Q7FP)O_D _G_6DOX>^
M=\V>GF)Z;\R.KC"Z-4C9KJ<W>WJT*>GF<4_;Q(Q?LZ1R_[]M6!8\\"?O3=;1
M/@[/N*9EXSR>?TQMQQON_B!4VQHNSW-^JPNW<;Q?RS W"@!0W/M7E7[?]+=L
M6M:V7H64L<;4[279'2-KOR-Q#"IN72P>] QHOB7Q'@]L7BL4_U*A_ZEKFW*U
MB5F;>TYJF&M,76O4Q!A!VQ>5)&A=RRH5T-.]Z;ER]WAZDY?(#0"06_]3^_MO
MFANS=O4$FOY8T]*I,7)B1&UA!GY01C/"$.09VC1*ESI>VSA7]&N<D0/^5?NG
M@J:7ONB[ (FJV%K[ K8"6":>BY@'>HF#(#]#(<7;T3O@YQ*/8A-0+H%G<+[H
MF^/MB?Z8:7N]J^9#S_6NJY;"!18E>"\R4/@8>AYU$IL(/X,I*^I$#F"?)1Q'
M)^,S QZCWQ"*QR'P8 +LC^1R/:%CH[#*FYAJ'EO-(+X3X,!;2&WHS]#SY*)"
M#OPL97+\"22:TA_@C+Q&'>_X!'N#&K2+5+J.7=PU5/Z![6Q<705G'>.]K-[/
M4J",D%$L2$$&S)V5LOH,? ]KH7\<_#[SA2,1LX4IW#%<G"VS[_0N<Y/<T&^N
M:!=OXT* $T5&9 :H0JC,7PI1"SKB'L&B^*<62F >_!F.T[#YW-@A3.$^_9;V
MBR5:W:X:='F09AMG<66S:A 15&VGN)BW#!PA]XR; ;DG;5SP ,*4#(S=CWT@
M6+&]J(#26-DV7)Q35Z^#EGZP[&0OKD ;;\&75]W2+\Z%@F9H]ZW"@'>I^Q>4
M@=U4)\;2<?D"ET%E/FNC4]N8HHH.NM9:\J-E#ZNTG-CH"$-6/K*:<WJK \VJ
ME9=!QXU^?L^K[^KGCHW'#?&?#H[/N[BMIY59N&T@5FM7$M_3QMQ9-M Y!WJF
MTK/5+L<+6-;(7)E2_;K>RP\)/&8N'>N.M^,/;XE /B]-:C:C-U0LUCAA.JJ>
M,,'8CR 2="L^%O(B^PF! T^)W4UL19)\1Y,*4'_;+Z&-PTP9.  /A&QLHB'.
MP.1J "H-D<: H?] _H0<Q'JC&[*=<&3LDA6?\8TXR_Q<@C.>;'>'@B4<W[08
ML@WWON$4C(F_K:0AO E#M(_(7J(<3$6'D,HR7V":R,'+?V"/DV_,$V$?4GSM
MS)1GU,0^+8C+]*KWA50S@^1_PN8P@ZEZ^%'F0E D$L(,R;B&>LF,63X+X\9<
MYG,>?8?I8E=(S60&]+H &\1)UBT@DT@F@T,@PIV48)BWX$[U5/@YP?3T*T@X
M'[1L'4K+.^H3@G+@9=KY4GLYW(V7J]RUC%IVM9?Z;^DJT%=5/MD)LE?1#QP#
MH\IGI'U$N$K[8VJ0T1+QW$9$L<1K]%?J%ZY=]XV*&]9M%DG5<PM6LJ[ZI/$'
MR0NLUPM^O0E%NJ5IX; ?&M_HGX@I*M7<1;"GRANC+]$B.$^[?<J?M[\P#U?^
M:'DBY@.O-782<T -=16591"HI7P#&S;->"X:"9]C<)US'-JM4X_>3H-R+G?U
MEB<,>)D3*[-Z"T6/@7.[4@@#U3?:$BH.@YN;6E._0M?6#T8]@ZVU?IVS 2(U
M"$8WT'2<PVVMI.DE!PU44G_Y3F$8N:@*C^^@3*O^5OZ:<@$"2G6@UL*V1\IH
MU8B]LT_28Y 7_AD!L&6M9#P%K- 7$+*@2L$HXGPX!"<C?D3ZE;TDG41=2IE+
M;L' (PY2JK%'9R^@7,6E_Z-(8UK"L6[8M)K1."\<DG<?[X3'8\'XSX3JTN>$
MOXB9ZQ.)1TGA$9-) M(+SSJ2EOQ[!YSFWG0(]8'V2:O N-$W</.P7G0YQ@,W
MF[ZC9 @_G_YDW3+";(9[^%+")4;XK'<$$L/N=\IN;H0C?056322J0!##<403
M^-M1%S$\OE?Q5FP-3[TV&]? <UM*QZ=P>V=!<0(N:F1D:TB#]ZMRU-Z(5\H5
MK,^HJ?)/R%/H0%E=T1^8!&EVL@*[7A(>=AW[5EPY\Q7FI'B=+9LC8&SS5-4R
M^#%C$FL:XJ4^%O$:-4'G5_@2':P)6W,#$Z$2A^5C#BLQ,]7H8H5M%Z;N$-30
M?$$IA=UKS&7F(<;4:1!+D9Z6W87AJ#A3P)H0=(;!(_0<^J+>:V8T:JF&:E-9
MD#<]1J4C;'D7EK$?GM7V%FY$E#;#"MJ0C(:4I&TH:9U=: [J9RUYQB%DDM:6
MVDQI+&-)@329A2Y/I+FSR)6?H096?34Q[RKK"OA2PA%V,&Q2R /V'O@MUVW<
MY8BP?Q2QR)C)F DR21(949!6ZBA&%4P$T3"LB)3<%XQ[R!_QWYBKT*J0*.8?
MF..NX:PMF%V_4S;($$6]@MXC'D7SQHXB/Z!5X/S 9-HF?$3.5[HC(3I^$1U-
M7+C(2+].O#K],&,-4? [M;W3CR$?HCP2[J;X4[$D(T5 O0ZB4.[0HG)<J*DT
MY6H,=1_MQJ)QM)GT\=.K:9ZT]I&_2W>!-);G).@CL;COB'S24^ZFZA1R!C<C
MVXM\E/,MSD!9P]D:G$O1<HC3GE!2.)FV;'Z1T"I?Q^\B^LI$!#[1*-4 \T@.
M$EY6-(DIYJWZB_11U!=TA!PB"IK&(1T1VNZE'8OGZB6\ZX2)-3[X[02&EEZE
M(;Q4[\]D$.&JA:M6$>\J[@05$/]69$Z+(C)EMI6#!HK[E5%X$?@0ZPG\!'R]
MA5SYB.!HFIIQA2#4OUO91 345 ?^21RK^S'U X&D8-H2_7?L]\Y9W)TX59L4
MQ\"];]959N/3&U09F?@CUN\K0PE1M=! ."'4+)\JPV]5V/:798%B9O%KYF11
M;]E1U 619R6T+$DX!+R^ 2_$@/V6!PBKH3$+=@M?P'8X.8A_P)+^490+TG1A
M6'4O(UK0"MZ&?"X(@EI*<?S3\(K4G7PITGF9BD]'J1:LY-]&JR9=$2:C/OSN
MKSQ)"7\L*I/NR6M%MR!>\.(PUTM(W'?8KRFWN;OP$V*N<@?P7_VV<#\11)/J
M>8_PKT:>4+R!.XWTF/J5<YALA ]QR!3_8CYG":4S!<"91)T=X\,92^7X!7*6
M4#=.JN:<HQ;;Z@!KV3EL&>4[>R:[!7: =9MM*)*QVMG(]2 6C9T<W<EBL(-\
M;["4;)=)&:P?K,>V1 ]FC95LH(0SKXHOP$8S:\4^A0>8):*<=0IFA- 8]9T9
M*!SGF\Z<)[@V:1*3RK>=&!<,,-YI)Y,IC&&- S2)H5!M+YS$2%6FK;W!6*AP
MCJIFN,H#YW^@WY-'3WS*6"(VV-1<AJ?E$ND1_9LY'K*)OMU86D"AH_05:Y/I
MB;K-D1?H8=J!^5S:0^W:B2?I?F+;+XH_1&>U#)#P]+*F'L@B^M2&R/R/M-W6
M@>3+-)&E)Y)(@YG_FN]+FVCTF2BEE8IM(P!SM>9+<37F3[6F;$851(6I:,_>
MJ>0!QR;L41P$185Y*;"0F5[GE3E0-X=4I1GZNPY /\F@J1X#.S'^RDV@QLK-
M"C.$E>TA;X6M3@B7W8 _"-TF8R 3O)1R/^1?#E#91^3KWRG[%KU/<05Q#ATM
M/XSRJ;@OVXVNR$J5GL4HXV722=B6T&!)%T[H%2[UP0T[D"0-^("1)Z0=E[T@
M/$'%2U\2N\MO2;Z0LC(%DJFD-ZNOB(O)M"4MHH_D1[-OBA/)+QSH(BUEKZT.
M\$2ZECD&29;D,>/+/<0P9E7&)I&2"5V=+CS)1"P)%X*8I-EU0CFSTD$N./+O
MKC1UKOBK,!ZQ0^PJ^%96(O(7B#(F"./XG^-V"NA\S.*W_$]\[]E(_A=^C(.&
MOXQ[W58'X(G>*^6(:-$,Q>G2>T(_^8ETDB!$UA'GP8=(-R\NX]V2+IF]D-<B
ME3C(N._X<)NR%_D;;L)W"+/T Z7%@OP:O[0/_&PM?96%Q],L#KG(_:P^YCG$
MK55==I!P'O!M)TS(S4)M0PH\0["G[F3)4_Y0[9$T+J_-W+PJG'O -#]$R/4U
M#GIR./VZ=PX,SC2^+5=B^FNO%FT&OC%_*HW+CS&5E6]=EVKXN_+;LO'Z/ZO'
M^M_5,T#UKL%& >CHKR0U"?*[#5EKT9\L3E5R(,B45(W*VVIH!J]<>T?O _D<
M,ZA["N/Y]^N0\(VN(7HW> U@D7H/<G#D7N@-IJGPN*IF Q2AS'.J.8D<7ANK
M2T%]BPG33L:,\\_1<#$G7*=K;V $ )P2C0\=42B=83'N7N6Y&@.^-S= -Y8
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MMV5S";Q5,$A+0MP34!%.R)^"B<5'T>/XW!069BSO9\P]S'6>>4$AYB</Z%R
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M_0*=[0^ O\] 0%.!MPLOYVF #, ),";$+E$,?YUK&EB"\,C[O6L[,@U>9<1
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MQDD!RXCS$C]'3A)[4DV]_$E@P&:;WV3/S*X-#RAYP.V:+-HSX*S<P&_!]F$
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MX@/2A4G8W*R,7ZD'4HC 2,"5D,2<@JSCKN? ICF%)EY@+EBUW!NN"YX]6\:
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MYA\CN__7[DUYDAG$M(MJ ,*8GO[DG*W,1;N]02&,/LMV4!]#L/%ESG/&@(X
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M\.B_E'N^A)S\TR%"4IWZV6RMY%IZZR:0% AXNN*W;#+#;'Z;6"MKUD*&STH
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M@,Z,PYD7LNX!W^7,!^F!MT/LH5ZY47EI,! <F4] ,)&B A6J EU?V(;9AQW
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MN*/K(><SXW);&,>QZGGC,&3>\<"R%@I*^M= @::$<-1UX$./DS(A^,R6+G2
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M#=_YOD-U\B/<(SU#@ -:U2:KEB))#17;%\/Y1K?XZ1Q(?<RO$CHFG>EX"UK
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MRYY&UJ;<E1TB5FB&2XL#:W.\9SW$HH06&=M9QWPN:/O9&S;\5.C8;78SQ63
M>RW*DP!GRG9V&^#"W''M=,ZWC"7-BSB,^-5U&.AW:')M':3SN:KIAQ)<E\G[
MH05VH:)^\.G:*]PWX)$R:=<907;.^S8+GYTQI\F-5Q$_WR+B1H:&&XZA[C[7
MU0\1=U<?V0LXP@XOFLXI6+>06PFIRFJZ7&4K<MZVOI.<SOBKD21>$3_;?$88
M&>IKF,:'?,ZK-W$ON8;*DE$?.[T0@+O6Q7#'<T++MG4>4#?D?&XM4-[,6-)P
M0\Z/_\ML)_D5&J O%<$^8ZHF@;5K@O0\]YY=IW A,KH.C_9PSA^Y6#8G[_Y
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M VI2)WI#XYQQ!-VON1/-1K>!2_QZT4L0X>R*C84EEA]H'HHA.]$9:*OD,?(
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M-4$09HZ311GCE"4'FC_YU[GI=_\^?/FOG]D>?[19!9;[U/RP(89V>V\&[DI
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M?SZG03"7U2HZF#DH'LL9$??ECM1UY ]+;)!AB:7@U0'2US\:&/N^!#5>JX'
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MFCW#LN;,L"RYOQR .PV(#7\%E!T? O:^98#ON0H(?#<#0; +J(WT?EH3'_J
MDQ9[JS(O[2JY+/\"!EMZ&DY#+I1P\(<*1.29/"5M*MO(&,^TL48R'.RAC"E.
M=_8!3DO.-,>2.UUMRI_F&/(/_&( X30@G0;J]G^#:I<O@<!])1#Y; 3BP-U
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MJ/^'F;L,:[*/_\9_TMC=G2@J#=+=-=C&8,4VV-BHP6#TZ.[N[BY1006Q,,#
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MN]S"H&'WRM#KG,:(:R['HJZP^J('6$,QYUV>Q)SB/([M<GT<V^;^.+;1X^^
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M*?;QP),NYX*.NPP'=[+'@YLYX\'U;N/!U>X3095_ 9Q_]Z/VBD$$VKU3%%=
MCL9Z*#38.E=LMN=S,4;Z?:&=XLL\BL:S3);1O41/F^O1_J0KH6&,\X%QG#Y^
MFF</+\_G!+?4K].C+K#-O3VDQ>V,H,EU,+3![7EHM<<+0;GG"T$)]T5($7=\
M0>"Z2P1X>\3^^S=SZ0K+(5]C+93H;_Y19KQSNMQ2:K(<*S-62E)YD,LPO)'F
MAKF<X$/LCPIV.A4:Q3D>E,3M\,_R;?$M"FCPK@JN]6H.K>*>#*OP' @OXSX.
M+_8:"ROP?AZ6QWL>FL-[(5C(?QGXZ/F(/2 )F?++H$A]-93K;/A29;CM?8WY
MGHD:FX./*^V5;Q71#*YD<S#]*=[$GO@ QK&H<$YK6!RW,3C-MR8@+[#"KRRD
MU+<AK,BG*R*?=RXRS^=N9+;O:$0F?RP\@S\6ELY_'KH0<$,S^.\4A7@I"<A!
M[\]2M55S55KK9FKU-K]I,-DQUF2U[UX-7FFPE*I_/I]E?3K3T^%8LA^C)4[
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M!>&\\+PX_Z#L]&"_S((P7D9U)#>C/<HCHS_:/?-^E&?ZLTBOU-$([^2Q\(4
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M'6>9)VGS \I>$7#>CW9OM/^'R"Z!*+55$*>W$>+-=D*L[8'O442YF5"ZZE2
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MZ/<?AJ#WV1CT/YK,#ZP.BH"YPK\[(^)@KR()%)WEX&BV'JBX;4!RW OVKM*
M\Y,%FT@EL$H]"N;YZF!:K@DF]5I@W*8#1B=TP;!/#PPOZX/!;=0+ S!XC_J"
M^FWPVQ#]DPD8?#0%PW=F\_LO@Z6<*.#EQ8"H)/G?#A'#9#W0L=N 2MD+)/8A
M(/C* 2Y<"3!)JF"5HP$6I5I@7J,#IBVZ8-JE!R9G],'XH@$8WS0$HU'46Z,Y
MHUFC7^C7-V,PG#9#_\8<C%]:@,E\P!K-@)$1_6]7@JH@ <X:RX%EO!Y8-MN
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MC@T.9ZF=Q#/47O(IRC5*-V6,<ISZD=+A^(/:3/M!;:#_H-0RY@<.Z!JPMHL
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M'A)]728O]K1"9='M$KUU5_*M=O5G$HYTI]".=L:S=9NCN*:U8?[6%2&AN)+
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MYQHU5IVL-=[66FESL+;$0;&L@*:9G^-BF)'I:9&<QK>-2PDA1"9&DP7QR;3
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M1>=?08__+H*XCR&(XQ2"$$ $P<!2Q Q6"QG )B%MV"FL!E(BRG!$1 $4165
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M D\U4' EU/N>3_J_.6&A0$7K[W^;8DQ#2WLZ-/=B0-,P)C1.8D'#7'8TJ.!
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M97>YCLDMN\PH;'=94-SJLEUIR?FP\F;GWY0WN#Q6F7?YH+K.!577NJ+JW']
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M!GM/"1GN>2"HO_N=L/XN%-';B:(_6B;/X/HA@ F2WTOR&TE^Z1) YDZ V'T
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MU1)3"2HX1Q.=HT'F2("[_ ]-I%]!^EE4^UBJN_\5P.E;P(:T!Y*VWN^ ^A^
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MZKK-.D)<UW5K?Z+K-N/= +?IW/_A&*W#G33VZTA_R0SRGAW E#GD_<@+%R\
M<A;RD;Y(&2F+]9'4:XGXWA%,3*\K&[G8AQ>^.$00LCA:%+0H2>*_*$OJNZA(
MYK6P6LEC8;/*Z)YV-9>>A>I./>LU1O4<)+[7&-7]6'/4_+\U1\[CM$9V_<O^
M<50#LD K2;^;\FXG[0D]Y/\7 _E+@22R1;%]BHA:I86(U:8(6VV#X-4CF<#5
M'HS_Z@#6=W4XWVMUO,!C=9K0;56^V'55I8+3J@;IR%739 Y]"^0C^M8J#>_;
M3UQ5&K[RD=*PY6^5ARWC5+ZD_RQN#>DO[J2U0%:L=1'Y[V7DO_O(_Y(7C=D
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MK[(D0%!:'"XJ*HI3*"A*5<PMS)%G%Q2K9!2,44O+;]1,R9NJG937I9N0NWQ
M7.X6O=C<X_JQN3\1S_3B<CGZ'J?[)3_2.)RFL=]72'.1]%>1_^PA9M%]6X4
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M-3%DIQ$&[[*$U:YAL-SM!(O=7C#?'8Q!>V)@MB<-IGN*8+*GCC':,X4QW+.
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ME;K5SY6-KE\A=ZG?3IR1NXR[+7<9^TKN4L=]P+7V(P=H#FZF?%>.!>:-H[5
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MNK6(QKO-%(]S6R"I<^M3J'7?IE#M?EPZQOV&M,KCB;32@U/XA.0S?U#MK_D
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M[U3PSELF]<K;JNB9=Y+X1=$S]X6B5RXG]<KYE\-4@ZVDMXILP+P"6@L%'\^
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M9TX0&OK3--"GOR#WYEC.7"]DG]MHARO9Y]QM]/_L;P1U?8\ KOPU&UIUDW.
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MYPGW.$\\QWF0'^>D/L[&C[,CQVGPCUTD--)'/R3?D!^PB+GN9I]K&6KA#,>
M/QJUB7-0?@W.'NH?H/X1ZM.N:].?JYZASZ9'QP55PC@N,(Z'&<?#+,@OTFL_
MPC@NL2"\Q)/_92[VEWF@7^8@7V;G+C,7EYF+2]?(;?(Q^1P+5BBNPRF;Y;&X
MA<?!+OE]4(#G4<#A)/6IJ7]!L?^B]"BUKY!K\SRAP@)(D\6H+G"#YN0I<Q9E
M+,J?D1?IS(>\,+C%1?\6Q^06!_H6!_;67N#Y<^1)OG^-_!M=&[DF;N,\9)^3
M#G$=H*[/6<")*3._#.A14X-#*#PYO__RW/Q>B)P7R4MBT!"Q,*91>XTY>=T$
M>-,&>,L->)=QO,<BY'W.C?>;:6(XR>]P@.]0Z Z3>8<=N?,4FAA6*7.=\1 0
M_3#G '6=J&M&7;VG +7[^R\OS>^]O#&_%_+O^7MSWKV_'Z($?* !?$3C^ ES
M\CGGR%>NP+<<E^]8C'S/$\\/7.Q^X.#?XV#?X\2Z=YJ<I^O]?^T_>)(PDDAR
MYNZ'^8M>]W>TXU?TX6<LI(L?QSTLI9.>H4=?2Y^\$5]C.[["7OKU(_B<?O=3
M7*9W?H:^_6VZ[J]PERW\/^]#@1YY</_!<OZ>G$#JQO*W,JA91+UJ:C7A&W12
M8X :(_AL_CJ,C[&2.NNHLYEM[L0=',![.$'EAYFNZ_3MK^)U1G2;+;W&EN6\
M^@ *;75R?__!A+H._&D?ZD:P?\GL02[URJA3QWZT4J.;&H-XAW&\A<4<FF4<
MHE746<_VM^(5[.'0'<$+.(-;> PW^?<S_,VGF;6GV+.YZS#(C7ED8A7^+1#Y
MJQ9SK<_^6N,+N+./P>Q;+(<[G7TJH$X%^U)/C39J]%!CD*V/<IHNQK.8ILYJ
M:FQD^SOP!'-Q%2?Q.![!HU2_Q&@?86\>QF]$]G^0<2K)<!\5YEF;_35A/QWP
M3^;B->;B)<Z+YY%%G6*V5D6-!FJT4:.'A^H@>SI*G4GJ+,=%SHT+')/SS,59
M'.6L.(]3_.D3;.D8Q^,8,WR42G*.S"/C(2Y3YM05*V[]^@]4V5\]ZEHRAZ[L
M5P!;B*)6"G5RV9<2QE[-EANIT<9L]^ A+*#.&'6F<)QS]"C'Y#!S<1"'L)]1
M[&,V]@@O8;?H8^Q2NH>=2C+L4%:P75F^)Z9XU,Z'\BU.+C4O<\EY3JS)<3+$
M%9$M+HD]<4$I!&>5X_"02AI.J.3AF&HICJA6X[!J(PZJMN. 6B_VJ0UAK]HX
M=JLMPT[UM=BAOA7;-/9CB\8I;-9\#!LU7\0&K8\PJ_T3UNG(L':>->0G?>!C
M4RXK7&IO<IF[QF7W4<9S24,;YS1-<4K;"<=T?'%8)P('=!*P5S<#NW7SL5.W
M##MT:[!-KPE;]3JP6:\/&_6&L4%O$K-Z*[%.?Q/6Z._%*OT36&EP&2L,7L"T
MX<=89O0SEAC+YIB:YRL+X!U[+D/.]-Y<[L_9TO?QL^-&*CALH(]]1C;892S!
M=N,@;#&)PB:39&PPR<*L22'6FI9CM6DM5IDV8\:T$RM,!S!M-H9E9M-88CZ+
M2?.=6&QQ%.,6%['(\B;&K.YBQ/I'#%O+L/ !/J+NJUS>G_"D[Y7P-,:E;1]/
M@;L9RPX+'6RV,L-Z:R>LM?'!:ILPS-C$8KEM*I;9YF");1&F;"NPV+8.$[:M
M6&37@S&[A1BQF\2P_6H,V6_%H,,A##B<1[_C4^AS?!\]3C^@VTDV1]<\[U+_
M.5_FWI^G5+[N\0:V,I:-C&7640.K'0VQPLD62YTEF'(.Q&(7*1:Y)&#,)1TC
M+GE8Z%*"(9<J#+HT8L"U WVN ^AU781NMQ7H<MN$#K?]:'<_([2Y7Q=:)6\+
MS9+OA&8/F= D1Z+@'SX\Y04#9\A^+NU;>)J992PKO>C_)2I8XJZ'"8D%QCR<
M,>SA@R'/4 QZQJ#?,QF]GIGH\2Q EV<9.CUKT>[5@C:O'K1XC:#9>QD:O=<+
M#=Y[A#J?4T*MSU6AUO<-H<;W&Z':]T\B^YN7J'DE@N,?SA*'S(;2;S&6)<S+
MA*^ 41\=#/F:8,#7'KU^'NCV"T2G7R3:_>+1YI>&%O\<-/L7H]&_$@W^C:CS
M[T1MP!"J Z:$JH"U0F7@+J$\\(10%O0XN2V4!GU%_A!*@F1SE)+GJ'DI2G$-
MS!8IL"J2^HQE40B]-^,;"-1$3Y A.H.LT1;DBI9@7S0%AZ(A.!KUP4FH#<Y$
M37 ^JD+*4!E2AXJ0-I2%#@BEH1-"<>AJH2ALNU 8=DQ4$/:H*#_\%?(%^5W(
M#Y<)^6$*GJ;F^5C.0Y8]&\@TR[!QQK*0<?0SOJXP-;2%Z:,YS (-X4ZH"_=$
M37@@JL(C41D1C_*(-)1%Y* DHAC%$=4HBFQ&062OD!\Y)N1)9X1<Z58A6WI$
ME!5UB;Q$/A-E1OW&5YF0)55PG9JG66;L(FO)%$N?$<;2SS@Z&5^+5!D-4AW4
M1IFB*LH>%5'N*(OR0TE4&(JC8E 8G82"Z$SD1Q<B+Z8".3&-R([I%K)B1X3,
MV.5">NP6(2WVL"@U[B)Y@7Q*?A6EQLKD"'+D]X2=2*3O)BO)1*)B_Z6;<;20
M^E@!U;':J(@U0FF<-8KC7% 8YXW\N&#DQDF1'1>/[/AT9,7G(3.A#!D)]4A+
MZ!12$Q<**8G+A.3$34)BXD%18M+#HH2D6^0344+B+T0F2E0@/,82YPA+\4UD
MFHPFTV_QLS;FHYZQ5"6PUDS41%&B 0J2+)&;Y(CL) ]D)04@(SD<Z<FQ2$M.
M16I*#E)22I"<4HNDU'8DI"X0XE.7"'&I&X38U .BF-0+HNBTF^0C473JS_Q:
M)HI)F4.0WY=V( U83Y:0(=+%SQJ9CRK&4\JX"E/5D)NFA^PT,V2DV2,MW1VI
MZ7Y(3@]%4D8T$C.2D)"1A?C,(L1E5B,VLP4QF0-"5.:D(,V<%2(S]PD16>=$
MX5G/D@]%$9D_$9D0D2$3(LF%3*Y+&< :,D$&2!NI82REM @%?)^3J8R,+!VD
M9ALC.=L&B=DN2,CQ1EQ.$&)SI(C)34!T;CJB<O,AS:M 9%X3PO/Z$)8W(83F
MK15"\O8(P7EGA*"\I\E=OO]1",Z5"<$Y,B&$G,ZFU2$S9)3TD"9206M0P-=L
MEN9I>0*2\K407V" V )+Q!0Z(JK0 ](B?T06A2.B*!;A1:D(*\Y%:'$9@HOK
M$53<C<#B,2&@>+7@5[Q+\"U^B-P@=P3?HGN"7Y%,\"M4<$Q^3QI92H9(1YYB
M#Z@DG_HLR5.+@(1B>L]2-4C+]!!19HJP<CN$EKLBI,('P17!"*J(0F!%$@(J
ML^!760S?REKX5'; NW($GI4S\*C<(4@J3Y(G!/?*]P1)Q?>"I/POP:-<)GB4
MR82#A8KKD29('VFF9A4IH&X&K5IB.6M^6J7P:B4$UV@CL-80_G56\*MSA&^=
M!WSJ_>%='PZO^CAXUJ=!TI /]X9*N#6TPK5A 5P:IN'<L!5.#<?AV' 5#@UO
MP;'^.SC6_2DXU<KFV,6R?X:,4*^+U).R,LZ!"B"E"HBMH7X]O5\3O4^+!CQ;
M]2!I-85[FRW<VES@VN8-E_8@.+=+X=2>!,?V;#ATE,*NHQ&V'7VPZ9B"=<<F
M6'4<@67[8[!H_P<LV[Z&5>L?L&J1S;&96DO((&F57P=$BJB=44OOW4#O2WL4
MU$;]3OKO'B4X]FG#OL\ =OT6L.VWATV_&ZP'?&$U$ K+@1A8#*3!?*  IH,U
M,!GL@O'@.(P&9V$X<  & X] ?^ 5&/1_"8.^WV#8*YMC+?NYB'13LY&4TQKF
M4CN%VE&T12&TJ[Z]]-^TBPX+ :M159@NTH')(D,8+[*$T;@##,<E,!CW@_YX
M.$F WD06="?*H#/1 NV)A=":6 G-\=W0&#\+]47/0F/1A] 8NP?-T3^A.2+#
M="/G(FDCM<QW$:UZ1KMB#RBL'_ ;HO^F=7<<IS[]N3']N=YR-6C/Z$!KQHA8
M0G/&$1HS'E"?"8#:C!0J,RE0GBF TDPM1#.]$&:6<,!IJ%?0O"^GQUS^%A?$
M+\F/Y#>,,\^]I)FZY1V<!SWTO@,< _8Y8!'UJ>NXC/KTY\:KJ;\.T-J@ I6-
M6A!M9#&ZB1YWDS5QX@'&8FPS3_R;8Q2;WUM*%3>>;68G-J_ES^PG--,;:98W
MT/=O^)[0.5*SD]3T\5A@OE.'>1RPST$,W9.ZCFL 2UIE(]I4W:WTX#L I=TT
M GO4@;TLR/<:\*3+HG@?X]C/HO0 BY\#//$?Y$)_,(?(;T;D8!YD @]L)S37
M^V^0=\@7_+WOT;^ :Q+S73H*9-(2Q['/H:L [UGZ[\W4IZ;1'D"'75"G91<=
MI0DY04[2')VD,3A%S_\0\_$0\W&:7OL,\W&6<9P+(SSQG.<!?YZ#?)Z=D_^'
MQ.?HM\]?XBO-_+D[Y#-TR*_#F0+REG,,V.>(C9R##->%NE;\<4-J:I\$5$_/
M[[\PE314H*6F"1 1-> Q+1;E- 17C("K- E/L"A^DG'<8!%R@R>?IWBP/R7_
M#^,I]#23^30;?%I^7\X+Y"TTSG!-9'CI['/T3LZ! SP&CP'63)G1.>H_ JC<
MWW]Y@CQU_UH4\BR1[T_<8DZ>Y]B\,']_SBMFP&T:AC<8QYLL0O[%D]*_.29O
M<9*_M1)XFQU\FYUZ^S$:BZ=0Q>F:NXOK,?L<RAQ[4M>._31^G/J<PDHWYO5N
MS>^#R*]#N3V/?#_DS0?V0]ZC:;S#\;E+P_81Q^93.^!+QO$5"\6O>.+YF@??
M-YR?WW!B?[N7,!_?7GA@_T%G?O_!>OX>D/O/!,FD6R_"[_28O\P]"Z,3]S!
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M."^>@!]U(MB/!+:4P?;SV7XI#\MJCG8#VV_%*<9Q@G$<9QQ',<EV9W"(8W(
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M5FF%R4HIR@*%2BZJ5%)QHQ*+>RFA9+#B2ZY37,DMBBU]6#&EBQ5=NE%1I8?
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M'.?&GJX0^:Z0R:Z0N*YPBN9' ,2L"4+41/;4^ GX6@/1T9/V=7'5@(J,?4B
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MMBHT.D0AT5$*CDE44$R&[+$%LL56RA;7+&M<7P7&CY0E?K+,\=/!8S+%KU-
M_ %P%OQ&IKAO=3WR!Z.O%W2U 52"8I ',K$GE?>20#SVQ( (KH7&>RHX/D#V
M!(ML"4&R)4;(FABGP,1469+R0)G,25UD2NZM@.2A\D^>(+_DN^6;/$\^R:O
M7GDGOR3OI$_DD_0GC4/^ /3U@)[5@W)0"+)!>J)1^R'?!;$@$H1R/2C90[84
M7P6FFF5)L\F<%BI36HP"TI+DGY8EO_1B^:;7RB>]A[S3!\HK8[P\,VZ71T:[
MW#.6RRU]-\)/\_B1W-*^TBCTM$&5NY)RUH 2D <R.^L_Z(P#43P/YWHP%,Z6
M[J' #%^9LDWRS[;*-SM8/MF1\LY.D%=VNCQR\N6>4RDWX^:)'+AF[ACG!NX<
M$O6<I8#D.YN,*?M#\)6&(;MWJG,O4B4H CD@G6O)( '$@ BNA4 3;%GD_]D>
M,N?ZR"_?).\"BSP*['(K- 8RG56(H85P_T(X7E&#\WC3(KAF$=RFB,R@D%RZ
M$!)0 .\N('LL^$J#D-T3V750P[+./4"\3H.^)[EJ4)%<"X5&VZ%M@= $<X&[
M_(M]Y%42(/=2)O0R)M-R)IKR2.=FJG*^4 &WJH#O.FHQ0P$$H@+N7[X8D#&4
M'0?O,P"^4AOMZHK\:L<]8+@,9'(M!<1G.VM087G$ !3:BEAS"1RDS%U>E=YR
MJV+!JV9!J0ET3NQ&8;D>7]3CBWJ^5 ^WJC<V%4!>Z^$4=1"8.HA++5E;+62D
MYEWPE7K3M@8^7M%9 ^)U.DCD>0QM#B]$/WJM99()D7[5DA?-4Q<6]@:X92.+
M:Q-V=,47W?!%=R:2[@1O=WS1O<1Y@TUWX^A58J(;&5(WLK6N9*W-A\#;?/<K
M=4='+2C]40THA>=QQ<0 71I4@?YJH_X#!Z=[/:"N+.+(A&OW]&*1Q8Y>V-%*
MG_0Q%EXF]GY,)OWP13\:T8\OM]$?;<, ,=&7N.RSDL_#=WM?!E^J$3U5I<Y]
M0'GH3>,Q 4H66<48H+U65_W'!W[NCBB2&&0 HQ[2'SL&8,= [!CLVI<R'#M&
MACD+X",SG<=2CT# "/IC^ 0 QQNVA,\R/H>040_^3'6TLQP4N?8!)6%V-&T.
M@9Y:T1N 7J]6E\[.&@Q-(CTQDCUGTF?L2QE'XC4>.VXPSDHA-FZB3VY*<MZ,
M. FADS!^(A^^\0YI C%Q@[$?A?$Y_A/5U!">QKU@/*;4$P.8S'(C*U_Q1Z_G
M0)=.0Q]=JO^Q'T6NF@@^N07.?SMQ>J?%>6;L?5'.0\KN-8X-9ZZXF_%Q-Q^^
M:S:?@;C?<9#/7U8UOBZDG]/Y2#QM#J/-U@'._3?NHUPZ.^LO/]Z+XMB'XDK&
MC?TA_SZOA*2XG81T+G8LP(['8IV'A2V@<^<C?!X"Y\(>YI+-=S!7M9]6*?[.
M;G'>AQ5!FZW#T3]6<IO@:M^M+GWWN?3,T ][4#K/B37J!)WGMAH;U9>Y.<]K
M7<MXV<A8V< XV4"PK\?)ZVC<FFG2ZGE\AO&Q\J#RC;-XT!UE[,$91_\SE;A-
M<^F]WZ6S0S_L0_GQ/3D_/J.D\\S6K?IAOX:Q@?PY_'&81?\P?7*(@'L.7QQD
MKGB6V#S G+E_NS*&.^^#"D:WB2G=_1X7V9JC_ZR#K-$/9Y-LUP_GDQA[3SIK
M(9V_['M"/_RRS 4?YUZ0RRS0EYAT+N*+UU!Z@;GB' T[N_8_Z@]_ _^ 6_T%
M3O.=PLC^XV'JF?J<#/RW9.P?D[>_#Z-XA\'Y!H/D"NSG(GSJ58+FG.-^E*DZ
M0["\@ -/TF''8*]'M K3=F'B"YCZJ>/>$^,,4*,&L>I']0?C'@QC#X9Q%L3O
MY.$X#_1=^-U;\)DWX)B7E:/SL(0S,(A3V'$<.X["8P[#M)Z#@3W+H#D "]Q/
M\.[%CMVPU1T$SS8"9@L!8IP&NAY+UNIMW/E7AV[C5TF,<S@?<]4?C',P/Y'S
M+$S#?2?E!S,-I VA?#,.QIZ&_#QDER&[!MF-R.[N^J62?L@?A/SAA,98Y$\@
M3&YVW'&QA&!Z4@NUF*N/.ZHRQFDE7Q%:SC,P9H%'@'$.J+$'Q+BMR>#@NQQ=
M[HGM)N3:002V)R(_ [_E8W\9(5+CV(>QR+$/HX6V]'7LPWC4L0]C+"%\(QQZ
M&CKNPXH.PNLIO++9M0?C$_!/Q]X+XPS..\$;KA#:[0IM,@S'%JS'\,5\./<\
MN.Y<N-U<)2$M$[GYR"W%_BH]!)M\$/;W -QN.C%R'S%R+W;<C1UW:B*1<1O_
M'M(MM/YF6F&<WCI%KVDRD389W3?]Z!Z0[:[0-X:!40-X2$8-PA-Y)N390!B(
M9;@F(S?3=1]("2VM1&X=<IN0V0.9K4R=!N,?[CB%XGK>&<\WQR%U##TSFEX<
M142-TN_!-0>,>T!VN-H^US4%&=/"+:[I:1)C9"*^N)$^F:!P$ =2D)V)ACQD
M%]/B"N37(K\1F=V1V8H% _'&2*)U@N.$CH'TQ@ BHC^>[D>/MQ'Q;<1F/_3W
M<]3GG%O2IKMT,TTXRN/&TC!*7BQ- <@,!,'(C0!QC,@49&<2B7G(+T9^.?)K
MD-=(9/2@5_IBR1 B=AS1,H6>NI>K\[!P)1&T%YQG^?^*QVL.&"5GHRP\S;44
M&4L$LRGR69KEAEQ?))H=]8<^"D%V)(A'?HIZ84=/Y2*_"/GER*M%=A,1TL+_
M^V/12'7!B_7T8!V15$M_U-#S-<P5-8[?9C).([KFZ/\[C/H+2]Y(IK2!//8%
MO5B.>S+M]R NNLD?V19D=]8?HI ?S\A(04<F.O+048R\2N36$ZU&1:0/O304
MR\8SDHR[B!XF@A;SJ4W@"'@/?.?XW? 'T#?%N#V8I7^0B?0&=#?2,W]GJE;O
MY:8Z-Q_D!R#?HFIBHXH8K6*L5"H!/2GHR$1'/O)*D%N-5QI5B)<*Z*E\>C6/
M_LAE9.80]=E:!XP3B"^"+\$_''_VF(#>82PM?4$/B_-/=;4L>55<K\"><C\/
ME7GYJM3=K!(W*WJ"T!..GACT)*(G#3W9Z"E$3SG/ZAU5HDQZ,H/^2&?$I+G=
MJU2W1[%X-=@'SH)/P?>ZU=B#@\Y!QI_F2,.:0"VHX'4IZ7(1[Q68W90?X*5\
M7W_E>9N5ZV53MF>PLCPBE.D1JPR/)*5[9BC-,T^I7B5*\:I1LE=7)7GW5:+W
M""7X3%2\SSV*\YFG6)^58(]BO,^ 3Q3C]8VFH&,4.ON1?G4GY:@'E4;=@]<%
M7,_%EFQLR;1X*-/LHXR  *7[693F9U.*;ZB2?:.4Y!>O1+]4)?AE*]Z_2''^
M58H-:%),0!]%FX8KRC11D:9[%&Z:!U8IS+1'H:;3X".%!GREB>@8AKY64HUF
M4N(:H_8""GB=@RV9O)>.+:E6-R5;/95D\562V:1$4Z#B34&*,X4KUARC&'.2
MHLV9BC(7*M)2J7!+D\(L?14:.$(A@9,49+U/=NM\V:QKP'Y9 U\!OY8M\&M=
MCX[!Z#.VJS>0#E>"8I#'ZTQL2>.]9&Q)!/%V#\7:O!5C]5.TU:RH0*LBK"$*
MMT8IS)J@4&NZ0FSY"K95*,C6*+N]53;[,%GM$V4-ND>6H$?!*IF#]LIL/RV3
M_2,>X=WH&("^'N'.&E 9*'#57M*Q)9GW$D <]D0'NRLRR%,1=F^%V0,48K<H
MV&Y74%"X[$%QL@6ERA:<(VMPJ0)#NL@2TDN6T,$RAUXO4]@="@AKEW_8,OF%
M[I1OZ$GPGOQ"OM1HHQ86[MP'5 -*2(7S>,P$*=B2R'MQ(!I[(D+=%!;JH9!0
M3P6%^LD6:I8US*; L%!9PJ)E"4^2.3Q3IH@B4*V 2&:6R/[RBQPKGZA;Y!TU
M0UY12^09N4T>D<?E$?&./"/^H!'&?6#H:S3V ($BD W20!+VQ/->#+9$@K!P
M-X6$N\L>X2EKE(\L42:9HZTR10<I(#I"_M%Q\HM)DV],GGQB*^0=VRC/V+[R
MB!LE][BI<HMC-8PC(8TEZ8R%;\:\!?Z@(9'.VQ:ZD(*7@WR0&>NL_R1P/19$
M84LX"(UR4U"4NVS1GK+$^L@4%R#_>(M\X^WR3@B35T*,/!.2Y9Z8+;=$XX_V
M]30$HI($04F"'"2Q*B21&21N!B2>"6^"+S30N!<-6E8;3S^ 7) >_Z/Z#^]'
M@E 0Q&M;G+LL\9XR)_K(/SE WBEF>:98Y9Y*8*5&.C?NI!G%@T+G 1YIQB$.
MQD&2D(4T"$(:*U3:1CYW!)"]I'RA-O0U)SCW(A6Z]@ 98A*-^@_O16%+.(_!
MP,9[@= W<XJ'_%.]Y9WN+X\,)KDL)I!L!E@V09.-H=FISDT<.>3R.1#D'$A3
M#JMQ#IE!-KET-@EZUF& #9E?JK>Q'\JX#PSD)SOW "6C)X'K,2 "A/#:SO5
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M**;$N0?(9M1_T.MCU'ZZN70:-9B^CB0/.7+60XS$SU$3(1D;A1UCL6,\=MS
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MA0I8?8FJ*(JL+*@MU>1%L-6Y$9PV)TS098>)NNP069\5HOS7 =<KDX#K[9G
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MJK@.7ED41545U*(U^1%,=5X$J\T-XW4CMP@ADCXK2#$\3AWUSS[1V3;^I=#
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M:S(5UNJ@SX,*FO_%T.S/AAP4Z/.!4U+[2I6</HQ*TH-1JKHPTLIVK%#3,MJ
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M'JR<'0O6S]L#MB[8"78MV@;V?[T9'/IF XA?MAXD+5\+TE:L 9DK5X/<5:M
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M,RP5G>D>57M:5%U_/*H*9D;5GJRHV@YER8ZJ'A8@008*9*#.>P60(4/9EGF
MLVLEX.S?=H]]./86,RGU!CTS_PH%AKI P)#.8,C, 023WUO,%W<72.2=N:J*
MCBQM9?MQ:U5;AE_3D!G1!++"U:[L<+4M)UQMS(UH#+F1JH<%R)"!"AEHD(&R
M9@9@;YX'>#M6 /Z>K?=XL;&W./$I-UAI^9<9^>CS5!3Y-('(ZB]E"+KA7%EG
MD;BB/:^BJC5;IVW)M.D:,X/Z8$Y [\P-&"QY 7U-?E"OS0_J- 4A[<,"%,A
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M[-G0[*!3"27<GMQ*]^-5U:XG#M8P<(]V[^BOY;3TUW+K+]?X5E^I#MAU=7=
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M-A"UB "1JXF0B_M_#7ZF:Q,7G#B\5?C#60GA@>MR0O?NJ"[MOVZ\K:??5OW
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MEPG;$?IG^S&7(8=O+L\IX_3[CM\9-Z@_&%=G 2R<@;Z%#QQE!8"E( P^FJ+
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M:%,#_8,:H'=<$_1ZM4#WJC;H/-4!G7<ZH/T5F](%_%^@!SJ3AJ#]S0AT/IF
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M3<#DLSF8O+<$TU=68/;$>F9 7D<$&PD^L)'E!P<Y0:"I"/]]/XAEL1)<*1O
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MT-S,C2$#&0="^S)^".O)?![2G87!G5D8V)&-_NW9Z->6A3[?@J$T TF4G2L
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M=(E9T>4>L7RA5\CX&I^@\;V^@<M_\0E<]L8G< Q]@A>A3^@"] Z?BU[?@@4
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MT5&4,CR"T@:'468ZNWNI!PL!EE+^(.6W3@!4;:/\/0#)ARB?E-#W- M<+O"
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M/RM.]<<64-J#08E0!L6I'Z(Y1#E!M1"E6H@.$ N)I<0JYI/H!/-1=)+Y('J
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MQ'W>\!+W::/[/,>-_N([8H3\AXQ0X( 1"NZ?PA %]TT#S6CO5H* UN2=]@*
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M;&=K[+G"UMCUFJ.^ [G4MB.WVB3RJ&W[7S92_Y=-O8M%=>\<I1[\\PPH92-
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M8='Z RQ;Z"V:Z2WFZMC.^BVOI!.F7@TI)&G\'%W#-J")GMX(3*:)'==*_7;
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MS?:]:'+8BD:'PV@8= 6S![V$VL'?8I:CA!J9P7_S,36?Y_+C*J>8(QS>M[L
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MK.MFE]*NQUQ*NO[F4M+Y);"YE'387$K;'7BH7;H>6G2T0SJMP[$K9WF'J?_
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M[_QI4SC]E82N7-I1@>V->I8^>5J##,<)VC"#[&5H6(/L3<C<J?NUGR@X2_?
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M%#^9IKC)7,5,EBEZJDY14QV*G!I2^-2,PJ;6*V1JOX*G+E'0U&T*F'H2O*W
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ML.,U[/@K=OP9.UZ%;?X>%OH*@_>W,-7?P+E_C2]^I=_I63QA]GP\[839>_&
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M>M+04X".2J0V(+\=^;V,@B'D3R!_(?*7(7,-HV,+7CB-'CF+Z+A$A_CK@_3
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MFTG*;X7SWP;7_BEVW$E"=B>Q<6>]\[X<\[AL&G('?WC'X_SF+9+X;^VGQBY
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M?D4[Y5MT5-Y%UVMNX</@3^ S>1?8Y .V(7\I]' 4^=W.&E U[TM!@:G_@ Q
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M=RLL\CR%1)Y0<,0C"HSXBX(BON"]32'A-NU!_BIS#Y39@Q-/_(%:4,'G8E!
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MJO&=6Q@,>7F8%6P_&#N'!Y@P[N\<T##\'0*YLK@N [F#(%<410H@?,5DB7*
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M,HJ_#TP>ZI.!7/'%7"?J;YG]^9?^7 AW+0K?\61.(#<_ 6?#$CQL.;SGYMC
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MM)HI[G(#XRB@$+W\!/ K-RO/3JJR1/F[(&^M%&^Y-G/1IP#:TBSO@5@#US6
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M)<"L50#<.GEP6G<*R.OEP'7]2?#<< )\-\@">\-QX/XC Q'_2$/,'P'WS6)
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ME@2__?/1V^U"B#FY#(3*:R%9>RNDF!Z$)'NY7_$4C6_1WL8SX1S;][Q(XMN
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M>KO&,BUE[B4[J%X54 S[(SRMNWDL?'L C]SD%T6O8PB]*CW3?<O<"UC%],J
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ME7K3MHT&[VS.&;^QOF3ZVNJ>V7/+EQ;C5C/F3VQ^&MW'@-XM6]"^A@6-J[,
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M>NJQH*<Y.WHX<J&;+R^ZQ*Q&YVPA=*H018>6M6C?*XYV(Q)HMX7\NSNET/:
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MV>G L*O#@9UN=@=.$X_(Y_-.CK-H[[0?;9?SMA+@>@?I_V'2WULHL'W7XGL
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MK9_7*%@\;U,T>S&H;/IBFXKQRZ,J1J]NJQB]>*MB].R'BM%35%[.J0& W1,
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M(H+)+(*8Q[H:JUE783LK/PZP\>$DL7-9;0?(^9,[D'F-S'\ X/,,P.D[D-D
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M#V=;AFTJI@<-U3KX#;8[>P\,NGH,3+N[#QQU=QNXX^8Y\-')>Q#M? ?1VG<
MK9;"3(#[50"7VP!.#E!@=HP".TC[3>P!&#JT GH/B5':#ZHSU\T:<9?OI0L5
M[':1R-SIHY \$ZP6MSU*.W);HD'(UDR3@"U%%CY3U3:>DVUVKI,##LZ3TXZ.
MDT>)/QV=)C_8NDS^LG:;0 O"?*D/Y!S^4P]PMH?T_V)_D_:;(.TU>( *72=9
MH?64,-2=5&(H/Z[/D7_,DC_CB)-HTB$OJ9B#@0KA!R+4@F<3UOGMS]#SVE=@
MZ+ZWVL1Y;ZNYPYX!2[L]6ZWI>XY:T_?>L;+=\\'";C>:V>]&8_M=:+34PW*
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MIT5SRKM':\)K2&?,:TIWL^<>_6'/4P9#GG<,!KS>Z0SX_-(8\$.5?G]4[ ]
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M0P/*&K2@"*,]11#=*:LPD,J'<=25F$/EP1HJ-VX@IFB<>)CXG7A-O/L?;=,
M%>3^9RW.OT#F_P[@\"> R0,R^PF \B< !:2"#+*3F3QDYFH015$01$E8A?+
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MFUF1LLR\-&7U[.+D,8O"Y .6!<F7K I2'L\N3/LTHRB=&!9GX-TO@^A,AX0
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M8@UTX@BX44?P9DCP W#J+P,BN.C(6@07&L$BDZO_8,&NJ3- @,2I?)R[R\\
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MNF_)A(9/R07DD9IOR2=EOQ*BX%]"Y*9S#?OP#?K_?NS!-LQ?WX UP"UP%]*
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M71_\K16)/S12\8NB -\KJO"UHAEWY9VXH^C#YXH!?*I8AH\5:_"1<A,^4.[
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M@ K;>QB#>8P!)>E<<K13$E8NY_.X$DB@+ NE+O<@IA*6:ZA!*9^-UVO 8-@
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MR,9"\R(L,*] OWD]YIJWH\^B%[,M!M [<15F3=R&KDF'T3GI$F9.?@LS+']
MFZ6(5BO"\A_<XW+[QG0N89[ .6_@*%_W,@W8YDC-92W#ZHF&6#YY I98VF/
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MLQ2)G@U(\.I$O-="Q'FO0XSW/D3[G!>B?=X4HGQ^)$0)&(&WB&>E__LKDOU
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M@4%K&)$$_=9\Z+760K=U%G1:ET.K=2<T6L]"H^4-:+;<AU8SL_@F%4;.0W4
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M3N]PT?N"D_%=/N1W&?B[#.Y=.G+W30J[+U'.89)YB/, N7W(ZW"!_/SUJ&<
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M$=0QHQH_8),P;!)0,%J^>;[RRK7*(S=$[GE1&IV7)->\+(W*)Y#R,6*^F;B
M)!= 6@O@6 7DL04DZODDQ_EO(G"]/)N.@K\7S"U]CG4HP\@L>/YDZ'(7]YO1
MI1+*F >%3L%FT=@D&)OX58R65YF/W$K]Y5)*YU%*)U)*(RXE:$H)H#("NXP?
MEL']RR#691##,DA3*82AE.2_E(RM!!U*;/8_1>\VY^).=:Q#68C,1/I1OX/[
M]="CDBY,AJ[Q^"<,NUF)'Y\&-[G5>^,H!I7: (0!KY:.M9:&7$NCKB6@:_ER
M+96KA;#7KG4\6+4&XE(-":G^HU3UN7T>Y@!J[IQ&/$+/EP_1)H8<6T?ZS%X<
M=*GD\SSLDH(N4>@;B%U\T<=]'(/J6/AE&[RNE4&E-1BR3$?60@-N(7!;Z'1:
M4+8%Y[;,Q*!PS>;]D"FX_QBRM:;7(/?HT&BS/[)DVRSG.A1,-A\:-# //\RF
M3:)+,;IDH&,<=@I!'S]LXT'5U$ORTP/?GL @/P%;F#4IW=BBFT&XF\ZD&W]T
M$Q/=*-T%2-<RQ"PL,(OK(6?M</]QZ##.ICU@;W:N0UFRU'$F;-\PU>)>)3KE
M\'DBI@Q'3RO5\<)>)"X.F8XMIC&X#_A^MR9EBEF3@BVFT'BFX(\I;8X''DVF
MT'[(?3_$;A*$<2)DK.\S^YZ@'6!O6$[_B*D6(%-7HN8*W,R]0E1/0:](OA-
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MN-@'K !P(L%(I/PLRBZF["K=A!XWX)?K87K7PL#.P<2NANF>18\S]I4&R['
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M: T#CR_X[ +DV8V]!P2[!P3H1!NXJ:K ;N3H22$$#0TD3D$/B9 Q0D(DS)
M*0?$3[H)XB,5@C:1 8G(D! 7N0K$2:$#<5!LA]@H'2!6RGT0"U4DQ$QU"MI
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M1'Y-\ !?FA_$6 (@@!/ ;EX'SC(_<$[Y@;/)!V3@_0:= /P/ ;ZAQLO[4%R
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M^(!3@JN-UA6?@3:.51O@+<2>P#5[R4$X0 D7P :?K*F!-3URN(^2#0- %V&
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ML-VDG^  "G@T!V_^4"T,( 4'W( !+.  >#P8!@<DP@ 7X8!#,$ O'(#GQ"C
M %YP0"0,X X']-#C O"G26!A$+X3LV2NIF=F9;O;">WFZ1M\@(!/2J1_+\T]
MJ\J/"[ CN/SP^5XB6I/_YQHI9($?D"[D6+/_KFPV>+-8&O=DQ3$'>/-?0L$L
M;@\L'3:[ $'R,"'.P0%,L.6%%C@ JL(%S.(!SL&$H(,#3L  "#@@& 8PA0/0
M,( /'& ! YR& [;! 'AND#0,\!K>BPG  $LZ,,!&." *!J"%;^UMHL4%D.+M
M[8/[07@;VYIQ/4H(?S$X9]64%14#&X$%Z6>5U;6-'<_Z1R;>?%AS[8](?P]]
M?K'&%HF9AHO'O*Q4^:D@)(%5MYYD6_'?M746+_TX[IB$-P'A C,7)&P"(A66
M#I'!G-X".  N!)Y[ $7"9, #P#LI83A &P8P@ ,D8(!]<  [#! '!U# %J1O
MX$D)6RUZA@> 5Z@0'% # UC! 45_)64>#- *[X.288"E73! +!QP=1TN( P.
M6/+"!>!/DRSLQ 'HX@% A0AND=]JM--Q7]"!HTG9! !$^COHU:-;.='N9GA3
MXH!F2J,=5'A^[9&,P$M^Z"6^NJK@@]Y2-!=N95/!(M9DN$5"9W !%_  L AD
M$ ^@"9,!+SK@@0&4\;)XA0MPQ / 5C!B\ "W<0&7\0"PB996/ !LP]H<*QRP
M'U8,#3C $P9PAP/L8 "\8,X0!NB""Z$, RS9P #B<,!Y&( ##OAHC0L@AP.6
MJF#A''S%:FGI&HY5XO6D@)KUL0E4S'R2&A9N1];874RD5?3A&>$]%%^[BI-#
M=FN)T6%_NAJ/'N[7_;UJ#S'UPI+KS6'FD(>;?A[/MX>%M'A^-Z2 "\";782H
M8$XO?(H#@F!3M7CN 70>%Q"$!XC&!>"%2?#0_0$> !9@3*Z' S1@JH1/<4);
M8 !XT\1S8N#A T0! Q3B20D## G  >]@" <XX 4,D <'P+?EOS*" 6!=[=+2
M65@OA>\?A)/B  A,WH>OCI0H3/ !2^=WN04>2LB^5MWYIZ>?B?0'O2&XRMJ5
M'VZC(B[(S<I B>^0+A5:X [?L';S$G?]$Y <+@!OW@Z"<*5HQP? %FKA:XL0
M!%L,WHX'@"T>1N,!5' !I7@ ;EQ /QD<0 I3U&:\+&"1-;Z4,+L-Q / CJMD
MX0%@RTGU5'# =5S 6[Q.*A-6#%<X !Y@Y,,!\/6F,?@TB0,,L)1$B0N .XQ+
MTWMQ 7"'<6FIQ1@7@0=8:@61$AV[D,Q6,\? N *"9Z1Z)N&](Y'^ 9I^VMY8
M5W/G=EGQ]2N7X9L/!@]8;I46Y&"B^:/'QUW8"\:S:0AWCR7>[@4("L)E@6?T
MD!XNP P/P(D+B,?G@;M(4HL/P"W&/ <> #8[ &\5$'0!%^"!!X#-!B?A 6"Q
M_6T\ "RV'^*' RQQ 4OPL1W:"@.$P %P+Z<0-O\ L<( D[KP+&  ^)X9?$ W
M?+[X.QQ1((D+> 8'+)WYH\.F9$?H.A+8/709%1AU,OM:5?LH\5C??Y F6V]?
MR4E-/'[D4&1HH*^G&P8W,*_>9X#@P+4Y&=P,X-8$062X /C>)$"X)R@2\0&X
M/@I\@S6$UWC%\0 >N  [/( 9+B 6#P!SM?"VBD";< %/V>" =;B K^IX6> "
MEC!_!<!7%0Q0C==3SN$"YO&Z:WC0BC>->@\&:(-[I? 5JZ4DF!3A<,"[0!R;
M8MH+!RR]"F3FE5#2M73VC\FZV47P$I>>5W]U.QR1_GVTN/!^?G9F>GIF'O?[
MOM*,HV%>Z-W6.XSU--64D @Q0=P)"&-AV+(=?%[^&)[1PT9>_$442!U7"#S'
M'#X[X(F?!2X ?XX#!FC&F\N!<%>+YN7Q "]PL[#' \#FDP_C 6"S U<HX0#8
M1.P3O+TB\$5Q^!(IWO1!"MPCA"](M</[![QY\Z.,N !N.* 7+@4<L'1ON1]C
MX);0L-@7>Y' (>RZR/C,@EL/NU_AN2]$^B^CV9&>1\T/:N[<*KE^I>#2I0+<
ME;^:6"][DVV*4F("W*R,M.18LV#! ?10X+4;F$')X0-P&R^!0*H+!U",#\!U
M8D;P%CBA-%PA=N !8&O!^+,]L CD+!Y@!RZ@41 .4(-IVA@.$,4%X,^C,,(
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M +#)GJ4G\"Y&%@982EL]Q;D1:8&WB#KLSPQ!).MYI;1L?.,N-Q&X1K+%Q_M
M8F[Q@]XY_#0B$>GOHR_#74WW[Y07%UZ^>#XO)RLK^RSLMHS#:&MC;34%Z2VB
M CSLS PTY/ 53OS=:+ %S+9->( X', BWD$2^"F.0W@ 6 1R!<\%@2T6=^+U
M<X*X@(]N<  =3%4G6> (&* ";S,9###N!>^,88"EO-7N&J.4.=YQET'_GU)0
MLFW6M LZ?8O K6+5-CI6Z*#8S!M-:YW/[FH?F5\CB4A$^H?IV^+71?Q9L=G*
MRSEI)T_$'CX8$1H<Z!\0%'H0=S%H>KN*M!@_UT9&6JH5)Q_6-O&C UC#R8*O
M7\(!3?@N""[@+?S0#E[;/(&W)18&*,:;[H$!GN'-Q,)U%<.)FTX&'_]+#%>E
MLBOOCH+G,!ZQW-O2\2M9^)PL(W#[<I6-N+*AG>>A].+V-79PEN7>?-BS]N7S
M1"+2OY>^SDV.#/1U/^WJ[.Q\_*1O>!IV=WK%B0,A?IYN:*<]]K8VNW;9[L'
MCOW>D^%E95R',U^+"W@#VS\-X6UG/TP.!\#V6%[#6P,IPP5TP8^!0%FX@(5(
MV (&?,_<TGG<V1R*+? ;NUJ=?L^3T$F8!^?"?\CJ8X+TST1Z0=5=P1F$KF!_
M@&+?K&JR-S"AH&&-/9J7#Z9=KOK3#9S$M1$B_5?18,?#>]65MVZ6E926EE?>
M;WX&]YW3/=%[;'?NV&YB9*"O9V!L;NL"VYY0(,) A3M':8T+Z(#OVH>'*!_"
MX!,I_# A\I P  ,,4(^S79U:Q@Y^N^K40=Z55$I18[_,.OB5'DL%/ST,4C8I
M([<31<\(S$(^"=HDHF2T)^CDM=8U9B"*_&/.%-;UK_W[-DLOB',71/H?HWNE
M5R_EGSN;EW<N_U+AS?OM@W#?_H2=Y79C ST=;2U-+6U],UMW^%FU7$GX/@P8
MX ',B]D(WZ0]&;$JP*"1<XS#NUTQ;^NO5')A([^,.OPHH,$%NXK*O%G'.;J@
MG= &JNE$^2T:.]RB<JK7NK"X)OC@Z2NU W^R#-K52_AJ:B(1Z7^8/KU[.S<W
M-__^,V'_^G-Q7F9Z6EK:F:R\"X6WZAZ/P)<7?R2:&^GKZNCHZ.KI&^^P<XN^
M L_BDN8?]U!0*:!.WL&[G;D!LSS50BYJ$I!=3V!Y8OR8U'+W</A2&^&-E-?,
M%8R<(M)N=J^U0[OK:.29DE8\SV05/>T@'CXE$I'^Y?1F?&SLY<2K-_-K#,[?
M2TXG)Z=FY.1?*:WN)-@&<RSU#4UW6#L&G+C137 /0ZDUQ"EO[A57U+7&+^"U
M^VCLC<BXW;.F?S";%WVICL"]\;]IK(,X??E?3/! ^=]-_Q?*OS2B^<TM,-!7
M14K*.T#2">WCC)%$^7A)A3KY2LE(2DM!:EM#?9U0'IA /F>,J[NWNL!<U3T!
M/G>TNL N>5-I4U]MC)N[0;@_QC+<S H5[H%21@MLU5BG%JH2ZN7KA0ETX@OU
M\O0.4 E5%_B9N0KXC/U:2H#O)R300UU $YO 9V-JSJ?MXX_A4Y1$(E#2TM)\
M,C(*DF@,1M9)45&"#RF-1$I)*TM)RR!D9%7D%56DE?A^D8#&.O"OFC_:1<5"
M1^\70_"7NL"ODH6$A$B&R$KZ^+M*R2@K@SR04D@D B 0 6'>@4ZA".\ P>5,
M5O+1P02@_-U] ]U]O/FP?SLY^P0%J@L(K.-;1<N,?%<QPE$A2  JE)4B]!(H
M.>&75O2^QDNFIG_^FI<7P3<# G6# __\S0"K,%^,E 4FP"?('X71#<9X!PH2
MSLH"LT:!"6<%X 0S0J/^R,4WR-_S9^V@45(83XP7X!T <I(A6)9 =Y<U^&-3
MUE0>)M1]C=>P*6N^YNOF$^@3X.:S1G7]D;R<@<;O'-1 ]:N8^_N@@U 8?PU3
M=Y2_3X"/2V!=$9^Y3PC&W]S'W1O[!U):1EE-"@>[*@]0XRK:_ABG0!]_*Q\?
MS[_*!@XGE!-&!SP:H#7)(J05$4AY*Z2,"E))10ZY15I>159Z52;+2%@>ICYH
M=Y<P GG(RJG(R:S.8Q42G@=H_VBG0*>_*9?56-Q\3$U5='Q005AK,=316.Y=
MT#XH=_3O2E-QDG&103K)NR"4T#)(A )&3@;AK(A$(Y25%-#*\@I.SHK.R)^,
M<#/#8V3H'1#HY(W"@#3PA:0[8** 49"65I151CBAE)P1&!<Y182S$]()@51"
MHESD,(K.3LJR*UFO>ATOZ^W^[J!?=?)<Q3XH")N_DIR,O)*R$D))4UX1(2>M
MIPNDUD0BY+0UE;05M$ 'B?Q#= )YX/$Q< \ =A&F@6/D/SL[2XP?[K<K"9[N
M/SL_7R?_  RV3:L+K#1J ;P7L._\[&94G%#8;E,CP"D8@U:3POEN[9?<\17L
MK(B6D5=40".<7)R=$2Y(.32H15D40E$)+2TKCU14<$%C5O)W)Z1@.(\0-XPW
MOKTA%5?L;15J[4RPK2_$R1^CZ0KTK+$\=)FOV!L?4E92GD]LE[LWVB<D0'PE
M2]QWULX;Y>;D[8I!:TBMO+CR!5[M2"U7S__%:G-15%144):60SC+RBDCT IR
MS@@G12<9A)R2G*RLG+RTD[R"R[^@VGYW$\1J U6$\O$.QO@'_AU5!_@X 4\,
MXQ^@X>+OX\7GY.OKZ8YRPKXE%>R-_C7(_=&5\@7Z\+E[.;EBI#"^ 7]4X*I,
M_HV%16/\W?\>*UTEY1]ZXOMO*_0_W3#_M@&+V#!AW^*.CBLC+OYHNN*2+-NF
M'M:Z_K;*5OOI4O\S72GL=4*YH_\A[P+O74)9^_Q3#LR:>>#K?)5J5Z>B42JH
M9:?W[_-M-'0PGH%.?T_5$^2$Y>_BX^_E%*BQNJOX_>TJ*#9"P3IKH(0_^QP-
M&34IO._@>!NLW7@&_4R3EY51D$-*2\D [4G_>G=U.OQ=V[]XU_9/WOV=M-/;
M/5 #^>L5V->KWL(&4BK:/IX^_I:^3BB,AH*\O*R\FA3\:_@;YNZA&$\;'7=0
M[P%8.62!<_?K+7@2P5=M?Z?+()$XK]H2?/5W>+#2BF&=F+0*\E<X)"(8JJRJ
MY^Z)X;.4XW/U=_)U<T<%(&3D)$'$QN?CB_'&H %$4W5-K_)W!MHJ#CL#P)CA
M\-/LP+\!'H$^O@YR\C)R2*6]TC)(!Q=L"W!P55!T0BI*^@:@^7YV^83S7^EE
M_]'\^5 ^OF&2P%17,5&3PM<,0;7]K$P0WV$TY%:_\_MK@F\9:FN#&-<%R*JQ
M4])2DF\7QIE/V\<).Q:+6>[:;B[.%XQ<G=TJ_,K4C!1L;F9YXD?JU\R/QCK0
M4ZS,.Q$:%O[U1&1"9$)D0F1"9$)D0F1"9$)D0F1"9$)D0F1"9$)D0F1"9$)D
M0F1"9$)D0F1"9$)D0F1"9$)D0F1"9$)D0F1"9$)D0F1"9$)D0F1"9$)D0F1"
M9$)D0F1"9$)D0F3R+V:R[O=-#AAOM+I B,!6C:5^2!LB^2<)F\D_FP?)TGV(
MB1H:)-U-1L($D3*1D#&1+-5#O! )1$I*A@6L7)I!34.YCH2"BIR,E!8 L%?9
M4I ##"7C>AH:&JJ-$"D9.04E1$)%3</$_W8#,XN,YHZ-K)Q*-DY^H5%)Z>=*
M:I_UK&-CYQ!0W!62>NOVX^Z1>7D%%>O@L#,WRX7%D+)RE@&G*P2%1+5T=R:G
ME8H8N/C''+VDK*=OX8QQ=3L<'7LLY7S!Y?J&QJZG@#L/$(N$G(QDU9T>)*24
M5-1DY#04(-F+"2(A(R4CHZ"DIV6@I:"B ' @'A,%OPSE!DTJ9I8=3I9^44F/
MWU)O%$ J6 6=RR^I[7K"*B>O:)%R^OS-\A$V=D'9G?X!@<')J:5E\T+"(EK:
MNGK61YX^$]5QCKF%<0'R7+B(3KM4]Z![Z3E$!P0A92)C@K9"1[YX."N02.YL
M/I[BJE:?@XR,EN57\4=Z/DVFYLO@2L)L,-2]>Z3TA%CQ$8HTZ @$>3(^KRV_
M;LNY.3R !5U+_^76P?.N R>_;1FIG!L*N192I,+L%3']J.;R]Z.+U1,'@S@:
M6U.;'T\M'MD:[MIN-7=O-N?;V/CVJUN=:N:4\P;U_-Z]45'?ZGMTSN3+E9HE
MZ$[(^Y.I&JO>/?WJP_<ZWKNR$Y<6?TR]Z-"P^IK_B7?V?<;WIZZ\DI;Y3Q:H
M#WQXE)DUMUAP4.F+Y>N3O0>K.EP7=F1'5IJ=W#[ O_A$8Y_/;YX_?O$<Q^,9
M7J0>^L+S5LSC)RQWWLR:>:'-+785<(=7R9HRWMRLE"0F+'N^HJ_(L%-,7HD\
M3.>:=#Z=D( <2069G_T)O<[Z;:<M='9GZ1QFW2!7P5"B_'%S5.K0S:9I#Z\Q
MGPVO1CG6^[DV8;S-J[.*D5;FP1/IMK;MRIR!UYITUI>ZA'H@8S!1"[=>-(OK
M1&4D<.BDN3=*^9F9&]\MXJ<L:-2KN_]YZOD> \Q8O ]CUSN2P5NF[B&A8@RG
M!HZJ]3I,^),?4OIXBBV0[?O4)NTM&P[O*AMMWB>RI62*,<[8'_-2OX.+0>*H
MV#E$=^";AAH^Z=&(\NHJZ@_WY?+-J-=)D[%X/PZ(G,(H*E8(20V<#/&=X(T(
M?Y)SDCGM2IA45<C<WN">H%FDP/.A;VR96WI-D[9=-]K8UZ@H:'=<LYE5R#)%
M%"UN=$7FL+!6$/F93\PT:M';D EB]X]@SC!!UL77(W;Q%10H"%![7190"*56
MO:KX8L'LA]^[&WE_5DFV@=-B;V9E4A"Q:).\XN(,CWTNJ8E,S7*+_++5YXV^
M=L9\/_,1,;V'QL+0S+/(:_;8$2>GDE=I!>8,F$RNH5A=PRW:8R=R9A1)VA.1
M-.X(/L8A!O)-YZDM=@N:'@]5UZG@?L^QJ21S9G[F20AR=(&R>H?$\_CLB<YC
MDF;7>S\N(MK9;BG2#5\B72#W*S<S8A+8$'7HT%4+6QWJD2/7./Q.U-[1VU%/
MDGJZY+#G$T%G1U%[TF$2E2QR2OWPKH60N)/UI9<$/L<:&8LUU2X>%6+JNL+-
M?;.-MHRK9=[$F;XI9WQ'UJU;N1?O2_DU-+)L&>H_<F:S/;.XQ+.89*ZA3^<&
M27*KSBNT>\R.T.J--=,%M<=D:](KE@@*"^:H!!Q%(H>4H_Q5A[E.%2MWF Z8
MH/A41)-+65M1?4;HJ32Q!#-,AIXH'[] UZ*_O+[LUAL^?N(JI?<&+3?)U8J]
M^]%VCDY=WE[@0FK5?*.IH+?>>P[F?K_+59ILW 'F*YKA9;(Y^HRW> D*R7XT
MFZ_TQ?_:2L.[_.+@H.J7QI;2OFZ+_C:4N/^1GU5S)5J:JRTXOKF@CR;G305#
MNUMN/WE)I4>MD65,A/8)*J%TZ>+>#\;,EZ5*)3K7?6C<*)2P/G%S2$E/618W
MYE)]M#-%0C:U^CG#P$.]E<,)FI)4]=;"'_5GM@Y.RBY>[M!PN'KG5PM=L9O"
MY_;)P;/4?10A:>-M PW1PCK1JD?HK>U2J1>:HD[>\#O/>^BXVIGQ)O-K88GJ
MPEJB<DWQ>^R8$'JVKQC,+K_FX!%L?2 0U: XJ_%8]NF]H*+!FC?'2>H^W3U>
MTL8H=$?3H[(O[J15 )O UX_1\Z]J;#6L^B_;&61.!>_H-7BN/. DU\U^\?7!
M4_;-*?762I5R%Y)*Z8UK@WU=+5YVO(J/F9J5F\B.V6;,7L@0DO;0X-UPTY4!
MF]'&V$:.P5 H[<X#44B3;_*,UA1%T61<7%S*F4HVCBE?:]$_+^\=K].WQKC5
MDC9EC\>_9X^P>L!Y6M0KJ#G%V2J+]TRQ8HL@PUEH;Z/'A?"358HJ^6R8/AID
M:9'TH?VGR(P%+B95M9V@DE-NKTA(&T+%;5+W/M>.4#\_P))N0!^731]5(JI%
MPAUZ>%W]@=7=]"[]@EG&[U-Y\GK+?>W.,VWO#@RB'DK0B/39JS6<;G&6J9P)
M35?+4!#S[IR*".5!(5F":3_/*$Q>&H.N,]VNT$'&>!PCN:=KT72%M]J6A6$P
M(C\HWV6[>UGF?K.S+[62T5Y%D[2'1EXG.L9%WV LGEO=(^]<&2-VK'3)+IT.
M*;?#$+5OKM*FRP8>;U%G3'VT^Y1PJ\7YG4G,T:57DUIYCO%[9L@DLJ*=M<K[
M+%B'K_EO8-GWE#%^6%1E^-Q\EQY)I/E-Y79'$1&;REEZ1R%%Q"0CB0*;H#Q_
M%W=TMB?-Q\9M-*)[(.8A6IK5H\K._9OR*K07+D4^X_JGAY7_Q%#F_>"^I!,B
MZY7OT$3R<9:[$WTW! 3+JL^]:?_^J)+Y=GV]UIZY8*OKNP(V")HRZ00//=W=
MAARF]I8)*"OIEDF]+W/=<0*EX*&MVYH7X A53N^UB$]A1>=9OS']S% >O'$^
MW5WLN(Z1P(X-QT[KG!=F$HO31:2-B=;'\<YX'XS2"4:VRQB8>;:4L#_8U764
M7.H=4ITKYYXL\O9"0*ZTW<O;%5D[1$P'O6DW%ED^7_0O%\V5I>=YL_V(4Y?E
M_84G@X]B12O>E\55MKG[%9\F\3<LAAA((M.?=FQZR^O(/4PY+4<>]6/?_-8;
MT0_7/U;V\?,*_U)0Y&/H^\@C4EZ_ZVJXU?<G\[;O+:>'Y[4_F-D/V.^I<9^:
MDN1XXQ-[^:O5E.7"]H>N[=M7OUQPH<*UO(8S?\KRXO;!K1OSY#5JUK-LU1F_
M^[!\>B(W-WDDM_OSOI,7S5*W!GZSCGSZ];.:^7?FM 76GAN9X>'&L1'V(U<U
M4E5PV/;_9]C^ATK[W\1VOU%HW[RY#GFL1!^%.*VO,::)SC*ZF 2R.Z:?>V;+
M!NH! ^B*<9"X54'I86]D47A 2_&BDQZYE&'Q@PC+:!1J4>[+IOQ%27WIG,WY
M=PX(:NS[<N"_3GV[GN8EY&VDP"#4)9O$+;3]?0M]E348[E.Q1/$]+="A,#:1
MVD!-8YG@?/,*:=B"Q#EQB^RX=1/9-N0?LNA8[RJQ*?"6;<\H4> MG?"DF2,-
M%36Z/)MW[%%FS=Y_7-YGKI%*%3D^K.%?_?<KR 9=W+-3(SUWV\':(@'GV?6B
MD=5?MBSV'RI;V!44QM#_PWZ0)[]R"1KZ7G";MS]\8^]N.H<>11J73S\^7DCM
MN35^-V#0PV'**V"X\OSEC/[^1W>O^U@\OOXU4R6M/.SHF\K3-9^?'&QP55E\
M^^,9VUO/'Y=WBX9/ACQRW71Q4K[IW$JG5B1H/"%-]N&@W.AM9<F:@KPJ3\_-
MZ$?<'5_JPHXP,V_2/.[J-VZI-%:D>D9[$^_NOJ$]7*<N.8?83+)94;2<5I&]
M9I%07:=ABA+:6-S"98YBF7,*9&R4D40V##?2L+_MKI!+'B:+B<DFV5+&Q/TD
M*WAOMGO9@&W:=$PM1>5AO=L\CE=$](R[Q6K.-9WOG(J]4J8[\37_RLS0KLPD
M_<>>1Z(59%P=C/EZ3U<B[L>>OY#HA;GJ$11A<MC\];E*[76L/=0;5&_>-C05
M+$1=W6_O\,FJLNW:E>!Y2;GVF,Z6YP'LHKY<C#1N%7X"VO[]'>_)=<C8*97>
M%4_2UL=+D;_6TSD4Q#K8M/%U]"/.*H']A^LUMSR]^7D[]_S>ME)#6NTR,S6?
MP*VDK>/2C:$.SR7\T^[?"#UVG6F[Z09E9J,DYE![H0-J;]UZ;3,MF!K;GI;?
M"//:J_9ML\C-:'[N12[!/8V0YR82C\PNJ0XVM?""#1XOG/B8-XWMV^/E\J-[
MDI2Z5>9Z4R<DMTZ>2>K)%P9D#;M/_+1%RCBGJ%A2JH V?1S9%HG^TUF;)F*I
M.'75M&+?LR1C;-XUU3O87ME!>4^F8L#,?:#IG1I-A'"JL[;"=P/Z(@]CX\'V
M==IF=(DR*15V0O>N\LU68#Q[>,80@V6RQ^NYZ&<#(F<3WOC<H=Q50J7!^J:B
M=HQ=3_5H8Y:?B/A#NK=B$_4O7]D7Z<9ND_[ J=<VT5;7965,(<:"*)&8-7I,
MZVXJ='"77,8U]><6KSYK^CON;HZZ\%Z0)MF0>TRN](Z^9?T\U\M,O5.32G?\
M:DR\I(03!ASI'=T'FA^:;H-LKWN_BHA]ZV$7"K7%SA>3)X\:BJJ3?CQYJ2.F
MT?^)\IN9YPEB)]N#%QWX+?7% T6H$":MUSLRSR5P^??G:\Y16Q4DW!1H;MIC
M%)!RGL280Y@DE%/WV+-"?\Y$YHT!YWPEKWED&)I_HM302S'??$'Z,*>FGTQ:
MWQU6N^%#_58\C+X*\4/6<@.DY)@$!N4I5.1GKLL4!1E'*9T,[C$B)XY*AB4:
M.#$&QX>M.X%AEO%L.,#J=2*V2E"3+I<DUOHN_QN3RU&" ?*"G!\]4.V)AC/[
MN*XR9YI]=Y!M>[W)N[8]:39I+BX;'5(0*CPSY*@H&D@_K'BLNUMMA_IUYKW2
MVIYDMQV\!,WT&C4S6CYM8MH\RA&Q-\1O5#CE_2?MAYG?9<YXW[)O#M-%VAYS
M1IYS8N\FJ4?X5D?FHF]^Z+AX+ENC<:,N"7^ 78+,C<T8)/(X652(C^S5SP7G
M/<8*$FU[6\10)Y_ZW,X+TGGXSINNJ*'J8%"^2.QMDX=.;:?+'P78C&V)*RL9
MH,/$--<$(ZB*)DOTJ\Q&W^>*)3DDW2I3#VNR>6WV[OIS'>H/UV_P#9^IYU?;
MK/68HE$K@!-]6>(%HTG_)@R_^)&T0JK3,?7OBUX5/E2<9*H\@QJ[B-'QEZ^Z
M/N2>&*)6S=8$=<P*-XQM<2!QW*A(Z3M%2RTR4:\<=4O!9^<AR'[ONH_IA2^N
M]JTGW] O&+U/PMM=J;.M5NC,YMC1MOUTJ7*>3Z4DE!2<+AE\;=![>76D2YY1
MAX;E"WEM\)B( ;>IO2AMK]X1]] L>JN Y)YGE?%%QZ^O3]._^42#SR4@^O@&
MQ6PA'R6>.G5-[Y!K!Y"MK TT,2]/=1_>M$D;XJ/EZ41R1@=$IGD5G_QZ_@UC
MWT.[UQ\O7FQ)?]05:Y4O(O? NJIB^%VY-K>(N_'UR>HR95NA^]456?QIET,G
M*UR$'TEM4A_981(ST/F8;%_T5,RV0@DZU?,"GZ*V&B5/G*6B+:ZW]?8]\^7N
M,.6[K5EE7\H8%1^%KK=MC_-&!PP-5?I<'1JLL?NR?@.'9)[D0\^VS'[:!^D>
MIDG.6_R.S-)*U0UGBS10HM(%<IW+J"76,7&WDG(>?2M;N55MLB>#I?*.H];3
MPHZ6S!Q3$K7>B'WU,<_69TXHTJ"24KP#JL<\)]3G FT5PZXS4MXL?=C.P"8C
M<S+D*65_J/<I^_V#3Y+<2)X_'W]Y2I-,X$(*ZM+&34$/&S D(];Q[LHC_9?>
ML+\7'N=W:CQYD<P8[7[WDI/@<53D)/MIS5+;9N$2]PO.8<S[Q.\)4:@L:)^=
M):_I,[PUS:0H*Z4@@I1EO!:8I./BH^(P.B'_3NM3C;3-A(IBQ9EW7,-Q%+NN
M#'E_>D7)?BC@MMGL-J78"L:9!U$<JA9=U1)M5ZXJ35+FI^J<\C#3;BU^HW3?
MM 1M>89.PY%"V=,^+(6ZR<@LINFQA,GY/7NX _<%!_L$F5Q^F?18-O=F]'&=
M]/+WQZY>R"Z9N*2TU]9\DM7@TX%Z=^>)AD6#,N7.:4;/W;ZR(A]V)SCR25?H
M#=KQO*[LV3,\L->_YQZM^.L"^FFG4SS',Z9SA>]S2-A2B<_Z5R-X5'E'^K@/
MH!O9'_I2^!U]E?U"Y&:1!@];G=1KUPW=2@T*3!+(5"<D<C[PEHF^WP>=9Z1&
MP5;&:I$#5EJN 2E4,AUIII^:N=$^=X*//9]L#I$+/Q=9.S&(R;7I5IE-#[2]
MP,C>SSA)%\WP_I![R4S+T$[V5I5M/^;Y4K=N/(SLUM9G>_R)BK4Z7:)VAL['
M)E?XZF/V6>UC)48!V0I[ZGJOW^.[783)2TU,3,"\%!5Q90F:N::(,'+=,EI(
M<MT]E[WU6C8/ETC D1M7DQY7MD?-^%$BZ2*' _5F&5CY+7IT,\H<O*@_ZAYB
M/99)33'<>Y24I^K.L!<JJ3QHGWU-JOV6BGBF^A+WD=  %3N&>VX7*[X&7'?L
M<"GNG]H>\#R[9-J(9<=3K;)>B[P4;F%Z_>HA%>>S,>:D3CE?S]FVK[?:S:M.
MI22>^<GJ/=OW=!E^X<:G>;W1U-X?B]CH(OM"H!!>YW>TBF]>^R/*RS_VL)66
M&'J;=E]I>_CL8:S?^?5AW:HQ-_T9CD]*RFES!U62*_ UB[OT-DUL\<HHYF7R
M#/ )H?,\;3HN=S9Y(PTUS:$TS05SVD N'FU.R981LDO7PSQU1R_<G?6X,BB.
MNMUJ'')<]6'UY)ML-MGL1F84ZV?T-C;(!B)74PRO6QALZ:&G"E%KC#/<_3F\
M9NQ;;$Z%C3WOJ$+.+06])A0IG<^6UHR3M*J>%P*/4N=D;G)^.)/(>5.1Y7QX
M>.R=>J&+J(69R$LS%M:/$+.BK'D9U^NYA-#ONUK<0QRXT6CS-O%!USGY04ZO
M+P8>#YZC-T 3/+5!AA-QNZ>UPUKCO-.58TT17I^\;TMKEL6>GQ[(1'\=J HO
M3S*3B'6ROCP@WN]]0=9]0BAMN%'OZ/4@[P?)PO5GT^N+ S>Q'E;H>+R1/$J6
M+-;$K$!$TF!BN%]JS^AUILTQ]R>>KN/,#7K/IGXS >U_RR7)W,5-^&3.G&1
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M=J91X^2W;8'*UJIQDQR3L<;<D[SW9$P=3W16C.]2>SJHXHF1E=J6;VO5.QK
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M_6B6$WEE!U\:Z23/*/32[04B,,0-:>3)V<-:VB;27E+92>]I0"9,$W]H8_F
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MX$,WNSRCUH^9*E(D<7@O9U0E1&2B8JLS3Y0MTI)IB8DJ.$A5I/@Q;MG3A-#
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MR#Y4H'%".V/L'7K /8TR"Z@/(9_,8]7V;..0B]4J I1=5TM\H8'@T2 ILNB
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M$G%VW-'F*#EH=_!:>3#J? ./F_%M?P%\&7X!K.ITYN?]?=4IN-I0>P$T8[\
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M.WSF0;E]/)U33)D#,?3.LK0W&Q KV/.8\B+(25.D(H7"+/!K?T)&N)HHN;4
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M9-NPN$C(X(G:%JB*S$/OMI?3!-L%Z>575Z*K/(\B-4L_QKLU60BY03!E3BJ
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MG&AQZ3"Y%9]D*E&!3*;5SDP%6E=+J4 #JCJQ@&O-@L0Q+'X/0C#"Z$BON^=
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M_U1A^F^[L32B23=M0PGZ3T_*4_8]#!_'DRW:"9=[KNNGT:WF'GL(J>2=:)I
M1MX<6#+=5//B *NUIN[RQ"I%L76FKZL7 GYU"C\1?4"^^$9V.UT 7+O$9KL9
M9A4B9+F\&F&\F\"@'& Q,'(#EI="'D'RYCEA_**PN>#DM\^:1.KYO1IRB1*=
M.@D_DE@STM75LJAEV6/E!R!VR9(;%YU"9AA>]PR8<7_)T#U:DHP?KYZQJ:!O
M^CWOS*=O/N'OVL3$?2Q1(.,P_>":WDXB*O8@@3246= *WPOOW52>=E*(G8=J
MAK%W=0.M\3.1BVYI*JJ,[5LPJSNS-8]-1@7M[N>1X?,1QZ]X3#4)IY+'7P$H
M*6/'WH,M(>U^5I9"/.L[YGFUM;$6C3=)EH/67I-]I K=YF7I[3Z&;<7913)^
MK82:!$LJXW_^]7+9P=E=2]9V-C59LSY0(:CZL.]]T9L("U+OKQ& (";NY6RN
MB"5F[-?6S#I-H^XHC^+//8X5C827 &'<0 @/\UH$?.-9-<7$F33&7NY.U2FD
MV=#0W'5#+-9!S%*"(8_CG<V]3U3W'Y\(51U.H!KKX$8^T.A1N/BH%%1:ZE3O
M@,3)<6SK==2$J.X4>W#+S@RX8^N,$G,P&MV#O,#A\&T/T0@S/Z+46>M%BMO<
MUK]@6/2,(\RA[.+I9H>M(^\EP%+ R-425X@\6M?;7Y/!\E<U848N'"+MZ+1E
M[7O_4SB\_'<X? ,)!%X"C#Y[ELU O9'F;B@H48D?2+5M'G?!@%"5ODU,&GYC
MRJ[6&M3HXXA<S&08<F0(;EM"J4'7)/7%O>-?@$/"]?5GH.)6<8MYJ@R">8U/
M]W\&_FYZ6_JKZ2V-<$>3;25I,D+4O^2/<H;]$X4KIDR^!%1NY%P"ZFNAM!=-
MK;"E$O//>;5_C@^PEM'5,Y^O4>GP7G,//O^^I]6BE]2#*(6 +CC95S1PMKTJ
M^ATG.C/ ?DVIIQ-!\<LU]XBTADT9&#:+QDVCJ7ZI)';3MX$T@7A7EF:1JI2D
MGQ$_0V@S4='L)*H-&HF!#-US08WM I%-0Z^]6V92X]M*PZWVYH5D+PRK(I5^
M!W6'ED<Q6%UH>'83Q9@/U31STB2/49#[05,.]Q'NN*@K'EY-U*9]":C6$_1!
MQ706N!QA@!73?]81_-V87"#RKBJ.]I(HGMXO\7PT+QRS,7(J9^#:KGT.5&7=
M^BST6$GUIFK"Z\B$Q(W>R#H8L^(GNF)(G= #<V:1N/C[ !)SSYF;"SR/R\T7
M0@2P?!VV>]PKRR?7'$0^R3XB0)$JSCTON03P:U!;VXF]V7?FUN1G0=XJ<[0L
M?-O@8?X='1&6_J^;B<+?9[)<^-^%'<%;SQG^F]>Z_N0UJ7#0;]\LQ0.ENT+8
M1)\)Y#=;*AX=3]GU];+ D!=ZL$M45-?T17_8**NN7\N@'RH<WCGPH0 SB$=A
MC;@L\G56"L<L3!+=)1S]2=W@AI> 8#"4<W]O99=!Z 8<6=7@Z0:X'6$D?EL<
M>2%^!NSB#X>IM15!I9.,"")O?BJE/CM=>W&]"QK\?K_QU7#&84V+_X]H[5/I
M_9,HN($V;<$97I?XI(,7$+UPX:6W+%KQ<PN[-(DL6JJ6/A>,]&P\340E@-%_
M!H+5^NK<7G>MH-GW+@$%YD?GF'!PPK]DZ>]? K@$XB\!TXL&!DF;QPF<GF('
MQ^<E8=,EDDU L[;IQL5C2'Z TT\G"9&O&-'#-7C-\*@:-(4AEV-N:8E6A,Q!
M+/SX=#O]%,@'&AK*&2_<W^^+IOT6T5E/E@<[E_/U=;\I>O5DG]&UM1KPXB'!
M;<)K,Z![WB5N2V; -K=CT 4CYD#.?Y)RZX<1V@A1[ZLIM9>8WJ5YB(EM\MLO
MW%WE$=)SL?YW1 >U*G;$Z.W>9+-)4/\BH=RX2/,(%^F LX]"3#1+#?YJ0IO,
M)[Z$^-5B*:LN 3U^WW&CFE7NZ"W7JCJCCC,)<I@A\/U2 ?5DN!$COT/C_M)4
MDD7H[3!VWXC(1BD])_2.CJJT],]4"Q^/2DI) W"0^PTUMZ'71@P=F/UCAIPA
ME:';H<JGM1E -<34U'=1@SYH&Q*E!(?S#7()86B[:,*/#A8PUUJ,,+?\*]E<
M#P<E+UZ5LAMF@JZH#?.;VF8Q&Z68@0>$8XZOP-..9M!,O1>7@!_.3=GO8>^_
M_&_4!B77>"S($ZVM99]JD!!MZ;),MGR:DGBH25-&G.)]3W"/,W+:9NZ^;XM:
MW<N7F0S,_:'ZRJ%*4YD_>YAWN\;;2TL<3;PD'U'F[\1:F05O1(^,4,8+9ZIT
M>D(982\$=;?")T(MRRS>M./3VM#OS!#YFB3)? \74K-7X7?HN]/'P<2CC,EV
M%7OZ.%],1G\L4]:J\M^.="&7<XX[>V&BJE_$O_Q:?.+Y<LT4\N8E(.7"JIV"
M]$".QN59-=TYZ!(P_I +@8&M'Z[ASB5@JO2_;">DI*4%&NMN\X=8XO?5S/=.
MD2&7H(9->1*X\Q7)("SZ*>U':4H'=P5.L>/:Z=/Y=N$F;SVU)&GBUUV8HR:I
M5*]+@,?Z<7S)7!,#,?!7%-7_@R+Z_,[O&'94U\R=&@T,ZWU:2%JO_S\'U1+.
MI:(T=[V!]$U<\WF+M4U^N$-$9,.U,2-HHR<8! )U?FGCOG*^R!(]JA,1!CQ:
M$C!I2O^<)".&S6RC"L7#>5X1]]WJ.GW:8_26FEB7H9>%_6VBQH$S@OAZ7G_,
MSAA1^,=EGJ*-DW%WZ@LPS#&L[!D/LCWKR#)ZSWN\'!DH4:?R8^@\H4,6OB0
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MEP!X8X;_^0UV^-8A2D<O=LAB^XBMYDSA/008!JV*8.B-X-[35Q7^!0\(5#
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MM)59OP(F\<5 R@FCFL!%PXJ>(JQ;#KOL*O3T.U29R"I[?<JF.1_[(\B$=.=
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MNI)A9%0,F*1&V5NSYEIK5Y<G2A@/[!-YI$YS[>63!IVT\3P)"O)@8]KT$YV
M5)H[C\B_"!!,W+?CT]^R'?NB^RI547^$4!\?[[[#GS-(DKF2GD!MD[%5FSZ*
MAEV U;H2/-$2ZZL/WI<[C%]>4!BP__-]LP4C?-RA.RE-WB=-<<;PNH=&OQZ
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M=-?T3>?VZAQ)Z]P$YP8\"H'6GOO7G,-:-@-MP[ U8L#B&;U9 :/F#7]4[27
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M3^Q=@#5IY[M,YT&9-+/PZ\Z?1CC.J1<3H K?!3O$[]&DF7!*Q#]6/0RS)S'
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MI;@:[I[T<I5",4LA(YJ5R<\@RM(>*@*0D'%$T#H^'S4F3O^]2(YU--=S!51
M_C#%VXYVPJ" 0>WUTMYE7B4O:4HSW!FI6^;0CIQJ\/*:/N$=.><2ZX&?@GQQ
M2Y5"CTT<P\R5/&)YH^.HGQ5^>1_,$RG0)")K@2=(XMV$W$HT1U3CQ(Y"G\!
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MNM/OJ+Z1)1MD'^A2(HL>^TOAC2ZG_C]02P,$%     @ <8O[5I?G@.^]WP
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MP1G)%;1T@>>+HD!H92Z@Z%>9OMUD\"MP\<?,1@40B0:=9<PF@]$<=(?-EG#
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M.3P."G8_6^*],6T Y5VA9 *PA'-!R.RS%**,1XB$P8(]1SJK+GL!R>:]KDA
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MC Q0W:&9<"]NA;E^"-"S/2RAYM!>W8XIK\>5\S3^MF9$:P9KR.:$,;BH6!:
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M9RD80C#D%.K2''H)RC04NUG."S$#U!FBE_"-XP'$!6^$$88#W<;>)\(&!,7
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MD'CC0>>]U1&OV[W;I+<<+1_>VB\M<;UUK+I3>*AY4_GXO-[_%E;0SI#U\2]
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M BBTT /51O&D5:MH.0_C$< A_HA(ZJCAA=E<;EO/X;C05K@29V1W:[\HE4G
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MW[3ED&LJU"B3F[OH4GN0PS]>6TCO>-<F375D&Y42W^D)CT_4J/I$K]P[$7+
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MI18N=5'U4&6FC):@JK%P!S(RHG)]NE1Y(A(KE9*YV<G\S6257FDMQ-P"R%^
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MNT[>K_OWOK^ON[]ONF=FS>JU9OZLNN>N<^ZY^SS/WL_>Y]PR,O1/K@DB0TW
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MSTZ@#WXG1VW(1VW+J1VH#8\K7>W".?F;ZTV&3R]:G=)L0I>#[MDY@?/[-=*
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M1C_+5<BO-ZFLO-EOL!MO195\7[ 1KA-17@'I1M@U35&<&3/I=4.KD89BBR0
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M9F!,P&M"XB-IM"%QUDOGBYBO2.K#3#6??/B#_8)!IQS:53[=94:8L(I0B,'
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MTI&Y82F.?4/P?/2BNUDGN(>U%:Z_O?!Z@=0;/5>-@_28(+XIY\98&EWOD,1
MI:8Y44/:N!8LWI!K?#FGBRC F#$'*L#&"8$9V?OVA/'>"/B/]0;AE3V*=KZ+
M*FFS9Q9H)&%NW-;8VKK]&HILUF.KHD;FP+&>)+M8DQ_J-8^9$%W3C@M&T%GQ
M9Y](L6QR!X?ZG/_YOQ[LAJ S6WNI,C- GDE,K0Q+**F5K"A^4]4. YM?^#5P
M"]=UE"_F[3> ;?%AQ9V1J;-A7+Q*#>$,AOJ&<JML0Y1N/_VG7XTZ8O"27.M9
MJ0TQ/MCAS 5Y:CJ\*C6E*'(>&,6LE6D74\5XHD@(25+1B9N 7#=8.,VOQ*1B
M%>Y=*\>SC HD(0.*2H,@KYR,_+/!0<]5L2"Y?@L7.W29.R_MU-D^,IME8C>+
M]XS#T"6+B8UY%/6XJMDC,*4ZH2N+M*8\,6V8ZH"RW(#._EJ$;UJLPWT.6GBL
MW6J3\X\+?B95B>!>,X;*!,G$XE\0!=M^),EB:Z[ N%\1"_CS[\Z^8+##?8B3
M#*$V^5!#_E-_] /R0BH#7TM:^_D1,TSGV9&J%45Y>4YN2$H.)!.U:S\KJ9N-
MI0^IP-%&^X.I9YKS%RU31BM/R^5CWRD0A+OF;H?9'P32,L?]98PYJS(^:_*Q
MUDP.QKDYT4=IL7]Q5YH_/XD5S!A0A:AS#V<LI9M?S_NM'='^4!X@B8Z8_<D:
M40Y1 AQ<B8CHS_+3:[:KY9L(<6WK>"CP:*4^+!=LL[AK/,/&";%R?L\)0+,D
M3<!8U&A >(]DA0I8^@#29*4B#VSEKDQZBZ7H3#@KL[BD/AH^:O4^&NSCG+31
M*?9#?XXCVH(C-$![)&:*OJ#F16?O%1#&WF9DWBAVA_H*B"I9Z+YMSI9]^1N5
M<#_^7<E;_A\K>?\567X_[7L>8><*YYKY,(]=GI&(&Q2F%S^>:]YW^"Q?"3Z+
M_\;S13+*8("P>MT_6M;/;3VS7G'##SWR7_'?W_M2,3WB'&4?R=TMU4!39\K^
MF;SX7Q-'+-FT!JP'&D4(VT@\?>"\HM0)YVR_SZJ/IM"B5\RYN ;TSV;PCGUX
M<S>HK#Z/JUW-YRI@?HV:HI8F?L$SQT^I%U4"5XQBS:"^]P9G@^>P=VZW]MZS
MZD+/;F6D]!":\N$:N.B(HSV,+[9SSM^[.KD/],I=)$(78F>"KR$ECAZ)/Z^M
M/8Z>01]82EX!CO/5E<BTX+N^C4?&$_&([)7I=>HRFXLSLT5)[UECO/[I)DL4
MEF7C8.Y?F_ME\7L 0DR"-E*[F Z</+'#&SY7SO1/;C\2/RY*6XFJ.G<^N=(C
MG?TX[\M<S2R[W2./6( -;7KY'/3#>T6E$"+S\S^M);5)+,VLK1YZ!82X^D$6
MJME1CQZ8;44V=<K4W3BE*N0WEEJM>?=#(_0'U0K*N#LHI+\)G?0M%AN+4[HA
M>,U>;X(%>05/NR#M'NGGOD0_^6?K%R)5U8DHO!> 2C<[*+6<E'J@1-(H=PZ'
M,2Z]]ZM-_5.&NS 2%T5[.Y!41]A]K:<(7^O! T(^ HYO4G+&V%C3]R.]6K>-
M2TPZD_B':E_;FY87_#:^G#Y-<3[KYAQ_[+OV)GD%H  -9+4BH3P(U^5F;;TX
MZE">E\E%Q25(<Y,&T_#%F)K<2UES)@A_[L?JQ2K%)54?Y!^?;U6DG0W82F]K
MVTT,T\ZL)B@<F8#-:S/9Z9ML^=SC0^/2I_EK96M?*/5@5*&&/]_)I=5H2N,:
M^\@"UN_HW:)N.O)#%A\-GKQ]P5?,J3&9!V!%D,_4,_DTT:ZNR?[QJ5Q@4U[Y
M8Y9Q.0O3K9O!70S_*X!C3.E@&]>R5[CT3R!X9WP^]K<18_.JJ"JGKJ50=)&X
MBQW+5'[::'H+72@G0C] .O5]?_.C^S3HS/T'9-GMB+;$I#34&]/ZXU)/77%>
M:4["<>WH3M5'JJ&BZEM/(H@F 8%U*<U.=JHC_[[^4[BO-=\!@R0!WPT1:]"T
MVM0N#F_NRJY=<@H3\Z&Y:(^!-"2B==8=O95IR<_6C'<G*7'BW2IHY/Y$+YS9
M1/413HBQU&SA9_D_8S.D@W>7IJ00>AR=U6C6"#8\QMITX$X=17@5Z@WKYT\U
MG.L6_:I<E?,3TKJBHH$"IF]:^RISF?##&.)46629!/IX@H5YZYH+21#\=K B
MKA]3+B/LO9ML<<NG,G"J2@K+Z'0Q)1O#)%-:J*/PAY&0?R:<XT,^SV'']NE0
M&H$/#P;?R0Z-;PT5'H\X]E<@1HCM1%MVQ<;F;I*7="$>RQ]W&\@>>'K$#IWK
M6N:KCF!_Z9\>G>VW&@3?F^5]+RX9T;C4[];#FA\!Z>,F$UA80"P%%KS@_0"1
MG.11[SOX_?PU8W 4 U'WF3Q'T_A#J"[E87"*%14"ZVJD"8 $GNMO/B\M?6>E
M&<\2C8S0C56(QJ#XU:[C4HQ1R%"%245:-4 :TZ[\&1'FPUY^F]XM=7_=^W^3
MIFH=!PU,0S.[ ]0?/3VW^^]]QNCJJ:F;MK2 3/16?Q7HN<QF#NF1G >Z'S',
MT?B]6;W !O)DW,;1^DV3S!OTV_>S^^G4F;\"3'Q3;S3/8F&?:66:'W/1IB-S
M$B^<ZUX!RVGRCIF98KCM:O_21PW2F07]:RRN0.7Y]R^^L'NA5Y>UPKYTKP >
MYJ;6H+:B1#'F#@;VGOA>9@-A6YR'I\P"H<"U!3\+WR _8>;NGE7CY3C!7YD$
M":G.7K7_+"1L-:@<N.F5O@NN\:L3=\Y8U.\(A3K>)<_.(1PE"WY?8:-<)79$
MSOTG!BM&YE. -">A183%6YX,3)K.G$N_XV#H<%U_!QSI)L\Q =<WG-CBB9)T
MU9KJ3:)13,>&HI/".MC"7P&V^# LV-HUM4'(!I V9(>6<EL>Q@HCE?\[<A%.
MHU?C(U"@[:Y0\^$XE9WE9"SG9IJ8LZ1'TT3-&VZ%<6@G-R.I8>M?,SAIDUM>
MF]YM'UI/ M56\"R@O!*MA[+[>B>:R,Y/OW2@A5HON!G1[_\U-ZB-X*X$8AM-
M=*_SBZFJ_><>RBII/EX]+5W$_7=YU3(*JYM7@VP5I?C8@H90AH3:)O-CZU&R
MN* :NDC1C>&C^48\BW59!=5VXN?[CBWR./KRD"=KZC"68I#ND$[W;^)=')A'
M?$7AZJG/RM)+&1H2&RP;&,?85N^^B<?4U[.()J/G,1+:\GT/KH[4RE;Y\=/N
M0^K%FR7<BQB?:ZJ*[,\*CKX"+M=/+^O"RYLQ\^K<AZU;]UB/G?G_T/<:MIFK
M),8V1$N>FYLOMKZV[L8#8V.7+Q@8$[%K_IJ,WS:*VY#(NR[^&QR;..%OI_?O
MP&F*WH-8;0=H1\Q;W%MX;6 @NU]EF_PC_9WT]Y>X?'V?B: #J0G9>UZHW\DH
M5</86';H&MV_HHCRT<2,#AWV!R[-R:=7@/";*XD'S\7,-FR_--SE5;'5:=GL
MQ+4$O(W!3=SRS+I0'U_%*1(Q!U!;=9M86V;BAO%II=T@<?=8^)!\8XM.]U^C
M7&6>WWHTH7@2UQ&&?N(=LV4V[#EN>)([M/EQ(Y?1?HJ'<1K)$S#Q%Y#A\A.6
M5)2%E)>\]7G/MKBM<E P676G7VFJM"+=4?HNO$J5I@F;H_=P3] I,K0Z%:;+
MU W%7(HWL1=H%[+G3%-&/!$A1Q+YDV4OCM)!JV:/B;E?>KWWMJ+VB*-VY&[!
M13' EB7DK<-_1[YY?ZLN^(_IE]'IVOFFSM/O7*'\&LIE;K2<*7%<)&"C'@+I
M+;I!:@8FCD@)LCH._+,]<]Z<E($-?_ JKIUP757:I9SL7H!]G?G3+5-O8F7Q
MLS\)SDS54:?FU'_M* 3-%5^,2CBH[K!&R,]A#N-CJC,(W'@3&5\ILF/]WLI5
MZB4$R!C560;'VN\$ICG?L<\*Y:,UC:34/5%1-Q(U?FO&N EN]#@C6B'7MSOH
MTJ,X1L)N[,,KJS*\-6T;NG;[DDHI<XR<'W,51>8K"PN.,,"'RZ']<GY#0$+(
M8=WU(?:S<>UOK*C#-Q&FBW=KO\T.,L6QFB(?@"N-FWT;DT.6\VI@[\OQ^$%*
M 0!EI97\*/SE[$>XT$BI71B5S%8!)V"#8W!S-G4\@.")GWKPR^DK #>89',
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MT!1YG/AV ISK#3F*3TB- 7(<I8\BGD]R*>W$;O@X$'X^B)TIK)N"1DV:'&6
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M%1T<DU2)\AHEZ36UAP1:IX)T(=IO;1.<!(&^]CS!""XT*X&.]DP '8;KWTC
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MZ=)T(M_BV4JQ<TXYMW!%V=BYHPR:EKWZW'B*#*J#'Q)M7 PRW]X! "9%TY]
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M"JL)74C]$K-5P0:L6%)<4-\(T%/GN%';9&?8,QK/6G:7 9]@H0PJ2C;MENX
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MG#W\K-%REZ=_U0:84;H8-:&MLF&9H=+MFA&H;:;#GSVB6*PVT"J_.CPH6$7
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MK(+M$6G??.K*_^$'\+R;^0]02P$"% ,4    " !PB_M6_$_Y$=X"  !1!P
M$0              @ $     9#0U,30R.&1E>#(S,2YH=&U02P$"% ,4
M" !PB_M6<XU? V("  !4!0  $0              @ $- P  9#0U,30R.&1E
M>#(S,BYH=&U02P$"% ,4    " !PB_M6Z#"JH]P*  #D&P  $0
M    @ &>!0  9#0U,30R.&1E>#DY,2YH=&U02P$"% ,4    " !PB_M6]BY7
MU&@$  "4#   $0              @ &I$   9#0U,30R.&1E>#DY,RYH=&U0
M2P$"% ,4    " !PB_M6Y[5'JK@(  !570  &               @ % %0
M9#0U,30R.&1E>&9I;&EN9V9E97,N:'1M4$L! A0#%     @ <(O[5N1?);2P
M40T M*)T  X              ( !+AX  &0T-3$T,CAD<S0N:'1M4$L! A0#
M%     @ <(O[5D"7+$ET&0  ]QH! !$              ( !"G - &9R97$M
M,C R,S S,S$N>'-D4$L! A0#%     @ <(O[5J*S2 Z,$   9/H  !4
M         ( !K8D- &9R97$M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M '"+^U8,50Y)@T(  -P=!  5              "  6R:#0!F<F5Q+3(P,C,P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " !PB_M6/@7D)'B,   T>0@ %0
M        @ $BW0T 9G)E<2TR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @
M<(O[5KA,9UA1:0  < L' !4              ( !S6D. &9R97$M,C R,S S
M,S%?<')E+GAM;%!+ 0(4 Q0    ( '"+^U;KVU4) M@! #,+ @ 1
M      "  5'3#@!G-#4Q-#(X9S P83$R+FIP9U!+ 0(4 Q0    ( '"+^U8-
MN0&2KX@! !?? 0 1              "  8*K$ !G-#4Q-#(X9S P83$S+FIP
M9U!+ 0(4 Q0    ( '"+^U8&M!RQ%?P! /HC @ 1              "  6 T
M$@!G-#4Q-#(X9S P83$V+FIP9U!+ 0(4 Q0    ( '"+^U:;WA%G!PD& /OU
M"  1              "  :0P% !G-#4Q-#(X9S P9C R+FIP9U!+ 0(4 Q0
M   ( '&+^U93"5&D_70   #$   1              "  =HY&@!G-#4Q-#(X
M9S P>C T+FIP9U!+ 0(4 Q0    ( '&+^U9UI!BZ(9P  .[R   1
M      "  0:O&@!G-#4Q-#(X9S Q838U+FIP9U!+ 0(4 Q0    ( '&+^U9!
MSVQ[W=(  (PH 0 1              "  59+&P!G-#4Q-#(X9S Q838V+FIP
M9U!+ 0(4 Q0    ( '&+^U9P7P;H<#(! -M_ 0 1              "  6(>
M' !G-#4Q-#(X9S Q8C8Y+FIP9U!+ 0(4 Q0    ( '&+^U89^0Y:@& " -:W
M @ 1              "  0%1'0!G-#4Q-#(X9S Q8C<W+FIP9U!+ 0(4 Q0
M   ( '&+^U95NQE43_$  (@K 0 1              "  ;"Q'P!G-#4Q-#(X
M9S Q;3,P+FIP9U!+ 0(4 Q0    ( '&+^U8!\,<EJ2P!  -K 0 1
M      "  2ZC( !G-#4Q-#(X9S R83,Y+FIP9U!+ 0(4 Q0    ( '&+^U9\
M& TMDS@  !YA   1              "  0;0(0!G-#4Q-#(X9S S9S P+FIP
M9U!+ 0(4 Q0    ( '&+^U:*T!PVEA4! 'QO 0 1              "  <@(
M(@!G-#4Q-#(X9S X>3DW+FIP9U!+ 0(4 Q0    ( '&+^U;9WOD.$$P! !>+
M 0 1              "  8T>(P!G-#4Q-#(X9S$Q=# Q+FIP9U!+ 0(4 Q0
M   ( '&+^U8*8WI<"[(  +GI   1              "  <QJ) !G-#4Q-#(X
M9S$W9S R+FIP9U!+ 0(4 Q0    ( '&+^U86QRN:4>@! $A" @ 1
M      "  08=)0!G-#4Q-#(X9S$W;C Q+FIP9U!+ 0(4 Q0    ( '&+^U;6
M4\*&'8X! )3/ 0 1              "  88%)P!G-#4Q-#(X9S(Q838P+FIP
M9U!+ 0(4 Q0    ( '&+^U:,1)J'A8<" +/3 @ 1              "  =*3
M* !G-#4Q-#(X9S(X83,R+FIP9U!+ 0(4 Q0    ( '&+^U;4?&-+R74" *K#
M @ 1              "  88;*P!G-#4Q-#(X9S(X8C,R+FIP9U!+ 0(4 Q0
M   ( '&+^U9*N)76X7@! -3* 0 1              "  7Z1+0!G-#4Q-#(X
M9S(X<#8Y+FIP9U!+ 0(4 Q0    ( '&+^U9VW>./":$   #<   1
M      "  8X*+P!G-#4Q-#(X9S,W83 R+FIP9U!+ 0(4 Q0    ( '&+^U;6
M17:N"-   !H+ 0 1              "  <:K+P!G-#4Q-#(X9S,X83 Q+FIP
M9U!+ 0(4 Q0    ( '&+^U9<$4X\ /(  %L9 0 1              "  ?U[
M, !G-#4Q-#(X9S0X:#8R+FIP9U!+ 0(4 Q0    ( '&+^U:VI_*@PX ! *VV
M 0 1              "  2QN,0!G-#4Q-#(X9S0X:#8S+FIP9U!+ 0(4 Q0
M   ( '&+^U8LR\G=T]   '8' 0 1              "  1[O,@!G-#4Q-#(X
M9S8R;3 W+FIP9U!+ 0(4 Q0    ( '&+^U9 N]PM3,P& (O,"0 1
M      "  2# ,P!G-#4Q-#(X9S8W83(W+FIP9U!+ 0(4 Q0    ( '&+^U:7
MYX#OO=\  +L@ 0 1              "  9N,.@!G-#4Q-#(X9SDT934Q+FIP
79U!+!08     )@ F &X)  "';#L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
